Current Protocols in Nucleic Acid Chemistry Contents Preface Foreword Chapter 1 Synthesis of Modified Nucleosides 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19.
Introduction Unit 1.1 Palladium-Mediated C5 Substitution of Pyrimidine Nucleosides Unit 1.2 Enzymatic Synthesis of M1G-Deoxyribose Unit 1.3 Synthesis of N2-Substituted Deoxyguanosine Nucleosides from 2-Fluoro-6-O(Trimethylsilylethyl)-2′-Deoxyinosine Unit 1.4 Unnatural Nucleosides with Unusual Base Pairing Properties Unit 1.5 Development of a Universal Nucleobase and Modified Nucleobases for Expanding the Genetic Code Unit 1.6 Syntheses of Specifically 15N-Labeled Adenosine and Guanosine Unit 1.7 Synthesis of Protected 2′-Deoxy-2′-fluoro-β-d-arabinonucleosides Unit 1.8 Synthesis, Characterization, and Application of Substituted Pyrazolopyrimidine Nucleosides Unit 1.9 Synthesis of 1,5-Anhydrohexitol Building Blocks for Oligonucleotide Synthesis Unit 1.10 Synthesis and Properties of 7-Substituted 7-Deazapurine (Pyrrolo[2,3-d]pyrimidine) 2′Deoxyribonucleosides Unit 1.11 Reduction of Ribonucleosides to 2′-Deoxyribonucleosides Unit 1.12 Synthesis of Fluorinated Nucleosides Unit 1.13 Synthesis of Ribonucleosides by Condensation Using Trimethylsilyl Triflate Unit 1.14 Synthesis of 2′-O-β-d-Ribofuranosylnucleosides Unit 1.15 Preparation of 2′-Deoxy-2′-Methylseleno-Modified Phosphoramidites and RNA Unit 1.16 Palladium-Catalyzed Cross-Coupling Reactions in C6 Modifications of Purine Nucleosides Unit 1.17 Nucleobase-Caged Phosphoramidites for Oligonucleotide Synthesis Unit 1.18 Synthesis of Altritol Nucleoside Phosphoramidites for Oligonucleotide Synthesis
Chapter 2 Protection of Nucleosides for Oligonucleotide Synthesis Introduction Unit 2.1 Nucleobase Protection of Deoxyribo- and Ribonucleosides Unit 2.2 Protection of 2′-Hydroxy Functions of Ribonucleosides Unit 2.3 Protection of 5′-Hydroxy Functions of Nucleosides Unit 2.4 A Base-Labile Protecting Group (Fluorenylmethoxycarbonyl) for the 5′-Hydroxy Function of Nucleosides 6. Unit 2.5 2′-Hydroxyl-Protecting Groups that are Either Photochemically Labile or Sensitive to Fluoride Ions 7. Unit 2.6 Deoxyribo- and Ribonucleoside H-Phosphonates 8. Unit 2.7 Deoxyribonucleoside Phosphoramidites 9. Unit 2.8 Regioselective 2′-Silylation of Purine Ribonucleosides for Phosphoramidite RNA Synthesis 10. Unit 2.9 Preparation of 2′-O-[(Triisopropylsilyl)oxy]methyl-protected Ribonucleosides 11. Unit 2.10 Preparation of 5′-Silyl-2′-Orthoester Ribonucleosides for Use in Oligoribonucleotide Synthesis 12. Unit 2.11 Enzymatic Regioselective Levulinylation of 2′-Deoxyribonucleosides and 2′-OMethylribonucleosides 1. 2. 3. 4. 5.
13. Unit 2.12 Nucleobase Protection with Allyloxycarbonyl 14. Unit 2.13 Universal 2-(4-Nitrophenyl)ethyl and 2-(4-Nitrophenyl)ethoxycarbonyl Protecting Groups
for Nucleosides and Nucleotides
Chapter 3 Synthesis of Unmodified Oligonucleotides 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17.
Introduction Unit 3.1 Solid-Phase Supports for Oligonucleotide Synthesis Unit 3.2 Attachment of Nucleosides to Solid-Phase Supports Unit 3.3 Synthetic Strategies and Parameters Involved in the Synthesis of Oligodeoxyribonucleotides According to the Phosphoramidite Method Unit 3.4 Synthesis of Oligodeoxyribo- and Oligoribonucleotides According to the H-Phosphonate Method Unit 3.5 Strategies for Oligoribonucleotide Synthesis According to the Phosphoramidite Method Unit 3.6 Oligoribonucleotides with 2′-O-(tert-Butyldimethylsilyl) Groups Unit 3.7 Synthesis of Oligoribonucleotides Using the 2-Nitrobenzyloxymethyl Group for 2′Hydroxyl Protection Unit 3.8 Chemical Synthesis of RNA Sequences with 2′-O-[(Triisopropylsilyl)oxy]methyl-protected Ribonucleoside Phosphoramidites Unit 3.9 3-(N-tert-Butylcarboxamido)-1-propyl and 4-Oxopentyl Groups for Phosphate/Thiophosphate Protection in Oligodeoxyribonucleotide Synthesis Unit 3.10 DNA Synthesis Without Base Protection Unit 3.11 The 4-Methylthio-1-Butyl Group for Phosphate/Thiophosphate Protection in Oligodeoxyribonucleotide Synthesis Unit 3.12 Nucleoside Phosphoramidites Containing Cleavable Linkers Unit 3.13 Microwave-Assisted Functionalization of Solid Supports for Rapid Loading of Nucleosides Unit 3.14 Solution-Phase Synthesis of Di- and Trinucleotides Using Polymer-Supported Reagents Unit 3.15 DNA Synthesis Without Base Protection Using the Phosphoramidite Approach Unit 3.16 A Universal and Recyclable Solid Support for Oligonucleotide Synthesis
Chapter 4 Synthesis of Modified Oligonucleotides and Conjugates 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15.
Introduction Unit 4.1 A Brief History, Status, and Perspective of Modified Oligonucleotides for Chemotherapeutic Applications Unit 4.2 Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups Unit 4.3 Direct Attachment of Conjugate Groups to the 5′ Terminus of Oligodeoxyribonucleotides Unit 4.4 Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides Unit 4.5 Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides Unit 4.6 3′-Modified Oligonucleotides and their Conjugates Unit 4.7 Synthesis and Purification of Oligonucleotide N3′ P5′ Phosphoramidates and their Phosphodiester and Phosphorothioate Chimeras Unit 4.8 Incorporation of Halogenoalkyl, 2-Pyridyldithioalkyl, or Isothiocyanate Linkers into Ligands Unit 4.9 Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands Unit 4.10 Conjugation of 5′-Functionalized Oligodeoxyribonucleotides with Properly Functionalized Ligands Unit 4.11 Synthesis and Purification of Peptide Nucleic Acids Unit 4.12 Locked Nucleic Acids: Synthesis and Characterization of LNA-T Diol Unit 4.13 Cellular Delivery of Locked Nucleic Acids (LNAs) Unit 4.14 Solid-Phase Synthesis of Branched Oligonucleotides
16. Unit 4.15 Solid-Phase Synthesis of 2′-Deoxy-2′-fluoro- β-d-Oligoarabinonucleotides (2′F-ANA) and
Their Phosphorothioate Derivatives
17. Unit 4.16 Chemistry of CpG DNA 18. Unit 4.17 Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Phosphorothioate
Linkages
19. Unit 4.18 Synthesis of Oligonucleotide Conjugates via Aqueous Diels-Alder Cycloaddition 20. Unit 4.19 5′-Iodination of Solid-Phase-Linked Oligodeoxyribonucleotides 21. Unit 4.20 Reversible Biotinylation of the 5′-Terminus of Oligodeoxyribonucleotides and its
Application in Affinity Purification
22. Unit 4.21 Uridine 2′-Carbamates: Facile Tools for Oligonucleotide 2′-Functionalization 23. Unit 4.22 Stepwise Solid-Phase Synthesis of Nucleopeptides 24. Unit 4.23 Synthesis of Oligoribonucleotides Containing N6-Alkyladenosine and 2-Methylthio-N6-
Alkyladenosine
25. Unit 4.24 Oligodeoxyribonucleotide Analogs Functionalized with Phosphonoacetate and
Thiophosphonoacetate Diesters
26. Unit 4.25 Base-Modified Oligodeoxyribonucleotides: Using Pyrrolo[2,3-d]pyrimidines to Replace
Purines
27. Unit 4.26 An Aminooxy-Functionalized Non-Nucleosidic Phosphoramidite for the Construction of
Multiantennary Oligonucleotide Glycoconjugates on a Solid Support 28. Unit 4.27 Large-Scale Preparation of Conjugated Oligonucleoside Phosphorothioates by the High-
Efficiency Liquid-Phase (HELP) Method
29. Unit 4.28 Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs 30. Unit 4.29 Methoxyoxalamido Chemistry in the Synthesis of Tethered Phosphoramidites and
Functionalized Oligonucleotides 31. Unit 4.30 Using Morpholinos to Control Gene Expression 32. Unit 4.31 Solid-Phase Oligonucleotide Labeling with DOTA
Chapter 5 Methods for Cross-Linking Nucleic Acids 1. 2. 3. 4. 5. 6. 7. 8.
Introduction Unit 5.1 Engineering Disulfide Cross-Links in RNA Using Thiol-Disulfide Interchange Chemistry Unit 5.2 Chemical and Enzymatic Methods for Preparing Circular Single-Stranded DNAs Unit 5.3 Engineering Specific Cross-Links in Nucleic Acids Using Glycol Linkers Unit 5.4 Engineering Disulfide Cross-Links in RNA Via Air Oxidation Unit 5.5 Use of Electrophilic Substitution to Form Site-Specific Cross-Links in DNA Unit 5.6 Synthesis of Endcap Dimethoxytrityl Phosphoramidites for Endcapped Oligonucleotides Unit 5.7 Engineering Terminal Disulfide Bonds Into DNA
Chapter 6 Chemical and Enzymatic Probes for Nucleic Acid Structure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10.
Introduction Unit 6.1 Probing RNA Structure with Chemical Reagents and Enzymes Unit 6.2 Probing Nucleic Acid Structure with Shape-Selective Rhodium and Ruthenium Complexes Unit 6.3 Probing RNA Structure by Lead Cleavage Unit 6.4 Probing Nucleic Acid Structure with Nickel- and Cobalt-Based Reagents Unit 6.5 Probing RNA Structures with Hydroxyl Radicals Unit 6.6 Chemical Reagents for Investigating the Major Groove of DNA Unit 6.7 Probing DNA Structure with Hydroxyl Radicals Unit 6.8 Probing RNA Structure and Metal-Binding Sites Using Terbium(III) Footprinting Unit 6.9 Probing RNA Structure and Function by Nucleotide Analog Interference Mapping
Chapter 7 Biophysical Analysis of Nucleic Acids
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.
Introduction Unit 7.1 Biophysical Analysis of Nucleic Acids Unit 7.2 NMR Determination of Oligonucleotide Structure Unit 7.3 Optical Methods Unit 7.4 Calorimetry of Nucleic Acids Unit 7.5 Molecular Modeling of Nucleic Acid Structure Unit 7.6 Methods to Crystallize RNA Unit 7.7 Recent Advances in RNA Structure Determination by NMR Unit 7.8 Molecular Modeling of Nucleic Acid Structure: Energy and Sampling Unit 7.9 Molecular Modeling of Nucleic Acid Structure: Electrostatics and Solvation Unit 7.10 Molecular Modeling of Nucleic Acid Structure: Setup and Analysis Unit 7.11 Characterization of DNA Structures by Circular Dichroism Unit 7.12 Biophysical Analysis of Triple-Helix Formation
Chapter 8 Nucleic Acid Binding Molecules 1. 2. 3. 4. 5. 6.
Introduction Unit 8.1 Determination of Binding Mode: Intercalation Unit 8.2 Determination of Binding Thermodynamics Unit 8.3 A Competition Dialysis Assay for the Study of Structure-Selective Ligand Binding to Nucleic Acids Unit 8.4 Chemistry of Minor Groove Binder–Oligonucleotide Conjugates Unit 8.5 A Fluorescent Intercalator Displacement Assay for Establishing DNA Binding Selectivity and Affinity
Chapter 9 Combinatorial Methods in Nucleic Acid Chemistry 1. 2. 3. 4. 5. 6. 7.
Introduction Unit 9.1 Theoretical Principles of In Vitro Selection Using Combinatorial Nucleic Acid Libraries Unit 9.2 Design, Synthesis, and Amplification of DNA Pools for In Vitro Selection Unit 9.3 In Vitro Selection of RNA Aptamers to a Protein Target by Filter Immobilization Unit 9.4 Selection for Catalytic Function with Nucleic Acids Unit 9.5 In Vitro Selection of RNA Aptamers to a Small Molecule Target Unit 9.6 In Vitro Selection Using Modified or Unnatural Nucleotides
Chapter 10 Purification and Analysis of Synthetic Nucleic Acids and Components Introduction Unit 10.1 Analysis of Oligonucleotides by Matrix-Assisted Laser Desorption/Ionization Time-ofFlight Mass Spectrometry 3. Unit 10.2 Analysis of Oligonucleotides by Electrospray Ionization Mass Spectrometry 4. Unit 10.3 Overview of Purification and Analysis of Synthetic Nucleic Acids 5. Unit 10.4 Polyacrylamide Gel Electrophoresis (PAGE) of Synthetic Nucleic Acids 6. Unit 10.5 Analysis and Purification of Synthetic Nucleic Acids Using HPLC 7. Unit 10.6 Base Composition Analysis of Nucleosides Using HPLC 8. Unit 10.7 Cartridge Methods for Oligonucleotide Purification 9. Unit 10.8 Analysis of Oxidized DNA Fragments by Gel Electrophoresis 10. Unit 10.9 Capillary Electrophoresis of DNA 11. Unit 10.10 Sequencing Oligonucleotides by Enrichment of Coupling Failures Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry 12. Unit 10.11 Mass Determination of Phosphoramidites 1. 2.
Chapter 11 RNA Folding Pathways
Introduction Unit 11.1 RNA Folding Pathways Unit 11.2 RNA Secondary Structure Prediction Unit 11.3 Thermal Methods for the Analysis of RNA Folding Pathways Unit 11.4 Probing RNA Folding Pathways by RNA Fingerprinting Unit 11.5 Characterization of Tertiary Folding of RNA by Circular Dichroism and Urea Unit 11.6 Time-Resolved Hydroxyl Radical Footprinting of RNA with X-Rays Unit 11.7 Rapid Magnesium Chelation as a Method to Study Real-Time Tertiary Unfolding of RNA Unit 11.8 Use of Fluorescence Spectroscopy to Elucidate RNA Folding Pathways Unit 11.9 Use of Chemical Modification To Elucidate RNA Folding Pathways Unit 11.10 Probing RNA Structural Dynamics and Function by Fluorescence Resonance Energy Transfer (FRET) 12. Unit 11.11 Site-Specific Fluorescent Labeling of Large RNAs with Pyrene 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.
Chapter 12 Nucleic Acid-Based Microarrays and Nanostructures 1. 2. 3. 4. 5. 6. 7. 8.
Introduction Unit 12.1 Key Experimental Approaches in DNA Nanotechnology Unit 12.2 Preparation of Gold Nanoparticle–DNA Conjugates Unit 12.3 Synthesis of 5′-O-Phosphoramidites with a Photolabile 3′-O-Protecting Group Unit 12.4 Derivatization of Glass and Polypropylene Surfaces Unit 12.5 DNA Microarray Preparation by Light-Controlled In Situ Synthesis Unit 12.6 Preparation of α-Oxo Semicarbazone Oligonucleotide Microarrays Unit 12.7 Synthesis of Covalent Oligonucleotide-Streptavidin Conjugates and Their Application in DNA-Directed Immobilization (DDI) of Proteins
Chapter 13 Nucleoside Phosphorylation and Related Modifications 1. 2. 3. 4. 5. 6. 7.
Introduction Unit 13.1 Overview of the Synthesis of Nucleoside Phosphates and Polyphosphates Unit 13.2 Chemoenzymatic Preparation of Nucleoside Triphosphates Unit 13.3 Synthesis and Polymerase Incorporation of 5′-Amino-2′,5′-Dideoxy-5′-N-Triphosphate Nucleotides Unit 13.4 Nucleoside-5′-Phosphoimidazolides: Reagents for Facile Synthesis of Dinucleoside Pyrophosphates Unit 13.5 Synthesis of Methylenebis(phosphonate) Analogs of Dinucleotide Pyrophosphates Unit 13.6 Chemical Phosphorylation of Deoxyribonucleosides and Thermolytic DNA Oligonucleotides
Chapter 14 Biologically Active Nucleosides 1. 2. 3. 4. 5. 6.
Introduction Unit 14.1 Synthesis of Acyclic Analogs of Adenosine Unit 14.2 Synthesis of Acyclic Nucleoside Phosphonates Unit 14.3 Synthesis of β-l-2′-Deoxythymidine (l-dT) Unit 14.4 Synthesis of Carbovir and Abacavir from a Carbocyclic Precursor Unit 14.5 Synthesis of 2′- and 3′-C-Methylribonucleosides
Chapter 15 Nucleoside Prodrugs and Delivery Strategies 1.
Introduction
2. 3. 4.
Unit 15.1 Synthesis of Amino Acid Phosphoramidate Monoesters via H-Phosphonate Intermediates Unit 15.2 Synthesis of Cidofovir and (S)-HPMPA Ether Lipid Prodrugs Unit 15.3 Chemistry of bisSATE Mononucleotide Prodrugs
Appendix 1 Standard Nomenclature, Data, and Abbreviations 1. 2. 3. 4. 5.
1A Selected Abbreviations Used in This Manual 1B Characteristics of Nucleic Acids 1C IUPAC-IUB Joint Commission on Biochemical Nomenclature Abbreviations and Symbols for the Description of Conformations of Polynucleotide Chains 1D Nucleoside and Nucleotide Nomenclature 1E A Convenient Stereochemical Notation for P-Chiral Nucleotide Analogs
Appendix 2 Laboratory Stock Solutions and Equipment 1.
2A Common Buffers and Stock Solutions
Appendix 3 Commonly Used Techniques 1. 2. 3. 4. 5.
3A References to Commonly Used Techniques 3B Denaturing Polyacrylamide Gel Electrophoresis 3C Introduction to the Synthesis and Purification of Oligonucleotides 3D Thin-Layer Chromatography 3E Column Chromatography
Appendix 4 Resources 1.
4A Useful Nucleic Acid Chemistry Web Sites
Appendix Suppliers 1.
Selected Suppliers of Reagents and Equipment
PREFACE hemistry has played a pivotal role in the development of molecular biology and biotechnology. The value of synthetic oligonucleotides became apparent when they provided the means for deciphering the genetic code. Modern cloning techniques and nucleic acid sequencing depend on the ability to obtain synthetic primers. In recent years intensive research has driven the technological development of high-throughput methods for nucleic acid analysis. Moreover, modified nucleic acids have been extensively studied and identified as highly specific therapeutic agents. At the same time, research efforts have provided new means to probe the structure of nucleic acids for a better understanding of all aspects of nucleic acid function and interactions in biology. Future applications of nucleic acids are likely to extend into material science, as nucleic acid sequences provide a code for information storage and manipulation as well as the means for self-assembly of complex devices and systems on the nanoscale.
C
The pathways by which the nucleoside building blocks of nucleic acids are biosynthesized and incorporated into nucleic acids are important targets for antiviral and chemotherapies. A large variety of modified nucleosides and nucleotides have been designed as tools for studying biochemical processes involving nucleotide binding proteins (as enzyme substrates or as cofactors), and many more have been evaluated as potential drugs. Detailed protocols for much of the early chemistry can be found in a useful series of books starting with Synthetic Procedures in Nucleic Acid Chemistry, Vols. 1 and 2 (Zorbach and Tipson, 1968) and continuing with four volumes, Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods and Techniques, Parts I-IV (Townsend and Tipson, 1978, 1986, 1991). The current methods applied to the synthesis of modified nucleosides and nucleic acids for structure-function studies, potential therapeutic agents, and as tools for molecular biology, have spawned a unique set of chemistries that provide the fundamental basis on which this volume of Current Protocols has evolved. In Current Protocols in Nucleic Acid Chemistry, the practical aspects of innovative methods for the preparation of modified nucleosides and nucleic acids are strongly emphasized. Chapters 1 to 4 describe detailed methodology for the synthesis of both natural and modified oligonucleotides. Chapter 1 focuses on the synthesis of a variety of modified nucleosides with the emphasis on compounds that could be used as components of oligonucleotides. Various methods for N-protection of nucleobases and functionalization of 5 -, 3 -, and/or 2 -hydroxyl groups of deoxyribo- and ribonucleosides are presented in Chapter 2 along with the preparation of their H-phosphonate or phosphoramidite derivatives to enable oligonucleotide synthesis. In Chapter 3, the development of solid supports and strategies for solid-phase synthesis of native DNA or RNA oligonucleotides, through a collection of properly functionalized H-phosphonate or phosphoramidite monomers, is emphasized. Such rapid and efficient methods for automated synthesis of oligonucleotides has led to the preparation of modified oligonucleotides for therapeutic applications. Methods for altering native oligonucleotide properties through nucleobase, carbohydrate, and internucleotidic phosphodiester modifications or through conjugation with ligands or reporter groups are the focus of Chapter 4. Chapters 5, 6, and 11 provide methods for probing DNA and RNA structures, including cross-linking strategies to stabilize secondary structure, chemical and enzymatic probes of structure, and techniques for elucidating RNA folding. Two chapters focus on purification Current Protocols in Nucleic Acid Chemistry Contributed by Serge L. Beaucage, Donald E. Bergstrom, Piet Herdewijn, and Akira Matsuda Current Protocols in Nucleic Acid Chemistry (2005) iii-vii C 2005 by John Wiley & Sons, Inc. Copyright
iii Supplement 24
and analysis. Chapter 7 covers important biophysical and computational methods of nucleic acid analysis, including X-ray crystallography, NMR, and molecular modeling strategies. Mass spectrometric analysis is covered in Chapter 10 along with common purification techniques including HPLC and electrophoresis. Two chapters cover different aspects of the binding of nucleic acids to other molecules. Chapter 8 focuses on protocols for measuring binding mode and affinity of small molecules to DNA, a topic of importance because of the significant numbers of drugs that function by binding to nucleic acids. Chapter 9 includes methods for generating nucleic acid aptamers. Chapter 12 focuses on nucleic acid chemistry as applied to the preparation of oligonucleotide arrays and introduces topics related to the development of nucleic acid related nanotechnology. In Chapter 13, protocols are provided for the synthesis of various phosphorylated derivatives of nucleosides. A newly added Chapter 14 provides protocols for synthesis of modified nucleosides that play an important role in the fight against infectious diseases and cancers.
HOW TO USE THIS MANUAL Format and Organization This publication is available in looseleaf, CD-ROM, Intranet, and online formats. For looseleaf purchasers, binders are provided to accommodate the growth of the manual via the quarterly update service. The looseleaf format of the binder allows easy insertion of new pages, units, and chapters that are added. The index and table of contents are updated with each supplement. Purchasers of the CD-ROM and Intranet versions receive a completely new disc every quarter and should dispose of their outdated discs. The material covered in all formats is identical. Subjects in this manual are organized by chapters, and protocols are contained in units. Units generally describe a method and include one or more protocols with listings of materials, steps and annotations, recipes for unique reagents and solutions, and commentaries on the “hows” and “whys” of the method; there are also “overview” units containing theoretical discussions that lay the foundation for subsequent protocols. Page numbering in the looseleaf version reflects the modular arrangement by unit; for example, page 2.3.5 refers to Chapter 2 (Protection of Nucleosides for Oligonucleotide Synthesis), UNIT 2.3 (Protection of the 5 -Hydroxy Function of Nucleosides), page 5 of that particular unit. Many reagents and procedures are employed repeatedly throughout the manual. Instead of duplicating this information, cross-references among units are used extensively. Crossreferencing helps to ensure that lengthy and complex protocols are not overburdened with steps describing auxiliary procedures needed to prepare raw materials and analyze results. For some widely used techniques (such as gel electrophoresis), readers are referred to APPENDIX 3.
Preface
Introductory and Explanatory Information Because this publication is first and foremost a compilation of laboratory techniques in nucleic acid chemistry, we have not offered extensive instructive material. We have, however, included explanatory information where required to help readers gain an intuitive grasp of the procedures. Some chapters begin with special overview units that describe
iv Supplement 24
Current Protocols in Nucleic Acid Chemistry
the state of the art of the topic matter and provide a context for the procedures that follow. Chapter and unit introductions describe how the protocols that follow connect to one another, and annotations to the actual protocol steps describe what is happening as a procedure is carried out. Finally, the Commentary that closes each protocol unit describes background information regarding the historical and theoretical development of the method, as well as alternative approaches, critical parameters, troubleshooting guidelines, anticipated results, and time considerations. All units contain cited references and many indicate key references to inform users of particularly useful background reading, original descriptions, or applications of a technique.
Protocols Many units in the manual contain groups of protocols, each presented with a series of steps. The basic protocol is presented first in each unit and is generally the recommended or most universally applicable approach. Alternate protocols are given where different equipment or reagents can be employed to achieve similar ends, where the starting material requires a variation in approach, or where requirements for the end product differ from those in the basic protocol. Support protocols describe additional steps that are required to perform the basic or alternate protocols; these steps are separated from the core protocol because they might be applicable to other uses in the manual, or because they are performed in a time frame separate from the basic protocol steps. Reagents and Solutions Reagents required for a protocol are itemized in the materials list before the procedure begins. Many are common stock solutions, others are commonly used buffers or media, whereas others are solutions unique to a particular protocol. Recipes for the latter solutions are supplied in each unit under the heading Reagents and Solutions. It is important to note that the names of some of these special solutions might be similar from unit to unit (e.g., SDS sample buffer) while the recipes differ; thus, it is essential to ensure that reagents are prepared from the proper recipes. On the other hand, recipes for commonly used stock solutions and buffers are listed once in APPENDIX 2A. These universal recipes are cross-referenced parenthetically in the materials lists rather than repeated with every usage. Commercial Suppliers In some instances throughout the manual, we have recommended commercial suppliers of chemicals, biological materials, or equipment. This has been avoided wherever possible, because preference for a specific brand is subjective and is generally not based on extensive comparison testing. Our guidelines for recommending a supplier are that (1) the particular brand has actually been found to be of superior quality, or (2) the item is difficult to find in the marketplace. The purity of chemical reagents frequently varies with supplier. Generally reagent grade chemicals are preferred. Special care must be paid to procedures that require dry solvents. Different suppliers provide special anhydrous grade solvents which may vary in water content depending on the supplier. Addresses, phone numbers, facsimile numbers, and Web sites of all suppliers mentioned in this manual are provided in the SUPPLIERS APPENDIX.
Safety Considerations Anyone carrying out these protocols will encounter the following hazardous or potentially hazardous materials: (1) radioactive substances, (2) toxic chemicals and carcinogenic or
Current Protocols in Nucleic Acid Chemistry
v Current Protocols in Nucleic Acid Chemistry
Supplement 24
teratogenic reagents, (3) pathogenic and infectious biological agents, and (4) recombinant DNA. Most governments regulate the use of these materials; it is essential that they be used in strict accordance with local and national regulations. Cautionary notes are included in many instances throughout the manual, but we emphasize that users must proceed with the prudence and precaution associated with good laboratory practice, and that all materials must be used in strict accordance with local and national regulations.
Reader Response The protocols included in this manual are used routinely by the authors who contribute them, and many are used in our own laboratories. To make them work for you, the authors have annotated critical steps and included critical parameters and troubleshooting guides in the commentaries to most units. However, the successful evolution of this manual depends upon readers’ observations and suggestions. Consequently, a selfmailing reader-response survey is included with each print supplement; we encourage readers to send in their comments. Electronic contact information is available at http://www3.interscience.wiley.com/c p/index.htm. ACKNOWLEDGMENTS This manual is the product of dedicated efforts by many of our scientific colleagues who are acknowledged in each unit, and by the hard work of the Current Protocols editorial staff at John Wiley & Sons, including Joe Ingram, Scott Holmes, Tom Cannon, Susan Lieberman, Allen Ranz, and Joseph White. The publisher’s commitment and continuing support for a nucleic acid chemistry manual have been essential for realizing and continuing this ambitious project. We are extremely grateful for the critical contributions made by Ann Boyle, who played a key role in bringing the initial project to completion, and to Beth Harkins, who continues to keep editors and contributors on track. Finally, we gratefully acknowledge the significant role of past editors Roger Jones and Gary Glick in developing Current Protocols in Nucleic Acid Chemistry during its first half-decade.
LITERATURE CITED Zorbach, W.W. and Tipson, R.S. (eds.) 1968. Synthetic Procedures in Nucleic Acid Chemistry, Vols. 1 and 2. Interscience Publishers, New York. Townsend, L.B. and Tipson, R.S. (eds.) 1978. Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods and Techniques, Parts I and II. John Wiley & Sons, New York. Townsend, L.B. and Tipson, R.S. (eds.) 1986. Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods and Techniques, Part III. John Wiley & Sons, New York. Townsend, L.B. and Tipson, R.S. (eds.) 1991. Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods and Techniques, Part IV. John Wiley & Sons, New York.
RECOMMENDED BACKGROUND READING Blackburn, G.M. and Gait, M.G. 1996. Nucleic Acids in Chemistry Biology, 2nd ed., IRL Press, London General introduction to fundamental aspects of nucleic acid chemistry. Hecht, S.M. 1996. Bioorganic Chemistry: Nucleic Acids. Oxford University Press, New York. Barton, D., Nakanishi, K., and Meth-Cohn, O. 2000. Comprehensive Natural Products Chemistry, Vol. 7: DNA and Aspects of Molecular Biology (E.T. Kool, ed.), Elsevier Science, London. Overviews of many important topics related to nucleic acid chemistry, structure, and biochemistry. De Clercq, E. and Herdewijn, P. 2005. Strategies in the design of antiviral drugs. In Drug Discovery Handbook, pp. 1135-1190. Wiley Intersciences, Hoboken, N.J. Overview of the design and synthesis of nucleoside analog antiviral agents.
Preface
Nelson, D.L. and Cox, M.M. 2004. Lehninger Principles of Biochemistry, 4th ed. W.H. Freeman and Company, New York. Basic biochemistry text that includes fundamentals of nucleic acid biochemistry.
vi Supplement 24
Current Protocols in Nucleic Acid Chemistry
Neidle, S. 1999. Oxford Handbook of Nucleic Acid Structure. Oxford University Press, Oxford. Neidle, S. 2002. Nucleic Acid Structure and Recognition, Oxford University Press, Oxford. The 1999 Oxford Handbook contains the most extensive and comprehensive coverage on nucleic acid structure. Gesteland, R.F., Cech, T.R., and Atkins, J.F. 1999. The RNA World, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. Reviews on many current topics in RNA biochemistry, chemistry and structure. Hartmann, R.K., Binderelf, A., Sch¨on, A. and Westhof, E. 2005. Handbook of RNA Biochemistry. John Wiley & Sons, Hoboken, N.J. Includes current laboratory techniques and protocols. Zubrick, J.W. 2003. The Organic Chem Lab Survival Manual, A Student’s Guide to Techniques, 6th ed. John Wiley & Sons, Hoboken, N.J. Laboratory manual that describes very basic techniques for synthetic chemistry. Silverstein, R.M., Webster, F.X., and Kiemle, D. 2004. Spectrometric Identification of Organic Compounds, 7th ed. John Wiley & Sons, Hoboken, N.J. Explores the identification of organic compounds by mass spectrometry, infrared spectrometry, and nuclear magnetic resonance spectrometry. Lee, T.A. 1998. A Beginner’s Guide to Mass Spectral Interpretation. John Wiley & Sons, New York. Identification of organic compound by mass spectrometry, emphasizing recognition of typical fragmentation patterns for different types of organic compounds. Macomber, R.S. 1998. A Complete Introduction to Modern NMR Spectroscopy. John Wiley & Sons, New York. Clear, accessible coverage of modern NMR spectroscopy methods.
Serge L. Beaucage, Donald E. Bergstrom, Piet Herdewijn, and Akira Matsuda
Current Protocols in Nucleic Acid Chemistry
vii Current Protocols in Nucleic Acid Chemistry
Supplement 24
Foreword Nucleic acid chemistry has developed at an accelerating pace in recent years. Today one can rapidly synthesize long DNA and RNA strands of any desired nucleotide sequence on a multigram to microgram scale. “DNA chips” containing thousands of different synthetic oligonucleotides, each at a unique, defined site on a 1 × 1–cm glass plate, can also be made. Elegant methods are available to prepare and incorporate into oligonucleotides a great variety of monomers containing tailored bases, sugars, and bridging units. Powerful analytical techniques, including high performance liquid chromatography, capillary gel electrophoresis, UV and laser spectroscopy, and mass spectrometry, enable rapid separation and characterization of polynucleotides. Advances in NMR spectroscopy and X-ray crystallography have broadened the horizons for structural elucidation, and sophisticated computational programs can now generate useful theoretical models to guide research. These and related developments provide current researchers with unprecedented problem-solving power and opportunities for discovery and invention. Yet the very breadth of the knowledge and the pace of innovation pose significant challenges for serious investigators seeking to capitalize on these advances. This manual, Current Protocols in Nucleic Acid Chemistry, brings together in one volume state-of-the-art protocols for the synthesis, isolation, characterization, modification, and design of a wide variety of compounds in the nucleic acid family. It will prove very useful for experts and practitioners working in the nucleic acid field. An attractive additional feature is a series of quarterly supplements that will describe new and improved methodologies as they emerge. These will be incorporated into the existing manual. Oligonucleotides and related derivatives are unique recognition molecules. They bind reversibly with high selectivity to polymers containing complementary nucleotide sequences, and key rules governing formation of the complexes are well established. Since very large numbers of different oligomers can be generated from different combinations of the four main building blocks, oligonucleotide chemistry offers unique opportunities for rationally designing a wide variety of self-assembling systems exhibiting predesignated properties. Increasingly, scientists in other disciplines are using synthetic oligonucleotides, modified oligonucleotides, or oligonucleotide conjugates as tools in their research. The impact of the chemistry has been greatest in molecular biology, where synthetic oligonucleotides now play an essential role as primers in sequencing and amplifying DNA, as models and probes for elucidating the structure and function of DNA and RNA, and as building units for the synthesis and modification of genes. Applications of oligonucleotide conjugates as nonradioactive probes in diagnostic medicine are expanding rapidly; a variety of modified oligonucleotides show promise as highly selective therapeutic agents; organic and inorganic chemists are finding oligonucleotides useful as tethers in positioning functional groups in complex assemblies; and an active new research area in materials science is directed toward creating novel materials from nanoparticle-oligonucleotide conjugates. Some visionaries even dream of employing oligonucleotides in building molecular-scale machines and computers. For the researchers from other disciplines who wish to utilize nucleic acid chemistry and for those working at the frontiers of several disciplines, this manual will be a special boon. The comprehensive collection of concise, explicit protocols will enable them to capitalize quickly on the opportunities opened by the advances in nucleic acid chemistry.
CHAPTER 1 Synthesis of Modified Nucleosides INTRODUCTION odified nucleosides have a wide variety of uses—often after incorporation into oligonucleotides—such as attachment to reporter groups and studies of basepairing altered by mutagens, by carcinogens, or by design (Beaucage and Iyer, 1993). This chapter will focus on sugar- and base-modified nucleosides. In keeping with Current Protocols format, the goal of this chapter is not to review the subject, but to provide a set of specific and detailed procedures leading to specific compounds. Within this framework, however, the procedures should enable researchers to undertake syntheses of related compounds that have been reported in the chemical literature.
M
The most widely used reaction in nucleoside chemistry is the sugar-base condensation reaction using the Vorbr¨uggen procedure. This reaction is used for synthesis of sugarmodified as well as base-modified nucleosides. It is a very elegant way to introduce heterocyclic bases at the anomeric center of sugars in a stereoselective manner (in case a 2 -O-acyl group is present for neighboring group participation). This reaction is described in UNIT 1.13. In a closely related unit, the synthesis of 2 -O-β-D-ribofuranosyl nucleosides are described in UNIT 1.14. The same principle is used here for the Lewis acid– catalyzed O-glycosylation reaction, in this case leading to disaccharide nucleosides. This procedure demonstrates the reaction conditions needed for the stereospecific formation of O-glycosidic bonds in nucleosides (with base moieties attached at the anomeric center). Disaccharide nucleosides occur widely in nature, especially as one of the modified nucleosides in tRNA. In some cases, modified nucleosides may themselves serve as key intermediates from which other modified nucleosides of interest can be prepared. For example, the palladiummediated C5 substitution of pyrimidines pioneered by Bergstrom has proved over the years to be a uniquely valuable route to these important compounds (Goodchild, 1990). An understanding of the synthetic procedure detailed in UNIT 1.1 will provide access to a large number of C5-modified pyrimidines. Similarly, UNIT 1.8 describes the synthesis and use of aminoalkyl-modified purine analogs. The palladium-catalyzed cross-coupling reaction for C-C bond formation is also used extensively in the purine field, in efforts to generate bioactive compounds. UNIT 1.16 describes the reaction of 6-chloropurine nucleosides with several organometallic reagents using palladium as catalyst, and these reactions are representative for the field. In addition, the 6-hydroxymethyl congener is used as example for further derivatization reactions, mainly for preparation of fluorinated nucleosides. The enzymatic coupling methods in UNITS 1.2 & 1.6 use enzymatic transglycosylation for synthesis of 2 -deoxyribonucleosides and ribonucleosides, respectively. Although nucleoside 2 -deoxyribosyltransferase is not commercially available at this time, the alternative enzymes (thymidine phosphorylase and purine nucleoside phosphorylase) are available. These routes then provide access to a wide variety of both 2 -deoxyribo- and ribonucleosides. UNIT 1.11 describes the widely used Robins procedure for chemically converting ribonucleosides to 2 -deoxyribonucleosides. Modified nucleosides containing reactive functionality, which have been denoted as “convertible” nucleosides when incorporated into oligonucleotides, are an increasingly
Current Protocols in Nucleic Acid Chemistry 1.0.1-1.0.3, September 2007 Published online September 2007 in Wiley Interscience (www.interscience.wiley.com). DOI: 10.1002/0471142700.nc0100s30 C 2007 John Wiley & Sons, Inc. Copyright
Synthesis of Modified Nucleosides
1.0.1 Supplement 30
important class of compounds, of which the 2-fluoro-2 -deoxyinosine derivative described in UNIT 1.3 is a timely example (Huang et al., 1999). UNIT 1.4 provides a discussion on the topic of unnatural nucleotides with unusual base-pairing properties and of universal nucleotides. UNIT 1.5 continues this topic by providing step-by-step procedures for synthesizing N- or C-nucleosides with a number of specific base analogs. Introduction of a fluorine atom in nucleosides has often led to compounds with a potent biological activity. This was demonstrated in the anti-HIV field, and UNIT 1.12 describes the example of 2 -fluoro-2 ,3 dideoxyadenosine. UNIT 1.7 describes the synthesis of 2 -deoxy-2 -fluoroarabinonucleosides. Oligonucleotides containing these modified bases form stable heteroduplexes with RNA that are substrates for RNase H, which is important to antisense applications. UNIT 1.9 addresses the use of nucleosides with a modified sugar to create hexitol nucleic acids (HNAs). This unit decribes the synthesis of 1,5-anhydrohexitol nucleoside monomers as well as their starting sugar compound. These can be used in automated oligonucleotide synthesis with standard phosphoramidite chemistry to synthesize HNAs, which hybridize to RNA and DNA in a sequence-specific manner and have applications in antisense and antiviral approaches. The altritol building blocks, described in UNIT 1.18, differ from the hexitol building blocks by the presence of an additional hydroxyl group on the sugar moiety. Therefore, altritol nucleic acids (ANAs) can be considered the RNA analogs of HNA. The hybridization properties of HNA and ANA are very similar. ANA can also be used for antisense and siRNA applications, and show excellent hybridization properties when used on arrays. UNIT 1.10 describes preparation of pyrrolo[2,3-d]pyrimidine analogs of 2 -deoxyadenosine, 2 -deoxyguanosine, and 2 -deoxyisoguanosine. The incorporation of these compounds into DNA oligomers is described in UNIT 4.25.
A problem encountered in nucleic acid crystallography is the phasing of data, and the use of selenium-labeled DNA and RNA has proven to be very helpful in this process. The preparation of 2 -methylseleno nucleosides and their corresponding phosphoramidites are described in UNIT 1.15. Procedures are also given for synthesis and purification of the modified oligonucleotides as well as their ligation using T4 RNA/DNA ligase. For molecular diagnostics and gene regulation, the development of caged oligonucleotides provides a useful application of nucleoside modification. The principle is that a biologically active oligonucleotide is made inactive by derivatizing some of its nucleobases with a photolabile group, which is the cage. The active oligomer can be released using laser (light) at the desired time and location. These tools can also be used for physicochemical studies (for example, to study oligonucleotide folding) and for biological purposes (for example, for the modulation of protein function using aptamers). UNIT 1.17 describes the synthesis of phosphoramidites derivatized with a 2-nitrophenylethyl or 2-nitrophenylpropyl cage; these provide building blocks for synthesis of caged oligonucleotides on an automated synthesizer. Several other chapters in this book describe specific types of nucleoside modifications or modifications for specific purposes. Chapter 2, for instance, describes nucleoside protection, which is essentially the transient modification of a nucleoside moeity to allow selective modification of other moeities during subsequent reactions. Chapter 13 describes nucleoside phosphorylation and related modifications, and Chapters 14 and 15 describe modifications designed for specific biological functionality and for delivery of nucleosides in a prodrug form.
Introduction
1.0.2 Supplement 30
Current Protocols in Nucleic Acid Chemistry
LITERATURE CITED Beaucage, S.L. and Iyer, R.P. 1993. The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications. Tetrahedron 49:6123-6194. Goodchild, J. 1990. Conjugates of olignucleotides and modified oligonucleotides: A review of their synthesis and properties. Bioconjugate Chem. 1:165-187. Huang, H., Chopra, R., Verdine, G.L., and Harrison, S.C. 1999. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 282:1669-1675.
Roger Jones and Piet Herdewijn
Synthesis of Modified Nucleosides
1.0.3 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Palladium-Mediated C5 Substitution of Pyrimidine Nucleosides
UNIT 1.1
One of the most efficient ways to link a reporter group to oligonucleotides is through the incorporation of a modified nucleoside during automated oligonucleotide synthesis. Most techniques, which make use of synthetic oligonucleotides, function by hybridization to a complementary sequence. In order to avoid interference with hybridization, reporter groups should ideally be attached so that they do not interfere with hybridization or destabilize dsDNA. Two different types of tethers are described here—a rigid amidopropynyl linker and a flexible aminoethylthioether linker. The rigid amidopropynyl tether, linked through C5 of deoxyuridine, is sufficiently long and positioned such that a reporter group attached at the distal end lies outside the major groove of a DNA duplex. Basic Protocol 1 describes a detailed procedure for the synthesis of one example of deoxyuridine modified by an amidopropynyl-linked reporter group, 5-(3-nicotinamidopropyn-1-yl)-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyuridine (Fig. 1.1.1). The procedure is general and may be applied to other amidopropynyl-linked functional groups. The nicotinoyl group was used only as an illustration of the strategy for incorporating a functional group on the amimopropynyl tether. For use in oligonucleotide synthesis, the C5-modified deoxyuridine is converted to a 3′-phosphoramite as described in UNIT 3.3. Basic Protocol 2 outlines the synthesis of 5-(3-acetamido-1-thiapropyl)-2′-deoxyuridine (Fig. 1.1.2). In contrast to the amidopropynyl tether, the more conformationally flexible thioether tether was designed to allow positioning of a molecular tool (e.g., chemical cleavage reagent or cross-linking reagent) on a complementary nucleic acid by hybridization of the modified oligonucleotide. The thiapropyl linker is capable of bridging the
O
O l HO
I
NH O
N
4,4'-dimethoxytrityl chloride
O
DMTrO
NH O
N
O
pyridine HO
HO 5-iodo-2'-deoxyuridine
5'-O-(4,4'-dimethoxytrityl)-5-iodo-2'-deoxyuridine
NH2
O
O
propargylamine
Cl N H Cl
N H
nicotinoyl chloride hydrochloride
Pd(PPh3)4 Cul
N
pyridine
N-(3-propyn-1-yl)nicotinamide
O
OCH3
O
N H
NH
N DMTrO
DMTr = H3CO
O
N
O
HO 4,4'-dimethoxytrityl
5-(3-nicotinamidopropyn-1-yl)-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyuridine
Figure 1.1.1 Synthetic scheme for the preparation of 5-(3-nicotinamidopropyn-1-yl)-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyuridine from 5-iodo-2′-deoxyuridine. The structure of 4,4′-dimethoxytrityl (DMTr) is shown in the lower left. Contributed by Mohammad Ahmadian, Douglas A. Klewer, and Donald E. Bergstrom Current Protocols in Nucleic Acid Chemistry (2000) 1.1.1-1.1.18 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Modified Nucleosides
1.1.1
span between two helices. For use in oligodeoxyribonucleotide synthesis, the N-acylated 5-(3-amino-1-thiapropyl)-2′-deoxyuridine is transformed to the 5′-dimethoxytrityl (DMTr) derivative as illustrated in Basic Protocol 1 for 5-iodo-2′-deoxyuridine, and is then converted to the 3′-phosphoramite as described in UNIT 3.3. Support Protocols 1 and 2 describe the preparation of two reagents needed for Basic Protocol 2—N,N′-bis(trifluoroacetyl)cystamine and N-acetoxysuccinimide, respectively. BASIC PROTOCOL 1
SYNTHESIS OF 5-(3-NICOTINAMIDOPROPYN-1-YL)-5′-O-(4,4′DIMETHOXYTRITYL)-2′-DEOXYURIDINE The sequence of reactions outlined here (see Fig. 1.1.1) illustrate conditions that are useful for the synthesis of a wide variety of reporter groups linked through C5 of deoxyuridine. The protocol includes three steps: synthesis of the N-acylated 3-aminopropyne (3-nicotinamidopropyne, in this example), reaction of 5-iodo-2′-deoxyuridine with 4,4′-dimethoxytrityl chloride, and palladium-catalyzed coupling of 3-nicotinamidopropyne with 5′-O-(4,4′-dimethoxytrityl)-5-iodo-2′-deoxyuridine. For the introduction of a different reporter group, 3-aminopropyne can be N-acylated by RCOCl (an acid chloride) or RC(O)OC(O)R (an anhydride) to obtain RC(O)NHCH2C≡CH, in which R is the desired reporter group. CAUTION: All reactions should be run in a suitable fume hood to avoid inhalation of toxic vapors. Materials Nicotinoyl chloride hydrochloride Pyridine, anhydrous Nitrogen (N2) stream Triethylamine, freshly distilled (dried and purified by distillation at atmospheric pressure over calcium hydride; boiling point = 89° to 90°C) Propargylamine, reagent grade (typically 99% pure) Dichloromethane, reagent grade 10% (w/v) hydrochloric acid in water
O
O
O NH
N
dR
(CF3CONHCH2CH2S)2
NH
2. NaCl
O
N
ClHg
1. Hg(OAc)2
F3C
Li2PdCl4
O
O N H
S
dR
2'-deoxyuridine
NH O
N dR
5-[3-(trifluoroacetamido)-1-thiapropyl]-2'-deoxyuridine
5-chloromercurio-2'-deoxyuridine
O DCC
O N-OH
NH4OH
CH3COH
+
acetic acid
O N-hydroxysuccinamide
O
O
N O O HO
O
dR = HO
H3C
O
O N H
O
S
H2N
NH
S
NH
N-succinimidylacetate N
O
dR
N
O
dR
deoxyribosyl
PalladiumMediated C5 Substitution of Pyrimidine Nucleosides
5-(3-acetamido-1-thiapropyl)-2'-deoxyuridine
5-(3-amino-1-thiapropyl)-2'-deoxyuridine
Figure 1.1.2 Synthetic scheme for the preparation of 5-(3-acetamido-1-thiapropyl)-2′-deoxyuridine from 2′-deoxyuridine. The structure of deoxyribosyl (dR) is shown in the lower left. DCC, dicyclohexylcarbodiimide.
1.1.2 Current Protocols in Nucleic Acid Chemistry
Sodium sulfate, anhydrous Silica gel (230 to 400 mesh) Methanol, reagent grade 5-Iodo-2′-deoxyuridine 4,4′-Dimethoxytrityl chloride Diethyl ether, anhydrous N,N-Dimethylformamide, anhydrous Argon gas (optional) Tetrakis(triphenylphosphine)palladium, [(C6H5)3P]4Pd Copper(I) iodide 5% (w/v) Na2EDTA in water Ethyl acetate, reagent grade 25- and 50-mL round-bottom flasks Inert atmosphere/vacuum manifold (see Fig. 1.1.3) 500-µL and 1-mL syringes with stainless steel needles 125- and 250-mL Ehrlenmeyer flask 100-mL separatory funnel Filter funnel and Whatman no. 1 filter paper Chromatotron and radial chromatography plate coated with silica gel (2-mm thickness; Harrison Research) Rotary evaporator with vacuum pump and water aspirator Glass column (2-cm i.d. × ≥20-cm length) with stopcock Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 4D) Synthesize N-(3-propyn-1-yl)nicotinamide 1. In a dry 25-mL round-bottom flask containing a 1⁄2-in. magnetic stir bar, add 1.068 g nicotinoyl chloride hydrochloride (6 mmol) to 10 mL of anhydrous pyridine under a nitrogen stream. It is important that the flask be dry because nicotinoyl chloride reacts with water to give nicotinic acid. Glassware can be effectively dried by heating in a drying oven at 120°C for 2 hr. A small magnetic stir bar is generally dried at the same time as the flask and added to the flask prior to addition of the reagents. A general setup for running small-scale reactions under a dry nitrogen atmosphere is shown in Figure 1.1.3. The apparatus is configured for air-sensitive palladium-catalyzed reactions. For most other reactions, it is not necessary to bubble nitrogen through the reaction mixture at inlet (b).
2. Add 500 µL triethylamine (700 mg, 7 mmol) with a 1-mL syringe and stainless steel needle, and stir the mixture on a magnetic stirrer at room temperature until the triethylamine is completely in solution. CAUTION: Wear reagent-impermeable protective gloves. Triethylamine and propargylamine are corrosive.
3. Add 250 µL propargylamine (365 mg, 6.6 mmol) dropwise to the reaction mixture with a 500-µL syringe and stainless steel needle, and continue stirring under nitrogen at room temperature for 4 hr. 4. Transfer contents of the flask to a 125-mL Ehrlenmeyer flask containing 40 mL water. Stir the mixture briefly, transfer to a 100-mL separatory funnel, and extract three times with 40 mL reagent-grade dichloromethane.
Synthesis of Modified Nucleosides
1.1.3 Current Protocols in Nucleic Acid Chemistry
Figure 1.1.3 Inert atmosphere/vacuum manifold setup for running reactions in a dry, oxygen-free atmosphere. As shown, the inert gas can be introduced into the reaction flask through stopcock (a) and a hypodermic needle inserted at (b; 14/20 standard taper joint). The slow stream of inert gas then passes through stopcock (d) and out through the gas bubbler. Care must be taken to avoid completely closing the system while the insert gas is being introduced under pressure through the manifold. The setup requires a source of dry nitrogen. For very oxygen-sensitive reactions, the solution is purged by bubbling the inert gas (nitrogen or argon) directly through the solution by lowering the stainless steal hypodermic needle into the solution. The needle is then pulled up above the level of the solution and the flask and condenser evacuated through stopcock (a) with stopcock (d) positioned to allow only the inert gas to pass through to the gas bubbler.
5. Wash the combined organic extracts twice with 20 mL of 10% hydrochloric acid and then once with 10 mL water. 6. Transfer the combined dichloromethane solution to a 250-mL Erlenmeyer flask and add 0.5 g anhydrous sodium sulfate. Swirl the solution for a few minutes and then allow to stand for 30 min. 7. Remove the drying agent by gravity filtration through a filter funnel fitted with Whatman no. 1 filter paper. PalladiumMediated C5 Substitution of Pyrimidine Nucleosides
8. Wash the solid with 10 mL dichloromethane and remove solvent under reduced pressure using a rotary evaporator and water aspirator at room temperature to obtain the crude product.
1.1.4 Current Protocols in Nucleic Acid Chemistry
With a water aspirator and a water bath temperature of 25°C, the dichloromethane can generally be completely removed within 30 min. Longer periods of time may be required for complete removal of other higher-boiling-temperature solvents, such as methanol (step 9).
9. Purify the crude product by radial chromatography according to manufacturer’s instructions using a chromatotron plate with 2-mm silica gel thickness. Elute with 96:4 (v/v) dichloromethane/methanol and collect the effluent in ∼10-mL fractions. The silica gel plates may be purchased from the manufacturer or prepared according to the manufacturer’s instructions. Alternatively, the crude product can be purified by column chromatography on silica gel (230 to 400 mesh; 12 × 2 cm) and eluted with the same solvent to give ∼10-mL fractions.
10. Analyze fractions by thin-layer chromatrography (TLC) on silica gel. Develop TLC plates with 96:4 (v/v) dichloromethane/methanol. 11. Combine all fractions that contain the desired product (Rf = 0.26). Evaporate the solvent under reduced pressure (see step 8) to obtain N-(3-propyn-1-yl)nicotinamide (784 mg, 78%) as a white solid. The compound is stable at room temperature and can be stored in a capped amber glass vial that has been purged with nitrogen. The authors do not generally store the product for >1 month, but it may be stable for a longer period of time. Unless otherwise specified, all intermediates synthesized as part of this protocol are stored under these conditions.
12. Analyze the product by mass spectrometry (MS) and by proton and carbon nuclear magnetic resonance (NMR) spectroscopy. N-(3-Propyn-1-yl)nicotinamide has the following spectroscopic characteristics: MS-EI 160 (M+), 106, 78 MS-CI 161 (M + H)+ H NMR 250 MHz (CHCl3-d1) d 9.0 (d, J = 1.6 Hz, H-2 aromatic, 1H), 8.74 (m, H-6, 1H), 8.16 (m, H-5, 1H), 7.41 (m, H-4, 1H), 6.79 (br s, H-N, 1H), 4.28 (dd, J1 = 5.2 Hz, J2 = 2.5 Hz, N-CH2-, 2H), 2.32 (t, J = 2.5 Hz, CCH, 1H)
1
C NMR 62.9 MHz (CHCl3-d1) δ 29.90, 72.32, 79.0, 123.62, 135.26, 147.94, 152.61
13
Analysis calculated for C9H8N2O: C, 67.5; H, 5.0; N, 17.5; observed: C, 67.24; H, 4.82; N, 17.65. All values are given as percentages. The same procedure may be used for the synthesis of other amide derivatives of propargylamine from carboxylic acid chlorides or anhydrides. The Rf and the spectral characteristics will differ depending on the nature of the acyl group.
Synthesize 5′-O-(4,4′-dimethoxytrityl)-5-iodo-2′-deoxyuridine 13. In a 50-mL round-bottom flask containing a 3⁄4-in. egg-shaped magnetic stir bar, dissolve 354 mg of 5-iodo-2′-deoxyuridine (1 mmol) in 10 mL anhydrous pyridine. CAUTION: The reaction must be performed in a well-vented fume hood. This reaction is sensitive to water, and anhydrous solvent(s) must be used under inert atmosphere. Anhydrous pyridine obtained in Sure/Seal bottles (e.g., Aldrich) is suitable for use in this reaction without further drying. Otherwise, the pyridine should be dried over solid KOH and distilled over Linde type 5Å molecular sieves and solid KOH. Pyridine has a fairly high boiling point (115°C).
14. Evaporate approximately half the solvent using a rotary evaporator connected to a vacuum pump.
Synthesis of Modified Nucleosides
1.1.5 Current Protocols in Nucleic Acid Chemistry
It is advisable to use a vacuum pump rather than a water aspirator in order to rapidly evaporate the pyridine. This procedure removes water from the reaction mixture that may have been associated with the nucleoside by way of a pyridine-water azeotrope. With a good vacuum (<1 mmHg) it is possible to concentrate the reaction mixture in 10 to 30 min.
15. Add 406 mg 4,4′-dimethoxytrityl chloride (1.2 mmol) to the resulting solution and stir the mixture overnight at room temperature under a dry nitrogen atmosphere (Figure 1.1.3). In this case it is not necessary to bubble nitrogen through the reaction mixture. The apparatus shown in Figure 1.1.3 provides a means to keep the reaction mixture dry. 4,4′-Dimethoxytrityl chloride may deteriorate if stored for long periods of time. The reagent should be light orange in color; do not use if it appears red. Although the reaction with 5-iodo-2′-deoxyuridine is allowed to run overnight, with pure reagents the reaction is typically compete within 1 to 2 hr.
16. Add 15 mL ice-cold water to the reaction mixture and then extract twice with 20 mL dichloromethane. 17. Combine the two organic extracts, wash with 10 mL water, and dry over anhydrous sodium sulfate (step 6). 18. Remove the drying agent, wash, and remove solvent as described (steps 7 and 8). 19. Dissolve the residue in ∼0.5 mL dichloromethane, introduce the resulting solution to a 10 × 2–cm column of 230- to 400-mesh silica gel, and elute with 98:2 (v/v) dichloromethane/methanol. 20. Collect the effluent in ∼10-mL fractions and analyze by TLC on silica gel. Develop the plates with 98:2 (v/v) dichloromethane/methanol. 21. Combine fractions that contain the desired product (Rf = 0.36) and evaporate the solvent under reduced pressure (step 8). 22. Add 2 mL anhydrous diethyl ether to the residue and evaporate under vacuum (step 8). Repeat this step until a white foam (646 mg, 98.5% yield) is obtained. It is important to continue the evaporation until a foam is obtained. Otherwise, the product will contain unacceptable amounts of solvents that may interfere with the subsequent reaction. This can generally be accomplished by using a rotary evaporator connected to a water aspirator, with the flask partially immersed in a room temperature water bath. The product may be stored under dry nitrogen in an amber bottle in the dark for a few weeks.
23. Analyze the product by mass spectrometry and by proton and carbon NMR spectroscopy. 5′-O-(4,4′-Dimethoxytrityl)-5-iodo-2′-deoxyuridine has the following spectroscopic characteristics: 1 H NMR 250 MHz (CHCl3-d1) d 8.38 (s, N3-H, 1H), 8.13 (s, H-6, 1H), 7.46 to 7.23 (m, DMTr aromatic protons, 9H), 6.85 (d, J = 8.8 Hz, DMTr aromatic protons, 4H), 6.30 (dd, J1 = 7.6 Hz, J2 = 5.5 Hz, H-1′, 1H), 4.54 (m, H-3′, 1H), 4.08 (m, H-4′, 1H), 3.80 (s, OCH3, 6H), 3.40 (m, H-5′, 2H), 2.33 and 2.44 (two sets of multiplets, H-2′, 2H), 1.98 (br s, 3′-OH, 1H)
PalladiumMediated C5 Substitution of Pyrimidine Nucleosides
C NMR 62.9 MHz (CHCl3-d1) d 159.83, 158.66, 149.7, 144.26, 135.39, 135.28, 130.08, 128.11, 128.01, 127.10, 123.80, 113.37, 87.06, 86.45, 85.55, 72.46, 68.51, 63.41, 55.27, 41.46
13
MS-PD m/z calculated for C30H29IN2O7: 656; observed: 656 (M+).
1.1.6 Current Protocols in Nucleic Acid Chemistry
The same procedure may be applied to other C5-substituted deoxyuridine derivatives such as 5-(3-acetamido-1-thiapropyl)-2′-deoxyuridine or 5-(3-trifluoroacetamido-1-thiapropyl)-2′-deoxyuridine (see Basic Protocol 2). The Rf and spectral characteristics will differ depending on the nature of the C5 substituent.
Synthesize 5-(3-nicotinamidopropyn-1-yl)-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyuridine 24. In a two-neck 25-mL round-bottom flask containing a 1⁄2-in. magnetic stir bar (see Fig. 1.1.3), dissolve 328 mg of 5′-O-(4,4′-dimethoxytrityl)-5-iodo-2′-deoxyuridine (0.5 mmol; step 22) in 4 mL anhydrous N,N-dimethylformamide. Anhydrous N,N-dimethylformamide obtained in Sure/Seal bottles (Aldrich) may be used without further drying. Alternatively, N,N-dimethylformamide may be dried by distillation at reduced pressure (boiling point = 76°C at 39 mmHg) over Linde type 4Å molecular sieves.
25. Remove any dissolved oxygen in the solution by alternating three times between a vacuum and inert gas (dry nitrogen or argon) in the reaction apparatus. As shown in Figure 1.1.3, the inert gas can be introduced directly to the solution through a tube attached at stopcock (a) and a hypodermic needle inserted at (b). When pulling a vacuum through stopcock (a), the needle must be lifted above the solution in the flask. The subsequent coupling reaction proceeds by way of a zero-valent palladium complex. Although the dry reagents may be weighed out in the atmosphere, the reaction is very sensitive to oxygen once the reagents are in solution. A complex mixture of products may result if all oxygen is not removed from the system at this point.
26. Add the following reagents in the order indicated and then stir the reaction mixture at room temperature under nitrogen for 8 hr. 300 µL freshly distilled triethylamine (218 mg, 2.15 mmol) 240 mg N-(3-propyn-1-yl)nicotinamide (1.5 mmol; step 10) 58 mg tetrakis(triphenylphosphine)palladium (0.05 mmol) 19 mg copper(I) iodide (0.1 mmol). Experience with many different alkyne-coupling reactions has shown that it is not always possible to predict which palladium reagent will work most effectively. In some cases (e.g., with 3,3-dimethoxypropyne), bis(triphenylphosphine)palladium dichloride is more effective.
27. Add 10 mL of 5% Na2EDTA to the reaction mixture and extract twice with 30 mL dichloromethane. 28. Combine extracts and wash with 10 mL water. Dry the organic solution over anhydrous sodium sulfate (step 6). 29. Remove sodium sulfate by filtration (step 7), wash, and evaporate the solvent (step 8) to obtain the crude product as a foamy solid. 30. Purify the crude product by radial chromatography as in step 9, but elute with 50:50:5 (v/v/v) ethyl acetate/dichloromethane/methanol. Alternatively, the crude product can be purified by column chromatography on silica gel (230 to 400 mesh; 10 × 2 cm) and eluted with 99:1 (v/v) dichloromethane/methanol.
31. Analyze fractions by TLC on silica gel. Develop TLC plates with 99:1 (v/v) dichloromethane/methanol.
Synthesis of Modified Nucleosides
1.1.7 Current Protocols in Nucleic Acid Chemistry
32. Combine all fractions that contain the desired product (Rf = 0.39). Evaporate the solvent under reduced pressure (step 8). 33. Add 2 mL diethyl ether to the residue and evaporate under vacuum (step 8). Repeat this step until a white foam (215 mg, 62.5% yield) is obtained. The product may be stored a short period of time (a few weeks) under nitrogen in an amber bottle. Normally, it is converted immediately to the phosphoramidite for incorporation into an oligonucleotide.
34. Analyze the product by mass spectrometry and by proton and carbon NMR spectroscopy. 5′-O-(4,4′-Dimethoxytrityl)-5-(3-nicotinamidopropyn-1-yl)-2′-deoxyuridine has the following spectroscopic characteristics: 1 H NMR 500 MHz (CHCl3-d1) d 12.84 (s, N3-H, 1H) 8.90 (d, J = 1.5, H-2 pyridine ring, 1H), 8.68 (dd, J1 = 4.5 Hz, J2 = 2 Hz, H-4 pyridine moiety, 1H), 8.22 (s, H-6 pyrimidine moiety, 1H), 7.90 (m, H-6 pyridine moiety, 1H), 7.65 (s, NH-CO-,1H), 7.47 to 7.17 (several sets, m, DMTr aromatic protons overlapped with H-5 pyridine ring, 10H), 6.80 (d, J = 7 Hz, DMTr aromatic protons, 4H), 6.14 (t, J = 10 Hz, H-1′, 1H), 4.59 (m, H-3′, 1H), 4.18 (m, -CH2N- and H-4′, 3H), 3.85 (s, OCH3, 6H), 3.35 (m, H-5′, 1H), 3.45 (m, H-5′′, 1H), 2.56 (m, H-2′, 1H), 2.32 (m, H-2′′, 1H) 13 C NMR 62.9 MHz (CHCl3-d1) d 162.42, 158.30, 151.84, 149.61, 149.18, 148.47, 148.26, 142.75, 135.58, 135.40, 135.19, 134.80, 129.79, 129.50, 127.72, 126.66, 123.33, 123.23, 122.94, 122.54, 113.05, 86.70, 65.61, 70.83, 63.42, 54.95, 41.69, 30.32
MS-CI m/z calculated for C39H36N4O8: 688; observed: 689 (M + H)+ MS-PD m/z observed: 688.8 (M)+, 303 (DMTr)+ Analysis calculated for C39H36N4O8: C, 68.01; H, 5.21; N, 8.13; observed: C, 67.72; H, 5.26; N, 8.31. All values are given as percentage. Other alkynes will give 5-substituted 2′-deoxyuridine products with different Rf values and spectral characteristics. BASIC PROTOCOL 2
SYNTHESIS OF 5-(3-ACETAMIDO-1-THIAPROPYL)-2′-DEOXYURIDINE This protocol describes synthesis of 5-(3-acetamido-1-thiapropyl)-2′-deoxyuridine. The sequence of reactions outlined here (Fig. 1.1.2) illustrates conditions useful for the synthesis of different functional groups linked through an aminothiapropyl tether to C5 of deoxyuridine. The protocol includes four steps: preparation of 5-chloromercurio-2′deoxyuridine, palladium-mediated coupling with N,N′-bis(trifluoroacetyl)cystamine, removal of the trifluoroacetyl protecting group by ammonia, and coupling of an active ester to the pendant amino group. The latter reaction is illustrated with the active ester N-acetoxysuccinimide. Other active esters may be used to link modifying groups to the aminothiapropyl tether. For example, a modified nucleoside that has a bipyridine ligand linked to the amino group of 5-(3-amino-1-thiapropyl)-2′-deoxyuridine was synthesized via an active ester of 4-carboxy-4′-methylbipyridine. This modified nucleotide was used to prepare oligonucleotides that function as metal-mediated sequence-specific nucleases (Bergstrom and Chen, 1996). CAUTION: Mercuric acetate and organomercury compounds are highly toxic. Wear gloves and properly dispose of all waste materials generated by this procedure.
PalladiumMediated C5 Substitution of Pyrimidine Nucleosides
Materials 2′-Deoxyuridine Mercury(II) acetate
1.1.8 Current Protocols in Nucleic Acid Chemistry
30% (w/v) and 0.1 M sodium chloride (reagent grade) in water Ethanol, anhydrous Diethyl ether, anhydrous N,N′-Bis(trifluoroacetyl)cystamine (see Support Protocol 1) 0.1 M Li2PdCl4 solution (see recipe) Hydrogen sulfide (H2S) Methanol, reagent grade Chloroform, reagent grade Silica gel (230 to 400 mesh) Concentrated ammonium hydroxide Dry ice/acetone (for freezing) N-Acetoxysuccinimide (see Support Protocol 2) Triethylamine, freshly distilled (dried and purified by distillation at atmospheric pressure over calcium hydride; boiling point = 89° to 90°C) Tetrahydrofuran, anhydrous Ethyl acetate, reagent grade 100- and 200-mL round-bottom flasks Temperature-controlled magnetic stirrer Mortar and pestle Whatman no. 1 filter paper 100-mm-diameter porcelain Buchner funnel Rotary evaporator with water aspirator Glass chromatography column (2-cm i.d. × ≥20-cm length) with stopcock Lyophilizer Synthesize 5-chloromercurio-2′-deoxyuridine 1. Dissolve 7.094 g of 2′-deoxyuridine (31.09 mmol) in 30 mL water in a 200-mL round-bottom flask and add a 1-in. magnetic stir bar. 2. Dissolve 10.449 g mercury(II) acetate (32.8 mmol) in 45 mL water and add to the deoxyuridine. 3. Add 25 mL water and stir on a magnetic stirrer at 50°C for 2 hr. During the course of the reaction, a dense white suspension of acetoxymercuriodeoxyuridine is formed. This is converted to the chloromercurio derivative in step 4.
4. While stirring, cool the reaction to 40°C and add 15 mL of 30% sodium chloride (4.5 g, 0.077 moles). 5. Cool the reaction mixture to room temperature and filter the solution using a 100-mm-diameter porcelain Buckner funnel and Whatman no. 1 filter paper. 6. Wash the fine white precipitate sequentially with 60 mL of 0.1 M NaCl, 40 mL water, 20 mL ethanol, and 30 mL anhydrous diethyl ether. 7. Dry the white precipitate in a vacuum oven under vacuum at 80°C to obtain 5-chloromercurio-2′-deoxyuridine (13.95 g; 97% yield; melting point = 210.5° to 211°C). 5-Chloromercurio-2′-deoxyuridine is neither water nor air sensitive. It has been successfully stored without decomposition in amber bottles at room temperature for >5 years.
8. Analyze the product by IR, UV, and 1H NMR spectroscopy. 5-Chloromercurio-2′-deoxyuridine has the following spectroscopic characteristics:
Synthesis of Modified Nucleosides
1.1.9 Current Protocols in Nucleic Acid Chemistry
H NMR (1.0 M KCN/D2O) d 7.70 (s, 1H), 6.35 (t, 1H, J = 6.5 Hz), 4.47 (m, 1H), 3.99 (m, 1H), 3.83 (m, 2H), 2.36 (2H, dd, J = 6 Hz) 1
IR (KBr) 3365, 1714, 1642, 1440, 1275, 1089, 1040 cm −1 UV (pH 1.0) lmax 266 (ε = 10,440),lmin 239 (ε = 4,180); (pH 9.0)lmax 266 (e = 10,120), lmin 242 (e = 5,440); (pH 12.3) lmax 267 (e = 8,870),lmin 253 (e = 7,070) Analysis calculated for C9H11N2O5HgCl: C 23.34; H 2.39; N 6.05; observed: C 23.54; H 2.32; N 5.89.
Synthesize 5-[3-(trifluoroacetamido)-1-thiapropyl]-2′-deoxyuridine 9. Grind 5-chloromercurio-2′-deoxyuridine to a fine powder using a mortar and pestle. CAUTION: In the process of grinding, the powder tends to accumulate static electricity and may be difficult to contain in the mortar and pestle. The mortar should be placed on a surface that can be easily cleaned. It is preferable to carry out this step in a hood to avoid breathing the powder. Grind ≥10% more material than required for the subsequent step to make up for loss that occurs during this process.
10. Place 0.926 g finely ground 5-chloromercurio-2′-deoxyuridine (2.0 mmol) and 1.720 g N,N′-bis(trifluoroacetyl)cystamine (5 mmol) in a 100-mL round-bottom flask. 11. Add 40 mL of 0.1 M Li2PdCl4 solution to the flask and stir on a magnetic stir plate for 16 hr at ambient temperature. The mixture turns orange to yellow shortly after the reagents are combined, and usually yields a clear orange-yellow solution within a few hours.
12. Rapidly bubble hydrogen sulfide through the solution for 30 sec. Filter the mixture through a filter funnel by gravity filtration through Whatman no. 1 filter paper, and wash the solid with 20 mL reagent-grade methanol. CAUTION: Hydrogen sulfide gas is highly toxic. All operations should be conducted in a well-ventilated fume hood. Hydrogen sulfide may be obtained in 1⁄2-lb (227-g) lecture bottles.
13. Using a rotary evaporator with a water aspirator, evaporate the solvent from the filtrate under reduced pressure to give an oil. Because the methanol solution still contains hydrogen sulfide gas, this evaporation should be done using a rotary evaporator located inside a fume hood. Water aspirator pressure is normally sufficient to remove the methanol within 30 min at room temperature.
14. Purify the crude product on a 12 × 2–cm, 230- to 400-mesh silica gel column, eluting with a linear chloroform/methanol gradient ranging from 10% to 18% methanol. 15. Combine fractions that contain material with Rf = 0.30 (CH3OH-CHCl3 1:9 v/v) or Rf = 0.71 (CH3OH-CHCl3 1:3 v/v), and evaporate the solvent on a rotary evaporator using a water aspirator to obtain 5-[3-(trifluoroacetamido)-1-thiapropyl]-2′-deoxyuridine (0.41 g; 51% yield). 5-[3-(Trifluoroacetamido)-1-thiapropyl]-2′-deoxyuridine is neither water nor air sensitive. It can be stored without decomposition in amber bottles at room temperature for many years.
16. Analyze the product by MS and by IR, 1H, and 13C NMR spectroscopy. PalladiumMediated C5 Substitution of Pyrimidine Nucleosides
5-[3-(trifluoroacetamido)-1-thiapropyl]-2′-deoxyuridine has the following spectroscopic characteristics: MS-FAB m/z calculated for C13H16F3N3O6S: 399.071; observed: 400.079 (M + H)+
1.1.10 Current Protocols in Nucleic Acid Chemistry
H NMR 300 MHz (CH3OH-d4) d 8.32 (s, 1H, H-6), 6.27 (t, 1H, J = 6.6 Hz, H-1′), 4.43 (m, 1H, H-3′), 3.95 (m, 1H, H-4′), 3.79 (m, 2H, H-5′), 3.47 (t, 2H, J = 6.0 Hz, H-3′′), 2.87 (m, 2H, H-2′), 2.32 (t, 2H, J = 6.0 Hz, H-2′′) 1
13
C NMR 125 MHz (CH3OH-d4) 164.5 (C4), 159.0 (q, J = 286.6 Hz, C5′′), 106.8 (C5), 89.0 (C1′), 86.8 (C4′), 72.0 (C3′), 62.7 (C5′), 41.4 (C2′), 39.7 (C3′′), 33.5 (C2′′) IR (KBr): 3550-2900 (br, O-H), 3423, 3443 (N-H), 1723, 1692, 1651 (C=O), 1660, 1553, 1461 (C=C), 1179, 1271 cm−1 Analysis calculated for C13H16F3N3O6S: C, 39.08; H, 4.01; N, 10.52; S, 8.03; observed: C, 39.35; H, 3.63; N, 10.38; S, 8.22.
Remove trifluoroacetyl protecting group 17. In a 100-mL round-bottom flask containing a 1-in. magnetic stir bar, dissolve 615 mg of 5-[3-(trifluoroacetamido)-1-thiapropyl]-2′-deoxyuridine (1.5 mmol) in 10 mL methanol. 18. Add 30 mL concentrated ammonium hydroxide, cap the reaction container, and stir at room temperature for 16 hr. 19. Remove excess ammonia and methanol under reduced pressure using a rotary evaporator with a water aspirator. Freeze the remainder of the solution with a mixture of dry ice and acetone. The methanol and ammonia can generally be removed on a rotary evaporator in 30 min or less at room temperature.
20. Remove water by lyophilization and dissolve the remaining solid in 3 mL anhydrous ethanol. Synthesize 5-(3-acetamido-1-thiapropyl)-2′-deoxyuridine 21. Prepare a solution of 315 mg N-acetoxysuccinimide (2 mmol) and 350 µL freshly distilled triethylamine (2.5 mmol) in 2 mL anhydrous tetrahydrofuran. Add to ethanolic solution and stir at room temperature for 4 hr. Other active esters may be used in place of N-acetoxysuccinimide to place a different functional group on the tether. The resulting chromatographic characteristics and spectroscopic properties will change accordingly.
22. Remove the solvent under reduced pressure using a rotary evaporator and a water aspirator to obtain the crude product. 23. Purify the crude product by column chromatography using a 12 × 2–cm silica gel column, and eluting with a gradient of 100% ethyl acetate to 80:20 (v/v) ethyl acetate/methanol. 24. Collect effluent in ∼10-mL fractions and analyze by TLC on silica gel, developing the plates with 85:15 (v/v) ethyl acetate/methanol. 25. Combine all fractions that contain the desired product (Rf = 0.32). Evaporate the solvent under reduced pressure using a rotary evaporator and a water aspirator to obtain 5-[3-acetamido-1-thiapropyl]-2′-deoxyuridine (462 mg; 87% yield) as a white solid. The product may be stored indefinitely under nitrogen in an amber bottle.
26. Analyze the product by MS and by UV, 1H, and 13C NMR spectroscopy. 5-(3-Acetamido-1-thiapropyl)-2′-deoxyuridine has the following spectroscopic characteristics:
Synthesis of Modified Nucleosides
1.1.11 Current Protocols in Nucleic Acid Chemistry
MS-FAB m/z calculated for C13H19N3O6S: 345.1073; observed: 346.1072 (M + H)+ H NMR 300 MHz (CH3OH-d4) d 8.33 (s, H-6, 1H), 6.25 (t, J = 7 Hz, H-1′), 4.41 (m, H-3′, 1H), 3.93 (m, H-4′, 1H), 3.78 (m, H-5′, 2H), 3.31 (m, SCH2-, 2H), 2.78 (t, J = 6 Hz, -CH2N-, 2H), 2.29 (m, H-2′, 2H), 1.95 (s, acetyl group’s CH3, 3H) 1
13
C NMR 125 MHz (DMSO-d6) 169.3, 161.65, 150.0, 142.55, 106.8, 87.54, 84.58, 70.23, 61.1, 39.94, 37.88, 32.1, 22.6 UV (methanol) lmax: 282.4, 202.0 nm Analysis calculated for C13H19N3O6S: C, 45.2; H, 5.5; N, 12.2; S, 9.3; observed: C, 44.88; H, 5.37; N, 12.27; S, 9.32.
SUPPORT PROTOCOL 1
SYNTHESIS OF N,N′-BIS(TRIFLUOROACETYL)CYSTAMINE The trifluoroacetyl group has found wide application as a base-sensitive protecting group. It can be removed by ammonia under the same conditions used to deprotect oligodeoxyribonucleotides following synthesis by the phosphoramidite method. Amines are most commonly converted to trifluoracetyl derivatives by treatment with trifluoroacetic anhydride and a tertiary amine. CAUTION: Both triethylamine and trifluoroacetic anhydride are corrosive. Wear gloves and work only in a suitable hood. Materials Chloroform, reagent grade Cystamine dihydrochloride Triethylamine, freshly distilled (dried and purified by distillation at atmospheric pressure over calcium hydride; boiling point = 89° to 90°C) Trifluoroacetic anhydride 10% (w/v) NaHCO3 2 N HCl Sodium sulfate, anhydrous Methanol, reagent grade Ethyl acetate, reagent grade Hexane, reagent grade 1-liter round-bottom flask Drying tube containing Drierite 5-mL syringe 1-liter separatory funnel Rotary evaporator with water aspirator Vacuum oven at 35°C Buchner funnel and Whatman no. 1 filter paper Synthesize N,N′-bis(trifluoroacetyl)cystamine 1. Filter reagent-grade chloroform through a short column of basic alumina and add 500 mL to a 1-liter round-bottom flask containing a magnetic stir bar and capped by a drying tube containing Drierite. Reagent-grade chloroform typically contains ethanol to inhibit decomposition, which produces HCl. The basic alumina removes the ethanol.
PalladiumMediated C5 Substitution of Pyrimidine Nucleosides
2. Add 9.0 g cystamine dihydrochloride (40 mmol) and 20.2 g triethylamine (27.8 mL, 0.2 mol) to the filtered chloroform.
1.1.12 Current Protocols in Nucleic Acid Chemistry
3. Cool the flask in a cold water bath (0° to 5°C) while slowly adding 1.5 mL trifluoroacetic anhydride (18.5 g, 88 mmol) with a 5-mL syringe. Trifluoroacetic anhydride, which hydrolyzes to trifluoroacetic acid when exposed to water, should be stored in a hood and protected from moisture.
4. Stir the reaction mixture at room temperature overnight. 5. Transfer the reaction mixture to a 1-liter separatory funnel and wash sequentially with 250 mL water, 10% NaHCO3, 2 N HCl, and water again. 6. Dry the chloroform solution over anhydrous sodium sulfate for 1 hr (see Basic Protocol 1, step 6). 7. Add 30 mL reagent-grade methanol, filter to remove the solid sodium sulfate (see Basic Protocol 1, step 7), and evaporate the solvent on a rotary evaporator using a water aspirator to yield a light yellow paste. 8. Add 100 mL of 2 N HCl to give a slurry of light yellow crystals, and stir for 20 min at room temperature. 9. Filter the slurry and wash the solid product with 100 mL of 2 N HCl and then with 100 mL water. 10. Dry the solid product in a vacuum oven at 35°C overnight. The product is of suitable purity for use in palladium coupling reactions. To obtain analytically pure product, recrystallize as described below. The product may be stored indefinitely in a closed bottle at room temperature.
Recrystallize product 11. Dissolve product in a minimum of hot methanol. 12. Slowly add ethyl acetate to the warm methanol solution and allow to cool. On cooling to room temperature, a colorless crystalline product separates (melting point = 111°C).
13. Collect crystals by vacuum filtration through a Buchner funnel using Whatman no. 1 filter paper. 14. Collect a second crop by adding hexane to the warmed methanol/ethyl acetate solution, and cooling and collecting crystals again. The total yield of crystalline product is 10.8 g (84%). The product may be stored indefinitely in a closed bottle at room temperature.
Analyze product 15. Analyze the product by 1H and 13C NMR spectroscopy. H NMR (250 MHz, acetone-d6) d 2.70 (t, CH2 4H, J = 10.4 Hz), 2.68 (q, CH2 4H)
1
C NMR (62.9 MHz, acetone-d6) d 37.2 (CH2, J = 10.4 Hz), 39.6 (CH2), 117.0 (CF3, J = 287 Hz), 157.8 (C=O).
13
SYNTHESIS OF N-ACETOXYSUCCINIMIDE N-Hydroxysuccinamide esters are generally prepared from carboxylic acids by reaction with dicyclohexylcarbodiimide and N-hydroxysuccinimide. The procedure outlined below can be applied to the synthesis of other N-hydroxysuccinimide esters. Active esters of some compound classes (e.g., amino acids) are commercially available.
SUPPORT PROTOCOL 2 Synthesis of Modified Nucleosides
1.1.13 Current Protocols in Nucleic Acid Chemistry
Materials N-Hydroxysuccinamide Tetrahydrofuran, anhydrous Nitrogen (N2) gas Glacial acetic acid Dicyclohexylcarbodiimide (DCC) Silica gel (optional; 230 to 400 mesh) Ethyl acetate, reagent grade Methanol, reagent grade Vacuum manifold apparatus (Fig. 1.1.3) modified with a 10-mL conical flask and a 500-µL syringe Filter funnel and Whatman no. 1 filter paper Glass chromatography column (optional; 2-cm i.d. × 10-cm length) with stopcock 1. In a 10-mL conical flask containing a small magnetic stir bar, prepare a solution of 345.3 mg N-hydroxysuccinamide (3 mmol) in 1 mL anhydrous tetrahydrofuran under an inert atmosphere (e.g., nitrogen). The setup shown in Figure 1.1.3 may be used with the inert gas inlet at (b) replaced by a 500-mL syringe containing glacial acetic acid (step 2). The apparatus is maintained under a positive pressure of nitrogen by the inlet line at (c).
2. Add 174 µL glacial acetic acid (3 mmol). 3. Dissolve 620 mg dicyclohexylcarbodiimide (3 mmol) in 1 mL tetrahydrofuran and add to the reaction mixture. Stir the resulting solution at room temperature overnight (12 hr). 4. Remove the white precipitate (dicyclohexylurea) by filtration through Whatman no. 1 filter paper in a filter funnel. 5. Optional: Purify filtrate on a 10 × 2–cm silica gel column, eluting with 9:1 (v/v) ethyl acetate/methanol. Collect appropriate fractions (Rf = 0.45) and evaporate on a rotary evaporator using a water aspirator to give a white powder melting at 120°C. Although N-acetoxysuccinimide can be used without purification, it is generally preferable to purify if the product is to be stored. The product may be stored indefinitely under dry nitrogen in an amber bottle.
6. Analyze by MS and by proton NMR spectroscopy. The purified product has the following spectroscopic characteristics: Rf = 0.45 (CH2Cl2, silica) 1
H NMR (500 MHz, CHCl3-d1) d 2.84 (s, CH2 4H), 2.34 (s, CH3 3H)
MS-CI calculated for C6H7NO4: 157; observed m/z: 158 (M + H)+.
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX. PalladiumMediated C5 Substitution of Pyrimidine Nucleosides
0.1 M Li2PdCl4 solution 1.77 g PdCl2 (0.01 mol) 0.84 g LiCl (0.02 mol) 70 mL anhydrous methanol Stir at room temperature for 24 hr
1.1.14 Current Protocols in Nucleic Acid Chemistry
Adjust volume to 100 mL with methanol The solution is generally not stored for more than a few weeks in a stoppered flask at room temperature.
COMMENTARY Background Information The C5 position of pyrimidine nucleosides is nearly ideal as a site for tethering molecular reporter groups and other molecular devices to oligodeoxyribonucleotides, as groups of different sizes may be attached without adversely affecting DNA duplex formation. In recent years, a variety of specialized probe moieties such as biotin (Langer et al., 1981; Shimkus et al., 1985; Cook et al., 1988), fluorophores (Prober et al., 1987; Tesler et al., 1989; Hagmar et al., 1995), paramagnetic probes (Spaltenstein et al., 1988, 1989; Kirchner et al., 1990), pendant catalytic moieties (Dreyer and Dervan, 1985; Bashkin et al., 1994; Kwiatkowski et al., 1994; Bergstrom and Chen, 1996; Shah et al., 1996), and cross-linkers (Gibson and Benkovic, 1987; Tabone et al., 1994; Chaudhuri and Kool, 1995; Meyer and Hanna, 1996) have been coupled to deoxyuridine and then incorporated into nucleic acids. The use of C5 linkers to functionalize nucleic acids has been reviewed (Goodchild, 1990). Although many kinds of linkers have been used to attach reporter groups to C5, alkynyl groups appear to be preferable because they enhance duplex stability (Sagi et al., 1993; Ahmadian et al., 1998). Synthesis of 5-carboxamidopropynyl-2′deoxyuridine derivatives was initiated by 4,4′dimethoxytrityl protection of the readily available 5-iodo-2′-deoxyuridine following a standard procedure (Jones, 1984). Tritylation of 5′-hydroxyl of 5-iodo-2′-deoxyuridine prior to the coupling reaction eliminated the need for toluyl protection and deprotection of the nucleoside hydroxyl groups (Robins and Barr, 1981, 1983). Palladium-mediated coupling reactions were carried out in dimethylformamide following a procedure similar to that reported by Hobbs (1989). The steps outlined in the preparation of 5-(3-nicotinamidopropyn-1-yl)-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyuridine provide a blueprint and strategy for the incorporation of many different kinds of reporter groups. As long as the desired reporter group has a reactive acyl functional group (carboxylic acid anhydride, chloride, or active ester), it is likely that it can be coupled to propargylamine and sub-
sequently linked to deoxyuridine by the organopalladium coupling reaction. The thioether-linked deoxyuridine derivative 5-[3-(trifluoroacetamido)-1-thiapropyl]2′-deoxyuridine was synthesized by the procedure reported by Bergstrom et al. (Bergstrom et al., 1991; Ahmadian et al., 1998) via a palladium-mediated reaction of the disulfide N,N′bis(trifluoroacetyl)cystamine with 5-chloromercurio-2′-deoxyuridine. Trifluoroacetyl functions as a base-sensitive protecting group that can be easily removed with aqueous ammonia. Because the trifluoroacetamido group is a poor ligand for palladium, it does not interfere with the palladium-mediated coupling reaction. Groups that are substantially more electron rich (such as acetamido) interfere with the coupling reaction. For this reason, the coupling reaction must be carried out prior to attaching electron-rich ligands to the cystamine amino group. 5-[3-(Trifluoroacetamido)-1-thiapropyl]-2′deoxyuridine may be incorporated into oligonucleotides as its 5′-O-dimethoxytrityl-3′phosphoramidite derivative (procedure not given). The trifluoroacetyl protecting group is subsequently cleaved during the final ammonia deprotection of the oligonucleotide. This leaves the amino group available for conjugation to reporter groups or molecular tools at the oligonucleotide stage. Alternatively, 5-[3-(trifluoroacetamido)-1-thiapropyl]-2′-deoxyuridine may be deprotected and conjugated to the desired reporter groups or molecular tool prior to transformation to the 5′-O-dimethoxytrityl3′-phosphoramidite derivative and incorporation into the oligonucleotide. Synthesis of 5-[3-(trifluoroacetamido)-1thiapropyl]-2′-deoxyuridine requires 5-chloromercurio-2′-deoxyuridine. This intermediate is obtained in high yield by direct electrophilic mercuration of 2′-deoxyuridine with mercuric acetate in aqueous solution (Bergstrom and Ruth, 1977). An important difference between the synthesis of the alkynyl-linked dU and the thioether-linked dU is that the former requires use of a protected dU and must be done with complete exclusion of oxygen, while the latter is not air sensitive and does not require protecting groups.
Synthesis of Modified Nucleosides
1.1.15 Current Protocols in Nucleic Acid Chemistry
Table 1.1.1
Estimated Times for Completion of Syntheses
Protocol Basic Protocol 1
Time (hr) 18 20 15
Basic Protocol 2
Support Protocol 1 Support Protocol 2
16 21 32 36 14
Synthesis N-(3-Propyn-1-yl)nicotinamide 5′-O-(4,4′-Dimethoxytrityl)-5-iodo-2′-deoxyuridine 5-(3-Nicotinamidopropyn-1-yl)-5′-O-(4,4′-dimethoxytrityl)2′-deoxyuridine 5-Chloromercurio-2′-deoxyuridine 5-[3-(Trifluoroacetamido)-1-thiapropyl]-2′-deoxyuridine 5-(3-Acetamido-1-thiapropyl)-2′-deoxyuridine N,N′-Bis(trifluoroacetyl)cystamine N-Acetoxysuccinimide
There are alternative types of linkers as well as alternative methods for preparing alkynyl and thioalkyl linkers. In addition to the alkynyl and thioether linkages described here, alkyl and alkenyl linkers may also be obtained through organopalladium coupling methodology (Bergstrom and Ogawa, 1978). Examples of reporter groups linked through alkyl and alkenyl linkers are included in Literature Cited. The advantage of the alkynyl linker is the ease of preparation of the C5-substituted deoxyuridine that contains the 5′ protecting group (dimethoxytrityl) needed for subsequent oligonucleotide synthesis via the phosphoramidite methodology. In addition to the nicotinamidopropyne coupling reaction, the preparation of a series of other carboxamidopropynyl derivatives has been described (Ahmadian et al., 1998). Since organopalladium reactions can tolerate a wide variety of functional groups (e.g., hydroxyl, amido, carboxamide, ester, cyano, nitro, keto), there may be relatively few limitations on the nature of the group that can be introduced at C5 as a component of carboxamidopropyne. Deoxyuridine C5 substitution is preferred over deoxycytidine N4 or deoxyadenosine N6 substitution because the latter two modifications destabilize doublestranded DNA.
Critical Parameters
PalladiumMediated C5 Substitution of Pyrimidine Nucleosides
The most critical parameter in each reaction is the purity of the reactants and the reagents. Even fresh commercial reagents should be checked by TLC and 1H NMR for purity and identity. 4,4′-Dimethoxytrityl chloride is sensitive to moisture and will deteriorate over time. The best results are obtained with a freshly opened bottle of the reagent. Alternatively, the authors store and transfer 4,4′-dimethoxytrityl chloride in a Vacuum Atmospheres dry box under a dry nitrogen atmosphere (any dry box
should be suitable). The condensation reaction between 5′-O-(4,4′-dimethoxytrityl)-5-iodo2′-deoxyuridine and the alkyne requires airsensitive tetrakis(triphenylphosphine)palladium. This reagent should also be stored and transferred under nitrogen or argon. Again, it is preferable to use freshly opened reagents, as they are supplied in sealed glass ampules that may be difficult to keep free of oxygen once opened. When planning the construction of a C5modified nucleoside for introduction into oligonucleotides, the intermediates must not contain functional groups that are likely to interfere either with phosphoramidite preparation (e.g., hydroxyl) or oligonucleotide synthesis.
Anticipated Results If the procedures are followed as described in this unit, the yields of isolated product should be comparable to that reported here. The palladium-catalyzed coupling reactions are especially sensitive to reagents and conditions. If an alkyne other than the one described in the protocol is used for the procedure, it may be necessary to try palladium catalysts other than tetrakis(triphenylphosophine)palladium. If the products are to be used to construct phosphoramidites for oligonucleotide synthesis, 50 mg of the C5-substituted 4,4′-dimethoxytrityl (DMTr) derivative is generally sufficient to obtain enough product to accomplish one coupling reaction on a 1-µmol synthesis scale.
Time Considerations The time required to complete each procedure is summarized in Table 1.1.1. The estimated times do not include the time necessary to purify solvents. In some cases, these may be purchased and used without further purification.
1.1.16 Current Protocols in Nucleic Acid Chemistry
Literature Cited Ahmadian, M., Zhang, P., and Bergstrom, D.E. 1998. A comparative study of the thermal stability of oligodeoxyribonucleotides containing 5substituted-2′-deoxyuridines. Nucl. Acids Res. 26:3127-3135. Bashkin, J.K., Sondhi, S.M., Sampath, U., d’Avignon, D.A., and Modak, A.S. 1994. Synthesis and connectivity assignment (by 2D-NMR) of a nucleoside-dipeptide: 5-[3-[[2-[[2-[[[2-Amino]1-oxo-3-[1H-imidazol-4-yl]propyl]amino]-1oxo-3-[1H-imidazol-4-yl]propyl]amino]ethyl] amino]-3-oxopropyl]-2′-deoxyuridine. New J. Chem. 18:305-318. Bergstrom, D.E. and Chen, J. 1996. Sequence-specific oligodeoxyribonucletide cleavage by a major-groove-positioned metal-binding ligand tethered to C-5 of deoxyuridine. Bioorg. Med. Chem. Lett. 6:2211-2214. Bergstrom, D.E. and Ogawa, M.K. 1978. C-5 substituted pyrimidine nucleosides. 2. Synthesis via olefin coupling to organopalladium intermediates derived from uridine and 2′-deoxyuridine. J. Am. Chem. Soc. 100:8106-8112. Bergstrom, D.E. and Ruth, J.L. 1977. Preparation of C-5 mercurated pyrimidine nucleosides. J. Carbohydrates Nucleotides Nucleosides 42:257269. Bergstrom, D.E., Beal, P., Jenson, J., and Lin, X. 1991. Palladium-mediated synthesis of C-5 pyrimidine nucleoside thioethers from disulfides and mercurinucleosides. J. Org. Chem. 56:5598-5602. Chaudhuri, N.C. and Kool, E.T. 1995. Very high affinity DNA recognition by bicyclic and crosslinked oligonucleotides. J. Am. Chem. Soc. 117:10434-10442. Cook, A.F., Vuocolo, E., and Brakel, C.L. 1988. Synthesis and hybridization of a series of biotinylated oligonucleotides. Nucl. Acids Res. 16:4077-4095. Dreyer, G.B. and Dervan, P.B. 1985. Sequence-specific cleavage of single-stranded DNA: Oligodeoxynucleotide-EDTA.Fe(II). Proc. Natl. Acad. Sci. U.S.A. 82:968-972. Gibson, K.J. and Benkovic, S.J. 1987. Synthesis and application of derivatizable oligonucleotides. Nucl. Acids Res. 15:6455-6467. Goodchild, J. 1990. Conjugates of oligonucleotides and modified oligonucleotides: A review of their synthesis and properties. Bioconjugate Chem. 1:165-187. Hagmar, P., Bailey, M., Tong, G., Haralambidis, J., Sawyer, W.H., and Davidson, B.E. 1995. Synthesis and characterization of fluorescent oligonucleotides. Effect of internal labelling on protein recognition. Biochim. Biophys. Acta 1244:259-268. Hobbs, F.W. Jr. 1989. Palladium-catalyzed synthesis of alkynylamino nucleosides. A universal linker for nucleic acids. J. Org. Chem. 54:3420-3422. Jones, R.A. 1984. Preparation of protected deoxyribonucleosides. In Oligonucleotide Synthesis: A Practical Approach (M.J. Gait, ed.) pp. 27-28. IRL Press, Washington, D.C.
Kirchner, J.J., Hustedt, E.J., Robinson, B.H., and Hopkins, P.B. 1990. DNA dynamics from a spin probe: Dependence of probe motion on tether length. Tetrahedron Lett. 31:593-596. Kwiatkowski, M., Samiotaki, M., Lamminmaki, U., Mukkala, V.-M., and Landegren, U. 1994. Solidphase synthesis of chelate-labelled oligonucleoties: Application in triple-color ligase-mediated gene analysis. Nucl. Acids Res. 22:2604-2611. Langer, P.R., Waldrop, A.A., and Ward, D.C. 1981. Enzymatic synthesis of biotin-labeled polynucleotides: Novel nucleic acid affinity probes. Proc. Natl. Acad. Sci. U.S.A. 78:66336637. Meyer, K.L. and Hanna, M.M. 1996. Synthesis and characterization of a new 5-thiol-protected deoxyuridine for site-specific modification of DNA. Bioconjugate Chem. 7:401-412. Prober, J.M., Trainor, G.L., Dam, R.J., Hobbs, F.W., Robertson, C.W., Zagursky, R.J., Cocuzza, A.J., Jensen, M.A., and Baumeister, K. 1987. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 238:336-341. Robins, M.J. and Barr, P.J. 1981. Nucleic acid related compounds. 31. Smooth and efficient palladium-copper catalyzed coupling of terminal alkynes with 5-iodouracil nucleosides. Tetrahedron Lett. 22:421-424. Robins, M.J. and Barr, P.J. 1983. Nucleic acid related compounds. 39. Efficient conversation of 5-iodo to 5-alkynyl and derived 5-substituted uracil bases and nucleosides. J. Org. Chem. 48:1854-1862. Sagi, J., Szemzo, A., Ebinger, K., Szabolcs, A., Sagi, G., Ruff, E., and Otvos, L. 1993. Basemodified oligodeoxynucleotides. I. Effect of 5-alkyl, 5-(1-alkenyl) and 5-(1-alkynyl) substitution of the pyrimidines on duplex stability a n d h y d r o p h o b i c i t y. Tetrahedron Lett. 34:2191-2194. Shah, K., Neenhold, H., Wang, Z., and Rana, T.M. 1996. Incorporation of an artificial protease and nuclease at the HIV-1 Tat binding site of transactivation responsive RNA. Bioconjugate Chem. 7:283-289. Shimkus, M., Levy, J., and Herman, T. 1985. A chemically cleavable biotinylated nucleotide: Usefulness in the recovery of protein-DNA complexes from avidin affinity columns. Proc. Natl. Acad. Sci. U.S.A. 82:2593-2597. Spaltenstein, A., Robinson, B.H., and Hopkins, P.B. 1988. A rigid and nonperturbing probe for duplex DNA motion. J. Am. Chem. Soc. 110:12991301. Spaltenstein, A., Robinson, B.H., and Hopkins, P.B. 1989. Sequence- and structure-dependent DNA base dynamics: Synthesis, structure, and dynamics of site and sequence specifically spin-labeled DNA. Biochemistry 28:9484-9495.
Synthesis of Modified Nucleosides
1.1.17 Current Protocols in Nucleic Acid Chemistry
Tabone, J.C., Stamm, M.R., Gamper, H.B., and Meyer, R.B. Jr. 1994. Factors influencing the extent and regiospecificity of cross-link formation between single-stranded DNA and reactive complementary oligodeoxynucleotides. Biochemistry 33:375-383. Tesler, J., Cruickshank, K.A., Morrison, L.E., and Netzel, T. 1989. Synthesis and characterization of DNA oligomers and duplex containing covalently attached molecular labels: Comparison of biotin, fluorescin, and pyrene labels by thermodynamic and optical spectroscopic measurements. J. Am. Chem. Soc. 111:6966-6976.
Contributed by Mohammad Ahmadian Cerus Corp. Concord, California Douglas A. Klewer Texas A&M University College Station, Texas Donald E. Bergstrom Purdue University West Lafayette, Indiana
PalladiumMediated C5 Substitution of Pyrimidine Nucleosides
1.1.18 Current Protocols in Nucleic Acid Chemistry
Enzymatic Synthesis of M1G-Deoxyribose
UNIT 1.2
M1G-deoxyribose (M1G-dR, 1,N2-pyrimido[1,2-α]purin-10(3H)-one, or pyrimidopurinone; see structure in Fig. 1.2.2, below) is an endogenous exocyclic DNA adduct formed by the reaction of the dicarbonyl compound malondialdehyde (MDA) with a deoxyguanosine residue in DNA. M1G-dR is an intermediate in the synthesis of a class of modified oligodeoxyribonucleotides that are used to study the mutagenicity and repair of M1G. This unit presents two methods for synthesizing M1G-dR using enzymatic coupling. The Basic Protocol describes a procedure for coupling the nucleobase to deoxyribose, in a reaction mediated by the enzyme nucleoside 2′-deoxyribosyltransferase, followed by preparation of the modified base (see Fig. 1.2.1A). Preparation of the enzyme is described in the Support Protocol. The Alternate Protocol uses two commercially available enzymes, purine nucleoside phosphorylase and thymidine phosphorylase (see Fig. 1.2.1B). Although the enzyme preparation step is avoided, additional purification steps are required that increase the time needed to complete the synthesis and decrease the yield (see Commentary). NOTE: Use deionized, distilled water in all recipes and protocol steps.
BASIC PROTOCOL
ENZYMATIC COUPLING USING NUCLEOSIDE 2′-DEOXYRIBOSYLTRANSFERASE Nucleoside 2′-deoxyribosyltransferase (trans-N-deoxyribosylase or nucleoside:purine(pyrimidine) deoxyribosyltransferase; E.C. 2.4.2.6) catalyzes the transfer of the deoxyribosyl moiety from a deoxyribonucleoside to any other nucleoside base (see Fig. 1.2.1A). This enzyme is found exclusively in Lactobacilli and related microorganisms that require deoxynucleosides for growth (Carson and Wasson, 1988). The enzyme’s broad specificity makes it a useful tool for synthesizing modified deoxyribonucleotides. This protocol describes the use of this enzyme (see Support Protocol for preparation) to transfer a deoxyriboside from 2′-deoxycytidine to M1G and produce M1G-dR. The two synthesis steps can be carried out in a single flask, which decreases the time needed to purify M1G-dR and significantly increases the yield of the reaction. A
C
HO
O
HO
transferase
HO
O
M1G
HO
M1G
C
B T
HO
O HO
HO
TPase
O HO
HPO42-
T
HO
PNPase
O
M1G
OPO32M1G
HPO42-
HO
Figure 1.2.1 Enzymatic coupling reactions. (A) Reaction catalyzed by nucleoside 2′-deoxyribosyltransferase (Basic Protocol). (B) Reaction catalysed by thymidine phosphorylase and purine nucleoside phosphorylase (Alternate Protocol). Contributed by Nathalie C. Schnetz-Boutaud, Marie-Christine Chapeau, and Lawrence J. Marnett Current Protocols in Nucleic Acid Chemistry (2000) 1.2.1-1.2.8 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Modified Nucleosides
1.2.1
Materials Guanine hydrochloride (Sigma) 1 N HCl Tetraethoxypropane (Aldrich) Methanol (MeOH; Aldrich) Potassium carbonate (Aldrich) Nanopure water (water purified using Nanopure system from Barnstead/Thermolyne) MES (2-[N-morpholino]ethanesulfonic acid; Sigma) 2′-Deoxycytidine (dC; Sigma) 1 N NaOH Nucleoside 2′-deoxyribosyltransferase (transferase; see Support Protocol) Dichloromethane (CH2Cl2; Fisher) 250-mL round-bottom flask Oil bath, 70°C Magnetic stir plate and stir bar Ice bath pH indicator strips Büchner funnel Whatman No. 1 filter paper Shaking incubator, 37°C Silica-gel thin-layer chromatography (TLC) plates Lyophilizer Silica gel (60 to 100 mesh; Fisher) 8 × 50–cm chromatography column Prepare modified base 1. In a 250-mL round-bottom flask, dissolve 1 g (5.3 mmol) guanine hydrochloride in 100 mL of 1 N HCl that has been heated to 70°C using an oil bath. Stir on a magnetic stir plate until dissolved. The dissolution can take from 30 min to 1 hr.
2. Mix 1.3 mL (5.86 mmol) tetraethoxypropane with 1.25 mL methanol. Add this dropwise to the solution from step 1. Slow addition of tetraethoxypropane favors the formation of the modified base and avoids the polymerization of MDA.
3. Let the reaction mixture stir for 30 min on a magnetic stir plate, then cool to 0°C in an ice bath. Cooling moderates the neutralization reaction to follow.
4. Neutralize by slowly adding potassium carbonate to pH 6, verifying the pH using pH indicator strips. Take special care when approaching the desired pH. 5. Remove unreacted guanine by filtering through Whatman no. 1 filter paper on a Büchner funnel under vacuum. Wash the precipitate twice with 20 mL of Nanopure water. The filtrate contains the modified base. The yield of the reaction is estimated at 30%. Enzymatic Synthesis of M1G-Deoxyribose
6. Add MES to a final concentration of 0.5 M. MES is used to buffer the enzymatic reaction.
1.2.2 Current Protocols in Nucleic Acid Chemistry
7. Add 1.2 g (5.3 mmol) 2′-deoxycytidine. 8. Equilibrate the solution to pH 6.0 with 1 N HCl or 1 N NaOH.
Perform enzymatic coupling 9. Add an appropriate amount of nucleoside 2′-deoxyribosyltransferase solution and incubate overnight at 37°C with shaking. Each enzymatic preparation has its own concentration and activity, which must be tested empirically by assaying the preparation’s ability to convert a small quantity of M1G to M1GdR to estimate the amount to use for the full-scale reaction.
10. Check the progress of the reaction by TLC on silica-gel plates using 9:1 (v/v) CH2Cl2/MeOH as the mobile phase. Add 50 mL methanol to 50 mL of reaction mix and spot on TLC plate using a capillary tube. If the reaction is not complete, add more enzyme and dC, but not more than one-fifth the amount used at the start of the reaction, and incubate an additional 6 to 12 hours.
11. Once the reaction is complete, lyophilize the reaction mixture to dryness. 12. Purify the crude product on a silica-gel column using 9:1 (v/v) CH2Cl2/MeOH for equilibration and elution. Elute by gravity and collect 50-mL fractions. The lyophilized reaction mixture may be added directly to the top of the packed column.
13. Confirm the purity of the product by 1H NMR. Store the product under nitrogen at –20°C. Under these conditions, it is stable for several years. A typical spectrum is presented in Figure 1.2.2. The estimated yield is 10% to 15%. O N N
HO
O
8 7
N N
N
6
HO
Figure 1.2.2
1
H NMR spectrum of M 1-GdR in D2O.
Synthesis of Modified Nucleosides
1.2.3 Current Protocols in Nucleic Acid Chemistry
SUPPORT PROTOCOL
PREPARATION OF NUCLEOSIDE 2′-DEOXYRIBOSYLTRANSFERASE Nucleoside 2′-deoxyribosyltransferase was first isolated by McNutt (1952). Partial purification of the enzyme from Lactobacillus leichmannii has been described by Beck and Levin (1963), and its complete purification and crystallization by Uerkvitz (1971). This protocol is based upon the latter method. The partial purification described here is sufficient for obtaining enzyme to be used in the Basic Protocol. Materials Lactobacillus broth AOAC (see recipe) Lactobacillus helveticus culture 0.15 M NaCl (4°C) 50 mM potassium phosphate buffers, pH 6.0 and 6.9 (see APPENDIX 2A; dilute with Nanopure water to desired molarity) 50 mM potassium phosphate, pH 5.1, containing 10 g/L NaCl 250-mL Erlenmeyer flask Centrifuge and rotors (e.g., Sorvall GS-3 and SS-34) Microtip sonicator (Virsonic 100) BCA Protein Assay (Pierce; optional) or equivalent Purify the enzyme 1. Using aseptic technique, place 25 mL of Lactobacillus broth in an Erlenmeyer flask. Add a loopful of Lactobacillus helveticus commercial stock and incubate overnight at 37°C without shaking. 2. Transfer the 25-mL culture into 1000 mL of fresh Lactobacillus broth. Grow 18 hr at 37°C without shaking. 3. Cool to 4°C and divide into centrifuge tubes. Centrifuge the tubes 10 min at 7000 × g (6500 rpm in a GS-3 rotor), 4°C. 4. Resuspend pellets in 100 mL cold 0.15 M NaCl and centrifuge again as in step 3. Repeat. 5. Suspend cell pellets in a total of 20 mL of 50 mM potassium phosphate, pH 6.0. 6. Sonicate 10 times for 1 min each time with a Virsonic 100 microtip sonicator at a setting of 4 to 5. 7. Centrifuge 30 min at 28,000 × g (15,000 rpm in an SS-34 rotor), 4°C. Save the supernatant. 8. Wash the pellets twice by resuspending in a minimal volume of 0.15 M NaCl and centrifuging as in step 7. Save the supernatants. 9. Combine the supernatants from the previous two steps, and dialyze overnight against 4 L of 50 mM potassium phosphate, pH 5.1, containing 10 g/L NaCl. 10. Heat 10 min at 55°C, then immediately place on ice. The heating denatures all heat-sensitive proteins that are present in the extract, thereby enriching for transferase, which is not heat sensitive.
11. Centrifuge again as in step 7. Enzymatic Synthesis of M1G-Deoxyribose
12. Collect the supernatant and dialyze overnight in 50 mM potassium phosphate, pH 6.9.
1.2.4 Current Protocols in Nucleic Acid Chemistry
To quantify the amount of total protein purified, the BCA Protein Assay (Pierce) can be used. For the purpose of this experiment, this level of purification is sufficient. Store the protein in aliquots at −20°C or proceed to coupling experiments (see Basic Protocol).
Assay the enzyme 13. Prepare five 5-mL aliquots of filtrate containing M1G (see Basic Protocol, step 8). 14. Add to the filtrate 50, 100, 150, 200, and 250 µL of supernatant containing the enzyme (from step 12). 15. Incubate overnight at 37°C with shaking. 16. Spot 10 µL of each reaction mixture three times on a TLC plate using 9:1 (v/v) CH2Cl2/MeOH as the mobile phase. Determine presence of M1G-dR. ENZYMATIC COUPLING USING PURINE NUCLEOSIDE PHOSPHORYLASE AND THYMIDINE PHOSPHORYLASE
ALTERNATE PROTOCOL
Purine nucleoside phosphorylase (PNPase; E.C. 2.4.2.1) catalyzes the displacement of phosphate from deoxyribose-1-phosphate on purines and purine analogs. The stereochemistry of purine attachment produces the naturally occurring β-isomers. Although ribose-1-phosphate is commercially available, it may be more conveniently and cost-effectively generated in situ by thymidine phosphorylase (TPase; E.C. 2.4.2.4)–catalyzed phosphorolysis of thymidine (see Fig. 1.2.1). This Alternate Protocol can be used to avoid the transferase preparation required for the Basic Protocol. First the modified base is synthesized and purified, then the enzymatic coupling is initiated, and finally the product is separated on a medium-performance liquid chromatography (MPLC) column. Due to the instability of M 1G, only 2% to 5% of product is recovered, regardless of the yields achieved in the transribosylation step. Additional Materials (also see Basic Protocol) Thymidine (e.g., Sigma) Purine nucleoside phosphorylase (PNPase; Sigma) Thymidine phosphorylase (TPase; Sigma) 20 mM potassium phosphate, pH 7.3 (APPENDIX 2A) MPLC buffer: 20% methanol in water UV lamp (254 and 365 nm) mPLC column (Baker C18-40 µm, 30 × 500 mm) Prepare modified base 1. Prepare modified base (see Basic Protocol, steps 1 to 5). 2. Concentrate the filtrate under vacuum. 3. Prepare a slurry of the residue with ∼10 g silica gel. 4. Purify by chromatography on a silica-gel column using 9:1 (v/v) CH2Cl2/MeOH for equilibration and elution. 5. Collect and combine the fractions containing M1G as determined by UV fluorescence. M1G base is fluorescent under the long-wavelength (365 nm) of the UV lamp.
Synthesis of Modified Nucleosides
1.2.5 Current Protocols in Nucleic Acid Chemistry
6. Evaporate under vacuum and store under nitrogen at –20°C. 7. Verify the purity of M1G base by 1H NMR. The estimated yield is 2% to 5%.
Perform enzymatic coupling 8. Dissolve 37 mg (0.2 mmol) M1G base and 73 mg (0.6 mmol) thymidine in 200 mL of 20 mM potassium phosphate buffer. Adjust the pH to 7.3 with 1 N HCl or 1 N NaOH. 9. Add 20 U TPase and 30 U PNPase. 10. Incubate the solution 18 hr at 37° to 39°C with shaking. Verify the completion of the enzymatic coupling by thin-layer chromatography (see Basic Protocol, step 10). If the reaction is not complete, continue the purification without further incubation.
11. Concentrate the reaction under vacuum. This and all subsequent vacuum steps may be performed using a side-arm flask with water aspiration.
12. Prepare a slurry of the residue with ∼5 g silica gel. 13. Purify by chromatography on a silica-gel column using 9:1 (v/v) CH2Cl2/MeOH for equilibration and elution. Elute by gravity and collect 50-mL fractions. 14. Collect the fractions containing M1G-dR as determined by yellow fluorescence at 365 nm. M1G and M1G-dR have different elution times.
15. Evaporate to dryness under vacuum. Redissolve two aliquots in 2 mL MPLC buffer each. 16. Purify by MPLC on a Baker C18 40 µm, 30 × 500–mm column, eluting with 20% methanol in water (isocratic) at a flow rate of 3 mL/min. This second column is necessary to separate thymidine from M1G-dR.
17. Collect the fluorescent fractions and evaporate to dryness under vacuum. 18. Verify the purity of the product by 1H NMR. A typical spectrum is presented in Figure 1.2.2 (see Basic Protocol). The estimated yield is 50% to 60%.
REAGENTS AND SOLUTIONS Use Nanopure water (water purified using Nanopure system from Barnstead/Thermolyne) where indicated, and deionized, distilled water in all other recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Enzymatic Synthesis of M1G-Deoxyribose
Lactobacillus broth AOAC Mix 38 g of Lactobacillus broth AOAC (Difco) into 1000 mL Nanopure water. Heat to boiling for 2 min. Autoclave 30 min and allow to cool to room temperature. Prepare fresh for each run.
1.2.6 Current Protocols in Nucleic Acid Chemistry
COMMENTARY Background Information Adducts formed between electrophiles and nucleic acid bases are believed to play a key role in chemically induced mutations and cancer (Singer and Grunnenberger, 1983). Chemical synthesis of deoxynucleoside adducts provides not only authentic standards for comparison to biologically derived materials but also reagents for the synthesis of adducted nucleotides (Basu and Essigmann, 1988). The preparation of certain classes of deoxynucleoside adducts is problematic because of the instability of the intermediates under the conditions used for synthetic manipulations (e.g., the acid lability of purine deoxyribosides). Synthetic approaches to preparing sensitive deoxynucleosides include coupling of adducted bases to activated deoxyribose derivatives (Srivasta et al., 1988) and attachment of deoxyribose moieties to modified bases (Garner and Ramakanth, 1988). However, there are inherent difficulties in controlling both the regiochemistry (e.g., to achieve attack at the N7 versus N9 atom of a purine) and the stereoselectivity (e.g., an SN2 attack on a sugar isomer is needed to generate the desired linkage). Chemical synthesis increases the difficulty of obtaining the correct regioselectivity, whereas enzymatic coupling on nonmodified bases generates only one regioselective isomer. Enzymatic coupling of purine or pyrimidine analogs to deoxyribose has been used to synthesize a number of compounds, including isotopically substituted deoxynucleosides, antitumor agents, and biological active molecules (Holy and Votruba, 1987; Krenitsky et al., 1981, 1986; Muller et al., 1996). When PNPase and TPase are used on M1G (see Alternate Protocol), N9 linkage is shown to be preferred over N7. With the use of transferase (see Basic Protocol), complete regioselectivity (for the N9 isomer only) is obtained.
the Alternate Protocol, which uses a combination of two commercially available enzymes, is more demanding in terms of time and purification. M1G base must be purified; moreover, when the crude mixture is reacted with the combination of PNPase and TPase, transribosylation is inefficient. Also, due to the close polarity of thymidine and M1G-dR (in a variety of solvents system used), a combination reversed-phase and straight-phase column must be employed to obtain pure material. The transferase used in the Basic Protocol and prepared in the Support Protocol has a higher selectivity and produces only the N9 isomer. The two-enzyme method of the Alternate Protocol produces a mixture of N7 and N9, increasing the difficulty of purification. Once a stock solution of transferase is prepared, the Basic Protocol is much easier to perform, less time-consuming, and gives better yields.
Anticipated Results The two protocols described in this unit allow preparation of the desired modified nucleoside in good yields. The Basic Protocol should give yields between 10% and 15% and the Alternate Protocol gives between 2% and 5%. Figure 1.2.2 shows the 1H NMR spectrum of M1G-dR.
Time Considerations Preparation of transferase (see Support Protocol) may take 3 to 4 days. The one-step condensation procedure using transferase (see Basic Protocol), from the synthesis of the modified base to the purification of the nucleoside, should take 24 hr with lyophylization. The alternative method using commercial phosphorylases (see Alternate Protocol) should take 2 or 3 days.
Literature Cited Critical Parameters Since the pyrimidopurinone M1G-dR synthesized in these procedures is base labile, the pH must stay below 7.5 for all protocols. M1G base is even less stable than M1G-dR. The Basic Protocol does not require purification of the modified base; the transferase can be added to the crude mixture. The desired nucleoside can be purified by simple column chromatography. This strategy not only shortens the time required for the synthesis, but also significantly improves the yield. In comparison
Basu, A.K. and Essigmann, J.M. 1988. Site-specifically modified oligonucleotides as probes for the structural and biological effects of DNA-damaging agents. Chem. Res. Toxicol. 1:1-18. Beck, W.S. and Levin, M. 1963. Purification, kinetics, and repression control of bacterial trans-Ndeoxyribosylase. J. Biol. Chem. 238:702. Carson, D.A. and Wasson, D.B. 1988. Synthesis of 2′,3′-dideoxynucleosides by enzymatic transglycosylation. Biochem. Biophys. Res. Comm. 155:829-834. Garner, P. and Ramakanth, S. 1988. A regiocontrolled synthesis of N7- and N9-guanine nucleosides. J. Org. Chem. 53:1294-1298.
Synthesis of Modified Nucleosides
1.2.7 Current Protocols in Nucleic Acid Chemistry
Holy, A. and Votruba, I. 1987. Facile preparation of purine and pyrimidine 2-deoxy-β-D-ribonucleosides by biotransformation on encapsulated cells. Seventh symposium on the Chemistry of Nucleic Acid Components August 30–September 5, 1987. Nucleic Acids Symp. Ser. 18:69-72. Krenitsky, T.A., Kozallka, G.W., and Tuttle, J.V. 1981. Purine nucleoside synthesis, an efficient method employing nucleoside phosphorylases. Biochemistry 20:3615-3621. Krenitsky, T.A., Rideout, J.L., Chao, E.Y., Koszalka, G.W., Gurney, F., Crouch, R.C., Cohn, N.K., Wolberg, G., and Vinegar, R. 1986. Imidazo[4,5c]pyridines (3-deazapurines) and their nucleosides as immunosuppresive and antiinflammatory agents. J. Med. Chem. 29:138-143. McNutt, W.S. 1952. The enzymically catalysed transfer of the deoxyribosyl group from one purine or pyrimidine to another. Biochem. J. 50:384. Muller, M., Hutchinson, L.K., and Guengerich, F.P. 1996. Addition of deoxyribose to guanine and modified DNA bases by Lactobacillus helveticus trans-N-deoxyribosylase. Chem. Res. Toxicol. 9:1140-1144.
Singer, B. and Grunnenberger, D. 1983. Molecular Biology of Mutagens and Carcinogens. Plenum, New York. Srivasta, P.C., Robins, R.K., and Meyer, R.B. 1988. Synthesis and properties of purine nucleosides and nucleotides. In Chemistry of Nucleosides and Nucleotides (L.B. Townsend, ed.) pp. 113281. Plenum, New York. Uerkvitz, W. 1971. Purification of nucleoside 2-deoxyribosyltransferase from Lactobacillus helveticus. Eur. J. Biochem. 23:387-395.
Key Reference Uerkvitz, 1971. See above. Decribes the purification and crystallization of the transferase.
Contributed by Nathalie C. Schnetz-Boutaud, Marie-Christine Chapeau, and Lawrence J. Marnett Vanderbilt University Nashville, Tennessee
Enzymatic Synthesis of M1G-Deoxyribose
1.2.8 Current Protocols in Nucleic Acid Chemistry
Synthesis of N2-Substituted Deoxyguanosine Nucleosides from 2-Fluoro-6-O(Trimethylsilylethyl)-2′-Deoxyinosine
UNIT 1.3
This unit describes the synthesis of 2-fluoro-6-O-(trimethylsilylethyl)-2′-deoxyinosine and gives examples of its use for the preparation of N2-substituted deoxyguanosine nucleosides. Such nucleoside derivatives are used for a variety of purposes including chemotherapy, enzyme mechanism studies, nuclear magnetic resonance (NMR) studies (when isotopically labeled), and as synthetic standards for identification of adducts formed by the reaction of DNA with xenobiotics. In addition, the O6-protected 2-fluoro2′-deoxyinosine compounds can be converted to phosphoramidites and used in the synthesis of oligonucleotides, thus allowing substitution reactions to be carried out after oligonucleotide assembly. 2-Halopurine derivatives have been used for many years for the preparation of N2-substituted guanosine derivatives, with the 2-fluoro substituent being the most easily displaced by nucleophiles (Montgomery and Hewson, 1960; Gerster and Robins, 1965, 1966). The 2-fluoro group is introduced by aqueous diazotization of guanosine in the presence of potassium fluoride or fluoroboric acid. However, these conditions are too harsh for 2′-deoxyguanosine and lead to depurination; hence, different synthetic methodology is needed for the deoxynucleoside. The fluorine atom can be introduced successfully by diazotization under anhydrous conditions with t-butyl nitrite as the diazotizing agent and HF in pyridine as the fluoride source (Robins and Uznanski, 1981; Lee et al., 1990; Harris et al., 1991). Success in the fluoridation step requires protection of the C6 oxygen group, which is done by Mitsunobu alkylation (Mitsunobu, 1981) with trimethylsilylethanol or other alcohols. The O6-protecting group also facilitates displacement of the halogen by nucleophiles. Basic Protocol 1 in this unit describes the synthesis of 2-fluoro-6-O-(trimethylsilylethyl)2′-deoxyinosine and comprises three separate procedures: (1) protection of the 2-NH2, 3′-OH, and 5′-OH groups of 2′-deoxyguanosine to make a triacetyl derivative, (2) protection of the O6 group by Mitsunobu alkylation with trimethylsilylethanol, and (3) introduction of the 2-fluoro group. Alternate Protocol 1 describes the preparation and use of 3′,5′-O-diacetyl-2′-deoxyguanosine and its use in the Mitsunobu reaction described in Basic Protocol 1. Alternate Protocol 1 gives lower yields than Basic Protocol 1, but is quicker and is better for the preparation of 6-O-(p-nitrophenethyl)-2′-deoxyguanosine, another commonly used O6-protected derivative. Basic Protocol 2 describes a general procedure for the synthesis of N2-substituted 2′-deoxyguanosines. Two specific examples are then given in Alternate Protocols 2 and 3, which give detailed directions for synthesis using an unhindered diamine to give a derivative with an alkylamine sidechain, and for using an amino alcohol to yield an N2 hydroxyalkenyl derivative. A Support Protocol outlines the procedure for carrying out reactions in an inert atmosphere. CAUTION: Several of the steps in these protocols involve the use of toxic, corrosive, and flammable chemicals. It is highly recommended that all operations be carried out in a fume hood. Good laboratory safety practices should be observed at all times, including the use of safety goggles, a laboratory coat, and disposable gloves. It is recommended that this synthesis be done only by personnel experienced in the handling of reactive and toxic chemicals. Contributed by Thomas M. Harris and Constance M. Harris Current Protocols in Nucleic Acid Chemistry (2000) 1.3.1-1.3.19 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Modified Nucleosides
1.3.1
NOTE: A variety of methods is used in these procedures to remove volatile solvents and reagents. The choice of method depends upon the boiling points of the volatiles, the stability of the products (e.g., sometimes heat cannot be used to hasten evaporation), and the volume to be removed. For additional details, see Critical Parameters and Troubleshooting. BASIC PROTOCOL 1
SYNTHESIS OF 2-FLUORO-6-O-(TRIMETHYLSILYLETHYL)-2′DEOXYINOSINE USING 2-N-3′,5′-O-TRIACETYL-2′-DEOXYGUANOSINE This protocol describes the synthesis of the 2-fluoro derivative of 6-O-(trimethylsilylethyl)2′-deoxyinosine (Fig. 1.3.1). It is divided into three basic procedures. (1) Protection of the 2-NH2, 3′-OH, and 5′-OH groups of 2′-deoxyguanosine (S.1) is performed by acetylation (S.2). (2) Protection of the O6 group is carried out via Mitsunobu alkylation with trimethylsilylethanol, diethyl azodicarboxylate, and triphenylphosphine. Sodium methoxide and methanol are then added to the reaction to remove the acetyl protecting groups, yielding the 6-O-trimethylsilylethyl (TMSE) derivative (S.3). (3) The 2-NH2 group is converted to the 2-fluoro substituent by performing nonaqueous diazotization and fluoridation at low temperature with t-butyl nitrite and HF/pyridine (Robins and Uznanski, 1981). An Alternate Protocol utilizing 3′,5′-O-diacetyl-2′-deoxyguanosine is also described (see Alternate Protocol 1). NOTE: Anhydrous solvents are required for several steps in these procedures. They can be purchased (e.g., from Aldrich in Sure/Seal bottles) or dried by distillation from appropriate desiccants and stored under nitrogen. Materials 2′-Deoxyguanosine (dG) monohydrate Pyridine, anhydrous (Aldrich; packed under nitrogen in a Sure/Seal bottle) Acetic anhydride, freshly distilled Triethylamine (d 0.726), distilled from calcium hydride 4-Dimethylaminopyridine (DMAP)
N
HO
O
N
NH N
NH2
a
N
AcO
O AcO
HO 1
Me3Si
O
O N
NH N
NHAc
O N
b,c
N
N
HO
N
O
NH2
HO 2
3
d
Me3Si
O N N
HO
O
N N
F
HO 4
Synthesis of N2-Substituted Deoxyguanosine Nucleosides
Figure 1.3.1 Synthesis of 2-fluoro-6-O-(trimethylsilylethyl)-2′-deoxyinosine (S.4) using 2-N-3′,5′O-triacetyl-2′-deoxyguanosine (S.2; see Basic Protocol 1). Reagents: (a) acetic anhydride, pyridine, 4-dimethylaminopyridine (steps 1 to 13): (b) triphenylphosphine, diethyl azodicarboxylate, 2-trimethylsilylethanol (steps 14 to 19); (c) sodium methoxide, methanol (steps 20 to 33); (d) HF/pyridine, t-butyl nitrite (steps 34 to 46).
1.3.2 Current Protocols in Nucleic Acid Chemistry
Dry nitrogen (N2) or argon (Ar) Methanol, anhydrous Methylene chloride (CH2Cl2), anhydrous Anisaldehyde/sulfuric acid spray (see recipe) Acetonitrile Dioxane, anhydrous, distilled from sodium metal before use Triphenylphosphine 2-Trimethylsilylethanol Diethyl azodicarboxylate (DEAD; from a fresh, unopened bottle) 0.35 M sodium methoxide in methanol (see recipe) Aqueous acetic acid: 6.2 mL glacial acetic acid in 30 mL water Sodium sulfate (Na2SO4), anhydrous 63- to 200-mesh silica gel Sand Dry ice/acetonitrile cooling bath (−35° to −40°C) 70% HF/pyridine solution (Aldrich) t-Butyl nitrite Potassium carbonate (K2CO3) Ethyl acetate 2-liter round-bottom flask Rotary evaporator equipped with a condenser cooled with chilled water or a dry ice condenser Reflux condenser with 24/40 joint and gas inlet adapter Temperature-controlled oil bath (up to ∼115°C) 0.25-mm silica gel 60F-254 glass thin-layer chromatography (TLC) plates UV light source Vacuum system (oil pump) capable of creating <1 mmHg pressure, with manifold and cold trap Filter paper (Whatman no. 1, 7-cm diameter) Buchner funnel 500-mL and l-liter Erlenmeyer flasks 1-liter, three-neck flask with 24/40 joints (oven dried) and rubber septa 10-mL glass syringes (oven dried) 1-liter, single-neck flask with 24/40 joint Water aspirator 500-mL separatory funnels Heavy-walled glass column (5-cm i.d. × 40-cm length) Abderhalden apparatus (drying pistol; 78°C) 50-mL polypropylene conical tubes with rubber septa 23-G syringe needles 20-mL plastic syringes with 3-in. (7.6-cm) 20-G needles 1-mL glass syringe (oven dried) Additional reagents and equipment for performing reactions under nitrogen (see Support Protocol) Protection of 2-NH2, 3′-OH, and 5′-OH Groups Remove water from dG 1. Place 8.54 g dG (S.1) in a 2-liter round-bottom flask.
Synthesis of Modified Nucleosides
1.3.3 Current Protocols in Nucleic Acid Chemistry
Table 1.3.1
Synthesis of 2-N-3′,5′-O-Triacetyl-2′-Deoxyguanosine (S.2)
Reagent 2′-Deoxyguanosine⋅H2O Pyridine (for coevaporation) Pyridine (for reaction) Acetic anhydride Triethylamine 4-Dimethylaminopyridine (DMAP) Methanol
Amount 8.54 g 450 mL 1200 mL 28 mL 46 mL 0.36 g
MW (g/mol) 285 79 79 102 101 122
Millimoles 30.0 5600 14900 299 330 2.99
Equivalents 1.0 187 497 10 11 0.1
350 mL
32
8640
288
Table 1.3.1 lists quantities of reagents for the synthesis of N2,O3′,O5′-triacetyl-2′-deoxyguanosine (S.2).
2. Add 150 mL anhydrous pyridine and then remove the pyridine under vacuum using a rotary evaporator equipped with a dry ice condenser and connected to an oil pump. The same oil pump used in step 8, capable of creating <1 mmHg pressure, can be used here; however, it is not necessary. For this step, 1 mmHg pressure would be sufficient.
3. Repeat the addition of pyridine and evaporation twice more. Alternatively, the dG can be dried under vacuum in an Abderhalden drying apparatus at 78°C (refluxing ethanol) for 16 hr.
Acetylate dG 4. Add the following reagents (see Table 1.3.1): 1200 mL anhydrous pyridine 28 mL acetic anhydride 46 mL triethylamine 0.36 g DMAP. 5. Place a large magnetic stir bar in the flask, fit the flask with a reflux condenser, and place the flask in a 55°C temperature-controlled oil bath on top of a magnetic stir plate. Stir the reaction at 55°C for 72 hr under nitrogen (see Support Protocol). 6. Monitor the reaction by occasionally removing a small sample (1 to 2 µL) and analyzing it by TLC. Perform TLC on 0.25-mm silica gel 60F-254 glass plates. Elute with 1:9 (v/v) methanol/methylene chloride. Detect product under UV light and also with anisaldehyde/sulfuric acid spray. Spray (or dip) the plate and heat on a hot plate for several seconds. Anisaldehyde/sulfuric acid spray is used for the detection of sugars. Spots should appear in various shades of blue and purple. The Rf of the product is 0.31 and that of the starting material is <0.1. CAUTION: Anisaldehyde/sulfuric acid spray should be used in a well-ventilated fume hood. It is corrosive and the vapors are highly irritating.
Synthesis of N2-Substituted Deoxyguanosine Nucleosides
Work up and purify 2-N-3′,5′-O-triacetyl-2′-deoxyguanosine 7. When TLC analysis indicates that the reaction is complete, cool in an ice bath and add 350 mL methanol. Stir for 5 min and remove solvents under reduced pressure using a rotary evaporator. A red oily residue should be present at this point.
1.3.4 Current Protocols in Nucleic Acid Chemistry
8. Connect the flask to a vacuum system capable of obtaining a vacuum of <1 mmHg and allow to dry overnight. It is important to remove the solvents as thoroughly as possible before recrystallization.
9. Add 100 mL acetonitrile and incubate at −20°C overnight. 10. While the reaction mixture is still cold, collect the resulting crystals by vacuum filtration using Whatman no. 1 filter paper and a Buchner funnel. 11. Rinse the precipitate with cold acetonitrile (4°C) and allow the crystals to air dry. 12. Recrystallize from a minimum amount of hot methanol. Place the solid in a 500-mL Erlenmeyer flask and add a few milliliters of methanol. Heat with gentle shaking on a hot plate or in a steam bath until boiling. Gradually add methanol until all the solid is dissolved. Remove from heat and allow to cool. Recrystallization can easily be carried out on a larger scale.
13. Cool at −20°C overnight, filter as in step 10, and air dry. The yield of compound S.2 should be 80% to 90% (9.5 to 10.5 g). The product can be stored indefinitely at room temperature.
Protection of the O6 Group by Mitsunobu Alkylation Perform Mitsunobu reaction 14. Equip a 1-liter, 24/40 three-neck flask with rubber septa on the two side necks, a 24/40 reflux condenser in the center neck, and a magnetic stir bar. Place a gas inlet adapter on top of the condenser and connect to a nitrogen source (see Support Protocol). 15. Remove one rubber septum, add the following reagents (see Table 1.3.2), and replace the septum. 430 mL dioxane 5.10 g triacetyl deoxyguanosine (S.2) 6.82 g triphenylphosphine. Table 1.3.2 lists quantities of reagents for the synthesis of 6-O-(trimethylsilylethyl)-2′-deoxyguanosine (S.3).
Table 1.3.2
Synthesis of 6-O-TMSE-2′-Deoxyguanosine (S.3) from S.2a
Reagent Dioxane 2-N-3′,5′-O-Triacetyl-dG (S.2) Triphenylphosphine 2-Trimethylsilylethanol Diethyl azodicarboxylate (DEAD) Methanol Sodium methoxide solution (0.35 M) Glacial acetic acidb
Amount 430 mL 5.10 g 6.82 g 3.75 mL 4.10 mL
MW (g/mol) 88 393 262 118 174
Millimoles 5052 13 26 26 26
Equivalents 389 1.00 2 2 2
120 mL 200 mL
32 54
2940 70
227 5
6.2 mL
60
109
8
aFor synthesis from the diacetyl derivative, use 4.56 g S.7 (MW 351) in place of S.2, and substitute 60 mL concentrated
NH4OH for the 200 mL sodium methoxide solution. bDiluted in 30 mL water.
Synthesis of Modified Nucleosides
1.3.5 Current Protocols in Nucleic Acid Chemistry
16. Transfer the reaction flask to a temperature-controlled oil bath placed on a magnetic stir plate. Start water circulating through the condenser and raise the temperature of the oil bath to ∼115°C. The solvent should begin gently refluxing.
17. Simultaneously add 3.75 mL of 2-trimethylsilylethanol with a 10-mL glass syringe through one rubber septum and 4.10 mL DEAD through the other. Best results are obtained when using DEAD from a fresh unopened bottle. The cloudy yellow suspension should become translucent and darker yellow in color.
18. Continue stirring the reaction mixture for 15 min at 100°C, and then cool to room temperature over ∼2 hr. 19. Transfer the solution to a 1-liter single-neck flask. Remove the solvents under reduced pressure using a rotary evaporator with a dry ice condenser and a water aspirator. Remove acetyl protecting groups 20. Redissolve the viscous red residue in 120 mL anhydrous methanol and slowly add 200 mL of 0.35 M sodium methoxide in methanol. Stir at room temperature for 7 hr. 21. Neutralize the reaction by adding 36.2 mL aqueous acetic acid. Stir for 1 hr at room temperature. 22. Check the pH of the solution using pH paper, and adjust to pH 7.0, if necessary. Work up and purify 6-O-(trimethylsilylethyl)-2′-deoxyguanosine 23. Evaporate the solution under reduced pressure as in step 19. Suspend the residue in 100 mL methylene chloride and transfer to a 500-mL separatory funnel. 24. Extract with 40 mL water. Back extract the aqueous layer with five 100-mL aliquots of methylene chloride. Combine the organic layers. 25. Add sufficient anhydrous Na2SO4 to the extract to cover the bottom of the flask. Swirl gently and allow the salt to settle. If the solution looks cloudy, add more Na2SO4. Allow the solution to stand for 30 to 60 min. 26. Filter by gravity through fluted filter paper into a round-bottom flask to remove the drying agent. Evaporate under reduced pressure (see step 19). 27. While the organic extract is drying, pack a 5 × 20–cm silica gel column using 250 g of 63- to 200-mesh silica gel in methylene chloride containing 0.2% triethylamine in a heavy-walled glass column. Column chromatography is carried out by flash chromatography techniques employing heavy-walled glass columns that can be connected to a gas inlet via a ball joint. Air pressure can be applied to the top of the column via the inlet to increase the flow rate.
28. Dissolve the crude product in 10 mL methylene chloride.
Synthesis of N2-Substituted Deoxyguanosine Nucleosides
29. Load the solution on the column and allow the solution to sink to the level of the column bed. 30. Rinse the flask with two 1-mL aliquots of methylene chloride, add each rinse to the bed, and allow them to sink to the level of the bed.
1.3.6 Current Protocols in Nucleic Acid Chemistry
31. Carefully add a 1-cm layer of sand to the top of the column and begin elution with a gradient of CH2Cl2/methanol/triethylamine ranging from 97.8:2.0:0.2 to 94.8:5.0:0.2 (v/v/v). 32. Collect 10-mL fractions and analyze by TLC (step 6; Rf = 0.41). 33. Combine fractions containing pure product in a round-bottom flask and evaporate to dryness with a rotary evaporator and a dry ice condensor, first under reduced pressure using a water evaporator and then under high vacuum using an oil pump. Impure fractions can be combined, dried, and reanalyzed under the same TLC conditions to yield additional pure product. The product is a pale yellow powder. Approximately 4.2 g (>85% yield) of purified 6-O-TMSE-2′-dG (S.3) should be obtained. It can be stored indefinitely at 4° or –20°C. The Mitsunobu reaction is readily scaled up as much as five fold.
Introduction of the 2-Fluoro Group Fluoridate 6-O-TMSE-2′-dG 34. Dry 0.53 g of 6-O-TMSE-2′-dG (S.3) overnight in an Abderhalden apparatus under vacuum at 78°C. The S.3 product should be quite dry after step 33. The weight should change very little after drying in the Abderhalden apparatus. Table 1.3.3 lists quantities of reagents for the synthesis of 2-fluoro-6-O-TMSE-2′-dI (S.4).
35. Transfer 6-O-TMSE-2′-dG to a 50-mL polypropylene conical tube with a stir bar and a rubber septum. Maintain the reaction under nitrogen using a 23-G syringe needle inserted through the septum. 36. Using a 10-mL glass syringe, place 5.4 mL anhydrous pyridine in a second conical tube, similarly equipped. 37. Place both conical tubes in a dry ice/acetonitrile cooling bath (−35° to −40°C). 38. Using a 20-mL plastic syringe with a 3-in. 20-G needle, add 9.6 mL of 70% HF/pyridine solution to the tube containing the anhydrous pyridine over a period of 3 min (final 45% HF). Stir for 15 min at −35° to −40°C. CAUTION: HF is highly corrosive and should be handled with care. The quality of the 70% HF/pyridine solution is critical to the success of this reaction. The color should be no darker than pale amber. Using a solution that is a dark red or brown leads to increased decomposition products.
Table 1.3.3
Synthesis of 2-Fluoro-6-O-TMSE-2′-Deoxyinosine (S.4) from S.3
Reagent 6-O-TMSE-2′-dG (S.3) Pyridine 70% HF/pyridine t-Butyl nitrite K2CO3
Amount 0.53 g 5.4 mL 9.6 mL 0.43 mL 23 g
a230 neutralizing eq.
MW (g/mol) 368 79 20 103 138
Millimoles 1.44 66 ~336 3.60 166
Equivalents 1.0 46 ~233 2.5 115a
Synthesis of Modified Nucleosides
1.3.7 Current Protocols in Nucleic Acid Chemistry
If the solution appears to be freezing, 2 to 4 mL anhydrous toluene can be added to keep the solution homogeneous.
39. Using another 20-mL plastic syringe and 3-in. 20-G needle, slowly transfer the HF/pyridine solution into the tube containing the dried 6-O-TMSE-2′-dG (S.3). Stir for 5 min at −35° to −40°C. 40. Using a 1-mL glass syringe, add 0.43 mL t-butyl nitrite to the reaction over 5 min while maintaining the bath temperature at −35° to −40°C. Stir the red reaction mixture for 25 min. Work up and purify 2-fluoro-6-O-TMSE-2′-dI 41. Dissolve 23 g K2CO3 in 34 mL water in a 1-liter Erlenmeyer flask. Begin stirring vigorously at 0°C (ice bath). 42. Quench the reaction by slowly pouring the reaction mixture (step 40) into the cold, stirring K2CO3 solution. Rinse the reaction tube with ethyl acetate and add the wash to the neutralized solution. 43. Transfer the solution to a 500-mL separatory funnel and extract five times with 40 mL ethyl acetate. Combine the ethyl acetate extracts. 44. Dry over anhydrous Na2SO4, filter to remove the drying agent, and evaporate to a red oil (steps 25 and 26). Place under high vacuum overnight (see step 8). 45. Purify the crude product by flash chromatography (steps 27 to 31) using an ∼2.5 × 15–cm silica gel column (50 g silica gel). Elute with a gradient of CH2Cl2/methanol/triethylamine ranging from 95:4:1 to 90:9:1 (v/v/v). 46. Analyze by TLC and evaporate appropriate fractions to dryness (steps 32 and 33; Rf = 0.36). Approximately 0.50 g (>90%) of 2-fluoro-6-O-(trimethylsilylethyl)-2′-deoxyinosine (S.4) should be obtained. The product can be stored indefinitely at –20°C under anhydrous conditions. NOTE: This reaction can be carried out starting with 6.7 g of S.3 using a 500-mL round-bottomed flask for the reaction. A mixture of 100 mL anhydrous pyridine and 50 mL toluene is used to dissolve the nucleoside before the addition of the HF/pyridine, which is not diluted before addition at −40°C. The yield of purified S.4 should be ∼70%. ALTERNATE PROTOCOL 1
SYNTHESIS OF 2-FLUORO-6-O-(TRIMETHYLSILYLETHYL)-2′DEOXYINOSINE USING 3′,5′-O-DIACETYL-2′-DEOXYGUANOSINE In this procedure, the Mitsunobu reaction can be carried out starting with 3′,5′-O-diacetyl-2′-deoxyguanosine (Fig. 1.3.2; Zajc et al., 1992), which is synthesized by the procedure of Matsuda et al. (1986). Although the yield of the Mitsunobu product (S.3) is not as high when the diacetyl derivative S.7 is used, the overall synthesis is much quicker because the synthesis of the diacetyl derivative takes only ∼1 hr compared to the 72 hr required for the synthesis of 2-N-3′,5′-O-triacetyl-2′-deoxyguanosine (S.2). This procedure is preferred when 6-O-(p-nitrophenethyl)-2′-deoxyinosine is desired instead of compound S.3, because the p-nitrophenethyl group is not stable in the presence of the sodium methoxide used for deacylation of the triacetyl derivative.
Synthesis of N2-Substituted Deoxyguanosine Nucleosides
Additional Materials (also see Basic Protocol 1) Concentrated ammonium hydroxide (NH4OH) 1-liter, three-neck, round-bottom flask with 24/40 joints
1.3.8 Current Protocols in Nucleic Acid Chemistry
N
HO
N
O
NH
NH N
Me3Si
O
O N
NH2
a
N
AcO
N
O
NH2
b,c
1
N
N
HO
AcO
HO
O N N
O
NH2
HO
7
3
d
Me3Si
O N N
HO
N N
F
O
HO
4
Figure 1.3.2 Synthesis of 2-fluoro-6-O-(trimethylsilylethyl)-2′-deoxyinosine (S.4) using 3′,5′-Odiacetyl-2′-deoxyguanosine (S.7; see Alternate Protocol 1). Reagents: (a) acetic anhydride, 4-dimethylaminopyridine, triethylamine (steps 1 to 5); (b) triphenylphosphine, diethyl azodicarboxylate, 2-trimethylsilylethanol (step 6); (c) NH4OH, methanol (steps 7 and 8); (d) HF/pyridine, t-butyl nitrite (step 9).
Protection of 3′- and 5′-OH Groups Remove water from dG 1. Dry 8.56 g dG in an Abderhalden apparatus (drying pistol) under vacuum at 78°C. Table 1.3.4 lists quantities of reagents used for the synthesis of 3′,5′-O-diacetyl-2′-deoxyguanosine (S.7). Water can also be removed by evaporation with pyridine, and this method is appropriate if the reaction is to be carried out in pyridine. Drying with an Abderhalden apparatus has the advantage of not involving solvent; however, there is a limit to the amount of material that can be effectively dried in a drying pistol.
Acetylate dG 2. Place dried dG in a 1-liter, three-neck, round-bottom flask equipped with a large magnetic stir bar, glass stoppers in two side arms, and a gas inlet tube in the center neck. Attach a nitrogen source to the gas inlet tube as described (see Support Protocol). 3. Add the following reagents (see Table 1.3.4) to produce a yellowish suspension: 0.36 g DMAP 325 mL acetonitrile 85 mL triethylamine 82 mL acetic anhydride. 4. Stir for 30 min to 1 hr at room temperature. During this time the suspension will become whiter. Synthesis of Modified Nucleosides
1.3.9 Current Protocols in Nucleic Acid Chemistry
Table 1.3.4
Synthesis of 3′,5′-O-Diacetyl-2′-Deoxyguanosine (S.7)
Reagent 2′-Deoxyguanosine⋅H2O 4-Dimethylaminopyridine (DMAP) Acetonitrile Triethylamine Acetic anhydride
Amount 8.56 g 0.36 g
MW (g/mol) 285 122
Millimoles 32.0 3.2
Equivalents 1.0 0.1
325 mL 85 mL 82 mL
41 101 102
623 610 869
195 19 27
Work up and purify 3′,5′-O-diacetyl-2′-deoxyguanosine 5. Filter the suspension using Whatman no. 1 filter paper, a Buchner funnel, and a water aspirator. Wash the precipitate with acetonitrile and dry overnight in the Abderhalden apparatus (78°C). This should yield 7.5 to 8.0 g (70%) of the S.7 product. If desired, the compound can be recrystallized from water, but this is not necessary. The compound can be stored indefinitely at room temperature.
Protection of the O6 Group by Mitsunobu Alkylation 6. Perform Mitsunobu reaction as described (see Basic Protocol 1, steps 14 to 19), starting with 4.56 g of the 3′,5′-O-diacetyl compound (S.7; Table 1.3.2). 7. Remove acetyl protecting groups as described (see Basic Protocol 1, steps 20 to 22), but use 60 mL concentrated NH4OH instead of 200 mL sodium methoxide (Table 1.3.2). The yield of the Mitsunobu reaction is not as high (∼50%) when starting with the diacetyl compound, but the overall reaction time is shortened considerably.
8. Work up and purify 6-O-TMSE-2′-dG as described (see Basic Protocol 1, steps 23 to 33). The Mitsunobu reaction is readily scaled up as much as five fold.
Introduction of the 2-Fluoro Group 9. Introduce the 2-fluoro group as described (see Basic Protocol 1, steps 34 to 46). BASIC PROTOCOL 2
GENERAL GUIDELINES FOR SYNTHESIS OF N2-SUBSTITUTED NUCLEOSIDES This protocol outlines a general procedure for the preparation of N2-substituted deoxyguanosines (Fig. 1.3.3A) from the 2-fluoro derivative S.4 synthesized using Basic Protocol 1 or Alternate Protocol 1. Alternate Protocols 2 and 3 give detailed directions for preparing specific aminoalkyl and hydroxyalkanyl derivatives. As can be seen in the Alternate Protocols, considerable latitude can be exercised in the relative amounts of diisopropylethylamine (DIEA) and dimethyl sulfoxide (DMSO) that are used; a greater excess of amine can also be employed without harm.
Synthesis of N2-Substituted Deoxyguanosine Nucleosides
Materials 2-Fluoro-6-O-(trimethylsilylethyl)-2′-deoxyinosine (S.4; see Basic Protocol 1 or Alternate Protocol 1) Amine of choice N,N-Diisopropylethylamine (DIEA), anhydrous Dimethylsulfoxide (DMSO), anhydrous, vacuum distilled from calcium hydride
1.3.10 Current Protocols in Nucleic Acid Chemistry
Me3Si N
A
Basic Protocol 2 Steps 1-3
N
N
HO
Me3Si
O
N
O
F
N
O
HO
Basic Protocol 2 Steps 4-8
N
N
HO
a
O
O N
H NR
N N
HO
b or c
N
O
NH H NR
HO
HO 4 Me3Si
B
4
Alternate Protocol 2 Steps 1-5 a
N
Alternate Protocol 2 Steps 6-13
N
N
HO
O
O
N
O
NH2
N H
b
N N
HO
O
Me3Si Alternate Protocol 3 Steps 1-6 a
O
O N
Alternate Protocol 3 Steps 7-9
N
N
HO
NH2
6
5
4
N H
HO
HO
C
NH N
N
O
N H
c
N
NH
N
HO
N
O
OH
N H
OH
HO
HO 7
8
Figure 1.3.3 (A) General guidelines for synthesis of N2-substituted nucleosides (see Basic Protocol 2). (B) Synthesis of 2-N-(3-aminopropyl)-2′-deoxyguanosine (S.6; see Alternate Protocol 2). (C) Synthesis of 2-N-[2(S)-1-hydroxybut-3-en-2-yl]-2′-deoxyguanosine (S.8; see Alternate Protocol 3). Reagents: (a) amine, diisopropylethylamine, dimethyl sulfoxide; (b) 0.1 M tetrabutylammonium fluoride; (c) 0.1 M acetic acid.
0.1 M aqueous acetic acid or 1 M tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF) Methanol, anhydrous 0.1 M sodium bicarbonate (NaHCO3) Vial or test tube with secure cap Temperature-controlled oil bath or heating block at 45° to 60°C Rotary evaporator with water aspirator and oil pump Additional reagents and equipment for thin-layer chromatography (TLC; see Basic Protocol 1), or high-performance liquid chromatography (HPLC) 1. Combine the following in a vial or a test tube that can be securely capped. 1 equivalent 2-fluoro-6-O-(trimethylsilylethyl)-2′-deoxyinosine 1.5 to 2.0 equivalents amine 2 equivalents DIEA 20 µL DMSO per mg of nucleoside. 2. Heat in a temperature-controlled oil bath or heating block at 45° to 60°C. If the reaction is not homogeneous after warming up, add additional anhydrous DMSO. 3. Continue heating for 1 to 2 days, until the fluoronucleoside (S.4) has been completely eliminated. Check the reaction periodically by TLC (see Basic Protocol 1, step 6; S.4 Rf ∼0.36).
Synthesis of Modified Nucleosides
1.3.11 Current Protocols in Nucleic Acid Chemistry
4. Evaporate the solvent under reduced pressure using a rotary evaporator, first with a water aspirator and then under high vacuum with an oil pump. A centrifugal vacuum evaporator (e.g., Speedvac) can also be used and is often more convenient for small-scale syntheses such as those described in Alternate Protocols 2 and 3.
5. Add 20 µL of 0.1 M aqueous acetic acid (or 20 µL of 1 M TBAF in THF) per mg nucleoside and incubate at room temperature for 2 hr to remove the trimethylsilylethyl protecting group. If necessary, add an organic solvent such as methanol to improve solubility. Monitor by TLC until deprotection is complete. Some of the TMSE protecting group will probably have fallen off the product by the end of the reaction. The deprotected product will have a lower Rf than the 6-O-TMSE compound.
6. Neutralize the reaction with 0.1 M NaHCO3 (20 µL if 0.1 M acetic acid was used) and check the pH (6.5 to 7.5) with pH paper. 7. Evaporate solvents under reduced pressure (step 4). 8. Purify the product by flash chromatography on silica gel, by preparative TLC, or by HPLC. The choice of purification technique will depend primarily on the scale of the reaction. The choice of solvent system will depend on the product characteristics. The alkylated nucleosides can be stored indefinitely at 4° or –20°C. ALTERNATE PROTOCOL 2
SYNTHESIS OF 2-N-(3-AMINOPROPYL)-2′-DEOXYGUANOSINE This protocol describes the preparation of a 2-N-aminopropyl derivative of 2′-deoxyguanosine (S.6) using tetrabutylammonium fluoride (TBAF) to remove the 6-Otrimethylsilylethyl group (see Fig. 1.3.3B). Additional Materials (also see Basic Protocol 2) 1,3-Diaminopropane Acetonitrile Concentrated NH4OH Silica gel Sand Tetrahydrofuran (THF), anhydrous 0.1 M ammonium formate in water, pH 6.4 12 × 75–mm glass test tube or conical vial with magnetic stir bar 2.5 × 20–cm column 100-mL round-bottom flask 10 × 250–mm C18 reversed-phase HPLC column (e.g., YMC-ODS-AQ column; YMC) 1. Combine the following in a 12 × 75–mm glass test tube or conical vial with a small magnetic stir bar. 50 mg (0.13 mmol) 2-fluoro-6-O-TMSE-2′-dI (S.4) 16.8 mg (0.13 mmol) DIEA 200 µL DMSO.
Synthesis of N2-Substituted Deoxyguanosine Nucleosides
2. Add 23 mg (0.31 mmol) of 1,3-diaminopropane, cap securely, and heat while stirring in a 45°C oil bath or heating block.
1.3.12 Current Protocols in Nucleic Acid Chemistry
Additional amine (well in excess of the 1 eq that is theoretically required) is used to ensure that only one of the amino groups in the diaminopropane reacts with the fluoronucleoside. It is possible for the diamine to react at both ends to form a bis(nucleoside) cross-linked with a propyl chain. If this is the desired product, the diamine can be used as the limiting reagent (e.g., 1 mmol of diamine to 3 mmol fluoronucleoside).
3. Continue heating until the fluoronucleoside (S.4) has been completely eliminated. Check the reaction periodically by TLC (see Basic Protocol 1, step 6), eluting with 85:8:7 (v/v/v) acetonitrile/H2O/concentrated NH4OH. The reaction should be finished after ∼20 hr. The Rf of 1-(6-O-trimethylsilylethyl)-N2-(3aminopropyl)-2′-deoxyguanosine (S.5) is ∼0.25, and that of S.4 is ~0.8.
4. Evaporate the solvent under reduced pressure (see Basic Protocol 2, step 4). 5. Prepare a column for flash chromatography by packing a 2.5 × 20–cm column with 20 g silica gel using the TLC solvent system (step 3). 6. Place the sample in a 100-mL round-bottom flask and add a few milliliters of methanol to dissolve it. Add ~1 g dry silica gel and evaporate the methanol using a rotary evaporator with a water aspirator. 7. Carefully add the powdery sample/gel mixture as evenly as possible to the top of the column. Add a layer of sand and elute using the TLC solvent mixture. 8. Collect 5- to 7-mL fractions and analyze by TLC (step 3). 9. Combine fractions containing pure product and evaporate to dryness using a rotary evaporator, first with a water aspirator and then under high vacuum with an oil pump. Yields of 70% to 75% (35 to 40 mg) of S.5 should be obtained.
10. Dissolve S.5 in 500 µL anhydrous THF. Add 200 µL of 1 M TBAF in THF and stir the reaction for 12 hr at room temperature. 11. Evaporate the solvent under reduced pressure (see Basic Protocol 2, step 4). 12. Monitor the deprotection reaction by TLC (step 3). The Rf of S.5 is 0.25. The deprotected product will have a much lower Rf .
13. Add 200 µL of 1:1 (v/v) DMSO/methanol and purify by HPLC using the following conditions: Column: 10 × 250–mm YMC-ODS-AQ Solvents: (A) 0.1 M ammonium formate, pH 6.4; (B) acetonitrile Flow rate: 5 mL/min Gradient: 99% to 90% A over 15 min, 90% to 80% A over 5 min, 80% to 0% A over 10 min, return to 99% A over 5 min. 2-N-(3-Aminopropyl)-2′-deoxyguanosine (S.6) elutes at ∼12 min. Yields of ∼50% should be expected for the deprotection and HPLC purification steps. The product can be stored indefinitely at 4° or –20°C.
Synthesis of Modified Nucleosides
1.3.13 Current Protocols in Nucleic Acid Chemistry
ALTERNATE PROTOCOL 3
SYNTHESIS OF 2-N-[2(S)-1-HYDROXYBUT-3-EN-2-YL]-2′DEOXYGUANOSINE This protocol describes the use of 2-amino-3-butenol to prepare an 2-N-hydroxyalkenesubstituted 2′-deoxyguanosine (S.8) using acetic acid to remove the 6-O-trimethylsilylethyl group (Fig. 1.3.3C). Additional Materials (also see Basic Protocol 2) 2(S)-Amino-3-butenol 0.1 M ammonium formate in water, pH 6.4 12 × 75–mm glass test tube or conical vial with a magnetic stir bar Lyophilizer 10 × 250–mm C18 reversed-phase HPLC column (e.g., YMC-ODS-AQ column; YMC) 1. Dry 10 mg of 2-fluoro-6-O-TMSE-2′-dI (S.4; 0.027 mmol) overnight in a 12 × 75–mm glass test tube under vacuum at room temperature using a rotary evaporator and an oil pump. 2. Add a small magnetic stir bar and the following reagents: 35 mg (0.041 mmol) 2(S)-amino-3-butenol 10 µL (0.057 mmol) DIEA 50 µL anhydrous DMSO. 3. Cap the tube securely and heat with stirring in a temperature-controlled oil bath or heating block at 60°C for 20 hr. 4. Monitor the reaction by TLC (see Alternate Protocol 2, step 3). The reaction mixture may contain both product with TMSE (S.7) and desilylated product (S.8). Starting material S.4 has an Rf of 0.8, and S.8 has an Rf of 0.22. S.7 will have an Rf between those of S.4 and S.8.
5. Remove the solvent under reduced pressure (see Basic Protocol 2, step 4). 6. Suspend the residue in 0.5 mL water and lyophilize. 7. Remove remaining TMSE protecting group by treating the product mixture with 200 µL of 0.1 M aqueous acetic acid at room temperature for 2 hr. 8. Neutralize with an equal volume of 0.l M NaHCO3 (final pH 6.5 to 7.5) and lyophilize. 9. Purify by HPLC using the following conditions: Column: 10 × 250-mm YMC-ODS-AQ Solvents: (A) 0.1 M ammonium formate, pH 6.4; (B) methanol Flow rate: 5 mL/min Gradient: 90% to 10% A over 25 min. The deprotected product (S.8) elutes at ∼12 min; protected product (S.7) elutes at ∼26 min. The yield from this reaction is ∼80%. The product can be stored indefinitely at 4° or –20°C. Synthesis of N2-Substituted Deoxyguanosine Nucleosides
1.3.14 Current Protocols in Nucleic Acid Chemistry
SETTING UP A NITROGEN ATMOSPHERE Many of the steps are carried out under a slight positive pressure of inert gas (usually nitrogen, although argon can also be used) to keep moisture and oxygen out of reactions. When a procedure is described as being carried out under nitrogen, this is accomplished by attaching a source of dry nitrogen gas via tubing to a Y- or T-shaped glass connector. One arm of the connector is attached to the inlet of a bubbler that is partially filled with a high-boiling inert liquid such as mineral oil; the outlet of the bubbler is open to the atmosphere. The third arm of the connector is connected via tubing to the reaction flask equipped with either a gas inlet adapter or a syringe needle inserted through a rubber septum in one of the joints of the flask. To ensure a slight positive pressure of inert gas in the system, the flow of nitrogen is adjusted so that a slow stream of bubbles is created in the bubbler. This arrangement is preferable to having nitrogen pass through the flask, which causes evaporation of solvents. A useful guide to handling air-sensitive reagents and working in an inert atmosphere can be found in Technical Bulletin AL-134 (Aldrich Chemical, 1983).
SUPPORT PROTOCOL
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Anisaldehyde/sulfuric acid spray Dissolve 5 mL of p-anisaldehyde in 90 mL of 95% ethanol. Carefully add 5 mL concentrated H2SO4 followed by three drops of glacial acetic acid. Store up to several months at 4° to 6°C or several days at room temperature. Reagent can be applied to TLC plates with a spray bottle or by dipping. CAUTION: Prepare and use this reagent only in a well-ventilated fume hood. It is corrosive and the vapors are highly irritating.
Sodium methoxide in methanol, 0.35 M Prepare a 0.35 M solution by adding 18.9 g solid sodium methoxide (Aldrich) to 1 liter anhydrous methanol. Prepare fresh before use or store for several days at room temperature under an inert atmosphere. Prepared solutions of sodium methoxide in methanol can be purchased from Aldrich. COMMENTARY Background Information Syntheses of N2-substituted guanine nucleosides have been studied for many years, primarily with ribosides. The primary route to these compounds has been via nucleophilic displacement of a halogen at the 2 position of an inosine bearing a substituent (such as O-benzyl or thione) at the 6 position (Montgomery and Hewson, 1960; Gerster and Robins, 1965, 1966). The halogen (bromo, chloro, or fluoro) is introduced by aqueous diazotization of the 2-amino group of a guanosine derivative in the presence of a halide source (Gerster and Robins, 1965), and the O6 substituent is converted by hydrogenation (for the benzyl substituent) or oxidation (for thione) to the 2-fluoro guanine derivative.
This strategy, while successful for ribosides, requires acidic conditions that are too vigorous for the acid-labile deoxyribosides. The current strategy takes advantage of methodology developed by Robins and Uznanski (1981) for low-temperature, nonaqueous diazotization of ribosides in organic solvents using t-butyl nitrite as the diazotizing agent and HF/pyridine as the fluoride source for the preparation of fluoro derivatives. Other fluoridating agents have also been explored (Acedo et al., 1994; Adib et al., 1997). The fluoro derivatives have proved to be the most useful because they are more reactive toward nucleophilic displacement than the other halogen derivatives (Gerster and Robins, 1965). Lee et al. (1990) reported that the nonaqueous diazotization strat-
Synthesis of Modified Nucleosides
1.3.15 Current Protocols in Nucleic Acid Chemistry
Synthesis of N2-Substituted Deoxyguanosine Nucleosides
egy could be used for the preparation of 2fluoro-6-O-benzyl-2′-deoxyinosine. Harris et al. (1991) then reported similar experiments that had been extended to the synthesis of 2fluoro-2′-deoxyinosine itself, and its incorporation into oligonucleotides via phosphoramidite chemistry. However, the 2-fluoro derivative without O6-protection did not react as well with nucleophiles, and its conversion to the corresponding phosphoramidite did not proceed in very high yield. Although the benzyl protecting group is easily introduced, its removal requires catalytic hydrogenation, which can cause problems if a polycyclic aromatic hydrocarbon (PAH) substituent has been introduced at N2 (Lee et al., 1990). Hence, it became apparent that a different O6-protecting group was required. The 4nitrophenethyl (NPE) group, which had been explored by Gaffney and Jones (1982) and Himmelsbach et al. (1984) for the protection of deoxyguanosine during oligonucleotide synthesis, has found wide use for preparation of the 2-fluoroinosine derivative (Zajc et al., 1992; Erlanson et al., 1993; Eritja et al., 1995; Lee et al., 1995; Schmid and Behr, 1995; Diaz et al., 1997). 2-Fluoro-6-O-(4-nitrophenethyl)-2′deoxyinosine can be prepared by the series of reactions described in this unit, starting with either triacetyl (Lee et al., 1995; see Basic Protocol 1) or diacetyl (Zajc et al., 1992; see Alternate Protocol 1) deoxyguanosine. Use of the 3′,5′-O-diacetyl derivative greatly shortens the synthesis, because several days of ammonia/methanol treatment are required for removal of the N2-acetyl group. There is risk of losing the NPE group by β-elimination if sodium methoxide is used for this step. The trimethylsilylethyl group is also very useful for O6-protection (Tsarouhtsis et al., 1995; DeCorte et al., 1996). Both groups can be used for preparation of O6-protected 2-fluoro-2′-deoxyinosine phosphoramidites and for oligonucleotide synthesis. The NPE group is usually removed by treatment with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU); it may be slowly lost if the substitution reaction requires prolonged heating in the presence of excess amine. The TMSE group, while quite stable in the fluoro derivative under anhydrous neutral or alkaline conditions, is often lost spontaneously once there is an amine substituent at C2, and generally requires only mild acid treatment to achieve complete deprotection. Allerson et al. (1997) have recently reported a synthesis of the 2-fluoro-6-O-(4-nitrophenethyl)-riboside derivative, in which the hydroxyls and N2 were
protected as triethylsilyl (TES) derivatives; the TES groups were removed in the course of the fluoridation reaction. Quite a number of substitution reactions have now been reported using a 2-fluoro-2′-deoxyinosine derivative, either at the nucleoside stage or in oligonucleotides. Amine nucleophiles have been used to attach a wide variety of substituents including amino alcohols (Zajc et al., 1992), polyamines (Schmid and Behr, 1995; Diaz et al., 1997), disulfide-containing diamines (Wolfe and Verdine, 1993), pyrrolizidine amines (Woo et al., 1993; Tsarouhtsis et al., 1995), heterocyclic amines (Wang and Bergstrom, 1993; Ramasamy et al., 1994), benzylic amines bearing large polycyclic substituents (Lee et al., 1990, 1995; Sangaiah et al., 1992; Zajc et al., 1992), and metal-binding ligands (Bergstrom and Gerry, 1994). In addition, 15N is easily introduced by use of 15NH3 at either the nucleoside or oligonucleotide stage (Acedo et al., 1994). An acylated derivative of 2-fluoro-6-ONPE-2′-deoxyinosine has been used in a reaction with the severely hindered triol amines derived from opening of the diol epoxide of benzo[a]pyrene with ammonia (Zajc et al., 1992); however, a high temperature was required for the reaction. The 2-triflate derivative of 2′-deoxyinosine (Steinbrecher et al., 1993; Edwards et al., 1997) offers promise for syntheses requiring very bulky, highly sterically hindered nucleophiles.
Compound Characterization 2-N-3′,5′-O-Triacetyl-2′-deoxyguanosine (S.2): mp 193° to 194°C (soften), 225°C (decompose); TLC Rf 0.31 (9:1 CH2Cl2/MeOH); 1H NMR (DMSO-d ) δ 12.20 to 11.40 (br, 2H, 6 2×NH), 8.23 (s, 1H, H8), 6.22 (dd 1H, J = 7.2 Hz, H1′), 5.33 (d, 1H, J = 5.7 Hz, H3′), 4.22 to 4.20 (m, 3H, H4′, H5′, H5′′), 2.95 (m, 1H, H2′), 2.52 (m, 1H, H2′′), 2.16 (s, 3H, CH3), 2.06 (s, 3H, CH3), 2.00 (s, 3H, CH3). 3′,5′-O-Diacetyl-2′-deoxyguanosine (S.7): mp 300°C (decompose); 1H NMR (DMSO-d6) δ 7.80 (s, 1H, H8), 6.40 (2H, bs, NH2), 6.03 (s, 1H, H1′), 5.19 (1H, m, H3′), 4.15 (1H, m, H5′′), 4.11 (2H, m, H5′′H4′), 2.81 (m, 1H, H2′), 2.33 (m, 1H, H2′′, 1.97 (s, 3H, CH3), 1.94 (s, 3H, CH3). 6-O-(Trimethylsilylethyl)-2′-deoxyguanosine (S.3): mp 66° to 68°C; TLC Rf 0.41 (9:1 CH2Cl2/MeOH); 1H NMR (MeOH-d4) δ 8.00 (s, 1H, H8), 6.30 (dd, 1H, J = 6.1 Hz, J = 2.1 Hz, H1′), 4.61 to 4.53 (m, 3H, OCH2CH2Si, H3′), 4.03 (q, 1H, J = 2.7 Hz, H4′), 3.83 (dd,
1.3.16 Current Protocols in Nucleic Acid Chemistry
1H, J = 3.3, 12.2, H5′), 3.73 (dd, 1H, J = 12.2, 2.9, H5′′), 2.76 (m, 1H, H2′), 2.34 (m, 1H, H2′′), 1.21 (m, 2H, CH2Si), 0.08 (s, 9H, (CH3)3Si); 1H NMR (CDCl3) δ 7.64 (s, 1H, H8), 6.16 (dd, 1H, J = 8.8 Hz, J = 5.7 Hz, H1′), 5.04 (s, 2H, NH2), 4.56 (d, 1H, J = 4.8 H z , H 3′) , 4 . 3 9 ( t , 2 H , J = 8 . 6 H z , OCH2CH2Si), 4.07 (br, 1H, H4′), 3.70 (m, 2H, H5′, H5′′), 2.73 (m, 1H, H2′), 2.21 (m, 1H, H2′′), 1.02 (t, 2H, J = 8.6 Hz, CH2Si), -0.10 (s, 9H, (CH3)3Si). 2-Fluoro-6-O-(trimethylsilylethyl)-2′deoxyinosine (S.4): mp 120° to 122°C; TLC Rf 0.36 (9:1 CH2Cl2/MeOH); 1H NMR (MeOH-d4) δ 8.46 (s, 1H, H8), 6.41 (t, 1H, J = 6.7 Hz, H1′), 4.67 to 4.72 (m, 2H, OCH2CH2Si), 4.56 (m, 1H, H3′), 4.02 (q, 1H, J = 3.6 Hz, H4′), 3.81 (dd, 1H, J = 3.6, H5′′), 3.73 (dd, 1H, J = 2.9, H5′), 2.77 (m, 1H, H2′′), 2.44 (m, 1H, H2′), 1.26 (m, 2H, CH2Si), 0.1 (s, 9H, (CH3)3Si); 1H NMR (CDCl3) δ 8.56 (s, 1H, H8), 6.31 (t, 1H, J = 6.7 Hz, H1′), 5.35 (d, 1H, J = 4.2 Hz, 3′-OH), 4.94 (t, 1H, J = 5.5 Hz, 5′-OH), 4.64 (t, 2H, J = 8.3 Hz, OCH2CH2Si), 4.40 (m, 1H, H3′), 3.87 (q, 1H, J = 4.0 Hz, H4′), 3.55 (m, 2H, H5′ and H5′′), 2.68 (m, 1H, H2′), 2.32 (m, 1H, H2′′), 1.20 (t, 2H, J = 8.3 Hz, CH2Si), 0.08 (s, 9H, (CH3)3Si); 19F NMR (MeOH-d4) δ -51.55; 19F NMR (CDCl ) δ −50.40. 3
Critical Parameters and Troubleshooting Overall, it is important that starting nucleosides for each step in the synthesis be thoroughly dried either by coevaporation with anhydrous pyridine or in an Abderhalden drying apparatus (overnight under vacuum at 78°C). Anhydrous solvents are also important. The solvents should either be freshly distilled and stored under nitrogen or argon, or should be taken from a freshly opened bottle of commercially prepared anhydrous solvent. It is best to purchase anhydrous solvents in the smallest size bottle that will fit the requirements of the synthesis. Acylation. Dry reagents are important for acylation. The main effect of moisture is to decrease the yield of product. Serious problems are seldom encountered in this step. Mitsunobu alkylation. This reaction is most sensitive to the quality of the DEAD reagent. The best yields are obtained when using reagent from a freshly opened bottle. Fluoridation. This reaction requires careful attention to three factors: (1) dryness of the
O6-protected nucleoside, (2) quality of the HF/pyridine reagent, which should be pale amber or lighter in color, and (3) maintenance of low temperature during the course of the reaction. Lack of attention to any of these factors can lead to depurination and failure to obtain any product. Substitution reactions. The nature of the nucleophile is the most critical parameter in this reaction. Sterically hindered amines require longer time and/or higher temperature for reaction. The rate of reaction is also determined by the concentrations of nucleoside and amine. Temperatures as high as 80° to 85°C have been used in certain cases. If the substituent is a bulky hydrocarbon, removal of the TMSE group may require more vigorous deprotection conditions (e.g., 5 mM HCl in methanol at 50°C for several hours). Evaporation of solvents. This is usually accomplished using rotary evaporation under vacuum. It is very helpful if the rotary evaporator is equipped with a dry ice condenser or with a condenser that is cooled with chilled water. The vacuum is normally applied with a water aspirator (25 to 30 mmHg), which is quite sufficient for materials with boiling points <100°C (at 760 mm). However, several of the reagents and solvents used in these procedures have boiling points >100°C. For these steps, it is better to use an oil pump to produce a vacuum of ≤1 mmHg. This allows higher-boiling compounds to be removed with the application of little or no heat. The general procedure is to remove the more volatile materials first using the water aspirator, and then remove the higherboiling compounds using the oil pump. The oil pump should not be used to remove the lowerboiling materials, particularly if there are chlorinated solvents present. If the only volatile material is water, it can also be removed by lyophilizaton or vacuum centrifugal evaporation (e.g., with a Speedvac evaporator). Small volumes of volatile organics can also be removed by this method if the instrument is equipped with a chemically resistant cold trap. This is, for example, an effective way to removed small volumes of DMSO.
Anticipated Results An overall yield of 45% to 55% of 2-fluoro6-O-TMSE-2′-deoxyinosine from 2′-deoxyguanosine can be obtained in this series of reactions. The yields of substitution reactions are generally very high, although the recovered yield of purified product may be considerably
Synthesis of Modified Nucleosides
1.3.17 Current Protocols in Nucleic Acid Chemistry
lower, depending upon the scale and method of purification.
Time Considerations An approximate time scale for the sequence of reactions described in this unit would be 3 to 5 days for acylation, depending upon whether the tri- or diacetyl derivative is chosen as the starting material; 3 days for the Mitsunobu reaction; 2 days for fluoridation; and 2 to 4 days for substitution reactions, depending upon the nucleophile and the mode of purification (e.g., HPLC generally takes longer than preparatory TLC). The reaction can be greatly accelerated by using a large excess of amine. Considerable variation in these times is to be expected and is based upon the time allowed for drying and/or distillation of reagents, recrystallization, chromatographic separation, and analysis, as well as on the experimenter’s level of synthetic chemistry experience.
Literature Cited Acedo, M., Fabrega, C., Avino, A., Goodman, M., Fagan, P., Wemmer, D., and Eritja, R. 1994. A simple method for N-15 labelling of exocyclic amino groups in synthetic oligodeoxynucleotides. Nucl. Acids Res. 22:2982-2989. Adib, A., Potier, P.F., Doronina, S., Huc, I., and Behr, J.-P. 1997. A high-yield synthesis of deoxy-2fluoroinosine and its incorporation into oligonucleotides. Tetrahedron Lett. 38:2989-2992. Aldrich Chemical. 1983. Technical Bulletin AL134: Handling Air-Sensitive Reagents. Aldrich Chemical Co., Milwaukee, Wis. Allerson, C.R., Chen, S.L., and Verdine, G.L. 1997. A chemical method for site-specific modification of RNA: The convertible nucleoside approach. J. Am. Chem. Soc. 119:7423-7433. Bergstrom, D.E. and Gerry, N.P. 1994. Precision sequence-specific cleavage of a nucleic acid by a minor-groove-directed metal-binding ligand linked through N-2 of deoxyguanosine. J. Am. Chem. Soc. 116:12067-12068. DeCorte, B.L., Tsarouhtsis, D., Kuchimanchi, S., Cooper, M.D., Horton, P., Harris, C.M., and Harris, T.M. 1996. Improved strategies for postoligomerization synthesis of oligodeoxynucleotides bearing structurally defined adducts at the N2 position of deoxyguanosine. Chem. Res. Toxicol. 9:630-637. Diaz, A.R., Eritja, R., and Garcia, R.G. 1997. Synthesis of oligodeoxynucleotides containing 2substituted guanine derivatives using 2-fluoro2′-deoxyinosine as common nucleoside precursor. Nucleosides Nucleotides 16:2035-2051. Synthesis of N2-Substituted Deoxyguanosine Nucleosides
Edwards, C., Boche, G., Steinbrecher, T., and Scheer, S. 1997. Synthesis of 2-substituted 2′-deoxyguanosines and 6-O-allylguanines via activation of C-2 by a trifluoromethanesulfonate group. J. Chem. Soc. Perkin Trans 1 1887-1893.
Eritja, R., Acedo, M., Avino, A., and Fabrega, C. 1995. Preparation of oligonucleotides containing non-natural base analogues. Nucleosides Nucleotides 14:821-824. Erlanson, D.A., Chen, L., and Verdine, G.L. 1993. DNA methylation through a locally unpaired intermediate. J. Am. Chem. Soc. 115:12583-12584. Gaffney, B.L. and Jones, R.A. 1982. A new strategy for the protection of deoxyguanosine during oligonucleotide synthesis. Tetrahedron Lett. 23:2257-2260. Gerster, J.F. and Robins, R.K. 1965. Purine nucleosides. X. The synthesis of certain naturally occurring 2-substituted amino-9-β-D-ribofuranosylpurin-6(1H)-ones (N2-substituted guanosines). J. Am. Chem. Soc. 87:3752-3759. Gerster, J.F. and Robins, R.K. 1966. Purine nucleosides. XIII. The synthesis of 2-fluoro- and 2chloroinosine and certain derived purine nucleosides. J. Org. Chem. 31:3258-3262. Harris, C.M., Zhou, L., Strand, E.A., and Harris, T.M. 1991. A new strategy for synthesis of oligonucleotides bearing adducts at exocyclic amino sites of purine nucleosides. J. Am. Chem. Soc. 113:4328-4329. Himmelsbach, F., Schulz, B.S., Trichtinger, T., Charubala, R., and Pfleiderer, W. 1984. The pnitrophenylethyl (NPE) group. A versatile new blocking group for phosphate and aglycone protection in nucleosides and nucleotides. Tetrahedron 40:59-72. Lee, H., Hinz, M., Stezowski, J.J., and Harvey, R.G. 1990. Syntheses of polycyclic aromatic hydrocarbon-nucleoside and oligonucleotide adducts specifically alkylated on the amino functions of deoxyguanosine and deoxyadenosine. Tetrahedron Lett. 31:6773-6776. Lee, H., Luna, E., Hinz, M., Stezowski, J.J., Kiselyov, A.S., and Harvey, R.G. 1995. Synthesis of oligonucleotide adducts of the bay region diol epoxide metabolites of carcinogenic polycyclic aromatic hydrocarbons. J. Org. Chem. 60:56045613. Matsuda, A., Shinozaki, M., Suzuki, M., Watanabe, K., and Miyasaka, T. 1986. A convenient method for the selective acylation of guanine nucleosides. Synthesis 385-386. Mitsunobu, O. 1981. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1-28. Montgomery, J.A. and Hewson, K. 1960. Synthesis of potential anticancer agents. XX. 2Fluoropurines. J. Am. Chem. Soc. 82:463-468. Ramasamy, K., Zounes, M., Gonzalez, C., Freier, S.M., Lesnik, E.A., Cummins, L.L., Griffey, R.H., Monia, B.P., and Cook, P.D. 1994. Remarkable enhancement of binding affinity of heterocycle-modified DNA to DNA and RNA. Synthesis, characterization and biophysical evaluation of N2-imidazolylpropylguanine and N2-imidazolylpropyl-2-aminoadenine modified oligonucleotides. Tetrahedron Lett. 35:215-218.
1.3.18 Current Protocols in Nucleic Acid Chemistry
Robins, M.J. and Uznanski, B. 1981. Nucleic acid related compounds. 34. Non-aqueous diazotization with tert-butyl nitrite. Introduction of fluorine, chlorine, and bromine at C-2 of purine nucleosides. Can. J. Chem. 59:2608-2611. Sangaiah, R., Gold, A., Ball, L.M., Matthews, D.L., and Toney, G.E. 1992. Synthesis and resolution of putative diastereomeric N2-deoxyguanosine and N6-deoxyadenosine adducts of biologically active cyclopentaPAH. Tetrahedron Lett. 33:5487-5490. Schmid, N. and Behr, J.-P. 1995. Recognition of DNA sequences by strand replacement with polyamino-oligonucleotides. Tetrahedron Lett. 36:1447-1450. Steinbrecher, T., Wameling, C., Oesch, F., and Seidel, A. 1993. Activation of the C2 position of purine by the trifluoromethanesulfonate group: Synthesis of N2-alkylated deoxyguanosines. Angew. Chem. Int. Ed. Engl. 32:404-406. Tsarouhtsis, D., Kuchimanchi, S., DeCorte, B.L., Harris, C.M., and Harris, T.M. 1995. Synthesis of oligonucleotides containing interchain crosslinks of bifunctional pyrroles. J. Am. Chem. Soc. 117:11013-11014. Wang, G. and Bergstrom, D.E. 1993. Synthesis of oligonucleotides containing N2-[2-(imidazol-4ylacetamido)ethyl]-2′-deoxyguanosine. Tetrahedron Lett. 34:6725-6728.
Wolfe, S.A. and Verdine, G.L. 1993. Ratcheting torsional stress in duplex DNA. J. Am. Chem. Soc. 115:12585-12586. Woo, J., Sigurdsson, S.T., and Hopkins, P.B. 1993. DNA interstrand cross-linking reactions of pyrrole-derived, bifunctional electrophiles: Evidence for a common target site in DNA. J. Am. Chem. Soc. 115:3407-3415. Zajc, B., Lakshman, M.K., Sayer, J.M., and Jerina, D.M. 1992. Epoxide and diol epoxide adducts of polycyclic aromatic hydrocarbons at the exocyclic amino group of deoxyguanosine. Tetrahedron Lett. 33:3409-3412.
Key References Gerster and Robins, 1965, 1966. See above. These papers describe the synthesis and some of the reactions of 2-fluoro-6-O-benzyl-inosine. Tsarouhtsis et al., 1995; DeCorte et al., 1996. See above. Synthesis of 2-fluoro-6-O-(trimethylsilylethyl)-2′deoxyinosine and the related phosphoramidite; oligonucleotide synthesis and substitution reactions.
Contributed by Thomas M. Harris and Constance M. Harris Vanderbilt University Nashville, Tennessee
Synthesis of Modified Nucleosides
1.3.19 Current Protocols in Nucleic Acid Chemistry
Unnatural Nucleosides with Unusual Base Pairing Properties Synthetic modified nucleosides designed to pair in unusual ways with the natural nucleic acid bases have many potential applications in nucleic acid biochemistry. These range from biochemical tools for probing nucleic acid structure or protein–nucleic acid interactions to tools for re-engineering DNA and ultimately proteins. Applications as components of nucleic acid–based diagnostic tools for clinical analysis have been envisioned. Furthermore, unnatural bases may be useful as components of antisense or antigene nucleic acid analogs in therapeutic applications. This unit serves to lay the foundation for future protocol units on unnatural base synthesis and application, with particular emphasis on unnatural base analogs that mimic natural bases in size, shape, and biochemical processing. A much more extensive compilation of unnatural nucleobases has recently been published by Luyten and Herdewijn (1998). To design bases that mimic natural bases in function, it is useful to consider the factors that are essential for effective base pairing and stable duplex formation. In addition to structures that are configured to hydrogen bond and base stack within the spatial confines of duplex DNA and RNA, any surrogate base pair must also conform to specific dimensions and geometry if it is to function in roles that require recognition by nucleic acid–processing enzymes. To be isosteric with AT or GC base pairs, the C1′ to C1′ distance must be in the range of 10.8 to 11.0 Å, and λ1 and λ2 should be ~50° (Fig. 1.4.1; Saenger, 1984). Just as it is important to know where to place hydrogen bond donor and acceptor sites, it is important to consider the availability of sur-
Watson-Crick base pair geometry λ
C1' - C1' ~ 10.8 to 11.0 Å
C1'
λ ~ 50 - 54° λ C1'
Figure 1.4.1 Base pair parameters. See APPENDIX 1B and Figure A.1B.4 for other base pairing schemes.
UNIT 1.4
rounding free space when designing new nucleobases. This can generally be determined by inspecting the groove regions of nucleic acid duplex and triplex models. Where the foundation for the design is a natural nucleobase, substitution is allowed at C5 of C, T, or U. N4 of C and N6 of A are also possible attachment sites, but generally compromise base association. N2 of G is acceptable and, unlike all other sites, allows minor groove placement of an appendage. C8 of A and G have been used as sites for attachment of appendages, but substitution here may influence the conformation preference about the glycosidic bond. Replacement of the purine N7 with a carbon provides a site for attachment of appendages in a sterically tolerated position. There are many examples of appendages that, when added to the natural nucleic acid bases, enhance base-pair stability. These include substituents that increase the acidity of proton donor sites (Yu et al., 1993) or increase hydrophobicity and aromatic surface area for enhanced base stacking (Inoue et al., 1985), as well as appended cations for electrostatic interactions with the phosphodiester backbone (Ueno et al., 1998).
BASE PAIRS WITH ALTERNATIVE HYDROGEN BONDING SCHEMES Purine-Pyrimidine-Like Base Pairs Benner and co-workers have described a set of nucleobase analogs that resemble natural bases, but have reconfigured hydrogen bonding patterns (Piccirilli et al., 1990). Six orthogonal base pairs (S.1 to S.6) are shown in Figure 1.4.2. Extensive studies on these nucleosides have revealed that even these subtle changes in structure can cause profound effects on thermodynamic (Voegel and Benner, 1994) and biochemical properties (Switzer et al., 1993; Horlacher et al., 1995). For example, the C-nucleoside pyrimidine mimics appear to base pair more weakly than equivalent base pairs composed of N-nucleosides. As far as biochemical properties, it appears that certain DNA polymerases require the pyrimidine O2 and purine N3 as recognition features for efficient template-mediated oligonucleotide synthesis (Horlacher et al., 1995).
Contributed by Donald E. Bergstrom Current Protocols in Nucleic Acid Chemistry (2001) 1.4.1-1.4.13 Copyright © 2001 by John Wiley & Sons, Inc.
Synthesis of Modified Nucleosides
1.4.1 Supplement 5
C-G N H
N
H
H
N
H N
H
N
H N
N
N
O
H
N
dR
H
N
H
H
H 2
H
N dR N
N
3
N
N
O
O dR
N
H
N
H
N dR N O
N
N dR
N N
N
N
N
H
1
O N
N
O
dR
H
H
N dR
O
N
N
H
N
H
4
dR
N H N
N
H
N
N O
N N H
H
N
H
N 5
N dR N
O
H
N
N
H
H
dR
H
N dR
O
H
O
N H
dR
N
CH3
O H 6
site itself, the duplex was destabilized more than when the triazole was placed opposite each of the natural bases. This result is in line with NMR studies on duplex DNA containing the triazole carboxamide opposite either G or T (Klewer et al., 2001). In both cases, the triazole prefers to adopt a conformation in which the amide group points out into the major groove rather than inward towards the opposing base pair. To achieve specific association through hydrogen bond interactions, one of the two triazole carboxamides in a self-pair would have to face with the amide projecting inward towards the opposing base. This example reflects parameters that one must consider when designing base pairs; the interior of the helix is a less hydrophilic environment and, without sufficient compensation, highly hydrophilic groups will prefer to assume positions that place them in a more hydrophilic environment.
HYDROPHOBIC BASE PAIRS Figure 1.4.2 Structures of six Watson-Cricktype base pairs utilizing mutually exclusive hydrogen bonding schemes.
Self-Complementary Nucleobases Another concept for new base pair development was proposed by Pochet and Marliére (1996). Based on the known ability of the mutagenic base 8-oxoguanine to base pair with A from a syn conformation, these researchers redesigned the base by removing the 6-oxo group. This yields the unnatural base 2-amino-8oxopurine (S.7), which they postulate would pair with itself according to the arrangement shown in Figure 1.4.3. The results of biochemical studies with this unusual base have not yet been reported. One can imagine similar selfpairing potential for azole carboxamide nucleosides, as illustrated in Figure 1.4.3 for 1,2,4triazole-3-carboxamide (S.8). However, Tm studies on a duplex containing 1,2,4-triazole3-carboxamide showed that when placed oppo-
H N H
N
N dR
Unnatural Nucleosides with Unusual Base Pairing Properties
H N
N N
N
O
N H H 7
Figure 1.4.3
N H
N
H O
There are now a significant number of examples of hydrophobic unnatural bases that pair with other hydrophobic bases or with themselves in duplex DNA with higher affinity than with any of the natural bases. 3-Nitropyrrole deoxyribonucleoside (S.26; Fig. 1.4.8), which was originally designed as a universal nucleobase, pairs with almost equal affinity to each of the natural bases, but a 12-mer duplex with nitropyrrole opposite itself is significantly more stable than the same duplex with nitropyrrole opposite each of the natural bases (Bergstrom et al., 1995; Zhang et al., 1998). The significance of the hydrophobic substituent (nitro) in mediating this effect is clear when one compares pyrrole-3-carboxamide, which in duplex DNA yields far more stable duplexes when paired opposite each of the natural bases than when paired opposite itself. Because of these results, hydrophobic base pairs are considered to be attractive candidates for extension of the genetic alphabet. Two themes are possible: (1) the development of a
N
O N
N H H
O
N
dR
N H
N
dR N
N dR 8
Self-pairing bases.
1.4.2 Supplement 5
Current Protocols in Nucleic Acid Chemistry
complementary hydrophobic pair, and (2) the creation of a single self-complementary hydrophobic base. The latter possibility is more attractive, because one need contend with the optimization of DNA replication with only one unnatural nucleoside. A series of recent papers from a research effort at Scripps Research Institute led by Romesberg and Schultz has described considerable progress in the development of hydrophobic self-pairing bases (McMinn et al., 1999; Berger et al., 2000a; Ogawa et al., 2000; Wu et al., 2000). Three of these nucleoside analogs, 1-β-D-deoxyribosyl-7-azaindole (S.10; Ogawa et al., 2000) and two different 7-propynyl isocarbostyril deoxyribonucleosides (S.9; R = H and CH3; McMinn et al., 1999) are shown in Figure 1.4.4. These nucleoside analogs, as assessed by Tm measurements, self-pair significantly more effectively than they pair with any of the natural bases. Furthermore, both contain a lone pair of electrons that may be positioned optimally in the minor groove for interaction with DNA polymerase. Kool and co-workers have designed a set of non-hydrogen-bonding base analogs for A and T (Fig. 1.4.4; S.12 to S15; Schweitzer and Kool, 1995; Guckian et al., 1998). In a 12-bp duplex, virtually all paired combinations of the hydrophobic bases gave higher Tm values than when each hydrophobic base was paired with any of the natural bases. Pyrene deoxyribonucleoside (S.11; Fig. 1.4.4) is noteworthy because of the high specificity with which it pairs opposite abasic sites (Matray and Kool, 1999).
The nonpolar nucleobase difluorotoluene (S.14), a thymine isostere lacking hydrogenbonding functionality, can effectively substitute for thymine in both the template strand and as the incoming nucleoside triphosphate. These results suggest that shape recognition in the absence of hydrogen bonding is an important factor in base pair recognition (Guckian and Kool, 1997; Moran et al., 1997a,b; Guckian et al., 1998; Kool, 1998). Similarly, 4-methylbenzimidazole (S.12) is an effective surrogate for adenine when matched opposite the difluorotoluene nucleobase (Morales and Kool, 1999).
METAL-MEDIATED ASSOCIATION OF LIGAND NUCLEOBASE MIMICS Another way of mediating specific association between nucleobase-like molecules contained on a deoxyribosephosphodiester backbone is to configure them to bind transition metals. The simplest configurations would involve metals that form either linear planar complexes (e.g., Hg) or square planar complexes (e.g., Cu). Two examples of nucleobase mimics that bind a metal in a square planar complex have been published. Meggers et al. (2000) synthesized oligonucleotides containing opposing pyridine and pyridine-2,6-dicarboxylate ligands. The duplex is significantly stabilized in the presence of copper (Fig. 1.4.5; S.16), but not by other metals. Tanaka and Shionoya (1999) have described the synthesis of the diaminophenyl deoxyri-
Hydrophobic self-pairing bases H dR R N dR
N dR
O 9
N P-φ base pair
dR 10 11
R = H, CH3 F N F
N dR
N dR 12
13
Hydrophobic purine analogs
Figure 1.4.4
dR
dR
Hydrophobic nucleobase analogs.
14
15
Hydrophobic pyrimidine analogs
Synthesis of Modified Nucleosides
1.4.3 Current Protocols in Nucleic Acid Chemistry
Supplement 5
O
O P O O
O N
O O P O
N
M
O O O
O
O
O
16
O
P O O H N
O
O
O P O O
H N M
N H
O O
N H 17
Figure 1.4.5 Metal-mediated duplex association through metal-chelating nucleoside analogs. M, metal.
bonucleoside S.17, which binds platinum in a square planar complex to yield a stable structure resembling a natural base pair. Incorporation of this modified base into DNA and metal-mediated assembly of duplexes has not yet been described. However, the concept is noteworthy and could be the prelude to the development of highly novel nucleic acid analogs with unusual applications in material science and nanotechnology.
DEGENERATE BASES Chemical and radiological damage of nucleic acid bases frequently leads to modified bases that exhibit the ability to direct the incorporation of more than one natural base. Harnessing this ability for the development of mo-
P - imino H
O
N dR
O
N N dR
H H
N N
H H
N dR
18
K - amino
H
N N
G H
19
MeO
N N dR
N N
H H N
H
O
N
O
C H
N dR
O
N
20
Figure 1.4.6
N
A
N N
N
N
P - amino
O
O
N dR
N dR
H
MeO N H
T
N
N
N N
Unnatural Nucleosides with Unusual Base Pairing Properties
H N
lecular tools could be useful. One example is use of multicoding bases for the introduction of low-level mutations to generate random sequences in protein engineering. Bases that have the ability to pair with one natural base on template-directed primer extension but code for another base on template-directed replication by DNA polymerase have been referred to as convertides. Such bases are potentially useful as components of PCR/ligation-based detection assays (Day et al., 1999a,b). Two types of convertides have been described: (1) analogs that alter hydrogen bonding pattern and base pairing properties through tautomerism, and (2) analogs that alter their hydrogen bonding profile through changes in conformation. Brown and co-workers have described a purine analog that can base pair as either A (S.20) or G (S.21) and a pyrimidine analog that can base pair as C (S.19) or T (S.18; Fig. 1.4.6; Lin and Brown, 1989; Brown and Lin, 1991a; Negishi et al., 1997; Hill et al., 1998). The purine analog can adopt the hydrogen bonding configurations of adenine and guanine (Fig. 1.4.6) and the pyrimidine analog can adopt the hydrogen bonding configurations of thymine and cytosine through tautomerism. Isosteric azole carboxamide nucleobases capable of mimicking different sets of natural bases have been described. These compounds can mimic more than one natural nucleobase by virtue of rotation about bonds α and χ (Fig. 1.4.7). Modeling studies with azole carboxamides paired with the four natural bases in a B-DNA duplex show that two important parameters of base-pair geometry are maintained: the C1′ to C1′ distances are in the range of 10.8 to 11.0 Å, and λ1 and λ2 are ~50°. Models of
N dR
N H
N N
H
O
K - imino 21
Tautomerically degenerate base analogs.
1.4.4 Supplement 5
Current Protocols in Nucleic Acid Chemistry
well with all of the natural bases in a nucleic acid duplex. Applications in which a nucleoside analog functions only passively as a partner for a natural base within a duplex represent only one aspect of the behavior necessary for a compound to be truly regarded as a universal nucleoside. Recognition of the triphosphate as a universal nucleotide substrate by DNA polymerase, or suitability of oligonucleotides containing the analog as substrates for enzymes such as restriction endonucleases or ligases, would also be useful functions. Although it is unlikely that a single nucleoside analog can be devised which would function as a universal nucleoside under all circumstances, it is likely that a variety of analogs will be found with universal nucleoside properties optimal for particular techniques.
azole carboxamide base pairs with a natural base pair yield C1′ to C1′ distances that fall within 0.2 Å and λ1 and λ2 within 3° of the natural base pairs (Bergstrom et al., 1996; Johnson et al., 1997; Zhang et al., 1998). 1,2,4Triazole-3-carboxamide deoxyribonucleoside illustrates the difficulty of predicting both structural and biochemical behavior of nucleoside analogs. Based on modeling studies, the author of this unit predicted that the triazole would base pair preferentially with G and T by the pairing motifs S.22 and S.23 (Fig. 1.4.7). Evidence in favor of this hypothesis included Tm data that showed that this analog gives significantly more stable duplexes when paired with G and T than when paired with C and A. However, an NMR study indicated that 1,2,4-triazole-3carboxamide paired opposite T assumes a conformation in which the carboxamide group is not hydrogen bonded to T as shown in Figure 1.4.7 (S.24). On the other hand, 1,2,4-triazole-3-carboxamide directs the incorporation of C and T (but not G) when a template containing this base analog is replicated by Taq DNA polymerase. The geometrically acceptable base pairs in this case would be structures S.25 and S.23.
Universal Base Specifications The specifications for an ideal universal base are the following. 1. It should form equally stable base pairs with each of the natural nucleobases in all sequence contexts as determined by thermal melting experiments (Tm). 2. It should be accepted as template base by DNA polymerase (preferably Taq DNA polymerase) as assessed by PCR replication of universal base–containing template and steadystate kinetic experiments for single-nucleotide primer extension.
UNIVERSAL NUCLEOSIDES Universal Nucleoside Concept The concept of a “wildcard” or “universal” nucleoside is generally understood to mean a nucleoside analog that can base pair equally
O
H
N O
H N
N
N N dR χ
H
22
G
N dR N χ
O N
N H
N
N
O
H
N
N dR
H H
N H
N dR
or
H
N
O N
23
O
N H
O N N dR
H 24
N dR
T
O
Thermodynamically favored base pairs
N O H
N
H H
N
α
N
N dR H
H
N
25 O
C
N
O
O
N N dR
H N
α
N dR
H 23
N dR
O
T
DNA polymerase favored base pairs
Figure 1.4.7
N
Conformationally degenerate base analogs.
Synthesis of Modified Nucleosides
1.4.5 Current Protocols in Nucleic Acid Chemistry
Supplement 5
discrimination (A > G = T > C). By comparison, 3-nitropyrrole (S.29) pairs with little discrimination between each of the four natural bases (Bergstrom et al., 1995, 1997); however, it is significantly destabilizing relative to a natural base. This has been used to advantage in at least two separate applications. 3-Nitropyrrole has been used to increase the selectivity of hybridization-based detection of single-nucleotide polymorphisms (Guo et al., 1997), and as a tool to elevate the fidelity of thermostable Thermus thermophilus (Tth) DNA ligase for the ligation of oligonucleotide primers (Luo et al., 1996). The introduction of a second aromatic ring (e.g., 5-nitroindole; S.30) led to substantial improvement in duplex stability without too great of a loss in pairing nondiscrimination (Loakes and Brown, 1994). Neither 3-nitropyrrole nor 5-nitroindole deoxyribonucleosides are effective substrates or template components for DNA polymerase (Loakes et al., 1995). They preferentially direct the incorporation of the less polar natural bases A and T (Hoops et al., 1997). More recently it has been shown that both nondiscriminatory base pairing and high stability can be achieved with nucleosides based on the quinolone heterocycle (S.31; Berger et al., 2000b). The emphasis of the latter study has been to develop analogs that are effective substrates for DNA polymerases.
3. The corresponding deoxyribonucleoside triphosphate should be suitable as a substrate for DNA polymerase as assessed by steadystate kinetic experiments for single-nucleotide primer extension. 4. The base should be a substrate for DNA ligase as primer component as assessed by ligase chain reaction. This list is by no means complete, but represents those specifications that would be of the greatest use for the manipulation of DNA in conventional molecular biology techniques. The factors that contribute to base pair stability as assessed by thermal denaturation studies are not directly related to template preference by DNA polymerase. This has been illustrated by comparison of a set of azole carboxamide nucleosides for which the order of thermodynamic stabilities differs substantially from their template coding properties (Hoops et al., 1997).
Nonpolar Nucleobase Analogs The development of universal nucleic acid bases has progressed along two parallel lines. The first class of analogs includes molecules that cannot associate through hydrogen bonding, but because of size, shape, and hydrophobicity prefer to occupy the interior of a duplex (Fig. 1.4.8). The first analog of this class, phenyl deoxyribonucleoside (S.28), was reported in 1984 (Millican et al., 1984). It is highly destabilizing and pairs with significant
Evolution of the non-hydrogen bonding, hydrophobic universal base
NO2
NO2
N dR
dR 28
N dR
29
O 30
31
N dR
Hydrogen bonding capable universal base candidates
O N
Unnatural Nucleosides with Unusual Base Pairing Properties
N
H
NH2
N N dR
N
N 26
N dR
27
Deoxyinosine
Figure 1.4.8
Universal base candidates.
1.4.6 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Polar Hydrogen Bonding Nucleobase Analogs The first studies of nucleoside analogs specifically designed to base pair with more than one of the four primary DNA bases appeared over a decade ago (Millican et al., 1984; Eritja et al., 1986; Seela and Kaiser, 1986; Habener et al., 1988; Lin and Brown, 1989; Brown and Lin, 1991b). The most extensively studied example is 2′-deoxyinosine (S.26; Fig. 1.4.8), which has been in use as a putative universal nucleoside in oligonucleotide probes and primers since 1985 (Ohtsuka et al., 1985). Structural studies on deoxyinosine-modified oligonucleotides show that dI can base pair to dC, dA (Corfield et al., 1987; Uesugi et al., 1987), T (Cruse et al., 1989; Carbonnaux et al., 1990), and dG (Oda et al., 1991). However, it is not a true universal nucleoside because the base pairs dI-dX (X = dA, dC, dG, T) differ in stability by as much as 2 to 3 kcal/mol (Martin and Castro, 1985; Kawase et al., 1989). More importantly, primers constructed with multiple sites of deoxyinosine substitution frequently give undecipherable results in sequencing experiments. More recently Seela and Debelak (2000) have developed a nucleoside analog, N8-(2′-deoxyribofuranoside) of 8-aza-7-deazaadenine (S.27; Fig. 1.4.8), which pairs with all four natural bases with significantly less discrimination than inosine, but with relatively high affinity.
TRIPLEX CONSTITUENTS Duplex formation occurs through WatsonCrick pairing of purine and pyrimidine bases, which involves hydrogen bonding of NH3 and O4 of thymine with N1 and NH6 of adenine, and O2, N3, and NH4 of cytosine with NH2, NH1, and O6 of guanine. This leaves two sites on each of the purine bases (N7 and NH6 of adenine and N7 and O6 of guanine) free for hydrogen bonding. A third oligonucleotide strand can associate with a duplex through hydrogen bond formation to these sites within the major groove to form a triplex. Triplex formation with natural nucleotides generally assumes one of two themes: parallel association between a homopyrimidine strand and a homopurine-homopyrimidine duplex following the base association schemes C+•GC (S.32; Fig. 1.4.9) and T•AT (S.33), or antiparallel association involving the triplets G•GC (S.34), A•AT (S.35), and T•AT. In each of these cases, base-base recognition from the third strand involves recognition of N7 and NH6 (adenine) or O6 (guanine). The reason that these base configurations are more stable than other pos-
sible arrangements of bases in a triplet configuration stems from geometry preferences, hydrogen bonding, and base stacking factors. Neither cytosine nor thymine can occupy the center strand, since both have only a single site (O6 of thymine and NH4 of cytosine) available for hydrogen bonding to a base in a third strand located in the major groove. On the other hand, each of the base-triplets illustrated in the figure has two hydrogen bonds between the central purine and the third-strand base. As a result, triplex formation is generally limited to polypurine strings within one stand of the duplex. This significantly limits the number of potential targets in an organism. T•TA, C•CG, C•TA, T•CG, A•TA, A•CG, G•TA, and G•CG, all of which could have at best one hydrogen bond between the third strand base and the central pyrimidine, are not stable. Furthermore, since C must be protonated at N3 in order to hydrogen bond to N7 of G, triplex formation through this motif is favored only at low pH. For these reasons, significant effort has been expended to (1) design third-strand unnatural bases that can bind opposite the pyrimidine bases, and (2) develop structural variations of cytosine that are protonated at neutral pH. Nucleobase design for triplex formation has been extensively reviewed (Ganesh et al., 1996; Doronina and Behr, 1997; Gowers and Fox, 1999). Rather than reiterate the extensive studies that have been done on unnatural nucleosides as third-strand components, this review will only provide a few examples to illustrate the different types of approaches that attempt to solve the problem. The triplets composed of C+•GC and T•AT are isomorphous. On the other hand, the G•GC, A•AT, and T•AT are not, which leads to significant dependence of triplex stability on the duplex sequence as well as on the relative number of GC and AT base pairs. Since the third-strand association of C by G requires that C be protonated, contiguous protonated C’s may lead to some destabilization through charge-charge repulsion. Consequently, nucleic acid chemists have sought nucleobase analogs that are protonated at this site at physiological pH. The approaches include modification of the cytosine to increase the pKa of protonated N3, and replacement of cytosine with unnatural bases that have hydrogen bond donor-donor configuration required to pair with the acceptor G. Figure 1.4.10 (S.36 to S.38) illustrates a few of the reported analogs designed to mimic protonated C.
Synthesis of Modified Nucleosides
1.4.7 Current Protocols in Nucleic Acid Chemistry
Supplement 5
H N H
H N dR N
H
N
O
H
O
H
dR N
H N H
H O
H
N
N
dR N
O
O
N 33
N O
N H N
H N
H
N dR
N
H
H
O
N N A•AT
dR
H N
N dR
N
H N H
N
G•GC
N
H N
N dR
N dR
N
H
N
N H T•AT
N H N
H N
H
32
O
N
N O
H
N
N dR
O
O dR N
O
N
N C+•GC
N dR
N
34
N
N
35
dR
Figure 1.4.9
Base association on triplex formation.
the base is a pyrazopyrimidine (P1) with both hydrogen-bond donating groups contained in the pyrimidine ring (Koh and Dervan, 1992). The third triple, S.38, contains a protonated 2-aminopyridine (designated as P in the figure; Cassidy et al., 1997). This is a more accurate structural mimic of protonated C than M or P1. The greater basicity of the pyridine (pKa ~ 6) means that the equilibrium will be shifted more towards the protonated form at physiological pH than in the case of C (pKa = 4.35).
The three structures shown in Figure 1.4.10 reflect three very different design strategies for mimicking protonated C. The first of these, S.36, contains the protonated-C mimic N6methyl-8-oxo-deoxyadenosine (designated as M in the figure; Krawczyk et al., 1992). The 8-oxo group shifts the equilibrium about the glycosidic bond toward a conformation (shown in the figure) that positions the hydrogen-bond donor sites on M for interaction with N7 and O6 of G. The second triple, S.37, also contains a neutral protonated-C mimic, but in this case
N N
H N H
Me N H
dR N
N
O
H
N
H
N N
N dR
M•GC
H
N
dR
P1•GC
H N H O
H N
Unnatural Nucleosides with Unusual Base Pairing Properties
P•GC
Figure 1.4.10 and P1.
N dR
N
N
N dR
O
H N N
N dR
N
H N H 37
N dR O
H N
O
H N
N H 36
H N
H
N O
H
H N H
H N
N
N N dR
O
N
O
N dR
H N H
38
Protonated cytosine analogs for triplex association. See text for definitions of M, P,
1.4.8 Supplement 5
Current Protocols in Nucleic Acid Chemistry
The expansion of base pair recognition beyond C+•GC, T•AT, G•GC, A•AT, and T•AT is not the only issue. The Tm values for thirdstrand dissociation are typically far lower than for duplex DNA of equivalent length. Consequently, further modifications have been explored to enhance triplex stability. Commonly, this has been achieved by attaching intercalators to one end of the third strand. Significant effort has even been expended to develop triplex-specific intercalators. An alternative is to develop base analogs that provide additional stabilization elements. One example, recently reported by Fox and co-workers, is the use of the nucleoside analog 5-(3-aminopropargyl)2′-deoxyuridine as a component of the third strand in place of thymidine (Bijapur et al., 1999). The increase in triplex stability, presumably due to association of the protonated amino group with the phosphodiester anion, was substantial. A challenge for nucleic acid chemists has been to design and develop modified nucleobases that can recognize CG and TA base pairs through association from the pyrimidine side of the major groove. Two examples of modified nucleosides designed to bind the CG base pair are illustrated in Figure 1.4.11. In S.39, only one hydrogen bond to the cytosine is present (Prévot-Halter and Leumann, 1999). In contrast, S.40 was designed to extend across the base pair and hydrogen bond to G as well as C (Huang et al., 1996). Rothman and Richards have proposed a number of structures from modeling experiments for TA base pair recognition (Rothman and Richards, 1996). The proposed structures, which contain alkyne/alkene spacers to a five-membered ring heterocycle, are predicted to form hydrogen bonds to O4 of T and N6 of A. They should be interesting candidates for future investigation.
MODIFYING NATURAL BASES TO TUNE PAIRING AFFINITY There are applications that would benefit from either decreasing base pair stability or increasing base pair stability while retaining base pair specificity. For natural sequences, CG base pairs contribute more to duplex stability than AT base pairs. This creates a problem in DNA-array-based strategies where it is advantageous for all sequences of the same length to have melting temperatures within a narrow temperature range. One would expect that to accomplish this without complicating sequence-specific effects would be difficult. A number of examples have been published that report progress in this direction. Nguyen et al. (1998) have reported that N4-ethylcytosine destabilizes a CG base pair to the extent that it resembles an AT base pair in stability. Alternatively, it is possible to increase the stability of AT base pairs by appending certain substituents at C5 of T in place of methyl. This is exemplified by the nucleoside analog 5-propynyl-2′deoxyuridine, which has found application in antisense oligonucleotides (Wagner et al., 1993). One would think that it would be possible to increase the affinity of association between A and T by adding an amino group to C2 of A to give 2,6-diaminopurine (2,6-DAP), which should hydrogen bond to T with three hydrogen bonds. However, in practice, this is not the case. The effect of the 2,6-DAP-T base pair on duplex DNA stability is dependent on sequence, and in some instances is not as stabilizing as an AT base pair. However, Matray et al. (2000) have discovered that 2,6-DAP is consistently stabilizing when it is incorporated into oligonucleotides containing the N3′→P5′ phosphoramidate linkage. This effect may be related to the adoption of A-type helices by this backbone modification. This example illustrates the difficulty of designing unnatural bases for manipulating DNA properties. Too many parame-
N dR N N O
H
N
T•CG
Figure 1.4.11
N dR
O H H
4H
39
N
N
N N dR
N H
N N
H
NH O
H
N
H H N
40
N dR
O
H
O
N
N
dR N
N
N H
N N
H
O
dR
Nucleobase analogs for triplex recognition of CG base pairs.
Synthesis of Modified Nucleosides
1.4.9 Current Protocols in Nucleic Acid Chemistry
Supplement 5
ters contribute to base pair stability to enable unambiguous prediction of the effects on duplex properties of even minor structural changes in the heterocycle. Yet another way that modified bases may be used to tune hybridization was reported by Kutyavin et al. (1996). 2-Thiothymine base pairs with adenine, but not with 2,6-DAP. This allowed Kutyavin and co-workers to develop a strategy for invasion of double-stranded DNA with formation of a stable three-arm junction. The complementary invading oligonucleotides contain 2-thiothymine and 2,6-DAP and do not form a stable duplex with each other, but they do hybridize effectively with the complementary natural sequences.
t-Bu
O
t-Bu O
Unnatural Nucleosides with Unusual Base Pairing Properties
O
N
t-Bu
O
N
N
H
H
41 H
N R
N
O
N H N
H N
O
H N
N R
N H
G•G mismatch recognition N
BASE PAIR RECOGNITION The unifying characteristic of the compounds discussed in the previous sections is that they are designed to function as nucleic acid components in place of natural nucleotides. However, the scope and potential uses for new molecules designed for nucleobase recognition extend well beyond those described above for unnatural nucleosides. Work on the recognition of base sequences through azole oligomers that bind to the nucleobases through the minor groove has led to the development of highly specific inhibitors of duplex DNA. Design of analogs that read single base pairs provides the opportunity for development of highly sensitive mismatch detection, which could in turn lead to tools for discovery of single-nucleotide polymorphisms. One example is the bisnaphthyridine intercalator (S.42) that binds specifically to GG base pairs (Fig. 1.4.12; Nakatani et al., 2001). It should be possible to design other analogs that selectively bind other mismatches. A second example illustrated in the figure is the hexylureido isoindolin-1-one derivative (S.41), which can associate with both bases of a CG base pair through hydrogen bonding in the major groove. The molecular details of recognition of multiple base pairs in a sequence through specific association of the bases with DNA-binding molecules such as netropsin are well recognized. Extensive research by Dervan and coworkers has cumulated in the design of polyamides capable of binding long duplex segments with high specificity through hydrogen bonding interactions in the minor groove (Dervan and Burli, 1999; Gottesfeld et al., 2000).
C•G base pair recognition
t-Bu
O N
N
H
H
N
N
N H
H
O N N R
O
N R
O H H N
N
N H
N
H
N
N N N
42
R
Figure 1.4.12 Molecules that recognize and bind combinations of natural bases.
CONCLUSION The objective of this review is to highlight a rapidly developing area of nucleic acid chemistry: unnatural base design. The design of new unnatural base pairs, universal bases, triplex components, and other bases with unusual base pairing specificities will continue to provide an attractive arena for molecular designers. It is hoped that the unit will provide some guidance and inspiration for synthetic chemists seeking problems in nucleic acid chemistry. Many potential uses for unnatural bases have been identified, and in most instances totally successful solutions have not yet been established.
LITERATURE CITED Berger, M., Ogawa, A.K., McMinn, D.L., Wu, Y., Schultz, P.G., and Romesberg, F.E. 2000a. Stable and selective hybridization of oligonucleotides with unnatural hydrophobic bases. Angew. Chem. Int. Ed. Engl. 39:2940-2942. Berger, M., Wu, Y., Ogawa, A.K., McMinn, D.L., Schultz, P.G., and Romesberg, F.E. 2000b. Universal bases for hybridization, replication and chain termination. Nucl. Acids Res. 28:29112914.
1.4.10 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Bergstrom, D.E., Zhang, P., Toma, P.H., Andrews, C.A., and Nichols, R. 1995. Synthesis, structure, and deoxyribonucleic acid sequencing with a universal nucleoside: 1-(2′-Deoxy-β-D-ribofuranosyl)-3-nitropyrrole. J. Am. Chem. Soc. 117:1201-1209.
Eritja, R., Horowitz, D.M., Walker, P.A., ZiehlerMartin, J.P., Boosalis, M.S., Goodman, M.F., Itakura, M., and Kaplan, B.E. 1986. Synthesis and properties of oligonucleotides containing 2′-deoxynebularine and 2′-deoxyxanthosine. Nucl. Acids Res. 14:8135-8153.
Bergstrom, D.E., Zhang, P., and Johnson, W.T. 1996. Design and synthesis of heterocyclic carboxamides as natural nucleic acid mimics. Nucleosides Nucleotides 15:59-68.
Ganesh, K.N., Kumar, V.A., and Barawkar, D.A. 1996. Synthetic control of DNA triplex structure through chemical modifications. In Supramolecular Control of Structure and Bonding (A.D. Hamilton, ed.) pp. 263-327. John Wiley & Sons, New York.
Bergstrom, D.E., Zhang, P., and Johnson, W.T. 1997. Comparison of the base pairing properties of a series of nitroazole nucleobase analogs in the oligod eoxyribonucleotide sequence 5′d(CGCXAATTYGCG)-3′. Nucl. Acids Res. 25:1935-1942. Bijapur, J., Keppler, M.D., Bergqvist, S., Brown, T., and Fox, K.R. 1999. 5-(1-Propargylamino)-2′deoxyuridine (Up): A novel thymidine analogue for generating DNA triplexes with increased stability. Nucl. Acids Res. 27:1802-1809. Brown, D.M. and Lin, P.K.T. 1991a. The structure and application of oligodeoxyribonucleotides containing modified, degenerate bases. Nucl. Acids Symp. Ser. 24:209-212. Brown, D.M. and Lin, P.K.T. 1991b. Synthesis and duplex stability of oligonucleotides containing adenine-guanine analogues. Carbohydr. Res. 216:129-139. Carbonnaux, C., Fazakerley, G.V., and Sowers, L.C. 1990. An NMR structural study of deaminated base pairs in DNA. Nucl. Acids Res. 18:40754081. Cassidy, S.A., Slickers, P., Trent, J.O., Capaldi, D.C., Roselt, P.D., Reese, C.B., Neidle, S., and Fox, K.R. 1997. Recognition of GC base pairs by triplex-forming oligonucleotides containing nucleosides derived from 2-aminopyridine. Nucl. Acids Res. 25:4891-4898. Corfield, P.W.R., Hunter, W.N., Brown, T., Robinson, P., and Kennard, O. 1987. Inosine-adenine base pairs in a B-DNA duplex. Nucl. Acids Res. 15:7935-7949. Cruse, W.B.T., Aymani, J., Kennard, O., Brown, T., Jack, A.G.C., and Leonard, G.A. 1989. Refined crystal structures of an octanucleotide duplex with I.T. mismatch base pairs. Nucl. Acids Res. 17:55-72. Day, J.P., Bergstrom, D., Hammer, R.P., and Barany, F. 1999a. Nucleotide analogs facilitate base conversion with 3′-mismatch primers. Nucl. Acids Res. 27:1810-1818. Day, J.P., Hammer, R.P., Bergstrom, D., and Barany, F. 1999b. Nucleotide analogs and new buffers improve a generalized method to enrich for low abundance mutations. Nucl. Acids Res. 27:18191827. Dervan, P.B. and Burli, R.W. 1999. Sequence-specific DNA recognition by polyamides. Curr. Opin. Chem. Biol. 3:688-693. Doronina, S.O. and Behr, J.-P. 1997. Towards a general triple helix mediated DNA recognition scheme. Chem. Soc. Rev. 26:63-71.
Gottesfeld, J.M., Turner, J.M., and Dervan, P.B. 2000. Chemical approaches to control of gene expression. Gene Expr. 9:77-91. Gowers, D.M. and Fox, K.R. 1999. Towards mixed sequence recognition by triple helix formation. Nucl. Acids Res. 27:1569-1577. Guckian, K.M. and Kool, E.T. 1997. Highly precise shape mimicry by a difluorotoluene deoxynucleoside, a replication-competent substitute for thymidine. Angew. Chem. Int. Ed. Engl. 36:2825-2828. Guckian, K.M., Morales, J.C., and Kool, E.T. 1998. Structure and base pairing properties of a replicable nonpolar isostere for deoxyadenosine. J. Org. Chem. 63:9652-9656. Guo, Z., Liu, Q., and Smith, L.M. 1997. Enhanced discrimination of single nucleotide polymorphisms by artificial mismatch hybridization. Nat. Biotechnol. 15:331-335. Habener, J.F., Vo, C.D., Le, D.B., Gryan, G.P., Ercolani, L., and Wang, A.H.J. 1988. 5-Fluorodeoxyuridine as an alternative to the synthesis of mixed hybridization probes for the detection of specific gene sequences. Proc. Natl. Acad. Sci. U.S.A. 85:1735-1739. Hill, F., Loakes, D., and Brown, D.M. 1998. Polymerase recognition of synthetic oligodeoxyribonucleotides incorporating degenerate pyrimidine and purine bases. Proc. Natl. Acad. Sci. U.S.A. 95:4258-4263. Hoops, G.C., Zhang, P., Johnson, W.T., Paul, N., Bergstrom, D.E., and Davisson, V.J. 1997. Template directed incorporation of nucleotide mixtures using azole-nucleobase analogs. Nucl. Acids Res. 25:4866-4871. Horlacher, J., Hottiger, M., Podust, V.N., Hubscher, U., and Benner, S.A. 1995. Recognition by viral and cellular DNA polymerases of nucleosides bearing bases with nonstandard hydrogen bonding patterns. Proc. Natl. Acad. Sci. U.S.A. 92:6329-6333. Huang, C.-Y., Bi, G., and Miller, P.S. 1996. Triplex formation by oligonucleotides containing novel deoxycytidine derivatives. Nucl. Acids Res. 24:2606-2613. Inoue, H., Imura, A., and Ohtsuka, E. 1985. Synthesis and hybridization of dodecadeoxyribonucleotides containing a fluorescent pyridopyrimidine deoxynucleoside. Nucl. Acids Res. 13:7119-7128.
Synthesis of Modified Nucleosides
1.4.11 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Johnson, W.T., Zhang, P., and Bergstrom, D.E. 1997. The synthesis and stability of oligodeoxyribonucleotides containing the deoxyadenosine mimic 1-(2′-deoxy-β- D-ribofuranosyl)imidazole-4carboxamide. Nucl. Acids Res. 25:559-567.
Matray, T., Gamsey, S., Pongracz, K., and Gryaznov, S. 2000. A remarkable stabilization of complexes formed by 2,6-diaminopurine oligonucleotide N3′→P5′ phosphoramidates. Nucleosides Nucleotides Nucleic Acids 19:1553-1567.
Kawase, Y., Iwai, S., and Ohtsuka, E. 1989. Synthesis and thermal stability of dodecadeoxyribonucleotides containing deoxyinosine pairing with four major bases. Chem. Phamacol. Bull. 37:599-601.
McMinn, D.L., Ogawa, A.K., Wu, Y., Liu, J., Schultz, P.G., and Romesberg, F.E. 1999. Efforts towards expansion of the genetic alphabet: DNA polymerase recognition of a highly stable, self pairing hydrophobic base. J. Am. Chem. Soc. 121:11585-11586.
Klewer, D., Zhang, P., Bergstrom, D.E., Davisson, V.J., and Liwang, A.C. 2001. Conformations of nucleoside analog 1-(2′-deoxy-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide in DNA duplexes with different sequence contexts. Biochemistry 40:1518-1527. Koh, J.S. and Dervan, P.B. 1992. Design of a nonnatural deoxyribonucleoside for recognition of GC base pairs by oligonucleotide-directed triplehelix formation. J. Am. Chem. Soc. 114:14701478. Kool, E.T. 1998. Replication of non-hydrogen bonded bases by DNA polymerases: A mechanism for steric matching. Biopolymers 48:3-17. Krawczyk, S.H., Milligan, J.F., Wadwani, S., Moulds, C., Froehler, B.C., and Matteucci, M.D. 1992. Oligonucleotide-mediated triple helix formation using an N3-protonated deoxycytidine analog exhibiting pH-independent binding within the physiological range. Proc. Natl. Acad. Sci. U.S.A. 89:3761-3764. Kutyavin, I.V., Lukhtanov, E.A., Gorn, V.V., Meyers, R.B. Jr., and Gamper, H.B. Jr. 1996. Oligonucleotides containing 2-aminoadenine and 2-thiothymine act as selectively binding complementary agents. Biochemistry 35:11170-11176. Lin, T.K.T. and Brown, D.M. 1989. Synthesis and duplex stability of oligonucleotides containing cytosine-thymine analogues. Nucl. Acids Res. 17:10373-10383. Loakes, D. and Brown, D.M. 1994. 5-Nitroindole as an universal base analogue. Nucl. Acids Res. 22:4039-4043. Loakes, D., Brown, D.M., Linde, S., and Hill, F. 1995. 3-Nitropyrrole and 5-nitroindole as universal bases in primers for DNA sequencing and PCR. Nucl. Acids Res. 23:2361-2366. Luo, J., Bergstrom, D.E., and Barany, F. 1996. Improving the fidelity of Thermus thermophilus DNA ligase. Nucl. Acids Res. 24:3071-3078. Luyten, I. and Herdewijn, P. 1998. Hybridization properties of base-modified oligonucleotides within the double and triple helix motif. Eur. J. Med. Chem. 33:515-576. Martin, F.H. and Castro, M.M. 1985. Base pairing involving deoxyinosine: Implications for probe design. Nucl. Acids Res. 13:8927-8938. Matray, T.J. and Kool, E.T. 1999. A specific partner for abasic damage in DNA. Nature 399:704-708.
Meggers, E., Holland, P.L., Tolman, W.B., Romesberg, F.E., and Schultz, P.G. 2000. A novel copper-mediated DNA base pair. J. Am. Chem. Soc. 122:10714-10715. Millican, T.A., Mock, G.A., Chauncey, M.A., Patel, T.P., Eaton, M.A.W., Gunning, J., Cutbush, S.D., Neidle, S., and Mann, J. 1984. Synthesis and biophysical studies of short oligodeoxynucleotides with novel modifications: A possible approach to the problem of mixed base oligodeoxynucleotide synthesis. Nucl. Acids Res. 12:7435-7453. Morales, J.C. and Kool, E.T. 1999. Minor groove interactions between polymerase and DNA: More essential to replication than Watson-Crick hydrogen bonds? J. Am. Chem. Soc. 121:23232324. Moran, S., Ren, R.X.-F., and Kool, E.T. 1997a. A thymidine triphosphate shape analog lacking Watson-Crick pairing ability is replicated with high sequence selectivity. Proc. Natl. Acad. Sci. U.S.A. 94:10506-10511. Moran, S., Ren, R.X.-F., Rumney, S.I., and Kool, E.T. 1997b. Difluorotoluene, a nonpolar isostere for thymine, codes specifically and efficiently for adenine in DNA replication. J. Am. Chem. Soc. 119:2056-2057. Nakatani, K., Sando, S., and Saito, I. 2001. Scanning of guanine-guanine mismatches in DNA by synthetic ligands using surface plasmon resonance. Nat. Biotechnol. 19:51-55. Negishi, K., Williams, D.M., Inoue, Y., Moriyama, K., Brown, D.M., and Hayatsu, H. 1997. The mechanism of mutation induction by a hydrogen bond ambivalent, bicyclic N-4-oxy-2′-deoxycytidine in Escherichia coli. Nucl. Acids Res. 25:1548-1552. Nguyen, N.K., Bonfils, E., Auffray, P., Costaglioli, P., Schmitt, P., Asseline, U., Durand, M., Maurizot, J.C., Dupret, D., and Thuong, N.T. 1998. The stability of duplexes involving AT and/or G(4Et)C base pairs is not dependent on their AT/G(4Et)C ratio content. Implication for DNA sequencing by hybridization. Nucl. Acids Res. 26:4249-4258. Oda, Y., Uesugi, S., Ikehara, M., Kawase, Y., and Ohtsuka, E. 1991. NMR studies for identification of dI:dG mismatch base-pairing structure in DNA. Nucl. Acids Res. 19:5263-5267.
Unnatural Nucleosides with Unusual Base Pairing Properties
1.4.12 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Ogawa, A.K., Wu, Y., McMinn, D.L., Liu, J., Schultz, P.G., and Romesberg, F.E. 2000. Efforts toward the expansion of the genetic alphabet: Information storage and replication with unnatural hydrophobic base pairs. J. Am. Chem. Soc. 122:3274-3287. Ohtsuka, E., Matsuki, S., Ikehara, M., Takahashi, Y., and Matsubara, K. 1985. An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions. J. Biol. Chem. 260:26052608. Piccirilli, J.A., Krauch, T., Moroney, S.E., and Benner, S.A. 1990. Enzymatic incorporation of a new base pair into DNA and RNA extends the genetic alphabet. Nature 343:33-37. Pochet, S. and Marliére, P. 1996. Construction of a self-complementary nucleoside from deoxyguanosine. C. R. Acad. Sci. (Paris) 319:1-7. Prévot-Halter, I. and Leumann, C.J. 1999. Selective recognition of a C-G base pair in the parallel DNA triple-helical binding motif. Bioorg. Med. Chem. Lett. 9:2657-2660. Rothman, J.H. and Richards, W.G. 1996. Novel Hoogsteen-like bases for configurational recognition of the T-A base pair by DNA triplex formation. Biopolymers 39:795-812. Saenger, W. 1984. Principles of Nucleic Acid Structure. Springer-Verlag, New York. Schweitzer, B.A. and Kool, E. 1995. Hydrophobic, non-hydrogen-bonding bases and base pairs DNA. J. Am. Chem. Soc. 117:1864-1872. Seela, F. and Debelak, H. 2000. The N8-(2′-deoxyribofuranoside) of 8-aza-7-deazaadenine: A universal nucleoside forming specific hydrogen bonds with the four canonical DNA constituents. Nucl. Acids Res. 28:3224-3232. Seela, F. and Kaiser, K. 1986. Phosphoramidites of base-modified 2′-deoxyinosine isosteres and solid-phase synthesis of d(GCI*CGC) oligomers containing an ambiguous base. Nucl. Acids Res. 14:1825-1844. Switzer, C.Y., Moroney, S.E., and Benner, S.A. 1993. Enzymatic recognition of the base pair between isocytidine and isoguanosine. Biochemistry 32:10489-10496.
Tanaka, K. and Shionoya, M. 1999. Synthesis of a novel nucleoside for alternative DNA base pairing through metal complexation. J. Org. Chem. 64:5002-5003. Ueno, Y., Mikawa, M., and Matsuda, A. 1998. Synthesis and properties of oligodeoxynucleotides containing 5-[N-[2[N,N-bis(2-aminoethyl)amino]ethyl]carbamoyl]-2′-deoxyuridine and 5[N-[3-[N,N-Bis(3-aminopropyl)amino]propyl] carbamoyl]-2′- deoxyuridine. Bioconjugate Chem. 9:33-39. Uesugi, S., Oda, Y., Ikehara, M., Kawase, Y., and Ohtsuka, E. 1987. Identification of I-A mismatch base-pairing structure in DNA. J. Biol. Chem. 262:6965-6968. Voegel, J.J. and Benner, S.A. 1994. Nonstandard hydrogen bonding in duplex oligonucleotides. The base pair between an acceptor-donor-donor pyrimidine analog and donor-acceptor-acceptor analog. J. Am. Chem. Soc. 116:6929-6930. Wagner, R.W., Matteucci, M.D., Lewis, J.G., Gutierrez, A.J., Moulds, C., and Froehler, B.C. 1993. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260:1510-1513. Wu, Y., Ogawa, A.K., Berger, M., McMinn, D.L., Schultz, P.G., and Romesberg, F.E. 2000. Efforts toward expansion of the genetic alphabet: Optimization of interbase hydrophobic interactions. J. Am. Chem. Soc. 122:7621-7632. Yu, H., Eritja, R., Bloom, L.B., and Goodman, M.F. 1993. Ionization of bromouracil and fluorouracil stimulates base mispairing frequencies with guanine. J. Biol. Chem. 268:15935-15943. Zhang, P., Johnson, W.T., Klewer, D., Paul, N., Hoops, G., Davisson, V.J., and Bergstrom, D.E. 1998. Exploratory studies on azole carboxamides as nucleobase analogs: Thermal denaturation studies on oligodeoxyribonucleotide duplexes containing pyrrole-3-carboxamide. Nucl. Acids Res. 26:2208-2215.
Contributed by Donald E. Bergstrom Purdue University West Lafayette, Indiana
Synthesis of Modified Nucleosides
1.4.13 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Development of a Universal Nucleobase and Modified Nucleobases for Expanding the Genetic Code
UNIT 1.5
This unit presents protocols for the synthesis and characterization of nucleosides with unnatural bases in order to develop bases for the expansion of the genetic alphabet or for nonselective pairing opposite natural bases. The faithful pairing of nucleobases through complementary hydrogen-bond (H-bond) donors and acceptors forms the foundation of the genetic code. However, there is no reason to assume that the requirements for duplex stability and replication must limit the genetic alphabet to only two base pairs, or, for that matter, hydrogen-bonded base pairs. Expansion of this alphabet to contain a third base pair would allow for the encoding of additional information and would make possible a variety of in vitro experiments using nucleic acids with unnatural building blocks. Previous efforts to generate orthogonal base pairs have relied on H-bonding patterns that are not found with the canonical Watson-Crick pairs. However, in all cases, the unnatural bases were not kinetically orthogonal, and instead competitively paired with natural bases during polymerase-catalyzed DNA synthesis (Horlacher et al., 1995; Lutz et al., 1996, 1998a,b). Tautomeric isomerism, which would alter H-bond donor and acceptor patterns, likely contributes to this kinetic infidelity (Roberts et al., 1997a,b; Robinson et al., 1998; Beaussire and Pochet, 1999). An alternative strategy is centered around developing unnatural bases that form pairs based not on hydrogen bonds, but rather on interbase hydrophobic interactions. Such hydrophobic bases should not pair stably opposite natural bases due to the forced desolvation of the purines or pyrimidines. Additionally, the use of nucleobase analogs, which are not restricted to the shape of H-bonding topologies of natural bases, allows for the use of a wider range of analogs. This unit describes the design, synthesis, and characterization of unnatural base pairs involving 1-β-D-2-deoxyribosyl-N- and -C-nucleosides. To be reasonable candidates for the modification of the genetic code, unnatural nucleosides must meet certain criteria. First, the unnatural bases must pair stably and selectively in duplex DNA. Second, the unnatural bases must be good substrates for DNA polymerases, being replicated with good efficiency and fidelity. Determination of these thermodynamic and kinetic parameters of the unnatural nucleosides is accomplished by incorporation into oligonucleotides and subsequent evaluation as described herein. A general procedure for the synthesis of 1-β-D-2-deoxyribosyl-N-nucleosides containing pyrimidine-like unnatural hydrophobic bases using a modified Silyl-Hilbert-Johnson reaction (Hilbert and Johnson, 1930), namely Vorbrüggen glycosylation (Niedballa and Vorbrüggen, 1970), is first described (see Basic Protocol 1). This methodology is very useful for the synthesis of pyrimidine-like hydrophobic base pairs, because under the necessary reaction conditions the polar (but otherwise often rather insoluble) pyrimidine bases are readily converted by silylation into lipophilic silyl compounds, which are then soluble in organic solvents. Thus, the homogeneous coupling with sugar moieties is permitted. Next, a general procedure is included for the synthesis of 1-β-D-2-deoxyribosyl-N-nucleosides containing purine-like bases using the metal salt procedure (see Basic Protocol 2), which entails the condensation of nucleobase sodium salts with a sugar halide (Kazimierczuk et al., 1984). The sodium salts of acidic heterocyclic systems such as imidazole, purine, triazole, and pyrazole are prepared in situ with NaH or analogous bases. Contributed by Floyd E. Romesberg, Chengzhi Yu, Shigeo Matsuda, and Allison A. Henry Current Protocols in Nucleic Acid Chemistry (2002) 1.5.1-1.5.36 Copyright © 2002 by John Wiley & Sons, Inc.
Synthesis of Modified Nucleosides
1.5.1 Supplement 10
The synthesis of 3,5-dimethylphenyl-C-nucleoside by (1) condensation of in situ–generated Grignard reagent from 1-bromo-3,5-dimethylbenzene with 1-α-chloro-3,5-di-Otoluoyl-2-deoxyribofuranose and (2) methoxide-mediated deprotection of the bistoluoyl groups is also described (see Basic Protocol 3). In addition, the unit includes a procedure for the synthesis of 1,4-dimethylnaphthaleneC-nucleoside (see Basic Protocol 4). The sugar precursor containing the aldehyde group is used; this is synthesized from 2-deoxyribose in seven steps (Eaton and Millican, 1988) and does not require the generation of any stereocenters beyond C1′. The condensation of the aryllithium reagent of 2-bromo-1,4-dimethylnaphthalene with the aldehyde, followed by in situ cyclization and deprotection of hydroxyl groups, affords the desired nucleoside. An Alternate Protocol describes the synthesis of 3-methyl-2-naphthalene-C-nucleoside. A different sugar precursor containing an aldehyde group at C3′ is generated from Felkin-Anh addition of an allylzinc nucleophile to isopropylidene-protected glyceraldehydes with high diastereoselectivity (Solomon and Hopkins, 1993). Mesylation, followed by treatment with excess trifluoroacetic acid, yields a diastereomeric mixture of separable C-nucleosides. The purification of DNA containing these unnatural bases is then presented (see Basic Protocol 5). Purified DNA products are used to characterize the unnatural base pairs as candidate pairs for expanding the genetic code. Finally, the thermodynamic (see Basic Protocol 6) and kinetic characterization (see Basic Protocol 7) of the unnatural bases are described. NOTE: All glassware used for reactions should be evacuated, flame-dried, and flushed with argon before use. All operations should be carried out in a well-ventilated fume hood. All reactions involving moisture-sensitive reagents should be performed under argon atmosphere (see Reagents and Solutions). NOTE: It is recommended that all products in this unit be stored in a desiccator at ≤4°C. BASIC PROTOCOL 1
GENERAL GUIDELINES FOR SYNTHESIS OF PYRIMIDINE-LIKE 1-β-D-2-DEOXYRIBOSYL-N-NUCLEOSIDES This protocol outlines a general procedure for the synthesis of unnatural hydrophobic pyrimidine-like N-nucleosides (Figs. 1.5.1 and 1.5.2; McMinn et al., 1999). Specific protocols are given for the synthesis of 7-propynylisocarbostyril (PICS) triphosphate (S.7), as well as the phosphoramidite of PICS (S.6). Synthesis of the other unnatural nucleosides shown in Figure 1.5.2 can be accomplished using similar synthetic transformations, starting from the appropriate pyrimidine. The introduction of propynyl groups, the deprotection of toluoyl groups, and the formation of the phosphoramidite and triphosphate described here are generally applied to all synthesis protocols in this unit.
Development of a Universal Nucleobase and Unnatural Nucleobases
Materials Argon (see recipe) Isocarbostyril (S.1; Aldrich) or pyrimidine of choice Acetonitrile, anhydrous N,O-Bis(trimethylsilyl)acetamide (Aldrich) Bis-toluoyl-protected chloroglycoside: 1-α-chloro-3,5-di-O-toluoyl-2-deoxyribofuranose (S.2; Berry & Associates; Takeshita et al., 1987)
1.5.2 Supplement 10
Current Protocols in Nucleic Acid Chemistry
TolO O N H 1
O
TolO
a
Cl
+
5'
OTol
HO
d N
O
N
O
O
O
4
TolO
2'
OTol 3
TolO
O 1'
3'
2
b, c
N O
4'
5
OH e, f g
DMTrO N
O
PiPiPiO
O
N
O
O O P
6
N(i -Pr) 2
O
OH
CN
7
Figure 1.5.1 General procedure for synthesis of unnatural hydrophobic pyrimidine-like N-nucleosides (see Basic Protocol 1). Reagents: (A) Bis-acetamide, SnCl4, CH3CN, 0°C to room temperature (steps 1 to 22); (B) ICl, CH2Cl2, reflux to room temperature (steps 23 to 30); (C) propyne, (Ph3P)2PdCl2, CuI, TEA, −78°C to room temperature (steps 31 to 43); (D) 0.5 M sodium methoxide, methanol, room temperature (steps 44 to 49); (E) DMTrCl, pyridine, room temperature (steps 50 to 62); (f) 2-cyanoethyl-diisopropylchlorophosphoramidite, DIPEA, CH2Cl2, 0°C (steps 63 to 71); (g) tetrabutylammonium pyrophosphate, POCl3, tributylamine, Proton-Sponge, trimethyl phosphate, 0°C (steps 72 to 80).
N
O
N
O
N
O
N
O
ICS
MICS
5MICS
Pyridone
(isocarbostyril)
(3-methylisocarbostyril)
(5-methylisocarbostyril)
(3,5-dimethyl-2-pyridone)
N
O
N
O
N
O
PIM
PPyridone
PICS
(7-propynyl-3-methylisocarbostyril)
(7-propynyl-3-methyl-2( 1H )-pyridone)
(7-propynylisocarbostyril)
Figure 1.5.2 Unnatural hydrophobic N-nucleosides (see Basic Protocol 1).
Synthesis of Modified Nucleosides
1.5.3 Current Protocols in Nucleic Acid Chemistry
Supplement 10
SnCl4, anhydrous, freshly distilled in vacuo Ethyl acetate Hexanes Ammonium molybdate solution (see recipe) Saturated sodium bicarbonate (NaHCO3) solution Saturated sodium chloride (NaCl) solution Sodium sulfate (Na2SO4), anhydrous Silica gel, 200 to 400 mesh, 60 Å Dichloromethane (CH2Cl2), freshly distilled from calcium hydride Ethyl ether, anhydrous Iodine monochloride (ICl; Aldrich; packaged under nitrogen in Sure/Seal vials) Saturated sodium thiosulfate (Na2S2O3) solution Magnesium sulfate (MgSO4), anhydrous Triethylamine (TEA), freshly distilled from calcium hydride Dichlorobis(triphenylphosphine) palladium(II) [(Ph3P)2PdCl2] (Aldrich) Copper(I) iodide (CuI) Dry ice/ethyl ether bath (–100°C) and dry ice/acetone bath Propyne Sodium methoxide (Aldrich) Methanol, anhydrous, distilled from magnesium turnings and stored over 3A molecular sieves Ammonium chloride (NH4Cl) Pyridine, anhydrous, distilled and stored on NaOH protected from light 4,4′-Dimethoxytrityl chloride (DMTr-Cl; Aldrich) Diisopropylethylamine (DIPEA), freshly distilled from calcium hydride 2-Cyanoethyl diisopropylchlorophosphoramidite (Aldrich) Trimethyl phosphate Proton-Sponge (Aldrich) Phosphorous oxychloride (POCl3), freshly distilled Tributylamine Tetrabutylammonium pyrophosphate (TBAP), stored over Drierite 1 M triethylammonium bicarbonate (TEAB), pH 7
Development of a Universal Nucleobase and Unnatural Nucleobases
10-, 25-, and 100-mL two-neck round bottom flasks with 14/20 joints, oven-dried Rubber septa Vacuum system (oil pump) with manifold and cold trap Silica gel 60 F254 alumina-backed thin-layer chromatography (TLC) plates (Fisher) Heat gun UV light source 100-, 250-, and 500-mL separatory funnels 300-mL round bottom flask Cotton Glass funnel Rotary evaporator (Büchi) equipped with a dry ice condenser and a vacuum system Heavy-walled glass columns (1.5-cm i.d.; 10-, 15-, and 20-cm length) with glass adapters attached to compressed air or nitrogen source (see flash chromatography steps in APPENDIX 3E) Sea sand Reflux condenser with 14/20 joint 23- and 18-G needles 100-mL three-neck flask with 14/20 joints Propyne inlet adapter (Aldrich, cat. no. Z41.577-4) Teflon caps for 14/20 joints
1.5.4 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Speedvac evaporator (Savant) High-performance liquid chromatography (HPLC) system Glass or disposable plastic syringes 10-mL test tubes Oil bath with temperature controller Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and flash chromatography (APPENDIX 3E) NOTE: Glass or disposable plastic syringes are generally used for addition of liquid reagents. The 10-mL test tubes are used for collection of eluting fractions in column chromatography. Oil baths with temperature controllers are used for heating reactions as necessary. Perform condensation of isocarbostyril (S.1) with bis-toluoyl-protected chloroglycoside (S.2) 1. Place a magnetic stir bar in an oven-dried 100-mL two-neck flask with two rubber septa, and place the flask on top of a magnetic stir plate. 2. Evacuate reaction flask on vacuum line, then flush with argon. Repeat this procedure three times and attach the flask to an argon line on the manifold. 3. Quickly remove the rubber septum on one of the side inlets, add 0.50 g (3.4 mmol) isocarbostyril (S.1) to the flask under argon, then immediately reinsert the septum. 4. Transfer 10 mL acetonitrile to the flask under argon. 5. Add, in dropwise fashion, 0.85 mL (3.4 mmol) N,O-bis(trimethylsilyl)acetamide and stir vigorously for 40 min at room temperature. During this time the suspension is cleared.
6. Add an additional 12 mL of acetonitrile to the clear reaction mixture, followed by 1.10 g (2.80 mmol) bis-toluoyl-protected chloroglycoside (S.2). Cool the reaction mixture in an ice-water bath. 7. Slowly add 0.18 mL (2 mmol) SnCl4 and continue to stir under argon at 0°C. Preparation of S.3 uses 1.0 eq S.1, 0.8 eq S.2, 1.0 eq N,O-bis(trimethylsilyl)acetamide, 0.6 eq SnCl4, and 129.4 eq acetonitrile. Increasing the quantity of SnCl4 from catalytic to substoichiometric amounts may improve yield.
8. Monitor the progress of the reaction by analytical TLC (APPENDIX 3D) as follows: a. Occasionally withdraw a small sample (1 to 5 µL) using a capillary tube and spot on silica gel 60 F254 alumina-backed plates. b. Develop the plate (APPENDIX 3D) with 4:1 (v/v) hexanes/ethyl acetate. c. Visualize by dipping plate into ammonium molybdate solution and heating with a heat gun. Examine with UV light source. For S.3, Rf = 0.4 (see APPENDIX 3D). To analyze the course of reactions by TLC, the anisaldehyde/sulfuric acid staining system (6 g of p-anisaldehyde, 50 mL of absolute ethanol and 2.5 mL of concentrated H2SO4) is useful for nucleosides. For nucleosides containing a DMTr group, 3% TFA/CH2Cl2 is also effective. Ammonium molybdate is used to assay the presence of carbohydrate derivatives and is sufficient for visualization of S.3. Spots generally appear in various shades of purple and blue.
Synthesis of Modified Nucleosides
1.5.5 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Work up and purify S.3 9. When TLC analysis indicates the reaction is complete, transfer the mixture to a 500-mL separatory funnel and add 250 mL ethyl acetate. 10. Extract twice, each time with 50 mL saturated NaHCO3 solution, then extract once with 100 mL saturated NaCl solution. 11. Insert cotton into a glass funnel and add a 2-cm-thick layer of anhydrous Na2SO4 over the cotton. Filter the organic layer by gravity into a 300-mL round-bottom flask. 12. Remove solvents under reduced pressure with a rotatory evaporator equipped with a dry ice condenser. It is recommended that the bath temperature not exceed 45°C.
13. Pack a 1.5 × 20–cm heavy-walled column with 60 g of 200 to 400 mesh silica gel in hexanes for flash column chromatography (APPENDIX 3E). Gas pressure (air or nitrogen) is applied via a glass adapter to the top of the column through the gas inlet to increase the flow rate to about 5 drops/sec.
14. Dissolve the crude product in 1 mL of dichloromethane. 15. Transfer the solution using a 3-mL glass pipet onto the silica gel and let the solution sink into the column bed. 16. Rinse the flask with two 1-mL aliquots of dichloromethane, add each rinse to the surface of silica gel, and allow the rinse to enter the column. 17. Carefully add a 0.5-cm layer of sea sand to the top of the silica gel bed. This step is optional. Keeping the surface of the silica gel flat is important for good separation.
18. Elute with a gradient of 8:1 to 4:1 (v/v) hexanes/ethyl acetate. Use a glass cylinder to freshly mix the solvents.
19. Collect 10-mL fractions and analyze by TLC (see step 8). To achieve the best separation, TLC using 5:1 hexanes/ethyl acetate should give an Rf value of ∼0.35 for the possible product.
20. Transfer fractions containing pure product to a 300-mL round-bottom flask and evaporate to dryness with a rotary evaporator. 21. Add 3 mL of anhydrous ethyl ether to triturate the product. Remove the solvent and evacuate the product until the weight of the flask is not changed. 22. Confirm the desired product by 1H NMR, NOESY, and COSY analysis (see, e.g., Lambert et al., 1998). Flash chromatography gives a pair of diastereoisomers as the α and β anomers. The desired product is the faster-migrating β anomer, which is a white foam. The assignment of β-stereochemistry at C1′ for each nucleoside is based on NOESY data, in which H1′ shows cross-peaks with both α-H4′ and α-H2′ (see Fig. 1.5.1). The optimal yield of 1′-β-3′,5′-O-toluoyl-2′-deoxyribosylisocarbostyril (S.3) is 48%.
Development of a Universal Nucleobase and Unnatural Nucleobases
Iodinate S.3 by Friedel-Crafts iodination 23. Assemble a 25-mL oven-dried two-neck flask with a 14/20 reflux condenser in the center neck, a rubber septum on the side neck, and a magnetic stirring bar. Maintain a smooth flow of argon using a 23-G needle inserted through another septum on top of the reflux condenser.
1.5.6 Supplement 10
Current Protocols in Nucleic Acid Chemistry
24. Mix 0.40 g (0.80 mmol) S.3 (from step 21) with 5 mL freshly distilled dichloromethane (CH2Cl2) and transfer solution to the flask under argon atmosphere. 25. Add, in a dropwise fashion, 0.96 mL of 1 M ICl in CH2Cl2 (0.96 mmol ICl). 26. Reflux the reaction mixture 1 min at 45°C, then cool to room temperature. Perform TLC analysis on the mixture as in step 8. CAUTION: Iodine monochloride is highly toxic and volatile and should be handled with care in a well-ventilated hood.
Work up the iodinated product 27. When TLC analysis indicates that all of the starting material has disappeared during the cooling period, add 10 mL saturated NaHCO3 followed by dropwise addition of saturated Na2S2O3 until the reaction solution is clear. 28. Transfer the mixture to a 100-mL separatory funnel. Extract the aqueous layer three times, each time with 20 mL dichloromethane. 29. Combine the organic extracts and dry over anhydrous MgSO4. 30. Repeat steps 11 and 12 and attach a vacuum line to dry the residue. The resulting crude iodinated product (not shown in the figures) is pure enough for use in the next step. It should be kept in darkness and used immediately.
Introduce propynyl group by Sonogashira coupling 31. Equip a 100-mL, 14/20 three-neck flask with rubber septa on the two side necks, a 14/20 dry-ice condenser-trap in the center neck, and a magnetic stir bar. Place a gas inlet adapter on top of the condenser and attach it to an argon line on the manifold. 32. Evacuate the apparatus and then purge it with argon three times to remove air. 33. Transfer ∼0.80 mmol of the iodinated compound and 15 mL triethylamine (TEA) to the flask and quickly add 0.01 g (0.02 mmol) (Ph3P)2PdCl2 and 0.01 g (0.06 mmol) CuI under argon. (Ph3P)2PdCl2 and CuI are highly sensitive to oxygen and light, respectively. They should be handled very carefully and quickly. High quality of these reagents is essential to the success of Sonogashira coupling reactions.
34. Cool the reaction vessel in dry ice/diethyl ether bath (−100°C). 35. Fill the condenser-trap with pulverized dry ice. 36. Quickly remove the rubber septum on one of the side inlets and insert a propyne inlet adapter. 37. Purge the flask with propyne for 10 min or until final volume is 50 mL. Preparation of S.4 uses 1.0 eq S.3, 1.2 eq ICl, 116.2 eq CH2Cl2, 0.07 eq CuI, 0.02 eq (Ph3P)2PdCl2, 134.5 eq TEA, and >120 eq propyne.
38. Turn off the propyne cylinder. Quickly remove the rubber septa and the propyne inlet, and seal inlets tightly with Teflon caps. 39. Remove dry-ice condenser and seal the inlet tightly with a Teflon cap. Continue to stir at room temperature for 5 hr. Synthesis of Modified Nucleosides
1.5.7 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Work up and purify S.4 40. Cool the reaction mixture in dry ice/acetone bath for 5 min, then remove the cold bath. 41. Remove the caps carefully to vent the remaining propyne at ambient temperature. Evaporate the solvent with a rotary evaporatory. 42. Purify the crude product by flash chromatography (steps 13 to 19) using a 1.5 × 15–cm silica gel column packed with 30 g silica gel. Elute with a gradient of 5:1 to 3:1 (v/v) hexanes/ethyl acetate. Perform TLC on the eluate (see step 8) using 4:1 hexanes/ethyl acetate. For S.4, Rf = ∼0.35.
43. Combine appropriate fractions based on TLC analysis and evaporate to dryness. Flash column chromatography yields 0.11 g (64%) of S.4 as a white foam.
Deprotect 3′- and 5′-OH groups 44. Equip a 10-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G needle threaded through the septum. 45. Add 0.10 g (0.20 mmol) S.4 (from step 43) and 4 mL anhydrous methanol sequentially to the flask. 46. Add dropwise 1.2 mL of 0.5 M sodium methoxide in methanol (0.60 mmol sodium methoxide) to the reaction mixture and continue to stir under argon for 20 min. Preparation of S.5 uses 1.0 eq S.4, 3 eq sodium methoxide, and 617 eq methanol.
Work up and purify S.5 47. Add ∼30 mg NH4Cl to quench the reaction and keep stirring for 10 min. 48. Evaporate solvents and purify the product by flash chromatography (steps 13 to 19) using a 1.5 × 10–cm silica gel column packed with 20 g silica gel. Elute with a gradient of 2:100 to 5:100 (v/v) methanol/CH2Cl2. Perform TLC on the eluate (see step 8) using 4:100 methanol/CH2Cl2. For S.5, Rf = ∼0.35.
49. Combine appropriate fractions based on TLC analysis and evaporate to dryness. The reaction is approximately quantitative and the product, 1-β-2′-deoxyribosyl-7propynylisocarbostyril (S.5), is obtained as a white solid.
Tritylate 5′-OH by Williamson etherification 50. Equip an oven-dried two-neck 10-mL flask with a stir bar and two rubber septa. Keep the vessel under argon using an 18-G needle threaded through the septum. 51. Add 0.046 g (0.154 mmol) S.5 (from step 49) and 4 mL anhydrous pyridine to the flask. 52. Using an 18-G needle, insert a vacuum line through one of the septa to remove most of the pyridine by vacuum evaporation. 53. Purge the reaction flask with argon and remove the vacuum line immediately. Development of a Universal Nucleobase and Unnatural Nucleobases
54. Transfer 0.7 mL anhydrous pyridine to the flask to dissolve S.5.
1.5.8 Supplement 10
Current Protocols in Nucleic Acid Chemistry
55. Prepare a solution of 0.08 g (0.23 mmol) 4,4′-dimethoxytrityl chloride in 0.3 mL pyridine and add in a dropwise fashion to the reaction mixture over a period of 20 min. Tritylation uses 1.0 eq S.5, 1.5 eq DMTr-Cl, and 82.3 eq pyridine.
56. Continue to stir at room temperature for an additional 20 min. Work up and purify tritylated nucleoside 57. Combine the reaction mixture with 20 mL of ethyl acetate, 5 mL saturated NaHCO3, and 5 mL saturated NaCl to partition. 58. Transfer the mixture to a 250-mL separatory funnel. Rinse the reaction vessel twice, each time with 5 mL of ethyl acetate, and transfer to the funnel. 59. Separate the organic layer and extract the aqueous layer twice, each time with 10 mL of ethyl acetate. 60. Filter and dry the organic layer as in steps 11 and 12. 61. Purify the crude product by flash chromatography (steps 13 to 19) using a 1.5 × 10–cm silica gel column packed with 20 g silica gel. Elute with a gradient of 5:1 to 3:1 (v/v) hexanes/ethyl acetate. Perform TLC on the eluate (see step 8) using 3.5:1 hexanes/ethyl acetate. For the DMTr-protected product of the above reaction, Rf = ∼0.35.
62. Combine appropriate fractions based on TLC analysis and evaporate to dryness. Chromatographic purification affords the DMTr-protected product (0.073 g, 79%) as a white foam.
Phosphitylate to give phosphoramidite S.6 63. Equip a 10-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G needle threaded through the septum. 64. Prepare a solution of 0.073 g (0.121 mmol) tritylated product (from step 62) in 1.3 mL of freshly distilled dichloromethane and transfer to the flask. 65. Add 0.084 mL (0.48 mmol) DIPEA to the solution and cool in ice-water bath. 66. Add, in a dropwise fashion, 0.041 mL (0.16 mmol) 2-cyanoethyl diisopropylchlorophosphoramidite and allow the reaction mixture to reach ambient temperature over 15 min. Relative to the starting nucleoside (S.5 in step 51), preparation of S.6 uses 3.2 eq DIPEA, 1.1 eq 2-cyanoethyldiisopropylchlorophosphoramidite, and 135.2 eq dichloromethane.
Work up and purify S.6 67. Dilute the reaction mixture with 50 mL dichloromethane. Transfer the reaction mixture to a 100-mL separatory funnel. 68. Wash with 5 mL saturated NaHCO3 and 5 mL saturated NaCl. 69. Filter and dry as in steps 11 and 12. 70. Perform flash chromatography (steps 13 to 19). Elute with a gradient of 6:1 to 4:1 (v/v) hexanes/ethyl acetate. Perform TLC (see step 8) using 5:1 hexanes/ethyl acetate. For S.6, Rf = ∼0.35.
Synthesis of Modified Nucleosides
1.5.9 Current Protocols in Nucleic Acid Chemistry
Supplement 10
71. Combine appropriate fractions based on TLC analysis and evaporate to dryness using a rotary evaporator. The phosphoramidite product (S.6) is a white foam (63 mg), prepared with 65% yield, and is stored in a desiccator at −20°C. Phosphoramidite compounds are used for automated DNA synthesis; isolation and desalting of oligonucleotides is carried out by PAGE and electrophoretic dialysis (see Basic Protocol 5). Oligonucleotides are used for duplex oligonucleotide denaturation temperature measurements and kinetic studies of DNA extension (see Basic Protocols 6 and 7).
Prepare triphosphate S.7 72. Equip a 10-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G needle threaded through the septum. 73. Quickly remove the septum on one of the side inlets, add 0.008 g (0.027 mmol) S.5 (from step 49) under argon, and insert the rubber septum back to the flask. 74. Coevaporate moisture and methanol twice from 0.1 mL anhydrous pyridine. 75. Add 0.134 mL (0.23 mmol) trimethyl phosphate and 9 mg (0.04 mmol) ProtonSponge, dissolve completely, and bring to 0°C. 76. Add 0.003 mL (0.032 mmol) POCl3 and continue to stir at 0°C for 2 hr. 77. Add 0.042 mL (0.03 mmol) tributylamine and 0.023 g (0.040 mmol) TBAP and stir for 1 min. Work up and purify S.7 78. Add 2.7 mL of 1 M TEAB, pH 7. 79. Stir the reaction mixture for 10 min and concentrate to dryness in a Speedvac evaporator. 80. Dissolve the crude product in 200 µL of 1:1 (v/v) DMSO/isopropanol and purify by HPLC (UNIT 10.5) using the following conditions: Column: Rainin C18-Dynamax 60 Å column (7.8 × 300 mm) Buffer A: 0.1 M TEAB, pH 7 Buffer B: Acetonitrile Gradient: 98% to 90% buffer A over 5 min, 90% to 75% buffer A over 25 min, 75% to 0% buffer A over 5 min, return to 98% A over 5 min. Flow rate: 10 mL/min. Approximately 1 mg of the product triphosphate (S.7) is yielded with a retention time of 27.5 min, where the gradient is ∼65% buffer A. The triphosphate compound could be used directly for kinetic studies of DNA incorporation. BASIC PROTOCOL 2
Development of a Universal Nucleobase and Unnatural Nucleobases
GENERAL GUIDELINES FOR SYNTHESIS OF PURINE-LIKE 1-β-D-2-DEOXYRIBOSYL-N-NUCLEOSIDES This protocol outlines a general procedure for the synthesis of unnatural hydrophobic purine-like N-nucleosides. The coupling strategy between 5H-pyrrolo[2,3-b]pyrazine (PP) and S.2 (Fig. 1.5.1) to generate the nucleoside 1′-β-3′,5′-O-toluoyl-2′-deoxyribosylN-5H-pyrrolo[2,3-b]pyrazine (S.8; Fig. 1.5.3) can be generally applied for the synthesis of other purine-like nucleosides such as those depicted in Figure 1.5.4 by starting with the appropriate purine analog. This protocol describes the synthesis of the 3′,5′-toluoylprotected nucleoside (S.8). Synthesis of the free nucleoside, phosphoramidite, and triphosphate are performed as in Basic Protocol 1.
1.5.10 Supplement 10
Current Protocols in Nucleic Acid Chemistry
N
TolO
N
TolO N
O
+
N H
N
O
Cl OTol
PP
N
OTol
2
8
Figure 1.5.3 General procedure for synthesis of unnatural hydrophobic purine-like N-nucleosides
N N
N
N
N
N
N
7AI
M7AI
ImPy
(7-azaindole)
(6-methyl-7-azaindole)
(imidazole pyridine)
N N
N
N
N
P7AI
PPP
(3-propynyl-7-azaindole)
(3-propynyl-4,7-diazaindole)
Figure 1.5.4 Unnatural hydrophobic purine-like N-nucleosides (see Basic Protocol 2).
Materials Argon (see recipe) 5H-Pyrrolo[2,3-b]pyrazine or purine analog of choice Acetonitrile, anhydrous 60% sodium hydride (NaH; see recipe) Bis-toluoyl-protected chloroglycoside: 1-α-chloro-3,5-di-O-toluoyl-2-deoxyribofuranose (S.2; Berry & Associates; Takeshita et al., 1987) Ethyl acetate Ethyl ether Saturated sodium bicarbonate (NaHCO3) Sodium sulfate (Na2SO4), anhydrous Silica gel, 200-400 mesh, 60 Å Hexanes 10-mL two-neck round-bottom flask with 14/20 joints, oven-dried Rubber septa 18-G needle Cotton Glass funnel 1.5 × 30–cm heavy-walled glass column with glass-adapters attached to compressed air or nitrogen source (see flash chromatography steps in APPENDIX 3E)
Synthesis of Modified Nucleosides
1.5.11 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Sea sand Silica gel 60 F254 alumina-backed thin-layer chromatography (TLC) plates (Fischer) Heat gun UV light source Rotary evaporator (Büchi) equipped with a dry ice condenser and a vacuum system Additional reagents and equipment for purification and analysis (see Basic Protocol 1). 1. Equip a 10-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G syringe needle threaded through the septum. 2. Add 100 mg (0.84 mmol) 5H-pyrrolo[2,3-b]pyrazine and 4.5 mL anhydrous acetonitrile and cool the solution 5 min in an ice-water bath. 3. Add 36 mg of 60% NaH (0.9 mmol) in three aliquots to the reaction mixture. Remove the cold bath and stir at ambient temperature for 10 min. 4. Add 326.8 mg bis-toluoyl-protected chloroglycoside (S.2) in three aliquots to the flask and stir at ambient temperature for 10 min. Preparation of S.8 uses 1.0 eq 5H-pyrrolo[2,3-b]pyrazine, 1.1 eq NaH, 1.2 eq S.2, and 523 eq CH3CN.
5. Add 25 mL of ethyl acetate and 20 mL of saturated aqueous NaHCO3 to partition the reaction mixture. 6. Extract the aqueous layer twice, each time with 20 mL ethyl acetate. 7. Dry and filter the organic layer (see Basic Protocol 1, steps 11 and 12). 8. Perform flash chromatography (see Basic Protocol 1, steps 13 to 19) using a 1.5 × 10–cm column packed with 20 g silica gel. Elute with a gradient of 6:1 to 3:1 (v/v) hexanes/ethyl acetate. Analyze fractions by TLC (see Basic Protocol 1, step 8) using 4:1 hexanes/ethyl acetate. For S.8, Rf = ∼0.35.
9. Combine the appropriate fractions and evaporate to dryness using a rotary evaporator. The bis-protected product (S.8) is prepared as a white foam (161 mg) at 41% yield. BASIC PROTOCOL 3
Development of a Universal Nucleobase and Unnatural Nucleobases
SYNTHESIS OF 3,5-DIMETHYLPHENYL-C-NUCLEOSIDE This protocol describes the synthesis of the 3,5-dimethylphenyl-C-nucleoside, involving the condensation of the Grignard reagent derived from 1-bromo-3,5-dimethylbenzene with the bis-toluoyl-protected chloroglycoside (S.2; Fig. 1.5.1; see Fig. 1.5.5 for the reaction). Deprotection yields the free nucleoside (S.11), followed by generation of the phosphoramidite (S.12) and triphosphate (S.13) derivatives. Two other C-nucleosides are prepared using a similar strategy (TM and 2Nap in Fig. 1.5.6A). Deprotection and formation of the phosphoramidite and triphosphate all follow the general procedures as described in Basic Protocol 1. Materials Argon (see recipe) Magnesium metal turnings Tetrahydrofuran (THF), anhydrous 1-Bromo-3,5-dimethylbenezene (S.9; Aldrich)
1.5.12 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Bis-toluoyl-protected chloroglycoside: 1-α-chloro-3,5-di-O-toluoyl-2-deoxyribofuranose (S.2; Takeshita et al., 1987) Ethyl acetate Saturated ammonium chloride (NH4Cl) solution Sodium sulfate, anhydrous Silica gel, 200-400 mesh, 60 Å Hexanes Ethyl ether, anhydrous Methanol, anhydrous Sodium methoxide (Aldrich or synthesized from sodium metal and methanol) Dichloromethane (CH2Cl2), freshly distilled from calcium hydride Pyridine, anhydrous Triethylamine (TEA), freshly distilled from calcium hydride 4,4′-Dimethoxytrityl chloride (DMTr-Cl; Aldrich) Saturated sodium bicarbonate (NaHCO3) solution 4-Dimethylaminopyridine (DMAP; Aldrich)
Me
Me
TolO O Cl OTol
Br
2
9 a
Me
Me
Me b
TolO
HO O
O OTol
OH
10 c, d
Me
Me
Me
PiPiPiO
O
O
P N(i -Pr)2 O
11 e
Me
DMTr O
O
Me
CN 12
OH 13
Figure 1.5.5 Synthesis of 3,5-dimethylphenyl-C-nucleoside and its phosphoramidite and triphosphate derivatives (see Basic Protocol 3). Reagents: (A) Mg0, then S.9, THF (steps 1 to 9); (B) sodium methoxide, methanol (steps 10 to 15); (C) DMTrCl, TEA, pyridine, CH2Cl2 (steps 16 to 24); (D) 2-cyanoethyl-diisopropylchlorophosphoramidite, triethylamine, CH2Cl2 (steps 25 to 31); (E) ProtonSponge, trimethyl phosphate, POCl3, tributylamine, tributylammonium pyrophosphate, DMF (steps 32 to 38).
Synthesis of Modified Nucleosides
1.5.13 Current Protocols in Nucleic Acid Chemistry
Supplement 10
2-Cyanoethyl diisopropylchlorophosphoramidite (Aldrich) Trimethyl phosphate (Aldrich) Proton-Sponge (Aldrich) Phosphorus oxychloride (POCl3) Tributylamine n-Tetrabutylammonium pyrophosphate (TBAP; Sigma) Dimethylformamide (DMF) Triethylammonium bicarbonate (TEAB; Fluka) Dimethylsulfoxide (DMSO) Isopropanol 25-mL and 100-mL two-neck round-bottom flasks with 14/20 joints, oven-dried Reflux condenser with 14/20 joint Rubber septa 18- and 23-G needles 125-mL separatory funnel Cotton Glass funnel Rotary evaporator (Büchi) equipped with a dry ice condenser and a vacuum system Heavy-walled glass columns (1.5-cm i.d.; 10- and 15-cm length) with glass adapters attached to compressed air or nitrogen source (see flash chromatography steps in APPENDIX 3E) Sea sand 300-mL round-bottom flask Filter paper Lyophilizer (e.g., Labconco freeze-dry system) Additional reagents and equipment for purification and analysis (see Basic Protocol 1) Perform condensation of 1-bromo-3,5-dimethylbenzene (S.9) with bis-toluoyl-protected chloroglycoside (S.2) 1. Assemble a 25-mL oven-dried two-neck round-bottom flask with a 14/20 reflux condenser in the center neck, a rubber septum on the side neck, and a magnetic stirring bar. Maintain a smooth flow of argon using a 23-G needle inserted through another septum on top of the reflux condenser. 2. Quickly add 52 mg (2.139 mmol) magnesium metal and 2 mL THF to the flask under argon atmosphere. 3. Add, in a dropwise fashion, 293 µL (2.156 mmol) 1-bromo-3,5-dimethylbenzene (S.9) and heat the resulting suspension to 50°C for 1 hr using a temperature-controlled oil bath. 4. Prepare a solution of 126 mg (0.324 mmol) bis-toluoyl-protected chloroglycoside (S.2) in 1 mL THF in another round-bottom flask under argon atmosphere. Add all of the prepared Grignard reagent (step 3) to this solution and stir 14 hr at room temperature. 5. During the 14-hr incubation, prepare another batch of Grignard reagent (repeat steps 1 to 3). At the end of the 14-hr incubation, add another 100 µL Grignard reagent to the reaction mixture (step 4) and continue to stir 1 hr at room temperature. Synthesis of S.10 uses 1.0 eq S.9, 0.992 eq magnesium metal, 0.150 eq S.2, and 17.16 eq THF. Development of a Universal Nucleobase and Unnatural Nucleobases
Work up and purify S.10 6. Add 10 mL of ethyl acetate and 10 mL of saturated aqueous NH4Cl and transfer to a 125-mL separatory funnel. Rinse the reaction vessel twice, each time with 5 mL ethyl acetate, and add to the funnel.
1.5.14 Supplement 10
Current Protocols in Nucleic Acid Chemistry
7. Extract separate, and retain the organic layer. Extract the aqueous layer twice, each time with 15 mL of ethyl acetate, and combine these organic layers with the original organic layer. 8. Filter and dry the organic layer (see Basic Protocol, steps 11 to 12). Perform flash chromatography (see Basic Protocol 1, steps 13 to 19). Elute with a gradient of 95:5 to 85:15 (v/v) hexanes/ethyl acetate. Perform TLC (see Basic Protocol 1, step 8) using 9:1 hexanes/ethyl acetate. For S.10, Rf = ∼0.30.
9. Evaporate eluate and analyze product by NMR (see Basic Protocol 1, steps 20 to 22). Approximately 13 mg (9% yield) of purified β-product (S.10) and 48 mg (32%) of α-product should be obtained.
Deprotect 3′- and 5′-OH groups 10. Equip a 100-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G syringe needle threaded through a septum. 11. Add 264 mg (0.576 mmol) S.10 (from step 9) and 10 mL anhydrous methanol to the flask. 12. Add, in a dropwise fashion, 2 mL of 1 M sodium methoxide (2.0 mmol) in methanol to the reaction mixture and keep stirring for 45 min. Synthesis of S.11 uses 1.0 eq S.10, 3.5 eq sodium methoxide, and 514 eq methanol.
Work up and purify S.11 13. Add 100 mg NH4Cl to quench the reaction and continue to stir for 10 min. 14. Evaporate solvents and purify the crude product by flash chromatography (see Basic Protocol 1, steps 13 to 19) using a 1.5 × 10–cm silica gel column packed with 20 g silica gel. Elute with a gradient of 1:99 to 5:95 (v/v) methanol/CH2Cl2. Perform TLC (see Basic Protocol, step 8) using 5:95 methanol/CH2Cl2. For S.11, Rf = ∼0.30.
15. Combine appropriate fractions based on TLC and evaporate to dryness in a rotary evaporator. Flash chromatography gives approximately 105 mg (82% yield) of purified product (S.11) as a white solid.
Tritylate 5′-OH 16. Equip a 100-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G syringe needle threaded through one of the septa. 17. Add 90 mg (0.405 mmol) of S.11 (from step 15), 2 mL anhydrous pyridine, and 2 mL CH2Cl2 to the flask. 18. Add, in a dropwise fashion, 0.30 mL (2.15 mmol) TEA, followed by 175 mg (0.516 mmol) 4,4′-DMTr-Cl in two portions over a 30-min period, and continue to stir for 2 hr at room temperature. Tritylation uses 1.0 eq S.11, 1.27 eq DMTr-Cl, 5.31 eq triethylamine, 61 eq pyridine, and 77 eq dichloromethane.
Work up and purify tritylated product 19. Add 20 mL ethyl acetate and 10 mL saturated NaHCO3 and transfer the mixture to a 125-mL separatory funnel. Rinse the reaction vessel twice, each time with 5 mL ethyl acetate, and add to the funnel.
Synthesis of Modified Nucleosides
1.5.15 Current Protocols in Nucleic Acid Chemistry
Supplement 12
20. Extract separate, and retain the organic layer. Extract the aqueous layer twice, each time with 20 mL ethyl acetate. 21. Combine the organic layers and dry over anhydrous Na2SO4. 22. Filter through filter paper into a 300-mL round-bottom flask and evaporate under reduced pressure in a rotary evaporator. 23. Purify the crude product by flash chromatography (see Basic Protocol 1, steps 13 to 19) using a 1.5 × 10–cm silica gel column packed with 20 g silica gel. Elute with a gradient of 1:1 to 4:1 (v/v) hexanes/ethyl acetate. Perform TLC (see Basic Protocol, step 8) using 1:1 hexanes/ethyl acetate. For the tritylated S.11, Rf = ∼0.3.
24. Combine the appropriate fractions based on TLC analysis and evaporate to dryness in a rotary evaporator. Flash chromatography affords 185 mg (87% yield) of purified DMTr-protected product as a white foam.
Prepare phosphoramidite S.12 by phosphitylation 25. Equip a 100-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G syringe needle threaded through one of the septa. 26. Add 185 mg (0.353 mmol) tritylated product (from step 24) and 3.5 mL anhydrous CH2Cl2 to the flask. 27. Add a catalytic amount (2 mg, 0.016 mmol) of DMAP, followed by 0.350 mL (2.512 mmol) triethylamine and 0.160 mL (0.718 mmol) 2-cyanoethyl diisopropylaminochlorophosphoramidite. 28. Continue to stir for 30 min at room temperature. Synthesis of S.12 uses 1.0 eq tritylated nucleoside, 0.045 eq DMAP, 7.1 eq TEA, 2.0 eq 2-cyanoethyl diisopropylaminochlorophosphoramidite, and 155 eq dichloromethane.
Work up and purify S.12 29. Add 20 mL ethyl acetate and 20 mL saturated NaHCO3 and repeat steps 19 to 22 of this protocol. 30. Purify the crude product by flash chromatography (see Basic Protocol 1, steps 13 to 19). Elute with a gradient of 1:9 to 3:7 (v/v) ethyl acetate/hexane containing 5% triethylamine. Perform TLC using 3:7 ethyl acetate/hexane. For S.12, Rf = ∼0.83.
31. Combine appropriate fractions based on TLC and evaporate to dryness. Flash chromatography affords 238 mg (93% yield) of phosphoramidite product (S.12) as a white foam.
Prepare triphosphate S.13 by phosphorylation of S.11 32. Equip a 25-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G needle threaded through the septum. 33. Add 16 mg (0.072 mmol) free nucleoside (S.11, from step 15) to the flask. 34. Add 0.36 mL (3.08 mmol) trimethyl phosphate and 23 mg (0.107 mmol) ProtonSponge. Cool to 0°C. Development of a Universal Nucleobase and Unnatural Nucleobases
35. Add 8 µL (0.090 mmol) POCl3 in a dropwise fashion and continue to stir for 2 hr at 0°C.
1.5.16 Supplement 12
Current Protocols in Nucleic Acid Chemistry
36. Add 105 µL (0.441 mmol) tributylamine, followed by a solution of 62 mg (0.171 mmol) TBAP in 0.8 mL DMF, and stir for 1 min. Synthesis of S.13 uses 1.0 eq S.11, 43 eq trimethyl phosphate, 1.5 eq Proton-Sponge, 1.3 eq POCl3, 6.1 eq tributylamine, 2.4 eq TBAP, and 143 eq DMF.
Work up and purify S.13 37. Add 7 mL of 1 M TEAB. Dilute the resulting crude solution ∼10 fold with water and lyophilize. 38. Dissolve in 200 mL of 1:1 (v/v) DMSO/isopropanol and purify by HPLC (UNIT 10.5) using the following conditions: Column: Rainin C18-Dynamax 60 Å column Buffer A: 0.1 M TEAB, pH 7.5 Buffer B: Acetonitrile Gradient: 96% to 70% buffer A from 0 to 30 min Flow rate: 10 mL/min. Approximately 1 mg of triphosphate (S.13) is obtained as a white solid after lyophilization.
SYNTHESIS OF 1,4-DIMETHYLNAPHTHALENE-C-NUCLEOSIDE This protocol describes the synthesis of 1,4-dimethylnaphthalene-C-nucleoside (DMN, see Fig. 1.5.6B), as derived from the condensation of the aryllithium species onto an aldehyde followed by a ring-closing reaction, shown in Figure 1.5.7 (Ogawa et al., 2000a). The steps below detail the synthesis of the free nucleoside (S.18). The preparation of the phosphoramidite and triphosphate are performed as described in Basic Protocol 3. A similar strategy may be used to synthesize the 1-methyl-3-naphthalene nucleoside (3MN; Fig. 1.5.6B), starting from 3-bromo-1-methylnaphthalene (Ogawa, et al., 2000b).
BASIC PROTOCOL 4
Materials Argon (see recipe) 2-Bromo-1,4-dimethylnaphthalene (S.14; Aldrich; Sharma, 1993) Tetrahydrofuran (THF), anhydrous n-Butyllithium (Aldrich) Cyclohexane Protected aldehyde of sugar precursor (S.15; Eaton and Millican, 1988) Ethyl acetate Saturated sodium bicarbonate (NaHCO3) solution Sodium sulfate (Na2SO4), anhydrous Silica gel, 200-400 mesh, 60 Å Hexane Ethyl acetate Pyridine, anhydrous Triethylamine (TEA), freshly distilled from calcium Methanesulfonyl chloride Acetic acid, glacial Methanol, anhydrous Trifluoroacetic acid Dichloromethane (CH2Cl2), freshly distilled from calcium hydride 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ; Aldrich) 25-mL, 50-mL, and 100-mL two-neck round bottom flasks with 14/20 joints, oven-dried Rubber septa 18-G needles
Synthesis of Modified Nucleosides
1.5.17 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Me
A
Me
4
Me
Me
3
5
2 6
Me
1
TM (trimethylbenzene)
DM (dimethylbenzene)
2Nap (2-naphthalene)
6 7
5
B
Me
4
Me
8
3 2
1
Me
3MN (1-methyl-3-naphthalene)
DMN (dimethylnaphthalene)
C
Me
2MN (3-methyl-2-naphthalene)
Figure 1.5.6 Unnatural hydrophobic C-nucleosides. Synthetic strategies are presented in (A) Basic Protocol 3, (B) Basic Protocol 4, and (C) Alternate Protocol.
OPMB
Me
DMTrO CHO OPMB 15
Me Br 14
a,b
Me
Me Me
DMTrO
c
Me
HO
O OPMB
O 16
OPMB
17
d
Me Me
HO O OH
Development of a Universal Nucleobase and Unnatural Nucleobases
18
Figure 1.5.7 Synthesis of 1,4-dimethylnaphthalene-C-nucleoside (see Basic Protocol 4). Reagents: (A) n-butyllithium, −78°C, then S.15, THF (steps 1 to 8); (B) methanesulfonyl chloride, triethylamine, pyridine, 0°C (steps 9 to 14); (C) acetic acid (steps 15 to 20); (D) DDQ (steps 21 to 26).
1.5.18 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Dry ice/acetone bath (−78°C) Cotton Glass funnel Rotary evaporator (Büchi) equipped with a dry ice condenser and a vacuum system Heavy-walled glass columns (1.5-cm i.d.; 10-, 15-, and 20-cm length) with glass adapters attached to compressed air or nitrogen source (see flash chromatography steps in APPENDIX 3E) Sea sand Additional reagents and equipment for purification and analysis (see Basic Protocol 1) NOTE: n-Butyllithium is flammable and sensitive to moisture. It should be handled carefully and quickly. Perform condensation of 2-bromo-1,4-dimethylnaphthalene (S.14) with protected aldehyde of sugar precursor (S.15) 1. Equip a 100-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G needle threaded through one of the septa. 2. Add 640 mg (2.72 mmol) 2-bromo-1,4-dimethylnaphthalene (S.14) and 15 mL THF to the flask under argon atmosphere and cool to −78°C in a dry ice/acetone bath. 3. Slowly add dropwise 2.0 mL of 2 M n-butyllithium (4.0 mmol) in cyclohexane and continue to stir for 15 min at −78°C. 4. Add, in a dropwise fashion, a solution of 1.214 g (1.801 mmol) of the protected aldehyde of the sugar precursor (S.15) in 5 mL THF and continue to stir for 1 hr at −78°C. 5. Remove the flask from the bath and warm to room temperature over 1.5 hr. Synthesis of the 1,4-dimethylnaphthalene derivative uses 1.0 eq S.14, 1.47 eq n-butyllithium, 0.66 eq S.15, and 90 eq THF.
Work up and purify product 6. Add 10 mL ethyl acetate and 10 mL saturated NaHCO3 to partition. Filter and dry the organic layer (see Basic Protocol 1, steps 11 and 12). 7. Perform flash chromatography (see Basic Protocol 1, steps 13 to 19). Elute with a gradient of 9:1 to 8:2 (v/v) hexane/ethyl acetate. Perform TLC (see Basic Protocol 1, step 8) using 7:3 hexane/ethyl acetate. For this product, Rf ∼0.23.
8. Combine the appropriate fractions based on TLC and evaporate to dryness with a rotary evaporator. Flash chromatography gives the C1 S-isomer (712 mg, 48% yield) and the C1 R-isomer (625 mg, 42% yield). S and R isomers were assigned based on the α or β anomer that was formed after cyclization.
Perform in situ cyclization of mesylate 9. Equip a 25-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G syringe needle threaded through one of the septa. 10. Add 712 mg (0.857 mmol) of the S-diastereomer (step 8) and 9 mL anhydrous pyridine to the flask and cool to 0°C.
Synthesis of Modified Nucleosides
1.5.19 Current Protocols in Nucleic Acid Chemistry
Supplement 10
11. Add 0.57 mL (4.09 mmol) triethylamine followed by 90 µL (1.17 mmol) methanesulfonyl chloride, and warm slowly to room temperature over 1.5 hr with stirring. Synthesis of S.16 uses 1.0 eq S-diastereomer, 4.8 eq triethylamine, 1.37 eq methanesulfonyl chloride, and 130 eq pyridine.
Work up and purify S.16 12. Add 2 mL saturated NaHCO3 to quench the reaction. 13. Perform flash chromatography (see Basic Protocol 1, steps 13 to 19). Elute with a gradient of 95:5 to 85:15 (v/v) hexane/ethyl acetate. Perform TLC using 7:3 hexane/ethyl acetate. For S.16, Rf = ∼0.68.
14. Collect appropriate fractions based on TLC and evaporate to dryness with a rotary evaporator. Flash chromatography yields 176 mg (30% yield) of purified product (S.16).
Detritylate 5′-OH group 15. Equip a 25-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G syringe needle threaded through one of the septa. 16. Add 190 mg (0.274 mmol) S.16, 6 mL acetic acid, and 1 mL methanol to the flask. 17. Add 1 mL trifluoroacetic acid in a dropwise fashion (∼10 drops) and continue stirring for 20 min at room temperature. Detritylation uses 1.0 eq S.16, 383 eq acetic acid, 90 eq methanol, and 47.4 eq trifluoroacetic acid.
Work up and purify S.17 18. Concentrate the reaction solution with a rotary evaporator. 19. Remove solvents (see Basic Protocol, step 12) and perform flash chromatography (see Basic Protocol 1, steps 13 to 19). Elute with a gradient of 4:1 to 1:1 (v/v) hexane/ethyl acetate. Perform TLC using ethyl acetate. For S.17, Rf = ∼0.75.
20. Combine appropriate fractions based on TLC and evaporate to dryness with a rotary evaporator. Flash chromatography affords 93 mg (86% yield) of purified product (S.17).
Remove 3′-PMB group 21. Equip a 50-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G syringe needle threaded through one of the septa. 22. Add 8 mg, 0.020 mmol S.17, 1 mL CH2Cl2, and 1 drop H2O to the flask. 23. Add 7 mg (0.031 mmol) DDQ and continue to stir for 1 hr at room temperature. Deprotection uses 1.0 eq S.17, 780 eq CH2Cl2, 277.5 eq H2O, and 1.55 eq DDQ.
Development of a Universal Nucleobase and Unnatural Nucleobases
Work up and purify S.18 24. Add 15 mL ethyl acetate and 15 mL saturated NaHCO3 to partition. Filter and dry the organic layer (see Basic Protocol 1, steps 11 and 12).
1.5.20 Supplement 10
Current Protocols in Nucleic Acid Chemistry
25. Perform flash chromatography (see Basic Protocol 1, steps 13 to 19). Elute with a gradient of 1:99 to 5:95 (v/v) methanol/CH2Cl2. Perform TLC using 3:97 methanol/CH2Cl2. For S.18, Rf = ∼0.3.
26. Combine appropriate fractions based on TLC and evaporate to dryness using rotary evaporator. Flash chromatography affords 3 mg (55% yield) of pure product (S.18).
SYNTHESIS OF 3-METHYL-2-NAPHTHALENE-C-NUCLEOSIDE This protocol describes the synthesis of the 3-methyl-2-naphthalene-C-nucleoside (Fig. 1.5.6C), which was derived from the condensation of the aryllithium species onto another aldehyde followed by in situ cyclization as shown in Figure 1.5.8 (Ogawa et al., 2000a). The preparation of phosphoramidite and triphosphate follows the general procedures described in Basic Protocol 3.
ALTERNATE PROTOCOL
Additional Materials (also see Basic Protocols 3 and 4) 2-Bromo-3-methylnaphthalene (S.19; prepared according to Lambert et al., 1979) Protected aldehyde of sugar precursor (S.20, prepared according to Solomon and Hopkins, 1993) Perform condensation of 2-bromo-3-methylnaphthalene (S.19) with the protected aldehyde of the sugar precursor (S.20) 1. Place a magnetic stir bar in a dry 100-mL two-neck flask with two rubber septa, and place the flask on top of a magnetic stir plate. 2. Evacuate the reaction flask on vacuum line and then flush it with argon. Repeat this procedure three times and attach the flask to an argon line on the manifold. 3. Add 595 mg (2.70 mmol) 2-bromo-3-methylnaphthalene (S.19) and 8.9 mL THF to the flask under argon atmosphere and cool to −78°C in a dry ice/acetone bath. 4. Add dropwise 1.50 mL of 2 M n-butyllithium (3.0 mmol) in cyclohexane over 10 min and continue to stir 15 min at −78°C. 5. Add dropwise a solution of 502 mg (1.74 mmol) aldehyde (S.20) in 4.4 mL THF over 5 min and continue to stir 30 min at −78°C. 6. Remove the flask from the bath and warm to room temperature. During this time the reaction color changes from deep green to brown. Condensation uses 1.0 eq S.19, 1.1 eq n-butyllithium, 0.64 eq S.20, and 61 eq THF.
O
a,b,c
O Me Br 19
CHO OTBS 20
Me
HO O
21 OH
Figure 1.5.8 Synthesis of 3-methyl-2-naphthalene-C-nucleoside (see Alternate Protocol). Reagents: (A) n-butyllithium, −78°C, then S.2, THF (steps 1 to 9); (B) methanesulfonyl chloride, triethylamine, pyridine, 0°C (steps 10 to 16); (C) TFA (steps 17 to 22).
Synthesis of Modified Nucleosides
1.5.21 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Work up and purify product 7. Add 10 mL ethyl acetate and 10 mL saturated NaHCO3 to partition. Filter and dry the organic layer (see Basic Protocol 1, steps 11 and 12). 8. Perform flash chromatography (see Basic Protocol 1, steps 13 to 19). Elute with a gradient of 9:1 to 5:1 (v/v) hexane/ethyl acetate. Perform TLC (see Basic Protocol 1, step 8) using 9:1 hexane/ethyl acetate. For this product, Rf = ∼0.30.
9. Combine appropriate fractions based on TLC and evaporate to dryness with a rotary evaporator. Flash chromatography gives a crude mixture of both diastereomers (532 mg, 1.24 mmol).
Mesylate hydroxy group 10. Equip a 100-mL two-neck flask with two rubber septa and a stir bar. Keep the vessel under argon using an 18-G syringe needle threaded through one of the septa. 11. Add 510 mg (1.19 mmol) product (step 9, both diastereomers) and 32 mL CH2Cl2 to the flask and cool to 0°C. 12. Add 0.332 mL (2.38 mmol) triethylamine, followed by 0.120 mL (1.55 mmol) methanesulfonyl chloride, and warm slowly to room temperature over 30 min with stirring. Relative to S.19 (step 3), mesylation uses 0.88 eq triethylamine, 0.57 eq methanesulfonyl chloride, and 185 eq CH2Cl2.
Work up and purify product 13. Add 30 mL saturated aqueous NaHCO3 and transfer to a 125-mL separatory funnel. Rinse the reaction vessel twice, each time with 5 mL ethyl acetate and add to the funnel. 14. Separate the organic layer and extract the aqueous layer twice, each time with 15 mL ethyl acetate. 15. Filter and dry the organic layer (see Basic Protocol 1, steps 11 and 12), and perform flash chromatography (see Basic Protocol 1, steps 13 to 19). Elute with a gradient of 95:5 to 85:15 (v/v) hexanes/ethyl acetate. Perform TLC using 9:1 hexanes/ethyl acetate. For this product, Rf = ∼0.30.
16. Evaporate eluate and analyze product by NMR (see Basic Protocol 1, steps 20 to 22). The resulting crude product is pure enough for use in the next step.
Perform in situ cyclization of mesylate 17. Set up the reaction flask as in steps 1 and 2 above. 18. Add 605 mg (1.19 mmol) crude product (step 16) and 56 mL of 4:1 (v/v) TFA/methanol and stir 20 min at room temperature. Relative to S.19 (step 3), cyclization uses 216 eq trifluoroacetic acid and 103 eq methanol.
Development of a Universal Nucleobase and Unnatural Nucleobases
Work up and purify S.21 19. Concentrate the solution with a rotary evaporator and then neutralize the residual TFA with a minimum volume of saturated NaHCO3. 20. Transfer to a separatory funnel and extract four times, each time with 20 mL CH2Cl2.
1.5.22 Supplement 10
Current Protocols in Nucleic Acid Chemistry
21. Filter and dry the organic layer (see Basic Protocol 1, steps 11 and 12), and perform flash chromatography (see Basic Protocol 1, steps 13 to 19). Elute with 3:97 (v/v) methanol/CH2Cl2. Perform TLC using the same solvent For S.21, Rf = ∼0.2.
22. Collect the appropriate fractions and evaporate to dryness with a rotary evaporator. Flash chromatography affords the desired β-anomer (S.21) at 108 mg (0.418 mmol, 24% yield over 3 steps).
PURIFICATION OF DNA OLIGONUCLEOTIDES Oligonucleotides containing an unnatural base are synthesized using an ABI 392 DNA/RNA synthesizer with automatic removal of the 5′-trityl protecting group (so-called trityl-off procedure; APPENDIX 3C). The oligonucleotides are then deprotected and cleaved from the CPG support according to the instrument instruction manual. Figure 1.5.9 shows the sequences of four oligonucleotides that are used in the thermodynamic and kinetic analyses described in Basic Protocols 6 and 7. dC-CPG (500Å, 1.0 µmol) is used for S.22, dG-CPG (500 Å, 1.0 µmol) is used for S.23, dA-CPG (500 Å, 1.0 µmol) is used for S.24, the universal support (500Å, 1.0 µmol) is used for S.25 and dA-CPG (500Å, 1.0 µmol) is used for S.26. To be suitable for use in Basic Protocols 6 and 7, the oligonucleotides are purified by preparative denaturing PAGE (UNIT 10.4 and APPENDIX 3B), excised from the gel, electroeluted using a Schleicher & Schuell Elutrap electrophoresis chamber, and ethanol precipitated to concentrate and desalt the sample. The oligonucleotides are stored at −20 °C.
BASIC PROTOCOL 5
Materials CPG-bound DNA oligonucleotide (APPENDIX 3C) Concentrated ammonium hydroxide 95% (v/v) formamide in 10 mM Tris⋅Cl, pH 8.5 (APPENDIX 2A), with and without 0.05% (w/v) xylene cyanol and bromphenol blue TBE buffer (see APPENDIX 2A) Absolute ethanol, prechilled to –20°C 5 M NaCl, ice cold 80% ethanol, ice cold 1.5-mL screw-cap vial 60° and 80°C Dri-baths (Thermolyne) Speed-Vac evaporator (Savant) 50-mL polypropylene centrifuge tubes UV/Vis spectrophotometer Electroelution unit (Schleicher and Schuell) Silica gel–coated preparative TLC plate UV lamp (hand held) Refrigerated centrifuge and rotor appropriate for sample size Additional reagents and equipment for denaturing PAGE (UNIT 10.4 and APPENDIX 3B) Deprotect oligonucleotide and cleave from support 1. Transfer the CPG-bound DNA oligonucleotide to a 1.5-mL screw-cap vial. 2. Add 1.5 mL concentrated ammonium hydroxide, tighten the cap, and incubate 12 hr at 80°C (for 24-mer) or 60°C (for 13-mer or 45-mer). 3. Cool to 0°C and evaporate to dryness in a Speed-Vac evaporator.
Synthesis of Modified Nucleosides
1.5.23 Current Protocols in Nucleic Acid Chemistry
Supplement 10
22 23 24 25 26
5 ′-dCGCATGXGTACGC 5 ′-dGCGTACXCATGCG 5 ′-dTAATACGACTCACTATAGGGAGA 5 ′-dTAATACGACTCACTATAGGGAGAX 5 ′-dCGCTAGGACGGCATTGGATCG XTCTCCCTATAGTGAGTCGTATTA
Figure 1.5.9 Oligonucleotides used for characterization of unnatural nucleobases.
Purify crude oligonucleotide 4. Add 300 µL water and 300 µL of 95% formamide/10 mM Tris⋅Cl, pH 8.5 (without xylene cyanol and bromphenol blue) and mix thoroughly. 5. Prepare a 12-well denaturing PAGE gel (UNIT according to the length of the oligonucleotide:
10.4
and
APPENDIX 3B)
as follows,
13-mer: 15% acrylamide; 42 cm long × 33 cm wide × 1.5 mm thick 24-mer: 20% acrylamide; 42 cm long × 33 cm wide × 1.5 mm thick 45-mer: 10% acrylamide; 42 cm long × 33 cm wide × 1.5 mm thick. 6. Load 60 µL of 95% formamide/10 mM Tris⋅Cl, pH 8.5, with 0.05% (w/v) xylene cyanol and bromphenol blue in each of the two outermost wells; load 60 µL of the sample in each of the ten innermost wells. 7. Purify the DNA to single-nucleotide resolution by denaturing PAGE (UNIT 10.4 and APPENDIX 3B) at 65 W until the full-length oligonucleotide has migrated two-thirds of the way down the gel, as indicated by the dye markers. 8. Excise the full-length DNA product by UV shadowing (UNIT 10.4). Isolate, desalt, and concentrate pure oligonucleotide 9. Place the gel slice in a 50-mL polypropylene centrifuge tube and crush thoroughly with a glass stirring rod. 10. Add 1× TBE electrophoresis buffer mix, and pour the gel slurry into the sample chamber of a properly assembled and oriented electroelution apparatus, according to the instrument instruction manual. 11. Electroelute the sample and monitor its progress by withdrawing small samples and measuring absorbance at 260 nm (A260). 12. Combine the most concentrated fractions. 13. Add 3 vol absolute ethanol (prechilled to –20°C) and 1⁄20 vol 5 M NaCl and freeze at −20°C for at least 30 min. 14. Centrifuge for at least 20 min at >15,000 × g, 4°C. 15. Carefully decant the supernatant, wash the DNA pellet twice with ice cold 80% ethanol, and allow it to air dry. 16. Dissolve DNA in an appropriate volume of sterile deionized water for determination of concentration and downstream applications. Development of a Universal Nucleobase and Unnatural Nucleobases
1.5.24 Supplement 10
Current Protocols in Nucleic Acid Chemistry
DETERMINATION OF THERMODYNAMIC STABILITY OF UNNATURAL BASE PAIRS Thermal stability or thermodynamic stability refers to the melting temperature (Tm) of a DNA duplex that contains the unnatural base pair. Thermodynamic selectivity refers to the difference in Tm between the desired unnatural base pair and the most stable mispair of an unnatural base with a natural base. Oligonucleotides S.22 and S.23 (Fig. 1.5.9) provide the sequence context for determination of the stability and selectivity of the unnatural nucleosides. Duplex oligonucleotide samples are prepared with the unnatural nucleoside in position X of, for example, S.22 and paired against S.23 containing each natural base as well as the same unnatural base (self-pair) and/or any other unnatural base to be tested. The complete set of pairs is also prepared with the unnatural nucleoside in S.23 to determine if there are sequence context effects (e.g., CXT versus TXC). The samples are heated and evaluated for temperature-dependent changes in absorption using a Cary 300 Bio UV-Vis spectrophotometer. Duplex melting curves are collected in triplicate, and melting temperatures are determined by the derivative method contained in the Cary WinUV-Vis software. For a more detailed description of Tm experiments, see UNIT 7.3.
BASIC PROTOCOL 6
Materials Complementary 13-mer oligonucleotides (e.g., S.22 and S.23 in water; see Basic Protocol 5) 2× Tm buffer (see recipe) Variable-temperature double-beam spectrophotometer (Cary 300 BIO UV-Vis spectrophotometer) with optically matched cuvettes 1. Prepare sample cells with 3 µM of each complementary oligonucleotide in 1× Tm buffer. Prepare reference cells with 1× Tm buffer alone. 2. Arrange cells in the spectrophotometer and monitor the sample absorbance at 260 nm while heating at a rate of 0.5°C/min from 20° to 80°C. 3. Collect three curves for each sample and analyze data by the first-derivative method provided with the instrument software. KINETIC ANALYSIS OF UNNATURAL BASE PAIR INCORPORATION, SELECTIVITY AND REPLICABILITY A rapid gel kinetic assay is used for the determination of steady-state parameters for the incorporation and extension of the unnatural base pairs, as well as to evaluate the selectivity, or fidelity of these steps. Initial velocities are determined by radiolabeled primer extension reactions at various concentrations of 5′-nucleoside triphosphate (natural or unnatural). To ensure single completed hit conditions, a final ratio of 30:1 primertemplate to enzyme is used, and less than 20% of the primer is extended. An example of a primer-template set for determining incorporation kinetics is shown in Figure 1.5.9 with S.24 as the primer and S.26 as the template. The reactions can be rapidly initiated and quenched by hand and analyzed by denaturing PAGE; a PhosphorImager (Molecular Dynamics) is used to quantify gel band intensities corresponding to the extended primer. Velocities are plotted against triphosphate concentration and fit to a rectangular hyperbola. Preliminary determination of KM is followed by kinetic analysis using triphosphate concentrations evenly distributed about the KM. Unnatural nucleosides are characterized both in the template strand and as the incoming triphosphate. Kinetic data are collected in triplicate. In general, these kinetic determinations follow the experimental protocols developed by Goodman and co-workers (Creighton et al., 1995).
BASIC PROTOCOL 7
Synthesis of Modified Nucleosides
1.5.25 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Materials 4 µM DNA oligonucleotide primer (e.g., S.24; see Basic Protocol 5) 10 U/µL T4 polynucleotide kinase and 10× buffer (New England Biolabs) 10 mCi/mL [γ-33P]ATP (2500 Ci/mmol) QIAquick Nucleotide Removal Kit (Qiagen) 1 µM DNA oligonucleotide template (e.g., S.26; see Basic Protocol 5) 10 U/µL exonuclease-free Klenow fragment (Amersham Pharmacia Biotech) and 10× random-prime buffer (see recipe) Unnatural triphosphates (see Basic Protocols 1 to 4 and Alternate Protocol) 100 mM stock of each natural dNTP (Amersham Pharmacia Biotech; sequencing grade) Enzyme dilution buffer (see recipe) Quench solution (see recipe) 1× TBE buffer (APPENDIX 2A) 37°, 25°, and 100°C Dri-Baths (Thermolyne) with heating blocks that accommodate 1.5- or 0.5-mL tubes Thin putty knife Geiger counter Chromatography paper (Whatman 3MM CHR, 35 × 45 cm) Gel dryer (Bio-Rad Model 583) Storage Phosphor Screen (Kodak or Molecular Dynamics, 35 × 43 cm) PhosphorImager (e.g., STORM Model 860; Molecular Dynamics) ImageQuant and compatible spreadsheet (MS Excel) and graphing (Kaleidagraph) software Additional reagents and equipment for denaturing PAGE (UNIT 10.4 and APPENDIX 3B) NOTE: Use autoclaved deionized water for all reagents. Radiolabel primer 1. Combine 25 µL of 4 µM oligonucleotide primer with 3.1 µl of 10× T4 polynucleotide kinase buffer, 2 µL of [γ-33P]ATP stock, and 1 µL of T4 polynucleotide kinase. Mix and incubate at 37°C for at least 30 min. 2. Remove excess nucleotide with the QIAquick Nucleotide Removal Kit, according to the manual, and observing proper radioactive waste disposal. 3. Dilute buffer EB (from QIAquick kit) five-fold and use 100 µL to elute the DNA. Store at 4°C. Allow the wetted column to sit for a few minutes before the final spin. Assuming 80% recovery of the labeled primer, this protocol yields 100 ìL of 800 nM 5′-radiolabeled primer.
Prepare analytical gel 5. Pour a 15% denaturing polyacrylamide gel (UNIT 10.4 and APPENDIX 3B) that is 42 cm long, 33 cm wide, and 0.5 mm thick, and has 34 wells. Make sure there are no trapped air bubbles. Allow the gel at least 1 hr to fully polymerize before use.
Development of a Universal Nucleobase and Unnatural Nucleobases
Anneal primer and template 6. Combine 25 µL of water, 10 µL of 10× random-prime buffer, 8 µL of 1 µM template oligonucleotide, and 5 µL of 5′-radiolabeled 800 nM primer oligonucleotide (from step 1) in a 1.5-mL microcentrifuge tube, mix well, then microcentrifuge briefly at maximum speed to bring all the solution to the bottom of the tube. This gives a two-fold excess of template over primer, necessary to ensure that greater than 95% of the primer is annealed to the template. The use of different primer or template sequences may require that this ratio be optimized.
1.5.26 Supplement 10
Current Protocols in Nucleic Acid Chemistry
7. Place the solution in a Dri-bath preheated to 100°C and immediately turn off the heating element. Allow the primer-template to anneal by slow cooling to room temperature in the Dri-bath (∼2 hr). This yields a final volume of 48 ìL, which, when combined with 2 ìL of enzyme, will yield sufficient volume for nine reactions of different triphosphate concentrations. Although it is best to use freshly annealed primer-template, annealed primer-templates can be stored at 4°C overnight. Warm to room temperature before use.
Perform reactions 8. Prepare 5-µL aliquots of 2× concentrations of the desired triphosphate range by combining the appropriate volume of 1 µM, 10 µM, 100 µM, 1 mM, or 10 mM of the previously diluted dNTP and water to a final volume of 5 µL. For the incorporation experiments, the unnatural triphosphate is used (in conjunction with the primer-template complex S.24-S.26) to determine the rate of unnatural base pair synthesis. To measure incorporation selectivity, each of the four natural triphosphates is used in conjunction with this primer-template. For the extension experiments, including both extension efficiency as well as extension fidelity, each of the four natural triphosphates is used in conjunction with primer-template S.25-S.26. It is a good idea to make a reasonably large number of small-volume aliquots of the various concentrations of dNTP to reduce the number of freeze-thaw cycles to which the dNTP is subjected. It is generally desirable to run a control for each experiment with only 5 ìL of water and no triphosphate.
9. Add 2 µL of the appropriate concentration of Klenow fragment freshly diluted in enzyme dilution buffer to cooled annealed primer-template. Mix thoroughly, but do not vortex. This yields 50 ìL of a 2× reaction solution that is 80 nM in primer-template, 2× in all buffer components, and 0.04× of the concentration of diluted enzyme used. This 2× reaction solution will be diluted to 1× when combined with the triphosphate aliquots to initiate the reaction. To ensure single completed hit conditions, make certain that the final enzyme concentration is no more than 1⁄30 that of the final primer-template concentration, final concentration referring to that achieved in step 10.
10. Add 5 µL enzyme-primer-template solution (from step 9) to each 5-µL aliquot of 2× triphosphate (from step 8), mix by pipetting up and down, close the tube, and place in a 25°C Dri-bath. Initiate all reactions in turn as quickly as possible (≤10 sec between starts). 11. Quench the reactions in turn with 20 µL quench solution precisely when the timer reaches the desired length for the experiment. Perform electrophoresis 12. Warm gel (prepared in step 5) by running it at 65 W in 1× TBE buffer until it reaches a temperature of at least 37°C. Wash the wells by pipetting 1× TBE into each a couple of times. 13. Load 8 µL quench solution into the three outermost lanes as well as any unused lanes. Load 8 µL of each quenched reaction into up to 28 of the innermost lanes. Run at 65 W. Up to 28 reactions can be loaded in one row of the gel. Four rows (112 reactions) can be run in one gel by allowing the first row to run at 65W for 30 min, stopping the gel and loading another row. The second row is run for 25 min, the third row for 20 min, and the fourth row until the dark blue dye band of the second row exits the gel. The wells are washed prior to loading each of the four rows.
Synthesis of Modified Nucleosides
1.5.27 Current Protocols in Nucleic Acid Chemistry
Supplement 10
14. Remove the gel from the apparatus and cool it under running water. Separate the plates by using a thin putty knife, taking care to notice which plate the gel will remain stuck to and allowing it to do so. 15. Find the region of the gel containing the extended primers by surveying with a Geiger counter. 16. Place a large piece of plastic wrap over the gel, smooth it out, and cut the relevant area. 17. Carefully transfer the gel (covered on one side with plastic wrap) to a 35 × 45–cm sheet of chromatography paper, gel-side down, and smooth it out. Dry the gel completely (time may vary with apparatus) and allow it to cool nearly to room temperature. 18. Cut the chromatography paper down to size, if necessary, and transfer the gel to a storage phosphor screen, plastic-wrap side facing the screen. Allow image to develop overnight. Analyze data 19. Remove the gel from the storage screen and read the plate with a PhosphorImager. 20. Using ImageQuant software, draw rectangles around primer and extended primer and obtain a volume report of the quantitative data from the gel quantitative data. Use the control reaction (no triphosphate) as the background to be subtracted in each series of triphosphate concentrations. 21. Calculate the fraction of primer extended at each triphosphate concentration as: v = Ip/(I0 + Ip) where I0 is the primer band count and Ip is the product band count. 22. Subtract the value obtained for the control reaction from each reaction. This will force the data set to the origin. Make sure that <20% of the primer is extended at the highest triphosphate concentration to ensure single completed hit conditions.
23. Multiply each corrected value by the final concentration of primer template (40 nM) and divide by the final concentration of enzyme and the reaction time. This gives kcat values in min−1. 24. Plot kcat against triphosphate concentration and fit the curve to the nonlinear form of the Michaelis-Menten equation to obtain kcat and KM. 25. After a preliminary determination of KM, adjust the experimental conditions to obtain data points in the Michaelis plot that evenly flank the experimentally determined KM to triphosphate concentrations ∼5-fold under and over this value. 26. Collect data in triplicate and average the values for kcat and KM.
Development of a Universal Nucleobase and Unnatural Nucleobases
1.5.28 Supplement 10
Current Protocols in Nucleic Acid Chemistry
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Ammonium molybdate solution 2.0 g ammonium molybdate 7.0 g ceric sulfate 250 mL 10% (v/v) H2SO4 Store indefinitely at 4°C Argon Argon should be purged through two Drierite desiccators and then introduced into the reaction flask via Tygon tubing installed on a manifold. To ensure a slightly positive pressure of argon in the reaction flask, flow rates should be adjusted by regulators on the argon tank so that a slow stream of argon bubbles (one bubble per sec) is obtained in the bubbler connected to the manifold. Enzyme dilution buffer 50 mM potassium phosphate, pH 7.0 (APPENDIX 2A) 1 mM DTT 0.1 mM EDTA 50% (v/v) glycerol Store up to 6 months at −20°C Quench solution 95% formamide 5 mM Tris⋅Cl, pH 8 (APPENDIX 2A) 20 mM EDTA 0.05% (w/v) xylene cyanol 0.05% (w/v) bromphenol blue Random-prime buffer, 10× 500 mM Tris-Cl, pH 7.5 (APPENDIX 2A) 100 mM MgCl2 10 mM DTT 500 µg/mL acetylated BSA Store indefinitely at −20°C Sodium hydride, 60% Purchase sodium hydride (NaH) as a 60% dispersion in mineral oil (Aldrich). Add to a flask and then add hexanes with a pipet. Mix to rinse and remove hexanes with a pipet. Repeat several times until the mineral oil is completely removed, then remove residual hexanes thoroughly using a high-vacuum oil pump. Tm buffer, 2× 20 mM PIPES, pH 7 20 mM MgCl2 200 mM NaCl Store indefinitely at room temperature
Synthesis of Modified Nucleosides
1.5.29 Current Protocols in Nucleic Acid Chemistry
Supplement 10
COMMENTARY Background Information
Development of a Universal Nucleobase and Unnatural Nucleobases
Synthesis of unnatural nucleosides The first synthesis of natural nucleosides was published in the late 1940s. Since then, nucleoside synthesis has enjoyed a long and rich history. To date, there are five typical methods for the synthesis of N-nucleosides (Vorbrüggen and Ruh-Pohlenz, 2001): (1) coupling of heterocyclic salts with halo sugars; (2) SilylHilbert-Johnson reaction followed by Vorbrüggen procedure; (3) addition of heterocycle to glycals; (4) derivation of glycosylamine derivatives; and (5) enzymatic transglycosylation. The first two methods have proven to be the most useful for nucleosidic bond formation. The use of sodium salts (Kazimierczuk et al., 1984) gives considerably higher yield of nucleoside product and is a significant improvement upon the Fischer-Helferich protocol (Fischer and Helferich, 1914), which uses toxic mercuric reagents. The reaction of peracylated sugars with persilylated heterocyclic nucleobases in the presence of a Lewis acids such as SnCl4 (Niedballa and Vorbrüggen, 1974) or trimethylsilyl triflate (TMSOTf; Vorbrüggen et al., 1981) has become a routine method for the synthesis of pyrimidine and purine nucleosides. TMSOTf is often the catalyst of choice, as it gives higher yields of β anomer and avoids the emulsion problems associated with tin residue during workup. Natural and modified C-nucleosides, in addition to being candidates for unnatural bases with interesting thermal or replication properties, have attracted great interest due to their anticancer and antiviral activities (Postema, 1992; Chaudhuri et al., 1997). There are many methods for synthesizing aromatic N- and Cnucleosides. For the purpose of preparing Cnucleoside-containing oligonucleotides, two main approaches have been used: (1) nucleophilic displacement of a halogen group from C1 of the deoxyribose by aryl Grignard reagents (Chaudhuri et al., 1997; Ogawa et al., 2000a) and (2) C-nucleophilic addition to the aldehyde of the deoxyribose precursor (Solomon and Hopkins, 1993; Eaton and Millican, 1988). The merit of the former method is its simplicity and the fact that the desired free nucleoside is directly obtained after deprotection of the hydroxy group. The latter method generally affords the desired product in higher yield than the former. As an alternative method for synthesis of C-nucleoside, ribonolactone
has been used with aryl reagents (Hildbrand et al., 1997). The step of nucleophilic addition in this method results in the intermediate formation of a corresponding hemiacetal, which selectively yields the β anomer upon reduction. Removing the 2′-hydroxy group, however, requires additional steps. Universal bases and unnatural base pairs Unnatural nucleosides that possess hydrophobic base analogs have been shown to form stable pairs in duplex DNA, and have also been demonstrated to be efficiently recognized by DNA polymerases, both when present in a template and as a nucleoside triphosphate. In fact, a wide variety of such unnatural bases, with no H bonding or shape complementarity, are surprisingly able to replace a natural base in duplex DNA or during enzymatic replication. These bases are not constrained to resemble the natural purines or pyrimidines, and a much wider variety of design strategies may be pursued. A variety of predominantly hydrophobic nucleobases have been developed with properties such as stable but nonselective pairing in duplex DNA (universal thermodynamic base), efficient but nonselective polymerase recognition (universal kinetic base), or orthogonal stability and replication (third base pair for expanding the genetic code). This unit describes the synthesis of both Nand C-nucleosides. The N-nucleosides retain the natural glycosidic linkage and maintain the minor groove carbonyl group hydrogen bond acceptor. The minor groove hydrogen bond acceptor may be important for stability in duplex DNA by binding water molecules, and also for polymerase recognition. The C-glycosides are aromatic, in order to retain planarity, and, to date, those examined (i.e., TM, DM, 2Nap, DMN, 3MN, and 2MN) do not possess minor groove hydrogen bond acceptors. The current set of bases has resulted from the derivatization of several scaffoldings that were originally found to be successful: the isocarbostyril framework (Fig. 1.5.2), the 7azaindole framework (Fig. 1.5.4), and the aromatic ring framework (Fig. 1.5.6). The thermodynamic and kinetic characterization of the modified scaffold structures was used to direct their further derivatization in a largely empirical fashion. Although this process has been largely empirical, a few general trends are beginning to emerge (McMinn et al., 1999; Berger
1.5.30 Supplement 10
Current Protocols in Nucleic Acid Chemistry
et al., 2000, 2002; Ogawa et al., 2000a,b; Wu et al., 2000; Tae et al., 2001). The development of universal bases that pair nondiscriminantly opposite any natural base would have useful applications for the design of hybridization probes where sequence ambiguities exist. There has been some success in the design of nucleobase analogs that can hybridize nonselectively to each of the native bases (reviewed in Loakes, 2001), but analogs that can universally hybridize without significant duplex destabilization are rare. Hydrophobic base analogs without H-bonding groups that pack efficiently in duplex DNA show little selectivity in pairing with native bases and are promising universal bases (Berger et al., 2000). For example, MICS and 5MICS (Fig. 1.5.2) form stable base pairs with each of the natural bases, when incorporated into the central position of either oligodeoxyribonucleotide strand of a 13-mer duplex (S.22 and S.23, shown in Fig. 1.5.9). When incorporated into S.22 at position X (Figure 1.5.9) and paired opposite each of the four natural bases in S.23, the average Tm for MICS and 5MICS is 54.6 ± 0.7°C and 55.3 ± 0.6°C, respectively. This compares favorably with the stability of the same duplex with a native dT:dA pair (Tm = 58.7°C). The spread in measured Tm values for both MICS and 5MICS opposite each natural base is the same, 1.4°C. A single MICS or 5MICS paired opposite any natural base is significantly more stable than a mispair in the same sequence context (∆Tm = 3.8° to 17°C for mispairs among the native bases in the same sequence context). When MICS and 5MICS are examined in the opposite strand (position X in S.23), paired opposite natural bases, the measured ∆Tm’s are slightly larger (∆Tm = 1.9° and 2.2°C for MICS and 5MICS, respectively). Less effort has been directed toward the identification of universal bases for DNA replication (Berger et al., 2000). No base analog is known that can act as a universal template for incorporation of each natural nucleoside triphosphate. Such bases would have important applications in the generation of oligonucleotide libraries. A variety of predominantly hydrophobic nucleobases that efficiently direct Klenow fragment to incorporate native triphosphates have been identified. Despite a compromise in absolute rate, when present in template, MICS directs the insertion of each native triphosphate with approximately equal efficiency (Berger et al., 2000). Each natural triphosphate is inserted by Klenow fragment opposite MICS with an efficiency of 5.8 × 103
to 2.4 × 104 M−1 min−1, with dATP and dTTP inserted slightly faster than dCTP and dGTP. Klenow fragment inserts each native triphosphate opposite MICS with only a four-fold variation in efficiency, and can synthesize fulllength DNA with high concentrations of dNTPs. The unnatural nucleoside triphosphate, dPIMTP, behaves as a universal chain terminator. The triphosphate is inserted opposite any natural base in the template with remarkable efficiency (only ∼40-fold reduced relative to insertion of a correct triphosphate) and with only 5-fold discrimination. After incorporation of dPIMTP, Klenow fragment is unable to continue DNA synthesis, even under forcing conditions (0.5-hr incubation time and 1 mM dNTPs). Therefore, PIM inserts efficiently but randomly into the growing oligonucleotide strand and then terminates synthesis. The average length of synthesized oligonucleotide may be tuned by choice of chain terminator concentration. The efficient insertion of dPIMTP opposite any native template results in the efficient generation of random-length oligonucleotides, with low concentrations of a single chain terminator. This contrasts with the conventional dideoxy method of chain termination, in which each dideoxynucleotide must be used in great excess to compete with more efficient incorporation of natural nucleoside triphosphates. For example, Klenow fragment prefers the natural dNTP substrates by several thousand-fold relative to the chain-terminator dideoxy analogs. In this regard, dPIMTP may have practical applications, for example, in the generation of random-length oligonucleotides for sequencing by mass spectrometry. In contrast to nucleobases designed to be universal bases, nucleobases designed as thirdbase-pair candidates should have orthogonal properties relative to the natural bases. They must form stable pairs in duplex DNA, as well as during enzymatic replication, only with their designed base pair partners. Much attention has been focused on unnatural nucleobases with phenyl, naphthyl, isocarbostyril, or 7-azaindole scaffolding. Modifications may be made and then evaluated in terms of base-pair stability (Tm) and replicability (steady-state kinetics). For example, d2MNTP is efficiently inserted by Klenow fragment opposite 2MN (S.21; Fig. 1.5.8) in the template (self-pair formation) with an efficiency of 4.4 × 107 M−1 min−1, but is also efficiently inserted opposite dA (1.0 × 107 M−1 min−1). It was reasoned that this might result from favorable interactions in the developing
Synthesis of Modified Nucleosides
1.5.31 Current Protocols in Nucleic Acid Chemistry
Supplement 10
minor groove between the 2MN methyl group and the methine of dA. Therefore, the nucleobase was modified, resulting in 3MN. The mispairing between 3MN and dA was selectively reduced (7.6 × 103 M−1 min−1), resulting in a 3MN:3MN unnatural base pair that is synthesized only 10-fold more slowly than natural base pairs (2.4 × 106 M−1 min−1) and with at least two orders of magnitude selectivity against all possible mispairs. Based on thermodynamic and kinetic characterization, a variety of self-pairs and heteropairs have been identified that are attractive candidates as third base pairs. These include the 7AI:7AI, PICS:PICS, and 3MN:3MN selfpairs, as well as the 7AI:ICS and PP:MICS heteropairs (Figure 1.5.10). It should be noted that the use of a self-pair in no way limits the effort to expand the genetic code. In fact, addition of a self-pair to the genetic alphabet would result in 64 new codons. Each of these unnatural base pairs are stable and replicable with reasonable efficiency and selectivity. The rate-limiting step for the synthesis of DNA with each of the unnatural base pairs is extension, i.e., the continued primer extension after incorporation of an unnatural base. This step may be optimized by design and direct evaluation of steady-state extension rates, or by examining different polymerases. Progress along both lines has been published. For example, it was found that Klenow fragment and polymerase β have complementary recognition of the 7AI:7AI self-pair. Although Klenow fragment efficiently inserts d7AITP opposite 7AI in the template, it is unable to continue primer extension. Polymerase β, while unable to synthesize the base pair, extends it with a
N
N
N
N
N
7AI:7AI
wild-type-like efficiency. The action of both polymerases allows for the synthesis of DNA containing the 7AI:7AI self-pair in addition to dG:dC and dA:dT (Lee et al., 2001). Further derivativization of the unnatural bases is also being evaluated with respect to extension. In particular, the effects of aromatic surface area and a minor groove hydrogen-bond acceptor are being evaluated. It is apparent that hydrophobicity is a suitable force for controlling internucleobase interactions in duplex DNA as well as during enzymatic replication. The approach is expected to be more versatile than one based on purine or pyrimidine analogs because a wider range of nucleobase analogs may be examined. It is perhaps surprising that such a wide range of nucleobase structures are tolerated in the duplex and polymerase environments. Nonetheless, this wide tolerance of structures may be taken advantage of to design nucleobase analogs with desired thermal and kinetic properties for use as a universal base or to expand the genetic code.
Compound Characterization
S.4: 1H NMR (400 MHz, CDCl3) δ 8.39 (1H, dd, J = 8.1, 1.1 Hz), 7.94-7.98 (4H, m), 7.91 (1H, d, J = 7.8 Hz), 7.70 (2H, m), 7.51 (1H, m), 7.20−7.27 (4H, m), 6.86 (1H, dd, J = 8.6, 5.4 Hz), 5.62 (1H, m), 4.79 (1H, dd, J = 12.2, 3.5 Hz), 4.70 (1H, dd, J = 12.1, 3.2 Hz), 4.60 (1H, m), 2.85 (1H, ddd, J = 14.3, 5.5, 1.6 Hz), 2.42 (3H, s), 2.38 (3H, s), 2.32 (1H, ddd, J = 14.6, 8.4, 6.8Hz), 1.94 (3H, s). S.5: 1H NMR (400 MHz, CD3OD) δ 8.28 (1H, m), 7.97 (1H, s), 7.94 (1H, dd, J = 8.1, 0.6 Hz), 7.76 (1H, m), 7.54 (1H, m), 6.63 (1H, dd,
O O PICS:PICS
N 3MN:3MN
N N
N
N O
Development of a Universal Nucleobase and Unnatural Nucleobases
7AI:ICS
N
N
O
N
PP:MICS
Figure 1.5.10 Unnatural base pairs for expansion of the genetic alphabet.
1.5.32 Supplement 10
Current Protocols in Nucleic Acid Chemistry
J = 7.3, 6.2 Hz), 4.4 (1H, m), 3.98 (1H, m), 3.83 (1H, dd, J = 11.9, 3.5 Hz), 3.76 (1H, dd, J = 12.0, 3.8 Hz), 2.41 (1H, ddd, J = 13.7, 6.2, 3.5 Hz), 2.17 (1H, ddd, J = 13.6, 7.4, 6.5 Hz), 2.10 (3H, s). 13C NMR (125 MHz, CD3OD) δ 160.0, 135.2, 131.7, 129.0, 126.0, 125.9, 123.5, 101.5, 87.6, 86.5, 84.1, 71.9, 69.8, 60.3, 39.7. HRMS (MALDI) anal. calcd. for C17H17NO4Na (MNa+) 322.1055; found 322.1045. S.6: 1H NMR (400 M Hz, CDCl3) δ 8.40 (1H, d, J = 8.1 Hz), 7.93 (2H, m), 7.70 (1H, m), 7.50 (3H, m), 7.37-7.41 (4H, m), 7.18-7.30 (4H, m), 6.82 (4H, m), 6.71 (1H, ddd, J = 12.8, 7.6, 5.7 Hz), 4.56 (1H, m), 4.24 (1H, m), 3.743.83 (8H, m), 3.52-3.65 (4H, m), 3.45 (1H, m), 3.33 (1H, m), 2.67 (1H, m), 2.61 (2H, t, J = 6.5 Hz), 2.42 (2H, t, J = 6.5 Hz), 2.26 (1H, m), 1.82 (3H, d, J = 11.9 Hz), 1.17 (9H, m), 1.06 (3H, d, J = 6.8 Hz). 31P NMR (160 MHz, CDCl3) δ 51.4, 50.7. S.7: 31P NMR (160 M Hz, 50 mM Tris (pH 7.5), 2mM EDTA in D2O) δ -6.11 (d, J = 19.2 Hz), -10.38 (d, J = 19.9 Hz), 21.55 (dd, J = 19.9, 19.2 Hz). S.8: 1H NMR (400 M Hz, CDCl3) δ 8.38 (1H, m), 8.08 (2H, d, J = 6.4 Hz), 8.02 (2H, d, J = 6.5 Hz), 7.78 (1H, d, J = 2.1 Hz), 7.36 (2H, d, J = 6.4 Hz), 7.34 (1H, s), 7.33 (2H, d, J = 6.7 Hz), 6.91 (1H, dd, J = 6.9, 4.4 Hz), 6.83 (1H, m), 5.87 (1H, m), 4.80 (1H, dd, J = 9.7, 3.2 Hz), 4.73 (1H, dd, J = 9.4, 3.2 Hz), 4.69 (1H, m), 3.08 (1H, ddd, J = 11.6, 6.6, 5.0 Hz), 2.83 (1H, ddd, J = 11.4, 4.5, 1.8 Hz), 2.52 (3H, s), 2.50 (3H, s). Deprotected S.8: 1H NMR (400 MHz, CD3OD) δ 8.37 (1H, d, J = 2.7 Hz), 8.24 (1H, d, J = 2.7 Hz), 8.05 (1H, d, J = 3.8 Hz), 6.68 (1H, dd, J = 8.1, 6.0 Hz), 6.67 (1H, d, J = 3.8 Hz), 4.53 (1H, m), 3.99 (1H, dd, J = 6.6, 4.1 Hz), 3.77 (1H, dd, J = 12.0, 3.5 Hz), 3.70 (1H, dd, J = 12.0, 4.1 Hz), 2.72 (1H, ddd, J = 13.8, 7.7, 6.0 Hz), 2.35 (1H, ddd, J = 13.5, 6.2, 3.0 Hz); HMRS anal. calcd. for C11H14N3O3 (MH+) 236.1035; found 236.1034. S.11: 1H NMR (400 MHz, CD3OD) δ 7.99 (4H, m), 7.28 (2H, d, J = 8.1 Hz), 7.24 (2H, d, J = 8.1 Hz), 7.02 (2H, s), 6.92 (1H, s), 5.62 (1H, m), 5.20 (1H, dd, J = 10.9, 5.0 Hz), 4.71 (1H, dd, J = 11.8, 4.0 Hz), 4.66 (1H, dd, J = 11.8, 3.6 Hz), 4.53 (1H, m), 2.50 (1H, m), 2.44 (3H, s), 2.41 (3H, s), 2.66 (7H, m). HRMS anal. calcd. for C29H31O5 (MH+) 459.2171; found 459.2179. S.12 31P NMR (140 MHz, CDCl3) δ 148.5, 148.3. S.18: 1H NMR (400 MHz, CDCl3) δ 8.07 (1H, m), 7.98 (1H, m), 7.50 (2H, m), 7.45 (1H,
s), 5.24 (1H, dd, J = 11.5, 1.7 Hz), 4.23 (1H, m), 3.96 (2H, m), 3.81 (1H, m), 2.67 (3H, s), 2.62 (3H, s), 2.10 (1H, m), 1.88 (1H, ddd, J = 14.2, 11.6, 2.3 Hz). 13C NMR (150 MHz, CDCl3) δ 135.5, 132.8, 132.7, 132.1, 127.6, 125.7, 125.3, 124.7, 124.5, 123.8, 76.0, 70.9, 69.2, 68.0, 36.5, 19.5, 13.8. HRMS anal. calcd. for C13H24NO3 (MNH4+) 290.1756; found 290.1764. S.21: 1H NMR (600 MHz, CD3OD) δ 8.03 (1H, s), 7.78 (1H, d, J = 7.1 Hz), 7.71 (1H, d, J = 7.1 Hz), 7.59 (1H, s), 7.37 (2H, m), 5.44 (1H, dd, J = 10.1, 5.3 Hz), 4.35 (1H, m), 3.98 (1H, m), 3.76 (2H, m), 2.47 (3H, s), 2.36 (1H, ddd, J = 13.2, 5.7, 1.8 Hz), 1.90 (1H, m). 13C NMR (150 MHz, CDCl3) δ 139.8, 133.8, 133.6, 133.1, 128.6, 128.2, 127.3, 126.1, 125.6, 124.1,88.2, 78.2, 73.8, 63.5, 42.8, 19.1. HRMS anal. calcd. for C16H18O3 (MNa+) 281.1154; found 281.1158.
Critical Parameters and Troubleshooting Generally, any reaction that involves moisture-sensitive reagents should be handled with care. The reaction equipment, including flasks, rubber septa, adapters, gas or liquid condensers, and syringes, must be predried in an oven or under an infrared lamp and flushed with dry argon before use. Anhydrous solvents are critical to the success of reactions. It is best to freshly distill solvents and use moisture-sensitive reagents in situ. Glycosylation. The Lewis acids used in Silyl-Hilbert-Johnson reactions such as Tin(IV) tetrachloride are generally moisturesensitive. The quality of these reagents dramatically affects the yield of product. Iodination. The reaction time is very critical. Excess time may cause significant side reactions. Propynation. The reaction system should be absolutely air-free, since copper(I) iodide and the palladium catalyst used are generally airand/or light-sensitive. The pressure tube should be sealed very well, otherwise propyne collected at low temperature will evaporate readily when the reaction is stirred at ambient temperature. Deprotection. There are no particular difficulties with this step. Tritylation. The substrate should be thoroughly dried by coevaporation with anhydrous pyridine prior to use. Slow addition of the solution of DMTr-Cl in pyridine or batchwise addition of DMTr-Cl solid is necessary; other-
Synthesis of Modified Nucleosides
1.5.33 Current Protocols in Nucleic Acid Chemistry
Supplement 10
wise, the yield of product will be greatly reduced. Phosphitylation. 2-Cyanoethyl diisopropychlorophosphoramidite should be strictly stored at −20°C and warmed to ambient temperature before use. Quickly transferring this reagent via a short needle to the reaction mixture produces optimal results. Phosphorylation. The moisture contained in the substrate should be removed by azeotropic evaporation from a small amount of anhydrous pyridine before the other reactants are added. SN2 displacement reactions. Sodium hydride should be dried and used in situ and quickly added into the reaction flask in several batches, because dry sodium hydride decomposes very readily during storage. Evaporation of solvents. A rotatory evaporator is routinely used to remove solvents. The efficiency of evaporation is largely dependent on the vacuum (normally between 10 to 20 mm Hg) and the dry-ice condenser. It is better to maintain the bath temperature below 45°C to prevent any chemical change of the crude product. To avoid loss of compound caused by a sudden burst of solvents into the splash-guard adapter, the evaporation flask should be cooled by slow rotary evaporation under low vacuum before it is immersed into the bath. Grignard reaction. This reaction should be carried out with exclusion of moisture. All apparatus must be thoroughly dried in a hot (>120°C) oven before use. Use anhydrous solvents. Deprotection of toluoyl group. There are no particular difficulties with this reaction; it will work effectively. Nucleophilic addition by aryllithium reagents. The reaction is moisture-sensitive. Anhydrous solvent is important for the reaction. Do not use n-butyllithium reagent with a milky precipitate, because such a reagent is decomposed in the presence of water. Removal of protecting group of hydroxy group. Difficulties are seldom encountered in this step.
Anticipated Results
Development of a Universal Nucleobase and Unnatural Nucleobases
An overall good yield of the free nucleoside (48% to 68%) of unnatural hydrophobic nucleobases can be achieved based on the strategies described in this unit. The yields of the nucleosidic glycosylation are generally good eno ug h f or th e pr ep ar atio n of phosphoramidites and triphosphates, although stereoselectivity of the desired β-anomer versus α-anomer may be mediocre in some cases.
The routine deprotection, phosphitylation, and phosphorylation are generally high-yielding. Although the Grignard addition described in Basic Protocol 3 generally favors the αanomer, acid treatment of the corresponding benzylic ethers in refluxing xylene will result in epimerization at C1′ to yield the β-anomer (Ren et al., 1996). Conversely, the aryllithium addition described in Basic Protocol 4 and the Alternate Protocol generally affords the desired product in a good yield. The product is a mixture of diastereomers, but is separable by column chromatography.
Time Considerations The estimated time to complete Basic Protocol 1 in its entirely is 3 weeks. The estimated time required to complete Basic Protocol 2 is 2 days. Basic Protocol 3 should take ∼6 days to complete. For Basic Protocol 4 and Alternate Protocol, allow ∼1 day for the Grignard reaction and several hours for all of the other reactions. For Basic Protocol 5, 2 to 3 days should be sufficient time to prepare the oligonucleotide. On day 1, the oligonucleotide is synthesized and the deprotection should be done overnight. Several hours should be allowed for gel pouring and polymerization; this step may also be done on day 1 or in the morning of day 2. The gel must be kept hydrated, regardless, by wrapping with plastic wrap. The electrophoresis step can take several hours. After separation, the excised gel slice may be stored at −20°C for further purification at a later date. To perform the electroelution, allow <2 hr. Ethanol precipitation can then be done overnight at −20°C and the final steps done the following morning. For Basic Protocol 7, about 1 hr should be allowed for radiolabeling the primer. Allow 2 hr for annealing the primer-template duplex, during which time the gel should be poured and allowed to polymerize. Annealed primer-templates can be stored at 4°C overnight, and the gel can also be stored overnight at room temperature (it must be protected from dehydration by first washing the wells with buffer, then covering with paper towels and wrapping tightly in plastic wrap). Allow the annealed primer-templates to return to room temperature before use. The time it takes to aliquot the triphosphates and run the reactions depends on the number and nature of the reactions. After final loading of the gel, it can be run at 90 W for about 1.5 hr. Excising the portion of the gel containing the radioactive bands and subsequent drying onto filter paper should take no
1.5.34 Supplement 10
Current Protocols in Nucleic Acid Chemistry
more than 1 hr. Finally exposure of the phosphor storage screen is routinely done overnight.
Literature Cited Beaussire, J.J. and Pochet, S. 1999. Recognition of 2′-deoxyisoinosine triphosphate by the Klenow fragment of DNA polymerase I. Nucleosides Nucleotides 18:403-410. Chaudhuri, N.C., Ren, R.X.F., and Kool, E.T. 1997. C-Nucleoside derived from simple aromatic hydrocarbons. Synlett. 341-347. Creighton, S., Bloom, L.B., and Goodman, M.F. 1995. Gel fidelity assay measuring nucleotide misinsertion, exonucleolytic proofreading, and lesion bypass efficiencies. Methods Enzymol. 262:232-256. Eaton, M.A.W. and Millican, T.A. 1988. New methodology for C-nucleoside synthesis: Preparation of 1,2-dideoxy-1-(3-pyridyl)-D-ribofuranose. J. Chem. Soc. Perkin Trans. I. 545-547. Fischer, E. and Helferich, B. 1914. Synthetische Glucoside der Purine. Chem. Ber. 47:210. Hilbert, G.E. and Johnson, T.B. 1930. Researches on pyrimidines. CXV. Alkylation on nitrogen of the pyrimidine cycle by application of a new technique involving molecular rearrangements. J. Am. Chem. Soc. 52:2001. Hildbrand, S., Blaser, A., Parel, S.P., and Leumann, C.J. 1997. 5-Substituted 2-aminopyridine C-nucleosides as protonated cytidine equivalents: Increasing efficiency and selectivity in DNA triplehelix formation. J. Am. Chem. Soc. 119:54995511. Horlacher, J., Hottiger, M., Podust, V.N., Hübscher, U., and Bennier, S.A. 1995. Recognition by viral and cellular DNA polymerases of nucleosides bearing bases with nonstandard hydrogen bonding patterns. Proc. Natl. Acad. Sci. U.S.A. 92:6329-6333. Kazimierczuk, Z., Cottam, H.B., Revankar, G.R., and Robins, R.K. 1984. Synthesis of 2′-deoxytubercidin, 2′-deoxyadenosine, and related 2′-deoxynucleosides via a novel direct stereospecific sodium salt glycosylation procedure. J. Am. Chem. Soc. 106:6379-6382. Kornberg, A. and Baker, T.A. 1992. DNA Replication, 2nd ed. W.H. Freeman and Co., New York. Lambert, J.B., Fabricus, D.M., and Hoard, J.A. 1979. Bond localization approach to the carbon analog of the Claisen rearrangement. Thermolysis of 4-aryl-1-butenes. J. Org. Chem. 44:1480-1485. Lambert, J.B., Shurvell, H.F., Lightner, D.A., and Cooks, R.G. 1998. Organic Structural Spectroscopy. Prentice Hall, Englewood Cliffs, N.J. Lee, E.L., Wu, Y., Xia, G., Schultz, P.G., and Romesberg, F.E. 2001. Efforts toward expansion of the genetic alphabet: Replication of DNA with three base pairs. J. Am. Chem. Soc. 123:7439-7440.
Lutz, M.J., Held, H.A., Hottiger, M., Hübscher, U., and Benner, S.A. 1996. Differential discrimination of DNA polymerases for variants of the non-standard nucleobase pair between xanthosine and 2,4-diaminopyrimidine, two components of an expanded genetic alphabet. Nucl. Acids Res. 24:1308-1313. Lutz, M.J., Horlacher, J., and Benner, S.A. 1998a. Recognition of 2′-deoxyisoguanosine triphosphate by HIV-reverse transcriptase and mammalian cellular DNA polymerases. Bioorg. Med. Chem. Letts. 8:499-504. Lutz, M.J., Horlacher, J., and Benner, S.A. 1998b. Recognition of a non-standard base pair by thermostable DNA polymerases. Bioorg. Med. Chem. Letts. 8:1149-1152. McMinn, D.L., Ogawa, A.K., Wu, Y., Liu, J., Schultz, P.G., and Romesberg, F.E. 1999. Efforts toward expansion of the genetic alphabet: DNA polymerase recognition of a highly stable, selfpairing hydrophobic base. J. Am. Chem. Soc. 121:11585-11586. Niedballa, U. and Vorbrüggen, H. 1970. A general synthesis of pyrimidine nucleosides. Angew. Chem. Int. Ed. Engl. 9:461. Niedballa, U. and Vorbrüggen, H. 1974. A general synthesis of N-glycosides. I. Synthesis of pyrimidine nucleosides. J. Org. Chem. 39:36543660. Ogawa, A.K., Wu, Y., McMinn, D.L., Liu, J., Schultz, P.G., and Romesberg, F.E. 2000a. Efforts toward the expansion of the genetic alphabet: Information storage and replication with unnatural hydrophobic base pairs. J. Am. Chem. Soc. 122:3274-3287. Ogawa, A.K., Wu, Y., Berger, M., Schultz, P.G., and Romesberg, F.E. 2000b. Rational design of an unnatural base pair with increased kinetic selectivity. J. Am. Chem. Soc. 122:8803-8804. Postema, M.H.D. 1992. Recent developments in the synthesis of C-glycosides. Tetrahedron 48:85458599. Ren, R.X.F., Chaudhuri, N.C., Paris, P.L., Rumney S., and Kool, E.T. 1996. Naphthalene, phenanthrene, and pyrene as DNA base analogues: Synthesis, structure, and fluorescence in DNA. J. Am. Chem. Soc. 118:7671-7678. Roberts, C., Chaput, J.C., and Switzer, C. 1997a. Beyond guanine quartets: Cation-induced formation of homogenous and chimeric DNA tetraplexes incorporating iso-guanine and guanine. Chem. & Biol. 4:899-908. Roberts, C., Bandaru, R., and Switzer, C. 1997b. Theoretical and experimental study of isoguanine and isocytosine: Base pairing in an expanded genetic system. J. Am. Chem. Soc. 119:46404649. Robinson, H., Gao, Y.-G., Bauer, C., Roberts, C., Switzer, C., and Wang, A.H. 1998. 2′-Deoxyisoguanosine adopts more than one tautomer to form base pairs with thymidine observed by high-resolution crystal structure analysis. Biochemistry 37:10897-10905.
Synthesis of Modified Nucleosides
1.5.35 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Sharma, P.K. 1993. A new synthesis of trans-3,4-dihydroxy-anti-1,2-epoxy-1,2,3,4-tetrahydro-7, 12-dimethylbenz[a]anthracene. Synth. Commun. 23:389-394. Solomon, M.S. and Hopkins, P.B. 1993. Chemical synthesis and characterization of duplex DNA containing a new base pair: A nondisruptive, benzofused pyrimidine analog. J. Org. Chem. 58: 2232-2243. Takeshita, M., Chang, C.N., Johnson, F., Will, S., and Grollman, A.P. 1987. Oligodeoxynucleotides containing synthetic abasic sites. J. Biol. Chem. 262:10171-10179. Vorbrüggen, H. and Ruh-Pohlenz, C. 2001. Handbook of Nucleoside Synthesis. John Wiley & Sons, New York. Vorbrüggen H., Krolikiewicz, K., and Bennua, B. 1981. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts. Chem. Ber. 114:1234-1235. Wu, Y., Ogawa, A.K., Berger, M., McMinn, D.L., Schultz, P.G., and Romesberg, F.E. 2000. Efforts toward expansion of the genetic alphabet: Optimization of interbase hydrophobic interactions. J. Am. Chem. Soc. 122:7621-7632.
Key References Berger, M., Wu, Y., Ogawa, A.K., McMinn, D.L., Schultz, P.G., and Romesberg, F.E. 2000. Universal bases for hybridization, replication and chain termination. Nucl. Acids Res. 28:29112914.
This paper describes the evaluation of a variety of unnatural bases as universal bases for hybridization and replication. Berger, M., Luzzi, S.D., Henry, A.A., and Romesberg, F.E. 2002. Stability and selectivity of unnatural DNA with five-membered-ring nucleobase analogues. J. Am. Chem. Soc. 124:12221226. This paper describes the evaluation of 5-membered ring nucleobase analogs. Lee et al., 2001. See above. This paper describes the replication of DNA containing the 7AI self-pair with the Klewnow fragment/pol β binary polymerase system. Ogawa et al., 2000a. See above. This paper describes the synthesis of the C-nucleosides reported herein. Ogawa et al., 2000b. See above. This paper describes the rational design of the 3MN:3MN self-pair.
Contributed by Floyd E. Romesberg, Chengzhi Yu, Shigeo Matsuda, and Allison A. Henry The Scripps Research Institute La Jolla, California
Development of a Universal Nucleobase and Unnatural Nucleobases
1.5.36 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Syntheses of Specifically 15N-Labeled Adenosine and Guanosine
UNIT 1.6
This unit describes the specific incorporation of 15N into the N7 and amino positions of adenosine (Basic Protocol 1), and conversion of the adenosine to guanosine labeled at the N1, N7, and amino positions (Basic Protocol 2). Two variations of the procedures are also presented that include either 12C or 13C at the C8 position of adenosine, and 13C at either the C8 or C2 position of guanosine. These 13C tags permit the incorporation of two 15 N-labeled nucleosides into an RNA strand while ensuring that their nuclear magnetic resonance (NMR) signals can be distinguished from each other by the presence or absence of C-N coupling. While the major application of these specifically 15N-labeled nucleosides is NMR, the additional mass makes them useful in mass spectrometry (MS) as well. The procedures can also be adapted to synthesize the labeled deoxynucleosides. The Support Protocol describes the synthesis of 7-methylguanosine. CAUTION: The procedures in this unit use a number of highly toxic and dangerous reagents. Raney nickel is pyrophoric when dry and may burst into flames if not kept wet. Phosphorous oxychloride (POCl3) is very reactive and hydrolyzes to hydrochloric and phosphoric acids, which are both highly corrosive to skin and tissue. Cyanogen bromide is very dangerous; improper use of this reagent has led to deaths in the laboratory. All reactions must be done with great care in an appropriate chemical fume hood. SYNTHESES OF [7,NH2-15N2]- AND [8-13C-7,NH2-15N2]ADENOSINE As shown in Figure 1.6.1, the procedures described here (Pagano et al., 1995; Zhao, 1997; Shallop and Jones, 2000) start with the inexpensive pyrimidine 4-amino-6-hydroxy-2mercaptopyrimidine and introduce the first 15N label by a direct nitrosation in high yield. Reduction of the nitroso group to an amino group is followed by ring closure using either diethoxymethylacetate in dimethylformamide (DMF) to give 12C at the C8 position, or [13C]sodium ethyl xanthate to give 13C at the C8 position. Removing the thiol group(s) with Raney nickel forms hypoxanthine, which can readily be converted to 6-chloropurine, a good substrate for enzymatic transglycosylation. The second 15N label is then introduced into the nucleoside by displacement of the chloride by 15NH3, which is generated in situ. Materials 4-Amino-6-hydroxy-2-mercaptopyrimidine monohydrate, also called 6-amino-2-thioxo-1,2-dihydro-4(3H)-pyrimidinone (Aldrich) 1 N HCl [15N]Sodium nitrite ([15N] NaNO2; Isotec or Cambridge Isotope Laboratories) 2:98 to 40:60 (v/v) gradient of acetonitrile/0.1 M triethylammonium acetate (TEAA), pH 6.8 95% (v/v) ethanol, 4°C Acetone, 4°C Phosphorous pentoxide (P2O5) Saturated aqueous NaHCO3 Sodium hydrosulfite (Na2S2O4) Glacial acetic acid 96% (v/v) formic acid Nitrogen gas source Dimethylformamide (DMF), anhydrous Diethoxymethyl acetate (DEMA), for 12C synthesis only Acetonitrile, room temperature and 4°C Contributed by Barbara L. Gaffney and Roger A. Jones Current Protocols in Nucleic Acid Chemistry (2002) 1.6.1-1.6.14 Copyright © 2002 by John Wiley & Sons, Inc.
BASIC PROTOCOL 1
Synthesis of Modified Nucleosides
1.6.1 Supplement 10
O
O [ 15N ] N a N O 2
NH H2N
N
O 15N H 2N
SH
1
O
N
H215N
Na 2S 2O 4
NH
NH
H2N
SH
N
2
SH
3 DEMA or [ 13C]NaSCSOEt
Cl
O
15
O
15
N
N
X N H
15
N
POCl 3
6a, X =12C 6b, X =13C
NH
X N H
N
N
RaNi
NH
X N H
N
5a, X =12C 5b, X =13C
N
SH
4a, X =12CH 4b, X =13CSH
7-MeG PNP 15
Cl 15
N
N
X N
HO
O HO
OH
7a, X =12C 7b, X =13C
N
NH2
15
N
[ 15N ] N H 4C l KHCO 3
N
X N
HO
O HO
N
OH
8a, X =12C 8b, X =13C
Figure 1.6.1 Steps for synthesis of [7,NH2-15N2]- and [8-13C-7,NH2-15N2]adenosine using Basic Protocol 1. DEMA, diethoxymethyl acetate; 7-MeG, 7-methylguanosine; [13C]NaSCSOEt, [13C]sodium ethyl xanthate; PNP, purine nucleoside phosphorylase; RaNi, Raney nickel.
[13C]NaSCSOEt (see recipe), for 13C synthesis only NaOH 50% aqueous Raney 2800 nickel (RaNi) slurry (Aldrich) Dipotassium salt of EDTA Boiling water Phosphorous oxychloride (POCl3) N,N-Dimethylaniline 5% (v/v) NH3, (diluted with water from 30% concentrated aqueous ammonia) Ethyl acetate Ethyl ether 1 M HCl 7-Methylguanosine (see Support Protocol) 0.02 M K2HPO4 3 M NaOH Purine nucleoside phosphorylase (Sigma) [15N]Ammonium chloride ([15N]NH4Cl; Isotec or Cambridge Isotope Laboratories) Dimethylsulfoxide (DMSO), anhydrous KHCO3, anhydrous Synthesis of Specifically N-Labeled Adenosine and Guanosine 15
1.6.2 Supplement 10
Current Protocols in Nucleic Acid Chemistry
100- and 250-mL round-bottom flasks Small glass vials 1-, 3-, 10-, and 20-ml syringes Vacuum desiccator Rubber septa fitted with large-bore vent needles Condenser Rotary evaporator, connected to water aspirator and a vacuum pump, the latter with a dry-ice trap Oil bath (silicone oil), 130°C Separatory funnel Continuous extraction apparatus for solvents lighter than water (Aldrich) 30°C oven with shaker 50-mL bomb with Teflon liner (Parr Instrument) 80°C oven Additional reagents and equipment for analytical and preparative reversed-phase high-performance liquid chromatography (HPLC; UNIT 10.5) Synthesize [5-15N]-6-amino-5-nitroso-2-thioxo-1,2-dihydro-4(3H)-pyrimidinone (S.2) 1. Weigh 0.805 g (5.0 mmol) of 4-amino-6-hydroxy-2-mercaptopyrimidine monohydrate into a 100-mL round-bottom flask with a stir bar. 2. Add 25 mL of 1 N HCl and chill the suspension 10 min in an ice bath. 3. Weigh 0.385 g (5.5 mmol, 1.1 eq) [15N]NaNO2 into a small glass vial, dissolve it in ∼1 mL water, and draw the solution into a 3-mL syringe. 4. Slowly add the sodium nitrite to the reaction mixture over ∼5 min. If the addition is too fast, the reaction may bubble over. Before long, the mixture will change from yellow to red.
5. Stir the mixture for ∼7 hr in the ice bath, while monitoring the reaction for completeness by reversed-phase HPLC with a gradient of 2:98 to 40:60 acetonitrile/0.1 M TEAA over 5 min. The peak representing the starting material should diminish to <3%, and a new peak representing the product should appear. Any reversed-phase column can be used. The sample should be injected immediately after mixing for comparison.
6. Collect S.2 by vacuum filtration and wash it with 5 mL cold water, then 5 mL cold 95% ethanol, and finally 5 mL cold acetone. 7. Without removing it from the funnel, dry S.2 over P2O5 in a vacuum desiccator overnight. The yield is usually >95%. See Table 1.6.1 for various data on this and other intermediates and products.
Synthesize [5-15N]-5,6-diamino-2-thioxo-1,2-dihydro-4(3H)-pyrimidinone (S.3) 8. Scrape out most of S.2 from the funnel into a 100-mL round-bottom flask. Rinse the funnel with portions of saturated aqueous NaHCO3 and add them to the flask to give a final volume of 40 mL. 9. Add a stir bar and place the mixture in an ice bath for 10 min. Stir gently.
Synthesis of Modified Nucleosides
1.6.3 Current Protocols in Nucleic Acid Chemistry
Supplement 10
10. Quickly weigh 2.61 g (15 mmol, 3 eq) Na2S2O4 into a small beaker. Using a spatula, gradually add it in portions to the reaction over 20 min. The sodium hydrosulfite smells bad, so it should be kept in the back of the hood. If the addition is too fast, the reaction will bubble over.
11. Insert a rubber septum containing a large-bore vent needle. 12. Stir the mixture for ∼7 hr in the ice bath, while monitoring the reaction for completeness by HPLC as described (step 5). The mixture will change from red to yellow.
13. Slowly add 1.6 mL glacial acetic acid over ∼5 min to neutralize the NaHCO3, and stir another 5 min. 14. Collect the product by vacuum filtration and wash it twice with 5 mL cold water and then twice with 5 mL cold 95% ethanol. 15. Without removing it from the funnel, dry S.3 over P2O5 in a vacuum desiccator overnight. The yield is usually >95%. The synthesis is continued using either diethoxymethylacetate in dimethylformamide (DMF) to give 12C at the 8 position (steps 16a to 26a) or [13C]sodium ethyl xanthate to give 13C at the 8 position (steps 16b to 22b).
Perform ring closure For [7-15N]-2-thioxohypoxanthine (S.4a): 16a. Scrape out most of S.3 from the funnel into a 100-mL round-bottom flask. Rinse the funnel with portions of 96% formic acid and add them to the flask to give a final volume of 25 mL.
Table 1.6.1 Molecular Weights, TLC and HPLC Mobilities, and UV λmax of 15N-Labeled Adenosine and Guanosine Intermediatesa
Compound
mol. wt. (Da)
TLC Rfb
HPLC retention time (min)c
UV λmax (nm)
S.2 S.3 S.4a S.4b S.5a/b S.6a/b S.7a/b S.8a/b S.9a/b S.12a/b S.13a/b
173 159 169 202 137/138 155/156 287/288 269/270 285/286 316 287
0.2 0.0 0.2 0.0 0.1 0.3 0.2 0.1 0.0 0.1 0.0
1.2 0.8 0.7 1.4 0.8 2.4 4.5 2.6 0.9 3.3 1.4
360 301 280 299 250 265 264 259 295 280 253
aAbbreviations: HPLC, high-performance liquid chromatography; mol. wt., molecular weight; TLC, thin-layer chroma-
tography.
Synthesis of Specifically 15 N-Labeled Adenosine and Guanosine
bR values determined with 10:90 (v/v) CH OH/CH Cl . f 3 2 2 cGradient of 2:98 to 40:60 (v/v) acetonitrile/0.1 M triethylammonium acetate, pH 6.8, over 5 min, on a Waters NovaPak
C18 column.
1.6.4 Supplement 10
Current Protocols in Nucleic Acid Chemistry
17a. Add a stir bar, attach a condenser, and reflux the solution for 1 hr to make the formate salt. 18a. Concentrate to dryness using a rotary evaporator and scrape down the sides of the flask with a spatula, if necessary. 19a. Insert a rubber septum and displace the air with nitrogen. 20a. Use syringes to add the following through the septum: 20 mL anhydrous DMF 1.63 mL DEMA (10 mmol, 2 eq) 0.24 mL of 96% formic acid (6 mmol, 1.2 eq). 21a. Heat the mixture for 3 hr in an oil bath set at 130°C. Follow the reaction by HPLC. The flask is lifted from the oil bath and allowed to cool briefly, and then a small syringe with a long, dry needle is used to get a sample for HPLC.
22a. Cool the flask, concentrate the solution to a solid using a rotary evaporator, and loosen it with a spatula if necessary. 23a. Add 15 mL acetonitrile to the flask, attach a condenser, and reflux it for 10 min using the 130°C oil bath. 24a. Cool the flask to room temperature, add 10 mL acetonitrile, and then chill it in an ice bath. 25a. Collect S.4a by vacuum filtration and wash it twice with 5 mL cold acetonitrile. 26a. Without removing it from the funnel, dry S.4a over P2O5 in the vacuum desiccator overnight. Proceed to step 27. The yield is usually >95%.
For [8-13C-7-15N]-2,8-dithioxohypoxanthine (S.4b): 16b. Scrape out most of S.3 from the funnel into a 100-mL round-bottom flask and add 0.80 g (5.5 mmol) [13C]NaSCSOEt. 17b. Insert a condenser into the flask, attach a nitrogen line and vent needle, and displace the air for 5 min. 18b. Add 15 mL DMF and reflux the mixture under nitrogen for ∼3 hr, using HPLC to monitor the reaction. 19b. Cool the mixture in an ice bath and add 50 mL cold acetonitrile to precipitate S.4b. 20b. Collect the solid S.4b by vacuum filtration and wash it twice with 5 mL cold acetonitrile. Save the filtrate and both washes. 21b. Concentrate the filtrate and washes, and purify this portion of S.4b by preparative reversed-phase chromatography. 22b. Dry the combined portions of S.4b over P2O5 in a vacuum desiccator overnight. Continue with step 27. The yield is usually >95%.
Synthesis of Modified Nucleosides
1.6.5 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Synthesize [7-15N]hypoxanthine and [8-13C-7-15N]hypoxanthine (S.5a/b) 27. Scrape out most of S.4a/b from the funnel into a 100-mL round-bottom flask. 28. Rinse the funnel with portions of water and add them to the flask to give a final volume of 30 mL. 29. Add a stir bar and 2 mL of 96% formic acid. 30. Weigh 4.5 g of 50% aqueous RaNi slurry into a small glass vial or beaker. CAUTION: RaNi is pyrophoric (will spontaneously burst into flames) if it is allowed to dry out. To weigh it, shake the bottle and immediately transfer some of the suspended RaNi to the vial. Continue adding the suspension (shaking the bottle each time) until 4.5 g of the 50:50 mixture of RaNi/water has been measured out.
31. Using a dropper, transfer the RaNi suspension over 5 min to the reaction flask, and add 1.5 g dipotassium salt of EDTA. Traces of remaining RaNi in the vial and dropper should be destroyed with 6 M HCl.
32. Connect a condenser to the flask. Using the 130°C oil bath, reflux for ∼2 hr while monitoring the reaction for completeness by HPLC. 33. Remove the flask from the oil bath and allow it to cool only briefly. 34. Remove the condenser from the flask and carefully filter the hot reaction mixture to remove the RaNi. Rinse the flask and then the funnel with three 10-mL portions of boiling water, adding these washes to the filtrate. To destroy the RaNi remaining in the funnel, the funnel should be transferred to a large beaker, and portions of 6 M HCl should be slowly added until no black particles can be observed.
35. Concentrate the filtrate and washes to dryness in a 100-mL round-bottom flask using the rotary evaporator. 36. Dry S.5a/b over P2O5 in the vacuum desiccator overnight. The yield is usually >95%. S.5a/b can be purified by reversed-phase chromatography if desired.
Synthesize [7-15N]- and [8-13C-7-15N]-6-chloropurine (S.6a/b) 37. Weigh 0.69 g (5.0 mmol) S.5a/b into a very dry 100-mL round-bottom flask. 38. Add 20 mL (215 mmol, 43 eq) POCl3 and 2 mL (16 mmol) N,N-dimethylaniline. Use great care with POCl3; it is very reactive.
39. Attach a condenser and reflux 20 min under nitrogen. The resulting solution should be black and homogeneous. It is essential for this reaction to remain anhydrous.
40. Monitor the reaction for completeness by HPLC and continue refluxing the mixture for ≤30 min more. 41. Concentrate the mixture to a very small volume using a rotary evaporator, first with an aspirator and then with a vacuum pump protected with a dry-ice trap. Add 10 mL N,N-dimethylaniline and continue the evaporation. Synthesis of Specifically N-Labeled Adenosine and Guanosine 15
It is necessary to remove all traces of POCl3, or localized heating from later neutralization with NH3 may cause the reaction to reverse. Be extremely careful to dry the evaporator condenser and trap prior to use, to keep dry ice in the traps throughout this process, and then to pour the collected POCl3 into a plastic container of ice to destroy it.
1.6.6 Supplement 10
Current Protocols in Nucleic Acid Chemistry
42. Cool the flask in an ice bath and very slowly add 30 mL of 5% NH3 to dissolve the black gum. As a neutral compound, 6-chloropurine is insoluble in water, but under basic conditions it will ionize and therefore dissolve.
43. Make sure the pH of the solution is >10 (add more NH3 if necessary) and then pour it into a separatory funnel. Wash it first with 30 mL ethyl acetate and then twice with 30 mL ethyl ether. Check the layers by HPLC. 44. Combine all organic layers that contain traces of product in a separatory funnel, backwash with 5% NH3, and add this aqueous layer to the main reaction mixture. 45. Concentrate this aqueous solution to dryness to remove all the NH3. It is necessary to remove all traces of NH3, or localized heating from later neutralization with HCl may cause the reaction to reverse. As the NH3 evaporates, it is very likely to bump, so a large enough flask should be used.
46. Add 20 mL water and chill the flask in an ice bath. Slowly acidify the solution to pH 2 using 1 M HCl. The mixture will turn cloudy.
47. Set up a continuous extraction apparatus for solvents lighter than water. Pour the aqueous layer into the extractor and add ethyl ether until the level is just under the side arm. 48. Fill a 250-mL round-bottom flask with ethyl ether, add a stir bar, connect to the extractor, and place it in an oil bath. Attach a condenser to the top of the extractor, and start heating the oil bath to 45°C. 49. Continue the extraction for 3 to 4 days, using fresh ether each day. Check both the aqueous and ether layers each day by HPLC. Verify that the pH of the aqueous layer is still <2 and, if it is not, adjust it with 1 M HCl. 50. Concentrate the ether layers to a small volume, whereupon a significant amount of S.6a/b should crystallize out. Collect S.6a/b by vacuum filtration and check it for purity by HPLC. Save the filtrate. 51. Concentrate the filtrate to dryness and dissolve it in 10 mL water. Purify by reversed-phase preparative chromatography. 52. Concentrate the fractions containing pure product to dryness. Dry both portions of S.6a/b in a vacuum desiccator over P2O5 overnight. The yield is usually between 80% and 90%.
Synthesize [7-15N]- and [8-13C-7-15N]-6-chloro-9-(β-D-erythropentofuranosyl) purine (S.7a/b) 53. Place 2.12 g (7.5 mmol, 1.5 eq) of 7-methylguanosine and 0.78 g (5 mmol) S.6a/b into a 100-mL round-bottom flask and add 20 mL of 0.02 M K2HPO4. Using pH paper, adjust the pH to 7.4 with 3 M NaOH, if necessary. 54. Add 250 units of purine nucleoside phosphorylase. Insert a septum and heat the mixture ∼3 days in an oven at 30°C with gentle agitation. Monitor the reaction for completeness each day by HPLC. 55. Pour the mixture into 10 mL DMF and stir ∼1 hr at room temperature.
Synthesis of Modified Nucleosides
1.6.7 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Table 1.6.2 Nuclear Magnetic Resonance Chemical Shifts (ppm) for 15N-Labeled Adenosine (S.8) and Guanosine (S.13)a
5′H
N1
N7
NH2 C2
C8
— 8.35 8.14 7.40 5.87 4.60 4.14 3.96 3.6 10.6 7.92 NA 6.44 5.68 4.38 4.07 3.85 3.6
— 148
242 244
83 75
140 135
Compound N1H H8 S.8a/b S.13a/b
H2
NH2 1′H
2′H
3′H
4′H
152 154
aAll NMR samples in DMSO-d . 15N data are relative to 15NH using external 1M [15N]urea in DMSO at 77.0 ppm as a reference. 6 3
Additional data (e.g., for intermediates) are available in Pagano et al. (1995), Zhao et al. (1997), and Shallop and Jones (2000).
Table 1.6.3 Nuclear Magnetic Resonance Coupling Constants (Hz) for 15N-Labeled Adenosine (S.8) and Guanosine (S.13)
Compound
13C8-15N7
13C2-15N1
13C2-15NH
S.8a/b S.13a/b
<1 <1
NA 12
NA 24
2
56. Filter the suspension to remove most of the solid 7-methylguanine. Suspend the solid in 5 mL fresh DMF, stir 15 min, and filter. 57. Concentrate the combined filtrates to a small volume using a rotary evaporator and add 15 mL water (more if necessary to dissolve the solid). 58. Purify the crude S.7a/b by preparative reversed-phase HPLC and dry it over P2O5 in the vacuum desiccator overnight. The yield is usually 85% to 95%.
Synthesize [7,NH2-15N2]- and [8-13C-7,NH2-15N2]adenosine (S.8a/b) 59. Place 1.44 g (5 mmol) S.7a/b into a clean Teflon liner of a bomb and add 0.54 g (10 mmol, 2 eq) of [15N]NH4Cl and 7 mL anhydrous DMSO. 60. Add 1.5 g (15 mmol, 3 eq) KHCO3 and immediately seal the bomb. 61. Heat the bomb 3 days in an 80°C oven, swirling the mixture once or twice each day. 62. Cool the bomb to room temperature and then to −20°C for ≥30 min. Open it carefully and dilute the mixture with 10 mL water. Adjust the pH to 7 with glacial acetic acid. Care should be taken when opening the bomb because CO2 will have been generated.
63. Check the reaction by HPLC. 64. Purify S.8a/b by preparative reversed-phase HPLC and dry it over P2O5 in the vacuum desiccator overnight. The yield is usually 80% to 90%. See Tables 1.6.2 and 1.6.3 for NMR chemical shifts and coupling constants.
Synthesis of Specifically N-Labeled Adenosine and Guanosine 15
1.6.8 Supplement 10
Current Protocols in Nucleic Acid Chemistry
SYNTHESIS OF 7-METHYLGUANOSINE Although 7-methylguanosine can be purchased from Sigma, it is quite easy to make. Commercial 7-methylguanosine is very expensive and the purity may not be as high.
SUPPORT PROTOCOL
Materials Guanosine N,N-Dimethylacetamide Nitrogen gas source Dimethyl sulfate Concentrated aqueous NH3 Acetone, 4°C 95% (v/v) ethanol Ethyl ether 250-mL round-bottom flask Rubber septum 10-mL syringes CAUTION: Dimethyl sulfate is very dangerous because it is a potent alkylating agent; wear gloves and use caution. Synthesize 7-methylguanosine 1. Place 9.91 g (35 mmol) guanosine in a 250-mL round-bottom flask along with a stir bar. 2. Add 80 mL N,N-dimethylacetamide as a solvent, insert a rubber septum, and displace the air with nitrogen gas. 3. Carefully withdraw 7.0 mL (74 mmol, 2.1 eq) dimethyl sulfate with a 10-mL syringe and add it to the suspension. 4. Stir mixture ∼6 hr and monitor the reaction for completeness by HPLC. 5. Slowly add 10 mL concentrated aqueous NH3 and then check the pH using pH paper. Continue to add more NH3 slowly, frequently checking the pH, until the mixture is pH 10. This step is essential and quenches the excess dimethyl sulfate.
6. Slowly add the mixture to 300 mL cold acetone in an ice bath to precipitate the product. 7. Collect the white precipitate by vacuum filtration. 8. Check the acetone filtrate by HPLC for product. If there is a significant amount, concentrate the filtrate to a small volume, chill it, and collect the additional product by vacuum filtration. Combine it with the rest. Purify 7-methylguanosine 9. Suspend the solid crude product in 300 mL of 95% ethanol, stir 5 min, and collect it by filtration. 10. Suspend the solid product in 300 mL ethyl ether, stir 5 min, and collect it by filtration. 11. Dry the pure product over P2O5 in a vacuum desiccator overnight. The yield is usually 80% to 90%. It is very important to keep this compound dry. It should be transferred to a bottle with a tight lid, the air should be displaced with nitrogen, and it should be stored at −20°C. It can be kept for up to 3 months.
Synthesis of Modified Nucleosides
1.6.9 Current Protocols in Nucleic Acid Chemistry
Supplement 10
BASIC PROTOCOL 2
SYNTHESIS OF [2-13C-1,7,NH2-15N3]- AND [8-13C-1,7,NH2-15N3]GUANOSINE As shown in Figure 1.6.2, in the adenosine to guanosine transformation (Zhao, 1997; Shallop and Jones, 2000), the adenosine amino group becomes the guanosine N1, while the guanosine amino and C2 come from potassium cyanide. Thus, to make [2-13C1,7,NH2-15N3]guanosine (S.13a), [7,NH2-15N2]adenosine (S.8a) is used with [13C,15N]KCN, and to synthesize [8-13C-1,7,NH2-15N3]guanosine (S.13b), [8-13C-7,NH215 N2]adenosine (S.8b) is used with [15N]KCN. The first step is the oxidation of adenosine (S.8a/b) to the N1 oxide (S.9a/b), which is followed by a one-flask set of reactions without purification to give S.12a/b. Labeled cyanogen bromide is generated in situ from labeled potassium cyanide and bromine, and its reaction with S.9a/b forms S.10a/b. Treatment with triethylamine opens the oxazolidine ring, allowing the N1 oxide to be methylated by methyl iodide to give S.11a/b. Aqueous sodium hydroxide then opens the pyrimidine ring, which deformylates, rearranges, and closes again upon neutralization and heating to give S.12a/b. Enzymatic deamination then gives the final product, S.13a/b.
15
NH
15NH 15
N N
HO
15
N
N
X
O
N
H N Y 15
NH2
2
N
X HO
15
MCPBA
HO
OH
N
O HO
12
8a, X = C 8b, X =13C
N
O
O
15
N
N
X Br2/[ 13C,15N]KCN or
HO
Br2/[ 15N]KCN
OH
N
O HO
9a, X =12C 9b, X =13C
N
OH
10a, X =12C, Y =13C 10b, X =13C, Y =12C
1) Et 3 N 2) CH 3 I
O 15
N
X HO
O
N
HN 15
15N
NH Y 15 N NH2
X HO
O
N
N
O C H3 15
15
N Y
X
N
15
OH
13a, X =12C, Y =13C 13b, X =13C, Y =12C
Synthesis of Specifically N-Labeled Adenosine and Guanosine 15
HO
NH 2
O
N
Y15N N
O C H3
N
1) NaOH
ADA HO
H 15N
HO
OH
12a, X =12C, Y =13C 12b, X =13C, Y =12C
2) HCl
HO
OH
11a, X =12C, Y =13C 11b, X =13C, Y =12C
Figure 1.6.2 Steps for synthesis of [2-13C-1,7,NH2-15N3]- and [8-13C-1,7,NH2-15N3]guanosine using Basic Protocol 2. ADA, adenosine deaminase; Et3N, triethylamine; MCPBA, 3-chloroperoxybenzoic acid.
1.6.10 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Materials [7,NH2-15N2]Adenosine or [8-13C-7,NH2-15N2]adenosine (S.8a or S.8b; see Basic Protocol 1) 50% (v/v) methanol 3-Chloroperoxybenzoic acid (MCPBA), purified (see recipe) Ethyl ether Phosphorous pentoxide (P2O5) [13C,15N]Cyanogen bromide or [15N]cyanogen bromide, freshly prepared (see recipe) 0.1 M potassium phosphate (KH2PO4), pH 7.5 Dimethyl formamide (DMF), anhydrous Acetonitrile Triethylamine Nitrogen gas source Methyl iodide 0.1 M NaOH 1 M HCl 95% (v/v) ethanol Adenosine deaminase (Sigma) 100-mL round-bottom flasks Rotary evaporator Vacuum desiccator Oil bath (silicone oil), 60°C Additional reagents and equipment for analytical and preparative reversed-phase high-performance liquid chromatography (HPLC; UNIT 10.5) Synthesize [7,NH2-15N2]- and [8-13C-7,NH2-15N2]adenosine-N1-oxide (S.9a/b) 1. Weigh 1.35 g (5.0 mmol) of [7,NH2-15N2]adenosine (S.8a) or [8-13C-7,NH215 N2]adenosine (S.8b) into a 100-mL round-bottom flask. Add a stir bar and 50 mL of 50% methanol. 2. Add 1.72 g (10 mmol, 2 eq) purified MCPBA, cover the flask with aluminum foil, stir 3 to 4 hr, and monitor the reaction for completeness by HPLC. Any reversed-phase column can be used.
3. Dilute the solution with 25 mL water and wash it with three 50-mL portions of ethyl ether. 4. Use a rotary evaporator to concentrate the aqueous solution to a small volume, purify S.9a/b by preparative reversed-phase HPLC, and dry it over P2O5 in a vacuum desiccator overnight in a 100-mL round-bottom flask. The yield is usually 90% to 95%. See Table 1.6.1 for various data on this and other intermediates and products.
Synthesize [2-13C-1,7,NH2-15N3]- and [8-13C-1,7,NH2-15N3]-2-amino-6(methoxyamino)-9-(β-D-ribofuranosyl)purine (S.12a/b) 5. Dissolve 1.43 g (5.0 mmol) S.9a/b in 40 mL water. 6. Add 7.5 mmol freshly prepared [13C,15N]cyanogen bromide or [15N]cyanogen bromide, stir for 2 hr, and monitor the reaction for completeness by HPLC. To make S.13a, [13C,15N]cyanogen bromide is used, and to make S.13b, [15N]cyanogen bromide is used.
Synthesis of Modified Nucleosides
1.6.11 Current Protocols in Nucleic Acid Chemistry
Supplement 10
CAUTION: The waste in the evaporator trap may contain excess cyanogen bromide. Dispose of this waste in an appropriately designated area, following the guidelines provided by the local safety officer.
7. Concentrate the solution to a very small volume using a rotary evaporator, add 10 mL anhydrous DMF and 10 mL acetonitrile, and concentrate again. Repeat this drying process two more times. CAUTION: Be very careful to dispose of the waste from the evaporator trap according to accepted regulations, because it may contain excess cyanogen bromide.
8. Add 25 mL anhydrous DMF and 2.8 mL (20 mmol, 4 eq) triethylamine under nitrogen gas. 9. Stir 45 min and then slowly add 2.5 mL (40 mmol, 8 eq) methyl iodide. Do not wait >1 hr to add the methyl iodide.
10. Cover the flask with aluminum foil and stir 3 to 4 hr while monitoring the reaction for completeness by HPLC. 11. Concentrate the solution to a yellow oil and add 85 mL of 0.1 M NaOH. Do not wait >4 hr to concentrate the solution and add the NaOH. CAUTION: The waste from the evaporator trap must be carefully disposed according to accepted regulations, because it may contain the excess methyl iodide.
12. Stir 20 min and then adjust the pH to 7.4 with 1 M HCl. 13. Add 80 mL of 95% ethanol, attach a condenser, and heat the solution in an oil bath at 60°C for 4 hr while monitoring the reaction for completeness by HPLC. 14. Concentrate the solution to a small volume using a rotary evaporator, purify S.12a/b by reversed-phase HPLC, and dry it over P2O5 in the vacuum desiccator overnight in a 100-mL round-bottom flask. The yield is usually 80% to 90%.
Synthesize [2-13C-1,7,NH2-15N3]- and [8-13C-1,7,NH2-15N3]guanosine (S.13a/b) 15. Dissolve 1.58 g (5 mmol) S.12a/b in 80 mL of 0.1 M KH2PO4, pH 7.5. 16. Add 300 units of adenosine deaminase, stopper the flask, and heat 4 days at 37°C with gentle agitation. Most of the product should crystallize out during this time.
17. Cool the mixture in an ice bath and collect crude S.13a/b by filtration. 18. Recrystallize S.13a/b by recrystallization from water and dry it over P2O5 in a vacuum desiccator overnight. The yield is usually 75% to 85%. See Tables 1.6.2 and 1.6.3 for NMR chemical shifts and coupling constants.
Synthesis of Specifically N-Labeled Adenosine and Guanosine 15
1.6.12 Supplement 10
Current Protocols in Nucleic Acid Chemistry
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
3-Chloroperoxybenzoic acid (MCPBA) Dissolve 10 g MCPBA in 200 mL ether and wash with three 150-mL portions of 0.1 M aqueous potassium phosphate, pH 7.5. Concentrate to dryness and dry over P2O5 in a vacuum desiccator overnight. Store up to 3 months at −20°C in a bottle with a tight cap. CAUTION: MCPBA is potentially explosive and must be handled with care. Commercial MCPBA is contaminated with 40% to 50% 3-chlorobenzoic acid, which can be removed by extraction.
[13C,15N]Cyanogen bromide Place 3 mL water into a small pear-shaped flask and add 1.2 g (0.38 mL, 7.5 mmol) bromine. Chill the flask in an ice bath, slowly add 0.50 g (7.5 mmol, 1 eq) [13C,15N]potassium cyanide dissolved in 20 mL water, and stir 30 min. Draw the solution into a syringe in order to add it to a reaction. CAUTION: Use great care in handling bromine, because it is highly toxic, is fairly volatile, and can cause severe burns. Place a balance in a hood, draw up the required volume of bromine into a preweighed syringe, weigh the syringe, and adjust accordingly. Potassium cyanide and cyanogen bromide are also highly toxic and must be handled with great care.
[15N]Cyanogen bromide Prepare as for [13C,15N]cyanogen bromide (see recipe), but use [15N]potassium cyanide instead of [13C,15N]potassium cyanide. [13C]Sodium ethyl xanthate ([13C]NaSCSOEt) Dissolve 0.40 g (10 mmol) NaOH in 40 mL absolute ethanol. Add 0.77 g (10 mmol, 1 eq) [13C]carbon disulfide ([13C]CS2; Isotec or Cambridge Isotope Laboratories). Cover the flask with aluminum foil and stir the solution overnight at room temperature. Concentrate to dryness and dry over P2O5 in a vacuum desiccator overnight. Store up to 6 months at −20°C. The yield is usually quantitative.
COMMENTARY Background Information 15N NMR studies of specifically 15N-labeled
DNA and RNA fragments have provided significant information about local interactions at nitrogen atoms, such as hydrogen bonding, stacking, and protonation (Wang et al., 1991; Zhang et al., 1997, 1998). The use of one or more multilabeled nucleosides can provide more information than single-labeled nucleosides, but only as long as all signals can be distinguished. The use of 13C tags adjacent to different nitrogens in a pair of nucleosides was designed to allow such differentiation (Zhao, 1997; Abad et al., 1998; Shallop and Jones, 2000). In addition, the 13C chemical shifts can provide valuable information. The route to labeled adenosine described here (Pagano et al., 1995) starts with a direct
nitrosation, which is more convenient than the azo coupling described earlier (Gaffney et al., 1990). This route has been designed so as to remove both thiol groups (in the case of S.4b) in the same step. The enzymatic coupling is done with 6-chloropurine, because the subsequent displacement with [15N]NH3 can be done using much milder conditions. Also, the lipophilicity of the 6-chloro group helps in the purification of the nucleoside. The purine nucleoside phosphorylase uses 7-methylguanosine as a sugar donor and both generates the ribose-α-1-phosphate and couples it to the 6chloropurine. The reaction is driven to completion by precipitation from solution of the very insoluble 7-methylguanine. The final ammination has been optimized so that it only requires two equivalents of [15N]NH4Cl with KHCO3.
Synthesis of Modified Nucleosides
1.6.13 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Although not described here, [7,NH215N ]adenosine can be converted to [1,7,NH 2 2 15N ]adenosine (Pagano et al., 1998). 3 The adenosine to guanosine transformation described here (Zhao, 1997; Shallop and Jones, 2000) is based on a previous method (Goswami and Jones, 1991) that was in turn derived from earlier work (Ueda et al., 1978).
Critical Parameters In the chlorination that converts S.5a/b to S.6a/b, it is essential to remove all excess POCl3, or heat generated during subsequent neutralization with ammonia will cause the reaction to reverse to some extent. During the one-flask set of reactions for the adenosine to guanosine transformation, the intermediates are not particularly stable, and the reactions should not be left for longer than the stated times. After formation of cyanogen bromide, there should be no excess bromine present (as indicated by an orange color). The order of addition during the formation of cyanogen bromide is also important. In the final enzymatic deammination to make S.13a/b, S.12a/b must be purified, or the enzymatic reaction will not work satisfactorily.
Anticipated Results The early steps in these protocols generally give high yields, even for inexperienced workers. The later steps are more challenging, and, with experience, the stated yields can be obtained. Because most of these compounds are fairly polar, the use of TLC to monitor reactions is not very convenient. Reversed-phase HPLC is somewhat more informative, while UV λmax data from an HPLC system with a diode array detector are particularly helpful.
Time Considerations The total time for Basic Protocol 1 is 2 to 3 weeks and that for Basic Protocol 2 is 1 to 2 weeks. The Support Protocol requires 1 to 2 days.
Gaffney, B.L., Kung, P.-P., and Jones, R.A. 1990. Nitrogen-15-labeled deoxynucleosides. 2. Synthesis of [7-15N]-labeled deoxyadenosine, deoxyguanosine, and related deoxynucleosides. J. Am. Chem. Soc. 112:6748-6749. Goswami, B. and Jones, R.A. 1991. Nitrogen-15-labeled deoxynucleosides. 4. Synthesis of [115N]and [2-15N]-labeled 2′-deoxyguanosines. J. Am. Chem. Soc. 113:644-647. Pagano, A.R., Lajewski, W.M., and Jones, R.A. 1995. Synthesis of [6,7-15N]-adenosine, [6,715 N]-2′-deoxyadenosine, and [7-15N]-hypoxanthine. J. Am. Chem. Soc. 117:11669-11672. Pagano, A.R., Zhao, H., Shallop, A., and Jones, R.A. 1998. Synthesis of [1,7-15N2]- and [1,7, NH215 N3]-adenosine and 2′-deoxyadenosine via an N1-alkoxy mediated Dimroth rearrangement. J. Org. Chem. 63:3213-3217. Shallop, A.J. and Jones, R.A. 2000. Use of a 13C “indirect tag” to differentiate two 15N7 specifically labeled nucleosides. Middle Atlantic Regional Meeting, ACS, May 15, 2000, Abstr. 33:215-ORGN. Ueda, T., Miura, K., and Kasai, T. 1978. Synthesis of 6-thioguanine and 2,6-diaminopurine nucleosides and nucleotides from adenine counterparts via a facile rearrangement in the base portion. Chem. Pharm. Bull. 26:2122-2127. Wang, C., Gao, H., Gaffney, B.L., and Jones, R.A. 1991. Nitrogen-15-labeled deoxynucleotides. 3. Protonation of the adenine N1 int he A⋅C and A⋅G m isp a irs of the du plexes an d [d[CG(15N1)AGAATTCCCG]}2 {d[CGGGAATTC(15N1)ACG]}2. J. Am. Chem. Soc. 113:5486-5488. Zhang, X., Gaffney, B.L., and Jones, R.A. 1997. 15N NMR of a specifically labeled RNA fragment containing intrahelical GU wobble pairs. J. Am. Chem. Soc. 119:6432-6433. Zhang, X., Gaffney, B.L., and Jones, R.A. 1998. 15N NMR of RNA fragments containing specifically labeled tandem G⋅A pairs. J. Am. Chem. Soc. 120:6625-6626. Zhao, H., Pagano, A.R., Wang, W., Shallop, A., Gaffney, B.L., and Jones, R.A. 1997. Use of a 13 C atom to differentiate two 15N-labeled nucleosides: syntheses of [15NH2]-adenosine, [1,NH2-15N2] - an d [2-13C-1,NH2-15N2]guanosine, and [1,7,NH2-15N3]- and [2-13C1,7,NH2-15N3]-2′-deoxyguanosine. J. Org. Chem. 62:7832-7835.
Literature Cited Abad, J.-L., Shallop, A.J., Gaffney, B.L., and Jones, R.A. 1998. Use of 13C tags with specifically 15 N-labeled DNA and RNA. Biopolymers 48:5763.
Contributed by Barbara L. Gaffney and Roger A. Jones Rutgers University Piscataway, New Jersey
Synthesis of Specifically N-Labeled Adenosine and Guanosine 15
1.6.14 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Synthesis of Protected 2′-Deoxy-2′-fluoro-β-D-arabinonucleosides
UNIT 1.7
This unit describes in detail the preparation of protected 2′-deoxy-2′-fluoroarabinonucleosides. These building blocks are required for the synthesis of 2′-deoxy-2′-fluoroarabinonucleic acid (2′F-ANA), an oligonucleotide analog exhibiting very promising antisense properties (Damha et al., 1998; Wilds and Damha, 2000; Lok et al., 2002). The preparation of phosphoramidites from these building blocks and the synthesis of 2′F-ANA are described in UNIT 4.15. SYNTHESIS AND CHARACTERIZATION OF N2-ISOBUTYRYL-9[2-DEOXY-2-FLUORO-5-O-(4-METHOXYTRITYL)-β-DARABINOFURANOSYL]GUANINE
BASIC PROTOCOL 1
Synthesis of araF-G (S.6; Figure 1.7.3) was accomplished via the condensation of 2,6-dichloropurine with either 2-deoxy-2-fluoro-1,3,5-tri-O-benzoyl-α-D-arabinofuranose (S.2; Figure 1.7.1) or 2-deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl bromide (S.3) as a key chemical step (Figure 1.7.2). Starting from S.3 gives a higher yield of S.4 and simplifies its purification. The versatile intermediate N9-β-glycoside (S.4) was transformed into araF-G in three steps (Figure 1.7.3). Treatment of S.4 with NaN3 in ethanol gave the 2,6-diazido derivative (Wower et al., 1994). This product was then subjected to reduction with SnCl2 in a mixture of dichloromethane/methanol to give its 2,6-diamino derivative (Tennila et al., 2000). Standard debenzoylation and deamination gave araF-G. Transient protection of the 3′- and 5′-OH of araF-G (Kierzek, 1985), followed by acylation at N2 and 5′-O-tritylation, gave S.7 (Figure 1.7.3) in acceptable yields. Materials Nitrogen gas source 1,3,5-Tri-O-benzoyl-α-D-ribofuranose (S.1; Pfanstiehl) Dichloromethane, dry (see recipe) [Bis(2-methoxyethyl)amino]sulfur trifluoride (MAST; Aldrich) or (diethylamino)sulfur trifluoride (DAST; Aldrich) Saturated aqueous sodium bicarbonate Sodium sulfate (Na2SO4), anhydrous Silica gel (230 to 400 mesh) Chloroform
BzO
O BzO
BzO
OBz CH Cl , 40o-50o C 2 2 HO 1
BzO
O F
MAST or DAST
OBz
BzO
O F
HBr/CH2Cl2 rt, 24 hr
BzO
2 (83%)
Br 3 (98%)
Figure 1.7.1 Synthesis of 2-deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl bromide (S.3). The expected yields are given in parentheses. Bz, benzoyl; DAST, diethylaminosulfur trifluoride; HBr, 30% (w/v) hydrogen bromide in acetic acid; MAST, [bis(2-methoxyethyl)amino]sulfur trifluoride.
Synthesis of Modified Nucleosides
Contributed by Mohamed I. Elzagheid, Ekaterina Viazovkina, and Masad J. Damha
1.7.1
Current Protocols in Nucleic Acid Chemistry (2002) 1.7.1-1.7.19 Copyright © 2002 by John Wiley & Sons, Inc.
Supplement 10
Cl N BzO
N H
O F Br
BzO
N Cl
N
NaH, CH3CN, 50o C, 48 hr
silica gel chromatography (35%-40%)
3 (98%)
Cl N BzO
O F
N
N N
Cl
BzO 4 (N9-β-isomer) Cl N BzO
N N Si(CH3)3
O F OBz
BzO
N
silica gel chromatography (38%)
Cl
TMS-Tfl, CH3CN, reflux
2 (83%)
Figure 1.7.2 Synthesis of 2,6-dichloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)purine (S.4) from S.3 or S.2. The expected yields are given in parentheses. Bz, benzoyl; NaH, 60% (w/v) sodium hydride in oil; TMS-Tfl, trimethylsilyl trifluoromethanesulfonate.
Cl N BzO
O F
N
NH2 N
N N
Cl
BzO
1. NaN3, EtOH (97%) 2. SnCl2, CH2Cl2/CH3OH (83%)
BzO
N
O F
N N
NH2
BzO
4
5 1. NH4OH/CH3OH 2. ADase O N
MMTrO
O F
N
N
NH N
NHi-Bu
1. TMSCl/(CH3)2CHCOCl/Py 2. NH4OH/H2O 3. MMTrCl/Py/4-DMAP
HO 7 (66%)
Synthesis of Protected 2′-Deoxy-2′-fluoroβ-D-arabinonucleosides
O
HO
O F
N
NH N
NH2
HO 6 (araF-G) (79%)
Figure 1.7.3 Synthesis of araF-G (S.6) in four steps from S.4, followed by introduction of isobutyryl (i-Bu) and monomethoxytrityl (MMTr) groups into the N2 and O5′ positions, respectively, to give S.7. The expected yields are given in parentheses. ADase, adenosine deaminase; 4-DMAP, 4-dimethylaminopyridine; EtOH, 95% (v/v) ethanol; NH4OH, 29.7% (w/w) aqueous ammonia; MMTr⋅Cl, p-anisylchlorodiphenylmethane (or monomethoxytrityl chloride); Py, pyridine; TMSCl, chlorotrimethylsilane.
1.7.2 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Sand Merck thin-layer chromatography (TLC) silica plates (Kieselgel 60 F-254; 0.2 mm thick) 30% (w/v) HBr in acetic acid Chlorotrimethylsilane (TMSCl) 2,6-Dichloropurine Hexamethyldisilazane (HMDS) Acetonitrile, dry (see recipe) Trimethylsilyl trifluoromethanesulfonate (TMS-Tfl) 5:1 (v/v) toluene/ethyl acetate Sodium hydride, as a 60% (w/v) solution in mineral oil (Aldrich) Sodium azide (NaN3) 95% (v/v) ethanol Tin dichloride (SnCl2) Methanol 29.7% (w/w) aqueous ammonia (Fisher) 5% and 10% (v/v) methanol in dichloromethane Adenosine deaminase solution in 50% glycerol (from calf intestine mucosa, specific activity 160 to 200 U/mg protein; Sigma) Phosphorus pentoxide (P2O5) Pyridine, dry (see recipe) Isobutyryl chloride 2:1:1 (v/v/v) water/ethyl acetate/ether 4-Dimethylaminopyridine (4-DMAP) p-Anisylchlorodiphenylmethane (monomethoxytrityl chloride or MMTr⋅Cl) 0% to 5% (v/v) gradient of methanol in dichloromethane Oven-dried glassware, including: 25-, 100-, and 250-mL round-bottom flasks 1-L Erlenmeyer flasks Reflux condenser Oil bath, 40° to 50°C 1-L separatory funnels Rotary evaporator equipped with a vacuum pump or water aspirator Chromatography columns: 5 × 50 cm, 3 × 15 cm, and 3 × 20 cm Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Fluorinate 1,3,5-tri-O-benzoyl-α-D-ribofuranose to give S.2 1. In an oven-dried 250-mL round-bottom flask equipped with a reflux condenser, a stir bar, and nitrogen gas source, dissolve 10 g S.1 in 100 mL dry dichloromethane. 2. While stirring, add 8 mL (43.39 mmol) MAST or 9 mL (68.12 mmol) DAST dropwise. It is better to use MAST. It is less expensive, gives higher yields, and makes purification easier. CAUTION: DAST is a flammable and corrosive liquid. MAST is a toxic and corrosive liquid. Both must be handled with gloves in a well-ventilated fume hood. In case of skin contact freely apply calcium gluconate gel (Pharmascience). Reapply and continue application for an additional 10 to 15 min while seeking medical assistance. Synthesis of Modified Nucleosides
1.7.3 Current Protocols in Nucleic Acid Chemistry
Supplement 10
3. Place the flask in an oil bath preheated to 40° to 50°C and stir 24 hr or until the reaction is complete as analyzed by TLC using Merck TLC (APPENDIX 3D) silica plates. The starting material should be run alongside the reaction for comparison. The plates are developed using dichloromethane, and the bands are visualized by UV shadowing and dipping the plate in 10% (v/v) sulfuric acid in methanol followed by heating. Typically, the Rf value of the desired compound (S.2) is 0.34 (dichloromethane).
4. Dilute the reaction mixture with 200 mL dichloromethane and add it carefully to 300 mL saturated aqueous sodium bicarbonate solution. 5. Pour the mixture into a 1-L separatory funnel and allow the phases to separate. Pour the lower, yellow organic phase into a 1-L Erlenmeyer flask. 6. Dry the organic layer over anhydrous Na2SO4. Filter and evaporate the filtrate to dryness in a rotary evaporator equipped with a vacuum pump or water aspirator to give a yellow solid. 7. Prepare a slurry of 350 g silica gel in chloroform. Pour slurry into a 5 × 50–cm chromatography column and carefully layer 2 cm sand on top of slurry (see APPENDIX 3E for column chromatography). 8. Dissolve the crude product (step 6) in a minimal amount of chloroform and layer it carefully on top of the column. 9. Elute with chloroform and collect 200-mL fractions (typically a total of 2 to 4 L). Combine fractions that contain pure product, as determined by TLC. Evaporate to dryness in a rotary evaporator and dry overnight under high vacuum. Typically, the Rf value of the desired product (S.2) is 0.34 (dichloromethane).
10. Check purity of the product. 2-Deoxy-2-fluoro-1,3,5-tri-O-benzoyl-α-D-arabinofuranose (S.2): 8.3 g (83%); TLC (dichloromethane) 0.34; 1H NMR (400 MHz, acetone-d6, tetramethylsilane as internal reference): 8.1 to 7.4 (15 H, m, Bz), 6.7 (1H, d, J1,F = 9.2 Hz, H-1), 5.6 and 5.7 (1H, dd, J3,F = 20 HZ, J3,2 = 3.6 HZ, H-3), 5.5 to 5.7 ( 1H, d, J2,F = 48 Hz, H-2), 4.9 (1H, m, H-4), 4.7 to 4.8 (2H, m, H-5 and H-5′); 19F NMR (300 MHz, dimethyl sulfoxide [DMSO]-d6, 99% trifluoracetic acid as external standard): −113 (ddd). To prepare S.4 from S.2, proceed to step 17a. It is better, however, to brominate as in steps 11 to 16 and use S.3 in the condensation reaction (go to step 17b). This gives a higher yield of S.4, and affords only the N7- and N9-β-isomers, making purification easier.
Brominate to give S.3 11. In an oven-dried 100-mL round-bottom flask, dissolve 2.2 g (4.85 mmol) S.2 in 30 mL dry dichloromethane and add 4 mL of 30% HBr in acetic acid. 12. Stir the reaction mixture 24 hr at room temperature. 13. Analyze the reaction by TLC. The starting material should be run alongside the reaction for comparison. The plates are developed using dichloromethane, and the bands are visualized by UV shadowing and dipping the plate in 10% (v/v) sulfuric acid in methanol followed by heating. Typically, the Rf value of the desired compound (S.3) is ∼0.55 (dichloromethane).
14. Dilute the reaction mixture with 100 mL dichloromethane and add it carefully to 200 mL saturated aqueous sodium bicarbonate. Synthesis of Protected 2′-Deoxy-2′-fluoroβ-D-arabinonucleosides
15. Pour the mixture into a clean 1-L separatory funnel and allow the phases to separate. Pour the lower, brown organic phase into a 1-L Erlenmeyer flask. Dry the organic layer over anhydrous Na2SO4. Filter and evaporate the filtrate to dryness in the rotary evaporator to give a brown oil.
1.7.4 Supplement 10
Current Protocols in Nucleic Acid Chemistry
16. Check the purity of the product. 2-Deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl bromide (S.3): 2.0 g (98%); TLC (dichloromethane) 0.55; 1H NMR (500 MHz, CD2Cl2 ): 8.2 to 7.3 (10 H, m, Bz), 6.8 (1H, d, J1,F = 19 Hz, H-1), 5.6 (1H, d, J2,F = 50 Hz, H-2), 5.4 (1H, dd, H-3), 4.8 (3H, m, H-4, H-5, and H-5′′).
Condense 2,6-dichloropurine with S.2 or S.3 For S.2: 17a. In an oven-dried 250-mL round-bottom flask equipped with a reflux condenser, stir bar, and nitrogen gas source, add 4 mL TMSCl to a suspension of 2.84 g (15 mmol) 2,6-dichloropurine in 40 mL HMDS. Reflux 2 to 3 hr at 120°C, cool down, and evaporate to dryness in the rotary evaporator. 18a. Azeotrope (co-evaporate) the residue with 50 mL dry acetonitrile. To this residue, add 4 g (8.0 mmol) S.2 in 100 mL dry acetonitrile followed by 4 mL TMS-Tfl. Reflux the resulting solution 45 min at 80°C. 19a. Analyze the reaction by TLC. The starting material should be run alongside the reaction for comparison. The plates are developed using 9:1 (v/v) toluene/ethyl acetate, and the bands are visualized by UV shadowing and dipping the plate in 10% (v/v) sulfuric acid in methanol followed by heating. Typically, the Rf value of the desired product, the N9-β-isomer (S.4), is 0.28 (9:1 toluene/ethyl acetate).
20a. Cool the mixture, dilute with 200 mL dichloromethane, and wash it carefully with 300 mL saturated sodium bicarbonate solution. 21a. Dry the dichloromethane layer over anhydrous Na2SO4, filter, and evaporate to dryness. 22a. Prepare a 5 × 50–cm silica chromatography column as described in step 7. Apply the residue (step 21a) to the column and elute with a mixture of 5:1 toluene/ethyl acetate. Collect 50-mL fractions and combine those that contain pure product (S.4) as determined by TLC. 23a. Evaporate combined fractions to dryness in the rotary evaporator and dry overnight under a high vacuum. Proceed to step 24. For S.3: 17b. In a clean oven-dried 250-mL round-bottom flask equipped with reflux condenser, stir bar, and nitrogen gas source, dissolve 0.54 g (2.84 mmol) of 2,6-dichloropurine and 0.07 g (2.95 mmol) sodium hydride in 30 mL dry acetonitrile. Stir 45 min at room temperature. 18b. Dissolve 1.2 g (2.84 mmol) S.3 in 20 mL dry acetonitrile and add it in portions to the flask. Place the flask in an oil bath and stir 48 hr at 50°C or until the reaction is complete as determined by TLC. The starting material should be run alongside the reaction for comparison. The plates are developed using 9:1 (v/v) toluene/ethyl acetate, and the bands are visualized by UV shadowing and dipping the plate in 10% (v/v) sulfuric acid in methanol followed by heating. Typically, the Rf value of the desired N9-β-isomer (S.4) is 0.28 (9:1 toluene/ethyl acetate). Side products have Rf values in the range of 0.20 to 0.23 with the same solvent system.
19b. Vacuum filter the resulting mixture and evaporate to dryness.
Synthesis of Modified Nucleosides
1.7.5 Current Protocols in Nucleic Acid Chemistry
Supplement 12
20b. Prepare a 5 × 50–cm silica chromatography column as described in step 7. Apply the residue (step 19b) to the column and elute with 5:1 toluene/ethyl acetate. Collect 50-mL fractions and combine those that contain the pure product (S.4) as determined by TLC. 21b. Evaporate combined fractions to dryness in the rotary evaporator and dry overnight under high vacuum. Proceed to step 24. 24. Check the purity of the product. 9-(2-Deoxy-2-fluoro-3,5-di-O-benzoyl-β-D-arabinofuranosyl)-2,6-dichloropurine (S.4): average yield of N9-β-isomer is 38% from each condensation (i.e., 2,6-dichloropurine with S.2 or S.3); TLC (9:1 [v/v] toluene/ethyl acetate) 0.28; 1H NMR (400 MHz, CDCl3 ): 8.1 to 7.1 (10 H, m, Bz), 8.4 (1H, d, J8,F = 3.2 Hz, H-8), 6.6 (1H, dd, J1′,2′ = 2.8 Hz, J1′,F = 22 Hz, H-1′), 5.7 (1H, dd, J3′,F = 17 Hz, J3′,4′ = 2.8 Hz, H-3′), 5.4 (1H, dd, J2′, F = 50 Hz, J2′,3′ = 2.0 Hz, H-2′), 4.7 to 4.8 (2H, dd, H-5′ and H-5′′), 4.61 (1H, m, H-4′); 19F NMR (300 MHz, DMSO-d6, 99% [v/v] trifluoroacetic acid as external reference): −113 (ddd). FAB-MS (fast atom bombardment mass spectrometry, NBA-matrix): 531 [M+H+].
Transform N9-β-glycoside (S.4) into araF-G (S.6) 25. In a clean oven-dried 250-mL round-bottom flask equipped with reflux condenser and stir bar, dissolve 0.4 g (0.75 mmol) S.4 and 0.25 g (3.7 mmol) NaN3 in 50 mL of 95% ethanol. Use sodium azide instead of lithium azide to avoid partial debenzoylation of the intermediary 2,6-diazido derivative.
26. Reflux the reaction mixture 2 hr in the 80°C oil bath. Cool mixture and evaporate to dryness. Precipitation of sodium chloride is a good sign of a successful reaction. The Rf values for the 2,6-diazido and 2,6-dichloro derivatives are 0.48 and 0.52, respectively, in 3:1 (v/v) toluene/ethyl acetate.
27. Dissolve the residue in dichloromethane, wash the organic layer with water, dry it over anhydrous Na2SO4, and evaporate to yield a syrupy product. A yield of 0.4 g (97%) is expected. Silica column chromatography is not required after this step.
28. Treat 0.4 g (0.73 mmol) of 2,6-diazidopurine nucleoside (step 27) with 0.42 g (2.22 mmol) SnCl2 in a mixture of 30 mL dichloromethane and 3 mL methanol for 40 min at room temperature. The Rf value for the 2,6-diamino derivative (S.5) is 0.42 in 9:1 (v/v) dichloromethane/methanol.
29. Dilute the mixture with 100 mL dichloromethane, wash the organic layer with water, dry it over anhydrous Na2SO4, and evaporate to yield a white solid. The expected yield is 0.3 g (83%). Silica column chromatography is not required after this step.
30. Treat 0.3 g (0.61 mmol) S.5 with a mixture containing 3 mL of 29.7% aqueous ammonia and 12 mL methanol for 48 hr at room temperature. Synthesis of Protected 2′-Deoxy-2′-fluoroβ-D-arabinonucleosides
The Rf value for the desired product is 0.06 in 9:1 (v/v) dichloromethane/methanol and 0.16 in 3:1 (v/v) chloroform/ethanol.
1.7.6 Supplement 12
Current Protocols in Nucleic Acid Chemistry
31. Evaporate the resulting solution to dryness. Dissolve the crude product in a minimal amount of 5% methanol in dichloromethane and place it carefully on the top of a 3 × 15–cm chromatography column containing 25 g silica gel. 32. Elute with 10% methanol in dichloromethane and collect 50-mL fractions. Combine fractions containing the desired product as determined by TLC and evaporate to dryness in the rotary evaporator to yield a white foam. 33. Check the product. 9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)-2,6-diaminopurine (S.5): 0.14 g (83%); TLC (3:1 [v/v] chloroform/ethanol) 0.16, (9:1 [v/v] dichloromethane/methanol) 0.06; UV (H2O) λmax, 280 nm; FAB-MS (NBA-matrix): 285 [M+H+], 307 [M+Na+].
34. Treat 0.14 g (0.49 mmol) of the product with 100 µL adenosine deaminase solution in 5 mL water for 24 hr at room temperature. 35. Collect the precipitated white material by filtration and wash it with 10 mL water and then with 10 mL methanol. Dry the white powder (S.6) over P2O5. This reaction has also been performed on a larger scale using 0.5 g substrate. A yield of 71% was obtained.
36. Check purity of the product. 9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)guanine (S.6): 0.11 g (79%); UV (H2O) λmax, 251 nm; 1H NMR (400 MHz, DMSO-d6): 10.6 (1H, s, N-H), 7.8 (1H, d, J8,F = 2.8 Hz, H-8), 6.5 (2H, br s, NH2), 6.1 (1H, dd, J1′,2′ = 4.4 Hz, J1′,F = 16 Hz, H-1′), 5.9 (1H, d, JOH,3′ = 4.8 Hz, HO-C3′), 5.0 and 5.1 (1H, dt or ddd, J2′,F = 33 Hz, J2′,3′ = 3.6 Hz, H-2′), 5.0 (1H, t, HO-C5′), 4.3 (1H, m, J3′,F = 14 Hz, H-3′), 3.8 (1H, m, H-4′), 3.6 (2H, m, H-5′ and H-5′′); 19 F NMR (300 MHz, DMSO-d6, 99% [v/v] trifluoroacetic acid as external reference): −120 (ddd); FAB-MS (NBA-matrix): 286 [M+H+]. See Figure 1.7.4 for 1H NMR.
Isobutyrylate and monomethoxytritylate to give S.7 37. In a clean oven-dried 25-mL round-bottom flask, dissolve 0.3 g (1.05 mmol) araF-G (S.6) in 5 mL dry pyridine, add 3 mL TMSCl, and stir mixture 45 min at room temperature. 38. Add 500 µL isobutyryl chloride and stir 2 hr at room temperature. 39. Immerse the reaction flask in an ice bath and add 1 mL water. After 10 min, add 1 mL of 29.7% aqueous ammonia and stir 20 min at room temperature. The Rf value for N2-isobutyryl-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)guanine is 0.45 in 3:1 (v/v) chloroform/ethanol.
40. Carefully evaporate the resulting mixture to near dryness and take up the residue in 120 mL 2:1:1 water/ethyl acetate/ether. Evaporate the aqueous layer to get the desired compound as a colorless powder. 41. Check purity of the product. N2-Isobutyryl-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)guanine: 0.35 g (94%); TLC (3:1 [v/v] chloroform/ethanol) 0.45; 1H NMR (300 MHz, DMSO-d6): 12.1 (1H, N-H), 11.7 (1H, N-H), 8.1 (1H, d, J8,F = 2.4 Hz, H-8), 6.17 (1H, dd, J1′,2′ = 5.6 Hz, J1′,F = 14 Hz, H-1′), 6.0 (1H, d, JOH,3′ = 6.0 Hz , HO-C3′), 5.1, 5.2 (1H, dt or ddd, J2’,F = 70 Hz, H-2’), 4.3 (1H, ddd, H-3′), 3.8 (1H, dd, H-4′), 3.6 (2H, m, H-5′ and H-5′′, 2.5(1H, m, H-C[CH3]2), 1.1 (6H, s,[CH3]2- CH).
42. Dissolve 0.3 g (0.85 mmol) of the product in 20 mL dry pyridine and add catalytic amount (∼30 mg) 4-DMAP and 0.4 g (1.3 mmol) MMTr⋅Cl. Stir mixture 48 hr at room temperature. The Rf value for the desired tritylated product is 0.41 in 9:1 (v/v) chloroform/methanol.
Synthesis of Modified Nucleosides
1.7.7 Current Protocols in Nucleic Acid Chemistry
Supplement 12
O N HO
O F
H-1 ′
NH
N
N
NH2
HO 6 (araF-G)
′ 5-OH
6.1
H-8
′ 3-OH
NH2
H-5 ′, H-5 ′′
H-4 ′ H-1 ′
NH
4.4
H-2 ′
7.80
11
Figure 1.7.4
10
7.78
9
4.3
H-3 ′
7.76
3.8
8
7
6
5
4
3
3.7
2
3.6
3.5
1
ppm
1
H NMR spectrum (400 MHz) of 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)guanine, araF-G (S.6), in DMSO-d6.
43. Evaporate pyridine, take up the residue in dichloromethane, wash the organic layer with saturated aqueous sodium bicarbonate, dry organic layer over anhydrous Na2SO4, and evaporate to dryness. 44. Dissolve the crude product in a minimal amount of dichloromethane and place it carefully on the top of a 3 × 20–cm chromatography column containing 38 g silica gel. 45. Elute with 0% to 5% methanol in dichloromethane and collect 50-mL fractions. Combine those containing pure product as determined by TLC. 46. Evaporate combined fractions to dryness in the rotary evaporator to get the desired product as a yellow foam. 47. Check purity of the final product.
Synthesis of Protected 2′-Deoxy-2′-fluoroβ-D-arabinonucleosides
N2-Isobutyryl-9-[2-deoxy-2-fluoro-5-O-(4-methoxytrityl)-β-D-arabinofuranosyl]guanine (S.7): 0.35 g (66%); TLC (9:1 [v/v] chloroform/methanol); 1H NMR (400 MHz, acetoned6): 7.8 (1H, d, J8,F = 3.2 Hz, H-8), 7.6 to 6.8 (14H, m, trityl), 6.2 (1H, dd, J1′,2′ = 6 Hz, J1′,F = 16 Hz, H1′), 5.1 (1H, dt or ddd, J2′,F = 54 Hz, H-2′), 4.6 (1H, m, H-3′), 4.2 (1H, m, H-4′), 3.6 (3H, s, CH3O), 3.5 and 3.2 (2H , 2dd, H-5′ and H-5′′), 2.1 (1H, m, H-C[CH3]2), 1.2 and 1.3 (6H, s, [CH3]2-CH).
1.7.8 Supplement 12
Current Protocols in Nucleic Acid Chemistry
BzO
O F
NABs/solvent
BzO
O F
Br
BzO
BzO 3
B 1. deprotection 2. 5’-tritylation 3. N-benzoylation
8a B = N 4-acetylcytosin-1-yl (55%) 8b B = thymin-1-yl (75%) 8c B = N 6-benzoyladenin-9-yl (58%)
MMTrO
O F
B
OH 9a B = N 4-benzoylcytosin-1-yl (58%) 9b B = thymin-1-yl (87%) 9c B = N 6-benzoyladenin-9-yl (52%)
Figure 1.7.5 Synthesis of 2′-deoxy-2′-fluoro-β-D-arabinonucleosides (S.9a-c). The expected yields are given in parentheses. Bz, benzoyl; MMTr, p-anisyldiphenylmethyl; NABs, nucleic acid bases (silylated-N-acetylcytosine or silylated-thymine or N-benzoylated-adenine); solvent, dichloromethane or carbon tetrachloride.
SYNTHESIS AND CHARACTERIZATION OF N4-BENZOYL-1-[2-DEOXY-2FLUORO-5-O-(4-METHOXYTRITYL)-β-D-ARABINOFURANOSYL]CYTOSINE Synthesis of araF-C was accomplished via the condensation of N4-acetylcytosine with 2-deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl bromide (S.3) as a key chemical step (Figure 1.7.5). This was followed by deprotection, benzoylation, and tritylation to give S.9a. Cytosine, N4-benzoylcytosine, or N4-acetylcytosine can be used for the condensation step. Better yields are observed with N4-acetylcytosine.
BASIC PROTOCOL 2
Materials Nitrogen gas source Chlorotrimethylsilane (TMSCl) N4-Acetylcytosine Hexamethyldisilazane (HMDS) 2-Deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl bromide (S.3; see Basic Protocol 1) Carbon tetrachloride (CCl4), anhydrous (Aldrich) Merck thin-layer chromatography (TLC) silica plates (Kieselgel 60 F-254; 0.2 mm thick) Dichloromethane, dry (see recipe) Saturated aqueous sodium bicarbonate Sodium sulfate (Na2SO4), anhydrous 29.7% (w/w) aqueous ammonia (Fisher) Methanol 5% (v/v) ethanol in chloroform Silica gel (230 to 400 mesh) Chloroform 3:1 (v/v) chloroform/ethanol Benzoic anhydride N,N-Dimethylformamide (DMF), anhydrous (Aldrich) Pyridine, dry (see recipe) p-Anisylchlorodiphenylmethane (monomethoxytrityl chloride or MMTr⋅Cl) 4-Dimethylaminopyridine (4-DMAP) 0% to 1% (v/v) gradient of methanol in chloroform 250-mL round-bottom flasks, oven dried Reflux condenser Oil bath, 120°C and 77°C Rotary evaporator equipped with a vacuum pump or water aspirator 3 × 20–cm chromatography column
Synthesis of Modified Nucleosides
1.7.9 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Condense N4-acetylcytosine with S.3 1. In an oven-dried 250-mL round-bottom flask equipped with a reflux condenser, stir bar, and nitrogen gas source, add 15 mL TMSCl to a suspension of 11 g (153.14 mmol) N4-acetylcytosine in 80 mL HMDS. 2. Reflux 24 hr in an oil bath at 120°C, cool mixture, and evaporate to dryness under reduced pressure using a rotary evaporator equipped with a vacuum pump or water aspirator. 3. Add 10 g (23.64 mmol) S.3 in 40 mL anhydrous CCl4 and reflux the resulting solution 4 days at 77°C. 4. Analyze the reaction by TLC (APPENDIX 3D) using Merck TLC silica plates. The starting material should be run alongside the reaction for comparison. The plates are developed using 9:1 (v/v) chloroform/methanol, and the bands are visualized by UV shadowing and dipping the plate in 10% (v/v) sulfuric acid in methanol followed by heating. Typically, the Rf value of the desired product N1⋅β-isomer is 0.6 (9:1 chloroform/methanol). The starting material, S.3, has an Rf value of 0.9 under these conditions.
5. Dilute reaction with 400 mL dry dichloromethane and wash it carefully with 500 mL saturated aqueous sodium bicarbonate solution. 6. Dry the dichloromethane layer over anhydrous Na2SO4, filter, and evaporate to dryness. No purification is needed at this step.
Deprotect 3′,5′-O-dibenzoyl araF-CAc 7. Treat 8.5 g crude compound with a mixture of 120 mL of 29.7% aqueous ammonia and 150 mL methanol for 48 hr at room temperature. This step removes O-benzoyl and N-acetyl groups. The Rf value for the desired product is 0.09 in 9:1 (v/v) chloroform/methanol and 0.17 in 3:1 (v/v) chloroform/ethanol.
8. Evaporate the resulting solution to dryness. Dissolve the crude product in a minimal amount of 5% ethanol in chloroform and place it carefully on top of a 3 × 20–cm silica gel chromatography column (see APPENDIX 3E for column chromatography). 9. Elute with 3:1 chloroform/ethanol and collect 50-mL fractions. Combine fractions containing pure product as determined by TLC. 10. Evaporate combined fractions to dryness in the rotary evaporator to yield the desired product as a white foam. A yield of 3.1 g (54% from S.3) is expected.
N4-Benzoylate araF-C 11. Dissolve 3.1 g (12.65 mmol) product and 3.43 g (15.16 mmol) benzoic anhydride in 20 mL anhydrous DMF and stir 35 hr to get araF-CBz. The Rf value of the desired product is 0.63 in 3:1 (v/v) chloroform/ethanol and 0.67 in 3:1 (v/v) chloroform/methanol. Synthesis of Protected 2′-Deoxy-2′-fluoroβ-D-arabinonucleosides
1.7.10 Supplement 10
Current Protocols in Nucleic Acid Chemistry
5′-Tritylate araF-CBz 12. Remove DMF under reduced pressure and co-evaporate the residue with dry pyridine. Add the following and stir 24 hr at room temperature: 20 mL pyridine 4.0 g (12.95 mmol) MMTr⋅Cl 30 mg 4-DMAP (catalytic amount). The Rf value for the desired product (S.9a) is 0.50 in 9:1 (v/v) chloroform/methanol and 0.20 in 20:1 (v/v) chloroform/methanol.
13. Quench with 10 mL methanol, evaporate the resulting mixture, take up the residue in 150 mL chloroform, wash the organic layer with 150 mL saturated aqueous sodium bicarbonate, dry organic layer over anhydrous Na2SO4, and evaporate to dryness. 14. Dissolve the crude product in a minimal amount of chloroform and place it carefully on the top of a 3 × 20–cm silica gel chromatography column. 15. Elute with 0% to 1% methanol in chloroform and collect 50-mL fractions. Combine the fractions containing pure product as determined by TLC. 16. Evaporate combined fractions to dryness in the rotary evaporator to get the desired product as a yellow foam. 17. Check purity of the final product. N4-Benzoyl-1-[2-deoxy-2-fluoro-5-O-(4-methoxytrityl)-β-D-arabinofuranosyl]cytosine (S.9a): 4.6 g (58% from araF-C); TLC (20:1 [v/v] chloroform/methanol); 1H NMR (400 MHz, acetone-d6, tetramethylsilane as internal reference): 8.0 (1H, d, H-6), 7.6 to 7.2 (19H, m, trityl, Bz), 6.9 (1H, d, H-5), 6.3 (1H, dd, J1′,2′ = 3.6 Hz, J1′,F = 14 Hz, H-1′), 5.2 (1H, m, J2′,F = 49 Hz, H-2′), 4.5 (1H, m, H-3′), 4.3 (1H, m, H-4′), 3.8 (3H, s, CH3O), 3.5 (2H, m, H-5′ and H-5′′).
SYNTHESIS AND CHARACTERIZATION OF N6-BENZOYL-9-[2-DEOXY-2FLUORO-5-O-(4-METHOXYTRITYL)-β-D-ARABINOFURANOSYL]ADENINE
BASIC PROTOCOL 3
N6-Benzoyl-9-(2-deoxy-2-fluoro-3,5-di-O-benzoyl-β-D-arabinofuranosyl)adenine was prepared by direct condensation of N6-benzoyladenine with 2-deoxy-2-fluoro-3,5-di-Obenzoyl-α-D-arabinofuranosyl bromide (S.3; Figure 1.7.5; Watanabe et al., 1988). Flash chromatography and the removal of benzoyl groups with ammonia gave araF-A, which was successfully 5′-tritylated and N6-benzoylated in a one-pot procedure to give the title compound, S.9c. Materials 2-Deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl bromide (S.3; see Basic Protocol 1) Dichloromethane, dry (see recipe) N6-Benzoyladenine, anhydrous Activated molecular sieves (type 4A) Pyridine, dry (see recipe) Chloroform Silica gel (230 to 400 mesh) 7:3 (v/v) chloroform/dichloromethane Merck thin-layer chromatography (TLC) silica plates (Kieselgel 60 F-254; 0.2 mm thick) Ethanol 29.7% (w/w) aqueous ammonia (Fisher) p-Anisylchlorodiphenylmethane (monomethoxytrityl chloride or MMTr⋅Cl)
Synthesis of Modified Nucleosides
1.7.11 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Trimethylsilyl chloride (TMSCl) Benzoyl chloride Brine (saturated aqueous NaCl) Magnesium sulfate, anhydrous 33:1 (v/v) dichloromethane/methanol 250- and 500-mL round-bottom flasks, oven dried Reflux condenser Oil bath, 40° to 50°C Rotary evaporator equipped with vacuum pump 7 × 15–cm chromatography column Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Condense N6-benzoyladenine with S.3 1. In a 250-mL round bottom flask equipped with a reflux condenser, dissolve 7.5 g (17.7 mmol) S.3 in 150 mL dry dichloromethane. 2. Add 10.5 g (44 mmol) anhydrous N6-benzoyladenine and 21 g activated molecular sieves (type 4A). 3. Place the flask in an oil bath preheated to 40° to 50°C and reflux for 4 days. 4. Cool reaction mixture to room temperature, add 50 mL dry pyridine, and filter. Rinse molecular sieves with 50 mL pyridine and combine both fractions. 5. Evaporate filtrate to dryness in a rotary evaporator to yield a brown oil. 6. Dissolve the crude product in a minimal amount of chloroform. 7. Apply the resulting solution to a 7 × 15–cm chromatography column packed with 100g silica gel in chloroform. Column chromatography is performed by using a small amount of air pressure at a rate of ∼1 inch of solvent per minute (Still et al., 1978; APPENDIX 3E).
8. Elute the product with chloroform and then continue with 7:3 chloroform/dichloromethane. Collect 100-mL fractions and combine those that contain pure product as determined by TLC (APPENDIX 3D) using Merck TLC silica plates. The Rf value for the desired product is 0.75 in 9:1 (v/v) dichloromethane/methanol.
9. Evaporate combined fractions and dry overnight under a high vacuum to get a white foam. 10. Check the purity of the product. N6-Benzoyl-9-(2-deoxy-2-fluoro-3,5-di-O-benzoyl-β-D-arabinofuranosyl)adenine (S.8c): 6 g as a white foam, (58% from S.3); TLC (9:1 [v/v] dichloromethane/methanol); 1H NMR (270 MHz, DMSO-d6): 8.8 (s, H-2), 8.5 (d, JH8,F = 2 Hz, H-8), 8.1 to 7.3 (m, Bz), 6.8 (dd, J1′, 2′ = 4 Hz, J1′,F = 18 Hz, H-1′), 6.0 (ddd, J3′,-F = 19 Hz, H-3′), 5.8 (ddd, J1′ 2′ = 4 Hz, J2′,3′ = 2 Hz, J2′,F = 52 Hz, H-2′), 4.8 (m, H-4′), 4.7 (m, H-5′ and H-5′′); 19F NMR (270 MHz, DMSO-d6, no external reference was used) –197 (ddd); FAB-MS (NBA-matrix): 582 (M+H+). The purified product contains ∼5% of α-isomer, which is removed in steps 24 to 26. Synthesis of Protected 2′-Deoxy-2′-fluoroβ-D-arabinonucleosides
1.7.12 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Deprotect N6-benzoyl-9-(2-deoxy-2-fluoro-3,5-di-O-benzoyl-β-D-arabinofuranosyl) adenine 11. In a 500-mL round-bottom flask equipped with magnetic stirrer, suspend 6 g (10.33 mmol) S.8c in 150 mL ethanol. 12. Add 150 mL of 29.7% aqueous ammonia and stir 2 days. Use TLC to determine when deprotection is complete. The Rf value for araF-A is 0.20 in 17:3 (v/v) dichloromethane/methanol.
13. Evaporate the resulting solution to dryness. No purification is needed after this step.
Tritylate and benzoylate 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine 14. Co-evaporate 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine (step 13) twice with 50 mL each dry pyridine. 15. Dissolve the residue in 50 mL dry pyridine. 16. Add 3.7 g (12 mmol) MMTr⋅Cl and stir the reaction mixture overnight at room temperature. Use TLC to ensure that the tritylation is complete. The Rf value for the desired product is 0.40 in 9:1 (v/v) dichloromethane/methanol. An additional portion of MMTr⋅Cl can be added if tritylation is not complete.
17. Add 6.4 mL (50 mmol) TMSCl and stir the resulting solution 30 min at room temperature. 18. Add 5.8 mL (50 mmol) benzoyl chloride and stir 2 hr. 19. Place the reaction flask into an ice bath to cool and add 10 mL water. Stir 5 min. 20. Add 20 mL of 29.7% aqueous ammonia and stir 30 min. 21. Carefully evaporate the reaction mixture to dryness. Avoid formation of foam, which makes evaporation difficult. 22. Redissolve the mixture in 200 mL chloroform, wash with 200 mL brine, dry over anhydrous magnesium sulfate, filter, and evaporate. 23. Dissolve the crude product in a minimal amount of dichloromethane. 24. Place it carefully on the top of a 7 × 15–cm silica gel chromatography column and elute with dichloromethane and then with 33:1 dichloromethane/methanol. Collect 100-mL fractions and combine those that contain pure product as determined by TLC. The Rf value for the desired product is 0.38 in 9:1 (v/v) chloroform/ethanol.
25. Combine fractions that contain pure product and evaporate and dry overnight at high vacuum to get a white foam. 26. Check the purity of the product. N6-Benzoyl-9-[2-deoxy-2-fluoro-5-O-(4-methoxytrityl)-β-D-arabinofuranosyl] adenine (S.9c): 3.8 g (as a white foam, 52% yield from S.8c); TLC (9:1 [v/v] chloroform/ethanol) 0.38; 1H NMR (500 MHz, acetone-d6) 10.0 (br s, N-H), 8.6 (s,H-2), 8.3 (d, JH8-F = 3 Hz, H-8), 8.1 to 6.9 (m, MMTr, Bz), 6.7 (dd, J1′,F = 18 Hz, J1′,2′ = 4 Hz, H-1′), 5.3 (ddd, J1′,H2′ = 4 Hz, J2′,F = 52 Hz, J2′,3′ = 4 Hz, H-2′), 4.7 (ddd, J2′,3′ = 4 Hz, J3′,F = 19 Hz, J3′,4′ = 3 Hz, H-3′), 4.2 (dd, J4′,5′,5′′ = 4 Hz, J3′,4′ = 3 Hz, H-4′), 3.8 (s, CH3O-), 3.5 to 3.4 (m, H-5′ and H-5′′); FAB-MS (NBA-matrix): 646 (M+H+).
Synthesis of Modified Nucleosides
1.7.13 Current Protocols in Nucleic Acid Chemistry
Supplement 10
BASIC PROTOCOL 4
SYNTHESIS AND CHARACTERIZATION OF 1-[2-DEOXY-2-FLUORO-5-O(4-METHOXYTRITYL)-β-D-ARABINOFURANOSYL]THYMINE 1-(Deoxy-2-fluoro-3,5-di-O-benzoyl-2-β-D-arabinofuranosyl)thymine was synthesized by direct coupling of silylated thymine and 2-deoxy-2-fluoro-3,5-di-O-benzoyl-α-Darabinofuranosyl bromide (S.3). Crystallization of the crude product gave pure 1-(2-deoxy-2-fluoro-3,5-di-O-benzoyl-β-D-arabinofuranosyl)thymine, which gave S.9b after deprotection and tritylation using standard procedures. Materials Thymine Ammonium sulfate Phosphorous pentoxide (P2O5) Acetonitrile, dry (see recipe) Hexamethyldisilazane (HMDS) 2-Deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl bromide (S.3; see Basic Protocol 1) Magnesium sulfate, anhydrous Carbon tetrachloride (CCl4), anhydrous (Aldrich) Dichloromethane, dry (see recipe) Ethanol Concentrated aqueous ammonia Merck thin-layer chromatography (TLC) silica plates (Kieselgel 60 F-254; 0.2 mm thick) Pyridine, dry (see recipe) p-Anisylchlorodiphenylmethane (monomethoxytrityl chloride or MMTr⋅Cl) Chloroform Brine (aqueous saturated NaCl) Silica gel (230 to 400 mesh) 19:1 (v/v) dichloromethane/methanol 250- and 500-mL round-bottom flasks, oven dried Oil bath, 100° Rotary evaporator attached to a vacuum pump 7 × 15–cm chromatography column chromatography (APPENDIX 3E) Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Silylate thymine 1. Dry 5.4 g (43 mmol) thymine and 540 mg ammonium sulfate in an oven-dried 250-mL round-bottom flask in a vacuum desiccator over P2O5 overnight. 2. Dissolve dry mixture in 160 mL dry acetonitrile and add 9 mL HMDS. 3. Put flask in a 100°C oil bath and allow reaction mixture to reflux for 4 hr. Once the reaction mixture becomes clear, the reaction is considered to be complete.
4. Let reaction cool to room temperature and evaporate excess solvents under reduced pressure.
Synthesis of Protected 2′-Deoxy-2′-fluoroβ-D-arabinonucleosides
Condense 2,4-bis-O-(trimethylsilyl)thymine with S.3 5. Dissolve 7g (16.5 mmol) S.3 in 70 mL dry CCl4. 6. Carefully transfer solution with a syringe to the flask containing silylated thymine (step 4).
1.7.14 Supplement 10
Current Protocols in Nucleic Acid Chemistry
7. Put flask in an oil bath and leave it to reflux for 4 days. The Rf value for the desired product, S.8b, is 0.49 in 9:1 (v/v) chloroform/methanol.
8. Cool down mixture to room temperature, dilute it with 500 mL dichloromethane, and wash with 1 L water. A large volume of water is necessary to get rid of salts formed during the coupling step.
9. Dry organic layer with anhydrous magnesium sulfate and concentrate under reduced pressure to obtain the crude product as a slightly brown solid. Usually 1-(2-deoxy-2-fluoro-3,5-di-O-benzoyl-2-β-D-arabinofuranosyl)thymine contains ∼2% to 3% of 1-(2-deoxy-2-fluoro-3,5-di-O-benzoyl-2-α-D-arabinofuranosyl)thymine, which cannot be removed by silica gel chromatography at this step. Crystallization (step 10), however, gives the analytically pure compound.
10. Dissolve the crude product in 40 mL dichloromethane and crystallize from 200 mL ethanol. 11. Check purity of the product. 1-(2-Deoxy-2-fluoro-3,5-di-O-benzoyl-2-β-D-arabinofuranosyl)thymine (S.8b) : 5. 8 g (75% yield from S.3); TLC (9:1 [v/v] chloroform/methanol) 0.49; 1H NMR (500 MHz, DMSO-d6): 11.5 (s, N-H), 8.0 to 7.4 (m, H-6 and Bz), 6.3 (dd, J1′,2′ = 4 Hz, J1′-F = 19 Hz, H-1′), 5.7 (ddd, J2′,3′ = 2 Hz, J3′,4′ = 4 Hz, J3′,F = 19 Hz, H-3′), 5.5 (ddd, J1′,2′ = 4 Hz, J2′,3′ = 2 Hz, J2′,F = 53 Hz, H-2′), 4.8 to 4.7 (m, H-5′ and H-5′′), 4.6 (m, H-4′), 1.6 (s, CH3-C5); FAB-MS (NBA-matrix): 468 [M+].
Deprotect 1-(2-deoxy-2-fluoro-3,5-di-O-benzoyl -β-D-arabinofuranosyl)thymine 12. In a 500-mL round bottom flask equipped with magnetic stirrer, suspend 5.8 g (12.38 mmol) S.8b in 150 mL ethanol. 13. Add 150 mL concentrated aqueous ammonia and stir the resulting mixture for 3 days. The Rf value for the desired product is 0.49 in 3:1 (v/v) chloroform/ethanol.
14. When deprotection is complete, as determined by TLC (APPENDIX 3D) using Merck TLC silica plates, evaporate solution to dryness. Tritylate 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)thymine 15. Co-evaporate 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)thymine (step 14) twice with 50 mL each dry pyridine and dissolve in 50 mL dry pyridine. 16. Add 4.4 g (14.23 mmol) MMTr⋅Cl and stir the reaction overnight. The Rf value for the desired product (S.9b) is 0.3 in 19:1 (v/v) chloroform/methanol.
17. Dilute mixture with 200 mL chloroform, wash with 200 mL brine, dry the organic layer over magnesium sulfate, filter, and evaporate to obtain the crude product. 18. Dissolve the crude product in a minimal amount of dichloromethane. 19. Load it onto a 7 × 15–cm chromatography column packed with 100 g silica gel (APPENDIX 3E). Elute with dichloromethane and then with 19:1 (v/v) dichloromethane/methanol. Collect 100-mL fractions and combine those that contain pure product as determined by TLC. The Rf value for the desired product is 0.3 in 19:1 (v/v) choloroform/methanol.
20. Combine fractions that contain pure product, evaporate, and dry overnight at high vacuum to obtain a white foam.
Synthesis of Modified Nucleosides
1.7.15 Current Protocols in Nucleic Acid Chemistry
Supplement 10
21. Check the purity of the product. 1-[2-Deoxy-2-fluoro-5-O-(4-methoxytrityl)-β-D-arabinofuranosyl]thymine (S.9b): 5.7 g (87%); TLC (9:1 [v/v] chloroform/methanol) 0.3; 1H NMR (500 MHz, DMSO-d6) 11.5 (br s, NH), 7.4 to 6.9 (m, H-6 and MMTr), 6.1 (dd, J1′-2′ = 4.5 Hz, J1′-F = 16 Hz, H-1′), 5.0 (ddd, J1′-2′ = 4 Hz , J2′,3′ = 2.5 Hz, J2′-F = 53 Hz, H-2′), 4.3 (ddd, J2′-3′ = 2.5 Hz, J3′-4′ = 4.5 Hz JH3′-F = 19 Hz, H-3′), 3.9 (m, H-4′), 3.7 (s, CH3O-), 3.3 (m, H-5′ and H-5′), 1.6 (s, CH3-C5); FAB-MS (NBA-matrix): 532 [M+].
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For work up of reaction mixtures and chromatography, use reagent grade solvents. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Acetonitrile Dry acetonitrile by refluxing over calcium hydride (Aldrich) or phosphorus pentoxide (P2O5; Fisher) for 10 hr followed by distillation under inert atmosphere. Dichloromethane Dry dichloromethane by refluxing over calcium hydride (Aldrich) for 24 hr followed by distillation under inert atmosphere. Pyridine Dry pyridine by refluxing over calcium hydride (Aldrich) for 8 hr followed by distillation under inert atmosphere. COMMENTARY Background Information
Synthesis of Protected 2′-Deoxy-2′-fluoroβ-D-arabinonucleosides
The interests of medicinal and organic chemists towards the construction of compounds that contain fluorine is derived from the relative stability of the carbon-fluorine bond, both chemically and metabolically, and from the strong electronegative character of fluorine, which alters the electronic properties of the molecule. In fact, many fluorinated organic compounds exhibit interesting biophysical properties. This has been shown to be the case for anti-inflammatory steroids (Herdewijn et al., 1989), collagen helices (Holmgren et al., 1 99 9) , n ucleo sides (Ma et al., 1997; Pankiewicz, 2000), and nucleic acids (Damha et al., 1998). For example, collagen chains in which fluorine atoms replace the hydroxyl groups form triple helices with extraordinary stability (Eberhardt et al., 1996). A number of highly selective nucleoside antiviral and antileukemic agents based on 2-deoxy-2fluoroarabinose have been prepared over the past 20 years (for reviews, see Burchenal et al., 1983; Pankiewicz, 2000). These compounds also serve as building blocks for the synthesis o f 2′-deoxy-2′-fluoroarabinonucleic acids (2′F-ANAs). It has recently been shown that 2′F-ANA forms a duplex with RNA that is more stable than a DNA:RNA duplex of identical
sequence (Damha et al., 1998; Wilds and Damha, 2000). The authors’ laboratory has also shown that 2′F-ANA:RNA heteroduplexes, like the natural DNA:RNA heteroduplex, are substrates of RNase H, an enzyme implicated in the mechanism of action of antisense oligonucleotides (Damha et al., 1998). This unit describes methods for the synthesis of protected 2′-deoxy-2′-fluoroarabinonucleosides. These methods, based on experience and facilities at hand, allow straightforward synthesis of suitable monomers that can be phosphitylated and used as building blocks for the synthesis of antisense oligonucleotides (Lok et al., 2002). The authors have optimized some of the key steps reported in the literature (Tann et al., 1985; Howell et al., 1988; Pankiewicz et al., 1992; Scharer and Verdine, 1995; Maruyama et al., 1999; Wilds and Damha, 2000), particularly those involved in the synthesis of araF-G (Tennila et al., 2000). A critical step is the fluorination of the ribose sugars, which may lead to loss of water (dehydration) via an elimination reaction. Elimination is virtually avoided by using DAST (or MAST) as the fluorinating reagent instead of HF, SF4, and HF-amine reagents (Middleton, 1975).
1.7.16 Supplement 10
Current Protocols in Nucleic Acid Chemistry
plished with a masked base, namely 2,6-dichloropurine, followed by its transformation into guanine in subsequent steps (Ma et al., 1997; Tennila et al., 2000; Figure 1.7.3). All steps work well, except for the N-glycosylation reaction, which proceeds to give the desired N9β-anomer in 35% to 40% yield (optimized). The authors are currently investigating coupling of S.3 to various purine derivatives in order to simplify and increase the yield of araF-G.
The most convenient method for the synthesis of araF-U, araF-T, and araF-C involves directly coupling 3,5-di-O-benzoyl-2-deoxy-2fluoro-α-D-arabinofuranosyl bromide with silylated pyrimidines (e.g., Howell et al., 1988; Wilds and Damha, 2000). This produces primarily the desired β-anomer with <5% of the α-stereoisomer, which is removed by chromatography and/or crystallization. This is in contrast to the results obtained during the synthesis of 2′-deoxynucleosides (lacking the 2′-fluorine atom) to afford anomeric mixtures that generally favor the α-anomer. This may be accounted for by the electronegative nature of the 2′-F atom, which effectively prevents the ionization of the C1′-leaving group to produce an SN1 oxonium ion intermediate. Therefore, the glycosylation reaction mainly proceeds via the energetically preferred SN2 pathway (Howell et al., 1988; Figure 1.7.6). Originally, the authors synthesized araF-A (Pankiewicz et al., 1992) and araF-G (Chu et al., 1989) starting from the ribonucleosides (rA and rG). Coupling the purines to the fluorinated arabinose sugar S.3, however, largely improves yields and minimizes the number of steps. A presilylation step for the synthesis of araF-A is not required. Synthesis of araF-G is accom-
Critical Parameters and Troubleshooting During the synthesis of araF-G (S.6), two important considerations have to be taken into account. First, the refluxing time for the synthesis of S.4 from S.2 should not exceed 1 hour; otherwise the yield of the desired product (S.4) will be low. Second, purification of the 2,6diaminopurine derivative is very important in order to get good yields of araF-G during the adenosine deaminase step. In the synthesis of araF-C and araF-T, both the coupling time and the equivalents of the heterocyclic bases used in the N-glycosylation reactions are very important factors for obtaining high yields of nucleosides. During synthesis of araF-A and
O
OTMS
NH
N BzO
N
O F Br
BzO
OTMS
SN2
BzO
O F
N
O
BzO
3 β-anomer
α-bromo sugar
SN1 OTMS N
+
BzO
N
O F
OTMS α- + β -anomers
BzO destabilized by 2-F
Figure 1.7.6 Coupling of 2,4-bis(trimethylsilyl)thymine with 2-fluoroarabinose sugar S.3. Under appropriate conditions (e.g., CCl4 solvent, reflux), the reaction proceeds primarily via an SN2 pathway, affording the β and α anomers in a ratio of 98:2. Bz, benzoyl; TMS, trimethylsilane.
Synthesis of Modified Nucleosides
1.7.17 Current Protocols in Nucleic Acid Chemistry
Supplement 10
araF-C, it is better to use N6-benzoyladenine (without silylation) and N4-acetylcytosine (with silylation), respectively, for coupling with S.3.
Anticipated Results The black sheep of the family of nucleosides is guanosine, and araF-G is no exception. The synthesis of araF-G requires more steps than for other araF nucleosides. Nevertheless, these procedures yield araF-G in high purity and moderate yields. Figure 1.7.4 shows the 1H NMR spectrum of araF-G. The purity of the isolated nucleoside (and all others reported here) is usually >98%. The additional splitting of the sugar proton signals is indicative of the presence of fluorine (spin = 1⁄2). The β-configuration of the N-glycosidic bond for all nucleosides was established by two-dimensional nuclear Overhauser effect (2D-NOE) NMR experiments (Wilds and Damha, 2000). A characteristic feature of the araF-A and araF-G spectra (1H NMR) is the doublet corresponding to the H-8 proton. The splitting of the H-8 signal is due to long-range 1H-19F coupling (likely through space via H8...2′-F bonding) that arises only for the βanomers (Wilds and Damha, 2000).
Time Considerations Each of the araF nucleosides presented in this unit can be prepared in 6 to 7 days except for araF-G, for which close to 2 weeks are required.
Literature Cited Burchenal, J.H., Leyland-Jones, B., Watanabe, B., Klein, R., Lopez, C., and Fox, J.J. 1983. Experimental and clinical studies on 2′-fluoroarabinosyl pyrimidines and purine-like C-nucleosides. In Nucleosides, Nucleotides, and Their Biological Applications, Proceedings 5th International Round Table, pp. 47-65. International Society for Nucleosides, Nucleotides, and Nucleic Acids, Montpellier, France. Chu, C.K., Matulic-Adamic, J., Huang, J.-T., Chou, T.-C., Burchenal, J.H., Fox, J.J., and Watanabe, K.A. 1989. Synthesis of some 9-(2-deoxy-2fluoro-β-D-arabinofuranosyl)-9H-purines and their biological activities. Chem. Pharm. Bull. 37:336-339.
Synthesis of Protected 2′-Deoxy-2′-fluoroβ-D-arabinonucleosides
Damha, M.J., Wilds, C.J., Novonha, A., Brunker, I., Borkow, G., Arion, D., and Parniak, M.A. 1998. Hybrids of RNA and arabinonucleic acids (ANA and 2′F-ANA) are substrates of ribonuclease H. J. Am. Chem. Soc. 120:12976-12977.
Eberhardt, E.S., Panasik, N. Jr., and Raines, R.T. 1996. Inductive effects on the energetics of prolyl peptide bond isomerization: Implications for collagen folding and stability. J. Am. Chem. Soc. 118:12261-12266. Herdewijn, P., VanAerschot, A., and Kerremans, L. 1989. Synthesis of nucleosides fluorinated in the sugar moiety. The application of diethylaminosulfur trifluoride to the synthesis of fluorinated nucleosides. Nucleosides Nucleotides 8:65-96. Holmgren, S.K., Bretscher, L.E., Taylor, K.M., and Raines, R.T. 1999. A hyperstable collagen mimic. Chem. Biol. 6:63-70. Howell, H.G., Brodfuehrer, P.R., Brundidge, S.P., Benigni, D.A., and Sapino, C. Jr. 1988. Antiviral nucleosides. A stereospecific, total synthesis of 2′-fluoro-2′-deoxy-β-D-arabinofuranosyl nucleosides. J. Org. Chem. 53:85-88. Kierzek, R. 1985. The synthesis of 5′-O-dimethoxytrityl-N-acetyl-2′-deoxynucleosides. Improved “transient protection” approach. Nucleosides Nucleotides 4:641-649. Ma, T., Lin, J.-S., Newton, M.G., Cheng, Y.-C., and Chu, C.K. 1997. Synthesis and anti hepatitis B virus activity of 9-(2-deoxy-2-fluoro-β-Larabinofuranosyl)purine nucleosides. J. Med. Chem. 40:2750-2754. Maruyama, T., Takamatsu, S., Kozai, S., Satoh, Y., and Izawa, K. 1999. Synthesis of 9-(2-deoxy-2fluoro-β-D-arabinofuranosyl)adenine bearing a selectively removable protecting group. Chem. Pharm. Bull. 47:966-970. Middleton, W.J. 1975. New fluorinating reagents. Dialkylaminosulfur fluorides. J. Org. Chem. 40:574-578. Lok, C.-N., Viazovkina, E., Min, K.-L., Nagy, E., Wilds, C.J., Damha, M.J., and Parniak, M.A. 2002. Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2′-deoxy-2′-fluoro-D-arabinose and 2′-deoxyribose nucleotides. Biochemistry 41:3457-3467. Pankiewicz, K.W. 2000. Fluorinated nucleosides. Carbohydr. Res. 327:87-105. Pankiewicz, K.W., Krzeminski, J., Cizewski, L.A., Ren, W.-Y., and Watanabe, K.A. 1992. Synthesis of 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine and hypoxanthine. An effect of C3′endo to C2′-endo conformational shift on the reaction course of 2′-hydroxyl group with DAST. J. Org. Chem. 57:553-559. Scharer, O.D. and Verdine, G.L. 1995. A designed inhibitor of base-excision DNA repair. J. Am. Chem. Soc. 117:10781-10782. Still, W.C., Kahn, M., and Mitra, A. 1978. Rapid chromatographic technique for preparative separation with moderate resolution. J. Org. Chem. 43:2923-2925.
1.7.18 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Tann, C.H., Brodfuehrer, P.R., Brundidge, S.P., Sapino, C. Jr., and Howell, H.G. 1985. Fluorocarbohydrate in synthesis. An efficient synthesis of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5iodouracil (β-FIAU) and 1-(2-deoxy-2-fluoroβ-D-arabinofuranosyl)thymine (β-FMAU). J. Org. Chem. 50:3644-3647. Tennila, T., Azhayev, E., Vepsalainen, J., Laatikainen, R., Azhayev, A., and Mikhailopulo, I.A. 2000. Oligonucleotides containing 9-(2-deoxy2-fluoro-β-D-arabinofuranosyl)-adenine and guanine: Synthesis, hybridization and antisense properties. Nucleosides Nucleotides Nucleic Acids 19:1861-1884.
Key References Herdewijn et al., 1989. See above. This article reviews the application of DAST to the synthesis of fluorinated nucleosides. Howell et al., 1988. See above. This article describes key connections and synthetic strategies of araF-nucleosides that form the basis of the procedures outlined in these protocols. Pankiewicz, 2000. See above. This review article focuses on the synthesis of sugar fluorinated nucleosides.
Wilds, C.J. and Damha M.J. 2000. 2′-Deoxy-2′fluoro-β-D-arabinonucleosides and oligonucleotides (2′F-ANA): Synthesis and physicochemical studies. Nucl. Acids Res. 28:36253635.
Tann et al., 1985. See above.
Watanabe, K.A., Chu, C.K., and Fox, J.J. June, 1988. 2-Fluoro-arabinofuranosyl purine nucleosides. U.S. patent 47,551,221.
This article provides procedures for the synthesis of araF-nucleosides and 2′F-ANA.
Wower, J., Hixson, S.S., Sylvers, L.A., Xing, Y., and Zimmermann, R.A. 1994. Synthesis of 2,6-diazido-9-(β-D-ribofuranosyl)purine 3′,5′-bisphosphate: Incorporation into transfer RNA and photochemical labelling of Escherichia coli ribosomes. Bioconjug. Chem. 5:158-161.
This article also describes synthetic strategies of araF-nucleosides. Wilds and Damha, 2000. See above.
Contributed by Mohamed I. Elzagheid, Ekaterina Viazovkina, and Masad J. Damha McGill University Montreal, Canada
Synthesis of Modified Nucleosides
1.7.19 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Synthesis, Characterization, and Application of Substituted Pyrazolopyrimidine Nucleosides
UNIT 1.8
This unit describes, in detail, the preparation of 3-aminopropyl-substituted pyrazolo[3,4d]pyrimidine analogs of the purines deoxyadenosine (dA) and deoxyguanosine (dG). Phosphoramidite reagents of these so-called aminopropyl-PPA and -PPG nucleosides (AP-PPA and AP-PPG, respectively) allow introduction of amino linkers into internal positions of synthetic DNA strands. Synthesis of suitably protected AP-PPA and AP-PPG phosphoramidites (S.1 and S.2) are described in the first two methods (see Basic Protocols 1 and 2). The stepwise alkynylation, hydrogenation, selective protection, and phosphoramidite synthesis is similar for both the PPA and PPG analogs. To demonstrate the application of these reagents, a simple DNA strand is synthesized and conjugated to a lipophilic activated ester (dabcyl-SE) to form a stable amide linkage (see Basic Protocol 3). Utility of this chemistry for preparing internally modified DNA conjugates is discussed. CAUTION: All reactions used for preparation of the phosphoramidites must be performed in a well-ventilated fume hood. These procedures should be performed only by personnel with experience in organic synthesis. In particular, operations involving hydrogenation under pressure are hazardous and require training beyond that described here. Standard precautions to prevent excessive exposure to toxic chemicals and solvents should be followed. All reactions should first be performed on a small scale. PREPARATION OF PROTECTED AMINOPROPYL-PPG PHOSPHORAMIDITE Synthesis of a suitably protected phosphoramidite reagent for incorporating AP-PPG (S.1) into DNA strands is shown in Figure 1.8.1. The starting material is a 3-iodopyrazolopyrimidine nucleoside. Preparation of this iodinated nucleoside is described elsewhere (Seela and Zulauf, 1998; Seela and Becher, 1999). The chemical reactions described here give good yields, and purification of the intermediates is straightforward. Materials 6-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-3-iodopyrazolo[3,4-d]pyrimidin4(5H)-one (Seela and Zulauf, 1998) CuI Tetrakis[triphenylphosphine]palladium[0] (Aldrich) Argon Anhydrous dimethylformamide (DMF), deoxygenated (i.e., argon purged) Anhydrous triethylamine N-Trifluoroacetylpropargylamine (Cruickshank and Stockwell, 1988) Chloroform 230- to 400-mesh (40- to 63-µm) silica gel (EM Sciences) Methanol Ethyl acetate Diethyl ether 20% (w/v) palladium hydroxide on carbon, preactivated (see recipe) 4 M triethylammonium formate buffer, pH 6.5 (see recipe) Hydrogen gas Celite (1.5-cm pad) Contributed by Robert O. Dempcy, Mikhail A. Podyminogin, and Michael W. Reed Current Protocols in Nucleic Acid Chemistry (2002) 1.8.1-1.8.15 Copyright © 2002 by John Wiley & Sons, Inc.
BASIC PROTOCOL 1
Synthesis of Modified Nucleosides
1.8.1 Supplement 11
N,N-Dimethylformamide dimethylacetal (Aldrich) Xylenes Anhydrous pyridine 4,4′-Dimethoxytrityl chloride 5% (w/v) sodium bicarbonate Sodium sulfate Anhydrous methylene chloride N,N-Diisopropylethylamine 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite Hexane 100-mL round-bottom flask Rotary evaporator equipped with a vacuum pump 5 × 35–cm chromatography columns Silica gel 60 F254 aluminum-backed TLC plates (EM Science) 254-nm UV lamp Oil pump (<1 mmHg)
H CF3CO N O
H NH
N N HO
NHCOCF3
O
I
N
NH2
O
N HO
OH
H
H
CF3CO N
CF3CO N
N
MeO N
O
N
H
HO
N 5
NH
N
OMe
N N
O OH
hydrogen (35 psi)
NH
N
NH2
3
20% Pd(OH)2 on carbon 4 M triethylammonium formate, pH 6.5 methanol
O
N
O
OH
HO
NH
N
triethylamine Cul Pd[Ph3P]4 DMF
N
NH2
O OH
DMF
4
DMTr⋅Cl pyridine H
H
CF3CO N
CF3CO N
O NH
N N DMTrO
O OH
N
N N
6
NH
N
i -Pr2NEt, CH2Cl2
N DMTrO
i -Pr2N NC
Pyrazolopyrimidine Nucleosides Substituted
O
i -Pr2NP(Cl)CH2CH2CN N
O
P
O
N N
1
O
Figure 1.8.1 Preparation of AP-PPG phosphoramidite (S.1). Abbreviations: DMF, N,N-dimethylformamide; DMTr⋅Cl, N,N′-dimethoxytrityl chloride.
1.8.2 Supplement 11
Current Protocols in Nucleic Acid Chemistry
500-mL Parr hydrogenation bottle 250-mL separatory funnel Additional reagents and equipment for column chromatography (APPENDIX 3E) and thin-layer chromatography (TLC; APPENDIX 3D) NOTE: 1H NMR spectra were obtained at 300 MHz on a Varian VXR-300 spectrometer. Two-dimensional COSY and NOE experiments assisted in the assignment of proton resonances. Elemental analyses were performed by Quantitative Technologies. NOTE: Like most phosphoramidite reagents, AP-PPA and -PPG are sensitive to hydrolysis and oxidation and must be handled with care after isolation. Desiccated storage at −20°C is recommended. Performance in DNA synthesis depends on good quality reagents; only reagent-grade chemicals should be used to synthesize these phosphoramidites. Characterization of the compounds as described here helps ensure purity. Prepare S.3 1. Weigh a mixture of 6.00 g (15.26 mmol) 6-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-3-iodopyrazolo[3,4-d]pyrimidin-4(5H)-one, 297 mg (1.56 mmol) CuI, and 0.91 g (0.79 mmol) tetrakis[triphenylphosphine]palladium[0] into a 100-mL roundbottom flask and purge with argon. 2. Add 30 mL deoxygenated (argon-purged) anhydrous DMF, 3.14 mL anhydrous triethylamine, and 4.29 g (28.41 mmol) N-trifluoroacetylpropargylamine. Stir the reaction solution 40 hr under argon. 3. Evaporate off the DMF on a rotary evaporator equipped with a vacuum pump, and triturate the residual oil in 150 mL chloroform. Vacuum filter the crude solid that forms (S.3) over Whatman no. 1 filter paper, rinse with chloroform, and dry using a rotary evaporator with a vacuum pump. 4. Dissolve the solid in a minimum volume of anhydrous DMF, adsorb onto a minimal amount of 230- to 400-mesh silica gel (so that gel is free flowing), and evaporate. Load the dry mixture onto a 5 × 35–cm chromatography column (5 × 25–cm bed volume) and elute with 10% (v/v) methanol in ethyl acetate (see APPENDIX 3E for column chromatography). 5. Monitor fractions by TLC (APPENDIX 3D) on silica gel 60 F254 aluminum-backed TLC plates using a mobile phase of 20% (v/v) methanol in ethyl acetate and visualize with a 254-nm UV lamp. Pool the product fractions (Rf = 0.59) and evaporate. 6. Precipitate by dissolving in a minimum volume of ethyl acetate and adding to ∼4 volume diethyl ether. Dry overnight at high vacuum on an oil pump (<1 mmHg). The resulting product, 6-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-3-(3-trifluoroacetamido-propyn-1-yl)-pyrazolo[3,4-d]pyrimidin-4(5H)-one (S.3), is obtained in 63% yield (4.0 g). 1H NMR (DMSO-d6): δ 10.79 (1H, s, N5-H), 10.16 (1H, t, J = 5.2 Hz, trifluoroacetamido N-H), 6.77 (2H, br s, 6-amino), 6.28 (1H, t, J = 6.3 Hz, 1′-H), 5.23 (1H, d, J = 4.1 Hz, 3′-OH), 4.72 (1H, t, J = 5.1 Hz, 5′-OH), 4.32 (3H, m, -CONH-CH2- and 3′-H), 3.75 (1H, m, 4′-H), 3.50-3.29 (2H, 2 × m, 5′-Hs), 2.65 and 2.15 (2H, 2 × m, 2′-Hs). Anal. calcd. For C15H15F3N6O5.0.74H2O: C, 41.93; H, 3.87; N, 19.56. Found: C, 42.33; H, 3.64; N, 19.13.
Synthesis of Modified Nucleosides
1.8.3 Current Protocols in Nucleic Acid Chemistry
Supplement 11
Prepare S.4 7. In a 500-mL Parr hydrogenation bottle, prepare a solution of 1.0 g (2.40 mmol) S.3 in 100 mL methanol containing 0.12 g of preactivated 20% palladium hydroxide on carbon. Always work with palladium catalysts under an inert atmosphere as oxygen and moisture will reduce yield.
8. Add 2.0 mL of 4 M triethylammonium formate buffer, pH 6.5. Shake the mixture 18 hr under 1810 mmHg (35 psi) hydrogen gas. CAUTION: Hydrogen gas is flammable. Use extreme caution to avoid ignition sources. This step should be supervised by an experienced chemist. During some runs it is necessary to add additional catalyst for complete reduction (as determined by TLC; 20% methanol in ethyl acetate). If necessary, add another 0.06 g catalyst and repeat reaction.
9. Filter the mixture through a 1.5-cm pad of Celite and evaporate the filtrate. 10. Crystallize the residual oil from water and dry overnight at high vacuum (using an oil pump). The resulting product, 6-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-3-(3-trifluoroacetamidopropyl) pyrazolo[3,4-d]pyrimidin-4(5H)-one, is obtained in 0.79 g (78%) yield. TLC (20% methanol in ethyl acetate): Rf = 0.52. 1H NMR (DMSO-d6): δ 10.59 (1H, s, N5-H), 9.47 (1H, br t, trifluoroacetimido N-H), 6.64 (2H, br s, 6-amino), 6.27 (1H, t, J = 6.3 Hz, 1′-H), 5.18 (1H, d, J = 4.4 Hz, 3′-OH), 4.75 (1H, t, J = 5.9 Hz, 5′-OH), 4.36 (1H, m, 3′-H), 3.75 (1H, m, 4′-H), 3.48 and 3.61 (2H, 2 × m, 5′-Hs), 3.22, 2.68 and 1.87 (6H, 3 × m, propyl methylene protons), 2.68 and 2.12 (2H, 2 × m, 2′-Hs). Anal. calcd. for C15H19F3N6O5.0.90H2O: C, 41.27; H, 4.80; N, 19.25. Found: C, 41.57; H, 4.50; N, 19.11.
Prepare S.5 11. Dissolve 0.80 g (1.98 mmol) S.4 in 5.0 mL anhydrous DMF. Add 3.1 mL N,N-dimethylformamide dimethylacetal and stir 2.0 hr under argon. 12. Evaporate off solvent, and then evaporate the residue twice from 20 mL xylenes. Place under high vacuum. 13. Triturate the amorphous solid that forms (S.5) in 30 mL diethyl ether, collect by vacuum filtration over no. 1 Whatman paper, and dry overnight at high vacuum. The resulting product, 1-(2-deoxy-β-D-erythro-pentofuranosyl)-6-[(dimethy-lamino) methylidenamino]-3-(3-trifluoroacetamidopropyl)pyrazolo[3,4-d]pyrimidin-4(5H)-one, is obtained in 773-mg (82%) yield. TLC (20% methanol in ethyl acetate): Rf = 0.47. 1H NMR (DMSO-d6): δ 11.22 (1H, br s, N5-H), 9.47 (1H, t, J = 5.5 Hz, trifluoroacetamido N-H), 8.67 (1H, s, N = CH-N), 6.42 (1H, t, J = 6.5 Hz, 1′-H), 5.22 (1H, d, J = 4.3 Hz, 3′-OH), 4.75 (1H, t, J = 6.1 Hz, 5′-OH), 4.40 (1H, m, 3′-H), 3.77 (1H, m, 4′-H), 3.50 and 3.38 (2H, 2 × s, 5′-Hs), 3.18 and 3.05 (6H, 2 × s, N,N-dimethyl Hs), 3.22, 2.72 and 1.89 (6H, 3 × m, propyl methylene Hs), 2.72 and 2.15 (2H, 2 × m, 2′-Hs). Anal. calcd. for C18H24F3N7O5.0.40H2O: C, 44.80; H, 5.18; N, 20.32. Found: C, 45.02; H, 4.96; N, 19.94.
Prepare S.6 14. Prepare a solution of 723 mg (1.52 mmol) S.5 in 9.0 mL anhydrous pyridine. 15. Add 0.61 g (1.80 mmol) 4,4′-dimethoxytrityl chloride and stir the reaction solution 3.0 hr under argon. Pyrazolopyrimidine Nucleosides Substituted
16. Pour the reaction mixture into a 250-mL separatory funnel containing 100 mL of 5% sodium bicarbonate.
1.8.4 Supplement 11
Current Protocols in Nucleic Acid Chemistry
17. Extract the aqueous solution twice with 200 mL ethyl acetate each, and dry the combined extracts over sodium sulfate. 18. Vacuum filter the solution over no. 1 Whatman paper and evaporate the filtrate. 19. Purify the crude product by silica gel chromatography using a 5 × 25–cm bed volume of 230- to 400-mesh silica gel. Elute with a solvent gradient of 0% to 5% (v/v) methanol in ethyl acetate containing 2% triethylamine. 20. Monitor fractions by TLC (see step 5) using a mobile phase of 5% (v/v) methanol/ethyl acetate. Pool the product fractions (Rf = 0.39), evaporate, and dry overnight at high vacuum to give S.6 as an amorphous solid. The resulting product, 1-[5-O-(4,4′-dimethoxytrityl)-2-deoxy-β-D-erythro-pentofuranosyl]-6-[(dimethylamino)methylidenamino]-3-(3-trifluoroacetamidopropyl)pyrazolo[3,4-d] pyrimidin-4(5H)-one, is obtained in 724-mg (61%) yield. 1H NMR (DMSO-d6): δ 11.27 (1H, s, N5-H), 9.43 (1H, t, J = 5.3 Hz, trifluoroacetamido N-H), 8.71 (1H, s, N=CH-N), 7.32, 7.17 and 6.76 (13H, 3 × m, aromatic), 6.45 (1H, t, J = 6.3 Hz, 1′-H), 5.26 (1H, d, J = 5.3 Hz, 3′-OH), 4.45 (1H, m, 3′-H), 3.90 (1H, m, 4′-H), 3.70 (6H, s, OMe Hs), 3.18 and 3.05 (10H, 2 × s, N,N-dimethyl, 5′-Hs and CONH-CH2), 2.62 and 1.65 (4H, 2 × m, methylene Hs), 2.62 and 2.20 (2H, 2 × m, 2′-Hs). Anal. calcd. for C39H42F3N7O7.0.30H2O: C, 59.81; H, 5.48; N, 12.52. Found: C, 59.80; H, 5.39; N, 12.63.
Prepare S.1 21. Prepare a solution of 700 mg (0.900 mmol) S.6 in 22 mL anhydrous methylene chloride containing 0.47 mL N,N-diisopropylethylamine. 22. Add 0.34 mL (1.52 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite and stir 30 min under argon at 25°C. 23. Treat the solution with 3.0 mL methanol and dilute with 200 mL ethyl acetate. 24. Wash the solution with 100 mL of 5% sodium bicarbonate and dry over sodium sulfate. 25. Vacuum filter the solution over no. 1 Whatman paper and evaporate the filtrate. 26. Purify the crude product by silica gel chromatography using a 5 × 25–cm bed volume of 230- to 400-mesh silica gel. Elute with 2% (v/v) triethylamine in ethyl acetate. 27. Monitor fractions by TLC (step 5) using ethyl acetate. Pool the product fractions (Rf = 0.38) and evaporate. 28. Precipitate the residue from 1:2 (v/v) diethyl ether/hexane, evaporate, and dry overnight at high vacuum to give S.1 as an amorphous solid. The resulting product is 1-[5-O-(4,4′-dimethoxytrityl)-2-deoxy-β-D-erythro-pentofuranosyl]-6-[(dimethylamino)methylidenamino]-3-(3-trifluoroacetamidopropyl)pyrazolo[3,4-d] pyrimidin-4(5H)-one 3′-[(2-cyanoethyl) N,N-diisopropylphosphoramidite], is obtained in 583-mg (66%) yield. 31P NMR (DMSO-d6, reference to 85% phosphoric acid): δ 145.50 and 144.72.
Synthesis of Modified Nucleosides
1.8.5 Current Protocols in Nucleic Acid Chemistry
Supplement 11
H CF3CO N NH2
I
NH2
N
N N HO
NHCOCF3 H
O
N HO
OH
7
20% Pd(OH)2 on carbon 4 M triethylammonium formate, pH 6.5 methanol H
hydrogen (35 psi)
H
N
CF3CO N
CF3CO N
N
NH2
N
N N
N
O
OH
HO
N
N
triethylamine Cul Pd[Ph3P]4 DMF
N
MeO
N
N N
O OH
N
N
OMe HO
N
O OH
DMF
DMTr⋅Cl pyridine H
N N
N
i -Pr2NP(Cl)CH2CH2CN
8
N
N
i -Pr2NEt, CH2Cl2
N DMTrO
O OH
N
N
CF3CO N
N N
DMTrO
H
N
CF3CO N
i -Pr2N NC
N
O
P
O
2
O
Figure 1.8.2 Preparation of AP-PPA phosphoramidite (S.2). Abbreviations: DMF, N,N-dimethylformamide; DMTr⋅Cl, N,N′-dimethoxytrityl chloride.
BASIC PROTOCOL 2
Pyrazolopyrimidine Nucleosides Substituted
PREPARATION OF PROTECTED AMINOPROPYL-PPA PHOSPHORAMIDITE To synthesize the AP-PPA phosphoramidite (S.2; Fig. 1.8.2), the method described for the AP-PPG phosphoramidite (see Basic Protocol 1) is utilized with the following exceptions. Some intermediates were not rigorously purified for the protocol described here. To ensure success, a careful step-wise approach on a small scale is advised. The protocol described here allowed successful preparation of the desired AP-PPA phosphoramidite (S.2) and shows the advanced user which intermediates can be taken on in crude form. The reactions described in Figure 1.8.2 were followed by analytical reversedphase HPLC using a 150 × 4.6–mm column, a gradient of acetonitrile (solvent B) in 0.1 M triethylammonium acetate, pH 7.5 (solvent A), and a flow rate of 1 mL/min. Each reaction was monitored by UV detection at 260 nm, and worked up when starting material was consumed. Elution gradients and retention times are noted for each reaction.
1.8.6 Supplement 11
Current Protocols in Nucleic Acid Chemistry
Materials 4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-3-iodo-1H-pyrazolo[3,4-d]pyrim idine (Seela and Zulauf, 1998) Celite (1.5–cm pad) N,N-Dimethylacetamide dimethylacetal (TCI America) Anhydrous triethylamine Anhydrous dimethylformamide (DMF) Xylenes 4,4′-Dimethoxytrityl chloride Anhydrous pyridine 230- to 400-mesh (40- to 63-µm) silica gel (EM Sciences) Ethyl acetate Methylene chloride Methanol 5 × 35–cm chromatography column Additional reagents and equipment for synthesizing AP-PPG (see Basic Protocol 1) Prepare S.7 1. Alkynylate 1.0 g of 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-3-iodo-1Hpyrazolo[3,4-d]pyrimidine by the general procedure described for the synthesis of S.3 (see Basic Protocol 1, steps 1 to 6). The resulting product is 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-3-(3-trifluoroacetamido-propyn-1-yl)-1H-pyrazolo[3,4-d]pyrimidine. Analytical HPLC using 0% to 100% solvent B over 20 min showed complete conversion of 3-iodo-substituted PPA (6 min) to S.7 (7.2 min) after 24 hr.
Prepare S.8 2. Hydrogenate 1.0 g (2.5 mmol) S.7 by the general procedure described for S.4 (see Basic Protocol 1, steps 7 to 10), but reduce the reaction time (step 8) to 1 hr. Analytical HPLC using 0% to 30% solvent B over 20 min showed complete hydrogenation of S.7 (16.5 min) to the desired product (14 min).
3. Filter the reaction mixture through a 1.5–cm Celite pad and evaporate the filtrate to dryness under high vacuum. 4. Dissolve the crude product in 20 mL anhydrous DMF and then add 1.46 mL (10 mmol) N,N-dimethylacetamide dimethylacetal and 2.0 mL triethylamine. Stir for 24 hr. Analytical HPLC using 0% to 60% solvent B over 20 min showed complete conversion of the starting amine (9 min) to the desired dimethylacetal product (11.5 min) after 24 hr. After 5 hr, an intermediate compound (12.3 min) was detected that eventually converted to product.
5. Evaporate the completed reaction solution to dryness, and then evaporate the residue twice from 20 mL xylenes. 6. React the crude product with 0.93 g of 4,4′-dimethoxytrityl chloride in 20 mL anhydrous pyridine for 16 hr. Evaporate the reaction mixture to dryness. Analytical HPLC using 0% to 100% solvent B over 20 min showed complete conversion of the alcohol (9 min) to the desired DMTr product S.8 (16 min).
Synthesis of Modified Nucleosides
1.8.7 Current Protocols in Nucleic Acid Chemistry
Supplement 11
7. Prewash a 5 × 25–cm column (bed volume) of 230- to 400-mesh silica gel with 1 column volume of 1:1 (v/v) triethylamine/ethyl acetate. Rinse with 500 mL ethyl acetate. Load the crude product onto the silica gel column in a minimum volume of 9:1 (v/v) ethyl acetate/methylene chloride (see APPENDIX 3E for column chromatography). Rinsing with ethyl acetate removes excess triethylamine and leaves the silica non-acidic. Chromatography can also be performed as in Basic Protocol 1, step 19.
8. Elute the product (S.8) with a gradient of 0% to 10% (v/v) methanol in ethyl acetate and evaporate to give an amorphous solid. The resulting product, 1-[5-O-(4,4′-dimethoxytrityl)-2-deoxy-β-D-erythro-pentofuranosyl]-4-[1-(dimethylamino)ethylidene]amino-3-(3-trifluoroacetamidopropyl)pyrazolo [3,4-d]pyrimidine, is obtained in 90% yield (1.75 g).
Prepare S.2 9. Phosphitylate 1.75 g (2.25 mmol) compound S.8 by the general procedure described for S.1 (see Basic Protocol 1, steps 21 to 28). The resulting product, 1-[5-O-(4,4′-dimethoxytrityl)-2-deoxy-β-D-erythro-pentofuranosyl]-4-[1-(dimethylamino)ethylidene]amino-3-(3-trifluoroacetimidopropyl)pyrazolo[3,4-d] pyrimidine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite], is obtained in 1.86 g (85%) yield. 31P NMR (DMSO-d6, reference to 85% phosphoric acid): δ 147.43 and 146.76. Analytical HPLC using 30% to 100% solvent B over 10 min followed by 100% solvent B for 10 min showed complete conversion of S.8 (16.5 min) to the desired phosphoramidite S.2 (12 min) after 3 hr. BASIC PROTOCOL 3
Pyrazolopyrimidine Nucleosides Substituted
SYNTHESIS OF DNA CONJUGATES USING AP-PPA AND AP-PPG PHOSPHORAMIDITES This protocol describes the preparation of DNA conjugates from the AP-PPA or AP-PPG modified oligonucleotides as described in Figure 1.8.3. DNA synthesis using these reagents is straightforward for someone trained in DNA synthesis, and is thus not described in detail. The phosphoramidite reagents S.1 and S.2 give good yields of AP-PPG- or AP-PPA-containing DNA strands using standard methods (for reference on standard methods, see UNIT 3.3 and APPENDIX 3C). The introduced aminopropyl linker groups allow reaction of the DNA strands with activated esters of conjugate groups. To demonstrate utility, the N-hydroxysuccinimide ester of a fluorescent quencher molecule (dabcyl-SE) is added to a 9-mer DNA strand containing an internal AP-PPA linker (S.9). As illustrated in Figure 1.8.3, the DNA is converted to the DMSO-soluble triethylammonium salt form (steps 1 to 4) and reacted with dabcyl-SE (step 5 to 8). The crude DNA conjugate is precipitated from DMSO and purified by reversed-phase HPLC (RP-HPLC, steps 9 to 12) to give the desired dabcyl-DNA conjugate (S.10). The protocol described here uses 0.2 µmol of an oligodeoxynucleotide from a 1.0-µmol scale DNA synthesis, but can be modified for synthesis of nucleic acid conjugates at any scale. Materials AP-PPA-modified 9-mer oligonucleotide from a 1-µmol-scale synthesis, trityl-on (e.g., Epoch Biosciences) 3 M sodium acetate Butanol Ethanol Solvent A: 0.1 M triethylammonium acetate, pH 7.5 Solvent B: acetonitrile Anhydrous dimethylsulfoxide (DMSO; e.g., Aldrich Sure-seal; store over calcium hydride) Anhydrous triethylamine (Fluka; store over calcium hydride)
1.8.8 Supplement 11
Current Protocols in Nucleic Acid Chemistry
N-Hydroxysuccinimidyl ester of dabcyl (dabcyl-SE; Molecular Probes) 2% (w/v) sodium perchlorate in acetone Acetone Centrifugal evaporator (i.e., Savant Speedvac) with high vacuum source (<1 mmHg) High-performance liquid chromatograph (HPLC) with: 4.6 × 250–mm C18 analytical column and appropriate guard column (Varian Dynamax) UV-Vis or photodiode array detector 14-mL polypropylene tubes UV-Vis spectrophotometer Additional reagents and equipment for RP-HPLC and detritylation (UNIT 10.5) Prepare starting oligonucleotide 1. Purify the starting AP-PPA-modified 9-mer oligonucleotide (trityl-on) by RP-HPLC and then detritylate with 80% acetic acid (UNIT 10.5). It is important to obtain the starting oligonucleotide (S.9) from a qualified DNA synthesis source. AP-PPA- and AP-PPG-containing oligonucleotides can be purchased from Epoch Biosciences (http://www.epochbio.com).
+
+
H3 N
H3 N
NH2 N
N N dT4-O
N
N
O
dT4-O
Salt Exchange
P
O-dT4
O−
Na+
RP-HPLC with triethylammonium acetate
N
O O
O
9 (Na salt)
P
O-dT4
O−
+NHEt 3
9 (TEA salt)
Acylation
O N Me2N
N
N
O O
NH2
dabcyl-SE anhydrous DMSO
N
N
NH2
H
N
N N dT4-O
O
N
Purification precipitation from DMSO RP-HPLC purification
crude DNA conjugate
O O
P
O-dT4
O−
+NHEt 3
10 (TEA salt)
Figure 1.8.3 Synthesis of dabcyl conjugate at internal AP-PPA linker position in a 9-mer oligonucleotide.
Synthesis of Modified Nucleosides
1.8.9 Current Protocols in Nucleic Acid Chemistry
Supplement 11
2. Precipitate with 0.5 mL of 3 M sodium acetate and 4 mL butanol. Wash with ethanol and dry in vacuo using a Speedvac evaporator. The resulting pellet is primarily the sodium salt of the DNA (S.9).
Perform salt exchange 3. Dissolve ∼200 nmol trityl-off S.9 in 500 µL water. Purify by RP-HPLC using a 4.6 × 250–nm C18 analytical column and guard column, with a gradient of 0% to 30% (v/v) solvent B over 20 min at a flow rate of 2 mL/min. Collect the desired fraction (∼15-min retention time) in a 14-mL polypropylene tube. 4. Dry in a centrifugal evaporator (SpeedVac) to dryness to give the pure detritylated oligodeoxynucleotide as a TEA salt. The appropriate amount of DNA can be aliquoted at this stage by dissolving the trityl-off pellet in water, measuring the A260, and drying the appropriate volume in a 1.5-mL microcentrifuge tube.
Perform conjugation 5. Add 30 µL anhydrous DMSO to 200 nmol dried TEA salt of S.9 in a 1.5-mL microcentrifuge tube. Vortex and examine closely to make sure the pellet is dissolved. If the pellet is not completely dissolved, gradually add more DMSO (up to 0.5 mL final). More dilute solutions slow the acylation reaction. Sonication or heating can often be used to help dissolve stubborn pellets.
oligonucleotide
AU
dabcyl conjugate
5
10 min
15
20
AU
0
200
Pyrazolopyrimidine Nucleosides Substituted
250
300
350
400 nm
450
500
550
600
Figure 1.8.4 Reversed-phase HPLC chromatograms and UV-Vis spectra of AP-PPA-modified oligonucleotides (S.9; dashed lines) and dabcyl conjugate (S.10; solid lines). The large difference in retention time simplifies isolation and analysis of the lipophilic conjugate.
1.8.10 Supplement 11
Current Protocols in Nucleic Acid Chemistry
6. Add 7 µL (50 µmol) anhydrous triethylamine. At higher than 5%, the triethylamine is insoluble in DMSO. Triethylamine can be added at up to 10% of the total final volume of DMSO without hurting the conjugation reaction.
7. Dissolve 1.1 mg dabcyl-SE in 100 µL DMSO in a second 1.5-mL microcentrifuge tube. Vortex until homogeneous. CAUTION: DMSO solutions of acylating agents can burn the skin. Wear nitrile (not latex) rubber gloves and handle tubes carefully. Before opening lids of the tubes, spin down liquids in a microcentrifuge. Open cautiously to prevent aerosols. Dispose of excess reagents with waste organic solvents.
8. Add 33 µL (366 µg, 1 µmol) dabcyl-SE solution to the solution of S.9 (step 6). Vortex and incubate 24 hr at room temperature. Monitor the reaction by RP-HPLC as described in step 3 (see Fig. 1.8.4). The reaction rate can be increased by incubating at 37°C. Analytical HPLC using this system can be extremely valuable for identifying the starting oligonucleotide (10.7 min) and desired conjugate peaks (16.7 min). If the acylating agent has a chromophore with an A260 that is unique from that of the oligonucleotide, a photodiode array detector is useful. Hydrolyzed acylating agents can elute in the HPLC collection window and complicate identification of the desired conjugate. In this example with dabcyl-SE, an unreactive peak (20% by A260 integration) remained with a retention time of 10.8 min.
Purify conjugate 9. After the reaction is deemed complete, precipitate the oligonucleotide products with 1.2 mL of 2% sodium perchlorate in acetone. Microcentrifuge the mixture 1 min at maximum speed. If reaction volume is >0.15 mL, precipitate the products by adding to 10 vol of 2% sodium perchlorate in acetone contained in a larger tube.
10. Wash the pellet with 0.5 mL acetone. Microcentrifuge again at maximum speed and dry 30 min in a SpeedVac evaporator. 11. Dissolve the crude DNA conjugate in ∼1 mL solvent A and purify by RP-HPLC as described in step 3. Evaporate the collected fraction to dryness in a Speedvac evaporator. 12. Dissolve the dried conjugate in 0.1 mL water and characterize by RP-HPLC and UV-Vis spectroscopy (Fig. 1.8.4). REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. Unless otherwise noted, reagent-grade chemicals should be used. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Palladium hydroxide, 20% (w/v), on carbon Available from Aldrich (also known as Pearlman’s catalyst). Before use, preactivate by gently warming a suspension of the palladium catalyst in 5 mL methanol containing 3 drops of formic acid for 5 min. Use immediately. Always work with palladium catalysts under an inert atmosphere.
Triethylammonium formate buffer, 4 M, pH 6.5 Make 4 M formic acid solution. Add one equivalent of triethylamine. Adjust pH to 6.5. Store tightly capped for up to 1 year at 4°C.
Synthesis of Modified Nucleosides
1.8.11 Current Protocols in Nucleic Acid Chemistry
Supplement 11
COMMENTARY Background Information
Pyrazolopyrimidine Nucleosides Substituted
Conjugation of ligands to the nucleobases of synthetic oligonucleotides allows preparation of modified nucleic acids for molecular biology and potential therapeutic applications. Specialty phosphoramidite reagents have been developed that allow preparation of modified DNA on automated DNA synthesizers (Beaucage and Iyer, 1993), but these ligands must survive the harsh ammonia deprotection conditio ns. Preparation of specialty phosphoramidites requires multistep organic synthesis, and these resources are not readily available to most DNA synthesis facilities. Linker phosphoramidites are available which contain functional groups that can be modified with reactive conjugate groups (Goodchild, 1990). Aminoalkyl linkers are usually incorporated into synthetic DNA at terminal positions of synthetic probes or at internal positions via non-nucleotide (abasic) linker groups. These amino linkers can be acylated with various “active esters” to introduce a wide variety of conjugate groups to give stable amide bonds. Internal abasic linkers can disrupt DNA duplex formation or prevent enzyme recognition; therefore, aminoalkyl-modified nucleotide phosphoramidites have been developed. Conjugate groups are well tolerated in the major groove of DNA duplexes and have been shown in some cases to stabilize dsDNA. Suitably protected C5-aminoalkyl-substituted pyrimidines are available as β-cyanoethyl phosphoramidite reagents (Glen Research; http://www.glenres.com). DNA sequences of interest can be synthesized using these reagents to introduce linker sites at various internal dC or dT positions in synthetic DNA probes. Substitution at C5 of the pyrimidine heterocycle places the attached conjugate groups in what will become the major groove in B-form DNA after hybridization with a complementary DNA strand. Unlike the pyrimidine analogs, aminoalkyl-modified purine analogs are not commercially available as phosphoramidite reagents. Deazapurines, modified at the 7 position, also place conjugate groups in the major groove, and are well tolerated in DNA duplexes. Phosphoramidite reagents and NTP analogs of the 7-aminoalkyl deazapurines have been reported (Seela et al., 1996). The 3-modified pyrazolo[3,4-d]pyrimidine analogs of adenosine and guanine (PPA and PPG) are isosteric with the 7-modified deazapurine heterocycles. An early application
of the 3-substituted PPA ring system in DNA probes was introduction of a biotin-labeled PPA nucleoside via the corresponding 5′triphosphate (Petrie et al., 1991). Multiple biotin modifications in DNA probes were tolerated with little decrease in Tm versus natural dA. Advances in the synthesis of 3-substituted PPA and PPG nucleosides allowed their incorporation into DNA probes via phosphoramidite chemistry (Seela and Becher, 1999; Seela and Zulauf, 1999). 3-Alkylamine-modified pyrazolopyrimidines were not prepared, but halogen and alkyne modifications at the 3 position were found to increase stability of DNA duplexes. The 3-aminopropyl-substituted pyrazolo[3,4-d]pyrimidine analogs of adenine (PPA) and guanine (PPG) described here allow postsynthetic modification of DNA sequences with a variety of conjugate groups. The authors briefly described the AP-PPA and AP-PPG nucleoside phosphoramidites (S.1 and S.2) and used these linkers to incorporate the fluorescent quencher molecule TAMRA into probes containing fluorogenic minor groove binders (Kutyavin et al., 2000). Synthesis of these phosphoramidites is described in detail above (see Basic Protocols 1 and 2). The 3-iodo-substituted PPA and PPG nucleosides are particularly valuable intermediates since they are readily alkynylated via Pd-catalyzed cross-coupling reactions. The authors have successfully used the published synthetic procedures for these key intermediates. Trifluoroacetylpropargylamine is a convenient, easily prepared source of the required aminoalkyl linker arm. The authors used the published synthetic procedure for this common intermediate. Alkynylation using trifluoroacetylpropargylamine has been reported for preparation of the C5-substituted dT phosphoramidite (Cruickshank and Stockwell, 1988). The TFA-protected amine survives the organic synthesis steps, yet is readily hydrolyzed during ammonia deprotection after DNA synthesis. Pd-catalyzed coupling to the 3-iodoPPA or -PPG intermediates generally proceeds in good yield, and is easily followed by TLC or analytical HPLC. Use of the aminoalkyne intermediates for synthesis of the corresponding PPA or PPG phosphoramidites is feasible and may be advantageous for some applications. The authors prepared the aminoalkyl linkers since the aliphatic chain is more flexible, and presumably allows attached conjugate groups
1.8.12 Supplement 11
Current Protocols in Nucleic Acid Chemistry
to find low-energy conformations that are less disruptive to DNA duplex formation. Sy nthesis of the aminoalkyl phosphoramidites (S.1 and S.2) from the alkynecoupled products uses well-established chemistry. Hydrogenation of the alkynes to give the aliphatic linkers proceeds in close-to-quantitative yield. Dimethyl formamidine or acetamidine protection of the exocyclic amino groups is readily accomplished by reaction with the corresponding dimethoxyketal. Tritylation of the 5′-hydroxy group uses standard conditions. As noted in the shortened AP-PPA protocol, the crude products from hydrogenation and acetamidine protection are suitably pure for direct use in the tritylation reaction. The tritylated products are easily isolated by silica gel chromatography and converted to the desired phosphoramidites using standard methods. DNA synthesis using S.1 and S.2 uses conventional phosphoramidite chemistry. The TFA and amidine protecting groups are nonbulky, and coupling yields are close to quantitative when introduced at internal positions in synthetic DNA sequences. To demonstrate the use of these linkers, a 9-mer oligonucleotide containing AP-PPA (S.9) was prepared and purified by reversed-phase HPLC. Basic Protocol 3 describes conjugation of a hydrophobic ligand (the NHS ester of dabcyl) to this internally modified 9-mer in anhydrous DMSO solution. Dabcyl-labeled DNA has applications in fluorogenic probes (Tyagi et al., 1998). The authors have used variations of Basic Protocol 3 for synthesis of hundreds of DNA conjugates. The simple method has been described elsewhere (Milesi et al., 1999), and is especially useful for preparation of the internally modified AP-PPA and AP-PPG conjugates described here. The authors have conjugated DNA alkylating agents (Podyminogin et al., 1996), lipophilic aryltin compounds (Karamychev et al., 1997), and sensitive fluorescent tags (Kutyavin et al., 2000) to aminoalkyl-modified nucleobases in DNA probes using the protocols described here.
Critical Parameters Synthesis of the phosphoramidites S.1 and S.2 from the 3-iodo-PPA and -PPG nucleosides is straightforward. Purification and chromatography of the intermediates at each step will ensure success. Likewise, DNA synthesis using S.1 and S.2 uses standard methods (UNIT 3.3 and APPENDIX 3C). The conjugation chemistry can be trickier, and will be the focus of the remainder of this section.
Active ester reagents such as NHS esters are commonly used for aqueous conjugation of ligands to the amino groups of biomolecules such as proteins or synthetic DNA. As a result, many desirable conjugate groups are available as active esters. These acylating agents generally have improved reactivity at nucleophilic aminoalkyl groups that can be introduced into DNA strands. Acylation of aminoalkyl linkers at internal positions in synthetic DNA strands can be difficult. Steric hindrance slows the acylation reaction, and hydrolysis of the acylating agent becomes a major side reaction. Standard aqueous conditions can often be used successfully for attaching hydrophilic conjugate groups to AP-PPA- and AP-PPG-modified oligonucleotides. For example, the authors previously reported addition of a TAMRA-NHS ester to fluorogenic DNA probes using an aqueous buffer system. However, the limited solubility or aqueous stability of some acylating agents presents a problem, especially for internal linker positions. Triethylammonium salts of oligonucleotides are quite soluble in anhydrous DMSO. This is the key to success with the conjugation chemistry presented here. Although oligonucleotides dried in vacuo always contain complexed water, minimizing the water content in the reaction mixture slows hydrolysis of the acylating agents. Nucleophilicity of the alkylamine group is also enhanced in DMSO, and this speeds the desired reaction with the activated ester. Use of the NHS ester of dabcyl (dabcyl-SE) provides an excellent example of the advantages of the DMSO conjugation chemistry. Standard aqueous methods are not feasible since organic solutions of dabcyl-SE precipitate upon addition to aqueous buffers. The TEA salt of the AP-PPA 9-mer (S.9) and dabcyl-SE are both readily soluble in DMSO. Excess triethylamine is added and the reaction proceeds at room temperature. The hydrophobic oligonucleotide conjugate is easily detected by reversed-phase HPLC and the course of the reaction can be followed. HPLC purification before and after the acylation reaction gives great confidence that the desired conjugate has been isolated.
Troubleshooting To ensure that the phosphoramidites perform as expected in DNA synthesis, the authors recommend preparation of a 9-mer probe such as that presented in Basic Protocol 3. Conjugation of a model ligand can give further confi-
Synthesis of Modified Nucleosides
1.8.13 Current Protocols in Nucleic Acid Chemistry
Supplement 11
dence that the reagent is in good shape. The conjugation chemistry presented here usually allows isolation of the desired product. However, each DNA probe conjugate has unique properties, and problems associated with aggregation of lipophilic compounds or structural complexes associated with certain sequences can always be a problem. DNA conjugates are complex biomolecules with inherent sequencespecific properties that can be difficult to predict. Long sequences and strands with significant self-complementarity or homopurine runs can lead to unusual aggregation problems, especially with lipophilic conjugate groups. The quality of DNA synthesis and the quality of the activated ester reagent are important factors in successful conjugation chemistry. The key to success with the conjugation chemistry is homogeneity of the DMSO reaction mixture. After reversed-phase HPLC purification of the AP-PPA- or AP-PPG-containing oligonucleotide, it is important that it be dried well in vacuo. Residual triethylammonium acetate or water can adversely affect the desired acylation reaction.
Anticipated Results
Pyrazolopyrimidine Nucleosides Substituted
With good-quality AP-PPA or AP-PPG amidites, DNA synthesis is routine. After tritylon purification by RP-HPLC and sodium-toTEA salt exchange by trityl-off RP-HPLC, a homogeneous product is obtained. For example, the analytical RP-HPLC in Figure 1.8.4 shows a single peak for the starting AP-PPAmodified 9-mer (S.9, TEA salt). Conjugation chemistry using lipophilic activated esters allows the extent of the reaction to be easily tracked by RP-HPLC. The shift in retention time from ∼12 min for the starting AP-PPAcontaining oligo to ∼17 min for the desired dabcyl conjugate is especially dramatic for the example shown in Figure 1.8.4. The yield of DNA conjugates using the anhydrous DMSO method of Basic Protocol 3 is typically 30% to 90%. As shown in Figure 1.8.4, RP-HPLC retention times and UV-Vis spectra are characteristic for oligonucleotide conjugates that are lipophilic or contain unique chromophores. Performance in DNA hybridization–based assays depends on sequence-specific binding with complementary sequences. UV melting studies (UNIT 7.3) can be used to measure the Tm of the AP-PPA- or AP-PPGmodified DNA conjugates. Mass spectral analysis using MALDI-TOF (UNIT 10.1) or elec-
trospray ionization (UNIT 10.2) methods is another approach that can be used to verify the presence of the desired conjugate group. Other assays are ultimately used to detect the presence of conjugate groups in DNA probes. Conjugate groups with specific physical or chemical properties are introduced to enhance performance in hybridization-based diagnostic or therapeutic assays, and these assays are the final screen for oligonucleotide conjugate quality.
Time Considerations Synthesis of the AP-PPA or AP-PPG phosphoramidites takes 2 to 3 days per reaction and purification, depending on the indicated reaction times. Time can be saved by skipping some purification steps as indicated in the preparation of S.2, but this is not advised for the initial synthetic attempts. The conjugation chemistry is not labor intensive, but the HPLC analytical and purification steps can slow the work. Drying in vacuo is generally carried out overnight, and there are several drying steps. Experienced chemists with dedicated instruments can shortcut many of these steps. For example, precipitation of DNA from reversed-phase HPLC buffer has been described (Milesi et al., 1999).
Literature Cited Beaucage, S.L. and Iyer, R.P. 1993. The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications. Tetrahedron 49:6123-6194. Cruickshank, K.A. and Stockwell, D.L. 1988. Oligonucleotide labeling: A concise synthesis of a modified thymidine phosphoramidite. Tetrahedron Lett. 29:5221-5224. Goodchild, J. 1990. Conjugates of oligonucleotides and modified oligonucleotides: A review of their synthesis and properties. Bioconjugate Chem. 1:165-187. Karamychev, V.N., Panyutin, I.G., Reed, M.W., and Neumann, R.D. 1997. Effect of radionuclide linker structure on DNA cleavage by 125I-labeled oligonucleotides. Antisense Nucl. Acid Drug Dev. 7:549-557. Kutyavin, I.V., Afonina, I.A., Mills, A., Gorn, V.V., Lukhtanov, E.A., Belousov, E.S., Singer, M.J., Walburger, D.K., Lokhov, S.G., Gall, A.A., Dempcy, R., Reed, M.W., Meyer, R.B.J., and Hedgpeth, J. 2000. 3′-Minor groove binderDNA probes increase sequence specificity at PCR extension temperatures. Nucl. Acids Res. 28:655-661. Milesi, D., Kutyavin, I.V., Lukhtanov, E.A., Gorn, V.V., and Reed, M.W. 1999. Synthesis of oligonucleotides in anhydrous dimethyl sulfoxide. Methods Enzymol. 313:164-173.
1.8.14 Supplement 11
Current Protocols in Nucleic Acid Chemistry
Petrie, C.R., Adams, A.D., Stamm, M., Van Ness, J., Watanabe, S.M., and Meyer, R.B.J. 1991. A novel biotinylated adenylate analogue derived from pyrazolo[3,4-d]pyrimidine for labeling DNA probes. Bioconjugate Chem. 2:441-446.
Seela, F. and Zulauf, M. 1999. Synthesis of oligonucleotides containing pyrazolo[3,4-d]pyrimidines: The influence of 7-substituted 8-aza-7deazaadenines on the duplex structure and stability. J. Chem. Soc. Perkin Trans. 1 (4):479-488.
Podyminogin, M.A., Meyer, R.B.J., and Gamper, H.B. 1996. RecA-catalyzed, sequence-specific alkylation of DNA by cross-linking oligonucleotides. Effects of length and nonhomologous base substitutions. Biochemistry 35:7267-7274.
Seela, F., Ramzaeva, N., and Becher, G. 1996. 7Deazapurine DNA: Oligonucleotides containing 7-substituted 7-deaza-2′-deoxyguanosine and 8aza-7-deaza-2′-deoxyguanosine. Collect. Czech. Chem. Commun. 61:258-261.
Seela, F. and Becher, G. 1998. Synthesis of 7-halogenated 8-aza-7-deaza-2′-deoxyguanosines and related pyrazolo[3,4-d]pyrimidine 2′-deoxyribonucleotides. Synthesis (9):207-214.
Tyagi, S., Bratu, D.P., and Kramer, F.R. 1998. Multicolor molecular beacons for allele discrimination. Nature Biotech. 16:49-53.
Seela, F. and Becher, G. 1999. Oligonucleotides containing pyrazolo[3,4-d]pyrimidines: The influence of 7-substituted 8-aza-7-deaza-2′-deoxyguanosines on the duplex structure and stability. Helv. Chim. Acta 82:1640-1655. Seela, F. and Zulauf, M. 1998. Synthesis of 7-alkynylated 8-aza-7-deaza-2′-deoxyadenosines via the Pd-catalysed cross-coupling reaction. J. Chem. Soc. Perkin Trans. 1 (19):3233-3240.
Contributed by Robert O. Dempcy, Mikhail A. Podyminogin, and Michael W. Reed Epoch Biosciences Bothell, Washington
Synthesis of Modified Nucleosides
1.8.15 Current Protocols in Nucleic Acid Chemistry
Supplement 11
Synthesis of 1,5-Anhydrohexitol Building Blocks for Oligonucleotide Synthesis
UNIT 1.9
Hexitol nucleic acids (HNA) represent a new oligomeric structure able to hybridize as well with DNA and RNA as with itself, and in a sequence-specific manner. In addition, HNA seems to be superior to its DNA and RNA analogs as an antisense construct. This is supported by a study demonstrating that HNA forms highly selective and exceptionally stable duplexes with RNA (Hendrix et al., 1997a) and that these HNA:RNA duplexes are stable towards nuclease degradation (Hendrix et al., 1997b). Furthermore, a high potential for antiviral activities has been reported (Verheggen et al., 1995). Hexitol nucleic acids are made up of phosphorylated 1,5-anhydro-D-arabino-2,3-dideoxyhexitol building blocks with a base moiety positioned in the 2 position. According to the Westheimer model, the base moiety of the hexitol nucleosides is axially oriented, avoiding the sterically unfavorable 1,3-diaxial repulsions (De Winter et al., 1998). This unit describes in detail the preparation of 1,5-anhydrohexitol (see Basic Protocol 1 and Fig. 1.9.1) and the 1,5-anhydrohexitol building blocks for oligonucleotide synthesis (hG, hA, hC, hT; see Basic Protocols 2 to 5 and Figs. 1.9.2 to 1.9.5, respectively). NOTE: Carry out reactions with anhydrous solvents and dried glassware (i.e., 2 hr at 70°C). NOTE: All chemicals are commercially available (e.g., ACROS, Fluka, Aldrich). All starting materials can be synthesized but are also available commercially. The sugar intermediate S.5 is now also commercially available. All reactions can be carried out with standard laboratory equipment and glassware (e.g., round-bottom and Erlenmeyer flasks, consensers, dropping funnels, separatory funnels, desiccators, ultrasonic baths, oil baths, and magnetic stirrers). PREPARATION OF 1,5-ANHYDRO-4,6-O-BENZYLIDINE-3-DEOXY-DGLUCITOL
BASIC PROTOCOL 1
In this protocol, synthesis of the sugar building block starting from tetra-O-acetyl-α-Dbromoglucose is given, as outlined in Figure 1.9.1 (Verheggen et al., 1993). The starting sugar, tetra-O-acetyl-α-D-bromoglucose, can be used to make both tolylsulfonyl and toluoyl intermediates (S.4a and S.4b, respectively). The latter is used to make S.5 (described below), which is then used to make the hG, hT, and hC nucleoside monomers (see Basic Protocols 2, 4, and 5, respectively). The former is used directly to make the hA monomer (see Basic Protocol 3). The chemical reactions described give good yields, and purification of the intermediates is straightforward. Materials 2,3,4,6-Tetra-O-acetyl-α-D-bromoglucose Diethyl ether: reflux overnight on sodium (Na, FeCl2, Et2O) and distill Azoisobutyronitrile [2,2′-azobis(2-methylpropionitrile); AIBN] Tri-n-butyltin hydride Precoated silica gel TLC plates (Alugram Sil G/UV254) Dichloromethane Anisaldehyde/sulfuric acid spray (UNIT 1.3) Potassium fluoride dihydrate Sodium sulfate Silica gel (0.060 to 0.200 nm) Methanol Contributed by Irene M. Lagoja, Arnaud Marchand, Arthur Van Aerschot, and Piet Herdewijn Current Protocols in Nucleic Acid Chemistry (2003) 1.9.1-1.9.22 Copyright © 2003 by John Wiley & Sons, Inc.
Synthesis of Modified Nucleosides
1.9.1 Supplement 14
AcO
HO
AcO O
OAc
Br
OAc
Bu3SnH, Et2O
OAc
KF/H2O
O
NaOMe
1
OH
OAc
O O
Bu2SnO benzene
O
O
OH
H O
TsCl or TolCl resp. dioxane
OR
PhCHO ZnCl2
O
Ph OH
H
O
OH
OAc
OAc
Ph
OH
OH
2
3a R = Tos 3b R = Tol CSCl2, DMAP, 2,4-Cl2C6H3OH, CH2Cl2 Bu3SnH, AIBN, toluene
O
Ph
Ph O
NaOMe
H
O
OR
OH
O H
O O
O
4a R = Tos 4b R = Tol 5 R=H
O
5
OH
Ph
O
5
NaOMe
Figure 1.9.1 Preparation of 1,5-anhydro-4,6-O-benzylidine-3-deoxy-D-glucitol (S.5). Abbreviations: AIBN, azoisobutyronitrile; Bu2SnO, dibutyltinoxide; Bu3SnH, tributyltinhydride; DMAP, 4-(dimethylamino)pyridine; NaOMe, sodium methoxide; PhCHO, benzaldehyde; TolCl, toluoyl chloride; TsCl, tosyl chloride.
0.1 N sodium methoxide, freshly prepared from sodium and dry methanol Acetic acid (glacial not necessary) Toluene Zinc chloride (dry fresh before use) Benzaldehyde Ethyl acetate n-Hexane Dibutyltinoxide Benzene Dioxane (reflux overnight on lithium aluminum hydride and distill) p-Toluenesulfonyl chloride (for S.3a) or p-toluoyl chloride (for S.3b) Delite Celite 4-(Dimethylamino)pyridine (DMAP) Dry ice/isopropanol Thiophosgene 2,4-Dichlorophenol 1 M potassium dihydrogenphosphate solution, pH 5 Nitrogen gas Synthesis of 1,5-Anhydrohexitol Building Blocks
Oil bath and magnetic stirrer Rotary evaporator equipped with a vacuum pump and cooling trap 5 × 35–, 6 × 50–, and 5 × 20–cm chromatography columns
1.9.2 Supplement 14
Current Protocols in Nucleic Acid Chemistry
2 × 18–cm test tubes 1-L round-bottom flask with rubber stopper Dropping funnel Glass funnel Dean-Stark condenser UV lamp, 254 nm Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and column chromatography (APPENDIX 3E) NOTE: The 1H and 13C NMR spectra given as examples were determined with a JEOL FX 90Q spectrometer or 400 MHz Bruker AMX with tetramethylsilane as internal standard. Electron-impact mass spectra (EIMS) and chemical-ionization mass spectra (CIMS) were obtained using a KRATOS Concept 1H mass spectrometer. Abbreviations: s, singlet; d, doublet; dd, double doublet; t, triplet; br s, broad signal; m, multiplet; ddd, double doublet of doublet; and dm, double multiplet. Prepare S.1 1. Dissolve 25.03 g (60.9 mmol) of 2,3,4,6-tetra-O-acetyl-α-D-bromoglucose in 375 mL diethyl ether. 2. Add 0.99 g (6.1 mmol) of AIBN and 25 mL (93.1 mmol) of tri-n-butyltin hydride. 3. Stir the mixture 1 hr at 35°C and then at room temperature until conversion is complete (2 to 12 hr). Monitor by TLC (APPENDIX 3D) by spotting the reaction mixture (100 µL) between two spots of starting material (1 mg diluted to 200 µL) as a reference. Use precoated silica gel plates and develop with dichloromethane. Visualize under a UV lamp (254 nm) and then spray the plate with anisaldehyde/sulfuric acid spray and dry at 150°C (also see Critical Parameters). 4. Dissolve 8.21 g potassium fluoride dihydrate in 40 mL water, add to the suspension, and stir 15 min. 5. Filter off the precipitated tri-n-butyltin hydride and wash the organic retentate (on top of the funnel) with 120 mL water. Set aside the aqueous layer and wash the organic layer two more times with 120 mL water. Combine all of the aqueous layers and wash three times with 60 mL diethyl ether. 6. Dry the combined organic layers from step 5 over sodium sulfate, filter, and evaporate to dryness using a rotary evaporator equipped with a vacuum pump and a cooling trap. 7. Divide the oily residue into two fractions and purify each by column chromatography (APPENDIX 3E) on 350 g of 0.060- to 0.200-nm silica gel in a 5 × 35–cm column. Use a step gradient from 1.5 L of 100% dichloromethane to 1.5 L of 99:1 (v/v) dichloromethane/methanol to elute. Collect fractions in 2 × 18–cm test tubes. See Critical Parameters for additional discussion of column chromatography.
8. Draw a roster of the fraction collector on a TLC plate and apply a drop of each fraction onto the corresponding field of the plate. Spray with anisaldehyde/sulfuric acid spray and dry at 150°C. Combine the product-containing fractions (blue) and remove solvents in vacuo on a rotary evaporator. The resulting product, 1,5-anhydro-2,3,4,6-tetra-O-acetyl-D-glucitol (S.1), should be obtained in a 93% yield (18.82 g, 56.9 mmol). The spectroscopic properties are identical with those previously described (Kocienski and Pant, 1982).
Synthesis of Modified Nucleosides
1.9.3 Current Protocols in Nucleic Acid Chemistry
Supplement 15
Prepare S.2 9. Weigh 30.06 g (90.5 mmol) S.1 into a 1-liter round-bottom flask. Add 400 mL of 0.1 N sodium methoxide (freshly prepared from 0.92 g sodium and 400 mL dry methanol) and stir the reaction 2 hr at room temperature. 10. Neutralize the reaction mixture with ∼2 mL acetic acid (confirm with pH paper) and evaporate the solvent. 11. Coevaporate the residue with 20 mL toluene four times. Add 12.40 g (91.0 mmol) zinc chloride and 46.50 mL (455.0 mmol) benzaldehyde. Close the reaction flask with a rubber stopper and vigorously stir the suspension for two days at room temperature. 12. Pour the reaction mixture into 250 mL ice-water and extract with 100 mL ethyl acetate four times. Dry the combined organic layers over sodium sulfate. 13. Remove excess benzaldehyde on a rotary evaporator in vacuo (bath temperature 70°C) and wash the obtained solid residue with 100 mL n-hexane on a glass funnel. 14. Purify by column chromatography using 700 g silica gel in a 6 × 50–cm column. Elute with a step gradient of 1.5 L each: 1:1 (v/v) n-hexane/dichloromethane 100% dichloromethane 98:2 (v/v) dichloromethane/methanol. Collect fractions in 2 × 18–cm test tubes and monitor by TLC as in step 8. Combine product-containing fractions and remove solvent in vacuo on a rotary evaporator. The resulting product, 1,5-anhydro-4,6-O-benzylidene-D-glucitol (S.2), is obtained in 75% yield (17.1 g, 68.0 mmol). CIMS (iC4H10): m/e 253 (MH+); 1H NMR (DMSO-d6): δ = 3.00-3.90 (m, 7H) and 4.10-4.30 (m, 1H) (H-1′, H-1′′, H-2′, H-3′, H-4′, H-5′, H-6′, H-6′′), 5.03-5.31 (dd, 2H, 2′-OH, 3′-OH), 5.55 (s, 1H, PhCH), 7.20-7.57 (m, 5H, aromatic H); 13 C NMR (DMSO-d6): δ = 68.0 (C-6′), 70.2, 70.4 (C-1′, C-5′), 71.0 (C-2′), 74.4 (C-3′), 81.1 (C-4′), 100.7 (PhCH), 126.3, 127.9, 128.7, 137.8 (arom. C).
Prepare S.3a or S.3b 15. Suspend 8.50 g (33.7 mmol) S.2 and 8.38 g (33.7 mmol) dibutyltinoxide in 250 mL benzene. 16. Reflux the mixture 16 hr with azeotropic removal of water using a Dean-Stark condenser until the volume is reduced to ∼100 mL. Add 150 mL dioxane. 17. For S.3a, add 7.06 g (37.0 mmol) p-toluenesulfonyl chloride and heat the mixture 6 hr at 50°C, until a quantitative conversion to a less polar product (higher Rf value) is demonstrated by TLC. For S.3b, add 4.44 mL (33.7 mmol) p-toluoyl chloride and stir the mixture 5 hr at room temperature. For both, perform TLC using 1:2 (v/v) n-hexane/dichloromethane and visualize the products under a UV lamp. 18. Concentrate the mixture in vacuo using a rotary evaporator, absorb on Delite Celite, and purify by column chromatography using a step gradient from 1:1 (v/v) n-hexane/dichloromethane to 100% dichloromethane. Combine product-containing fractions and evaporate solvent on a rotary evaporator.
Synthesis of 1,5-Anhydrohexitol Building Blocks
1,5-Anhydro-4,6-O-benzylidene-2-O-(p-tolylsulfonyl)-D-glucitol (S.3a) is obtained in 82% yield (11.22 g, 27.6 mmol). EIMS: m/e 406 (MH+); 1H NMR (400 MHz, DMSO-d6): δ = 2.42 (s, 3H, CH3), 3.35-3.42 (m, 2H, H-4′, H-5′), 3.49 (t, 1H, J = 11 Hz, H-1′α), 3.61 (m, 1H, H-6′α), 3.67 (m, 1H, H-3′), 3.87 (dd, J = 5.5 and 11 Hz, 1H, H-1′β), 4.14-4.25 (m, 2H, H-2′, H-6′β), 5.05 (s, 1H, PhCH), 5.12 (d, J = 5.5 Hz, 1H, OH), 7.35-7.50 (m, 7H, H-aromatic), 7.85 (m, 2H, H-aromatic); 13C NMR (90 MHz, DMSO-d6): δ = 21.0 (CH3), 66.9, 67.6 (C-1, C-6), 70.7, 70.8 (C-3, C-5), 79.2, 80.4 (C-2, C-4), 100.7 (PhCH), + aromatic C.
1.9.4 Supplement 15
Current Protocols in Nucleic Acid Chemistry
1,5-Anhydro-4,6-O-benzylidene-2-O-(p-toluoyl)-D-glucitol (S.3b) is obtained in 78% yield (9.73 g, 26.3 mmol). CIMS (iC4H10): m/e 371 (MH+); 1H NMR (DMSO-d6): δ = 2.40, (s, 3H, CH3), 3.19-4.51 (m, 8H, H-1′, H-1′′, H-2′, H-3′, H-4′, H-5′, H-6′, H-6′′), 4.93-5.50 (br, s, 3′-OH), 5.55 (s, 1H, PhCH), 7.05-8.03 (m, 9H, H-aromatic); 13C NMR (DMSO-d6): δ = 21.5 (CH3), 67.2, 68.4 (C-1, C-6),70.9, 71.9, (C-3, C-5), 72.6 (C-2), 80.9( C-4), 101.9 (PhCH), 165.9 (C=O), + aromatic C.
Prepare S.4a or S.4b 19. Dissolve 23.60 g (193.0 mmol) DMAP and either 11.22 g (27.6 mmol) S.3a or 10.21 g (27.6 mmol) S.3b in 400 mL dichloromethane. 20. Cool the reaction mixture to −40°C with a dry ice/isopropanol mixture and add 2.53 mL (33.1 mmol) thiophosgene under vigorous stirring. 21. Allow the mixture to come slowly to room temperature and continue stirring 1 hr at room temperature. 22. Add 6.30 g (38.6 mmol) 2,4-dichlorophenol and continue stirring another 2 hr. Monitor by TLC using 1:5 (v/v) n-hexane/dichloromethane and visualize with a UV lamp. 23. Pour the mixture into 300 mL of 1 M potassium dihydrogenphosphate solution, pH 5, and extract with 300 mL dichloromethane twice. 24. Dry the organic layers over sodium sulfate, filter, and evaporate the solvent. 25. Purify the residue using a 5 × 35–cm flash column and a step gradient from 1.5 L of 2:8 (v/v) n-hexane/dichloromethane to 1.5 L of 100% dichloromethane. Combine product-containing fractions and evaporate solvent. 26. Dissolve the obtained thiocarbonyl compound in 300 mL toluene. 27. Bubble nitrogen gas through the solution for 10 min and then add 7.84 mL (29.1 mmol) tri-n-butyltin hydride and 0.33 g (2.0 mmol) AIBN. 28. Heat the reaction mixture overnight at 80°C. 29. Evaporate the mixture and purify by column chromatography as in step 25. 1,5-Anhydro-4,6-O-benzylidene-3-deoxy-2-O-(p-tolylsulfonyl)-D-ribohexitol (S.4a) is obtained in 64% yield (6.90 g, 17.7 mmol). CIMS (NH3): m/e 391 (MH+); 1H NMR (CDCl3): δ = 1.50-2.10 (m, 2H, H-3′, H-3′′), 2.48 (s, 3H, CH3), 3.06-4.84 (m, 7H, H-1′, H-1′′, H-2′, H-4′, H-5′, H-6′, H-6′′), 5.50 (s, 1H, PhCH), 7.04-7.98 (m, 9H, H aromat.); 13C NMR (CDCl3): δ = 21.4 (CH3), 35.3 (C-3′), 68.7, 69.0 (C-1′, C-6′), 72.9, 73.1 (C-4′, C-5′), 75.7 (C-2′), 101.5 (PhCH) + aromatic C. 1,5-Anhydro-4,6-O-benzylidene-3-deoxy-2-O-(p-toluoyl)-D-ribohexitol (S.4b) is obtained in 75% yield (7.12 g, 20.7 mmol). CIMS (iC4H10): m/e 355 (MH+); 1H NMR (CDCl3): δ = 1.42-2.12 (m, 2H, H-3′, H-3′′), 2.39 (s, 3H, CH3), 3.12-3.92 (m, 4H) and 4.02-4.49 (m, 2H) (H-1′, H-1′′, H-4′, H-5′, H-6′, H-6′′), 4.95-5.43 (m, 1H, H-2′), 5.54 (s, 1H, PhCH), 7.10-8.08 (m, 9H, H aromat.); 13C NMR (CDCl3): δ = 21.5 (CH3), 34.8 (C-3′), 66.9 (C-5′), 69.0, 69.1 (C-1′, C-6′), 73.4 (C-2′), 76.0 (C-4′), 101.5 (PhCH), 165.3 (C=O), + aromatic C.
Synthesis of Modified Nucleosides
1.9.5 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Prepare S.5 30. Weigh 6.79 g (19.7 mmol) S.4b into a 1-liter round-bottom flask. 31. Add 300 mL of 0.1 N sodium methoxide (freshly prepared from 0.70 g sodium and 300 mL dry methanol) and stir the reaction 4 hr at room temperature. 32. Neutralize the reaction mixture with acetic acid (∼6 mL), confirming with pH paper, and evaporate the solvent. 33. Purify by flash chromatography using a 5 × 20–cm column and eluting with 99:1 (v/v) dichloromethane/methanol. Combine product-containing fractions and remove solvent in vacuo on a rotary evaporator. The resulting product of 1,5-anhydro-4,6-O-benzylidene-3-deoxy-D-glucitol (S.5) is obtained in 80% yield (3.72 g, 15.8 mmol). CIMS (iC4H10): m/e 237 (MH+); 1H NMR (DMSO-d6): δ = 1.20-1.66 (m, 1H, H-3′), 2.06-2.42 (m, 1H, H-3′′), 2.99-3.98 (m, 6H) and 4.05-4.30 (m, 1H) (H-1′, H-1′′, H-2′, H-4′, H-5′, H-6′, H-6′′), 5.08 (d, 1H, 2′-OH), 5.57 (s, 1H, PhCH), 7.17-7.67 (m, 5H, H aromatic); 13C NMR (DMSO-d6): δ = 38.3 (C-3′), 65.4 (C-5′), 69.1 (C-6′), 72.3, 73.0 (C-1′, C-2′), 76.3 (C-4′), 101.6 (PhCH), 126.1, 128.2, 129.0, 137.2 (arom. C). BASIC PROTOCOL 2
SYNTHESIS OF 1′,5′-ANHYDRO-2′,3′-DIDEOXY-2′-(N2-ISOBUTYRYLGUANIN-9-YL)-6′-O-MONOMETHOXYTRITYL-D-ARABINOHEXITOL This protocol details the synthesis of the hG 1,5-anhydrohexitol building block S.9 from S.5 (see Fig. 1.9.2 and DeBouvere et al., 1997). Materials 6-Chloro-9H-purine-2-amine 1,5-Anhydro-4,6-O-benzylidene-3-deoxy-D-glucitol (S.5; see Basic Protocol 1) Triphenylphosphine Dioxane (reflux overnight on lithium aluminum hydride and distill) Nitrogen gas Diisopropyl azodicarboxylate (DIAD) n-Hexane Ethyl acetate 10% (v/v) HCl Dichloromethane (store over phosphorous pentoxide and distill before use) Phenolpthalein solution 4 N sodium hydroxide Phosphorous pentoxide Pyridine (reflux overnight over potassium hydroxide distill before use) Bis(trimethylsilyl)acetamide (BSA) Isobutyric anhydride 25% (v/v) ammonia Diethyl ether Dimethylformamide (DMF; remove water by distillation with benzene followed by distillation under vacuum) 4-Monomethoxytrityl chloride (MMTr⋅Cl) Methanol Saturated sodium bicarbonate solution Sodium sulfate Toluene
Synthesis of 1,5-Anhydrohexitol Building Blocks
Dropping funnel Rotary evaporator equipped with a vacuum pump and cooling trap
1.9.6 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Cl
Cl O O Ph
OH +
O
N
N H2 N
DIAD, Ph3P dioxane Ph
N H
N
5
Ph
P
O NH
N
MMTr⋅Cl pyridine DMF
O
N
O
6 O
N
N
HN NH
O MMTrO
N
O N
HN
10% HCl N O
O Ph O
N
N
Ph
N
N
1) BSA, pyridine 2) isobutyric anhydr. 3) NH3, H2O
H2N
HO 9
HO
HO
N
N
O
O
HO
N
HN
8
HO 7
Figure 1.9.2 Preparation of protected hG (S.9). Abbreviations: BSA, bis(trimethylsilyl)acetamide; DIAD, diisopropyl azodicarboxylate; DMF, dimethylformamide; MMTr⋅Cl, 4-monomethoxytrityl chloride; Ph3P, triphenylphosphine.
Oil bath and magnetic stirrer 5 × 35– and 4 × 25–cm chromatography columns Additional reagents and equipment for TLC and column chromatography (see Basic Protocol 1 and Critical Parameters) NOTE: The 1H NMR and 13C NMR spectra were determined with a 200 MHz Varian Gemini spectrometer with tetramethylsilane as internal standard. Abbreviations: s, singlet; d, doublet; dd, double doublet; t, triplet; br s, broad signal; m, multiplet; ddd, double doublet of doublet; dm, double multiplet. Liquid secondary-ion (LSIMS) mass spectra were obtained using a KRATOS Concept 1H mass spectrometer. Prepare S.6 1. Suspend 6.78 g (40.0 mmol) 6-chloro-9H-purine-2-amine, 4.72 g (20.0 mmol) S.5, and 13.12 g (50.0 mmol) triphenylphosphine in 200 mL dioxane. Carry out the reaction under a nitrogen gas atmosphere. 2. Add a solution of 9.84 mL (50.0 mmol) DIAD in 25 mL dioxane via a dropping funnel over a period of 200 min. 3. Stir the mixture overnight at room temperature. Monitor by TLC (see Basic Protocol 1, step 3) using 3:2 (v/v) n-hexane/ethyl acetate. Visualize product using a UV lamp (254 nm). 4. Remove volatiles by evaporation under vacuum using rotary evaporator equipped with a vacuum pump and cooling trap.
Synthesis of Modified Nucleosides
1.9.7 Current Protocols in Nucleic Acid Chemistry
Supplement 14
5. Absorb the crude product on 15.0 g of 0.060- to 0.200-nm silica gel in a 5 × 35–cm chromatography column and elute with a gradient from 1.5 L of 3:2 (v/v) to 1.5 L of 2:3 (v/v) n-hexane/ethyl acetate. Collect fractions in 2 × 18–cm test tubes. 6. Draw a roster of the fraction collector on a TLC plate and apply a drop of each fraction to the corresponding field on the plate. Visualize product-containing fractions using a UV lamp (254 nm). Combine the product-containing fractions and remove solvents in vacuo on a rotary evaporator. The resulting product, 1′,5′-anhydro-4′,6′-O-benzylidene-2′-6-chloro-2[(triphenylphosphoranylidene)amino]-9H-purin-9-yl-2′,3′-dideoxy-D-arabinohexitol (S.6) is obtained in 64% yield (8.31 g, 12.8 mmol). mp: 158°C; LSIMS (thygly): m/z: 648 [M+H]+; 1H NMR (CDCl3): δ = 2.00 (dt ,1H, 3′ax-H, J = 11.6 Hz, J = 4.5 Hz), 2.29 (br, d, 1H, 3′-eq-H, J = 13.0 Hz), 3.57 (m, 2H, 5′-H, 4′-H), 3.76 (t, 1H, 6′ax-H, J = 9.7 Hz), 4.10 (dd, 1H, 1′ax-H, J = 13.2 Hz, J = 2.8 Hz), 4.36 (m, 2H, 1′eq-H, 6′eq-H), 4.73 (br, s, 1H, 2′-H), 5.49 (s, 1H, PhCH), 7.19-7.72 (m, 21H, H aromat.), 8.15 (s, 1H, 8-H); 13C NMR (CDCl3): δ = 32.9 (C-3′), 50.2 (C-2′), 68.9 (C-6′), 69.5 (C-1′), 73.9 (C-4′), 74.5 (C-5′), 101.8 (PhCH), 122.8 (C-5), 125.9 (,2,6-C Ph), 127.5-133.4 (C, CH Ar),137.2 (C-6), 140.2 (C-8), 149.6 (C-4), 158.7 (C-2).
Prepare S.7 7. Suspend 8.20 g (12.6 mmol) S.6 in 160 mL of 10% HCl. Heat the reaction mixture 2 hr at 100°C. 8. Cool to room temperature and wash the yellow-brown solution with 60 mL dichloromethane to remove benzaldehyde and triphenylphosphine. 9. Add a drop of phenolphthalein solution as an indicator and neutralize the aqueous layer with 120 mL of 4 N sodium hydroxide. At pH 7 the product begins to precipitate.
10. Concentrate the suspension in vacuo using a rotary evaporator. 11. Dissolve the obtained white product in 745 mL boiling water and filter hot. 12. Cool to room temperature and incubate the mixture overnight at 4°C. 13. Filter off the obtained crystals and dry over phosphorus pentoxide. The resulting product, 1′,5′-anhydro-2′,3′-dideoxy-2′-(guanin-9-yl)-D-arabinohexitol (S.7) is obtained in 83% yield (2.95 g, 10.5 mmol). mp: >300°C; UV (H2O): λmax ε = 253 nm (9100); LSIMS (thgly): m/z: 282 [M+H]+; 1H NMR (DMSO-d6): δ = 1.80 (m, 1H, 3′ax-H), 2.17 (br, 1H, 3′eq-H), 3.20-3.70 (m, 2H, 5′-H, 4′-H, 6A-H), 3.79 (dd, 1H, 1′ax-H, J = 12.5 Hz, J = 2.2 Hz), 4.05-4.15 (m, 2H, 1′eq-H, 6B-H), 4.52 (s, br, 1H, 2′-H), 4.63 (t, 1H, 6′-OH, J = 6.0 Hz), 4.91 (d, 1H, 4′-OH, J = 5.3 Hz), 6.46 (br, s, 2H, NH2), 7.87 (s, 1H, 8-H); 13C NMR (DMSO-d6): δ = 36.3 (3′-C), 50.2 (2′-C), 61.0 ( 6′-C), 61.2 (4′-C), 68.4 (1′-C), 83.2 (5′-C), 116.3 (C-5), 136.9 (C-8), 151.5 (C-4), 154.1 (C-2), 157.9 (C-6).
Prepare S.8 14. Suspend 3.58 g (12.7 mmol) S.7 in 160 mL pyridine. 15. Add 16.57 mL (63.7 mmol) BSA and reflux 8 hr. 16. Stir the dark-red solution overnight (16 hr) at room temperature. 17. Add 10.00 g (63.7 mmol) isobutyric anhydride and stir 24 hr. 18. Cool the mixture to 0°C and add 20 mL water. Synthesis of 1,5-Anhydrohexitol Building Blocks
19. After 15 min, add 20 mL of 25% ammonia.
1.9.8 Supplement 14
Current Protocols in Nucleic Acid Chemistry
20. Continue stirring 2 hr at room temperature. 21. Evaporate the volatiles under vacuum and add 200 mL water. 22. Stir the suspension 10 min, then filter off the precipitate. Wash once with 50 mL water followed by three washes of 100 mL of 1:1 (v/v) ethyl acetate/diethyl ether. The resulting product, 1′,5′-anhydro-2′,3′-dideoxy-2′-(N2-isobutyrylguanin-9-yl)-D-arabinohexitol (S.8) is obtained in 90% yield (3.74 g, 10.7 mmol). mp: 258°C; LSIMS (thgly): m/z: 352 [M+H]+; 1H NMR (DMSO-d6): δ = 1.13 (d, 6H, 2 × CH3, J = 7 Hz), 1.87 (dt, 1H, 3′ax-H, J = 12.3 Hz, 4.2 Hz), 2.23 (br, d, 1H, 3′eq-H, J = 12.8 Hz), 2.78 (sept, 1H, CH, J = 7 Hz), 3.18 (m, 2H, 5′-H, 4′-H), 3.45-3.75 (m, 2H, 6′-H), 3.85 (dd, 1H, 1′ax-H, J = 12.5 Hz, J = 2.7 Hz), 4.17 (d, 1H, 1′eq-H, J = 12.4 Hz), 4.65 (m, 2H, 2′-H, 6′-OH), 5.01 (br, s, 1H, 4′-OH), 8.15 (s, 1H, 8-H), 10.2 (br, s, 1H, NH); 13C NMR (DMSO-d6): δ = 19.0 (2 × CH3), 34.8 (C-3′), 36.2 (CH), 50.4 (C-2′), 60.6 (C-6′, C-4′), 68.0 (C-1′), 83.1 (C-5′), 119.7 (C-5), 138.6 (C-8), 148.0 (C-2), 148.7 (C-4), 155.1 (C-6), 180.2 (HNC=O).
Prepare S.9 23. Suspend 4.03 g (11.5 mmol) S.8 in a mixture of 60 mL DMF and 60 mL pyridine. 24. Heat the suspension to 120°C until a clear red-brown solution is obtained. 25. Cool to room temperature and add 4.6 g (14.92 mmol, 1.3 eq) MMTr⋅Cl. 26. Stir the reaction overnight at room temperature. 27. Monitor the reaction by TLC using 94:6 (v/v) dichloromethane/methanol and visualize the product using a UV lamp (the product has a higher Rf value than the starting material). 28. Quench the reaction with 200 mL saturated sodium bicarbonate solution. 29. Extract with 100 mL dichloromethane four times. 30. Dry the organic layer over sodium sulfate. 31. Remove the solvent and coevaporate with 10 mL toluene three times. 32. Purify by flash chromatography on a 4 × 25–cm column using a step gradient from 500 mL of 100% dichloromethane to 99:1 (1 L), 98:2 (1 L), and 97:3 (v/v) dichloromethane/methanol. Combine product-containing fractions and evaporate solvents in vacuo on a rotary evaporator. The resulting product, 1′,5′-anhydro-2′,3′-dideoxy-2′-(N2-isobutyrylguanin-9-yl)-6′-Omonomethoxytrityl-D-arabinohexitol (S.9) is obtained in 93% yield (6.65 g, 10.7 mmol). mp: 165°C; LSIMS (thgly): m/z: 646 [M+Na]+; 1H NMR (CDCl3): δ = 1.19 (d, 6H, 2 x CH3, J = 6.8 Hz), 1.80 (t, 1H, 3′ax-H), J = 12.6 Hz), 2.20 (s, 1H, 4′-OH), 2.32 (br, d, 1H, 3′eq-H, J = 12.1 Hz), 2.70 (sept, 1H, CH, J = 6.9 Hz), 3.35-3.50 (m, 4H, 5′-H, 4′-H, 6A-H, 6B-H), 3.75 (m, 4H, 1′ax-H, OCH3), 4.20 (d, 1H, 1′eq-H, J = 13.4 Hz), 4.52 (br, s, 1H, 2′-H), 6.80 (d, 2H, aromatic H), 7.10-7.50 (m, 12H, aromatic H), 8.10 (s, 1H, 8-H), 9.66 (br, s, 1H, NH); 13C NMR (CDCl3): δ = 18.8 (CH3), 18.9 (CH3), 35.8 (3′-C), 36.0 (CH), 50.7 (2′-C), 55.1 (OCH3), 63.3 (4′-C), 63.9 (6′-C), 68.5 (1′-C), 81.1 (5′-C), 86.7 (O-C-Tr), 113.1 (m′-C, 2C), 120.0 (C-5), 126.9 (p-C, 2C), 127.8 (o-C, 4C), 128.3 (m-C, 4C), 130.2 (o′-C, 2C), 135.2 (i′C), 138.6 (C-8), 144.1 (iC, 2C), 147.8 (C-2), 148.8 (C-4), 156.0 (C-6), 158.5 (p’C), 180.0 (HNC=O).
Synthesis of Modified Nucleosides
1.9.9 Current Protocols in Nucleic Acid Chemistry
Supplement 14
NHBz
NH2 N
N adenine, LiH, 12-crown-4 DMF
O OTs O Ph
O
O Ph
4a
N
N
O
N
N BzCl pyridine
N
O Ph
O
N
O O
10
11
80% HOAc
NHBz
NHBz N
N N
N
N
MMTr⋅Cl pyridine
N
N
N
O
O HO
MMTrO
HO
HO 13
12
Figure 1.9.3 Preparation of protected hA (S.13). Abbreviations: BzCl, benzoyl chloride; DMF, dimethylformamide; HOAc, acetic acid; MMTr⋅Cl, monomethoxytrityl chloride.
BASIC PROTOCOL 3
SYNTHESIS OF 1′,5′-ANHYDRO-6′-MONOMETHOXYTRITYL-2′,3′DIDEOXY-2′-(N6-BENZOYLADENIN-9-YL)-D-ARABINOHEXITOL This protocol details the synthesis of the hA 1,5-anhydrohexitol building block S.13 from S.4a (see Fig. 1.9.3 and DeBouvere et al., 1997).
Synthesis of 1,5-Anhydrohexitol Building Blocks
Materials Adenine Lithium hydride 12-Crown-4 Dimethylformamide (DMF; remove water by distillation with benzene followed by distillation under vacuum) Nitrogen gas 1,5-Anhydro-4,6-O-benzylidene-3-deoxy-2-O-(p-tolylsulfonyl)-D-ribohexitol (S.4a; see Basic Protocol 1) n-Hexane Ethyl acetate Dichloromethane Saturated sodium bicarbonate solution Sodium sulfate Methanol Pyridine (reflux over potassium hydroxide overnight and distill) Benzoyl chloride 25% (v/v) ammonia
1.9.10 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Toluene 80% (v/v) acetic acid Diethyl ether: reflux overnight on sodium (Na, FeCl2, Et2O) and distill Pyridine (reflux over potassium hydroxide overnight and distill) 4-Monomethoxytrityl chloride (MMTr⋅Cl) Oil bath and magnetic stirrer Rotary evaporator equipped with a vacuum pump and cooling trap 3 × 30–, 5 × 40–, and 4 × 30–cm chromatography columns Additional reagents and equipment for TLC and column chromatography (see Basic Protocol 1 and Critical Parameters) NOTE: The 1H NMR and 13C NMR spectra were determined with a 200 MHz Varian Gemini spectrometer with tetramethylsilane as internal standard. Abbreviations: s, singlet; d, doublet; dd, double doublet; t, triplet; br s, broad signal; m, multiplet; ddd, double doublet of doublet; dm, double multiplet. Liquid secondary-ion (LSIMS) mass spectra were obtained using a KRATOS Concept 1H mass spectrometer. Prepare S.10 1. Suspend 1.35 g (10.0 mmol) adenine, 0.08 g (9.6 mmol) lithium hydride, and 0.32 mL of 12-crown-4 (2.0 mmol) in 60 mL DMF. Carry out the reaction under a nitrogen gas atmosphere. 2. Heat the reaction mixture 1 hr at 110°C. 3. Add a solution of 1.95 g (5.0 mmol) of S.4a in 13 mL DMF with stirring. 4. Continue stirring at 110°C for 8 hr. 5. Test the reaction by TLC (see Basic Protocol 1, step 3) using 8:2 (v/v) hexane/ethyl acetate as solvent. 6. Cool the reaction mixture to room temperature and quench with 0.09 mL (5.0 mmol) water. 7. Concentrate the mixture under reduced pressure using a rotary evaporator with a vacuum pump. 8. Dissolve the residue in 100 mL dichloromethane and wash with 200 mL saturated sodium bicarbonate followed by two washes with 100 mL water. 9. Dry over sodium sulfate, filter, concentrate, and purify the residue by flash chromatography on a 3 × 30–cm column using a step gradient of 99:1 (1 L), 98:2 (1 L), 97:3 (1 L), and 96:4 (v/v) dichloromethane/methanol. Combine product-containing fractions and evaporate solvent in vacuo on a rotary evaporator. The resulting product, 2′-(adenin-9-yl)-1′,5′-anhydro-4′,6′-O-benzylidene-2′,3′-dideoxyD-arabinohexitol (S.10) is obtained in 82% yield (1.45 g, 4.1 mmol). mp: 227°C; UV (MeOH): λmax (ε) = 262 nm (11300); EIMS: m/z: 353 [M]+; 1H NMR (DMSO-d6): δ = 2.17 (dt, 1H, H- 3′ax, J = 12 Hz, J = 1.3 Hz, J = 4 Hz), 2.46 (m, 1H, H-3′eq), 3.53 (ddd, 1H, H-5′, J = 9 Hz, J = 10 Hz, J = 5 Hz), 3.73 (ddd, 1H, H-4′, J = 12.9 Hz, J = 4 Hz), 3.80 (t, 1H, H-6′ax, J = 10 Hz), 4.10 (dd, 1H, H-1′ax, J = 13 Hz, J = 2.5 Hz), 4.22 (dd, 1H, H-6′eq, J = 5 Hz), 4.44 (d, 1H, H-1′eq, J = 13 Hz), 4.90 (br, s, 1H, H-2′), 5.62 (s, 1H, PhCH), 7.30-7.40 (m, 7H, aromatic H, NH2), 8.18 (s, 1H, H-2), 8.27 (s, 1H, H-8); 13C NMR (DMSO-d6): δ = 32.2 (C-3′), 50.5 (C-2′), 68.1, 68.9 (C-1′, C-6′), 73.4, 73.8 (C-4′, C-5′), 100.9 (PhCH), 118.6 (C-5), 126.2 (2,6-C), 128.1 (3,5-C), 128.9 (4-C), 137.8 (1-C), 139.3 (C-8), 149.5 (C-4), 152.6 (C-2), 156.2 (C-6).
Synthesis of Modified Nucleosides
1.9.11 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Prepare S.11 10. Dissolve 5.90 g (16.7 mmol) S.10 in 100 mL pyridine and coevaporate three times. 11. Add 160 mL pyridine and then cool to 0°C. 12. Add 9.7 mL (83.57 mmol) benzoyl chloride. 13. Allow the mixture to come to room temperature and continue stirring overnight. 14. Cool the orange-brown solution in an ice-bath and add 18 mL water. 15. After 5 min add 35 mL of 25% ammonia and continue stirring 2 hr at room temperature. 16. Remove the volatiles under reduced pressure and coevaporate three times with 20 mL toluene. 17. Dilute the resulting solid with 250 mL dichloromethane and wash with 200 mL saturated sodium bicarbonate solution. 18. Dry the organic layer over sodium sulfate, remove the solvent, and purify by column chromatography using a 5 × 40–cm silica gel column and a step gradient from 1.5 L of 2:8 (v/v) n-hexane/ethyl acetate to 1 L of 1:9 n-hexane/ethyl acetate, to 1 L of 100% ethyl acetate. Combine product-containing fractions and evaporate solvent. The resulting product, 1′,5′-anhydro-2′-(N6-benzoyladenin-9-yl)-4′,6′-O-benzylidene2′,3′-dideoxy-D-arabinohexitol (S.11) is obtained in 94% yield (7.20 g, 15.8 mmol). mp: 150°C; LSIMS (thygly): m/z: 458 [M+H]+; 1H NMR (CDCl3): δ = 2.25 (m, 1H, 3′ax-H, 2.66 (br, d, 1H, 3′eq-H, J = 12 Hz), 3.65 (m, 2H, 5′-H, 4′-H), 3.78 (t, 1H, 6′ax-H, J = 9.8 Hz), 4.16 (dd, 1H, 1′ax-H, J = 13.5 Hz, J = 2.5 Hz), 4.38 (dd, 1H, 6′eq-H, J = 10.2 Hz, J = 3.6 Hz), 4.48 (br, d, 1H, 1′eq-H, J = 13.3 Hz), 5.07 (br, s, 1H, 2′-H, 5.49 (s, 1H, PhCH), 7.50 (m, 8H, aromatic H), 8.04 (d, 2H, aromatic H, J = 6.7 Hz), 8.55 (s, 1H, 8-H), 8.77 (s, 1H, 2-H), 9.30 (s, 1H, NH); 13C NMR (CDCl3): δ = 33.1 (C-3′), 51.0 (C-2′), 68.8 (C-6′), 69.4 (C-1′), 73.8 (C-4′), 74.5 (C-5′), 102.0 (PhCH), 122.8 (C-5), 125.9 (2,6-C Ph), 127.9 (3,5C Ph), 128.2 (3,5-C Bz), 128.8 (2,6-C Bz), 129.1 (4-C Ph), 132.7 (4-C Bz), 133.5 (1-C Bz), 136.9 (1-C Ph), 142.0 (C-8), 149.6 (C-4), 152.0 (C-2), 152.5 (C-6), 164.7 (HNC=O).
Prepare S.12 19. Dissolve 8.06 g (17.6 mmol) S.11 in 450 mL of 80% (v/v) acetic acid. 20. Heat the reaction mixture 6 hr at 60°C. 21. Evaporate the solvent under reduced pressure using a rotary evaporator with a vacuum pump and coevaporate with 25 mL toluene three times. 22. Dissolve the residue in a minimal volume of 1:1 (v/v) dichloromethane/methanol. 23. Slowly add 500 mL diethyl ether while stirring. 24. Filter off the precipitate, wash with diethyl ether, and dry over phosphorous pentoxide.
Synthesis of 1,5-Anhydrohexitol Building Blocks
The resulting product, 1′,5′-anhydro-2′-(N6-benzoyladenin-9-yl)-2′,3′-dideoxy-D-arabinohexitol (S.12) is obtained in 82% yield (5.35 g, 14.5 mmol). mp: 220°C; LSIMS (thygly): m/z: 370 [M+H]+; 1H NMR (DMSO-d6): δ = 1.97 (dt, 1H, 3′ax-H, J = 13 Hz, J = 3.9 Hz), 2.36 (br, d, 1H, 3′eq-H, J = 13.2 Hz), 3.23 (m, 1H, 5′-H), 3.50-3.80 (m, 3H, 6′-H, 4′H), 3.93 (dd, 1H, 1′ax-H, J = 12.7 Hz, J = 2.1 Hz), 4.30 (br, d, 1H, 1′eq-H, J = 12.5 Hz), 4.7 (t, 1H, 6′-OH, J = 6.2 Hz), 4.98 (br, s, 1H, 2′-H), 5.00 (d, 1H, 4′-OH, J = 5.5 Hz), 7.58 (m, 3H, aromatic H), 8.05 (d, 2H, aromatic H, J = 6.9 Hz), 8.62 (s, 1H, 8-H), 8.75 (s, 1H, 2-H), 11.18 (s, 1H, NH); 13C NMR (DMSO-d6): δ = 35.8 (C-3′), 50.7 (C-2′), 60.5 (C-6′, C-4′), 67.9 (C-1′), 83.1 (C-5′)125.1 (C-5), 128.6 (2,3,5,6-C Bz), 132.5 (4-C Bz), 133.5 (1-C Bz), 143.5 (C-8), 150.2 (C-4), 151.5 (C-2), 152.4 (C-6), 165.7 (HNC=O).
1.9.12 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Prepare S.13 25. Dissolve 5.35 g (14.5 mmol) S.12 in 100 mL pyridine and coevaporate three times. 26. Add 340 mL pyridine and dissolve. 27. Add 7.85 g (24.6 mmol) MMTr⋅Cl. 28. Stir the reaction 2 days at room temperature. 29. Monitor by TLC using 94:6 (v/v) dichloromethane/methanol (the product has a higher Rf value than the starting material). 30. Quench the reaction with 300 mL saturated sodium bicarbonate solution. 31. Extract with 400 mL dichloromethane twice. 32. Dry the organic layer over sodium sulfate, evaporate the solvent, and then coevaporate with 25 mL toluene three times. 33. Purify the residue by flash chromatography on a 4 × 30–cm column using a step gradient from 1.5 L of 100% dichloromethane to 99:1 (1 L), 98:2 (1 L), and 97:3 (v/v) dichloromethane/methanol. Combine product-containing fractions and evaporate the solvent. The resulting product, 1′,5′-anhydro-6′-monomethoxytrityl-2′,3′-dideoxy-2′-(N6-benzoyladenin-9-yl)-D-arabinohexitol (S.13) is obtained in 84% yield (7.79 g, 12.2 mmol). mp: 125°C; LSIMS (thygly/NaOAc): m/z: 664 [M+Na]+; 1H NMR (CDCl3): δ = 1.98 (dt, 1H, 3′ax-H, J = 11.6 Hz, J = 4.4 Hz), 2.54 (br, d, 1H, 3′eq-H, J = 12.6 Hz), 2.88 (br, s, 1H, 4′-OH), 3.47 (m, 3H, 5′-H, 4′-H, 6A-H), 3.77 (br, s, 4H, 6B-H, OCH3), 3.96 (dd, 1H, 1′ax-H, J = 12.9 Hz, J = 2.5 Hz), 4.34 (br, d, 1H, 1′eq-H, J = 12.8 Hz), 4.98 (br, s, 1H, 2′-H), 6.84 (d, 2H, aromatic H, J = 8.9 Hz), 7.38 (m, 15H, aromatic H), 8.02 (d, 2H, aromatic H, J = 8.3 Hz), 8.54 (s, 1H, 8-H), 8.77 (s, 1H, 2-H), 9.30 (br, s, 1H, NH); 13C NMR (CDCl3): δ = 35.7 (C-3′), 50.6 (C-2′), 55.2 (OCH3), 64.3 (C-4′, C-6′), 69.0 (C-1′), 80.6 (C-5′), 87.2 (O-C-MMTr), 113.1 (3′5′C MMTr), 120.0 (C-5), 127.1 (4C MMTr 2x), 127.9 (3,5C Bz), 128.0 (2,6C MMTr, 2×), 128.2 (3,5C MMTr, 2x), 128.8 (2,6C Bz), 130.2 (2′6′C MMTr), 132.7 (4C Bz), 133.7 (1C Bz), 134.9 (1′C MMTr), 142.4 (C-8), 143.8 (1C MMTr, 2×), 149.5 (C-4), 152.5 (C-2, C-6), 158.7 (HNC=O).
SYNTHESIS OF 1′,5′-ANHYDRO-6′-O-MONOMETHOXYTRITYL-2′,3′DIDEOXY-2′-(THYMIN-1-YL)-D-ARABINOHEXITOL
BASIC PROTOCOL 4
This protocol details the synthesis of the hT 1,5-anhydrohexitol building block S.16 from S.5 (see Fig. 1.9.4 and DeBouvere et al., 1997). Materials N3-Benzoylthymine 1,5-Anhydro-4,6-O-benzylidene-3-deoxy-D-glucitol (S.5; see Basic Protocol 1) Triphenylphosphine Tetrahydrofuran (THF; reflux overnight on lithium aluminum hydride and distill) Nitrogen gas Diethyl azodicarboxylate (DEAD) n-Hexane Ethyl acetate Saturated ammonia in methanol Dichloromethane Toluene 80% (v/v) acetic acid Methanol
Synthesis of Modified Nucleosides
1.9.13 Current Protocols in Nucleic Acid Chemistry
Supplement 14
O Bz N
Bz
OH O
Ph
O
O
O +
O
DEAD, Ph3P THF
N
O O
5
N H
N
O O
Ph
14
1) MeOH, NH3 2) 80% HOAc
O
O HN
HN O
MMTr⋅Cl pyridine
O
N
O MMTrO
HO 16
N
O HO
HO 15
Figure 1.9.4 Preparation of protected hT (S.16). Abbreviations: DEAD, diethyl azodicarboxylate; THF, tetrahydrofuran; Ph3P, triphenylphosphine; HOAc, acetic acid; MMTr⋅Cl, monomethoxytrityl chloride.
Pyridine (reflux over potassium hydroxide overnight and distill) Monomethoxytrityl chloride (MMTr⋅Cl) Saturated sodium bicarbonate solution Sodium sulfate Oil bath and magnetic stirrer Dropping funnel Rotary evaporator equipped with a vacuum pump and cooling trap 3 × 35– and 4 × 35–cm chromatography columns Additional reagents and equipment for TLC and column chromatography (see Basic Protocol 1 and Critical Parameters) NOTE: The 1H NMR and 13C NMR spectra were determined with a 200-MHz Varian Gemini spectrometer with tetramethylsilane as internal standard. Liquid secondary-ion (LSIMS) mass spectra were obtained using a KRATOS Concept 1H mass spectrometer. Abbreviations: s, singlet; d, doublet; dd, double doublet; t, triplet; br s, broad signal; m, multiplet; ddd, double doublet of doublet; dm, double multiplet.
Synthesis of 1,5-Anhydrohexitol Building Blocks
1.9.14 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Prepare S.14 1. Dissolve 2.40 g (10.5 mmol) N3-benzoylthymine, 1.23 g (5.2 mmol) S.5, and 3.43 g (13.1 mmol) triphenylphosphine in 100 mL THF. Carry out the reaction under a nitrogen atmosphere. 2. Add a solution of 2.06 mL (13.1 mmol) DEAD in 15 mL THF via a dropping funnel over a period of 60 min. 3. Stir the mixture at room temperature overnight. 4. Remove the volatiles under vacuum using a rotary evaporator with a vacuum pump. 5. Absorb the crude product on 20 g of 0.060- to 0.200-nm silica gel and purify by flash chromatography in a 3 × 35–cm column using a step gradient of 1 L each of 8:2, 7:3, and 6:4 (v/v) n-hexane/ethyl acetate. Combine product-containing fractions and evaporate solvent in vacuo on a rotary evaporator. The resulting product, 1′,5′-anhydro-2′-(N3-benzoylthymin-1-yl)-4′,6′-O-benzylidene2′,3′-dideoxy-D-arabinohexitol (S.14) is obtained in 80% yield (1.88 g, 4.2 mmol). mp: 200°C; LSIMS (thygly): m/z: 449 [M+H]+; 1H NMR (CDCl3): δ = 2.02 (s, 3H, CH3), 2.07 (m, 1H, 3′ax-H), 2.47 (d, br, 1H, 3′eq-H, J = 13.9 Hz), 3.53 (dt, 1H, 5′-H, J = 9.6 Hz, J = 4.7 Hz), 3.8 (m, 1H, 4′-H), 3.80 (t, 1H, 6′ax-H, J = 10.2 Hz), 4.02 (dd, 1H, 1′ax-H, J = 13.7 Hz, J = 3.5 Hz), 4.28 (d, br, 1H, 1′eq-H, J = 13.9 Hz), 4.37 (dd, 1H, 6′eq-H, J = 10.5 Hz, J = 4.7 Hz), 4.73 (s, br, 1H, 2′-H), 5.64 (s, 1H, PhCH), 7.30-7.90 (m, 8H, aromatic H), 7.95 (s, + d, 3H, 6-H + aromatic 2H); 13C NMR (CDCl3): δ = 32.9 (C-3′), 51.7 (C-2′), 68.8 (C-6′, C-1′), 73.6 (C-4′), 74.2 (C-5′), 102.0 (PhCH), 110.7 (C-5), 126.0 (2,6C Ph), 128.3 (4C Ph), 129.1 (2,3,56C Bz), 130.4 (3,5 C Ph), 131.5 (1C Bz), 135.0 (4C Bz), 137.0 (1C Ph), 137.7 (C-6), 149.7 (C-2), 162.6 (C-4), 168.9 (HNC = O).
Prepare S.15 6. Dissolve 1.83 g (4.1 mmol) S.14 in 100 mL saturated ammonia in methanol. 7. Once a precipitate has formed, add 50 mL dichloromethane and continue stirring 90 min at room temperature. 8. Check the reaction by TLC (see Basic Protocol 1, step 3) using 1:1 (v/v) n-hexane/ethyl acetate (the starting material has the higher Rf value). 9. Evaporate the volatiles and coevaporate three times with 15 mL toluene. 10. Dissolve the crude product (1.8 g) in 75 mL of 80% (v/v) acetic acid. 11. Heat the reaction mixture 3 hr at 60°C. 12. Evaporate the volatiles on a rotary evaporator and coevaporate three times with 15 mL toluene. 13. Purify the residue by column chromatography using a 3 × 25–cm column and a gradient from 1 L of 95:5 to 1 L of 93:7 (v/v) dichloromethane/methanol. Combine product-containing fractions and evaporate the solvent. The resulting product, 1′,5′-anhydro-2′,3′-dideoxy-2′-(thymin-1-yl)-D-arabinohexitol (S.15) is obtained in 82% yield (0.86 g, 3.4 mmol). mp: 170°C; UV (MeOH): λmax (ε) = 272 nm (9500); LSIMS (thygly): m/z: 357 [M+H]+; 1H NMR (DMSO-d6): δ = 1.75 m, 1H, 3′ax-H), 1.76 (s, 3H, CH3), 2.08 (d, br, 1H, 3′eq-H, J = 13.8 Hz), 3.13 (m, 1H, 5′-H), 3.35 (m, 1H, 4′-H), 3.60 (m, 2H, 6′-H), 3.73 (dd, 1H, 1′ax-H, J = 12.9 Hz, J = 3.4 Hz), 3.99 (d,br, 1H, 1′eq-H, J = 12.8 Hz), 4.50 (s br,, 1H, 2′-H), 4.65 (s, br, 1H, 6′-OH), 4.91 (s, br, 1H, 4′-OH), 7.88 (s, 1H, 6-H), 11.25 (s, 1H, 3-H); 13C NMR (DMSO-d6): δ = 12.5 (CH3), 35.2 (C-3′), 50.1 (C-2′), 60.3 (C′-6′), 60.7 (C-4′), 67.0 (C-1′), 82.4 (C-5′), 108.4 (C-5), 139.0 (C-6), 151.0 (C-2), 163.9 (C-4).
Synthesis of Modified Nucleosides
1.9.15 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Prepare S.16 14. Dissolve 2.77 g (10.8 mmol) S.15 in 40 mL pyridine and coevaporate three times. 15. Dissolve in 100 mL pyridine. 16. Add 5.85 g (18.4 mmol) MMTr⋅Cl. 17. Stir the reaction at room temperature overnight. 18. Check by TLC using 9:1 (v/v) dichloromethane/methanol as the solvent (the reaction mixture has the higher Rf value). 19. Quench the reaction with 200 mL saturated sodium bicarbonate solution. 20. Extract twice with 200 mL dichloromethane. 21. Dry the organic layer over sodium sulfate, evaporate the solvent, and coevaporate with 15 mL toluene three times. 22. Purify the residue by column chromatography on a 4 × 35–cm column using a step gradient from 500 mL of 100% dichloromethane to 1 L each of 99:1, 98:2, and 95:5 (v/v) dichloromethane/methanol. Combine product-containing fractions and evaporate solvents. The resulting product, 1′,5′-anhydro-6′-O-monomethoxytrityl-2′,3′-dideoxy-2′-(thymin-1yl)-D-arabinohexitol (S.16) is obtained in 86% yield (4.90 g, 9.3 mmol). mp: 125°C; LSIMS (thygly / NaOAc): m/z: 551 [M+Na]+; 1H NMR (CDCl3): δ = 1.85 (m, 1H, 3′ax-H), 1.86 (s, 3H, CH3), 2.28 (d, 1H, 4′-OH, J = 3.8 Hz), 2.38 (d, br, 1H, 3′eq-H, J = 14 Hz), 3.31 (m, 1H, 5′-H), 3.45 (m, 2H, 4′H, 6′ax-H), 3.78 (s, 3H, OCH3), 3.81 (dd, 1H, 1′ax-H, J = 13Hz, J = 3.4 Hz), 3.98 (m, 1H, 6′eq-H), 4.18 (d, br, 1H, 1′eq-H, J = 13.2 Hz), 4.67 (s, br, 1H, 2′-H), 6.83 (d, 2H, aromatic H, J = 8.7 Hz), 7.20-7.50 (m, 12H, aromatic H), 8.00 (s, 1H, 6-H), 9.20 (s, br, 1H, NH); 13C NMR (CDCl3): δ = 12.8 (CH3), 35.5 (C-3′), 51.0 (C-2′), 55.2 (OCH3), 63.1 (C-4′), 63.3 (C-6′), 68.5 (C-1′), 80.9 (C-5′), 86.8 (OC MMTr), 110.4 (C-5), 113.2 (3′5′C MMTr), 127.1 (4 MMTr, 2×), 128.0 (2,6C MMTr, 2×), 128.2 (3,5C MMTr, 2×), 130.2 (2′6′C MMtr), 135.0 (1′C MMTr), 138.6 (C-6), 143.9 (1C MMTr, 2×), 151.0 (C-2), 158.7 (4′C MMTr), 163.8 (C-4). BASIC PROTOCOL 5
SYNTHESIS OF 1′,5′-ANHYDRO-2′-(N4-BENZOYLCYTOSIN-1-YL)-2′,3′DIDEOXY-6′-MONOMETHYOXYTRITYL-D-ARABINOHEXITOL This protocol details the synthesis of the hC 1,5-anhydrohexitol building block S.20 from S.5 (see Fig. 1.9.5 and DeBouvere et al., 1997).
Synthesis of 1,5-Anhydrohexitol Building Blocks
Materials N4-Benzoyluracil 1,5-Anhydro-4,6-O-benzylidene-3-deoxy-D-glucitol (S.5; see Basic Protocol 1) Triphenylphosphine Dioxane (reflux overnight on lithium aluminum hydride and distill) Nitrogen gas Diethyl azodicarboxylate (DEAD) Saturated ammonia in methanol Dichloromethane Methanol Toluene Triazole Pyridine (reflux overnight over potassium hydroxide and distill) Phosphoroxy chloride 25% ammonia
1.9.16 Supplement 14
Current Protocols in Nucleic Acid Chemistry
O
O O
Ph
N
+ O
5
O
1. DEAD, Ph3P THF
Bz
OH O
HN
O
2. MeOH/NH3
N H
N
O O
Ph
O
17
1. triazole/POCl3 2. NH4OH NHBz N O O MMTrO
N
MMTr⋅Cl pyridine N
20
O O
HO
HO
NH2
NHBz N
1. BzCl, NH3 2. TFA/CH2Cl2 N
HO
O O
O
Ph
19
N
O 18
Figure 1.9.5 Preparation of protected hC (S.20). Abbreviations: BzCl, benzoylchloride; DEAD, diethyl azodicarboxylate; MMTr⋅Cl, 4-monomethoxy chloride; POCl3, phosphoroxy chloride; TFA, trifluoroacetic acid.
Sodium sulfate Benzoyl chloride Saturated sodium bicarbonate solution Trifluoroacetic acid (TFA) Diethyl ether: reflux overnight on sodium (Na, FeCl2, Et2O) and distill Monomethoxytrityl chloride (MMTr⋅Cl) Dropping funnel Rotary evaporator equipped with a vacuum pump and cooling trap 4 × 30– and 3 × 35–cm chromatography columns Oil bath and magnetic stirrer Drying tube Additional reagents and equipment for TLC and column chromatography (see Basic Protocol 1 and Critical Parameters) NOTE: The 1H NMR and 13C NMR spectra were determined with a 200 MHz Varian Gemini spectrometer with tetramethylsilane as an internal standard. Abbreviations: s, singlet; d, doublet; dd, double doublet; t, triplet; br s, broad signal; m, multiplet; ddd, double doublet of doublet; dm, double multiplet. Liquid secondary-ion (LSIMS) mass spectra were obtained using a KRATOS Concept 1H mass spectrometer.
Synthesis of Modified Nucleosides
1.9.17 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Prepare S.17 1. Suspend 6.48 g (30.0 mmol) N3-benzoyluracil, 4.72 g (20 mmol) S.5, and 7.87 g (30.0 mmol) triphenylphosphine in 200 mL dioxane. Carry out the reaction under a nitrogen atmosphere. 2. Add a solution of 5.90 mL (30.0 mmol) DEAD in 30 mL dioxane via a dropping funnel over a period of 200 min. 3. Stir the mixture overnight at room temperature. 4. Filter off the precipitate formed during the reaction and wash the precipitate with 50 mL dioxane. 5. Remove the volatiles of the filtrate by evaporation under vacuum in a rotary evaporator with a vacuum pump. 6. Dissolve the obtained residue in 100 mL saturated ammonia in methanol. 7. Stir the mixture 90 min at room temperature. 8. Check the reaction by TLC (see Basic Protocol 1, step 3) using 97.5:2.5 (v/v) dichloromethane/methanol. 9. Remove the volatiles and coevaporate with 20 mL toluene three times. 10. Purify the residue by column chromatography on a 4 × 30–cm column using a gradient from 1 L of 100% dichloromethane to 1 L of 97:3 (v/v) dichloromethane/methanol. Combine product-containing fractions and evaporate solvents in vacuo on a rotary evaporator. The resulting product, 1′,5′-anhydro-4′,6′-O-benzylidene-2′,3′-dideoxy-2′-(uracil-1-yl)-Darabinohexitol (S.17) is obtained in 67% yield (4.24 g, 12.8 mmol). mp: 200°C; LSIMS (thygly): m/z: 331 [M+H]+; 1H NMR (CDCl3): δ = 2.12 (dt, 1H, 3′ax-H, J = 11.9 Hz, J = 4.8 Hz), 2.52 (d ,br, 1H, 3′eq-H, J = 12.9 Hz), 3.48-3.74 (m, 2H, 5′-H, 4′-H), 3.79 (t, 1H, 6′ax-H, J = 10.2 Hz), 4.06 (dd, 1H, 1′ax-H, J = 13.7 Hz, J = 3.0 Hz), 4.37 (d, 1H, 1′eq-H, J = 13.8 Hz), 4.36 (dd, 1H, 6′eq-H, J = 10 Hz, J = 4.7 Hz), 4.78 (s, br, 1H, 2′-H), 5.59 (s, 1H, PhCH), 5.80 (d, 1H, J = 8.0 Hz,5-H), 7.34-7.51 (m, 5H, Ph H), 8.09 (d, 1H, 6-H, J = 8.0 Hz), 9.30 (s, br, 1H, NH); 13C NMR (CDCl3): δ = 32.8 (C-3′), 51.5 (C-2′), 68.8 (C-6′), 68.8 (C-1′), 73.6 (C-4′), 74.3 (C-5′), 102.0, 102.2 (PhCH, C-5), 126.0 (2,6-C Ph), 128.4 (3,5-C Ph), 129.3 (4-C Ph), 137.1 (1-C Ph), 142.4 (C-6), 150.9 (C-2), 163.2 (C-4).
Prepare S.18 11. Dissolve 6.23 g (96.0 mmol) triazole in 120 mL pyridine. 12. Add 2.61 mL (28.0 mmol) phosphoroxy chloride and continue stirring at room temperature for 25 min. 13. Add 2.64 g (8 mmol) S.17. The solution should turn yellow.
14. Continue stirring 45 min at room temperature. 15. Remove the volatiles in vacuo on a rotary evaporator and coevaporate with 15 mL toluene three times. 16. Dissolve the brown residue in 80 mL dioxane and add 40 mL of 25% ammonia. 17. Continue stirring another 30 min. Synthesis of 1,5-Anhydrohexitol Building Blocks
18. Evaporate to dryness, dissolve in 100 mL dichloromethane, and wash with 200 mL water.
1.9.18 Supplement 14
Current Protocols in Nucleic Acid Chemistry
19. Dry the organic layer over sodium sulfate and remove the solvent. 20. Purify the crude product by column chromatography using 95:5 (v/v) dichloromethane/methanol as a solvent. Combine product-containing fractions and evaporate solvent. The resulting product, 1′,5′-anhydro-4′,6′-O-benzylidene-2′,3′-dideoxy-2′-(cytosin-1-yl)D-arabinohexitol (S.18) is obtained in 71% yield (1.87 g, 5.7 mmol). mp: 200°C; LSIMS (thygly): m/z: 330 [M+H]+; 1H NMR (CDCl3): δ = 2.05 (dt, 1H, 3′ax-H, J = 11.9 Hz, J = 4.8 Hz), 2.58 (d, br 1H, 3′eq-H, J = 12.9 Hz), 3.43-3.69 (m, 2H, 5′-H, 4′-H), 3.74 (t, 1H, 6′ax-H, J = 10.2 Hz), 4.00 (dd, 1H, 1′ax-H, J = 13.7 Hz, J = 3.0 Hz), 4.20 (d, 1H, 1′eq-H, J = 13.8 Hz), 4.30 (dd, 1H, 6′eq-H, J = 10 Hz, J = 4.7 Hz), 4.82 (s, br, 1H, 2′-H), 5.54 (s, 1H, PhCH), 5.86 (d, 1H, 5-H, J = 7.4 Hz, 7.30-7.47 (m, 5H, aromatic H), 8.05 (d, 1H, 6-H, J = 7.4 Hz); 13C NMR (CDCl3): δ = 32.5 (C-3′), 51.7 (C-2′), 68.8 (C-6′), 69.2 (C-1′), 73.8 (C-4′), 74.1 (C-5′), 94.5 (C-5), 101.9 (PhCH), 126.0 (2,6-C Ph), 128.3 (3,5-C Ph), 129.1 (4-C Ph), 137.2 (1-C Ph), 143.5 (C-6), 156.3 (C-2), 162.0 (C-4), 165.7 (HNC=O).
Prepare S.19 21. Dissolve 2.31 g (7.0 mmol) S.18 in 70 mL pyridine in a 250-mL round-bottom flask equipped with a drying tube. 22. Add 4.1 mL (35.0 mmol, 5 eq) benzoyl chloride and stir the reaction mixture overnight. 23. Analyze by TLC using 95:5 (v/v) dichloromethane/methanol as a solvent. 24. Cool the reaction mixture to 0°C and add 10 mL of 25% ammonia. 25. Continue stirring 1 hr at room temperature. 26. Remove the volatiles, coevaporate with 15 mL toluene three times, and dissolve the residue in 100 mL dichloromethane. 27. Wash with 100 mL saturated sodium bicarbonate solution, dry the organic layer over sodium sulfate, and remove the solvent in vacuo on a rotary evaporator. 28. Dissolve the resulting brownish foam in 70 mL dichloromethane. 29. Slowly add 30 mL TFA and continue stirring 45 min at room temperature. 30. Monitor by TLC using 9:1 (v/v) dichloromethane/methanol. 31. Evaporate the volatiles and coevaporate with 15 mL toluene three times. 32. Purify the resulting foam by column chromatography using a 3 × 35–cm column and a step gradient from 1.5 L of 95:5 to 1.5 L of 93:7 (v/v) dichloromethane/methanol. Collect product-containing fractions. 33. Reduce volatiles in vacuo on a rotary evaporator to a volume of 10 mL. Precipitate by adding 50 mL diethyl ether. The resulting product, 1′,5′-anhydro-2′-(N4-benzoylcytosin-1-yl)-2′,3′-dideoxy-D-arabinohexitol (S.19) is obtained in an overall yield of 67% (1.08 g, 3.1 mmol). mp: 130°C; LSIMS (thygly): m/z: 346 [M+H]+; 1H NMR (DMSO-d6): δ = 1.79 (dt, 1H, 3′ax-H, J = 13.6 Hz, J = 4.4 Hz), 2.20 (d, br, 1H, 3′eq-H, J = 13.7 Hz), 3.14 (m, 1H, 5′-H), 3.50-3.70 (m, 3H, 6′-H, 4′-H), 3.81 (dd, 1H, 1′ax-H, J = 12.9 Hz, J = 2.9 Hz), 4.14 (d, br, 1H, 1′eq-H, J = 13.2 Hz), 4.60 (m, 2H, 6′-OH, + 2′-H), 4.95 (d, 1H, 4′-H, J = 5.1 Hz), 7.31 (d, 1H, 5-H, J = 7.3 Hz), 7.57 (m, 3H, aromatic H), 8.01 (d, 2H, aromatic H, J = 7 Hz), 8.50 (d, 1H, 6-H, J = 7.4 Hz), 11.19 ( s, 1H, HNC=O); 13C NMR (DMSO-d6): δ = 34.8 (C-3′), 52.3 (C-2′), 60.5 (C-6′, C-4′), 67.2 (C-1′), 82.8 (C-5′), 95.9 (C-5), 128.5 (2,3,5,6-C Bz), 132.8 (1,4-C Bz), 148.1 (C-6), 155.0 (C-4), 162.6 (C-4), 167.5 (HNC=O).
Synthesis of Modified Nucleosides
1.9.19 Current Protocols in Nucleic Acid Chemistry
Supplement 15
Prepare S.20 34. Dissolve 2.72 g (7.9 mmol) S.19 in 40 mL pyridine and coevaporate three times (40 mL each). 35. Dissolve in 100 mL pyridine. 36. Add 4.26 g (13.4 mmol) of MMTr⋅Cl. 37. Stir the reaction at room temperature overnight. 38. Monitor by TLC using 95:5 (v/v) dichloromethane/methanol. 39. Quench the reaction with 200 mL saturated sodium bicarbonate solution. 40. Extract twice with 200 mL dichloromethane. 41. Dry the organic layer over sodium sulfate, evaporate the solvent, and coevaporate three times with 20 mL toluene. 42. Purify the residue by column chromatography on a 3 × 35–cm column using a step gradient of 1 L each 99:1, 98:2, 97:3, and 96:4 (v/v) dichloromethane/methanol. Combine product-containing fractions and evaporate solvents. Th e resu lting product, 1′,5′-anhydro-2′-(N4-benzoylcytosin-1-yl)-2′,3′-dideoxy-6′monomethoxytrityl-D-arabinohexitol (S.20) is obtained in 80% yield (3.88 g, 6.3 mmol). mp: 140°C; LSIMS (thygly / NaOAc): m/z: 640 [M+Na]+; 1H NMR (CDCl3): δ = 1.90 (m, 1H, 3′ax-H), 2.55 (br, d, 1H, 3′eq-H, J = 12.2 Hz), 3.08 (s, br, 1H, 5′-H), 3.42 (m, 3H, 4′H, 6′-H), 3.79 (s, 3H, OCH3), 3.89 (dd, 1H, 1′ax-H, J = 13.5 Hz, J = 2.9 Hz), 4.01 (s, br, 1H, 4′-OH), 4.25 (d, br, 1H, 1′eq-H, J = 13.5 Hz), 4.83 (s, br, 1H, 2′-H), 6.85 (d, 2H, aromatic H, J = 8.8 Hz), 7.20-7.70 (m, 18H, aromatic H + 5-H), 8.73 (br, d, 2H, NH + 6-H, J = 7.6 Hz); 13C NMR (CDCl3): δ = 35.0 (C-3′), 52.7 (C-2′), 55.1 (OCH3), 62.1 (C-4′), 62.7 (C-6′), 68.4 (C-1′), 80.9 (C-5′), 86.8 (OC Tr), 96.4 (C-5), 113.2 (3′5′C), 127.1 (4C, 2×), 127.9 (3,5C Bz), 128.0 (2,6C 2×), 128.4 (3,5C 2×), 128.9 (2,6C Bz), 130.0 (2′6′C), 132.7 (4C Bz), 132.9 (1C Bz), 135.0 (1′C), 143.9 (1C 2×), 148.0 (C-6), 155.5 (C-2), 158.6 (4′C), 161.9 (C-4), 166.3 (HNC=O).
COMMENTARY Background Information
Synthesis of 1,5-Anhydrohexitol Building Blocks
Hexitol nucleic acid (HNA) is the first example of an oligonucleotide with a six-membered carbohydrate moiety that hybridizes with natural nucleic acids. The base moiety is connected to the 2′-position of the sugar, which means that the nucleic acids have no anomeric center. These nucleic acids are stable against enzymatic and chemical degradation (Hendrix et al., 1997a,b). HNA can be synthesized by the phosphoramidite method (Hendrix et al., 1997a,b; also see UNIT 3.3) starting from the building blocks described in this protocol. HNAs are RNA-selective oligonucleotides, which means that they hybridize more strongly to RNA as the complement than to DNA (Hendrix et al., 1997a,b). The HNA-RNA duplex is thermally more stable than the DNA-RNA duplex, making HNA suitable as a steric blocking agent for antisense purposes (∆Tm/mod +1° to + 5°C). This higher stability is mainly based on its preorganization (entropy factor).
The NMR structure of an HNA-RNA duplex has been solved (Lescrinier et al., 2000a,b) and it shows typical A-form geometry. The hexitol nucleoside itself is a good mimic of a furanose nucleoside in its 2′-exo,3′-endo conformation (northern type). In a qualitative model, cellular uptake of HNA seems to be similar to that of phoshorothioate oligonucleotides, using cationic lipids as a transfecting agent (Atkins et al., 2000). Hybridization of HNA with RNA is more sequence specific than between DNA and RNA, which is demonstrated by the larger difference in Tm between match and mismatch duplexes of HNA-RNA versus DNA-RNA (Hendrix et al., 1997b). HNA functions as a very efficient template for nonenzymatic oligomerization of activated ribonucleoside monophosphates (Kozlov et al., 1999a,b). HNA templates are chiral-discriminating in that they selectively accept D-nucleotides over L-nucleotides for primer extension
1.9.20 Supplement 15
Current Protocols in Nucleic Acid Chemistry
(Kozlov et al., 1999a,b). Two HNA codons (6 nucleotides) incorporated in an otherwise intact RNA are accepted as messenger in the translation process (Lavrik et al., 2001). Hexitol nucleoside triphosphates may be used by polymerases for enzymatic incorporation into oligodeoxyribonucleotides (Vastmans et al., 2000).
Critical Parameters Overall, it is important that for each step of the syntheses the starting sugar- and basebuilding blocks or nucleosides, respectively, are thoroughly dried either by coevaporation with anhydrous pyridine or in a desiccator over phosphorus pentoxide. The MMtr-protected building blocks (S.9, S.13, S.16, and S.20) are dried over silica blue (not over phosphorous pentoxide) and can be stored at 4°C. For all reactions using anhydrous solvents, the glassware must be predried at 70°C for at least 2 hr. All solvents must be distilled before use. Anhydrous solvents are very important. They should either be freshly distilled and stored under nitrogen or argon, or be taken from a freshly opened bottle of commercially prepared anhydrous solvent. For evaporation of solvents, it is helpful if the rotary evaporator is equipped with a dry ice condenser. For all compounds, a sample of 100 mg should be kept as a reference. In all cases, the reaction progress is followed by TLC. The starting material (1 mg diluted to 200 µL) as well as the reaction mixture (100 µL) are prepared. A baseline is marked and the spots of the solutions are placed at equal distances, with the reaction mixture in the middle surrounded by starting material. After developing in the appropriate solvent, the end line of the TLC is marked, and spots are identified first under a UV lamp (254 nm) and then by spraying the plates with anisaldehyde/sulfuric acid spray and heating to 150°C. The sugar-containing products turn blue. The monomethoxytritylated products (S.9, S.13, S.16, and S.20) turn yellow immediately after spraying (deprotection). After heating, the product-containing spots turn green. Before each column purification, TLC is performed on the reaction mixture to evaluate the completeness of the reaction and the presence of starting materials to be recovered. Silica gel (0.060 to 0.200 nm) is suspended in the first solvent and loaded into the column, which is tightly packed by gentle tapping. The silica
layer is topped by a 1-cm layer of sand. The crude product is dissolved in a minimum volume of solvent and applied to the column. The fractions are collected with a fraction collector and a roster of the collector is drawn on a TLC plate. A drop from each fraction is applied to the corresponding field on the plate, and the plates are evaluated under a UV lamp and by applying anisaldehyde/sulfuric acid spray. The fraction-containing products (or unreacted starting material) are tested for homogeneity by TLC. Elution of the column is continued with the final solvent of the indicated gradient until all product has been isolated. Product-containing fractions are combined and solvents are removed in vacuo on a rotary evaporator.
Troubleshooting Preparation of hC The identical product can be obtained by Mitsunobu reaction of N4-benzoylcytosine with the hexitol building block S.5 as demonstrated in De Bouvere et al. (1997). In this case the yield was rather modest (34%) and turned out to be less reproducible. Furthermore, in some attempts the 1′,5′-anhydro-2′-(N4-benzoylcytosin-2-yl)-4′,6′-O-benzylidene-2′,3′dideoxy-D-arabin ohexitol (O-nucleoside) instead of the desired 1′,5′-anhydro-2′-(N4benzoylcytosin-1-yl)-4′,6′-O-benzylidene-2′, 3′-dideoxy-D-arabinohexitol (N-nucleoside) was obtained. Preparation of hG Due to the high price of 6-iodo-9H-purine2-amine, the synthesis of hG may be performed using the Mitsunobu reaction of 6-chloro-9Hpurine-2-amine with the hexitol building block S.5. If 6-iodo-9H-purine-2-amine is available, another approach for obtaining hG is described in De Bouvere et al. (1997).
Anticipated Results Preparation of appropriately protected anhydrohexitol building blocks is straightforward using the described protocols. Automated oligomer assembly using standard phosphoramidite chemistry cycles—as provided by the manufacturers of automated DNA synthesizers—will yield anhydrohexitol oligomers.
Time Considerations In the planning of the syntheses it has to be considered that most of reactions have to be stirred overnight. Normally each step (includ-
Synthesis of Modified Nucleosides
1.9.21 Current Protocols in Nucleic Acid Chemistry
Supplement 14
ing purification and spectroscopic analysis) can be performed in 1.5 to 2 working days.
Literature Cited Atkins, D., Miller, M., De Bouvere, B., Van Aerschot, A., and Herdewijn, P. 2000. Evaluation of the cellular uptake of hexitol nucleic acids in HeLa cells. Pharmazie 55:615-617. De Bouvere, P., Kerremans, L., Rozenski, J., Janssen, G., Van Aerschot A., Claes, P., Busson, R., and Herdewijn, P. 1997. Improved synthesis of anhydrohexitol building blocks for oligonucleotide synthesis. Liebigs Ann./Recueil 14531461. De Winter, H., Lescrinier, E., Van Aerschot, A., and Herdewijn, P. 1998. Molecular dynamics simulation to investigate differences in minor groove hydration of HNA/RNA hybrids as compared to HNA/DNA complexes. J. Am. Chem. Soc. 120:5381-5394. Hendrix, C., Verheggen, I., Rosemeyer, H., Seela, F., Van Aerschot, A., and Herdewijn, P. 1997a. 1′,5′Anhydrohexitol oligonucleotides: Synthesis, base pairing and recognition by regular oligodeoxyribonucleotides and oligoribonucleotides. Chem. Eur. J. 3:110-119. Hendrix, C., Rosemeyer, H., De Bouvere, B., Van Aerschot A., Seela, F., and Herdewijn, P. 1997b. 1′,5′-Anhydrohexitol oligonucleotides: Hybridization and strand displacement with oligoribonucleotides, interaction with RNase H and HIV reverse transcriptase. Chem. Eur.J. 3:15131520. Kocienski, P. and Pant, C. 1982. A convenient preparation of some 2,3,4,6-tetraacetyl-1,5-anhydroD-hexitols. Carbohydr. Res. 110:330–332. Kozlov, I.A., Politis, P.K., Pitsch, S., Herdewijn, P., and Orgel, L.E. 1999a. A highly enantio-selective hexitol nucleic acid template for nonenzymatic oligoguanylate synthesis. J. Am. Chem. Soc. 121:1108-1109.
Kozlov, I.A., Politis, P.K., Van Aerschot, A., Busson, R., Herdewijn, P., and Orgel, L.E. 1999b. Nonenzymatic synthesis of RNA and DNA oligomers on hexitol nucleic acid templates: The importance of the A structure. J. Am. Chem. Soc. 121:2613-2656. Lavrik, I.N., Avdeeva, O.N., Dontsova, O.A., Froeyen, M., and Herdewijn, P.A. 2001. Translational properties of mHNA, a messenger RNA containing anhydrohexitol nucleotides. Biochemistry 40:11777-11784. Lescrinier, E., Esnouf, R.M., Schraml, J., Busson, R., and Herdewijn, P. 2000a. Solution structure of a hexitol nucleic acid duplex with four consecutive T.T base pairs. Helv. Chim. Acta 83:1291-1310. Lescrinier, E., Esnouf, R.M., Schraml, J., Busson, R., Heus, H.A., Hilbers, C.W., and Herdewijn, P. 2000b. Solution structure of a HNA-RNA hybrid. Chem. & Biol. 7:719-731. Vastmans, K., Pochet, S., Peys, A., Kerremans, L., Van Aerschot, A., Hendrix, C., Marlière, P., and Herdewijn, P. 2000. Enzymatic incorporation in DNA of 1,5-anhydrohexitol nucleotides. Biochemistry 39:12757-12765. Verheggen, I., Van Aerschot, A., Toppet, S. Snoeck, R., Janssen, G., Balzarini, J., De Clercq, E., and Herdewijn, P. 1993. Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. J. Med. Chem. 36:2033-2039. Verheggen, I., Van Aerschot, A., Van Meervelt, L., Rozenski, J., Wiebe, L., Snoek, R., Andrei, G., Balzarini, J., Claes, P., De Clercq, E., and Herdewijn, P. 1995. Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides J. Med. Chem. 38:826835.
Contributed by Irene M. Lagoja, Arnaud Marchand, Arthur Van Aerschot, and Piet Herdewijn Rega Institute for Medical Research Leuven, Belgium
Synthesis of 1,5-Anhydrohexitol Building Blocks
1.9.22 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Synthesis and Properties of 7-Substituted 7-Deazapurine (Pyrrolo[2,3-d]pyrimidine) 2-Deoxyribonucleosides
UNIT 1.10
This unit describes the synthesis of 7-deazapurine nucleosides, including their 7-substituted derivatives. (Systematic numbering is used for compound naming in protocol steps, while purine numbering is used elsewhere in the unit.) Initially, the synthesis of 7-deazapurine nucleosides was made difficult by the particular properties of the 7-deazapurine system. While the imidazole nitrogen of a purine base can easily be attacked by an electrophile (e.g., a sugar cation) without affecting the state of aromaticity, eletrophilic reactions at the pyrrole nitrogen of a 7-deazapurine would destroy the aromatic character of the pyrrole ring. Thus, the pyrrole nitrogen is rather inert to glycosylation, with the consequence that the reaction is instead directed to the pyrimidine moiety or to the pyrrole carbons. In 1983, the nucleobase anion method for glycoslyation of 7-deazapurines was developed (Winkeler and Seela, 1983; Seela et al., 1988). From this work, it became apparent that reaction via the pyrrolyl anion occurred regioselectively at N9 and proceeded in a stereocontrolled manner, with the exclusive formation of 2 -deoxy-β-D-ribonucleosides. Figure 1.10.1 shows a selection of 7-deazapurine 2 deoxyribonucleosides and 7-substituted derivatives that have been synthesized by the nucleobase anion glycosylation method. This unit focuses on the synthesis of the 7-substituted 7-deazapurine 2 deoxyribonucleosides S.1d, S.2d, S.3c, S.4c, S.5d, and S.6d. The preparation of the 7-iodo-7-deazapurine 2 -deoxyribonucleosides S.1d, S.2d, S.5d, and S.6d is described first (see Basic Protocol 1 and Basic Protocol 2), followed by the preparation of the brominated nucleosides S.3c and S.4c (see Basic Protocol 3). Selective halogenation reactions are performed either on the nucleobases or on the nucleosides, using N-halosuccinimides. Nucleobase anion glycosylation is carried out in acetonitrile in the presence of powdered potassium hydroxide and a phase-transfer catalyst. The determination of pKa values of 7-deazapurine nucleosides is summarized in Basic Protocol 4. Fluorescence properties are also discussed (see Background Information).
PREPARATION OF 7-SUBSTITUTED 7-DEAZAPURINE NUCLEOSIDES RELATED TO 2 -DEOXYADENOSINE AND 2 -DEOXYINOSINE
BASIC PROTOCOL 1
The syntheses of 7-iodo-7-deaza-2 -deoxyadenosine (S.1d) and the analog 7-iodo-7deaza-2 -deoxyinosine (S.5d) are shown in Figure 1.10.2. The 7-iodinated nucleobase S.7 serves as the starting material. The preparation of this nucleobase is reported elsewhere (Pudlo et al., 1990; Rolland et al., 1997). The chemical conversions described here proceed in high yields, and the purification of intermediates is straightforward.
Materials Potassium hydroxide (KOH) powder (purity, ≥85%; Sigma) Anhydrous acetonitrile (MeCN) Tris[2-(2-methoxyethoxy)ethyl]amine (TDA-1) 4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (S.7; see Pudlo et al., 1990) 2-Deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride (S.8; see Hoffer, 1960; Rolland et al., 1997) Anhydrous dichloromethane (CH2 Cl2 ) Silica gel 60 (particle size, <0.063 mm; Merck)
Contributed by Frank Seela and Xiaohua Peng Current Protocols in Nucleic Acid Chemistry (2005) 1.10.1-1.10.20 C 2005 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Nucleosides
1.10.1 Supplement 21
Figure 1.10.1 The structures of selected 7-deazapurine 2 -deoxyribonucleosides. Purine and systematic numbering systems are shown in the first two structures. Compounds: S.1, 7-deaza-2 -deoxyadenosine; S.2, 7-deaza-2 -deoxyguanosine; S.3, 2-amino-7-deaza-2 -deoxyadenosine; S.4, 7-deaza-2 -deoxyisoguanosine; S.5, 7-deaza-2 -deoxyinosine; S.6, 7deaza-2 -deoxyxanthosine. References: S.1a (Seela and Kehne, 1983); S.1b-e (Seela and Thomas, 1994; Seela and Zulauf, 1996); S.1f (Seela et al., 2005); S.2a (Winkeler and Seela, 1983); S.2b-e (Ramzaeva and Seela, 1995); S.3a (Seela et al., 1987); S.3b-d (Seela and Peng, 2004); 4a (Seela and Wei, 1999); S.4b,c (Seela and Peng, 2004); S.5a (Seela and Menkhoff, 1985); S.5b-d (Ramzaeva et al., 1999); S.6a (Seela et al., 1985); and S.6b-d (Seela and Shaikh, 2004).
7-Substituted 7-Deazapurine (Pyrrolo[2,3d]pyrimidine) 2 -Deoxyribonucleosides
Ethyl acetate (EtOAc) Petroleum ether (b.p. range, 40◦ to 80◦ C) Isopropanol (i-PrOH) Methanol (MeOH) 1,4-Dioxane 25% (v/v) ammonium hydroxide (NH4 OH) Palladium catalyst Pd(PPh3 )4 Copper iodide (CuI) Argon gas Anhydrous dimethylformamide (DMF) Triethylamine (Et3 N) Cyclopentylacetylene Sodium methoxide (NaOMe) 2 M NaOH 1 M HCl 10-, 50-, and 100-mL round-bottom flasks 3-cm-diameter Buchner funnel with filter paper circles Rotary evaporator connected to a vacuum pump
1.10.2 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Figure 1.10.2 Preparation of 7-deaza-7-iodo-2 -deoxyadenosine (S.1d) and 7-deaza-7-iodo-2 -deoxyinosine (S.5d) is carried out by glycosylation of an iodinated nucleobase. S1.d can then be used in a palladium-catalyzed Sonogashira crosscoupling reaction to yield the 7-alkynyl derivative S.10 (Seela et al., 2000). TDA-1, tris[2-(2-methoxyethoxy)ethyl]amine; Tol, p-toluoyl.
3 × 50– and 4 × 50–cm chromatography columns 0.2-mm-thick silica gel 60 F254 aluminum TLC plates (Merck) 254-nm UV lamp High-vacuum pump (final pressure, <1 mmHg) Steel bomb (autoclave) Reflux condenser Heating mantle with controller Additional reagents and equipment for flash chromatography (APPENDIX 3E) and thin-layer chromatography (TLC; APPENDIX 3D) Prepare common precursor S.9 1. In a 100-mL round-bottom flask equipped with a Teflon stir bar, suspend 0.50 g (8.91 mmol) powdered KOH in 60 mL MeCN. 2. Add 75 µL (0.23 mmol) TDA-1 and stir the resulting mixture 10 min at room temperature. 3. Add 1.0 g (3.57 mmol) 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (S.7) and stir 10 min at room temperature.
Synthesis of Modified Nucleosides
1.10.3 Current Protocols in Nucleic Acid Chemistry
Supplement 21
4. Add 1.7 g (4.37 mmol) 2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride (S.8) and stir 10 min at room temperature. 5. Remove the insoluble material by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, washing with three 10-mL aliquots of MeCN. Evaporate the filtrate using a rotary evaporator connected to a vacuum pump. 6. Dissolve the residue in 30 mL CH2 Cl2 , adsorb on ∼3 g silica gel 60, and evaporate the solvent using a rotary evaporator. 7. Load the dry material onto a 4 × 50–cm column packed with silica gel 60 (bed height, 15 cm) and perform flash chromatography (APPENDIX 3E), eluting with 800 mL of 1:4 (v/v) EtOAc/petroleum ether. Collect 15-mL fractions. 8. Monitor fractions by TLC (APPENDIX 3D) on silica gel 60 F254 plates using 1:4 (v/v) EtOAc/petroleum ether as the eluent. Visualize product under 254-nm light using a UV lamp. 9. Pool all product fractions and evaporate the solvent using a rotary evaporator. 10. Crystallize the purified product from i-PrOH, collect the crystals by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, and dry overnight under high vacuum (<1 mmHg). 4-Chloro-7-[2-deoxy-3,5-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-5-iodo-7Hpyrrolo[2,3-d]pyrimidine (S.9) is obtained as colorless crystals (1.5 g, 66% yield). m.p. 138◦ C. TLC (EtOAc/petroleum ether, 1:4): Rf = 0.5. UV (MeOH): λmax (ε) = 235 nm (25,600). 1 H NMR (DMSO-d6 ): δ 2.39 and 2.41 (2 × s, 6H, 2 × CH3 ), 2.78 (m, 1H, 2 -Hα ), 3.11 (m, 1H, 2 -Hβ ), 4.56 (m, 2H, 5 -H), 4.66 (m, 1H, 4 -H), 5.77 (m, 1H, 3 -H), 6.77 (t, J = 7.0 Hz, 1H, 1 -H), 7.34 and 7.90 (2 × dd, J = 7.8 Hz, J = 7.9 Hz, 8H, 2 × C6 H4 ), 8.18 (s, 1H, 6-H), 8.66 (s, 1H, 2-H). Anal. calcd. for C27 H23 ClIN3 O5 : C, 51.32; H, 3.67; N, 6.65; found: C, 51.55; H, 3.78; N, 6.80.
Prepare 2 -deoxyadenosine analog S.1d 11. In a 100-mL round-bottom flask equipped with a Teflon stir bar, suspend 1.6 g (2.53 mmol) compound S.9 in 40 mL 1,4-dioxane, and then place the flask in an autoclave. 12. Add 80 mL of 25% NH4 OH and stir 15 hr at 110◦ C under pressure. 13. Adsorb reaction mixture onto ∼4 g silica gel 60 and evaporate the solvent using a rotary evaporator. 14. Purify the crude product by flash chromatography (step 7; bed height, 20 cm) using an elution gradient from 95:5 (v/v) CH2 Cl2 /MeOH (300 mL) to 90:10 (v/v) CH2 Cl2 /MeOH (600 mL). Collect 10-mL fractions. 15. Monitor fractions by TLC (step 8) using 9:1 (v/v) CH2 Cl2 /MeOH as the eluent. 16. Pool all product fractions and evaporate the solvent using a rotary evaporator. 17. Crystallize purified product from MeOH, collect the crystals by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, and dry overnight under high vacuum (<1 mmHg).
7-Substituted 7-Deazapurine (Pyrrolo[2,3d]pyrimidine) 2 -Deoxyribonucleosides
4-Amino-7-(2-deoxy-β-D-erythro-pentofuranosyl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (S.1d) is obtained as colorless crystals (612 mg, 64% yield). m.p. 194◦ C. TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.40. UV (MeOH): λmax (ε) = 283 nm (8500). 1 H NMR (DMSO-d6 ): δ 2.16 (m, 1H, 2 -Hα ), 2.46 (m, 1H, 2 -Hβ ), 3.54 (m, 2H, 5 -H), 3.81 (m, 1H, 4 -H), 4.33 (m, 1H, 3 -H), 5.00 (t, J = 5.4 Hz, 1H, 5 -OH), 5.23 (d, J = 3.9 Hz, 1H, 3 -OH), 6.49 (t, J = 7.0 Hz, 1H, 1 -H), 6.65 (br s, 2H, NH2 ), 7.65 (s, 1H, 6-H), 8.10 (s, 1H, 2-H). Anal. calcd. for C11 H13 IN4 O3 : C, 35.12; H, 3.48; N, 14.89; found: C, 35.33; H, 3.60; N, 15.01.
1.10.4 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Prepare S.10 by cross-coupling of S.1d 18. In a 10-mL round-bottom flask equipped with a Teflon stir bar, load 100 mg (0.27 mmol) compound S.1d, 31 mg (0.027 mmol) Pd(PPh3 )4 , and 10.1 mg (0.05 mmol) CuI. After loading, purge flask with argon for 5 min at room temperature. 19. Add 3.0 mL anhydrous DMF, 54 mg (0.53 mmol) Et3 N, and 500 mg (5.31 mmol) cyclopentylacetylene under argon, and stir the resulting mixture 4 hr at room temperature under argon. 20. Evaporate the contents of the flask to dryness using a rotary evaporator. Redissolve the residue in 20 mL MeOH, adsorb on ∼2 g silica gel 60, and evaporate the solvent once more using a rotary evaporator. 21. Purify the crude product by flash chromatography (step 7) using a 3 × 50–cm column (bed height, 12 cm) and an elution gradient from 97:3 (v/v) CH2 Cl2 /MeOH (300 mL) to 90:10 (v/v) CH2 Cl2 /MeOH (300 mL). Collect 5-mL fractions. 22. Monitor fractions by TLC (step 8) using 9:1 (v/v) CH2 Cl2 /MeOH as the eluent. 23. Pool all product fractions, evaporate the solvent using a rotary evaporator, and dry the resulting sample overnight under high vacuum (<1 mmHg). 5-(2-Cyclopentylethynyl)-7-(2-deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3d]pyrimidin-4-amine (S.10) is obtained as a colorless foam (59 mg, 64% yield). TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.46. UV (MeOH): λmax (ε) = 280 nm (10,500), 242 nm (13,900). 1 H NMR (DMSO-d6 ): δ 1.60-2.02 (several m, 8H, 4 × CH2 ), 2.18 (m, 1H, 2 -Hα ), 2.46 (m, 1H, 2 -Hβ ), 2.93 (quintet, J = 7.1 Hz, 1H, CH), 3.54 (m, 2H, 5 -H), 3.82 (m, 1H, 4 -H), 4.34 (m, 1H, 3 -H), 5.03 (t, J = 5.0 Hz, 1H, 5 -OH), 5.24 (d, J = 3.9 Hz, 1H, 3 -OH), 6.48 (t, J = 7.0 Hz, 1H, 1 -H), 6.70 (br s, 2H, NH2 ), 7.64 (s, 1H, 6-H), 8.11 (s, 1H, 2-H). Anal. calcd. for C18 H22 N4 O3 : C, 63.14; H, 6.48; N, 16.36; found: C, 62.74; H, 6.37; N, 16.77.
Prepare 4-methoxy precursor S.11 24. In a 50-mL round-bottom flask equipped with a Teflon stir bar, dissolve 1.26 g (2.0 mmol) compound S.9 in 20 mL of MeOH containing 0.5 M NaOMe. Stir overnight at room temperature. 25. Adsorb reaction mixture onto ∼4 g silica gel 60 and evaporate the solvent using a rotary evaporator. 26. Purify the crude product by flash chromatography (step 7; bed height, 20 cm) using an elution gradient from 95:5 (v/v) CH2 Cl2 /MeOH (600 mL) to 90:10 (v/v) CH2 Cl2 /MeOH (300 mL). Collect 12-mL fractions. 27. Monitor fractions by TLC (step 8) using 9:1 (v/v) CH2 Cl2 /MeOH as the eluent. 28. Pool all product fractions, evaporate the solvent using a rotary evaporator, and dry the resulting sample overnight under high vacuum (<1 mmHg). 7-(2-Deoxy-β-D-erythro-pentofuranosyl)-5-iodo-4-methoxy-7H-pyrrolo[2,3d]pyrimidine (S.11) is obtained as a colorless solid (700 mg, 90% yield). TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.60. UV (MeOH): λmax (ε) = 260 nm (9,400), 282 nm (10,800). 1 H NMR (DMSO-d6 ): δ 2.24 (m, 2H, 2 -H), 3.56 (m, 2H, 5 -H), 3.83 (m, 1H, 4 -H), 4.05 (s, 3H, MeO), 4.35 (m, 1H, 3 -H), 4.96 (t, J = 5.3 Hz, 1H, 5 -OH), 5.26 (d, J = 4.0 Hz, 1H, 3 -OH), 6.58 (t, J = 6.9 Hz, 1H, 1 -H), 7.84 (s, 1H, 6-H), 8.43 (s, 1H, 2-H). Anal. calcd. for C12 H14 IN3 O4 : C, 36.85; H, 3.61; N, 10.74; found: C, 36.70; H, 3.80; N, 10.60. Synthesis of Modified Nucleosides
1.10.5 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Prepare 2 -deoxyinosine analog S.5d 29. In a 100-mL round-bottom flask equipped with a Teflon stir bar, dissolve 1.2 g (3.07 mmol) compound S.11 in 20 mL of 2 M NaOH. 30. Stir reaction mixture 5 hr under reflux. 31. Cool reaction mixture to room temperature. 32. Precipitate product by acidifying with 1 M HCl. Collect precipitate by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, wash with H2 O, and dry overnight under high vacuum (<1 mmHg). 7-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,7-dihydro-5-iodo-4H-pyrrolo[2,3d]pyrimidin-4-one (S.5d) is obtained as a colorless solid (995 mg, 86% yield). TLC (CH2 Cl2 /MeOH, 4:1): Rf = 0.69. UV (MeOH): λmax (ε) = 265 nm (13,100), 282 nm (12,000). 1 H NMR (DMSO-d6 ): δ 2.20 (m, 1H, 2 -Hα ), 2.38 (m, 1H, 2 -Hβ ), 3.43 (m, 2H, 5 -H), 3.80 (m, 1H, 4 -H), 4.31 (m, 1H, 3 -H), 4.94 (t, J = 6.6 Hz, 1H, 5 -OH), 5.26 (d, J = 4.0 Hz, 1H, 3 -OH), 6.42 (t, J = 6.3 Hz, 1H, 1 -H), 7.53 (s, 1H, 6-H), 7.92 (s, 1H, 2-H), 12.01 (s, 1H, NH). Anal. calcd. for C11 H12 IN3 O4 : C, 35.03; H, 3.21; N, 11.14; found: C, 35.09; H, 3.43; N, 10.93. BASIC PROTOCOL 2
PREPARATION OF 7-IODO-7-DEAZAPURINE NUCLEOSIDES RELATED TO 2 -DEOXYGUANOSINE AND 2 -DEOXYXANTHOSINE In the synthesis of 7-iodo-7-deaza-2 -deoxyguanosine (S.2d) and the analog 7-iodo7-deaza-2 -deoxyxanthosine (S.6d), the 2-amino-protected nucleoside S.12 is used as starting material (Fig. 1.10.3). Regioselective iodination is performed on the protected nucleoside S.13. The protocols described for the preparation of nucleosides S.2d and S.6d give good yields, and the purification of intermediates is straightforward.
Materials
7-Substituted 7-Deazapurine (Pyrrolo[2,3d]pyrimidine) 2 -Deoxyribonucleosides
7-(2-Deoxy-β-D-erythro-pentofuranosyl)-2-(formylamino)-4-methoxy-7Hpyrrolo[2,3-d]pyrimidine (S.12; see Seela and Driller, 1989) Anhydrous acetonitrile (MeCN) Isobutyric anhydride Triethylamine Silica gel 60 (particle size, <0.063 mm; Merck) Anhydrous dichloromethane (CH2 Cl2 ) Acetone Cyclohexane N,N-Dimethylformamide (DMF) N-Iodosuccinimide 5% (w/v) sodium bicarbonate (NaHCO3 ) Anhydrous sodium sulfate (Na2 SO4 ) 2 M NaOH 1 M HCl Methanol (MeOH) Sodium methoxide (NaOMe) 10% (v/v) acetic acid (AcOH) in H2 O Sodium nitrite (NaNO2 ) Ethanol (EtOH) Sodium iodide (NaI) Chlorotrimethylsilane (Me3 SiCl) 0.1 M NaH2 PO4 buffer, pH 7.0 (see recipe) 25-, 50-, and 250-mL round-bottom flasks Rotary evaporator connected to a vacuum pump
1.10.6 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Figure 1.10.3 Preparation of 7-iodo-7-deaza-2 -deoxyguanosine (S.2d) and 7-iodo-7-deaza-2 -deoxyxanthosine (S.6d) is carried out by iodination of a precursor nucleoside. i-Bu2 O, isobutyric anhydride; DMF, N,N-dimethylformamide; NIS, N-iodosuccinimide.
4 × 50–cm chromatography columns 0.2-mm-thick silica gel 60 F254 aluminum TLC plates (Merck) 254-nm UV lamp 3-cm-diameter Buchner funnel with filter paper circles High-vacuum pump (final pressure, <1 mmHg) Separatory funnel 5-cm-diameter funnel with folded 10-cm-diameter Whatman no. 1 filter Reflux condenser Heating mantle with controller Additional reagents and equipment for flash chromatography (APPENDIX 3E) and thin-layer chromatography (TLC; APPENDIX 3D) Prepare common protected nucleoside S.13 1. In a 50-mL round-bottom flask equipped with a Teflon stir bar, suspend 1.0 g (3.24 mmol) 7-(2-deoxy-β-D-erythro-pentofuranosyl)-2-(formylamino)-4-methoxy7H-pyrrolo[2,3-d]pyrimidine (S.12) in 20 mL MeCN. 2. Add 5 mL (30.15 mmol) isobutyric anhydride and 2.3 mL (16.38 mmol) triethylamine and stir the reaction mixture overnight at room temperature to give a clear solution. 3. Evaporate the solution to dryness using a rotary evaporator connected to a vacuum pump. 4. Load the dry material onto a 4 × 50–cm column packed with silica gel 60 (bed height, 15 cm) and perform flash chromatography (APPENDIX 3E), eluting with 800 mL of 95:5 (v/v) CH2 Cl2 /acetone. Collect 12-mL fractions.
Synthesis of Modified Nucleosides
1.10.7 Current Protocols in Nucleic Acid Chemistry
Supplement 21
5. Monitor fractions by TLC (APPENDIX 3D) on silica gel 60 F254 plates using 95:5 (v/v) CH2 Cl2 /acetone as the eluent. Visualize products under 254-nm light using a UV lamp. 6. Pool all product fractions and evaporate the solvent using a rotary evaporator. 7. Dissolve the residue in 8 mL CH2 Cl2 and precipitate the purified product by adding 80 mL cyclohexane. Collect the precipitate by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, and dry overnight under high vacuum (<1 mmHg). 7-[2-Deoxy-3,5-bis-O-(2-methylpropanoyl)-β-D-erythro-pentofuranosyl]-2-(formyl amino)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidine (S.13) is obtained as a colorless solid (1.2 g, 82% yield). m.p. 136◦ -137◦ C. TLC (CH2 Cl2 /acetone, 95:5): Rf = 0.4. 1 H NMR (DMSO-d6 ): δ 1.09 (d, J = 7.0 Hz, 6H, 2 × CH3 ), 1.15 (d, J = 7.0 Hz, 6H, 2 × CH3 ), 2.47, 2.57, 2.62, 2.92 (4 × m, 4H, 2 × CH, 2 × 2 -H), 4.04 (s, 3H, OCH3 ), 4.18 (m, 2H, 5 -H), 4.27 (m, 1H, 4 -H), 5.37 (m, 1H, 3 -H), 6.49 (m, 1H, 1 -H), 6.55 (d, J = 3.7 Hz, 1H, 5 -H), 7.42 (d, J = 3.7 Hz, 1H, 6-H), 9.46 (d, J = 9.9 Hz, 1H, NH), 10.75 (d, J = 9.9 Hz, 1H, HCO). Anal. calcd. for C21 H28 N4 O7 : C, 56.24; H, 6.29; N, 12.49; found: C, 56.44; H, 6.26; N, 12.44.
Perform iodination (prepare S.14) 8. In a 25-mL round-bottom flask equipped with a Teflon stir bar, prepare a solution of 500 mg (1.12 mmol) compound S.13 in 5 mL DMF. 9. Add 264 mg (1.17 mmol) N-iodosuccinimide and stir 23 hr at room temperature. 10. Dilute the reaction mixture with 40 mL CH2 Cl2 and pour into a separatory funnel containing 10 mL of 5% NaHCO3 . Wash the organic layer with 20 mL H2 O. 11. Collect the organic layer and dry over 3 g anhydrous Na2 SO4 . Filter off the Na2 SO4 by gravity filtration through a folded 10-cm-diameter filter. Evaporate the filtrate to dryness using a rotary evaporator. 12. Purify the crude product by flash chromatography (step 4) using 600 mL of 95:5 (v/v) CH2 Cl2 /acetone as the eluent. Collect 12-mL fractions. 13. Monitor fractions by TLC (step 5) using 95:5 (v/v) CH2 Cl2 /acetone as the eluent. 14. Pool all product fractions and evaporate to dryness using a rotary evaporator. 15. Dissolve the residue in 4 mL CH2 Cl2 . Crystallize the purified product by adding 40 mL cyclohexane, collect the crystals by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, and dry overnight under high vacuum. 7-[2-Deoxy-3,5-bis-O-(2-methylpropanoyl)-β-D-erythro-pentofuranosyl]-2-(formyl amino)-5-iodo-4-methoxy-7H-pyrrolo[2,3-d]pyrimidine (S.14) is obtained as colorless crystals (590 mg, 92% yield). m.p. 129◦ -130◦ C. TLC (CH2 Cl2 /acetone, 95:5): Rf = 0.4. 1 H NMR (DMSO-d6 ): δ 1.09 (d, J = 7.0 Hz, 6H, 2 × CH3 ), 1.15 (d, J = 7.0 Hz, 6H, 2 × CH3 ), 2.46, 2.60, 2.89 (3 × m, 4H, 2 × CH, 2 × 2 -H), 4.06 (s, 3H, OCH3 ), 4.17 (m, 2H, 5 -H), 4.27 (m, 1H, 4 -H), 5.35 (m, 1H, 3 -H), 6.46 (m, 1H, 1 -H), 7.62 (s, 1H, 6-H), 9.55 (d, J = 9.7 Hz, 1H, NH), 10.81 (d, J = 9.9 Hz, 1H, HCO). Anal. calcd. for C21 H27 IN4 O7 : C, 43.91; H, 4.74; N, 9.75; found: C, 43.98; H, 4.75; N, 9.82.
7-Substituted 7-Deazapurine (Pyrrolo[2,3d]pyrimidine) 2 -Deoxyribonucleosides
Prepare 2 -deoxyguanosine analog S.2d 16. Convert 200 mg (0.35 mmol) compound S.14 to nucleoside S.2d using the general procedure described for converting S.11 to nucleoside S.5d (see Basic Protocol 1, steps 29 to 32). 2-Amino-7-(2-deoxy-β-D-erythro-pentofuranosyl)-3,7-dihydro-5-iodo-4H-pyrrolo[2,3d]pyrimidin-4-one (S.2d) is obtained as colorless crystals (126 mg, 92% yield). m.p. 218◦ -220◦ C. TLC (CH2 Cl2 /MeOH, 4:1): Rf = 0.7. UV (MeOH): λmax (ε) = 266 nm
1.10.8 Supplement 21
Current Protocols in Nucleic Acid Chemistry
(12,000), 285 nm (sh 8,400). 1 H NMR (DMSO-d6 ): δ 2.08 (m, 1H, 2 -Hα ), 2.30 (m, 1H, 2 -Hβ ), 3.48 (m, 2H, 5 -H), 3.74 (m, 1H, 4 -H), 4.26 (m, 1H, 3 -H), 4.89 (t, J = 5.7 Hz, 1H, 5 -OH), 5.18 (d, J = 4.3 Hz, 1H, 3 -OH), 6.25 (t, J = 6.5 Hz, 1H, 1 -H), 6.34 (br s, 2H, NH2 ), 7.09 (s, 1H, 6-H), 10.51 (br s, 1H, NH). Anal. calcd. for C11 H13 IN4 O4 : C, 33.69; H, 3.34; N, 14.29; found: C, 33.78; H, 3.42; N, 14.29.
Prepare deprotected iodo precursor S.15 17. In a 250-mL round-bottom flask equipped with a Teflon stir bar, dissolve 2.1 g (3.66 mmol) compound S.14 in 150 mL of MeOH containing 0.5 M NaOMe. Stir overnight at room temperature. 18. Adsorb reaction mixture onto ∼6 g silica gel 60 and evaporate the solvent using a rotary evaporator. 19. Purify the crude product by flash chromatography (step 4; bed height, 10 cm) using an elution gradient from 95:5 (v/v) CH2 Cl2 /MeOH (800 mL) to 90:10 (v/v) CH2 Cl2 /MeOH (300 mL). Collect 15-mL fractions. 20. Monitor fractions by TLC (step 5) using 90:10 (v/v) CH2 Cl2 /MeOH as the eluent. 21. Pool all product fractions, evaporate the solvent using a rotary evaporator, and dry the resulting sample overnight under high vacuum. 2-Amino-7-(2-deoxy-β-D-erythro-pentofuranosyl)-5-iodo-4-methoxy-7H-pyrrolo[2,3d]pyrimidine (S.15) is obtained as a colorless solid (1.17 g, 79% yield). m.p. 159◦ -160◦ C. TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.48. UV (MeOH): λmax (ε) = 233 nm (31,200), 266 nm (2,800), 289 nm (7,300). 1 H NMR (DMSO-d6 ): δ 2.08 (m, 1H, 2 -Hα ), 2.36 (m, 1H, 2 -Hβ ), 3.48 (m, 2H, 5 -H), 3.75 (m, 1H, 4 -H), 3.92 (s, 3H, MeO), 4.27 (m, 1H, 3 -H), 4.94 (t, J = 5.4 Hz, 1H, 5 -OH), 5.22 (d, J = 3.7 Hz, 1H, 3 -OH), 6.37 (t, J = 5.8 Hz, 1H, 1 -H), 6.39 (s, 2H, NH2 ), 7.29 (s, 1H, 6-H). Anal. calcd. for C12 H15 IN4 O4 : C, 35.48; H, 3.72; I, 31.24; N, 13.79; found: C, 35.62; H, 3.84; I, 30.72; N, 13.84.
Perform deamination (prepare S.16) 22. In a 250-mL round-bottom flask equipped with a Teflon stir bar, dissolve 1.0 g (2.46 mmol) compound S.15 in 150 mL of 10% AcOH. 23. Add a solution of 290 mg (4.2 mmol) NaNO2 in 10 mL H2 O dropwise and stir 30 min at room temperature. 24. Adsorb reaction mixture onto ∼4 g silica gel 60 and evaporate the solvent using a rotary evaporator. 25. Purify the crude product by flash chromatography (step 4; bed height, 10 cm), eluting with 900 mL of 95:5 (v/v) CH2 Cl2 /MeOH. Collect 12-mL fractions. 26. Monitor fractions by TLC (step 5) using 90:10 (v/v) CH2 Cl2 /MeOH as the eluent. 27. Pool all product fractions and evaporate the solvent using a rotary evaporator. 28. Crystallize purified product from EtOH, collect the crystals by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, and dry overnight under high vacuum (<1 mmHg). 7-(2-Deoxy-β-D-erythro-pentofuranosyl)-1,7-dihydro-5-iodo-4-methoxy-2Hpyrrolo[2,3-d]pyrimidin-2-one (S.16) is obtained as colorless crystals (654 mg, 65% yield). m.p. 158◦ -160◦ C. TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.40. UV (MeOH): λmax (ε) = 227 nm (23,200), 286 nm (6,300). 1 H NMR (DMSO-d6 ): δ 2.13 (m, 1H, 2 -Hα ), 2.39 (m, 1H, 2 -Hβ ), 3.52 (m, 2H, 5 -H), 3.79 (m, 1H, 4 -H), 3.96 (s, 3H, MeO), 4.30 (m, 1H, 3 -H), 5.04 (br s, 1H, 3 -OH), 5.25 (t, J = 3.7 Hz, 1H, 5 -OH), 6.37 (dd, J = 6.6 Hz, J = 7.2 Hz, 1H, 1 -H), 7.46 (s, 1H, 6-H), 11.57 (br s, 1H, NH). Anal. calcd. for C12 H14 IN3 O5 : C, 35.40; H, 3.47; I, 31.17; N, 10.32; found: C, 35.48; H, 3.55; I, 31.20; N, 10.34.
Synthesis of Modified Nucleosides
1.10.9 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Prepare 2 -deoxyxanthosine analog S.6d 29. In a 50-mL round-bottom flask equipped with a Teflon stir bar, suspend 620 mg (1.53 mmol) compound S.16 and 450 mg (3.00 mmol) NaI in 20 mL MeCN. 30. Add 442 µL (3.48 mmol) Me3 SiCl and stir 1 hr at room temperature. 31. Subject the reaction mixture to vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, wash the solid with 5 mL MeCN, and collect the filter cake. 32. Crystallize purified product from 10 mL H2 O, collect the crystals by vacuum filtration, and dry overnight under high vacuum (<1 mmHg). 7-(2-Deoxy-β-D-erythro-pentofuranosyl)-1,3,7-trihydro-5-iodo-2H,4H-pyrrolo[2,3d]pyrimidin-2,4-dione (S.6d) is obtained as colorless crystals (543 mg, 90% yield). m.p. >210◦ C. TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.36. UV (0.1 M NaH2 PO4 buffer, pH 7.0): λmax (ε) = 224 nm (21,500), 259 nm (9,700), 285 nm (6,800). 1 H NMR (DMSO-d6 ): δ 2.16 (m, 1H, 2 -Hα ), 2.27 (m, 1H, 2 -Hβ ), 3.57 (m, 2H, 5 -H), 3.82 (m, 1H, 4 -H), 4.28 (m, 1H, 3 -H), 5.28 (d, J = 3.3 Hz, 1H, 3 -OH), 5.53 (br s, 1H, 5 -OH), 6.12 (dd, J = 7.0 Hz, J = 6.5 Hz, 1H, 1 -H), 7.14 (s, 1H, 6-H), 10.70 (s, 1H, NH), 11.70 (s, 1H, NH). Anal. calcd. for C11 H12 IN3 O5 : C, 33.61; H, 3.08; I, 32.28; N, 10.69; found: C, 34.14; H, 3.34; I, 31.56; N, 10.46.
BASIC PROTOCOL 3
PREPARATION OF 7-BROMO-7-DEAZA-2 -DEOXYISOGUANOSINE This protocol describes the preparation of 2-amino-7-bromo-7-deaza-2 -deoxyadenosine (S.3c) and its subsequent oxidation to give 7-bromo-7-deaza-2 -deoxyisoguanosine (S.4c; Fig. 1.10.4). Regioselective bromination is performed on the 2-amino-protected nucleobase S.18. Convergent nucleoside synthesis is accomplished by nucleobase anion glycosylation. The procedure described here allows the successful preparation of the desired nucleoside, S.4c. The chemical reactions give good yields, and the purification of intermediates is straightforward.
Materials
7-Substituted 7-Deazapurine (Pyrrolo[2,3d]pyrimidine) 2 -Deoxyribonucleosides
2-Amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (S.17; see Seela et al., 1987) Anhydrous pyridine Pivaloyl chloride Potassium hydroxide (KOH) powder (purity, ≥85%; Sigma) Anhydrous dichloromethane (CH2 Cl2 ) N-Bromosuccinimide Methanol (MeOH) Anhydrous acetonitrile (MeCN) Tris[2-(2-methoxyethoxy)ethyl]amine (TDA-1) 2-Deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride (S.8; see Hoffer, 1960; Rolland et al., 1997) Silica gel 60 (particle size, <0.063 mm; Merck) Petroleum ether (b.p. range, 40◦ to 80◦ C) 1,4-Dioxane 25% (v/v) ammonium hydroxide (NH4 OH) 1:5 (v/v) acetic acid (AcOH)/H2 O Sodium nitrite (NaNO2 ) Isopropanol (i-PrOH) 100- and 250-mL round-bottom flasks Rotary evaporator connected to a vacuum pump
1.10.10 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Figure 1.10.4 Preparation of 7-bromo-7-deaza-2 -deoxyisoguanosine (S.4c) is carried out by glycosylation of a brominated nucleobase followed by amination at C4 and selective deamination at C2 . NBS, N-bromosuccinimide; Piv, pivaloyl; TDA-1, tris[2-(2-methoxyethoxy)ethyl]amine; Tol, p-toluoyl. For structure of S.8, see Figure 1.10.2.
3-cm-diameter Buchner funnel with filter paper circles High-vacuum pump (final pressure, <1 mmHg) 5 × 50–cm chromatography columns 0.2-mm-thick silica gel 60 F254 aluminum TLC plates (Merck) 254-nm UV lamp Steel bomb (autoclave) 5 × 20–cm Serdolit AD-4 column (resin particle size, 0.1 to 0.2 mm; Serva) Additional reagents and equipment for flash chromatography (APPENDIX 3E) and thin-layer chromatography (TLC; APPENDIX 3D) Protect exocyclic amine (prepare S.18) 1. In a 100-mL round-bottom flask equipped with a Teflon stir bar, prepare a solution of 8.70 g (51.61 mmol) 2-amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (S.17) in 40 mL anhydrous pyridine. 2. Add 8.0 mL (64.95 mmol) pivaloyl chloride dropwise, with stirring, over the course of 15 min, and then stir the reaction mixture 5 hr at room temperature. 3. Evaporate the reaction mixture to near-dryness using a rotary evaporator equipped with a vacuum pump. 4. Remove traces of pyridine by performing two rounds of coevaporation with 10 mL water. 5. Add 100 mL water to the reaction flask. Collect the resulting solid by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, wash with three 80-mL aliquots of cold water, and dry in vacuo over KOH. 4-Chloro-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine (S.18) is obtained as a reddish solid (10.9 g, 84% yield). m.p. 226◦ C. TLC (CH2 Cl2 /MeOH, 95:5): Rf = 0.52. 1 H NMR (DMSO-d6 ): δ 1.24 (s, 9H, 3 × CH3 ), 6.53 (m, 1H, 5-H), 7.63 (m, 1H, 6-H), 10.06 (s, 1H, CONH), 12.34 (s, 1H, NH). Synthesis of Modified Nucleosides
1.10.11 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Perform bromination (prepare S.19) 6. In a 250-mL round-bottom flask equipped with a Teflon stir bar, prepare a solution of 5.7 g (22.56 mmol) compound S.18 in 100 mL CH2 Cl2 . 7. Add 4.82 g (27.08 mmol) N-bromosuccinimide in four portions over 10 min and stir the resulting mixture 5 hr at room temperature. 8. Using a rotary evaporator, evaporate the yellow solution to yield an amber residue. 9. Isolate the purified product in the following way. a. Crystallize product from 200 mL MeOH, collect the crystals by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, and wash crystals twice with 20-mL aliquots of prechilled MeOH. b. Condense filtrate to 80 mL and refrigerate at 5◦ C overnight. Collect the resulting crystals by vacuum filtration, and wash crystals twice with 5-mL aliquots of prechilled MeOH. c. Combine crystals from substeps a and b and dry under high vacuum (<1 mmHg). 5-Bromo-4-chloro-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine (S.19) is obtained as pink crystals (6.0 g, 80% yield). m.p. 204◦ C (dec.). TLC (CH2 Cl2 / MeOH, 95:5): Rf = 0.58. 1 H NMR (DMSO-d6 ): δ 1.23 (s, 9H, 3 × CH3 ), 7.78 (s, 1H, 6-H), 10.16 (s, 1H, CONH), 12.72 (s, 1H, NH). Anal. calcd. for C11 H12 BrClN4 O: C, 39.84; H, 3.65; N, 16.90; found: C, 39.87; H, 3.63; N, 16.90.
Prepare nucleoside precursor S.20 10. In a 100-mL round-bottom flask equipped with a Teflon stir bar, suspend 1.15 g (17.42 mmol) powdered KOH in 60 mL MeCN. 11. Add 0.2 mL (0.63 mmol) TDA-1 and stir the resulting mixture 5 min at room temperature. 12. Under constant stirring, add 1.66 g (5.01 mmol) compound S.19 in three equal portions over the course of 15 min. After addition is complete, stir the reaction mixture for another 15 min at room temperature. 13. Add 2.53 g (6.51 mmol) 2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride (S.8) in four portions over 15 min and stir the resulting mixture 30 min at room temperature. 14. Remove the insoluble material by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, washing with three 20-mL aliquots of MeCN. Evaporate the filtrate to dryness using a rotary evaporator. 15. Load the crude product onto a 5 × 50–cm column packed with silica gel 60 (bed height, 15 cm). Perform flash chromatography (APPENDIX 3E) using an elution gradient from 100% CH2 Cl2 (800 mL) to 99:1 (v/v) CH2 Cl2 /MeOH (400 mL). Collect 15-mL fractions. 16. Monitor fractions by TLC (APPENDIX 3D) on silica gel 60 F254 plates using 99:1 (v/v) CH2 Cl2 /MeOH as the eluent. Visualize products under 254-nm light using a UV lamp. 17. Pool all product fractions and evaporate the solvent using a rotary evaporator.
7-Substituted 7-Deazapurine (Pyrrolo[2,3d]pyrimidine) 2 -Deoxyribonucleosides
18. Dissolve the residue in 20 mL CH2 Cl2 . Crystallize the purified product by adding 100 mL petroleum ether, store 10 hr at 5◦ C, collect the crystals by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, and dry overnight under high vacuum (<1 mmHg).
1.10.12 Supplement 21
Current Protocols in Nucleic Acid Chemistry
5-Bromo-4-chloro-7-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-2pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine (S.20) is obtained as colorless needles (2.32 g, 68% yield). m.p. 229◦ -230◦ C. TLC (CH2 Cl2 /MeOH, 99:1): Rf = 0.53. UV (MeOH): λmax (ε) = 245 nm (55,300). 1 H NMR (CDCl3 ): δ 1.38-1.47 (m, 9H, 3 × CH3 ), 2.55 (s, 3H, CH3 ), 2.57 (s, 3H, CH3 ), 2.91-2.93 (m, 1H, 2 -H), 3.04-3.08 (m, 1H, 2 -H), 4.69-4.70, 4.76-4.78, and 4.85-4.87 (3 × m, 3H, 4 -H, 5 -H), 5.88-5.91 (m, 1H, 3 -H), 6.84 (t, J = 6.7 Hz, 1H, 1 -H), 7.37, 7.43, 8.03, and 8.10 (4 × d, J = 8.1 Hz, 8H, 2 × C6 H4 ), 8.28 (s, 1H, 6-H), 10.29 (s, 1H, NH). Anal. calcd. for C32 H32 BrClN4 O6 : C, 56.19; H, 4.72; N, 8.19; found: C, 56.12; H, 4.79; N, 8.33.
Prepare 2-amino-2 -deoxyadenosine analog S.3c 19. Convert 1.5 g (2.19 mmol) nucleoside S.20 to compound S.3c using the general procedure described for converting S.9 to nucleoside S.1d (see Basic Protocol 1, steps 11 to 17), but stir the reaction 24 hr at 120◦ C after adding NH4 OH. 5-Bromo-7-(2-deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-2,4diamine (S.3c) is obtained as colorless crystals (667 mg, 88% yield). m.p. 208◦ C (dec.). TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.33. UV (MeOH): λmax (ε) = 228 nm (27,800), 268 nm (9,300), 288 nm (sh 7,500). 1 H NMR (DMSO-d6 ): δ 2.00-2.06 and 2.29-2.40 (2 × m, 2H, 2 -H), 3.48-3.52 (m, 2H, 5 -H), 3.74-3.78 (m, 1H, 4 -H), 4.25-4.29 (m, 1H, 3 -H), 4.99 (t, J = 5.4 Hz, 1H, 5 -OH), 5.21 (d, J = 3.6 Hz, 1H, 3 -OH), 5.86 (br s, 2H, NH2 ), 6.28 (br s, 2H, NH2 ), 6.34 (dd, J = 6.5 Hz, J = 6.9 Hz, 1H, 1 -H), 7.15 (s, 1H, 6-H). Anal. calcd. for C11 H14 BrN5 O3 : C, 38.39; H, 4.10; N, 20.35; found: C, 38.22; H, 4.08; N, 20.25.
Prepare 2 -deoxyisoguanosine analog S.4c 20. In a 100-mL round-bottom flask equipped with a Teflon stir bar, dissolve 500 mg (1.45 mmol) nucleoside S.3c in 40.0 mL of 1:5 (v/v) AcOH/H2 O. 21. Add a solution of 250 mg (3.62 mmol) NaNO2 in 8.0 mL H2 O dropwise, with stirring, to the reaction flask. Stir the reaction mixture for an additional 30 min at room temperature after all of the solution has been added. 22. Adjust the pH of the dark solution to 7.0 with 25% NH4 OH. 23. Purify the crude product by loading it onto a 5 × 20–cm Serdolit AD-4 column (resin particle size, 0.1 to 0.2 mm) and performing flash chromatography (APPENDIX 3E). Elute with 300 mL H2 O followed by 500 mL of 95:5 (v/v) H2 O/i-PrOH and 400 mL of 90:10 (v/v) H2 O/i-PrOH. Collect 15-mL fractions. 24. Monitor fractions by TLC (step 16) using 5:1 (v/v) CH2 Cl2 /MeOH as the eluent. 25. Pool all product fractions and use a rotary evaporator to reduce the volume to 20% of the original pooled volume. Collect the resulting crystals by vacuum filtration through a 3-cm Buchner funnel equipped with a filter paper circle, and dry under high vacuum (<1 mmHg). 4-Amino-5-bromo-7-(2-deoxy-β-D-erythro-pentofuranosyl)-3,7-dihydro-2H pyrrolo[2,3d]pyrimidin-2-one (S.4c) is obtained as yellowish crystals (325 mg, 65% yield). m.p. 220◦ C (dec.). TLC (25% NH4 OH/i-PrOH/H2 O, 1:7:2): Rf = 0.9. TLC (CH2 Cl2 /MeOH, 5:1): Rf = 0.28 (tailing). UV (MeOH): λmax (ε) = 232 nm (26,800), 262 nm (5,900), 310 nm (5,800). 1 H NMR (DMSO-d6 ): δ = 2.00-2.08 and 2.25-2.33 (2 × m, 2H, 2 -H), 3.503.51 (m, 2H, 5 -H), 3.74-3.77 (m, 1H, 4 -H), 4.25-4.28 (m, 1H, 3 -H), 5.04-5.06 (m, 1H, 5 -OH), 5.23 (d, J = 3.9 Hz, 1H, 3 -OH), 6.25 (dd, J = 5.8 Hz, J = 6.5 Hz, 1H, 1 -H), 6.85 (br s, 2H, NH2 ), 7.21 (s, 1H, 6-H), 10.77 (br s, 1H, NH). Anal. calcd. for C11 H13 BrN4 O4 : C, 38.28; H, 3.80; N, 16.23; found: C, 38.54; H, 3.72; N, 16.45.
Synthesis of Modified Nucleosides
1.10.13 Current Protocols in Nucleic Acid Chemistry
Supplement 21
BASIC PROTOCOL 4
DETERMINATION OF pK a VALUES OF NUCLEOSIDES This protocol describes the determination of nucleoside pKa values by spectrophotometric titration (pH 1.5 to 13.5; Albert and Serjeant, 1971) at 220 to 350 nm. As a representative example, the pKa measurement of compound S.4c is described. The pKa values of several 7-deazapurine nucleosides are summarized in Table 1.10.1. From Table 1.10.1, it is apparent that the 7-halogenated derivatives of 2-amino-7-deaza2 -deoxyadenosine (S.3b-d) have very similar pKa values (4.8 to 4.9), which are lower than that of the parent nucleoside S.3a (pKa = 5.7). This is because electron-withdrawing halogens reduce the basicity of the 7-deazaadenine moiety. Similar results were observed for the 7-deaza-2 -deoxyxanthosines (pKa = 6.7, 6.0, and 6.1 for S.6a, S.6c, and S.6d, respectively). Given their pKa values, deprotonation of S.6a-d occurs under almost neutral conditions, with 7-halogen substituents further enhancing the acidity of these compounds. In the case of the 7-deazaguanine derivatives S.2a and S.2d and the 7-deazaisoguanine analogs S.4a-c, two pKa values are observed. The lower value corresponds to protonation of the nucleobase, whereas the higher one corresponds to the removal of a proton from the 3 position (systematic numbering). The introduction of 7-halogen substituents leads to decreased pKa values (pKa = 3.9 and 9.7 for S.4b and 3.8 and 9.8 for S.4c, compared with 4.6 and 10.5 for the parent nucleoside S.4a). These differences reflect the increased acidity of 7-halogenated 7-deaza-2 -deoxyisoguanosines.
Materials 4-Amino-5-bromo-7-(2-deoxy-β-D-erythro-pentofuranosyl)-3,7-dihydro-2Hpyrrolo[2,3-d]pyrimidin-2-one (S.4c; see Basic Protocol 3) Phosphate buffer solution, pH 4.5 (see recipe) 1 M H3 PO4 3 M NaOH 100-mL volumetric flask 100-mL beaker pH meter UV-Vis spectrophotometer 1. In a 100-mL volumetric flask, dissolve 2.0 mg S.4c in 100 mL phosphate buffer solution, pH 4.5.
Table 1.10.1 pKa Values of Selected 7-Deazapurine 2 -Deoxyribonucleosidesa
Wavelength (nm)b
pKa
Compound
Wavelength (nm)b
pKa
290
1.7
S.4a
255
4.6
295
10.2
275
10.5
S.2d
300
10.0 and <1.5
S.4b
264
3.9 and 9.7
S.3a
282
5.7
S.4c
264
3.8 and 9.8
S.3b
284
4.9
S.6a
250
6.7
S.3c
286
4.9
S.6c
260
6.0
S.3d
288
4.8
S.6d
260
6.1
Compound S.2a
7-Substituted 7-Deazapurine (Pyrrolo[2,3d]pyrimidine) 2 -Deoxyribonucleosides
a Measured in phosphate buffer solution (see recipe) over a pH range of 1.5 to 12.0. b Wavelength used for pK determination (i.e., wavelength at which the absorbance changed most significantly as a function a
of pH).
1.10.14 Supplement 21
Current Protocols in Nucleic Acid Chemistry
2. Transfer a 50-mL aliquot of the S.4c solution to a 100-mL beaker. Vary the pH of the aliquot from 4.5 to 1.5 in steps of 0.5 pH units by adding 1 M H3 PO4 to the beaker in dropwise fashion. At each pH level, obtain a UV absorption spectrum from 220 to 350 nm. 3. Transfer another 50-mL aliquot of the S.4c solution to a clean 100-mL beaker. Vary the pH of the aliquot from 4.5 to 13.5 in steps of 0.5 pH units by adding 3 M NaOH to the beaker in dropwise fashion. At each pH level, obtain a UV absorption spectrum from 220 to 350 nm. 4. Collect all absorbance data obtained at 264 nm (i.e., the wavelength at which the most significant change in UV absorbance as a function of pH is observed) and plot a profile of absorbance versus pH (origin, pH 7.0). 5. Calculate the first derivative of absorbance with respect to pH, dA/d(pH), at each point on the plot. Define the pKa of the nucleoside as the pH that gives a maximal value for dA/d(pH).
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
NaH2 PO4 buffer, 0.1 M, pH 7.0 Dissolve 7.9 g NaH2 PO4 ·H2 O in 500 mL H2 O Neutralize with 1 M NaOH to pH 7.0 Store tightly capped for up to 4 months at room temperature Phosphate buffer solution, pH 4.5 Dissolve 7.8 g NaH2 PO4 ·H2 O in 500 mL H2 O Stir 2 hr at room temperature Store tightly capped for up to 4 months at room temperature COMMENTARY Background Information A series of naturally occurring 7deazapurines (pyrrolo[2,3-d]pyrimidines) have been isolated from natural sources. Among them are monomeric, naturally occurring nucleosides such as tubercidin and its 7-substituted derivatives (Suhadolnik, 1970). Other such nucleosides are found as metabolites or antimetabolites of marine organisms, and some of them carry halogens at the 7 position of the 7-deazapurine moiety. 7-Deazapurine ribonucleosides (e.g., queuosine, archaeosine) are found as constituents of naturally occurring nucleic acids such as tRNA (Kasai et al., 1975; Kilpatrick and Walker, 1982). Several naturally occurring 7-deazapurine nucleosides or chemically designed analogs exhibit antiviral and/or anticancer activity (Martin, 1989; Simons, 2001). As the shape of the 7-deazapurine nucleosides closely resembles that of the
purine nucleosides, these molecules can substitute for the canonical constituents of DNA and RNA. They have also been used in their triphosphate forms for nucleic acid labeling or sequencing (Mizusawa et al., 1986; Prober et al., 1987). The frequent natural occurrence and unusual biological properties of this class of compounds have prompted ample studies directed toward their synthesis, toward analysis of their biological activity, and toward their incorporation into oligonucleotides (Revankar and Robins, 1991). In an effort to investigate the association of these compounds with stabilizing effects on oligonucleotides or with antiviral activity, a number of 7-deazapurine nucleosides have been synthesized. These compounds became synthetically accessible with the development of stereoselective nucleobase anion glycosylation (Winkeler and Seela, 1983;
Synthesis of Modified Nucleosides
1.10.15 Current Protocols in Nucleic Acid Chemistry
Supplement 21
7-Substituted 7-Deazapurine (Pyrrolo[2,3d]pyrimidine) 2 -Deoxyribonucleosides
Seela et al., 1988). A number of 7-deazapurine 2 -deoxyribonucleosides have been synthesized by this method. A similar method was later applied to other base-modified nucleosides (Kazimierczuk et al., 1984), many of which have been incorporated into oligonucleotides. Substituents—in particular, halogen or alkynyl substituents—are well accommodated in the major groove of duplex DNA. Some nucleosides have the potential to be used for further chemical and functional manipulations. Detailed investigations have been performed to study the selective halogenation of 7-deazapurines at C7. In the case of 7-deazapurines containing a 2-amino group, halogenation can also be directed to C8 or to both C7 and C8, yielding 7,8-dihalogenated products. In the absence of a 2-amino group, 7-halogenated 7-deazapurines are formed. It was eventually found that regioselective 7-halogenation with N-halosuccinimides can be accomplished when the 2-amino group is protected (Ramzaeva and Seela, 1995; Balow et al., 1998; Seela and Peng, 2004). From 7iodo derivatives, the 7-alkynyl-7-deazapurine nucleosides are prepared using the palladiumcatalyzed Sonogashira cross-coupling reaction (Seela and Zulauf, 1996). The reaction is performed under argon in anhydrous DMF with tetrakis(triphenylphosphine)palladium(0), copper(I) iodide, and triethylamine. The synthesis of the 7-halogenated derivatives S.1-6 via nucleobase anion glycosylation uses well-established chemistry. Glycosylation of the nucleobases is performed in acetonitrile with 2-deoxy-3,5-di-O-(ptoluoyl)-α-D-erythro-pentofuranosyl chloride (S.8). The glycosylation reaction is stereoselective and gives the β-D anomer exclusively in most cases. Deprotection, amination, deamination, and hydroxylation of 7-deazapurine nucleosides produce close-to-quantitative yields. Two general routes are employed for the synthesis of 7-halogenated 7-deazapurine nucleosides: (1) conversion of a preformed nucleoside precursor to a 7-halogenated nucleoside (see Basic Protocol 2) and (2) halogenation of the nucleobase followed by glycosylation (see Basic Protocol 1 and Basic Protocol 3). Though this unit presents only representative halogenated (i.e., iodo and bromo) derivatives in each protocol, the modifications for preparation of other halogenated analogs (bromo, iodo, chloro, and fluoro) are straightforward, involving primarily the substitution of the appropriate halogenated
reagents. For additional details, refer to the references provided in Figure 1.10.1. The pKa values of the nucleobases reflect the strength of the hydrogen bonds they form in double-stranded DNA, which is an important factor in assessing the biophysical properties of nucleosides. The authors have reported pKa values for a series of 7-modified 7-deazapurine nucleosides. A method for determining pKa values is presented in Basic Protocol 4. A few 7-deazapurine 2 -deoxyribonucleosides show interesting photophysical properties. Among these are the 2-amino and 2-hydroxy derivatives S.21 and S.22 (Fig. 1.10.5), which exhibit strong fluorescence (Seela and Steker, 1984; Seela and Engelke, 1985; Seela et al., 1994). In contrast, 7-deaza-2 -deoxyguanosine (S.2a) and 7-deaza-2 -deoxyisoguanosine (S.4a) serve as efficient fluorescence quenchers (Latimer and Lee, 1991; Li et al., 2004). The fluorescence emission maximum of S.21 is observed at 395 nm (excitation 311 nm), and a quantum yield (φf ) of 0.47 has been determined (Seela and Becher, 2000). Replacement of the amino group with a hydroxyl group (which can take part in keto-enol tautomerization, S.22) results in a bathochromic shift in absorption (331 nm) and emission (444 nm), as well as a decreased fluorescence quantum yield (φf = 0.22; Seela et al., 1998). The strong fluorescence of S.21 is quenched to approximately 1/10 of its original intensity when it is incorporated into a dinucleotide (Seela and Engelke, 1985). This quenching is a result of the strong stacking interactions between nucleobases. When incorporated into oligonucleotides, S.2a and S.4a quench the fluorescence of ethidium bromide (Latimer and Lee, 1991; Li et al., 2004). Normally, the fluorescence of ethidium bromide is enhanced strongly when it intercalates into duplex DNA (LePecq and Paoletti, 1967). However, when S.2a or S.4a is incorporated into duplex DNA in place of deoxyguanosine or deoxyisoguanosine, the fluorescence of the dye is totally quenched (Li et al., 2004). This quenching results from a photoinduced electron transfer from 7-deaza2 -deoxyguanosine to ethidium bromide (Kelley and Barton, 1998).
Compound Characterization 1
H and 13 C NMR spectra were measured for all analogs using AC-250 and AMX500 spectrometers (Bruker); δ values are given in ppm downfield from internal tetramethylsilane (SiMe4 ). The signals are assigned
1.10.16 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Figure 1.10.5 properties.
Structures of 7-deazapurine 2 -deoxyribonucleosides with interesting fluorescence
unambiguously. UV spectra were measured using a U-3200 spectrometer (Hitachi), and extinction coefficients were determined (λmax in nm, ε in M−1 ·cm−1 ). Melting points were measured using a Linstr¨om apparatus. Elemental analyses were performed in all cases by Mikroanalytisches Laboratorium Beller (G¨ottingen, Germany). Mass spectrometric characterization of organic compounds does not provide information on the purity of the material tested. Elemental analyses, UV data, 1 H NMR data, and melting points are given in the protocol steps; 13 C NMR data are shown in Table 1.10.2.
Critical Parameters
The synthesis of 7-deazapurine 2 deoxyribonucleosides via nucleobase anion glycosylation is straightforward. Purification of the intermediates can be performed under regular laboratory conditions. Exposure of the reaction mixture to sunlight should be avoided. The workup must be performed carefully, as protecting groups can be lost due to the alkaline conditions employed in the glycosylation reaction and in the workup. With regard to high glycosylation yields, the purity of the nucleobase is the key to a successful reaction. Impurities that are not removed after halogenation, such as traces of Nhalosuccinimides, will lower the reaction yields significantly. Amination of the 6halogenated intermediates is performed in a
mixture of 1,4-dioxane and aqueous NH3 to reduce the displacement of halogen substituents by hydroxides.
Troubleshooting The solubility of the deprotected nucleosides will sometimes lead to problems during purification (e.g., crystallization on the silica gel column). Crystallization of the deprotected glycosylation product from methanol or other alcohols without column chromatography is often successful. Chromatographic separation on a Serdolit AD-4 column (resin particle size, 0.1 to 0.2 mm; Serva) is useful for purifying guanosine or isoguanosine analogs.
Anticipated Results The nucleobase anion glycosylation reaction allows for large-scale preparation of various 7-deazapurine 2 -deoxyribonucleosides in a regioselective and stereoselective way. Regioselective 7-halogenation can be performed on either the nucleobase or the nucleoside. The position at which the modification occurs and the reactivity observed depend on the reaction conditions and on the structure of the starting material.
Time Considerations The time needed for synthesis and purification of the various reaction intermediates and products depends on the required reaction time, the ease of purification, and the
Synthesis of Modified Nucleosides
1.10.17 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Table 1.10.2
13
C NMR Chemical Shifts (δ) for 7-Deazapurine 2 -Deoxyribonucleosidesa,b
Sys Pur
C(2)c C(2)
C(4)c C(6)
C(4a) C(5)
S.9
150.7
151.2
116.7
S.10 S.1d S.11
151.1
151.4
152.0
157.3
151.2
150.9
116.7 103.2 106.5
C(5) C(7) 53.9 53.3 51.9 162.1
C(6) C(8)
C(7a)c C(4)
C(1 )
C(2 )
C(3 )
C(4 )
C(5 )
133.3
150.5
83.7
—d
74.7
81.5
63.9
85.5
d
70.8
87.8
61.7
d
71.0
87.5
62.0
d
70.7
87.4
61.6
d
133.5 126.9 51.1
150.5 149.8 129.0
83.0 83.6
— — —
S.5d
144.6
147.2
108.0
157.7
55.4
125.6
83.2
—
70.9
87.6
61.8
S.14
152.3
162.8
103.3
52.5
127.3
152.2
82.9
37.8
74.0
81.2
63.5
S.2d
152.7
157.7
99.8
102.2
121.5
150.5
82.2
38.5
70.9
87.0
61.9
82.9
d
70.8
87.9
62.7
d
70.7
87.2
61.6
d
S.15 S.16 S.6d e
S.20 S.3c S.4c
160.2
163.6
159.8
163.8
99.5 100.2
49.4 51.9
124.9 125.5
155.0 151.7
83.0
— —
150.3
158.8
103.1
56.2
122.2
138.7
85.4
—
70.6
87.4
61.3
152.5
151.7
112.0
89.8
125.4
151.3
84.5
40.3
74.8
82.6
63.9
81.9
—
d
70.9
86.9
61.9
—
d
70.8
87.2
61.8
160.1
157.2
153.6
156.0
94.3 91.0
87.4 87.4
117.0
152.1
118.8
f
—
82.5
a Sys, carbon position in systematic numbering scheme; Pur, carbon position in purine numbering scheme. b Measured in DMSO-d unless otherwise indicated. 6 c Peak assignments are tentative. d Superimposed upon DMSO-d peak. 6 e Measured in CDCl . 3
f Not detected.
experience of the person running the experiments. For an experienced chemist, the synthesis of S.1d or S.5d starting from nucleobase S.7 (Basic Protocol 1) and synthesis of S.2d from nucleoside S.12 (Basic Protocol 2) can all be performed in ∼2 weeks. Synthesis of S.6d from S.12 (Basic Protocol 2) and of S.4c from nucleobase S.17 (Basic Protocol 3) require ∼3 weeks. In these syntheses, many intermediates can be purified by crystallization without using column chromatography.
Literature Cited Albert, A. and Serjeant, E.P. 1971. Determination of ionization constants by spectrometry. In The Determination of Ionization Constants, pp. 44-64. Chapman & Hall, London. Balow, G., Mohan, V., Lesnik, E.A., Johnston, J.F., Monia, B.P., and Acevedo, O.L. 1998. Biophysical and antisense properties of oligodeoxynucleotides containing 7-propynyl-, 7-iodo- and 7-cyano-7-deaza-2-amino-2 deoxyadenosines. Nucl. Acids Res. 26:33503357. 7-Substituted 7-Deazapurine (Pyrrolo[2,3d]pyrimidine) 2 -Deoxyribonucleosides
Hoffer, M. 1960. α-Thymidin. Chem. Ber. 93:27772781. Latimer, L.J. and Lee, J.S. 1991. Ethidium bromide does not fluoresce when intercalated adjacent to
7-deazaguanine in duplex DNA. J. Biol. Chem. 266:13849-13851. LePecq, J.B. and Paoletti, C. 1967. A fluorescent complex between ethidium bromide and nucleic acids. Physical-chemical characterization. J. Mol. Biol. 27:87-106. Kasai, H., Ohashi, Z., Harada, F., Nishimura, S., Oppenheimer, N.J., Crain, P.F., Liehr, J.G., von Minden, D.L., and McCloskey, J.A. 1975. Structure of the modified nucleoside Q isolated from Escherichia coli transfer ribonucleic acid. 7-(4,5-cis-Dihydroxy-1-cyclopenten-3ylaminomethyl)-7-deazaguanosine. Biochemistry 14:4198-4208. Kazimierczuk, Z., Cottam, H.B., Revankar, G.R., and Robins, R.K. 1984. Synthesis of 2 deoxytubercidin, 2 -deoxyadenosine, and related 2 -deoxynucleosides via a novel direct stereospecific sodium salt glycosylation procedure. J. Am. Chem. Soc. 106:63796382. Kelley, S.O. and Barton, J.K. 1998. DNA-mediated electron transfer from a modified base to ethidium: Pi-stacking as modulator of reactivity. Chem. Biol. 5:413-425. Kilpatrick, M.W. and Walker, R.T. 1982. The nucleotide-sequence of the transferRNA-met(m) from the archaebacterium thermoplasma-acidophilum. Zentralbl. Bakteriol. Mikrobiol. Hyg. 1 Abt. Orig. C 3: 79-89.
1.10.18 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Li, H., Peng, X., and Seela, F. 2004. Fluorescence quenching of parallel-stranded DNA bound ethidium bromide: The effect of 7deaza-2 -deoxyisoguanosine and 7-halogenated derivatives. Bioorg. Med. Chem. Lett. 14: 6031-6034. Martin, J.C. (ed.) 1989. Nucleotide Analogues as Antiviral Agents. American Chemical Society, Washington, D.C. Mizusawa, S., Nishimura, S., and Seela, F. 1986. Improvement of the dideoxy chain termination method of DNA sequencing by use of deoxy-7deazaguanosine triphosphate in place of dGTP. Nucl. Acids Res. 14:1319-1324. Prober, J.M., Trainor, G.L., Dam, R.J., Hobbs, F.W., Robertson, C.W., Zagursky, R.J., Cocuzza, A.J., Jensen, M.A., and Baumeister, K. 1987. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 238:336-341. Pudlo, J.S., Nassiri, M.R., Kern, E.R., Wotring, L.L., Drach, J.C., and Townsend, L.B. 1990. Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2propoxy)methyl]pyrrolo[2,3-d]pyrimidines. J. Med. Chem. 33:1984-1992. Ramzaeva, N. and Seela, F. 1995. 7-Substituted 7-deaza-2 -deoxyguanosines: Regioselective halogenation of pyrrolo[2,3-d]pyrimidine nucleosides. Helv. Chim. Acta 78:10831090. Ramzaeva, N., Mittelbach, C., and Seela, F. 1999. 7-Halogenated 7-deaza-2 -deoxyinosines. Helv. Chim. Acta 82:12-18. Revankar, G.R. and Robins, R.K. 1991. Pyrrolo[2,3-d]pyrimidine (7-deazapurine) nucleosides. In Chemistry of Nucleosides and Nucleotides (L.B. Townsend, ed.) pp. 200-247. Plenum, New York. Rolland, V., Kotera, M., and Lhomme, J. 1997. Convenient preparation of 2-deoxy-3,5-di-Op-toluoyl-α-D-erythro-pentofuranosyl chloride. Synth. Commun. 27:3505-3511. Seela, F. and Becher, G. 2000. Synthesis, base pairing, and fluorescence properties of oligonucleotides containing 1H-pyrazolo[3,4d]pyrimidin-6-amine (8-aza-7-deazapurin-2amine) as an analogue of purin-2-amine. Helv. Chim. Acta 83:928-942. Seela, F. and Driller, H. 1989. 7-Deaza-2 -deoxyO6 -methylguanosine: Selective N2 -formylation via a formamidine, phosphoramidite synthesis and properties of oligonucleotides. Nucleosides Nucleotides 8:1-21. Seela, F. and Engelke, U. 1985. Ein Purin/7Desazapurin-Dinucleosid-Monophosphat mit 2Amino-7H-pyrrolo[2,3-d]pyrimidin als fluoreszierender Base. Liebigs Ann. Chem. 11751184. Seela, F. and Kehne, A. 1983. 2 -Desoxytubercidin: Synthese eines 2 -Desoxyadenosin-Isosteren durch Phasentransferglycosylierung. Liebigs Ann. Chem. 876-884.
Seela, F. and Menkhoff, S. 1985. Synthese von 7Desaza-2 -desoxyinosin durch Phasentransferglycosylierung. Liebigs Ann. Chem. 1360-1366. Seela, F. and Peng, X. 2004. Regioselective syntheses of 7-halogenated 7-deazapurine nucleosides related to 2-amino-7-deaza-2 -deoxyadenosine and 7-deaza-2 -deoxyisoguanosine. Synthesis 1203-1210. Seela, F. and Shaikh, K. 2004. 7Halogenated 7-deaza-2 -deoxyxanthine 2 -deoxyribonucleosides. Helv. Chim. Acta 87:1325-1332. Seela, F. and Steker, H. 1984. Synthese von 2 -desoxyribofuranosiden des 7H-Pyrrolo[2,3d]pyrimidins: Einfluβ des C-2-Substituenten auf Fluoreszenz. Liebigs Ann. Chem. 1719-1730. Seela, F. and Thomas, H. 1994. Synthesis of certain 5-substituted 2 -deoxytubercidin derivatives. Helv. Chim. Acta 77:897-903. Seela, F. and Wei, C. 1999. The base-pairing properties of 7-deaza-2 -deoxyisoguanosine and 2 deoxyisoguanosine in oligonucleotide duplexes with parallel and antiparallel chain orientation. Helv. Chim. Acta 82:726-745. Seela, F. and Zulauf, M. 1996. Palladium-catalyzed cross coupling of 7-iodo-2 -deoxytubercidin with terminal alkynes. Synthesis 726-730. Seela, F., Driller, H., and Liman, U. 1985. 7Desaza-Isostere von 2 -Desoxyxanthosin und 2 -Desoxyspongosin: Synthese via Glycosylierung von 2,4-Dichlor-7H-pyrrolo[2,3d]pyrimidin. Liebigs Ann. Chem. 312320. Seela, F., Steker, H., Driller, H., and Bindig, U. 1987. 2-Amino-2 -desoxytubercidin und verwandte Pyrrolo[2,3-d]pyrimidinyl-2 desoxyribofuranoside. Liebigs Ann. Chem. 15-19. Seela, F., Westermann, B., and Bindig, U. 1988. Liquid-liquid and solid-liquid phase-transfer glycosylation of pyrrolo[2,3-d]pyrimidines: Stereospecific synthesis of 2-deoxy-βD-ribofuranosides related to 2 -deoxy-7carbaguanosine. J. Chem. Soc., Perkin Trans. I 697-702. Seela, F., Chen, Y., Bindig, U., and Kazimierczuk, Z. 1994. Synthesis of 2 -deoxyisoinosine and related 2 -deoxyribonucleosides. Helv. Chim. Acta 77:194-202. Seela, F., Chen, Y., and Sauer, M. 1998. Synthesis of 2 ,3 -didehydro-2 ,3 -dideoxyisoinosine and oxidation of fluorescent 2-hydroxypurine nucleosides by xanthine oxidase. Nucleosides Nucleotides 17:39-52. Seela, F., Zulauf, M., Sauer, M., and Deimel, M. 2000. 7-Substituted 7-deaza-2 deoxyadenosines and 8-aza-7-deaza-2 deoxyadenosines: fluorescence of DNA-base analogues induced by the 7-alkynyl side chain. Helv. Chim. Acta 83:910-927. Seela, F., Chittepu, P., He, Y., He, J., and Xu, K. 2005. 6-Azapyrimidine and 7-deazapurine Syn2 -deoxy-2 -fluoroarabinonucleosides: thesis, conformation and properties of
Synthesis of Modified Nucleosides
1.10.19 Current Protocols in Nucleic Acid Chemistry
Supplement 21
oligonucleotides. Nucleosides Nucleic Acids In press.
Nucleotides
Simons, C. 2001. Nucleoside Mimetics: Their Chemistry and Biological Properties. Gordon and Breach Science Publishers, Amsterdam. Suhadolnik, R.J. 1970. Pyrrolopyrimidine nucleosides. In Nucleoside Antibiotics, pp. 298-353. Wiley-Interscience, New York. Winkeler, H.D. and Seela, F. 1983. Synthesis of 2-amino-7-(2 -deoxy-β-D-erythropentofuranosyl)-3,7-dihydro-4H-pyrrolo[2,3d]pyrimidin-4-one, a new isostere of 2 deoxyguanosine. J. Org. Chem. 48:31193122.
Contributed by Frank Seela and Xiaohua Peng Universit¨at Osnabr¨uck Osnabr¨uck, Germany and Center for Nanotechnology (CeNTech) M¨unster, Germany
7-Substituted 7-Deazapurine (Pyrrolo[2,3d]pyrimidine) 2 -Deoxyribonucleosides
1.10.20 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Reduction of Ribonucleosides to 2-Deoxyribonucleosides
UNIT 1.11
This unit describes details of a four-step procedure for the conversion of ribonucleosides (RNA components) to 2 -deoxyribonucleosides (DNA components) originally reported in (Robins and Wilson, 1981, 1991; Robins et al., 1983a). These procedures provide an efficient chemical analogy to the biosynthetic reduction of ribonucleoside 5 -di- or 5 -triphosphates to 2 -deoxyribonucleotides, which is catalyzed by ribonucleotide reductases. The general four-step procedure is first illustrated for the conversion of adenosine to 2 -deoxyadenosine (see Basic Protocol). As shown in Figure 1.11.1, the procedure involves (1) simultaneous protection of the 3 - and 5 -hydroxyl groups of adenosine with a bifunctional cyclic disiloxane moiety, (2) thioacylation of the 2 -hydroxyl group with phenoxythiocarbonyl chloride, (3) free radical–induced reductive cleavage of the C2 –O2 bond with tributyltin hydride, and (4) deprotection with tetrabutylammonium fluoride. Using this procedure, adenosine (S.1) is converted to 2 -deoxyadenosine (S.5) with a combined yield of 78%. This approach constitutes a convenient and efficient overall chemical 2 -deoxygenation of a ribonucleoside, with an average yield of 94% for each of the four steps and without the need for chromatographic purification of any intermediates. Analytical samples of intermediates S.2, S.3, and S.4 can be obtained by performing chromatography and/or recrystallization. The use of tributyltin deuteride in the reduction step gives 2 -deuterio-2 -deoxyadenosine (S.7; Fig. 1.11.2) with >85% stereoselectivity for retention of configuration. This variation is presented (see Alternate Protocol 1), as are slightly modified procedures for the synthesis of 2 -deoxyguanosine (see Alternate Protocol 2), 2 -deoxyuridine (see Alternate Protocol 3), and 2 -deoxycytidine (see Alternate Protocol 4). CAUTION: Procedures in this unit use several toxic [e.g., tributyltin hydride, 4-(dimethylamino)pyridine] and sensitive (e.g., phenoxythiocarbonyl chloride) reagents, which require handling with great care. All reactions must be performed in an efficient chemical fume hood. It is highly recommended that all workup (i.e., isolation) and purification operations (including column chromatography on silica gel with organic chemical elution solvents) also be performed in a fume hood. Methods for disposal of all toxic materials must be in compliance with the National Research Council’s Prudent Practices in the Laboratory: Handling and Disposal of Chemicals (NRC, 1995).
PREPARATION OF 2 -DEOXYADENOSINE BY REDUCTION OF ADENOSINE
BASIC PROTOCOL
The first step in the overall 2 -deoxygenation procedure involves synthesis of 3 ,5 -OTPDS-adenosine (3 ,5 -O-TPDS-Ado; S.2; Fig. 1.11.1) by treatment of adenosine (S.1) with 1,3-dichloro-1,1,3,3-tetraisopropyl-1,3-disiloxane (TPDS-Cl2 ) in pyridine. This disiloxane reagent effects simultaneous protection of the 3 - and 5 -hydroxyl groups of ribonucleosides and provides ready access to selective funtionalization of the 2 -hydroxyl group (Markiewicz, 1979; Robins and Wilson, 1981; Robins et al., 1983a,b). The second step involves thioacylation of the 2 -hydroxyl group. To that end, synthesis of 3 ,5 -O-TPDS-2 -O-PTC-Ado (S.3) is accomplished by treatment of 3 ,5 -O-TPDS-Ado with 1.25 molar equivalents of phenoxythiocarbonyl chloride (PTC-Cl) in anhydrous acetonitrile, using 2 molar equivalents of 4-(dimethylamino)pyridine (DMAP) as a catalyst. The development of the thiocarbonyl reagent PTC-Cl was crucial for the efficient overall conversion of ribonucleosides to 2 -deoxyribonucleosides. PTC-Cl is a moderately active
Contributed by Morris J. Robins and Stanislaw F. Wnuk Current Protocols in Nucleic Acid Chemistry (2005) 1.11.1-1.11.14 C 2005 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Nucleosides
1.11.1 Supplement 21
Figure 1.11.1 Synthesis of 2 -deoxyadenosine from adenosine via a four-step procedure. The expected overall yield of S.5 from S.1 is given in parentheses. The stated yield is achieved if chromatographic purification of the intermediates S.2, S.3, and S.4 is not required. AIBN, α,α -azobisisobutyronitrile; DMAP, 4-(dimethylamino)pyridine; PTC-Cl, phenoxythiocarbonyl chloride; TBAF, tetrabutylammonium fluoride; THF, tetrahydrofuran; TPDS-Cl2 , 1,1,3,3-tetraisopropyl-1,3dichlorodisiloxane; rt, room temperature.
acylating reagent and converts the secondary 2 -hydroxyl group of S.2 to the thionocarbonate ester of S.3 in high yield. This conversion requires catalysis by DMAP (Robins and Wilson, 1981; Robins et al., 1983a). The third step involves free radical–induced reductive cleavage of the C2 –O2 bond in the phenyl thionocarbonate ester using tributyltin hydride. The thionoester undergoes clean homolytic hydrogenolysis (Barton and McCombie, 1975) upon treatment with 1.5 molar equivalents of tributyltin hydride with α,α -azobisisobutyronitrile (AIBN) as the radical initiator (Robins and Wilson, 1981; Robins et al., 1983a), to give 2 -deoxy-3 ,5 -O-TPDSAdo (S.4).
Reduction of Ribonucleosides to 2 -Deoxyribonucleosides
The fourth and final step involves removal of the silyl protection from the 3 - and 5 hydroxyl groups with tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF). Treatment of S.4 with TBAF/THF at ambient temperature followed by heating in an oil bath at 75◦ C for an hour produces 2 -deoxyadenosine (S.5). Convenient chromatographic purification with Dowex 1 × 2 (OH− ) ion-exchange resin followed by recrystallization gives 2 -deoxyadenosine in 78% yield overall from adenosine (Robins and Wilson, 1981, 1991; Robins et al., 1983a).
1.11.2 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Materials Adenosine (S.1; Yamasa Shoyu or Aldrich) Nitrogen gas Dried pyridine (see recipe) or anhydrous pyridine in Sure/Seal bottles (Aldrich) 1,3-Dichloro-1,1,3,3-tetraisopropyl-1,3-disiloxane (Aldrich) Chloroform Methanol Ethyl acetate 1 M HCl, ice cold Saturated NaHCO3 solution Saturated NaCl solution (brine) Anhydrous sodium sulfate (Na2 SO4 ) Silica gel (Merck Kieselgel 60, 230 to 400 mesh) Hot acetonitrile (∼70◦ C) Dried acetonitrile (see recipe) 4-(Dimethylamino)pyridine (DMAP; Aldrich) Phenoxythiocarbonyl chloride (phenyl chlorothionoformate; PTC-Cl; Aldrich) Dried toluene (see recipe) α,α -Azobisisobutyronitrile (AIBN; Aldrich) Tributyltin hydride (Aldrich) Oxygen-free nitrogen Ethanol Dried tetrahydrofuran (see recipe) 1 M tetrabutylammonium fluoride (TBAF) in THF (solution purchased from Aldrich) Diethyl ether Dowex 1 × 2 (OH− ) ion-exchange resin (see recipe) Phosphorus pentoxide (P2 O5 ) Heating mantle Reflux condensers Vacuum drying pistol (Ace Glass) Oven-dried 100-mL two- or three-neck round-bottom flasks with septa Syringes and syringe needles TLC plates (Merck Kieselgel 60 F254 aluminum-backed sheets or equivalent) Ultraviolet lamp (254 nm) B¨uchi rotary evaporator with Dewar dry ice condenser, connected to a “house” vacuum system or vacuum pump 50- and 250-mL separatory funnels Glass funnel with Whatman no. 1 fluted filter paper 3 × 40–cm, 2 × 30–cm, and 1 × 20–cm chromatography columns Silicon oil bath Wide-mouth 50-mL Erlenmeyer flask Desiccator or other closed glass vessel Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and column chromatography (APPENDIX 3E) NOTE: All evaporations are effected with a B¨uchi rotary evaporator equipped with a Dewar dry ice condenser. This is connected to a house vacuum system (≤15 Pa) when evaporating more volatile materials and to a mechanical oil pump (<1 Pa) when evaporating less volatile materials in vacuo. The heating bath for the evaporation flask is maintained at ≤40◦ C.
Synthesis of Modified Nucleosides
1.11.3 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Prepare 3 ,5 -O-protected adenosine 1. Dry an adenosine sample (S.1) 24 hr at ≤10 Pa, 100◦ C (refluxing water), in a vacuum drying pistol. 2. Place 267 mg (1.0 mmol) dried adenosine in an oven-dried 100-mL two- or threeneck round-bottom flask containing a stir bar. Seal each neck with a septum, flush the flask and its contents with nitrogen using a slow positive nitrogen flow through a syringe, and maintain a nitrogen atmosphere to protect the contents from moisure. 3. Add 10 mL dried pyridine using a dry syringe inserted through one septum. Alternatively, anhydrous pyridine from a Sure/Seal bottle (Aldrich) can be used.
4. To the resulting suspension, add 320 µL (316 mg, 1.0 mmol) 1,3-dichloro-1,1,3,3tetraisopropyl-1,3-disiloxane over ∼1 min using a dry syringe. 5. Stir the mixture at ambient temperature for ∼6 hr. Monitor reaction progress by TLC (APPENDIX 3D) on silica gel plates. Apply adenosine to the plate beside the reaction mixture for comparison. Develop plates with 9:1 (v/v) chloroform/MeOH, and visualize bands under a UV lamp (254 nm). The Rf value for the product (S.2) is higher than that for adenosine (S.1).
6. When the reaction is complete, evaporate all volatile materials in vacuo using a B¨uchi rotary evaporator equipped with a Dewar dry ice condenser and oil pump. 7. Add 50 ml ethyl acetate to the oily residue in the flask, transfer to a 250-mL separatory funnel, and wash with 30 mL water. 8. Separate the organic layer and wash it successively with ice-cold 1 M HCl (2 × 20 mL), ice-cold water (15 mL), saturated NaHCO3 (15 mL), and saturated NaCl (15 mL). 9. Dry the washed organic layer over ∼70 g anhydrous Na2 SO4 . Filter off the Na2 SO4 by gravity filtration with a glass funnel and Whatman no. 1 fluted filter paper, and evaporate the filtrate to dryness using a rotary evaporator connected to a vacuum system. Dry the resulting amorphous solid overnight in vacuo. The dried amorphous solid S.2 (∼500 mg, ∼98% yield) is of sufficient purity for direct use in the subsequent thioacylation step. If desired, it can be purified further on a silica gel column and recrystallized as described in steps 10 to 15.
10. Prepare a slurry of ∼100 g silica gel in chloroform and pour it into a 3 × 40–cm chromatography column. 11. Dissolve the dried product in a minimal amount of chloroform and layer it carefully on top of the silica gel. 12. Elute with 100 mL chloroform followed by 0.5% to 4.0% MeOH/chloroform, increasing the polarity by 0.5% MeOH for each additional 50 mL chloroform. Collect 25-mL fractions. 13. Evaluate fractions by TLC (as in step 5) and combine fractions that contain only S.2. Evaporate the volatile materials from the combined fractions using a rotary evaporator equipped with a vacuum system, and dry the purified S.2 overnight in vacuo. Reduction of Ribonucleosides to 2 -Deoxyribonucleosides
14. Recrystallize the amorphous glass by adding a small amount of hot (∼70◦ C) acetonitrile (∼30 mL) and chilling the resulting solution at ∼4◦ C. 15. Collect the precipitate by vacuum filtration and dry it in vacuo.
1.11.4 Supplement 21
Current Protocols in Nucleic Acid Chemistry
16. Check the purity of the product if analytically pure material is required. The yield of purified 3 ,5 -O-(1,1,3,3-tetraisopropyldisilox-1,3-diyl)adenosine (S.2) is ∼433 mg (85%). m.p. 98◦ –99.5◦ C. UV (MeOH) max 259 nm (ε 14,900). 1 H NMR (400 MHz, DMSO-d6 ): δ 1.05–1.10 (m, 28H), 3.92 (dd, J = 12.6, 2.6 Hz, 1H), 4.00 (dt, J = 8.0, 3.0 Hz, 1H), 4.05 (dd, J = 12.6, 3.2 Hz, 1H), 4.51 (“t”, J = 5.0 Hz, 1H), 4.78 (dd, J = 8.0, 5.0 Hz, 1H), 5.60 (d, J = 4.7 Hz, 1H), 5.86 (d, J = 0.9 Hz, 1H), 7.30 (br s, 2H), 8.10 (s, 1H), 8.19 (s, 1H). HRMS (EI) m/z 509.2485 (M+ [C22 H39 N5 O5 Si2 ] = 509.2490).
Perform thioacylation of 2 -OH 17. In an oven-dried 100-mL two- or three-neck round-bottom flask containing a stir bar, dissolve the vacuum-dried sample of compound S.2 (from step 9 or step 15) in 15 mL dried acetonitrile. Protect from moisture by flushing with nitrogen and maintaining a nitrogen atmosphere at a positive pressure. 18. Add 250 mg (2.05 mmol) DMAP in one portion. 19. Slowly add 172 µL (215 mg, 1.25 mmol) PTC-Cl using a dry syringe inserted through one of the septa. 20. Stir the mixture at ambient temperature for ∼16 hr. Monitor reaction progress by TLC as in step 5, but develop plates with 19:1 (v/v) chloroform/MeOH. The Rf value for the product (S.3) is higher than that for the starting material (S.2).
21. When the reaction is complete, evaporate all volatile materials in vacuo. 22. Add 50 mL ethyl acetate to the oily residue, transfer to a 250-mL separatory funnel, and wash with 30 mL water. 23. Separate the organic layer and wash it successively with ice-cold 1 M HCl (20 mL), ice-cold water (15 mL), saturated NaHCO3 (15 mL), and saturated NaCl (15 mL). 24. Dry the washed organic layer over ∼60 g anhydrous Na2 SO4 , filter off the Na2 SO4 by gravity filtration, and evaporate the filtrate to dryness using a rotary evaporator connected to a vacuum system. Dry the resulting light-yellow oil overnight in vacuo to give a solid foam. The amorphous product S.3 (∼625 mg, ∼97% yield from S.1) is of sufficient purity for direct use in the subsequent cleavage step. If desired, it can be purified further on a silica gel column as described in steps 25 to 28.
25. Prepare a slurry of 100 g silica gel in chloroform and pour it into a 3 × 40–cm chromatography column. 26. Dissolve the amorphous product in a minimal amount of chloroform and layer it carefully on top of the silica gel. 27. Elute with 100 mL chloroform followed by 0.5% to 2.0% MeOH/chloroform, increasing the polarity by 0.5% MeOH for each additional 75 mL chloroform. Collect 25-mL fractions. 28. Evaluate fractions by TLC (step 5) using 49:1 (v/v) chloroform/MeOH as the eluent, and combine fractions that contain only S.3. Evaporate the combined fractions using a rotary evaporator equipped with a vacuum system, and dry the resulting oily residue overnight in vacuo. Synthesis of Modified Nucleosides
1.11.5 Current Protocols in Nucleic Acid Chemistry
Supplement 21
29. Check the purity of the product if analytically pure material is required. The yield of purified 2 -O-(phenoxythiocarbonyl)-3 ,5 -O-(1,1,3,3-tetraisopropyldisilox1,3-diyl)adenosine (S.3) is ∼586 mg (91% from S.1). UV (MeOH) max 259 and 228 nm, min 245 nm. 1 H NMR (400 MHz, DMSO-d6 ): δ 1.05–1.10 (m, 28H), 3.98 ( br d, J = 13.0 Hz, 1H), 4.00 (m, 1H), 4.05 (dd, J = 13.0, 4.1 Hz, 1H), 5.53 (dd, J = 8.7, 5.5 Hz, 1H), 6.36 (d, J = 1.2 Hz, 1H), 6.53 (dd, J = 5.5, 1.2 Hz, 1H), 7.17 (d, J = 7.8 Hz, 2H), 7.37 (t, J = 7.4 Hz, 1H), 7.43 (br s, 2H), 7.52 (t, J = 7.8 Hz, 2H), 8.08 (s, 1H), 8.32 (s, 1H). HRMS (EI) m/z 602.1924 (M+ − i-Pr [C26 H36 N5 O6 SSi2 ] = 602.1927).
Cleave the C2 –O2 bond 30. In an oven-dried 100-mL two- or three-neck round-bottom flask containing a stir bar, dissolve the vacuum-dried sample of S.3 (from step 24 or step 28) in 20 mL dried toluene. 31. Add 32 mg (0.2 mmol) AIBN in one portion. 32. Slowly add 400 µL (436 mg, 1.5 mmol) tributyltin hydride to the reaction mixture using a dry syringe. 33. To purge (deoxygenate) the reaction mixture, cap each neck of the reaction flask with a septum, insert a syringe needle attached to an oxygen-free nitrogen source deep into the reaction mixture through one septum, insert a second syringe needle that is open to air into another septum (the outlet port), and then flow nitrogen into the flask for at least 20 min. The cleavage reaction is conducted under an atmosphere of oxygen-free nitrogen for best yields.
34. Remove the outlet septum from the flask and replace it with a reflux condenser. Stop the flow of nitrogen, and close the condenser to the external atmosphere by capping it with a septum. 35. Heat the reaction mixture with magnetic stirring for 3 hr in an oil bath at 75◦ C. At this point, if isolation of S.4 is desired, the investigator can add 2 mL (2 mmol) of 1 M TBAF/THF to the reaction mixture, heat an additional 1 hr at 75◦ C, and then skip to step 49.
36. Evaporate all volatile materials using a rotary evaporator equipped with a vacuum system. 37. Add 50 ml ethyl acetate to the oily residue, transfer to a 250-mL separatory funnel, and wash with 20 mL saturated NaHCO3 followed by 20 mL saturated NaCl. 38. Dry the washed organic layer over ∼60 g anhydrous Na2 SO4 . Filter off the Na2 SO4 by gravity filtration, and evaporate the filtrate to dryness using a rotary evaporator connected to a vacuum system. The resulting oil of S.4 (yield >100%, due to traces of tin byproducts) is of sufficient purity for direct use in the subsequent deprotection step. If desired, it can be purified further on a silica gel column and then recrystallized as described in steps 39 to 44.
39. Prepare a slurry of 100 g silica gel in chloroform and pour it into a 2 × 30–cm chromatography column. 40. Dissolve the product in a minimal amount of chloroform and layer it carefully on top of the silica gel. Reduction of Ribonucleosides to 2 -Deoxyribonucleosides
41. Elute with 100 mL chloroform followed by 0.5% to 3.0% MeOH/chloroform, increasing the polarity by 0.5% MeOH with each additional 60 mL chloroform. Collect 25-mL fractions.
1.11.6 Supplement 21
Current Protocols in Nucleic Acid Chemistry
42. Evaluate fractions by TLC (step 5) using 49:1 chloroform/MeOH as the eluent, and combine the fractions that contain only S.4. Evaporate the combined fractions using a rotary evaporator connected to a vacuum system, and dry the residual foam overnight in vacuo. The Rf value for S.4 is lower than that for S.3.
43. Recrystallize the product from ethanol in as small a volume as possible, by heating until dissolved and then cooling slowly to a final temperature of 4◦ C, to give analytically pure S.4. 44. Collect the precipitate by vacuum filtration and dry it in vacuo. 45. Check the purity of the product if analytically pure material is required. The yield of recrystallized 2 -deoxy-3 ,5 -O-(1,1,3,3-tetraisopropyldisilox-1,3-diyl)adenosine (S.4) is ∼385 mg (75% from S.1). m.p. 113◦ –114.5◦ C. UV (MeOH) max 259 nm (ε 14,000). 1 H NMR (400 MHz, DMSO-d6 ): δ 1.0–1.1 (m, 28H), 2.56 (dt, J = 13.3, 8.3 Hz, 1H), 2.82 (ddd, J = 13.3, 7.9, 2.6 Hz, 1H), 3.79 (m, 1H), 3.90 (m, 2H), 5.19 (“q”, J = 7.7 Hz, 1H), 6.28 (dd, J = 8.1, 2.5 Hz, 1H), 7.30 (br s, 2H), 8.07 (s, 1H), 8.21 (s, 1H). HRMS (EI) m/z 493.2538 (M+ [C22 H39 N5 O4 Si2 ] = 493.2544).
Perform deprotection 46. In an oven-dried 100-mL two- or three-neck round-bottom flask containing a stir bar, dissolve the product S.4 (from step 38 or step 44) in 10 mL dried THF under a nitrogen atmosphere. 47. Add 2 mL (2 mmol) of 1 M TBAF in THF using a dry syringe. 48. Stir the reaction mixture 1 hr at ambient temperature, and then 1 hr in an oil bath at 50◦ C. 49. Evaporate all volatile materials to dryness in vacuo. 50. Partition the oily residue between 10 mL H2 O and 10 mL diethyl ether using a 50-mL separatory funnel. 51. Separate the aqueous layer and wash it with an additional 2 mL diethyl ether. 52. Concentrate the aqueous layer to a volume of ∼2 mL. 53. Apply the aqueous concentrate to a 1 × 20–cm chromatography column containing 15 mL of Dowex 1 × 2 (OH– ) ion-exchange resin packed in water. 54. Elute with water and collect 7-mL fractions. Elution volume will vary; monitor fractions by TLC as in step 55 until elution is complete.
55. Monitor fractions by TLC (step 5) using 9:1 (v/v) chloroform/MeOH as the eluent, and combine the fractions that contain only S.5. Evaporate the combined fractions to dryness in vacuo using a rotary evaporator connected to a vacuum system. The Rf value for S.5 is lower than that for S.4.
56. Dissolve the residue in a small amount of ethanol (∼2 mL) in a wide-mouth 50-mL Erlenmeyer flask, applying heat if necessary. Perform diffusion crystallization by placing the flask in a closed chamber (e.g., a desiccator) containing a significant volume of diethyl ether and allowing it to stand for several days. The diffusion crystallization process (Robins et al., 1976) gives better yields of higherpurity crystals than does the usual “heating/cooling” crystallization method with the same solvents.
Synthesis of Modified Nucleosides
1.11.7 Current Protocols in Nucleic Acid Chemistry
Supplement 21
57. Collect the crystals by vacuum filtration and dry in vacuo over P2 O5 at 100◦ C (refluxing water). 58. Check the purity of the product if analytically pure material is required. The yield of purified 2 -deoxyadenosine (S.5) is ∼195 mg (78% overall yield from S.1, without purification of intermediates). m.p. 191◦ –192◦ C. UV (MeOH) max 259 nm (ε 14,100). 1 H NMR (400 MHz, DMSO-d6 ): δ 2.26 (ddd, J = 13.2, 6.1, 2.8 Hz, 1H), 2.73 (ddd, J = 13.3, 7.8, 5.8 Hz, 1H), 3.53 (ddd, J = 11.7, 6.7, 4.3 Hz, 1H), 3.63 (dt, J = 11.8, 4.7 Hz, 1H), 3.88 (m, 1H), 4.41 (m, 1H), 5.25 (dd, J = 4.9, 6.6 Hz, 1H), 5.31 (d, J = 4.0 Hz, 1H), 6.35 (dd, J = 7.7, 6.1 Hz, 1H), 7.31 (s, 2H), 8.13 (s, 1H), 8.32 (s, 1H). HRMS (EI) m/z 251.1073 (M+ [C10 H13 N5 O3 ] = 251.1082). ALTERNATE PROTOCOL 1
PREPARATION OF 2 -DEUTERIO-2 -DEOXYADENOSINE BY REDUCTION OF ADENOSINE The 2 -O-phenoxythiocarbonyl ester S.3 is reduced as described in the Basic Protocol, but with tributyltin deuteride in place of tributyltin hydride to give S.6 (Fig. 1.11.2). Deprotection of S.6 (as described in the Basic Protocol) followed by purification on a Dowex 1 × 2 (OH– ) ion-exchange column and recrystallization gives 2 -deuterio2 -deoxyadenosine (S.7) in 89% overall yield from S.3 (81% from S.1). The ratio of ribo/arabino (2 -R/S) deuterium substitution in S.7 is ∼88:12, based on analysis of 400 MHz 1 H NMR spectra (Robins et al., 1983a). 2 -Deuterio-2 -deoxyadenosine (S.7): 1 H NMR (400 MHz, DMSO-d6 ): δ 2.30 (dd, J2 –1 = 2.8 Hz, J2 –3 = 5.8 Hz, 0.12H, H2 , S epimer), 2.71 (dd, J2 –1 = 7.5 Hz, J2 –3 = 5.8 Hz, 0.88H, H2 , R epimer), 3.57 (dd, J5 –4 = 4.2 Hz, J5 –5 = 12.0 Hz, 1H, H5 ), 3.68 (dd, J5 –4 = 4.2 Hz, J5 –5 = 12.0 Hz, 1H, H5 ), 3.94 (m, 1H, H4 ), 4.46 (dd, J3 –4 = 2.8 Hz, J3 –2 = 5.8 Hz, 1H, H3 ), 5.35 (m, 2H, 3 -OH and 5 -OH), 6.39 (d, J1 –2 = 7.5 Hz, ∼0.9H, H1 , R epimer), 7.29 (s, 2H, NH2 ), 8.18 (s, 1H, H2), 8.36 (s, 1H, H8).
ALTERNATE PROTOCOL 2
PREPARATION OF 2 -DEOXYGUANOSINE BY REDUCTION OF GUANOSINE Guanosine (S.8a; Fig. 1.11.3) is converted to 2 -deoxyguanosine (S.12a) with 57% overall yield, using the steps outlined in the Basic Protocol. Its 3 ,5 -O-TPDS derivative (S.9a) is obtained in 70% yield from S.8a, the lowest of any of the nucleosides examined, but the subsequent three reactions proceed smoothly, giving a combined yield of 81% (Robins et al., 1983a). Purification of 2 -deoxyguanosine (S.12a) is performed on a column of Dowex 1 × 2 (OH– ) ion-exchange resin, but after application of the sample (see Basic Protocol, step 53), the column is washed with water (100 mL) and S.12a is eluted with 0.25 M aqueous triethylammonium bicarbonate (TEAB) buffer, pH ∼9 (see recipe). (Elution with water is precluded by the strong binding of S.12a to the basic resin due to the acidic proton on N1 of the guanine ring.) The fractions containing only S.12a are combined and evaporated (see Basic Protocol, step 55), and then water (∼50 mL) is added and evaporated in vacuo several times (as needed) to remove residual TEAB. The product is recrystallized by adding a minimal volume of hot water and then cooling, instead of using diffusion crystallization with ethanol and diethyl ether (Robins et al., 1983a). The amount of hot water needed varies, but more is required when there is less residual TEAB.
Reduction of Ribonucleosides to 2 -Deoxyribonucleosides
2 -Deoxyguanosine (S.12a): m.p. 251◦ –252◦ C. UV (0.1 M HCl) max 255 nm (ε 12,300), (0.1 M NaOH) max 260 nm (ε 9200). 1 H NMR (400 MHz, DMSO-d6 ): δ 2.20 (ddd, J = 13.0, 6.1, 2.8 Hz, 1H), 2.50 (ddd, J = 13.0, 7.4, 6.0 Hz, 1H), 3.53 (m, 2H), 3.63 (dt, J = 11.8, 4.7 Hz, 1H), 3.80 (m, 1H), 4.34 (m, 1H), 4.96 (t, J = 5.7 Hz, 1H), 5.29 (d, J = 4.0 Hz, 1H), 6.13 (t, J = 6.8 Hz, 1H), 7.45 (s, 2H), 7.93 (s, 1H), 10.96 (br s, 1H). HRMS (EI) m/z 249.0864 (M+ [C10 H13 N5 O4 ] – 18 = 249.0853).
1.11.8 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Figure 1.11.2 Synthesis of 2 -deuterio-2 -deoxyadenosine. The expected overall yield of S.7 from S.3 is given in parentheses. AIBN, α,α -azobisisobutyronitrile; TBAF, tetrabutylammonium fluoride; THF, tetrahydrofuran.
Figure 1.11.3 Synthesis of 2 -deoxyguanosine (S.12a), 2 -deoxyuridine (S.12b), and 2 -deoxycytidine (S.12c). The expected overall yields of these products from S.8a, S.8b, and S.8c , respectively, are given in parentheses. For cytidine, the N-acetyl form S.12c is synthesized from S.8c and then deprotected to give S.12c. AIBN, α,α -azobisisobutyronitrile; DMAP, 4-(dimethylamino)pyridine; PTC-Cl, phenoxythiocarbonyl chloride; TBAF, tetrabutylammonium fluoride; THF, tetrahydrofuran; TPDS-Cl2 , 1,1,3,3-tetraisopropyl-1,3-dichlorodisiloxane; rt, room temperature. Synthesis of Modified Nucleosides
1.11.9 Current Protocols in Nucleic Acid Chemistry
Supplement 21
ALTERNATE PROTOCOL 3
PREPARATION OF 2 -DEOXYURIDINE BY REDUCTION OF URIDINE Uridine (S.8b) is converted to 2 -deoxyuridine (S.12b) with 68% overall yield by following the Basic Protocol. No cyclization of S.10b to give a 2,2 -anhydro byproduct is observed during the free radical–mediated reduction of 3 ,5 -O-TPDS-2 -O-PTC-uridine (S.10b). Chromatographic purification of 2 -deoxyuridine (S.12b) is performed on a column of coarsely ground charcoal with a stepwise elution gradient from 20% to 40% (v/v) ethanol in water. Dowex 1 × 2 (OH– ) ion-exchange resin is not used, as it binds S.12b strongly due to the acidic proton on N3 of the uracil ring (Robins et al., 1983a). 2 -Deoxyuridine (S.12b), chromatographically purified and recrystallized: m.p. 162◦ –163◦ C. UV (MeOH) max 260 nm (ε 9800). 1 H NMR (400 MHz, DMSO-d6 ): δ 2.08 (m, 2H), 3.55 (m, 2H), 3.77 (m, 1H), 4.20 (m, 1H), 5.00 (t, J = 5.5 Hz, 1H), 5.23 (d, J = 4.0 Hz, 1H), 5.61 (d, J = 8.0 Hz, 1H), 6.15 (t, J = 6.4 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 11.30 (br s, 1N). HRMS (EI) m/z 228.0742 (M+ [C9 H12 N2 O5 ] = 228.0746).
ALTERNATE PROTOCOL 4
PREPARATION OF 2 -DEOXYCYTIDINE BY REDUCTION OF CYTIDINE Because of the well-known propensity of cytidine (S.8c) to undergo acylation at the 4-amino group, the overall four-step 2 -deoxygenation procedure begins with 4-Nacetylcytidine (S.8c ). Commercially available S.8c is converted to 2 -deoxycytidine (S.12c) with 65% overall yield. Silylation of 4-N-acetylcytidine (S.8c ) using the procedure described in the Basic Protocol readily gives the 3 ,5 -O-TPDS derivative S.9c . Thioacylation of S.9c with PTC-Cl proceeds slowly and does not go to completion under the usual conditions. However, clean and rapid formation of S.10c is achieved upon increasing the quantity of DMAP to 6 to 9 molar equivalents (see Basic Protocol, step 18). The deprotection protocol requires treatment of S.11c with TBAF/THF (see Basic Protocol, steps 47 and 48) followed by an additional overnight treatment of the dried S.12c (step 49) with methanolic ammonia at room temperature to remove the 4-N-acetyl group and give 2 -deoxycytidine (S.12c). Methanolic ammonia is prepared by cooling reagentgrade methanol to ∼4◦ C in an ice-water bath and then bubbling ammonia gas vigorously through the cold solution for at least 30 min. A tube with a sintered glass tip works well for the introduction of ammonia gas. The product is purified on a Dowex 1 × 2 (OH– ) column (using water for elution) and recrystallized from anhydrous methanol (instead of diffusion crystallization with ethanol and diethyl ether). 2 -Deoxycytidine (S.12c): m.p. 203◦ –206◦ C. UV (0.1 M HCl) max 280 nm (ε 13,200), (0.1 M NaOH) max 271 nm (ε 9000). 1 H NMR (400 MHz, DMSO-d6 ): δ 2.10 (dt, J = 13.4, 6.2 Hz, 1H), 2.21 (ddd, J = 13.4, 5.9, 4.0 Hz, 1H), 3.55 (dd, J = 12.0, 3.7 Hz, 1H), 3.60 (dd, J = 12.0, 3.5 Hz, 1H), 3.82 (m, 1H), 4.25 (m, 1H), 5.15 (br s, 1H), 5.33 (br s, 1H), 6.07 (t, J = 6.4 Hz, 1H), 6.11 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 7.8 Hz, 1H), 8.48 (br s, 1H), 9.40 (br s, 1H). HRMS (EI) m/z 227.0906 (M+ [C9 H13 N3 O4 ] = 227.0907).
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Reduction of Ribonucleosides to 2 -Deoxyribonucleosides
Dowex 1 × 2 (OH– ) ion-exchange resin In a large column, wash a large volume of Dowex 1 × 2 (Cl– ) resin (2% cross-linking, 200 to 400 mesh; Aldrich) with water until the eluate is colorless, and then wash with 4 additional column volumes of water. Wash resin with 4 column volumes of 0.5 M HCl, then wash with water until the pH of the eluate is ∼7, and continued
1.11.10 Supplement 21
Current Protocols in Nucleic Acid Chemistry
continue washing with 4 additional column volumes of water. Next, wash with 1 M NaOH until no chloride anion is detected in the eluate. To test for chloride anion, acidify an aliquot of the eluate to a pH of <4 with HNO3 and then add several drops of aqueous AgNO3 . If no chloride anion is present, no precipitation of AgCl will be observed. Finally, wash resin with water until the pH of the eluate is once again ∼7, and then wash with an additional 2 column volumes of water. After washing, filter under suction and air-dry the OH– form of the resin. Store refrigerated (4◦ C) in a bottle protected from light (i.e., wrapped in aluminum foil) for long periods of time (>2 years).
Dried solvents Acetonitrile Heat reagent-grade acetonitrile at reflux for several hours over a drying agent (P2 O5 or CaH2 ). Distill the dried acetonitrile from the drying agent under an argon atmosphere. Pyridine Allow reagent-grade pyridine to stand with the drying agent CaH2 for 8 hr and then heat at reflux for ∼16 hr over CaH2 . Distill the dried pyridine from the drying agent under an argon atmosphere. Tetrahydrofuran (THF) Allow reagent-grade THF to stand with the drying agent CaH2 for several hours and then heat at reflux for 8 to 16 hr over CaH2 . Distill the dried THF from the drying agent under an argon atmosphere. Toluene Distill ∼25% of an ∼100-mL portion of reagent-grade toluene. Then distill and collect the constant-boiling fraction (∼50 mL) for use in the synthesis protocol. Alternatively, solvent drying systems that filter reagent-grade solvents through an activated alumina column under pressure provide dried solvents of excellent quality. Commercial anhydrous solvents can also be used without disadvantage in most cases.
Triethylammonium bicarbonate (TEAB) buffer Add 34.8 mL (25.3 g, 0.25 mmol) triethylamine to a 1-L volumetric flask, and then fill flask to graduation line with water. Transfer this solution to a 2-L round-bottom flask and cool in an ice-water bath to ∼4◦ C. Bubble carbon dioxide gas through the cold solution for at least 2 hr, until a weakly basic buffer solution (pH ∼9) is achieved. Store in a brown bottle at 4◦ C. COMMENTARY Background Information
Preparation of 2 -deoxyribonucleosides by coupling an activated deoxy sugar derivative with a protected nucleobase or modified precursor produces mixtures of α and β anomers. Regioisomeric mixtures are also formed in some cases. Enzymatic methods that employ transglycosylation of the sugar moiety from a naturally occurring purine or pyrimidine 2 deoxyribonucleoside to a nucleobase analog often give low yields of the desired product. Base analogs with modified structures can fail to function as alternative glycosyl-acceptor substrates. Likewise, a ribonucleotide analog
might fail to function as an alternative substrate for ribonucleotide reductases, and chemical or enzymatic phosphorylation of the precursor nucleoside is required to produce the alternative substrate 5 -di- or 5 -triphosphate. The present four-step procedure overcomes these disadvantages. Conversion of ribonucleosides of known structure to the corresponding 2 -deoxyribonucleosides retains both the regio- and stereochemical integrity of the starting compound. The four steps are generally applicable to a wide range of nucleosides, in contrast to the restrictive specificity of enzymatic approaches. Thus, this approach can be
Synthesis of Modified Nucleosides
1.11.11 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Reduction of Ribonucleosides to 2 -Deoxyribonucleosides
applied with a high degree of confidence for syntheses of 2 -deoxy analogs of accessible ribonucleosides. Introduction of hydrogen isotopes at C2 with high retentive stereoselectivity can also be performed. Initial regiospecific approaches for 2 deoxygenation of ribonucleosides were impeded by the lack of convenient methods for differentiating the cis secondary 2 - and 3 hydroxyl groups. This problem was solved by Markiewicz (1979) through the development of a reagent for selective, simultaneous protection of the 3 - and 5 -hydroxyl groups. Treatment of ribonucleosides with the bifunctional compound 1,3-dichloro-1,1,3,3tetraisopropyldisiloxane results in selective initial attack at the primary 5 -hydroxyl group followed by a second, slower reaction at O3 to give the 3 ,5 -O-l,1,3,3-tetraisopropyldisilox1,3-diyl (3 ,5 -O-TPDS) nucleoside derivatives (e.g., S.2, S.9) in high yield. Removal of the 3 ,5 -O-TPDS group is effected with tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF). Barton and coworkers employed thionobenzoate, S-methyl xanthate, thiocarbonylimidazolide, and cyclic thionocarbonate derivatives for deoxygenation of secondary alcohols, including carbohydrate derivatives (Barton and McCombie, 1975; Barton and Subramanian, 1977; Barton, 1994). However, the basic reaction conditions used for preparation of the xanthate esters were not applicable to 3 ,5 -O-TPDS-protected nucleosides, and the two-stage preparation of thionobenzoates employed toxic and noxious conditions (phosgene/N,N-dimethylbenzamide followed by hydrogen sulfide). Preparation of the xanthates also required the use of two inconvenient and toxic reagents, carbon disulfide and methyl iodide. Additionally, it had been reported that imidazole (a byproduct of the reduction of thiocarbonylimidazolides) was capable of catalyzing the decomposition of the tributyltin hydride reductant. Phenoxythiocarbonyl chloride (PTC-Cl) is used as a convenient thionoacylation agent. PTC-Cl is moderately reactive with the somewhat hindered secondary 2 -hydroxyl group of 3 ,5 -O-TPDS-nucleosides. Reactions using pyridine as a catalyst are sluggish, but more powerful catalysis by 4(dimethylamino)pyridine (DMAP) results in high yields of the 2 -O-phenoxythiocarbonyl esters in a reasonable time period at ambient temperature. The phenyl thionocarbonate esters (e.g., S.3, S.10) are designed to undergo free radical–mediated hydrogenolysis of the
C2 –O2 bond with complete selectivity. The initial radical intermediate, formed by attack of the tributyltin radical on sulfur, undergoes β-scission exclusively at the secondary carbon (C2 ) in preference to the phenyl carbon, as scission at the latter would produce an aryl radical of much higher energy (Robins and Wilson, 1981; Robins et al., 1983a). The first Barton-McCombie deoxygenations (Barton and McCombie, 1975) employed tributyltin hydride as the hydrogen source in thermal reactions with thionoester derivatives. However, no mention or use of a free radical initiator is found in those first procedures. The introduction of the free radical initiator α,α -azobisisobutyronitrile (AIBN) into the Barton-McCombie deoxygenation yielded clean, radical-mediated homolytic hydrogenolysis of the phenyl thionocarbonate esters S.3 and S.10 with tributyltin hydride in toluene at 75◦ C (Robins and Wilson, 1981). Barton-McCombie deoxygenations now routinely use AIBN or other radical initiators. Reductive 2 -deoxygenation of thionoesters with tributyltin deuteride provides ready access to 2 -deuterio-2 -deoxyribonucleosides (e.g., S.6). The authors obtained >85% retention of configuration under standard conditions at 75◦ C, which compares well with the complete retention of configuration observed in enzymatic 2 -deoxygenations mediated by ribonucleotide reductases. Other hydrogen sources, initiators, substituted phenylthiocarbonyl chloride reagents, and experimental conditions have been developed for the homolytic hydrogenolysis of 2 -thionocarbonate esters derived from nucleosides and carbohydrates. Kawashima et al. (1995) reported triethylborane-initiated reductions of 2 -O-PTC esters using tin deuteride at ambient temperature, and also found that triethylborane-initiated reductions of 2 -bromo-2 -deoxyribonucleosides with tin deuteride at low temperatures (less than −69◦ C) proceed with very high retention of configuration (≥99%). Silyl hydrides have been used as less toxic substitutes for tin hydrides (Chatgilialoglu and Ferreri, 1993). For example, a tris(trimethylsilyl)[2 H]silane/triethylborane system reduces 2 -O-PTC esters of nucleosides in high yields with retention of stereochemistry (2 -R/S ≥99:1) at 0◦ C (Kawashima et al., 1997), and triphenylsilyl radical–mediated hydrogenolysis of 3 -O-PTC esters of nucleosides proceeds in high yields with benzoyl peroxide as the radical initiator (Robins et al., 1996). Hypophosphorous
1.11.12 Supplement 21
Current Protocols in Nucleic Acid Chemistry
acid and dialkyl phosphites have also been employed as radical hydrogen-transfer sources for hydrogenolysis of O-thiocarbonyl groups (or halides) on the sugar moieties of nucleosides (Takamatsu et al., 2001). The directed single-site labeling of nucleosides (i.e., stereoselective introduction of deuterium) using the radical deoxygenation procedure presented here has advantages relative to other methods for the synthesis of selectively deuterated nucleosides, which usually involve reduction of ketonucleosides (Hansske et al., 1984; Robins et al., 1997) or multistep elaboration of sugars followed by coupling with heterocyclic bases (F¨oldesi et al., 2004).
Characterization Data Physical and spectroscopic data for all products and intermediates were reported in Robins et al. (1983a,b). Data for all final products are reported here, and were identical to those for authentic samples of the natural products. Data for intermediates in the reduction of adenosine are also presented here. Data for intermediates of the other nucleosides are similar to those for adenosine (see Robins et al., 1983a).
Critical Parameters It is essential that oven-dried glassware and dried solvents be used in these protocols. Protection of reaction mixtures from atmospheric moisture and oxygen enhances yields. In particular, the reaction mixture for the deoxygenation step must be carefully deoxygenated. In the Alternate Protocols, the ratios of the TLC and column chromatography solvents should be adjusted slightly from those in the Basic Protocol to accommodate differences in the polarities of intermediates with different nucleobases. Guanosine and cytidine analogs are more polar than their adenosine and uridine counterparts, respectively, and greater proportions of methanol relative to chloroform should be used with the more polar compounds. Crystalline intermediates and the final product 2 -deoxyribonucleosides are usually stable at room temperature for extended periods of time. Storage in a refrigerator at ∼4◦ C (in a sealed container that contains a desiccant) markedly extends the storage life. An amorphous intermediate should be subjected to the next step as quickly as convenient. Serious decomposition of an amorphous intermediate is usually not observed if it is stored overnight in a refrigerator at ∼4◦ C (in a sealed container that contains a desiccant).
Anticipated Results The method presented here generally gives high yields even for inexperienced workers. The deoxygenation step and the purification of the final 2 -deoxyribonucleosides on Dowex 1 × 2 (OH– ) resin are more involved. With experience, however, the stated yields can be obtained reliably.
Time Considerations The four-step preparation of each of the 2 -deoxyribonucleosides presented in this unit can be performed in about five days (one week) when the intermediate products (S.2, S.3, and S.4 for adenosine) are used directly in subsequent reactions without further chromatographic purification. Each reaction requires a total of one day (with proper time management), assuming that the first two reactions (protection and thioacylation) are allowed to proceed to completion overnight.
Literature Cited Barton, D.H.R. 1994. The invention of chemical reactions of relevance to the chemistry of natural products. Pure Appl. Chem. 66:1943-1954. Barton, D.H.R. and McCombie, S.W. 1975. A new method for the deoxygenation of secondary alcohols. J. Chem. Soc., Perkin Trans. 1 1574-1585. Barton, D.H.R. and Subramanian, R. 1977. Reactions of relevance to the chemistry of aminoglycoside antibiotics. Part 7. Conversion of thiocarbonates into deoxy-sugars. J. Chem. Soc., Perkin Trans. 1 1718-1723. Chatgilialoglu, C. and Ferreri, C. 1993. Progress of the Barton-McCombie methodology: From tin hydrides to silanes. Res. Chem. Intermed. 19:755-775. F¨oldesi, A., Kundu, M.K., Dinya, Z., and Chattopadhyaya, J. 2004. Synthesis of [2 -2 H1 ]ribonucleosides. Helv. Chim. Acta 87:742-757. Hansske, F., Madej, D., and Robins, M.J. 1984. 2 and 3 -Ketonucleosides and their arabino and xylo reduction products. Convenient access via selective protection and oxidation of ribonucleotides. Tetrahedron 40:125-135. Kawashima, E., Aoyama, Y., Sekine, T., Miyahara, M., Radwan, M.F., Nakamura, E., Kainosho, M., Kyogoku, Y., and Ishido, Y. 1995. Sonochemical and triethylborane-induced tin deuteride reduction for the highly diastereoselective synthesis of (2 R)-2 -deoxy[2 -2 H]ribonucleoside derivatives. J. Org. Chem. 60:6980-6986. Kawashima, E., Uchida, S., Miyahara, M., and Ishido, Y. 1997. Tris(trimethylsilyl)[2 H]silanetriethylborane system producing the highly diastereoselective deuteration (>99:1) of 2 -bromo-2 -deoxy- and 2 -Ophenoxythiocarbonylribonucleosides at 0◦ C. Tetrahedron Lett. 42:7369-7372.
Synthesis of Modified Nucleosides
1.11.13 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Markiewicz, W.T. 1979. Tetraisopropyldisiloxane1,3-diyl, a group for simultaneous protection of 3 - and 5 -hydroxy functions of nucleosides. J. Chem. Res., Synop. 24-25 and J. Chem. Res., Miniprint. 181-197. NRC (National Research Council, Committee on Prudent Practices for Handling, Storage, and Disposal of Chemicals in Laboratories). 1995. Prudent Practices in the Laboratory: Handling and Disposal of Chemicals. National Academy Press, Washington, D.C. Robins, M.J. and Wilson, J.S. 1981. Smooth and efficient deoxygenation of secondary alcohols. A general procedure for the conversion of ribonucleosides to 2 -deoxynucleosides. J. Am. Chem. Soc. 103:932-933. Robins, M.J. and Wilson, J.S. 1991. 2 -Deoxyadenosine and 2 -deoxy-2 -deuterioadenosine. Regiospecific and stereoselective 2 -deoxygenation of a ribonucleoside. In Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods and Techniques, Vol. 4 (L.B. Townsend and R.S. Tipson, eds.) pp. 194-200. John Wiley & Sons, New York. Robins, M.J., Mengel, R., Jones, R.A., and Fouron, Y. 1976. Nucleic acid related compounds. 22. Transformation of ribonucleoside 2 ,3 -O-ortho esters into halo, deoxy, and epoxy sugar nucleosides using acyl halides. Mechanism and structure of products. J. Am. Chem. Soc. 98:82048213. Robins, M.J., Wilson, J.S., and Hansske, F. 1983a. Nucleic acid related compounds. 42. A general procedure for the efficient deoxygenation of secondary alcohols. Regiospecific and stereoselective conversion of ribonucleosides to 2 deoxynucleosides. J. Am. Chem. Soc. 105:40594065.
Robins, M.J., Wilson, J., Sawyer, L., and James, M.N.G. 1983b. Nucleic acid related compounds. 41. Restricted furanose conformations of 3 ,5 -O-(1,1,3,3-tetraisopropyldisilox1,3-diyl)nucleosides provide a convenient evaluation of anomeric configuration. Can. J. Chem. 61:1911-1920. Robins, M.J., Wnuk, S.F., Hernandez, A.E., and Samano, M.C. 1996. Nucleic acid related compounds. 91. Biomimetic reactions are in harmony with loss of 2 -substituents as free radicals (rather than anions) during mechanismbased inactivation of ribonucleotide reductases. Differential interactions of C2 azide, halogen, and alkylthio groups with tributylstannane and triphenylsilane. J. Am. Chem. Soc. 118:1134111348. Robins, M.J., Sanker, S., Samano, V., and Wnuk, S.F. 1997. Nucleic acid related compounds. 94. Remarkably high stereoselective reductions of 2 - and 3 -ketonucleoside derivatives to give arabino, ribo, and xylofuranosyl nucleosides with hydrogen isotopes at C2 and C3 . Tetrahedron 53:447-456. Takamatsu, S., Katayama, S., Hirose, N., Naito, M., and Izawa, K. 2001. Radical deoxygenation and dehalogenation of nucleoside derivatives with hypophosphorous acid and dialkyl phosphites. Tetrahedron Lett. 42:7605-7608.
Contributed by Morris J. Robins Brigham Young University Provo, Utah Stanislaw F. Wnuk Florida International University Miami, Florida
Reduction of Ribonucleosides to 2 -Deoxyribonucleosides
1.11.14 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Synthesis of Fluorinated Nucleosides
UNIT 1.12
The fluorination of organic compounds often leads to a dramatic change in their biological activity. As a result, many fluorine-containing pharmaceuticals have been approved by the FDA over the past few decades, including the nucleoside analog gemcitabine. Recently, 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)adenine (FddA, lodenosine) has attracted much attention due to its high potency against HIV reverse transcriptase and its stability under the acidic conditions present in the human stomach. In principle, there are two routes to produce FddA. The first route, glycosylation of the adenine base with the fluoro-sugar, has two drawbacks: (1) the production of the fluoro-sugar requires several steps and (2) poor selectivity is normally observed in the final glycosylation. The second route, direct fluorination of adenosine, leads to the rearrangement of the base and the formation of an isonucleoside. The fluorination of 3 -deoxyadenosine with DAST results in very low yields. This unit presents two efficient methods for synthesis of FddA in which fluorination proceeds very smoothly, uses inexpensive reagents, and produces high yields. Basic Protocols 1 and 2 describe the synthesis of FddA (as well as FdaraA) via selective protection of 6-chloropurine riboside. The key fluorination is successfully achieved with non-corrosive triethylamine trihydrofluoride via imidazolesulfonate or triflate. The deoxygenation of the 3 -OH group was conveniently carried out using radical reduction. Basic Protocols 3 and 4 describe an alternate synthesis of FddA via 6-chloropurine 3 -deoxyriboside. For the synthesis of 6-chloropurine 3 -deoxyriboside from readily available inosine, the key step is radical debromination using hypophosphorous acid as a reducing agent. The fluorination of 5 -tritylated 6-chloropurine 3 -deoxyriboside is carried out using perfluorobutanesulfonyl fluoride with subsequent conversion to FddA by conventional means. NOTE: All reagents and solvents were purchased from commercial sources and were used without further purification.
PREPARATION OF 6-CHLOROPURINE 3 -O-BENZOYL-5 -OTRITYLRIBOSIDE
BASIC PROTOCOL 1
6-Chloropurine riboside (S.1; Fig. 1.12.1) is converted to the 3 -O-benzoate (S.2) via a stannylene complex. This is further modified to 3 -O-benzoyl-5 -O-tritylriboside (S.3) using trityl chloride in the presence of triethylamine. In both reactions, the 3 -O-benzoates are isolated from their 2 -isomers by crystallization (see Commentary for further discussion).
Materials 6-Chloropurine riboside (S.1), 99% pure (Aldrich) Di-n-butyltin(IV) oxide, 95+% Methanol (MeOH), 99.8+% Triethylamine, 99+% Benzoyl chloride, 99+% Diethyl ether, 99.5+% Magnesium sulfate (MgSO4 ), anhydrous, 99.5+% Dichloromethane (CH2 Cl2 ), 99+% Ethanol (EtOH), 99.5% N,N-Dimethylformamide (DMF), anhydrous, 99.8+%
Synthesis of Modified Nucleosides
Contributed by Satoshi Katayama, Satoshi Takamatsu, Naoko Hirose, Kunisuke Izawa, and Tokumi Maruyama
1.12.1
Current Protocols in Nucleic Acid Chemistry (2006) 1.12.1-1.12.30 C 2006 by John Wiley & Sons, Inc. Copyright
Supplement 25
Figure 1.12.1
Preparation of 6-chloro-(3-O-benzoyl-5-O-trityl-β-D-ribofuranosyl)purine.
Benzene, 99.5+% 4-Dimethylaminopyridine (DMAP), 99+% Trityl chloride, 98+% Chloroform (CHCl3 ), 99+% Pyridine, dehydrated for organic synthesis, 99+% Dimethylsulfoxide (DMSO) 3:2 and 1:4 (v/v) 10 mM phosphoric acid/MeOH Reflux condenser Vacuum filtration unit with glass filter Rotary evaporator equipped with vacuum oil pump 3.5 × 50–cm and 6.5 × 35–cm sintered glass chromatography columns packed with silica gel G TLC plates: silica-coated aluminum plate with fluorescent indicator (Merck silica gel 60 F254 ) 254-nm UV lamp HPLC apparatus with: Cosmosil guard column 5C18-MS (4.6 × 10–mm, Nacalai Tesque) Cosmosil packed column 5C18-MS (4.6 × 150–mm, Nacalai Tesque) CCPD pump (Toso) SPD-M10A photo diode array UV-VIS detector (Shimadzu) Introduce 3 -O-benzoyl group 1. Suspend 14.34 g (50 mmol) 6-chloropurine riboside (S.1) and 12.45 g (50 mmol) di-n-butyltin(IV) oxide in 500 mL MeOH and then reflux for 1 hr at 80◦ C. 2. Cool the solution to room temperature and then add 34.8 mL (250 mmol) triethylamine.
Synthesis of Fluorinated Nucleosides
1.12.2 Supplement 25
3. Add 29.0 mL (250 mmol) benzoyl chloride in a dropwise manner with magnetic stirring. Cool the solution to room temperature and then continue stirring for 30 min. 4. Remove the insoluble materials by vacuum filtration using a glass filter, then evaporate the filtrate on a rotary evaporator equipped with a vacuum oil pump. Current Protocols in Nucleic Acid Chemistry
Table 1.12.1 Selected Data for the 1 H NMR Spectra of S.2 and S.3 in CDCl3
H1
H2
H3
H4
6.20
5.05
5.59
4.37-4.39
d
q
dd
m
J (Hz)
6.6
5.9
5.5, 2.7
ppm
6.48
5.88
4.66
4.15-4.17
d
dd
q
m
J (Hz)
4.9
5.2, 4.9
5.1
ppm
6.20
5.25
5.68
4.48-4.50
d
q
dd
J (Hz)
5.5
5.5
5.5, 4.4
ppm
6.51
6.05-6.10
d
NDa
Compound S.2 (3 -O-Bz)
S.2 (2 -O-Bz)
S.3 (5 -O-Tr-3 -O-Bz)
S.3 (5 -O-Tr-2 -O-Bz)
ppm
J (Hz)
3.6
H5 a
H5 b
2 - or 3 -OH
5 -OH
6.02
5.35
d
t
6.0
5.5
5.81
5.24
d
dd
5.8
5.5, 5.2
3.34-3.43
6.05-6.10
—
m
m
NDa
4.87
4.28
3.34-3.43
5.83
q
dt
m
d
6.1
6.9, 4.4
3.77-3.81 3.71-3.75 m
m
3.66-3.69 3.00-3.83 m
m
6.0
a ND, not determined.
5. Partition the resulting liquor between 400 mL diethyl ether and 250 mL water. Wash the aqueous layer two times with 200 mL diethyl ether. 6. Combine the organic layers and wash with 100 mL water. 7. Dry over MgSO4 until the solution becomes clear, filter the drying agent under vacuum, and concentrate to a small volume on a rotary evaporator. 8. Apply column chromatography (APPENDIX 3E) to the residual solution over a 6.5 × 35–cm column of silica gel G using 1 L CH2 Cl2 and 4 L of 0% to 10% EtOH in CH2 Cl2 as eluents. Monitor and identify correct fractions by TLC (see data in step 10). 9. Concentrate the fraction of the monobenzoyl derivatives to dryness on a rotary evaporator. Crystallize from 50 mL MeOH overnight at room temperature. 10. Characterize the product by TLC (on silica gel), HPLC (see step 21), elemental analysis, UV, MS, and 1 H NMR. The compound is stable for at least 12 months when stored at 4◦ C. 6-Chloro-9-(3-O-benzoyl-β-D-ribofuranosyl)purine (S.2). Yield of pale yellowish crystals: 12.67 g (65%). m.p. 174◦ -177◦ C. TLC (95:5 v/v CH2 Cl2 /EtOH): Rf = 0.40. Anal. calcd. (C17 H15 ClN4 O5 ): C, 51.77; H, 3.94; N, 14.21%; found: C, 51.80; H, 3.99; N, 14.05. MS: m/z 360, 362 (M+ -CH2 O), 385, 387 (M+ -C6 H5 CO). UV λmax (MeOH): 264.5 nm. 1 H NMR (CDCl3 ): δ 8.97, 8.91 (each 1H, s, H2, H8), 7.5-8.1 (5H, m, C6 H5 CO), 6.16 (1H, d, J = 6.5 Hz, H1 ), 5.95 (1H, m, 2 -OH), 5.55 (1H, dd, J = 6.5, 2.4 Hz, H3 ), 5.28 (1H, br s, 5 -OH), 5.00 (1H, m, H2 ), 4.33 (1H, m, H4 ), 3.72 (2H, t, J = 2.8 Hz, H5 ). The 1 H NMR spectrum reveals that the signal of H3 appears in a relatively high field (5.55 ppm), and the two protons exchangeable with deuterium oxide are identified as 2 -OH and 5 -OH, indicating that the benzoyl group is introduced at the 3 -OH position. Analysis of the sample by HPLC indicates the presence of a small amount of the 2 -Obenzoate (3.9%). A comparison of NMR spectra for the 2 - and 3 -isomers can be found in Table 1.12.1.
Synthesis of Modified Nucleosides
1.12.3 Current Protocols in Nucleic Acid Chemistry
Supplement 25
—
Tritylate 5 -hydroxyl 11. Dissolve 10.72 g (25 mmol) S.2 in 220 mL anhydrous DMF and co-evaporate the solution with 100 mL benzene. 12. Add 11.0 mL (78.9 mmol) triethylamine, 1.01 g (8.25 mmol) DMAP, and 23.00 g (82.5 mmol) trityl chloride to the solution with magnetic stirring and keep overnight at 50◦ C. 13. Cool the solution to room temperature. Add 10 mL water and then evaporate to dryness under vacuum. 14. Partition the residue between 300 mL CHCl3 and 150 mL water. Wash the organic layer with 150 mL water. 15. Dry over MgSO4 until the solution becomes clear, filter the drying agent under vacuum, and concentrate to a small volume on a rotary evaporator. 16. Apply column chromatography to the residual solution over a 3.5 × 50–cm column packed with silica gel G using 1 L CH2 Cl2 and 4 L of 0% to 2.5% EtOH in CH2 Cl2 . Monitor and identify correct fractions by TLC (see step 18). 17. Concentrate the solution to dryness on a rotary evaporator, then crystallize the residue from 150 mL MeOH overnight at room temperature. 18. Characterize the product by TLC (on silica gel), HPLC (see step 21), elemental analysis, UV, MS, and 1 H NMR. The compound is stable for at least 12 months when stored at 4◦ C. 6-Chloro-9-(3-O-benzoyl-5-O-trityl-β-D-ribofuranosyl)purine (S.3). Yield of white crystals: 11.21 g (71%). m.p. 102◦ -106◦ . TLC (95:5 v/v CH2 Cl2 /EtOH): Rf = 0.56. Anal. calcd. (C36 H29 ClN4 O5 . 0.8H2 O): C, 66.78; H, 4.76; N, 8.65%; found: C, 66.86; H, 4.81; N, 8.43. MS: m/z 555, 557 (M+ -C6 H5 ), 389, 391 (M+ -trityl). UV λmax (MeOH): 264 nm. 1 H NMR (CDCl3 ): δ 8.69, 8.38 (each 1H, s, H2, H8), 7.2-8.05 (ca 20H, m, C6 H5 CO, trityl), 6.18 (1H, d, J = 6.1 Hz, H1 ), 5.74 (1H, dd, J = 5.5, 2.5 Hz, H3 ), 5.29 (1H, m, H2 ), 4.59 (1H, m, H4 ), 3.95 (1H, d, J = 4.5 Hz, 2 -OH), 3.53 (2H, t, J = 3.6 Hz, H5 ). HPLC confirms the presence of a small amount of the 2 -O-benzoate (2.0%). A comparison of NMR spectra for the 2 - and 3 -isomers can be found in Table 1.12.1.
Check stability of S.3 19. Dissolve 100 mg of S.3 in a solution of 4.1 mL dry CH2 Cl2 and 0.076 mL dehydrated pyridine and reflux for 5 hr at 45◦ C. 20. Cool the solution to room temperature. Dilute 100 µl solution with 2 mL DMSO and then remove the volatile compounds under vacuum. 21. Subject this sample to HPLC analysis using the following conditions:
Columns: Cosmosil guard column 5C18-MS (4.6 × 10–mm) and Cosmosil packed column 5C18-MS (4.6×150–mm) Eluent: 10 mM phosphoric acid/MeOH, 3:2 (v/v) for S.2 or 1:4 (v/v) for S.3 Flow rate: 1 mL/min Column temperature: 50◦ C. The ratio of the 2 -O-benzoate and the 3 -O-benzoate of S.3 is 3.1 to 96.9.
Synthesis of Fluorinated Nucleosides
1.12.4 Supplement 25
Current Protocols in Nucleic Acid Chemistry
SYNTHESIS OF FddA FROM 6-CHLOROPURINE 3 -O-BENZOYL-5 -O-TRITYLRIBOSIDE
BASIC PROTOCOL 2
The common first step in the synthesis of both FddA and FdaraA is fluorination of the C2 -β of S.3. This can be achieved using diethylaminosulfur trifluoride (DAST) in CH2 Cl2 in the presence of pyridine to give the 2 -deoxy-2 -fluoroarabinoside (S.4; Fig. 1.12.2) in good yield, although the non-corrosive triethylamine trihydrofluoride (Et3 N·3HF) is better for large-scale syntheses. The latter method can be performed via an imidazolesulfonate intermediate or a triflate intermediate. All three of these routes are presented here. The 3 -O-benzoyl-5 -O-trityl system is suitable for selective deprotection. Therefore, S.4 can be treated with ammonia in methanol to afford the 5 -O-trityl compound (S.5). Detritylation of S.5 to give FdaraA (S.6) is presented in the Alternate Protocol. To obtain FddA (S.10), the 3 -OH can be removed in two steps: conversion of S.5 to the phenoxythiocarbonyl compound S.7 or the xanthate S.8, followed by radical deoxygenation using tris(trimethylsilyl)silane or hypophosphorous acid as hydrogen donors to produce S.9. Finally, detritylation by acid treatment converts S.9 to FddA (S.10).
Figure 1.12.2
Preparation of FdaraA and FddA from 6-chloropurine 3 -O-benzoyl-5 -O-tritylriboside. Synthesis of Modified Nucleosides
1.12.5 Current Protocols in Nucleic Acid Chemistry
Supplement 25
Materials 6-Chloro-9-(3-O-benzoyl-5-O-trityl-β-D-ribofuranosyl)purine (S.3; see Basic Protocol 1) Dichloromethane (CH2 Cl2 ), anhydrous, 99.8% Pyridine, dehydrated for organic synthesis, 99+% Diethylaminosulfur trifluoride (DAST), 95+% 5% (w/v) and saturated sodium hydrogen carbonate (NaHCO3 ), 99.5+% Chloroform (CHCl3 ), 99+% Magnesium sulfate (MgSO4 ), anhydrous, 99.5+% Ethyl acetate (EtOAc), 99+% n-Hexane, 95+% Sulfuryl chloride, 99+% Imidazole, 99+% Sodium sulfate (Na2 SO4 ), anhydrous, 99+% Toluene, anhydrous, 99.8+% Triethylamine trihydorofluoride (Et3 N·3HF), 98% Acetonitrile (CH3 CN), 99.5+% 70:30 and 50:50 (v/v) 0.02 M aq. KH2 PO4 (pH 3.2) in CH3 CN 4-Dimethylaminopyridine (DMAP), 99+% Trifluoromethanesulfonyl chloride, 99+% Saturated aq. ammonium chloride (NH4 Cl), 99+% Saturated aq. sodium chloride (NaCl), 99+% Triethylamine, 99+% Methanol (MeOH), 99.8+% Ammonia, anhydrous, 99.99+% Phenyl chlorothionoformate, 98+% 2,2 -Azobis(isobutyronitrile) (AIBN), 98+% Tris(trimethylsilyl)silane, 96+% Nitrogen, 99.998+% Dimethylsulfoxide (DMSO), anhydrous, 99.9+% 5 M aq. sodium hydroxide (NaOH) Carbon disulfide, 99.9+% Iodomethane, 99.5+% 1,2-Dimethoxyethane, 99+% 50% (v/v) aq. hypophosphorous acid (H3 PO2 ) 35% to 37% (v/v) hydrochloric acid (conc. HCl) Amberlite IRA-900 (OAc– form; ICN) Reflux condenser Rotary evaporator equipped with a vacuum oil pump 3.5 × 50–cm and 2.5 × 32–cm chromatography columns packed with silica gel G Vacuum filtration unit with glass filter 22 × 3–cm, 230- to 400-mesh silica gel column TLC plates: silica-coated aluminum plate with fluorescent indicator (Merck silica gel 60 F254 ) HPLC with Inertsil ODS 2 4.6 × 150–mm column (GL Science) Glass filter with aspirator Vacuum oil pump 40-mm-diameter Kiriyama filter funnel (glass B¨uchner-type funnel) and no. 5B filter paper ◦ 50 C vacuum oven Synthesis of Fluorinated Nucleosides
CAUTION: DAST should be handled with gloves. This material can cause burns.
1.12.6 Supplement 25
Current Protocols in Nucleic Acid Chemistry
Perform fluorination Using DAST 1a. Dissolve 4.76 g (7.5 mmol) S.3 in a solution of 100 mL anhydrous CH2 Cl2 and 3.6 mL (44.5 mmol) pyridine. Cool the solution on ice. 2a. Add 2.25 mL (17 mmol) DAST in a dropwise manner and warm to room temperature. Reflux for 5 hr at 50◦ C. 3a. Cool the solution to room temperature. Add the solution to 500 mL of 5% NaHCO3 in a dropwise manner with magnetic stirring, and then continue stirring for 20 min. 4a. Separate the organic layer and wash the aqueous layer with 100 mL CHCl3 . Combine the organic layers and wash with 200 mL water. 5a. Dry over MgSO4 until the solution becomes clear, filter the drying agent under vacuum, and concentrate to a small volume on a rotary evaporator equipped with a vacuum oil pump. 6a. Apply column chromatography (APPENDIX 3E) to the residual solution over a 3.5 × 50–cm column packed with silica gel G using 4 L of 0% to 25% EtOAc in n-hexane. Monitor and identify fractions by TLC (see data in step 8a). 7a. Evaporate the desired fraction to dryness on a rotary evaporator. 8a. Characterize the product by TLC (on silica gel), UV, MS, and 1 H NMR. Proceed to step 14. The compound is stable for at least 1 month when stored at 4◦ C. 6-Chloro-9-(3-O-benzoyl-5-O-trityl-2-deoxy-2-fluoro-β - D -arabinofuranosyl)purine (S.4). Yield of a foam: 3.71 g (78%). TLC (50:1 v/v CH2 Cl2 /EtOH): Rf = 0.61. MS: m/z 391, 393 (M+ -trityl), 375, 377 (M+ -trityloxy). UV λmax (MeOH): 263 nm. 1 H NMR (CDCl3 ): δ 8.76 (1H, s, H2), 8.36 (1H, d, J = 3.0 Hz, H8), 7.2-8.1 (ca 20H, m, C6 H5 CO, trityl), 6.66 (1H, dd, J = 21.7, 2.7 Hz, H1 ), 5.70 (1H, dd, J = 17.0, 3.0 Hz, H3 ), 5.28 (1H, m, JHCF = 50.0 Hz, H2 ), 4.42 (1H, m, H4 ), 3.62 (1H, dd, J = 10.4, 5.2 Hz, H5 a), 3.54 (1H, dd, J = 10.4, 4.1 Hz, H5 b). The 1 H NMR spectrum of S.4 shows that the 2 -fluorine causes a downfield shift and a large H2 -C-F geminal coupling (50.0 Hz) of the 2 -proton, suggesting a 2 -fluoro structure.
Using triethylamine trihydrofluoride via imidazolesulfonate 1b. Dissolve 2.0 g (3.1 mmol) S.3 in 15.5 mL anhydrous CH2 Cl2 and then cool to −35◦ C. 2b. Add 0.45 mL (5.57 mmol) pyridine and 0.30 mL (3.72 mmol) sulfuryl chloride and then stir the mixture for 30 min. 3b. Add 0.96 g (13.9 mmol) imidazole and return the solution to room temperature. Stir the solution overnight at room temperature. 4b. Add 10 mL water for phase separation. 5b. Wash the aqueous layer with 10 mL CH2 Cl2 . Combine the organic layers. 6b. Dry over Na2 SO4 until the solution becomes clear, filter the drying agent under vacuum, and evaporate the solution to dryness using a rotary evaporator. 7b. Purify the residue on a 22 × 3–cm, 230- to 400-mesh silica gel column, eluting with a linear EtOAc/n-hexane gradient ranging from 25% to 50% (v/v) EtOAc in a
Synthesis of Modified Nucleosides
1.12.7 Current Protocols in Nucleic Acid Chemistry
Supplement 25
total volume of 2.5 L. Monitor by TLC. Use the activated product (the imidazolesulfonate) immediately for the next reaction without characterization. 6-Chloro-9-(3-O-benzoyl-5-O-trityl-2-O-imidazolesulfonyl-β-D-ribofuranosyl)purine. Yield of oil: 2.28 g (96%). TLC (4:1 v/v toluene/EtOAc): Rf = 0.21.
8b. Dissolve 377 mg (0.494 mmol) of the imidazolesulfonate in 2.4 mL toluene and then add 0.49 mL (3.00 mmol) Et3 N·3HF to the solution. Stir overnight at 70◦ C. Since Et3 N·3HF is non-corrosive, the glassware does not show any indication of corrosion even after several days under these reaction conditions.
9b. Cool to room temperature. Add 10 mL EtOAc and 10 mL saturated NaHCO3 for phase separation. 10b. Wash the aqueous layer with 10 mL EtOAc and combine the organic layers. 11b. Dry over Na2 SO4 until the solution becomes clear, and filter the drying agent under vacuum. Evaporate the solution to dryness using a rotary evaporator. 12b. Dissolve the residue in 5 mL CH3 CN. Remove 100 µL, dilute with 10 mL mobile phase, and analyze by HPLC.
Column: Inertsil ODS 2 4.6 × 150–mm Mobile phase: 70:30 (v/v) 0.02 M aq. KH2 PO4 (pH 3.2) in CH3 CN Flow rate: 1.0 mL/min Column temperature: 40◦ C Injection volume: 10 µL Detection: UV at 262 nm. Under these conditions, the retention time is 12.6 min for S.4 and the yield is calculated as 81% by comparison of the peak area to the external standard sample. The product can also be isolated as in steps 6a and 7a.
13b. Characterize the product by TLC (on silica gel), UV, MS, and 1 H and 13 C NMR. Proceed to step 14. The analytical sample was obtained by purification via preparative TLC using 4:1 (v/v) toluene/EtOAc (Rf = 0.59). The compound is stable for at least 1 month when stored at 4◦ C. 6-Chloro-9-(3-O-benzoyl-5-O-trityl-2-deoxy-2-fluoro-β - D -arabinofuranosyl)purine (S.4). HRMS (FAB+) calcd. for C36 H29 N4 O4 FCl (M + H)+ 635.1861, found 635.1846. Anal. calcd. for C36 H29 N4 O4 FCl: C, 68.08; H, 4.44; N, 8.82; F, 2.99; Cl, 5.58; found: C, 68.11; H, 4.54; N, 8.69; F, 2.65; Cl, 5.82. IR (KBr): ν 3061, 1732, 1567, 1592, 1492, 1450, 1218, 1265, 1092 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 8.76 (1H, s, H2), 8.36 (1H, d, J = 3.0 Hz, H8), 8.07 (2H, d, J = 7.2 Hz, C6 H5 CO), 7.66 (1H, t, J = 7.3 Hz, C6 H5 CO), 7.23-7.54 (ca. 17H, m, C6 H5 CO, trityl), 6.66 (1H, dd, J = 21.7, 2.8 Hz, H1 ), 5.67 (1H, dd, J = 16.9, 3.2 Hz, H3 ), 5.28 (1H, dd, J = 50.0, 2.8 Hz, H2 ), 4.41 (1H, m, H4 ), 3.63 (1H, dd, J = 10.3, 5.9 Hz, H5 a), 3.54 (1H, dd, J = 10.3, 4.2 Hz, H5 b). 13 C NMR (DMSO-d6 , 300 MHz): δ 164.9, 152.2, 151.5, 149.8, 146.1 (d, J = 5.1 Hz), 143.6, 134.2, 129.8, 129.0, 128.9, 128.4, 128.1, 127.3, 93.4 (d, J = 193.2 Hz), 86.6, 82.7 (d, J = 16.9 Hz), 79.6, 76.5 (d, J = 27.3 Hz), 63.4.
Using triethylamine trihydrofluoride via triflate 1c. Dissolve 1.3 g (2.0 mmol) S.3 in 20.0 mL toluene and then cool to 0◦ C.
Synthesis of Fluorinated Nucleosides
2c. Add 0.59 g (4.8 mmol) DMAP and 0.51 mL (4.8 mmol) trifluoromethanesulfonyl chloride, and then stir the mixture overnight at room temperature. 3c. Add 10 mL water for phase separation.
1.12.8 Supplement 25
Current Protocols in Nucleic Acid Chemistry
4c. Wash the organic layer with 10 mL saturated aq. NaHCO3 , 10 mL saturated aq. NH4 Cl, and 10 mL saturated aq. NaCl. 5c. Add anhydrous Na2 SO4 until the organic layer becomes clear, and filter the drying agent under vacuum. Evaporate the solution to dryness using a rotary evaporator equipped with a vacuum oil pump. An amount of 1.35 g crude triflate was obtained and half that amount was used in the following reaction. Use the activated product (a triflate) immediately for the next reaction without characterization.
6c. Dissolve the crude triflate in 10 mL EtOAc, then add 0.42 mL (3.0 mmol) triethylamine and 0.98 mL (6.00 mmol) Et3 N·3HF to the solution. 7c. Reflux the mixture overnight at 80◦ C and cool to room temperature. 8c. Evaporate the mixture to a minimum volume using a rotary evaporator, and dissolve the residue in 10 mL MeOH. 9c. Dilute with 5 mL of 1:1 (v/v) CH3 CN/water and quantify 100 µL by HPLC analysis as in step 12b. HPLC analysis indicates the yield is 88% (by comparison to the external standard sample). The product can be isolated as in steps 6a and 7a.
Deprotect 3 -hydroxyl with ammonia 14. Dissolve 3.15 g (4.98 mmol) of S.4 in 100 mL anhydrous MeOH and saturate ammonia into the solution at 0◦ C (∼20% NH3 in MeOH). 15. Keep in a sealed tube (stainless autoclave-type reactor) for 2 days at 100◦ C. 16. Cool on ice and then evaporate carefully to dryness on a rotary evaporator. 17. Dissolve the residue with 100 mL CHCl3 . 18. Remove insoluble materials by diaphragm vacuum filtration using a glass filter, and then concentrate the filtrate to a small volume on a rotary evaporator. 19. Apply column chromatography to the solution over a 3.5 × 50–cm column packed with silica gel G using 4 L of 3% to 10% EtOH in CH2 Cl2 as eluents. Monitor by TLC. 20. Characterize the product by TLC (on silica gel), UV, MS, and 1 H NMR. The compound is stable for at least 12 months when stored at ambient temperature. 9-(5-O-Trityl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine (S.5). Yield of prism-like crystals: 1.87 g (73%). m.p. 210.5◦ -212.5◦ C. TLC (10:1 v/v CH2 Cl2 /EtOH): Rf = 0.45. Anal. calcd. for C29 H26 FN5 O3 : C, 68.09; H, 5.12; N, 13.69%; found: C, 68.06; H, 5.15; N, 13.70. MS: m/z 511 (M+ ), 376 (M+ -adenine), 268 (M+ -trityl). UV λmax (MeOH): 258.5 nm. 1 H NMR ([2 H6 ]DMSO): δ 8.15 (1H, s, H2), 8.05 (1H, d, J = 2.5 Hz, H8), 7.37 (2H, br s, NH2 ), 7.23-7.42 (15H, m, trityl), 6.46 (1H, dd, J = 15.4, 4.7 Hz, H1 ), 6.02 (1H, d, J = 5.2 Hz, 3 -OH), 5.22 (1H, ddd, J = 52.5, 4.7, 3.6 Hz, H2 ), 4.48 (1H, ddt, J = 19.2(d), 5.2(t), 3.6(d) Hz, H3 ), 4.04-4.07 (1H, m, H4 ), 3.24-3.38 (2H, m, H5 ).
Perform radical deoxygenation Via phenoxythiocarbonyl 21a. Dissolve 419 mg (0.82 mmol) S.5 and 273 mg (2.23 mmol) DMAP in 10 mL CH3 CN. 22a. Add 0.22 mL (1.63 mmol) phenyl chlorothionoformate and stir for 3 hr at room temperature.
Synthesis of Modified Nucleosides
1.12.9 Current Protocols in Nucleic Acid Chemistry
Supplement 25
23a. Concentrate the solution to a small volume on a rotary evaporator and apply column chromatography over a 2.5 × 32–cm column of silica gel G using 1.2 L of 0% to 10% EtOH in CHCl3 as eluents. Monitor by TLC. TLC (10:1 v/v CH2 Cl2 /EtOH): Rf = 0.58.
24a. Evaporate the desired fraction to dryness on a rotary evaporator. 25a. Characterize the product by UV and 1 H NMR. The compound is stable for at least 12 months when stored at 4◦ C. 9-(3-O-Phenoxythiocarbonyl-5-O-trityl-2-deoxy-2-fluoro-β - D -arabinofuranosyl)adenine (S.7). Yield of a foam: 406 mg (80%). UV λmax (MeOH): 256 nm, 230 nm (sh); λmax (0.05 M HCl): 255 nm, 230 nm (sh). 1 H NMR (CDCl3 ): δ 8.38 (1H, s, H2), 8.08 (1H, d, J = 3.3 Hz, H8), 7.09-7.54 (ca 20H, m, trityl, Ph), 6.60 (1H, dd, J = 23.1, 2.6 Hz, H1 ), 5.95 (1H, dd, J = 17.6, 2.2 Hz, H3 ), 5.80 (1H, br s, NH2 ), 5.35 (1H, dd, J = 52.0, 2.6 Hz, H2 ), 4.45 (1H, m, H4 ), 3.57 (2H, d, J = 4.8 Hz, H5 ).
26a. Dissolve 386 mg (0.63 mmol) S.7 in 4 mL anhydrous toluene. 27a. Add 60 mg (0.37 mmol) AIBN and 0.6 mL (1.95 mmol) tris(trimethylsilyl)silane and heat at 100◦ C under an N2 atmosphere for 30 min. 28a. Cool the solution to room temperature and then collect the product using a glass filter under reduced pressure using an aspirator. 29a. Wash the product with 3 mL toluene and dry the crystals for 15 hr using a vacuum oil pump at 50◦ C. 30a. Characterize the product by TLC (on silica gel), elemental analysis, UV, MS, and 1 H NMR. Proceed to detritylation (step 37). The compound is stable for at least 12 months when stored at 4◦ C. 9-(2,3-Dideoxy-2-fluoro-5-O-trityl-β-D-threo-pentofuranosyl)adenine (S.9). Yield of crystals: 229 mg (73%). m.p. 226◦ -229◦ C. TLC (5:1 v/v toluene/MeOH): Rf = 0.59. Anal. calcd. for C29 H26 FN5 O2 : C, 70.29; H, 5.29; N, 14.13%; found: C, 70.20; H, 5.30; N, 14.24. MS: m/z 252 (M+ -trityl), 135 (adenine). UV λmax (MeOH): 258 nm. 1 H NMR (CDCl3 ): δ 8.36 (1H, s, H2), 8.07 (1H, d, J = 2.6 Hz, H8), 7.1-7.6 (ca 15H, m, trityl), 6.33 (1H, dd, J = 17.0, 3.0 Hz, H1 ), 5.70 (2H, br s, NH2 ), 5.22 (1H, m, JHCF = 43.6 Hz, H2 ), 4.4 (1H, m, H4 ), 3.46 (1H, dd, J = 8.2, 5.9 Hz, H5 a), 3.26 (1H, dd, J = 8.2, 3.2 Hz, H5 b), 2.2-2.65 (2H, m, H3 ).
Via xanthate 21b. Dissolve 6.60 g (12.9 mmol) S.5 in 52.4 mL anhydrous DMSO and cool to 10◦ C. 22b. Add 2.84 mL (14.2 mmol) of 5 M aq. NaOH. 23b. Add 3.19 mL (51.6 mmol) carbon disulfide in a dropwise manner to keep the temperature below 15◦ C. 24b. Add 1.60 mL (25.7 mmol) iodomethane and immediately pour the solution into a stirring mixture of 80 mL EtOAc and 80 mL water. 25b. Separate the layers and wash the organic layer with 80 mL water. 26b. Concentrate the organic layer to a minimum volume using a rotary evaporator and add 50 mL CH3 CN to the residue. 27b. Heat the mixture to 70◦ C and stir mixture 30 min at 70◦ C. The crude xanthate is dissolved and then crystallization occurs. Synthesis of Fluorinated Nucleosides
28b. Cool the mixture to 0◦ C and filter the product under vacuum through a 40-mm Kiriyama funnel (no. 5B filter paper).
1.12.10 Supplement 25
Current Protocols in Nucleic Acid Chemistry
29b. Dry the product in a 50◦ C vacuum oven to obtain the xanthate (7.32 g, 91.8% wt. purity, 86.6% yield). Use the xanthate S.8 immediately for the next reaction.
30b. Dissolve 7.32 g (91.8% wt, 11.2 mmol) S.8 in 30 mL of 1,2-dimethoxyethane. 31b. Add 9.1 mL (65.2 mmol) triethylamine and 6.2 mL (59.4 mmol) 50% aq. H3 PO2 . 32b. Heat the mixture to 90◦ C and add a solution of 0.59 g (3.56 mmol) AIBN in 18 mL of 1,2-dimethoxyethane in three portions at 30-min intervals. Stir an additional 30 min at 90◦ C after the final addition. 33b. Cool the solution to room temperature and then add 300 mL CH2 Cl2 and 200 mL water for phase separation. 34b. Concentrate the organic layer to dryness using a rotary evaporator. Add 80 mL MeOH to the residue, heat the mixture to 60◦ C, and stir for 2 hr at 60◦ C. 35b. Cool the mixture to 0◦ C and filter the resulting slurry under vacuum. 36b. Dry the crystal overnight in a 50◦ C vacuum oven to give S.9 (4.6 g, 92% wt purity, 76% yield). Characterize the product (step 30a) and proceed to detritylation (step 37).
Perform detritylation 37. Suspend 300 mg (0.605 mmol) S.9 in 18 mL MeOH. Add 1.2 mL conc. HCl and stir for 1.5 hr at room temperature. 38. Add 4 mL Amberlite IRA 900 (OAc– form) and stir for 5 min. 39. Remove the resin by filtration using a water aspirator and wash with 10 mL MeOH. Concentrate the filtrate to 2 mL using a rotary evaporator. 40. Dilute the solution with 40 mL water. Wash three times with 10 mL of CHCl3 (total 30 mL). 41. Concentrate the aqueous layer to 5 mL on a rotary evaporator to give crystrals. 42. Characterize the product by TLC (on silica gel), elemental analysis, UV, MS, and 1 H NMR. The compound is stable for at least 12 months when stored at ambient temperature. 9-(2,3-Dideoxy-2-fluoro-β-D-threo-pentofuranosyl)adenine (FddA, S.10). Yield of prism-like crystals: 135 mg (88%). m.p. 226.8◦ -227.7◦ C (lit 227◦ C). TLC (5:1 v/v toluene/MeOH): Rf = 0.17. Anal. calcd. for C10 H12 FN5 O2 : C, 47.43; H, 4.78; N, 27.66%; found: C, 47.60; H, 4.94; N, 27.47. MS: m/z 253 (M+ ), 164 (adenine+CHO). UV λmax (MeOH): 258 nm. 1 H NMR ([2 H6 ]DMSO): δ 8.26 (1H, d, J = 2.5 Hz, H8), 8.16 (1H, s, H2), 7.34 (2H, br s, NH2 ), 6.32 (1H, dd, J = 15.9, 4.1 Hz, H1 ), 5.43 (1H, ddt, J = 54.4(d), 5.8(d), 3.5(t) Hz, H2 ), 5.06 (1H, dd, J = 5.8, 6.0 Hz, 5 -OH), 4.16-4.20 (1H, m, H4 ), 3.58-3.65 (2H, m, H5 ), 2.52-2.62 (1H, m, H3 a), 2.22-2.31 (1H, m, H3 b).
SYNTHESIS OF FdaraA FROM 6-CHLOROPURINE 3 -O-BENZOYL-5 -O-TRITYLRIBOSIDE
ALTERNATE PROTOCOL
Preparation of FdaraA proceeds as described for FddA in the initial fluorination and 3 -deprotection steps. Acid treatment of S.5 yields the detritylated product.
Additional Materials (also see Basic Protocol 2) 9-(5-O-Trityl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine (S.5; see Basic Protocol 2) Trifluoroacetic acid, 98+% Aspirator Current Protocols in Nucleic Acid Chemistry
Synthesis of Modified Nucleosides
1.12.11 Supplement 25
1. Dissolve 100 mg (0.195 mmol) S.5 in 2 mL of 80% trifluoroacetic acid and keep for 10 min at room temperature. 2. Evaporate to dryness under reduced pressure with an aspirator, then co-evaporate with 5 mL water. 3. Partition the residue between 5 mL CHCl3 and 10 mL water. Wash the aqueous layer with 5 mL CHCl3 . 4. Neutralize the aqueous layer with triethylamine and then evaporate to dryness on a rotary evaporator. 5. Crystallize the solid from 150 mL EtOH overnight at room temperature. 6. Characterize the product by elemental analysis, UV, MS, and 1 H NMR. The compound is stable for at least 12 months when stored at ambient temperature. 9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)adenine (FdaraA, S.6). Yield of white crystals: 39 mg (74%). m.p. 229◦ -232◦ C (lit 231◦ -234◦ C). Anal. calcd. for C10 H12 FN5 O3 : C, 44.61; H, 4.49; N, 26.01%; found: C, 44.36; H, 4.62; N, 25.57. MS: m/z 269 (M+ ), 164 (adenine+CHO). UV λmax (MeOH): 258 nm. 1 H NMR ([2 H6 ]DMSO): δ 8.24 (1H, d, J = 0.9 Hz, H8), 8.17 (1H, s, H2), 7.35 (2H, br s, NH2 ), 6.41 (1H, dd, J = 14.5, 4.6 Hz, H1 ), 5.96 (1H, d, J = 5.0 Hz, 3 -OH), 5.05-5.36 (2H, m, H2 , 5 -OH), 4.38-4.54 (1H, m, H3 ), 3.82-3.90 (1H, m, H4 ), 3.60-3.74 (2H, m, H5 ). BASIC PROTOCOL 3
Figure 1.12.3
PREPARATION OF 6-CHLOROPURINE 3 -DEOXYRIBOSIDE The sequence of the reactions shown in Figure 1.12.3 illustrates a practical procedure for preparation of 6-chloropurine 3 -deoxyriboside (S.15), an alternate intermediate to FddA. Acetoxybromination of inosine (S.11) and then debromination by radical reduction using hypophosphorous acid and a water-soluble radical initiator gives the purine 3 -deoxyriboside analog S.13. Chlorination of the 6-position of the purine base by Vilsmeier conditions, followed by removal of the acetyl groups, gives 6-chloropurine 3 -deoxyriboside S.15.
Preparation of 6-chloropurine-3 -deoxyriboside from inosine.
1.12.12 Supplement 25
Current Protocols in Nucleic Acid Chemistry
Materials Inosine (S.11), 98+% Acetic acid, 99.5+% Trimethyl orthoacetate, 99+% Acetonitrile (CH3 CN), 99.8+% Acetyl bromide, 97+% 85:15 and 80:20 (v/v) 0.02 M aq. KH2 PO4 (pH 3.2) in CH3 CN 25% (w/v) aq. sodium hydroxide (NaOH) 50% (v/v) aq. hypophosphorous acid (H3 PO2 ) Triethylamine, 99+% 6 M hydrochloric acid (HCl) 2,2 -Azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride, 97+% (VA-044; Wako Pure Chemical Industries) Dichloromethane (CH2 Cl2 ), 99+% Dimethylformamide (DMF), 99.5+% Thionyl chloride, 98+% Saturated aq. sodium hydrogen carbonate (NaHCO3 ), 99.5+% Saturated aq. sodium chloride (NaCl), 99+% Sodium sulfate (Na2 SO4 ), anhydrous, 98+% Methanol (MeOH), 99.8+% 28% (w/w) sodium methoxide solution in methanol 1- and 2-L four-neck round-bottom flasks Mechanical stirrer Thermometers Reflux condensers Vacuum oil pump HPLC with Inertsil ODS 2 4.6 × 150–mm column (GL Science) Dropping funnel Separatory funnel Rotary evaporator with vacuum pump or water aspirator 1-L one-neck round-bottom flask 60-mm-diameter Kiriyama filter funnel (glass B¨uchner-type funnel) and no. 5B filter paper 50◦ C vacuum oven 300-mL three-neck round-bottom flask Perform acetoxybromination 1. To a 1-L four-neck round-bottom flask equipped with a mechanical stirrer, a thermometer, and a reflux condenser, add 150 g (559.2 mmol) inosine (S.11) and 450 mL acetic acid. 2. Add 100.7 g (838.3 mmol) trimethyl orthoacetate and stir for 3 hr at 35◦ C. 3. Concentrate the reaction mixture to half volume under reduced pressure using a vacuum oil pump. Keep the inner temperature at 35◦ C. 4. Add 150 mL acetic acid and concentrate again as in step 3. 5. Dissolve the concentrate in 300 mL CH3 CN and cool to 5◦ C. 6. Slowly add 103.3 mL (1.4 mol) acetyl bromide over 1 hr. This step is exothermic. Keep the inner temperature <10◦ C.
7. Stir the reaction mixture for 3 hr at 10◦ C. 8. Monitor the reaction by HPLC using HPLC condition A as follows:
Synthesis of Modified Nucleosides
1.12.13 Current Protocols in Nucleic Acid Chemistry
Supplement 25
Column: Inertsil ODS 2 4.6 × 150–mm Mobile phase: 85:15 (v/v) 0.02 M aq. KH2 PO4 (pH 3.2) in CH3 CN Flow rate: 1.0 mL/min Column temperature: 40◦ C Injection volume: 10 µL Detection: UV at 262 nm. Under these conditions, the retention times are 14.0 min for S.12 and 12.4 min for the byproduct, triacetylinosine. The ratio of target compound/triacetylinosine is normally ∼7:1 to 9:1 (by HPLC peak area ratio).
9. Use a dropping funnel to add the reaction mixture dropwise into 600 mL of ice-cold 1:1 (v/v) water/CH3 CN while controlling the pH at ∼5 to 6 by dropwise addition of 25% aq. NaOH. 10. Adjust to pH 7 using 25% NaOH. 11. Separate the layers using a separatory funnel, and then extract the aqueous layer with 300 mL CH3 CN. 12. Combine the organic layers and concentrate to a minimum volume using a rotary evaporator with a water aspirator to obtain the target compound (150.3 g, 65% yield, calculated by quantitative HPLC analysis). This results in 30% to 50% wt. of the target compound in a solution of CH3 CN. This can be used without further purification in the next reaction. An analytical sample can be obtained by silica gel column chromatography using 5:1 (v/v) CHCl3 /MeOH, followed by crystallization from CH3 CN.
13. Characterize the product by NMR, IR, UV, and MS. 9-(2,5-Di-O-acetyl-3-bromo-3-deoxy-β - D -xylofuranosyl)-1,9-dihydro-6H-purine6-one (S.12). m.p. 171◦ -172◦ C. 1 H NMR (300 MHz, CDCl3 ): δ 8.34 (s, 1H, H2), 8.24 (s, 1H, H8), 6.20 (bs, 1H, H1 ), 5.74 (bs, 1H, H2 ), 4.4-4.6 (m, 4H, H3 , H4 , H5 ab), 2.20 (s, 3H, 5 O-Ac), 2.14 (s, 3H, 2 O-Ac). 13 C NMR (75 MHz, CDCl3 ): δ 170.4, 158.8, 148.4, 146.0, 138.4, 124.2, 87.9, 83.0, 78.6, 64.7, 20.7. IR (KBr): ν 1750, 1698, 1376, 1226, 1044 cm−1 . UV λmax (MeOH): 206, 245 nm. HRMS (FAB+) calcd. for C14 H16 N4 O6 Br (M + H)+ 415.0253; found 415.0248.
Remove bromine 14. In a 1-L round-bottom flask, dilute 118.6 g (898 mmol) 50% aq. H3 PO2 with 620 mL water, and then add 90.9 g (898 mmol) triethylamine at 18◦ C. 15. To a separate 2-L four-neck round-bottom flask equipped with a mechanical stirrer, a thermometer, and a reflux condenser, add 327 g CH3 CN solution of S.12 (38.0% wt., 299 mmol). 16. Add the H3 PO2 /triethylamine solution to the solution of S.12 and heat to 50◦ C. During heating, adjust pH to 7 to 8 by adding triethylamine and 6 M HCl. 17. Add 9.7 g (30.0 mmol) VA-044 in 50 mL water. 2,2 -Azobis(2-methylpropionamide) dihydrochloride (V-50) is also useful for this reaction. VA-044 and V-50 are known to be water-soluble azo polymerization initiators, and are available from Wako Pure Chemical Industries. A common radical initiator, 2,2 -azobis(2-methylpropionitrile) (AIBN), is also effective for this reaction, but it co-precipitates with the product due to its low solubility in aqueous media. Therefore, a water-soluble radical initiator is preferable. Synthesis of Fluorinated Nucleosides
18. Stir the reaction mixture for 4 hr at 50◦ C, controlling the pH at 3 to 4 by adding 25% NaOH.
1.12.14 Supplement 25
Current Protocols in Nucleic Acid Chemistry
19. Perform HPLC analysis using HPLC condition A (see step 8) to check completion of the reaction. Under these conditions, the retention times are 6.8 min for S.13, 10.9-11.0 min for triacetylinosine, and 11.5-12.3 min for S.12.
20. Cool to 10◦ C on ice and adjust to pH 6 by adding 25% NaOH. After cooling, the target compound precipitates. Because the product obtained in this step contains inorganic salts, it should be purified as described in the following steps.
21. Filter the resulting slurry through a 60-mm Kiriyama funnel (no. 5B filter paper) under vacuum, and wash with 375 mL water. 22. Add the wet crystal to 1 L of 9:1 (v/v) CH3 CN/water. 23. Heat to 60◦ C, stir the slurry for 1 hr, and then cool to 10◦ C. 24. Filter the product through a 60-mm Kiriyama funnel (no. 5B filter paper) under vacuum and rinse with 375 mL water. 25. Dry overnight in a 50◦ C vacuum oven to give the product S.13 (69 g, 94% wt. purity, 65% yield). 26. Characterize the product by MS and NMR. 2 ,5 -Di-O-acetyl-3 -deoxyinosine (S.13). 1 H NMR (300 MHz, CDCl3 ): δ 8.08 (s, 1H, H2), 8.07 (s, 1H, H8), 6.04 (d, 1H, J = 1.1 Hz, H1 ), 5.59 (bd, 1H, J = 5.9 Hz, H2 ), 4.60 (m, 1H, H4 ), 4.39 (dd, 1H, J = 12.3, 2.9 Hz, H5 a), 4.22 (dd, 1H, J = 12.3, 5.2 Hz, H5 b), 2.50 (ddd, 1H, J = 14.0, 10.5, 5.9 Hz, H3 a), 2.16 (ddd, 1H, J = 14.0, 5.8, 1.1 Hz, H3 b), 2.09 (s, 3H, 5 O-Ac), 2.04 (s, 3H, 2 O-Ac). 1 H NMR (300 MHz, DMSO-d6 ): δ 8.26 (s, 1H, H2), 8.10 (s, 1H, H8), 6.11 (d, 1H, J = 1.4 Hz, H1 ), 5.61 (bd, 1H, J = 6.3 Hz, H2 ), 4.52 (m, 1H, H4 ), 4.29 (dd, 1H, J = 12.0, 2.9 Hz, H5 a), 4.16 (dd, 1H, J = 12.0, 5.8 Hz, H5 b), 2.60 (ddd, 1H, J = 14.1, 10.3, 6.3 Hz, H3 a), 2.22 (ddd, 1H, J = 14.1, 5.9, 1.1 Hz, H3 b), 2.10 (s, 3H, 5 O-Ac), 1.99 (s, 3H, 2 O-Ac). 13 C NMR (75 MHz, DMSO-d6 ): δ 170.3, 170.1, 156.7, 147.9, 146.2, 138.9, 124.6, 88.6, 78.2, 77.7, 64.6, 32.6, 20.9, 20.7. HRMS (FAB+) calcd. for C14 H17 N4 O6 (M + H)+ 337.1148; found 337.1153.
Introduce chlorine 27. In a 1 L four-neck round-bottom flask equipped with a thermometer and a reflux condenser, suspend 37.6 g (94% wt., 105 mmol) S.13 in 475 mL CH2 Cl2 . 28. Add 32.8 mL (423 mmol) DMF and 30.9 mL (423 mmol) thionyl chloride and stir with magnetic stirring. The reaction is exothermic. Keep the inner temperature <30◦ C.
29. Reflux the reaction mixture for 6.5 hr at 50◦ C. 30. Check completion of the reaction by HPLC analysis using HPLC condition B as follows:
Column: Inertsil ODS 2 4.6 × 150–mm Mobile phase: 80:20 (v/v) 0.02 M aq. KH2 PO4 (pH 3.2) in CH3 CN Flow rate: 1.0 mL/min Column temperature: 40◦ C Injection volume: 10 µL Detection: UV at 262 nm. Under these conditions, the retention times are 1.7 min for hypoxantine, 2.4 min for 6-chloropurine, 4.0 min for S.13, and 16.8 min for S.14.
31. Cool the reaction mixture to 10◦ C and pour into 400 mL ice-cold water.
Synthesis of Modified Nucleosides
1.12.15 Current Protocols in Nucleic Acid Chemistry
Supplement 25
32. Separate the layers and wash the organic layer with 300 mL water, 400 mL saturated aq. NaHCO3 , and then 400 mL saturated aq. NaCl. 33. Dry over anhydrous Na2 SO4 until the solution becomes clear, and filter off the drying agent through a 60-mm Kiriyama funnel (no. 5A filter paper) under vacuum. 34. Remove solvent under reduced pressure using a rotary evaporator with a water aspirator, and use a vacuum oil pump to obtain the crude product S.14 as a yellow foam (33.5 g, 89.9% yield). 35. Analyze the compound by NMR, IR, and MS. 6-Chloro-9-(2,5-di-O-acetyl-3-deoxy-β-D-erythro-pentofuranosyl)-9H-purine (S.14). 1 H NMR (300 MHz, CDCl3 ): δ 8.77 (s, 1H, H2), 8.32 (s, 1H, H8), 6.15 (d, 1H, J = 1.3 Hz, H1 ), 5.74 (d, 1H, J = 5.8 Hz, H2 ), 4.63-4.74 (m, 1H, H4 ), 4.46 (dd, 1H, J = 12.3, 2.8 Hz, H5 a), 4.30 (dd, 1H, J = 12.3, 5.1 Hz, H5 b), 2.65 (ddd, 1H, J = 14.1, 10.6, 6.0 Hz, H3 a), 2.27 (ddd, 1H, J = 14.1, 5.6, 1.3 Hz, H3 b), 2.17 (s, 3H, 5 O-Ac), 2.08 (s, 3H, 2 O-Ac). 1 H NMR (300 MHz, DMSO-d6 ): δ 8.85 (s, 2H, H2, H8), 6.31 (s, 1H, H1 ), 5.76 (s, 1H, H2 ), 4.55-4.64 (m, 1H, H4 ), 4.32 (dd, 1H, J = 12.1, 2.8 Hz, H5 a), 4.22 (dd, 1H, J = 12.1, 5.8 Hz, H5 b), 2.67 (ddd, 1H, J = 14.2, 10.3, 6.1 Hz, H3 a), 2.01-2.32 (m, 1H, H3 b), 2.13 (s, 3H, 5 O-Ac), 1.97 (s, 3H, 2 O-Ac). 13 C NMR (75 MHz, DMSO-d6 ): δ 170.3, 170.1, 152.0, 151.3, 149.6, 140.6, 131.5, 89.2, 78.6, 77.4, 64.5, 32.4, 20.9, 20.6. IR (neat): ν 1745, 1674, 1592, 1562, 1387, 1339, 1232, 1094, 1053 cm−1 . HRMS (FAB+) calcd. for C14 H16 N4 O5 Cl (M + H)+ 355.0809; found 355.0816.
Remove acetyl protection 36. In a 300-mL three-neck round-bottom flask equipped with a thermometer, dissolve 26.3 g (74.1 mmol) S.14 in 39.5 mL MeOH. 37. Cool the mixture at 5◦ C and add 2.8 g of 28% sodium methoxide in methanol (14.5 mmol). 38. Stir the mixture for 3 hr at ambient temperature. The clear solution turns to a thick, white slurry.
39. Employ HPLC analysis using HPLC condition A (see step 8) to check completion of the reaction. Under these conditions, the retention times are 3.4-3.5 min for the fully deprotected S.15 and 9.7 min for a monoacetyl intermediate.
40. Cool the reaction mixture to 5◦ C and stir for 2 hr. 41. Filter the product through a 40-mm Kiriyama funnel (no. 5B filter paper) under vacuum and rinse with cold MeOH. 42. Dry overnight in a 50◦ C vacuum oven to give the target compound S.15 (14.7 g, 98% wt. purity, 71% yield). It is possible to recover a second crop from the mother liquor. After concentrating the mother liquor to about half the volume, filter the solid precipitate and purify by recrystallization from 25% (v/v) aqueous MeOH to produce pure S.15 (2.4 g, ∼45% recovery). An analytical sample is obtainable by recrystallization from 1:3 (v/v) MeOH/water.
43. Analyze the compound by melting point, UV, IR, MS, and NMR.
Synthesis of Fluorinated Nucleosides
1.12.16 Supplement 25
6-Chloro-9-(3-deoxy-β-D-erythro-pentofuranosyl)-9H-purine (S.15). m.p. 180◦ -181◦ C. 1 H NMR (300 MHz, CDCl3 ): δ 8.68 (s, 1H, H2), 8.33 (s, 1H, H8), 5.83 (d, 1H, J = 4.6 Hz, H1 ), 4.92 (ddd, 1H, J = 7.2, 6.5, 4.6 Hz, H2 ), 4.53-4.59 (m, 1H, H4 ), 3.98 (dd, 1H, J = 12.5, 2.1 Hz, H5 a), 3.60 (dd, 1H, J = 12.5, 2.6 Hz, H5 b), 2.53 (ddd, 1H, J = 12.9, 7.2, 5.7 Hz, H3 a), 2.18 (ddd, 1H, J = 12.9, 8.0, 6.5 Hz, H3 b). 1 H NMR (300 MHz, DMSO-d6 ): δ 8.97 (s, 1H, H2), 8.82 (s, 1H, H8), 6.06 (d, 1H, J = 1.4 Hz, H1 ), 5.80 (d, Current Protocols in Nucleic Acid Chemistry
1H, J = 3.9 Hz, 2 -OH), 5.12 (dd, 1H, J = 5.3, 5.2 Hz, 5 -OH), 4.62-4.68 (m, 1H, H2 ), 4.42-4.50 (m, 1H, H4 ), 3.78 (ddd, 1H, J = 12.1, 5.3, 3.2 Hz, H5 a), 3.59 (ddd, 1H, J = 12.1, 5.2, 3.8 Hz, H5 b), 2.28 (ddd, 1H, J = 13.3, 9.6, 5.3 Hz, H3 a), 1.93 (ddd, 1H, J = 13.3, 6.0, 2.2 Hz, H3 b). 13 C NMR (75 MHz, DMSO-d6 ): δ 151.8, 151.3, 149.3, 145.4, 131.5, 91.6, 81.9, 75.2, 62.1, 33.6. IR (KBr): ν 3331, 1596, 1562, 1442, 1405, 1391, 1337, 1207, 1129, 1079, 1068 cm−1 . UV λmax (MeOH): 204, 265 nm. HRMS (FAB+) calcd. for C10 H12 N4 O3 Cl (M + H)+ 271.0598; found 271.0584.
PREPARATION OF FddA FROM 6-CHLOROPURINE 3 -DEOXYRIBOSIDE The sequence of reactions shown in Figure 1.12.4 illustrates a useful procedure for a practical synthesis of FddA (S.20) from 6-chloropurine 3 -deoxyriboside (S.15). Trityl protection of the C5 -OH of S.15 followed by fluorination at the C2 -β position by perfluorobutanesulfonyl fluoride affords the fluorinated compound S.17 along with the byproduct S.18. Selective decomposition of S.18 in an acidic medium allows for isolation of S.17. Finally, amination of the C6 position of the purine base and subsequent detritylation gives FddA in good yields.
Figure 1.12.4
BASIC PROTOCOL 4
Preparation of FddA from 6-chloro-9-(3-deoxy-β-D-erythro-pentofuranosyl)-9H-purine.
Materials 6-Chloro-9-(3-deoxy-β-D-erythro-pentofuranosyl)-9H-purine (S.15) Acetonitrile (CH3 CN), 99.8+% Nitrogen 2,4,6-Collidine, 99+% Trityl chloride, 98+% Mobile phase: HPLC-grade MeOH, far-UV-grade CH3 CN, and 0.1% H3 PO4 (see Tables 1.12.2 and 1.12.3 for gradients) Methanol (MeOH), 99.8+% Dichloromethane (CH2 Cl2 ), 99+% 6 M hydrochloric acid (HCl) Saturated aq. sodium hydrogencarbonate (NaHCO3 ), 99.5+% Sodium sulfate (Na2 SO4 ), anhydrous, 98+% Benzotrifluoride, 98+% n-Hexane, 95+% Toluene, 99.5+%
Synthesis of Modified Nucleosides
1.12.17 Current Protocols in Nucleic Acid Chemistry
Supplement 25
Perfluorobutanesulfonyl fluoride, 90+% N,N-Dimethylcyclohexylamine, 98+% 5.0% aq. ammonium chloride (NH4 Cl), 99.5+% 80% aq. acetic acid, 99.7+% Cyclohexane, 99.5+% Tetrahydrofuran, 99.5+% Ammonia (NH3 ), anhydrous, 99.99+% 35% to 37% hydrochloric acid (conc. HCl) 25% aq. ammonia (NH3 ) Ethyl acetate (EtOAc), 99.5+% 500-mL and 1-L round-bottom flasks Reflux condensers HPLC with Zorbax SB-phenyl 4.6 × 250–mm column (Chrompack) Rotary evaporator with vacuum pump and water aspirator Separatory funnel 60- and 40-mm Kiriyama filter funnels (glass B¨uchner-type funnel) with no. 5A and 5B filter papers 50◦ C vacuum oven 500-mL four-neck round-bottom flasks 1-L stainless steel pressure vessel equipped with a pressure gauge Water trap unit Glass filter holder with PTFE membrane filter Perform 5 -tritylation 1. In a 500-mL round-bottom flask equipped with a reflux condenser, suspend 20 g (99% purity, 73.1 mmol) S.15 in 140 mL anhydrous CH3 CN and stir with magnetic stirring under a nitrogen stream. As trityl chloride is moisture sensitive, the reaction should be carried out under dry conditions.
2. Add 11.6 mL (87.7 mmol) 2,4,6-collidine and 22.4 g (80.4 mmol) trityl chloride. 3. Heat the reaction mixture to 45◦ C and stir for 3 hr under a nitrogen atmosphere. 4. Monitor the reaction by HPLC using HPLC condition C as follows:
Column: Zorbax SB-phenyl 4.6 × 250–mm (Chrompack) Mobile phase: see Table 1.12.2 for gradient Flow rate: 1.0 mL/min Column temperature: ambient Injection volume: 10 µL Detection: UV at 262 nm (220 nm for analysis of non-nucleoside impurities). Under these conditions, the retention times are 5.0-5.5 min for S.15, 13.5-14.5 min for toluene, 18.4 min for triphenylmethyl alcohol (TrOH), 20.0 min for S.16, 23.0 min for methyltriphenylmethyl ether (TrOMe), and 29.0 min for a 2 ,5 -di-O-trityl impurity.
5. Add 1.5 mL (37.1 mmol) MeOH and stir the mixture for 1 hr at 45◦ C. Quenching with methanol leads to the formation of TrOMe, which is easily removed during crystallization.
6. Cool to room temperature. Concentrate the reaction mixture to a minimum volume using a rotary evaporator with a water aspirator. Synthesis of Fluorinated Nucleosides
1.12.18 Supplement 25
Current Protocols in Nucleic Acid Chemistry
Table 1.12.2 Gradient Program for HPLC Condition Ca
Time (min)
% aq. H3 PO4
% CH3 CN
% MeOH
0
60
10
30
5
60
10
30
8
30
60
10
16
30
60
10
19
10
80
10
32
10
80
10
35
60
10
30
45
60
10
30
a Using HPLC-grade MeOH, far-UV-grade CH CN, and 0.1% H PO 3 3 4
(2.94 mL 85% H3 PO4 adjusted to 2.5 L with deionized water).
7. Add 100 mL water and 200 mL CH2 Cl2 . Adjust to pH 3 with 6 M HCl, and separate the layers using a separatory funnel. The aqueous layer contains 2,4,6-collidine, HCl, and CH3 CN.
8. Add 100 mL water to the organic layer and adjust to pH 3 with 6 M HCl, then wash and separate the layers. 9. Add 100 mL water to the organic layer and adjust to pH 7 with saturated aq. NaHCO3 , then wash and separate the layers. 10. Dry the organic layer over anhydrous Na2 SO4 until the solution becomes clear, filter off the drying agent through a 60-mm Kiriyama funnel (no. 5A filter paper) under vacuum, and remove the solvent under reduced pressure using a rotary evaporator with a water aspirator. 11. Add 220 mL benzotrifluoride and concentrate to a minimum volume under reduced pressure. CH2 Cl2 is removed by co-evaporation with benzotrifluoride.
12. Add 180 mL benzotrifluoride, heat to 80◦ C, and then cool to room temperature. The product S.16 is crystallized from benzotrifluoride.
13. Filter the crystals over a 60-mm Kiriyama funnel (no. 5B filter paper) under vacuum and wash with 50 mL benzotrifluoride and 50 mL n-hexane. 14. Dry overnight in a 50◦ C vacuum oven to obtain the product S.16 (31.9 g, 85.0% yield). 15. Analyze the product by melting point, UV, IR, MS, and NMR. 6-Chloro-9-[3-deoxy-5-O-(triphenylmethyl)-β - D-erythro-pentofuranosyl]-9H-purine (S.16). m.p. 205◦ -206◦ C. 1 H NMR (300 MHz, CDCl3 ): δ 8.64 (s, 1H, H2), 8.40 (s, 1H, H8), 7.21-7.41 (m, 15H, 5 -OTr), 6.04 (d, 1H, J = 2.2 Hz, H1 ), 4.85-4.91 (m, 1H, H2 ), 4.68-4.78 (m, 1H, H4 ), 3.44 (dd, 1H, J = 10.6, 3.1 Hz, H5 a), 3.33 (dd, 1H, J = 10.6, 4.6 Hz, H5 b), 2.30 (ddd, 1H, J = 13.3, 7.7, 5.6 Hz, H3 a), 2.17 (ddd, 1H, J = 13.3, 6.5, 3.9 Hz, H3 b). 13 C NMR (75 MHz, CDCl3 ): δ 151.4, 151.2, 150.4, 146.7, 143.3, 132.4, 128.5, 127.8, 127.2, 93.1, 87.0, 80.7, 76.0, 64.3, 33.9. IR (KBr): ν 3354, 3059, 1592, 1562, 1491, 1449, 1440, 1338, 1206, 1130, 1078, 1018 cm−1 . UV λmax (MeOH): 207, 265 nm. HRMS (FAB+) calcd. for C29 H26 N4 O3 Cl (M + H)+ 513.1693; found 513.1717.
Synthesis of Modified Nucleosides
1.12.19 Current Protocols in Nucleic Acid Chemistry
Supplement 25
Perform fluorination 16. In a 500-mL four-neck round-bottom flask equipped with a mechanical stirrer, a thermometer, and a reflux condenser, suspend 30.0 g (58.5 mmol) S.16 in 300 mL toluene. 17. Add 23.3 mL (117 mmol) perfluorobutanesulfonyl fluoride and 17.7 mL (117 mmol) N,N-dimethylcyclohexylamine at 20◦ C. Although conventional fluorinating reagents such as DAST and MOST can be effective for this reaction, for safety purposes, perfluorobutanesulfonyl fluoride is highly preferable (see Commentary).
18. Heat to an internal temperature of 50◦ C and stir the reaction mixture for 23 hr. 19. Monitor the reaction by HPLC using HPLC condition D as follows:
Column: Zorbax SB-phenyl 4.6 × 250–mm (Chrompack) Mobile phase: see Table 1.12.3 for gradient Flow rate: 1.0 mL/min Column temperature: ambient Injection volume: 10 µL Detection: UV at 262 nm (220 nm for the analysis of non-nucleoside impurities). Under these conditions, the retention times are 3.4 min for 6-chloropurine (a deribose byproduct), 4.6-4.7 min for toluene, 5.0 min for N,N-dimethylcyclohexylamine, 7.7-7.8 min for S.16, 10.9-11.0 min for S.18, 11.5-12.3 min for S.17, 13.5 min for 2 -(trityloxymethyl)furane, 16.5 min for a 5 -O-trityl-2 -perfluorobuntanesulfonate intermediate, and 19.5 min for a 2 ,5 -di-O-trityl impurity. The elimination product (S.18) is obtained as a byproduct. The ratio of S.17 to S.18 is 7:3 (HPLC peak area ratio).
20. Add 75 mL of 5.0% aq. NH4 Cl with stirring at 50◦ C and then separate the layers. During extraction at 50◦ C, the mixture forms three layers. The lowest layer contains mostly perfluoro compounds, the middle layer contains water, and the upper layer contains the organic compounds.
21. Extract the lower layer with 30 mL toluene at 50◦ C. 22. Wash the combined toluene layer with 75 mL of 5.0% aq. NH4 Cl at 50◦ C and separate the layers. 23. Wash the organic layer with 75 mL water at 50◦ C and separate the layers. 24. Concentrate the organic layer to half the volume under reduced pressure using a rotary evaporator with a water aspirator. Table 1.12.3 Gradient Program for HPLC Condition Da
Synthesis of Fluorinated Nucleosides
1.12.20 Supplement 25
Time (min)
% aq. H3 PO4
% CH3 CN
% MeOH
0
30
60
10
8
30
60
10
10
10
80
10
20
10
80
10
22
30
60
10
30
30
60
10
a Using HPLC-grade MeOH, far-UV-grade CH CN, and 0.1% H PO 3 3 4
(2.94 mL 85% H3 PO4 adjusted to 2.5 L with deionized water). Current Protocols in Nucleic Acid Chemistry
25. Cool to 10◦ C. Add 150 mL of 80% aq. acetic acid and stir the reaction mixture for 3 hr at 10◦ C. The fluorinated compound (S.17) is stable in an acidic medium due to the effect of the C2 -β fluoride. In contrast, the elimination product (S.18) is acid-labile due to acidolysis of the glycosyl bond. Therefore, S.17 can be purified by selective decomposition of S.18 by means of treatment with acetic acid.
26. Separate the layers and wash the organic layer with 150 mL water. 27. Add 150 mL cyclohexane to crystallize the product and stir the mixture for 1 hr at 20◦ C. 28. Cool to 0◦ C and stir for 1 hr. 29. Filter the crystals over a 60-mm Kiriyama funnel (no. 5B filter paper) under vacuum and wash with 150 mL cyclohexane. 30. Dry overnight in a 50◦ C vacuum oven to obtain the product S.17 (15.0 g, 49.6% yield). 31. Characterize the product by UV, IR, MS, and NMR. 6-Chloro-9-[2,3-dideoxy-2-fluoro-5-O-(triphenylmethyl)-β-D-threo-pentofuranosyl]9H-purine (S.17). 1 H NMR (300 MHz, CDCl3 ): δ 8.73 (s, 1H, H2), 8.34 (d, 1H, J = 2.8 Hz, H8), 7.22-7.52 (m, 15H, 5 -OTr), 6.41 (dd, 1H, J = 19.1, 3.1 Hz, H1 ), 5.25 (dddd, 1H, J = 53.7, 5.2, 3.1, 2.0 Hz, H2 ), 4.42-4.50 (m, 1H, H4 ), 3.48 (dd, 1H, J = 9.9, 6.6 Hz, H5 a), 3.30 (dd, 1H, J = 9.9, 3.8 Hz, H5 b), 2.57 (dddd, 1H, J = 35.0, 14.8, 9.0, 5.6 Hz, H3 a), 2.36 (dddd, 1H, J = 27.5, 15.1, 5.1, 1.7 Hz, H3 b). 13 C NMR (75 MHz, CDCl3 ): δ 152.0, 151.2 (d, J = 16.8 Hz), 144.7 (d, J = 5.8 Hz), 143.6, 128.6, 127.9, 127.2, 90.6 (d, J = 188.9 Hz), 86.9, 85.0 (d, J = 16.4 Hz), 76.8, 65.7, 33.8 (d, J = 20.5 Hz). IR (KBr): ν 1593, 1567, 1492, 1220, 1206, 1079 cm−1 . UV λmax (MeOH): 206, 264 nm. HRMS (FAB+) calcd. for C29 H25 N4 O2 FCl (M + H)+ 515.1650; found 515.1658. Anal. calcd. for C29 H24 N4 O2 FCl: C, 67.64; H, 4.70; N, 10.88; Cl, 6.88%; found: C, 67.34; H, 4.81; N, 10.61; Cl, 6.98.
Perform amination 32. Fill a 1-L stainless steel pressure vessel with 15.0 g (29 mmol) S.17 and 250 mL tetrahydrofuran. The starting material dissolves in the tetrahydrofuran.
33. Blow NH3 gas into the solution at a pressure of 2.5 bar. The NH3 gas slowly dissolves into the solution. It may take ∼1 hr to add NH3 at a pressure of 2.5 bar. Stir for an additional 1 hr to make sure the pressure stabilizes.
34. Heat to 70◦ C and stir the reaction mixture for 72 hr. The pressure will rise from 2.5 bar to a maximum of 8 bar. During the reaction some crystallization of NH4 Cl occurs.
35. Cool to 20◦ C and release NH3 gas to a water trap unit filled with water. 36. Employ HPLC analysis using HPLC condition D (see step 19) to check that the reaction has proceeded to completion. Under these conditions, the retention times are 6.5 min for S.19, 10.9-11.0 min for S.18, 11.5-12.3 min for S.17, and 13.5 min for 2-(trityloxymethyl)furane.
37. Concentrate the solution to a minimum volume. This concentration results in a very thick slurry that can be used directly in the next reaction.
38. Characterize the product S.19 by UV, IR, MS, and NMR.
Synthesis of Modified Nucleosides
An analytical sample can be obtained by recrystallization from methanol.
1.12.21 Current Protocols in Nucleic Acid Chemistry
Supplement 25
9-[2,3-Dideoxy-2-fluoro-5-O-(triphenylmethyl)-β - D -threo-pentofuranosyl]adenine (S.19). m.p. 235◦ -236◦ C. 1 H NMR (300 MHz, CDCl3 ): δ 8.33 (s, 1H, H2), 8.06 (d, 1H, J = 3.0 Hz, H8), 7.20-7.52 (m, 15H, 5 -OTr), 6.33 (dd, 1H, J = 19.9, 2.9 Hz, H1 ), 6.18 (bs, 2H, 6-NH2 ), 5.20 (dm, 1H, J = 53.8 Hz, H2 ), 4.35-4.45 (m, 1H, H4 ), 3.46 (dd, 1H, J = 10.0, 6.5 Hz, H5 a), 3.27 (dd, 1H, J = 10.0, 4.1 Hz, H5 b), 2.50 (dddd, J = 35.5, 14.9, 9.0, 5.4 Hz, H3 a), 2.31 (dddd, 1H, J = 27.5, 14.9, 4.8, 1.4 Hz, H3 b). 13 C NMR (75 MHz, CDCl3 ): δ 155.4, 152.9, 149.6, 143.6, 140.1 (d, J = 6.9 Hz), 128.6, 127.9, 127.1, 119.0, 90.6 (d, J = 188.6 Hz), 86.7, 84.7 (d, J = 16.7 Hz), 76.2, 65.8, 33.9 (d, J = 20.6 Hz). IR (KBr): ν 3151, 1649, 1599, 1578, 1403, 1063 cm−1 . UV λmax (MeOH): 208, 259 nm. HRMS (FAB+) calcd. for C29 H27 N5 O2 F (M+H)+ 496.2149; found 496.2141.
Perform detritylation 39. In a 1-L round-bottom flask, dilute the thick slurry of S.19 with 144 mL MeOH. 40. Add 4.8 mL of conc. (37%) HCl. Stir the solution for 4 hr at 20◦ C. This reaction is slightly exothermic. The reaction mixture turns to a clear solution.
41. Employ HPLC analysis using HPLC condition C (see step 4) to check that the reaction has proceeded to completion. Under these conditions, the retention times are 3.5 min for S.20 (FddA) and 18.1 min for S.19.
42. Neutralize the reaction mixture with a slight excess of 25% aq. NH3 to adjust the pH to ∼6. 43. Evaporate the solvent to a minimum volume using a rotary evaporator with a water aspirator. Keep the bath temperature below 35◦ C.
44. Add 43 mL EtOAc to the residue and evaporate again to a minimum volume. MeOH may cause product loss because S.20 dissolves to a certain extent in EtOAc/MeOH.
45. Add 43 mL EtOAc and 43 mL water to the residue. 46. Add 2.0 mL conc. HCl to the solution to adjust the pH to ∼2. Stir and then separate the layers. 47. Wash the aqueous layer with 14.4 mL EtOAc two times. Filter the aqueous layer on a membrane filter. 48. Add 25% aq. NH3 to the filtrate to adjust the pH value to 7 to 8. 49. Stir the suspension overnight and then cool to 0◦ C. 50. Filter the product through a 40-mm Kiriyama funnel (no.5B filter paper) under vacuum at 0◦ C, and wash three times with 14.4 mL water. 51. Dry the product for 24 hr in a 50◦ C vacuum oven to obtain FddA (S.20; 5.3 g, 99.1% purity, 73% yield in two steps). 52. Characterize of the product by UV, IR, MS, and NMR.
Synthesis of Fluorinated Nucleosides
1.12.22 Supplement 25
9-(2,3-Dideoxy-2-fluoro-β-D-threo-pentofuranosyl)adenine (FddA, lodenosine, S.20). m.p. 226◦ -227◦ C. 1 H NMR (300 MHz, DMSO-d6 ): δ 8.27 (d, 1H, J = 2.3 Hz, H8), 8.16 (s, 1H, H2), 7.33 (bs, 2H, 6-NH2 ), 6.32 (dd, 1H, J = 16.1, 3.9 Hz, H1 ), 5.43 (dm, 1H, J = 54.4 Hz, H2 ), 5.07 (t, 1H, J = 5.9 Hz, 5 -OH), 4.13-4.23 (m, 1H, H4 ), 3.54-3.69 (m, 2H, H5 ab), 2.47-2.68 (m, 1H, H3 a), 2.17-2.36 (m, 1H, H3 b). 13 C NMR (75 MHz, DMSO-d6 ): δ 156.2, 152.9, 149.3, 139.7 (d, J = 4.7 Hz), 118.4, 91.5 (d, J = 185.9 Hz), 83.8 (d, J = 16.1 Hz), 77.9, 63.1, 32.6 (d, J = 19.3 Hz). IR (KBr): ν 3328, 3208, 3136, 1661, 1076, 1061 cm−1 . UV λmax (MeOH): 204, 259 nm. HRMS (FAB+) calcd. for C10 H13 N5 O2 F (M + H)+ 254.1053; found 254.1048. Anal. calcd. for C10 H12 N5 O2 F: C, 47.43; H, 4.78; N, 27.66; F, 7.50%; found: C, 47.45; H, 4.84; N, 27.46; F, 7.13. Current Protocols in Nucleic Acid Chemistry
COMMENTARY Background Information Lodenosine activity Lodenosine (FddA) is an anti-HIV agent that is a C2 -β-fluorinated dideoxynucleoside (Herdewijn et al., 1987; Marquez et al., 1987, 1990; Ruxrungtham et al., 1996; Graul et al., 1998). Like other nucleoside derivatives such as zidovudine (AZT), 2 ,3 -dideoxyadenosine (ddA), and 2 ,3 -dideoxyinosine (ddI), FddA acts as an inhibitor of HIV reverse transcriptase (RT). FddA was chosen for evaluation as one of the most selective inhibitors in a series of 2 ,3 -dideoxyadenosines with either an azido, fluorine, or hydroxyl group substituted in the “up” or “down” position of the C2 and C3 of the ribose moiety. Although it is less active than the parent compound ddA (Herdewijn et al., 1987), FddA is stable in the acidic conditions found in the human stomach, which are known to decompose ddA and ddI (Marquez et al., 1987, 1990). Furthermore, FddA does not exhibit cross-resistance to AZT, zalcitabine (ddC), and ddI (Driscoll et al., 1997), and even has synergetic activity with AZT. FddA also acts synergistically with other anti-HIV agents including HIV protease inhibitors such as Ritonavir, thus providing new possible combination therapy protocols for HIV. Consequently, FddA has progressed into development as a novel antiHIV agent exhibiting significant advantages in terms of high stability, high oral bioavailability (Ruxrungtham et al., 1996), and effectiveness against strains resistant to existing dideoxynucleosides (Ueno and Mitsuya, 1997). Synthetic approaches The considerable attention that FddA received from antiviral researchers because of its biological activity and chemical and metabolic stability (Chu et al., 1989; Marquez et al., 1990) has led many groups to strive to develop efficient methods for synthesizing C2 -β-fluorinated purine deoxynucleosides. Although condensation of fluorinated sugar derivatives with a nucleobase is a wellknown means of obtaining C2 -β-fluorinated nucleosides (Wysocki et al., 1991; Siddiqui et al., 1994; Chou et al., 1996), the synthesis of the fluorinated sugar derivatives themselves requires many steps, and the condensation remains subject to α-anomer formation (Barchi et al., 1991). The introduction of fluorine at the 2 -(S)ara site of a nucleoside is difficult. The first problem is the poor yields associated with
3 ,5 -di-O-protection by a trityl group (Pankiewicz et al., 1992a,b). Pankiewicz et al. (1992a) reported an excellent method for the fluorination of ribosides at the C2 -β position employing advantageous conformational control to synthesize 2 -fluorinated araA (FaraA). They found that the C2 -β-fluorinated com pound could be obtained from O3 ,O5 ,N6 tritrityladenosine in 30% yield, but only in the presence of an unexpected and undesired isonucleoside in 51% yield, due to migration caused by an intramolecular nucleophilic attack of N3 at the electrophilic C2 . Recently, a new synthetic approach to FddA was reported via dehydration of a 2 deoxy-2 -fluoroadenosine and subsequent hydrogenation of the vinyl fluoride intermediate (Siddiqui et al., 1998). However, the preparation of the 2 -deoxy-2 -fluoroadenosine starts with a costly compound, 9-(β-Darabinofuranosyl)adenine (Kawasaki et al., 1993), and requires a multi-step synthesis. This unit presents methods for fluorination of 6-chloropurine derivatives, which are subsequently aminated to give the desired FddA. Fluorination of a 6-chloropurine riboside The first approach (see Basic Protocols 1 and 2) is an efficient method for preparing FddA and FdaraA (S.6; Maruyama et al., 1996) from a 3 -O-benzoyl-5 -O-tritylriboside (S.3; Fig. 1.12.2; Maruyama et al., 1999). FdaraA is an important fluorinated nucleoside that has potent anti-tumor activities (Sato et al., 1984; Parker et al., 2003). One of the major advantages of this method is that these biologically important nucleosides, FddA and FdaraA, can be synthesized via a common intermediate, 9-(5-O-trityl-2-deoxy-2-fluoro-βD-arabinofuranosyl)adenine (S.5). The protocol begins with 6-chloropurine riboside (S.1; Fig. 1.12.1), which is commercially available and can also be prepared from inosine (Zemlicka and Sorm, 1965). 3 -O-Benzoylation. The treatment of ribonucleosides with acyl chloride usually produces a mixture of monoacyl, diacyl, or triacyl derivatives. However, the 2 ,3 -O-din-butylstannylene complex is a useful intermediate for the introduction of a single benzoyl group onto the 2 - and/or 3 -OH (Wagner et al., 1974; Maruyama et al., 1998). Thus, 6-chloropurine riboside (S.1; Zemlicka and Owens, 1978) can be successively treated with di-n-butyltin oxide and excess benzoyl chloride in the presence of triethylamine in
Synthesis of Modified Nucleosides
1.12.23 Current Protocols in Nucleic Acid Chemistry
Supplement 25
methanol. Workup and purification by silica gel chromatography give an inseparable mixture of the 2 -O- and 3 -O-benzoates. Crystallization from methanol produces the 3 -Obenzoate (S.2) as pale yellowish crystals in 65% yield. The purity at this point can be checked by HPLC, which reveals that the product is the 3 -O-benzoate (96.1%) mixed with the 2 -O-benzoate (3.9%). 5 -O-Tritylation. Trityl (triphenylmethyl) chloride has been employed to achieve selective protection of primary alcohols. A base such as pyridine promotes this reaction. However, the reaction of S.2 in pyridine causes nucleophilic displacement at the 6-chloro moiety and the solution becomes colored. To overcome this undesired reaction, triethylamine is used in an amount less than that of trityl chloride. Under such reaction conditions, however, the 3 -O-benzoyl group migrates to the 2 -OH position, rapidly reaching equilibrium. TLC of the mixture shows spots of both 5 -Otrityl-2 -O-benzoylriboside and 5 -O-trityl-3 O-benzoylriboside (S.3). Therefore, the mixture is crystallized from methanol to afford S.3 in 71% yield. Analysis by HPLC reveals S.3 to be of 98% purity (Fig. 1.12.5). Acyl migration. The 2 -OH of a ribonucleoside is preferentially acetylated over the 3 -OH group. However, because 2 -acyl derivatives are unstable with respect to their 3 -isomers, subsequent equilibrium results in acetyl migration, with the 3 -O-acylate being obtainable by crystallization from the equilibrium mixture (Brown et al., 1956; Reese and Trentham, 1965; Johnston, 1968; Reese et al., 1975). The acidity of the 2 -OH group explains this tendency (Brown and Robins, 1965; Gin and Dekker, 1968). In this manner, the 3 O-benzoates (S.2, S.3) can be isolated from
Synthesis of Fluorinated Nucleosides
mixtures of the 3 - and 2 -isomers. Acyl migration can be controlled during fluorination. Migration was explored using the 3 -O-benzoate S.2 in methanol under acidic and basic conditions by means of HPLC analysis. S.2 reached equilibrium rapidly in a 1 mM triethylamine solution. However, the rate of migration was slow in a 1 mM pyridine solution and was similar to that in methanol alone. In a 1 mM imidazole solution, an intermediate value was obtained. Under acidic conditions, no migration was observed even after 1 day (Fig. 1.12.6). The acyl migration of S.3 was also examined since the fluorination reaction of S.3 with diethylaminosulfur trifluoride (DAST) should be carried out in the presence of an amine to protect the acid-labile 5 -O-trityl group. S.3 was heated under reflux in the presence of 6 eq of pyridine in CH2 Cl2 for 5 hr. Only 3.1% of the 2 -O-benzoate was observed in the mixture. This result indicates that the 3 -O-benzoyl group does not migrate to the 2 -hydroxl group in CH2 Cl2 containing a small amount of pyridine at reflux. Fluorination with DAST. Fluorination using DAST liberates acidic HF and cleaves the 5 -O-trityl group. To prevent deprotection, the addition of a base is effective. However, a strong base such as triethylamine accelerates the migration of the 3 -O-benzoate. Pyridine in CH2 Cl2 prevents deprotection without acyl migration as mentioned above. This enables the fluorination of S.3 using DAST in the presence of pyridine. S.4 is obtained in 78% yield. Fluorination with Et3 N·3HF via imidazolesulfonate. DAST is corrosive and should be avoided in large-scale industrial production if possible. Chou and colleagues reported a large-scale synthesis of C2-(arabino)-fluorinated sugar derivatives
Figure 1.12.5 Chromatogram of 5 -O-trityl-3 -O-benzoyl-6-chloropurine riboside (S.3) by HPLC. ◦ Operating conditions: detector λ, 265 nm; column, 5C18-MS (4.6 A, 150 mm); eluent, 1:4 (v/v) 10 mM H3 PO4 /MeOH.
1.12.24 Supplement 25
Current Protocols in Nucleic Acid Chemistry
Figure 1.12.6 Ratio of the 2 -O-benzoate mixed with 3 -O-benzoate S.2 as a function of elapsed time in MeOH alone (×), and 1 mM solution of Et3 N (circle), imidazole (up triangle), pyridine (down triangle), and HCl (square). Table 1.12.4 Fluorination of the Imidazolesulfonate Derived from S.3
Temperature (◦ C) Time (hr) Yield (%)a
Run
Solvent
Et3 N·3HF (eq.)
Et3 N (eq.)
1
EtOAc
6.0
—
70
24
67
2
EtOAc
6.0
3.0
70
24
54
3
Toluene
6.0
—
70
24
78
4
CH3 CN
6.0
—
70
24
62
5
CH2 Cl2
6.0
—
70
24
60
a Yields include imidazolesulfonation of S.4a.
using non-corrosive triethylamine trihydrofluoride (Et3 N·3HF; McClinton, 1995; Chou et al., 1996; Haufe, 1996). The only previously reported use of Et3 N·3HF in the synthesis of nucleoside derivatives was for 3 -β-fluorinated thymidine (von Janta-Lipinski et al., 1983). For fluorination of the sugar moiety of S.3, the 2 -OH should first be converted to an imidazolesulfonate, and then reacted with Et3 N·3HF in several solvents at 70◦ C (Table 1.12.4). HPLC analysis shows that the yield of S.4 varies from 54% to 78%, including imidazolesulfonation. The best result is obtained using toluene as the solvent. Fluorination with Et3 N·3HF via triflate. Fluorination with Et3 N·3HF can also be achieved via a trifluoromethanesulfonate, which is obtained quantitatively from S.3. S.3 is similarly reacted with 6 eq Et3 N·3HF and 3 eq triethylamine in ethyl acetate at reflux temperature overnight. HPLC analysis indicates that the yield of S.4 is 88%. However,
the activating agents imidazole and sulfuryl chloride are much less expensive than trifluoromethansulfonyl chloride. Therefore, from an industrial point of view, the imidazolesulfonate route may be more suitable. Treatment of S.4 with ammonia. Nucleophilic displacement of the 6-chloro function and removal of the 3 -O-benzoyl group is achieved by treatment of S.4 with ammonia in methanol to produce S.5 as prism-like crystals. Since S.5 exhibits a nuclear Overhauser effect (NOE) between H1 and H2 in the two-dimensional NOE (NOESY) spectrum, the configuration of S.5 can be identified as a 2 -(S)-arabinoside structure. Part of the product is converted to the known product FdaraA (S.6). The measured data for S.6 are identical with the published values (Pankiewicz et al., 1992a). Radical deoxygenation. The 3 -OH of S.5 is esterified using phenyl chlorothionoformate to give S.7 in 80% yield. S.7 is then hydrogenated
Synthesis of Modified Nucleosides
1.12.25 Current Protocols in Nucleic Acid Chemistry
Supplement 25
with tris(trimethylsilyl)silane in the presence of 2,2 -azobis(isobutyronitrile) (AIBN) in toluene under a nitrogen atmosphere to give S.9 as white crystals in 73% yield. The 3 deoxygenation can also be accomplished by preparation of the xanthate S.8 (87%) and radical reduction by hypophosphorous acid (93%). Preparation of FddA. Treatment of S.9 with concentrated HCl gives FddA (S.10) as prismlike crystals in good yield (Table 1.12.4). This sample was identical in all respects to the published data (Marquez et al., 1987), and the NOESY spectrum supported the structure. Thus, the first synthesis of FddA is accomplished from 6-chloropurine riboside, which is obtainable from inosine.
Synthesis of Fluorinated Nucleosides
Fluorination of a 6-chloropurine 3 -deoxyriboside The disadvantage to the above approach is that it requires deoxygenation of the 3 -OH group after the crucial fluorination step, which results in a loss of the precious fluorinated compound. To develop a more direct approach to the synthesis of FddA that can be performed on a large scale, direct fluorination at the C2 -β position of a 3 -deoxynucleoside was chosen as a potentially more straightforward approach. Marquez et al. (1987) studied the fluorination of protected 3 -deoxyadenosine with tetrabutylammonium fluoride, but a fluorinated compound was not obtained. Herdewijn et al. (1987) and Shiragami et al. (1992) reported the fluorination of 5 -Oprotected 3 -deoxyadenosine with DAST, but the yields of the fluorinated compounds were only 10% in both cases. In contrast, fluorination of 5 -O-protected 6-chloropurine 3 deoxyriboside proceeds in good yield, and the substrate is easily prepared from the readily available inosine (Takamatsu et al., 2001a,b; Izawa et al., 2003). This approach is presented in Basic Protocols 3 and 4. Acetoxybromination and radical debromination. Synthesis of the 6-chloropurine 3 deoxyriboside (S.15; Fig. 1.12.3) from inosine is achieved by acetoxybromination chemistry already developed for large-scale synthesis of ddA (Shiragami et al., 1996), followed by radical debromination using hypophosphorous acid as a reducing agent in the presence of a water-soluble radical initiator such as VA-044 or V-50 (Wako Pure Chemical Industries). Although the acetoxybromination yield of inosine is less than that of adenosine due to its acid lability, S.12 can nevertheless be obtained in moderate yield. Subsequent debromination is carried out by radical re-
duction (Takamatsu et al., 2001c). Though conventional n-Bu3 SnH/AIBN conditions are applicable to this reaction, the removal of the residual Sn compound is generally troublesome, and it is difficult to remove the AIBN that co-precipitates with the product. Barton et al. (1992, 1993) reported that the commercially available and inexpensive hypophosphorous acid could be used for radical reduction instead of n-Bu3 SnH. Although Barton et al. used these reagents for rather simple substrates, the application of this reaction in the deoxygenation or dehalogenation of sugar moieties of nucleosides proved successful. Furthermore, water-soluble radical initiators can be used in the aqueous reaction medium and, since the product S.13 is crystallized from aqueous medium, it proved easy to remove both the reducing agent and the radical initiator. Chlorination. Chlorination of the 6position of the purine base is accomplished under Vilsmeier conditions. Though acidic cleavage of the glycoside bond is a major side reaction, it can be decreased to a negligible level by monitoring the reaction carefully and by cooling the reaction mixture immediately at the end of the reaction. Finally, 2 ,5 -Oacetyl groups can be removed by treatment with sodium methoxide in methanol to give S.15. 5 -O-Tritylation. Because tritylation of primary alcohols is much faster than that of secondary alcohols, the reaction selectively proceeds at the 5 -OH group. Pyridine-type bases such as 2,4-6-collidine or 2-picoline are preferable for this reaction, as the reaction is a type of SN 1 conversion (trityl chloride reacts as a trityl cation, which is stabilized by an aromatic base). The crystallization of the 5 -Otrityl product S.16 is rather tricky, as it can be crystallized only from benzotrifluoride. Fluorination. The fluorination is carried out using a combination of perfluorobutanesulfonyl fluoride (nonaflate) and N, N-dimethylcyclohexylamine in toluene to give S.17 (Fig. 1.12.4; Takamatsu et al., 2002). Although treatment of S.16 with DAST gives S.17 in a moderate yield (Takamatsu et al., 2001a,b), DAST is not suitable for large-scale synthesis because of its high toxicity and corrosiveness. Moreover, it is not commercially available in large quantities due to its explosive nature. Fluorination of the triflate of S.16 can be performed using triethylamine trihydrogenfluoride (Et3 N·3HF; Izawa et al., 2003); however, this requires activation of the hydroxyl group as a triflate with the expensive
1.12.26 Supplement 25
Current Protocols in Nucleic Acid Chemistry
reagent triflic anhydride. Among the reagents that can achieve dehydroxy-fluorination in a single step, perfluoroalkanesulfonyl fluoride (Beyl et al., 1970) appears to be the reagent of choice, since it is only mildly corrosive and is readily available from commercial sources. This reagent is stable at room temperature and is less moisture-sensitive, thus rendering it suitable for use in large-scale syntheses. Fluorination using perfluoroalkanesulfonyl fluoride had previously been applied only to simple compounds (BennuaSkalmowski, 1994; Bennua-Skalmowski and Vorbruggen, 1995). For fluorination of the C2 -β position of a 3 -deoxy compound such as S.16, an eliminated byproduct S.18 is obtained together with the fluorinated compound S.17. The choice of base and solvent has a big impact on the reactivity and the S.17/S.18 selectivity. The combination of N,N-dimethylcyclohexylamine as the base and toluene as the solvent was selected after many screening tests, which indicated that an apolar condition is required to reduce the eliminated byproduct. Using optimized conditions to isolate the fluorinated compound, S.17 can be isolated by selective decomposition of S.18 in an acetic acid solution, because S.18 is very unstable under acidic conditions while S.17 is stable. Amination. The subsequent amination of the 6-position of the purine base is a very clean reaction, although somewhat slow. An autoclave reactor is required due to the pressure of the NH3 gas (8 bar at the maximum). The choice of solvent may be important; THF has, thus far, given the best result. Detritylation. The final deprotection proceeds under normal acidic conditions, such as HCl in methanol. Methanol causes losses of FddA in the organic layer, so it must be distilled completely before extraction. Hydrophobic impurities are removed in the organic layer, while hydrophilic material such as FddA, adenine, and residual S.17 (where the reaction has not run to completion) stays in the aqueous layer. Neutralization of the aqueous layer with NH4 OH causes precipitation of FddA. The purity of FddA obtained is normally >99%.
Compound Characterization Via 6-chloropurine riboside. Melting points were determined on a Yanagimoto micromelting point apparatus (hot-stage type). UV spectra were obtained on a Shimadzu UV190 digital spectrometer. Low-resolution mass spectra were obtained on a Shimadzu-LKB
9000B mass spectrometer in the direct-inlet mode, while high-resolution spectra were obtained on a JMS AX-500 spectrometer in the direct-inlet mode. 1 H NMR spectra were obtained on a Varian Unity 200 (200 MHz) or Varian Unity 600 (600 MHz) in CDCl3 (or DMSO-d6 ) with tetramethylsilane as an internal standard. Via 6-chloropurine 3 -deoxyriboside. All intermediates and products were characterized by standard NMR, IR, and MS techniques as listed in the protocols. In addition, the use of HPLC is recommended to monitor the reactions and to check the purity of the compounds. Conditions (two isocratic conditions and two gradient conditions) and retention times are also listed in the protocols. Because this approach was developed as an industrial process with the HPLC control, TLC was not used to monitor reactions. Melting points were determined on a Yanagimoto micro-melting point apparatus (hot-stage type). UV spectra were obtained on a Shimadzu UV-1600 spectrometer. NMR spectra were obtained on a Varian XL-300 (300 MHz) in CDCl3 (or DMSO-d6 ) with tetramethylsilane as an internal standard. Infrared (IR) spectra were obtained on a Perkin Elmer PARAGON-1000 FT-IR spectrometer. High-resolution mass spectra were obtained on a JOEL JMS-700V spectrometer using FAB (fast atom bombardment) ionization.
Critical Parameters and Troubleshooting General laboratory safety is of primary concern because hazardous materials are involved in the course of the synthesis. Knowledge of the basic procedures of organic synthesis and basic analytical methods is also required. One of the most critical parameters of the synthesis is the purity of the reactants and reagents. Although all the reagents and solvents can be readily purchased and used without further purification, checking the purity of the reactants or intermediates by suitable methods such as TLC, HPLC, and NMR is highly recommended. In particular, it is better to analyze the isolatable intermediates by NMR, IR, MS, UV, and HPLC. If the purity is not high enough, further purification is recommended. S.2 and S.3 can be purified by crystallization from MeOH. S.5, S.13, S.14, and the products FddA (S.6) and FddA (S.10 = S.20) can be purified by recrystallization from aqueous MeOH. S.16 and S.17 can be recrystallized by repeating their respective isolation procedures.
Synthesis of Modified Nucleosides
1.12.27 Current Protocols in Nucleic Acid Chemistry
Supplement 25
Table 1.12.5 Estimated Operation Time for Synthesis of FddA from Inosine
Reaction 1 2 3 4 5
2 ,5 -OAc-3 -Br-3 -deoxyinosine (S.12)
2
2
2
2 ,5 -OAc-3 -deoxyinosine (S.13) 2 ,5 -OAc-3 -deoxy-6-chloropurine riboside (S.14)
3 -deoxy-6-chloropurine riboside (S.15)
5 -OTr-3 -deoxy-6-chloropurine riboside (S.16)
2 3
6
5 -OTr-2 -fluoro-2 ,3 -dideoxy-6-chloropurine riboside (S.17)
4
7
5 -OTr-2 -fluoro-ddA (S.19)
4
8
FddA (S.20)
2
From inosine to FddA
21
Total
Anticipated Results Via 6-chloropurine riboside. Adherence to the methods outlined in Basic Protocols 1 and 2 will yield the total synthesis of FdaraA and FddA on a large scale (e.g., 10 to 20 g scale with 20% to 30% overall yield of FddA from S.1). Many 6-substituted derivatives of FddA could also be obtainable from 6-chloro-9-(3-O-benzoyl-5-O-trityl-2deoxy-2-fluoro-β-D-arabinofuranosyl)purine (S.4). However, the second approach may be preferable for FddA preparation, as there is less loss of product after the fluorination reaction. Via 6-chloropurine 3 -deoxyriboside. Adherence to the methods outlined in Basic Protocols 3 and 4 will yield the total synthesis of FddA on a large scale. As this method is robust and reproducible, highly pure FddA may be obtained in a short period of time. The overall yield from 6-chloro-9-(3-deoxy-β-D-erythropentofuranosyl)-9H-purine (S.15) is ∼31%.
Time Considerations Following the procedures in Basic Protocol 1 and the Alternate Protocol, the synthesis of FdaraA can be accomplished in ∼2 weeks. The synthesis of lodenosine may be accomplished in ∼1 month using either approach. The time required to complete each step from inosine to FddA (see Basic Protocols 3 and 4) is summarized in Table 1.12.5. The estimated time does not include time for analysis.
Literature Cited Synthesis of Fluorinated Nucleosides
Estimated time (days)
Product
Barchi, J.J. Jr., Marquez, V.E., Driscoll, J.S., Ford, H. Jr., Mitsuya, H., Shirasaka, T., Aoki, S., and Kelley, J.A. 1991. Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs. J. Med. Chem. 34:1647-1655.
Barton, D.H.R., Jang, D.O., and Jaszberenyi, J.Cs. 1992. Hypophosphorous acid and its salts: New reagents for radical chain deoxygenation, dehalogenation and deamination. Tetrahedron Lett. 33:5709-5712. Barton, D.H.R., Jang, D.O., and Jaszberenyi, J.Cs. 1993. The invention of radical reactions. 32. Radical deoxygenations, dehalogenations, and deaminations with dialkyl phosphates and hypophosphorous acid as hydrogen sources. J. Org. Chem. 58:6838-6842. Bennua-Skalmowski, B. and Vorbruggen, H. 1995. A facile conversion of primary or secondary alcohols with n-perfluorobutanesulfonyl fluoride/1,8-diazabicyclo[5.4.0]undec-7-ene into their corresponding fluorides. Tetrahedron Lett. 36:2611-2614. Bennua-Skalmowski, B., Krolikiewicz, K., and Vorbruggen, H. 1994. The reaction of perfluorobutanesulfonyl fluoride with alcohols in the presence of 4-dialkylaminopyridines. Bull. Soc. Chim. Belg. 103:453-461. Beyl, V., Niederpruem, H., and Voss, P. 1970. New reaction of perfluoroalkylsulfonyl fluorides. Liebigs Ann. Chem. 731:58-66. Brown, A.D. and Robins, R.K. 1965. The direct preparation of 2 -O-methyladenosine from adenosine. J. Amer. Chem. Soc. 87:1145-1146. Brown, D.M., Todd, A., and Varadarajan, S. 1956. Nucleotides. XXXVII The structure of uridylic acids a and b, and a synthesis of spongouridine (3-β-D-arabofuranosyluracil). J. Chem. Soc. 2388-2393. Chou, T.S., Becke, L.M., O’Toole, J.C., Carr, M.A., and Parker, B.E. 1996. Triethylamine poly(hydrogen fluorides) in the synthesis of a fluorinated nucleoside glycon. Tetrahedron Lett. 37:17-20. Chu, C.K., Matulic-Adamic, J., Huang, J.T., Chou, T.C., Burchenal, J.H., Fox, J.J., and Watanabe, K.A. 1989. Nucleosides. CXXXV. Synthesis of some 9-(2-deoxy-2-fluoro-βD-arabinofuranosyl)-9H-purines and their
1.12.28 Supplement 25
Current Protocols in Nucleic Acid Chemistry
biological activities. Chem. Pharm. Bull. 37:336-339. Driscoll, J.S., Mayers, D.L., Barder, J.P., Weislow, O.S., Johns, D.G., and Buckheit, R.W. Jr. 1997. 2-Fluoro-2 ,3-dideoxyarabinosyladenine (F-ddA): Activity against drug-resistant human immunodeficiency virus strains and clades A-E. Antivir. Chem. Chemother. 8:107-111. Gin, J.B. and Dekker, C.A. 1968. The preparation and properties of O-methylated adenosine derivatives. Biochemistry 7:1413-1420. Graul, A., Silvestre, J., and Castaner, J. 1998. Lodenosine, anti-HIV reverse transcriptase inhibitor. Drugs Future 23:1176-1189. Haufe, G. 1996. Triethylamine trishydrofluoride in synthesis. J. Prakt. Chem. 338:99-113. Herdewijn, P., Pauwels, R., Baba, M., Balzarini, J., and De Clercq, E. 1987. Synthesis and anti-HIV activity of various 2 - and 3 -substituted 2 ,3 dideoxyadenosines: A structure-activity analysis. J. Med. Chem. 30:2131-2137. Izawa, K., Takamatsu, S., Katayama, S., Hirose, N., Kozai, S., and Maruyama, T. 2003. An industrial process for synthesizing Lodenosine (FddA). Nucleosides Nucleotides Nucleic Acids 22:507517. Johnston, G.A.R. 1968. Acetylation of nucleosides and acetyl migration. Tetrahedron 24:69876993. Kawasaki, A.M., Casper, M.D., Freier, S.M., Lesnik, E.A., Zounes, M.C., Cummins, L.L., Gonzalez, C., and Cook, P.D. 1993. Uniformly modified 2 -deoxy-2 -fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36:831-841. Marquez, V.E., Tseng, C.K.-H., Kelley, J.A., Mitsuya, H., Broder, S., Roth, J.S., and Driscoll, J.S. 1987. 2 ,3 -Dideoxy-2 -fluoro-ara-A, an acid stable purine nucleoside active against human immunodeficiency virus (HIV). Biochem. Pharmacol. 36:2719-2722. Marquez, V.E., Tseng, C.K.-H., Mitsuya, H., Aoki, S., Kelley, J.A., Ford, H. Jr., Roth, J.S., Border, S., Johns, D.G., and Driscoll, J.S. 1990. Acid stable 2 -fluoro purine dideoxynucleoside as active agents against HIV. J. Med. Chem. 33:978985. Maruyama, T., Sato, Y., Oto, Y., Takahashi, Y., Snoeck, R., Andrei, G., Witvrouw, M., and De Clercq, E. 1996. Synthesis and antiviral activity of 6-chloropurine arabinoside and its 2 deoxy-2 -fluoro derivative. Chem. Pharm. Bull. 44:2331-2334. Maruyama, T., Sato, Y., and Sakamoto, T. 1998. Synthesis of 8-substituted analogs of 3 -deoxy3 -fluoroadenosine. Nucleosides Nucleotides 17:115-122. Maruyama, T., Takamatsu, S., Kozai, S., Satoh, Y., and Izawa, K. 1999. Synthesis of 9-(2-deoxy-2fluoro-β-D-arabinofuranosyl)adenine bearing a selectively removable protecting group. Chem. Pharm. Bull. 47:966-970.
McClinton, M.A. 1995. Triethylamine tris(hydrogen fluoride): Applications in synthesis. Aldrichimica Acta 28:31-35. Pankiewicz, K.W., Krzeminski, J., Ciszewski, L.A., Ren, W.-Y., and Watanabe, K.A. 1992a. A synthesis of 9-(2-deoxy-2-fluoro-βD-arabinofuranosyl)adenine and -hypoxanthine. An effect of C3 -endo to C2 -endo conformational shift on the reaction course of 2 -hydroxyl group with DAST. J. Org. Chem. 57:553-559. Pankiewicz, K.W., Krzeminski, J., and Watanabe, K.A. 1992b. Synthesis of 2 -β-Fluoro- and 3 -α-Fluoro-substituted guanine nucleosides. Effects of sugar conformational shifts on nucleophilic displacement of 2 -hydroxy and 3 hydroxy group with DAST. J. Org. Chem. 57:7315-7321. Parker, W.B., Allan, P.W., Hassan, A.E.A., Secrist, J.A. 3rd, Sorscher, E.J., and Waud, W.R. 2003. Antitumor activity of 2-fluoro-2 deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther. 10:23-29. Reese, C.B. and Trentham, D.R. 1965. 2 -O-Acyl ribonucleoside derivatives. Tetrahedron Lett. 2459-2465. Reese, C.B., Stewart, J.C.M., van Boom, J.H., de Leeuw, H.P.M., Nagel, J., and de Rooy, J.F.M. 1975. Synthesis of oligoribonucleotides. XI. Preparation of ribonucleoside 2 -acetal 3 -esters by selective deacylation. J. Chem. Soc., Perkin Trans. 1 934-942. Ruxrungtham, K., Bonne, E., Ford, H. Jr., Driscoll, J.S., Davey, R.T. Jr., and Lane, H.C. 1996. Potent activity of 2 -β-fluoro-2 ,3 -dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice. Antimicrob. Agents Chemother. 40:2369-2374. Sato, A., Montgomery, J.A., and Cory, J.G. 1984. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2fluoroadenine nucleosides and hydroxyurea or 2,3-dihdro-1H-pyrazole[2,3-a]imidazole. Cancer Res. 44:3286-3290. Shiragami, H., Tanaka, Y., Uchida, Y., Iwagami, H., Izawa, K., and Yukawa, T. 1992. A novel method for the synthesis of ddA and F-ddA via regioselective 2 -O-deacetylation of 9-(2,5-di-O-acetyl-3-bromo-3-deoxy-β-Dxylofuranosyl)adenine. Nucleosides Nucleotides 11:391-400. Shiragami, H., Amino, Y., Honda, Y., Arai, M., Tanaka, Y., Iwagami, H., Yukawa, T., and Izawa, K. 1996. Synthesis of 2 ,3 dideoxypurinenucleosides via the palladium catalyzed reduction of 9-(2,5-di-O-acetyl-3bromo-3-deoxy-β- D -xylofuranosyl)purine derivatives. Nucleosides Nucleotides 15:31-45. Siddiqui, M.A., Marquez, V.E., Driscoll, J.S., and Barchi, J.J. Jr. 1994. A diastereoselective synthesis of (S,S)-α-fluoro-2,2-dimethyl1,3-dioxolane-4-propanoic acid methyl ester, a key intermediate for the preparation of antiHIV effective fluorodideoxynucleosides. Tetrahedron Lett. 35:3263-3266.
Synthesis of Modified Nucleosides
1.12.29 Current Protocols in Nucleic Acid Chemistry
Supplement 25
Siddiqui, M.A., Driscoll, J.S., and Marquez, V.E. 1998. A new synthetic approach to the clinically useful, anti-HIV-active nucleoside, 9-(2,3-dideoxy-2-fluoro-β-D-threopentofuranosyl)adenine (β-FddA). Introduction of a 2 -β-fluoro substituent via inversion of a readily obtainable 2 -α-fluoro isomer. Tetrahedron Lett. 39:1657-1660.
Wagner, D., Verheyden, J.P.H., and Moffat, J.G. 1974. Preparation and synthetic utility of some organotin derivatives of nucleosides. J. Org. Chem. 39:24-30. Wysocki, R.J. Jr., Siddiqui, M.A., Barchi, J.J. Jr., Driscoll, J.S., and Marquez, V.E. 1991. A more expedient approach to the synthesis of anti-HIV-active 2,3-dideoxy-2-fluoro-βD-threo-pentofuranosyl nucleosides. Synthesis 11:1005-1008.
Takamatsu, S., Maruyama, T., Katayama, S., Hirose, N., Naito, M., and Izawa, K. 2001a. Synthesis of 9-(2,3-dideoxy-2-fluoro-β-Dthreo-pentofuranosyl)adenine (FddA) via a purine 3 -deoxynucleoside. J. Org. Chem. 66:7469-7477.
Zemlicka, J. and Owens, J. 1978. 6-Chloro-9-β-Dribofuranosylpurine. A versatile intermediate in the synthesis of purine ribonucleosides. Nucleic Acid Chem. 2:611-614.
Takamatsu, S., Maruyama, T., Katayama, S., Hirose, N., Naito, M., and Izawa, K. 2001b. Practical synthesis of 9-(2,3-dideoxy-2-fluoroβ-D-threo-pentofuranosyl)adenine (FddA) via a purine 3 -deoxynucleoside. Tetrahedron Lett. 42:2325-2328.
Zemlicka, J. and Sorm, F. 1965. Nucleic acids components and their analogs. LX. The reaction of chloromethylenedimethylammonium chloride with 2 ,3 ,5 -tri-O-acetylinosine. A new synthesis of 6-chloro-9-(β-D-ribofuranosyl)purine. Collect. Czech. Chem. Commun. 30:1880-1889.
Takamatsu, S., Katayama, S., Hirose, N., Naito, M., and Izawa, K. 2001c. Radical deoxygenation and dehalogenation of nucleoside derivatives with hypophosphorous acid and dialkyl phosphates. Tetrahedron Lett. 42:7605-7608. Takamatsu, S., Katayama, S., Hirose, N., De Cook, E., Schelkens, G., Demillequand, M., Brepoels, J., and Izawa, K. 2002. Convenient synthesis of fluorinated nucleosides with perfluoroalkanesulfonyl fluoride. Nucleosides Nucleotides Nucleic Acids 21:849-861. Ueno, T. and Mitsuya, H. 1997. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2 ,3 -dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 36:1092-1099.
Contributed by Satoshi Katayama, Satoshi Takamatsu, Naoko Hirose, and Kunisuke Izawa AminoScience Laboratories Ajinomoto Co. Kanagawa, Japan Tokumi Maruyama Tokushima Bunri University Kagawa, Japan
von Janta-Lipinski, M., Langen, P., and Czech, D. 1983. Cleavage of 2,3 -anhydronucleosides with hydrohalic acids. Z. Chem. 23:335.
Synthesis of Fluorinated Nucleosides
1.12.30 Supplement 25
Current Protocols in Nucleic Acid Chemistry
Synthesis of Ribonucleosides by Condensation Using Trimethylsilyl Triflate
UNIT 1.13
This unit provides protocols for the synthesis of each of the four common ribonucleosides adenosine (S.16, Fig. 1.13.2), cytidine (S.14), guanosine (S.18), and uridine (S.12) from the heterocycles uracil (S.1, Fig. 1.13.1), cytosine (S.2), N6 -benzoyladenine (S.3), and N2 -acetylguanosine (S.4). A procedure for silylation of each of the heterocycles is provided (see Support Protocols 1 and 2) and glycosylation mediated by trimethylsilyl triflate (S.10) of the silylated heterocycles by 1-O-acetyl-2,3,5-tri-O-benzoylribofuranose (S.9) is described (see Basic Protocols 1 through 4). The protocols may be applied to many modified pyrimidines and purines as well as other related heterocycles to construct modified nucleosides (Vorbr¨uggen and Ruh-Pohlenz, 2000, 2001). The chemical reactions described here produce good yields, and purification of the intermediates is straightforward. Mechanistic details of the glycosylation reaction are outlined in the Commentary.
Figure 1.13.1 Heterocyclic bases (S.1-4) and silylated intermediates (S.5-8) obtained by treatment of bases with hexamethyldisilazane (HMDS; see Support Protocol 1) or N,Obis(trimethylsilyl)acetamide (BSA; see Support Protocol 2).
¨ Contributed by Helmut Vorbruggen, Irene M. Lagoja, and Piet Herdewijn Current Protocols in Nucleic Acid Chemistry (2006) 1.13.1-1.13.16 C 2006 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Nucleosides
1.13.1 Supplement 27
Figure 1.13.2 Glycosylation of silylated bases using TMSOTf (S.10) to yield (after ammonia deprotection) the natural ribonucleosides uridine (S.12), cytidine (S.14), adenosine (S.16), and guanosine (S.18).
1.13.2 Supplement 27
Current Protocols in Nucleic Acid Chemistry
NOTE: All reagents and solvents must be anhydrous. HMDS and other silyl derivatives can be obtained from Fa. Bucher. All starting materials are commercially available (e.g., Acros, Aldrich, Fluka, Lancaster).
PREPARATION OF URIDINE Uracil (S.1) is first converted to 2,4-bis(trimethylsilyloxy)pyrimidine (S.5; Fig. 1.13.1) following the procedure outlined in Support Protocol 1. S.5 is then allowed to react with 1-O-acetyl-2,3,5-tri-O-benzoylribofuranose (S.9) and trimethylsilyl triflate (S.10) in dry 1,2-dichloroethane (Fig. 1.13.2). The resulting uridine 2 ,3 ,5 -tri-O-benzoate (S.11) is purified by chromatography on silica gel, and the benzoyl protecting groups removed by treatment with methanolic ammonia to yield uridine (S.12).
BASIC PROTOCOL 1
Materials 2,4-Bis(trimethylsilyloxy)pyrimidine (S.5; see Support Protocol 1) Anhydrous 1,2-dichloroethane (reflux overnight on P2 O5 and distill before use) 1-O-Acetyl-2,3,5-tri-O-benzoylribofuranose (S.9) Trimethylsilyltrifluoromethanesulfonate (TMSOTf; S.10) Dichloromethane (CH2 Cl2 ) Methanol (MeOH) Saturated sodium bicarbonate (sat. NaHCO3 ) solution, ice cold Sodium sulfate (Na2 SO4 ) Silica gel (0.060 to 0.200 nm) Benzene (optional) Saturated ammonia in methanol (sat. NH3 /MeOH) Ethanol (EtOH) 100- and 250-mL round-bottom flask Balloon filled with nitrogen or argon Reflux condenser Precoated TLC plates (e.g., Alugram Sil G/UV254 , Macherey-Nagel) 254-nm UV lamp (for TLC) 500-mL separatory funnel 500-mL Erlenmeyer flask Buchner funnel Filter paper 250-mL filter flask Rotary evaporator equipped with a vacuum pump 5 × 35–cm chromatography column Desiccator Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare uridine 2 ,3 ,5 -tri-O-benzoate (S.11) 1. Dissolve 1.32 g (5.15 mmol) of 2,4-bis(trimethylsilyloxy)pyrimidine (S.5) in 18 mL of 1,2-dichloroethane in a 100-mL round-bottom flask. 2. Add 2.57 g (5.0 mmol) 1-O-acetyl-2,3,5-tri-O-benzoylribofuranose (S.9). 3. Add 0.55 g (2.5 mmol) TMSOTf (S.10) and heat the mixture under nitrogen protection under reflux (90◦ -95◦ C) for 4 hr. CAUTION: TMSOTf is toxic and reacts violently with water, and should be protected from moisture.
Synthesis of Modified Nucleosides
1.13.3 Current Protocols in Nucleic Acid Chemistry
Supplement 27
4. Monitor by TLC (APPENDIX 3D) using 95:5 (v/v) CH2 Cl2 /MeOH (Rf = 0.64). When the starting material is completely depleted, cool the mixture to room temperature and dilute the clear yellow solution with 50 mL CH2 Cl2 . 5. Extract with 50 mL ice-cold sat. NaHCO3 solution in a 500-mL separatory funnel. 6. Wash the organic layer three times with 20 mL water. 7. Collect the organic layers in a 500-mL Erlenmeyer flask and dry over Na2 SO4 . Filter off the drying agent using filter paper and 250-mL round-bottom flask, and evaporate to dryness (2.80 g colorless foam) on a rotary evaporator. 8. To remove traces of impurities, purify by column chromatography (APPENDIX 3E) using a 5 × 35–cm column with 250 g silica gel, eluting with 1.5 L of 9:1 (v/v) CH2 Cl2 /MeOH, or crystallize 2.80 g crude product from 40 mL benzene for 2 hr at 24◦ C. Yield of uridine 2 ,3 ,5 -tri-O-benzoate (S.11) following chromatography: 2.63 g (95%). Yield following crystallization: 2.25 g (81%). m.p. 138◦ -140◦ C. TLC (95:5 CH2 Cl2 /MeOH): Rf 0.64. FAB+ : C30 H25 N2 O9 [M+H] 557.1. 1 H NMR (300 MHz, CDCl3 ): δ 4.66-4.73 (2H, 2 × H5 ), 4.84 (1H, H4 ), 5.91 (1H, H3 ), 6.17 (1H, H2 ), 6.34 (1H, d, J = 5.6 Hz, 5-H), 6.60 (1H, d, J = 3.3 Hz, H1 ), 7.27-8.13 (16H, 3 × Bz, 6-H), 8.78 (1H, s, br, ex, NH). 13 C NMR (75 MHz, CDCl3 ): δ = 63.7 (C5 ), 71.1 (C2 ), 73.7 (C3 ), 80.5 (C4 ), 88.1 (C1 ), 103.4 (5-C), 128.3-133.7 (3 × C Bz), 139.6 (6-C), 149.9 (2-C), 162.5 (4-C), 165.3, 165.4, 166.0 (3 × C=O Bz).
Prepare uridine (S.12) 9. Dissolve 2.00 g (3.59 mmol) S.11 in 50 mL sat. NH3 /MeOH. Keep the reaction mixture overnight at room temperature. 10. Evaporate the volatiles on a rotary evaporator to obtain a colorless crystalline material. 11. Stir material in 10 mL of 1:1 (v/v) CH2 Cl2 /MeOH for 2 hr at room temperature. 12. Filter off the crystals using a Buchner funnel and 250-mL filter flask, and wash with 20 mL CH2 Cl2 . 13. Crystallize from a minimum amount of boiling ethanol and then dry the product in a desiccator. Yield of uridine (S.12): 0.82 g (89%). m.p. 165◦ -166◦ C. The spectroscopic properties (NMR, MS, UV, m.p.) of the obtained nucleosides are identical with those previously described. TLC (2:1 CH2 Cl2 /MeOH): Rf 0.67. FAB+ : C9 H13 N2 O6 [M+H]: 245.1. 1 H NMR (300 MHz, DMSO-d6 ): δ = 3.54-3.61 (2H, 2 × H5 ), 3.84 (1H, H4 ), 3.96 (1H, H3 ), 4.01 (1H, m, H2 ), 5.06, 5.08, 5.37 (3H, (d), (t), (d), J ∼ 5.6 Hz, OH), 5.77 (1H, d, J = 8.1 Hz, 5-H), 5.78 (1H, d, J = 5.3 Hz, H1 ), 7.89 (1H, d, J = 8.1 Hz, 6-H), 11.29 (1H, s, br, ex, NH). 13 C NMR (75 MHz, DMSO-d6 ): δ = 61.3 (C5 ), 70.3 (C2 ), 74.0 (C3 ), 85.3 (C4 ), 88.1 (C1 ), 102.2 (5-C), 141.2 (6-C), 151.2 (2-C), 163.6 (4-C). UV (H2 O) λmax 261 nm. BASIC PROTOCOL 2
Synthesis of Ribonucleosides by Condensation Using Trimethylsilyl Triflate
PREPARATION OF CYTIDINE Cytosine is first converted to 4-(trimethylsilylamino)-2-(trimethylsilyloxy)pyrimidine (S.6) following the procedure outlined in Support Protocol 1. S.6 is then allowed to react with 1-O-acetyl-2,3,5-tri-O-benzoylribofuranose (S.9) and trimethylsilyl triflate (S.10) in dry 1,2-dichloroethane. The resulting cytidine 2 ,3 ,5 -tri-O-benzoate (S.13) is treated with methanolic ammonia to remove the protecting groups, and the resulting cytidine (S.14) is purified by recrystallization from ethanol.
1.13.4 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Materials 4-(Trimethylsilylamino)-2-(trimethylsilyloxy)pyrimidine (S.6; Support Protocol 1) Anhydrous 1,2-dichloroethane (reflux overnight over P2 O5 and distill before use) 1-O-Acetyl-2,3,5-tri-O-benzoylribofuranose (S.9) Trimethylsilyltrifluoromethanesulfonate (TMSOTf, S.10) Dichloromethane (CH2 Cl2 ) Methanol (MeOH) Saturated sodium bicarbonate (sat. NaHCO3 ) solution, ice cold Sodium sulfate (Na2 SO4 ) Silica gel (0.060 to 0.200 nm) Ethanol (EtOH), hot Charcoal Celite Saturated ammonia in methanol (sat. NH3 /MeOH) 250-mL round-bottom flask Balloon filled with nitrogen or argon Reflux condenser Precoated TLC plates (e.g., Alugram Sil G/UV254 , Macherey-Nagel) 254-nm UV lamp (for TLC) 500-mL separatory funnel 500-mL Erlenmeyer flask Filter paper Buchner funnel 250-mL filter flask Rotary evaporator equipped with a vacuum pump Desiccator Additional reagents and equipment for TLC (APPENDIX 3D) Prepare cytidine 2 ,3 ,5 -tri-O-benzoate (S.13) 1. Dissolve 2.56 g (5.15 mmol) 4-(trimethylsilylamino)-2-(trimethylsilyloxy)pyrimidine (S.6) in 35 mL of 1,2-dichloroethane in a 250-mL round-bottom flask. 2. Add 5.04 g (10.0 mmol) 1-O-acetyl-2,3,5-tri-O-benzoylribofuranose (S.9). 3. Add 2.67 g (12 mmol) TMSOTf (S.10) and heat the mixture under nitrogen protection under reflux (90◦ -95◦ C) for 1 hr. CAUTION: TMSOTf is toxic and reacts violently with water, and should be protected from moisture.
4. Monitor by TLC (APPENDIX 3D) using 9:1 (v/v) CH2 Cl2 /MeOH (Rf = 0.57). When all starting material is depleted, cool the mixture to room temperature and dilute the clear yellow solution with 100 mL CH2 Cl2 . 5. Extract with 50 mL ice-cold sat. NaHCO3 solution using a 500-mL separatory funnel. 6. Wash the organic layer three times with 20 mL water. 7. Collect the organic layers in a 500-mL Erlenmeyer flask and dry over Na2 SO4 . Filter off the drying agent using filter paper and 250-mL round-bottom flask, and evaporate to dryness (brownish foam) on a rotary evaporator. 8. Dissolve the obtained foam in 150 mL boiling ethanol. Treat with 0.2 g charcoal and continue refluxing for 15 min. Synthesis of Modified Nucleosides
1.13.5 Current Protocols in Nucleic Acid Chemistry
Supplement 27
9. Filter hot over a Buchner filter equipped with a bed (4-mm layer) of celite and evaporate the volatiles on a rotary evaporator. Yield of cytidine 2 ,3 ,5 -tri-O-benzoate (S.13): 4.50 g (98%). TLC (9:1 CH2 Cl2 /MeOH): Rf 0.57. FAB+ : C30 H26 N3 O8 [M+H]: 556.1. 1 H NMR (300 MHz, CDCl3 ): δ 4.51-4.56 (2H, 2 × H5 ), 4.83 (1H, H4 ), 5.84 (2H, H3 , H2 ), 5.82 (2H, s, br ex, NH2 ), 5.99 (1H, d, J = 4.2 Hz, 5-H), 6.44 (1H, d, J = 1.3 Hz, H1 ), 7.33-8.10 (16H, 3 × Bz, 6-H). 13 C NMR (75 MHz, CDCl3 ): δ 63.8 (C5 ), 71.1 (C2 ), 74.5 (C3 ), 79.7 (C4 ), 90.5 (C1 ), 95.9 (5-C), 128.4-133.6 (3 × C Bz), 141.5 (6-C), 155.5 (2-C), 165.3 (4-C), 165.4, 166.0, 166.2 (3 × C = O Bz).
Prepare cytidine (S.14) 10. Dissolve 4.00 g (7.2 mmol) S.13 in 100 mL sat. NH3 /MeOH. Keep the reaction mixture overnight at room temperature. 11. Evaporate the volatiles on a rotary evaporator to obtain a colorless crystalline material. 12. Stir material in 15 mL of 1:1 (v/v) CH2 Cl2 /MeOH for 2 hr at room temperature. 13. Filter off the crystals using a Buchner funnel and 250-mL filter flask, and wash with 20 mL CH2 Cl2 . 14. Crystallize from a minimum amount of boiling EtOH and then dry the product in a desiccator. Yield of cytidine (S.14): 1.62 g (91%). m.p. 210◦ -212◦ C. The spectroscopic properties (NMR, MS, UV, m.p.) of the obtained nucleosides are identical with those previously described. TLC (2:1 CH2 Cl2 /MeOH): Rf 0.54. FAB+ : C9 H13 N3 O5 [M+H]: 244.1. 1 H NMR (300 MHz, DMSO-d6 ): δ 3.51-3.57 (2H, 2 × H5 ), 3.68 (1H, H4 ), 3.82-3.95 (2H, H3 , H2 ), 4.99, 5.04, 5.30 (3H, (d), (t) (d), J ∼ 4.5 Hz, OH), 5.70 (1H, d, J = 7.4 Hz, 5-H), 5.77 (1H, d, J = 3.7 Hz, H1 ), 7.19 (2H, s, br, ex, NH2 ), 7.83 (1H, d, J = 7.4 Hz, 6-H). 13 C NMR (75 MHz, DMSO-d6 ): δ 61.1 (C5 ), 69.9 (C2 ), 74.4 (C3 ), 84.5 (C4 ), 89.6 (C1 ), 94.4 (5-C), 142.0 (6-C), 155.9 (2-C), 166.0 (4-C). UV (H2 O) λmax 272 nm. BASIC PROTOCOL 3
PREPARATION OF ADENOSINE N6 -Benzoyladenine is first converted to N6,9 -bis(trimethylsilyl)-N6 -benzoyladenine (S.7) following the procedure outlined in Support Protocol 1. Silylated adenine (S.7) is then allowed to react with 1-O-acetyl-2,3,5-tri-O-benzoylribofuranose (S.9) and trimethylsilyl triflate (S.10) in dry 1,2-dichloroethane. The resulting N6 -benzoyladenine 2 ,3 ,5 -tri-Obenzoate (S.15) is treated with methanolic ammonia to remove the protecting groups, and the resulting adenosine is purified by recrystallization from methanol/water.
Materials
Synthesis of Ribonucleosides by Condensation Using Trimethylsilyl Triflate
N6,9 -Bis(trimethylsilyl)-N6 -benzoyladenine (S.7) obtained from 10 mmol N6 -benzoyladenine (see Support Protocol 1) 1-O-Acetyl-2,3,5-tri-O-benzoylribofuranose (S.9) Anhydrous 1,2-dichloroethane (reflux overnight on P2 O5 and distill before use) Trimethylsilyltrifluoromethanesulfonate (TMSOTf, S.10) Dichloromethane (CH2 Cl2 ) Methanol (MeOH) Saturated sodium bicarbonate (sat. NaHCO3 ) solution, ice cold Sodium sulfate (Na2 SO4 ) Silica gel (0.060 to 0.200 nm) Petroleum ether (optional) Saturated ammonia in methanol (sat. NH3 /MeOH)
1.13.6 Supplement 27
Current Protocols in Nucleic Acid Chemistry
250-mL round-bottom flasks Balloon filled with nitrogen or argon Reflux condenser Precoated TLC plates (e.g., Alugram Sil G/UV254 , Macherey-Nagel) 254-nm UV lamp (for TLC) 500-mL separatory funnel 500-mL Erlenmeyer flask Filter paper Buchner funnel 250-mL filter flask Rotary evaporator equipped with a vacuum pump 5 × 50–cm chromatography column Desiccator Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare N6 -benzoyladenosine 2 ,3 ,5 -tri-O-benzoate (S.15) 1. Dissolve the solid yellowish N 6,9 -bis(trimethylsilyl)-N 6 -benzoyladenine (S.7) obtained from 10 mmol N6 -benzoyladenine in Support Protocol 1, plus 5.04 g (10 mmol) 1-O-acetyl-2,3,5-tri-O-benzoylribofuranose (S.9), in 25 mL dry 1,2-dichloroethane in a 250-mL round-bottom flask. 2. Add 0.22 g (1.0 mmol) TMSOTf (S.10) and heat the mixture under nitrogen protection under reflux (90◦ -95◦ C) for 4 hr. CAUTION: TMSOTf is toxic and reacts violently with water, and should be protected from moisture.
3. Monitor by TLC (APPENDIX 3D) using 95:5 (v/v) CH2 Cl2 /MeOH (Rf = 0.82). When all starting material is depleted, cool the mixture to room temperature and then dilute the clear yellow solution with 100 mL CH2 Cl2 . 4. Extract with 50 mL ice-cold sat. NaHCO3 solution using a 500-mL separatory funnel. 5. Wash the organic layer three times with 20 mL water. 6. Collect the organic layers in a 500-mL Erlenmeyer flask and dry over Na2 SO4 . Filter off the drying agent using filter paper and 250-mL round-bottom flask, and evaporate to dryness (brownish foam) on a rotary evaporator. Yield of crude N6 -benzoyladenosine 2 ,3 ,5 -tri-O-benzoate (S.15): 7.10 g (quant.).
7. To remove traces of impurities, purify by column chromatography (APPENDIX 3E) using a 5 × 50–cm column with 500 g silica gel, eluting with 2.5 L of 95:5 (v/v) CH2 Cl2 /MeOH, or crystallize the crude product from a minimum amount of petroleum ether. Yield of N6 -benzoyladenosine 2 ,3 ,5 -tri-O-benzoate (S.15) after chromatography: 6.73 g (95%.). m.p. 88◦ -92◦ C. TLC (95:5 CH2 Cl2 /MeOH): Rf 0.82. FAB+ : C38 H30 N5 O8 [M+H]: 684.2. 1 H NMR (300 MHz, CDCl3 ): δ 4.73-4.97 (3H, 2 × H5 , H4 ), 6.31 (1H, H3 ), 6.46 (1H, H2 ), 6.53 (1H, s, H1 ), 7.38-8.13 (20H, 4 × Bz), 8.23 (1H, s, 2-H), 8.71 (1H, s, 8-H), 9.31 (1H, s, br, ex, NH). 13 C NMR (75 MHz, CDCl3 ): δ 63.5 (C5 ), 71.5 (C2 ), 73.9 (C3 ), 80.9 (C4 ), 87.0 (C1 ), 123.6 (5-C), 127.9-133.8 (4 × C Bz), 141.7 (8-C), 149.8 (6-C), 151.7 (4-C), 152.9 (2-C), 165.1, 165.3, 165.4, 166.1 (4 × C=O Bz).
Prepare adenosine (S.16) 8. Dissolve 7.00 g (10 mmol) S.15 in 250 mL sat. NH3 /MeOH. Keep the reaction mixture overnight at room temperature.
Synthesis of Modified Nucleosides
1.13.7 Current Protocols in Nucleic Acid Chemistry
Supplement 27
9. Evaporate the volatiles on a rotary evaporator to obtain a crystalline material. 10. Stir material in 10 mL of 1:1 (v/v) CH2 Cl2 /MeOH for 2 hr at room temperature. 11. Filter off the crystals using a Buchner funnel and 250-mL filter flask, and wash with 20 mL CH2 Cl2 . 12. Crystallize from 200 mL of 2:1 (v/v) MeOH/water. After cooling, filter off crystals with a Buchner funnel, and then dry the product in a desiccator. Yield of pure adenosine (S.16): 2.16 g (80.9%). m.p. 143◦ -145◦ C. The spectroscopic properties (NMR, MS, UV, m.p.) of the obtained nucleosides are identical with those previously described. TLC (2:1 CH2 Cl2 /MeOH): Rf 0.51. FAB+ : C10 H14 N5 O4 [M+H]: 268.1. 1 H NMR (300 MHz, DMSO-d6 ): δ 3.52-3.59 (2H, 2 × H5 ), 3.97 (1H, H3 ), 4.15 (1H, H4 ), 4.60 (1H, H2 ), 5.18, 5.44 (3H, OH), 5.88 (1H, d, J = 6.2 Hz, H1 ), 7.35 (2H, s, br, ex, NH2 ), 8.14 (1H, s, 2-H), 8.35 (1H, s, 8-H). 13 C NMR (75 MHz, DMSO-d6 ): δ 62.1 (C5 ), 71.1 (C2 ), 73.9 (C3 ), 86.4 (C4 ), 88.4 (C1 ), 119.8 (5-C), 140.4 (8-C), 149.5 (4-C), 152.8 (2-C), 156.6 (6-C). UV (H2 O) λmax 259 nm. BASIC PROTOCOL 4
PREPARATION OF GUANOSINE N2 -Acetylguanine (S.4) is first converted to 6-(trimethylsilyloxy)-2-(N-trimethylsilylacetamido)-(N9 -trimethylsilyl)purine (S.8) following the procedure outlined in Support Protocol 1. Silylated guanine S.8 is then allowed to react with 1-O-acetyl-2,3,5-tri-Obenzoylribofuranose (S.9) and trimethylsilyl triflate (S.10) in dry 1,2-dichloroethane. The resulting N2 -acetylguanosine 2 ,3 ,5 -tri-O-benzoate (S.17) is treated with methanolic ammonia to remove the protecting groups, and the resulting guanosine (S.18) purified by recrystallization from water.
Materials
Synthesis of Ribonucleosides by Condensation Using Trimethylsilyl Triflate
6-(Trimethylsilyloxy)-2-(N-trimethylsilylacetamido)-(N9 -trimethylsilyl)purine (S.8) obtained from 4.09 mmol N2 -acetylguanine (S.4) (see Support Protocol 1) 1-O-Acetyl-2,3,5-tri-O-benzoylribofuranose (S.9) Anhydrous 1,2-dichloroethane (reflux overnight on P2 O5 and distill before use) Trimethylsilyltrifluoromethanesulfonate (TMSOTf, S.10) Dichloromethane (CH2 Cl2 ) Methanol (MeOH) Saturated sodium bicarbonate solution (sat. NaHCO3 solution), ice cold Sodium sulfate (Na2 SO4 ) Silica gel (0.060 to 0.200 nm) Saturated ammonia in methanol (sat. NH3 /MeOH) 250-mL round-bottom flask Balloon filled with nitrogen or argon Reflux condenser Precoated TLC plates (e.g., Alugram Sil G/UV254 , Macherey-Nagel) 254-nm UV lamp (for TLC) 500-mL separatory funnel 500-mL Erlenmeyer flask Filter paper Buchner funnel 250-mL filter flask Rotary evaporator equipped with a vacuum pump 5 × 35–cm chromatography column Desiccator Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E)
1.13.8 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Prepare N2 -acetylguanosine 2 ,3 ,5 -tri-O-benzoate (S.17) 1. Dissolve the solid yellowish 6-(trimethylsilyloxy)-2-(N-trimethylsilylacetamido)(N9 -trimethylsilyl)purine (S.8) obtained from 4.09 mmol N2 -acetylguanine (S.4) in Support Protocol 1, and 1.86 (3.7 mmol) 1-O-acetyl-2,3,5-tri-O-benzoylribofuranose (S.9), in 35 mL dry 1,2-dichloroethane in a 250-mL round-bottom flask. 2. Add 0.99 g (4.46 mmol) TMSOTf (S.10) and heat the mixture under nitrogen protection under reflux (90◦ -95◦ C) for 1.5 hr. CAUTION: TMSOTf is toxic and reacts violently with water, and should be protected from moisture.
3. Monitor by TLC (APPENDIX 3D) using 9:1 CH2 Cl2 /MeOH (Rf = 0.72). When all starting material is depleted, cool the mixture to room temperature, and dilute the clear yellow solution with 20 mL CH2 Cl2 . 4. Extract with 20 mL ice-cold sat. NaHCO3 solution using a 500-mL separatory funnel. 5. Wash the organic layer three times with 20 mL water. 6. Collect the organic layers in a 500-mL Erlenmeyer flask and dry over Na2 SO4 . Filter off the drying agent using filter paper and 250-mL round-bottom flask, and evaporate to dryness on a rotary evaporator. Yield: 2.32 g (98%) crude product.
7. To remove traces of impurities (i.e., the N7-isomer), purify by column chromatography (APPENDIX 3E) using a 5 × 35–cm column with 250 g of silica gel, eluting with 1.5 L of 9:1 (v/v) CH2 Cl2 /MeOH. Yield of N2 -acetylguanosine 2 ,3 ,5 -tri-O-benzoate (S.17): 2.32 g as a yellowish foam. TLC (9:1 CH2 Cl2 /MeOH): Rf 0.72 (0.60 for N7 isomer). FAB+ : C33 H28 N5 O9 [M+H]: 638.2. 1 H NMR (300 MHz, CDCl3 ): δ 2.32 (3H, s, CH3 ), 4.70-5.00 (3H, 2 × H5 , H4 ), 6.24 (1H, H3 ), 6.35 (2H, H2 , H1 ), 7.27-8.10 (15H, 3 × Bz), 7.91 (1H, s, 8-H), 9.78 (1H, s, br, ex, 1-NH), 12.0 (1H, s, br, ex, NHAc). 13 C NMR (75 MHz, CDCl3 )): δ 24.3 (CH3 ), 63.0 (C5 ), 71.5 (C2 ), 74.0 (C3 ), 80.0 (C4 ), 88.3 (C1 ), 122.8 (5-C), 128.4-133.9 (3 × C Bz), 133.9 (8-C), 138.9 (2-C), 147.5 (4-C), 155.5 (6-C), 165.2, 165.4, 166.8 (3 × C=O Bz), 172.0 (C=O Ac).
Prepare guanosine (S.18) 8. Dissolve 2.30 g (3.60 mmol) S.17 in 125 mL sat. NH3 /MeOH. Keep the reaction mixture for 42 hr at room temperature. 9. Evaporate the volatiles on a rotary evaporator to obtain a colorless crystalline material. 10. Stir material in 10 mL of 1:1 (v/v) CH2 Cl2 /MeOH for 2 hr at room temperature. 11. Filter off the crystals using a Buchner funnel and 250-mL filter flask, and wash with 20 mL CH2 Cl2 . 12. Crystallize from a minimum amount of boiling water and then dry the product in a desiccator. Yield of guanosine (S.18): 0.69 g (66%). m.p. 238◦ -239◦ C. The spectroscopic properties (NMR, MS, UV, m.p.) of the obtained nucleosides are identical with those previously described. TLC (2:1 CH2 Cl2 /MeOH): 0.46. FAB+ : C10 H14 N5 O5 [M+H]: 284.1. 1 H NMR (300 MHz, DMSO-d6 ): δ 3.52-3.60 (2H, 2 × H5 ), 3.86 (1H, H3 ), 4.08 (1H, H4 ),4.39 (1H, H2 ), 5.02, 5.11, 5.39 (3H, (t), (d) (d), J ∼ 6.0 Hz, OH), 5.69 (1H, d, J = 6.0 Hz, H1 ), 6.46 (2H, s, br, ex, NH2 ), 7.94 (1H, s, 8-H), 10.65 (1H, s, br, ex, NH). 13 C NMR (75 MHz, DMSO-d6 ): δ = 61.8 (C5 ), 70.8 (C2 ), 74.1 (C3 ), 85.6 (C4 ), 86.8 (C1 ), 117.1 (5-C), 136.0 (8-C), 151.8 (4-C), 154.1 (2-C), 157.2 (6-C). UV (H2 O) λmax 251 nm.
Synthesis of Modified Nucleosides
1.13.9 Current Protocols in Nucleic Acid Chemistry
Supplement 27
SUPPORT PROTOCOL 1
PREPARATION OF SILYLATED HETEROCYCLES USING HMDS This procedure is used for conversion of uracil (S.1) to 2,4-bis(trimethylsilyloxy)pyrimidine (S.5), cytosine (S.2) to 4-(trimethylsilylamino)-2-(trimethylsilyloxy)pyrimidine (S.6), N6 -benzoyladenine (S.3) to N6,9 -bis(trimethylsilyl)-N6 -benzoyladenine (S.7), and N2 -acetylguanine (S.4) to 6-(trimethylsilyloxy)-2-(N-trimethylsilylacetamido)-(N9 trimethylsilyl)purine (S.8). It is applicable to most other heterocyclic bases.
Materials Heterocyclic base, e.g., uracil (S.1), cytosine (S.2), N6 -benzoyladenine (S.3), or N2 -acetylguanine (S.4) Hexamethyldisilazane (HMDS) Ammonium chloride (NH4 Cl) Trimethylchlorosilane (TCS) Pyridine Xylenes (mixture of isomers, extra pure; Acros) 50-mL round-bottom flask Reflux condenser 1. In a 50-mL round-bottom flask with a reflux condenser, heat 10 mmol heterocyclic base in 20 to 30 mL HMDS and a few crystals of NH4 Cl to 145◦ C. 2. If the base does not dissolve after 0.5 to 2 hr, add either 0.1 mL trimethylchlorosilane (TCS; e.g., for 5-nitrouracil, lumazine) or 10 mL pyridine (e.g., for 4-aminopyridine, N6 -benzoyladenine, N2 -acetylguanine, xanthine) to accelerate the silylation. 3. After a clear solution is obtained, remove excess HMDS by co-distillation with two 25- to 50-mL portions of xylenes. 4. Use the obtained silylated base immediately (no purification) for the condensation reaction. SUPPORT PROTOCOL 2
PREPARATION OF SILYLATED HETEROCYCLES USING BSA This silylation procedure is applicable to nucleic acid bases and other closely related substituted pyrimidines and purines. The advantage of this method is that the silylated product is prepared in situ, making the evaporation of the solvent and redissolving of the silylated base unnecessary.
Materials Heterocyclic base, e.g., uracil (S.1), cytosine (S.2), N6 -benzoyladenine (S.3), or N2 -acetylguanine (S.4) Anhydrous 1,2-dichloroethane Nitrogen source N,O-Bis(trimethylsilyl)acetamide (BSA) 1. Suspend 10 mmol heterocyclic base in 25 mL of 1,2-dichloroethane. 2. Under a nitrogen atmosphere, add BSA at 1.1 eq. per NH of the base (i.e., 22 mmol for uracil, 44 mmol for 6-aminouracil). 3. Stir at room temperature until a clear solution is obtained (30 to 60 min). Synthesis of Ribonucleosides by Condensation Using Trimethylsilyl Triflate
4. Add the protected sugar and TMSOTf and continue as described in Basic Protocols 1 through 4.
1.13.10 Supplement 27
Current Protocols in Nucleic Acid Chemistry
COMMENTARY Background Information The protocols in this unit provide the most efficient procedure for synthesis of ribonucleosides from heterocyclic bases. There are a wide variety of methods for synthesis of nucleosides from purine and pyrimidine as well as many other heterocycles; these have been extensively reviewed elsewhere (Vorbr¨uggen and Ruh-Pohlenz, 2000, 2001). The Lewis acid– mediated glycosylation of silylated pyrimidines and purines is one of the most efficient high-yield reactions in nucleoside chemistry. The introduction of Friedel-Crafts catalysts such as SnCl4 (S.20; Niedballa and Vorbr¨uggen, 1970, 1974a-e) for the sugar-base condensation reaction as a more effective version of the silyl-Hilbert-Johnson synthesis of nucleosides, was followed by the use of the Lewis acid trimethylsilyl triflate (TMSOTf; S.10) in the condensation reaction, which is the subject of this unit (Vorbr¨uggen and Kroliliewicz, 1975; Vorbr¨uggen et al., 1981). Understanding the mechanism of this reaction is essential for its effective application. The details of the mechanism have been worked out for the two C5-substituted pyrimidine nucleosides 5-methoxy- and 5-morpholinouridine, which are reviewed here to illustrate the pathway likely followed for most silylated pyrimidine bases upon TMSOTf-mediated glycosylation, including the two syntheses outlined in Basic Protocols 1 and 2. The TMSOTfmediated glycosylation of silylated purines is more complex. The proposed mechanistic pathways are outlined below for the reactions in Basic Protocols 3 and 4. Synthesis of pyrimidine ribonucleosides Due to their basic character, silylated nucleobases form σ-complexes with Lewis acids (Fig. 1.13.3). In the case of stronger basic heterocycles, an equivalent amount of the Lewis acid is “neutralized or deactivated” as σcomplex with the silylated base. Therefore, any further reaction of these σ-complexes is much slower. In the 13 C NMR spectra of the (rather basic) silylated 5-methoxyuracil (S.22, R = OMe) in the presence of TMSOTf (S.10) or SnCl4 (S.20), the signal of C6 at 139 ppm is broadened for the SnCl4 -σ-complex. This proves a tight binding of SnCl4 to N1, the center of highest electron density. The corresponding C6 signal of the σ-complex S.25 is sharp and indicates a rather loose binding and a rapid exchange of the weaker Lewis acid with
N1 (Vorbr¨uggen et al., 1978; Vorbr¨uggen and Hoefle, 1981; Fig. 1.13.3). As a result, TMSOTf, which is a much weaker Lewis acid than SnCl4 , is a superior if not optimal catalyst for nucleoside synthesis. TMSOTf converts stable O-acylated sugars such as S.9 via O-silylation of the 1-β-Oacetyl group into trimethylsilyl acetate and reactive cyclic sugar salts (S.21). However, the decreased acidity of TMSOTf leads to lower amounts of the σ-complex S.25 (formed between S.22 and TMSOTf) than of the σcomplex S.27 (formed between S.22 and the stronger Lewis acid SnCl4 ) (Vorbr¨uggen et al., 1978; Vorbr¨uggen and Hoefle, 1981). Whereas only free persilylated base S.22 reacts with the activated sugar salt S.21 to give the desired silylated N1 -nucleoside S.23, the σ-complex S.25 (in which N1 is blocked) can only condense in a slower reaction with S.21 to deliver the undesired N3 -nucleoside S.26. Particularly, in the rather apolar solvent 1,2-dichlorethane, less of the N1 -nucleoside S.23 and more of the N3 -nucleoside S.26 is obtained, since much more of the σ-complex S.27 is formed during reaction with SnCl4 . Both the silylated N1 -nucleoside S.23 and, in particular, the undesired silylated N3 -nucleoside S.26 can further react with S.21 to give the N1 ,N3 bisriboside S.24. The more polar solvent acetonitrile (in comparison to 1,2-dichlorethane) also forms σ-complexes with S.10, or with S.20 (Vorbr¨uggen and Ruh-Pohlenz, 2001), as depicted in Figure 1.13.3. Therefore, the polar acetonitrile as solvent competes with the silylated base S.22 for the Lewis acids S.10 and S.20, resulting in formation of reduced amounts of the σ-complexes S.25 or S.27, and consequently a diminished formation of the N3 -nucleoside S.26 and increased formation of the desired natural protected N1 -nucleoside S.23 (Vorbr¨uggen et al., 1978; Vorbr¨uggen and Hoefle, 1981; Fig. 1.13.3). In particular, in the case of basic silylated pyrimidines such as silylated 5methoxyuracil S.22 (R = OMe) or silylated 5-morpholinouracil S.22 (R = C4 H8 NO), the use of TMSOTf instead of SnCl4 results (after workup with aqueous bicarbonate) in much higher yields of the desired protected natural N1 -nucleosides S.23 (R = OMe and R = C4 H8 NO) and a dramatically reduced formation of the undesired protected N3 -nucleosides S8 (R = OMe and R = C4 H8 NO) and N1 ,N3 -bisribosides S.24 (Vorbr¨uggen et al.,
Synthesis of Modified Nucleosides
1.13.11 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Figure 1.13.3 Pathway for Lewis acid–mediated condensation of 1-O-acetyl-2,3,5-tri-O-benzoylribofuranose (S.9) with 5-methoxy- and 5-morpholino-2,4-bis(trimethylsilyloxy)pyrimidine (S.22).
Synthesis of Ribonucleosides by Condensation Using Trimethylsilyl Triflate
1978; Vorbr¨uggen and Hoefle, 1981). Reactions in acetonitrile (after aqueous workup) lead to higher yields of the desired protected N1 -nucleosides S.23 and thus decreased amounts of the undesired N3 -nucleosides S26 (R = OMe and R = C4 H8 NO) for previously mentioned reasons. In the less polar solvent 1,2-dichloroethane, much more σcomplex between the silylated bases and the Lewis acids is formed, resulting in more N3 nucleosides and N1 ,N3 -bisribosides. The variation in yields of the N1 -riboside, N3 -riboside, and N1 ,N3 -bisriboside as a function of Lewis acid and solvent is summarized in Figure
1.13.4 (Vorbr¨uggen et al., 1978; Vorbr¨uggen and Hoefle, 1981). Silylated cytosine forms strong σcomplexes with Lewis acids S.10 and S.20, in analogy to the silylated uracils S.23. Therefore, the less basic silylated N4 -acylated cytosine should always be used in acetonitrile for the TMSOTf- or SnCl4 -catalyzed silyl-Hilbert-Johnson synthesis of cytidines (Vorbr¨uggen and Ruh-Pohlenz, 2000, 2001). Synthesis of purine ribonucleosides The advantage of employing TMSOTf as catalystis even more evident for the
1.13.12 Supplement 27
Current Protocols in Nucleic Acid Chemistry
N3
OSiMe3 R
R
1
Me3SiO
1) Lewis acid 10 or 20 solvent
N
22
BzO
HN
BzO
BzO
BzO
N
O BzO
OBz
BzO
R
N
N 1, N 3-bisribosides O
O
OAc O
1 3
O
NH O
2) NaHCO3
O
24
OBz 29
28 OBz
9
a) R = -OMe
b) R = -N
Figure 1.13.4
O
28
29
24
TMSOTf (10), ClCH2CH2Cl SnCl4 (20), ClCH2CH2Cl SnCl4 (20), CH3CN
89% 53% 90%
27% 3%
13% -
TMSOTf (10), ClCH2CH2Cl SnCl4 ( 20), ClCH2CH2Cl SnCl4 ( 20), CH3CN
89% 53% 90%
27% 3%
13% -
Variation of N 1 and N 3 glycosylation yields with Lewis acid and solvent.
synthesis of purine nucleosides. On the basis of 13 C NMR studies (Vorbr¨uggen and Hoefle, 1981) following the downfield shift of C8, it is assumed that the most basic N1 in persilylated N6 -benzoyladenine (S.7) is trimethylsilylated by TMSOTf to form the σ-complex S.30 (Fig. 1.13.5). This complex eliminates TMSOTf to form the activated putative isomeric silylated N6 -benzoyladenine, S.31. It was suggested (Vorbr¨uggen and Ruh-Pohlenz, 2000) that compounds S.7, S.30, and S.31 react reversibly with the sugar salt S.21 in an initially kinetically controlled reaction to give the protected N1 -nucleoside S.32 and the N3 nucleoside S.33, the latter of which can be isolated at the start of the reaction. However, S.32 and S.33 occur in equilibrium with S.31 and S.21, and subsequent reaction of S.31 with S.21 furnishes primarily a mixture of the undesired protected N7 -nucleoside S.34 and the desired N9 -nucleoside S.35. On boiling the reaction mixture in the rather unpolar solvent 1,2-dichloroethane (compared to acetonitrile), σ-complex formation of the undesired products S.32, S.33, and S.34 with TMSOTf is favored, and thus rearrangement and formation of equilibria between S.32, S.33, and S.34 with S.31 and S.21 occurs (cf. the depicted TMSOTf-catalyzed cleavage of S.34 to S.31
and S.21 shown in the box at the bottom of Fig. 1.13.5). This eventually results in the nearly exclusive formation of the desired and thermodynamically favored protected natural N9 nucleoside adenosine S.35. On ammonolysis of S.35 with methanolic ammonia, crystalline adenosine (S.16) is obtained in 81% overall yield starting from S.7 and S.9 (Vorbr¨uggen et al., 1981; Fig. 1.13.5). Framski et al. (2006) have demonstrated that on reacting N6 -benzoyladenine S.3 in the presence of TMSOTf with 1,2,3,5-tetraO-acetyl-β-D-ribofuranose (whose bridged cation corresponding to S.9 is less stable than that of the benzoylated intermediate S.9 and whose nucleosides consequently rearrange more slowly), the initially formed N1 -nucleoside can be isolated as the major product, together with the corresponding N9 -nucleoside as well as the N1 ,N9 bisriboside. Persilylated N2 -acetylguanine S.4 affords, on reaction with the protected sugar S.9 in the presence of TMSOTf in boiling 1,2dichloroethane and subsequent ammonolysis with methanolic ammonia, crystalline natural guanosine S.18 in 66% overall yield (Niedballa and Vorbr¨uggen, 1976). These results were confirmed by others, and the ratio between the desired natural N9 -guanosine S.18
Synthesis of Modified Nucleosides
1.13.13 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Bz
N
SiMe3 N
N1
7 9
3
Bz
TMSOTf (10) ClCH2CH2Cl ∆
Me3Si
SiMe3
N 30
Bz
TMSOTf (10) ClCH2CH2Cl ∆
N
N 3
N SiMe3
N
N
7 9
Me3Si
N SiMe3
31
± 21
± 21
BzO
N O BzO
Bz
N SiMe3 N
N
N
N
3
1
N
BzO
N Bz SiMe3
O BzO
32
BzO
N
O
Bz
N SiMe3
OBz
BzO
O
N
OBz
35
O 31
O O
BzO 21
BzO
N
BzO
N
N
BzO
Me3Si ........OTf
N O
SiMe3
34
33
N
N
SiMe3
9
BzO
O
N
N N
N
N
OBz
N
7
BzO
Bz
OBz
N
N
Bz N
N
7 9
3
± 21
N
SiMe3
N1
7
± 21
N
OTf Ph
O Ph
Figure 1.13.5
Pathway for TMSOTf (S.10)-mediated glycosylation of N 6,9 -bis(trimethylsilyl)-N 6 -benzoyladenine (S.7).
Synthesis of Ribonucleosides by Condensation Using Trimethylsilyl Triflate
and the undesired N7 -guanosine S.19 was estimated to be 6:1 (Fig. 1.13.2). The use of SnCl4 in acetonitrile or 1,2-dichloroethane leads to an excess of the undesired N7 -guanosine S.20 (Garrner and Ramakanth, 1988). 1,2-Dichloroethane (which favors σcomplex formation of the purine moieties with TMSOTf and also favors the rearrangement of the initially formed kinetically controlled intermediates to give the thermodynamically most stable products) is thus the preferred solvent for the synthesis of purine nucleosides (Vorbr¨uggen et al. 1981; Vorbr¨uggen and RuhPohlenz, 2000, 2001). Finally, in comparing the TMSOTf with SnCl4, the workup using TMSOTf is much simpler. By addition of an ice-cold solution of aqueous sodium bicarbonate to the reaction mixtures, no emulsions are obtained using TMSOTf as they nearly always are upon aqueous workup of reactions employing
SnCl4 (Vorbr¨uggen et al., 1981; Vorbr¨uggen and Ruh-Pohlenz, 2000, 2001). Alternative procedures Working under careful exclusion of moisture during the silylation of polar heterocyclic bases with hexamethyldisilazane (HMDS) and during the subsequent nucleoside synthesis is often rather difficult for scientists with only limited training in preparative organic chemistry. One can, therefore, simplify the nucleoside synthesis by combining the reactions for (1) acid-catalyzed silylation of the heterocyclic bases, (2) silylation of free triflic acid to give TMSOTf, and (3) nucleoside synthesis in acetonitrile (Vorbr¨uggen and Bennua, 1981). In this one-pot reaction, purines such as adenine and N6 -benzoyladenine, or pyrimidines such as N4 -acylcytidines, can also be reacted with protected sugars such as S.9 in the presence of excess SnCl4 . The catalyst
1.13.14 Supplement 27
Current Protocols in Nucleic Acid Chemistry
apparently forms partially soluble σcomplexes with these bases in ethylene chloride, producing protected nucleosides in yields of 70% to 90%. The Lewis acid–catalyzed condensation of nucleobases and acyl-protected sugars has become a well-established method over the years, allowing, e.g., the preparation of the naturally occurring β-nucleosides in good yields. The method has not only been applied to the preparation of ribosides, but also for sugar and/or base-modified nucleosides (Vorbr¨uggen and Ruh-Pohlenz, 2000).
Critical Parameters and Troubleshooting For all syntheses, freshly prepared dry solvents and water-free reagents are used. The reactions are carried out in oven-dried glassware under exclusion of moisture, preferably under nitrogen or argon protection. Neutralization of the reaction mixture with a saturated solution of sodium bicarbonate must be done very carefully (foaming). Reactions should be monitored by TLC, especially if the kinetic reaction products are desired. Silylation with HMDS can be replaced by silylation with N,O-bis(trimethylsilyl)acetamide (BSA), which appears to be a very gentle working silylating agent. However, when using BSA, it has to be taken into consideration that the N-monosilylacetamide formed can interact as a “base” in the nucleoside synthesis (Vorbr¨uggen and Ruh-Pohlenz, 2000). In the case of very poorly soluble nuclebases, an excess of nucleobase is used for the glycosylation reaction to obtain a better yield of the desired nucleoside. In these cases, after quenching the reaction mixture with sat. NaHCO3 solution, the mixture should first be filtered (paper filter) to remove the unreacted base. The resulting residue is then washed with CH2 Cl2 . The organic and aqueous layers of the filtrate are separated and further treated as described.
Anticipated Results The synthesis of ribonucleosides by condensation using trimethylsilyl triflate is a generally applicable method for the synthesis of the naturally occurring β-nucleosides. The quality of the reagents and dryness of the solvents will have a significant impact on product yield and purity. This method is also applicable for the synthesis of base-modified ribonucleosides or for sugar-modified nucleosides. In the latter case, a 1,2-diacyl (acyl = acetyl, benzoyl. . .) proCurrent Protocols in Nucleic Acid Chemistry
tection is necessary to obtain β-nucleosides following the herein discussed reaction mechanism. For the naturally occurring nucleosides and closely related bases, coupling yields in the range of 80% to 95% (pyrimidines) and 60% to 85% (purines) can be expected. All reactions described in this unit can be scaled up to yield ∼500 mmol of the nucleosides by linearly increasing the amounts of all materials used in the procedures. Reaction times have to be adjusted by TLC monitoring.
Time Considerations Deprotected β-nucleosides (A, G, C, U) and closely related nucleosides can be obtained in 2 days. On the first day, the glycosylation reaction is carried out (silylation ∼1 hr, condensation 2 to 4 hr) followed by flash chromatography to obtain the pure, protected nucleoside derivatives. The deprotection reaction is preferably carried out overnight. The second day is used for drying the product in a desiccator and for spectroscopic characterization. When glycosylating various unnatural heterocyclic bases, the time needed will depend on the reaction time of the glycosylation reaction (in most cases, between 2 and 10 hr).
Literature Cited Framski, G., Gdaniec, Z., Gdaniec, M., and Boryski, J. 2006. A reinvestigated mechanism of ribosylation of adenine under silylating conditions. Tetrahedron 62:10123-10129. Garner, P. and Ramakanth, S. 1988. A regioncontrolled synthesis of N7 - and N9 -guanine nucleosides. J. Org. Chem. 53:1294-1298. Niedballa, U. and Vorbr¨uggen, H. 1970. A general synthesis of pyrimidine nucleosides. Angew. Chem. Int. Ed. 9:461-462. Niedballa, U. and Vorbr¨uggen, H. 1974a. Synthesis of nucleosides. 9. General synthesis of Nglycosides. I. Synthesis of pyrimidine nucleosides. J. Org. Chem. 39:3654-3659. Niedballa, U. and Vorbr¨uggen, H. 1974b. Synthesis of nucleosides. 10. General synthesis of N-glycosides. II. Synthesis of 6-methyluridines. J. Org. Chem. 39:3660-3663. Niedballa, U. and Vorbr¨uggen, H. 1974c. Synthesis of nucleosides. 11. General synthesis of N-glycosides. III. Simple synthesis of pyrimidine disaccharide nucleosides. J. Org. Chem. 39:3664-3667. Niedballa, U. and Vorbr¨uggen, H. 1974d. Synthesis of nucleosides. 12. General synthesis of N-glycosides. IV. Synthesis of nucleosides of hydroxy and mercapto nitrogen heterocycles. J. Org. Chem. 39:3668-3671. Niedballa, U. and Vorbr¨uggen, H. 1974e. Synthesis of nucleosides. 13. General synthesis of N-glycosides. V. Synthesis of 5-azacytidines. J. Org. Chem. 39:3672-3673.
Synthesis of Modified Nucleosides
1.13.15 Supplement 27
Niedballa, U. and Vorbr¨uggen, H. 1976. Synthesis of nucleosides. 17. A general synthesis of Nglycosides. 6. On the mechanism of the stannic chloride catalyzed silyl Hilbert-Johnson reaction. J. Org. Chem. 41:2084-2086. Vorbr¨uggen, H. and Bennua, B. 1981. Nucleoside syntheses. XXV. A new simplified nucleoside synthesis. Chem. Ber. 114:1279-1286. Vorbr¨uggen, H. and Hoefle, G. 1981. Nucleoside syntheses. XXIII. On the mechanism of nucleoside synthesis. Chem. Ber. 114:1256-1268. Vorbr¨uggen, H. and Krolikiewicz, K. 1975. New catalysts for nucleoside synthesis. Angew. Chem. 87:417. Vorbr¨uggen, H. and Ruh-Pohlenz, C. 2000. Synthesis of nucleosides. Organic Reactions 55:1630. Vorbr¨uggen, H. and Ruh-Pohlenz, C. 2001. Handbook of Nucleoside Synthesis. Wiley Interscience, New York.
Vorbr¨uggen, H., Niedballa, U., Krolikiewicz, K., Bennua, B., and H¨ofle, G. 1978. On the mechanism of nucleoside synthesis. In Chemistry and Biology of Nucleosides and Nucleotides (R.E. Harman,R.K. Robins, andL.B. Townsend, eds.) pp. 251-266. Academic Press, New York. Vorbr¨uggen, H., Krolikiewicz, K., and Bennua, B. 1981. Nucleoside syntheses. XXII. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts. Chem. Ber. 114:1234-1255.
Contributed by Helmut Vorbr¨uggen Free University Berlin Berlin, Germany Irene M. Lagoja and Piet Herdewijn Rega Institute for Medical Research Leuven, Belgium
Synthesis of Ribonucleosides by Condensation Using Trimethylsilyl Triflate
1.13.16 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Synthesis of 2 -O-β-dRibofuranosylnucleosides
UNIT 1.14
This unit describes a three-step procedure for the preparation of 2 -O-β-D-ribofuranosylnucleosides (Mikhailov et al., 1997a; Markiewicz et al., 1998). First, the complete synthesis of 2 -O-β-D-ribofuranosyladenosine is described (see Basic Protocol). As shown in Figure 1.14.1, the procedure involves (1) condensation of a small excess of 1-O-acetyl2,3,5-tri-O-benzoyl-β-D-ribofuranose activated with tin tetrachloride with an N-protected 3 ,5 -O-tetraisopropyldisiloxane-1,3-diyl-ribonucleoside in 1,2-dichloroethane, (2) removal of silyl protecting group with tetrabutylammonium fluoride, and (3) deacylation with ammonia in methanol. Using these procedures, 2 -O-β-D-ribofuranosyladenosine is prepared in a 61% overall yield. The 2 -O-ribosylation proceeds stereospecifically with the formation of a β-glycosidic bond. The presence of a participating 2-O-benzoyl group leads exclusively to 1,2-trans-ribofuranoside. This reaction is carried out under mild conditions (0◦ C, 1,2-dichloroethane, 2 hr for pyrimidine nucleosides, 7 to 16 hr for purine derivatives) and yields of the target compounds are 72% to 80% (Mikhailov et al., 1997a). At room temperature, the reaction occurs faster (30 min), but the yields in the coupling steps are lower (40% to 77%; Markiewicz et al., 1998). These variations are presented as slightly modified procedures for the preparation of four other 2 -O-β-D-ribofuranosylnucleosides (see Alternate Protocols 1 through 4; Fig. 1.14.3). CAUTION: Carry out all operations involving organic solvents and reagents in a wellventilated fume hood, and wear gloves and protective glasses.
PREPARATION OF 2 -O-β -D-RIBOFURANOSYLADENOSINE The first step of preparation of 2 -O-β-D-ribofuranosyladenosine involves the condensation of N6 -benzoyl-3 ,5 -(1,1,3,3-O-tetraisopropyldisiloxane-1,3-diyl)adenosine (S.1; Markiewicz and Wiewiorowski, 1986; UNIT 2.4) with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-Dribofuranose (S.2) in the presence of tin tetrachloride in 1,2-dichloroethane at 0◦ C (Fig. 1.14.1). To obtain the product S.3 in high yield and to simplify its isolation, it is recommended to run the reaction under nitrogen and to perform preactivation of the sugar with tin tetrachloride; usually the reaction is complete in 7 to 8 hr. During workup of the reaction mixture with saturated sodium bicarbonate solution, a suspension is formed, which should be filtered through a 2- to 3-cm layer of Hyflo Super Cel before the separation of organic and aqueous layers. The second step involves removal of the silyl protection from the 3 - and 5 -hydroxyl groups with tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF) for 15 to 20 min at room temperature followed by silica gel column chromatography. In the last step, all benzoyl groups from S.4 are removed with 5 M ammonia (half-saturated at 0◦ C) in methanol for 2 to 3 days at room temperature followed by recrystallization from methanol to give 2 -O-β-D-ribofuranosyladenosine (S.5) in an overall yield of 61%.
BASIC PROTOCOL
Materials 1-O-Acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (S.2) N6 -Benzoyl-3 ,5 -(1,1,3,3-O-tetraisopropyldisiloxane-1,3-diyl)adenosine (S.1; UNIT 2.4; Fig. 2.4.5) Phosphorus pentoxide (P2 O5 ) Balloon of nitrogen or argon 1,2-Dichloroethane, anhydrous Tin tetrachloride (SnCl4 ) Methanol (MeOH), analytical grade
Synthesis of Modified Nucleosides
Contributed by Sergey N. Mikhailov, Ekaterina V. Efimtseva, Andrei A. Rodionov, Georgii V. Bobkov, Irina V. Kulikova, and Piet Herdewijn
1.14.1
Current Protocols in Nucleic Acid Chemistry (2006) 1.14.1-1.14.19 C 2006 by John Wiley & Sons, Inc. Copyright
Supplement 27
Methylene chloride (CH2 Cl2 ), reagent grade Saturated sodium bicarbonate solution (sat. NaHCO3 ) Hyflo Super Cel (Fluka) Sodium sulfate, anhydrous (Na2 SO4 ) Silica gel (e.g., Kieselgel 60, 0.06 to 0.20 mm; Merck) Tetrabutylammonium fluoride trihydrate (TBAF) Tetrahydrofuran (THF), reagent grade Chloroform (CHCl3 ), reagent grade 5 M ammonia in methanol (half-saturated at 0◦ C) Diethyl ether, reagent grade 50- and 250-mL round-bottom flasks Vacuum desiccator Vacuum oil pump TLC plate: silica-coated aluminum plate with fluorescent indicator (Merck silica gel 60 F254 ) 254-nm UV lamp Long disposable capillaries 100-mL funnels with sintered glass disc filters (porosity 3) 100- and 250-mL separatory funnel Rotary evaporator equipped with a water aspirator 3 × 20–cm and 3 × 15–cm sintered glass chromatography columns, porosity 3 Stainless steel spatula Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare S.3 1. Weigh 1.26 g (2.5 mmol) of 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (S.2) into a 250-mL round-bottom flask containing a stir bar and weigh 1.23 g (2 mmol) of nucleoside S.1 into a separate flask. 2. Put both flasks in a vacuum desiccator with phosphorus pentoxide and evacuate using a vacuum oil pump for 10 to 15 min. Close the stopcock of the desiccator and leave overnight at room temperature. 3. Connect the desiccator with a balloon of nitrogen or argon and open the stopcock of the desiccator. Open the desiccator and quickly close the flasks. 4. Dissolve 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (S.2) in 25 mL of 1,2dichloroethane, close with stopcock and balloon of nitrogen or argon, and put the flask in the ice-water bath (Fig. 1.14.2A). 5. Add 0.35 mL (3 mmol) of tin tetrachloride in one portion under stirring and keep the reaction mixture for 10 min at 0◦ C. 6. Add 1.23 g (2 mmol) of nucleoside S.1 in one portion and stir the reaction mixture for 7 hr at 0◦ C. 7. Monitor reaction by TLC (APPENDIX 3D) using 2% (v/v) MeOH in CH2 Cl2 . To protect the reaction mixture from atmospheric moisture, remove the sample using a long capillary as shown in Figure 1.14.2B. The starting compound S.1 (Rf = 0.21) usually disappears after 6 to 7 hr at 0◦ C. The product S.3 (Rf = 0.31) moves faster in the same solvent. Synthesis of 2 -O-β β-dRibofuranosylnucleosides
1.14.2 Supplement 27
8. Add 10 mL saturated sodium bicarbonate solution and stir the suspension for 20 min at 0◦ C. 9. Lay a 2- to 3-cm layer of Hyflo Super Cel on a 100-mL funnel with sintered disc (porosity 3) and wash it with 20 mL CH2 Cl2 . Filter the suspension using a vacuum Current Protocols in Nucleic Acid Chemistry
Figure 1.14.1 Synthesis of 2 -O-β-D-ribofuranosyladenosine (S.5). The expected overall yield of S.5 from S.1 is given in parentheses. DCE, 1,2-dichloroethane; TBAF, tetrabutylammonium fluoride; THF, tetrahydrofuran.
pump, and wash the layer with 20 mL CH2 Cl2 and 20 mL of 5% (v/v) MeOH in CH2 Cl2 . 10. Separate the organic layer using a 250-mL separatory funnel and wash the organic layer with 20 mL water. 11. Dry the organic layer over ∼10 g Na2 SO4 , filter off Na2 SO4 by gravity filtration, wash the precipitate with 20 mL CH2 Cl2 , and evaporate the combined filtrates using a rotary evaporator connected to vacuum system. 12. Prepare a slurry of 50 g silica gel in CH2 Cl2 and pour into a 3 × 20–cm chromatography column (APPENDIX 3E). 13. Dissolve the residue in a minimal amount of CH2 Cl2 and layer it carefully on top of the silica gel. 14. Wash the column with 300 mL CH2 Cl2 and 300 mL of 0.5% (v/v) MeOH in CH2 Cl2 . Elute with 1% (v/v) MeOH in CH2 Cl2 . Collect 25-mL fractions.
Synthesis of Modified Nucleosides
1.14.3 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Figure 1.14.2 Protection from atmospheric moisture for synthesis of 2 -O-β-D-ribofuranosylnucleosides. (A) A 250-mL round-bottom flask with adaptor and stopcock connected with a balloon of nitrogen or argon in an ice-water bath. (B) Checking the reaction mixture with a long capillary (diameter ∼1 mm). The diameter of the hole in the stopcock is ∼3 mm.
15. Evaluate fractions by TLC using 2% (v/v) MeOH in CH2 Cl2 and combine the fractions that contain only S.3. Evaporate the volatile materials from the combined fractions using a rotary evaporator connected to vacuum system, and dry the residual foam for 2 to 3 hr using a vacuum oil pump. 16. Grind the foam with a stainless steel spatula and dry the resulting powder 12 to 16 hr using a vacuum oil pump. 17. Characterize the product by TLC, 1 H NMR, and 13 C NMR. The compound is stable for at least 12 months at ambient temperature.
Synthesis of 2 -O-β β-dRibofuranosylnucleosides
N6-Benzoyl-9-[3,5-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2-O-(2,3,5-tri-O-benzoylβ-D-ribofuranosyl)-β-D-ribofuranosyl]adenine (S.3). Yield of white amorphous solid 1.57 g (74%). TLC: Rf 0.31 (98:2 v/v CH2 Cl2 /MeOH).1 H NMR (400 MHz, CDCl3 ): 9.02 brs (1H, NH), 8.72 s (1H, H8), 8.15 s (1H, H2), 8.03-7.87 m (8H, Bz), 7.61-7.28 m (12H, Bz), 6.09 d (1H, J1 ,2 = 1.0 Hz, H1 , Ado), 5.96 dd (1H, J3 ,2 = 4.8 Hz, J3 ,4 = 6.2 Hz, H3 , Rib), 5.88 d (1H, H2 , Rib), 5.82 s (1H, H1 , Rib), 4.96 dd (1H, J3 ,2 = 4.7 Hz, J3 ,4 = 9.0 Hz, H3 , Ado), 4.90 dd (1H, H2 , Ado), 4.81-4.65 m (3H, H4 , Ado; H4 ,5 a, Rib), 4.18 d (1H, J5 a,5 b = −13.4 Hz, H5 a, Ado), 4.13 dd (1H, J5 b,4 = 1.0 Hz, J5 b,5 a = −9.5 Hz, H5 b, Rib), 4.03 dd (1H, J5 b,4 = 1.5 Hz, H5 b, Ado), 1.08-1.03 m (28H, iPr). 13 C NMR (CDCl3 ): 166.01, 165.37, 164.97 and 164.43 (C=O), 152.70 (C2), 150.76 (C6), 149.35 (C4), 141.80 (C8), 133.41, 133.16, 132.69, 129.71, 129.64, 129.10, 128.83, 128.34 and 127.78 (Bz), 123.40 (C5), 105.65 (C1 , Rib), 88.81 (C1 , Ado), 81.34 (C4 , Ado), 79.55 (C4 , Rib), 78.47 (C2 , Ado), 75.51 (C2 , Rib), 72.53 (C3 , Rib), 69.84 (C3 , Ado), 65.27 (C5 , Rib), 59.70 (C5 , Ado), 17.26, 17.04, 16.87, 16.77, 13.31, 12.89, 12.74 and 12.59 (iPr).
1.14.4 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Prepare S.4 18. Weigh 1.06 g (1 mmol) S.3 into a 50-mL round-bottom flask, add 5 mL of 0.5 M TBAF in THF, stopper the flask, and keep the solution for 20 to 30 min at room temperature. Monitor deprotection by TLC using 5% (v/v) MeOH in CH2 Cl2 . The starting compound S.3 (Rf = 0.93) usually disappears after 20 to 30 min at 20◦ C. The product S.4 (Rf = 0.22) moves slower in the same solvent.
19. When the reaction is complete, evaporate all volatile material to dryness in vacuo using a rotary evaporator. Add 10 mL chloroform to the residue and evaporate to dryness. 20. Dissolve the residue in a minimal amount (3 to 4 mL) of chloroform and apply on a 3 × 15–cm column containing 30 g silica gel. Wash column with 300 mL CH2 Cl2 and 200 mL of 1% (v/v) MeOH in CH2 Cl2 . Elute with 2% (v/v) MeOH in CH2 Cl2 and collect 25-mL fractions. 21. Evaluate fractions by TLC using 5% (v/v) MeOH in CH2 Cl2 and combine the fractions that contain only S.4. Evaporate the combined fractions using a rotary evaporator connected to a vacuum system, and dry the residual foam for 2 to 3 hr using a vacuum oil pump. 22. Grind the foam with a stainless steel spatula and dry the resulting powder 12 to 16 hr using a vacuum oil pump. 23. Characterize the compound by TLC, 1 H NMR, and 13 C NMR. The compound is stable for at least 12 months at 0◦ C. N6 -Benzoyl-9-[2-O-(2,3,5-tri-O-benzoyl-β - D-ribofuranosyl)-β-D-ribofuranosyl]adenine (S.4). Yield of white amorphous solid 0.74 g (91%). TLC: Rf 0.22 (95:5 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 ): 9.52 brs (1H, NH), 8.78 s (1H, H8), 8.18 s (1H, H2), 8.06-7.88 m (8H, Bz), 7.53-7.34 m (12H, Bz), 6.05 d (1H, J1 ,2 = 7.2 Hz, H1 , Ado), 5.72 dd (1H, J3 ,2 = 5.3 Hz, J3 ,4 = 5.0 Hz, H3 , Rib), 5.64 dd (1H, J2 ,1 = 2.2 Hz, H2 , Rib), 5.21 d (1H, H1 , Rib), 5.20 dd (1H, J2 ,3 = 4.7 Hz, H2 , Ado), 4.59 brd (1H, H3 , Ado), 4.54 dd (1H, J5 a,4 = 4.1 Hz, J5 a,5 b = −11.8 Hz, H5 a, Rib), 4.48 ddd (1H, J4 ,5 b = 4.2 Hz, H4 , Rib), 4.30 brs (1H, H4 , Ado), 4.11 dd (1H, H5 b, Rib), 3.96 brd (1H, J5 a,5 b = −12.7 Hz, H5 a, Ado), 3.75 brd (1H, H5 b, Ado). 13 C NMR (CDCl3 ): 165.71, 165.21 and 164.66 (C=O), 151.96 (C2), 150.26 (C6), 150.11 (C4), 143.85 (C8), 133.47, 133.36, 133.16, 132.54, 129.51, 129.41, 128.94, 128.54 and 127.82 (Bz), 123.80 (C5), 106.19 (C1 , Rib), 88.86 (C1 , Ado), 86.99 (C4 , Ado), 80.48 (C4 , Rib), 79.53 (C2 , Ado), 75.61 (C2 , Rib), 72.18 (C3 , Rib), 71.06 (C3 , Ado), 64.12 (C5 , Rib), 62.73 (C5 , Ado).
Prepare S.5 24. Dissolve 408 mg (0.5 mmol) S.4 in 15 mL of 5 M ammonia in methanol (halfsaturated at 0◦ C) in a 50-mL round-bottom flask, stopper the flask, and keep the solution for 2 to 3 days at room temperature. 25. Evaporate all volatile material under reduced pressure using a rotary evaporator. 26. Partition the residue between 10 mL CH2 Cl2 and 20 mL water using a 100-mL separatory funnel. Separate the aqueous layer and wash it two additional times with 10 mL CH2 Cl2 . 27. Concentrate the aqueous layer to a volume of ∼1 mL, add 7 mL MeOH, and keep the mixture 16 hr at 0◦ C. 28. Collect the precipitate by vacuum filtration on a glass filter (porosity 3), wash with 2 to 3 mL MeOH followed by 5 mL diethyl ether, and dry in a vacuum desiccator with phosphorus pentoxide for 24 hr at room temperature.
Synthesis of Modified Nucleosides
1.14.5 Current Protocols in Nucleic Acid Chemistry
Supplement 27
29. Characterize the compound by TLC, UV spectroscopy, 1 H NMR, and 13 C NMR. The compound is stable for at least 12 months at 0◦ C. 9-(2-O-β-D-Ribofuranosyl-β-D-ribofuranosyl)adenine (S.5): Yield of white crystals 190 mg (91%). According to elemental analysis, S.5 is obtained as a monohydrate. m.p. 212◦ -214◦ C (softening at 162◦ -164◦ C). TLC: Rf 0.12 (8:2 v/v CH2 Cl2 /MeOH). [α]20 D −97◦ (c 0.76, DMSO). UV (pH 7-13): λmax 261 nm (ε 14200); (pH 1): λmax 261 nm (ε 13700). LSIMS (C15 H21 N5 O8 + H): calcd. 400.1468, found 400.1465. 1 H NMR (400 MHz, D2 O): 8.32 s (1H, H8, Ade), 8.19 s (1H, H2, Ade), 6.12 d (1H, J1 ,2 = 6.4 Hz, H1 , Ado), 5.07 s (1H, H1 , Rib), 4.80 dd (1H, J2 ,3 = 5.0 Hz, H2 , Ado), 4.55 dd (1H, J3 ,4 = 3.3 Hz, H3 , Ado), 4.29 ddd (1H, J4 ,5 a = 2.6 Hz, J4 ,5 b = 3.6 Hz, H4 Ado), 4.13 d (1H, J2 ,3 = 4.5 Hz, H2 , Rib), 3.99 dd (1H, J3 ,4 = 7.4 Hz, H3 , Rib), 3.92 dd (1H, J5 a,5 b = −13.0 Hz, H5 a, Ado), 3.83 dd (1H, H5 b, Ado), 3.82 ddd (1H, J4 ,5 a = 3.7 Hz, J4 ,5 b = 6.8 Hz, H4 Rib), 3.32 dd (1H, J5 a,5 b = −12.0 Hz, H5 a, Rib), 2.75 dd (1H, H5 b, Rib). 13 C NMR (D2 O): 156.14 (C6), 153.06 (C2), 149.74 (C4), 141.08 (C8), 119.42 (C5), 106.42 (C1 , Rib), 87.44 (C1 , Ado), 86.84 (C4 , Ado), 83.11 (C4 , Rib), 78.64 (C2 , Ado), 74.75 (C2 , Rib), 71.31 (C3 , Rib), 69.43 (C3 , Ado), 63.16 (C5 , Rib), 61.88 (C5 , Ado). ALTERNATE PROTOCOL 1
PREPARATION OF 2 -O-β -D-RIBOFURANOSYLURIDINE 3 ,5 -(1,1,3,3-O-Tetraisopropyldisiloxane-1,3-diyl)uridine (S.6a; Markiewicz and Wiewiorowski, 1986; UNIT 2.10; Fig. 2.10.2) is converted to 2 -O-β-D-ribofuranosyluridine (S.9a) with an overall yield of 56% (Mikhailov et al., 1997a) using the steps outlined in the Basic Protocol (Fig. 1.14.3). The reaction uses the same molar equivalent of starting nucleoside (i.e., 2 mmol S.6a) and the same amounts of other reagents as in the Basic Protocol. The condensation reaction of pyrimidine nucleoside S.6a with 1O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (S.2) is carried out in 1,2-dichloroethane for 2 hr at 0◦ C. 2 -O-β-D-Ribofuranosyluridine (S.9a) is isolated by crystallization from a minimal amount of water. 1-[3,5-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-2-O-(2,3,5-tri-O-benzoyl-β-Dribofuranosyl)-β-D-ribofuranosyl]uracil (S.7a). Yield of white amorphous solid 76%. TLC: Rf 0.30 (98:2 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 ): 8.35 brs (1H, NH), 8.05-7.85 m (6H, Bz), 7.80 d (1H, J6,5 = 8.0 Hz, H6), 7.56-7.26 m (9H, Bz), 5.88 dd (1H, J3 ,2 = 5.0 Hz, J3 ,4 = 6.5 Hz, H3 , Rib), 5.82 d (1H, H2 , Rib), 5.81 s (1H, H1 , Urd), 5.80 s (1H, H1 , Rib), 5.65 d (1H, H5), 4.80-4.75 m (3H, H3 ,4 , Urd; H4 , Rib), 4.41 d (1H, J2 ,3 = 4.8 Hz, H2 , Urd), 4.30 dd (1H, J5 a,4 = 4.0 Hz, J5 a,5 b = −9.6 Hz, H5 a, Rib), 4.23 d (1H, J5 a,5 b = −13.4 Hz, H5 a, Urd), 4.08 dd (1H, J5 b,4 = 1.0 Hz, H5 b, Rib), 3.95 dd (1H, J5 ,4 = 1.5 Hz, H5 b, Urd), 1.09-0.96 m (28H, iPr). 13 C NMR (400 MHz, CDCl3 ): 166.01, 165.22 and 164.95 (C=O), 163.51 (C4), 149.68 (C2), 139.41 (C6), 133.31, 133.21, 133.00, 132.83, 129.64, 129.10, 128.87, 128.32 and 128.21 (Bz), 105.44 (C1 , Rib), 101.45 (C5), 89.25 (C1 , Urd), 81.52 (C4 , Urd), 79.33 (C4 , Rib), 78.47 (C2 , Urd), 75.47 (C2 , Rib), 72.96 (C3 , Rib), 68.71 (C3 , Urd), 65.60 (C5 , Rib), 59.22 (C5 , Urd), 17.22, 17.12, 17.01, 16.77, 16.67, 13.26, 12.91, 12.75 and 12.42 (iPr).
Synthesis of 2 -O-β β-dRibofuranosylnucleosides
1-[2-O-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-β-D-ribofuranosyl]uracil (S.8a). Yield of white amorphous solid 92%. TLC: Rf 0.20 (95:5 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 ): 8.47 brs (1H, NH), 8.08-7.91 m (6H, Bz), 7.54-7.36 m (10H, H6, Bz), 5.82 dd (1H, J3 ,2 = 5.3 Hz, J3 ,4 = 5.9 Hz, H3 , Rib), 5.74 dd (1H, J2 ,1 = 1.9 Hz, H2 , Rib), 5.70 d (1H, J1 ,2 = 4.7 Hz, H1 , Urd), 5.65 d (1H, J5,6 = 8.0 Hz, H5), 5.48 d (1H, H1 , Rib), 4.78-4.69 m (3H, H2 , Urd; H4 ,5 a, Rib), 4.49-4.42 m (2H, H3 , Urd; H5 b, Rib), 3.93-3.87 m (2H, H4 ,5 a, Urd), 3.75 dd (1H, J5 b,4 = 2.3 Hz, J5 b,5 a = −12.4 Hz, H5 b, Urd). 13 C NMR (400 MHz, CDCl3 ): 166.12 and 165.46 (C=O), 163.78 (C4), 150.41 (C2), 142.54 (C6), 133.51, 133.47, 133.28, 129.69, 129.34, 128.68 and 128.42 (Bz), 106.82 (C1 , Rib), 102.08 (C5), 91.10 (C1 , Urd), 84.51 (C4 , Urd), 80.65 (C4 , Rib), 79.75 (C2 , Urd), 75.77 (C2 , Rib), 72.40 (C3 , Rib), 69.08 (C3 , Urd), 64.65 (C5 , Rib), 61.14 (C5 , Urd).
1.14.6 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Figure 1.14.3 Synthesis of 2 -O-β-D-ribofuranosyluridine (S.9a), 2 -O-β-D-ribofuranosylthymidine (S.9b), 2 -O-β-D-ribofuranosylcytidine (S.9c), and 2 -O-β-D-ribofuranosylguanosine (S.9d). The expected overall yields are given in parentheses. DCE, 1,2-dichloroethane; TBAF, tetrabutylammonium fluoride; THF, tetrahydrofuran.
Synthesis of Modified Nucleosides
1.14.7 Current Protocols in Nucleic Acid Chemistry
Supplement 27
1-(2-O-β-D-Ribofuranosyl-β-D-ribofuranosyl)uracil (S.9a): Yield of white crystals 80%. m.p. 224◦ -225◦ C (water). TLC: Rf 0.15 (8:2 v/v CH2 Cl2 /MeOH). [α]20 D −36◦ (c 0.68, DMSO). UV (pH 1-7): λmax 262 nm (ε 9400); (pH 13): λmax 262 nm (ε 6900). LSIMS (C14 H20 N2 O10 + H): calcd. 377.1196, found 377.2801. 1 H NMR (400 MHz, D2 O): 7.87 d (1H, J5,6 = 8.1 Hz, H6, Ura), 6.04 d (1H, J1 ,2 = 5.0 Hz, H1 , Urd), 5,92 d (1H, H5, Ura), 5.15 s (1H, H1 , Rib), 4.44 dd (1H, J2 ,3 = 5.4 Hz, H2 , Urd), 4.36 dd (1H, J3 ,4 = 5.1 Hz, H3 , Urd), 4.19 dd (1H, J3 ,2 = 4.8 Hz, J3 ,4 = 6.9 Hz, H3 , Rib), 4.16 d (1H, H2 , Rib), 4.11 ddd (1H, J4 ,5 a = 2.9 Hz, J4 ,5 b = 4.5 Hz, H4 , Urd), 3.99 ddd (1H, J4 ,5 a = 3.4 Hz, J4 ,5 b = 6.6 Hz, H4 , Rib), 3.88 dd (1H, J5 a,5 b = −12.7 Hz, H5 a, Urd), 3.79 dd (1H, H5 b, Urd), 3.75 dd (1H, J5 a,5 b = −12.1 Hz, H5 a, Rib), 3.48 dd (1H, H5 b, Rib). 13 C NMR (D2 O): 166.66 (C4), 152.17 (C2), 142.55 (C6), 107.28 (C1 , Rib), 103.06 (C5), 88.47 (C1 , Urd), 85.11 (C4 , Urd), 83.35 (C4 , Rib), 78.93 (C2 , Urd), 74.85 (C2 , Rib), 71.14 (C3 , Rib), 68.87 (C3 , Urd), 63.34 (C5 , Rib), 61.17 (C5 , Urd). ALTERNATE PROTOCOL 2
PREPARATION OF 2 -O-β -D-RIBOFURANOSYLTHYMIDINE 3 ,5 -(1,1,3,3-O-Tetraisopropyldisiloxane-1,3-diyl)thymidine (S.6b; Markiewicz and Wiewiorowski, 1986; see Support Protocol) is converted to 2 -O-β-D-ribofuranosylthymidine (S.9b) with an overall yield of 48% (Mikhailov et al., 1997a) using the steps outlined in the Basic Protocol (Fig. 1.14.3). The reaction uses the same molar equivalent of starting nucleoside (i.e., 2 mmol S.6b) and the same amounts of other reagents as in the Basic Protocol. The condensation reaction of pyrimidine nucleoside S.6b with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (S.2) is carried out in 1,2dichloroethane for 2 hr at 0◦ C. 2 -O-β-D-Ribofuranosylthymidine (S.9b) is isolated by crystallization from a minimal amount of 9:1 (v/v) ethanol/water. 1-[3,5-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-2-O-(2,3,5-tri-O-benzoyl-β-Dribofuranosyl)-β-D-ribofuranosyl]thymine (S.7b). Yield of white amorphous solid 74%. TLC: Rf 0.30 (98:2 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 ): 8.21 brs (1H, NH), 8.00-7.83 m (6H, Bz), 7.55-7.25 m (10H, Bz, H6), 5.85 dd (1H, J3 ,2 = 5.0 Hz, J3 ,4 = 6.5 Hz, H3 , Rib), 5.78 d (1H, H2 , Rib), 5.76 s (1H, H1 , Thd), 5.75 s (1H, H1 , Rib), 4.77-4.69 m (3H, H3 ,4 , Thd; H4 , Rib), 4.39 d (1H, J2 ,3 = 4.3 Hz, H2 , Thd), 4.30 dd (1H, J5 a,4 = 4.4 Hz, J5 a,5 b = −9.5 Hz, H5 a, Rib), 4.18 d (1H, J5 a,5 b = −13.4 Hz, H5 a, Thd), 4.04 dd (1H, J5 b,4 = 2.0 Hz, H5 b, Rib), 3.92 dd (1H, J5 b,4 = 2.6 Hz, H5 b, Thd), 1.86 d (3H, J5,6 = 1.2 Hz, Me5), 1.07-0.92 m (28H, iPr). 13 C NMR (CDCl3 ): 166.11 and 165.32 (C=O), 165.01 (C4), 149.55 (C2), 135.27 (C6), 133.39, 133.30, 132.96, 129.72, 129.18, 128.94, 128.41, 128.29 and 128.25 (Bz), 110.09 (C5), 105.51 (C1 , Rib), 89.64 (C1 , Thd), 81.48 (C4 , Thd), 79.38 (C4 , Rib), 78.52 (C2 , Thd), 75.53 (C2 , Rib), 73.05 (C3 , Rib), 69.02 (C3 , Thd), 65.77 (C5 , Rib), 59.25 (C5 , Thd), 17.41, 17.33, 17.22, 17.13, 17.01, 16.88, 16.77, 13.42, 12.86 and 12.68 (iPr), 12.57 (Me5). 1-[2-O-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-β-D-ribofuranosyl]thymine (S.8b). Yield of white amorphous solid 87%. TLC: Rf 0.20 (95:5 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 -CD3 OD): 7.98-7.81 m (6H, Bz), 7.42 q (1H, J6,5 = 1.2 Hz, H6), 7.497.25 m (9H, Bz), 5.76 d (1H, J1 ,2 = 4.2 Hz, H1 , Thd), 5.74 dd (1H, J3 ,2 = 5.1 Hz, J3 ,4 = 6.2 Hz, H3 , Rib), 5.69 dd (1H, J2 ,1 = 1.2 Hz, H2 , Rib), 5.44 d (1H, H1 , Rib), 4.53 ddd (1H, J4 ,5 a = 4.8 Hz, J4 ,5 b = 5.9 Hz, H4 , Rib), 4.41 dd (1H, J5 a,5 b = −11.8 Hz, H5 a, Rib), 4.30 dd (1H, H5 b, Rib), 4.28 dd (1H, J2 ,3 = 5.3 Hz, H2 , Thd), 4.13 dd (1H, J3 ,4 = 5.6 Hz, H3 , Thd), 3.77 ddd (1H, J4 ,5 a = 2.3 Hz, J4 ,5 b = 2.5 Hz, H4 , Thd), 3.66 dd (1H, J5 a,5 b = −12.4 Hz, H5 a, Thd), 3.52 dd (1H, H5 b, Thd), 1.76 d (3H, Me5). 13 C NMR (CDCl3 -CD3 OD): 166.15 and 165.48 (C=O), 164.33 (C4), 150.55 (C2), 137.74 (C6), 133.62, 133.47, 133.21, 129.62, 129.54, 129.18, 128.55, 128.48, 128.38, 128.31 and 128.28 (Bz), 110.48 (C5), 106.31 (C1 , Rib), 89.92 (C1 , Thd), 84.36 (C4 , Thd), 79.31 (C4 , Rib), 77.32 (C2 , Thd), 75.57 (C2 , Rib), 72.36 (C3 , Rib), 68.89 (C3 , Thd), 64.69 (C5 , Rib), 60.79 (C5 , Thd), 11.96 (Me5).
Synthesis of 2 -O-β β-dRibofuranosylnucleosides
1.14.8 Supplement 27
Current Protocols in Nucleic Acid Chemistry
1-(2-O-β-D-Ribofuranosyl-β-D-ribofuranosyl)thymine (S.9b). Yield of white crystals 75%. m.p. 236◦ -237◦ C (aq. EtOH). TLC: Rf 0.16 (8:2 v/v CH2 Cl2 /MeOH). [α]20 D −52◦ (c 0.82, water). UV (pH 1-7): λmax 269 nm (ε9400); (pH 13): λmax 262 nm (ε7100). LSIMS (C15 H22 N2 O10 + H): calcd. 391.1352, found 391.1362. 1 H NMR (400 MHz, D2 O): 7.66 q (1H, J6,CH3 = 1.2 Hz, H6, Thy), 6.03 d (1H, J1 ,2 = 5.5 Hz, H1 , Thd), 5.12 s (1H, H1 , Rib), 4.44 dd (1H, J2 ,3 = 5.5 Hz, H2 , Thd), 4.38 dd (1H, J3 ,4 = 4.7 Hz, H3 , Thd), 4.14 dd (1H, J2 ,3 = 4.7 Hz, J3 ,4 = 6.7 Hz, H3 , Rib), 4.13 dd (1H, H2 , Rib), 4.11 ddd (1H, J4 ,5 a = 3.1 Hz, J4 ,5 b = 4.5 Hz, H4 , Urd), 3.99 ddd (1H, J4 ,5 a = 3.6 Hz, J4 ,5 b = 6.7 Hz, H4 , Rib), 3.88 dd (1H, J5 a,5 b = −12.7 Hz, H5 a, Thd), 3.81 dd (1H, H5 b, Urd), 3.71 dd (1H, J5 a,5 b = −12.1 Hz, H5 a, Rib), 3.44 dd (1H, H5 b, Rib), 1.91 d (1H, Me5). 13 C NMR (D2 O): 167.28 (C4), 152.71 (C2), 138.49 (C6), 112.82 (C5), 107.71 (C1 , Rib), 88.50 (C1 , Thd), 85.60 (C4 , Thd), 83.88 (C4 , Rib), 79.17 (C2 , Thd), 75.32 (C2 , Rib), 71.74 (C3 , Rib), 69.32 (C3 , Thd), 64.03 (C5 , Rib), 61.71 (C5 , Thd), 12.47 (Me5).
PREPARATION OF 2 -O-β -D-RIBOFURANOSYLCYTIDINE N4-Benzoyl-3,5 -(1,1,3,3-O-tetraisopropyldisiloxane-1,3-diyl)cytidine (S.6c; Markiewicz and Wiewiorowski, 1986; UNIT 2.4; Fig. 2.4.4) is converted to 2 -O-β-D-ribofuranosylcytidine (S.9c) with an overall yield of 72% (Mikhailov et al., 1997a) using the steps outlined in the Basic Protocol (Fig. 1.14.3). The reaction uses the same molar equivalent of starting nucleoside (i.e., 2 mmol S.6c) and the same amounts of other reagents as in the Basic Protocol. The condensation reaction of pyrimidine nucleoside S.6c with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (S.2) is carried out in 1,2dichloroethane for 2 hr at 0◦ C. After step 26, the aqueous layer containing product S.9c is evaporated to dryness in vacuo, the residue is dissolved in 5 mL methanol, and is evaporated to dryness again. The residual foam is dried for 2 to 3 hr using a vacuum oil pump, and is finally dried in a vacuum desiccator with phosphorus pentoxide.
ALTERNATE PROTOCOL 3
N4-Benzoyl-1-[3,5-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2-O-(2,3,5-tri-O-benzoylβ-D-ribofuranosyl)-β-D-ribofuranosyl]cytosine (S.7c). Yield of white amorphous solid 80%. TLC: Rf 0.32 (98:2 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 ): 8.77 brs (1H, NH), 8.30 d (1H, J6,5 = 7.6 Hz, H6), 8.02-7.82 m (8H, Bz), 7.55-7.24 m (13H, H5, Bz), 5.96 s (1H, H1 , Cyd), 5.92 dd (1H, J3 ,2 = 5.0 Hz, J3 ,4 = 6.3 Hz, H3 , Rib), 5.89 s (1H, H1 , Rib), 5.81 d (1H, H2 , Rib), 4.83-4.78 m (3H, H3 ,4 , Cyd; H4 , Rib), 4.49 d (1H, J2 ,3 = 4.1 Hz, H2 , Cyd), 4.28 dd (1H, J5 a,4 = 3.8 Hz, J5 a,5 b = −9.4 Hz, H5 a, Rib), 4.24 d (1H, J5 a,5 b = −13.4 Hz, H5 a, Cyd), 4.17 dd (1H, J5 b,4 = 1.0 Hz, H5 b, Rib), 3.98 dd (1H, J5 ,4 = 1.5 Hz, H5 b, Cyd), 1.10-0.96 m (28H, iPr). 13 C NMR (CDCl3 ): 166.09, 165.28 and 165.05 (C=O) 162.40 (C4), 155.02 (C2), 144.36 (C6), 133.31, 133.18, 132.80, 129.74, 129.23, 128.98, 128.37, 128.21 and 127.53 (Bz), 105.48 (C1 , Rib), 96.02 (C5), 90.14 (C1 , Cyd), 81.81 (C4 , Cyd), 79.07 (C4 , Rib), 78.51 (C2 , Cyd), 75.63 (C2 , Rib), 73.10 (C3 , Rib), 68.71 (C3 , Cyd), 65.51 and 59.32 (C5 ), 17.41, 17.28, 17.06, 16.91, 16.77, 13.31, 13.02, 12.85 and 12.50 (iPr). N4 -Benzoyl-1-[2-O-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-β-D-ribofuranosyl]cytosine (S.8c). Yield of white amorphous solid 95%. TLC: Rf 0.25 (95:5 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 ): 9.18 brs (1H, NH), 8.05-7.89 m (9H, H6, Bz), 7.58-7.33 m (13H, H5, Bz), 5.84 dd (1H, J3 ,2 = 5.2 Hz, J3 ,4 = 5.3 Hz, H3 , Rib), 5.77 d (1H, J1 ,2 = 3.8 Hz, H1 , Cyd), 5.74 dd (1H, J2 ,1 = 1.6 Hz, H2 , Rib), 5.60 d (1H, H1 , Rib), 4.92 dd (1H, J2 ,3 = 5.0 Hz, H2 , Cyd), 4.76 dd (1H, J5 a,4 = 4.0 Hz, J5 a,5 b = −11.9 Hz, H5 a, Rib), 4.69 ddd (1H, J4 ,3 = 5.3 Hz, J4 ,5 a = 4.3 Hz, H4 , Rib), 4.49-4.45 m (2H, H3 , Cyd; H5 b, Rib), 4.03 brd (1H, J4 ,3 = 5.3 Hz, H4 , Cyd), 3.94 brd (1H, J5 a,5 b = −12.8 Hz, H5 a, Cyd), 3.77 brd (1H, H5 b, Cyd). 13 C NMR (CDCl3 ): 166.66, 166.05 and 165.37 (C=O), 162.77 (C4), 155.31 (C2), 147.17 (C6), 133.46, 133.35, 133.14, 132.95, 129.67, 129.42, 128.76, 128.35 and 127.71 (Bz), 106.66 (C1 , Rib), 96.87 (C5), 92.38 (C1 , Cyd), 84.87 (C4 , Cyd), 80.67 (C4 , Rib), 79.51 (C2 , Cyd), 75.87 (C2 , Rib), 72.57 (C3 , Rib), 68.34 (C3 , Cyd), 64.82 (C5 , Rib), 60.56 (C5 , Cyd). Synthesis of Modified Nucleosides
1.14.9 Current Protocols in Nucleic Acid Chemistry
Supplement 27
1-(2-O-β-D-Ribofuranosyl-β-D-ribofuranosyl)cytosine (S.9c): Yield of white amorphous solid 95%. TLC: Rf 0.04 (8:2 v/v CH2 Cl2 /MeOH). [α]20 D −29◦ (c 0.53, water). UV (pH 7-13): λmax 271 nm (ε8200); (pH 1): λmax 279 nm (ε 12200). LSIMS (C14 H21 N3 O9 + H): calcd. 376.1355, found 376.1338. 1 H NMR (400 MHz, D2 O): 7.81 d (1H, J5,6 = 7.6 Hz, H6, Cyt), 6.06 d (1H, H5, Cyt), 6.04 d (1H, J1 ,2 = 5.1 Hz, H1 , Cyd), 5.12 s (1H, H1 , Rib), 4.37 dd (1H, J2 ,3 = 5.5 Hz, H2 , Cyd), 4.33 dd (1H, J3 ,4 = 4.7 Hz, H3 , Cyd), 4.17 dd (1H, J3 ,2 = 4.6, J3 ,4 = 6.8, H3 , Rib), 4.16 d (1H, H2 , Rib), 4.11 ddd (1H, J4 ,5 a = 3.0 Hz, J4 ,5 b = 4.4 Hz, H4 , Cyd), 3.97 ddd (1H, J4 ,5 a = 3.4 Hz, J4 ,5 b = 6.7 Hz, H4 , Rib), 3.88 (1H, J5 a,5 b = −12.7 Hz, H5 a, Cyd), 3.79 dd (1H, H5 b, Cyd), 3.71 dd (1H, J5 a,5 b = −12.2 Hz, H5 a, Rib), 3.37 dd (1H, H5 b, Rib). 13 C NMR (D2 O): 166.57 (C4), 158.03 (C2), 142.28 (C6), 106.96 (C1 , Rib), 97.17 (C5), 88.70 (C1 , Cyd), 85.08 (C4 , Cyd), 83.30 (C4 , Rib), 78.92 (C2 , Cyd), 74.84 (C2 , Rib), 71.23 (C3 , Rib), 68.90 (C3 , Cyd), 63.51 (C5 , Rib), 61.35 (C5 , Cyd). ALTERNATE PROTOCOL 4
PREPARATION OF 2 -O-β -D-RIBOFURANOSYLGUANOSINE N2 -Isobutyryl-3 ,5 -(1,1,3,3-O-tetraisopropyldisiloxane-1,3-diyl)guanosine (S.6d; Markiewicz and Wiewiorowski, 1986; UNIT 2.4; Fig. 2.4.6) is converted to 2 -O-β-Dribofuranosylguanosine (S.9d) with an overall yield of 46% (Mikhailov et al., 1997a) using the steps outlined in the Basic Protocol (Fig. 1.14.3) with some modifications described here. The reaction uses the same molar equivalent of starting nucleoside (i.e., 2 mmol S.6d) and the same amounts of other reagents as in the Basic Protocol. The condensation reaction of guanosine nucleoside S.6d with 1-O-acetyl-2,3,5-tri-O-benzoyl-βD-ribofuranose (S.2) is carried out in 1,2-dichloroethane for 16 hr at 0◦ C. The guanosine derivatives form stable complexes with tin tetrachloride. After the condensation reaction (step 6), the reaction mixture is taken up with a long capillary (Fig. 1.14.2B) and is added to a microcentrifuge tube containing 0.2 mL saturated sodium bicarbonate solution and 0.2 mL ethyl acetate. The tube is shaken and kept for 5 to 10 min at 20◦ C to destroy the tin tetrachloride complexes. A sample from the upper organic layer is then checked by TLC using 2% (v/v) MeOH in CH2 Cl2 (step 7). The starting compound S.6d (Rf = 0.14) usually disappears after 16 hr at 0◦ C, and the product S.7d (Rf = 0.25) moves faster in the same solvent. After TLC, the purification of S.7d resumes with step 8. After step 26, the aqueous layer containing 2 -O-β-D-ribofuranosylguanosine (S.9d) is evaporated to dryness in vacuo. The residue is dissolved in 10 mL ethanol and the mixture is kept for 16 hr at 0◦ C. The resulting precipitate is collected by vacuum filtration on a glass filter (porosity 3), washed with 5 ml diethyl ether, and dried for 24 hr in a vacuum desiccator with phosphorus pentoxide. N2 - Isobutyryl-9-[3,5-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2-O-(2,3,5-triO-benzoyl-β-D-ribofuranosyl)-β-D-ribofuranosyl]guanine (S.7d). Yield of white amorphous solid 72%. TLC: Rf 0.25 (98:2 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 ): 12.19 brs (1H, NH), 9.81 brs (1H, NH), 8.08 s (1H, H8), 8.00-7.82 m (6H, Bz), 7.55-7.26 m (9H, Bz), 6.10 dd (1H, J3 ,2 = 5.1 Hz, J3 ,4 = 5.8 Hz, H3 , Rib), 5.86 dd (1H, J2 ,1 = 0.9 Hz, H2 , Rib), 5.79 d (1H, H1 , Rib), 5.72 s (1H, H1 , Guo), 4.87-4.53 m (5H, H2 ,3 ,4 , Guo; H4 ,5 a, Rib), 4.23 d (1H, J5 a,5 b = −13.5 Hz, H5 a, Guo), 4.15 dd (1H, J5 b,4 = 2.2 Hz, J5 b,5 a = −9.4 Hz, H5 b, Rib), 3.96 dd (1H, J5 ,4 = 2.5 Hz, H5 b, Guo), 2.86 sep (1H, J = 6.8 Hz, CH, iBu), 1.32 d (3H, Me, iBu), 1.22 d (3H, Me, iBu), 1.07-0.92 m (28H, iPr). 13 C NMR (CDCl3 ): 179.42, 167.87, 165.34 and 165.00 (C=O), 155.42 (C6), 148.27 (C2), 147.09 (C4), 135.91 (C8), 134.01, 133.57, 129.71, 128.95, 128.83, 128.66 and 128.45 (Bz), 121.60 (C5), 105.46 (C1 , Rib), 87.32 (C1 , Guo), 81.17 (C4 , Guo), 79.38 (C4 , Rib), 78.75 (C2 , Guo), 75.81 (C2 , Rib), 73.29 (C3 , Rib), 69.31 (C3 , Guo), 65.65 (C5 , Rib), 59.41 (C5 , Guo), 36.10 (CH, iBu), 19.21 (Me, iBu), 18.92 (Me, iBu), 17.48, 17.31, 17.13, 16.96, 16.80, 16.71, 13.32, 13.06, 12.82 and 12.53 (iPr).
Synthesis of 2 -O-β β-dRibofuranosylnucleosides
1.14.10 Supplement 27
Current Protocols in Nucleic Acid Chemistry
N2 -Isobutyryl-9-[2-O-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-β-D-ribofuranosyl]guanine (S.8d). Yield of white amorphous solid 84%. TLC: Rf 0.15 (95:5 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 ): 12.27 brs (1H, NH), 9.67 brs (1H, NH), 8.62 s (1H, H8), 7.99-7.88 m (6H, Bz), 7.55-7.32 m (9H, Bz), 6.07 dd (1H, J3 ,2 = 5.0 Hz, J3 ,4 = 5.9 Hz, H3 , Rib), 5.88 d (1H, J1 ,2 = 1.9 Hz, H1 , Guo), 5.85 d (1H, H2 , Rib), 5.80 s (1H, H1 , Rib), 4.76 dd (1H, J5 a,4 = 5.9 Hz, J5 a,5 b = −11.3 Hz, H5 a, Rib), 4.73-4.66 m (2H, H3 , Guo; H4 , Rib), 4.53 dd (1H, J5 b,4 = 3.7 Hz, H5 b, Rib), 4.40 dd (1H, J2 ,3 = 4.4 Hz, H2 , Guo), 4.17 brd (1H, J4 ,3 = 8.2 Hz, H4 , Guo), 4.06brs (2H, H5 a,5 b, Guo), 2.82 sep (1H, J = 6.8 Hz, CH, iBu), 1.31 d (3H, Me, iBu), 1.24 d (3H, Me, iBu). 13 C NMR (CDCl3 ): 179.73, 167.77 and 165.27 (C=O), 155.95 (C6), 148.03 (C2), 147.48 (C4), 138.98 (C8), 133.93, 133.48, 129.87, 129.73, 129.69, 128.99, 128.83, 128.64, 128.45 and 128.39 (Bz), 120.50 (C5), 105.48 (C1 , Rib), 87.97 (C1 , Guo), 83.67 (C4 , Guo), 79.25 (C4 , Rib), 77.32 (C2 , Guo), 75.82 (C2 , Rib), 73.07 (C3 , Rib), 68.79 (C3 , Guo), 65.57 (C5 , Rib), 59.83 (C5 , Guo), 36.05 (CH, iBu), 19.13 (Me, iBu), 18.85 (Me, iBu). 9-(2-O-β-D-Ribofuranosyl-β-D-ribofuranosyl)guanine (S.9d): Yield of white crystals 76%. m.p. 215◦ -216◦ C (EtOH). TLC: Rf 0.09 (8:2 v/v CH2 Cl2 /MeOH). [α]20 D −75◦ (c 0.92, water). UV (pH 1): λmax 257 nm (ε 10800); (pH 7): λmax 254 nm (ε 12000); (pH 13): λmax 263 nm (ε 10000). LSIMS (C15 H21 N5 O9 + H): calcd. 416.1417, found 416.1413. 1 H NMR (400 MHz, D2 O): 8.03 s (1H, H6, Guo), 6.01 d (1H, J1 ,2 = 6.3 Hz, H1 , Guo), 5,12 d (1H, J1 ,2 = 0.8 Hz, H1 , Rib), 4.81 dd (1H, J2 ,3 = 5.3 Hz, H2 , Guo), 4.56 dd (1H, J3 ,4 = 3.3 Hz, H3 , Guo), 4.26 ddd (1H, J4 ,5 a = 3.1 Hz, J4 ,5 b = 4.1 Hz, H4 , Guo), 4.17 dd (1H, J2 ,3 = 4.6 Hz, H2 , Rib), 4.08 dd (1H, J3 ,4 = 7.3 Hz, H3 , Rib), 3.92 ddd (1H, J4 ,5 a = 3.8 Hz, J4 ,5 b = 6.8 Hz, H4 , Rib), 3.91 dd (1H, J5 a,5 b = −12.8 Hz, H5 a, Guo), 3.85 dd (1H, H5 b, Guo), 3.47 dd (1H, J5 a,5 b = −11.9 Hz, H5 a, Rib), 3.01 dd (1H, H5 b, Rib). 13 C NMR (D2 O): 159.89 (C6), 154.86 (C2), 150.85 (C4), 139.28 (C8), 117.67 (C5), 107.18 (C1 , Rib), 87.52 (C1 , Guo), 87.03 (C4 , Guo), 83.80 (C4 , Rib), 78.98 (C2 , Guo), 75.37 (C2 , Rib), 72.06 (C3 , Rib), 69.96 (C3 , Guo), 64.02 (C5 , Rib), 62.41 (C5 , Guo).
PREPARATION OF THE 3 ,5 -PROTECTED RIBOTHYMIDINE 1-[3,5-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-β-D-ribofuranosyl]thymine (S.6b) is prepared starting from thymine and 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (Fig. 1.14.4). A procedure proposed by Vorbr¨uggen and Ruh-Pohlenz (2000) has completely replaced the previously employed methods for the synthesis of nucleosides and their analogs. The method involves glycosylation of trimethylsilyl derivatives of heterocyclic bases with peracylated sugars in aprotic solvents in the presence of Lewis acids such as SnCl4 or trimethylsilyl trifluoromethanesulfonate (TMSOTf; UNIT 1.13). The use of this approach has significantly simplified the reaction procedure and increased the yields of the target products. The presence of a 2-O-acyl group in a carbohydrate residue is believed to be crucial for the stereochemistry of this reaction, since it stabilizes C1 carbonium ion generated via an intermediate 1,2-acyloxonim ion and yields 1,2-trans derivatives. In the first step of this procedure, crystalline 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)thymine (S.11) is prepared from thymine derivative S.10 and 1-O-acetyl-2,3,5-tri-Obenzoyl-β-D-ribofuranose (S.2) in a yield of 82%. In the second step, the cleavage of the benzoyl protecting groups is achieved using sodium methoxide in methanol under mild conditions, and 1-(β-D-ribofuranosyl)thymine (S.12) is purified by crystallization from ethanol. In the third step, nucleoside S.12 is simultaneously protected on its 3 - and 5 -hydroxy groups by the bifunctional protecting reagent 1,3-dichloro1,1,3,3-tetraisopropyldisiloxane developed by Markiewicz and Wiewiorowski (1986). The derivative S.6b is formed in high yield (86% from S.12) due to the higher reactivity of the primary 5 -hydroxy group and the subsequently favorable cyclization to the 3 hydroxy group. Chromatography is required only in the last step of the sequence. Using this three-step procedure, S.6b is prepared in an overall yield of 55%.
SUPPORT PROTOCOL
Synthesis of Modified Nucleosides
1.14.11 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Figure 1.14.4 Synthesis of 1-[3,5-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-ribofuranosyl]thymine (S.6b) The expected overall yield is given in parentheses. DCE, 1,2dichloroethane; TMSOTf, trimethylsilyl trifluoromethanesulfonate; TPDSCl2 , 1,3-dichloro-1,1,3,3tetraisopropyldisiloxane.
Additional Materials (also see Basic Protocol) Thymine Ammonium sulfate [(NH4 )2 SO4 ] 1,1,1,3,3,3-Hexamethyldisilazane, reagent grade Calcium chloride (CaCl2 ), anhydrous Trimethylsilyl trifluoromethanesulfonate (TMSOTf) 0.2 N sodium methoxide (NaOMe), freshly prepared from sodium and dry methanol Dowex 50 × 4 (100 to 200 mesh) in H+ form Pyridine, anhydrous Markiewicz reagent: 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane, 96% pure (Wacker) Toluene, reagent grade 100-, 250-, and 500-mL round-bottom flasks Reflux condensers CaCl2 protection tubes Oil bath with temperature control Adapters with stopcocks and vacuum pump (Fig. 1.14.5) 250- and 500-mL separatory funnels Glass filters (porosity 3) 3 × 20–cm chromatography columns Synthesis of 2 -O-β β-dRibofuranosylnucleosides
1.14.12 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Prepare S.11 1. Weigh 3.78 g (30 mmol) of thymine and 20 mg of (NH4 )2 SO4 into a 250-mL round-bottom flask, add 50 mL of 1,1,1,3,3,3-hexamethyldisilazane (b.p. 125◦ C), and attach a condenser equipped with CaCl2 protection tube. 2. Reflux the mixture in an oil bath set at 130◦ C until complete dissolution of thymine (10 to 12 hr). 3. Cool the flask, remove the condenser, and attach an adaptor with a stopcock (Fig. 1.14.5A). Concentrate the solution to a viscous oil using a rotary evaporator connected to a vacuum system (bath temperature ∼30◦ to 35◦ C). The resulting bis-O-trimethylsilylthymine S.10 is very hygroscopic.
4. Close the stopcock of adaptor and attach a second adaptor with stopcock to the flask. Connect the system to a vacuum pump (Fig. 1.14.5B), evacuate the system, and close the upper stopcock. Connect the system with a balloon of nitrogen or argon and open the upper stopcock to fill the adaptor with nitrogen. Repeat this procedure (evacuation and flash with nitrogen) and then open both stopcocks to fill the entire system with nitrogen (Fig. 1.14.5C). 5. Dissolve the residue in 30 mL of anhydrous 1,2-dichloroethane and concentrate the solution to a viscous oil using a rotary evaporator with a bath temperature ∼30◦ to 35◦ C. 6. Repeat step 4. 7. Dissolve the residue in 120 mL of anhydrous 1,2-dichloroethane. Add 12.6 g (25 mmol) of 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (S.2) in one portion and 5.79 mL (32 mmol) of trimethylsilyl trifluoromethanesulfonate (TMSOTf) with gentle hand stirring. 8. Attach a condenser equipped with CaCl2 protection tube and heat the clear solution for 1 hr in a 100◦ C oil bath. Monitor reaction by TLC in 98:2 (v/v) CH2 Cl2 /MeOH. The starting S.2 (Rf = 0.91) usually disappears after 1 hr at 100◦ C. The product S.11 (Rf = 0.45) moves slower in the same solvent.
9. Cool the flask to room temperature. Remove the condenser, add 50 mL of saturated sodium bicarbonate solution, and stir the suspension for 20 min at 20◦ C. 10. Put a 2- to 3-cm layer of Hyflo Super Cel on a 100-mL funnel with a sintered disc (porosity 3) and wash with 20 mL CH2 Cl2 . Filter the suspension using vacuum pump and wash the layer with 50 mL CH2 Cl2 . 11. Separate the organic layer using a 250-mL separatory funnel and wash the organic layer with 50 mL of water. 12. Dry the organic layer over ∼20 g Na2 SO4 , filter off Na2 SO4 by gravity filtration, and wash the precipitate with 40 mL CH2 Cl2 . 13. Concentrate the combined filtrates to a solid using a rotary evaporator connected to vacuum system. 14. Add 100 mL of ethanol, attach a condenser, and reflux (79◦ C) until the solid is completely dissolved. Cool the flask to room temperature and keep the mixture for 16 hr at 0◦ C. 15. Collect the precipitate by vacuum filtration on a glass filter (porosity 3), wash the precipitate with 10 mL ethanol, and dry S.11 over phosphorus pentoxide in a vacuum desiccator overnight.
Synthesis of Modified Nucleosides
1.14.13 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Figure 1.14.5 Protection from atmospheric moisture for synthesis of the 3 ,5 -protected starting thymidine nucleoside. (A) Evaporation of volatile solvents from a 250-mL round-bottom flask with adaptor and stopcock using a rotary evaporator connected to a vacuum system. (B) A 250-mL round-bottom flask with two adaptors and stopcocks connected to a vacuum system. The upper stopcock is opened. (C) Flashing the whole reaction system with nitrogen or argon using a 250-mL round-bottom flask with two adaptors connected to a balloon of nitrogen or argon with both stopcocks opened.
Synthesis of 2 -O-β β-dRibofuranosylnucleosides
1.14.14 Supplement 27
Current Protocols in Nucleic Acid Chemistry
16. Characterize the compound by TLC and 1 H NMR. The compound is stable for at least 12 months at 20◦ C. 1-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)thymine (S.11): Yield of white crystals 11.7 g (82%). m.p. 158◦ -159◦ C (EtOH). TLC: Rf 0.45 (98:2 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 ): 8.32 brs (1H, NH), 8.15-7.32 m (15H, Ph), 7.13 q (1H, J6,Me = 1.2, H6), 6.39 d (1H, J1 ,2 = 6.4, H1 ), 5.87 dd (1H, J3 ,2 = 6.0, J3 ,4 = 3.7, H3 ), 5.74 dd (1H, H2 ), 4.83 dd (1H, J5 a,4 = 2.6, J5 a,5 b = −12.2, H5 a), 4.63 ddd (1H, J4 ,5 b = 3.4, H4 ), 4.61 dd (1H, H5 b), 1.55 d (3H, Me).
Prepare S.12 17. Weigh 11.4 g (20 mmol) S.11 into a 500-mL round-bottom flask. Add 200 mL of 0.2 N NaOMe, stopper the flask, and stir the reaction for 30 min at room temperature. 18. Monitor reaction by TLC in 98:2 (v/v) CH2 Cl2 /MeOH. The starting S.11 (Rf = 0.45) usually disappears after 30 min at 20◦ C. The product S.12 (Rf = 0.01) moves slower in the same solvent.
19. Remove MeOH under reduced pressure using a rotary evaporator in vacuo and dissolve the residue in 100 mL water and 100 mL chloroform. 20. Separate the aqueous layer using a 500-mL separatory funnel and wash with 50 mL chloroform. 21. Apply aqueous solution to a 3 × 20–cm chromatography column containing 50 mL of Dowex 50 × 4 (100 to 200 mesh) in H+ form packed in water. 22. Elute with water and collect 50-mL UV-containing fractions until elution is complete (elution volume will vary from 200 to 400 mL). Monitor fractions by TLC using 9:1 (v/v) CH2 Cl2 /MeOH (Rf = 0.11.). 23. Combine the fractions that contain S.12 in a 500-mL round-bottom flask and evaporate to dryness using a rotary evaporator connected to a vacuum system. 24. Add 30 mL EtOH, stopper the flask, and keep the mixture for 16 hr at 0◦ C. 25. Collect the precipitate by vacuum filtration on a glass filter (porosity 3), wash the precipitate with 10 mL EtOH followed by 10 mL diethyl ether, and dry S.12 over phosphorus pentoxide in a vacuum desiccator overnight. 26. Characterize the compound by TLC, UV, and 1 H NMR. The compound is stable for at least 12 months at 20◦ C. 1-(β-D-Ribofuranosyl)thymine (S.12): Yield of white crystals 4.0 g (78%). m.p. 180◦ 181◦ C (EtOH). TLC: Rf 0.11 (9:1 v/v CH2 Cl2 /MeOH). UV (pH 1-7): λmax 269 nm (ε9200); (pH 13): λmax 264 nm (ε7300). 1 H NMR (400 MHz, D2 O): 7.62 s (1H, H6), 5.85 d (1H, J1 ,2 = 4.9 Hz, H1 ), 4.29 dd (1H, J2 ,3 = 5.2 Hz, H2 ), 4.19 dd (1H, J3 ,4 = 5.4 Hz, H3 ), 4.08 ddd (1H, J4 ,5 a = 3.0 Hz, J4 ,5 b = 4.3 Hz, H4 ), 3.87 dd (1H, J5 a,5 b = −12.8 Hz, H5 a), 3.78 dd (1H, H5 b), 1.85 s (3H, Me).
Prepare S.6b 27. Weigh 2.6 g (10 mmol) of dry S.12 in a 100-mL round-bottom flask and add 20 mL anhydrous pyridine. Evaporate using a rotary evaporator equipped with a water aspirator and then apply a dry nitrogen atmosphere (steps 3 to 4, Fig. 1.14.5). 28. Dissolve the residue in 40 mL pyridine with magnetic stirring. Rapidly add 3.14 mL (10 mmol) 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (Markiewicz reagent) in one portion, stopper the flask, and keep 4 hr at 20◦ C.
Synthesis of Modified Nucleosides
1.14.15 Current Protocols in Nucleic Acid Chemistry
Supplement 27
29. Monitor reaction by TLC using 98:2 (v/v) CH2 Cl2 /MeOH. The starting S.12 (Rf = 0.01) usually disappears after 4 to 6 hr at 20◦ C. The product S.6b (Rf = 0.23) moves faster in the same solvent.
30. Remove nearly all the pyridine using a rotary evaporator connected to a vacuum system and dissolve the residue in 50 mL water and 100 mL CH2 Cl2 . 31. Separate the organic layer using a 250-mL separatory funnel and wash with 20 mL saturated sodium bicarbonate solution and then with 20 mL water. 32. Dry the organic layer over ∼10 g Na2 SO4 , filter off Na2 SO4 by gravity filtration, and wash the precipitate with 20 mL CH2 Cl2 . 33. Evaporate the combined filtrates using a rotary evaporator connected to a vacuum system. Remove traces of pyridine by co-evaporating two times with 20 mL toluene. 34. Prepare a slurry of 50 g of silica gel in CH2 Cl2 and pour it into a 3 × 20–cm chromatography column. 35. Dissolve the obtained residue in a minimal amount CH2 Cl2 and layer it carefully on top of the silica gel. 36. Wash column with 300 mL CH2 Cl2 and 300 mL of 0.5% (v/v) MeOH in CH2 Cl2 . Elute with 1% (v/v) MeOH in CH2 Cl2 . Collect 25-mL fractions. 37. Evaluate fractions by TLC and combine the fractions that contain only S.6b. Evaporate the volatile materials from the combined fractions using a rotary evaporator connected to a vacuum system, and dry the residual foam for 2 to 3 hr using a vacuum oil pump. 38. Grind the foam with a stainless steel spatula and dry the resulting powder 12 to 16 hr using a vacuum oil pump. 39. Characterize the product by TLC and 1 H NMR. The compound is stable for at least 12 months at ambient temperature. 1-[3,5-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-β-D-ribofuranosyl]thymine (S.6b): Yield of white amorphous solid 4.30 g (86%). TLC: Rf 0.23 (98:2 v/v CH2 Cl2 /MeOH). 1 H NMR (400 MHz, CDCl3 ): 9.18 brs (1H, NH), 7.44 s (1H, H6), 5.70 s (1H, H1 ), 4.38 dd (1H, J3 ,2 = 5.1, Hz J3 ,4 = 8.6 Hz, H3 ), 4.18 dd (1H, J5 a,4 = 2.5 Hz, J5 a,5 b = −13.2 Hz, H5 a), 4.17 d (1H, H2 ), 3.95 ddd (1H, J4 ,5 b = 2.9 Hz, H4 ), 4.01 dd (1H, H5 b), 1.89 s (3H, Me), 1.09-1.02 m (28H, iPr). 13 C NMR (CDCl3 ): 163.93 (C4), 150.21 (C2), 135.99 (C6), 110.74 (C5), 91.42 (C1 ), 82.14 (C4 ), 75.15 (C2 ), 69.57 (C3 ), 60.81 (C5 ), 17.57, 17.50, 17.41, 17.38, 17.22, 17.14, 17.10, 17.02, 13.59, 13.15, 12.91 and 12.76 (iPr), 12.63 (Me).
COMMENTARY Background Information
Synthesis of 2 -O-β β-dRibofuranosylnucleosides
Disaccharide nucleosides belong to an important group of natural compounds that form poly(ADP-ribose) and are found in tRNA, antibiotics, and other physiologically active compounds. To date, ∼100 disaccharide nucleosides and related derivatives have been isolated from a variety of natural sources. These compounds contain an extra carbohydrate residue linked to one of the nucleoside hydroxyl groups via an O-glycosidic bond. The disaccharide residue and heterocyclic base make their properties similar to those of carbo-
hydrates and nucleosides. These compounds manifest a broad spectrum of biological activities, including antibacterial, fungicidal, herbicidal, antitumoral, and antiviral (Lerner, 1991; Efimtseva and Mikhailov, 2004; Nauwelaerts et al., 2004). An effective and simple synthesis of 2 -Oβ-D-ribofuranosylnucleosides, minor tRNA components, has been recently elaborated (Mikhailov et al., 1997a; Markiewicz et al., 1998). The method consists of the condensation of a small excess of 1-O-acetyl-2,3,5-triO-benzoyl-β-D-ribofuranose activated with
1.14.16 Supplement 27
Current Protocols in Nucleic Acid Chemistry
tin tetrachloride with N-protected 3 ,5 -Otetraisopropyldisiloxane-1,3-diyl-ribonucleosides in 1,2-dichloroethane. O-Glycosylation proceeds stereospecifically with the formation of a β-glycosidic bond. Yields of disaccharide nucleosides reach 70% to 80% if the reaction is performed at 0◦ C (Mikhailov et al., 1997a). O-Glycosylation proceeds stereospecifically with formation of a β-glycosidic bond. After complete deprotection, 2 -O-βD-ribofuranosylnucleoside disaccharide nucleosides are obtained in good overall yields (Mikhailov et al., 1997a; Markiewicz et al., 1998). This method has been used for the preparation of pyrimidine 3 -O-β-Dribofuranosyl-2 -deoxyribonucleosides and 3 -O-β-D-ribopyranosyl-2 -deoxyribonucleosides (Mikhailov et al., 1996), and for 5 -O-β-D-ribofuranosyl-2 -deoxyribonucleosides and 5 -O-β-D-ribofuranosylnucleosides (Mikhailov et al., 1997b, 1998). To study the broad applicability of the method, some other sugars such as fully acylated D- and L-arabinofuranose, D-ribopyranose, and D-erythrofuranose have been used in the Oglycosylation reaction, and the corresponding disaccharide nucleosides have been incorporated into oligodeoxyribonucleotides and oligoribonucleotides (Efimtseva et al., 2001). Melting point determinations demonstrated that modified oligonucleotides containing disaccharide nucleosides form stable duplexes with complementary RNA (Tm = 0◦ C; Efimtseva et al., 2001). The duplex RNA maintains an A-type helical geometry with the extra 2 -O-ribose moiety located in the minor groove. This implies that the voluminous extra sugar moiety has almost no effect on the stability of the RNA duplex (Luyten et al., 2000). Oligonucleotides containing 2 -O-ribofuranosylnucleosides have been used as modified primers in RNA-templated DNA synthesis catalyzed by HIV reverse transcriptase. It was shown that an additional 2 -ribofuranose residue in a specific position (-3-4) of the primer prevents elongation (Andreeva et al., 2002). An important feature of these oligonucleotides is the presence of an additional cis-diol group, which may be readily oxidized with sodium periodate to give oligonucleotide derivatives with aldehyde groups placed anywhere in the sequence (Efimtseva and Mikhailov, 2002). Such oligonucleotides were used for affinity labelling of different enzymes (Tunitskaya et al., 1999; Gritsenko et al., 2002). The incorporation of disaccharide nucleosides into oligonucleotides opens
new possibilities for the functionalization of nucleic acids. The extra sugar ring attached to a nucleoside can serve several purposes. For the synthetic work, it is important that acyl blocking groups used in disaccharide synthesis are compatible with the chemistry of automated oligonucleotide synthesis.
Compound Characterization The structure of the compound is supported by NMR spectroscopy and mass spectrometry. The 1 H NMR spectra of the obtained compounds are rather complicated due to the presence of two ribofuranose residues. In spite of this, most of the chemical shifts and coupling constants may be calculated directly from the NMR spectra. In some cases, comparison with the published spectra of disaccharide nucleosides and 1 H-13 C correlation and COSY spectra were used for assignment. The chemical shifts were assigned using double resonance techniques and COSY experiments. Several conclusions were drawn from the 1 H NMR spectral analysis. In nucleosides S.1 and S.6 and disaccharide nucleosides S.3 and S.7 with a 1,1,3,3-tetraisopropyldisiloxane1,3-diyl group, the coupling constants J1 ,2 of nucleoside moieties are <0.5 Hz (Robins et al., 1983). The O-glycosylation reaction proceeded stereospecifically with the formation of 1 ,2 -trans-substituted disaccharide nucleosides S.3 and S.7. The coupling constants (J1 ,2 ) in the additional ribose moiety are <0.5 Hz. As in the case of disaccharide nucleosides (Mikhailov et al., 1997a) and 2 O-methylnucleosides (Robins et al., 1981), incorporation of the 2 -O-substitutent results in a low field shift (+2+3 ppm) of C2 of the nucleoside moiety in 13 C NMR spectra.
Critical Parameters and Troubleshooting
The synthesis of 2 -O-β-D-ribofuranosylnucleosides is short, straightforward, and fairly efficient. However, careful attention to details of basic organic synthesis procedures is required. Preparation of the various compounds requires prior experience with routine chemical laboratory techniques such as solvent evaporation, extraction, TLC, and column chromatography. Characterization of the products demands knowledge of 1 H and 13 C NMR, UV, and mass spectroscopy. General laboratory safety is also of primary concern when hazardous materials are involved. Strict adherence to the outlined methods is therefore highly recommended.
Synthesis of Modified Nucleosides
1.14.17 Current Protocols in Nucleic Acid Chemistry
Supplement 27
All solvents should be distilled before use. Anhydrous solvents are very important. They should be either freshly distilled and stored over molecular sieves, or be taken from a freshly opened bottle of commercially prepared anhydrous solvent. It is important for each step of the syntheses that the starting compounds be thoroughly dried either by coevaporation with anhydrous pyridine or in a desiccator over P2 O5 . Protection of reaction mixtures from atmospheric moisture (as shown in Figs. 1.14.2 and 1.14.5) will enhance yields, especially in the case of ribosylation and silylation reactions. For all compounds, a sample of 50 to 100 mg should be kept as a reference. In all cases, the reaction progress is followed by TLC. A baseline is marked and the spots (∼1 optical unit) of the reaction mixture and starting material are placed at equal distances. For the preparation of S.3 and S.7, where the Rf values of the starting compounds and products are very similar, a mixed sample containing both starting compound and reaction mixture may be placed on the TLC plate. After developing in the appropriate solvent, the end-line of the TLC is marked, and spots are identified under a UV lamp (254 nm). Before each column purification, TLC is performed on the reaction mixture to evaluate the completeness of the reaction and to choose the optimal elution system for column chromatography. The silica gel for column chromatography (0.06 to 0.20 mm) is suspended in methylene chloride and loaded into the column, which is tightly packed by gentle tapping until there is a constant volume. The crude product is dissolved in a minimal volume of solvent and is carefully applied using a glass Pasteur pipet. After sample application, the flask and column walls are washed with a minimal volume of solvent. For protection, the silica layer is topped by a 1-cm layer of sand.
Anticipated Results
Synthesis of 2 -O-β β-dRibofuranosylnucleosides
The method presented here generally produces high yields even for inexperienced workers. Good overall yields (46% to 72%) of the final 2 -O-ribofuranosylnucleosides (S.5 and S.9) from the Markiewicz-protected nucleosides (S.1 and S.6) are expected following these procedures. 2 -O-Ribosylation proceeds stereospecifically with formation of a β-glycosidic bond. The first ribosylation reaction is carried out under mild conditions (0◦ C, 1,2-dichloroethane, 2 hr for pyrimidine nucleosides, 7 to 16 hr for purine derivatives) and
the yields of the target compounds are 72% to 80% (Mikhailov et al., 1997a). At room temperature, the reaction occurs faster (30 min), but the yields in the coupling steps are lower (40% to 77%; Markiewicz et al., 1998).
Time Considerations
The three-step preparation of 2 -Oβ-D-ribofuranosylnucleosides starting from Markiewicz-protected nucleosides can be accomplished in 1 week. Each column chromatography step requires 3 to 5 hr. Normally the first two steps (ribosylation and silylation) may be performed in 3 to 4 working days, including purification and spectroscopic analysis. The final deacylation reaction normally proceeds in 2 to 3 days at room temperature and may be run over a weekend. The three-step preparation of the protected thymine starting nucleoside (S.6b) may be accomplished in 1 week.
Literature Cited Andreeva, O.I., Golubeva, A.S., Kochetkov, S.N., Van Aerschot, A., Herdewijn, P., Efimtseva, E.V., Ermolinsky, B.S., and Mikhailov, S.N. 2002. An additional 2 -ribofuranose residue at a specific position of DNA primer prevents its elongation by HIV-1 reverse trancriptase. Bioorg. Med. Chem. Lett. 12:681-684. Efimtseva, E.V. and Mikhailov, S.N. 2002. Disaccharide nucleosides and oligonucleotides on their bases. New tools for the study of enzymes of nucleic acid metabolism. Biochemistry 67:1136-1144. Efimtseva, E.V. and Mikhailov, S.N. 2004. Disaccharide nucleosides. Russ. Chem. Rev. 73:401414. Efimtseva, E.V., Bobkov, G.V., Mikhailov, S.N., Van Aerschot, A., Schepers, G., Busson, R., Rozenski, J., and Herdewijn, P. 2001. Oligonucleotides containing disaccharide nucleosides. Helv. Chim. Acta 84:2387-2397. Gritsenko, O.M., Koudan, E.V., Mikhailov, S.N., Ermolinsky, B.S., Van Aerschot, A., Herdewijn, P., and Gromova, E.S. 2002. Affinity modification of EcoRII DNA methyltransferase by the dialdehyde-substituted DNA duplexes: Mapping the enzyme region that interacts with DNA. Nucleosides Nucleotides Nucleic Acids 21:753764. Lerner, L.M. 1991. Synthesis and Properties of Various Disaccharide Nucleosides. In Chemistry of Nucleosides and Nucleotides, Vol. 2 (L.B. Townsend, ed.) pp. 27-79. Plenum Press, New York. Luyten, I., Esnouf, R.M., Mikhailov, S.N., Efimtseva, E.V., Michiels, P., Heus, H.A., Hilbers, C.W., and Herdewijn, P. 2000. Solution structure of a RNA decamer duplex, containing 9-[(2-O-(β-D-ribofuranosyl)-(β-Dribofuranosyl]adenine, a special residue in lower
1.14.18 Supplement 27
Current Protocols in Nucleic Acid Chemistry
eukaryotic initiator tRNAs. Helv. Chim. Acta 83:1278-1289. Markiewicz, W.T. and Wiewiorowski, M. 1986. 1-[3,5-(1,1,3,3-Tetraisopropyldisiloxane-1,3diyl)ribonucleosides. In Nucleic Acid Chemistry. Improved and New Synthetic Procedures and Techniques, Part 3: (L.B. Townsend and R.S. Tipson, eds.) pp. 229-231. John Wiley & Sons, Hoboken. Markiewicz, W.T., Niewczyk, A., Gdaniec, Z., Adamiak, D.A., Dauter, Z., Rypniewski, W., and Chmielewski, M. 1998. Studies on synthesis and structure of O-β-D-ribofuranosyl (1 →2 )ribonucleosides and oligonucleotides. Nucleosides Nucleotides Nucleic Acids 17:411424. Mikhailov, S.N., De Clercq, E., and Herdewijn, P. 1996. Ribosylation of pyrimidine 2 deoxynucleosides. Nucleosides Nucleotides Nucleic Acids 15:1323-1334. Mikhailov, S.N., Efimtseva, E.V., Gurskaya, G.V., Zavodnik, V.E., De Bruyn, A., Janssen, G., Rozenski, J., and Herdewijn, P. 1997a. An efficient synthesis and physico-chemical properties of 2 -O-β-D-ribofuranosyl-nucleosides, minor tRNA components. J. Carbohydr. Chem. 16:75-92. Mikhailov, S.N., Rodionov, A.A., Efimtseva, E.V., Fomitcheva, M.V., Padyukova, N.Sh., Herdewijn, P., and Oivanen, M. 1997b. Preparation of pyrimidine 5 -O-β-D-ribofuranosylnucleosides, and hydrolytic stability of O-Dribofuranosyl-nucleosides. Carbohydrate Lett. 2:321-328. Mikhailov, S.N., Rodionov, A.A., Efimtseva, E.V., Ermolinsky, B.S., Fomitcheva, M.V., Padyukova, N.Sh., Rothenbacher, K., Lescrinier, E., and Herdewijn, P. 1998. Formation of trisaccharide nucleoside during disaccharide nucleoside synthesis. Eur. J. Org. Chem. 2193-2199.
Nauwelaerts, K., Efimtseva, E.V., Mikhailov, S.N., and Herdewijn, P. 2004. Disaccharide nucleosides, an important group of natural compounds In Frontiers in Nucleosides and Nucleic Acids (R.F. Schinazi and D.C. Liotta, eds.) pp 187-220. IHL Press, Arlington, MA. Robins, M.J., Hansske, F., and Bermier, S.E. 1981. Nucleic acid related compounds. 36. Synthesis of the 2 -O-methyl and 3 -O-methyl ethers guanosine and 2-amino adenosine and correlation of O -methylnucleoside C13 NMR spectral shifts. Can. J. Chem. 59:3360-3364. Robins, M.J., Wilson, J.S., Sawyer, L., and James, M.N.G. 1983. Nucleic acid related compounds. 41. Restricted furanose conformations of 3 ,5 -(1,1,3,3-tetraisopropyldisilox-1,3diyl)nucleosides provide a convenient evaluation of anomeric configuration. Can. J. Chem. 59:1911-1920. Tunitskaya, V.L., Rusakova, E.E., Memelova, L.V., Kochetkov, S.N., Van Aerschot, A., Herdewijn, P., Efimtseva, E.V., Ermolinsky, B.S., and Mikhailov, S.N. 1999. The mapping of T7 RNA polymerase active site with novel reagents—Oligonucleotides with reactive dialdehyde groups. FEBS Lett. 442:20-24. Vorbr¨uggen, H. and Ruh-Pohlenz, C. 2000. Synthesis of nucleosides. Org. React. 55:1-630.
Contributed by Sergey N. Mikhailov, Ekaterina V. Efimtseva, Andrei A. Rodionov, Georgii V. Bobkov, and Irina V. Kulikova Russian Academy of Sciences Engelhardt Institute of Molecular Biology Moscow, Russia Piet Herdewijn Rega Institute for Medical Research Leuven, Belgium
Synthesis of Modified Nucleosides
1.14.19 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Preparation of 2 -Deoxy-2 -MethylselenoModified Phosphoramidites and RNA
UNIT 1.15
This unit contains procedures for the preparation of RNA possessing site-specifically incorporated ribose 2 -deoxy-2 -methylseleno (2 -Se-methyl) groups. The unit begins with the preparation of 5 -O-DMTr-3 -phosphoramidites of 2 -deoxy-2 -methylselenouridine (see Basic Protocol 1), N4 -acetyl-2 -deoxy-2 -methylselenocytidine (see Alternate Protocol 1), N6 -acetyl-2 -deoxy-2 -methylselenoadenosine (see Alternate Protocol 2), and N2 acetyl-2 -deoxy-2 -methylselenoguanosine (see Alternate Protocol 3). Methods are also presented for solid-phase synthesis of oligoribonucleotides labeled with 2 -methylseleno groups using 2 -O-[(triisopropylsilyl)oxy]methyl (TOM) phosphoramidites (see Basic Protocol 2; also see UNITS 2.9 & 3.8), along with their deprotection and purification (see Basic Protocol 3). The final protocols describe enzymatic ligation of the oligonucleotides to produce biologically interesting RNA targets (see Basic Protocol 4 and Alternate Protocol 4). CAUTION: Carry out all operations involving organic solvents and reagents in a wellventilated fume hood, and wear gloves and protective glasses. Procedures involving trifluoromethanesulfonyl chloride and dimethyl diselenide should be performed only by personnel trained and experienced in organic synthesis. Standard precautions to prevent excessive exposure to toxic chemicals should be followed. All reactions should first be performed on a small scale.
PREPARATION OF 2 -DEOXY-2 -METHYLSELENOURIDINE PHOSPHORAMIDITE
BASIC PROTOCOL 1
This protocol describes the synthesis of 5 -O-(4,4 -dimethoxytrityl)-2 -deoxy-2 methylselenouridine 3 -O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite. The synthesis involves four steps: (1) transformation of uridine into 2,2 -anhydrouridine (S.1), (2) regioselective introduction of the 5 -O-DMTr-group to give S.2, (3) SN 2-ring opening by sodium methylselenide to produce S.3, and (4) 3 -OH phosphitylation using 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite to give S.4. These steps are illustrated in Figure 1.15.1.
Materials Diphenyl carbonate (Fluka) N,N-Dimethylformamide (DMF) Uridine (Fluka) Sodium bicarbonate (NaHCO3 ) Methanol (MeOH) Balloon of argon Anhydrous pyridine 4,4 -Dimethoxytrityl chloride (DMTr-Cl; Fluka) Dichloromethane (CH2 Cl2 ) 5% (w/v) citric acid solution in water Half-saturated sodium bicarbonate solution in water Sodium sulfate (Na2 SO4 ) Silica gel 60 (230 to 400 mesh; Fluka) Triethylamine (TEA) Anisaldehyde reagent (see recipe) Sodium borohydride (NaBH4 ; Fluka)
Synthesis of Modified Nucleosides
Contributed by Ronald Micura, Claudia H¨obartner, Renate Rieder, Christoph Kreutz, Barbara Puffer, Kathrin Lang, and Holger Moroder
1.15.1
Current Protocols in Nucleic Acid Chemistry (2006) 1.15.1-1.15.34 C 2006 by John Wiley & Sons, Inc. Copyright
Supplement 27
Figure 1.15.1 Preparation of a 2 -deoxy-2 -methylselenouridine phosphoramidite building block for RNA solid-phase synthesis (see Basic Protocol 1). DMF, N,N-dimethylformamide; DMTr, 4,4 -dimethoxytrityl.
Anhydrous tetrahydrofuran (THF) Dimethyl diselenide (Aldrich) 30% (v/v) H2 O2 solution Anhydrous ethanol 0.2 M triethylammonium acetate (TEAA) buffer, pH 7.0 Ethyl acetate Saturated aqueous sodium chloride (NaCl) solution N-Ethyldimethylamine (Fluka) 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite (Aldrich) Hexanes Chloroform (CHCl3 ) 25-mL two-neck round-bottom flask Reflux condenser Glass-fritted B¨uchner funnel (pore size 3) Filter paper (Macherey-Nagel MN 615) Vacuum oil pump (rotary vane vaccuum pump; for all steps requiring drying in vacuo) 50-mL one-neck round-bottom flasks equipped with rubber septa Rotary evaporator equipped with a membrane pump (for all evaporation steps) 250-, 500-, and 1000-mL separatory funnels 100-mL two-neck round-bottom flasks with rubber septa Glass filter tube 1- and 20-mL syringes and 21-G needles 500-µL Hamilton syringe Additional reagents and equipment for column chromatography (APPENDIX 3E) and TLC (APPENDIX 3D) 2 -MethylselenoModified Phosphoramidites and RNA
Prepare 2,2 -anhydrouridine 1. Prepare a stirred suspension of 1.92 g (9.0 mmol) diphenyl carbonate in 2.2 mL dry DMF in a 25-mL two-neck flask equipped with a condenser and stir bar.
1.15.2 Supplement 27
Current Protocols in Nucleic Acid Chemistry
2. Add 2.0 g (8.2 mmol) uridine and heat the slurry to 80◦ C with stirring. 3. Add 25 mg (0.3 mmol) NaHCO3 , heat to 120◦ C, and continue stirring for 3 to 4 hr. Gas evolution is observed and a clear solution is obtained from which the solid product soon precipitates.
4. Cool the solution to room temperature and isolate the precipitate by filtration using a glass-fritted B¨uchner funnel. Wash the precipitate with 15 mL MeOH. 5. Dry the resulting white powder 2 hr in vacuo using a vacuum oil pump. 2,2 -O-Anhydro-(β-D-arabinofuranosyl)uracil (S.1). Yield: 1.4 g (75%). TLC (85:15 CH2 Cl2 /MeOH): Rf 0.2. 1 H NMR (300 MHz, DMSO- d6 ): δ 3.17-3.28 (m, 2H, H5 ); 4.06 (m, 1H, H4 ); 4.37 (m, 1H, H3 ); 4.95 (triplettoid, 1H, 5 -OH); 5.18 (d, J = 6.2 Hz, 1H, H2 ); 5.84 (m, 2H, H5 + 3 -OH); 6.29 (d, J = 6.2 Hz, 1H, H1 ); 7.82 (d, J = 7.4 Hz, 1H, H6).
Protect 5 -hydroxy group 6. In a 50-mL one-neck flask equipped with a rubber septum, an argon-filled balloon, and a stir bar, suspend 1.0 g (4.4 mmol) S.1 in 10 mL dry pyridine. 7. Add 1.65 g (4.8 mmol) DMTr-Cl in three 0.55-g portions at 20-min intervals. Continue stirring at room temperature until a clear solution is obtained (4 to 6 hr). 8. Add 1.0 mL MeOH, stir for 30 min, and evaporate the solvents. 9. Dissolve the residue in 300 mL CH2 Cl2 . 10. Wash two times each with 200 mL of 5% citric acid, 200 mL water, and 200 mL of half-saturated sodium bicarbonate solution in a 1000-mL separatory funnel. 11. Dry the organic phase with 70 g Na2 SO4 , remove the solid by means of a glassfritted B¨uchner funnel and filter paper, and evaporate the filtrate to dryness. 12. Purify the residue on a chromatography column (APPENDIX 3E) containing 50 g of 230 to 400-mesh silica gel, using a solvent system of 2% to 10% (v/v) MeOH/1% (v/v) TEA in CH2 Cl2 . 13. Combine fractions containing product S.2 as determined by TLC (APPENDIX 3D) using 9:1 (v/v) CH2 Cl2 /MeOH as eluent and visualizing the product with anisaldehyde reagent. Evaporate and then coevaporate with 20 mL CH2 Cl2 . 14. Dry the residue in vacuo to obtain the product as a colorless foam. 2,2 -O-Anhydro-5 -O-(4,4 -dimethoxytrityl)-(β-D-arabinofuranosyl)uracil (S.2). Yield: 1.55 g (67%). TLC (9:1 CH2 Cl2 /MeOH): Rf 0.6. 1 H NMR (500 MHz, DMSO-d6 ): δ 2.80 (dd, J = 10.0, 7.5 Hz, 1H, H5 a); 2.93 (dd, J = 10.0, 4.0 Hz, 1H, H5 b); 3.72 (s, 6H, 2 × OCH3 ); 4.20 (m, 1H, H4 ); 4.29 (m, 1H, H3 ); 5.19 (d, J = 6.0 Hz, 1H, H2 ); 5.86 (d, J = 7.5 Hz, 1H, H5); 5.94 (s, br, 1H, 3 -OH); 6.31 (d, J = 6.0 Hz, 1H, H1 ); 6.82 (m, 4H, H-C(ar)); 7.12-7.28 (m, 9H, H-C(ar)); 7.93 (d, J = 7.5 Hz, 1H, H6).
Introduce 2 -methylseleno group 15. In a 100-mL two-neck round-bottom flask, place 430 mg (11.3 mmol) NaBH4 and a stir bar. 16. Attach a glass filter tube on the flask and connect a second 100-mL two-neck round-bottom flask on top (needed for filtration under inert conditions in step 20). Evacuate using a vacuum oil pump to deplete all oxygen, and expand argon into the apparatus from a balloon by injection through one of the rubber septa. 17. Using a 20-mL syringe and 21-G needle, inject 14 mL dry THF through the septum to suspend the NaBH4 .
Synthesis of Modified Nucleosides
1.15.3 Current Protocols in Nucleic Acid Chemistry
Supplement 27
18. Inject 0.36 mL (3.8 mmol) dimethyl diselenide through the septum using a 500-µL Hamilton syringe. Rinse the injection needle, syringe, and all glassware contaminated by the selenide reagent with 30% H2 O2 solution and collect the waste in a separate bottle.
19. Add anhydrous ethanol dropwise by injection through the septum until gas bubbles start to appear in the yellow mixture (requires ∼0.3 to 0.4 mL). Stir the solution for 1 hr at room temperature. The solution turns almost colorless when the reaction is complete.
20. Filter the solution under argon from remaining NaBH4 by cautiously turning the apparatus upside down and pressurizing via the argon balloon. Optionally, apply a soft vacuum on the second flask to accelerate the filtration process.
21. Via the septum, transfer the filtered solution into a 20-mL syringe and slowly inject it into a stirred solution of 1.0 g (1.89 mmol) S.2 in 20 mL dry THF under argon. 22. Monitor the reaction by TLC using 92:8 (v/v) CH2 Cl2 /MeOH. The reaction is usually complete after ∼1 to 2 hr.
23. Add 30 mL of aqueous 0.2 M TEAA buffer, pH 7.0. 24. Reduce the solution to half-volume by evaporation. 25. Dilute with 100 mL water and extract the product three times with 20 mL ethyl acetate. 26. Wash the combined ethyl acetate phases with 200 mL saturated NaCl solution. 27. Dry the organic phase with 20 g Na2 SO4 , remove the solid by means of a glassfritted B¨uchner funnel and filter paper, and evaporate the filtrate to dryness. 28. Purify the residue on a 40-g silica gel column using a solvent system of 1% to 2% (v/v) MeOH in CH2 Cl2 . 29. Combine the fractions containing the product S.3, as determined by TLC using 92:8 (v/v) CH2 Cl2 /MeOH. Evaporate and then coevaporate with 15 mL CH2 Cl2 . 30. Dry the residue in vacuo to obtain the product as a colorless foam. 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxy-2 -methylselenouridine (S.3). Yield: 1.08 g (92%). TLC (92:8 CH2 Cl2 /MeOH): Rf 0.75. 1 H NMR (300 MHz, CDCl3 ): δ 2.12 (s, 3H, SeCH3 ); 2.62 (d, J = 3.0 Hz, 1H, 3 -OH); 3.51-3.61 (m, 3H, 2 × H5 , H2 ); 3.81 (s, 6H, 2 × OCH3 ); 4.19 (m, 1H, H4 ); 4.39 (m, 1H, H3 ); 5.38 (d, J = 8.3 Hz, 1H, H5); 6.18 (d, J = 7.5 Hz, 1H, H1 ); 6.85 (m, 4H, H-C(ar)); 7.25-7.38 (m, 9H, H-C(ar)); 7.78 (d, J = 8.3 Hz, 1H, H6); 8.11 (s, br, 1H, NH). FTICR ESI-MS (m/z): calcd. for C31 H32 N2 O7 Se [M+Na]+ 647.12756, found 647.12756.
Prepare phosphoramidite 31. In a 50-mL one-neck flask equipped with a stir bar, a rubber septum, and an argon balloon, prepare a stirred mixture of 1.04 mL (9.6 mmol) N-ethyldimethylamine and 10 mL dry CH2 Cl2 . 32. Add 0.6 g (0.96 mmol) S.3 and dissolve.
2 -MethylselenoModified Phosphoramidites and RNA
33. Slowly add 340 mg (1.44 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite using a 1-mL syringe and continue stirring for 2 hr at room temperature.
1.15.4 Supplement 27
Current Protocols in Nucleic Acid Chemistry
34. Monitor the reaction by TLC using 7:3 (v/v) ethyl acetate/hexanes. The reaction is usually complete after 2 to 4 hr.
35. Add 0.4 mL MeOH to quench the excess phosphine. Continue stirring for 15 min. 36. Dilute the reaction mixture with 50 mL of CH2 Cl2 and wash with 40 mL of halfsaturated sodium bicarbonate solution. 37. Dry the organic phase with 10 g Na2 SO4 , remove the solid by means of a glassfritted B¨uchner funnel and filter paper, and evaporate the filtrate to dryness. 38. Purify the residue on a 14-g silica gel column using a solvent system of 50% to 70% (v/v) ethyl acetate/1% (v/v) TEA in hexanes. 39. Combine the fractions containing product S.4, as determined by TLC using 7:3 (v/v) ethyl acetate/hexanes. Evaporate and then coevaporate with 10 mL CHCl3 . 40. Dry the residue in vacuo to obtain the product as a colorless foam. 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxy-2 -methylselenouridine 3 -O-(2-cyanoethyl)-N,Ndiisopropylphosphoramidite (S.4). Yield: 0.74 g (93%; mixture of diastereoisomers). TLC (7:3 ethyl acetate/hexanes): Rf 0.6. 1 H NMR (500 MHz, CDCl3 ): δ 1.05-1.28 (m, 24H, ((CH3 )2 CH)2 N); 2.04, 2.08 (2s, 6H, SeCH3 ); 2.37, 2.62 (2m, 4H, CH2 CN); 3.413.69 (m, 10H, ((CH3 )2 CH)2 N, POCH2 , 2 × H5 ); 3.79 (2s, 12H, 2 × OCH3 ); 3.90, 3.93 (2m, 2H, POCH2 ); 4.24, 4.30 (2m, 2H, H4 ); 4.63, 4.68 (2m, 2H, H3 ); 5.25, 5.31 (2d, 2H, J = 8.0 Hz, H5); 6.33 (d, J = 6.8 Hz, 2H, H1 ); 6.84 (m, 8H, H-C(ar)); 7.24-7.37 (m, 18H, H-C(ar)); 7.80 (d, 2H, J = 8.0 Hz, H6); 8.36 (s, br, 2H, NH). 31 P NMR (121 MHz, CDCl3 ): δ 151.1, 151.9. FTICR ESI-MS (m/z): calcd. for C40 H49 N4 O8 PSe [M+Na]+ 847.23560, found 847.23285; calcd [M+K]+ 863.20954, found 863.20837.
PREPARATION OF 2 -DEOXY-2 -METHYLSELENOCYTIDINE PHOSPHORAMIDITE
ALTERNATE PROTOCOL 1
This protocol describes the synthesis of N4 -acetyl-5 -O-(4,4 -dimethoxytrityl)-2 deoxy-2 -methylselenocytidine 3 -O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite. The synthesis starts from the uridine precursor S.3 (see Basic Protocol 1) and proceeds in six steps: (1) 3 -OH silylation of S.3 to give S.5, (2) O4 -sulfonation to S.6, (3) NH3 -mediated conversion of S.6 to S.7, (4) N4 -acetylation to give S.8, (5) 3 O-desilylation to give S.9, and (6) 3 -OH phosphitylation using 2-cyanoethyl-N,Ndiisopropylchlorophosphoramidite to give S.10. These steps are illustrated in Figure 1.15.2.
Additional Materials (also see Basic Protocol 1) S.3 (see Basic Protocol 1) Imidazole (Fluka) tert-Butyldimethylsilyl chloride (TBDMS-Cl; Fluka) 4-(N,N-Dimethylamino)pyridine (DMAP; Fluka) 2,4,6-Triisopropylbenzenesulfonyl chloride (TPS-Cl; Fluka) Saturated sodium bicarbonate solution in water 32% (v/v) aqueous ammonia Acetic anhydride (Fluka) Tetrabutylammonium fluoride trihydrate (TBAF; Fluka) Acetic acid (AcOH) 25-mL one-neck round-bottom flasks equipped with rubber septa Protect 3 -hydroxyl group of S.3 1. In a 50-mL one-neck flask equipped with a stir bar, a rubber septum, and an argon balloon, dissolve 1.0 g (1.60 mmol) S.3 in 8 mL DMF.
Synthesis of Modified Nucleosides
1.15.5 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Figure 1.15.2 Preparation of a 2 -deoxy-2 -methylselenocytidine phosphoramidite building block for RNA solid-phase synthesis (see Alternate Protocol 1). DMAP, 4-(N,N-dimethylamino)pyridine; DMF, N,N-dimethylformamide; DMTr, 4,4 dimethoxytrityl; TBAF, tetra-n-butylammonium fluoride; TBDMS, tert-butyldimethylsilyl; THF, tetrahydrofuran; TPS, 2,4,6triisopropylbenzenesulfonyl.
2. While stirring, add 0.44 g (6.40 mmol) imidazole and then 0.48 g (3.20 mmol) TBDMS-Cl. Keep stirring for 18 hr at room temperature. 3. Evaporate the solvents and precipitate the product from the resulting oil by adding 35 mL water. 4. Isolate the precipitate by filtration on a glass-fritted B¨uchner funnel with filter paper. Wash the precipitate with 20 mL water and 20 mL hexanes, and dry in vacuo using a vacuum oil pump.
2 -MethylselenoModified Phosphoramidites and RNA
3-O-tert-Butyldimethylsilyl-5-O-(4,4-dimethoxytrityl)-2-deoxy-2 -methylselenouridine (S.5). Yield: 1.12 g (95%). TLC (98:2 CH2 Cl2 /MeOH): Rf 0.65. UV (MeOH): λ(ε) 260 (11600) nm (L mol−1 cm−1 ). 1 H NMR (300 MHz, CDCl3 ): δ −0.02 (s, 3H, SiCH3 ); 0.12 (s, 3H, SiCH3 ); 0.86 (s, 9H, SiC(CH3 )3 ); 2.04 (s, 3H, SeCH3 ); 3.38 (dd, J = 11.0, 2.3 Hz, 1H, H5 a); 3.47 (m, 1H, H2 ); 3.56 (dd, J = 11.0, 3.0 Hz, 1H, H5 b); 3.81 (s, 6H, 2 × OCH3 ); 4.09 (m, 1H, H4 ); 4.48 (m, 1H, H3 ); 5.33 (d, J = 8.3 Hz, 1H, H5); 6.34 (d, J = 7.1 Hz, 1H, H1 ); 6.85 (d, J = 8.7 Hz, 4H, H-C(ar)); 7.25-7.38 (m, 9H, H-C(ar)); 7.88 (d, J = 8.3 Hz, 1H, H6); 7.95 (s, br, 1H, NH). 13 C NMR (75 MHz, CDCl3 ): δ −4.8 (SiCH3 ); −4.7 (SiCH3 ); 3.3 (SeCH3 ); 18.1 (SiC(CH3 )3 ); 25.7 (SiC(CH3 )3 ); 48.6 (C2 ); 55.2 (OCH3 ); 62.4 (C5 ); 73.5 (C3 ); 85.6 (C4 ); 87.3; 90.0 (C1 ); 102.5 (C5); 113.3 (C(ar)); 127.2, 128.0, 128.2, 130.1 (C(ar)); 134.9, 135.1, 140.2 (C6); 144.0, 150.3, 158.8, 163.1. FTICR ESI-MS (m/z): calcd. for C37 H46 N2 O7 SeSi [M+Na]+ 761.21421, found 761.21496.
1.15.6 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Sulfonate O4 and displace adduct with ammonia 5. In a 50-mL one-neck flask equipped with a stir bar, a rubber septum, and an argon balloon, dissolve 1.0 g (1.36 mmol) S.5, 20 mg (0.16 mmol) DMAP, and 1.9 mL (13.6 mmol) TEA in 10 mL dry CH2 Cl2 . 6. Slowly add 0.62 g (2.04 mmol) 2,4,6-triisopropylbenzenesulfonyl chloride and stir for 1 hr at room temperature. 7. Dilute the reaction mixture with 100 mL CH2 Cl2 and wash with 80 mL saturated sodium bicarbonate solution. 8. Dry over 20 g Na2 SO4 , remove the solid by means of a glass-fritted B¨uchner funnel and filter paper, and evaporate the solvents. 9. Dry the resulting intermediate S.6 (yellow foam) for 1 hr in vacuo using a vacuum oil pump. 10. Dissolve S.6 in 20 mL THF, add 30 mL of 32% aqueous ammonia, and stir overnight at room temperature. 11. Evaporate the solvents and purify the residue on a chromatography column (APPENDIX 3E) containing 40 g silica gel, using a solvent system of 2% to 8% (v/v) MeOH in CH2 Cl2 . 12. Combine the fractions containing product S.7, as determined by TLC (APPENDIX 3D) using 95:5 (v/v) CH2 Cl2 /MeOH. Evaporate on a rotary evaporator and then coevaporate with 10 mL CH2 Cl2 . 13. Dry the residue in vacuo using a vacuum oil pump to obtain the product as a colorless foam. 3-O-tert-Butyldimethylsilyl-5-O-(4,4-dimethoxytrityl)-2-deoxy-2 -methylselenocytidine (S.7). Yield: 0.79 g (79%). TLC (95:5 CH2 Cl2 /MeOH): Rf 0.45. UV (MeOH): λ(ε) 260 (10300) nm (L mol−1 cm−1 ). 1 H NMR (300 MHz, CDCl3 ): δ −0.08 (s, 3H, SiCH3 ); 0.08 (s, 3H, SiCH3 ); 0.81 (s, 9H, SiC(CH3 )3 ); 2.13 (s, 3H, SeCH3 ); 3.30 (dd, J = 2.3, 10.5 Hz, 1H, H5 a); 3.58 (m, 1H, H2 ); 3.63 (dd, J = 3.0, 10.5 Hz, 1H, H5 b); 3.80 (s, 6H, 2 × OCH3 ); 4.14 (m, 1H, H4 ); 4.46 (m, 1H, H3 ); 5.30 (d, J = 7.5 Hz, 1H, H5); 6.38 (d, J = 3.9 Hz, 1H, H1 ); 6.84 (d, J = 7.6 Hz, 4H, H-C(ar)); 7.26-7.40 (m, 9H, H-C(ar)); 8.12 (d, J = 7.5 Hz, 1H, H6). 13 C NMR (75 MHz, CDCl3 ): δ −4.9 (SiCH3 ); −4.7 (SiCH3 ); 3.1 (SeCH3 ); 18.1 (SiC(CH3 )3 ); 25.7 (SiC(CH3 )3 ); 49.1 (C2 ); 55.3 (OCH3 ); 61.9 (C5 ); 72.1 (C3 ); 84.6 (C4 ); 87.0; 90.7 (C1 ); 94.9 (C5); 113.2, 113.3 (C(ar)); 127.1, 127.9, 128.3, 130.2 (C(ar)); 135.3, 135.3; 141.2 (C(6)); 144.3, 158.8, 165.4. FTICR ESI-MS (m/z): calcd. for C37 H47 N3 O6 SeSi [M+Na]+ 760.23018, found 760.22880.
Acetylate N4 14. In a 25-mL one-neck flask equipped with a stir bar, a rubber septum, and an argon balloon, dissolve 0.4 g (0.54 mmol) S.7 in 1.0 mL dry pyridine and cool to 0◦ C. 15. Add 130 µL (136 mmol) acetic anhydride, allow solution to warm up to room temperature, and stir for 45 min. 16. Quench the reaction by adding 0.6 mL MeOH and evaporate the solvents. 17. Dissolve the oily residue in 100 mL CH2 Cl2 . 18. Wash two times each with 50 mL of 5% citric acid, 50 mL water, and 50 mL saturated sodium bicarbonate solution. 19. Dry over 15 g Na2 SO4 , remove the solid by means of a glass-fritted B¨uchner funnel and filter paper, and evaporate the solvents.
Synthesis of Modified Nucleosides
1.15.7 Current Protocols in Nucleic Acid Chemistry
Supplement 27
20. Purify the residue on a 16-g silica gel column using a solvent system of 1% to 5% (v/v) MeOH in CH2 Cl2 . 21. Combine the fractions containing product S.8, as determined by TLC using 97:3 (v/v) CH2 Cl2 /MeOH. Evaporate and then coevaporate with 5 mL CH2 Cl2 . 22. Dry the residue in vacuo to obtain the product as a colorless foam. N4 -Acetyl-3 -O-tert-butyldimethylsilyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxy-2 -methylselenocytidine (S.8). Yield: 0.39 g (94%). TLC (97:3 CH2 Cl2 /MeOH): Rf 0.65. UV (MeOH): λ(ε) 272 (6000), 300 (5800) nm (L mol−1 cm−1 ). 1 H NMR (300 MHz, CDCl3 ): δ −0.06 (s, 3H, SiCH3 ); 0.08 (s, 3H, SiCH3 ); 0.82 (s, 9H, SiC(CH3 )3 ); 2.15 (s, 3H, SeCH3 ); 2.27 (s, 3H, COCH3 ); 3.38 (dd, J = 2.0, 10.5 Hz, 1H, H5 a); 3.58 (m, 1H, H2 ); 3.67 (dd, J = 2.0, 10.5 Hz, 1H, H5 b); 3.82 (s, 6H, 2 × OCH3 ); 4.20 (m, 1H, H4 ); 4.44 (m, 1H, H3 ); 6.39 (d, J = 3.9 Hz, 1H, H1 ); 6.86 (d, J = 8.0 Hz, 4H, H-C(ar)); 7.08 (d, J = 7.5 Hz, 1H, H5); 7.28-7.40 (m, 9H, H-C(ar)); 8.47 (d, J = 7.5 Hz, 1H, H6); 10.37 (s, br, 1H, NH). 13 C NMR (75 MHz, CDCl3 ): δ −5.0 (SiCH3 ); −4.7 (SiCH3 ); 3.2 (SeCH3 ); 18.0 (SiC(CH3 )3 ); 24.8 (COCH3 ); 25.6 (SiC(CH3 )3 ); 49.3 (C2 ); 55.2 (OCH3 ); 61.5 (C5 ); 71.7 (C3 ); 85.0 (C4 ); 87.2; 91.1 (C1 ); 97.0 (C5); 113.3 (C(ar)); 127.3, 128.0, 128.3, 130.2 (C(ar)); 135.0, 135.1, 143.9; 144.7 (C6); 155.1, 158.8, 163.1, 171.0. FTICR ESI-MS (m/z): calcd. for C39 H49 N3 O7 SeSi [M+Na]+ 802.24080, found 802.24121.
Deprotect 3 -hydroxyl group 23. In a 25-mL one-neck flask equipped with a stir bar, a rubber septum, and an argon balloon, dissolve 0.41 g (0.52 mmol) S.8 in 1.0 mL of 1 M TBAF/0.5 M AcOH in THF. Stir for 2.5 hr at room temperature. 24. Evaporate the solvents and purify the residue on a 14-g silica gel column using a solvent system of 2% to 6% (v/v) MeOH in CH2 Cl2 . 25. Combine the fractions containing product S.9, as determined by TLC using 97:3 (v/v) CH2 Cl2 /MeOH. Evaporate and then coevaporate with 5 mL CH2 Cl2 . 26. Dry the residue in vacuo to obtain the product as colorless foam. N4 -Acetyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxy-2 -methylselenocytidine (S.9). Yield: 0.30 g (87 %). TLC (97:3 CH2 Cl2 /MeOH): Rf 0.40. UV (MeOH): λ(ε) 272 (7200), 300 (7400) nm (L mol−1 cm−1 ). 1 H NMR (300 MHz, CDCl3 ): δ 2.17 (s, 3H, SeCH3 ); 2.19 (s, 3H, COCH3 ); 3.00 (s, br, 1H, 3 -OH); 3.54 (2dd, J = 3.0, 11.3 Hz, 2H, H5 ); 3.66 (m, 1H, H2 ); 3.81 (s, 6H, 2 × OCH3 ); 4.15 (m, 1H, H4 ); 4.39 (m, 1H, H3 ); 6.30 (d, J = 4.5 Hz, 1H, H1 ); 6.86 (d, J = 9.2 Hz, 4H, H-C(ar)); 7.14 (d, J = 7.5 Hz, 1H, H5); 7.26-7.42 (m, 9H, H-C(ar)); 8.30 (d, J = 7.5 Hz, 1H, H6); 9.48 (s, br, 1H, NH). 13 C NMR (75 MHz, CDCl3 ): δ 4.6 (SeCH3 ); 24.7 (COCH3 ); 51.5 (C2 ); 55.2 (OCH3 ); 62.2 (C5 ); 70.0 (C3 ); 84.4 (C4 ); 87.2; 90.2 (C1 ); 97.0 (C5); 113.4 (C(ar)); 127.2, 128.0, 128.1, 130.1 (C(ar)); 135.2, 135.4, 144.2; 144.5 (C6); 155.3, 158.8, 162.9, 170.8. FTICR ESI-MS (m/z): calcd. for C33 H35 N3 O7 Se [M+H]+ 666.17217, found 666.17208; calcd. [M+Na]+ 688.15414, found 688.15344.
Prepare phosphoramidite 27. Apply Basic Protocol 1, steps 31 to 40, to 0.64 g (0.96 mmol) S.9. For column purification of S.10, use 14 g silica gel and a solvent system of 70% (v/v) ethyl acetate/1% (v/v) TEA in hexanes.
2 -MethylselenoModified Phosphoramidites and RNA
N4 -Acetyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxy-2 -methylselenocytidine 3 -O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (S.10). Yield: 0.68 g (82%; mixture of diastereoisomers). TLC (96:4 CH2 Cl2 /MeOH): Rf 0.55. UV (MeOH): λ(ε) 274 (7830), 300 (7950) nm (L mol−1 cm−1 ). 1 H NMR (500 MHz, CDCl3 ): δ 0.98-1.25 (m, 24H, ((CH3 )2 CH)2 N); 2.11 (s, 6H, COCH3 ); 2.15, 2.17 (2s, 6H, SeCH3 ); 2.33, 2.59 (2m, 4H, CH2 CN); 3.41-3.70 (m, 12H, ((CH3 )2 CH)2 N, POCH2 , 2 × H5 , H2 ); 3.78 (2s, 12H, 2 × OCH3 ); 3.80-3.93 (m, 2H, POCH2 ); 4.29 (m, 2H, H4 ); 4.55, 4.61 (2m, 2H, H3 ); 6.36 (m, 2H, H1 ); 6.81 (m, 8H, H-C(ar)); 6.89, 6.95 (2d, br, 2H, H5); 7.22-7.37 (m,
1.15.8 Supplement 27
Current Protocols in Nucleic Acid Chemistry
18H, H-C(ar)); 8.30 (m, 2H, H6); 8.78 (s, br, 2H, NH). 31 P NMR (121 MHz, CDCl3 ): δ 151.23, 151.49. FTICR ESI-MS (m/z): calcd. for C42 H52 N5 O8 PSe [M+H]+ 866.28022, found 866.27866.
PREPARATION OF 2 -DEOXY-2 -METHYLSELENOADENOSINE PHOSPHORAMIDITE
ALTERNATE PROTOCOL 2
This protocol describes the synthesis of N6 -acetyl-5 -O-(4,4 -dimethoxytrityl)-2 deoxy-2 -methylselenoadenosine 3 -O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (S.17). The synthesis starts from the precursor 5 -O-(4,4 -dimethoxytrityl)-3 -O{[(triisopropylsilyl)oxy]methyl}adenosine S.11 (Pitsch et al., 2001; also see UNITS 2.9 & 3.8) and proceeds in six steps: (1) triflation of the 2 -hydroxyl group to give S.12, (2) SN 2-displacement of the 2 -O-triflate ester by potassium trifluoroacetate to produce S.13, (3) 2 -OH activation to S.14, (4) SN 2-displacement of the 2 -O-triflate ester by sodium methylselenide to give S.15, (5) fluoride-assisted removal of the 3 OTOM group to give S.16, and (6) 3 -OH phosphitylation using 2-cyanoethyl-N,Ndiisopropylchlorophosphoramidite to give S.17. These steps are illustrated in Figure 1.15.3.
Figure 1.15.3 Preparation of a 2 -deoxy-2 -methylselenoadenosine phosphoramidite building block for RNA solid-phase synthesis (see Alternate Protocol 2). DMAP, 4-(N,N-dimethylamino)pyridine; DMTr, 4,4 -dimethoxytrityl; TBAF, tetra-nbutylammonium fluoride; Tf, trifluoromethanesulfonyl; THF, tetrahydrofuran; TOM, [(triisopropylsilyl)oxy]methyl. Synthesis of Modified Nucleosides
1.15.9 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Additional Materials (also see Basic Protocol 1) 5 -O-(4,4 -Dimethoxytrityl)-3 -O-{[(triisopropylsilyl)oxy]methyl}adenosine (S.11; Pitsch et al., 2001; UNIT 2.9) 4-(N,N-Dimethylamino)pyridine (DMAP; Fluka) Trifluoromethanesulfonyl chloride (Tf-Cl; Fluka) Saturated sodium bicarbonate solution in water Anhydrous toluene N-Ethyldiisopropylamine (Fluka) Potassium trifluoroacetate (Fluka) 18-Crown-6-ether (Fluka) Tetrabutylammonium fluoride trihydrate (TBAF; Fluka) Acetic acid (AcOH) 25- and 100-mL one-neck round-bottom flasks equipped with rubber septa Activate 2 -hydroxyl group 1. In a 100-mL one-neck flask equipped with a stir bar, a rubber septum, and an argon balloon, dissolve 1.46 g (1.82 mmol) S.11, 334 mg (2.74 mmol) DMAP, and 635 µL (4.56 mmol) TEA in 35 mL dry CH2 Cl2 . 2. Cool the stirred solution to 0◦ C, then slowly add 289 µL (2.74 mmol) Tf-Cl. Continue stirring for 20 min at room temperature. 3. Dilute the reaction mixture with 250 mL CH2 Cl2 and wash with 250 mL saturated sodium bicarbonate solution. 4. Dry over 40 g Na2 SO4 , remove the solid using a glass-fritted B¨uchner funnel and filter paper, and evaporate the solvents. 5. Purify the residue on a chromatography column (APPENDIX 3E) containing 35 g silica gel, using a solvent system of 0.5% (v/v) MeOH in CH2 Cl2 . 6. Combine the fractions containing product S.12, as determined by TLC (APPENDIX 3D) using 94:6 (v/v) CH2 Cl2 /MeOH. Evaporate and then coevaporate with 15 mL CH2 Cl2 . 7. Dry the residue in vacuo to obtain the product as a colorless foam. N6 -Acetyl-5 -O-(4,4 -dimethoxytrityl)-2 -O-trifluoromethanesulfonyl-3 -O-{[(triisopropylsilyl)oxy]methyl}adenosine (S.12). Yield: 1.02 g (60%). TLC (94:6 CH2 Cl2 /MeOH): Rf 0.51. 1 H NMR (300 MHz, CDCl3 ): δ 1.02 (m, 21H, (iPr)3 Si); 2.65 (s, 3H, COCH3 ); 3.40 (dd, J = 3.9, 10.8 Hz, 1H, H5 a); 3.62 (dd, J = 2.7, 10.8 Hz, 1H, H5 b); 3.79 (s, 6H, 2 × OCH3 ); 4.51 (m, 1H, H4 ); 4.89 (m, 1H, H3 ); 4.96 (d, J = 5.0 Hz, 1H, OCH2 O); 5.11 (d, J = 5.0 Hz, 1H, OCH2 O); 6.21 (m, 1H, H2 ); 6.36 (d, J = 5.1 Hz, 1H, H1 ); 6.80 (d, J = 8.7 Hz, 4H, H-C(ar)); 7.28 (m, 7H, H-C(ar)); 7.40 (m, 2H, H-C(ar)); 8.10 (s, 1H, H8); 8.57 (s, 1H, H2); 8.68 (s, 1H, HN6 ). 13 C NMR (75 MHz, CDCl3 ): δ 11.8 (SiCH(CH3 )2 ); 17.7 (SiCH(CH3 )2 ); 25.6 (COCH3 ); 55.1 (OCH3 ); 62.6 (C5 ); 74.4 (C3 ); 83.3 (C4 ); 84.2 (C2 ); 85.6 (C1 ); 86.9; 89.9 (OCH2 O); 113.2, 122.0, 127.0, 127.8, 128.1, 130.0, 130.1, 135.2, 135.3 (C(ar)); 141.4 (C8); 144.2, 149.4, 150.8 (C(ar)); 152.6 (C2); 158.7 (C(ar)); 170.3 (COCH3 ). ESI-MS (m/z): [M+H]+ calcd. for C44 H54 F3 N5 O10 SSi, 930.1, found 929.5.
Perform inversion of configuration at C2 8. In a 100-mL two-neck flask equipped with a stir bar, a rubber septum, a reflux condenser, and an argon balloon, dissolve 1.02 g (1.10 mmol) S.12 in 50 mL dry toluene. 2 -MethylselenoModified Phosphoramidites and RNA
9. Add 470 µL (2.74 mmol) N-ethyldiisopropylamine, 1.39 g (9.12 mmol) potassium trifluoroacetate, and 965 mg (3.65 mmol) 18-crown-6-ether, and stir the reaction mixture 11 hr at 80◦ C.
1.15.10 Supplement 27
Current Protocols in Nucleic Acid Chemistry
10. Evaporate the solvents, dissolve the residue in 200 mL CH2 Cl2 , and wash with 150 mL of half-saturated sodium bicarbonate. 11. Dry over 30 g Na2 SO4 , remove the solid using a glass-fritted B¨uchner funnel and filter paper, and evaporate again. 12. Purify the residue on a 40-g silica gel column using a solvent system of 0.2% to 1.0% (v/v) MeOH in CH2 Cl2 . 13. Combine the fractions containing product S.13, as determined by TLC using 92:8 (v/v) CH2 Cl2 /MeOH. Evaporate and then coevaporate with 10 mL CH2 Cl2 . 14. Dry the residue in vacuo to obtain the product as sligthly yellow foam. N6 -Acetyl-5 -O-(4,4 -dimethoxytrityl)-3 -O-[(triisopropylsilyl)oxy]methyl-(-D-arabinofuranosyl)adenine (S.13). Yield: 0.79 g (89%). TLC (92:8 CH2 Cl2 /MeOH): Rf 0.50. 1 H NMR (300 MHz, CDCl3 ): δ 1.09 (m, 21H, (iPr)3 Si); 2.63 (s, 3H, COCH3 ); 3.42 (dd, J = 3.5, 10.7 Hz, 1H, H5 a); 3.66 (dd, J = 2.6, 10.7 Hz, 1H, H5 b); 3.80 (s, 6H, 2 × OCH3 ); 4.25 (m, 1H, H4 ); 4.41 (m, 2H, H3 , 2 -OH); 4.48 (m, 1H, H2 ); 4.96 (d, J = 5.3 Hz, 1H, OCH2 O); 5.05 (d, J = 5.3 Hz, 1H, OCH2 O); 6.42 (d, J = 3.9 Hz, 1H, H1 ); 6.84 (d, J = 8.4 Hz, 4H, H-C(ar)); 7.27 (m, 7H, H-C(ar)); 7.42 (d, J = 6.9 Hz, 2H, H-C(ar)); 8.43 (s, 1H, H8); 8.66 (s, 1H, H2); 8.71 (s, 1H, HN6 ). 13 C NMR (75 MHz, CDCl3 ): δ 11.9 (SiCH(CH3 )2 ); 17.7 (SiCH(CH3 )2 ); 25.5 (COCH3 ); 55.2 (OCH3 ); 63.2 (C5 ); 74.8 (C2 ); 81.9 (C4 ); 82.8 (C3 ); 84.9 (C1 ); 87.6; 89.6 (OCH2 O); 113.3, 121.4, 127.1, 128.0, 128.2, 130.07, 130.12, 135.0, 135.2 (C(ar)); 142.7 (C8); 143.8, 149.0, 151.2 (C(ar)); 152.2 (C2); 158.7 (C(ar)); 170.3 (COCH3 ). UV (MeOH): λmax 271 nm. ESI-MS (m/z): [M+H]+ calcd. for C43 H55 N5 O8 Si, 798.0, found 797.5.
Activate 2 -hydroxyl group 15. In a 50-mL one-neck flask equipped with a stir bar, a rubber septum, and an argon balloon, dissolve 0.45 g (0.56 mmol) S.13, 104 mg (0.86 mmol) DMAP, and 196 µL (1.42 mmol) TEA in 12 mL of dry CH2 Cl2 . 16. Cool the stirred solution to 0◦ C, slowly add 90 µL (0.86 mmol) Tf-Cl, and continue stirring for 20 min at room temperature. 17. Dilute the reaction mixture with 120 mL CH2 Cl2 and wash with 80 mL saturated sodium bicarbonate solution. 18. Dry over 15 g Na2 SO4 , remove the solid using a glass-fritted B¨uchner funnel and filter paper, and evaporate the solvent. The product can be used without further purification for the next step. For analysis, the product was purified by silica gel column chromatography using a solvent system of 0.1% to 0.6% (v/v) MeOH in CH2 Cl2 . N6 -Acetyl-5-O-(4,4-dimethoxytrityl)-2 -O-trifluoromethanesulfonyl-3 -O-[(triisopropylsilyl)oxy]methyl-(β-D-arabinofuranosyl)adenine (S.14). Yield: 0.51 g (98%). TLC (94:6 CH2 Cl2 /MeOH): Rf 0.51. 1 H NMR (300 MHz, CDCl3 ): δ 1.07 (m, 21H, (iPr)3 Si); 2.65 (s, 3H, COCH3 ); 3.52 (m, 2H, H5 ); 3.81 (s, 6H, 2 × OCH3 ); 4.34 (m, 1H, H4 ); 4.72 (m, 1H, H3 ); 5.04 (s, 2H, OCH2 O); 5.53 (m, 1H, H2 ); 6.60 (d, J = 3.3 Hz, 1H, H1 ); 6.85 (d, J = 8.7 Hz, 4H, H-C(ar)); 7.29 (m, 7H, H-C(ar)); 7.48 (d, J = 7.2 Hz, 2H, H-C(ar)); 8.10 (s, 1H, H8); 8.62 (s, 1H, HN6 ); 8.67 (s, 1H, H2). 13 C NMR (75 MHz, CDCl3 ): δ 11.8 (SiCH(CH3 )2 ); 17.7 (SiCH(CH3 )2 ); 25.6 (COCH3 ); 55.2 (OCH3 ); 62.7 (C5 ); 80.5 (C4 ); 82.9 (C3 ); 83.2 (C1 ); 86.3 (C2 ); 86.6; 89.5 (OCH2 O); 113.2, 121.2, 126.9, 127.9, 128.0, 130.0, 135.49, 135.53, (C(ar)); 141.1 (C8); 144.4, 149.2, 150.5 (C(ar)); 152.6 (C2); 158.7 (C(ar)); 170.2 (COCH3 ). UV (MeOH): λmax 270 nm. ESI-MS (m/z): [M+H]+ calcd. for C44 H54 F3 N5 O10 SSi 930.1, found 929.5. Synthesis of Modified Nucleosides
1.15.11 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Introduce 2 -methylseleno group 19. Apply Basic Protocol 1, steps 15 to 24, for 1.79 g (1.89 mmol) S.14 in place of S.2. 20. Dilute with 200 mL water and extract the product three times with 100 mL CH2 Cl2 . 21. Wash the combined CH2 Cl2 phases with 200 mL of 0.2 M TEAA solution and then with 200 mL saturated NaCl solution. 22. Dry the organic phase with 30 g Na2 SO4 , filter using a glass-fritted B¨uchner funnel and filter paper, and evaporate the filtrate to dryness. 23. Purify the residue on a 50-g silica gel column using a solvent system of 0.2% to 1.0% (v/v) MeOH in CH2 Cl2 . 24. Combine the fractions containing product S.15, as determined by TLC using 94:6 (v/v) CH2 Cl2 /MeOH. Evaporate and then coevaporate with 10 mL CH2 Cl2 . 25. Dry the residue in vacuo to obtain the product as a colorless foam. N6 -Acetyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxy-2 -methylseleno-3 -O-{[(triisopropylsilyl)oxy]methyl}adenosine (S.15). Yield: 0.81 g (49%). TLC (94:6 CH2 Cl2 /MeOH): Rf 0.45. 1 H NMR (300 MHz, CDCl3 ): δ 1.08 (m, 21H, (iPr)3 Si); 1.69 (s, 3H, SeCH3 ); 2.64 (s, 3H, COCH3 ); 3.44 (dd, J = 4.4, 10.4 Hz, 1H, H5 a); 3.50 (dd, J = 4.2, 10.4 Hz, 1H, H5 b); 3.80 (s, 6H, 2 × OCH3 ); 4.38 (m, 1H, H2 ); 4.51 (m, 1H, H4 ); 4.56 (m, 1H, H3 ); 5.01 (d, J = 5.1 Hz, 1H, OCH2 O); 5.09 (d, J = 5.1 Hz, 1H, OCH2 O); 6.36 (d, J = 8.4 Hz, 1H, H1 ); 6.81 (d, J = 8.4 Hz, 4H, H-C(ar)); 7.28 (m, 7H, H-C(ar)); 7.46 (d, J = 6.6 Hz, 2H, H-C(ar)); 8.11 (s, 1H, H8); 8.56 (s, 1H, H2); 8.62 (s, 1H, HN6 ). 13 C NMR (75 MHz, CDCl3 ): δ 3.5 (SeCH3 ); 11.9 (SiCH(CH3 )2 ); 17.8 (SiCH(CH3 )2 ); 25.6 (COCH3 ); 45.0 (C2 ); 55.1 (OCH3 ); 63.6 (C5 ); 79.8 (C3 ); 84.5 (C4 ); 86.6; 89.8 (OCH2 O); 91.1 (C1 ); 113.1, 122.2, 126.9, 127.8, 128.2, 130.07, 130.10, 135.66, 135.70 (C(ar)); 142.0 (C8); 144.6, 149.2, 151.3 (C(ar)); 152.3 (C2); 158.6 (C(ar)); 170.3 (COCH3 ). UV (MeOH): λmax 276 nm. ESI-MS (m/z): [M+H]+ calcd. for C44 H57 N5 O7 SeSi 875.0, found 875.5.
Deprotect 3 -hydroxyl group 26. In a 25-mL one-neck flask equipped with a stir bar, a rubber septum, and an argon balloon, dissolve 0.68 g (0.78 mmol) S.15 in 3.4 mL of 1 M TBAF/0.5 M AcOH in THF and stir for 2.5 hr at room temperature. 27. Evaporate the solvents and purify the residue on a 40-g silica gel column using a solvent system of 0.5% to 2.0% (v/v) MeOH in CH2 Cl2 . 28. Combine the fractions containing product S.16, as determined by TLC using 92:8 (v/v) CH2 Cl2 /MeOH. Evaporate and then coevaporate with 5 mL CH2 Cl2 . 29. Dry the residue in vacuo to obtain the product as colorless foam.
2 -MethylselenoModified Phosphoramidites and RNA
N6 -Acetyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxy-2 -methylselenoadenosine (S.16). Yield: 0.44 g (82%). TLC (92:8 CH2 Cl2 /MeOH): Rf 0.49. 1 H NMR (300 MHz, CDCl3 ): δ 1.95 (s, 3H, SeCH3 ); 2.63 (s, 3H, COCH3 ); 2.90 (s, br, 1H, 3 -OH); 3.45 (dd, J = 4.2, 10.5 Hz, 1H, H5 a); 3.53 (dd, J = 4.4, 10.5 Hz, 1H, H5 b); 3.80 (s, 6H, 2 OCH3 ); 4.34 (m, 1H, H4 ); 4.41 (m, 1H, H2 ); 4.50 (m, 1H, H3 ); 6.22 (d, J = 8.7 Hz, 1H, H1 ); 6.82 (d, J = 8.7 Hz, 4H, H-C(ar)); 7.28 (m, 7H, H-C(ar)); 7.45 (d, J = 1.5 Hz, 2H, H-C(ar)); 8.12 (s, 1H, H8); 8.58 (s, 1H, H2); 8.79 (s, 1H, HN6 ). 13 C NMR (75 MHz, CDCl3 ): δ 4.5 (SeCH3 ); 25.6 (COCH3 ); 48.8 (C2 ); 55.2 (OCH3 ); 63.6 (C5 ); 72.6 (C3 ); 85.1 (C4 ); 86.7; 88.8 (C1 ); 113.2, 122.2, 127.0, 127.8, 128.1, 130.0, 135.7 (C(ar)); 141.9 (C8); 144.5, 149.2, 151.3 (C(ar)); 152.3 (C2); 158.6 (C(ar)); 170.4 (COCH3 ). UV (MeOH): λmax 271 nm. FTICR ESI-MS (m/z): [M+H]+ calcd. for C34 H35 N5 O6 Se 690.18341, found 690.18238.
1.15.12 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Prepare phosphoramidite 30. Apply Basic Protocol 1, steps 31 to 40, to 0.66 g (0.96 mmol) S.16. For column purification of S.17, use 14 g silica gel and a solvent system of 50% to 70% (v/v) ethyl acetate/1% (v/v) TEA in hexanes. N6 -Acetyl-5-O-(4,4-dimethoxytrityl)-2 -deoxy-2-methylselenoadenosine 3 -O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (S.17). Yield: 0.78 g (91%; mixture of diastereoisomers). TLC (94:6 CH2 Cl2 /MeOH): Rf 0.44. 1 H NMR (500 MHz, CDCl3 ): δ 1.09-1.29 (m, 24H, ((CH3 )2 CH)2 N); 1.61 (s, 3H, SeCH3 ); 1.69 (s, 3H, SeCH3 ); 2.34 (m, 2H, CH2 CN); 2.66 (m, 8H, COCH3 , CH2 CN); 3.38 (m, 2H, H5 a); 3.47-3.75 (m, 8H, ((CH3 )2 CH)2 N, H5 b, POCH2 ); 3.78, 3.79 (2s, 12H, OCH3 ); 3.90-3.99, 4.09-4.22 (2m, 2H, POCH2 ); 4.41 (m, 4H, H2 , H4 ); 4.67, 4.73 (2m, 2H, H3 ); 6.31 (m, 2H, H1 ); 6.80, 7.22-7.45 (m, 26H, H-C(ar)); 8.11 (s, 1H, H8); 8.15 (s, 1H, H8); 8.49 (s, br, 2H, HN6 ); 8.54, 8.55 (2s, 2H, H2). 31 P NMR (121 MHz, CDCl3 ): δ 150.8, 152.4. UV (MeOH): λmax 271 nm. FTICR ESI-MS (m/z): [M+H]+ calcd. for C43 H52 N7 O7 PSe 890.29147, found 890.29005.
PREPARATION OF 2 -DEOXY-2 -METHYLSELENOGUANOSINE PHOSPHORAMIDITE
ALTERNATE PROTOCOL 3
This protocol describes the synthesis of N2 -acetyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxy2 -methylselenoguanosine 3 -O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (S.27). The synthesis starts from 9-[β-D-arabinofuranosyl]guanine (S.18) and proceeds in nine steps: (1) protection of the 3 - and 5 -hydroxyl groups to give S.19, (2) N2 - and 2 O-acetylation to give S.20, (3) O6 -protection with 2-(4-nitrophenyl)ethyl group under Mitsunobu conditions to give S.21, (4) removal of the 2 -O-acetyl group by selective ester cleavage to give S.22, (5) triflation of the 2 -OH to give S.23, (6) SN 2displacement of the 2 -O-triflate ester by sodium methylselenide to produce S.24, (7) fluoride-assisted removal of the O6 -, 3 -OH, and 5 -OH protecting groups to give S.25, (8) 5 -O-tritylation to give S.26, and (9) 3 -O-phosphitylation using 2-cyanoethyl-N,Ndiisopropylchlorophosphoramidite to give S.27. These steps are illustrated in Figure 1.15.4.
Additional Materials (also see Basic Protocol 1) 9-[β-D-Arabinofuranosyl]guanine (S.18; Metkinen Oy) 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane (TIPSCl2 ; Fluka) Acetic anhydride (Fluka) Triphenylphosphine (PPh3 ; Fluka) 2-(4-Nitrophenyl)ethanol (NPE-OH; Fluka) Anhydrous dioxane Diisopropyl azodicarboxylate (DIAD; Aldrich) Saturated sodium bicarbonate solution in water 0.5 M sodium hydroxide (NaOH) solution in water Acetic acid 4-(N,N-Dimethylamino)pyridine (DMAP; Fluka) Trifluoromethanesulfonyl chloride (Tf-Cl; Fluka) Tetrabutylammonium fluoride trihydrate (TBAF; Fluka) 250- and 500-mL one-neck round-bottom flasks 500-, 1000-, and 2000-mL separatory funnels Protect 3 - and 5 -hydroxyl groups 1. In a 500-mL one-neck flask, coevaporate 4.16 g (14.7 mmol) S.18 three times with 30 mL dry pyridine. Then, suspend in 160 mL DMF and 14 mL pyridine. 2. Add 4.86 g (15.4 mmol) TIPSCl2 dropwise and keep the reaction mixture stirring 16 hr at room temperature.
Synthesis of Modified Nucleosides
1.15.13 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Figure 1.15.4 Preparation of a 2 -deoxy-2 -methylselenoguanosine phosphoramidite building block for RNA solidphase synthesis (see Alternate Protocol 3). DIAD, diisopropyl azodicarboxylate; DMAP, 4-(N,N-dimethylamino)pyridine; DMF, N,N-dimethylformamide; DMTr, 4,4 -dimethoxytrityl; NPE, 2-(4-nitrophenyl)ethyl; PPh3 , triphenylphosphine; TBAF, tetra-n-butylammonium fluoride; Tf, trifluoromethanesulfonyl; THF, tetrahydrofuran; TIPSCl2 , 1,3-dichloro-1,1,3,3tetraisopropyldisiloxane. 2 -MethylselenoModified Phosphoramidites and RNA
1.15.14 Supplement 27
Current Protocols in Nucleic Acid Chemistry
3. Precipitate the reaction mixture by pouring into 2.6 L ice-water under vigorous stirring. 4. Collect the crude product on a glass-fritted B¨uchner funnel with filter paper, and dry the residue in vacuo. The dried residue is used in the next step without further purification. For analysis, a small portion of the crude product was crystallized from ethanol. 9-[3 ,5 -O-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-β-D-arabinofuranosyl]guanine (S.19). Yield: 7.60 g (98%). TLC (94:6 CH2 Cl2 /MeOH): Rf 0.65. 1 H NMR (300 MHz, DMSO-d6 ): δ 1.06 (m, 28H, (iPr)4 Si2 O); 3.74 (m, 1H, H4 ); 3.95 (m, 2H, H5 a and H5 b); 4.30 (m, 1H, H3 ); 4.42 (m, 1H, H2 ); 5.78 (d, J = 5.9 Hz, 1H, 2 -OH); 5.95 (d, J = 6.4 Hz, 1H, H1 ); 6.43 (s, 2H, NH2 ); 7.60 (s, 1H, H8); 10.57 (s, 1H, HN1 ). 13 C NMR (75 MHz, DMSO-d6 ): δ 11.9, 12.3, 12.4, 12.8, 16.7, 16.8, 16.9, 17.1, 17.11, 17.13, 17.3 (iPr)4 Si2 O); 61.2 (C5 ); 74.5 (C2 ); 75.3 (C3 ); 79.4 (C4 ); 80.5 (C1 ); 115.8 (C(ar)); 135.9 (C8); 151.2, 153.6, 156.7 (C(ar)). UV (MeOH): λmax 252 nm. ESI-MS (m/z): calcd. for C22 H39 N5 O6 Si2 [M+H]+ 526.76, found 526.10; calcd. [M+Na]+ 548.74, found 548.17.
Acetylate 2 -hydroxyl and exocyclic amino group 5. In a 500-mL one-neck flask, coevaporate S.19 three times with 30 mL pyridine. 6. Suspend the residue in 80 mL DMF, 80 mL pyridine, and 80 mL acetic anhydride under an argon atmosphere. Stir the reaction mixture for 16 hr at 80◦ C. 7. Remove the solvents under vacuum and partition the brown viscous oil between 500 mL CH2 Cl2 and 500 mL aqueous 5% citric acid. 8. Separate the organic layer, and extract the aqueous layer four times with 700 mL CH2 Cl2 . 9. Wash the combined organic layers with 600 mL saturated aqueous NaCl. 10. Dry the organic phase with 50 g Na2 SO4 , filter using a glass-fritted B¨uchner funnel and filter paper, and evaporate the filtrate to dryness. 11. Purify the residue on a chromatography column containing 200 g silica gel, using a solvent system of 1.0% to 8.0% (v/v) MeOH in CH2 Cl2 . 12. Combine the fractions containing product S.20, as determined by TLC using 9:1 (v/v) CH2 Cl2 /MeOH. Evaporate and then coevaporate with 40 mL CH2 Cl2 . 13. Dry the residue in vacuo to obtain the product as a colorless foam. A mixture of N2 -acetyl-9-[2 -O-acetyl-3 ,5 -O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)-β-D-arabinofuranosyl]guanine (S.20a) and the N2 ,N2 -diacetyl byproduct (S.20b) is obtained and can be used in the next reaction step. Yield: 2.91 g S.20a; 5.20 g S.20a + S.20b (64%). TLC (9:1 CH2 Cl2 /MeOH): Rf = 0.57 (S.20b), 0.63 (S.20a). The higher Rf value of S.20a, though unexpected, is correct. For S.20a: 1 H NMR (300 MHz, CDCl3 ): δ 0.95-1.05 (m, 28H, (iPr)4 Si2 O); 1.75 (s, 3H, COCH3 ); 2.30 (s, 3H, NHCOCH3 ); 3.87 (m, 1H, H4 ); 4.08 (m, 2H, H5 a and H5 b); 4.64 (m, 1H, H3 ); 5.49 (m, 1H, H2 ); 6.26 (d, J = 6.4 Hz, 1H, H1 ); 7.97 (s, 1H, H8); 9.58 (s, 1H, HN1 ); 12.03 (s, 1H, H2). 13 C NMR (75 MHz, CDCl3 ): δ 12.4, 12.8, 13.0, 13.3, 16.70, 16.72, 16.8, 16.9, 17.26, 17.34, 17.4 (iPr)4 Si2 O); 20.1 (COCH3 ); 24.3 (NHCOCH3 ); 60.6 (C5 ); 71.1 (C3 ); 76.4 (C2 ); 80.4 (C4 ); 80.4 (C1 ); 120.8 (C(ar)); 137.6 (C8); 147.5, 148.1, 155.7 (C(ar)); 169.8, 172.1 (2 × COCH3 ). UV (MeOH): λmax 256 nm. ESI-MS (m/z): calcd. for C26 H43 N5 O8 Si2 [M+H]+ 610.82, found 610.10; calcd. [M+Na]+ 632.81, found 632.26. Synthesis of Modified Nucleosides
1.15.15 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Protect O6 group 14. In a 250-mL one-neck flask, coevaporate 4.65 g (7.48 mmol) S.20, 2.94 g (11.2 mmol) triphenylphosphine, and 1.88 g (11.2 mmol) 2-(4-nitrophenyl)ethanol with 30 mL dry dioxane. 15. Suspend in 150 mL dioxane and stir for 30 min at room temperature. 16. Add 2.36 mL (12.0 mmol) DIAD and continue stirring for 45 min. 17. Remove the solvents under vacuum and partition the residue between 500 mL CH2 Cl2 and 500 mL saturated sodium bicarbonate solution. 18. Separate the organic layer, and extract the aqueous layer two times with 700 mL CH2 Cl2 . 19. Dry the combined organic layers with 40 g Na2 SO4 , filter using a glass-fritted B¨uchner funnel and filter paper, and evaporate the filtrate to dryness. 20. Purify the residue on a 120-g silica gel column using a solvent system of 10% to 50% (v/v) EtOAc in hexanes. 21. Combine the fractions containing product S.21, as determined by TLC using 2:8 hexanes/EtOAc. Evaporate and then coevaporate with 30 mL CH2 Cl2 . 22. Dry the residue in vacuo to obtain the product as a colorless foam. A mixture of N2 -acetyl-9-[2 -O-acetyl-3 ,5 -O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)-β-D-arabinofuranosyl]-O6 -[2-(4-nitrophenyl)ethyl]guanine (S.21a) and the N2 ,N2 -diacetyl byproduct (S.21b) is used in the next step. Yield: 3.63 g S.21 as yellowish foam (64%). TLC (2:8 hexanes/EtOAc): Rf = 0.55 (S.21a), 0.72 (S.21b). For S.21a: 1 H NMR (300 MHz, CDCl3 ): δ 0.98-1.25 (m, 28H, (iPr)4 Si2 O); 1.71 (s, 3H, COCH3 ); 2.56 (s, 3H, NHCOCH3 ); 3.31 (t, J = 6.8 Hz, 2H, CH2 -C6 H4 -NO2 ); 3.90 (m, 1H, H4 ); 4.10 (m, 2H, H5 a and H5 b); 4.69 (m, 1H, H3 ); 4.74 (m, 2H, O6 -CH2 ); 5.56 (m, 1H, H2 ); 6.41 (d, J = 6.2 Hz, 1H, H1 ); 7.50 (d, J = 8.5 Hz, 2H, 4-nitrophenyl H2/H6); 7.84 (s, 1H, HN2 ); 8.09 (s, 1H, H8); 8.18 (d, J = 8.5 Hz, 2H, 4-nitrophenyl H3/H5). 13 C NMR (75 MHz, CDCl3 ): δ 12.4, 12.97, 13.03, 13.4, 16.7, 16.8, 16.9, 17.26, 17.32, 17.39, 17.42 ((iPr)4 Si2 O); 20.0 (COCH3 ); 25.1 (NHCOCH3 ); 35.0 (CH2 -C6 H4 NO2 ); 60.5 (C5 ); 66.9 (O6 -CH2 ); 71.3 (C3 ); 76.4 (C2 ); 80.5 (C4 ); 80. 6 (C1 ); 117.3 (C(ar)); 123.8 (4-nitrophenyl C2/C6); 129.9 (4-nitrophenyl C3/C5); 140.3 (C8); 145.5, 147.0, 152.2, 152. 8, 160.5 (C(ar)); 169.3, 172.0 (COCH3 ). UV (MeOH): λmax 269 nm. ESI-MS (m/z): calcd. for C34 H5 0N6 O10 Si2 [M+H]+ 759.97, found 759.26; calcd. for [M+Na]+ 781.96, found 781.42. For S.21b: 1 H NMR (300 MHz, CDCl3 ): δ 0.99-1.17 (m, 28H, (iPr)4 Si2 O); 1.69 (s, 3H, COCH3 ); 2.27 (s, 6H, 2 × COCH3 ); 3.30 (t, J = 6.9 Hz, 2H, CH2 -C6 H4 -NO2 ); 3.91 (m, 1H, H4 ); 4.10 (m, 2H, H5 a and H5 b); 4.78 (m, 1H, H3 ); 4.79 (m, 2H, O6 -CH2 ); 5.55 (dd, J = 6.4, 8.0 Hz, 1H, H2 ); 6.44 (d, J = 6.4 Hz, 1H, H1 ); 7.46 (d, J = 8.7 Hz, 2H, 4-nitrophenyl H2/H6); 7.84 (s, 1H, HN2 ); 8.15 (d, J = 8.7 Hz, 2H, 2H, 4-nitrophenyl H3/H5); 8.26 (s, 1H, H8). 13 C NMR (75 MHz, CDCl3 ): δ 12.4, 12.97, 12.99, 13.3, 16.7, 16.8, 16.9, 17.26, 17.33, 17.38, 17.42 ((iPr)4 Si2 O); 19.9 (COCH3 ); 26.0 (2 × COCH3 ); 35.0 (CH2 -C6 H4 -NO2 ); 61.1 (C5 ); 67.3 (O6 -CH2 ); 72.0 (C3 ); 76.7 (C2 ); 80.8 (C4 ); 81.3 (C1 ); 120.4 (C(ar)); 123.8 (4-nitrophenyl C2/C6); 129.9 (4-nitrophenyl C3/C5); 142.7 (C8); 145.3, 147.0, 152.5, 152.9, 161.3 (C(ar)); 169.4, 171.9 (COCH3 ). UV (MeOH): λmax 260 nm. ESI-MS (m/z): calcd. for C36 H52 N6 O11 Si2 [M+H]+ 802.00, found 801.07; calcd. for [M+Na]+ 823.99, found 823.31.
2 -MethylselenoModified Phosphoramidites and RNA
1.15.16 Supplement 27
Deprotect 2 -hydroxyl group 23. In a 250-mL one-neck flask, dissolve 3.41 g (4.49 mmol) S.21 in 130 mL of 5:4 (v/v) THF/MeOH and cool the stirred solution to 0◦ C. 24. Add 150 mL of 0.5 M NaOH under vigorous stirring for 7 min. 25. Add 160 mL of 0.5 M acetic acid under vigorous stirring. Current Protocols in Nucleic Acid Chemistry
26. Evaporate the solvents. Dissolve the residue in 400 mL CH2 Cl2 and wash with 400 mL water. 27. Dry the combined organic layers with 20 g Na2 SO4 , filter using a glass-fritted B¨uchner funnel and filter paper, and evaporate the filtrate to dryness. 28. Purify the residue on a 240-g silica gel column using a solvent system of 1.0% to 2.0% (v/v) MeOH in CH2 Cl2 . 29. Combine the fractions containing product S.22, as determined by TLC using 2:8 (v/v) hexanes/EtOAc. Evaporate and then coevaporate with 20 mL CH2 Cl2 . 30. Dry the residue in vacuo to obtain the product as a colorless foam. N2-Acetyl-9-[3 ,5 -O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-arabinofuranosyl]O6 -[2-(4-nitrophenyl)ethyl]guanine (S.22). Yield: 1.84 g (57%). TLC (2:8 hexanes/EtOAc): Rf = 0.46. 1 H NMR (300 MHz, CDCl3 ): δ 1.01-1.14 (m, 28H, (iPr)4 Si2 O); 2.37 (s, 3H, COCH3 ); 2.29 (t, J = 6.8 Hz, 2H, CH2 -C6 H4 -NO2 ); 3.86 (m, 1H, H4 ); 4.05 (m, 2H, H5 a and H5 b); 4.51 (t, J = 7.3 Hz, 1H, H3 ); 4.30 (s, 1H, 2 -OH); 4.64(m, 1H, H2 ); 4.74 (m, 2H, O6 -CH2 ); 6.14 (d, J = 5.7 Hz, 1H, H1 ); 7.49 (d, J = 8.7 Hz, 2H, 4-nitrophenyl H2/H6); 8.07 (s, 1H, HN2 ); 8.14 (s, 1H, H8); 8.16 (d, J = 8.7 Hz, 2H, 4-nitrophenyl H3/H5). 13 C NMR (75 MHz, CDCl3 ): δ 12.5, 13.0, 13.1, 13.5, 16.89, 16.95, 17.0, 17.3, 17.4, 17.5 (iPr)4 Si2 O); 24.9 (COCH3 ); 35.0 (CH2 -C6 H4 -NO2 ); 61.5 (C5 ); 67.0 (O6 -CH2 ); 74.6 (C3 ); 76.7 (C2 ); 81.7 (C4 ); 83.8 (C1 ); 117.7 (C(ar)); 123.8 (4-nitrophenyl C2/C6); 129.9 (4-nitrophenyl C3/C5); 141.4 (C8); 145.4, 147.0, 151.6, 152.5, 160.2 (C(ar)), 169.9 (COCH3 ). UV (MeOH): λmax 260 nm. ESI-MS (m/z): calcd. for C32 H48 N6 O9 Si2 [M+H]+ 717.93, found 717.11; calcd. for [M+Na]+ 739.92, found 739.29.
Activate 2 -hydroxyl group 31. In a 250-mL one-neck flask, coevaporate 0.60 g (0.837 mmol) S.22 with 10 mL dry pyridine and dissolve in 100 mL CH2 Cl2 . 32. Add 153 mg (1.26 mmol) DMAP and 169 mg (233 µL, 1.67 mmol) TEA. 33. Cool the stirred solution to 0◦ C, add 211 mg (158 µL, 1.26 mmol) Tf-Cl, and continue stirring for 2 hr at room temperature. 34. Dilute the reaction mixture with 300 mL CH2 Cl2 and wash with 300 mL saturated sodium bicarbonate solution. 35. Dry over 10 g Na2 SO4 , filter using a glass-fritted B¨uchner funnel and filter paper, and evaporate the solvent. 36. Purify the residue on a 34-g silica gel column using a solvent system of 10% to 50% (v/v) EtOAc in hexanes. 37. Combine the fractions containing product S.23, as determined by TLC using 1:1 (v/v) hexanes/EtOAc. Evaporate and then coevaporate with 5 mL CH2 Cl2 . 38. Dry the residue in vacuo to obtain the product as a colorless foam. N2-Acetyl-9-{2-O-[(trifluoromethyl)sulfonyl]-3 ,5 -O-(1,1,3,3-tetraisopropyldisiloxane1,3-diyl)-β-D-arabinofuranosyl}-O6 -[2-(4-nitrophenyl)ethyl]guanine (S.23). Yield: 490 mg (69%). TLC (1:1 hexanes/EtOAc): Rf = 0.44. 1 H NMR (300 MHz, CDCl3 ): 1.00-1.16 (m, 28H, (iPr)4 Si2 O); 2.55 (s, 3H, COCH3 ); 3.35 (t, J = 6.8 Hz, 2H, CH2 -C6 H4 -NO2 ); 3.94 (m, 1H, H4 ); 4.12 (m, 2H, H5 a and H5 b); 4.83 (t, J = 6.8 Hz, 2H, O6 -CH2 ); 4.95 (m, 1H, H3 ); 4.30 (s, 1H, 2 -OH); 5.46 (m, 1H, H2 ); 6.42 (d, J = 5.9 Hz, 1H, H1 ); 7.49 (d, J = 8.7 Hz, 2H, 4-nitrophenyl H2/H6); 7.88 (s, 1H, HN2 ); 8.05 (s, 1H, H8); 8.17 (d, J = 8.7 Hz, 2H, 4-nitrophenyl H3/H5). 13 C NMR (75 MHz, CDCl3 ): δ 12.6, 13.0, 13.1, 13.2, 16.6, 16.7, 16.8, 17.2, 17.3, 17.4 ((iPr)4 Si2 O); 25.1 (COCH3 ); 35.0 (CH2 -C6 H4 -NO2 ); 61.0 (C5 ); 67.0 (O6 -CH2 ); 72.7 (C3 ); 80.0
Synthesis of Modified Nucleosides
1.15.17 Current Protocols in Nucleic Acid Chemistry
Supplement 27
(C1 ); 80.9 (C4 ); 87.7 (C2 ); 117.4 (C(ar)); 123.8 (4-nitrophenyl C2/C6); 129.9 (4-nitrophenyl C3/C5); 139.7 (C8); 145.4, 147.0, 152.3, 152.8, 160.7 (C(ar)); 170.6 (COCH3 ). UV (MeOH): λmax 268 nm. ESI-MS (m/z): calcd. for C33 H47 F3 N6 O11 SSi2 [M+H]+ 849.99, found 849.37; calcd. for [M+Na]+ 871.98, found 871.27.
Introduce 2 -methylseleno group 39. Apply Basic Protocol 1, steps 15 to 24, for 230 mg (0.27 mmol) S.23 instead of S.2, scaling down all quantities used by a factor of 7.0. 40. Extract the product three times with 150 mL CH2 Cl2 . 41. Wash the combined CH2 Cl2 phases with 200 mL of 0.2 M TEAA solution and then with 200 mL saturated NaCl solution. 42. Dry the organic phase with 3 g Na2 SO4 , filter using a glass-fritted B¨uchner funnel and filter paper, and evaporate the filtrate to dryness. 43. Purify the residue on a 17-g silica gel column using a solvent system of 15% to 60% (v/v) EtOAc in hexanes. 44. Combine the fractions containing product S.24, as determined by TLC using 4:6 (v/v) hexanes/EtOAc. Evaporate and then coevaporate with 5 mL CH2 Cl2 . 45. Dry the residue in vacuo to obtain the product as a colorless foam. N2 -Acetyl-3 ,5 -O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-O6 -[2-(4-nitrophenyl)ethyl]-2 -deoxy-2 -methylselenoguanosine (S.24). Yield: 186 mg (87%). TLC (4:6 hexanes/EtOAc): Rf = 0.49. 1 H NMR (300 MHz, CDCl3 ): δ 0.97-1.10 (m, 28H, (iPr)4 Si2 O); 1.93 (s, 3H SeCH3 ); 2.55 (s, 3H, COCH3 ); 3.31 (t, J = 6.8 Hz, 2H, CH2 -C6 H4 -NO2 ); 3.94 (dd, J = 4.4, 4.5 Hz, 1H, H2 ); 4.06 (m, 2H, H5 a and H5 b); 4.16 (m, 1H, H4 ); 4.75 (s, 1H, H3 ); 4.78 (m, 2H, O6 -CH2 ); 6.21 (d, J = 4.5 Hz, 1H, H1 ); 7.49 (d, J = 8.7 Hz, 2H, 4-nitrophenyl H2/H6); 7.87 (s, 1H, HN2 ); 8.07 (s, 1H, H8); 8.16 (d, J = 8.7 Hz, 2H, 4-nitrophenyl H3/H5). 13 C NMR (75 MHz, CDCl3 ): δ 12.7, 13.0, 13.1, 13.5, 16.8, 16.96, 16.97, 17.1, 17.27, 17.28, 17.3, 17.4 ((iPr)4 Si2 O); 25.1 (COCH3 ); 35.0 (CH2 -C6 H4 -NO2 ); 47.0 (C2 ); 61.8 (C5 ); 66.9 (O6 -CH2 ); 71.7 (C3 ); 84.6 (C4 ); 89.7 (C1 ); 118.3 (C(ar)); 123.8 (4-nitrophenyl C2/C6); 129.9 (4-nitrophenyl C3/C5); 139.9 (C8); 145.5, 147.0, 152.0, 152.3, 160.6 (C(ar)); 170.6 (COCH3 ). UV (MeOH): λmax 269 nm. ESI-MS (m/z): calcd. for C33 H50 N6 O8 SeSi2 [M+H]+ 794.92, found 794.97; calcd. for [M+Na]+ 816.93, found 817.15.
Remove O6 - and 3 ,5 -OH protecting groups 46. In a 250-mL one-neck flask, dissolve 735 mg (0.73 mmol) S.24 in 25 mL THF and add 6 mL of 1 M TBAF in THF. Stir the solution 2.5 hr at room temperature. 47. Evaporate the solvent and purify the residue on a 40-g silica gel column using a solvent system of 3% to 7% (v/v) MeOH in CH2 Cl2 . 48. Combine the fractions containing product S.25, as determined by TLC using 85:15 (v/v) CH2 Cl2 /MeOH. Evaporate and then coevaporate with 5 mL CH2 Cl2 . 49. Dry the residue in vacuo to obtain the product as colorless foam.
2 -MethylselenoModified Phosphoramidites and RNA
N2 -Acetyl-2 -deoxy-2 -methylselenoguanosine (S.25). Yield: 230 mg (79%). TLC (85:15 CH2 Cl2 /MeOH): Rf = 0.45. 1 H NMR (300 MHz, DMSO-d6 ): δ 1.63 (s, 3H SeCH3 ); 2.18 (s, 3H, COCH3 ); 3.57 (m, 2H, H5 a and H5 b); 3.97 (m, 1H, H4 ); 4.01 (m, 1H, H2 ); 4.31 (s, 1H, H3 ); 5.02 (t, J = 5.5 Hz, 1H, 5 -OH); 5.82 (d, J = 4.6 Hz, 1H, 3 -OH); 6.14 (d, J = 9.1 Hz, 1H, H1 ); 8.30 (s, 1H, H8); 11.68 (s, 1H, HN2 ); 12.05(s, 1H, HN1 ). 13 C NMR (75 MHz, DMSO-d6 ): δ 2.9 (SeCH3 ); 24.2 (COCH3 ); 46.8 (C2 ); 62.0 (C5 ); 73.2 (C3 ); 87.7 (C4 ); 88.9 (C1 ); 120.5 (C(ar)); 138.2 (C8); 148.5, 149.3, 155.2, (C(ar)); 173.9 (COCH3 ). UV (MeOH): λmax 277 nm. ESI-MS (m/z): calcd. for C13 H17 N5 O5 Se [M+H]+ 403.26, found 403.76; calcd. for [M+Na]+ 425.25, found 426.04.
1.15.18 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Tritylate 5 -hydroxyl group 50. In a 25-mL one-neck flask, coevaporate 178 mg (0.44 mmol) S.25 with dry pyridine, then dissolve in 2 mL pyridine. 51. Add 165 mg (0.48 mmol) DMTr-Cl in two portions within 1 hr to the stirred solution. Continue stirring overnight at room temperature. 52. Evaporate the solvents and dissolve the residue in 200 mL CH2 Cl2 . Wash with 100 mL of 5% citric acid, 100 mL water, and then 100 mL of half-saturated sodium bicarbonate solution in a 500-mL separatory funnel. 53. Dry the organic phase with 10 g Na2 SO4 , remove the solid using a glass-fritted B¨uchner funnel and filter paper, and evaporate the filtrate to dryness. 54. Purify the residue on a 15-g silica gel column using a solvent system of 2% to 5% (v/v) MeOH in CH2 Cl2 . 55. Combine the fractions containing product S.26, as determined by TLC using 9:1 (v/v) CH2 Cl2 /MeOH. Evaporate and then coevaporate with 3 mL CH2 Cl2 . 56. Dry the residue in vacuo to obtain the product as colorless foam. N2 -Acetyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxy-2 -methylselenoguanosine (S.26). Yield: 184 mg (59%). TLC (9:1 CH2 Cl2 /MeOH): Rf = 0.56. 1 H NMR (300 MHz, CDCl3 ): δ 1.76 (s, 3H SeCH3 ); 1.87 (s, 3H, COCH3 ); 3.27 (m, 1H, H5 a); 3.45 (m, 1H, H5 b); 3.73, 3.74 (2s, 6H, OCH3 ); 3.90 (m, 1H, 3 -OH); 4.11 (m, 1H, H2 ); 4.29 (m, 1H, H4 ); 4.57 (s, 1H, H3 ); 5.98 (d, J = 9.0 Hz, 1H, H1 ); 7.18-7.47 (m, 13H, trityl-H); 7.87 (s, 1H, H8); 9.63 (s, 1H, HN2 ); 12.11(s, 1H, HN1 ). 13 C NMR (75 MHz, CDCl3 ): δ 4.05 (SeCH3 ); 23.8 (COCH3 ); 49.0 (C2 ); 55.2 (2 × OCH3 ); 64.1 (C5 ); 72.9 (C3 ); 85.4 (C4 ); 96.5 (C(ar)); 88.9 (C1 ); 113.2, 121.5, 127.1, 127.9, 128.0, 130.0, 135.5, 135.0 (C(ar)); 138.4 (C8); 144.8, 147.5, 148.8, 155.8, 158.7 (C(ar)); 172.5 (COCH3 ). UV (MeOH): λmax 260 nm. FTICR ESI-MS (m/z): calcd. for C34 H35 N5 O7 Se [M+H]+ 706.17833, found 706.17730.
Prepare phosphoramidite 57. Apply Basic Protocol 1, steps 31 to 40, to 220 mg (0.32 mmol) S.26, scaling down all quantities used by a factor of 3. For column purification of S.27, use 15 g silica gel and a solvent system of 0.5% to 1.5% (v/v) MeOH in CH2 Cl2 . N2 -Acetyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxy-2 -methylselenoguanosine 3 -O-(2cyanoethyl)-N,N- diisopropylphosphoramidite (S.27). Yield: 248 mg (88%). TLC (97:3 CH2 Cl2 /MeOH): Rf = 0.63. 1 H NMR (500 MHz, CDCl3 ): δ 1.00-1.27 (m, 24H, 2 × ((CH3 )2 CH)2 N); 1.37, 1.48 (s, 6H, 2 × SeCH3 ); 1.69, 1.73 (s, 6H, COCH3 ); 2.24, 2.28 (2 × m, 2H, CH2 CN); 2.62, 2.66 (2 × t, 2H, CH2 CN); 3.15 (m, 2H, H5 a); 3.54-3.63 (m, 4H, ((CH3 )2 CH)2 N, 2H, H5 b, 2H, POCH2 ); 3.77, 3.78 (2s, 12H, OCH3 ); 3.91-3.99, 4.10-4.22 (2m, 2H, POCH2 ); 4.36, 4.41 (m, 2H, H4 ); 4.45 (m, 2H, H2 ); 4.71, 4.76 (m, 1H, H3 ); 6.01, 6.06 (2 × d, J = 9.0 Hz, 9.34 Hz, 2H, H1 ); 6.80, 7.26, 7.40, 7.55 (4 × m, 26H, trityl-H); 7.80 (s, 2H, H8); 7.67 (s, 2H, HN2 ); 11.93 (s, 2H, HN1 ). 31 P NMR (121 MHz, CDCl3 ): δ 151.3, 150.4. UV (MeOH): λmax 235 nm. FTICR ESI-MS (m/z): calcd. for C34 H35 N5 O7 Se [M+H]+ 906.28639, found 906.28685.
SYNTHESIS OF RNA OLIGONUCLEOTIDES CONTAINING 2 -METHYLSELENO NUCLEOSIDES
BASIC PROTOCOL 2
This protocol describes the automated solid-phase assembly of RNA sequences using 2 -O-TOM-phosphoramidites (UNIT 3.8) and 2 -methylseleno phosphoramidites for sitespecific incorporation of 2 -methylseleno labels. The protocol was developed for a 1µmol synthesis on a Gene Assembler (Amersham Pharmacia Biotech), but can easily be adapted to other automated DNA/RNA synthesizers. Coupling times of 3.0 to 4.0 min are recommended to achieve stepwise coupling yields >98%.
Synthesis of Modified Nucleosides
1.15.19 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Although 2 -methylseleno nucleoside phosphoramidites are stable in the solid state over prolonged storage at −20◦ C, solutions of 2 -methylseleno nucleoside phosphoramidites in CH3 CN should not be stored >20 hr at room temperature (23◦ C). For reliable preparation of selenium-containing oligoribonucleotides, in particular for sequences with >10 to 15 nt, treatment with threo-1,4-dimercapto-2,3-butanediol (DTT) is required during automated assembly (after each step of oxidation; Table 1.15.1) and during deprotection and ligation. This treatment guarantees a uniformly labeled product without oxidation byproducts.
Materials 2 -Methylseleno phosphoramidites (S.4, S.10, S.17, S.27; see Basic Protocol 1 and Alternate Protocols 1 through 3) 2 -O-TOM-phosphoramidites (Glen Research; also see UNITS 2.9 & 3.8) 5-Benzylthio-1H-tetrazole (BTT; Glen Research) Anhydrous acetonitrile (CH3 CN; <30 ppm water; Biosolve) ◦ 4-A molecular sieves (optional) Detritylation solution (see recipe) Oxidation solution (see recipe) Capping solutions A and B (see recipes) 100 mM DTT solution (see recipe) 1,2-Dichloroethane (Fluka) Solid support: e.g., long-chain alkylamine controlled-pore glass (LCAA-CPG; 500 ◦ ◦ A for <40 nt; 1000 A for >40 nt) derivatized with 5 -O-(4,4 -dimethoxytritylated) nucleosides (Glen Research) or polystyrene base supports (PS200; GE Biosciences) Automated DNA synthesizer (e.g., Gene Assembler; Amersham Pharmacia Biotech) Syringes Synthesis column for 1-µmol scale Additional reagents and equipment for automated oligonucleotide synthesis (APPENDIX 3C) 1. Calculate the amounts of phosphoramidites and activator (BTT) required to assemble the desired sequence (∼12 mg phosphoramidite and ∼21 mg BTT per coupling) and add an extra 30 mg phosphoramidite/50 mg BTT to give enough material to purge the lines of the synthesizer. 2. Place the calculated amounts of phosphoramidites and BTT into the appropriate vials of the DNA synthesizer. 3. Use a syringe to add the required amount of dry acetonitrile to obtain ∼0.1 M phosphoramidite solutions (i.e., 1 mL/100 mg solid phosphoramidite) and ∼0.30 M BTT solution (i.e., 1 mL/58 mg solid BTT). ◦
When working with Gene Assembler, 4-A molecular sieves may also be added to these reagents.
4. Create methods for the assembly of the desired sequence. In principle, methods employed for synthesis of DNA sequences can be used here. The steps listed in Tables 1.15.1 and 1.15.2 are recommended.
2 -MethylselenoModified Phosphoramidites and RNA
1.15.20 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Table 1.15.1 Oligoribonucleotide Assembly on a 1.3-µmol Scale with 2 -Methylseleno-Modified Phosphoramidites
Meaninga
Comments
Go to DETRIT method
Deprotection of the last added nucleotide
2.1
Set valve 2 to pos 1
Dichloroethane wash
VALVE POS
2.3
Set valve 2 to pos 3
Acetonitrile wash
K
INTEGRATE
0
4.00
A
ML/MIN
6
4.00
F
LOOP TIMES
7
4.00
B
VALVE POS
8
4.05
A
9
4.15
10
Line
Time
Command
Function
1
0.00
D
CALL METHOD
2
1.50
B
VALVE POS
3
2.50
B
4
2.70
5
Value DETRIT
Stop integrator, peak Peak data can be data available displayed on screen
0.00
Stop the flow
2
Start of loop
Do following steps two times
1.8
Set valve 1 to pos 8
Addition of 90 µL BTT solution
ML/MIN
0.90
Set flow rate 0.9 mL/min
A
ML/MIN
0.00
Stop the flow
4.15
B
VALVE POS
1.#
Set valve 1 to pos #
11
4.20
A
ML/MIN
0.60
Set flow rate 0.6 mL/min
12
4.30
A
ML/MIN
0.00
Stop the flow
13
4.30
B
VALVE POS
1.8
Set valve 1 to pos 8
14
4.35
A
ML/MIN
0.90
Set flow rate 0.9 mL/min
15
4.45
A
ML/MIN
0.00
Stop the flow
16
4.45
G
END OF LOOP
17
4.45
B
VALVE POS
1.1
Set valve 1 to pos 1
18
4.50
A
ML/MIN
1.00
Set flow rate 1 mL/min
19
4.60
A
ML/MIN
0.00
Stop the flow
20
4.60
F
LOOP TIMES
7
Start the loop
21
4.60
C
STEP VALVE
3
Step valve 3 to next pos
Set valve 3 in recycle position
22
4.60
G
END OF LOOP
23
4.65
A
ML/MIN
2.50
Set flow rate 2.5 mL/min
Coupling for 3 min
24
7.65
A
ML/MIN
0.00
Stop the flow
25
7.65
C
STEP VALVE
3
Step valve 3 to next pos
Addition of 60 µL amidite solution
Addition of 90 µL BTT solution
Push BTT and amidite into the recycle loop with acetonitrile
Set valve 3 in flow through pos continued
Synthesis of Modified Nucleosides
1.15.21 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Table 1.15.1 Oligoribonucleotide Assembly on a 1.3-µmol Scale with 2 -Methylseleno-Modified Phosphoramidites, continued
Line
Time
Command
Function
Value
Meaninga
Comments
26
7.70
A
ML/MIN
2.50
Set flow rate 2.5 mL/min
Acetonitrile wash for 0.3 min
27
8.00
A
ML/MIN
0.00
Stop the flow
28
8.05
B
VALVE POS
2.5
Set valve 2 to pos 5
29
8.10
A
ML/MIN
1.00
Set flow rate 1 mL/min
30
8.10
F
LOOP TIMES
4
Start the loop
31
8.10
B
VALVE POS
2.5
Set valve 2 to pos 5
Capping A for 0.1 min
32
8.20
B
VALVE POS
2.6
Set valve 2 to pos 6
Capping B for 0.1 min
33
8.30
G
END OF LOOP
34
8.35
B
VALVE POS
2.3
Set valve 2 to pos 3
Acetonitrile wash for 0.5 min
35
8.35
A
ML/MIN
2.00
Set flow rate 2 mL/min
36
8.85
B
VALVE POS
2.4
Set valve 2 to pos 4
Oxidation for 1 min
37
9.85
B
VALVE POS
2.3
Set valve 2 to pos 3
Acetonitrile wash for 1.5 min
38
11.35
A
ML/MIN
0.00
Stop the flow
39
11.40
B
VALVE POS
2.5
Set valve 2 to pos 5
40
11.45
A
ML/MIN
1.00
Set flow rate 1 mL/min
41
11.45
F
LOOP TIMES
2
Start the loop
42
11.45
B
VALVE POS
2.5
Set valve 2 to pos 5
Capping A for 0.1 min
43
11.55
B
VALVE POS
2.6
Set valve 2 to pos 6
Capping B for 0.1 min
44
11.65
G
END OF LOOP
45
11.65
A
ML/MIN
0.00
Stop the flow
46
11.70
B
VALVE POS
2.3
Set valve 2 to pos 3
47
11.75
A
ML/MIN
2.50
Set flow rate 2.5 mL/min
48
12.25
A
ML/MIN
0.00
Stop the flow
49
12.30
B
VALVE POS
2.7
Set valve 2 to pos 7
50
12.35
A
ML/MIN
0.50
Set flow rate 0.5 mL/min
51
14.35
A
ML/MIN
0.00
Stop the flow
Acetonitrile wash for 0.5 min
Treatment with 1 mL DTT solution in 2 min (100 mM DTT in 2:3 v/v EtOH/H2 O)
continued 2 -MethylselenoModified Phosphoramidites and RNA
1.15.22 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Table 1.15.1 Oligoribonucleotide Assembly on a 1.3-µmol Scale with 2 -Methylseleno-Modified Phosphoramidites, continued
Meaninga
Comments
2.3
Set valve 2 to pos 3
Push residual DTT over column with acetonitrile for 0.55 min
ML/MIN
0.50
Set flow rate 0.5 mL/min
A
ML/MIN
2.00
Set flow rate 2 mL/min
16.50
A
ML/MIN
0.00
Stop the flow
56
16.55
B
VALVE POS
2.5
Set valve 2 to pos 5
57
16.60
A
ML/MIN
1.00
Set flow rate 1 mL/min
58
16.60
F
LOOP TIMES
2
Start the loop
59
16.60
B
VALVE POS
2.5
Set valve 2 to pos 5
Capping A for 0.1 min
60
16.70
B
VALVE POS
2.6
Set valve 2 to pos 6
Capping B for 0.1 min
61
16.80
G
END OF LOOP
62
16.80
A
ML/MIN
0.00
Stop the flow
63
16.85
B
VALVE POS
2.3
Set valve 2 to pos 3
64
16.90
A
ML/MIN
2.5
Set flow rate 2.5 mL/min
65
17.40
A
ML/MIN
0.00
Stop the flow
66
17.40
F
LOOP TIMES
7
Start of loop
67
17.40
C
STEP VALVE
3
Set valve 3 to next pos
68
17.40
G
END OF LOOP
Line
Time
Command
Function
52
14.40
B
VALVE POS
53
14.45
A
54
15.00
55
Value
Acetonitrile wash for 1.5 min
Acetonitrile wash for 0.5 min
Set valve 3 in recycle position
a # = 2 for A-amidite, 3 for C-amidite, 4 for G-amidite, 5 for U-amidite, 6 for custom X-amidite, 7 for custom Y-amidite.
5. Connect the following reagents to the synthesizer according to the manufacturer’s instructions:
Detritylation solution Oxidation solution Capping solutions A and B DTT solution 1,2-Dichloroethane Dry acetonitrile Phosphoramidite solutions BTT solution 6. Calculate the required amount of solid support based on its nucleoside load (as reported by the manufacturer) and the synthesis scale. Fill an empty synthesis column with the RNA support and connect it to the synthesizer. For example, a 1-µmol RNA synthesis requires a column filled with 25 mg of support carrying a nucleoside load of 40 µmol/g.
Synthesis of Modified Nucleosides
1.15.23 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Table 1.15.2 Detritylation Subroutine of the Method File for the Pharmacia Gene Assembler
Line
Time
Command
Function
Value
Meaning
Comments
1
0.00
B
VALVE POS
1.1
Set valve 1 to pos 1
2
0.00
B
VALVE POS
2.1
Set valve 2 to pos 1
3
0.00
C
STEP VALVE
3
4
0.00
A
ML/MIN
2.50
5
1.00
M
PORT SET
9.1
6
1.00
B
VALVE POS
2.2
7
1.10
M
PORT SET
9.0
8
1.10
H
CLEAR DATA
9
1.10
I
MONITOR
1
Selects monitor
Should be 1, only one monitor connected
10
1.10
J
LEVEL%
4
Specifies the value that the monitor signal has to pass to start/stop the integrator
Should be 4
11
1.10
K
INTEGRATE
1
Start integration
12
1.10
E
PS CALL
13
4.00
B
VALVE POS
2.1
Set valve 2 to pos 1
14
6.00
A
ML/MIN
0.00
Stop the flow
15
6.00
B
VALVE POS
2.7
Set valve 2 to pos 7
16
6.00
E
PS CALL
17
6.00
L
HOLD
18
6.00
A
ML/MIN
2.50
Set flow rate 2.5 mL/min
19
6.00
B
VALVE POS
2.2
Set valve 2 to pos 2
Dichloroethane wash
Step valve 3 to next pos Set flow rate 2.5 mL/min Auto zero the UV monitor Set valve 2 to pos 2
Start detritylation Initialization for new peak data
DETR-RET Peak Start Call
Conditional jump to method DETR-RETa if the start of a peak is detected
The software will indicate a HOLD instruction has been reached and will ask whether to continue
0
a This is a method for returning from the detritylation subroutine to the chain elongation method after a peak start was detected.
7. Purge the lines of the synthesizer with all solutions and solvents. 8. Carry out the assembly according to the manufacturer’s instructions. Choose the DMTr-OFF option in the setup menu. After the tenth coupling cycle, coupling yields of >99% can be expected when assayed by the detritylation colorimetric test. 2 -MethylselenoModified Phosphoramidites and RNA
9. Remove the synthesis column from the synthesizer and dry it in vacuo or under a stream of argon. 10. Deprotect the assembled, still fully protected oligoribonucleotide (see Basic Protocol 3).
1.15.24 Supplement 27
Current Protocols in Nucleic Acid Chemistry
DEPROTECTION, PURIFICATION, AND ANALYSIS OF RNA OLIGONUCLEOTIDES CONTAINING 2 -METHYLSELENO LABELS
BASIC PROTOCOL 3
This protocol describes the three-step deprotection of Se-modified RNA sequences assembled according to Basic Protocol 2. In the first step, the fully protected oligoribonucleotide attached to the solid-support is treated with a freshly prepared DTT solution in ethanol/H2 O to reduce potentially formed selenoxides. In the second step, methylamine in 50% ethanol is used to release the sequence from the solid support, eliminate the cyanoethyl groups, and remove the acetyl-protecting groups from the nucleobases. In the third step, TBAF in THF is used to remove the 2 -O-TOM protecting groups. This reaction is quenched by addition of aqueous TEAA solution (pH 7.4). A final desalting procedure with commercially available size-exclusion columns yields the crude RNA oligonucleotide. Additionally, this protocol describes purification by anion-exchange HPLC and determination of molecular weights of Se-modified RNA by LC-ESI mass spectrometry.
Materials Se-modified, protected oligoribonucleotide attached to the solid support (see Basic Protocol 2) 150 mM and 2 M DTT solutions (see recipe) 8 M methylamine in ethanol (Fluka) 40% (v/v) aqueous methylamine (Fluka) 50% (v/v) ethanol in water 1 M tetrabutylammonium fluoride trihydrate (TBAF·3H2 O; Fluka) in dry tetrahydrofuran (THF) N-Methylpyrrolidone (NMP) or N,N-dimethylformamide (DMF; optional) 1 M triethylammonium acetate (TEAA) buffer, pH 7.4, or 1 M Tris·Cl buffer, pH 7.4 (RNase-free, sterile; Fluka, for molecular biology) Eluant A: 25 mM Tris·Cl (pH 8.0; APPENDIX 2A)/6 M urea Eluant B: 25 mM Tris·Cl (pH 8.0)/0.5 M NaClO4 /6 M urea 0.1 M triethylammonium bicarbonate (TEAB) buffer Acetonitrile (CH3 CN) Ethylenediaminetetraacetic acid (EDTA) Eluant C: 8.6 mM triethylamine (TEA)/100 mM 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) in H2 O, pH 8.3 Eluant D: MeOH 1.5- or 2.0-mL microcentrifuge tubes (twist-top and/or screw-cap) 10-mL one-neck round-bottom flasks Rotary evaporator Speedvac evaporator ¨ ¨ HPLC system (e.g., Amersham AKTAprime or AKTApurifier system) with: 2.6 × 10–cm Amersham HiPrep 26/10 desalting column (Sephadex G25) 4 × 250– and 9 × 250–mm Dionex NucleoPac PA-100 or 200 columns C18 SepPak cartridges (Waters/Millipore) Lyophilizer LC-ESI mass spectrometer (e.g., Finnigan LCQ Advantage MAX ion trap) 2.1 × 100–mm Amersham µRPC C2/C18 column Perform DTT treatment 1. Remove solid support containing the Se-modified, protected oligoribonucleotide from the synthesis cartridge and transfer it into a 2.0-mL sealable screw-cap vial. 2. Add 200 µL of 150 mM DTT solution. Keep the closed vial 1 to 3 hr at room temperature with periodic shaking.
Synthesis of Modified Nucleosides
1.15.25 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Remove acetyl and cyanoethyl groups and release oligoribonucleotide from support 3. Add 0.6 mL of 8 M methylamine in ethanol, 0.6 mL of 40% methylamine in H2 O, and 95 µL of 2 M DTT solution (final DTT concentration 150 mM). 4. Incubate 6 hr at room temperature with periodic shaking. 5. Centrifuge 3 min at 12,500 × g, room temperature, and transfer supernatant from the 2.0-mL vial into a 10-mL one-neck flask. Alternatively, filter the solution through a small glass frit.
6. Wash solid support two times with 0.6 mL of 50% ethanol and add the washes to the flask. 7. Evaporate the solution to dryness on a rotary evaporator and dry briefly in vacuo.
Remove TOM groups 8. Add 0.95 mL of 1 M TBAF in dry THF to the 10-mL flask, and dissolve the crude 2 -O-TOM-protected oligoribonucleotide by vortexing. If the oligoribonucleotide is not dissolved after 10 min, add a few drops of NMP or DMF. Increase solution volume up to 1.6 mL for better solubility of long RNA sequences.
9. Incubate the solution overnight at room temperature with periodic shaking. 10. Quench the reaction by adding an equal volume of 1 M TEAA buffer, pH 7.4 (or 1 M Tris·Cl buffer, pH 7.4). 11. Concentrate to a volume of 0.8 mL. IMPORTANT NOTE: Do not overevaporate to dryness. Check the remaining volume frequently.
Desalt crude oligoribonucleotide 12. Apply the remaining solution to size-exclusion chromatography using a 2.6 × ¨ 10–cm Amersham HiPrep desalting column on an Amersham AKTAprime or ¨ AKTApurifier system, with simultaneous detection by conductivity and UV absorption. Elute with sterile water, pool the oligonucleotide-containing fractions, and evaporate to dryness. This step is required to remove excess TBAF, TEAA, and DTT. Alternatively, desalting can be performed on NAP-10 cartridges.
13. Dissolve the residue in 1.0 mL sterile water in a 2.0-mL screw-cap vial. This stock solution of the crude oligonucleotide can be stored for up to 1 week at −20◦ C.
Purify oligoribonucleotide 14. Prior to purification, analyze the crude product by anion-exchange chromatography. Use 1 to 2 µL of stock solution under the following conditions: Column: 4 × 250–mm Dionex NucleoPac PA-100 or 200 Temperature: 80◦ C Flow rate: 1 mL/min Eluant A: 25 mM Tris·Cl (pH 8.0)/6 M urea Eluant B: 25 mM Tris·Cl (pH 8.0)/0.5 M NaClO4 /6 M urea Gradient: 0% to 60% B in A over 45 min UV detection at 260 nm. 2 -MethylselenoModified Phosphoramidites and RNA
15. Purify the oligonucleotide by anion-exchange chromatography. Use 50- to 150-µL fractions of stock solution to avoid overloading the column. Combine productcontaining fractions.
1.15.26 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Column: 9 × 250–mm Dionex NucleoPac PA-100 Temperature: 80◦ C Flow rate: 2 mL/min Eluant A: 25 mM Tris·Cl (pH 8.0)/6 M urea Eluant B: 25 mM Tris·Cl (pH 8.0)/0.5 M NaClO4 /6 M urea Gradient: 8% to 25% B in A over 20 min UV detection at 275 nm. Desalt purified oligonucleotide 16. Dilute product-containing fractions with an approximately equal volume of 0.1 M TEAB buffer. 17. Load on a conditioned C18 SepPak cartridge. 18. Wash with 10 mL of 0.1 M TEAB buffer and then with 20 mL H2 O. 19. Elute product with 30 mL of 6:4 (v/v) H2 O/CH3 CN. 20. Lyophylize RNA-containing fractions.
Determine molecular weight 21. Apply 250 pmol Se-modified RNA oligonucleotide dissolved in 20 µL of 20 mM EDTA solution to an LC-ESI mass spectrometer (injection volume: 10 to 20 µL). Determine the molecular weight of the oligoribonucleotide in the negative-ion mode. Column: 2.1 × 100–mm Amersham µRPC C2/C18 Temperature: 21◦ C Flow rate: 100 µL/min Eluant C: 8.6 mM TEA/100 mM HFIP in H2 O, pH 8.3 Eluant D: MeOH Gradient: 0% to 100% D in C over 30 min UV detection at 254 nm. The above conditions were used with a Finnigan LCQ Advantage MAX ion trap instrument connected to an Amersham Ettan micro HPLC system with –4 kV applied to the spray needle.
ENZYMATIC LIGATION OF SELENIUM-MODIFIED RNA OLIGONUCLEOTIDES USING T4 RNA LIGASE
BASIC PROTOCOL 4
This protocol describes the enzymatic ligation of 2 -methylseleno-modified oligoribonucleotides at a nanomolar scale using T4 RNA ligase, as exemplified by the preparation of an adenine deaminase (add) adenine riboswitch aptamer domain (Fig. 1.15.5).
Materials 2 -Methylseleno-modified RNA oligonucleotide (see Basic Protocol 3) T4 RNA ligase 1 (ssRNA ligase, 20,000 U/mL) and 10× ligation buffer (New England Biolabs) Phenol (water-saturated) Chloroform Isoamyl alcohol 1.5-mL screw-cap vials 21◦ and 90◦ C heating block HPLC and LC-ESI-MS systems (see Basic Protocol 3)
Synthesis of Modified Nucleosides
1.15.27 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Figure 1.15.5 Enzymatic ligation of the adenine deaminase (add) adenine riboswitch aptamer domain (Vibrio vulnificus) with 2 -methylseleno labels. Ligation of the 71-nt RNA was achieved using T4 RNA ligase (0.20 U/µL; cRNA = 40 µM each strand; donor/acceptor = 1/1) at 21◦ C. DTT in ligation buffer is dithiothreitol. Analysis of the experiment by anion-exchange HPLC, denaturating PAGE, and LC-ESI-MS.
1. In a 1.5-mL screw-cap vial, mix 16 nmol of each of the 2 -methylseleno-modified RNA donor/acceptor strands drawn from their respective aqueous stock solutions. 2. Adjust the volume to 360 µL with water. 3. Heat to 90◦ C for 3 min, then allow to cool to 25◦ C within 15 min. 4. Add 40 µL of 10× ligation buffer and 4.0 µL (80 U) of T4 RNA ligase (in storage solution). This results in a final RNA concentration of 40 µM for each RNA fragment and a final ligase concentration of 0.2 U/µL. The 1× ligation buffer is 50 mM Tris·Cl, 10 mM MgCl2 , 10 mM dithiothreitol, 1 mM ATP, pH 7.8 at 25◦ C. For alternative ligation sites, optimize ligase concentration on a small scale.
5. Incubate the reaction solution 2 hr at 21◦ C. For alternative ligation sites, optimize ligation temperature and time on a small scale (using 400 pmol of each RNA fragment).
6. Inactivate the reaction solution by heating to 90◦ C for 3 min. 2 -MethylselenoModified Phosphoramidites and RNA
1.15.28 Supplement 27
Current Protocols in Nucleic Acid Chemistry
7. Extract the reaction mixture two times with an equal volume of 25:24:1 (v/v/v) phenol/chloroform/isoamyl alcohol and once with an equal volume of 24:1 (v/v) chloroform/isoamyl alcohol. This step is necessary to remove ligase protein, which may impair analysis and purification by HPLC in the following step.
8. Analyze and purify the ligation product by anion-exchange HPLC (see Basic Protocol 3, step 15). Alternatively, analyze and purify by denaturating polyacrylamide gel electrophoresis (APPENDIX 3B). HPLC purification is preferred as it leads to higher isolated yields.
9. Determine the molecular weight of the ligation product by LC-ESI mass spectrometry (see Basic Protocol 3, step 21).
ENZYMATIC LIGATION OF SELENIUM-MODIFIED RNA OLIGONUCLEOTIDES USING T4 DNA LIGASE
ALTERNATE PROTOCOL 4
This protocol describes the enzymatic ligation of 2 -methylseleno-modified oligoribonucleotides at a nanomolar scale using T4 DNA ligase, as exemplified by the preparation of an adenine deaminase (add) adenine riboswitch aptamer domain (Fig. 1.15.6). Because T4 DNA ligase catalyzes ligation of nicks in a duplex, a complementary oligonucleotide splint is used to bring the donor/acceptor sites together and form a duplex substrate.
Additional Materials (also see Basic Protocol 4) 2 -O-Methyl RNA oligonucleotide splint T4 DNA ligase (5 U/µL) and 10× ligation buffer (Fermentas) 50% (w/v) polyethylene glycol (PEG) 4000 (Fermentas) 1. In a 1.5-mL screw-cap vial, mix equimolar amounts of the splint oligonucleotide and each of the 2 -methylseleno-modified RNA donor/acceptor strands drawn from their respective aqueous stock solutions. 2. Dilute the resulting mixture with water to achieve a concentration of 20 to 40 µM for each oligonucleotide. 3. Heat to 90◦ C for 3 min, then allow to cool to 25◦ C within 15 min. 4. Calculate the final volume needed to bring each oligonucleotide to a concentration of 10 µM. Add 1/10 of this volume of 10× DNA ligase buffer (final 1× buffer = 40 mM Tris·Cl) and 1/10 vol of 50% (w/v) PEG 4000 (final 5%). 5. Adjust the reaction volume with water as needed to give 19/20 of the final volume. 6. Add 1/20 vol of 5 U/µL T4 DNA ligase (final 0.25 U/µL). 7. Incubate the reaction solution 4 hr at 37◦ C. For alternative ligation sites, optimize ligation temperature and time on a small scale.
8. Perform Basic Protocol 4, steps 6 to 9.
Synthesis of Modified Nucleosides
1.15.29 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Figure 1.15.6 Enzymatic ligation of the adenine deaminase (add) adenine riboswitch aptamer domain (Vibrio vulnificus) with 2 -methylseleno labels. Ligation of the 71-nt RNA was achieved using T4 DNA ligase and a 2 -Omethyl RNA splint oligonucleotide (0.25 U/µL; cRNA = 10 µM each strand; donor/acceptor/splint = 1/1/1) at 37◦ C. DTT in ligation buffer is dithiothreitol. (*Slight degradation of the product at 37◦ C was accepted for higher reaction rates).
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Anisaldehyde reagent In a clean container, mix 10 mL anisaldehyde with 180 mL ethanol. While stirring, add 10 mL concentrated sulfuric acid, followed by 2 mL acetic acid. Store up to 3 months at 4◦ C in the dark; avoid contamination with acetone. For staining, TLC plates are dipped into the solution and heated with a heat-gun until reaction compounds appear as dark spots.
Capping solution A 100 mL acetonitrile 6 g DMAP (0.5 M) Store in a dark well-sealed bottle up to 2 months at 25◦ C 2 -MethylselenoModified Phosphoramidites and RNA
1.15.30 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Capping solution B 50 mL acetonitrile 30 mL sym-collidine 20 mL acetic anhydride Store in a dark well-sealed bottle up to 2 months at 25◦ C Detritylation solution 40 mL dichloroacetic acid 960 mL 1,2-dichloroethane (or toluene) Store in a dark well-sealed bottle up to 2 months at 25◦ C DTT solution for oligonucleotide deprotection, 150 mM and 2 M 0.07 g or 0.92 g threo-1,4-dimercapto-2,3-butanediol (DTT) 1.5 mL ethanol 1.5 mL water Prepare fresh (preferred) or store in a vial up to 2 to 3 days in the dark at 4◦ C DTT solution for oligonucleotide synthesis, 100 mM 0.77 g threo-1,4-dimercapto-2,3-butanediol (DTT) 20 mL ethanol 30 mL water Prepare fresh (preferred) or store in a dark well-sealed bottle up to 2 to 3 days in the dark at 4◦ C Oxidation solution 0.40 g iodine (10 mM) 100 mL acetonitrile 9.2 mL sym-collidine 46 mL water Dissolve iodine in acetonitrile, then add sym-collidine followed by water. Store in a dark well-sealed bottle up to 1 week at 25◦ C.
COMMENTARY Background Information Application of 2 -methylseleno RNA In nucleic acid crystallography, seleniumlabeled DNA and RNA oligonucleotides were recently recognized to represent useful derivatives for convenient phasing of X-ray crystallographic data. Pioneering work by Egli, Huang, and co-workers led to the successful MAD-phasing of a short Z-form DNA duplex via phosphoroselenoate backbone modifications and of an A-form DNA duplex via 2 -methylselenouridine modifications (Du et al., 2002; Wilds et al., 2002). Advanced procedures for the preparation of 2 -methylseleno-modified RNA labeled at specific bases have since been introduced (H¨obartner and Micura, 2004; H¨obartner et al., 2005; Moroder et al., 2006) and are described in this unit. The use of threo-1,4-dimercapto-
2,3-butanediol (DTT) during all crucial steps of RNA preparation, including the solid-phase synthesis cycle, represents a major breakthrough. This innovation enables high performance in the preparation of high-purity RNAs with up to 100 nucleotides containing multiple Se-modified residues. Successful applications of the Se-derivatized RNAs have been reported recently for the X-ray structure determination of the group I intron with both exons (Adams et al., 2004) and for the structure determination of the Diels-Alder ribozyme by the SAD technique via site-specific incorporation of 2 -methylseleno pyrimidine derivatives (Serganov et al., 2005). Positioning of labels The replacement of the native 2 -hydroxyls with 2 -methylseleno groups does not significantly interfere with RNA secondary or
Synthesis of Modified Nucleosides
1.15.31 Current Protocols in Nucleic Acid Chemistry
Supplement 27
tertiary structure if the labels are properly positioned. As long as the 2 -methylseleno moieties reside in the covariant, double-helical regions of the target fold, and as long as the labeled and native RNAs comprise the same functional groups at their 5 and 3 ends (phosphates, triphosphates, cyclophosphates, or hydroxyl groups), crystallization behavior and structure of the Se-modified RNAs compare well with their nonlabeled counterparts (Du et al., 2002; Teplova et al., 2002; H¨obartner et al., 2005; Moroder et al., 2006). Comparison with other methods of derivatization Although heavy metal ion derivatization, achieved by soaking crystals in heavy atom salt solutions, is the established way to obtain crystals with anomalous scattering centers, labeling with covalent 2 -methylseleno groups is most competitive for structure analysis of RNAs comprising 30 to ∼80 nucleotides. Heavy atom search is a time-consuming process that requires soaking of the RNA crystals with dozens of compounds at various concentrations to obtain reasonably good crystals. Derivatization of RNA with selenium has more impact on nucleic acid crystallography than derivatization with 5-halogenated pyrimidines. Because of the availability of all four nucleoside phosphor2 -methylseleno amidites, there is greater flexibility for adequate positioning of the labels within an RNA target. In addition, nucleobase stacking interactions can be severely perturbed by 5-halogenated pyrimidines (Teplova et al., 2002). Moreover, in contrast to 2 -methylseleno nucleosides, 5-halogenated pyrimidine derivatives are highly photoreactive species (Gott et al., 1991; Xu and Sugiyama, 2004; Zeng and Wang, 2004); inherent radiation damage of 5-halogenmodified nucleic acids during MAD data collection has been documented as a limitation (Ennifar et al., 2002).
Critical Parameters
2 -MethylselenoModified Phosphoramidites and RNA
Nucleoside synthesis There are two critical features in the synthesis of 2 -methylseleno phosphoramidite building blocks. The first is the preparation of the sodium methyl selenoate in THF using dimethyl diselenide and an excess of sodium borohydride. Starting the reaction with anhydrous ethanol (see Basic Protocol 1, step 19) and filtering under inert conditions at the end of the reduction (see Basic Protocol 1, steps
20 and 21) is required to avoid interference by any nucleophiles other than the sodium methyl selenoate that would result in the generation of unwanted products. The second critical feature is the activation of 2 -hydroxyl groups required in the synthesis of the adenosine derivative S.12. Commercial trifluoromethanesulfonyl chloride of the highest quality should be used (see Alternate Protocol 2, step 2). Once the reagent bottle has been opened, it should be used for no longer than 1 month when stored at 4◦ C under argon. In addition, one should not use a larger excess of triethylamine than is described in Alternate Protocol 2 (steps 1 and 15; i.e., 2.5 equivalents) to prevent formation of elimination side products. For small-scale preparation, the equivalent-amounts of triethylamine can be reduced or can be replaced with N-ethyldiisopropylamine (see Alternate Protocol 2, step 1). Automated RNA solid-phase synthesis The DTT treatment step in the solid-phase synthesis cycle, as implemented in the Pharmacia Gene Assembler instrumentation (see Tables 1.15.1 and 1.15.2), is highly recommended. Furthermore, 2 -methylseleno phosphoramidite solutions should not be stored for more than 20 hr at room temperature. Contingent with RNA target design, it is advantageous to place the 2 -methylseleno labels closer to the 5 end than to the 3 end to minimize their exposure to the oxidation solution during synthesis. RNA deprotection, purification, and mass analysis The use of DTT during deprotection is required for high reproducibility (reflected in HPLC chromatograms of crude deprotected materials) and for high yields of the isolated 2 -methylseleno-modified RNA. The authors have evidence that DTT treatment is responsible for the conversion of 2 -methylselenoxides back to 2 -methylseleno groups (Moroder et al., 2006; unpub. observ.). During RNA oligonucleotide purification by anion-exchange chromatography, oligoribonucleotides with 2 -methylselenoxides elute faster than the desired 2 -methylseleno products under the conditions provided in Basic Protocol 3. If other RNA by-products are detected in minor amounts by mass analysis of the isolated product (e.g., 2-cyanoethyl adducts or partially deprotected RNAs), the authors recommend additional purification by ion-exchange chromatography (Dionex
1.15.32 Supplement 27
Current Protocols in Nucleic Acid Chemistry
DNAPac column) using a LiClO4 buffer system at 40◦ to 80◦ C without urea (eluant A: 25 mM Tris·Cl, pH 8.0; eluant B: 25 mM Tris·Cl, pH 8.0, 0.5 M LiClO4 ). Under these conditions, the elution of 2-cyanoethyl adducts and other partially deprotected RNAs is significantly slower and thus permits the contaminants to be well separated. RNA ligation The choice of ligation site is critical to obtain high overall yields when using T4 RNA ligase. Specifically, the site of ligation is best positioned within a single-stranded region comprising 1 to ∼10 nucleotides. The two strands to be ligated should be involved in strong inter-strand pairing interactions that are entropically favorable. Moreover, donor strands (providing the 5 -phosphate) with 5 -terminal pyrimidines are preferred slightly over purines by T4 RNA ligase, whereas 3 -terminal adenosines are the best acceptors. Cytidines and guanosines show intermediate reactivity, and terminal uridines are poor substrates (Arn and Abelson, 1998). It is also recommended to use donor strands that are 5 ,3 -bisphosphates to avoid cyclization of the donor strands and oligomerization by repeated ligation of the donor with previously formed ligation products. When using T4 DNA ligase, annealing of the two ligation fragments is supported by a splint oligonucleotide. Usually a 40- to 60-nt DNA splint is used; however, 16 to 26 nt are recommended for 2 -O-methyl RNA splints. Base-pairing between 2 -O-methyl RNA and RNA is thermodynamically favored compared to base-pairing of RNA with DNA. Therefore, competitive intramolecular secondary structure interactions are more easily broken up with a 2 -O-methyl RNA oligonucleotide compared to a DNA oligonucleotide of the same length. After ligation, during final HPLC purification under denaturing conditions, the ligation product can easily be separated from the splint oligonucleotide by the significant size difference.
Anticipated Results The isolated yields reported in the protocols for each step during phosphoramidite synthesis are representative of the yields typically obtained. The quality of reagents and the dryness of the solvents used will have a significant impact on product yield and purity, as will the amount of care taken during chromatographic purifications.
For a 1-µmol solid-phase synthesis, typical yields of HPLC-purified 2 -methylselenomodified RNA oligonucleotides are 50 to 200 nmol for sequences up to 50 nt with up to 6 methylseleno groups. When using T4 RNA ligase for ligation reactions, isolated yields of HPLC-purified 2 methylseleno-modified RNA are typically in the range of 40% to 60%. A total amount up to 40 nmol is easily obtained for sequences up to 90 nt. Yields are slightly lower for ligations using T4 DNA ligase (30% to 50%).
Time Considerations Each of the intermediates described in this unit can be prepared within 1 or 2 days. Synthesis of the 2 -methylselenouridine phosphoramidite is by far the shortest (5 days) compared to that of the 2 -methylselenocytidine phosphoramidite and 2 methylselenoadenosine phosphoramidite (2 to 3 weeks each), and that of the 2 methylselenoguanosine phosphoramidite (3 to 4 weeks). Solid-phase synthesis (1-µmol scale), deprotection, and purification of three to four 2 methylseleno-modified oligoribonucleotides of 25 to 30 nt each can typically be achieved within 5 days. Ligations of 2 -methylseleno-modified RNAs (product <100 nt), including optimization of ligation conditions on a small scale, are typically completed within 3 to 5 days, although several testing rounds may be needed to find the optimal ligation site.
Literature Cited Adams, P.L., Stahley, M.R., Kosek, A.B., Wang, J., and Strobel, S.A. 2004. Crystal structure of a self-splicing group I intron with both exons. Nature 430:45-50. Arn, E.A. and Abelson, J. 1998. RNA ligases: Function, mechanism, and sequence conservation. In RNA Structure and Function (R.W. Simons and M. Grunberg-Manago, eds.) pp. 695-726. CSHL Press, Cold Spring Harbor, N.Y. Du, Q., Carrasco, N., Teplova, M., Wilds, C.J., Egli, M., and Huang, Z. 2002. Internal derivatization of oligoribonucleotides with selenium for X-ray crystallography using MAD. J. Am. Chem. Soc. 124:24-25. Ennifar, E., Carpentier, P., Ferrer, J.L., Walter, P., and Dumas, P. 2002. X-ray-induced debromination of nucleic acids at the Br K absorption edge and implications for MAD phasing. Acta Crystallogr. D Biol. Crystallogr. 58:1262-1268. Gott, J.M., Wu, H., Koch, T.H., and Uhlenbeck, O.C. 1991. A specific, UV-induced RNAprotein cross-link using 5-bromouridinesubstituted RNA. Biochemistry 30:6290-6295.
Synthesis of Modified Nucleosides
1.15.33 Current Protocols in Nucleic Acid Chemistry
Supplement 27
H¨obartner, C. and Micura, R. 2004. The chemical synthesis of selenium-modified oligoribonucleotides and their enzymatic ligation leading to an U6 snRNA stem-loop segment. J. Am. Chem. Soc. 126:1141-1149. H¨obartner, C., Rieder, R., Kreutz, C., Puffer, B., Lang, K., Polonskaia, A., Serganov, A., and Micura, R. 2005. Combined chemical and enzymatic syntheses of RNAs with up to 100 nucleotides containing site-specific 2 -Se-methyl labels for use in X-ray crystallography. J. Am. Chem. Soc. 127:12035-12045. Moroder, H., Kreutz, C., Lang, K., Serganov, A., and Micura, R. 2006. Synthesis, oxidation behavior, crystallization and structure of 2 -methylseleno guanosine containing RNAs. J. Am. Chem. Soc. 128:9909-9918. Pitsch, S., Weiss, P.A., Jenny, L., Stutz, A., and Wu, X. 2001. Reliable chemical synthesis of oligoribonucleotides (RNA) with 2 O-[(triisopropylsilyl)oxy]methyl (2’-O-TOM) protected phosphoramidites. Helv. Chim. Acta 84:3773-3795. Serganov, A., Keiper, S., Malinina, L., Tereshko, V., Skripkin, E., H¨obartner, C., Polonskaia, A., Phan, A.T., Wombacher, R., Micura, R., Dauter, Z., Jaschke, A., and Patel, D.J. 2005. Structural basis for Diels-Alder ribozyme catalyzed carbon-carbon bond formation. Nat. Struct. Mol. Biol. 12:218-224.
Teplova, M., Wilds, C.J., Wawrzak, Z., Tereshko, V., Du, Q., Carrasco, N., Huang, Z., and Egli, M. 2002. Covalent incorporation of selenium into oligonucleotides for X-ray crystal structure determination via MAD: Proof of principle. Biochimie 84:849-858. Wilds, C.J., Pattanayek, R., Pan, C., Wawrzak, Z., and Egli, M. 2002. Selenium-assisted nucleic acid crystallography: Use of phosphoroselenoates for MAD phasing of a DNA structure. J. Am. Chem. Soc. 124:14910-14916. Xu, Y. and Sugiyama, H. 2004. Highly efficient photochemical 2 -deoxyribonolactone formation at the diagonal loop of a 5-iodouracilcontaining antiparallel G-quartet. J. Am. Chem. Soc. 126:6274-6279. Zeng, Y. and Wang, Y. 2004. Facile formation of an intrastrand cross-link lesion between cytosine and guanine upon pyrex-filtered UV light irradiation of d(Br CG) and duplex DNA containing 5-bromocytosine. J. Am. Chem. Soc. 126:65526553.
Contributed by Ronald Micura, Claudia H¨obartner, Renate Rieder, Christoph Kreutz, Barbara Puffer, Kathrin Lang, and Holger Moroder Leopold-Franzens University Innsbruck, Austria
2 -MethylselenoModified Phosphoramidites and RNA
1.15.34 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Palladium-Catalyzed Cross-Coupling Reactions in C6 Modifications of Purine Nucleosides
UNIT 1.16
The most efficient methodology for introducing carbon substituents to carbon atoms of purine derivatives (positions 2, 6, and 8) consists of palladium-catalyzed cross-coupling reactions of halopurines with organometallics. The protocols in this unit describe typical examples of reactions for modification of protected 6-chloropurine nucleosides. Basic Protocol 1 describes cross-coupling reactions of nucleoside S.1 with arylboronic acids, hetarylstannanes, trialkylaluminium, and benzylzinc chloride (Fig. 1.16.1), while Basic Protocol 2 describes the reaction of S.10 with (acetyloxy)methylzinc iodide (Fig. 1.16.2). The latter method affords tris-O-toluoyl-protected 6-(acetyloxymethyl)purine nucleoside S.12, which can be selectively deacetylated by ammonia in the presence of zinc chloride. The resulting sugar-protected 6-(hydroxymethyl)purine nucleoside S.13 can be converted to 6-(fluoromethyl)-, 6-(formyl)-, and 6-(difluoromethyl)purine nucleosides (see Basic Protocols 3 and 4). All the sugar-acylated nucleosides are easily deprotected by treatment with catalytic sodium methoxide in methanol.
CROSS-COUPLING OF AN ACETYL-PROTECTED 6-CHLOROPURINE NUCLEOSIDE
BASIC PROTOCOL 1
C6 modification of the acetyl-protected 6-chloropurine S.1 is described using four different cross-coupling reagents and one of two palladium catalysts, as shown in Figure 1.16.1. The four acetyl-protected products S.2-S.5 are purified and deprotected using a common set of steps.
Materials 6-Chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine (S.1; Buck and Reese, 1990) Cross-coupling reagent (Sigma-Aldrich): Phenylboronic acid 2-(Tributylstannyl)thiophene Trimethylaluminium (AlMe3 , 2 M solution in toluene) Benzylzinc chloride (1 M solution in THF) Potassium carbonate (K2 CO3 , anhydrous, Sigma-Aldrich) Palladium catalyst (Sigma-Aldrich): Tetrakis(triphenylphosphine)palladium (Pd(PPh3 )4 ) Bis(triphenylphosphine)palladium dichloride (PdCl2 (PPh3 )2 ) Argon Toluene (dried, degassed, and flushed with argon) Ethyl acetate N,N-Dimethylformamide (DMF, anhydrous under argon, Sigma-Aldrich) Tetrahydrofuran (THF, anhydrous, freshly distilled from Na/benzophenone under argon) Ammonium chloride (NH4 Cl) Anhydrous magnesium sulfate (MgSO4 ) Silica gel (200 to 400 mesh) Hexanes Chloroform Anhydrous methanol
ˇ ar Contributed by Michal Hocek and Peter Silh´ Current Protocols in Nucleic Acid Chemistry (2007) 1.16.1-1.16.17 C 2007 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Nucleosides
1.16.1 Supplement 28
Figure 1.16.1
Synthesis of 6-substituted purine nucleosides.
1 M sodium methoxide (NaOMe) in methanol Heptane 50-, 100-, and 250-mL round-bottom flasks with 14/20 joints, flame dried Rubber septa 21-G needles Vacuum system (oil pump with manifold and cold trap) Oil bath Glass frit (10- to 20-µm) Rotary evaporator (B¨uchi) equipped with a vacuum system (membrane pump Vacuubrand) Glass columns (3.5-cm i.d., 40-cm length) Silica gel 60 F254 aluminium TLC sheets (Merck) UV lamp and heat gun Vacuum pump Additional reagents and equipment for column chromatography (APPENDIX 3E) and TLC (APPENDIX 3D) Perform cross-coupling With phenylboronic acid 1a. Add 413 mg (1 mmol) S.1, 244 mg (2 mmol) phenylboronic acid, 200 mg (1.5 mmol) K2 CO3 , and 59 mg (0.05 mmol) Pd(PPh3 )4 to a flame-dried 100-mL round-bottom flask. 2a. Place a magnetic stir bar in the flask and seal it with a rubber septum. Place the flask on a magnetic stir plate, and connect to an argon/vacuum line via a 21-G needle inserted through the septum. 3a. Evaporate using the vacuum line, then flush with argon very slowly to prevent scattering of the powders. Repeat this procedure three times and leave the flask attached to the argon line on the manifold. 4a. Add 10 mL toluene through the septum. 5a. Place in an oil bath on the magnetic stir plate and heat the reaction flask to 90◦ C. Stir the reaction mixture 8 hr at 90◦ C. PalladiumCatalyzed C6 Modifications of Purine
6a. Cool the reaction mixture to ambient temperature.
1.16.2 Supplement 28
Current Protocols in Nucleic Acid Chemistry
7a. Dilute with 50 mL ethyl acetate and filter through a 10- to 20-µm frit. Wash the frit with 20 mL ethyl acetate. 8a. Evaporate the solution in vacuo. Proceed to step 10.
With 2-(tributylstannyl)thiophene 1b. Add 413 mg (1 mmol) S.1, 560 mg (1.5 mmol) 2-(tributylstannyl)thiophene, and 35 mg (0.05 mmol) PdCl2 (PPh3 )2 to a flame-dried 50-mL round-bottom flask. 2b. Place a magnetic stir bar in the flask and seal it with a rubber septum. Place the flask on a magnetic stir plate, and connect to an argon/vacuum line via a 21-G needle inserted through the septum. 3b. Evaporate using the vacuum line, then flush with argon very slowly to prevent scattering of the powders. Repeat this procedure three times and leave the flask attached to the argon line on the manifold. 4b. Add 5 mL DMF through the septum. 5b. Place in an oil bath on the magnetic stir plate and heat the reaction flask to 90◦ C. Stir the reaction mixture 8 hr at 90◦ C. 6b. Cool the reaction mixture to ambient temperature. 7b. Evaporate the solution in vacuo. Proceed to step 10.
With trimethylaluminium 1c. Add 413 mg (1 mmol) S.1 and 59 mg (0.05 mmol) Pd(PPh3 )4 to a flame-dried 100-mL round-bottom flask. 2c. Place a magnetic stir bar in the flask and seal it with a rubber septum. Place the flask on a magnetic stir plate, and connect to an argon/vacuum line via a 21-G needle inserted through the septum. 3c. Evaporate using the vacuum line, then flush with argon very slowly to prevent scattering of the powders. Repeat this procedure three times and leave the flask attached to the argon line on the manifold. 4c. Add 10 mL THF through the septum. 5c. While stirring, add dropwise 1 mL of 2 M trimethylaluminium (2 mmol). 6c. Place in an oil bath on the magnetic stir plate and heat the reaction flask to 70◦ C. Stir the reaction mixture 8 hr at 70◦ C. 7c. Cool the reaction mixture to ambient temperature. 8c. Pour the mixture onto a mixture of 200 mL crushed ice and 5 g NH4 Cl, and extract three times with 150 mL ethyl acetate. 9c. Dry the collected organic phases with anhydrous MgSO4 , filter, and evaporate in vacuo. Proceed to step 10.
With benzylzinc chloride 1d. Add 413 mg (1 mmol) S.1 and 59 mg (0.05 mmol) Pd(PPh3 )4 to a flame-dried 100-mL round-bottom flask. 2d. Place a magnetic stir bar in the flask and seal it with a rubber septum. Place the flask on a magnetic stir plate, and connect to an argon/vacuum line via a 21-G needle inserted through the septum.
Synthesis of Modified Nucleosides
1.16.3 Current Protocols in Nucleic Acid Chemistry
Supplement 28
3d. Evaporate using the vacuum line, then flush with argon very slowly to prevent scattering of the powders. Repeat this procedure three times and leave the flask attached to the argon line on the manifold. 4d. Add 10 mL THF through the septum. 5d. While stirring, add dropwise 2 mL of 1 M benzylzinc chloride (2 mmol). 6d. Place in an oil bath on the magnetic stir plate and heat the reaction flask to 70◦ C. Stir the reaction mixture 8 hr at 70◦ C. 7d. Cool the reaction mixture to ambient temperature. 8d. Pour the mixture onto a mixture of 200 mL crushed ice and 5 g NH4 Cl, and extract three times with 150 mL ethyl acetate. 9d. Dry the collected organic phases with anhydrous MgSO4 , filter, and evaporate in vacuo. Proceed to step 10.
Purify by chromatography 10. Pack a 3.5 × 40–cm glass column with 150 g of 200 to 400 mesh silica gel in 3:1 (v/v) hexanes/ethyl acetate. 11. Dissolve the evaporated residue of the crude acylated nucleoside (S.2-S.5) in 2 to 3 mL chloroform and apply it to the top of the silica gel column using a glass Pasteur pipet. Let the solution settle into the silica gel. 12. Elute with 500 mL each of 3:1, 2:1, and 1:1 (v/v) hexanes/ethyl acetate, followed by 500 mL pure ethyl acetate. Collect 40- to 50-mL fractions. 13. Analyze fractions by TLC using 2:1 (v/v) hexanes/ethyl acetate. 14. Transfer fractions containing pure product to a 250-mL round-bottom flask, evaporate, and dry under vacuum. 15. Confirm the structure of the product by NMR. 9-(2,3,5-Tri-O-acetyl-β-D-ribofuranosyl)-6-phenylpurine (S.2). Colorless amorphous solid, yield 79%. FAB MS, m/z (rel. %): 455 (22) [M+H], 197 (100) [M+H-AcRf]. 1 H NMR (400 MHz, CDCl3 ): 2.09, 2.13, and 2.16 (3 × s, 3 × 3H, CH3 ); 4.37-4.50 (m, 3H, H4 and 2 × H5 ); 5.71 (dd, 1H, J = 3.6 and 5.4 Hz, H3 ); 6.02 (t, 1H, J = 5.4 Hz, H2 ); 6.30 (d, 1H, J = 5.3 Hz, H1 ); 7.52-7.58 (m, 3H, HPh); 8.28 (s, 1H, H8); 8.76 (dd, 2H, J = 1.6 and 8.0 Hz, HPh); 9.03 (s, 1H, H2). 6-(2-Thienyl)-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine (S.3). Colorless amorphous solid, yield 89%. FAB MS, m/z (rel. %): 461 (100) [M+H]. 1 H NMR (400 MHz, CDCl3 ): 2.09, 2.14, and 2.16 (3 × s, 3 × 3H, CH3 CO); 4.37-4.50 (m, 3H, H4 and 2 × H5 ); 5.70 (dd, 1H, J = 5.4 and 4.4 Hz, H3 ); 6.00 (t, 1H, J = 5.4 Hz, H2 ); 6.28 (d, 1H, J = 5.4 Hz, H1 ); 7.27 (m, 1H, H-arom. overlapped with CHCl3 ); 7.63 (dd, 1H, J = 4.9 and 0.9 Hz, H-arom.); 8.26 (s, 1H, H8); 8.66 (dd, 1H, J = 3.7 and 0.9 Hz, H-arom.); 8.90 (s, 1H, H2). 13 C NMR (100 MHz, CDCl3 ): 20.37, 20.49, and 20.74 (3 × CH3 ); 63.04 (C5 ); 70.67 (C3 ); 73.11 (C2 ); 80.42 (C4 ); 86.33 (C1 ); 128.82 (CH-arom.); 129.44 (C5); 131.11 and 132.95 (CH-arom.); 139.70 (C-i-arom.); 142.47 (C8); 150.64 and 151.58 (C4 and C6); 152.75 (C2); 169.32, 169.54, and 170.27 (3 × CO). HRMS (FAB): calcd. for C20 H21 N4 O7 S [M+H], 461.1131; found, 461.1137.
PalladiumCatalyzed C6 Modifications of Purine
6-Methyl-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine (S.4). Colorless oil, yield 66%. 1 H NMR (400 MHz, CDCl3 ): 2.09, 2.13, and 2.16 (3 × s, 3 × 3H, CH3 CO); 2.87 (s, 3H, CH3 -6); 4.38 (dd, 1H, Jgem = 12.8, J5 b,4 = 5.2 Hz, H5 b); 4.44-4.49 (m, 2H, H4 and H5 a); 5.69 (dd, 1H, J3 ,2 = 5.6, J3 ,4 = 4.5 Hz, H3 ); 5.98 (t, 1H, J2 ,3 = 5.6, J2 ,1 = 5.2 Hz, H2 ); 6.24 (d, 1H, J1 ,2 = 5.2 Hz, H1 ); 8.18 (s, 1H, H8); 8.87 (s, 1H, H2). 13 C NMR (100.6 MHz, CDCl3 ): 19.51 (CH3 -6); 20.37, 20.52, and 20.74 (CH3 CO);
1.16.4 Supplement 28
Current Protocols in Nucleic Acid Chemistry
63.01 (C5 ); 70.61 (C3 ); 73.06 (C2 ); 80.35 (C4 ); 86.43 (C1 ); 133.65 (C5); 142.01 (C8); 150.12 (C4); 152.56 (C2); 159.94 (C6); 169.35, 169.56, and 170.29 (CO). 6-Benzyl-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine (S.5). Colorless amorphous solid, yield 62%. FAB MS, m/z (rel. %): 469 (14) [M+H], 211 (100). 1 H NMR (400 MHz, CDCl3 ): 2.07, 2.10, and 2.15 (3 × s, 3 × 3H, CH3 CO); 4.35-4.47 (m, 3H, H4 and 2 × H5 ); 4.52 (s, 2H, CH2 -Ph); 5.68 (dd, 1H, J = 4.3, 5.5 Hz, H3 ); 5.98 (dd, 1H, J = 5.3, 5.5 Hz, H2 ); 6.23 (d, 1H, J = 5.3 Hz, H1 ); 7.17-7.49 (m, 5H, H-arom.); 8.20 (s, 1H, H8); 8.90 (s, 1H, H2). 13 C NMR (100 MHz, CDCl3 ): 20.40, 20.54, and 20.74 (3 × CH3 ); 39.57 (CH2 Ph); 63.08 (C5 ); 70.69 (C3 ); 73.07 (C2 ); 80.45 (C4 ); 86.43 (C1 ); 126.75, 128.62, and 129.39 (CH-arom.); 133.17 and 137.62 (C5 and C-i-Ph); 142.52 (C8); 150.80 (C4); 152.92 (C2); 161.34 (C6); 169.36, 169.57, and 170.31 (3 × CO). HRMS (FAB): calcd. for C23 H25 N4 O7 [M+H], 469.1723; found, 469.1694.
Deprotect hydroxyl groups 16. Dissolve 0.5 to 0.9 mmol of purified acylated nucleoside (S.2-S.5) in 100 mL anhydrous methanol in a 250-mL round-bottom flask. 17. Add 100 µL of 1 M NaOMe (0.1 mmol) and allow to stand overnight at ambient temperature. Monitor the progress of the reaction by TLC using ethyl acetate. 18. Evaporate the solvent. Recrystallize the product from a mixture of 5 mL methanol and 5 mL toluene and subsequent addition of 20 mL hot heptane. 19. Confirm the structure by NMR. 6-Phenyl-9-(β-D-ribofuranosyl)purine (S.6). Colorless crystals, yield 66%. m.p. 228◦ 230◦ C. [α]D −56.1 (c 0.5 DMF). FAB MS, m/z (rel. %): 329 (35) [M+H], 197 (75) [M+H-Rf]. 1 H NMR (400 MHz, DMSO-d6 ): 3.31 (s, 3H, CH3 ); 3.59-3.65 and 3.70-3.76 (2 × m, 2H, CH2 -5 ); 4.02 (m, 1H, H4 ); 4.23 (m, 1H, H3 ); 4.67 (ddd, 1H, J = 4.8, 5.5 and 5.7 Hz, H2 ); 5.13 (t, 1H, J = 5.4 Hz, 5 -OH); 5.25 (d, 1H, J = 5.0 Hz, 3 -OH); 5.56 (d, 1H, J = 5.7 Hz, 2 -OH); 6.11 (d, 1H, J = 5.5 Hz, H1 ); 7.55-7.65 (m, 3H, H-Ph); 8.84 (d, 2H, J = 8.0 Hz, H-Ph); 8.93 (s, 1H, H8); 9.02 (s, 1H, H2). UV λmax (ε): methanol, 290 (18300); water, pH 7, 289 (16800); pH 2, 298 (15700); pH 11, 289 (17100). Anal. calcd. for C16 H16 N4 O (280.3): C, 68.55; H, 5.75; N, 19.99; found: C, 68.82; H, 4.79; N, 20.04. 6-(2-Thienyl)-9-(β-D-ribofuranosyl)purine (S.7). Colorless crystals, yield 66%. m.p. 126◦ -129◦ C (96% aq. EtOH/toluene). [α]D −55.26 (c 0.2, DMF). FAB MS, m/z (rel. %): 335 (19) [M+H], 93 (100). 1 H NMR (400 MHz, DMSO-d6 ): 3.58-3.64 and 3.703.75 (2 × m, 2H, CH2 -5 ); 4.01 (m, 1H, H4 ); 4.22 (m, 1H, H3 ); 4.65 (ddd, 1H, J = 4.7, 5.4 and 5.9 Hz, H2 ); 5.13 (t, 1H, J = 5.5 Hz, 5 -OH); 5.24 (d, 1H, J = 5.0 Hz, 3 -OH); 5.55 (d, 1H, J = 5.9 Hz, 2 -OH); 6.07 (d, 1H, J = 5.4 Hz, H1 ); 7.35 (dd, 1H, J = 3.2 and 4.9 Hz, H-arom.); 7.94 (d, 1H, J = 4.9 Hz, H-arom.); 8.65 (d, 1H, J = 3.2 Hz, H-arom.); 8.87 and 8.90 (2 × s, 2 × 1H, H8 and H2). 13 C NMR (100.6 MHz, DMSO-d6 ): 61.23 (C5 ); 70.27 (C3 ); 73.80 (C2 ); 85.71 (C4 ); 87.76 (C1 ); 128.63 (C5); 129.13, 131.87 and 132.54 (CH-arom.); 139.59 (C-i-arom.); 145.06 (C8); 148.76 (C6); 151.67 (C4); 152.02 (C2). UV (MeOH) λmax (εmax ): 323 (23300), 270 (6400), 228 (8900). Anal. calcd. for C14 H16 N4 O5 S·H2 O (352.4): C, 47.72%; H, 4.58%; N, 15.90%; found: C, 47.81%; C, 4.60%; N, 15.67%. 6-Methyl-9-(β-D-ribofuranosyl)purine (S.8). Colorless crystals, yield 80%. m.p. 207◦ 209◦ C. [α]D −51.2 (c 0.2, DMF) [Lit.: m.p. 209◦ C, [α]D −52.1 (MeOH)]. 1 H NMR (400 MHz, DMSO-d6 ): 2.73 (s, 3H, CH3 ); 3.57 (ddd, 1H, Jgem =12.0, J5 b,OH =6.1, J5 b,4 = 4.0 Hz, H5 b); 3.69 (ddd, 1H, Jgem = 12.0, J5 a,OH = 5.2, J5 a,4 = 4.0 Hz, H5 a); 3.98 (q, 1H, J4 ,5 = 4.0, J4 ,3 = 3.6 Hz, H4 ); 4.19 (td, 1H, J3 ,2 = J3,OH = 4.9, J3 ,4 = 3.6 Hz, H3 ); 4.63 (q, 1H, J2 ,OH = 6.0, J2 ,1 = 5.7, J2 ,3 = 4.9 Hz, H2 ); 5.13 (t, 1H, JOH,5 = 6.1, 5.2 Hz, 5 -OH); 5.25 (d, 1H, JOH,3 = 4.9 Hz, 3 -OH); 5.53 (d, 1H, JOH,2 = 6.0 Hz, 2 -OH); 6.02 (d, 1H, J1 ,2 = 5.7 Hz, H1 ); 8.76 and 8.79 (2 × s, 2 × 1H, H2, H8). 13 C NMR (100.6 MHz, DMSO-d6 ): 19.28 (CH3 ); 61.48 (C5 ); 70.51 (C3 ); 73.84 (C2 ); 85.87 (C4 ); 87.81 (C1 ); 133.09 (C5); 144.19 (C8); 150.26 (C4); 151.84 (C2); 158.53 (C6).
Synthesis of Modified Nucleosides
1.16.5 Current Protocols in Nucleic Acid Chemistry
Supplement 28
6-Benzyl-9-(β-D-ribofuranosyl)purine (S.9). Colorless crystals, yield 66%. m.p. 97◦ 100◦ C (EtOH/toluene/heptane). [α]D −47.73 (c 0.2, DMF). FAB MS, m/z (rel. %): 343 (16) [M+H], 52 (32), 185 (45), 93 (100). 1 H NMR (500 MHz, DMSO-d6 ): 3.55-3.60 and 3.66-3.71 (2 × m, 2H, CH2 -5 ); 3.98 (m, 1H, H4 ); 4.19 (m, 1H, H3 ); 4.42 (s, 2H, CH2 Ph); 4.65 (m, 1H, H2 ); 5.09 (t, 1H, J = 5.5 Hz, 5 -OH); 5.22 (d, 1H, J = 4.8 Hz, 3 -OH); 5.51 (d, 1H, J = 5.9 Hz, 2 -OH); 6.02 (d, 1H, J = 5.7 Hz, H1 ); 7.15-7.39 (m, 5H, H-arom.); 8.81 and 8.83 (2 × s, 2 × 1H, H8 and H2). 13 C NMR (100 MHz, DMSO-d6 ): 38.57 (CH2 Ph); 61.23 (C5 ); 70.29 (C3 ); 73.52 (C2 ); 85.67 (C4 ); 87.58 (C1 ); 126.32, 128.34 and 129.02 (CH-arom.); 132.36 and 137.92 (C5 and C-i-arom.); 144.52 (C8); 151.88 (C2); 150.67 and 159.75 (C4 and C6). UV (MeOH), λmax (εmax ): 263 (5600). Anal. calcd. for C17 H18 N4 O4 (342.3): C, 59.64%; H, 5.30%; N, 16.37%; found: C, 59.25%; H, 5.31%; N, 15.99%. BASIC PROTOCOL 2
CROSS-COUPLING OF A TOLUOYL-PROTECTED 6-CHLOROPURINE NUCLEOSIDE C6-modification of the toluoyl-protected 6-chloropurine S.10 with (acetyloxymethyl)zinc iodide is shown in Figure 1.16.2. The acetylated product S.12 can be deacetylated and deprotected to yield S.14, or can be deacetylated to yield S.13, which is the starting compound for further substitution reactions described in Basic Protocols 3 and 4.
Materials ˇ ar et al., 6-Chloro-9-[2,3,5-tri-O-(p-toluoyl)-β-D-ribofuranosyl]purine S.10 (Silh´ 2005b) Tetrakis(triphenylphosphine)palladium (Pd(PPh3 )4 ) Argon Tetrahydrofuran (THF, anhydrous, freshly distilled from Na/benzophenone under argon) 1 M (acetyloxymethyl)zinc iodide in THF (S.11, see Support Protocol) 1 M NaH2 PO4 Chloroform Anhydrous magnesium sulfate (MgSO4 ) Silica gel (200 to 400 mesh) Hexanes Ethyl acetate Dichloromethane Ethanol Zinc chloride Anhydrous methanol 25%wt. aq. ammonia 1 M sodium methoxide (NaOMe) in methanol 25- and 250-mL round-bottom flasks with 14/20 joints, flame dried Rubber septum Vacuum system (oil pump with manifold and cold trap) 21-G needle Rotary evaporator (B¨uchi) equipped with a vacuum system (membrane pump Vacuubrand) Glass columns (3-cm i.d., 20-cm length) Silica gel 60 F254 aluminium TLC sheets (Merck) UV lamp and heat gun Vacuum pump PalladiumCatalyzed C6 Modifications of Purine
Additional reagents and equipment for column chromatography (APPENDIX 3E) and TLC (APPENDIX 3D)
1.16.6 Supplement 28
Current Protocols in Nucleic Acid Chemistry
Figure 1.16.2
Synthesis and transformations of 6-(hydroxymethyl)purines.
Perform cross-coupling with (acetyloxymethyl)zinc iodide 1. Add 641 mg (1 mmol) S.10 and 59 mg (0.05 mmol) Pd(PPh3 )4 to a flame-dried 25-mL round-bottom flask. 2. Place a magnetic stir bar in the flask and seal it with a rubber septum. Place the flask on a magnetic stir plate, and connect to an argon/vacuum line via a 21-G needle inserted through the septum. 3. Evaporate using the vacuum line, then flush with argon very slowly to prevent scattering of the powders. Repeat this procedure three times and leave the flask attached to the argon line on the manifold. 4. Add 10 mL THF through the septum. 5. While stirring, add 3 mL of 1 M (acetyloxymethyl)zinc iodide (S.11, 3 mmol) in THF. Continue stirring 8 hr at ambient temperature. 6. Pour the mixture into 50 mL of 1 M NaH2 PO4 and extract four times with 50 mL chloroform. 7. Dry the collected organic phases with anhydrous MgSO4 , filter, and evaporate.
Synthesis of Modified Nucleosides
1.16.7 Current Protocols in Nucleic Acid Chemistry
Supplement 28
8. Pack a 3 × 20–cm glass column with 200 to 400 mesh silica gel in 3:1 (v/v) hexanes/ethyl acetate. 9. Dissolve the evaporated residue in 2 to 3 mL chloroform and apply it to the top of the silica gel column using a glass Pasteur pipet. Let the solution settle into the silica gel. 10. Elute with 500 mL each of 3:1, 2:1, 1:1, and 1:2 (v/v) hexanes/ethyl acetate. Collect 40- to 60-mL fractions. 11. Analyze fractions by TLC using 1:1 (v/v) hexanes/ethyl acetate. Beside the desired product S.12, a small amount of more polar deacetylated (hydroxymethyl)purine S.13 forms.
12. Transfer fractions containing pure products to a 250-mL round-bottom flask and evaporate. 13. Co-evaporate the residues with 50 mL dichloromethane. Dry the resulting foams under vacuum. 14. Confirm the structure of the products by NMR. 6-(Acetyloxymethyl)-9-[2,3,5-tri-O-(p-toluoyl)-β-D-ribofuranosyl]purine (S.12). Yield: 550 mg (81%) of yellowish foam. Exact mass (FAB HRMS) found: 679.2415; calcd. for C37 H35 N4 O9 : 679.2404. FAB MS m/z (%): 679 (MH+ , 1); 487 (10); 193 (4); 151 (5); 119 (100). 1 H NMR (400 MHz, CDCl3 ): 2.21 (s, 3H, CH3 -Ac); 2.38 and 2.42 (2 × s, 9H, CH3 -Tol); 4.66 (dd, 1H, Jgem = 12.2, J5 b,4 = 4.1 Hz, H5 b); 4.82 (td, 1H, J4 ,3 = 4.6, J4 ,5 = 4.1, 3.1 Hz, H4); 4.89 (dd, 1H, Jgem = 12.2, J5 a,4 = 3.1 Hz, H5 a); 5.60 (s, 2H, O-CH2 ); 6.20 (dd, 1H, J3 ,2 = 5.8, J3 ,4 = 4.6 Hz, H3 ); 6.38 (t, 1H, J2 ,3 = 5.8, J2 ,1 = 5.5 Hz, H2 ); 6.48 (d, 1H, J1 ,2 = 5.5 Hz, H1 ); 7.16, 7.22, and 7.26 (3 × m, 3 × 2H, H-m-Tol); 7.81, 7.91, and 7.99 (3 × m, 3 × 2H, H-o-Tol); 8.23 (s, 1H, H8); 8.85 (s, 1H, H2). 13 C NMR (100.6 MHz, CDCl3 ): 20.80 (CH3 -Ac); 21.70 and 21.73 (CH3 -Tol); 62.42 (O-CH2 ); 63.41 (C5 ); 71.39 (C3 ); 73.66 (C2 ); 81.06 (C4 ); 86.84 (C1 ); 125.60, 125.99, and 126.56 (C-i-Tol); 129.22, 129.26, and 129.34 (CH-m-Tol); 129.77, 129.86, and 129.88 (CH-o-Tol); 132.35 (C5); 143.41 (C8); 144.24, 144.59, and 144.71 (C-p-Tol); 151.27 (C4); 152.65 (C2); 155.69 (C6); 165.15, 165.37, and 166.18 (CO-Tol); 170.74 (CO-Ac). 6-(Hydroxymethyl)-9-[2,3,5-tri-O-(p-toluoyl)-β-D-ribofuranosyl]purine (S.13). Yield: 63 mg (10%) of yellowish foam. Exact mass (FAB HRMS) found: 673.2313; calcd. for C35 H33 N4 O8 : 673.2298. FAB MS m/z (%): 637 (MH+ , 4); 487 (5); 151 (4); 119 (100). 1 H NMR (500 MHz, DMSO-d6 ): 2.34, 2.38, and 2.39 (3 × s, 3 × 3H, CH3 -Tol); 4.63 (dd, 1H, Jgem = 12.3, J5 b,4 = 4.8 Hz, H5 b); 4.78 (dd, 1H, Jgem = 12.3, J5 a,4 = 3.6 Hz, H5 a); 4.85 (ddd, 1H, J4 ,3 = 5.7, J4 ,5 = 4.8, 3.6 Hz, H4); 4.89 (d, 2H, JCH2,OH = 6.3 Hz, CH2 -OH); 5.46 (t, 1H, JOH,CH2 = 6.3 Hz, OH); 6.23 (dd, 1H, J3 ,2 = 6.0, J3 ,4 = 5.7 Hz, H3 ); 6.51 (dd, 1H, J2 ,3 = 6.0, J2 ,1 = 4.7 Hz, H2 ); 6.66 (d, 1H, J1 ,2 = 4.7 Hz, H1 ); 7.25, 7.30, and 7.31 (3 × m, 3 × 2H, H-m-Tol); 7.76, 7.85 and 7.87 (3 × m, 3 × 2H, H-o-Tol); 8.76 (s, 1H, H2); 8.79 (s, 1H, H8). 13 C NMR (125.8 MHz, DMSO-d6 ): 21.36, 21.37, and 21.39 (CH3 -Tol); 60.14 (CH2 -OH); 63.19 (C5 ); 70.76 (C3 ); 72.91 (C2 ); 79.59 (C4 ); 86.75 (C1 ); 125.75, 126.07, and 126.72 (C-i-Tol); 129.45, 129.52, 129.60, and 129.62 (CH-Tol); 131.81 (C5); 144.06, 144.57, and 144.69 (C-p-Tol); 145.59 (C8); 150.61 (C4); 152.07 (C2); 160.36 (C6); 164.66, 164.86, and 165.59 (CO-Tol).
Selectively deacetylate S.12 15. Dissolve 500 mg (0.736 mmol) of 6-(acetyloxymethyl)purine derivative S.12 in 25 mL ethanol. PalladiumCatalyzed C6 Modifications of Purine
16. Add 120 mg (0.883 mmol) zinc chloride and 0.4 mL of 25 %wt. aqueous ammonia (6 mmol).
1.16.8 Supplement 28
Current Protocols in Nucleic Acid Chemistry
17. Stir the reaction mixture for 36 hr at ambient temperature and monitor the reaction by TLC using 1:1 (v/v) hexanes/ethyl acetate. Even after 36 hr a small amount of starting compound S.12 is present.
18. Add 3 g silica gel to the reaction mixture and evaporate solvents. 19. Pack a 3 × 20–cm glass column with 200 to 400 mesh silica gel in 2:1 (v/v) hexanes/ethyl acetate. 20. Add the adsorbed product on the top of the silica gel column. 21. Elute with 500 mL each of 1:1, 1:2, and 1:3 (v/v) hexanes/ethyl acetate. Collect 40to 60-mL fractions. 22. Analyze fractions by TLC using 1:2 (v/v) hexanes/ethyl acetate. Beside the desired deacetylated product S.13, a small amount (∼10%) of less polar starting compound S.12 can be eluted.
23. Transfer fractions containing pure product to a 250-mL round-bottom flask and evaporate. 24. Co-evaporate the residue with 50 mL dichloromethane. Dry the resulting foam under vacuum. 25. Characterize the product by NMR. Yield of S.13: 277 mg (59%) as white foam.
Deprotect S.12 26. Dissolve 0.5 to 0.9 mmol S.12 in 100 mL anhydrous methanol in a 250-mL roundbottom flask. 27. Add 100 µL of 1 M NaOMe (0.1 mmol) and allow the solution to stand overnight at ambient temperature. Monitor the progress by TLC using 10:1 (v/v) ethyl acetate/ methanol. 28. Add 3 g silica gel to the reaction mixture and evaporate solvents. 29. Pack a 3 × 20–cm glass column with silica gel in 1:3 (v/v) hexanes/ethyl acetate. 30. Add the adsorbed product on the top of the silica gel column and elute with 300 mL of 10:1 and 600 mL of 8:2 (v/v) ethyl acetate/methanol. Collect 40- to 60-mL fractions. 31. Analyze by TLC using 10:1 (v/v) ethyl acetate/methanol. 32. Transfer fractions containing pure product to a 250-mL round-bottom flask and evaporate solvents. 33. Confirm the structure by NMR. 6-(Hydroxymethyl)-9-(β-D-ribofuranosyl)purine (S.14). Yield: 80% of white hygroscopic solid (lyophilized from water). 1 H NMR (400 MHz, MeOD): 3.77 (dd, 1H, Jgem = 12.3, J5 b,4 = 3.3 Hz, H5 b); 3.89 (dd, 1H, Jgem = 12.3, J5 a,4 = 3.0 Hz, H5 a); 4.16 (q, 1H, J4 ,3 = 3.6, J4 ,5 b = 3.3, J4 ,5 a = 3.0 Hz, H4 ); 4.36 (dd, 1H, J3 ,2 = 5.1, J3 ,4 = 3.6 Hz, H3 ); 4.74 (t, 1H, J2 ,1 = 5.6, J2 ,3 = 5.1 Hz, H2 ); 5.09 (s, 2H, O-CH2 ); 6.14 (d, 1H, J1 ,2 = 5.6 Hz, H1 ); 8.74 (s, 1H, H8); 8.89 (s, 1H, H2). 13 C NMR (100.6 MHz, MeOD): 61.51 (O-CH2 ); 62.99 (C5 ); 72.18 (C3 ); 75.76 (C2 ); 87.62 (C4 ); 90.71 (C1 ); 132.82 (C5); 146.32 (C8); 152.10 (C4); 153.05 (C2); 161.07 (C6). Anal. calcd. for C11 H14 N4 O5 ·H2 O: C, 44.00; H, 5.37; N, 18.66; found: C, 44.40; H, 5.29; N, 18.37.
Synthesis of Modified Nucleosides
1.16.9 Current Protocols in Nucleic Acid Chemistry
Supplement 28
SUPPORT PROTOCOL
PREPARATION OF (ACETYLOXYMETHYL)ZINC IODIDE Preparation of (acetyloxymethyl)zinc iodide is performed in three reactions and is illustrated in the top of Figure 1.16.2.
Materials Paraformaldehyde (Sigma-Aldrich) Zinc chloride (ZnCl2 , Sigma-Aldrich) Dichloromethane Acetyl chloride (AcCl; Sigma-Aldrich) Sodium iodide (NaI; Sigma-Aldrich) Argon Dry acetone Hexanes Zinc dust (Sigma-Aldrich) Dry tetrahydrofuran (THF) 1,2-Dibromoethane (Sigma-Aldrich) Chlorotrimethylsilane (Sigma-Aldrich) Iodomethyl acetate 25-mL, 250-mL, and 1-L round-bottom flasks, flame dried Reflux condenser Dropping funnel with a by-pass Vacuum system (oil pump with manifold and cold trap) Distillation head Vacuum pump Glass frit Rotary evaporator (B¨uchi) equipped with a vacuum system (membrane pump Vacuubrand) Rubber septum 21-G needles Prepare chloromethyl acetate 1. Add 15 g (0.5 mol) paraformaldehyde, 0.68 g (5 mmol) dry ZnCl2 , and a magnetic stir bar to a 250-mL round-bottom flask. 2. Add 30 mL dichloromethane and fit the flask with a reflux condenser. Place on a magnetic stir plate and mix the suspension. Place a dropping funnel with a by-pass on top of the condenser. 3. Add 36 mL (0.51 mol) acetyl chloride dropwise from the dropping funnel into the stirred suspension. CAUTION: The reaction is considerably exothermic. Add AcCl slowly. The exothermic reaction starts after addition of ∼5 to 10 mL of AcCl.
4. After complete addition of AcCl, stir the reaction mixture for 8 hr at ambient temperature. 5. Fit the flask with a distillation head and distill the chloromethyl acetate in vacuo. Collect the fraction with a boiling point of 48◦ to 53◦ C/100 mbar. Yield: 24 g (45%). This crude chloromethyl acetate is used directly for preparation of iodomethyl acetate. PalladiumCatalyzed C6 Modifications of Purine
Prepare iodomethyl acetate 6. Add 43 g (0.288 mol) NaI to a 1-L round-bottom flask and heat it to ∼200◦ C for 5 min. Dry under vacuum. Fill the flask with argon.
1.16.10 Supplement 28
Current Protocols in Nucleic Acid Chemistry
7. Add a magnetic stir bar and 150 mL dry acetone to the flask. 8. Add the crude chloromethyl acetate (24 g, 0.221 mol) to the NaI solution (solid NaCl begins to separate immediately) and stir the reaction mixture 5 hr at ambient temperature. 9. To crystalize unreacted NaI, add 600 mL hexanes to the reaction mixture and filter off the solids through a glass frit. 10. Evaporate the solvents in vacuo. 11. Purify iodomethyl acetate by vacuum distillation. Collect the fraction with a boiling point of 33◦ to 35◦ C/5 mbar. Yield: 26.5 g (60%). 1 H NMR (200 MHz, CDCl3 ): 2.10 (s, 3H, Ac); 5.90 (s, 2H, CH2 ).
12. Store iodomethyl acetate at −20◦ C. Iodomethyl acetate is a slightly unstable compound; after 1 to 2 months it turns dark.
Prepare (acetyloxymethyl)zinc iodide 13. Add 1.31 g (20 mmol) zinc dust to a flame-dried 25-mL round-bottom flask. 14. Place a magnetic stir bar in the flask and seal it with a rubber septum. Place the flask on a magnetic stir plate, and connect to an argon/vacuum line via a 21-G needle inserted through the septum. 15. Evaporate using the vacuum line, then flush with argon. Repeat this procedure three times and leave the flask attached to the argon line on the manifold. 16. Add 4 mL dry THF, 20 µL of 1,2-dibromoethane, and 20 µL chlorotrimethylsilane through the septum and stir 15 min at ambient temperature. 17. While stirring, add dropwise a solution of 2.00 g (10 mmol) iodomethyl acetate in 5 mL dry THF at 0◦ to 5◦ C. 18. Stir the reaction mixture 1 hr at 0◦ to 5◦ C. 19. Allow nonreacted zinc to settle, leaving a clear solution of (acetyloxymethyl)zinc iodide (S.11) in THF. This solution can be stored at −20◦ C in a septum-sealed flask under an argon atmosphere for 1 to 2 weeks. If desired, the concentration of organozinc can be determined by complexometric titration of Zn(II) ions in a hydrolyzed aliquot (average value ∼1.0 M).
PREPARATION OF 6-(FLUOROMETHYL)PURINE Deoxo-fluorination of the 6-(hydroxymethyl)purine derivative S.13 is performed in a single reaction, followed by purification and deprotection to yield the 6-(fluoromethyl)purine S.16 (Fig. 1.16.2).
BASIC PROTOCOL 3
Materials 6-(Hydroxymethyl)purine (S.13; see Basic Protocol 2) Argon Dry dichloromethane Deoxo-Fluor ([bis-(2-methoxyethyl)amino]sulfur trifluoride, Sigma-Aldrich) 5% aq. NaHCO3 Chloroform Anhydrous magnesium sulfate (MgSO4 ) Ethyl acetate Methanol
Synthesis of Modified Nucleosides
1.16.11 Current Protocols in Nucleic Acid Chemistry
Supplement 28
25-mL round-bottom flask Rubber septum 21-G needles Vacuum system (oil pump with manifold and cold trap) Rotary evaporator (B¨uchi) equipped with a vacuum system (membrane pump Vacuubrand) Additional reagents and equipment for deprotection and purification (see Basic Protocol 2) Perform deoxo-fluorination 1. Add 320 mg (0.5 mmol) of 6-(hydroxymethyl)purine S.13 to a 25-mL round-bottom flask. 2. Place a magnetic stir bar in the flask and seal it with rubber septum. Place the flask on a magnetic stir plate, and connect to an argon/vacuum line via a 21-G needle inserted through the septum. 3. Evaporate using the vacuum line, then flush with argon very slowly to prevent scattering of the powders. Repeat this procedure three times and leave the flask attached to the argon line on the manifold. 4. Add 20 mL dry dichloromethane through the septum and cool the solution to −20◦ C. 5. While stirring, add 185 µL (1 mmol) Deoxo-Fluor and allow the reaction mixture to warm to ambient temperature. Stir the reaction mixture 8 hr at ambient temperature. 6. Pour the mixture into 40 mL of cold 5% aq. NaHCO3 and extract four times with 40 mL chloroform. 7. Combine the organic phases, dry with anhydrous MgSO4 , filter, and evaporate. 8. Purify the fluorinated nucleoside S.15 by chromatography as in Basic Protocol 2, steps 8 through 14. For TLC analysis, the desired product S.15 is less polar than the starting compound. 6-(Fluoromethyl)-9-[2,3,5-tri-O-(p-toluoyl)-β-D-ribofuranosyl]purine (S.15). Yield: 130 mg (41%) of white foam. Exact mass (FAB HRMS) found: 639.2228; calcd. for C35 H32 FN4 O7 : 639.2255. FAB MS m/z (%): 639 (M+ , 2); 621 (2); 487 (10); 119 (100). 1 H NMR (400 MHz, CDCl3 ): 2.38, 2.42, and 2.43 (3 × s, 3 × 3H, CH3 -Tol); 4.66 (dd, 1H, Jgem = 12.3, J5 b,4 = 4.1 Hz, H5 b); 4.83 (td, 1H, J4 ,3 = 4.6, J4 ,5 = 4.1, 3.1 Hz, H4); 4.91 (dd, 1H, Jgem = 12.3, J5 a,4 = 3.1 Hz, H5 a); 5.86 (d, 2H, JH,F = 46.6 Hz, CH2 -F); 6.22 (dd, 1H, J3 ,2 = 5.8, J3 ,4 = 4.6 Hz, H3 ); 6.40 (t, 1H, J2 ,3 = 5.8, J2 ,1 = 5.4 Hz, H2 ); 6.49 (d, 1H, J1 ,2 = 5.4 Hz, H1 ); 7.16, 7.23, and 7.26 (3 × m, 3 × 2H, H-m-Tol); 7.81, 7.92, and 7.98 (3 × m, 3 × 2H, H-o-Tol); 8.27 (s, 1H, H8); 8.88 (s, 1H, H2). 13 C NMR (100.6 MHz, CDCl3 ): 21.71 and 21.75 (CH3 -Tol); 63.30 (C5 ); 71.37 (C3 ); 73.68 (C2 ); 80.79 (d, JC,F = 173 Hz, CH2 -F); 81.11 (C4 ); 87.00 (C1 ); 125.57, 125.98, and 126.52 (C-i-Tol); 129.24, 129.29, and 129.35 (CH-m-Tol); 129.76 and 129.88 (CH-o-Tol); 132.11 (d, JC,F = 1 Hz, C5); 143.86 (C8); 144.29, 144.63, and 144.76 (C-p-Tol); 151.55 (C4); 152.69 (C2); 154.98 (d, JC,F = 18 Hz, C6); 165.18, 165.39, and 166.17 (CO-Tol).
PalladiumCatalyzed C6 Modifications of Purine
Deprotect S.15 9. Perform deprotection and purification as in Basic Protocol 2, steps 26 to 33, but use 400 mL of 30:1 and 500 mL of 10:1 (v/v) ethyl acetate/methanol to elute the column in step 30. 6-(Fluoromethyl)-9-(β-D-ribofuranosyl)purine (S.16). Yield: 82% of white solid (crystalization from MeOH/EtOAc/heptane, m.p. 184◦ -185◦ C). 1 H NMR (400 MHz,
1.16.12 Supplement 28
Current Protocols in Nucleic Acid Chemistry
DMSO-d6 ): 3.58 (ddd, 1H, Jgem = 12.0, J5 b,OH = 5.9, J5 b,4 = 4.1 Hz, H5 b); 3.70 (dt, 1H, Jgem = 12.0, J5 a,OH = 5.2, J5 a,4 = 4.1 Hz, H5 a); 3.99 (q, 1H, J4 ,5 = 4.1, J4 ,3 = 3.8 Hz, H4 ); 4.20 (bq, 1H, J3 ,2 = 5.1, J3 ,OH = 5.0, J3 ,4 = 3.8 Hz, H3 ); 4.63 (q, 1H, J2 ,OH = 5.7, J2 ,1 = 5.6, J2 ,3 = 5.1 Hz, H2 ); 5.10 (t, 1H, JOH,5 = 5.9, 5.2, 5 -OH); 5.26 (d, 1H, JOH,3 = 5.0 Hz, 3 -OH); 5.56 (d, 1H, JOH,2 = 5.7 Hz, 2 -OH); 5.84 (d, 2H, JH,F = 46.6 Hz, CH2 -F); 6.07 (d, 1H, J1 2 = 5.6 Hz, H1 ); 8.90 (s, 1H, H8); 8.99 (s, 1H, H2). 13 C NMR (100.6 MHz, DMSO-d6 ): 61.36 (C5 ); 70.42 (C3 ); 73.94 (C2 ); 80.71 (d, JC,F = 167 Hz, CH2 -F); 85.90 (C4 ); 87.87 (C1 ); 131.97 (d, JC,F = 2 Hz, C5); 145.74 (C8); 151.76 (C4); 152.08 (C2); 153.62 (d, JC,F = 17 Hz, C6). 19 F NMR (100.6 MHz, DMSO-d6 ): −216.76 (t, JF,H = 46.6 Hz).
PREPARATION OF 6-(DIFLUOROMETHYL)PURINE Oxidation of the 6-(hydroxymethyl)purine derivative S.13 is performed using the DessMartin reagent to give 6-(formyl)purine S.17 (Fig. 1.16.2). This product can undergo deoxo-fluorination and deprotection to yield the 6-(difluoromethyl)purine S.19.
BASIC PROTOCOL 4
Materials 6-(Hydroxymethyl)purine (S.13; see Basic Protocol 2) Dry dichloromethane Dess-Martin reagent [1,1,1-Tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one, Sigma-Aldrich] Saturated aq. NaHCO3 Chloroform Anhydrous magnesium sulfate (MgSO4 ) Silica gel (200 to 400 mesh) Hexanes Acetone Argon Deoxo-Fluor ([bis-(2-methoxyethyl)amino]sulfur trifluoride, Sigma-Aldrich) Ethyl acetate Methanol 25-, 50-, and 250-mL round-bottom flasks Vacuum system (oil pump with manifold and cold trap) Rotary evaporator (B¨uchi) equipped with a vacuum system (membrane pump Vacuubrand) 3 × 20–cm glass columns Vacuum pump TLC plates Vacuum system (oil pump with manifold and cold trap) 21-G needles Rubber septum Additional reagents and equipment for column chromatography (APPENDIX 3E), TLC (APPENDIX 3D), and deprotection and purification (see Basic Protocol 2) Perform oxidation 1. Add 640 mg (1.0 mmol) 6-(hydroxymethyl)purine S.13 to a 50-mL round-bottom flask. 2. Add 15 mL dry dichloromethane and 510 mg (1.2 mmol) Dess-Martin periodinane. 3. Stir the reaction mixture 2 hr at ambient temperature. 4. Pour the mixture into 50 mL saturated aqueous NaHCO3 and extract four times with 50 mL chloroform.
Synthesis of Modified Nucleosides
1.16.13 Current Protocols in Nucleic Acid Chemistry
Supplement 28
5. Dry the collected organic phases with anhydrous MgSO4 , filter, and evaporate. 6. Pack a 3 × 20–cm glass column with 200 to 400 mesh silica gel in 4:1 (v/v) hexanes/acetone. 7. Dissolve the evaporated residue in 2 to 3 mL chloroform and add it to the top of the silica gel column using glass Pasteur pipet. Let the solution settle into the silica gel. 8. Elute with 500 mL of 3:1 (v/v) hexanes/acetone followed by 2:1 hexanes/acetone. Collect 40- to 60-mL fractions. 9. Analyze by TLC using 2:1 (v/v) hexanes/acetone. The desired product S.17 is slightly less polar than the starting compound.
10. Transfer fractions containing pure product to a 250-mL round-bottom flask, evaporate solvents, and dry amorphous solid on vacuum. 11. Confirm the structure of the product by NMR. 6-Formyl-9-[2,3,5-tri-O-(p-toluoyl)-β-D-ribofuranosyl]purine (S.17). Yield: 621 mg (98%) of white amorphous solid. Exact mass (FAB HRMS) found: 635.2175; calcd. for C35 H31 N4 O8 : 635.2142. FAB MS m/z (%): 635 (MH+ , 1); 487 (42); 369 (5); 149 (7); 119 (100). 1 H NMR (500 MHz, CDCl3 ): 2.38, 2.42, and 2.43 (3 × s, 3 × 3H, CH3 -Tol); 4.67 (dd, 1H, Jgem = 12.3, J5 b,4 = 4.0 Hz, H5 b); 4.85 (td, 1H, J4 ,3 = 4.6, J4 ,5 = 4.0, 3.1 Hz, H4 ); 4.93 (dd, 1H, Jgem = 12.3, J5 a,4 = 3.1 Hz, H5 a); 6.21 (dd, 1H, J3 ,2 = 5.8, J3 ,4 = 4.6 Hz, H3 ); 6.41 (t, 1H, J2 ,3 = 5.8, J2 ,1 = 5.4 Hz, H2 ); 6.52 (d, 1H, J1 ,2 = 5.4 Hz, H1 ); 7.16, 7.24, and 7.25 (3 × m, 3 × 2H, H-m-Tol); 7.80, 7.93, and 7.97 (3 × m, 3 × 2H, H-o-Tol); 8.46 (s, 1H, H8); 9.05 (s, 1H, H2); 10.45 (s, 1H, HCO). 13 C NMR (125.8 MHz, CDCl3 ): 21.71 and 21.75 (CH3 -Tol); 63.17 (C5 ); 71.35 (C3 ); 73.66 (C2 ); 81.28 (C4 ); 87.23 (C1 ); 125.46, 125.91, and 126.43 (C-i-Tol); 129.26, 129.31, and 129.38 (CH-m-Tol); 129.73 and 129.87 (CH-oTol); 131.97 (C5); 144.38, 144.71, and 144.84 (C-p-Tol); 147.06 (C8); 147.16 (C6); 152.94 (C2); 154.16 (C4); 165.17, 165.39, and 166.13 (CO); 191.31 (CHO).
Perform deoxo-fluorination 12. Add 320 mg (0.5 mmol) 6-formylpurine S.17 to a 25-mL round-bottom flask. 13. Place a magnetic stir bar in the flask and seal it with a rubber septum. Place the flask on a magnetic stir plate, and connect to an argon/vacuum line via a 21-G needle inserted through the septum. 14. Evaporate using a vacuum line, then flush with argon. Repeat this procedure three times and leave the flask attached to the argon line on the manifold. 15. Add 10 mL dry dichloromethane through the septum and cool the solution to −20◦ C. 16. While stirring, add 320 µL (1.75 mmol) Deoxo-Fluor and allow the reaction mixture to warm to ambient temperature. Stir the reaction mixture 14 hr at ambient temperature. 17. Pour the mixture into 40 mL cold 5% aq. NaHCO3 and extract four times with 40 mL chloroform. 18. Dry the collected organic phases with anhydrous MgSO4 , filter, and evaporate. 19. Pack a 3 × 20–cm glass column with silica gel in 3:1 (v/v) hexanes/ethyl acetate. PalladiumCatalyzed C6 Modifications of Purine
20. Dissolve the evaporated residue in 2 to 3 mL chloroform and add it to the top of the silica gel column using a glass Pasteur pipet. Let the solution settle into the silica gel.
1.16.14 Supplement 28
Current Protocols in Nucleic Acid Chemistry
21. Elute with 500 mL each 3:1, 2:1, and 1:1 (v/v) hexanes/ethyl acetate. Collect 40- to 60-mL fractions. 22. Analyze by TLC using 1:1 (v/v) hexanes/ethyl acetate. The desired product S.18 is less polar than the starting compound.
23. Transfer fractions containing pure product to a 250-mL round-bottom flask and evaporate. 24. Co-evaporate the residues with 50 mL dichloromethane. Dry the resulting foam under vacuum. 25. Confirm the structure of the product by NMR. 6-(Difluoromethyl)-9-[2,3,5-tri-O-(p-toluoyl)-β-D-ribofuranosyl]purine (S.18). Yield: 157 mg (48%) of white foam. Exact mass (FAB HRMS) found: 657.2145; calcd. for C35 H31 F2 N4 O7 : 657.2161. FAB MS m/z (%): 657 (MH+ , 0.5); 487 (16), 119 (100). 1 H NMR (500 MHz, CDCl3 ): 2.38, 2.42, and 2.43 (3 × s, 3 × 3H, CH3 -Tol); 4.67 (dd, 1H, Jgem = 12.4, J5 b,4 = 4.1 Hz, H5 b); 4.86 (td, 1H, J4 ,3 = 4.6, J4 ,5 = 4.1, 3.1 Hz, H4 ); 4.92 (dd, 1H, Jgem = 12.4, J5 a,4 = 3.1 Hz, H5 a); 6.20 (dd, 1H, J3 ,2 = 5.8, J3 ,4 = 4.6 Hz, H3 ); 6.40 (t, 1H, J2 ,3 = 5.8, J2 ,1 = 5.4 Hz, H2 ); 6.50 (d, 1H, J1 ,2 = 5.4 Hz, H1 ); 7.01 (t, 1H, JH,F = 53.8 Hz, CH-F2 ); 7.16, 7.23, and 7.25 (3 × m, 3 × 2H, H-m-Tol); 7.80, 7.92, and 7.98 (3 × m, 3 × 2H, H-o-Tol); 8.36 (s, 1H, H8); 8.92 (s, 1H, H2). 13 C NMR (100.6 MHz, CDCl3 ): 21.71 and 21.75 (CH3 -Tol); 63.22 (C5 ); 71.33 (C3 ); 73.63 (C2 ); 81.22 (C4 ); 87.10 (C1 ); 111.79 (t, JC,F = 242 Hz, CH-F2 ); 125.49, 125.93, and 126.46 (C-i-Tol); 129.25, 129.30, and 129.37 (CH-m-Tol); 129.73 and 129.87 (CH-o-Tol); 131.46 (C5); 144.36, 144.68, and 144.81 (C-p-Tol); 145.27 (C8); 150.11 (t, JC,F = 26 Hz, C6); 152.54 (C2); 152.70 (C4); 165.17, 165.38, and 166.15 (CO-Tol).
Deprotect S.18 26. Perform deprotection and purification as in Basic Protocol 2, steps 26 to 33, but use 400 mL of 30:1 and 500 mL of 10:1 (v/v) ethyl acetate/methanol to elute the column in step 30. 6-(Difluoromethyl)-9-(β-D-ribofuranosyl)purine (S.19). Yield: 83% of white solid (crystalization from MeOH/EtOAc/heptane; m.p. 181◦ -182◦ C). 1 H NMR (400 MHz, DMSOd6 ): 3.59 (ddd, 1H, Jgem = 12.1, J5 b,OH = 5.7, J5 b,4 = 4.0 Hz, H5 b); 3.71 (dt, 1H, Jgem = 12.1, J5 a,OH = 5.3, J5 a,4 = 4.0 Hz, H5 a); 4.00 (q, 1H, J4 ,5 = 4.0, J4 ,3 = 3.8 Hz, H4 ); 4.21 (bq, 1H, J3 ,OH = 5.2, J3 ,2 = 4.9, J3 ,4 = 3.8 Hz, H3 ); 4.62 (q, 1H, J2 ,OH = 5.7, J2 ,1 = 5.4, J2 ,3 = 4.9 Hz, H3 ); 5.11 (t, 1H, JOH,5 = 5.7, 5.3 Hz, 5 -OH); 5.28 (d, 1H, JOH,3 = 5.2 Hz, 3 -OH); 5.60 (d, 1H, JOH,2 = 5.7 Hz, 2 -OH); 6.10 (d, 1H, J1 ,2 = 5.4 Hz, H1 ); 7.36 (t, 1H, JH,F = 53.3 Hz, CH-F2 ); 9.01 (s, 1H, H8); 9.09 (s, 1H, H2). 13 C NMR (100.6 MHz, DMSO-d6 ): 61.27 (C5 ); 70.35 (C3 ); 74.10 (C2 ); 85.94 (C4 ); 88.05 (C1 ); 112.28 (t, JC,F = 240 Hz, CH-F2 ); 131.00 (C5); 147.11 (C8); 148.87 (t, JC,F = 25, C6); 152.05 (C2); 153.02 (C4). 19 F NMR (188.2 MHz, DMSO-d6 ): −118.80 (t, JF,H = 53.3 Hz).
COMMENTARY Background Information Several types of purines bearing Csubstituents in position 6 are biologically active. 6-Aryl-, 6-hetaryl-, and 6-benzylpurine (Hocek et al., 2000, 2001) as well as 6trifluoromethylpurine (Hockova et al., 1999) ribonucleosides display significant cytostatic activity, and some 6-hetarylpurine ribonucleosides (Hocek et al., 2005) exert potent antiviral activity against hepatitis C virus (HCV). 6Methylpurine and its ribonucleoside are highly
cytotoxic (Montgomery and Hewson, 1968), and the liberation of the nucleobase from its non-toxic deoxyribonucleoside by purine nucleoside phosphorylases was proposed as a novel principle in gene therapy for cancer (Parker et al., 1997). Recently, it has been found that 6-(hydroxymethyl)purine ribonucleoside exerts a very high cytostatic effect against leukemia cell lines (IC50 = 10 to 100 nM) and moderate inhibition of ˇ ar et al., 2004, adenosine deaminase (Silh´
Synthesis of Modified Nucleosides
1.16.15 Current Protocols in Nucleic Acid Chemistry
Supplement 28
PalladiumCatalyzed C6 Modifications of Purine
2005a), while 6-(fluoromethyl)purine and 6(difluoromethyl)purine ribonucleosides possess lower cytostatic effect and do not inhibit ˇ ar et al., 2005b, 2006). this enzyme (Silh´ C-substituted purines can be prepared by several approaches, including heterocyclization, radical substitution, and nucleophilic substitution. However, the use of crosscoupling reactions of halopurines with diverse organometallics is the most versatile, efficient, and practical approach. The limitations of the previous methodologies and the advantages of the cross-coupling reactions are reviewed in detail in Hocek (2003). The synthesis of purine nucleosides bearing simple aryl or alkyl substituents in position 6 is very easily performed by the Pd-catalyzed cross-coupling reactions of acetyl-protected 6chloropurine riboside S.1 (Fig. 1.16.1). Its reaction with phenyl boronic acid in toluene in the presence of Pd(PPh3 )4 gives the corresponding protected 6-phenylpurine nucleoside in good yield (Hocek et al., 2000). Analogous Stille coupling of S.1 with 2thienyl(tributyl)tin in DMF gives the 6-(2thienyl)purine nucleoside (Hocek et al., 2001). Reaction of S.1 with trimethylaluminium or benzylzinc chloride in THF gives the corresponding 6-methyl- and 6-benzylpurine nucleosides (Hocek et al., 2001, 2006). In all cases, the treatment of the acyl-protected nucleosides with catalytic NaOMe in methanol cleanly produces the desired free nucleosides. Introduction of a hydroxymethyl group to position 6 of the purine ring represents an entry to the field of functionalized substituents since it is easily transformed to many other types of functional groups. A new methodology of hydroxymethylation of purines consists of the cross-coupling reactions of halopurines with (acyloxymethyl)zinc iodides, easily available from chloromethyl esters (Fig. 1.16.2; ˇ ar et al., 2004). The reaction of this Silh´ organozinc reagent with 6-chloropurine nucleoside S.10 in the presence of Pd(PPh3 )4 gives a mixture of 6-(acetyloxymethyl)- and 6-(hydroxymethyl)purine nucleosides. The acetyl group at the hydroxymethyl group can be selectively cleaved, in the presence of toluoyl protection of the sugar moiety, by using aqueous ammonia in the presence of ZnCl2 ˇ ar et al., 2005b). The resulting protected (Silh´ 6-(hydroxymethyl)purine nucleoside is converted to 6-(fluoromethyl)purine nucleoside ˇ ar et al., using the Deoxo-Fluor reagent (Silh´ 2005b). To prepare 6-(difluoromethyl)purines, the 6-(hydroxymethyl)purine is first oxidized to 6-formylpurine by the Dess-Martin reagent,
followed by deoxofluorination by Deoxoˇ ar et al., 2006). Again, all toluoylFluor (Silh´ protected nucleosides are deprotected by NaOMe in methanol.
Critical Parameters The most critical parameter in each crosscoupling reaction is ensuring the absence of oxygen, which destroys the catalyst. Therefore, all reactions must be carried out in argonpurged flasks using septum techniques and a vacuum line. In the case of organozinc and trialkyl aluminium reagents, the absence of any trace of water is necessary for successful reactions; therefore, all reagents and solvents must be perfectly pure and anhydrous. The catalyst Pd(PPh3 )4 should be stored under an argon atmosphere at 4◦ C; however, it can be manipulated in air if it is done reasonably quickly and cleanly.
Anticipated Results The yields of all the cross-coupling reactions should be from 60% to 90% and the separation of the products by column chromatography is very easy. The cleavage of the protecting groups usually proceeds with very high yields. The deoxofluorination of hydroxymethyl- and formylpurines with the Deoxo-Fluor reagent produces only moderate yields of ∼40% to 50%.
Time Considerations The cross-coupling reactions with simple commercial organometallics are usually completed within 8 to 10 hr, and subsequent separation and characterization take an additional 3 to 5 hr. The deprotections are performed overnight, and again the purification and characterization of the products requires an additional 3 to 5 hr. Altogether, it should be feasible to accomplish the two steps within 3 days. In the case of hydroxymethylation, synthesis of 6-(acetyloxymethyl)purine starting from protected 6-chloropurine ribonucleoside can be accomplished in 3 to 4 days. Subsequent selective deacetylation and transformation of the hydroxymethyl group can be accomplished in another 3 to 4 days.
Literature Cited Buck, I.M. and Reese, C.B. 1990. An unambiguous synthesis of adenylosuccinic acid and its constituent nucleoside. J. Chem. Soc., Perkin Trans. 1, 2937-2942. Hocek, M. 2003. Syntheses of purines bearing carbon substituents in positions 2, 6 or 8 by metalor organometallics-mediated C-C bond forming reactions. Eur. J. Org. Chem. 245-254.
1.16.16 Supplement 28
Current Protocols in Nucleic Acid Chemistry
Hocek, M., Hol´y, A., Votruba, I., and Dvoˇra´ kov´a, H. 2000. Synthesis and cytostatic activity of substituted 6-phenylpurine bases and nucleosides: Application of the Suzuki-Miyaura crosscoupling reactions of 6-chloropurine derivatives with phenylboronic acids. J. Med. Chem. 43:1817-1825. Hocek, M., Hol´y, A., Votruba, I., and Dvoˇra´ kov´a, H. 2001. Cytostatic 6-arylpurine nucleosides III. Synthesis and structure-activity relationship study in cytostatic activity of 6-aryl-, 6-hetaryland 6-benzylpurine ribonucleosides. Collect. Czech. Chem. Commun. 66:483-499. Hocek, M., Nauˇs, P., Pohl, R., Votruba, I., Furman, P.A., Tharnish, P.M., and Otto, M.J. 2005. Cytostatic 6-arylpurine nucleosides. 6. SAR in antiHCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides. J. Med. Chem. 48:5869-5873. ˇ ar, P., Shih, I., Mabery, E., and Hocek, M., Silh´ Mackman, R. 2006. Cytostatic and antiviral 6-arylpurine ribonucleosides. Part 7: Synthesis and evaluation of 6-substituted purine L-ribonucleosides. Bioorg. Med. Chem. Lett. 16:5290-5293. Hockov´a, D., Hocek, M., Dvoˇra´ kov´a, H., and Votruba, I. 1999. Synthesis and cytostatic activity of nucleosides and acyclic nucleoside analogues derived from 6-(trifluoromethyl)purines. Tetrahedron 55:11109-11118. Montgomery, J.A. and Hewson, K. 1968. Analogs of 6-methyl-9-β-D-ribofuranosylpurine. J. Med. Chem. 11:48-52.
Parker, W.B., King, S.A., Allan, P.W., Bennett, L.L. Jr., Secrist, J.A. III, Montgomery, J.A., Gilbert, K.S., Waud, W.R., Wells, A.H., Gillespie, G.Y., and Sorscher, E.J. 1997. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum. Gene Ther. 8:1637-1644. ˇ ar, P., Pohl, R., Votruba, I., and Hocek, Silh´ M. 2004. Facile and efficient synthesis of 6-(hydroxymethyl)purines. Org. Lett. 6:32253228. ˇSilh´ar, P., Pohl, R., Votruba, I., and Hocek, M. 2005a. Synthesis of 2-substituted 6(hydroxymethyl)purine bases and nucleosides. Collect. Czech. Chem. Commun. 70:1669-1695. ˇSilh´ar, P., Pohl, R., Votruba, I., and Hocek, M. 2005b. The first synthesis and cytostatic activity of novel 6-(fluoromethyl)purine bases and nucleosides. Org. Biomol. Chem. 3:3001-3007. ˇSilh´ar, P., Pohl, R., Votruba, I., and Hocek, M. 2006. Synthesis and cytostatic activity of novel 6-(difluoromethyl)purine bases and nucleosides. Synthesis 1848-1852.
Contributed by Michal Hocek and Peter ˇ ar Silh´ Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic Prague, Czech Republic
Synthesis of Modified Nucleosides
1.16.17 Current Protocols in Nucleic Acid Chemistry
Supplement 28
Nucleobase-Caged Phosphoramidites for Oligonucleotide Synthesis
UNIT 1.17
Caged compounds are biologically active compounds that have been made temporarily inactive via modification with a photolabile group (Pelliccioli and Wirz, 2002; Goeldner and Givens, 2005; Mayer and Heckel, 2006). The caged derivative can then be applied, for example, to a model organism and, with the help of (laser) light and a confocal microscope, the active compound can be released with exact spatiotemporal and dosage control. More simple setups are also possible. Due to the localized and ideally infinitesimal jump in concentration of the active form, elaborate kinetic experiments become possible. This unit focuses on the preparation of phosphoramidites that bear such a caging group, and their incorporation into oligonucleotides by standard solid-phase synthesis. The resulting nucleobase-caged oligonucleotides add an element of spatiotemporal control to oligonucleotide-based applications, such as gene regulation, modulation of protein function (e.g., via aptamers), molecular diagnostics, or DNA nanoarchitectures. The protocols in this unit describe the synthesis of the protected precursors S.1a, S.1b, S.2, and S.3 for the introduction of TNPE , TNPP , dGNPP , and dCNPE residues into oligonucleotides, respectively (Fig. 1.17.1). Each of these residues bears its respective caging group on the nucleobase, which makes the formation of the corresponding Watson-Crick base pair difficult or prevents it entirely. Nucleobase-caged nucleotides can be seen as temporary mismatches. The residues shown have been applied in the light-regulation of transcription (Kr¨ock and Heckel, 2005), the light-control of protein function via caged aptamers (Heckel and Mayer, 2005; Mayer et al., 2005), and the light-induction of oligonucleotide folding (Mayer et al., 2005). By applying an antisense strategy (Heckel et al., 2006), it becomes possible not only to liberate an active oligonucleotide (switch
Figure 1.17.1 Protected phosphoramidites used for solid-phase synthesis of oligonucleotides containing TNPE , TNPP , dGNPP , or dCNPE residues. DMTr, 4,4 -dimethoxytrityl; NPE, 1-(2-nitrophenyl)ethyl, NPP, 2-(2-nitrophenyl)propyl.
Contributed by Alexander Heckel Current Protocols in Nucleic Acid Chemistry (2007) 1.17.1-1.17.26 C 2007 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Nucleosides
1.17.1 Supplement 29
it on), but also to sequester it (switch it off). The NPE and NPP cages yield different cleavage products with different toxicological profiles. NOTE: Since most of the reaction steps are sensitive to moisture, great care must be taken to use anhydrous solvents and dry argon or nitrogen as a protecting gas. However, it is sufficient to close the reaction apparatus with a rubber septum and provide a protecting gas balloon for pressure equalization. CAUTION: All reactions must be carried out in a well-ventilated chemical fume hood, and protective gloves, a laboratory coat, and safety glasses must be worn. BASIC PROTOCOL 1
PREPARATION OF PROTECTED NPE- AND NPP-CAGED THYMIDINE PHOSPHORAMIDITES The synthesis scheme for two thymidine phosphoramidites, S.1a and S.1b, is shown in Figure 1.17.2. These phosphoramidites are used for synthesis of oligonucleotides containing TNPE and TNPP caged residues, respectively. The NPE and the NPP groups have different photocleavage products and hence different toxicological profiles. The cleavage of the NPP group (Walbert et al., 2001) from oligonucleotides has been shown to occur more quickly and cleanly than that of the NPE group (Kr¨ock and Heckel, 2005).
Materials Thymidine (S.4) Acetic anhydride (Ac2 O) Pyridine Hexane Acetone Chloroform 1 M aqueous sulfuric acid, 4◦ C Saturated aqueous NaHCO3 Anhydrous Na2 SO4 Diethyl ether Ethanol Acetonitrile Argon source 4-(N,N-Dimethylamino)pyridine (DMAP) Triethylamine (Et3 N) 2,4,6-Triisopropylbenzenesulfonyl chloride (iPr3 C6 H2 SO2 Cl) Cyclohexane 1-(2-Nitrophenyl)ethan-1-ol (NPE-OH; S.22; see Support Protocol 1) or 2-(2-nitrophenyl)propan-1-ol (NPP-OH; S.24; see Support Protocol 2) 1 M aqueous HCl Anhydrous MgSO4 Methanol (MeOH) 33% (v/v) aqueous ammonium hydroxide solution (NH4 OH) 4,4 -Dimethoxytrityl chloride (DMTr-Cl) Dichloromethane (CH2 Cl2 ) N,N-Diisopropylethylamine (DIPEA, H¨unig’s base) 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite
Nucleobase-Caged Phosphoramidites
50-, 100-, and 250-mL round-bottom flasks Reflux condenser 90◦ C oil bath Rotary evaporator connected to vacuum pump High vacuum system
1.17.2 Supplement 29
Current Protocols in Nucleic Acid Chemistry
Figure 1.17.2 Overview of the synthesis of the protected phosphoramidites S.1a and S.1b, for the introduction of TNPE and TNPP into oligonucleotides, starting from thymidine (S.4). DMAP, 4-(N,N-dimethylamino)pyridine; DMTr-Cl, 4,4 -dimethoxytrityl chloride; NPE, 1-(2-nitrophenyl)ethyl; NPP, 2-(2-nitrophenyl)propyl.
500-µL syringes Separatory funnels Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Acetylate thymidine 1. In a 250-mL round-bottom flask equipped with a reflux condenser, suspend 10.0 g (41.3 mmol) thymidine (S.4) in 70 mL acetic anhydride and add 5 mL pyridine. 2. Add a stir bar and heat the reaction mixture slightly in a 90◦ C oil bath until it becomes clear (∼30 min). 3. Allow the reaction to cool to room temperature and continue stirring for an additional 1 hr. 4. Check for complete conversion by TLC using 1:1 (v/v) hexane/acetone as eluent. Traces of pyridine can be removed before developing the TLC by placing the TLC plate in a round-bottom flask of appropriate size and applying vacuum for several minutes. Inspection of the developed TLC plate under UV light (254 nm) should show almost complete conversion (Rf of S.5 ∼0.5, Rf of thymidine <0.1).
5. Pour the reaction mixture into 400 mL cold (4◦ C) water and stir the mixture for 30 min. Two layers will form.
6. Extract the mixture three times with 250 mL chloroform. 7. Combine the organic extracts and wash with 100 mL of 1 M cold (4◦ C) sulfuric acid. During this step and the next, great care must be exercised to prevent spillage of the contents of the separation funnel due to overpressure. Current Protocols in Nucleic Acid Chemistry
Synthesis of Modified Nucleosides
1.17.3 Supplement 29
8. Wash the organic phase with 100 mL saturated aqueous NaHCO3 . 9. Dry the organic extracts with Na2 SO4 . Filter off the drying agent. 10. Remove the organic solvents from the filtrate, first on a rotary evaporator connected to a vacuum pump then in a high vacuum. This affords a colorless syrup.
11. Add 100 mL diethyl ether to initiate precipitation of the product, then remove the organic solvent again on a rotary evaporator connected to a vacuum pump. 12. Recrystallize the crude product from 20 to 30 mL ethanol. 13. Characterize the product by melting point determination, TLC, and 1 H NMR. 3 ,5 -Di-O-acetylthymidine (S.5): Yield 11.7 g (86%). m.p. 125◦ C. TLC (silica, 1:1 v/v hexane/acetone): Rf = 0.5. 1 H NMR (CDCl3 /TMS): δ 9.35 (1H, br s), 7.26 (1H, s), 6.25 (1H, m), 5.15 (1H, m), 4.27 (2H, m), 4.18 (1H, m), 2.40 (1H, m), 2.1 (1H, m), 2.07 (6H, s), 1.85 (3H, s).
Add caging group by O4 -modification 14. In a 50-mL round-bottom flask dissolve 1.5 g (4.6 mmol) S.5 in 20 mL acetonitrile under an argon atmosphere. 15. Add 1.12 g (9.2 mmol) DMAP and 1.28 mL Et3 N, and stir the reaction mixture for 10 min at room temperature. 16. Add 2.8 g (9.2 mmol) 2,4,6-triisopropylbenzylsulfonyl chloride and stir at room temperature. The reaction mixture turns yellow and after some minutes a precipitate forms. If the reaction mixture becomes too thick for the stir bar, dilute with a small amount of acetonitrile (20 mL maximum).
17. After 3 hr, check by TLC using 1:1 (v/v) cyclohexane/acetone to verify that all starting material has reacted. Upon inspection under UV light (254 nm) there should be no spot visible from the starting material (Rf = 0.5).
18. Dilute 2.3 g (13.8 mmol) NPE-OH (S.22) or 2.5 g (13.8 mmol) NPP-OH (S.24) with a small amount of acetonitrile and 1.92 mL (13.8 mmol) Et3 N, and add to the reaction mixture. During this procedure, the precipitate can disappear and reappear later.
19. Stir the reaction mixture overnight at room temperature. 20. Add 200 mL chloroform and 200 mL water to the reaction mixture and separate the layers. Extract the aqueous layer two additional times with 200 mL chloroform each time. 21. Combine the organic phases and wash with 200 mL of 1 M HCl. 22. Wash the organic phases with saturated aqueous NaHCO3 and dry with MgSO4 . Filter off the drying agent. During this step, great care must be exercised to prevent spillage of the contents of the separation funnel. TLC control of all the phases at this point should show product only in the organic phase.
Nucleobase-Caged Phosphoramidites
23. Remove the solvent from the filtrate on a rotary evaporator connected to a vacuum pump to afford a brown oil.
1.17.4 Supplement 29
Current Protocols in Nucleic Acid Chemistry
24. Perform column chromatography using a 5 × 24–cm silica gel bed and 2 L of 2:1 (v/v) cyclohexane/acetone as eluent. Analyze fractions by TLC. Isolate the spot that runs just below the spot of the respective alcohol used. The excess alcohol can be recovered.
25. Combine the pure fractions and remove the solvents on a rotary evaporator. 26. Characterize the product by TLC, 1 H NMR, and MS. 3 ,5 -Di-O-acetyl-TNPE (S.6a): Yield 1.3 g (60%). TLC (silica, 1:1 v/v hexane/acetone): Rf = 0.5. 1 H NMR (CDCl3 /TMS): δ 7.85 (1H), 7.58 (2H), 7.50 (1H), 7.37 (1H), 6.73 (1H), 6.20 (1H), 5.14 (1H), 4.30 (2H), 4.22 (1H), 2.60 (1H), 2.00 (10H), 1.70 (3H). HRMS (EI): calcd. for C22 H25 N3 O9 (M+ ) 475.1591; found 475.1591. 3 ,5 -Di-O-acetyl-TNPP (S.6b): Yield 1.6 g (58%). TLC (silica, 1:1 v/v cyclohexane/ acetone): Rf = 0.38. 1 H NMR (CDCl3 /TMS): δ 7.71 (1H), 7.52 (1H), 7.47 (2H), 7.33 (1H), 6.27 (1H), 5.16 (1H), 4.50 (2H), 4.31 (2H), 4.24 (1H), 3.80 (1H), 2.64 (1H), 2.01 (7H), 1.79 (3H), 1.37 (3H). HRMS (EI): calcd. for C23 H27 N3 O9 (M+ ) 489.175; found 489.174.
Deacetylate and tritylate 27. Prepare a mixture of 20 mL MeOH and 6 mL of 33% aq. NH4 OH. 28. In a 100-mL round-bottom flask, dissolve 2.65 g (5.58 mmol) S.6a or 2.73 g (5.58 mmol) S.6b in this mixture. Add a stir bar and stir for 2.5 hr at room temperature. 29. Check for complete deprotection by TLC using 1:1 (v/v) cyclohexane/acetone. Upon inspection under UV light (254 nm), there should be a single spot at Rf = 0.2.
30. Remove the solvent using a rotary evaporator connected to a vacuum pump. The bath temperature should be <40◦ C. Ensure that the exhaust fumes of the vacuum pump are led into the fume hood.
31. Dissolve the residue in 30 mL MeOH and evaporate the solvents again completely on a rotary evaporator connected to a vacuum pump. Repeat this step at least two additional times. After this step, clean the rotary evaporator well to ensure that no traces of NH4 OH are left.
32. Dissolve the residue in 30 mL pyridine and add a stir bar and a few crystals of DMAP. 33. Cool the solution by putting the flask in an ice-water bath. 34. Suspend 3.8 g (11.2 mmol) DMTr-Cl in 20 mL pyridine and add the suspension to the reaction mixture. Continue stirring overnight in the ice-water bath. The ice will melt overnight and the reaction temperature will gradually rise to room temperature.
35. Check for an almost complete conversion by TLC using 1:2 (v/v) cyclohexane/acetone with 1% Et3 N as eluent. Traces of pyridine can be removed before developing the TLC by putting the TLC plate in a round-bottom flask of appropriate size and applying a vacuum for several minutes. Under UV light (254 nm), the TLC will show three spots: the top spot is excess DMTr-Cl, the middle spot is the desired product, and the bottom spot is traces of remaining starting material.
36. Add 20 mL ethanol and evaporate the solvents using a rotary evaporator connected to a vacuum pump.
Synthesis of Modified Nucleosides
1.17.5 Current Protocols in Nucleic Acid Chemistry
Supplement 29
37. Perform column chromatography using a 5 × 27–cm silica gel bed and 2.5 L of 1:1 (v/v) cyclohexane/acetone with 1% Et3 N as eluent. Analyze fractions by TLC. 38. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump. 39. Characterize the product by TLC, 1 H NMR, and MS. 5 -O-DMTr-TNPE (S.8a): Yield 3.3 g (84%). TLC (silica, 1:1 v/v hexane/acetone + 1% Et3 N): Rf = 0.34. 1 H NMR (CDCl3 /TMS): δ 7.80 (2H), 7.53 (2H), 7.30 (3H), 7.17 (7H), 6.73 (4H), 6.67 (1H), 6.2 (1H), 4.45 (1H), 4.05 (1H), 3.70 (6H), 3.32 (2H), 2.88 (1H, br s), 2.52 (1H), 2.12 (1H), 1.66 (3H), 1.53 (3H). MS (EI): 693.5 (M+ ). 5 -O-DMTr-TNPP (S.8b): Yield 3.7 g (94%). TLC (silica, 1:2 v/v cyclohexane/acetone + 1% Et3 N): Rf = 0.5. 1 H NMR (CDCl3 /TMS): δ 7.75 (1H), 7.65 (1H), 7.45 (2H), 7.27 (3H), 7.16 (7H), 6.72 (4H), 6.28 (1H), 4.45 (3H), 4.05 (1H), 3.70 (7H),3.35 (2H), 2.95 (1H, br s), 2.55 (1H), 2.15 (1H), 1.35 (6H). MS (FAB): 708.2 (MH+ ).
Prepare phosphoramidite 40. In a 50-mL round-bottom flask, dissolve 208 mg (0.3 mmol) S.8a or 212 mg (0.3 mmol) S.8b in 5 mL dichloromethane and add a stir bar. In steps 40 to 43, special care must be taken that pure and dry reagents are used and that the reaction mixture is kept under argon atmosphere at all times. Failure to do so will prevent any reaction.
41. Add 282 µL (1.65 mmol) DIPEA via a 500-µL syringe and allow to stir for 10 min at room temperature. 42. Add 134 µL (0.6 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite and continue stirring for 1.5 hr at room temperature. Ideally, this reagent should be completely clear. Proper handling is critical. Upon contact with air, the reagent becomes cloudy in a matter of minutes.
43. Check for complete conversion by TLC using 1:1 (v/v) cyclohexane/acetone with 1% Et3 N as eluent. Upon inspection under UV light (254 nm), no starting material (Rf = 0.3) should be detectable; rather, there should be a new spot at Rf = 0.6. At this step, the reaction mixture can again be handled in air, but steps 44 to 52 should be performed without unnecessary interruption.
44. Dilute the reaction mixture with 80 mL dichloromethane and transfer it into a separatory funnel. 45. Add 50 mL saturated aqueous NaHCO3 , shake gently, and separate the layers. Extract the aqueous phase two additional times with 50 mL dichloromethane each time. 46. Combine the organic phases and dry them with MgSO4 . Filter off the drying agent. 47. Remove the solvent from the filtrate using a rotary evaporator connected to a vacuum pump. 48. Perform column chromatography using a 3 × 22–cm silica gel bed and 0.5 L of 3:2 (v/v) cyclohexane/acetone with 1% Et3 N as eluent. Analyze fractions by TLC. 49. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump.
Nucleobase-Caged Phosphoramidites
50. To remove traces of volatile components, dissolve the product in 30 mL dichloromethane and remove the solvents again, first on a rotary evaporator
1.17.6 Supplement 29
Current Protocols in Nucleic Acid Chemistry
connected to a vacuum pump and then under high vacuum. Repeat this procedure at least two additional times. This will result in a colorless brittle foam.
51. Characterize the product by TLC, 1 H NMR, 31 P NMR, and MS. 5 -O-DMTr-TNPE -3 -O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.1a): Yield 255 mg (95%). TLC (silica, 1:1 v/v hexane/acetone + 1% Et3 N): Rf = 0.6. 1 H NMR (CDCl3 /TMS): δ 7.57 (14H), 6.80 (5H), 6.30 (1H), 4.60 (1H), 4.16 (1H), 3.77 (7H), 3.55 (4H), 3.33 (1H), 2.65 (2H), 2.41 (1H), 2.22 (1H), 1.75 (3H), 1.58 (3H), 1.11 (12H). 31 P NMR (CDCl3 /H3 PO4 ): δ 151.45, 151.47, 152.07, 152.16. 5 -O-DMTr-TNPP -3 -O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.1b): Yield 256 mg (94%). TLC (silica, 1:1 v/v cyclohexane/acetone + 1% Et3 N): Rf = 0.6. 1 H NMR (CDCl3 /TMS): δ 7.50 (14H), 6.83 (4H), 6.38 (1H), 4.58 (3H), 4.16 (1H), 3.80 (8H), 3.54 (4H), 3.33 (1H), 2.67 (2H), 2.40 (1H), 2.25 (1H), 1.41 (6H), 1.12 (12H). 31 P NMR (CDCl3 /H3 PO4 ): δ 151.46, 151.94, 152.05, 152.05. MS (FAB): 908.5 (MH+ ).
52. Dissolve the foam under argon in the appropriate amount of dry acetonitrile to form a 0.1 M solution (in this case 2.8 mL). To ensure that there are no insoluble residues, the solution can be centrifuged or filtered through a syringe filter. The clear solution is ready for use on an automated DNA synthesizer (APPENDIX 3C). Due to the base lability of the caging groups on O4 of thymidine, a different set of protecting groups must be used for the uncaged nucleobases so that conditions not harsher than NH4 OH (33%) at room temperature will be sufficient for deprotection. The Ultramild protecting groups, for example, satisfy this requirement (phosphoramidites are available from Glen Research).
PREPARATION OF A PROTECTED NPP-CAGED DEOXYGUANOSINE PHOSPHORAMIDITE
BASIC PROTOCOL 2
The synthesis scheme for the deoxyguanosine phosphoramidite S.2 is shown in Figure 1.17.3. This phosphoramidite is used for synthesis of oligonucleotides containing dGNPP caged residues.
Materials 2 -Deoxyguanosine (S.9) Pyridine N,N-Dimethylformamide (DMF) Imidazole tert-Butyldimethylsilyl chloride (TBDMS-Cl) Dichloromethane (CH2 Cl2 ) Methanol (MeOH) Ethanol (EtOH), cold (4-Isopropylphenoxy)acetyl chloride (iPrPacCl; S.30; see Support Protocol 4) Cyclohexane Acetone Tetrahydrofuran (THF) 2-(2-Nitrophenyl)propan-1-ol (NPP-OH; S.24; see Support Protocol 2) Triphenylphosphine 40% diethylazodicarboxylate (DEAD) in toluene Ethyl acetate Brine (saturated NaCl) Anhydrous MgSO4 Glacial acetic acid
Synthesis of Modified Nucleosides
1.17.7 Current Protocols in Nucleic Acid Chemistry
Supplement 29
Figure 1.17.3 Overview of the synthesis of the protected phosphoramidite S.2, for the introduction of dGNPP into oligonucleotides, starting from deoxyguanosine (S.9). DEAD, diethylazodicarboxylate; DMTr-Cl, 4,4 -dimethoxytrityl chloride; NPP, 2-(2-nitrophenyl)propyl; Pac, phenoxyacetyl; TBAF, tetrabutylammonium fluoride; TBDMS-Cl, tert-butyldimethylsilyl chloride.
1 M tetrabutylammonium fluoride (TBAF) in THF 4,4 -Dimethoxytrityl chloride (DMTr-Cl) Triethylamine (Et3 N) N,N-Diisopropylethylamine (DIPEA, H¨unig’s base) 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite Saturated aqueous NaHCO3 Dry acetonitrile 50-, 100-, and 250-mL round-bottom flasks Rotary evaporator connected to a vacuum pump High vacuum B¨uchner funnel connected to a vacuum pump Water aspirator Syringes Separatory funnels Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Silylate deoxyguanosine 1. In a 100-mL round-bottom flask, suspend 5 g (18.6 mmol) 2 -deoxyguanosine (S.9) in 50 mL pyridine and remove the solvent with a rotary evaporator connected to a vacuum pump. Repeat this procedure two additional times and dry the residue well using a high vacuum. Nucleobase-Caged Phosphoramidites
This step is for the azeotropic removal of any water.
1.17.8 Supplement 29
Current Protocols in Nucleic Acid Chemistry
2. Suspend the residue in 40 mL DMF and add 8.3 g (122.6 mmol) imidazole and 10.6 g (70.6 mmol) TBDMS-Cl. Add a stir bar and stir 20 hr at room temperature. The deoxyguanosine will not dissolve completely at the beginning, but the reaction mixture will slowly become clear upon stirring.
3. Check for complete conversion by TLC using 9:1 (v/v) CH2 Cl2 /MeOH as eluent. Traces of pyridine can be removed before developing the TLC by placing the TLC plate in a round-bottom flask of appropriate size and applying vacuum for several minutes. Upon inspection under UV light (254 nm), the starting material should appear as a baseline spot and the product at Rf = 0.6.
4. Add 50 mL EtOH and place the flask in an ice-water mixture. The formation of some precipitate can already be observed in the reaction mixture, and this significantly intensifies upon addition of EtOH.
5. Filter the precipitate off using a B¨uchner funnel connected to a vacuum pump and wash it with a little cold (4◦ C) EtOH (10 mL). 6. Dry the colorless powder first with a water aspirator and later under high vacuum. 7. Characterize the product by TLC and 1 H NMR. 3 ,5 -Di-O-TBDMS-2 -dG (S.10): Yield 7.1 g (77%). TLC (silica, 9:1 v/v CH2 Cl2 /MeOH): Rf = 0.6. 1 H NMR (DMSO/DMSO): δ 10.60 (1H, s), 7.88 (1H, s), 6.47 (1H, s), 6.10 (1H, dd, J = 7.6, 6.4 Hz), 4.48 (1H, m), 3.80 (1H, m), 3.67 (2H, m), 2.64 (1H, m), 2.22 (1H, m), 0.88 (9H, s), 0.86 (9H, m), 0.10 (6H, s), 0.04 (3H, s), 0.03 (3H, s).
Perform N2 -protection 8. In a 250-mL round-bottom flask dissolve 3 g (6.05 mmol) S.10 in 40 mL pyridine. Add a stir bar and place the flask in an ice-water bath. 9. Add 1.93 g (9.1 mmol) of (4-isopropylphenoxy)acetyl chloride (S.30) dropwise using a syringe. 10. Stir for 2 hr, keeping the reaction flask in the ice-water bath. Then, take the flask out of the bath and continue stirring for an additional 1 hr. 11. Check for complete conversion by TLC using 19:1 (v/v) CH2 Cl2 /MeOH as eluent. Traces of pyridine can be removed before developing the TLC by placing the TLC plate in a round-bottom flask of appropriate size and applying vacuum for several minutes. Upon inspection under UV light (254 nm), the product will show up at Rf = 0.3. The spot above results from excess acid chloride (S.30).
12. Cool the reaction mixture by placing the flask in an ice-water bath. Then, add 120 mL MeOH dropwise. 13. Remove the solvents using a rotary evaporator connected to a vacuum pump. 14. Dissolve the residue in 50 mL MeOH and remove the solvent using the rotary evaporator. This step helps to remove traces of pyridine.
15. Perform column chromatography using a 5 × 30–cm silica gel bed and a gradient from 3:1 to 2:1 (v/v) cyclohexane/acetone as eluent. Analyze fractions by TLC. 16. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump. Synthesis of Modified Nucleosides
1.17.9 Current Protocols in Nucleic Acid Chemistry
Supplement 29
17. Characterize the product by TLC, 1 H NMR, and MS. 3 ,5 -Di-O-TBDMS-N-(iPrPac)-2 -dG (S.11): Yield 2.2 g (54%). TLC (silica, 95:5 v/v CH2 Cl2 /MeOH): Rf = 0.33. 1 H NMR (CDCl3 /TMS): δ 11.75 (1H, br s), 9.06 (1H, br s), 7.99 (1H, s), 7.22 (2H, d, J = 8.6 Hz), 6.93 (2H, J = 8.6 Hz), 6.28 (1H, t, J = 6.5 Hz), 4.66 (2H, s), 4.49 (1H, m), 3.87 (1H, m), 3.76 (2H, m), 2.88 (1H, sept, J = 6.9 Hz), 2.42 (2H, m), 1.22 (6H, d, J = 6.9 Hz), 0.89 (18H, s), 0.07 (12H, s). HRMS (EI): calcd. for C33 H53 N5 O6 Si2 (M+ ) 671.3534; found 671.3515.
Add caging group by O6 -modification 18. In a 100-mL round-bottom flask dissolve 2 g (2.98 mmol) S.11 in 15 mL THF and add a stir bar to the flask. 19. Add 0.81 g (4.47 mmol) NPP-OH (S.24) and 1.17 g (4.47 mmol) triphenylphosphine. 20. While stirring, slowly add 2.05 mL (4.47 mmol) of 40% DEAD in toluene. 21. Continue stirring for 20 min at room temperature and then check for complete conversion by TLC using 3:1 (v/v) cyclohexane/ethyl acetate as eluent. Upon inspection under UV light (254 nm), the product spot is visible at Rf = 0.37.
22. Transfer the reaction mixture to a separatory funnel with a total of 150 mL CH2 Cl2 . Wash the organic phase with 100 mL water and then with 100 mL brine. 23. Dry the organic phase using MgSO4 and filter off the drying agent. 24. Remove the organic solvent from the filtrate using a rotary evaporator connected to a vacuum pump. 25. Purify the residue by column chromatography using a 5 × 30–cm silica gel bed and a gradient from 3:1 to 1:1 (v/v) cyclohexane/ethyl acetate as eluent. Analyze fractions by TLC. 26. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump. 27. Characterize the product by TLC, 1 H NMR, and MS. 3 ,5 -Di-O-TBDMS-N-(iPrPac)-2 -dGNPP (S.12): Yield 1.7 g (69%). TLC (silica, 3:1 v/v cyclohexane/ethyl acetate): Rf = 0.37. 1 H NMR (CDCl3 /TMS): δ 8.85 (1H, br s), 8.13 (1H), 7.72 (1H), 7.62 (1H), 7.53 (1H), 7.33 (1H), 7.19 (2H), 6.96 (2H), 6.31 (1H), 4.72 (5H), 4.00 (2H), 3.84 (2H), 2.88 (1H), 2.55 (2H), 1.53 (3H), 1.24 (6H), 0.91 (18H), 0.09 (12H). MS (EI): 834.4 (M+ ).
Desilylate 28. In a 50-mL round-bottom flask, dissolve 0.5 g (0.6 mmol) S.12 in 15 mL THF. Add a stir bar and chill the reaction mixture with stirring in an ice-water bath. 29. Add 0.2 mL (3.6 mmol) glacial acetic acid and then slowly add 1.8 mL (1.8 mmol) of 1 M TBAF in THF. 30. Remove the ice-water bath and continue stirring for 24 hr at room temperature. 31. Check for complete conversion by TLC using 9:1 (v/v) CH2 Cl2 /MeOH as eluent. Upon inspection under UV light (254 nm), the product spot is visible at Rf = 0.32.
32. Remove the organic solvents using a rotary evaporator connected to a vacuum pump.
Nucleobase-Caged Phosphoramidites
33. Purify the residue by column chromatography using a 3 × 26–cm silica gel bed and a gradient from 99:1 to 92.5:7.5 (v/v) CH2 Cl2 /MeOH as eluent. Analyze fractions by TLC.
1.17.10 Supplement 29
Current Protocols in Nucleic Acid Chemistry
34. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump. 35. Characterize the product by TLC, 1 H NMR, and MS. N-(iPrPac)-2 -dGNPP (S.13): Yield 0.36 g (99%). TLC (silica, 9:1 v/v CH2 Cl2 /MeOH): Rf = 0.32. 1 H NMR (CDCl3 /TMS): δ 9.04 (1H), 8.03 (1H), 7.71 (1H), 7.62 (1H), 7.53 (1H), 7.33 (1H), 7.18 (2H), 6.96 (2H), 6.35 (1H), 4.96 (1H), 4.72 (4H), 4.13 (1H), 3.91 (3H), 2.99 (1H), 2.88 (1H), 2.41 (1H), 1.49 (3H), 1.22 (6H). HRMS (EI): calcd. for C30 H34 N6 O8 (M+ ) 606.2438; found 606.2439.
Tritylate 36. In a 50-mL round-bottom flask, dissolve 250 mg (0.41 mmol) S.13 in 5 mL pyridine and remove the solvent using a rotary evaporator connected to a vacuum pump. 37. Repeat this procedure two additional times, then dry the residue well under a high vacuum. 38. Dissolve the residue in 8 mL pyridine and add 168 mg (0.49 mmol) DMTr-Cl. Add a stir bar and stir 15 hr at room temperature. 39. Check for complete conversion by TLC using 95:5 (v/v) CH2 Cl2 /MeOH with 1% Et3 N as eluent. Upon inspection under UV light (254 nm), the product spot should be visible at Rf = 0.29.
40. Add 10 mL MeOH to the reaction mixture and remove the solvents in a rotary evaporator connected to a vacuum pump. 41. Add another 10 mL MeOH to the residue and remove the solvent on the rotary evaporator. This will help to remove traces of pyridine for the subsequent chromatography step.
42. Purify the residue by column chromatography using a 2 × 26–cm silica gel bed and 99:1 (v/v) CH2 Cl2 /MeOH with 1% Et3 N as eluent. Analyze fractions by TLC. 43. Combine fractions that contain the main product and remove the solvent with a rotary evaporator. 44. Characterize the product by TLC, 1 H NMR, and MS. 5 -O-DMTr-N-(iPrPac)-2 -dGNPP (S.14): Yield 319 mg (85%). TLC (silica, 95:5 v/v CH2 Cl2 /MeOH + 1% Et3 N): Rf = 0.29. 1 H NMR (CDCl3 /TMS): δ 8.93 (1H), 8.03 (1H), 7.71 (1H), 7.61 (1H), 7.53 (1H), 7.30 (12H), 6.95 (2H), 6.77 (4H), 6.65 (1H), 4.70 (5H), 4.23 (1H), 4.00 (1H), 3.74 (6H), 3.50 (1H), 3.37 (2H), 2.87 (1H), 2.67 (2H), 1.49 (3H), 1.22 (6H). MS (FAB): 909.4 (MH+ ).
Prepare phosphoramidite 45. In a 50-mL round-bottom flask dissolve 100 mg (0.11 mmol) S.14 in 2 mL THF and add a stir bar. In steps 45 to 48, special care must be taken that pure and dry reagents are used and the reaction mixture must be kept under argon atmosphere at all times. Failure to do so will prevent any reaction.
46. Add 66 µL (0.39 mmol) DIPEA via syringe and stir 10 min at room temperature. 47. Add 49 µl (0.22 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite and continue stirring for 1.5 hr at room temperature. Ideally, this reagent should be completely clear. Proper handling is critical. Upon contact with air, the reagent becomes cloudy in a matter of minutes.
Synthesis of Modified Nucleosides
1.17.11 Current Protocols in Nucleic Acid Chemistry
Supplement 29
48. Check for complete conversion by TLC using 1:4 (v/v) cyclohexane/ethyl acetate with 1% Et3 N as eluent. Upon inspection under UV light (254 nm), the product spot will be visible at Rf = 0.5. At this step, the reaction mixture can again be handled in air, but steps 49 to 57 should be performed without unnecessary interruption.
49. Transfer the reaction mixture to a separatory funnel using 100 mL ethyl acetate. 50. Add 100 mL saturated aqueous NaHCO3 solution, shake gently, and separate the layers. Extract the aqueous phase two additional times with 50 mL ethyl acetate each time. 51. Combine the organic phases, wash with brine, and dry with MgSO4 . Filter off the drying agent. 52. Remove the solvent from the filtrate using a rotary evaporator connected to a vacuum pump. 53. Perform column chromatography using a 2 × 20–cm silica gel bed and a gradient from 4:1 to 1:4 (v/v) cyclohexane/ethyl acetate with 1% Et3 N as eluent. Analyze fractions by TLC. 54. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump. 55. To remove traces of volatile components, dissolve the product in 30 mL dichloromethane and remove the solvents again, first on a rotary evaporator and then under high vacuum. Repeat this procedure at least two times. This will result in a colorless brittle foam.
56. Characterize the product by TLC, 1 H NMR, 31 P NMR, and MS. 5 -O-DMTr-2 -dGNPP -3 -O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.2): Yield 99 mg (81%). TLC (silica, 1:4 v/v cyclohexane/ethyl acetate + 1% Et3 N): Rf = 0.5. 1 H NMR (CDCl3 /TMS): δ 8.78 (1H), 8.01 (1H), 7.73 (1H), 7.63 (1H), 7.53 (1H), 7.30 (12H), 6.96 (2H), 6.78 (4H), 6.43 (1H), 4.76 (5H), 4.27 (1H), 4.00 (1H), 3.76 (6H), 3.76 (2H), 3.58 (2H), 3.36 (2H), 2.89 (1H), 2.62 (1H), 2.72 (2H), 2.45 (1H), 1.52 (3H), 1.24 (6H), 1.14 (12H). 31 P NMR (CDCl3 /H3 PO4 ): δ 151.84. MS (FAB): 1109.5 (MH+ ).
57. Dissolve the foam under argon in the appropriate amount of dry acetonitrile to form a 0.1 M solution (in this case 0.9 mL). To ensure that there are no insoluble residues, the solution can be centrifuged or filtered through a syringe filter. The clear solution is ready for use on an automated DNA synthesizer (APPENDIX 3C). BASIC PROTOCOL 3
PREPARATION OF A PROTECTED NPE-CAGED DEOXYCYTIDINE PHOSPHORAMIDITE The scheme for synthesizing the deoxycytidine phosphoramidite S.3 from 2 deoxyuridine is shown in Figure 1.17.4. This phosphoramidite is used for synthesis of oligonucleotides containing dCNPE caged residues.
Materials
Nucleobase-Caged Phosphoramidites
2 -Deoxyuridine (S.15) Pyridine 4,4 -Dimethoxytrityl chloride (DMTr-Cl) Dichloromethane (CH2 Cl2 ) Methanol (MeOH) Ethanol (EtOH)
1.17.12 Supplement 29
Current Protocols in Nucleic Acid Chemistry
O
O NH
HO
N
O
O
O NH
DMTr-Cl pyridine
N
DMTrO
OH 15
O
O
NH Ac2O pyridine
N
DMTrO
OH 16
OAc 17
NO2
O S O O
HN N
N Me3C6H2SO2Cl DMAP, Et 3N
N
DMTrO
O
NPE-NH2
O
N
DMTrO
OAc 18
O
O OAc 19
NO2
HN-NPE
HN
N N
MeNH2 EtOH
DMTrO
N
O
O
O
N
DMTrO
CEOP(Cl)NiPr2
O
O
O OH 20
NC
O
O P NiPr2
3
Figure 1.17.4 Overview of the synthesis of the protected phosphoramidite S.3, for the introduction of dCNPE into oligonucleotides, starting from deoxyuracil (S.15). DMAP, 4-(N,N-dimethylamino)pyridine; DMTr-Cl, 4,4 dimethoxytrityl chloride; NPE, 1-(2-nitrophenyl)ethyl.
Ethyl acetate Saturated aqueous NaHCO3 Brine (saturated NaCl) Anhydrous MgSO4 n-Hexane 4-(N,N-Dimethylamino)pyridine (DMAP) Acetic anhydride (Ac2 O) Triethylamine (Et3 N) 5% (w/v) aqueous citric acid 2-Mesitylenesulfonyl chloride (Me3 C6 H2 SO2 Cl) N,N-Dimethylformamide (DMF) 1-(2-Nitrophenyl)ethylamine (NPE-NH2 ; S.26; see Support Protocol 3) 33% methylamine in ethanol N,N-Diisopropylethylamine (DIPEA, H¨unig’s base) 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite Cyclohexane Acetone Acetonitrile 50-mL, 250-mL, and 1-L round-bottom flasks Rotary evaporator connected to a vacuum pump Glass sinter filter High vacuum Syringes
Synthesis of Modified Nucleosides
1.17.13 Current Protocols in Nucleic Acid Chemistry
Supplement 29
Reflux condenser 90◦ C oil bath Silicone septa, optional Separatory funnel Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Tritylate deoxyuridine 1. In a 250-mL round-bottom flask, dissolve 5 g (22 mmol) 2 -deoxyuridine (S.15) in 160 mL pyridine, and remove ∼60 mL with a rotary evaporator connected to a vacuum pump. This step is for the azeotropic removal of any water.
2. Add 8.91 g (27 mmol) DMTr-Cl and a stir bar. Stir 4 hr at room temperature. 3. Check for complete conversion by TLC using 95:5 (v/v) CH2 Cl2 /MeOH as eluent. Traces of pyridine can be removed before developing the TLC by placing the TLC plate in a round-bottom flask of appropriate size and applying vacuum for several minutes. Upon inspection under UV light (254 nm), the starting material would appear as a baseline spot and the product will show up at Rf = 0.25.
4. Add 25 mL ethanol and continue stirring 15 min at room temperature. 5. Remove all solvents using a rotary evaporator connected to a vacuum pump. 6. Dissolve the residue with 300 mL ethyl acetate. Wash the organic phase two times with 300 mL saturated aqueous NaHCO3 and then one time with 300 mL brine. 7. Dry the organic phase with anhydrous MgSO4 and filter off the drying agent. 8. Remove the organic solvent from the filtrate using a rotary evaporator connected to a vacuum pump. 9. Dissolve the residue in 100 mL ethyl acetate. 10. Prepare a 1-L round-bottom flask with 500 mL n-hexane, add a stir bar, and begin stirring vigorously. Add the product dropwise to this flask. A colorless precipitate will form.
11. Collect the precipitate by filtration using a glass sinter filter and dry well under high vacuum. 12. Characterize the product by TLC and 1 H NMR. 5 -O-DMTr-2 -dU (S.16): Yield 11.3 g (97%). TLC (silica, 95:5 v/v CH2 Cl2 /MeOH): Rf = 0.25. 1 H NMR (DMSO/DMSO): δ 11.31 (1H), 7.63 (1H), 7.31 (10H), 6.89 (3H), 6.14 (1H), 5.37 (1H), 5.32 (1H), 4.28 (1H), 3.87 (1H), 3.73 (6H), 3.20 (2H), 2.18 (2H).
Acetylate 13. In a 250-mL round-bottom flask, dissolve 10.25 g (19.3 mmol) S.16 in 60 mL pyridine. 14. Add 244 mg (2.0 mmol) DMAP followed by 2.7 mL (29 mmol) acetic anhydride. Place a stir bar into the flask and stir the reaction mixture 3 hr at room temperature. 15. Check for complete conversion by TLC using 98:2 (v/v) CH2 Cl2 /MeOH with 1% Et3 N as eluent. Nucleobase-Caged Phosphoramidites
1.17.14 Supplement 29
Traces of pyridine can be removed before developing the TLC by placing the TLC plate in a round-bottom flask of appropriate size and applying vacuum for several minutes. Upon inspection under UV light (254 nm), the starting material would appear at Rf = 0.07 and the product will show up at Rf = 0.24. Current Protocols in Nucleic Acid Chemistry
16. Add 2 mL methanol to the reaction mixture and remove the solvent in a rotary evaporator connected to a vacuum pump. 17. Dissolve the residue in 200 mL dichloromethane and wash this organic phase with 200 mL of 5% aqueous citric acid, followed by 200 mL water, and then 200 mL saturated aqueous NaHCO3 . In the last extraction, care must be taken to prevent spillage due to overpressure in the separatory funnel.
18. Dry the organic phase with MgSO4 and filter off the drying agent. 19. Remove the solvent from the filtrate in a rotary evaporator connected to a vacuum pump. When most of the solvent has been removed, continue drying under high vacuum. This affords compound S.17 as a yellowish foam that does not need to be purified further.
20. Characterize the product by TLC, 1 H NMR, and MS. 5 -O-DMTr-3 -O-acetyl-2 -dU (S.17): Yield 11.6 g (quant.). TLC (silica, 98:2 v/v CH2 Cl2 /MeOH + 1% Et3 N): Rf = 0.24. 1 H NMR (DMSO/DMSO): δ 11.38 (1H), 7.63 (1H), 7.14 (13H), 6.14 (1H), 5.45 (1H), 5.24 (1H), 4.07 (1H), 3.73 (6H), 3.29 (2H), 2.38 (2H), 2.04 (3H). HRMS (EI): calcd. for C32 H32 N2 O8 (M+ ) 572.2158; found 572.2156.
Add caging group by O4 -modification 21. In a 50-mL round-bottom flask, dissolve 1.0 g (1.75 mmol) S.17 in 10 mL dichloromethane and add 21.3 mg (0.17 mmol) DMAP. Add a stir bar and start stirring at room temperature. 22. Add 1.22 mL (8.75 mmol) Et3 N, followed by 498 mg (2.28 mmol) 2mesitylenesulfonyl chloride. Continue stirring for 2 hr at room temperature. The reaction solution will become dark red.
23. Check for complete conversion by TLC using 98:2 (v/v) CH2 Cl2 /MeOH with 1% Et3 N as eluent. Upon inspection under UV light (254 nm), the starting material would appear at Rf = 0.24 and the product will show up at Rf = 0.60.
24. Dilute the reaction mixture with 150 mL dichloromethane and wash this organic phase with saturated aqueous NaHCO3 . 25. Dry the organic phase with MgSO4 and filter of the drying agent. 26. Remove the solvent from the filtrate using a rotary evaporator connected to a vacuum pump. 27. Perform column chromatography using a 3 × 22–cm silica gel bed and a gradient from CH2 Cl2 to 99:1 (v/v) CH2 Cl2 /MeOH to 98:2 (v/v) CH2 Cl2 /MeOH, each with 1% Et3 N, as eluent. Analyze fractions by TLC. It is sufficient if this purification step separates the remaining 2-mesitylenesulfonyl chloride with Rf = 0.90 (silica, 98:2 v/v CH2 Cl2 /MeOH + 1% Et3 N). Under these conditions, the intermediate S.18 runs at Rf = 0.60.
28. Combine all product-containing fractions and remove the solvent using a rotary evaporator connected to a vacuum pump. This crude product (750 mg) can be used without any further purification and characterization.
Synthesis of Modified Nucleosides
1.17.15 Current Protocols in Nucleic Acid Chemistry
Supplement 29
29. Dissolve the crude product in 4.5 mL DMF, add a stir bar, and start stirring at room temperature. 30. Dissolve 415 mg (2.5 mmol) NPE-NH2 (S.26) in 7.5 mL DMF and add this solution dropwise with a syringe to the stirring solution. 31. Place a reflux condenser on the reaction flask and heat the reaction mixture with stirring for 45 min in a 90◦ C oil bath. 32. Check for complete conversion by TLC using ethyl acetate with 1% Et3 N as eluent. Traces of DMF can be removed before developing the TLC by placing the TLC plate in a round-bottom flask of appropriate size and applying vacuum for several minutes. Upon inspection under UV light (254 nm), the intermediate S.18 would appear at Rf = 0.66 and the product S.19 will show up at Rf = 0.17.
33. Remove the organic solvent with a rotary evaporator connected to a high vacuum pump. Dissolve the residue in 100 mL dichloromethane. 34. Wash the organic solution with 100 mL of 5% aqueous citric acid, then 100 mL water, and finally 100 mL saturated aqueous NaHCO3 . 35. Dry with MgSO4 and filter off the drying agent. 36. Remove the solvent from the filtrate using a rotary evaporator connected to a vacuum pump. 37. Perform column chromatography using a 3 × 25–cm silica gel bed and ethyl acetate with 1% Et3 N as eluent. Analyze fractions by TLC. 38. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump. 39. Characterize the product by TLC, 1 H NMR, and MS. 5 -O-DMTr-3 -O-acetyl-2 -dCNPE (S.19): Yield 453 mg (62%). TLC (ethyl acetate + 1% Et3 N): Rf = 0.17. 1 H NMR (DMSO/DMSO): δ 8.40 (1H), 7.93 (1H), 7.62 (4H), 7.13 (13H), 6.09 (1H), 5.69 (1H), 5.51 (1H), 5.20 (1H), 4.05 (1H), 3.75 (6H), 3.25 (2H), 2.24 (2H), 2.02 (3H), 1.49 (3H). MS (FAB): 721.2 (MH+ ).
Perform deprotection 40. In a 50-mL round-bottom flask dissolve 427 mg (0.592 mmol) S.19 in 5 mL of 33% methylamine in ethanol. Add a stir bar and close the reaction flask, preferably with a silicone septum. Stir the reaction mixture for 1 hr at room temperature. 41. Check for complete conversion by TLC using 96:4 (v/v) CH2 Cl2 /MeOH with 1% Et3 N as eluent. Upon inspection under UV light (254 nm), the intermediate S.19 would appear at Rf = 0.27 and the product S.20 will show up at Rf = 0.16.
42. Remove the solvent using a rotary evaporator connected to a vacuum pump. Make sure that the outlet of the vacuum pump leads into a fume hood, and rinse the rotary evaporator well after this procedure to remove remaining methylamine.
43. Perform column chromatography using a 3 × 25–cm silica gel bed and 98:2 (v/v) CH2 Cl2 /MeOH with 1% Et3 N as eluent. Analyze fractions by TLC. 44. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump. Nucleobase-Caged Phosphoramidites
1.17.16 Supplement 29
Current Protocols in Nucleic Acid Chemistry
45. Characterize the product by TLC, 1 H NMR, and MS. 5 -O-DMTr-2 -dCNPE (S.20): Yield 402 mg (quant.). TLC (96:4 v/v CH2 Cl2 /MeOH + 1% Et3 N): Rf = 0.16. 1 H NMR (DMSO/DMSO):δ 8.35 (1H), 7.93 (1H), 7.61 (4H), 7.13 (13H), 6.08 (1H), 5.65 (1H), 5.50 (1H), 5.26 (1H), 4.22 (1H), 3.85 (1H), 3.75 (6H), 3.18 (2H), 1.96 (2H), 1.49 (3H). HRMS (ESI): calcd. for C38 H39 N4 O8 (MH+ ) 679.2768; found 679.2756.
Prepare phosphoramidite 46. In a 50-mL round-bottom flask, dissolve 129 mg (0.19 mmol) S.20 in 4 mL dichloromethane and add a stir bar. In steps 46 to 49, special care must be taken that pure and dry reagents are used and that the reaction mixture is kept under argon atmosphere at all times. Failure to do so will prevent any reaction.
47. Add 146 µL (0.89 mmol) DIPEA via a syringe and allow to stir for 10 min at room temperature. 48. Add 85 µl (0.38 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite and continue stirring for 1.5 hr at room temperature. Ideally, this reagent should be completely clear. Proper handling is critical. Upon contact with air the reagent becomes cloudy in a matter of minutes.
49. Check for complete conversion by TLC using 1:1 (v/v) cyclohexane/acetone with 1% Et3 N as eluent. No starting material (Rf = 0.1) should be detectable; there should be a new spot at Rf = 0.36. At this step, the reaction mixture can again be handled in air, but steps 50 to 58 should be performed without unnecessary interruption.
50. Dilute the reaction mixture with 100 mL dichloromethane and transfer to a separatory funnel. 51. Add 100 mL saturated aqueous NaHCO3 solution, shake gently, and separate the layers. Extract the aqueous phase two additional times with 50 mL dichloromethane each time. 52. Combine the organic phases, wash with brine, and then dry with MgSO4 . Filter off the drying agent. 53. Remove the solvent from the filtrate using a rotary evaporator connected to a vacuum pump. 54. Perform column chromatography using a 2 × 22–cm silica gel bed and 2:1 (v/v) cyclohexane/acetone with 1% Et3 N as eluent. Analyze fractions by TLC. 55. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump. 56. To remove traces of volatile components, dissolve the product in 30 mL dichloromethane and remove the solvents again, first on a rotary evaporator and then under high vacuum. Repeat this procedure at least two times. This will result in a colorless brittle foam.
57. Characterize the product by TLC, 1 H NMR, 31 P NMR, and MS. 5 -O-DMTr-2 -dCNPE -3 -O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.3): Yield 115 mg (68%). TLC (silica, 1:1 v/v cyclohexane/acetone + 1% Et3 N): Rf = 0.36. 1 H NMR (DMSO/DMSO):δ 8.40 (1H), 7.93 (1H), 7.69 (3H), 7.5 (1H), 7.3 (9H), 6.9 (4H),
Synthesis of Modified Nucleosides
1.17.17 Current Protocols in Nucleic Acid Chemistry
Supplement 29
6.10 (1H), 5.70 (1H), 5.52 (1H), 4.48 (1H), 4.00 (1H), 3.75 (6H), 3.70 (1H), 3.60 (1H), 3.50 (2H), 3.25 (2H), 2.75 (1H), 2.65 (1H), 2.30 (1H), 2.10 (1H), 1.50 (3H), 1.10 (12H). 31 P NMR: (DMSO/H3 PO4 ):δ 145.53, 145.18. MS (FAB): 879.4 (MH+ ).
58. Dissolve the foam under argon in the appropriate amount of dry acetonitrile to form a 0.1 M solution (in this case 1.3 mL). To ensure that there are no insoluble residues, the solution can be centrifuged or filtered through a syringe filter. The clear solution is ready for use on an automated DNA synthesizer (APPENDIX 3C). SUPPORT PROTOCOL 1
PREPARATION OF THE CAGING PRECURSOR 1-(2-NITROPHENYL)ETHAN-1-OL This protocol is taken from the “progenitor” caging paper by Kaplan et al. (1978). The single reaction for preparation of NPE-OH (S.22) from 2-nitroacetophenone is shown in Figure 1.17.5.
Materials 2-Nitroacetophenone (S.21) 1,4-Dioxane Methanol (MeOH) Sodium borohydride (NaBH4 ) Dichloromethane (CH2 Cl2 ) Anhydrous MgSO4 250-mL round-bottom flask Rotary evaporator connected to a vacuum pump Separatory funnel Additional reagents and equipment for TLC (APPENDIX 3D)
Figure 1.17.5 Overview of the synthesis of caging group precursors S.22, S.24, and S.26, as well as the acid chloride S.30 used for N-protection of guanosine. NBS, N-bromosuccinimide. Nucleobase-Caged Phosphoramidites
1.17.18 Supplement 29
Current Protocols in Nucleic Acid Chemistry
1. In a 250-mL round-bottom flask, dilute 5 g (30.2 mmol) 2-nitroacetophone (S.21) in 75 mL of 2:3 (v/v) 1,4-dioxane/MeOH. Add a stir bar and begin stirring. 2. Cool the reaction mixture in an ice/water bath. 3. Add 3.5 g (92.5 mmol) NaBH4 in small portions. After addition is complete, continue stirring in the ice/water bath for an additional 30 min. Strong bubbles are observed after each addition. A precipitate will form after addition is complete.
4. Remove the cooling bath and continue stirring for 2 hr at room temperature. 5. Remove the solvent using a rotary evaporator connected to a vacuum pump. 6. Add 150 mL water and stir the mixture for 1.5 hr at room temperature. 7. Add 100 mL dichloromethane and transfer the mixture to a separatory funnel. Separate the layers and extract the aqueous phase two additional times with 100 mL dichloromethane. 8. Combine the organic layers and dry them with MgSO4 . Filter off the drying agent. 9. Remove the organic solvents from the filtrate using a rotary evaporator connected to a vacuum pump. 10. Characterize the product by TLC and 1 H NMR. 1-(2-Nitrophenyl)ethan-1-ol (S.22): Yield 4.64 g (92%). TLC (silica, chloroform): Rf = 0.20. 1 H NMR (CDCl3 /TMS):δ 7.82 (2H), 7.61 (1H), 7.39 (1H), 5.36 (1H), 2.76 (1H, br s), 1.51 (3H).
PREPARATION OF THE CAGING PRECURSOR 2-(2-NITROPHENYL)PROPAN-1-OL
SUPPORT PROTOCOL 2
The single reaction for preparation of NPP-OH (S.24) from 1-ethyl-2-nitrobenzene is shown in Figure 1.17.5. This protocol is adapted from Tsuji et al. (1990).
Materials 1-Ethyl-2-nitrobenzene (S.23) Dimethylsulfoxide (DMSO) Paraformaldehyde 40% Triton B (BuMe3 NOH) in methanol Cyclohexane Acetone 100-mL round-bottom flask Reflux condenser 90◦ C oil bath Distillation apparatus Additional reagents and equipment for TLC (APPENDIX 3D) 1. In a 100-mL round-bottom flask, dissolve 22.7 g (150 mmol) 1-ethyl-2-nitrobenzene (S.23) in 20 mL DMSO. Add a stir bar and begin stirring at room temperature. 2. Add 1.85 g (62 mmol) paraformaldehyde and 1.8 ml of 40% Triton B in MeOH. The reaction mixture will change color several times and become clear.
3. Add a reflux condenser and heat the reaction mixture 3 hr in a 90◦ C oil bath.
Synthesis of Modified Nucleosides
1.17.19 Current Protocols in Nucleic Acid Chemistry
Supplement 29
4. Perform TLC with 3:2 (v/v) cyclohexane/acetone as eluent. Upon inspection under UV light (254 nm), apart from the spot resulting from excess starting material (Rf = 0.6), the product will result in a spot at Rf = 0.4.
5. Perform distillation under reduced pressure (1 mbar). Collect the main fraction, which distills at ∼140◦ C vapor temperature. 6. Characterize the product by TLC and 1 H NMR. 2-(2-Nitrophenyl)propan-1-ol (S.24): Yield 7.61 g (68%). TLC (3:2 v/v cyclohexane/acetone): Rf = 0.40. 1 H NMR (CDCl3 /TMS): δ 7.67 (1H), 7.48 (1H), 7.41 (1H), 7.28 (1H), 3.70 (2H), 3.45 (1H), 1.26 (3H). SUPPORT PROTOCOL 3
PREPARATION OF THE CAGING PRECURSOR 1-(2-NITROPHENYL)ETHYLAMINE The preparation of NPE-NH2 (S.26) is performed in two steps starting from 1-ethyl-2nitrobenzene and is shown in Figure 1.17.5.
Materials 1-Ethyl-2-nitrobenzene (S.23) Tetrachlorocarbon (CCl4 ) N-Bromosuccinimide (NBS) Dibenzoyl peroxide [(BzO)2 ] Hexane Acetone Cyclohexane N,N-Dimethylformamide (DMF) Potassium phthalimide Ethyl acetate Dichloromethane (CH2 Cl2 ) Saturated aqueous NaHCO3 Anhydrous MgSO4 Ethanol 80% hydrazinium hydroxide solution in water Methanol Triethylamine (Et3 N) 100- and 500-mL round-bottom flasks Reflux condensers 60◦ , 77◦ , and 155◦ C oil baths B¨uchner funnel connected to a vacuum pump Rotary evaporator connected to a vacuum pump Separatory funnels High vacuum Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Perform bromination 1. In a 500-mL round-bottom flask, dissolve 30 g (198 mmol) 1-ethyl-2-nitrobenzene (S.23) in 300 mL CCl4 . Add a stir bar and begin stirring at room temperature. CAUTION: Make sure to avoid all contact with the liquid or vapor, as CCl4 is toxic. Dispose of all waste properly. Nucleobase-Caged Phosphoramidites
2. Add 53 g (298 mmol) N-bromosuccinimide and 720 mg (3 mmol) dibenzoyl peroxide. Equip the flask with a reflux condenser and heat the reaction mixture to reflux (77◦ C) for 4 hr.
1.17.20 Supplement 29
Current Protocols in Nucleic Acid Chemistry
3. Check for complete conversion by TLC using 9:1 (v/v) hexane/acetone as eluent. Upon inspection under UV light (254 nm), there should be no visible spot of the starting material (Rf = 0.88), and the product should be visible at Rf = 0.40.
4. Remove the oil bath and let the reaction mixture cool to room temperature. 5. Filter off any solid material using a B¨uchner funnel connected to a vacuum pump. This will result in a clear orange solution.
6. Remove the organic solvent using a rotary evaporator connected to a vacuum pump. This will afford the crude product as an orange oil.
7. Perform column chromatography using an 8 × 20–cm silica gel bed and 1.2 L of 9:1 (v/v) cyclohexane/acetone as eluent. Analyze fractions by TLC. 8. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump. 9. Characterize the product by TLC and 1 H NMR. 1-(2-Nitrophenyl)ethylbromide (S.25): Yield 46.5 g (quant.). TLC (9:1 v/v cyclohexane/acetone): Rf = 0.40. 1 H NMR (CDCl3 /TMS): δ 7.88 (1H), 7.80 (1H), 7.6 (1H), 7.40 (1H), 5.80 (1H), 2.08 (3H).
Perform substitution 10. In a 100-mL round-bottom flask, dissolve 5 g (21.7 mmol) S.25 in 20 mL DMF. Add a stir bar and begin stirring at room temperature. 11. Add 4.03 g (21.7 mmol) potassium phthalimide. 12. Add a reflux condenser and heat the reaction mixture 1 hr in a 155◦ C oil bath. 13. Remove the oil bath and allow it to cool to room temperature. 14. Check for complete conversion by TLC using 1:1 (v/v) cyclohexane/ethyl acetate as eluent. Upon inspection under UV light (254 nm), there should be no spots resulting from either the starting material (Rf = 0.9) or the phthalimide (Rf = 0.7), and a new spot should be visible at Rf = 0.8.
15. Add 400 mL dichloromethane and transfer the solution to a separatory funnel. Wash this organic phase first with saturated aqueous NaHCO3 and then with water. 16. Dry the organic phase with anhydrous MgSO4 and filter off the drying agent. 17. Remove the solvent from the filtrate using a rotary evaporator connected to a vacuum pump, and dry the residue under high vacuum. 18. Dissolve the residue in 80 mL ethanol, add a stir bar, and begin stirring at room temperature. 19. Add 1.36 mL of 80% hydrazinium hydroxide solution. Equip the flask with a reflux condenser and heat the reaction mixture 1.5 hr at 60◦ C. CAUTION: Make sure to avoid any contact with the liquid or vapor, as hydrazine is toxic.
20. Add an additional 1.36 mL of 80% hydrazinium hydroxide solution and continue heating for an additional 1 hr. 21. Allow solution to cool to room temperature.
Synthesis of Modified Nucleosides
1.17.21 Current Protocols in Nucleic Acid Chemistry
Supplement 29
22. Check for complete conversion by TLC using 95:5 (v/v) CH2 Cl2 /MeOH with 0.5 % Et3 N as eluent. Upon inspection under UV light (254 nm), there should be a prominent product spot at Rf = 0.10 and only a few spots above it.
23. Remove any solid by filtering the suspension using a B¨uchner funnel connected to a vacuum pump. Wash the solid well with ethanol. 24. Remove the solvent from the combined filtrates using a rotary evaporator connected to a vacuum pump. 25. Dissolve the residue in 150 mL dichloromethane and transfer the solution to a separatory funnel. Wash this organic phase with 150 mL water. 26. Dry the organic phase using MgSO4 and filter off the drying agent. 27. Remove the solvent from the filtrate using a rotary evaporator connected to a vacuum pump. 28. Perform column chromatography using a 5 × 22–cm silica gel bed and 95:5 (v/v) CH2 Cl2 /MeOH with 0.5 % Et3 N as eluent. Analyze fractions by TLC. 29. Combine fractions that contain the main product and remove the solvent with a rotary evaporator connected to a vacuum pump. 30. Characterize the product by TLC and 1 H NMR. 1-(2-Nitrophenyl)ethylamine (S.26): Yield 1.3 g (36%). TLC (95:5 v/v CH2 Cl2 /MeOH + 0.5% Et3 N): Rf = 0.10. 1 H NMR (DMSO/DMSO): δ 7.90 (1H), 7.77 (1H), 7.68 (1H), 7.44 (1H), 4.32 (1H), 2.02 (2H), 1.03 (3H). SUPPORT PROTOCOL 4
PREPARATION OF (4-ISOPROPYLPHENOXY)ACETYL CHLORIDE FOR PROTECTION OF DEOXYGUANOSINE The acid chloride S.30 is prepared from 4-isopropylphenol in three steps as illustrated in Figure 1.17.5.
Materials 60% NaH in paraffin Tetrahydrofuran (THF) 4-Isopropylphenol (S.27) Bromoacetic acid methyl ester Diethyl ether Anhydrous MgSO4 1,4-Dioxane Lithium hydroxide Half-concentrated HCl Ethyl acetate Thionyl chloride (SOCl2 ) 100-, 250-, and 500-mL round-bottom flasks Dropping funnel Rotary evaporator connected to a vacuum pump Separatory funnels Reflux condenser 90◦ C oil bath Distillation bridge Nucleobase-Caged Phosphoramidites
1.17.22 Supplement 29
Current Protocols in Nucleic Acid Chemistry
Perform acetylation 1. In a 250-mL round-bottom flask, suspend 5.88 g of 60% NaH in 50 mL THF. Add a stir bar and begin stirring at room temperature. Be extremely careful when handling NaH, and be certain to exclude any water from the reaction.
2. Equip the flask with a dropping funnel. Dissolve 20 g (147 mmol) 4-isopropylphenol (S.27) in 160 mL THF and add this solution carefully, dropwise, to the reaction mixture using the dropping funnel. 3. Continue stirring for 1.5 hr at room temperature. 4. Cool the reaction mixture using an ice/water bath. 5. Transfer 14.4 mL (147 mmol) bromoacetic acid methyl ester to the dropping funnel and carefully add dropwise to the reaction mixture. 6. Continue stirring overnight at room temperature. 7. Remove the solvent using a rotary evaporator connected to a vacuum pump. 8. To the residue, add 150 mL water and 250 mL diethyl ether. Transfer the mixture to a separatory funnel and separate the layers. Extract the aqueous phase two additional times with 250 mL diethyl ether each time. 9. Combine the organic extracts and dry with anhydrous MgSO4 . Filter off the drying agent. 10. Remove the solvent from the filtrate using a rotary evaporator connected to a vacuum pump. 11. Purify the crude product by distillation under reduced pressure (6 mbar). Collect the fraction that distills at ∼130◦ C vapor temperature. 12. Characterize the product by 1 H NMR. (4-Isopropylphenoxy)acetic acid methyl ester (S.28): Yield 29.5 g (97%). 1 H NMR (CDCl3 /TMS): δ 7.05 (2H), 6.77 (2H), 4.53 (2H), 3.73 (3H), 2.80 (1H), 1.12 (6H).
Perform saponification 13. In a 500-mL round-bottom flask, dissolve 29.5 g (142 mmol) S.28 in 300 mL of 1,4-dioxane, add a stir bar, and begin stirring at room temperature. 14. Dissolve 4.06 g lithium hydroxide in 200 mL water and add this solution to the reaction mixture. Continue stirring for 13 hr at room temperature. 15. Remove the solvents using a rotary evaporator connected to a vacuum pump. 16. Adjust the reaction mixture to pH 1 by careful dropwise addition of half-concentrated HCl. 17. Transfer the reaction mixture to a separatory funnel and extract it three times with 300 mL ethyl acetate each time. 18. Combine the organic phases and dry with anhydrous MgSO4 . Filter off the drying agent. 19. Remove the solvent from the filtrate using a rotary evaporator connected to a vacuum pump. This results in a colorless solid.
Synthesis of Modified Nucleosides
1.17.23 Current Protocols in Nucleic Acid Chemistry
Supplement 29
20. Characterize the product by 1 H NMR. (4-Isopropylphenoxy)acetic acid (S.29): Yield 27.1 g (98%). 1 H NMR (CDCl3 /TMS): δ 9.0 (br s, 1H), 7.08 (2H), 6.78 (2H), 4.6 (2H), 2.8 (1H), 1.16 (6H).
Convert to acid chloride 21. In a 100-mL round-bottom flask, dissolve 5 g (25.7 mmol) S.29 in 50 mL thionyl chloride. Add a stir bar and begin stirring at room temperature. CAUTION: Make sure to handle thionyl chloride very carefully and avoid any contact with liquid or vapor.
22. Equip the reaction flask with a reflux condenser and heat the reaction mixture 16 hr in a 90◦ C oil bath. 23. Allow reaction to cool to room temperature and exchange the reflux condenser with a distillation bridge. First distill off the excess thionyl chloride under ambient pressure. 24. Cooling to room temperature again, then carefully apply vacuum (1 mbar) to the reaction setup and continue distilling under reduced pressure. Collect the main fraction, which will distill at ∼112◦ C vapor temperature. 25. Characterize the product by 1 H NMR. (4-Isopropylphenoxy)acetyl chloride (S.30): Yield 5 g (91%). 1 H NMR (CDCl3 /TMS): δ 7.08 (2H), 6.73 (2H), 4.85 (2H), 2.77 (1H), 1.12 (6H).
COMMENTARY Background Information
Nucleobase-Caged Phosphoramidites
The term “caged compounds” for biologically active substances that have been temporarily inactivated and can be triggered by light-irradiation is a rather unfortunate choice. It is misleading because most chemists will think of cage compounds in a topological sense, and the lack of semantic precision in this term makes literature searches in the field difficult. The origin of the field dates back to the late 1970s, when Engels and co-workers prepared a cAMP bearing a photolabile group on the phosphate (Engels and Schlaeger, 1977), and J.F. Hoffman and co-workers synthesized ATP with a photolabile group on the γ -phosphate (Kaplan et al., 1978). Only the latter group called their compounds “caged.” Since that time, the concept of caging has been applied to a whole variety of compounds, including many small molecules, peptides, proteins, and, only recently, nucleic acids. For a deeper insight, especially in the field of caged oligo(deoxy)nucleotides, the reader is referred to available reviews (Pelliccioli and Wirz, 2002; Goeldner and Givens, 2005; Mayer and Heckel, 2006). Using light-reactive compounds (either irreversibly triggerable, caged, or reversibly switchable ones based, e.g., on azo benzene), intriguing experiments have become possible, such as the spatiotemporally controlled release of calcium or the light-driven transport of cal-
cium across membranes (Bennett et al., 2002). Trauner, Isacoff, and colleagues succeeded in making ion channels that can be activated by light (Volgraf et al., 2006), and Feringa, Meijberg, and colleagues were successful in a similar approach (Koc¸er et al., 2005), to name only a few recent highlights. The applicability of caging technology depends on the broad spectrum of tools used to generate and manipulate light, also with high spatiotemporal precision. In addition to expensive but powerful lasers, LEDs are now available that have excellent technical specifications at a price that is lower by two orders of magnitude. Experiments have already shown that they can, in fact, compete with the more established light sources (Bernardinelli et al., 2005).
Critical Parameters and Troubleshooting Phosphoramidite synthesis The flask-scale synthesis procedures reported in this unit are all very straightforward. The only step that is sometimes unsuccessful, especially for novice researchers, is the preparation of the phosphoramidites. It is crucial that the flask and the solvents be completely dry and that fresh reagents be used. As noted in the protocols, fresh 2-cyanoethylN,N-diisopropylchlorophosphoramidite is a
1.17.24 Supplement 29
Current Protocols in Nucleic Acid Chemistry
colorless and clear liquid that becomes cloudy upon contact with air in a matter of minutes. It is best to use as little of this reagent as possible, and it is very important to remove any excess in the purification of the phosphoramidite. It is a good idea to always check the purity of the phosphoramidite via 31 P NMR. For NMR, some batches of CDCl3 contain traces of acid, which will result in spectra of decomposed phosphoramidite despite the fact that the amidite is ready to be used. As a solution, DMSO-d6 can be used as a substitute, or the CDCl3 can be filtered through neutral aluminium oxide. One should not be surprised by splitting of signals in the NMR spectra or by spots in the TLC resulting from the formation of diastereomeric mixtures upon introduction of the respective caging groups. However, the sole disadvantage of having slightly more complicated NMR spectra does not justify a stereoselective synthesis. For optimal results, the phosphoramidites described here should not be stored for more than several days. It is therefore advisable to keep a stock of the precursors (S.8a, S.8b, S.14, and S.20), and always prepare the respective phosphoramidites fresh just before the DNA synthesis. With storage at −20◦ C, no decomposition of precursors has been observed. Oligonucleotide synthesis The phosphoramidites can be used in regular solid-phase synthesis protocols. Prolonged coupling times are possible but not necessary. Due to the lability of the caging group under basic conditions, the presence of a TNPE or TNPP residue requires that a different set of nucleobase-protecting groups be used in the solid-phase synthesis. Ultramild protection has been shown to work very well. Ultramildprotected phosphoramidites for the uncaged nucleobases are commercially available from Glen Research. The deprotection conditions should not be harsher than 33% NH4 OH at room temperature. The dGNPP and dCNPE residues are much more tolerant towards base treatment and do not require any additional measures. For higher purity, a DMTr-on synthesis is advisable, followed by solution-phase DMTr-deprotection and repurification. Purification is best performed by RP-HPLC (UNIT 10.5) using a gradient between 0.1 M triethylammonium acetate (TEAA) and acetonitrile. One need not worry about unwanted uncaging due to the light from the detector. The same is true for melting point studies, which are performed by following the temperature-
dependent absorbance. Characterization of the caged oligonucleotides is conveniently performed by ESI-MS, since the samples can be injected right away after the aforementioned HPLC purification with TEAA buffer. Much better results are obtained, however, using an LC-ESI-MS coupling (in which case the aqueous buffer should have a concentration of only 5 mM TEAA). Caged oligonucleotides do not need to be handled in a dark room. In fact, the authors have never observed any unwanted uncaging. Nonetheless, caged oligonucleotides are stored in brown microcentrifuge tubes at –20◦ C without deleterious effects.
Anticipated Results With few exceptions, the reported procedures can be performed with good yields so that it is possible to make a sufficiently large stock of phosphoramidite precursors. The introduction of the caged phosphoramidites in the solid-phase synthesis is also usually unproblematic. The many different reaction steps in the solid-phase synthesis do lead to some loss of caging groups, but since each caging group leads to a very significant time shift in the RP-HPLC, these sequences can be separated very easily, and the peak with the highest retention time is usually by far the biggest peak.
Time Considerations The preparation of each caged phosphoramidite can be completed in ∼2 weeks. An additional 2 weeks are required for synthesis of the precursors described in the Support Protocols (S.22, S.24, S.26, and S.30). As mentioned previously, the phosphoramidites should not be stored but rather used right away. Thus, it is better to keep a stock of the respective precursors (S.8a, S.8b, S.14, and S.20) and prepare the phosphoramidites fresh. The solid-phase synthesis with subsequent deprotection, purification, DMTr-cleavage and repurification, characterization, and quantification will take ∼3 days.
Literature Cited Bennett, I.M., Farfano, H.M.V., Bogani, F., Primak, A., Liddell, P.A., Otero, L., Sereno, L., Silber, J.J., Moore, A.L., Moore, T.A., and Gust, D. 2002. Active transport of Ca2+ by an artificial photosynthetic membrane. Nature 420:398401. Bernardinelli, Y., Haeberli, C., and Chatton, J.Y. 2005. Flash photolysis using a light emitting diode: An efficient, compact, and affordable solution. Cell Calcium 37:565-572.
Synthesis of Modified Nucleosides
1.17.25 Current Protocols in Nucleic Acid Chemistry
Supplement 29
Engels, J. and Schlaeger, E.J. 1977. Synthesis, structure, and reactivity of adenosine cyclic 3 ,5 -phosphate benzyl triesters. J. Med. Chem. 20:907-911.
Mayer, G., Kr¨ock, L., Mikat, V., Engeser, M., and Heckel, A. 2005. Light-induced formation of G-quadruplex DNA secondary structures. ChemBioChem 6:1966-1970.
Goeldner, M. and Givens, R. 2005. Dynamic studies in biology. Wiley-VCH, Weinheim, Germany.
Pelliccioli, A.P. and Wirz, J. 2002. Photoremovable protecting groups: Reaction mechanisms and applications. Photochem. Photobiol. Sci. 1:441458.
Heckel, A. and Mayer, G. 2005. Light-regulation of aptamer activity: An anti-thrombin aptamer with caged thymidine nucleobases. J. Am. Chem. Soc. 127:822-823. Heckel, A., Buff, M.C.R., Raddatz, M.-S.L., M¨uller, J., P¨otzsch, B., and Mayer, G. 2006. An anticoagulant with light-triggered antidote activity. Angew. Chem. Int. Ed. 45:6748-6750. Kaplan, J.H., Forbush, B. III, and Hoffman, J.F. 1978. Rapid photolytic release of adenosine 5 triphosphate from a protected analogue: Utilization by the Na:K pump of human red blood cell ghosts. Biochemistry 17:1929-1935. Koc¸er, A., Walko, M., Meijberg, W., and Feringa, B.L. 2005. A light-actuated nanovalve derived from a channel protein. Science 309:755-758. Kr¨ock, L. and Heckel, A. 2005. Photoinduced transcription by using temporarily mismatched caged oligonucleotides. Angew. Chem. Int. Ed. 44:471-473. Mayer, G. and Heckel, A. 2006. Biologically active molecules with a “light switch”. Angew. Chem. Int. Ed. 45:4900-4921.
Tsuji, Y., Kotachi, S., Huh, K.-T., and Watanabe, Y. 1990. 2-Aminophenethyl alcohols and 2-nitrophenyl alcohols. J. Org. Chem. 55:580584. Volgraf, M., Gorostiza, P., Numano, R., Kramer, R.H., Isacoff, E.Y., and Trauner, D. 2006. Allosteric control of an ionotropic glutamate receptor with an optical switch. Nat. Chem. Biol. 2:47-52. Walbert, S., Pfleiderer, W., and Steiner, U.E. 2001. Photolabile protecting groups for nucleosides: Mechanistic studies on the 2-(2nitrophenyl)ethyl group. Helv. Chim. Acta 84:1601-1611.
Contributed by Alexander Heckel University of Bonn Bonn, Germany
Nucleobase-Caged Phosphoramidites
1.17.26 Supplement 29
Current Protocols in Nucleic Acid Chemistry
Synthesis of Altritol Nucleoside Phosphoramidites for Oligonucleotide Synthesis
UNIT 1.18
Mikhail Abramov1 and Piet Herdewijn1 1
Rega Institute for Medical Research, Leuven, Belgium
ABSTRACT This unit describes in detail the optimized preparations of altritol nucleoside phosphoramidite building blocks for oligonucleotide synthesis (aA, aG, aC, aU). D-Altritol nucleosides with adenine and uracil bases are obtained by nucleophilic opening of the epoxide ring of 1,5:2,3-dianhydro-4,6-O-benzylidene-D-allitol using the 1,8diazabicyclo[5.4.0]undec-7-ene salts of the above-mentioned salts, while phase transfer catalysis (18-crown-6, K2 CO3 ) is optimal for alkylation of 2-amino-6-chloropurine. The cytosine nucleoside is synthesized starting from the uracil congener. The 3 -hydroxyl function of hexitol sugar is protected with the benzoyl group. Curr. Protoc. Nucleic Acid C 2007 by John Wiley & Sons, Inc. Chem. 30:1.18.1-1.18.21. Keywords: altritol nucleic acid (ANA) r altritol nucleoside phosphoramidites r aA r aG r aC r aU
INTRODUCTION Altritol nucleic acids (ANA) represent a new oligomeric structure able to hybridize in a sequence-selective manner with RNA and with itself. In contrast to most chemically modified nucleic acids, ANA possess a free secondary hydroxyl group, which contributes to the stability of RNA-ANA duplexes. The hybridization strength with RNA is higher than with DNA (Allart et al., 1999b; Abramov et al., 2007b). ANA has superior siRNA activity (Fisher et al., 2007) and is an efficient template for nonenzymatic catalyzed polymerization reactions (Kozlov et al., 2000). ANAs are composed of phosphorylated 1,5-anhydro-2-deoxy-D-altro-hexitol building blocks with a base moiety in the 2 -position. During recent years the synthesis of hexitol nucleic acids (HNA) has been developed and described in detail (De Bouvere et al., 1997; UNIT 1.9). ANA nucleosides are very similar to HNA; they differ only by the presence of a supplementary hydroxyl group in the 3 −α-position. Due to the presence of this 3 -hydroxyl function, which requires selective protection, the synthesis of the D-altritol phosphoramidite building blocks takes more time than the synthesis of the 1,5-anhydrohexitol analogs. This unit describes in detail the preparation of the phosphoramidite building blocks (aU, aC, aA, and aG) used for ANA oligonucleotide synthesis (Allart et al., 1999a). Synthesis of the ANA nucleosides is presented in Basic Protocols 1 through 4, followed by a general procedure in Basic Protocol 5 for their phosphitylation, yielding the phosphoramidite derivatives. The chemical reactions described here have optimized yields, and purification of the intermediates is straightforward.
SYNTHESIS OF 1 ,5 -ANHYDRO-3 -O-BENZOYL-6 -OMONOMETHOXYTRITYL-2 -DEOXY-2 -(URACIL-1-YL)-D-ALTROHEXITOL Synthesis of the protected nucleoside from uracil is performed in four steps that are illustrated in Figure 1.18.1. Reaction of the DBU salt of uracil with 1,5:2,3-dianhydro-4,6O-benzylidene-D-allitol yields the altro-derivative (S.1). Treatment with excess benzoyl Current Protocols in Nucleic Acid Chemistry 1.18.1-1.18.21, September 2007 Published online September 2007 in Wiley Interscience (www.interscience.wiley.com). DOI: 10.1002/0471142700.nc0118s30 C 2007 John Wiley & Sons, Inc. Copyright
BASIC PROTOCOL 1
Synthesis of Modified Nucleosides
1.18.1 Supplement 30
Figure 1.18.1 Preparation of protected aU. Bz, benzoyl; DBU, 1,8-diazabicyclo[5.4.0]undec-7ene; DCE, 1,2-dichloroethane; DMF, N,N-dimethylformamide; MMTr, monomethoxytrityl; Py, pyridine; TFA, trifluoroacetic acid.
chloride leads to protection of the 3 -hydroxyl group. Benzylidene cleavage with TFA followed by monomethoxytritylation provides aU (S.4).
Materials Uracil, 99+% 1,5:2,3-Dianhydro-4,6-O-benzylidene-D-allitol (CMS Chemical, http://www.cms-chemicals.com, or Brockway et al., 1984) N,N-Dimethylformamide (DMF), anhydrous Nitrogen gas 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) Dry ice (solid CO2 for cooling bath) Acetic acid (AcOH) Brine (saturated aqueous sodium chloride solution) Ethyl acetate (EtOAc) Sodium sulfate (Na2 SO4 )Silica gel (0.060- to 0.200-nm) Dichloromethane PA (DCM) Methanol (MeOH) Anhydrous pyridine Benzoyl chloride (BzCl) Toluene Saturated aqueous sodium bicarbonate solution (sat. aq. NaHCO3 ) Chloroform Hexane PA 1,2-Dichloroethane, 99.8+% (DCE) Trifluoroacetic acid (TFA) Monomethoxytrityl chloride (MMTr-Cl) Synthesis of Altritol Nucleoside Phosphoramidites
100-, 250-, and 500-mL round-bottom flasks Gas balloon Dropping funnel
1.18.2 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Rotary evaporator equipped with a vacuum pump 5 × 35–cm and 5 × 70–cm chromatography columns 500- and 1000-mL separatory funnels Glass filters (porosity 3) Vacuum desiccator Additional reagents and equipment for column chromatography (APPENDIX 3E) NOTE: All reactions are carried out with anhydrous solvents. All starting materials are commercially available. All evaporations are accomplished in vacuo using a rotary evaporator at 40◦ C. All filtrations are performed using a glass filter under vacuum.
Perform condensation 1. Dissolve 8.0 g uracil (71.4 mmol) and 10 g 1,5:2,3-dianhydro-4,6-O-benzylideneD-allitol (42.7 mmol) in 80 mL anhydrous DMF in a 500-mL flask. Carry out the reaction under N2 atmosphere using a gas balloon. 2. Add 12 mL DBU (79 mmol) in 20 mL anhydrous DMF via a dropping funnel over a period of 30 min. 3. Stir the reaction mixture at 95◦ C for 4 hr. 4. Cool the light-brown solution to room temperature and remove the volatiles in vacuo. 5. Add 300 mL water and suspend the crude product. 6. Cool suspension with an ice-water bath and neutralize with 5 to 6 mL AcOH. 7. Add 200 mL brine and extract three times with 200 mL EtOAc in a 1000-mL separatory funnel. 8. Dry the organic layer over Na2 SO4 , filter off the drying agent under vacuum using a glass filter, and evaporate the solvent from the filtrate using a rotary evaporator equipped with a vacuum pump. 9. Purify the residue by column chromatography (APPENDIX 3E) using 200 g of silica gel with gradient elution (98:2, 96:4 DCM/MeOH). 1 ,5 -Anhydro-4 ,6 -O-benzylidene-2 -deoxy-2 -(uracil-1-yl)-D-altro-hexitol (S.1): 85% yield (12.5 g). TLC (96:4 DCM/MeOH): Rf = 0.2. UV (MeOH): λmax = 266 nm. 1 H NMR (CDCl3 ) δ 3.65 (dd, 1H, J = 9.6 and 2.5 Hz, 4 -H); 3.72 (t, 1H, J= 10.6 Hz, 6 -Ha); 3.85 (br s, 1H, 3 -OH); 3.89 (app d, J = 13.6 Hz, 1 -Ha); 4.10 (dt, 1H, J= 4.7 and 9.9 Hz; 5 -H); 4.26-4.44 (m, 3H, 6 -He, 1 -He, 3 -H); 4.43 (t, 1H, 2 -H); 5.60 (s, 1H, Ph-CH); 5.78 (dd, 1H, J = 8.1 and 2.0 Hz, 5-H); 7.33-7.47 (m, 5H, ar-H), 7.99 (d, 1H, J = 8.1 Hz, 6-H). 13 C NMR (CDCl3 ) δ 56.60 (C-2 ); 64.01 (C-1 ); 65.83 (C-3 ); 66.20 (C-5 ); 68.80 (C-6 ); 76.51 (C-4 ); 102.13 (Ph-CH); 102.86 (C-5); 126.17 (ar-Co ); 128.26 (ar-Cm ); 129.23 (ar-Cp ); 137.00 (ar-Ci ); 142.19 (C-6); 151.36 (C-2); 163.41 (C-4). HRMS (thgly) calcd. for C17 H18 N2 O6 (MH)+ 347.1243, found 347.1291.
Benzoylate 3-hydroxy 10. Dissolve 8.5 g of S.1 (25 mmol) in 100 mL dry pyridine in a 500-mL flask and cool to 0◦ C. 11. Add 5.9 mL BzCl (50 mmol) and allow the mixture to come to room temperature. Continue stirring overnight. 12. Cool the brown solution with an ice bath and add 10 mL water. 13. Remove the volatiles under reduced pressure using a rotary evaporator and coevaporate three times with 50 mL toluene.
Synthesis of Modified Nucleosides
1.18.3 Current Protocols in Nucleic Acid Chemistry
Supplement 30
14. Dissolve the resulting solid in 700 mL DCM and wash two times with 200 mL saturated NaHCO3 in a 1000-mL separatory funnel. 15. Dry the organic layer over Na2 SO4 , filter off the drying agent using a glass filter, and evaporate the solvent from the filtrate using a rotary evaporator at 40◦ C. 16. Absorb the crude product on silica gel by suspending the product in 250 mL chloroform in a 500-mL flask with stirring, then adding 50 g silica gel and evaporating the suspension carefully to dryness. Purify by column chromatography with gradient elution (40:60, 10:90 hexane/EtOAc and 100% EtOAc). 1 ,5-Anhydro-3-O-benzoyl-4 ,6 -O-benzylidene-2 -deoxy-2 -(uracil-1-yl)-D-altro-hexitol (S.2): 80% yield (8.7 g). TLC (50:50 hexane/EtOAc): Rf = 0.25. 1 H NMR (DMSO-d6 ) δ 3.72-3.90 (m, 1H, 4 -H); 4.10 (m, 2H, 5 -H, and 6 -Ha); 4.22-4.45 (m, 3H, 6 -He, 1 -Ha, and 1 -He); 4.48 (t, 1H, 2 -H); 5.69 (s, 1H, Ph-CH); 5.71 (d, 1H, J = 8.1 Hz, 5-H); 5.73 (br s, 1H, 3 -H); 7.20-7.35 (m, 5H, Bn); 7.54-7.85 (m, 3H, Bz m+p ); 7.96 (d, 1H, J = 8.1 Hz, 6-H); 8.13 (d, 2H, J = 7.0 Hz, Bzo ); 11.42 (br s, 1H, N3-H). HRMS (thgly) calcd. for C24 H23 N2 O7 (MH)+ 451.1505, found 451.1510.
Cleave benzylidene protecting group 17. Suspend 3.6.g of S.2 (8 mmol) in dry 50 mL DCE in a 100-mL flask and cool to 0◦ C. 18. Add 4 mL TFA (50 mmol) and stir yellow-clear solution for 30 min at 0◦ C. 19. Add 160 µL water (9 mmol) and continue stirring for 20 min at 0◦ C. 20. Neutralize the reaction mixture with 4.8 mL pyridine (60 mmol) and continue stirring the colorless solution at 0◦ C for 2-6 hr. 21. Filter off white crystalline solid using a glass filter, wash twice with 5 mL cold DCM, and dry overnight in a vacuum desiccator. 1 ,5 -Anhydro-3 -O-benzoyl-2 -deoxy-2 -(uracil-1-yl)-D-altro-hexitol (S.3): 82% yield (2.4 g). TLC (95:5 DCM/MeOH): Rf = 0.05. 1 H NMR (DMSO-d6 ) δ 3.60-3.80 (m, 3H, 4 -H, 6 -Ha, and 6 -He); 3.95 (m, 1H, 5 -H); 4.0-4.13 (m, 2H, 1 -Ha+e); 4.66 (dd, 1H, 2 -H); 4.77 (t, 1H, 6 -OH); 5.33 (d, 1H, J = 5.5 Hz, 4 -OH); 5.50 (dd, 1H, J = 6.0 and 2.9Hz, 3 -H); 5.59 (dd, 1H, J = 8.1 and 2.1 Hz, 5-H); 7.50-7.75 (m, 3H, Bzm+p ); 7.98-8.10 (m, 3H, Bzo , 6-H); 11.35 (br s, 1H, N3-H). HRMS (thgly) calcd. for C17 H18 N2 O7 (MH+ ) 363.1192, found 363.1185.
Tritylate 6-hydroxy 22. Co-evaporate 2.4 g of S.3 (6.6 mmol) with 15 mL dry pyridine in a 250-mL flask. 23. Add 5 mL dry pyridine and 50 mL DCM and cool to 0◦ C. 24. Add 2.25 g MMTr-Cl (7.2 mmol), allow the mixture to come to room temperature, and then stir for 3 hr. 25. Add 1 mL MeOH with stirring for 15 min to decompose excess MMTr-Cl. 26. Add 150 mL DCM and wash three times with 100 mL water in a 500-mL separatory funnel. 27. Dry the organic layer over Na2 SO4 , filter off the drying agent using a glass filter, and evaporate the solvent using a rotary evaporator at 40◦ C until 30 to 40 mL remains. 28. Add the solution dropwise over 30 min to 200 mL hexane at 0◦ C with stirring. Continue stirring 1 hr at 0◦ C. Synthesis of Altritol Nucleoside Phosphoramidites
29. Filter off the white fine powder using a glass filter, wash twice with 10 mL cold hexane, and dry overnight in a vacuum desiccator. The dry product can be stored in the dark at –20◦ C for 6 months.
1.18.4 Supplement 30
Current Protocols in Nucleic Acid Chemistry
1 ,5 -Anhydro-3 -O-benzoyl-6 -O-monomethoxytrityl-2 -deoxy-2 -(uracil-1-yl)-D-altrohexitol (S.4): 90% yield (3.8 g). TLC (80:20 EtOAc/hexane): Rf = 0.7. 1 H NMR (CDCl3 ) δ 3.42 (dd, J = 10.4 and 3.1 Hz, 6 -Ha); 3.54 (dd, 1H, J = 10.4 and 2.7 Hz, 6 -He); 3.77 (s, 3H, O-CH3 ); 3.75-3.85 (m, 1H, 4 -H); 4.12 ( dd, 1H, J = 14.0 and 7.2 Hz, 1 -Ha); 4.31 (dd, 1H, J = 14.0 and 3.6 Hz, 1 -He); 4.17-4.38 (m, 1H, 5 -H); 4.73 (app t, 1H, 2 -H); 5.69-5.80 (m, 2H, 3 -H and 5-H); 6.82 (d, 2H, J = 8.9 Hz, ar-H); 7.18-7.60 (m, 15H, ar-H); 7.99 (d, 2H, J = 7.0 Hz, ar-H); 8.29 (d, 1H, J = 8.2 Hz, 6-H); 8.80 (br s, 1H, N3-H). 13 C NMR (CDCl3 ) δ 53.70 (C-2 ); 55.20 (O-CH3 ); 62.12 (C-6 ); 64.50 (C-4 ); 64.69 (C-1 ); 69.92 (C-3 ); 76.37 (C-5 ); 86.65 (CTr -O); 102.89 (C-5); 113.21, 127.07, 127.91, 128.14, 128.32, 128.52, 129.17, 129.85, 130.39, 133.55, 135.08, 144.12, 158.55 (ar-C); 142.43 (C-6); 150.77 (C-2); 162.72 (C-4); 165.63 (Bz-CO). HRMS (thgly:NaOAc) calcd. for C37 H34 N2 O8 Na (M+Na)+ 657.2213 found 657.2219.
SYNTHESIS OF 1 ,5 -ANHYDRO-3 -O-BENZOYL-6 -OMONOMETHOXYTRITYL-2 -DEOXY-2 -(N4 -BENZOYLCYTOSIN-1-YL)-DALTRO-HEXITOL
BASIC PROTOCOL 2
Synthesis of the protected nucleoside starts with the uracil intermediate S.2 and is illustrated in Figure 1.18.2. The cytosine altro-nucleoside (S.5) is prepared from S.2 via ammonium treatment of the 1,2,4-triazolyl intermediate. Treatment of S.5 with excess benzoyl chloride leads to protection of 3 -hydroxyl group and the exocyclic amino group of cytosine. Benzylidene cleavage with TFA followed by monomethoxytritylation provides aC (S.8).
Figure 1.18.2 Preparation of protected aC. Bz, benzoyl; DCE, 1,2-dichloroethane; MMTr, monomethoxytrityl; Py, pyridine; TFA, trifluoroacetic acid.
Synthesis of Modified Nucleosides
1.18.5 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Materials 1,2,4-1H-Triazole, 99.5% Phosphorus oxychloride (POCl3 ) Anhydrous pyridine Dry ice (solid CO2 for cooling bath) Triethylamine 1 ,5 -Anhydro-3 -O-benzoyl-4 ,6 -O-benzylidene-2 -deoxy-2 -(uracil-1-yl)-D-altrohexitol (S.2; see Basic Protocol 1) Toluene PA Dichloromethane PA (DCM) Brine (saturated aqueous sodium chloride solution) Sodium sulfate (Na2 SO4 )Dioxane Concentrated aqueous ammonia (25% NH3 ) Methanol (MeOH) Celite Silica gel (0.060- to 0.200-nm) Benzoyl chloride (BzCl)1,2-Dichloroethane, 99.8+% (DCE) Trifluoroacetic acid (TFA) Monomethoxytrityl Chloride (MMTr-Cl) Hexane PA 100-, 250-, and 500-mL round-bottom flasks Dropping funnel 5 × 35–cm and 5 × 70–cm chromatography columns Gas balloon Rotary evaporator equipped with a vacuum pump Glass filters (porosity 3) Vacuum desiccator Additional reagents and equipment for column chromatography (APPENDIX 3E) NOTE: All reactions are carried out with anhydrous solvents. All starting reagents are commercially available. All evaporations are accomplished in vacuo using a rotary evaporator at 40◦ C. All filtrations are performed using a glass filter under vacuum.
Convert uracil to cytosine 1. Prepare a mixture of 5.2 g 1,2,4-1H-triazole (75 mmol) and 1.5 mL phosphorus oxychloride (15.8 mmol) in 40 mL dry pyridine at 0◦ C in a 500-mL flask. 2. Add 10 mL triethylamine (72 mmol) dropwise and continue stirring at 0◦ C for 30 min. 3. Add a solution of 3.2 g S.2 (8.25 mmol) in 40 mL dry pyridine and stir the reaction mixture at room temperature for 2 hr. The solution turns yellow.
4. Remove the volatiles under vacuum using a rotary evaporator at 40◦ C and coevaporate three times, each time with 25 mL toluene. 5. Dissolve the residue in 250 mL DCM and wash two times with 100 mL brine using a 500-mL separatory funnel. 6. Wash the combined aqueous layer with 50 mL DCM. Synthesis of Altritol Nucleoside Phosphoramidites
7. Combine organic layers, dry over Na2 SO4 , filter off the drying agent under vacuum using a glass filter, and evaporate to dryness using a rotary evaporator equipped with a vacuum pump.
1.18.6 Supplement 30
Current Protocols in Nucleic Acid Chemistry
8. Dissolve the brown residue in 180 mL dioxane in a 500-mL flask and cool to 0◦ C. 9. Add 60 mL concentrated aqueous ammonia and leave the solution overnight at room temperature. 10. Evaporate to dryness using a rotary evaporator under vacuum and co-evaporate three times, each time with 50 mL toluene. 11. Dissolve in 100 mL of 50:50 DCM/MeOH and filter through a small Celite pad. 12. Absorb the crude product on silica gel and purify by column chromatography (APPENDIX 3E), eluting with 98:2 to 95:5 DCM/MeOH. Unreacted starting material S.2 (0.1 to 0.3 g) can be recovered. 1 ,5 -Anhydro-4 ,6 -O-benzylidene-2 -deoxy-2 -(cytosin-1-yl)-D-altro-hexitol (S.5): 70% yield by NMR (3.0 g) as a yellow-orange foam (contains benzamide), used without further purification for the next step. TLC (90:10 DCM/MeOH): Rf = 0.25. UV (MeOH): λmax = 276 nm. 1 H NMR (DMSO-d6 ) δ 3.60 (dd, 1H, J = 2.3 and 9.6 Hz, 4 -H); 3.64 (t, 1H, J = 10.2 Hz, 6 -Ha); 3.91 (dd, 1H, J = 4.9 and 9.6 Hz, 5 -H); 4.00 (m, 1H, 3 -H); 4.00-4.26 (m, 3H, 1 -Ha, 1 -He, and 6 -He); 4.29 (m, 1H, 2 -H); 5.65 (s, 1H, Ph-CH); 5.72 (d, 1H, J = 4.2 Hz, 3 -OH); 5.77 (d, 1H, J = 7.5 Hz, 5-H); 7.05 and 7.19 (2 br s, 2H, 4-NH2 ); 7.30-7.45 (m, 5H, ar-H); 7.94 (d, 1H, J = 7.5 Hz, 6-H). 13 C NMR (DMSO-d6 ) δ 57.46 (C-2 ); 64.00 (C-1 ); 64.87 (C-3 ); 65.79 (C-5 ); 68.28 (C-6 ); 76.50 (C-4 ); 94.09 (C-5); 101.20 (Ph-CH); 126.50 (2C, ar-Co ); 128.10 (2C, ar-Cm ); 128.95 (ar-Cp ); 137.93 (ar-Ci ); 143.75 (C-6); 154.98 (C-2); 165.19 (C-4). HRMS (thgly) calcd. for C17 H20 N3 O5 (MH)+ 346.1403, found 346.1380.
Benzoylate 3-hydroxy and nucleobase 13. Dissolve 3.0 g of S.5 in 50 mL dry pyridine in a 250-mL round-bottom flask equipped with a gas balloon. 14. Add 2.5 mL benzoyl chloride (20.0 mmol) and stir the reaction mixture overnight at room temperature. 15. Cool the reaction mixture to 0◦ C, add 1 mL water, and stir for 20 min. 16. Add 10 mL concentrated aqueous ammonia and continue stirring at room temperature for 1 hr. 17. Remove the volatiles under reduced pressure using a rotary evaporator, and coevaporate three times, each time with 15 mL toluene. 18. Absorb the crude product on silica gel and purify by column chromatography (APPENDIX 3E), eluting with 98:2 DCM/MeOH. The title product crystallized in tubes during collection of the fractions. 1 ,5-Anhydro-3 -O-benzoyl-4 ,6 -O-benzylidene-2 -deoxy-2 -(N4 -benzoylcytosin-1-yl)-Daltro-hexitol (S.6): overall yield 61% (2.8 g, 5.0 mmol) from S.2. TLC (95:5 DCM/MeOH): Rf = 0.25. 1 H NMR (DMSO-d6 ) δ 3.85 (m, 1H, 4 -H); 4.00-4.60 (m, 5H, 5 -H, 1 -Ha, 1 -He, 6 -Ha, and 6 -He); 4.63 (br s, 1H, 2 -H); 5.70 (s, 1H, Ph-CH); 5.81 (br s, 1H, 3 -H); 7.20-7.35 (m, 5H, ar-H); 7.45-7.80 (m, 7H, 2 × Bz, 5-H); 8.04 (d, 2H, J = 7 Hz, Bzo ); 8.15 (d, 2H, J = 7 Hz, Bzo ); 8.48 (d, 1H, J = 7.7 Hz, 6-H); 11.35 (br s, 1H, N4-H). 13 C NMR (DMSO-d6 ) δ 55.83 (C-2 ); 64.84 (C-1 ); 66.20 and 67.23 (C-3 , C-5 ); 68.08 (C-6 ); 74.21 (C-4 ); 97.14 (C-5); 100.81 (Ph-CH); 126.03, 128.18, 128.64, 128.97, 129.08, 129.44, 129.76, 132.95, 133.29, 133.88, 137.60 (ar-C); 147.71 (C-6); 155.20 (C-2); 163.24 (C-4); 164.11 (PhCONH and PhCOO). HRMS (thgly) calcd. for C31 H28 N3 O7 (MH)+ 554.1927, found 554.1892.
Cleave benzylidene protecting group 19. Suspend 2.8 g of S.6 (5.0 mmol) in 25 mL dry DCE in a 100-mL flask and cool to 0◦ C.
Synthesis of Modified Nucleosides
1.18.7 Current Protocols in Nucleic Acid Chemistry
Supplement 30
20. Add 2.5 mL TFA (30 mmol) and stir yellow-clear solution for 30 min at 0◦ C. 21. Add 110 µl water (6 mmol) and continue stirring for 20 min at 0◦ C. 22. Neutralize the reaction mixture with 3.2 mL pyridine (40 mmol) and continue stirring the colorless solution at 0◦ C for 2 to 4 hr. 23. Filter off white crystalline solid using a glass filter, wash twice with 5 mL cold DCM, and dry overnight on a vacuum desiccator. 1 ,5 -Anhydro-3 -O-benzoyl-2 -deoxy-2 -(N4 -benzoylcytosin-1-yl)-D-altro-hexitol (S.7): 80% yield (1.8 g). TLC (95:5 DCM/MeOH): Rf = 0.25. 1 H NMR (DMSO-d6 ) δ 3.60-4.00 (m, 3H, 4 -H, 6 -Ha, and 6 -He); 4.10-4.40 (m, 3H, 5 -H, 1 -Ha, and 1 -He); 4.65-4.85 (m, 2H, 2 -H and 6 -OH); 5.25 (br s, 1H, 4 -OH); 5.65 (m, 1H, 3 -H); 7.35 (d, 1H, J = 7.8 Hz, 5-H); 7.45-7.80 (m, 6H, ar-H); 7.90-8.15 (m, 4H, ar-H); 8.48 (d, 1H, J = 7.8 Hz, 6-H); 11.35 (br s, 1H, N4-H). LSIMS (thgly, negative mode) 466.2 (MH)+ . HRMS (thgly) calcd. for C24 H23 N3 O7 (MH+ ) 466.1614, found 466.1603.
Tritylate 6-hydroxy 24. Co-evaporate 1.8 g S.7 (4.0 mmol) with 10 mL dry pyridine in a 250-mL flask. 25. Add 3 mL dry pyridine and 20 mL DCM and cool to 0◦ C. 26. Add 1.4 g MMTr-Cl (4.4 mmol) in two portions over 30 min. Allow the mixture to come to room temperature and stir for 3 hr. 27. Add 1 mL MeOH to decompose excess MMTr-Cl and stir for 15 min. 28. Add 150 mL DCM and extract three times, each time with 100 mL water. 29. Dry the organic layer over Na2 SO4 , filter off the drying agent using a glass filter, and evaporate the solvent until 30 to 40 mL of solution remains. 30. Add solution dropwise over 30 min to 150 mL hexane at 0◦ C with stirring. Continue stirring for 1 hr at 0◦ C. 31. Filter off the white fine powder using a glass filter, wash two times with 10 mL cold hexane, and dry overnight in a vacuum desiccator. The dry product can be stored in the dark at –20◦ C for 6 months. 1’,5’-Anhydro-3’-O-benzoyl-6’-O-monomethoxytrityl-2’-deoxy-2’-(N4-benzoylcytosin-1-yl)D-altro-hexitol (S.8): 75% yield (2.2 g). TLC (80:20 DCM/acetone): Rf = 0.58. 1 H NMR (DMSO-d6) δ 3.43 (dd, 1H, J = 10.1 and 3.1 Hz, 6’-Ha); 3.53 (dd, 1H, 6’-He); 3.65 (m, 1H, 4’-H); 3.79 (s, 3H, OCH3 ); 3.75-3.90 (m, 1H, 5’-H); 4.05-4.42 (m, 3H, 1’-Ha, 1’-He, 4’-OH); 4.93 (br s, 1H, 2’-H); 5.84 (app t, 1H, J= 3.1 Hz, 3’-H); 6.86 (d, 2H, J = 8.8 Hz, ar-H); 7.15-7.70 (m, 19H, ar-H, 5-H); 7.90-8.05 (m, 4H, ar-H); 8.78 (d, 1H, J = 7.7 Hz, 6-H). 13 C NMR (CDCl3 ) δ 55.07 and 55.20 (C-2’, OCH3 ); 62.08 (C-6’); 64.24 (C-4’); 64.82 (C-1’); 69.66 (C-3’); 75.96 (C-5’); 86.59 (CTr -O); 97.28 (C-5); 113.21; 127.07, 127.65, 127.91, 128.46, 129.02, 129.32, 129.86, 130.16, 133.02, 133.17, 133.47, 135.57, 143.99, 144.13 and 158.62 (ar-C); 147.56 (C-6); 155.0 (C-2); 162.20 (C-4); 165.83 (CO-O and CO-N). HRMS (thgly) calcd. for C44 H39 N3 O8 Na (M+Na)+ 760.2635 found 760.2642. BASIC PROTOCOL 3
Synthesis of Altritol Nucleoside Phosphoramidites
SYNTHESIS OF 1 ,5 -ANHYDRO-3 -O-BENZOYL-6 -OMONOMETHOXYTRITYL-2 -DEOXY-2 -(N6 -BENZOYLADENIN-9-YL)-DALTRO-HEXITOL Synthesis of the protected nucleoside from adenine is illustrated in Figure 1.18.3. The key product is prepared in four steps. Reaction of the DBU salt of adenine with 1,5:2, 3-dianhydro-4,6-O-benzylidene-D-allitol yields the altro-derivative S.9. Treatment with excess benzoyl chloride leads to protection of the 3 -hydroxyl group. Benzylidene cleavage with TFA followed by monomethoxytritylation provides aA (S.12).
1.18.8 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Figure 1.18.3 Preparation of protected aA. Bz, benzoyl; DBU, 1,8-diazabicyclo[5.4.0]undec-7ene; DCE, 1,2-dichloroethane; DMF, N,N-dimethylformamide; MMTr, monomethoxytrityl; Py, pyridine; TFA, trifluoroacetic acid.
Materials Adenine, 99+% 1,5:2,3-Dianhydro-4,6-O-benzylidene-D-allitol (CMS Chemical, http://www.cms-chemicals.com, or Brockway et al., 1984) N,N-Dimethylformamide (DMF), dry Nitrogen gas 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU)Dry ice (solid CO2 for cooling bath) Acetic acid (AcOH) Anhydrous pyridine Benzoyl chloride (BzCl) Concentrated aqueous ammonia (25% NH3 ) Toluene PA Dichloromethane PA (DCM) Silica gel (0.060- to 0.200-nm) Hexane PA Ethyl acetate (EtOAc) 1,2-Dichloroethane 99.8+% (DCE), dry Trifluoroacetic acid (TFA) Monomethoxytrityl chloride (MMTr-Cl) Methanol (MeOH) Sodium sulfate (Na2 SO4 ) 100-, 250-, and 500-mL round-bottom flasks Gas balloon Dropping funnel Ice bath 500-mL and 1-L separatory funnels 5 × 35–cm and 5 × 70–cm chromatography columns Glass filters (porosity 3)
Synthesis of Modified Nucleosides
1.18.9 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Oven at 70◦ to 80◦ C Rotary evaporator equipped with a vacuum pump Vacuum desiccator Additional reagents and equipment for column chromatography (APPENDIX 3E) NOTE: All reactions are carried out with anhydrous solvents. All starting reagents are commercially available. All evaporations are accomplished in vacuo using a rotary evaporator at 40◦ C. All filtrations are performed using a glass filter under vacuum.
Perform condensation 1. Dissolve 9.0 g adenine (67 mmol) and 10.0 g 1,5:2,3-dianhydro-4,6-O-benzylideneD-allitol (mmol) in 80 mL anhydrous DMF in a 500-mL flask. Carry out the reaction under N2 atmosphere using a gas balloon. 2. Add 12 mL DBU (79 mmol) in anhydrous 20 mL DMF via a dropping funnel over a period of 30 min. Continue stirring the reaction mixture for 4 hr at 95◦ C. 3. Cool the light-brown solution to room temperature and remove the volatiles in vacuo. 4. Add 300 mL water and suspend the crude product. 5. Cool the suspension with an ice-water bath and neutralize with 5 to 6 ml AcOH. 6. Filter off white crystalline solid using a glass filter and wash three times, each time with 50 mL cold water. 7. Dry the white solid in an oven overnight at 70◦ to 80◦ C. 1,5-Anhydro-4,6-O-benzylidene-2-deoxy-2-(adenin-9-yl)-D-altro-hexitol (S.9): 85% yield (13.4 g). TLC (90:10 DCM/MeOH): Rf = 0.35. UV (MeOH) : λmax = 262 nm. 1 H NMR (DMSO-d6 ) δ 3.60 (dd, 1H, 4 -H); 3.80 (t, 1H, 6 -Ha); 4.0 (m, 1H, 5 -H); 4.20-4.40 (m, 4H, 1 -Ha, 1 -He, 3 -H, and 6 -He); 4.60 (br s, 1H, 2 -H); 5.62 (s, 1H, Ph-CH); 5.99 (d, 1H, J = 4.4 Hz, 3 -OH); 7.25-7.40 (m, 5H, ar-H); 8.18 (s, 1H, 2-H); 8.26 (s, 1H, 8-H); 8.55 (br s, 2H, 6-NH2 ). 13 C NMR (DMSO-d6 ) δ 56.17 (C-2 ); 64.55 (C-1 ); 65.28 (C-3 ); 66.61 (C-5 ); 68.34 (C-6 ); 76.35 (C-4 ); 101.30 (Ph-CH); 118.54 (C-5); 126.65 (2C, ar-Co ); 128.32 (2C, ar-Cm ); 129.17 (ar-Cp ); 138.03 (ar-Ci ); 139.49 (C-8); 149.96 (C4); 152.99 (C-2); 156.42 (C-6). HRMS (thgly) calcd. for C18 H20 N5 O4 (MH)+ 370.1515, found 370.1559.
Benzoylate 3-hydroxy and nucleobase 8. Dissolve 13.4 g of S.9 (36 mmol) in 100 mL dry pyridine in a 500-mL flask and cool to 0◦ C. 9. Add 24 mL BzCl (200 mmol) and allow the mixture to come to room temperature. Continue stirring overnight. 10. Cool the brown solution with an ice bath and add 10 mL water. 11. After 5 min add 35 mL aqueous 25% NH3 and continue stirring 1 hr at 0◦ C. 12. Remove the volatiles under reduced pressure and co-evaporate three times, each time with 50 mL toluene. 13. Suspend the resulting solid in 250 mL DCM in a 500-mL flask and filter off precipitate using a glass filter.
Synthesis of Altritol Nucleoside Phosphoramidites
14. Co-evaporate mother liquid with 50 g silica gel and purify the crude product by column chromatography (APPENDIX 3E) with gradient elution (40:60, 10:90 hexane/EtOAc, 100% EtOAc).
1.18.10 Supplement 30
Current Protocols in Nucleic Acid Chemistry
1 ,5 -Anhydro-3 -O-benzoyl-4 ,6 -O-benzylidene-2 -deoxy-2 -(N6 -benzoyladenin-9-yl)-Daltro-hexitol (S.10): 75% yield (15.6 g). TLC (95:5 DCM/MeOH): Rf = 0.5. 1 H NMR (DMSO-d6 , 500 MHz) δ 3.82 (t, 1H, J = 10.25 Hz, 6 -Ha); 3.91 (dd, 1H, J = 9.7 and 2.6 Hz, 4 -H); 4.28 (dt, 1H, J= 5.1 and 9.7 Hz, 5 -H); 4.46 (m, 2H, 1 -Ha, and 6 -He); 4.57 (dd, 1H, J = 2.6 and 13.3 Hz, 1 -He); 5.08 (t, 1H, J = 2.6 Hz, 2 -H); 5.52 (s, 1H, PhCH); 5.99 (t, 1H, J = 2.6 Hz, 3 -H); 7.22-7.27 and 7.30-7.34 (m, 5H, Bn); 7.48-7.54 (m, 4H, two Bzo ); 7.58-7.64 (m, 2H, two Bzp ); 8.05 (d, 2H, J = 7.3 Hz); 8.16 (d, 2H, J = 8.4 Hz, Bzm ); 8.63 (s, 1H, 2-H); 8.85 (s, 1H, 8-H); 9.19 (br s, 2H, 6-NH2 ). 13 C NMR (DMSO-d6 ) δ 53.42 (C-2 ); 65.74 (C-1 ); 67.02 (C-5 ); 68.41 (C-3 ); 68.96 (C-6 ); 74.79 (C-4 ); 102.13 (Ph-CH); 122.83 (C-5); 125.99, 128.02, 128.20, 128.66, 128.87, 129.12, 129.35, 129.96, 132.88, 133.69 and 136.70 (ar-C); 141.77 (C-8); 149.78 (C-4); 152.51 (C-2); 153.21 (C-6); 164.89 (two Bz-Co ). HRMS (thgly) calcd. for C32 H28 N5O6 (MH)+ 578.2040, found 578.2073.
Cleave benzylidene protecting group 15. Suspend 5.0 g of S.10 (8.7 mmol) in 50 mL dry DCE in a 100-mL flask and cool to 0◦ C. 16. Add 4 mL TFA (50 mmol) and stir yellow clear solution for 30 min at 0◦ C. 17. Add 180 µl water (10 mmol) and continue stirring for 20 min at 0◦ C. 18. Neutralize reaction mixture with 4.8 mL pyridine (60 mmol) and continue stirring at 0◦ C for 2 to 6 hr until the precipitation is complete. 19. Filter off white crystalline solid using a glass filter, wash two times with 5 mL cold DCM, and dry overnight in a vacuum desiccator. 1 ,5 -Anhydro-3 -O-benzoyl-2 -deoxy-2 -(N6 -benzoyladenin-9-yl)-D-altro-hexitol (S.11): 90% yield (3.8 g). TLC (95:5 DCM/MeOH): Rf = 0.05. 1 H NMR (DMSO-d6 ) δ 3.704.00 (m, 4H, 4 -H, 5 -H, 6 -Ha, and 6 -He); 4.28 (dd, 1H, J = 2.9 and 12.9 Hz, 1 -Ha); 4.39 (dd, 1H, J = 2.2 and 12.9 Hz, 1 -He); 4.87 (br s, 1H, 6 -OH); 5.06 (br d, 1H, 2 -H); 5.34 (br d, 1H, 4 -OH); 5.74 (dd, 1H, J = 2.5 Hz and 4.5 Hz, 3 -H); 7.50-7.75 (m, 6H, two Bzm+p ); 8.05 (d, 4H, two Bzo ); 8.76 (s, 1H, 2-H); 8.80 (s, 1H, 8-H); 11.21 (br s, 2H, 6-NH2 ). 13 C NMR (DMSO-d6 ) δ 52.62 (C-2 ); 59.85 (C-6 ); 62.61 (C-4 ); 63.82 (C-1 ); 70.38 (C-3 ); 78.34 (C-5 ); 125.43 (C-5); 128.59, 128.85, 128.20, 129.65, 132.57, 133.47 and 133.68 (12C, ar-C); 143.56 (C-8); 150.42 (C-4); 151.85 (C-2); 152.66 (C-6); 164.78, 165.71 (two Bz-Co). HRMS (thgly) calcd. for C25 H24 N5 O6 (MH)+ 490.1727, found 490.1740.
Tritylate 6-hydroxy 20. Co-evaporate 4.0 g of S.11 (8.2 mmol) with 15 mL dry pyridine in a 250-mL flask. 21. Add 5 mL dry pyridine and 50 mL DCM and cool to 0◦ C. 22. Add 2.7 g MMTr-Cl (8.7 mmol) in three portions over 30 min. Allow the mixture to come to room temperature and stir for 3 hr. 23. Add 1 mL MeOH to decompose excess MMTr-Cl and stir for 15 min. 24. Add 150 mL DCM and wash three times, each time with 100 mL water in a 500-mL separatory funnel. 25. Dry the organic layer over Na2 SO4 , filter off the drying agent under vacuum using a glass filter, and evaporate the solvent using a rotary evaporator equipped with a vacuum pump until 30 to 40 mL remains. 26. Add solution dropwise over 30 min to 200 mL hexane at 0◦ C with stirring. Continue stirring suspension for 1 hr at 0◦ C. 27. Filter off white fine powder using a glass filter, wash two times with 10 mL cold hexane, and dry overnight in a vacuum desiccator.
Synthesis of Modified Nucleosides
1.18.11 Current Protocols in Nucleic Acid Chemistry
Supplement 30
The dry product can be stored in the dark at –20◦ C for 6 months. 1,5-Anhydro-3-O-benzoyl-6-O-monomethoxytrityl-2 -deoxy-2 -(N6 -benzoyladenin-9-yl)D-altro-hexitol (S.12): 70% yield (4.4 g). TLC (80:20 EtOAc/hexane) : Rf = 0.45. 1 H NMR (DMSO-d6 ) δ 3.20-3.50 (m, 2H, 6 -Ha, and 6 -He); 3.71 (s, 3H, OCH3 ); 4.01 (br s, 2H, 4 -H, and 5 -H); 4.34 (br d, J = 12.5 Hz, 1 -Ha); 4.52 (br d, 1H, J = 12.5 Hz, 1 -He); 5.06 (m, 1H, 2 -H); 5.27 (t, 1H, 4 -OH); 5.85 (d, 1H, J = 4.7 Hz, 3 -H); 6.91 (d, 2H, J = 9.2 Hz, ar-H); 7.17-7.75 (m, 18H, ar-H); 8.07 (d, 4H, J = 7.7 Hz, ar-H); 8.79 (s, 2H, 2-H and 8-H); 11.27 (br s, 1H, 6-NH). 13 C NMR (DMSO-d6 ) δ 52.94 (C-2 ); 55.08 (OCH3 ); 62.34 (C-6 ); 62.87 (C-4 ); 63.88 (C-1 ); 70.03 (C-3 ); 76.42 (C-5 ); 85.65 (CTr -O); 125.24 (C-5); 113.29, 126.90, 127.97, 128.22, 128.58, 128.80, 129.58, 129.70, 130.08, 132.56, 133.48, 133.65, 135.46, 144.36 and 158.20 (ar-C); 143.39 (C-8); 150.57 (C-4); 151.85 (C-2); 152.62 (C-6); 164.77 (CO-O); 165.75 (CO-N). HRMS (thgly) calcd. for C45 H39 N5 O7 Na (M+Na)+ 784.2747, found 784.2743. BASIC PROTOCOL 4
SYNTHESIS OF 1 ,5 -ANHYDRO-3 -O-BENZOYL-6 -OMONOMETHOXYTRITYL-2 -DEOXY-2 -(N2 (DIMETHYLAMINO)METHYLENE-GUANIN-9-YL)-D-ALTRO-HEXITOL Synthesis of the protected nucleoside starts from 2-amino-6-chloropurine and is completed in six steps, as illustrated in Figure 1.18.4. Reaction of the salt of 2-amino6-chloropurine with 1,5:2,3-dianhydro-4,6-O-benzylidene-D-allitol yields the altroderivative S.13. The displacement of chlorine in S.13 by sodium hydroxide, assisted by DABCO, affords the guanine analog S.14. The N2 -protecting group is introduced using N,N-dimethylformamide diethylacetal. Treatment of S.15 with excess benzoyl cyanide leads to protection of the 3 -hydroxyl group. Benzylidene cleavage with TFA followed by monomethoxytritylation provides aG (S.18).
Materials
Synthesis of Altritol Nucleoside Phosphoramidites
2-Amino-6-chloropurine, 99+% 1,5:2,3-Dianhydro-4,6-O-benzylidene-D-allitol (CMS Chemical, http://www.cms-chemicals.com, or Brockway et al., 1984) Hexamethylenephosphorotriamide (HMPA), anhydrous Nitrogen gas Aqueous potassium carbonate (K2 CO3 ), anhydrous 18-Crown-6 Dichloromethane PA (DCM) Sodium sulfate (Na2 SO4 ) Silica gel (0.060- to 0.200-nm) Methanol (MeOH) 1,8-Diazabicyclo[2.2.2]octane (DABCO) 1 N NaOH Dry ice (solid CO2 for cooling bath) 1 N HCl N,N-Dimethylformamide diethyl acetal N,N-Dimethylformamide (DMF), anhydrous p-Xylene Silica gel (0.060 to 0.200 nm) Chloroform (CHCl3 ) Tri-n-butylamine Benzoyl cyanide 1,2-Dichloroethane, 99.8+% (DCE) Trifluoroacetic acid (TFA) Pyridine (Py), anhydrous Monomethoxytrityl chloride (MMTr-Cl) Hexane PA
1.18.12 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Figure 1.18.4 Preparation of protected aG. Bz, benzoyl; DCE, 1,2-dichloroethane; dmf, dimethylaminomethylene; DMF, N,N-dimethylformamide; HMPA, hexamethylenephosphorotriamide; MMTr, monomethoxytrityl; Py, pyridine; TFA, trifluoroacetic acid.
100-, 250-, and 500-mL round-bottom flasks Gas balloon 5 × 35–cm and 5 × 70–cm chromatography columns Glass filters (porosity 3) Vacuum desiccator Rotary evaporator equipped with a vacuum pump 500-mL and 1-L separatory funnels Additional reagents and equipment for column chromatography (APPENDIX 3E) NOTE: All reactions are carried out with anhydrous solvents. All starting reagents are commercially available. All evaporations are accomplished in vacuo using a rotary evaporator at 40◦ C. All filtrations are performed using a glass filter under vacuum.
Perform condensation 1. Suspend 5.4 g 2-amino-6-chloropurine (60 mmol) and 10.0 g 1,5:2,3-dianhydro4,6-O-benzylidene-D-allitol (42.7 mmol) in 150 mL anhydrous HMPA in a 500-mL flask. Carry out the reaction under N2 atmosphere using a gas balloon.
Synthesis of Modified Nucleosides
1.18.13 Current Protocols in Nucleic Acid Chemistry
Supplement 30
2. Add 6 g K2 CO3 (43 mmol) and 5.0 g 18-crown-6 (519 mmol), and stir the reaction mixture at 90◦ C for 3 hr. 3. Cool the light-brown solution to room temperature. 4. Pour into 500 mL ice-water and stir suspension for 1 hr. 5. Filter off white-crystalline solid using a glass filter and wash three times, each time with 50 mL cold water. 6. Dissolve wet paste in 500 mL DCM, separate organic layer using a 1000-mL separatory funnel, and dry over Na2 SO4 . 7. Filter off the drying agent under vacuum using a glass filter, evaporate to dryness, and purify crude material by column chromatography (APPENDIX 3E) on silica gel using 2% MeOH in DCM. 1,5-Anhydro-4 ,6-O-benzilidene-2 -deoxy-(2-amino-6-chloropurin-9-yl)-D-altro-hexitol (S.13): 65% yield (11.3 g). TLC (97.5:2.5 DCM/MeOH): Rf = 0.2. 1 H NMR (DMSO-d6 , 500 MHz) δ 3.69 (1H, dd, J = 2.4 and 9.5 Hz, 4 -H); 3.80 (t, 1H, J = 10.2 Hz, 6 ax-H), 4.00 (td, 1H, J = 5.1 and 10.2 Hz, 5 -H); 4.23-4.30 (m, 4H, 1 eq-H, 1 ax-H, 3 -H, and 6 eq-H); 4.46 (br s, 1H, 2 -H); 5.64 (s, 1H, PhCH); 5.88 (d, 1H, J = 4.5 Hz, 3 -OH), 6.98 (s, 2H, NH2 ); 7.32-7.34 (m, 3H, ar-H); 7.38-7.40 (m, 2H, ar-H); 8.23 (s, 1H, 8-H). 13 C NMR (DMSO-d6 , 125 MHz): δ 55.87 (2 -C); 64.29 (1 -C); 64.77 (3 -C); 66.46 (5 -C); 68.13 (6 -C); 76.27 (4 -C); 101.06 (PhCH); 123.02 (5-C); 126.41-137.75 (4 × C arom); 141.37 (8-C); 149.73 (2-C); 154.26 (4-C); 159.93 (6-C). HRMS: calcd for C18 H19 ClN5 O4 (M+H)+ 404.1125, found 404.1119.
Convert nucleobase to guanine 8. Prepare a suspension of 11.3 g of S.13 (28 mmol) and 1 g DABCO in 100 mL 1 N NaOH using a 500-mL flask. Stir the reaction mixture 2 hr at 90◦ C. 9. Cool the resulting clear colorless solution with an ice bath. 10. Adjust the pH to neutral with 1 N HCl at 0◦ C. 11. Filter off formed solid using a glass filter and wash three times, each time with 50 mL cold water. 12. Dry the fine heavy solid in a desiccator under reduced pressure at room temperature. 1 ,5 -Anhydro-4 ,6 -O-benzilidene-2 -deoxy-(guanin-9-yl)-D-altro-hexitol (S.14): 82% yield (10.0 g). 1 H NMR (DMSO-d6 ) δ 3.67 (dd, 1H, J = 1.8 and 9.5 Hz, 4 -H); 3.79 (t, 1H, J = 9.9 Hz; 6 -Ha); 3.98 (dt, 1H, J = 4.8 and 9.9 Hz, 5 -H); 4.07-4.31 (m, 4H, 1 -Ha, 1 -He, 6 -He, and 3 -H); 4.34 (br s, 1H, 2 -H); 5.66 (s, 1H, Ph-CH); 5.81 (d, 1H, J = 4.3 Hz, 3 -OH); 6.55 (br s, 2H, 2-NH2 ); 7.28-7.49 (m, 5H, ar-H); 7.88 (s, 1H, 8-H). 13 C NMR (DMSO-d6 ) δ 55.50 (C-2 ); 64.68 (C-1 ); 65.36 (C-3 ); 66.45 (C-5 ); 68.25 (C-6 ); 76.37 (C-4 ); 101.17 (Ph-CH); 116.29 (C-5); 126.55 (ar-Co ); 128.11 (ar-Cm ); 128.98 (ar-Cp ); 135.88 (C-8); 137.88 (ar-Ci ); 151.49 (C-4); 153.88 (C-2); 157.04 (C-6). HRMS (thgly) calcd for C18 H19 N5 O5 (MH)+ 386.1464, found 386.1496.
Perform nucleobase protection 13. Prepare a mixture of 10.0 g of S.14 (26 mmol) and 20 mL N,N-dimethylformamide diethyl acetal in 100 mL DMF in a 500-mL flask. Stir the reaction mixture at room temperature overnight. 14. Cool the resulting clear light-yellow solution with an ice bath. 15. Add 20 mL water and stir for 30 min. Synthesis of Altritol Nucleoside Phosphoramidites
16. Evaporate to dryness in vacuo and co-evaporate three times, each time with 30 mL xylene.
1.18.14 Supplement 30
Current Protocols in Nucleic Acid Chemistry
17. Absorb the crude product on 50 g silica gel and purify by column chromatography (APPENDIX 3E) with gradient elution (98:2; 90:10 chloroform/MeOH). 1,5-Anhydro-4 ,6-O-benzylidene-2 -deoxy-2 -(N2 -(dimethylamino)methylene-guanin-9yl)-D-altro-hexitol (S.15): 88% yield (10.0 g). TLC (93:7 DCM/MeOH): Rf = 0.5. 1 H NMR (CDCl3 ) δ 3.04 and 3.13 (two s, 6H), (N(CH3 )2 ); 3.60-4.60 (m, 7H, 1 -Ha, 1 -He, 3 -H, 4 -H, 5 -H, 6 -Ha, and 6 -He); 4.68 (br s, 1H, 2 -H); 5.30 (s, 1H, 3 -OH); 5.52 (s, 1H, Ph-CH); 7.20-7.48 (m, 5H, ar-H); 8.10 (s, 1H, 8-H); 8.61 (s, 1H, N=CH-N); 10.06 (N1-H). 13 C NMR (CDCl3 ) δ 35.09 and 41.34 (N(CH3 )2 );54.72 (C-2 ); 65.10 (C-1 ); 66.38 and 66.80 (C-3 ,C-5 ); 68.90 (C-6 ); 76.36 (C-4 ); 101.98 (Ph-CH); 119.61 (C-5); 126.05 (ar-Co ); 128.14 (ar-Cm ); 129.08 (ar-Cp ); 137.00 (ar-Ci ), 137.25; 150.63 (C-4); 156.97 (C-2,C-6); 158.37 (N=CH-N). LSIMS (thgly) 441 (MH)+ . HRMS (thgly) calcd. for C21 H24 N6 O5 (MH+ ) 441.1886, found 441.1879.
Benzoylate 3-hydroxy 18. Prepare a solution of 10.0 g of S.15 (23 mmol) and 4.6 mL tri-n-butylamine (19 mmol) in 80 mL dry DMF in a 500-mL flask. 19. Add 6.0 g benzoyl cyanide (45 mmol) and stir reaction mixture under nitrogen at room temperature for 3 hr. 20. Add 10 mL MeOH and stir 30 min to destroy the excess reagent. 21. Evaporate the solvent in vacuo and co-evaporate two times, each time with 50 mL p-xylene. 22. Dissolve the residue in 250 mL CHCl3 and adsorb on 25 g silica. 23. Purify by column chromatography (APPENDIX 3E) with gradient elution (100:0; 98:2 chloroform/MeOH). 1,5-Anhydro-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-2-(N2-(dimethylamino)methylene -guanin-9-yl)-D-altro-hexitol (S.16): 80% yield (10.0 g). TLC (97:3 DCM/MeOH): Rf = 0.1. Product can be crystallized from EtOH. 1 H NMR (CDCl3 ) δ 3.16 and 3.32 (two s, 6H, N(CH3 )2 ); 3.80 (t, 1H, J = 10 Hz, 6 -Ha); 3.83 (dd, 1H, J = 10.6 and 2.6 Hz, 4 -H); 4.25 (dt, 1H, J = 4.8 and 9.9 Hz, 5 -H); 4.39-4.53 (m, 3H, J = 5 Hz, 1 -Ha, 1 -He, and 6 -He); 4.65 (br d, 1H, 2 -H); 5.52 (s, 1H, Ph-CH); 6.20 (t, 1H, J = 2.9 Hz, 3 -H); 7.20-7.40 (m, 5H, Bn); 7.42-7.67 (m, 3H, BZm+p ); 8.05 (s, 1H, 8-H); 8.13 (d, 2H, Bzo ); 9.15 (s, 1H, N=CH-N); 9.38 (N1-H). 13 C NMR (CDCl3 ) δ 35.06 and 41.40 (N(CH3 )2 );53.72 (C-2 ); 65.01 (C-1 ); 67.14 (C-5 ); 68.30 (C-3 ); 68.99 (C-6 ); 74.42 (C-4 ); 102.19 (Ph-CH); 119.89 (C-5); 126.08, 128.20, 128.72, 129.11 (ar-C); 129.75, 133.69, 136.85, 136.24 (C-8), 150.66 (C-4); 157.67 (C-2); 158.00 (C-6); 160.25 (N=CH-N); 165.14 (Bz-CO). LSIMS (thgly) 545 (MH)+ . HRMS (thgly) calcd. for C28 H28 N6 O6 (MH+ ) 545.2148, found 545.2145.
Cleave benzylidene protecting group 24. Suspend 5.3 g of S.16 (10 mmol) in 50 mL dry DCE in a 100-mL flask and cool to 0◦ C. 25. Add 5 mL TFA (62.5 mmol) and stir yellow clear solution for 30 min at 0◦ C. 26. Add 270 µl water (15 mmol) and continue stirring for 20 min at 0◦ C. 27. Neutralize reaction mixture with 5.2 mL pyridine (65 mmol) and continue stirring at 0◦ C for 1 to 2 hr until the precipitation is complete. 28. Filter off white heavy crystalline solid using a glass filter, wash two times with 10 mL cold DCE, and dry overnight in a vacuum desiccator. 1,5 -Anhydro-3-O-benzoyl-2-deoxy-2-(N2-(dimethylamino)methyleneguanin-9-yl)-D-altrohexitol (S.17): 90% yield (4.1 g). TLC (95:5 DCM/MeOH): Rf = 0.05. 1 H NMR (DMSO-d6 ) δ 3.09 and 3.27 (two s, 6H, N(CH3 )2 ); 3.57-3.84 (m, 4H, 4 -H, 5 -H, 6 -Ha, and 6 -He); 4.21 (dd, 1H, 1 -Ha); 4.38 (br d, 1H, 1 -He); 4.74 (br d, 1H, 2 -H); 5.65 (br
Synthesis of Modified Nucleosides
1.18.15 Current Protocols in Nucleic Acid Chemistry
Supplement 30
s, 1H, 6 -OH); 5.86 (br s, 1H, 3 -H); 6.20 (br s, 1H, 4 -OH); 7.50-7.78 (m, 3H,Bzm+p ); 8.07 (s, 1H, 8-H); 8.08 (d, 2H, J = 7.0 Hz, Bzo ); 8.43 (br s, 1H, N1-H); 8.93 (s, 1H, N=CH-N). 13 C NMR (DMSO-d6 ) δ 34.83 and 40.85 (N(CH3 )2 );53.29 (C-2 ); 60.18 (C-6 ); 62.18 (C-4 ); 63.46 (C-1 ); 70.04 (C-3 ); 78.21 (C-5 ); 126.13 (C-5); 128.95 (ar-Co ); 129.75 (ar-Cm ); 133.78 (ar-Cp ); (ar-Ci not detected); 144.49 (C-8); (C-4 not detected); 157.82 (C-2); 158.12 (C-6); 159.34 (N=CH-N); 165.13 (Bz-CO). HRMS (thgly) calcd. for C21 H24 N6 O6 (MH+ ) 457.1835, found 457,1827.
Tritylate 6-hydroxy 29. Co-evaporate 4.1 g of S.17 (9.0 mmol) with 15 mL dry pyridine in a 250-mL flask. 30. Add 5 mL dry pyridine and 50 mL DCM and cool to 0◦ C. 31. Add 3.0 g MMTr-Cl (9.7 mmol) in three portions over 1 hr. Allow the mixture to come to room temperature and then stir for 3 hr. 32. Add 1 mL MeOH and stir for 15 min to decompose excess MMTr-Cl. 33. Add 150 mL DCM and wash three times, each time with 100 mL water using a 500-mL separatory funnel. 34. Dry the organic layer over Na2 SO4 , filter off the drying agent under vacuum using a glass filter, and evaporate the solvent using a rotary evaporator equipped with a vacuum pump until 30 to 40 mL remains. 35. Add solution dropwise over 30 min to 200 mL hexane at 0◦ C with stirring. Continue stirring suspension for 1 hr at 0◦ C. 36. Filter off white fine powder using a glass filter, wash two times, each time with 10 mL cold hexane, and dry overnight in a vacuum desiccator. The dry product can be stored in the dark at –20◦ C for 6 months. 1 ,5 -Anhydro-3 -O-benzoyl-6 -O-monomethoxytrityl-2 -deoxy-2 -(N2 -(dimethylamino)methylene-guanin-9-yl)-D-altro-hexitol (S.18): 75% yield (4.9 g). TLC (50:50 CH2 Cl2 /acetone): Rf = 0.33. 1 H NMR (CDCl3 , 200 MHz) δ 3.08 and 3.24 (two s, 3H, N(CH3 )2 ); 3.36-3.65 (m, 2H, 6 -Ha, and 6 -He); 3.77 (s, 3H, OCH3 ); 3.85-4.10 (m, 2H, 4 -H, 5 -H); 4.23-4.48 (m, 2H, 1 -Ha and 1 -He); 4.60 (br d, 1H, J = 2.9 Hz, 2 -H); 6.02 (t, 1H, J = 3.0 Hz, 3 -H); 6.84 (d, 2H, ar-H); 7.10-7.70 (m, 15H, ar-H); 8.06 (d, 2H, J = 5.8 Hz, ar-H); 8.08 (s, 1H, 8-H); 8.97 (s, 1H, N=CH-N); 9.26 (1-NH). 13 C NMR (CDCl3 , 50 MHz) δ 34.97 and 41.34 (N(CH3 )2 );53.18 (C-2 ); 55.15 (OCH3 ); 63.77 (C-6 ); 64.47 (C-4 ); 64.80 (C-1 ); 69.60 (C-3 ); 76.03 (C-5 ); 86.93 (CTr -O); 119.67 (C-5); 113.27, 127.08, 128.02, 128.35, 128.63, 129.75, 130.33, 133.57 and 135.18; 136.85 (C-8); 144.11 (MMTr); 150.69 (C-4); 157.31 (C-2); 158.10 (C-6); 158.73 (MMTr); 159.83 (N=CH-N); 165.44 (PhCO/OBz). HRMS (thgly:NaOAc) calcd. for C41 H40 N6 O7 Na (MNa)+ 751.2856 found 751.2878. BASIC PROTOCOL 5
GENERAL PROCEDURE FOR PHOSPHORAMIDITE SYNTHESIS Preparation of altritol nucleoside phosphoramidites from the protected nucleosides is illustrated in Figure 1.18.5.
Materials
Synthesis of Altritol Nucleoside Phosphoramidites
Altritol nucleoside S.4 (Basic Protocol 1), S.8 (Basic Protocol 2), S.12 (Basic Protocol 3), or S.18 (Basic Protocol 3) Dioxane, dry 2,4,6-Collidine N-Methylimidazole N,N-Diisopropyl(cyanoethyl)phosphonamidic chloride (CEPA) Dichloromethane PA (DCM)
1.18.16 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Figure 1.18.5 Preparation of protected altritol amidites. Bz, benzoyl; CEPA, N,N-diisopropyl(cyanoethyl)phosphonamidic chloride; DCM, dichloromethane; dmf, dimethylaminomethylene; MMTr, monomethoxytrityl; Py, pyridine.
Acetone PA Triethylamine PA (TEA) 5% Aqueous sodium bicarbonate solution (NaHCO3 ) Sodium sulfate (Na2 SO4 ) Silica gel (0.035- to 0.060-mm) Hexane PA Glass syringe Gas balloon Glass filter (porosity 3) Rotary evaporator equipped with a vacuum pump Vacuum desiccator 2 × 35–cm chromatography column 100-mL round bottom flasks 250-mL separatory funnel Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) NOTE: The reactions are carried out with dry dioxane under nitrogen in 1 to 2 mmol scale. All starting reagents are commercially available. All evaporations are accomplished in vacuo using a rotary evaporator at 25◦ C. All filtrations are performed using a glass filter under vacuum. 1. Dissolve dry protected nucleoside S.4, S.8, S.12, or S.18 (1 mmol) in 5 mL dry dioxane in a 100-mL flask. 2. Add 990 µL 2,4,6-collidine (7.5 mmol) followed by N-methylimidazole (0.5 mmol). 3. Add 560 µL N,N-diisopropylamino(cyanoethyl)phosphonamidic chloride (2.5 mmol) dropwise over 5 min via a glass syringe under nitrogen (using a gas balloon). 4. Stir the reaction for 1 to 2 hr and monitor the progress of the reaction by TLC (APPENDIX 3D) using the solvent systems in step 10. 5. Add 100 µl water and stir for 10 min. 6. Dilute the reaction mixture with 50 mL DCM. Wash DCM solution once with 50 mL 5% NaHCO3 and twice with 100 mL water using a 250-mL separatory funnel.
Synthesis of Modified Nucleosides
1.18.17 Current Protocols in Nucleic Acid Chemistry
Supplement 30
7. Dry over Na2 SO4 , filter off the drying agent using a glass filter, and remove solvent in vacuo using a rotary evaporator. 8. Co-evaporate viscous oil twice with 10 mL toluene. 9. Purify the crude phosphoramidite by flash column chromatography (APPENDIX 3E) on 40 g silica gel using the solvent systems indicated for TLC in step 10. 10. Dissolve oil in 5 mL DCM and add dropwise over 5 min to 100 mL hexane at –60◦ C with stirring. Continue stirring suspension for 30 min at –60◦ C. 11. Filter off white fine powder using a glass filter, wash two times with 10 mL cold (0◦ C) hexane, and dry product overnight in a vacuum desiccator at room temperature. The dry product can be stored in the dark at –20◦ C for 6 months. 1 ,5 -Anhydro-3 -O-benzoyl-6 -O-monomethoxytrityl-2 -deoxy-2 -(uracil-1-yl)-D-altrohexitol 3 -(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.19): yield 85%. TLC (59:40:1 hexane/acetone/Et3 N): Rf = 0.39. 31 P NMR: 151.16/150.21. LSIMS (thgly:NaOAc) 856 [M + Na]+ . 1 ,5-Anhydro-3-O-benzoyl-6-O-monomethoxytrityl-2 -deoxy-2 -(N4 -benzoylcytosin-1-yl)3 -(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.20): yield 75%. TLC (64:35:1 hexane/acetone/Et3 N): Rf = 0.27. 31 P NMR: 151.45/150.07. LSIMS (thgly:NaOAc) 960 [M + Na]+ .
D-altro-hexitol
1 ,5-Anhydro-3-O-benzoyl-6-O-monomethoxytrityl-2-deoxy-2 -(N6 -benzoyladenin-9-yl)3 -(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.21): yield 95%. TLC (59:40:1 hexane/acetone/Et3 N): Rf = 0.28. 31 P NMR: 151.64/149.54. LSIMS (thgly:NaOAc) 984 [M + Na]+ .
D-altro-hexitol
1 ,5 -Anhydro-3 -O-benzoyl-6 -O-monomethoxytrityl-2 -deoxy-2 -(N2 -(dimethylamino)methylene-guanin-9-yl)-D-altro-hexitol 3 -(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.22): yield 85%. TLC (19:80:1 hexane/acetone/Et3 N): Rf = 0.33. 31 P NMR: 151.49/149.97. LSIMS (thgly:NaOAc) 929 [M + Na]+ .
COMMENTARY Background Information Altritol nucleic acid (ANA) is an example of an oligonucleotide with a six-membered carbohydrate moiety that hybridizes with natural nucleic acids. These nucleic acids are stable against enzymatic and chemical degradation because they do not have a glycosyl bond. ANA can be synthesized by the phosphoramidite method starting from the building blocks described in this protocol.
Synthesis of Altritol Nucleoside Phosphoramidites
Synthesis The problems in ANA oligonucleotide synthesis are defined by the need to protect the additional 3 -hydroxyl group of altritol nucleosides for oligonucleotide synthesis. These problems have been largely overcome by the use of the benzoyl protecting group for the 3 hydroxyl group (Allart et al., 1999a). However, the problem of 3 →4 benzoyl migration during synthesis of the protected building blocks results in difficulties for large-scale preparation of isomerically pure phosphoramidites.
Therefore, the use of the 3 -O-TBDMS protecting group in ANA oligonucleotide synthesis has also been investigated (Abramov et al., 2004). Although RNA can be produced using this process, the deprotection steps are much more difficult for the preparation of ANA sequences than for RNA sequences. Steric hindrance in the ANA amidites, as of the 3 axial TBDMS group, requires longer coupling times, which increases the formation of side products. Base deprotection with ammonia requires a longer reaction time, which may cause internucleotide cleavage. Desilylation with TBAF is very sensitive to water, and produces salts that must be removed prior to analysis. Triethylamine trihydrogen fluoride (TEA-3HF) has been used as an alternative to TBAF, but is likewise unsuccessful for long stretches of ANA. Because of the variable and not always reproducible deprotection results of the 3 -OTBDMS group in ANA oligonucleotides synthesis, an Fmoc protecting strategy for ANA
1.18.18 Supplement 30
Current Protocols in Nucleic Acid Chemistry
synthesis has been studied as well. The synthesis of four phosphoramidite building blocks of altritol nucleosides with Fmoc protection on the nucleobase and sugar moieties has been accomplished successfully (Abramov et al., 2007a). Coupling yields in oligonucleotide synthesis are generally lower than with 3 -Obenzoyl protected building blocks, but the excellent compatibility with Pac-RNA chemistry for synthesis of chimeric oligonucleotides has been shown, although complete deprotection of the synthesized oligonucleotides proves to be cumbersome at this moment. This could be due to steric hindrance and/or to the low solubility of the growing oligonucleotides in the solvents used for synthesis and deprotection. In conclusion, the benzoyl group is a better protecting group than TBDMS or Fmoc (for the 3 -hydroxy function) in the synthesis of ANA. Further research has focused on the synthesis of 3 -O-benzoyl-protected altritol nucleoside phosphoramidite building blocks, and reaction protocols for large-scale synthesis have been optimized to avoid migration reactions. The results are presented in this unit. Properties of altritol oligonucleotides Oligonucleotides composed of a phosphorylated D-altritol backbone, with nucleobases introduced in the 2 position, hybridize strongly and in a sequence-selective manner with RNA in an antiparallel way. The order of hybridization strength is: dsANA> ANA:RNA>ANA:DNA. Complexes between ANA and RNA or DNA are more stable than those between natural oligonucleotides or hexitol nucleic acids (HNA; UNIT 1.9). The dsANA hybrid is extremely stable. When compared
with an identical dsDNA sequence, the Tm per modification is more than +10◦ C for a hexamer (Table 1.18.1). The Tm /base decreases as a function of oligonucleotide length. CD spectral analysis indicates that ANA complexes are very similar to the A-form dsRNA duplex. ANA are stable in alkaline medium up to pH 12, and are not degraded in human serum (Allart et al., 1999b). ANA oligomers are also superior to the corresponding DNA, RNA, and HNA for nonenzymatic template-directed synthesis of complimentary RNAs (Kozlov et al., 2000). They have also been shown to be useful for developing siRNA with enhanced pharmacological effectiveness (Fisher et al., 2007). Novel analytical platforms based on ANA units have been evaluated for their potential to be used as chimeric oligonucleotide microarrays on glass solid supports for single nucleotide polymorphism detection in DNA and RNA targets. It has been shown that the intensity and selectivity of hybridization signals for RNA targets is higher than for DNA and increases when applying to ANA arrays (ANA > HNA > DNA). Certainly in the new field of RNA detection based on miRNA levels, ANA arrays could be very beneficial (Abramov et al., 2007b).
Compound Characterization TLC was performed on precoated Alugram Sil G/UV254 plates, and compounds were detected using sulfuric acid/anisaldehyde spray and a 254-nm UV lamp. The 1 H and 13 C NMR spectra for nucleosides were determined with a Varian Gemini 200 MHz spectrometer with tetramethylsilane as the internal standard. Abbreviations are: s = singlet, d = doublet,
Table 1.18.1 Melting Temperatures of Fully Modified Hexamers and Dodecamers
Sequencea 6 -h(AGG AGA)
Tm DNA complimentb,c
Tm RNA complimentb,c
31.2
44.8
39.2
59.7
10.0
—
64.8
84.0
73.5
88.1
49.0
47.6
6 -a(AGG AGA) 5 -AGG AGA 6 -h(AGG GAG AGG AGA) 6 -a(AGG GAG AGG AGA) 5 -AGG GAG AGG AGA
a 1,5-Anhydrohexitol oligomers (h); altrohexitol oligomers (a). ◦ m values given in C at 260 nm, and determined in 0.1 M NaCl, 20 mM KH2 PO4 , pH 7.5, 0.1 mM EDTA with 4 µM each oligonucleotide. c Duplexes formed with complimentary sequences 5 -TCT CCT, 5 -TCT CCT CTC CCT as the respective DNA complements and 5 -TT-r(UCU CCU)-TT and 5 -TT-r(UCU CCU CUC CCU) as the respective RNA compliments.
bT
Synthesis of Modified Nucleosides
1.18.19 Current Protocols in Nucleic Acid Chemistry
Supplement 30
dd = double doublet, t = triplet, br s = broad signal, m = multiplet, ddd = double doublet of doublet, dm = double multiplet, app= apparent, a = axial, e = equatorial, ar = aryl. The 31 P NMR spectra for phosphoramidites were determined with a Varian Unity-500 spectrometer (500 MHz for 1 H). 31 P NMR chemical shifts quoted are downfield from 85% H3 PO4 (external). All liquid secondary-ion mass spectra (LSIMS) were obtained using a KRATOS Concept 1H mass spectrometer. Thgly = thioglycerol.
Critical Parameters Overall, it is important for each step of the syntheses that the starting sugar and base building blocks or starting nucleosides are dried thoroughly, either by co-evaporation with anhydrous pyridine or in a desiccator. Anhydrous solvents are very important. They should be either freshly distilled or stored under nitrogen or argon, or be taken from a freshly opened bottle of commercially prepared anhydrous solvent. For all reactions using anhydrous solvents, the glassware should be predried at 70◦ C for at least 2 hr. For evaporation of solvents, it is helpful if the rotary evaporator is equipped with a dryice trap.
Troubleshooting
Synthesis of Altritol Nucleoside Phosphoramidites
A major drawback of the 3 -O-benzoyl group is its migration from the 3 -axial to the 4 -equatorial position during deprotection of the benzylidene group, mandating a change of conditions for benzylidene cleavage and subsequent monomethoxytritylation. Whereas treatment of the benzylidene-protected compounds 2 and 6 with 80% aqueous acetic acid at 80◦ C, or 90% aqueous trifluoroacetic acid at ambient temperature, provides a mixture of 3 - and 4 -O-benzoyl regioisomers, a short treatment of 2 and 6 with anhydrous trifluoroacetic acid at low temperature, followed by neutralization of the acid and precipitation of the product, afforded the expected 3 -Obenzoylated derivatives 3 and 7. Benzoyl migration from the 3 -position to the 4 -position occurred rapidly upon chromatography on silica gel applying protic as well as nonprotic solvents. Using precise amounts of reagent and careful monitoring of reactions allows one to exclude the chromatography purification step and minimize benzoyl migration. Benzoylation of S.15. Treatment of S.15 with BzCl yields S.16 (40%) together with an N2 -benzoyl derivative. This transamidation
can be avoided when the reaction is carried out with benzoyl cyanide in the presence of tributylamine, as described in this unit. Deprotection with TFA. In large-scale experiments, starting nucleoside derivatives are contaminated with 5% to 10% wt of benzamide, which forms on the previous step and is difficult to remove by column chromatography. The presence of this by-product does not influence the yield of the reaction. The deprotected products could contain up to 10% wt of pyridinium trifluoroacetate. Monomethoxytritylation. In large-scale experiments, the starting nucleoside derivatives contained pyridinium trifluoroacetate, which forms in the previous step. The presence of this impurity does not influence the yield of the reaction. During purification, most of the monomethoxytrityl alcohol and its methyl ether could be removed by careful repeated precipitations, but reaction products might contain up to 5 % wt of these contaminants, which are more easily removed on the next step.
Anticipated Results The synthesized altritol nucleoside phosphoramidite building blocks have been successfully used in synthesis of fully modified ANA oligonucleotides as well as for incorporation of ANA units into DNA and RNA sequences (Allart et al., 1999b; Abramov et al., 2007a). The synthesis of oligonucleotides was accomplished by the standard phosphoramidite method on an Exedite synthesizer (Applied Biosystem) with an extended 12-min coupling step. A 15-fold excess of nucleobase acetonitrile solution (200 µl of 0.07 M) and an excess of activator (200 µl) relative to CPGbound 5 -hydroxyl group was used in each coupling cycle, and the synthesis scale was 1.0 µmol. Average coupling yields were monitored by an online colorimeter by colorimetric quantitation of the trityl fractions. Detritylation solution was 3% TCA in DCM, capping was performed with Ac2 O-THF and 10% 1methylimidazole-THF-PyH. Oxidation solution was 0.02 M I2 in THF-H2 O-PyH. Tetrazole solution was 0.45 M in acetonitrile. SEthylthioterazole solution (0.25 M in MeCN) or pyridinium trifluoroacetate solution (0.22 M in MeCN) was used as an activator.
Time Considerations Each step (including purification and spectroscopic analysis) can usually be performed in 1.5 to 2 working days. All synthesized and carefully purified and dried nucleosides
1.18.20 Supplement 30
Current Protocols in Nucleic Acid Chemistry
including phosphoramidites can be stored up to 6 months in the dark at –20◦ C or below under argon or nitrogen. In the planning of the syntheses, it has to be considered that some of reactions must be stirred overnight.
Allart, B., Khan, K., Rosemeyer, H., Schepers, G., Hendrix, C., Rothenbacher, K., Seela, F., Van Aerschot, A., and Herdewijn, P. 1999b. D-Altritol nucleic acids (ANA): Hybridization properties, stability, and initial structural analysis. Chem. Eur. J. 5:2424-2431.
Literature Cited
Brockway, C., Kocienski, P., and Pant, C. 1984. Unusual stereochemistry in the copper-catalysed ring opening of a carbohydrate oxirane with vinylmagnesium bromide. J. Chem. Soc. Perkin Trans. I 875-878.
Abramov, M., Marchand, A., and Herdewijn, P. 2004. Synthesis of D-altritol nucleosides with a 3 -O-tert-butyldimethylsilyl protecting group. Nucleosides, Nucleotides and Nucleic Acids 23:439-455. Abramov, M., Schepers, G., Van Aerschot, A., and Herdewijn, P. 2007a. Fmoc-protected altritol phosphoramidite building blocks and their application in the synthesis of altritol nucleic acids (ANAs). Eur. J. Org. Chem. 14461456. Abramov, M., Schepers, G., Van Aerschot, A., and Herdewijn, P. 2007b. HNA and ANA highaffinity arrays for detections of DNA and RNA single-base mismatches. Biosensors and Bioelectronics, in press. Allart, B., Busson, R., Rozenski, J., Van Aerschot, A., and Herdewijn, P. 1999a. Synthesis of protected D-altritol nucleosides as building blocks for oligonucleotide synthesis. Tetrahedron 55:6527-6546.
De Bouvere, B., Kerremans, L., Rozenski, J., Janssen, G., Van Aerschot, A., Claes, P., Busson, R., and Herdewijn, P. 1997. Improved synthesis of anhydrohexitol building blocks for oligonucleotide synthesis. Liebigs Ann. 1453-1461. Fisher, M., Abramov, M., Van Aerschot, A., Xu, D., Juliano, R.L., and Herdewijn, P. 2007. Inhibition of MDR1 expression with altritol-modified siRNAs. Nucl. Acids Res. 35:1064-1074. Kozlov, I.A., Zielinski, M., Allart, B., Kerremans, L., Van Aerschot, A., Busson, R., Herdewijn, P., and Orgel, L.E. 2000. Nonenzymatic templatedirected reactions on altritol oligomers, preorganized analogues of oligonucleotides. Chem. Eur. J. 6:151-155.
Synthesis of Modified Nucleosides
1.18.21 Current Protocols in Nucleic Acid Chemistry
Supplement 30
CHAPTER 2 Protection of Nucleosides for Oligonucleotide Synthesis INTRODUCTION ince the discovery of the helical structure of DNA by Watson and Crick in 1953, tremendous strides in the chemical synthesis of oligonucleotides have been made in an attempt to produce substantial quantities of synthetic DNA or RNA of defined sequences. The availability of synthetic oligonucleotides has facilitated investigations on gene structure and function, and has intensified research efforts in deciphering the nature of nucleic acid interactions in complex cellular functions.
S
The essence of DNA and RNA synthesis is the correct formation of internucleotide phosphodiester linkages. This is complicated by the presence of reactive functional groups within nucleotide monomers that require protection prior to incorporation into DNA or RNA oligonucleotides. The presence of two and three hydroxyls in deoxyribonucleosides and ribonucleosides, respectively, demands proper protection of these groups to ensure formation of internucleotide linkages with precise directional polarity during chain assembly. In addition to hydroxy groups, the functional groups of the nucleobases require protection to prevent formation of side products during internucleotide coupling reactions. One objective of this chapter is to provide literature overviews of the functional groups that have been used for nucleobase protection along with those employed as protecting groups for the 5 - and 2 -hydroxyls of nucleosides. For example, UNIT 2.1 outlines protective groups for the imide/lactam function of thymine/uracil and guanine, respectively. This class of protecting groups prevents irreversible nucleobase modifications that may occur in the presence of alkylating or condensing reagents; these are commonly used in nucleoside protection strategies and during oligonucleotide synthesis. UNIT 2.1 also identifies protecting groups for the exocyclic amino function of cytosine, adenine, and guanine. In this context, the overview addresses oligonucleotide depurination during synthesis, and examines purine N-protecting groups that have been shown to minimize this problem. Finally, UNIT 2.1 explores recent trends in nucleobase protection that would permit reliable oligonucleotide synthesis and facile removal of N-protecting groups under very mild conditions. relates to 2 -hydroxyl protection of oligoribonucleotides, which, in fact, dictates the selection of both nucleobase and 5 -hydroxyl-protecting groups. The unit surveys in exquisite detail the various types of protecting groups that have been used in the past and those that are currently being used in the synthesis of oligoribonucleotides. The requirements that a protective group must satisfy to become the 2 -hydroxyl-protecting group of choice, in regard to effective oligoribonucleotide synthesis, are delineated in the unit. Furthermore, the issue of 2 -O-acyl and 2 -O-silyl group migration to the 3 hydroxy function of ribonucleosides during protection along with the consequences of the conditions used for their removal on the stability of internucleotide linkages are authoritatively presented. The wealth of information emerging from UNIT 2.2 shall allow one to undertake oligoribonucleotide synthesis with confidence. UNIT 2.2
Current Protocols in Nucleic Acid Chemistry 2.0.1-2.0.3, September 2007 Published online September 2007 in Wiley Interscience (www.interscience.wiley.com). DOI: 10.1002/0471142700.nc0200s30 C 2007 John Wiley & Sons, Inc. Copyright
Protection of Nucleosides for Oligonucleotide Synthesis
2.0.1 Supplement 30
Methods for protecting the 5 -hydroxy function of nucleosides are equally well reviewed in UNIT 2.3. Acid-labile protecting groups that can be used as hydrophobic ligands in the purification of synthetic oligonucleotides are particularly useful and compatible with the most popular oligonucleotide synthesis protocols. Alternatively, 5 -hydroxyl protection of nucleosides with base-labile protecting groups is particularly attractive because it eliminates the risk of oligonucleotide depurination encountered in the stepwise deprotection of acid-labile 5 -O-protecting groups during synthesis. Base-labile 5 -O-protecting groups enable the development of orthogonal protection systems for oligoribonucleotides by expanding the choice of acid-labile 2 -O-protecting groups that can be used. The utilization of the 9-fluorenylmethoxycarbonyl (Fmoc) group for 5 O-protection and 4-methoxytetrahydropyran-4-yl for 2 -O-protection of ribonucleosides is an excellent example of orthogonal protection in oligoribonucleotide synthesis. This method is detailed in UNIT 2.4.
Introduction
In addition to acid- and base-labile protecting groups, 5 -O-silyl-blocking groups that are removable by fluoride ions, photolabile 5 -O-protecting groups, and other functional groups that can be removed under near neutral conditions have been carefully examined in UNIT 2.3. The overviews presented in this chapter will provide anyone interested in oligonucleotide synthesis with the basic knowledge to proceed with the preparation of properly protected nucleoside phosphoramidites or H-phosphonate monomers for incorporation into oligonucleotides. In this regard, a number of synthetic protocols delineating the stepby-step preparation of nucleosides functionalized with N-, 5 -O-, and 2 -O-protecting groups will eventually be included in this chapter to illustrate the versatility of protecting group combinations that allow, in a number of ways, the synthesis of oligonucleotides with well-defined physicochemical properties. Syntheses of N-protected ribonucleosides having a 4,4 -dimethoxytrityl (DMTr) group for 5 -O-protection and a photolabile 2nitrobenzyloxymethyl (NBOM) group or a fluoride-sensitive tert-butyldimethylsilyl (TBDMS) group for 2 -O-protection are outlined in UNIT 2.5, and are representative examples of such synthetic protocols. The preparation of deoxyribonucleosides and ribonucleosides functionalized with a DMTr, TBDMS, and allyloxycarbonyl (AOC) group for 5 -O-, 2 -O- and nucleobase N-protection, respectively, is featured in UNIT 2.12 along with the synthesis of their 3 -phosphoramidite derivatives. Given that the N-AOC protecting group can eventually be removed under near neutral conditions by treatment with an organopalladium(0) catalyst in the presence of an appropriate nucleophile, the preparation of oligonucleotides modified with base-labile nucleobases and/or internucleosidic linkages can now be achieved. The 2-(4-nitrophenyl)ethyl (NPE) group for protection of thymine/uracil at O4 and guanine at O6, along with the 2-(4-nitrophenyl)ethoxycarbonyl (NPEOC) group for protection of cytosine, adenine, and guanine at N4, N6, and N2, respectively, also offer an attractive nucleobase protection strategy for deoxyribonucleosides and ribonucleosides. As described in UNIT 2.13, 5 -O-dimethoxytritylation and 3 -O-phosphinylation of NPE/NPEOC-protected deoxyribonucleosides provide phosphoramidite monomers suitable for solid-phase oligonucleotide synthesis. The cleavage of the NPE/NPEOC groups requires only treatment with a strong, non-nucleophilic base. This step can be performed while the oligonucleotide is still attached to the solid support, thereby allowing removal of all deprotection side products and reagents. An elegant method for the highly regioselective synthesis of 2 -O-TBDMS purine ribonucleosides is presented in UNIT 2.8. A creative modification of the NBOM group has led to the development of the fluoride-sensitive [(triisopropylsilyl)oxy]methyl (TOM) group for 2 -O-protection of ribonucleosides. The detailed preparation of N-protected 5 -O-DMTr-2 -O-TOM ribo-nucleosides is provided in UNIT 2.9. Alternatively, UNIT 2.10 addresses the preparation of N-protected 5 -O-benzhydroxy-bis(trimethylsilyloxy)silyl2 -O-bis(acetoxyethyloxy)-methyl ribonucleosides and their phosphoramidite derivatives as innovative precursors to the solid-phase synthesis of oligoribonucleotides.
2.0.2 Supplement 30
Current Protocols in Nucleic Acid Chemistry
The production of oligonucleotides on a large scale for therapeutic applications presents a challenge that may be dealt with advantageously through a solution-phase oligonucleotide synthesis approach rather than a traditional solid-phase approach. For this purpose, the levulinyl group for 5 -/3 -hydroxyl protection of nucleoside precursors in the synthesis of oligonucleotides is attractive given its compatibility with nucleobase-protecting groups, stability during oligonucleotide assembly, and rapid removal at neutral pH. The details of a regioselective “levulinylation” of 2 -deoxyribonucleoside or 2 -O-methylribonucleoside derivatives using commercial lipases are included in UNIT 2.11. The conversion of suitably protected deoxyribonucleosides and ribonucleosides to Hphosphonate derivatives is carefully described in UNIT 2.6. Alternatively, the conversion of protected deoxyribonucleosides to phosphoramidite derivatives functionalized with groups different than the conventional 2-cyanoethyl group for P-protection is delineated in UNIT 2.7. The generality of these methods ensures the reliable preparation of monomeric nucleoside building blocks for oligonucleotide syntheses. It should be noted that with the advent of oligonucleotide microarrays as powerful diagnostic tools, deoxyribonucleoside phosphoramidites functionalized with photosensitive groups for 5 -/3 -hydroxyl protection have been developed to enable the synthesis of oligonucleotides on planar glass surfaces. To this end, the preparation of 3 -O-[2-(2nitrophenyl)propoxycarbonyl] deoxyribonucleoside 5 -phosphoramidites is reported in UNIT 12.3. Serge L. Beaucage
Protection of Nucleosides for Oligonucleotide Synthesis
2.0.3 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Nucleobase Protection of Deoxyribo- and Ribonucleosides SALIENT FEATURES OF OLIGONUCLEOTIDE SYNTHESIS DNA and RNA are biopolymers comprised of nucleotide units. The synthesis of DNA and RNA as segments consisting of several nucleotides each, referred to as oligonucleotides, is quite a challenging endeavor, requiring the rapid and quantitative coupling of nucleosidic units to form internucleotidic linkages. In order to achieve high efficiency in the coupling reactions, it is necessary to direct the reaction to the desired site in the nucleoside. This is achieved by using appropriate protecting group strategies. To date, five methods of oligonucleotide synthesis have been reported, all of which use protected nucleosides: (1) The H-phosphonate approach (Michelson and Todd, 1955; Hall et al., 1957; Froehler et al., 1986, and references therein; Garegg et al., 1986, and references therein; UNIT 3.4); (2) the phosphodiester approach, pioneered by Khorana and co-workers (Gilham and Khorana, 1958; Khorana, 1979); (3) the phosphotriester approach, which heralded a new era in nucleic acid synthesis by enabling more rapid synthesis and purification (Letsinger and Ogilvie, 1969, and references therein; Reese, 1978); (4) the phosphite strategy (Letsinger and Lunsford, 1976, and references therein; Matteucci and Caruthers, 1980); and (5) the phosphoramidite approach, presently the most popular method for oligonucleotide synthesis (Beaucage and Caruthers, 1981; UNIT 3.3). Over the years, improvements in coupling chemistries, along with advances in methods of solid-phase assembly, have revolutionized the art of oligonucleotide synthesis. In the synthesis of oligonucleotides, persistent as well as transient protection of amino, imido, and hydroxy groups of nucleosides are employed. Transient protecting groups are used to temporarily block one of the hydroxy groups. For example, the 4,4′-dimethoxy trityl group (DMTr) is used for transient protection of the 5′ hydroxyl of a nucleoside (UNIT 2.3). The transient protecting group is removed at the beginning of each coupling cycle. This enables the coupling reaction to be directed to the desired hydroxy group during the synthesis cycle. On the other hand, persistent protecting groups are those that remain on the nucleoside throughout chain assembly and are only removed at the end
UNIT 2.1
of synthesis. For example, the exocyclic amino groups of nucleobases, the 2′-hydroxy groups of sugars (UNIT 2.2), and the internucleotidic phosphodiester functions, are protected using persistent protecting groups. The present commentary addresses issues related to the persistent protection of nucleobases. The commentary is not a comprehensive review of published literature but is intended to highlight the salient features of nucleobase protection. Only selected references are cited, and readers should refer to recent reviews (Beaucage and Iyer, 1992; Iyer and Beaucage, 1999) and primary literature for more comprehensive citations.
GENERAL ASPECTS OF NUCLEOBASE PROTECTION The choice of nucleobase protecting groups and deprotection protocols is of paramount importance in oligonucleotide synthesis, and is dictated by many considerations. The protecting groups for nucleosides should be designed on the basis of several criteria, which have been summarized by Reese (1978). (1) It should be possible to introduce the protecting group using a stable reagent that is readily obtainable. (2) The group should be achiral. (3) The nuclear magnetic resonance (NMR) spectrum of the protected nucleoside should be simple to interpret. (4) The protecting group should be readily installed on the nucleoside. (5) The group should enhance the solubility of the nucleoside in organic solvents so that it can be adapted for coupling reactions. (6) The group should be stable to reagents employed in oligonucleotide synthesis. (7) The group should not cause other structural changes in the nucleoside during its installation or removal, or during oligonucleotide assembly. A number of nucleobase protecting groups have been reported. Improved procedures for their installation and removal have been published. Nevertheless, unforeseen problems have been reported when certain protecting groups are employed in oligonucleotide synthesis. For example, N-acylated purine nucleosides, particularly N-acylated deoxyadenosine, are more predisposed to depurination than their unprotected counterparts, making the growing oligonucleotide chain susceptible to cleavage during the synthesis cycle. In fact, each pro-
Contributed by Radhakrishnan P. Iyer Current Protocols in Nucleic Acid Chemistry (2000) 2.1.1-2.1.17 Copyright © 2000 by John Wiley & Sons, Inc.
Protection of Nucleosides for Oligonucleotide Synthesis
2.1.1
Table 2.1.1 pKa Values of Nucleoside Nucleobases
tected purine and pyrimidine nucleobase exhibits different patterns of reactivity compared with the unprotected nucleoside. Certain protecting groups are also sensitive to reagents used in oligonucleotide synthesis, resulting either in their premature removal or in production of base-modified products (reviewed by Beaucage and Iyer, 1992). The sections that follow attempt to highlight the structural basis for the nucleophilicity and reactivity of nucleosides. An overview of the strategies employed for nucleobase protection is also provided.
Nucleobase (site of protonation/ pKa deprotonation)a 2′-Deoxythymidine (N3) Guanosine (N1) Uridine (N3) Cytidine (N3) Adenosine (N1)
aFor numbering of nucleoside positions, see Figure 2.1.1. For additional pKa values, see Clauwaert and Stockx (1986); Dunn and Hall (1975).
tions, the tautomeric equilibrium could shift to where both imino and enol forms could exist (Saenger, 1984). In turn, these factors influence the reactivity of the nucleosides.
NUCLEOSIDE TAUTOMERISM AND pKa VALUES The nucleophilicity of nucleobases (Fig. 2.1.1) is dictated by the pKa of the amino and amido functions and their tautomeric forms. Table 2.1.1 lists the pKa values of nucleobases. The amide-like nitrogens (N3 of uridine and N1 of guanosine) are acidic in character, whereas the ring nitrogens are basic. Therefore, at strongly alkaline pH, the proton at N3 of uridine and thymidine and that at N1 of guanosine are removed. Under acidic conditions (at pH ∼3), the sites of protonation are N1 of adenosine and N3 of cytidine. At more acidic pH, the N7 of guanosine and adenosine and O4 of uridine are protonated. Thus, all the bases remain mostly uncharged in the physiological range of pH 5 to 9 (Saenger, 1984). It is noteworthy that each of the nucleosides A, C, and G becomes protonated at one of the ring nitrogens rather than on the exocyclic amino group. Thus, the electron pair of the amino group can delocalize into the heteroaromatic ring. Indeed the C–NH2 bonds of A, C, and G are ∼1.34 Å long and have 40% to 50% double-bond character (Saenger, 1984). The charge on a nucleobase, its tautomeric structures, and its ability to form and accept hydrogen bonds are also determined by its pKa values as well as by the pH of the medium. At physiological pH, the major nucleobases exist almost exclusively in the amino and keto tautomeric forms. However, under appropriate pH condi-
NH2
7
6
N 5 8
HO
Nucleobase Protection of Deoxyribo- and Ribonucleosides
O
9N
4
N
2
8
HO
O
3
HO
REACTIVITY OF NUCLEOSIDES Nucleosides participate in electrophilic and nucleophilic substitution reactions as well as addition reactions (Shabarova and Bogdanov, 1994). Quite clearly, protecting groups and the protocols for their installation and removal should be designed to avoid various side reactions. Nucleobases undergo substitution reactions with electrophilic reagents. For example, both N- and O-alkylation of the imide and lactam groups occur with alkylating agents. The N7 position of purines is also a potential site for electrophilic attack (Fig. 2.1.5). Because of these competing reactions, simple alkylation of exocyclic amino function is not a viable protection strategy for nucleobases. On the other hand, it is possible to chemoselectively acylate the exocyclic amino group. Thus, acyl-type protecting groups are widely used for the protection of the exocyclic amino groups of nucleosides (Fig. 2.1.7). The imide/lactam NH of thymidine, uridine (pKa, 9.38), and guanosine (pKa, 9.42) is weakly acidic and can deprotonate under basic conditions. The resulting nucleophilic anion can react with a variety of reagents such as activated phosphates, dicyclohexylcarbodi-
O
O 7 1 N 5 6 NH 9N
H3C 5
2 4
N 3
HO
deoxyadenosine
Figure 2.1.1
N1
deoxyguanosine
NH2
9.93 9.42 9.38 4.17 3.52
6
HO
O
4
NH2 4
3
NH
1 2
N
O
5'1 5'2
H H 6 HO 5' O 4' 3'
HO deoxythymidine
5
HO
O
N3
5'1 5'2
1 2
N 2'
1'
H2'1
deoxycytosine
O
3 4 NH 1 2
5
H H 6 HO 5' O 4'
3'
HO
N 2'
O
1'
OH
uridine
Structures and numbering of nucleosides.
2.1.2 Current Protocols in Nucleic Acid Chemistry
Tri-O-acetyluridine (S.1) reacts with MSNT to produce the triazolo derivative S.2 (Fig. 2.1.2; Reese and Ubasawa, 1980). During deprotection with ammonium hydroxide, S.2 gives cytidine (S.3). Interestingly, during deprotection with either the tetramethylguanidinium salt of syn-4-nitrobenzaldoxime or tetrabutylammonium fluoride (TBAF), S.2 reverts to uridine (den Hartog et al., 1982). The triazolo derivative S.2 is also known to react with other nucleophiles. For example, in the presence of methanol and 1,8-diazabicyclo[3.4.0]undecene-7 (DBU), S.2 gives the corresponding 4-OMe derivative (Li et al., 1987). S.1 reacts with phosphorylating reagents at O4 and undergoes 4-triazolation in the presence of the phosphorylating reagent 2- or 4-chlorophenyl phosphorodi-1,2,4-triazolide. The triazolo derivative is converted to the fluorescent pyridinium salt S.4 in the presence of pyridine (Divakar and Reese, 1982; Sung, 1982; Huynh-Dinh et al., 1985). Further reaction with triazole gives S.5 (Fig. 2.1.3). The purine nucleosides also react with electrophilic reagents. For example, guanine nucleosides react with MSNT to form the corresponding triazolo derivatives. Reaction of the N2-protected guanosine nucleoside S.6 with mesitylene sulfonyl chloride gives the crystal-
imide (DCC), mesitylene sulfonyl chloride, 1(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT), acid chlorides, phosphitylating reagents, and electrophilic reagents that are employed during coupling reactions. These side reactions result in nucleobase-derived N- and O-products. Nucleosides also react with a variety of nucleophilic reagents. For example, cytosine reacts with hydroxylamine at neutral and acidic pH to give the corresponding hydroxylamine derivative. It reacts with hydrazine at neutral pH to give the corresponding hydrazide. Indeed, nucleophilic substitution reaction of the exocyclic amino groups of cytosine proceeds rapidly in the presence of alkali and amines. Under oxidative conditions, certain nucleobases (for example, adenine and cytosine) can form N-oxides. Also, the C8 position of guanosine is vulnerable to hydrolytic attack under either strongly acidic or strongly alkaline conditions. The 5,6 double bond of pyrimidine nucleosides also reacts with halogens and halohydrins to give the corresponding addition products (Shabarova and Bogdanov, 1994). Selected examples of the side reactions that occur during oligonucleotide synthesis are given below.
NO2 N N O
AcO
N
O AcO
NH2
N NH O
N
N NH3
MSNT AcO
O
(PhO)2P(O)OH/C5H5N OAc
AcO
1
N
O
HO
O HO
OAc
N
O
OH 3
2
MSNT, 1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole
Figure 2.1.2 Conversion of tri-O-acetyluridine to cytidine via a nitrotriazolide intermediate. Reprinted from Iyer and Beaucage (1999) with permission from Elsevier Science Publishing.
N N O NH AcO
O AcO
N
N
N
O
N
N 1,2,4-triazole
MSNT AcO
O
4-ClPhOP(O)Cl2/C5H5N OAc
1
AcO
N
OAc 4
O
AcO
O AcO
N
O
OAc 5
Figure 2.1.3 Formation of the triazolo derivative S.5 via the pyridinium intermediate S.4. MSNT, 1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole. Reprinted from Iyer and Beaucage (1999) with permission from Elsevier Science Publishing.
Protection of Nucleosides for Oligonucleotide Synthesis
2.1.3 Current Protocols in Nucleic Acid Chemistry
R O S O O
O N AcO
AcO
NH
N
O
N
N
R-SO2-Cl
AcO
NHTr
O
DMAP AcO
OAc
N
N
N
NHTr
OAc 7
6
DMAP, 4-dimethylaminopyridine; Tr, triphenylmethyl
Figure 2.1.4 Formation of an O6-sulfonated derivative of guanosine. R⋅SO2⋅Cl, mesitylene sulfonyl chloride. Reprinted from Iyer and Beaucage (1999) with permission from Elsevier Science Publishing. R, 2,4,6-trimethylphenyl.
line O6-sulfonated derivative S.7 (Fig. 2.1.4; Bridson et al., 1977; Francois et al., 1985). In the presence of pyridine, S.7 is converted to the corresponding C6 pyridinium compound. The side reactions that are predominant in phosphodiester and phosphotriester chemistry have been summarized (Reese and Ubasawa, 1980). These side reactions are of concern when the H-phosphonate method is employed in oligonucleotide synthesis in conjunction with phosphorochloridates as coupling reagents. The imide and lactam functions of nucleosides also react with phosphitylating reagents. For example, the 2′-deoxyguanosine derivative S.20 (Fig. 2.1.5) reacts with methyl phosphoramidites to give the O6-phosphitylated product S.8 (Pon et al., 1985a; Nielsen et al.,
1987). During oxidation of S.8 with iodine, Oto N-phosphoryl migration occurs (S.9 → S.10; Pon et al., 1985b). Once formed, S.10 induces depurination resulting in chain-cleaved products upon treatment with ammonium hydroxide during the final step of deprotection. It is pertinent that base modifications can also occur during oligonucleotide deprotection. For example, thymine residues are significantly modified as N3-methylthymine during deprotection of oligonucleoside methyl phosphotriesters with aqueous ammonium hydroxide (Urdea et al., 1986). However, when deprotection of the methyl phosphate backbone of oligonucleotides is accomplished by treatment with thiophenol or 2-mercaptobenzothiazole, followed by aqueous ammonium hydroxide to
OR′ O N DMTrO
N
O
RO P O
N NH NHi-Bu
N
N
RO P
N
OR′ DMTrO
AcO
N
O
NHi-Bu
N
AcO 8
20
[31P NMR, d 133.95, 133.79 ppm]
I2
OR′ O
RO P
N DMTrO
O
N
AcO
I OR′ RO P O
O
N
NH N
NHi-Bu
DMTrO
O
N N
NHi-Bu
AcO 10
Nucleobase Protection of Deoxyribo- and Ribonucleosides
N
9 DMTr, 4,4'-dimethoxytriphenylmethyl; i-Bu, isobutyryl
Figure 2.1.5 Reaction of an N2-isobutyryl-2′-deoxyguanosine derivative with phosphitylating reagents. R, Me; R′, nucleoside.
2.1.4 Current Protocols in Nucleic Acid Chemistry
remove nucleobase protecting groups, the formation of N3-methylthymine is considerably reduced (McBride et al., 1987; Andrus and Beaucage, 1988). The reactivity of nucleosides and the attendant risk of base modification suggest an apparent need to protect imide and lactam groups of nucleosides in oligonucleotide synthesis. It is expected that the use of protecting groups at
Protecting group
the imide/lactam function of nucleosides can potentially avert the side reactions. This has been borne out by success in the synthesis of a number of polynucleotides (Reese, 1978).
PROTECTION OF IMIDE AND LACTAM FUNCTIONS A number of groups have been proposed for the protection of thymine and uracil and N3 and
Nucleobase (protection site)
Deprotection conditions
References
U (O4)
syn-4-Nitrobenzaldoxime/ tetramethylguanidine
Nylias et al., 1987 MacMillan and Verdine, 1991
G (O6) U (O4)
syn-4-Nitrobenzaldoxime/ tetramethylguanidine
Jones et al., 1981 Zhou and Chattopadhyaya, 1986 Zhou et al., 1986 Reese and Skone, 1984
T (O4) U (O4)
syn-4-Nitrobenzaldoxime/ tetramethylguanidine
Jones et al., 1981 Reese and Skone, 1984 Scalfi-Happ et al., 1987 Rao et al., 1987
G (O6)
syn-4-Nitrobenzaldoxime/ tetramethylguanidine
Reese and Skone, 1984 Rao et al., 1987 Hagen and Chladek, 1989
G (N1, O6) T/U (N3)
NH4OH, heat
Mag and Engels, 1988
T/U (N3)
10% Pd/H2
Krecmerová et al., 1990
G (O6) T (O4)
Pyridine-2-aldoxime/ tetramethylguanidine 0.5 M DBU/pyr
Pfister et al., 1988 Van Aerschot et al., 1988
G (O6)
R=Me3Si: n-Bu4NF/THF R=PhS: 4-NO2PhS: NaIO4/ NH4OH, heat; R=CN; DBU, or NH4OH
Hagen and Chladek, 1989 Gaffney and Jones, 1982 Engels and Mag, 1982
G (O6) T (O4)
Pd(PPh3)4/PPh3, n-BuNH3+HCO2-
2,4,6-trimethylphenyl NO2
2-nitrophenyl R
R R = H or Me Cl
R R = H or Cl
O
O S
(4-NO2)Ph
2-(4-nitrophenylsulfonyl)ethyl
Ph
O
benzyloxymethyl
R
R = NO2 or CN
R
R = Me3Si; PhS; CN; 4-NO2PhS
Hayakawa et al., 1993
allyl
Figure 2.1.6 Protecting groups for the imide/lactam functions of guanine, uracil, and thymine. DBU, 1,8-diazabicyclo[3.4.0]undecene-7; NalO4, sodium periodate; pyr, pyridine; THF, tetrahydrofuran.
Protection of Nucleosides for Oligonucleotide Synthesis
2.1.5 Current Protocols in Nucleic Acid Chemistry
Protecting group
Ph3C S
Nucleobase (protection site)
Deprotection conditions
References
U (N3)
0.1 M I2/THF/collidine/H2O
Takaku et al., 1988
G (O6)
NH4OH
Kamimura et al., 1983b
U (N3)
DBU/morpholine/pyr
Nyilas et al., 1988
U (N3, O4)
NH4OH
Sekine, 1989, Kamimura et al., 1983a Kamaike et al., 1988
U (N3)
Pyr/H2O or 0.2 M n-Bu4NF/ THF
Sekine, 1989 Welch et al., 1985
G (N2, O6); U (N3)
NH4OH/MeOH
Fujii et al., 1987
Pd[PPh3]4/PPh3, n-BuNH2/THF
Hayakawa et al., 1986
triphenylmethyl sulfenyl O Ph2N diphenylcarbamoyl O O O S O R R = H; Me
O
R R = H; Me; OMe; Cl
NO2 S
R
R = H; Me; NO2
O
n-BuS butylthiocarbonyl O
U (N3, O4)
O allyloxycarbonyl MeO
U (N3)
O
NH4OH, heat, or Ph3C+BF4-/MeCN/H2O
Ito et al., 1986
(methoxyethoxy)methyl
Figure 2.1.6
Nucleobase Protection of Deoxyribo- and Ribonucleosides
(Continued)
O4, and of guanine at O6. A representative list of these groups is shown in Figure 2.1.6. For the benefit of the readers, references that include experimental details are cited. The imide- and lactam-protecting groups can be installed in two steps: sulfonylation or triazolation, followed by displacement of the resulting O-sulfonate or triazolide by the nucleophilic protecting group. The protecting groups can also be installed directly—for example, via Mitsunobu alkylation (UNIT 1.2) or via the transient protection approach. The preparation of these protected nucleosides appears to be straightforward (Jones et al., 1981; Gaffney and Jones, 1982; Trichtinger et al., 1983; Nyilas et al., 1987; Kamaike et al., 1988). However, it is still a matter of debate whether imide and lactam protection is necessary in oligonucleotide synthesis. There are a number of factors to be considered. (1) As noted before,
when using the phosphotriester method in oligonucleotide synthesis, O6-modified guanine and O4-modified uracil revert to guanine and uracil residues upon “oximate” treatment that follows chain assembly. (2) When the phosphoramidite method is used, O6-phosphitylated deoxyguanosine reverts to deoxyguanosine on contact with water or acetate ions (Mag and Engels, 1988). Thus, during the synthesis cycle, if capping is performed (using acetic anhydride) after coupling, any O6-modified deoxyguanosine can potentially revert back to deoxyguanosine. (3) Base modifications generated during oligonucleotide chain assembly depend on the reagents employed and the contact time. Solid-phase oligonucleotide synthesis uses automated pulsed delivery of reagents, resulting in shorter reaction times compared with solution-phase synthesis. Consequently, side
2.1.6 Current Protocols in Nucleic Acid Chemistry
reactions during oligonucleotide chain assembly appear to be minimal. Thus, in principle, appropriate adjustment of synthesis protocols may obviate the necessity for imide and lactam protection. Nevertheless, β-cyanoethyl protection is generally recommended for protection of guanosine at O6 or uridine at O4, and anisoyl for uridine at N3.
PROTECTION OF EXOCYCLIC AMINO GROUPS On the basis of a number of criteria for protecting groups, as outlined previously, Nacyl-type protection for the exocyclic amino groups has emerged as a logical choice. Figure 2.1.7 shows selected examples of N-acyl protecting groups and the reagents used to effect their deprotection. The N-acyl groups are introduced into nucleosides by a number of procedures. (1) They
Protecting group
can be installed by peracylation of the nucleoside followed by chemoselective O-deacylation (Schaller et al., 1963). (2) The recent trend has been to use the “transient” protection approach (Ti et al., 1982). In this procedure, the nucleoside is persilylated using a silylating agent, and the acyl function is installed on the amino group using the corresponding acid chloride or acid anhydride. (3) Some acyl functions such as benzoyl, α-phenylcinnamoyl, and naphthaloyl are directly incorporated on the nucleobase using the corresponding anhydride (Watanabe and Fox, 1966; Bhat et al., 1989). (4) The exocyclic amino group of cytidine and deoxycytidine can be directly acylated using activated esters (Igolen and Morin, 1980), acid chlorides (Mishra and Misra, 1986, and references therein), or alkyloxycarbonylbenzotriazoles (Himmelsbach et al., 1984). (5) Recent reports suggest that site-selective incorporation
Nucleobase (protection site)
Deprotection conditions
References
7-Deaza-6-methyl-G (N2)
NH4OH
Seela and Driller, 1989
C (N4)
NH3/EtOH (1:1)
Köster et al., 1981 Chaix et al., 1989
G (N2); C (N4)
NH4OH, heat
Köster et al., 1981 Büchi and Khorana, 1972 Schulhof et al. 1987
G (N2)
NH4OH
Schulhof et al., 1987
G (N2); A (N6); C (N4)
Pd[PPh3]4/HCO2H/Et2NH
Hayakawa et al., 1986 Hayakawa et al., 1990
G (N2); A (N6); C (N4)
NH4OH
Uznanski et al., 1989
G (N2); A (N6); C (N4)
0.5 M NH2NH2·H2O/ pyr/AcOH (4:1)
Ogilvie et al., 1982
G (N2); A (N6); C (N4)
Multiple protocols
Iyer et al., 1997
O H formyl O
acetyl O
isobutyryl O MeO methoxyacetyl O O allyloxycarbonyl O
i-PrO isopropoxyacetyl O
O
levulinyl O
4-pentenoyl
Figure 2.1.7 Protecting groups for the exocyclic amino function of nucleobases. RT, room temperature; pyr, pyridine.
Protection of Nucleosides for Oligonucleotide Synthesis
2.1.7 Current Protocols in Nucleic Acid Chemistry
Protecting group O
Nucleobase (protection site)
Deprotection conditions
References
G (N2); A (N6); C (N4)
DBU or DBU/pyr
Himmelsbach et al., 1984 Pfleiderer et al., 1985 Pfister and Pfleiderer, 1989
G (N2)
5 M NH3/ MeOH
Jones et al., 1981 Rao et al., 1987 Köster et al., 1981 Balgobin et al., 1981
G (N2); A (N6); C (N4)
NH4OH/pyr Et3N/pyr
Scalfi-Happ et al., 1987 Hagen and Chládek, 1989 Heikkilä and Chattopadhyaya, 1983
G (N2); A (N6); C (N4)
NH4OH, heat
Nagaich and Misra, 1989
G (N2); A (N6)
NH4OH
Chaix et al., 1989 Schulhof et al., 1987 Singh and Misra, 1988
G (N2); A (N6); C (N4)
0.2 M NaOH/MeOH or NH4OH or NH3 gas
(4-NO2)Ph
O 4-nitrophenylethyloxycarbonyl R
O
R = H, C(CH3)3
O O
9-fluorenylmethoxycarbonyl O Ph Ph H α-phenylcinnamoyl R
O O
R = H, Cl
R
O O
CH3C
Köster et al., 1981 Sinha et al., 1993 Boal et al., 1996
R = H, Cl
4-(tert-butyl)phenoxyacetyl O Brown et al., 1989 Rao et al., 1987 Tanimura et al., 1988 Schaller et al., 1963 Balgobin et al., 1981
G (N2); A (N6); C (N4)
NH4OH
G (N2); A (N6); C (N4)
TetramethylguaniNyilas et al., 1988 dine/morpholine/pyr; DBU/morpholine/pyr; NH4OH/morpholine/pyr.
G (N2)
NH4OH, heat
Marugg et al., 1984
G (N2)
0.2 M NaOH/MeOH
Koster et al., 1981
G (N2); A (N6); C (N4)
NH4OH, heat
Mishra and Misra, 1986
R R = H, OMe, Cl, NO2, NMe2, CMe3
O
O
O S
O
R R =H; Cl; NO2
O Ph Ph diphenylacetyl O Cl Cl 3,4-dichlorobenzoyl O MeO PhO 3-methoxy-4-phenoxybenzoyl
Nucleobase Protection of Deoxyribo- and Ribonucleosides
Figure 2.1.7
(Continued)
2.1.8 Current Protocols in Nucleic Acid Chemistry
Protecting group
Nucleobase (protection site)
Deprotection conditions
References
C (N4)
0.2 M NaOH/MeOH (1:1)
Köster et al., 1981
G (N2); A (N6); C (N4)
0.05 M K2CO3/MeOH; NH4OH, RT
Kuijpers et al., 1990
G (N2); A (N6); C (N4)
NH4OH, heat
Dikshit et al., 1988
G (N2); A (N6); C (N4)
n-Bu4NF/pyr/H2O
Dreef-Tromp et al., 1990
O
PhN N 4-(phenylazo)benzoyl O
O
R O
R = Ac, Ph
O
O
1,8-naphthaloyl O
O
Ph Si C(CH3)3 Ph
2-(tert-butyldiphenylsilyloxymethyl)benzoyl
Figure 2.1.7
(Continued)
and removal of N-acyl protecting groups can also be achieved by enzymatic methods (Prasad and Wengel, 1996). Overall, most N-acyl protecting groups are stable in neutral or acidic medium and moderately stable at high pH (pH >13). However, many N-acyl protecting groups are readily removed by ammonolysis. This observation forms the basis for the widespread use of 28% NH4OH as a deprotection reagent when N-acylprotected nucleosides are employed in oligonucleotide synthesis. A salient feature of N-acyl protecting groups is that their stability in alkaline pH can be modulated by the steric and electronic characteristics of specific acyl groups. A study comparing the stability of various N-acyl nucleosides in alkaline medium (0.2 N NaOH/MeOH) has been reported (Köster et al., 1981). Importantly, the stability of the acyl function towards alkaline hydrolysis is determined by the nature of the heterocyclic base. For example, the rate of deacylation of N-acyl derivatives of deoxycytidine is faster than that of
deoxyadenosine or deoxyguanosine. The hydrolytic lability is also determined by inductive, resonance, and steric effects. For example, in a series of N-acyl nucleosides, N-benzoyl nucleosides are hydrolyzed sixteen times faster than N-(2,4-dimethyl)benzoyl nucleosides, presumably because of steric effects. Similarly, N-(2,4dimethoxy)benzoyl nucleoside is hydrolyzed eight times faster than N-(4-dimethylamino)benzoyl nucleoside, perhaps due to a combination of inductive and resonance effects. The choice of a particular N-acyl protecting group also depends on the type of coupling chemistry that is employed. For example, when phosphodiester and phosphotriester chemistries are used in oligonucleotide synthesis, it is necessary to select sturdy N-acyl protecting groups that can withstand the harsh reagents and conditions employed during synthesis. This requirement is met by the benzoyl group for adenine and cytosine, and the isobutyryl group for guanine. However, removal of these protecting groups requires prolonged heating
Protection of Nucleosides for Oligonucleotide Synthesis
2.1.9 Current Protocols in Nucleic Acid Chemistry
(12 to 14 hr) with 28% NH4OH at 55°C. In spite of this limitation, these protecting groups have remained popular even with the advent of automated solid-phase oligonucleotide synthesis using phosphoramidite and H-phosphonate chemistries.
mechanism for depurination of deoxyadenosine (Fig. 2.1.8) involves initial protonation of the nucleoside to produce the N1-protonated form S.11, and then equilibration (prototropic shift) to the N7-protonated species S.12 or S.13, followed by cleavage of the glycosidic bond to give S.15 via the oxonium S.14 (Zoltewicz et al., 1970; Zoltewicz and Clark, 1972). It is also conceivable that, at lower pH, depurination can occur via protonation of the purine nucleobase at both N1 and N7. Presence of the 2′-OH has a significant effect on the nucleoside’s susceptibility to depurination. For example, guanosine and adenosine are more resistant to depurination compared with deoxyadenosine and deoxyguanosine. Deoxyadenosine itself depurinates 1200 times faster than adenosine (York, 1981). Interestingly, N-acyl-protected purine nucleosides (particularly deoxyadenosine) are more prone to depurination than unprotected nucleosides. Among N-acyl-protected deoxyadenosines, protection at N6 with αphenylcinnamoyl, naphthaloyl, 3-methoxy-4phenoxybenzoyl, 9-fluorenylmethoxycarbonyl (FMOC), and tert-butylphenoxyacetyl (t-PAC) groups (Fig. 2.1.7) provides greater resistance to depurination than with N6-benzoyl (reviewed in Beaucage and Iyer, 1992). It is believed that in the case of acyl-protected
PROTECTION OF PURINE NUCLEOBASES: THE PROBLEM OF DEPURINATION The development of suitable protecting groups for purine nucleobases has been an area of considerable interest because purine nucleosides rapidly depurinate under acidic conditions. The problem is compounded by the acidlabile DMTr group used for protection of the 5′-OH in solid-phase oligonucleotide synthesis. Prior to each coupling step in the synthesis cycle, the DMTr group is removed by exposure to a strong acid such as 2% dichloroacetic acid in dichloromethane. Consequently, the growing oligonucleotide chain is repeatedly exposed to strongly acidic conditions, potentially resulting in depurination and reduced yield of the desired “full-length” product. The kinetics and mechanisms of nucleoside depurination have been investigated by several research groups (Romero et al., 1978; Oivanen et al., 1987; Suzuki et al., 1994). The presumed
7
N
NH2 6
NH2 N
N1
9
HO
O
N
H
N
HO
3
HO
N
O
NH N
HO 11
H N HO
O HO 15
HO OH
HO
O
HO oxonium ion 14
O
N
NH2 N N
HO 12
H N HO
O
N
O NH N
NH2
HO 13
Nucleobase Protection of Deoxyribo- and Ribonucleosides
Figure 2.1.8 Scheme showing the proposed depurination mechanism for 2′-deoxyguanosine and 2′-deoxyadenosine catalyzed by protic acids. Modified from Iyer and Beaucage (1999) with permission from Elsevier Science Publishing.
2.1.10 Current Protocols in Nucleic Acid Chemistry
Cl
Cl
Cl
OCOPh OCOPh
Cl Ph
O
N
RO
O
O
N
N
O
N
N
RO
RO
O
O
O
N
N
N
N
O
HN N
N N
RO
RO 16
N
RO
O
N
N
N
Ph
N
RO
O
N
OCOPh
N
RO 18
17
C
19
Figure 2.1.9 Examples of N6-protecting groups for 2′-deoxyadenosine derivatives that reduce depurination. Reprinted from Iyer and Beaucage (1999) with permission from Elsevier Science Publishing. R, DMTr.
purine nucleosides under acidic conditions, the initial site of protonation is N7, rendering the protonated species more prone to glycosidic cleavage. Naturally, caution should be exercised in the synthesis of oligonucleotides whose sequence contains deoxyadenosines at the 3′ terminus. Bis-acylation has also been studied as a strategy to reduce depurination. Imide protecting groups S.16 and S.17, as well as the diamide protecting group S.18, have been investigated (Fig. 2.1.9; Kume et al., 1982, 1984). However, these groups were labile to aqueous pyridine, a
Protecting group
solvent used during the oxidation step in solidphase oligonucleotide synthesis. Thus, alternate oxidants have to be employed for the oxidation step. Since N-acyl-protected purine nucleosides are sensitive to deacylation, alternate protecting groups have been investigated. Prominent among these are the amidine protecting groups, which are introduced using an exchange reaction with appropriate amidine acetals. Interestingly, N-amidine-protected nucleosides (Fig. 2.1.10) resist depurination 20-fold better than the corresponding N-benzoyl nucleosides
Nucleobase (protection site)
Deprotection conditions
References
G (N2), A (N6)
NH4OH, heat
Smrt and Sorm, 1967 Vu et al., 1990 Sproat et al., 1991 Caruthers et al., 1985 McBride et al., 1986
G (N2), A (N6)
NH4OH, heat; 0.5 M NH2NH2·H2O/pyr/AcOH
McBride et al., 1986 Froehler and Matteucci, 1983
A (N6)
NH4OH/10% NH4OAc/heat; 0.5 M NH2NH2·H2O/pyr/AcOH
Froehler and Matteucci, 1983
G (N2), A (N6)
NH4OH, heat
McBride et al., 1986
A (N6)
NH4OH/10% NH4OAc/heat; 0.5 M NH2NH2·H2O/pyr/AcOH
Froehler and Matteucci, 1983
C (N4)
NH4OH, heat
McBride et al., 1986
H Me2N (dimethylamino)methylene
H
n-Bu2N (di-n-butylamino)methylene
H
i-Pr2N (diisopropylamino)methylene
Me2N 1-(dimethylamino)ethylidene
H
i-Bu2N (diisobutylamino)methylene
N Me N-methylpyrrolidin-2-ylidene
Figure 2.1.10
Amidine protecting groups for exocyclic amino functions. Pyr, pyridine.
Protection of Nucleosides for Oligonucleotide Synthesis
2.1.11 Current Protocols in Nucleic Acid Chemistry
(Smrt and Sorm, 1967; Holy and Zemlicka, 1969, and references therein; Froehler and Matteucci, 1983; Caruthers et al., 1985; Vu et al., 1990; Sproat et al., 1991). It is presumed that the protonation sites of amidine-protected nucleosides are N1 and N6 instead of N1 and N7, respectively, resulting in a slower rate of depurination. Indeed, amidineprotected nucleoside phosphoramidites are frequently employed in solid-phase oligonucleotide synthesis. However, changes are required in the oxidation step to avoid nucleobase modifications (Mullah et al., 1995). Nucleosides protected with O-nitrophenylsulfonyl and tris(benzoyloxy)trityl (S.19) groups also appear to be more resistant to depurination (Shimidzu and Letsinger, 1968; Honda et al., 1984, and references therein). However, the derived nucleoside phosphoramidites couple less efficiently than the N-acyl-protected nucleoside phosphoramidites (Sekine et al., 1985). Depurination is also influenced by other factors such as the nature of the solid support (controlled-pore glass versus polystyrene; see UNIT 3.1), the composition of the deblocking solution and deblocking time, and the washing solvent and washing time that are employed in solid-phase synthesis of oligonucleotides (Paul and Royappa, 1996). Depurination is faster at terminal sites than at internal sites in an oligonucleotide chain (Suzuki et al., 1994). Interestingly, a solution of 15% dichloroacetic acid (DCA) in methylene chloride was ideal as a detritylating reagent that induced minimal depurination compared to the traditionally used 2% DCA/methylene chloride. It is pertinent that with modern DNA synthesizers the pulsed delivery of reagents to the synthesis columns, in conjunction with optimized synthesis programs, results in short contact times and has greatly minimized the depurination problem. Thus, N-acyl-protected nucleoside (benzoyl for dA and dC, and isobutyryl for dG) phosphoramidites and H-phosphonates can be used for the efficient synthesis of oligonucleotides.
RECENT TRENDS IN NUCLEOBASE PROTECTION
Nucleobase Protection of Deoxyribo- and Ribonucleosides
Over the past few years, new applications of oligonucleotides in diagnostics and therapeutics have emerged, necessitating the expeditious synthesis of large numbers of oligonucleotides. In order to speed the synthesis process, more “labile” N-acyl protecting groups for nucleosides have been sought. As the simplest
member of the family of N-acyl protecting groups, the N4-acetyl of cytosine has been used for “ultrafast” DNA synthesis using the phosphoramidite approach. Rapid deprotection rates were achieved using methylamine/ammonia (Reddy et al., 1994). This group is unsuitable for use in phosphodiester and phosphotriester chemistries, however. The synthesis of oligonucleotide analogs carrying sensitive backbones requires protecting groups that (1) withstand the synthetic rigors of chain assembly, and (2) can be removed chemoselectively under mild conditions. Nucleobases protected by phenoxyacetyl (Singh and Misra, 1988; Chaix et al., 1989; Sproat et al., 1991), and their derivatives such as t-PAC, show accelerated deacylation (Köster et al., 1981; Sinha et al., 1993) under mildly basic conditions. It is presumed that the inductive effect of the phenoxy group renders the amide carbonyl group more susceptible to nucleophilic attack, facilitating rapid base-catalyzed hydrolysis. Thus, PAC- and t-PAC-phosphoramidites have been employed for rapid synthesis of oligonucleotides and certain analogs. As a rule, following oligonucleotide assembly on solid support, the PAC and t-PAC groups are removed under milder conditions (28% NH4OH, room temperature; Sinha et al., 1993) or, according to a recent report, using gaseous amines under pressure (Boal et al., 1996). However, the use of t-PAC-protected nucleoside phosphoramidites results in trans acylation of the t-PAC protecting groups during the capping step when acetic anhydride is employed as a capping reagent. Thus, tert-butylphenoxyacetic anhydride should be used for the capping step in solid-phase oligonucleotide synthesis (Sinha et al., 1993). The concept of neighboring-group participation has also been used to design acyl protecting groups and to accelerate the deprotection step (Dreef-Tromp et al., 1990; Kuijpers et al., 1990). For example, removal of the 2-(acetoxymethyl)benzoyl group from nucleosides under basic conditions is accelerated by intramolecular participation of the deacylated hydroxymethyl group. New protecting groups have also been introduced that can be chemoselectively removed under neutral or mildly basic conditions. Indeed, the allyloxycarbonyl protecting group (Hayakawa et al., 1986, 1990) is chemoselectively removed using Pd(0), whereas the (p-nitrophenyl)ethoxycarbonyl group (Trichtinger et al., 1983; Pfleiderer et al., 1985; Pfister et al., 1988) and the 2-dansylethoxy cabonyl group
2.1.12 Current Protocols in Nucleic Acid Chemistry
(Wagner and Pfleiderer, 1997) are selectively removed using DBU. Consequently, supportbound oligonucleotides can be prepared using building blocks that carry these protecting groups. Recently, the N-pent-4-enoyl (PNT) group has been introduced as a new acyl protecting group for situations where multiple deprotection protocols are used (Iyer et al., 1997; see also references therein). PNT-protected nucleoside phosphoramidites can potentially be used for the rapid synthesis of oligonucleotides and oligonucleotide analogs, as well as for the preparation of support-bound oligonucleotides. Several groups have been reported for nucleobase protection and may be particularly valuable in the synthesis of oligonucleotides intended for specific applications. Figure 2.1.7 shows a partial list of protecting groups. A complete list of such groups is covered in other reviews (Sonveaux, 1986; Beaucage and Iyer, 1992; Iyer and Beaucage, 1999). Nonetheless, it should be noted that many of these still need to be evaluated in routine synthesis. Because of various issues associated with nucleobase protection, oligonucleotide synthesis has been evaluated using building blocks bearing unprotected nucleobases. However, these efforts have met with only limited success (Narang et al., 1972; Fourrey and Varenne, 1985; Gryaznov and Letsinger, 1991; Uchiyama et al., 1993, and references therein). Clearly, more work is necessary in this area.
CONCLUSION Evidently, a nucleobase protecting group should meet several criteria before it can be adapted for routine oligonucleotide synthesis. It is imperative, therefore, that the potential for side reactions be closely examined when designing new reagents, evaluating new protecting groups, and implementing modifications of established protocols during oligonucleotide synthesis, as well as during the manufacture of oligonucleotides and their analogs. The development of nucleobase protecting groups and deprotection protocols has been crucial for the successful synthesis of oligonucleotides, functionalized oligonucleotides, oligonucleotide analogs, ribonucleotides, and phosphorylated biomolecules (reviewed in Beaucage and Iyer, 1992, 1993a,b,c). As in the past, oligonucleotides are expected to play a dominant role in fostering advances in functional genomics, proteomics, diagnostics, and therapeutics. Consequently, continued demand exists for simultaneous synthesis of large numbers of oligonucleotides in miniature formats,
and for the synthesis and manufacture of novel analogs. It is hoped that the present commentary will serve as a framework for developing new protecting group strategies for oligonucleotide synthesis that could meet these challenges.
ACKNOWLEDGMENT The author wishes to thank Dr. WenQiang Zhou for his help with the artwork in this manuscript.
LITERATURE CITED Andrus, A. and Beaucage, S.L. 1988. 2-Mercaptobenzothiazole—an improved reagent for the removal of methylphosphate protecting groups from oligodeoxynucleotide phosphotriesters. Tetrahedron Lett. 29:5479-5482. Balgobin, N., Josephson, S., and Chattopadhyaya, J.B. 1981. A general approach to the chemical synthesis of oligodeoxyribonucleotides. Acta. Chem. Scand. B35:201-212. Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862. Beaucage, S.L. and Iyer, R.P. 1992. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:22232311. Beaucage, S.L. and Iyer, R.P. 1993a. The functionalization of oligonucleotides via phosphoramidite derivatives. Tetrahedron 49:19251963. Beaucage, S.L. and Iyer, R.P. 1993b. The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications. Tetrahedron 49:6123-6194. Beaucage, S.L. and Iyer, R.P. 1993c. The synthesis of specific ribonucleotides and unrelated phosphorylated biomolecules by the phosphoramidite method. Tetrahedron 49:10441-10488. Bhat, V., Ugarkar, B.G., Sayeed, V.A., Grimm, K., Kosora, N., and Domenico, P. 1989. A simple and convenient method for the selective N-acylations of cytosine nucleosides. Nucleosides Nucleotides 8:179-183. Boal, J.H., Wilk, A., Harindranath, N., Max, E.E., Kempe, T., and Beaucage, S.L. 1996. Cleavage of oligodeoxyribonucleotides from controlledpore glass supports and their rapid deprotection by gaseous amines. Nucl. Acids Res. 24:31153117. Bridson, P.K., Markiewicz, W., and Reese, C.B. 1977. Acylation of 2′,3′,5′-tri-O-acetylguanosine. J. Chem. Soc., Chem. Commun. 791-792. Brown, J.M., Christodoulou, C., Modak, A.S., Reese, C.B., and Serafinowska, H.T. 1989. Synthesis of the 3′-terminal half of yeast alanine transfer ribonucleic acid (tRNAala) by the phosphotriester approach in solution. Part 2. J. Chem. Soc. Perkin Trans. 1:1751-1767.
Protection of Nucleosides for Oligonucleotide Synthesis
2.1.13 Current Protocols in Nucleic Acid Chemistry
Büchi, H. and Khorana, H.G. 1972. CV. Total synthesis of the structural gene for an alanine transfer ribonucleic acid from yeast. Chemical synthesis of an icosadeoxyribonucleotide corresponding to the nucleotide sequence 31 to 50. J. Mol. Biol. 72:251-288. Caruthers, M.H., McBride, L.J., Bracco, L.P., and Dubendorff, J.W. 1985. Studies on nucleotide chemistry 15. Synthesis of oligodeoxynucleotides using amidine protected nucleosides. Nucleosides Nucleotides 4:95-105. Chaix, C., Molko, D., and Téoule, R. 1989. The use of labile base protecting groups in oligoribonucleotide synthesis. Tetrahedron Lett. 30:71-74. Clauwaert, J. and Stockx, J. 1986. Interactions of polynucleotides and their components. I. Dissociation constants of the bases and their derivatives. Z. Naturforsch. B. 23:25-30. den Hartog, J.A.J., Willie, G., Scheublin, R.A., and van Boom, J.H. 1982. Chemical synthesis of a messenger ribonucleic acid fragment: AUGUUCUUCUUCUUCUUC. Biochemistry 21:10091018. Dikshit, A., Chaddha, M., Singh, R.K., and Misra, K. 1988. Naphthaloyl group: A new selective amino protecting group for deoxynucleosides in oligonucleotide synthesis. Can. J. Chem. 66:2989-2994. Divakar, K.J. and Reese, C.B. 1982. 4-(1,2,4-Triazol-1-yl)- and 4-(3-nitro-1,2,4-triazol-1-yl)-1(β-D-2,3,5-tri-O-acetylarabinofuranosyl)pyrim idin-2(1H)-ones. Valuable intermediates in the synthesis of derivatives of 1-(β-D-arabinofuranosyl)cytosine (Ara-C). J. Chem. Soc. Perkin Trans. 1:1171-1176. Dreef-Tromp, C.M., van Dam, E.M.A., van den Elst, H., van der Marel, G.A., and van Boom, J.H. 1990. Solid-phase synthesis of H-Phe-Tyr(pATAT)-NH2: A nucleopeptide fragment from the nucleoprotein of bacteriophage φX174. Nucl. Acids Res. 18:6491-6495. Dunn, D.B., and Hall, R.H. 1975. Purines, pyrimidines, nucleosides and nucleotides: Physical constants and spectral properties. In Handbook of Biochemistry and Molecular Biology, 3rd ed., Vol. 1: Nucleic Acids (G.D. Fasman, ed.) pp. 65-125. CRC Press, Boca Raton, Fla. Engels, J.W. and Mag, M. 1982. Amide protection in oligodeoxynucleotide synthesis. Nucleosides Nucleotides 6:473-475. Fourrey, J.-L. and Varenne, J. 1985. Preparation and phosphorylation reactivity of N-nonacylated nucleoside phosphoramidites. Tetrahedron Lett. 26:2663-2666. Francois, P., Hamoir, G., Sonveaux, E., Vermeersch, H., and Ma, Y. 1985. On the phosphorylation of deoxyribonucleosides and the protection of deoxyguanosine. Bull. Soc. Chim. Belg. 94:821823. Nucleobase Protection of Deoxyribo- and Ribonucleosides
Froehler, B.C. and Matteucci, M.D. 1983. Dialkylformamidines: Depurination resistant N6-protecting group for deoxyadenosine. Nucl. Acids Res. 11:8031-8036.
Froehler, B.C., Ng, P.G., and Matteucci, M.D. 1986. Synthesis of DNA via deoxynucleoside H-phosphonate intermediates. Nucl. Acids Res. 14:5399-5407. Fujii, M., Yamakage, S., Takaku, H., and Hata, T. 1987. (Butylthio)carbonyl group: A new protecting group for the guanine residue in oligoribonucleotide synthesis. Tetrahedron Lett. 28:57135716. Gaffney, B.L. and Jones, R.A. 1982. A new strategy for the protection of deoxyguanosine during oligonucleotide synthesis. Tetrahedron Lett. 23:2257-2260. Garegg, P.J., Lindh, I., Regberg, T., Stawinski, J., Strömberg, R., and Henrichson, C. 1986. Nucleoside H-phosphonates. IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach. Tetrahedron Lett. 27:4055-4058. Gilham, P.T. and Khorana, H.G. 1958. Studies on polynucleotides. I. A new and general method for the chemical synthesis of the C5′-C3′ internucleotidic linkage. Syntheses of deoxyribo-dinucleotides. J. Am. Chem. Soc. 80:6212-6222. Gryaznov, S.M. and Letsinger, R.L. 1991. Synthesis of oligonucleotides via monomers with unprotected bases. J. Am. Chem. Soc. 113:5876-5877. Hagen, M.D. and Chládek, S. 1989. General synthesis of 2′(3′)-O-aminoacyl oligoribonucleotides. The protecion of the guanine moiety. J. Org. Chem. 54:3189-3195. Hall, R.H., Todd, A.R., and Webb, R.F. 1957. Nucleotides. Part XLI. Mixed anhydrides as intermediates in the synthesis of dinucleoside phosphates. J. Chem. Soc. 3291-3296. Hayakawa, Y., Kato, H., Uchiyama, M., Kajino, H., and Noyori, R. 1986. Allyloxycarbonyl group: A versatile blocking group for nucleotide synthesis. J. Org. Chem. 51:2400-2402. Hayakawa, Y., Wakabayashi, S., Kato, H., and Noyori, R. 1990. The allylic protection method in solid-phase oligonucleotide synthesis. An efficient preparation of solid-anchored DNA oligomers. J. Am. Chem. Soc. 112:1691-1696. Hayakawa, Y., Hirose, M., and Noyori, R. 1993. O-Allyl protection of guanine and thymine residues in oligodeoxyribonucleotides. J. Org. Chem. 58:5551-5555. Heikkilä, J. and Chattopadhyaya, J. 1983. The 9fluorenylmethoxycarbonyl (Fmoc) group for the protection of amino functions of cytidine, adenosine, guanosine and their 2′-deoxysugar derivatives. Acta Chem. Scand. B37:263-265. Himmelsbach, F., Schulz, B.S., Trichtinger, T., Charubala, R., and Pfleiderer, W. 1984. The pnitrophenylethyl (NPE) group. A versatile new blocking group for phosphate and aglycone protection in nucleosides and nucleotides. Tetrahedron 40:59-72.
2.1.14 Current Protocols in Nucleic Acid Chemistry
Holy, A. and Zemlicka, J. 1969. Oligonucleotidic compounds. XXXIII. A study on hydrolysis of N-dimethylaminomethylenecytidine, -adenosine, -guanosine, and related 2′-deoxy compounds. Collect. Czech. Chem. Commun. 34:2449-2458. Honda, S., Urakami, K., Koura, K., Terada, K., Sato, Y., Kohno, K., Sekine, M., and Hata, T. 1984. Synthesis of oligoribonucleotides by use of S,Sdiphenyl N-monomethoxytrityl ribonucleoside 3′-phosphorodithioates. Tetrahedron 40:153163. Huynh-Dinh, T., Langlois d’Estaintot, B., Allard, P., and Igolen, J. 1985. Synthèse simplifiée de sondes mixtes avec des triazolo-nucléosides. Tetrahedron Lett. 26:431-434. Igolen, J. and Morin, C. 1980. Rapid synthesis of protected 2′-deoxycytidine derivatives. J. Org. Chem. 45:4802-4804. Ito, T., Ued a, S., and Takaku, H. 19 86. (Methoxyethoxy)methyl group: New amide and hydroxyl protecting groups of uridine in oligonucleotide synthesis. J. Org. Chem. 51:931933. Iyer, R.P. and Beaucage, S.L. 1999. Oligonucleotide synthesis. In Comprehensive Natural Products Chemistry, Vol. 7: DNA and Aspects of Molecular Biology (E.T. Kool, ed.) pp. 105-152. Elsevier Science Publishing, New York. Iyer, R.P., Yu, D., Habus, I., Ho, N.H., Johnson, S., Devlin, T., Jiang, Z., Zhou, W., Xie, J., and Agrawal, S. 1997. N-Pent-4-enoyl (PNT) group as a universal nucleobase protector: Applications in the rapid and facile synthesis of oligonucleotides, analogs and conjugates. Tetrahedron 53:2731-2750. Jones, S.S., Reese, C.B., Sibanda, S., and Ubasawa, A. 1981. The protection of uracil and guanine residues in oligonucleotide synthesis. Tetrahedron Lett. 22:4755-4758.
Krecmerová, M., Hrebabecky, H., and Holy, A. 1990. Synthesis of 5′-O-phosphonomethyl derivatives of pyridine 2′-deoxynucleosides. Collect. Czech. Chem. Commun. 55:2521-2536. Kuijpers, W.H.A., Huskens, J., and van Boeckel, C.A.A. 1990. The 2-(acetoxymethyl)benzoyl (AMB) group as a new base-protecting group, designed for the protection of phosphate modified oligonucleotides. Tetrahedron Lett. 31:6729-6732. Kume, A., Sekine, M., and Hata, T. 1982. Phthaloyl group: A new amino protecting group of deoxyadenosine in oligonucleotide synthesis. Tetrahedron Lett. 23:4365-4368. Kume, A., Iwase, R., Sekine, M., and Hata, T. 1984. Cyclic diacyl groups for protection of the N6amino group of deoxyadenosine in oligodeoxynucleotide synthesis. Nucl. Acids Res. 12:8525-8538. Letsinger, R.L. and Ogilvie, K.K. 1969. Synthesis of oligothymidylates via phosphotriester intermediates. J. Am. Chem. Soc. 91:3350-3355. Letsinger, R.L. and Lunsford, W.B. 1976. Synthesis of thymidine oligonucleotides by phosphite triester intermediates. J. Am. Chem. Soc. 98:36553661. Li, B.F.L., Reese, C.B., and Swann, P.F. 1987. Synthesis and characterization of oligodeoxynucleotides containing 4-O-methylthymine. Biochemistry 26:1086-1093. MacMillan, A.M. and Verdine, G.L. 1991. Engineering tethered DNA molecules by the convertible nucleoside approach. Tetrahedron 47:26032616. Mag, M. and Engels, J.W. 1988. Synthesis and structure assignments of amide protected nucleosides and their use as phosphoramidites in deoxyoligonucleotide synthesis. Nucl. Acids Res. 16:3525-3543. Marugg, J.E., Tromp, M., Jhurani, P., Hoyng, C.F., van der Marel, G.A., and van Boom, J.H. 1984. Synthesis of DNA fragments by the hydroxybenzotriazole phosphodiester approach. Tetrahedron 40:73-78.
Kamaike, K., Hasegawa, Y., and Ishido, Y. 1988. A simple, preparative procedure for N3-anisoyluridine and O6-diphenylcarbamoylguanosine 2′O-(tetrahydropyran-2-yl) derivatives via the corresponding 3′,5′-dibenzoates. Nucleosides Nucleotides 7:37-43.
Matteucci, M.D. and Caruthers, M.H. 1980. The synthesis of oligodeoxypyrimidines on a polymer support. Tetrahedron Lett. 21:719-722.
Kamimura, T., Masegi, T., Urakami, K., Honda, S., Sekine, M., and Hata, T. 1983a. A new protecting tactics for the uracil residue in oligoribonucleotide synthesis. Chem. Lett. 1051-1054.
McBride, L.J., Kierzek, R., Beaucage, S.L., and Caruthers, M.H. 1986. Amidine protecting groups for oligonucleotide synthesis. J. Am. Chem. Soc. 108:2040-2048.
Kamimura, T., Tsuchiya, M., Koura, K., Sekine, M., and Hata, T. 1983b. Diphenylcarbamoyl and propionyl groups: A new combination of protecting groups on the guanine residue. Tetrahedron Lett. 24:2775-2778.
McBride, L.J., Eadie, J.S., Efcavitch, J.W., and Andrus, A. 1987. Base modification and the phosphoramidite approach. Nucleosides Nucleotides 6:297-300.
Khorana, H.G. 1979. Total synthesis of a gene. Science 203:614-625.
Michelson, A.M. and Todd, A.R. 1955. Nucleotides. Part XXXII. Synthesis of a dithymidine dinucleotide containing a 3′:5′-internucleotidic linkage. J. Chem. Soc. 2632-2638.
Köster, H., Kulikowski, K., Liese, T., Heikens, W., and Kohli, V. 1981. N-acyl protecting groups for deoxynucleosides. A quantitative and comparative study. Tetrahedron 37:363-369.
Mishra, R.K. and Misra, K. 1986. Improved synthesis of oligodeoxyribonucleotide using 3methoxy-4-phenoxybenzoyl group for amino protection. Nucl. Acids Res. 14:6197-6213.
Protection of Nucleosides for Oligonucleotide Synthesis
2.1.15 Current Protocols in Nucleic Acid Chemistry
Mullah, B., Andrus, A., Zhao, H., and Jones, R.A. 1995. Oxidative conversion of N-dimethylformamidine nucleosides to N-cyano nucleosides. Tetrahedron Lett. 36:4373-4376.
Prasad, A.K. and Wengel, J. 1996. Enzyme-mediated protecting group chemistry on the hydroxyl groups of nucleosides. Nucleosides Nucleotides 15:1347-1359.
Nagaich, A.K. and Misra, K. 1989. Highly efficient synthesis of oligodeoxyribonucleotides using αphenyl cinnamoyl group for selective amino protection. Nucl. Acids Res. 17:5125-5134.
Rao, T.S., Reese, C.B., Serafinowska, H.T., Takaku, H., and Zappia, G. 1987. Solid-phase synthesis of the 3′-terminal nonadecaribonucleoside octadecaphosphate sequence of yeast alanine transfer ribonucleic acid. Tetrahedron Lett. 28:48974900.
Narang, S.A., Itakura, K., and Wightman, R.H. 1972. A simplification in the synthesis of deoxyribooligonucleotides. Can. J. Chem. 50:769770. Nielsen, J., Dahl, O., Remaud, G., and Chattopadhyaya, J. 1987. Phosphitylation of guanine or inosine bases during the preparation of nucleoside phosphoramidites. Isolation of model products as thiophosphoric amide derivatives and structure elucidation by 15N NMR spectroscopy. Acta. Chem. Scand. B41:633-639. Nyilas, A., Zhou, X.-X., Welch, C.J., and Chattopadhyaya, J. 1987. A versatile strategy for the O4protection and modification of the lactam function of uridine and uridylic acid. Nucl. Acids Res. Symp. Ser. 18:157-160. Nyilas, A., Földesi, A., and Chattopadhyaya, J. 1988. Arenesulfonylethoxycarbonyl—A set of amino protecting groups for DNA and RNA synthesis. Nucleosides Nucleotides 7:787-793. Ogilvie, K.K., Nemer, M.J., Hakimelahi, G.H., Proba, Z.A., and Lucas, M. 1982. N-Levulination of nucleosides. Tetrahedron Lett. 23:26152618. Oivanen, M., Lönnberg, H., Zhou, X.X., and Chattopadhyaya, J. 1987. Acidic hydrolysis of 6-substituted 9-(2-deoxy-β-D-erythro-pentofuranosyl)purines and their 9-(1-alkoxyethyl) counterparts: Kinetics and mechanism. Tetrahedron 43:1133-1140. Paul, C.H. and Royappa, A.T. 1996. Acid binding and detritylation during oligonucleotide synthesis. Nucl. Acids Res. 24:3048-3052. Pfister, M. and Pfleiderer, W. 1989. New results in oligoribonucleotide synthesis. Nucleosides Nucleotides 8:1001-1006. Pfister, M., Farkas, S., Charubala, R., and Pfleiderer, W. 1988. Recent progress in oligoribonucleotide synthesis. Nucleosides Nucleotides 7:595-600. Pfleiderer, W., Himmelsbach, F., Charubala, R., Schirmeister, H., Beiter, A., Schulz, B., and Trichtinger, T. 1985. The p-nitrophenylethyl group—An universal blocking group in nucleoside and nucleotide chemistry. Nucleosides Nucleotides 4:81-94. Pon, R.T., Damha, M.J., and Ogilvie, K.K. 1985a. Necessary protection of the O6-position of guanosine during the solid phase synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron Lett. 26:2525-2528. Nucleobase Protection of Deoxyribo- and Ribonucleosides
Pon, R.T., Damha, M.J., and Ogilvie, K.K. 1985b. Modification of guanine bases by nucleoside phosphoramidite reagents during the solid phase synthesis of oligonucleotides. Nucl. Acids Res. 13:6447-6465.
Reddy, M.P., Hanna, N.B., and Farooqui, F. 1994. Fast cleavage and deprotection of oligonucleotides. Tetrahedron Lett. 35:4311-4314. Reese, C.B. 1978. The chemical synthesis of oligoand poly-nucleotides by the phosphotriester approach. Tetrahedron 34:3143-3179. Reese, C.B. and Ubasawa, A. 1980. Reaction between 1-arenesulphonyl-3-nitro-1,2,4-triazoles and nucleoside residues. Elucidation of the nature of side-reactions during oligonucleotide synthesis. Tetrahedron Lett. 21:2265-2268. Reese, C.B. and Skone, P.A. 1984. The protection of thymine and guanine residues in oligodeoxyribonucleotide synthesis. J. Chem. Soc. Perkin Trans. 1:1263. Romero, R., Stein, R., Bull, H.G., and Cordes, E.H. 1978. Secondary deuterium isotope effects for acid-catalyzed hydrolysis of inosine and adenosine. J. Am. Chem. Soc. 100:7620-7624. Saenger, W. 1984. Principles of Nucleic Acids Structure. Springer-Verlag, New York. Scalfi-Happ, C., Happ, E., and Chládek, S. 1987. New approach to the synthesis of 2′(3′)-O-aminoacyl-oligoribonucleotides related to the 3′-terminus of aminoacyl transfer ribonucleic acid. Nucleosides Nucleotides 6:345-348. Schaller, H., Weimann, G., Lerch, W.B., and Khorana, H.G. 1963. Studies on polynucleotides. XXIV. The stepwise synthesis of specific deoxyribopolynucleotides (4). Protected derivatives of deoxyribonucleosides and new syntheses of deoxyribonucleoside-3′ phosphates. J. Am. Chem. Soc. 85:3821-3827. Schulhof, J.C., Molko, D., and Teoule, R. 1987. Facile removal of new base protecting groups useful in oligonucleotide synthesis. Tetrahedron Lett. 28:51-54. Seela, F. and Driller, H. 1989. 7-Deaza-2′-deoxyO6-methylguanosine: Selective N2-formylation via a formamidine, phosphoramidite. Synthesis and properties of oligonucleotides. Nucleosides Nucleotides 8:1-21. Sekine, M. 1989. General method for the preparation of N3- and O4-substituted uridine derivatives by phase-transfer reactions. J. Org. Chem. 54:2321-2326. Sekine, M., Masuda, N., and Hata, T. 1985. Introduction of the 4,4′,4′′-tris(benzoyloxy)trityl group into the exo amino groups of deoxyribonucleosides and its properties. Tetrahedron 41:5445-5453.
2.1.16 Current Protocols in Nucleic Acid Chemistry
Shabarova, Z. and Bogdanov, A. 1994. Advanced organic chemistry of nucleic acids. VCH Publishers, New York. Shimidzu, T. and Letsinger, R.L. 1968. Synthesis of deoxyguanylyl-deoxyguanosine on an insoluble polymer support. J. Org. Chem. 33:708-711. Singh, R.K. and Misra, K. 1988. Improvements in oligodeoxyribonucleotide synthesis using phenoxyacetyl as amino protecting group. Indian J. Chem. 27B:409-417. Sinha, N.D., Davis, P., Usman, N., Pérez, J., Hodge, R., Kremsky, J., and Casale, R. 1993. Labile exocyclic amine protection of nucleosides in DNA, RNA and oligonucleotide analog synthesis facilitating N-deacylation, minimizing depurination and chain degradation. Biochimie 75:1323. Smrt, J. and Sorm, F. 1967. Oligonucleotidic compounds. XVIII. Synthesis of guanylyl-(3′-5′)uridylyl-(3′-5′)-arabinofuranosyluracil and guanylyl-(3′-5′)-uridylyl-(3′-5′)-arabinofurano -sylcytosine. Collect. Czech. Chem. Commun. 32:3169-3176. Sonveaux, E. 1986. The organic chemistry underlying DNA synthesis. Bioorganic Chem. 14:274325. Sproat, B.S., Iribarren, A.M., Guimil Garcia, R., and Beijer, B. 1991. New synthetic routes to synthons suitable for 2′-O-allyloligoribonucleotide assembly. Nucl. Acids Res. 19:733-738. Sung, W.L. 1982. Synthesis of 4-(1,2,4-triazol-1yl)pyrimidin-2(1H)-one-ribonucleotide and its application in synthesis of oligoribonucleotides. J. Org. Chem. 47:3623-3628. Suzuki, T., Ohsumi, S., and Makino, K. 1994. Mechanistic studies on depurination and apurinic site chain breakage in oligodeoxyribonucletides. Nucl. Acids Res. 22:4997-5003. Takaku, H., Imai, K., and Nagai, M. 1988. Triphenylmethanesulfenyl group. A new protecting group for the uracil residue in oligoribonucleotide synthesis. Chem. Lett. 857-860. Tanimura, H., Fukazawa, T., Sekine, M., Hata, T., Efcavitch, J.W., and Zon, G. 1988. The practical synthesis of RNA fragments in the solid phase approach. Tetrahedron Lett. 29:577-578. Ti, G.S., Gaffney, B.L., and Jones, R.A. 1982. Transient protection: Efficient one-flask synthesis of protected deoxynucleosides. J. Am. Chem. Soc. 104:1316-1319. Trichtinger, T., Charubala, R., and Pfleiderer, W. 19 83. Synth esis of O6-p-nitrophenylethyl guanosine and 2′-deoxyguanosine derivatives. Tetrahedron Lett. 24:711-714. Uchiyama, M., Aso, Y., and Noyori, R. 1993. O-Selective phosphorylation of nucleosides without N-protection. J. Org. Chem. 58:373-379.
Urdea, M.S., Ku, L., Horn, T., Gee, Y.G., and Warner, B.D. 1986. Base modification and cloning efficiency of oligodeoxyribonucleotides synthesized by the phosphoramidite method: Methyl versus cyanoethyl phosphorous protection. Nucl. Acids Res. Symp. Ser. 16:257-260. Uznanski, B., Grajkowski, A., and Wilk, A. 1989. The isopropoxyacetic group for convenient base protection during solid-support synthesis of oligodeoxyribonucleotides and their triester analogs. Nucl. Acids Res. 17:4863-4871. Van Aerschot, A., Herdewijn, P., Janssen, G., and Vanderhaeghe, H. 1988. Protection of the lactam function of 2′-deoxyinosine with a 2-(4-nitrophenyl)-ethyl moiety. Nucleosides Nucleotides 7:519-536. Vu, H., McCollum, C., Jacobson, K., Theisen, P., Vinayak, R., Spiess, E., and Andrus, A. 1990. Fast oligonucleotide deprotection phosphoramidite chemistry for DNA synthesis. Tetrahedron Lett. 31:7269-7272. Wagner, T. and Pfleiderer, W. 1997. Aglycone protection by the (2-dansylethoxy)carbonyl (= {2{[5-(dimethylamino)naphthalen-1-yl] sulfonyl}ethoxy}carbonyl; dnseoc) group—A new variation in oligodeoxyribonucleotide synthesis. Helv. Chim. Acta 80:200-212. Watanabe, K.A. and Fox, J.J. 1966. A simple method for selective acylation of cytidine on the 4-amino group. Angew. Chem. Intl. Ed. Engl. 5:579-580. Welch, C.J., Bazin, H., Heikkilä, J., and Chattopadhyaya, J. 1985. Synthesis of C-5 and N-3 arenesulfenyl uridines. Preparation and properties of a new class of uracil protecting group. Acta Chem. Scand. B39:203-212. York, J.L. 1981. Effect of structure of the aglycon on the acid-catalyzed hydrolysis of adenine nucleosides. J. Org. Chem. 46:2171-2173. Zhou, X.-X. and Chattopadhyaya, J. 1986. Site-specific modification of the pyrimidine residue during the deprotection of the fully-protected diuridylic acid. Tetrahedron 42:5149-5156. Zhou, X.X., Sandström, A., and Chattopadhyaya, J. 1986. A convenient preparation of 2-N-(4-tbutylbenzoyl)-6-O-(2-nitrophenyl)guanosine and its application in the synthesis of 5′(GpGpGpU)3′ constituting the 3′-anticodon stem of E.coli tRNAIle. Chem. Scr. 26:241-249. Zoltewicz, J.A. and Clark, D.F. 1972. Kinetics and mechanism of the hydrolysis of guanosine and 7-methylguanosine nucleosides in perchloric acid. J. Org. Chem. 37:1193-1197. Zoltewicz, J.A., Clark, D.F., Sharpless, T.W., and Grahe, G. 1970. Kinetics and mechanism of the hydrolysis of some purine nucleosides. J. Am. Chem. Soc. 92:1741-1750.
Contributed by Radhakrishnan P. Iyer OriGenix Technologies Laval, Quebec, Canada
Protection of Nucleosides for Oligonucleotide Synthesis
2.1.17 Current Protocols in Nucleic Acid Chemistry
Protection of 2′-Hydroxy Functions of Ribonucleosides The methods used to protect 2′-hydroxy functions of ribonucleosides have recently been reviewed (Beaucage and Iyer, 1992; Sonveaux, 1994; Beaucage and Caruthers, 1996). In addition, there have been earlier brief reviews (Ohtsuka and Iwai, 1987; Reese, 1989). The main purpose of this article is to discuss 2′-protection in the context of effective oligoribonucleotide synthesis. For this reason, emphasis will be placed on what are now, or are likely to become, the 2′-protecting groups of choice in the synthesis of oligo- and poly-ribonucleotides (RNA sequences). As a result, only some of the protecting groups that have been suggested for this purpose are considered in detail here, and some interesting chemistry has necessarily been omitted.
CONSIDERATIONS FOR 2′-PROTECTING GROUPS IN OLIGORIBONUCLEOTIDE SYNTHESIS There are three main general criteria that all protecting groups should fulfill (Reese, 1978). (1) They should be easy to introduce and, as part of this criterion, the reagents involved in their introduction should be readily accessible. (2) They should be stable and remain intact until it is appropriate to remove them. (3) They should be removable at the appropriate time using conditions under which the desired product is completely stable. In the case of chiral substrates such as ribonucleosides, achiral protecting groups are desirable for analytical (e.g., NMR, TLC, and HPLC) purposes. In the case of all substrates, it is desirable that the introduction of protecting groups should not result in unduly complex NMR spectra.
O
The successful chemical synthesis of polynucleotides (including RNA sequences) depends on the choice of suitable protecting groups and effective phosphorylation procedures. Arguably the most crucial single decision that has to be made in oligoribonucleotide synthesis is the choice of the protecting group (R; see S.1) for the 2′-hydroxy functions (Reese, 1978). This protecting group must remain intact until the very last step of the synthesis (Fig. 2.2.1), and must then be removable under conditions that are mild enough to avoid subsequent attack of the released 2′-hydroxy functions (see S.2) on the vicinal phosphodiester internucleotide linkages, thereby leading to their cleavage or migration. Protecting groups are often removed hydrolytically under either basic or acidic conditions. Cleavage of interribonucleotide linkages can occur under relatively mild basic conditions (Järvinen et al., 1991; Kuusela and Lönnberg, 1994). This process, illustrated in Figure 2.2.2A, essentially involves an ester exchange reaction between the 2′-hydroxy function of the 3′-linked nucleoside residue and the 5′-hydroxy function of the 5′-linked nucleoside residue, leading to a (2′,3′)-cyclic phosphate (S.3). This intermediate then undergoes further basecatalyzed hydrolysis to give a mixture of isomeric 2′- and 3′-phosphates (S.5 and S.6, respectively). Under acidic conditions (Fig. 2.2.2B), internucleotide cleavage and migration can both occur (Griffin et al., 1968). These processes are both believed to proceed via a phosphorane intermediate (S.7; Järvinen et al., 1991). If the P-O(2′) bond is then cleaved, starting material S.2 is regenerated. If the PO(3′) bond is cleaved, the isomeric product S.8
B
O
O
O P O O
O O
B'
Figure 2.2.1
OH
O P O O
OR
1
B
O O
OR
O
UNIT 2.2
O O
B'
OH
2
Scheme showing protected 2′-hydroxy functions. B and B′ are bases.
Contributed by Colin B. Reese Current Protocols in Nucleic Acid Chemistry (2000) 2.2.1-2.2.24 Copyright © 2000 by John Wiley & Sons, Inc.
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.1
O O
B
O
O O
O
OH
B
O
A
P
O
O
HO
O
O
O P O
3
HO
B
O
OH
5
HO
O P O O
O O
B' HO
B'
O
O
B
O
OH O
2
OH
O
OH
O P O
4
OH 6
B O
B
O 3' 2' O HO
O
B
O O
OH
P
O
O OH
5'
O
O
H3O
B' O OH
H3O
7
O P O O
O O
B
O HO
O O P O
B'
O H3O
OH
O O
B'
OH
8
2
O
B
O O O
P
HO O O
3
O O
B'
OH 4
Figure 2.2.2 Scheme showing cleavage of interribonucleotide linkages under (A) basic and (B) acidic conditions. Although only shown in panel A, the hydrolysis of S.3 can yield either the 2′-phosphate (S.5) or the 3′-phosphate (S.6) under either basic or acidic conditions.
Protection of 2′Hydroxy Functions of Ribonucleosides
with the migrated internucleotide linkage is obtained. Finally, if the P-O(5′) bond is cleaved, the (2′,3′)-cyclic phosphate S.3 is obtained. The cyclic phosphate S.3 undergoes further hydrolysis to give an isomeric mixture of the corresponding 2′- and 3′-phosphates (S.5 and S.6, respectively) under acidic as well as under basic conditions. The significance of these reactions in the context of oligo- and poly-ribonucleotide synthesis will be considered later. However, it is clearly of crucial importance that the 2′-protecting group should strictly satisfy the above criteria (1) and (2). As will become apparent, this is a very demanding requirement, as the 2′-pro-
tecting group must also be fully compatible with the groups that are used to protect the 5′-terminal hydroxy function, the base residues, and the internucleotide linkages. It is therefore appropriate to consider these other protecting group requirements at the outset.
Protection of the 5′-Terminal Hydroxy Function Figure 2.2.3 illustrates a number of groups (R′ in S.9) used to protect the 5′-terminal hydroxy function. Although a good deal of work has been carried out on the synthesis of oligoribonucleotides in solution, most of the recent studies in this area have been concerned with
2.2.2 Current Protocols in Nucleic Acid Chemistry
R'O
B
O O
Ph
Ph C
R
OMe O
OR
9
10a, R = H (MMTr) 10b, R = OMe (DMTr)
CHBr2
O O
11 (Px)
O O
O
O 12 (Fmoc)
Figure 2.2.3
13 (Lev)
14 (Dbmb)
S
O
15 (Ptmt)
Several protecting groups for 5′-terminal hydroxy functions.
solid-phase synthesis. The 5′-terminal protecting group (R′) that has been used most widely for this purpose is the (di-p-anisyl)phenylmethyl group (also known as 4,4′-dimethoxytrityl or DMTr; S.10b; Schaller et al., 1963; UNIT 2.3). The 9-phenylxanthen-9-yl (pixyl or Px, S.11) group has very similar properties to the DMTr group and is equally suitable (Chattopadhyaya and Reese, 1978). The somewhat less labile p-anisyl(diphenyl)methyl group (4-monomethoxytrityl or MMTr; S.10a; Schaller et al., 1963) has also been used, but its greater stability to acid makes it generally less suitable. The great advantage of the DMTr (S.10b) and Px (S.11) protecting groups in solid-phase synthesis, and perhaps also in solution-phase synthesis, is that they can be rapidly and quantitatively removed by treatment with acids, such as diand tri-chloroacetic acids, in anhydrous dichloromethane solution (Sproat and Gait, 1984). A further advantage shared by all three of these protecting groups is that with acid treatment they give rise to colored carbocations that can easily be assayed spectrophotometrically. This permits coupling efficiencies to be monitored. Clearly, if one of these three protecting groups is used in oligoribonucleotide synthesis, the 2′-protecting group (R in formula S.9) must be completely stable under the acidic conditions required for 5′-deprotection. Numerous other 5′-protecting groups have been suggested (Sonveaux, 1994; UNIT 2.3), some of which are removable under mildly basic or virtually neutral conditions. Protecting groups in this latter category include 9-fluorenylmethoxycarbonyl (Fmoc; S.12; Pathak and
Chattopadhyaya, 1985), levulinyl (Lev; S.13; van Boom and Burgers, 1976), 2-(dibromomethyl)benzoyl (Dbmb; S.14; Chattopadhyaya et al., 1979), and 2-(isopropylthiomethoxymethyl)benzoyl (Ptmt; S.15; Brown et al., 1989a). None of these protecting groups has found widespread use in the solidphase synthesis of RNA sequences, but some have proved to be useful in solution-phase synthesis.
Protection of Base Residues The protection of base residues is illustrated in Figure 2.2.4. In the solid-phase synthesis of RNA sequences (Rao et al., 1993), adenine, cytosine, and guanine residues are generally protected by N-acylation (as in S.16, S.18, and S.19, respectively), while uracil residues are left unprotected (as in S.23; UNIT 2.1). The N-acyl protecting groups are usually removed by ammonolysis in the step before the removal of the 2′-protecting groups. As RNA can undergo internucleotide cleavage (Fig. 2.2.2A) under ammonolytic conditions, the base-protecting groups must be removable using conditions under which the 2′-protecting groups are completely stable. Thus, the choice of an N-acyl protecting group for a particular base residue is, to some extent, dependent on the 2′-protecting group used. The dimethylaminomethylene protecting group, which is also removable under ammonolytic conditions, has been recommended for the protection of adenine and guanine residues (as in S.17 and S.20, respectively; Vinayak et al., 1992). Particularly in the solution-phase synthesis of RNA sequences, it may be desir-
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.3 Current Protocols in Nucleic Acid Chemistry
O
O HN N N
N
R N
N
N
N
HN
NMe2
N
N
N O
N
NH
N
N
N
18
17
16
O
R
O
N H
R
19 O
O N N
NH N
N
N
N
NMe2
OAr
HN
N N
N H
N
R
21
O
O
N
O
N
20
O
O R
N
N H
N
R
O NO2
N O
24
O
N
22
N
N N
23
NPh2
O
OAr N
N
OH
26
25
OH
27
Figure 2.2.4 Several protecting groups for base residues (A: S.16 and S.17; C: S.18; G: S.19 to S.22; U: S.23 to S.25). S.26 and S.27 are used in oximate treatment for the removal of aryl (Ar) groups.
able to protect guanine residues on O6 as well as on N2 (as in S.21 and S.22). Aryl protecting groups are particularly suitable for this purpose (as in S.21; Ar = 2-nitrophenyl, 3-chlorophenyl, and 3,5-dichlorophenyl; Jones et al., 1981; Reese and Skone, 1984; Brown et al., 1989a); they may readily be removed by treatment with the N1,N1,N3,N3-tetramethylguanidinium salt of (E)-2-nitrobenzaldoxime S.26 or of (E)pyridine-2-carboxaldoxime S.27 (oximate treatment; Reese and Zard, 1981) before the ammonolytic removal of the N-acyl protecting groups. The N,N-diphenylcarbamoyl group (as in S.22; Kamimura et al., 1984) is removable by ammonolysis (UNIT 2.1). In the solution-phase synthesis of RNA sequences, it may also be desirable to protect
O
NC
B
O
O O
Protection of 2′Hydroxy Functions of Ribonucleosides
28
Figure 2.2.5 group.
Protection of Internucleotide Linkages Virtually all of the groups commonly used to protect the internucleotide linkages in both solid- and solution-phase oligo- and poly-ribonucleotide synthesis are removed under basic conditions (Fig. 2.2.5). The 2-cyanoethyl group (as in S.28; Sinha et al., 1983) is by far
O
O OR O P O O
uracil residues on O4 with an aryl group (as in S.24; Ar = 2,4-dimethylphenyl; Jones et al., 1981) or on N3 with an acyl group (as in S.25; R = 4-MeO.C6H4; Kamimura et al., 1984). O4-Aryl and N3-acyl protecting groups may be removed from uracil residues by oximate treatment and by ammonolysis, respectively (UNIT 2.1). It should be noted that the ammonolytic and oxime treatment conditions are both basic.
O
OR
O P O O
B'
O
Cl OR
O 29
O
B
O
B'
B
O
O OR ArS P O O O O
OR
B'
OR
30
Several protecting groups for internucleotide linkages. Ar is phenyl or another aryl
2.2.4 Current Protocols in Nucleic Acid Chemistry
the most commonly used protecting group for the internucleotide linkages in the solid-phase synthesis of RNA sequences, and the 2-chlorophenyl group (as in S.29; Reese, 1970) has been widely used for this purpose in solutionphase synthesis. Another approach to the synthesis of oligoribonucleotides was pioneered by Hata and co-workers (Honda et al., 1984) and involves intermediate S-aryl phosphorothioates (S.30, Ar = Ph). 2-Cyanoethyl protecting groups are usually removed at the same time as N-acyl base-protecting groups by treatment with ammonia (Sinha et al., 1983). 2-Chlorophenyl-protected oligo- and poly-ribonucleotides are best unblocked by treatment with the conjugate base of (E)-2-nitrobenzaldoxime S.26 or (E)-pyridine-2-carboxaldoxime S.27 (Reese et al., 1978; Reese and Zard, 1981). S-Aryl phosphorothioates (S.30), which are masked phosphodiesters, may also be unblocked by oximate treatment (Kamimura et al., 1984). In order to avoid internucleotide cleavage (Fig. 2.2.2A), it is necessary that the 2′-protecting group (R in S.28, S.29, and S.30) should be completely stable under the basic conditions used in the unblocking of the internucleotide linkages.
tions required to remove the 5′-terminal DMTr protecting group S.10b. The 2′-protecting groups must also be stable under the basic conditions (i.e., concentrated aqueous ammonia and oximate ions) required to unblock the base residues and the internucleotide linkages. It is further desirable that 2′-protecting groups not be excessively bulky and thereby impede the coupling process. For the successful removal of the 2′-protecting groups, it must always be borne in mind that RNA is a very sensitive material that is unstable under both acidic and basic conditions and in the presence of various hydrolytic enzymes. It is therefore desirable that manipulation should be kept to a minimum in the isolation of fully unblocked RNA.
Ether Protecting Groups The protection of the 2′-hydroxy functions as readily cleavable ether groups would appear at first sight to be an attractive proposition. Indeed, the possibility of using the benzyl protecting group was first examined over 30 years ago (Griffin et al., 1966). Uridine was converted into its 2′-O-benzyl derivative S.31, which was then successfully converted via the protected dinucleoside phosphate S.32 into uridylyl(3′→5′)-uridine (S.33; Fig. 2.2.6). The benzyl protecting group, which is stable both to acidand base-catalyzed hydrolysis, was removed by catalytic hydrogenolysis in the presence of palladized charcoal. However, it was subsequently reported that concomitant hydrogenation of the uracil 5,6-double bond can occur (Reitz and Pfleiderer, 1975). There is also a danger that the total removal of all of the 2′-protecting groups of per-2′-O-benzylated RNA sequences may not always be possible. The 2-nitrobenzyl group (as in S.34; Fig. 2.2.7), which was introduced by Ikehara and
PROTECTION OF THE 2′-HYDROXY FUNCTION IN OLIGORIBONUCLEOTIDE SYNTHESIS It is clear from the above discussion that the requirements for a 2′-protecting group in oligoand polyribonucleotide synthesis are very demanding indeed. With regard to solid-phase synthesis, in addition to meeting the above general criteria for protecting groups, it is crucially important that 2′-protecting groups be stable to repeated exposure to the acidic condi-
Me3C O
N
O HO
Ura
O
HO
O
O
OBn
O P O O
O
Ura
O
O
H
OMe
32
31
OH
O
O
Ura
O
O NH
HO
O
O P O O
O HO
Ura
OH
33
Ura = uracil-1-yl Bn = PhCH2
Figure 2.2.6 uridine.
Scheme showing the preparation of uridylyl-(3′→5′)-uridine from 2′-O -benzyl (Bn)-
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.5 Current Protocols in Nucleic Acid Chemistry
O
B
O O O O P O O
O
O
B OMe
O O O P O
NO2
R
O 35a, R = H 35b, R = OMe
34
Figure 2.2.7 The 2-nitrobenzyl (S.34), 4-methoxybenzyl (S.35a), and 3,4-dimethoxybenzyl (S.35b) protecting groups.
co-workers (Ohtsuka et al., 1978), is potentially a more useful 2′-protecting group. Like the benzyl group, it is stable both to acid- and base-catalyzed hydrolysis. However, it may be cleaved photochemically by irradiation with ultraviolet light (λ > 280 nm). It was later reported that photolytic cleavage of the 2-nitrobenzyl protecting group proceeds more efficiently in slightly acidic (pH 3.5) 0.1 mol dm−3 ammonium formate solution (Hayes et al., 1985). A serious drawback to the use of the 2-nitrobenzyl protecting group is that the photolytic cleavage reaction does not always proceed quantitatively (Ohtsuka and Iwai, 1987), especially in the unblocking of relatively highmolecular-weight RNA sequences. Takaku and co-workers have used the 4methoxybenzyl (as in S.35a; Takaku and Kamaike, 1982; Takaku et al., 1984) and 3,4dimethoxybenzyl (S.35b; Takaku et al., 1986) groups to protect 2′-hydroxy functions in solution-phase oligoribonucleotide synthesis. The 4-methoxybenzyl protecting groups were removed from a hexaribonucleoside pentaphosphate (Takaku et al., 1984) by treatment for 3 hr at room temperature with a reagent prepared by adding triphenylmethyl tetrafluoroborate (∼0.10 mmol/mL) to acetonitrile/water (4:1 v/v). However, Takaku et al. (1986) reported that incomplete unblocking and some cleavage of the glycosidic linkages can occur under these presumably rather acidic conditions. Some cleavage and migration of the internucleotide linkages might also be expected to occur. The 3,4-dimethoxybenzyl protecting group may be
removed (Takaku et al., 1986) under somewhat milder conditions by treatment with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in wet dichloromethane; this group would appear to be potentially more promising than the 4-methoxybenzyl group for the protection of the 2′-hydroxy functions in oligoribonucleotide synthesis.
The tert-Butyldimethylsilyl Protecting Group The tert-butyldimethylsilyl group (TBDMS; as in S.37 and S.38; Fig. 2.2.8) was originally suggested by Stork and Hudrlik (1968) for the protection of enols, and was first used by Corey and Venkateswarlu (1972) for the protection of alcoholic hydroxy functions. Ogilvie and coworkers (Ogilvie et al., 1974) then introduced it as a protecting group for the 2′-hydroxy functions of ribonucleoside building blocks. The TBDMS group is at present the most widely used 2′-protecting group in solid-phase oligoribonucleotide synthesis (Damha and Ogilvie, 1993). It meets some but by no means all of the above general requirements for protecting groups. It may be readily introduced (Usman et al., 1987), for example, by treating a 5′-O-DMTr-ribonucleoside derivative (S.36) with tert-butylchlorodimethylsilane and imidazole in N,N-dimethylformamide (DMF) solution (Fig.2.2.8). Although the regiochemistry of the silylation reaction can be controlled to some extent (Hakimelahi et al., 1982), a mixture of 2′- and 3′-isomers (S.37 and S.38, respectively) is in-
DMTrO DMTrO
O
B
HO
Protection of 2′Hydroxy Functions of Ribonucleosides
36
Figure 2.2.8 group.
OH
DMTrO
O 3'
2'
Me2Si(t-Bu)Cl imidazole
B
O
HO O Me Si Me t-Bu 37
B
OH O Me Si Me t-Bu 38
Scheme showing introduction of the tert-butyldimethylsilyl (TBDMS) protecting
2.2.6 Current Protocols in Nucleic Acid Chemistry
AcO
O
Ade
AcO
O
Ade
OH O Me Si Me t-Bu
HO
O Me Si Me t-Bu 39
40 Ade = adenin-9-yl
Figure 2.2.9 Scheme showing the interconversion of the 2′-O - (S.39) and 3′-O - (S.40) TBDMS adenosine derivatives.
variably obtained. Fortunately, such isomeric mixtures can usually be separated by chromatography on silica gel. However, great care has to be taken in the purification and isolation of the 2′-protected ribonucleoside building blocks (S.37), as the TBDMS group readily migrates from the 2′- to the 3′-hydroxy function and vice versa. Interconversion between the adenosine derivatives S.39 and S.40 (Fig. 2.2.9) was found to be a base-catalyzed first-order equilibration reaction (Jones and Reese, 1979). Equilibration rates were observed to be the same in both directions, and the equilibrium constant was estimated to be 1.0. The half time (t1/2) for equilibration in anhydrous pyridine solution at 36°C was 19 hr. The equilibration rate was increased by a factor of 3.0 when 0.1 mol equiv. (with respect to substrate) of benzylamine (pKa 9.34) was added. Equilibration was faster still (t1/2 = ∼1 hr at 36°C) in methanol-d4 solution without added base. When 0.1 mol equiv. of triethylamine (pKa 10.87) was added to the methanol-d4 solution at 20°C, equilibration was complete within ∼5 min. Precautions must be taken to avoid migration of the TBDMS protecting group during the purification and isolation of 2′-O-TBDMS-5′O-DMTr-ribonucleoside derivatives (S.37) and during the course of their conversion into the required monomeric building blocks. Otherwise, the resulting synthetic RNA sequences will be contaminated with material containing
DMTrO
O HO
(2′→5′)-internucleotide linkages. Thus, in the preparation of 3′-phosphoramidite building blocks (S.41; Fig. 2.2.10), it is advisable that the presence of a strong base such as diisopropylethylamine be avoided. Usman and coworkers (Scaringe et al., 1990) have recommended that a mixture of 2,4,6-collidine and 1-methylimidazole be used. Although the presence of contaminating isomeric 2′-phosphoramidites (S.42) can be detected above a certain level by 31P NMR spectroscopy, these impurities cannot readily be removed. It was recently reported that the oligoribonucleotide r[(Up)20U], prepared by treating its per-2′-O-TBDMS derivative with tetra-n-butylammonium fluoride, contained an average of 1.3% (2′→5′)-internucleotide linkages (Morgan et. al., 1995). As acid was not used either during or after the unblocking process, a reasonable explanation for this observation is that the phosphoramidite S.41 (B = uracil-1-yl) used in its synthesis was contaminated with 1.3% of its 2′-isomer (S.42; B = uracil-1-yl). Using an analytical procedure similar to that described by Morgan et al., it was later concluded that some commercially supplied 2′-OTBDMS-protected ribonucleoside phosphoramidites (S.41) were contaminated with comparable amounts (i.e., >1%) of isomeric 2′-phosphoramidites (S.42; Reese et al., unpub. observ.). However, some other batches of commercially supplied material were estimated to contain smaller quantities of the corresponding
DMTrO
B
OTBDMS
NC
B
O
i O
OTBDMS
B
O
TBDMSO
O
O P N(i-Pr)2
37
DMTrO
41
P O
CN
(i-Pr)2N 42
Figure 2.2.10 Scheme showing conversion of 2′-O -TBDMS-5′-O -DMTr-ribonucleoside into its corresponding 3′-phosphoramidite (S.41) and the structure of the possibly contaminating isomeric 2′-phosphoramidite (S.42). Reagents (i): NCCH2CH2OPN(i-Pr)2Cl, base.
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.7 Current Protocols in Nucleic Acid Chemistry
2′-isomer (S.42; Reese et al., unpub. observ.). It would therefore appear that migration of the TBDMS group can to a large extent be controlled if careful manufacturing protocols are observed. The use of the TBDMS protecting group in the solid-phase synthesis of RNA sequences can lead to long coupling times and unsatisfactory coupling efficiencies, possibly due to the bulk of this protecting group. However, the use of 5-ethylthio-1H-tetrazole (S.43b; Fig. 2.2.11) instead of 1H-tetrazole (S.43a) as the phosphoramidite activator can result in shorter coupling times and higher quality products (Sproat et al., 1995; UNIT 3.5). One important advantage of the TBDMS protecting group is that it appears to be stable under the acidic conditions used to remove the 5′-terminal DMTr protecting group in solid-phase synthesis. Problems have arisen in the unblocking of 2′-O-TBDMS-protected RNA sequences. The standard unblocking procedure used in the solid-phase synthesis of DNA sequences involves heating the fully loaded solid support with concentrated aqueous ammonia at 55°C overnight (Brown and Brown, 1991). These ammonolytic conditions lead to the release of the oligodeoxyribonucleotides from the solid support, the removal of the 2-cyanoethyl protecting groups from the internucleotide linkages, and the removal of N-acyl protecting groups from the base residues (in oligodeoxyribonucleotide synthesis, the adenine and cytosine residues are usually protected with benzoyl groups as in S.16 and S.18, R = Ph, and the guanine residues are usually protected with isobutyryl groups as in S.19, R = Me2CH). If these ammonolysis conditions are also used in the unblocking of 2′-O-TBDMS-protected oligoribonucleotides, appreciable loss of the 2′O-TBDMS protecting groups and concomitant cleavage of the internucleotide linkages are likely to occur (Stawinski et al., 1988). This problem of premature removal of 2′-OTBDMS protecting groups has been largely
N N N N H 43a, R = H 43b, R = SEt R
Protection of 2′Hydroxy Functions of Ribonucleosides
Et3N • 3HF
44
Figure 2.2.11 Phosphoramidite activators 5ethylthio-1H-tetrazole (S.43b) and 1H-tetrazole (S.43a), and the unblocking reagent triethylamine trihydrofluoride (S.44).
overcome by protecting the base residues with more labile acyl groups (Chaix et al., 1989), and by replacing concentrated aqueous ammonia with a more selective reagent such as 35% aqueous ammonia/ethanol (3:1 v/v) ammonia/ethanol (Mullah and Andrus, 1996), anhydrous ethanolic ammonia (Goodwin et al., 1994), or aqueous methylamine (Wincott et al., 1995). Téoule and co-workers (Chaix et al., 1989) have recommended that adenine and guanine residues be protected with phenoxyacetyl groups (as in S.16 and S.19, R = CH2OPh) and that cytosine residues be acetylated (as in S.18, R = Me). These workers found that the half times for removal of the latter protecting groups in aqueous ammonia/ethanol (1:1 v/v) at room temperature ranged from 10 to 15 min. It should therefore be possible completely to unblock base residues that are protected in this way without any significant loss of the 2′-O-TBDMS protecting groups and without internucleotide cleavage. In the final unblocking step, the TBDMS protecting groups are removed from the 2′-hydroxy functions of the synthetic RNA sequences. Until recently, a solution of tetra-nbutylammonium fluoride in tetrahydrofuran (Damha and Ogilvie, 1993) was almost always used for this unblocking process. However, it has been reported that the use of the latter reagent results in an inconvenient work-up procedure and can lead to incomplete unblocking (Sproat et al., 1995). More recently, it has been suggested that triethylamine trihydrofluoride (S.44; Fig. 2.2.11; Gasparutto et al., 1992; Westman and Strömberg, 1994) is a more suitable reagent for this purpose. Both the neat reagent S.44, which is slightly acidic as evidenced by the concomitant loss of 5′-O-DMTr protecting groups (Mullah and Andrus, 1996), and a solution of S.44 and triethylamine in 1-methylpyrrolidone (Wincott et al., 1995) have been used. There now seems to be little doubt that, if the above precautions are taken and the most suitable base-protecting groups and reagents are used, the TBDMS group may be used effectively for the protection of the 2′-hydroxy functions in the solid-phase synthesis of RNA sequences. 2′-O-TBDMS-ribonucleoside 3′H-phosphonate building blocks (S.45; Fig. 2.2.12) have also been used successfully in the solid-phase synthesis of oligoribonucleotides (Rozners et al., 1994). It is reasonable to assume that the same precautions and considerations that apply to solid-phase synthesis based on phosphoramidite building blocks (S.41) should
2.2.8 Current Protocols in Nucleic Acid Chemistry
DMTrO
sequences containing one or more (2′→5′)-internucleotide linkages.
B
O
O OTBDMS O P O H 45
Figure 2.2.12 2′-O -TBDMS-ribonucleoside 3′-H-phosphonate.
be taken into account if good quality RNA sequences are to be obtained from the corresponding H-phosphonates (S.45).
Acetal Protecting Groups In general, acetal groups have several distinct advantages over the TBDMS group as far as the protection of the 2′-hydroxy functions in oligoribonucleotide synthesis is concerned. First, acetal protecting groups can usually be placed regiospecifically on the 2′-hydroxy functions (see below) and, once in position, they cannot migrate. Secondly, they are completely stable under the basic conditions that normally obtain during the unblocking of internucleotide linkages and base residues. Thirdly, the 2′-protected RNA sequences obtained after the removal of the other protecting groups (Rao et al., 1993) can be purified under neutral or basic conditions without any danger of endonuclease-promoted digestion. However, there is one important drawback to the use of acetal protecting groups in that they are generally removed by acid-catalyzed hydrolysis. Unless the acidic conditions used are particularly mild, both cleavage and migration of the internucleotide linkages can occur (Griffin et al., 1968; Capaldi and Reese, 1994; Fig. 2.2.2B). While cleavage of internucleotide linkages is clearly highly undesirable, migration is a very much more serious matter as it is virtually impossible to free even a relatively low-molecular-weight RNA sequence from contaminating isomeric
AcO
O
B
HO
B
O
i, ii OH
AcO
The tetrahydropyran-2-yl (Thp) group In the 1960s, the use of the 2′-O-tetrahydropyran-2-yl protecting group (Thp) in oligoribonucleotide synthesis was examined (Smith et al., 1962; Smrt and Šorm, 1962; Griffin and Reese, 1964). Pure 2′-O-Thp derivatives of uridine and adenosine (S.47a and S.47b, respectively) were prepared according to the procedure indicated in Figure 2.2.13, and were converted into dinucleoside phosphates by the methods then available (Griffin and Reese, 1964; Griffin et al., 1968). Careful unblocking studies were carried out in 0.01 mol dm−3 hydrochloric acid (pH 2.0) at 24°C (Griffin et al., 1968), and the half time (t1/2) for the conversion of 2′-O-Thp-UpU (S.49; Fig. 2.2.14) into completely unprotected uridylyl(3′→5′)-uridine (UpU; S.50) was found to be 29 min. It can therefore be estimated that >99.9% removal of the Thp group would occur in <5 hr under these conditions. It was also found that after UpU (S.50) had been allowed to stand in 0.01 mol dm−3 hydrochloric acid (pH 2.0) at 25°C for 216 hr, it underwent ∼99% ribonuclease A–catalyzed digestion to uridine-3′-phosphate and uridine, thereby indicating that not more than 1% isomerization to uridylyl-(2′→5′)-uridine (S.51) had occurred (Griffin et al., 1968). Under these conditions (i.e., pH 2.0, 25°C, 216 hr), UpU also underwent ∼0.5% hydrolytic cleavage (Fig. 2.2.2B). It can therefore be estimated that in the time required for >99.9% removal of the Thp protecting group from 2′-O-ThpUpU, not more than 0.02% phosphoryl migration and 0.01% internucleotide cleavage would be expected to occur. Thus, it seemed reasonable to conclude from the data then available that the Thp group was suitable for the protection of the 2′-hydroxy functions in oligoribonucleotide synthesis.
HO
O
O
O (Thp)
46
47
48
a, B = uracil-1-yl b, B = adenin-9-yl
Figure 2.2.13 Scheme showing preparation of 2′-O -Thp derivatives of uridine and adenosine. Reagents: (i) 3,4-dihydro-2H-pyran (S.48), toluene-4-sulfonic acid (TsOH), dioxane; (ii) NaOMe, MeOH.
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.9 Current Protocols in Nucleic Acid Chemistry
HO
O
Ura
HO
O OThp O P O O
Ura
HO
O
O HO
OH
49
Ura
O HO
O OH O P O
H3O Ura
O HO
O
Ura
O O P O O
OH
HO
O
Ura
OH
51
50
Ura = uracil-1-yl
Figure 2.2.14 Scheme showing conversion of 2′-O -Thp-UpU into unprotected uridylyl-(3′→5′)uridine (S.50) and the structure of its (2′→5′)-isomer (S.51).
A particular disadvantage of the Thp group is that it is chiral, and therefore its use in the protection of ribonucleoside derivatives and other chiral compounds leads to mixtures of diastereoisomers. Thus, two diastereoisomers each of 2′-O-Thp-uridine (S.47a) and 2′-OThp-adenosine (S.47b) were obtained (Fig. 2.2.13; Griffin et al., 1968). Although both pairs of diastereoisomers were easily separable and all four compounds were obtained as pure crystalline solids, this is clearly an undesirable complication. The 4-methoxytetrahydropyran-4-yl (Mthp) group A search for an achiral alternative to the Thp protecting group led to the introduction of the 4-methoxytetrahydropyran-4-yl group (Mthp; Reese et al., 1967; 1970). 2′-O-Mthp derivatives of ribonucleosides (S.54) were first prepared from 3′,5′-di-O-acyl-ribonucleosides (S.53; Fig. 2.2.15). However, they are more
R
conveniently prepared from the corresponding 3′,5′-O-(1,1,3,3-tetraisopropyl- disiloxan-1,3diyl) derivatives (S.56; Brown et al., 1989a). 2′-O-Mthp derivatives (S.54) are usually obtained as pure crystalline solids in satisfactory to good yields (Reese et al., 1970). The half times for the hydrolysis of 2′-OMthp-uridine and 2′-O-Mthp-adenosine (S.54, B = uracil-1-yl and adenosine-9-yl, respectively) in 0.01 mol dm−3 hydrochloric acid at 22°C were found to be 18.7 and 34 min, respectively (Norman et al., 1984). It is interesting to note that the removal of the Mthp protecting group from 2′-O-Mthp-uridylyl-(3′→5′)-uridine (S.57a) and 2′-O-Mthp-adenylyl-(3′→5′)adenosine (S.57b; Fig. 2.2.16) under the same conditions was found to proceed at significantly faster rates (t1/2 = 6.1 and 19.9 min, respectively; Norman et al., 1984). The rate of removal of the Thp protecting group from 2′O-Thp-UpU (S.49) is also faster than from 2′-O-Thp-uridine (S.47a; Griffin et al., 1968).
B
O
O
O R'
O
O HO
OH
i, ii
O 53
B
HO
OH
B
HO
HO
iii
OMe
O O
OMe O
i, iv
52
O (i-Pr)2Si O (i-Pr)2Si O
B
O
55
O 54
(Mthp)
OH
56
Protection of 2′Hydroxy Functions of Ribonucleosides
Figure 2.2.15 Scheme showing preparation of 2′-O -Mthp ribonucleoside derivatives (S.54) via 3′,5′-di-O-acyl-ribonucleosides (S.53) or 3′,5′-O-(1,1,3,3-tetraisopropyldisiloxan-1,3-diyl) derivatives (S.56). Reagents: (i) 4-methoxy-5,6-dihydro-2 H-pyran (S.55), toluene-4-sulfonic acid (TsOH), dioxane; (ii) NH3, MeOH; (iii) (i-Pr)2Si(Cl)OSi(Cl)(i-Pr)2, imidazole, MeCN; (iv) Et4NF, MeCN.
2.2.10 Current Protocols in Nucleic Acid Chemistry
HO
O
B
HO
O
O OMthp O P O O
O HO
B
O
OH
O P O
H3O B
O
OH
O HO
57
B
OH
58
a, B = uracil-1-yl b, B = adenin-9-yl
Figure 2.2.16
Scheme illustrating the removal of the Mthp protecting group.
The fact that the presence of a vicinal phosphodiester internucleotide linkage appears to facilitate the acid-catalyzed unblocking of a 2′-O-Mthp- or 2′-O-Thp-protected hydroxy function is clearly advantageous if migration and cleavage of the internucleotide linkages (Fig. 2.2.2B) in the final unblocking step of oligoribonucleotide synthesis are to be kept to a minimum. As well as being achiral, Mthp has an additional advantage over Thp in that it is more labile to acidic hydrolysis. The Mthp and Thp protecting groups have been used in both solution- and solid-phase synthesis of RNA sequences. The Mthp group was introduced particularly for solution-phase synthesis, and it has been used successfully in the preparation of the 3′-terminal decamer, nonadecamer, and heptatriacontamer (37-mer) sequences (r[UpCpGpUpCpCpApCpCpA], r[ApUpUpCpCpGpGpApCpUpCpGpUpCpCpApCpCpA], and r[GpGpApGpApGpGpUpCpUpCpCp GpGpTpψpCpGpApUpUpCpCpGpGpApCpUpCpGpUpCpCpApCpCpA], respectively) of yeast alanine transfer RNA (tRNAAla; Jones et al., 1980, 1983; Brown et al., 1989a,b). This work has already been reviewed (Reese, 1989). The tetrahydrofuran-2-yl (Thf) and 1,5dimethoxycarbonyl-3-methoxypentan-3-yl (Mdmp) groups The above approach to the solution-phase synthesis of RNA sequences was successful largely because treatment with acid was completely avoided until the final unblocking step. However, other workers (Ohtsuka et al., 1984) reported a solution-phase block synthesis of a tritriacontamer (33-mer) sequence of E. coli tRNA2Gly using tetrahydrofuran-2-yl (Thf; S.59; Fig. 2.2.17) and DMTr groups for the protection of the 2′- and 5′-hydroxy functions, respectively. The 5′-terminal DMTr protecting groups were removed by treatment with zinc
bromide in dry dichloromethane/isopropanol solution rather than with a protic acid. Although Thf is more labile than Thp (and probably also Mthp) to acid-catalyzed hydrolysis (Kruse et al., 1979), the latter combination of protecting groups was apparently effective. There are a number of reports in the literature relating to solid-phase RNA synthesis in which the 2′-hydroxy functions are protected by Thp, Mthp, or Thf groups and the 5′-hydroxy functions are also protected with acid-labile groups (Tanaka et al., 1986; Kierzek et al., 1986; Iwai et al., 1987; Tanimura et al., 1989; Tanimura and Imada, 1990). Such acid-labile groups include DMTr (S.10b), 9-phenylxanthen-9-yl (S.11), and 9-(4-methoxyphenyl)xanthen-9-yl (S.60; Fig. 2.2.17; UNIT 2.3). Although some sequences appear to have been prepared successfully in this way, other reports suggest that this is an unsound strategy, particularly for the synthesis of comparatively high-molecular-weight RNA sequences (Reese and Skone, 1985; Christodoulou et al., 1986; Kierzek, 1994). Even when precautions are taken to maintain stringently anhydrous conditions, the repeated exposure of the growing protected oligoribonucleotide to di- or tri-chloroacetic acid in order to remove the 5′-protecting group in each synthetic cycle is likely to lead to some loss of such relatively labile 2′-
MeO
O
O
59
60
Figure 2.2.17 Tetrahydrofuran-2-yl (S.59) and 9-(4-methoxyphenyl)xanthen-9-yl (S.60) protecting groups.
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.11 Current Protocols in Nucleic Acid Chemistry
O O (Lev)
B
O
HO
B
O
O NC
O
OThf
i
NC
O P O O
B
O O
O O
(Fmoc) NC
O
OThf
O
61
O
OThf
O P O B
OThf
62
O
B
O
HO
O
B
O
ii O
OMthp
NC
O P O O
O O
B
OMthp
63
O
OMthp
O P O O
O O
B
OMthp
64
Figure 2.2.18 Scheme showing removal of levulinyl (top) and Fmoc (bottom) protecting groups. Reagents: (i) N2H4⋅H2O, C5H5N, AcOH; (ii) 0.1 M 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), MeCN.
Protection of 2′Hydroxy Functions of Ribonucleosides
protecting groups, resulting both in cleavage and migration of internucleotide linkages (Pathak and Chattopadhyaya, 1985; Reese and Skone, 1985; Kierzek, 1994). If Thp, Mthp, or Thf groups are to be used to protect the 2′-hydroxy functions, it would appear to be a better strategy in solid-phase synthesis to protect the 5′-terminal hydroxy function with a group that is readily removable under virtually neutral or mildly basic conditions. Thus, following van Boom’s use of the levulinyl group (as in S.61; Fig. 2.2.18) for the protection of the 5′-hydroxy functions in solution-phase synthesis (den Hartog et al., 1981), other workers (Iwai and Ohtsuka, 1988) successfully used Lev in conjunction with Thf in solid-phase oligoribonucleotide synthesis. The Lev group was removed (Fig. 2.2.18) in the usual way (den Hartog et al., 1981) by treatment with hydrazine hydrate in pyridine/acetic acid solution. A number of RNA sequences, including a heneicosamer (21mer), were prepared in this way. In another study (Lehmann et al., 1989), the Fmoc group (S.12) was used to protect the 5′-hydroxy functions in solid-phase oligoribonucleotide synthesis. These workers protected the 2′-hydroxy functions with Mthp groups (as in S.63) and removed the Fmoc group with 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU) in acetonitrile solution (Fig. 2.2.18). As the authors (Lehmann
et al., 1989) pointed out, it is very likely that some concomitant loss of the 2-cyanoethyl protecting groups from the partially protected oligoribonucleotides (S.63) occurs during DBU treatment. A nonadecamer and an icosamer (20-mer) RNA sequence were prepared successfully in this way. Although the above approach using either 2′-O-Thf and 5′-O-Lev protection or 2′-OMthp and 5′-O-Fmoc protection (Fig. 2.2.18) was successful, it is much more convenient to use the acid-labile DMTr (S.10b) or Px (S.11) groups to protect the 5′-hydroxy functions in solid-phase RNA synthesis. The latter modified trityl groups can be rapidly and quantitatively removed under anhydrous conditions and the released carbocations can easily be assayed spectrophotometrically (Brown and Brown, 1991). For this reason, attempts have been made to develop somewhat more sophisticated acetal protecting groups that are stable under normal “detritylation” conditions and are also sufficiently labile to acidic hydrolysis in the final unblocking step for cleavage and migration of the internucleotide linkages (Fig. 2.2.2B) to be avoided. Chattopadhyaya and co-workers (Sandström et al., 1985) showed that the 1,5-dimethoxycarbonyl-3-methoxypentan-3-yl (Mdmp) group (as in S.65; Fig. 2.2.19), derived from dimethyl 4-ketopimelate, was
2.2.12 Current Protocols in Nucleic Acid Chemistry
HO
B
O HO
HO
OMe
O
CO2Me
concentrated aqueous NH3
B
O HO
O
OMe
CO2Me
CONH 2 CONH 2
(Mdmp) 66
65
X
O
OMe O
O
B
O
Thy O
O
OMe
HO 67a, X = O 67b, X = S 67c, X = SO2
Figure 2.2.19
O
B
O
H O
O
N
NAr 68
OMe H Ar
69
Thy = thymin-1-yl Ar = aryl
Acetal protecting groups labile to acidic hydrolysis.
converted under the standard ammonolytic unblocking conditions used in solid-phase synthesis into the corresponding bis-amide (S.66), which was seventeen times more labile to acidic hydrolysis than the bis-ester (S.65). However, the Mdmp protecting group itself is unlikely to find application in solid-phase synthesis of oligoribonucleotides as it undergoes hydrolysis in 4:1 (v/v) acetic acid/water solution even more rapidly than the Mthp group.
The 1-Aryl-4-methoxypiperidin-4-yl (Ctmp and Fpmp) groups Acetal hydrolysis is a second-order reaction; its rate, which is proportional to the concentrations both of substrate and hydrogen ions, is very sensitive to inductive effects (Kreevoy and Taft, 1955). Thus 5′-O-(4methoxytetrahydrothiopyran-4-yl)-thymidine (S.67b; Fig. 2.2.19) was found to be ∼5 times more labile to acidic hydrolysis than the corresponding Mthp derivative (S.67a) and was estimated to be >2000 times more labile than the corresponding sulfone (S.67c; van Boom et al., 1972). It seemed possible that, if the aryl substituent Ar were selected carefully, a 1-aryl-4methoxypiperidin-4-yl protecting group (as in S.68) could be identified that would be almost fully protonated (as in S.69) under detritylation conditions (i.e., in dichloromethane containing, for instance, 2% to 3% trichloroacetic
acid), but would be virtually unprotonated (as in S.68) under the milder conditions of acidic hydrolysis obtaining in the final unblocking step of oligoribonucleotide synthesis. Although it would, of course, depend on the aryl substituent, it seemed possible that the rate of hydrolysis of the unprotonated and protonated piperidinyl species might correspond approximately to those of the Mthp (S.67a) and sulfone (S.67c) derivatives, respectively. In the overall rate expression for the hydrolysis of a 1-aryl4-methoxypiperidin-4-yl derivative, it is reasonable to assume that the component relating to the hydrolysis of the conjugate acid S.69 is likely to be negligible in comparison with that relating to the unprotonated S.68 and that, as a first approximation, it can be ignored. If this is the case, the observed rate of hydrolysis of the 1-aryl-4-methoxypiperidin-4-yl acetal system should be pH independent. For example, if the pH of the hydrolytic medium is lowered by one unit, the concentration of the unprotonated acetal S.68 will decrease by an order of magnitude, and at the same time the rate of hydrolysis of the remaining unprotonated acetal will increase by an order of magnitude. Despite the very limited synthetic methodology available at the outset, it was possible to prepare 2′-O-[1-(2-chloro-4-methylphenyl)-4methoxypiperidin-4-yl] (Ctmp) ribonucleoside derivatives (S.71a; Fig. 2.2.20A) and
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.13 Current Protocols in Nucleic Acid Chemistry
A B
O
HO
O
(i-Pr)2Si O (i-Pr)2Si O
OH
B
O
i, ii HO
O
OMe R
1
N
56
2
R 71
B O Cl
O
iii Cl
Cl
Cl
72
MeO
OMe
OMe
73 iv
N
v R
N
1
1
R
NH2 R
1 2
R
2
2
R
R
75
70
74 1
2
a, R = Cl, R = Me 1 2 b, R = F, R = H
Figure 2.2.20 (A) Scheme showing preparation of Ctmp (S.71a) and Fpmp (S.71a) ribonucleoside derivatives. (B) Preparation of the 1-aryl-4-methoxy-1,2,5,6-tetrahydropyridines (S.70) required in (A). Reagents (i) S.70, CF3CO2H, CH2Cl2; (ii) Et4NF, MeCN; (iii) ethylene, AlCl3, CH2Cl2; (iv) toluene-4-sulfonic acid monohydrate (TsOH⋅H2O), MeOH, and reflux followed by (MeO)3CH; (v) (i-Pr)2NEt, Et2O→BF3, CH2Cl2, 0°C.
Protection of 2′Hydroxy Functions of Ribonucleosides
show that the Ctmp protecting group had the desired properties (Reese et al., 1986). Thus it can be seen from Figure 2.2.21 that the rate of hydrolysis of 2′-O-Ctmp-uridine (S.71a, B = uracil-1-yl) at 30°C is only 1.75 times faster at pH 0.5 than it is at pH 2.5. At 25°C, 2′-O-Ctmpuridine is ∼40 times more stable than 2′-OMthp-uridine (S.54, B = uracil-1-yl) at pH 1.0 (Reese et al., 1986), but it is nearly 1.6 times more labile than 2′-O-Mthp-uridine at pH 3.0. The first general criterion that all protecting groups should meet (see above) is that they should be easy to introduce, and an important part of this criterion is that the reagent required should be readily accessible. The Ctmp and related piperidine-derived protecting groups are easy to introduce, but until recently the preparation of the enol ether reagents (such as S.70) involved a number of steps. However, these 1-aryl-4-methoxy-1,2,5,6-tetrahydropyridine derivatives can now be readily prepared (Fig. 2.2.20B) in two steps and in good overall yields (Faja et al., 1997) from 1,5-dichloropentan-3-one (S.73; Owen and Reese, 1970) and the appropriate primary aromatic amine (S.74). The procedure for the preparation of 2′-O-(1-aryl-4-methoxypiperidin-4-yl) ribonucleoside derivatives (such as S.71; Fig.
Figure 2.2.21 Dependence of half times (t1/2) on pH for hydrolysis of 2′-O -Ctmp-uridine (S.71a) and 2′-O -Fpmp-uridine (S.71b) at 30°C.
2.2.14 Current Protocols in Nucleic Acid Chemistry
PxO
O
NC
B
O
DMTrO
OCtmp
N(i-Pr)2
77
Ctmp-protected phosphoramidite (S.76) and H-phosphonate (S.77).
2.2.20A; Rao et al., 1987, 1993) is closely similar to that used in the preparation of the corresponding 2′-O-Mthp derivatives (S.54; Fig. 2.2.15), except that a much smaller excess of the enol ether reagent S.70 is needed. The 2′-O-Ctmp protecting group was used in conjunction with the 5′-O-Px protecting group (Rao et al., 1987) or the 5′-O-DMTr protecting group (Sakatsume et al., 1989) in the solid-phase synthesis of oligoribonucleotides. Phosphoramidite building blocks (S.76; Fig. 2.2.22) were successfully used in the preparation of the 3′-terminal nonadecamer sequence r[ApUpUpCpCpGpGpApCpUp CpGpUpCpCpApCpCpA] of yeast tRNA Ala (Rao et al., 1987), and H-phosphonate building blocks (S.77) were used successfully in the preparation of the octadecamer sequence, r[ApGpUpApUpApApGpApGpGpApCpApUp ApUpG] (Sakatsume et al., 1989). However, the required enol ether reagent (S.70) was difficult to prepare by the original procedure (Reese et al., 1986), and its preparation by the improved protocol (Fig. 2.2.20B; Faja et al., 1997) involves either the use of an expensive aromatic amine (S.74a) or an additional chlorination step. It was later found that several other 1-aryl4-methoxypiperidin-4-yl groups were also suitable for the protection of the 2′-hydroxy functions in solid-phase oligoribonucleotide synthesis. Among these is the 1-(2fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) protecting group (as in S.71b; Reese and Thompson, 1988). The Fpmp protecting group has two distinct advantages over the Ctmp group. First, the enol ether reagent S.70b,
PxO
NC
B
OCtmp O O P O Et3NH H
O P 76
Figure 2.2.22
O
B
O O
OFpmp
O P
which is a low-melting solid, is readily prepared (Faja et al., 1997) from 2-fluoroaniline (S.74b), which is an inexpensive starting material. Secondly, the Fpmp group is somewhat more stable than the Ctmp group to acidic hydrolysis in the pH range of 0.5 to 1.0 (∼1.4 times at 30°C; Fig. 2.2.21), and therefore the risk of concomitant 2′-unblocking in the detritylation steps is even smaller. However, removal of the 2′-O-Fpmp protecting group occurs more slowly than removal of the 2′-OCtmp group in the final unblocking step of oligoribonucleotide synthesis, and this can be disadvantageous (see below). It can be seen from Figure 2.2.21 that at 30°C the rate of hydrolysis of 2′-O-Fpmp-uridine (S.71b; B = uracil-1-yl) is only about twice as fast at pH 0.5 as at pH 2.5. The 2′-O-Fpmp protecting group has been widely used in solid-phase oligoribonucleotide synthesis (Beijer et al., 1990; Rao et al., 1993; Capaldi and Reese, 1994; Pieles et al., 1994; Sproat et al., 1994; Rao and Macfarlane, 1995; McGregor et al., 1996). The 5′-O-Px2′-O-Fpmp phosphoramidite building blocks S.78 (Fig. 2.2.23) were used successfully in the synthesis of r[UpCpGpUpCpCpApCpCpA], r[ApUpUpCpCpGpGpApUpCpGpUpCpCp ApCpCpA], and r[GpGpApGpApGpGpUp CpUpCp CpGpGpUpUpCpGpApUpUpCpCpGp GpApCpUpCpGpUpCpCpApCpCpA], the 3′-decamer, nonadecamer, and heptatriacontamer (37-mer) sequences, respectively, of unmodified yeast tRNAAla (Rao et al., 1993). Sproat and co-workers (Pieles et al., 1994) carried out the solid-phase synthesis of some modified oligoribonucleotides containing
DMTrO
NC
O
OFpmp
O P
DMTrO
NC
79
B
O O
OMe
O P
Ni-Pr2
Ni-Pr2 78
B
O
Ni-Pr2 80
Figure 2.2.23 5′-O -Px-2′-O -Fpmp phosphoramidite (S.78), 5′-O -DMTr-2′-O -Fpmp phosphoramidite (S.79), and 5′-O -DMTr-2′-O -methyl-ribonucleoside phosphoramidite (S.80).
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.15 Current Protocols in Nucleic Acid Chemistry
O
B
O
O O
O
B
O
O
CO2R
O P O
R
O
1
O
O
O
O P O O R 1
RO2C
2
2
81a, R = NO2, R = H 1 2 81b, R = H, R = NO2
82a, R = Me 82b, R = H
Figure 2.2.24 Additional acetal protecting groups: (2-nitrobenzyloxy)methyl (S.81a), (4-nitrobenzyloxy)methyl (S.81b), (2,6-dimethoxycarbonyl)phenoxymethyl (S.82a), and (2,6-dicarboxy)phenoxymethyl (S.82b).
Protection of 2′Hydroxy Functions of Ribonucleosides
pseudouridine, 2′-O-methylpseudouridine, and some other 2′-O-methyl-ribonucleoside residues starting from the appropriate 5′-ODMTr-2′-O-Fpmp and 5′-O-DMTr-2′-Omethyl-ribonucleoside phosphoramidites (S.79 and S.80, respectively). In all of the early work (Rao et al., 1993), the 2′-O-Fpmp and 5′-terminal Px (or DMTr) protecting groups were removed by treatment with 0.01 mol dm−3 hydrochloric acid (pH ∼2) at room temperature. However, it soon became clear that the susceptibility of the internucleotide linkages of oligoribonucleotides to acid-catalyzed cleavage and migration was sequence dependent, and that certain sequences were unstable at pH 2 and room temperature (Capaldi and Reese, 1994). Thus, despite the relative stability of uridylyl(3′→5′)-uridine (S.50; Griffin et al., 1968) at pH 2 and room temperature, r[(Up)9U] and r[(Up)19U] both underwent virtually complete degradation in the course of the removal of the 2′-O-Fpmp protecting groups under the same conditions (Capaldi and Reese, 1994). However, when unblocking was carried out at room temperature above pH 3.0, virtually no internucleotide cleavage or migration could be detected (see Conclusions). Other workers subsequently reported that no cleavage or migration of the internucleotide linkages could be detected after r[(Up)20U] had been allowed to stand at pH 3.25 in 0.5 M sodium acetate buffer solution at room temperature for 96 hr (Rao and Macfarlane, 1995), which is very much more than the time required to remove the 2′-O-Fpmp protecting groups. These workers went on to recommend that 2′-O-Fpmp protecting groups be removed at pH 3.25 and 30°C in 0.5 M sodium acetate buffer solution. They successfully unblocked RNA sequences containing up to 50 nucleoside residues under these conditions, and obtained oligoribonucleotides that
were active as ribozymes and ribozyme substrates. Other acetal groups Three other interesting and potentially useful acetal groups have recently been suggested for the protection of the 2′-hydroxy functions in solid-phase oligoribonucleotide synthesis. Like the 2-nitrobenzyl group (as in S.34, see above), the (2-nitrobenzyloxy)methyl group (as in S.81a; Schwartz et al., 1992; Fig. 2.2.24) is removable photochemically; however, possibly for steric reasons, its use leads to faster and more efficient coupling reactions. The (2-nitrobenzyloxy)methyl protecting group has been used successfully in the solid-phase synthesis of a number of RNA sequences including a dodecamer, a hexadecamer, and a tritriacontamer (33-mer) sequence that are all components of ribozyme structures. The related (4-nitrobenzyloxy)methyl protecting group (as in S.81b; Gough et al., 1996), which has also been used successfully in solid-phase oligoribonucleotide synthesis, is removable by treatment with tetra-n-butylammonium fluoride in THF solution. Finally the (2,6-dimethoxycarbonyl)phenoxymethyl protecting group (as in S.82a; Rastogi and Usher, 1995), which has been used in the solid-phase synthesis of two dinucleoside phosphates, is extremely (over 100 times more than the Fpmp group) stable under standard detritylation conditions. After the assembly of the desired RNA sequences, the two methoxycarbonyl groups are saponified by treatment with aqueous sodium hydroxide, which also releases the product from the solid support and removes base-labile protecting groups. The resulting (2,6-dicarboxy)phenoxymethyl acetal system (as in S.82b) is estimated to be >1300 times more labile to acidic hydrolysis at pH 3.0 than the original (2,6-di-
2.2.16 Current Protocols in Nucleic Acid Chemistry
R2O
HO
R2O
B
O O
O
O
R1
O
OH
R1
83
Figure 2.2.25 derivatives.
B
O
84
Scheme showing interconversion of isomeric 2′- and 3′-O -acyl-ribonucleoside
methoxycarbonyl)phenoxymethyl acetal system; however, it is still ∼2.3 times more stable at pH 3.0 than the Fpmp protecting group.
with 2′,3′-di-O-acetyluridine 5′-phosphate (S.86) by the now obsolete phosphodiester approach in solution to give, after deprotection, guanylyl-(3′→5′)-uridine (S.87; B = guanin-9yl) and cytidylyl-(3′→5′)-uridine (S.87; B = cytosin-1-yl), respectively. Both of the latter dinucleoside phosphates were apparently free from their (2′→5′)-isomers. Two later studies relating to the use of 2′-Oacyl protecting groups in solid-phase oligoribonucleotide synthesis are also of interest. In one study (Kempe et al., 1982), oligoribonucleotides and chimeric RNA:DNA sequences were prepared from 2′-O-benzoyl-protected phosphoramidites (S.88; Fig. 2.2.27). However, as these phosphoramidites (S.88) were contaminated with 1% to 3% of the isomeric 2′-phosphoramidites, the integrity of the internucleotide linkages in the target RNA sequences was to some extent compromised. The other study (Rozners et al., 1992) described the solid-phase synthesis of oligoribonucleotides from 2′-O-(2-chlorobenzoyl)3′-H-phosphonate building blocks (S.89). This is a more promising approach for two reasons. First, it was possible to separate the isomeric
Ester Protecting Groups It has been known for many years that isomeric 2′- and 3′-O-acyl-ribonucleoside derivatives (S.83 and S.84, respectively; Fig. 2.2.25) interconvert under mildly basic conditions, and that the equilibrium mixture eventually obtained is generally somewhat richer in the 3′isomer (Reese and Trentham, 1965). Unlike corresponding mixtures of 2′- and 3′-OTBDMS derivatives (e.g., S.39 and S.40; Fig. 2.2.9), it is usually very difficult or even impossible to separate isomeric mixtures of 2′- and 3′-esters (S.83 and S.84) by standard chromatographic methods. Furthermore, acyl migration can occur during chromatography. For these reasons, 2′-O-acyl protecting groups have only very rarely been used in oligoribonucleotide synthesis. However, in an early study (Fromageot et al., 1968), N2,O2′,O5′-tribenzoylguanosine (S.85a; Fig. 2.2.26) and N4,O2′,O5′triacetylcytidine (S.85b), two pure crystalline compounds, were both successfully coupled
R
O
B
O
O HO
O
HO
O
O
B
R 85 i, ii O HO P O
O
O AcO
O OH O P O O O
Ura
OAc
HO
Ura
OH
87
86 Ura = uracil-1-yl a, B = 2-N-benzoylguanin-9-yl, R = Ph b, B = 4-N-acetylcytosin-1-yl, R = Me
Figure 2.2.26 Scheme showing preparation of guanylyl-(3′→5′)-uridine and cytidylyl-(3′→5′)uridine using a 2′-O -acyl protecting group. Reagents: (i) mesitylene-2-sulfonyl chloride, C5H5N; (ii) MeNH2, EtOH, or NH3, MeOH.
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.17 Current Protocols in Nucleic Acid Chemistry
DMTrO DMTrO
O
B
O
B
O
O O O P O H
OBz
MeO P NMe2
DMTrO
O
O Cl
O
Cl
89
88
B
O O P H
90
Figure 2.2.27 2′-O -Benzoyl-protected 3′-phosphoramidite (S.88), 2′-O -(2-chlorobenzoyl)-protected 3′-H-phosphonate (S.89), and the isomeric 2′-H-phosphonate (S.90).
2′- and 3′-H-phosphonates (S.90 and S.89, respectively) by chromatography on silica gel, and thereby obtain isomerically pure building blocks (S.89). Secondly, after the desired RNA sequences had been assembled, the 2′-protecting groups could be removed by ammonolysis under conditions that were mild enough to avoid cleavage of the internucleotide linkages. A number of RNA sequences of moderate length were prepared successfully by this approach.
CONCLUSIONS At present, the TBDMS group (as in S.37; Fig. 2.2.28) is the most widely used protecting group for 2′-hydroxy functions in solid-phase oligoribonucleotide synthesis. The Fpmp (as in S.71b; Fig. 2.2.28) group is also widely used. Both 2′-O-TBDMS- and 2′-O-Fpmp-protected phosphoramidites (S.41 and S.79, respectively) are commercially available. So far, there is no report in the literature that constitutes a thorough and definitive comparison of these two protecting groups. However, it is worthwhile discussing how they meet the necessary criteria
DMTrO
O
HO
B
B
O HO
for protecting groups in oligoribonucleotide synthesis, and also whether improvements could be made by modifying them. With regard to the introduction of these two protecting groups, the reagents required, namely tert-butylchlorodimethylsilane and 1(2-fluorophenyl)-4-methoxy-1,2,5,6-tetrahydropyridine (S.70b; Fig. 2.2.28) are both readily available. However, as far as the introduction of these protecting groups is concerned, the Fpmp group has the edge over the TBDMS group inasmuch as it can be introduced regiospecifically (Fig. 2.2.20A) and cannot then migrate. As indicated above, great care has to be exercised in the preparation of TBDMS-protected building blocks (S.41) in order to avoid contamination with the isomeric 2′-phosphoramidites (S.42; Fig. 2.2.10), the presence of which will inevitably lead to (2′→5′)-internucleotide linkages in the final product. In solid-phase synthesis involving phosphoramidite building blocks, it seems clear that coupling rates and efficiencies are generally lower when ribonucleoside rather than 2′-deoxyribonucleoside building blocks are used
DMTrO O
O
OMe F
HO O Me Si Me t-Bu
NC
N
O
B
OTBDMS
O P N(i-Pr)2 41
71b
37
OMe DMTrO
NC
O O
B
OFpmp
N F
O P N(i-Pr)2
Protection of 2′Hydroxy Functions of Ribonucleosides
79
70b
Figure 2.2.28 Structures relating to a discussion of the relative merits of the TBDMS and Fpmp protecting groups.
2.2.18 Current Protocols in Nucleic Acid Chemistry
DMTrO
B
O O
HO
O
OFpmp
B
O
OH
O P O
O P O O
B
O O
O
OFpmp
n-2
O HO
O
n-2
OH
O P O
O P O O
B
O
H3O
B
O
HO
OH
91
O
B
OH
92
Figure 2.2.29 Unblocking of 2′-O -Fpmp-protected oligoribonucleotides under mild conditions of acidic hydrolysis.
(Hayakawa et al., 1996). It is not yet clear whether TBDMS-protected or Fpmp-protected phosphoramidites (S.41 or S.79; Fig. 2.2.28) are the more hindered. Although TBDMS ethers (Kawahara et al., 1996) and Fpmp acetals are both susceptible to acid-catalyzed hydrolysis, the available evidence suggests that both groups remain intact under the anhydrous acidic conditions used during the detritylation steps. The Fpmp group has advantages over the TBDMS protecting group in the ammonolytic unblocking step at the end of the synthesis. First, in the Fpmp approach, adenine, cytosine, and guanine base residues are protected with relatively stable acyl groups (as in S.16, R = Me3C, S.18, R = Ph, and S.19, R = PhCH2, respectively; Fig. 2.2.4; Rao et al., 1993). However, it is advisable to use much more labile acyl protecting groups in the TBDMS approach (Chaix et al., 1989). More importantly, as the Fpmp protecting group is completely stable under the ammonolytic conditions, “Fpmp-on” RNA sequences (S.91; Fig. 2.2.29) are obtained (Rao et al., 1993). Such “Fpmp-on” oligoribonucleotides are stable to endonucleases and base, and may be conveniently purified and stored. On treatment with aqueous acid under very mild conditions (see below), they are readily converted into unprotected RNA sequences (S.92). “TBDMS-on” RNA sequences do not appear to have been purified and isolated in this way. The one clear advantage that the TBDMS approach has over the Fpmp approach is that removal of the TBDMS protecting group in the final unblocking step does not normally involve acidic hydrolysis, and therefore cannot lead to migration of the internucleotide linkages. However, such migration in the Fpmp approach can be virtually eliminated by carefully controlling
the unblocking conditions. Hecht and co-workers (Morgan et al., 1995) reported that when S.91 (B = uracil-1-yl, n = 21; Fig.2.2.29) was unblocked in 0.5 mol dm−3 sodium acetate buffer, pH 3.25, at 25°C for 20 hr, analysis of the resulting r[(Up)20U] (S.92; B = uracil-1-yl, n = 21) revealed that an average of 0.40% migration per internucleotide linkage had occurred. However, Reese et al. (unpub. observ.) have found that under somewhat milder unblocking conditions (0.5 mol dm−3 sodium acetate buffer, pH 4.0, at 35°C), unblocking of S.91 (B = uracil-1-yl, n = 20) was complete after 9 hr and no migration of internucleotide linkages could be detected in the resulting r[(Up)19U] (S.92; B = uracil-1-yl, n = 20). As has been suggested before (Capaldi and Reese, 1994), it cannot be concluded from the results obtained by Strömberg and co-workers (Rozners et al., 1994) in connection with the use of 2′-O-Ctmp5′-O-DMTr-uridine 3′-H-phosphonate (S.77; B = uracil-1-yl; Fig. 2.2.22) and the corresponding Fpmp-protected H-phosphonate building block in the synthesis of r[(Up)11U] and r[(Up)11A] that Ctmp and Fpmp are unsuitable protecting groups for the 2′-hydroxy functions in the H-phosphonate approach to the solid-phase RNA synthesis. A much more likely explanation for Strömberg’s observations is that r[(Up)11U] and r[(Up)11A], like r[(Up)9U] and r[(Up)19U] (Capaldi and Reese 1994), are particularly labile at pH 2.0 and room temperature. Although it is clear that the solid-phase synthesis of relatively high-molecular-weight RNA sequences using TBDMS, Fpmp, or other groups to protect the 2′-hydroxy functions is now a feasible proposition, it is likely that even better protecting groups will be identified in the
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.19 Current Protocols in Nucleic Acid Chemistry
future. The next generation of 2′-protecting groups could include modifications of TBDMS, Fpmp, and some of the other groups described above, and it could also include completely different groups. Any alternative silyl protecting group (S.93; Fig. 2.2.30) would need to be bulky to be sufficiently stable, and so far there is no evidence that any such group is likely to have superior properties to those of the TBDMS group itself. However, modification of the Fpmp group could well lead to improvements. A choice is already available between the Fpmp group, which has the advantage of being more stable at low pH (Fig. 2.2.21) during the detritylation steps, and the Ctmp group, which has the advantage of being more labile at high pH during the final unblocking step. It might well be possible, by a careful choice of R1 and R2, to identify a 1-aryl-4-alkoxypiperidin-4-yl protecting group (S.94; Fig. 2.2.30) that is as stable as (or perhaps even more stable than) the Fpmp group at low pH and as labile as (or perhaps even more labile than) the Ctmp group at high pH. Most of the above discussion has been concerned with the small-scale synthesis of RNA sequences on a solid support. In the light of recent developments in the possible use of oligonucleotide analogs in chemotherapy, a demand has arisen for the development of methods for large-scale synthesis. This may well involve a shift from solid-phase to solutionphase methodology. While this need not necessarily affect the strategy of 2′-protection, the cost of the requisite monomeric building blocks is likely to become a matter of crucial importance. Therefore, particular emphasis will need to be laid on the first general criterion for protecting groups–that they should be easy to introduce and that the reagents involved should be readily accessible. It is not envisaged that this will present a problem for the Fpmp and most other related 1-aryl-4-alkoxypiperidin-4yl protecting groups (S.94). Apart from the practical problems associated with the prepara-
N
R3
Protection of 2′Hydroxy Functions of Ribonucleosides
93
94
ACKNOWLEDGMENT The author would like to acknowledge the huge contributions that his co-workers have made over a period of more than 30 years to studies on the chemical synthesis of oligo- and poly-ribonucleotides, and especially to those studies relating to the problem of 2′-protection. Some of their names appear in the references below; they are all owed an enormous debt of gratitude.
LITERATURE CITED Beaucage, S.L. and Caruthers, M.H. 1996. The chemical synthesis of DNA/RNA. In Bioorganic Chemistry: Nucleic Acids (S.M. Hecht, ed.) pp. 36-74. Oxford University Press, New York and Oxford. Beaucage, S.L. and Iyer, R.P. 1992. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:22232311. Beijer, B., Sulston, I., Sproat, B.S., Rider, P., Lamond, A.I., and Neuner, P. 1990. Synthesis and applicatons of oligoribonucleotides with selected 2′-O-methylation using the 2′-O-[1-(2fluorophenyl)-4-methoxypiperidin-4-yl] protecting group. Nucl. Acids Res. 18:5143-5151. Brown, T. and Brown, D.J.S. 1991. Modern machine-aided methods of oligoribonucleotide synthesis. In Oligonucleotides and Analogues. A Practical Approach (F. Eckstein, ed.) pp. 1-24. IRL Press, Oxford. Brown, J.M., Christodoulou, C., Jones, S.S., Modak, A.S., Reese, C.B., Sibanda, S., and Ubasawa, A. 1989a. Synthesis of the 3′-terminal half of yeast alanine transfer ribonucleic acid (tRNAAla) by the phosphotriester approach in solution. Part 1. Preparation of nucleoside building blocks. J. Chem. Soc. Perkin Trans. 1 1735-1750. Brown, J.M., Christodoulou, C., Modak, A.S., Reese, C.B., and Serafinowska, H.T. 1989b. Synthesis of the 3′-terminal half of yeast alanine transfer ribonucleic acid (tRNAAla) by the phosphotriester approach in solution. Part 2. J. Chem. Soc. Perkin Trans. 1 1751-1767.
R1O R2 R1 Si
tion of very large quantities of 2′-O-TBDMS5′-O-DMTr-protected 3′-phosphoramidites (S.41) that are free from their 2′-isomers (S.42), there is no obvious reason why the TBDMS group should not also be used to protect 2′-hydroxy functions in the large-scale synthesis of RNA sequences in solution.
R2
Figure 2.2.30 Substituted silyl and 1-aryl-4alkoxypiperidin-4-yl protecting groups.
Capaldi, D.C. and Reese, C.B. 1994. Use of the 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) and related protecting groups in oligoribonucleotide synthesis: Stability of internucleotide linkages to aqueous acid. Nucl. Acids Res. 22:2209-2216.
2.2.20 Current Protocols in Nucleic Acid Chemistry
Chaix, C., Molko, D., and Téoule, R. 1989. The use of labile base protecting groups in oligoribonucleotide synthesis. Tetrahedron Lett. 30:71-74. Chattopadhyaya, J.B. and Reese, C.B. 1978. The 9-phenylxanthen-9-yl protecting group. J.Chem. Soc., Chem. Commun. 639-640. Chattopadhyaya, J.B., Reese, C.B., and Todd, A.H. 1979. 2-Dibromobenzoyl: An acyl protecting group removable under exceptionally mild conditions. J. Chem. Soc., Chem. Commun. 987988. Christodoulou, C., Agrawal, S., and Gait, M.J. 1986. Incompatibility of acid-labile 2′ and 5′ protecting groups for solid-phase synthesis of oligoribonucleotides. Tetrahedron Lett. 27:1521-1522. Corey, E.J. and Venkateswarlu, A. 1972. Protection of hydroxyl groups as tert-butyldimethylsilyl derivatives. J. Am. Chem. Soc. 94:6190-6191. Damha, M.J. and Ogilvie, K.K. 1993. Oligoribonucleotide synthesis. The silyl-phosphoramidite method. In Protocols for Oligonucleotides and Analogs (S. Agrawal, ed.) pp. 81-114. Humana Press, Totowa, N.J. den Hartog, J.A.J., Wille, G., and van Boom, J.H. 1981. Synthesis of oligoribonucleotides with sequences identical to the nucleation region of tobacco mosaic virus RNA: Preparation of AAG, AAGAAG and AAGAAGUUG via phosphotriester methods. Rec. Trav. Chim. 100:320-330. Faja, M., Reese, C.B., Song, Q., and Zhang, P.-Z. 1997. Facile preparation of acetals and enol ethers derived from 1-arylpiperidin-4-ones. J. Chem. Soc. Perkin Trans. 1 191-194. Fromageot, H.P.M., Reese, C.B., and Sulston, J.E. 1968. The synthesis of oligoribonucleotides. VI. 2′-O-Acyl ribonucleoside derivatives as intermediates in the synthesis of dinucleoside phosphates. Tetrahedron 24:3533-3540. Gasparutto, D., Livache, T., Bazin, H., Duplaa, A.M., Guy, A., Khorlin, A., Molko, D., Roget, A., and Téoule, R. 1992. Chemical synthesis of a biologically active natural RNA with its minor bases. Nucl. Acids Res. 20:5159-5166. Goodwin, J.T., Stanick, W.A., and Glick, G.D. 1994. Improved solid-phase synthesis of long oligoribonucleotides. Application to tRNAPhe and tRNAGly. J. Org. Chem. 59:7941-7943. Gough, G.R., Miller, T.J., and Mantick, N.A. 1996. p-Nitrobenzyloxymethyl: A new fluoride-removable protecting group for ribonucleoside 2′hydroxyls. Tetrahedron Lett. 37:981-982. Griffin, B.E. and Reese, C.B. 1964. Oligoribonucleotide synthesis via 2,5-protected ribonucleoside derivatives. Tetrahedron Lett. 29252931. Griffin, B.E., Reese, C.B., Stephenson, G.F., and Trentham, D.R. 1966. Oligoribonucleotide synthesis from nucleoside 2′-O-benzyl ethers. Tetrahedron Lett. 4349-4354.
Griffin, B.E., Jarman, M., and Reese, C.B. 1968. The synthesis of oligoribonucleotides. IV. Preparation of dinucleoside phosphates from 2′,5′-protected ribonucleoside derivatives. Tetrahedron 24:639-662. Hakimelahi, G.H., Proba, Z.A., and Ogilvie, K.K. 1982. New catalysts and procedures for the dimethoxytritylation and selective silylation of ribonucleosides. Can. J. Chem. 60:1106-1113. Hayakawa, Y., Kataoka, M., and Noyori, R. 1996. Benzimidazolium triflate as an efficient promoter for nucleotide synthesis via the phosphoramidite method. J. Org. Chem. 61:79967997. Hayes, J.A., Brunden, M.J., Gilham, P.T., and Gough, G.R. 1985. High-yield synthesis of oligoribonucleotides using o-nitrobenzyl protection of 2′-hydroxyls. Tetrahedron Lett. 26:24072410. Honda, S., Urakami, K., Koura, K., Terada, K., Sato, Y., Kohno, K., Sekine, M., and Hata, T. 1984. Synthesis of oligoribonucleotides by the use of S,S-diphenyl N-monomethoxytrityl ribonucleoside 3′-phosphorodithioates. Tetrahedron 40:153-163. Iwai, S. and Ohtsuka, E. 1988. 5′-Levulinyl and 2′-tetrahydrofuranyl protection for the synthesis of oligoribonucleotides by the phosphoramidite approach. Nucl. Acids Res. 16:9443-9456. Iwai, S., Yamada, E., Asaka, M., Hayasa, Y., Inone, H., and Ohtsuka, E. 1987. A new solid phase synthesis of oligoribonucleotides by the phosphoro-p-anisidate method using tetrahydrofuranyl protection of 2′-hydroxyl groups. Nucl. Acids Res. 15:3761-3772. Järvinen, P., Oivanen, M., and Lönnberg, H. 1991. Interconversion and phosphoester hydrolysis of 2′,5′ and 3′,5′-dinucleoside monophosphates: Kinetics and mechanisms. J. Org. Chem. 56:5396-5401. Jones, S.S. and Reese, C.B. 1979. Migration of t-butyldimethylsilyl protecting groups. J. Chem. Soc. Perkin Trans. 1 2762-2764. Jones, S.S., Rayner, B., Reese, C.B., Ubasawa, A., and Ubasawa, M. 1980. Synthesis of the 3′-terminal decaribonucleoside nonaphosphate of yeast alanine transfer ribonucleic acid. Tetrahedron 36:3075-3085. Jones, S.S., Reese, C.B., Sibanda, S., and Ubasawa, A. 1981. The protection of uracil and guanine residues in oligonucleotide synthesis. Tetrahedron Lett. 22:4755-4758. Jones, S.S., Reese, C.B., and Sibanda, S. 1983. Studies directed towards the synthesis of yeast alanine tRNA. In Current Trends in Organic Synthesis (H. Nozaki, ed.) pp. 71-81. Pergamon Press, Oxford. Kamimura, T., Tsuchiya, M., Urakami, K., Koura, K., Sekine, M., Shinozaki, K., Miura, K., and Hata, T. 1984. Synthesis of a dodecaribonucleotide GUAUCAAUAAUG by use of fully protected ribonucleotide building blocks. J. Am. Chem. Soc. 106:4552-4557.
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.21 Current Protocols in Nucleic Acid Chemistry
Kawahara, S., Wada, T., and Sekine, M. 1996. Unprecedented mild acid-catalyzed desilylation of the 2′-O-tert-butyldimethylsilyl group from chemically synthesized oligoribonucleotide intermediates via neighbouring group participation of the internucleotide phosphate residue. J. Am. Chem. Soc. 118:9461-9468. Kempe, T., Chow, F., Sundquist, W.I., Nardi, T.J., Paulson, B., and Peterson, S.M. 1982. Selective 2′-benzoylation at the cis 2′,3′-diols of protected ribonucleosides. New solid phase synthesis of RNA and DNA-RNA mixtures. Nucl. Acids Res. 10:6695-6714. Kierzek, R. 1994. The stability of trisubstituted internucleotide bond in the presence of vicinal 2′hydroxyl. Chemical synthesis of uridylyl(2′phosphate)-(3′→5′)-uridine. Nucleosides Nucleotides 13:1757-1768. Kierzek, R., Caruthers, M.H., Longfellow, C.E., Swinton, D., Turner, D.H., and Freier, S.M. 1986. Polymer-supported RNA synthesis and its application to test the nearest-neighbour model for duplex stability. Biochemistry 25:7840-7846. Kreevoy, M.M. and Taft, R.W. Jr. 1955. The evaluation of inductive and resonance effects on reactivity. I. Hydrolysis rates of acetals of non-conjugated aldehydes and ketones. J. Am.Chem. Soc. 77:5590-5595. Kruse, C.G., Jonkers, F.L., Dert, V., and van der Gen, A. 1979. Synthetic applications of 2-chlorotetrahydrofuran: Protection of alcohols as tetrahydro2-furanyl (THF) ethers. Rec.Trav. Chim. 98:371380. Kuusela, S. and Lönnberg, H. 1994. Hydrolysis and isomerisation of the internucleosidic phosphodiester bonds of polyuridylic acids: Kinetics and mechanism. J. Chem. Soc. Perkin Trans. 2 21092113. Lehmann, C., Xu, Y.-Z., Christodoulou, C., Tan, Z.-K., and Gait, M.J. 1989. Solid-phase synthesis of oligoribonucleotides using 9-fluorenylmethoxycarbonyl (Fmoc) for 5′-hydroxyl protection. Nucl. Acids Res. 17:2379-2390. McGregor, A., Rao, M.V., Duckworth, G., Stockley, P.G., and Connolly, B.A. 1996. Preparation of oligoribonucleotides containing 4-thiouridine using Fpmp chemistry. Photo crosslinking to RNA bridging proteins using 350 nm irradiation. Nucl. Acids Res. 24 : 3173-3180. Morgan, M.A., Kazakov, S.A., and Hecht, S.M. 1995. Phosphoryl migration during the chemical synthesis of RNA. Nucl. Acids Res. 23:3949-3953. Mullah, B. and Andrus, A. 1996. Purification of 5′-O-trityl-on oligoribonucleotides. Investigation of phosphate migration during purification and detritylation. Nucleosides Nucleotides 15:419-430. Protection of 2′Hydroxy Functions of Ribonucleosides
Norman, D.G., Reese, C.B., and Serafinowska, H.T. 1984. The protection of 2′-hydroxy functions in oligoribonucleotide synthesis. Tetrahedron Lett. 25:3015-3018.
Ogilvie, K.K., Sadana, K.L., Thompson, A.E., Quillian, M.A., and Westmore, J.B. 1974. The use of silyl groups in protecting the hydroxyl functions of ribonucleosides. Tetrahedron Lett. 28612863. Ohtsuka, E. and Iwai, S. 1987. Chemical synthesis of RNA. In Synthesis and Applications of DNA and RNA (S.A. Narang, ed.) pp. 115-136. Academic Press, San Diego. Ohtsuka, E., Tanaka, S., and Ikehara, M. 1978. Synthesis of the heptanucleotide corresponding to a eukaryotic initiator tRNA loop sequence. J. Am. Chem. Soc. 100:8210-8213. Ohtsuka, E., Yamane, A., Doi, T., and Ikehara, M. 1984. Chemical synthesis of the 5′-half molecule of E.coli tRNA2Gly. Tetrahedron 40:47-57. Owen, G.R. and Reese, C.B. 1970. A convenient preparation of tetrahydro-4H-pyran-4-one. J. Chem. Soc. C 2401-2403. Pathak, T. and Chattopadhyaya, J. 1985. The 2′-hydroxy function assisted cleavage of the internucleotide phosphotriester bond of a ribonucleotide under acidic conditions. Acta Chem. Scand. B 39:799-806. Pieles, U., Beijer, B., Bohmann, K., Weston, S., O’Loughlin, S., Adam, V., and Sproat, B.S. 1994. New and convenient protection system for pseudouridine, highly suitable for solid phase oligoribonucleotide synthesis. J. Chem. Soc. Perkin Trans. 1 3423-3429. Rao, M.V. and Macfarlane, K. 1995. Improvements to the chemical synthesis of biologically-active RNA using 2′-O-Fpmp chemistry. Nucleosides Nucleotides 14:911-915. Rao, T.S., Reese, C.B., Serafinowska, H.T., Takaku, H., and Zappia, G. 1987. Solid phase synthesis of the 3′-terminal nonadecaribonucleoside octadecaphosphate sequence of yeast alanine transfer ribonucleic acid. Tetrahedron Lett. 28:48974900. Rao, M.V., Reese, C.B., Schehlmann, V., and Yu, P.S. 1993. Use of the 1-(2-fluorophenyl)-4methoxypiperidin-4-yl (Fpmp) protecting group in the solid phase synthesis of oligo- and polyribonucleotides. J. Chem. Soc. Perkin Trans. 1 43-55. Rastogi, H. and Usher, D.A. 1995. A new 2′-hydroxyl protecting group for the automated synthesis of oligoribonucleotides. Nucl. Acids Res. 23:4872-4877. Reese, C.B. 1970. A systematic approach to oligoribonucleotide synthesis. Colloq. Int. Cent. Natl. Rech. Sci. 182:319-328. Reese, C.B. 1978. The chemical synthesis of oligoand poly-nucleotides by the phosphotriester approach. Tetrahedron 34:3143-3179. Reese, C.B. 1989. The chemical synthesis of oligoand poly-ribonucleotides. In Nucleic Acids and Molecular Biology, Vol. 3 (F. Eckstein and D.M.J. Lilley, ed.) pp. 164-181. Springer-Verlag, Berlin.
2.2.22 Current Protocols in Nucleic Acid Chemistry
Reese, C.B. and Skone, P.A. 1984. The protection of thymine and guanine residues in oligodeoxyribonucleotide synthesis. J. Chem. Soc. Perkin Trans. 1 1263-1271. Reese, C.B. and Skone, P.A. 1985. Action of acid on oligoribonucleotide phosphotriester intermediates. Effects of released vicinal hydroxy functions. Nucl. Acids Res. 13:5215-5231. Reese, C.B. and Thompson, E.A. 1988. A new synthesis of 1-arylpiperidin-4-ols. J. Chem. Soc. Perkin Trans. 1 2881-2885. Reese, C.B. and Trentham, D.R. 1965. Acyl migration in ribonucleoside derivatives. TetrahedronLett. 2467-2472. Reese, C.B. and Zard, L. 1981. Some observations relating to oximate ion promoted unblocking of oligonucleotide aryl esters. Nucl. Acids Res. 9:4611-4626. Reese, C.B., Saffhill, R., and Sulston, J.E. 1967. A symmetrical alternative to the tetrahydropyranyl protecting group. J. Am. Chem. Soc. 89:33663368. Reese, C.B., Saffhill, R., and Sulston, J.E. 1970. 4-Methoxytetrahydropyran-4-yl. A symmetrical alternative to the tetrahydropyranyl protecting group. Tetrahedron 26:1023-1030. Reese, C.B., Titmas, R.C., and Yau, L. 1978. Oximate ion promoted unblocking of oligonucleotide phosphotriester intermediates. Tetrahedron Lett. 30:2727-2730. Reese, C.B., Serafinowska, H.T., and Zappia, G. 1986. An acetal group suitable for the protection of 2′-hydroxy functions in rapid oligoribonucleotide synthesis. Tetrahedron Lett. 27:22912294. Reitz, G. and Pfleiderer, W. 1975. Synthese und Eigenschaften von O-benzyl substituierten Diuridylphosphaten. Chem. Ber. 108:2878-2894. Rozners, E., Renhofa, R., Petrova, M., Popelis, J. Kumpins, V., and Bizdena, E., 1992. Synthesis of oligoribonucleotides by the H-phosphonate approach using base labile 2′-O-protecting groups. V. Recent progress in development of the method. Nucleosides Nucleotides 11:579-1593. Rozners, E., Westman, W., and Strömberg, R. 1994. Evaluation of 2’-hydroxyl protection in RNA synthesis using the H-phosphonate approach. Nucl. Acids Res. 22:94-99. Sakatsume, O., Ohtsuki, M., Takaku, H., and Reese, C.B. 1989. Solid phase synthesis of oligoribonucleotides using the 1-[(2-chloro-4-methyl)]-4methoxypiperidin-4-yl (Ctmp) group for the protection of the 2′-hydroxy functions and the H-phosphonate approach. Nucl. Acids Res. 17:3689-3697. Sandström, A., Kwiatkowski, M., and Chattopadhyaya, J. 1985. Chemical synthesis of a pentaribonucleoside tetraphosphate constituting the 3′acceptor stem sequence of E. coli tRNAIle using 2′-O-(3-methoxy-1,5-dicarbomethoxypentan3-yl)-ribonucleoside building blocks. Acta Chem. Scand. B 39:273-290.
Scaringe, S.A., Francklyn, C., and Usman, N. 1990. Chemical synthesis of biologically active oligoribonucleotides using β-cyanoethyl protected ribonucleoside phosphoramidites. Nucl.Acids Res. 18:5433-5441. Schaller, H., Weimann, G., Lerch, B., and Khorana, H.G. 1963. Protected derivatives of deoxyribonucleosides and new syntheses of deoxyribonucleoside-3′ phosphates. J. Am.Chem. Soc. 85:3821-3827. Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., deBear, J.S., and Gough, G.R. 1992. Rapid synthesis of oligoribonucleotides using 2′-O-(o-nitrobenzyloxymethyl)-protected monomers. Bioorg. Med. Chem. Lett. 2:1019-1024. Sinha, N.O., Biernat, J., and Köster, H. 1983. β-Cyanoethyl N,N-dialkylamino/N-morpholinomonochlorophosphoramidites, new phosphitylating agents facilitating ease of deprotection and work-up of synthesized oligonucleotides. Tetrahedron Lett. 24:5843-5846. Smith, M., Rammler, D.H., Goldberg, I.H., and Khorana, H.G. 1962. Studies on polynucleotides XIV. Specific synthesis of the C-3′-C-5′ inter ribonucleotide linkage. Synthesis of uridylyl(3′→5′)-uridine and uridylyl-(3′→5′)-adenosine. J. Am. Chem. Soc. 84:430-440. Smrt, J. and Šorm, F. 1962. Oligonucleotidic compounds I. The direct blocking of 2′-hydroxyl in ribonucleoside-3′ phosphates. The synthesis of 6-azauridylyl-(5′→3′)-uridine. Coll. Czech. Chem. Commun. 27:73-86. Sonveaux, E. 1994. Protecting groups in oligonucleotide synthesis. In Protocols for Oligonucleotide Conjugates: Synthesis and Analytical Techniques (S. Agrawal, ed.) pp. 1-71. Humana Press, Totowa, N.J. Sproat, B.S. and Gait, M.J. 1984. Solid-phase synthesis of oligodeoxyribonucleotides by the phosphotriester method. In Oligonucleotide Synthesis. A Practical Approach (M.J. Gait, ed.) pp. 83-115. IRL Press, Oxford. Sproat, B.S., Beijer, B., Groetli, M., Ryder, U., Morand, K.L., and Lamond, A.I. 1994. Novel solid-phase synthesis of branched oligoribonucleotides including a substrate for RNA debranching enzyme. J. Chem. Soc. Perkin Trans. 1 419-431. Sproat, B.S., Calonna, F., Mullah, B., Tsou, D., Andrus, A., Hampel, A., and Vinayak, R. 1995. An efficient method for the isolation and purification of oligoribonucleotides. Nucleosides Nucleotides 14:255-273. Stawinski, J., Strömberg, R., Thelin, M., and Westman, E. 1988. Studies on the t-butyldimethylsilyl group as 2′-O-protection in oligoribonucleotide synthesis via the H-phosphonate approach. Nucl. Acids Res. 16:9285-9298. Stork, G. and Hudrlik, P.F. 1968. Isolation of ketone enolates as trialkylsilyl ethers. J. Am.Chem. Soc. 90:4462-4464.
Protection of Nucleosides for Oligonucleotide Synthesis
2.2.23 Current Protocols in Nucleic Acid Chemistry
Takaku, H. and Kamaike, K. 1982. Synthesis of oligoribonucleotides using 4-methoxybenzyl group as a new protecting group of the 2′-hydroxyl group of adenosine. Chem. Lett. 189-192.
van Boom, J.H. and Burgers, P.M.J. 1976. Use of levulinic acid in the protection of oligonucleotides via the modified phosphotriester method: Synthesis of the decaribonucleotide UAUAUAUAUA. Tetrahedron Lett. 4875-4878.
Takaku, H., Kamaike, K., and Tsuchiya, H. 1984. Synthesis of ribooligonucleotides using the 4methoxybenzyl group as a new protecting group for the 2′-hydroxyl group. J. Org. Chem. 49:5156.
van Boom, J.H., van Deursen, P., Meeuse, J., and Reese, C.B. 1972. Two sulphur-containing protecting groups for alcoholic hydroxyl functions. J. Chem. Soc., Chem. Commun. 766-767.
Takaku, H., Ito, T. and Iwai, K. 1986. Use of the 3,4-dimethoxybenzyl group as a protecting group for the 2′-hydroxyl group in the synthesis of oligoribonucleotides. Chem. Lett. 1005-1008.
Vinayak, R., Anderson, P., McCollum, C., and Hampel, A. 1992. Chemical synthesis of RNA using fast oligonucleotide deprotection chemistry. Nucl. Acids Res. 20:1265-1269.
Tanaka, T., Fujino, K., Tamatsukuri, S., and Ikehara, M. 1986. Synthesis of oligoribonucleotides via the phosphite triester approach on a solid support. Chem. Pharm. Bull. Jpn. 34:4126-4132.
Westman, E. and Strömberg, R. 1994. Removal of t-butyldimethylsilyl protection in RNA synthesis. Triethylamine trihydrofluoride (TEA,3HF) is a more reliable alternative to tetrabutylammonium fluoride (TBAF). Nucl. Acids Res. 22:2430-2431.
Tanimura, H. and Imada, T. 1990. The utility of 2′-Thp group in the synthesis of the relatively long RNA fragments on the solid support. Chem. Lett. 2081-2084. Tanimura, H., Mieda, M., Fukazawa, T., Sekine, M., and Hata, T. 1989. Chemical synthesis of the 24 RNA fragments corresponding to hop stunt viroid. Nucl. Acids Res. 17:8135-8147. Usman, N., Ogilvie, K.K., Jiang, M.Y., and Cedergren, R.J. 1987. Automated chemical synthesis of long oligoribonucleotides using 2′-O-silylated ribonucleoside 3′-phosphoramidites on a controlled pore glass support: Synthesis of a 43-nucleotide sequence similar to the 3′-half molecule of Escherichia coli formylmethionine tRNA. J. Am. Chem. Soc.109:7845-7854.
Wincott, F., DiRenzo, A., Shaffer, C., Grimm, S., Tracz, D., Workman, C., Sweedler, D., Gonzalez, C., Scaringe, S., and Usman, N. 1995. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucl. Acids Res. 23:2677-2684.
Contributed by Colin B. Reese King’s College London London, United Kingdom
Protection of 2′Hydroxy Functions of Ribonucleosides
2.2.24 Current Protocols in Nucleic Acid Chemistry
Protection of 5′-Hydroxy Functions of Nucleosides The 5′-OH group is the primary hydroxy group of nucleosides. It is the least influenced by the electron-withdrawing effects of the other substituents on the sugar moiety. Moreover, it is the least sterically hindered hydroxy function, and shows the highest reactivity of all nucleoside hydroxy groups in nucleophilic substitutions. Although nucleobases can eventually be left unprotected, and nucleosides with free 3′-hydroxy groups have been used in some triester syntheses, it is mandatory to protect 5′ hydroxyls in all methods of oligonucleotide synthesis that require nucleoside synthons. For chemical oligonucleotide synthesis, the blocking groups for the 5′-hydroxy function must be integrated into an orthogonal protection system. Several such systems have been proposed and are in use for deoxyribo- and ribooligonucleotide synthesis as well as for the preparation of structurally modified oligonucleotide analogs. These protection schemes, details of which are described elsewhere (e.g., UNITS 2.1-2.5 and 3.1-3.4), can be distinguished by requiring, in principle, three alternative methods for 5′-deprotection: (1) acid conditions, (2) alkaline or ammoniacal conditions, or (3) selective deblocking reagents applied essentially in the absence of acid or base. Protecting groups for 5′-hydroxy functions can be broadly classified into these three categories, and the subsequent sections of this unit will follow this division. Additional criteria governing the choice of 5′-hydroxyl-protecting groups include (1) the direction of chain lengthening, (2) the use of polymer supports and/or other purification handles, and (3) additional features related to molecular instability or chemical reactivity in the case of oligonucleotides deviating from biological structure. In particular, the direction of chain extension determines whether a 5′-hydroxyl-protecting group will be permanent (i.e., remain attached to the growing oligonucleotide chain) or intermediary (i.e., will have to be removed prior to each chain extension). If lengthening occurs from the 5′ to the 3′ end, a permanent protecting group is used. If chain extension is done from the 3′ to the 5′ end, which is currently most common, the 5′-hydroxy function must be substituted by an intermediary protecting group. In polymer support synthesis, the poly-
UNIT 2.3
meric carrier assumes the role of a permanent protecting group and is now usually attached to the 3′-hydroxy end. However, there are a number of mostly earlier publications that describe carrier fixation through the 5′ end (see Miscellaneous Acid-Labile 5′-Substituents and see 5′-Hydroxyl-Protecting Groups Cleaved Under Nonacidic and Nonalkaline Conditions). In polymer support synthesis and in some solution methods, it is desirable to simplify the workup of the crude product obtained after oligonucleotide chain extensions. A variety of 5′-hydroxyl-protecting groups have been designed that serve as “purification handles” for this purpose (see Triaryl-methyl Groups as Affinity Ligands). The underlying idea is to single out the product chain from a complex admixture of truncated and failure sequences, although this may still be an unattainable goal. Nevertheless, such “handle” methods may significantly reduce the time and effort for oligonucleotide purification, especially on a preparative scale. A final point in these introductory remarks is that there is no protecting group exclusively in use for the 5′-hydroxy function. Only the conditions of the reaction determine whether the same group will serve for the protection of the 5′, the 3′, or the 2′ hydroxyl, or even of functional groups at nucleobases, because there are only subtle differences in the reactivity of all of these functions. To master these subtle differences is an art of regioselective substitution and comprises much of the challenge of oligonucleotide synthesis. Additionally, there are differences in the approach used for deoxyribo- versus ribooligonucleotide synthesis, and these will be discussed in the subsequent sections.
SCOPE OF THIS OVERVIEW This unit will deal with substituents for the 5′-hydroxy function that fulfill the following criteria of protecting groups. (1) The substituents can be affixed to/removed from the 5′hydroxy function of a growing oligonucleotide chain before/after chain elongation or in the context of other reactions of the oligonucleotide chain. (2) The substituents remain bound during chain elongation and do not interfere with other oligonucleotide reactions. Substituents that serve to permanently modify
Contributed by H. Seliger Current Protocols in Nucleic Acid Chemistry (2000) 2.3.1-2.3.34 Copyright © 2000 by John Wiley & Sons, Inc.
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.1
the 5′ position are not in the scope of this unit. This includes chemical modifications of the 5′-hydroxy function as well as the substitution of the 5′-hydroxy function by linkers, labels, spacers, and other groups that are meant to remain an integral part of the completed oligonucleotide chain (e.g., UNITS 4.2 & 4.3). Also, protecting groups used specifically for the preparation of certain oligonucleotide analogs will not be treated here, as such syntheses are discussed in further units (e.g., see Chapter 4). Protected nucleoside-5′-phosphates have played a role especially in the early days of oligonucleotide synthesis. Essentially, a 5′phosphate residue can be used for protection of the terminus, because enzymatic hydrolysis can easily reconvert to a 5′ hydroxyl. However, only those cases when this was the declared reason for 5′-phosphorylation will be mentioned in the following text (see examples given in Fig. 2.3.10). The topic of 5′-hydroxyl protection is essential to oligonucleotide synthesis and, therefore, is generally included in all textbooks on preparative nucleotide chemistry, as well as in books and articles dealing specifically with the field of protective groups. A few recent reviews have dealt more extensively with groups for protection of 5′ hydroxyls, including articles by Sonveaux (1986) and Beaucage and Iyer (1992, 1993). More extensive reviews in the earlier literature are given by Kössel and Seliger (1975) and Reese (1978).
ACID-LABILE PROTECTING GROUPS Triarylmethyl and Related Substituents
Protection of 5′-Hydroxy Functions of Nucleosides
Introduction of trityl and substituted trityl groups The triphenylmethyl (trityl or Tr) group (S.1; Fig. 2.3.1), a well-known sugar protecting group, was first used for nucleoside 5′-protection in Lord Todd’s laboratory (Andersen et al., 1954) during hydrogenolytic removal. However, this work had limited success. The breakthrough came from H.G. Khorana’s group, who discovered that detritylation in acidic medium is greatly facilitated if the trityl group is modified with one to three p-methoxy substituents (Gilham and Khorana, 1958; Smith et al., 1962). In 80% acetic acid, the rate of hydrolysis increased roughly 10-fold with each introduction of an additional methoxy group.
R
R'
C
R'' 1 2 3 4
R = R' = R'' = H R = R' = H; R'' = OCH3 R = H; R' = R'' = OCH3 R = R' = R'' = OCH3
Figure 2.3.1 Trityl and p-methoxy-substituted trityl protecting groups.
Since their introduction as acid-labile protecting groups for ribo- (Smith et al., 1962) and deoxyribonucleotide (Schaller et al., 1963) chemistry, the mono- and dimethoxytrityl groups (MMTr, S.2, and DMTr, S.3, respectively; Fig. 2.3.1) have become standard for the protection of the 5′-hydroxy function. The DMTr group has especially proven its value in automated solid-phase deoxyribooligonucleotide synthesis, for five main reasons (Sonveaux, 1986). (1) It can be introduced regiospecifically and in high yield at the 5′-hydroxy function of (base-protected) nucleosides. (2) It can be readily and quantitatively removed from the growing oligonucleotide chain by nonaqueous acid. (3) It is sufficiently stable to tetrazole, which is used as an activator in the chain extension step. (4) Its deprotection in nonaqueous acid gives an intense color reaction (ascribed to a cationic species), which can be monitored by spectroscopy to estimate yields of chain elongation. (5) A terminal 5′-DMTr group conveys a certain hydrophobicity to the longest oligonucleotide chain in the crude product released from the polymer support. This hydrophobicity is often used to isolate the target oligonucleotide from the mixture of truncated and failure chains. These considerations (1 to 5) will be elaborated on further throughout this unit. Other trityl protecting groups are less useful for automated synthesis. Unsubstituted trityl and MMTr require conditions that are too harsh for multistep removal with the complication of depurination (see below). The trimethoxytrityl group (TMTr; S.4; Fig. 2.3.1) is extremely sensitive. It can be introduced readily and in high yield at the 5′-position of deoxyribonucleosides and was found to be completely stable when stored at −20°C for ∼6 months; however, it is partially removed in a mixture of tetrazole
2.3.2 Current Protocols in Nucleic Acid Chemistry
for tritylation. This method is no longer in use. The more elegant route B relies on transient silyl protection to apply acyl groups regioselectively to the nucleobases in a procedure that can be carried out in a single reaction tube (Ti et al., 1982; also see “silylation first” procedure in Fritz et al., 1982). The alternative route C uses initial 5′-tritylation followed by silylation and then acylation (“tritylation first” procedure, Fritz et al., 1982; for a recent report see Wada et al., 1998a,b). In most cases, pyridine serves both to dissolve the reactants and to neutralize the ensuing hydrochloric acid. If necessary, trityl groups can be substituted at the unprotected 5′-hydroxy function of oligonucleotide chains, either postsynthesis or in exchange for other protecting groups. This can be done by treating a support-bound oligonucleotide with 4,4′-DMTr chloride in pyridine/4-dimethylaminopyridine for 1 hr, which restores ∼95% of the previously removed DMTr (Kotschi, 1987; Reddy et al., 1987). This reaction could even be performed in the presence of unprotected internucleotidic bonds due to the lability of phosphoric acid trityl esters (Reddy et al., 1987). With support-bound nucleosides, however, the reaction was more sluggish and had to be
and acetonitrile (Kotschi, 1987). This detritylation occurred more readily with purine than with pyrimidine nucleosides. Also, an oligoadenylate prepared with TMTr-deoxyadenosine contained a significant admixture of longer chains, obviously arising from multiple monomer addition. The trityl protecting groups are generally introduced by treatment of nucleosides with the respective trityl chloride. The reactivity of these trityl chlorides increases with increasing number of p-methoxy substituents. If the reaction is run at room temperature and with not more than a slight excess of trityl chloride, the substitution will be highly regiospecific at the 5′ hydroxyl. If the reagent is in higher excess and the temperature is raised, the substitution also occurs on the more sterically hindered 3′ hydroxyl. Exocyclic amino groups are usually protected prior to tritylation, because they would otherwise react with trityl chlorides. Three routes to base-protected, 5′-tritylated nucleosides are described in Figure 2.3.2. The classical approach (route A) from Khorana’s laboratory uses per-acylation of all hydroxy and amino functions, followed by treatment with strong alkali, which selectively cleaves acyl esters and thus liberates 5′ and 3′ hydroxyls
route A AcylO
O
route B
B
Acyl
HO
AcylO
B
O
acylation
route C DMTrO
HO
B
OH 3',5'-silylation
Me3SiO
O
tritylation
B
O
3'-silylation DMTrO
O
B
alkaline deesterification Me3SiO
Me3SiO acylation
HO
Acyl
O
B
Acyl
Me3SiO
O
desilylation
OH
B
DMTrO
DMTrO
O
B
Acyl
Me3SiO
Me3SiO
tritylation
acylation
Acyl
O
B
desilylation
OH
Figure 2.3.2 Three routes to N-protected, 5′-O-tritylated 2′-deoxyribonucleosides (modified from Fritz et al., 1982, with permission from Verlag Chemie).
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.3 Current Protocols in Nucleic Acid Chemistry
activated by addition of tetra-n-butylammonium nitrate and 2,4,6-collidine in dimethylformamide (DMF). The retritylation procedure has recently been applied to the preparation of oligonucleotide-polyamide conjugates (Tong et al., 1993) and to the postsynthetic introduction of the 4-(17-tetrabenzo(a,c,g,i)fluorenylmethyl)-4′,4′′-dimeth oxytrityl protecting group (TBF-DMTr; S.25; Fig. 2.3.8; Ramage and Wahl, 1993; see Triarylmethyl Groups as Affinity Ligands). Other methods of tritylation can be applied if this is required by the sensitivity of modified nucleoside or oligonucleotide reactants. Reports have described the application of powdered molecular sieves as acid scavengers (Kohli et al., 1980), and the use of 4-N,N-dimethylaminopyridine in a mixture of triethylamine and DMF as an alternative solvent (Chaudhary and Hernandez, 1979). As alternatives to trityl chlorides, N-tritylpyridinium fluoroborate (Fersht and Jencks, 1970) and DMTr tetrafluoroborate (Lakshman and Zajc, 1996) have been described.
Removal of trityl and substituted trityl groups The removal of trityl groups was initially performed with 80% aqueous acetic acid (e.g., Smith et al., 1962; Schaller et al., 1963), and such aqueous media are still in use if the deprotection is carried out in the last step of oligonucleotide workup. Nuclear magnetic resonance (NMR) studies have shown that the chemical shifts of all nucleoside protons change upon removal of 5′-trityl groups. On this basis, rate constants were determined for the hydrolysis of different methoxy-substituted trityl groups from the 5′ and 3′ positions of deoxythymidine in aqueous tetrahydrofuran solution brought to different pHs with HCl; a linear relationship between pH and hydrolysis rate was established (Regel et al., 1974).
If detritylations are done as intermediate steps during machine-aided polymer-support synthesis, nonaqueous acidic media are generally applied. The most common are solutions of strong protic acids, such as trichloro- or dichloroacetic acid (Adams et al., 1983; for a recent survey of detritylation conditions see Habus and Agrawal, 1994). Methylene chloride is routinely used as a solvent, although there is a tendency to avoid chlorinated hydrocarbons. For this reason, toluene has been recommended as an alternative for detritylation with dichloroacetic acid (Krotz et al., 1999; Table 2.3.1). This was the result of extensive kinetic studies that showed that the rate of detritylation decreases in the series DMTrdGi-Bu > DMTrdABz > DMTrdCBz > DMTrdT (where Bz is benzoyl), and is highest not only in haloaliphatic but also in aromatic solvents, but is slow in DMF, hexane, ethylacetate, tetrahydrofuran, or tertbutylmethyl ether. Unwanted retritylation can occur through reversal of the equilibrium generated by nonaqueous detritylation, between the colored cationic species and the DMTr-oligonucleotide (Fig. 2.3.3; Dellinger et al., 1998). The same problem was reported for the 9-phenylxanthen9-yl group (see discussion of pixyl and related protecting groups, below; Reese et al., 1986). This is usually not a problem in solid-support oligonucleotide synthesis, since this equilibrium is shifted by washing and filtration; however, it can lead to incomplete deblocking in solution-phase synthesis. Detritylation steps in solid-phase oligonucleotide synthesis are generally believed to be complete when appropriate treatment with nonaqueous acid and extensive washing leave resins and wash solutions colorless. Minute deviations from this scheme of quantitative deblocking, which can occur, for example, through trace impurities in the deblocking solution, are listed among the reasons for the occurrence of truncated sequences in the crude
OCH3
H3CO
Protection of 5′-Hydroxy Functions of Nucleosides
C O
P
Figure 2.3.3
OCH3
O
B
CI2CHCOOH
H3CO
C
CI2CHCOO
HO
O
O
O
P
P
B
= polymer support
Detritylation equilibrium.
2.3.4 Current Protocols in Nucleic Acid Chemistry
products released from the polymer support (e.g., Fearon et al., 1995). Whether this is a potential reason for failure cannot be decided without distinguishing between the efficiencies of the individual steps in the elongation cycle. The literature appears undecided about whether such failures occur statistically throughout all cycles (Fearon et al., 1995) or with higher probability during the initial chain elongation (Temsamani et al., 1995). Depurination as a side reaction during detritylation The most stringent problem, however, is the avoidance of depurination on removal of trityl groups. N-Acylated nucleosides and N-acylated units in oligonucleotides are especially susceptible to deglycosidation. This leads to the formation of apurinic sites, with subsequent chain cleavage during ammoniacal deprotection. This side reaction becomes more and more problematic with longer oligonucleotide chains or larger-scale preparations. The incentive to overcome the depurination problem has led to the development of a wide variety of finely tuned acid-deprotection conditions; examples are given in Table 2.3.1. Although most publications list only the optimum detritylation conditions without giving background data, recent studies, stimulated by large-scale oligonu-
cleotide support synthesis, have been accompanied by extensive analyses of detritylation versus depurination kinetics (Paul and Royappa, 1996; Septak, 1996). The essence of their findings is that haloacetic acids bind strongly to immobilized growing oligonucleotide chains. If, as usual, very dilute acid solutions are applied, detritylation is slowed by depletion of acid from the medium, whereas depurination is allowed to proceed through acid saturation. The authors, therefore, recommend using a short pulse of more concentrated acid (e.g., 15% dichloroacetic acid in methylene chloride) and avoiding any acetonitrile contamination. The length of the acid treatment must be adjusted to the length of the growing oligonucleotide chain. In some cases, ion exchange resins in the H+ form may be a good choice for detritylation (Patil et al., 1994), especially to substitute for acetic acid in large-scale preparations (Iyer et al., 1995). A long treatment with silica gel was found advantageous in the preparation of sensitive nucleosides (Rosowsky et al., 1989). Lewis acid deprotection of trityl and substituted trityl groups and miscellaneous detritylation methods Great expectations to solve the depurination problem had accompanied the introduction of
Table 2.3.1 Examples of Acidic Deprotection Conditions of 5′-Trityl Groupsa
Protecting group DMTr DMTr DMTr DMTr DMTr DMTr DMTr DMTr DMTr DMTr DMTr
Deprotection conditions
Application
Reference
Benzene sulfonic acid in 9:1 (v/v) DMF/DCM 3% (w/v) TCA in DCM
ODN solid phase
Patel et al. (1982)
3% (w/v) TCA in 95:5 (v/v) DCM/CH3OH 0.1 M p-toluene sulfonic acid in THF 0.1 M p-toluene sulfonic acid in acetonitrile 2% (v/v) DCA/0.1% (v/v) CH3OH in DCM 3% (v/v) DCA in 1,2-dichloroethane 3% (v/v) DCA in toluene 3% (w/v) TCA in 1% CH3OH/nitromethane 2% (w/v) benzene sulfonic acid in 7:3 (v/v) DCM/CH3OH 15% (v/v) DCA in DCM
A-rich ODN solid phase Tanaka and Oishi (1985) Protected dA Takaku et al. (1983) ODN solid phase
ODN solid phase
Matteucci and Caruthers (1981) Seliger et al. (1987); Septak (1996) Habus and Agrawal (1994) Sproat and Gait (1984)
ODN solid phase ODN solid phase
Krotz et al. (1999) Sinha et al. (1984)
ODN solution
Gaffney et al. (1984)
ODN solid phase
Habus and Agrawal (1994)
ODN solid phase ODN solid phase
aAbbreviations: DCA, dichloroacetic acid; DCM, dichloromethane; DMF, dimethylformamide; DMTr, dimethoxytrityl; ODN, conditions applied in oligodeoxynucleotide synthesis; TCA, trichloroacetic acid; THF, tetrahydrofuran.
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.5 Current Protocols in Nucleic Acid Chemistry
OCH3
CH3O
MeOH
Ph
HN N
C O
ZnBr2
O
B
OH
Protection of 5′-Hydroxy Functions of Nucleosides
N
N
HO
O HO
O ZnBr2
N
H
Figure 2.3.4 Proposed mechanism for the selective removal of 5′-O-DMTr groups by ZnBr2 in organic solvent (according to Matteucci and Caruthers, 1980).
Figure 2.3.5 Deacylation of nucleobases as a side reaction in the removal of 5′-O-trityl protecting groups with zinc bromide (Kierzek et al., 1981).
zinc bromide as a detritylating agent (Kohli et al., 1980; Matteucci and Caruthers, 1980). The mechanism, described for βmethoxyethoxymethyl ethers by Corey et al. (1976), involves the formation of a bidentate complex with O-C5′ and intracyclic oxygen (Fig. 2.3.4). This explains the selectivity for 5′-hydroxy over 3′-hydroxy detritylation, which was found to disappear upon addition of an alcohol (Waldmeier et al., 1982). This does not play a role in oligonucleotide support synthesis, since the 3′-hydroxy function, conventionally, is anchored to a support. Here the objective is to ensure the most efficient and quantitative deblocking of immobilized growing chains. Initially, a saturated (∼0.1 M) solution of zinc bromide in nitromethane was applied (Matteucci and Caruthers, 1980, 1981). Under these conditions, depurination of N6benzoyl-deoxyadenosine was found to be insignificant over a 24-hr period. However, the formation of an unreactive chain end (presumably a zinc compound) was observed under anhydrous conditions, requiring a hydrolytic wash after detritylation. Additionally, the time required for complete deblocking was relatively long (∼15 min for purine, ∼30 min for pyrimidine; Matteucci and Caruthers, 1981). Therefore, it was found advantageous to add 1% water (Seliger et al., 1982; Winnacker and Dörper, 1982) or 5% methanol (Caruthers, 1982) to the nitromethane solution, which serves to increase the zinc bromide concentration. Applying zinc bromide in a number of protic solvents, Itakura and colleagues (Kierzek et al., 1981) found that a 0.7 M solution of zinc bromide in 9:1 (v/v) chloroform/methanol would lead to complete detritylation within 1 min. Depurination was not detected; however, on prolonged treatment, N-acyl groups were found to be removed, especially from the adenine moiety (Fig. 2.3.5). Since this was also attributed to a nucleophilic attack on a chelate
of zinc bromide with the protected base (Kierzek et al., 1981; Beaucage and Iyer, 1992), sterically hindered alcohol components were found to suppress this side reaction. A 1 M solution of zinc bromide in 85:15 (v/v) dichloromethane/isopropanol was found to be an optimal deblocking reagent (Kierzek et al., 1981; Ito et al., 1982; Itakura et al., 1984). Addition of zinc bromide to amide groups linking the oligonucleotide chains to the support was also postulated (Ito et al., 1982; Adams et al., 1983). In spite of these extensive investigations, neither zinc bromide nor other Lewis acids— such as TiCl4, AlCl3 (Matteucci and Caruthers, 1981), diethyl and diisopropyl aluminum chloride (Köster and Sinha, 1982), or boron trifluoride, applied as etherate (Engels, 1979) or methanol complex (Mitchell et al., 1990)—are of importance in current automated solid-phase deoxyribooligonucleotide synthesis. One of the reasons may be the deposition or adsorption of reagents and by-products (e.g., zinc salts) within the oligonucleotide/solid support system, resulting in the necessity for extensive and time-consuming washes. Outside the mainstream, a number of studies have reported the application of unusual detritylation reagents. Examples are formic acid (Bessodes et al., 1986), 1,1,1,3,3,3-hexafluoro2-propanol (Leonard and Neelima, 1995), chlorine/chloroform solution (Fuentes et al., 1994), or diethyl oxomalonate/methanol solution (Sekine, 1994); some earlier reports are summarized in other reviews (e.g., Beaucage and Iyer, 1992). Other noteworthy detritylation alternatives, such as reductive cleavage with radical anion (Letsinger and Finnan, 1975) or electrochemical deblocking (Mairanovsky, 1976), may not be easily adaptable to automated oligonucleotide synthesis. In routine solid-phase oligonucleotide synthesis, the detritylation solution usually goes to waste after yield monitoring. However, this is
2.3.6 Current Protocols in Nucleic Acid Chemistry
not tolerable for syntheses scaled up to kilogram dimensions and beyond, because the DMTr group comprises ∼35% of the total weight of constituent-protected nucleoside phosphoramidites. Recently, a process has been reported for the workup and neutralization of the detritylation solution, coupled with the reconversion of the ensuing dimethoxytrityl alcohol (DMTrOH) to DMTr chloride. This process resulted in the recycling of 89% of the weight of DMTr residues. At the same time, >90% of the hazardous solvent dichloromethane was recovered with >95% purity (Guo et al., 1998). Pixyl and related protecting groups As a structural analog to the trityl group, the 9-phenylxanthen-9-yl (pixyl or Px) protecting group (S.5, Fig. 2.3.6) has been described (Chattopadhyaya and Reese, 1978; Chattopadhyaya, 1980). This protecting group is removed by acid at approximately the same rate as the DMTr group; however, the pixyl derivatives of nucleosides can be more readily purified by crystallization. The preparation of monomeric (Christodoulou and Reese, 1983) and all sixteen dimeric (Balgobin et al., 1981b) building blocks for deoxyriboolignucleotide synthesis in solution has been done using the pixyl group, and the combination of such blocks to deoxyribooligonucleotides of biological interest has been described (Josephson and Chattopadhyaya, 1981; Balgobin and Chattopadhyaya, 1982b). A more acid-labile variant is the 9-(panisyl)xanthen-9-yl (MOX) group (S.6; Kwiatkowski et al., 1983; Kwiatkowski and Chattopadhyaya, 1984; Tanimura et al., 1988, 1989; Tanimura and Imada, 1990). Alternatively, the 9-phenylthioxanthen-9-yl (S-pixyl; S.7) and 9-phenyl-7-chlorothioxanthen-9-yl (S.8) groups were introduced to modulate deprotection (Balgobin and Chattopadhyaya, 1982a). The recent finding that the pixyl substituent is susceptible to photochemical cleav-
R
R' X 5 6 7 8
X = O; R = H; R' = H X = O; R = OCH3; R' = H X = S; R = H; R' = H X = S; R = H; R' = Cl
Figure 2.3.6 9-Phenylxanthen-9-yl and related 5′-hydroxyl-protecting groups.
age (Misetic and Boyd, 1998) may revive interest in this 5′-protecting group. Trityl and related groups for 5′-hydroxyl protection in oligoribonucleotide synthesis Somewhat different considerations apply to the use of trityl and related groups for 5′-hydroxyl protection in oligoribonucleotide synthesis. Depurination is not very problematic in this case, which allowed the application of MMTr as the preferred protecting group in earlier studies focusing on the preparation of relatively short sequences by solution methods (for reviews, see Reese, 1978, 1989; Ohtsuka and Iwai, 1987). Detailed procedures for the chemical preparation of small oligoribonucleotides were described by van Boom and Wreesmann (1984). In such oligoribonucleotide syntheses where the conditions of acid deprotection are not of great concern, essentially all of the previously described trityl-derived protecting groups should be applicable in RNA synthesis. This has, in fact, been shown in a number of publications cited earlier; however, for simplicity, most protecting groups have been tested first (and often only) in DNA chemistry. Nonetheless, modern strategies of oligoribonucleotide synthesis, in particular the preparation of long sequences on solid phase, require orthogonality of the complete set of protecting groups used for all functionalities of the RNA synthons. In particular, the intermediate protecting group for the 5′ hydroxyl must blend with the groups used for 2′-hydroxyl protection. The latter must be stable throughout all chain elongations, and their removal after completion of synthesis, in the presence of unprotected phosphodiester internucleotide bonds, should not be done in an alkaline medium for risk of isomerization (e.g., Beaucage and Iyer, 1992). Therefore, 2′-hydroxyl-protecting groups should be removed in acidic solution or by a specific reagent in near-neutral medium. Hence, acid-labile protecting groups of the trityl type can be used for 5′-protection of ribonucleotide synthons only under the following conditions. (1) If an acid-labile protecting group is used for the 2′ hydroxyl, there must be a significant difference in the deprotection rates for the 5′ and 2′ functionalities. (2) If the 2′-hydroxyl-protecting groups are stable to acid and released by a specific reagent in a close-to-neutral medium, there is free choice of acid-labile 5′-hydroxyl protection. (3) An acid-labile protecting group can be used for 2′-hydroxyl protection in combination with a substituent for
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.7 Current Protocols in Nucleic Acid Chemistry
Protection of 5′-Hydroxy Functions of Nucleosides
5′-hydroxyl protection that can be removed under nonacidic conditions. This alternative will be discussed below (see Blocking Groups Labile to Nonacidic Conditions). It is beyond the scope of this unit to give credit to all publications that have described solutions to the above protection alternatives (1) and (2); these are treated in detail in recent reviews (Beaucage and Iyer, 1992, 1993). As a general guideline, it can be said that the combination of the most common acid-labile protecting groups (i.e., DMTr or pixyl for 5′ hydroxyls, and tetrahydropyranyl or 4-methoxytetrahydropyranyl for 2′ hydroxyls) is not fully compatible with approach (1). This can be remedied by changing the conditions or properties of the 5′-hydroxyl-protecting groups or by changing the nature of the 2′-hydroxyl-protecting group. For instance, it was found that the 5′-DMTr group could be deprotected selectively at 0°C without cleavage of 2′-tetrahydropyranyl (Seliger et al., 1983; Caruthers et al., 1986). Since this condition does not lend itself to automated support synthesis, the use of the 4,4′,4′′-trimethoxytrityl protecting group was investigated for the 5′ hydroxyl (Seliger et al., 1986); however, the lability of this substituent caused substantial loss on chromatographic purification of the synthons. A number of 2′-hydroxyl-protecting groups with modulated or increased acid stability have been described that are compatible with 5′DMTr protection. Examples are the 1-(2chloro-4-methylphenyl)-4-methoxypiperidin -4-yl (CTMP) and 1-(2-fluorophenyl)-4methoxypiperidin-4-yl (FPMP) groups (Reese et al., 1986; Reese and Thompson, 1988), and the 1-(2-chloro-ethoxy)ethyl (Yamakage et al., 1989) and 3-methoxy-1,5dicarbomethoxypentan-3-yl (Sandström et al., 1985) groups. However, none of these approaches is of widespread application in current solid-support oligoribonucleotide synthesis. The approach that has currently won the competition for a DMTr-compatible system of 2′- and 5′-hydroxyl protection comes from alternative (2) above, namely the introduction of appropriate silyl groups at the 2′ hydroxyl. This approach, which was mainly developed in the laboratory of Ogilvie (Usman et al., 1987, and references therein; Ogilvie et al., 1988), has been extensively investigated during recent years (for discussion, see Beaucage and Iyer, 1992) and is at present the most commonly used method for automated solid-phase oligoribonucleotide preparations.
Triarylmethyl Groups as Affinity Ligands Up to now, the modification of trityl protecting groups has been discussed only with respect to steering the acid lability by introduction of one, two, or three p-methoxy substituents. In an attempt to simplify the workup of the crude product of polymer-support synthesis, it was first shown that MMTr or DMTr groups can serve to single out the target chains by hydrophobic chromatography if they remain bound to the last monomer unit after completion of chain elongations (“trityl-on purification”; Seliger et al., 1977a, 1978). Subsequent to purification, these groups are cleaved with 80% acetic acid to generate the unprotected oligonucleotide. Such groups are referred to as “purification handles.” More recently, a number of trityl groups substituted with longer alkyl chains, ranging from C8H17 to C16H33 (S.9 to S.13; Table 2.3.2), have been described as lipophilic protecting groups (Görtz and Seliger, 1981) and used for separation on reversed-phase columns (Seliger and Görtz, 1981). The structures of substituted trityl groups tailored for purification assistance and other special applications are summarized in Table 2.3.2. The 4-decyloxytrityl (C10Tr or DTr) group (S.10, Fig. 2.3.7; Seliger and Schmidt, 1987) was found to be especially useful for the purification of genes and gene fragments with lengths up to 147 bases (Seliger et al., 1987; Schmidt et al., 1988). The C16Tr group (S.13) has the highest lipophilic affinity; however, the solubility of C16Tr-nucleosides in acetonitrile and other solvents common for oligonucleotide synthesis is somewhat decreased. In order to minimize the risk of depurination during terminal acid deprotection, a series of more labile 4-methoxy-4′-alkoxytrityl groups (S.14 to S.20; Table 2.3.2) was proposed for purification assistance (Gupta et al., 1991). Of these, the 4-methoxy-4′-octyloxytrityl group (S.19; MOTr; Fig. 2.3.7) was found most suitable. The 4,4′-dianisyl-2′′-hexadecyloxyphenyl group (S.21; Table 2.3.2) has mainly been used for oligoribonucleotide purification (van Boom and Wreesman, 1984). The pixyl (S.5), MOX (S.6; Kwiatkowski et al., 1983; Kwiatkowski and Chattopadhyaya, 1984; Tanimura et al., 1988, 1989; Tanimura and Imada, 1990), and especially the 9-(4-octadecyloxyphenyl)xanthen-9-yl (C18Px; S.22; Fig. 2.3.7; Welch et al., 1986) groups have been used as purification handles in solution- and solid-phase oligonucleotide synthesis.
2.3.8 Current Protocols in Nucleic Acid Chemistry
Table 2.3.2 5′-Hydroxyl-Protecting Groups (R1, R2, and R3) of the Substituted Triarylmethyl Type as Purification Handles or for Other Special Applicationsa,b
StrucR1 ture S.2 Phenyl S.3
Phenyl
p-Anisyl
p-Anisyl
S.5
Phenyl
Xanthen-9-yl
Xanthen-9-yl
AbbreviaDeprotection tion MMTr Acid, ZnBr2, etc. DMTr Acid, ZnBr2, etc. Px Acid
S.6
p-Anisyl
Xanthen-9-yl
Xanthen-9-yl
C1Px
Acid
S.9 Phenyl S.10 Phenyl
Phenyl Phenyl
4-Octyloxyphenyl 4-Decyloxyphenyl
Acid Acid
S.11 Phenyl
Phenyl
Acid
Seliger and Schmidt (1987)
S.12 Phenyl
Phenyl
C14Tr
Acid
Seliger and Schmidt (1987)
S.13 Phenyl
Phenyl
C16Tr
Acid
Seliger and Schmidt (1987)
S.14 S.15 S.16 S.17 S.18 S.19 S.20
p-Anisyl p-Anisyl p-Anisyl p-Anisyl p-Anisyl p-Anisyl p-Anisyl
4-Dodecyloxyphenyl 4-Tetradecyloxyphenyl 4-Hexadecyloxyphenyl 4-Propyloxyphenyl 4-Butyloxyphenyl 4-Pentyloxyphenyl 4-Hexyloxyphenyl 4-Heptyloxyphenyl 4-Octyloxyphenyl 4-Dodecyloxyphenyl 2-Hexadecyloxyphenyl Xanthen-9-yl
C8Tr C10Tr or DTr C12Tr
Chattopadhyaya and Reese (1978) Kwiatkowski and Chattopadhyaya (1984) Seliger and Schmidt (1987) Seliger and Schmidt (1987)
Acid Acid Acid Acid Acid Acid Acid
Gupta et al. (1991) Gupta et al. (1991) Gupta et al. (1991) Gupta et al. (1991) Gupta et al. (1991) Gupta et al. (1991) Gupta et al. (1991)
Acid
Phenyl Phenyl Phenyl Phenyl Phenyl Phenyl Phenyl
S.21 p-Anisyl
R2
R3
Phenyl
p-Anisyl
p-Anisyl
S.22 4-Octadecyl- Xanthen-9-yl oxyphenyl S.23 p-Anisyl p-Anisyl S.24 Phenyl Phenyl S.25 p-Anisyl
p-Anisyl
S.26 p-Anisyl
p-Anisyl
S.30 Phenyl S.31 o-Anisyl S.32 Phenyl S.33 Phenyl S.34 Phenyl S.35 p-Anisyl
p-Anisyl o-Anisyl p-Fluorophenyl Phenyl o-Anisyl p-Anisyl
S.36 p-Anisyl
p-Anisyl
Pyrenyl 4-(17-Tetrabenzo(a,c,g,i)fluorenylmethyl)phenyl 4-(17-Tetrabenzo(a,c,g,i)fluorenylmethyl)phenyl 4-[(Succinimidyl-Noxy)carbonyl]phenyl 1-Naphthyl 1-Naphthyl 1-Naphthyl p-Tolyl o-Anisyl 3-(Imidazolyl-1methyl)phenyl 3-(Imidazolyl-1ethylcarbamoyl) phenyl
MOTr
Reference Seliger et al. (1978) Seliger et al. (1978)
C18Px
Acid
BMPM TBF-Tr
Acid Acid
van Boom and Wreesman (1984) Kwiatkowski and Chattopadhyaya (1984) Fourrey et al. (1987) Ramage and Wahl (1993)
TBFDMTr
Acid
Ramage and Wahl (1993)
Acid
Gildea et al. (1990)
Acid, ZnBr2 Acid, ZnBr2 Acid, ZnBr2
Fisher and Caruthers (1983) Fisher and Caruthers (1983) Fisher and Caruthers (1983)
IDTr
Acid, ZnBr2 Acid, ZnBr2 Acid
Fisher and Caruthers (1983) Fisher and Caruthers (1983) Sekine and Hata (1987)
IETr
Acid
Sekine et al. (1993)
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.9 Current Protocols in Nucleic Acid Chemistry
Table 2.3.2 Continued
StrucR1 ture S.37 p-Anisyl
R2
R3
p-Anisyl
S.38 p-Anisyl
p-Anisyl
S.39 p-Anisyl
p-Anisyl
S.40 p-Anisyl
p-Anisyl
3-(Imidazolyl-1propylcarbamoyl) phenyl 3-(Imidazolyl-1IBTr butylcarbamoyl)phenyl 3-(Imidazolyl-1IHTr hexylcarbamoyl)phenyl 3-(N-MethylimidIMTr azolyl-2-ethylcarbamoyl)phenyl p-Benzoyloxyphenyl
S.41 p-Benzoyl- p-Benzoyloxyl oxyphenyl S.42 p-(4,5p-(4,5-DichloroDichlorophthalimido) phthalimido) phenyl phenyl S.43 p-(Levulin p-(Levulin yloxy)phenyl yloxy)phenyl S.44 p-Anisyl
p-Anisyl
S.45 p-Anisyl
p-Anisyl
p-(4,5-Dichlorophthalimido) phenyl
AbbreviaDeprotection tion IPTr Acid
CPTr
p-(Levulinyloxy)phenyl p-(Fluorenyl-9-methoxycarbonyl)phenyl p-(Fluorenyl-9-methoxy carbonyl)aminophenyl
Reference Sekine et al. (1993)
Acid
Sekine et al. (1993)
Acid
Sekine et al. (1993)
Acid
Sekine et al. (1993)
Alkali
Sekine and Hata (1983)
Hydrazine in Sekine and Hata (1984); pyridine/acetic Happ and Scalfi-Happ acid (1988) Hydrazine in Sekine and Hata (1985) pyridine/acetic acid β- elimination Happ and Scalfi-Happ (1988) β-elimination Happ and Scalfi-Happ (1988)
aAbbreviations: BMPM, 1,1-bis(4-methoxyphenyl)-1-pyrenylmethyl; CPTr, tris-(4,5-dichlorophthalimido)trityl; DMTr, dimethoxytrityl; DTr, 4-decyloxytrityl; IBTr, (imidazolyl-1-butylcarbamoyl)dimethoxytrityl; IDTr, (imidazolyl-1-methylcarbamoyl)dimethoxytrityl; IETr, (imidazolyl-1-ethylcarbamoyl)dimethoxytrityl; IHTr, (imidazolyl-1-hexylcarbamoyl)dimethoxytrityl; IMTr, N-methylimidazolyl-(Z-ethylcarbamoyl)dimethoxytrityl; IPTr, (imidazolyl-1-propylcarbamoyl)dimethoxytrityl; MOTr, 4-methoxy-4′-octyloxytrityl; MMTr, monomethoxytrityl; Px, 9-phenylxanthen-9-yl (pixyl); Tr, triphenylmethyl (trityl). bOther applications might include purification, fluorescent labeling, visible absorption, biotin substitution, color coding, 3′-phosphate activation, and nonacidic cleavage.
Protection of 5′-Hydroxy Functions of Nucleosides
The 1,1-bis(4-methoxyphenyl)-1-pyrenylmethyl (BMPM) group (S.23; Fig. 2.3.8; Table 2.3.2; Fourrey et al., 1987) not only allows the easy purification of target sequences from the solid-phase preparation of deoxyribooligonucleotides and their methyl phosphonate analogs, but also allows their detection by thinlayer chromatography (TLC) or gel electrophoresis down to the picomole level by virtue of the fluorescence of the 5′ substituent in the visible range. Ramage and Wahl (1993) have described the 4-(17-tetrabenzo(a,c,g,i)fluorenylmethyl)trityl (TBF-Tr; S.24) and 4-(17tetrabenzo(a,c,g,i)fluorenylmethyl)-4′,4′′dimethoxytrityl (TBF-DMTr; S.25; Fig. 2.3.8; Table 2.3.2) protecting groups. The latter group was especially found interesting for the purification of long oligonucleotides. Its acid hydrolysis is about twice as fast as that of DMTr, and the product is easily identified through the visible absorption of the substituent. The yields
of TBF-DMTr-protected synthons in phosphoramidite synthesis were only between 70% and 88%, but this problem could be circumvented by postsynthetic treatment of the 5′-deprotected, support-bound oligonucleotide with TBF-DMTrCl. Gildea et al. (1990) have described a DMTr group substituted with a hydroxysuccinimide active ester residue (S.26; Fig. 2.3.9). This linker allowed the addition of, for example, biotin, allowing the possibility of purifying a target oligonucleotide from a crude solid-phase product on a streptavidin-agarose column (Fig. 2.3.9). The 5′-hydroxyl-protecting group could subsequently be released by acid treatment to elute the unprotected oligonucleotide. This trityl-on purification scheme can be coupled with chemical 5′ phosphorylation, as demonstrated by Lönnberg and collaborators (see protecting group S.27 in Figure 2.3.10; Guzaev et al., 1995). Bannwarth and Wippler have de-
2.3.10 Current Protocols in Nucleic Acid Chemistry
OC18H37
C10H21O
CH3O
C
C
O OC8H17
10 (DTr)
22 (C18Px)
19 (MOTr)
Figure 2.3.7 Examples of trityl or pixyl groups modified to serve as purification handles (for complete list see Table 2.3.2).
scribed an interesting approach to combined purification and phosphorylation by adding a protected uridine-5′-phosphate at the 5′ terminus of an oligonucleotide chain. The uridine base was modified with a DMTr-protected thioether residue (S.28 in Fig. 2.3.10). After detritylation, the target sequence was selectively retained and purified by disulfide formation with the activated thiol function of a resin. The oligonucleotide was released by periodate treatment with formation of a terminal 5′ phosphate (Bannwarth and Wippler, 1990). Of course, the “dual applications” described above for many modified or substituted trityl groups can be similarly found in oligoribonucleotide chemistry. The trityl-on purification, for instance, is adaptable in the ribonucleotide series, and a recent publication has established that the deprotection of DMTr does not cause migration of the internucleotidic linkages (Mullah and Andrus, 1996). The 4,4′-dimethoxy-2′′-hexadecyloxytrityl group (S.21; van Boom and Wreesmann, 1984) and the 9(4-octadecyloxyphenyl)xanthen-9-yl group (S.22; Welch et al., 1986) were alternatively introduced to promote the separation of RNA fragments. A problem inherent to polymer-support synthesis is that the product is always a more or less complex mixture of the desired chain with
CH3O
truncated and failure sequences (Földes-Papp et al., 1998, and references therein). In view of the efficiency and selectivity of affinity techniques, a solution-phase synthesis using “affinity protecting groups” would be an interesting alternative to solid-phase preparations (Seliger, 1993). An example of such an affinity separation–based solution synthesis was described (Seliger et al., 1977b) using a combination of the 5′-MMTr and 3′-lipoyl groups. Very recently, an approach to large-scale oligonucleotide synthesis was described in which the chain elongation was done in solution and the extended chain was intermediately anchored to a polymer via a Diels-Alder reaction, so as to allow filtration of educts and by-products (product-anchored sequential synthesis or PASS; Pieken, 1997). A purification-oriented oligonucleotide synthesis in solution has also been achieved through the use of a bridged bis-DMTr 5′-protecting group as soluble carrier (S.29 in Fig. 2.3.11; Biernat et al., 1983).
Color-Coded Triarylmethyl Groups and Triarylmethyl Groups with a Catalytic Function In order to modulate the visible absorption of the species obtained after nonaqueous acid deprotection, a variety of groups of the triarylmethyl type has been constructed (see S.30 to
OCH3
OCH3
C
C
OCH3
23 (Bmpm)
25 (Tbf-DMTr)
Figure 2.3.8 Examples of trityl groups tailored to serve as combined purification handles and visible-absorbing fluorescent markers.
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.11 Current Protocols in Nucleic Acid Chemistry
OCH3
CH3O
C
O
O
N
O
O
26
OCH3
HN
C O oligonucleotide−OH
CH3O
O NH H N
S
N H
O
O
Figure 2.3.9 A hydroxysuccinimide-substituted DMTr group and its biotinyl derivative for affinity purification of solid-phase oligonucleotide products.
S.34 in Table 2.3.2). This should allow the “color coding” of different synthons (Fisher and Caruthers, 1983), a principle that has not found application in routine automated oli-
EtO2C CO2Et DMTrO
DMTrO
B
O
EtO2C CO2Et
O
O P O O
NC O
gonucleotide synthesis, but may be useful to monitor the mixed simultaneous addition of two or more nucleotides.
O
O O
DMTrO
B
O
O P O − O
NH3
O
B
OH
O 27
P
P AcOH / H2O 1. Cl2CHCO2H / CH2Cl2 2. NH3
−
EtO2C CO2Et
O
O P O − O
O
HO
B base
O
O P O − O
OH
O
B
OH
BzO O OBz O MMTrS
O P OR
N 11
Protection of 5′-Hydroxy Functions of Nucleosides
O
N
O O
O
B
OH 28
Figure 2.3.10
5′-Phosphorylation via DMTr- or MMTr-protected protecting groups.
2.3.12 Current Protocols in Nucleic Acid Chemistry
Cl3CCH2O Cl3CCH2O P O O O
B
O C O
O C O
O
B
O O P OCH2CCl3 OCH2CCl3
29
Figure 2.3.11 Example of modified trityl protection for a purification-oriented solution synthesis (Biernat et al., 1983).
tuted derivatives, other acid-labile residues do not play a role as protecting groups in current oligonucleotide chemistry. Acetal groups have, for example, been used in early syntheses (e.g., Grams and Letsinger, 1970), and 5′-O-tetrahydropyranyl or 5′-O-methoxytetrahydropyranyl derivatives have been mentioned (Reese, 1978). Although a thorough discussion is not in the scope of this unit, there are also approaches to solid-phase oligonucleotide synthesis that use a support anchored to the 5′-hydroxy function. A number of studies appeared, especially in the 1980s, in which support-bound trityl groups were used as anchors for oligonucleotide preparations in the 5′-to-3′ direction (Shabarova, 1980; Belagaje and Brush, 1982; BirchHirschfeld et al., 1983; Rosenthal et al., 1983). The availability of 3′-protected nucleoside-5′phosphoramidites or -H-phosphonates allows
Through another structural modification, namely the introduction of an imidazol-1-ylmethyl residue, the DMTr substituent could be transformed into a protecting group that serves to activate a protected 3′-phosphate moiety (S.35; Fig. 2.3.12; Sekine and Hata, 1987). This concept was recently exended to the introduction of a number of 3-imidazolylalkylcarbamoylphenyl-4,4′-dianisylmethyl substituents (S.36 to S.39, Fig. 2.3.12), as well as a corresponding N-methylimidazolyl derivative (S.40; Sekine et al., 1993; Wada et al., 1998b). In addition to accelerating the rate of internucleotide bond formation, a shift in the ratio of diastereomeric triester was observed in some cases.
Miscellaneous Acid-Labile 5′-Substituents In view of the multiple advantages of trityl groups, as well as their modified and substi-
OCH3
OCH3
CH3O
C
O
O
B
CH3O
O N
+
N P O
−
Cl
C
OCH3
O
O O
O
O P SPh
HN
SPh
n
SPh
CH3O
C
O
O
B
O
O
O P SPh
HN
SPh
N MeN
N 35
B
36 37 38 39
n=2 n=3 n=4 n=6
N
40
Figure 2.3.12 DMTr groups substituted with imidazolyl residues for 3′-phosphate activation (S.36 to S.40), and a proposed activated intermediate (S.35).
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.13 Current Protocols in Nucleic Acid Chemistry
the use of all timely methods of solid-phase synthesis in both directions of chain growth. Finally, it may be noteworthy that Tr or DMTr groups present at the 5′ terminus of deoxyribooligonucleotides were found to enhance their anti-HIV activity (Furukawa et al., 1994; Hotoda et al., 1994), a fact that was attributed to the enhancement of membrane permeability through the remaining protecting group.
BLOCKING GROUPS LABILE TO NONACIDIC CONDITIONS Acyl Substituents and Base-Labile Triarylmethyl Groups
Protection of 5′-Hydroxy Functions of Nucleosides
In spite of their obvious advantages, acidlabile protecting groups for the 5′-hydroxy function have some limitations to their application in oligonucleotide synthesis. In the deoxyribonucleotide series, even a small number of statistically distributed depurination sites may seriously impair the quality of a solid-phase or large-scale synthesis product. In the ribonucleotide series, multiple acid deprotection steps may interfere with the stability of 2′-hydroxylprotecting groups. This has stimulated the search for new orthogonal protection schemes involving 5′-hydroxyl-protecting groups that can be deblocked under nonacidic conditions. Of course, there are limitations to the use of simple acyl groups such as acetyl or benzoyl as long as the exocyclic amino groups of nucleobases are blocked by acyl residues as well. Thus, acetyl protecting groups are found in the recent literature only for syntheses at the monomer level—e.g., in the preparation of 15N-labeled (Kamaike et al., 1995, 1996) or 2H-labeled nucleosides (Kawashima et al., 1995, 1997), or of components for oligodeoxyribonucleotides with base-modified or mutagenic units (Matsuda et al., 1993; Ozaki et al., 1994; for earlier literature see, e.g., Kössel and Seliger, 1975; Reese, 1978; Sonveaux, 1986). From the preparative standpoint, methods for rapid O-acylation of nucleoside hydroxy groups through phase-transfer catalysis may be noteworthy (Sekine, 1993). Isobutyryl (Gaffney and Jones, 1982a,b) or methoxyacetyl groups (Reese and Skone, 1984) were introduced at sugar hydroxy functions in order to allow the additional protection of the 6-oxo group of deoxyguanosine as well as the 4-oxo group of thymidine. Acyl groups that can be removed under virtually neutral conditions are more attractive. Earlier examples, such as methoxy- and phenoxyacetyl (Reese and Stewart, 1968), did not
completely fulfill the expectations. A more interesting alternative was the o-bromomethylbenzoyl group (S.46; Fig. 2.3.13; Chattopadhyaya et al., 1979), which was used for the preparation of an SV40-specific deoxyribooligonucleotide (Chattopadhyaya and Reese, 1980). Derivatives of the 4-hydroxybutyryl and 2-hydroxymethylbenzoyl groups (Brown et al., 1984; van Boom and Wreesman, 1984; Reese, 1985; Brown et al., 1989a,b) are similarly of interest, since the neighboring participation of the hydroxy groups allows their hydrolysis under extremely mild conditions. Of course, the hydroxy groups have to be protected during chain elongation. In case of the 4-(methylthiomethoxy)butyryl (MTMB; S.51), 2-(methylthiomethoxymethyl)benzoyl (MTMT; S.47), and 2-(isopropylthiomethoxymethyl)benzoyl (DTMT; S.48) groups (Fig. 2.3.13), the deblocking of the methylthiomethyl residue was done with mercury(II) perchlorate and 2,4,6-collidine within 3 hr at room temperature, and the subsequent treatment with K2CO3 in tetrahydrofuran/water released the 2-hydroxymethylbenzoyl substituent within 30 sec (Fig. 2.3.14). As an alternative, the 2-(2,4-dinitrophenylsulfenyloxymethyl) benzoyl (DNBSB) group (S.49; Fig. 2.3.13) was initiated by removal of the sulfenyl residue with p-toluenethiol (Christodoulou et al., 1987a,b). Although these “protected protecting groups” are appealing from their deprotection conditions, difficulties in in-
O R'
R 46 R = Br; R' = H 47 R = OCH2SCH3; R' = H 48 R = OCH2SCH(CH3)2; R' = H 49 R = O S
NO2
R' = H
O2N 50 R = OCOCH2CH2COCH3; R' = NO2 O
R'' 51 R'' = OCH2SCH3
Figure 2.3.13 Acyl substituents for removal at close-to-neutral pH.
2.3.14 Current Protocols in Nucleic Acid Chemistry
S O O
O
OH
Hg(CIO4)2
T
O
collidine
O
T
K2CO3 THF/H2O
HO
O
T
O
O
HO
HO
HO
Figure 2.3.14 Example of two-step removal of an ortho-substituted benzoyl protecting group (Brown et al., 1984; Reese, 1985).
troduction and, in particular, the two-step procedure of removal make them less practical for current automated oligonucleotide synthesis. The β-benzoylpropionyl (S.52; Letsinger et al., 1967) and the levulinyl (S.53; van Boom and Burgers, 1976; Iwai and Ohtsuka, 1988; Iwai et al., 1990) groups can be deprotected by hydrazine in a pyridine/acetic acid mixture (Fig. 2.3.15). However, a partial deprotection of acyl groups from the nucleobases was also observed under the conditions of hydrazinolysis of the β-benzoylpropionyl group (Letsinger and Miller, 1969). Especially mild conditions of hydrazinolytic deprotection apply to the 2-levulinyloxymethyl-5-nitrobenzoyl group (S.50; Fig. 2.3.13; Kamaike et al., 1997). Appropriate substitution with electrondonating substituents that stabilize a trityl cation may strongly modify the conditions of cleavage. Based upon the earlier finding that the 4-hydroxytrityl group is hydrolyzed much more easily than the corresponding 4-acetoxytrityl residue (Taunton-Rigby et al., 1972), the 4,4′,4′′-tris(benzoyloxy)trityl substituent (S.41; Table 2.3.2) was prepared as an acid-stable but base-labile “protected 5′-protecting group” (Sekine and Hata, 1983), the removal of which is shown in Figure 2.3.16. This principle was further extended to 4,4′,4′′-tris(4,5dichlorophthalimido)trityl (S.42; Sekine and Hata, 1984) and 4,4′,4′′-tris(levulinyloxy)trityl (S.43; Table 2.3.2; Sekine and Hata, 1985) as protecting groups labile to hydrazine treatment in pyridine/acetic acid. Based on the same general concept, the 4-(9-fluorenylmethoxycarbonyl)oxy-4′,4′′-dimethoxytrityl (S.44) and 4-(9-fluorenyl-
methoxycarbonyl)amino-4′,4′′-dimethoxytrityl) (S.45; Table 2.3.2) groups were introduced. Their release could be triggered through β-elimination (Scalfi-Happ et al., 1987; Happ and Scalfi-Happ, 1988). The usefulness of hydrazine-labile modified trityl groups such as 4,4′,4′′-tris(4,5-dichlorophthalimido)trityl (S.42; Sekine and Hata, 1984, 1986; ScalfiHapp et al., 1987) and the S.44 and S.45 groups for β-elimination-triggered deprotection (Happ and Scalfi-Happ, 1988) was also demonstrated for large-scale oligoribonucleotide synthesis and for the preparation of 2′(3′)-Oaminoacyl-oligoribonucleotides (Scalfi-Happ et al., 1987).
Carbonate-Type Protecting Groups Protecting groups of the carbonate type, most popular in peptide chemistry, have also received much attention in oligonucleotide synthesis. In earlier work, the isobutyloxycarbonyl group (S.54; Fig. 2.3.17; Ogilvie and Letsinger, 1967) and the p-nitrophenyloxycarbonyl (NPOC) group (S.55; Letsinger and Ogilvie, 1967) were shown to be introduced rather selectively at 5′-hydroxy functions en route to 3′-tritylated thymidine and uridine derivatives. However, their removal in dilute sodium hydroxide/dioxane would not be compatible with exocyclic acyl protection of nucleobases. p-Nitrophenyloxycarbonyl and a number of other carbonate protecting groups could also be introduced into partially protected thymidine and uridine via the corresponding 5′-chloroformates (Seliger, 1972). These studies later led to the introduction of the 5′-p-phenylazophenyl-
O O
R
O
B
O HO
NH2NH2
HO
N NH R
O
O
B
pyridine / acetic acid HO
52 R = phenyl 53 R = methyl
Figure 2.3.15 groups.
Hydazinolytic deprotection of β-benzoylpropionyl (S.52) and levulinyl (S.53)
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.15 Current Protocols in Nucleic Acid Chemistry
O Ph
O
O
O
O
Ph O O
C X
OH
O
C X
C
HX HX
O Ph
O
O
X = nucleoside-5'-oxy
O 41
Figure 2.3.16 group.
Protection of 5′-Hydroxy Functions of Nucleosides
4,4′,4′′-Tris(benzoyloxy)trityl as an acid-stable, base-labile 5′-hydroxyl-protecting
oxycarbonyl (PAPOC) group (S.56; Kössel and Seliger, 1975), which was introduced via pphenylazophenylchloroformate (Seliger and Kotschi, 1985; Seliger et al., 1986). This group could be released by a two-step treatment with β-cyanoethanol/triethylamine and diazabicycloundecene (DBU). This group retains some of the features of trityl- or pixyl-type substituents (i.e., its deprotection gives a visible-absorbing solution), and the PAPOC nucleosides are readily crystalline; however, the two-step deprotection procedure is less advantageous. More attention has been given to the 9-fluorenylmethoxycarbonyl (FMOC) group (S.57, Fig. 2.3.17), a standard in peptide protection. FMOC-protected synthons allowed an alternative protocol for solid-support deoxyribooligonucleotide synthesis, retaining the standard acyl protection for the bases and avoiding acid deblocking steps (Gioeli and Chattopadhyaya, 1982; Balgobin and Chattopadhyaya, 1987; Ma and Sonveaux, 1987, 1989). The potential of 5′-FMOC protection for oligoribonucleotide synthesis was demonstrated by Fukuda et al. (1988) and by the group of Gait (Lehmann et al., 1989). The FMOC group was also used in acetal-linked solid-support oligonucleotide synthesis (Palom et al., 1993). Recently, the p-chlorophenyloxycarbonyl group (S.57a, Fig. 2.3.17) was found to be removed in <2 min in a solution of peroxyanions buffered to pH 9.6 (10 ml LiOH⋅H2O, 12 ml 30% H2O2, 1.78 g m-chloroperbenzoic acid, 15 ml 1.5 M AMP buffer, pH 10.3, in 50 ml dioxane; Caruthers et al., 1994; Dellinger et al., 1998). This allowed the design of a solid-phase two-step chain-elongation cycle consisting of only a coupling step and the combined deprotection/oxidation step (excluding capping), reducing the phosphoramidite cycle time to 6 min.
Other carbonate protecting groups that could be selectively released in the presence of baseprotecting acyl groups include 2-(trimethylsilyl)ethoxycarbonyl (S.58; Fig. 2.3.17; Gioeli et al., 1981) and 2-(phenylsulfonyl)ethoxycarbonyl (S.59; Balgobin et al., 1981a). More recently, Pfleiderer and colleagues have developed an orthogonal protection scheme for solution- and solid-phase deoxyribo- and ribooligonucleotide synthesis, with avoidance of acid-deprotection steps. The main feature is the exclusive use of protecting groups that can be cleaved by β-elimination. For instance, in combination with the p-nitrophenylethyl (NPE) phosphate protecting group, the 2-(4-nitrophenyl)ethoxycarbonyl (NPEOC; S.60) or 2-(2,4-dinitrophenyl)ethoxycarbonyl (DNPEOC; S.61) substituents were applied for 5′-protection (Schirmeister et al., 1993; Fig. 2.3.18). The NPE/NPEOC strategy was further extended to large-scale oligonucleotide synthesis (Weiler and Pfleiderer, 1995). Particularly attractive is the dansylethoxycarbonyl group (S.62; Bergmann and Pfleiderer, 1994a,b,c), which
O R
O
O
O
B
HO
54 55 56 57 57a 58 59 88
R = isobutyl R = p-nitrophenyl R = p-phenylazophenyl R = fluoren-9-methyl R = p-chlorophenyl R = 2-trimethylsilylethyl R = 2-phenylsulfonylethyl R = o-nitrophenyl
Figure 2.3.17 Carbonate protecting groups for the 5′-hydroxy function.
2.3.16 Current Protocols in Nucleic Acid Chemistry
RO2C O
O
B NO2
O (i-Pr)2N
P
O
60 R = NO2
61 R = O2N
NO2
O S 62 R =
O NMe2
Figure 2.3.18 Carbonate substituents for 5′OH as part of an orthogonal scheme of protecting groups that can be cleaved by β-elimination.
can easily be cleaved with dilute DBU in aprotic solvent and allows yield monitoring by far UV or fluorescence detection at 530 nm, even in small-scale synthesis of long RNA molecules (Pfleiderer et al., 1995). A further advantage of this scheme of deprotection via β-elimination in solid-phase synthesis is the possibility of retaining a deprotected oligonucleotide product on the support, which facilitates purification of the target sequence.
5′-O-Silyl Protecting Groups The use of silyl groups for 5′-hydroxyl protection does not have any major advantages over trityl in the deoxyribonucleotide series; examples in the literature are concerned with modeling the behavior of different silyl groups (e.g., S.63 to S.67; Fig. 2.3.19; Ogilvie et al., 1974) or the preparation of structurally modified nucleosides (e.g., keto-nucleosides; Robins et al., 1990; McEldoon and Wiemer, 1995). In oligoribonucleotide synthesis, however, silyl protecting groups are nearly essential in developing orthogonal protection systems. The alternative of 2′-silyl protection combined with 5′-MMTr or 5′-DMTr has been discussed above (see Triarylmethyl and Related Substituents). A new route to orthogonal ribonucleoside protection uses acid-labile groups for the 2′-hydroxy function in combination with silyl sub-
stituents at the 5′-hydroxy function. In this case, the tetra(isopropyl)disiloxane-1,3-diyl group (S.68; Fig. 2.3.19; Markiewicz, 1979, 1980) can be elegantly used as a transient bifunctional protecting group for 3′ and 5′ hydroxyls, which ensures the regioselective introduction of an acid-labile group at the 2′ position. Subsequent to deblocking of the disiloxane-diyl group, another silyl substituent is selectively attached to protect the 5′-hydroxy function. Two approaches of this kind have recently been described. The 1,1,3,3-tetraisopropyl-3[2-(triphenylmethoxy)ethoxy]disiloxane-1-yl (TES) group (S.69; Fig. 2.3.19; Hirao et al., 1998), a “trityl-protected silyl protecting group,” can be deblocked with 0.1 M tetrabutylammonium fluoride in tetrahydrofuran within 1 min at room temperature. The resultant deblocking solution will be colored on addition of acid. In solid-phase synthesis, using terephthalate as an anchor to the support, the silyl deprotection conditions do not lead to removal of other blocking groups except for the β-cyanoethyl residue at the internucleotidic linkages, which is lost during this treatment. A better solution to this orthogonality problem has recently been reported (Caruthers, 1998, and pers. comm.). A number of silyl substituents (S.70 to S.86; Fig. 2.3.20) can be regioselectively introduced and deprotected in <30 sec with tetrabutylammonium fluoride in tetrahydrofuran. On testing for stability in acid and base (Table 2.3.3), this author found that the bis(trimethylsiloxyl)cyclooctyloxysilyl group (S.83) was best for 5′-hydroxyl protection, as the resulting fully protected phosphoramidite synthons (Fig. 2.3.21) could be prevented from oiling out on workup. The internucleotidic bonds, in this case, were protected by the methoxy group, which was found to be resistant to fluoride cleavage, but is released with a thiol reagent. Alternatively, the bis(trimethylsiloxyl)-1,3-(trityloxy)propyl-2-oxysilyl group (S.87; Fig. 2.3.20) can be designated for monitoring the deprotection step.
Photosensitive 5′-Hydroxyl-Protecting Groups Groups that can be cleaved by photochemical methods have not been of relevance to 5′-hydroxyl protection in earlier times, although photolabile phosphate-protecting groups such as o-nitrobenzyl were in use (Hasan et al., 1997, and references therein). Only recently has the photochemical cleavage of 5′-hydroxyl-protecting groups become an
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.17 Current Protocols in Nucleic Acid Chemistry
R2
O
R1 Si O
O
R3
O
B
Si
B
O
TrO
O Si
HO
Si O
Si O
OH
63 R1 = CH3; R2, R3 = isopropyl
69
68
64 R1 = isopropyl; R2, R3 = cyclopentyl 65 R1, R2 = CH3; R3 = t-butyl 66 R1, R2, R3 = isopropyl 67 R1 = t-butyl; R2, R3 = cyclopentyl
Figure 2.3.19
Silyl protecting groups for the 5′-hydroxy function.
of relevant oligonucleotide spots in a technique similar to photolithography. The efficiency of this technique relies very much on the ease of photochemical deprotection and the extent to which it can be quantified. Several new protecting groups been developed for this purpose. Based on the experience of investigations on carbonate protecting groups, the o-nitrophenyloxycarbonyl (NPOC; S.88;
interesting option, since Fodor and collaborators pointed out the possibility of producing DNA arrays on glass substrates (DNA “chips”) by light-directed solid-phase synthesis (Fodor et al., 1991; Pease et al., 1994). Arrays containing up to 106 unique oligonucleotide sequences per square centimeter can be constructed by the elongation of each sequence triggered through photodeprotection of the 5′-hydroxy function R1 R2 Si O
O
R3
B
HO
O a
Si O PAP
b
Me3SiO
Me d
c
e
O O
TrO
O
O O
g
f
h
i OAc
Ph3SiO j
Protection of 5′-Hydroxy Functions of Nucleosides
O
l
k
Structure
R1
R2
R3
70 71 72 73 74 75 76 77
a a a a a a b b
b h j
78 79
d j
80 81 82 83 84 85 86 87 104 105
a j
a a a a a b b b j k a j
e e e k i e methyl isopropyl
e e k k e e methyl isopropyl
f g b b j j k c k e k k k e i i i
Figure 2.3.20 Silyl protecting groups that are rapidly deblocked by tetrabutylammonium fluoride (Caruthers, 1998). PAP, 4-phenylazophenyl.
2.3.18 Current Protocols in Nucleic Acid Chemistry
Table 2.3.3 Fluoride Deprotection and Acid/Base Degradation of Silyl Protecting Groups S.70 to S.86a
Structure
R1, R2, R3
S.70 S.71 S.72 S.73 S.74 S.75 S.76 S.77 S.78 S.79 S.80 S.81 S.82 S.83 S.84 S.85 S.86
a,a,b a,a,h a,a,j a,a,f a,a,g a,b,b b,b,b b,b,j d,j,j j,k,k a,a,c j,j,k e,e,e e,e,k e,k,k k,k,k i,e,e
Fluoride deprotectionb <1 min <15 sec <15 sec <30 sec <30 sec <30 sec <15 sec <15 sec <15 sec <15 sec <15 sec <15 sec <15 sec <15 sec <15 sec <15 sec <15 sec
Acid degradation (%)c 1% 24 hr 100% 24 hr 1% 24 hr 1% 24 hr 5% 13 hr NA 5% 5 hr 1% 24 hr NA NA NA NA NA NA NA NA NA
Base degradation (%)d 0% 24 hr 75% 24 hr 0% 24 hr 0% 24 hr 5% 13 hr NA 5% 5 hr 0% 24 hr NA NA NA NA NA NA NA NA NA
aFrom Caruthers (1998 and pers. comm.). See Figure 2.3.20 for structures and substituents (R1, R2, R3). bTime for complete removal of protecting group with 5 eq tetrabutylammonium fluoride in tetrahydrofuran. cPercent degradation in 0.01 M HCl within specified time. NA, data not available. dPercent degradation in 10% aqueous triethylamine within specified time. NA, data not available.
Fig. 2.3.17) and o-nitrophenylethoxycarbonyl (NPEOC; S.89; Fig. 2.3.22) groups were reported from Pfleiderer’s laboratory (Hasan et al., 1997). Their photochemical cleavage leads to the formation of o-nitrobenzaldehyde and CO2 in the case of NPOC, or o-nitrostyrene and CO2 in the case of NPEOC (Fig. 2.3.23). The parent nucleosides were recovered in a clean reaction after irradiation at 365 nm, with a half-life of 7.5 min for NPEOC (Bühler et al., 1999; Table 2.3.4). Such long deprotection times are, of course, less suitable if a great
Me3SiO
O Si O
B
O
Me3SiO MeO
P i-Pr2N
O
O
O O
OAc OAc
B = uracil-yl
N4-acetyl-cytosin-yl N6-benzoyl-adenin-yl N2-isobutyryl-guanin-yl
Figure 2.3.21 5′-O-Silyl-protected synthons for oligoribonucleotide synthesis (Caruthers, 1998).
number of parallel oligonucleotide chain extensions are to be performed in a fast and efficient way. Therefore, a number of new protecting groups have been described that are either of the o-NPEOC type (S.90 to S.94, Fig. 2.3.22) or of the o-nitrophenylethylsulfonyl type (S.95 to S.101, Fig. 2.3.22) (Bühler et al., 1999), for which half-lives of photochemical deprotection are reported to be between 10 min and 50 sec (Table 2.3.4). Up to 85% of unprotected nucleosides were recovered after 10 min irradiation time. Other protecting groups such as methylnitropiperonyloxycarbonyl (MeNPOC; S.102; Fig. 2.3.22; Pease et al., 1994) and 3′,5′-dimethoxybenzoinoxycarbonyl (DMBOC; S.103; Fig. 2.3.22; Pirrung and Bradley, 1995a,b) have been tested in solid-support oligonucleotide synthesis. A comparison of results obtained with both protecting groups and with conventional DMTr protection showed that cycle yields are diminished with photochemical deprotection with respect to cycles including conventional detritylation, and some by-product was obtained due to damage of N-benzoyl cytosine bases. In a parallel study, the removal of the MeNPOC group (Fig. 2.3.24) was found to be independent of the length and terminal base of the growing oligonucleotide chain, and was most rapid in nonpolar solvents or in absence of solvent (t1/2 =
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.19 Current Protocols in Nucleic Acid Chemistry
2
1
R
R
O O
3
NO2 R 1
2
3
Structure
R
R
R
89 90 91 92 93 94
H Cl H H H H
H H H Cl Br I
H H CH3 CH3 CH3 CH3
1
R 2
R
3
O S O
R NO2 1
3
R
R
R
95 96 97 98 99 100 101
H Cl H H H H
H H Cl H Cl Br I
H H H CH3 CH3 CH3 CH3
H
O O O
2
Structure
CH3O
OCH3 O
O O
NO2 O (MeNPOC)
(DMBOC)
102
103
Figure 2.3.22 Photochemically cleaved 5′-hydroxyl-protecting groups of the carbonate or sulfonate type. Taken in part from Bühler et al. (1999) with permission from Marcel Dekker.
Protection of 5′-Hydroxy Functions of Nucleosides
10 to 13 sec at A = 365 nm, irradiation intensity 27.5 mW/cm2). The average yield of chain elongation was 92% to 94% in solid-support reactions and ∼96% on photolysis in solution, as compared to 98% in conventional cycles (McGall et al., 1997). A thorough investigation on the DMBOC group (Pirrung et al., 1998) showed half times of deprotection on a glass surface in the presence of dioxane (326.5 nm, irradiation with 44.5 mW/cm2) to be between 5 and 13 sec. The use of shorter wavelengths decreases the deprotection time, but is discouraged due to the risk of damage to the deoxyribooligonucleotide chain. The yields per chain extension cycle were found to be base dependent, ranging from 91% to 98% for T, 82% to 95% for C, 79% to 92% for G, and 74% to 84% for A.
Recently, McGall and collaborators have proposed a technique for the preparation of oligonucleotide arrays that combines photolithography with acid deprotection (McGall et al., 1996; Wallraff et al., 1997). In this case, spots of growing oligonucleotide chains are grafted to the surface of a functionalized carrier (chip), which is then covered by a photosensitive polymer coating (a “photoresist”). Oligonucleotide spots that are meant for chain lengthening are first exposed to further chain elongation by photoetching of the polymer coating. They can then be subjected to conventional 5′-deprotection and chain lengthening. It is likely that, in further pursuit of light-directed combinatorial oligonucleotide synthesis, new protecting groups will have to be developed. Some of these may deviate from the
2.3.20 Current Protocols in Nucleic Acid Chemistry
Table 2.3.4 Photolabile 5′-Protecting Groups of the o-Nitrophenylethoxycarbonyl and o-Nitrophenylethylsulfonyl Typesa
Structure Carbonate groups S.89 S.90 S.91 S.92 S.93 S.94 Sulfonate groups S.95 S.96 S.97 S.98 S.99 S.100 S.101
R1
R2
R3
t1/2b
H Cl H H H H
H H H Cl Br I
H H CH3 CH3 CH3 CH3
7.5 min 82 min 56 sec 62 sec 60 sec 53 sec
H Cl H H H H H
H H C1 H C1 Br I
H H H CH3 CH3 CH3 CH3
10.9 min 16.3 min 10.9 min 82 sec 66 sec 70 sec 60 sec
aData from Bühler et al. (1999) with permission from Marcel Dekker. Deprotection conditions: irradiation with a 200 W mercury lamp (365 nm) in 1:1 (v/v) methanol/water. See Figure 2.3.22 for structures and substituents (R 1, R2, R3). bValues given for 5′-protected thymidine derivatives.
structural concept of carbonate esters, which are now the first choice. Examples include photochemically cleavable silyl groups such as hydroxystyryldimethylsilyl (HSDMS; S.104; Fig. 2.3.20) and hydroxystyryldiisopropylsilyl (HSDIS; S.105; Fig. 2.3.20; Pirrung and Lee, 1993). However, these do not seem to have been
NO2
O O
O R
hv
O N OH
O O
O R
NO2 H C
CH2
CO2
ROH
Figure 2.3.23 Proposed mechanism for photodeprotection of the o-nitrophenylethoxycarbonyl group (Hasan et al., 1997).
extensively tested for oligonucleotide synthesis.
5′-Hydroxyl-Protecting Groups Cleaved Under Nonacidic and Nonalkaline Conditions The general interest in 5′-hydroxyl-protecting groups that are cleaved under nonacidic and nonalkaline conditions has yielded a number of interesting solutions. Structural modifications of trityl that allow deprotection under nonacidic conditions (e.g., in a two-step procedure involving hydrazine in a near-neutral solution) have been discussed in the previous section (see Acyl Substituents and Base-Labile Triarylmethyl Groups). 2,4-Dinitrobenzenesulfenyl residues (S.106, Fig. 2.3.25) have been introduced by reaction with the corresponding sulfenyl chloride (Grams and Letsinger, 1968). This protecting group can be removed by treatment with a nucleophilic reagent such as thiophenol in pyridine (Letsinger et al., 1964). Stereochemical and mechanistic aspects of introduction and release of sulfenyl groups have been investigated (Bazin et al., 1985). The protection of hydroxy functions of sugar derivates by p-methoxybenzyl (S.107) and 3,4-dimethoxybenzyl groups (S.108; Fig. 2.3.25), which are susceptible to oxidative cleavage with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ), has been described (Oikawa et al., 1982), but these groups are not in use in oligonucleotide chemistry. The p-methoxybenzyl group could also be released from the 5′ hydroxyl in 68% yield by treatment with ceric
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.21 Current Protocols in Nucleic Acid Chemistry
NO2
O O
O
O
hv
O O
B
O O
O P OMe
Figure 2.3.24
O
CO2
O
O O
HO
NO
B
O
O P OMe O
CN
CN
Proposed photocleavage of the MeNPOC protecting group.
ammonium nitrate in aqueous acetonitrile (Luzzio and Menes, 1994); attempts at hydrogenolytic removal of the benzyl group did not give satisfactory results. The 1,1-dianisyl-2,2,2-trichloroethyl residue (S.109, Fig. 2.3.25) was introduced in the laboratory of Ugi as a protecting group that is stable to acid and base, but is readily removed by reductive fragmentation with the supernucleophile lithium cobalt(I)-phthalocyanine (Karl et al., 1995; Klösel et al., 1996). The application of this group in the preparation of a dinucleoside-trifluoromethyl-phosphonate was demonstrated (Karl et al., 1996). Again, it is beyond the scope of this unit to review all publications that describe the linkage of the 5′ hydroxyl to polymer supports with a non-acid-labile anchor. Examples of anchoring through ester linkage (e.g., Shimidzu and Letsinger, 1968) or, more often, through succinate groups (Ohtsuka et al., 1984; Weiss et al., 1984) are in the literature; in each case, the chain extension was carried out from the 5′ to the 3′ end.
done with acetic anhydride/4-dimethylaminopyridine (e.g., Köster et al., 1983, 1984). In order to blend with a set of protecting groups removable under β-elimination conditions, Reiner and Pfleiderer have proposed a number of β-substituted ethylsulfonylchlorides as capping reagents. The resulting sulfonyl groups are removed with DBU together with the protecting groups for bases and internucleotide linkages, as well as the terminal 5′-NPEOC group (Reiner and Pfleiderer, 1987). In oligonucleotide synthesis with 5′-DMTrprotected phosphoramidite synthons, capping with acetic anhydride activated by 4-dimethylaminopyridine or N-methylimidazole has been the standard procedure from the beginning (Atkinson and Smith, 1984). Because the yields of chain extension in phosphoramidite support synthesis average 98% to 99%, only ∼1% to 2% of unreacted ends are left over for capping NO2 S O2 N
Capping of the 5′-Hydroxy Terminus in Oligonucleotide Synthesis
Protection of 5′-Hydroxy Functions of Nucleosides
Capping refers to the introduction of a protecting group at the 5′-hydroxy function as a postcondensation step during solid-phase oligonucleotide synthesis. The capping step is meant to mask growing chain ends that have escaped elongation and, therefore, will remain as truncated or failure sequences. For this reason, the groups substituted during capping should not be removed before the end of chain growth, if at all. Hence, capping groups should (1) be easily attached even to longer oligonucleotide chains through a highly reactive and sterically unhindered reagent, and (2) be compatible with the chemistry chosen for chain elongation. For solid-phase preparations of oligonucleotides according to the phosphotriester method, phenylisocyanate has been used as a capping reagent in earlier procedures (e.g., Gait et al., 1982). Subsequently, capping was mostly
106
R CH3O 107 R = H 108 R = OCH3
CCl3 CH3O
OCH3 109
Figure 2.3.25 Miscellaneous 5′-hydroxylprotecting groups labile to nonacidic conditions.
2.3.22 Current Protocols in Nucleic Acid Chemistry
during each cycle. The acetylation is generally assumed to be nearly quantitative, but there are no experimental methods to detect average capping yields. Recently, an estimation of capping efficiency has been available through the correlation of calculations using fractal mathematics with the results of capillary electrophoretic separation of the crude product of oligonucleotide preparations of up to 60 bases in length. For support syntheses using the common controlled-pore glass (CPG) or polystyrene supports, the best correlation between calculated and experimentally determined chain length distributions was observed if capping was assumed to proceed with not more than 70% to 80% of the non-elongated chain ends (Földes-Papp et al., 1996, 1998). When the phenoxyacetyl group was used for the protection of exocyclic amino groups, partial replacement of this group by acetyl on the guanine base was observed during conventional capping. This could be avoided by using phenoxyacetic anhydride in place of acetic anhydride (Chaix et al., 1989). The choice of capping procedure necessarily influences the workup of the solid support product. The capping procedures described so far have the common feature that the protecting groups attached to the truncated chains are hydrolyzed on removal of the polymer support and deprotection of bases and internucleotidic bonds. This, again, is prerequisite to the tritylon purifications described in a previous section (see Triarylmethyl Groups as Affinity Ligands). Horn and Urdea have described an alternative route where bases, internucleotidic bonds, and truncated chain ends are deprotected while the crude product—with DMTr on the 5′ end of the full-length oligonucleotide— remains bound to the support. This allows the use of phosphodiesterase to selectively digest the truncated chains and, thus, further simplify the workup (Horn and Urdea, 1985). Other capping alternatives result in an irreversible modification of the truncated chains. This applies to the application of highly reactive phosphite derivatives, for instance, to a mixture of diethoxy-N,N-diisopropylphosphoramidite with tetrazole (Yu et al., 1994), or to diethoxytetrazolophosphane, a stable tetrazole derivative of diethoxyphosphorous acid (Berner et al., 1989). Also, bis(1,1,1,3,3,3hexafluoro-2-propyl)-2-propylphosphite, activated by N-methylimidazole, has been described as a capping reagent to blend with oligonucleotide syntheses using deoxyribonucleoside-3′-bis(1,1,1,3,3,3-hexafluoro-2-pro
pyl)phosphite synthons (Hosaka et al., 1991). In these cases, an adjustment of workup and purification procedures may be required. Recently, a capping procedure that leads to complete reversal of the removal of truncated chains has been described (Natt and Häner, 1997). In this case, capping is done using β-cyanoethoxy-(n-octyloxy)-phosphoramidite/tetrazole as a lipophilic phosphitylating reagent (“lipocap”). If the synthesis is conducted to generate a crude "trityl-off" product, reversedphase high-performance liquid chromatography (RP-HPLC) will lead to a stronger retention of the more lipophilic truncated chains. The target sequence was eluted first and found to be recovered in higher quantity than through “trityl-on” purification. In oligonucleotide syntheses with H-phosphonate intermediates, the average yields of chain elongation are slightly lower due to “selfcapping” with the acyl chloride activating agent. Therefore, an additional capping step is generally unnecessary. Yet, in order to avoid further elongation of reactive truncated chain ends, especially in large-scale preparations, some authors have recommended a capping procedure with, for example, triethylammonium isopropyl phosphite (Andrus et al., 1988) or β-cyanoethyl-H-phosphonate (Gaffney and Jones, 1988).
ENZYMATIC METHODS FOR 5′-HYDROXYL PROTECTION AND DEPROTECTION Compared to the efficiency of automated chemical solid-phase preparation techniques, enzymatic methods play only a minor role in current oligonucleotide synthesis. This is all the more true for 5′-hydroxyl protection or deprotection methods, which are often considered more or less trivial steps in the elongation cycle. Nevertheless, there are some noteworthy arguments in favor of performing protection/deprotection steps via enzyme catalysis. Enzymatic reactions are regio- and stereospecific and often proceed with good yields and high selectivity. Such points are particularly important, for instance, for large-scale oligonucleotide synthesis, an area where enzymatic routes may be worth consideration. The state of enzymatic protecting-group techniques for biomolecules has been reviewed by Waldmann and Sebastian (1994). A specialized survey of enzymatic oligonucleotide acylation/deacylation reactions has recently been published by Prasad and Wengel (1996). A summary of enzymatic reactions leading to the
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.23 Current Protocols in Nucleic Acid Chemistry
introduction of 5′-protecting groups is given in Table 2.3.5. Essentially, two classes of enzymes are known to introduce acyl or alkoxycarbonyl substituents at the 5′-hydroxy function of nucleosides, namely subtilisin and lipases. The best results, so far, were obtained with subtilisin 8350, an enzyme prepared from subtilisin via site-specific mutagenesis. Catalysis of acetyl-group transfer from isopropenyl acetate in anhydrous DMF occurred selectively to the 5′-hydroxy group of various deoxyribo- or ribonucleosides in yields ranging from 65% to nearly 100% (Wong et al., 1990). Somewhat lower yields were found for acyl transfer from trichloro- or trifluoroethylbutyrate to ribonucleosides catalyzed by subtilisin in DMF or pyridine (Riva et al., 1988; Singh et al., 1994). Lipases from various sources have alternatively been applied, but the yields are generally lower and the conditions must be chosen very carefully to ensure the introduction of acyl or alkoxycarbonyl groups selectively or predominantly at the 5′-hydroxy position (Nozaki et al., 1990; Moris and Gotor, 1992a,b, 1993; GarciaAlles et al., 1993; Garcia-Alles and Gotor, 1995; Ozaki et al., 1995). Enzyme-catalyzed deacylations were of interest in early times of nucleotide chemistry, when an enzymatic approach to oligonucleotide chain lengthening seemed to be a feasible alternative to the still cumbersome methods of phosphodiester chemistry. The dihydrocinnamoyl protecting group received some attention at that time, because 3′-dihydrocinnamoyl-nucleoside-5′-diphosphates were dis-
covered as monoaddition substrates for polynucleotide phosphorylase (Kaufmann et al., 1971), and the same protecting group could be removed by chymotrypsin (Sachdev and Starkovsky, 1969; Taunton-Rigby, 1973). If, however, a 3′,5′-disubstituted nucleoside derivative was the substrate, a distinct preference for the hydrolysis of the 5′-O-acyl group was demonstrated (Taunton-Rigby, 1973). The regioselective 5′-O-deacetylation of 2′,3′,5′-triacetyl nucleosides was described by Singh et al. (1993). In recent times, the tendency has been to reverse the action of the before-mentioned enzymes, subtilisin and lipase. Whereas lipase from Pseudomonas fluorescens has a preference for the removal of secondary O-acyl groups, subtilisin attacks first the acyl substituent on the 5′-hydroxy moiety (Uemura et al., 1989a,b). In both cases, however, the reaction can proceed to complete deprotection. Selective deprotection of 5′-O-acyl was found with lipase from porcine pancreas, which yielded 3′-O-acetylthymidine from the 3′,5′-disubstituted nucleoside in 98% yield (Wong et al., 1990). Similarly, 2′,3′,5′-tri-O-acetylated pyrimidine and purine ribonucleosides (A, C, G, U, and modified bases) were selectively 5′-deprotected by subtilisin to give 2′,3′-di-Oacyl nucleosides in 40% to 92% yield (Singh et al., 1993). In general, it appears that the potential of enzymatic protection/deprotection reactions for the 5′-hydroxy function remains to be further exploited. The isolation of enzymes from different sources, as well the adaptation of enzyme specificity through mutagenesis, protein
Table 2.3.5 Enzymatic Introduction of Protecting Groups at the 5′-Hydroxy Function
Acyl group transferred Butyryl Butyryl Acetyl Acyl Alkoxycarbonyl Protection of 5′-Hydroxy Functions of Nucleosides
Acyl
Enzyme Subtilisin
Substrate acyl donor
Trichloroethylbutyrate in DMF Subtilisin Trifluoroethylbutyrate in pyridine Subtilisin 8350 Isopropenyl acetate
Product
5′-O-Acyl predominant 67%-82% 5′-O-acyl 80%-100% 5′-O-acyl Lipase SP 435 Alkane carbonyl oxime 5′-O-Acyl esters r(d)A, G, T, U (Candida antarctica) Lipase SP 435 Alkoxy carbonyl oxime 5′-O-Alkoxy(Candida esters r(d)A, G, T, U carbonyl antarctica) 31%-75% Pentanoic acid Lipase 5′-O-Acyl (Pseudomonas anhydride, preferably dC fluorescens)
Reference Riva et al. (1988) Singh et al. (1994) Wong et al. (1990) Moris and Gotor (1992a,b, 1993) Moris and Gotor (1992a,b, 1993) Nozaki et al. (1990)
2.3.24 Current Protocols in Nucleic Acid Chemistry
engineering, and in vitro evolution and selection techniques, may provide tools tailored to perform highly specific reactions and, thus, to match chemical methods for introduction and removal of protecting groups.
PROTECTION OF 5′-HYDROXY FUNCTIONS: REMAINING PROBLEMS, CONSIDERATIONS, AND OPTIONS Protection and deprotection of the 5′-hydroxy group remain essential operations for oligonucleotide synthesis, independent of the chemistry used for the formation of the internucleotidic bond. To many researchers involved in routine small-scale oligonucleotide synthesis, questions connected with 5′-hydroxyl-protecting groups appear to be solved, although the protection chemistry used in >95% of all syntheses is now 35 years old. Failures that arise through incomplete deprotection or capping during the elongation cycles have been discussed above. Many attempts have been made to minimize these failures through the design of new protecting groups for the 5′ hydroxyl, nucleobases, or other functional groups of the oligonucleotide, or through the development of an altogether new orthogonal protection scheme. However, no method exists, so far, that allows detection and quantitative analysis of, for example, small numbers of depurination sites statistically distributed within a population of long-chain oligonucleotide molecules. Techniques still have to be developed that might help assess such homogeneity problems, which are of importance especially when oligonucleotides are produced in large numbers, large scale, or extended length. Generally, more consideration should be given to the avoidance of acid deprotection steps. A particularly interesting new deprotection chemistry comes from the application of photolabile protecting groups. Considerable efforts are still necessary to establish quantitative and selective removal of such groups, and new developments are under way at several laboratories. For solid-phase bulk synthesis, other deprotection alternatives that use neither acid nor alkaline/ammoniacal media may have to be investigated. The availability of silyl protecting groups that can be released in <1 min by fluoride treatment at room temperature may find application beyond oligoribonucleotide synthesis. Recent years have seen rapid progress in the preparation of structurally modified oligonucleotides, among them structures highly sensitive to acid or base. These syntheses often
require a new kind of protection chemistry; such developments may feed back into routine preparations of unmodified oligonucleotides. One of the reasons that trityl groups have been the first choice for several decades is that, beyond their application for the protection of the growing chain, they can be endowed by appropriate substitution with additional properties useful for oligonucleotide synthesis and purification. Examples—such as the monitoring of chain extension yields, the simplification of the separation of support products, or the activation of a 3′-phosphate moiety—have been discussed above. There will be a general interest to also endow non-acid-labile protecting groups with similar properties; examples are in the literature, but there are still options for new developments. Such projects may also yield new solutions to simple practical questions, e.g., the choice of nontoxic, environmentally unproblematic coupling and deprotection solvents. The development of synthetic oligonucleotides that are ready to move into the drug market has led to the budding of a new field: the technology of industrial oligonucleotide production. In this frame, protection and deprotection steps are part of a series of unit operations that have to be carefully analyzed and optimized with respect to technical performance. In the previous sections, reference has occasionally been given to investigations that have been performed on this technical background, with the idea in mind that these investigations may well add new experience to small-scale routine synthesis as well. Future reviews may have to give broader attention to technical aspects as this field develops into a science of its own. In this context, it is interesting to see that oligonucleotide synthesis in the past years has developed in the direction of ever new chemistry, while chemical production in general looks more and more to biotechnology as a tool to solve problems connected with the utilization of fossil carbon sources, environmental pollution, or waste disposal. The impact of such problems is already recognized and will be increasingly felt as oligonucleotide synthesis moves more towards bulk production. Enzymatic methods, which may be in the foreground of future developments, necessarily require a new approach to questions of protection and deprotection.
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.25 Current Protocols in Nucleic Acid Chemistry
LITERATURE CITED Adams, S.P., Kavka, K.S., Wykes, E.J., Holder, S.B., and Galluppi, G.R. 1983. Hindered dialkylamino nucleoside phosphite reagents in the synthesis of two DNA 51-mers. J. Am. Chem. Soc. 105:661663. Andersen, W., Hayes, D.H., Michelson, A.M., and Todd, A.R. 1954. Deoxyribonucleosides and related compounds. Part IV. The configuration at the glycosidic centre in deoxyadenosine and deoxycytidine. J. Chem. Soc. 1882-1887. Andrus, A., Efcavitch, J.W., McBride, L.J., and Giusti, B. 1988. Novel activating and capping reagents for improved hydrogen-phosphonate DNA synthesis. Tetrahedron Lett. 29:861-864. Atkinson, T. and Smith, M. 1984. Solid-phase synthesis of oligodeoxyribonucleotides by the phosphate triester method. In A Practical Approach to Oligonucleotide Synthesis (M.J. Gait, ed.) pp. 35-81. IRL Press, Oxford. Balgobin, N. and Chattopadhyaya, J.B. 1982a. Two sulfur containing protecting groups for alcoholic hydroxyl function. Chem. Scr. 19:143-144. Balgobin, N. and Chattopadhyaya, J.B. 1982b. An efficient chemical synthesis of a biologically functional DNA molecule, 5′d(A-T-G-G-G-T-TT-C-T-T-C-G-C-)3′, through the phospho-triester approach. Chem. Scr. 20:133-138. Balgobin, N. and Chattopadhyaya, J. 1987. Solid phase synthesis of DNA under a non-depurinating condition with a base labile 5′-protecting group (Fmoc) using phosphiteamidite approach. Nucleosides Nucleotides 6:461-463. Balgobin, N., Josephson, S., and Chattopadhyaya, J.B. 1981a. The 2-phenylsulfonylethylcarbonyl (PSEC) group for the protection of the hydroxyl function. Tetrahedron Lett. 22:3667-3670. Balgobin, N., Josephson, S., and Chattopadhyaya, J.B. 1981b. A general approach to the chemical synthesis of oligodeoxyribonucleotides. Acta Chem. Scand. B 35:201-212. Bannwarth, W. and Wippler, J. 1990. A new combined purification/phosphorylation procedure for oligodeoxynucleotides. Helv. Chim. Acta 73:1139-1147. Bazin, H., Heikkilä, J., and Chattopadhyaya, J. 1985. Some aspects of the reaction of arenesulfenyl chlorides with hydroxyl functions of ribonucleosides. Acta Chem. Scand. B 39:391400. Beaucage, S.L. and Iyer, R.P. 1992. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:22232311. Protection of 5′-Hydroxy Functions of Nucleosides
Beaucage, S.L. and Iyer, R.P. 1993. The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications. Tetrahedron 49:6123-6194.
Belagaje, R. and Brush, C.K. 1982. Polymer supported synthesis of oligonucleotides by a phosphotriester method. Nucl. Acids Res. 10:62956303. Bergmann, F. and Pfleiderer, W. 1994a. The 2-dansylethoxycarbonyl (= 2-{[5-(dimethylamino)naphthalen-1-yl]sulfonyl}ethoxycarbonyl; Dnseoc) group for protection of the 5′-hydroxy function in oligodeoxyribonucleotide synthesis. Helv. Chim. Acta 77:203-215. Bergmann, F. and Pfleiderer, W. 1994b. The 2-dansylethoxycarbonyl (= 2-{[5-(dimethylamino)naphthalen-1-yl]sulfonyl}ethoxycarbonyl; Dnseoc) group for protection of the 5′-hydroxy function in oligoribonucleotide synthesis. Helv. Chim. Acta 77:481-501. Bergmann, F. and Pfleiderer, W. 1994c. Solid-phase synthesis of oligoribonucleotides using the 2dansylethoxycarbonyl (= 2-{[5-(dimethylamino)naphthalen-1-yl]sulfonyl}ethoxycarbonyl; Dnseoc) group for 5′-hydroxy protection. Helv. Chim. Acta 77:988-998. Berner, S., Mühlegger, K., and Seliger, H. 1989. Studies on the role of tetrazole in the activation of phosphoramidites. Nucl. Acids Res. 17:853-864. Bessodes, M., Komiotis, D., and Antonakis, K. 1986. Rapid and selective detritylation of primary alcohols using formic acid. Tetrahedron Lett. 27:579-580. Biernat, J., Wolter, A., and Köster, H. 1983 Purification oriented synthesis of oligodeoxynucleotides in solution. Tetrahedron Lett. 24:751-754. Birch-Hirschfeld, E., Weiss, R., Rosenthal, A., and Cech, D. 1983. Festphasensynthese von Oligodesoxyribonucleotiden an Polystyren-TeflonTrägern nach der Diestermethode. J. Prakt. Chem. 325:133-142. Brown, J.M., Christodoulou, C., Reese, C.B., and Sindona, G. 1984. Two new protected acyl protecting groups for alcoholic hydroxy functions. J. Chem. Soc. Perkin Trans. 1 1785-1790. Brown, J.M., Christodoulou, C., Jones, S.S., Modak, A.S., Reese, C.B., Sibanda, S., and Ubasawa, A. 1989a. Synthesis of the 3′-terminal half of yeast alanine transfer ribonucleic acid (tRNAAla) by the phosphotriester approach in solution. Part 1. Preparation of the nucleoside building blocks. J. Chem. Soc. Perkin Trans. 1 1735-1750. Brown, J.M., Christodoulou, C., Modak, A.S., Reese, C.B., and Serafinowska, H.T. 1989b. Synthesis of the 3′-terminal half of yeast alanine transfer ribonucleic acid (tRNAAla) by the phosphotriester approach in solution. Part 2. J. Chem. Soc. Perkin Trans. 1 1751-1767. Bühler, S., Giegrich, H., and Pfleiderer, W. 1999. New photolabile protecting groups of the 2-(2nitrophenyl)ethoxycarbonyl and the 2-(2-nitrophenyl)ethylsulfonyl type for the oligonucleotide synthesis. Nucleosides Nucleotides 8:1281-1283.
2.3.26 Current Protocols in Nucleic Acid Chemistry
Caruthers, M.H. 1982. Chemical synthesis of oligodeoxynucleotides using the phosphite triester intermediates. In Chemical and Enzymatic Synthesis of Gene Fragments: A Laboratory Manual (H.G. Gassen and A. Lang, eds.) pp. 71-79. Verlag Chemie, Weinheim, Germany. Caruthers, M.H. 1998. Synthesis of DNA, RNA, and various new analogs on polymer supports. Lecture, 8th International Conference on PolymerBased Technology, Ma’ale Hachamisha, Israel. Caruthers, M.H., Dellinger, D., and Prosser, K. 1986. Nucleic acid synthesis and applications to molecular biology. Chem. Scr. 26:25-30. Caruthers, M.H., Wyrzikiewicz, T., and Dellinger, D.J. 1994. Synthesis of oligonucleotides and oligonucleotide analogs on polymer supports. In Innovation and Perspectives in Solid Phase Synthesis (R. Epton, ed.) pp. 39-44. Mayflower, Birmingham, U.K. Chaix, C., Molko, D., and Teoule, R. 1989. The use of labile base protecting groups in oligoribonucleotide synthesis. Tetrahedron Lett. 30:71-74. Chattopadhyaya, J.B. 1980. Synthesis of adenylyl(2′-5′)-adenylyl-(2′-5′)-adenosine (2-5A core). Tetrahedron Lett. 21:4113-4116. Chattopadhyaya, J.B. and Reese, C.B. 1978. The 9-phenylxanthen-9-yl protecting group. J. Chem. Soc., Chem. Commun. 639-640. Chattopadhyaya, J.B. and Reese, C.B. 1980. Chemical synthesis of a tridecanucleoside dodecaphosphate sequence of SV40 DNA. Nucl. Acids Res. 8:2039-2053. Chattopadhyaya, J.B., Reese, C.B., and Todd, A.H. 1979. 2-Dibromomethylbenzoyl: An acyl protecting group removable under exceptionally mild conditions. J. Chem. Soc., Chem. Commun. 987-988. Chaudhary, S.K. and Hernandez, O. 1979. 4-Dimethylaminopyridine: An efficient and selective catalyst for the silylation of alcohols. Tetrahedron Lett. 20:99-102. Christodoulou, C. and Reese, C.B. 1983. Dealkylation of nucleoside arylmethyl 2-chlorophenyl phosphates: The 2,4-dinitrobenzyl protecting group. Tetrahedron Lett. 24:951-954. Christodoulou, C., Agrawal, S., and Gait, M.J. 1987a. A new 5′-protecting group for use in the solid-phase synthesis of oligoribonucleotides Nucleosides Nucleotides 6:341-344. Christodoulou, C., Agrawal, S., and Gait, M.J. 1987b. Progress towards solid-phase synthesis of oligoribonucleotides. In Biophosphates and Their Analogues—Synthesis, Structure, Metabolism and Activity (K.S. Bruzik and W.J. Stec, eds.) pp 99-106. Elsevier/North-Holland, Amsterdam. Corey, E.J., Gras, J.-L., and Ulrich, P. 1976. A new general method for the protection of the hydroxyl function. Tetrahedron Lett. 11:809-812.
Dellinger, D.J., Wyrzkewicz, T.K., Betley, J.R., and Caruthers, M.H. 1998. Solid-phase synthesis of oligodeoxyribonucleotides using phosphoramidite synthons in a two step synthesis cycle. XIIIth International Round Table: Nucleosides, Nucleotides and their Biological Applications, Montpellier. Poster 209. Engels, J. 1979. Selektive elektrochemische Schutzgruppenabspaltung in der Nucleotidsynthese. Angew. Chem. 91:155-156 Fearon, K.L., Stults, J.T., Bergot, B.J., Christensen, L.M., and Raible, A.M. 1995. Investigation of the ‘n-1’ impurity in phosphorothioate oligodeoxynucleotides synthesized by the solid-phase β-cyanoethyl phosphoramidite method using stepwise sulfurization. Nucl. Acids Res. 23:2754-2761. Fersht, A.R. and Jencks, W.P. 1970. The acetylpyridinium ion intermediate in pyridine-catalyzed hydrolysis and acyl transfer reactions of acetic anhydride. Observation, kinetics, structure-reactivity correlations, and effects of concentrated salt solutions. J. Am. Chem. Soc. 92:5432-5442. Fisher, E.F. and Caruthers, M.H. 1983. Color coded triarylmethyl protecting groups useful for deoxypolynucleotide synthesis. Nucl. Acids Res. 11:1589-1599. Fodor, S.P.A., Read, J.L., Pirrung, M.C., Stryer, L., Lu, A.T., and Solas, D. 1991. Light-directed, spatially addressable parallel chemical synthesis. Science 251:767-773. Földes-Papp, Z., Birch-Hirschfeld, E., Eickhoff, H., Baumann, G., Peng, W.-G., Biber, T., Seydel, R., Kleinschmidt, A.K., and Seliger, H. 1996. Fractals for multicyclic synthesis conditions of biopolymers; examples of oligonucleotide synthesis measured by high-performance capillary electrophoresis and ion-exchange high-performance liquid chromatography. J. Chromatogr. 739:431-447. Földes-Papp, Z., Baumann, G., Birch-Hirschfeld, E., Eickhoff, H., Greulich, K.O., Kleinschmidt, A.K., and Seliger, H. 1998. The analysis of oligonucleotide preparations by fractal measures. Biopolymers 45:361-379. Fourrey, J.L., Varenne, J., Blonski, C., Dousset, P., and Shire, D. 1987. 1,1-Bis-(4-methoxyphenyl)1′-pyrenyl methyl (bmpm): A new fluorescent 5′ protecting group for the purification of unmodified and modified oligonucleotides. Tetrahedron Lett. 28:5157-5160. Fritz, H.-J., Frommer, W.-B., Kramer, W., and Werr, W. 1982. Simplified preparations of blocked 2′deoxyribonucleosides as starting materials for chemical oligonucleotide synthesis. In Chemical and Enzymatic Synthesis of Gene Fragments: A Laboratory Manual (H.G. Gassen and A. Lang, eds.) pp. 43-52. Verlag Chemie, Weinheim, Germany. Fuentes, J., Cuevas, T., and Pradera, M.A. 1994. A mild and efficient detritylation of some carbohydrate derivatives. Synth. Commun. 24:22372245.
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.27 Current Protocols in Nucleic Acid Chemistry
Fukuda, T., Hamana, T., and Marumoto, R. 1988. Synthesis of RNA oligomer using 9-fluorenylmethoxycarbonyl (Fmoc) group for 5′-hydroxyl protection. Nucl. Acids Res. Symp. Ser. 19:13-16.
Görtz, H.-H. and Seliger, H. 1981. New hydrophobic protecting groups for the chemical synthesis of oligonucleotides. Angew. Chem., Int. Ed. Engl. 20:681-683.
Furukawa, H., Momota, K., Agatsuma, T., Yamamoto, I., Kimura, S., and Shimada, K. 1994. Mechanism of inhibition of HIV-1 infection in vitro by guanine-rich oligonucleotides modified at the 5′ terminal by dimethoxytrityl residue. Nucl. Acids Res. 22:5621-5627.
Grams, G.W. and Letsinger, R.L. 1968. N6,3′-ODisubstituted deoxyadenosine. J. Org. Chem. 33:2589-2590.
Gaffney, B.L. and Jones, R.A. 1982a. Synthesis of O-6-alkylated deoxyguanosine nucleosides. Tetrahedron Lett. 23:2253-2256. Gaffney, B.L. and Jones, R.A. 1982b. A new strategy for the protection of deoxyguanosine during oligonucleotide synthesis. Tetrahedron Lett. 23:2257-2260. Gaffney, B.L. and Jones, R.A. 1988. Large-scale oligonucleotide synthesis by the H-phosphonate method. Tetrahedron Lett. 29:2619-2622. Gaffney, B.L., Marky, L.A., and Jones, R.A. 1984. The influence of the purine 2-amino group on DNA conformation and stability. II. Synthesis and physical characterization of d(CGT(2NH2) ACG), d(CGU(2-NH2)ACG), and d(CGT(2-NH2)AT(2-NH2)ACG). Tetrahedron 40:3-13. Gait, M.J., Matthes, H.W.D., Singh, M., Sproat, B.S., and Titmas, R.C. 1982. Synthesis of oligodeoxyribonucleotides by a continuous flow, pho sphotries ter meth od on a kieselgur/polyamide support. In Chemical and Enzymatic Synthesis of Gene Fragments: A Laboratory Manual (H.G. Gassen and A. Lang, eds.) pp. 1-42. Verlag Chemie, Weinheim, Germany. Garcia-Alles, L.F. and Gotor, V. 1995. Synthesis of 5′-O- and 3′-O-nucleoside carbamates. Tetrahedron 51:307-316.
Protection of 5′-Hydroxy Functions of Nucleosides
Grams, G.W. and Letsinger, R.L. 1970. Synthesis of a diribonucleoside monophosphate by the β-cyanoethyl phosphotriester method. J. Org. Chem. 35:868-870. Guo, Z., Pfundheller, H.M., and Sanghvi, Y. 1998. A process for the capture and reuse of DMT group during manufacturing of oligonucleotides. Abstracts XIIIth International Round Table: Nucleosides, Nucleotides and their Biological Applications, Montpellier. Poster 194. Gupta, K.C., Gaur, R.K., and Sharma, P. 1991. Use of the 4-methoxy-4′-octyloxytrityl group as an affinity handle for the purification of synthetic oligonucleotides. J. Chromatogr. 541:341-348. Guzaev, A., Salo, H., Azhayev, A., and Lönnberg, H. 1995. A new approach for chemical phosphorylation of oligonucleotides at the 5′-terminus. Tetrahedron 51:9375-9384. Habus, I. and Agrawal, S. 1994. Improvement in the synthesis of oligonucleotides of extended length by modification of detritylation step. Nucl. Acids Res. 22:4350-4351 Happ, E. and Scalfi-Happ, C. 1988. New trityl-based protecting groups with a mild two-step removal. Nucleosides Nucleotides 7:813-816. Hasan, A., Stengele, K.-P., Giegrich, H., Cornwell, P., Isham, K.R., Sachleben, R.A., Pfleiderer, W., and Foote, R.S. 1997. Photolabile protecting groups for nucleosides: Synthesis and photodeprotection rates. Tetrahedron 53:4247-4264.
Garcia-Alles, L.F., Moris, F., and Gotor, V. 1993. Chemo-enzymatic synthesis of 2′-deoxynucleoside urethanes. Tetrahedron Lett. 34:63376338.
Hirao, I., Koizumi, M., Ishido, Y., and Andrus, A. 1998. 1,1,3,3-Tetraisopropyl-3-(2-(triphenylmethoxy)ethoxy)disiloxane-1-yl group, a potential 5′-O-protecting group for solid-phase RNA synthesis. Tetrahedron Lett. 39:2989-2992.
Gildea, B.D., Coull, J.M., and Köster, H. 1990. A versatile acid-labile linker for modification of synthetic biomolecules. Tetrahedron Lett. 31:7095-7098.
Horn, T. and Urdea, M.S. 1985. Enzymatic purification of chemically synthesized oligodeoxyribonucleotides prior to removal from a solid-support. Nucl. Acids Res. Symp. Ser. 16:153-156.
Gilham, P.T. and Khorana, H.G. 1958. Studies on Polynucleotides. I. A new and general method for the chemical synthesis of the C5′-C3′ internucleotidic linkage. Syntheses of deoxyribo-dinucleotides. J. Am. Chem. Soc. 80:6212-6222.
Hosaka, H., Suzuki, Y., Gug-Kim, S., and Takaku, H. 1991. A convenient approach to the synthesis of medium size deoxyribooligonucleotides by improved new phosphite method. Tetrahedron Lett. 32:785-788.
Gioeli, C. and Chattopadhyaya, J.B. 1982. The fluoren-9-ylmethoxycarbonyl group for the protection of hydroxy-groups; its application in the synthesis of an octathymidylic acid fragment. J. Chem. Soc. Chem. Commun. 672-673.
Hotoda, H., Momota, K., Furukawa, H., Nakamura, T., and Kaneko, M. 1994. Biologically active oligodeoxyribonucleotides. II. Structure activity relationships of anti-HIV-1 pentadecadeoxyribonucleotides bearing 5′-endmo difications. Nucleosides Nucleotides 13:1375-1395.
Gioeli, C., Balgobin, N., Josephson, S., and Chattopadhyaya, J.B. 1981. 2-(Trimethylsilyl)ethyl chloroformate: A convenient reagent for protection of hydroxyl function. Tetrahedron Lett. 22:969-972.
Itakura, K., Rossi, J.J., and Wallace, R.B. 1984. Synthesis and use of synthetic oligonucleotides. Annu. Rev. Biochem. 53:323-356.
2.3.28 Current Protocols in Nucleic Acid Chemistry
Ito, H., Ike, Y., Ikuta, S., and Itakura, K. 1982. Solid phase synthesis of polynucleotides. VI. Further studies on polystyrene copolymers for the solid support. Nucl. Acids Res. 10:17551769. Iwai, S. and Ohtsuka, E. 1988. 5′-Levulinyl and 2′-tetrahydrofuranyl protection for the synthesis of oligoribonucleotides by the phosphoramidite approach. Nucl. Acids Res. 16:9443-9456. Iwai, S., Sasaki, T., and Ohtsuka, E. 1990. Large scale synthesis of oligoribonucleotides on a solid support: Synthesis of a catalytic RNA duplex. Tetrahedron 46:6673-6688. Iyer, R.P., Jiang, Z., Yu, D., Tan, W., and Agrawal, S. 1995. Improved procedure for the detritylation of DMT-oligonucleotides: Use of Dowex. Synth. Commun. 25:3611-3623. Josephson, S. and Chattopadhyaya, J.B. 1981. The application of the 2-phenylsulfonylethyl-, a novel phosphate protecting group, in the synthesis of DNA fragments of defined sequences. Chem. Scr. 18:184-188. Kamaike, K., Takahashi, M., Utsugi, K., Tomizuka, K., and Ishido, Y. 1995. An efficient method for the synthesis of [4-15N]cytidine and [615 N]adenosine derivatives from uridine and inosine. Tetrahedron Lett. 36:91-94. Kamaike, K., Takahashi, M., Utsugi, K., Tomizuka, K., Okazaki, Y., Tamada, Y., Kinoshita, K., Masuda, H., and Ishido, Y. 1996. An efficient method for the synthesis of [415 N]cytidine, 2′-deoxy[4-15N]cytidine, [615 N]adenosine, and 2′-deoxy[6-15N]adenosine derivatives. Nucleosides Nucleotides 15:749-769. Kamaike, K., Takahashi, H., Kakinuma, T., Morohoshi, K., and Ishido, Y. 1997. Oligonucleotide synthesis by the use of a 2-(levulinyloxymethyl)5-nitrobenzoyl group as the novel base-labile protecting group for the 5′-hydroxyl groups of ribonucleoside and 2′-deoxyribonucleoside 3′phosphoramidites. Tetrahedron Lett. 38:68576860. Karl, R.M., Klösel, R., König, S., Lehnhoff, S., and Ugi, I. 1995. 1,1-Dianisyl-2,2,2-trichlorethyl ethers—a new protection for the hydroxyl group. Tetrahedron Lett. 51:3759-3766. Karl, R.M., Richter, W., Klösel, R., Mayer, M., and Ugi, I. 1996. The 1,1-dianisyl-2,2,2-trichloroethyl moiety as a new protective group for the synthesis of dinucleoside trifluoromethylp h o s p h o n at es . Nucleosides Nucleotides 15:379-386. Kaufmann, G., Fridkin, M., Zutra, A., and Littauer, U. 1971. Monofunctional substrates of polynucleotide phosphorylase. The monoadd i t i o n o f 2′(3′)-O-isovaleryl-nucleoside diphosphate to an initiator oligonucleotide. Eur. J. Biochem. 24:4-11.
Kawashima, E., Aoyama, Y., Sekine, T., Miyahara, M., Radwan, M.F., Nakamura, E., Kainosho, M., Kyogoku, Y., and Ishido, Y. 1995. Sonochemical and triethylborane-induced tin deuteride reduction for the highly diastereoselective synthesis of (2′R)-2′-deoxy[2′-2H]ribonucleoside derivatives. J. Org. Chem. 60:6980-6986. Kawashima, E., Toyama, K., Ohshima, K., Kainosho, M., Kyogoku, Y., and Ishido, Y. 1997. Novel approach to diastereoselective synthesis of 2′-deoxy[ 5′-2H1]ribonucleoside derivatives by reduction of the corresponding 5′-Oacetyl-2′-deoxy-5′-phenylselenoribonucleoside derivatives with a Bu3Sn2H-Et3B system. Chirality 9:435-442. Kierzek, R., Ito, H., Bhatt, R., and Itakura, K. 1981. Selective N-deacylation of N,O-protected nucleosides by zinc bromide. Tetrahedron Lett. 22:3761-3764. Klösel, R. König, S., and Lehnhoff, S. 1996. The 1,1-dianisyl-2,2,2-trichloroethyl group as 2′hydroxyl protection of ribonucleotides. Tetrahedron 52:1493-1502. Kohli, V., Blöcker, H., and Köster, H. 1980. The triphenylmethyl (trityl) group and its uses in nucleotide chemistry. Tetrahedron Lett. 21:2683-2686. Kössel, H. and Seliger, H. 1975. Recent advances in polynucleotide synthesis. Fortschr. Chem. Org. Naturst. 32:297-508. Köster, H. and Sinha, N.D. 1982. Dialkyl aluminium chloride: A reagent for removal of trityl group from trityl ethers of deoxynucleosides, deoxynucleotides, and oligodeoxynucleotides. Tetrahedron Lett. 23:26412644. Köster, H., Stumpe, A., and Wolter, A. 1983. Polymer support oligonucleotide synthesis 13: Rapid and efficient synthesis of oligodeoxynucleotides on porous glass support using triester approach. Tetrahedron Lett. 24:747750. Köster, H., Biernat, J., McManus, J., Wolter, A., Stumpe, A., Narang, C.K., and Sinha, N.D. 1984. Polymer support oligonucleotide synthesis. XV. Synthesis of oligodeoxynucleotides on controlled pore glass (CPG) using phosphate and a new phosphite triester approach. Tetrahedron 40:103-112. Kotschi, U. 1987. Präparative und apparative Beiträge zur Festphasensynthese von Nucleinsäure-Fragmenten. Dissertation, University of Ulm, Germany. Krotz, A.H., Cole, D.L., and Ravikumar, V.T. 1999. Dimethoxytrityl removal in organic medium: Efficient oligonucleotide synthesis without chlorinated solvents. Nucleosides Nucleotides 18:1207-1209. Protection of Nucleosides for Oligonucleotide Synthesis
2.3.29 Current Protocols in Nucleic Acid Chemistry
Kwiatkowski, M. and Chattopadhyaya, J. 1984. The 9-(4-octadecyloxyphenyl-xanthen)-9-yl-group. A new acid-labile hydroxyl protective group and its application in the preparative reverse-phase chromatographic separation of oligoribonucleotides. Acta Chem. Scand. B 38:657-671. Kwiatkowski, M., Heikkilä, S., Björkman, S., and Chattopadhyaya, J.B. 1983. Chemical synthesis of an undecaribonucleoside decaphosphate constituting the 3′-terminal acceptor stem sequence of yeast tRNAPhe. Chem. Scripta 22:30-48. Lakshman, M.K. and Zajc, B. 1996. A rapid, highyield method for 5′-hydroxyl protection in very reactive and amino group modified nucleosides using dimethoxytrityl tetrafluoroborate. Nucleosides Nucleotides 15:1029-1039. Lehmann, C., Xu, Y-Z., Christodoulou, C., Tan, Z.-K., and Gait, M.J. 1989. Solid-phase synthesis of oligoribonucleotides using 9-fluorenylmethoxycarbonyl (Fmoc) for 5′-hydroxyl protection. Nucl. Acids Res. 17:2379-2390. Leonard, N.J. and Neelima 1995. 1,1,1,3,3,3Hexafluoro-2-propanol for the removal of the 4,4′-dimethoxytrityl protecting group from the 5′-hydroxyl of acid-sensitive nucleosides and nucleotides. Tetrahedron Lett. 36:7833-7836. Letsinger, R.L. and Finnan, J.L. 1975. Selective deprotection by reductive cleavage with radical anions. J. Am. Chem. Soc. 97:7197-7198. Letsinger, R.L. and Miller, P.S. 1969. Protecting groups for nucleosides used in synthesizing oligonucleotides. J. Am. Chem. Soc. 91:3356-3359. Letsinger, R.L. and Ogilvie, K.K. 1967. Use of p-nitrophenyl chloroformate in blocking hydroxyl groups in nucleosides. J. Org. Chem. 32:296-300. Letsinger, R.L., Fontaine, J., Mahadevan, V., Schexnayder, D.A., and Leone, R.E. 1964. 2,4Dinitrobenzenesulfenyl as a blocking group for hydroxyl functions in nucleosides. J. Org. Chem. 29:2615-2618. Letsinger, R.L., Caruthers, M.H., Miller, P.S., and Ogilvie, K.K. 1967. Oligonucleotide syntheses utilizing β-benzoylpropionyl, a blocking group with a trigger for selective cleavage. J. Am. Chem. Soc. 89:7146-7147. Luzzio, F.A. and Menes, M.E. 1994. A facile route to pyrimidine-based nucleoside olefins: Application to the synthesis of d4T (stavudine). J. Org. Chem. 59:7267-7272. Ma, Y. and Sonveaux, E. 1987. The 9-fluorenylmethyloxycarbonyl (Fmoc) group as a 5′-O base labile protecting group in solid supported oligonucleotide synthesis. Nucleosides Nucleotides 6:491-493.
Protection of 5′-Hydroxy Functions of Nucleosides
Markiewicz, W.T. 1979. Tetraisopropyldisiloxane1,3-diyl, a group for simultaneous protection of 3′- and 5′-hydroxy functions of nucleosides. J. Chem. Res., Miniprint 0181-0197. Markiewicz, W.T. 1980. The reaction of 1,3-dichloro-1,1,3,3,-tetraisopropyldisiloxane with some open chain polyhydroxy compounds. Tetrahedron Lett. 21:4523-4524. Matsuda, A., Inada, M., Nara, H., Ohtsuka, E., and Ono, A. 1993. Nucleosides and nucleotides. 126. Incorporation of a mutagenic nucleoside, 5-formyl-2′-deoxyuridine, into an oligodeoxyribonucleotide. Bioorg. Med. Chem. Lett. 3:2751-2754. Matteucci, M.D. and Caruthers, M.H. 1980. The use of zinc bromide for removal of dimethoxytrityl ethers from deoxynucleotides. Tetrahedron Lett. 21:3243-3246. Matteucci, M.D. and Caruthers, M.H. 1981. Synthesis of deoxyoligonucleotides on a polymer support. J. Am. Chem. Soc. 103:3185-3191. McEldoon, W.L. and Wiemer, D.F. 1995. Synthesis of nucleoside 3′-phosphonates via 3′-keto nucleosides. Tetrahedron 51:7131-7148. McGall, G.H., Labadie, J., Brock, P., Wallraff, G., Nguyen, T., and Hinsberg, W. 1996. Light-directed synthesis of high-density oligonucleotide arrays using semiconductor photoresists. Proc. Natl. Acad. Sci. U.S.A. 93:13555-13560. McGall, G.H., Barone, A.D., Diggelmann, M., Fodor, S.P.A., Gentalen, E., and Ngo, N. 1997. The efficiency of light-directed synthesis of DNA arrays on glass substrates. J. Am. Chem. Soc. 119:5081-5090. Misetic, A. and Boyd, M.K. 1998. The pixyl (Px) group: A novel photocleavable protecting group for primary alcohols. Tetrahedron Lett. 39:16531656. Mitchell, M.J., Hirschowitz, W., Rastinejad, F., and Lu, P. 1990. Boron trifluoride-methanol complex as a non-depurinating detritylating agent in DNA synthesis. Nucl. Acids. Res. 18:5321. Moris, F. and Gotor, V. 1992a. A novel and convenient route to 3′-carbonates from unprotected 2′deoxynucleosides through an enzymatic reaction. J. Org. Chem. 57:2490-2492. Moris, F. and Gotor, V. 1992b. Lipase-mediated alkoxycarbonylation of nucleosides with oxime carbonates. Tetrahedron 48:9869-9876. Moris, F. and Gotor, V. 1993. A useful and versatile procedure for the acylation of nucleosides through an enzymatic reaction. J. Org. Chem. 58:653-660.
Ma, Y. and Sonveaux, E. 1989. The 9-fluorenylmethyloxycarbonyl group as a 5′-OH protection in oligonucleotide synthesis. Biopolymers 28:965-973.
Mullah, B. and Andrus, A. 1996. Purification of 5′-O-trityl-on oligoribonucleotides. Investigation of phosphate migration during purification and detritylation. Nucleosides Nucleotides 15:419-430.
Mairanovsky, V.G. 1976. Elektro-deblockierung— elektrochemische Abspaltung von Schutzgruppen. Angew. Chem. 9:283-294.
Natt, F. and Häner, R. 1997. Lipocap: A lipophilic phosphoramidite-based capping reagent. Tetrahedron 53:9629-9636.
2.3.30 Current Protocols in Nucleic Acid Chemistry
Nozaki, K., Uemura, A., Yamashita, J., and Yasumoto, M. 1990. Enzymatic regioselective acylation of the 3′-hydroxyl groups of 2′-deoxy-5fluorouridine (FUdR) and 2′-deoxy-5-trifluoromethyluridine (CF3UdR). Tetrahedron Lett. 31:7327-7328. Ogilvie, K.K. and Letsinger, R.L. 1967. Use of isobutyloxycarbonyl as a blocking group in pr eparation of 3′-O-p-monomethoxytritylthymidine. J. Org. Chem. 32:2365-2366. Ogilvie, K.K., Thompson, E.A., Quilliam, M.A., and Westmore, J.B. 1974. Selective protection of hydroxyl groups in deoxynucleosides using alkylsilyl reagents. Tetrahedron Lett. 33:2865-2868. Ogilvie, K.K., Usman, N., Nicoghosian, K., and Cedergren, R.J. 1988. Total chemical synthesis of a 77-nucleotide-long RNA sequence having methionine-acceptance. Proc. Natl. Acad. Sci. U.S.A. 85:5764-5768. Ohtsuka, E. and Iwai, S. 1987. Chemical synthesis of RNA. In Synthesis and Application of DNA and RNA (S.A. Narang, ed.) pp. 115-136. Academic Press, Orlando, Fla. Ohtsuka, E., Taniyama, Y., Iwai, S., Yoshida, T., and Ikehara, M. 1984. Deoxyribonucleic acids and related compounds. VIII. Solid-phase synthesis of deoxyribooligonucleotides with 3′-modification by elongation in the 3′-direction. Chem. Pharm. Bull. 32:85-93. Oikawa, Y., Yoshioka, T., and Yonemitsu, O. 1982. Specific removal of o-methoxybenzyl protection by DDQ oxidation. Tetrahedron Lett. 23:885-888. Ozaki, H., Nakamura, A., Arai, M., Ogawa, Y., and Sawai, H. 1994. Synthesis and property of oligodeoxyribonucleotide bearing 5-aminoalkyl2′-deoxyuridine derivatives. Nucl. Acids Res. Symp. Ser. 31:49-50.
Pfleiderer, W., Stengele, K.P., Bergmann, F., Resmini, M., and Henke, C. 1995. How to synthesize a tRNA? Nucleosides Nucleotides 14:843-846. Pieken, W. 1997. Product anchored sequential synthesis: A novel process for the preparation of oligonucleotides. Abstracts, International Symposium on Nucleic Acids and Related Macromolecules, Ulm, Germany. Pirrung, M.C. and Bradley, J.-C. 1995a. Dimethoxybenzoin carbonates: Photochemically removable alcohol protecting groups suitable for phosphoramidite-based DNA synthesis. J. Org. Chem. 60:1116-1117. Pirrung, M.C. and Bradley, J.-C. 1995b. Comparison of methods for photochemical phosphoramidite-based DNA synthesis. J. Org. Chem. 60:6270-6276. Pirrung, M.C. and Lee, Y.R. 1993. Photochemically removable silyl protecting groups. J. Org. Chem. 58:6961-6963. Pirrung, M.C., Fallon, L., and McGall, G. 1998. Proofing of photolithographic DNA synthesis with 3′,5′-dimethoxybenzoinyloxycarbonylprotected deoxynucleoside phosphoramidites. J. Org. Chem. 63:241-246. Prasad, A.K. and Wengel, J. 1996. Enzyme-mediated protecting group chemistry on the hydroxyl groups of nucleosides. Nucleosides Nucleotides 15:1347-1359. Ramage, R. and Wahl, F.O. 1993. 4-(17-Tetrabenzo[a,c,g,i]fluorenylmethyl)-4′,4′′-dimethoxytrityl chloride: A hydrophobic 5′-protecting group for the separation of synthetic oligonucleotides. Tetrahedron Lett. 34:7133-7136.
Ozaki, S., Yamashita, K., Konishi, T., Maekawa, T., Eshima, M., Uemura, A., and Ling, L. 1995. Enzyme aided regioselective acylation of nucleosides. Nucleosides Nucleotides 14:401-404.
Reddy, M.P., Rampal, J.B., and Beaucage, S.L. 1987. An efficient procedure for the solid phase tritylation of nucleosides and nucleotides. Tetrahedron Lett. 28:23-26.
Palom, Y., Alazzouzi, E., Gordillo, F., Grandas, A., and Pedroso, E. 1993. An acid-labile linker for solid-phase oligoribonucleotide synthesis using Fmoc group for 5′-hydroxyl protection. Tetrahedron Lett. 34:2195-2198.
Reese, C.B. 1978. The chemical synthesis of oligoand polynucleotides by the phosphotriester approach. Tetrahedron 34:3143-3179.
Patel, T.P., Millican, T.A., Bose, C.C., Titmas, R.C., Mock, G.A., and Eaton, M.A.W. 1982. Improvements to solid phase phosphotriester synthesis of deoxyoligonucleotides. Nucl. Acids Res. 18:5605-5620. Patil, S.V., Mane, R.B., and Salunkhe, M.M. 1994. A facile method for detritylation of 5′-O-dimethoxy-trityl-3′-O-tert-butyldimethylsilyl-2′deoxynucleosides. Synth. Commun. 24:2423-2428. Paul, C.H. and Royappa, A.T. 1996. Acid binding and detritylation during oligonucleotide synthesis. Nucl. Acids Res. 24:3048-3052. Pease, A.C., Solas, D., Sullivan, E.J., Cronin, M.T., Holmes, C.P., and Fodor, S.P.A. 1994. Lightgenerated oligonucleotide arrays for rapid DNA sequence analysis. Proc. Natl. Acad. Sci. U.S.A. 91:5022-5026.
Reese, C.B. 1985. Some aspects of the chemical synthesis of oligoribonucleotides. Nucleosides Nucleotides 4:117-127. Reese, C.B. 1989. The chemical synthesis of oligoand polyribonucleotides. In Nucleic Acids and Molecular Biology, Vol. 3 (F. Eckstein and D.M.J. Lilley, eds.) pp. 164-181. Springer-Verlag, Berlin. Reese, C.B. and Skone, P.A. 1984. The protection of thymine and guanine residues in oligodeoxyribonucleotide synthesis. Chem. Soc. Perkin Trans. 1 1263-1271. Reese, C.B. and Stewart, J.C.M. 1968. Methoxyacetyl as a protecting group in ribonucleoside chemistry. Tetrahedron Lett. 40:4273-4276. Reese, C.B. and Thompson, E.A. 1988. A new synthesis of 1-arylpiperidin-4-ols. J. Chem. Soc. Perkin Trans. 1 2881-2885.
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.31 Current Protocols in Nucleic Acid Chemistry
Reese, C.B., Serafinowska, H., and Zappia, G. 1986. An acetal group suitable for the protection of 2′-hydroxy functions in rapid oligoribonucleotide synthesis. Tetrahedron Lett. 27:2291-2294. Regel, W., Stengele, E., and Seliger, H. 1974. Kinetik der Schutzgruppenabspaltung an Nucleosiden mittels 1H-NMR-Spektroskopie. Chem. Ber. 107:611-615. Reiner, T. and Pfleiderer, W. 1987. β-Substituted ethylsulfonyl chlorides as 5′-OH protecting groups in nucleoside and nucleotide chemistry. Nucl. Acids Res. Symp. Ser. 18:161-164. Riva, S., Chopineau, J., Kieboom, A.P.G., and Klibanov, A.M. 1988. Protease-catalyzed regioselective esterification of sugars and related compounds in anhydrous dimethylformamide. J. Am. Chem. Soc. 110:584-589. Robins, M.J., Samano, V., and Johnson, M.D. 1990. Periodinane oxidation, selective primary deprotection, and remarkably stereoselective reduction of tert-butyldimethylsilylprotected ribonucleosides. Synthesis of 9-(βD-xylofuranosyl)adenine or 3′-deuterioadenosine from adenosine. J. Org. Chem. 55:410-412. Rosenthal, A., Cech, D., Veiko, V.P., Orezkaja, T.S., Kuprijanova, E.A., and Shabarova, Z.A. 1983. Tr iester- Fes tphasensynthese von Oligodesoxyribonucleotiden an Polystyren-Teflon Trägern. Tetrahedron Lett. 24:1691-1694. Rosowsky, A., Solan, V.C., Sodroski, J.G., and Ruprecht, R.M. 1989. Synthesis of the 2-chloro analogues of 3′-deoxyadenosine, 2′,3′-dideoxyadenosine, and 2′,3′-didehydro-2′,3′-dideoxyadenosine as potential antiviral agents. J. Med. Chem. 32:1135-1140. Sachdev, H.S. and Starkovsky, N.A. 1969. Enzymatic removal of acyl protecting groups. The use of dihydrocinnamoyl group in oligonucleotide synthesis and its cleavage by α-chymotrypsin. Tetrahedron Lett. 9:733-736. Sandström, A., Kwiatkowski, M., and Chattopadhyaya, J. 1985. Chemical synthesis of a pentaribonucleoside tetraphosphate constituting the 3′acceptor stem sequence of E. coli tRNAIle using 2′-O-(3-methoxy-1,5-dicarbomethoxypentan-3yl)-ribonucleoside building blocks. Application of a new achiral and acid-labile 2′-hydroxyl protecting group in tRNA synthesis. Acta Chem. Scand. B 39:273-290. Scalfi-Happ, C., Happ, E., and Chládek, S. 1987. New approach to the synthesis of 2′(3′)-O-aminoacyl-oligoribonucleotides related to the 3′-terminus of aminoacyl transfer ribonucleic acid. Nucleosides Nucleotides 6:345-348.
Protection of 5′-Hydroxy Functions of Nucleosides
Schaller, H., Weimann, G., Lerch, B., and Khorana, H.G. 1963. Studies on polynucleotides. XXIV. The stepwise synthesis of specific deoxyribopolynucleotides (4). Protected derivatives of deoxyribonucleosides and new syntheses of deoxyribonucleoside-3′-phosphates. J. Am. Chem. Soc. 85:3821-3827.
Schirmeister, H., Himmelsbach, F., and Pfleiderer, W. 1993. The 2-(4-nitrophenyl)ethoxycarbonyl (npeoc) and 2-(2,4-dinitrophenyl)ethoxycarbonyl (dnpeoc) groups for protection of hydroxy functions in ribonucleosides and 2′-deoxyribonucleosides. Helv. Chim. Acta 76:385-401. Schmidt, G., Schlenk, R., and Seliger, H. 1988. The 4-decyloxytrityl group as an aid in the affinity chromatography of synthetic oligonucleotides. Nucleosides Nucleotides 7:795-799. Sekine, M. 1993. Selective and rapid O-acylation of hydroxyl groups of nucleosides by means of phase transfer catalysis. Nat. Prod. Lett. 1:251-256. Sekine, M. 1994. A new method for removal of modified trityl and pixyl groups by use of an acid species generated by reaction of diethyl oxomalonate with methanol. Nucleosides Nucleotides 13:1397-1414. Sekine, M. and Hata, T. 1983. 4,4′,4′′-Tris(benzoyloxy)trityl as a new type of base-labile group for protection of primary hydroxyl groups. J. Org. Chem. 48:3011-3014. Sekine, M. and Hata, T. 1984. 4,4′,4′′-Tris(4,5-dichlorophthalimido)trityl: A new type of hydrazine-labile group as a protecting group of primary alcohols. J. Am. Chem. Soc. 106:57635764. Sekine, M. and Hata, T. 1985. 4,4′,4′′-Tris(levulinoyloxy)trityl as a new type of primary hydroxyl protecting group. Bull. Chem. Soc. Jpn. 58:336339. Sekine, M. and Hata, T. 1986. Synthesis of short oligoribonucleotides bearing a 3′- or 5′-terminal phosphate by use of 4,4′,4′′-tris(4,5-dichlorophthalimido)trityl as a new 5′-hydroxyl protecting group. J. Am. Chem. Soc. 108:4581-4586. Sekine, M. and Hata, T. 1987. 3-(Imidazol-1-ylmethyl)-4′,4′′-dimethoxytrityl: A new functionalized 5′-hydroxyl protecting group capable of rapid internucleotidic bond formation in the phosphorothio ester approach. J. Org. Chem. 52:946-948. Sekine, M., Mori, T., and Wada, T. 1993. New 5′-hydroxyl protecting groups for rapid internucleotide bond formation. Tetrahedron Lett. 34:8289-8292. Seliger, H. 1972. Chlorameisensäureester von Nucleosiden—neue Zwischenprodukte für Synthesen mit Nucleinsäurebausteinen. Tetrahedron Lett. 39:4043-4046. Seliger, H. 1993. Scale-up of oligonucleotide synthesis. Solution phase. In Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs (S. Agrawal, ed.) pp. 391-435. Humana Press, Totowa, N.J. Seliger, H. and Görtz, H.-H. 1981. Specific separation of products in supported oligonucleotide syntheses using the triester method. Angew. Chem., Int. Ed. Engl. 20:683-684. Seliger, H. and Kotschi, U. 1985. The p-phenylazophenyloxycarbonyl protecting group: Selective deblocking and oligonucleotide synthesis avoiding acid steps. Nucleosides Nucleotides 4:153-155.
2.3.32 Current Protocols in Nucleic Acid Chemistry
Seliger, H. and Schmidt, G. 1987. Derivatization with the 4-decyloxytrityl group as an aid in the affinity chromatography of oligo- and polynucleotides. J. Chromatogr. 397:141-151. Seliger, H., Holupirek, M., and Görtz, H.-H. 1977a. Oligonucleotide support synthesis with affinity-chromatographic separation of the product. Abstracts, XXVIth IUPAC International Congress of Pure and Applied Chemistry, Tokyo. Abstract 265. Seliger, H., Holupirek, M., and Bach, T.C. 1977b. The lipoyl affinity group and its use in oligonucleotide synthesis. Commun. (Posters), Brit. Chem. Soc. Nucl. Group, 10th anniversary meeting, British Chem. Soc., Birmingham, U.K. Seliger, H., Holupirek, M., and Görtz, H.-H. 1978. Solid-phase oligonucleotide synthesis with affinity-chromatographic separation of the product. Tetrahedron Lett. 24:2115-2118. Seliger, H., Klein, S., Narang, C.K., SeemannPreising, B., Eiband, J. and Hauel, N. 1982. Solid-phase synthesis of oligonucleotides using the phosphite method. In Chemical and Enzymatic Synthesis of Gene Fragments: A Laboratory Manual (H.G. Gassen and A. Lang, eds.) pp. 81-96. Verlag Chemie, Weinheim, Germany. Seliger, H., Zeh, D., Azuru, G., and Chattopadhyaya, J.B. 1983. Two new and efficient routes to the preparation of oligoribonucleotides of defined sequence. Chem. Scripta 22:95-101. Seliger, H., Gupta, K.C., Kotschi, U., Spaney, T., and Zeh, D. 1986. New preparative methods in oligonucleotide chemistry and their application to gene synthesis. I. Improvements in the chemistry of solid-phase oligonucleotide synthesis. Chem. Scr. 26:561-567. Seliger, H., Schmidt, G., and Berner, S. 1987. Substituents with long alkyl chains as tools for the purification and immobilization of nucleic acids and their constituents. Biol. Chem. Hoppe-Seyler 368:773-774. Septak, M. 1996. Kinetic studies on depurination and detritylation of CPG-bound intermediates during oligonucleotide synthesis. Nucl. Acids Res. 24:3053-3058. Shabarova, Z.A. 1980. The application of solid phase method-synthesized oligodeoxyribonucleotides to molecular biology problems. Nucl. Acids Res. Symp. Ser. 7:259-279. Shimidzu, T. and Letsinger, R.L. 1968. Synthesis of deoxyguanylyldeoxyguanosine on an insoluble polymer support. J. Org. Chem. 33:708-711. Singh, H.K., Cote, G.L., and Sikorski, R.S. 1993. Enzymatic regioselective deacylation of 2′,3′,5′tri-O-acylribonucleosides: Enzymatic synthesis of 2′,3′-di-O-acylribonucleosides. Tetrahedron Lett. 34:5201-5204. Singh, H.K., Cote, G.L., and Hadfield, T.M. 1994. Manipulation of enzyme regioselectivity by solvent engineering: Enzymatic synthesis of 5′-Oacylribonucleosides. Tetrahedron Lett. 35:13531356.
Sinha, N.D., Biernat, J., McManus, J., and Köster, H. 1984. Polymer support oligonucleotide synthesis. XVII. Use of β-cyanoethyl-N,N-dialkylamino/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucl. Acids Res. 12:45394557. Smith, M., Rammler, D.H., Goldberg, I.H., and Khorana, H.G. 1962. Studies on polynucleotides. XIV. Specific synthesis of the C3′-C5′ interribonucleotide linkage. Syntheses of uridylyl-(3′→5′)-uridine and uridylyl-(3′→5′)adenosine. J. Am. Chem. Soc. 84:430-440. Sonveaux, E. 1986. The organic chemistry underlying DNA synthesis. Bioorg. Chem. 14:271-325. Sproat, B.S. and Gait, M.J. 1984. Solid-phase synthesis of oligodeoxyribonucleotides by the phosphotriester method. In Oligonucleotide Synthesis: A Practical Approach (M.J. Gait, ed.) pp. 83-115. IRL Press, Oxford. Takaku, H., Morita, K., and Sumiuchi, T. 1983. Selective removal of terminal dimethoxytrityl groups. Chem. Lett. 1661-1664. Tanaka, T. and Oishi, T. 1985. Chemical synthesis of deoxyribonucleotides containing deoxyadenosine at the 3′-end on a polystyrene polymer support. Chem. Pharm. Bull. 33:5178-5183. Tanimura, H. and Imada, T. 1990. Practical chemical synthesis of RNA fragments. Improvements in the preparation of ribonucleoside phosphoramidite units. Chem. Lett. 1715-1718. Tanimura, H., Fukazawa, T., Sekine, M., Hata, T., Efcavitch, J.W., and Zon, G. 1988. The practical synthesis of RNA fragments in the solid phase approach. Tetrahedron Lett. 29:577-578. Tanimura, H., Maeda, M., Fukazawa, T., Sekine, M., and Hata, T. 1989. Chemical synthesis of the 24 RNA fragments corresponding to hop stunt viroid. Nucl. Acids Res. 17:8135-8147. Taunton-Rigby, A. 1973. Oligonucleotide synthesis. III. Enzymatically removable acyl protecting groups. J. Org. Chem. 38:977-985. Taunton-Rigby, A., Kim, Y.-H., Crosscup, C.J., and Starkovsky, N.A. 1972. Oligonucleotide synthesis. II. The use of substituted trityl groups. J. Org. Chem. 37:956-964. Temsamani, J., Kubert, M., and Agrawal, S. 1995. Sequence identity of the n-1 product of a synthetic oligonucleotide. Nucl. Acids Res. 23:18411844. Ti, G.S., Gaffney, B.L., and Jones, R.A. 1982. Transient protection: Efficient one-flask syntheses of protected deoxynucleosides. J. Am. Chem. Soc. 104:1316-1319. Tong, G., Lawlor, J.M., Tregear, G., and Haralambidis, J. 1993. The synthesis of oligonucleotidepolyamide conjugate molecules suitable as PCR primers. J. Org. Chem. 58:2223-2231. Uemura, A., Nozaki, K., Yamashita, J., and Yasumoto, M. 1989a. Lipase-catalyzed regioselective acylation of sugar moieties of nucleosides. Tetrahedron Lett. 30:3817-3818.
Protection of Nucleosides for Oligonucleotide Synthesis
2.3.33 Current Protocols in Nucleic Acid Chemistry
Uemura, A., Nozaki, K., Yamashita, J., and Yasumoto, M. 1989b. Regioselective deprotection of 3′,5′-O-acylated pyrimidine nucleosides by lipase and esterase. Tetrahedron Lett. 30:38193820. Usman, N., Ogilvie, K.K., Jiang, M.-Y., and Cedergren, R.J. 1987. Automated chemical synthesis of long oligoribonucleotides using 2′-O-silylated ribonucleoside 3′-O-phosphoramidites on a controlled-pore glass support: Synthesis of a 43-nucleotide sequence similar to the 3′-half molecule of an Escheria coli formylmethionine tRNA. J. Am. Chem. Soc. 109:7845-7854. van Boom, J.H. and Burgers, P.M.J. 1976. Use of levulinic acid in the protection of oligonucleotides via the modified phosphotriester method; synthesis of decaribonucleotide U-A-U-A-U-A-U-A-U-A. Tetrahedron Lett. 52:4875-4878. van Boom, J.H. and Wreesmann, C.T.J. 1984. Chemical synthesis of small oligoribonucleotides in solution. In Oligonucleotide Synthesis: A Practical Approach (M.J. Gait, ed.) pp. 153-183. IRL Press, Oxford. Wada, T., Mochizuki, A., Sato, Y., and Sekine, M. 1998a. Functionalisation of solid supports with N-unprotected deoxyribonucleotides. Tetrahedron Lett. 39:5593-5596. Wada, T., Naotake, K., Mori, T., and Sekine M. 1998b. Stereocontrolled synthesis of dithymidine phosphorothioates by use of a functionalized 5′-protecting group bearing an imidazole residue. Nucleosides Nucleotides 17:351-364. Waldmann, H. and Sebastian, D. 1994. Enzymatic protecting group techniques. Chem. Rev. 94:911937. Waldmeier, F., de Bernardini, S., Leach, C.A., and Tamm, C. 1982. 246. Nucleosides and Nucleotides. Part 19. On detritylation with zinc bromide in oligonucleotide synthesis. Helv. Chim. Acta 65:2472-2475. Wallraff, G., Labadie, J., Brock, P., Di Pietro, R., Nguyen, T., Huynh, T., Hinsberg, W., and McGall, G. 1997. DNA sequencing on a chip. CHEMTECH 22-32.
Weiler, J. and Pfleiderer, W. 1995. An improved method for large scale synthesis of oligonucleotides applying the NPE/NPEOC-strategy. Nucleosides Nucleotides 14:917-920. Weiss, R., Birch-Hirschfeld, E., and Witkowski, W. 1984. Comparative study of the synthesis of oligodeoxynucleotides achieved by the phosphotriester method on various supports. Nucl. Acids Res. Symp. Ser. 14:313-314. Welch, C.J., Zhou, X.-X., and Chattopadhyaya, J. 1986. Synthesis of an mRNA fragment of alanyltRNA synthetase gene in Escherichia coli using the 6-methyl-3-pyridyl group for protection of the imide functions of uridine and guanosine. Acta Chem. Scand. B 40:817-825. Winnacker, E.-L. and Dörper, T. 1982. Solid-phase synthesis of oligonucleotides using the phosphoramidite method. In Chemical and Enzymatic Synthesis of Gene Fragments: A Laboratory Manual (H.G. Gassen and A. Lang, eds.) pp. 97-102. Verlag Chemie, Weinheim, Germany. Wong, C.-H., Chen, S.-T., Hennen, W.J., Bibbs, J.A., Wang, Y.-F., Liu, J.L.-C., Pantoliano, M.W., Whitlow, M., and Bryan, P.N. 1990. Enzymes in organic synthesis: Use of subtilisin and a highly stable mutant derived from multiple site-specific mutations. J. Am. Chem. Soc. 112:945-953. Yamakage, S., Sakatsume, O., Furuyama, E., and Takaku, H. 1989. 1-(2-Chloroethoxy)ethyl group for the protection of 2′-hydroxyl group in the synthesis of oligoribonucleotides. Tetrahedron Lett. 30:6361-6364. Yu, D., Tang, J., Iyer, R.P., and Agrawal, S. 1994. Diethoxy-N,N-diisopropyl phosphoramidite as an improved capping reagent in the synthesis of oligonucleotides using phosphoramidite chemistry. Tetrahedron Lett. 35:8565-8568.
Contributed by H. Seliger University of Ulm Ulm, Germany
Protection of 5′-Hydroxy Functions of Nucleosides
2.3.34 Current Protocols in Nucleic Acid Chemistry
A Base-Labile Protecting Group (Fluorenylmethoxycarbonyl) for the 5′-Hydroxy Function of Nucleosides
UNIT 2.4
Once the exocyclic amino functions of a nucleoside have been protected (UNIT 2.1), further functionalization aimed towards assembly into oligonucleotides requires consideration of the specific regioselective protection of the hydroxy groups present in the monomeric building block. Some years ago it was found that, in the case of 2′-deoxynucleosides, the two hydroxy groups (3′- and 5′-) could be satisfactorily differentiated by the application of the triarylmethyl (trityl) family of acid-labile protecting groups for temporary protection of the primary 5′-hydroxy function (UNIT 2.3). In the case of the ribonucleoside series, however, the differentiation of the three hydroxy groups (2′-, 3′-, and 5′-) has to be achieved at the extremely high level of efficiency required for the iterative steps involved in oligonucleotide assemblies carried out on synthesizer machines. This increased complexity has led to a number of alternative synthetic pathways to oligoribonucleotides, some of which are now commercialized; other pathways remain to be explored more profoundly. Most of the present oligoribonucleotide synthesis strategies adhere to the popular 5′-Otrityl chemistry and aim at finding solutions for 2′-O-protection (UNIT 2.2), such as the t-butyldimethylsilyl (TBDMS) group, which can be removed by treatment with fluoride ion. In contrast, the authors chose to take advantage of the well-established ketal-type group for 2′-O-protection, which allows final deprotection under particularly mild and isomerization-free acidolytic aqueous conditions at the end of the synthesis (UNIT 2.2), and investigated for 5′-protection the base-labile 9-fluorenylmethoxycarbonyl (FMOC) group as a valuable orthogonal complement. The following Basic Protocol presents a reliable procedure for the regioselective introduction of the FMOC group at the 5′-hydroxy position of nucleosides, starting with deoxythymidine or with 4-methoxytetrahydropyran-4-yl (MTHP)–protected ribonucleosides. The Basic Protocol includes steps for the isolation and characterization of all four 5′-O-FMOC-2′-O-MTHP-protected ribonucleosides and of 5′-O-FMOC-2′-deoxythymidine, which serves as a reference for the deoxyribonucleoside series. No modification is required for 5′-O-FMOC-2′-dABz, -dCBz, or -dGi-Bu (yields are ~65% for dGi-Bu and 70% to 80% for dABz and dCBz; Balgobin and Chattopadhyaya, 1987; Ma and Sonveaux, 1987). Additionally, four Support Protocols describe the preparation of the starting N-protected-2′-O-MTHP-ribonucleosides, which are not commercially available and are considered key intermediates for the preparation of the 5′-O-FMOC-protected ribonucleoside building blocks. Characterization of the various products requires experience in thin-layer chromatography, short column (flash) chromatography, and proton NMR. ACYLATION OF THE 5′-HYDROXY GROUP OF 2′-O-(4-METHOXYTETRAHYDROPYRAN-4-YL)-RIBONUCLEOSIDES WITH 9-FLUORENYLMETHOXYCARBONYL CHLORIDE
BASIC PROTOCOL
The procedure describes the acylation of the 5′-hydroxy function of N-base- and 2′-Oprotected ribonucleosides with 9-fluorenylmethoxycarbonyl (FMOC) chloride in pyridine at moderately low temperature. The FMOC workup procedure and the chromatographic isolation and 1H-NMR spectroscopic characterization of the resulting 5′-O-(9-fluorenylmethyl)carbonates S.2a to S.2e (Fig. 2.4.1) are presented in this protocol. The starting intermediates are the four 2′-O-MTHP-protected ribonucleotides rUMTHP, rCBzMTHP, rABzMTHP, and rGi-BuMTHP (S.1a to S.1d; Fig. 2.4.1 and Fig. 2.4.2) and
Protection of Nucleosides for Oligonucleotide Synthesis
Contributed by Michael J. Gait and Christian Lehmann
2.4.1
Current Protocols in Nucleic Acid Chemistry (2000) 2.4.1-2.4.22 Copyright © 2000 by John Wiley & Sons, Inc.
HO
O
4' 3'
HO
[Fmoc]
B
5'
1' 2'
O
Fmoc chloride OCH3
O
pyridine, 0ºC
B
O
O
O
O HO
[Mthp]
O
OCH3
O 1a: 1b: 1c: 1d: 1e:
B = U = uracil-1-yl Bz 4 B = C = N -benzoylcytosin-1-yl Bz 6 B = A = N -benzoyladenin-9-yl -Bu 2 B = Gi = N -isobutyrylguanin-9-yl B = T = thymin-1-yl; 2'-deoxy
2a: 2b: 2c: 2d: 2e:
B=U Bz B=C Bz B=A -Bu B = Gi B = T; 2'-deoxy
Figure 2.4.1 General procedure for the preparation of 5′-O-fluorenylmethoxycarbonyl-2′-O-(4methoxytetrahydropyran-4-yl)-ribonucleosides (S.2a-d) and of 5′-O-fluorenylmethoxycarbonyl-2′deoxythymidine (S.2e).
deoxythymidine (dT; S.1e; Fig. 2.4.1). Support Protocols 1 to 4 provide a summary for the preparation of the starting key intermediates S.1a to S.1d. Materials 2′-Deoxythymidine or 2′-O-MTHP-ribonucleoside: 2′-O-(4-methoxytetrahydropyran-4-yl)-rU, -rCBz, -rABz, or -rGi-Bu (see Support Protocols 1 to 4) Dry pyridine, freshly distilled from calcium hydride (5 g/L) after refluxing for 2 hr under an inert atmosphere Nitrogen gas 9-Fluorenylmethoxycarbonyl (FMOC) chloride (Cambridge Research Biochemicals), recrystallized from ether/pentane in a large desiccator (vapor diffusion method) Diethyl ether (analytical grade) Chloroform stabilized with 1% ethanol (commercially available analytical grade) Methanol (analytical grade) Anisaldehyde reagent (see recipe) Ethane-1,2-diol (analytical grade) Saturated aqueous sodium bicarbonate solution Sodium sulfate (anhydrous) Toluene (analytical grade) Ethanol (analytical grade) Pentane (analytical grade) Silica-coated thin-layer chromatography (TLC) plate with fluorescent indicator Kieselgel 60F254 (Merck 5554 glass plates or 5744 aluminium foils) UV light source D4 glass-filter crucible Short column (diameter 5 cm; length ~10 cm) containing 50 g Kieselgel 60H without calcium sulfate (Merck 7736 or Fluka 60770, particle size 5-40 µm; or Merck 11677, particle size 15 µm), preconditioned with chloroform Glass-fiber tissue A Base-Labile Protecting Group
CAUTION: Wear gloves and perform all operations involving TLC solvents and reagents in a well-ventilated fume hood.
2.4.2 Current Protocols in Nucleic Acid Chemistry
[Bz]
O HN
O 4 5
2
6
N1
O
4'
6
O
O
4'
2'
3'
5'
HO
1'
HO
3
5
NH
5'
HO
4
3
2
O
N1 1' 2'
3'
HO
OMthp
N
OMthp
1a
1b
from uridine
from cytidine
O HN
7
6
N 5 5'
O
4' 3'
HO
N 4 N 9 1'
1
2
3
2'
5'
O
4' 3'
OMthp
6 1
N 5
NH
8
HO
HO
[i-Bu]
O
7
N
8
HO
[Bz]
N 4 N 9 3
1'
O
2
N H
2'
OMthp
1c
1d
from adenosine
from guanosine
Figure 2.4.2 2′-O-(4-Methoxytetrahydropyran-4-yl)-ribonucleosides used as starting intermediates for FMOC protection. Preparation of these intermediates is shown in Figures 2.4.3 to 2.4.6.
Introduce FMOC group 1. Coevaporate 3.0 mmol of 2′-O-MTHP-ribonucleoside or deoxythymidine derivative (S.1a to S.1e) twice from 25 mL dry pyridine under reduced pressure using a rotary evaporator, and then apply a dry nitrogen atmosphere. 2. Dissolve the substrate in a third 25-mL portion of dry pyridine and cool to 0°C. 3. Stir the solution and add 3.6 mmol crystalline FMOC chloride. Stir under nitrogen for 30 min at 0°C. Normally, all the FMOC chloride will have dissolved by this time.
Check reaction by TLC 4. Resolve products on a silica-coated TLC plate with fluorescent indicator. Develop with diethyl ether followed by 9:1 (v/v) chloroform/methanol. Predevelopment in diethyl ether is used to disperse the pyridine.
5. Visualize under UV light (254 nm). 6. Stain by spraying with anisaldehyde reagent and heating on a hot plate at 80°C. Coloring plates containing nucleoside materials (summarized in Jork et al., 1990) is necessary for compounds that do not absorb strongly in the 254-nm region (i.e., unprotected rUMTHP and dT). TLC shows complete conversion into products with higher Rf values than the starting nucleosides. The major component is the 5′-O-FMOC derivative (see respective Rf values for each nucleoside following step 18; when starting with S.1b, the 5′-derivative Rf = 0.54). A very minor component at slightly higher Rf is identified as the 3′-O-FMOC derivative
Protection of Nucleosides for Oligonucleotide Synthesis
2.4.3 Current Protocols in Nucleic Acid Chemistry
(Rf = 0.68 when starting with S.1b). Some 3′,5′-di-O-FMOC derivative can be found at a very much higher Rf (0.80 when starting with S.1b). If complete conversion is not observed, the reaction in step 3 can be continued. It should not exceed 2 hr, however, as this leads to increased production of the 3′,5′-di-O-FMOC derivative.
Isolate product by chromatography 7. Terminate the reaction by adding 200 µL of ethane-1,2-diol and concentrate the mixture to an oil using a rotary evaporator with a vacuum pump. 8. Dissolve the oil in 150 mL chloroform and wash with 50 mL saturated aqueous sodium bicarbonate solution. Remove the aqueous phase and wash twice with 50 mL chloroform. 9. Dry the combined chloroform extracts over ~20 g anhydrous sodium sulfate. 10. Filter the dried extract under vacuum with a D4 glass filter crucible, and concentrate under reduced pressure (step 7). 11. Coevaporate the residual oil from ∼50 mL each toluene (twice), ethanol (once), and chloroform (once). This removes traces of pyridine that are still contained in the dried, concentrated extract (step 10).
12. Apply as concentrated as possible (i.e., in ∼5 mL) to a short 50-g Kieselgel 60H column preconditioned with chloroform. Apply a circular piece of glass-fiber tissue (not sea sand) to the top of the column. Short-column chromatography is performed according to Hunt and Rigby (1967) and is similar to the flash chromatography described by Still et al. (1978).
13. Elute minor side products first with chloroform (first 1 to 2 column volumes; 20-mL fraction size), then elute the major product-containing fractions with a gradient of 1% to 5% (v/v) ethanol/chloroform. Do not use >1 atm pressure for elution (Hunt and Rigby, 1967; Still et al., 1978). 14. Combine the product-containing fractions and concentrate to a foam. 15. Dissolve foam in 5 mL chloroform, precipitate by dropwise addition to 500 mL rapidly stirring pentane, and decant off most of the supernatant (∼450 mL). 16. Collect solids by centrifuging 10 min at 3000 rpm g, 15°C, and decant the pentane. 17. Wash twice by resuspending in 50 mL fresh pentane and repeating the centrifugation. Dry the resulting white powder (S.2a to S.2e) in vacuo using a high vacuum from an oil pump. Characterize the product 18. Characterize the final product by TLC and 1H-NMR. Chemical characterization data is provided below for S.2a to S.2e. 1H-NMR spectra (250 MHz) were measured on a Bruker WM 250 instrument in DMSO-d6. Chemical shifts (δ) are given in ppm downfield from tetramethylsilane (TMS, 0 ppm). Coupling constants (J) are given in Hz. D2O exchange was performed on all samples.
A Base-Labile Protecting Group
5′-O-FMOC-2′-O-MTHP-uridine (S.2a): yield 64%; Rf (silica, chloroform/methanol 9:1): 0.43; 1H-NMR (250 MHz, DMSO-d6): 1.6-1.9 (m×m, 4H; -CH2-(3,5) of MTHP), 2.98 (s, 3H; H3CO- of MTHP), 3.3-3.7 (m×m, 4H; -CH2-(2,6) of MTHP), 3.9-4.6 (m×m, 8H; -CH-(4′, 3′, 2′), -CH2-(5′), fluorenyl-H9 and -CH2-), 5.4 (dbr, 1H, exchangeable with D2O;
2.4.4 Current Protocols in Nucleic Acid Chemistry
3′-OH), 5.63 (d, J = 8.0 , 1H; uridyl-H5), 5.99 (d, J = 6.3, 1H; -CH-(1′)), 7.29-7.95 (m×m, 9H; uridyl-H6, fluorenyl-aromatic H), 11.4 (sbr, 1H, exchangeable; uridyl-N3-H). 5′-O-FMOC-2′-O-MTHP-4-N-benzoyl-cytidine (S.2b): yield 61%; Rf (silica, chloroform/methanol 9:1): 0.54; 1H-NMR (250 MHz, DMSO-d6): 1.5-1.9 (m×m, 4H; -CH2-(3,5) of MTHP), 2.95 (s, 3H; H3CO- of MTHP), 3.2-3.7 (m×m, 4H; -CH2-(2,6) of MTHP), 4.00-4.35 (m×m, 5H; -CH-(4′, 3′, 2′), -CH2-(5′)), 4.47 (t, J = 6.0, 1H; fluorenyl-H9), 4.54 (d, J = 6.0, 2H; fluorenyl-CH2-), 5.4 (d, J = 5, 1H, exchangeable with D2O; 3′-OH), 6.09 (d, J = 6.4, 1H; -CH-(1′)), 7.3-8.3 (m×m, 15H; cytidyl-H5 and -H6, fluorenyl- and benzoyl-aromatic H), 11.3 (sbr, 1H, exchangeable; cytidyl-N4-H). 5′-O-FMOC-2′-O-MTHP-6-N-benzoyl-adenosine (S.2c): yield 65%; Rf (silica, chloroform/methanol 9:1): 0.56; 1H-NMR (250 MHz ,DMSO-d6): 1.4-1.9 (m×m, 4H; -CH2-(3,5) of MTHP), 2.62 (s, 3H; H3CO- of MTHP), 3.2-3.7 (m×m, 4H; -CH2-(2,6) of MTHP), 4.18-4.48 (m×m, 4H; -CH-(4′, 3′), -CH2-(5′)), 4.30 (t, J = 6.0, 1H; fluorenyl-H9), 4.51 (d, J = 6.0, 2H; fluorenyl-CH2-), 5.08 (d×d, J2′-1′ = 6.8, J2′-3′ = 5.0; 1H; -CH-(2′)), 5.6 (d, J = 4.5, 1H, exchangeable with D2O; 3′-OH), 6.21 (d, J = 6.8, 1H; -CH-(1′)), 7.2-8.4 (m×m, 13H; fluorenyl- and benzoyl-aromatic H), 8.73 and 8.74 (2s, 2H; adenyl-H2 and H8), 11.3 (sbr, 1H, exchangeable; adenyl-N6-H). 5′-O-FMOC-2′-O-MTHP-2-N-isobutyryl-guanosine (S.2d): yield 52%; Rf (silica, chloroform/methanol 9:1): 0.37; 1H-NMR (250 MHz, DMSO-d6): 1.12 (2d, J = 7.0, 6H; (H3C)2CH-)), 1.4-1.9 (m×m, 4H; -CH2-(3,5) of MTHP), 2.67 (s, 3H; H3CO- of MTHP), 2.75 (septet, J = 7.0, 1H; (H3C)2CH-)), 3.2-3.7 (m×m, 4H; -CH2-(2,6) of MTHP), 4.12-4.37 (m×m, 4H; -CH-(4′, 3′), -CH2-(5′)), 4.34 (m(t), 1H; fluorenyl-H9), 4.53 (d, J = 6.0, 2H; fluorenyl-CH2-), 4.81 (d×d, J2′-1′ = 7.5, J2′-3′ = 4.7, 1H; -CH-(2′)), 5.4 (d, J = 4, 1H, exchangeable with D2O; 3′-OH), 5.99 (d, J = 7.5, 1H; -CH-(1′)), 7.2-8.0 (m×m, 8H; fluorenyl-aromatic H), 8.25 (s, 1H; guanyl-H8), 11.6 and 12.1 (2sbr, 2H, exchangeable; guanyl-N1-H and N2-H). 5′-O-FMOC-2′-deoxythymidine (S.2e): obtained in analytically pure form by subsequent crystallization from ethyl acetate (76%; mp. 183°-185°C (decomp.); calc.: C 64.65, H 5.21, N 6.03%; found: C 64.54, H 5.09, N 5.82%); Rf (silica, chloroform/methanol 9:1): 0.44; 1 H-NMR (250 MHz, DMSO-d6): 1.69 (s, 3H; thymidyl-5-CH3), 2.10 (m, 2H; -CH2-(2′)), 3.90 (m, 1H; fluorenyl-H9), 4.10-4.40 (m×m, 4H; -CH-(4′, 3′), -CH2-(5′)), 4.58 (m(d), 2H; fluorenyl-CH2-), 5.44 (d, J = 4.4, 1H, exchangeable with D2O; 3′-OH), 6.17 (t, J = 6.3, 1H; -CH-(1′)), 7.29-7.91 (m×m, 9H; thymidyl-H6, fluorenyl-aromatic H), 11.3 (sbr, 1H, exchangeable; thymidyl-N3-H).
PREPARATION OF 2′-O-(4-METHOXYTETRAHYDROPYRAN-4-YL)URIDINE (S.1a) FROM URIDINE
SUPPORT PROTOCOL 1
Starting from uridine (S.3; Fig. 2.4.3), the desired key intermediate S.1a is obtained by a series of well-described reactions that handle the three ribonucleoside hydroxy groups differentially without protection of the base (Fromageot et al., 1967; Reese et al., 1970; van Boom and Wreesmann, 1984). Chromatography is necessary only in the last step of the sequence, which makes the procedure particularly useful for the preparation of large amounts of material. In the first step, reaction of uridine (S.3) with trimethyl orthoacetate gives the 2′,3′-methoxyethylidene derivative S.4, which is then acylated at the 5′-OH group to yield S.5. This derivative is cleaved by partial acidic hydrolysis to give a mixture of 2′,5′-di-O- and 3′,5′-di-O-acetates, of which the latter (S.6) can be fractionally crystallized in good yield. Acid-catalyzed ketalization with 5,6-dihydro-4-methoxy-2Hpyran followed by ammonolysis subsequently gives 2′-O-MTHP-uridine (S.1a). Additional Materials (also see Basic Protocol) Uridine (Sigma or Fluka), dried before use for 2 hr at 50°C over phosphorus pentoxide in vacuo Toluene-p-sulfonic acid monohydrate (analytical grade)
Protection of Nucleosides for Oligonucleotide Synthesis
2.4.5 Current Protocols in Nucleic Acid Chemistry
O
O 4
3
5 6 5'
HO
O
4'
O NH
NH
NH
2
N1
O
steps 1-2
N
HO
O
steps 3-9
1'
N
AcO
O
O
O
2'
3'
HO
O
OH
O
H3C
3
O H3C
OCH3
5
4
O
O
NH
NH steps 10-19
N
AcO
O
steps 20-31
O AcO
O OCH3
N
HO
HO
OH
O
O O
OCH3
O
6 1a
Figure 2.4.3 Scheme showing the preparation of 2′-O-MTHP-uridine (S.1a) from uridine (see Support Protocol 1).
Dioxane (analytical grade), dried by keeping over activated basic aluminum oxide, then distilled before use from sodium/benzophenone after refluxing until the blue color indicates complete dryness Trimethyl orthoacetate (purum, 97%), dried by refluxing over calcium hydride (5 g/L) and distilled under inert atmosphere Pyridine (analytical grade), dried by refluxing over calcium hydride (5 g/L) and then distilled under inert atmosphere Acetic anhydride (analytical grade) Methylene chloride (analytical grade) Saturated (~1 M) aqueous sodium hydrogen carbonate Magnesium sulfate Formic acid (analytical grade) 5,6-Dihydro-4-methoxy-2H-pyran (analytical grade; Sigma or Fluka pract., ~90%; b.p.20 59° to 61°C) Half-saturated methanolic ammonia solution (see recipe) 500-mL separatory funnel Prepare 2′,3′-methoxyethylidene derivative (S.4) 1. Prepare a mixture of 24.2 g dry uridine (S.3; 100 mmol) 100 mg toluene-p-sulfonic acid monohydrate 150 mL dry dioxane 17 mL dry trimethyl orthoacetate and stir for 6 hr at room temperature. 2. Check the reaction by TLC (see Basic Protocol, steps 4 to 6). A Base-Labile Protecting Group
TLC should show complete conversion of the starting material (Rf = 0.04) to the less polar cyclic orthoester S.4 (Rf = 0.38).
2.4.6 Current Protocols in Nucleic Acid Chemistry
Prepare 5′-acetylated derivative (S.5) 3. Combine 150 mL dry pyridine and 50 mL acetic anhydride. Add this acylating solution dropwise over 15 min at room temperature to the stirred reaction mixture (step 1), and leave overnight. 4. Check the reaction by TLC. TLC should show that the acetylation has gone to completion to yield a product (S.5) with higher mobility (Rf = 0.63).
5. Add 50 mL methanol dropwise to the reaction mixture at 0°C to destroy excess acetic anhydride. 6. Concentrate the mixture to a colorless oil under reduced pressure using a rotary evaporator. 7. Dissolve in 250 mL methylene chloride and wash with 100 mL of 1 M aqueous sodium hydrogen carbonate. 8. Extract the aqueous layer five times with 100 mL methylene chloride for each extraction. 9. Dry the combined organic layers over 25 g magnesium sulfate and concentrate to a thick oil. Prepare 3′,5′-di-O-acetyluridine (S.6) 10. Coevaporate the resulting oil twice from 100 mL ethanol to remove traces of pyridine. 11. Dissolve S.5 in 150 mL of 9:1 (v/v) formic acid/water and incubate 15 min at room temperature. 12. Check the reaction by TLC. TLC should show that the cleavage of the methoxyethylidene function is complete, yielding 2′,5′-di-O- and 3′,5′-di-O-acetyluridines (Rf ≈ 0.4).
13. Evaporate the aqueous formic acid under reduced pressure with a rotary evaporator, and coevaporate the residue twice with 100 mL toluene and twice with 100 mL ethanol. 14. Dissolve in 250 mL chloroform and transfer to a 500-mL separatory funnel containing 150 mL saturated aqueous sodium hydrogen carbonate solution. Shake carefully and separate out the chloroform layer. 15. Extract the aqueous layer twelve times with 50-mL portions of chloroform. 16. Dry the combined chloroform extracts over ~80 g anhydrous sodium sulfate, filter (see Basic Protocol, step 10), and evaporate to a glass. 17. Dissolve the crude product in 500 to 1000 mL boiling ethanol and store the solution for 2 days at room temperature. 18. Filter off the crystals and dry at high vacuum. 19. Determine the isomeric purity by 1H-NMR spectroscopy. Recrystallize the product if the 2′,5′-isomer is present. 3′,5′-Di-O-acetyluridine (S.6): yield 23.9 g (73% from S.3; m.p. = 152°-155°C); Rf (silica, chloroform/methanol 9:1): 0.42; 1H-NMR (250 MHz, DMSO-d6 /D2O, 1:1, containing three drops of acetic acid per mL): 7.57 (d, J = 7.5, 1H; uridyl-H6), 5.89 (d, J = 7.5, 1H; uridyl-H5), 5.88 (d, J = 5.5, 1H; -CH-(1′)); the 2′,5′-isomer shows a slightly different
Protection of Nucleosides for Oligonucleotide Synthesis
2.4.7 Current Protocols in Nucleic Acid Chemistry
1
H-NMR spectrum (same conditions): 7.57 (d, J = 7.5, 1H; uridyl-H6), 5.89 (d, J = 7.5, 1H; uridyl-H5), 5.86 (d, J = 6.0, 1H; -CH-(1′)).
Prepare 2′-O-MTHP-uridine (S.1a) 20. Combine 138 mg toluene-p-sulfonic acid monohydrate and 250 mL dry dioxane and stir until clear. 21. Add 32.8 g of 3′,5′-di-O-acetyluridine (S.6; 100 mmol) and 57 g of 5,6-dihydro4-methoxy-2H-pyran (57 g, 5.0 eq) to the mixture and stir for 20 hr at room temperature. 22. Check the reaction by TLC. TLC should indicate complete reaction of the starting material.
23. Cool the clear solution in an ice water bath. The solution should be below 0°C to absorb exothermicity during neutralization.
24. Neutralize the reaction mixture by adding 800 µl of half-saturated methanolic ammonia solution. 25. Concentrate under reduced pressure and redissolve in 500 mL methanolic ammonia. Let stand overnight and check the reaction by TLC. TLC should show complete deacetylation.
26. Evaporate off methanolic ammonia and apply the residue to a column of silica gel (300 g; 12 × 7 cm) packed in methylene chloride. Short-column chromatography is performed according to Hunt and Rigby (1967) and is similar to the flash chromatography described by Still et al. (1978). Do not use air pressure >1 atm.
27. Elute the column with the following methylene chloride/methanol solutions: 500 mL of 98:2 (v/v); 500 mL of 96:4 (v/v); 1000 mL of 9:1 (v/v); and 1000 mL of 8:2 (v/v). Combine the product-containing fractions and evaporate to a colorless glass. 28. Dissolve the residue in 25 mL chloroform, precipitate by dropwise addition to 2500 mL rapidly stirring pentane, and decant off most of the supernatant (>2000 mL). 29. Collect solids by centrifuging 10 min at 3000 rpm, 15°C, and decant the pentane. 30. Wash twice by resuspending in 250 mL fresh pentane and repeating the centrifugation. Dry the resulting white powder (S.1a) in vacuo. 31. Characterize the final product by TLC and 1H-NMR. 2′-O-MTHP-uridine (S.1a): yield 26.1 g (73% from S.6); Rf (silica, chloroform/methanol 9:1): 0.24; 1H-NMR (250 MHz, DMSO-d6): 1.50-1.90 (m×m, 4H; -CH2-(3,5) of MTHP), 2.95 (s, 3H; H3CO- of MTHP), 3.35-3-50 (m, 2H, -CH2-(5′)), 3.5-3.8 (m×m, 4H; -CH2-(2,6) of MTHP), 3.90 (m, 1H; -CH-(4′)), 3.96 (m, 1H, -CH-(3′)), 4.25-4.36 (m, 1H; -CH-(2′)), 5.10-5.25 (d×tbr, 2H, exchangeable with D2O; 3′/5′-OH), 5.73 (d, J = 8.1, 1H; uridyl-H5), 6.00 (d, J = 7.8, 1H; -CH-(1′)), 7.93 (d, 1H; uridyl-H6), 11.4 (sbr, 1H, exchangeable; uridyl-N3-H).
A Base-Labile Protecting Group
2.4.8 Current Protocols in Nucleic Acid Chemistry
PREPARATION OF 2′-O-(4-METHOXYTETRAHYDROPYRAN-4-YL)4-N-BENZOYLCYTIDINE (S.1b) FROM CYTIDINE
SUPPORT PROTOCOL 2
In the first step of this procedure, cytidine (S.7; Fig. 2.4.4) is simultaneously protected on its 3′- and 5′-hydroxy groups by the bifunctional protecting reagent 1,3-dichloro1,1,3,3-disiloxane (Markiewicz and Wiewerowski, 1985). The derivative S.8 is formed exclusively, due to the higher reactivity of the sterically more accessible 5′-hydroxy group and the subsequently favorable cyclization to the 3′-hydroxy group. Selective benzoylation on N4 of the base is then achieved by treatment with the active ester 1-hydroxybenzotriazolyl benzoate to give S.9. The latter compound is ketalized at the 2′-hydroxy group upon reaction with 5,6-dihydro-4-methoxy-2H-pyran. Then a solution of n-tetrabutylammonium fluoride in acetonitrile removes the disiloxane protecting group to give 2′-OMTHP-4-N-benzoylcytidine (S.1b) in good yield (cf. Reese et al., 1970; van Boom and Wreesmann, 1984). Chromatography is required only for the last step of the sequence. Additional Materials (also see Basic Protocol and Support Protocol 1) Cytidine (S.7; Sigma or Fluka), dried before use for 2 hr at 50°C over phosphorus pentoxide in vacuo N,N-Dimethylformamide, dried by stirring overnight at room temperature with calcium hydride (5 g/L) and subsequent distillation under reduced pressure (b.p. 70° to 80°C, 20 to 30 mmHg) Dry pyridine (see Support Protocol 1 for drying procedure) 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane (see Support Protocol 5) 2 M triethylammonium bicarbonate buffer (see recipe) Acetone (analytical grade) 1-Hydroxybenzotriazole (Fluka), dried before use for 72 hr at 50°C over phosphorus pentoxide in vacuo Triethylamine, dried by refluxing 2 hr over calcium hydride (5 g/L) followed by distillation Benzoyl chloride (Fluka, puriss.) Acetonitrile (analytical grade) 1 M n-tetrabutylammonium fluoride (Aldrich/Fluka) in acetonitrile CAUTION: 1-Hydroxybenzotriazole may explode at higher temperatures.
NH2 4
N N1
5'
O
4'
N 2
6
HO
NH2
3
5
steps 1-7
O
Si
1' 2'
3'
HO
N
O
steps 8-15
O
O
O Si O
OH
OH
7 O
O
8
HN
HN N
Si
N
O
O
N O
steps 16-30
N
HO
O
O
O Si
O
OH
HO
O
OCH3
O 9
1b
Figure 2.4.4 Scheme showing the preparation of 2′-O-MTHP-4-N-benzoylcytidine (S.1b) from cytidine (see Support Protocol 2).
Protection of Nucleosides for Oligonucleotide Synthesis
2.4.9 Current Protocols in Nucleic Acid Chemistry
Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)cytidine (S.8) 1. Prepare and stir a suspension of the following: 12.12 g dry cytidine (S.7; 50 mmol) 200 mL dry N,N-dimethylformamide 40 mL dry pyridine (40 mL). 2. Add 18 mL of 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (62.5 mmol) to 50 mL dry N,N-dimethylformamide and add dropwise to the stirred cytidine solution over a period of 15 min. Stir the reaction mixture for 1 hr at room temperature. 3. Check the reaction by TLC (see Basic Protocol, steps 4 to 6). TLC should indicate complete reaction of the starting material (Rf < 0.05) to S.8 (Rf = 0.28).
4. Neutralize with 75 mL of 2 M triethylammonium bicarbonate buffer and concentrate under reduced pressure to a small volume (100 mL) using a rotary evaporator. 5. Dissolve in 1000 mL methylene chloride and wash with 500 mL of 1 M aqueous sodium hydrogen carbonate followed by 500 mL water. 6. Dry the organic layer over 50 g magnesium sulfate and concentrate to a colorless oil. 7. Crystallize from 500 mL acetone to produce pure 3′,5′-O-(tetraisopropyldisiloxane1,3-diyl)cytidine. 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)cytidine (S.8): yield 19.5 g (85%), m.p. 226-228 (decomp.), Rf = 0.28. 1H-NMR (CDCl3/CD3OD): 8.00 (d, J = 7.5, 1H; cytidyl-H6), 7.58 (d, J = 7.5, 1H; cytidyl-H5), 5.64 (d, J = 5.5, 1H; -CH-(1′)); 13C-NMR (CDCl3/CD3OD): 166.2 (C4), 156.3 (C2), 140.6 (C6), 94.7 (C5), 91.5 (C1′), 81.6 (C4′), 75.1 (C3′), 68.2 (C2′), 60.0 (C5′), 17.4, 17.0 13.5, 13.0, 12.5 (TIPS).
Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-4-N-benzoyl-cytidine (S.9) 8. Prepare and stir a solution of the following: 10.0 g dry 1-hydroxybenzotriazole (75 mmol) 300 mL dry dioxane 21 mL dry triethylamine (150 mmol). 9. Combine 8.70 mL benzoyl chloride (75 mmol) and 50 mL dry dioxane, and add dropwise to the above mixture (step 8) over 15 min. Stir for 1 hr at room temperature. 10. Filter off the precipitated triethylammonium chloride salts under inert atmosphere using a glass filter crucible, and add the filtrate to a solution containing 24.25 g of 2′-O-(tetraisopropyldisiloxane-1,3-diyl)cytidine (S.8; 50 mmol) in 150 mL dry N,Ndimethylformamide. 11. Evaporate off a volume of ∼100 mL under reduced pressure and stir the residue at room temperature for 3 days. Check the reaction by TLC. TLC should indicate complete reaction of the starting material.
12. Add 5 mL water and concentrate the reaction mixture under reduced pressure to a small volume (100 mL). 13. Dissolve in 1000 mL methylene chloride and wash as in step 5. A Base-Labile Protecting Group
14. Dry the organic layer over 50 g magnesium sulfate and concentrate to a light brown oil.
2.4.10 Current Protocols in Nucleic Acid Chemistry
15. Crystallize from a minimal amount of refluxing acetonitrile to yield analytically pure 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-4-N-benzoylcytidine (S.9). 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)-4-N-benzoylcytidine (S.9): yield 22.6 g (77% in first crop). Rf = 0.40 (silica, chloroform/methanol 9:1). Elemental analysis: calc.; C 57.04, H 7.30, N 7.26%; found: C 56.36, H 7.08, N 7.26%.
Prepare 2′-O-MTHP-4-N-benzoylcytidine (S.1b) 16. Dissolve 4.75 g toluene-p-sulfonic acid monohydrate (25 mmol) in 125 mL dry dioxane and evaporate under reduced pressure to a colorless oil to remove traces of water. 17. Under an inert atmosphere, add 29.45 g of 3′,5′-O-(tetraisopropyldisiloxane-1,3diyl)-4-N-benzoylcytidine (S.9; 50 mmol) followed by 250 mL dry dioxane. 18. To the resulting clear solution, add 29 mL of 5,6-dihydro-4-methoxy-2H-pyran (28.5 g; 250 mmol). Stir 20 hr at room temperature and check the reaction by TLC. TLC should show complete reaction of the starting material.
19. Neutralize the reaction with 3.5 mL half-saturated methanolic ammonia solution (check with moist pH indicator paper) and concentrate immediately under reduced pressure to a small volume (100 mL). 20. Dissolve in 1000 mL methylene chloride and wash as in step 5. 21. Dry the organic layer over 50 g magnesium sulfate and concentrate to a glass. 22. Add 250 mL of 1 M n-tetrabutylammonium fluoride in acetonitrile, stir for 1 hr at room temperature, and check the reaction by TLC. TLC should show complete removal of the silyl protecting group. n-Tetrabutylammonium fluoride in acetonitrile must be prepared by the experimenter. Commercially available solutions in tetrahydrofuran can also be used.
23. Concentrate under reduced pressure to a small volume (100 mL). Dissolve in methylene chloride, wash, and dry as in steps 20 and 21. 24. Dissolve with a minimal amount of dichloromethane and apply to a column of silica gel (300 g; 12 × 7 cm) packed in methylene chloride. Short-column chromatography is performed according to Hunt and Rigby (1967) and is similar to the flash chromatography described by Still et al. (1978). Do not use air pressure >1 atm.
25. Elute the column with the following methylene chloride/methanol solutions: 500 mL of 98:2 (v/v); 500 mL of 96:4 (v/v); and 1000 mL of 9:1 (v/v). 26. Collect the main product-containing fractions and evaporate to a glass. 27. Dissolve the residue in 25 mL chloroform, precipitate by dropwise addition to 2500 mL rapidly stirring pentane, and decant off most of the supernatant (>2000 mL). 28. Collect the solids by centrifuging 10 min at 3000 rpm g, 15°C, and decant the pentane. 29. Wash twice by resuspending in 250 mL fresh pentane and repeating the centrifugation. Dry the resulting white powder (S.1b) in vacuo. 30. Characterize the final product by TLC and 1H-NMR. 2′-O-MTHP-4-N-benzoylcytidine (S.1b): yield 16.1 g (70% from S.9); Rf (silica, chloroform/methanol 9:1): 0.43; 1H-NMR (250 MHz, DMSO-d6): 1.50-1.90 (m×m, 4H; -CH2-
Protection of Nucleosides for Oligonucleotide Synthesis
2.4.11 Current Protocols in Nucleic Acid Chemistry
(3,5) of MTHP), 2.93 (s, 3H; H3CO- of MTHP), 3.40-3.60 (m, 2H, -CH2-(5′)), 3.5-3.8 (m×m, 4H; -CH2-(2,6) of MTHP), 3.96 (m, 1H; -CH-(4′)), 4.02 (m, 1H, -CH-(3′)), 4.39 (m(d×d), 1H; -CH-(2′)), 5.19 (d, J = 6.5, 1H, exchangeable with D2O; 3′-OH), 5.25 (t, J = 2.7, 1H, exchangeable with D2O; 5′-OH), 6.14 (d, J = 6.8, 1H; -CH-(1′)), 7.36 (d, J = 7.7, 1H; cytidyl-H5), 7.4-8.1 (m×m, 5H; benzoyl-aromatic H), 8.43 (d, 1H; cytidyl-H6), 11.3 (sbr, 1H, exchangeable with D2O; cytidyl-N4-H). SUPPORT PROTOCOL 3
PREPARATION OF 2′-O-(4-METHOXYTETRAHYDROPYRAN-4-YL)6-N-BENZOYLADENOSINE (S.1c) FROM ADENOSINE In this protocol, adenosine (S.10, Fig. 2.4.5) is base protected prior to 3′,5′-disilylation by benzoylation of its crystalline 2′,3′,5′-tri-O-acetyl-derivative (S.11), yielding 6-N-benzoyladenosine (S.12) after deacetylation in situ. The chosen route (cf. Schaller et al., 1963; Reese et al., 1970; Büchi and Khorana, 1972; Jones, 1984; van Boom and Wreesmann, 1984; Markiewicz and Wiewerowski, 1985) is then comparable to the cytidine case (see Support Protocol 2): 3′,5′-disilylation to yield S.13, followed by acid-catalyzed ketalization of the 2′-OH by 5,6-dihydro-4-methoxy-2H-pyran, and cleavage of the silyl protecting group by fluoride ion to yield 2′-O-MTHP-6-N-benzoyladenosine (S.1c) in good chromatographically isolated yield. Additional Materials (also see Basic Protocol and Support Protocols 1 and 2) Adenosine (S.10; Sigma or Fluka), dried before use for 2 hr at 50°C over phosphorus pentoxide in vacuo Dry pyridine (see Support Protocol 1 for drying procedure) Acetic anhydride, fractionally distilled with 10% toluene to remove acetic acid 25% (w/v) sodium methoxide in methanol (pract., Aldrich, Fluka) Acetic acid (analytical grade) Diethyl ether (analytical grade) Imidazole (analytical grade) 0.1 M hydrochloric acid
O NH2
7
6
N 5 HO
N 4 N 9
5'
O
4' 3'
HO
1
N
N
8
steps 1-5
2
3
1'
HN
NH2
N
AcO
O
N
N steps 6-18
N
N
HO
O
N N
steps 19-27
2'
OH
AcO
10
HO
OAc
O
O HN
HN N O Si
N O
N
N N
OH
12
11
step 28
N
HO
O
N N
O Si O
OH 13
HO
O
OCH3
O 1c
A Base-Labile Protecting Group
Figure 2.4.5 Scheme showing the preparation of 2′-O-MTHP-6-N-benzoyladenosine (S.1c) from adenosine (see Support Protocol 3). The final step from S.13 to S.1c is performed as in steps 16 to 30 of Support Protocol 2 (see Fig. 2.4.4).
2.4.12 Current Protocols in Nucleic Acid Chemistry
Prepare 2′,3′,5′-tri-O-acetyladenosine (S.11) 1. Prepare and stir a suspension of 10.0 g adenosine (S.10; 37.4 mmol) in 50 mL dry pyridine. 2. Add 23 mL acetic anhydride (0.24 mol) and stir overnight at room temperature. 3. Cool in an ice bath and quench with 40 mL methanol. 4. Remove from the ice bath and stir 1 hr at room temperature. 5. Concentrate to dryness, and recrystallize the white solid residue twice from 100 mL hot ethanol to yield 12.0 g (82%) tri-O-acetyladenosine (S.11). Check the product by TLC (see Basic Protocol, steps 4 to 6). The product is sufficiently pure (Rf = 0.31) for use in the subsequent steps.
Prepare 6-N-benzoyladenosine (S.12) 6. Dissolve crystalline S.11 in 50 mL pyridine, cool in an ice bath, and add 5.3 mL benzoyl chloride (45.8 mmol). 7. Let the reaction mixture warm to room temperature and stir for 2 hr. 8. Quench with 6 mL water and stir for another 30 min. 9. Concentrate to a syrup using a rotary evaporator. 10. Partition the residue between 100 mL chloroform and 100 mL saturated aqueous sodium hydrogen carbonate solution. Reextract the aqueous phase with two 50-mL portions of chloroform. 11. Dry the combined organic extracts over ~20 g anhydrous sodium sulfate and evaporate to a glass (Rf = 0.71). 12. Redissolve in 50 mL of 1:1 (v/v) methanol/pyridine, cool on ice, and then add 15 mL (∼3 eq) of 25% sodium methoxide in methanol. 13. Let the reaction mixture warm to room temperature and monitor by TLC. Deacetylation to the more polar product (Rf = 0.24) occurs in <15 min.
14. Neutralize with 4.0 mL acetic acid and evaporate to a small volume (~13 ) under reduced pressure. 15. Pour the concentrated product mixture into 100 mL saturated aqueous sodium hydrogen carbonate and extract with 200 mL chloroform. 16. Collect the precipitate that settles between the chloroform and aqueous layers by centrifuging 10 min at 3000 rpm, 15°C. 17. Resuspend in ∼100 mL water and centrifuge again. Repeat with ∼100 mL each ethanol and then diethyl ether. 18. Dry the white solid first in air and then under high vacuum to yield 7.15 g (63%) S.12 as a white solid. Check the product by TLC. The product is sufficiently pure (Rf = 0.24) for use in the subsequent steps.
Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-6-N-benzoyladenosine (S.13) 19. Dissolve 2.40 g of 6-N-benzoyladenosine (S.12; 6.46 mmol) in 32 mL dry pyridine. 20. Add 2.16 g imidazole followed by 2.50 mL of 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (7.9 mmol; 1.2 eq).
Protection of Nucleosides for Oligonucleotide Synthesis
2.4.13 Current Protocols in Nucleic Acid Chemistry
21. Stir the reaction overnight. Check the reaction by TLC. TLC should show complete reaction of the starting material.
22. Add 10 mL methanol, stir for another 15 min, and concentrate under reduced pressure. 23. Take up the residue in 50 mL chloroform and wash sequentially with 25 mL saturated sodium hydrogen carbonate solution, 50 mL of 0.1 M hydrochloric acid, and 30 mL water. 24. Evaporate the organic layer. 25. Remove traces of pyridine by coevaporating with ∼50 mL (once each) toluene, ethanol, and chloroform. 26. Purify the crude product by short-column chromatography (see Basic Protocol, step 12). Elute with chloroform until the product appears, then with chloroform containing 2% (v/v) ethanol (∼700 mL total in 20-mL fractions). Do not use >1 atm pressure for elution (Hunt and Rigby, 1967; Still et al., 1978). 27. Combine the product-containing fractions, evaporate the solvent, and dry under high vacuum to yield 3.21 g (81%) chromatographically pure S.13 as a colorless foam. Check by TLC (Rf = 0.58). Prepare 2′-O-MTHP-6-N-benzoyladenosine (S.1c) 28. Introduce the MTHP protecting group and perform desilylation (see Support Protocol 2, steps 16 to 30), replacing S.9 (29.45 g; 50 mmol) with the corresponding adenosine derivative S.13 (30.84 g; 50 mmol) to yield S.1c as a dry white powder. 2′-O-MTHP-6-N-benzoyladenosine (S.1c): yield 18.9 g (78% from S.13); Rf (silica, chloroform/methanol 9:1): 0.30; 1H-NMR (250 MHz, DMSO-d6): 1.40-1.90 (m×m, 4H; -CH2(3,5) of MTHP), 2.55 (s, 3H; H3CO- of MTHP), 3.20-3.80 (m×m, 2H, -CH2-(5′)), 3.3-3.8 (m×m, 4H; -CH2-(2,6) of MTHP), 4.05 (m, 1H; -CH-(4′)), 4.18 (m, 1H, -CH-(3′)), 5.00 (m(d×d), 1H; -CH-(2′)), 5.27 (t, J = 5.5, 1H, exchangeable with D2O; 5′-OH), 5.33 (d, J = 4.5, 1H, exchangeable with D2O; 3′-OH), 6.19 (d, J = 7.4, 1H; -CH-(1′)), 7.5-8.1 (m×m, 5H; benzoyl-aromatic H), 8.77 (2s, 2H; adenyl-H2/8), 11.3 (sbr, 1H, exchangeable with D2O; adenyl-N6-H). SUPPORT PROTOCOL 4
PREPARATION OF 2′-O-(4-METHOXYTETRAHYDROPYRAN-4-YL)-2-NISOBUTYRYLGUANOSINE (S.1d) FROM GUANOSINE Guanosine (S.14; Fig. 2.4.6) is base protected on N2 (S.16) by reaction with isobutyryl chloride after transiently blocking the 2′-, 3′-, and 5′-hydroxy groups by persilylation (S.15). The chosen route is then comparable to the cytidine and adenosine cases: 3′,5′-disilylation to S.17, followed by acid-catalyzed ketalization of the 2′-OH by 5,6-dihydro-4-methoxy-2H-pyran and cleavage of the silyl protecting group by fluoride ion to yield 2′-O-MTHP-2-N-isobutyrylguanosine (S.1d) in satisfactory isolated yield. Generally, the higher basicity and polarity of guanosine derivatives renders them more difficult to handle, and the yields are frequently compromised by loss of material in aqueous extraction media or on polar silica gel phases. Nevertheless, the proposed sequence is a viable route that is based on well-described literature procedures (Reese et al., 1970; Ti et al., 1982; Jones, 1984; van Boom and Wreesmann, 1984; Markiewicz and Wiewerowski, 1985; McLaughlin et al., 1985).
A Base-Labile Protecting Group
Additional Materials (also see Basic Protocol and Support Protocols 1 and 2) Guanosine (S.14; Sigma or Fluka), dried before use for 2 hr at 50°C over phosphorus pentoxide in vacuo Dry pyridine (see Support Protocol 1 for drying procedure)
2.4.14 Current Protocols in Nucleic Acid Chemistry
O
O 7 N 5
6 1
N 4 N 9
5'
HO
O
4' 3'
HO
1'
N
NH
8 3
2
NH2
steps 1-2
N
(H3C)3SiO
O
O N
NH N
NH2
steps 3-9
NH
N
HO
N
O
O
N H
steps 10-16
2'
(H3C)3SiO
OH
OSi(CH3)3
HO
15
14
O
O N O Si
N O
NH N
OH
16
N H
N
O steps 17-33
N
HO
O
NH N
O
N H
O Si O
OH
HO
O
OCH3
17 O 1d
Figure 2.4.6 Scheme showing the preparation of 2′-O-MTHP-2-N-isobutyrylguanosine (S.1d) from guanosine (see Support Protocol 4).
Trimethylsilyl chloride (analytical grade) Isobutyryl chloride (analytical grade) Concentrated aqueous ammonia (~25%) Methylene chloride (analytical grade) Phosphorus pentoxide Prepare 2-N-isobutyrylguanosine (S.16) 1. Suspend 14.15 g dry guanosine (S.14; 50 mmol) in 200 mL dry pyridine. 2. Add 47.5 mL trimethylsilyl chloride (375 mmol) and stir for 3 hr at ambient temperature to produce S.15. 3. Cool to 0°C and add 15.6 mL isobutyryl chloride (150 mmol), dropwise, over a period of 30 min. 4. Allow to warm to room temperature and stir overnight. 5. Cool again to 0°C and quench by adding 50 mL water. Stir for another 10 min at room temperature. 6. Add 100 mL concentrated aqueous ammonia to the clear solution and stir for an additional 30 min. 7. Pour the mixture into 800 mL water and extract with 150 mL methylene chloride. 8. Evaporate the aqueous phase to dryness and crystallize three times from 50 to 100 mL boiling water. 9. Dry the resulting solids for 2 days under high vacuum over phosphorus pentoxide to obtain 7.25 g (41%) 2-N-isobutyrylguanosine (S.16) as a grayish-white, chromatographically homogenous powder. Check by TLC (see Basic Protocol, steps 4 to 6; Rf = 0.074). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2-N-isobutyrylguanosine (S.17) 10. Dissolve 7.05 g of 2-N-isobutyrylguanosine (S.16; 20.0 mmol) in 125 mL dry pyridine. 11. Add 6.6 mL of 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (24 mmol) and stir overnight. Check the reaction by TLC. TLC shows complete reaction of the starting material.
Protection of Nucleosides for Oligonucleotide Synthesis
2.4.15 Current Protocols in Nucleic Acid Chemistry
12. Evaporate the suspension and partition between 250 mL chloroform and 250 mL saturated aqueous sodium hydrogen carbonate solution. 13. Reextract the aqueous layer twice with 125 mL chloroform, dry the organic layer over ~30 g sodium sulfate, and evaporate to a glass using a rotary evaporator. 14. Remove traces of pyridine by azeotropic rotoevaporation from 100 mL toluene (twice), 100 mL ethanol (once), and 100 mL chloroform (once). 15. Purify the crude product by short-column chromatography using 200 g silica gel (see Basic Protocol, step 12). Elute with chloroform until the product appears, then with chloroform containing 2% (v/v) ethanol (∼1500 mL total in 30-mL fractions). Do not use >1 atm pressure for elution (Hunt and Rigby, 1967; Still et al., 1978). 16. Combine the product-containing fractions, evaporate the solvent, and dry under high vacuum to give 7.25 g (61%) chromatographically pure S.17 as a colorless foam. Check by TLC (Rf = 0.55). Prepare 2′-O-MTHP-2-N-isobutyrylguanosine (S.1d) 17. Dissolve 0.95 g of toluene-p-sulfonic acid monohydrate (5 mmol) in 25 mL dry dioxane and evaporate under reduced pressure to a colorless oil to remove traces of water. 18. Under an inert atmosphere, add 5.95 g of 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)2-N-isobutyrylguanosine (S.17; 10 mmol) followed by 50 mL dry dioxane. 19. To the resulting clear solution, add 5.8 mL of 5,6-dihydro-4-methoxy-2H-pyran (5.7 g, 50 mmol). Stir 20 hr at room temperature and check the reaction by TLC. TLC should show complete reaction of the starting material.
20. Neutralize the reaction with 0.8 mL half-saturated methanolic ammonia solution and concentrate immediately under reduced pressure to a small volume (20 mL). 21. Dissolve the residue in 200 mL chloroform and wash with 100 mL of 1 M aqueous sodium hydrogen carbonate solution. 22. Dry the organic layer over 50 g magnesium sulfate and concentrate to a glass. 23. Add 50 mL of 1 M n-tetrabutylammonium fluoride in acetonitrile, stir for 1 hr at room temperature, and check the reaction by TLC. TLC should show complete removal of the silyl group.
24. Concentrate under reduced pressure to a small volume (20 mL). Dissolve in chloroform and wash as in step 21. 25. Reextract the aqueous phase twice with 100 mL chloroform. 26. Dry the organic layer over 10 g anhydrous sodium sulfate and concentrate to a glass. 27. Dissolve the residue with minimal amount of chloroform and apply to a column of silica gel (100 g; 8 × 5 cm) packed in chloroform.
A Base-Labile Protecting Group
28. Elute the column with chloroform until the product appears, and then collect 20-mL fractions with the following chloroform/ethanol solutions: 300 mL of 98:2 (v/v); 300 mL of 96:4 (v/v), 600 mL of 9:1 (v/v). 29. Collect the main product-containing fractions and evaporate to a glass.
2.4.16 Current Protocols in Nucleic Acid Chemistry
30. Dissolve the residue in 25 mL chloroform, precipitate by dropwise addition to 500 mL rapidly stirring pentane, and decant off most of the supernatant (>400 mL). 31. Collect the solids by centrifuging 10 min at 3000 rpm, 15°C, and decant the pentane. 32. Wash the solids twice by resuspending in 100 mL fresh pentane and repeating the centrifugation. Dry the resulting white powder (S.1d) in vacuo. 33. Characterize the final product by TLC and 1H-NMR. 2′-O-MTHP-2-N-isobutyrylguanosine (S.1d): yield 2.42 g (52% from S.17); Rf (silica, chloroform/methanol 9:1): 0.29; 1H-NMR (250 MHz, DMSO-d6): 1.12 (2d, J = 6.8, 6H; (H3C)2CH-)), 1.40-1.90 (m×m, 4H; -CH2-(3,5) of MTHP), 2.55 (s, 3H; H3CO- of MTHP), 2.75 (septet, J = 6.8, 1H; (H3C)2CH-)), 3.19-3.33 (m×m, 2H, -CH2-(5′)), 3.4-3.7 (m×m, 4H; -CH2-(2,6) of MTHP), 3.98 (m(t), 1H; -CH-(4′)), 4.10 (m(t), 1H, -CH-(3′)), 4.74 (m(d×d), 1H; -CH-(2′)), 5.77 (m(t), 1H, exchangeable with D2O; 5′-OH), 5.19 (m(d), 1H, exchangeable with D2O; 3′-OH), 6.98 (d, J = 7.9, 1H; -CH-(1′)), 7.5-8.1 (m×m, 5H; benzoyl-aromatic H), 8.31 (s, 1H; guanyl-H8), 11.7/12.1 (2sbr, 2H, exchangeable with D2O; guanyl-N1-H and N2-H).
PREPARATION OF 1,3-DICHLORO-1,1,3,3TETRAISOPROPYLDISILOXANE
SUPPORT PROTOCOL 5
Although this reagent is commercially available (e.g., Fluka), this protocol provides a convenient procedure for its preparation. Materials Magnesium curls Dry diethyl ether, distilled from phosphorus pentoxide (30 g/L) Isopropyl bromide, distilled from calcium hydride (5 g/L) Trichlorosilane, freshly distilled 0.1 N hydrochloric acid Magnesium sulfate Methylene chloride (analytical grade), dried by passage through activated basic alumina Chlorine gas, dried over concentrated sulfuric acid NaCl plates for infrared (IR) spectroscopy Additional reagents and equipment for IR spectroscopy Prepare 1,1,3,3-tetraisopropyldisiloxane 1. Combine 64 g magnesium curls and 200 mL dry diethyl ether. 2. Add a solution of 270 mL isopropyl bromide in 400 mL dry diethyl ether dropwise to the solution. 3. Stir the reaction mixture mechanically and heat under reflux for 3.5 hr. 4. Add a solution of 100 mL trichlorosilane and 400 mL dry diethyl ether dropwise to the stirred solution (step 3) and heat under reflux overnight. 5. Quench by adding 800 mL of 0.1 N hydrochloric acid in a dropwise fashion. 6. Stir the mixture and heat under reflux for another 3.5 hr. 7. Separate out the organic layer and extract the aqueous layer three times with 300 mL diethyl ether.
Protection of Nucleosides for Oligonucleotide Synthesis
2.4.17 Current Protocols in Nucleic Acid Chemistry
8. Dry the combined organic layers over ~50 g magnesium sulfate and concentrate to a colorless oil under reduced pressure. 9. Distill the residue to produce pure 1,1,3,3-tetraisopropyldisiloxane (100 g; b.p. 80° to 90°C, 10 mmHg) as a colorless oil. Prepare 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane 10. Dissolve the above product (100 g of 1,1,3,3-tetraisopropyldisiloxane) in 500 mL methylene chloride and pass a stream of dry chlorine gas through the solution. Protect the apparatus from atmospheric moisture using a paraffin oil bubbler. Calcium chloride drying tubes are entirely inefficient and will lead to reaction failure.
11. When the temperature rises to ∼27° to 30°C, cool the reaction mixture to 17° to 20°C by immersing it in an ice water bath while continuing the stream of chlorine gas. 12. After 2 hr, and then after every hour, withdraw a small sample of the reaction mixture and analyze by IR spectroscopy using NaCl plates. 13. Stop the chlorination when the IR spectrum indicates the disappearance of the absorption band at 2100 cm−1 (Si-H). 14. Evaporate off the volatile compounds and distill the residue under diminished pressure (b.p. 85° to 90°C, 2 mmHg) to give 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (70 g) as a colorless oil. Store dry at 0°C for up to several months or even years. REAGENTS AND SOLUTIONS Use distilled, deionized water for all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Anisaldehyde reagent 1 mL 4-methoxybenzaldehyde 2 mL concentrated sulfuric acid 10 mL glacial acetic acid 87 mL methanol (analytical grade) Store up to 6 months at room temperature All analytical-grade reagents are preferred if available.
Methanolic ammonia solution, half-saturated (∼8 M) Pass dry ammonia gas (passed over solid potassium hydroxide pellets) through 500 mL analytical-grade methanol at −20°C until saturation. Dilute with 500 mL analytical-grade methanol. Store up to 4 weeks at –18°C. Triethylammonium bicarbonate buffer, 2 M Combine 825 mL analytical-grade triethylamine and 2175 mL water. Saturate with carbon dioxide gas at 0°C until the pH of the clear solution reaches 7.5. Store up to 4 weeks at 4°C. COMMENTARY Background Information
A Base-Labile Protecting Group
Within the field of solid-phase peptide synthesis, the introduction of a base-labile protecting group for the nucleophilic (amino-) center has been very successful, exceeding by far the status of alternative and becoming a standard
technique in many laboratories (Atherton and Sheppard, 1989, and references cited therein). The base-sensitive amino-protecting 9-fluorenylmethoxycarbonyl (FMOC) group, first introduced by Carpino and Han in 1970 (for a review see Carpino, 1987), is strictly orthogo-
2.4.18 Current Protocols in Nucleic Acid Chemistry
nal to the acid-labile protecting groups used for the side chains. Orthogonality is fulfilled when permanent side-chain protecting groups remain completely stable during peptide assembly while being repeatedly exposed to the conditions applied for removal of the temporary terminal protecting group. For solid-phase oligonucleotide assemblies, the use of 5′-OFMOC chemistry may provide an opportunity for such orthogonality, and also avoids the problem of depurination occasionally observed during repeated acidolytic steps required for 5′-O-detritylation. Compared to solid-phase peptide synthesis, functional protection is less demanding in oligonucleotide synthesis due to the smaller number of building blocks. In the deoxyribonucleotide series, very satisfactory protecting groups have resulted from the pioneering efforts in the chemical synthesis of genes by the group of Khorana (e.g., Schaller et al., 1963; Büchi and Khorana, 1972). For example, permanent protection of the exocyclic amino functions as N-acyl and N-aroyl derivatives, respectively, is compatible with nonnucleophilic conditions, but the protecting groups may be cleaved at the very end of the synthesis by hydrolysis in aqueous ammonium hydroxide at elevated temperature. On the other hand, an adequate treatment of the protecting group strategy in RNA synthesis requires the differential handling of the 2′-, 3′-, and 5′-hydroxy groups. If phosphoramidite chemistry is chosen for chain extension, the central problem is the selection of a suitable combination of the permanent 2′-hydroxylprotecting group together with a temporary 5′-hydroxyl-protecting group. The former must remain intact until the very end of the synthesis, including base deprotection, whereafter it must be removed very cleanly and under conditions that leave the phosphate-ribose backbone in complete constitutional and regiochemical integrity. This was convincingly shown both for the acetal (tetrahydropyranyl or THP) as well as the presently applied 4-methoxytetrahydropyranyl (MTHP) ketal-type of 2′-hydroxylprotecting groups some years ago by the research group of Reese (Norman et al., 1984). It was demonstrated by HPLC analysis that diuridine and diadenosine phosphates are stable in 0.01 N hydrochloric acid for time periods over ten times longer than that required for complete 2′-deprotection. Moreover, the authors (Christodoulou et al., 1986) and others (Reese and Skone, 1985) showed that if a conventional acid-labile group such as di-O-(p-an-
isyl)phenylmethyl (dimethoxytrityl or DMTr) or 9-phenylxanthen-9-yl (pixyl or Px) is used to protect the 5′ position, concomitant cleavage of the 2′-O-THP or 2′-O-MTHP takes place to an unacceptable extent. For orthogonal protection of the 5′-hydroxy group, the authors therefore chose the base-labile FMOC protecting group (Fig. 2.4.1 and Fig. 2.4.7). FMOC was first proposed for 5′-O-protection in the deoxyribonucleotide series for solidphase synthesis of an octathymidylic acid fragment (Gioeli and Chattopadhyaya, 1982), and was later used in the same laboratory for the regioselective construction of a 2′-O-pixylprotected dinucleotide (Pathak and Chattopadhyaya, 1985). Later, the results reported for oligothymidylic acids were extended to deoxyribonucleotide sequences containing 4-Nbenzoyl-2′-deoxycytidine and 6-N-benzoyl-2′deoxyadenosine, whereby the above procedure for the regioselective introduction of the FMOC group was again confirmed (Ma and Sonveaux, 1987; Balgobin and Chattopadhyaya, 1987). An approach for a solution-phase RNA synthesis combining an acid-labile acetal group (1ethoxyethyl) for 2′-protection with 5′-OFMOC was proposed by Fukuda et al. (1988). However, the drawback of using chiral protecting groups on chiral nucleoside building blocks has been commented on with crystallographic data (Lehmann et al., 1991). Further efforts to incorporate the FMOC strategy within the framework of solid-phase
B = U; CBz; ABz; Gi-Bu
O [Fmoc] temporary base-labile 5'-O-protection
O O RO
B
5'
O 3'
2'
O O P N(i-Pr)2
OCH3
O [Mthp]
permanent acid-labile 2'-O-protection
phosphate protection R = CH2CH2CN R = CH3 R = CH2CHCH2
Figure 2.4.7 Orthogonal protection scheme for solid-phase RNA synthesis applying a temporary base-labile (FMOC) 5′-O-protecting group and a permanent acid-labile (MTHP) 2′O-protecting group within the phosphoramidite strategy. Compatibility with current variants of phoshate internucleotide protection as well as anchorage to the solid support are discussed in the text.
Protection of Nucleosides for Oligonucleotide Synthesis
2.4.19 Current Protocols in Nucleic Acid Chemistry
A Base-Labile Protecting Group
oligonucleotide chemistry were aimed at avoiding unwanted side reactions during deprotection. Primarily, it was reported (Gao et al., 1985) that, under strongly basic deprotection conditions (5% 1,8-diazabicyclo-[5.4.0]undec7-ene [DBU] in acetonitrile), methyl group transfer to the N3 position of thymine (and presumably uracil) occurs via an intramolecular SN2-reaction from the phosphotriester linkage if the common methyl phosphoramidite chemistry is applied. It was not possible to use H-phosphonates, since the latter are decomposed immediately under the action of base (Lehmann et al., 1989). The authors therefore first applied cyanoethyl phosphoramidites, presently in use for DNA synthesis, conscious of the fact that probably some or all of the phosphate protection is lost during FMOC cleavage. Nevertheless, the results were remarkably encouraging, and it was possible to assemble oligomers of up to 20 residues containing all four ribonucleosides in good yield and in regiochemically homogenous form. The fact that phosphoramidite building blocks are of a significantly basic nature and are prone to hydrolysis to the corresponding H-phosphonates on normal silica gel surfaces demands deactivation of such surfaces by the addition of base to the eluent. If the kind of base (which should be nonnucleophilic and of a low pKa) is chosen inadequately or the 5′-OFMOC-nucleoside-3′-O-phosphoramidite is exposed to higher concentrations of base at elevated temperatures, some loss of the protecting group may occur during isolation, which may lead to a danger of double couplings. The authors therefore recommend (Lehmann et al., 1989) repeated coevaporation of the derived phosphoramidite fractions from toluene under high vacuum followed by immediate precipitation of the product. An evaluation of the less basic N-morpholino phosphoramidite derivatives (McBride and Caruthers, 1983) may be advantageous in the present context. From the more recent literature, two improvements to the FMOC strategy emerge as particularly noteworthy. First, it was possible to apply a safer protection of the phosphate moiety by use of the allyl group as described for a variety of solid-phase protocols by Hayakawa et al. (1990). Moreover it was found (Bergmann et al., 1995) that the final deprotection conditions normally used for removal of the base amino protecting groups (concentrated ammonia, several hours at 55°C) simultaneously take off the allyl groups on the internucleotide phosphate linkage. A second improve-
ment consists of the development of a different linker unit to the solid support, which is of the acetal type and hence is acid labile (2′,3′-Omethylidene-4-phenoxyacetyl; Palom et al., 1993). This allows cleavage of the FMOC group under nucleophilic conditions (10% piperidine in N,N-dimethylformamide) that are significantly less basic and are therefore compatible with an oligonucleotide assembly via methyl phosphoramidites. In addition, two recently introduced alternatives to the FMOC group (BSMOC and MSPOC; Carpino and Mansour, 1999), which are cleaved with lower concentrations of weak nucleophilic bases such as piperidine or morpholine, may be particularly well suited for this oligonucleotide assembly scheme. The linker arm to the support previously used by the authors (succinyl-sarcosyl; Brown et al., 1989) is stable under strongly basic conditions (up to 5% DBU in CH3CN), but is cleaved by exposure to nucleophiles. Finally, the authors would like to encourage the exploitation of new chemistries potentially compatible with the FMOC strategy. For instance, it might be possible to combine the photolabile o-nitrobenzyloxymethyl group (Schwartz et al., 1992; Pitsch, 1997) with the base-labile FMOC group to further increase the scope of this remarkably versatile tool in the chemical synthesis of biooligomers.
Critical Parameters and Troubleshooting The synthesis outlined in the Basic Protocol is fairly short and straightforward. Other than careful attention to basic organic synthesis techniques, little troubleshooting advice needs to be offered. Critical to achieving the expected yields is strict adherence to the given reaction and isolation conditions. The syntheses of the starting materials are considerably more involved, although the expected yields are quite good. Success is dependent upon careful operational planning inherent to multistep syntheses.
Anticipated Results Following the synthesis strategy outlined in the Basic Protocol, yields of between 52% and 65% can be achieved for ribonucleosides protected at the 5′ hydroxyl by FMOC, and 76% can be achieved for 5′-O-FMOC-2′-deoxythymidine. Similarly, good to excellent yields are reported in the literature for deoxyguanosine, deoxyadenosine, and deoxycytidine derivatives (Balgobin and Chattopadhyaya, 1987; Ma and Sonveaux, 1987). The four Support
2.4.20 Current Protocols in Nucleic Acid Chemistry
Protocols for the preparation of the starting materials (2′-O-MTHP-protected ribonucleosides) provide yields of ∼70%, except for the synthesis of 2′-O-MTHP-2-N-isobutyrylguanosine, which provide a yield of ∼52%.
Time Considerations The procedure described in the Basic Protocol may be carried out within 1 to 2 days starting from 2′-O-MTHP-protected ribonucleosides. The preparation of the MTHP-protected starting intermediates can take 2 to 3 weeks per nucleoside derivative. The authors suggest starting with uridine (the simplest case) and allowing time for crystallization of the 3′,5′diacetyl intermediate.
Literature Cited Atherton, E. and Sheppard, R.C. 1989. Solid-Phase Peptide Synthesis: A Practical Approach. IRL Press, Oxford. Balgobin, N. and Chattopadhyaya, J.B. 1987. Solid phase synthesis of DNA under a non-depurinating condition with a base labile 5′-protecting group (Fmoc) using phosphite-amidite approach. Nucleosides Nucleotides 6:461-463. Bergmann, F., Kueng, E., Iaiza, P., and Bannwarth, W. 1995. Allyl as internucleotide protecting group in DNA synthesis to be cleaved off by ammonia. Tetrahedron 51:6971-6976. Brown, T., Pritchard, C.E., Turner, G., and Salisbury, S.A. 1989. A new base-stable linker for solidphase oligonucleotide synthesis. J. Chem. Soc., Chem. Commun. 891-893. Büchi, H. and Khorana, H.G. 1972. Total synthesis of the structural gene for an alanine transfer ribonucleic acid from yeast. Chemical synthesis of an icosadeoxyribonucleotide corresponding to the nucleotide sequence 31 to 50. J. Mol. Biol. 72:251-288. Carpino, L.A. 1987. The 9-fluorenylmethoxycarbonyl family of base-sensitive amino-protecting groups. Acc. Chem. Res. 20:401-407.
Fukuda, T., Hamana, T., and Marumoto, R. 1988. Synthesis of RNA oligomers using 9-fluorenylmethoxycarbonyl (Fmoc) group for 5′-hydroxyl protection. Nucl. Acids Res. 16:13-16. Gao, X., Gaffney, B.L., Senior, M., Riddle, R.R., and Jones, R.A. 1985. Methylation of thymine residues during oligonucleotide synthesis. Nucl. Acids Res. 13:573-584. Gioeli, C. and Chattopadhyaya, J.B. 1982. The fluoren-9-ylmethoxycarbonyl group for the protection of hydroxy-groups; its application in the synthesis of an octathymidylic acid fragment. J. Chem. Soc. Chem. Commun. 1982:672-674. Hayakawa, Y., Uchiyama, M., Kato, H., and Noyori, R. 1990. Allylic protection of internucleotide linkage. Tetrahedron Lett. 26:6505-6508. Hunt, B.J. and Ribgy, W. 1967. Short column chromatography. Chem. Ind. 1967:1868-1869. Jones, R.A. 1984. Preparation of protected deoxyribonucleotides. In Oligonucleotide Synthesis: A Practical Approach (M.J. Gait, ed.) pp. 23-34. IRL Press, Oxford. Jork, H., Funk, W., Fischer, W., and Wimmer, H. 1990. Thin-Layer Chromatography, Vol. Ia: Reagents and Detection Methods, pp. 195-198. VCH-Verlagsgesellschaft, Weinheim. Lehmann, C., Xu, Y.-Z., Christodoulou, C., Tan, Z.-K., and Gait, M.J. 1989. Solid-phase synthesis of oligoribonucleotides using 9-fluorenylmethoxy-carbonyl (Fmoc) for 5′-hydroxyl protection. Nucl. Acids Res. 17:2379-2390. Lehmann, C., Xu, Y.-Z., Christodoulou, C., Gait, M.J., Van Meervelt, L., Moore, M., and Kennard, O. 1991. 3′/5′-Regioselectivity of introduction of the 9-fluorenylmethoxy-carbonyl group to 2′O-tetrahydropyran-2-yl and 2′-O-(4methoxytetrahydropyran-4-yl)-nucleosides: Useful intermediates for solid-phase RNA synthesis. Nucleosides Nucleotides 10:1599-1614. Ma, Y. and Sonveaux, E. 1987. The 9-fluorenylmethyloxycarbonyl (Fmoc) group as a 5′-O base labile protecting group in solid supported oligonucleotide synthesis. Nucleosides Nucleotides 6:491-493.
Carpino, L.A. and Han, G.Y. 1970. the 9-fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group. J. Am. Chem. Soc. 92:5748-5749.
Markiewicz, W.T. and Wiewerowski, M. 1985. Simultaneous protection of 3′- and 5′-hydroxyl groups of nucleosides. In Nucleic Acid Chemistry, Section III: Nucleosides (L.B. Townsend and R.S. Tipson, eds.) pp. 229-231. John Wiley & Sons, New York.
Carpino, L.A. and Mansour, E.M.E. 1999. The 2methylsulfonyl-3-phenyl-1-prop-2-enyloxycarbonyl (MSPOC) amino-protecting group. J. Org. Chem. 64:8399-8401.
McBride, L.J. and Caruthers, M.H. 1983. An investigation of several deoxynucleoside phosphoramidites useful for synthesizing deoxyoligonucleotides. Tetrahedron Lett. 24:245-248.
Christodoulou, C., Agrawal, S., and Gait, M.J. 1986. Incompatibility of acid-labile 2′ and 5′ protecting groups for solid-phase synthesis of oligoribonucleotides. Tetrahedron Lett. 27:1521-1522.
McLaughlin, L.W., Piel, N., and Hellmann, T. 1985. Preparation of protected ribonucleotides suitable for chemical oligoribonucleotide synthesis. Synthesis 1985:322-323.
Fromageot, W.P.M., Griffin, B.E., Reese, C.B., and Sulston, J.E. 1967. Monoacylation of ribonucleosides and derivatives via orthoester exchange. Tetrahedron 23:2315-2331.
Norman, D.G., Reese, C.B., and Serafinowska, H.T. 1984. The protection of 2′-hydroxy functions in oligoribonucleotide synthesis. Tetrahedron Lett. 25:3015-3018.
Protection of Nucleosides for Oligonucleotide Synthesis
2.4.21 Current Protocols in Nucleic Acid Chemistry
Palom, Y., Alazzouzi, E-M., Gordillo, F., Grandas, A., and Pedroso, E. 1993. An acid-labile linker for solid-phase oligoribonucleotide synthesis using Fmoc group for 5′-hydroxyl protection. Tetrahedron Lett. 34:2195-2198. Pathak, T. and Chattopadhyaya, J. 1985. The 2′-hydroxyl function assisted cleavage of the internucleotide phosphotriester bond of a ribonucleotide under acidic conditions. Acta Chem. Scand. B39:799-806.
van Boom, J.H. and Wreesmann, C.T.J. 1984. Chemical synthesis of small oligoribonucleotides in solution. In Oligonucleotide Synthesis: A Practical Approach (M.J. Gait, ed.) pp. 153-183. IRL Press, Oxford.
Key-References Blackburn, M. and Gait, M.J. (eds.) 1996. Nucleic Acids in Chemistry and Biology. Oxford University Press, New York.
Pitsch, S. 1997. An efficient synthesis of enantiomeric ribonucleic acid from D-glucose. Helv. Chim. Acta 80:2286-2314.
In particular, chapter 3 on chemical synthesis is very recommendable as an illustrative overview to the present topics.
Reese, C.B. and Skone, P.A. 1985. Action of acid on oligoribonucleotide phosphotriester intermediates. Effect of released vicinal hydroxy functions. Nucl. Acids Res. 13:5215-5231.
Gait, M.J. (ed.) 1984. Oligonucleotide Synthesis: A Practical Approach, IRL Press, Oxford.
Reese, C.B., Saffhill, R., and Sulston, J. 1970. 4Methoxytetrahydropyran-4-yl: A symmetrical alternative to the tetrahydropyranyl group. Tetrahedron 26:1023-1030. Schaller, H., Weiman, G., Lerch, B., and Khorana, H.G. 1963. Protected derivatives of deoxyribonucleotides and new syntheses of deoxyribonucleotide-3′ phosphates. J. Am. Chem. Soc. 85:3821-3827. Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., deBear, J.S., and Gough, G.R. 1992. Rapid synthesis of oligoribonucleotides using 2′-O-(o-nitrobenzyloxymethyl)-protected monomers. Bioorg. Med. Chem. Lett. 2:1019-1024. Still, W.C., Kahn, M., and Mitra, A. 1978. Rapid chromatographic technique for preparative separations with moderate resolution. J. Org. Chem. 43:2923-2925. Ti, G.S., Gaffney, B.L., and Jones, R.A. 1982. Transient protection: Efficient one-flask synthesis of protected deoxynucleosides. J. Am. Chem. Soc. 104:1316-1319.
Basic principles of oligonucleotide synthesis are illustrated by practical advice through further stepby-step protocols; some of the chapters may be regarded as primers for units in the present volume. Lehmann et al., 1989. See above. The procedure in the Basic Protocol is first described for the four 2′-O-MTHP-protected ribonucleosides. For more background information on particular complications arising when the chiral 2′-O-tetrahydropyranyl (THP) group is used, see Lehmann et al., 1991.
Contributed by Michael J. Gait MRC Laboratory of Molecular Biology Cambridge, United Kingdom Christian Lehmann Institute of Organic Chemistry University of Lausanne Lausanne, Switzerland
A Base-Labile Protecting Group
2.4.22 Current Protocols in Nucleic Acid Chemistry
2′-Hydroxyl-Protecting Groups That Are Either Photochemically Labile or Sensitive to Fluoride Ions
UNIT 2.5
Automated chemical synthesis of RNA, like that of DNA, uses protected nucleotide monomers for construction of oligonucleotide chains. RNA monomers, however, are more difficult to obtain than their deoxy counterparts, because of the necessity of protecting their 2′-hydroxyl functions. This unit describes the stepwise preparation, starting from uridine, cytidine, adenosine, and guanosine, of some suitably 2′-protected ribonucleosides. In addition, details are given for protecting the 5′-hydroxyl and the nucleobase, affording ribonucleosides that can be easily converted into either phosphoramidite or phosphonate derivatives, ready to be used in a synthesizer for making RNA. Two alternative sets of protected ribonucleosides are represented here. They are distinguished by the differing conditions required for removal of their 2′-protecting groups. The first consists of uridine, cytidine, adenosine, and guanosine derivatives carrying 2-nitrobenzyloxymethyl (NBOM) groups on their 2′-hydroxyls. The synthesis of these four ribonucleosides is described in Basic Protocols 1 to 4. Oligoribonucleotides synthesized from these components are deprotected by exposure to long-wave UV light (UNIT 3.7). The second set of nucleosides has its 2′-hydroxyls protected with tert-butyldimethylsilyl (TBDMS) groups; these can be removed from product oligoribonucleotides by treatment with tetra-n-butylammonium fluoride. Their syntheses are described in Alternate Protocols 1 to 4. CAUTION: The syntheses in these protocols involve the use of chemicals that have various degrees and kinds of toxicity. Avoid skin contact and inhalation of dusts or vapors. Most operations should be carried out in a well-vented fume hood. NOTE: These reactions should be carried out under strictly anhydrous conditions, using anhydrous solvents and reagents. All glassware should be dried in an oven prior to use. All connections to atmospheric pressure should be through a drying tower containing a desiccant. NOTE: For general information regarding thin-layer chromatography (TLC) or column chromatography, see APPENDIX 3D and APPENDIX 3E, respectively. PREPARATION OF N-PROTECTED 5′-O-(4,4′-DIMETHOXYTRITYL)2′-O-(2-NITROBENZYLOXYMETHYL) NUCLEOSIDES These protocols describe the preparation of ribonucleoside derivatives that incorporate 2-nitrobenzyloxymethyl groups for protection of their 2′-hydroxyls (Figure 2.5.1). In all cases, the 2-nitrobenzyloxymethyl group is introduced into the nucleosides by means of an alkylation reaction utilizing the reagent 2-nitrobenzyl chloromethyl ether, which is prepared as required from its precursor, 2-nitrobenzyl methylthiomethyl ether (see Support Protocol 1). Before any of the nucleoside syntheses described below are carried out, an adequate stock of the methylthiomethyl ether should be accumulated. In addition to the synthesis details, data pertaining to the Rf values from TLC (Table 2.5.1), proton nuclear magnetic resonance (1H NMR; Tables 2.5.2 and 2.5.3), and 13C NMR (Table 2.5.4) of the various 2-nitrobenzyloxymethyl-protected nucleosides are shown.
Contributed by Tod J. Miller, Miriam E. Schwartz, and Geoffrey R. Gough Current Protocols in Nucleic Acid Chemistry (2000) 2.5.1-2.5.36 Copyright © 2000 by John Wiley & Sons, Inc.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.1 Supplement 3
CH3O DMTrO
B
O 3'
2'
DMTr = OH
O
C
O NO2 CH3O O
O NH
B= N
O
HN
O
Uracil-1-yl
HN N
N N
N
O
N4-benzoylcytosin-1-yl
O N
N
N
N
N6-benzoyladenin-9-yl
NH N
O
N H
N2-isobutyrylguanin-9-yl
Figure 2.5.1 The four 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl) ribonucleosides. The general structure of these ribonucleosides is in the upper-left corner and the four bases (B) are shown below. DMTr is the 4,4′-dimethoxytrityl group.
These data should prove useful in confirming the identities of the products and their synthetic intermediates. NOTE: 2-Nitrobenzyloxymethyl groups are designed to be removable by irradiation with long-wave UV light. Sunlight, or even the light emitted by standard overhead fluorescent bulbs, contains enough UV light to cause slow loss of these protecting groups. Minimize exposure of sensitive compounds by carrying out operations in an area, such as a fume hood, fitted with yellow fluorescent tubes (GE or Sylvania Golds). As an added precaution, wrap flasks and chromatography columns in aluminum foil.
Table 2.5.1 Rf Values of 2-Nitrobenzyloxymethyl-Protected Ribonucleosides on Merck Silica Gel 60 F254 TLC Plates
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
Ribonucleosidea
Rf valueb
Solvent system
U2′NBOM U3′NBOM A2′NBOM A3′NBOM ABz2′NBOM Gi-Bu2′NBOM 5′DMTrU2′NBOM 5′DMTrU3′NBOM 5′DMTrC2′NBOM 5′DMTrCBz2′NBOM 5′DMTrABz2′NBOM 5′DMTrGi-Bu2′NBOM
0.31 0.31 0.42 0.33 0.56 0.24 0.51 0.29 0.05 0.42 0.56 0.38
9:1 (v/v) chloroform/methanol 9:1 (v/v) chloroform/methanol 9:1 (v/v) chloroform/methanol 9:1 (v/v) chloroform/methanol 9:1 (v/v) chloroform/methanol 9:1 (v/v) chloroform/methanol 2:1 (v/v) ethyl acetate/hexane 2:1 (v/v) ethyl acetate/hexane 2:1 (v/v) ethyl acetate/hexane 2:1 (v/v) ethyl acetate/hexane 2:1 (v/v) ethyl acetate/hexane 2:1 (v/v) ethyl acetate/hexane
a Abbreviations: A, adenosine; C, cytidine; G, guanosine; U, uridine; Bz, benzoyl; DMTr, 4,4′-dimethoxytrityl; i-Bu, isobutyryl; NBOM, 2-nitrobenzyloxymethyl. b TLC Rf values are notoriously irreproducible unless measured under strictly controlled conditions. However, the relative mobilities of substances run on the same plate in the same solvent are valuable guides to compound identification.
2.5.2 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Table 2.5.2 Derivativesb
1H-NMR
Chemical Shiftsa of Nontritylated 2-Nitrobenzyloxymethyl Ribonucleoside
Hydrogen(s)
A2′NBOM
A3′NBOM
ABz2′NBOM
Gi-Bu2′NBOM
H1′ H2′ H3′ H4′ H5′ H2 or H5 H6 or H8 -CH2-O -CH2-Ar Ar(NBOM) 2′- or 3′-OH 5′-OH N6-NH2 Ar (Bz)
6.07 d 4.87 m 4.34 bs 4.03 bs 3.67 m 8.02 s 8.35 s 4.75 s 4.56 s 7.3-8.0 m 5.39 d 5.53 bs 7.29 bs NA
5.96 d 4.85 m 4.34 bs 4.12 bs 3.65 m 8.20 s 8.42 s 5.04 s 5.01 s 7.6-8.1 m 5.71 d 5.63 bs 7.46 bs NA
6.12 d 5.26 m 4.59 d 4.40 bs 3.98 d, 3.78 d 8.60 s 8.69 s 4.73 d 4.90 m 7.4-8.1 m ND ND 7.26 bs 7.3-8.1 m
5.97 d 5.16 m 4.30 bs 3.97 bs 3.61 d 8.27 s ND 4.87 m 4.71 bs 7.2-8.1 m ND ND NA NA
The internal reference for 1H-NMR spectra was tetramethylsilane at 0 ppm. The solvents were dimethy sulfoxide-d6 for the A derivatives and acetonitrile-d3 for the G derivative. All shifts are measured in ppm. b Abbreviations: A, adenosine; G, guanosine; Ar, aromatic; Bz, benzoyl; i-Bu, isobutyryl; NBOM, 2-nitrobenzyloxymethyl; bs, broad singlet; d, doublet; m, multiplet; s, singlet; NA, not applicable; ND, not determined. a
Table 2.5.3 1H-NMR Chemical Shiftsa of 5′-Dimethoxytritylated 2-Nitrobenzyloxymethyl Ribonucleoside Derivativesb
Hydrogen(s)
5′DMTrU2′ NBOM
5′DMTrC2′ NBOM
5′DMTrCBz2′ 5′DMTrABz2′ 5′DMTrGi-Bu NBOM NBOM 2′NBOM
H1′ H2′ H3′ H4′ H5′ H2 or H5 H6 or H8 -OCH3 Ar (DMTr) -CH2-O-CH2-Ar Ar (NBOM) 2′- or 3′-OH N1- or N3-H N4- or N6-H Ar (Bz) i-Bu-CH(CH3)2
6.06 d 4.40 dd 4.51 m 4.11 bs 3.56 bs 5.21 d 7.96 d 3.82 s 6.80-7.40 m 5.00-5.15 bs 5.00-5.15 bs 7.40-8.41 m 5.19 bs 10.00 s NA NA NA
5.87 d 4.15 d 4.26 m 4.00 d 3.28 bs 5.44 d 7.79 d 3.73 s 6.87-7.40 m 4.85-5.05 m 4.85-5.05 m 7.57-8.08 m 5.30 d NA ND NA NA
6.10 bs 4.58 m 4.43 d 4.19 d 3.64 bs 5.46 d 7.93 d 3.86 s 6.80-7.50 m 5.12 m 5.12 m 7.50-8.20 m ND NA ND 7.10-8.70 m NA
5.99 d 5.26 m 4.78 d 4.40 bs 3.91 m 8.72 s 8.68 bs 3.80 s 6.75-7.40 m 4.60 m 4.83 m 7.40-8.10 m ND NA 10.00 s 7.10-8.10 m NA
5.99 d 5.20 m 4.60 dd 4.26 d 3.48 d, 3.21 dd 8.65 bs ND 3.79 s 6.70-7.40 m 4.81 m 4.90 m 7.40-8.70 m ND 9.28 s NA NA 0.92 dd
a The internal reference for 1H-NMR spectra was tetramethylsilane at 0 ppm. The solvent was chloroform-d. All shifts are measured in ppm. b Abbreviations: A, adenosine; C, cytidine; G, guanosine; U, uridine; Ar, aromatic; Bz, benzoyl; DMTr, 4,4′-dimethoxytrityl; i-Bu, isobutyryl; NBOM, 2-nitrobenzyloxymethyl; bs, broad singlet; d, doublet; dd, doublet of doublets; m, multiplet; s, singlet; NA, not applicable; ND, not determined.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.3 Current Protocols in Nucleic Acid Chemistry
Supplement 3
Table 2.5.4
13C-NMR
Chemical Shiftsa of 2-Nitrobenzyloxymethyl Ribonucleoside Derivativesb
Carbon
A2′NBOM
U2′NBOM
Gi-Bu2′NBOM
C1′ C2′ C3′ C4′ C5′ C2 C4 C5 C6 C8 -OCH2-OCH2-Ar NBOM (C1) NBOM (C2) NBOM (C3) NBOM (C4) NBOM (C5) NBOM (C6) i-Bu (CH3) i-Bu (CH3) i-Bu (CH) i-Bu C=O
86.5 78.3 69.3 86.2 61.5 152.2 148.7 119.2 156.0 139.7 65.6 94.0 133.6 146.6 133.3 128.1 124.3 128.3 NA NA NA NA
86.4 78.5 68.7 85.3 60.6 150.2 163.1 102.0 140.4 NA 65.9 94.1 133.9 147.1 133.7 128.6 124.6 128.8 NA NA NA NA
86.7 81.0 70.3 85.0 61.8 149.0 148.4 120.3 154.9 137.7 66.2 95.2 134.3 146.5 134.0 127.9 124.7 128.7 19.1 19.3 35.1 180.4
a The internal reference for 13C-NMR spectra was dimethyl sulfoxide-d6 at 39.7 ppm. The solvent was dimethyl sulfoxide-d6. While not exhaustive, these useful and commonly observed resonances are listed with tentative assignments. All shifts are measured in ppm. b Abbreviations: A, adenosine; G, guanosine; U, uridine; Ar, aromatic; i-Bu, isobutyryl; NBOM, 2-nitrobenzyloxymethyl; NA, not applicable.
BASIC PROTOCOL 1
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
Synthesis of 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine In this protocol, uridine is converted into its dibutylstannylene derivative, then alkylated using 2-nitrobenzyl chloromethyl ether. The resulting mixture of 2′- and 3′-O-(2-nitrobenzyloxymethyl)uridine is treated with 4,4′-dimethoxytrityl chloride. The dimethoxytrityl derivatives are separated by silica-gel chromatography, affording pure 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine. The overall reaction sequence is illustrated in Figure 2.5.2. Materials Methanol Uridine Dibutyltin oxide Phosphorus pentoxide Anhydrous tetra-n-butylammonium bromide Anhydrous dimethylformamide, store over 4A molecular sieves 2-Nitrobenzyl chloromethyl ether, make fresh (see Support Protocol 1) Anhydrous pyridine, store over coarse granules of calcium hydride 9:1 and 95:5 (v/v) chloroform/methanol 66% (v/v) aqueous pyridine Silica gel 60, 70 to 230 mesh ASTM (e.g., EM Science)
2.5.4 Supplement 3
Current Protocols in Nucleic Acid Chemistry
O
O
NH
NH HO
N
O
O
HO MeOH
OH
OH
N
O
Dibutyltin oxide O
O 2-Nitrobenzyl chloromethyl ether Bu4NBr/DMF
O Sn
Bu
Bu
O
O NH
HO
N
O OH
NH
O
DMTrO 1. DMTrCl/Pyridine
O
2. Separation of isomers
O NO2
+
N
O OH
O
O
O NO2
3'-isomer
Figure 2.5.2 Preparation of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine from uridine. Bu is n-butyl.
2.5 × 30–cm and 3 × 60–cm glass chromatography columns packed with silica gel 60, 70 to 230 mesh ASTM, in chloroform to a bed height of 25 and 50 cm, respectively (see Support Protocol 3) Chloroform Anhydrous triethylamine, store over coarse granules of calcium hydride 4,4′-Dimethoxytrityl chloride Ethyl acetate 1 M NaHCO3 2 M NaCl Anhydrous sodium sulfate 2:1 (v/v) ethyl acetate/hexane 0% to 1% (v/v) methanol in chloroform, containing 0.25% (v/v) pyridine 250-mL and 2-L round-bottom flasks Boiling chips Water-cooled reflux condenser Heating mantle Rotary evaporator connected interchangeably to water aspirator and vacuum pump 50-mL pressure-equalizing dropping funnel Large petri plate Filter paper, coarse porosity and fast flow rate (e.g., Quantitative Q8, Fisher) Additional reagents and equipment for TLC and column chromatography (see Support Protocol 3) Prepare 2′,3′-O-(dibutylstannylene)uridine 1. Add a stir-bar to 1 L methanol in a 2-L round-bottom flask and begin stirring. Add 4.88 g (20 mmol) uridine and 5.00 g (20 mmol) dibutyltin oxide.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.5 Current Protocols in Nucleic Acid Chemistry
Supplement 3
2. Remove stir-bar, add boiling chips, and fit flask with a water-cooled reflux condenser. Heat mixture to a boil using a heating mantle, reflux 45 min to 1 hr, and let cool to room temperature. 3. Decant solution from boiling chips into a second 2-L flask and remove methanol using a rotary evaporator connected to a water aspirator. 4. Dry crystalline residue to constant weight in a vacuum desiccator over phosphorus pentoxide. A yield of 9 g 2′,3′-O-(dibutylstannylene)uridine (with a melting point of 232° to 234°C) is expected. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
Alkylate to form 2′- and 3′-O-(2-nitrobenzyloxymethyl)uridine 5. Add 5.10 g (10.7 mmol) dry 2′,3′-O-(dibutylstannylene)uridine and 1.72 g (5.35 mmol) anhydrous tetra-n-butylammonium bromide to 40 mL anhydrous dimethylformamide in a 250-mL round-bottom flask, while stirring. Fit flask with a 50-mL pressure-equalizing dropping funnel. 6. Use dropping funnel to add a freshly prepared solution of 2-nitrobenzyl chloromethyl ether (from 16 mmol 2-nitrobenzyl methylthiomethyl ether; see Support Protocol 1) dropwise over a 5-min period while stirring, then seal flask and stir 2 hr at room temperature. 7. Add 5 mL anhydrous pyridine followed by 2 mL water and continue stirring 20 min at room temperature. 8. Check reaction by TLC (see Support Protocol 3) using 9:1 chloroform/methanol. The unresolved 1:1 mixture of 2′- and 3′-isomers will be visible under UV light as a dark band about a third of the way up the plate (Table 2.5.1).
9. Remove volatile solvents using the rotary evaporator connected to water aspirator, then continue evaporation under high vacuum (i.e., with a vacuum pump) to remove as much of the dimethylformamide as possible. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
Purify 2′- and 3′-O-(2-nitrobenzyloxymethyl)uridine 10. Dissolve residue in the minimum volume of 66% aqueous pyridine and, using a Pasteur pipet, transfer it dropwise onto 10 g silica gel 60 in a large petri plate. Allow wet silica to dry in the moving airstream inside a fume hood. An overnight drying time should be adequate if most of the dimethylformamide was removed and the minimum amount of aqueous pyridine was used.
11. Pulverize the dry, coated silica. Divide the powdery material into halves and layer them onto two 2.5 × 30–cm glass chromatography columns. 12. Wash each column with 100 mL chloroform, elute with 95:5 chloroform/methanol, and collect fractions as described (see Support Protocol 3). 2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
The volume of 95:5 chloroform/methanol should be determined from TLC results.
13. Monitor fractions by TLC using 9:1 chloroform/methanol, comparing selected fractions against samples of the original reaction mixture to locate the products.
2.5.6 Supplement 3
Current Protocols in Nucleic Acid Chemistry
14. Pool and evaporate the appropriate fractions using the rotary evaporator connected to a water aspirator. A yield of 4.2 g of a 1:1 mixture of the 2′- and 3′-isomers of (2-nitrobenzyloxymethyl)uridine is expected. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine 15. Dry 4.2 g (10.3 mmol) mixed 2′- and 3′-O-(2-nitrobenzyloxymethyl)uridine isomers by three co-evaporations with 30 mL anhydrous pyridine using the rotary evaporator connected to a vacuum pump. 16. Dissolve residue in 114 mL anhydrous pyridine, then add 1.60 mL (11.4 mmol) anhydrous triethylamine and 3.87 g (11.4 mmol) 4,4′-dimethoxytrityl chloride. Stir 3 hr at room temperature. 17. Add 5 mL methanol, allow to stand 10 min, then remove solvents on the rotary evaporator connected to a vacuum pump. 18. Dissolve residue in 250 mL ethyl acetate. Extract three times with 100 mL of 1 M NaHCO3 and once with 100 mL of 2 M NaCl. CAUTION: Carbon dioxide is released during the sodium bicarbonate extractions.
19. Dry ethyl acetate layer by addition of 5 g anhydrous sodium sulfate, filter through filter paper to remove salt, and rotary evaporate filtrate to a yellow foam using a water aspirator. 20. Analyze this material by TLC in 2:1 ethyl acetate/hexane. Two major bands should be visible. The upper (faster-running) one is the 2′-isomer (Table 2.5.1). If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
Purify 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine 21. Dissolve foam (∼8 g) in 5 to 10 mL chloroform and add it to the top of a 3 × 60–cm silica gel column. Elute products from column using a 1.2-L stepwise gradient of 0% to 1% methanol in chloroform containing 0.25% pyridine as described. 22. Monitor fractions by TLC using 2:1 ethyl acetate/hexane. Any mixed fractions containing both isomers can be rechromatographed to obtain more pure 2′-isomer. Gradients of ethyl acetate in hexane may also be used for purification of these dimethoxytrityl nucleosides, as preliminary results with this alternative solvent mixture have been encouraging.
23 Combine those fractions containing the pure 2′-isomer, and rotary evaporate them to a foam using a water aspirator. A yield of 40% 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine, based on the starting quantity of uridine, is expected.
24. Store protected nucleoside in the dark at −20°C in a sealed flask containing a trace of pyridine (stable for many months).
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.7 Current Protocols in Nucleic Acid Chemistry
Supplement 3
BASIC PROTOCOL 2
Synthesis of 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N4benzoylcytidine In this protocol, 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine (see Basic Protocol 1) is converted into its corresponding cytidine derivative, then selectively benzoylated with pentafluorophenyl benzoate at the N4 position. The reaction sequence is illustrated in Figure 2.5.3. Materials 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine (see Basic Protocol 1) Anhydrous pyridine, stored over coarse granules of calcium hydride Acetic anhydride Ethyl acetate 1 M NaHCO3 2 M NaCl Anhydrous sodium sulfate 1,2,4-Triazole 4-Chlorophenyl phosphorodichloridate 3:1 (v/v) pyridine/concentrated ammonium hydroxide 2.5 × 30–cm glass chromatography column packed with silica gel 60, 70 to 230 mesh ASTM, in chloroform to a bed height of 25 cm (see Support Protocol 3) 0% to 1% and 0% to 4% (v/v) methanol in chloroform, containing 0.25% (v/v) pyridine 2:1 (v/v) ethyl acetate/hexane Pentafluorophenyl benzoate (see Support Protocol 2)
O
O NH
DMTrO
N
O OH
NH
O
DMTrO
O
O
N
O
Acetic anhydride/Pyridine AcO
O
O
O
NO2
NO2 O O P Cl Cl
1. Cl
2. NH4OH
Triazole/Pyridine O NH2
HN
N
N DMTrO
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
N
O OH
O
DMTrO Pentafluorophenyl benzoate
O
Pyridine
O NO2
N
O OH
O
O
O NO2
Figure 2.5.3 Preparation of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N4-benzoylcytidine from 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine.
2.5.8 Supplement 3
Current Protocols in Nucleic Acid Chemistry
250- and 500-mL separatory funnels Filter paper, coarse porosity and fast flow rate (e.g., Quantitative Q8, Fisher) Rotary evaporator connected interchangeably to water aspirator and vacuum pump 10- and 25-mL round-bottom flasks Additional reagents and equipment for TLC and column chromatography (see Support Protocol 3) Protect 3′-hydroxyl of 5′-O-(4,4′-dimethoxytrityl)-2′-O(2-nitrobenzyloxymethyl)uridine 1. Add 580 mg (0.82 mmol) 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine to a flask containing 3 mL anhydrous pyridine and stir to dissolve. 2. Add 1.64 mL (17 mmol) acetic anhydride and allow reaction mixture to stand 2 hr at room temperature. 3. Cool flask in an ice bath and add 2.5 mL anhydrous pyridine, followed by dropwise addition over a 5-min period of 4 mL water, while stirring and cooling continuously. 4. Add an additional 1 mL anhydrous pyridine to redissolve any precipitate, and allow solution to stand 18 hr at room temperature in the dark. 5. Transfer mixture to a 250-mL separatory funnel using 50 mL ethyl acetate and extract the organic layer three times with 50 mL of 1 M NaHCO3 and three times with 50 mL of 2 M NaCl. CAUTION: Carbon dioxide is released during the sodium bicarbonate extractions. The 3′-hydroxyl is temporarily protected as an acetate ester.
Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)cytidine 6. Dry ethyl acetate layer over 3 g anhydrous sodium sulfate, filter through filter paper to remove salt, and evaporate filtrate to a foam using a rotary evaporator connected to a water aspirator. 7. Co-evaporate the product three times with 10 mL anhydrous pyridine in a 25-mL round-bottom flask using the rotary evaporator connected to a vacuum pump. Dissolve final residue in 2.7 mL anhydrous pyridine. 8. Add 314 mg (4.54 mmol) 1,2,4-triazole, stir to dissolve (∼1 hr), then add 0.36 mL (2.2 mmol) 4-chlorophenyl phosphorodichloridate. Stir 1 hr and then let stand 72 hr at room temperature in the dark. 9. Cool flask in an ice bath and add 0.2 mL water while stirring. Stir 30 min at 0°C, then add 3 mL anhydrous pyridine. 10. Use a disposable Pasteur pipet to add the resulting solution dropwise to 80 mL of 3:1 pyridine/concentrated ammonium hydroxide while stirring. Loosely stopper the container and allow reaction mixture to stand 48 hr at room temperature in the dark. 11. Concentrate solution to a slurry by rotary evaporation using a water aspirator and transfer to a 500-mL separatory funnel using 150 mL ethyl acetate. 12. Extract three times with 100 mL of 1 M NaHCO3, then three times with 100 mL of 2 M NaCl. 13. Repeat step 6.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.9 Current Protocols in Nucleic Acid Chemistry
Supplement 3
14. Layer residue on a 2.5 × 30–cm silica gel column and elute products using a 1-L stepwise gradient of 0% to 4% methanol in chloroform containing 0.25% pyridine as described (see Support Protocol 3). 15. Monitor fractions by TLC (see Support Protocol 3) using 2:1 ethyl acetate/hexane. 16. Evaporate appropriate fractions using the rotary evaporator connected to a water aspirator to produce the pure product, 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)cytidine. A 71% yield, based on the starting quantity of 5′-O-(4,4’-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine, is expected. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N4benzoylcytidine 17. Dissolve 412 mg (0.58 mmol) 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)cytidine in 1 mL anhydrous pyridine in a 10-mL round-bottom flask. 18. Add 251 mg (0.87 mmol) pentafluorophenyl benzoate and swirl flask to dissolve. Seal flask and allow solution to stand 6 days at room temperature in the dark. 19. Examine mixture by TLC using 2:1 ethyl acetate/hexane, comparing it to the starting material to confirm complete conversion to the N-benzoyl derivative. 20. Transfer reaction mixture to a 250-mL separatory funnel using 100 mL ethyl acetate, then extract as in step 5. 21. Repeat step 6. 22. Repeat steps 14 to 16, using a 1.2-L stepwise gradient of 0% to 1% methanol in chloroform containing 0.25% pyridine in step 14. A 91% yield based on the starting quantity of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)cytidine is expected.
23. Store protected nucleoside in the dark at −20°C in a sealed flask containing a trace of pyridine (stable for many months). BASIC PROTOCOL 3
Synthesis of 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N6-benzoyladenosine In this protocol, adenosine is converted into its dibutylstannylene derivative, then alkylated with 2-nitrobenzyl chloromethyl ether, and the resulting 2′- and 3′-O-(2-nitrobenzyloxymethyl)adenosines are separated by column chromatography. Benzoylation at the N6 position (to protect the nucleobase), followed by dimethoxytritylation (to protect the 5′-hydroxyl), completes the synthesis. The reaction sequence is illustrated in Figure 2.5.4.
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
Materials Methanol Adenosine Dibutyltin oxide Phosphorous pentoxide Anhydrous tetra-n-butylammonium bromide Anhydrous dimethylformamide, stored over 4A molecular sieves 2-Nitrobenzyl chloromethyl ether, make fresh (see Support Protocol 1)
2.5.10 Supplement 3
Current Protocols in Nucleic Acid Chemistry
NH2 N HO
NH2 N
N
N
N
N
HO
O
O
Dibutyltin oxide MeOH
OH OH
N N 2-Nitrobenzyl chloromethyl ether
O
Bu4NBr/DMF
O Sn Bu
Bu
O NH2 N HO
O
HN N
N
N
HO
N 1. Separation of isomers
OH O
2. Me3SiCl/Pyridine 3. Benzoyl chloride 4. NH4OH
O NO2
+
O
N
N
OH O
N
O NO2
3'-isomer
O DMTrCl/Pyridine HN N DMTrO
O OH
N
N
O
N
O NO2
Figure 2.5.4 Preparation of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N6-benzoyladenosine from adenosine. Bu is n-butyl.
Anhydrous pyridine, store over coarse granules of calcium hydride 9:1 and 95:5 (v/v) chloroform/methanol 66% (v/v) aqueous pyridine Silica gel 60, 70 to 230 mesh ASTM (e.g., EM Science) 2.5 × 25–cm, 2.5 × 30–cm, and 3 × 60–cm glass chromatography columns packed with silica gel 60, 70 to 230 mesh ASTM, in chloroform (see Support Protocol 3) 1% to 5% (v/v) methanol in chloroform 80% (v/v) aqueous acetonitrile Acetonitrile Trimethylchlorosilane Benzoyl chloride Concentrated ammonium hydroxide Ethyl acetate 1 M NaHCO3 2 M NaCl Anhydrous sodium sulfate Chloroform Triethylamine, stored over coarse granules of calcium hydride 4,4′-Dimethoxytrityl chloride 0% to 1% (v/v) methanol in chloroform containing 0.25% (v/v) pyridine 2:1 (v/v) ethyl acetate/hexane 100-mL, 250-mL, and 2-L round-bottom flasks Boiling chips Water-cooled reflux condenser Heating mantle
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.11 Current Protocols in Nucleic Acid Chemistry
Supplement 3
Rotary evaporator connected interchangeably to water aspirator and vacuum pump Oil bath, 60°C 50-mL pressure-equalizing dropping funnel 500-mL separatory funnel Filter paper, coarse porosity and fast flow rate (e.g., Quantitative Q8, Fisher) Additional reagents and equipment for TLC and column chromatography (see Support Protocol 3) Prepare 2′,3′-O-(dibutylstannylene)adenosine 1. Add a stir-bar to 700 mL methanol in a 2-L round-bottom flask and begin stirring. Add 6.7 g (25 mmol) adenosine and 6.25 g (25 mmol) dibutyltin oxide. 2. Remove stir-bar, add boiling chips, and fit flask with a water-cooled reflux condenser. Heat mixture to boiling using a heating mantle, reflux 45 min, and let cool to room temperature. 3. Decant solution from boiling chips into a second 2-L flask and remove methanol using a rotary evaporator connected to a water aspirator. 4. Dry residue to constant weight in a vacuum desiccator over phosphorus pentoxide. A yield of 10.5 g is expected. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
Alkylate to form 2′- and 3′-O-(2-nitrobenzyloxymethyl)adenosine 5. Add 8 g (16 mmol) dry 2′,3′-O-(dibutylstannylene)adenosine and 7.7 g (16 mmol) anhydrous tetra-n-butylammonium bromide to 65 mL anhydrous dimethylformamide in a 250-mL round-bottom flask while stirring. 6. Heat to 60°C in an oil bath and fit flask with a 50-mL pressure-equalizing dropping funnel. 7. Use the dropping funnel to add freshly prepared 2-nitrobenzyl chloromethyl ether (from 16 mmol 2-nitrobenzyl methylthiomethyl ether; see Support Protocol 1) dropwise over a 5-min period while stirring at 60°C. Seal flask and stir 1 hr at 60°C. 8. Add 20 mL anhydrous pyridine and stir 25 min at room temperature. 9. Examine reaction mixture by TLC (see Support Protocol 3) in 9:1 chloroform/methanol. The 2′- and 3′-isomers are visible as two closely spaced bands in the lower half of the plate. The upper band of this pair is the 2′-isomer (Table 2.5.1).
10. Remove solvents by rotary evaporation, using high vacuum (i.e., with a vacuum pump) to remove as much dimethylformamide as possible. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
Purify 2′-O-(2-nitrobenzyloxymethyl)adenosine 11. Dissolve residue in the minimum volume of 66% aqueous pyridine and, using a Pasteur pipet, transfer it dropwise onto 15 g silica gel 60 in a large petri plate. Allow wet silica to dry in the moving stream of air inside a fume hood.
2.5.12 Supplement 3
Current Protocols in Nucleic Acid Chemistry
An overnight drying time should be adequate if most of the dimethylformamide was removed and the minimum amount of aqueous pyridine was used.
12. Pulverize the dry, coated silica. Layer powder onto a 3 × 60–cm glass chromatography column and elute with 95:5 chloroform/methanol, collecting fractions as described (see Support Protocol 3). The volume of 95:5 chloroform/methanol should be determined from TLC results.
13. Monitor fractions by TLC in 9:1 chloroform/methanol. 14. Combine all fractions containing the 2′-isomer and rotary evaporate to dryness using a water aspirator. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
15. Dry material on 6 g silica gel 60 as in step 11 and repeat step 12 using a 1-L stepwise gradient of 1% to 5% methanol in chloroform (beginning with 200 mL of 1% methanol, followed by 200 mL of 2% methanol, and so on). 16. Repeat steps 13 and 14. 2′-O-(2-Nitrobenzyloxymethyl)adenosine contaminated with a trace of the 3′-isomer is left after solvent removal. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
17. Dissolve residue in a minimal amount of 80% aqueous acetonitrile with heating, then use the rotary evaporator connected to water aspirator to repeatedly co-evaporate with acetonitrile to a final volume of ∼5 mL until crystallization of the 2′-isomer occurs. A 24% yield of white crystals is obtained, based on the starting quantity of 2′,3′-O-(dibutylstannylene)adenosine. This material may be further recrystallized from water. The melting point of the product is 175° to 177°C. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
Prepare 2′-O-(2-nitrobenzyloxymethyl)-N6-benzoyladenosine 18. Add 1.08 g (2.5 mmol) 2′-O-(2-nitrobenzyloxymethyl)adenosine to 10 mL anhydrous pyridine in a 100-mL round-bottom flask while stirring to dissolve. Add 1.59 mL (12.5 mmol) trimethylchlorosilane, seal flask, and stir 2 hr at room temperature. 19. Add 1.45 mL (12.5 mmol) benzoyl chloride and reseal flask. Stir 2 hr, then cool to 0°C and add 2.5 mL water. Stir 10 min, then add 5 mL concentrated ammonium hydroxide. Cover (do not seal) flask and stir 30 min at room temperature. Ammonium hydroxide from a newly opened bottle should be used, and the reaction should be checked with pH paper to make certain it remains alkaline throughout the 30 min. More ammonium hydroxide should be added in 1-mL aliquots, if necessary, to maintain alkalinity.
20. Remove ammonia and solvents by rotary evaporation using a water aspirator. 21. Transfer reaction mixture to a 500-mL separatory funnel using 150 mL ethyl acetate and extract three times with 100 mL of 1 M NaHCO3, then three times with 100 mL of 2 M NaCl. 22. Dry ethyl acetate layer over 5 g anhydrous sodium sulfate, filter through filter paper to remove salt, and rotary evaporate filtrate using a water aspirator.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.13 Current Protocols in Nucleic Acid Chemistry
Supplement 3
If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
23. Layer residue on a 2.5 × 25–cm silica gel column and elute with 100 mL chloroform, followed by 300 mL of 1% methanol in chloroform and 800 mL of 2% methanol in chloroform as described (see Support Protocol 3). 24. Monitor fractions by TLC using 9:1 chloroform/methanol. 25. Use the rotary evaporator connected to a water aspirator to evaporate appropriate fractions and produce 2′-O-(2-nitrobenzyloxymethyl)-N 6-benzoyladenosine. A yield of 88%, based on the starting quantity of 2′-O-(2-nitrobenzyloxymethyl)adenosine, is expected. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N6benzoyladenosine 26. Dry 1.05 g (1.96 mmol) 2′-O-(2-nitrobenzyloxymethyl)-N6-benzoyladenosine by three co-evaporations with 30 mL anhydrous pyridine using the rotary evaporator connected to a vacuum pump. 27. Dissolve residue in 30 mL anhydrous pyridine, then add 0.34 mL (2.4 mmol) triethylamine and 0.80 g (2.4 mmol) 4,4′-dimethoxytrityl chloride. Stir 3 hr at room temperature. 28. Add 1 mL methanol and, after 10 min, remove solvents by rotary evaporation using a vacuum pump. 29. Repeat steps 21 to 25 with the following exceptions: a. Extract three times with NaHCO3 but only once with NaCl in step 21. b. Use a 2.5 × 30–cm silica gel column and a 1.2-L stepwise gradient of 0% to 1% methanol in chloroform containing 0.25% pyridine in step 23. c. Use 2:1 ethyl acetate/hexane for TLC in step 24. The yield of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N6-benzoyladenosine is expected to be 91% based on the starting quantity of 2′-O-(2-nitrobenzyloxymethyl)-N6-benzoyladenosine.
30. Store 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N6-benzoyladenosine in the dark at −20°C in a sealed container containing a trace of pyridine (stable for many months). BASIC PROTOCOL 4
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
Synthesis of 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N2isobutyrylguanosine In this protocol, guanosine is protected at its N2 position with the isobutyryl group, then converted into its dibutylstannylene derivative and alkylated with 2-nitrobenzyl chloromethyl ether. The resulting 2′-O-(2-nitrobenzyloxymethyl) nucleoside is purified by silica-gel chromatography, then crystallized from an acetonitrile/water mixture. Dimethoxytritylation for protection of the 5′-hydroxyl is the final step in the synthesis. The reaction sequence is illustrated in Figure 2.5.5.
2.5.14 Supplement 3
Current Protocols in Nucleic Acid Chemistry
O N HO
O N
NH
N
N
O
HO
NH2
O
1. Isobutyryl chloride/Pyridine 2. Aq. NaOH in ethanol
OH OH
N
NH N
O
N H
OH OH
Dibutyltin oxide MeOH
O
O N HO
O OH
O
O
NH
N
N
N
N H
HO
2-Nitrobenzyl chloromethyl ether
O
O O
N
NH N
O
N H
O Sn
NO2
Bu
Bu
O DMTrCl/Pyridine
N DMTrO
N
O OH
NH
O
N
O
N H
O NO2
2 Figure 2.5.5 Preparation of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N -isobutyrylguanosine from guanosine. Bu is n-butyl.
Materials Guanosine hydrate Anhydrous pyridine, stored over coarse granules of calcium hydride Isobutyryl chloride Ethyl acetate 1 M NaHCO3 2 M NaCl Anhydrous sodium sulfate Ethanol 2 N NaOH, ice cold Dowex AG50W-X8 ion exchange resin (pyridinium form) 5 × 60–cm glass chromatography column filled with 50 mL Dowex AG50W-X8 ion-exchange resin (pyridinium form) in water 4:1 (v/v) chloroform/methanol Phosphorus pentoxide Dibutyltin oxide Methanol Anhydrous dimethylformamide, stored over 4A molecular sieves 2-Nitrobenzyl chloromethyl ether, make fresh (see Support Protocol 1) Silica gel 60, 70 to 230 mesh ASTM (e.g., EM Science) 2.5 × 25–cm and 2.5 × 30–cm glass chromatography columns packed with silica gel 60, 70 to 230 mesh ASTM, in chloroform to a bed height of 20 and 25 cm, respectively (see Support Protocol 3) Chloroform 2%, 4%, 6%, and 8% (v/v) methanol in chloroform
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.15 Current Protocols in Nucleic Acid Chemistry
Supplement 4
9:1 (v/v) chloroform/methanol 80% (v/v) aqueous acetonitrile Acetonitrile Triethylamine, stored over coarse granules of calcium hydride 4,4′-Dimethoxytrityl chloride 0% to 1% (v/v) methanol in chloroform, containing 0.25% (v/v) pyridine 2:1 (v/v) ethyl acetate/hexane Oven, 130°C 500-mL and 2-L round-bottom flasks 100-mL pressure-equalizing dropping funnel Rotary evaporator connected interchangeably to water aspirator and vacuum pump 1-L separatory funnel Filter paper, coarse porosity and fast flow rate (e.g., Quantitative QB, Fisher) Water-cooled reflux condenser Heating mantle Additional reagents and equipment for TLC and column chromatography (see Support Protocol 3) NOTE: The pyridinium form of Dowex AG50W-X8 ion-exchange resin is made by washing the hydrogen form with several changes of 20% aqueous pyridine. Prepare tetraisobutyrylguanosine 1. Dry guanosine hydrate to constant weight in an oven at 130°C. A couple of hours drying is sufficient to drive off the water of crystallization.
2. Add 28.3 g (100 mmol) dry guanosine to 1 L anhydrous pyridine in a 2-L round-bottom flask while stirring. Fit flask with a 100-mL pressure-equalizing dropping funnel. The guanosine will form a suspension in the pyridine.
3. Cool mixture to 0°C in an ice bath and use the dropping funnel to add 100 mL isobutyryl chloride dropwise over a 10-min period with vigorous stirring at 0°C. Stir 2 hr at 0°C. 4. Use the dropping funnel to add 100 mL water dropwise to the stirring solution, slowly enough that the temperature is maintained <5°C. Allow mixture to stand overnight at 0°C. 5. Evaporate reaction mixture to ∼200 mL using a rotary evaporator connected to a vacuum pump. 6. Transfer slurry to a 4-L Erlenmeyer flask using 500 mL ethyl acetate. Stir vigorously while slowly adding 2 L of 1 M NaHCO3. Stir overnight at room temperature. CAUTION: The mixture froths violently as carbon dioxide is evolved.
7. Transfer mixture in portions to a 1-L separatory funnel, removing the water layer at each transfer until only the ethyl acetate layer remains in the funnel. Extract three times with 300 mL of 1 M NaHCO3 and three times with 300 mL of 2 M NaCl. 2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
8. Dry ethyl acetate solution over 10 g anhydrous sodium sulfate, filter through filter paper to remove salt, and rotary evaporate filtrate using a water aspirator to a foam consisting of tetraisobutyrylguanosine.
2.5.16 Supplement 4
Current Protocols in Nucleic Acid Chemistry
If desired, this intermediate can be stored at –20°C in a sealed dry container (stable for many months).
Prepare N2-isobutyrylguanosine 9. Add 11.3 g (20 mmol) tetraisobutyrylguanosine to 165 mL ethanol and stir to dissolve completely. Cool solution to 0°C in an ice bath. 10. Add 165 mL ice-cold 2 N NaOH to mixture while stirring at 0°C. Stir 5 min, then warm mixture quickly to room temperature and let stand 10 min. The timing of this step is critical.
11. Immediately pour solution into a 1.5-L beaker that contains 450 mL Dowex AG50WX8 ion-exchange resin (pyridinium form) while stirring. The pH should now be near neutral.
12. Pour contents of the beaker into a 5 × 60–cm glass chromatography column filled with 50 mL Dowex AG50W-X8 ion-exchange resin (pyridinium form) and wash column with 3 L water, collecting eluate. 13. Using the rotary evaporator connected to water aspirator, evaporate eluate to dryness, co-evaporate twice with 100 mL water, and then crystallize the residue from water. 14. Examine reaction mixture by TLC (see Support Protocol 3) in 4:1 chloroform/methanol. An 80% to 90% yield (based on the starting quantity of guanosine) of N2-isobutyrylguanosine is expected. A band with an Rf of 0.4 should be visible following TLC.
15. Dry the N2-isobutyrylguanosine in a vacuum desiccator over phosphorus pentoxide before use. If desired, this intermediate can be stored at –20°C in a sealed dry container (stable for many months).
Prepare 2′,3′-O-dibutylstannylene-N 2-isobutyrylguanosine 16. Add 5.3 g (15 mmol) dry N2-isobutyrylguanosine and 3.75 g (15 mmol) dibutyltin oxide to 750 mL methanol in a 2-L round-bottom flask while stirring. 17. Attach a water-cooled reflux condenser, heat to boiling with a heating mantle, reflux mixture 45 min, and allow to cool. 18. Rotary evaporate resulting clear solution using a water aspirator to remove methanol, then dry the white solid, 2′,3′-O-dibutylstannylene-N2-isobutyrylguano-sine, in a vacuum desiccator over phosphorus pentoxide. A yield of 8 g is expected. If desired, this intermediate can be stored at –20°C in a sealed dry container (stable for many months).
Prepare 2′-O-(2-nitrobenzyloxymethyl)-N2-isobutyrylguanosine 19. Add 6.51 g (11.2 mmol) 2′,3′-O-dibutylstannylene-N2-isobutyrylguanosine to 100 mL anhydrous dimethylformamide in a 500-mL round-bottom flask, while stirring to dissolve. Heat mixture to 60°C with a heating mantle. 20. Add freshly prepared 2-nitrobenzyl chloromethyl ether (from 16 mmol 2-nitrobenzyl methylthiomethyl ether as described; see Support Protocol 1) dropwise over a 5-min period while stirring at 60°C. Seal flask and stir 2 hr at room temperature.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.17 Current Protocols in Nucleic Acid Chemistry
Supplement 3
21. Add 5 mL anhydrous pyridine, followed by 2 mL water while stirring. Stir 20 min at room temperature. 22. Concentrate mixture using the rotary evaporator connected to a vacuum pump to remove as much dimethylformamide as possible. If desired, this intermediate can be stored at –20°C in a sealed dry container (stable for many months).
Purify 2′-O-(2-nitrobenzyloxymethyl)-N2-isobutyrylguanosine 23. Dissolve residue in a minimum volume of anhydrous pyridine and, using a Pasteur pipet, transfer it dropwise onto 10 g silica gel 60 in a large petri plate. Allow wet silica to dry in the moving airstream inside a fume hood. An overnight drying time should be adequate if most of the dimethylformamide was removed and the minimum amount of pyridine was used.
24. Pulverize the dry, coated, crusty silica. Layer powder onto a 2.5 × 25–cm glass chromatography column and elute with 100 mL chloroform, followed by 200 mL of 2% methanol in chloroform, 200 mL of 4% methanol in chloroform, and 6% methanol in chloroform until all product is off the column (see Support Protocol 3). 25. Monitor fractions by TLC in 9:1 chloroform/methanol. 26. Combine appropriate fractions and rotary evaporate to dryness using a water aspirator. 27. Repeat steps 23 to 26, except use 2.5 g silica gel 60 in a 2.5 × 30–cm glass chromatography column and elute with 100 mL of 2% methanol in chloroform, 100 mL of 4% methanol in chloroform, 200 mL of 6% methanol in chloroform, then 8% methanol in chloroform. A yield of 1.7 g (30% of the starting quantity of 2′,3′-O-dibutylstannylene-N2-isobutyrylguanosine) is expected. If desired, this intermediate can be stored at –20°C in a sealed dry container (stable for many months).
28. Dissolve dry 2′-O-(2-nitrobenzyloxymethyl)-N 2-isobutyrylguanosine in a minimal amount of 80% aqueous acetonitrile with heating. 29. Using the rotary evaporator connected to a water aspirator, co-evaporate several times with acetonitrile to a volume of ~5 mL until crystallization of the desired 2′-isomer occurs. Additional crops may be obtained that require recrystallization. The 2′-isomer has a melting point of 176° to 177°C. If desired, this intermediate can be stored at –20°C in a sealed dry container (stable for many months).
Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N2isobutyrylguanosine 30. Using the rotary evaporator connected to vacuum pump, dry 1.2 g (2.32 mmol) 2′-O-(2-nitrobenzyloxymethyl)-N2-isobutyrylguanosine by two co-evaporations with 30 mL anhydrous pyridine. 2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
31. Dissolve residual oil in 30 mL anhydrous pyridine, then add 0.39 mL (2.8 mmol) triethylamine and 0.94 g (2.8 mmol) 4,4′-dimethoxytrityl chloride. Stir 3 hr at room temperature.
2.5.18 Supplement 3
Current Protocols in Nucleic Acid Chemistry
32. Add 0.5 mL methanol and, after 10 min, rotary evaporate using a vacuum pump to remove solvents. 33. Dissolve residue in 150 mL ethyl acetate and extract three times with 100 mL of 1 M NaHCO3 and once with 100 mL of 2 M NaCl. 34. Repeat step 8, using 5 g of anhydrous sodium sulfate. 35. Layer ~1-g portions of this material dissolved in a minimal amount of chloroform on 2.5 × 30–cm silica gel columns and elute with a 1-L stepwise gradient of 0% to 1% methanol in chloroform containing 0.25% pyridine. 36. Monitor fractions by TLC in 2:1 ethyl acetate/hexane. 37. Using the rotary evaporator connected to a water aspirator, evaporate appropriate fractions to produce 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N2isobutyrylguanosine. A yield of 1.8 g is expected.
38. Store the pure protected nucleoside in the dark at −20°C in a sealed container containing a trace of pyridine (stable for many months). PREPARATION OF N-PROTECTED 5′-O-(4,4′-DIMETHOXYTRITYL)2′-O-(tert-BUTYLDIMETHYLSILYL) NUCLEOSIDES The following protocols describe the preparation of an alternative set of ribonucleoside derivatives, utilizing the tert-butyldimethylsilyl group for protection of their 2′-hydroxyls (Figure 2.5.6). In the cases of adenosine and guanosine, the exocyclic amine functions of the nucleobases are protected by phenoxyacetyl groups; these form part of a quick deprotection strategy (see Commentary). As an adjunct to the synthesis procedures detailed below, information regarding the properties of the tert-butyldimethylsilyl-protected nucleosides can be found in Tables 2.5.5 and 2.5.6; these data should prove useful in characterizing the title compounds and their synthetic intermediates. CAUTION: Chromatographic solvents used in these protocols are flammable. Avoid spills and work in a well-vented fume hood away from potential ignition sources.
DMTrO
B
O
H3C TBDMS =
HO
OTBDMS
H3C
O HN
O B= N
N
O
uracil-1-yl
CH3
O Ph N O
4
N -benzoylcytosin-1-yl
OPh
HN
N
NH
CH3
H3C C Si
N 6
O N
N
N
N
N -phenoxyacetyladenin-9-yl
NH N
N H
O OPh
2
N -phenoxyacetylguanin-9-yl
Figure 2.5.6 The four 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl) ribonucleosides. The general structure of these ribonucleosides is in the upper-left corner and the four bases (B) are shown below. DMTr is the 4,4′-dimethoxytrityl group (Fig. 2.5.1), and TBDMS is the tert-butyldimethylsilyl group.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.19 Current Protocols in Nucleic Acid Chemistry
Supplement 3
Table 2.5.5 Rf Values of tert-Butyldimethylsilyl-Protected Ribonucleosides and Their Precursors on Merck Silica Gel 60 F254 TLC Platesa
Ribonucleosideb
Rf value
Solvent system
APa
0.60 0.32 0.28 0.30 0.82 0.55 0.22 0.77 0.82 0.45
4:1 methylene chloride/methanol 4:1 methylene chloride/methanol 9:1 chloroform/methanol 9:1 chloroform/methanol 9:1 methylene chloride/methanol 9:1 methylene chloride/methanol 3:1 diethyl ether/hexane 19:1 chloroform/methanol 1:1 methylene chloride/ethyl acetate 1:1 methylene chloride/ethyl acetate
GPa 5′DMTrU 5′DMTrCBz 5′DMTrAPa 5′DMTrGPa 5′DMTrU2′TBDMS 5′DMTrCBz2′TBDMS 5′DMTrAPa2′TBDMS 5′DMTrGPa2′TBDMS a
Data are from Hakimelahi et al. (1982) and Chaix et al. (1989). Abbreviations: A, adenosine; C, cytidine; G, guanosine; U, uridine; Bz, benzoyl; DMTr, 4,4′-dimethoxytrityl; Pa, phenoxyacetyl; TBDMS, tert-butyldimethylsilyl. b
CAUTION: Use fresh diethyl ether when removal of this solvent by evaporation is required, otherwise explosive peroxides may develop. NOTE: Excellent chromatographic separations are obtained using the fine grade of silica gel recommended in Alternate Protocols 1 through 4. However, with small column diameters, solvents must be pushed through the silica by the application of external pressure, so flash chromatography columns are required. In other respects, the separation methods are based on information provided in Hakimelahi et al. (1982), Chaix et al. (1989), and Sinha et al. (1993). ALTERNATE PROTOCOL 1
Synthesis of 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)uridine In this protocol, uridine is converted into its 5′-O-(4,4′-dimethoxytrityl) derivative, which, upon reaction with tert-butyldimethylsilyl chloride in the presence of silver nitrate as catalyst, forms predominantly the desired 2′-O-(tert-butyldimethylsilyl) isomer. The reaction scheme is shown in Figure 2.5.7.
Table 2.5.6 1H-NMR Chemical Shiftsa of tert-Butyldimethylsilyl-Protected Purine Ribonucleosides and Their Synthetic Intermediatesb
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
Hydrogen
APa
GPa
5′DMTrAPa 5′DMTrGPa
5′DMTrAPa2′ TBDMS
5′DMTrGPa2′ TBDMS
H1′ H2′ H3′ H4′ H5′′ H5′ H2 H8
6.21 4.98 4.55 4.30 3.92 3.92 8.70 8.76
6.01 4.78 4.54 4.22 3.91 3.91 NA 8.27
6.27 5.12 4.76 4.39 3.54 3.54 8.70 8.61
6.27 5.24 4.64 4.40 3.58 3.57 8.71 8.62
6.06 4.93 4.52 4.34 3.57 3.52 NA 8.18
6.05 4.87 4.59 4.33 3.51 3.51 NA 8.12
a The internal reference for 1H-NMR spectra was tetramethylsilane at 0 ppm. The solvent was acetone-d6. All shifts are measured in ppm. These data, from Chaix et al. (1989), are useful and commonly observed resonances. b Abbreviations: A, adenosine; G, guanosine; DMTr, 4,4′-dimethoxytrityl; Pa, phenoxyacetyl; TBDMS, tert-butyldimethylsilyl; NA, not applicable.
2.5.20 Supplement 3
Current Protocols in Nucleic Acid Chemistry
O
O NH
HO
O
N
NH
O
DMTrO
DMTrCl
O
N
O
Pyridine HO
OH
HO
OH
O NH DMTrO
HO
Figure 2.5.7 uridine.
N
O
1. TBDMS-Cl/AgNO3/THF/Pyridine 2. Separation of isomers
O
OTBDMS
Preparation of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)uridine from
Materials Uridine Anhydrous pyridine, stored over coarse granules of calcium hydride 4,4′-Dimethoxytrityl chloride Methanol Methylene chloride 1 M NaHCO3 Anhydrous sodium sulfate 1:20 (v/v) chloroform/hexane 3 × 30–cm and 3 × 60–cm flash chromatography columns (with reservoirs and flow controller), packed with silica gel 60, 230 to 400 Mesh ASTM (see Support Protocol 3) Diethyl ether containing 0.25% (v/v) pyridine Ethyl acetate containing 0.25% (v/v) pyridine 9:1 (v/v) chloroform/methanol Anhydrous tetrahydrofuran Silver nitrate tert-Butyldimethylsilyl chloride 3:1 (v/v) diethyl ether/hexane 2 M NaCl Diethyl ether 30% (v/v) ethyl acetate in hexane 100- and 250-mL round-bottom flasks Rotary evaporator connected interchangeably to water aspirator and vacuum pump 250-mL separatory funnels Filter paper, coarse porosity and fast flow rate (e.g., Quantitative Q8, Fisher) Additional reagents and equipment for TLC and column chromatography (see Support Protocol 3) Prepare 5′-O-(4,4′-dimethoxytrityl)uridine 1. Add 2.44 g (10 mmol) uridine to 20 mL anhydrous pyridine in a 250-mL round-bottom flask, while stirring to dissolve. Seal flask and cool solution in an ice bath. Protection of Nucleosides for Oligonucleotide Synthesis
2.5.21 Current Protocols in Nucleic Acid Chemistry
Supplement 3
2. Add 0.5 g (1.5 mmol) 4,4′-dimethoxytrityl chloride and reseal flask. Stir at 0°C. Each hour thereafter for 7 hr, add 0.5 g more 4,4′-dimethoxytrityl chloride, for a total of 4 g (∼12 mmol). Stir an additional 3 hr at 0°C. 3. Add 3 mL methanol and, after 10 min, concentrate mixture to a small volume using a rotary evaporator connected to a vacuum pump. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
4. Add 50 mL methylene chloride and stir. Slowly add 50 mL of 1 M NaHCO3 and stir until evolution of carbon dioxide ceases. CAUTION: Carbon dioxide is evolved.
5. Transfer layers to a 250-mL separatory funnel with 50 mL methylene chloride and run off the organic layer into a second funnel. Wash organic layer with 50 mL water, dry it over 5 g anhydrous sodium sulfate, filter through filter paper to remove salt, and rotary evaporate filtrate to a thick oil using a water aspirator. 6. Triturate oil with 10 mL of 1:20 chloroform/hexane to remove most of the residual pyridine. Decant the wash. Purify 5′-O-(4,4′-dimethoxytrityl)uridine 7. Apply residue to a 3 × 60–cm silica gel flash chromatography column packed in diethyl ether. Wash with 300 mL diethyl ether containing 0.25% pyridine, elute with ethyl acetate containing 0.25% pyridine at a rate of 3 mL/min, and collect 15-mL fractions as described (see Support Protocol 3). CAUTION: Diethyl ether is a highly flammable solvent that should be handled with extreme care.
8. Assay fractions by TLC (see Support Protocol 3) using 9:1 chloroform/methanol. 5′-O-(4,4′-Dimethoxytrityl)uridine has an Rf of 0.28 (Table 2.5.5).
9. Pool appropriate fractions, rotary evaporate to dryness using a water aspirator, and crystallize the residue (∼4.5 g) from diethyl ether. 5′-O-(4,4′-Dimethoxytrityl)uridine has a melting point of 111° to 112°C. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)uridine 10. Using the rotary evaporator connected to vacuum pump, dry 2.73 g (5 mmol) 5′-O-(4,4′-dimethoxytrityl)uridine by two co-evaporations with 25 mL anhydrous pyridine in a 100-mL round-bottom flask. 11. Dissolve residue in 50 mL anhydrous tetrahydrofuran, then add 1.5 mL (18.5 mmol) anhydrous pyridine and 1 g (6 mmol) silver nitrate. Stir until silver nitrate dissolves (∼5 min). 12. Add 1 g (6.6 mmol) tert-butyldimethylsilyl chloride and stir 5 hr at room temperature. 13. Examine reaction mixture by TLC in 3:1 diethyl ether/hexane. 2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
The 2′-isomer has an Rf of 0.22 and should be visible as the major product, running ahead of the 3′-isomer .
2.5.22 Supplement 3
Current Protocols in Nucleic Acid Chemistry
14. Filter reaction mixture through filter paper into 50 mL of 1 M NaHCO3, then extract with 300 mL methylene chloride. Extract organic layer with 100 mL of 2 M NaCl. 15. Dry organic layer over 10 g anhydrous sodium sulfate, filter through filter paper to remove salt, and rotary evaporate filtrate to an oil using a water aspirator. 16. Dissolve residue in 50 mL diethyl ether, filter to remove undissolved material, then remove solvent by rotary evaporation using a water aspirator without heating. 17. Layer mixture on a 3 × 30–cm silica gel flash chromatography column packed in hexane, elute using 30% ethyl acetate in hexane, and collect fractions as described. Some experimentation may be required to determine the precise mixture or gradient of ethyl acetate in hexane that gives optimum separation of isomers.
18. Monitor fractions by TLC using 3:1 diethyl ether/hexane and rotary evaporate fractions containing the 2′-isomer using a water aspirator to produce the pure product, 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)uridine. A yield of ∼2.3 g, or 70% based on the starting quantity of 5′-O-(4,4′-dimethoxytrityl)uridine, is expected. The product can be stored at –20°C in a sealed, dry container (stable for many months).
Synthesis of 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N4-benzoylcytidine
ALTERNATE PROTOCOL 2
In this protocol, cytidine is selectively benzoylated at its N4 position, then dimethoxytritylated to protect its 5′-hydroxyl. Subsequent reaction with tert-butyldimethylsilyl chloride in the presence of silver nitrate gives predominantly the 2′-O-(tert-butyldimethylsilyl) derivative. The reaction sequence is illustrated in Figure 2.5.8. Additional Materials (also see Alternate Protocol 1) Cytidine Benzoic anhydride Chloroform
O HN
NH2
N
N HO
HO
O
N
O
Benzoic anhydride/MeOH
HO
OH
O HO
N
O
OH
DMTrCl Pyridine
O
O
HN
HN N
DMTrO
O HO
N
N O
DMTrO
O
1. TBDMS-Cl/AgNO3/THF/Pyridine OTBDMS
2. Separation of isomers
HO
N
O
OH
Figure 2.5.8 Preparation of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N4-benzoylcytidine from cytidine.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.23 Current Protocols in Nucleic Acid Chemistry
Supplement 3
19:1 (v/v) chloroform/methanol 1-L round-bottom flasks Water-cooled reflux condenser Heating mantle Coarse sintered funnel Prepare N4-benzoylcytidine 1. Add 5 g (20.6 mmol) cytidine and 5 g (22.3 mmol) benzoic anhydride to 500 mL methanol in a 1-L round-bottom flask, while stirring. Fit flask with a water-cooled reflux condenser and heat mixture to a boil using a heating mantle. 2. At the end of each hour for the first 3 hr, briefly cool mixture and add an additional 5 g benzoic anhydride. Reflux for a total of 5 hr. Let mixture cool to 0°C. 3. Collect crystals of N4-benzoylcytidine by filtration through a coarse sintered funnel. Wash with 25 mL ice-cold methanol, then with diethyl ether to remove residual benzoic acid. A yield of 4.5 g product (with a melting point of 218° to 219°C) is expected. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
Prepare 5′-O-(4,4′-dimethoxytrityl)-N4-benzoylcytidine 4. Using a rotary evaporator connected to a vacuum pump, dry 3.5 g (10 mmol) N4-benzoylcytidine by two co-evaporations with 20 mL anhydrous pyridine. 5. Dissolve residue in 20 mL anhydrous pyridine in a 100-mL round-bottom flask while stirring. Seal flask and cool solution in an ice bath to 0°C. 6. Continue with dimethoxytritylation (see Alternate Protocol 1, steps 2 to 6), with the following exceptions: a. Increase methanol to 5 mL in step 3. b. Decrease methylene chloride and 1 M NaHCO3 to 25 mL in step 4. c. Wash organic layer with 50 mL of 2 M NaCl instead of water in step 5. d. Increase 1:20 chloroform/hexane to 50 mL in step 6. 7. Dissolve residue in 15 mL chloroform and apply to a 3 × 60–cm silica gel flash chromatography column packed in chloroform. Wash column with 100 mL chloroform and elute with 9:1 chloroform/methanol as described (see Support Protocol 3). 8. Assay fractions by TLC (see Support Protocol 3) in 9:1 chloroform/methanol. Combine fractions containing pure 5′-O-(4,4′-dimethoxytrityl)-N4 -benzoylcytidine and rotary evaporate to dryness using a water aspirator. This product can be crystallized (see Alternative Protocol 1, step 9), but this is probably not required. A yield of ∼5.5 g product (with a melting point of 109° to 111°C) is expected. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months). 2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
2.5.24 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Prepare 5′-O-(4,4′-dimethoxytrityl)-2 ′-O-(tert-butyldimethylsilyl)-N4-benzoylcytidine 9. Prepare the 2′-O-tert-butyldimethylsilyl isomer as described (see Alternate Protocol 1, steps 10 to 18), but dry 3.25 g (5 mmol) 5′-O-(4,4′-dimethoxytrityl)-N4 -benzoylcytidine in step 10, and use 19:1 chloroform/methanol for TLC in steps 13 and 18. A yield of 2.5 g is expected.
Synthesis of 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N6-phenoxyacetyladenosine
ALTERNATE PROTOCOL 3
In this protocol, the exocyclic amine at the N6 position of adenosine is protected as a phenoxyacetyl amide, then a dimethoxytrityl group is added to the 5′-hydroxyl. Treatment with tert-butyldimethylsilyl chloride and imidazole produces a mixture of the 2′- and 3′-O-tert-butyldimethylsilyl derivatives, which are separated by column chromatography. The reaction sequence is shown in Figure 2.5.9. Materials Adenosine Anhydrous pyridine, stored over coarse granules of calcium hydride Trimethylchlorosilane 1-Hydroxybenzotriazole Anhydrous acetonitrile Phenoxyacetyl chloride Concentrated ammonium hydroxide Chloroform 90% (v/v) ethanol 4,4′-Dimethoxytrityl chloride 9:1 (v/v) methylene chloride/methanol Methanol Ethyl acetate 1 M NaHCO3, 5°C 2 M NaCl Anhydrous sodium sulfate
O
N HO
O HO
N
N
N
N
1. Me3SiCl/Pyridine
O
N
O HO
N N
OH
O OPh N 1. TBDMS-Cl/Imidazole/Pyridine
OPh
HN
N N
N
DMTrCl Pyridine
O HN
DMTrO
HO
2. Phenoxyacetyl chloride, 1-Hydroxybenzotriazole, MeCN-Pyridine (1:1 v/v) 3. NH4OH
OH
N
OPh
HN
NH2
DMTrO
O
N
N N
2. Separation of isomers HO
OTBDMS
HO
OH
Figure 2.5.9 Preparation of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N6-phenoxyacetyladenosine from adenosine.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.25 Current Protocols in Nucleic Acid Chemistry
Supplement 3
3 × 30–cm and 3 × 60–cm flash chromatography columns (with reservoirs and flow controller), packed with silica gel 60, 230 to 400 Mesh ASTM (see Support Protocol 3) 2% to 10% (v/v) ethanol in ethyl acetate Imidazole tert-Butyldimethylsilyl chloride 1:1 (v/v) methylene chloride/ethyl acetate 1% and 35% (v/v) ethyl acetate in hexane Rotary evaporator connected interchangeably to water aspirator and vacuum pump 250-mL round-bottom flasks with rubber septa 5- and 50-mL syringes and vent needles 100-mL pressure-equalizing dropping funnel 500-mL separatory funnel Filter paper, coarse porosity and fast flow rate (e.g., Quantitative Q8, Fisher) Additional reagents and materials for TLC and column chromatography (see Support Protocol 3) Prepare N6-phenoxyacetyladenosine 1. Using a rotary evaporator connected to a vacuum pump, dry 5.34 g (20 mmol) adenosine by two co-evaporations with 40 mL anhydrous pyridine in a 250-mL round-bottom flask. 2. Suspend residue in 100 mL anhydrous pyridine and add 19 mL (150 mmol) trimethylchlorosilane dropwise while stirring. Stir 25 min at room temperature. 3. Using the rotary evaporator connected to a water aspirator, dry 4.16 g (31.6 mmol) 1-hydroxybenzotriazole in a second 250-mL round-bottom flask by three co-evaporations with 30 mL anhydrous acetonitrile. Add 10 mL anhydrous acetonitrile and 10 mL anhydrous pyridine and stir to suspend residue. The formation of colored side products is prevented by the use of 1-hydroxybenzotriazole.
4. Fit flask with a rubber septum. Using a 5-mL syringe and vent needle, add 4.2 mL (30 mmol) phenoxyacetyl chloride dropwise through the septum, and stir 5 min at room temperature. 5. Cool both flasks in an ice bath to 0°C, then, using a 50-mL syringe and a vent needle, add the contents of the first flask (containing the adenosine) dropwise through the septum to the acylating agent in the second flask. Stir overnight at room temperature. 6. Cool flask to 5°C and add 20 mL cold water, followed by 10 mL concentrated ammonium hydroxide. Stir 15 min at 5°C. 7. Immediately remove ammonia and solvents by rotary evaporation using a water aspirator and dissolve residual gum in 600 mL water. Extract aqueous solution twice with 300 mL chloroform, then rotary evaporate to dryness using a water aspirator. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
8. Crystallize product from 90% ethanol. 2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
A yield of 5.2 g N6-phenoxyacetyladenosine (or 65% based on the starting quantity of adenosine) is expected. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
2.5.26 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Prepare 5′-O-(4,4′-dimethoxytrityl)-N6-phenoxyacetyladenosine 9. Using the rotary evaporator connected to a vacuum pump, dry 4 g (10 mmol) N6-phenoxyacetyladenosine by two co-evaporations with 10 mL anhydrous pyridine in a 250-mL round-bottom flask. 10. Dissolve residue in 60 mL anhydrous pyridine. Put a stir-bar in the flask, fit it with a 100-mL pressure-equalizing dropping funnel, and cool mixture to 5°C. 11. Dissolve 3.73 g (11 mmol) 4,4′-dimethoxytrityl chloride in 40 mL anhydrous pyridine, then add it dropwise over a 2-hr period to the N6-phenoxyacetyladenosine while stirring. Let stand overnight at 5°C. 12. Examine solution by TLC (see Support Protocol 3) in 9:1 methylene chloride/methanol. The 5′-O-(4,4′-dimethoxytrityl) derivative is the major product.
13. Add 5 mL methanol, stir 5 min, then rotary evaporate reaction mixture to a slurry using a vacuum pump. 14. Using 200 mL ethyl acetate, transfer residue to a 500-mL separatory funnel. Extract twice with 100 mL cold (5°C) 1 M NaHCO3 and once with 100 mL of 2 M NaCl. 15. Dry organic layer over 5 g anhydrous sodium sulfate, filter through filter paper to remove salt, and rotary evaporate filtrate to a yellow foam using a water aspirator. If desired, this intermediate can be stored at –20°C in a sealed, dry container (stable for many months).
16. Layer material on a 3 × 60–cm silica gel flash chromatography column packed in ethyl acetate and elute initially with ethyl acetate, then with a stepwise gradient of 2% to 10% ethanol in ethyl acetate as described (see Support Protocol 3). Use 200-mL portions of ethyl acetate, then 2% ethanol, 4% ethanol, and so on. 17. Monitor fractions by TLC using 9:1 methylene chloride/methanol and rotary evaporate appropriate fractions using a water aspirator to produce the pure product, 5′-O-(4,4′-dimethoxytrityl)-N6-phenoxyacetyladenosine. A 55% yield is expected based on the starting quantity of N6-phenoxyacetyladenosine.
Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N6-phenoxyacetyladenosine 18. Using the rotary evaporator connected to a vacuum pump, dry 2.8 g (4 mmol) 5′-O-(4,4′-dimethoxytrityl)-N6-phenoxyacetyladenosine by two co-evaporations with 10 mL anhydrous pyridine. Dissolve residue in 40 mL anhydrous pyridine. 19. Add 0.8 g (11.8 mmol) imidazole, followed by 0.35 g (2.4 mmol) tert-butyldimethylsilyl chloride. Stir 24 hr at room temperature. 20. Add another 0.35 g tert-butyldimethylsilyl chloride and stir 24 hr at room temperature. 21. Repeat step 20. 22. Check reaction by TLC in 1:1 methylene chloride/ethyl acetate. The starting material should be completely converted into its 2′-silyl, 3′-silyl, and 2′,3′-disilyl derivatives. The 2′,3′-disilyl derivative is the fastest running product, followed by the 2′-silyl derivative, and then the 3′-silyl derivative.
23. Cool mixture to 0°C and add 5 mL water.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.27 Current Protocols in Nucleic Acid Chemistry
Supplement 3
24. Rotary evaporate mixture to dryness using a vacuum pump, dissolve residue in 300 mL chloroform, and extract chloroform solution twice with 150 mL cold 1 M NaHCO3 and once with 150 mL water. Remove chloroform by rotary evaporation using a water aspirator. 25. Layer residual mixture on a 3 × 30–cm silica gel flash chromatography column packed in 1% ethyl acetate in hexane and elute with 35% ethyl acetate in hexane. Some experimentation may be required to determine the precise mixture or gradient of ethyl acetate in hexane that gives optimum separation of isomers.
26. Monitor fractions by TLC using 1:1 methylene chloride/ethyl acetate, combine fractions containing pure 2′-isomer, and rotary evaporate them using a water aspirator to produce the pure product, 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N6-phenoxyacetyladenosine. A yield of 35%, based on the starting quantity of 5′-O-(4,4′-dimethoxytrityl)-N6-phenoxyacetyladenosine, is expected. The product can be stored at –20°C in a sealed, dry container (stable for many months). ALTERNATE PROTOCOL 4
Synthesis of 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N2-phenoxyacetylguanosine In this protocol, the exocyclic amine at the N2 position of guanosine is protected as a phenoxyacetyl amide, then a 4,4′-dimethoxytrityl group is added to the 5′-hydroxyl. Treatment with tert-butyldimethylsilyl chloride and imidazole gives a mixture of the 2′- and 3′-O-tert-butyldimethylsilyl derivatives, which are separated by column chromatography. The reaction sequence is shown in Figure 2.5.10. This protocol is performed by following steps 1 to 26 of Alternate Protocol 3, with the exceptions outlined below. Additional Materials (also see Alternate Protocol 3) Guanosine hydrate 50% (v/v) ethyl acetate in hexane Oven, 130°C
O N HO
O HO
O N
NH
N
N
NH2
1. Me3SiCl/Pyridine
HO
2. Phenoxyacetyl chloride, 1-Hydroxybenzotriazole, MeCN-Pyridine (1:1 v/v) 3. NH4OH
OH
O OH
N
NH N
O OPh
N H
OH
DMTrCl Pyridine O N N
DMTrO
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
O
O NH
N
N H
N
O OPh 1. TBDMS-Cl, Imidazole/Pyridine
DMTrO
O
N
NH N
N H
O OPh
2. Separation of isomers HO
OTBDMS
HO
OH
Figure 2.5.10 Preparation of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N2-phenoxyacetylguanosine from guanosine.
2.5.28 Supplement 3
Current Protocols in Nucleic Acid Chemistry
1a. Dry guanosine hydrate to constant weight in an oven at 130°C. Dry guanosine can be stored for many months in a sealed container at room temperature.
2a. Suspend 5.66 g (20 mmol) dry guanosine in 100 mL anhydrous pyridine and add 19 mL (150 mmol) trimethylchlorosilane dropwise while stirring. Stir 25 min at room temperature. 9a. Using a rotary evaporator connected to a vacuum pump, dry 4.12 g (10 mmol) of N2-phenoxyacetylguanosine by two co-evaporations with 10 mL anhydrous pyridine in a 250-mL round-bottom flask. 18a. Using the rotary evaporator connected to a vacuum pump, dry 2.9 g (4 mmol) 5′-O-(4,4′-dimethoxytrityl)-N2-phenoxyacetylguanosine by two co-evaporations with 10 mL anhydrous pyridine. Dissolve residue in 40 mL anhydrous pyridine. 25a. Layer residual mixture on a 3 × 30–cm silica gel flash chromatography column packed in hexane and elute with 50% ethyl acetate in hexane as described. Expected yields are: 60% N2-phenoxyacetylguanosine, 50% 5′-O-(4,4′-dimethoxytrityl)N2-phenoxyacetylguanosine, and 32% 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N2-phenoxyacetylguanosine, all based on the amount of starting material.
PREPARATION OF 2-NITROBENZYL CHLOROMETHYL ETHER 2-Nitrobenzyl chloromethyl ether is the alkylating agent used to convert nucleosides to their 2′-O-(2-nitrobenzyloxymethyl) derivatives. It is moderately unstable and must be prepared fresh each time it is used. The reaction is shown in Figure 2.5.11. The precursor, 2-nitrobenzyl methylthiomethyl ether, can be synthesized in quantity and stored for many months in the dark at −20°C.
SUPPORT PROTOCOL 1
CAUTION: A foul-smelling aqueous layer is produced in step 7. Work in a fume hood with yellow lights. Materials 2-Nitrobenzyl alcohol Dimethyl sulfoxide, dried over 4A molecular sieves Acetic anhydride Acetic acid 1:1 (v/v) diethyl ether/hexane Sodium bicarbonate 1:1 (v/v) ethyl acetate/hexane Saturated sodium bicarbonate 2 M NaCl Anhydrous sodium sulfate 5 × 60–cm chromatography column packed with silica gel 60, 70 to 230 mesh ASTM, in hexane to a bed height of 56 cm (see Support Protocol 3) 1%, 5%, 10%, and 15% (v/v) diethyl ether in hexane
NO2 OH
DMSO Ac2O/AcOH
NO2 O
SCH3
2-Nitrobenzyl methylthiomethyl ether
Figure 2.5.11
SO2Cl2
NO2
CH2Cl2
O
Cl
2-Nitrobenzyl chloromethyl ether
Preparation of 2-nitrobenzyl chloromethyl ether from 2-nitrobenzyl alcohol.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.29 Current Protocols in Nucleic Acid Chemistry
Supplement 3
Anhydrous methylene chloride Ethanol (for dry ice/ethanol bath) 1 M SO2Cl2 in methylene chloride Anhydrous dimethylformamide, store over 4A molecular sieves 500-mL separatory funnel Filter paper, coarse porosity and fast flow rate (e.g., Quantitative Q8, Fisher) Rotary evaporator connected to water aspirator 250-mL round-bottom flask 50-mL pressure-equalizing dropping funnel Additional reagents and equipment for TLC and column chromatography (see Support Protocol 3) CAUTION: The sulfuryl chloride (SO2Cl2) solution is corrosive and extremely toxic. Prepare 2-nitrobenzyl methylthiomethyl ether 1. Dissolve 23 g (150 mmol) 2-nitrobenzyl alcohol in 150 mL dry dimethyl sulfoxide in a 1-L flask. 2. Add 108 mL acetic anhydride and 77 mL acetic acid and stir to dissolve. Allow the homogeneous, yellow-tinted solution to stand 24 hr at room temperature in the dark. 3. Examine the mixture by TLC (see Support Protocol 3) using 1:1 diethyl ether/hexane. The fastest-running of the three UV-absorbing bands is the desired product.
4. Pour reaction mixture into a 500-mL separatory funnel, then add it dropwise over a 2-hr period to a vigorously stirred slurry of 330 g sodium bicarbonate in 1.5 L water. Stir 24 hr in the dark. The evolution of carbon dioxide is well controlled by the dropwise addition of the mixture.
5. Allow the oily product to settle to the bottom of the container, then decant the aqueous supernatant. 6. Dissolve oil in 400 mL of 1:1 ethyl acetate/hexane and extract this solution three times with 100 mL saturated sodium bicarbonate and once with 100 mL of 2 M NaCl. 7. Dry organic layer over 10 g anhydrous sodium sulfate, filter through filter paper to remove salt, and remove volatile organic solvents on a rotary evaporator connected to a water aspirator. The large volume of foul-smelling aqueous supernatant can be deodorized by treatment with household bleach before disposal.
Purify 2-nitrobenzyl methylthiomethyl ether 8. Layer yellow residue on a 5 × 60–cm silica gel column packed in 1% diethyl ether in hexane and elute at a rate of 5 to 10 mL/min using a stepwise gradient consisting of 500 mL of 1% diethyl ether in hexane followed by 1 L each of 5%, 10%, and 15% diethyl ether in hexane (see Support Protocol 3). Allow the first liter of eluate to run into a flask, then collect 250-mL fractions until the product begins to emerge, as judged by TLC using 1:1 diethyl ether/hexane. Thereafter, collect 100-mL fractions. 2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
CAUTION: These solvents are flammable.
9. Assay fractions by TLC using 1:1 diethyl ether/hexane. Pool fractions containing the pure product, 2-nitrobenzyl methylthiomethyl ether.
2.5.30 Supplement 3
Current Protocols in Nucleic Acid Chemistry
10. Remove volatile solvents on the rotary evaporator to afford a viscous, yellow oil. A yield of 15 to 20 g is expected.
11. Store this stock reagent at −20°C in a sealed container in the dark (stable for many months). 1
H- and 13C-NMR data for this material can be found in Schwartz et al. (1992).
Prepare 2-nitrobenzyl chloromethyl ether 12. Dissolve 3.4 g (16 mmol) 2-nitrobenzyl methylthiomethyl ether in 30 mL anhydrous methylene chloride in a 250-mL round-bottom flask and fit flask with a 50-mL pressure-equalizing dropping funnel. 13. Cool mixture to −78°C using a dry ice/ethanol bath. 14. Using the pressure-equalizing dropping funnel, add 16 mL of 1 M SO2Cl2 in methylene chloride dropwise over a 5-min period while stirring at −78°C. Continue to cool the mixture and stir 30 min. 15. Quickly transfer flask to rotary evaporator and remove solvent and volatile products. 16. Repeat rotary evaporation three times with 20 mL anhydrous methylene chloride, then add 15 mL anhydrous dimethylformamide and use the clear solution immediately. PREPARATION OF PENTAFLUOROPHENYL BENZOATE Pentafluorophenyl benzoate is used to selectively protect cytidine at N4 in Basic Protocol 2.
SUPPORT PROTOCOL 2
Materials 2,3,4,5,6-Pentafluorophenol Anhydrous dimethylformamide, store over 4A molecular sieves Benzoic acid 1,3-Dicyclohexylcarbodiimide Ethyl acetate Ethanol Phosphorus pentoxide Filter paper, coarse porosity and fast flow rate (e.g., Quantitative Q8, Fisher) Rotary evaporator connected interchangeably to water aspirator and vacuum pump Coarse sintered funnel CAUTION: Pentafluorophenol, pentafluorophenyl benzoate, and 1,3-dicyclohexylcarbodiimide are toxic irritants. Avoid skin contact. 1. Add 2.9 g (15.7 mmol) 2,3,4,5,6-pentafluorophenol to a flask containing 7 mL anhydrous dimethylformamide and stir to dissolve. Stopper flask to minimize exposure to atmospheric moisture and cool in an ice bath. 2. Add 1.92 g (15.7 mmol) benzoic acid, followed by 3.5 g (17.9 mmol) 1,3-dicyclohexylcarbodiimide. Stir 1 hr at 0°C. A white suspension will be visible.
3. Warm mixture to room temperature and remove precipitate by suction filtration through filter paper.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.31 Current Protocols in Nucleic Acid Chemistry
Supplement 3
4. Evaporate filtrate to dryness using a rotary evaporator under high vacuum (i.e., with a vacuum pump) and a water-bath temperature <40°C. 5. Dissolve residue in 20 mL ethyl acetate, filter through filter paper to remove undissolved solid, and evaporate filtrate to dryness using the rotary evaporator connected to a water aspirator. 6. Dissolve residue in ∼20 mL ethanol with gentle warming (<50°C). Evaporate to ∼10 mL using the rotary evaporator connected to water aspirator and cool to 0 °C. 7. Collect crystals of pentafluorophenyl benzoate by filtration through a coarse sintered funnel. Dry material over phosphorus pentoxide in a vacuum desiccator. 8. Store in an amber bottle at −20°C and make sure moisture is excluded (stable for many months). A yield of ∼2.5 g product (with a melting point of 76° to 78°C) is expected. SUPPORT PROTOCOL 3
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
CHROMATOGRAPHIC TECHNIQUES Some skill in various techniques of chromatography, both analytical and preparative, are required in these protocols. Reaction mixtures are invariably analyzed by thin-layer chromatography (TLC) on 2 × 8–cm or 6 × 8–cm aluminum-backed sheets of Merck silica gel 60 F254 (e.g., EM Science). A 2-µL sample of the mixture to be analyzed is applied with a micropipettor in a thin 1-cm line to the origin on the TLC plate. After blowing off excess solvent in a rapidly moving stream of cool air, chromatography is carried out using an appropriate mixture of solvents in a developing jar (e.g., Eastman Kodak). The plate is then dried and placed under short-wave UV light in a viewing box. The products should be visible as well-defined bands against the fluorescent background of the TLC plate. If they are not, the original sample may need to be diluted with acetonitrile or ethyl acetate and reanalyzed. It should also be noted that when the original mixture contains pyridine, as is often the case, the residue of this solvent is visible on the chromatogram as a dark, diffuse band, which can be removed by heating the developed plate in an oven at 140°C for a few minutes. This treatment also causes dimethoxytrityl compounds, of which there are many in these protocols, to develop a characteristic yellow color. As a general rule, all reactions and all column fractions should be monitored by TLC. Moreover, it is very important that a reference sample (100 to 200 µL) of each reaction mixture be removed and stored (at −20°C) for checking against column fractions during the purification process. For additional details on TLC, see APPENDIX 3D. Preparative chromatographic separations to purify products are carried out on silica gel (e.g., EM Science) packed in glass chromatography columns using the starting solvent. The type and mesh size of the silica gel is important and is specified in each protocol. Columns are generally packed to a bed height of 5 to 10 cm below their full length to allow loading of the compound mixtures. For additional details on column chromatography, including general packing instructions, see APPENDIX 3E. The sample is applied as a narrow band at the top of the column, and products are eluted with increasingly polar solvent mixtures. Many of the separations in this unit are effected using stepwise gradients. A gradient described as, for example, 1.2 L of 0% to 10% methanol in chloroform refers to elution with 200 mL chloroform, then with 200 mL of 2% methanol in chloroform, then with 200 mL of 4% methanol in chloroform, and so on up to 10% methanol in chloroform. At that point, elution is continued with the 10% solvent mixture, if necessary, until all product is removed from the column, as determined by TLC. The columns are run at such a rate that elution is complete in 6 to 8 hr. The eluate emerging from the column is collected as 15- to 20-mL fractions in 18 × 150–mm disposable glass
2.5.32 Supplement 3
Current Protocols in Nucleic Acid Chemistry
culture tubes using a fraction collector. The fractions are then assayed by TLC to locate the desired product. To reduce the number of analyses, every fifth fraction, for example, can be analyzed by TLC, and then these results can be used to narrow down the remaining fractions to assay. COMMENTARY Background Information Chemical synthesis of RNA is now almost as simple as that of DNA. However, it requires a specialized set of monomers derived from the four common ribonucleosides U, C, A, and G; each of these monomers must carry an extra protecting group to prevent reaction at its 2′hydroxyl. The protocols in this unit describe the syntheses of two useful sets of protected ribonucleosides. These products are ready to be converted into their corresponding phosphoramidites for use in RNA synthesis (UNIT 3.7; Sinha et al., 1993). 2-Nitrobenzyloxymethyl protection The first set consists of the 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl) derivatives of U and of N-protected C, A, and G. In Basic Protocols 1 and 3, respectively, the readily available nucleosides U and A are first converted into their 2′,3′-O-dibutylstannylene derivatives (Wagner et al., 1974). Their 2′,3′glycol systems are susceptible to monoalkylation after this step. The alkylation is carried out using 2-nitrobenzyl chloromethyl ether and a catalyst, tetra-n-butylammonium bromide. This reaction is nonselective, however, and results in formation of the 2′-O-(2-nitrobenzyloxymethyl) derivatives of U and A along with equal amounts of their respective 3′-isomers. In the case of adenosine, the 2′- and 3′-isomers can be separated chromatographically. The pure 2′-isomer is isolated and protected at its N6 position by benzoylation, using the transient protection method of Ti et al. (1982). Its 5′-hydroxyl is then protected by reaction with 4,4′-dimethoxytrityl chloride, to give 5′-O-(4,4′dimethoxytrityl)-2′ -O-(2-nitrobenzyloxymethyl)N6-benzoyladenosine. In contrast, the mixture of 2′- and 3′-O-(2nitrobenzyloxymethyl)uridines is first protected at the 5′-hydroxyls, and then chromatographically separated, affording pure 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)uridine. In Basic Protocol 4, guanosine is alkylated after protection of its exocyclic amine with an isobutyryl group (Ohtsuka et al., 1978).
Subsequent conversion to its dibutylstannylene derivative and alkylation in the absence of a catalyst leads to exclusive production of the 2′-O-(2-nitrobenzyloxymethyl) isomer. This material is purified and 5′-protected to give 5′-O(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-N2-isobutyrylguanosine. Cytidine, because of the susceptibility of its aminopyrimidone ring to side-alkylation (Wagner et al., 1974), cannot be derivatized in the same way as the other ribonucleosides. Accordingly, some of the 5′-O-(4,4′-dimethoxytrityl)2′-O-(2-nitrobenzyloxymethyl)uridine obtained in Basic Protocol 1 is converted directly into its corresponding cytidine derivative in Basic Protocol 2, using the substitution procedure of Sung (1982). Its N4 amino group is then selectively benzoylated using pentafluorophenyl benzoate (Igolen and Morin, 1980) to give 5′-O-(4,4′-dimethoxytrityl)-2′-O(2-nitrobenzyloxymethyl)-N4-benzoylcytidine. After conversion to their respective phosphoramidites, the protected nucleosides can be used in the construction of RNA (UNIT 3.7). The particular advantage of these amidites lies in their short coupling times; they allow RNA to be synthesized almost as rapidly as DNA (Schwartz et al., 1992). Although alternative groups for protecting the 2′-hydroxyls of ribonucleosides are now available that allow coupling times to be reduced nearly to those for protected deoxyribonucleoside phosphoramidites, this was not the case as recently as 3 to 5 years ago. Upon completion of synthesis, the 2-nitrobenzyloxymethyl groups are removed from the resulting oligoribonucleotide products by irradiation with long-wave UV light. tert-Butyldimethylsilyl protection The second set of protected ribonucleosides has the 2′-hydroxyl protected with the tertbutyldimethylsilyl group (Alternate Protocols 1 to 4). This particular group has been used extensively in RNA synthesis (Wincott et al., 1995), and phosphoramidite monomers incorporating it are widely available commercially. The strategy for preparing 2′-O-(tert-butyldimethylsilyl) ribonucleosides in the laboratory
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.33 Current Protocols in Nucleic Acid Chemistry
Supplement 3
differs in a number of respects from that used for the corresponding nitrobenzyloxymethyl derivatives. Again, the starting materials are the four common ribonucleosides, but in this case the exocyclic amines on C, A, and G are all protected first. Cytidine is selectively benzoylated at its N4 position with benzoic anhydride in boiling methanol (Watanabe and Fox, 1966); adenosine and guanosine are phenoxyacetylated at their N6 and N2 positions, respectively, using the transient protection method (Ti et al., 1982). These N-acyl derivatives and uridine are then dimethoxytritylated to protect their 5′ positions (Hakimelahi et al., 1982; Chaix et al., 1989). The silyl groups are introduced last, by treating the 5′-O-(4,4′-dimethoxytrityl)-N-acyl nucleosides with tert-butyldimethylsilyl chloride (Hakimelahi et al., 1982; Chaix et al., 1989). Mixtures of the 2′- and 3′-isomers are formed in each case, from which the pure 2′O-(tert-butyldimethylsilyl) nucleosides are isolated by column chromatography. They can then be converted into their phosphoramidites using standard procedures (Sinha et al., 1984, 1993). The tert-butyldimethylsilyl groups can be quantitatively removed from oligoribonucleotides by treatment with tetra-n-butylammonium fluoride (Usman et al., 1987). They are also somewhat sensitive to ammonia, however, and their loss during the ammonia treatment that is part of the standard oligoribonucleotide deprotection procedure has caused problems in the past by leading to strand cleavage of the product RNA. Much effort has been expended, therefore, in finding ways to make the ammonolysis conditions less severe. One such method is replacement of the traditional but relatively stable benzoyl and isobutyryl groups on A and G, respectively, with more base-labile ones such as phenoxyacetyl (Chaix et al., 1989) and tert-butylphenoxyacetyl (Sinha et al., 1993). It is the phenoxyacetyl derivatives whose preparation is described in this unit.
Compound Characterization
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
Relevant Rf values and available NMR data are shown in Tables 2.5.1 to 2.5.6. Other properties, such as the melting points of crystalline compounds, can be found at the appropriate places in the protocols, and further data are provided in the cited literature. Methods for distinguishing and identifying 2′- and 3′-isomers of derivatized ribonucleosides by NMR are described in Fromageot et al. (1966) and Chaix et al. (1989).
Critical Parameters The success of the operations described here can be affected by a number of critical factors. For example, many of the reagents and reaction mixtures are sensitive to water, and precautions should be taken to exclude moisture. All reactions, unless otherwise specified, should be conducted with dry starting material and anhydrous solvents. The air inlet to the rotary evaporator should be connected to a drying tower, so that no moist air is drawn into the apparatus. If necessary, materials should be co-evaporated with dry solvent a few times before being redissolved in the required reaction volume. Flasks should be opened only long enough for addition or removal of materials, and cold flasks or reagent bottles should always be allowed to reach room temperature before being opened. Some of the protecting groups used in these protocols are labile, as indeed they are usually designed to be. The 4,4′-dimethoxytrityl group, for example, is removed rapidly under acidic conditions such as those found on some types of silica TLC plates, in silica-gel columns, and as contaminants in solvents such as chloroform. Detritylation and loss of product can be prevented under these circumstances by adding trace amounts of pyridine. The phenoxyacetyl group, on the other hand, is quite base-labile, and alkaline treatments should be strictly limited. The 2′-O-(tert-butyldimethylsilyl) ribonucleosides should also be treated with care. The tert-butyldimethylsilyl group is known to isomerize between the 2′- and 3′-hydroxyls of the ribose ring in protic solvents such as methanol and in aqueous solutions such as pyridine in water; these environments should be avoided. The 2-nitrobenzyloxymethyl group is sensitive to UV light and is slowly removed even under normal conditions of laboratory illumination. Exposure of nitrobenzyloxmethyl compounds to UV should be minimized by replacing the overhead white fluorescent bulbs in the work area with yellow ones. Flasks and chromatography columns should be wrapped in foil, and storage containers should be kept in the dark. The most important consideration of all is the requirement for absolute isomeric purity of the 2′-protected ribonucleosides described here. These products should be examined scrupulously by loading them heavily on TLC plates and looking for the presence of traces of contaminating 3′-isomer after chromatogra-
2.5.34 Supplement 3
Current Protocols in Nucleic Acid Chemistry
phy. If any of the 3′-isomer is found, the suspect nucleoside should be repurified; it is better to sacrifice a small amount of yield for absolute purity. The consequences of isomeric contamination can be put in perspective by realizing that the presence of the 3′-isomer at a level of 1% in the monomers means that, for an oligonucleotide 100 units long, not a single molecule is likely to possess all natural 3′→5′ linkages.
Anticipated Results The experimentalist can expect to obtain one to several grams of each protected nucleoside, ready for phosphitylation and use in an automated synthesizer. By repetition and/or judicious scaling up of the reactions, one can accumulate multigram quantities. Each gram of material corresponds to upwards of 100 nucleotide incorporations on a 0.2-µmol synthesis scale.
Time Considerations The many partially protected intermediates in these protocols can be safely stored either as crude mixtures ready for chromatographic purification or as purified materials awaiting the next synthesis step. They should be stored in sealed dry containers at −20°C and are stable for many months under these conditions. Within the protocols, each set of preparation and purification steps can be completed in 1 to 2 days, with the following exceptions: preparing the cytidine and benzoylcytidine derivatives in Basic Protocol 2 requires 6 and 7 days, respectively; purifying the isobutyryl guanosine derivative in Basic Protocol 4 requires 3 days; and preparing the tert-butyldimethylsilyl derivatives in Alternate Protocols 3 and 4 requires 4 days. Support Protocols 1 and 2 can be completed in 3 to 4 days and 1 day, respectively. After some familiarity with the methods has been achieved, ∼2 weeks should be required to complete each protocol.
Literature Cited Benneche, T., Strande, P., and Undheim, K. 1983. A new synthesis of chloromethyl benzyl ethers. Synthesis 1983:762-763. Chaix, C., Duplaa, A.M., Molko, D., and Teoule, R. 1989. Solid phase synthesis of the 5′-half of the initiator t-RNA from B. subtilis. Nucl. Acids Res. 17:7381-7393. Fromageot, H.P.M., Griffin, B.E., Reese, C.B., Sulston, J.E., and Trentham, D.R. 1966. Orientation of ribonucleoside derivatives by proton magnetic resonance spectroscopy. Tetrahedron 22:705710.
Hakimelahi, G.H., Proba, Z.A., and Ogilvie, K.K. 1982. New catalysts and procedures for the dimethoxytritylation and selective silylation of ribonucleosides. Can. J. Chem. 60:1106-1113. Igolen, J. and Morin, C. 1980. Rapid synthesis of protected 2′-deoxycytidine derivatives. J. Org. Chem. 45:4802-4804. Ohtsuka, E., Nakagawa, E., Tanaka, T., Markham, A.F., and Ikehara, M. 1978. Studies on transfer ribonucleic acids and related compounds. XXI. Synthesis and properties of guanine rich fragments from E. coli tRNAfMet 5′ end. Chem. Pharm. Bull. 26:2998-3006. Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., deBear, J.S., and Gough, G.R. 1992. Rapid synthesis of oligoribonucleotides using 2′-O-(2-nitrobenzyloxymethyl)-protected monomers. BioMed. Chem. Lett. 2:1019-1024. Sinha, N.D., Biernat, J., McManus, J., and Köster, H. 1984. Polymer support oligonucleotide synthesis XVIII: Use of β-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucl. Acids Res. 12:45394557. Sinha, N.D., Davis, P., Usman, N., Perez, J., Hodge, R., Kremsky, J., and Casale, R. 1993. Labile exocyclic amine protection of nucleosides in DNA, RNA and oligonucleotide analog synthesis facilitating N-deacylation, minimizing depurination and chain degradation. Biochimie 75:1323. Sung, W.L. 1982. Synthesis of 4-(1,2,4-triazol-1yl)pyrimidin-2(1H)-one ribonucleotide and its application in synthesis of oligoribonucleotides. J. Org. Chem. 47:3623-3628. Ti, G.S., Gaffney, B.L., and Jones, R.A. 1982. Transient protection: Efficient one-flask synthesis of protected deoxynucleosides. J. Am. Chem. Soc. 104:1316-1319. Usman, N., Ogilvie, K.K., Jiang, M.-Y., and Cedergren, R.J. 1987. Automated chemical synthesis of long oligoribonucleotides using 2′-O-silylated ribonucleoside 3′-O-phosphoramidites on a controlled pore glass support: Synthesis of a 43-nucleotide sequence similar to the 3′-half molecule of an Escherichia coli formylmethionine tRNA. J. Am. Chem. Soc. 109:7845-7854. Wagner, D., Verheyden, J.P.H., and Moffatt, J.G. 1974. Preparation and synthetic utility of some organotin derivatives of nucleosides. J. Org. Chem. 39:24-30. Watanabe, K.A. and Fox, J.J. 1966. A simple method for selective acylation of cytidine on the 4-amino group. Angew. Chem., Int. Ed. Engl. 5:579-580. Wincott, F., DiRenzo, A., Shaffer, C., Grimm, S., Tracz, D., Workman, C., Sweedler, D., Gonzalez, C., Scaringe, S., and Usman, N. 1995. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucl. Acids Res. 23:2677-2684.
Protection of Nucleosides for Oligonucleotide Synthesis
2.5.35 Current Protocols in Nucleic Acid Chemistry
Supplement 3
Key References
Wincott et al., 1995. See above.
Schwartz et al., 1992. See above.
This publication describes some recent advances in RNA synthesis using the tert-butyldimethylsilyl group.
The general strategy involved in using the 2′-O-(2nitrobenzyloxymethyl protecting group is presented by this method’s developers. Usman et al., 1987. See above. The general strategy involved in using the 2′-O(tert-butyldimethylsilyl) protecting group is presented by this method’s developers.
Contributed by Tod J. Miller, Miriam E. Schwartz, and Geoffrey R. Gough Purdue University West Lafayette, Indiana
2′-OH-Protecting Groups That Are Photochemically Labile or Sensitive to Fluoride Ions
2.5.36 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Deoxyribo- and Ribonucleoside H-Phosphonates
UNIT 2.6
This unit includes a collection of four synthetic methods for nucleoside H-phosphonate building blocks and a variant on one of these syntheses. All the methods are quite efficient and experimentally simple, and they use readily available reagents. Depending on reactivity and reaction conditions, different methods may be preferred for preparation of different building blocks. The phosphonylation of protected nucleosides with the in situ–generated tris-(1-imidazolyl)phosphine (from phosphorus trichloride and imidazole), followed by hydrolysis of the formed nucleoside diimidazolyl phosphite intermediate, is described in Basic Protocol 1. This method (or its variants with other azoles) is probably the most widely used and can be recommended as a general basic method applicable for the preparation of both deoxyribo- and ribonucleoside 3′-H-phosphonates. Imidazole from the first published procedure (Garegg et al., 1986c) is preferred over the other azoles (e.g., triazole; Froehler et al., 1986) because it is less expensive and forms the least reactive species. Since tris-(1-imidazolyl)phosphine is a trifunctional reagent, it should be used in excess in the phosphonylation reaction to avoid the formation of symmetrical H-phosphonate diesters. There are several variants of this protocol that differ in the kind of azoles, external bases, or solvents used, including procedures for ribonucleoside building blocks that combine 2′-O-protection and 3′-O-phosphonylation. The Alternate Protocol describes one of these procedures (also see Commentary). In Basic Protocol 2, pyridinium H-pyrophosphonate, generated in situ from phosphorous acid and a condensing agent, is used. This one-step reaction is most likely carried out by a nucleophilic attack of nucleoside on a phosphorus center of H-pyrophosphonate. Usually 5 mol eq in excess of the nucleoside is used to speed up the reaction. The chemical nature of a condensing agent is of minor importance for the final yield of the H-phosphonate monoesters. Phosphonylation of ribonucleosides protected with 2′-O-tertbutyldimethylsilyl (2′-O-TBDMS) occurs very slowly with this reagent, which makes it less suitable for use in preparation of ribonucleoside building blocks. Basic Protocol 3 describes a convenient approach for the preparation of nucleoside H-phosphonate monoesters based on transesterification of diphenyl H-phosphonate with protected nucleosides. Diphenyl H-phosphonate is relatively inexpensive, commercially available, stable, and easy to handle. It also gives high yields of nucleoside H-phosphonates. This is the newest of the presented methods and thus the least used, but some clear advantages of the method could make it a generally preferred choice. It should, however, be noted that synthesis of ribonucleoside building blocks with this method requires more basic work-up conditions, which may prevent its use with N-protections that are quite base labile. Basic Protocol 4 makes use of 2-chloro-4H-1,3,2-benzo-dioxaphosphinan-4-one (salicylchlorophosphite) as the phosphonylating reagent. The reaction with nucleosides is usually fast and quantitatively produces a phosphite intermediate that is converted into the H-phosphonate monoester upon hydrolysis. Since salicylchlorophosphite is practically a monofunctional phosphonylating agent, it can be used in nearly stoichiometric amounts. The formation of symmetrical dinucleoside H-phosphonate diesters is usually negligible, but removal of byproducts from the reagent can sometimes be a problem. Protection of Nucleosides for Oligonucleotide Synthesis Contributed by Jacek Stawinski and Roger Strömberg Current Protocols in Nucleic Acid Chemistry (2001) 2.6.1-2.6.15 Copyright © 2001 by John Wiley & Sons, Inc.
2.6.1 Supplement 4
NOTE: These reactions should be carried out under strictly anhydrous conditions, using anhydrous solvents and reagents. All glassware should be dried in an oven prior to use. The nucleosidic component should be rendered anhydrous by consecutive evaporation of added pyridine or acetonitrile depending on solvent used for the reaction. All connections to atmospheric pressure should be through a drying tower containing a desiccant. BASIC PROTOCOL 1
SYNTHESIS OF PROTECTED DEOXYRIBONUCLEOSIDE OR RIBONUCLEOSIDE 3′-H-PHOSPHONATES USING THE PHOSPHORUS TRICHLORIDE/IMIDAZOLE/TRIETHYLAMINE REAGENT This is a general-purpose protocol, applicable to both ribo- and deoxyribonucleosides bearing standard protecting groups. This reaction is shown in Figure 2.6.1. Materials Imidazole, made anhydrous by repeated evaporation of added dry acetonitrile Dichloromethane (99.9+%; HPLC grade), stored over 3A molecular sieves Acetone (for dry ice/acetone bath) Phosphorus trichloride, freshly distilled Triethylamine, distilled, stored over calcium hydride Protected deoxyribo- or ribonucleoside (see Chapter 2), dried by repeated evaporation of added pyridine 9:1 (v/v) chloroform/methanol 2 M TEAB, pH 7.5 (see recipe) Sodium sulfate 5 × 25–cm glass chromatography column, packed with Merck silica gel 60, 230 to 400 mesh ASTM (e.g., EM Science) or matrix silica, 35 to 70 µm (Millipore) in chloroform (bed height, 15 to 20 cm) Methanol Chloroform 0.5:1:8.5 or 1:2:7 (v/v/v) concentrated ammonia/water/isopropanol 1:1 (v/v) hexane/diethyl ether TLC silica-gel plates (e.g., Merck silica gel 60 F254, EM Science) Rotary evaporator connected to water aspirator Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and column chromatography (APPENDIX 3E)
Deoxyribo- and Ribonucleoside H-Phosphonates
Figure 2.6.1
Synthesis of nucleoside 3′-H-phosphonates using PCl3/Im/TEA reagent system.
2.6.2 Supplement 4
Current Protocols in Nucleic Acid Chemistry
Prepare phosphorus trichloride/imidazole/triethylamine reagent 1. Dissolve 5.8 g imidazole (86 mmol) in 300 mL dichloromethane and cool solution to approximately −10°C in a dry ice/acetone bath. Dry acetonitrile and tetrahydrofuran can be used as alternative solvents, but with dichloromethane the work-up procedure is more convenient.
2. While stirring, add dropwise 2.45 mL phosphorus trichloride (28 mmol) and then 12.5 mL triethylamine (90 mmol) mixed with 10 mL dichloromethane. Stir 15 to 30 min at 0° to −10°C and then cool to −78°C in dry ice/acetone bath. Prepare 3′-H-phosphonates 3. Add a protected deoxyribo- or ribonucleoside (8 mmol) dissolved in 200 mL dichloromethane dropwise over ∼30 min while stirring at −78°C. Stir 1 hr at −78°C. Steps 1 to 3 can be somewhat simplified by cooling the mixture with an ice/water bath instead; however, this is not recommended for guanosine and deoxyguanosine derivatives because substantial amounts of side products, and thus a lower yield, can be produced following subsequent reactions (presumably with the lactam system).
4. Monitor reactions for disappearance of the starting nucleoside and the formation of a baseline material by TLC (APPENDIX 3D) on silica-gel plates using 9:1 chloroform/methanol as the solvent. 5. When the reaction is complete (as determined by TLC analysis), pour the cold mixture directly onto 300 mL of 2 M TEAB and wash the organic layer with an additional 300 mL of 2 M TEAB. With acetonitrile as solvent, 20 mL of 0.5 M TEAB should be added to the cold mixture. The mixture is then concentrated under reduced pressure (at 30° to 40°C) and the residue is dissolved in 300 mL dichloromethane and washed twice with 150 mL of 2 M TEAB.
6. Separate the organic layer, dry it over ~20 g sodium sulfate, and evaporate solvent under reduced pressure using a rotary evaporator connected to a water aspirator. Purify 3′-H-phosphonates 7. Purify crude product by short-column silica-gel chromatography (APPENDIX 3E) on a 5 × 25–cm glass chromatography column using a stepwise gradient of methanol in chloroform to elute products. For example, a stepwise gradient of 0% to 12% methanol in chloroform containing 0.1% triethylamine can be used. Unwanted isomers of the ribonucleoside H-phosphonates, that is 3′-TBDMS (or 2-ClBz) 2′-H-phosphonates, if present, are readily removed by silica-gel chromatography.
8. Check eluate fractions for H-phosphonate purity by TLC using 0.5:1:8.5 or 1:2:7 (v/v/v) concentrated ammonia/water/isopropanol as the solvent. The polarity, and thus the mobility on TLC, of an H-phosphonate will be affected by its protecting group. The latter solvent is probably better for more polar compounds. For compounds bearing more base-labile N-protection, the use of 3:7 or 2:8 (v/v) isopropanol/1 M TEAB can be advantageous.
9. Combine fractions containing the desired product and concentrate them to a white foam using the rotary evaporator. Store at <4°C. A yield of 70% to 95% 3′-H-phosphonate monoesters (triethylammonium salts), based on the staring quantity of nucleoside, is expected.
Protection of Nucleosides for Oligonucleotide Synthesis
2.6.3 Current Protocols in Nucleic Acid Chemistry
Supplement 4
Occasionally, DBUH+ salts of H-phosphonate monoesters can be preferred to TEAH+ salts. The transformation can be effected by washing a solution of nucleoside H-phosphonate monoester (triethylammonium salt) in dichloromethane with 0.2 M 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) bicarbonate buffer (pH 8.5).
10. Optional: Dissolve foam in a small amount of dichloromethane and add it dropwise while stirring vigorously to 100 to 150 mL of 1:1 hexane/diethyl ether per mmol product. Store at <4°C. The nucleoside H-phosphonate is stored as a microcrystalline solid. Although stable for several months at room temperature, it should be stored in the freezer to prevent decomposition due to residual solvents. Under such conditions, no decomposition is seen even after several months. ALTERNATE PROTOCOL
SYNTHESIS OF RIBONUCLEOSIDE 3′-H-PHOSPHONATES VIA IN SITU 2′-O-2-CHLOROBENZOYLATION FOLLOWED BY PHOSPHONYLATION This procedure is specific for ribonucleosides bearing a 2′-O-chlorobenzoyl group and permits simultaneous 2′-O-benzoylation and 3′-O-H-phosphorylation as a “one pot” reaction. Additional Materials (also see Basic Protocol 1) Protected ribonucleoside with free 2′- and 3′-hydroxyls (see Chapter 2), dried by repeated evaporation of added pyridine Pyridine (HPLC grade; e.g., LabScan), dried by and stored over 4A molecular sieves 2-Chlorobenzoyl chloride 1. Dissolve a protected ribonucleoside with free 2′- and 3′-hydroxyls (8 mmol) in 95 mL dichloromethane and add 5 mL pyridine. Cool to −78°C in a dry ice/acetone bath while stirring. 2. Mix 1.18 mL 2-chlorobenzoyl chloride (8.8 mmol) and 10 mL dichloromethane, and add dropwise over a 15-min period. Incubate 30 min at −78°C with stirring. 3. Prepare phosphorus trichloride/imidazole/triethylamine reagent as described (see Basic Protocol 1, steps 1 and 2). 4. Add phosphorus trichloride/imidazole/triethylamine reagent dropwise over 15 to 30 min to nucleoside mixture while stirring at −78°C. Stir 1 hr at −78°C. 5. Continue with synthesis and purification as described (see Basic Protocol 1, steps 4 to 10). A yield of 40% to 70%, based on the starting quantity of nucleoside, is expected.
BASIC PROTOCOL 2
SYNTHESIS OF PROTECTED DEOXYRIBONUCLEOSIDE 3′-H-PHOSPHONATES USING H-PYROPHOSPHONATE This procedure is suitable for phosphorylation of hydroxyl groups in deoxyribonucleosides or 5′-hydroxyl groups in ribonucleosides. This reaction is shown in Figure 2.6.2.
Deoxyribo- and Ribonucleoside H-Phosphonates
Materials Protected deoxyribonucleoside (see Chapter 2), dried by repeated evaporation of added pyridine 2 M phosphorous acid (H3PO3) solution (see recipe)
2.6.4 Supplement 4
Current Protocols in Nucleic Acid Chemistry
Figure 2.6.2
Synthesis of nucleoside 3′-H-phosphonates using H-pyrophosphonate.
Condensing agent (select one): 5,5-Dimethyl-2-oxo-2-chloro-1,3,2-dioxaphosphinane (NEPCl; see recipe) Pivaloyl chloride (PV⋅Cl), commercial grade (e.g., Aldrich), distilled before use (store <2 months at −20°C) 9:1 (v/v) chloroform/methanol 1 M and 2 M TEAB, pH 7.5 (see recipe) Dichloromethane (HPLC grade), stored over 3A molecular sieves Sodium sulfate 4 × 25–cm glass chromatography column, packed with Merck silica gel 60, 230 to 400 mesh ASTM (e.g., EM Science) or Matrix silica, 35 to 70 µm (Millipore) in chloroform (bed height, 10 to 15 cm) Methanol Chloroform 0.5:1:8.5 or 1:2:7 (v/v/v) concentrated ammonia/water/isopropanol 1:1 (v/v) hexane/diethyl ether TLC silica-gel plates (e.g., Merck silica gel 60 F254, EM Science) Rotary evaporator connected to water aspirator Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) 1. Dissolve protected deoxyribonucleoside (2 mmol) in 10 mL of 2 M H3PO3 solution (20 mmol). 2. Stir reaction mixture and slowly add 2.0 g NEPCl (11 mmol) or 1.35 mL PV⋅Cl (11 mmol). Stir ∼3 hr. The reaction can be left overnight at 20°C (room temperature). The specified amount of a condensing agent should not be exceeded, otherwise more reactive species can be generated from phosphorous acid, which may result in a significant formation of symmetrical H-phosphonate diesters. Instead of generating H-pyrophosphonate in situ from phosphorous acid and a condensing agent, a 1 M stock solution of this phosphonylating reagent can be prepared by adding 0.5 mol eq PV⋅Cl or NEPCl to 2 M H3PO3 in pyridine. The stock solution of pyridinium H-pyrophosphonate in pyridine is stable for several months at room temperature.
3. Monitor reactions for disappearance of the starting nucleoside and the formation of a baseline material by TLC (APPENDIX 3D) on silica-gel plates using 9:1 chloroform/methanol as the solvent.
Protection of Nucleosides for Oligonucleotide Synthesis
2.6.5 Current Protocols in Nucleic Acid Chemistry
Supplement 4
4. When the reaction is complete (as determined by TLC analysis), add 2 mL of 1 M TEAB and partition reaction mixture between 75 mL dichloromethane and 50 mL of 2 M TEAB. 5. Separate the organic layer, dry it over ~10 g sodium sulfate, and evaporate solvent under reduced pressure using a rotary evaporator connected to a water aspirator. 6. Purify crude product by short-column silica-gel chromatography (APPENDIX 3E) on a 4 × 25–cm glass chromatography column using a stepwise gradient of methanol in chloroform to elute products. For example, a stepwise gradient of 0% to 12% methanol in chloroform containing 0.1% triethylamine can be used. Unwanted isomers of the ribonucleoside H-phosphonates, that is 3′-TBDMS (or 2-ClBz) 2′-H-phosphonates, if present, are readily removed by silica-gel chromatography.
7. Check eluate fractions for H-phosphonate purity by TLC using 0.5:1:8.5 or 1:2:7 (v/v/v) concentrated ammonia/water/isopropanol as the solvents. The polarity, and thus the mobility on TLC, of an H-phosphonate will be affected by its protecting group. The latter solvent is probably better for more polar compounds. For compounds bearing more base-labile N-protection, the use of 3:7 or 2:8 (v/v) isopropanol/1M TEAB can be advantageous.
8. Combine fractions containing the desired product and concentrate them to a white foam using the rotary evaporator. Store at <4°C. A yield of 85% to 95% 3′-H-phosphonate monoesters (triethylammonium salts), based on the starting quantity of nucleoside, is expected. Occasionally, DBUH+ salts of H-phosphonate monoesters can be preferred to TEAH+ salts. The transformation can be effected by washing a solution of nucleoside H-phosphonate monoester (triethylammonium salt) in dichloromethane with 0.2 M 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) bicarbonate buffer (pH 8.5). When NEPCl is used to generate H-pyrophosphonate from phosphorous acid, the isolated nucleoside H-phosphonate monoesters can be occasionally contaminated by hydrolysis products of the condensing agent. If this is the case (as shown by 31P NMR), the product should be dissolved in 20 mL dichloromethane and washed twice with 5 mL of 0.05 M TEAB buffer.
9. Optional: Dissolve the foam in a small amount of dichloromethane and add it dropwise while stirring vigorously to 100 to 150 mL of 1:1 hexane/diethyl ether per mmol product. Store at <4°C. The nucleoside H-phosphonate is stored as a microcrystalline solid. Although stable for several months at room temperature, it should be stored in the freezer to prevent decomposition due to residual solvents. Under such conditions, no decomposition is seen even after several months. BASIC PROTOCOL 3
SYNTHESIS OF PROTECTED NUCLEOSIDE 3′-H-PHOSPHONATES USING DIPHENYL H-PHOSPHONATE This is a general-purpose procedure, applicable to both ribo- and deoxyribonucleosides. One should exercise some caution when base-sensitive protecting groups are present in the substrates (see Commentary). This reaction is shown in Figure 2.6.3.
Deoxyribo- and Ribonucleoside H-Phosphonates
2.6.6 Supplement 4
Current Protocols in Nucleic Acid Chemistry
Figure 2.6.3
Synthesis of nucleoside 3′-H-phosphonates using diphenyl H-phosphonate.
Materials Protected deoxyribo- or ribonucleoside (see Chapter 2), dried by repeated evaporation of added pyridine Pyridine (HPLC grade; e.g., Labscan), dried by and stored over 4A molecular sieves Diphenyl H-phosphonate, commercial grade (e.g., Aldrich) 9:1 (v/v) chloroform/methanol Triethylamine, distilled, stored over calcium hydride 5% (w/v) sodium bicarbonate Dichloromethane, distilled Sodium sulfate 4 × 25–cm glass chromatography column, packed with Merck silica gel 60, 230 to 400 mesh ASTM (e.g., EM Science) or Matrix chloroform (bed height, 10 to 15 cm) Methanol Chloroform 0.5:1:8.5 or 1:2:7 (v/v/v) concentrated ammonia/water/isopropanol 1:1 (v/v) hexane/diethyl ether TLC silica-gel plates (e.g., Merck silica gel 60 F254, EM Science) Rotary evaporator connected to water aspirator Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) 1. Add a protected deoxyribo- or ribonucleoside (1 mmol) to 5 mL pyridine and stir. Add 1.34 mL diphenyl H-phosphonate (7 mmol) in one portion. Stir ∼15 min. An excess of phosphonylating agents is necessary to avoid the formation of symmetrical dinucleoside H-phosphonate diesters. Diphenyl H-phosphonate may be listed by some suppliers as diphenyl phosphite. In the instance of 2′-O-protected ribonucleosides, the amount of diphenyl H-phosphonate can be reduced to 3 mol eq.
2. Monitor reactions for disappearance of the starting nucleoside and the formation of a baseline material by TLC (APPENDIX 3D) on silica-gel plates using 9:1 chloroform/methanol as the solvent. 3. When the reaction is complete (as determined by TLC analysis), add 1 mL water and 1 mL triethylamine to quench the reaction, and let mixture stand 15 min.
Protection of Nucleosides for Oligonucleotide Synthesis
2.6.7 Current Protocols in Nucleic Acid Chemistry
Supplement 4
4. Use a rotary evaporator connected to a water aspirator to evaporate solvents, and partition the residue between 20 mL dichloromethane and 20 mL of 5% sodium bicarbonate. 5. Extract organic phase twice with 20 mL of 5% sodium bicarbonate, dry it over ~10 g sodium sulfate, and evaporate the solvent to produce an oil. Most phenol and phenyl H-phosphonates formed during the reaction and from hydrolysis of diphenyl H-phosphonate are removed by the aqueous sodium bicarbonate extraction. Crude reaction products (after extraction with aqueous sodium bicarbonate) can be precipitated from dichloromethane into 1:1 (v/v) hexane/diethyl ether to produce nucleoside H-phosphonates of >95% purity, without chromatography.
6. Purify crude product by short-column silica-gel chromatography (APPENDIX 3E) on a 4 × 25–cm glass chromatography column using a stepwise gradient of methanol in chloroform to elute products. For example, a stepwise gradient of 0% to 12% methanol in chloroform containing 0.1% triethylamine can be used. Unwanted isomers of the ribonucleoside H-phosphonates, that is 3′-TBDMS (or 2-ClBz) 2′-H-phosphonates, if present, are readily removed by silica-gel chromatography.
7. Check eluate fractions for H-phosphonate purity by TLC using 0.5:1:8.5 or 1:2:7 concentrated ammonia/water/isopropanol. The polarity, and thus the mobility on TLC, of an H-phosphonate will be affected by its protecting group. The latter solvent is probably better for more polar compounds. For compounds bearing more base-labile N-protection, the use of 3:7 or 2:8 (v/v) isopropanol/1M TEAB can be advantageous.
8. Combine fractions containing the desired product and concentrate them in the rotary evaporator to a white foam. Store at <4°C. A yield of 75% to 90% 3′-H-phosphonate monoesters (triethylammonium salts), based on the starting quantity of nucleoside, is expected.
9. Optional: Dissolve the foam in a small amount of dichloromethane and add it dropwise while stirring vigorously to 100 to 150 mL of 1:1 hexane/diethyl ether per mmol product. Store at <4°C. The nucleoside H-phosphonate is stored as a microcrystalline solid. Although stable for several months at room temperature, it should be stored in the freezer to prevent decomposition due to residual solvents. Under such conditions, no decomposition is seen even after several months. BASIC PROTOCOL 4
SYNTHESIS OF PROTECTED NUCLEOSIDE 3′-H-PHOSPHONATES USING 2-CHLORO-4H-1,3,2-BENZO-DIOXAPHOSPHINAN-4-ONE This is a general-purpose protocol applicable to both ribo- and deoxyribonucleotides. This reaction is shown in Figure 2.6.4.
Deoxyribo- and Ribonucleoside H-Phosphonates
Materials Protected deoxyribo- or ribonucleoside (see Chapter 2), dried by repeated evaporation of added pyridine 2:1 (v/v) dichloromethane/pyridine 1.25 M 2-chloro-4H-1,3,2-benzo-dioxaphosphinan-4-one solution (see recipe) 9:1 (v/v) chloroform/methanol 1 M TEAB, pH 7.5 (see recipe)
2.6.8 Supplement 4
Current Protocols in Nucleic Acid Chemistry
Figure 2.6.4
Synthesis of nucleoside 3′-H-phosphonates using salicylchlorophosphite.
Dichloromethane (99%; HPLC grade), stored over 3A molecular sieves Sodium sulfate 5 × 25–cm glass chromatography column, packed with Merck silica gel 60, 230 to 400 mesh ASTM (e.g., EM Science) or Matrix silica, 35 to 70 µm (Millipore) in chloroform (bed height, 10 to 15 cm) Methanol Chloroform 0.5:1:8.5 or 1:2:7 (v/v/v) concentrated ammonia/water/isopropanol 1:1 (v/v) hexane/diethyl ether TLC silica-gel plates (e.g., Merck silica gel 60 F254, EM Science) Rotary evaporator connected to water aspirator Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) 1. Dissolve a protected deoxyribo- or ribonucleoside (1 mmol) in 20 mL of 2:1 dichloromethane/pyridine while stirring and cool solution with an ice/water bath. 2. Add 1 mL of 1.25 M 2-chloro-4H-1,3,2-benzo-dioxaphosphinan-4-one solution in one portion, while stirring. Remove from bath and stir 15 min. 3. Monitor reactions for disappearance of the starting nucleoside and the formation of a baseline material by TLC (APPENDIX 3D) on silica-gel plates using 9:1 chloroform/methanol as the solvent. 4. When the reaction is complete (as determined by TLC analysis), add 100 mL of 1 M TEAB to quench reaction and extract the aqueous phase three times with 50 mL dichloromethane. Collect and pool organic phases. 5. Dry organic phase over ~10 g sodium sulfate, and evaporate solvent under reduced pressure using a rotary evaporator connected to a water aspirator. 6. Purify crude product by short-column silica-gel chromatography (APPENDIX 3E) on a 5 × 25–cm glass chromatography column using a stepwise gradient of methanol in chloroform to elute products. For example, a stepwise gradient of 0% to 12% methanol in chloroform containing 0.1% triethylamine can be used.
Protection of Nucleosides for Oligonucleotide Synthesis
2.6.9 Current Protocols in Nucleic Acid Chemistry
Supplement 4
Unwanted isomers of the ribonucleoside H-phosphonates, that is 3′-TBDMS (or 2-ClBz) 2′-H-phosphonates, if present, are readily removed by silica-gel chromatography.
7. Check eluate fractions for H-phosphonate purity by TLC using 0.5:1:8.5 or 1:2:7 concentrated ammonia/water/isopropanol as the solvents. The polarity, and thus the mobility on TLC, of an H-phosphonate will be affected by its protecting group. The latter solvent is probably better for more polar compounds. For compounds bearing more base-labile N-protection, the use of 3:7 or 2:8 (v/v) isopropanol/1M TEAB can be advantageous. With nucleoside H-phosphonate monoesters produced in this way, it can sometimes be troublesome to remove contaminants resulting from the decomposition products of the phosphonylating reagent (these are visible as fluorescent spots on TLC plates under a UV lamp). In such cases, the samples should be rechromatographed.
8. Combine fractions containing the desired product and concentrate them in the rotary evaporator to a white foam. Store at <4°C. A yield of 80% to 90% 3′-H-phosphonate monoesters (triethylammonium salts), based on the starting quantity of nucleoside, is expected. Occasionally, DBUH+ salts of H-phosphonate monoesters can be preferred to TEAH+ salts. The transformation can be effected by washing a solution of nucleoside H-phosphonate monoester (triethylammonium salt) in dichloromethane with 0.2 M 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) bicarbonate buffer (pH 8.5).
9. Optional: Dissolve the foam in a small amount of dichloromethane and add it dropwise while stirring vigorously to 100 to 150 mL of 1:1 hexane/diethyl ether per mmol product. Store at <4°C. The nucleoside H-phosphonate is stored as a microcrystalline solid. Although stable for several months at room temperature, it should be stored in the freezer to prevent decomposition due to residual solvents. Under such conditions, no decomposition is seen even after several months.
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
2-Chloro-4H-1,3,2-benzo-dioxaphosphinan-4-one solution, 1.25 M Prepare crystalline 2-chloro-4H-1,3,2-benzo-dioxaphosphinan-4-one (salicylchlorophosphite) as described (Young, 1952) or purchase commercially (e.g., Aldrich). Dissolve 2.52 g in 6 mL dioxane and adjust final volume to 10 mL. Prepare fresh. Store crystalline product several months at 4°C. Salicylchlorophosphite was previously called 2-chloro-4H-1,3,2-benzodioxaphosphorin-4one and may still be listed as such by some suppliers.
5,5-Dimethyl-2-oxo-2-chloro-1,3,2-dioxaphosphinane (NEPCl) Prepare this crystalline reagent as described (McConnell and Coover, 1959). Store several months at room temperature. Phosphorous acid (H3PO3) solution, 2 M Evaporate 1.62 g H3PO3 (commercial grade, e.g., Aldrich) from dry pyridine (HPLC grade, dried and stored over 4A molecular sieves) and dissolve residue in 8 mL dry pyridine. Adjust final volume to 10 mL. Stored several months at room temperature. Deoxyribo- and Ribonucleoside H-Phosphonates
Phosphorous acid in pyridine is prepared according to Stawinski and Thelin (1990a).
2.6.10 Supplement 4
Current Protocols in Nucleic Acid Chemistry
Triethylammonium bicarbonate (TEAB), 2 M, pH 7.5 Bubble CO2 through a suspension of 280 mL triethylamine (2 mol) in 700 mL water until the pH of the solution reaches 7.5. Adjust final volume to 1 L. Store buffer up to a few weeks at 4°C and check pH before use. Dilute as needed to appropriate molarity. COMMENTARY Background Information The methods for the preparation of H-phosphonate monoesters of natural products can be divided into four major types. They are based on: (1) esterification of phosphorous acid in the presence of various condensing reagents (Hata and Sekine, 1974; Holy et al., 1965; Schofield and Todd, 1961; Sekine and Hata, 1975); (2) reactions of phosphorus trichloride (or reactive species derived thereof) with alcohols (Holy and Sorm, 1966; Honjo et al., 1966; Sekine et al., 1979); (3) transesterification of trialkyl or triaryl phosphites with appropriate hydroxylic components (Holy and Smrt, 1966); and (4) transesterification of β-substituted dialkyl Hphosphonate diesters with alcohols, followed by hydrolysis of the produced mixed diesters (Gibbs and Larsen, 1984; Takaku et al., 1988). Most of these methods, unfortunately, suffer from variable yields and are often incompatible with common protecting groups used in oligonucleotide synthesis. This unit describes four variants of the above general types for the preparation of nucleoside H-phosphonate monoesters: Basic Protocol 2 is a type 1 reaction; Basic Protocol 1, the Alternate Protocol, and Basic Protocol 4 are type 2 reactions; and Basic Protocol 3 is related to the type 4 reaction. These methods consistently give high yields of the desired products (75% to 90%), and taken together they provide an arsenal of phosphonylation (phosphitylation) procedures that are compatible with most common protecting groups used in oligodeoxyribo- and oligoribonucleotide synthesis. Phosphonylation using phosphorus trichloride Phosphonylation of protected nucleosides using the phosphorus trichloride/imidazole/triethylamine reagent system (Basic Protocol 1) is a mild and efficient method (with yields of 75% to 90%) for the preparation of protected deoxyribo- (Garegg et al., 1986a,c) and ribonucleoside 3′-H-phosphonates (Garegg et al., 1986b; Stawinski et al., 1988; Rozners et al., 1995b, 1998) as well as for arabinonucleoside H-phosphonates (Rozners et al., 1995a). A popular variant of this proce-
dure involves the replacement of imidazole by 1,2,4-triazole (Froehler, 1993; Froehler et al., 1986). Gaffney and Jones (1988) also reported that using N-methylmorpholine instead of triethylamine as an acid scavenger offers some advantages. Acetonitrile and dichloromethane are commonly used as solvents in this procedure. The phosphonylating reagent is generated in situ immediately prior to synthesis and the reaction is frequently carried out in a dry ice/acetone bath (or a similar bath well below 0°C), which is particularly beneficial with guanine-containing nucleosides as these are prone to side reactions. (The side products that can be formed are readily removed, but they will lower the yields.) The reagent is probably made less suitable for a large-scale production of building blocks, because of the use of a sub-zero cold bath. A convenient procedure for one-flask 2′-hydroxyl protection (2-chlorobenzoylation) and subsequent phosphonylation using this reagent (Alternate Protocol) has also been developed (Rozners et al., 1990, 1992, 1995b, 1998) and used for the preparation of formacetal-linked (Rozners and Strömberg, 1997) as well as amide-linked (D. Katkevica, E. Rozners, E. Bizdena, and R. Strömberg, unpub. observ.) dimeric H-phosphonate building blocks. Another recent procedure for preparation of purine-containing ribonucleoside building blocks is based on the reaction of tris(triazolyl)phosphine with 2′,3′-unprotected purine ribonucleosides to produce, after hydrolysis, an isomeric mixture of 2′- and 3′-H-phosphonates. Upon silylation with TBDMS⋅Cl, this mixture gives a remarkable selectivity of 85% to 90% for 2′-O-silylation (Zhang et al., 1997). Phosphonylation using phosphorous acid esterification Direct condensation of phosphorous acid with appropriate alcohols in the presence of an arene sulfonyl derivative (Sekine and Hata, 1975) to produce H-phosphonate monoesters is of little synthetic value due to the concomitant formation of H-phosphonate diesters (Sekine et al., 1988) and oxidation of H-phosphonate monoesters (Garegg et al.,
Protection of Nucleosides for Oligonucleotide Synthesis
2.6.11 Current Protocols in Nucleic Acid Chemistry
Supplement 4
1987). However, by using a limited amount of a condensing agent such as pivaloyl chloride or 5,5-dimethyl-2-oxo-2-chloro-1,3,2dioxaphosphinane (McConnell and Coover, 1959; Basic Protocol 2), it is possible to convert phosphorous acid into its H-pyrophosphonate (Stawinski and Thelin, 1990b), which in turn may act as a mild phosphonylating agent (Stawinski and Thelin, 1990a). The procedure is experimentally simple and reliable, and produces deoxyribonucleoside 3′-H-phosphonate in yields of 86% to 92% (Stawinski and Thelin, 1990a). Pyridinium H-pyrophosphonate can also be prepared and stored for several months at room temperature as a stock solution in pyridine. Reaction mixtures containing a nucleoside and 5 mol eq of pyrophosphonate can be left overnight without the danger of side reactions with heterocyclic base residues because of this reagent’s moderate reactivity (Stawinski and Thelin, 1990a). However, this reagent is rather slow to react with sterically hindered hydroxyl functions such as the 3′-hydroxyl group in 2′O-TBDMS ribonucleosides (Stawinski and Thelin, 1990a), and thus cannot be recommended for preparation of ribonucleoside Hphosphonate building blocks. The mild reaction conditions, experimental simplicity, and inexpensive starting materials make this method a strong candidate for large-scale preparations of deoxyribonucleotide H-phosphonates.
Deoxyribo- and Ribonucleoside H-Phosphonates
Phosphonylation by transesterification Transesterification of diphenyl H-phosphonate with protected nucleosides (Basic Protocol 3) is a most convenient approach for the preparation of H-phosphonate building blocks. Diphenyl H-phosphonate is an inexpensive and commercially available reagent that is stable and easy to handle. H-Phosphonate monoesters are synthesized with a purity usually >95% even without column chromatography (Jankowska et al., 1994). No side reactions involving the heterocyclic bases were detected. The same observation has also been reported for nucleosides with unprotected nucleobases (Wada et al., 1997). Although the reagent in pyridine undergoes disproportionation (Kers et al., 1996), this process is much slower than the transesterification reaction, and the side products formed (phenyl H-phosphonate and triphenyl phosphite) are easily removed during subsequent purification steps. Diphenyl H-phosphonate usually has to be used in a 3 to 7 mol eq excess of the nucleoside
to minimize the formation of symmetrical Hphosphonate diesters. However, by introducing some changes into the protocol (Jankowska et al., 1994), it is possible to reduce significantly the excess of diphenyl H-phosphonate. The method has been used for the preparation of both deoxyribo- and ribonucleoside H-phosphonates. It may, however, pose some problems when applied to ribonucleosides carrying more base-labile protection (e.g., N-phenoxyacetyl protection), due to the relatively basic conditions required for hydrolysis of 2′-O-TBDMSprotected nucleoside 3′-(phenyl H-phosphonate). Phosphonylation using salicylchlorophosphite Nucleoside H-phosphonate monoesters are also easily accessible via the salicylchlorophosphite method (Basic Protocol 4), which utilizes 2-chloro-4H-1,3,2-benzo-dioxaphosphinan-4-one as the phosphonylating reagent (Marugg et al., 1986). Salicylchlorophosphite is crystalline, stable, readily prepared (Young, 1952), and also commercially available. Although the phosphonylation is virtually quantitative, some amounts of the hydroxylic component (∼5%) are occasionally regenerated during hydrolysis of the phosphite intermediate (Froehler, 1993). The most serious inconvenience of the method is that it often can be difficult to separate the nucleoside Hphosphonate from hydrolysis products of the phosphonylating reagent. Some other synthetic methods that have been used for preparation of nucleoside Hphosphonate monoesters are: (1) phosphonylation of nucleosides with 2-cyanoethyl phosphordiamidite, hydrolysis to the H-phosphonate diester, and β-elimination of the 2-cyanoethyl group (Garegg et al., 1985); (2) phosphonylation of nucleosides with 2-cyanoethyl H-phosphonate, followed by β-elimination (Szabó et al., 1995); (3) condensation of aryl H-phosphonates with nucleosides, followed by hydrolysis (Ozola et al., 1996); (4) anionic debenzylation of nucleoside benzyl Hphosphonates (Hall et al., 1957); (5) oxidative phosphonylation with phosphinic acid in the presence of mesitylenedisulfonyl chloride (Sekine et al., 1988); (6) reaction of nucleoside bis-(N,N-di-isopropylamino)chlorophosphine, followed by acidolysis (Marugg et al., 1986); and (7) condensation of phosphorous acid with nucleosides promoted by triphosgene (Bhongle and Tang, 1995).
2.6.12 Supplement 4
Current Protocols in Nucleic Acid Chemistry
Critical Parameters For these protocols, anhydrous reaction conditions must be used, especially if the phosphonylating reagent is present in almost stoichiometric amounts. Solvents should be stored over molecular sieves (or be freshly distilled). All glassware should be dried in an oven prior to use. The air inlets of apparatuses used in syntheses should be connected to atmospheric pressure through a drying tower. All nucleosides should be anhydrous, which is usually most conveniently accomplished by repeated evaporation of added pyridine. The purity of the produced compounds should be checked by NMR spectroscopy (31P and 1H), but TLC is also most convenient, especially for the detection of minor amounts of impurities. For example, the contamination of ribonucleoside H-phosphonate building blocks with the 3′-O-protected 2′-H-phosphonate isomers can be conveniently detected by TLC analysis, as these separate well in ammonia/water/isopropanol systems (and usually also in isopropanol/TEAB). In the phosphorus trichloride/imidazole method, the slow addition of nucleoside (see Basic Protocol 1, step 3) is important to reduce the formation of symmetrical H-phosphonate diesters. It is also important to note that a low temperature is required to avoid side reactions on guanine-containing nucleosides. Although the procedure is rather insensitive to the kind of azole used, there is a higher risk of formation of the symmetrical H-phosphonate esters using triazole (or tetrazole) rather than imidazole due to the higher reactivity of the former reagents. Imidazole is also less costly. If overly concentrated solutions or too small an excess of reagent is used, or if the nucleoside solution is added too quickly, smaller or larger amounts of symmetrical H-phosphonate diesters can be formed. These can be easily hydrolyzed during subsequent purification (giving monoester product and nucleoside), but their formation will lower the yield of the H-phosphonate monoesters. For the pyrophosphonate method, pyridine seems to be an optimal solvent. Strong bases (e.g., triethylamine) or basic nucleophilic catalysts (e.g., N-methylimidazole) should be avoided, because they usually slow down the phosphonylation. When NEPCl is used to generate H-pyrophosphonate, the resulting Hphosphonate monoesters should be checked for impurities arising from the condensing agent (e.g., by 31P NMR). During the phosphonylation of nucleosides, two species are formed
from the condensing agent: 5,5-dimethyl-2oxo-2-hydroxy-1,3,2-dioxaphosphinane and its pyrophosphate. The first product is usually completely removed during the extraction step. The second product is easy to remove during chromatography, but may slowly hydrolyze on silica gel, releasing 5,5-dimethyl-2-oxo-2-hydroxy-1,3,2-dioxaphosphinane. Transesterification of diphenyl H-phosphonate also works best when pyridine is used as solvent and base. The reaction in neutral solvents in the presence of a strong base (e.g., triethylamine) may fail due to rapid disproportionation of the phosphonylation reagent under such conditions. Formation of symmetrical H-phosphonates is usually not detected when salicylchlorophosphite is used as a phosphonylating reagent. The purity of nucleoside H-phosphonates prepared by this method should be carefully checked, however, for the presence of fluorescent spots visible on TLC plates under UV light. These are due to contamination by hydrolysis products of the phosphonylating reagent, which may be nontrivial to remove by silica-gel chromatography.
Anticipated Results All methods described in this unit afford, after silica-gel column chromatography, nucleoside H-phosphonate monoesters of comparable quality and in comparable yields, but they vary in their suitability for the preparation of different nucleoside derivatives. All methods can be scaled up to ~25-mmol reactions. A 1-mmol scale generates 0.5 to 1 g product and a 25-mmol scale generates 15 to 25 g. Compounds prepared by any of these methods are suitable for solid-phase as well as solution synthesis of oligonucleotides and their analogs. For deoxyribonucleoside H-phosphonates bearing quite stable N-acyl protection, all methods can produce good results. For ribonucleoside H-phosphonates, the pyrophosphonate method seems to be too slow, although it may be preferred in large-scale preparation of deoxyribonucleoside building blocks (another possible choice for this being the diphenyl H-phosphonate method). For use with ribonucleosides carrying more base-labile N-protection, the phosphorus trichloride/imidazole method is still preferred, with the salicylchlorophosphite approach being the second alternative. Protection of Nucleosides for Oligonucleotide Synthesis
2.6.13 Current Protocols in Nucleic Acid Chemistry
Supplement 4
Time Considerations None of the procedures described in this unit are very time consuming. The whole synthesis procedure including workup usually does not take more than a few hours. The pyrophosphonate method is the slowest one, but in this instance the reaction mixtures can conveniently be left overnight. Together with chromatographic purification, it will take from half a day to a day, depending on method, to obtain the purified nucleoside H-phosphonates. The method that probably involves the least manual effort and technical skill is the diphenyl Hphosphonate procedure.
Literature Cited Bhongle, N.N. and Tang, J.Y. 1995. A convenient synthesis of nucleoside 3′-H-phosphonate monoesters using triphosgene. Tetrahedron Lett. 36:6803-6806. Froehler, B.C. 1993. Oligodeoxynucleotide synthesis. H-Phosphonate approach. In Protocols for Oligonucleotides and Analogs (S. Agrawal, ed.) pp. 63-80. Humana Press, Totowa, N.J. Froehler, B.C., Ng, P.G., and Matteucci, M.D. 1986. Synthesis of DNA via deoxynucleoside H-phosphonate intermediates. Nu cl. Acids Res. 14:5399-5407. Gaffney, B.L. and Jones, R.A. 1988. Large-scale oligonucleotide synthesis by the H-phosphonate method. Tetrahedron Lett. 29:2619-2622. Garegg, P.J., Regberg, T., Stawinski, J., and Strömberg, R. 1985. Formation of internucleotidic bond via phosphonate intermediates. Chem. Scr. 25:280-282. Garegg, P.J., Lindh, I., Regberg, T., Stawinski, J., Strömberg, R., and Henrichson, C. 1986a. Nucleoside H-Phosphonates. III. Chemical synthesis of oligodeoxyribonucleotides by the hydrogenphosphonate approach. Tetrahedron Lett. 27:4051-4054. Garegg, P.J., Lindh, I., Regberg, T., Stawinski, J., Strömberg, R., and Henrichson, C. 1986b. Nucleoside H-phosphonates. IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach. Tetrahedron Lett. 27:4055-4058.
Deoxyribo- and Ribonucleoside H-Phosphonates
Hall, R.H., Todd, A., and Webb, R.F. 1957. Nucleotides. Part XLI. Mixed anhydrides as intermediates in the synthesis of dinucleoside phosphates. J. Chem. Soc. (1957):3291-3296. Hata, T. and Sekine, M. 1974. Oxidation of nucleoside phosphites by means of 2,2′-dipyridilyl disulfide via nucleoside silylphosphite intermediates. Tetrahedron Lett. (1974):3943-3946. Holy, A. and Smrt, J. 1966. Oligonucleotidic compounds. XI. Synthesis of ribonucleoside 2′,3′cyclophosphates from nucleosides via nucleoside 2′,3′-phosphites. Collect. Czech. Chem. Commun. 31:1528-1534. Holy, A. and Sorm, F. 1966. Nucleic acids components and their analogues. LXXX. Preparation of nucleoside phosphites by the reaction of nucleosides with triphenyl phosphites. Collect. Czech. Chem. Commun. 31:1544-1561. Holy, A., Smrt, J., and Sorm, F. 1965. Nucleic acids components and their analogues. LIX. The preparation and properties of nucleoside phosphites. Collect. Czech. Chem. Commun. 30:1635-1641. Honjo, M., Marumoto, R., Kobayashi, K., and Yoshioka, Y. 1966. Phosphorylation of ribonucleosides with phosphorus trichloride. Tetrahedron Lett. (1966):3851-3856. Jankowska, J., Sobkowski, M., Stawinski, J., and Kraszewski, A. 1994. Studies on aryl H-phosphonates. I. Efficient method for the preparation of deoxyribo- and ribonucleoside 3′-H-phosphonate monoesters by transesterification of diphenyl H-phosphonate. Tetrahedron Lett. 35:3355-3358. Kers, A., Kers, I., Stawinski, J., Sobkowski, M., and Kraszewski, A. 1996. Studies on aryl H-phosphonates. 3. Mechanistic investigations related to the disproportionation of diphenyl H-phosphonate under anhydrous basic conditions. Tetrahedron 52:9931-9944. Marugg, J.E., Tromp, M., Kuyl-Yeheskiely, E., van der Marel, G.A., and van Boom, J.H. 1986. A convenient and general approach to the synthesis of properly protected d-nucleoside-3′ hydrogenphosphonates via phosphite intermediates. Tetrahedron Lett. 27:2661-2664. McConnell, R.L. and Coover, H.W. 1959. Phosphorus-containing derivatives of 2,2-dimethyl-1,3propanediol. J. Org. Chem. 24:630-635.
Garegg, P.J., Regberg, T., Stawinski, J., and Strömberg, R. 1986c. Nucleoside hydrogenphosphonates in oligonucleotide synthesis. Chem. Scr. 26:59-62.
Ozola, V., Reese, C.B., and Song, Q.L. 1996. Use of ammonium aryl H-phosphonates in the preparation of nucleoside H-phosphonate building blocks. Tetrahedron Lett. 37:8621-8624.
Garegg, P.J., Stawinski, J., and Strömberg, R. 1987. Activation of nucleoside hydrogenphosphonates by use of aryl sulfonyl chlorides. Nucleosides Nucleotides 6:425-427.
Rozners, E. and Strömberg, R. 1997. Synthesis and properties of oligoribonucleotide analogs having formacetal internucleoside linkages. J. Org. Chem. 62:1846-1850.
Gibbs, D.E. and Larsen, C. 1984. Bis[2,2,2-trifluoroethyl] phosphite, a new reagent for synthesizing mono- and diesters of phosphorus acid. Synthesis (1984):410-413.
Rozners, E., Kumpins, V., Rekis, A., and Bizdena, E. 1988. Solid phase synthesis of oligoribonucleotides by the H-phosphonate method using 2′-O-benzoyl protective group. Bioorg. Khim. 14:1580-1582.
2.6.14 Supplement 4
Current Protocols in Nucleic Acid Chemistry
Rozners, E., Rekis, A., Kumpins, V., and Bizdena, E. 1990. Synthesis of oligoribonucleotides by the H-phosphonate method using base-labile 2′O-protecting groups. II. Some aspects of use of 2′-O-benzoyl and anisoyl protecting groups. Bioorg. Khim. 16:1531-1536.
Takaku, H., Yamakage, S., Sakatsume, O., and Ohtsuki, M. 1988. A convenient approach to the synthesis of deoxyribonucleoside 3′-hydrogenphosphonates via bis(1,1,1,3,3,3-hexafluoro-2propyl) phosphonate intermediate. Chem. Lett. (1988):1675-1678.
Rozners, E., Renhofa, R., Petrova, M., Popelis, J., Kumpins, V., and Bizdena, E. 1992. Synthesis of oligoribonucleotides by the H-phosphonate approach using base labile 2′-O-protecting groups. 5. Recent progress in development of the method. Nucleosides Nucleotides 11:15791593.
Wada, T., Sato, Y., Honda, F., Kawahara, S., and Sekine, M. 1997. Chemical synthesis of oligodeoxyribonucleotides using N-unprotected Hphosphonate monomers and carbonium and phosphonium condensing reagents: O-Selective phosphonylation and condensation. J. Am. Chem. Soc. 119:12710-12721.
Rozners, E., Strömberg, R., and Bizdena, E. 1995a. Synthesis of oligoarabinonucleotides using Hphosphonates. Nucleosides Nucleotides 14:851853.
Young, R.W. 1952. A re-examination of the reaction between phosphorus trichloride and salicylic acid. J. Am. Chem. Soc. 74:1672-1673.
Rozners, E., Strömberg, R., and Bizdena, E. 1995b. Synthesis of RNA fragments using the H-phosphonate method and 2′-(2-chlorobenzoyl) protection. Nucleosides Nucleotides 14:855-857. Schofield, J.A. and Todd, A. 1961. Nucleotides. Part XLVI. A new method for the preparation of nucleoside phosphites. J. Ch em. Soc. (1961):2316-2320. Sekine, M. and Hata, T. 1975. Phenylthio group as a protecting group of phosphates in oligonucleotide synthesis via phosphotriester approach. Tetrahedron Lett. (1975):1711-1714. Sekine, M., Mori, H., and Hata, T. 1979. New type of chemical oxidative phosphorylation: Activation of phosphonate function by use of triisopropylbenzenesulfonyl chloride. Tetrahedron Lett. (1979):1145-1148.
Zhang, X., Abad, J.-L., Huang, Q., Zeng, F., Gaffney, B., and Jones, R. 1997. High yield protection of purine ribonucleosides for H-phosphonate RNA synthesis. Tetrahedron. Lett. 38:7135-7138.
Key References Froehler et al., 1986. See above. Garegg et al., 1986c. See above. Rozners et al., 1995b. See above. Stawinski et al., 1988. See above. Provide primary sources with complete experimental details for Basic Protocol 1. Stawinski and Thelin, 1990a. See above. Provides primary sources with complete experimental details for Basic Protocol 2.
Sekine, M., Narui, S., and Hata, T. 1988. A convenient method for the synthesis of deoxyribonucleoside 3′-hydrogenphosphonates. Tetrahedron Lett. 29:1037-1040.
Jankowska et al., 1994. See above.
Stawinski, J. and Thelin, M. 1990a. Nucleoside H-Phosphonates. XI. A convenient method for the preparation of nucleoside H-phosphonates. Nucleosides Nucleotides 9:129-135.
Marugg et al., 1986. See above.
Stawinski, J. and Thelin, M. 1990b. Studies on the activation pathway of phosphonic acid using acyl chlorides as activators. J. Chem. Soc., Perkin Trans. 2. (1990):849-853.
Stawinski, J. 1992. Some Aspects of H-Phosphonate Chemistry. In Handbook of Organophosphorus Chemistry (R. Engel, ed.) pp. 377-434. Marcel Dekker, New York.
Stawinski, J., Strömberg, R., Thelin, M., and Westman, E. 1988. Studies on the t-butyldimethylsilyl group as 2′-O-protection in oligoribonucleotide synthesis via the H-phosphonate approach. Nucl. Acids Res. 16:9285-9298.
Stawinski, J. and Strömberg, R. 1993. H-Phosphonates in Oligonucleotide Synthesis. Trends Org. Chem. 4:31-67.
Szabó, T., Almer, H., Strömberg, R., and Stawinski, J. 1995. 2-Cyanoethyl H-phosphonate. A reagent for the mild preparation of nucleoside H-phosphonate monoesters. Nucleosides Nucleotides 14:715-716.
Provides primary sources with complete experimental details for Basic Protocol 3.
Provides primary sources with complete experimental details for Basic Protocol 4.
Provide general aspects of the underlying chemistry in the context of nucleotide and oligonucleotide synthesis.
Contributed by Jacek Stawinski Stockholm University Stockholm, Sweden Roger Strömberg Karolinska Institutet Stockholm, Sweden
Protection of Nucleosides for Oligonucleotide Synthesis
2.6.15 Current Protocols in Nucleic Acid Chemistry
Supplement 4
Deoxyribonucleoside Phosphoramidites
UNIT 2.7
This unit provides methods for converting N- and 5′-O-protected deoxyribonucleosides to deoxyribonucleoside phosphoramidites, which are the building blocks in solid-phase DNA oligonucleotide synthesis. Deoxyribonucleoside phosphoramidites carrying the 2-cyanoethyl group for P(III)-protection are extensively used in oligonucleotide synthesis and are commercially available. The preparation of deoxyribonucleoside phosphoramidites bearing a different P(III)-protecting group will be described in this unit; phosphoramidites functionalized with the 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl groups will be synthesized. Considering the importance of phosphordiamidite precursors in the preparation of deoxyribonucleoside phosphoramidites, two syntheses of these phosphinylating agents will be reported. These detailed methods provide a convenient and reliable approach to the synthesis of various deoxyribonucleoside phosphoramidites, assuming compatibility of the nucleosidic N- and 5′-O-protecting groups with the reagents used for such syntheses. PREPARATION OF 5′-O-(4,4′-DIMETHOXYTRITYL)-3′-O(N,N-DIISOPROPYLAMINO)-{4-[N-METHYL-N-(2,2,2-TRIFLUOROACETYL) AMINO]BUTOXY}PHOSPHINYL-2′-DEOXYRIBONUCLEOSIDES
BASIC PROTOCOL
This protocol describes a general method for the synthesis of deoxyribonucleoside phosphoramidites S.3a-d from commercially available N- and 5′-O-protected deoxyribonucleosides S.1a-d and N,N,N′,N′-tetraisopropyl-O-{4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl}phosphordiamidite S.2 (see Support Protocol 1) in the presence of 1H-tetrazole. This approach to the preparation of deoxyribonucleoside phosphoramidites is illustrated in Figure 2.7.1. Materials 5′-O-(4,4′-Dimethoxytrityl)-2′-deoxythymidine (S.1a; Chem-Impex International) N4-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxycytidine (S.1b; Chem-Impex International) 6 N -Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine (S.1c; Chem-Impex International) N2-Isobutyryl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyguanosine (S.1d; Chem-Impex International) Anhydrous methylene chloride (Aldrich)
i
DMTrO
B
Pr2N P i O Pr2N
O OH
1a b c d
CH3 N CF3 2
O
1H-Tetrazole/CH2Cl2
B = Thymin-1-yl 4 B = N -benzoylcytosin-1yl 6 B = N -benzoyladenin-9-yl 2 B = N -isobutyrylguanin-9-yl
B
DMTrO
i
Pr2N
P
O O CF3
O
N O CH3
3a-d
DMTr: 4,4'dimethoxytrityl; iPr: isopropyl
Figure 2.7.1 Preparation of deoxyribonucleoside phosphoramidites from N- and 5′-O-protected deoxyribonucleosides.
Protection of Nucleosides for Oligonucleotide Synthesis
Contributed by Andrzej Wilk, Andrzej Grajkowski, Marcin K. Chmielewski, Lawrence R. Phillips, and Serge L. Beaucage
2.7.1
Current Protocols in Nucleic Acid Chemistry (2001) 2.7.1-2.7.12 Copyright © 2001 by John Wiley & Sons, Inc.
Supplement 4
N,N,N′,N′-Tetraisopropyl-O-{4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl}phosphordiamidite (S.2; see Support Protocol 1) Sublimed 1H-tetrazole (Aldrich) 9:1 (v/v) benzene/triethylamine (both available from Aldrich) 230- to 400-mesh silica gel 60Å (Merck) 50-mL three-necked round-bottom flask and rubber septa 15-mL powder addition funnel (Labglass) Vacuum desiccator Rotary evaporator High vacuum pump Dry argon gas cylinder 10-mL syringe 2.5 × 20–cm disposable Flex chromatography columns (Kontes) Fraction collector Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and column chromatography (APPENDIX 3E) 1. Dry 2 mmol of a suitably protected deoxyribonucleoside (S.1a-d) in a 50-mL three-necked round-bottom flask for 2 hr at 25°C under high vacuum in a desiccator. Seal the flask with a 15-mL powder addition funnel containing 140 mg (2 mmol) dry 1-H tetrazole, and rubber septa. 2. Under an argon atmosphere, using a 10-mL syringe, add 10 mL anhydrous methylene chloride followed by 900 mg (2.1 mmol) N,N,N′,N′-tetraisopropyl-O-{4[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl}phosphordiamidite S.2 and stir with magnetic stir bar. 3. Add the 140 mg (2 mmol) 1H-tetrazole in the 15-mL powder addition funnel over a 0.5-hr period. 4. Monitor the progress of the reaction by TLC (APPENDIX 3D) using 9:1 benzene/triethylamine as an eluent. Phosphinylation of suitably protected 2′-deoxynucleosides S.1a-c is usually complete within 1 hr at ambient temperature. For best results, phosphinylation of properly protected 2′-deoxyguanosine S.1d should be allowed to proceed for 12 hr at 25°C.
5. Concentrate the reaction mixture to a foam using a rotary evaporator/vacuum pump system. 6. Suspend the crude product in a minimum amount (∼3 mL) of 9:1 benzene/triethylamine and apply the suspension to a 2.5 × 20–cm disposable Flex column containing 40 g silica gel (APPENDIX 3E) that has been equilibrated in 9:1 benzene/triethylamine. 7. Elute the column with 9:1 benzene/triethylamine. Collect in a fraction collector, pool appropriate fractions, and concentrate using a rotary evaporator/vacuum pump system. Each deoxyribonucleoside phosphoramidite S.3a-d is isolated as a white amorphous foam in yields ranging from 92% to 98%. Pure S.3a-d can be stored indefinitely at –20°C in sealed amber glass vials.
Deoxyribonucleoside Phosphoramidites
5′-O-(4,4′-Dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-{4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butoxy}phosphinyl-2′-deoxythymidine S.3a: 31P-NMR (121 MHz, C6D6): δ 143.3, 143.4, 143.66, 143.75. FAB-HRMS: calcd. for C44H56F3N4O9P (M+Na)+ 895.3635, found 895.3599.
2.7.2 Supplement 4
Current Protocols in Nucleic Acid Chemistry
N4-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-{4-[(N-methyl-N(2,2,2-trifluoroacetyl)amino]butoxy}phosphinyl-2′-deoxycytidine S.3b: 31P-NMR (121 MHz, C6D6): δ 143.82, 143.87, 143.92. FAB-HRMS: calcd. for C50H59F3N5O9P (M+Na)+ 984.3900, found 984.3908. N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-{4-[N-methyl-N(2,2,2-trifluoroacetyl)amino]butoxy}phosphinyl-2′-deoxyadenosine S.3c: 31P-NMR (121 MHz, C6D6): δ 143.5, 143.6, 143.8, 144.0. FAB-HRMS: calcd. for C51H59F3N7O8P (M+Na)+ 1008.4010, found 1008.3970. N2-Isobutyryl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-{4-[N-methyl-N(2,2,2-trifluoroacetyl)amino]butoxy}phosphinyl-2′-deoxyguanosine S.3d: 31P-NMR (121 MHz, C6D6): δ 142.9, 143.1, 143.5, 143.7. FAB-HRMS: calcd. for C48H61F3N7O9P (M+Na)+ 990.4118, found 990.4099.
PREPARATION OF N,N,N′,N′-TETRAISOPROPYL-O-{4-[N-METHYL-N(2,2,2-TRIFLUOROACETYL)AMINO]BUTYL}PHOSPHORDIAMIDITE
SUPPORT PROTOCOL 1
4-[N-Methyl-N-(2,2,2-trifluoroacetyl)amino]butan-1-ol S.4 (see Support Protocol 2; Fig. 2.7.2) is treated with phosphorus trichloride to generate the corresponding O-{4-[Nmethyl-N-(2,2,2-trifluoroacetyl)amino]butyl}phosphordichloridite S.5, which is then purified by vacuum distillation. Condensation of the phosphordichloridite S.5 with N,N-diisopropylamine affords N,N,N′,N′-tetraisopropyl-O-{4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl}phosphordiamidite S.2, which can be purified further by silica gel chromatography. As shown in Figure 2.7.1, the phosphordiamidite S.2 is required for the phosphinylation of N- and 5′-O-protected deoxyribonucleosides S.1a-d (see Basic Protocol). Materials Phosphorus trichloride (Aldrich), freshly distilled Anhydrous acetonitrile (Aldrich) 4-[N-Methyl-N-(2,2,2-trifluoroacetyl)amino]butan-1-ol (S.4; see Support Protocol 2) Anhydrous petroleum ether (Aldrich), freshly distilled from phosphorus pentoxide Drierite, 8 mesh (Aldrich) Anhydrous N,N-diisopropylamine (Aldrich) 250- and 1000-mL round-bottom flasks 25-mL pressure-equalizing dropping funnel Vacuum distillation head 24/40 and appropriate thermometer Three-way stopcock Reflux condenser
CH3 N
F3C
PCl3 OH
O
MeCN
Pr2NH
P
Cl
5
i
Pr2N P Pr2N O
CH3 N CF3
i
Petroleum ether
O
O
4
i
Cl
CH3 N
F3C
O
2
Figure 2.7.2 Preparation of N,N,N′,N′-tetraisopropyl-O-{4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl}phosphordiamidite.
Protection of Nucleosides for Oligonucleotide Synthesis
2.7.3 Current Protocols in Nucleic Acid Chemistry
Supplement 4
Drying tube Rubber septum 250-mL sintered glass funnel (coarse porosity) Rotary evaporator/vacuum pump system NOTE: Phosphordichloridites are very sensitive to moisture. Reaction yields depend on the dryness of the reaction conditions. It is recommended that all glassware be oven-dried overnight at 120°C. The dried glassware should then be cooled to ambient temperature under an inert gas atmosphere in a desiccator. Acetonitrile is refluxed over calcium hydride for ≥2 hr prior to distillation. Prepare O-{4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl}phosphordichloridite 1. Dissolve 6.8 g (50 mmol) freshly distilled phosphorus trichloride in 50 mL anhydrous acetonitrile in an oven-dried 250-mL round-bottom flask. 2. Place 8 g (40 mmol) of 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butan-1-ol S.4 and 10 mL anhydrous acetonitrile in a 25-mL pressure-equalizing dropping funnel connected to a vacuum line via a three-way stopcock. 3. Add the S.4 solution dropwise over a 2-hr period to the magnetically stirred phosphorus trichloride solution from step 1. CAUTION: During the course of the addition, a slight vacuum should be applied through the dropping funnel to maintain an internal pressure of ∼750 mmHg. This lower-than-atmospheric pressure ensures the removal of gaseous hydrogen chloride that is being generated.
4. Stir the reaction mixture for an additional 3 hr at 40°C and ∼40 mmHg. 5. Fractionally distill the remaining material under reduced pressure. O-{4-[N-Methyl-N-(2,2,2-trifluoroacetyl)amino]butyl}phosphordichloridite S.5 is a colorless liquid boiling at 110°C/0.1 mmHg. Yield 11 g (37 mmol, 92%). 1H-NMR (300 MHz, C6D6): δ [1.01(bm) (33%) and 1.11 (bm) (67%) (4H)], [2.38 (bs) (67%) and 2.45 (bs) (33%), (3H)], [2.75 (m) (33%) and 2.88 (m) (67%) (2H)], 3.77 (m, 2H). 13C-NMR (75 MHz, C6D6): δ 22.3, 23.9, 26.0, 26.3, 33.2, 33.5, 47.9, 48.0, 67.5 (d, 2JPC = 10.6 Hz), 67.7 (d, 2JPC = 10.6 Hz), 116.9 (q, 1JCF = 288 Hz), 117.0 (q, 1JCF = 288 Hz), 156.6 (q, 2JCF = 36.0 Hz), 156.7 (q, 2JCF = 36.0 Hz). 31P-NMR (121 MHz, C6D6): δ 174.2, 174.3. Although S.5 can be stored for a week at –20°C without significant decomposition, it is recommended to use S.5 when freshly distilled.
Prepare N,N,N′,N′-tetraisopropyl-O-{4 -[N-methyl-N-(2,2,2trifluoroacetyl)amino]butyl}phosphordiamidite 6. Add 300 mL anhydrous petroleum ether and 11 g (37 mmol) S.5 to an oven-dried 1000-mL round-bottom flask equipped with a reflux condenser fitted with a drying tube filled with Drierite. 7. Add in portions over a 15-min period a solution of 28 mL (200 mmol) anhydrous N,N-diisopropylamine in 100 mL anhydrous petroleum ether through the reflux condenser to the vigorously stirred phosphordichloridite solution. Large quantities of white precipitate (N,N-diisopropylammonium hydrochloride) are produced.
Deoxyribonucleoside Phosphoramidites
8. As the resulting suspension cools to ambient temperature, remove the reflux condenser and seal the flask with a rubber septum. Allow the reaction mixture to stir for an additional 48 hr at 25°C.
2.7.4 Supplement 4
Current Protocols in Nucleic Acid Chemistry
9. Filter off the precipitated N,N-diisopropylammonium hydrochloride salt using a 250-mL sintered glass funnel of coarse porosity. 10. Concentrate the filtrate on a rotary evaporator/vacuum pump system and keep under high vacuum for 12 hr. As prepared, compound S.2 is sufficiently pure for phosphinylating properly protected deoxyribonucleosides. However, S.2 can be purified by silica gel chromatography (APPENDIX 3E) using ∼20 g of silica gel per gram of crude product, and 9:1 (v/v) benzene/triethylamine as the eluent. Fractions containing pure S.2 are detected on analytical TLC plates (APPENDIX 3D) by staining with a saturated solution of silver nitrate in ethanol and then briefly heating the TLC plate at 50°C. N,N,N′,N′-Tetraisopropyl-O-{4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl}phosphordiamidite S.2. Yield 15 g (35 mmol, 95%). 1H-NMR (300 MHz, C6D6): δ 1.21 (m, 24H), 1.40 (m, 4H), [2.41 (q, 5JHF = 1.6 Hz) (67%) and 2.50 (q, 5JHF = 0.7 Hz, (33%), (3H)], [2.89 (tq, J = 7.4 Hz, 5JHF = 1.0 Hz) (33%) and 3.04 (t, J = 6.9 Hz) (67%), (2H)], 3.43 (m, 2H), 3.50 (m, 4H). 13C-NMR (75 MHz, C6D6): δ 23.2, 23.7, 23.8, 24.3, 24.5, 25.0, 28.3, 28.4, 28.5, 28.6 33.3, 33.5 (q, 4JCF = 4.2 Hz), 44.3, 44.5, 48.5, 48.7 (q, 4JCF = 4.2 Hz), 63.4 (d, 2JCP = 6.4 Hz), 63.7 (d, 2JCP = 6.4 Hz), 117.0 (q, 1JCF = 288 Hz), 117.1 (q, 1JCF = 288 Hz), 156.1 (q, 2JCF = 36 Hz). 31P-NMR (121 MHz, C6D6): δ 117.9, 118.2. FAB-MS: calcd. for C19H39F3N3O2P (M+H)+ 430, found 430. Pure S.2 can be stored indefinitely at –20°C in sealed amber glass vials.
PREPARATION OF 4-[N-METHYL-N-(2,2,2-TRIFLUOROACETYL)AMINO]BUTAN-1-OL
SUPPORT PROTOCOL 2
As shown in Figure 2.7.3, 4-(N-methyl)aminobutan-1-ol S.8 is prepared from the reaction γ-butyrolactone S.6 with gaseous methylamine followed by reduction of the resulting amido alcohol S.7 with lithium aluminum hydride. Chemoselective N-trifluoroacetylation is performed by condensing 4-(N-methyl)aminobutan-1-ol S.8 with methyl trifluoroacetate. 4-[N-Methyl-N-(2,2,2-trifluoroacetyl)amino]butan-1-ol S.4 is required in the preparation of N,N,N′,N′-tetraisopropyl-O-{4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl}phosphordiamidite S.2 (see Support Protocol 1). Materials γ-Butyrolactone (S.6; Aldrich) Anhydrous gaseous methylamine (Aldrich) Diethyl ether (Malinckrodt), freshly distilled from sodium Drierite (Aldrich) Lithium aluminum hydride powder (LAH, Aldrich)
O
O
CH3NH2
O HO
2.5 bar 6
7
HO
CF3CO2CH3 NHCH3
LAH NHCH3
Et2O
O HO
N
CF3
CH3
8
4
LAH: lithium aluminum hydride
Figure 2.7.3
Preparation of 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butan-1-ol.
Protection of Nucleosides for Oligonucleotide Synthesis
2.7.5 Current Protocols in Nucleic Acid Chemistry
Supplement 4
Triethanolamine (Aldrich) Methyl trifluoroacetate (Aldrich) 250-mL pressure vessel (Barrskogen) 2-L three-necked round-bottom flask Mechanical stirrer (Arrow) Pressure-equalizing dropping funnel Reflux condenser connected to a drying tube Dry argon gas cylinder 250-mL sintered glass funnel (coarse porosity) Rotary evaporator/water aspirator system 50-mL round-bottom flask Prepare N-methyl-4-hydroxybutyramide 1. Place 17.2 g (199 mmol) γ-butyrolactone S.6 in a 250-mL pressure vessel. 2. Evacuate the vessel to ∼2 mmHg and fill it with anhydrous gaseous methylamine. 3. Stir the reaction mixture overnight under a positive pressure of methylamine (∼2.5 bar). CAUTION: This reaction involves highly irritating gaseous methylamine under pressure. Ensure that the pressure vessel is tight and placed in a well-ventilated chemical fume hood. Use moist pH-indicator paper to check for leaks. Even trace amounts of strongly alkaline methylamine can be detected using this test.
4. Carefully release excess methylamine to the atmosphere of a well-ventilated chemical fume hood. 5. Evacuate the vessel and maintain the reaction product under vacuum (2 mmHg) for 1 hr. N-Methyl-4-hydroxybutyramide S.7 is isolated as a pure (>98%) crystalline mass (mp 32° to 34°C) in near quantitative yield (23.1 g, 197 mmol). 1H-NMR (300 MHz, DMSO-d6): δ 1.63 (dt, J = 7.6, 6.4 Hz, 2H), 2.10 (t, J = 7.6 Hz, 2H), 2.56 (d, J = 4.6 Hz, 3H), 3.37 (t, J = 6.4 Hz, 2H), 3.58 (b, ∼1H), 7.75 (b, 1H). 13C-NMR (75 MHz, DMSO-d6): δ 25.6, 28.7, 32.2, 60.5, 173.1. S.7 can be stored indefinitely at –20°C in sealed amber glass vials.
Reduce N-methyl-4-hydroxybutyramide 6. Add 1 L diethyl ether to an oven-dried 2-L three-necked round-bottom flask equipped with a mechanical stirrer, a pressure-equalizing dropping funnel, and a reflux condenser connected to a drying tube filled with Drierite. 7. Add, under an argon atmosphere, 36 g (0.94 mol) lithium aluminum hydride powder. 8. Melt 58.5 g (0.50 mol) N-methyl-4-hydroxybutyramide S.7 and place in the dropping funnel. 9. Add the neat supercooled liquid (S.7) to the mechanically stirred LAH suspension, dropwise, over a 2-hr period at 25°C. 10. Reflux the reaction mixture for 6 hr and stir for an additional 6 hr at 25°C.
Deoxyribonucleoside Phosphoramidites
CAUTION: Diethyl ether is highly flammable. Lithium aluminum hydride is extremely sensitive to water; traces of water from the solvent and the environment will result in the release of highly flammable hydrogen gas. Consequently, steps 7 to 10 must be performed with the utmost care to exclude moisture from the reaction mixture. A flow of anhydrous argon gas through the reaction vessel greatly reduces the danger of fire.
2.7.6 Supplement 4
Current Protocols in Nucleic Acid Chemistry
11. Quench the reduction reaction while stirring by first adding 125 mL (0.94 mol) triethanolamine dropwise over a 1-hr period (Powell et al., 1986; Gardrat et al., 1990), followed by 50 mL (2.8 mol) water dropwise over a 1-hr period. 12. Stir the resulting slurry for 12 hr at 25°C. 13. Filter the slurry through a 250-mL sintered glass funnel (coarse porosity) and wash the solid cake three times with 200 mL diethyl ether. 14. Pool the etheral filtrates and evaporate on a rotary evaporator/water aspirator system. Distill the residue under reduced pressure. The amino alcohol S.8 (34.3 g ,0.33 mol, 67%) is obtained as a colorless liquid boiling at 47°C/0.25 mmHg. 1H-NMR (300 MHz, CDCl3): δ 1.64 (m, 4H), 2.42 (s, 3H), 2.62 (dd, J = 6.0, 5.3 Hz, 2H), 3.57 (dd, J = 5.3, 4.6 Hz, 2H). 13C-NMR (75 MHz, CDCl3): δ 28.3, 32.3, 35.7, 51.7, 62.5. S.8 can be stored indefinitely at –20°C in sealed amber glass vials.
Perform chemoselective trifluoroacetylation of 4-(N-methyl)aminobutan-1-ol 15. To 5 g (48 mmol) of 4-(N-methyl)aminobutan-1-ol S.8 in a 50-mL round-bottom flask, add 7.8 g (60 mmol) methyl trifluoroacetate. 16. Stir the reaction mixture for 12 hr at 25°C. 17. Remove methanol and excess methyl trifluoroacetate by distillation at atmospheric pressure. 18. Distill the residue under reduced pressure. 4-[N-Methyl-N-(2,2,2-trifluoroacetyl)amino]butan-1-ol S.4 is obtained as a slightly viscous colorless liquid (8.9 g, 45 mmol, 94%) boiling at 71°C/0.36 mmHg. 1H-NMR (300 MHz, CDCl3): δ 1.56 (m, 2H), 1.70 (m, 2H), [3.00 (q, 5JHF = 0.7 Hz) (33%) and 3.14 (q, 5 JHF = 1.6 Hz) (67%), (3H)], 3.46 (m, J = 7.4 Hz, 2H), 3.65 (t, J = 6.1 Hz, 2H). 13C-NMR (75 MHz, CDCl3): δ 22.8, 24.7, 29.2, 29.3, 34.1, 34.6, 49.1, 49.4, 61.7, 61.8, 116.5 (q, 1JCF = 288 Hz), 116.6 (q, 1JCF = 288 Hz), 156.7 (q, 2JCF = 36.0 Hz), 156.8 (q, 2JCF = 36.0 Hz). Pure S.4 can be stored indefinitely at –20°C in sealed amber glass vials.
PREPARATION OF N,N,N′,N′-TETRAISOPROPYL-O{2-[(N-FORMYL-N-METHYL)AMINO]ETHYL}PHOSPHORDIAMIDITE
ALTERNATE PROTOCOL
Depending on the protecting group used for P(III), the preparation of phosphordichloridites may be problematic and could complicate the synthesis of phosphordiamidites, which are required for the preparation of deoxyribonucleoside phosphoramidites. A number of phosphordichloridites have been reported to decompose violently when heated (Beaucage, 1993). This protocol describes the generation of bis(N,N-diisopropylamino)chlorophosphine S.9 in situ from phosphorus trichloride and N,N-diisopropylamine, and its reaction with 2-(N-formyl-N-methyl)aminoethan-1-ol S.10 to give the desired phosphordiamidite S.11 (Fig. 2.7.4). The method thus alleviates the need of distilling potentially hazardous phosphordichloridites. Additional Materials (also see Basic Protocol) 2-(Methylamino)ethanol (Aldrich) Ethyl formate (Aldrich) Anhydrous benzene Freshly distilled phosphorous trichloride Anhydrous N,N-diisopropylamine 95:5 (v/v) anhydrous benzene/triethylamine Toluene
Protection of Nucleosides for Oligonucleotide Synthesis
2.7.7 Current Protocols in Nucleic Acid Chemistry
Supplement 4
O HO
PCl3
i-Pr2NH dry C6H6
i-Pr2N
P i-Pr2N
Cl
N H CH3
10
O
i-Pr2N
P i-Pr2N
O
N H CH3
11
9
Figure 2.7.4 Preparation of N,N,N′,N′-tetraisopropyl-O-{2-[(N-methyl-N-formyl)amino]ethyl}phosphordiamidite.
100- and 250-mL round-bottom flasks equipped with a reflux condenser Heating mantle 60-mL sintered glass funnel (coarse porosity) 3 × 20–cm chromatography column (APPENDIX 3E) Prepare 2-(N-formyl-N-methyl)aminoethan-1-ol 1. Place 51.0 g (0.68 mol) of 2-(methylamino)ethanol into a 250-mL round-bottom flask equipped with a reflux condenser, and cool to 5°C by immersion in an ice bath. 2. Add, in portions through the condenser, 75.0 g (1.01 mol) ethyl formate to the stirred amino alcohol over a 5-min period at 5°C. CAUTION: This reaction is exothermic.
3. Remove the ice bath and bring the solution to reflux for 1 hr using a heating mantle. 4. Distill the solution at atmospheric pressure to remove excess ethyl formate, and then carefully distill the remaining residue under high vacuum. 2-(N-Formyl-N-methyl)aminoethan-1-ol S.10 was obtained as a clear colorless liquid (63.1 g, 0.61 mol, 90%) boiling at 120° to 122°C at 0.15 mmHg. 1H-NMR (300 MHz, DMSO-d6): δ [2.75 (s) and 2.94 (s, 30%) (3H)], 3.27 (m, 2H), 3.47 (m, 3H), [7.94 (s) and 7.99 (s, 30%) (1H)]. 13C-NMR (75 MHz, DMSO-d6): δ 29.2, 34.9, 46.2, 51.2, 57.8, 57.9, 58.1, 58.2, 162.7, 163.0. EI-MS: calcd. for C4H9NO2 (M•+) 103, found 103. Pure S.10 can be stored indefinitely at –20°C in sealed amber glass vials.
Prepare N,N,N′,N′-tetraisopropyl-O-{2 -[(N-formyl-N-methyl)amino]ethyl}phosphordiamidite 5. To an oven-dried 100-mL round-bottom flask containing 50 mL anhydrous benzene under a dry argon atmosphere, add by syringe through a rubber septum 876 µL (10 mmol) freshly distilled phosphorus trichloride. 6. Cool the stirred solution to 5°C by immersing in an ice bath and then, over a 30-min period, add 7.7 mL (55 mmol) of anhydrous N,N-diisopropylamine under argon using a 10-mL syringe. 7. Remove the ice bath and allow the stirred reaction to warm to 25°C under a positive pressure of argon until the formation of bis(N,N-diisopropylamino)chlorophosphine S.9 is complete.
Deoxyribonucleoside Phosphoramidites
The rate of the reaction is monitored by 31P-NMR spectroscopy; after ∼48 hr, the presence of S.9 (132.0 ppm downfield relative to a phosphoric acid external standard) is observed as the major (>96%) reaction product.
2.7.8 Supplement 4
Current Protocols in Nucleic Acid Chemistry
8. Add 1.03 mL (10 mmol) of 2-(N-formyl-N-methyl)aminoethan-1-ol S.10 to the suspension. Stir resulting mixture for 2 hr at 25°C under a positive pressure of argon. 31
P-NMR indicates that the reaction is essentially quantitative (∼96%). Spectrum of the product in benzene-d6 shows two singlets at 118.0 and 118.7 ppm.
9. Filter the suspension through a 60-mL sintered glass funnel (coarse porosity) and wash the collected salt with 20 mL anhydrous benzene. 10. Evaporate the filtrates under reduced pressure to an oil and dissolve with a minimum amount (∼3 mL) of 95:5 anhydrous benzene/triethylamine. 11. Apply the viscous solution uniformly to the top of a 3 × 20–cm chromatography column (APPENDIX 3E) packed with 30 g of a 60 Å silica gel slurry in a solution of 95:5 benzene/triethylamine. 12. Elute the column isocratically with 95:5 benzene/triethylamine collecting 8-mL fractions. 13. Analyze the fractions by TLC (APPENDIX 3D) and pool the fractions that contain the product. Evaporate fractions containing the phosphordiamidite S.11 to an oil on a rotary evaporator/vacuum pump system. Using 95:5 benzene/triethylamine as the eluent, S.11 has an Rf ~ 0.49. S.11 is visible only by staining the TLC with silver nitrate as recommended in Support Protocol 1, step 10.
14. Co-evaporate the oil four times with 10 mL toluene to remove traces of triethylamine. Leave under high vacuum for ≥3 hr. N,N,N′,N′-tetraisopropyl-O-{2 -[(N-formyl-N-methyl)amino]ethyl}phosphordiamidite S. 11. Yield: 2.43 g (7.3 mmol, 73%). 1H-NMR (300 MHz, C6D6): δ [1.14 (d, J = 6.9 Hz), 1.16 (d, J = 6.7 Hz) 1.18 (d, J = 6.7 Hz) (24H)], [2.40 (s, 34%) and 2.64 (s, 66%) (3H)], 2.80 (t, J = 5.4 Hz, 2H), 3.43 (m, 4H), [3.29 (dt, J =5.4 Hz, JHP = 6.6 Hz) and 3.60 (dt, J =5.4 Hz, JHP = 6.6 Hz)(2H)], [7.82 (s, 34%) and 7.98 (s, 66%) (1H)]. 13C-NMR (75 MHz, C6D6): δ 24.1, 24.2, 24.6, 24.7, 44.7, 44.9, 45.8 (d, 2JCP = 8.5 Hz), 50.4(d, 2JCP = 8.5 Hz), 61.3, 61.5, 61.9, 62.2, 161.9, 162.3. 31P-NMR (121 MHz, C6D6): δ 118.0, 118.7. EI-MS: calcd. for C16H36N3O2P (M•+) 333.2545, found 333.2528. Pure S.11 can be stored indefinitely at –20°C in sealed amber glass vials.
COMMENTARY Background Information Since its inception in the early 1980s, the phosphoramidite method for oligonucleotide synthesis (Beaucage and Caruthers, 1981; Beaucage and Iyer, 1992; UNIT 3.3) has been extensively used to produce polynucleotides (Pon et al., 1994) on solid supports. The method is most convenient when using the 2-cyanoethyl group for phosphate protection (Sinha et al., 1984) on small-scale syntheses of oligonucleotides. This group is eventually removed along with nucleobase-protecting groups during oligonucleotide deprotection by treatment with either concentrated ammonium hydroxide or pressurized ammonia gas (Boal et al., 1996). Under these conditions, 2-cyanoethyl groups undergo β-elimination, generating acrylonitrile as a side-product (Tener,
1961). Acrylonitrile is a potent carcinogen (Solomon et al., 1984), and alkylation of the nucleobase of nucleosides and oligonucleotides by this reagent is well documented (Chambers, 1965; Solomon et al., 1984; Prokopczyk et al., 1988; Crippa et al., 1993). In an effort to obviate nucleobase modification during oligonucleotide deprotection at any scale level, an alternative to the 2-cyanoethyl group for phosphate protection is recommended. The use of the 4-[N-methyl-N-(2,2,2trifluoroacetyl)]aminobutyl group for phosphodiester protection in the synthesis of oligodeoxyribonucleotides was recently reported (Wilk et al., 1999). Polydeoxyribonucleotides carrying this phosphodiester protecting group are easily deprotected by treatment with concentrated ammonium hydroxide. Cleavage of
Protection of Nucleosides for Oligonucleotide Synthesis
2.7.9 Current Protocols in Nucleic Acid Chemistry
Supplement 4
that, unlike the 2-cyanoethyl group, it can be removed in the absence of base under neutral conditions (authors’ unpub. observ.). The use of (N,N-diisopropylamino)-O-alkylchlorophosphine (Sinha et al., 1984) in the preparation of deoxyribonucleoside phosphoramidites will not be discussed in this unit as these phosphinylating reagents are, because of their inherent reactivity, less stable to moisture than the corresponding phosphordiamidites, and are consequently much less convenient to handle.
the 2,2,2-trifluoroacetyl groups is rate limiting, and is followed by rapid cyclo-deesterification of the resulting 4-(N-methyl)aminobutyl phosphotriesters to give the corresponding phosphodiesters with the concomitant formation of N-methylpyrrolidine (Fig. 2.7.5). When compared to the potential DNA-alkylating properties of acrylonitrile, 2,2,2-trifluoroacetamide and N-methylpyrrolidine, which are produced during oligonucleotide deprotection, are quite innocuous. The high coupling efficiency of the deoxyribonucleoside phosphoramidites S.3a-d (Fig. 2.7.1), their stability in acetonitrile solutions, and the relative ease of 4-(N-methyl)aminobutyl phosphotriester deprotection prompted the authors to describe the preparation of these phosphoramidites in this unit as alternatives to the commercially available 2-cyanoethyl deoxyribonucleoside phosphoramidites. Given that the procedure for preparing phosphoramidites S.3a-d is similar to that of the 2-cyanoethyl phosphoramidites, it shall serve as a relevant model for the synthesis of deoxyribonucleoside phosphoramidites, which carry different P(III) protecting groups. In this context, depending on the group selected for P(III) protection, the method used for the preparation of either the phosphordiamidite S.2 or the analogous N,N,N′,N′-tetraisopropyl-O-(2-cyanoethyl)phosphordiamidite may not be adequate. For example, the phosphordiamidite S.11 (Fig. 2.7.4) could not be conveniently prepared from a phosphordichloridite precursor. Thus, the phosphordiamidite S.11 was prepared from bis(N,N-diisopropylamino)chlorophosphine, which provides added versatility to the synthesis of phosphordiamidites as phosphinylating agents. The advantage of the 2-[(N-formyl-N-methyl)amino]ethyl group for oligonucleotide phosphodiester protection is
O
X
O
O CH3
O O P
N
O
O
O
X
CF3 O
NH4OH − CF3CONH2
O
Critical Parameters and Troubleshooting Since 4-(N-methyl)aminobutan-1-ol S.8 (see Support Protocol 2) is not commercially available, its synthesis has been studied for careful optimization. The lithium aluminum hydride reduction of the parent amido alcohol S.7 is demanding in that it requires strict anhydrous conditions and a mechanical stirrer for optimal performance. In addition, quenching the reduction reaction by adding triethanolamine followed by water to destroy aluminum complexes (as recommended by Powell et al., 1986, and Gardrat et al., 1990), and carefully washing the solid aluminate cake with diethyl ether (see Support Protocol 2, steps 11 to 13) must be performed to ensure a maximum recovery of S.8. The selection of acetonitrile as the solvent for converting 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butan-1-ol S.4 to its phosphordichloridite S.5 under lower than atmospheric pressure conditions (see Support Protocol 1) is required for optimal production of S.5. The use of other solvents will result in a considerably lower yield of S.5. Performing the reaction at atmospheric instead of reduced pres-
B
O
CH3
O O P
O
HN
O O O
O NH4OH
O B
B
O
O P
O
−
O
+
NH4 O
+
CH3N
B
O
X = Thy or N-protected nucleobase; B = Thy, Ade, Cyt, or Gua
Deoxyribonucleoside Phosphoramidites
Figure 2.7.5 Deprotection of oligodeoxyribonucleotides carrying the 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl phosphate protecting group under standard basic conditions.
2.7.10 Supplement 4
Current Protocols in Nucleic Acid Chemistry
sure will also result in unwanted formation of side-products. It is important to mention that the preparation of phosphordiamidites from the bis(N,Ndiisopropylamino)chlorophosphine intermediate S.9 (see Alternate Protocol) should be performed under strictly anhydrous conditions to minimize the formation of side-products resulting from hydrolysis. These side-products unfortunately co-elute with deoxyribonucleoside phosphoramidites during silica gel chromatography. Depending on the amount of contaminating side-products, the stoichiometry of deoxyribonucleoside phosphoramidites required for solid-phase oligonucleotide synthesis may be difficult to determine accurately. Furthermore, the chemical reactivity of the phosphorus-containing hydrolysis side-products is not known; these side-products may react with activated phosphoramidites and further decrease the effective concentration of the amidites. Occasionally, deoxyribonucleoside phosphoramidites may not produce the expected coupling efficiency during conventional solidphase oligonucleotide synthesis. A number of parameters may be responsible for such an apparent lack of reactivity. (1) Phosphoramidites may be contaminated with the triethylamine used with benzene as an eluent during purification on silica gel chromatography. Triethylamine stoichiometrically neutralizes 1H-tetrazole, the weak acid required for the activation of deoxyribonucleoside phosphoramidites in solid-phase oligonucleotide synthesis. Thus, it will prevent optimal coupling efficiency of the phosphoramidites to an extent corresponding to its concentration. It is therefore critical that the phosphoramidites be subjected to high-vacuum foaming after chromatographic purification to ensure complete removal of triethylamine contaminants. Alternatively, lyophilization of a frozen benzene solution of deoxyribonucleoside phosphoramidites is an efficient method for the removal of residual triethylamine. (2) Phosphoramidites may be contaminated with adventitious moisture upon storage, which will result in lower coupling efficiency. It is recommended that deoxyribonucleoside phosphoramidites be dried overnight under high vacuum in a desiccator containing phosphorus pentoxide as a drying agent. (3) The overall purity of deoxyribonucleoside phosphoramidites, as determined by 31P-NMR spectroscopy, should be >95%; phosphoramidites contaminated with >15% of phosphorus-containing hydrolysis products invariably exhibit lower coupling efficiency
when compared to that of pure deoxyribonucleoside phosphoramidites.
Anticipated Results It should be emphasized that deviation from Support Protocol 1 in regard to preparing phosphordichloridite S.5 with a solvent other than acetonitrile at atmospheric pressure will generally cause the yield of the product to drop to 50% to 60%. Caution should be exercised when attempting the distillation of unknown phosphordichloridites; a number of these compounds may decompose or even explode on heating (Beaucage, 1993). In this context, the preparation of phosphordiamidites from bis(N,N-diisopropylamino)chlorophosphine S.9 generated in situ (see Alternate Protocol) is a much safer process and is easier to perform experimentally. Furthermore, the purification of phosphordiamidites on silica gel chromatography is milder than distillation to the phosphonylating reagents and safer to perform. Isolated yields of phosphordiamidites after silica gel chromatography range between 70% and 80% based on the starting amido alcohol S.10; it should be noted that formation of some hydrolysis side-products cannot be avoided, only minimized by careful attention to experimental detail. The synthesis of deoxyribonucleoside phosphoramidites S.3a-d from phosphordiamidite S.2 (see Basic Protocol) is performed essentially as recommended by Barone et al. (1984). More reaction time is required for the preparation of S.3d to optimize yields. It is possible that phosphinylation at O6 of guanine by S.2 might occur and serve as a secondary, slower, phosphinylating path (Barone et al., 1984) for the nucleoside S.1d. The phosphoramidites S.3a-d are very soluble and stable in acetonitrile. For example, an acetonitrile solution of S.3d, unlike the corresponding 2-cyanoethyl phosphoramidite, does not precipitate upon storage exceeding 3 days. In fact, the coupling efficiency of phosphoramidites S.3a-d is essentially unchanged after being in acetonitrile solution for 1 week (Wilk et al., 1999).
Time Considerations The preparation and purification of 4-(Nmethyl)aminobutan-1-ol S.8 can be accomplished in ∼3 days. The conversion of S.8 to the amido alcohol S.4 can be done in one day, and the purified phosphordiamidite S.2 can be obtained from S.4 within 3 days. The synthesis and purification of deoxyribonucleoside phosphoramidites S.3a-d require ∼2 days to com-
Protection of Nucleosides for Oligonucleotide Synthesis
2.7.11 Current Protocols in Nucleic Acid Chemistry
Supplement 4
plete. Alternatively, the synthesis and purification of the amido alcohol S.10 takes a half day, and its conversion to the purified phosphordiamidite S.11 takes ∼3 days.
Literature Cited Barone, A.D., Tang, J.-T., and Caruthers, M.H. 1984. In situ activation of bis-dialkylaminophosphines—A new method for synthesizing deoxyoligonucleotides on polymer supports. Nucl. Acids Res. 12:4051-4061. Beaucage, S.L. 1993. Oligodeoxyribonucleotides synthesis—Phosphoramidite approach. In Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs (S. Agrawal, ed.) pp. 33-61. Humana Press, Totowa, N.J. Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidite—A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862. Beaucage, S.L. and Iyer, R.P. 1992. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:22232311. Boal, J.H., Wilk, A., Harindranath, N., Max, E.E., Kempe, T., and Beaucage, S.L. 1996. Cleavage of oligodeoxyribonucleotides from controlledpore glass supports and their rapid deprotection by gaseous amines. Nucl. Acids Res. 24:31153117. Chambers, R.W. 196 5. The chemistry of pseudouridine. IV. Cyanoethylation. Biochemistry 4:219-226. Crippa, S., Di Gennaro, P., Lucini, R., Orlandi, M., and Rindone, B. 1993. Characterization of adducts of nucleic bases and acrylic-monomers. Gazz. Chim. Ital. 123:197-203. Gardrat, C., Latxague, L., and Picard, J.P. 1990. A new sy nthesis of dl-5-vinyloxazolidine-2thione, a natural antithyroid factor. J. Het. Chem. 27:811-812. Grajkowski, A., Wilk, A., Chmielewski, M.K., and Beaucage, S.L. 2000, unpublished results.
Powell, J., James, N., and Smith, S.J. 1986. Lithium aluminum hydride reductions: A new hydrolysis method for intractable products. Synthesis 338340. Prokopczyk, B., Bertinato, P., and Hoffman, D. 1988. Synthesis and kinetics of decomposition of 7-(2-cyanoehtyl)guanine and O-6-(2-cyanoethyl)guanine, markers for reaction of acrylonitrile and 3-(methylnitrosamino)propionitrile with DNA. Carcinogenesis 9:2125-2128. Sinha, N.D., Biernat, J., McManus, J., and Köster, H. 1984. Polymer support oligonucleotide synthesis. 18. Use of β-cyanoethyl-N,N,-dialkylamino/-N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucl. Acids Res. 12:45394557. Solomon, J.J., Cote, I.L., Wortman, M., Decker, K., and Segal, A. 1984. In vitro alkylation of calf thymus DNA by acrylonitrile—Isolation of cyanoethyl adducts of guanine and thymine and carboxyethyl adducts of adenine and cytosine. Chem.-Biol. Interactions 51:167-190. Tener, G.M. 1961. 2-Cyanoethyl phosphate and its use in the synthesis of phosphate esters J. Am. Chem. Soc. 83:159-168. Wilk, A., Grajkowski, A., Phillips, L.R., and Beaucage, S.L. 1999. The 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl group as an alternative to the 2-cyanoethyl group for phosphate protection in the synthesis of oligodeoxyribonucleotides. J. Org. Chem. 64:7515-7522.
Contributed by Andrzej Wilk, Andrzej Grajkowski, Marcin K. Chmielewski, and Serge L. Beaucage Food and Drug Administration Bethesda, Maryland Lawrence R. Phillips National Cancer Institute Frederick, Maryland
Pon, R.T., Buck, G.A., Niece, R.L., Robertson, M., Smith, A.J., and Spicer, E. 1994. A survey of nucleic-acid services in core laboratories. BioTechniques 17:526-534.
Deoxyribonucleoside Phosphoramidites
2.7.12 Supplement 4
Current Protocols in Nucleic Acid Chemistry
Regioselective 2′-Silylation of Purine Ribonucleosides for Phosphoramidite RNA Synthesis
UNIT 2.8
This unit describes high-yield procedures for protection of purine ribonucleosides based on a reaction that allows highly regioselective 2′-silylation. The H-phosphonate monoester group produced in the silylation reaction is then cleaved, without silyl migration (Song et al., 1999; Zhang et al., 1997), to give intermediates ready for phosphitylation to yield the phosphoramidites. This method gives overall yields that are three times the best yields available by conventional procedures for adenosine (see Basic Protocol 1) and guanosine (see Basic Protocol 2), but offers no advantage for cytidine or uridine. SYNTHESIS OF 5′-O-(4,4′-DIMETHOXYTRITYL)-2′-O-tertBUTYLDIMETHYLSILYL-6-N-ACYLADENOSINE
BASIC PROTOCOL 1
This protocol makes use of transient protection of the 2′,3′-diol moiety of a ribonucleoside (S.2 in Fig. 2.8.1) by reaction with N,N-dimethylformamide dimethylacetal (Zemlicka, 1963) to prevent the small, but potentially troublesome, tritylation of the 2′-hydroxyl that otherwise accompanies tritylation of the 5′-hydroxyl (Zhang et al., 1997). The 2′,3′-Odimethylaminomethylene group is cleaved by any protic solvent. The N-dimethylaminomethylene group is cleaved by treatment with either aqueous ammonia or methylamine. The phenoxyacetylation reaction is carried out using the hydroxybenzotriazole active ester of phenoxyacetic acid after transient hydroxyl protection with trimethylchlorosilane. The regioselective silylation of the N- and 5′-O-protected adenosine and guanosine derivatives (S.4 and S.13, respectively) presumably occurs by a reaction sequence in which the phenyl-H-phosphonate reacts first with tert-butyldimethylchlorosilane to generate the corresponding diester, which then undergoes a transesterification with S.4/S.13 to generate a mixture of isomers (S.5/S.14). Subsequent transfer of the tert-butyldimethylsilyl (TBDMS) group predominantly to the more acidic 2′-hydroxyl gives S.6a/S15a along with 10% to 15% of the 3′-O-TBDMS isomers. The H-phosphonate moiety is removed by reaction of the isomers of S.6a,b/S15a,b with ethylene glycol or glycerol. The extraordinarily facile transesterification of H-phosphonate diesters in the presence of a vicinal hydroxyl group effects the conversion to S.8a,b/S.17a,b quantitatively within minutes, presumably via the intermediate S.7a,b/S.16a,b. After careful purification, S8a/S.17a are converted to the phosphoramidites S.9/S.18 by reaction with 2-cyanoethyl tetraisopropylphosphorodiamidite using diisopropylammonium tetrazolide as a catalyst. A short silica gel column removes the excess reagent. For H-phosphonate synthesis, monomers like S.6a/S.15a but without amino protection can be prepared by a similar route (Zhang et al., 1997). The labile phenoxyacetyl group used here does not survive the polar conditions required for purification of the charged H-phosphonates. Materials Adenosine Pyridine (reagent grade or better) Dimethylformamide dimethyl acetal Nitrogen source Contributed by Barbara L. Gaffney and Roger A. Jones Current Protocols in Nucleic Acid Chemistry (2001) 2.8.1-2.8.13 Copyright © 2001 by John Wiley & Sons, Inc.
Protection of Nucleosides for Oligonucleotide Synthesis
2.8.1 Supplement 6
Figure 2.8.1 Dimethoxytritylation N-phenoxyacetylation, silylation, dephosphonylation, and phosphitylation of adenosine. Abbreviations: Ad, adamantanecarbonyl; DBU, 1,8-diazabyclyclo[5.4.0]undex-7-ene; DMTr, 4,4′-dimethoxytrityl; HOBT, 1-hydroxybenzotriazole; Ph, phenyl; i-Pr, isopropyl; TMS, trimethylsilyl; TBDMS, tert-butyldimethylsilyl.
Regioselective 2′-Silylation of Purine Ribonucleosides for Phosphoramidite RNA Synthesis
Acetonitrile (anhydrous, dried over 3Å molecular sieves) 0.1 M triethylammonium acetate (TEAA) 4,4′-Dimethoxytrityl chloride (DMTr-Cl) 5% (v/v) methanol in dichloromethane Dichloromethane Concentrated aqueous ammonium hydroxide N-Methylmorpholine Trimethylchlorosilane Adenosine phenoxyacetylating reagent (see recipe) Sodium bicarbonate Ethyl acetate
2.8.2 Supplement 6
Current Protocols in Nucleic Acid Chemistry
Petroleum ether Ammonium phenyl-H-phosphonate (see recipe) 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) tert-Butyldimethylsilyl chloride (TBDMS⋅Cl) 0.5 M potassium phosphate buffer, pH 7.0 (APPENDIX 2A) Glycerol 1-Adamantanecarbonyl chloride Diisopropylammonium tetrazolide Argon source 2-Cyanoethyl tetraisopropylphosphorodiamidite Methylene chloride (anhydrous) Triethylamine (anhydrous) 250-mL and 25-mL round-bottom flask Rotary evaporator Silica gel 60F TLC plates (Merck) Waters XTerra 2.5-µm C18 chromatography column Vacuum pump Septum Vent needle Desiccator with P2O5 Additional reagents and equipment for TLC (APPENDIX 3D), column chromatography (APPENDIX 3E), and HPLC (UNIT 10.5) Tritylate adenosine 1. Suspend 1.34 g (5 mmol) adenosine in 10 mL pyridine in a 250-mL round-bottom flask with a magnetic stir bar and concentrate to dryness using a rotary evaporator and vacuum pump. Repeat this azeotropic drying process two times with 10-mL portions of pyridine. 2. Suspend the dry adenosine in 60 mL pyridine, reduce the volume to ∼50 mL, and add 2.6 mL (20 mmol) dimethylformamide dimethyl acetal. 3. Seal the flask with a septum and displace the air with nitrogen through a vent needle in the septum. After a few minutes, remove the nitrogen line and vent needle. Allow to sit for 1 hr. 4. Concentrate to an oil, dissolve the oil in 60 mL pyridine, and concentrate to ∼50 mL. 5. Add 2.03 g (6 mmol) 4,4′-dimethoxytrityl chloride and stir 2 to 3 hr. 6. Check the reaction by HPLC using a gradient of 2:98 to 80:20 acetonitrile: 0.1 M TEAA, pH 6.8 on a C18 column or by TLC (APPENDIX 3D) on silica gel plates using 60F methanol in dichloromethane (Table 2.8.1). Examine the plate under UV light, and then hold it over an open container of fresh aqueous HCl to observe trityl-containing spots. When the TLC plate is held over an open container of HCl, the fumes will cause any trityl-containing spots to turn a bright orange. If the reaction is not complete after 1 hr, add 0.5 mmol more of 4,4′-dimethoxytrityl chloride and wait an additional 1 hr. HPLC and TLC mobility of compounds in the reaction are listed in Table 2.8.1.
Protection of Nucleosides for Oligonucleotide Synthesis
2.8.3 Current Protocols in Nucleic Acid Chemistry
Supplement 6
Table 2.8.1
HPLC and TLC Mobility of Compounds Described in Figures 2.8.1 and 2.8.2
Adenosine TLC Rf (methanol:dichloromethane) (5:95)
(10:90)
HPLCa Retention time, min
0.09 0.08 0.01 minor 0.03 major 0.55 0.48 0.80, 0.84
0.27 0.37 0.08 minor 0.13 major 0.83 0.75 0.73, 0.90
11.3 12.5 12.7 major 13.4 minor 15.7 16.2 —b
11 13 15a,b
0.00 0.05 —
0.10 0.44 —
17a 17b 18
0.41 0.32 0.38, 0.43
0.58 0.53 0.58, 0.83
— 11.0 11.1 major 12.2 minor 13.9 14.5 —b
Compound (structure number in figures) 3 4 6a,6b 8a 8b 9 Guanosine
a
Gradient of 2:98 to 80:20 acetonitrile:0.1 M TEAA (pH 6.8) over 10 min, remaining at 80:20 for 5 min, then back down to 2:98 over 2 min, at 1 mL/min on a Waters XTerra 2.5 µm C18 column. b Too hydrophobic to analyze conveniently on HPLC.
7. Add 10 mL methanol to quench the excess reagent, wait 5 min, and then pour the solution into 100 mL water containing 1 g (12 mmol) sodium bicarbonate. 8. Extract the solution two times with 80-mL portions of dichloromethane, concentrate the combined organic layers, dissolve the residue in 25 mL pyridine, and add 25 mL concentrated aqueous ammonium hydroxide. Seal the flask tightly and heat 5 hr at 60°C. Use caution in heating this closed system. Use a shield and carefully inspect the flask for cracks or defects that might weaken it.
9. Cool to room temperature, open the flask carefully, and check the mixture by HPLC or TLC to have a record of the retention time or Rf value of S.3 (Table 2.8.1). 10. Concentrate the mixture with frequent additions of pyridine so that the water is removed azeotropically to give S.3 as an oil. Dry by evaporation of pyridine as in step 1, leaving dry S.3 in ∼50 mL pyridine. Phenoxyacetylate 11. To the solution of S.3 in 50 mL dry pyridine, add 5.5 mL (50 mmol) N-methylmorpholine. Seal the flask with a septum and displace the air with nitrogen through a vent needle in the septum. Keep the nitrogen flowing slowly.
Regioselective 2′-Silylation of Purine Ribonucleosides for Phosphoramidite RNA Synthesis
12. Cool this mixture in an ice-bath and add 3.2 mL (25 mmol) trimethylchlorosilane over 3 to 5 min. Trimethylchlorosilane is highly moisture sensitive. Use of special bottles such as the Aldrich SURE-SEAL system will help to prevent deterioration of the reagent.
13. Remove the flask from the ice-bath and maintain for 1 hr at room temperature.
2.8.4 Supplement 6
Current Protocols in Nucleic Acid Chemistry
14. Add all of the freshly prepared adenosine phenoxyacetylating reagent using a syringe. Remove the nitrogen line and vent needle and stir 12 to 18 hr. 15. Check the reaction by HPLC or TLC. If the reaction is not complete, add 0.5 mmol more of the phenoxyacetylating reagent and wait an additional 2 hr.
16. Pour the mixture into 100 mL water containing 2.5 g (30 mmol) sodium bicarbonate, extract two times with 100-mL portions of dichloromethane, and concentrate the combined organic layers to dryness. 17. Dissolve the residue in 50 mL pyridine, add 25 mL water, and stir 12 to 18 hr. 18. Concentrate the solution and check the mixture by HPLC or TLC. 19. Purify the residue by column chromatography (APPENDIX 3E) on silica gel using 0:100 to 15:85 (v/v) methanol/dichloromethane to give pure S.4 in yields of up to ∼90%. Silylate 20. To 2.63 g (15 mmol) of ammonium phenyl-H-phosphonate, add 2.3 mL (15 mmol) DBU and co-evaporate with 50 mL pyridine. 21. Dissolve the residue in 120 mL pyridine, concentrate to ∼100 mL, add 2.26 g (15 mmol) TBDMS-Cl and mix. Place 3.52 g (5 mmol) S.4 in a dry 250-mL round-bottom flask and dry by evaporation of pyridine as in step 1. Using a syringe, add the mixture prepared in step 21 to S.4, followed by 3.8 mL (25 mmol) DBU. The silylation reaction can be performed using other N- and 5′-O-protected adenosine derivatives.
22. Stir 5 to 8 hr and check the reaction by HPLC or TLC. If the reaction is not complete, add 1 mmol more of DBU and wait another 2 hr.
23. Pour the mixture into 100 mL of 0.5 M aqueous potassium phosphate buffer, pH 7.0, and extract two times with 100-mL portions of dichloromethane. Concentrate the combined organic layers to dryness. Dephosphonylate 24. Add 1.38 g (15 mmol) glycerol to the residue and dry the mixture by co-evaporation with 50 mL pyridine. 25. Dissolve the residue in 60 mL pyridine, concentrate to ∼50 mL, and add 2.98 g (15 mmol) of 1-adamantanecarbonyl chloride. Stir 10 min. 26. Pour the solution into 100 mL of 0.5 M aqueous potassium phosphate buffer and extract two times with 100-mL portions of dichloromethane. Concentrate the combined organic layers to dryness. 27. Check the mixture by HPLC or TLC and purify the residue by column chromatography in silica gel using 60:40 to 100:0 (v/v) ethyl acetate petroleum ether to give S.8a in yields of ∼65% from S.4. The isomers can be distinguished because the 2′-O-silyl isomer runs faster than the 3′-O-silyl isomer both on silica gel and C18 reversed-phase chromatography. See Table 2.8.2 for NMR data. If desired, the identity can be verified by two-dimensional COSY NMR: for the 2′-O-silyl isomer, the hydroxyl resonance only shows a cross-peak to the 3′-H resonance, while for the 3′-O-silyl isomer, the hydroxy resonance only shows a cross-peak to the 2′-H resonance.
Protection of Nucleosides for Oligonucleotide Synthesis
2.8.5 Current Protocols in Nucleic Acid Chemistry
Supplement 6
Phosphitylate 28. In an oven-dried 25-mL round-bottom flask, place 3.05 g (3.0 mmol) of pure S.8a and 0.28 g (1.5 mmol) of diisopropylammonium tetrazolide. Dry the flask and a rubber septum (not inserted) in an evacuated desiccator over P2O5 overnight. It is critical that the reaction be absolutely anhydrous. Further, the starting material must be pure, since the product can only tolerate a very fast chromatographic purification to remove the excess reagent.
29. Open the desiccator under argon and immediately insert the septum. Displace any air with argon through a vent needle in the septum. Add 15 mL of dry dichloromethane through the septum and swirl 5 to 10 min to dissolve the solids completely. 30. Cool the flask in an ice bath at 0° and add 1.00 mL (3.0 mmol) of 2-cyanoethyl tetraisopropylphosphorodiamidite. Keep the mixture at 0° for one hour and swirl it every 15 min or so. 31. Remove a small sample carefully with a syringe with an oven-dried needle to check by HPLC or TLC. Normally, the reaction will be about 75% to 85% done. 32. Remove the flask from the ice bath and keep it at room temperature. Add another 0.5 mL (1.5 mmol) of the phosphitylating reagent and allow the reaction to proceed for several more hours. Check by HPLC or TLC no more than once per hr, each time using a dry syringe needle. Note that the product exists as a pair of diastereomers, since the phosphorus atom is chiral. Any inadvertent hydrolysis of the product results in a pair of hydrogen phosphonate diesters that are much more polar than the product. Some hydrolysis will occur during HPLC and TLC analysis.
33. Prepare a small glass column containing about 10 cm of silica gel packed in 98:2 dry methylene chloride:triethylamine. 34. Place the reaction mixture directly onto this column and load it using nitrogen pressure. Wash the column using nitrogen pressure with about 30 mL of 98:2 dry methylene chloride:triethylamine, followed by 49:1:50 dry methylene chloride:triethylamine:dry acetonitrile. The product normally elutes after 20 to 50 mL, sometimes just after a yellow impurity. It is very important to work as quickly as possible so as not to leave the product in solution any longer than necessary, since it will start to degrade immediately. A quick way to check the fractions for product is to spot them on a grid marked on a TLC plate. The plate does not have to be developed, just checked for UV-active material. Then the first and last fractions can be checked by HPLC or on a developed TLC plate.
36. Combine the fractions containing pure product and evaporate to a foam. Dry the product in a desiccator over P2O5. 37. Check the product for purity by 31P NMR (Table 2.8.2). BASIC PROTOCOL 2
Regioselective 2′-Silylation of Purine Ribonucleosides for Phosphoramidite RNA Synthesis
SYNTHESIS OF 5′-O-(4,4′-DIMETHOXYTRITYL)-2′-O-tertBUTYLDIMETHYSILYL-2-N-ACYLGUANOSINE In this protocol, N- and 5′-O-protected guanosine (S.13 in Fig. 2.8.2) is generated in a similar fashion as S.4 in Basic Protocol 1, except that guanosine is first amino protected (whereas adenosine is first tritylated) because the N-phenoxyacetyl derivative is crystalline and therefore easier to isolate. Silylation, dephosphorylation, and phosphitylation are performed following the procedures for adenosine.
2.8.6 Supplement 6
Current Protocols in Nucleic Acid Chemistry
Figure 2.8.2 N-Phenoxylacetylation, dimethoxytritylation, silylation, dephosphonylation, and phosphitylation of guanosine. Abbreviations: Ad, adamantanecarbonyl; DBU, 1,8-diazabyclyclo[5.4.0]undec-7-ene; DMTr, 4,4′-dimethoxytrityl; HOBT, 1-hydroxybenzotriazole; Ph, phenyl; i-Pr, isopropyl; TMS, trimethylsilyl; TBDMS, tert-butyldimethylsilyl.
Materials Guanosine Pyridine Nitrogen source Trimethylchlorosilane Guanosine phenoxyacetylating reagent (see recipe) 2-Propanol Methanol Dichloromethane Acetonitrile (anhydrous, dried over 3Å molecular sieves) 0.1 M triethylammonium acetate (TEAA) Dimethylformamide dimethyl acetal 4,4′-Dimethoxytrityl chloride (DMTr-Cl) Methanol
Protection of Nucleosides for Oligonucleotide Synthesis
2.8.7 Current Protocols in Nucleic Acid Chemistry
Supplement 6
Sodium bicarbonate Dichloromethane Ammonium phenyl-H-phosphonate (see recipe) 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) tert-Butyldimethylsilyl chloride (TBDMS-Cl) 0.5 M potassium phosphate buffer, pH 7.0 (APPENDIX 2A) Glycerol 1-Adamantanecarbonyl chloride 5:95 to 15:85 (v/v) acetone/dichloromethane (optional; for phosphoramidite synthesis) 250-mL round-bottom flasks Magnetic stir bar Rotary evaporator Silica gel 60F TLC plates (Merck) Waters XTerra 2.5-µm C18 chromatography column Vacuum pump Septum Vent needle Desiccator with P2O5 Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Phenoxyacetylate guanosine 1. Suspend 1.42 g (5 mmol) guanosine in 10 mL pyridine in a 250-mL round-bottom flask with a magnetic stir bar and concentrate to dryness using a rotary evaporator and vacuum pump. Repeat this azeotropic drying process two times with 10-mL portions of pyridine. 2. Suspend the dry guanosine in 60 mL pyridine and concentrate to ∼50 mL. 3. Seal the flask with a septum and displace the air with nitrogen through a vent needle in the septum. Keep the nitrogen flowing slowly. 4. Cool this mixture in an ice-bath and add 3.8 mL (30 mmol) trimethylchlorosilane over 3 to 5 min. Trimethylchlorosilane is highly moisture sensitive. Use of special bottles such as the Aldrich SURE-SEAL system will help to prevent deterioration of the reagent.
5. Remove the flask from the ice bath and maintain 1 hr at room temperature. 6. Add all the freshly prepared guanosine phenoxyacetylating reagent using a syringe. Remove the nitrogen line and vent needle and stir 36 hr. 7. Add 30 mL water, concentrate the solution, and co-evaporate two times with 30-mL portions of water to a final volume of ~15 mL. 8. Filter the slurry. The solid contains both the product (S.11) and some 1-hydroxybenzotriazole from the guanosine phenoxyacetylating reagent. Regioselective 2′-Silylation of Purine Ribonucleosides for Phosphoramidite RNA Synthesis
9. To remove the 1-hydroxybenzotriazole, shake the solid thoroughly with a 50-mL portion of water and filter. Repeat with 20 mL water followed by three 20-mL portions of 2-propanol to give S.11 as a colorless solid in yields of up to 95%.
2.8.8 Supplement 6
Current Protocols in Nucleic Acid Chemistry
10. Check the product by HPLC using a gradient of 2:98 to 80:20 acetonitrile: 0.1 M TEAA pH 6.8 on a C18 column or TLC (APPENDIX 3D) on silica gel 60F plates using the appropriate concentration of methanol in dichloromethane (Table 2.8.1). 11. Dry the product in a desiccator over P2O5 at least overnight and check that the yield is <100%. A yield >100% means that the product is contaminated with hydroxybenzotriazole and one should repeat the thorough shaking with 2-propanol.
Tritylate 12. Dissolve the dry S.11 in 60 mL pyridine, concentrate to ∼50 mL, and add 0.8 mL (6 mmol) dimethylformamide dimethyl acetal. 13. Seal the flask with a septum and displace the air with nitrogen through a vent needle in the septum. After a few minutes, remove the nitrogen line and vent needle. Allow to sit for 1 hr. The dimethylformamide dimethyl acetal will slowly replace the phenoxyacetyl group so the time and the amount of this reagent used is kept to a minimum.
14. Concentrate to an oil, dissolve the oil in 60 mL pyridine, and concentrate to ∼50 mL. 15. Add 2.03 g (6 mmol) 4,4′-dimethoxytrityl chloride and stir 2 to 3 hr. 16. Check the reaction by HPLC or TLC. Examine the plate under UV light, and then hold it over an open container of fresh aqueous HCl to observe trityl-containing spots. When the TLC plate is held over an open container of HCl, the fumes will cause any trityl-containing spots to turn a bright orange. If the reaction is not complete after 1 hr, add an additional 0.5 mmol of 4,4′-dimethoxytrityl chloride and wait another 1 hr.
17. Add 10 mL methanol to quench the excess reagent, wait 5 min, and then pour the solution into 100 mL water containing 1 g (12 mmol) sodium bicarbonate. 18. Extract the solution two times with 80-mL portions of dichloromethane and concentrate the combined organic layers to dryness. 19. Check the mixture by HPLC or TLC. Purify the residue by column chromatography (APPENDIX 3E) on silica gel using 0:100 to 10:90 (v/v) methanol/dichloromethane to give pure S.13 in yields of up to ∼90%. Silylate 20. To 2.63 g (15 mmol) ammonium phenyl-H-phosphonate, add 2.3 mL (15 mmol) DBU and co-evaporate with 50 mL pyridine. 21. Dissolve the residue in 120 mL pyridine, concentrate to ∼100 mL, add 2.26 g (15 mmol) TBDMS-Cl and mix. Place 3.52 g (5 mmol) S.4 in a dry 250-mL round-bottom flask and dry by evaporation of pyridine as in step 1. Using a syringe, add the mixture prepared in step 21 to S.4, followed by 3.8 mL (25 mmol) DBU. The silylation reaction can be performed using other N- and 5′-O-protected guanosine derivatives.
22. Stir 5 to 8 hr and check the reaction by HPLC or TLC. If the reaction is not complete, add 1 mmol more of DBU and wait another 2 hr.
Protection of Nucleosides for Oligonucleotide Synthesis
2.8.9 Current Protocols in Nucleic Acid Chemistry
Supplement 6
23. Pour the mixture into 100 mL of 0.5 M aqueous potassium phosphate buffer, pH 7.0, and extract two times with 100-mL portions of dichloromethane. Concentrate the combined organic layers to dryness. Dephosphonylate 24. Add 1.38 g (15 mmol) glycerol to the residue and dry the mixture by co-evaporation with 50 mL pyridine. 25. Dissolve the residue in 60 mL pyridine, concentrate to about ∼50 mL, and add 2.98 g (15 mmol) of 1-adamantanecarbonyl chloride. Stir 10 min. 26. Pour the solution into 100 mL of 0.5 M potassium phosphate buffer, pH 7.0, and extract two times with 100-mL portions of dichloromethane. Concentrate the combined organic layers to dryness. 27. Check the mixture by HPLC or TLC and purify the residue by column chromatography on silica gel using 5:95 to 15:85 acetone/dichloromethane to give S.17a in yields of ∼65% from S.13. The isomers can be distinguished because the 2′-O-silyl isomer runs faster than the 3′-O-silyl isomer both on silica gel and C18 reversed-phase chromatography. See Table 2.8.2 for NMR data. If desired, the identity can be verified by two-dimensional COSY NMR: for the 2′-O-silyl isomer, the hydroxyl resonance only shows a cross-peak to the 3′-H resonance, while for the 3′-O-silyl isomer, the hydroxyl resonance only shows a cross-peak to the 2′-H resonance.
Phosphitylate 28. In an oven-dried 25-mL round-bottom flask, place 3.05 g (3.0 mmol) of pure S.17a and 0.28 g (1.5 mmol) of diisopropylammonium tetrazolide. Dry the flask and a rubber septum (not inserted) in an evacuated desiccator over P2O5 overnight. It is critical that the reaction be absolutely anhydrous. Further, the starting material must be pure, since the product can only tolerate a very fast chromatographic purification to remove the excess reagent.
29. Open the desiccator under argon and immediately insert the septum. Displace any air with argon through a vent needle in the septum. Add 15 mL of dry dichloromethane through the septum and swirl 5 to 10 min to dissolve the solids completely. 30. Cool the flask in an ice bath at 0° and add 1.00 mL (3.0 mmol) of 2-cyanoethyl tetraisopropylphosphorodiamidite. Keep the mixture at 0° for 1 hr and swirl it every 15 min or so. 31. Remove a small sample carefully with a syringe with an oven-dried needle to check by HPLC or TLC. Normally, the reaction will be about 75% to 85% done. 32. Remove the flask from the ice bath and keep it at room temperature. Add another 0.5 mL (1.5 mmol) of the phosphitylating reagent and allow the reaction to proceed for several more hours. Check by HPLC or TLC no more than once per hr, each time using a dry syringe needle.
Regioselective 2′-Silylation of Purine Ribonucleosides for Phosphoramidite RNA Synthesis
Note that the product exists as a pair of diastereomers, since the phosphorus atom is chiral. Any inadvertent hydrolysis of the product results in a pair of hydrogen phosphonate diesters that are much more polar than the product. Some hydrolysis will occur during HPLC and TLC analysis.
33. Prepare a small glass column containing about 10 cm of silica gel packed in 98:2 dry methylene chloride:triethylamine.
2.8.10 Supplement 6
Current Protocols in Nucleic Acid Chemistry
Protection of Nucleosides for Oligonucleotide Synthesis
2.8.11 Current Protocols in Nucleic Acid Chemistry
Supplement 6
34. Place the reaction mixture directly onto this column and load it using nitrogen pressure. Wash the column using nitrogen pressure with about 30 mL of 98:2 dry methylene chloride:triethylamine, followed by 49:1:50 dry methylene chloride:triethylamine:dry acetonitrile. The product normally elutes after 20 to 50 mL, sometimes just after a yellow impurity. It is very important to work as quickly as possible so as not to leave the product in solution any longer than necessary, since it will start to degrade immediately. A quick way to check the fractions for product is to spot them on a grid marked on a TLC plate. The plate does not have to be developed, just checked for UV-active material. Then the first and last fractions can be checked by HPLC or on a developed TLC plate.
36. Combine the fractions containing pure product and evaporate to a foam. Dry the product in a desiccator over P2O5. 37. Check the product for purity by 31P NMR (Table 2.8.2). REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Adenosine phenoxyacetylating reagent Co-evaporate 2.03 g (15 mmol) of 1-hydroxybenzotriazole and 2.2 mL (20 mmol) N-methylmorpholine two times with 20-mL portions of acetonitrile. Dissolve the residue in 50 mL dichloromethane. Add 2.1 mL (15 mmol) phenoxyacetyl chloride and shake for 10 min. Prepare fresh. Ammonium phenyl-H-phosphonate Add 38.3 mL (0.20 mol) diphenyl phosphite over 10 min to 400 mL of 7.4 M aqueous ammonia. Stir for 1 hr. Concentrate to dryness and co-evaporate the residue two times with 100-mL portions of absolute ethanol. Stir the residue with 400 mL ethyl ether for 30 min to give up to 85% of the colorless crystalline product. Store up to 1 month at –20°C. Diisopropylammonium tetrazolide Place 2.00 g (28.5 mmol) of solid tetrazole in a dry 250-mL round-bottom flask containing a dry stir bar and add 130 mL of dry acetonitrile. Stir until dissolved, then add 9.0 mL (63.9 mmol) of freshly distilled diisopropylamine. After 2 min of stirring, collect the white precipitate by filtration in a dry glass funnel and wash it four times with 10-mL portions of dry acetonitrile. Dry the solid in a desiccator over P2O5. Store up to 3 months at –20°C. Guanosine phenoxyacetylating reagent Co-evaporate 1.35 g (10 mmol) of 1-hydroxybenzotriazole and 1.1 mL (10 mmol) N-methylmorpholine two times with 20-mL portions of acetonitrile. Dissolve the residue in 25 mL dichloromethane. Add 1.39 mL (10 mmol) phenoxyacetyl chloride and shake for 10 min. Prepare fresh. COMMENTARY Background Information Regioselective 2′-Silylation of Purine Ribonucleosides for Phosphoramidite RNA Synthesis
The procedures described here use adenosine and guanosine that are 5′-protected with the 4,4′-dimethoxytriyl (DMTr) group and amino-protected with the labile phenoxyacetyl group (Wu et al., 1988; Chaix et al., 1989; Singh
and Nahar, 1995; Sinha et al., 1995). They should also be applicable to nucleosides containing most other amino-protecting groups. Amino protection of adenosine with the benzoyl group and guanosine with the isobutyryl group can be carried out by standard literature
2.8.12 Supplement 6
Current Protocols in Nucleic Acid Chemistry
procedures, and these derivatives are more easily handled than are the more-labile phenoxyacetylated compounds. A general discussion of amino-protecting groups and literature references is given in UNIT 2.1. The procedures developed by Ogilvie for 2′-silylation proceed with only modest regioselectivity (Ogilvie, 1978, 1979). Although use of silver nitrate improves the selectivity, the results are variable and do not approach the selectivity of the above protocols (Hakimelahi, 1982). A general discussion of 2′-protecting groups, including the 2′-TBDMS group, is given in UNIT 2.2.
Critical Parameters The most difficult of the above protocols to carry out are the tritylation and phenoxyacetylation steps used for preparation of S.4 and S.13. Skill and practice are required to achieve high yields on these protection reactions, largely because of the phenoxyacetyl group. In contrast, the regioselective silylation and dephosphonylation reactions work well even in the hands of unskilled researchers.
Anticipated Results For the reasons discussed above, some experience is required to achieve high yields for the phenoxyacetylation reactions, and initial efforts are likely be give more modest yields (e.g., 50%). With experience, yields of ~90% can be expected. The regioselectivity of the silylation reaction is invariably 85% to 90% regardless of experience.
Time Considerations The total time for conversion of adenosine or guanosine to the fully protected derivatives S.8a and S.17a, respectively, is ∼1 week.
Literature Cited Chaix, C., Duplaa, A.M., Molko, D., and Téoule, R. 1989. Solid phase synthesis of the 5′-half of the initiator t-RNA from B. subtilis. Nucl. Acids Res. 17:7381-7393.
Hakimelahi, G.H., Proba, Z.A., and Ogilvie, K.K. 1982. New catalysts and procedures for the dimethoxytritylation and selective silylation of ribonucleosides. Can. J. Chem. 60:1106-1113. Ogilvie, K.K., Beaucage, S.L., Schifman, A.L., Theriault, N.Y., and Sadana, K.L. 1978. The synthesis of oligoribonucleotides. II. The use of silyl protecting groups in nucleoside and nucleotide chemistry. VII. Can. J. Chem. 56:27682780. Ogilvie, K.K., Schifman, A.L., and Penney, C.L. 1979. The synthesis of oligoribonucleotides. III. The use of silyl protecting groups in nucleoside and nucleotide chemistry. VIII. Can. J. Chem. 57:2230-2238. Singh, K.K. and Nahar, P. 1995. An improved method for the synthesis of N-phenoxyacetylribonucleosides. Synth. Commun. 25:1997-2003. Sinha, N.D., Davis, P., Schultze, L.M., and Upadhya, K. 1995. A simple method for N-acylation of adenosine and cytidine nucleosides using carboxylic acids activated in situ with carbonyldiimidazole. Tetrahedron Lett. 36:9277-9280. Song, Q., Wang, W., Fischer, A., Zhang, X., Gaffney, B.L., and Jones, R.A. 1999. High yield protection of purine ribonucleosides for phosphoramidite RNA synthesis. Tetrahedron Lett. 40:4153-4156. Wu, T., Ogilvie, K.K., and Pon, R.T. 1988. N-Phenoxyacetylated guanosine and adenosine phosphoramidites in the solid phase synthesis of oligoribonucleotides: Synthesis of a ribozyme sequence. Tetrahedron Lett. 29:4249-4252. Zemlicka, J. 1963. Reactions of dimethylformamide acetals with some heterocyclic systems. Collect. Czech. Chem. Commun. 28:1060-1062. Zhang, X., Abad, J.-L., Huang, Q., Zeng, F., Gaffney, B.L., and Jones, R.A. 1997. High yield protection of purine ribonucleosides for H-phosphonate RNA synthesis. Tetrahedron Lett. 38:7135-7138.
Contributed by Barbara L. Gaffney and Roger A. Jones Rutgers, The State University of New Jersey Piscataway, New Jersey
Protection of Nucleosides for Oligonucleotide Synthesis
2.8.13 Current Protocols in Nucleic Acid Chemistry
Supplement 6
Preparation of 2′-O-[(Triisopropylsilyl)oxy]methylprotected Ribonucleosides
UNIT 2.9
This unit describes, in detail, the preparation of 2′-O-[(triisopropylsilyl)oxy]methyl (TOM)–protected phosphoramidite building blocks derived from the ribonucleosides adenosine, cytidine, guanosine, and uridine (see Basic Protocol). These building blocks are suitable for the chemical synthesis of RNA oligonucleotides under DNA-coupling conditions. Additionally, protocols are presented for the preparation of suitably protected purines, N6-acetyl-5′-O-(4,4′-dimethoxytrityl)adenosine and N2-acetyl-5′-O-(4,4′-dimethoxytrityl)guanosine (see Support Protocols 1 and 2, respectively), and for the protecting group reagent [(triisopropylsilyl)oxy]methyl chloride (TOM⋅Cl; see Support Protocol 3). The two corresponding pyrimidine derivatives are commercially available (e.g., ChemGenes). The preparation of phosphoramidites from these building blocks and the synthesis of oligoribonucleotides is described in UNIT 3.8. CAUTION: All reactions must be performed in a well-ventilated fume hood to avoid exposure to dibutyltin dichloride and TOM⋅Cl. These procedures should be performed only by personnel trained and experienced in organic synthesis. Standard precautions to prevent excessive exposure to toxic chemicals and solvents should be followed. All reactions should first be performed on a small scale. INTRODUCTION OF THE [(TRIISOPROPYLSILYL)OXY]METHYL GROUP INTO N-ACETYLATED, 5′-O-DIMETHOXYTRITYLATED RIBONUCLEOSIDES
BASIC PROTOCOL
The introduction of the TOM group into the four N-acetylated, 5′-O-dimethoxytritylated ribonucleosides is presented in Figure 2.9.1. Alkylation of the 2′,3′-diols of ribonucleosides is achieved by first forming their cyclic 2′,3′-di-O-dibutylstannyl derivatives under basic conditions with n-dibutyltin dichloride and N-ethyl-N,N-diisopropylamine in 1,2-dichloroethane for 1 hr at 25°C. These activated intermediates are subsequently treated with 1.1 to 1.3 equivalents of TOM⋅Cl for 20 min at 80°C. After the aqueous workup, the 2′-O-alkylated and 3′-O-alkylated nucleosides (S.3a-d and S.2a-d, respectively) are isolated in pure form by chromatography on silica gel (unreacted starting materials can also be recovered). Under these optimized reaction conditions, side reactions (alkylation of the base moieties) are observed only to a very small extent (<5%). Fair to good yields of the desired 2′-O-alkylated products S.3a-d are obtained (40% to 60%), along with various amounts of the 3′-O-alkylated isomers S.2a-d (5% to 30%). In all cases, the predominant first-eluting isomer is the desired 2′-O-alkylated compound. In the following protocol, 5′-O-dimethoxytritylated, N-acetylated ribonucleoside derivatives are used as starting materials. However, employing the identical reaction conditions, the TOM group can also be introduced with similar results to 5′-O-dimethoxytritylated ribonucleosides that are protected with other N-acyl protecting groups (e.g., benzoyl, isobutyryl).
Protection of Nucleosides for Oligonucleotide Synthesis Contributed by Stefan Pitsch and Patrick A. Weiss Current Protocols in Nucleic Acid Chemistry (2001) 2.9.1-2.9.14 Copyright © 2001 by John Wiley & Sons, Inc.
2.9.1 Supplement 7
Figure 2.9.1 Preparation of the N-acetylated-5′-O-DMTr-2′-O-TOM-protected ribonucleosides S.3a-d. n-Bu2SnCl2, n-dibutyltin chloride; DMTr, 4,4′-dimethoxytrityl; i-Pr2NEt, N-ethyl-N,N-diisopropylamine.
Materials Nitrogen source 5′-O-Dimethoxytritylated, N-acetylated ribonucleosides: N6-Ac-5′-O-DMTr-adenosine (S.1a; see Support Protocol 1) N2-Ac-5′-O-DMTr-guanosine (S.1b; see Support Protocol 2) N4-Ac-5′-O-DMTr-cytidine (S.1c; ChemGenes) 5′-O-DMTr-uridine (S.1d; ChemGenes) 1,2-Dichloroethane (reagent grade) N-Ethyl-N,N-diisopropylamine n-Dibutyltin dichloride [(Triisopropylsilyl)oxy]methyl chloride (TOM⋅Cl; S.6; see Support Protocol 3) Ethyl acetate (for chromatography, technical grade) Saturated aqueous sodium bicarbonate (NaHCO3) 9:1 (v/v) ethyl acetate/hexane (for A, C, and U) 19:1 (v/v) dichloromethane/methanol (for G) Anisaldehyde reagent (see recipe) Dichloromethane (CH2Cl2) with and without 5% triethylamine (with TEA for G only) Magnesium sulfate Celite Silica gel (230 to 400 mesh) 6:4, 5:5, 4:6, and so on (v/v) hexane/ethyl acetate containing 2% triethylamine (for A, C, and U) Sand Methanol (for G) 95:5:0.1 (v/v/v) dichloromethane/methanol/triethylamine
Preparation of 2′-O[(Triisopropylsilyl)oxy]methylprotected Ribonucleosides
500-mL two-neck flask equipped with a reflux condenser and stir bar Balloon Rubber septum 80°C water bath TLC plates (Merck silica gel 60, 4 × 10–cm) 254-nm UV lamp 1-L separatory funnel
2.9.2 Supplement 7
Current Protocols in Nucleic Acid Chemistry
1-L Erlenmeyer flask 6-cm glass filter Rotary evaporator equipped with a vacuum pump or water aspirator 5-cm-diameter chromatography column Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare TOM-protected ribonucleosides 1. In a 500-mL two-neck flask equipped with a reflux condenser, a stir bar, a balloon filled with N2, and a rubber septum, dissolve 50 mmol of 5′-O-dimethoxytritylated, N-acetylated ribonucleoside in 200 mL of 1,2-dichloroethane. 2. While stirring, add 29.2 mL (180 mmol) N-ethyl-N,N-diisopropylamine and then slowly add 18.8 g (50 mmol) solid n-dibutyltin dichloride. Stir 1 hr at room temperature. It is extremely important that the dibutyltin dichloride be added after the N-ethyl-N,N-diisopropylamine. CAUTION: Dibutyltin dichloride is very toxic and quite volatile. It must be handled in a well-ventilated fume hood.
3. Place the flask in an 80°C water bath and stir 5 to 10 min. 4. Add 14 mL (65 mmol) TOM⋅Cl (S.6) with a syringe and continue stirring and heating for an additional 15 min at 80°C. Remove the flask from the water bath. 5. Using a syringe, transfer ∼50 µL of the clear reaction mixture to a small tube containing 50 µL ethyl acetate/50 µl saturated aqueous NaHCO3 and mix thoroughly. 6. Analyze the clear supernatant by TLC (APPENDIX 3D). Co-spot the starting material for comparison. Elute with 9:1 (v/v) ethyl acetate/hexane for adenosine, cytidine, and uridine derivatives, and with 19:1 (v/v) dichloromethane/methanol for the guanosine derivative. 7. Visualize by exposing the plate to a 254-nm UV lamp and staining it with anisaldehyde reagent. Typically, the Rf value of the desired 2′-O-alkylated compound S.3a-d is ∼0.55 and the Rf value of the 3′-O-alkylated byproduct S.2a-d is ∼0.45. The Rf value of the starting material S.1a-d is ∼0.1, and the Rf value of the nucleobase-alkylated byproduct is ∼0.9.
8. Optional: If the turnover is less than ∼70% to 80% (∼20% remaining starting material), return the reaction mixture to the 80°C water bath and add an additional 0.2 eq TOM⋅Cl. Stir an additional 15 min at 80°C and analyze again by TLC. No more TOM⋅Cl should be added if the amount of nucleobase-alkylated byproducts (Rf ∼0.9) exceeds 5% to 10%.
9. Dilute the reaction mixture (step 4) with 250 mL dichloromethane and add it under stirring to 400 mL saturated aqueous NaHCO3. Stir the biphasic mixture for 10 to 15 min. During this time a white solid precipitates.
10. Pour the mixture into a 1-L separatory funnel and allow the phases to separate. Pour the lower, yellow-colored organic phase (which contains some colorless, solid material) into a 1-L Erlenmeyer flask.
Protection of Nucleosides for Oligonucleotide Synthesis
2.9.3 Current Protocols in Nucleic Acid Chemistry
Supplement 7
11. Extract the aqueous phase once more with 250 mL dichloromethane. Combine this organic phase with first organic phase in the 1-L Erlenmeyer flask. 12. Add 5 to 10 g solid magnesium sulfate and vacuum filter the organic phase by means of a 6-cm glass filter covered with 1.5 cm Celite. 13. Wash the Celite with dichloromethane and evaporate the filtrate to dryness in a rotary evaporator. Isolate 2′-O-TOM-protected ribonucleosides 14. Prepare a slurry of 400 g silica gel in 6:4 (v/v) hexane/ethyl acetate containing 2% triethylamine for A, C, and U (S.3a,c,d) or in dichloromethane containing 5% triethylamine for G (S.3b). For detailed procedures for column chromatography, see APPENDIX 3E.
15. Pour slurry into a 5-cm-diameter column and carefully layer ∼3 cm sand on top. 16. Dissolve the crude product in a minimal amount of dichloromethane and place it carefully on top of the column. 17. Elute first with 1 L of the solvent mixture used to pack the column, and then with gradually more polar solvent, collecting 200-mL fractions. a. For A, C, and U, use 1 L each of hexane/ethyl acetate at serial dilutions of 5:5, 4:6, and so on. b. For G, use 1-L portions of dichloromethane with increased methanol at 0.5% increments (1000:5, 1000:10, and so on). Always include the amount of triethylamine indicated in step 14.
18. Check fractions periodically by TLC. As soon as the two alkylation products are completely eluted, wash column with 3 L of 95:5:0.1 (v/v/v) dichloromethane/methanol/triethylamine in order to isolate unreacted starting material. 19. Pool fractions that contain pure 2′-O-TOM-substituted ribonucleosides (the firsteluting main product, Rf typically 0.55). 20. Pool fractions that contain impure product separately and repeat chromatography with these fractions on an appropriate smaller scale. 21. Combine fractions that contain pure product, evaporate to dryness in a rotary evaporator, and dry overnight at high vacuum (<0.05 mbar). Typically, ∼15 to 20 g (40% to 60%) pure 2′-O-TOM-protected ribonucleoside derivatives are obtained in the form of a solid foam.
22. Check purity of the material by 1H-NMR. Only pure products (purity >95%) should be used for phosphoramidite and oligoribonucleotide synthesis (UNIT 3.8).
Preparation of 2′-O[(Triisopropylsilyl)oxy]methylprotected Ribonucleosides
N6-Ac-5′-O-DMTr-2′-O-TOM-adenosine (S.3a): 15.9 g (40%). TLC (hexane/ethyl acetate 1:9) 0.60; [a]D25 +11.5 (c = 1.36, CDCl3); λmax (methanol) 272 (20,500), 234 (24,700); δH (CDCl3) 0.99-1.08 (21 H, m, i-Pr3Si); 2.61 (s, CH3CO), 3.07 (br. d, J ≈ 3 Hz, HO-3′), 3.40 (dd, J = 3.9, 10.6 Hz, H-5′), 3.53 (dd, J = 3.5, 10.6 Hz, H′-5′), 3.78 (s, 2 OCH3), 4.30 (q, J = 3.7 Hz, H-4′), 4.57 (br. q, J ≈ 3 Hz, H-3′), 4.96 (t, J = 5.3 Hz, H-2′), 4.98 and 5.14 (2d, J = 5.0 Hz, OCH2O), 6.21 (d, J = 5.3 Hz, H-1′), 6.78-6.81 (4 H, m, DMTr), 7.23-7.44 (9 H, m, DMTr), 8.16 (s, H-2), 8.60 (s, H-8), 8.65 (br. s, HN); δC (CDCl3) 11.8 (d), 17.8 (q), 25.9 (q), 55.3 (q), 63.4 (t), 71.0 (d), 82.2 (d), 84.6 (d), 86.8 (s), 87.4 (d), 91.0 (t), 113.4 (d), 122.5 (s), 127.2 (d), 128.1 (d), 128.4 (d), 130.3 (d), 135.9, (s), 142.1 (d), 144.8 (s), 149.4 (s), 151.4 (s), 152.7 (d), 158.9 (s), 170.7 (s); m/z 798 (29, MH+), 303 (100). Anal. calcd. for C43H55N5O8Si: C, 64.72; H, 6.95; N, 8.78. Found: C, 64.64; H, 7.06; N, 8.74.
2.9.4 Supplement 7
Current Protocols in Nucleic Acid Chemistry
N2-Ac-5′-O-DMTr-2′-O-TOM-guanosine (S.3b): 24.4 g (60%). TLC (CH2Cl2/methanol 19:1) 0.55; [a]D25 +7.7 (c = 0.85, CDCl3); λmax (methanol) 282sh (13,500), 275 (14,300), 260sh (17,500), 251 (19,200), 235 (26,500); δH (CDCl3) 0.94-1.12 (21 H, m, i-Pr3Si), 1.46 (s, CH3CO), 3.03 (br. d, J ≈ 3 Hz, HO-3′), 3.13 (dd, J = 2.8, 10.6 Hz, H-5′), 3.53 (dd, J = 2.0, 10.6 Hz, H′-5′), 3.76 and 3.78 (2s, 2 OCH3), 4.24 (q, J = 2.0 Hz, H-4′), 4.57 (ddd, J = 1.5, 5.0 Hz, 3.0, H-3′), 4.95 and 5.14 (2d, J = 4.7 Hz, OCH2O), 5.09 (dd, J = 5.3, 7.5 Hz, H-2′), 5.90 (d, J = 7.5 Hz, H-1′), 6.78-6.83 (4 H, m, DMTr), 7.18-7.57 (9 H, m, DMTr), 7.75 (br. s, NH), 7.81 (s, H-8), 11.82 (br. s, NH); δC (CDCl3) 11.8 (d), 17.8 (q), 23.7 (q), 55.4 (q), 63.9 (t), 70.8 (d), 81.5 (d), 84.5 (d), 86.5 (d), 86.9 (s), 91.1 (t), 113.5 (d), 122.4 (s), 127.3 (d), 128.2 (d), 128.3 (d), 130.3 (d), 135.9 (s), 136.3 (s), 139.1 (d), 145.3 (s), 147.4 (s), 148.7 (s), 156.3 (s), 159.0 (s), 171.8 (s). m/z 814 (17, MH+), 303 (100). Anal. calcd. for C43H55N5O9Si: C, 63.45; H, 6.81; N, 8.60. Found: C, 63.34; H, 6.84; N, 8.35. N4-Ac-5′-O-DMTr-2′-O-TOM-cytidine (S.3c): 17.4 g (45%). TLC (hexane/ethyl acetate 1:9) 0.55; [a]D25 +46.8 (c = 0.94, CDCl3); λmax (methanol) 300 (6,800), 283 (6,800), 236 (27,200); δH (CDCl3) 1.04-1.15 (21 H, m, i-Pr3Si), 2.21 (s, CH3CO), 3.34 (d, J = 8.4 Hz, HO-3′), 3.53 (dd, J = 2.5, 10.9 Hz, H-5′), 3.62 (dd, J = 1.8, 10.9 Hz, H’-5′), 3.81 and 3.82 (2s, 2 OCH3), 4.09 (br. dt, J ≈ 9, 2 Hz, H-4′), 4.23 (d, J = 5.0 Hz, H-2′), 4.37 (m, H-3′), 5.15 and 5.28 (2d, J = 4.6 Hz, OCH2O), 5.97 (s, H-1′), 6.84-6.88 (4 H, m, DMTr), 7.04 (d, J = 7.1 Hz, H-5), 7.24-7.44 (9 H, m, DMTr), 8.48 (d, J = 7.4 Hz, H-6), 8.62 (br. s, HN); δC (CDCl3) 11.9 (d), 17.8 (q), 24.9 (q), 55.3 (q), 61.4 (t), 67.9 (d), 83.50 (d), 83.55 (d), 87.2 (s), 90.2 (d), 90.9 (t), 96.8 (d), 113.5 (d), 127.4 (d), 128.3 (d), 128.4 (d), 128.5 (d), 130.4 (d), 135.6 (s), 135.8 (s), 144.6 (s), 145.1 (d), 155.3 (s), 159.0 (s), 163.1 (s), 170.6 (s); m/z 774 (23, MH+), 303 (100). Anal. calcd. for C42H55N3O9Si: C, 65.18; H, 7.16; N, 5.43. Found: C, 64.89; H, 7.18; N, 5.42. 5′-O-DMTr-2′-O-TOM-uridine (S.3d): 14.6 g (40%). TLC (hexane/ethyl acetate 1:4) 0.65; [a]D25 +42.9 (c = 1.00, CDCl3); λmax (methanol) 267 (13,100), 226 (28,600); δH (CDCl3) 1.05-1.15 (21 H, m, i-Pr3Si), 3.17 (br. d, J ≈ 3 Hz, HO-3′), 3.52 (br. d, J ≈ 11 Hz, H-5′), 3.55 (br. d, J ≈ 11 Hz, H′-5′), 3.80 (s, 2 OCH3); 4.11 (m, H-4′), 4.26 (dd, J = 3.5, 5.0 Hz, H-2′), 4.55 (br. t, J ≈ 3 Hz, H-3′), 5.03 and 5.23 (2d, J = 5.0 Hz, OCH2O), 5.29 (d, J = 8.1 Hz, H-5), 6.03 (d, J = 3.1 Hz, H-1′), 6.83-6.87 (4 H, m, DMTr); 7.24-7.40 (9 H, m, DMTr), 7.94 (d, J = 8.1 Hz, H-6), 8.38 (br. s, HN); δC (CDCl3) 11.9 (d), 17.8 (q), 55.3 (q), 62.3 (t), 69.5 (d), 83.0 (d), 83.8 (d), 87.3 (s), 88.0 (d), 90.8 (t), 102.4 (d), 113.5 (d), 127.4 (d), 128.2 (d), 128.4 (d), 130.4 (d), 135.4 (s), 135.6 (s), 140.4 (d), 144.6 (s), 150.4 (s), 159.0 (s), 159.1 (s), 163.3 (s); m/z 732 (21, M+), 303 (100). Anal. calcd. for C40H52N2O9Si: C, 65.55; H, 7.15; N, 3.82. Found: C, 65.29; H, 7.08; N, 4.02.
PREPARATION OF N6-ACETYL-5′-O-(4,4′-DIMETHOXYTRITYL)ADENOSINE
SUPPORT PROTOCOL 1
In this protocol, the preparation of N6-acetyl-5′-O-(4,4′-dimethoxytrityl)adenosine (S.1a) is presented. In this two-step process (Figure 2.9.2), N6-acetyladenosine (S.4a) is synthesized by first silylating the hydroxyl groups with trimethylsilyl chloride and then acetylating the amino group with acetyl chloride. Extractive work-up and cleavage of the trimethylsilyl ethers is carried out with acetic acid in methanol. The introduction of the 5′-O-(4,4′-dimethoxytrityl) group into the intermediates is carried out under standard conditions with 4,4′-dimethoxytrityl chloride/pyridine, giving the title compound (S.1a) in good yields. The intermediate (S.4a) is isolated by crystallization and the dimethoxytritylated compound (S.1a) is isolated by chromatography on silica gel. Materials Adenosine Pyridine (reagent grade) Nitrogen source Trimethylsilyl chloride (TMS⋅Cl) Acetonitrile (reagent grade), dry Acetyl chloride
Protection of Nucleosides for Oligonucleotide Synthesis
2.9.5 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Figure 2.9.2 Preparation of the N-acetylated-5′-O-dimethoxytritylated purine ribonucleosides S.1a and S.1b. Ac, acetyl; DMTr, 4,4′-dimethoxytrityl.
Dichloromethane, precooled Magnesium sulfate Toluene Acetic acid Dimethoxytrityl chloride (DMTr⋅Cl) Triethylamine Silica gel (230 to 400 mesh) Sand Saturated sodium bicarbonate solution in water 250- and 500-mL two-neck flasks Pressure-equilizing dropping funnel Balloon Rubber septum Stir bar 1-L separatory funnels Rotary evaporator with vacuum pump 1-L Erlenmeyer flasks 3-cm glass filter 3-cm-diameter chromatography column Additional reagents and equipment for thin-layer chromatography (TLC, APPENDIX 3D) and column chromatography (APPENDIX 3E)
Preparation of 2′-O[(Triisopropylsilyl)oxy]methylprotected Ribonucleosides
Acetylate adenosine 1. In an ice bath, prepare a suspension of 10 g adenosine (0.037 mol) in 75 mL pyridine in a 500-mL two-neck flask equipped with a pressure-equilizing dropping funnel, nitrogen-filled balloon, rubber septum, and stir bar. 2. Add 47.3 mL trimethylsilyl chloride (0.37 mol) dropwise to the precooled (4°C) suspension.
2.9.6 Supplement 7
Current Protocols in Nucleic Acid Chemistry
3. Remove the cooling bath and stir suspension 14 hr at room temperature. 4. Dilute with 110 mL dry acetonitrile and cool to 4°C using an ice bath. 5. Slowly add 4 mL (0.056 mol) acetyl chloride by syringe and stir 1 hr at 4°C. 6. Pour reaction mixture into a 1-L Erlenmeyer flask. While stirring, add 220 mL precooled (4°C) dichloromethane and 150 mL precooled (4°C) water. Pour into a 1-L separatory funnel. 7. Pour the lower organic layer into another 1-L separatory funnel. Add 200 mL ice-water to the funnel, shake, and pour the lower organic layer into a 1-L Erlenmeyer flask. 8. Add magnesium sulfate until a clear solution is obtained and vacuum filter by means of a 3-cm glass filter. 9. Evaporate the filtrate to dryness using a rotary evaporator. 10. Add 200 mL toluene and evaporate to dryness using a rotary evaporator. Repeat. Evaporation with toluene removes the pyridine.
11. Dissolve residue in 75 mL methanol and add 22.5 mL acetic acid. Keep the mixture at −20°C for 2 days to crystallize product. 12. Collect crystals by vacuum filtration on a 3-cm glass filter, wash them with a small amount of methanol, and dry them at high vacuum. N6-Acetyladenosine (S.4a): 9.1 g (80%) as off-white powder. TLC (CH2Cl2/methanol 7:3) 0.50; m.p. 175°C; [a]D25 -53.7 (c = 0.98, H2O/methanol 1:1); λmax (H2O) 273 (16,700), 209 (21,700); δH (CD3OD/D2O 1:1) 2.36 (s, CH3CO), 3.80 (dd, J = 3.3, 12.6 Hz, H-5′), 3.92 (dd, J = 2.8, 12.6 Hz, H′-5′), 4.23 (br. q, J ≈ 3 Hz, H-4′), 4.39 (dd, J = 3.4, 5.5 Hz, H-3′), 4.77 (t, J = 5.6 Hz, H-2′), 6.10 (d, J = 5.9 Hz, H-1′), 8.58 and 8.65 (2s, H-2 and H-8); δC (CD3OD/D2O 1:1) 24.9 (q), 63.2 (t), 72.4 (d), 75.7 (d), 87.8 (d), 90.8 (d), 125.1 (s), 145.3 (d), 150.9 (s), 153.0 (s), 153.5 (d), 173.4 (s); m/z 310 (100, MH+), 178 (55), 107 (40). Anal. calcd. for C12H15N5O5.(0.25H2O): C, 45.93; H, 4.98; N, 22.31. Found: C, 46.00; H, 4.87; N, 22.23.
Tritylate N6-acetyladenosine 13. In a 250-mL two-neck flask equipped with a rubber septum, nitrogen-filled balloon, and stir bar, dissolve 7.7 g (0.025 mol) N6-acetyladenosine (S.4a) in 80 mL pyridine. 14. Add 10.2 g (0.03 mol) dimethoxytrityl chloride in four 2.55-g portions at 20-min intervals. Keep the solution 1 hr at room temperature. 15. Pour reaction mixture into a 1-L Erlenmeyer flask. While stirring, add 250 mL dichloromethane and 150 mL water. Pour the mixture into a 1-L separatory funnel. Pour the lower organic layer into a 1-L Erlenmeyer flask. 16. Wash the aqueous phase with 100 mL dichloromethane. Allow phases to separate and then pour the organic phase into the same 1-L Erlenmeyer flask. 17. Add magnesium sulfate until a clear solution is obtained, filter by means of a 3-cm glass filter, and evaporate the filtrate to dryness in a rotary evaporator. 18. Add 100 mL toluene and evaporate again to dryness in a rotary evaporator. Repeat. Evaporation with toluene removes the pyridine. Protection of Nucleosides for Oligonucleotide Synthesis
2.9.7 Current Protocols in Nucleic Acid Chemistry
Supplement 7
19. Prepare a slurry of 40 g silica gel in 98:2 (v/v) dichloromethane/triethylamine and pour into a 3-cm-diameter chromatography column. Add ∼2-cm layer of sand on top of the column. 20. Dissolve the crude product in a minimal amount of dichloromethane and place it carefully on top of the column. 21. Start eluting with 250 mL of 98:2 (v/v) dichloromethane/triethylamine and continue eluting with gradually more polar solvent by adding stepwise 1% methanol (250 mL for each step). Collect 100-mL fractions. Always add 2% triethylamine to solvents.
22. Check fractions periodically by TLC (APPENDIX 3D). Pool the fractions that contain the main product [Rf = 0.55 in 9:1 (v/v) dichloromethane/methanol] and evaporate to dryness using a rotary evaporator. 23. Dissolve residue in 150 mL dichloromethane, add 100 mL saturated sodium bicarbonate solution, and stir 5 min. 24. Transfer mixture to a 1-L separatory funnel. Pour the lower organic layer into a 1-L Erlenmeyer flask. 25. Wash the aqueous phase with 100 mL dichloromethane. Allow phases to separate and pour the organic phase into the same 1-L Erlenmeyer flask. Add magnesium sulfate until a clear solution is obtained and vacuum filter by means of a 3-cm glass filter. 26. Evaporate to dryness using a rotary evaporator and dry overnight at high vacuum (<0.05 mbar). N6-Ac-5′-O-DMTr-adenosine (S.1a): 11.4 g (75%) as yellow, solid foam. TLC (CH2Cl2/methanol 9:1) 0.50; [a]D25 −7.4 (c = 0.87, CDCl3); λmax (methanol) 272 (18,700), 234 (22,700); δH (CDCl3) 2.58 (s), 3.31 (dd, J = 3.4, 10.6 Hz, H-5′), 3.44 (dd, J = 3.1, 10.6 Hz, H′-5′), 3.53 (br. s, OH), 3.75 (s, 2OCH3), 4.43 (br. q, J ≈ 2.5 Hz, H-4’), 4.49 (dd, J = 2.5, 5.3 Hz, H-3′), 4.88 (t, J = 5.3 Hz, H-2′), 5.74 (br. s, OH), 6.05 (d, J = 5.6 Hz, H-1′), 6.72-6.75 (4 H, m, DMTr), 7.16-7.29 (9 H, m, DMTr), 8.23 (s, H-2), 8.60 (s, H-8), 8.94 (br. s, NH); δC (CDCl3) 25.7 (q), 55.3 (q), 63.7 (t), 72.7 (d), 76.0 (d), 86.1 (d), 86.8 (s), 90.7 (d), 113.4 (d), 122.2 (s), 127.2 (d), 128.1 (d), 128.2 (d), 130.1 (d), 130.2 (d), 135.7 (s), 141.7 (d), 144.6 (s), 149.6 (s), 150.8 (s), 152.2 (d), 158.9 (s), 170.7 (s); m/z 612 (17, MH+), 303 (100). Anal. calcd. for C33H33N5O7: C, 64.80; H, 5.44; N, 11.45. Found: C, 64.56; H, 5.55; N, 11.18. SUPPORT PROTOCOL 2
PREPARATION OF N2-ACETYL-5′-O-(4,4′-DIMETHOXYTRITYL)GUANOSINE As with the protected adenosine (see Support Protocol 1), the preparation N2-acetyl-5′O-(4,4′-dimethoxytrityl)guanosine (S.1b) is a two-step process. N2-Acetylguanosine (S.4b) is prepared by peracetylation of guanosine with acetic anhydride in dimethylformamide/pyridine, followed by cleavage of the O-bound acetyl groups with NaOH in tetrahydrofuran/methanol/water. Tritylation is performed as in Support Protocol 1, although dimethylformamide is used as a co-solvent in the reaction with the guanosine derivative. Isolation of the intermediate (S.4b) is performed by chromatography and crystallization, and isolation of the product (S.1b) is performed by chromatography.
Preparation of 2′-O[(Triisopropylsilyl)oxy]methylprotected Ribonucleosides
Additional Materials (also see Support Protocol 1) Guanosine Dimethylformamide Acetic anhydride 1 M hydrochloric acid Methanol
2.9.8 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Tetrahydrofuran 10 M NaOH 250-mL two-neck flasks Reflux condenser 135°C bath Distillation apparatus (15 × 2.9–cm Vigreux column equipped with a condenser and water aspirator) 500-mL flask 4A molecular sieves Acetylate guanosine 1. In a 250-mL two-neck flask equipped with a reflux condenser, stir bar, and nitrogenfilled balloon, prepare a mixture of: 5.7 g (0.02 mol) guanosine 25 mL dimethylformamide 25 mL pyridine 25 mL acetic anhydride. 2. Heat 3 hr at reflux in a 135°C bath. 3. Remove all liquids by distillation on a 15 × 2.9–cm Vigreux column equipped with a condenser and water aspirator, at 100°C and 30 mbar, and dissolve the residue in 100 mL dichloromethane. 4. Extract with 100 mL of 1 M hydrochloric acid. 5. Extract the organic phase with 100 mL saturated sodium bicarbonate solution. 6. Dry organic phase with magnesium sulfate until a clear solution is obtained and vacuum filter by means of a 3-cm glass filter. 7. Add 15 g silica gel to the filtrate and evaporate to dryness using a rotary evaporator. 8. Place the powder on top of a chromatography column containing 20 g silica gel in dichloromethane. Elute with 500 mL dichloromethane, and then with 250 mL each (in order) 98:2, 96:4, 94:6, 92:8, and 90:10 (v/v) dichloromethane/methanol. Collect 100-mL fractions. 9. Check fractions periodically by TLC (APPENDIX 3D). Pool the fractions containing the intermediate N2-acetyl-2′,3′, 5′-tri-O-acetylguanosine (Rf = 0.5 in 95:5 [v/v] dichloromethane/methanol) in a 500-mL flask and evaporate them to dryness using a rotary evaporator. 10. Dissolve the residue in 200 mL of 10:8:7 (v/v/v) tetrahydrofuran/methanol/water and add 2 mL of 10 M NaOH. Stir solution 20 min at room temperature. 11. Add 2.5 mL acetic acid and concentrate the solution to 40 mL using a rotary evaporator. Keep the solution 1 day at 4°C to crystallize the product. 12. Collect crystals by vacuum filtration by means of a 3-cm glass filter, wash with a small amount of water, and dry at high vacuum (<0.05 mbar). N2-Acetylguanosine (S.4b): 5.05 g (77%) as an off-white powder. TLC (CH2Cl2/methanol 7:3) 0.30; m.p. 226°C; [a]D25 -19.0 (c = 0.94, H2O); λmax (H2O) 280sh (11,200), 259 (16,300); δH (D2O) 2.28 (s, CH3CO), 3.83 (dd, J = 4.0, 12.6 Hz, H-5′), 3.92 (dd, J = 1.0, 12.6 Hz, H′-5′), 4.21 (m, H-4′), 4.45 (t, J = 4.7 Hz, H-3′), 4.72 (t, J = 4.6 Hz, H-2′), 5.97 (d, J = 4.4 Hz, H-1′), 8.18 (s, H-8). δC (D2O) 26.2 (q), 64.0 (t), 72.9 (d), 76.8 (d), 87.8 (d), 90.9 (d), 122.9 (s), 142.5 (d), 150.6 (s), 152.1 (s), 160.2 (s), 178.3 (s); m/z 326 (100, MH+). Anal. calcd. for C12H15N5O6.(0.33H2O): C, 43.51; H, 4.77; N, 21.14. Found: C, 43.65; H, 5.14; N, 21.16.
Protection of Nucleosides for Oligonucleotide Synthesis
2.9.9 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Tritylate N2-acetylguanosine 13. In a 250-mL two-neck flask equipped with a rubber septum, nitrogen-filled balloon, and stir bar, dissolve 8.3 g (0.026 mol) N2-acetylguanosine (S.4b) in 75 mL pyridine and 25 mL dimethylformamide. 14. Add 5 g of 4A molecular sieves and stir mixture 1 hr at room temperature. 15. Perform tritylation reaction and purification of product as described for adenosine (see Support Protocol 1, steps 14 to 26). N2-Ac-5′-O-DMTr-guanosine (S.1b): 13.4 g (81%) as a yellow powder. TLC (CH2Cl2/methanol 9:1) 0.35; m.p. 174°C; [a]D25 + 15.5 (c = 0.93, methanol); λmax (methanol) 282 sh (13,700) 274 (14,600), 260 sh (18,300), 251 sh (19,600), 235 (25,800); δH (CDCl3/CD3OD 3:1) 2.02 (s, CH3CO), 3.20 (dd, J = 4.3, 10.5 Hz, H-5′), 3.26 (dd, J = 2.8, 10.5 Hz, H-5′), 3.62 (s, 2 OCH3), 3.69 (br. s, H-4′), 4.22 (t, J = 4.9 Hz, H-3′), 4.45 (t, J = 4.9 Hz, H-2′), 5.76 (d, J = 4.8 Hz, H-1′), 6.64 (6 H, m, DMTr), 7.03-7.26 (9 H, m, DMTr), 7.74 (s, H-8); δC (CDCl3/CD3OD 3:1) 23.4 (q), 55.1 (q), 63.6 (t), 71.0 (d), 74.8 (d), 84.2 (d), 86.6 (d), 88.6 (s), 113.2 (d), 120.8 (s), 127.0 (d), 127.9 (d), 128.2 (d), 130.1 (d), 135.8 (s), 137.8 (d), 144.6 (s), 147.9 (s), 148.8 (s), 156.2 (s), 158.7 (s), 173.3 (s); m/z 628 (74, MH+), 303 (100). Anal. calcd. for C32H35N4O8: C, 63.15; H, 5.30; N, 11.16; Found: C, 63.08; H, 5.35; N, 10.91. SUPPORT PROTOCOL 3
PREPARATION OF [(TRIISOPROPYLSILYL)OXY]METHYL CHLORIDE This protocol describes the two-step synthesis of the reagent TOM⋅Cl, required for introduction of the 2′-O-TOM group into 5′-O-dimethoxytritylated, nucleobase-protected ribonucleosides. The two reactions are illustrated in Figure 2.9.3. In the first reaction, the adduct formed from formaldehyde and ethanethiol in situ according to a procedure by Gundersen et al. (1989) is converted with triisopropylsilyl chloride (TIPS⋅Cl)/imidazole into the corresponding silylated S,O-acetal (S.5). Upon treatment of this intermediate with sulfuryl chloride, TOM⋅Cl (S.6) is formed. The reaction can easily be performed on a larger scale than that presented; however, the authors recommend that it be carried out first on the scale described here. Both the intermediate (S,O-acetal) and TOM⋅Cl are isolated by distillation. After distillation, TOM⋅Cl can be stored for at least 1 year in pure form at −20°C. Materials Paraformaldehyde Ethanethiol Nitrogen or argon gas 10 M aqueous NaOH
Preparation of 2′-O[(Triisopropylsilyl)oxy]methylprotected Ribonucleosides
Figure 2.9.3 Preparation of [(triisopropylsilyl)oxy]methyl chloride (TOM⋅Cl; S.6). Et, ethyl; i-Pr, isopropyl.
2.9.10 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Dichloromethane (CH2Cl2; reagent grade) Imidazole Triisopropylsilyl chloride (TIPS⋅Cl) Hexane (technical grade) 10% (w/v) NaH2PO4 Anhydrous magnesium sulfate (MgSO4) Sulfuryl chloride (SO2Cl2) 250- and 1000-mL one-neck round-bottom flasks Balloon Oil bath, 40°C 1-L separatory funnel 3-cm glass filter Rotary evaporator with a vacuum pump 10-cm 14.5-mm Vigreux distillation column Vacuum distillation equipment (head, thermometer, and so on) with high-vacuum pump 250-mL two-neck flask Rubber septum Syringes Prepare [(triisopropylsilyl)oxy]methylthioethyl ether 1. In a well-ventilated fume hood, mix 3.06 g (0.102 mol) paraformaldehyde with 7.5 mL (0.102 mol) ethanethiol in a 250-mL one-neck round-bottom flask equipped with a magnetic stir bar and a balloon filled with nitrogen or argon gas. 2. Place the suspension in an ice bath and stir until the temperature reaches 4°C (∼5 min). 3. While the solution stirs, remove the gas-filled balloon, add one drop 10 M aqueous NaOH and then quickly replace the balloon. Let the reaction mixture warm up slowly by removing it from the ice bath. At a temperature between 15° and 23°C, a sudden exothermic reaction occurs, forming a colorless solution. The violent reaction results from depolymerization of the paraformaldehyde. If it does not occur spontaneously, heat the reaction mixture gently until the depolymerization reaction starts. Do not heat above 40°C.
4. Place the flask in a preheated oil bath and stir 1 hr at 40°C. 5. Cool the reaction mixture to room temperature and dilute with 100 mL dichloromethane. 6. Add 13.9 g (0.204 mol) solid imidazole, quickly followed by 20.5 mL (0.097 mol) triisopropylsilyl chloride. Replace the balloon. The imidazole does not need to be completely dissolved before addition of the triisopropylsilyl chloride. It is very important that the triisopropylsilyl chloride be added quickly.
7. Stir the resulting colorless suspension overnight at room temperature. 8. Pour the reaction mixture into a 1-L flask containing a stirred mixture of 250 mL hexane and 150 mL of 10% NaH2PO4. 9. Separate the two phases in a 1-L separatory funnel. 10. Re-extract the aqueous phase with 200 mL hexane and combine the organic extracts.
Protection of Nucleosides for Oligonucleotide Synthesis
2.9.11 Current Protocols in Nucleic Acid Chemistry
Supplement 7
11. Dry the extract over anhydrous magnesium sulfate, vacuum filter by means of a 3-cm glass filter, and evaporate the solvents in a rotary evaporator with a vacuum pump. 12. Distill the residue in vacuo by means of a 10-cm, 14.5-mm Vigreux column using a vacuum that is <0.1 mbar and a heating bath temperature that does not exceed 100°C. Collect the main fraction, which typically distills at 70°C (0.05 mbar). 13. Check the purity of the product by 1H-NMR. If the purity of the product is <95%, repeat the distillation carefully. Typically, the product is obtained in yields between 80% and 90%. {[(Triisopropylsilyl)oxy]methyl}thioethyl ether (S.5): 20.6 g (85%) as a colorless liquid, b.p. 72°C (0.05 torr); δH (CDCl3) 1.08-1.18 (21 H, m, i-Pr3Si), 1.31 (t, J = 7.4 Hz, CH3), 2.71 (q, J = 7.4 Hz, CH2), 4.88 (s, CH2); δC (CDCl3) 12.0 (CH), 15.0 (CH3), 17.9 (CH3), 24.7 (CH2), 66.1 (CH2).
Prepare [(triisopropylsilyl)oxy]methyl chloride 14. In a 250-mL two-neck round-bottom flask equipped with a rubber septum and a magnetic stir bar, and connected to a continuous nitrogen flow, dissolve 17.6 g (0.07 mol) {[(triisopropylsilyl)oxy]methyl}thioethyl ether (S.5) in 50 mL dry dichloromethane. Place the colorless solution in an ice bath and stir for 10 min. CAUTION: This reaction must be carried out in a well-ventilated hood, since one byproduct of this reaction (ethanesulfenyl chloride) is toxic and an irritant.
15. Over a 15-min period, add 5.75 mL (0.07 mol) sulfuryl chloride by syringe, remove the ice bath, and continue stirring. The solution turns gradually more yellow. During the reaction, sulfur dioxide and ethanesulfenyl chloride are produced.
16. Stir 1 hr at room temperature. 17. Connect the flask to a dry rotary evaporator and start to evaporate slowly and carefully. The yellow ethanesulfenyl chloride distills together with the dichloromethane and the residue turns colorless again.
18. Remove the solvent completely. The reaction mixture contains the partially dissolved gaseous compounds sulfur dioxide and ethanesulfenyl chloride; apply initially only a gentle vacuum.
19. Distill the residue in vacuo by means of a 10-cm, 14.5-mm Vigreux column. Use a vacuum that is <0.05 mbar and a heating bath temperature that does not exceed 80°C. Collect the main fraction, which typically distills at 40°C (0.01 mbar). 20. Check the purity of the product by 1H-NMR. If the purity of the product is <85%, repeat the distillation carefully. Typically, the product is obtained in yields between 90% and 95%. [(Triisopropylsilyl)oxy]methyl chloride (S.6): 14.8 g (95 %) as a colorless liquid, b.p. 40°C (0.01 torr); δH (CDCl3) 1.08-1.10 (21 H, m, i-Pr3Si), 5.66 (s, CH2); δC (CDCl3) 11.8 (CH), 17.7 (CH3), 76.6 (CH2).
Preparation of 2′-O[(Triisopropylsilyl)oxy]methylprotected Ribonucleosides
2.9.12 Supplement 7
Current Protocols in Nucleic Acid Chemistry
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. Use dry solvents (reagent grade) for all reactions. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Anisaldehyde reagent In a clean container, mix 10 mL anisaldehyde with 180 mL ethanol. Add slowly, while stirring, 10 mL concentrated sulfuric acid, followed by 2 mL acetic acid. Store in the dark for up to 3 months at 25°C. Contamination with acetone must be avoided. For staining, TLC plates are dipped into this mixture and heated with a heat gun until dark spots, corresponding to the reaction products, appear on a pink to red background.
COMMENTARY Background Information The chemical synthesis of DNA sequences b ased on 5′-O-dimethoxytritylated phosphoramidite building blocks is straightforward and very reliable. This extremely powerful methodology can, in principle, also be applied to the synthesis of RNA oligonucleotides, which are structurally very similar. However, compared to DNA, each RNA nucleoside contains an additional 2′-OH group that must be protected during chemical assembly of the nucleotide chain. Since RNA products are base labile, the removal of these supplementary protecting groups is carried out separately, after removing all other protecting groups under basic, nucleophilic conditions (Beaucage and Caruthers, 1996). Among the large number of 2′-O-protecting groups investigated thus far, the fluoride-labile tert-butyldimethylsilyl (TBDMS) group (Ogilvie et al., 1974; UNIT 3.6) has the widest application. However, several factors have limited the length of routinely synthesized RNA sequences using this protecting group. In particular, relatively low coupling yields of ≤98% are obtained with these RNA phosphoramidites despite rather long coupling times of ~15 min, com pared to >99% with DNA phosphoramidites using coupling times of ~2 min. A very attractive alternative was the photolabile 2-nitrobenzyloxymethyl (NBOM) group (Schwartz et al., 1992; UNIT 3.7), which leads to coupling yields of ~99% under DNA coupling conditions. The superior coupling behavior of these building blocks is presumably the result of the minimal steric demand of the NBOM group, achieved by connecting the photocleavable 2-nitrobenzyl protecting group via a sterically nondemanding formaldehyde acetal linker to the 2′-O position of the ribonucleosides (Schwartz et al., 1992; Pitsch, 1997). The 2′-O-TOM protecting group represents an
advantageous combination of the TBDMS and NBOM protecting groups. First, it is completely stable towards all reaction conditions applied during the assembly and the first (basic) deprotection step. Second, it does not interfere with the coupling reaction and leads to very good coupling yields under DNA coupling conditions (99% with a coupling time of 2.5 min). Third, its final cleavage occurs quantitatively without concomitant destruction of the RNA product sequences (UNIT 3.8). The introduction of the TOM group into partially protected ribonucleosides is carried out according to a method originally developed for the introduction of the related NBOM group (Pitsch, 1997, Wu and Pitsch, 1998; Pitsch et al., 1999). The separation of the two regioisomeric TOM-substituted ribonucleosides, formed during the dibutyltin-mediated alkylation reaction, is straightforward and leads to uniform products. In contrast to the TBDMS protecting group, the TOM group does not migrate from the 2′-O to the 3′-O position, even under strongly basic conditions. These factors allow the routine preparation of very pure phosphoramidites, which result in the exclusive formation of 3′→5′ phosphodiester moieties. Furthermore, due to the stability of the 2′-O-TOM group, a variety of nucleobase and sugar manipulations can be carried out after its introduction (Wu and Pitsch, 1998; Stutz et al., 2000). Although the Basic Protocol in this unit uses N-acetylated-5′-O-dimethoxytritylated starting nucleosides, the authors have also introduced the TOM group into a large number of different nucleosides, including nucleosides with different acyl-type nucleobase-protecting groups, unnatural backbones, or noncanonical nucleobases. To date, the reaction has failed only with 5′-O-dimethoxytritylated inosine, which consequently was prepared from 2′-OTOM-substituted adenosine by deamination.
Protection of Nucleosides for Oligonucleotide Synthesis
2.9.13 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Alkylation of dialkyl-stannylated nucleosides with TOM⋅Cl occurred under a variety of reaction conditions. Performing the reaction at 80°C and using 1,2-dichloroethane as solvent favors the formation of the 2′-O-alkylated products, whereas formation of the 3′-O-alkylated products can predominate at lower temperatures and with other solvents (tetrahydrofuran, acetonitrile, benzene). Slightly higher yields (5% to 10%) of 2′-O-TOM-protected nucleosides can sometimes be obtained by forming the stannylated nucleosides with tert-Bu2SnCl2 instead of n-Bu2SnCl2. However, since tertBu2SnCl2 is very expensive, the authors use it only for the alkylation of precious nucleosides.
Critical Parameters
Preparation of 2′-O[(Triisopropylsilyl)oxy]methylprotected Ribonucleosides
In general, there are two important considerations for a successful preparation of 2′-OTOM-protected ribonucleosides. The reaction always results in the formation of a mixture of 2′-O- and 3′-O-alkylated products. Fortunately, the chromatographic behavior (on silica gel) of these two regioisomers differs substantially (∆Rf ≥ 0.1). In all experiments to date, the more quickly migrating isomer has always been the desired 2′-O-alkylated product, which by careful chromatography could be obtained in pure form. The unambiguous identification of the products is conveniently carried out by 1HNMR spectroscopy. Irradiation experiments provide the identification of the signals from the sugar-bound protons and the remaining hydroxyl protons. By irradiation (or D2O-exchange) of the latter, their connection to either C3′ or C2′ can be established, and therefore the alkylation sites can be identified (Pitsch, 1997). Under the authors’ preferred reaction conditions, employing only 1.1 to 1.3 eq of TOM⋅Cl, a significant portion of starting material can be recovered. It is recommended that a larger excess of TOM⋅Cl not be used, since this generally results not in better product yields, but only in the formation of nucleobase-alkylated byproducts, which are quite difficult to remove from the desired product. As a rule, the addition of extra equivalents of TOM⋅Cl should be stopped when more than ~5% of nucleobase-alkylated byproducts (eluting substantially faster then the 2′-O-alkylated product) are detected by TLC analysis. The unreacted starting materials can be isolated by elution with 95:5 (v/v) dichloromethane/methanol. If required, the 3′-O-alkylated regioisomers can be transformed into the starting materials by short treatment (e.g., 30 min) with 0.25 M Bu4NF/THF or 0.25 M, tetraethylammonium fluoride/acetonitrile.
Anticipated Results Introduction of the TOM group into nucleosides depends on the structure of the starting material and on the reaction conditions. In the authors’ experience, yields may range from 25% and 60%. The successful separation of the two diastereoisomers formed can require careful optimization of the chromatography conditions. However, the unique properties of TOMprotected phosphoramidites for RNA synthesis justify the efforts required for their introduction.
Time Considerations Each of the intermediates and products described in this unit can be prepared and isolated within 1 or 2 days.
Literature Cited Beaucage, S.L. and Caruthers, M.H. 1996. The chemical synthesis of DNA/RNA. In Bioorganic Chemistry: Nucleic Acids (S.M. Hecht, ed.) pp. 36-74. Oxford University Press, Oxford. Gundersen, L.L., Benneche, T., and Undheim, K.A. 1989. Chloromethoxysilanes as protecting reagents for sterically hindered alcohols. Acta Chem. Scand. 43:706-709. Ogilvie, K.K., Sadana, K.L., Thompson, E.A., Quilliam, M.A., and Westmore, J.B. 1974. The use of silyl protecting groups in protecting the hydroxyl functions of ribonucleosides. Tetrahedron Lett. 15:2861-2863. Pitsch, S. 1997. An efficient synthesis of enantiomeric oligoribonucleotides from D-glucose. Helv. Chim. Acta 80:2286-2314. Pitsch, S., Weiss, P.A., and Jenny, L. Nov. 1999. Ribonucleoside-derivative and method for preparing the same. US Patent 5,986,084. Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., deBear, J.S., and Gough, G.R. 1992. Rapid synthesis of oligoribonucleotides using 2′-O-(ortho-nitrobenzyloxymethyl)-protected monomers. Bioorg. Med. Chem. Lett. 2:1019-1024. Stutz, A., Höbartner, C., and Pitsch, S. 2000. Synthesis of 3′-O-aminoacylated RNA-fragments with novel, fluoride-labile base-protecting groups. Helv. Chim. Acta 83:2477-2503. Wu, X. and Pitsch, S. 1998. Synthesis and pairing properties of oligoribonucleotide analogues containing a metal-binding site attached to β-D-allofuranosyl cytosine. Nucl. Acids Res. 26:43154323.
Contributed by Stefan Pitsch Institut de Chimie Organique, EPFL Lausanne, Switzerland Patrick A. Weiss Xeragon AG Zürich, Switzerland
2.9.14 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Preparation of 5′-Silyl-2′-Orthoester Ribonucleosides for Use in Oligoribonucleotide Synthesis
UNIT 2.10
This unit describes the synthesis of chemically protected ribonucleoside monomers that can be used to prepare oligoribonucleotides using either manual or automated synthesis approaches. The protection strategy employs two orthogonal protecting groups—a fluoride ion–labile silyl ether on the 5′-hydroxyl and an acid-labile orthoester on the 2′-hydroxyl—as described by Scaringe et al. (1998). The structures of the protected phosphoramidite derivatives of the four standard ribonucleosides (rA, rC, rG, and U) are shown in Figure 2.10.1. These reagents are used with appropriate modifications of standard solid-phase synthesis methods (Matteucci and Caruthers, 1981) to efficiently and rapidly assemble oligoribonucleotides.
O O O Me3Si O Si
N
O
Me3Si O MeO
O
NH O
P
O
Me3Si O Si
O
N O
O O
N
MeO
OAc
N
O
Me3Si O O
CH3
HN
P
O
O
O
OAc
O
N
OAc
O
OAc
cytidine
uridine
O HN N
O Me3Si O Si
O
MeO
O
Me3Si O Si
N
Me3Si P N
O
O
O O
N
O
N
N
O
Me3Si O
Ph
OAc OAc
adenosine
O O
O MeO
P N
O
NH
N
O
N
O O
O
N H
OAc OAc
guanosine
Figure 2.10.1 Protected ribonucleoside phosphoramidites for 5′-O-silyl-2′-O-orthoester RNA synthesis.
Protection of Nucleosides for Oligonucleotide Synthesis
Contributed by Stephen A. Scaringe, David Kitchen, Robert J. Kaiser, and William S. Marshall
2.10.1
Current Protocols in Nucleic Acid Chemistry (2004) 2.10.1-2.10.16 Copyright © 2004 by John Wiley & Sons, Inc.
Supplement 16
The choice of protecting groups described above is predicated on the following requirements. (1) The 2′-hydroxyl must be protected with a species that is stable to the conditions of chain assembly. (2) The synthesis procedure must protect against product cleavage from the solid support and against removal of the protecting groups on the nucleobases. (3) The protecting group must be easily removed at the end of the procedure under mildly acidic aqueous conditions. (4) Given items 1 to 3, the acid-labile 4,4′-dimethoxytrityl (DMTr) group that is traditionally used to protect the 5′-hydroxyl in deoxyribonucleotide synthesis must be replaced with a moiety that does not require acidic or basic conditions for its rapid removal. The 5′-O-silyl ether and 2′-O-orthoester groups fit these criteria and have been structurally optimized to provide crude oligoribonucleotides of excellent purity and biological activity. Using commercial synthesizers, the 5′-O-silyl-2′-O-orthoester chemistry enables routine synthesis of oligoribonucleotides up to 80 bases in length, regardless of sequence or secondary structure. Synthesis of the required monomers begins from the standard base-protected ribonucleosides rABz (benzoyl), rCAc (acetyl), rGi-Bu (isobutyryl), and U (unprotected). The procedure for synthesizing the protected uridine phosphoramidite is presented in detail (see Basic Protocol). The syntheses of the other three phosphoramidites—adenosine, guanosine, and cytidine—are essentially identical. Modifications to the purification procedures, as well as compound characterization data, are detailed below (see Alternate Protocols 1 to 3). BASIC PROTOCOL
SYNTHESIS OF 2′-ACE-PROTECTED URIDINE RIBONUCLEOSIDE PHOSPHORAMIDITE This protocol describes the synthesis of 5′-O-benzhydroxy-bis(trimethylsilyloxy)silyl-2′O-bis(acetoxyethyloxy)methyl-3′-O-(N,N-diisopropylamino)methoxyphosphinyl uridine. The general strategy for preparation of the 5′-O-silyl-2′-O-orthoester-ribonucleoside-3′-O-phosphoramidites consists of five steps: (1) simultaneous temporary protection of the 5′- and 3′-hydroxyls, (2) conversion of the 2′-hydroxyl to the 2′-O-orthoester using tris(acetoxyethyl)orthoformate (ACE orthoformate), (3) removal of the temporary 5′- and 3′-hydroxyl-protecting groups, (4) regioselective introduction of the 5′-O-silyl-ether protecting group using benzhydroxy-bis(trimethylsilyloxy)chlorosilane (BzH-Cl), and (5) preparation of the 3′-O-phosphoramidite. These steps are illustrated for the uridine derivatives in Figures 2.10.2 to 2.10.6. NOTE: All reactions must be carried out using proper ventilation (fume hood) and personal protective wear (e.g., gloves, eye protection). All reagents without specified vendors should be of the highest purity and dryness possible. Glassware for performing the synthetic transformations should be thoroughly cleaned and dried in an oven at 110°C for ≥30 min before use.
Preparation of 5′-Silyl-2′Orthoester Ribonucleosides
Materials Uridine (S.1; 244 g/mol; Monomer Sciences) Pyridine 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane (TIPS-Cl2; 315 g/mol; d = 0.986 g/mL; Monomer Sciences) Toluene Dichloromethane 5% and 8% (w/v) aqueous sodium bicarbonate (NaHCO3) Saturated aqueous sodium chloride (NaCl) Anhydrous sodium sulfate (Na2SO4)
2.10.2 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Silica gel 60 (for column chromatography) Hexane Ethyl acetate (EtOAc) Silica gel thin-layer chromatography (TLC) plates Methanol (MeOH) Acetonitrile (MeCN) Tris(2-acetoxyethyl) orthoformate (322 g/mol; Dharmacon Inc.) Pyridinium p-toluenesulfonate (251 g/mol) Triethylamine (TEA) 4-tert-Butyldimethylsiloxy-3-penten-2-one (238 mL/mol; Silar) N,N,N′,N′-Tetramethylethylene diamine (TEMED; 150 mL/mol) 48% (w/v) aqueous hydrofluoric acid (HF; 32 mL/mol) Diisopropylamine (140 mL/mol) Benzhydroxy-bis(trimethylsilyloxy)chlorosilane (BzH-Cl; 425 g/mol; Dharmacon Inc.) Acetone Bis(N,N-diisopropylamino)methoxyphosphine (262 g/mol; Monomer Sciences) 0.45 M 1H-tetrazole in MeCN (AIC) Ethanol (EtOH) Rotary evaporator 1-L separatory funnel Glass-fritted Buchner funnel (coarse porosity) and side-arm Erlenmeyer flask High-vacuum pump Water aspirator 50 × 600–mm chromatography column Additional reagents and equipment for flash chromatography (APPENDIX 3E) and TLC (APPENDIX 3D) NOTE: For solvent evaporation on a rotary evaporator, the required vacuum source will depend on the boiling point of the solvent involved. For dichloromethane and hexane, a water aspirator or diaphragm pump will suffice. For all other solvents, a high-vacuum oil pump is needed. NOTE: The efficiency of reactions as well as the results of column chromatography at each step are assessed by TLC on silica gel plates. It is suggested that the TLC plates be spotted in three horizontal locations at the origin of the plate as follows: (1) starting material alone, (2) co-spot of starting material plus crude reaction mixture or product fraction, and (3) crude reaction mixture or product fraction alone. In this way, the conversion of starting material to product, or the purity of the product fraction, can be conveniently monitored. Protect 3′- and 5′-OH (S.2) 1. Co-evaporate 40 mmol (9.76 g) uridine (S.1; Fig. 2.10.1) with 50 mL pyridine on a rotary evaporator equipped with a vacuum pump. Dissolve residue in 50 mL fresh pyridine and chill reaction mixture in an ice bath. 2. Add 13.86 mL (44 mmol; 1.1 equiv per equiv uridine) TIPS-Cl2 dropwise over 60 min to the stirred, cold uridine solution. Remove ice bath and stir solution at room temperature for an additional 30 min. Add 2 mL water to quench the reaction. 3. Remove pyridine on the rotary evaporator, and then co-evaporate the residue once with 100 mL toluene to remove as much pyridine as possible.
Protection of Nucleosides for Oligonucleotide Synthesis
2.10.3 Current Protocols in Nucleic Acid Chemistry
Supplement 16
4. Add 300 mL dichloromethane to the residue and swirl to dissolve. Transfer the solution to a 1-L separatory funnel and wash once with 300 mL of 5% aqueous NaHCO3. 5. Separate the layers and wash the aqueous phase with an additional 150 mL dichloromethane. 6. Combine the dichloromethane extracts and wash once with 200 mL saturated aqueous NaCl. 7. Wash the NaCl solution with 50 mL dichloromethane. 8. Combine the dichloromethane extracts and dry over 50 g anhydrous Na2SO4. Remove the solid by vacuum filtration using a glass-fritted Buchner funnel (coarse porosity) and a side-arm Erlenmeyer flask. 9. Remove the dichloromethane on the rotary evaporator, and then co-evaporate the residue once with 100 mL toluene to remove any remaining pyridine. Dry the crude product under high vacuum (with a high-vacuum pump) for 1 hr. 10. Prepare a flash chromatography (APPENDIX 3E) column using 250 g silica gel 60 in a 50 × 600–mm chromatography column and a 50:50 (v/v) hexane/EtOAc solvent system. 11. Dissolve the dry product in 50 mL of 50:50 hexane/EtOAc and load onto the column. Elute with the same solvent system (typically 2 L). Collect 20-mL fractions and monitor the results of the separation by TLC (APPENDIX 3D) on silica gel plates in 6% (v/v) MeOH/CH2Cl2. Visualize TLC separation using UV light. The product has an Rf of 0.5 under these conditions.
12. Pool the fractions containing pure product and evaporate to dryness on the rotary evaporator to obtain a white crystalline powder. The molecular weight of 3′,5′-O-TIPS-uridine (S.2; Fig. 2.10.2) is 486 g/mol. The yield is 15.57 g (80%). 1H NMR (CDCl3): δ 10.41 (b, 1H), 7.81 (d, J = 8.4 Hz, 1H), 5.72–5.69 (m, 1H), 5.66 (d, J = 8.4 Hz, 1H), 4.38 (b, 1H), 4.23–4.18 (m, 4H), 3.96 (d, J = 12.8 Hz, 1H), 1.05–0.90 (m, 28H). 13C NMR (CDCl3): δ 164.0, 150.7, 139.9, 102.1, 91.1, 81.8, 75.1, 68.4, 60.0, 17.6, 17.5, 17.4, 17.3, 17.1, 17.02, 17.01, 16.9, 13.4, 13.1, 13.0, 12.5. Exact mass calculated for C21H38N2O7Si2: 486.2; found by ESMS (M + H): 487.
O
O NH
HO
O HO
O
O TIPS-Cl2
OH
1 Preparation of 5′-Silyl-2′Orthoester Ribonucleosides
N
NH
pyridine
O
Si O Si
O
N
O
OH
2
Figure 2.10.2 3′,5′-Protection of the nucleoside. Synthesis of 3′,5′-O-(tetraisopropyldisiloxane1,3-diyl)uridine from uridine. TIPS-Cl2, 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane.
2.10.4 Supplement 16
Current Protocols in Nucleic Acid Chemistry
O
O NH
O
O
Si O Si
O
N
NH
O CH(OCH 2CH2OAc) 3, CH2Cl2
OH
pyridinium p -toluenesulfonate
O O Si
N
O
Si O
O
O O
2
O
OAc OAc
3
Figure 2.10.3 2′-ACE protection. Synthesis of 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2′-O-bis(acetoxyethyloxy)methyl uridine from 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)uridine.
Perform 2′-O-ACE protection (S.3) 13. Dry the product S.2 by co-evaporating twice with 100-mL portions of MeCN. 14. Add, in order, tris(2-acetoxyethyl) orthoformate (2.3 equiv per equiv S.2), dichloromethane (2 mL per mmol S.2), and pyridinium p-toluenesulfonate (0.2 equiv per equiv S.2). Stir reaction at room temperature. 15. To check the progress of the reaction by TLC, dilute a 40-µL aliquot of the reaction solution with 40 µL TEA and 200 µL CH2Cl2. Analyze 1 to 5 µL of this solution using a solvent system of 5% (v/v) MeOH in CH2Cl2. The product, 3′,5′-O-TIPS-2′-O-ACE-uridine (S.3; Fig. 2.10.3), typically migrates with a slightly faster Rf than the starting material.
16. After TLC analysis shows that the reaction is progressing well (∼60 min), add 4-tert-butyldimethylsiloxy-3-penten-2-one (1.8 equiv per equiv S.2) and stir the reaction for an additional 36 to 48 hr at room temperature. If necessary, the reaction can be accelerated by gently refluxing at 38° to 40°C. The solution should appear clear, with a slightly yellow or orange color. If the reaction still appears to be sluggish or stagnant, an additional aliquot of pyridinium p-toluenesulfonate (up to 1.0 equiv total) can be added. The 4-tert-butyldimethylsiloxy-3-penten-2-one is added to drive the reaction to completion. The 2′-ACE reaction is an equilibrium exchange of the 2′-hydroxyl with one of the three alcohols in the orthoester reagent. 4-tert-Butyldimethylsiloxy-3-penten-2-one reacts selectively with the primary hydroxyl of the liberated 2-acetoxy-ethanol byproduct, rendering it unable to react further, and thereby forcing the equilibrium to the 2′-ACE product.
17. When TLC indicates that the reaction is ≥95% complete, add TEMED (0.5 equiv per equiv S.2) to neutralize the reaction mixture. 4-tert-Butyldimethylsiloxy-3-penten-2-one is UV absorbing and volatile. It appears on the TLC plate as a dark spot or as a pair of spots (two isomers) migrating at the solvent front. Upon standing, the spots will slowly disappear. If additional pyridinium p-toluenesulfonate was added to accelerate the reaction, additional TEMED (up to 2.5 equiv) must be added to compensate. Protection of Nucleosides for Oligonucleotide Synthesis
2.10.5 Current Protocols in Nucleic Acid Chemistry
Supplement 16
18. Prepare a flash chromatography column with 250 g silica gel 60 using a solvent mix of 75:25 (v/v) hexane/EtOAc containing 0.5% (v/v) TEMED. Dilute the reaction solution with 2 vol (90 mL) hexane and load this mixture directly onto the column. Only TEMED should be used as the base. TEA or another tertiary amine should not be used. TEMED-HF is used to deprotect the 5′- and 3′-hydroxyls in the next step. If TEA is present in that step, the HF salt of TEA will be generated. The TEA-HF salt migrates on silica gel and is difficult or impossible to separate from the 2′-O-ACE nucleoside product. This problem does not occur with the more polar TEMED-HF salt.
19. Elute the product using 49:50:0.5:0.5 (v/v/v/v) hexane/EtOAc/MeOH/TEMED (typically 2 L). Collect 20-mL fractions and monitor by TLC. It is very important to remove the several small impurities that elute just ahead of the desired product. If present, they severely complicate subsequent purifications. Therefore, when the product begins to elute, collect smaller fractions and analyze carefully by TLC. Because the excess orthoester reagent and any remaining starting material often co-elute with the product, the product cannot be fully characterized at this point. Carry it through to the next reaction, in which the TIPS protecting group will be removed. After the next reaction, all impurities can be easily removed by column chromatography, and the pure product can be readily characterized.
Remove 3′,5′-TIPS protection (S.4) 20. To the semi-pure S.3, add 2 mL MeCN per mmol of starting protected uridine in step 13).
(S.2
21. Prepare TEMED-HF reagent in a separate flask as follows. Place 2 mL MeCN per mmol S.2 in a separate vessel on ice. Add 5 equiv TEMED (per equiv S.2). Then slowly add (over 5 min) 48% (w/v) aqueous HF (3.5 equiv per equiv S.2). Stir on ice for 5 min. 22. Slowly add TEMED-HF solution to the nucleoside solution over 2 min, with stirring. Stir reaction at room temperature for ∼4 hr. Monitor the progress of the reaction by TLC on silica gel using 8% (v/v) MeOH in CH2Cl2 until it is complete. The desired product moves considerably more slowly on the TLC plate than does the starting material in this solvent systems.
23. Remove MeCN from the reaction on the rotary evaporator. When most of the solvent is removed, add 100 mL dichloromethane, 20 mL hexane, and 2 mL TEMED. Mix well. 24. Slowly load this solution directly onto a 50 × 600–mm flash chromatography column containing 250 g silica gel poured in 15:85 (v/v) hexane/EtOAc containing 0.5% (v/v) TEMED. The solution should be loaded slowly onto the column using gravity flow, as heat tends to be generated and may disrupt the silica gel bed.
25. Elute the product using 94:6 (v/v) EtOAc/MeOH containing 0.5% (v/v) TEMED (typically 2 L). Collect 20-mL fractions.
Preparation of 5′-Silyl-2′Orthoester Ribonucleosides
The molecular weight of 2′-O-ACE-uridine (S.4; Fig. 2.10.4) is 462 g/mol. The yield is 11.83 g (65% to 80%) overall (steps 13 to 25 combined). 1H NMR (CDCl3): δ 7.79 (d, J = 8.4 Hz, 1H), 5.80 (d, J = 4.0 Hz, 1H), 5.66 (d, J = 8.0 Hz, 1H), 5.42 (s, 1H), 4.45–4.43 (m, 1H), 4.26–4.23 (m, 1H), 4.15–4.10 (m, 4H), 4.02–4.00 (m, 1H), 3.87–3.82 (m, 1H), 3.74–3.66 (m, 5H), 1.98 (s, 3H), 1.97 (s, 3H). 13C NMR (CDCl3): δ 171.25, 171.22, 164.2, 150.7, 141.8, 112.4, 102.2, 89.2, 84.9, 76.2, 69.4, 63.1, 63.0, 62.97, 62.8, 61.2, 30.9, 20.84, 20.82. Exact mass calculated for C18H26N2O12: 462.2; found by ESMS (M + H): 463.
2.10.6 Supplement 16
Current Protocols in Nucleic Acid Chemistry
O
O
NH
NH O Si O Si
N
O O
HO
O TEMED-HF
O
O O
3
MeCN OAc
N
O HO
O
O
O O
OAc
OAc OAc
4
Figure 2.10.4 Removal of 3′,5′-protection. Synthesis of 2′-O-bis(acetoxyethyloxy)methyl uridine from 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2′-O-bis(acetoxyethyloxy)methyl uridine. TEMED, N,N,N′,N′-tetramethylethylenediamine.
Perform 5′-O-silylation (S.5) 26. Dissolve S.4 in 5 mL CH2Cl2 (per mmol S.4) and add diisopropylamine (1 equiv per equiv S.4). Cool solution to 0°C with an ice bath. 27. In a separate flask, dissolve 1.5 equiv BzH-Cl (per equiv S.4) in CH2Cl2 (2 mL/g BzH-Cl). 28. Add 1 equiv diisopropylamine (per equiv BzH-Cl) to the silyl chloride solution (step 27) slowly over 1 min. Shake resulting solution for 5 min and ensure that it remains clear. If the solution does not clear after several minutes, the mixture is not sufficiently anhydrous, and the solution should be made again using fresh, dry dichloromethane and N,N-diisopropylamine. These materials can be conveniently dried by storing them over 4A molecular sieves for at least 24 hr.
29. Slowly add the diisopropylamine-activated silylating reagent (step 28) to the nucleoside solution (step 26) while stirring at 0°C. Begin by adding 0.5 equiv aliquots of the silylating reagent, and then taper to smaller aliquots as the reaction proceeds to completion. Add each aliquot over a period of 10 to 15 min. Monitor the reaction by TLC on silica gel after each addition using 5% (v/v) MeOH/CH2Cl2. Continue to add the silylating solution until the start material disappears, and then add slightly more to ensure that any 3′-O-silylated nucleoside is converted to the 3′,5′-O-disilylated nucleoside. Keep the total reaction time <3 hr. The reaction will start out clear, but will turn cloudy as the silylating solution is added. The silylating reagent appears to react slightly with the nucleobases on uridine and guanosine, requiring >1.0 equiv to 5′-protect all of the starting material. The silylating reagent reacts preferentially with the primary 5′-hydroxyl but will also react with the 3′-hydroxyl. The 3′-O-silylated nucleoside contaminant chromatographs immediately ahead of the desired 5′-O-silylated product, and is difficult to separate. However, the 3′,5′-bis-silylated product runs very quickly in the TLC solvent given, near the solvent front. It is well separated from the desired 5′-O-silylated product and can be removed easily during the chromatography step. Therefore, the reaction is continued until all of the starting material is consumed, in order to also 5′-O-silylate any 3′-O-silylated nucleoside that has formed. It is best to do this reaction steadily, without pausing for an extended time between additions of silyl reagent. As soon as TLC shows the reaction is complete, immediately work up the reaction.
Protection of Nucleosides for Oligonucleotide Synthesis
2.10.7 Current Protocols in Nucleic Acid Chemistry
Supplement 16
O
O NH
HO
N
O HO
O
Me3Si
O
BzH-Cl O
O O 4
NH
O
CH2Cl2, DIPA
Me3Si
Si O
N
O
O
O HO
OAc
O
O O
OAc
OAc OAc
5
Figure 2.10.5 5′-Silylation. Synthesis of 5′-O-benzhydroxy-bis(trimethylsilyloxy)silyl-2′-O-bis(acetoxyethyloxy)methyl uridine from 2′-O-bis(acetoxyethyloxy)methyl uridine. BzH-Cl, benzhydroxy-bis(trimethylsilyloxy)silyl chlorosilane; DIPA, N,N-diisopropylamine.
30. Immediately after the reaction is complete according to TLC, extract the reaction mixture with 200 mL of 8% (w/v) aqueous NaHCO3, followed by 200 mL saturated aqueous NaCl. Dry the organic phase over 50 g Na2SO4 and concentrate on the rotary evaporator. 31. Dissolve the residue in a solution of 50 mL CH2Cl2/150 mL hexane/1 mL TEA. Load onto a 50 × 600–mm flash chromatography column filled with 250 g silica gel 60 in 80:20 (v/v) hexane/acetone containing 0.5% (v/v) TEA. 32. Elute the product using 50:30:20 (v/v/v) hexane/EtOAc/acetone containing 0.5% (v/v) TEA (typically 2 L). Collect 20-mL fractions. The molecular weight of 5′-O-BzH-2′-O-ACE-uridine (S.5; Fig. 2.10.5) is 850 g/mol. The yield is 17.43 g (75% to 90%). 1H NMR (CDCl3): δ 7.79 (d, J = 8.0 Hz, 1H), 7.32–7.18 (m, 10H), 5.99 (d, J = 3.2 Hz, 1H), 5.92–5.89 (m, 1H), 5.48–5.47 (m, 1H), 5.46 (s, 1H), 4.25–4.13 (m, 6H), 4.02–3.84 (m, 2H), 3.83–3.74 (m, 5H), 2.03 (s, 3H), 2.01 (s, 3H), 1.89 (s, 1H), 0.04 (s, 9H), 0.03 (s, 9H). 13C NMR (CDCl3): δ 171.0, 163.9, 150.8, 143.8, 139.9, 128.4, 127.5, 126.4, 126.3, 112.7, 102.4, 87.6, 84.2, 77.1, 68.8, 63.2, 63.1, 63.06, 63.02, 61.6, 20.94, 20.90, 1.6. Exact mass calculated for C37H54N2O15Si3: 850.3; found by ESMS (M + H): 851.
Prepare 3′-phosphoramidite (S.6) 33. Co-evaporate S.5 once with 2.5 mL MeCN per mmol S.5. Add 2 mL CH2Cl2 per mmol S.5, cap the reaction flask with a rubber septum, and stir the solution at 0°C in an ice bath. 34. In a separate flask under anhydrous conditions, dilute the phosphinylating reagent bis(N,N-diisopropylamino)methoxyphosphine (1.25 equiv per equiv S.5) with CH2Cl2 (2 mL per mmol phosphine). Add a solution of 0.45 M 1H-tetrazole in MeCN (0.5 equiv tetrazole per equiv S.5) and shake for 5 min. 35. Add the solution of activated phosphinylating reagent to the well-stirred solution of nucleoside at room temperature.
Preparation of 5′-Silyl-2′Orthoester Ribonucleosides
36. After 15 min, remove a 40-µL aliquot of the crude reaction mixture and add to 200 µL of CH2Cl2 containing 10% (v/v) TEA. Spot on a TLC plate pre-run in 60:30:10 (v/v/v) hexane/CH2Cl2/TEA. Develop the plate in this solvent mixture to check that the reaction is progressing. Continue to stir at room temperature until the reaction is complete by TLC analysis (12 to 18 hr). The desired product will move more quickly on the plate than the starting material.
2.10.8 Supplement 16
Current Protocols in Nucleic Acid Chemistry
O
O
Me3Si
O
NH
O Me3Si
O
Si O
N
O
Me3Si O
O i
O HO
O
O O
5
OAc OAc
Me3Si
NH
Si O
MeO
N
O
O P
O
O
O
O O
N
OAc OAc
6
Figure 2.10.6 Preparation of the phosphoramidite monomer for oligoribonucleotide synthesis. Synthesis of 5′-O-benzhydroxy-bis(trimethylsilyloxy)silyl-2′-O-bis(acetoxyethyloxy)methyl-3′-O-(N,N-diisopropylamino)methoxyphosphinyl uridine from 5′-O-benzhydroxy-bis(trimethylsilyloxy)silyl-2′-O-bis(acetoxyethyloxy)methyl uridine. i: bis(N,N-diisopropylamino)methoxyphosphine; 1H-tetrazole, CH2Cl2, 12 hr.
37. Add 10 equiv EtOH per equiv S.5 to quench the excess phosphine. Continue stirring for 30 min. Dry reaction on the rotary evaporator. 38. Purify the product on silica gel. Take up the residue from a 20-mmol reaction in a solution of 25 mL CH2Cl2/125 mL hexane/1 mL TEA and load onto a 50 × 600–mm flash chromatography column filled with 25 mL silica/g product in a solvent mix of 94:5:1 (v/v/v) hexane/CH2Cl2/TEA. 39. Elute the product with 75:25 (v/v) hexane/acetone containing 0.5% (v/v) TEA (typically 2 L). Collect 20-mL fractions, monitor by TLC (step 36), and pool fractions containing purified product. 40. Co-evaporate the pooled fractions with 100 mL toluene to ensure the amidite is not concentrated down into TEA. Finish with two co-evaporations using 100 mL portions of MeCN under high vacuum. Th e product, 5′-O-benzhydroxy-bis(trimethylsilyloxy)silyl-2′-O-bis(acetoxyethyloxy)methyl-3′-O-(N,N-diisopropylamino)methoxyphosphinyl uridine (S.6; Fig. 2.10.6), is a clear syrup, often pale yellow in color. The molecular weight is 1011 g/mol; the yield is 18.65 g (75% to 95%). 1H NMR (CDCl3, mixture of diasteromers): δ 8.08 (b, 1H), 7.81 and 7.80 (each as d, J = 8.0 Hz, 1H), 7.34–7.21 (m, 10H), 6.05 and 6.01 (each as d, J = 4.4 Hz, 1H), 5.93 and 5.92 (each as s, 1H), 5.58 and 5.45 (each as s, 1H), 5.41 and 5.35 (each as d, J = 8.0 Hz, 1H), 4.34–4.13 (m, 8H), 3.99–3.96 and 3.92–3.89 (each as m, 1H), 3.82–3.73 (m, 5H), 3.60–3.57 (m, 2H), 3.38 and 3.31 (each as d, J = 12.0 Hz, 3H), 2.08 and 2.06 (each as s, 6H), 1.20–1.15 (m, 12H), and 0.06, 0.06, 0.04, and 0.02 (each as s, 18H). 31P NMR (CDCl3, mixture of diasteromers): δ 152.2, 152.0. Exact mass calculated for C44H70N3O16PSi3: 1011.4; found by ESMS (M + H): 1012.
Protection of Nucleosides for Oligonucleotide Synthesis
2.10.9 Current Protocols in Nucleic Acid Chemistry
Supplement 16
ALTERNATE PROTOCOL 1
SYNTHESIS OF 2′-ACE-PROTECTED ADENOSINE RIBONUCLEOSIDE PHOSPHORAMIDITE The procedure for the synthesis of the N6-benzoyl-5′-O-silyl-2′-O-ACE-adenosine 3′-Ophosphoramidite is generally the same as for the uridine derivative (see Basic Protocol). The only significant changes occur in the solvent mixtures used for flash chromatographic purification of the various intermediates. Isolated yields per step are generally within ±10% of the yields obtained for the uridine derivatives. The TLC conditions for the analysis of the crude reaction mixtures described in the Basic Protocol may be used for analysis in this protocol as well. Although the Rf values of the adenosine derivatives will differ slightly from those of the uridine derivatives, the differences between starting material and desired product will be similar at each step. Additional Materials (also see Basic Protocol) N6-Benzoyladenosine (337 g/mol; Monomer Sciences) 1. Synthesize N6-benzoyl-3′,5′-O-TIPS-adenosine from N6-benzoyladenosine as described (see Basic Protocol, steps 1 to 12). For flash chromatography (steps 10 and 11), use a solvent system of 40:60 (v/v) hexane/EtOAc. The product has an Rf of 0.5 under these conditions. Its molecular weight is 579 g/mol. 1H NMR (CDCl3): δ 9.78 (b, 1H), 8.58 (s, 1H), 8.27 (s, 1H), 6.02 (s, 1H), 4.94–4.91 (m, 1H), 4.56 (d, J = 5.2 Hz, 1H), 4.39 (b, 1H), 4.09–4.06 (m, 2H), 3.96–3.92 (m, 1H), 3.28–3.24 (m, 1H), 1.20–1.17 (m, 6H), 1.03–0.84 (m, 28H). 13C NMR (CDCl3): δ 176.9, 152.3, 150.4, 142.0, 122.7, 81.9, 80.8, 74.9, 70.2, 61.1, 35.6, 19.1, 19.07, 17.3, 17.15, 17.14, 17.13, 16.9, 16.8, 16.79, 16.7, 13.1, 12.8, 12.6, 12.4. Exact mass calculated for C26H45N5O6Si2: 579.3; found by ESMS (M + H): 580.
2. Synthesize N6-benzoyl-3′,5′-O-TIPS-2′-O-ACE-adenosine as described (see Basic Protocol, steps 13 to 19). Elute the product (step 19) using 55:42:3:0.5 (v/v/v/v) hexane/EtOAc/MeOH/TEMED. Characterization data are not provided, because the crude product is directly carried to the next synthesis step.
3. Synthesize N6-benzoyl-2′-O-ACE-adenosine as described (see Basic Protocol, steps 20 to 25). Elute the product (step 25) using 95:5 (v/v) EtOAc/MeOH containing 0.5% (v/v) TEMED. The molecular weight of the product is 555 g/mol. 1H NMR (CDCl3): δ 9.23 (b, 1H), 8.63 (s, 1H), 8.14 (s, 1H), 5.99 (d, J = 7.6 Hz, 1H), 5.97 (b, 1H), 5.18 (s, 1H), 5.02 (dd, J = 4.8 Hz, 7.2 Hz, 1H), 4.48 (d, J = 4.8 Hz, 1H), 4.31–4.28 (m, 1H), 4.00–3.90 (m, 5H), 3.72–3.68 (m, 1H), 3.60–3.55 (m, 3H), 3.43–3.38 (m, 2H), 3.24–3.20 (m, 1H), 1.98 (s, 3H), 1.97 (s, 3H), 1.23 (d, J = 7.2 Hz, 6H). 13C NMR (CDCl3): δ 176.7, 170.9, 152.1, 150.2, 143.3, 123.5, 112.5, 89.2, 87.7, 76.3, 71.9, 63.3, 63.1, 62.7, 62.6, 62.57, 36.1, 20.8, 19.2. Exact mass calculated for C23H33N5O11: 555.2; found by ESMS (M + H): 556.
4. Synthesize N6-benzoyl-5′-O-BzH-2′-O-ACE-adenosine as described (see Basic Protocol, steps 26 to 32). Elute the product (step 32) using 45:35:20 (v/v/v) hexane/EtOAc/acetone containing 0.5% (v/v) TEA.
Preparation of 5′-Silyl-2′Orthoester Ribonucleosides
The molecular weight of the product is 943 g/mol. 1H NMR (CDCl3): δ 8.68 (b, 1H), 8.67 (s, 1H), 8.29 (s, 1H), 7.33–7.15 (m, 10H), 6.21 (d, J = 5.2 Hz, 1H), 5.91 (s, 1H), 5.31 (s, 1H), 4.83–4.79 (m, 1H), 4.36–4.33 (m, 1H), 4.13–4.09 (m, 3H), 4.05–4.03 (m, 2H), 3.91–3.87 (m, 1H), 3.78–3.75 (m, 1H), 3.69–3.62 (m, 3H), 3.52–3.46 (m, 1H), 3.28–3.24 (m, 1H), 3.05 (m, 1H), 1.99 (s, 6H), 1.27 (d, J = 6.8 Hz, 6H), 0.04 (s, 9H), 0.03 (s, 9H). 13 C NMR (CDCl3): δ 176.4, 170.8, 152.6, 151.2, 149.4, 144.0, 141.7, 128.3, 127.3, 126.4, 122.3, 112.5, 88.6, 84.9, 77.0, 76.97, 70.5, 63.1, 63.0, 62.8, 62.7, 62.6, 36.1, 20.8, 19.3, 1.5. Exact mass calculated for C42H61N5O14Si3: 943.4; found by ESMS (M + H): 944.
2.10.10 Supplement 16
Current Protocols in Nucleic Acid Chemistry
5. Synthesize N6-benzoyl-5′-O-BzH-2′-O-ACE-3′-O-(N,N-diisopropylamino)methoxyphosphinyl adenosine as described (see Basic Protocol, steps 33 to 40). Elute the product (step 39) with 70:30 (v/v) hexane/acetone containing 0.5% (v/v) TEA. The product (Fig. 2.10.1) is a clear syrup, often pale yellow in color. The molecular weight is 1105 g/mol. 1H NMR (CDCl3, mixture of diasteromers): δ 8.68 and 8.67 (each as s, 1H); 8.40 (b, 1H); 8.29 and 8.25 (each as s, 1H); 7.35–7.17 (m, 10H); 6.25 and 6.23 (each as d, J = 4.4 Hz, 1H); 5.93 and 5.91 (each as s, 1H); 5.41 and 5.31 (each as s, 1H); 4.85–4.82 (m, 1H); 4.59–4.55 (m, 1H); 4.29–4.21 (m, 1H); 4.10–3.91 (m, 5H); 3.78–3.54 (m, 7H); 3.40 and 3.33 (each as d, J = 12.0 Hz, 3H); 3.32–3.26 (m, 1H); 2.02 and 2.00 (each as s, 6H); 1.31 (d, J = 6.8 Hz, 6H); 1.28–1.14 (m, 12H); 0.06, 0.04, 0.03, and 0.02 (each as s, 18H). 31P NMR (CDCl3, mixture of diasteromers): δ 152.2, 151.4. Exact mass calculated for C49H77N6O15PSi3: 1104.5; found by ESMS (M + H): 1106.
SYNTHESIS OF 2′-ACE-PROTECTED GUANOSINE RIBONUCLEOSIDE PHOSPHORAMIDITE
ALTERNATE PROTOCOL 2
The procedure for the synthesis of the N2-isobutyryl-5′-O-silyl-2′-O-ACE-guanosine 3′-O-phosphoramidite is generally the same as for the uridine derivative (see Basic Protocol). The only significant changes occur in the solvent mixtures used for flash chromatographic purification of the various intermediates. Isolated yields per step are generally within ±10% of the yields obtained for the uridine derivatives. The TLC conditions for the analysis of the crude reaction mixtures described in the Basic Protocol may be used for analysis in this protocol as well. Although the Rf values of the guanosine derivatives will differ slightly from those of the uridine derivatives, the differences between starting material and desired product will be similar at each step. Additional Materials (also see Basic Protocol) N2-Isobutyrylguanosine (353 g/mol; Monomer Sciences) 1. Synthesize N2-isobutyryl-3′,5′-O-TIPS-guanosine from N2-isobutyrylguanosine as described (see Basic Protocol, steps 1 to 12). For flash chromatography (steps 10 and 11), use a solvent system of 30:70 (v/v) hexane/EtOAc. The product has an Rf of 0.5 under these conditions. Its molecular weight is 595 g/mol. 1H NMR (CDCl3): δ 12.30 (b, 1H), 10.66 (b, 1H), 7.94 (s, 1H), 5.72 (m, 1H), 4.45–4.42 (m, 1H), 4.28–4.26 (m, 1H), 4.14–4.09 (m, 2H), 4.01–3.93 (m, 1H), 2.94–2.88 (m, 1H), 1.26–1.21 (m, 6H), 1.08–0.86 (m, 28H). 13C NMR (CDCl3): δ 180.1, 156.1, 148.4, 148.1, 136.8, 121.3, 89.1, 81.7, 75.3, 69.6, 60.6, 36.2, 31.7, 36.2, 19.2, 19.1, 17.6, 17.43, 17.41, 17.3, 17.1, 16.9, 13.5, 13.1, 13.0, 12.6. Exact mass calculated for C26H45N5O7Si2: 595.3; found by ESMS (M + H): 596.
2. Synthesize N2-isobutyryl-3′,5′-O-TIPS-2′-O-ACE-guanosine as described (see Basic Protocol, steps 13 to 19). Elute the product (step 19) using 47:50:3:0.5 (v/v/v/v) hexane/EtOAc/MeOH/TEMED. Characterization data are not provided, because the crude product is directly carried to the next synthesis step.
3. Synthesize N2-isobutyryl-2′-O-ACE-guanosine as described (see Basic Protocol, steps 20 to 25). Elute the product (step 25) using 64:30:6 (v/v/v) EtOAc/acetone/MeOH containing 0.5% (v/v) TEMED. The molecular weight of the product is 571 g/mol. 1H NMR (CDCl3): δ 12.30 (b, 1H), 10.38 (b, 1H), 8.15 (s, 1H), 5.93 (d, J = 4.4 Hz, 1H), 5.37 (s, 1H), 4.92 (b, 1H), 4.73–4.70 (m, 1H), 4.57–4.45 (m, 1H), 4.37 (b, 1H), 4.12–4.02 (m, 5H), 3.89–3.85 (m, 1H), 3.77–3.74 (m, 1H), 3.67–3.56 (m, 4H), 2.82–2.74 (m, 1H), 1.97 (s, 3H), 1.95 (s, 3H), 1.17–1.14 (m, 6H). 13C NMR (CDCl3): δ 180.3, 171.3, 171.2, 155.7, 148.3, 139.1, 120.9, 112.4, 87.5, 85.6, 76.7, 70.0, 63.2, 63.1, 62.9, 62.3, 61.5, 35.9, 31.0, 20.9, 19.0. Exact mass calculated for C23H33N5O12: 571.2; found by ESMS (M + H): 572.
Protection of Nucleosides for Oligonucleotide Synthesis
2.10.11 Current Protocols in Nucleic Acid Chemistry
Supplement 16
4. Synthesize N2-isobutyryl-5′-O-BzH-2′-O-ACE-guanosine as described (see Basic Protocol, steps 26 to 32). Elute the product (step 32) using 45:35:30 (v/v/v) hexane/EtOAc/acetone containing 0.5% (v/v) TEA. The molecular weight of the product is 959 g/mol. 1H NMR (CDCl3): δ 12.29 (b, 1H), 10.04 (b, 1H), 7.96 (s, 1H), 7.31–7.12 (m, 10H), 5.96 (d, J = 5.2 Hz, 1H), 5.90 (s, 1H), 5.22 (s, 1H), 4.53–4.50 (m, 1H), 4.36–4.30 (m, 1H), 4.20–4.14 (m, 1H), 4.10–4.06 (m, 4H), 3.82–3.80 (m, 1H), 3.77–3.75 (m, 1H), 3.68–3.61 (m, 3H), 3.52–3.50 (m, 1H), 4.41–3.38 (m, 1H), 2.83–2.78 (m, 1H), 2.00 (s, 3H), 1.99 (s, 3H), 1.19 (t, J = 7.2 Hz, 6H), 0.01 (s, 9H), 0.00 (s, 9H). 13C NMR (CDCl3): δ 179.8, 171.3, 171.0, 155.9, 148.6, 148.1, 143.9, 143.8, 137.3, 128.24, 128.23, 127.2, 126.32, 126.29, 121.0, 112.4, 86.2, 84.8, 77.8, 76.9, 70.5, 63.15, 63.07, 62.9, 62.80 62.6, 36.0, 20.9, 20.8, 19.00, 18.98, 14.8, 14.7. Exact mass calculated for C42H61N5O15Si3: 959.4; found by ESMS (M + H): 960.
5. Synthesize N2-isobutyryl-5′-O-BzH-2′-O-ACE-3′-O-(N,N-diisopropylamino)methoxyphosphinyl guanosine as described (see Basic Protocol, steps 33 to 40). Elute the product (step 39) with 70:30 (v/v) hexane/acetone containing 0.5% (v/v) TEA. The product (Fig. 2.10.1) is a clear syrup, often pale yellow in color. The molecular weight is 1120 g/mol. 1H NMR (CDCl3, mixture of diasteromers): δ 12.06 (b, 1H); 9.05 and 8.97 (each as b, 1H); 8.00 and 7.96 (each as s, 1H); 7.35–7.17 (m, 10H); 6.09 and 6.03 (each as d, J = 4.0 Hz, 1H); 5.93 and 5.91 (each as s, 1H); 5.39 and 5.26 (each as s, 1H); 4.50–4.45 (m, 2H); 4.24–4.11 (m, 8H); 3.86–3.83 (m, 2H); 3.76–3.56 (m, 9H); 3.38 and 3.34 (each as d, J = 12.0 Hz, 3H); 2.69–2.64 (m, 1H); 2.07, 2.06, and 2.05 (each as s, 6H); 1.29–1.17 (m, 12H); 0.06, 0.04, 0.04, and 0.02 (each as s, 18H). 31P NMR (CDCl3, mixture of diasteromers): δ 152.0, 151.8. Exact mass calculated for C49H77N6O16PSi3: 1120.4; found by ESMS (M + H): 1121. ALTERNATE PROTOCOL 3
SYNTHESIS OF 2′-ACE-PROTECTED CYTIDINE RIBONUCLEOSIDE PHOSPHORAMIDITE The procedure for the synthesis of the N4-acetyl-5′-O-silyl-2′-O-ACE-cytidine 3′-Ophosphoramidite is generally the same as for the uridine derivative (see Basic Protocol). The only significant changes occur in the solvent mixtures used for flash chromatographic purification of the various intermediates. Isolated yields per step are generally within ±10% of the yields obtained for the uridine derivatives. The TLC conditions for the analysis of the crude reaction mixtures described in the Basic Protocol may be used for analysis in this protocol as well. Although the Rf values of the cytidine derivatives will differ slightly from those of the uridine derivatives, the differences between starting material and desired product will be similar at each step. Additional Materials (also see Basic Protocol) N4-Acetylcytidine (285 g/mol; Monomer Sciences) 1. Synthesize N4-acetyl-3′,5′-O-TIPS-cytidine from N4-acetylcytidine as described (see Basic Protocol, steps 1 to 12). For flash chromatography (steps 10 and 11), use a solvent system of 45:55 (v/v) hexane/EtOAc. The product has an Rf of 0.5 under these conditions. Its molecular weight is 527 g/mol. 1H NMR (CDCl3,): δ 10.63 (b, 1H), 8.14 (d, J = 7.6 Hz, 1H), 7.35 (d, J = 7.6 Hz, 1H), 5.71 (s, 1H), 4.19–4.13 (m, 4H), 3.92–3.80 (m, 2H), 2.21 (s, 3H), 0.99–0.79 (m, 28H). 13C NMR (CDCl3): δ 171.6, 163.4, 155.0, 144.2, 96.7, 91.5, 81.8, 75.0, 63.3, 59.8, 24.8, 17.4, 17.3, 17.23, 17.19, 16.9, 16.8, 16.7, 16.6, 13.3, 12.9, 12.8, 12.3. Exact mass calculated for C23H41N3O7Si2: 527.3; found by ESMS (M + H): 528.
Preparation of 5′-Silyl-2′Orthoester Ribonucleosides
2.10.12 Supplement 16
Current Protocols in Nucleic Acid Chemistry
2. Synthesize N4-acetyl-3′,5′-O-TIPS-2′-O-ACE-cytidine as described (see Basic Protocol, steps 13 to 19). Elute the product (step 19) using 46:50:4:0.5 (v/v/v/v) hexane/EtOAc/MeOH/TEMED. Characterization data are not provided, because the crude product is directly carried to the next synthesis step.
3. Synthesize N4-acetyl-2′-O-ACE-cytidine as described (see Basic Protocol, steps 20 to 25). Elute the product (step 25) using 67:30:3 (v/v/v) EtOAc/acetone/MeOH containing 0.5% (v/v) TEMED. The molecular weight of the product is 503 g/mol. 1H NMR (CDCl3): δ 9.65 (b, 1H), 8.27 (d, J = 7.6 Hz, 1H), 7.41 (d, J = 7.2 Hz, 1H), 5.77 (d, J = 2.8 Hz, 1H), 5.60 (s, 1H), 4.62–4.59 (m, 1H), 4.38–4.36 (m, 1H), 4.23–4.13 (m, 5H), 4.03–3.98 (m, 2H), 3.85–3.79 (m, 5H), 3.52 (b, 1H), 2.23 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H). 13C NMR (CDCl3): δ 171.2, 171.16, 163.1, 155.6, 146.8, 112.9, 97.1, 92.4, 85.3, 68.6, 63.25, 63.17, 63.10, 62.9, 60.8, 25.1, 21.1, 21.0. Exact mass calculated for C20H29N3O12: 503.2; found by ESMS (M + H): 504.
4. Synthesize N4-acetyl-5′-O-BzH-2′-O-ACE-cytidine as described (see Basic Protocol, steps 26 to 32). Elute the product (step 32) using 30:50:20 (v/v/v) hexane/EtOAc/acetone containing 0.5% (v/v) TEA. The molecular weight of the product is 891 g/mol. 1H NMR (CDCl3): δ: 10.23 (b, 1H), 8.30 (δ, J = 7.6 Hz, 1H), 7.36–7.14 (m, 10H), 5.93–5.91 (m, 2H), 5.67 (s, 1H), 5.23 (s, 1H), 4.24–4.16 (m, 5H), 4.11–3.98 (m, 3H), 3.88–3.76 (m, 5H), 3.01 (δ, J = 8.0 Hz, 1H), 2.26 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 0.07 (s, 9H), 0.05 (s, 9H). 13C NMR (CDCl3): δ 171.0, 163.2, 155.0, 144.6, 143.91, 143.87, 128.3, 127.3, 126.35, 126.29, 112.8, 96.7, 89.4, 83.8, 78.5, 77.0, 67.2, 63.2, 63.1, 63.0, 62.9, 62.7, 60.6, 53.5, 24.9, 20.9, 20.8, 1.6. Exact mass calculated for C39H57N3O15Si3: 891.3; found by ESMS (M + H): 892.
5. Synthesize N4-acetyl-5′-O-BzH-2′-O-ACE-3′-O-(N,N-diisopropylamino)methoxyphosphinyl cytidine as described (see Basic Protocol, steps 33 to 40). Elute the product (step 39) with 65:35 (v/v) hexane/acetone containing 0.5% (v/v) TEA. The product (Fig. 2.10.1) is a clear syrup, often pale yellow in color. The molecular weight is 1052 g/mol. 1H NMR (CDCl3, mixture of diasteromers): δ 8.77 (b, 1H); 8.36 and 8.34 (each as d, J = 4.8 Hz, 1H); 7.36–7.15 (m, 10H); 6.00 (d, J = 6.8 Hz, 1H); 5.94 (d, J = 4.8 Hz, 1H); 5.81 and 5.76 (each as s, 1H); 4.30–4.15 (m, 8H); 4.10–4.02 (m, 1H); 3.96–3.77 (m, 5H); 3.60–3.52 (m, 3H); 3.34 and 3.31 (each as d, J = 12.0 Hz, 3H); 2.23 (s, 3H); 2.05, 2.05, and 2.04 (each as s, 6H); 1.20–1.13 (m, 12H); 0.08, 0.07, 0.06, and 0.04 (each as s, 18H). 31P NMR (CDCl3, mixture of diasteromers): δ 152.2, 151.4. Exact mass calculated for C46H73N4O16PSi3: 1052.4; found by ESMS (M + H): 1053.
COMMENTARY Background Information Until recently, most advancements in oligonucleotide synthesis technologies focused on DNA. One reason for this “DNA-centricity” is that DNA is easier to work with than RNA, making advancements in DNA technologies easier to develop. Another, more important, reason is that biologists have traditionally attributed DNA with far more therapeutic significance than RNA. As a result, the market for synthetic RNA has traditionally been small and highly specialized. The recent discovery that small interfering RNAs (siRNAs) induce gene suppression in mammalian cells (Elbashir et al., 2001) has,
however, sparked tremendous interest in developing siRNA-based assays and high-throughput screens to identify and study disease targets. Reliable, efficient, and high-quality RNA synthesis methods are now critically important for enabling cutting-edge research in drug discovery and therapeutic intervention. As a result, a substantial and rapidly growing market for synthetic RNA has been created. Three methods for chemically synthesizing siRNAs are now well established: 2′-TBDMS, 2′- TOM, and 2′-ACE. 2′-O-tert-Butyldimethylsilyl (TBDMS) chemistry was originally developed in the 1980s, when Ogilvie and Usman applied a 2′-TBDMS strategy for 2′-hy-
Protection of Nucleosides for Oligonucleotide Synthesis
2.10.13 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Preparation of 5′-Silyl-2′Orthoester Ribonucleosides
droxyl protection (Usman et al., 1987) to classical phosphoramidite-based DNA synthesis (Caruthers, 1987; also see UNIT 2.5). The more recently developed 2′-O-triisopropylsilyloxymethyl (TOM) 2′-hydroxyl chemistry implements a 2′-silyl protecting group to achieve improved synthesis efficiencies relative to 2′TBDMS (Wu and Pitsch, 1998; also see UNIT 2.9). 2′-TOM chemistry is still limited, however, by such factors as oligonucleotide length and yield. Significant improvements in RNA synthesis were ach ieved with the 5′-silyl-2′-acetoxyethoxy (ACE) chemistry (Scaringe et al., 1998) described in this unit. For synthetic RNA to be useful to biological practitioners studying gene function, it has to meet certain physical, quality, and convenience criteria. Some of the characteristics of synthetic RNA that are important to the user are: 1. Sequence integrity: assurance that the sequence desired is actually the one produced. 2. Scalability: the ability to obtain large quantities of RNA for use in high-throughput screens or animal models. 3. Strand length: the ability to obtain long strands of RNA (e.g., to make hairpin structures). 4. Chemical modifications: the ability to obtain RNA featuring chemical labels or preservatives (e.g., to improve pharmacokinetics in animal tissues). 5. Robustness: the ability of the RNA protecting groups to repel nucleases, facilitating handling and long-term storage. 6. Labor intensiveness: the ease of deprotecting, annealing, purifying, and/or preparing the RNA for use in a biological assay. 7. Short- and long-term cost: as measured in both time and money. 2′-ACE chemistry is the only method capable of meeting all of the criteria listed above. First, 2′-ACE chemistry provides superior sequence integrity; 99% efficiencies for 21-mers are routinely achieved at coupling speeds as fast as 2 nucleotides/min. By comparison, 2′-TOM chemistry achieves 99% efficiency when one nucleotide is coupled every 2 to 6 min. Second, 2′-ACE chemistry delivers a crude product of high purity. 2′-ACE chemistry produces milligram to kilogram quantities of >90% pure material for high-throughput or in vivo efforts in less time, and at a lower cost, than any other method. Third, 2′-ACE is the only chemical method that can be used to economically synthesize long double-stranded RNA (dsRNA) or siRNA hairpins >30 bases in length; oligori-
bonucleotides of up to 80 bases can be synthesized at efficiencies of ∼60%, far greater than for any other method. By comparison, 2′-TOM chemistry achieves 36% efficiencies for synthesis of 50-mers. Fourth, the 2′-ACE protecting scheme enables virtually any chemical modification to be easily incorporated into the oligoribonucleotide. For in vivo applications, such chemical modifications are required to increase RNA stability in tissues and fluids. The 2′-TBDMS and 2′-TOM methods are more restricted in the type and number of modifications that can be added. Fifth, 2′-ACE-protected RNA provides superior handling properties relative to other methods. As with other protecting strategies, the 2′-ACE group renders the oligoribonucleotide resistant to nuclease and other forms of degradation during handling and purification. 2′-ACE chemistry is the only method, however, in which the last deprotection step can be carried out in a mild, aqueous solution. This step is typically done using 100 mM acetic acid, pH 3.8 (conditions under which the RNA is quite stable) and takes only 30 min to complete. Finally, when considering cost, 2′-ACE chemistry provides better economies of scale than the other methods. For smallscale production runs, 2′-ACE is slightly more expensive than 2′-TBDMS and 2′-TOM; however, when larger-scale production runs are required, fast coupling times and high coupling efficiencies ensure that 2′-ACE chemistry is cheaper than competing technologies.
Critical Parameters and Troubleshooting For all of these protocols, anhydrous reaction conditions must be maintained. Traces of water will severely affect the yield and purity of the product at each step. Solvents should be stored over molecular sieves or should be freshly distilled from an appropriate drying agent. All glassware must be thoroughly cleaned and dried in an oven for 30 min at 110° to 120°C prior to use. Thin-layer chromatography (TLC) on silica gel is conveniently used throughout these protocols to monitor the progress of the various reactions. It is also used to provide a rapid initial assessment of the purity of the chromatographically isolated products. The absolute purity of the product compounds, however, should be determined by NMR spectroscopy (1H, 13C, or 31P, where appropriate) and/or mass spectrometry. During the synthesis of 3′,5′-O-TIPS-2′-OACE-nucleosides from 3′,5′-O-TIPS-nucleo-
2.10.14 Supplement 16
Current Protocols in Nucleic Acid Chemistry
sides (e.g., S.3; see Basic Protocol, steps 13 to 19), an additional aliquot of pyridinium p-toluenesulfonate (up to 1.0 equiv total) can be added to complete the reaction. If additional pyridinium p-toluenesulfonate is added, however, additional TEMED (up to 2.5 equiv) must be added to compensate. This reaction typically takes 36 to 48 hr to complete at room temperature, but it can be accelerated by gently refluxing at 38° to 40°C. The solution should eventually appear clear, with a slight yellow or orange color. When analyzing the progress of this reaction with TLC, beware that 4-tertbutyldimethylsiloxy-3-penten-2-one is UV absorbing and volatile. It appears on the TLC plate as a dark spot or pair of spots (two isomers) migrating at the solvent front. Upon standing, the spots will slowly disappear. When preparing a silica gel flash chromatography column to purify the desired product (see Basic Protocol, step 18), only use TEMED as the base. Do not use TEA or another tertiary amine. TEMED-HF is used to deprotect the 5′and 3′-hydroxyls in the next step. If TEA is present in that step, the HF salt of TEA will be generated. The TEA-HF salt migrates on silica gel and is difficult or impossible to separate from the 2′-O-ACE nucleoside product. This problem does not occur with the more polar TEMED-HF salt. When eluting, it is very important to remove the several small impurities that elute just ahead of the desired product. If present, they severely complicate subsequent purifications. Therefore, when the product begins to elute, collect smaller fractions and analyze carefully by TLC. During the synthesis of 2′-ACE-nucleosides f rom 3′,5′-O-TIPS-2′-O-ACE-nucleosides (see Basic Protocol, steps 20 to 25), it is important to take care when loading the silica gel flash chromatography column. If the product is not loaded slowly, heat can be generated, which may disrupt the silica gel bed. During the synthesis of 5′-O-BzH-2′-OACE-nucleosides from 2′-O-ACE-nucleosides (see Basic Protocol, steps 26 to 32), it is important to add the diisopropylamine-activated silylating reagent slowly to the nucleoside solution. Begin by adding 0.5 equiv of the silylating reagent, and then taper to smaller aliquots as the reaction proceeds to completion. It is best to do this reaction steadily, over a period of 10 to 15 min, without pausing for an extended time between additions of silyl reagent. The silylating reagent appears to react somewhat with the nucleobases on uridine and guanosine, requiring more than 1.0 equiv to 5′-protect all of the
starting material. As soon as TLC shows that the reaction is complete, immediate work-up of the reaction is required. At the end of the final synthesis step, yielding 5′-O-BzH-2′-O-ACE-3′-O-(N,N-diisopropylamino)methoxyphosphinyl nucleosides from 5′-O-BzH-2′-O-ACE-nucleosides, elute the final product from the chromatography column, and then co-evaporate the pooled fractions with toluene to ensure the amidite is not concentrated down into TEA. Finish with one or two co-evaporations using acetonitrile on high vacuum.
Anticipated Results The isolated yields presented in the protocols represent typical values obtained. The quality of the reagents and the dryness of the solvents will have a significant impact on product yield and purity, as will the amount of care taken during the chromatographic purifications. The product yields are explicitly given at each step for uridine in the Basic Protocol. These values are also representative of the yields obtained for the corresponding adenosine, guanosine, and cytidine derivatives, within about ±10%. The TIPS-protected nucleosides obtained in the first step of the synthetic scheme (S.2) are generally white solids; all other products are generally viscous syrups, often pale yellow in color. It is possible to analyze all products by reversed-phase high-performance liquid chromatography (RP-HPLC). Typical conditions are as follows: analytical C18 column (available from a variety of vendors); linear gradient of HPLC-grade acetonitrile in aqueous 0.05 M ammonium acetate, pH 8.5; and UV detector monitoring at 260 nm. Typical HPLC analytical data for the final phosphoramidites (Waters NovaPak C18 column, 3.9 × 150–mm plus guard cartridge; flow rate, 1 mL/min; linear gradient from 25% to 100% [v/v] acetonitrile over 30 min): retention times of 33 to 35 min; purities ≥97% (by integration of all peaks in the 260-nm chromatogram); ≤0.1% desilylated material (retention times of 16 to 18 min); ≤1% hydrolyzed material (retention times of 25 to 27 min). All methods described in this unit can be scaled up to yield ∼300 mmol (∼300 g) of phosphoramidites simply by linearly increasing the amounts of all materials used in the procedures. The protected phosphoramidite monomers prepared using these methods are ideal for solid-phase RNA oligonucleotide synthesis.
Protection of Nucleosides for Oligonucleotide Synthesis
2.10.15 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Time Considerations Chemical synthesis of 2′-ACE-protected phosphoramidites is an involved process that, from start to finish, takes experienced chemists days to weeks to complete. The following time estimates include reagent preparation, labor, reaction, evaporation, purification, and drying, and assume that all reactions proceed smoothly. Synthesis of 3′,5′-O-(tetraisopropyldisiloxane1,3-diyl)uridine from uridine (steps 1 to 12 of the Basic Protocol) takes ∼2 days. Synthesis of 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2′O-ACE-uridine (steps 13 to 19) takes ∼3 days. Synthesis of 2′-O-ACE-uridine (steps 20 to 25) and synthesis of 5′-O-BzH-2′-O-ACE-uridine (steps 26 to 32) each take 1 day. Synthesis of 5′-O-BzH-2′-O-ACE-3′-O-(N,N-diisopropylamino)methoxyphosphinyl uridine (steps 33 to 40) takes ∼2 days. As such, synthesis of 2′-OACE-protected uridine ribonucleoside phosphoramidites takes ∼9 days in total. Times for Alternate Protocols 1 to 3 are similar.
Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494498. Matteucci, M.D. and Caruthers, M.H. 1981. Synthesis of deoxyoligonucleotides on a polymer support. J. Am. Chem. Soc. 103:3185-3191. Scaringe, S.A., Wincott, F.E., and Caruthers, M.H. 1998. Novel RNA synthesis method using 5′silyl-2′-orthoester protecting groups. J. Am. Chem. Soc. 120:11820-11821. Usman, N.O., Ogilvie, K.K., Jiang, M.Y., and Cedergren, R.J. 1987. The automated chemical synthesis of long oligoribonucleotides using 2′-Osilylated ribonucleoside 3′-O-phosphoramidites on a controlled-pore glass support: Synthesis of a 43-nucleotide sequence similar to the 3′-half molecule of an Escherichia coli formylmethionine tRNA. J. Am. Chem. Soc. 109:7845-7854. Wu, X. and Pitsch, S. 1998. Synthesis and pairing properties of oligoribonucleotide analogues containing a metal-binding site attached to β-D-allofuranosyl cytosine. Nucl. Acids Res. 26:43154323.
Literature Cited Caruthers, M.H. 1985. Gene synthesis machines: DNA chemistry and its uses. Science 230:281285.
Contributed by Stephen A. Scaringe, David Kitchen, Robert J. Kaiser, and William S. Marshall Dharmacon Inc. Lafayette, Colorado
Preparation of 5′-Silyl-2′Orthoester Ribonucleosides
2.10.16 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Enzymatic Regioselective Levulinylation of 2-Deoxyribonucleosides and 2-O-Methylribonucleosides
UNIT 2.11
With the recent success of various aptamers, ribozymes, and other oligonucleotides (e.g., antisense, immunostimulatory CpG-containing, and RNAi-related) undergoing human clinical trials, the possibility of their commercial launch in the near future may require production of very large quantities of these products. Thus, development of methods for their large-scale synthesis has become a high priority (Pon et al., 1999). Particularly when ton quantities of oligonucleotides are required, solution-phase synthesis appears to be a preferred alternative to traditional solid-phase synthesis. The key building blocks for solution-phase oligonucleotide synthesis are appropriately 3 - and/or 5 -protected nucleosidic monomers. Of the limited number of protecting groups available for 3 and/or 5 -hydroxyl protection, the levulinyl group is frequently chosen, as it is stable under oligonucleotide coupling reaction conditions and can be selectively cleaved at neutral pH without affecting other protecting groups in the same molecule (Greene and Wuts, 1999; Kocie´nski, 2004; also see other units in this chapter). Until recently, the preparation of these building blocks had been carried out through several tedious chemical protection/deprotection steps (Kumar and Poonian, 1984; Iwai and Ohtsuka, 1988; Iwai et al., 1990; Krotz et al., 1997; Eleuteri et al., 1999; Reese and Song, 1999; March´an et al., 2004). Clearly, such methods for the synthesis of 3 - and/or 5 -levulinyl-protected nucleosides are not suitable for the large-scale production of these key building blocks. Selective protection and deprotection of compounds such as nucleosides that contain multiple hydroxyl groups is a challenging problem in organic synthesis. For the manipulation of protecting groups, application of biocatalysts in organic synthesis has become an attractive alternative to conventional chemical methods (Bornscheuer and Kazlauskas, 1999; Carrea and Riva, 2000; Patel, 2000; Klibanov, 2001; Koeller and Wong, 2001). Enzymes have been reported to catalyze reactions with high chemo-, regio-, and stereoselectivity (Ferrero and Gotor, 2000a,b). Furthermore, enzyme-catalyzed reactions are less hazardous, polluting, and energy consuming than their conventional counterparts. Among various commercial enzymes, the authors have had success with the use of lipases as versatile biocatalysts in organic synthesis (Garc´ıa et al., 2002, 2003, 2004a,b). Lipases are attractive because they are readily available, do not require cofactors, are inexpensive and highly stable, exhibit broad substrate specificity, and retain a high degree of activity in organic solvents. The following Basic Protocols present reliable procedures using commercial lipases for the regioselective introduction of the levulinyl group at the 3 - or 5 -hydroxy position of a 2 -deoxyribonucleoside or a 2 -O-methylribonucleoside. Additionally, Support Protocols describe the preparation of O-levulinyl acetonoxime from levulinic acid and acetonoxime (see Support Protocol 1) and the synthesis of 3 ,5 -di-O-levulinyl esters (see Support Protocols 2 and 3), which serve as starting material in several methods.
SYNTHESIS OF 3 -O-LEVULINYL-2 -DEOXYRIBONUCLEOSIDES The preparation of 3 -O-levulinyl-2 -deoxyribonucleosides involves regioselective acylation of the 3 -hydroxyl function of deoxyribonucleosides with O-levulinyl acetonoxime using immobilized Pseudomonas cepacia lipase (PSL-C), as illustrated in Figure 2.11.1. Protection of Nucleosides for Oligonucleotide Synthesis Contributed by Iv´an Lavandera, Javier Garc´ıa, Susana Fern´andez, Miguel Ferrero, Vicente Gotor, and Yogesh S. Sanghvi
2.11.1
Current Protocols in Nucleic Acid Chemistry (2005) 2.11.1-2.11.36 C 2005 by John Wiley & Sons, Inc. Copyright
Supplement 21
Figure 2.11.1 Regioselective levulinylation of deoxyribonucleosides using Pseudomonas cepacia lipase (PSL-C) or Candida antarctica lipase B (CAL-B). Abbreviations: ABz , N 6 -benzoyladenin9-yl; CBz , N 4 -benzoylcytosin-1-yl; Gi-Bu , N 2 -isobutyrylguanin-9-yl; T, thymin-1-yl.
Figure 2.11.2 Regioselective hydrolysis of N 2 -isobutyryl-3 ,5 -di-O-levulinyl-2 -deoxyguanosine (S.4d) using CAL-B. Abbreviations: DCC, 1,3-dicyclohexylcarbodiimide; DMAP, 4-(dimethylamino)pyridine; Et3 N, triethylamine; Lev, levulinyl; LevOH, levulinic acid.
This is a general procedure for T (see Basic Protocol 1), dC (see Basic Protocol 2), and dA (see Basic Protocol 3). Preparation of O-levulinyl acetonoxime from levulinic acid and acetonoxime is presented in Support Protocol 1. Enzymatic Regioselective Levulinylation of Nucleosides
Because direct regioselective enzymatic acylation of N2 -isobutyryl-2 -deoxyguanosine using PSL-C does not work efficiently, another lipase-catalyzed approach is used to prepare the dG monomer (see Basic Protocol 4). The dG monomer is prepared from N2 isobutyryl-3 ,5 -di-O-levulinyl-2 -deoxyguanosine via regioselective hydrolysis of the
2.11.2 Supplement 21
Current Protocols in Nucleic Acid Chemistry
5 -O-levulinyl ester, catalyzed by Candida antarctica lipase B (CAL-B) as depicted in Figure 2.11.2. Preparation of 3 ,5 -di-O-levulinylated deoxyguanosine using levulinic acid is presented in Support Protocol 2. CAUTION: Wear safety glasses and gloves, and perform all operations involving solvents and reagents in a well-ventilated fume hood.
Preparation of 3 -O-Levulinylthymidine via Regioselective Enzymatic Acylation with PSL-C
BASIC PROTOCOL 1
Materials Thymidine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Pseudomonas cepacia lipase (PSL-C; 904 propyl laurate units per gram [PLU/g]; Amano Enzyme) Anhydrous nitrogen Anhydrous tetrahydrofuran (THF), freshly distilled from sodium and benzophenone Methanol (MeOH) Dichloromethane (CH2 Cl2 ) p-Anisaldehyde solution (see recipe) Saturated sodium bicarbonate (NaHCO3 ) solution Sodium sulfate (Na2 SO4 ) Diethyl ether (Et2 O), cold (4◦ C) Silica gel Ethyl acetate (EtOAc) 1-L Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 30◦ C Microcentrifuge tubes Capillary tubes Silica gel 60 F254 aluminum-backed TLC plates UV light source Heat gun Buchner funnels with filter paper circles 250- and 500-mL round-bottom flasks Rotary evaporator equipped with a cooling condenser 500-mL separatory funnel 250-mL Erlenmeyer flasks 1-L filter flask Glass funnel with Whatman no. 1 filter paper Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) Perform levulinylation 1. Add 10 g (41.28 mmol) thymidine, 21.2 g (123.86 mmol) O-levulinyl acetonoxime, and 20 g PSL-C to a 1-L Erlenmeyer flask equipped with a three-way glass stopcock. 2. Evacuate the Erlenmeyer flask on a vacuum line, and then flush the flask with nitrogen. Repeat this procedure three times. 3. Add 206 mL dry THF. 4. Seal the flask with a rubber septum and place in an orbital shaker kept at 30◦ C. Shake the reaction mixture at 250 rpm.
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.3 Current Protocols in Nucleic Acid Chemistry
Supplement 21
5. Monitor the progress of the reaction by analytical TLC (APPENDIX 3D) as follows: a. Take a sample (usually 20 to 50 µL) under nitrogen using a capillary tube. b. Transfer the sample to a microcentrifuge tube, dilute with 50 to 100 µL MeOH, and spot on a silica gel 60 F254 aluminum-backed plate. c. Develop plate using 10% (v/v) MeOH/CH2 Cl2 as the eluent. d. Visualize spots first under UV light and then by dipping the plate into panisaldehyde solution and warming with a heat gun. At this point in the synthesis, the solution becomes clear, with immobilized lipase that will be filtered off. The levulinylation reaction takes between 14 and 16 hr to complete. To analyze the course of reactions by TLC, the p-anisaldehyde solution is useful for visualizing nucleosides.
Work up and purify product 6. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel and filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 7. Wash PSL-C twice with 50 mL CH2 Cl2 , collecting washes in the same round-bottom flask. 8. Concentrate the filtrate under reduced pressure using a rotary evaporator. The resulting oil will develop an orange color due to the presence of excess oxime ester.
9. Dissolve the residue in 100 mL CH2 Cl2 and transfer to a 500-mL separatory funnel. 10. Remove unreacted thymidine by extracting the organic layer four times with 20 mL saturated NaHCO3 solution, collecting the phases in 250-mL Erlenmeyer flasks. Verify that thymidine has been completely removed from the organic phase by analytical TLC of both phases. 11. Extract the aqueous phases six to eight times with 20 mL CH2 Cl2 to recover any extracted product, again collecting in a 250-mL Erlenmeyer flask. 12. Pool the organic phases from step 11 and verify by TLC that they contain no residual thymidine. If thymidine is present, re-extract with 20 mL saturated NaHCO3 solution. 13. Pool the organic phases from steps 10 and 12 and dry over 4 g Na2 SO4 for 10 to 15 min. Remove the drying agent by gravity filtration through Whatman no. 1 filter paper in a glass funnel, and collect the filtrate in a 500-mL round-bottom flask. 14. Wash the Na2 SO4 four times with 25 mL CH2 Cl2 , and collect all washes in the same round-bottom flask. 15. Concentrate the dried organic extract under reduced pressure using a rotary evaporator. The orange color may persist.
16. Dissolve the residue in 10 mL CH2 Cl2 . Gradually add the solution to a beaker containing 50 mL cold (4◦ C) Et2 O to precipitate the product as a white solid. Cool the precipitate at 4◦ C overnight.
Enzymatic Regioselective Levulinylation of Nucleosides
17. Filter off the precipitate under vacuum using a Buchner funnel and filter paper circle, collecting the filtrate in a 250-mL round-bottom flask. Wash the white solid twice with 50 mL cold Et2 O into the same round-bottom flask. Dry the white solid under vacuum. The average yield of levulinylated product obtained in this step is 75% to 80%.
2.11.4 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Recover product from filtrate 18. Evaporate Et2 O washes under reduced pressure using a rotary evaporator. 19. To recover product by dry column chromatography, weigh out 50 g silica gel and place in a Buchner funnel with filter paper circle, attached to a 1-L filter flask connected to a vacuum line. Wash the silica with 200 mL of 25% (v/v) EtOAc/Et2 O. 20. Using a Pasteur pipet, spread the residue carefully on top of the silica bed. 21. Elute the residual oxime ester with ∼500 to 700 mL of 25% (v/v) EtOAc/Et2 O. 22. Using clean filter flasks to collect 100-mL fractions, elute the desired product with ∼800 to 1200 mL of 10% (v/v) MeOH/CH2 Cl2 . Monitor fractions by analytical TLC. 23. Transfer fractions containing pure levulinylated product to a 500-mL round-bottom flask, and remove solvents under reduced pressure using a rotary evaporator. 24. Add 5 mL Et2 O and triturate the product. Evaporate the solvent on a rotary evaporator, collect the product, and combine it with the product from step 17. An additional 5% to 15% of the product can be recovered by the process outlined in steps 18 to 24. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
25. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. 3 -O-Levulinylthymidine (S.2a) is obtained in an overall combined yield of ∼85% to 95%. ◦ TLC (10% MeOH/CH2 Cl2 ): Rf = 0.40. m.p. 50◦ -52◦ C. [α]20 D = −4.7 (c 0.8, CHCl3 ). IR (KBr): υ 3449, 3065, 2927, 1706 cm−1 . 1 H NMR (MeOH-d4 , 200 MHz): δ 2.09 (d, 4 JHH = 1.3 Hz, 3H, Me), 2.39 (s, 3H, Me-Lev), 2.57 (m, 2H, H2 ), 2.80 (t, 3 JHH = 6.0 Hz, 2H, CH2 -Lev), 3.05 (t, 3 JHH = 6.2 Hz, 2H, CH2 -Lev), 4.01 (m, 2H, H5 ), 4.29 (m, 1H, H4 ), 5.02 (m, 1H, H3 ), 6.50 (dd, 3 JHH = 8.1, 6.5 Hz, 1H, H1 ), 8.04 (d, 4 JHH = 1.3 Hz, 1H, H6). 13 C NMR (CDCl3 , 75 MHz): δ 12.4 (Me), 27.8 (CH2 -Lev), 29.6 (Me-Lev), 37.1 (C2 ), 37.7 (CH2 -Lev), 62.2 (C5 ), 74.9 and 85.0 (C3 + C4 ), 85.7 (C1 ), 111.1 (C5), 136.5 (C6), 150.6 (C2), 164.3 (C4), 172.4 (C=O Lev), 206.8 (C=O Lev). ESI-MS (m/z): 363 [(M + Na)+ , 100%], 379 [(M + K)+ , 30%]. Anal. calcd. (%) for C15 H20 N2 O7 : C, 52.92; H, 5.93; N, 8.23; found: C, 53.0; H, 5.8; N, 8.2.
Preparation of O-Levulinyl Acetonoxime from Levulinic Acid and Acetonoxime O-Levulinyl acetonoxime is now commercially available form Sai Life Sciences (http://www.sailifesciences.com). The main advantage to preparing it is cost.
SUPPORT PROTOCOL 1
Additional Materials (also see Basic Protocol 1) Acetone oxime (Aldrich) Levulinic acid (Aldrich) 1,3-Dicyclohexylcarbodiimide (DCC; Aldrich) 25-L three-neck round-bottom flask equipped Overhead stirrer Thermometer Addition funnel Cooling bath 1. In a 25-L three-neck round-bottom flask equipped with an overhead stirrer, a thermometer, an addition funnel, and a stir bar, dissolve 500 g (6.84 mol) acetone oxime in 12 L anhydrous CH2 Cl2 . Cool the flask to −5◦ C using an external cooling bath.
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.5 Current Protocols in Nucleic Acid Chemistry
Supplement 21
2. With the solution still stirring, add 794 g (6.84 mol) levulinic acid over a period of 1 hr under a nitrogen atmosphere, maintaining the internal reaction temperature at 0◦ C. 3. Dissolve 1.41 kg (6.86 mol) DCC in 3 L CH2 Cl2 and add to the reaction mixture slowly over a period of 2 hr, still at 0◦ C. After 2 hr, the reaction mixture will become heterogeneous due to the precipitation of 1,3-dicyclohexylurea, indicating the completion of the reaction.
4. Stir for an additional 2 hr at 5◦ to 10◦ C. 5. Filter off the 1,3-dicyclohexylurea under vacuum, collecting the filtrate in a filter flask. Wash the precipitate twice with 1 L CH2 Cl2 , collecting the washes in the same vessel. 6. Concentrate the combined filtrate under vacuum in a rotary evaporator to give the product as a pale yellow oil. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
7. Confirm product purity by TLC; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. O-Levulinyl acetonoxime is obtained in a yield of 1.14 kg (97%). TLC (EtOAc): Rf = 0.37. IR (NaCl): υ 1756, 1719 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 1.99 (s, 3H, Me), 2.01 (s, 3H, Me), 2.19 (s, 3H, MeCO), 2.66 (t, 3 JHH = 6.6 Hz, 2H, CH2 -Lev), 2.82 (t, 3 JHH = 6.8 Hz, 2H, CH2 -Lev). 13 C NMR (CDCl3 , 75 MHz): δ 16.9 (Me), 21.8 (Me), 26.5 (CH2 -Lev), 29.8 (Me), 37.7 (CH2 -Lev), 163.9 (C=N), 170.4 (C=O), 206.3 (C=O). ESI-MS (m/z): 172 [(M + H)+ , 30%], 194 [(M + Na)+ , 100%]. Anal. calcd. (%) for C8 H13 NO3 : C, 56.13; H, 7.65; N, 8.18; found: C, 56.3; H, 7.4; N, 8.3. The product is visualized on the TLC plate in an iodine chamber (APPENDIX 3D). BASIC PROTOCOL 2
Preparation of N4 -Benzoyl-3 -O-Levulinyl-2 -Deoxycytidine via Regioselective Enzymatic Acylation with PSL-C Materials N4 -Benzoyl-2 -deoxycytidine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Pseudomonas cepacia lipase (PSL-C; 904 propyl laurate units per gram; Amano Enzyme) Anhydrous nitrogen Anhydrous tetrahydrofuran (THF), freshly distilled from sodium and benzophenone Methanol (MeOH), hot (65◦ C) Diethyl ether (Et2 O), cold (4◦ C) 1-L Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 40◦ C Buchner funnels with filter paper circles 500-mL round-bottom flasks Rotary evaporator Additional reagents and equipment for TLC (see Basic Protocol 1)
Enzymatic Regioselective Levulinylation of Nucleosides
Perform levulinylation 1. Add 10 g (30.19 mmol) N4 -benzoyl-2 -deoxycytidine, 15.5 g (90.57 mmol) Olevulinyl acetonoxime, and 20 g PSL-C to a 1-L Erlenmeyer flask equipped with a three-way glass stopcock.
2.11.6 Supplement 21
Current Protocols in Nucleic Acid Chemistry
2. Evacuate the Erlenmeyer flask on a vacuum line, and then flush the flask with nitrogen. Repeat this procedure three times. 3. Add 302 mL dry THF. 4. Seal the flask with a rubber septum and place on an orbital shaker kept at 40◦ C. Shake the reaction mixture at 250 rpm. 5. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). At this point in the synthesis, the reaction mixture will appear as a white suspension. The levulinylation reaction will take between 14 and 16 hr to complete.
Work up and purify product 6. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 7. Wash the PSL-C ten times with 100 mL hot (65◦ C) MeOH. When the 500-mL flask is full, evaporate the solvent under vacuum on a rotary evaporator and continue washes. Because of the poor solubility of the product in MeOH, additional washes may be required for complete recovery.
8. Remove solvents under reduced pressure using a rotary evaporator. The excess oxime ester will impart an orange color to the residual product.
9. Filter under vacuum using a Buchner funnel with a filter paper circle. Wash the white solid (i.e., the purified product) three times with 50 mL cold Et2 O, and then dry the solid under vacuum. Since the product is relatively insoluble in Et2 O, additional extraction is not required. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
10. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. N4 -Benzoyl-3 -O-levulinyl-2 -deoxycytidine (S.2b) is obtained in 80% to 85% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.30. m.p. 189◦ -191◦ C. [α]20 D = +20.5 (c 1.0, MeOH). IR (KBr): υ 3289, 2929, 1727, 1709 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 2.20 (s, 3H, MeLev), 2.44 (m, 1H, H2 ), 2.59 (m, 2H, CH2 -Lev), 2.73 (m, 3H, H2 + CH2 -Lev), 3.97 (m, 2H, H5 ), 4.20 (m, 1H, H4 ), 5.37 (m, 1H, H3 ), 6.26 (apparent t, 3 JHH = 6.8 Hz, 1H, H1 ), 7.58 (m, 4H, H5 + Hm + Hp ), 7.90 (apparent d, 3 JHH = 7.3 Hz, 2H, Ho ), 8.30 (d, 3 JHH = 7.4 Hz, 1H, H6). 13 C NMR (DMSO-d6 , 75 MHz): δ 27.8 (CH2 -Lev), 29.6 (Me-Lev), 37.5 (CH2 -Lev), 38.2 (C2 ), 61.2 (C5 ), 74.9 and 85.6 (C3 + C4 ), 86.4 (C1 ), 96.3 (C5), 128.5 (Co + Cm ), 132.8 (Ci ), 133.1 (Cp ), 145.0 (C6), 154.5 (PhC=O), 163.3 (C4), 167.4 (C2), 172.1 (C=O), 207.0 (C=O). ESI-MS (m/z): 430 [(M + H)+ , 30%], 452 [(M + Na)+ , 52%], 468 [(M + K)+ , 95%]. Anal. calcd. (%) for C21 H23 N3 O7 : C, 58.74; H, 5.40; N, 9.79; found: C, 58.7; H, 5.5; N, 9.8.
Preparation of N6 -Benzoyl-3 -O-Levulinyl-2 -Deoxyadenosine via Regioselective Enzymatic Acylation with PSL-C
BASIC PROTOCOL 3
Materials N6 -Benzoyl-2 -deoxyadenosine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Pseudomonas cepacia lipase (PSL-C; 904 propyl laurate units per gram; Amano Enzyme) Anhydrous nitrogen
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.7 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Anhydrous tetrahydrofuran (THF), freshly distilled from sodium and benzophenone Dichloromethane (CH2 Cl2 ) Diethyl ether (Et2 O), cold (4◦ C) 1-L Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 40◦ C Buchner funnels with filter paper circles 500-mL round-bottom flasks Rotary evaporator Additional reagents and equipment for TLC (see Basic Protocol 1) Perform levulinylation 1. Add 10 g (28.15 mmol) N6 -benzoyl-2 -deoxyadenosine, 14.4 g (84.45 mmol) Olevulinyl acetonoxime, and 30 g PSL-C to a 1-L Erlenmeyer flask equipped with a three-way glass stopcock. 2. Evacuate the Erlenmeyer flask on a vacuum line, and then flush the flask with nitrogen. Repeat this procedure three times. 3. Add 282 mL dry THF. 4. Seal the flask with a rubber septum and place in an orbital shaker kept at 40◦ C. Shake the reaction mixture at 250 rpm. 5. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). At this point in the synthesis, the reaction mixture will appear as a white suspension. The levulinylation reaction will take between 16 and 18 hr to complete.
Work up and purify product 6. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 7. Wash the PSL-C three times with 50 mL CH2 Cl2 . 8. Remove solvents under reduced pressure using a rotary evaporator. The excess oxime ester will impart an orange color to the residual product.
9. Filter under vacuum using a Buchner funnel with a filter paper circle. Wash the white solid (i.e., the purified product) three times with 50 mL cold Et2 O, and then dry the solids under vacuum. Since the product is relatively insoluble in Et2 O, additional extraction is not required. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
10. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis.
Enzymatic Regioselective Levulinylation of Nucleosides
N6 -Benzoyl-3 -O-levulinyl-2 -deoxyadenosine (S.2c) is obtained in 80% to 85% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.44. m.p. 125◦ -127◦ C. [α]20 D = −26.7 (c 0.9, CHCl3 ). IR (KBr): υ 2360, 2341, 1733, 1715, 1687 cm−1 . 1 H NMR (CDCl3 , 200 MHz): δ 2.22 (s, 3H, Me-Lev), 2.61 (m, 3H, CH2 -Lev + H2 ), 2.82 (m, 2H, CH2 -Lev), 3.18 (m, 1H, H2 ), 3.97 (m, 2H, H5 ), 4.31 (s, 1H, H4 ), 5.57 (apparent d, 3 JHH = 5.4 Hz, 1H, H3 ), 6.38 (dd, 3 JHH = 9.8, 5.2 Hz, 1H, H1 ), 7.57 (m, 3H, Hm + Hp ), 8.05 (m, 2H, Ho ), 8.17 (s, 1H, H2 or H8), 8.79 (s, 1H, H8 or H2). 13 C NMR (CDCl3 , 75 MHz): δ 27.7 (CH2 Lev), 29.6 (Me-Lev), 37.6 (CH2 -Lev + C2 ), 62.8 (C5 ), 76.1 and 86.8 (C3 + C4 ), 87.0
2.11.8 Supplement 21
Current Protocols in Nucleic Acid Chemistry
(C1 ), 124.3 (C5), 127.8 and 128.6 (Co + Cm ), 132.7 (Cp ), 133.2 (Ci ), 142.3 (C2 or C8), 150.1 (C4), 150.6 (C6), 151.9 (C8 or C2), 164.8 (PhC=O), 172.1 (C=O), 206.4 (C=O). ESI-MS (m/z): 454 [(M + H)+ , 20%], 476 [(M + Na)+ , 33%], 492 [(M + K)+ , 5%]. Anal. calcd. (%) for C22 H23 N5 O6 : C, 58.27; H, 5.11; N, 15.44; found: C, 58.2; H, 5.2; N, 15.5.
Preparation of N2 -Isobutyryl-3 -O-Levulinyl-2 -Deoxyguanosine via Regioselective Enzymatic Hydrolysis with CAL-B
BASIC PROTOCOL 4
Materials N2 -Isobutyryl-3 ,5 -di-O-levulinyl-2 -deoxyguanosine (S.4d; see Support Protocol 2) 1,4-Dioxane 0.15 M KH2 PO4 buffer (see recipe) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram [PLU/g]; Novo Nordisk) Dichloromethane (CH2 Cl2 ) Saturated sodium bicarbonate (NaHCO3 ) solution Chloroform (CHCl3 ) Sodium sulfate (Na2 SO4 ) Diethyl ether (Et2 O) 500-mL Erlenmeyer flask with rubber septum Orbital shaker, 40◦ C Buchner funnel with filter paper circles 500-mL round-bottom flasks Rotary evaporator 500-mL separatory funnel 250-mL Erlenmeyer flasks Glass funnel with Whatman no. 1 filter paper Additional reagents and equipment for TLC (see Basic Protocol 1) Perform regioselective hydrolysis 1. Add 5 g (9.37 mmol) N2 -isobutyryl-3 ,5 -di-O-levulinyl-2 -deoxyguanosine, 16.4 mL 1,4-dioxane, 77.4 mL of 0.15 M KH2 PO4 buffer, and 5 g CAL-B to a 500-mL Erlenmeyer flask, and then seal the flask with a rubber septum. 2. Place the flask on an orbital shaker kept at 40◦ C. Shake the reaction mixture at 250 rpm. 3. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5), but using 20% (v/v) MeOH/CH2 Cl2 as the eluent. After spotting, it will be necessary to dry the TLC plate with a heat gun to evaporate the water in the sample. At this point in the synthesis, the reaction mixture will be clear. The hydrolysis reaction typically takes between 13 and 15 hr to complete.
Work up and purify product 4. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 5. Wash the CAL-B twice with 50 mL CH2 Cl2 , collecting washes in the same flask. 6. Remove solvents under reduced pressure using a rotary evaporator.
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.9 Current Protocols in Nucleic Acid Chemistry
Supplement 21
7. Dissolve the residue in 100 mL CH2 Cl2 and transfer to a 500-mL separatory funnel. 8. Extract the organic layer four times with 25 mL saturated NaHCO3 solution, using two 250-mL Erlenmeyer flasks to separate the phases. Monitor the progress of the extraction by performing analytical TLC on both phases. N2 -Isobutyryl-2 -deoxyguanosine and levulinic acid are extracted into the aqueous phase. Additional extractions may be needed for complete removal from the organic phase. Alternatively, brine can be used to separate the phases effectively.
9. Pool the aqueous phases and recover product from the aqueous phase by extracting four times with 25 mL CH2 Cl2 and four times with 25 mL CHCl3 , collecting the combined organic phases in a 250-mL Erlenmeyer flask. 10. Pool the organic phases from step 9 and verify by TLC that they contain no residual N2 -isobutyryl-2 -deoxyguanosine. If any is present, re-extract with 20 mL saturated NaHCO3 solution. Re-extraction is unnecessary if N2 -isobutyryl-2 -deoxyguanosine is already absent from the organic phase.
11. Pool the organic phases from steps 8 and 10 and dry over 4 g Na2 SO4 for 10 to 15 min. Remove the drying agent by gravity filtration through Whatman no. 1 filter paper in a glass funnel, and collect the filtrate in a 500-mL round-bottom flask. 12. Wash the Na2 SO4 four times with 25 mL CH2 Cl2 , and collect all washes in the same round-bottom flask. 13. Evaporate solvents under reduced pressure using a rotary evaporator. 14. Add 10 mL Et2 O and triturate the product. Evaporate the solvent on a rotary evaporator and collect the product. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
15. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. N2 -Isobutyryl-3 -O-levulinyl-2 -deoxyguanosine (S.2d) is obtained in ∼70% to 75% yield. TLC (20% MeOH/CH2 Cl2 ): Rf = 0.75. m.p. 170◦ -172◦ C. [α]20 D = +1.0 (c 1.1, DMSO). IR (KBr): υ 3415, 2961, 2929, 2859, 1725, 1686, 1614 cm−1 . 1 H NMR (MeOH-d4 , 200 MHz): δ 1.41 (d, 3 JHH = 6.8 Hz, 6H, Me-iBu), 2.38 (s, 3H, Me-Lev), 2.70-3.09 (m, 7H, 2CH2 -Lev + 2H2 + CH-iBu), 3.98 (d, 3 JHH = 3.6 Hz, 2H, 2H5 ), 4.32 (m, 1H, H4 ), 5.57 (m, 1H, H3 ), 6.51 (dd, 3 JHH = 6.1, 8.0 Hz, 1H, H1 ), 8.43 (s, 1H, H8). 13 C NMR (MeOHd4 , 50 MHz): δ 19.3 (Me-iBu), 28.9 (CH2 -Lev), 29.7 (Me-Lev), 36.9 (CH-iBu), 38.6 and 39.0 (C2 + CH2 -Lev), 63.0 (C5 ), 76.6 and 85.6 (C3 + C4 ), 87.0 (C1 ), 121.2 (C5), 139.6 (C8), 149.7 and 150.2 (C2 + C4), 157.3 (C6), 173.9 (C=O), 181.7 (iBu-C=O), 209.5 (C=O). ESI-MS (m/z): 436 [(M + H)+ , 15%], 458 [(M + Na)+ , 50%]. Anal. calcd. (%) for C19 H25 N5 O7 : C, 52.41; H, 5.79; N, 16.08; found: C, 52.6; H, 5.8; N, 16.2. SUPPORT PROTOCOL 2
Enzymatic Regioselective Levulinylation of Nucleosides
Preparation of N2 -Isobutyryl-3 ,5 -Di-O-Levulinyl-2 -Deoxyguanosine Additional Materials (also see Basic Protocol 1) N2 -Isobutyryl-2 -deoxyguanosine (Rasayan) Triethylamine (Et3 N) Anhydrous 1,4-dioxane, freshly distilled from sodium and benzophenone Levulinic acid 1,3-Dicyclohexylcarbodiimide (DCC) 4-(Dimethylamino)pyridine (DMAP; Aldrich)
2.11.10 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Perform levulinylation 1. Add a magnetic stir bar and 5.0 g (14.82 mmol) N2 -isobutyryl-2 -deoxyguanosine to a 500-mL round-bottom flask equipped with a three-way glass stopcock. Seal the flask with a rubber septum. 2. Evacuate the flask on a vacuum line, and then flush the flask with nitrogen. Repeat this procedure three times. 3. Add 12.60 mL (88.92 mmol) Et3 N, 150 mL dry 1,4-dioxane, 7.9 mL (77.06 mmol) levulinic acid, 15.86 g (77.06 mmol) DCC, and 148 mg (1.19 mmol) DMAP. Close the three-way glass stopcock and place the flask on a magnetic stirrer. 4. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5), but using 20% (v/v) MeOH/CH2 Cl2 as the eluent. The levulinylation reaction is complete in 2 to 3 hr. After 2 hr the reaction mixture becomes heterogeneous due to the precipitation of 1, 3-dicyclohexylurea (DCU).
Work up and purify product 5. When the reaction is complete, filter the suspension under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. This filtration step is performed to remove the DCU formed during the reaction.
6. Wash DCU twice with 50 mL CH2 Cl2 , collecting washes in the same round-bottom flask. 7. Remove solvents under reduced pressure using a rotary evaporator. The product that results will be an orange oil.
8. Dissolve the residue in 50 mL CH2 Cl2 and transfer to a 500-mL separatory funnel. 9. Remove levulinic acid by extracting the organic layer two to three times with 20 mL saturated NaHCO3 solution. Separate the layers into two 250-mL Erlenmeyer flasks, and verify that all levulinic acid has been removed from the organic phase by performing analytical TLC on both phases. Additional extractions may be needed for complete removal. Alternatively, brine can be used to clarify both phases.
10. Dry the organic layer over 4 g Na2 SO4 for 10 to 15 min, and then remove the drying agent by gravity filtration using a glass funnel and Whatman no. 1 filter paper. Collect the filtrate in a 500-mL round-bottom flask. 11. Wash the Na2 SO4 four times with 25 mL CH2 Cl2 , and collect all washes in the same round-bottom flask. 12. Evaporate solvents under reduced pressure using a rotary evaporator. The product that results will again be an orange oil.
13. To recover product by dry column chromatography, weigh out 100 g silica gel and place in a Buchner funnel with a filter paper circle, attached to a 1-L filter flask connected to a vacuum line. Wash the silica with 200 mL of 25% (v/v) Et2 O/EtOAc. 14. Using a Pasteur pipet, spread the residue carefully on top of the silica bed. 15. Elute any residual 1,3-dicyclohexyl-1-levulinylurea with ∼500 to 800 mL of 25% (v/v) Et2 O/EtOAc.
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.11 Current Protocols in Nucleic Acid Chemistry
Supplement 21
16. Using clean filter flasks to collect 100-mL fractions, elute the desired product with ∼800 to 1200 mL of 10% (v/v) MeOH/CH2 Cl2 . Monitor fractions by analytical TLC. 17. Transfer fractions containing pure product to a 500-mL round-bottom flask, and remove solvents under reduced pressure using a rotary evaporator. If desired, solvents can be recovered by distillation.
18. Add 30 mL Et2 O and triturate the product. Evaporate the solvent on a rotary evaporator and collect the pale yellow product. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
19. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. N2 -Isobutyryl-3 ,5 -di-O-levulinyl-2 -deoxyguanosine (S.4d) is obtained in ∼85% to 90% yield. TLC (20% MeOH/CH2 Cl2 ): Rf = 0.85. m.p. 45◦ -47◦ C. [α]20 D = −8.8 (c 1.0, DMSO). IR (KBr): υ 3413, 2935, 1740, 1714, 1680, 1613 cm−1 . 1 H NMR (DMSO-d6 , 200 MHz): δ 1.23 (d, 3 JHH = 6.5 Hz, 6H, Me-iBu), 2.15 (s, 3H, Me-Lev), 2.20 (s, 3H, Me-Lev), 2.55-3.19 (several m, 11H, 4CH2 -Lev + 2H2 + CH-iBu), 4.32 (m, 3H, H4 + 2H5 ), 5.35 (m, 1H, H3 ), 6.35 (apparent t, 3 JHH = 7.2 Hz, 1H, H1 ), 8.35 (s, 1H, H8), 11.80 (br s, 1H, NH), 12.20 (br s, 1H, NH). 13 C NMR (DMSO-d6 , 50 MHz): δ 18.86 (Me-iBu), 18.91 (Me-iBu), 27.5 (CH2 -Lev), 27.6 (CH2 -Lev), 29.5 (Me-Lev), 29.6 (Me-Lev), 34.8 (CH-iBu), 35.5 (C2 ), 37.38 (CH2 -Lev), 37.45 (CH2 -Lev), 63.7 (C5 ), 74.6 and 81.7 (C3 + C4 ), 82.9 (C1 ), 120.3 (C5), 137.3 (C8), 148.3 and 148.7 (C2 + C4), 154.8 (C6), 172.1 (C=O), 172.2 (C=O), 180.2 (iBu-C=O), 206.9 (C=O), 207.1 (C=O). ESI-MS (m/z): 534 [(M + H)+ , 100%], 556 [(M + Na)+ , 60%], 572 [(M + K)+ , 27%]. Anal. calcd. (%) for C24 H31 N5 O9 : C, 54.01; H, 5.86; N, 13.13; found: C, 54.2; H, 5.8; N, 13.2.
SYNTHESIS OF 5 -O-LEVULINYL-2 -DEOXYRIBONUCLEOSIDES The preparation of 5 -O-levulinyl-2 -deoxyribonucleosides consists of regioselective acylation of the 5 -hydroxyl function of deoxyribonucleosides with O-levulinyl acetonoxime using Candida antarctica lipase B (CAL-B) as illustrated in Figure 2.11.1. This is a general procedure for the T, C, A, and G monomers. BASIC PROTOCOL 5
Preparation of 5 -O-Levulinylthymidine via Regioselective Enzymatic Acylation with CAL-B Materials Thymidine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) Anhydrous nitrogen Anhydrous tetrahydrofuran (THF), freshly distilled from sodium and benzophenone 1-L Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 10◦ C Additional reagents and equipment for analysis and work up of regioselectively levulinated thymidine (see Basic Protocol 1)
Enzymatic Regioselective Levulinylation of Nucleosides
Perform levulinylation 1. Add 10 g (41.28 mmol) thymidine, 21.2 g (123.86 mmol) O-levulinyl acetonoxime, and 10 g CAL-B to a 1-L Erlenmeyer flask equipped with a three-way glass stopcock.
2.11.12 Supplement 21
Current Protocols in Nucleic Acid Chemistry
2. Evacuate the Erlenmeyer flask on a vacuum line and then flush with nitrogen. Repeat this procedure three times. 3. Add 206 mL dry THF. 4. Seal the flask with a rubber septum and place in an orbital shaker kept at 10◦ C. Shake the reaction mixture at 250 rpm. 5. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). The reaction mixture containing immobilized lipase will remain clear throughout the course of the reaction, which takes 5 to 7 hr to complete.
Work up and purify product 6. Work up, purify, and recover the product as described for compound S.2a (see Basic Protocol 1, steps 6 to 24). The initial isolated yield (steps 6 to17) is ∼50% to 60%, and the recovery process (steps 18 to 24) yields another ∼15% to 25%. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
7. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. 5 -O-Levulinylthymidine (S.3a) is obtained in an overall combined yield of ∼75% to 80%. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.22. m.p. 141◦ -143◦ C. [α]20 D = +21.5 (c 0.5, MeOH). IR (KBr): υ 3393, 3215, 2934, 1737, 1724, 1643, 1629 cm−1 . 1 H NMR (DMSOd6 , 200 MHz): δ 1.91 (s, 3H, Me), 2.27 (s, 3H, Me-Lev), 2.30 (m, 2H, H2 ), 2.66 (m, 2H, CH2 -Lev), 2.89 (t, 3 JHH = 6.2 Hz, 2H, CH2 -Lev), 4.07 (m, 1H, H4 ), 4.35 (m, 3H, H3 + 2H5 ), 5.55 (d, J = 4.8 Hz, 1H, OH), 6.32 (t, 3 JHH = 7.0 Hz, 1H, H1 ), 7.6 (s, 1H, H6), 11.45 (s, 1H, NH). 13 C NMR (DMSO-d6 , 50 MHz): δ 12.02 (Me), 27.4 (CH2 -Lev), 29.4 (Me-Lev), 37.2 (C2 ), 38.4 (CH2 -Lev), 63.8 (C5 ), 70.1 and 83.5 (C3 + C4 ), 83.6 (C1 ), 109.7 (C5), 135.7 (C6), 150.3 (C4), 163.6 (C2), 172.1 (C=O Lev), 206.7 (C=O Lev). ESI-MS (m/z): 341 [(M + H)+ , 40%], 363 [(M + Na)+ , 100%], 379 [(M + K)+ , 80%]. Anal. calcd. (%) for C15 H20 N2 O7 : C, 52.92; H, 5.93; N, 8.23; found: C, 52.7; H, 5.8; N, 8.2.
Preparation of N4 -Benzoyl-5 -O-Levulinyl-2 -Deoxycytidine via Regioselective Enzymatic Acylation with CAL-B
BASIC PROTOCOL 6
Materials N4 -Benzoyl-2 -deoxycytidine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) Anhydrous nitrogen Anhydrous tetrahydrofuran (THF), freshly distilled over sodium and benzophenone Dichloromethane (CH2 Cl2 ) Methanol (MeOH) Diethyl ether (Et2 O), cold (4◦ C) 1-L Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 30◦ C Buchner funnels with filter paper circles 500-mL round-bottom flask
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.13 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Rotary evaporator 1-L filter flask 250-mL Erlenmeyer flask Horst heating mantle Additional reagents and equipment for TLC (see Basic Protocol 1) Perform levulinylation 1. Add 10 g (30.19 mmol) N4 -benzoyl-2 -deoxycytidine, 15.5 g (90.57 mmol) Olevulinyl acetonoxime, and 10 g CAL-B to a 1-L Erlenmeyer flask equipped with a three-way glass stopcock. 2. Evacuate the Erlenmeyer flask on a vacuum line and then flush with nitrogen. Repeat this procedure three times. 3. Add 302 mL dry THF. 4. Seal the flask with a rubber septum and place in an orbital shaker kept at 30◦ C. Shake the reaction mixture at 250 rpm. 5. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). The reaction mixture is a white suspension, and the reaction is complete in 16 to 18 hr.
Work up and purify product 6. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 7. Wash the CAL-B twice with 50 mL CH2 Cl2 and then twice with 50 mL MeOH. Because of the poor solubility of the product in MeOH, additional washings may be required for complete recovery.
8. Remove solvents under reduced pressure using a rotary evaporator. The excess oxime ester will impart an orange color to the product.
9. Dissolve the residue in 20 mL CH2 Cl2 and precipitate the product from 40 to 60 mL Et2 O as a white solid. Cool the precipitate at 4◦ C overnight. 10. Transfer the precipitate to a Buchner funnel with a filter paper circle, attached to a 1-L filter flask connected to a vacuum line. Wash twice with 50 mL cold (4◦ C) Et2 O, and then dry the white solid under vacuum. Since the levulinylation reaction goes to completion, no further extractions are required.
11. Crystallize the product from 50 to 60 mL MeOH using a Horst heating mantle, and collect the filtrate in a 250-mL Erlenmeyer flask. This separates the 5 -acylated product from its 3 -regioisomer (5% to 10% of the crude product).
12. Collect the solid by vacuum filtration through a Buchner funnel with a filter paper circle, and then wash twice with 40 mL cold Et2 O. Dry the white solid under vacuum. Et2 O removes traces of MeOH and dissolves the undesired 3 -acylated regioisomer. Enzymatic Regioselective Levulinylation of Nucleosides
If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
2.11.14 Supplement 21
Current Protocols in Nucleic Acid Chemistry
13. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. N4 -Benzoyl-5 -O-levulinyl-2 -deoxycytidine (S.3b) is obtained in ∼70% to 75% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.37. m.p. 50◦ -52◦ C. [α]20 D = +71.1 (c 0.5, MeOH). IR (KBr): υ 3410, 2919, 1738, 1701, 1650 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 2.20 (s, 3H, Me-Lev), 2.25 (m, 1H, H2 ), 2.58 (m, 2H, CH2 -Lev), 2.75 (m, 1H, H2 ), 2.82 (m, 2H, CH2 -Lev), 3.35 (s, 1H, OH), 4.25 (m, 1H, H3 ), 4.40 (m, 3H, 2H5 + H4 ), 6.30 (apparent t, 3 JHH = 6.2 Hz, 1H, H1 ), 7.55 (m, 4H, H5 + 2Hm + Hp ), 7.90 (apparent d, 3 JHH = 7.1 Hz, 2H, Ho ), 8.20 (d, 3 JHH = 7.4 Hz, 1H, H6), 8.78 (s, 1H, NH). 13 C NMR (CDCl3 , 75 MHz): δ 27.7 (CH2 -Lev), 29.6 (Me-Lev), 37.7 (CH2 -Lev), 41.3 (C2 ), 63.7 (C5 ), 70.6 and 84.8 (C3 + C4 ), 87.4 (C1 ), 96.8 (C5), 127.6 and 128.7 (Co + Cm ), 132.8 (Ci ), 133.0 (Cp ), 144.2 (C6), 155.1 (C2), 162.4 (C4), 166.7 (PhC=O), 172.6 (C=O), 206.8 (C=O). ESI-MS (m/z): 430 [(M + H)+ , 20%], 452 [(M + Na)+ , 65%], 468 [(M + K)+ , 40%]. Anal. calcd. (%) for C21 H23 N3 O7 : C, 58.74; H, 5.40; N, 9.79; found: C, 58.8; H, 5.6; N, 9.7.
Preparation of N6 -Benzoyl-5 -O-Levulinyl-2 -Deoxyadenosine via Regioselective Enzymatic Acylation with CAL-B
BASIC PROTOCOL 7
Materials N6 -Benzoyl-2 -deoxyadenosine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) Anhydrous nitrogen Anhydrous tetrahydrofuran (THF), freshly distilled over sodium and benzophenone Methanol (MeOH), hot (65◦ C) Diethyl ether (Et2 O), cold (4◦ C) 1-L Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 30◦ C Buchner funnels with filter paper circles 500-mL round-bottom flask Rotary evaporator 1-L filter flask Additional reagents and equipment for TLC (see Basic Protocol 1) Perform levulinylation 1. Add 10 g (28.15 mmol) N6 -benzoyl-2 -deoxyadenosine, 14.4 g (84.45 mmol) Olevulinyl acetonoxime, and 10 g CAL-B to a 1-L Erlenmeyer flask equipped with a three-way glass stopcock. 2. Evacuate the Erlenmeyer flask on a vacuum line and flush with nitrogen. Repeat this procedure three times. 3. Add 140 mL dry THF. 4. Seal the flask with a rubber septum and place in an orbital shaker kept at 30◦ C. Shake the reaction mixture at 250 rpm. 5. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). The reaction mixture will remain a white suspension and the reaction is complete in 24 to 26 hr.
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.15 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Work up and purify product 6. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 7. Wash the CAL-B five times with 100 mL hot (65◦ C) MeOH. When the flask becomes full, evaporate the solvent under vacuum on a rotary evaporator and continue washes. Because of the poor solubility of the product in MeOH, additional washes may be required for complete recovery.
8. Remove solvents under reduced pressure using a rotary evaporator. The excess oxime ester will impart an orange color to the product.
9. Transfer the solid to a Buchner funnel with a filter paper circle, attached to a 1-L filter flask connected to a vacuum line, and then triturate and wash the solid three times with 50 mL cold (4◦ C) Et2 O. Dry the white solid under vacuum. Since the levulinylation reaction goes to completion, no further extractions are required. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
10. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. N6 -Benzoyl-5 -O-levulinyl-2 -deoxyadenosine (S.3c) is obtained in 70% to 75% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.50. m.p. 137◦ -139◦ C. [α]20 D = −5.9 (c 1.1, MeOH). IR (KBr): υ 3413, 2959, 2928, 1726, 1637, 1616 cm−1 . 1 H NMR (DMSO-d6 , 300 MHz): δ 2.06 (s, 3H, Me-Lev), 2.45 (m, 3H, CH2 -Lev + H2 ), 2.66 (m, 2H, CH2 -Lev), 2.90 (m, 1H, H2 ), 4.03 (m, 1H, H4 ), 4.20 (m, 2H, 2H5 ), 4.51 (m, 1H, H3 ), 5.55 (s, 1H, OH), 6.50 (apparent t, 3 JHH = 6.5 Hz, 1H, H1 ), 7.58 (m, 3H, 2Hm + Hp ), 8.03 (m, 2H, 2Ho ), 8.69 (s, 1H, H2 or H8), 8.74 (s, 1H, H8 or H2), 11.20 (s, 1H, NH). 13 C NMR (DMSO-d6 , 75 MHz): δ 27.7 (CH2 -Lev), 29.8 (Me-Lev), 37.6 and 38.7 (CH2 -Lev + C2 ), 64.2 (C5 ), 70.8 and 83.8 (C3 + C4 ), 84.5 (C1 ), 126.1 (C5), 128.7 and 128.8 (Co + Cm ), 132.7 (Cp ), 133.6 (Ci ), 143.4 (C2 or C8), 150.7 (C4), 151.9 (C8 or C2), 152.1 (C6), 165.9 (PhC=O), 172.5 (C=O), 207.1 (C=O). ESI-MS (m/z): 476 [(M + Na)+ , 100%], 492 [(M + K)+ , 53%]. Anal. calcd. (%) for C22 H23 N5 O6 : C, 58.27; H, 5.11; N, 15.44; found: C, 58.4; H, 4.9; N, 15.3. BASIC PROTOCOL 8
Preparation of N2 -Isobutyryl-5 -O-Levulinyl-2 -Deoxyguanosine via Regioselective Enzymatic Acylation with CAL-B Materials
Enzymatic Regioselective Levulinylation of Nucleosides
N2 -Isobutyryl-2 -deoxyguanosine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) Anhydrous nitrogen Anhydrous tetrahydrofuran (THF), freshly distilled over sodium and benzophenone Methanol (MeOH) Dichloromethane (CH2 Cl2 ) Saturated sodium bicarbonate (NaHCO3 ) solution Chloroform (CHCl3 ) Sodium sulfate (Na2 SO4 ) Silica gel Ethyl acetate (EtOAc) Diethyl ether (Et2 O)
2.11.16 Supplement 21
Current Protocols in Nucleic Acid Chemistry
1-L Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 40◦ C Buchner funnels with filter paper circles 500-mL round-bottom flasks Rotary evaporator 500-mL separatory funnel Glass funnel with Whatman no. 1 filter paper 1-L filter flask Additional reagents and equipment for TLC (see Basic Protocol 1) Perform levulinylation 1. Add 10 g (29.64 mmol) N2 -isobutyryl-2 -deoxyguanosine, 15.2 g (88.94 mmol) Olevulinyl acetonoxime, and 10 g CAL-B to a 1-L Erlenmeyer flask equipped with a three-way glass stopcock. 2. Evacuate the Erlenmeyer flask on a vacuum line and flush with nitrogen. Repeat this procedure three times. 3. Add 148 mL dry THF. 4. Seal the flask with a rubber septum and place in an orbital shaker kept at 40◦ C. Shake the reaction mixture at 250 rpm. 5. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5), but using 20% (v/v) MeOH/CH2 Cl2 as the eluent. At this point, the reaction mixture will be clear. The levulinylation reaction usually takes 16 to 18 hr to complete.
Work up and purify product 6. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 7. Wash the CAL-B six times with 50 mL MeOH. 8. Remove solvents under reduced pressure using a rotary evaporator. The product is an orange-colored oil due to the presence of excess oxime ester.
9. Dissolve the residue in 100 mL CH2 Cl2 and transfer to a 500-mL separatory funnel. 10. Extract the organic layer four times with 25 mL saturated NaHCO3 solution, using two 250-mL Erlenmeyer flasks to separate the phases. Monitor the progress of the extraction by performing analytical TLC on both phases. N2 -Isobutyryl-2 -deoxyguanosine is extracted into the aqueous phase. Additional extractions may be needed for complete removal from the organic phase. Alternatively, brine can be used to separate the phases effectively.
11. Pool the aqueous phases and recover product from the aqueous phase by extracting four times with 25 mL CH2 Cl2 and four times with 25 mL CHCl3 . 12. Pool the organic phases from step 11 and verify by TLC that they contain no residual N2 -isobutyryl-2 -deoxyguanosine. If any is present, re-extract with 20 mL saturated NaHCO3 solution. 2
Re-extraction is unnecessary if N -isobutyryl-2 -deoxyguanosine is already absent from the organic phase.
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.17 Current Protocols in Nucleic Acid Chemistry
Supplement 21
13. Pool the organic phases from steps 10 and 12 and dry over 4 g Na2 SO4 for 10 to 15 min. Remove the drying agent by gravity filtration through Whatman no. 1 filter paper in a glass funnel, and collect the filtrate in a 500-mL round-bottom flask. 14. Wash the Na2 SO4 four times with 25 mL CH2 Cl2 , and collect all washes in the same round-bottom flask. 15. Evaporate solvents under reduced pressure using a rotary evaporator. The product is an orange oil, which fails to precipitate from Et2 O, perhaps due to oxime ester contamination. Separation by chromatography is therefore necessary.
16. To recover product by dry column chromatography, weigh out 100 g silica gel and place in a Buchner funnel with a filter paper circle, attached to a 1-L filter flask connected to a vacuum line. Wash the silica with 200 mL of 25% (v/v) EtOAc/Et2 O. 17. Using a Pasteur pipet, spread the residue carefully on top of the silica bed. 18. Elute the residual oxime ester with ∼1500 to 1800 mL of 25% (v/v) EtOAc/Et2 O. 19. Using clean filter flasks to collect 100-mL fractions, elute the desired product with ∼1700 to 2200 mL of 10% (v/v) MeOH/CH2 Cl2 . Monitor fractions by analytical TLC. 20. Transfer fractions containing pure levulinylated product to a 500-mL round-bottom flask, and remove solvents under reduced pressure using a rotary evaporator. If desired, solvents can be recovered by distillation.
21. Add 10 mL Et2 O and triturate the product. Evaporate the solvent on a rotary evaporator and collect the product. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
22. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. N2 -Isobutyryl-5 -O-levulinyl-2 -deoxyguanosine (S.3d) is obtained in 75% to 80% yield. TLC (20% MeOH/CH2 Cl2 ): Rf = 0.60. m.p. 45◦ -47◦ C. [α]20 D = +3.0 (c 1.0, MeOH). IR (KBr): υ 3415, 2930, 1720, 1685 cm−1 . 1 H NMR (MeOH-d4 , 300 MHz): δ 1.42 (d, 3 JHH = 6.8 Hz, 6H, Me-iBu), 2.32 (s, 3H, Me-Lev), 2.59-3.07 (m, 7H, 2CH2 -Lev + 2H2 + CHiBu), 4.32 (m, 1H, H4 ), 4.50 (m, 2H, H5 ), 4.75 (m, 1H, H3 ), 6.53 (apparent t, 3 JHH = 6.5 Hz, 1H, H1 ), 8.33 (s, 1H, H8). 13 C NMR (MeOH-d4 , 75 MHz): δ 19.7 (Me-iBu), 29.0 (CH2 -Lev), 29.9 (Me-Lev), 37.2 (CH-iBu), 38.9 and 41.1 (C2 + CH2 -Lev), 65.3 (C5 ), 72.6 and 86.1 (C3 + C4 ), 86.5 (C1 ), 121.8 (C5), 139.8 (C8), 150.0 and 150.5 (C2 + C4), 157.8 (C6), 174.5 (C=O), 182.0 (iBu-C=O), 209.7 (C=O). ESI-MS (m/z): 436 [(M + H)+ , 20%], 458 [(M + Na)+ , 100%], 474 [(M + K)+ , 50%]. Anal. calcd. (%) for C19 H25 N5 O7 : C, 52.41; H, 5.79; N, 16.08; found: C, 52.3; H, 5.8; N, 16.2.
SYNTHESIS OF 3 -O-LEVULINYL-2 -O-METHYLRIBONUCLEOSIDES Because the enzymatic acylation of 2 -O-methyl derivatives with PSL-C is not regioselective, 3 -O-levulinyl-2 -O-methylribonucleosides are prepared via regioselective enzymatic hydrolysis of 3 ,5 -di-O-levulinyl-2 -O-methylribonucleosides with CAL-B as illustrated in Figure 2.11.3. This is a general procedure for the U, C, A, and G monomers. Synthesis of the 3 ,5 -di-O-levulinyl-2 -O-methylribonucleosides using levulinic acid is presented in Support Protocol 3. Enzymatic Regioselective Levulinylation of Nucleosides
2.11.18 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Figure 2.11.3 Regioselective hydrolysis of 3 ,5 -di-O-levulinyl-2 -O-methylribonucleosides (S.6a-d) using CAL-B. Abbreviations: ABz , N 6 -benzoyladenin-9-yl; CBz , N 4 -benzoylcytosin-1-yl; DCC, 1,3-dicyclohexylcarbodiimide; DMAP, 4-(dimethylamino)pyridine; Et3 N, triethylamine; Gi-Bu , N 2 -isobutyrylguanin-9-yl; Lev, levulinyl; LevOH, levulinic acid; U, uracil-1-yl.
Preparation of 3 -O-Levulinyl-2 -O-Methyluridine via Regioselective Enzymatic Hydrolysis with CAL-B
BASIC PROTOCOL 9
Materials 3 ,5 -Di-O-levulinyl-2 -O-methyluridine (S.6a; see Support Protocol 3) 1,4-Dioxane 0.15 M KH2 PO4 buffer (see recipe) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) 500-mL Erlenmeyer flask Rubber septum Orbital shaker, 30◦ C Additional reagents and equipment for TLC (see Basic Protocol 1) and for workup and purification of the product (see Basic Protocol 4) 1. Add 1 g (2.20 mmol) 3 ,5 -di-O-levulinyl-2 -O-methyluridine, 3.9 mL 1,4-dioxane, 18.2 mL of 0.15 M KH2 PO4 buffer, and 1 g CAL-B to a 500-mL Erlenmeyer flask. 2. Seal the flask with a rubber septum and place on an orbital shaker kept at 30◦ C. Shake the reaction mixture at 250 rpm. 3. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). After spotting, it will be necessary to dry the TLC plate with a heat gun to evaporate the water in the sample. The reaction mixture remains a white suspension and the reaction is usually complete in 9 to 11 hr.
4. Work up and purify the product as described for compound S.2d (see Basic Protocol 4, steps 4 to 14). If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months. Protection of Nucleosides for Oligonucleotide Synthesis
2.11.19 Current Protocols in Nucleic Acid Chemistry
Supplement 21
5. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR analysis; mass spectrometry; and elemental analysis. 3 -O-Levulinyl-2 -O-methyluridine (S.7a) is obtained in 75% to 80% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.32. m.p. 106◦ -108◦ C. [α]20 D = −2.6 (c 1.0, DMSO). IR (NaCl): υ 3452, 2934, 1693 cm−1 . 1 H NMR (DMSO-d6 , 300 MHz): δ 2.10 (s, 3H, Me-Lev), 2.54 (m, 2H, CH2 -Lev), 2.73 (m, 2H, CH2 -Lev), 3.24 (s, 3H, OMe), 3.59 (m, 2H, H5 ), 4.03 (m, 2H, H2 + H4 ), 5.23 (m, 1H, H3 ), 5.34 (br s, 1H, OH), 5.70 (d, 3 JHH = 8.0 Hz, 1H, H5), 5.87 (d, 3 JHH = 6.5 Hz, 1H, H1 ), 7.89 (d, 3 JHH = 8.2 Hz, 1H, H6). 13 C NMR (DMSO-d6 , 75 MHz): δ 31.7 (CH2 -Lev), 33.6 (Me-Lev), 41.4 (CH2 -Lev), 62.1 (OMe), 64.8 (C5 ), 74.9, 84.6, 87.2, 89.6 (C1 + C2 + C3 + C4 ), 106.6 (C5), 144.3 (C6), 154.7 (C4), 167.0 (C2), 175.8 (C=O), 210.7 (C=O). ESI-MS (m/z): 357 [(M + H)+ , 25%], 379 [(M + Na)+ , 100%], 395 [(M + K)+ , 21%]. Anal. calcd. (%) for C15 H20 N2 O8 : C, 50.56; H, 5.66; N, 7.86; found: C, 50.8; H, 5.9; N, 7.7. BASIC PROTOCOL 10
Preparation of N4 -Benzoyl-3 -O-Levulinyl-2 -O-Methylcytidine via Regioselective Enzymatic Hydrolysis with CAL-B Materials N4 -Benzoyl-3 ,5 -di-O-levulinyl-2 -O-methylcytidine (S.6b; see Support Protocol 3) 1,4-Dioxane 0.15 M KH2 PO4 buffer (see recipe) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) 500-mL Erlenmeyer flask Rubber septum Orbital shaker, 30◦ C Additional reagents and equipment for TLC (see Basic Protocol 1) and for workup and purification of the product (see Basic Protocol 4) 1. Add 1 g (1.79 mmol) N4 -benzoyl-3 ,5 -di-O-levulinyl-2 -O-methylcytidine, 3.6 mL 1,4-dioxane, 14.3 mL of 0.15 M KH2 PO4 buffer, and 1 g CAL-B to a 500-mL Erlenmeyer flask. 2. Seal the flask with a rubber septum and place on an orbital shaker kept at 30◦ C. Shake the reaction mixture at 250 rpm. 3. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). After spotting, it will be necessary to dry the TLC plate with a heat gun to evaporate the water in the sample. The reaction mixture remains a white suspension and the reaction is usually complete in 9 to 11 hr.
4. Work up and purify the product as described for compound S.2d (see Basic Protocol 4, steps 4 to 14). Since the product is hygroscopic, storage under a nitrogen atmosphere at −20◦ C is recommended. Under such conditions, no decomposition is seen even after several months.
5. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. Enzymatic Regioselective Levulinylation of Nucleosides
N4 -Benzoyl-3 -O-levulinyl-2 -O-methylcytidine (S.7b) is obtained in 70% to 75% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.48. m.p. not available (hygroscopic foam). [α]20 D = +10.1 (c 0.6, DMSO). IR (NaCl): υ 3318, 2931, 2359, 2339, 1739, 1715, 1698 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 2.16 (s, 3H, Me-Lev), 2.63 (m, 2H, CH2 -Lev), 2.76 (m, 2H,
2.11.20 Supplement 21
Current Protocols in Nucleic Acid Chemistry
CH2 -Lev), 3.48 (s, 3H, OMe), 3.78 (m, 1H, H5 ), 4.05 (m, 1H, H5 ), 4.28 (m, 2H, H2 + H4 ), 5.26 (apparent t, 3 JHH = 5.5 Hz, 1H, H3 ), 5.87 (d, 3 JHH = 3.4 Hz, 1H, H1 ), 7.437.54 (m, 4H, H5 + Hm + Hp ), 7.86 (m, 2H, Ho ), 8.37 (d, 3 JHH = 7.7 Hz, 1H, H6), 9.08 (br s, 1H, NH). 13 C NMR (CDCl3 , 75 MHz): δ 29.6 (CH2 -Lev), 29.5 (Me-Lev), 37.6 (CH2 -Lev), 58.6 (OMe), 60.2 (C5 ), 69.9, 81.6, 82.7, 89.9 (C1 + C2 + C3 + C4 ), 97.0 (C5), 127.6 and 128.6 (Co + Cm ), 132.7 (Ci ), 132.8 (Cp ), 145.8 (C6), 154.9 (C2), 162.6 (PhC=O), 166.8 (C4), 172.1 (C=O), 206.5 (C=O). ESI-MS (m/z): 460 [(M + H)+ , 100%], 482 [(M + Na)+ , 20%], 498 [(M + K)+ , 7]. ESI-HRMS (m/z): calcd. for C22 H25 N3 O8 , 459.1642; found, 459.1646. Anal. calcd. (%) for C22 H25 N3 O8 : C, 57.51; H, 5.48; N, 9.15; found: C, 57.3; H, 5.4; N, 8.9.
Preparation of N6 -Benzoyl-3 -O-Levulinyl-2 -O-Methyladenosine via Regioselective Enzymatic Hydrolysis with CAL-B
BASIC PROTOCOL 11
Materials N6 -Benzoyl-3 ,5 -di-O-levulinyl-2 -O-methyladenosine (S.6c; see Support Protocol 3) 1,4-Dioxane 0.15 M KH2 PO4 buffer (see recipe) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) Dichloromethane (CH2 Cl2 ) Silica gel Acetone Diethyl ether (Et2 O) 500-mL Erlenmeyer flask Rubber septum Orbital shaker, 30◦ C Buchner funnels with filter paper circles 500-mL round-bottom flasks Rotary evaporator 1-L filter flask Additional reagents and equipment for TLC (see Basic Protocol 1) Perform hydrolysis 1. Add 1 g (1.72 mmol) N6 -benzoyl-3 ,5 -di-O-levulinyl-2 -O-methyladenosine, 3.5 mL 1,4-dioxane, 13.7 mL of 0.15 M KH2 PO4 buffer, and 1 g CAL-B to a 500-mL Erlenmeyer flask. 2. Seal the flask with a rubber septum and place on an orbital shaker kept at 30◦ C. Shake the reaction mixture at 250 rpm. 3. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). After spotting, it will be necessary to dry the TLC plate with a heat gun to evaporate the water in the sample. The reaction mixture remains a white suspension and the reaction is usually complete in 13 to 15 hr.
Work up and purify product 4. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 5. Wash the CAL-B twice with 50 mL CH2 Cl2 , and collect all washes in the same round-bottom flask. Current Protocols in Nucleic Acid Chemistry
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.21 Supplement 21
6. Remove solvents under reduced pressure using a rotary evaporator. 7. To recover product by dry column chromatography, weigh out 50 g silica gel and place in a Buchner funnel with a filter paper circle, attached to a 1-L filter flask connected to a vacuum line. Wash the silica with 200 mL of 25% (v/v) acetone/CH2 Cl2 . Acetone must be used in this case, as the product is unstable when exposed to MeOH or when subjected to extraction with saturated NaHCO3 solution.
8. Using a Pasteur pipet, spread the residue carefully on top of the silica bed. 9. Elute residual levulinic acid and N6 -benzoyl-3 ,5 -di-O-levulinyl-2 -O-methyladenosine with ∼200 to 400 mL of 25% (v/v) acetone/CH2 Cl2 . 10. Using clean filter flasks to collect 50-mL fractions, elute the desired product with ∼600 to 800 mL of 40% (v/v) acetone/CH2 Cl2 . Monitor fractions by analytical TLC. 11. Transfer fractions containing pure product to a 500-mL round-bottom flask, and remove solvents under reduced pressure using a rotary evaporator. 12. Add 10 mL Et2 O and triturate the product. Evaporate the solvent on a rotary evaporator and collect the product. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
13. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. N6 -Benzoyl-3 -O-levulinyl-2 -O-methyladenosine (S.7c) is obtained in 80% to 85% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.47. m.p. 56◦ -58◦ C. [α]20 D = −11.4 (c 1.0, DMSO). IR (NaCl): υ 3331, 1720, 1708, 1611cm−1 . 1 H NMR (CDCl3 , 200 MHz): δ 2.21 (s, 3H, Me-Lev), 2.71 (m, 2H, CH2 -Lev), 2.80 (m, 2H, CH2 -Lev), 3.27 (s, 3H, OMe), 3.84 (m, 2H, H5 ), 4.35 (m, 1H, H4 ), 4.74 (m, 1H, H2 ), 5.64 (apparent d, 3 JHH = 4.9 Hz, 1H, H3 ), 5.90 (d, 3 JHH = 8.0 Hz, 1H, H1 ), 7.46-7.61 (m, 3H, 2Hm + Hp ), 8.02 (m, 2H, 2Ho ), 8.12 (s, 1H, H2 or H8), 8.79 (s, 1H, H8 or H2). 13 C NMR (CDCl3 , 50 MHz): δ 27.7 (CH2 -Lev), 29.7 (Me-Lev), 37.7 (CH2 -Lev), 59.0 (OMe), 62.7 (C5 ), 72.1, 80.9, 86.3, 89.4 (C1 + C2 + C3 + C4 ), 124.6 (C5), 127.9 and 128.7 (Co + Cm ), 132.8 (Cp ), 133.2 (Ci ), 143.1 (C2 or C8), 150.4 (C4), 151.9 (C6 + C8 or C2), 164.6 (PhC=O), 171.8 (C=O), 206.3 (C=O). ESI-MS (m/z): 484 [(M + H)+ , 100%], 506 [(M + Na)+ , 7%]. ESI-HRMS (m/z): calcd. for C23 H25 N5 O7 , 483.1754; found, 483.1750. Anal. calcd. (%) for C23 H25 N5 O7 : C, 57.14; H, 5.21; N, 14.49; found: C, 57.2; H, 5.3; N, 14.7.
BASIC PROTOCOL 12
Preparation of N2 -Isobutyryl-3 -O-Levulinyl-2 -O-Methylguanosine via Regioselective Enzymatic Hydrolysis with CAL-B Materials
Enzymatic Regioselective Levulinylation of Nucleosides
N2 -Isobutyryl-3 ,5 -di-O-levulinyl-2 -O-methylguanosine (S.6d; see Support Protocol 3) 1,4-Dioxane 0.15 M KH2 PO4 buffer (see recipe) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) 500-mL Erlenmeyer flask Rubber septum Orbital shaker, 30◦ C Additional reagents and equipment for TLC (see Basic Protocol 1) and for workup and purification of the product (see Basic Protocol 4)
2.11.22 Supplement 21
Current Protocols in Nucleic Acid Chemistry
1. Add 1 g (1.76 mmol) N2 -isobutyryl-3 ,5 -di-O-levulinyl-2 -O-methylguanosine, 3.2 mL 1,4-dioxane, 14.4 mL of 0.15 M KH2 PO4 buffer, and 1 g CAL-B to a 500-mL Erlenmeyer flask. 2. Seal the flask with a rubber septum and place on an orbital shaker kept at 30◦ C. Shake the reaction mixture at 250 rpm. 3. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). After spotting, it will be necessary to dry the TLC plate with a heat gun to evaporate the water in the sample. The reaction mixture remains a white suspension and the reaction is usually complete in 9 to 11 hr.
4. Work up and purify the product as described for compound S.2d (see Basic Protocol 4, steps 4 to 14). If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
5. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. N2 -Isobutyryl-3 -O-levulinyl-2 -O-methylguanosine (S.7d) is obtained in 85% to 90% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.49. m.p. 82◦ -84◦ C. [α]20 D = −6.2 (c 1.0, DMSO). IR (NaCl): υ 3352, 2972, 2885, 1747, 1682, 1615, 1563 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 1.20 (d, 3 JHH = 6.7 Hz, 6H, Me-iBu), 2.17 (s, 3H, Me-Lev), 2.63-2.82 (several m, 5H, 2CH2 -Lev + CH-iBu), 3.21 (s, 3H, OMe), 3.73-3.94 (m, 2H, H5 ), 4.21 (br s, 1H, H4 ), 4.55 (m, 1H, H2 ), 5.18 (br s, 1H, OH), 5.48 (m, 1H, H3 ), 5.77 (d, 3 JHH = 6.8 Hz, 1H, H1 ), 8.01 (s, 1H, H8), 9.85 (br s, 1H, NH), 12.30 (br s, 1H, NH). 13 C NMR (CDCl3 , 75 MHz): δ 18.7 (Me-iBu), 18.8 (Me-iBu), 27.7 (CH2 -Lev), 29.6 (Me-Lev), 36.0 (CH-iBu), 37.7 (CH2 -Lev), 58.8 (OMe), 61.8 (C5 ), 71.7, 81.3, 84.4, and 87.3 (C1 + C2 + C3 + C4 ), 121.5 (C5), 138.8 (C8), 147.8 and 147.9 (C2 + C4), 155.4 (C6), 171.9 (C=O), 179.4 (iBu-C=O), 206.5 (C=O). ESI-MS (m/z): 466 [(M + H)+ , 100%], 488 [(M + Na)+ , 24%]. Anal. calcd. (%) for C20 H27 N5 O8 : C, 51.61; H, 5.85; N, 15.05; found: C, 51.7; H, 6.0; N, 14.8.
Preparation of 3 ,5 -Di-O-Levulinyl-2 -O-Methylribonucleosides Additional Materials (also see Basic Protocol 1)
SUPPORT PROTOCOL 3
2 -O-Methylribonucleoside (Rasayan): 2 -O-methyluridine, N4 -benzoyl-2 -O-methylcytidine, N6 -benzoyl-2 -O-methyladenosine, or N2 -isobutyryl-2 -O-methylguanosine Triethylamine (Et3 N) Anhydrous 1,4-dioxane, freshly distilled from sodium and benzophenone Levulinic acid Dicyclohexylcarbodiimide (DCC) 4-(Dimethylamino)pyridine (DMAP) 200-mL round-bottom flask equipped with a three-way glass stopcock Perform levulinylation 1. Add a magnetic stir bar and 1 g of 2 -O-methylribonucleoside to a 200-mL roundbottom flask equipped with a three-way glass stopcock. One gram corresponds to 3.87 mmol 2 -O-methyluridine, 2.76 mmol N4 -benzoyl2 -O-methylcytidine, 2.59 mmol N6 -benzoyl-2 -O-methyladenosine, or 2.72 mmol N2 isobutyryl-2 -O-methylguanosine.
2. Evacuate the flask on a vacuum line and flush with nitrogen. Repeat this procedure three times.
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.23 Current Protocols in Nucleic Acid Chemistry
Supplement 21
3. Add the following reagents: a. For 2 -O-mU: 1.30 mL (9.67 mmol) Et3 N, 25 mL dry 1,4-dioxane, 2.05 mL (20.13 mmol) levulinic acid, 4.15 g (20.13 mmol) DCC, and 38 mg (0.31 mmol) DMAP. b. For 2 -O-mCBz : 0.96 mL (6.90 mmol) Et3 N, 20 mL dry 1,4-dioxane, 1.47 mL (14.39 mmol) levulinic acid, 2.96 g (14.39 mmol) DCC, and 27 mg (0.22 mmol) DMAP. c. For 2 -O-mABz : 0.90 mL (6.47 mmol) Et3 N, 20 mL dry 1,4-dioxane, 1.38 mL (13.50 mmol) levulinic acid, 2.78 g (13.50 mmol) DCC, and 26 mg (0.21 mmol) DMAP. d. For 2 -O-mGi-Bu : 1.00 mL (6.80 mmol) Et3 N, 20 mL dry 1,4-dioxane, 1.45 mL (14.15 mmol) levulinic acid, 2.90 g (14.15 mmol) DCC, and 27 mg (0.22 mmol) DMAP. 4. Close the stopcock and begin stirring on a magnetic stirrer. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). The reaction is complete in 2 to 3 hr. After 2 hr, the reaction mixture will become heterogeneous due to the precipitation of 1, 3-dicyclohexylurea (DCU).
Work up and purify product 5. When the reaction is complete, filter the reaction mixture under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL roundbottom flask. This filtration step removes the DCU formed during the reaction.
6. Wash the DCU twice with 50 mL CH2 Cl2 and collect all washes in the same roundbottom flask. 7. Remove solvents under reduced pressure using a rotary evaporator. The product is an orange oil.
8. Dissolve the residue in 50 mL CH2 Cl2 and transfer to a 500-mL separatory funnel. 9. Remove levulinic acid by extracting the organic layer two to three times with 20 mL saturated NaHCO3 solution, using two 250-mL Erlenmeyer flasks to separate the layers. Verify that all levulinic acid has been removed from the organic phase by performing analytical TLC on both phases. Additional extractions may be needed for complete removal. Alternatively, brine can be used to clarify both phases.
10. Dry the organic layer over 4 g Na2 SO4 for 10 to 15 min. Remove the drying agent by gravity filtration using a glass funnel and Whatman no. 1 filter paper, collecting the filtrate in a 500-mL round-bottom flask. 11. Wash the Na2 SO4 four times with 25 mL CH2 Cl2 , collecting all washes in the same round-bottom flask. 12. Evaporate solvents under reduced pressure using a rotary evaporator. The product is obtained as orange oil due to 1,3-dicyclohexyl-1-levulinylurea contamination. Enzymatic Regioselective Levulinylation of Nucleosides
13. To recover product by dry column chromatography, weigh out 50 g silica gel and place in a Buchner funnel with a filter paper circle, attached to a 1-L filter flask connected to a vacuum line. Wash the silica with 100 mL of 25% (v/v) Et2 O/EtOAc.
2.11.24 Supplement 21
Current Protocols in Nucleic Acid Chemistry
14. Using a Pasteur pipet, spread the residue carefully on top of the silica bed. 15. Elute 1,3-dicyclohexyl-1-levulinylurea with ∼200 to 300 mL of 25% (v/v) Et2 O/EtOAc. 16. Using clean filter flasks to collect 50-mL fractions, elute the desired product with ∼300 to 500 mL of 10% (v/v) MeOH/CH2 Cl2 . Monitor fractions by analytical TLC. 17. Transfer fractions containing pure product to a 500-mL round-bottom flask, and remove solvents under reduced pressure using a rotary evaporator. If desired, solvents can be recovered by distillation.
18. Add 10 mL Et2 O and triturate the product. Evaporate the solvent on a rotary evaporator and collect the orange product. If desired, products S.6b-d can be stored at −20◦ C. Since product S.6a is hygroscopic, storage of this compound under a nitrogen atmosphere at −20◦ C is recommended. Under such conditions, no decomposition is seen even after several months.
19. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. 3 ,5 -Di-O-levulinyl-2 -O-methyluridine (S.6a) is obtained in 90% to 95% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.51. m.p. not available (hygroscopic foam). [α]20 D = +2.5 (c 1.1, DMSO). IR (NaCl): υ 3209, 2933, 1738, 1714 cm−1 . 1 H NMR (CDCl3 , 200 MHz): δ 2.18 (s, 3H, Me-Lev), 2.19 (s, 3H, Me-Lev), 2.55-2.90 (m, 8H, 4CH2 -Lev), 3.44 (s, 3H, OMe), 4.03 (m, 1H, H4 ), 4.27-4.45 (m, 3H, H2 + 2H5 ), 5.09 (apparent t, 3 JHH = 5.3 Hz, 1H, H3 ), 5.81 (d, 3 JHH = 8.2 Hz, 1H, H5), 5.97 (d, 3 JHH = 4.6 Hz, 1H, H1 ), 7.64 (d, 3 JHH = 8.2 Hz, 1H, H6), 9.55 (br s, 1H, NH). 13 C NMR (CDCl3 , 50 MHz): δ 27.7 (CH2 -Lev), 27.7 (CH2 -Lev), 29.6 (Me-Lev), 29.7 (Me-Lev), 37.7 (CH2 -Lev), 37.8 (CH2 -Lev), 58.9 (OMe), 62.7 (C5 ), 70.1, 79.6, 81.3, and 87.6 (C1 + C2 + C3 + C4 ), 102.9 (C5), 139.4 (C6), 150.2 (C4), 163.1 (C2), 171.9 (C=O), 172.1 (C=O), 206.1 (C=O), 206.4 (C=O). ESI-MS (m/z): 455 [(M + H)+ , 66%], 477 [(M + Na)+ , 100%], 493 [(M + K)+ , 12%]. ESI-HRMS (m/z): calcd. for C20 H26 N2 O10 , 454.1587; found, 454.1565. Anal. calcd. (%) for C20 H26 N2 O10 : C, 52.86; H, 5.77; N, 6.16; found: C, 52.6; H, 5.8; N, 6.2. N4 -Benzoyl-3 ,5 -di-O-levulinyl-2 -O-methylcytidine (S.6b) is obtained in 90% to 95% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.61. m.p. 220◦ -222◦ C (decomposed). [α]20 D = +10.5 (c 1.1, DMSO). IR (NaCl): υ 2359, 2339, 1742, 1715, 1667 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 2.20 (s, 3H, Me-Lev), 2.22 (s, 3H, Me-Lev), 2.59 (m, 4H, 2CH2 -Lev), 2.87 (m, 4H, 2CH2 -Lev), 3.60 (s, 3H, OMe), 4.13 (m, 1H, H4 ), 4.36-4.51 (m, 3H, H2 + 2H5 ), 4.93 (dd, 3 JHH = 7.8, 5.6 Hz, 1H, H3 ), 6.04 (m, 1H, H1 ), 7.50-7.65 (m, 4H, H5 + Hm + Hp ), 7.90 (m, 2H, Ho ), 8.23 (d, 3 JHH = 7.4 Hz, 1H, H6), 8.65 (br s, 1H, NH). 13 C NMR (DMSO-d6 , 75 MHz): δ 27.6 (CH2 -Lev), 29.6 (Me-Lev), 37.5 (CH2 -Lev), 58.3 (OMe), 63.1 (C5 ), 70.4, 79.4, 80.7, and 89.2 (C1 + C2 + C3 + C4 ), 97.0 (C5), 128.6, 128.7 (Co + Cm ), 132.5 (Cp ), 132.9 (Ci ), 145.3 (C6), 154.4 (C2), 163.5 (PhC=O), 167.5 (C4), 171.8 (C=O), 172.3 (C=O), 206.8 (C=O), 207.0 (C=O). ESI-MS (m/z): 558 [(M + H)+ , 100%], 580 [(M + Na)+ , 19%], 596 [(M + K)+ , 3%]. Anal. calcd. (%) for C27 H31 N3 O10 : C, 58.16; H, 5.60; N, 7.54; found: C, 58.2; H, 5.4; N, 7.7. N6 -Benzoyl-3 ,5 -di-O-levulinyl-2 -O-methyladenosine (S.6c) is obtained in 90% to 95% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.55. m.p. 52◦ -54◦ C. [α]20 D = −23.1 (c 1.1, DMSO). IR (NaCl): υ 2932, 2341, 1741, 1715, 1610 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 2.19 (s, 3H, Me-Lev), 2.21 (s, 3H, Me-Lev), 2.26 (m, 2H, CH2 -Lev), 2.71 (m, 2H, CH2 -Lev), 2.80 (m, 4H, 2CH2 -Lev), 3.42 (s, 3H, OMe), 4.44 (m, 3H, H4 + 2H5 ), 4.74 (apparent t, 3 JHH = 5.3 Hz, 1H, H2 ), 5.43 (apparent t, 3 JHH = 4.4 Hz, 1H, H3 ), 6.16 (d, 3 JHH = 5.4 Hz, 1H, H1 ), 7.53-7.61 (m, 3H, 2Hm + Hp ), 8.02 (m, 2H, 2Ho ), 8.30 (s, 1H, H2 or H8), 8.81 (s, 1H, H8 or H2), 9.05 (br s, 1H, NH). 13 C NMR (CDCl3 , 75 MHz): δ 27.7 (CH2 -Lev), 29.7 (Me-Lev), 37.7 (CH2 -Lev), 37.8 (CH2 -Lev), 59.1 (OMe), 63.0 (C5 ), 70.8, 80.5, 81.1, and 87.0 (C1 + C2 + C3 + C4 ), 123.6 (C5), 127.8 and 128.7 (Co + Cm ), 132.7 (Cp ), 133.5 (Ci ), 141.6 (C2 or C8), 149.6 (C4), 151.6 (C6), 152.7 (C8 or
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.25 Current Protocols in Nucleic Acid Chemistry
Supplement 21
C2), 164.7 (PhC=O), 171.8 (C=O), 172.2 (C=O), 206.1 (C=O), 206.4 (C=O). ESI-MS (m/z): 582 [(M + H)+ , 100%], 604 [(M + Na)+ , 3%]. Anal. calcd. (%) for C28 H31 N5 O9 : C, 57.83; H, 5.37; N, 12.04; found: C, 58.1; H, 5.2; N, 12.2. N2 -Isobutyryl-3 ,5 -di-O-levulinyl-2 -O-methylguanosine (S.6d) is obtained in 90% to 95% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.59. m.p. 55◦ -57◦ C. [α]20 D = −10.1 (c 1.0, DMSO). IR (NaCl): υ 3374, 2972, 2931, 1719, 1689, 1611, 1467, 1380, 1266 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 1.22 (d, 3 JHH = 6.8 Hz, 6H, Me-iBu), 2.13 (s, 3H, Me-Lev), 2.18 (s, 3H, Me-Lev), 2.55-2.80 (several m, 9H, 4CH2 -Lev + CH-iBu), 3.30 (s, 3H, OMe), 4.39-4.56 (m, 4H, H2 + H4 + 2H5 ), 5.39 (m, 1H, H3 ), 5.81 (d, 3 JHH = 5.7 Hz, 1H, H1 ), 7.83 (s, 1H, H8), 9.75 (br s, 1H, NH), 12.18 (br s, 1H, NH). 13 C NMR (CDCl3 , 75 MHz): δ 18.7 (Me-iBu), 18.8 (Me-iBu), 27.6 (CH2 -Lev), 27.8 (CH2 -Lev), 29.5 (Me-Lev), 29.6 (Me-Lev), 36.0 (CH-iBu), 37.6 (CH2 -Lev), 37.7 (CH2 -Lev), 58.9 (OMe), 63.1 (C5 ), 71.0, 80.2, 80.9, and 87.4 (C1 + C2 + C3 + C4 ), 121.9 (C5), 138.0 (C8), 147.8 and 147.9 (C2 + C4), 155.5 (C6), 171.8 (C=O), 172.8 (C=O), 179.2 (iBu-C=O), 206.2 (C=O), 206.4 (C=O). ESI-MS (m/z): 564 [(M + H)+ , 100%], 586 [(M + Na)+ , 7%]. Anal. calcd. (%) for C25 H33 N5 O10 : C, 53.28; H, 5.90; N, 12.43; found: C, 53.3; H, 5.9; N, 12.2.
SYNTHESIS OF 5 -O-LEVULINYL-2 -METHYLRIBONUCLEOSIDES The preparation of 5 -O-levulinyl-2 -O-methylribonucleosides involves regioselective acylation of the 5 -hydroxyl function of 2 -O-methylribonucleosides with O-levulinyl acetonoxime using CAL-B as shown in Figure 2.11.4. This is a general procedure for the U, C, A, and G monomers. BASIC PROTOCOL 13
Preparation of 5 -O-Levulinyl-2 -O-Methyluridine via Regioselective Enzymatic Acylation with CAL-B Materials 2 -O-Methyluridine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) Anhydrous nitrogen Anhydrous tetrahydrofuran (THF), freshly distilled over sodium and benzophenone Dichloromethane (CH2 Cl2 ) Diethyl ether (Et2 O), cold (4◦ C) 1-L Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 40◦ C
Enzymatic Regioselective Levulinylation of Nucleosides
Figure 2.11.4 Regioselective levulinylation of 2 -O-methylribonucleosides (S.5a-d) using CAL-B. Abbreviations: ABz, N 6 -benzoyladenin-9-yl; CBz, N 4 -benzoylcytosin-1-yl; Gi-Bu, N 2 -isobutyrylguanin9-yl; Lev, levulinyl; U, uracil-1-yl.
2.11.26 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Buchner funnels with filter paper circles 500-mL round-bottom flask Rotary evaporator Additional reagents and equipment for TLC (see Basic Protocol 1) Perform levulinylation 1. Add 5 g (19.36 mmol) 2 -O-methyluridine, 9.9 g (58.08 mmol) O-levulinyl acetonoxime, and 5 g CAL-B to a 1-L Erlenmeyer flask equipped with a three-way glass stopcock. 2. Evacuate the Erlenmeyer flask on a vacuum line and flush with nitrogen. Repeat this procedure three times. 3. Add 97 mL dry THF. 4. Seal the flask with a rubber septum and place on an orbital shaker kept at 40◦ C. Shake the reaction mixture at 250 rpm. 5. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). The reaction mixture remains a white suspension and the reaction is complete in 5 to 7 hr.
Work up and purify product 6. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 7. Wash the CAL-B twice with 50 mL CH2 Cl2 , collecting all washes in the same roundbottom flask. 8. Remove solvents under reduced pressure using a rotary evaporator. 9. Dissolve the residue in 5 mL CH2 Cl2 and slowly add to 30 to 40 mL Et2 O to precipitate the product as a white solid. Cool the solution 2 to 3 days at 4◦ C. 10. Filter off the precipitated product under vacuum using a Buchner funnel with a filter paper circle. Wash the precipitate two to three times with 50 mL cold (4◦ C) Et2 O, and then dry the solid under vacuum. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
11. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. 5 -O-Levulinyl-2 -O-methyluridine (S.8a) is obtained in 90% to 95% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.38. m.p. 114◦ -116◦ C. [α]20 D = +9.1 (c 1.0, DMSO). IR (NaCl): υ 2359, 2340, 1698 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 2.19 (s, 3H, Me-Lev), 2.56 (m, 2H, CH2 -Lev), 2.81 (m, 2H, CH2 -Lev), 3.63 (s, 3H, OMe), 3.84 (m, 1H, H4 ), 4.14 (m, 2H, H2 + H3 ), 4.43 (m, 2H, H5 ), 5.79 (d, 3 JHH = 8.0 Hz, 1H, H5), 5.91 (m, 1H, H1 ), 7.72 (d, 3 JHH = 8.0 Hz, 1H, H6), 9.54 (br s, 1H, NH). 13 C NMR (CDCl3 , 75 MHz): δ 27.7 (CH2 -Lev), 29.6 (Me-Lev), 37.8 (CH2 -Lev), 58.7 (OMe), 62.4 (C5 ), 68.6, 81.6, 83.1, and 87.8 (C1 + C2 + C3 + C4 ), 102.4 (C5), 139.5 (C6), 150.1 (C4), 163.3 (C2), 172.3 (C=O), 206.5 (C=O). ESI-MS (m/z): 357 [(M + H)+ , 12%], 379 [(M + Na)+ , 100%], 395 [(M + K)+ , 7%]. Anal. calcd. (%) for C15 H20 N2 O8 : C, 50.56; H, 5.66; N, 7.86; found: C, 50.4; H, 5.7; N, 7.8.
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.27 Current Protocols in Nucleic Acid Chemistry
Supplement 21
BASIC PROTOCOL 14
Preparation of N4 -Benzoyl-5 -O-Levulinyl-2 -O-Methylcytidine via Regioselective Enzymatic Acylation with CAL-B Materials N4 -Benzoyl-2 -O-methylcytidine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) Anhydrous nitrogen Anhydrous tetrahydrofuran (THF), freshly distilled over sodium and benzophenone Dichloromethane (CH2 Cl2 ) Saturated sodium bicarbonate (NaHCO3 ) solution Sodium sulfate (Na2 SO4 ) Diethyl ether (Et2 O), cold (4◦ C) 1-L Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 40◦ C Buchner funnels with filter paper circles 500-mL round-bottom flasks Rotary evaporator 250-mL separatory funnel Glass funnel with Whatman no. 1 filter paper Filter flask Additional reagents and equipment for TLC (see Basic Protocol 1) Perform levulinylation 1. Add 5 g (13.84 mmol) N4 -benzoyl-2 -O-methylcytidine, 7.1 g (41.52 mmol) Olevulinyl acetonoxime, and 5 g CAL-B to a 1-L Erlenmeyer flask equipped with a three-way glass stopcock. 2. Evacuate the Erlenmeyer flask on a vacuum line and flush with nitrogen. Repeat this procedure three times. 3. Add 69 mL dry THF. 4. Seal the flask with a rubber septum and place on an orbital shaker kept at 40◦ C. Shake the reaction mixture at 250 rpm. 5. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). The reaction mixture remains a white suspension and the reaction is complete in 7 to 9 hr.
Work up and purify product 6. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 7. Wash the CAL-B twice with 50 mL CH2 Cl2 , and collect all washes in the same round-bottom flask. 8. Remove solvents under reduced pressure using a rotary evaporator. 9. Dissolve the residue in 50 mL CH2 Cl2 and transfer to a 250-mL separatory funnel. Enzymatic Regioselective Levulinylation of Nucleosides
10. Remove unreacted starting material by extracting the organic layer three times with 10 mL saturated NaHCO3 solution, using two 250-mL Erlenmeyer flasks to
2.11.28 Supplement 21
Current Protocols in Nucleic Acid Chemistry
separate the phases. Verify that N4 -benzoyl-2 -O-methylcytidine has been removed completely from the organic phase by performing analytical TLC on both phases. N4 -Benzoyl-2 -O-methylcytidine is partially soluble in the aqueous phase. Alternatively, brine can be used to separate the phases effectively.
11. Pool the aqueous phases and extract twice with 10 mL CH2 Cl2 to recover any product. 12. Pool the organic phases from step 11 and verify by TLC that they contain no residual N4 -benzoyl-2 -O-methylcytidine. If any is present, re-extract with 10 mL saturated NaHCO3 solution. This extraction is unnecessary if N4 -benzoyl-2 -O-methylcytidine is absent from the organic phase.
13. Pool the organic phases from steps 10 and 12 and dry over 3 g Na2 SO4 for 10 to 15 min. Remove the drying agent by gravity filtration with a glass funnel and Whatman no. 1 filter paper, collecting the filtrate in a 500-mL round-bottom flask. 14. Wash the Na2 SO4 five times with 15 mL CH2 Cl2 , and collect all washes in the same round-bottom flask. 15. Evaporate solvents under reduced pressure using a rotary evaporator. The product is an orange oil due to oxime ester contamination.
16. Cool the crude product at 4◦ C overnight to precipitate the product. 17. Transfer the solid to a Buchner funnel with a filter paper circle, attached to a filter flask connected to a vacuum line. Wash the orange solid (i.e., the final product) five to six times with 20 mL cold Et2 O, and then dry the solid under vacuum. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
18. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. N4 -Benzoyl-5 -O-levulinyl-2 -O-methylcytidine (S.8b) is obtained in 80% to 85% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.52. m.p. 134◦ -136◦ C. [α]20 D = +68.5 (c 1.0, DMSO). IR (NaCl): υ 3318, 2947, 2359, 2339, 1738, 1698, 1651 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 2.16 (s, 3H, Me-Lev), 2.58 (m, 2H, CH2 -Lev), 2.79 (m, 2H, CH2 -Lev), 3.66 (s, 3H, OMe), 3.83 (m, 1H, H3 ), 4.13 (m, 2H, H2 + H4 ), 4.47 (m, 2H, H5 ), 5.92 (m, 1H, H1 ), 7.46-7.57 (m, 4H, H5 + Hm + Hp ), 7.89 (m, 2H, Ho ), 8.26 (d, 3 JHH = 7.4 Hz, 1H, H6), 9.26 (br s, 1H, NH). 13 C NMR (CDCl3 , 75 MHz): δ 27.8 (CH2 -Lev), 29.7 (Me-Lev), 37.8 (CH2 -Lev), 58.8 (OMe), 62.0 (C5 ), 68.0, 81.4, 83.2, and 88.9 (C1 + C2 + C3 + C4 ), 96.8 (C5), 127.5 and 128.9 (Co + Cm ), 132.8 (Ci ), 133.1 (Cp ), 144.2 (C6), 154.5 (C2), 162.5 (PhC=O), 166.8 (C4), 172.4 (C=O), 206.4 (C=O). ESI-MS (m/z): 460 [(M + H)+ , 100%], 482 [(M + Na)+ , 22%], 498 [(M + K)+ , 6%]. ESI-HRMS (m/z): calcd. for C22 H25 N3 O8 , 459.1642; found, 459.1639. Anal. calcd. (%) for C22 H25 N3 O8 : C, 57.51; H, 5.48; N, 9.15; found: C, 57.3; H, 5.7; N, 9.4.
Preparation of N6 -Benzoyl-5 -O-Levulinyl-2 -O-Methyladenosine via Regioselective Enzymatic Acylation with CAL-B
BASIC PROTOCOL 15
Materials N6 -Benzoyl-2 -O-methyladenosine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) Anhydrous nitrogen
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.29 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Anhydrous tetrahydrofuran (THF), freshly distilled over sodium and benzophenone Dichloromethane (CH2 Cl2 ) Silica gel Acetone Diethyl ether (Et2 O), cold (4◦ C) 1-L Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 40◦ C Buchner funnels with filter paper circles 500-mL round-bottom flasks Rotary evaporator 1-L filter flask Additional reagents and equipment for TLC (see Basic Protocol 1) Perform levulinylation 1. Add 5 g (12.97 mmol) N6 -benzoyl-2 -O-methyladenosine, 6.7 g (38.93 mmol) Olevulinyl acetonoxime, and 5 g CAL-B to a 1-L Erlenmeyer flask equipped with a three-way glass stopcock. 2. Evacuate the Erlenmeyer flask on a vacuum line and flush with nitrogen. Repeat this procedure three times. 3. Add 65 mL dry THF. 4. Seal the flask with a rubber septum and place on an orbital shaker kept at 40◦ C. Shake the reaction mixture at 250 rpm. 5. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). The reaction mixture remains a white suspension and the reaction is complete in 18 to 20 hr.
Work up and purify product 6. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 500-mL round-bottom flask. 7. Wash the CAL-B twice with 50 mL CH2 Cl2 , and collect all washes in the same round-bottom flask. 8. Remove solvents under reduced pressure using a rotary evaporator. 9. To recover product by dry column chromatography, weigh out 100 g silica gel and place in a Buchner funnel with a filter paper circle, attached to a 1-L filter flask connected to a vacuum line. Wash the silica with 200 mL of 10% (v/v) acetone/CH2 Cl2 . Acetone must be used in this protocol, as the product is unstable when exposed to MeOH or when subjected to extraction with saturated NaHCO3 solution.
10. Using a Pasteur pipet, spread the residue carefully on top of the silica bed. 11. Elute the excess oxime ester with ∼500 to 700 mL of 10% (v/v) acetone/CH2 Cl2 .
Enzymatic Regioselective Levulinylation of Nucleosides
12. Using clean filter flasks to collect 100-mL fractions, elute the desired product with ∼1200 to 1500 mL of 25% (v/v) acetone/CH2 Cl2 . Monitor fractions by analytical TLC.
2.11.30 Supplement 21
Current Protocols in Nucleic Acid Chemistry
13. Transfer fractions containing pure product to a 500-mL round-bottom flask, and remove solvents under reduced pressure using a rotary evaporator. 14. Transfer the solid to a Buchner funnel with a filter paper circle, attached to a filter flask connected to a vacuum line. Wash the white solid (i.e., the final product) three to four times with 20 mL cold (4◦ C) Et2 O, and then dry the solid under vacuum. If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
15. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis. N6 -Benzoyl-5 -O-levulinyl-2 -O-methyladenosine (S.8c) is obtained in 75% to 80% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.44. m.p. 51◦ -53◦ C. [α]20 D = −6.7 (c 1.0, DMSO). IR (NaCl): υ 2931, 2359, 1716, 1612 cm−1 . 1 H NMR (DMSO-d6 , 200 MHz): δ 2.09 (s, 3H, Me-Lev), 2.50 (m, 2H, CH2 -Lev), 2.71 (m, 2H, CH2 -Lev), 3.41 (s, 3H, OMe), 4.15-4.59 (m, 5H, H2 + H3 + H4 + 2H5 ), 5.56 (br s, 1H, OH), 6.20 (d, 3 JHH = 3.2 Hz, 1H, H1 ), 7.53-7.65 (m, 3H, 2Hm + Hp ), 8.06 (m, 2H, 2Ho ), 8.70 (s, 1H, H2 or H8), 8.78 (s, 1H, H8 or H2). 13 C NMR (DMSO-d6 , 50 MHz): δ 27.5 (CH2 -Lev), 29.5 (Me-Lev), 37.4 (CH2 -Lev), 57.8 (OMe), 63.8 (C5 ), 68.9, 81.8, 82.3, and 85.8 (C1 + C2 + C3 + C4 ), 125.8 (C5), 128.5, 128.6 (Co + Cm ), 132.5 (Cp ), 133.3 (Ci ), 143.1 (C2 or C8), 150.6 (C4), 151.8 (C8 or C2), 152.0 (C6), 165.8 (PhC=O), 172.2 (C=O), 206.8 (C=O). ESI-MS (m/z): 484 [(M + H)+ , 100%], 506 [(M + Na)+ , 5%], 522 [(M + K)+ , 1%]. Anal. calcd. (%) for C23 H25 N5 O7 : C, 57.14; H, 5.21; N, 14.49; found: C, 57.3; H, 5.7; N, 14.5.
Preparation of N2 -Isobutyryl-5 -O-Levulinyl-2 -O-Methylguanosine via Regioselective Enzymatic Acylation with CAL-B
BASIC PROTOCOL 16
Materials N2 -Isobutyryl-2 -O-methylguanosine (Rasayan) O-Levulinyl acetonoxime (see Support Protocol 1) Immobilized Candida antarctica lipase B (CAL-B, under the trade name Novozyme 435; 10,000 propyl laurate units per gram; Novo Nordisk) Anhydrous nitrogen Anhydrous tetrahydrofuran (THF), freshly distilled over sodium and benzophenone Dichloromethane (CH2 Cl2 ) Silica gel Ethyl acetate (EtOAc) Diethyl ether (Et2 O) Methanol (MeOH) 500-mL Erlenmeyer flask equipped with a three-way glass stopcock Rubber septum Orbital shaker, 40◦ C Buchner funnels with filter paper circles 250- and 500-mL round-bottom flasks Rotary evaporator 1-L filter flask Additional reagents and equipment for TLC (see Basic Protocol 1) Perform levulinylation 1. Add 1 g (2.72 mmol) N2 -isobutyryl-2 -O-methylguanosine, 1.40 g (8.16 mmol) Olevulinyl acetonoxime, and 1 g CAL-B to a 500-mL Erlenmeyer flask equipped with a three-way glass stopcock. 2. Evacuate the Erlenmeyer flask on a vacuum line and flush with nitrogen. Repeat this procedure three times.
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.31 Current Protocols in Nucleic Acid Chemistry
Supplement 21
3. Add 14 mL dry THF. 4. Seal the flask with a rubber septum and place on an orbital shaker kept at 40◦ C. Shake the reaction mixture at 250 rpm. 5. Monitor the progress of the reaction by analytical TLC as described for the synthesis of compound S.2a (see Basic Protocol 1, step 5). The reaction mixture remains a white suspension and the reaction is complete in 6 to 8 hr.
Work up and purify product 6. When the reaction is complete, filter off the lipase under vacuum using a Buchner funnel with a filter paper circle, and collect the filtrate in a 250-mL round-bottom flask. 7. Wash the CAL-B twice with 20 mL CH2 Cl2 , and collect all washes in the same round-bottom flask. 8. Remove solvents under reduced pressure using a rotary evaporator. The excess oxime ester imparts an orange color to the crude product. Because the product does not precipitate, a chromatography step is necessary.
9. To recover product by dry column chromatography, weigh out 50 g silica gel and place in a Buchner funnel with a filter paper circle, attached to a 1-L filter flask connected to a vacuum line. Wash the silica with 200 mL of 25% (v/v) EtOAc/Et2 O. 10. Using a Pasteur pipet, spread the residue carefully on top of the silica bed. 11. Elute the excess oxime ester with ∼300 to 500 mL of 25% (v/v) EtOAc/Et2 O. 12. Using clean filter flasks to collect 50-mL fractions, elute the desired product with ∼500 to 800 mL of 10% (v/v) MeOH/CH2 Cl2 . Monitor fractions by analytical TLC. 13. Transfer fractions containing pure product to a 500-mL round-bottom flask, and remove solvents under reduced pressure using a rotary evaporator. 14. Add 10 mL Et2 O and triturate the product. Evaporate the solvent on a rotary evaporator and collect the white compound (i.e., the final product). If desired, the product can be stored at −20◦ C. Under such conditions, no decomposition is seen even after several months.
15. Confirm product purity by TLC; m.p. analysis; optical rotation analysis; infrared (IR), 1 H NMR, and 13 C NMR spectroscopy; mass spectrometry; and elemental analysis.
Enzymatic Regioselective Levulinylation of Nucleosides
N2 -Isobutyryl-5 -O-levulinyl-2 -O-methylguanosine (S.8d) is obtained in 90% to 95% yield. TLC (10% MeOH/CH2 Cl2 ): Rf = 0.40. m.p. 57◦ -59◦ C. [α]20 D = −1.5 (c 1.0, DMSO). IR (NaCl): υ 3374, 2972, 1712, 1688, 1609, 1467, 1380, 1161 cm−1 . 1 H NMR (CDCl3 , 300 MHz): δ 1.24 (d, 3 JHH = 6.5 Hz, 6H, Me-iBu), 2.15 (s, 3H, Me-Lev), 2.56-2.92 (several m, 5H, 2CH2 -Lev + CH-iBu), 3.44 (s, 3H, OMe), 4.26-4.63 (several m, 5H, H2 + H3 + H4 + 2H5 ), 5.90 (d, 3 JHH = 3.4 Hz, 1H, H1 ), 7.96 (s, 1H, H8), 10.38 (br s, 1H, NH), 12.39 (br s, 1H, NH). 13 C NMR (CDCl3 , 50 MHz): δ 18.8 (Me-iBu), 19.0 (Me-iBu), 27.8 (CH2 -Lev), 29.6 (Me-Lev), 36.0 (CH-iBu), 37.8 (CH2 -Lev), 58.7 (OMe), 63.7 (C5 ), 69.7, 82.2, 83.2, and 87.5 (C1 + C2 + C3 + C4 ), 121.4 (C5), 138.2 (C8), 148.1 (C2 + C4), 155.7 (C6), 172.8 (C=O), 179.9 (iBu-C=O), 206.9 (C=O). ESI-MS (m/z): 466 [(M + H)+ , 100%], 488 [(M + Na)+ , 23%], 504 [(M + K)+ , 7%]. Anal. calcd. (%) for C20 H27 N5 O8 : C, 51.61; H, 5.85; N, 15.05; found: C, 51.4; H, 6.1; N, 15.2.
2.11.32 Supplement 21
Current Protocols in Nucleic Acid Chemistry
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
p-Anisaldehyde solution Prepare 2.5% (v/v) anisaldehyde in ethanol. Dissolve and then add 3.5% (v/v) H2 SO4 and 1% (v/v) acetic acid. Store up to 2 months at room temperature. Apply to TLC plates with a spray bottle or by dipping the plate in the solution. CAUTION: Prepare and use this reagent only in a well-ventilated fume hood. It is corrosive, and its vapors are highly irritating.
KH2 PO4 buffer, 0.15 M To prepare 100 mL of buffer, dissolve 2.04 g KH2 PO4 in 70 mL distilled water and gradually add 0.1 N KOH until pH 7 is attained. Add water to 100 mL. Store up to 4 months at room temperature. COMMENTARY Background Information The increasing demand for oligonucleotides in therapeutic, diagnostic, and target validation has impelled research aimed at the development of improved synthetic protocols. Among these protocols, solid-phase synthesis is the current method of choice due to its speed and high coupling efficiency. In recent years, however, interest in solution-phase synthesis of oligonucleotides has been steadily growing due to much anticipated success with therapeutic oligonucleotides, which may trigger a very large demand for such products (Reese and Yan, 2001). In order to assemble oligonucleotides on a large scale, it is essential that investigators have access to appropriately protected nucleosides as building blocks. Since nucleosides have multiple reactive sites, such as primary and secondary hydroxyl groups and exocyclic amino groups, these compounds must be protected in an orthogonal way, such that one group is selectively excised over others. This is a serious problem in multifunctional molecules such as oligonucleotides, which must be fully protected from unwanted reactions during their assembly. A number of 3 - and 5 -hydroxyl-protecting groups have been reported to date for synthesis of oligonucleotides (see Chapter 2). Among the arsenal of available protecting groups, the levulinyl group has been well recognized and well established as a very useful orthogonal protecting group for hydroxyl groups. The reason for its popularity is easy to understand: it is stable to phosphorus coupling and is cleaved under mild conditions without affecting other protecting groups in the molecule,
such as acyl groups on exocyclic amines, internucleotidic phosphate-protecting groups, and the dimethoxytrityl group. Importantly, the levulinyl group is unmasked under essentially neutral conditions: 0.5 M hydrazine hydrate in 4:1 (v/v) pyridine/acetic acid at room temperature within 2 to 4 min in solution-phase synthesis protocols (van Boom and Burgers, 1976), or 10 to 15 min in solid-phase syntheses (Iwai and Ohtsuka, 1988; Iwai et al., 1990). Until recently, syntheses of 3 - and/or 5 -Olevulinyl-protected nucleosides were carried out using multiple tedious protection and deprotection steps and resulted in relatively low yields. In 2002, the authors reported an improved synthesis of such nucleosides via regioselective enzymatic hydrolysis of 3 ,5 -diO-levulinyl nucleosides (Garc´ıa et al., 2002). Although that protocol works very well, it requires a two-step procedure: chemical bisacylation of the nucleoside followed by selective hydrolysis of one of the levulinyl groups. In 2003, the authors further improved the protocol by regioselectively acylating nucleosides (Garc´ıa et al., 2003). Arguably, one-step direct acylation using lipases constitutes the shortest method that is both cost-efficient and environmentally friendly. Today, lipases have been established as valuable reagents for industrial-scale organic synthesis. Lipases promote the hydrolysis of carboxylic esters as well as acyl transfer onto hydroxyl groups with unparalleled stereo-, regio-, and chemoselectivity. Furthermore, the authors have utilized lipases that are immobilized, providing additional advantages such as enhanced stability with ease of handling, ability to recycle and reuse, convenient
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.33 Current Protocols in Nucleic Acid Chemistry
Supplement 21
separation from the reaction mixture by simple filtration, and commercial availability on a large scale. The protocols in this unit describe the lipase-mediated syntheses of two sets of 3 -levulinyl-protected and two sets of 5 -levulinyl-protected nucleosides that are essential raw materials for oligonucleotide assembly. 3 -O-Levulinyl nucleosides The direct protection of the secondary 3 hydroxyl group in an unprotected nucleoside is a challenging problem due to the competing primary hydroxyl group in the same molecule. Although several chemical methods are available for regioselective acylation of a primary hydroxyl group in a nucleoside, a method for direct chemical acylation of the 3 -hydroxyl group in a nucleoside is nonexistent. In contrast, selective introduction of an acyl group onto the 3 -hydroxyl group of a nucleoside has been successfully accomplished with lipases. This unit presents syntheses of 3 -O-levulinyl derivatives of T, dCBz , dABz , dGi-Bu as well as 2 -O-Me analogs of U, CBz , ABz and Gi-Bu . In Basic Protocols 1 to 3, the readily available nucleosides T, dCBz , and dABz are treated with O-levulinyl acetonoxime (prepared in Support Protocol 1) in the presence of PSL-C at 30◦ C in THF for 14 to 18 hr. The resulting 3 -Olevulinylated derivatives are isolated in >80% yields without column chromatography. Because all of the authors’ attempts to acylate dGi-Bu in a single step resulted in formation of a mixture of products with low selectivity, 3 -O-levulinyl dGi-Bu is prepared using a twostep protocol that involves bis-acylation of the nucleoside followed by CAL-B-mediated hydrolysis (see Basic Protocol 4). Similarly, the preparation of 3 -O-levulinyl-2 -O-Me nucleosides resulted in a mixture of products under direct acylation conditions. As a result, this set of nucleosides is prepared via CAL-B-driven hydrolysis of di-O-levulinylated nucleosides (S.6a-d) to furnish 3 -O-levulinylated products (S.7a-d) in 75% to 90% yields. To the best of the authors’ knowledge, this is the first synthesis of S.7a-d to be reported in the literature. Furthermore, these protocols demonstrate that lipases are able to accept a broad range of substrates with structural diversity.
Enzymatic Regioselective Levulinylation of Nucleosides
5 -O-Levulinyl nucleosides Enzymatic acylation methods have shown an increasing tendency to proceed preferentially at the 5 -hydroxyl group of a nucleoside. Until recently, however, this technique had not been exploited for the installation of levulinyl
groups. Highly regioselective enzymatic levulinyl transfer to the 5 -hydroxyl group has been studied in the authors’ laboratory. In Basic Protocols 5 to 8, CAL-B-catalyzed syntheses of 5 -O-levulinyl derivatives of T, dCBz , dABz , and dGi-Bu that result in 70% to 90% yields are described. The scalability of this acylation method has been clearly demonstrated by performing the syntheses of S.3a-d on a 10-g scale. Similarly, Basic Protocols 13 to 16 describe the CAL-B-catalyzed syntheses of 5 -O-levulinyl-2 -O-Me ribonucleosides in excellent yields. Importantly, the syntheses of the 5 -O-levulinyl derivatives S.8a-d are the first that have been reported in the literature.
Critical Parameters The success of the various reactions described here can be affected by several factors. For example, all starting materials, including nucleosides, must be thoroughly dried under vacuum prior to use in acylation reactions, which are carried out in freshly distilled anhydrous THF. It is important to note that some levulinyl-protected nucleosides are partially soluble in water. Thus, after the initial extraction, back-extraction of the aqueous layer may be required for complete recovery of the desired product. Yields are invariably improved after performing back-extraction. Although these protocols use excess oxime ester and lipase, both of these reagents are easy to recapture and recycle. A large-scale (25-g) study on the 3 -O-acylation of thymidine demonstrated that PSL-C can be recycled more than four times without loss of enzyme activity. Since the cost of lipases is relatively high, recycling of both CAL-B and PSL-C is recommended. Furthermore, excess oxime ester could potentially be captured and recycled should there be a need. It is noteworthy that the use of excess oxime ester during acylation reactions results in formation of orange-colored products. This color is easily eliminated via simple precipitation of the product from ether or hexanes. The color is also eliminated by chromatography. Generally, all products described in this unit are obtained as white solids; should the orange color persist, there is a possibility that a trace amount of oxime ester is present as an impurity. Although the protocols described in this unit may appear to be very similar, they differ in subtle but important ways. For example, the amount of THF required for each reaction is dependent on the solubility of the starting material. Also, the speed and temperature of the orbital shaker are critical to the successful
2.11.34 Supplement 21
Current Protocols in Nucleic Acid Chemistry
outcome of these reactions. The use of dry column chromatography (Pedersen and Rosenbohm, 2001) results in significantly reduced solvent consumption and minimizes the waste stream. It should be emphasized that a magnetic stirrer is not recommended for enzymatic reactions involving immobilized lipases due to the possibility of grinding the beads. As indicated, best results are obtained when reactions are carried out on an orbital shaker at constant temperature.
Anticipated Results Lipase activity and selectivity are strongly influenced by the quality of solvents used, the substrate concentration, the reaction time, the temperature, and the moisture content. As indicated, hydrolytic reactions can be carried out in buffered aqueous solutions, whereas acylation is achieved in anhydrous solvents. More importantly, the type of acyl donor has a great influence on reactivity and selectivity. Use of acetonoxime levulinate as an acyl donor has been found to be best for all acylation protocols described in this unit. Some of these protocols have been scaled up without serious issues and show great potential for adaptation into industrial processes. Since the shelf lives of both CAL-B and PSL-C are excellent, it is advisable to purchase a large lot of lipase with good activity that can be used for an extended period of time. This will eliminate the lot-to-lot variation in enzyme activity and help produce consistent results. Also, it is more cost-effective to buy reagents in bulk. In the authors’ experience, all protocols described in this unit are safe, scalable, robust, and easy to perform, and all provide consistent results when good-quality raw materials and reagents are used. Furthermore, the use of enzymes for organic synthesis is ecofriendly and creates less waste compared with chemical methods.
Time Considerations All protocols described in this unit can be completed in 1 to 3 days with common laboratory equipment. It is noteworthy that these reactions are highly specific and that extending the reaction times for a few extra hours does not compromise the yield or quality of the products. In fact, one of the key advantages of working with lipases is that their specificity is fine-tuned, minimizing the potential for product damage. The partially protected nucleoside intermediates and reagents used in these protocols are now commercially available, which
may save significant time in the synthesis of the target products.
Literature Cited Bornscheuer, U.T. and Kazlauskas, R.J. 1999. Hydrolases in Organic Synthesis. Regioand Stereoselective Biotransformations. WileyVCH, Weinheim, Germany. Carrea, G. and Riva, S. 2000. Properties and synthetic applications of enzymes in organic solvents. Angew. Chem. Int. Ed. Engl. 39:22262254. Eleuteri, A., Cheruvallath, Z.S., Capaldi, D.C., Cole, D.L., and Ravikumar, V.T. 1999. Synthesis of dimer phosphoramidite synthons for oligodeoxyribonucleotide phosphorothioates using diethyldithiocarbonate disulfide as an efficient sulfurizing reagent. Nucleosides Nucleotides Nucleic Acids 18:1803-1807. Ferrero, M. and Gotor, V. 2000a. Biocatalytic selective modifications of conventional nucleosides, carbocyclic nucleosides, and C-nucleosides. Chem. Rev. 100:4319-4347. Ferrero, M. and Gotor, V. 2000b. Chemoenzymatic transformations in nucleoside chemistry. Monatsh. Chem. 131:585-616. Garc´ıa, J., Fern´andez, S., Ferrero, M., Sanghvi, Y.S., and Gotor, V. 2002. Building blocks for the solution phase synthesis of oligonucleotides: Regioselective hydrolysis of 3 ,5 -diO-levulinylnucleosides using an enzymatic approach. J. Org. Chem. 67:4513-4519. Garc´ıa, J., Fern´andez, S., Ferrero, M., Sanghvi, Y.S., and Gotor, V. 2003. Novel enzymatic synthesis of levulinyl protected nucleosides useful for solution phase synthesis of oligonucleotides. Tetrahedron Asymmetr. 14:3533-3540. Garc´ıa, J., Fern´andez, S., Ferrero, M., Sanghvi, Y.S., and Gotor, V. 2004a. Mild, efficient and regioselective enzymatic procedure for 5 -Obenzoylation of 2 -deoxynucleosides. Tetrahedron Lett. 45:1709-1712. Garc´ıa, J., Fern´andez, S., Ferrero, M., Sanghvi, Y.S., and Gotor, V. 2004b. Regioselective enzymatic acylation of β-L-2 -deoxynucleosides: Application in resolution of β-D/L-2 -deoxynucleosides. Org. Lett. 6:3759-3762. Greene, T.W. and Wuts, P.G.M. 1999. Protective Groups in Organic Synthesis, 3rd ed., p. 168. John Wiley & Sons, New York. Iwai, S. and Ohtsuka, E. 1988. 5 -Levulinyl and 2 tetrahydrofuranyl protection for the synthesis of oligoribonucleotides by the phosphoramidite approach. Nucl. Acids Res. 16:9443-9456. Iwai, S., Toshiro, S., and Ohtsuka, E. 1990. Large scale synthesis of oligoribonucleotides on a solid support: Synthesis of a catalytic RNA duplex. Tetrahedron 46:6673-6688. Klibanov, A.M. 2001. Improving enzymes by using them in organic solvents. Nature 409:241-246. Kocie´nski, P.J. 2004. Protecting Groups, 3rd ed., pp. 464 and 475. Georg Thieme Verlag, Stuttgart, Germany.
Protection of Nucleosides for Oligonucleotide Synthesis
2.11.35 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Koeller, K.M. and Wong, C.H. 2001. Enzymes for chemical synthesis. Nature 409:232-240. Krotz, A.H., Klopchin, P., Cole, D.L., and Ravikumar, V.T. 1997. Improved impurity profile of phosphorothioate oligonucleotides through the use of dimeric phosphoramidite synthons. Nucleosides Nucleotides Nucleic Acids 16:16371640. Kumar, G. and Poonian, M.S. 1984. Improvements in oligodeoxyribonucleotide synthesis: Methyl N,N-dialkylphosphoramidite dimer units for solid support phosphite methodology. J. Org. Chem. 49:4905-4912. March´an, V., Cie´slak, J., Livengood, V., and Beaucage, S.L. 2004. 2,2,5,5Tetramethylpyrrolidin-3-one-1-sulfinyl group for 5 -hydroxyl protection of deoxyribonucleoside phosphoramidites in the solid-phase preparation of DNA oligonucleotides. J. Am. Chem. Soc. 126:9601-9610. Patel, R.N. 2000. Stereoselective Biocatalysis. Marcel Dekker, New York. Pedersen, D.S. and Rosenbohm, C. 2001. Dry column vacuum chromatography. Synthesis 24312434.
Reese, C.B. and Song, Q. 1999. The H-phosphonate approach to the solution phase synthesis of linear and cyclic oligoribonucleotides. Nucl. Acids Res. 27:963-971. Reese, C.B. and Yan, H. 2001. Solution phase synthesis of ISIS 2922 (Vitravene) by the modified H-phosphonate approach. J. Chem. Soc., Perkin Trans. 1 2619-2633. van Boom, J.H. and Burgers, P.M.J. 1976. Use of levulinic acid in the protection of oligonucleotides via the modified phosphotriester method: Synthesis of decaribonucleotide U-A-U-A-U-A-UA-U-A. Tetrahedron Lett. 17:4875-4878.
Contributed by Iv´an Lavandera, Javier Garc´ıa, Susana Fern´andez, Miguel Ferrero, and Vicente Gotor Universidad de Oviedo Oviedo, Spain Yogesh S. Sanghvi Rasayan, Inc. Encinitas, California
Pon, R.T., Yu, S., Guo, Z., and Sanghvi, Y.S. 1999. Multiple oligodeoxyribonucleotide syntheses on a reusable solid-phase CPG support via the hydroquinone-O,O -diacetic acid (Q-Linker) linker arm. Nucl. Acids Res. 27:1531-1538.
Enzymatic Regioselective Levulinylation of Nucleosides
2.11.36 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Nucleobase Protection with Allyloxycarbonyl
UNIT 2.12
This unit includes protocols for preparation of four N-allyloxycarbonyl-protected 2 deoxyribonucleosides and three N-allyloxycarbonyl-protected ribonucleosides from the corresponding parent nucleosides, including steps for OH-protection with 4,4 -dimethoxytrityl (DMTr) and tert-butyldimethylsilyl (TBDMS). The protected 2 -deoxyribonucleosides include N6 -AOC-5 -O-DMTr-2 -deoxyadenosine, N4 -AOC-5 O-DMTr-2 -deoxycytidine, N2 -AOC-5 -O-DMTr-2 -deoxyguanosine, and N2 -AOC-O6 allyl-5 -O-DMTr-2 -deoxyguanosine. The protected ribonucleosides include N6 -AOC2 -O-TBDMS-5 -O-DMTr-adenosine, N4 -AOC-2 -O-TBDMS-5 -O-DMTr-cytidine, and N2 -AOC-O6 -allyl-2 -O-TBDMS-5 -O-DMTr-guanosine. CAUTION: All operations involving organic solvents and reagents should be carried out in a well-ventilated chemical fume hood, and gloves and protective glasses should be worn.
SYNTHESIS OF N6 -ALLYLOXYCARBONYL-5 -O(4,4 -DIMETHOXYTRITYL)-2 -DEOXYADENOSINE
BASIC PROTOCOL 1
This compound is prepared from 2 -deoxyadenosine through a reaction sequence consisting of (1) 5 -O-dimethoxytritylation using 4,4 -dimethoxytrityl chloride in the presence of triethylamine and 4-(dimethylamino)pyridine in pyridine to give 5 -O-DMTr-2 deoxyadenosine, (2) 3 -O-protection by treatment with tert-butyldimethylsilyl chloride in the presence of imidazole to afford 3 -O-TBDMS-5 -O-DMTr-2 -deoxyadenosine, (3) N-allyloxycarbonylation using 1-(allyloxycarbonyl)tetrazole to provide N6 -AOC-3 O-TBDMS-5 -O-DMTr-2 -deoxyadenosine, and (4) removal of the TBDMS protecting group by exposure to tetrabutylammonium fluoride. The overall reaction sequence is illustrated in Figure 2.12.1. All operations are carried out at room temperature unless otherwise noted.
Materials 2 -Deoxyadenosine (S.1), 99% (Mitsui Chemicals) Triethylamine, distilled from CaH2 4-(Dimethylamino)pyridine (DMAP), 99% (Aldrich, TCI) Pyridine, distilled from CaH2 4,4 -Dimethoxytrityl chloride (DMTr-Cl), 97% (Aldrich, TCI) Ethyl acetate, 99% (Aldrich, Kishida) Sodium sulfate, 99% (Aldrich, Nacarai Tesque) N,N -Dimethylformamide (DMF), distilled from 4A molecular sieves Imidazole, 99% (Aldrich, Nacarai Tesque) tert-Butyldimethylsilyl chloride (TBDMS-Cl), 99% (Aldrich, Shinetsu) Hexane, 99% (Aldrich, Kishida) Brine: saturated solution of sodium chloride (99%; Aldrich, Wako) Silica gel 60 (spherical, neutrality, particle size 75 µm; Merck, Nacarai Tesque) Methanol, 99% (Aldrich, Kishida) Dichloromethane, 99% (Aldrich, Nacarai Tesque) 1-(Allyloxycarbonyl)tetrazole (AOC-Tet; see recipe) Tetrahydrofuran (THF), distilled from sodium benzophenone ketyl Aqueous saturated sodium hydrogencarbonate (NaHCO3 ; 99%; Aldrich, Nacarai Tesque) 1.0 M tetrabutylammonium fluoride in THF (Aldrich) Chloroform, 99% (Aldrich, Wako)
Contributed by Mamoru Hyodo and Yoshihiro Hayakawa Current Protocols in Nucleic Acid Chemistry (2005) 2.12.1-2.12.26 C 2005 by John Wiley & Sons, Inc. Copyright
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.1 Supplement 23
Figure 2.12.1
Preparation of N 6 -AOC-5 -O-DMTr-2 -deoxyadenosine.
Glass column Diaphragm pump Rotary evaporator equipped with a diaphragm pump and cooling unit Vacuum oil pump TLC plate: silica-coated glass plate with fluorescent indicator (Merck silica gel 60 F254 ) 254-nm UV lamp Additional reagents and equipment for column chromatography (APPENDIX 3E) and TLC (APPENDIX 3D) Prepare 3 -O-TBDMS-5 -O-DMTr-2 -deoxyadenosine 1. Prepare a solution of 3.05 g (12.1 mmol) 2 -deoxyadenosine (S.1), 2.50 mL (17.9 mmol) triethylamine, and 80.5 mg (0.659 mmol) DMAP in 100 mL pyridine. 2. Add 5.72 g (16.9 mmol) DMTr-Cl and stir the mixture at 13◦ C for 12 hr in the dark. 3. Pour the reaction mixture into 650 mL water. 4. Extract the whole mixture once with 150 mL and then twice with 100 mL ethyl acetate. Combine the organic layers and dry the organic solution over ∼15 g sodium sulfate. Remove the drying agent by filtration through a glass column with a cotton stopper under vacuum from a diaphragm pump. 5. Evaporate the resulting organic solution to dryness using a rotary evaporator with a diaphragm pump and a cooling unit. 6. Dry residue for 5 hr using a vacuum oil pump. 7. Dissolve the dried material in 50 mL DMF. Add 1.02 g (15.0 mmol) imidazole and 2.65 g (17.6 mmol) TBDMS-Cl, and stir the resulting mixture at 13◦ C for 4.5 hr. 8. Quench the reaction by adding 250 mL water. 9. Extract twice with 100 mL and then once with 50 mL of 1:1 (v/v) hexane/ethyl acetate, and combine the organic extracts. 10. Wash the organic extracts with 50 mL brine and dry the organic solution over sodium sulfate. 11. Concentrate the dried organic solution using a rotary evaporator.
Nucleobase Protection with Allyloxycarbonyl
12. Purify residue by column chromatography (APPENDIX 3E) on a column of 150 g silica gel with 1:30 (v/v) methanol/dichloromethane as eluent. Monitor fractions by TLC (APPENDIX 3D) using 1:20 (v/v) methanol/dichloromethane (Rf = 0.25). Visualize under UV light (254 nm).
2.12.2 Supplement 23
Current Protocols in Nucleic Acid Chemistry
13. Collect all fractions containing the desired product. Evaporate to dryness using a rotary evaporator. 3 -O-(tert-Butyldimethylsilyl)-5 -O-(4,4 -dimethoxytrityl)-2 -deoxyadenosine (S.2): 5.1 g (63%) as white powder. m.p. 151◦ –152◦ C. TLC (1:20 methanol/dichloromethane): Rf = 0.25. IR (KBr) 3330, 3160, 2960, 2940, 2860, 1670, 1650, 1510, 1260, 1180 cm–1 . UV λmax : 236 nm (ε 23,400), 260 (16,100). 1 H NMR: 0.03, 0.33 (2 s, 6H, Si(CH3 )2 ), 0.89 (s, 9H, Si-tert-C4 H9 ), 2.01 (ddd, 1H, J = 3.6, 6.0, and 13.2 Hz, H2 ), 2.81 (dt, 1H, J = 6.0 and 13.2 Hz, H2 ), 3.36 (t, 2H, J = 4.5 Hz, H5 ), 3.82 (s, 6H, 2 × OCH3 ), 4.12 (dd, 1H, J = 4.5 and 7.5 Hz, H4 ), 4.63 (m, 1H, H3 ), 5.83 (br, 2H, NH2 ), 6.46 (t, 1H, J = 6.0 Hz, H1 ), 6.73–6.95 (m, 4H, protons ortho to OCH3 of DMTr), 7.20–7.53 (m, 9H, arom. protons of DMTr), 8.06 (s, 1H, H2), 8.35 (s, 1H, H8).
Prepare N6 -AOC-5 -O-DMTr-2 -deoxyadenosine 14. Add 18.0 g (0.027 mol) S.2 to a solution of ∼0.1 mol AOC-Tet in 150 mL THF, and stir the resulting mixture at 70◦ C for 3 hr. 15. Cool the reaction mixture to 25◦ C and rotary evaporate. 16. Dissolve residue in 300 mL ethyl acetate and pour the resulting solution into 100 mL of an aqueous solution saturated with NaHCO3 . 17. Extract once with 300 mL ethyl acetate, wash the organic layer with 50 mL brine, and dry over sodium sulfate. 18. Evaporate the solvent using a rotary evaporator. 19. Dissolve residue in 100 mL THF and add 50 mL (0.05 mol) of 1.0 M TBAF in THF. Stir the mixture for 12 hr. 20. Evaporate the solvent with a rotary evaporator and dissolve residue in 150 mL ethyl acetate. 21. Wash the organic solution with 50 mL brine and dry over sodium sulfate. 22. Concentrate the dried organic solution using a rotary evaporator. 23. Purify residue by column chromatography over 300 g silica gel using an eluent of trace:1:50 (v/v/v) to trace:1:30 (v/v/v) triethylamine/methanol/chloroform. Monitor fractions by TLC using 1:20 (v/v) methanol/chloroform (Rf = 0.33). 24. Collect fractions including the desired product and concentrate using a rotary evaporator. N6 -Allyloxycarbonyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxyadenosine (S.3): 14.4 g (84%) as white powder. m.p. 84◦ –86◦ C. TLC (1:20 methanol/chloroform): Rf = 0.33. IR (KBr) 3410, 2960, 2940, 1760, 1620, 1515, 1470, 1255, 1220, 1180 cm−1 . UV λmax : 236 nm (ε 23,300), 268 (19,100). 1 H NMR: 2.37–3.04 (m, 2H, H2 ), 3.43 (br d, 2H, J = 5.1 Hz, H5 ), 3.76 (s, 6H, 2 × OCH3 ), 4.24 (br d, 1H, J = 3.0 Hz, H4 ), 4.74 (d, 3H, J = 5.7 Hz, CH2 CH= =CH2 and H3 ), 5.25 (dd, 1H, J = 1.5 and 10.2 Hz, cis-CH2 CH= =CH2 ), 5.37 (dd, 1H, J = 1.5 and 17.4 Hz, trans-CH2 CH= =CH2 ), 6.00 (ddt, 1H, J = 10.2, 17.4, and 5.7 Hz, CH2 CH= =CH2 ), 6.52 (t, 1H, J = 6.0 Hz, H1 ), 6.80 (d, 4H, J = 9.0 Hz, protons ortho to OCH3 of DMTr), 7.13–7.50 (m, 9H, arom. protons of DMTr), 8.18 (s, 1H, H2), 8.73 (s, 1H, H8).
SYNTHESIS OF N4 -ALLYLOXYCARBONYL-5 -O(4,4 -DIMETHOXYTRITYL)-2 -DEOXYCYTIDINE This compound is synthesized from 2 -deoxycytidine hydrochloride via (1) conversion of the starting nucleoside to N4 -AOC-2 -deoxycytidine by successive treatment with trimethylsilyl chloride in pyridine, allyl 1-benzotriazolyl carbonate, and an aqueous NaHCO3 solution without isolation of the intermediary that is formed, and (2) dimethoxytritylation using 4,4 -dimethoxytrityl chloride in pyridine to afford
BASIC PROTOCOL 2
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.3 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Figure 2.12.2
Preparation of N 4 -AOC-5 -O-DMTr-2 -deoxycytidine.
N4 -AOC-5 -O-DMTr-2 -deoxycytidine. The overall reaction sequence is illustrated in Figure 2.12.2. All operations are carried out at room temperature unless otherwise noted.
Materials 2 -Deoxycytidine hydrochloride (S.4), 99% (Aldrich, Mitsui Chemicals) Pyridine, distilled from CaH2 Trimethylsilyl chloride (TMS-Cl), 99% (Aldrich, Shinetsu) Allyl 1-benzotriazolyl carbonate (AOCOBT; see recipe) Saturated aqueous sodium hydrogencarbonate (NaHCO3 ), 99% (Aldrich, Nacarai Tesque) Dichloromethane, 99% (Aldrich, Nacarai Tesque) Sodium sulfate, 99% (Aldrich, Nacarai Tesque) 4,4 -Dimethoxytrityl chloride (DMTr-Cl), 97% (Aldrich, TCI) Hexane, 99% (Aldrich, Kishida) Ethyl acetate, 99% (Aldrich, Kishida) Brine: saturated aqueous sodium chloride (99%; Aldrich, Wako) Silica gel 60 (spherical, neutrality, particle size 75 µm; Merck, Nacarai Tesque) Chloroform, 99% (Aldrich, Wako) Methanol, 99% (Aldrich, Kishida) Glass column Diaphragm pump Rotary evaporator equipped with a diaphragm pump and cooling unit Vacuum oil pump TLC plate: silica-coated glass plate with fluorescent indicator (Merck silica gel 60 F254 ) 254-nm UV lamp Additional reagents and equipment for column chromatography (APPENDIX 3E) and TLC (APPENDIX 3D) Prepare crude N4 -AOC-2 -deoxycytidine 1. Add 7.5 mL (59.1 mmol) trimethylsilyl chloride to a suspension of 3.09 g (11.7 mmol) 2 -deoxycytidine hydrochloride (S.4) in 30 mL pyridine. Stir the mixture at 10◦ C for 1.5 hr. 2. Add 5.14 g (23.5 mmol) AOCOBT and stir the mixture for another 24 hr at 0◦ C. 3. Add 50 mL saturated NaHCO3 solution and continue stirring for an additional 30 min at room temperature. Nucleobase Protection with Allyloxycarbonyl
4. Pour the reaction mixture into 100 mL water and extract the resulting aqueous mixture with 30 mL dichloromethane.
2.12.4 Supplement 23
Current Protocols in Nucleic Acid Chemistry
5. Separate the aqueous layer and extract four times with 50 mL of 1:1 (v/v) dichloromethane/pyridine. 6. Dry the organic layer over ∼15 g sodium sulfate. Remove the drying agent by filtration through a glass column with a cotton stopper under vacuum from a diaphragm pump. Concentrate the organic solution using a rotary evaporator with a diaphragm pump and a cooling unit.
Prepare N4 -AOC-5 -O-DMTr-2 -deoxycytidine 7. Dissolve the residue of crude S.5 in 30 mL pyridine. 8. Add 3.96 g (11.7 mmol) DMTr-Cl and stir the resulting solution at 10◦ C for 24 hr. 9. Pour the reaction mixture into 300 mL water and extract three times with 1:1 (v/v) hexane/ethyl acetate. 10. Combine the organic layers and wash with 100 mL brine. 11. Dry the organic solution over sodium sulfate and concentrate the dried solution with a rotary evaporator. 12. Purify the crude residue on a 100 g silica gel column (APPENDIX 3E) with 1:50 (v/v) methanol/chloroform as eluent. Monitor fractions by TLC (APPENDIX 3D) using 1:20 (v/v) methanol/chloroform (Rf = 0.24). Visualize the product under UV light (254 nm). 13. Collect fractions containing the desired product and concentrate using a rotary evaporator. N4 -Allyloxycarbonyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxycytidine (S.6): 4.97 g (69%) as white solid. m.p. 98◦ –102◦ C (4.97 g, 69%). TLC (1:20 methanol/chloroform): Rf = 0.24. IR (KBr) 3400, 2940, 1750, 1650, 1630, 1610, 1560, 1510, 1255, 1210, 1100, 1040 cm−1 . UV λmax : 237 nm (ε 30,600), 285 (8,400). 1 H NMR: 2.28 (m, 1H, H2 ), 2.81 (m, 1H, H2 ), 3.46 (br, 2H, H5 ), 3.80 (s, 6H, 2 × OCH3 ), 4.21 (m, 1H, H4 ), 4.40–4.80 (m, 3H, CH2 CH= =CH2 and H3 ), 5.15–5.51 (m, 2H, CH2 CH= =CH2 ), 5.96 (m, 1H, CH2 CH= =CH2 ), 6.32 (t, 1H, J = 5.7 Hz, H1 ), 6.70–7.55 (m, 14H, H5 and arom. protons of DMTr), 8.27 (d, 1H, J = 7.5 Hz, H6).
SYNTHESIS OF N2 -ALLYLOXYCARBONYL-5 -O(4,4 -DIMETHOXYTRITYL)-2 -DEOXYGUANOSINE
BASIC PROTOCOL 3
This compound is prepared starting from 2 -deoxyguanosine via a reaction sequence consisting of (1) 5 -O-tert-butyldimethylsilylation using tert-butyldimethylsilyl chloride in the presence of imidazole to afford 3 ,5 -di-O-TBDMS-2 -deoxyguanosine, (2) N-allyloxycarbonylation by treatment with tert-butylmagnesium chloride, HMPA, and allyloxycarbonyl chloride to produce N2 -AOC-3 ,5 -di-O-TBDMS-2 -deoxyguanosine, (3) removal of the silyl protecting groups using tetrabutylammonium fluoride to give N2 -AOC-2 -deoxyguanosine, and (4) 5 -O-dimethoxytritylation by treatment with 4,4 dimethoxytrityl chloride in pyridine to provide N2 -AOC-5 -O-DMTr-2 -deoxyguanosine. The overall reaction sequence is illustrated in Figure 2.12.3. All operations are carried out at room temperature unless otherwise noted.
Materials 2 -Deoxyguanosine (S.7), 99% (Aldrich, Mitsui Chemicals) Imidazole, 99% (Aldrich, Nacarai Tesque) N,N -Dimethylformamide (DMF), distilled from 4A molecular sieves tert-Butyldimethylsilyl chloride (TBDMS-Cl), 99% (Aldrich, Shinetsu) Ethanol, 99.5% (Aldrich, Nacarai Tesque) tert-Butylmagnesium chloride, 99% (Aldrich)
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.5 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Figure 2.12.3
Preparation of N 2 -AOC-5 -O-DMTr-2 -deoxyguanosine.
Tetrahydrofuran (THF), distilled from sodium benzophenone ketyl Hexamethylphosphoric triamide (HMPA), 99% (Aldrich) Allyloxycarbonyl chloride (AOC-Cl), 99% (Aldrich, TCI) Methanol, 99% (Aldrich, Kishida) Diethyl ether, distilled from sodium benzophenone ketyl 0.15 M ethylenediamine tetraacetic acid (EDTA; 99%; Aldrich, Nacarai Tesque) Saturated aqueous sodium hydrogencarbonate (NaHCO3 ; 99%; Aldrich, Nacarai Tesque) Brine: saturated aqueous sodium chloride (99%; (Aldrich, Wako) Sodium sulfate, 99% (Aldrich, Nacarai Tesque) Silica gel 60 (spherical, neutrality, particle size 75 µm; Merck, Nacarai Tesque) Ethyl acetate, 99% (Aldrich, Kishida) Hexane, 99% (Aldrich, Kishida) 1.0 M tetrabutylammonium fluoride (TBAF) in THF (Aldrich) Pyridine, distilled from CaH2 Dichloromethane, 99% (Aldrich, Nacarai Tesque) 4,4 -Dimethoxytrityl chloride (DMTr-Cl), 97% (Aldrich, TCI) Chloroform, 99% (Aldrich, Wako) Rotary evaporator equipped with a diaphragm pump and cooling unit Glass column Diaphragm pump Vacuum oil pump TLC plate: silica-coated glass plate with fluorescent indicator (Merck silica gel 60 F254 ) 254-nm UV lamp Additional reagents and equipment for column chromatography (APPENDIX 3E) and TLC (APPENDIX 3D) Nucleobase Protection with Allyloxycarbonyl
2.12.6 Supplement 23
Prepare 3 ,5 -di-O-TBDMS-2 -deoxyguanosine 1. Prepare a solution of 10.0 g (35 mmol) 2 -deoxyguanosine (S.7) and 17 g (247 mmol) imidazole in 20 mL DMF. 2. Add 21 g (139 mmol) TBDMS-Cl and stir at room temperature for 24 hr. Current Protocols in Nucleic Acid Chemistry
3. Quench the reaction by adding 50 mL ethanol and evaporate the mixture on a rotary evaporator with a diaphragm pump and a cooling unit. 4. Wash the residual solid with 200 mL cold (4◦ C) ethanol and then 200 mL water. Dry the solid under reduced pressure with a vacuum pump. 3 ,5 -Di-O-(tert-butyldimethylsilyl)-2 -deoxyguanosine (S.8): 14.9 g (86%). 1 H NMR (DMSO-d6 ): 0.02, 0.08 (2 s, 12H), 0.85, 0.87 (2 s, 18H), 2.17–2.22 (m, 1H), 2.26 (s, 1H), 2.59–2.66 (m, 1H), 3.60–3.77 (m, 3H), 3.77–3.83 (m, 1H), 6.05–6.08 (m, 1H), 6.43 (br, 2H), 7.84 (s, 1H), 10.57 (br, 1H).
Prepare N2 -AOC-3 ,5 -di-O-TBDMS-2 -deoxyguanosine 5. Add dropwise 16.0 mL (20.3 mmol) of 1.27 M tert-butylmagnesium chloride in THF to a solution of 3.40 g (6.86 mmol) S.8 and 10 mL HMPA in 70 mL THF. Stir the mixture at 25◦ C for 20 min. CAUTION: HMPA is a suspected carcinogen. Handle with gloves in a well-ventilated chemical fume hood.
6. Add a solution of 1.80 mL (17.0 mmol) AOC-Cl in 10 mL THF and continue stirring for an additional 15 min. 7. Quench the reaction by adding 5 mL methanol and evaporate the reaction mixture on a rotary evaporator. 8. Dissolve the residue in 200 mL diethyl ether. 9. Wash the ether solution once with 150 mL of 0.15 M EDTA, once with 50 mL saturated aqueous NaHCO3 , and once with 50 mL brine. 10. Dry the ether solution over ∼15 g sodium sulfate. Remove the drying agent by filtration through a glass column with a cotton stopper under vacuum from a diaphragm pump. Concentrate the dried solution. 11. Subject the residue to column chromatography (APPENDIX 3E) using a 100 g silica gel column and 3:2 (v/v) hexane/ethyl acetate as eluent. Monitor fractions by TLC (APPENDIX 3D) with 1:1 (v/v) hexane/ethyl acetate (Rf = 0.36). Visualize the product under UV light (254 nm). 12. Collect fractions containing the desired product and concentrate the fractions using a rotary evaporator. N2 -Allyloxycarbonyl-3 ,5 -di-O-(tert-butyldimethylsilyl)-2 -deoxyguanosine (S.9): 3.09 g (78%) as a foam. TLC (1:1 ethyl acetate/hexane): Rf = 0.36. IR (KBr) 3250, 2950, 2930, 2850, 1715, 1690, 1610, 1240, 1100 cm−1 . UV λmax : 257 nm (ε 14,700), 280 (sh). 1 H NMR: 0.06, 0,08 (2 s, 12H, 2 × Si(CH3 )2 ), 0.90 (s, 18H, 2 × Si-tert-C4 H9 ), 1.90 (m, 1H, H2 ), 2.40 (m, 1H, H2 ), 3.76 (d, 2H, J = 3.6 Hz, H5 ), 3.98 (dd, 1H, J = 3.6 and 6.6 Hz, H4 ), 4.57 (dd, 1H, J = 3.9 and 7.5 Hz, H3 ), 4.73 (d, 2H, J = 6.0 Hz, CH2 CH= =CH2 ), =CH2 ), 5.37 (dd, 1H, J = 1.8 and 17.4 Hz, 5.32 (dd, 1H, J = 1.8 and 10.5 Hz, cis-CH2 CH= trans-CH2 CH= =CH2 ), 5.94 (ddt, 1H, J = 10.5, 17.4, and 6.0 Hz, CH2 CH= =CH2 ), 6.23 (t, 1H, J = 6.3 Hz, H1 ), 7.95 (s, 1H, H8).
Prepare N2 -AOC-5 -O-DMTr-2 -deoxyguanosine 13. Add 20 mL (20 mmol) of 1.0 M TBAF in THF to a solution of 2.20 g (3.79 mmol) S.9 in 20 mL THF. Stir the resulting mixture at 10◦ C for 30 min. 14. Concentrate the mixture and add 20 mL water to the resulting residue. 15. Extract the aqueous mixture three times with 50 mL of 1:1 (v/v) dichloromethane/pyridine and combine the organic layers. 16. Dry the organic extracts over sodium sulfate and then concentrate to dryness with a rotary evaporator.
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.7 Current Protocols in Nucleic Acid Chemistry
Supplement 23
17. Dissolve the residual oil in 30 mL pyridine and add 1.32 g (3.90 mmol) DMTr-Cl. Stir the resulting mixture at 10◦ C for 15 hr. 18. Pour the mixture into 300 mL water and extract three times with 100 mL of 1:1 (v/v) hexane/ethyl acetate. 19. Dry the combined organic layers over sodium sulfate and concentrate them using a rotary evaporator. 20. Subject the residue to column chromatography on a 70 g silica gel column and elute with 1:30 (v/v) methanol/chloroform. Monitor fractions by TLC using 1:10 (v/v) methanol/chloroform (Rf = 0.72). 21. Collect fractions containing the desired product and concentrate them using a rotary evaporator. N2 -Allyloxycarbonyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxyguanosine (S.10): 1.62 g (65%) as a white solid. m.p. 124◦ –127◦ C. TLC (1:10 methanol/chloroform): Rf = 0.72. IR (KBr) 3400, 3250, 2970, 2940, 1700, 1615, 1570, 1515, 1250, 1180, 1100, 1040 cm−1 . UV λmax : 234 nm (ε 33,300), 276 (sh). 1 H NMR: 2.47–2.90 (m, 2H, H2 ), 3.40 (br, 2H, H5 ), 3.72 (s, 6H, 2 × OCH3 ), 4.28 (m, 1H, H4 ), 4.80 (br d, 2H, J = 4.8 Hz, CH2 CH= =CH2 ), 5.05 =CH2 ), 5.74–6.40 (m, 2H, CH2 CH= =CH2 and (m, 1H, H3 ), 5.18–5.53 (m, 2H, CH2 CH= H1 ), 6.74 (d, 4H, J = 9.9 Hz, protons ortho to OCH3 of DMTr), 7.02–7.53 (m, 9H, arom. protons of DMTr), 7.77 (s, 1H, H8). BASIC PROTOCOL 4
SYNTHESIS OF N2 -ALLYLOXYCARBONYL-O6 -ALLYL-5 -O(4,4 -DIMETHOXYTRITYL)-2 -DEOXYGUANOSINE This O6 -protected compound is synthesized from N2 -AOC-3 ,5 -di-O-TBDMS-2 deoxyguanosine (S.9) prepared as in the previous protocol. The reaction sequence includes (1) O6 -allylation of S.9 by treatment with 2-mesitylenesulfonyl chloride in the presence of triethylamine and 4-(dimethylamino)pyridine followed by allyl alcohol in the presence of trimethylamine and 1,8-diazabicyclo[5,4,0]undec-7-ene to afford N2 AOC-O6 -allyl-3 ,5 -di-O-TBDMS-2 -deoxyguanosine, (2) removal of the silyl protecting groups using tetrabutylammonium fluoride to give N2 -AOC-O6 -allyl-2 -deoxyguanosine, and (3) O-dimethoxytritylation by treatment with 4,4 -dimethoxytrityl chloride in pyridine to provide N2 -AOC-O6 -allyl-5 -O-DMTr-2 -deoxyguanosine. The overall reaction sequence is illustrated in Figure 2.12.4. All operations are carried out at room temperature unless otherwise noted.
Figure 2.12.4
Preparation of N 2 -AOC-O 6 -allyl-5 -O-DMTr-2 -deoxyguanosine.
Nucleobase Protection with Allyloxycarbonyl
2.12.8 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Materials N2 -Allyloxycarbonyl-3 ,5 -di-O-(tert-butyldimethylsilyl)-2 -deoxyguanosine (S.9; see Basic Protocol 3) Triethylamine, distilled from CaH2 4-(Dimethylamino)pyridine (DMAP), 99% (Aldrich, TCI) Dichloromethane, 99% (Aldrich, Nacarai Tesque) 2-Mesitylenesulfonyl chloride, 99% (Aldrich, TCI) Saturated aqueous sodium hydrogencarbonate (NaHCO3 ; 99%, Aldrich, Nacarai Tesque) Sodium sulfate, 99% (Aldrich, Nacarai Tesque) Trimethylamine, anhydrous gas (Aldrich) Allyl alcohol, distilled from Mg 1,8-Diazabicyclo[5,4,0]undec-7-ene (DBU), 99% (Aldrich, Nacarai Tesque) Brine: saturated aqueous sodium chloride (99%; Aldrich, Wako) Silica gel 60 (spherical, neutrality, particle size 75 µm; Merck, Nacarai Tesque) Ethyl acetate, 99% (Aldrich, Kishida) Hexane, 99% (Aldrich, Kishida) 1.0 M tetrabutylammonium fluoride (TBAF) in THF (Aldrich, Aldrich) Tetrahydrofuran (THF), distilled from sodium benzophenone ketyl Pyridine, distilled from CaH2 4,4 -Dimethoxytrityl chloride (DMTr-Cl), 97% (Aldrich, TCI) Methanol, 99% (Aldrich, Kishida) Chloroform, 99% (Aldrich, Wako) Glass column Diaphragm pump Rotary evaporator equipped with a diaphragm pump and cooling unit Vacuum oil pump TLC plate: silica-coated glass plate with fluorescent indicator (Merck silica gel 60 F254 ) 254-nm UV lamp Additional reagents and equipment for column chromatography (APPENDIX 3E) and TLC (APPENDIX 3D) Prepare N2 -AOC-O6 -allyl-3 ,5 -di-O-TBDMS-2 -deoxyguanosine 1. Prepare a mixture of 11.2 g (19.4 mmol) N2 -AOC-3 ,5 -di-O-TBDMS-2 -deoxyguanosine (S.9), 11 mL (7.99 g, 78.9 mmol) triethylamine, and 278 mg (2.27 mmol) DMAP in 100 mL dichloromethane. 2. Add 5.54 g (25.3 mmol) 2-mesitylenesulfonyl chloride and stir the mixture at room temperature for 3 hr. 3. Pour the mixture into 200 mL dichloromethane. Wash twice with 100 mL water and twice with 100 mL of saturated aqueous NaHCO3 solution. 4. Dry the organic layer over ∼15 g sodium sulfate. Remove the drying agent by filtration through a glass column with a cotton stopper under vacuum from a diaphragm pump. Remove the organic solvent using a rotary evaporator with a diaphragm pump and a cooling unit. Dry the residue with a vacuum oil pump. 5. Dissolve the dried material in 100 mL dichloromethane. 6. Add 27 mL (17.7 g, 300 mmol) trimethylamine followed by 20 mL (17.1 g, 290 mmol) allyl alcohol at 0◦ C with stirring. Continue stirring at the same temperature for 10 min. 7. Add 3 mL (3.05 g, 20.1 mmol) DBU and stir the resulting mixture overnight at 0◦ C. Current Protocols in Nucleic Acid Chemistry
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.9 Supplement 23
8. Warm the mixture to room temperature and remove the resulting precipitates by filtering through a glass column with a cotton stopper under vacuum with a diaphragm pump. 9. Dilute the filtrate with 200 mL dichloromethane. 10. Wash the dichloromethane solution once with 200 mL water and twice with 200 mL brine. 11. Concentrate the dichloromethane solution with a rotary evaporator. 12. Purify the residue by column chromatography (APPENDIX 3E) on a 100 g silica gel column using 1:2 (v/v) ethyl acetate/hexane as eluent. Monitor fractions by TLC (APPENDIX 3D) using 1:1 (v/v) ethyl acetate/hexane (Rf = 0.40). Visualize under UV light (254 nm). 13. Combine fractions containing the desired product and evaporate them with a rotary evaporator. N 2 -Allyloxycarbonyl-O6 -allyl-3 ,5 -di-O-(tert-butyldimethylsilyl)-2 -deoxyguanosine (S.11): 9.64 g (80%) as a foam. TLC (1:1 ethyl acetate/hexane): Rf = 0.40. IR 3418, 1661, 1537 cm−1 . UV λmax : 284 nm (ε 7,300), 207 (sh, 20,000). 1 H NMR: 0.06 (s, 6H, (CH3 )2 Si), 0.87 (s, 9H, t-C4 H9 Si), 1.95 (s, 3H, CH3 C= =), 2.27 (ddd, 1H, J = 13.4, 6.4, and 3.9 Hz, H2 ), 2.47 (dt, 1H, J = 13.4 and 6.4 Hz, H2 ), 3.23 (dd, 1H, J = 6.2 and 3.1 Hz, 5 -OH), 3.71–3.78 (m, 1H, H5 ), 3.91–3.95 (m, 2H, H4 and H5 ), 4.50 (dt, 1H, J = 6.2 and 3.9 Hz, H3 ), 4.88 (d, 2H, J = 5.9 Hz, CH2=CHCH2 ), 5.26 (dd, 1H, J = 10.4 and 1.5 Hz, cis-CH2=CHCH2 ), 5.37 (dd, 1H, J = 17.3 and 1.5 Hz, trans-CH2=CHCH2 ), 5.95–6.10 (m, 2H, CH2=CHCH2 and H1 ), 7.62 (s, 1H, H6). Anal. calcd. for C19 H32 N2 O5 Si: C, 57.53; H, 8.15; N, 7.06; found: C, 57.35; H, 8.29; N, 7.23.
Prepare N2 -AOC-O6 -allyl-5 -O-DMTr-2 -deoxyguanosine 14. Add 20 mL (20 mmol) of 1.0 M TBAF in THF to a solution of 2.35 g (3.79 mmol) S.11 in THF (20 mL). Stir the resulting mixture at 10◦ C for 30 min. 15. Concentrate the mixture with a rotary evaporator and add 20 mL water to the residue. 16. Extract the aqueous mixture three times with 50 mL of 1:1 (v/v) dichloromethane/pyridine and dry the combined organic extracts over sodium sulfate. 17. Concentrate to dryness using a vacuum oil pump. 18. Dissolve the residue in 30 mL pyridine and add 1.32 g (3.90 mmol) DMTr-Cl. Stir the mixture at 10◦ C for 15 hr. 19. Pour the reaction mixture into 300 mL water and extract three times with 100 mL of 1:1 (v/v) hexane/ethyl acetate. 20. Dry the combined organic extracts with sodium sulfate and concentrate with a rotary evaporator. 21. Subject the residue to column chromatography with a 70 g silica gel column and 1:30 (v/v) methanol/chloroform as eluent. Monitor fractions by TLC with 1:10 (v/v) methanol/chloroform (Rf = 0.35). 22. Collect fractions containing the desired product and concentrate using a rotary evaporator.
Nucleobase Protection with Allyloxycarbonyl
N 2 -Allyloxycarbonyl-O6 -allyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxyguanosine (S.12): 1.58 g (60%) as an amorphous solid. m.p. = 76◦ C. TLC (1:10 methanol/chloroform): Rf = 0.35. UV λmax : 254 nm (shoulder, ε 12,900), 268 (14,000). 1 H NMR (400 MHz, DMSO-d6 ): 2.23–2.29 (m, 1H), 2.69–2.75 (m, 1H), 3.47–3.61 (m, 2H), 3.82–3.85 (m, 1H), 4.41 (m, 1H), 4.61–4.62 (m, 2H), 4.85 (t, 1H, J = 5.6 Hz), 5.05 (d, 2H, J = 5.9 Hz),
2.12.10 Supplement 23
Current Protocols in Nucleic Acid Chemistry
5.21–5.48 (m, 5H), 5.92–6.02 (m, 1H), 6.10–6.20 (m, 1H), 6.20–6.32 (m, 1H), 8.41 (s, 1H), 10.32 (s, 1H). Anal. calcd. for C17 H21 N5 O6 : C, 52.17; H, 5.41; N, 17.89; found: C, 52.18; H, 5.65; N, 17.80.
SYNTHESIS OF N6 -ALLYLOXYCARBONYL-2 -O-(tertBUTYLDIMETHYLSILYL)-5 -O-(4,4 -DIMETHOXYTRITYL)ADENOSINE
BASIC PROTOCOL 5
This compound is prepared from adenosine via the following sequence of reactions: (1) N6 -allyloxycarbonylation by successive treatment with hexamethyldisilazane in the presence of ammonium sulfate as a catalyst, with allyloxycarbonyl chloride in the presence of N-methylimidazole, and with triethylamine in methanol to give N6 -AOC-adenosine, (2) 5 -O-dimethoxytritylation by reaction with 4,4 -dimethoxytrityl chloride in pyridine to provide N6 -AOC-5 -O-DMTr-adenosine, (3) tert-butyldimethylsilylation using tert-butyldimethylsilyl chloride in the presence of imidazole to afford a mixture of N6 AOC-2 -O-TBDMS-5 -O-DMTr-adenosine and its 3 -O-TBDMS isomer, and (4) chromatographic separation of this mixture on a silica gel column to furnish N6 -AOC-2 -OTBDMS-5 -O-DMTr-adenosine. Following separation, the 3 -O-silylated byproduct is isomerized to increase the yield of the desired 2 -isomer. The overall reaction sequence is illustrated in Figure 2.12.5. All operations are carried out at room temperature unless otherwise noted.
Materials Hexamethyldisilazane (HMDS), 99% (Aldrich, Shinetsu) Adenosine (S.13), 99% (Sigma) Ammonium sulfate, 99% (Aldrich, Wako) 1,4-Dioxane, distilled from sodium benzophenone ketyl Toluene, distilled from sodium benzophenone ketyl
Figure 2.12.5
Preparation of N 6 -AOC-2 -O-TBDMS-5 -O-DMTr-adenosine. Protection of Nucleosides for Oligonucleotide Synthesis
2.12.11 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Dichloromethane, 99% (Aldrich, Nacarai Tesque) N-Methylimidazole (Aldrich, Nacarai Tesque) Allyloxycarbonyl chloride (AOC-Cl), 99% (Aldrich, TCI) 1.0 M phosphate buffer, pH 7 Sodium sulfate, 99% (Aldrich, Nacarai Tesque) Methanol, 99% (Aldrich, Kishida) Triethylamine, distilled from CaH2 Diethyl ether, 99% (Aldrich, Nacarai Tesque) Diphosphorus pentoxide (P2 O5 ), 98% (Aldrich, Nacarai Tesque) Pyridine, distilled from CaH2 N,N -Dimethylformamide (DMF), distilled from 4A molecular sieves 4,4 -Dimethoxytrityl chloride (DMTr-Cl), 97% (Aldrich, TCI) Silica gel 60 (spherical, neutrality, particle size 75 µm; Merck, Nacarai Tesque) Ethyl acetate, 99% (Aldrich, Kishida) Hexane, 99% (Aldrich, Kishida) Chloroform, 99% (Aldrich, Wako) Imidazole, 99% (Aldrich, Nacarai Tesque) tert-Butyldimethylsilyl chloride (TBDMS-Cl), 99% (Aldrich, Shinetsu) Glass column Diaphragm pump Reflux condenser Rotary evaporator equipped with a diaphragm pump and cooling unit Vacuum oil pump TLC plate: silica-coated glass plate with fluorescent indicator (Merck silica gel 60 F254 ) 254-nm UV lamp Additional reagents and equipment for column chromatography (APPENDIX 3E) and TLC (APPENDIX 3D) Prepare N6 -AOC-adenosine 1. Add 130 mL HMDS to a suspension of 15.0 g (56 mmol) adenosine (S.13) and a catalytic amount of ammonium sulfate in 140 mL dry dioxane. Heat under reflux for 3 hr (b.p. 125◦ C; oil bath 145◦ C). 2. Evaporate the solvent on a rotary evaporator with a diaphragm pump and a cooling unit, and then dry the residue by co-evaporating twice with 50 mL dry toluene. 3. Dissolve residue in 500 mL dichloromethane and then add 14.5 mL (14.9 g, 180 mmol) N-methylimidazole followed by 18.5 mL (21.0 g, 170 mmol) AOC-Cl. Stir the mixture overnight. 4. Add more 4.50 mL (4.60 g, 56.0 mmol) N-methylimidazole and 6.00 mL (6.80 g, 56.0 mmol) AOC-Cl and stir the mixture for an additional 12 hr. 5. Pour into 300 mL of 1.0 M phosphate buffer, pH 7, and extract three times with 50 mL dichloromethane. 6. Combine the organic extracts and dry over ∼15 g sodium sulfate. Remove the drying agent by filtration through a glass column with a cotton stopper under vacuum from a diaphragm pump. Evaporate with a rotary evaporator. 7. Dissolve the residue in 500 mL methanol and add 130 mL triethylamine. Stir the mixture at room temperature for 12 hr. Nucleobase Protection with Allyloxycarbonyl
8. Collect precipitates by vacuum filtration through a glass column with a cotton stopper, and wash with 300 mL diethyl ether.
2.12.12 Supplement 23
Current Protocols in Nucleic Acid Chemistry
9. Concentrate the filtrate to a volume of 300 mL. 10. Collect the resulting precipitates by vacuum filtration as above, and wash with 300 mL diethyl ether. 11. Combine all precipitates and dry them over P2 O5 under reduced pressure with a vacuum oil pump. N6 -(Allyloxycarbonyl)adenosine (S.14): 17.5 g (89%) as a white solid. m.p. 164◦ –166◦ C. TLC (1:9 methanol/dichloromethane): Rf = 0.3. UV λmax : 267 nm (ε 18,000). 1 H NMR (270 MHz, DMSO-d6 ): 3.55–3.71 (m, 2H), 3.95–3.97 (m, 1H), 4.17 (m, 1H), 4.61–4.66 (m, 3H), 5.12 (t, 1H, J = 5.6 Hz), 5.21–5.22 (m, 1H), 5.23 (d, 1H, J = 10.6 Hz), 5.38 (dd, 1H, J = 1.4 and 15.8 Hz), 5.52 (d, 1H, J = 6.3 Hz), 5.90–6.04 (m, 2H), 8.63 (s, 1H), 8.68 (s, 1H), 10.66 (s, 1H). Anal. calcd. for C14 H17 N5 O6 : C, 47.86; H, 4.88; N, 19.93; found: C, 47.86; H, 4.86; N, 20.14.
Prepare N6 -AOC-5 -O-DMTr-adenosine 12. Prepare a solution of 15.0 g (42.7 mmol) S.14 in 150 mL of 1:1 (v/v) pyridine/DMF and cool to 0◦ C. 13. Add 15.6 g (46.0 mmol) DMTr-Cl in small portions over 20 min. Stir at the same temperature for an additional 20 min and then at room temperature for 12 hr. 14. Pour into 1.2 L ice-cold water. Collect the precipitates by vacuum filtration as above, and wash with 200 mL water. 15. Dry at 50◦ C under vacuum with a vacuum oil pump. 16. Purify the solid by column chromatography (APPENDIX 3E) using a 300 g silica gel column. Monitor fractions by TLC (APPENDIX 3D) using 1:9 (v/v) methanol/dichloromethane. Visualize under UV light (254 nm). Elute the column first with 1.2 L of 4:6 (v/v) ethyl acetate/hexane to remove the byproducts, and then with 1:9 (v/v) methanol/ethyl acetate to collect the desired product (Rf = 0.76). 17. Evaporate the fractions containing the desired product using a rotary evaporator. N6 -Allyloxycarbonyl-5 -O-(4,4 -dimethoxytrityl)adenosine (S.15): 21.5 g (77%) as an amorphous solid. TLC (1:9 methanol/dichloromethane): Rf = 0.76. 1 H NMR (270 MHz, DMSO-d6 ): 3.22–3.24 (m, 2H), 3.71 (s, 6H), 4.06–4.11 (m, 1H), 4.30–4.34 (m, 1H), 4.64–4.66 (m, 2H), 4.73–4.78 (m, 1H), 5.25–5.27 (m, 2H), 5.42 (dd, 1H, J = 1.5 and 17.3 Hz), 5.60 (d, 1H, J = 5.3 Hz), 5.90–6.04 (m, 2H), 6.79–6.84 (m, 4H), 7.18–7.36 (m, 9H), 8.56 (s, 2H), 10.65 (s, 1H). Anal. calcd. for C35 H35 N5 O8 ·1/2 H2 O: C, 63.44; H, 5.48; N, 10.57; found: C, 63.31; H, 5.30; N, 10.30.
Prepare N6 -AOC-2 -O-TBDMS-5 -O-DMTr-adenosine 18. Add 4.4 g (64.6 mmol) imidazole to a solution of 19.8 g (30.3 mmol) S.15 in DMF (35 mL). 19. Add 4.85 g (32.2 mmol) TBDMS-Cl and stir overnight. 20. Dilute the reaction mixture with 400 mL ethyl acetate and wash three times with 150 mL water. 21. Dry the organic layer over sodium sulfate and remove the organic solvent using a rotary evaporator. 22. Subject the crude material to column chromatography using a 500 g silica gel column. Monitor fractions by TLC using 3:2 (v/v) ethyl acetate/hexane. 23. Elute first with 2:8 (v/v) ethyl acetate/hexane to remove all undesired 2 ,3 -di-Osilylated product. In this preparation, 3.2 g (12% yield) of the 2 ,3 -di-O-silylated product are obtained (Rf = 0.45; 1:3 ethyl acetate/hexane). Current Protocols in Nucleic Acid Chemistry
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.13 Supplement 23
24. Elute next with 35:65 (v/v) ethyl acetate/hexane and collect fractions containing first the desired N6 -AOC-2 -O-TBDMS-5 -O-DMTr-adenosine (S.16; Rf = 0.64) and then its 3 -O-TBDMS isomer (Rf = 0.40). 25. Finally, elute with ethyl acetate to collect the starting material (S.15). 26. Dissolve the 3 -isomer in 1.1 L of 1:5:5 (v/v/v) triethylamine/methanol/ethyl acetate and leave at room temperature for 12 hr to isomerize to the 2 -isomer. 27. Concentrate the resulting solution. Subject the residue to column chromatography using 50 g silica gel and elute the 2 - and 3 -isomers as described above. 28. Concentrate fractions including the desired product S.16 with a rotary evaporator. N6 -Allyloxycarbonyl-2 -O-(tert-butyldimethylsilyl)-5 -O-(4,4 -dimethoxytrityl)adenosine (S.16): 7.68 g (33%) as an amorphous solid. m.p. = 95◦ C. TLC (3:2 ethyl acetate/hexane): Rf = 0.64. UV λmax : 236 nm (ε 24,800), 268 (20,800). 1 H NMR (270 MHz, DMSO-d6 ): –0.15 (s, 3H), –0.05 (s, 3H), 0.73 (s, 9H), 3.27–3.68 (m, 2H), 3.71 (s, 6H), 4.11–4.28 (m, 2H), 4.63–4.65 (m, 2H), 4.86 (t, 1H, J = 4.8 Hz), 5.20 (s, 1H), 5.21 (dd, 1H, J = 1.7 and 10.55 Hz), 5.36 (dd, 1H, J = 1.7 and 17.3 Hz), 5.89–6.04 (m, 2H), 7.19–7.47 (m, 4H), 7.80–7.84 (m, 9H), 8.54 (s, 1H), 8.62 (s, 1H), 10.65 (s, 1H). Anal. calcd. for C41 H49 N5 O8 Si: C, 64.13; H, 6.43; N, 9.12; found: C, 64.12; H, 6.40; N, 8.72. After carrying out the isomerization procedure one time, 10.5 g (45% yield) of the 3 -Osilylated byproduct (Rf = 0.40; 3:2 ethyl acetate/hexane) remain. BASIC PROTOCOL 6
SYNTHESIS OF N4 -ALLYLOXYCARBONYL-2 -O(tert-BUTYLDIMETHYLSILYL)-5 -O-(4,4 -DIMETHOXYTRITYL)CYTIDINE This compound is prepared via (1) N4 -allyloxycarbonylation of cytidine by successive treatment with hexamethyldisilazane in the presence of ammonium sulfate as a catalyst, with allyloxycarbonyl chloride in the presence of N-methylimidazole, and with triethylamine in methanol to produce N4 -AOC-cytidine, (2) 5 -O-dimethoxytritylation by exposure to 4,4 -dimethoxytrityl chloride in pyridine to give N4 -AOC-5 -O-DMTr-cytidine, (3) tert-butyldimethylsilylation using tert-butyldimethylsilyl chloride in the presence of imidazole to afford a mixture of N4 -AOC-2 -O-TBDMS-5 -O-DMTr-cytidine and its 3 O-TBDMS isomer, and (4) chromatographic separation of this mixture on a silica gel column to furnish N4 -AOC-2 -O-TBDMS-5 -O-DMTr-cytidine. Following separation, the 3 -O-silylated byproduct is isomerized to increase the yield of the desired 2 -isomer. The overall reaction sequence is illustrated in Figure 2.12.6. All operations are carried out at room temperature unless otherwise noted.
Materials
Nucleobase Protection with Allyloxycarbonyl
Hexamethyldisilazane (HMDS), 99% (Aldrich, Shinetsu) Cytidine (S.17), 99% (Sigma) Ammonium sulfate, 99% (Aldrich, Wako) 1,4-Dioxane, distilled from sodium benzophenone ketyl Toluene, distilled from sodium benzophenone ketyl Dichloromethane, 99% (Aldrich, Nacarai Tesque) N-Methylimidazole, (Aldrich, Nacarai Tesque) Allyloxycarbonyl chloride (AOC-Cl), 99% (Aldrich, TCI) Methanol, 99% (Aldrich, Kishida) Triethylamine, distilled from CaH2 Ethyl acetate, 99% (Aldrich, Kishida) Diphosphorus pentoxide (P2 O5 ), 98% (Aldrich, Nacarai Tesque) Pyridine, distilled from CaH2 N,N -Dimethylformamide (DMF), distilled from 4A molecular sieves
2.12.14 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Figure 2.12.6
Preparation of N 4 -AOC-2 -O-TBDMS-5 -O-DMTr-cytidine.
4,4 -Dimethoxytrityl chloride (DMTr-Cl), 97% (Aldrich, TCI) Silica gel 60 (spherical, neutrality, particle size 75 µm; Merck, Nacarai Tesque) Imidazole, 99% (Aldrich, Nacarai Tesque) tert-Butyldimethylsilyl chloride (TBDMS-Cl), 99% (Aldrich, Shinetsu) Sodium sulfate, 99% (Aldrich, Nacarai Tesque) Hexane, 99% (Aldrich, Kishida) Rotary evaporator equipped with a diaphragm pump and cooling unit. Vacuum oil pump TLC plate: silica-coated glass plate with fluorescent indicator (Merck silica gel 60 F254 ) 254-nm UV lamp Glass column Diaphragm pump Additional reagents and equipment for column chromatography (APPENDIX 3E) and TLC (APPENDIX 3D) Prepare N4 -AOC-cytidine 1. Add 150 mL HMDS to a mixture of 15.0 g (61.7 mmol) cytidine (S.17) and a catalytic amount of ammonium sulfate in 150 mL dioxane. Reflux the mixture for 3 hr (b.p. 125◦ C, oil bath 145◦ C). 2. Evaporate the solvent on a rotary evaporator with a diaphragm pump and a cooling unit, and then dry the residue by co-evaporating twice with 100 mL dry toluene. 3. Dissolve the residue in 500 mL dichloromethane and add 6.70 mL (6.90 g, 84.0 mmol) N-methylimidazole followed by 8.90 mL (10.1 g, 83.9 mmol) AOCCl. Stir the mixture for 12 hr. 4. Evaporate the reaction mixture and dissolve the residue in a mixture of 500 mL methanol and 130 mL triethylamine. Stir the solution at room temperature for 12 hr.
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.15 Current Protocols in Nucleic Acid Chemistry
Supplement 23
5. Evaporate the reaction mixture with a rotary evaporator and collect the resulting solid residue. 6. Recrystallize the solid residue from a mixture of 30 mL methanol and 250 mL ethyl acetate. 7. Collect the crystals by filtering through a glass column with a cotton stopper under vacuum from a diaphragm pump. Wash with ethyl acetate. 8. Dry the crystals over P2 O5 at 50◦ C under vacuum with a vacuum oil pump. N4 -(Allyloxycarbonyl)cytidine (S.18): 20.0 g (99%) as colorless powdery crystals. m.p. 103◦ –107◦ C. TLC (1:9 methanol/dichloromethane): Rf = 0.3. 1 H NMR (400 MHz, DMSOd6 ): 3.57–3.97 (m, 5H), 4.62–4.64 (m, 2H), 5.03 (d, 1H, J = 5.4 Hz), 5.15 (t, 1H, J = 4.9 Hz), 5.22–5.38 (m, 2H), 5.47 (d, 1H, J = 4.4 Hz), 5.77 (d, 1H, J = 2.4 Hz), 5.91–5.98 (m, 1H), 7.00 (d, 1H, J = 7.3 Hz), 8.40 (d, 1H, J = 7.3 Hz), 10.80 (s, 1H). Anal. calcd. for C13 H17 N3 O7 ·1/2 H2 O: C, 46.43; H, 5.39; N, 12.49; found: C, 46.03; H, 5.16; N, 12.49.
Prepare N4 -AOC-5 -O-DMTr-cytidine 9. Prepare a solution of 9.52 g (33.4 mmol) S.18 in 150 mL of 1:1 (v/v) pyridine/DMF and cool to 0◦ C. 10. Add 15.6 g (46.0 mmol) DMTr-Cl in small portions over 20 min. Stir the mixture at the same temperature for 20 min and then at room temperature for 12 hr. 11. Pour the reaction mixture into 1.2 L of ice-cold water. 12. Collect the resulting precipitates by vacuum filtration as above, and wash with 300 mL water. 13. Dry the precipitates at 50◦ C under vacuum with a vacuum oil pump. 14. Dissolve the dried solid material in 50 mL dichloromethane and apply to a 500 g silica gel column (APPENDIX 3E). Monitor fractions by TLC (APPENDIX 3D) with 1:9 methanol/dichloromethane. Visualize under UV light (254 nm). Elute the column first with 1.5 L of 1:20 (v/v) methanol/dichloromethane to remove byproducts, and then with 1:9 (v/v) methanol/dichloromethane to collect the product (Rf = 0.64). 15. Combine fractions containing the desired product and concentrate using a rotary evaporator. 16. Crystallize the product from 200 mL methanol and collect the resulting crystals by vacuum filtration as above. N4 -Allyloxycarbonyl-5 -O-(4,4 -dimethoxytrityl)cytidine (S.19): 15.7 g (26.7 mmol, 80%) as colorless powdery crystals. m.p. 118◦ –120◦ C. TLC (1:9 methanol/dichloromethane): Rf = 0.64. 1 H NMR (400 MHz, CDCl3 ): 2.01 (br 1H), 3.38–3.48 (m, 2H), 3.79 (s, 6H), 4.38 (s, 3H), 4.67 (d, 2H, J = 5.4 Hz), 5.27–5.38 (m, 2H), 5.85–5.98 (m, 3H), 6.81–6.84 (m, 4H), 7.04 (d, 1H, J = 7.3 Hz), 7.20–7.36 (m, 9H), 8.23 (d, 1H, J = 7.3 Hz).
Prepare N4 -AOC-2 -O-TBDMS-5 -O-DMTr-cytidine 17. Prepare a solution of 15.4 g (26.1 mmol) S.19 in 25 mL DMF. Add 3.9 g (57.5 mmol) imidazole and begin stirring the mixture. 18. Add 4.33 g (28.8 mmol) TBDMS-Cl and continue stirring overnight. 19. Dilute the reaction mixture with 400 mL ethyl acetate and wash three times with 150 mL water. Nucleobase Protection with Allyloxycarbonyl
20. Dry the organic layer over ∼15 g sodium sulfate. Remove the drying agent by filtration through a glass column with a cotton stopper under vacuum from a diaphragm pump. Evaporate with a rotary evaporator.
2.12.16 Supplement 23
Current Protocols in Nucleic Acid Chemistry
21. Subject the residue to column chromatography on a 500 g silica gel column. Monitor fractions by TLC using 3:7 (v/v) ethyl acetate/hexane. 22. Elute first with 1:30:30 (v/v/v) methanol/ethyl acetate/hexane to collect the undesired 2 ,3 -di-O-silylated product (Rf = 0.70). In this preparation, 6.13 g (29% yield) of the 2 ,3 -di-O-silylated product are obtained.
23. Elute next with 1:20:20 (v/v/v) methanol/ethyl acetate/hexane and collect fractions containing first the desired N6 -AOC-2 -O-TBDMS-5 -O-DMTr-cytidine (S.20; Rf = 0.52) and then its 3 -O-TBDMS isomer (Rf = 0.37). 24. Finally, elute with ethyl acetate to collect the starting material (S.19). 25. Dissolve the 3 -isomer in 1.1 L of 1:5:5 (v/v/v) triethylamine/methanol/ethyl acetate and leave at room temperature for 12 hr to isomerize to the 2 -isomer. 26. Concentrate the resulting solution. Subject the residue to column chromatography using 50 g silica gel and elute the 2 - and 3 -isomers as described above. 27. Evaporate fractions containing S.20 with a rotary evaporator. N4 -Allyloxycarbonyl-2 -O-(tert-butyldimethylsilyl)-5 -O-(4,4 -dimethoxytrityl)cytidine (S.20): 4.05 g (22%) as an amorphous solid. m.p. = 110◦ C. TLC (3:7 ethyl acetate/ hexane): Rf = 0.52. 1 H NMR (400 MHz, CDCl3 ): 0.19 (s, 3H), 0.32 (s, 3H), 0.93 (s, 9H), 1.62 (br, 1H), 2.35 (d, J = 9.8 Hz, 1H), 3.51–3.60 (m, 2H), 3.81 (s, 6H), 4.08 (d, J = 7.8 Hz, 1H), 4.28–4.35 (m, 2H), 4.66 (d, J = 5.8 Hz, 2H), 5.28–5.38 (m, 2H), 5.89–5.97 (m, 2H), 6.85 (d, J = 8.8 Hz, 4H), 7.25–7.42 (m, 10H), 8.45 (d, J = 7.8 Hz, 1H). After carrying out the isomerization procedure one time, 2.58 g (14% yield) of the 3 -Osilylated byproduct (Rf = 0.37; 3:7 ethyl acetate/hexane) remain.
SYNTHESIS OF N2 -ALLYLOXYCARBONYL-O6 -ALLYL-2 -O-(tertBUTYLDIMETHYLSILYL)-5 -O-(4,4 -DIMETHOXYTRITYL)GUANOSINE
BASIC PROTOCOL 7
This compound is synthesized by (1) tri-O-acetylation of guanosine using acetic anhydride in pyridine to give 2 ,3 ,5 -tri-O-(acetyl)guanosine, (2) O6 -allylation by treatment with allyl alcohol in the presence of triphenylphosphine, dioxane, and diethyl azodicarboxylate to afford O6 -allyl-2 ,3 ,5 -tri-O-(acetyl)guanosine, (3) N-allyloxycarbonylation by treatment with allyloxycarbonyl chloride in the presence of tert-butylmagnesium chloride and tetrahydrofuran to produce N2 -AOC-O6 -allyl-2 ,3 ,5 -tri-O-(acetyl)guanosine, (4) removal of the acetyl protecting groups using sodium hydroxide in ethanol to give N2 -AOC-O6 -(allyl)guanosine, (5) 5 -O-dimethoxytritylation by treatment with 4,4 dimethoxytrityl chloride in pyridine and N,N-dimethylformamide to provide N2 -AOCO6 -allyl-5 -O-DMTr-guanosine, and (6) O-silylation with tert-butyldimethylsilyl in the presence of imidazole and N,N-dimethylformamide. Following silylation, the desired 2 -O-silylated product, N2 -AOC-O6 -allyl-2 -O-TBDMS-5 -O-DMTr-guanosine, is separated from the 3 -O-silylated and 2 ,3 -di-O-silylated byproducts by chromatography, and the 3 -O-silylated product is isomerized to increase the yield of the desired 2 -O-silylated product. The overall reaction sequence is illustrated in Figure 2.12.7. All operations are carried out at room temperature unless otherwise noted.
Materials Guanosine (S.21), 99% (Aldrich) Pyridine, distilled from CaH2 N,N -Dimethylformamide (DMF), distilled from 4A molecular sieves Acetic anhydride, 99% (Aldrich, Kishida) 2-Propanol, 99% (Aldrich, Kishida) Triphenylphosphine, recrystallized from hexane
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.17 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Figure 2.12.7
Preparation of N 2 -AOC-O 6 -allyl-2 -O-TBDMS-5 -O-DMTr-guanosine.
Allyl alcohol, distilled from Mg 1,4-Dioxane, distilled from sodium benzophenone Diethyl azodicarboxylate (DEAD), 40% solution in toluene (Aldrich, TCI) Dichloromethane, 99% (Aldrich, Nacarai Tesque) Silica gel 60 (spherical, neutrality, particle size 75 µm; Merck, Nacarai Tesque) Ethyl acetate, 99% (Aldrich, Kishida) Hexane, 99% (Aldrich, Kishida) Tetrahydrofuran (THF), distilled from sodium benzophenone ketyl Allyloxycarbonyl chloride (AOC-Cl), 99% (Aldrich, TCI) tert-Butylmagnesium chloride, 99% (Aldrich) Methanol, 99% (Aldrich, Kishida) Saturated aqueous ammonium chloride (99%; Aldrich, Kishida) Aqueous saturated sodium hydrogencarbonate (NaHCO3 ; 99%; Aldrich, Nacarai Tesque) Brine: aqueous saturated sodium chloride Ethanol, 99.5% (Aldrich, Nacarai Tesque) Sodium hydroxide 80% (v/v) aqueous acetic acid 4,4 -Dimethoxytrityl chloride (DMTr-Cl), 97% (Aldrich, TCI) Sodium sulfate, 99% (Aldrich, Nacarai Tesque) Imidazole, 99% (Aldrich, Nacarai Tesque) tert-Butyldimethylsilyl chloride (TBDMS-Cl), 99% (Aldrich, Shinetsu) Triethylamine, distilled from CaH2
Nucleobase Protection with Allyloxycarbonyl
Vacuum oil pump Rotary evaporator equipped with a diaphragm pump and cooling unit TLC plate: silica-coated glass plate with fluorescent indicator (Merck silica gel 60 F254 ) 254-nm UV lamp Glass column Diaphragm pump Additional reagents and equipment for column chromatography (APPENDIX 3E) and TLC (APPENDIX 3D)
2.12.18 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Prepare 2 ,3 ,5 -tri-O-(acetyl)guanosine 1. Prepare a suspension of 15 g (52.9 mmol) guanosine (S.21) in a mixture of 15 mL pyridine and 37.5 mL DMF. 2. Add 30 mL (317 mmol) acetic anhydride, heat to 70◦ C, and stir for 3 hr at this temperature. 3. Cool the mixture to room temperature. 4. Add 100 mL 2-propanol and stir for 30 min. 5. Collect the resulting precipitates by filtering through a glass column with a cotton stopper under vacuum from a diaphragm pump. Wash with 300 mL 2-propanol. 6. Dry the precipitates under reduced pressure with a vacuum oil pump. 2 ,3 ,5 -Tri-O-(acetyl)guanosine (S.22): 17.4 g (79%) as a white solid. m.p. 230◦ –234◦ C. 1 H NMR (400 MHz, DMSO-d6 ): 2.04 (2 s, 6H), 2.11 (s, 3H), 4.23–4.39 (m, 3H), 5.48–5.51 (m, 1H), 5.79 (t, J = 5.9 Hz, 1H), 5.98 (d, J = 6.1 Hz, 1H), 7.92 (s, 1H), 10.72 (br, 1H).
Prepare N2 -AOC-O6 -(allyl)guanosine 7. Add 5.40 g (20.6 mmol) triphenylphosphine and 7.50 mL (6.41 g, 110 mmol) allyl alcohol to a suspension of 4.90 g (12.0 mmol) S.22 in 90 mL dry dioxane. Heat the mixture at 80◦ C for 45 min. 8. Cool the reaction mixture to room temperature. Add 3.50 mL (3.71 g, 21.3 mmol) diethyl azodicarboxylate and then heat at 60◦ C for 3 hr. 9. Evaporate the reaction mixture and dissolve the residue in 15 mL dichloromethane. Keep the solution in a refrigerator (at 4◦ C) for 2 to 3 hr. If no precipitate forms during this time, cool for another 2 to 3 hr.
10. Remove the resulting precipitates by vacuum filtration as above, and wash with 50 mL cold dichloromethane. 11. Combine the filtrates and concentrate on a rotary evaporator with a diaphragm pump and a cooling unit. 12. Subject the residue to column chromatography (APPENDIX 3E) using 250 g silica gel. Monitor fractions by TLC (APPENDIX 3D) using 3:1 (v/v) ethyl acetate/hexane. Visualize under UV light (254 nm). Elute the column first with 1.5 L of 3:7 (v/v) ethyl acetate/hexane to remove undesired byproducts, and then with 3:2 (v/v) ethyl acetate/hexane obtain the target compound (Rf = 0.48). 13. Evaporate the fractions containing the desired product with a rotary evaporator. O6 -Allyl-2 ,3 ,5 -tri-O-(acetyl)guanosine: 4.30 g (80%) as a colorless amorphous solid. TLC (3:1 ethyl acetate/hexane): Rf = 0.48. 1 H NMR (400 MHz, DMSO-d6 ): 2.03 (s, 6H), 2.12 (s, 3H), 4.25–4.42 (m, 3H), 4.95 (d, 2H, J = 5.9 Hz), 5.26 (d, 1H, J = 10.3 Hz), 5.40 (dd, 1H, J = 1.5 and 19.0 Hz), 5.54–5.56 (m, 1H), 5.86–5.89 (m, 1H), 6.07–6.12 (m, 2H), 6.55 (s, 2H), 8.11 (s, 1H).
14. Dissolve the residue in 60 mL THF and add 3.00 mL (28.3 mmol) AOC-Cl. 15. Cool the solution to 5◦ C and add dropwise (over 10 min) 18.0 mL (25.2 mmol) of 1.4 M tert-butylmagnesium chloride in THF. Stir at the same temperature for an additional 60 min. 16. Quench the reaction by adding 3 mL methanol. 17. Dilute the mixture with 100 mL ethyl acetate and wash with 100 mL aqueous saturated ammonium chloride.
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.19 Current Protocols in Nucleic Acid Chemistry
Supplement 23
18. Wash the organic layer with 100 mL aqueous saturated NaHCO3 followed by 100 mL brine. 19. Evaporate the organic solution with a rotary evaporator. 20. Purify residue by column chromatography using 250 g silica gel with 2:3 (v/v) ethyl acetate/hexane as eluent. Monitor by TLC using 1:1 ethyl acetate/hexane (Rf = 0.53). 21. Concentrate fractions containing the desired compound with a rotary evaporator. N2 -Allyloxycarbonyl-O6 -allyl-2 ,3 ,5 -tri-O-(acetyl)guanosine: 3.90 g (66%) as an oily product. TLC (1:1 ethyl acetate/hexane): Rf = 0.53. 1 H NMR (400 MHz, DMSO-d6 ): 1.96 (s, 3H), 2.02 (s, 3H), 2.10 (s, 3H), 4.40–4.18 (m, 3H), 4.68–4.67 (m, 4H), 5.04 (d, 2H, J = 5.4 Hz), 5.60–5.15 (m, 6H), 5.74–5.73 (m, 1H), 5.91–5.81 (m, 3H), 6.12–6.06 (m, 1H), 6.27 (d, 1H, J = 3.4 Hz), 8.69 (s, 1H). FAB-MS: m/z 618 (M+ + H).
22. Dissolve residue in 35 mL ethanol and add 200 mL of 0.1 M sodium hydroxide in 95% ethanol. Stir the resulting mixture for 30 min. 23. Add the reaction mixture to 30 mL of 80% aqueous acetic acid and evaporate with a rotary evaporator. 24. Purify residue by chromatography on a short 50 g silica gel column with 1:5:5 (v/v/v) methanol/ethyl acetate/hexane as eluent. Monitor fractions by TLC using 1:10 (v/v) methanol/dichloromethane (Rf = 0.35). 25. Concentrate fractions containing the target product with a rotary evaporator. N2 -Allyloxycarbonyl-O6 -(allyl)guanosine (S.23): 2.55 g (52% overall yield) as an amorphous solid. TLC (1:10 methanol/dichloromethane): Rf = 0.35. 1 H NMR (400 MHz, DMSO-d6 ): 3.52–3.54 (m, 1H), 3.62–3.65 (m, 1H), 3.90–3.91 (m, 1H), 4.17 (m, 1H), 4.61–4.62 (m, 3H), 4.93 (br s, 1H), 5.04–5.05 (m, 2H), 5.16–5.48 (m, 6H), 5.88 (d, 1H, J = 5.9 Hz), 5.91–6.00 (m, 1H), 6.12–6.19 (m, 1H), 8.43 (s, 1H), 10.38 (s, 1H). FAB-MS (C17 H21 N5 O7 ): m/z 408 (M+ + H).
Prepare N2 -AOC-O6 -allyl-5 -O-DMTr-guanosine 26. Add 1.54 g (4.55 mmol) DMTr-Cl to a solution of 1.73 g (4.25 mmol) S.23 in 20 mL of 1:1 (v/v) pyridine/DMF. Heat at 55◦ C for 1.5 hr. 27. Pour into 100 mL of saturated aqueous NaHCO3 and extract three times with 30 mL ethyl acetate. 28. Dry the combined organic extracts over ∼15 g sodium sulfate. Remove the drying agent by filtration through a glass column with a cotton stopper under vacuum from a diaphragm pump. Evaporate with a rotary evaporator. 29. Subject residue to column chromatography using 100 g silica gel. Monitor elution by TLC using 3:1 (v/v) ethyl acetate/hexane. Elute first with 1.5 L of 3:7 (v/v) ethyl acetate/hexane to remove byproducts, and then with 3:2 (v/v) ethyl acetate/hexane to collect fractions containing the target product (Rf = 0.61). 30. Concentrate the fractions with a rotary evaporator.
Nucleobase Protection with Allyloxycarbonyl
N2 -Allyloxycarbonyl-O6 -allyl-5 -O-(4,4 -dimethoxytrityl)guanosine (S.24): 2.31 g (77%) as colorless foam. TLC (3:1 ethyl acetate/hexane): Rf = 0.61. UV λmax : 237 nm (ε 26,800), 269 (17,400). 1 H NMR (400 MHz, DMSO-d6 ): 3.16–3.56 (m, 2H), 3.69 (s, 3H), 3.70 (s, 3H), 4.02–4.03 (m, 1H), 4.33–4.37 (m, 1H), 4.59–4.60 (m, 2H), 4.69–4.72 (m, 1H), 5.04 (d, 2H, J = 4.9 Hz), 5.10 (d, 1H, J = 5.9 Hz), 5.22 (d, 1H, J = 10.7 Hz), 5.29 (d, 1H, J = 10.7 Hz), 5.38 (d, 1H, J = 17.6 Hz), 5.47 (d, 1H, J = 17.1 Hz), 5.57 (d, 1H, J = 5.9 Hz), 5.92–5.99 (m, 2H), 6.13–6.20 (m, 1H), 6.72–6.78 (m, 4H), 7.16 (m, 9H), 8.33 (s, 1H), 10.34 (s, 1H). Anal. calcd. for C38 H39 N5 O9 : C, 64.31; H, 5.54; N, 9.87; found: C, 64.32; H, 5.46; N, 9.69.
2.12.20 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Prepare N2 -AOC-O6 -allyl-2 -O-TBDMS-5 -O-DMTr-guanosine 31. Add 0.29 g (4.3 mmol) imidazole to a solution of 1.38 g (1.94 mmol) S.24 in 2 mL DMF. 32. Add 0.32 g (2.1 mmol) TBDMS-Cl and stir at 60◦ C for 1 hr. 33. Pour the reaction mixture into 50 mL ice-cold water and extract three times with 20 mL ethyl acetate. 34. Combine the organic extracts, dry over sodium sulfate, and evaporate with a rotary evaporator. 35. Purify residue by column chromatography over 75 g silica gel. Monitor fractions by TLC using 3:7 (v/v) ethyl acetate/hexane. 36. Elute first with 2:8 (v/v) ethyl acetate/hexane to separate the 2 ,3 -di-O-silylated product (Rf = 0.67). In this preparation, 613 mg (38% yield) of the 2 ,3 -di-O-silylated product are obtained.
37. Elute next with 1:3 (v/v) ethyl acetate/hexane and collect fractions containing first the desired N2 -AOC-O6 -allyl-2 -O-TBDMS-5 -O-DMTr-guanosine (S.25; Rf = 0.34) and then its 3 -O-TBDMS isomer (Rf = 0.22). 38. Finally, elute with ethyl acetate to collect the starting material (S.24). 39. Dissolve the 3 -isomer in 1.1 L of 1:5:5 (v/v/v) triethylamine/methanol/ethyl acetate and leave at room temperature for 12 hr to isomerize to the 2 -isomer. 40. Concentrate the resulting solution. Subject the residue to column chromatography using 50 g silica gel and elute the 2 - and 3 -isomers as described above. 41. Combine all fractions containing the desired product (S.25) and concentrate with a rotary evaporator. N2 -Allyloxycarbonyl-O6 -allyl-2 -O-(tert-butyldimethylsilyl)-5 -O-(4,4 -dimethoxytrityl) guanosine (S.25): 457 mg (29% yield) as an amorphous solid. m.p. = 81◦ C. TLC (3:7 ethyl acetate/hexane): Rf = 0.34. UV λmax : 237 nm (ε 24,300), 269 (15,900). 1 H NMR (400 MHz, DMSO-d6 ): –0.16 (s, 3H), –0.05 (s, 3H), 0.74 (s, 9H), 3.21–3.24 (m, 1H), 3.35–3.56 (m, 1H), 3.70 (s, 3H), 3.71 (s, 3H), 3.74–4.05 (m, 1H), 4.24–4.28 (m, 1H), 4.57–4.58 (m, 2H), 4.88–4.89 (m, 1H), 4.96–4.98 (m, 1H), 5.04 (d, 2H, J = 5.9 Hz), 5.21 (dd, 1H, J = 1.71 and 10.5 Hz), 5.30 (d, 1H, J = 10.2 Hz), 5.37 (dd, 1H, J = 1.5 and 17.1 Hz), 5.45 (dd, 1H, J = 1.5 and 17.1 Hz), 5.92–5.99 (m, 2H), 6.12–6.19 (m, 1H), 6.75–6.80 (m, 4H), 7.15–7.34 (m, 9H), 8.33 (s, 1H), 10.25 (s, 1H). Anal. calcd. for C44 H53 N5 O9 Si: C, 64.14; H, 6.48; N, 8.50; found: C, 64.13; H, 6.43; N, 8.35. After carrying out the isomerization procedure one time, 213 mg (12% yield) of the 3 -O-silylated byproduct (Rf = 0.22; 3:7 ethyl acetate/hexane) remain.
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
1-(Allyloxycarbonyl)tetrazole (AOC-Tet) Add 12.0 mL (0.113 mol) allyloxycarbonyl chloride (AOC-C1; 99%; Aldrich, TCI) dropwise to a solution of 7.0 g (0.100 mol) 1H-tetrazole (99%; Dozindo) and 15.0 mL (0.108 mol) triethylamine in 150 mL tetrahydrofuran (THF) at 0◦ C over 15 min. Stir the resulting mixture for 30 min. Remove the resulting precipitates by vacuum filtration through a pad of Celite 545 (Aldrich, Nacarai Tesque) and wash with 150 mL THF. Concentrate the resulting THF solution containing AOC-Tet to ∼30 mL. Prepare immediately before use. AOC-Tet is used for N-allyloxycarbonylation of 2 -deoxyadenosine. Current Protocols in Nucleic Acid Chemistry
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.21 Supplement 23
Allyl 1-benzotriazolyl carbonate (AOCOBT) To a solution of 13.5 g (0.10 mol) 1-hydroxybenzotriazole and 16.7 mL (0.12 mol) triethylamine in 350 mL tetrahydrofuran, add 11.8 mL (0.11 mol) allyloxycarbonyl chloride (AOC-C1; 99%; Aldrich, TCI) dropwise with vigorous stirring at 0◦ C. Continue stirring for an additional 10 min. Remove the resulting precipitates by vacuum filtration through a pad of Celite 545 (Aldrich, Nacarai Tesque). Wash the pad three times with 30 mL ethyl acetate. Combine the filtrate and washes, and evaporate the solvent using a rotary evaporator with a diaphragm pump and a cooling unit. Recrystallize the resulting crystalline residue from 100 mL ethyl acetate. Prepare immediately before use. AOCOBT is used for N-allyloxycarbonylation of 2 -deoxycytidine. Yield: (19.9 g, 91%) as a white solid. m.p. 107◦ –111◦ C. IR (KBr) 1760, 1430, 1390, 1260, 770 cm−1 . UV λmax : 236 nm (ε 13,900), 321 (11,800), 334 (10,000). 1 H NMR: 5.07 (dt, 2H, J = 5.4 and 1.8 Hz, =CH2 ), 5.4–5.7 (m, 2H, CH2 CH= =CH2 ), 6.14 (ddt, 1H, J = 10.2, 17.1, and 5.4 Hz, CH2 CH= CH2 CH= =CH2 ), 7.5–8.3 (m, 4H, arom. protons).
COMMENTARY Background Information
Nucleobase Protection with Allyloxycarbonyl
Currently, the synthesis of oligodeoxyribonucleotides and oligoribonucleotides is most generally achieved via the phosphoramidite method, in which acyl and aroyl protecting groups (including benzoyl, panisoyl, and isobutyryl groups) are normally used for protection of nucleobases (Letsinger et al., 1975; Beaucage and Caruthers, 1981; Matteucci and Caruthers, 1981; McBride and Caruthers, 1983; Sinha et al., 1983; Dorman et al., 1984). However, the acyl and aroyl N-protecting groups are not useful for the synthesis of compounds with base-labile functions, because these protecting groups require heating, usually at 55◦ C, for several hours with concentrated aqueous ammonia. In order to improve on the acyl/aroyl protection of nucleobases, alternative protecting groups have been developed; the representative ones are phenoxyacetyl (Schulhof et al., 1987), isopropoxyacetyl (Uznanski et al., 1989; Vinogradov et al., 1993), tertbutylphenoxyacetyl (K¨oster et al., 1981), 2-(acetoxymethyl)benzoyl (Kuijpers et al., 1990), 2-(tert-butyldiphenylsilyloxymethyl) benzoyl (Dreef-Tromp et al., 1990), formamidine (Vu et al., 1990), 9-fluorenylmethoxycarbonyl (Koole et al., 1989), and 2-(pnitrophenyl)ethoxycarbonyl (Himmelsbach et al., 1984). Removal of these protecting groups can be achieved under rather mild conditions, but still requires basic reagents, thus involving a risk of undesirable decomposition in the synthesis of base-sensitive derivatives. In addition, some of these protecting groups are themselves labile to bases, and are
thus at risk from basic treatment during synthesis. There is thus a strong demand for a nucleobase-protecting group that can be removed under non-basic and mild conditions but is stable under conditions employed for the oxidation of the phosphite intermediate and the removal of the 5 -O-DMTr group using dichloroacetic acid. The allyloxycarbonyl (AOC) group is one example of an N-protecting group that meets these requirements. The AOC group is quite stable to acids, including dichloroacetic acid and trichloroacetic acid; to bases, including concentrated ammonia; and to oxidizing agents such as an I2 /H2 O/pyridine mixture, tert-butyl hydroperoxide (Hayakawa et al., 1986a), bis(trimethylsilyl) peroxide in the presence of trimethylsilyl triflate (Hayakawa et al., 1986a), and 2-butanone peroxide (Kataoka et al., 2001). These are reagents that are normally used for the synthesis of nucleotides via the phosphoramidite method. By contrast, the AOC group is very sensitive to organic Pd(0) complexes such as =CH)2 CO]3 · Pd[P(C6 H5 )3 ]4 or Pd2 [(C6 H5 CH= CHCl3 in the presence of a nucleophile, leading to clean and smooth removal of the protecting group. As the nucleophile, butylammonium formate, diethylammonium hydrogencarbonate, diethylammonium carbonate, or dimedone can be used. The deprotection is performed under nearly neutral conditions (Hayakawa et al., 1986b). The AOC group is stable under conditions normally employed for conversion of the protected nucleoside to the 3 -phosphoramidite using an (alkoxy)bis(diisopropylamino)phosphine
2.12.22 Supplement 23
Current Protocols in Nucleic Acid Chemistry
in the presence of isopropylammonium tetrazolide (Hayakawa et al., 1990; Heidenhain and Hayakawa, 1999).
Compound Characterization Chemical characterization data are provided for all compounds. NMR spectra were recorded on a JEOL JNM-α400 or ECA-500 instrument. The 1 H, 13 C, and 31 P NMR chemical shifts are described as δ values in ppm relative to (CH3 )4 Si (for 1 H and 13 C) and 85% H3 PO4 (for 31 P). Infrared (IR) spectra were measured with a JASCO FT/IR-460 spectrometer. Ultraviolet (UV) spectra were obtained in methanol, unless otherwise noted, on a JASCO V-550 spectrometer.
Critical Parameters and Troubleshooting
For 2 -deoxycytidine, adenosine, and cytidine, allyloxycarbonylation of the parent nucleoside takes place at the amino group of the nucleobase in a chemoselective manner to give the desired product in a satisfactory yield. Therefore, preparation of N4 -AOC-5 -O-DMTr-2 -deoxycytidine, N6 AOC-5 -O-DMTr-adenosine, and N4 -AOC5 -O-DMTr-cytidine can be carried out by N-allyloxycarbonylation followed by dimethoxytritylation, which is the shortest and most convenient route. In contrast, allyloxycarbonylation of 2 -deoxyadenosine takes place competitively at the amino group of the nucleobase and at the 5 - and 3 hydroxy groups, so that the desired Nallyloxycarbonylated product is not obtained in a high yield. Dimethoxytritylation of deoxyadenosine, however, is achieved in a highly 5 -O-selective manner. For this reason, although it is more tedious, N6 -AOC-5 -ODMTr-2 -deoxyadenosine should be prepared by 5 -O-dimethoxytritylation, 3 -O-silylation, N-allyloxycarbonylation, and finally removal of the 3 -O-TBDMS protecting group. In Basic Protocol 1, dimethoxytritylation of 2 -deoxyadenosine takes place regioselectively at the 5 -hydroxyl under the conditions described in the text, but the reaction does not go to completion, leaving a small amount of unmodified 2 -deoxyadenosine. Nevertheless, the amount of 4,4 -dimethoxytrityl chloride should never be increased. When extra dimethoxytrityl chloride is added, 3 O-dimethoxytritylation leads to formation of 3 ,5 -di-O-DMTr-2 -deoxyadenosine, and separation of this compound from the target 5 O-DMTr derivative is rather tedious. The allyloxycarbonyl tetrazolide (AOC-Tet) reagent
used for the N-allyloxycarbonylation of S.2 is rather sensitive to moisture; thus, the reaction should be carried out with all possible precautions for maintaining anhydrous conditions. If the reaction is not satisfactory, dry the AOCTet reagent by co-evaporation with toluene before use. In trimethylsilylation of 2 -deoxycytidine, adenosine, and cytidine (in Basic Protocol 2, 5, and 6), the parent nucleoside is not completely dissolved in the reaction solvent, and thus the reaction mixture is heterogeneous at the initial stage. However, since the di-O-silylated 2 deoxycytidine and the tri-O-silylated adenosine and cytidine are all soluble in the reaction solvent, the mixtures become homogeneous as the reactions go to completion. For the N-allyloxycarbonylation of di-Osilylated 2 -deoxycytidine, the use of the AOCOBT reagent is crucial for obtaining the desired product in a satisfactory yield. When AOC-Tet is used, a complex mixture is formed. In most cases, the trimethylsilyl protecting groups of the product resulting from N-allyloxycarbonylation are completely eliminated during aqueous workup (see Basic Protocol 2, step 4). However, in some cases the desilylation is not completely achieved, so it is important to check by TLC or 1 H NMR whether the silyl groups have been removed completely. If desilylation was incomplete, an excess of triethylamine in methanol (25◦ C, 30 min) can be used to complete the deprotection. In the preparation of N6 -AOC-2 -OTBDMS-5 -O-DMTr-adenosine, the compound is separated by silica column chromatography from its 3 -O-TBDMS isomer, which is produced in an almost equal amount. Efficiency of the separation strongly depends on the activity of the silica gel. Because it is very difficult to use silica gel of the same activity in every experiment, reproducibility of this separation is not very high. If chromatography under conditions described in this unit do not allow fine separation, repeat the separation using a larger amount of silica gel. The same attention is required in the purification of N4 -AOC-2 -O-TBDMS-5 -O-DMTrcytidine and N2 -AOC-O6 -allyl-2 -O-TBDMS5 -O-DMTr-guanosine. The undesired 3 -Osilylated isomers of these three ribonucleoside derivatives can be partially (∼50%) converted to the desired 2 -O-silylated compounds by treatment (25◦ C, overnight) with a 1:5:5 mixture of triethylamine, methanol, and ethyl acetate (Heidenhain and Hayakawa, 1999).
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.23 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Nucleobase Protection with Allyloxycarbonyl
Several methods have been developed for preparation of N-allyloxycarbonylated 5 O-DMTr-guanosine and -2 -deoxyguanosine derivatives. Among them, the approaches described in this text provide the best yields of the target compounds. Because the C(2)NH2 group of guanine has low reactivity to acylation, the amino group does not undergo allyloxycarbonylation using AOC-Cl, AOC-Tet, and AOC-OBT. As a result, Nallyloxycarbonylation of guanosine and 2 deoxyguanosine derivatives requires a tedious and tricky procedure. The NH2 group is first activated by treatment with tertbutylmagnesium chloride to give the magnesium amide, which then is reacted with AOCCl to produce the desired compound. In this procedure, three equivalents of the Grignard reagent should be used, because two equivalents are consumed for neutralizing two protons of higher acidity than C(2)-NH2 , i.e., N(1)H and C(2)-NHCOOCH2 CH= =CH2 of the allyloxycarbonylated product. The Grignard reagent is extremely sensitive to moisture and oxygen (air). Therefore, this reaction should be carried out with great care to exclude moisture. Dryness of the THF used as the reaction solvent is critical. The solvent should be freshly distilled from sodium benzophenone immediately before use. In some cases (not always), it is necessary to dry the starting materials S.8 and S.22 by co-evaporation with toluene. For the derivatives presented in this unit, it is recommended that an alkyl group be introduced to the O6 position (although this is not always necessary), because it greatly increases the solubility of guanosine derivatives in organic solvents, reducing the required volume of solvents in later reaction steps. Use of the allyl group is most strongly recommended, as it can be removed at the same time as the N-allyloxycarbonyl group by the organopalladium-catalyzed reaction. In the O6 -allylation of the guanine base described in Basic Protocol 4, the O6 -sulfonylguanosine derivative produced as an intermediate should be used as soon as possible (within a few days) after preparation, because this compound is not absolutely stable, particularly to moisture. Trimethylamine, which is used for the next step (the conversion of the O6 sulfonylguanosine derivative to the O6 -allyl compound S.11), is a toxic gas (b.p. 3◦ –4◦ C) with an unpleasant odor, and should be used in a well-ventilated hood. Recently, it was reported that the use of a mixture of triethylamine (b.p. 88◦ –89◦ C) and DABCO in place of the trimethylamine and DBU described in
this text serves as a useful promoter for the reaction of the O6 -sulfonylguanosine and an alcohol to give the O6 -alkyl compound (Grotli et al., 1997). Use the former mixture might be preferred. The allylation of S.22 by means of Mitsunobu reaction takes place specifically at the O6 position. No N(1)-allylated product is formed. In this reaction, perfect separation of the desired product and triphenylphosphine oxide is considerably difficult, and the allylated product often contains a small amount of the phosphine oxide following a single purification by chromatography. In such cases, it is necessary to repeat the chromatography to obtain pure material. Alternatively, an effective method for removing the phosphine oxide is to dissolve the chromatographed product in ethyl acetate, leave it in a refrigerator at 4◦ C, and remove the resulting precipitates (triphenylphosphine oxide) by vacuum filtration. For protection of hydroxyl groups on the carbohydrate moiety, use of the TBDMS and acetyl groups are recommeded for 2 deoxyguanosine and guanosine derivatives, respectively. In the authors’ experience, use of acetyl for protection of deoxyguanosine hydroxyls or TBDMS for protection of guanosine hydroxyls leads to markedly decreased yields of the desired products. In triacetylation of guanosine in Basic Protocol 7, guanosine is not sufficiently dissolved in a mixture of DMF and pyridine, and thus the reaction mixture is heterogeneous at the starting point. As the reaction proceeds, the mixture becomes nearly homogeneous, perhaps because the monoacetylated product is soluble, although this has not been determined. Finally, the mixture becomes heterogeneous again because the target is not completely soluble. In the authors’ experience, no N2 acetylated compound was produced in this reaction. However, since N-acetylation can occur, the reaction time and temperature should not be modified from the conditions given in the protocol, in order to avoid this side reaction.
Anticipated Results The allyloxycarbonyl group serves as a protecting group for not only nucleobases but also the sugar hydroxy groups of nucleosides. Further, in the synthesis of nucleotides, the allyl group has been developed as a protecting group for internucleotide linkages. This protecting group is also removed by means of the abovementioned organopalladium method under mild, nearly neutral
2.12.24 Supplement 23
Current Protocols in Nucleic Acid Chemistry
conditions (Hayakawa et al., 1985). Accordingly, the combined use of allyloxycarbonyl and allyl groups for the protection of nucleobases and/or hydroxyls and internucleotide linkages, respectively, has allowed for the efficient synthesis of a variety of natural and artificial nucleic acid– related compounds with base-sensitive structures and functions, producing them in higher yields and at greater levels of purity than methods that use acyl or aroyl and 2cyanoethyl groups for protection of nucleobases and internucleotide linkages, respectively. Compounds prepared by means of the allyl-protection method include O-(cytidine5 -monophosphono)-N-acetylneuraminic acid (CMP-Neu5Ac; Makino et al., 1993), 5 cytosinearabinosyl 5-nitrofurufuryl N-methylN-(4-chlorobutyl) phosphoramidate (Tobias and Borch, 2004), adenylyl(2 –5 )adenylyl(2 – 5 )adenosine (2–5A core; Hayakawa et al., 2001), oligodeoxyribonucleotides with the enzyme-labile 2-(acetylthio)ethyl group on the internucleotide linkage (Spinelli et al., 2002), nucleotide-peptide conjugates with base-labile phosphodiester linkers (Sakakura and Hayakawa, 2000; Jeyaraj and Waldmann, 2001), a DNA oligomer with sitespecific addition of alkaline-labile and mutagenic and/or cytotoxic (5R)-5,6-dihydro5-hydroxythymidine (Matray and Greenberg, 1994), N-acetylcytidine-incorporated RNA oligomers (Bogdan and Chow, 1998), and 2 -deoxy-3-isoadenosine-incorporated DNA oligomers (Bhat et al., 1996). The allylprotection method also allows for high yield and high purity in the synthesis of normal DNA (Hayakawa et al., 1990) and RNA (Hayakawa et al., 2001) oligomers.
Time Considerations Approximate times required for preparation, workup, and purification of key compounds are as follows: S.2: 3 days; S.3: 2 days; S.6: 3 days; S.8: 2 days; S.9: 1 days, S.10: 3 days, S.11: 2 days, S.12: 3 days, S.14: 2 days, S.15: 2 days, S.16: 3 days, S.18: 2 days, S.19: 2 days, S.20: 3 days, S.22: 1 days, S.23: 3 days, S.24: 2 days, S.25: 3 days.
Literature Cited Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites—a new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862. Bhat, B., Neelima, H., Leonard, N.J., Robinson, H., and Wang, A.H.-J. 1996. 2 -Deoxy-3isoadenosine forms Hoogsteen-type base pairs
with thymidine in the d(CG[iA]TCG)2 duplex. J. Am. Chem. Soc. 118:3065-3066. Bogdan, F.M. and Chow, C.S. 1998. The synthesis of allyl- and allyloxycarbonyl-protected RNA phosphoramidites. Useful reagents for solidphase synthesis of RNAs with base-labile modifications. Tetrahedron Lett. 39:1897-1900. Dorman, M.A., Noble, S.A., McBride, L.J., and Caruthers, M.H. 1984. Synthesis of oligodeoxynucleotides and oligodeoxynucleotide analogs using phosphoramidite intermediates. Tetrahedron 40:95-102. Dreef-Tromp, C.M., Hoogerhout, P., van der Marel, G.A., and van Boom, J.H. 1990. A new protected acyl protecting group for exocyclic amino functions of nucleobases. Tetrahedron Lett. 31:427430. Grotli, M., Douglas, M., Beijer, B., Garcia, G., Eritja, R., and Sproat, B. 1997. Protection of the guanine residue during synthesis of 2 O-alkylguanosine derivatives. J. Chem. Soc., Perkin Trans. 1 18:2779-2788. Hayakawa, Y., Uchiyama, M., Kato, H., and Noyori, R. 1985. Allyl protection of internucleotide linkage. Tetrahedron Lett. 26:6505-6508. Hayakawa, Y., Uchiyama, M., and Noyori, R. 1986a. Nonaqueous oxidation of nucleoside phosphites to the phosphates. Tetrahedron Lett. 27:4191-4194. Hayakawa, Y., Kato, H., Uchiyama, M., Kajino, H., and Noyori, R. 1986b. Allyloxycarbonyl group: A versatile blocking group for nucleotide synthesis. J. Org. Chem. 51:2400-2402. Hayakawa, Y., Wakabayashi, S., Kato, H., and Noyori, R. 1990. The allylic protection method in solid-phase oligonucleotide synthesis. An efficient preparation of solid-anchored DNA oligomers. J. Am. Chem. Soc. 112:1691-1696. Hayakawa, Y., Kawai, R., Hirata, A., Sugimoto, J., Kataoka, M., Sakakura, A., Hirose, M., and Noyori, R. 2001. Acid/azole complexes as highly effective promoters in the synthesis of DNA and RNA oligomers via the phosphoramidite method. J. Am. Chem. Soc. 123:81658176. Heidenhain, S.B. and Hayakawa, Y. 1999. Improved methods for the preparation of 2 deoxyribonucleoside and ribonucleoside 3 phosphoramidites with allylic protectors. Nucleosides Nucleotides Nucleic Acids 18:1771-1787. Himmelsbach, F., Schulz, B.S., Trichtinger, T., Charubala, R., and Pfleiderer, W. 1984. The pnitrophenylethyl (NPE) group: A versatile new blocking group for phosphate and aglycone protection in nucleosides and nucleotides. Tetrahedron 40:59-72. Jeyaraj, D.A. and Waldmann, H. 2001. Synthesis of nucleopeptides by an enzyme labile urethane protecting group. Tetrahedron Lett. 42:835-837. Kataoka, M., Hattori, A., Okino, S., Hyodo, M., Asano, M., Kawai, R., and Hayakawa, Y. 2001. 2-Butanone peroxide as an efficient reagent for the oxidation of nucleoside phosphites into
Protection of Nucleosides for Oligonucleotide Synthesis
2.12.25 Current Protocols in Nucleic Acid Chemistry
Supplement 23
phosphates under anhydrous conditions. Org. Lett. 3:815-818. Koole, L.H., Moody, H.M., Broeders, N.L.H.L., Quaedflieg, P.J.L.M., Kuijpers, W.H.A., van Genderen, M.H.P., Coenen, A.J.J.M., van der Wal, S., and Buck, H.M. 1989. Synthesis of phosphate-methylated DNA fragments using 9-fluorenylmethoxycarbonyl as transient base protecting group. J. Org. Chem. 54:1657-1664. K¨oster, H., Kulikowski, K., Liese, T., Heikens, W., and Kohli, V. 1981. N-Acyl protecting groups for deoxynucleosides: A quantitative and comparative study. Tetrahedron 37:363-369. Kuijpers, W.H.A., Huskens, J., and van Boeckel, C.A.A. 1990. The 2-(acetoxymethyl)benzoyl (AMB) group as a new base–protecting group, designed for the protection of (phosphate) modified oligonucleotides. Tetrahedron Lett. 46:6729-6732. Letsinger, R.L., Finann, J.L., Heavner, G.A., and Lunsford, W.B. 1975. Phosphite coupling procedure for generating internucleotide links. J. Am. Chem. Soc. 97:3278-3279. Makino, S., Ueno, Y., Ishikawa, M., Hayakawa, Y., and Hata, T. 1993. Chemical synthesis of cytidine-5 -monophosphono-Nacetylneuraminic acid (CMP-Neu5Ac). Tetrahedron Lett. 34:2775-2778. Matray, T.J. and Greenberg, M.M. 1994. Sitespecific incorporation of the alkaline labile, oxidative stress product (5R)-5,6-dihydro-5hydroxythymidine in an oligonucleotide. J. Am. Chem. Soc. 116:6931-6932. Matteucci, M.D. and Caruthers, M.H. 1981. Synthesis of deoxyribonucleotides on a polymer support. J. Am. Chem. Soc. 103:3185-3191. McBride, L.J. and Caruthers, M.H. 1983. An investigation of several deoxynucleoside phosphoramidites useful for synthesizing deoxyoligonucleotides. Tetrahedron Lett. 24:245-248.
Schulhof, J.C., Molko, D., and Teoule, R. 1987. The final deprotection step in oligonucleotide synthesis is reduced to a mild and rapid ammonia treatment by using labile base–protecting groups. Nucl. Acids Res. 15:397-416. Sinha, N.D., Biernat, J., and K¨oster, H. 1983. β-Cyanoethyl N,N-dialkylamino/Nmorpholinomonochloro phosphoramidites, new phosphitylating agents facilitating ease of deprotection and work-up of synthesized oligonucleotides. Tetrahedron Lett. 24:58435846. Spinelli, N., Meyer, A., Hayakawa, Y., Imbach, J.-L., and Vasseur, J.-J. 2002. Use of allylic protecting groups for the synthesis of base-sensitive prooligonucleotides. Eur. J. Org. Chem. 49-56. Tobias, S.C. and Borch, R.F. 2004. Synthesis and biological evaluation of a cytarabine phosphoramidite prodrug. Mol. Pharm. 1:112-116. Uznanski, B., Grajkowski, A., and Wilk, A. 1989. The isopropoxyacetic group for convenient base protection during solid–support synthesis of oligodeoxyribonucleotides and their triester analogs. Nucl. Acids Res. 17:4863-4871. Vinogradov, S., Asseline, U., and Thuong, N.T. 1993. Synthesis and physicochemical studies of partially phosphate-methylated oligodeoxyribonucleotides. Tetrahedron Lett. 34:5899-5902. Vu, H., McCollum, C., Jacobson, K., Theisen, P., Vinayak, R., Spiess, E., and Andrus, A. 1990. Fast oligonucleotide deprotection phosphoramidite chemistry for DNA synthesis. Tetrahedron Lett. 31:7269-7272.
Contributed by Mamoru Hyodo and Yoshihiro Hayakawa Nagoya University Nagoya, Japan
Sakakura, A. and Hayakawa, Y. 2000. A novel synthesis of oligonucleotide–peptide conjugates with a base-labile phosphate linker between the two components according to the allyl-protected phosphoramidite strategy. Tetrahedron 56:44274435.
Nucleobase Protection with Allyloxycarbonyl
2.12.26 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Universal 2-(4-Nitrophenyl)ethyl and 2-(4-Nitrophenyl)ethoxycarbonyl Protecting Groups for Nucleosides and Nucleotides
UNIT 2.13
Wolfgang Pfleiderer1 1
Konstanz University, Konstanz, Germany
ABSTRACT A universal blocking group strategy for nucleobases is described, using the 2-(4-nitrophenyl)ethyl (NPE) group for O4 -T-, O4 -U-, O6 -dG-, and O6 -G-protection as well as the 2-(4-nitrophenyl)ethoxycarbonyl (NPEOC) group for amino protection in dC, C, dA, A, dG, and G. Conversion into the corresponding 5 -Odimethoxytrityl derivatives and subsequent phosphitylation to form the fully protected 3 O-(2-cyanoethyl-N,N-diisopropylphosphoramidites) and 3 -O-(2-(4-nitrophenyl)ethylN,N-diisopropylphosphoramidites) produces a new class of interesting building blocks for oligonucleotide synthesis. Curr. Protoc. Nucleic Acid Chem. 30:2.13.1C 2007 by John Wiley & Sons, Inc. 2.13.25. Keywords: NPE and NPEOC protection r Mitsunobu reaction r dimethoxytritylation r phosphitylation r fully protected building blocks
INTRODUCTION The well-established solid-support approach to oligo-2 -deoxyribonucleotides by the phosphoramidite methodology (Caruthers et al., 1982) generally uses monomeric building blocks that have been standardized regarding the functional groups at the sugar moiety (5 -O-dimethoxytrityl-3 -O-(2-cyanoethyl-N,N-diisopropylphosphoramidite), but vary broadly where the protection of the nucleobases is concerned. Usually, the amino groups are blocked by various acyl groups, whereas the amide functions in thymidine, uridine, and guanosine are considered to be chemically inert in the applied strategies. Often, however, solubility problems arise, especially with 2 -deoxyguanosine and guanosine derivatives, which form strong intermolecular hydrogen bonds due to the unprotected amide groups. This unit describes a strategy to overcome these disadvantages using a new universal protecting group that fulfills all anticipated expectations. The outstanding properties of the 2-(4-nitrophenyl)ethyl (NPE) group first applied in the phosphotriester approach (Uhlmann et al., 1981) suggested a more general application of this interesting group for protection of various other functions present in the aglycones and sugar moieties of nucleosides and nucleotides. The NPE group can be used for O-protection of uracil and thymine (see Basic Protocol 1) and of guanine (see Basic Protocols 4 and 6). The related 2-(4-nitrophenyl)ethoxycarbonyl (NPEOC) group is used to protect the amino groups of cytosine (see Basic Protocol 2), adenine (see Basic Protocol 3 and Alternate Protocols 1 and 2), and guanine (see Basic Protocols 5 and 6). The advantage of a universal protection strategy over the multiplicity of previously used protecting group combinations appears obvious at least during the final deprotection steps, which are considerably simplified by this approach. Deprotection generally requires only a DBU treatment to cleave the NPE and NPEOC groups by a ß-elimination process and an acid cleavage of the dimethoxytrityl group to form the free oligonucleotide from its
Current Protocols in Nucleic Acid Chemistry 2.13.1-2.13.25, September 2007 Published online September 2007 in Wiley Interscience (www.interscience.wiley.com). DOI: 10.1002/0471142700.nc0213s30 C 2007 John Wiley & Sons, Inc. Copyright
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.1 Supplement 30
fully protected synthetic precursor. These deblocking steps can even be performed while the oligonucleotide is still attached to the solid support, allowing the clean removal of all protecting groups and reagents. Final ammonia treatment then yields the clean oligomer cleaved from the solid support. BASIC PROTOCOL 1
O4 -p-NPE PROTECTION OF THYMIDINE AND URIDINE Extended studies of the phosphotriester approach revealed some side reactions at the aglycone residues of thymidine and uridine (Reese and Ubasawa, 1980). Condensing agents of the type of arenesulfonyl 1,2,4-triazolide, nitrotriazolide, and tetrazolide, as well as phosphorylating agents, activate the amide function and lead to 4-azol-1-ylpyrimidin2-one nucleosides. This base modification introduces the possibility of nucleophilic displacement reactions leading to cytidine derivatives with ammonia and amines. A successful amide protection has been achieved by phenol and 2,4-dimethylphenol (Jones et al., 1981), two blocking groups that can be cleaved simultaneously with the substituted aryl phosphotriester functions by the oximate procedure. This protocol describes the introduction of the 2-(4-nitrophenyl)ethyl group onto O4, and is shown in Figure 2.13.1. Since the Mitsunobu reaction does not afford O4 but rather N3 substitution, the silver-catalyzed SN 1-type alkylation with 2-(4-nitrophenyl)ethyl iodide in toluene is applied. 3 ,5 -Di-O-acetylthymidine (S.1; Beltz and Visser, 1955) and 2 ,3 ,5 -tri-O-acetyluridine (S.2; Brown et al., 1956) were chosen as starting materials to give the corresponding O4 -2-(4-nitrophenyl)ethyl derivatives S.3 and S.4, which can be deacetylated with ammonia in methanol or dioxane to give O4 -2-(4nitrophenyl)ethylthymidine (S.5) and -uridine (S.6), respectively. The synthesis of the starting reagent, 2-(4-nitrophenyl)ethyl iodide, is as described in Himmelsbach et al. (1984).
Materials Sodium iodide (NaI) Ethyl methyl ketone 2-(4-Nitrophenyl)ethyl chloride Acetone Chloroform (CHCl3 ) 1% aqueous sodium hydrosulfite (Na2 S2 O3 ) Anhydrous sodium sulfate (Na2 SO4 ) Diethyl ether 3 ,5 -Di-O-acetylthymidine (S.1; Beltz and Visser, 1955) or 2 ,3 ,5 -tri-O-acetyluridine (S.2; Brown et al., 1956)
Figure 2.13.1
2-(4-Nitrophenyl)ethylation of 3 ,5 -di-O-acetyl-thymidine (S.1) and 2 ,3 ,5 -tri-O-acetyl-uridine (S.2).
2.13.2 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Absolute toluene Silver carbonate (Ag2 CO3 ) Silica gel 60 (220 to 440 mesh; Fluka) n-Hexane 1,4-Dioxane Saturated ammonia in MeOH Ethyl acetate (EtOAc) Methanol (MeOH) 100- and 250-mL round-bottom flasks Reflux condensers Oil bath G4 glass filters Rotary evaporator equipped with water aspirator Filter paper 30 × 4–cm and 11 × 3–cm chromatography columns 20 × 20 × 0.2–cm TLC silica-gel plates (silica gel PF60254 , Fluka) Silica-coated TLC-plate with fluorescent indicator UV light (254 nm) Vacuum desiccator with P2 O5 Prepare 2-(4-nitrophenyl)ethyl iodide 1. Dissolve 8.8 g (59 mmol) NaI in 100 mL ethyl methyl ketone in a 250-mL roundbottom flask with magnetic stir bar and condenser. 2. Add 10 g (54 mmol) of 2-(4-nitrophenyl)ethyl chloride and reflux 24 hr at 80◦ C. 3. Filter off the solid by suction through a G4 glass filter, wash with 20 mL acetone, and evaporate the combined filtrates on a rotatory evaporator. 4. Dissolve the residue in 150 mL CHCl3 , wash two times with 50 mL of 1% aqueous Na2 S2 O3 solution, and separate the two layers. 5. Dry the organic phase over Na2 SO4 , filter through filter paper, and evaporate again under reduced pressure to dryness. 6. Recrystallize the residue from 30 mL diethyl ether and 3 mL CHCl3 to give 2-(4nitrophenyl)ethyl iodide as yellowish crystals after standing overnight at 7◦ C. 2-(4-Nitrophenyl)ethyl iodide: yield 13.9 g (93%). m.p. 100o -101◦ C. C8 H8 INO2 (277.0): C 34.68, H 2.91, N 5.06; found: C 34.73, H 2.88, N 4.97.
Perform 2-(4-nitrophenyl)ethylation 7. Prepare a suspension of 10 mmol (3.26 g) 3 ,5 -di-O-Ac-T (S.1) or 10 mmol (3.6 g) 2 ,3 ,5 -tri-O-Ac-U (S.2) in 50 mL absolute toluene and 15 mmol (2.5 g) Ag2 CO3 in a 100-mL round-bottom flask with magnetic stir bar and condenser. Heat 2 hr under reflux to 110◦ C. 8. Cool to 50◦ C. Add 15 mmol (4.16 g) 2-(4-nitrophenyl)ethyl iodide and stir 48 hr at 50◦ C. 9. Filter off the precipitate through a G4 glass filter by suction, wash with CHCl3 , and evaporate the filtrate on a rotary evaporator. 10. Dissolve the residue in CHCl3 and load the solution onto a silica gel column (30 × 4–cm, 100 g silica gel 60). Elute first with 100 mL CHCl3 followed by 300 mL of 4:1 CHCl3 /acetone. 11. Collect the product fractions (check by TLC) and evaporate under reduced pressure to give a solid foam. Current Protocols in Nucleic Acid Chemistry
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.3 Supplement 30
12. Further purify a small sample by preparative TLC on a silica gel plate (20 × 20 × 0.2–cm) with CHCl3 . Elute the main zone, evaporate, and dissolve the residue in 5 mL CHCl3 . 13. Precipitate dissolved residue by adding it dropwise to 100 mL of rapidly stirring n-hexane, yielding an amorphous solid. 14. Dry 1 day in a vacuum desiccator over P2 O5 . 3 ,5 -Di-O-acetyl-O4 -NPE-T (S.3): yield 3.47 g (73%). Rf (CHCl3 /acetone 10:1): 0.41. UV (MeOH): 276 (4.19). 1 H NMR (CDCl3 ): 8.14 (d, 2H, H o to NO2 ); 7.51 (s, 1H, H-C6); 7.39 (d, 2H, H m to NO2 ); 6.29 (m, 1H, H-C1 ); 5.17 (m, 1H, H-C3 ); 4.63 (t, 2H, OCH2 CH2 ); 4.33 (m, 2H, H-C5 ); 4.26 (m, 1H, H-C4 ); 3.16 (t, 2H, OCH2 CH2 ); 2.67 (m, 1H, H-C2 ); 2.06 + 2.07 (2s, 6H, 2CH3 ); 2.00 (m, 1H, H-C2 ); 1.87 (s, 3H, H3 C-C5). C22 H25 N3 O9 (475.5): C 55.58, H 5.30, N 8.84; found: C 55.39, H 5.39, N 8.62. 2 ,3 ,5 -Tri-O-acetyl-O4 -NPE-U (S.4): yield 3.84 g (74%). Rf (toluene/EtOAc 1:1): 0.37. UV (MeOH): 204 (4.47), 273 (4.20). 1 H NMR (CDCl3 ): 8.18 (d, 2H, H o to NO2 ); 7.71 (s, 1H, H-C6); 7.42 (d, 2H, H m to NO2 ); 6.13 (d, 1H, H-C1 ); 5.91 (d, 1H, H-C5); 5.34 (m, 2H, H-C2 ,3 ); 4.66 (t, 2H, OCH2 CH2 ); 4.40 (m, 3H, H-C4 ,5 ); 3.16 (t, 2H, OCH2 CH2 ); 2.13 (s, 3H, CH3 ); 2.11 (s, 6H, 2CH3 ). C23 H25 N3 O11 (519.5): C 53.18, H 4.85, N 8.09; found: C 53.70, H 4.71, N 7.67.
Deacetylate 15. Prepare a solution of 1.5 mmol (1.15 g) S.3 or 1.5 mmol (1.9 g) S.4 in 5 mL of 1,4-dioxane. Add 10 mL saturated ammonia in MeOH and stir 24 hr at room temperature. 16. Evaporate on a rotary evaporator. 17. Either recrystallize the residue from EtOAc or purify by column chromatography. For chromatography, dissolve the residue in CHCl3 , put onto a silica gel column for chromatography (11 × 3–cm, 30 g), and elute first with 100 mL CHCl3 and then with 500 mL of 20:1 CHCl3 /MeOH. 18. Collect the product fractions (check by TLC) and evaporate in a vacuum to give a solid foam. 19. Recrystallize from EtOAc to give colorless crystals after standing overnight at 7◦ C. O4 -NPE-T (S.5): yield 0.55 g (94%). m.p. 143o -148◦ C. Rf (toluene/EtOAc/MeOH 5:4:1): 0.23. UV (MeOH): 276 (4.19). 1 H NMR (CDCl3 ): 8.14 (d, 2H, H o to NO2 ); 7.68 (s, 1H, H-C6); 7.40 (d, 2H, H m to NO2 ); 6.10 (pt, 1H, H-C1 ); 4.63-4.55 (m, 3H, H-C3 , OCH2 CH2 ); 4.03 (m, 1H, H-C4 ); 3.85 (m, 2H, H-C5 ); 3.27-3.13 (m, 4H, OCH2 CH2 , HO-C3 , HO-C5 ); 2.40 (m, 2H, H-C2 ,2 ); 1.86 (s, 3H, H3 C-C5). C18 H21 N3 O7 (391.4): C 55.24, H 5.41, N 10.74; found: C 55.26, H 5.21, N 10.71. O4 -NPE-U (S.6): yield 0.50 g (85%). m.p. 147o -148◦ C. Rf (CHCl3 /MeOH 95:5): 0.78. UV (MeOH): 204 (4.43), 275 (4.22). 1 H NMR (DMSO-d6 ): 8.29 (s, 1H, H-C6); 8.17 (d, 2H, H o to NO2 ); 7.58 (d, 2H, H m to NO2 ); 5.98 (d, 1H, H-C5); 5.76 (pd, 1H, H-C1 ); 5.44 (d, 1H, HO-C2 ); 5.14 (d, 1H, HO-C5 ); 5.02 (d, 1H, HO-C3 ); 4.52 (t, 2H, OCH2 CH2 ); 3.90 (m, 3H, H-C2 ,3 ,4 ); 3.70-3.56 (m, 2H, H-C5 ); 3.16 (t, 3H, OCH2 CH2 ). C17 H19 N3 O8 (393.4): C 51.91, H 4.87, N 10.68; found: C 51.42, H 4.90, N 10.69. BASIC PROTOCOL 2
Universal NPE and NPEOC Protecting Groups
N4 -p-NPEOC PROTECTION OF 2 -DEOXYCYTIDINE AND CYTIDINE The amino group in 2 -deoxycytidine (S.7) and cytidine (S.8) is highly nucleophilic, which allows direct 2-(4-nitrophenyl)ethoxycarbonylation with the appropriate acylating agent, e.g., 1-[2-(4-nitrophenyl)ethoxycarbonyl]benztriazole, without protection of the sugar hydroxy groups. The method is shown in Figure 2.13.2.
2.13.4 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Figure 2.13.2
2-(4-Nitrophenyl)ethoxycarbonylation of 2 -deoxycytidine (S.7) and cytidine (S.8).
Materials 2-(4-Nitrophenyl)ethanol (Sigma-Aldrich) Methylenechloride (CH2 Cl2 , analytical grade), cold 1-(Chlorocarbonyl)benztriazole Triethylamine Anhydrous sodium sulfate (Na2 SO4 ) Benzene (analytical grade) Cytidine or 2 -deoxycytidine (Sigma-Aldrich, Pharma Waldhof) 1-[2-(4-Nitrophenyl)ethoxycarbonyl]benztriazole N,N-Dimethylformamide (DMF, anhydrous) 100- and 250-mL round-bottom flasks Reflux condenser 60◦ C oil bath G4 glass filters 50◦ C oven Prepare 1-[2-(4-nitrophenyl)ethoxycarbonyl]benztriazole 1. Dissolve 8.35 g (50 mmol) 2-(4-nitrophenyl)ethanol in 70 mL cold absolute CH2 Cl2 (0◦ to 5◦ C) in a 250-mL round-bottom flask with magnetic stir bar. Add 9.05 g (50 mmol) 1-(chlorocarbonyl)benztriazole. 2. Add slowly (dropwise) a solution of 10 mL triethylamine in 10 mL CH2 Cl2 under stirring. 3. Warm to room temperature with stirring for 1 hr, and continue stirring for 30 min at room temperature. 4. Add 250 mL CH2 Cl2 and shake the solution three times with 200 mL ice water. 5. Separate the organic layer, dry over Na2 SO4 , filter through filter paper, and evaporate to dryness. 6. Recrystallize the residue from 120 mL dry benzene to give yellowish crystals after standing overnight at room temperature. 1-[2-(4-Nitrophenyl)ethoxycarbonyl]benztriazole: yield 14.4 g (92%). m.p. 135o -136◦ C. 1 H NMR (CDCl3 ): 8.22 (d, 2H, arom. H); 8.05 (d, 2H, arom. H); 7.65 (m, 1H, arom. H); 7.54 (d, 2H, arom. H); 7.52 (m, 1H, arom. H); 4.88 (t, 2H, CH2 ); 3.37 (t,
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.5 Current Protocols in Nucleic Acid Chemistry
Supplement 30
2H, CH2 ). Rf (toluene/EtOAc 7:3): 0.65. C15 H12 N4 O4 (312.3): C 57.69, H 3.87, N 17.94; found: C 57.59, H 3.79, N 17.95.
Perform nitrophenylethoxycarbonylation 7. Dissolve 15 mmol (3.43 g) 2 -deoxycytidine (S.7) or 15 mmol (3.63 g) cytidine (S.8) and 4.7 g (15 mmol) 1-[2-(4-nitrophenyl)ethoxycarbonyl]benztriazole in a 100-mL round-bottom flask with condenser in 50 mL absolute DMF and heat 20 hr in a 60◦ C oil bath with magnetic stirring. 8. Distill off the DMF under high vacuum and treat the oily residue with a mixture of 30 mL H2 O and 30 mL CH2 Cl2 with vigorous shaking. 9. Collect the resulting precipitate by suction through a G4 glass filter, wash with H2 O, and dry in a 50◦ C oven to give colorless crystals. N4 -NPEOC-2 -dC (S.9): yield 5.86 g (91%). m.p. 114o -120◦ C. Rf (CHCl3 /MeOH 19:1): 0.28. UV: 242 (4.24), 281 (4.16). 1 H NMR (DMSO-d6 ): 10.72 (s, 1H, H-N); 8.28 (d, 1H, H-C6); 8.15 (d, 2H, H o to NO2 ); 7.59 (d, 2H, H m to NO2 ); 6.97 (d, 1H, H-C5); 6.08 (pt, 1H, H-C1 ); 5.26 (d, 1H, HO-C3 ); 5.04 (t, 1H, HO-C5 ); 4.35 (t, 2H, OCH2 CH2 ); 4.20 (m, 1H, H-C3 ); 3.84 (m, 1H, H-C4 ); 3.57 (m, 2H, H-C5 ); 3.08 (t, 2H, OCH2 CH2 ); 2.26 (m, 1H, H-C2 ); 2.00 (m, 1H, H-C2 ). C18 H20 N4 O8 ·H2 O (438.4): C 50.35, H 4.93, N 13.05; found: C 50.63, H 4.67, N 13.03. N4 -NPEOC-C (S.10): yield 4.77 g (70%). m.p. 85o -89◦ C. Rf (CHCl3 /MeOH 9:1): 0.30. UV: 242 (4.23), 280 (4.14). 1 H NMR (DMSO-d6 ): 10.76 (bs, 1H, H-N); 8.39 (d, 1H, H-C6); 8.17 (d, 2H, H o to NO2 ); 7.60 (d, 2H, H m to NO2 ); 6.96 (d, 1H, H-C5); 5.76 (d, 1H, H-C1 ); 5.49 (d, 1H, HO-C2 ); 5.16 (t, 1H, HO-C5 ); 5.05 (d, 1H, HO-C3 ); 4.35 (t, 2H, OCH2 CH2 ); 4.02-3.82 (m, 3H, H-C4 ,3 ,2 ); 3.80-3.52 (m, 2H, H-C5 ); 3.08 (t, 2H, OCH2 CH2 ). C18 H20 N4 O9 ·H2 O (454.4): C 47.58, H 4.88, N 12.33; found: C 47.36, H 4.51, N 12.29. BASIC PROTOCOL 3
N6 -p-NPEOC PROTECTION OF ACETYLATED 2 -DEOXYADENOSINE AND ADENOSINE Direct 2-(4-nitrophenyl)ethoxycarbonylation of 2 -deoxyadenosine and adenosine can not be achieved with 1-[2-(4-nitrophenyl)ethoxycarbonyl]benztriazole in the same manner as in the cytidine series due to the lower nucleophilic potential of the amino function of adenosine. The more reactive 2-(4-nitrophenyl)ethyl chloroformate in pyridine, however, smoothly acylates 3 ,5 -di-O-acetyl-2 -deoxyadenosine (S.13; Hayes et al., 1955) and 2 ,3 ,5 -tri-O-acetyladenosine (S.14; Bredereck, 1947), respectively, to form mixtures of N6 -mono-(S.15, S.16) and N6 -di-2-(4nitrophenyl)ethoxycarbonyl derivatives (S.17, S.18; Fig. 2.13.3). These can be converted with ammonia into N6 -2-(4-nitrophenyl)ethoxycarbonyl-2 -deoxyadenosine (S.19) and N6 -2-(4-nitrophenyl)ethoxycarbonyladenosine (S.20). Two strategies for monoalkylation of adenosine are presented in Alternate Protocols 1 and 2.
Materials
Universal NPE and NPEOC Protecting Groups
Toluene (anhydrous) Phosgene 2-(4-Nitrophenyl)ethanol (Sigma-Aldrich) Methylenechloride (CH2 Cl2 ) 3 ,5 -Di-O-acetyl-2 -deoxyadenosine (S.13; Hayes et al., 1955) or 2 ,3 ,5 -tri-O-acetyladenosine (S.14; Bredereck, 1947) Pyridine (anhydrous) Chloroform (CHCl3 ) Phosphate buffer, pH 7 Na2 SO4 Toluene
2.13.6 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Figure 2.13.3 2-(4-Nitrophenyl)ethoxycarbonylation of 3 ,5 -di-O-acetyl-2 -deoxy- (S.13) and 2 ,3 ,5 -tri-O-acetyladenosine (S.14).
Silica gel Methanol (MeOH) Concentrated aqueous ammonia Ethanol (EtOH) 500-mL three-neck round-bottom flasks 50◦ C oil bath Condenser with drying tube Gas inlet tubes 20 × 4–cm chromatography column 250- and 500-mL round-bottom flasks Rotatory evaporator Prepare 2-(p-nitrophenyl)ethyl chloroformate 1. Using a 500-mL three-neck round-bottom flask with condenser and gas inlet tube, cool 200 mL of dry toluene in an ice bath to 0◦ to 5◦ C and bubble 70 g (0.7 mol) phosgene from a storage tank into the solution under stirring. 2. Prepare a solution of 33.4 g (0.2 mol) 2-(4-nitrophenyl)ethanol in a mixture of 100 mL CH2 Cl2 and 50 mL toluene, and add dropwise with stirring to the phosgene solution. 3. Allow to warm to room temperature, then stir 1 hr at room temperature, and finally raise slowly to 50◦ C (within 5 hr) in an oil bath. 4. After 5 hr at 50◦ C, cool the mixture to room temperature (∼1 hr) and evaporate under vacuum. 5. Let stand overnight to allow the residue to crystallize. Dry under high vacuum at room temperature to give chromatographically pure material that can be used for further reactions. 6. Obtain an analytically pure sample by recrystallization from toluene to give yellowish crystals. 2-(4-Nitrophenyl)ethyl chloroformate: yield 45.0 g (98%). m.p. 42◦ C. 1 H NMR (CDCl3 ): 8.15 (d, 2H, arom. H); 7.38 (d, 2H, arom. H); 4.53 (t, 2H, CH2 ); 3.14 (t, 2H, CH2 ).
Perform nitrophenylethoxycarbonylation 7. Prepare an ice-cold solution of 5 mmol (1.68 g) 3 ,5 -di-O-Ac-2 -dA (S.13) or 5 mmol (2.02 g) 2 ,3 ,5 -tri-O-Ac-A (S.14) in 10 mL absolute pyridine.
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.7 Current Protocols in Nucleic Acid Chemistry
Supplement 30
8. With magnetic stirring, add 12.5 mmol (2.88 g) 2-(4-nitrophenyl)ethyl chloroformate. Continue stirring 1 hr at 0◦ to 5◦ C and then 2 hr at room temperature. 9. Dilute with 200 mL CHCl3 and treat with 100 mL phosphate buffer, pH 7, three times with intensive shaking, separating the organic layer each time. 10. Wash the CHCl3 phase with H2 O, dry over Na2 SO4 , evaporate under reduced pressure to dryness, and coevaporate three times with 20 mL toluene. 11. Dissolve the residue in 5 mL CHCl3 , place onto to a silica gel column (20 × 4–cm), elute the reagents first with CHCl3 , and then co-elute with 49:1 (v/v) CHCl3 /MeOH the mixed N6 -mono- and N6 -di-NPEOC derivatives S.15 plus S.17 and S.16 plus S.18, respectively. See Alternate Protocol 1 for characterization data for S.15 and S.16.
Remove acetyl groups and additional NPE group 12. Evaporate the mixture of S.15 plus S.17 or S.16 plus S.18, respectively, in a 500-mL round-bottom flask, dissolve the residue in 200 mL MeOH, and then treat with 60 mL concentrated aqueous ammonia under magnetic stirring for 1 hr at room temperature. 13. Evaporate and recrystallize the residue from 20 mL EtOH and 2 mL H2 O to give 1.78 g (80%) of S.19 and 1.9 g (83%) of S.20, respectively, as colorless crystals. See Alternate Protocol 1 for characterization data for S.19 and S.20. ALTERNATE PROTOCOL 1
MONO-N6 -p-NPEOC PROTECTION OF ACETYLATED 2 -DEOXYADENOSINE AND ADENOSINE By analogy to various reports (Watkins et al., 1982), monoalkoxycarbonylation of S.13 and S.14 can be effected directly with 1-methyl-3-[2-(4-nitrophenyl)ethoxycarbonyl]imidazolium chloride (prepared from 2-(4-nitrophenyl)ethyl chloroformate and N-methylimidazole in CH2 Cl2 ) to give S.15 and S.16, respectively, in 85% yield. Deacetylation with triethylamine in MeOH produces S.19 and S.20 almost quantitatively.
Materials 2-(4-Nitrophenyl)ethyl chloroformate (see Basic Protocol 3) Methylenechloride (CH2 Cl2 anhydrous) N-Methylimidazole N2 atmosphere 3 ,5 -Di-O-acetyl-2 -deoxyadenosine (S.13; Hayes et al., 1955) or 2 ,3 ,5 -tri-O-acetyladenosine (S.14; Bredereck, 1947) 1,2-Dichloroethane Silica gel Chloroform (CHCl3 ) Methanol (MeOH) Ethyl acetate (EtOAc) P2 O5 Triethylamine Ethanol
Universal NPE and NPEOC Protecting Groups
100- and 500-mL round-bottom flasks Reflux condensers Drying tube G4 glass filters High-vacuum pump Drying pistol Rotatory evaporator
2.13.8 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Chromatography column (8 × 30–cm) Silica-coated TLC plate with fluorescent indicator 50◦ C oven Prepare 1-methyl-3-[2-(4-nitrophenyl)ethoxycarbonyl]imidazolium chloride 1. In a 100-mL round-bottom flask with condenser and drying tube, dissolve 20 mmol (4.6 g) 2-(4-nitrophenyl)ethyl chloroformate in 40 mL dry CH2 Cl2 . Cool in an ice bath and then add 20 mmol (1.7 mL) N-methylimidazole under magnetic stirring. 2. Stir the mixture 15 min at 0◦ to 5◦ C and then another 30 min at room temperature. 3. Collect the precipitate by suction under a dry N2 atmosphere, wash with absolute CH2 Cl2 , and dry under high vacuum in a drying pistol. 1-Methyl-3-[2-(4-nitrophenyl)ethoxycarbonyl]imidazolium chloride: yield 5.0 g (80%). m.p. 92o -95◦ C. 1 H NMR (DMSO-d6 ): 10.15 (s, 1H, H-C2); 8.17 (d, 2H, arom. H); 8.09 (d, 1H, H-C4); 7.98 (d, 1H, H-C5); 7.70 (d, 2H, arom. H); 4.74 (t, 2H, CH2 ); 4.00 (s, 3H, CH3 ); 3.27 (t, 2H, CH2 ). C13 H14 ClN3 O4 (311.7): C 50.09, H 4.53, N 13.48; found: C 49.98, H 4.44, N 13.38.
Perform nitrophenylethoxycarbonylation 4. Dissolve 10 mmol (3.35 g) 3 ,5 -di-O-Ac-2 -dA (S.13) or 10 mmol (4.0 g) 2 ,3 ,5 tri-O-Ac-A (S.14) in 60 mL dry CH2 Cl2 . Add 14 mmol (4.36 g) 1-methyl-3-[2-(4nitrophenyl)ethoxycarbonyl]imidazolium chloride and stir 18 hr at room temperature. 5. Filter off the precipitate from the suspension by suction through a G4 glass filter, wash the residue with CH2 Cl2 , combine the filtrates, and evaporate under vacuum. 6. Dissolve the resulting residue in 1,2-dichloroethane for short-column silica-gel (50 g) chromatography using an 8 × 30–cm chromatography column (Hunt and Rigby, 1967) and subsequently elute with 1,2-dichloroethane, CHCl3 , and 50:1 (v/v) CHCl3 /MeOH. Do not use >1 atm pressure for elution. 7. Collect the product fractions (check by TLC), evaporate, and treat the resulting solid with EtOAc to give colorless crystals. 8. Dry under vacuum in a drying pistol over P2 O5 . 3 ,5 -Di-O-acetyl-N6 -NPEOC-2 -dA (S.15): yield 4.15 g (78%). m.p. 134o -136◦ C. Rf (CHCl3 /MeOH 19:1): 0.63. UV (MeOH): 267 (4.45). 1 H NMR (CDCl3 ): 8.70 (bs, 1H, H-N); 8.66 (s, 1H, H-C8); 8.11 (d, 2H, H o to NO2 ); 8.11 (s, 1H, H-C2); 7.39 (d, 2H, H m to NO2 ); 6.44 (dd, 1H, H-C1 ); 5.42 (m, 1H, H-C3 ); 4.53 (t, 2H, OCH2 CH2 ); 4.35 (m, 3H, H-C4 ,5 ); 3.14 (t, 2H, OCH2 CH2 ); 2.95 (m, 1H, H-C2 ); 2.70-2.58 (m, 1H, H-C2 ); 2.13 (s, 3H, ac); 2.06 (s, 3H, ac). C23 H24 N6 O9 (528.5): C 52.27, H 4.58, N 15.90; found: C 52.51, H 4.59, N 15.93. 2 ,3 ,5 -Tri-O-acetyl-N6 -NPEOC-A (S.16): yield 5.1 g (87%). m.p. 149o -151◦ C. Rf (CHCl3 /MeOH 19:1): 0.69. UV (MeOH): 267 (4.46). 1 H NMR (CDCl3 ): 8.70 (s, 1H, H-C8); 8.47 (bs, 1H, H-N); 8.14 (d, 2H, H o to NO2 ); 8.09 (s, 1H, H-C2); 7.40 (d, 2H, H m to NO2 ); 6.18 (dd, 1H, H-C1 ); 5.90 (pt, 1H, H-C2 ); 5.64 (m, 1H, H-C3 ); 4.52 (t, 2H, OCH2 CH2 ); 4.48-4.30 (m, 3H, H-C4 ,5 ); 3.14 (t, 2H, OCH2 CH2 ); 2.14 (s, 3H, ac); 2.10(s, 3H, ac); 2.06 (s, 3H, ac). C25 H26 N6 O11 (586.5): C 51.20, H 4.47, N 14.33; found: C 51.19, H 4.36, N 14.58.
Deacetylate 9. Dissolve 5 mmol (2.64 g) S.15 or 5 mmol (2.93 g) S.16 in 300 mL MeOH and add 60 mL triethylamine at room temperature. 10. Stir for 18 hr, filter off the resulting precipitate by suction through a G4 glass filter, wash the solid with MeOH, and dry overnight in a 50◦ C oven.
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.9 Current Protocols in Nucleic Acid Chemistry
Supplement 30
11. Evaporate the reaction filtrate to dryness in vacuum, shake the residue with a mixture of 40 mL H2 O and 40 mL of 1,2-dichloroethane to get a second crop of chromatographically pure crystals. 12. Recrystallize from EtOH to get an analytical sample if necessary. N6 -NPEOC-2 -dA (S.19): yield: 2.17 g (94%). m.p. 100o -110◦ C. Rf (CHCl3 /MeOH 9:1) 0.37. UV(MeOH): 267 (4.44). 1 H NMR (DMSO-d6 ): 10.56 (s, 1H, H-N); 8.62 (s, 1H, H-C8); 8.60 (s, 1H, H-C2); 8.16 (d, 2H, H o to NO2 ); 7.60 (d, 2H, H m to NO2 ); 6.42 (pt, 1H, H-C1 ); 5.37 (d, 1H, HO-C3 ); 5.03 (t, 1H, HO-C5 ); 4.50-4.30 (m, 3H, H-C3 , OCH2 CH2 ); 3.89 (m, 1H, H-C4 ); 3.70-3.45 (m, 2H, H-C5 ); 3.11 (t, 2H, OCH2 CH2 ); 2.76 (m, 1H, H-C2 ); 2.32 (m, 1H, H-C2 ). C19 H20 N6 O7 × H2 O (462.4): C 49.35, H 4.80, N 18.17; found: C 49.29, H 4.74, N 18.04. N6 -NPEOC-A (S.20): yield: 1.96 g (85%). m.p. 152o -160◦ C. Rf (CHCl3 /MeOH 9:1) 0.37. UV (MeOH): 267 (4.45). 1 H NMR (DMSO-d6 ): 10.60 (s, 1H, H-N); 8.86 (s, 1H, H-C8); 8.62 (s, 1H, H-C2); 8.17 (d, 2H, H o to NO2 ); 7.61 (d, 2H, H m to NO2 ); 5.99 (pt, 1H, H-C1 ); 5.53 (d, 1H, HO-C2 ); 5.24 (d, 1H, HO-C3 ); 5.14 (t, 1H, HO-C5 ); 4.62 (m, 1H, H-C2 ); 4.40 (t, 2H, OCH2 CH2 ); 4.18 (m, 1H, H-C3 ); 3.98 (m, 1H, H-C4 ); 3.75-3.50 (m, 2H, H-C5 ); 3.11 (t, 2H, OCH2 CH2 ). C19 H20 N6 O8 (460.4): C 49.57, H 4.38, N 18.25; found: C 49.42, H 4.26, N 18.30. ALTERNATE PROTOCOL 2
N6 -p-NPEOC PROTECTION OF TRIMETHYLSILYLATED 2 -DEOXYADENOSINE An even simpler one-pot reaction leads directly to S.19 and S.20, respectively, starting from 2 -deoxyadenosine (S.11) and adenosine (S.12). The starting nucleosides are first silylated by hexamethyldisilazane to form 3 ,5 -bis-O-trimethylsilyl-2 -deoxyadenosine (S.21) and 2 ,3 ,5 -tri-O-trimethylsilyladenosine (S.22) as sugar-protected intermediates. Addition of 1-methyl-3-[2-(4-nitrophenyl)ethoxycarbonyl]imidazolium chloride causes monoacylation, and work-up with triethylamine in methanol leads to S.19 and S.20, respectively, in 86% to 90% yield.
Materials 2 -Deoxyadenosine or adenosine (Sigma-Aldrich, Pharma Waldhof) Dioxane (anhydrous) Hexamethyldisilazane (Sigma-Aldrich) Ammonium sulfate ((NH4 )2 SO4 ) Toluene (anhydrous) Methylenechloride (CH2 Cl2 , anhydrous) 1-Methyl-3-(2-(4-nitrophenyl)ethoxycarbonyl)imidazolium chloride Triethylamine Methanol (MeOH) 100-mL round-bottom flasks Reflux condenser with drying tube 120◦ C oil bath G4 glass filters Rotatory evaporator 50◦ C drying oven
Universal NPE and NPEOC Protecting Groups
Perform trimethylsilylation 1. In a 100-mL round-bottom flask with stir bar and a condenser with a drying tube, heat a mixture of 10 mmol (2.54 g) dry 2 -deoxyadenosine (S.11) or 10 mmol (2.7 g) dry adenosine (S.12) in 25 mL dry dioxane with 25 mL hexamethyldisilazane and 50 mg (NH4 )2 SO4 under reflux 3 hr in a 120◦ C oil bath to achieve trimethylsilylation of the hydroxyl functions.
2.13.10 Supplement 30
Current Protocols in Nucleic Acid Chemistry
2. Evaporate under vacuum, dissolve the residue in 100 mL dry toluene, and filter off the insoluble material through a G4 glass filter. 3. Evaporate the filtrate to give S.21 and S.22, respectively, as as a colorless syrup.
Perform nitrophenylethyloxycarbonylation 4. Dissolve S.21 or S.22 in 200 mL dry CH2 Cl2 , then add 20 mmol (6.24 g) 1-methyl3-[2-(4-nitrophenyl)ethoxycarbonyl]imidazolium chloride and stir 18 hr at room temperature. 5. Filter off the insoluble material from the suspension through a G4 glass filter and evaporate the filtrate to dryness under vacuum.
Desilylate 6. Dissolve the residue in 100 mL MeOH, add 25 ml triethylamine, and stir overnight at room temperature. 7. Collect the precipitate solid, wash with MeOH, and dry overnight in a 50◦ C drying oven to give S.19 in 86% yield or S.20 in 90% yield. See Alternate Protocol 1 for characterization data for S.19 and S.20.
O6 -p-NPE PROTECTION OF ACYLATED 2 -DEOXYGUANOSINE AND GUANOSINE DERIVATIVES
BASIC PROTOCOL 4
A long-standing problem in oligonucleotide synthesis is dealing with the various side reactions of the guanine residue as well as its low solubility in organic solvents. Protection of the amide function in the guanine moiety seems to be an obvious necessity to overcome these difficulties. Various efforts have been undertaken to protect the O6 position using the 2-nitrophenyl (Jones et al., 1981), silyl, sulfonyl, phosphoryl, and phosphinothioyl groups (Daskalov et al., 1981), as well as substituted ethyl groups that are prone to ß-elimination cleavage reactions (Gaffney and Jones, 1982). The initial introduction of the 2-(4-nitrophenyl)ethyl group in the O6 position was a multistep procedure and the expected nucleophilic displacement of a 6-chloro or 6-methanesulfonyl substituent by 2-(4nitrophenyl)ethanol was unsuccessful. However, as reported in Trichtinger et al. (1983), the Mitsunobu reaction (Mitsunobu, 1981) offers a good approach to direct O-alkylation if the 2-amino group of the guanine moiety is acylated. In this method, outlined in Figure 2.13.4, treatment of N2 ,3 ,5 -triisobutyryl (S.23), N2 ,2 ,3 ,5 -tetraisobutyryl (S.24), and N2 ,2 ,3 ,5-tetrabenzoyl (S.25) guanine residues with 1.5 molar equivalent each of diethyl azodicarboxylate, triphenylphosphine, and 2-(4-nitrophenyl)ethanol, respectively, in 1,2-dioxane leads directly to the corresponding O6 -2-(4-nitrophenyl)ethyl derivatives S.26 to S.28 in high yields. Cleavage of the sugar acyl groups in conc. ammonia/MeOH proceeds in 3 hr to give S.31 to S.33. Finally, cleavage of the N2 -acyl group, without harming the O6 -NPE substituent, is best performed by prolonged treatment with aqueous ammonia in methanol (up to 5 to 6 days), yielding S.34 and S.35, respectively.
Materials N2 ,3 ,5 -Triisobutyryl-2 -deoxyguanosine (S.23; Flockerzi et al., 1981), N2 ,2 ,3 ,5 -tetraisobutyrylguanosine (S.24; Pharma Waldhof), or N2 ,2 ,3 ,5 -tetrabenzoylguanosine (S.25; Himmelsbach et al., 1984) Triphenylphosphine 2-(4-Nitrophenyl)ethanol (Sigma-Aldrich) 1,2-Dioxane (anhydrous) Diethyl azodicarboxylate (DEAD; Sigma-Aldrich) Chloroform (CHCl3 ) Methanol (MeOH)
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.11 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Figure 2.13.4
Mitsunobu reaction with acylated 2 -deoxyguanosine and guanosine derivatives.
n-Hexane Tetrachloromethane (CCl4 ) Conc. aqueous ammonia Saturated methanolic ammonia Ethanol (EtOH) Silica-gel PF 60254 (Sigma-Aldrich) Toluene Ethyl acetate (EtOAc) Silica gel 60, 220 to 440 mesh (Sigma-Aldrich) 100- and 250-mL round-bottom flasks G4 glass filters 60 × 2.5–cm and 20 × 5–cm chromatography columns Preparative silica-gel plates (20 × 20 × 0.2–cm) Silica-coated TLC plate with fluorescent indicator Rotatory evaporator Drying pistol 50◦ C oven
Universal NPE and NPEOC Protecting Groups
Perform nitrophenylethylation 1. Dissolve a mixture of 2 mmol (0.95 g) N2 ,3 ,5 -triisobutyryl-2 -dG (S.23), 2 mmol (1.13 g) N2 ,2 ,3 ,5 -tetraisobutyryl-G (S.24), or 2 mmol (1.4 g) N2 ,2 ,3 ,5 tetrabenzoyl-G (S.25) plus 3 mmol triphenylphosphine (0.77 g) and 3 mmol 2(4-nitrophenyl)ethanol (0.5 g) in 40 mL dry dioxane.
2.13.12 Supplement 30
Current Protocols in Nucleic Acid Chemistry
2. Add 3 mmol diethyl azodicarboxylate (0.52 g) and stir magnetically 24 hr at room temperature (Himmelsbach et al., 1984). 3. Evaporate to a smaller volume and filter off the precipitated diethyl hydrazinedicarboxylate. 4. Evaporate the filtrate to dryness, dissolve the residue in CHCl3 , and put onto a silica gel column (20 × 5–cm) for chromatography, eluting with 300 mL CHCl3 followed by 99:1 (v/v) CHCl3 /MeOH. 5. Collect the product fractions (check by TLC), evaporate to dryness, and recrystallize the resulting solid either from CHCl3 /n-hexane or from CCl4 . N2 ,3 ,5 -Triisobutyryl-O6 -NPE-2 -dG (S.26): yield: 1.06 g (85%). Rf (CHCl3 /MeOH 19:1) 0.49. UV: 218 (4.42), 269 (4.40). 1 H NMR (CDCl3 ): 8.13 (s, 2H, H o to NO2 ); 7.94 (s, 1H, H-N); 7.92 (s, 1H, H-C8); 7.49 (d, 2H, H m to NO2 ); 6.34 (m, 1H, H-C1 ); 5.39 (m, 1H, H-C3 ); 4.81 (t, 2H, OCH2 CH2 ); 4.48-4.35 (m, 2H, H-C5 ); 4.30 (m, 1H, (H-C4 ); 3.18 (t, 2H, OCH2 CH2 ); 2.99-2.88 (m, 2H, H-C2 ,2 ); 2.61-2.51 (m, 3H, H-CMe2 ); 1.27-1.11 (m, 18H, 3 (H3 C)2 CH). C30 H37 N6 O9 (625.7): C 57.59, H 5.96, N 13.43; found: C 57.10, H 5.91, N 13.11. N2 ,2 ,3 ,5 -Tetraisobutyryl-O6 -NPE-G (S.27): yield: 1.01 g (70%). Rf (CHCl3 /MeOH 19:1) 0.87. UV: 217 (4.46), 268 (4.46). 1 H NMR (CDCl3 ): 8.14 (s, 2H, H o to NO2 ); 7.96 (s, 1H, H-N); 7.91 (s, 1H, H-C8); 7.50 (d, 2H, H m to NO2 ); 6.06 (m, 1H, HC1 ); 5.86 (m, 1H, H-C2 ); 5.76 (m, 1H, H-C3 ); 4.82 (t, 2H, OCH2 CH2 ); 4.41 (m, 3H, H-C4 ,5 ); 3.18 (t, 2H, OCH2 CH2 ); 2.63-2.50 (m, 3H, H-CMe2 ); 1.26-1.08 (m, 18H, 3 (H3 C)2 CH). C34 H44 N6 O11 (712.7): C 57.29, H 6.22, N 11.79; found: C 57.18, H 6.12, N 12.01. N2 ,2 ,3 ,5 -Tetrabenzoyl-O6 -NPE-G (S.28): yield: 1.23 g (71%). m.p. 168◦ C. Rf (CHCl3 /MeOH 19:1) 0.91. UV: 230 (4.77), 270 (4.55). 1 H NMR (DMSO-d6 ): 10.89 (s, 1H, H-N); 8.48 (s, 1H, H-C8); 8.19 (d, 2H, H o to NO2 ); 7.96-7.86 (m, 8H, arom. H); 7.68-7.55 (m, 6H, arom. H); 7.51-7.40 (m, 8H, arom. H, H m to NO2 ); 6.57 (d, 1H, HC1 ); 6.50 (m, 1H, H-C2 ); 6.39 (m, 1H, H-C3 ); 4.91-4.71 (m, 5H, H-C4 ,5 , OCH2 CH2 ); 3.34 (t, 2H, OCH2 CH2 ). 1 H NMR (CDCl3 ): 8.93 (s, 1H, H-N); 8.18 (d, 2H, H o to NO2 ); 8.05-7.88 (m, 9H, H-C8, 8 arom. H); 7.59-7.26 (m, 14H, arom. H, H m to NO2 ); 6.76 (d, 1H, H-C1 ); 6.43 (m. 1H, H-C2 ); 6.28 (m, 1H, H-C3 ); 4.97-4.75 (m, 5H, H-C4 ,5 , OCH2 CH2 ); 3.36 (t, 2H, OCH2 CH2 ). C46 H36 N6 O11 × H2 O (866.8): C 63.74, H 4.42, N 9.70; found: C 63.52, H 4.12, N 9.83.
Remove 3 ,5 -hydroxyl protection 6. Dissolve 1 mmol S.26 (0.626 g), S.27 (0.713 g), or S.28 (0.867 g) in 20 mL of 1,2-dioxane. Add 20 mL conc. aqueous ammonia or saturated methanolic ammonia at room temperature and stir for 1 to 2 days. Check progress of reaction by TLC. 7. Evaporate to dryness and recrystallize the residue from MeOH or EtOH. 8. Prepare an analytical sample by chromatography on a preparative silica gel plate (20 × 20 × 0.2–cm) and develop with 4:1 (v/v) CHCl3 /MeOH. 9. Cut out the main band, elute with 1:1 (v/v) CHCl3 /MeOH, evaporate to dryness, and dry in a 50◦ C oven. N2 -Isobutyryl-O6 -NPE-2 -dG (S.31): yield: 0.414 g (85%). Rf (CHCl3 /MeOH 9:1) 0.13. UV: 218 (4.44), 269 (4.42). 1 H NMR (DMSO-d6 ): 9.45 (s, 1H, H-N); 8.16 (d, 2H, H o to NO2 ); 7.64 (d, 2H, H m to NO2 ); 7.57 (s, 1H, H-C8); 6.31 (m, 1H, H-C1 ); 4.66 (t, 2H, OCH2 CH2 ); 4.47 (d, 1H, HO-C3 ); 4.06 (t, 1H, HO-C5 ); 3.56 (m, 1H, H-C3 ); 3.20 (t, 2H, OCH2 CH2 ); 3.00 (m, 1H, H-C4 ); 2.74-2.66 (m, 2H, H-C5 ); 2.01 (m, 1H, H-C2 ); 1.85 (m, 1H, H-C2 ); 1.49-1.39 (m, 1H, H-CMe2 ); 0.24 (d, 6H, (H3 C)2 CH). C22 H26 N6 O7 (486.5): C 54.23, H 5.39, N 17.28; found: C 54.09, H 5.31, N 17.18.
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.13 Current Protocols in Nucleic Acid Chemistry
Supplement 30
N2 -Isobutyryl-O6 -NPE-G (S.32): yield: 0.382 g (76%). Rf (CHCl3 /MeOH 9:1) 0.39. UV: 228 (4.43), 268 (4.40). 1 H NMR (DMSO-d6 ): 10.45 (s, 1H, H-N); 8.45 (s, 1H, H-C8); 8.18 (d, 2H, H o to NO2 ); 7.66 (d, 2H, H m to NO2 ); 5.89 (m, 1H, H-C1 ); 5.51 (d, 1H, HO-C2 ); 5.21 (d, 1H, HO-C3 ); 4.99 (t, 1H, HO-C5 ); 4.79 (t, 2H, OCH2 CH2 ); 4.55 (m, 1H, H-C2 ); 4.16 (m, 1H, H-C3 ); 3.92 (m, 1H, H-C4 ); 3.60 (m, 2H, H-C5 ); 3.32 (t, 2H, OCH2 CH2 ); 2.84 (m, 1H, H-CMe2 ); 1.09 (d, 6H, (H3 C)2 CH). C22 H26 N6 O8 (502.5): C 52.59, H 5.22, N 16.73; found: C 52.64, H 5.14, N 16.60. N2 -Benzoyl-O6 -NPE-G (S.33): yield: 0.311 g (57%). m.p. 194◦ C. Rf (CHCl3 /MeOH 9:1) 0.41. UV: 230 (4.31), 271 (4.49). 1 H NMR (DMSO-d6 ): 10.93 (s, 1H, H-N); 8.51 (s, 1H, H-C8); 8.18 (d, 2H, H o to NO2 ); 7.95 (d, 2H, arom. H); 7.57 (d, 2H, H m to NO2 ); 7.51 (m, 3H, arom. H); 5.93 (m, 1H, H-C1 ); 5.50 (d, 1H, HO-C2 ); 5.22 (d, 1H, HO-C3 ); 5.00 (t, 1H, HO-C5 ); 4.77 (t, 2H, OCH2 CH2 ); 4.60 (m, 1H, H-C2 ); 4.17 (m, 1H, H-C3 ); 3.92 (m, 1H, H-C4 ); 3.70-3.52 (m, 2H, H-C5 ); 3.33 (t, 2H, OCH2 CH2 ). C25 H24 N6 O8 ·0.5 H2 O (554.5): C 55.04, H 4.62, N 15.41; found: C 54.99, H 4.49, N 15.24.
Remove N2 protection 10. Suspend 2 mmol S.31 (0.97 g), S.32 (1.0 g), or S.33 (1.09 g) in 75 mL MeOH. Add 75 mL conc. aqueous ammonia and stir 5 to 6 days at room temperature. Check progress of deacylation by TLC. 11. Evaporate to dryness on a rotatory evaporator. 12. Recrystallize the residue from H2 O or purify by silica gel column chromatography (60 × 2.5–cm) using 10:8:3 (v/v/v) toluene/EtOAc/MeOH. 13. Collect the product fractions and evaporate to dryness. 14. Dry under vacuum at 40◦ C in a drying pistol. O6 -NPE-2 -dG (S.34): yield: 0.66 g (76%). m.p. amorphous solid. Rf (CHCl3 /MeOH 9:1) 0.28. UV: 250 (4.16), 279 (4.25). 1 H NMR (DMSO-d6 ): 8.20 (d, 2H, H o to NO2 ); 8.18 (s, 1H, H-C8); 7.63 (d, 2H, H m to NO2 ); 6.48 (s, 2H, NH2 ); 6.21 (d, 1H, H-C1 ); 5.28 (d, 1H, HO-C3 ); 5.00 (t, 1H, HO-C5 ); 4.65 (t, 2H, OCH2 CH2 ); 4.34 (dd, 1H, H-C3 ); 3.81 (m, 1H, H-C4 ); 3.53 (m, 2H, H-C5 ); 3.25 (t, 2H, OCH2 CH2 ); 2.57 (m, 1H, H-C2 ); 2.19 (m, 1H, H-C2 ). C18 H20 N6 O6 ·H2 O (434.4): C 49.76, H 5.10, N 19.34; found: C 50.12, H 4.65, N 19.15. O6 -NPE-G (S.35): yield: 0.51 g (59%). m.p. > 320◦ C. Rf (CHCl3 /MeOH 9:1) 0.48. UV: 251 (4.17), 278 (4.26). 1 H NMR (DMSO-d6 ): 8.19 (d, 2H, H o to NO2 ); 8.10 (s, 1H, H-C8); 7.64 (d, 2H, H m to NO2 ); 6.49 (s, 2H, NH2 ); 5.77 (d, 1H, H-C1 ); 5.41 (d, 1H, HO-C2 ); 5.15 (d, 1H, HO-C3 ); 5.10 (t, 1H, HO-C5 ); 4.67 (t, 2H, OCH2 CH2 ); 4.46 (dd, 1H, H-C2 ); 4.09 (dd, 1H, H-C3 ); 3.89 (m, 1H, H-C4 ); 3.56 (m, 2H, H-C5 ); 3.25 (t, 2H, OCH2 CH2 ). C18 H20 N6 O7 (432.4): C 50.00, H 4.66, N 19.44; found: C 50.18, H 4.55, N 19.72. BASIC PROTOCOL 5
N2 -p-NPEOC PROTECTION OF 2 -DEOXYGUANOSINE The N2 -NPEOC-protected nucleoside S.40 is synthesized from 2 -deoxyguanosine (S.36) by the transient protection method (Ti et al., 1982) using trimethylsilyl chloride for intermediary blocking of the sugar hydroxyl groups, followed by acylation with 2-(4nitrophenyl)ethyl chloroformate and desilylation by aqueous sodium bicarbonate.
Materials
Universal NPE and NPEOC Protecting Groups
2 -Deoxyguanosine (S.36; Sigma-Aldrich, Pharma Waldhof) Pyridine (anhydrous) Trimethylsilyl chloride (Sigma-Aldrich) 2-(4-Nitrophenyl)ethyl chloroformate (see Basic Protocol 3) Chloroform (CHCl3 ) Methanol (MeOH)
2.13.14 Supplement 30
Current Protocols in Nucleic Acid Chemistry
10% aqueous sodium bicabonate solution (NaHCO3 ) Diethyl ether Silica-coated TLC plate with fluorescent indicator Rotatory evaporator Drying pistol Vacuum pump 1. Coevaporate 1 mmol (0.267 g) 2 -dG (S.36) three times with 3 mL dry pyridine. Suspend the residue in 20 mL dry pyridine. 2. Add 0.64 mL (5 mmol) trimethylsilyl chloride (0.543 g) with stirring at room temperature. Continue stirring 30 min. Check progess of reaction by TLC. 3. Cool the mixture consisting of S.37 in an ice-bath and then slowly add 2 mmol 2-(4nitrophenyl)ethyl chloroformate (0.46 g) dissolved in 4 mL CHCl3 dropwise with stirring. Continue stirring 1 hr at 0◦ to 5◦ C, then stir for 2 days at room temperature. 4. Add 10 mL MeOH to the reaction mixture and stir for 5 hr at room temperature. 5. Evaporate to dryness and then treat the residue overnight with 20 mL 10% aqueous NaHCO3 under stirring. 6. Collect the resulting colorless precipitate, S.40. Wash with 20 mL diethyl ether and dry in a drying pistol at 50◦ C under vacuum. N2 -NPEOC-2 -dG (S.40): yield: 0.23 g (50%). m.p. 185o -190◦ C. Rf (CHCl3 /MeOH 4:1) 0.36. UV: 251 (sh 4.37), 258 (4.41), 272 (sh 4.26). 1 H NMR (DMSO-d6 ): 11.46, 11.32 (2s, 2H, NH); 8.21 (s, 1H, H-C8); 8.17 (d, 2H, o to NO2 ); 7.63 (d, 2H, m to NO2 ); 6.21 (t, 1H, H-C1 ); 5.32 (d, 1H, HO-C3 ); 4.95 (t, 1H, HO-C5 ); 4.48 (t, 2H, OCH2 CH2 ); 4.36 (m, 1H, H-C3 ); 3.82 (m, 1H, H-C4 ); 3.59-3.45 (m, 2H, H-C5 ); 3.14 (t, 2H, OCH2 CH2 ); 2.99 (m, 1H; H-C2 ); 2.55 (m, 1H, H-C2 ). C18 H20 N6 O8 (460.4): C 49.57, H 4.38, N 18.25; found: C 49.21, H 4.19, N 18.20.
O6 -p-NPE AND N2 -p-NPEOC PROTECTION OF 2 -DEOXYGUANOSINE AND GUANOSINE
BASIC PROTOCOL 6
An interesting combination in the universal blocking group strategy is seen in the application of N2 -NPEOC protection of guanosine derivatives in combination with O6 NPE protection (Lang et al., 1999). The preparation of compounds S.41 and S.42 is achieved in a one-pot reaction starting from 3 ,5 -di-O-acetyl-2 -deoxyguanosine (S.38) or 2 ,3 ,5 -tri-O-acetylguanosine (S.39), respectively. These are first subjected to a Mitsunobu reaction with 2-(4-nitrophenyl)ethanol to give the O6 -NPE-protected S.29 and S.30, respectively. Subsequent 2-(4-nitrophenyl)ethoxycarbonylation and final treatment with ammonia afford S.41 and S.42 in good overall yields.
Materials 3 ,5 -Di-O-acetyl-2 -deoxyguanosine (S.38; Schaller et al., 1963) or 2 ,3 ,5 -tri-O-acetylguanosine (S.39; Pharma Waldhof) Triphenylphosphine 2-(4-Nitrophenyl)ethanol (Sigma-Aldrich) Dioxane (anhydrous) Diethyl azodicarboxylate (Sigma-Aldrich) Pyridine (anhydrous) 2-(4-Nitrophenyl)ethyl chloroformate (see Basic Protocol 3) Chloroform (CHCl3 ; anhydrous) Sodium sulfate (Na2 SO4 ) Toluene
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.15 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Silica gel (Merck 60) Methylenechloride (CH2 Cl2 ) Methanol (MeOH) Conc. aqueous ammonia 100-mL round-bottom flasks Rotary evaporator Chromatography column (20 × 2.5–cm) Silica-coated TLC plate with fluorescent indicator Drying pistol, 50◦ C Perform three-step synthesis 1. In a 100-mL round-bottom flask, prepare a solution of 2 mmol (0.69 g) 3 ,5 -di-Oacetyl-2 -dG (S.38) or 2 mmol (0.82 g) 2 ,3 ,5 -tri-O-acetyl-G (S.39) with 3.2 mmol triphenylphosphine (0.84 g) and 3 mmol 2-(4-nitrophenyl)ethanol (0.50 g) in 40 mL dry dioxane. Stir for 10 min at room temperature. 2. Add 3.2 mmol diethyl azodicarboxylate (0.558 g) and stir for 1 hr to obtain a clear solution. 3. Evaporate under vacuum in a rotatory evaporator and coevaporate with 40 mL dry pyridine. 4. Dissolve the residue in 10 mL dry pyridine and cool 30 min in an ice bath. 5. While stirring, add a solution of 6 mmol 2-(4-nitrophenyl)ethyl chloroformate (1.38 g) in 10 mL dry CHCl3 slowly dropwise. Stir 1 hr at 0◦ to 5◦ C and then 3 hr at room temperature. 6. Dilute with 100 mL H2 O and extract four times with 50 mL CHCl3 . 7. Combine the organic layers and dry over Na2 SO4 . Filter off the drying agent through filter paper, evaporate the filtrate, and coevaporate two times with 10 mL toluene. 8. Purify the resulting residue by silica gel column chromatography (20 × 2.5–cm), eluting first with CH2 Cl2 , followed by CHCl3 . 9. Collect the product fractions (check by TLC), evaporate again, and treat the residue in 25 mL dioxane and 25 mL MeOH with 25 mL conc. aqueous ammonia, keeping the reaction mixture for 24 hr at 7◦ C. 10. Evaporate under vacuum and recrystallize the resulting solid from MeOH. Dry under vacuum in the drying pistol at 50◦ C. N2 -NPEOC-O6 -NPE-2 -dG (S.41): yield: 0.81 g (66%). m.p. 179o -182◦ C. Rf (CHCl3 /MeOH 9:1) 0.53. UV: 216 (4.63), 269 (4.54). 1 H NMR (DMSO-d6 ): 10.33 (s, 1H, NH); 8.40 (s, 1H, H-C8); 8.17 (d, 4H, o to NO2 ); 7.64 (d, 2H, m to NO2 ); 7.61 (d, 2H, H m to NO2 ); 6.30 (t, 1H, H-C1 ); 5.32 (d, 1H, HO-C3 ); 4.89 (t, 1H, HO-C5 ); 4.73 (t, 2H, OCH2 CH2 ); 4.41 (m, 1H, H-C3 ); 4.37 (t, 2H, OCH2 CH2 ); 3.83 (m, 1H, H-C4 ); 3.67-3.42 (m, 2H, H-C5 ); 3.30 (t, 2H, OCH2 CH2 ); 3.11 (t, 2H, OCH2 CH2 ); 2.71 (m, 1H; H-C2 ); 2.25 (m, 1H, H-C2 ). C27 H27 N7 O10 × 0.5 H2 O (618.5): C 52.43, H 4.56, N 15.85; found: C 52.32, H 4.67, N 15.63.
Universal NPE and NPEOC Protecting Groups
N2 -NPEOC-O6 -NPE-G (S.42): yield: 0.834 g (65%). m.p. 172o -174◦ C (decomp.) Rf (CHCl3 /MeOH 9:1) 0.50. UV (MeOH): 216 (4.62), 269 (4.53). 1 H NMR (DMSO-d6 ): 10.37 (s, 1H, NH); 8.42 (s, 1H, H-C8); 8.17 (d, 4H, o to NO2 ); 7.64 (d, 2H, m to NO2 ); 7.61 (d, 2H, m to NO2 ); 5.89 (t, 1H, H-C1 ); 5.49 (d, 1H, HO-C2 ); 5.20 (d, 1H, HOC3 ); 4.98 (t, 1H, HO-C5 ); 4.77 (t, 2H, OCH2 CH2 ); 4.60 (m, 1H, H-C2 ); 4.38 (t, 2H, OCH2 CH2 ); 4.18 (m, 1H, H-C3 ); 3.92 (m, 1H, H-C4 ); 3.72-3.47 (m, 2H, H-C5 ); 3.30 (t, 2H, OCH2 CH2 ); 3.10 (t, 2H, OCH2 CH2 ). C27 H27 N7 O11 ·H2 O (643.5): C 50.38, H 4.54, N 15.23; found: C 50.40, H 4.38, N 15.25.
2.13.16 Supplement 30
Current Protocols in Nucleic Acid Chemistry
PREPARATION OF NPE- AND NPEOC-PROTECTED 2 -DEOXYRIBONUCLEOSIDE 3 -O-PHOSPHORAMIDITES
BASIC PROTOCOL 7
The most common and highly successful oligo-2 -deoxyribonucleotide synthesis is based on the phosphoramidite approach initiated and developed by Caruthers (Caruthers et al., 1982; UNIT 3.3). The general synthetic strategy involves adding mononucleotides sequentially to a nucleoside that is covalently attached to an insoluble solid support. The monomers of choice are 5 -O-dimethoxytrityl-2 -deoxyribonucleoside-3 -O(2-cyanoethyl-N,N-diisopropylphosphoramidites) in which the nucleobases are protected by various acyl groups. Using the universal NPE/NPEOC approach, the sugar moiety can be substituted as in S.48 to S.52 (Fig. 2.13.5), or can be modified by the 3 -O-NPE-N,Ndiisopropylphosphoramidite functionality as in S.53 to S.56 (Lang et al., 1999). In this protocol, dimethoxytritylation of the unprotected sugar moiety is performed using a standard procedure, leading selectively to the corresponding 5 -O-dimethoxytrityl derivatives S.43 to S.47. Phosphitylation to give phosphoramidites S.48 to S.52 is performed by standard methods using 2-cyanoethyl-N,N,N ,N -tetraisopropylphosphordiamidite (Barone et al., 1984; Sinha et al., 1984; Zon et al., 1985) and 1H-tetrazole in an aprotic solvent. Phosphitylation to give S.53 to S.56 can be performed with bis-[N,N-diisopropylamino2-(4-nitrophenyl)ethoxyphosphane] (Sobol et al., 1995) and 1H-tetrazole or with chloro-N,N-diisopropyl-2-(4-nitrophenyl)ethoxyphosphane (Sobol et al., 1995) and triethylamine in acid-free CH2 Cl2 under argon atmosphere.
Figure 2.13.5
NPE- and NPEOC-protected 2 -deoxyribonucleoside-3 -O-phosphoramidites.
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.17 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Materials Protected nucleoside: O4 -NPE-thymidine (S.5) N4 -NPEOC-2 -deoxycytidine (S.10) N6 -NPEOC-2 -deoxyadenosine (S.19) N2 -NPEOC-2 -deoxyguanosine (S.40) N2 -NPEOC-O6 -NPE-2 -deoxyguanosine (S.41) Pyridine (anhydrous) 4,4 -Dimethoxytrityl chloride (Sigma-Aldrich) Methanol (MeOH) Methylenechloride (CH2 Cl2 , anhydrous and acid-free) Sodium sulfate (Na2 SO4 ) Toluene Silica-gel (Merck 60, 63 to 200 mesh) Chloroform (CHCl3 ) Triethylamine (Et3 N) 2-Cyanoethyl-N,N,N ,N -tetraisopropylphosphordiamidite (Sigma-Aldrich) 1H-Tetrazole (Sigma-Aldrich) Argon pressure bottle Saturated NaHCO3 solution Ethyl acetate (EtOAc) Trichlorophosphane (PCl3 , freshly distilled) Diethyl ether (anhydrous) Nitrogen pipeline 2-(4-Nitrophenyl)ethanol (Sigma-Aldrich) N,N-Diisopropylamine Isopropanol N,N-Diisopropyltrimethylsilylamine (Sigma-Aldrich) 50- and 100-mL round-bottom flasks Rotatory evaporator Chromatography columns (40 × 2.5–cm, 50 × 2.5–cm, and 60 × 2.5–cm) 100- and 250-mL three-neck round-bottom flasks Condenser with drying tube Gas inlet tube G4 glass filter High-vacuum pump 100-mL two-neck round-bottom flasks Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Perform 5 -O-dimethoxytritylation 1. Dissolve in a 100-mL round-bottom flask 5 mmol of dry nucleoside O4 -NPE-T (S.5) (1.96 g), N4 -NPEOC-dC (S.10) (2.15 g), N6 -NPEOC-dA (S.19) (2.31 g), N2 NPEOC-dG (S.40) (2.30 g), or N2 -NPEOC-O6 -NPE-dG (S.41) (3.09 g) in 25 mL pyridine. Add 6 mmol of 4,4 -dimethoxytrityl chloride (2.0 g) and stir 2 to 20 hr at room temperature. Monitor by TLC (APPENDIX 3D). 2. Add 10 mL MeOH to the mixture after completion of the reaction and evaporate to 1/4 of its volume on a rotary evaporator. Universal NPE and NPEOC Protecting Groups
2.13.18 Supplement 30
3. Dilute with 25 mL CH2 Cl2 , wash two times with 10 mL H2 O, and separate the organic layer. 4. Dry over Na2 SO4 , filter through filter paper, evaporate the filtrate, and then coevaporate with toluene. Current Protocols in Nucleic Acid Chemistry
5. Purify the residue by silica gel column or flash chromatography (APPENDIX 3E) using a 50 × 2.5–cm column and the appropriate solvent mixture: S.43: flash chromatography (50:1 v/v CHCl3 /MeOH) S.44: flash chromatography (CH2 Cl2 to 95:5 CH2 Cl2 /MeOH) S.45: flash chromatography (25:1 v/v CHCl3 /MeOH) S.46: column chromatography (100:0.2 v/v CHCl3 /Et3 N to 90:10:02 CHCl3 / MeOH/Et3 N) e. S.47: column chromatography (100:0.2 v/v CHCl3 /Et3 N to 99:1:02 v/v/v CHCl3 / MeOH/Et3 N)
a. b. c. d.
6. Collect the product fractions and evaporate under vacuum to give a colorless foam. 7. Dry under high vacuum at room temperature. 5 -O-DMTr-O4 -NPE-T (S.43): yield: 3.46 g (95%). Rf (CHCl3 /MeOH 95:5) 0.82. UV: 232 (sh 4.40), 275 (4.26), 280 (sh 4.25). 1 H NMR (CDCl3 ): 8.14 (d, 2H, o to NO2 ); 7.92 (s, 1H, H-C6); 7.30 (m, 9H, arom. H); 6.81 (d, 4H, o to MeO); 6.40 (pt, 1H, H-C1 ); 4.61 (m, 3H, H-C3 , OCH2 CH2 ); 4.16 (m, 1H, H-C4 ); 3.77 (s, 6H, MeO); 3.73 (d, 1H, HO-C3 ); 3.41 (m, 2H, H-C5 ); 3.15 (t, 2H, OCH2 CH2 ); 2.66 (m, 1H, H-C2 ); 2.23 (m, 1H, H-C2 ); 1.46 (s, 3H, H3 C-C5). C39 H38 N3 O9 ·2H2 O (728.7): C 64.28, H 5.81, N 5.76; found: C 64.30, H 5.46, N 5.81. 5 -O-DMTr-N4 -NPEOC-2 -dC (S.44): yield: 3.11 g (86%). Rf (CHCl3 /MeOH 95:5) 0.36. UV: 235 (4.56), 275 (4.25), 280 (sh 4.25). 1 H NMR (CDCl3 ): 8.25-8.15 (m, 4H, 2H o to NO2 , H-N, H-C6); 7.42-7.19 (m, 11H, arom. H); 6.95 (m, 1H, H-C5): 6.86-6.81 (m, 4H, o to MeO); 6.29 (m, 1H, H-C1 ); 4.51 (m, 3H, H-C3 ); 4.41 (t, 2H, OCH2 CH2 ); 4.15 (m, 1H, H-C4 ); 3.78 (s, 6H, MeO); 3.60-3.36 (m, 3H, HO-C3 , H-C5 ); 3.09 (t, 2H, OCH2 CH2 ); 2.75 (m, 1H, H-C2 ); 2.27-2.16 (m, 1H, H-C2 ). C39 H38 N4 O10 (722.8): C 64.81, H 5.30, N 7.75; found: C 64.89, H 5.56, N 7.67. 5 -O-DMTr-N6 -NPEOC-2 -dA (S.45): yield: 3.17 g (84%). Rf (CHCl3 /MeOH 95:5) 0.34. UV: 236 (4.43), 268 (4.47), 276 (sh 4.41). 1 H NMR (CDCl3 ): 8.66 (s, 1H, H-C8); 8.36 (bs, 1H, H-N); 8.16 (d, 2H, o to NO2 ); 8.11 (s, 1H, H-C2); 7.44-7.15 (m, 9H, arom. H); 6.80 (d, 4H, o to MeO); 6.44 (pt, 1H, H-C1 ); 4.71 (m, 3H, H-C3 ); 4.53 (t, 2H, OCH2 CH2 ); 4.24 (m, 1H, H-C4 ); 3.77 (s, 6H, MeO); 3.73 (d, 1H, HO-C3 ); 3.52-3.40 (m, 2H, H-C5 ); 3.14 (t, 2H, OCH2 CH2 ); 2.91-2.51 (m, 2H, H-C2 ,2 ). C40 H38 N6 O9 ·0.5H2 O (755.8): C 63.57, H 5.20, N 11.12; found: C 63.62, H 5.21, N 10.95. 5 -O-DMTr-N2 -NPEOC-2 -dG (S.46): yield: 3.01 g (79%). Rf (CHCl3 /MeOH 95:5) 0.40. UV: 237 (4.46), 249 (4.42), 258 (4.42), 272 (sh 4.38). 1 H NMR (CDCl3 ): 11.27 (s, 1H, NH); 9.76 (s, 1H, NH); 8.00 (d, 2H, o to NO2 ); 7.75 (s, 1H, H-C8); 7.32-7.03 (m, 9H, arom. H); 6.67 (d, 4H, o to MeO); 6.15 (pt, 1H, H-C1 ); 4.80 (m, 3H, H-C3 ); 4.44 (m, 3H, HO-C3 , OCH2 CH2 ); 4.15 (m, 1H, H-C4 ); 3.65 (s, 6H, MeO); 3.30 (m, 2H, H-C5 ); 3.01 (t, 2H, OCH2 CH2 ); 2.60-2.46 (m, 2H, H-C2 ,2 ). C40 H38 N6 O10 (762.8): C 62.99, H 5.02, N 11.02; found: C 62.43, H 5.14, N 10.95. 5 -O-DMTr-N2 -NPEOC-O6 -NPE-2 -dG (S.47): yield: 3.88 g (85%). Rf (CHCl3 /MeOH 95:5) 0.43. UV: 235 (4.47), 268 (4.55). 1 H NMR (CDCl3 ): 8.15-800 (m, 3H, NH, o to NO2 ); 7.96 (s, 1H, H-C8); 7.50-7.13 (m, 9H, arom. H); 6.77 (d, 4H, o to MeO); 6.48 (m, 1H, H-C1 ); 4.81-4.74 (m, 3H, H-C3 , OCH2 CH2 ); 4.45 (t, 2H, OCH2 CH2 ); 4.16 (m, 1H, H-C4 ); 3.75 (s, 6H, MeO); 3.56-3.25 (m, 4H, H-C5 , OCH2 CH2 ); 3.09-3.03 (t, 3H, HO-C3 , OCH2 CH2 ); 2.75 (m, 1H, H-C2 ); 2.55 (m, 1H, H-C2 ). C48 H45 N7 O12 (911.9): C 63.22, H 4.97, N 10.75; found: C 63.08, H 5.14, N 10.67.
Prepare 3 -O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidites 8. Dissolve in a 50-mL round-bottom flask 1 mmol S.43 (0.729 g), S.44 (0.719 g), S.45 (0.756 g), S.46 (0.763 g), or S.47 (0.912 g) and 1.5 mmol of 2-cyanoethylN,N,N ,N -tetraisopropylphosphordiamidite in 15 mL acid-free CH2 Cl2 . Add 0.5 mmol of 1H-tetrazole (35 mg) and stir 2.5 hr at room temperature under argon atmosphere.
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.19 Current Protocols in Nucleic Acid Chemistry
Supplement 30
9. Dilute the solution with 100 mL CH2 Cl2 , extract two times with 50 mL saturated NaHCO3 solution, and reextract the aqueous phase with CH2 Cl2 . 10. Combine the organic phases, dry over Na2 SO4 , filter through filter paper, and evaporate under vacuum. 11. Purify the resulting residue by column chromatography or flash chromatography using a 40 × 2.5–cm column and the appropriate solvent system: a. b. c. d.
S.48 flash chromatography (1:1 v/v toluene/EtOAc) S.49 flash chromatography (2:1 and 1:1 v/v toluene/EtOAc) S.50 flash chromatography (3:7 and 1:1 v/v toluene/EtOAc) S.51 column chromatography (97.5:2:0.5 to 91.5:8:0.5 v/v/v CH2 Cl2 /MeOH/ Et3 N) e. S.52 column chromatography (99:1 v/v EtOAc/Et3 N) 12. Evaporate under vacuum to give a diastereoisomeric mixture as a solid foam. Dry under high vacuum at room temperature. 5 -O-DMTr-O4 -NPE-T-3 -O-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.48): yield: 0.662 g (74%). Rf (toluene/EtOAc 1:1): 0.42. UV (MeOH): 232 (sh 4.39), 275 (4.25), 280 (sh 4.24). 1 H NMR (CDCl3 ): 8.16 (d, 2H o to NO2 ); 7.90 (2s, 1H, H-C6); 7.30 (m, 11H, arom. H); 6.82 (dd, 4H o to MeO); 6.38 (m, 1H, H-C1 ); 4.63 (m, 3H, H-C3 , OCH2 CH2 ); 4.15 (m, 1H, H-C4 ); 3.78 (m, 7H, 2 MeO, OCH2 CH2 CN); 3.54 (m, 4H, 2 Me2 CHN), OCH2 CH2 CN, H-C5 ); 3.32 (m, 1H, H-C5 ); 3.16 (t, OCH2 CH2 ); 2.64 (m, 2H, OCH2 CH2 CN); 2.32 (m, 2H, H-C2 ,2 ); 1.41 (2s, 3H, H3 C-C5); 1.11 (m. 12H, 2 MeCH). 31 P NMR (CDCl3 ): 149.71, 149.16. C48 H56 N5 O12 P (894.0): C 64.49, H 6.31, N 7.83; found: C 64.45, H 6.54, N 7.31. 5 -O-DMTr-N4 -NPEOC-2 -dC-3 -O-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.49): yield: 0.785 g (85%). Rf (n-hexane/EtOAc/Et3 N 3:7:1): 0.24. UV (MeOH): 236 (4.65), 274 (4.42), 280 (sh 4.40). 1 H NMR (CDCl3 ): 8.20 (m, 2H o to NO2 ); 8.20 (2s, 1H, H-C6); 7.51-7.12 (m, 11H, arom. H); 6.74 (dd, 4H o to MeO); 6.35 (m, 2H, H-C1 , H-C5); 4.80 (m, 1H, H-C3 ); 4.80 (t, 2H, OCH2 CH2 ); 4.43 (t, 2H, OCH2 CH2 ); 4.21 (m, 1H, H-C4 ); 3.90 (m, 2H, OCH2 CH2 ); 3.73 (2s, 6H, 2 MeO); 3.70-3.47 (m, 4H, 2 Me2 CHN, OCH2 CH2 CN); 3.32 (m, 2H, H-C5 ); 3.08 (m, OCH2 CH2 ); 2.92 (m, 1H, H-C2 ); 2.75 (m, 1H, H-C2 ); 2.64 (m, 2H, OCH2 CH2 CN); 1.10-0.91 (m, 12H, 2 MeCH). 31 P NMR (CDCl3 ): 150.0, 149.9. C48 H55 N6 O11 P (923.0): C 62.46, H 6.00, N 9.10; found: C 62.46, H 6.08, N 8.83. 5 -O-DMTr-N6 -NPEOC-2 -dA-3 -O-(2-cyanoethyl-N,N-diisopropylphosphor-amidite) (S.50): yield: 0.871 g (92%). Rf (n-hexane/EtOAc/Et3 N 3:7:1): 0.25. UV (MeOH): 236 (4.45), 266 (4.47), 275 (sh 4.41). 1 H NMR (CDCl3 ): 8.68 (s, 1H, H-C8); 8.25-8.15 (m, 2H o to NO2 ); 8.01 (m, 1H, NH); 7.35 (d, 2H m to NO2 ); 7.35-7.18 (m, 11H, arom. H); 6.74 (dd, 4H o to MeO); 6.45 (m, 1H, H-C1 ); 4.74 (m, 1H, H-C3 ); 4.51 (t, 2H, OCH2 CH2 ); 4.43 (t, 2H, OCH2 CH2 ); 4.29 (m, 1H, H-C4 ); 3.75 (m, 8H, OCH2 CH2, 2 MeO); 3.52-3.43 (m, 4H, 2 Me2 CHN)); 3.31 (m, 2H, H-C5 ); 3.13 (m, OCH2 CH2 ); 2.82 (m, 1H, H-C2 ); 2.60 (m, 1H, H-C2 ); 2.59, 2.44 (2t, 2H, OCH2 CH2 CN); 1.27-1.08 (m. 12H, 2 MeCH). 31 P NMR (CDCl3 ): 149.6, 149.5. C49 H55 N8 O10 P (947.0): C 62.14, H 5.85, N 11.83; found: C 61.93, H 6.06, N 11.32.
Universal NPE and NPEOC Protecting Groups
5 -O-DMTr-N2 -NPEOC-2 -dG-3 -O-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.51): yield: 0.568 g (60%). Rf (n-hexane/EtOAc/Et3 N 95:5:2): 0.52. UV (MeOH): 237 (4.46), 249 (4.42), 258 (4.42), 272 (4.37), 281 (sh 4.31). 1 H NMR (CDCl3 ): 8.15-8.11 (m, 2H o to NO2 ); 7.76, 7.72 (2s, 1H, H-C8); 8.01 (m, 1H, NH); 7.35 (d, 2H m to NO2 ); 7.38-7.18 (m, 10H, NH, arom. H); 6.74 (d, 4H o to MeO); 6.16 (m, 1H, H-C1 ); 4.74-4.61 (m, 1H, H-C3 ); 4.44 (t, 2H, OCH2 CH2 ); 4.24 (m, 1H, H-C4 ); 3.74, 3.73 (2s, 6H, 2 MeO); 4.14-3.45 (m, 4H, OCH2 CH2 CN, 2 Me2 CHN)); 3.34-3.20 (m, 2H, H-C5 ); 3.09 (t, 2H, OCH2 CH2 ); 2.81-2.32 (m, 4H, H-C2 ,2 , OCH2 CH2 CN); 1.30-1.06 (m, 12H, 2 MeCH). 31 P NMR (CDCl3 ): 149.48, 148.89. C49 H55 N8 O11 P (963.0): C 61.12, H 5.76, N 11.64; found: C 60.80, H 5.90, N 11.40.
2.13.20 Supplement 30
Current Protocols in Nucleic Acid Chemistry
5 -O-DMTr-N2 -NPEOC-O6 -NPE-2 -dG-3 -O-(2-cyanoethyl-N,N-diisopropyl-phosphoramidite) (S.52): yield: 0.956 g (86%). Rf (EtOAc/Et3 N 99:1): 0.81, 0.72. UV (MeOH): 236 (4.48), 269 (4.55). 1 H NMR (CDCl3 ): 8.17-8.11 (m, 4H o to NO2 ); 7.96, 7.95 (2s, 1H, H-C8); 7.51-7.13 (m, 12H, H m to NO2 , NH, arom. H); 6.74 (d, 4H o to MeO); 6.36 (m, 1H, H-C(1 )); 4.82-4.70 (m, 3H, H-C3 , OCH2 CH2 ); 4.42 (t, 2H, OCH2 CH2 ); 4.24 (m, 1H, H-C4 ); 3.74 (2s, 6H, 2 MeO); 3.86-3.48 (m, 4H, OCH2 CH2 CN, 2 Me2 CHN); 3.37-3.26 (m, 4H, H-C5 , OCH2 CH2 ); 3.09 (t, 2H, OCH2 CH2 ); 2.87-2.55 (m, 2H, H-C2 ,2 ); 2.62, 2.41 (2t, 2H, OCH2 CH2 CN); 1.26-1.07 (m, 12H, 2 MeCH). 31 P NMR (CDCl3 ): 149.59, 140.38. C57 H62 N9 O13 P (1112.2): C 61.56, H 5.62, N 11.33; found: C 61.76, H 5.65, N 11.05.
Prepare phosphitylating reagent for NPE phosphoramidites For bis-(N,N-diisopropylamino)-2-(4-nitrophenyl)ethoxyphosphane 13a. Dissolve in a 100-mL round-bottom flask 28 mL (280 mmol) of freshly distilled PCl3 in 30 mL anhydrous diethyl ether under nitrogen atmosphere and cool down to −5◦ C. 14a. Add 8.35 g (50 mmol) 2-(4-nitrophenyl)ethanol in small portions over a period of 30 min, and then continue stirring 15 min at −5◦ C and finally 1.5 hr at room temperature. 15a. Evaporate under high vacuum and dissolve the resulting syrup in 200 mL anhydrous diethyl ether. 16a. Cool to −10◦ C, add slowly dropwise 64 mL (450 mmol) N,N-diisopropylamine under N2 atmosphere, and stir 15 min at −10◦ C and then 16 hr at room temperature. 17a. Filter off the precipitate of N,N-diisopropylamine hydrochloride through a G4 glass funnel and evaporate the filtrate under high vacuum to give 17.6 g (89%) of a yellowish syrup, which crystallizes on storage at −20◦ C. The product is pure enough for phosphitylation reactions. Bis-(N,N-diisopropylamino)-2-(4-nitrophenyl)ethoxyphosphane: 1 H NMR (CHCl3 ): 8.11 (d, 2H, H o to NO2 ); 7.38 (d, 2H, H m to NO2 ); 3.79 (q, 2H, P-OCH2 ); 3.513.36 (m, 2H, N-CHMe2 ); 2.97 (t, 2H, P-O-CH2 CH2 ); 1.09 (2d, 12H, N-CH(CH3 )2 ). 31 P NMR (CHCl3 ): 123.53.
For chloro-N,N-diisopropylamino-2-(4-nitrophenyl)ethoxyphosphane 13b. Dissolve in a 100-mL round-bottom flask 14 mL freshly distilled PCl3 in 40 mL anhydrous diethyl ether and cool under N2 atmosphere to −30◦ C in an isopropanol/dry ice bath. 14b. Under magnetic stirring, add 4.16 g (25 mmol) 2-(4-nitrophenyl)ethanol in small portions over a period of 45 min. 15b. Stir 1.5 hr at room temperature and evaporate under high vacuum. 16b. Cool the residue to 0◦ C and add dropwise under N2 atmosphere 4.33 g (25 mmol) N,N-diisopropyltrimethylsilylamine. Stir 30 min at 0◦ C and then 20 hr at room temperature. 17b. Evaporate under high vacuum to give 7.1 g (85%) of a yellowish syrup, which crystallizes on storage at −20◦ C. The product is pure enough for further use. Chloro-N,N-diisopropylamino-2-(4-nitrophenyl)ethoxyphosphane: 1 H NMR (CDCl3 ): 8.15 (m, 2H, H o to NO2 ); 7.41 (m, 2H, H m to NO2 ); 4.11 (m, 2H, P-OCH2 ); 3.71 (m, 2H, N-CHMe2 ); 3.10 (t, 2H, P-OCH2 CH2 ); 1.27-1.14 (2d, 12H, N-CH(CH3 )2 ). 31 P NMR (CH2 Cl2 ): 181.60.
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.21 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Prepare 3 -O-(2-(4-nitrophenyl)ethylphosphoramidites 18a. Under argon atmosphere, dissolve in a 50-mL round-bottom flask a mixture of 1 mmol tritylated nucleoside S.43 (0.729 g), S.44 (0.719 g), S.45 (0.756 g), or S.47 (0.912 g) and 1.5 mmol bis-(N,N-diisopropylamino)-2-(4-nitrophenyl) ethoxyphosphane (0.6 g) in 15 mL acid-free CH2 Cl2 . Add 0.5 mmol 1H-tetrazole (35 mg) and stir 2.5 hr at room temperature. Monitor by TLC. 18b. Alternatively, treat with 1.2 mmol chloro-N,N-diisopropylamino-2-(4nitrophenyl)ethoxyphosphane (0.416 g) and 3.8 mmol triethylamine (0.7 mL) in 15 mL acid-free CH2 Cl2 . Stir for 30 min at room temperature. Monitor by TLC. 19. Dilute the reaction mixture with 100 mL CH2 Cl2 , extract two times with 50 mL saturated NaHCO3 solution, and reextract the aqueous phase with CH2 Cl2 . 20. Combine the organic phases, dry over Na2 SO4 , filter, and evaporate. 21. Purify either by flash chromatography using a 60 × 2.5–cm column and the appropriate solvent system: a. b. c. d.
S.53 flash chromatography (99:1 v/v EtOAc/Et3 N) S.54 flash chromatography (96:4 EtOAc/Et3 N) S.55 flash chromatography (70:30:1 to 50:50:1 v/v/v toluene/EtOAc/Et3 N) S.56 flash chromatography (96:4 v/v EtOAc/Et3 N)
22. Evaporate under high vacuum to give a diastereoisomeric mixture as a solid foam. 5 -O-DMTr-O4 -NPE-T-3 -O-(2-(4-nitrophenyl)ethyl-N,N-diisopropylphosphoramidite) (S.53): yield: 0.871 g (88%). Rf (EtOAc): 0.77. UV (MeOH): 234 (sh 4.33), 275 (4.32), 281 (sh 4.30). 1 H NMR (CDCl3 ): 8.63 (m, 4H o to NO2 ); 7.61 (m, 1H, H-C6); 7.42-7.21 (m, 13H, arom. H); 6.76 (m, 4H o to MeO); 6.43 (m, 1H, H-C1 ); 4.64 (m, 3H, H-C3 , OCH2 CH2 ); 4.16 (m, 1H, H-C4 ); 3.79 (2s, 6H, 2 MeO); 3.93-3.62 (m, 4H, OCH2 CH2 ); 3.60-3.26 (m, 6H, H-C5 , 2 MeCHN, OCH2 CH2 ); 3.05-2.82 (2t, 2H, OCH2 CH2 ); 2.51 (m, 1H, H-C2 ); 2.17 (m, 1H, H-C2 ); 1.42 (s, 3H, H3 C-C5); 1.17-0.99 (m, 12H, 2 MeCH). 31 P NMR (CDCl3 ): 148.50, 147.23. C53 H60 N5 O12 P (990.1): C 64.29, H 6.18, N 7.07; found: C 63.92, H 5.96, N 6.89. 5 -O-DMTr-N4 -NPEOC-dC-3 -O-(2-(4-nitrophenyl)ethyl-N,N-diisopropylphosphoramidite) (S.54): yield: 0.927 g (91%). Rf (EtOAc/Et3 N 96:4): 0.68. UV (MeOH): 236 (4.56), 276 (4.41), 282 (sh 4.41). 1 H NMR (CDCl3 ): 8.46 8s, 1H, NH); 8.19 (2s, 1H, H-C6); 8.14-8.04 (m, 4H o to NO2 ); 7.42-7.02 (m, 13H, arom. H); 6.84 (m, 1H, H-C5, 4H o to MeO); 6.23 (m, 2H, H-C1 ); 4.58 (m, 1H, H-C3 ); 4.42 (t, 2H, OCH2 CH2 ); 4.15 (m, 1H, H-C4 ); 3.88-3.61 (m, 8H, 2 MeO, OCH2 CH2 ); 3.47 (m, 4H, H-C5 , 2 Me2 CHN); 3.10 (t, 2H, OCH2 CH2 ); 2.87 (2t, 2H, OCH2 CH2 ); 2.69 (m, 1H, H-C2 ); 2.18 (m, 1H, H-C2 ); 1.20-1.01 (m, 12H, 2 MeCHN). 31 P NMR (CDCl3 ): 148.81, 148.47. C53 H60 N6 O13 P (1019.0): C 62.46, H 5.83, N 8.24; found: C 62.24, H 5.81, N 8.00.
Universal NPE and NPEOC Protecting Groups
5-O-DMTr-N6 -NPEOC-dA-3 -O-(2-(4-nitrophenyl)ethyl-N,N-diisopropylphosphoramidite) (S.55): yield: 0.907 g (87%). Rf (EtOAc): 0.66. UV (MeOH): 236 (4.45), 267 (4.58), 274 (sh 4.55). 1 H NMR (CDCl3 ): 8.68 (s, 1H, H-C8); 8.31 (bs, 1H, NH); 8.25 (s, 1H, H-C2); 8.15 (m, 4H o to NO2 ); 7.42-7.12 (m, 13H, arom. H); 6.75 (d, 4H o to MeO); 6.35 (m, 1H, H-C1 ); 4.65 (m, 1H, H-C3 ); 4.42 (t, 2H, OCH2 CH2 ); 4.21 (m, 1H, H-C4 ); 3.90-3.70 (m, 2H, OCH2 CH2 ); 3.73 (2s, 6H, 2 MeO); 3.52-3.43 (m, 4H, 2 Me2 CHN); 3.31 (m, 2H, H-C5 ); 3.08 (t, OCH2 CH2 ); 3.00-2.82 (m, 3H, H-C2 , OCH2 CH2 ); 2.62 (m, 1H, H-C2 ); 1.25-1.02 (m. 12H, 2 MeCH). 31 P NMR (CDCl3 ): 148.67, 148.37. C54 H59 N8 O12 P (1043,1): C 62.18, H 5.70, N 10.74; found: C 61.78, H 6.07, N 9.96.
2.13.22 Supplement 30
Current Protocols in Nucleic Acid Chemistry
5-O-DMTr-N2 -NPEOC-O6 -NPE-dG-3 -O-(2-(4-nitrophenyl)ethyl-N,N-diisopropylphosphoramidite) (S.56): yield: 1.1 g (91%). Rf (EtOAc/Et3 N 96:4): 0.83. UV (MeOH): 237 (4.46), 269 (4.60). 1 H NMR (CDCl3 ): 8.17-8.05 (m, 6H o to NO2 ); 7.95 (s, 1H, H-C8); 7.51-7.14 (m, 15H, arom. H); 6.74 (d, 4H o to MeO); 6.35 (m, 1H, H-C1 ); 4.80 (t, 2H, OCH2 CH2 ); 4.65 (m, 1H, H-C3 ); 4.43 (t, 2H, OCH2 CH2 ); 4.20 (m, 1H, H-C4 ); 3.90 (m, 2H, OCH2 CH2 ); 3.73 (2s, 6H, 2 MeO); 3.52-3.43 (m, 4H, 2 Me2 CHN); 3.31 (2m, 4H, H-C5 , OCH2 CH2 ); 3.09 (t, 2H, OCH2 CH2 ); 3.00-2.84 (m, 2H, OCH2 CH2 ); 2.82 (m, 1H, H-C2 ); 2.45 (m, 1H, H-C2 ); 1.25-1.02 (m, 12H, 2 MeCH). 31 P NMR (CDCl3 ): 148.37, 148.28. C62 H66 N9 O15 P (1208.2): C 61.63, H 5.51, N 10.43; found: C 60.77, H 5.75, N 10.20.
COMMENTARY Background Information The chemical synthesis of oligonucleotides during the last 50 years was marked by a tremendous effort to develop new protecting groups for the various funtionalities of nucleosides and nucleotides. It is common practice to use different protecting groups for each functional group of the nucleobase, the sugar moiety, and the phosphite and phosphate functions. This approach works very well in many instances, but has the disadvantage of a multistep reaction sequence to remove, in the final procedure, all blocking groups and yield the unprotected oligonucleotide. The deprotection process can be simplified by using universal protecting groups (Himmelsbach et al., 1984), especially for the functional groups of the nucleobases and, if necessary, for the hydroxyl groups of the sugar moiety as well as the phosphite and phosphate functions. These universal protecting groups are removed in a one-step reaction at the end of oligonucleotide synthesis. This unit describes the use of an improved protection methodology in the phosphotriester and phosphoramidite approach of oligonucleotide synthesis. The 2-(4-nitrophenyl)ethyl group (Uhlmann and Pfleiderer, 1978, 1980, 1981) provides an advanced phosphateprotecting group due to its chemical inertness in the condensation steps, its stability towards mild acid and base hydrolyses, and its easy cleavage in aprotic solvents by DBU and DBN, respectively, in a β-elimination reaction (Pfleiderer, 1978; Pfleiderer et al., 1980; Pfleiderer and Ichiba, 1981; Uhlmann et al., 1981; Charubala and Pfleiderer 1982; Himmelsbach and Pfleiderer, 1982). In addition, the phenylethyl group can be tuned regarding its stability in the β-elimination process by virtue of the nature of the electron-attracting and electron-donating substituents at the phenyl moiety. In its initial development, the 2-(4-nitrophenyl)ethyl group turned out to fulfill all criteria best in
oligonucleotide synthesis and was considered the most appropriate universal protecting group (Uhlmann and Pfleiderer, 1981).
Compound Characterization 1
H NMR spectra (250 MHz) were measured on a Bruker WM 250 instrument and 31 P NMR spectra on a Jeol 400 (400 MHz) instrument in DMSO-d6 or CDCl3 . Chemical shifts are given in ppm. UV spectra were performed on a Perkin-Elmer Lambda 15 instrument in MeOH (λ max in nm; log ε in brakets; sh = shoulder).
Critical Parameters The protection procedures are straightforward and can be performed by a skilled researcher without problems when following the protocols as outlined. The phosphitylations are more problematic due to the sensitivity of the reaction products, and require some practice and experience with this type of chemistry. The described reaction conditions should not be modified, and the applied starting materials and synthesized intermediates should always be of high purity. Phosphoramidites should be stored in sealed vials in a deep freezer at −20◦ C. Crystalline substances are always more stable than amorphous solids or syrupy materials. Preparative scales for the synthesis of the NPE- and NPEOC-protected nucleosides and their 5 -O-dimethoxytrityl derivatives can be increased without loss of the anticipated yields.
Anticipated Results Following the detailed protocols coupled with experience in nucleic acid chemistry will lead to the reported high yields. The advantage of the NPE- and NPEOC-protected nucleosides is seen in their relatively high stability towards weak acidic and basic reaction conditions allowing chemical modifications at the sugar moiety. The synthesized nucleoside derivatives are very stable and can be stored
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.23 Current Protocols in Nucleic Acid Chemistry
Supplement 30
at room temperature for a long period of time without decomposition.
Time Considerations The total time from a starting nucleoside to its fully protected nucleoside-3 -Ophosphoramidite will be at least 1 week.
Literature Cited Barone, A.D., Tang, J.Y., and Caruthers, M.H. 1984. In situ activation of bis-dialkylaminophosphines—A new method for synthesizing deoxyoligonucleotides on polymer supports. Nucl. Acids Res. 12:4051-4061. Beltz, R.E. and Visser, D.W. 1955. Growth inhibition of Escherichia coli by new thymidine analogs. J. Am. Chem. Soc. 77:736-738. Bredereck, H. 1947. Methylierung von nucleosiden durch diazomethan. Chem. Ber. 80:401-405. Brown, D.M., Todd, A., and Varadarajan, S. 1956. The structure of uridylic acids a and b, and a synthesis of spongouridine (3-β-D-arabofuranosyluracil). J. Chem. Soc. 1956:2388-2393. Caruthers, M.H., Beaucage, S.L., Becker, C., Efcavitch, W., Fisher, E.F., Galluppi, G., DdeHaseth, P., Martin, F., Mateucci, M., and Stabinsky, Y. 1982. Genetic Engineering Principles and Methods (J.K. Setlow and A. Hollaender, eds.) Vol. 4, p. 1. Plenum Press, New York.
Jones, S.S., Reese, C.B., Sibanda, S., and Ubasawa, A. 1981. The protection of uracil and guanine residues in oligonucleotide synthesis. Tetrahedron Lett. 22:4755-4758. Lang, H., Gottlieb, M., Schwarz, H., Farkas, S., Schulz, B.S., Himmelsbach, F., Charubala, R., and Pfleiderer, W. 1999. New 2-(4-nitrophenyl)ethyl (NPE)- and 2-(4-nitrophenyl)ethoxycarbonyl (NPEOC)protected 2 -deoxyribonucleosides and their 3 -phosphoramidites—Versatile building blocks for oligonucleotide synthesis. Helv. Chim. Acta 82:2172-2185. Mitsunobu, O. 1981. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1-28. Pfleiderer, W. 1978. Modern strategy in oligonucleotide chemistry. Les Colloques de l’INSERM. Nucleosides Nucleotides 81:177193. Pfleiderer, W. and Ichiba, M. 1981. Chemical synthesis of the ribo-hexamer CpApApCpCpA. Nucl. Acids Res. 9:169-172. Pfleiderer, W., Uhlmann, E., Charubala, R., Flockerzi, D., Silber, G., and Varma, R.S. 1980. Recent progress in oligonucleotide synthesis. Nucl. Acids Res. 7:61-71.
Charubala, R. and Pfleiderer, W. 1982. Synthesis of inosinate trimer I2 p5 I2 p5 I and tetramer I2 p5 I2 p5 I2 p5 I. Tetrahedron Lett. 23:47894792.
Reese, C.B. and Ubasawa, A. 1980. Reaction between 1-arenesulphonyl-3-nitro-1,2,4-triazoles and nucleoside base residues. Tetrahedron Lett. 22:2265-2268.
Daskalov, H.P., Sekine, M., and Hata, T. 1981. Synthesis and properties of O6-substituted guanosine derivatives. Bull. Chem. Soc. Jpn. 54: 3076-3083.
Schaller, H., Weimann, G., Lerch, B., and Khorana, H.G. 1963. The stepwise synthesis of specific deoxyribopolynucleotides. Protected derivatives of deoxyribonucleosides and new syntheses of deoxyribonucleoside-3 -phosphates. J. Am. Chem. Soc. 85:3821-3827.
Flockerzi, D., Silber, G., Charubala, R., Schlosser, W., Varma, R.S., Creegan, F., and Pfleiderer, W. 1981. Synthese und eigenschaften von 2 -O-und 3 -O-(tert.Butyldimethyl-silyl)-5 -O(4-methoxytrityl)-sowie 2 ,3 -Bis-O-(tert.butyldimethylsilyl(ribonucleosiden—Ausgangssubstanzen f¨ur oligoribonucleotid-synthesen. Liebigs Ann. Chem. 1981:1568-1585. Gaffney, B.L. and Jones, R.A. 1982. A new strategy for the protection of deoxyguanosine during oligonucleotide synthesis. Tetrahedron Lett. 23:2257-2260. Hayes, D.H., Michelson, A., and Todd, A.R. 1955. Mononucleotides derived from deoxyadenosine and deoxyguanosine. J. Chem. Soc. 1955:803815. Himmelsbach, F. and Pfleiderer, W. 1982. Bis-(pnitrophenylethyl)phosphoromono-chloridate, a versatile phosphorylating agent. Tetrahedron Lett. 23:4793-4796.
Universal NPE and NPEOC Protecting Groups
Hunt, B.J. and Rigby, W. 1967. Short column chromatography. Chem. Ind. 65:1868-1869.
Himmelsbach, F., Schulz, B.S., Trichtinger, T., Charubala, R., and Pfleiderer, W. 1984. The pnitrophenylethyl (NPE) group, a versatile new blocking group for phosphate and aglycone protection in nucleosides and nucleotides. Tetrahedron 40:59-72.
Sinha, N.D., Biernat, J., and K¨oster, H. 1984. Polymer support oligonucleotide synthesis XVIII: Use of β-cyanoethyl-N,Ndialkylamino/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucl. Acids Res. 12:4539-4557. Sobol, R.W., Henderson, E.E., Kon, N., Shao, J., Hitzges, P., Mordechai, E., Reichenbach, N.L., Charubala, R., Pfleiderer, W., and Suhadolnik, R.J. 1995. Inhibition of HIV1 replication and activation of RNase L by phosphorothioate/phosphodiester 2 ,5 oligoadenylate derivatives. J. Biol. Chem. 270:5963-5678. Ti, G.S., Gaffney, B.L., and Jones, R. 1982. Transient protection: Efficient one-flask syntheses of protected deoxynucleosides. J. Am. Chem. Soc. 104:1316-1319. Trichtinger, T., Charubala, R., and Pfleiderer, W. 1983. Synthesis of O6 -p-nitrophenyl-ethyl guanosine and 2 -deoxyguanosine derivatives. Tetrahedron Lett. 25:711-714.
2.13.24 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Uhlmann, E. and Pfleiderer, W. 1978. New phosphate protecting groups in nucleotide synthesis. Nucl. Acids Res. 4:s25-s28. Uhlmann, E. and Pfleiderer, W. 1980. New improvements in oligonucleotide synthesis by use of the p-nitrophenylethyl phosphate blocking group and its deprotection by DBU or DBN. Tetrahedron Lett. 22:1181-1184. Uhlmann, E. and Pfleiderer, W. 1981. Substituierte β-phenylethyl-gruppen. Neue schutzgruppen f¨ur oligonucleotide-synthesen nach dem phosphors¨auretriester-verfahren. Helv. Chim. Acta 64:1688-1703. Uhlmann, E., Charubala, R., and Pfleiderer, W. 1981. Synthesis of 3 -terminal nucleoside phosphates using the p-nitrophenylethyl blocking group. Nucl. Acids Res. 9:131-134. Watkins, B.E., Kiely, J.S., and Rapoport, H. 1982. Synthesis of oligodeoxyribo-nucleotides using N-benzyloxycarbonyl-blocked nucleosides. J. Am. Chem. Soc. 104:5702-5708. Zon, G., Gallo, K.A., Samson, C.J., Shao, K., Byrd, R.A., and Summers, M.F. 1985. Analytical studies of ‘mixed sequence’ oligodeoxyribonucleotides synthesized by competitive coupling of either methyl- or β-cyanoethyl-N,Ndiisopropylamino phosphoramidite reagents, including 2 -deoxyinosine. Nucl. Acids Res. 13:8181-8196.
Protection of Nucleosides for Oligonucleotide Synthesis
2.13.25 Current Protocols in Nucleic Acid Chemistry
Supplement 30
CHAPTER 3 Synthesis of Unmodified Oligonucleotides INTRODUCTION ecause of the significant progress achieved in the chemical synthesis of oligonucleotides during the past four decades, synthetic oligonucleotides have become readily available and have fueled the biotechnology revolution that has irreversibly changed biomedical research and the pharmaceutical industry. For example, without the ability to rapidly and efficiently synthesize DNA oligonucleotides, the development of the polymerase chain reaction (PCR) and its multiple applications would have been difficult, if not impossible, because this technology is completely dependent upon the use of DNA primers. Similarly, the availability of synthetic oligonucleotides has been instrumental in the development of automated DNA sequencing, which is also dependent on the use of DNA primers. An important biological application of synthetic oligonucleotides relates to site-specific mutagenesis of genes. Mutagenesis of this type has been utilized to study protein structure-function relationships, and to alter the therapeutic spectrum of pharmaceutically active proteins. Synthetic oligonucleotides have also found application as diagnostic hybridization probes and, more recently, in the use of DNA chips for highthroughput detection of genetic diseases and identification of genomic single-nucleotide polymorphisms. Furthermore, the availability of synthetic RNA oligonucleotides has led to the preparation of ribozymes, which are RNAs with catalytic activity. In this regard, it is being speculated that RNA may have been the primary self-replicating molecule from which life originated. Collectively, the multiple biomedical applications of synthetic DNA and RNA oligonucleotides are a direct measure of the colossal impact the methods for rapid and efficient preparation of these biomolecules have had on the life sciences.
B
Like Chapter 2, this chapter is composed of a number of overviews that provide investigators with a fundamental knowledge of solid-phase oligonucleotide synthesis, as well as a number of step-by-step protocols delineating the preparation of various oligonucleotides from suitably protected nucleoside phosphoramidite or H-phosphonate derivatives. browses through the physical and chemical properties of liquid-phase and solidphase supports that have been developed over the years, and compares their suitability for oligonucleotide synthesis. The unit also examines the properties of linkers for transient or permanent attachment of properly protected nucleosides to the derivatized support of interest. Conditions for the release of synthetic oligonucleotides from specific supports have been discussed in detail. A step-by-step protocol for the attachment of nucleosides to commonly functionalized supports via either a succinyl or a hydroquinone-O,O -diacetyl linker is provided in UNIT 3.2. In this context, an ultra fast and efficient functionalization of solid supports has been achieved using microwave-assisted protocols. The details of these innovative procedures are addressed in UNIT 3.13. To facilitate synthesis in multiwell plates, deoxyribonucleoside phosphoramidites that have a cleavable linker between the 3 -hydroxyl of the nucleoside and the phosphoramidite moiety have been developed to functionalize underivatized amino supports in any well. This approach eliminates the error-prone placement of nucleoside-specific prederivatized supports into the correct wells for the preparation of specific DNA sequences. Moreover, this approach enables one to synthesize and isolate oligonucleotides with a free 3 -hydroxyl without the requirement for additional cleavage or deprotection steps. UNIT 3.12 outlines the preparation of these UNIT 3.1
Current Protocols in Nucleic Acid Chemistry 3.0.1-3.0.3, September 2007 Published online September 2007 in Wiley Interscience (www.interscience.wiley.com). DOI: 10.1002/0471142700.nc0300s30 C 2007 John Wiley & Sons, Inc. Copyright
Synthesis of Unmodified Oligonucleotides
3.0.1 Supplement 30
novel phosphoramidite synthons and their use in the synthesis of oligonucleotides in multi-well plates or in the tandem synthesis of multiple oligonucleotides in a single strand. UNIT 3.16 features the use of 5 -O-DMTr-deoxyribonucleoside tert-butyl phosphoramidites in the phosphitylation of a hydroxylated solid support. Cleavage of the 5 -O-DMTr group from the nucleoside phosphite triester under acidic conditions allows standard solidphase oligonucleotide synthesis to proceed while generating a strategic H-phosphonate diester function linking the oligonucleotide to the solid support. This H-phosphonate diester linkage enables post-synthesis release of the oligonucleotide with free 5 - and 3 hydroxyls from the universal and recyclable solid support via a simple transesterification reaction. Solid-phase synthesis of oligonucleotides is governed by a number of parameters. For example, UNIT 3.3 reviews the mechanism of activation of deoxyribonucleoside phosphoramidites, the type of activators required for such activation, and the consequences of an activator’s acidity on the production of synthetic oligonucleotides. Steric factors affecting the condensation rates of deoxyribonucleoside phosphoramidites and the significance of “capping” and oxidation reactions in the chemical synthesis of oligonucleotides, along with oligonucleotide deprotection strategies, are discussed at length in the unit. Finally, UNIT 3.3 deals with the application of dinucleotide and trinucleotide phosphoramidites as alternatives to monomeric deoxyribonucleoside phosphoramidites in the synthesis of DNA oligonucleotides. In this regard, UNIT 3.14 provides a detailed procedure for the solution-phase synthesis of short oligonucleotides using deoxyribonucleoside phosphoramidites with solid-supported reagents such as polyvinyl pyridinium tosylate as an activator for the coupling reaction and polymer-bound periodate or tetrathionate as an oxidant. The method is particularly attractive for the clean preparation of di- and trinucleotides, which can be converted to 3 -phosphoramidite or 3 -H-phosphonate monoester building blocks and used in solid-phase oligonucleotide synthesis. Additional synthetic strategies and parameters related to the synthesis of oligodeoxyriboand oligoribonucleotides according to the H-phosphonate method are discussed in UNIT 3.4. An optimized synthetic protocol for oligoribonucleotide synthesis is described to further validate the potential of the method. The chemical synthesis of DNA oligonucleotides without nucleobase protection has been and is still an elusive goal. An overview of the strategies that have been developed so far to achieve this goal is presented in UNIT 3.10. A successful synthetic approach to the preparation of deoxyribonucleoside phosphoramidites without nucleobase protecting groups is summarized in UNIT 3.15. These monomeric phosphoramidites are amenable to automated solid-phase oligonucleotide synthesis and may thus become invaluable tools. Strategies in the selection of N-, 5 -O-, and 2 -O-protecting groups for efficient synthesis of oligoribonucleotides according to the phosphoramidite approach are discussed in depth in UNIT 3.5. Critical synthesis parameters such as the type of support being used and selection of the optimal activator for ribonucleoside phosphoramidites, as well as oligonucleotide deprotection protocols, are also reviewed in the unit to provide a comprehensive account of RNA phosphoramidite chemistry. As a logical extension of UNIT 3.5, the solid-phase synthesis of oligoribonucleotides with 2 -O-tert-butyldimethylsilyl, 2 -O-(2nitrobenzyloxymethyl), or 2 -O-[(triisopropylsilyl)oxy]methyl groups according to the phosphoramidite approach is delineated in UNITS 3.6–3.8, respectively, along with detailed methods for the deprotection of these oligonucleotides.
Introduction
In future supplements, this chapter will also incorporate step-by-step protocols describing new methods for the synthesis of unmodified DNA oligonucleotides that employ either new phosphate-protecting groups or novel coupling procedures to accommodate specific nucleic acid applications. In this regard, the use of 3-(N-tert-butylcarboxamido)-1-propyl
3.0.2 Supplement 30
Current Protocols in Nucleic Acid Chemistry
and 4-oxopentyl groups for phosphate/thiophosphate protection in solid-phase DNA synthesis is presented in UNIT 3.9, along with that of the 4-methylthio-l-butyl group in UNIT 3.11. These protecting groups may find application in large-scale preparations of therapeutic oligonucleotides. Likewise, oligoribonucleotide synthesis protocols comparing the properties of selected 2 -O-protecting groups, coupling methods, and deprotection conditions will be included in an effort to contribute the best nucleic acid tools to investigators pushing further the frontiers of knowledge. Serge L. Beaucage
Synthesis of Unmodified Oligonucleotides
3.0.3 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Solid-Phase Supports for Oligonucleotide Synthesis INTRODUCTION TO SOLID-PHASE SYNTHESIS The quest to understand and create biological molecules has long challenged synthetic chemists. In particular, the chemical synthesis of peptides and nucleic acids has always been a major pursuit. The primary structure of these molecules is a linear assembly of repeating units linked together in a defined orientation. Although solution-phase synthetic methods for coupling small units together were developed many years ago, the large number of couplings needed to assemble useful sequences was daunting. This was because each step required some type of workup, extraction, or purification, and the labor and cumulative loss of material from all the manipulations rapidly became significant problems. Indeed, the pioneering work by Khorana (1979) on total gene synthesis was not considered of practical importance by some researchers because of the enormous effort involved. The problems involved in performing so many repetitive steps were addressed by Merrifield (1965) with the introduction of solidphase synthesis (Fig. 3.1.1). In this strategy, a large insoluble support is covalently linked to the end of the sequence being assembled. The product on the surface of the support is available to react with reagents in the surrounding solution phase. The extended products remain covalently linked to the insoluble support while unreacted reagents remain free in solution. Therefore, at the completion of each step, the products can be rapidly and conveniently isolated by simply washing the unbound reagents away from the support. This can be performed as easily as filtering off the support and washing it with solvent. The support with its attached product is then ready for immediate use in the next step, as long as moisture contamination has not been introduced (in which case the support must be dried before use). In practice, it is convenient to handle the supports inside sealed reactors or columns so exposure to the atmosphere is minimized. This is also ideal for automation and the necessary reagent additions and solvent washes are readily mechanized. The process of adding each unit is repeated over and over until the desired sequence has been assembled on the surface of the support. The product can then be released from the support
UNIT 3.1
by cleavage of the covalent attachment (linker arm), and after removing the protecting groups, the synthesis is complete. This strategy was originally applied to peptide synthesis, but it is also applicable to other linear macromolecules, such as DNA and RNA (Beaucage and Iyer, 1992) and oligosaccharides (Adinolfi et al., 1996). Recently, there has been a great deal of interest in applying this strategy to the combinatorial synthesis of small molecules and a new field of solid-phase organic chemistry (SPOC) is rapidly developing (Fruchtel and Jung, 1996; Porco et al., 1997). In this review, the main focus is on supports for oligodeoxyribonucleotide and oligoribonucleotide synthesis. The synthetic strategies are often similar, particularly when synthetic libraries are prepared.
ADVANTAGES OF SOLID-PHASE SYNTHESIS The principal advantage of solid-phase synthesis is the ease with which immobilized products can be separated from other reactants and by-products. The simple filtration and washing steps are readily automated, and the method is ideal for the synthesis of linear molecules, which require the repetition of the same steps for every chain extension cycle. The use of insoluble solid-phase supports also permits relatively small quantities of material to be synthesized, because the additional physical bulk of the support, which is ~10 to 100 times the mass of the attached nucleoside, can be handled more easily than the nucleoside alone. Also confinement of the support inside a synthesis column eliminates handling losses. A small synthesis scale is important because of the high cost of reagents. Very little material is required for many biochemical applications and most syntheses actually prepare much more material than required. Therefore, as instrumentation has improved, the synthesis scale has decreased. Presently, synthesis on a 40-nmol scale, instead of a 0.2- to 1-µmol scale, is preferred for may applications. Oligonucleotide synthesis on a picomole scale or less may eventually become more common (Weiler and Hoheisel, 1997). It is already possible to synthesize molecules on single beads and to characterize the picomole quantities of synthetic peptides (Rapp, 1997) or oligonu-
Contributed by Richard T. Pon Current Protocols in Nucleic Acid Chemistry (2000) 3.1.1-3.1.28 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Unmodified Oligonucleotides
3.1.1
Solid-Phase Supports for Oligonucleotide Synthesis
Figure 3.1.1 The general strategy for solid-phase oligonucleotide synthesis. The first step is attachment of a mononucleoside/tide (N1) to the surface of an insoluble support (P) through a covalent bond. Excess monomers, which are not chemically attached to the support, are washed away. Before chain elongation can proceed, the terminal-protecting group (=) on the nucleoside must be removed. This exposes a free 5′-OH or 3′-OH group, depending on the orientation of the synthesis. Usually synthesis proceeds from the 3′- to 5′-direction and the terminal protecting group is an acid-labile DMTr group. The next nucleotide unit (N2) can then be added using the appropriate synthesis chemistry (usually phosphoramidite). An excess of reagent is used to force the coupling reaction to occur on as many of the immobilized nucleotides as possible. After the coupling reaction, excess reagents are washed away. Depending on the coupling chemistry, the reaction is followed by a capping step, to block off nonextended sites, and an oxidation step (these steps are not shown; see UNIT 3.3 for details) to complete the chain-extension cycle. The process of terminal-protecting group removal and chain extension is then repeated, using different bases, until the desired sequence has been assembled. Some or all of the protecting groups may optionally be removed, and then the covalent attachment to the support is hydrolyzed to release the product. After removal of any remaining protecting groups, the oligonucleotide is ready for purification and use.
3.1.2 Current Protocols in Nucleic Acid Chemistry
cleotides (Seliger et al., 1997) present on single beads. The simplicity and similarity of the steps required for each chain extension reaction also greatly facilitate synthesis of modified oligonucleotides. As long as the modified substituents do not require any incompatible chemical treatments (i.e., to remove protecting groups), the inclusion of different bases and nucleosides, linkage inversions, branch points, non-nucleotide units, and end modifications can be readily accomplished. This is particularly so when the modified substituents are available as phosphoramidite derivatives, which use the same coupling chemistry as do regular bases (Beaucage and Iyer, 1993). Chimeric oligonucleotides containing peptide or peptide nucleic acid (PNA) sequences can, however, also be prepared (Bergmann and Bannwarth, 1995; Hyrup and Nielsen, 1996; van der Laan et al., 1997). Although, in these cases, the different coupling conditions and protecting groups require much more attention to ensure overall compatibility. Finally, combinatorial methods can be used to create large numbers of different sequences. In the simplest application, multiple bases (“mixed bases”) can be incorporated at defined positions by using a mixture of different monomers, instead of a single monomer, in the chain extension reaction. This procedure was originally developed to prepare oligonucleotide probes from peptide sequences when the exact codon usage was unknown. Later, this method became important when large libraries of degenerate or random sequences were required for in vitro selection experiments, such as the systematic evolution of ligands by exponential enrichment (SELEX) technique (Gold et al., 1995; see Chapter 9). Although DNA synthesizers can prepare mixed-base sites by on-line mixing, large numbers of degenerate sites are best made up by manually preparing solutions containing the desired ratio of nucleotides and incorporating the premixed reagents on the synthesizer. This is also the procedure used in base doping, when only one base, at random, within a particular section needs to be mutated (Hermes et al., 1989). Another combinatorial approach was developed to simplify the synthesis of large numbers of oligonucleotides. This procedure used cellulose disks of filter paper as the insoluble support and became known as filter disk or segmented solid-phase synthesis (Frank et al., 1983; Matthes et al., 1984; Ott and Eckstein, 1984; Frank, 1993). In this procedure, multiple filter disks
(each producing one unique oligonucleotide) are stacked together and handled at once. Reagents can be easily passed through the stack from top to bottom, and the number of oligonucleotides synthesized is limited only by the maximum stack height that can be manipulated. A different oligonucleotide sequence is prepared on each disk by interrupting the synthesis after each chain extension step. The individual filter disks are then sorted into separate piles according to the next base to be added. The insoluble support in this case provides the means to sort the products and to separate them from the excess reagents. For normal oligonucleotides, the sorting results in a maximum of four piles, because only dA, dC, dG, and T base additions are required. Thus an operator manipulating four concurrent syntheses can produce a large number of oligonucleotides per day. This method is not limited to paper filter disks; stackable “synthesis wafers” containing packets of support in bead form have also been used. The sorting step, however, is quite difficult to automate; and although semimechanized instruments have been reported (Seliger et al., 1987; Beattie et al., 1988), the segmented approach has not been widely adopted. The ease with which immobilized oligonucleotides can be manipulated has also lead to the development of combinatorial strategies for the synthesis of oligonucleotide libraries. Unlike the above strategies, which release the oligonucleotide product from the support at the end of the synthesis, the oligonucleotides are left attached to the insoluble support (Markiewicz et al., 1994). This method can be used to create dispersed libraries, when the sequences are prepared on separate beads, or integrated libraries, when one- or two-dimensional arrays of sequences are prepared on a single surface. The sequence identity of each element in an integrated array is known from its spatial coordinates, whereas the sequence of elements in a dispersed library must be deduced from either direct sequencing (Seliger et al., 1997) or other sequence tags. The most elegant and powerful demonstration of this technique is the synthesis of high-density arrays on small (1.28 cm2) glass chips using photolithography and light-sensitive protecting groups (Fodor et al., 1991). With the appropriate masking, any set of oligonucleotides of length N can be performed using only 4N coupling steps, and this technique can produce arrays of >106 different sequences (Lipshutz et al., 1995; McGall et al., 1996). Other combinatorial strategies using either glass plates (Milner et al., 1997) or
Synthesis of Unmodified Oligonucleotides
3.1.3 Current Protocols in Nucleic Acid Chemistry
polypropylene sheets (Matson et al., 1995; Weiler and Hoheisel, 1996) as the insoluble support have been described for the synthesis of oligonucleotide arrays, although the array densities were much lower.
DISADVANTAGES OF SOLID-PHASE SUPPORTS Although a powerful technique, solid-phase synthesis has some drawbacks. The main limitation is the need for very high coupling yields in every chain extension step. This is because the overall yield of product decreases rapidly as the number of consecutive chain extension steps increases (Fig. 3.1.2). For example, if each base addition step had a yield of 90%, then the amount of dinucleotide produced (one base addition) is 90%. The yield of trinucleotide (two base additions) is 0.90 × 0.90 × 100% = 81%; the yield of tetranucleotide (three base additions) is 0.90 × 0.90 × 0.90 × 100% = 73%; and so on. Note that the first nucleoside is attached to the insoluble support before the start of oligonucleotide synthesis and the efficiency of that step is not included in the calculation. The mathematical relationship between the overall yield (OY) and the average coupling efficiency (AY) is either n
AY OY = × 100% 100
or N−1
AY OY = 100
Solid-Phase Supports for Oligonucleotide Synthesis
× 100%
where n is the number of coupling steps and N is the length of the oligonucleotide. The second equation assumes that the synthesis was performed by extending the product by one base at a time, as is usual. The consequence of the exponential relationship between overall yield and average coupling efficiency is that long oligonucleotides cannot be prepared without very high yields in every step. The most difficult step is usually the coupling reaction; but in some strategies (e.g., light-directed synthesis of arrays or the use of liquid-phase supports), quantitative removal of the terminal-protecting group is also problematic. Coupling yields that would be acceptable for most solution-phase reactions (e.g., the 90% yield assumed in the above example) are not adequate; only yields >98% are acceptable. The lack of a coupling reaction that could reliably produce such high efficiencies was the major reason why solid-phase oligonucleotide synthesis was not successful until the early 1980s. After the discovery of trivalent phosphite–coupling chemistry and phosphoramidite derivatives (Caruthers, 1991), however, average coupling efficiencies of 99% or more were possible. Such high coupling efficiencies now allow oligonucleotides as long as 200 bases to be prepared (Bader et al., 1997b). Another consequence of producing less than 100% coupling efficiencies is the accumulation of failure sequences containing deletions. The number of these failure products can be greatly reduced by the addition of a capping step after each chain extension reaction. This step, which typically uses acetic anhydride to acetylate nonextended molecules, prevents the failure
Figure 3.1.2 Overall yield vs. number of couplings. The overall yield of full-length product decreases with the number of coupling reactions for average coupling efficiencies of 90%, 95%, 98%, and 99%.
3.1.4 Current Protocols in Nucleic Acid Chemistry
sequences from participating in any further reactions; however, a series of failure sequences, each one base shorter than the desired full-length product, will be present at the end of the synthesis. Separating the full-length product (of length N) from the shorter failure sequences and especially the N – 1 failure sequence is another significant problem. This purification step becomes more difficult as oligonucleotide length increases, and for oligonucleotides greater than ~30 bases long, only polyacrylamide gel electrophoresis (PAGE) has sufficient resolving power to separate the full-length product from the N – 1 component. Fortunately, however, many biochemical applications do not have stringent purity requirements; and if the coupling efficiency was high enough, the mixture of products produced can often be used with either minimal (desalting) or no purification (Pon et al., 1996). Analysis of the synthetic products still attached to the surface of the insoluble support also presents a major difficulty for researchers developing new techniques or new solid-phase supports. This is an especially significant problem for applications using immobilized arrays, because removal of the products for characterization is often difficult, if not impossible. Nuclear magnetic resonance (NMR) studies of immobilized products on solvent-swollen (gelphase) polymers (Bardella et al., 1993) can be performed; but because such supports are not preferred for oligonucleotide synthesis, there have been few studies relating to oligonucleotide synthesis. Rigid supports can be studied using NMR and magic angle spinning, but there has been only one report of 31P NMR performed on controlled-pore glass (CPG) particles with oligonucleotides (Macdonald et al., 1996). Recently, ellipsometry, interferometry, and optical wave guides have been used to study oligonucleotide arrays (Stimpson et al., 1995; Gray et al., 1997), but these techniques do not provide specific information about the fidelity of the oligonucleotide synthesis. Finally, the cost of the support is a major factor when performing large-scale syntheses because, even with high loading supports, ∼3 g of support is required for each gram of oligonucleotide product. Because most supports are expensive and can be used only once, there is a strong economic incentive to develop methods for regenerating and reusing the supports, especially when tonne quantities of products are required. Recently, examples of up to 12 syntheses of oligonucleotide phosphodiester
(Pon et al., 1999) and phosphorothioate (Pon et al., 1998) sequences on the same reusable supports have appeared, and further improvements in this area are expected.
CHEMICAL REQUIREMENTS FOR SOLID-PHASE SUPPORTS A wide variety of different insoluble support materials have been developed for different applications. The ideal support should contain an appropriate chemical group on its surface that can be selectively coupled, usually through a linker arm, to the first monomer unit. Normally, supports for oligonucleotide synthesis are purchased with primary amino group functionality, although hydroxyl and carboxyl derivatized supports may also be obtained. The amount of surface derivatization (loading) on the support determines the maximum amount of product that can be prepared. Supports with loadings of 100 to 1000 µmol/g or more are available for the synthesis of either peptides or small molecules (Winter, 1996). Oligonucleotide synthesis, however, is almost always performed using nucleoside loadings of less than ~100 µmol/g; optimum results are obtained on supports with less than ~40 µmol/g of nucleoside, because the efficiency of coupling decreases as the number of molecules on the surface increases. Because the amount of support can usually be increased to accommodate the scale required, supports with loadings >50 µmol/g are not commonly used. The lower coupling efficiencies obtained with higher loaded supports can actually make it counterproductive to use these materials in most automated DNA synthesizers. The structure of the compound(s) used to join the surface of the support to the first nucleoside is also of critical importance (Fig. 3.1.3). This attachment is generally composed of two distinct portions. The first portion is the spacer that connects the active functional group (usually NH2 or OH groups) to the matrix of the insoluble support. This spacer can be as simple as a single methylene group (e.g., aminomethyl polystyrene) or it can be a lengthy alkyl or alkyloxy chain (e.g., long-chain alkylamine CPG). Generally, a long chain is preferred to distance the terminal functional group from the support’s surface. Usually, the supports are sold with a satisfactory spacer, but sometimes additional spacers are added to change the terminal functional group or to increase the overall length (Katzhendler et al., 1987; van Aerschot et al., 1988; Arnold et al., 1989).
Synthesis of Unmodified Oligonucleotides
3.1.5 Current Protocols in Nucleic Acid Chemistry
A second difunctional molecule is then required to connect the amino group on the support to the first nucleoside unit. In oligonucleotide synthesis, this structure is commonly referred to as a linker or linker arm. In peptide synthesis and combinatorial synthesis, this structure is referred to as either a handle or anchor, terms not usually associated with oligonucleotide synthesis. In oligonucleotide synthesis, the linker arms are usually dicarboxylic acids, such as succinic acid (Pon et al., 1988; Damha et al., 1990; Bhongle and Tang, 1995) or hydroquinone-O,O-diacetic acid (Pon and Yu, 1997a), that connect the nucleoside to the support via ester and amide bonds. The length, rigidity, and hydrophobicity of the linker arm can affect coupling efficiency (Katzhendler et al., 1989), and the chemical stability restricts the conditions that can be used during synthesis. This affects the choice of protecting groups. Most linkers for oligonucleotide synthesis are resistant to acidic conditions and cleavable by basic conditions. This allows the most popular combination of protecting groups—acid-labile 5′-dimethoxytrityl (DMTr) groups and baselabile N-acyl and cyanoethyl phosphate protecting groups—to be used. As will be discussed later, the speed with which the linker arm can be cleaved is also an important consideration. Strategies that require removal of oligonucleotide-protecting groups without cleavage from the support also require linker arms that are either very stable or removable using
DMTO
O
conditions orthogonal to the deprotection conditions. Finally, different linker arms can be used to prepare oligonucleotides with terminal end modifications, such as 3′-phosphate, amino, carboxyl, thiol, or other substituents. The chemical properties of the rest of the surface should be either inert or capable of being made inert by silylation, benzoylation, or other similar passivating treatment (Pon, 1993; Tang and Tang, 1997). This is because residual groups, such as amino, hydroxyl, or silanol groups, can also react with phosphoramidite derivatives. This creates failure sequences coupled to the support through either phosphoramidate or phosphodiester linkages and lacking the correct 3′-nucleoside. When coupling reactions are monitored by quantitation of the orange dimethoxytrityl cation released during detritylation, the formation of such failure sequences can be deduced from apparent coupling yields of >100%. Fortunately, the phosphodiester linkages to the surface of the support are difficult to hydrolyze, and these failure sequences are not released from the support by the usual cleavage conditions (Pon et al., 1988). The hydrophobicity of the support’s surface is another consideration. Supports that are quite hydrophobic, such as polystyrene and benzoylated polymethacrylate, are sometimes preferred over supports such as CPG and polyethylene glycol (PEG), which have hydrophilic surfaces (McCollum and Andrus, 1991; Tang
B O
O
N H
A O
OR
H N
O
O
O
succinyl linker long-chain alkyl amine spacer
DMTO
O
Si
CPG support
B O
O B O succinyl linker
Solid-Phase Supports for Oligonucleotide Synthesis
N H aminomethylpolystyrene support
Figure 3.1.3 The structure of the two most commonly used solid-phase supports for oligonucleotide synthesis. (A) LCAA-CPG. (B) Aminomethyl polystyrene (nonswelling and highly cross-linked). In both cases, a nucleoside is attached to the amino group of the support through a succinic acid linker, which can be cleaved by ammonium hydroxide after the synthesis. DMT, 5′-dimethoxytrityl (DMTr).
3.1.6 Current Protocols in Nucleic Acid Chemistry
and Tang, 1997). All phosphoramidite-coupling reactions are sensitive to moisture contamination, and such contamination is presumed to be more easily washed off the hydrophobic supports. This may allow greater synthesis efficiency with smaller excesses of reagent; however, quantitative comparisons are difficult to make, and both rigid polystyrene and CPG supports are widely used.
PHYSICAL AND CHEMICAL PROPERTIES OF SOLID-PHASE SUPPORTS The accessibility of the support’s surface to incoming reagents is probably the most important consideration when choosing the physical properties of the insoluble support. Although a greater surface area provides higher capacity, increased porosity must be balanced against steric restrictions and rate-limiting diffusion. The following sections discuss the major classes of solid-phase supports, categorized by the type of surface accessibility.
is about 100 mg per gram of starting support (Bonora, 1995). The advantages of having a homogeneous solution include lower costs, because less reagent excess is required, and the ability to use spectroscopic methods (UV/VIS, NMR, Fourier transform-IR) to monitor the reactions and quality of the immobilized products. Furthermore, the method does not require any elaborate instrumentation because the reactions and precipitation/filtration steps are performed in ordinary glassware. Consequently, liquid-phase supports were some of the earliest supports to be used (Cramer et al., 1966; Hayatsu and Khorana, 1966). The method, however, is not easily automated, and each chain extension cycle requires several hours to perform. Moisture contamination must also be scrupulously avoided, because the PEG supports are very hydrophilic. Nevertheless, this method is suitable for larger scale oligonucleotide synthesis, when cost is more important than speed.
Gelatinous Polymer Supports Liquid-Phase Supports Liquid-phase supports are high molecular weight polymers that can be completely dissolved in the solvents required for synthesis but can be precipitated or crystallized in other solvents or solvent conditions. When they are dissolved in solution, coupling reactions on liquid-phase supports are performed in the same manner as conventional solution-phase synthesis. After completion of the coupling reaction, however, the liquid-phase support is precipitated by adding a solvent in which it is insoluble. The resulting precipitated support can then be filtered off and washed free of excess reagents in the same manner as other insoluble supports. After the washing step, the support is redissolved in the appropriate solvent, and the synthesis continued. Alternately, dialysis or ultrafiltration can also be used to remove low molecular weight impurities. The most widely used liquid-phase supports are PEG polymers (Bonora, 1995) with average molecular weights varying between 5,000 and 20,000, although cellulose acetate (Kamaike et al., 1988) and poly(N-acryloylmorpholine) polymers (Bonora et al., 1996) have also been used. These supports are soluble in solvents such as dichloromethane, pyridine, and acetonitrile but insoluble in solvents such as ethers and alcohols. Nucleoside loadings of ∼100 to 200 µmol/g are generally obtained, and the purified yield of oligonucleotide 8- to 20-mers
The first insoluble supports developed were polystyrene-divinylbenzene polymers with only a small amount (1% to 5%) of cross-linking (Pon, 1993). These supports could swell up to five times their dry volume in nonpolar solvents, such as dichloromethane, to provide a large surface area and loading capacity (0.1 to 1.5 mmol/g). Other swellable polyacrylamide-containing supports, with loadings up to 5 mmol/g, have also been developed (Winter, 1996). In these supports, up to 99% of the reactive sites are located inside the bead. They are classified as gelatinous polymer supports because of the gel-like environment in which the reactions take place (Rapp, 1996). These supports perform very poorly when used for solid-phase oligonucleotide synthesis because they don’t swell satisfactorily in the polar solvents required and because reagent diffusion into and out of the supports is slow. Therefore, the swollen beads can be used only in batch reactors and not in continuous flow synthesizers (Belagaje and Brush, 1982; Ito et al., 1982; Ohsima et al., 1984). Only the very earliest oligonucleotide syntheses were attempted on these types of supports; and with one exception (Montserrat et al., 1994), their present use is restricted to peptide synthesis.
Macroporous Supports The difficulties mentioned above were overcome by the development of rigid macroporous
Synthesis of Unmodified Oligonucleotides
3.1.7 Current Protocols in Nucleic Acid Chemistry
Solid-Phase Supports for Oligonucleotide Synthesis
supports. These supports are based on inorganic materials, such as silica gel and CPG, or highly cross-linked polymers, such as polystyrene or polymethacrylate. Well-defined pores are created in these supports to increase the surface area and loading capacity. They do not become swollen with solvent and have permanent porosity. Their rigidity allows them to be used in packed continuous-flow columns, and their properties are very similar to the packing materials used in HPLC separations. The maximum loading possible on the rigid supports, however, is much less than on the swellable supports. Silica gel and porous glass supports are ideal nonswelling materials that are readily derivatized using techniques developed by the glass fiber and chromatography industries. CPG beads, which are stronger and easier to handle than is silica gel, are preferred and are available in three particle sizes—125 to 177 µm, 74 to 125 µm, and 37 to 74 µm—with large (75 to 4000 Å in diameter) and very uniformly sized pores. The maximum pore diameter distribution is only ±10% for 80% of the pore volume. A variety of chemically derivatized CPG supports with different functional groups is available, including magnetic CPG beads. The surface area and loading depend on the pore size; the beads with larger pores have lower loadings. Long-chain alkylamine (LCAA) derivatized CPG supports with 500-Å pores and amino loadings of ∼100 µmol/g are the most commonly used. These supports are usually derivatized with 30 to 40 µmol/g of nucleoside (Pon, 1993) and are suitable for the synthesis of oligonucleotides of up to 50 to 60 bases. The 500-Å pore size begins to restrict the coupling efficiency of longer oligonucleotides because of steric factors; however, much longer oligonucleotides (100 to 150 bases) can be prepared on 1000-Å CPG supports (Efcavitch et al., 1986). Synthesis of very long oligonucleotides also benefits from a support with a low surface loading (~5 µmol/g), because it contributes to greater coupling efficiency. Highly cross-linked rigid polymer beads with large pores have also been developed as an alternative to CPG. These were developed primarily to overcome cost and supply problems associated with CPG supports. The greater inertness of the polymers relative to CPG, especially during alkaline deprotection conditions, was also an advantage. The first rigid synthetic polymer, introduced by Perkin-Elmer/Applied Biosystems Division (PE/ABD), was a highly cross-linked polysty-
rene support with 1000-Å pores (McCollum and Andrus, 1991). These supports produce excellent quality oligonucleotides, and prepacked ABI LV40 (40 nmol) and ABI LV200 (200 nmol) columns are widely used. The nucleoside capacity of the supports, however, is lower than that of CPG, and prepacked columns >200 nmol are not available. A second rigid polymer based on a polymethacrylate vinyl alcohol copolymer with 1000-Å pores has also been used (Reddy et al., 1994b). This copolymer is sold as a chromatographic medium by both Merck and TosoHaas, respectively, under the trade names Fractogel and Toyopearl. It can be purchased with either hydroxyl functional groups (for size exclusion chromatography) or amino functional groups (for affinity chromatography). These supports are easy to handle, durable, and inexpensive, and their loading capacity is much higher (up to 135 µmol of nucleoside/g) than either rigid polystyrene or CPG supports. Composite macroporous supports Composite supports have been prepared that combine the advantages of gelatinous and rigid supports. These supports are prepared by polymerizing a low cross-linked polyacrylamide inside the pores of a rigid macroporous substrate, such as silica gel, or highly cross-linked polystyrene beads. Typical capacities are between 100 and 500 µmol/g. The soft gelatinous phase is protected by the rigid carrier, and these supports can be used in a continuous flow column system. The supports, however, are fragile, and swelling differences can create unwanted fines. Although this type of support was once used for oligonucleotide synthesis by the phosphotriester method (Gait et al., 1982), present use of commercially available composite supports is limited to other fields.
Grafted Polymeric Carriers Another method of creating hybrid supports, which combine the advantages of gelatinous supports and rigid supports, is to covalently couple or graft long polymeric chains onto the surface of a rigid support. The surface polymers are not cross-linked and are readily solvated, whereas the rigid core remains insoluble. The low thickness of the surface layer and the absence of cross-linking increase the rate of mass exchange and allow a large number of functional sites to be introduced for nucleoside attachment (up to 160 µmol/g). These supports can, therefore, be used in continuous flow column synthesis because the supports are me-
3.1.8 Current Protocols in Nucleic Acid Chemistry
chanically stable, do not show significant swelling, and allow reagents to be removed using short wash steps. The first example of this type of support in oligonucleotide synthesis (by the phosphodiester method) was a polystyrenepolytetrafluoroethylene (PS-PTFE) graft copolymer. This was prepared by 60Co irradiation of PTFE beads and vapor-phase styrene deposition (Potapov et al., 1979). Another coated Teflon support, in the form of fibers not beads, was also commercially available in the 1980s (Bower et al., 1987; Duncan and Cavalier, 1988). More recently, PS-PTFE beads have been found very satisfactory for oligonucleotide synthesis using the phosphoramidite method (Birch-Hirschfield et al., 1996). Another group of widely used graft copolymers are the polyethylene glycol-polystyrene (PEG-PS) tentacle polymers produced by Rapp Polymere under the TentaGel trade name (Rapp, 1996). These supports are prepared by anionic polymerization of ethylene glycol on hydroxyl derivatized cross-linked polystyrene. Copolymers with PEG chains of about 3000 Da are considered optimal, but the polymerization process can produce PEG chains as large as 20,000 Da. Unlike the previous hydrophobic PS-PTFE copolymers, the PEG-PS copolymers have an insoluble polystyrene core and a hydrophilic PEG coating. The relative amounts of material in the coating and the core are also quite different. The PS-PTFE supports have between 2% and 10% polystyrene as the surface coating, whereas the PEG-PS supports have 70% PEG as the coating and only 30% polystyrene as the core. Therefore, the properties of the TentaGel resins are mostly dictated by the PEG coating. The supports swell considerably (3 to 5 times dry volume) in solvents that dissolve PEG, but owing to the insoluble core, they are suitable for both batch and continuous flow processing. The gel-like environment surrounding these supports allows coupling reactions to proceed in a manner similar to solution-phase reactions. This environment presumably allows cyclization reactions to proceed much more efficiently than on CPG supports, and circular oligonucleotides of up to 32 bases have been prepared (Alazzouzi et al., 1997). A number of different TentaGel resins are commercially available with different functional end groups, particle sizes (ranging from uniformly sized 10 µm beads to 750 µm macrobeads), and loading capacities (0.25 to 1.3 mmol/g) for all types of solid-phase and combinatorial synthesis (Winter, 1996). The high
capacity of these supports has found particular use in large-scale (200 to 1000 µmol) oligonucleotide synthesis (Wright et al., 1993).
Nonporous Supports Rigid nonporous beads without surface copolymerization have also been used as supports of oligonucleotide synthesis, although the capacity is two to three orders of magnitude less than similar porous supports. Nonporous silica beads allow long oligonucleotides to be prepared with high coupling yields because of the absence of restrictive pores (Seliger et al., 1989, 1995). The very small diameter (1.5 µm) particles required to provide an acceptable surface loading (2 µmol/g), however, made this support very difficult to work with. Similar handling problems also occurred when nonporous 4.5µm magnetic Dynabeads were used (Albretsen et al., 1990). A more practical application for nonporous supports is the synthesis of immobilized oligonucleotides. Although a large number of methods have been developed to immobilize previously synthesized oligonucleotides on insoluble supports, it is simpler to synthesize the oligonucleotide directly onto the support required for the final hybridization assay. This type of synthesis requires a stable linker that can withstand the conditions used to remove all of the protecting groups (typically 55°C NH4OH, 16 hr) after completion of the synthesis. The deprotected oligonucleotides left attached to the support can then be used as hybridization probes. Both nonporous glass (Maskos and Southern, 1992) and polystyrene beads, with respective loadings of 50 to 70 and 150 nmol/g, have been used. In the latter case, time-resolved fluorescence detection on single Dynosphere beads was performed (Hakala et al., 1997). Hybridization assays using two-dimensional formats, however, are much more common than assays using beads. Consequently, a great deal of effort has gone into the synthesis of oligonucleotide arrays on flat glass and polypropylene supports. The surfaces of glass slides can be derivatized using the same techniques developed for silica gel and CPG supports. Typical surface loadings of 10 to 40 pmol/cm2 are obtained (Maskos and Southern, 1992; McGall et al., 1997), although one account of ∼166 pmol/cm2 was reported when phosphoramidite reagents were reacted directly with surface silanol groups (Cohen et al., 1997). Oligonucleotide synthesized with permanent linkages to quartz fibers has also been used as a DNA sensor (Uddin et al., 1997).
Synthesis of Unmodified Oligonucleotides
3.1.9 Current Protocols in Nucleic Acid Chemistry
Recently, polypropylene sheets have been used as solid-phase supports for oligonucleotide synthesis (Matson et al., 1994, 1995 Wehnert et al., 1994). Polypropylene has the advantages of greater flexibility, physical strength, and chemical stability at high pH. It also has low nonspecific adsorption of biomolecules. One report, however, has mentioned an incompatibility between polypropylene supports and the tetrahydrofuran (THF) solvent commonly used in capping and oxidation reagents (Weiler and Hoheisel, 1996). The inertness of this polymer makes chemical derivatization difficult. Amino-modified supports are prepared by exposure of the polypropylene surfaces to ammonia vapor inside a radio frequency plasma (RFP) generator (Chu et al., 1992). This results in an amino group loading of about 15 to 25 nmol/cm2. Oligonucleotides have been attached to these amino groups, either directly via phosphoramidate linkages (Matson et al., 1994) or through intermediate spacers with terminal hydroxyl (Shchepinov et al., 1997) or amino groups (Weiler and Hoheisel, 1996) to give supports with respective loadings of 10, 0.3, and 0.03 to 0.09 nmol/cm2. Efficient hybridization requires optimization of both loading density and spacer length, because duplex formation can be inhibited by too close spacing and by spacers that are either too short or too long. Polypropylene can also be chemically derivatized without requiring an RFP generator. Bromination using N-bromosuccinimide and 2,2′-azobisisobutyronitrile followed by amination with long-chain diamines or amino alcohols has recently been described, but no surface loadings were reported (Seliger et al., 1995). Oxidation of polypropylene with chromium(VI) oxide followed by borane-tetrahydrofuran complex and H2O2/NaOH treatment has also been used to produce hydroxyl-derivatized polypropylene tapes. Direct reaction of phosphoramidites to this tape yielded a nucleotide loading of 7 nmol/cm2. These polypropylene tapes have been used to prepare a 200-base-long polythymidylic acid sequence and overlapping one-dimensional arrays (Bader et al., 1997a,b).
Filter Disks, Membranes, and Sintered Blocks Solid-Phase Supports for Oligonucleotide Synthesis
This section deals with supports whose physical properties are not easily categorized. Paper filter disks probably represent the cheapest and most readily accessible insoluble support for oligonucleotide synthesis. These sup-
ports contain cellulose fibers that have many hydroxyl groups available for oligonucleotide attachment and that are resistant to all of the chemical conditions required for oligonucleotide synthesis. Paper filter disks were ideal supports for synthesizing multiple oligonucleotides simultaneously using the “segmental solid-phase” procedure, because they could be easily labeled and sorted (Frank et al., 1983; Matthes et al., 1984; Ott and Eckstein, 1984; Frank, 1993). Another important innovation was the development of commercially available MemSyn DNA synthesis supports (Perseptive Biosystems). These contain a membrane-based support made of porous PTFE and coated with an aminopropyl linker. These membranes are sealed inside specially designed low dead volume disposable housings, which resemble common syringe filters, and have loadings of either 50 or 200 nmol. The membranes are easier to handle than are particulate supports, and mass-produced synthesis cartridges are presumably more reliable and easier to manufacture. The large pore diameter of these filter membranes (0.2 µm or 2000 Å) allow both large and small oligonucleotides to be synthesized. Finally a new process, developed at NASA, has been used to derivatize polyethylene (Devivar et al., 1999). In this process, gaseous amine radicals are used to aminate porous polyethylene sintered blocks (FlowGenix, Webster, TX). The amino functionalized sites can then be derivatized with nucleosides for oligonucleotide synthesis. This technology allows supports in the form of plugs and disks to be produced, which should be more convenient to handle than are particulate supports. This discussion clearly indicates that a wide range of insoluble supports have been developed for an increasing number of different applications. Selection of an appropriate support requires consideration of both the chemical properties and the physical characteristics of the support. The size and shape of support beads can vary from small uniformly sized or irregularly sized particles to large macrobeads. Supports in sheet and plate form are amenable to extremely sensitive isotopic or fluorescent detection schemes. High-density arrays or “gene chips” are also emerging as important tools for gene expression studies. Supports in membrane or foam formats provide the synthesis capacity of porous beads but greatly simplify the handling and manufacturing steps required to mass produce ready-to-use synthesis cartridges.
3.1.10 Current Protocols in Nucleic Acid Chemistry
SUPPORT DERIVATIZATION: NUCLEOSIDE AND LINKER ARM COUPLING STRATEGIES Nucleosides are attached to the surface of the support through an intermediate linker arm, whose design must be carefully considered. The linker arm should allow easy nucleoside attachment to the support and be compatible with all of the conditions required for synthesis. Furthermore, the linker must be designed to accommodate different cleavage and deprotection strategies. The many different types of possible linkages can be classified into four groups for strategies that require either: 1.
cleavage from the support with concomitant or postcleavage deprotection;
2.
deprotection of the immobilized products with optional postdeprotection cleavage;
3.
deprotection of the immobilized products with no cleavage from the support; or
4.
linkers that impart terminal end modifications to the oligonucleotide products.
The following section discusses how different linkers have been use in the first three strategies. The use of different linkers and insoluble supports in the synthesis of end-modified oligonucleotides will be discussed in future units.
Linker Arms Cleaved after Synthesis Succinyl linker arm The most commonly used linker arm in oligonucleotide synthesis is succinic acid (Fig. 3.1.3). This linker was used in the early 1970s and has remained very popular because of low cost and ease of incorporation (Yip and Tsou, 1971). Both succinyl dichloride (Sharma et al., 1992) and succinic anhydride have been used as starting materials, but the anhydride is greatly preferred because of its easier handling. A suitably protected 2′-deoxyribonucleoside can be succinylated at either the 5′- or 3′hydroxyl position, and the resulting 5′- or 3′O-hemisuccinate is coupled to an amino- or hydroxyl-derivatized support. Alternatively, the support can be succinylated first and then coupled to a nucleoside (Damha et al., 1990). This method has the advantage of not requiring the synthesis of an inventory of succinylated
nucleosides. Coupling of a nucleoside to a succinylated support, however, is more difficult and usually gives lower nucleoside loadings than does attachment of a presynthesized nucleoside 3′-O-hemiester. The coupling reactions between the succinate and the nucleoside or support have usually been performed using carbodiimide coupling reagents, such as dicyclohexylcarbodiimide (Montserrat et al., 1993), 1-(3-dimethylaminopropyl)ethylcarbodiimide (Pon et al., 1988), and diisopropylcarbodiimide (Bhongle and Tang, 1995), and required coupling times between 1 and 24 hr. A faster coupling reaction—involving reaction of a nucleoside-3′-O-hemisuccinate with 2,2′dithiobis(5-nitropyridine) (DTNP) and dimethylaminopyridine (DMAP) followed by addition of triphenylphosphine (TPP) and LCAA-CPG—can reduce the coupling time to 2 to 30 min (Kumar et al., 1996). Extremely fast coupling of a nucleoside-3′-O-hemisuccinate to LCAA-CPG can be obtained using a variety of phosphonium or uronium coupling agents and DMAP. These reactions are complete in the time required to add the reagent to the support ~4 sec) and allow for the possibility of automated on-line support derivatization (Pon and Yu, 1997b). After completion of the oligonucleotide assembly, the protected products can be cleaved from the support by hydrolysis of the succinyl linker arm with either concentrated aqueous ammonium hydroxide (1 to 2 hr) or gaseous ammonia at 10 bar pressure (15 min; Boal et al., 1996). Faster hydrolysis can be performed by including stronger reagents, such as methylamine (Reddy et al., 1994a) or sodium hydroxide (Chow and Kempe, 1997), with the ammonium hydroxide. These reagents can reduce the cleavage time to 5 min and speed up the removal of base-protecting groups. There are, however, potential problems with the modification of cytosine bases through either aminoalkylation (Macmillan and Verdine, 1991) or deamination (Debear et al., 1987) with these reagents. Although the succinic acid linker has been widely used for a long time, the succinyl linker is unnecessarily stable for oligonucleotide synthesis. The relatively harsh conditions required to hydrolyze the succinyl linker are incompatible with a number of base-sensitive minor bases, backbone modifications, and dye labels; and the time required to cleave the succinyl linker with NH4OH is unnecessarily long (Alul et al., 1991; Avino et al., 1996; Pon and Yu, 1997a). Therefore, a number of more easily
Synthesis of Unmodified Oligonucleotides
3.1.11 Current Protocols in Nucleic Acid Chemistry
DMTO
O
T O2N P
HN
A
O CH2
O
O O
DMTO B
O O
T O2N
O O
O CH2 O
C
O2N
DMTO
D
OMe O H O P N OCE
DMTO
O
N H
P
P
T
O
O
Si O
H N
O
P
O DMTO
E
O
B
O
Si O Si O P O OCE DMTO F
O O
O
H N
O
N H
O
P
B
O
O P O CH2CH2 S CH2 OClPh O
P
Figure 3.1.4 Structure of labile linker arms that can be cleaved under milder conditions than a succinic acid linker. (A) o-Nitrobenzyl carbonate photolabile linker arm (Greenberg and Gilmore, 1994). (B) 5-Methoxy-2-nitrobenzyl carbonate photolabile linker arms (Venkatesan and Greenberg, 1996). (C) o-Nitrophenyl-1,3-propanediol base photolabile linker for 3′-phosphorylated oligonucleotides (Dell’Aquila et al., 1997). (D) Fluoride ion labile diisopropylsilyl linker arm (Routledge et al., 1995). (E) Fluoride ion labile disiloxyl phosphoramidite linker arm (Kwiatkowski et al., 1996). (F) Benzenesulfonylethyl linker arm cleavable with triethylamine/dioxane (Efimov et al., 1983). (G) NPE carbonate linker arm cleavable with DBU/pyridine (Eritja et al., 1991). (H) 9-Fluorenylmethyl linker cleavable with DBU (Avino et al., 1996). (I) Phthaloyl linker arm cleavable with DBU (Avino et al., 1996; Brown et al., 1989). (J) Oxalyl linker, cleavable under very mild conditions (Alul et al., 1991). (K) Malonic acid linker for the synthesis of 3′-phosphorylated oligonucleotides (Guzaev and Lonnberg, 1997). (L) Diglycolic acid linker used to make 3′-TAMRA dye-labeled oligonucleotides (Mullah et al., 1998). (M) Hydroquinone-O,O′-diacetic acid (Q-linker), which can be used for routine oligonucleotides to improve synthesis productivity or to synthesize base-labile products (Pon and Yu, 1997a). DMT, 5′-dimethoxytrityl (DMTr).
cleavable linker arms have been investigated (Fig. 3.1.4).
Solid-Phase Supports for Oligonucleotide Synthesis
Labile linker arms Photolysis offers a very mild method for cleavage. Photolabile linker arms based on onitrobenzyl groups (Greenberg and Gilmore,
1994) have been used to synthesize oligonucleotides with 3′-hydroxyl (Fig. 3.1.4A and B), 3′-phosphate (Fig. 3.1.4C), and other 3′-end modifications. The photolysis can, however, cause small amounts (<3%) of thyminethymine photodimers, and alkaline or other conditions still need to be employed to remove
3.1.12 Current Protocols in Nucleic Acid Chemistry
DMTO
B
O O
G
DMTO
NO2
H
DMTO
N H
O
O
P
B
J O
HN
NH
O
O
H N O
P
L
O
DMTO M
O
B
O
O
RO
O O
P
O
O
DMTO
K
H N
O
O
P
O
HN
O
O O
I
B
O
RO
P
H N
O O
P
O
B
O O
H N
O
P
O
Figure 3.1.4 Continued
base-protecting groups. In addition, N-benzoyl-protected dA and dC nucleosides must also be avoided. Very mild cleavage, under non-nucleophilic conditions and neutral pH, can be obtained through silyl- or disiloxyl-based linker arms (Fig. 3.1.4D and E), which are cleavable with fluoride ion. Triethylamine has been used to cleave a benzylsulfonylethanol linker arm to yield 3′-phosphorylated oligonucleotide blocks suitable for solution-phase coupling (Fig. 3.1.4F). An even more labile 2-(4-carboxyphenylsulfonyl)ethanol linker arm was considered unsuitable for phosphotriester synthesis but was not evaluated using phosphoramidite synthesis (Schwyzer et al., 1984). The non-nucleophilic base, 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU), can also be used to cleave the 2-(o-nitrophenyl)ethyloxycarbonyl (NPE) linker, N-[9-(hydroxymethyl)-2fluorenyl]-succinamic acid (Fmoc) linker, and phthaloyl linker arms (Fig. 3.1.4G to I). When using DBU cleavage, however, thymine and
guanine modification can occur if methoxy- or cyanoethyl phosphate–protecting groups are not removed before the DBU treatment. Furthermore, oligonucleotides with terminal TT sequences are not efficiently cleaved. All of the above linker arms were either difficult to prepare or did not offer any speed advantage. In addition, the requirement for deprotection conditions or reagents different from the simple NH4OH cleavage used in standard oligonucleotide synthesis procedures was an obstacle to the widespread adoption of any of these linker arms. More satisfactory alternatives would be other dicarboxylic acid linkers, especially if they were readily available and compatible with the derivatization and cleavage methods used for succinic acid. The most labile dicarboxylic acid linker reported has been the oxalyl linker (Fig. 3.1.4J). This was completely cleaved by concentrated NH4OH in only a few seconds, and cleavage with a number of other milder reagents was also possible. The oxalyl linker, however, was too
Synthesis of Unmodified Oligonucleotides
3.1.13 Current Protocols in Nucleic Acid Chemistry
Solid-Phase Supports for Oligonucleotide Synthesis
labile for routine use, and oxalyl derivatized supports had to be used within a few weeks because significant spontaneous nucleoside loss occurred (Pon and Yu, 1997a). More stable linkages have been created using either malonic acid or diglycolic acid as the linker arm (Fig. 3.1.4K and L). Treatment of diglycolic acid (Pon and Yu, 1997a) and malonic acid (Guzaev and Lonnberg, 1997) linkers with room temperature concentrated NH4OH for 10 min was sufficient to respectively hydrolyze 68% and 90% of these linker arms, conditions that caused only 15% cleavage of the succinyl linker. The malonic acid linker arm was used in combination with a diethyl 2,2-bis(hydroxymethyl)malonate spacer to afford 3′phosphorylated methyl phosphotriester and methylphosphonate analogues. The diglycolic acid linker has principally been used in combination with a branching spacer, such as 2amino-1,3-propanediol, to prepare 3′-tetramethylrhodamine (TAMRA) labeled oligonucleotides, which are damaged by conventional ammonium hydroxide hydrolysis (Mullah et al., 1998). In this case t-butylamine/methanol/water (1:1:2) was used for cleavage from the support (20 to 60 min at room temperature) and subsequent base deprotection (1 to 3 hr at 65° to 85°C). A more satisfactory replacement for succinic acid is hydroquinone-O,O′-diacetic acid, which is used to create a Q-linker arm (Fig. 3.1.4M). This linker is sufficiently stable so decomposition during room temperature storage is not a problem. The Q-linker, however, can be cleaved much faster than either the succinyl or diglycolic acid linkers (Pon and Yu, 1997a). For example, cleavage using NH4OH required only 2 to 3 min and cleavage using t-butylamine/methanol/water was performed in only 5 min, instead of the 45 min described above. Moreover, for routine use, supports derivatized with the Q-linker can be used without any modifications to either protecting groups, reagents, or synthesis procedures (other than a reduction in cleavage time). Thus the Q-linker can serve as a general replacement for the succinyl linker in the synthesis of either unmodified or base-sensitive oligonucleotides. The main advantage of the Q-linker, however, is the improved productivity that results from the decreased cleavage time. Unlike postsynthesis deprotection, which is performed off the automated synthesizer, the cleavage step is usually performed by the instrument; and subsequent runs cannot be started until the cleavage is complete. Because typical oligonu-
cleotide syntheses are usually complete within 2 hr, waiting an additional 1 or 2 hr for cleavage of a succinyl linker represents a significant bottleneck. Recently, the Q-linker arm has also been included in a strategy for oligonucleotide synthesis on reusable solid-phase supports (Pon et al., 1998, 1999). In this approach, an hydroxyl derivatized support is used to form ester linkages, which can be easily cleaved and regenerated for subsequent use. The mild cleavage conditions required to release the oligonucleotide reduce damage to the support’s surface and reduce the time required to prepare the support for another use. This approach will be very useful in the large-scale (>1000 kg/y) manufacturing of oligonucleotide pharmaceuticals in which the support is the most expensive single consumable. Universal linkers In the supports discussed above, attachment of the first nucleoside is always done separately from the actual oligonucleotide synthesis, because of the different chemistry and long coupling times required. In the past, maintaining an inventory of prederivatized supports was not problematic because of the limited number of common nucleosides. The recent development of high throughput DNA synthesizers. however, has created a need for universal supports that have the terminal nucleoside added as part of the automated synthesis. This is required not so much for inventory purposes but because manual setup of prederivatized supports is time-consuming and error prone. Universal linkers are also an advantage for the synthesis of oligonucleotides containing rare or modified bases that one wishes to incorporate at internal sites and at the 3′-end. In this way it is necessary to synthesize or purchase only the phosphoramidite derivative of the rare or modified base. Automation of the nucleoside-coupling reaction using very fast uronium coupling reagents and DMAP is one possible approach (Pon and Yu, 1997b); however, implementation of this strategy requires construction of new DNA synthesizers with additional reagent reservoirs. A simpler approach would be to design a linker arm that could use a conventional nucleoside-3′-phosphoramidite as the first monomeric unit. It is fairly simple to design universal supports that can produce oligonucleotides with 3′-phosphate ends using either amino or hydroxyl end functions (Fig. 3.1.4A to F). Furthermore, a sulfonyldiethanol phos-
3.1.14 Current Protocols in Nucleic Acid Chemistry
a neighboring hydroxyl group so a cyclic phosphate can form via an intramolecular attack (Fig. 3.1.6). A linker containing a single ribonucleoside in an inverted orientation, so chain extension occurs from the 2′- (or 3′-) hydroxyl position and not the 5′-position, will allow cleavage of the phosphate group via a mechanism similar to the alkaline cleavage of RNA. This will produce the desired oligonucleotide with a 3′-hydroxyl terminus and a uridine-2′, 3′-cyclic phosphate. This strategy was first used on cellulose supports (Crea and Horn, 1980; van der Marel et al., 1982); however, because dinucleotide units with inverted 3′-2′ (3′) linkages were
phoramidite, usually used for 5′-phosphorylation, can be used to synthesize 3′-phosphorylated sequences on any amino- or hydroxylderivatized support (Fig. 3.1.5G). Obtaining an oligonucleotide with a free 3′-hydroxyl terminus instead of a 3′-phosphate is essential, however, if the oligonucleotides are to be enzymatically extended (e.g., used as DNA sequencing or polymerase chain reaction primers). Removal of the terminal 3′-phosphate group introduced by the 3′-phosphoramidite reagents is usually difficult, because the negative charge(s) on phosphodiester and phosphomonoester bonds make them very resistant to hydrolysis. This difficulty can be overcome by introducing
O A
B
C
N H
NH2
HO
H N
O S O
Si
P
O
O Si
P
CH3
DMTO
S S
DMTO
S S
Si
P
O D
O
N H
O O
H N
P
P
E HO NO2
DMTO
O
F
G
N H
DMTO
O
O
S O
O P O OCE
P
P
Figure 3.1.5 Structure of universal linkers for 3′-phosphorylated oligonucleotides (see Fig. 3.1.4C and K). (A) Benzidine linker arm (Markiewicz and Wyrzykiewicz, 1989). (B) Hydroxyethylsulfonyl linker arm (Markiewicz and Wyrzykiewicz, 1989). (C) Hydroxyethyl disulfide linker (Kumar et al., 1991). (D) Hydroxyethyl disulfide linker (Asseline and Thuong, 1989; Gupta et al., 1991). (E) NPE linker (Eritja et al., 1991). (F) Universal allyl linker, 9-O-(4,4′-dimethoxytrityl)-10-undecenoic (Zhang and Jones, 1996). (G) Dimethoxytrityl sulfonyldiethanol phosphoramidite linker (Bader et al., 1997b; Shchepinov et al., 1997). DMT, 5′-dimethoxytrityl (DMTr).
Synthesis of Unmodified Oligonucleotides
3.1.15 Current Protocols in Nucleic Acid Chemistry
oligonucleotide
oligonucleotide
O
B
O O O
O O
O
O
O
B
O
O
1
O
NCCH2CH2O P O
oligonucleotide
2
O
O P O R
U
OH
O
HO
O
O P
O O
O O
HO
U
B
O
U
O
O P
NH
3
O
oligonucleotide
O P
O
O HO
O
O
B
HO
O
U
Figure 3.1.6 Mechanism of terminal phosphate cleavage in universal supports. (1) The first step in the cleavage/deprotection process is hydrolysis of the ester from the hydroxyl group adjacent to the first phosphate linkage. This step occurs concurrently with the removal of the cyanoethyl groups on the phosphate linkages and hydrolysis of the ester attachment to the support. (2) The deprotected hydroxyl group can then cyclize by attacking the phosphorus atom. (3) Formation of a 2′,3′-cyclic phosphodiester releases the oligonucleotide sequence with a free 3′-OH group.
Solid-Phase Supports for Oligonucleotide Synthesis
prepared in solution before attachment to the support the method was not truly universal (Fig. 3.1.7A). The universal support concept was first fully examined when uridine mononucleosides were attached to CPG through 5′-succinate linkages (Fig. 3.1.7Ba to c). Oligonucleotide synthesis, using nucleoside-3′-phosphoramidites, can then be performed from the 2′ (or 3′) hydroxyl position of the uridine linker in the normal manner. Cleavage from the linker, however, involves two steps: hydrolysis of the succinyl linker to release the material from the support and elimination of the terminal uridine as the 2′,3′-cyclic phosphate. Although both steps, along with removal of base-protecting groups, can be performed simultaneously, elimination of the terminal cyclic phosphate is the rate-limiting step. After normal NH4OH deprotection, treatment at neutral pH with lead acetate (18 hr at 37°C) can complete the terminal deblocking (Gough et al., 1983). Complete deblocking can be performed with extended NH4OH hydrolysis, although the rate depends on the nature of the adjacent nucleoside with all ribonucleosides > dA, dG > T > dC (Debear et al., 1987). Therefore, NH4OH deprotection conditions ranging from 16 hr at 50°C to 24 hr at 65°C were first proposed, and a sub-
sequent paper has used 48 hr at 65°C (Schwartz et al., 1995). Attachment of a ribonucleotide through the N4-position of a cytosine base (Fig. 3.1.7C), with subsequent chain extension from the 3′-phosphate group, has also been used (Pochet et al., 1987). In this case, cleavage was performed using 2N NaOH (10 min at 60°C); however, use of alkali hydroxides is not recommended because of possible damage to cytosine bases. A reversed uridine phosphoramidite reagent can also be used to convert previously derivatized supports into universal supports (Fig. 3.1.7D). Universal supports with N-benzoylcytidine linkers (Fig. 3.1.7Bd) are commercially available (Biogenex, San Ramon, CA), and the addition of 0.5 M lithium chloride to the NH4OH reagent has been recommended for their cleavage and deprotection (15 hr at 55°C). A ribonucleoside is not essential for a universal linker, and other diol linkers have been used. An acyclic 3-amino-1,2-propanediol linker has been reported (Lyttle et al., 1996) that uses neighboring group participation by the amino group to cleave the oligonucleotide under mild conditions (0.1 M triethylamine acetate [1 mL] plus 3% NH4OH [40 µL], 2 hr at room temperature; Fig. 3.1.7E). This linker,
3.1.16 Current Protocols in Nucleic Acid Chemistry
DMTO
B
O
OR2
R1O O O P OR1 OR2 O
A
O P
P
O
O P O
O
B
U OR3 Aa, R1 = R3 = 4-chlorophenyl, R2 = acetyl Ab, R1 = 2-chlorophenyl, R2 = methoxytetrahydropyranyl, R3 = 4-t-butyl-2-chlorophenyl
Ba, B = uracil, R1 = H, R2 = benzoyl Bb, B = uracil, R1 = H, R2 = acetyl 3 Bc, B = N -anisoyluracil, R1 = H, R2 = benzoyl 4 Bd, B = N -benzoylcytosine, R1 = acetyl, R2 = DMT Be, B = H, R1 = DMT, R2 = chloroacetyl
O O C
DMTO
O O
O P O
C
O C O
AcO
O
O D
N
U
O P OCE O
O
O
B O
N O
P
HN
N H
O O
O DMTO
N H
E
F
H N
P
O
O P O OCE
P
O
O
O
O O
B
O
Cl
O
O
O
N H
O O
O O
O
O P O OCE
O O G
DMTO
H N
O
P
O
Figure 3.1.7 Universal linker arms for the synthesis of oligonucleotides with free 3′-OH ends. (A) First 3′-2′(3′) inverted linkages (Crea and Horn, 1980; van der Marel et al., 1982). (B) Universal supports based on: (a) 2′(3′)-O-benzoyluridine (Gough et al., 1983); (b) 2′(3′)-O-acetyluridine (Cosstick and Eckstein, 1985); (c) N3-anisoyluridine (Debear et al., 1987); (d) commercially available N4-benzoylcytidine universal support (Biogenex, San Ramon, CA); (e) 1,4-anhydroribitol (Scheuerlarsen et al., 1997). (C) Inverted linkage attached through N4-position of cytidine (Pochet et al., 1987). (D) Inverted linkage obtained through use of a “universal” 5′-phosphoramidite (Schwartz et al., 1995). (E) Acyclic universal linker with a 3-N-allyloxycarbonyl-protecting group (Lyttle et al., 1996). (F) Special phosphoramidite linkage to allow the synthesis of a second oligonucleotide on the 5′-end of another (Hardy et al., 1998). (G) 1,4-Anhydroerythreitol coupled via a succinyl linker to CPG (Nelson et al., 1997). DMT, 5′-dimethoxytrityl (DMTr).
however, required a preliminary step with tetrakis(triphenylphosphine) palladium to remove the N-allyloxycarbonyl-protecting group, and not all of the oligonucleotide was released from the support. The rate of cleavage has been found to depend strongly on the stereochemistry of the attacking hydroxyl group, as reported in studies
that used the cyclic cis diol 1,4-anhydroerythritol (Scott et al., 1994; Hardy et al., 1998). These studies developed a novel linker, phosphoramidite, that allowed consecutive oligonucleotide sequences to be synthesized on the same support (Fig. 3.1.7F). Cleavage with NH4OH (16 hr at 80°C) or NH4OH/MeNH2 (16 hr at 60°C) was recommended. The 1,4-anhy-
Synthesis of Unmodified Oligonucleotides
3.1.17 Current Protocols in Nucleic Acid Chemistry
droerythritol linker has also been coupled to CPG supports through a succinic acid linker (Fig. 3.1.7G); these Rainbow Universal CPG supports are commercially available (Clontech, Palo Alto, CA). Deprotection and cleavage from the Rainbow Universal CPG supports was performed using either 0.5 M LiCl/NH4OH (16 hr at 55°C) or 0.23 M triethylamine/0.5 M LiCl/NH4OH (1 hr at 80°C) as the cleavage reagent (Nelson et al., 1997). Deprotection of the hydroxyl group adjacent to the phosphate linkage is a requirement before this group can participate in the cyclization and phosphate group elimination reactions. Therefore, faster deprotection can be obtained when the very labile chloroacetyl-protecting group is used instead of acetyl, benzoyl, or succinyl groups (Scheuerlarsen et al., 1997). This strategy was first applied to a 1,4-anhydroribitol linker arm using a specific 2′-5′ linkage (Fig. 3.1.7Be), and cleavage of the terminal cyclic phosphate was achieved under “normal” deprotection conditions (NH4OH for either 12 hr at 55°C or 72 hr at 22°C).
Linker Arms for the Deprotection of Immobilized Products with Optional Postdeprotection Cleavage
Solid-Phase Supports for Oligonucleotide Synthesis
A number of applications require the removal of all or some of the protecting groups before the oligonucleotide is cleaved from the support (i.e., deprotection conditions orthogonal to cleavage conditions). Removal of the terminal 4′-dimethoxytrityl-protecting group is easily performed because the acidic conditions do not affect the acid-resistant linker arms most commonly used. In contrast, removal of the phosphate-protecting groups from the internucleotide linkages or the amino-protecting groups from the adenine, cytosine, and guanine bases requires special consideration if these groups are to be removed without cleaving the product from the solid-phase support. If, however, these deprotection steps are performed while the product remains immobilized (i.e., attached to the support), then the solid-phase support can provide the same handling and workup advantages as realized during the solidphase synthesis. After these steps, the linker arm can be cleaved to release the products. In certain cases, the final product will be used while immobilized on the support, but it is still helpful to be able to cleave samples off for characterization and quality analysis. Generally, succinyl linkers are not sufficiently stable to allow removal of any protecting groups other than O-methyl- or cyanoethyl
phosphate–protecting groups. Succinyl linkers, however, can be left intact if different protecting group and deprotection schemes are employed. For example, hydrazine hydrate/pyridine/acetic acid can be used as the deprotection reagent if the N6-isobutyryl-protecting group on deoxyguanosine is replaced with an N6(N′,N′-dibutylformamidine)-protecting group (Urdea and Horn, 1986). Base deprotection using ethanolamine can also be accomplished, but the N4-protection on deoxycytidine must be modified to prevent N4-hydroxyethylation (Berner et al., 1989). Allylic protection on all of the bases and on the phosphate linkages can also be removed using palladium reagents without affecting the succinyl linker (Hayakawa et al., 1990). Attachment of a succinyl linker to a secondary N-methyl amino group on an intermediate linker such as N-methyl glycine (sarcosine), bis-1,6-dimethylaminohexane, or N-propyl polyethylene glycol (Fig. 3.1.8A to C) instead of a primary amino group (such as LCAACPG) creates linkages that are resistant to cleavage by the non-nucleophilic base DBU. These linkages have been used with base labile 5′-Fmoc-protecting groups to make acid-sensitive oligodeoxyribonucleotides and oligoribonucleotides (Brown et al., 1989) or with 2-(4-nitrophenyl)ethoxycarbonyl/NPE baseprotecting groups to allow on-column deprotection (Stengele and Pfleiderer, 1990; Weiler and Pfleiderer, 1995). A triethylamine-resistant sarcosine-succinic acid linker arm (Fig. 3.1.8D) has also been used to prepare branched RNA and DNA/RNA chimeras (Grotli et al., 1997). In each case, after synthesis or deprotection, the products are easily released from the support by conventional hydrolysis with NH4OH. A stronger linkage can also be created by attaching the succinyl linker to the amino group of a base instead of a hydroxyl group (Figs. 3.1.7C and 3.1.8E and F). Alkaline hydrolysis or oxidative cleavage with NaIO4 can then release the product. This strategy, however, requires two orthogonal-protecting groups for the 5′- and 3′(2′)-positions and does not offer any advantage, except for the synthesis of cyclic oligonucleotides. A number of different linker arms have also been developed that take advantage of the resistance of phosphate ester and amide bonds to alkaline hydrolysis and allow protecting group removal before cleavage from the support. Thus thioether and thiophosphate linkers cleavable by oxidative cleavage (Fig. 3.1.8G and H), allyl
3.1.18 Current Protocols in Nucleic Acid Chemistry
DMTO
O
B O
A
O
N CH3 O
O DMTO
O
H N
P
B O
B
O
N CH3
O DMTO
O
CH3 N O
P
O
B O
O
C
O
N Pr
O
P
O CH2
n n = 40-70 O O O
D
O
O O
H N
P
O O
N CH3
O
O
O
H N
HN
DMTO
O
N
P H N
O
N E
B
HN O
N
F DMTO
O O P O OCE
O
N
N
O
NH O
N
OAc OAc Cl P
Figure 3.1.8 Linker arms that allow on-column deprotection and then optional cleavage. (A) Succinic acid linked to an N-methylglycine (sarcosine) derivatized support (Brown et al., 1989). (B) Succinic acid linked to 1,6-bis methylaminohexane spacer (Stengele and Pfleiderer, 1990). (C) Succinic acid linked to N-propyl polyethylene glycol Tentagel support (Weiler and Pfleiderer, 1995). (D) Succinyl-sarcosine linkage for the solid-phase synthesis of branched oligonucleotides (Grotli et al., 1997). (E) Linkage through the amino group of cytosine for branched and cyclic oligonucleotide synthesis (De Napoli et al., 1995). (F) Oxidizable solid support (Bower et al., 1987; Markiewicz et al., 1994). (G) Phenyl thioether linker, which is stable until oxidized into a phenylsulfone (Felder et al., 1984). (H) Thiophosphate linker, cleavable by iodine/water oxidation or acetic acid hydrolysis (Tanaka et al., 1989). (I) 3-Chloro-4-hydroxyphenyl linker for the solid-phase synthesis of cyclic oligonucleotides (Alazzouzi et al., 1997). (J) Linker arm produced from tolylene 2,6-diisocyanate with more stable carbamate and urethane linkages (Kumar, 1994; Sproat and Brown, 1985). DMT, 5′-dimethoxytrityl (DMTr).
linkers cleavable with tetrakis(triphenylphosphine) palladium (Fig. 3.1.5F), and phosphoroamidate linkages cleavable by acidic hydrolysis have been developed (Gryaznov and
Letsinger, 1992). These supports can also be considered as universal supports because the first nucleotide is added as part of the automated synthesis. All of these methods, how-
Synthesis of Unmodified Oligonucleotides
3.1.19 Current Protocols in Nucleic Acid Chemistry
DMTO
T
O
G O O P OCE O
H
O S
O O P S O
C HN
O
H N
N H
T
O
O
O
I
P
O
Cl
DMTO
P
N H
O P O OCE
P
Cl
DMTO
B
O
J
H N
O O
H N
H N
P
O
Figure 3.1.8 Continued
Solid-Phase Supports for Oligonucleotide Synthesis
ever, produced oligonucleotides with a terminal 3′-phosphate instead of a 3′-hydroxyl group. An exception was the solid-phase synthesis of cyclic oligonucleotides. In this approach, 3chloro-4-hydroxylphenylacetic acid served as both the linker arm and a phosphate-protecting group (Fig. 3.1.8I). The phosphotriester linkage was converted into a phosphodiester by selective removal of the cyanoethyl-protecting group, and then cyclization of the 5′-end to the 3′-terminal phosphodiester group was achieved using 1-mesitylenesulfonyl-3-nitro-1,2,4-triazole as the coupling agent. The linker was then cleaved with tetramethylguanidinium syn-2-aldoximate (8 hr), and a circular oligonucleotide was released (Alazzouzi et al., 1997). The requirement for a 3′-phosphate has also been avoided by insertion of a disiloxyl linkage between the nucleoside and the phosphate linkage (Fig. 3.1.4E). This linkage was stable to mild base, and preliminary purification by selective cleavage of apurinic sites using triethylamine/ethanol (1:1, 3 hr at 20°C), was possible
(Kwiatkowski et al., 1996). After this treatment, the products were cleaved from the support with tetrabutylammonium fluoride and then deprotected with NH4OH. Isocyanate reagents can react with hydroxyl groups and amino groups to produce carbamate and urethane bonds, respectively, which are more resistant to hydrolysis than are esters. Although acyclic diisocyanates have not been successful, the more rigid tolylene 2,6-diisocyanate reagent (Sproat and Brown, 1985) has been used to create a stable linker arm (Fig. 3.1.8J). The carbamate linkage can be hydrolyzed by long exposure to NH4OH (24 to 48 hr at 55°C), whereas deprotection under milder conditions allowed the product to remain attached to the support. Two methods have been developed for removing failure or depurinated sequences from the full-length product while both are still attached to the support. In the first method (Urdea and Horn, 1986), spleen phosphodiesterase was used to selectively degrade non-full-length oli-
3.1.20 Current Protocols in Nucleic Acid Chemistry
A
O
H N
HO
DMTO
B
P
N H
P
O C
DMTO O
DMTO
D
O
O
O
B
a, R = b, R =
O O O P O R O P
H N
P
O n CE
O CE
n = 0-30 (8-10 optimum)
P
N CH2 H
c, R =
(CH2)3 CH2CH2 O CH2CH2 CH2CH2 O CH2CH2 O CH2CH2
d, R =
CH2 CH CH2
e, R =
CH2 CH CH2 NH O
NH3
NH3 DMTO
E
O
B
O
O
O P O O
S O
CE
DMTO F
O
O O H O P O R O P N O O n CE CE
P
n = 0-30 (8-10 optimum)
B
O O P O Si OCE
P
Figure 3.1.9 Linker arms for permanent attachment to solid-phase supports. (A) Hydroxy propylamine linker (Seliger et al., 1995). (B) Dimethoxytrityl glycolic acid linker (Hakala et al., 1997). (C) Dimethoxytrityl-4,7,10,13-tetraoxatridecanoate linker (Markiewicz et al., 1994). (D) Long spacer linkages prepared using repetitive coupling of various phosphoramidites (Shchepinov et al., 1997). (E) Cleavable spacer linkage used in conjunction with the preceding phosphoramidites to control the surface oligonucleotide density (Shchepinov et al., 1997), (F) Direct phosphate linkage to surface silanol groups (Cohen et al., 1997). (G) Diol linker formed from 3-glycidoxypropyl trimethoxysilane (Maskos and Southern, 1992). (H) Polyethylene glycol linkers (Maskos and Southern, 1992). (I) Bis-(2-hydroxethyl)-aminopropylsilane linker with hexaethylene glycol spacer phosphoramidites (Pease et al., 1994). (J) N-(3-(triethoxysilyl)-propyl)-4-hydroxybutyramide linker (McGall et al., 1997). (K) Linkage through the N4-position of cytosine (Markiewicz et al., 1994). (L) Triethylene glycol ethylacrylamide linker (Markiewicz et al., 1994). DMT, 5′-dimethoxytrityl (DMTr).
gonucleotides. This method required a careful selection of protecting groups and a special capping reagent (levulinic anhydride) that could be selectively removed without exposing the full-length product (blocked by a DMTr or 5′-benzoyl group) to enzymatic digestion. In a second approach (Horn and Urdea, 1988; Kwiatkowski et al., 1996), the purification of 5′-dimethoxytritylated oligonucleotides was
improved by selective fragmentation of sequences containing apurinic defects, while still attached to the support. This treatment greatly reduced the proportion of DMTr-labeled oligonucleotides that were not full-length and allowed oligonucleotides as long as 118 bases to be purified by a simple reverse-phase cartridge procedure.
Synthesis of Unmodified Oligonucleotides
3.1.21 Current Protocols in Nucleic Acid Chemistry
OH G
HO
HO H
O
P
Si
O
O
O
Si
n
n = 0, 4, 5
O O P O 6 OCE
DMTO I
P
N
Si
P
O O P O OCE 6
DMTO
O J
HO
N H
P
Si
Si
HN
P
NH K DMTO
O
N
O
AcO
O L
DMTO
O
O
O
N H
Si
P
Figure 3.1.9 Continued
Linker Arms for Permanent Attachment to the Support
Solid-Phase Supports for Oligonucleotide Synthesis
Linker arms for permanent attachment of the oligonucleotide to the support must be very resistant to the hydrolysis conditions used to remove protecting groups. The most common method for permanent attachment is through phosphodiester or phosphoroamidate linkages by the direct coupling of phosphoramidite reagents, respectively, to hydroxyl or amino derivatized supports. The phosphoramidate linkages are particularly common when aminated polypropylene films are used as supports (Matson et al., 1994, 1995; Wehnert et al., 1994; Shchepinov et al., 1997). Other derivatized supports have been converted into hydroxyl functionalized materials using either 3-amino-1propanol, dimethoxytrityl glycolic acid, sodium 13-O-dimethoxytrityl-4,7,10,13-tetra-oxatrid ecanoate, or a variety of consecutive spacer
phosphoramidites (Fig. 3.1.9A to D). These spacer phosphoramidites may also contain cleavable sulfonyldiethanol groups (Fig. 3.1.9E) or positively charged 2-amino-1,2propandiol groups so that the surface density and charge can be modulated as well as the spacer chain length. Although a recent publication has described the direct coupling of phosphoramidite reagents to the silanol groups on acid-washed glass slides (Fig. 3.1.9F), most glass surfaces are derivatized with alkoxysilanes to produced linker arms extending away from the surface. Several hydroxy-derivatized linkers on glass based on 3-glycidoxypropyl trimethoxysilane and ethylene glycol ethers have been described (Fig. 3.1.9G and H). Unfortunately, however, these linkers were not completely resistant to NH4OH (5 to 10 hr at 55°C), and much of the product was lost. Other hydroxyl linker arms on glass plates have been based on bis-(2-hy-
3.1.22 Current Protocols in Nucleic Acid Chemistry
droxyethyl)-aminopropylsilane or N-(3(triethoxysilyl)-aminopropyl)-4-hydroxybutyramide and used in the synthesis of high-density oligonucleotide arrays (Fig. 3.1.9I and J). In these reports, base deprotection was accomplished using 1,2-diaminoethane/ethanol (1:1, 2 to 6 hr at room temperature) instead of hot NH4OH, and no linker cleavage was reported. Linkages to CPG beads using attachments through the N4-position of 2′-deoxycytidine or through a triethylene glycol ethylacrylamide linker have also been reported (Fig. 3.1.9K and L); however, the researchers noted that the lability of the disiloxane bond (Si-O-Si) between any silica-based support and silane linker arm is a limiting factor and, although certain resistance to aqueous NH4OH is possible, use of pyridine/NH4OH always results in substantial cleavage (Markiewicz et al., 1994).
CONCLUSIONS Solid-phase oligonucleotide synthesis was once considered to be a “mature” technology limited to incremental improvements; however, new and ingenious applications for oligonucleotide based materials continue to be developed, and the role of solid-phase synthesis is clearly going to be very important in making these new materials available. Quite remarkably, the scale of these applications spans the range from the extremely minute (i.e., single molecule detection and nanoengineering) to large-scale oligonucleotide pharmaceuticals. Success in any of these areas requires a firm understanding of the chemical requirements of every step involved. It is hoped that this short review provides enough introduction to convey the power and diversity of solid-phase oligonucleotide synthesis techniques and convince the reader that new technology can be developed in even mature fields.
Literature Cited Adinolfi, M., Barone, G., Denapoli, L., Iadonisi, A., and Piccialli, G. 1996. Solid phase synthesis of oligosaccharides. Tetrahedron Lett. 37:50075010. Alazzouzi, E., Escaja, N., Grandas, A., and Pedroso, E. 1997. A straightforward solid-phase synthesis of cyclic oligodeoxyribonucleotides. Angew. Chem. Intl. Ed. Engl. 36:1506-1508. Albretsen, C., Kalland, K.-H., Haukanes, B.-I., Håvarstein, L.-S., and Kleppe, K. 1990. Applications of magnetic beads with covalently attached oligonucleotides in hybridization: Isolation and detection of specific measles virus mRNA from a crude cell lysate. Anal. Biochem. 189:40-50.
Alul, R.H., Singman, C.N., Zhang, G.R., and Letsinger, R.L. 1991. Oxalyl-CPG—A labile support for synthesis of sensitive oligonucleotide derivatives. Nucl. Acids Res. 19:1527-1532. Arnold, L., Tocík, Z., Bradková, E., HostomskO, Z., Paces, V., and Smrt, J. 1989. Automated chloridite and amidite synthesis of oligodeoxyribonucleotides on a long chain support using amidine protected purine nucleosides. Collect. Czech. Chem. Commun. 54:523-532. Asseline, U. and Thuong, N.T. 1989. Solid-phase synthesis of modified oligodeoxyribonucleotides with an acridine derivative or a thiophosphate group at their 3′ end. Tetrahedron Lett. 30:2521-2524. Avino, A., Garcia, R.G., Diaz, A., Albericio, F., and Eritja, R. 1996. A comparative study of supports for the synthesis of oligonucleotides without using ammonia. Nucleos. Nucleot. 15:1871-1889. Bader, R., Brugger, H., Hinz, M., Rembe, C., Hofer, E.P., and Seliger, H. 1997a. A rapid method for the preparation of a one dimensional sequenceoverlapping oligonucleotide library. Nucleos. Nucleot. 16:835-842. Bader, R., Hinz, M., Schu, B., and Seliger, H. 1997b. Oligonucleotide microsynthesis of a 200-mer and of one dimensional arrays on a surface of hydroxylated polypropylene tape. Nucleos. Nucleot. 16:829-833. Bardella, F., Eritja, R., Pedroso, E., and Giralt, E. 1993. Gel-phase P-31 NMR—A new analytical tool to evaluate solid phase oligonucleotide synthesis. Bioorgan. Med. Chem. Lett. 3:2793-2796. Beattie, K.L., Logsdon, N.J., Anderson, R.S., Espinosa-Lara, J.M., Maldonado-Rodriguez, R., and Frost, J.D.I. 1988. Gene synthesis technology: Recent developments and future prospects. Biotechnol. Appl. Biochem. 10:510-521. Beaucage, S.L. and Iyer, R.P. 1992. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:22232311. Beaucage, S.L. and Iyer, R.P. 1993. The functionalization of oligonucleotides via phosphoramidite derivatives. Tetrahedron 49:1925-1963. Belagaje, R. and Brush, C.K. 1982. Polymer supported synthesis of oligonucleotides by a phosphotriester method. Nucl. Acids Res. 10:62956303. Bergmann, F. and Bannwarth, W. 1995. Solid phase synthesis of directly linked peptide-oligodeoxynucleotide hybrids using standard synthesis protocols. Tetrahedron Lett. 36:1839-1842. Berner, S., Gröger, G., and Seliger, H. 1989. A new option in solid phase synthesis of DNA fragments. Nucleos. Nucleot. 8:1165-1167. Bhongle, N.N. and Tang, J.Y. 1995. A convenient and practical method for derivatization of solid supports for nucleic acid synthesis. Synth. Commun. 25:3671-3679.
Synthesis of Unmodified Oligonucleotides
3.1.23 Current Protocols in Nucleic Acid Chemistry
Birch-Hirschfield, E., Foldespapp, Z., Guhrs, K.H., and Seliger, H. 1996. Oligonucleotide synthesis on polystyrene-grafted poly(tetrafluoroethylene) support. Helv. Chim. Acta 79:137-150. Boal, J.H., Wilk, A., Harindranath, N., Max, E.E., Kempe, T., and Beaucage, S.L. 1996. Cleavage of oligodeoxyribonucleotides from controlledpore glass supports and their rapid deprotection by gaseous amines. Nucl. Acids Res. 24:31153117. Bonora, G.M. 1995. Polyethylene glycol. A high efficiency liquid phase (HELP) for the large scale synthesis of the oligonucleotides. Appl. Biochem. Biotechnol. 54:3-17. Bonora, G.M., Baldan, A., Schiavon, O., Ferruti, P., and Veronese, F.M. 1996. Poly(N-acryloylmorpholine) as a new soluble support for the liquidphase synthesis of oligonucleotides. Tetrahedron Lett. 37:4761-4764. Bower, M., Summers, M.F., Kell, B., Hoskins, J., Zon, G., and Wilson, W.D. 1987. Synthesis and characterization of oligodeoxyribonucleotides containing terminal phosphates. NMR, UV spectroscopic and thermodynamic analysis of duplex formation of [d(pGGATTCC)]2, [d(GGAATTCCp)]2 and [d(pGGAATTCCp)]2. Nucl. Acids Res. 15:3531-3547. Brown, T., Pritchard, C.E., Turner, G., and Salisbury, S.A. 1989. A new base-stable linker for solidphase oligonucleotide synthesis. J. Chem. Soc. Chem. Commun. 891-893. Caruthers, M.H. 1991. Chemical synthesis of DNA and DNA analogues. Acc. Chem. Res. 24:278284. Chow, F. and Kempe, T. 1997. Process and reagents for processing synthetic oligonucleotides. United States Patent #5,656,741. Chu, T.J., Caldwell, K.D., Weiss, R.B., Gesteland, R.F., and Pitt, W.G. 1992. Low fluorescence background electroblotting membrane for DNA sequencing. Electrophoresis 13:105-114. Cohen, G., Deutsch, J., Fineberg, J., and Levine, A. 1997. Covalent attachment of DNA oligonucleotides to glass. Nucl. Acids Res. 25:911-912. Cosstick, R. and Eckstein, F. 1985. Synthesis of d(GC) and d(CG) octamers containing alternating phosphorothioate linkages: Effect of the phosphorothioate group on the B-Z transition. Biochemistry 24:3630-3638.
Solid-Phase Supports for Oligonucleotide Synthesis
Debear, J.S., Hayes, J.A., Koleck, M.P., and Gough, G.R. 1987. A universal glass support for oligonucleotide synthesis. Nucleos. Nucleot. 6:821-830. Dell’Aquila, C., Imbach, J.L., and Rayner, B. 1997. Photolabile linker for the solid-phase synthesis of base-sensitive oligonucleotides. Tetrahedron Lett. 38:5289-5292. De Napoli, L., Galeone, A., Mayol, L., Messere, A., Montesarchio, D., and Piccialli, G. 1995. Automated solid phase synthesis of cyclic oligonucleotides: A further improvement. Bioorgan. Med. Chem. 3:1325-1329. Devivar, R.V., Koontz, S.L., Peltier, W.J., Pearson, J.E., Guillory, T.A., and Fabricant, J.D. 1999. A new solid-support for oligonucleotide synthesis. Biorg. Med. Chem. Lett. 9:1239-1242. Duncan, C.H. and Cavalier, S.L. 1988. Affinity chromatography of a sequence-specific DNA binding protein using Teflon-linked oligonucleotides. Anal. Biochem. 169:104-108. Efcavitch, J.W., McBride, L.J., and Eadie, J.S. 1986. Effect of pore diameter on the support-bound synthesis of long oligodeoxynucleotides. In Biophosphates and Their Analogues—Synthesis, Structure, Metabolism and Activity (K.S. Bruzik and W.J. Stec, eds.) pp. 65-70. Elsevier Science Publishing, New York. Efimov, V.A., Buryakova, A.A., Reverdatto, S.V., Chakhmakhcheva, O.G., and Ovchinnikov, Y.A. 1983. Rapid synthesis of long-chain deoxyribooligonucleotides by the N-methylimidazole phosphotriester method. Nucl. Acids Res. 11:8369-8387. Eritja, R., Robles, J., Fernandezforner, D., Albericio, F., Giralt, E., and Pedroso, E. 1991. NPE-resin, a new approach to the solid-phase synthesis of protected peptides and oligonucleotides. 1. Synthesis of the supports and their application to oligonucleotide synthesis. Tetrahedron Lett. 32:1511-1514. Felder, E., Schwyzer, R., Charubala, R., Pfleiderer, W., and Schulz, B. 1984. A new solid phase approach for rapid synthesis of oligonucleotides bearing a 3′-terminal phosphate group. Tetrahedron Lett. 25:3967-3970. Fodor, S.P.A., Read, J.L., Pirrung, M.C., Stryer, L., Lu, T.L., and Solas, D. 1991. Light-directed, spatially addressable parallel chemical synthesis. Science 251:767-773.
Cramer, F., Helbig, R., Hettler, H., Scheit, K.H., and Seliger, H. 1966. Oligonucleotide synthesis with a soluble polymer as a carrier. Angew. Chem. Intl. Ed. Engl. 5:601-601.
Frank, R. 1993. Strategies and techniques in simultaneous solid phase synthesis based on the segmentation of membrane type supports. Bioorgan. Med. Chem. Lett. 3:425-430.
Crea, R. and Horn, T. 1980. Synthesis of oligonucleotides on cellulose by a phosphotriester method. Nucl. Acids Res. 8:2331-2348.
Frank, R., Heikens, W., Heisterberg-Moutsis, G., and Blocker, H. 1983. A new general approach for the simultaneous chemical synthesis of large numbers of oligonucleotides: Segmental solid supports. Nucl. Acids Res. 13:4365-4377.
Damha, M.J., Giannaris, P.A., and Zabarylo, S.V. 1990. An improved procedure for derivatization of controlled pore glass beads for solid-phase oligonucleotide synthesis. Nucl. Acids Res. 18:3813-3821.
Fruchtel, J.S. and Jung, G. 1996. Organic chemistry on solid supports. Angew. Chem. Intl. Ed. Engl. 35:17-42.
3.1.24 Current Protocols in Nucleic Acid Chemistry
Gait, M.J., Matthes, H.W.D., Singh, M.S., Sproat, B.S., and Titmas, R.C. 1982. Rapid synthesis of oligodeoxyribonucleotides VII. Solid phase synthesis of oligodeoxyribonucleotides by a continuous flow phosphotriester method on a kieselguhr-polyamide support. Nucl. Acids Res. 10:6243-6254. Gold, L., Polisky, B., Uhlenbeck, O., and Yarus, M. 1995. Diversity of oligonucleotide functions. Annu. Rev. Biochem. 64:763-797. Gough, G.R., Brunden, M.J., and Gilham, P.T. 1983. 2′(3′)-O-Benzoyluridine 5′ linked to glass: An all purpose support for solid phase synthesis of oligodeoxyribonucleotides. Tetrahedron Lett. 24:5321-5324. Gray, D.E., Case-Green, S.C., Fell, T.S., Dobsen, P.J., and Southern, E.M. 1997. Ellipsometric and interferometric characterization of DNA probes immobilized on a combinatorial array. Langmuir 13:2833-2842. Greenberg, M.M. and Gilmore, J.L. 1994. Cleavage of oligonucleotides from solid-phase supports using O-nitrobenzyl photochemistry. J. Org. Chem. 59:746-753. Grotli, M., Eritja, R., and Sproat, B. 1997. Solid phase synthesis of branched RNA and branched DNA/RNA chimeras. Tetrahedron 53:1131711347. Gryaznov, S.M. and Letsinger, R.L. 1992. A new approach to synthesis of oligonucleotides with 3′ phosphoryl groups. Tetrahedron Lett. 33:41274128. Gupta, K.C., Sharma, P., Kumar, P., and Sathyanarayana, S. 1991. A general method for the synthesis of 3′-sulfhydryl and phosphate group containing oligonucleotides. Nucl. Acids Res. 19:3019-3025. Guzaev, A. and Lonnberg, H. 1997. A novel solid support for synthesis of 3′-phosphorylated chimeric oligonucleotides containing internucleosidic methyl phosphotriester and methylphosphonate linkages. Tetrahedron Lett. 38:3989-3992. Hakala, H., Heinonen, P., Iitia, A., and Lonnberg, H. 1997. Detection of oligonucleotide hybridization on a single microparticle by time-resolved fluorometry: Hybridization assays on polymer particles obtained by direct solid phase assembly of the oligonucleotide probes. Bioconjugate Chem. 8:378-384.
Hermes, J.D., Parekh, S.M., Blacklow, S.C., Köster, H., and Knowles, J.R. 1989. A reliable method for random mutagenesis: The generation of mutant libraries using spiked oligodeoxyribonucleotide primers. Gene 84:143-151. Horn, T. and Urdea, M.S. 1988. Solid-supported hydrolysis of apurinic sites in synthetic oligonucleotides for rapid and efficient purification on reverse- phase cartridges. Nucl. Acids Res. 16:11559-11571. Hyrup, B. and Nielsen, P.E. 1996. Peptide nucleic acids (PNA): synthesis, properties and potential applications. Bioorgan. Med. Chem. 4:5-23. Ito, H., Ike, Y., Ikuta, S., and Itakura, K. 1982. Solid phase synthesis of polynucleotides. VI. Further studies on polystyrene copolymers for the solid support. Nucl. Acids Res. 10:1755-1769. Kamaike, K., Hasegawa, Y., and Ishido, Y. 1988. Efficient synthesis of an oligonucleotide on a cellulose acetate derivative as a novel polymersupport using phosphotriester approach. Tetrahedron Lett. 29:647-650. Katzhendler, J., Cohen, S., Weisz, M., Ringel, I., Camerini-Oterio, R.D., and Deutsch, J. 1987. Spacer effect on the synthesis of oligonucleotides by the phosphite method. Reactive Polymers 6:175-187. Katzhendler, J., Cohen, S., Rahamim, E., Weisz, M., Ringel, I., and Deutsch, J. 1989. The effect of spacer, linkage and solid support on the synthesis of oligonucleotides. Tetrahedron 45:2777-2792. Khorana, H.G. 1979. Total synthesis of a gene. Science 203:614-625. Kumar, A. 1994. Development of a suitable linkage for oligonucleotide synthesis and preliminary hybridization studies on oligonucleotides synthesized in situ. Nucleos. Nucleot. 13:21252134. Kumar, P., Bose, N.K., and Gupta, K.C. 1991. A versatile solid phase method for the synthesis of oligonucleotide-3′- phosphates. Tetrahedron Lett. 32:967-970. Kumar, P., Sharma, A.K., Sharma, P., Garg, B.S., and Gupta, K.C. 1996. Express protocol for functionalization of polymer supports for oligonucleotide synthesis. Nucleos. Nucleot. 15:879888.
Hardy, P.M., Holland, D., Scott, S., Garman, A.J., Newton, C.R., and McLean, M.J. 1998. Reagents for the preparation of two oligonucleotides per synthesis (TOPS). Nucl. Acids Res. 22:2998-3004.
Kwiatkowski, M., Nilsson, M., and Landegren, U. 1996. Synthesis of full-length oligonucleotides: Cleavage of apurinic molecules on a novel support. Nucl. Acids Res. 24:4632-4638.
Hayakawa, Y., Wakabayashi, S., Kato, H., and Noyori, R. 1990. The allylic protection method in solid-phase oligonucleotide synthesis: An efficient preparation of solid-anchored DNA oligomers. J. Am. Chem. Soc. 112:1691-1696.
Lipshutz, R.J., Morris, D., Chee, M., Hubbell, E., Kozal, M.J., Shah, N., Shen, N., Yang, R., and Fodor, S.P.A. 1995. Using oligonucleotide probe arrays to access genetic diversity. BioTechniques 19:442-447.
Hayatsu, H. and Khorana, H.G. 1966. Deoxyribooligonucleotide synthesis on a polymer support. J. Am. Chem. Soc. 88:3182-3183.
Lyttle, M.H., Hudson, D., and Cook, R.M. 1996. A new universal linker for solid phase DNA synthesis. Nucl. Acids Res. 24:2793-2798.
Synthesis of Unmodified Oligonucleotides
3.1.25 Current Protocols in Nucleic Acid Chemistry
Macdonald, P.M., Damha, M.J., Ganeshan, K., Braich, R., and Zabarylo, S.V. 1996. Phosphorus 31 solid state NMR characterization of oligonucleotides covalently bound to a solid support. Nucl. Acids Res. 24:2868-2876. Macmillan, A.M. and Verdine, G.L. 1991. Engineering tethered DNA molecules by the convertible nucleoside approach. Tetrahedron 47:2603-2616. Markiewicz, W.T. and Wyrzykiewicz, T.K. 1989. Universal solid supports for the synthesis of oligonucleotides with terminal 3′-phosphates. Nucl. Acids Res. 17:7149-7158. Markiewicz, W.T., Adrych-Rozek, K., Markiewicz, M., Zebrowska, A., and Astriab, A. 1994. Synthesis of oligonucleotides permanently linked with solid supports for use as synthetic oligonucleotide combinatorial libraries. In Innovation and Perspectives in Solid Phase Synthesis: Peptides, Proteins and Nucleic Acids: Biological and Biomedical Applications (R. Epton, ed.) pp. 339346. Mayflower Worldwide, Birmingham.
Mullah, B., Livak, K., Andrus, A., and Kenney, P. 1998. Efficient synthesis of double dye-labeled oligodeoxyribonucleotide probes and their application in a real time PCR assay. Nucl. Acids Res. 26:1026-1031. Nelson, P.S., Muthini, S., Vierra, M., Acosta, L., and Smith, T.H. 1997. Rainbow universal CPG: A versatile solid support for oligonucleotide synthesis. BioTechniques 22:752-756. Ohsima, S.-I., Morita, K., and Takaku, H. 1984. Solid-phase synthesis of deoxyribooligonucleotides by the phosphotriester method employing a new polymer support. Chem. Pharm. Bull. 32:4690-4693. Ott, J. and Eckstein, F. 1984. Filter disc supported oligonucleotide synthesis by the phosphite method. Nucl. Acids Res. 12:9137-9142.
Maskos, U. and Southern, E.M. 1992. Oligonucleotide hybridizations on glass supports: A novel linker for oligonucleotide synthesis and hybridisation properties of oligonucleotides synthesized in situ. Nucl. Acids Res. 20:1679-1684.
Pease, A.C., Solas, D., Sullivan, E.J., Cronin, M.T., Holmes, C.P., and Fodor, S.P.A. 1994. Lightgenerated oligonucleotide arrays for rapid DNA sequence analysis. Proc. Natl. Acad. Sci. U.S.A. 91:5022-5026.
Matson, R.S., Rampal, J.B., and Coassin, P.J. 1994. Biopolymer synthesis on polypropylene supports. Anal. Biochem. 217:306-310.
Pochet, S., Huyn-Dinh, T., and Igolen, J. 1987. Synthesis of DNA fragments linked to a solid phase support. Tetrahedron 43:3481-3490.
Matson, R.S., Rampal, J., Pentoney, S.L., Jr., Anderson, P.D., and Coassin, P. 1995. Biopolymer synthesis on polypropylene supports: Oligonucleotide arrays. Anal. Biochem. 224:110-116.
Pon, R.T. 1993. Solid-phase supports for oligonucleotide synthesis. In Protocols for Oligonucleotides and Analogs (S. Agrawal, ed.) pp. 465496. Humana Press, Totowa, N.J.
Matthes, H.W.D., Zenke, W.M., Grundström, T., Staub, A., Wintzerith, M., and Chambon, P. 1984. Simultaneous rapid chemical synthesis of over one hundred oligonucleotides on a microscale. EMBO J. 3:801-805.
Pon, R.T. and Yu, S. 1997a. Hydroquinone-O,O′diacetic acid (‘Q-linker’) as a replacement for succinyl and oxalyl linker arms in solid phase oligonucleotide synthesis. Nucl. Acids Res. 25:3629-3635.
McCollum, C. and Andrus, A. 1991. An optimized polystyrene support for rapid, efficient oligonucleotide synthesis. Tetrahedron Lett. 32:40694072. McGall, G., Labadie, J., Brock, P., Wallraff, G., Nguyen, T., and Hinsberg, W. 1996. Light-directed synthesis of high-density oligonucleotide arrays using semiconductor photoresists. Proc. Natl. Acad. Sci. U.S.A. 93:13555-13560. McGall, G.H., Barone, A.D., Diggelmann, M., Fodor, S.P.A., Gentalen, E., and Ngo, N. 1997. The efficiency of light-directed synthesis of DNA arrays on glass substrates. J. Am. Chem. Soc. 119:5081-5090. Merrifield, R.B. 1965. Automated synthesis of peptides. Science 150:178-185.
Solid-Phase Supports for Oligonucleotide Synthesis
Montserrat, F.X., Grandas, A., Eritja, R., and Pedroso, E. 1994. Criteria for the economic large scale solid-phase synthesis of oligonucleotides. Tetrahedron 50:2617-2622.
Pon, R.T. and Yu, S. 1997b. Rapid automated derivatization of solid-phase supports for oligonucleotide synthesis using uronium or phosphonium coupling reagents. Tetrahedron Lett. 38:3331-3334. Pon, R.T., Usman, N., and Ogilvie, K.K. 1988. Derivatization of controlled pore glass beads for solid phase oligonucleotide synthesis. BioTechniques 6:768-775. Pon, R.T., Buck, G.A., Hager, K.M., Naeve, C.W., Niece, R.L., Robertson, M., and Smith, A.J. 1996. Multi-facility survey of oligonucleotide synthesis and an examination of the performance of unpurified primers in automated DNA sequencing. BioTechniques 21:680-685.
Milner, N., Mir, K.U., and Southern, E.M. 1997. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotechnol. 15:537-541.
Pon, R.T., Yu, S., Guo, Z., Yang, X., and Sanghvi, Y.S. 1998. Reusable solid-phase supports for oligonucleotide synthesis using hydroquinoneO,O′-diacetic acid (Q-linker). Nucleos. Nucleot. In press.
Montserrat, F.X., Grandas, A., and Pedroso, E. 1993. Predictable and reproducible yields in the anchoring of DMT-nucleoside-succinates to highly loaded aminoalkyl-polystyrene. Nucleos. Nucleot. 12:967-971.
Pon, R.T., Yu, S., Guo, Z., and Sanghvi, Y.S. 1999. Multiple oligodeoxyribonucleotide syntheses on a reusable solid-phase CPG support via the hydroquinone-O,O′-diacetic acid (Q-linker) linker arm. Nucl. Acids Res. 27:1531-1538.
3.1.26 Current Protocols in Nucleic Acid Chemistry
Porco, J.A., Deegan, T., Devonport, W., Gooding, O.W., Heisler, K., Labadie, J.W., Newcomb, B., Nguyen, C., van Eikeren, P., Wong, J., and Wright, P. 1997. Automated chemical synthesis: From resins to instruments. Mol. Divers. 2:197206.
Seliger, H., Kotschi, U., Scharpf, C., Martin, R., Eisenbeiss, F., Kinkel, J.N., and Unger, K.K. 1989. Polymer support synthesis XV. Behaviour of non-porous surface coated silica gel microbeads in oligonucleotide synthesis. J. Chromatogr. 476:49-57.
Potapov, V.K., Veiko, V.P., Korolev, O.N., and Shabarova, Z.A. 1979. Rapid synthesis of oligodeoxyribonucleotides on a grafted polymer support. Nucl. Acids Res. 6:2041-2057.
Seliger, H., Bader, R., Birch-Hirschfield, E., FöldesPapp, Z., Hinz, M., and Scharpf, C. 1995. Surface reactive polymers for special applications in nucleic acid synthesis. Reactive Functional Polymers 26:119-126.
Rapp, W. 1996. PEG grafted polystyrene tentacle polymers: Physico-chemical properties and application in chemical synthesis. In Combinatorial Peptide and Non-Peptide Libraries: A Handbook (G. Jung, ed.) pp. 425-464. VCH, Weinheim. Rapp, W.E. 1997. Macro beads as microreactors: New solid-phase synthesis methodology. In Combinatorial Chemistry: Synthesis and Application, (S.R. Wilson and A.W. Czarnik, eds.) pp. 65-93. John Wiley & Sons, New York.
Seliger, H., Bader, R., Hinz, M., Rotte, B., Astriab, A., Markiewicz, M., and Markiewicz, W.T. 1997. Synthetic oligonucleotide combinatorial libraries—Tools for studying nucleic acid interactions. Nucleos. Nucleot. 16:703-710. Sharma, P., Sharma, A.K., Malhotra, V.P., and Gupta, K.C. 1992. One pot general method for the derivatization of polymer support for oligonucleotide synthesis. Nucl. Acids Res. 20:4100-4100.
Reddy, M.P., Hanna, N.B., and Farooqui, F. 1994a. Fast cleavage and deprotection of oligonucleotides. Tetrahedron Lett. 35:4311-4314.
Shchepinov, M.S., CaseGreen, S.C., and Southern, E.M. 1997. Steric factors influencing hybridisation of nucleic acids to oligonucleotide arrays. Nucl. Acids Res. 25:1155-1161.
Reddy, M.P., Michael, M.A., Farooqui, F., and Girgis, S. 1994b. New and efficient solid support for the synthesis of nucleic acids. Tetrahedron Lett. 35:5771-5774.
Sproat, B.S. and Brown, D.M. 1985. A new linkage for solid phase synthesis of oligodeoxyribonucleotides. Nucl. Acids Res. 13:2979-2987.
Routledge, A., Wallis, M.P., Ross, K.C., and Fraser, W. 1995. A new deprotection strategy for automated oligonucleotide synthesis using a novel silyl-linked solid support. Bioorgan. Med. Chem. Lett. 5:2059-2064. Scheuerlarsen, C., Rosenbohm, C., Jorgensen, T.J.D., and Wengel, J. 1997. Introduction of a universal solid support for oligonucleotide synthesis. Nucleos. Nucleot. 16:67-80. Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., and Gough, G.R. 1995. A universal adapter for chemical synthesis of DNA or RNA on any single type of solid support. Tetrahedron Lett. 36:27-30. Schwyzer, R., Felder, E., and Failli, P. 1984. 148. The CAMET and CASET links for the synthesis of protected oligopeptides and oligodeoxynucleotides on solid and soluble supports. Helv. Chim. Acta 67:1316-1327. Scott, S., Hardy, P., Sheppard, R.C., and McLean, M.J. 1994. A universal support for oligonucleotide synthesis. In Innovation and Perspectives in Solid-Phase Synthesis. Peptides, Proteins, and Nucleic Acids, Biological and Biomedical Applications (R. Epton, ed.) pp. 115124. Mayflower Worldwide, Ltd., Birmingham, UK. Seliger, H., Herold, A., Kotschi, U., Lyons, J., and Schmidt, G. 1987. Semi-mechanized simultaneous synthesis of multiple oligonucleotide fragments. In Biophosphates and Their Analogues— Synthesis, Structure, Metabolism and Activity (K.S. Bruzik and W.J. Stec, eds.) pp. 43-58. Elsevier Science Publishers, New York.
Stengele, K.P. and Pfleiderer, W. 1990. Improved synthesis of oligodeoxyribonucleotides. Tetrahedron Lett. 31:2549-2552. Stimpson, D.I., Hoijer, J.V., Hsieh, W.T., Jou, C., Gordon, J., Theriault, T., Gamble, R., and Baldeschwieler, J.D. 1995. Real-time detection of DNA hybridization and melting on oligonucleotide arrays by using optical wave guides. Proc. Natl. Acad. Sci. U.S.A. 92:6379-6383. Tanaka, T., Yamada, Y., Uesugi, S., and Ikehara, M. 1989. Preparation of a new phosphorylating agent: S-(N-monomethoxytritylaminoethyl)-O(o-chlorophenyl)phosphorothioate and its application in oligonucleotide synthesis. Tetrahedron 45:651-660. Tang, J.Y. and Tang, J.X. 1997. Passivated polymer supports for nucleic acid synthesis. United States Patent #5,668,268. Uddin, A.H., Piunno, P.A., Hudson, R.H., Damha, M.J., and Krull, U.J. 1997. A fiber optic biosensor for fluorimetric detection of triple-helical DNA. Nucl. Acids Res. 25:4139-4146. Urdea, M.S. and Horn, T. 1986. Solid-supported synthesis, deprotection and enzymatic purification of oligodeoxyribonucleotides. Tetrahedron Lett. 27:2933-2936. van Aerschot A., Herdewijn, P., and Vanderhaeghe, H. 1988. Silica gel functionalised with different spacers as solid support for oligonucleotide synthesis. Nucleos. Nucleot. 7:75-90. van der Laan, A.C., Brill, R., Kuimelis, R.G., Kuylyeheskiely, E., Vanboom, J.H., Andrus, A., and Vinayak, R. 1997. A convenient automated solid-phase synthesis of PNA-(5′)-DNA-(3′)PNA chimera. Tetrahedron Lett. 38:2249-2252.
Synthesis of Unmodified Oligonucleotides
3.1.27 Current Protocols in Nucleic Acid Chemistry
van der Marel, G.A., Marugg, J.E., de Vroom, E., Wille, G., Tromp, M., van Boeckel, C.A.A., and van Boom, J.H. 1982. Phosphotriester synthesis of DNA fragments on cellulose and polystyrene solid supports. Recl. Trav. Chim. Pays-Bas 101:234-241. Venkatesan, H. and Greenberg, M.M. 1996. Improved utility of photolabile solid phase synthesis supports for the synthesis of oligonucleotides containing 3′-hydroxyl termini. J. Org. Chem. 61:525-529. Wehnert, M.S., Matson, R.S., Rampal, J.B., Coassin, P., and Caskey, C.T. 1994. A rapid scanning strip for tri- and dinucleotide short tandem repeats. Nucl. Acids Res. 22:1701-1704. Weiler, J. and Hoheisel, J.D. 1996. Combining the preparation of oligonucleotide arrays and synthesis of high-quality primers. Anal. Biochem. 243:218-227. Weiler, J. and Hoheisel, J.D. 1997. Picomole syntheses of high quality oligonucleotide primers in combination with the preparation of oligonucleotide arrays. Nucleos. Nucleot. 16:17931796.
Weiler, J. and Pfleiderer, W. 1995. An improved method for the large scale synthesis of oligonucleotides applying the NPE/NPEOC strategy. Nucleos. Nucleot. 14:917-920. Winter, M. 1996. Supports for solid-phase organic synthesis. In Combinatorial Peptide and NonPeptide Libraries: A Handbook (G. Jung, ed.) pp. 465-510. VCH, Weinheim. Wright, P., Lloyd, D., Rapp, W., and Andrus, A. 1993. Large scale synthesis of oligonucleotides via phosphoramidite nucleosides and a highloaded polystyrene support. Tetrahedron Lett. 34:3373-3376. Yip, K.F. and Tsou, K.C. 1971. A new polymer support method for the synthesis of ribooligonucleotide. J. Am. Chem. Soc. 93:3272-3276. Zhang, X.H. and Jones, R.A. 1996. A universal allyl linker for solid-phase synthesis. Tetrahedron Lett. 37:3789-3790.
Contributed by Richard T. Pon University of Calgary Calgary, Alberta, Canada
Solid-Phase Supports for Oligonucleotide Synthesis
3.1.28 Current Protocols in Nucleic Acid Chemistry
Attachment of Nucleosides to Solid-Phase Supports
UNIT 3.2
The first step in any solid-phase synthesis is the covalent attachment of a monomeric unit (i.e., a nucleoside or mononucleotide) to the surface of an insoluble support. For oligonucleotide synthesis, this process is performed separately from the automated coupling steps used for chain elongation because of the different coupling chemistry involved. This unit provides protocols for using amide and ester linkages to attach nucleosides to long-chain alkylamine–controlled-pore glass (LCAA-CPG) bead supports. Protocols and descriptions of the coupling chemistry used by automated synthesizers to create internucleotide phosphodiester linkages are contained in subsequent units, and the properties and applications of a large variety of solid supports are reviewed in UNIT 3.1. Although prederivatized solid supports are commercially available from a number of sources, preparation of these materials in the lab is a very reasonable alternative to their purchase: the procedures are very simple, and a single support synthesis can produce sufficient material for a great number of oligonucleotide syntheses. Significant savings can also be obtained by filling one’s own synthesis columns instead of purchasing ready-to-use columns. In addition, many minor-nucleoside- and special non-nucleosidederivatized supports are either not commercially available or quite costly. This unit provides protocols for attaching nucleosides to supports via two different dicarboxylic acid linkers: succinic anhydride, S.4, and hydroquinone-O,O′-diacetic acid (HQDA or Q-linker), S.8. Basic Protocol 1 describes how commercially available nucleoside-3′-O-succinate hemiesters can be attached to LCAA-CPG through an amide linkage. Alternate Protocol 1 describes how nucleosides with free 3′-OH groups can be attached to succinylated LCAA-CPG through an ester linkage. Basic Protocol 2 describes how to synthesize nucleoside-3′-O-hydroquinone diacetyl hemiesters from nucleosides and HQDA and how they are coupled to LCAA-CPG. Alternate Protocol 2 describes the preparation of an HQDA-derivatized LCAA-CPG support and how nucleosides with free 3′-OH groups can be coupled to it through an ester linkage. Protocols for quantitating dimethoxytrityl (DMTr) groups attached to a support (Support Protocol 1), for converting surface amino or hydroxyl groups into DMTr derivatives for quantitation (Support Protocol 2), and for quantitating surface carboxylic acid groups as either p-nitrophenol (Support Protocol 3) or N-monomethoxytrityl-6-amino-1-hexanol (Support Protocol 4) derivatives are also included. The succinic acid linker has the advantage of being the most widely used linker arm, and both succinic anhydride and protected nucleoside-3′-O-succinyl hemiester starting materials are readily available. On the other hand, the hydroquinone-O,O′-diacetic acid linker offers greater compatibility with base-sensitive sequence modifications and greater synthetic throughput, because it can be cleaved under milder and faster conditions than can the succinyl linker. No changes in oligonucleotide synthesis protocols, other than reducing the cleavage time (i.e., from 60 to 90 min to only 2 to 3 min), are required when Q-linker is substituted for a succinyl linker. Almost any application requiring synthetic oligonucleotides can be satisfied using one of these linker arms. The major exceptions are applications that require leaving the final oligonucleotide immobilized on the support after synthesis and deprotection, i.e., the direct synthesis of immobilized oligonucleotide libraries. Researchers interested in this application should consult UNIT 3.1 for the appropriate noncleavable linker arms.
Synthesis of Unmodified Oligonucleotides
Contributed by Richard T. Pon
3.2.1
Current Protocols in Nucleic Acid Chemistry (2000) 3.2.1-3.2.23 Copyright © 2000 by John Wiley & Sons, Inc.
STRATEGIC PLANNING: SELECTING A LINKER ARM AND COUPLING PROTOCOL The protocols in this unit involving the two linker arms (succinic acid and HQDA) are each divided into two separate procedures, depending on the site where the linker is first attached. When the linker arm is attached to the 3′-hydroxyl position of a suitably protected nucleoside to produce a nucleoside-3′-O-hemiester, such as S.2 or S.9, a separate synthetic preparation is necessary for each different nucleoside. The alternate approach, which first couples the linker arm to the support to give a carboxyl-derivatized support, such as S.5 or S.12, eliminates the need for a separate hemiester preparation for each nucleoside. The coupling reaction between a carboxyl-derivatized support and the secondary 3′-OH of a nucleoside (i.e., S.6), however, is more difficult; this method is also slower and generates less nucleoside attached to the surface of the support. The selection of the best protocol depends on the cost and availability of the required nucleosides as well as each researcher’s experience with organic synthesis. Researchers who want to perform only minimal synthetic manipulations should choose Basic Protocol 1 (Fig. 3.2.1). This method consists of only one coupling step, if commercially available nucleoside succinate, S.2, is purchased. Researchers requiring supports derivatized with minor or unusual nucleosides, which are often very costly, and who will be preparing oligonucleotides with no unusual sensitivity to basic cleavage conditions should use Alternate Protocol 1, involving succinylated LCAA-CPG (Fig. 3.2.2). The succinylated LCAA-CPG support, S.5, is very easy to prepare, and this approach minimizes consumption of rare and expensive nucleosides. The two protocols using the Q-linker require a slightly greater familiarity with synthesis methodology, although these protocols are still within the ability of most “beginners.” Basic Protocol 2 describes the preparation of nucleoside hemiesters of HQDA (which are not yet commercially available) and their subsequent attachment to LCAA-CPG (Fig. 3.2.3). This method has the advantage of providing higher nucleoside loadings and is particularly important for synthesis on reusable supports (Pon et al., 1998, 1999). Researchers with more limited chemical resources should use Alternate Protocol 2 to prepare HQDA-derivatized LCAA-CPG (Fig. 3.2.4), at least until nucleoside-3′-O-hemiesters of HQDA become commercially available. As with Alternate Protocol 1 for the succinyl linker, this method is simple and eliminates the need for nucleoside-3′-O-hemiesters of HQDA, S.9. This method is also attractive because it avoids any use of pyridine. Use of the Q-linker rather than the succinyl linker is highly recommended for facilities wishing to increase their daily synthesis throughput or for projects requiring base-sensitive sequences, such as methyl phosphonate or methyl phosphotriester backbones, basesensitive nucleosides, and 3′-linked fluorescent dye labels. BASIC PROTOCOL 1
COUPLING OF NUCLEOSIDE-3′-O-SUCCINYL HEMIESTERS TO LCAA-CPG SUPPORT This protocol (Fig. 3.2.1) attaches 5′-dimethoxytrityl-N-protected nucleoside-3′-O-succinate hemiesters, S.2, directly to long-chain alkylamine–controlled-pore glass (LCAACPG; S.1). This protocol has the advantage of using commercially available succinate DMTO P
NH2 1
Attachment of Nucleosides to Solid-Phase Supports
O
O +
O
HO O 2
B
DMTO DEC/DMAP pyridine
O
B
O P
O
N H
O 3
Figure 3.2.1 Coupling of LCAA-CPG, S.1, directly to a nucleoside-3′-O-succinyl hemiester, S.2, as described in Basic Protocol 1. DMT, dimethoxytrityl group.
3.2.2 Current Protocols in Nucleic Acid Chemistry
P
O
O
NH2
O
+
1
4
DMAP/pyridine
O P DMTO
OH
N H
O
B
O
5 1 pentachlorophenol DEC/DMAP/pyridine 2 piperidine
HO DEC/DMAP pyridine
6
DMTO
O
B O
O P
N
N H
P
O
N H
O
O 7
3
Figure 3.2.2 Synthesis of succinylated support, S.5, by reaction of succinic anhydride, S.4, with LCAA-CPG, S.1. Nucleosides with a free 3′-OH group, S.6, can then be esterified to S.5 to yield support S.3. Unreacted succinic acid groups are blocked by conversion into an active pentachlorophenyl ester followed by treatment with piperidine to yield the unreactive site shown as support S.7. DMT, dimethoxytrityl group.
O
DMTO
O
HO C CH2 O
O CH2 C OH
O
B
+ HO
8
6
DEC/DMAP/pyridine DMTO O
B
O
O
HO C CH2 O
O CH2 C O 9
DMTO
O
+
B
DMTO
O O
O
B
O
C CH2 O
O CH2 C O 10
P
NH2
DEC/DMAP/pyridine
1 DMTO
P
H O N C CH2 O
O
B
O O CH2 C O 11
Figure 3.2.3 Synthesis of nucleoside-3′-O-hydroquinone diacetyl hemiester, S.9, from HQDA, S.8, and a protected nucleoside, S.6. A nucleoside diester, S.10, is also produced as a minor byproduct. The mixture of S.9 and S.10, however, is used directly in the coupling reaction with LCAA-CPG, S.1, to produce nucleoside-derivatized support S.11. DMT, dimethoxytrityl group.
Synthesis of Unmodified Oligonucleotides
3.2.3 Current Protocols in Nucleic Acid Chemistry
O P
NH2
O
HO C CH2 O
+
1
O CH2 C OH 8
HBTU/DMAP acetonitrile
H O N C CH2 O
P
O O CH2 C OH 12
DMTO
O
B HBTU/DMAP acetonitrile
HO 6
DMTO
P
H O N C CH2 O
O
B
O O CH2 C O 11
Figure 3.2.4 Coupling of LCAA-CPG, S.1, to HQDA, S.8, using HBTU and DMAP to produce HQDA-derivatized support S.12. A suitably protected nucleoside, S.6, with a 3′-OH group is then esterified to S.12 to generate nucleoside-derivatized support S.11. DMT, dimethoxytrityl group.
hemiester starting materials, S.2, and so the synthesis of these reagents is not included in this protocol. Researchers requiring derivatives of nucleosides other than the four common deoxyribonucleosides (dA, dC, dG, and T) may need to prepare them by coupling succinic anhydride with the appropriately protected rare nucleoside, according to established procedures (Gait et al., 1980; Miyoshi et al., 1980; Chow et al., 1981; Kumar et al., 1993; Markiewicz et al., 1997).
Materials LCAA-CPG beads (other amino-derivatized nonswelling support materials may also be used; see recipe) 5′-Dimethoxytrityl-N-protected nucleoside 3′-O-succinyl hemiester (see recipe) 4-Dimethylaminopyridine (DMAP) 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DEC; see recipe) Triethylamine, reagent grade Anhydrous pyridine, for coupling reactions (see recipe) Methanol, reagent grade Dichloromethane, reagent grade Pyridine, reagent-grade, for washing supports Cap A capping solution (see recipe) Cap B capping solution (see recipe) Screw-capped glass vials or round-bottom flasks Pasteur pipet Buchner funnel Whatman no. 1 filter paper Shaker, wrist action or similar Attachment of Nucleosides to Solid-Phase Supports
Additional reagents and solutions for trityl analysis (see Support Protocol 1)
3.2.4 Current Protocols in Nucleic Acid Chemistry
CAUTION: Carbodiimide reagents, such as DEC, can cause severe skin or eye irritation and allergic reactions. Use appropriate skin and eye protection, and wipe up all work areas and utensils with a wet cloth immediately after use (DEC is water soluble). NOTE: If the amino group loading of the starting support is not known, it is recommended that dimethoxyl derivatization to assay for amino and hydroxyl groups (see Support Protocol 2) be performed to verify the support’s capacity before starting the nucleoside derivatization.
Couple nucleoside 3′-O-succinyl hemiesters to LCAA-CPG 1. Combine in a small glass screw-capped vial or round-bottom flask: 1.0 g LCAA-CPG 0.2 mmol 5′-dimethoxytrityl-N-protected nucleoside 3′-O-succinyl hemiester 12 mg (0.1 mmol) DMAP 382 mg (2.0 mmol) DEC. 2. Add 80 µL triethylamine and ∼5 to 10 mL anhydrous pyridine. Quickly seal the vial, and shake at room temperature. The reaction time used depends on the nucleoside loading desired. Reactions as short as 1 hr can yield loadings of ∼20 to 30 mmol/g, whereas overnight reactions can yield loadings of up to 60 mmol/g. A coupling time of 2 to 3 hr, which usually gives a loading of between 30 and 40 mmol/g, is generally most satisfactory.
3. If desired, periodically monitor the course of the coupling reaction by removing a small sample of support (10 to 20 mg) with a Pasteur pipet and applying it to a Buchner funnel. Wash with 20 mL methanol and then 20 mL dichloromethane; dry uncovered at room temperature, ~15 min. Quickly determine the nucleoside loading by trityl analysis (see Support Protocol 1). 4. After sufficient nucleoside loading has been obtained, filter off the support, working in the fume hood. 5. Wash successively with ∼5 to 10 mL reagent-grade pyridine, ∼10 to 20 mL methanol, and finally ∼20 to 30 mL dichloromethane. Allow the support to dry at room temperature.
Cap unreacted amino groups 6. Return the support to a clean vial or flask, and add equal volumes (∼5 mL) of Cap A and Cap B capping reagents. Seal the vial and shake 1 to 2 hr at room temperature. 7. Filter off the support, and wash with ∼10 to 20 mL methanol and then ∼20 to 30 mL dichloromethane. Allow to air dry. 8. Determine the nucleoside loading by trityl analysis of a small portion of the final product (see Support Protocol 1). Store at room temperature in a sealed screw-capped vial. Supports can be stored for several years at room temperature.
Synthesis of Unmodified Oligonucleotides
3.2.5 Current Protocols in Nucleic Acid Chemistry
ALTERNATE PROTOCOL 1
NUCLEOSIDE COUPLING TO SUCCINYLATED LCAA-CPG This protocol describes the coupling of succinic anhydride, S.4, to LCAA-CPG, S.1, to produce a succinylated support, S.5 (Fig. 3.2.2). Suitably protected nucleosides, S.6, with a free 3′-OH group are then esterified to the succinylated support. Once the succinylated support has been prepared, only 5′-dimethoxytrityl-N-protected nucleosides (with free 3′-OH groups) are required. This provides an advantage over Basic Protocol 1, because a greater variety of nucleosides are commercially available as 5′- and N-protected derivatives than as 5′- and N-protected 3′-O-succinates. Additional Materials (also see Basic Protocol 1) Succinic anhydride, reagent grade Ninhydrin solution: 2% (w/v) ninhydrin in ethanol Pentachlorophenol, reagent grade Piperidine, reagent grade Water aspirator 13 × 75–mm glass test tube Additional reagents and solutions for quantitative nitrophenol assay (see Support Protocol 3), N-monomethoxytrityl-6-amino-1-hexanol assay (see Support Protocol 4), and trityl analysis (see Support Protocol 1) CAUTION: Carbodiimide reagents, such as DEC, can cause severe skin or eye irritation and allergic reactions. Use appropriate skin and eye protection, and wipe up all work areas and utensils with a wet cloth immediately after use (DEC is water soluble). CAUTION: Pentachlorophenol is highly toxic. CAUTION: Piperidine has a strong unpleasant odor and is highly toxic. Wear gloves and always handle in a fume hood. CAUTION: Avoid skin contact with the ninhydrin solution; blue stains will form. Couple succinic anhydride to LCAA-CPG 1. Combine in a screw-capped vial (such as a glass scintillation vial) or small roundbottom flask: 1.0 g LCAA-CPG 200 mg (2.0 mmol) succinic anhydride 24 mg (0.2 mmol) DMAP. Immediately add ∼5 to 10 mL anhydrous pyridine and seal the vial. Perform the pyridine addition quickly, and immediately seal the vial tightly, to minimize exposure to moisture in the air. Laboratories with very high humidity can avoid moisture contamination by sealing the vial with a septum and using a syringe for the pyridine transfer, but this is not necessary in most (air-conditioned) laboratories.
2. Shake the vial at room temperature overnight, using a speed sufficient to keep the support in a gentle suspension. Attachment of Nucleosides to Solid-Phase Supports
Do not use a magnetic stirrer for this or any subsequent steps, because the stir bar can break up the LCAA-CPG particles and produce unwanted fines.
3. Inside a fume hood, filter off the LCAA-CPG using a Buchner funnel, Whatman no. 1 filter paper, and vacuum provided by a water aspirator.
3.2.6 Current Protocols in Nucleic Acid Chemistry
4. Wash the support successively with ∼5 to 10 mL pyridine, then ∼10 to 20 mL methanol, and finally ∼20 to 30 mL dichloromethane. 5. Transfer the support to a piece of smooth, white paper and allow to sit uncovered at room temperature until dry, ∼15 to 30 min. The succinylated LCAA-CPG support can be stored indefinitely at room temperature.
6. Place 2 to 3 mg succinylated LCAA-CPG in a clean 13 × 75–mm glass test tube, and add 1 or 2 drops of ninhydrin solution. Warm the mixture until the solvent evaporates and the beads are dry. Any unreacted amino groups will form a very dark blue color on the beads, whereas the succinylated support should only have a faint blue color. This is a qualitative test, and it is helpful to treat a sample of LCAA-CPG alongside the test material to observe the color difference.
7. Verify the extent of the succinylation reaction by performing the quantitative nitrophenol (see Support Protocol 3) or N-monomethoxytrityl-6-amino-1-hexanol (see Support Protocol 4) assay for carboxylic acid loading. If the test results are unsatisfactory, repeat the succinylation reaction on the support. The carboxyl loading obtained on succinyl-derivatized LCAA-CPG should be close to the amino loading determined by the LCAA-CPG manufacturer. Owing to differences in the nature of the amino and carboxyl determinations, it is normal to observe some difference.
Couple nucleoside to the succinylated LCAA-CPG 8. Combine in a small screw-capped glass vial or round-bottom flask: 1.0 g succinylated LCAA-CPG 0.1 mmol 5′-dimethoxytrityl-N-protected 2′-deoxyribonucleoside 12 mg (0.1 mmol) DMAP 192 mg (1.0 mmol) DEC. Add 80 µL triethylamine and ∼5 to 10 mL anhydrous pyridine. Quickly seal the vial, and shake overnight at room temperature. 9. Verify the progress of the coupling reaction by removing ∼10 to 20 mg of support using a Pasteur pipet. Apply the sample to a Buchner funnel, and wash with 10 to 20 mL methanol and then 20 to 30 mL dichloromethane. Allow the support to dry, and then determine the nucleoside loading by trityl analysis (see Support Protocol 1). If the loading is satisfactory (i.e., a minimum of 20 and preferably 30 to 40 µmol/g), then proceed to step 10. Otherwise, extend the shaking for another day or repeat the reaction by adding more of the reagents (nucleoside, DEC, DMAP, and triethylamine) to the flask. Cap unreacted carboxyl and amino sites on the support 10. Add 134 mg (0.5 mmol) pentachlorophenol to the reaction mixture, and shake 16 to 24 hr at room temperature. Pentachlorophenol is added to convert any unreacted carboxyl groups into activated pentachlorophenyl esters. When treated with the cyclic amine piperidine (step 11), the pentachlorophenyl esters are converted into an unreactive amide, S.7.
11. Add 5 mL piperidine and continue shake 5 min at room temperature. Prolonged exposure to piperidine will also hydrolyze the succinyl linker and decrease the nucleoside loading on the support.
Synthesis of Unmodified Oligonucleotides
3.2.7 Current Protocols in Nucleic Acid Chemistry
12. Inside a fume hood, filter off the LCAA-CPG beads and wash successively with ∼5 to 10 mL reagent-grade pyridine, ∼10 to 20 mL methanol, and finally ∼20 to 30 mL dichloromethane. Allow the support to sit at room temperature until dry. 13. Return the support to a clean glass screw-capped vial or small round-bottom flask and add equal amounts (∼5 mL) of Cap A and Cap B capping reagents. Seal the vial and shake 1 to 2 hr at room temperature. This reaction is performed to acetylate any amino groups on the support that may not have been succinylated in the first reaction.
14. Filter off the LCAA-CPG on a Buchner funnel and wash with ∼10 to 20 mL methanol and then ∼20 to 30 mL dichloromethane. Allow to dry at room temperature. 15. Determine the nucleoside loading by trityl analysis of a small portion of the final product (see Support Protocol 1). Store at room temperature in a sealed screw-capped vial. Supports can be stored for several years. BASIC PROTOCOL 2
COUPLING OF NUCLEOSIDE-3′-O-HYDROQUINONE-O,O′-DIACETYL HEMIESTERS TO LCAA-CPG In this protocol, the hydroquinone-O,O′-diacetic acid (HQDA), S.8, is first attached to the 3′-OH of a suitably protected nucleoside, S.6, by using 1-(3-dimethylaminopropyl)3-ethylcarbodiimide hydrochloride (DEC) as the coupling reagent. Unfortunately, selective coupling to only one end of the diacid linker is not possible, and a mixture of nucleoside hemiesters, S.9, and diesters, S.10, always occurs (Fig. 3.2.3). Fortunately, chromatographic separation of the hemiesters and diesters is not necessary, because only the hemiester can couple to the long-chain alkylamine–controlled-pore glass (LCAACPG) support. Thus the preparation of the HQDA hemiesters is not much more difficult than the synthesis of nucleoside-3′-O-succinyl hemiesters. Coupling of the HQDA hemiesters to LCAA-CPG is performed in the same manner as the succinyl compounds.
Attachment of Nucleosides to Solid-Phase Supports
Materials 5′-Dimethoxytrityl-N-protected deoxyribonucleoside (see recipe) Hydroquinone-O,O′-diacetic acid (HQDA; Lancaster Synthesis) 4-Dimethylaminopyridine (DMAP), reagent grade 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DEC; see recipe) Triethylamine, reagent grade Anhydrous pyridine, for coupling reactions (see recipe) Toluene, reagent grade Chloroform, reagent grade 5% (v/v) methanol/chloroform, for TLC analysis Saturated aqueous sodium bicarbonate solution Anhydrous magnesium sulfate Pyridine, reagent-grade, for washing supports AG 50W-X4 H+ form cation-exchange resin (Bio-Rad) LCAA-CPG beads (other amino-derivatized nonswelling support materials may also be used; see recipe) Methanol, reagent grade Dichloromethane, reagent grade Cap A capping solution (see recipe) Cap B capping solution (see recipe)
3.2.8 Current Protocols in Nucleic Acid Chemistry
50- and 100-mL round-bottom flasks Magnetic stir bar Pasteur pipet Fluorescent silica gel thin-layer chromatography (TLC) plates, ∼2.5 cm × 10 cm (Merck 60 or similar) Covered jar for TLC Shortwave UV (254-nm) lamp Separatory funnel Shaker, wrist action or similar Rotary evaporator Additional reagents and solutions for dimethoxyl derivatization to assay for amino and hydroxyl groups present (see Support Protocol 2; optional) and trityl analysis (see Support Protocol 1) CAUTION: Carbodiimide reagents, such as DEC, can cause severe skin or eye irritation and allergic reactions. Use appropriate skin and eye protection, and wipe up all work areas and utensils with a wet cloth immediately after use (DEC is water soluble). Synthesize nucleoside-3′-O-HQDA hemiesters 1. Combine in a 100-mL round-bottom flask with a magnetic stir bar: 10 mmol 5′-dimethoxytrityl-N-protected deoxyribonucleoside 3.39 g (15 mmol) HQDA 122 mg (1 mmol) DMAP 2.88 g (15 mmol) DEC. Add 0.8 mL triethylamine and 50 mL anhydrous pyridine. Seal the flask and stir overnight at room temperature. 2. Remove 50 to 100 µL of the solution using a Pasteur pipet and place in a 50-mL round-bottom flask. Add ∼1 to 2 mL toluene and evaporate to dryness using a rotary evaporator. 3. Redissolve in ∼100 to 200 µL chloroform. 4. Spot the sample near the bottom edge of an ∼2.5 × 10–cm TLC plate, alongside samples of the starting nucleoside and HQDA. Place the TLC plate in a jar containing a small amount of 5% (v/v) methanol/chloroform (the liquid should be ∼2 to 4 mm deep), and allow the solvent to rise most of the way up the TLC plate. 5. Remove plate and examine under a shortwave UV (254-nm) lamp. The desired hemiester will appear as a UV-absorbing spot near the baseline, and the diester product will be a UV-absorbing spot near the top of the plate. The starting nucleoside will migrate to near the middle of the plate. The coupling reaction is complete when all the starting nucleoside is converted into the faster- (diester) and slower-migrating (hemiester) products. If more than a trace of starting nucleoside is visible, add more DEC (2 to 5 mmol) to the reaction, and continue stirring for another day. Repeat steps 2 to 5.
6. When TLC shows complete disappearance of the starting nucleoside, concentrate the solution on the rotary evaporator until a thick oil forms. 7. Redissolve the oil in ∼200 mL chloroform and transfer to a separatory funnel. Wash the solution twice with ∼100 mL saturated aqueous sodium bicarbonate. CAUTION: Carbon dioxide gas is released during this extraction step. Shake the separatory funnel slowly with frequent venting until gas evolution stops.
Synthesis of Unmodified Oligonucleotides
3.2.9 Current Protocols in Nucleic Acid Chemistry
8. Wash the chloroform solution three times with ∼100 mL water each time. Collect the chloroform phase and discard the aqueous phase. Do not shake the separatory funnel vigorously at this step, because the mixture will form an emulsion that is slow to separate. Invert the funnel slowly to mix the phases. If an inseparable emulsion does form, then either (for small volumes) centrifugation or (for large volumes) precipitation by addition of hexanes followed by filtration and redissolution of the sticky precipitate back into chloroform can be performed.
9. Add the chloroform solution to ∼5 g anhydrous magnesium sulfate, and mix to remove residual moisture from the solution. Filter off the magnesium sulfate, wash with a small amount of chloroform, and then evaporate the chloroform solution to dryness using the rotary evaporator. A light brown foam should form and solidify. The crude product, which contains a mixture of diester and nucleoside hemiester sodium salt, is suitable for coupling directly to LCAA-CPG using the DEC/pyridine coupling procedure that follows. The sodium salt, however, may not be sufficiently soluble in other solvents for other types of coupling reactions. In this case, the sodium salt can be easily converted into the more soluble pyridinium salt by the procedure outlined in step 10.
10. Conversion into pyridinium salt (optional): Dissolve the crude sodium salt in ∼50 to 100 mL of reagent-grade pyridine, and add 2 eq AG 50W-X4 H+ cation-exchange resin. Stir ∼5 to 10 min; then filter off the ion-exchange resin. Evaporate the pyridine solution to dryness; a light brown foam will form and solidify. Dry under vacuum overnight to remove excess pyridine. Store in sealed, moisture-proof containers at −20°C. Samples are stable for at least 1 to 2 years. Older samples should be checked by TLC to determine the extent of decomposition, if any.
Couple nucleoside 3′-O-HQDA hemiesters to LCAA-CPG 11. If the amino-group loading of the starting support is not known: Verify the support’s capacity by dimethoxyl derivatization to determine the number of amino and hydroxyl groups present (see Support Protocol 2) before starting the nucleoside derivatization. 12. Combine in a round-bottom flask: 5.0 g LCAA-CPG 2 g (2.0 mmol) crude nucleoside 3′-O-HQDA hemiester (step 9 or 10) 122 mg (0.1 mmol) DMAP 1.44 g (7.5 mmol) DEC. Add 1 mL triethylamine and 30 mL anhydrous pyridine and quickly seal the flask. Shake overnight at room temperature. 13. In the fume hood, filter off the support and wash successively with ∼25 to 50 mL reagent-grade pyridine, ∼50 to 100 mL methanol, and finally ∼100 to 150 mL dichloromethane. Allow to dry at room temperature. 14. Remove a small aliquot for trityl analysis to determine the nucleoside loading (see Support Protocol 1).
Attachment of Nucleosides to Solid-Phase Supports
15. If the nucleoside loading is acceptable, return the support to a clean flask, and add equal amounts (∼25 mL) of Cap A and Cap B capping solutions. Seal the flask and shake 1 hr at room temperature. 16. Filter off the support and wash with ∼50 to 100 mL methanol and then ∼100 to 150 mL dichloromethane. Allow to dry at room temperature.
3.2.10 Current Protocols in Nucleic Acid Chemistry
17. Verify the nucleoside loading by performing trityl analysis (see Support Protocol 1) on a sample of the final product. Supports derivatized with the Q-linker have been stored for 3 years at room temperature without any significant loss of nucleoside.
NUCLEOSIDE COUPLING TO HYDROQUINONE-O,O′-DIACETIC ACID DERIVATIZED LCAA-CPG
ALTERNATE PROTOCOL 2
In this protocol HQDA, S.8, is coupled to LCAA-CPG, S.1, to give a carboxyl-derivatized support, S.12 (Fig. 3.2.4). This coupling reaction must be performed in the presence of a coupling reagent because HQDA is not available as an acid anhydride (as succinic anhydride is for use in succinylation approaches). In addition, the coupling reactions involving immobilized HQDA—especially the formation of esters to the secondary hydroxyl group of protected nucleosides, S.6—are best performed using a more reactive coupling reagent than the carbodiimide used in the above protocols. Therefore, 2-(1Hbenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), which is a coupling reagent developed for peptide synthesis (Dourtoglou et al., 1984), is used instead of DEC along with an increased amount of DMAP. Another advantage to using HBTU is that anhydrous acetonitrile can be substituted for pyridine as the solvent. Additional Materials (also see Basic Protocol 2) 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) Anhydrous diisopropylethylamine (DIEA; see recipe) Anhydrous acetonitrile (see recipe) Acetonitrile, reagent grade Screw-capped glass vials or round-bottom flasks Syringes Buchner funnel Whatman no. 1 filter paper Additional reagents and solutions for N-monomethoxytrityl-6-amino-1-hexanol assay of carboxylic acid loading (see Support Protocol 4) and trityl analysis (see Support Protocol 1) CAUTION: All coupling reagents, such as HBTU, can potentially cause adverse reactions and lead to severe allergic reactions. Although specific data on HBTU are not available, safe laboratory practices (i.e., no skin or eye contact or inhalation of powders) should always be followed when handling this type of reagent. Couple HQDA to LCAA-CPG 1. Combine in a glass screw-capped vial or small glass-round bottom flask: 1.0 g LCAA-CPG 90 mg (0.4 mmol) HQDA 46 mg (0.38 mmol) DMAP 144 mg (0.36 mmol) HBTU. Via syringe, add 140 µL (0.8 mmol) DIEA and 10 mL anhydrous acetonitrile. Seal the vial and shake 2 hr at room temperature. 2. Filter off the support using a Buchner funnel and wash the LCAA-CPG successively with ∼10 to 20 mL acetonitrile, ∼10 to 20 mL methanol, and finally ∼20 to 30 mL dichloromethane. Allow the support to dry at room temperature.
Synthesis of Unmodified Oligonucleotides
3.2.11 Current Protocols in Nucleic Acid Chemistry
3. Verify the extent of the HQDA derivatization by performing the N-monomethoxytrityl-6-amino-1-hexanol assay of carboxylic acid loading (see Support Protocol 4). A carboxyl loading of 30 to 40 mmol/g is typical. Supports can be stored indefinitely at room temperature. Store the support at room temperature in a sealed glass vial.
Couple nucleoside to the HQDA-derivatized LCAA-CPG 4. Combine in a screw-capped glass vial or small glass round-bottom flask: 1.0 g HQDA-derivatized LCAA-CPG 0.2 g (0.2 mmol) 5′-dimethoxytrityl-N-protected deoxyribonucleoside 24 mg (0.2 mmol) DMAP 76 mg (0.2 mmol) HBTU. Via syringe, add 140 µL (0.8 mmol) DIEA and 5 mL anhydrous acetonitrile. Quickly seal the vial, and shake 2 to 3 hr at room temperature. 5. Filter off the support using a Buchner funnel and wash successively with ∼10 to 20 mL acetonitrile, ∼10 to 20 mL methanol, and finally ∼10 to 20 mL dichloromethane. Allow the support to dry at room temperature. 6. Determine the nucleoside loading by trityl analysis of a small sample of support (see Support Protocol 1). Cap unreacted amino groups 7. Return the support into a clean vial or flask and add equal amounts (∼5 mL) of Cap A and Cap B capping reagents. Seal the vial and shake 1 hr at room temperature. 8. Filter off the support and wash with ∼10 to 20 mL methanol and then with ∼10 to 20 mL dichloromethane. Allow to dry at room temperature. 9. Determine the nucleoside loading by trityl analysis of a small portion of the final product (see Support Protocol 1). Label the support with this loading value and the date of synthesis, and store at room temperature in a sealed screw-capped vial. Supports can be kept for several years. SUPPORT PROTOCOL 1
QUANTITATIVE TRITYL ANALYSIS OF SURFACE LOADING OF DERIVATIZED SUPPORTS This procedure describes how the surface loading of supports containing trityl groups can be determined by colorimetric analysis. This method detects the 5′-trityl protecting group on nucleoside-derivatized supports or trityl groups added to derivatize aminoor hydroxyl-functionalized supports (see Support Protocol 2). This assay is based on the fact that acid-labile dimethoxytrityl (from nucleoside-derivatized supports) or monomethoxytrityl protecting groups (from N-monomethoxytrityl-6-amino-1-hexanol–derivatized supports) can be rapidly and quantitatively hydrolyzed to form intensely orangeand yellow-colored solutions.
Attachment of Nucleosides to Solid-Phase Supports
Materials Derivatized LCAA-CPG support (see Basic Protocols 1 and 2 and Alternate Protocols 1 and 2) Detritylation reagent (see recipe)
3.2.12 Current Protocols in Nucleic Acid Chemistry
10-mL volumetric flask Analytical balance accurate to 0.1 mg Quartz cuvettes UV/visible spectrophotometer or colorimeter 1. Tare an empty 10-mL volumetric flask on an analytical balance. 2. Place ∼4 mg dry, derivatized LCAA-CPG support directly into the flask and weigh. Record the weight to at least 2 significant figures. 3. Add detritylation reagent to the volumetric flask to the mark. Seal the flask and mix. An orange-colored dimethoxytrityl cation (yellow if monomethoxytrityl groups are being measured) will immediately form. The orange color is stable if moisture contamination and evaporation are avoided and the solution can be kept at room temperature indefinitely.
4. Fill a reference cuvette with detritylating reagent or, if using a single-beam spectrophotometer, run a baseline. The dichloromethane solvent requires quartz rather than disposable polystyrene cuvettes.
5. Measure the spectrum of the sample from 400 to 600 nm. Record the absorbance of the peak maximum at ∼503 to 505 nm (dimethoxytrityl group) or ∼470 nm (monomethoxytrityl group). If the absorbance exceeds the maximum reliable value for the spectrophotometer (usually 2 to 3 absorbance units), prepare another sample with less support or perform a serial dilution using detritylation reagent as the diluent.
6. Calculate the loading of the support using the following equation (for a cuvette with a 1-cm path length): Loading =
volume × absorbance 1000 × weight ε
where loading is in micromoles per gram, the solution volume in milliliters, and the support weight is in milligrams; and ε is the extinction coefficient of either the dimethoxytrityl group (76 mL cm−1 µmol−1) or the monomethoxytrityl group (56 mL cm−1 µmol−1). DIMETHOXYTRITYL DERIVATIZATION OF AMINO- AND/OR HYDROXYL-FUNCTIONALIZED SUPPORTS
SUPPORT PROTOCOL 2
A variety of methods have been developed to determine the primary amino group content of insoluble supports (Horn and Novak, 1987). The most convenient method, however, uses the dimethoxytrityl chloride/tetrabutylammonium perchlorate reagent developed for the solid-phase tritylation of nucleosides and nucleotides (Reddy et al., 1987). This reagent will also tritylate amino groups, and it has been used to monitor coupling efficiency in solid-phase peptide synthesis (Reddy and Voelker, 1988). This is a very fast, sensitive, and general method for determining the number of amino and hydroxyl groups on insoluble supports. Materials LCAA-CPG support 0.25 M dimethoxytrityl (see recipe) chloride stock solution (see recipe) 0.25 M tetrabutylammonium perchlorate stock solution (see recipe) Methanol, reagent grade
Synthesis of Unmodified Oligonucleotides
3.2.13 Current Protocols in Nucleic Acid Chemistry
Dichloromethane, reagent grade Screw-capped glass vials 1. Place ∼10 to 20 mg of LCAA-CPG support in a small screw-capped glass vial and add equal amounts (∼500 µL) of 0.25 M dimethoxytrityl chloride and 0.25 M tetrabutylammonium perchlorate. Seal the vial and shake 10 min at room temperature. 2. Filter off the support and wash first with 10 to 20 mL dichloromethane, then with 10 to 20 mL methanol, and finally with 20 to 30 mL dichloromethane again. The methanol wash is important to remove any adsorbed trityl reagent from the support.
3. Allow the support to dry and then perform the colorimetric trityl analysis (see Support Protocol 1). SUPPORT PROTOCOL 3
DETERMINATION OF CARBOXYLIC ACID GROUPS ON INSOLUBLE SUPPORTS BY p-NITROPHENOL DERIVATIZATION The amount of carboxylic acid attached to the surface on an insoluble support can be determined by titration, but this consumes large amounts (gram quantities) of support. A better and more sensitive method is to derivatize the support with an appropriate reporter molecule. p-Nitrophenol is a convenient and readily available label that has been widely used. When this label is removed from the support, by hydrolysis with aqueous sodium hydroxide, a yellow-green solution is produced that can be quantitated by colorimetry (Matteucci and Caruthers, 1981; Damha et al., 1990). Although the extinction coefficient for the p-nitrophenoxide group is only one-fifth as large as for the dimethoxytrityl cation (see Support Protocol 1), this test is useful for measuring the succinic acid surface loading produced in Alternate Protocol 1. This method does not, however, work with HQDA-derivatized LCAA-CPG (see Support Protocol 4 instead). Additional Materials (see Basic Protocol 1 and Alternate Protocol 1) p-Nitrophenol, reagent grade 0.1 M aqueous NaOH solution N-Monomethoxytrityl-6-amino-1-hexanol 10-mL volumetric flask Analytical balance UV/visible spectrophotometer or colorimeter Additional reagents and solutions for DEC/DMAP coupling (see Alternate Protocol 1) and trityl analysis (see Support Protocol 1) 1. Combine in a small screw-capped glass vial or round-bottom flask: 1.0 g succinylated LCAA-CPG 14 mg (0.1 mmol) p-nitrophenol 190 mg (0.1 mmol) DEC. Via syringe, add 40 µL triethylamine and 1 mL anhydrous pyridine. Seal the vial, and shake overnight at room temperature.
Attachment of Nucleosides to Solid-Phase Supports
2. Filter off the support and wash sequentially with 5 mL pyridine, 10 mL methanol, and 10 to 20 mL dichloromethane. Leave the support uncovered at room temperature to dry. The capping steps (see Alternate Protocol 1, steps 10 to 15) are unnecessary or this protocol.
3.2.14 Current Protocols in Nucleic Acid Chemistry
3. Accurately weigh ∼10 mg of support directly into a 10-mL volumetric flask. Add 0.1 M NaOH solution to the mark and mix. 4. Determine the absorbance of the solution at 400 nm. Calculate the support loading using an extinction coefficient (ε) of 15.7 mL cm−1 µmol−1 for the nitrophenoxide group; see Support Protocol 1, step 6, for formula. DETERMINATION OF CARBOXYLIC ACID GROUPS ON INSOLUBLE SUPPORTS BY MONOMETHOXYTRITYL DERIVATIZATION
SUPPORT PROTOCOL 4
This protocol is an alternate to Support Protocol 3. Unlike Support Protocol 3, this method can be used to determine the carboxyl loading of both succinyl- and HQDA-derivatized LCAA-CPG. This method requires synthesis of a custom reporter molecule, Nmonomethoxytrityl-6-amino-1-hexanol, developed by Pon and Yu (1997a). The carboxyl loading determination is more sensitive, because the yellow color produced from the monomethoxytrityl group (in acid solution; i.e., see Support Protocol 1) is more than three times as intense as that produced by the p-nitrophenoxide group. Additional Materials (see Basic Protocol 2 and Alternate Protocol 2) 6-Amino-1-hexanol Monomethoxytrityl chloride N-Monomethoxytrityl-6-amino-1-hexanol (see recipe) Silica gel, Merck 60, for flash chromatography Glass chromatography column for flash chromatography, ~4 to 5 cm diameter × ~50 to 60 cm long Silica-gel TLC plates (Merck, ~2.5 × 8 cm) CAUTION: All coupling reagents, such as HBTU, can potentially cause adverse reactions and lead to severe allergic reactions. Although specific data on HBTU are not available, safe laboratory practices (i.e., no skin or eye contact or inhalation of powders) should always be followed when handling this type of reagent. 1. Dissolve 2.42 g (20 mmol) 6-amino-1-hexanol and 6.37 g (20 mmol) monomethoxytrityl chloride in 100 mL anhydrous pyridine, and stir 1 to 2 days at room temperature. 2. Concentrate the solution on a rotary evaporator to 10 to 15 mL. 3. Redissolve in 75 mL chloroform, wash with 25 mL aqueous sodium bicarbonate solution, and wash twice with 25 mL water. Dry over anhydrous magnesium sulfate. 4. Concentrate the chloroform solution to an oil. 5. Apply to a flash chromatography column packed ~20 cm high with Merck 60 silica gel. Begin the purification by eluting the column with 5% methanol/chloroform and collect the eluate in ~50- to 100-mL fractions. 6. Monitor the separation by spotting a small amount (~2 to 5 µL) of each fraction on a silica-gel TLC plate (~2.5 × 8 cm). Develop the plate in 20% methanol/chloroform and detect the products either by UV or by spraying with detritylation reagent and then gently warming the plate (e.g., with a hair dryer) for a few seconds: monomethoxytrityl-containing products will appear as yellow spots. Once all the unreacted monomethoxytrityl chloride has eluted from the column or when the desired product begins to appear, change the solvent to 15% methanol/chloroform.
Synthesis of Unmodified Oligonucleotides
3.2.15 Current Protocols in Nucleic Acid Chemistry
Initially, hydrolyzed, unreacted monomethoxytrityl chloride will appear as an impurity moving near the solvent front. The desired product will have a much slower mobility (Rf ~ 0.15). Unreacted aminohexanol will remain bound to the silica gel. 7. Combine fractions containing the desired product. Evaporate on a rotary evaporator to obtain pure N-monomethoxytrityl-6-amino-1-hexanol as a thick brown liquid (5.5 g, 71% yield). 8. Combine in a screw-capped glass vial or small glass round-bottom flask: 0.1 g succinyl- or HQDA-derivatized LCAA-CPG 38 mg (0.1 mmol) N-monomethoxytrityl-6-amino-1-hexanol 24 mg (0.02 mmol) DMAP 38 mg (0.1 mmol) HBTU. Via syringe, add 14 µL DIEA (0.08 mmol) and ∼0.5 mL anhydrous acetonitrile. Quickly seal the vial and shake 2 to 3 hr at room temperature. 9. Filter off the support using a Buchner funnel, and wash successively with ∼10 to 20 mL acetonitrile, ∼10 to 20 mL methanol, and finally ~20 to 30 mL dichloromethane. Allow the support to dry uncovered at room temperature. 10. Determine the monomethoxytrityl loading by trityl analysis (see Support Protocol 1). NOTE: The monomethoxytrityl group generates a yellow rather than an orange color, and the measurement must be made with the wavelength and extinction coefficient specified in Support Protocol 1.
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Anhydrous acetonitrile Distill from calcium hydride or obtain from commercially available “low-water” reagents suitable for automated oligonucleotide synthesis. Store over molecular sieves in tightly sealed bottles. Discard or redistill after each day’s use. Anhydrous diisopropylethylamine (DIEA) Purchase as the 99.5% redistilled grade (Aldrich), and keep anhydrous by storage over type 4A molecular sieves. Store in septum-sealed bottles at room temperature, protected from light. Anhydrous pyridine Prepare by distillation from calcium hydride, and keep anhydrous by storage over type 4A molecular sieves in tightly sealed bottles. Store up to 1 year at room temperature. Alternatively, this may be purchased ready to use in Sure/Seal bottles (Aldrich).
Attachment of Nucleosides to Solid-Phase Supports
Cap A and Cap B capping reagents Cap A: 94 mL 1 M acetic anhydride/116 mL 1 M 2,6-lutidine or pyridine in 790 mL tetrahydrofuran (THF). Store indefinitely at room temperature. Cap B: 160 mL 2 M N-methylimidazole in 840 mL THF. Store indefinitely at room temperature. These are the same reagents used as capping reagents on automated DNA synthesizers, and may be purchased commercially.
3.2.16 Current Protocols in Nucleic Acid Chemistry
Detritylation reagent 5% Dichloroacetic acid (v/v) or 3% trichloroacetic acid (w/v) in 1,2-dichloroethane or dichloromethane. Store indefinitely at room temperature. There is no significant difference between these reagents in the trityl analysis, although dichloroacetic acid reagents are more suitable for the synthesis of long oligonucleotides. To reduce solvent vapors, it is recommended that the less volatile 1,2-dichloroethane be substituted for the more commonly used dichloromethane. Detritylation reagent may be purchased commercially (sometimes referred to as “deblock” reagent). CAUTION: Many older references suggest the use of perchloric acid solutions to dilute the trityl colors. Such a strong acid is not required, and for safety reasons, perchloric acid solutions should not be used. The same detritylation reagent used on the DNA synthesizers can be used to dilute the colors for measurement.
Dimethoxytrityl chloride stock solution, 0.25 M Dissolve 847 mg (2.5 mmol) dimethoxytrityl chloride in 10 mL dichloromethane. Store in a sealed glass vial up to 3 to 4 weeks at room temperature. 5′-Dimethoxytrityl-N-protected nucleosides Purchase 5′-dimethoxytrityl nucleosides with a free 3′-OH or, for ribonucleosides, free 2′- and 3′-OH groups (Chem-Impex, Sigma, and ChemGenes). N6-benzoyl-5′dimethoxytrityl-2′-deoxyadenosine, N4-benzoyl-5′-dimethoxytrityl-2′-deoxycytidi ne, N2-isobutyryl-5′-dimethoxytrityl-2′-deoxyguanosine, and 5′-dimethoxytritylthymidine are the most commonly used standard nucleosides and are compatible with the protocols described in this unit. Store indefinitely at room temperature. 5′-Dimethoxytrityl-N-protected nucleoside succinyl hemiesters Purchase nucleosides with the standard protecting groups—N6-benzoyl-5′-dimethoxytrityl-2′-deoxyadenosine-3′-O-succinate, N4-benzoyl-5′-dimethoxytrityl2′-deoxycytidine-3′-O-succinate, N2-isobutyryl-5′-dimethoxytrityl-2′-deoxy-guanosine3′-O-succinate, and 5′-dimethoxytritylthymidine-3′-O-succinate (Chem-Impex and Sigma). Store indefinitely at room temperature. Only the standard succinates are available for purchase; more unusual or complicated succinates must be made up.
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DEC) Also referred to as 3-ethyl-1-(3-dimethylaminopropyl)-carbodiimide (EDC) and water soluble carbodiimide (WSC). Readily available from commercial suppliers. Store indefinitely at –20°C. Long-chain alkylamine–controlled-pore glass (LCAA-CPG) Available in a variety of pore and particle sizes and sieved into three sets of particle sizes: 80 to 120 mesh (125 to 177 µm), 120 to 200 mesh (74 to 125 µm), and 200 to 400 mesh (37 to 74 µm); the two largest size ranges are the most suitable for oligonucleotide synthesis. Generally, 500-Å-diameter pores are used for oligonucleotides of up to ∼50 bases in length, and 1000-Å-diameter pores are required for longer oligonucleotides. Store indefinitely at room temperature. N-Monomethoxytrityl-6-amino-1-hexanol Prepare from monomethoxytrityl chloride and 6-amino-1-hexanol (see Support Protocol 4 or Pon and Yu, 1997a). Store indefinitely at room temperature. Tetrabutylammonium perchlorate stock solution, 0.25 M Dissolve 854 mg (2.5 mmol) tetrabutylammonium perchlorate (Sigma) in 0.3 mL 2,6-lutidine and 9.7 mL dichloromethane. Store in a sealed glass vial up to 3 to 4 weeks at room temperature.
Synthesis of Unmodified Oligonucleotides
3.2.17 Current Protocols in Nucleic Acid Chemistry
COMMENTARY Background Information
Attachment of Nucleosides to Solid-Phase Supports
The succinic acid linker was one of the earliest linkages used to immobilize nucleosides to insoluble supports (Ogilvie and Kroeker, 1971; Yip and Tsou, 1971), and it has remained widely used since. Although a variety of different linkages have been developed for specialized applications (UNIT 3.1; Pon, 1993), routine oligonucleotide synthesis has been well served by the succinyl linker, primarily because succinic anhydride, S.4, does not need any activation to react with hydroxyl (or amino) groups and selectively produces only hemiesters (or amides). The low cost and easy handling of this reagent are also advantageous. Once the anhydride has been opened, however, coupling to the terminal free carboxylic acid group is more difficult. This group requires activation by conversion to an acid chloride (Ogilvie and Kroeker, 1971; Sharma et al., 1992), an activated ester, or a symmetrical anhydride (Gait et al., 1980) or by reaction with a coupling reagent such as dicyclohexylcarbodiimide (DCC; Chow et al., 1981; Matteucci and Caruthers, 1981; Montserrat et al., 1993). Because acid chlorides are difficult to work with and the DCC coupling reagent does not perform well with LCAA-CPG supports, most early work was performed using activated nucleoside-3′-O-succinyl pentachlorophenyl (Miyoshi et al., 1980), p-nitrophenyl (Koster et al., 1983), or pentafluorophenyl esters (Efimov et al., 1993). These intermediates, however, require an additional coupling step to prepare, and the support derivatization reactions are slow. Later it was discovered that the carbodiimide reagent DEC could rapidly couple unactivated nucleoside succinates directly to LCAA-CPG (Pon et al., 1988). Given that coupling reactions with DEC are completed in as little as 1 hr, this technique has become the preferred approach. Recently, however, improved coupling methods have been described using diisopropylcarbodiimide and hydroxybenzotriazole (Bhongle and Tang, 1995) or DCC and 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (Walsh et al., 1997), which allow satisfactory derivatization of LCAA-CPG supports. Other new coupling reagents have also been used to speed up the derivatization reactions. Use of an oxidation-reduction coupling reagent combination, triphenylphosphine and 2,2′dithiobis(5-nitropyridine), reduces the coupling time to between 2 and 30 min (Kumar et
al., 1996). Extremely fast derivatization (4 sec) is obtained by using either uronium- or phosphonium-coupling reagents and DMAP (Pon and Yu, 1997b); however, none of these methods has been widely adopted. Another benefit of the DEC coupling reagent is that it can also be used to create a secondary ester linkage between the 3′ (or 2′) hydroxyl group of a nucleoside and a succinylated support (Damha et al., 1990). Because forming a secondary ester is more difficult than creating a primary amide, the coupling reaction is slower and support loadings are often not as high as obtained from coupling a pre-formed nucleoside-3′-succinate to LCAA-CPG. Not having to prepare nucleoside succinates is a significant advantage, however, especially when limited starting materials are available. Recently, the huge success of solid-phase oligonucleotide synthesis has created a great demand for large numbers of synthetic oligonucleotides, and a number of productivity enhancements have been implemented. New high-throughput DNA synthesizers have been developed, and more labile protecting groups and faster deprotection conditions have been introduced to speed up processing times. A significant increase in productivity can also be obtained by replacing the succinyl linker with a more rapidly cleavable linker. This is particularly so with instrumentation that performs the cleavage step automatically after completion of oligonucleotide synthesis. In this case, the automated synthesizer essentially remains idle for the 60 to 90 min required for the cleavage of the succinyl linker arm by ammonium hydroxide. A very labile oxalic acid linker arm, which can be cleaved in only a few seconds, was introduced for the synthesis of base-sensitive oligonucleotide modifications (Alul et al., 1991). Unfortunately, the oxalyl linker proved to be too labile for routine use, because of spontaneous cleavage during storage at room temperature. Therefore, a linker arm that was more stable than oxalic acid but more easily cleaved than succinic acid was sought. This resulted in the introduction of hydroquinoneO,O′-diacetic acid (HQDA or Q-linker), S.8, as a new all-purpose linker arm (Pon and Yu, 1997a). Using Q-linker, ammonium hydroxide cleavage requires only 2 min for oligodeoxyribonucleotides, 5 min for oligoribonucleotides, and 10 min for phosphorothioate-modified oligonucleotides. Cleavage can also be performed using a number of other reagents (Table 3.2.1)
3.2.18 Current Protocols in Nucleic Acid Chemistry
Table 3.2.1 Conditions for Cleavage of HQDA
Amount of cleavage (%) at room temperature Reagent 40% aqueous MeNH2/NH4OH, 1:1 (v/v) 0.05 M K2CO3 in MeOH 9.3 bar (140 psi) ammonia gas Triethylamine trihydrofluoride (neat) 1 M tetrabutylammonium fluoride in THF 1:2:1 (v/v/v) t-butylamine/MeOH/H2O NH3 in MeOH (saturated) 5% NH4OH in MeOH 20% piperidine/DMF 0.5 M (7.5%) DBU in pyridine 1:1 (v/v) triethylamine/EtOH
1 min 100 100 94 46 36 97 27 9
to accommodate base-sensitive oligonucleotides. The stability of HQDA is sufficient for long-term storage at room temperature (>3 years) and for virtually complete resistance to oligonucleotide synthesis conditions. Prepacked synthesis columns with Q-linker are now commercially available (Glen Research), and if the current emphasis on faster production and milder deprotection continues, HQDA may eventually replace the succinyl linker.
Compound Characterization Characterization of products attached to the surface of insoluble supports is very difficult, if not impossible. This is especially so with a rigid, nonswelling, inorganic support such as controlled-pore glass beads. Therefore, the success of nucleoside derivatization reactions is usually determined indirectly by examining cleavage products. This can range from the comprehensive characterization of nucleoside or oligonucleotide products hydrolyzed from the support to the simple trityl analysis described in this unit. The dimethoxytrityl protecting group, commonly used to block the 5′-OH of nucleosides, provides a convenient and highly sensitive marker (Support Protocol 1). There is a 1:1 relationship between the amount of orange-colored dimethoxytrityl cation released and the amount of nucleoside present, so nucleoside loading of any support can be easily determined by a colorimetric measurement. Because the trityl group is easily hydrolyzed (by mild acid) from the support and generates such a distinctive and easily quantitated species, it is much simpler and faster to perform a trityl analysis than a nucleoside analysis.
5 min
15 min
100 100 83
99
75 27
98 63
2
4
60 min
98 15 7 5
t1/2 <10 sec <10 sec ≈10 sec ≈1 min ≈2 min ≈1 min ≈3 min ≈11 min ≈3 hr ≈16 hr
The trityl results can be quite accurate and reproducible, as long as care is taken to avoid the following three possibilities. First, the trityl colors are most stable in the presence of excess acid. Therefore, dilutions should be performed by adding acidic deprotection reagent and not plain solvent. Second, the orange color is quenched by traces of protic solvents, such as water or alcohols. Thus glassware and cuvettes should be clean and dry before use. Finally, the trityl assay does not distinguish between nucleosides (or trityl groups) that are covalently and noncovalently bound. Thus it is possible for supports that have not been adequately washed to give false trityl results. This is not usually a problem, because most unbound reagents are easily removed by a methanol wash. Positively charged amino supports can, however, sometimes bind negatively charged nucleoside hemiesters strongly enough to resist washing. This is one reason why the derivatization protocols recommend checking the trityl loading both before and after acetylation of the surface amino groups (i.e., the capping step with Cap A and Cap B reagents). The number of functional groups on the surface of the support can also be determined by trityl analysis, if they can be derivatized with trityl groups. Amino and/or hydroxyl surface loadings are easily determined through the dimethoxytrityl derivatization procedure described in Support Protocol 2 (Reddy and Voelker, 1988). Surface carboxylic acids groups cannot be directly tritylated, so an ester derivative containing a chromophore is made instead. p-Nitrophenyl ester derivatives (Matteucci and Caruthers, 1981; Damha et al., 1990) can be used to measure succinic acid groups
Synthesis of Unmodified Oligonucleotides
3.2.19 Current Protocols in Nucleic Acid Chemistry
(Support Protocol 3), but this method does not work for HQDA groups. Instead, a ligand bearing a monomethoxytrityl group on the amino end of 6-amino-1-hexanol is used as the chromophore (Support Protocol 4). It is generally useful to know the extent of surface modification before proceeding with any nucleoside derivatization. This ensures that the support functionalization was successful and that the desired degree of nucleoside loading can be achieved. Characterization of nucleoside hemiesters, either succinyl or HQDA, can be most easily performed by thin-layer chromatography (TLC), especially if samples of authentic material are available for comparison. Even if authentic samples are not available, observation of the complete conversion of the starting nucleoside into either slower-moving products (hemiesters) or faster-moving products (diesters) is sufficient for most casual users. TLC analysis of the nucleoside hemiesters along with satisfactory trityl results from the derivatized support are usually sufficient if the identity of the starting nucleosides is well established (i.e., commercially available material). Of course, researchers working with novel compounds will also require the usual NMR, UV, and mass or elemental composition analyses to sufficiently confirm structures for publication.
Critical Parameters and Troubleshooting Handling of the support Insoluble supports must be handled carefully to prevent particle fracturing and the formation of fines because these small particles can plug filters or create higher back pressures in synthesis columns. Although CPG particles are much more durable than the silica gel supports previously used, it is still important to avoid the use of stirrers (magnetic or otherwise) when performing coupling reactions. A shaker, such as a wrist-action shaker, is the preferred method for keeping reaction mixtures agitated.
Attachment of Nucleosides to Solid-Phase Supports
Quality reagents and solvents Lower-than-expected support loadings are obtained if the coupling reagents (DEC or HBTU) are more than several years old or have been exposed to moisture contamination. These reagents should be kept at −20°C for long-term storage and not opened until warmed to room temperature to prevent contamination from moisture condensation. A more common prob-
lem is the presence of moisture in the anhydrous reactions. Both pyridine and acetonitrile are quite hygroscopic, and storage over molecular sieves is strongly recommended. Although the coupling reactions described in this unit are not extremely sensitive to moisture contamination, because a large excess of coupling reagent is used in each protocol, excessive moisture will cause poor results. Reagent concentration One of the most important factors in reactions involving solid-phase supports is the solution concentration, and the easiest way to improve results, without consuming more of the reagents, is to increase the concentration of either nucleoside or coupling reagent by reducing the reaction volume. This method is limited, however, by the volume required to suspend the support. Typically, 4 to 5 mL of solution per gram of LCAA-CPG is the minimum required. Generally, the protocols described in this unit do not depend strongly on reagent concentration, and reasonable results can be obtained without careful measurement of solvent volume. Researchers should be aware, however, that excessive solvent will lower results through both dilution effects and increased moisture content (if solvents are not completely anhydrous). Ribonucleosides Although, for simplicity, the figures and text in this unit refer only to 2′-deoxyribonucleosides, the coupling procedures are also applicable to ribonucleosides. When a ribonucleoside is attached to an insoluble support, it is of no consequence whether the linkage is through the 2′ or 3′ hydroxyl group. Therefore, ribonucleosides with a single unprotected 2′ or 3′ hydroxyl group can be used, as well as mixtures of the 2′ and 3′ isomers. It is also possible to use ribonucleosides with both 2′ and 3′ hydroxyl groups unprotected (i.e., only 5′and N-protecting groups). In this case, after attachment of the nucleoside to the support through one hydroxyl group, the adjacent unreacted hydroxyl group is acetylated by the same capping step used to acetylate unreacted amino groups. HBTU side reaction with amines Researchers should also be aware that the HBTU coupling reagent can form a Schiff base with amino groups (Gausepohl et al., 1992; Story and Aldrich, 1994). Therefore, this reagent should never be added to LCAA-CPG in
3.2.20 Current Protocols in Nucleic Acid Chemistry
the absence of the carboxylic acid component of the coupling reaction (which normally, and very rapidly, reacts preferentially with HBTU). Thus only 0.9 eq of HBTU are used in the protocol for coupling HQDA to LCAA-CPG. Accidental incorporation of >1 eq of HBTU into this reaction results in conversion of surface amino groups to unreactive Schiff bases. Capping of unreacted amino groups on the support An essential part of each nucleoside coupling protocol is the blocking or capping of unreacted functional groups on the surface of the support. These unreacted groups are present because the amount of nucleoside added is almost always less than the total capacity of the support. In particular, it is very important to cap off any unreacted amino groups by acetylating them with acetic anhydride. Otherwise they will react with the phosphoramidite reagents delivered during subsequent oligonucleotide synthesis cycles to produce oligonucleotide fragments with a 3′ deletion (i.e., the terminal nucleoside will be missing). These deletion fragments will be attached to the solid support via a 3′-phosphoramidate linkage and can be released from the support by either acidic hydrolysis (cleavage of the phosphoramidate bond) or prolonged ammonium hydroxide hydrolysis (cleavage of the silyl bonds joining the linker arm to the LCAA-CPG surface). Although normal cleavage conditions (NH4OH, ≤1 hr, room temperature) do not release significant amounts of these 3′-deletion products, they still reduce coupling yields and oligonucleotide quality by steric hindrance and competition for reagents. The effectiveness of the support capping can be determined by comparing the amount of trityl color released from the first nucleoside with the amount of color released after the first phosphoramidite-coupling cycle (Pon et al., 1988). The second amount should be the same as, or slightly less than, the first amount, if coupling occurred only on the immobilized nucleoside (i.e., the yield of the coupling is ≤100%); however, if the second color is more intense than the first (i.e., apparent coupling yields of >100%), then unwanted coupling to the surface of the support is occurring. In this case, the supports should be capped again before further use. The pore size of the support For rigid, macroporous supports, such as the LCAA-CPG particles described in this unit, the pore size is the most important parameter. This
is because the pore size affects the amount of nucleoside loading that can be obtained and the coupling efficiency of subsequent chain extension steps during oligonucleotide synthesis. The smaller the pore size, the greater the surface area and the higher the nucleoside loading. Too small a pore size, however, results in poor coupling efficiency and limits the oligonucleotide length that can be synthesized. LCAACPG supports with 500-Å pores are good choices for most oligonucleotide syntheses (shorter than ∼50 bases), and LCAA-CPG supports with 1000-Å pores are recommended for the synthesis of oligonucleotides longer than ∼50 bases (see UNIT 3.1).
Anticipated Results The amount of nucleoside attached to the surface of the support is generally not very critical, because most oligonucleotide synthesis columns can produce a great deal more product than required. Generally, however, LCAA-CPG supports are prepared with nucleoside loadings in the 30- to 40-µmol/g range; and the protocols in this unit should produce supports like these. This amount of loading gives excellent results for all but the very longest oligonucleotides. The greater the nucleoside loading, the more crowded the surface of the support; and this crowding appears to have an effect on coupling efficiency, especially with nucleoside loadings >50 µmol/g. Therefore, it is not necessary, and actually detrimental, to try to obtain nucleoside loadings greater than ∼40 to 50 µmol/g. For very long oligonucleotides (75 to 150 bases), use 1000-Å-pore-sized LCAA-CPG supports with only 5 to 10 µmol/g of nucleoside. The lower nucleoside loading presumably improves coupling efficiency by reducing steric hindrance and increasing the amount of excess coupling reagents. With this low loading, however, the maximum capacity of a synthesis column is reduced. It is also important to ensure that the synthesis reagents are of the highest quality and that the acidic detritylation conditions are minimized (to avoid unwanted depurination and chain cleavage) when preparing long oligonucleotides.
Time Considerations The total time required to perform each support derivatization varies between 1 and 4 days; however, the time required for the actual setup and workup is much less. Setup time for most reactions is very short (<15 min), because the reactants just need to be weighed and added
Synthesis of Unmodified Oligonucleotides
3.2.21 Current Protocols in Nucleic Acid Chemistry
to a single flask. Workup of the support derivatization reactions is also very fast (<10 min), because this involves only filtering off the support and washing it with solvent. Use of a vacuum aspirator to pull the solvent through the support during the wash steps makes very quick work. After the final dichloromethane wash recommended for each procedure, the LCAACPG beads are left to dry uncovered at room temperature. Evaporation of the dichloromethane solvent is quite fast, and the beads are usually sufficiently dry for trityl analysis or other use within 10 to 20 min. Also, preparations of the succinyl- or HQDA-derivatized LCAA-CPG supports should be performed in bulk, and the intermediate carboxyl derivatized supports saved for future nucleoside coupling reactions. Thus conversion of the LCAA-CPG support to a carboxylic acid–derivatized support does not need to be repeated each time. The time required for the synthesis of nucleoside hemiesters (of either succinic acid or HQDA) is more substantial, because these products must be worked up by conventional solution phase methods. An experienced chemist will require at least 2 to 3 days to synthesize and purify each reaction, and this process must be repeated for each nucleoside required. Therefore, these products are best purchased, if synthetic resources are not readily available. Once the support derivatization methods are mastered, it is very easy to prepare sufficient material for a large number of oligonucleotide syntheses. For example, a 5-g support preparation is sufficient for about 500 0.2-µmol-scale syntheses or about 2000 40-nmol-scale syntheses.
Literature Cited
E fi mov, V. A . , K a l in k in a , A.L., an d Chakhmakhcheva, O.G. 1993 . Dipentafluorophenyl carbonate—A reagent for the synthesis of oligonucleotides and their conjugates. Nucl. Acids Res. 21:5337-5344. Gait, M.J., Singh, M., and Sheppard, R.C. 1980. Rapid synthesis of oligodeoxyribonucleotides IV. Improved solid phase synthesis of oligodeoxyribonucleotides through phosphotriester intermediates. Nucl. Acids Res. 8:1081-1097. Gausepohl, H., Pieles, U., and Frank, R.W. 1992. Schiff’s base analog formation during in situ activation by HBTU and TBTU. In Peptides: Chemistry and Biology (J.A. Smith and J.E. Rivier, eds.) pp. 523-524. ESCOM, Leiden. Horn, M. and Novak, C. 1987. A monitoring and control chemistry for solid-phase peptide synthesis. Am. Biotechnol. Lab. 5:12-21. Koster, H., Stumpe, A., and Wolter, A. 1983. Polymer support oligonucleotide synthesis 13: Rapid and efficient synthesis of oligodeoxynucleotides on porous-glass support using triester approach. Tetrahedron Lett. 24:747-750. Kumar, P., Ghosh, N.N., Sadana, K.L., Garg, B.S., and Gupta, K.C. 1993. Improved methods for 3′-O-succinylation of 2′-deoxyribo- and ribonucleosides and their covalent anchoring on polymer supports for oligonucleotide synthesis. Nucleos. Nucleot. 12:565-584. Kumar, P., Sharma, A.K., Sharma, P., Garg, B.S., and Gupta, K.C. 1996. Express protocol for functionalization of polymer supports for oligonucleotide synthesis. Nucleos. Nucleot. 15:879888. Markiewicz, W.T., Groger, G., Rosch, R., Zebrowska, A., Markiewicz, M., Klotz, M., Hinz, M., Godzina, P., and Seliger, H. 1997. A new method of synthesis of fluorescently labelled oligonucleotides and their application in DNA sequencing. Nucl. Acids Res. 25:3672-3680.
Alul, R.H., Singman, C.N., Zhang, G.R., and Letsinger, R.L. 1991. Oxalyl-CPG—A labile support for synthesis of sensitive oligonucleotide derivatives. Nucl. Acids Res. 19:1527-1532.
Matteucci, M.D. and Caruthers, M.H. 1981. Synthesis of deoxyoligonucleotides on a polymer support. J. Am. Chem. Soc. 103:3185-3191.
Bhongle, N.N. and Tang, J.Y. 1995. A convenient and practical method for derivatization of solid supports for nucleic acid synthesis. Synth. Commun. 25:3671-3679.
Miyoshi, K.-I., Miyake, T., Hozumi, T., and Itakura, K. 1980. Solid-phase synthesis of polynucleotides. II. Synthesis of polythymidylic acids by the block coupling phosphotriester method. Nucl. Acids Res. 8:5473-5489.
Chow, F., Kempe, T., and Palm, G. 1981. Synthesis of oligodeoxyribonucleotides on silica gel support. Nucl. Acids Res. 12:2807-2817. Attachment of Nucleosides to Solid-Phase Supports
Dourtoglou, V., Gross, B., Lambropoulou, V., and Zio u d r ou , C. 1 984. O-BenzotriazolylN,N,N′,N′-tetramethyluronium hexafluorophosphate as a coupling reagent for the synthesis of peptides of biological interest. Synthesis 572-574.
Damha, M.J., Giannaris, P.A., and Zabarylo, S.V. 1990. An improved procedure for derivatization of controlled pore glass beads for solid-phase oligonucleotide synthesis. Nucl. Acids Res. 18:3813-3821.
Montserrat, F.X., Grandas, A., and Pedroso, E. 1993. Predictable and reproducible yields in the anchoring of DMT-nucleoside-succinates to highly loaded aminoalkyl-polystyrene. Nucleos. Nucleot. 12:967-971. Ogilvie, K.K. and Kroeker, K. 1971. Synthesis of oligothymidylates on an insoluble polymer support. Can. J. Chem. 50:1211-1215.
3.2.22 Current Protocols in Nucleic Acid Chemistry
Pon, R.T. 1993. Solid-phase supports for oligonucleotide synthesis. In Protocols for Oligonucleotides and Analogs (S. Agrawal, ed.) pp. 465496. Humana Press, Totowa, N.J.
Reddy, M.P. and Voelker, P.J. 1988. Novel method for monitoring the coupling efficiency in solid phase peptide synthesis. Int. J. Pept. Protein Res. 31:345-348.
Pon, R.T. and Yu, S. 1997a. Hydroquinone-O,O′diacetic acid (‘Q-linker’) as a replacement for succinyl and oxalyl linker arms in solid phase oligonucleotide synthesis. Nucl. Acids Res. 25:3629-3635.
Reddy, M.P., Rampal, J.B., and Beaucage, S.L. 1987. An efficient procedure for the solid phase tritylation of nucleosides and nucleotides. Tetrahedron Lett. 28:23-26.
Pon, R.T. and Yu, S. 1997b. Rapid automated derivatization of solid-phase supports for oligonucleotide synthesis using uronium or phosphonium coupling reagents. Tetrahedron Lett. 38:3331-3334. Pon, R.T., Usman, N., and Ogilvie, K.K. 1988. Derivatization of controlled pore glass beads for solid phase oligonucleotide synthesis. Biotechniques 6:768-775. Pon, R.T., Yu, S., Guo, Z., Yang, X., and Sanghvi, Y.S. 1999. Reusable solid-phase supports for oligonucleotide synthesis using hydroquinoneO,O′-diacetic acid (Q-Linker). Nucleos. Nucleot. In press. Pon, R.T., Yu, S., Guo, Z., and Sanghvi, Y.S. 1999. Multiple oligodeoxyribonucleotide syntheses on a reusable solid-phase CPG support via the hydroquinone-O,O′-diacetic acid (Q-Linker) linker arm. Nucleic Acids Res. 27:1531-1538.
Sharma, P., Sharma, A.K., Malhotra, V.P., and Gupta, K.C. 1992. One pot general method for the derivatization of polymer support for oligonucleotide synthesis. Nucl. Acids Res. 20:4100-4100. Story, S.C. and Aldrich, J.V. 1994. Side-product formation during cyclization with HBTU on a solid support. Int. J. Pept. Protein Res. 43:292296. Walsh, A.J., Clark, G.C., and Fraser, W. 1997. A direct and efficient method for derivatisation of solid supports for oligonucleotide synthesis. Tetrahedron Lett. 38:1651-1654. Yip, K.F. and Tsou, K.C. 1971. A new polymer support method for the synthesis of ribooligonucleotide. J. Am. Chem. Soc. 93:3272-3276.
Contributed by Richard T. Pon University of Calgary Calgary, Alberta, Canada
Synthesis of Unmodified Oligonucleotides
3.2.23 Current Protocols in Nucleic Acid Chemistry
Synthetic Strategies and Parameters Involved in the Synthesis of Oligodeoxyribonucleotides According to the Phosphoramidite Method The study of nucleic acids has, over the years, driven the development of fundamental methodologies necessary for the examination of their structure and chemistry. The ability to produce substantial quantities of sequence-defined synthetic DNA has been invaluable to nucleic acid research. Synthetic oligonucleotides have facilitated structural investigations and provided a better understanding of the interactions between nucleic acids and, for example, binding and/or modifying proteins. In addition, synthetic oligodeoxyribonucleotides have been extensively applied to the preparation of primers for enzymatic synthesis, amplification, and DNA sequencing. They have also been commonly used in site-directed mutagenesis experiments and as hybridization probes for diagnostic purposes. More recently, modified synthetic oligonucleotides have been targeted to cellular messenger RNAs in an attempt to control gene expression and develop therapeutic agents against various types of cancer and human infectious diseases (Beaucage and Iyer, 1993; Crooke and Bennett, 1996). On this basis, the availability of synthetic oligonucleotides has undoubtedly paved the way to the biotechnology revolution. The basic strategy in oligonucleotide synthesis resembles that of the stepwise synthesis of polypeptides. Typically, a functionally protected nucleotide monomer is linked to a growing oligonucleotide chain that is then chemoselectively deprotected and allowed to couple with the next nucleotide monomer of the desired sequence. Although the coupling of nucleotide monomers was traditionally carried out in solution according to the phosphodiester (Khorana, 1968) and phosphotriester (Letsinger and Ogilvie, 1969) methods, these strategies ultimately culminated in the development of modern automated techniques using the phosphoramidite method (Beaucage and Caruthers, 1981; Caruthers et al., 1987a). Given the major impact the phosphoramidite approach has had on the synthesis of oligonucleotides since its inception in the early 1980s, this commentary provides an overview of the parameters affecting the performance of the method and a number of compatible
UNIT 3.3
strategies for the preparation of oligodeoxyribonucleotides. Milestones that led to the discovery of the phosphoramidite method for oligodeoxyribonucleotide synthesis are chronologically reported. Alternate strategies to the preparation of deoxyribonucleoside phosphoramidites are then described to underscore the versatility with which these synthons can be obtained. The mechanisms of deoxyribonucleoside phosphoramidite activation and the factors affecting condensation rates are discussed along with the importance of “capping” and oxidation reactions toward defining optimal performance conditions for oligonucleotide synthesis. Finally, alternate phosphoramidite methods to oligodeoxyribonucleotide synthesis and additional deprotection strategies are presented to demonstrate facile access to synthetic oligonucleotides for a variety of applications. This unit is intended to complement APPENDIX 3C on the synthesis and purification of oligonucleotides.
ACCOUNTS OF CHEMICAL RESEARCH IN DNA OLIGONUCLEOTIDE SYNTHESIS A major advance in the chemical synthesis of oligodeoxyribonucleotides was accomplished in the mid-1970s through the development of the “phosphite triester” method (Letsinger and Lunsford, 1976). This approach relied on the use of P(III) chemistry and entailed the reaction of 5′-O-phenoxyacetyl thymidine S.1 with 2,2,2-trichloroethyl phosphorodichloridite S.2 to generate the corresponding deoxyribonucleoside-3′-O-phosphorochloridite S.3 and variable amounts of (3′→3′)-dinucleoside phosphite triester S.4 (Fig. 3.3.1). Addition of 3′-O-monomethoxytrityl thymidine to the reaction mixture gave, after treatment with aqueous iodine, the dinucleoside phosphate triester S.5 along with the symmetrical (3′→3′)- and (5′→5′)dinucleoside phosphate triesters S.6 and S.7, respectively. The formation of S.7 presumably resulted from the reaction of 3′-Omonomethoxytrityl thymidine with unreacted S.2. It should be noted that the phosphite triester
Contributed by Serge L. Beaucage and Marvin H. Caruthers Current Protocols in Nucleic Acid Chemistry (2000) 3.3.1-3.3.20 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Unmodified Oligonucleotides
3.3.1
Thy
PhOCH2COO Thy
PhOCH2COO
O
Cl3CCH2OPCl2 2
Thy
PhOCH2COO
2,6-lutidine/THF
OH 1
Cl
O
O O P
Cl3CCH2O
O P
O
OCH2CCl3
O
PhOCH2COO
Thy
3 4
Thy
HO
O
Thy
PhOCH2COO
PhOCH2COO
O
MMTrO
Thy O
1. O
MMTrO 2.
O
I2/H2O
Thy
O
PhOCH2COO
MMTrO MMTr, 4-methoxytrityl Ph, phenyl
O
O O P OCH2CCl3 O
O P OCH2CCl3
5
O Thy
O P OCH2CCl3 O
O
Thy
O MMTrO
Thy 6
7
Figure 3.3.1 The phosphite triester method to oligodeoxyribonucleotide synthesis.
and inert atmosphere. Although nucleoside chlorophosphites/tetrazolides led to the rapid and efficient preparation of DNA oligonucleotides on silica supports, the technical hardship associated with handling these synthons impeded automation of oligodeoxyribonucleotide syntheses. These problems vanished when deoxyribonucleoside phosphoramidites were developed in the early 1980s (Beaucage and Caruthers, 1981). These synthons were stable to air oxidation and hydrolysis under normal laboratory conditions but readily activated under mild acidic conditions to form internucleotide linkages in near-quantitative yields. Because of these properties, deoxyribonucleoside phosphoramidites have been conducive to automated oligonucleotide synthesis on polymeric supports and are still the preferred synthons for such syntheses. The preparation of these reagents was straightforward and involved the reaction of protected deoxyribonucleosides, such as S.11, with chloro-(N,N-dimethy-
approach to oligonucleotide synthesis was remarkably rapid; the preparation of S.5 was complete within 1 hr. In the mid-1970s, the formation of internucleotide linkages with such kinetics was unmatched. Later, the deoxyribonucleoside chlorophosphite S.8 (Fig. 3.3.2) was synthesized and reacted with deoxyribonucleosides covalently attached to a silica support (S.9) through a 3′-O-succinate linkage (Matteucci and Caruthers, 1981; see also UNITS 3.1 and 3.2). The dinucleoside phosphate triester S.10 was produced in yields > 90%. Addition of 1H-tetrazole to chlorophosphite S.8 significantly improved condensation rates and coupling yields. The application of nucleoside chlorophosphites or the corresponding tetrazolides to solid-phase synthesis of oligonucleotides was, however, tedious. Because of inherent sensitivity to moisture and air oxidation, the preparation of these reagents from reactive bifunctional phosphitylating agents had to be performed at −78°C under rigorously anhydrous conditions
B
DMTrO B
DMTrO
O
B
HO
O
I2/H2O
O P
O OMe
O
8
9
O O P OMe
O
Cl
O
N H
P
B
O
O O O O
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Method
DMTr, 4,4'-dimethoxytrityl B, Thy or any N-protected nucleobase Me, methyl P, solid support
N H
P
10
Figure 3.3.2 Application of the phosphite triester approach to solid-phase DNA synthesis.
3.3.2 Current Protocols in Nucleic Acid Chemistry
Cl DMTrO
B O OH
Me2N
P
OMe
B
DMTrO
O
12
i-Pr2NEt
Me2N
11
O P
OMe 13
Et, ethyl i-Pr, isopropyl
Figure 3.3.3 Preparation of deoxyribonucleoside phosphoramidite monomers.
lamino)methoxyphosphine S.12 and N,N-diisopropylethylamine (Fig. 3.3.3). The rapid reaction afforded deoxyribonucleoside phosphoramidites S.13 without the wasteful formation of (3′→3′)-dinucleoside phosphite triesters. The phosphoramidites S.13 were isolated by conventional laboratory techniques and stored as dry powders (Beaucage and Caruthers, 1981). The phosphoramidite method is distinctive in that it enables the conversion of relatively stable deoxyribonucleoside phosphoramidite derivatives into highly reactive intermediates suitable for DNA oligonucleotide synthesis. For example, addition of 1H-tetrazole to the phosphoramidite S.13 and 3′-O-levulinyl thymidine S.14 in dry acetonitrile generated the dinucleoside phosphite triester S.15 (Fig. 3.3.4) in almost quantitative yields within a few minutes, according to 31P-NMR spectroscopy (Beaucage and Caruthers, 1981). This methodology has been successfully applied to the solid-phase synthesis of oligodeoxyribonucleotides of varying chain lengths (Caruthers et al., 1982; Josephson et al., 1984). The sensitivity of phosphoramidite S.13 to a slightly acidic environment, however, precluded silica gel purification. Consequently, the chemical stability of crude S.13 in acetonitrile was variable, and the use of this type of phosphoramidite in automated systems not always reliable. Thus deoxyribonucleoside phosphoramidites with N,N-dialkylamino groups different from N,Ndimethylamino were investigated as potential alternatives to S.13 in automated solid-phase
DNA synthesis (Adams et al., 1983; McBride and Caruthers, 1983). For instance, the deoxyribonucleoside phosphoramidite S.16 (Fig. 3.3.5), unlike S.13, survived silica gel purification and, as a result, consistently showed stability in acetonitrile solutions for several days without significant decomposition (Adams et al., 1983). This class of phosphoramidites enabled reliable oligodeoxyribonucleotide syntheses (51-mers) on controlled-pore glass (CPG). In the early 1980s, these 51-mers were the largest DNA segments ever chemically synthesized. One drawback to the use of S.16 in automated oligonucleotide synthesis is the noxious thiophenolate treatment required for postsynthesis removal of the methyl phosphate protecting groups (Daub and van Tamelen, 1977). Although demethylation of methyl phosphotriesters can be effected by 2-mercaptobenzothiazole (S.17; Andrus and Beaucage, 1988) or disodium 2-carbamoyl-2-cyanoethylene-1,1dithiolate (S.18; Dahl et al., 1990) under odorless conditions, this deprotection step was inconvenient because it added to the time and reagents needed for oligonucleotide processing (Fig. 3.3.5). In an effort to simplify and shorten postsynthesis deprotection protocols, the deoxyribonucleoside phosphoramidite S.19 (Sinha et al., 1984) was prepared under conditions similar to those originally reported by Beaucage and Caruthers (Fig. 3.3.5). This phosphoramidite derivative was more stable than the methyl phosphoramidite S.16 in wet acetonitrile (Zon et al., 1985). Furthermore, phosphoramidite S.19 generated oligonucleotides from which the 2-cyanoethyl phosphate protecting groups are cleaved under the basic conditions required for deprotection of the nucleobase protecting groups (Tener, 1961; Letsinger and Mahadevan, 1966; Letsinger and Olgilvie, 1969). Such a convenient “single step–single reagent” postsynthesis deprotection protocol led to the widespread acceptance of phosphoramidite S.19 for automated solidphase oligonucleotide synthesis.
B
DMTrO HO
O
Thy O
1H-tetrazole
13
O P OCH3
MeCN
LevO
O
O
Thy
14 LevO Lev, levulinyl
15
Figure 3.3.4 Activation of deoxyribonucleoside phosphoramidites toward oligonucleotide synthesis.
Synthesis of Unmodified Oligonucleotides
3.3.3 Current Protocols in Nucleic Acid Chemistry
B
DMTrO
O
SH
i-Pr2N
O P
B
DMTrO
O
Na
− +Na
O
S OMe
− +
S
NC
N
S NH2
17
O P
i-Pr2N
18
OCH2CH2CN 19
16
Figure 3.3.5 Deoxyribonucleoside phosphoramidite monomers with improved stability properties and reagents for the deprotection of methyl phosphate triesters.
ALTERNATE STRATEGIES TO THE PREPARATION OF DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES The basicity and/or nucleophilicity of aminophosphine derivatives such as S.20 depends on the nature of the functional groups bound to phosphorus and on the interactions each of these groups might have with the vacant d orbital of the phosphorus atom through pπ-dπ overlap (Boudjebel et al., 1975). The bis-(dialkylamino) phosphine S.20 (Fig. 3.3.6) would, therefore, be more prone to protonation by a weak acid than would the deoxyribonucleoside phosphoramidite S.21, because it has been demonstrated that an alkoxy group contributes less to pπ-dπ interactions than does a dialkylamino group (Mathis et al., 1974). This concept was convincingly tested when the deoxyribonucleoside S.11 was reacted with bis-(pyrrolidino)methoxyphosphine S.20 and the weak acid 4,5-dichloroimidazole (Beaucage, 1984; Moore and Beaucage, 1985) to generate the deoxyribonucleoside phosphoramidite S.21 within 10 min, in yields exceeding 86% (Fig. 3.3.6). Presumably because of weaker pπ-dπ interactions, further activation of S.21 by 4,5-
dichloroimidazole produced only a small amount of (3′→3′)-dinucleoside phosphite triester (< 10%). Thus, as soon as it was generated, phosphoramidite S.21 was immediately activated by addition of 1H-tetrazole and used in the manual synthesis of an oligodeoxyribonucleotide (22-mer). This strategy eliminated the tedious isolation and purification of deoxyribonucleoside phosphoramidites and problems associated with the stability of phosphoramidite solutions. Despite these appealing features, this novel approach to the synthesis of deoxyribonucleoside phosphoramidites and oligonucleotides has never been automated, perhaps because of engineering limitations. In this context, it has been shown that reaction of the deoxyribonucleoside S.11 with bis-(N,Ndiisopropylamino)methoxyphosphine S.22 (Fig. 3.3.7) and limiting amounts of 1H-tetrazole or its N,N-diisopropylammonium salt afforded the corresponding deoxyribonucleoside phosphoramidite S.16 in isolated yields varying between 82% and 92% (Barone et al., 1984; Lee and Moon, 1984). This method is definitely recommended for the preparation of a variety of 2-cyanoethyl deoxyribonucleoside phosphoramidite derivatives (like S.19) from phos-
B
DMTrO
11 N
N P
O
4,5-dichloroimidazole O OMe
N-methylpyrrolidone N
P
OMe 21
20
Figure 3.3.6 Chemoselective preparation of deoxyribonucleoside phosphoramidites in situ using bis-(pyrrolidino)methoxyphosphine and 4,5-dichloroimidazole.
B
DMTrO 11
i-Pr2N P i-Pr2N OR
22 R = CH3 23 R = CH2CH2CN
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Method
O
N,N-diisopropylammonium tetrazolide or 1H-tetrazole
i-Pr2N
O P
OR
16 R = CH3 19 R = CH2CH2CN
Figure 3.3.7 Chemoselective preparation of deoxyribonucleoside phosphoramidites using bis(N,N-diisopropyl)alkoxyphosphine and limiting amounts of 1H-tetrazole or its N,N-diisopropylammonium salt.
3.3.4 Current Protocols in Nucleic Acid Chemistry
NEt2 Et2N
P
NEt2
B
DMTrO
B
DMTrO
O
24
O
CF3CONH(CH2)4OH
11 O
N,N-diethylammonium tetrazolide
P
Et2N
NEt2
25
N,N-diethylammonium tetrazolide
O Et2N
P
O(CH2)4NHCOCF3 26
Figure 3.3.8 Preparation of deoxyribonucleoside phosphoramidites using hexaethylphosphorus triamide and limiting amounts of N,N-diethylammonium tetrazolide.
phorodiamidite S.23 (Fig. 3.3.7) because of the mildness and high chemoselectivity of the phosphinylation reaction. Along similar lines, reaction of S.11 with hexaethylphosphorus triamide S.24 (Fig. 3.3.8) and an equimolar amount of the N,N-diethylammonium salt of 1H-tetrazole cleanly gave the nucleoside phosphorodiamidite S.25 (Yamana et al., 1989). Addition of, for example, 4-(N-trifluoroacetylamino)butan-1-ol to the reaction mixture produced the deoxyribonucleoside phosphoramidite S.26 (Fig. 3.3.8) in isolated yields exceeding 90% (Wilk et al., 1997). The versatility of this procedure allows facile access to phosphoramidites different from the conventional methyl or 2-cyanoethyl deoxyribonucleoside phosphoramidites.
ACTIVATION OF DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES The elegance of the phosphoramidite approach to oligodeoxyribonucleotide synthesis emanates from the transformation of relatively stable deoxyribonucleoside phosphoramidite derivatives to highly reactive intermediates for rapid and efficient chain extension reactions. Such a conversion is catalyzed by weak acids. For example, activation of phosphoramidite S.13 with N,N-dimethylaniline hydrochloride (pKa ≈ 5.15) generated the deoxyribonucleoside chlorophosphite S.27 (Fig. 3.3.9) in quantitative yield according to 31P-NMR spectroscopy (Beaucage and Caruthers, 1981). Because most tertiary amine hydrochlorides are hygroscopic, these could not be used in routine
B
DMTrO
O
N,N-dimethylaniline hydrochloride 13 O
CHCl3 Cl
P
OMe 27
Figure 3.3.9 Activation of deoxyribonucleoside phosphoramidites with N,N-dimethylaniline hydrochloride.
automated oligodeoxyribonucleotide synthesis because anhydrous conditions are absolutely necessary for optimum coupling reactions. Instead, the nonhygroscopic weak acid 1H-tetrazole has been and is still extensively used as an activator for deoxyribonucleoside phosphoramidites. In an incisive experiment, Seliger and Gupta (1985) demonstrated that activation of the solid-phase-linked deoxyribonucleoside phosphoramidite S.28 with 1Htetrazole generated the putative phosphorotetrazolide derivative S.29 (Fig. 3.3.10). Immediate condensation of S.29 with a deoxyribonucleoside covalently attached to a solid support (such as S.9) gave the dinucleoside phosphite triester S.30 in yields greater than 95%. The generation of S.29 during activation of deoxyribonucleoside phosphoramidites by 1Htetrazole was further investigated using diethoxy(N,N-diisopropylamino)phosphine S.31 and diethoxy-(N-tetrazolyl)phosphine S.32 (Fig. 3.3.11) as models (Berner et al., 1989). 31P-NMR spectrum of S.32 shows a resonance at 126 ppm. This resonance is also apparent when S.31 or phosphoramidite S.16 is mixed with 1H-tetrazole in acetonitrile (McBride and Caruthers, 1983). It should be noted that P-diastereomerically pure S.16 (Sp or Rp) rapidly epimerized at phosphorus upon activation with 1H-tetrazole and produced a diastereomeric deoxyribonucleoside phosphite triester when reacted with ethanol (Stec and Zon, 1984). These data indicate that activation of deoxyribonucleoside phosphoramidites with 1H-tetrazole occurs through a rapid and reversible protonation followed by a slower and reversible formation of the phosphorotetrazolide intermediate S.29. Paradoxically, activation of the nucleoside bicyclic phosphoramidites S.33-S.35 (Fig. 3.3.12) with 1H-tetrazole proceeded with low epimerization at phosphorus and led to highly stereoselective syntheses of oligonucleoside phosphorothioates (Guo et al., 1998; Iyer et al., 1998). A higher energy barrier to pseudorotation is apparently responsible for the reduced P-epimerization of these oxazaphospholidi-
Synthesis of Unmodified Oligonucleotides
3.3.5 Current Protocols in Nucleic Acid Chemistry
B
DMTrO
MeO
O P
MeCN MeO
O
B
DMTrO
O
1H-tetrazole Et N CH2
B
DMTrO
O
O P
O
9 MeO
P
O
O
N N N N
B O
O
29 P
O
28
P
N H
30
Figure 3.3.10 Mechanism of the activation of deoxyribonucleoside phosphoramidites by 1Htetrazole during solid-phase oligonucleotide synthesis.
nes during activation (Guo et al., 1998). It is somehow surprising that, although the conformationally restricted bicyclic oxazaphospholidines S.33 a n d S.34 allowed highly stereoselective syntheses of dinucleoside phosphorothioates (SP:RP > 9:1), the bicyclic phosphoramidite S.36 produced the same dinucleotides with only moderate stereoselectivity (RP:SP ≈ 3:1) (Guo et al., 1998). The bicyclic phosphoramidites S.33-S.35 a r e nonetheless promising candidates for the preparation of P-diastereomerically enriched oligonucleoside phosphorothioates. Reagents other than 1H-tetrazole have also been used to activate deoxyribonucleoside phosphoramidites, including N-methylimidazolium trifluoromethanesulfonate (Arnold et al., 1989); N-methylimidazole hydrochloride (Hering et al., 1985); pyridinium tetrafluoroborate (Brill et al., 1991); pyridinium chloride, pyridinium bromide, and pyridinium 4-methylbenzinesulfonate (Beier and Pfleiderer, 1999); N-methylanilinium trifluoroacetate (Fourrey and Varenne, 1984); N-methylanilinium trichloroacetate (Fourrey et al., 1987); benzimidazolium triflate (Hayakawa et al., 1996); imidazolium triflate (Hayakawa and Kataoka, 1998); pyridine hydrochloride/imidazole (Gryaznov and Letsinger, 1992); 5-trifluoromethyl-1H-tetrazole (Hering et al., 1985); 5-(4-nitrophenyl)-1H-tetrazole (Froehler and Matteucci, 1983); 5-(2-nitrophenyl)1H-tetrazole (Pon, 1987; Montserrat et al., 1994); 1-hydroxybenzotriazole (Claesen et al., 1984); 2,4,5-tribromo- and 2-nitro-imidazoles
(Xin and Just, 1996); benzotriazole and 5-chlorobenzotriazoles (Xin and Just, 1996); and 4,5dichloro-, 2-bromo-4,5-dicyano-, and 4,5-dicyano-imidazoles (Xin and Just, 1996). 5Ethylthio- and 5-benzylthio-1H-tetrazoles are also potent in the activation of phosphoramidites; these activators have been particularly useful in RNA synthesis (Wincott et al., 1995; Wu and Pitsch, 1998). It is important to note, however, that 1H-tetrazole and those more acidic activators (pKa < 4.8) can cleave the 5′-dimethoxytrityl (DMTr) group of deoxyribonucleoside phosphoramidites to a small extent and trigger the formation of activated dimers. The coupling of these dimers during chain extension produced oligonucleotides longer (n + 1) than the expected size (n) (Krotz et al., 1997a). The rates of DMTr deprotection by an activator depend on its acidity, exposure time, and nature of the nucleobase carrying the DMTr group (purines deprotect faster than pyrimidines). Typically, when the activation of deoxyribonucleoside phosphoramidites is performed by 1H-tetrazole for a period of 100 sec, ∼0.3%–0.9% of (n + 1)-mers is observed; however, when 1H-tetrazole is replaced by 5ethylthio-1H-tetrazole under similar conditions, ∼1.0%–4.3% of (n + 1)-mers are generated. It should, therefore, be understood that extended coupling times and the use of more acidic activators during solid-phase oligode-
B
DMTrO
O
O
O P
OEt OEt
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Method
31
N N N
OEt N P OEt
O
X N
S
i-Pr2N P
B
DMTrO
33 X = H 34 X = OMe
O
O P
X N
R
35 X = H 36 X = OMe
32
Figure 3.3.11 Model compounds used in the study of phosphoramidite activation by 1Htetrazole.
Figure 3.3.12 Nucleoside bicyclic phosphoramidites for the preparation of P-diastereomerically enriched oligonucleoside phosphorothioates.
3.3.6 Current Protocols in Nucleic Acid Chemistry
oxyribonucleotide synthesis will result in lower recovery of full-length oligomers, because longer than full-length oligonucleotides will be produced. These observations prompted an extensive search for less-acidic, more-nucleophilic activators. It has been reported that 4,5-dicyanoimidazole (Xin and Just, 1996) is less acidic (pKa 5.2), more soluble, and more nucleophilic than 1H-tetrazole (Vargeese et al., 1998). Moreover, the usefulness of 4,5-dicyanoimidazole relates not only to efficient synthesis of oligonucleotides but also to the preparation of nucleoside phosphoramidites from phosphorodiamidite S.23. Even though 1H-tetrazole is still very popular as an activator for deoxyribonucleoside phosphoramidites, 4,5dicyanoimidazole is an attractive option for the activation of deoxyribonucleoside and ribonucleoside phosphoramites in solid-phase oligonucleotide synthesis.
pling yields averaging 45% on a CPG support (Sekine et al., 1986). Under similar conditions, activated S.38 required a coupling time of 60 min to produce yields of 65%–70% (Casale and McLaughlin, 1990). Such coupling yields are far below those obtained with conventional deoxyribonucleoside phosphoramidites (∼99%) and thus underscore the importance of steric hindrance when designing nucleobase protecting groups and/or modified nucleobases toward the synthesis of oligodeoxyribonucleotides and their analogues. One effective approach to lessening steric interferences is to increase the distance between the bulky entity and the phosphoramidite function by the use of flexible linkers. For example, unlike S.38, the deoxyribonucleoside phosphoramidite S.39 (Fig. 3.3.13) has been efficiently incorporated into oligonucleotides under the conditions used for standard 2-cyanoethyl deoxyribonucleoside phosphoramidites (Bergstrom and Gerry, 1994). Other factors influencing the coupling rates of activated deoxyribonucleoside phosphoramidites have been investigated by Dahl and his colleagues (1987). In a systematic study, it was observed that condensation rates varied with the nature of phosphoramidite Oalkyl and N,N-dialkylamino groups. Typically, coupling rates decreased according to the following order: O-methyl > O-(2-cyanoethyl) > O-(1-methyl-2-cyanoethyl) > O-(1,1-dimethyl-2-cyanoethyl) and N,N-diethylamino >
FACTORS AFFECTING THE CONDENSATION RATES OF DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES The steric bulk of specific guanine N-2 functional groups has been shown to affect significantly condensation rates and coupling efficiency of these deoxyribonucleoside phosphoramidite derivatives. Two classic examples illustrating this fact are the activation of phosphoramidites S.37 and S.38 with 1H-tetrazole (Fig. 3.3.13). In the case of activated S.37, a condensation time of 10 min generated cou-
O
O N N
O O
O
NH
N
DMTrO
N
P
N OBz
N
PixO
NH
O
NH N
NH
O
BzO OBz
OMe
i-Pr2N
P
OCH2CH2CN 38
37 4-NO2PhCH2CH2O N N
DMTrO
O
N N
N H
O
N N
O
i-Pr2N
P
Bz, benzoyl 4-NO2Ph, 4-nitrophenyl Pix, 9-phenylxanthen-9-yl
OCH2CH2CN 39
Figure 3.3.13 Deoxyribonucleoside phosphoramidites functionalized with nucleobase bulky groups.
Synthesis of Unmodified Oligonucleotides
3.3.7 Current Protocols in Nucleic Acid Chemistry
N,N-diisopropylamino > N-morpholino > Nmethylanilino. The effect of steric hindrance on coupling rates is further illustrated by activation of the 2′-substituted nucleoside phosphoramidites S.40-S.43 (Fig. 3.3.14) and their competitive condensations with thymidine covalently attached to a solid support (Kierzek et al., 1987). Dimer formation was quantitated and correlated with the condensation rates of S.40-S.43. The amount of dimers formed decreased when the groups at C-2′ increased in sizes; thus 2′-H > 2′-O-methyl > 2′-O-tetrahydropyranyl > 2′O-tert-butyldimethylsilyl (Kierzek et al., 1987). In agreement with these findings, the deoxyribonucleoside phosphoramidites S.44 (Polushin, 1996) and S.45 (Jørgensen et al., 1994) have also exhibited significantly lower condensation rates and coupling efficiency because of steric factors (Fig. 3.3.14). Like sterically hindered groups attached to nucleobases (vide supra), it is also possible to decrease the steric demand of 2′-O-bulky protecting groups by increasing the distance between these groups and the phosphoramidite function. Specifically, the ribonucleoside 2′-O-triisopropylsilyloxymethyl phosphoramidite S.46 (Weiss, 1998; Wu and Pitsch, 1998; Fig. 3.3.15) allows much faster coupling reactions (2 min) in solid-phase oligoribonucleotide synthesis than do ribonucleoside 2′-O-tertbutyldimethysilyl phosphoramidites (5–8 min) under essentially identical conditions (see UNIT 3.4). Similarly, coupling reactions of t h e r i b o n u c l e o s i d e 2′-O-(o-nitrobenzyloxymethyl) phosphor- amidite S.47 (Fig. 3.3.15) are faster (2 min) than those effected b y r i b o n u c l e o s i d e 2′-O-(o-nitrobenzyl) phosphoramidites (10 min) under the same conditions (deBear et al., 1987; Schwartz et al., 1992). Thus functional groups generating
B
DMTrO
i-Pr2N
O
P
O
O
O
Si
NCCH2CH2O 46
B
DMTrO
O O
i-Pr2N
P
O2N O
O
OCH2CH2CN 47
Figure 3.3.15 Efficient ribonucleoside phosphoramidites for solid-phase RNA synthesis.
steric bulk near the nucleosidic phosphoramidite moiety are likely to interfere with coupling rates and should be given consideration when developing novel phosphoramidite monomers.
SIGNIFICANCE OF THE “CAPPING” REACTION IN THE CHEMICAL SYNTHESIS OF OLIGODEOXYRIBONUCLEOTIDES The phosphoramidite approach to oligodeoxyribonucleotide synthesis is renowned for its high coupling efficiency. Nonetheless, oligonucleotide chain extension does not occur quantitatively even under optimum conditions. As a result, the desired n-mer oligodeoxyribonucleotide is contaminated in the final product with a population of shorter (n − 1)-oligomers. Separation of the n-mer oligonucleotide from (n − 1)-mers can be challenging; however, this problem is almost completely eliminated by acetylation of the remaining unphosphitylated oligonucleotides after each condensation step. This “capping” reaction terminates the elongation of the unphosphitylated oligomers
NHBz N N
DMTrO
O
O
DMTrO
Ura
Thy
DMTrO TBDMSO
O
O
O
i-Pr2N
O P
40 41 42 43
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Method
R OCH2CH2CN R=H R = OMe R = OThp R = OTBDMS
O i-Pr2N P NCCH2CH2O
HN
OMe O
44
i-Pr2N
O P
OCH2CH2CN 45
Thp, tetrahydropyran-2-yl TBDMS, tert-butyldimethylsilyl
Figure 3.3.14 Nucleoside phosphoramidites functionalized with 2′- or 3′-sterically demanding groups.
3.3.8 Current Protocols in Nucleic Acid Chemistry
that would otherwise occur during the next coupling step. A very effective capping reagent is a solution of acetic anhydride, 2,6-lutidine, and N-methylimidazole in tetrahydrofuran (Farrance et al., 1989). Such a capping formulation not only prevents extension of unphosphitylated oligomers but also efficiently reduces the concentration of O6-phosphitylated guanine residues that are generated during the condensation step (Pon et al., 1986; Eadie and Davidson, 1987). The capping formulation is rich in acetate ions; these nucleophiles efficiently cleave O6-phosphitylated guanine adducts by attacking tricoordinated “enol phosphites” (like S.48; Fig. 3.3.16) and releasing unmodified guanine residues. Adducts such as S.48 or its oxidized form S.49, if not destroyed, can serve as secondary sites for oligonucleotide synthesis and lead to the formation of a complex mixture of branched oligodeoxyribonucleotides. The generation of these adducts is most efficiently minimized when the capping reaction is performed before the oxidation step. O,O-Diethyl-N,N-diisopropyl phosphoramidite has also been reported as an improved capping reagent in oligonucleotide synthesis (Yu et al., 1994). On the basis of the data presented, this phosphoramidite exhibited a capping efficiency that was only modestly superior to that of the standard acetic anhydride/N-methylimidazole/2,6-lutidine capping formulation. The phosphoramidite capping reagent was also claimed to not produce nucleobase modification; supporting data were, however, not shown. Interestingly, recent use of the lipophilic O-(2-cyanoethyl),O-octyl-N,N-diisopropyl phosphoramidite as a capping re-
B O O O
O
B
DMTrO
O
O O P
N
O
B
DMTrO
O
O P OCH2CH2CN O
OCH2CH2CN
N
O P OR N
Oxidation of a newly generated phosphite triester linkage to the corresponding phosphate triester function is an essential step in automated synthesis of oligodeoxyribonucleotides by the phosphoramidite approach. Without oxidation, an internucleoside phosphite triester function decomposes under the acidic conditions required for cleavage of the 5′-dimethoxytrityl group (Matteucci and Caruthers, 1981). Thus oxidation of phosphite triesters is absolutely necessary to ensure consistent highyielding oligodeoxyribonucleotide syntheses. An aqueous solution of iodine (0.05–0.1 M)
O
N
O
THE OXIDATION REACTION IN THE SYNTHESIS OF OLIGODEOXYRIBONUCLEOTIDES ACCORDING TO THE PHOSPHORAMIDITE METHOD
B
DMTrO
DMTrO
agent in solid-phase oligonucleotide synthesis has allowed facile separation of capped failure sequences from trityl-off full-length oligonucleotides by reverse-phase HPLC (RP-HPLC; Natt and Häner, 1997). This capping method simplified RP-HPLC purification of synthetic oligonucleotides and resulted in higher isolated yields. Phosphoramidite capping reagents may, however, like nucleoside phosphoramidites, phosphitylate nucleobases (especially at O-6 of guanosines) and eventually lead to the formation of, for example, 2,6-diaminopurine residues (Eadie and Davidson, 1987). This potential problem has not, as yet, been thoroughly investigated. Until this issue is resolved, use of the standard and well-studied acetic anhydride/N-methylimidazole/2,6-lutidine capping formulation during solid-phase oligonucleotide synthesis is recommended.
N
N
O P OR NHi-Bu
O
O
O
O
P
P 48 R = CH2CH2CN
N
N
NHi-Bu
49 R = CH2CH2CN
i-Bu, isobutyryl
6
Figure 3.3.16 Postulated O -guanine adducts generated during the chain extension step of the synthesis cycle according to the phosphoramidite method.
Synthesis of Unmodified Oligonucleotides
3.3.9 Current Protocols in Nucleic Acid Chemistry
and 2,6-lutidine (Letsinger and Lunsford, 1976) or pyridine (Usman et al., 1985) in tetrahydrofuran is generally used for this task; this formulation is stable and provides rapid-reaction kinetics, usually without formation of side products. When the N-2 amino function of guanine is protected with a N,N-dimethylformamidine group (Zemlicka and Holy, 1967; McBride et al., 1986; Vu et al., 1990) during automated oligonucleotide synthesis, however, use of the traditional iodine formulation as oxidant led to cyanation of guanine at N-2 (Mullah et al., 1995). It has also been shown that this side reaction is completely eliminated by the use of a lower-concentration (0.02 M) iodine oxidation reagent without losing speed and efficiency in the conversion of internucleoside phosphite triesters to phosphate triesters (Mullah et al., 1995). Thus the latter aqueous iodine formulation is recommended for standard oligonucleotide synthesis. For specific applications, however, nonaqueous oxidizing reagents may advantageously offer an alternative to aqueous iodine for the oxidation of oligodeoxyribonucleoside phosphite triesters. For example, m-chloroperbenzoic acid (Tanaka and Letsinger, 1982); iodobenzene diacetate and tetra-n-butylammonium periodate (Fourrey and Varenne, 1985); tert-butyl hydroperoxide (Hayakawa et al., 1986; Hayakawa and Kataoka, 1998); ditert-butyl hydroperoxide; cumene hydroperoxide; hydrogen peroxide; bis-trimethylsilyl peroxide, and catalytic amounts of trimethylsilyl triflate (Hayakawa et al., 1986); dinitrogen tetroxide and molecular oxygen in the presence of 2,2′-azobis(2-methylpropionitrile) under thermal or photochemical conditions (Bentrude et al., 1989); and (1S)-(+)-(10-camphorsulfonyl) oxaziridine (S.50; Ugi et al., 1988) have been effective. The oxaziridine S.50 (Fig. 3.3.17) is particularly useful for the synthesis of oligonucleotide containing multiple 7deaza-2′-deoxyguanosine residues. Incorpora-
Thy
DMTrO
N S O O O 50
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Method
i-Pr2N
O O P
CH3 O 51
Figure 3.3.17 An oxaziridine derivative as a useful oxidant in the synthesis of oligonucleotides containing iodine sensitive residues, and a benzylic deoxyribonucleoside phosphoramidite suitable for the preparation of oligonucleotide analogues.
tion of this modified 2′-deoxyguanosine into oligonucleotides via the phosphoramidite approach is sensitive to iodine-containing solutions regardless of iodine concentration (Anonymous, 1996). In this context, it should be noted that when applied to oligonucleotide synthesis, the benzylic deoxyribonucleoside phosphoramidite S.51 (Fig. 3.3.17) generated internucleoside o-methylbenzyl phosphite esters that were sensitive to aqueous iodine oxidation. This sensitivity to iodine resulted in the loss of benzylic phosphate protection (Caruthers et al., 1987b). The absence of phosphate protecting groups did not, however, impair subsequent additions of S.51 to the DNA chain. In fact, an oligothymidylic acid (20-mer) was prepared by the iterative incorporation of S.51 with an average coupling efficiency of 96%. It was speculated that phosphate-phosphite mixed anhydrides could have been generated from the interaction of phosphate diesters with activated S.51 and then cleaved by excess 1H-tetrazole to regenerate the deoxyribonucleoside phosphorotetrazolide intermediates needed for chain extension. Because of the inherent hazards involved with handling peroxides, the use of oxaziridine S.50 is, therefore, recommended for the oxidation of phosphite triesters of those modified oligonucleotides that are reactive to iodine and/or necessitate rigorously anhydrous conditions. Moreover, the use of S.50 in oligonucleotide synthesis does not lead to detectable nucleobase modifications (Anonymous, 1996). It has also been shown that oxidation of the dinucleoside 2-cyano-1,1-dimethylethyl phosphite triester S.52 (Fig. 3.3.18) with iodine in the presence of water, alcohols, and amines produced the corresponding dinucleoside phosphate S.54, phosphate triester S.55, and phosphoramidate S.56, respectively (Nielsen and Caruthers, 1988). It is postulated that under these oxidative Arbuzov-type conditions, elimination of the 2-cyano-1,1-dimethylethyl group led to the dinucleoside phosphoryl iodide intermediate S.53. The formation of S.53 is supported by 31P-NMR data and thus provides a versatile pathway to the synthesis of oligodeoxyribonucleotide analogues from deoxynucleoside 3′-O-(2-cyano-1,1-dimethylethyl) or o-methylbenzyl phosphoramidites. Another example of the importance of P(III) oxidation in oligodeoxyribonucleotide synthesis according to the phosphoramidite approach is the incorporation of internucleotide phosphorothioates linkages into these bio-
3.3.10 Current Protocols in Nucleic Acid Chemistry
P
O
I2
O P O
O
Thy
THF
H2O I
O
AcO
O
Thy
or ROH
O O
O P OR O
O
Thy
AcO
AcO
52
Thy
DMTrO
O
O O
NCCH2C(CH3)2O
Thy
DMTrO
Thy
DMTrO
53
54 R = H 55 R = CH3
R'NH2
Thy
DMTrO
O O
O P NHR' O
O
Thy
AcO Ac, acetyl
56 R' = n-butyl
Figure 3.3.18 Access to oligodeoxyribonucleotide analogues from deoxynucleoside (2-cyano1,1-dimethylethyl) phosphoramidites.
molecules. Oligonucleotides carrying internucleotide phosphorothioate diesters display enhanced resistance to hydrolysis catalyzed by nucleases (Eckstein, 1985). Because of this property, oligodeoxyribonucleoside phosphorothioates have been extensively used as antisense molecules in the inhibition of gene expression. Automated synthesis of these modified oligonucleotides via the phosphoramidite method consists of replacing the aqueous iodine oxidation step by a sulfurization reaction that had originally been effected by elemental sulfur. Given the poor solubility of elemental sulfur in organic solvents, its use in automated systems has been difficult. This problem was eliminated when phenylacetyl disulfide (S.57; Kamer et al. 1989; Roelen et al., 1991) and 3H-1,2-benzodithiol-3-one 1,1-dioxide (S.58; Iyer et al., 1990; Regan et al., 1992) were employed as sulfurization reagents (Fig. 3.3.19). These compounds are soluble in organic solvents and produce efficient and rapid sulfurization kinetics. For example, S.58 converted the dinucleoside phosphite triester S.59 to the corresponding phosphorothioate dimer S.60 in yields exceeding 99% within 30 sec at 25°C (Iyer et al., 1990; Regan et al., 1992). Deprotection of S.60 afforded the dinucleoside phosphorothioate S.61 (Fig. 3.3.19). Thus the sulfur-transfer reagent S.58 has enabled reliable automated synthesis of phosphorothioated oligomers carrying either exclusively or a predetermined number of phos-
phorothioate groups (Iyer et al., 1990). Given the biological significance of oligonucleoside phosphorothioates, application of S.58 to the synthesis of these modified oligonucleotides has spurred interest in the development of additional sulfurizing reagents. The most notable sulfur-transfer agents that have been reported during this decade include N,N,N′,N′tetraethylthiuram disulfide (Vu and Hirschbein, 1991), dibenzoyl tetrasulfide (Rao et al., 1992), bis-(O,O-diisopropoxyphosphinothioyl) disulfide (Stec et al., 1993), benzyltriethylammonium tetrathiomolybdate (Rao and Macfarlane, 1994), bis(p-toluenesulfonyl)disulfide (Efimov et al., 1995), 3-ethoxy1,2,4-dithiazoline-5-one (Xu et al., 1996), thiiranes (Arterburn and Perry, 1997), bis(ethoxythiocarbonyl)tetrasulfide (Zhang et al., 1998), and 3-methyl-1,2,4-dithiazoline-5one (Zhang et al., 1999). Out of these sulfurtransfer reagents, 3H-1,2-benzodithiol-3-one 1,1-dioxide and 3-ethoxy-1,2,4-dithiazoline-5one are currently the most extensively used in solid-phase synthesis of oligonucleoside phosphorothioates.
STRATEGIES IN THE DEPROTECTION OF SYNTHETIC OLIGODEOXYRIBONUCLEOTIDES The efficiency of the phosphoramidite method for solid-phase synthesis of oligodeoxyribonucleotides is such that oligonucleotides up to 50 bases long can be synthesized
Synthesis of Unmodified Oligonucleotides
3.3.11 Current Protocols in Nucleic Acid Chemistry
O
O S
S
S S
O
O
57
B
DMTrO O
S O
O
O
58
O
O O
P − + S
O S
P OCH2CH2CN
O
B
DMTrO
O O
S
O
58
B
O
OCH2CH2CN
O
O
O
O
P
P
B
59
B
HO
O
−
deprotection
O P S O
B
DMTrO
O
O O
S P OCH2CH2CN O
B
OH
O
O
B
O
61 P 60
Figure 3.3.19 Preparation of oligodeoxyribonucleoside phosphorothioates according to the solidphase phosphoramidite method.
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Method
within a few hours. While the cleavage of these oligonucleotides from solid supports is normally accomplished by treatment with concentrated ammonium hydroxide for ∼1 hr at ambient temperature, it will take ∼10 hr at elevated temperature (55°C) to deprotect the N-isobutyryl group of guanines, and N-benzoyl group of cytosines and adenines (see UNIT 2.1). This time-consuming deprotection step clashed with the urgent demand for synthetic oligodeoxyribonucleotides and thus provided an incentive to improve the chemistry involved with postsynthesis oligonucleotide processing. Specifically, methods for rapid removal of oligonucleotide protecting groups have attracted considerable attention and motivated the development of novel base-labile blocking groups for nucleobases (Schulhof et al., 1987; Uznanski et al., 1989; Kuijpers et al., 1990; Vu et al., 1990; Beaucage and Iyer, 1992; Sinha et al., 1993; Iyer et al., 1997; see also UNIT 2.1). Concentrated solutions of ammonia in water, ethanol, or methanol have been used for the cleavage of these groups. Alternatively, an aqueous
solution of methylamine and ammonium hydroxide has been employed for the deprotection of oligonucleotides carrying N-acetyl cytosines, N-benzoyl adenines, and N-isobutyryl guanines (Reddy et al., 1994). With this reagent, oligonucleotides were cleaved from solid supports in 5 min at ambient temperature, and complete deprotection was accomplished in 5 min at 65°C. It should, however, be emphasized that an aqueous solution of methylamine and ammonium hydroxide cannot be used for the deprotection of oligonucleotides bearing conventional N-benzoyl cytosines because primary amines have been reported to attack N4-anisoyl- or N4-benzoyl-2′-deoxycytidine at C-4 to produce N4-alkylated 2′-deoxycytidine derivatives (Weber and Khorana, 1972; Reddy et al., 1997). Gaseous amines such as ammonia or methylamine have also been employed under pressure to achieve mild and rapid deprotection conditions (Boal et al., 1996). For example, oligodeoxyribonucleotides having cytosines, adenines, and guanines N-protected with a tert-
3.3.12 Current Protocols in Nucleic Acid Chemistry
butylphenoxyacetyl group were released from CPG supports and fully deprotected at 25°C by pressurized ammonia or methylamine within 35 or 2 min, respectively. It has also been shown that when the N-benzoyl group is used for protection of cytosines and adenosines, and N-isobutyryl for guanines, complete deprotection of oligodeoxyribonucleotides by ammonia gas will take ∼7 hr at 25°C. At that temperature, it would take ∼36 hr for concentrated aqueous ammonium hydroxide to accomplish the same task (Boal et al., 1996). The use of ammonia or methylamine gas allows the simultaneous deprotection of a large number of oligodeoxyribonucleotides. In fact, the number of oligonucleotides or CPG columns that can be deprotected is limited only by the size of the pressure vessel employed. Because no water is present during deprotection, fully deblocked oligonucleotides remain adsorbed to CPG and thus prevent cross-contamination between columns. Oligonucleotides can then be eluted from individual columns with a minimum amount of water for further purification, if desired. This deprotection procedure eliminates hazards inherent to the handling and heating of aqueous amine solutions in glass vials and, more important, the time-consuming evaporation of these solutions. The gas-phase deprotection methodology is recommended when oligonucleotides carrying base-sensitive nucleobases demand mild deprotection conditions or when rapid deprotection is needed to accelerate the production of synthetic oligonucleotides.
ALTERNATE STRATEGIES TO THE SYNTHESIS OF OLIGODEOXYRIBONUCLEOTIDES ACCORDING TO THE PHOSPHORAMIDITE METHOD The versatility of the phosphoramidite approach to oligodeoxyribonucleotide synthesis has been further demonstrated by the use of deoxyribonucleoside phosphoramidites with unprotected nucleobases. The success of this strategy depends on a modified synthesis cycle protocol that involves treatment of the solid support with an equimolar solution (0.1 M) of pyridine hydrochloride and aniline in acetonitrile (Gryaznov and Letsinger, 1991) or benzimidazolium triflate in methanol (Hayakawa and Kataoka, 1998) immediately after each condensation reaction. This treatment destroys nucleobase adducts that are forming on the oligonucleotidic chain during each coupling step. This procedure should facilitate the syn-
thesis of oligonucleotides bearing base-sensitive functional groups because treatment with concentrated ammonium hydroxide at elevated temperature will no longer be required for oligonucleotide deprotection. Furthermore, depurination of adenine and guanine residues under the acidic conditions required for the removal of the 5′-O-DMTr group will become even less likely. More data are still needed to assess whether the synthesis of oligodeoxyribonucleotides according to the phosphoramidite method without nucleobase protection is trouble-free. The method is promising in that it may significantly expedite the production of synthetic oligonucleotides by shortening postsynthesis oligonucleotide processing time. Another strategy toward the preparation of oligodeoxyribonucleotides entails the stepwise condensation of dinucleotide phosphoramidite blocks such as S.62-S.65 (Fig. 3.3.20) instead of conventional monomeric deoxyribonucleoside phosphoramidites for chain extension. Activation of S.62 with 1H-tetrazole produced coupling yields (∼99%) similar to those generated by monomeric phosphoramidites (Kumar and Poonian, 1984). The incorporation of S.63 into oligonucleotides allowed syntheses of randomized DNA sequences containing the 20 codons corresponding to all natural amino acids (Neuner et al., 1998). The efficiency of dinucleotide phosphoramidites to solid-phase oligonucleotide synthesis has been further demonstrated by the preparation of a large oligomer (101-mer) through repetitive condensations of the dimeric phosphoramidite S.64 (Wolter et al., 1986). Furthermore, the impurity profile of oligonucleoside phosphorothioates synthesized by iterative coupling of the thioated dinucleotide phosphoramidite S.65 (Krotz et al., 1997b) showed at least 70% reduction of the (n − 1)-mers and a ∼50% reduction of phosphodiester formation when compared to profiles obtained by standard monomer phosphoramidite couplings. The use of dimeric phosphoramidites in the synthesis of unmodified oligodeoxyribonucleotides has not been widely adopted, probably because a library of up to 16 combinatorial dimers had to be prepared to accomplish the synthesis of one oligonucleotide. Conversely, the application of dimeric phosphoramidites to oligonucleotide analogue synthesis has been popular especially for the incorporation of modified internucleotide bridges. For example, the dimeric 5′-phosphonate–linked thymidine phosphoramidite S.66 (Zhao and Caruthers, 1996) and S.67 (Kofoed and Caruthers, 1996)
Synthesis of Unmodified Oligonucleotides
3.3.13 Current Protocols in Nucleic Acid Chemistry
B
DMTrO
Thy
DMTrO
O
O O
O
X P OCH2CH2CN
O P OMe O
O
R2N
O P
B
O
i-Pr2N
OR'
Thy
O O P
OCH2CH2CN
64 X = O 65 X = S
62 R = R' = CH3 63 R = CH(CH3)2, R' = CH2CH2CN
Figure 3.3.20 Solid-phase oligonucleotide synthesis using dinucleotide phosphoramidite derivatives.
have been prepared and incorporated into oligodeoxyribonucleotides to assess the physicochemical and biochemical properties imparted by such modifications (Fig. 3.3.21). For similar purposes, and given the growing interest in the development of therapeutic oligonucleotides, a plethoric number of dimeric phosphoramidites structurally related to S.66-S.68 have been prepared in recent years. Because of the intense activity in this area of research, only a fraction of the work has, so far, been reviewed (see Beaucage and Iyer, 1993; Sanghvi and Cook, 1994; Agrawal and Iyer, 1995; Iyer et al., 1999). Oligodeoxyribonucleotides have also been prepared by the condensation of trinucleotide phosphoramidite blocks to enable oligonucleotide-directed mutagenesis. More and more, oligonucleotides of mixed composition are being used to generate combinatorial libraries of variants in the search for peptides and proteins with improved properties. The most direct route to controlled mutagenesis is indeed the use of trinucleotide synthons that correspond to the amino acid codons needed. The synthesis of trinucleotide phosphoramidites S.69 (Sondek
and Shortle, 1992; Virnekäs et al., 1994), S.70 (Lyttle et al., 1995), S.71 (Ono et al., 1995; Kayushin et al., 1996; Zehl et al., 1996), and S.72 (Gaytán et al., 1998; Fig. 3.3.22) representing the codons for all 20 amino acids has been achieved. The incorporation of S.69 into oligonucleotides was accomplished by allowing a coupling time of 1 min and performing the trinucleotide condensation step twice. Under these conditions, coupling yields averaged 96%–98.5% (Virnekäs et al., 1994). Considering that each trinucleotide condensation adds three nucleobases to the growing oligonucleotide chain, these coupling yields are equivalent to three individual monomeric phosphoramidite condensations, each with a coupling efficiency of 98%–99.5%. Incorporation of the trinucleotide phosphoramidites S.71 and S.72 into oligonucleotides via automated solidphase synthesis occurred in yields that varied with the sequence of the trinucleotide block used. Nonetheless, the incorporation of these trinucleotide phosphoramidite blocks into synthetic DNA in the controlled, codon-by-codon construction of combinatorial libraries of struc-
B
DMTrO DMTrO
Thy
O
O
1 O
O
2 O
O P OPhCl-2
O O P
O
Thy O
BnO O
i-Pr2N
O
Thy
DMTrO
P
OCH2CH2CN
i-Pr2N
O P
Thy
3 O 4 O
OCH2CH2CN
i-Pr2N 66
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Method
67
O P
O
B
OCH2CH2CN
68
Bn, benzyl PhCl-2, o-chlorophenyl
n , atom or group of atoms O
Figure 3.3.21 Solid-phase synthesis of oligonucleotide analogues from dimeric phosphoramidites carrying modified internucleotidic linkages.
3.3.14 Current Protocols in Nucleic Acid Chemistry
tural genes will be invaluable in creating molecular diversity by mutagenesis.
CONCLUDING REMARKS Owing to the high performance of the phosphoramidite method, synthetic oligodeoxyribonucleotides became readily available and fueled the biotechnology revolution that has irreversibly changed biomedical research and the pharmaceutical industry. For example, without the ability to rapidly and efficiently synthesize DNA oligonucleotides, the development of the polymerase chain reaction (PCR) and its multiple applications would have been difficult, if not impossible, because this technology completely depends on the use of DNA primers. Similarly, the phosphoramidite method has been instrumental in the development of automated DNA sequencing, which also requires rapid and efficient synthesis of fluorescent DNA primers. Another important biological application for oligodeoxyribonucleotides generated by the phosphoramidite method relates to site-specific mutagenesis of protein genes. Mutagenesis of this type has been used to study protein structure-function relationships and to alter the therapeutic spectrum of pharmaceutically active proteins. In addition, the phosphoramidite method has been particularly useful in the synthesis of modified oligonucleotides for diagnostic applications and as potential therapeutic drugs. Although the latter research area is relatively new, several oligonucleotide-based drugs have already reached the clinic, and others are under preclinical investigation to benefit public health and push further the frontiers of knowledge.
B
DMTrO
O
Adams, S.P., Kavka, K.S., Wykes, E.J., Holder, S.B., and Galluppi, G.R. 1983. Hindered dialkylamino nucleoside phosphite reagents in the synthesis of two DNA 51-mers. J. Am. Chem. Soc. 105:661663. Agrawal, S. and Iyer, R.P. 1995. Modified oligonucleotides as therapeutic and diagnostic agents. Curr. Opin. Biotechnol. 6:12-19. Andrus, A. and Beaucage, S.L. 1988. 2-Mercaptobenzothiazole—An improved reagent for the removal of methyl phosphate protecting groups from oligodeoxynucleotide phosphotriesters. Tetrahedron Lett. 29:5479-5482. Anonymous. 1996. Non-aqueous oxidation with 10camphorsulfonyl-oxaziridine. The Glen Report 9:8-9. Arnold, L., Tocik, Z., Bradkova, E., Hostomsky, Z., Paces, V., and Smrt, J. 1989. Automated chloridite and amidite synthesis of oligodeoxyribonucleotides on a long chain support using amidine protected purine nucleosides. Collect. Czech. Chem. Commun. 54:523-532. Arterburn, J.B. and Perry, M.C. 1997. Rhenium catalyzed sulfurization of phosphorus(III) compounds with thiiranes: New reagents for phosphorothioate ester synthesis. Tetrahedron Lett. 38:7701-7704. Barone, A.D., Tang, J.-Y., and Caruthers, M.H. 1984. In situ activation of bis-dialkylaminophosphines—A new method for synthesizing deoxyoligonucleotides on polymer supports. Nucl. Acids Res. 12:4051-4061. Beaucage, S.L. 1984. A simple and efficient preparation of deoxynucleoside phosphoramidites in situ. Tetrahedron Lett. 25:375-378. Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862. Beaucage, S.L. and Iyer, R.P. 1992. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:22232311.
B
R'O
O
LITERATURE CITED
O O
O P OR B
O
Beaucage, S.L. and Iyer, R.P. 1993. The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications. Tetrahedron 49:6123-6194.
O P OPhCl-2
O
O O
O P OR O
i-Pr2N
B
O
O
O P OPhCl-2 O
O P
B
OR
69 R = CH3 70 R = CH2CH2CN
O
i-Pr2N
O O P
B
Beier, M. and Pfleiderer, W. 1999. Pyridinium salts–An effective class of catalysts for oligonucleotide synthesis. Helv. Chim. Acta 82:879887.
OCH2CH2CN
71 R' = DMTr 72 R' = Fmoc
Fmoc, 9-fluorenylmethoxycarbonyl PhCl-2, o-chlorophenyl
Figure 3.3.22 Trinucleotide phosphoramidite blocks for the controlled, codon-by-codon, construction of combinatorial gene libraries.
Bentrude, W.G., Sopchik, A.E., and Gajda, T. 1989. Stereo- and regiochemistries of the oxidations of 2-methoxy-5-tert-butyl-1,3,2-dioxaphosphori nanes and the cyclic methyl 3′,5′-phosphite of thymidine by H2O/I2 and O2/AIBN to P-chiral phosphates. 17O NMR assignment of phosphorus configuration to the diastereomeric thymidine cyclic methyl 3′,5′-monophosphates. J. Am. Chem. Soc. 111:3981-3987.
Synthesis of Unmodified Oligonucleotides
3.3.15 Current Protocols in Nucleic Acid Chemistry
Bergstrom, D.E. and Gerry, N. 1994. Precision sequence-specific cleavage of a nucleic acid by a minor-groove-directed metal-binding ligand linked through N-2 of deoxyguanosine. J. Am. Chem. Soc. 116:12067-12068. Berner, S., Mühlegger, K., and Seliger, H. 1989. Studies on the role of tetrazole in the activation of phosphoramidites. Nucl. Acids Res. 17:853864. Boal, J.H., Wilk, A., Harindranath, N., Max, E.E., Kempe, T., and Beaucage, S.L. 1996. Cleavage of oligodeoxyribonucleotides from controlledpore glass supports and their rapid deprotection by gaseous amines. Nucl. Acids Res. 24:31153117. Boudjebel, H., Gonçalves, H., and Mathis, F. 1975. Étude de la liaison P—N dans le motif S2P— NMe3 en résonance magnétique nucléaire et par la réaction d’échange avec le trifluoroacétate de méthyle. Bull. Chem. Soc. Chim. France 628634. Brill, W.K.-D., Nielsen, J., and Caruthers, M.H. 1991. Synthesis of deoxydinucleoside phosphorodithioates. J. Am. Chem. Soc. 113:39723980. Caruthers, M.H., Beaucage, S.L., Becker, C., Efcavitch, W., Fisher, E.F., Galluppi, G., Goldman, R., deHaseth, P., Martin, F., Matteucci, M., and Stabinsky, Y. 1982. New methods for synthesizing deoxyoligonucleotides. In Genetic Engineering: Principles and Methods, Vol. 4 (J.K. Setlow and A. Hollaender, eds.) pp. 1-17. Plenum, New York. Caruthers, M.H., Barone, A.D., Beaucage, S.L., Dodds, D.R., Fisher, E.F., McBride, L.J., Matteucci, M., Stabinsky, Z., and Tang, Y.-Y. 1987a. Chemical synthesis of deoxyoligonucleotides by the phosphoramidite method. In Methods and Enzymology; Vol. 154 (R. Wu and L. Grossman, eds.) pp. 287-313. Academic Press, San Diego; and references therein. Caruthers, M.H., Kierzek, R., and Tang, J.Y. 1987b. Synthesis of oligonucleotides using the phosphoramidite method. In Biophosphates and Their Analogues—Synthesis, Structure, Metabolism and Activity (K.S. Bruzik and W.J. Stec, eds.) pp. 3-21. Elsevier/North Holland, Amsterdam. Casale, R. and McLaughlin, L.W. 1990. Synthesis and properties of an oligodeoxynucleotide containing a polycyclic aromatic hydrocarbon site specifically bound to the N2 amino group of a 2′-deoxyguanosine residue. J. Am. Chem. Soc. 112:5264-5271.
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Method
Dahl, B.H., Nielsen, J., and Dahl, O. 1987. Mechanistic studies on the phosphoramidite coupling reaction in oligonucleotide synthesis. I. Evidence for nucleophilic catalysis by tetrazole and rate variations with the phosphorus substituents. Nucl. Acids Res. 15:1729-1743. Dahl, B.H., Bjergårde, K., Henriksen, L., and Dahl, O. 1990. A highly reactive, odourless substitute for thiophenol/triethylamine as a deprotection reagent in the synthesis of oligonucleotides and their analogues. Acta Chem. Scand. 44:639-641. Daub, G.W. and van Tamelen, E.E. 1977. Synthesis of oligoribonucleotides based on the facile cleavage of methyl phosphotriester intermediates. J. Am. Chem. Soc. 99:3526-3528. deBear, J.S., Hayes, J.A., Koleck, M.P., and Gough, G.R. 1987. A universal glass support for oligonucleotide synthesis. Nucleosides Nucleotides 6:821-830. Eadie, J.S. and Davidson, D.S. 1987. Guanine modification during chemical DNA synthesis. Nucl. Acids Res. 15:8333-8349. Eckstein, F. 1985. Nucleoside phosphorothioates. Annu. Rev. Biochem. 54:367-402. Efimov, V.A., Kalinkina, A.L., Chakhmakhcheva, O.G., Schmaltz Hill, T. and Jayaraman, K. 1995. New efficient sulfurizing reagents for the preparation of oligodeoxyribonucleotide phosphorothioate analogues. Nucl. Acids Res. 23:4029-4033. Farrance, I.K., Eadie, J.S., and Ivarie, R. 1989. Improved chemistry for oligodeoxyribonucleotide synthesis substantially improves restriction enzyme cleavage of a synthetic 35 mer. Nucl. Acids Res. 17:1231-1245. Fourrey, J.-L. and Varenne, J. 1984. Improved procedure for the preparation of deoxynucleoside phosphoramidites: Arylphosphoramidites as new convenient intermediates for oligodeoxynucleotide synthesis. Tetrahedron Lett. 25:45114514. Fourrey, J.-L. and Varenne, J. 1985. Introduction of a nonaqueous oxidation procedure in the phosphite triester route for oligonucleotide synthesis. Tetrahedron Lett. 26:1217-1220. Fourrey, J.-L., Varenne, J., Fontaine, C., Guittet, E., and Yang, Z.W. 1987. A new method for the synthesis of branched ribonucleotides. Tetrahedron Lett. 28:1769-1772. Froehler, B. and Matteucci, M.D. 1983. Substituted 5-phenyltetrazoles: Improved activators of deoxynucleoside phosphoramidites in deoxyoligonucleotide synthesis. Tetrahedron Lett. 24:3171-3174.
Claesen, C., Tesser, G.I., Dreef, C.E., Marugg, J.E., van der Marel, G.A., and van Boom, J.H. 1984. Use of 2-methylsulfonylethyl as a phosphorus protecting group in oligonucleotide synthesis via a phosphite triester approach. Tetrahedron Lett. 25:1307-1310.
Gaytán, P., Yañez, J., Sánchez, F., Mackie, H., and Soberón, X. 1998. Combination of DMTmononucleotide and Fmoc-trinucleotide phosphoramidites in oligonucleotide synthesis affords an automatable codon-level mutagenesis method. Chem. Biol. 5:519-527.
Crooke, S.T. and Bennett, C.F. 1996. Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 36:107-129.
Gryaznov, S.M. and Letsinger, R.L. 1991. Synthesis of oligonucleotides via monomers with unprotected bases. J. Am. Chem. Soc. 113:5876-5877.
3.3.16 Current Protocols in Nucleic Acid Chemistry
Gryaznov, S.M. and Letsinger, R.L. 1992. Selective O-phosphitilation with nucleoside phosphoramidite reagents. Nucl. Acids Res. 20:18791882. Guo, M., Yu, D., Iyer, R.P., and Agrawal, S. 1998. Solid-phase stereoselective synthesis of 2′-Omethyl oligoribonucleoside phosphorothioates using nucleoside oxazaphospholidines. Bioorg. Med. Chem. Lett. 8:2539-2544. Hayakawa, Y. and Kataoka, M. 1998. Facile synthesis of oligodeoxyribonucleotides via the phosphoramidite method without nucleoside base protection. J. Am. Chem. Soc. 120:12395-12401. Hayakawa, Y., Uchiyama, M., and Noyori, R. 1986. Nonaqueous oxidation of nucleoside phosphites to the phosphates. Tetrahedron Lett. 27:41914194. Hayakawa, Y., Kataoka, M., and Noyori, R. 1996. Benzimidazolium triflate as an efficient promoter for nucleotide synthesis via the phosphoramidite method. J. Org. Chem. 61:79967997. Hering, G., Stöcklein-Schneiderwind, R., Ugi, I., Pathak, T., Balgobin, N., and Chattopadhyaya, J. 1985. Preparation and properties of chloroN,N-dialkylamino-2,2,2-trichloroethoxy- and chloro-N,N-dialkylamino-2,2,2-trichloro-1,1dimethylethoxyphosphines and their deoxynucleoside phosphiteamidates. Nucleosides Nucleotides 4:169-171. Iyer, R.P., Phillips, L.R., Egan, W., Regan, J.B., and Beaucage, S.L. 1990. The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagent. J. Org. Chem. 55:46934698. Iyer, R.P., Yu, D., Habus, I., Ho, N.-H., Johnson, S., Devlin, T., Jiang, Z., Zhou, W., Xie, J., and Agrawal, S. 1997. N-Pent-4-enoyl (PNT) group as a universal nucleobase protector: Applications in the rapid and facile synthesis of oligonucleotides, analogs, and conjugates. Tetrahedron 53:2731-2750. Iyer, R.P., Guo, M.-J., Yu, D., and Agrawal, S. 1998. Solid-phase stereoselective synthesis of oligonucleoside phosphorothioates: The nucleoside bicyclic oxazaphospholidines as novel synthons. Tetrahedron Lett. 39:2491-2494. Iyer, R.P., Roland, A., Zhou, W., and Ghosh, K. 1999. Modified oligonucleotides—Synthesis, properties and applications. Curr. Opin. Mol. Ther. 1:344-358. Jørgensen, P.N., Stein, P.C., and Wengel, J. 1994. Synthesis of 3′-C-(hydroxymethyl) thymidine: Introduction of a novel class of dexoynucleosides and oligodeoxynucleotides. J. Am. Chem. Soc. 116:2231-2232. Josephson, S., Lagerholm, E., and Palm, G. 1984. Automatic synthesis of oligodeoxynucleotides and mixed oligodeoxynucleotides using the phosphoramidite method. Acta Chem. Scand. B38:539-545.
Kamer, P.C.J., Roelen, H.C.P.F., van den Elst, H., van der Marel, G.A., and van Boom, J.H. 1989. An efficient approach toward the synthesis of phosphorothioate diesters via the Schönberg reaction. Tetrahedron Lett. 30:6757-6760. Kayushin, A.L., Korosteleva, M.D., Miroshnikov, A.I., Kosch, W., Zubov, D., and Piel, N. 1996. A convenient approach to the synthesis of trinucleotide phosphoramidites—Synthons for the generation of oligonucleotide/peptide libraries. Nucl. Acids Res. 24:3748-3755. Khorana, H.G. 1968. Nucleic acid synthesis. Pure Appl. Chem. 17:349-381. Kierzek, R., Rozek, M., and Markiewicz, W.T. 1987. Some steric aspects of synthesis of oligoribonucleotides by phosphoramidite approach on solid support. Nucl. Acids Res. Symp. Ser. No. 18:201204. Kofoed, T. and Caruthers, M.H. 1996. Synthesis of 5′-phosphonate linked thymidine deoxyoligonucleotides. Tetrahedron Lett. 37:6457-6460. Krotz, A.H., Klopchin, P.G., Walker, K.L., Srivatsa, G.S., Cole, D.L., and Ravikumar, V.T. 1997a. On the formation of longmers in phosphorothioate oligodeoxyribonucleotide synthesis. Tetrahedron Lett. 38:3875-3878. Krotz, A.H., Klopchin, P., Cole, D.L., and Ravikumar, V.T. 1997b. Improved purity profile of phosphorothioate oligonucleotides through the use of dimeric phosphoramidite synthons. Nucleosides Nucleotides 16:1637-1640. Kuijpers, W.H.A., Huskens, J., and van Boeckel, C.A.A. 1990. The 2-(acetoxymethyl)benzoyl (AMB) group as a new base-protecting group, designed for the protection of (phosphate) modified oligonucleotides. Tetrahedron Lett. 31:6729-6732. Kumar, G. and Poonian, M.S. 1984. Improvements in oligodeoxyribonucleotide synthesis: Methyl N,N-dialkylphosphoramidite dimer units for solid support phosphite methodology. J. Org. Chem. 49:4905-4912. Lee, H.-J. and Moon, S.-H. 1984. Bis-(N,N-dialkylamino)-alkoxyphosphines as a new class of phosphite coupling agent for the synthesis of oligonucleotides. Chem. Lett. 1229-1232. Letsinger, R.L. and Lunsford, W.B. 1976. Synthesis of thymidine oligonucleotides by phosphite triester intermediates. J. Am. Chem. Soc. 98:36553661. Letsinger, R.L. and Mahadevan, V. 1966. Stepwise synthesis of oligodeoxyribonucleotides on an insoluble polymer support. J. Am. Chem. Soc. 88:5319-5324. Letsinger, R.L. and Ogilvie, K.K. 1969. Synthesis of oligothymidylates via phosphotriester intermediates. J. Am. Chem. Soc. 91:3350-3355. Lyttle, M.H., Napolitano, E.W., Calio, B.L., and Kauvar, L.M. 1995. Mutagenesis using trinucleotide β-cyanoethyl phosphoramidites. BioTechniques 19:274-280.
Synthesis of Unmodified Oligonucleotides
3.3.17 Current Protocols in Nucleic Acid Chemistry
Mathis, R., Lafaille, L., and Burgada, R. 1974. Fréquence d’absorption de la liaison P-N dans des composés du phosphore tricoordonné. Spectrochim. Acta, Part A 30:357-370. Matteucci, M.D. and Caruthers, M.H. 1981. Synthesis of deoxyoligonucleotides on a polymer support. J. Am. Chem. Soc. 103:3185-3191. McBride, L.J. and Caruthers, M.H. 1983. An investigation of several deoxynucleoside phosphoramidites useful for synthesizing deoxyoligonucleotides. Tetrahedron Lett. 24:245-248. McBride, L.J., Kierzek, R., Beaucage, S.L., and Caruthers, M.H. 1986. Amidine protecting groups for oligonucleotide synthesis. J. Am. Chem. Soc. 108:2040-2048. Montserrat, F.X., Cerandas, A., Eritja, R., and Pedroso, E. 1994. Criteria for the economic large scale solid-phase synthesis of oligonucleotides. Tetrahedron 50:2617-2622. Moore, M.F. and Beaucage, S.L. 1985. Conceptual basis of the selective activation of bis(dialkylamino)methoxyphosphines by weak acids and its application toward the preparation of deoxynucleoside phosphoramidites in situ. J. Org. Chem. 50:2019-2025. Mullah, B., Andrus, A., Zhao, H., and Jones, R.A. 1995. Oxidative conversion of N-dimethylformamidine nucleosides to N-cyano nucleosides. Tetrahedron Lett. 36:4373-4376. Natt, F. and Häner, R. 1997. Lipocap: A lipophilic phosphoramidite-based capping reagent. Tetrahedron 53:9629-9636. Neuner, P., Cortese, R., and Monaci, P. 1998. Codon-based mutagenesis using dimer-phosphoramidites. Nucl. Acids Res. 26:1223-1227. Nielsen, J. and Caruthers, M.H. 1988. Directed Arbuzov-type reactions of 2-cyano-1,1-dimethylethyl deoxynucleoside phosphites. J. Am. Chem. Soc. 110:6275-6276. Ono, A., Matsuda, A., Zhao, J., and Santi, D.V. 1995. The synthesis of blocked triplet-phosphoramidites and their use in mutagenesis. Nucl. Acids Res. 23:4677-4682. Polushin, N.N. 1996. Synthesis of functionally modified oligonucleotides from methoxyoxalamido precursors. Tetrahedron Lett. 37:32313234. Pon, R.T., Usman, N., Damha, M.J., and Ogilvie, K.K. 1986. Prevention of guanine modification and chain cleavage during the solid phase synthesis of oligonucleotides using phosphoramidite derivatives. Nucl. Acids Res. 14:6453-6470.
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Method
Pon, R.T. 1987. Enhanced coupling efficiency using 4-dimethylamino pyridine (DMAP) and either tetrazole, 5-(o-nitrophenyl) tetrazole or 5-(pnitrophenyl) tetrazole in the solid phase synthesis of oligoribonucleotides by the phosphoramidite procedure. Tetrahedron Lett. 28: 3643-3646.
Rao, M.V. and Macfarlane, K. 1994. Solid phase synthesis of phosphorothioate oligonucleotides using benzyltriethylammonium tetrathiomolybdate as a rapid sulfur transfer reagent. Tetrahedron Lett. 35:6741-6744. Rao, M.V., Reese, C.B., and Zhengyun, Z. 1992. Dibenzoyl tetrasulphide—A rapid sulphur transfer agent in the synthesis of phosphorothioate analogues of oligonucleotides. Tetrahedron Lett. 33:4839-4842. Reddy, M.P., Hanna, N.B., and Farooqui, F. 1994. Fast cleavage and deprotection of oligonucleotides. Tetrahedron Lett. 35:4311-4314. Reddy, M.P., Hanna, N.B., and Farooqui, F. 1997. Ultrafast cleavage and deprotection of oligonucleotides—Synthesis and use of CAc derivatives. Nucleosides Nucleotides 16:1589-1598. Regan, J.B., Phillips, L.R., and Beaucage, S.L. 1992. Large-scale preparation of the sulfurtransfer reagent 3H-1,2-benzodithiol-3-one 1,1dioxide. Org. Prep. Proc. Int. 24:488-492. Roelen, H.C.P.F., Kamer, P.C.J., van den Elst, H., van der Marel, G.A., and van Boom, J.H. 1991. A study on the use of phenylacetyl disulfide in the solid-phase synthesis of oligodeoxynucleoside phosphorothioates. Recl. Trav. Chim. Pays-Bas 110:325-331. Sanghvi, Y.S. and Cook, P.D. 1994. Carbohydrates: Synthetic methods and applications in antisense therapeutics. In ACS Symposium Series 580— Carbohydrate Modifications in Antisense Research (Y.S. Sanghvi and P.D. Cook, eds.) pp. 1-22. American Chemical Society, Washington, D.C. Schulhof, J.C., Molko, D., and Teoule, R. 1987. The final deprotection step in oligonucleotide synthesis is reduced to a mild and rapid ammonia treatment by using labile base-protecting groups. Nucl. Acids Res. 15:397-416. Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., deBear, J.S., and Gough, G.R. 1992. Rapid synthesis of oligoribonucleotides using 2′-O-(o-nitrobenzyloxymethyl)-protected monomers. Bioorg. Med. Chem. Lett. 2:1019-1024. Sekine, M., Masuda, N., and Hata, T. 1986. Synthesis of oligodeoxyribonucleotides involving a rapid procedure for the removal of base-protecting groups by use of the 4,4′,4′′-tris(benzoyloxy)trityl (TBTr) group. Bull. Chem. Soc. Jpn. 59:1781-1789. Seliger, H. and Gupta, K.C. 1985. Three-phase synthesis of oligonucleotides. Angew. Chem. Int. Ed. Engl. 24:685-687. Sinha, N.D., Biernat, J., McManus, J., and Köster, H. 1984. Polymer support oligonucleotide synthesis XVIII: Use of β-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucl. Acids Res. 12:45394557.
3.3.18 Current Protocols in Nucleic Acid Chemistry
Sinha, N.D., Davis, P., Usman, N., Pérez, J., Hodge, R., Kremsky, J., and Casale, R. 1993. Labile exocyclic amine protection of nucleosides in DNA, RNA and oligonucleotide analog synthesis facilitating N-deacylation, minimizing depurination and chain degradation. Biochimie 75:1323. Sondek, J. and Shortle, D. 1992. A general strategy for random insertion and substitution mutagenesis: Substoichiometric coupling of trinucleotide phosphoramidites. Proc. Natl. Acad. Sci. U.S.A. 89:3581-3585. Stec, W.J. and Zon, G. 1984. Stereochemical studies of the formation of chiral internucleotide linkages by phosphoramidite coupling in the synthesis of oligodeoxyribonucleotides. Tetrahedron Lett. 25:5279-5282. Stec, W.J., Uznanski, B., Wilk, A., Hirschbein, B.L., Fearon, K.L., and Bergot, B.J. 1993. Bis(O,O-diisopropoxy phosphinothioyl) disulfide—A highly efficient sulfurizing reagent for cost-effective synthesis of oligo(nucleoside phosphorothioate)s. Tetrahedron Lett. 34:5317-5320. Tanaka, T. and Letsinger, R.L. 1982. Syringe method for the stepwise chemical synthesis of oligonucleotides. Nucl. Acids Res. 10:32493260. Tener, G.M. 1961. 2-Cyanoethyl phosphate and its use in the synthesis of phosphate esters. J. Am. Chem. Soc. 83:159-168. Ugi, I., Jacob, P., Landgraf, B., Rupp, C., Lemmen, P., and Verfürth, U. 1988. Phosphite oxidation and the preparation of five-membered cyclic phosphorylating reagents via the phosphites. Nucleosides Nucleotides 7:605-608. Usman, N., Pon, R.T., and Ogilvie, K.K. 1985. Preparation of ribonucleoside 3′-O-phosphoramidites and their application to the automated solid phase synthesis of oligonucleotides. Tetrahedron Lett. 26:4567-4570. Uznanski, B., Grajkowski, A., and Wilk, A. 1989. The isopropoxyacetic group for convenient base protection during solid-support synthesis of oligodeoxyribonucleotides and their triester analogs. Nucl. Acids Res. 17:4863-4871. Vargeese, C., Carter, J., Yegge, J., Krivjansky, S., Settle, A., Kropp, E., Peterson, K., and Pieken, W. 1998. Efficient activation of nucleoside phosphoramidites with 4,5-dicyanoimidazole during oligonucleotide synthesis. Nucl. Acids Res. 26:1046-1050. Virnekäs, B., Ge, L., Plückthun, A., Schneider, K.C., Wellnhofer, G., and Moroney, S.E. 1994. Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. Nucl. Acids Res. 22:5600-5607. Vu, H. and Hirschbein, B.L. 1991. Internucleotide phosphite sulfurization with tetraethylthiuram disulfide. Phosphorothioate oligonucleotide synthesis via phosphoramidite chemistry. Tetrahedron Lett. 32:3005-3008.
Vu, H., McCollum, C., Jacobson, K., Theisen, P., Vinayak, R., Spiess, E., and Andrus, A. 1990. Fast oligonucleotide deprotection phosphoramidite chemistry for DNA synthesis. Tetrahedron Lett. 31:7269-7272. Weber, H. and Khorana, H.G. 1972. CIV. Total synthesis of the structural gene for an alanine transfer ribonucleic acid from yeast. Chemical synthesis of an icosadeoxynucleotide corresponding to the nucleotide sequence 21 to 40. J. Mol. Biol. 72:219-249. Weiss, P. 1998. TOM-protecting group—A major improvement in RNA synthesis. The Glen Report 11:2-4. Wilk, A., Srinivasachar, K., and Beaucage, S.L. 1997. N-Trifluoroacetylamino alcohols as phosphodiester protecting groups in the synthesis of oligodeoxyribonucleotides. J. Org. Chem. 62:6712-6713. Wincott, F., DiRenzo, A., Shaffer, C., Grimm, S., Tracz, D., Workman, C., Sweedler, D., Gonzalez, C., Scaringe, S., and Usman, N. 1995. Synthesis, deprotection, analysis and purification of RNA and ribosymes. Nucl. Acids Res. 23:2677-2684. Wolter, A., Biernat, J., and Köster, H. 1986. Polymer support oligonucleotide synthesis XX: Synthesis of a henhectacosa deoxynucleotide by use of a dimeric phosphoramidite synthon. Nucleosides Nucleotides 5:65-77. Wu, X. and Pitsch, S. 1998. Synthesis and pairing properties of oligoribonucleotide analogues containing a metal-binding site attached to β-D-allofuranosyl cytosine. Nucl. Acids Res. 26:43154323. Xin, Z. and Just, G. 1996. Diastereoselective synthesis of phosphite triesters. Tetrahedron Lett. 37:969-972. Xu, Q., Barany, G., Hammer, R.P., Musier-Forsyth, K. 1996. Efficient introduction of phosphorothioates into RNA oligonucleotides by 3ethoxy-1,2,4-dithiazoline-5-one (EDITH). Nucl. Acids Res. 24:3643-3644. Yamana, K., Nishijima, Y., Oka, A., Nakano, H., Sangen, O., Ozaki, H., and Shimidzu, T. 1989. A simple preparation of 5′-O-dimethoxytrityl deoxyribonucleoside 3′-O-phosphor-bisdiethylamidites as useful intermediates in the synthesis of oligodeoxyribonucleotides and their phosphorodiethylamidate analogs on a solid support. Tetrahedron 45:4135-4140. Yu, D., Tang, J.-Y., Iyer, R.P., and Agrawal, S. 1994. Diethoxy N,N-diisopropyl phosphoramidite as an improved capping reagent in the synthesis of oligonucleotides using phosphoramidite chemistry. Tetrahedron Lett. 35:8565-8568. Zehl, A., Starke, A., Cech, D., Hartsch, T., Merkl, R., and Fritz, H.-J. 1996. Efficient and flexible access to fully protected trinucleotides suitable for DNA synthesis by automated phosphoramidite chemistry. Chem. Commun. 26772678.
Synthesis of Unmodified Oligonucleotides
3.3.19 Current Protocols in Nucleic Acid Chemistry
Zemlicka, J. and Holy, A. 1967. Preparation of N-dimethylaminomethylene derivatives—A new method of a selective substitution of nucleoside amino groups. Coll. Czech. Chem. Commun. 32:3159-3168. Zhang, Z., Nichols, A., Alsbeti, M., Tang, J.X., and Tang, J.Y. 1998. Solid phase synthesis of oligonucleotide phosphorothioate analogues using bis(ethoxythiocarbonyl)tetrasulfide as a new sulfur-transfer reagent. Tetrahedron Lett. 39:24672470. Zhang, Z., Nichols, A., Tang, J.X., Han, Y., and Tang, J.Y. 1999. Solid phase synthesis of oligonucleotide phosphorothioate analogues using 3methyl-1,2,4-dithiazolin-5-one (MEDITH) as a new sulfur-transfer reagent. Tetrahedron Lett. 40:2095-2098.
Zon, G., Gallo, K.A., Samson, C.J., Shao, K., Summers, M.F., and Byrd, R.A. 1985. Analytical studies of ‘mixed sequence’ oligodeoxyribonucleotides synthesized by competitive coupling of either methyl- or β-cyanoethyl-N,N-diisopropylamino phosphoramidite reagents, including 2′deoxyinosine. Nucl. Acids Res. 13:8181-8196.
Contributed by Serge L. Beaucage Center for Biologics Evaluation and Research Food and Drug Administration Bethesda, Maryland Marvin H. Caruthers University of Colorado Boulder, Colorado
Zhao, Z. and Caruthers, M.H. 1996. Synthesis and preliminary biochemical studies with 5′-deoxy5′-methylidyne phosphonate linked thymidine oligonucleotides. Tetrahedron Lett. 37:62396242.
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Method
3.3.20 Current Protocols in Nucleic Acid Chemistry
Synthesis of Oligodeoxyribo- and Oligoribonucleotides According to the H-Phosphonate Method This protocol outlines a general procedure for the preparation of oligodeoxyribo- and oligoribonucleotides using H-phosphonate monomers. It is followed by an in-depth discussion of the advantages of the H-phosphonate approach as well as its underlying chemistry (see Commentary). The preparation of the H-phosphonate monomers can be achieved by a variety of methods; these are presented in UNIT 2.6.
UNIT 3.4
BASIC PROTOCOL
Oligonucleotide synthesis employing H-phosphonates is considerably simpler than synthesis using the phosphotriester or phosphoramidite procedures. The elongation cycle includes only two chemical steps: deprotection of the terminal 5 -OH function of the support-bound oligonucleotide, and coupling of the 5 -OH with a nucleoside 3 -Hphosphonate in the presence of a condensing agent (Fig. 3.4.1). After completion of the desired number of elongation cycles (i.e., assembly of the oligomeric chain), a single oxidation cycle is performed to convert the internucleoside H-phosphonate functions to phosphodiesters (or some analog, such as phosphorothioates). Finally, the linkage between the oligomer and the support is cleaved under ammonolytic conditions, which is also the final deprotection step for oligodeoxyribonucleotide and oligoribonucleotide synthesis with 2 -O-2-chlorobenzoyl groups (also see UNIT 2.6). Purification by standard methods is then carried out to isolate the oligonucleotides. The synthetic protocol described below was optimized for oligoribonucleotide synthesis with 5 -O-MMTr and 2 -O-TBDMS protection on a modified Gene Assembler (Pharmacia) with a polystyrene support. It also gives good results with 2 -O-alkyl RNA and fairly good results for oligodeoxyribonucleotide synthesis. Controlled-pore glass (CPG) can be used, but has proven to be less reliable in the authors’ experience. The efficiency of each elongation step in solid-phase oligonucleotide synthesis is usually high, but technical aspects of the procedure may have to be adjusted for each particular machine. The most important of these are probably (1) the time of H-phosphonate preactivation before it reaches the solid support, (2) the concentration of the condensing agent, and (3) the proportion of pyridine in the solvent mixture. Some recently introduced condensing agents—e.g., bis(pentafluorophenyl) carbonate (Efimov et al., 1993) and carbonium- and phosphonium-based condensing agents (Wada et al., 1997)—seem to make the condensation less sensitive to these factors. The reaction conditions for the removal of the acid-labile 5 -O-MMTr or 5 -O-DMTr groups (usually 1% to 2% of various haloacetic acids in an anhydrous chlorinated solvent) have been shown not to affect the integrity of the H-phosphonate linkages within a relevant time (Stawinski et al., 1988). The most important factors affecting the condensation and oxidation steps are discussed later (see Commentary).
Materials 1,2-Dichloroethane (DCE; BDH) over 4-Å molecular sieves Trifluoroacetic acid (TFA; Fluka) Dichloroacetic acid (DCA; Lancaster, 99%), distilled Acetonitrile (MeCN; Lab-Scan) over 3-Å molecular sieves Synthesis of Unmodified Oligonucleotides Contributed by Roger Str¨omberg and Jacek Stawinski Current Protocols in Nucleic Acid Chemistry (2004) 3.4.1-3.4.15 C 2004 by John Wiley & Sons, Inc. Copyright
3.4.1 Supplement 19
Figure 3.4.1 Condensation of protected nucleoside H-phosphonate monoester with a nucleoside and conversion to the dinucleoside phosphate or backbone-modified analog.
Pyridine (Py; Lab-Scan, Anhydroscan) over 4-Å molecular sieves Protected nucleoside 3 -H-phosphonate building blocks (triethylammonium salts; see Commentary and UNIT 2.6) Pivaloyl chloride (Pv-Cl; Acros Organics, 99%), freshly distilled Polystyrene support (PE Applied Biosystems) loaded at 20 to 30 µmol/g with a 5 -O-(4,4 -dimethoxytrityl) (DMTr)– or 5 -O-(4-monomethoxytrityl) (MMTr)–protected nucleoside succinate (or equivalent nucleoside-loaded solid support) I2 Diethyl ether Concentrated (28% to 32%) aqueous ammonium hydroxide (NH4 OH) or 3:1 (v/v) concentrated NH4 OH/ethanol Triethylamine trihydrofluoride (for RNA synthesis with 2 -O-TBDMS protection) n-Butanol 20 mM sodium acetate buffer, pH 6.5, containing 30% and 10% MeCN LiClO4 0.1 M triethylammonium acetate (TEAA) buffer, pH 6.5 Automated oligonucleotide synthesizer (Gene Assembler, Pharmacia) 5-mL syringes with Luer lock 1.5-mL cryovials with screw caps Glass sintered funnel of coarse porosity Speedvac evaporator and a vacuum pump C18 cartridge (Waters Sep-Pac) Syringe filters (Millex-GV13 filter, 0.22-µm, 13 mm) and disposable syringes 4 × 250–mm Dionex NucleoPac PA-100 column Lyophilizer 4.6 × 150–mm Supelcosil LC-18 (3 µm) column Additional reagents and equipment for automated oligonucleotide synthesis (APPENDIX 3C) and purification by ion-exchange and reversed-phase HPLC (UNIT 10.5) Synthesis of Oligonucleotides According to the H-Phosphonate Method
3.4.2 Supplement 19
Current Protocols in Nucleic Acid Chemistry
Table 3.4.1 Stepwise Oligonucleotide Synthesis Program
Step
Reagenta
Wash
DCE
Detritylation
Time (min)
Flow rate (mL/min)
2.0
2
1.0
2
2.0
2
3.5% DCA/DCE
2.5
2
DCE
2.0
2
MeCN
1.0
2
3:1 (v/v) MeCN/Py
1.0
2
50 mM phosphonate
0.1
1
225 mM Pv-Cl
0.1
1
50 mM phosphonate
0.1
1
225 mM Pv-Cl
0.1
1
50 mM phosphonate
0.1
1
Pump forward
0.4
1
Pump reverse
1.0
0.5
3:1 (v/v) MeCN/Py
1.0
2
MeCN
1.0
2
For 5 -O-MMTr-RNA or 2 -O-alkyl-RNA: 1% TFA/DCE
For 5 -O-DMTr-DNA: 3.5% DCA/DCE
For mixed 5 -O-MMTr-RNA/2 -O-alkyl-RNA and DNA: Wash
Coupling
Wash Total time per cycle
10.9–12.4
a Abbrevations: DCA, dichloroacetic acid; DCE, 1,2-dichloroethane; DMTr, 4,4 -dimethoxytrityl; MeCN, acetonitrile;
MMTr, 4-methoxytrityl; Pv-Cl, pivaloyl chloride; Py, pyridine; TFA, trifluoroacetic acid.
Prepare reagents 1. Charge the synthesizer with solvents and detritylation solution needed for the steps shown in Table 3.4.1. These can usually be kept on the synthesizer until they are consumed.
2. Dissolve the protected nucleoside 3 -H-phosphonates (triethylammonium salts) in pyridine and evaporate the solvent (two times) under reduced pressure in a rotary evaporator. Use 15 µmol/coupling plus 15 µmol extra for margins and priming of solutions. 3. Dissolve the residue in 3:1 (v/v) MeCN/pyridine to a concentration of 50 mM and transfer to appropriate vessels for attachment to the synthesizer. 4. Prepare a solution of 225 mM pivaloyl chloride in 3:1 (v/v) MeCN/pyridine directly in the vessel that will be used for synthesis. Prepare 0.2 mL/coupling plus 1 to 2 mL extra for margins. Attach the vessel to the synthesizer. 5. Prime the solutions and connect a column/cartridge filled with 0.2 to 1 µmol nucleoside-loaded support. 6. Immediately before the final oxidation step, prepare an iodine solution by dissolving 0.4 g I2 in 20 mL of 98:2 (v/v) pyridine/water.
Synthesis of Unmodified Oligonucleotides
The solution should be prepared no more than 30 min before use.
3.4.3 Current Protocols in Nucleic Acid Chemistry
Supplement 19
Table 3.4.2 Final Oxidation Program
Step
Reagenta
Wash
Time (min)
Flow rate (mL/min)
DCE
2
2
Detritylation
1% TFA/DCE
1
2
Wash
DCE
2
2
MeCN
1
2
Oxidation
2% I2 in 98:2 (v/v) Py/H2 O
30
0.5
Wash
MeCN
10
2
Total time
46
a Abbrevations: DCE, 1,2-dichloroethane; MeCN, acetonitrile; Py, pyridine; TFA, trifluoroacetic acid.
Synthesize oligonucleotide 7. Perform automated oligonucleotide synthesis (APPENDIX 3C) using the synthesis cycle shown in Table 3.4.1, with a final oxidation step as shown in Table 3.4.2. In the coupling step, program the synthesis so that the H-phosphonate and pivaloyl chloride are taken up in alternating 100-µL portions. The volume of the tubing between the valve and the column (including the pump hose of the peristaltic pump, through which the reagents flow) is 0.4 mL, which means that the front of the condensation mixture reaches the column when the last segment is taken up from the reagent bottles. The segments are then passed through the column (0.4 min at 1 mL/min), and then the flow is lowered and the direction reversed (1 min at 0.5 mL/min), giving a total condensation cycle time of 1.9 min, with an effective condensation time of ∼1.5 min. The effective time of preactivation for the nucleoside H-phosphonate when it first reaches the column is ∼0.3 min, for a total of 1.8 min at the end of condensation.
Purify oligonucleotide 8. Remove the cartridge/column from the synthesizer and wash the support with ∼10 mL diethyl ether using a 5-mL syringe with a Luer fitting. 9. Air dry the support using the above 5-mL syringe with a Luer fitting by pushing air through the column a few times. 10. Remove the support from the cartridge and transfer it to a 1.5-mL cryovial (with screw cap). 11. Carry out ammonolysis by adding 3:1 (v/v) concentrated NH4 OH/ethanol (∼1 mL for up to a 1-µmol scale synthesis) and incubating 8 to 16 hr at 20◦ to 25◦ C (8-hr incubations for sequences up to 25-mers; 16-hr incubations for longer sequences, e.g., 50- to 60-mers). The above conditions are for RNA oligomers with N2 -phenoxyacetyl guanosine protection, N6 -butyryl adenosine protection, and N4 -propionyl cytidine protection, which are recommended to avoid cleavage of TBDMS groups (and subsequent cleavage of RNA) upon ammonolysis at elevated temperatures (Stawinski et al., 1988), which is required for more stable base protection. Other reagents and conditions may be needed for other protecting groups. For DNA or for 2 -O-alkyl-RNA, concentrated NH4 OH should be used alone for ∼20 hr at 55◦ to 60◦ C.
12. Filter off the support using a glass sintered funnel of medium porosity. Synthesis of Oligonucleotides According to the H-Phosphonate Method
13. Wash support with 1 mL of 3:1 (v/v) concentrated NH4 OH/ethanol (or concentrated NH4 OH alone) and combine the filtrates. 14. Concentrate the oligonucleotide using a Speedvac evaporator and a vacuum pump.
3.4.4 Supplement 19
Current Protocols in Nucleic Acid Chemistry
15. For RNA synthesis with 2 -O-TBDMS protection, perform deprotection step with triethylamine trihydrofluoride (Westman and Str¨omberg, 1994) using the following steps: a. Dissolve the residue in 0.3 mL neat triethylamine trihydrofluoride and incubate 14 to 16 hr at room temperature. b. Add 30 µL water and 1 mL n-butanol, and incubate 1 hr at –20◦ C. c. Centrifuge and remove the liquid supernatant. Dissolve the pellet in HPLC buffer (see step 16). 16. Purify by ion-exchange and reversed-phase HPLC (UNIT 10.5). a. Dissolve the deprotected oligoribonucleotides in 0.5 mL of 20 mM sodium acetate buffer, pH 6.5, containing 30% MeCN and filter through a disposable C18 cartridge. b. Wash the cartridge with 1 mL of buffer, then combine fractions and filter through a disposable syringe attached to a 0.22-µm filter before HPLC purification. c. Purify by anion-exchange HPLC on a 4 × 250–mm Dionex NucleoPac PA-100 column using a linear gradient of LiClO4 in 20 mM sodium acetate buffer, pH 6.5, containing 10% MeCN at a flow rate of 1 mL/min. For analysis, inject 0.2 OD260 units; for purification, inject 15 to 30 OD260 units of crude oligoribonucleotides. d. Lyophilize the collected fractions, dissolve in 1 mL of 0.1 M triethylammonium acetate (TEAA) buffer, pH 6.5, and filter through a disposable syringe attached to a 0.22-µm filter. e. Further purify by reversed-phase HPLC on a 4.6 × 150–mm Supelcosil LC-18 column using a linear gradient of MeCN in 0.1 M TEAA buffer, pH 6.5, at a flow rate of 1 mL/min. f. Collect the fractions containing the product, lyophilize, dissolve in 1 mL water, and lyophilize again.
COMMENTARY Background Information General information and synthetic strategies Although the most common method today for synthesis of oligonucleotides and their analogs is the phosphoramidite approach (Beaucage and Iyer, 1993, see also UNIT 3.3), the newer H-phosphonate methodology can often be a preferred alternative (Garegg et al., 1985, 1986a,b,c; Froehler and Matteucci, 1986; Froehler et al., 1986). The use of H-phosphonates in nucleotide synthesis was pioneered by Sir Todd’s group in Cambridge, UK, who in 1952 demonstrated the formation of H-phosphonate diesters in a condensation reaction of H-phosphonate monoesters with a protected nucleoside, promoted by diphenyl phosphorochloridate (Corby et al., 1952; Hall et al., 1957). This chemical principle was, however, not explored further; it was rediscovered three decades later (Garegg et al., 1985, 1986c) and explored for oligonu-
cleotide synthesis (Froehler and Matteucci, 1986; Froehler et al., 1986; Garegg et al., 1986a,b,c, 1987a). The method consists of condensing a protected nucleoside H-phosphonate monoester (UNIT 2.6) with a nucleoside in the presence of a coupling agent to produce the corresponding dinucleoside H-phosphonate diester. This, under various experimental conditions, can be converted to the dinucleoside phosphate or to a variety of backbone-modified analogs, e.g., phosphorothioates, phosphoramidates, etc. (Fig. 3.4.1). The condensation step of the elongation cycles (i.e., the formation of an internucleoside H-phosphonate linkage between a nucleoside 3 -H-phosphonate monoester and the supportbound 5 -hydroxylic component) is usually carried out in pyridine-acetonitrile mixtures. Out of the various condensing agents initially tested, pivaloyl chloride (Pv-Cl) gave the best results in automated solid-support synthesis
Synthesis of Unmodified Oligonucleotides
3.4.5 Current Protocols in Nucleic Acid Chemistry
Supplement 19
Synthesis of Oligonucleotides According to the H-Phosphonate Method
of oligonucleotides, and it is still the most frequently used reagent. The reaction in pyridine or acetonitrile-pyridine mixtures using 2 to 5 equiv of Pv-Cl is usually fast and goes to completion in <1 min. Nowadays, an array of other condensing agents (see below) is available; these reagents can, in some instances, be superior to Pv-Cl. The H-phosphonate methodology became commercially available (for use in automated synthesizers from Applied Biosystems and Biosearch) soon after the initial reports on oligonucleotide synthesis using this approach were published. The research group at Applied Biosystems also introduced 1adamantanecarbonyl chloride as an alternative to Pv-Cl (Andrus et al., 1988). Although a capping step during oligonucleotide synthesis via H-phosphonate intermediates initially seemed to be superfluous, its incorporation into the synthetic protocol was shown to potentially improve the overall performance of the method. The procedure simply consists of an additional condensation step using isopropyl H-phosphonate after each nucleoside H-phosphonate coupling (Andrus et al., 1988). The use of 2-cyanoethyl Hphosphonate for capping was also reported, although this reagent has the disadvantage of being less accessible. The capping procedure routinely used in the phosphoramidite approach (acylation with acetic anhydride in the presence of nucleophilic catalysts more powerful than pyridine) is not compatible with H-phosphonate chemistry, owing to the occurrence of P-acylation (see below). Since the introduction of the H-phosphonate methodology for synthesis of oligonucleotides, a number of improvements have been introduced. These involve new condensing agents and new reaction conditions. Oligodeoxynucleotide synthesis via H-phosphonates has been scaled up to 10 to 14 µmol using only a few equivalents of monomeric building blocks relative to a support-bound oligomer per condensation (Gaffney and Jones, 1988). The H-phosphonate approach was used in a cartridgebased procedure for simultaneous synthesis of multiple oligodeoxynucleotides (Seliger and R¨osch, 1990). The H-phosphonate methodology has been used in the synthesis of a number of different oligonucleotide analogs, for example, phosphoramidates (Froehler, 1986) and phosphorothioates (Agrawal and Tang, 1990; Stein et al., 1990), including those with all-Rp -linkages (Almer et al., 1996). It has also been used in the synthesis of oligonu-
cleotides bearing modified heterocyclic bases (Ramzaeva et al., 1997; Seela and Wei, 1997). One particularly interesting feature of oligonucleotide synthesis when using the Hphosphonate methodology is that it can be performed without protection of the nucleobases (Kung and Jones, 1992; Wada et al., 1997; UNIT 3.10). RNA synthesis is perhaps where the advantages of the H-phosphonate approach are most apparent. In the first report, the t-butyldimethylsilyl (TBDMS) group was used for protection of the 2 -OH and the protocol was similar to that described for DNA synthesis (Garegg et al., 1986a,b). A number of subsequent reports have differed in the choice of 2 -OH protection (see UNITS 2.2 and 3.5). These include the use of photolabile groups (e.g., o-nitrobenzyl; Tanaka et al., 1987), acid-sensitive groups (such as 1-(2chloro-4-methylphenyl)-4-methoxypiperidin4-yl; Ctmp; Sakatsume et al., 1989), and base-labile benzoyl derivatives (Rozners et al., 1988, 1990, 1992). The H-phosphonate approach seems to be even more suited for RNA than for DNA synthesis. Potential problems such as double activation (i.e., the bis-acyl phosphite formation) and P-acylation are significantly suppressed when using ribonucleoside Hphosphonates (Stawinski et al., 1991b). The condensation reaction is virtually as fast as for DNA synthesis and at least as efficient, even with bulky 2 -O-protection. Synthesis of oligoribonucleotides of up to 50 to 60 nucleotide residues in length is readily achieved (Agrawal and Tang, 1990; Rozners et al., 1998), and the deprotection steps have been adjusted to more base-labile N-protection that gives better performance (Rozners et al., 1998). The most common choice for 2 -OH protection in oligoribonucleotide synthesis is the TBDMS group (see UNIT 3.5). Studies on the stability of this group under the reaction conditions used for removal of N-acyl groups have been carried out (Stawinski et al., 1988; Wu and Ogilvie, 1990). A conclusion (relevant not only to the H-phosphonate approach) was that synthesis of longer RNA oligonucleotides with 2 -O-TBDMS protection would benefit from the use of more labile N-acylprotecting groups for the heterocyclic base moieties. These were later duly introduced to the synthesis of oligoribonucleotides, both by the phosphoramidite approach (Wu and Ogilvie, 1988; Chaix et al., 1989) and the H-phosphonate method (Westman et al. 1993, 1994; Rozners et al., 1998).
3.4.6 Supplement 19
Current Protocols in Nucleic Acid Chemistry
Although Pv-Cl (Froehler et al., 1986; Garegg et al., 1986a) and perhaps adamantane carbonyl chloride (Andrus et al., 1988) are the most popular condensing agents used in solidphase synthesis of oligonucleotides via the H-phosphonate approach, several others that may be considered for different applications have also been evaluated. These include various pivalic (Str¨omberg and Stawinski, 1987) or other carboxylic acid derivatives (J¨ager et al., 1987), diphenyl phosphorochloridate (Hall et al., 1957; Garegg et al., 1985), 2-chloro5,5-dimethyl-2-oxo-1,3,2-dioxaphosphinane (Str¨omberg and Stawinski, 1987), bis(2oxo-3-oxazolidinyl)phosphinic chloride (Str¨omberg and Stawinski, 1987), various dialkyl phosphorochloridates (Str¨omberg and Stawinski, 1987; Stawinski et al., 1988), arene sulfonic acid derivatives (Garegg et al., 1985; J¨ager et al., 1987; Dan’kov et al., 1988), 1,3-dimethyl-2-chloro-imidazolium
chloride (Sakatsume et al., 1989, 1990), bis(pentafluorophenyl)carbonate (Efimov et al., 1993), and a number of carbonium and phosphonium derivatives (Wada et al., 1997). Parameters of the underlying chemistry Activation of H-phosphonate monoesters The formation of an internucleoside linkage by the H-phosphonate approach, using acyl chlorides, proceeds via a mixed phosphonocarboxylic anhydride that reacts with the nucleosidic component to produce an Hphosphonate diester (Garegg et al., 1987c; Fig. 3.4.2). The order in which the reactants are added in solution synthesis with near equimolar amounts of phosphonate and nucleoside was found to be important for the efficiency of H-phosphonate diester formation (Garegg et al., 1985, 1986c). The coupling reaction is virtually quantitative when the condensing
Figure 3.4.2 Activation of H-phosphonate monoesters. R1 = protected nucleoside-3 -yl; R2 = protected nucleoside-5 -yl.
Synthesis of Unmodified Oligonucleotides
3.4.7 Current Protocols in Nucleic Acid Chemistry
Supplement 19
Synthesis of Oligonucleotides According to the H-Phosphonate Method
agent is added to a solution containing both the alcohol and the H-phosphonate monoester. If, on the other hand, the H-phosphonate is preactivated with a condensing agent before the addition of an alcohol, the reaction is considerably less efficient. This phenomenon was investigated and traced back to the further activation of the initially formed intermediates in the absence of an alcohol (Garegg et al., 1987c,d,e). Irrespective of the condensing agent used, tricoordinated phosphite derivatives were formed; upon reaction with an alcohol, these species (the chemical nature of which depends on the coupling agent used) always gave various unwanted products in addition to the H-phosphonate diesters. Preactivation of H-phosphonate monoesters with acyl chlorides produces bis-acyl phosphites (Garegg et al., 1987c). The consequence of such preactivation is that, in solution synthesis with near equimolar amounts of H-phosphonate and alcohol, formation of phosphite triesters is unavoidable (at least to some extent). It is quite clear that such species must also be formed to some extent when the condensing agent and H-phosphonate are mixed before entering the column in a synthesizer. No side products that could arise from this species have so far been detected in solid-phase synthesis products, but it has been shown that too long of a preactivation substantially slows down the coupling reaction, and the competing reaction of alcoholic functions with the condensing agent becomes more pronounced (Gaffney and Jones, 1988). It has also been shown that even if condensation with nucleoside bis-acyl phosphites gave the correct product on a solid support, the reaction of a bis-acyl phosphite with a nucleoside is substantially slower than that of the corresponding H-phosphonate which is postulated to proceed via the mixed phosphono-carboxylic anhydride (shown in Fig. 3.4.2; Garegg et al., 1987c; Efimov and Dubey, 1990). Because an excess of H-phosphonate to alcohol is normally used in solid-phase synthesis, some formation of bis-acyl phosphite is tolerable. It is clear that the preactivation time should be minimized so that the mixture reaching the column has the highest ratio of mixed phosphono-carboxylic anhydride to bis-acyl phosphite as possible. Otherwise, the oligonucleotide synthesis will lose in efficiency. A preactivation time that is too long can probably not be compensated to the full extent by longer condensation time, because competing reactions become more prominent. Apart from minimizing preactivation time, it is
also possible to reduce or change the amount of condensing agent (which is usually used in excess) and control the reaction by varying solvent composition (see below). It is convenient to use enough condensing agent to achieve conditions that are not too moisture sensitive; but over a certain level, additional excess of acyl chloride increases the level of side reactions that may lower the coupling efficiency and overall yield. Particularly noteworthy was the observation that H-phosphonate monoesters when activated in the absence of a base (like pyridine) produce only monoactivated species (Garegg et al., 1987c). Efimov and co-workers found that replacing pyridine by the slightly weaker base quinoline is sufficient to suppress the formation of bis-acyl phosphite and keep its amount <5% to 10% within the period of time necessary for a condensation (Efimov and Dubey, 1990; Efimov et al., 1990). This novel solvent mixture (acetonitrile-quinoline, 4:1 v/v) was used in the synthesis of oligodeoxynucleotides up to 39 units in length (Efimov and Dubey, 1990). Although the replacement of pyridine by quinoline in oligonucleotide synthesis via the H-phosphonate approach offers some advantages, the rate of condensation is usually lower and quinoline gives some side reactions with activated H-phosphonate monoesters (Stawinski et al., 1991a). The influence of base strength on preactivation of ribonucleoside H-phosphonates was examined, and substituted pyridines that were less basic than pyridine itself were found to suppress formation of tricoordinated species (Stawinski et al., 1991b). With these less basic pyridine derivatives, the side reactions observed with quinoline could not be detected. Steric factors are also likely to be important for double activation, because, for example, the formation of tricoordinated species is slower for 2 -O-TBDMS-protected ribonucleoside H-phosphonates than for the corresponding 2 deoxyribo derivatives. Recently, bis(pentafluorophenyl) carbonate (PFPC) was advocated as a condensing agent for H-phosphonate diesters formation (Efimov et al., 1993). The reagent may be as reactive as Pv-Cl in promoting condensations and compares favorably with Pv-Cl in regard to its reactivity toward heterocyclic bases and the 5 hydroxyl function of a nucleosidic component (Efimov et al., 1993). Although the reagent produces double-activated species from Hphosphonate monoesters, these are as reactive as the initially formed monoactivated intermediate. Truncated sequences are claimed to be
3.4.8 Supplement 19
Current Protocols in Nucleic Acid Chemistry
significantly reduced compared to the protocol that uses Pv-Cl as a condensing agent. The utility of the reagent was demonstrated in the synthesis of several oligodeoxyribonucleotides (chain length 22 to 40) and oligonucleotidephospholipid conjugates (Efimov et al., 1993). Competing O-acylation Direct reaction of a condensing agent with hydroxylic functions in competition with the desired coupling reaction is another potential source of inefficiency in oligonucleotide synthesis. The suggestion that capping is important when using the H-phosphonate approach for oligonucleotide synthesis points to a rather low extent of acylation during the condensation step (Andrus et al., 1988; Gaffney and Jones, 1988). Self-capping by the acyl chlorides used for condensation was estimated to account for only ∼10% to 50% of nonphosphonylated hydroxyls (Gaffney and Jones, 1988), which represents 0.1% to 0.5% of an average coupling yield of 99%. When a fourfold excess of H-phosphonate to nucleoside and 5 equiv Pv-Cl were reacted for 1.5 min, however, the total amount of 5 -O-acylation was ∼0.8% (Gaffney and Jones, 1988). The extent of O-acylation depends heavily on reaction conditions, such as ratios and concentrations of reagents, and is likely to be substantially lower when a larger excess of H-phosphonate is used in conjunction with fewer equivalents of Pv-Cl. The authors assert that the most important reason for the occurrence of competing 5 -O-acylation in machine-assisted synthesis is that the condensation is slowed down owing to formation of bis-acyl phosphites (see
Figure 3.4.3
P-acylation side reaction.
above). Acylation of 5 -OH functions has never been observed when the condensation reaction is carried out in solution without preactivation. Minimizing formation of the less reactive tricoordinated species (from preactivation) should result in higher coupling efficiency. Using fewer equivalents of condensing agent relative to H-phosphonate monoester is likely to be the most efficient way to decrease 5 -Oacylation, because it will affect the rate of both O-acylation and bis-acyl phosphite formation. Changes in solvent composition may also be beneficial (e.g., less pyridine). P-acylation Another side reaction that potentially can occur when using acyl chlorides as condensing agents in the H-phosphonate approach to oligonucleotide synthesis is the formation of acylphosphonates (Fig. 3.4.3). When the synthesis of an H-phosphonate diester is carried out with all reactants in solution under standard conditions (approximately equimolar amounts of H-phosphonate and nucleosidic components together with 2 to 3 equiv of coupling agent), the reaction can be quenched long before any P-acylation can be detected. In solid-support oligonucleotide synthesis, however, because of iterative condensation steps, reaction of H-phosphonate functions with the condensing agent could become a problem. Acylphosphonate formation was not detected when H-phosphonate diesters were exposed to 3 to 5 equiv of Pv-Cl in pyridine for 30 min (Regberg et al., 1988). In a study of P-acylation, however, a slow conversion of a di(deoxyribonucleoside) H-phosphonate to the corresponding pivaloylphosphonate went
Synthesis of Unmodified Oligonucleotides
3.4.9 Current Protocols in Nucleic Acid Chemistry
Supplement 19
Synthesis of Oligonucleotides According to the H-Phosphonate Method
to completion in the presence of 5 equiv of PvCl in pyridine-acetonitrile after 15 hr at 20◦ C (Kuyl-Yeheskiely et al., 1986). The P-acylation during a condensation reaction should in principle be less pronounced, owing to the inhibitory effect of pyridinium ions that are formed (Str¨omberg, 1987). In a condensation mixture containing 5 equiv of Pv-Cl (in pyridine-acetonitrile 1:1 v/v), only ∼15% of the produced H-phosphonate diester is pivaloylated in 14 hr (Str¨omberg, 1987). In the presence of bases stronger than pyridine (e.g., N-methylimidazole, triethylamine), the P-acylation is considerably faster (Str¨omberg, 1987). Note, however, that even if P-acylation occurred to some extent during oligonucleotide synthesis, this modification could not be easily carried through to the fully deprotected oligonucleotide. Oligonucleotidic chains bearing acylphosphonate modifications will be cleaved during final deprotection upon treatment with aqueous ammonia, and thus only a decrease in the yield of oligomers with the desired chain length is expected. Reactions of protected ribonucleoside Hphosphonate diesters with Pv-Cl are considerably slower than those of deoxyribonucleoside derivatives (Stawinski et al., 1991b). The presence of a bulky 2 -O-TBDMS-protecting group vicinal to the H-phosphonate linkage in the ribonucleoside derivatives is likely to be one reason for the observed difference. In a typical condensation reaction (5 equiv of Pv-Cl in pyridine-acetonitrile; 1:1 v/v), only a few percent of the produced H-phosphonate diester is pivaloylated within 22 hr (Stawinski et al., 1991b), which corresponds to the time required for 880 standard condensations reactions. As a rough estimate, a 50-residue-long 2 -O-TBDMSoligoribonucleoside H-phosphonate synthesized with 5 equiv of Pv-Cl and 50% pyridineacetonitrile (1:1 v/v) gives truncated sequences (owing to P-acylation and subsequent cleavage) to a level of 0.1%; it is further estimated that decreasing the excess Pv-Cl to 3 equiv in pyridine-acetonitrile (1:3 v/v), would only produce ∼0.025% P-acylation. For oligodeoxyribonucleotide synthesis, the corresponding levels should be roughly 0.9% and 0.2% to 0.3% for a coupling time of 1 min. This suggests that P-acylation could well be responsible for a substantial part of the observation that DNA synthesis with H-phosphonates, in contradistinction to oligoribonucleotide synthesis, is not quite as efficient as with phosphoramidites (when using 5 equiv of PvCl in pyridine-acetonitrile, 1:1 v/v). It seems
clear that oligodeoxyribonucleotide synthesis would benefit even more than oligoribonucleotide synthesis from reducing the excess of coupling agent and pyridine (and possibly the basicity by using a substituted pyridine; see below). In the earlier discussion on preactivation, some advantages connected with using a slightly weaker base than pyridine as a co-solvent during the condensation step were mentioned. Such conditions are also advantageous when considering P-acylation. The extent of this reaction is substantially decreased when quinoline or some substituted pyridines are used instead of pyridine (Stawinski et al., 1991b). In the case of deoxyribonucleoside H-phosphonate diesters, only traces of P-acylation can be detected (31 P NMR) after 22 hr when 5 equiv of Pv-Cl in quinoline-acetonitrile (1:3 v/v) is used. For ribonucleoside H-phosphonate diesters, this side reaction cannot be detected even after 22 hr under the same conditions (Stawinski et al., 1991b). Other potential side reactions Not many studies on the extent of base modification when using the H-phosphonate approach for oligonucleotide synthesis have been reported. Error rates in oligodeoxynucleotides that were produced using the H-phosphonate methodology have been estimated by sequencing (Vasser et al., 1990). The average number of substitutions was found to be 1/1783 bases. These are not necessarily caused by base modification during synthesis, but they at least indicate the maximum level of modification one may anticipate to be present in purified oligomers. Guanosine-containing dinucleoside Hphosphonates have been reported to react with some condensing agents (Regberg et al., 1988). The guanine residue reacts with Pv-Cl to produce a modification (most likely pivaloylation of the lactam function) that is reversed by treatment with ammonia for a much shorter time than that used for the deprotection of oligonucleotides. Because this reaction is also considerably slower than the condensation, protection of the heteroaromatic lactam system in guanine seems to be unnecessary for most applications when using H-phosphonate chemistry. It may, however, be advisable to analyze for base modifications if novel condensing reagents are being used. Some concern has been expressed about the possibility of a partial loss of the 4,4 dimethoxytrityl group from 5 -protected
3.4.10 Supplement 19
Current Protocols in Nucleic Acid Chemistry
H-phosphonates upon standing in vials on automated synthesizers (Froehler et al., 1986; Froehler and Matteucci, 1987). It was estimated that 5 -O-(4,4 -dimethoxytrityl)thymidine H-phosphonate (triethylammonium salt (TEAH+ )) dissolved in pyridine-acetonitrile (1:1 v/v) loses 2% of its 5 -protection within 4 weeks (Froehler and Matteucci, 1987). Assuming a first-order reaction, this would translate to ∼0.05% detritylation per 1000 min. If fresh solutions are prepared before synthesis, this can be considered a measure of the extent to which the loss of 5 -protection could be for the last added nucleotide unit in the synthesis of a 100-mer (assuming a 10-min cycle time). The replacement of TEAH+ by 2,3,4,6,7,8,9,10-octahydropyrimido[1,2a]azeponium (DBUH+ ) salts of nucleoside H-phosphonate monoesters was also claimed to decrease the amount of oligomers with a chain length of n + 1 (Froehler and Matteucci, 1987) owing to suppression of partial detritylation during the condensation step. It is, therefore, conceivable that the loss of the 5 -O-(4-monomethoxytrityl group) frequently used in RNA synthesis should probably be negligible under these conditions. Although the detritylation step has been shown to be completely compatible with H-phosphonate linkages (Stawinski et al., 1988), be aware that using acid-labile 2 -O-protecting groups in H-phosphonate-based oligoribonucleotide synthesis may cause problems (Rozners et al., 1994). These can be alleviated by using the fluoride-labile 2 -O-TBDMS or base-labile 2 -O-(2-chlorobenzoyl) groups. The former group can be recommended for the synthesis of longer oligoribonucleotides, whereas the latter can be selected for shorter fragments, owing to the simplicity and cost of preparation of starting materials. The oxidation step In the phosphoramidite approach, the oxidation step is carried out after each coupling reaction (Beaucage and Caruthers, 1981; Matteucci and Caruthers, 1981; see also UNIT 3.3). It may be feasible to do so via the H-phosphonate method, because the condensation reaction can be accomplished in the presence of phosphodiester functions (F¨oldesi et al., 1989; Gryaznov and Potapov, 1990). Given that H-phosphonate functions remain intact throughout the oligomeric chain assembly, the oxidation reaction can be carried out in a single step upon completion of the synthesis. This can be advantageous for the preparation of
uniformly modified oligonucleotides (e.g., elemental sulfur can produce phosphorothioate oligomers in one step from H-phosphonate oligonucleotides). The final oxidation step in the Hphosphonate method for oligonucleotide synthesis is usually performed using a solution of iodine in aqueous pyridine (Garegg et al., 1986a,b, 1987b) or with iodine-water in the presence of another base (triethylamine, N-methylimidazole; Froehler and Matteucci, 1986; Froehler et al., 1986). Completeness of the oxidation reaction is, of course, important for efficient synthesis of oligonucleotides. Any oligomeric chain containing an H-phosphonate function will be immediately cleaved in the subsequent ammonia treatment step (Hammond, 1962). Incomplete oxidation will produce shorter than expected oligomers, thus reducing the yield of the desired product. An oxidation time of 10 min with 2% iodine in pyridine-water (98:2) seems to be sufficient for solid-phase synthesis of 20-mers (Garegg et al., 1986a,b). Because the oxidation reaction needs to be carried out only once after chain assembly, one can extend the oxidation time (rather than using stronger bases) to ensure complete reaction within a marginal time loss. A longer oxidation time may still be advisable for longer oligonucleotides. Competitive hydrolysis of H-phosphonate diesters during aqueous oxidation may be considered a potential problem. This has not yet been reported, but it may be justified to discuss this issue because H-phosphonate diesters are very unstable under aqueous basic conditions (Nyl´en, 1937; Westheimer et al., 1988). The rate constant (kOH ) for hydroxide-catalyzed oxidation with iodine was reported to be ∼1400 to 4300 times larger than that for hydrolysis of a series of dialkyl H-phosphonates (Nyl´en, 1937, 1938). These values have been used to estimate that an aqueous pyridine solution containing 2% iodine should give no more than ∼5 to 25 ppm H-phosphonate diester cleavage (Stawinski and Str¨omberg, 1993). This suggests that hydrolysis during oxidation is not a serious problem in oligonucleotide synthesis according to the Hphosphonate approach. The rate of oxidation of nucleoside Hphosphonate diesters with iodine-pyridinewater can be increased by including a presilylation step (e.g., treatment with trimethylsilyl chloride) in the synthetic protocol (Hata and Sekine, 1974; Garegg et al., 1987b). This has, however, been used infrequently in oligonucleotide synthesis.
Synthesis of Unmodified Oligonucleotides
3.4.11 Current Protocols in Nucleic Acid Chemistry
Supplement 19
Critical Parameters
Synthesis of Oligonucleotides According to the H-Phosphonate Method
The detritylation step has been shown to be completely compatible with H-phosphonate linkages (Stawinski et al., 1988). However, using acid-labile 2 -O-protecting groups in Hphosphonate-based oligoribonucleotide synthesis may cause problems (Rozners et al., 1994). These problems can be alleviated by using the fluoride-labile 2 -O-TBDMS or baselabile 2 -O-2-chlorobenzoyl groups. The former group can be recommended for the synthesis of longer oligoribonucleotides, while the latter can be a choice for shorter fragments, due to the simplicity and cost of preparing the starting materials. The preactivation time, i.e., contact of a condensing agent with nucleoside 3 -Hphosphonates before they reach the reaction chamber, should be minimized as much as possible, since an extended preactivation time adversely affects rate and efficiency of internucleotide bond formation. The amount of condensing agent and proportion of pyridine in the solvent is also important. It is convenient to use enough condensing agent to obtain conditions that are not too moisture sensitive. Over a certain level, however, excess acyl chloride increases the extent of side reactions that may lower the coupling efficiency and overall yield. The quality of the pivaloyl chloride is important for the outcome of the synthesis. Since the reagent decomposes with time, it should be distilled approximately once a month. The distilled material, divided into a number of smaller vials to avoid too frequent opening and closing of the same bottle, can be safely stored at −18◦ to –20◦ C. The best results are obtained if the reagent solutions are prepared fresh just before the start of oligonucleotide synthesis. This is most beneficial for the pivaloyl chloride solution and the oxidation solution. The latter degrades with time (particularly when a base stronger than pyridine is used in the oxidation solution) and it is recommended that a fresh oxidation solution be used for each synthesis. A shorter oxidation time than that stated in the protocol can be used for shorter oligonucleotides, but since this is only carried out once, the time savings are not significant and a standard time of 30 min that appears to result in complete oxidation (with some margin for 50- to 60-mers) may be best.
Anticipated Results
Since 2 -protected ribonucleoside 3 -Hphosphonates are less susceptible to double
activation with a condensing agent, and diribonucleoside H-phosphonate diesters are more resistant to P-acylation by acyl chlorides used as condensing agent, the H-phosphonate approach is particularly suited for the preparation of oligoribonucleotides. Because oxidation is carried out as a final synthetic step, the Hphosphonate approach can also be a method of choice for the preparation of uniformly modified oligonucleotides. With the reported protocol, one should be able to routinely synthesize oligoribonucleotides of up to ∼50 to 60 residues with high yield when using 5 -MMTr and 2 -O-TBDMS protection (and N4 -propionyl for cytidine, N6 butyryl for adenosine, and N2 -phenoxyacetyl for guanosine). For oligodeoxyribonucleotides, one could expect similar results. When using 2 -O-2-chlorobenzoyl protection, oligoribonucleotides of up to ∼20- to 30-mers can be produced with fairly good yields. Average coupling yields per step are usually 98% to 99+% depending on the building blocks used.
Time Considerations Using the protocol in this unit, the total time for the machine-assisted part of synthesis of a 20-mer and 50-mer RNA is 4 hr 13 min and 9 hr 40 min, respectively. The total time will depend upon protecting groups, linker to support, deprotection conditions, and purification procedures used. The procedure should not be stopped before the oxidation step, because the H-phosphonate linkages are rather labile. One can take a break after oxidation. At that point, the oligonucleotide is more stable than at the corresponding stage in the phosphoramidite method, since phosphodiesters are obtained after this step. The support-bound oligonucleotide can be stored at –20◦ C until the ammonolysis step is carried out to release the oligonucleotide from the support and remove the N-acyl protection.
Literature Cited Agrawal, S. and Tang, J.-Y. 1990. Efficient synthesis of oligoribonucleotide and its phosphorothioate analog using H-phosphonate approach. Tetrahedron Lett. 31:7541-7544. Almer, H., Stawinski, J., and Str¨omberg, R. 1996. Solid support synthesis of all Rpoligoribonucleoside phosphorothioates. Nucl. Acids Res. 24:3811-3820. Andrus, A., Efcavitch, J.W., McBride, L.J., and Giusti, B. 1988. Novel activating and capping reagent for improved hydrogen-phosphonate DNA synthesis. Tetrahedron Lett. 29:861-864.
3.4.12 Supplement 19
Current Protocols in Nucleic Acid Chemistry
Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites—a new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862. Beaucage, S.L. and Iyer, R.P. 1993. The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications. Tetrahedron 49:6123-6194. Chaix, C., Molko, D., and Teoule, R. 1989. The use of labile base protecting groups in oligoribonucleotide synthesis. Tetrahedron Lett. 30:71-74. Corby, N.S., Kenner, G.W., and Todd, A.R. 1952. Nucleotides. Part XVI. Ribonucleoside-5 phosphites. A new method for the preparation of mixed secondary phosphites. J. Chem. Soc. 3669-3675. Dan’kov, Y.V., Batchikova, N.V., Scaptsova, N.V., Besidsky, E.S., and Azhayev, A.V. 1988. H-Phosphonate solid-phase synthesis of oligodeoxyribonucleotides in syringe. Bioorg. Khim. 14:615-620. Efimov, V.A. and Dubey, I.Y. 1990. Modification of the H-phosphonate oligonucleotide synthesis on polymer support. Bioorg. Khim. 16:211-218. Efimov, V.A., Dubey, I.Y., and Chakhmakhcheva, O.G. 1990. NMR study and improvement of Hphosphonate oligonucleotide synthesis. Nucleosides Nucleotides 9:473-477. Efimov, V.A., Kalinkina, A.L., and Chakhmakhcheva, O.G. 1993. Dipentafluorophenyl carbonate–a reagent for the synthesis of oligonucleotides and their conjugates. Nucl. Acids Res. 21:5337-5344. F¨oldesi, A., Balgobin, N., and Chattopadhyaya, J. 1989. Synthesis of a “branched” trinucleotide using the H-phosphonate chemistry. Tetrahedron Lett. 30:881-884. Froehler, B.C. 1986. Deoxynucleoside Hphosphonate diester intermediates in the synthesis of internucleotide phosphate analogs. Tetrahedron Lett. 27:5575-5578. Froehler, B.C. and Matteucci, M.D. 1986. Nucleoside H-phosphonates: Valuable intermediates in the synthesis of deoxyoligonucleotides. Tetrahedron Lett. 27:469-472. Froehler, B.C. and Matteucci, M.D. 1987. The use of nucleoside H-phosphonates in the synthesis of deoxyoligonucleotides. Nucleosides Nucleotides 6:287-291. Froehler, B.C., Ng, P.G., and Matteucci, M.D. 1986. Synthesis of DNA via deoxynucleoside H-phosphonate intermediates. Nucl. Acids Res. 14:5399-5407. Gaffney, B.L. and Jones, R.A. 1988. Large-scale oligonucleotide synthesis by the H-phosphonate method. Tetrahedron Lett. 29:2619-2622. Garegg, P.J., Regberg, T., Stawinski, J., and Str¨omberg, R. 1985. Formation of internucleotidic bond via phosphonate intermediates. Chem. Scr. 25:280-282. Garegg, P.J., Lindh, I., Regberg, T., Stawinski, J., Str¨omberg, R., and Henrichson, C. 1986a. Nucleoside H-phosphonates. III. Chemical
synthesis of oligodeoxyribonucleotides by the hydrogenphosphonate approach. Tetrahedron Lett. 27:4051-4054. Garegg, P.J., Lindh, I., Regberg, T., Stawinski, J., Str¨omberg, R., and Henrichson, C. 1986b. Nucleoside H-phosphonates. IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach. Tetrahedron Lett. 27:4055-4058. Garegg, P.J., Regberg, T., Stawinski, J., and Str¨omberg, R. 1986c. Nucleoside hydrogenphosphonates in oligonucleotide synthesis. Chem. Scr. 26:59-62. Garegg, P.J., Henrichson, C., Lindh, I., Regberg, T., Stawinski, J., and Str¨omberg, R. 1987a. Automated solid phase synthesis of DNA and RNA fragments by the hydrogenphosphonate approach. In Biophosphates and Their Analogs— Synthesis, Structure, Metabolism and Activity (K.S. Bruzik and W.J. Stec, eds.) pp. 93-98. Elsevier/North-Holland, Amsterdam. Garegg, P.J., Regberg, T., Stawinski, J., and Str¨omberg, R. 1987b. Nucleoside Hphosphonates. VII. Studies on the oxidation of nucleoside hydrogenphosphonate esters. J. Chem. Soc. Perkin Trans. I:1269-1273. Garegg, P.J., Regberg, T., Stawinski, J., and Str¨omberg, R. 1987c. Nucleosides H-phosphonates. V. The mechanism of hydrogenphosphonate diester formation using acyl chlorides as coupling agents in oligonucleotide synthesis by the hydrogenphosphonate approach. Nucleosides Nucleotides 6:655662. Garegg, P.J., Stawinski, J., et al. 1987d. Nucleoside H-phosphonates. VI. Reaction of nucleoside hydrogenphosphonates with arenesulfonyl chlorides. J. Chem. Soc. Perkin Trans. II:12091214. Garegg, P.J., Stawinski, J., and Str¨omberg, R. 1987e. Nucleoside H-phosphonates. VIII. activation of hydrogenphosphonate monoesters by chlorophosphates and aryl sulfonyl derivatives. J. Org. Chem. 52:284-287. Gryaznov, S.M. and Potapov, V.K. 1990. New approach in synthesis of natural and modified oligodeoxyribonucleotides by H-phosphonate method. Bioorg. Khim. 16:1419-1422. Hall, R.H., Todd, A., and Webb, R.F. 1957. Nucleotides. Part XLI. Mixed anhydrides as intermediates in the synthesis of dinucleoside phosphates. J. Chem. Soc. 3291-3296. Hammond, P.R. 1962. A simple preparation of alkyl ammonium phosphonates and some comments on the reaction. J. Chem. Soc. 2521-2522. Hata, T. and Sekine, M. 1974. Silyl phosphites. I. The reaction of silyl phosphites with diphenyl disulphides. Synthesis of S-phenyl nucleoside phosphorothioates. J. Am. Chem. Soc. 96:73637364. J¨ager, A., Charubala, R., and Pfleiderer, W. 1987. Synthesis and characterization of deoxy and ribo H-phosphonate dimers. Nucl. Acids Symp. Ser. 18:197-200.
Synthesis of Unmodified Oligonucleotides
3.4.13 Current Protocols in Nucleic Acid Chemistry
Supplement 19
Kung, P.-P. and Jones, R.A. 1992. H- phosphonate DNA synthesis without amino protection. Tetrahedron Lett. 33:5869-5872. Kuyl-Yeheskiely, E., Spierenberg, M., van den Elst, H., Tromp, M., van der Marel, G.A., and van Boom, J.H. 1986. Reaction of pivaloyl chloride with internucleosidic H-phosphonate diesters. Recl. Trav. Chim. Pays-Bas 105:505-506. Matteucci, M.D. and Caruthers, M.H. 1981. Synthesis of deoxyoligonucleotides on a polymer support. J. Am. Chem. Soc. 103:3185-3191. Nyl´en, P. 1937. Die Kinetik der Verseifung von Dialkylphosphiten. II. Allgemeine S¨aureund Basekatalyse bei der Hydrolyse von Di¨athylphosphit. Svensk Kem. Tidskr. 49:7996. Nyl´en, P. 1938. Die S¨aure- und Basekatalyse bei der Reaktion zwischen Dialkylphosphiten und Jod. Z. Anorg. Allg. Chem. 235:161-182. Ramzaeva, N., Mittelbach, C., and Seela, F. 1997. 7deazaguanine DNA: Oligonucleotides with hydrophobic or cationic side chains. Helv. Chim. Acta 80:1809-1822. Regberg, T., Stawinski, J., and Str¨omberg, R. 1988. Nucleoside H-phosphonates. IX. Possible sidereactions during hydrogenphosphonate diester formation. Nucleosides Nucleotides 7:23-35. Rozners, E., Kumpins, V., Rekis, A., and Bizdena, E. 1988. Solid phase synthesis of oligoribonucleotides by the H-phosphonate method using 2 -O-benzoyl protective group. Bioorg. Khim. 14:1580-1582. Rozners, E., Rekis, A., Kumpins, V., and Bizdena, E. 1990. Synthesis of oligoribonucleotides by the H-phosphonate method using base-labile 2 O-protecting groups. II. Some aspects of use of 2 -O-benzoyl and anisoyl protecting groups. Bioorg. Khim. 16:1531-1536. Rozners, E., Renhofa, R., Petrova, M., Popelis, J., Kumpins, V., and Bizdena, E. 1992. Synthesis of oligoribonucleotides by the H-phosphonate approach using base labile 2 -O-protecting groups. 5. Recent progress in development of the method. Nucleosides Nucleotides 11:15791593. Rozners, E., Westman, E., and Str¨omberg, R. 1994. Evaluation of 2 -hydroxyl protection in RNAsynthesis using the H-phosphonate approach. Nucl. Acids Res. 22:94-99. Rozners, E., Westman, E., Stawinski, J., Garegg, P.J., Bizdena, E., and Str¨omberg, R. 1998. Oligoribonucleotide synthesis with H-phosphonates. An improved procedure with base labile N-acyl protection and two alternative 2 -O-protecting groups. Manuscript in preparation.
Synthesis of Oligonucleotides According to the H-Phosphonate Method
Sakatsume, O., Ohtsuka, M., Takaku, H., and Reese, C.B. 1989. Solid phase synthesis of oligoribonucleotides using the 1-[2-chloro4-methyl)phenyl]-4-methoxypiperidin-4-yl (Ctmp) group for the protection of the 2 hydroxy functions and the H-phosphonate approach. Nucl. Acids Res. 17:3689-3696. Sakatsume, O., Yamane, H., Takaku, H., and Yamamoto, N. 1990. Use of new phospho-
nylating and coupling agents in the synthesis of oligodeoxyribonucleotides via the H-phosphonate approach. Nucl. Acids Res. 18:3327-3331. Seela, F. and Wei, C.F. 1997. 7-Deazaisoguanine quartets: Self-assembled oligonucleotides lacking the Hoogsteen motif. Chem. Commun. 18691870. Seliger, H. and R¨osch, R. 1990. Simultaneous synthesis of multiple oligonucleotides using nucleoside H-phosphonate intermediates. DNA Cell Biol. 9:691-696. Stawinski, J. and Str¨omberg, R. 1993. Hphosphonates in oligonucleotide synthesis. Trends Org. Chem. 4:31-67. Stawinski, J., Str¨omberg, R., Thelin, M., and Westman, E. 1988. Studies on the tbutyldimethylsilyl group as 2 -O-protection in oligoribonucleotide synthesis via the H-phosphonate approach. Nucl. Acids Res. 16:9285-9298. Stawinski, J., Str¨omberg, R., and Westman, E. 1991a. Ribonucleoside H-phosphonates. Pyridine vs quinoline–influence on condensation rate. Nucleosides Nucleotides 10:519520. Stawinski, J., Str¨omberg, R., and Westman, E. 1991b. Studies on reaction conditions for ribonucleotide synthesis via the H-phosphonate approach. Nucl. Acids Symp. Ser. 24:228. Stein, A., Iversen, P.L., Subasinghe, C., Cohen, J.S., Stec, W.J., and Zon, G. 1990. Preparation of 35 S-labelled polyphosphorothioate oligodeoxyribonucleotides by use of hydrogenphosphonate chemistry. Anal. Biochem. 188:11-16. Str¨omberg, R. 1987. Nucleoside H-phosphonates. Chemical studies directed towards oligonucleotide synthesis. Chem. Commun. Stockholm Univ. 1:1-54. Str¨omberg, R. and Stawinski, J. 1987. Evaluation of some new condensing reagents for hydrogenphosphonate diester formation. Nucl. Acids Symp. Ser. 18:185-188. Tanaka, T., Tamatsukuri, S., and Ikehara, M. 1987. Solid phase synthesis of oligoribonucleotides using the o-nitrobenzyl group for 2 -hydroxyl protection and H-phosphonate chemistry. Nucl. Acids Res. 15:7235-7248. Vasser, M., Ng, P.G., Jhurani, P., and Bischofberger, N. 1990. Error rates in oligodeoxynucleotides synthesized by the H-phosphonate method. Nucl. Acids Res. 18:3089. Wada, T., Sato, Y., Honda, F., Kawahara, S., and Sekine, M. 1997. Chemical synthesis of oligodeoxyribonucleotides using N-unprotected H-phosphonate monomers and carbonium and phosphonium condensing reagents: O-Selective phosphonylation and condensation. J. Am. Chem. Soc. 119:12710-12721. Westheimer, F.H., Huang, S., and Covitz, F. 1988. Rates and mechanisms of hydrolysis of esters of phosphorous acid. J. Am. Chem. Soc. 110:181185.
3.4.14 Supplement 19
Current Protocols in Nucleic Acid Chemistry
Westman, E. and Str¨omberg, R. 1994. Removal of tbutyldimethylsilyl protection in RNA-synthesis. Triethylamine trihydrofluoride (TEA, 3HF) is a more reliable alternative to tetrabutylammonium fluoride (TBAF). Nucl. Acids Res. 22:24302431. Westman, E., Stawinski, J., and Str¨omberg, R. 1993. RNA-synthesis using H-phosphonates. Synchronizing 2 -OH and N-protection. Collect. Czech. Chem. Commun. 58:236-237. Westman, E., Sigurdsson, S., Stawinski, J., and Str¨omberg, R. 1994. Improving the Hphosphonate approach to oligoribonucleotide synthesis. Nucl. Acids Symp. Ser. 31:25.
Wu, T. and Ogilvie, K.K. 1990. A study on the alkylsilyl groups in oligoribonucleotide synthesis. J. Org. Chem. 55:4717-4724.
Contributed by Roger Str¨omberg Karolinska Institute Stockholm, Sweden Jacek Stawinski Stockholm University Stockholm, Sweden
Wu, T. and Ogilvie, K.K. 1988. NPhenoxyacetylated guanosine and adenosine phosphoramidites in the solid phase synthesis of oligoribonucleotides: synthesis of a ribozyme sequence. Tetrahedron Lett. 29:4249-4251.
Synthesis of Unmodified Oligonucleotides
3.4.15 Current Protocols in Nucleic Acid Chemistry
Supplement 19
Strategies for Oligoribonucleotide Synthesis According to the Phosphoramidite Method Research in the many roles of ribonucleic acids was hindered by limited means of producing such biologically relevant molecules (Gold, 1988; Francklyn and Schimmel, 1989; Cook et al., 1991; Cech, 1992). Although enzymatic methods existed, protocols that allowed one to probe structure-function relationships were limited. Only uniform postsynthetic chemical modification (Karaoglu and Thurlow, 1991) or site-directed mutagenesis (Johnson and Benkovic, 1990) was available. In the latter case, researchers were limited to use of natural bases. Fortunately, adaptation of the phosphoramidite protocol for DNA synthesis to RNA synthesis has greatly accelerated our understanding of RNA. Site-specific introduction of modified nucleotides to any position in a given RNA has now become routine. Furthermore, one is not confined to a single modification but can include many variations in each molecule. It is seemingly out of proportion that one small structural modification could cause such a dilemma; however, the presence of a single hydroxyl at the 2′-position of the ribofuranose ring has been the major reason that research in the RNA field has lagged so far behind comparable DNA studies. Progress has been made in improving methods for DNA synthesis that have enabled the production of large amounts of antisense deoxyoligonucleotides for structural and therapeutic applications. Only recently have similar gains been achieved for ribonucleotides (Sproat et al., 1995; Wincott et al., 1995; Vargeese et al., 1998). The chasm between DNA and RNA synthesis is the result of the difficulty of identifying orthogonal protecting groups for the 5′- and 2′-hydroxyls. Historically, two standard approaches were taken by scientists attempting to solve the RNA synthesis problem: (1) developing a method that is compatible with state-ofthe-art DNA synthesis and (2) designing an approach specifically suited for RNA. Although adaptation of the DNA process provides a more universal procedure in which non-RNA amidites can easily be incorporated into RNA oligomers, the advantage to the latter approach is that one can develop a process that is best for RNA synthesis, allowing better yields to be realized. In both cases, however, similar issues are faced; for example identifying protecting
UNIT 3.5
groups that are compatible with synthesis conditions and yet can be removed at the appropriate juncture. This problem refers not only to the 2′- and 5′-OH groups but also to the base- and phosphate-protecting groups. Consequently, the accompanying deprotection steps, in addition to the choice of ancillary agents, are affected. Another shared issue is the need for efficient synthesis of the monomer building blocks.
BASIC CHEMISTRY OF OLIGORIBONUCLEOTIDE SYNTHESIS Solid-phase synthesis of oligoribonucleotides follows the same pathway as DNA synthesis (UNIT 3.3). A solid support with an attached nucleoside is subjected to removal of the protecting group on the 5′-hydroxyl. The incoming amidite is coupled to the growing chain in the presence of an activator. Any unreacted 5′-hydroxyl is capped, and the phosphite triester is then oxidized to provide the desired phosphotriester linkage. The process is then repeated until an oligomer of the desired length results. The actual reagents used may vary according to the 5′- and 2′-protecting groups. Other ancillary reagents may also differ. Once the oligoribonucleotide has been synthesized, it must then be deprotected. This is typically a two-step process that entails cleavage of the oligomer from the support and deprotection of the base- and phosphate-blocking groups, followed by removal of the 2′-protecting groups. Occasionally, a different order of reactions or separate deprotection of the phosphate groups is required. In all cases, it is imperative that indiscriminate removal of protecting groups not occur; this is particularly an issue in the classic situation wherein the first step is base mediated. In this case, if the 2′-hydroxyl is revealed under these conditions, strand scission will result because of attack of the vicinal hydroxyl group on the neighboring phosphate backbone (UNIT 2.2). Two other concerns that are prevalent in RNA synthesis but play no part in DNA synthesis are the propensity for (3′→2′)-phosphodiester migration to provide undesired (2′→5′)-linkages and the susceptibility of oligoribonucleotides to degradation by ribonucleases. The latter fact has led many researchers to develop 2′-protecting
Contributed by Francine E. Wincott Current Protocols in Nucleic Acid Chemistry (2000) 3.5.1-3.5.12 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Unmodified Oligonucleotides
3.5.1
groups that can remain in place until the oligomer is required for the desired experiment. Obviously, the parameters of 2′-deprotection are dictated by the protecting groups used; they will be discussed in the appropriate sections.
SOLID SUPPORTS As in DNA synthesis, the solid-phase synthesis of RNA by the phosphoramidite approach requires that one start with a solid support that is functionalized with the appropriate nucleoside corresponding to the 3′-end of the desired oligoribonucleotide. Typically, the nucleoside is attached to the support through a succinate linkage that is cleaved under alkaline conditions at the end of the synthesis (UNITS 3.1 & 3.2). Controlled-pore glass (CPG; Pon et al., 1988; Damha et al., 1990) and polystyrene (McCollum and Andrus, 1991) are the most commonly used solid supports for the synthesis of RNA. There have been reports that polystyrene resins are optimal for the synthesis of RNA on small scales, <50 µmol (Sproat et al., 1995; Wincott et al., 1995); however, recent literature describes excellent syntheses of RNA on CPG on scales of ≥100 µmol (Vargeese et al., 1998). In both cases, the best results are obtained with loadings of ∼30 µmol/g.
ACTIVATION OF RIBONUCLEOSIDE PHOSPHORAMIDITES
Strategies for Oligoribonucleotide Synthesis According to the Phosphoramidite Method
A drawback to solid-phase RNA synthesis has been the coupling step. (See Fig. 3.5.1 for the activators discussed below.) An activator reacts with the incoming amidite to produce a reactive electrophilic intermediate that is attacked by the 5′-hydroxyl of the growing polymer chain. Because of the usually bulky 2′-protecting group, coupling reactions between ribonucleoside phosphoramidites are typically sluggish. Reaction times of as much as 1 hr have been reported, although incubation times of anywhere from 10 to 30 min have usually been achieved with 1H-tetrazole (S.1) as the activator (Usman et al., 1987; Scaringe et al., 1990). This is in contrast to the extremely short coupling times required for DNA, typically on the order of 30 sec. Furthermore, coupling is usually not as efficient as observed with DNA, average stepwise yields (ASY) of 97% are common, whereas ASY of 99% are regularly achieved with DNA. Changes in concentration and/or coupling time result only in additional side products, not increased coupling yields. Recently the use of substituted 1H-tetrazoles (Leiber and Enkoju, 1961) as activators
for DNA and RNA synthesis was reported (Andrus et al., 1986; Vinayak et al., 1994). 5Ethylthio-1H-tetrazole (S.2) was found to be a more effective activator than 1H-tetrazole because of its higher solubility in acetonitrile and greater acidity (Sproat et al., 1995; Wincott et al., 1995). There are also a number of reports of the use of 5-(3-nitrophenyl)-1H-tetrazole (S.3) as an effective activator for RNA synthesis. Coupling times as short as 6 min have been reported (Rao et al., 1993). Two additional activators were recently described in the literature: 4,5-dicyanoimidazole (S.4; Vargeese et al., 1998) and benzimidazolium triflate (S.5; Hayakawa et al., 1996). These reagents rely on increased nucleophilicity to enhance the rate of the coupling reaction without increasing acidity. It should also be emphasized that choosing the appropriate protecting groups is the key to successful oligoribonucleotide synthesis. Although the 2′- and 5′-protecting groups will be discussed in depth, one cannot ignore the importance of the base- and phosphate-blocking groups. The interplay between the protecting groups is crucial. Some base- and phosphateblocking groups are not stable to the conditions required for the repetitive removal of the 5′blocking group during each nucleotide addition cycle. In other cases, the protecting group may not be stable to the conditions required to produce the monomers. Specific cases will be discussed in this unit; however, generic protection strategies are delineated below.
NUCLEOBASE-PROTECTING GROUPS Standard DNA nucleobase-protecting groups (benzoyl for A and C and isobutyryl for G) can be easily removed by treatment with
H N N N N
X
1, X = H 2, X = S-CH2CH3
NC N NC
N H 4
NO2
H N N N N 3
H N N+ H
CF3SO3
5
Figure 3.5.1 Activators commonly used for the synthesis of oligoribonucleotides.
3.5.2 Current Protocols in Nucleic Acid Chemistry
concentrated NH4OH. Many of the 2′-protecting groups used in RNA synthesis, however, are unstable to this harsh reagent. Although milder deprotection conditions have been developed—NH4OH/EtOH (3/1, v/v; Usman et al., 1987) or EtOH/NH3 (Scaringe et al., 1990)— long incubation times are still required (∼16 hr at 55°C to 65°C). Consequently, protecting groups with increased base sensitivity were developed: phenoxyacetyl (S.6; Wu et al., 1988), (4-isopropylphenoxy)acetyl (S.7), (4-tbutylphenoxy)acetyl (S.8; Chaix et al., 1989; Sinha et al., 1993), and N,N-dialkylformamidines (S.9; Theisen et al., 1993). See Figure 3.5.2 for the structures. These nucleobase-protecting groups can be removed by treatment with NH4OH/EtOH (3/1, v/v) within 4 hr at 55°C. Because of this short deprotection protocol, better yields of higher-quality RNA product were obtained. An even faster deprotection method for synthetic RNA oligonucleotides was recently reported (Reddy et al., 1995; Wincott et al., 1995). The method entails the use of aqueous methylamine at 65°C, which reduces oligonucleotide deprotection time to 10 min and produces full-length product in yields higher than those obtained with the standard NH4OH/EtOH (3/1, v/v) deprotection protocol (Wincott et al., 1995). With this reagent, however, the cytosines of any given oligonucleotide must by N-protected with an acetyl group to prevent transamination during deprotection (Reddy et al., 1994). Another family of nucleobase-protecting groups for RNA synthesis relates to the 2-(4nitrophenyl)ethyl (Npe) S.10 and 2-(4-nitrophenyl)ethoxycarbonyl (Npeoc) S.11 groups (Himmelsbach et al., 1984). They are stable to both weak acids and weak bases and yet can be readily removed with a non-nucleo-
O N
O N
Another approach to optimizing the coupling step in RNA synthesis has been to modify either the dialkylamine or the protecting group component of the ribonucleoside phosphoramidite function. In most cases, the 2-cyanoethyl/N,N-diisopropylamino combination is used for the synthesis of oligoribonucleotides. The use of lower-alkyl-substituted phosphoramidites, such as diethylamino, instead of diisopropylamino has been reported to improve coupling yields in RNA synthesis when measured by dimethoxytrityl cation quantitation (Lyttle et al., 1991). These compounds, however, have not been used extensively because of their instability. In regard to the phosphate-protecting groups, the 2-cyanoethyl is most favored; however, in some instances other protecting groups must be employed. For example, different phosphate-protecting groups may be required because of incompatibility of the 2-cyanoethyl group with synthesis or deprotection conditions or for increasing coupling rates by offsetting the bulky 2′-protecting group with a smaller phosphorous moiety. In these cases, the Npe (Himmelsbach et al., 1984) or methyl (Usman et al., 1985) group may advantageously replace the 2-cyanoethyl group for phosphate protection. The selection of phosphate protecting groups along with appropriate deprotection conditions will be discussed on a case-by-case basis in conjunction with the groups being used for 5′ and 2′ protection. Now that the general parameters regarding the synthesis of oligoribonucleotides have been reviewed, specific synthetic strategies that affect the choice of 5′- and 2′-protecting groups will be discussed.
2′-HYDROXYL PROTECTION 9
N
O
NO2
O O 10
PHOSPHATE PROTECTION
NMe2
R 6, R = H 7, R = i-Pr 8, R = t-Bu
NO2
philic base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The use of these β-eliminating blocking groups is usually indicated when an acid-labile 5′-protecting group is present.
11
Figure 3.5.2 Base-protecting groups typically used for the synthesis of oligoribonucleotides.
The most common paradigm has been to adapt DNA synthesis to the preparation of RNA oligonucleotides. As a result, a 2′-hydroxylprotecting group must be identified that is compatible with DNA-protecting groups and easily be removed once the oligomer is synthesized (UNIT 2.2). See Figure 3.5.3 for the 2′-hydroxylprotecting groups discussed below. Owing to constraints placed by the existing amide-protecting groups on the bases and the 5′-O-dimethoxytrityl (DMTr) group—or in some
Synthesis of Unmodified Oligonucleotides
3.5.3 Current Protocols in Nucleic Acid Chemistry
DMTrO
B
O O P
R'2N
R = 12-24 R' = i-Pr/Me R" = CE/Me/Npe
OR OR"
OMe
N
OMe
O
Me Me Si Me
Cl
O
Me Me
Me 15
14
13
12
F
OMe CO2Me O
N F
16
O
Cl
Me
O
O O
Me O
MeO2C
17
18
19 NO2
OMe X1
O2 N
X2 O
CCl3
O
NO2
S O OMe
20
21, X1 = NO2, X2 = H 22, X1 = H, X2 = NO2
23
24
Figure 3.5.3 2′-Protecting groups that are compatible with solid-phase oligonucleotide synthesis protocols.
cases the 5-O-(9-(phenyl)xanthen-9-yl (Px) group—the 2′-blocking group must be stable to both acid and base. In addition, the group must also be inert to the oxidizing and capping reagents. Although the most widely used 2′-hydroxyl-protecting group is the tert-butyldimethylsilyl (TBDMS) group, many others have been explored because of the longer coupling times required when the bulky 2′-O-TBDMS substituent is used. Other types of 2′ protection will be covered in the following sections (a number of these can also be found in Gait et al., 1991, and Beaucage and Iyer, 1992).
The TBDMS Group Strategies for Oligoribonucleotide Synthesis According to the Phosphoramidite Method
By far the most popular 2′-protecting group is the TBDMS (S.12), developed principally by Ogilvie and co-workers (Usman et al., 1987). Synthesis of 2′-O-TBDMS nucleoside derivatives can be quite readily accomplished in good yields (Scaringe et al., 1990). The
chemistry used in the construction of oligoribonucleotides is completely compatible with the DNA synthesis cycle, thereby allowing for the simple preparation of DNA/RNA chimeras. In addition, many of the earlier disadvantages of the TBDMS group no longer exist. Although amidite coupling times are not as short as with DNA, through the use of 5-ethylthio-1H-tetrazole (S.2), coupling times have been reduced from 30 min to as low as 5 min (Wincott et al., 1995). Furthermore, new deprotection protocols have not only reduced incubation times but also greatly increased the quality of the product to the extent that contaminating oligonucleotides with (2′→5′) phosphodiester linkages can be eliminated completely. Deprotection of oligoribonucleotides containing 2′-O-TBDMS groups was once a twostep process that first entailed a basic step similar to that used for the deprotection of DNA oligonucleotides, in which an oligomer was
3.5.4 Current Protocols in Nucleic Acid Chemistry
cleaved from the support and the base and phosphate groups were removed. As stated earlier, through the use of methylamine this step has been reduced to 10 min. The second step was the removal of the 2′-O-TBDMS groups from the oligonucleotide. In the past, this was accomplished by treatment with 1 M ntetrabutyl ammonium fluoride (TBAF) in tetrahydrofuran (THF) at room temperature over 24 hr (Usman et al., 1987; Scaringe et al., 1990). Unfortunately, the use of this deprotecting agent produces salts that must be removed before analysis and purification. In addition, the long exposure time required for complete removal of the protecting group, coupled with the reagent’s sensitivity to adventitious water (Hogrefe et al., 1994), made it less than ideal. Although a few reports were published regarding the use of neat triethylamine trihydrofluoride (TEA•3HF) as a desilylating reagent (Gasparutto et al., 1992; Westman and Strömberg, 1994), results were mixed. A solution of TEA•3HF in N-methyl pyrrolidinone (NMP; Wincott et al., 1995) or N,N-dimethylformamide (DMF; Sproat et al., 1995) has also been described from which full deprotection can be achieved in 30 to 90 min at 65°C or 4 to 8 hr at room temperature. As an added advantage, because no salts are produced, the product can be directly precipitated from the desilylating reagent. More recently, a further improved procedure was reported in which both the basic deprotection and desilylation reaction can be accomplished in one pot using a mixture of methylamine in ethanol followed by the addition of TEA•3HF (Bellon, 1999). This protocol allows for the complete deprotection of an oligoribonucleotide in <2 hr without any evidence of (3′→2′)-phosphodiester migration.
Acetal-Protecting Groups Because of concerns about conversion of the desired (3′→5′)-internucleotidic linkages to (2′→5′) linkages, acid-labile acetals were thought to be the ideal 2′-protecting groups. They are stable to alkaline conditions and can be hydrolyzed with dilute acids; therefore, there are no residual reagents to complicate purification. Furthermore, the oligonucleotide can be isolated with the 2′-protecting group intact, thereby allowing one to store the oligonucleotide in a nuclease-resistant form. A number of different acetals have been investigated. The 2′-O-tetrahydropyranyl (Thp) S.13 and 2′-O-methoxytetrahydropyranyl (Mthp) S.14 groups proved to be
unstable to the conditions required for iterative removal of the 5′-O-DMTr group (Reese and Skone, 1985; Christodoulou et al., 1986). Although some successful syntheses have resulted from the use of these acetals, they have been limited to very short oligomers. As a result, aryl-substituted piperidines were developed. The 2′-O-[1-(2-chloro-4-methylphenyl)4-methoxypiperidin-4-yl] (Ctmp) group (S.15) and the 2′-O-[1-(2-fluorophenyl)-4-methoxypiperidin-4-yl] (Ftmp) group (S.16) were first investigated by Reese and co-workers (1986; UNIT 2.2). The Fpmp group is relatively easy to prepare and readily incorporated into ribonucleosides to provide the required phosphoramidite monomers. The 2′-O-Fpmp group is more stable to acidic hydrolysis than 2′-OThp and 2′-O-Mthp acetals (Beijer et al., 1990) and can, therefore, be used in conjunction with either a 5′-O-DMTr or a 5′-O-Px group in solid-phase RNA synthesis. Coupling times of 3 to 12 min have been reported for ribonucleoside 2′-O-Fpmp phosphoramidite derivatives upon activation with nitrophenyl-substituted 1H-tetrazoles (Beijer et al., 1990; Rao et al., 1993; Capaldi and Reese, 1994). Early reports indicated that deprotections of 2′-OFpmp oligonucleoties was optimal at pH 2.0 for 20 hr at room temperature (Rao et al., 1993). It has since, however, been determined that the rate of acid-catalyzed hydrolysis of internucleotidic linkages is sequence dependent. To avoid hydrolytic cleavage and phosphodiester migration, the removal of the 2′-O-Fpmp groups should be performed at a pH above 3.0 for 24 hr at room temperature (Capaldi and Reese, 1994; UNIT 2.2). Another approach to acetal protection of the 2′-hydroxy function led to the development of the 1-(2-chloroethoxy)ethyl group (S.17; Sakatsume et al., 1991a,b). Oligoribonucleotides of up to 20 residues in length have been prepared using S.17 for 2′-OH protection. This protecting group is stable under the acidic conditions required for removing the 5′-ODMTr group and yet can be removed postsynthetically within 30 hr upon hydrolysis with 0.01 N HCl (pH 2.0) at room temperature. No base modification or phosphodiester migration was detected. In light of the results of Capaldi and Reese (1994), deprotection at pH 3.0 might be worth investigating. Furthermore, synthesis of the 2′-O-protected ribonucleosides proceeds quite smoothly from the corresponding Markiewicz-protected nucleosides. More recently, a new 2′-protecting group was reported: the 2-hydroxyisophthalate for-
Synthesis of Unmodified Oligonucleotides
3.5.5 Current Protocols in Nucleic Acid Chemistry
maldehyde acetal (S.18; Rastogi and Usher, 1995). This is a convertible protecting group that, as the diester, is stable to acidic treatment during synthesis but is converted upon treatment with ammonia to a diacid that is more labile under acidic conditions than the parent diester. The half-life for the deprotection of the resulting diacid is ∼390 min at pH 3 compared to 166 min for the cleavage of S.16 under the same conditions. At this time only UpU and UpG dimers and the corresponding uridine phosphoramidite have been synthesized. Finally, Pfleiderer et al. (1996) designed a new acetal for the solid-phase synthesis of oligoribonucleotides that is used successfully in conjunction with a 5′-O-DMTr group. Like the 2′-protecting group S.18, the 2′-O-acetal, 1-{4[2-(4-nitrophenyl)ethoxycarbonyloxy]-3fluorobenzyloxy}ethyl (S.19), is a convertible, or “protected protecting,” group. Cleavage of the (4-nitrophenyl)ethoxycarbonyl group from S.19 results in a 2′-O-acetal that can be hydrolyzed within 4 hr under acidic conditions; this is in sharp contrast to the 24 hr required for hydrolysis of the parent 2′-O-acetal S.19 under the same conditions. Ribonucleoside phosphoramidites functionalized with the 2′-Oacetal S.19 and Npe/Npeoc (S.10/S.11) baseprotecting groups require a 20 min coupling time for optimal solid-phase RNA synthesis. Oligoribonucleotides were treated with DBU to remove base- and phosphate-protecting groups as well as the (4-nitrophenyl)ethoxycarbonyl group of the 2′-O-acetal S.19. After cleavage from the support, the deprotected 2′O-acetal was cleaved from RNA oligomers upon acidification with 0.5% AcOH for 18 hr at room temperature. The use of 80% AcOH (pH <3) led to (3′→2′)-phosphodiester migration along with strand scission (Capaldi and Reese, 1994).
Strategies for Oligoribonucleotide Synthesis According to the Phosphoramidite Method
amidite was accomplished in 15 min with tetrazole as the activator or 2.5 min using 5-(p-nitrophenyl)1H-tetrazole in conjunction with the methyl phosphate–protecting group (Tanaka et al., 1986). After oligonucleotide deprotection under basic conditions, the remaining 2′-O-(o-nitrobenzyl) groups were cleaved upon irradiation of the oligomer with longwave UV light at pH 3.5 for 1 hr in solutions that have been purged with N2. At higher pH, the formation of side products occurred. Because the 2′-O-(o-nitrobenzyl) group (in conjunction with the 2-cyanoethyl phosphate group) requires extended amidite coupling times (deBear et al., 1987), the o-nitrobenzyloxymethyl (S.21) group was proposed as an alternative 2′-photolabile-protecting group (Schwartz et al., 1992). It was postulated that the extended arm present in this group might ease steric crowding, thereby reducing amidite coupling times. Synthesis of the corresponding ribonucleoside phosphoramidite monomers proceeds similarly to that of the 2′-O-TBDMS amidites. Unlike silyl-protected ribonucleotides, however, these amidites required only a 2-min coupling time. After a standard basic deprotection protocol—pyridine:NH4OH (1:4, v/v), 50°C, 24 hr—the 2′protected oligomers were exposed to longwave UV light at pH 3.7 for 4.5 hr at room temperature to remove the o-nitrobenzyloxymethyl groups. More recently, the p-nitrobenzyloxymethyl (S.22) group was recommended for 2′-OH protection (Gough et al., 1996). This protecting group behaves almost identically to S.21 in regard to amidite monomers synthesis and coupling times; however, it can be removed from 2′-protected oligoribonucleotides within 24 hr upon reaction with TBAF at room temperature.
Photolabile Groups
The 1,1-Dianisyl-2,2,2-Trichloroethyl Group
Another approach to the protection of the ribonucleoside 2′-hydroxyl is the use of photolabile-protecting groups. This strategy has many advantages. The protecting groups are completely orthogonal, because they are resistant to both acid and base and, as a result, remain intact throughout synthesis and final deprotection. Furthermore, incorporation of such protecting groups into ribonucleosides is accomplished quite readily without any migration. Originally, the 2′-O-(o-nitrobenzyl) group (S.20) was the photolabile-protecting group of choice (Ohtsuka et al., 1981; Hayes et al., 1985). Coupling of the corresponding
Klosel et al. (1996) described a completely new protecting group for 2′ protection of ribonucleosides: the 2′-O-1,1-dianisyl-2,2,2trichloroethy group (S.23). This β-haloalkyl group is stable to acid and base and yet is cleavable under mild, neutral conditions via reductive fragmentation. Furthermore, there is no migration after the protecting group between the 2′- and the 3′-hydroxyls. Only synthesis of the uridine phosphoramidite and the corresponding UpT dimer has been described. Synthesis of the amidite monomer is fairly straightforward; the product is prepared in five steps from uridine. A 15-min
3.5.6 Current Protocols in Nucleic Acid Chemistry
coupling time is required for the activated amidite to form the dimer. After treatment with ammonia, the dimer was exposed to lithium cobalt(I)phthalocyanine and phenol in MeOH (O2 free) for 14 hr at room temperature to effect cleavage of the 2′-protecting group. The reaction mixture was then quenched by the addition of buffer; upon analysis it was shown that the backbone was intact and that no (2′→5′)-phosphodiester linkage was present.
when the Npeoc and 2-cyanoethyl groups are used for base and phosphate protection, respectively. Treatment of 2′-protected oligonucleotides with DBU results in the removal of all protecting groups. Unfortunately, this 2′protection strategy is not compatible with uridine that is unprotected at O4 because of concomitant anhydro nucleoside formation. As a result, protection of O4 with a 2-cyanoethyl group was explored. This group can also be removed upon exposure to DBU, however only at elevated temperatures (50°C).
The p-Nitrophenylethyl Sulfonyl Group
ALTERNATIVE TO 5′-TRITYL DERIVATIVES FOR THE 5′-OH PROTECTION OF RIBONUCLEOSIDES
The p-nitrophenylethyl sulfonyl group (S.24) has also been proposed as a 2′-protecting group for ribonucleosides (Pfister et al., 1988). The advantages of this sulfonate-derived group are acid stability and the absence of (2′→3′) migration. This protecting group works best
B
PO
R'2N
In many cases, researchers have chosen a de novo approach to the synthesis of oligoribonucleotides in which the focus is not on develop-
O O P
R' = i-Pr/Me R" = CE/Me/Npe OR
OR"
P Me
R Me
N
OMe
O
S
O
O
O
O 14
25 O
O Me O 27
26
O Me
Me Me
O 28
O
14 or 29 O
TMSO OTMS Si O
O O
O O
Me O
Me 30
31
Figure 3.5.4 5′(P)- and 2′(R)-protecting group combinations for the synthesis of oligoribonucleotides.
Synthesis of Unmodified Oligonucleotides
3.5.7 Current Protocols in Nucleic Acid Chemistry
ing a method that is compatible with DNA synthesis but rather evolving a process that is best for RNA synthesis. A number of different approaches have been explored. In most cases, the decision was made to proceed with an acetal-protecting group for 2′-protection. This choice was made for all the reasons stated earlier: there is no (2′→3′) migration during amidite monomer synthesis; no residual reagents are present after deprotection; and oligomers can be stored with the 2′-protecting groups in place until the RNA product is needed, thereby protecting it against nuclease degradation. Because these groups are acid labile, the 5′-protecting groups that have been developed are typically base labile or sensitive to fluoride ions. Obviously, these constraints further affect the choice of suitable nucleobases and phosphate-protecting groups. Some of the options that have been explored are presented in this unit (see Fig. 3.5.4).
The 2-Dansylethoxycarbonyl Group
Strategies for Oligoribonucleotide Synthesis According to the Phosphoramidite Method
One approach to resolving the incompatibility of 2′-O-acetal-protecting groups with the standard acid-labile 5′-O-DMTr and 5′-O-Px groups in oligoribonucleotide synthesis was the development of the 2-dansylethoxycarbonyl group for 5′ protection (S.25; Bergmann and Pfleiderer, 1994a). This base-labile group can be readily removed (in 140 sec) using dilute DBU (Bergmann and Pfleiderer, 1994b). As a result, the more stable 2-(4-nitrophenyl)ethyl phosphate-protecting group is required in place of the traditional 2-cyanoethyl group; Npe (S.10) and Npeoc (S.11) are used for base protection. When this protecting group scheme was used in conjunction with a 2′-O-Mthp group, the coupling reaction time of the corresponding phosphoramidite was 12 min with 1H-tetrazole. Oligomers of 20 nucleotides were synthesized; and in special cases, polymers of 40 nucleotides were prepared. It was determined that the best results were obtained with the N,N-diethylphosphoramidite rather than with the N,N-diisopropyl analog. Deprotection of the oligoribonucleotide first required a 10-hr treatment with 0.5 to 1 M DBU to remove the nucleobase- and phosphate-protecting groups, followed by cleavage from the support by ammonolysis (200 min). The oligomer could be stored at this point or exposed to acid to remove the 2′-O-Mthp group (S.14).
The Levulinyl Group Oligoribonucleotides (21-mers) were synthesized using a 5′-O-levulinyl (S.26)/2′-O-
tetrahydrofuranyl (S.27) protecting group combination (Iwai et al., 1987; Iwai and Ohtsuka, 1988). The 5′-O-levulinyl group is removed during solid-phase synthesis by hydrozinolysis. After ammonia treatment, the base- and phosphate-deprotected oligomer is then treated with 0.01 N HCl (pH 2) for 24 hr to effect removal of the 2′-O-acetal. Although, no base modification is observed, there are some drawbacks to this scheme. As in the case of a number of 5′-protecting groups, removal of the levulinyl group cannot be monitored. Furthermore, because of the prolonged amount of time required for full removal of the 5′-O-levulinyl group, cycle times are very long. Finally, introduction of the levulinyl group to the 5′-position of ribonucleosides is not selective, thereby reducing yields.
The 9-Fluorenylmethoxycarbonyl Group The lability of acetal groups to iterative acidic treatment led to the development of the 9-fluorenylmethoxycarbonyl (Fmoc) group (S.28) as an alternative to the DMTr group for 5′-hydroxyl protection (Lehmann et al., 1989). The Fmoc group is readily introduced to the 5′-position of the 2′-O-Mthp-protected nucleosides. During solid-phase oligonucleotide synthesis, the 5′-O-Fmoc group is removed before each chain elongation step by a brief treatment (2 min) with 0.1 M DBU in acetonitrile. The release of the Fmoc group can be monitored by UV spectroscopy, thereby allowing quantitation of the ribonucleoside phosphoramiditecoupling efficiency. The coupling reaction time of incoming amidites activated by 5-(pnitrophenyl)-1H-tetrazole ranges between 2 and 10 min. Upon completion of the synthesis, the oligoribonucleotide is treated with ammonia to remove nucleobase- and phoshate-protecting groups and release it from the support. At this point, the 2′-protected oligoribonucleotide can be purified, if so desired. Deprotection of the 2′-O-Mthp groups takes place at pH 2.0 within 4 hr at room temperature. After careful analysis, it was shown that all internucleotidic linkages were (3′→5′) and that no base modification occurred. Oligomers of up to 20 residues have been successfully synthesized using this combination of protecting groups. Ogawa et al. (1991) substituted the acidlabile 1-(isopropoxy) ethyl (IPE) group (S.29) for the 2′-O-Mthp group. The desired nucleosides were prepared from the corresponding Markiewicz-protected intermediates in a fourstep procedure in good yields. Removal of the
3.5.8 Current Protocols in Nucleic Acid Chemistry
5′-O-Fmoc group during solid-phase synthesis was accomplished with 0.1 M piperidine in acetonitrile (2 min), whereas amidite coupling was effected with 1H-tetrazole over a period of 20 to 25 min. Oligonucleotide deprotection consisted of a treatment with ammonia for 6 to 12 hr at 55°C; the 2′-O-IPE group was removed last at pH 2.0 within 3 hr at room temperature. Again, no (2′→5′)-phosphodiester isomerization or base modification was observed under these conditions. Oligomers up to 21 residues were reported using this combination of protecting groups.
oligomers of up to 36 residues in length have been reported. Careful analysis of the deprotected oligomers showed there was no base modification and no sign of (2′→5′)-phosphodiester migration. Furthermore, appropriate molecular weights and enzymatic activity were observed for the oligomers that were synthesized. It should be noted that when oligoribonucleotides are identically produced by either 5′-O-DMTr/2′-O-TBDMS or the 5′-OSIL/2′-O-ACE phosphoramidite method, better yields of RNA oligonucleotides were obtained with the 5′-O-SIL/2′-O-ACE phosphoramidite protocol.
The Bis(trimethylsiloxy) cyclooctyloxysilyl Group
SUMMARY
A completely different approach to 5′-protection was taken by Scaringe et al. (1998), wherein a 5′-O-silyl ether was used in tandem with a 2′-O-orthoester. The 5′-O-bis(trimethylsiloxy)cyclooctyloxysilyl ether (SIL; S.30) can be removed by fluoride ion treatment under conditions that will not affect an acid-labile 2′-protecting group. The 2′-O-bis(2-acetoxyethoxy) methyl orthoester (ACE; S.31) is a convertible protecting group that is stable to all synthesis conditions but is modified during nucleobase deprotection under basic conditions. The resulting 2′-O-bis(2-hydroxyethoxy)methyl orthoester is 10 times more acid labile than the original orthoesterprotecting group. The 2′-O-protected ribonucleosides can be produced in four steps from the Markiewicz-protected nucleosides in overall yields of 45% to 55%. Because 2-cyanoethyl groups are not compatible with repeated exposure to fluoride ion, methyl N,N-diisopropylphosphoramidite derivatives are used. The 5′O-silyl group is removed in 35 sec upon reaction with 1.1 M HF in TEA/DMF. Amidite coupling is complete after 90 sec when 5ethylthio-1H-tetrazole (S.2) is used as the activator; coupling yields were reported as >99%. Once the oligomer has been synthesized, deprotection of the methyl phosphate group is effected by disodium-2-carbamoyl-2-cyanoethylene-1,1-dithiolate (10 min;- Dahl et al., 1990); followed by treatment with aqueous 40% methylamine at 55°C for 10 min. The 2′-protected oligomer can then be analyzed; purified, if necessary; and then stored. To remove the modified 2′-O-orthoester, the oligoribonucleotide is heated to 55°C for 10 min in a pH 3 buffer, followed by incubation at pH 7.7 to 8.0 for 10 min at 55°C. This final step cleaves any remaining 2′-O-formyl groups that result from the orthoester deprotection. Syntheses of
Significant advances in RNA biology and biochemistry can be achieved only through concomitant advances in RNA chemistry. The current state of the art in ribozyme research would not have been possible without the recent improvements in RNA synthesis. The current technology, however, is still limiting. There is no report of routine syntheses of tRNAs or even hairpin ribozymes. Until RNA synthesis chemistry can provide oligoribonucleotides as readily as DNA, the search for new and better methods for the synthesis of RNA will continue. Currently, the 5′-O-DMTr/2′-O-TBDMS is the benchmark for the synthesis of oligoribonucleotides (Usman et al., 1987; Scaringe et al., 1990; Sproat et al., 1995; Wincott et al., 1995). The use of the TBDMS-protecting group (S.12) was first described in the 1970s. In the ensuing years, many other methods for the synthesis of RNA were developed, but none has gained the popularity of the TBDMS chemistry. Recent advances in the use of this silyl chemistry in terms of synthesis (Sproat et al., 1995; Wincott et al., 1995; Vargeese et al., 1998) and deprotection (Sproat et al., 1995; Wincott et al., 1995; Bellon, 1999) have made it an even more viable approach to the production of oligoribonucleotides. In the early 1990s the 5′-O-DMTr/2′O-Fpmp strategy to RNA synthesis showed great promise (Rao et al., 1993; Capaldi and Reese, 1994). Since that time, however, there have been very few reports of successful RNA syntheses using this protocol, although these monomers are commercially available. The results obtained with the 2′-O-(o-nitrobenzyloxymethyl) (S.21; Schwartz et al., 1992) and 2′-O-(p-nitrobenzyloxymethyl) (S.22; Gough et al., 1996) groups also appeared quite encouraging. Again, since the initial reports describing this chemistry, there have been few follow-ups,
Synthesis of Unmodified Oligonucleotides
3.5.9 Current Protocols in Nucleic Acid Chemistry
and the use of these 2′-protecting groups does not appear to have gained an appreciable audience beyond its initial developers. Other 2′-protecting groups that, like TBDMS and Fpmp, are compatible with current DNA synthesis protocols are the convertible protecting groups S.18 (Rastogi and Usher, 1995) and S.19 (Pfleiderer et al., 1996). These 2′-O-acetal-derived groups look interesting, but there have been few reports since the initial publications. Of the synthetic methods that have been designed specifically for RNA synthesis, none is currently commercially available. Around 1990, there were reports citing the combination of 5′-O-Fmoc and either 2′-O-Mthp (Lehmann et al., 1989) or 2′-O-IPE (Ogawa et al., 1991) that provided good-quality oligoribonucleotides; however, the longest oligomer synthesized was a 21-mer. No further communication regarding oligoribonucleotide synthesis with these protecting groups have surfaced. The 5′-O-SIL/2′-O-ACE protocol, however, looks very attractive (Scaringe et al., 1998). The quality of the product is excellent, and oligomers of up to 36 residues have been synthesized. Currently, none of these amidites is commercially available, although efforts are under way to commercialize the 5′-O-SIL/2′-O-ACE method. It seems clear that TBDMS chemistry is the current choice for the synthesis of oligoribonucleotides. The amidites are commercially available, and quality products can be produced on a reasonable scale. RNA synthesis chemistry using the 2′-O-TBDMS group, however, has not yet reached the level achieved by DNA synthesis. As a result, the search for improved protocols or new approaches altogether persists.
LITERATURE CITED Andrus, A., Beaucage, S., Ohms, J., and Wert, K. 1986. American Chemical Society Meeting, New York, Organic Division, Abstract 333. Beaucage, S.L. and Iyer, R.P. 1992. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:22232311. Beijer, B., Sulston, I., Sproat, B.S., Rider, P., Lamond, A.I., and Neuner, P. 1990. Synthesis and applications of oligoribonucleotides with selected 2′-O-methylation using the 2′-O-[1-(2fluorophenyl)-4-methoxypiperidin-4-yl] protecting group. Nucl. Acids Res. 18:5143-5151. Strategies for Oligoribonucleotide Synthesis According to the Phosphoramidite Method
Bellon, L. 2000. Oligoribonucleotides with 2′-O-(tbutyldimethylsilyl) groups. In Current Protocols in Nucleic Acid Chemistry (S.L. Beaucage, D.E. Bergstrom, G.D. Glick and R.A. Jones, eds.) in press. John Wiley & Sons, New York.
Bergmann, F. and Pfleiderer, W. 1994a. Solid-phase synthesis of oligoribonucleotides using the 2dansylethoxycarbonyl group for 5′-hydroxy protection. Helvetica Chim. Acta 77:481-500. Bergmann, F. and Pfleiderer, W. 1994b. The 2-dansylethoxycarbonyl group for the protection of the 5′-hydroxy function in oligoribonucleotide synthesis. Helvetica Chim. Acta 77:989-998. Capaldi, D.C. and Reese, C.B. 1994. Use of the 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) and related protecting groups in oligoribonucleotide synthesis: Stability of internucleotide linkages to aqueous acid. Nucl. Acids Res. 22:2209-2216. Cech, T. 1992. Ribozyme engineering. Curr. Opin. Struct. Biol. 2:605-609. Chaix, C., Duplaa, A.M., Molko, D., and Téoule, R. 1989. Solid phase synthesis of the 5′-half of the initiator t-RNA from B. subtilis. Nucl. Acids Res. 17:7381-7393. Christodoulou, C., Agrawal, S., and Gait, M.J. 1986. Incompatibility of acid-labile 2′ and 5′ protecting groups for solid-phase synthesis of oligoribonucleotides. Tetrahedron Lett. 27:1521-1522. Cook, K.S., Fisk, G.J., Hauber, J., Usman, N., Daly, T.J., and Rusche, J.R. 1991. Characterization of HIV-1 REV protein: Binding stoichiometry and minimal RNA substrate. Nucl. Acids Res. 19:1577-1583. Dahl, B.J., Bjergarde, K., Henriksen, L., and Dahl, O. 1990. Deoxyribonucleoside phosphorodithioates. Preparation of dinucleoside phosphorodithioates from nucleoside thiophosphoramidites. Acta Chem. Scand. 44:639-641. Damha, M.J., Giannaris, P.A., and Zabarylo, S.V. 1990. An improved procedure for derivitization of controlled-pore glass beads for solid-phase oligonucleotide synthesis. Nucl. Acids Res. 18:3813-3820. deBear, J.S., Hayes, J.A., Koleck, M.P., and Gough, G.R. 1987. A universal glass support for oligonucleotide synthesis. Nucleosides Nucleotides 6:821-830. Francklyn, C. and Schimmel, P.R. 1989. Aminoacylation of RNA minihelixes with alanine. Nature 337:478-481. Gait, M.J., Pritchard, C., and Slim, G. 1991. Oligoribonucleotide synthesis. In Oligonucleotides and Analogues, A Practical Approach (F. Eckstein, ed.) pp 25-48. Oxford University Press, Oxford. Gasparutto, D., Livache, T., Bazin, H., Duplaa, A.M., Guy, A., Khorlin, A., Molko, D., Roget, A., and Téoule, R. 1992. Chemical synthesis of a biologically active natural tRNA with its minor bases. Nucl. Acids Res. 20:5159-5166. Gold, L. 1988. Posttranscriptional regulatory mechanisms in Escherichia coli. Annu. Rev. Biochem. 57:199-233. Gough, G.R., Miller, T.J., and Mantick, N.A. 1996. p-Nitrobenzyloxymethyl: A new fluoride-removable protecting group for ribonucleoside 2′hydroxyls. Tetrahedron Lett. 37:981-982.
3.5.10 Current Protocols in Nucleic Acid Chemistry
Hayakawa, Y., Kataoka, M., and Noyori, R. 1996. Benzimidazolium triflate as an efficient promoter for nucleotide synthesis via the phosphoramidite approach. J. Org. Chem. 61:79967997.
Ogawa, T., Hosaka, H., Makita, T., and Takaku, H. 1991. Solid-phase synthesis of oligoribonucleotides using 5′-9-fluorenylmethoxycarbonyl and 2′-1-(isopropoxyl)ethyl protection. Chem. Lett. 1169-1172.
Hayes, J.A., Brunden, M.J., Gilham, P.T. and Gough, G.R. 1985. High-yield synthesis of oligoribonucleotides using o-nitrobenzyl protection of 2′-hydroxyls. Tetrahedron Lett. 26:24072410.
Ohtsuka, E., Fujiyama, K., and Ikehara, M. 1981. Studies on transfer ribonucleic acids and related compounds. XL. Synthesis of an eicosaribonucleotide corresponding to residues 35-54 of tRNAfMet from E. coli. Nucl. Acids Res. 9:35033522.
Himmelsbach, F., Schulz, B.S., Trichtinger, T., Charubala, R., and Pfleiderer, W. 1984. The pnitrophenylethyl (Npe) group. Tetrahedron 40:59-72. Hogrefe, R.I., McCaffrey, A.P., Borozdina, L.U., McCampbell, E.S., and Vaghefi, M.M. 1994. Effect of excess water on the desilylation of oligoribonucleotides using tetrabutylammonium fluoride. Nucl. Acids Res. 21:4739-4741. Iwai, S. and Ohtsuka, E. 1988. 5′-Levulinyl and 2′-tetrahydrofuranyl protection for the synthesis of oligoribonucleotides by the phosphoramidite approach. Nucl. Acids Res. 16:9443-9456. Iwai, S., Yamada, E., Asaka, M., Hayase,Y., Inoue, H., and Ohtsuka, E. 1987. A new solid-phase synthesis of oligoribonucleotides by the phosphoro-p-anisidate method using tetrahydrofuranyl protection of 2′-hydroxyl groups. Nucl. Acids Res. 15:3761-3772. Johnson, K.A. and Benkovic, S.J. 1990. Analysis of protein function by mutagenesis. In The Enzymes, Vol. 19 (Sigman, D.S. and Boyer, P.D., eds) pp. 159-211. Academic Press, San Diego. Karaoglu, D. and Thurlow, D.L. 1991 A chemical interference study on the interaction of ribosomal protein L11 from in Escherichia coli with RNA molecules containing its binding site from 23S rRNA. Nucl. Acids Res. 19:5293-5300. Klosel, R., Konig, S., Lehnhoff, S., and Karl, R.M. 1996. The 1,1-dianisyl-2,2,2-trichloroethyl group as a 2′-hydroxyl protection of ribonucleotides. Tetrahedron 52:1493-1502. Lehmann, C., Xu, Y.Z., Christodoulou, C., Tan, Z.K., and Gait, M.J. 1989. Solid-phase synthesis of oligoribonucleotides using 9-fluorenylmethoxycarbonyl (Fmoc) for 5′-hydroxyl protection. Nucl. Acids Res. 17:2379-2390. Leiber, E. and Enkoju, T. 1961. Synthesis and properties of 5-(substituted) mercaptotetrazoles. J. Org. Chem. 26:4472-4479. Lyttle, M.H., Wright, P.B., Sinha, N.D., Bain, J.D., and Chamberlin, A.R. 1991. New nucleoside phosphoramidites and coupling protocols for solid-phase RNA synthesis. J. Org. Chem. 56:4608-4615. McCollum, C. and Andrus, A. 1991. An optimized polystyrene support for rapid, efficient oligonucleotide synthesis. Tetrahedron Lett. 32:40694072.
Pfister, M., Farkas, S., Charubala, R., and Pfleiderer, W. 1988. Recent progress in oligoribonucleotide synthesis. Nucleosides Nucleotides 7:595-600. Pfleiderer, W., Matysiak, S., Bergmann, F., and Schnell, R. 1996. Recent progress in oligonucleotide synthesis. Acta Biochim. Polonica 43:37-44. Pon, R.T., Usman, N., and Ogilvie, K.K. 1988. Derivitization of controlled pore glass beads for solid phase oligonucleotide synthesis. BioTechniques 6:768-774. Rao, M.V., Reese, C.B., Schehlmann, V., and Yu, P.S. 1993. Use of the 1-(2-fluorophenyl)-4methoxypiperidin-4-yl (Fpmp) protecting group in the solid-phase synthesis of oligo- and polyribonucleotides. J. Chem. Soc. Perkin Trans. I:43-55. Rastogi, J. and Usher, D. 1995. A new 2′-hydroxyl protecting group for the automated synthesis of oligoribonucleotides. Nucleic Acids Res. 23:4872-4877. Reddy, M.P., Hanna, N.B., and Farooqui, F. 1994. Fast cleavage and deprotection of oligonucleotides. Tetrahedron Lett. 35:4311-4314. Reddy, M.P., Hanna, N.B., and Farooqui, F. 1995. Methylamine deprotection provides increased yield of oligoribonucleotides. Tetrahedron Lett. 36:8929-8932. Reese, C.B. and Skone, P.A. 1985. Action of acid on oligoribonucleotide phosphotriester intermediates. Effect of released vicinal hydroxy functions. Nucl. Acids Res. 13:3501-. Reese, C.B., Serafinowska, H.T., and Zappia, G. 1986. An acetal group suitable for the protection of 2′-hydroxy functions in rapid oligoribonucleotide synthesis. Tetrahedron Lett. 27:22912294. Sakatsume, O., Yamaguchi, T., Ishikawa, M., Hirao, I., Miura, K., and Takaku, H. 1991a. Solid phase synthesis of oligoribonucleotides by the phosphoramidite approach using 2′-O-1-(2-chloroethox y)ethyl p ro tection. Tetrahedron 47:8717-8728. Sakatsume, O., Ogawa, T., Hosaka, H., Kawashima, M., Takaki, M., and Takaku, H. 1991b. Synthesis and properties of non-hammerhead RNA using 1-(2-chloroethoxy)ethyl group for the protection of 2′-hydroxyl function. Nucleosides Nucleotides 10:141-153. Synthesis of Unmodified Oligonucleotides
3.5.11 Current Protocols in Nucleic Acid Chemistry
Scaringe, S.A., Francklyn, C., and Usman, N. 1990. Chemical synthesis of biologically active oligoribonucleotides using β-cyanoethyl protected ribonucleoside phosphoramidites. Nucl. Acids Res. 18:5433-5341. Scaringe, S.A., Wincott, F.E., and Caruthers, M.H. 1998. Novel RNA synthesis method using 5′-Osilyl-2′-O-orthoester protecting groups. J. Am. Chem Soc. 120:11820-11821. Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., deBear, J.S., and Gough, G.R. 1992. Rapid synthesis of oligoribonucleotides using 2′-O-(o-nitrobenzyloxymethyl)-protected monomers. Bioorg. Med. Chem. Lett. 2:1019-1024. Sinha, N.D., Davis, P., Usman, N., Pérez, J., Hodge, R., Kremsky, J., and Casale, R. 1993. Labile exocyclic amine protection in DNA, RNA and oligonucleotide analog synthesis facilitating Ndeacylation, minimizing depurination and chain degradation. Biochimie 75:13-23. Sproat, B., Colonna, F., Mullah, B., Tsou, D., Andrus, A., Hampel, A., and Vinayak, R. 1995. An efficient method for the isolation and purification of oligoribonucleotides. Nucleosides Nucleotides 14:255-273. Tanaka, T., Tamatsukuri, S., and Ikehara, M. 1986. Solid phase synthesis of oligoribonucleotides using o-nitrobenzyl protection of 2′-hydroxyl via a phosphite triester approach. Nucl. Acids Res. 14:6265-6279. Theisen, P., McCollum, C., and Andrus, A. 1993. N-6-Dialkylformamidine-2′-deoxyadenosine phosphoramidites in oligodeoxynucleotide synthesis. Rapid deprotection of oligodeoxynucleotides. Nucleosides Nucleotides 12:10331046. Usman, N., Pon, R.T., and Ogilvie, K.K. 1985. Preparation of ribonucleoside 3′-O-phosphoramidites and their application to the automated solid phase synthesis of oligonucleotides. Tetrahedron Lett. 26:4567-4570.
Usman, N., Ogilvie, K.K., Jiang, M.-Y., and Cedergren, R.J. 1987. Automated chemical synthesis of long oligoribonucleotides using 2′-O-silylated ribonucleoside 3′-O-phosphoramidites on a controlled-pore glass support: Synthesis of a 43-nucleotide sequence similar to the 3′-half molecule of an in Escherichia coli formylmethionine tRNA. J. Am. Chem. Soc. 109:78457854. Vargeese, C., Carter, J., Yegge, J., Krivjansky, S., Settle, A., Kropp, E., Peterson, K., and Pieken, W. 1998. Efficient activation of nucleoside phosphoramidites with 4,5-dicyanoimidazole during oligonucleotide synthesis. Nucl. Acids Res. 26:1046-1050. Vinayak, R., Ratmeyer, L., Wright, P., Andrus, A., and Wilson, D. 1994. Chemical synthesis of biologically active RNA using labile protecting groups. In Innovations and Perspectives in Solid Phase Synthesis (R. Epton, ed.) pp 45-50. Mayflower Worldwide, Birmingham. Westman, E. and Strömberg, R. 1994. Removal of t-butyldimethylsilyl protection in RNA-synthesis. Triethylamine trihydrofluoride (TEA, 3HF) is a more reliable alternative to tetrabutylammonium fluoride (TBAF). Nucl. Acids Res. 22:2430-2431. Wincott, F., DiRenzo, A., Shaffer, C., Grimm, S., Tracz, D., Workman, C., Sweedler, D., Gonzalez, C., Scaringe, S., and Usman, N. 1995. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucl. Acids Res. 23:2677-2684. Wu, T., Ogilvie, K.K., and Pon, R.T. 1988. N-Phenoxyacetylated guanosine and adenosine phosphoramidites in the solid phase synthesis of oligoribonucleotides: Synthesis of a ribozyme sequence. Tetrahedron Lett. 34:4249-4252.
Contributed by Francine E. Wincott Ribozyme Pharmaceuticals, Inc. Boulder, Colorado
Strategies for Oligoribonucleotide Synthesis According to the Phosphoramidite Method
3.5.12 Current Protocols in Nucleic Acid Chemistry
Oligoribonucleotides with 2′-O-(tert-Butyldimethylsilyl) Groups
UNIT 3.6
This unit describes current methodologies to chemically synthesize oligoribonucleotides on solid support by means of automated DNA synthesizers. It also includes an updated collection of protocols describing the deprotection of base-labile phosphate, and nucleobase protecting groups, and fluoride-labile 2′-O-(tert-butyldimethylsilyl) protecting groups of crude synthetic oligoribonucleotides. Small-scale synthesis (i.e., 0.2 µmol scale) of oligoribonucleotide provides ∼400 to 600 µg of purified material, which is usually enough for a wide range of biochemical applications. Such synthesis can be readily achieved using the exocyclic amine-protected 5′-O-dimethoxytrityl-2′-O-tert-butyldimethylsilyl-3′-O-(2-cyanoethyl-N,N-diisopropyl) -ribonucleoside phosphoramidites in combination with the acidic 5-ethylthio-1H-tetrazole (SET, pKa = 4.28) as the activator (Wincott et al., 1995; Vinayak et al., 1995; see Basic Protocol 1). Alternatively, the use of less acidic activators such as 4,5-dicyanoimidazole (DCI, pKa = 5.2; Vargeese et al., 1998) or 1H-tetrazole (TET, pKa = 4.8; Usman et al., 1987; Scaringe et al., 1990; Usman and Cedergren, 1992) also allows for efficient oligoribonucleotide synthesis at comparable scales. DCI is better suited for larger-scale (i.e., >500 µmol) syntheses due to lesser acidity (Vargeese et al., 1998) that may limit the activator-induced detritylation of incoming phosphoramidite during extended coupling time (Krotz et al., 1997). Historically, crude oligoribonucleotides have been fully deprotected with a 3:1 mixture of concentrated ammonium hydroxide/ethanol followed by an n-tetrabutylammonium fluoride (TBAF) treatment (Usman et al., 1987; Stawinsky et al., 1988; see Basic Protocol 2). The use of aqueous methylamine followed by treatment with the triethylamine trihydrofluoride complex (see Alternate Protocol 1) constitutes a significant improvement in the deprotection process (Wincott et al., 1995; Vinayak et al., 1995), alleviating premature deprotection of the 2′-hydroxyl during the basic treatment, eliminating the well-known sensitivity of the TBAF to water (Hogrefe et al., 1993), and shortening the overall deprotection time considerably. Crude oligoribonucleotides can also be efficiently deprotected in a “one-pot” reaction using anhydrous methylamine and neat triethylamine trihydrofluoride (see Alternate Protocol 2). This alternate deprotection protocol eliminates the time-consuming evaporation step, thereby reducing the overall deprotection time to 45 min, which allows for a high-throughput production mode (Bellon, 2000). AUTOMATED OLIGORIBONUCLEOTIDE SYNTHESIS This protocol describes automated chemical synthesis of oligoribonucleotides by means of the phosphoramidite method (UNIT 3.5) according to the synthetic scheme pictured in Figure 3.6.1. The procedure described below was developed for the ABI 394 DNA/RNA synthesizer at the 0.2 µmol scale although it can be modified to utilize any standard synthesizer.
BASIC PROTOCOL 1
Materials Aminomethyl polystyrene (RNA primer solid support) derivatized with 5′-O-DMTr-2′-O-TBDMS-3′-O-succinyl ribonucleosides (Amersham Pharmacia Biotech) Synthesis of Unmodified Oligonucleotides Contributed by Laurent Bellon Current Protocols in Nucleic Acid Chemistry (2000) 3.6.1-3.6.13 Copyright © 2000 by John Wiley & Sons, Inc.
3.6.1 Supplement 1
Phosphoramidite Coupling Reaction DMTrO
B DMTrO
Cycle Entry
5'-Hydroxyl Deprotection
DMTrO
B
O
HO
O
i-Pr2N
B
O
OR
O
N H
O
O P
B
O
OR O
OCE
OR
P OCE
O O
N H
O
OR
EtS
O
O
H N
O
HO
+
B
O
N N N
O
N H
O
B
O O
N H
OR
OR
O
O
To Next Cycle Capping 5'-Unreacted Hydroxyl DMTrO
B
O
DMTrO O
AcO
OR
+
O P OCE O
O
B
O N H
O O
O
PhosphiteTriester Oxidation
O N H
O O
B
O
B
OR
OR
P OCE O
O
OR
O
O N H
O
AcO
+ B
OR
O
B
O N H
O
OR
O
O
Cycle End
DMTr, 4,4′-dimethoxytrityl; R, tert-butyldimethylsilyl; CE, 2-cyanoethyl; Ac, acetyl; B, uracil-1-yl (U); N 4-acetylcytosin-1-yl (CAc); N 6-phenoxyacetyladenin-9-yl (APAC); N2-[(4-isopropyl)phenoxy]acetylguanin-9-yl (GiPrPAC)
Figure 3.6.1 Synthesis of oligoribonucleotide with 2′-O-TBDMS groups on solid-support via the phosphoramidite approach.
RNA phosphoramidites (Amersham Pharmacia Biotech; diluted on the synthesizer to 0.1 M in acetonitrile, using automated protocols) 5′-O-DMTr-N6-(phenoxyacetyl)-2′-O-TBDMS-adenosine-3′-O-(β-cyanoethylN,N-diisopropyl) phosphoramidite 5′-O-DMTr-N2-(isopropylphenoxyacetyl)-2′-O-TBDMS-guanosine-3′-O-(βcyanoethyl-N,N-diisopropyl) phosphoramidite 5′-O-DMTr-N4-(acetyl)-2′-O-TBDMS-cytidine-3′-O-(β-cyanoethyl-N,Ndiisopropyl) phosphoramidite 5′-O-DMTr-2′-O-TBDMS-uridine-3′-O-(β-cyanoethyl-N,N-diisopropyl) phosphoramidite. 3% (v/v) TCA in methylene chloride (PE Biosystems) Cap A: 10% (v/v) acetic anhydride/10% (v/v) 2,6-lutidine in THF (PE Biosystems) Cap B: 16% (v/v) 1-methyl imidazole in THF (PE Biosystems) Iodine solution: 16.9 mM I2/49 mM pyridine/9% (v/v) water in THF (PE Biosystems) Synthesis grade acetonitrile (Burdick & Jackson) Activator (prepare in acetonitrile): 0.25 M 5-ethylthio-1H-tetrazole (SET), made from solid (American International Chemical) or 0.5 M 4,5-dicyanoimidazole solution (DCI), made from solid (Proligo) or 0.45 M 1H-tetrazole (TET; Glen Research). Synthesis columns for 0.2-µmol-scale syntheses (PE Biosystems) ABI 394 DNA/RNA synthesizer (PE Biosystems)
Oligoribonucleotides with 2′-O(tert-Butyldimethylsilyl) Groups
1. Load an empty synthesis column with ∼8 mg of the RNA primer solid-support (i.e., ∼25 µmol/g) corresponding to the first nucleotide at the 3′- end of the oligoribonucleotide.
3.6.2 Supplement 1
Current Protocols in Nucleic Acid Chemistry
Table 3.6.1 Equivalents to the Synthesis Scale and Wait Time Required for Optimal Solid-Phase Synthesis
Reagentsa
Equivalents Wait time (sec)
Phosphoramidites 15 Activator: SET 39 DCI 80 TET 70 Acetic anhydride (Cap A) 655 1-Methylimidazole (Cap B) 1245 TCA 700 Iodine solution 21
465 465 465 465 5 5 10 15
aDescriptions of these reagents have been shortened; see Basic Protocol 1 materials list for complete information.
2. Perform synthesis on an ABI 394 synthesizer according to the cycle outlined in Tables 3.6.1 and 3.6.2. See materials list above as well as Tables 3.6.1 and 3.6.2 for synthesis materials.
3. At the end of the synthesis, perform a manual detritylation cycle on the synthesizer (optional) to remove the dimethoxytrityl group at the 5′-end of the oligonucleotide. 4. Remove the synthesis column from the synthesizer and dry it either under a stream of argon or in a vacuum dessicator for 10 to 15 min. 5. Deprotect the oligoribonucleotide (see Basic Protocol 2, Alternate Protocol 1, or Alternate Protocol 2). OLIGORIBONUCLEOTIDE DEPROTECTION WITH NH4OH/ETHANOL AND TBAF
BASIC PROTOCOL 2
This protocol describes a deprotection scheme using a 3:1 cocktail of concentrated ammonium hydroxide and ethanol to cleave the oligoribonucleotide from the solid support, perform the β-elimination of the cyanoethyl phosphodiester protecting group, and cleave the exocyclic N-acyl protecting groups. A subsequent treatment with ntetrabutylammonium fluoride effects cleavage of the tert-butyldimethylsilyl group protecting the 2′-hydroxyl functionality. (Fig. 3.6.2). Materials Oligoribonucleotide attached to solid support (see Basic Protocol 1) 3:1 (v/v) 29% ammonium hydroxide (Mallinckrodt Baker)/100% ethanol (prepare immediately before use) 3:1:1 (v/v/v) ethanol/acetonitrile/H2O 1.0 M n-tetrabutylammonium fluoride (TBAF) in THF (Aldrich) 50 mM and 2 M triethylammonium bicarbonate (TEAB), pH 7.8 (see recipe) Heating blocks 4-mL glass screw-top vial with Teflon lined lid (Wheaton) 14-mL centrifuge tubes (Falcon) Qiagen-tip 500 column (Qiagen) 1. Transfer the dried oligoribonucleotide on solid support from the synthesis column (see Basic Protocol 1) to a 4-mL glass screw top vial with Teflon-lined lid.
Synthesis of Unmodified Oligonucleotides
3.6.3 Current Protocols in Nucleic Acid Chemistry
Supplement 1
Table 3.6.2 Summary of a 0.2 µmol–Scale Cycle for Oligoribonucleotide Synthesis on ABI 394 DNA/RNA Synthesizera
Step
Function
Wash steps 1 Acetonitrile to waste 2 Acetonitrile to column 3 Argon reverse flush 4 Argon block flush Chain extension steps 5 Activator to waste 6 Amidite + activator to column 7 Push to column 8 Wait 9 Push to column 10 Wait 11 Repeat steps 9-10 (6 times) 12 Argon flush to waste Wash steps 13 Acetonitrile to waste 14 Repeat steps 3 and 4 Capping steps 15 Cap A and B to column 16 Wait Wash steps 17 Repeat steps 13 and 14 Oxidation steps 18 Iodine to column 19 Wait Wash steps 20 Repeat steps 13 and 14 21 Acetonitrile to column 22 Argon flush to waste 23 Acetonitrile to column 24 Repeat steps 3 and 4 25 Repeat steps 21, 23 and 24 Detritylation steps 26 TCA/DCM to column 27 Wait 28 Argon trityl flush 29 Repeat steps 26-28 Wash steps 30 Acetonitrile to column 31 Argon trityl flush 32 Repeat steps 2, 3, and 4 33 End
Time (sec) 3 10 8 4 1.7 1.2 NA 150 0.1 45 0.1 4
4 5
4 15
10 4 10
6 5 5
10 5
aDelivery flow rate are ∼3.1 mL/min for phosphoramidites and activators and ∼3.6 mL/min for all other reagents.
Oligoribonucleotides with 2′-O(tert-Butyldimethylsilyl) Groups
3.6.4 Supplement 1
Current Protocols in Nucleic Acid Chemistry
2. Add 2 mL of a 3:1 ammonium hydroxide/ethanol solution to the vial, screw cap on tightly, and place in a heat block for 4 hr at 65°C. 3. Remove the vial from the heat block, place it in a block kept at room temperature, and place the block in a –20°C freezer until cooled (i.e., ∼30 min). IMPORTANT NOTE: To avoid loss of contents, it is important to cool the sample vial in step 4 before opening the screw cap.
4. Decant the solution (containing the deprotected oligonucleotide) into a 14-mL Falcon tube. Add 1 mL of ethanol/acetonitrile/H2O solution, vortex well, and allow the support to settle. Decant wash and add to deprotected oligonucleotide solution. Repeat wash twice. Due to the presence of the hydrophobic 2′-O-TBDMS groups on the RNA, this organic wash helps increase the recovery yield.
5. Evaporate the combined supernatant from step 4 in the 14-mL tube on a Speedvac evaporator (i.e., ∼2.5 hr on medium heat). 6. Add 1 mL of 1.0 M TBAF to the 14-mL tube containing the dried RNA and allow to react at room temperature for 24 hr. 7. Quench the desilylation reaction by adding 9 mL of 50 mM TEAB, then refrigerate at 4°C until ready for desalting. Deprotected oligoribonucleotides are highly sensitive to nuclease degradation. Therefore, gloves should always be worn when manipulating deprotected synthetic RNA; sterile disposable containers, nuclease-free laboratory reagents, and Milli-Q water should always be used to limit potential exposure to nucleases.
8. Prewash the Qiagen-tip 500 cartridge with 10 mL of 50 mM TEAB. 9. Load the quenched reaction in TEAB onto the Qiagen-tip 500 anion-exchange cartridge. 10. Wash the loaded cartridge with 10 mL of 50 mM TEAB and discard the eluent. Elute the RNA with 10 mL of 2 M TEAB into a sterile tube, and dry to a white powder on a Speedvac evaporator. OLIGORIBONUCLEOTIDE DEPROTECTION WITH AQUEOUS METHYLAMINE AND TRIETHYLAMINE TRIHYDROFLUORIDE
ALTERNATE PROTOCOL 1
This protocol describes a deprotection scheme using aqueous methylamine and triethylamine trihydrofluoride as alternate reagents to effect nucleobase, 2′-hydroxyl and phosphodiester deprotection (Fig. 3.6.2.). Also see APPENDIX 3C, Basic Protocol 3, for general discussion of RNA oligonucleotide of deprotection. Additional Materials (also see Basic Protocol 2) 40% (w/v) aqueous methylamine (Aldrich) Triethylamine trihydrofluoride/NMP/TEA solution (see recipe) 3 M aqueous sodium acetate (e.g., Fluka) n-butanol 70% aqueous ethanol 1. Transfer the oligoribonucleotide attached to the solid-support from the synthesis column (see Basic Protocol 1) to a 4-mL glass screw top vial. 2. Add 1 mL of 40% aqueous methylamine to the vial, screw the cap on tightly, and place in a heat block at 65°C for 10 min.
Synthesis of Unmodified Oligonucleotides
3.6.5 Current Protocols in Nucleic Acid Chemistry
Supplement 1
3. Remove the vial from the heat block, place it in block kept at room temperature, and place the block in −20°C freezer until cooled (e.g., ~20 min). 4. Decant the solution into a 14-mL tube. Add 1 mL of 3:1:1 ethanol/acetonitrile/H2O solution, vortex well, and allow the support to settle. Decant wash solution and add to deprotection solution. Repeat wash twice, for a total of three washes. 5. Evaporate the combined supernatants in the tube on a Speedvac evaporator (i.e., ∼2.5 hr on medium heat). 6. Add 0.3 mL of triethylamine trihydrofluoride/NMP/TEA solution to the tube containing the dried RNA, cap the tube, and place on a heat block for 90 min at 65°C. After incubation, bring to room temperature. 7. Precipitate the oligoribonucleotide directly from the desilylation reaction by adding 25 µL of 3 M aqueous sodium acetate, followed by 1 mL of n-butanol. If the oligoribonucleotide has been synthesized trityl-off, proceed to quenching and desalting steps (see Basic Protocol 2, steps 7 to 10).
8. Cool the mixture to −20°C for 2 hr to overnight and centrifuge 30 min at 4000 × g (3750 rpm in a Beckman GS-GR rotor), 4°C. 9. Decant the solution and wash the pellet with 70% ethanol. Centrifuge 10 min at 4000 × g (3750 rpm in a Beckman GS-GR rotor), 4°C. Decant the supernatant and dry the oligoribonucleotide pellet by using a Speedvac evaporator. This precipitation procedure cannot be applied to the TBAF procedure (see Basic Protocol 2) because of the high organic content of the desilylation reaction. Alternately, if a trityl-on deprotected oligoribonucleotide is sought, quench the desilylation reaction by adding 5 mL of 1.5 M ammonium bicarbonate, pH 7.5 (see recipe in Reagents and Solutions). ALTERNATE PROTOCOL 2
“ONE-POT” OLIGORIBONUCLEOTIDE DEPROTECTION WITH ANHYDROUS METHYLAMINE AND NEAT TRIETHYLAMINE TRIHYDROFLUORIDE This protocol describes an expedited deprotection scheme for oligoribonucleotides using anhydrous ethanolic methylamine and triethylamine trihydrofluoride to effect nucleobase, 2′-hydroxyl, and phosphodiester deprotection (Fig. 3.6.2).
HO
B
O O
R
HO
OTBDMS
Nucleobase Deprotection
O
B
NH4OH:EtOH (3:1) or 40% aq. CH3NH2 or 33% CH3NH2 in EtOH
R
O
n
2'-O-Deprotection
−
O
H
B
O O
OH
O P O O
O
OTBDMS
O
HO
OTBDMS
O O P O
O P OCE O
B
O
1.0 M TBAF in THF or TEA•3HF/NMP/TEA or TEA•3HF
B
−
O
O O
OTBDMS n
H
B
OH n
O NH
Oligoribonucleotides with 2′-O(tert-Butyldimethylsilyl) Groups
BR = U, CAc, APAC, GiPrPAC B = U, C, A, G TBDMS, tert-butyldimethylsilyl; TBAF, tetra-n-butylammonium fluoride; NMP, 1-methyl-2-pyrrolidinone; TEA, triethylamine
Figure 3.6.2 Deprotection of chemically synthesized oligoribonucleotides with 2′-O-TBDMS groups.
3.6.6 Supplement 1
Current Protocols in Nucleic Acid Chemistry
Additional Materials (also see Basic Protocol 2) 1:1 (v/v) mixture of 33% ethanolic methylamine and anhydrous DMSO 1.5 M ammonium bicarbonate, pH 7.5 (see recipe) Acetonitrile 1:1:1 (v/v/v) acetonitrile/methanol/H2O RNase-free H2O/DEPC-treated C18 SepPak cartridges (Waters) 1. Transfer the dried solid support-bound oligoribonucleotide from the synthesis column to a 4-mL glass screw top vial. 2. Add 0.8 mL of a 1:1 (v/v) mixture of 33% methylamine/DMSO to the vial, screw the cap on tightly, and place on a heat block at 65°C for 15 min. DMSO is useful for solubilizing the partially deprotected oligoribonucleotide and helps prevent alkaline hydrolysis of the fully deprotected RNA.
3. Remove the vial from the heat block and place it in a block kept at room temperature. 4. Add 0.1 mL of neat triethylamine trihydrofluoride, vortex well, and place on a heating block for 15 min at 65°C. Cool the sample vial at room temperature and then at –20°C for 10 min. The solution usually gels after the addition of triethylamine trihydrofluoride.
5. Quench the reaction by adding 1 mL of 1.5 M ammonium bicarbonate, pH 7.5. Allow the support to settle and decant the supernatant. If sample is not cool enough, addition of ammonium bicarbonate solution may lead to significant effervescence.
6. Prewash the C18 Sep-pak cartridge successively with 10 mL of acetonitrile, 10 mL of 1:1:1 acetonitrile/methanol/H2O solution, and 20 mL of RNase free H2O. 7. Apply the quenched solution to the prewashed C18 Sep-pak cartridge and wash the loaded cartridge with 10 mL of RNase-free H 2O to remove salts. 8. Elute the product from the column by using 10 mL of 1:1:1 acetonitrile/methanol/H2O and evaporate the eluate to dryness on a Speedvac. This desalting step will detritylate a trityl-on deprotected oligoribonucleotide. The precipitation procedure of Alternate Protocol 1 (steps 7 to 9) cannot be applied to the “one-pot” deprotection protocol because of the high organic content.
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Ammonium bicarbonate,1.5 M (pH 7.5) Weigh 118.59 g of solid NH4HCO3 and bring up to 1 L with Milli-Q water. Store the buffer solution up to 2 months at 4°C. Triethylamine trihydrofluoride/NMP/TEA solution, 1.5:0.75:1 (v/v/v) Combine, in the following order, 0.75 mL 1-methyl-2-pyrrolidinone (NMP), 1.0 mL triethylamine (TEA), and 1.5 mL triethylamine trihydrofluoride. If the reagent is not used immediately after preparation, store it in a capped container on a warm (55° to 65°C) heat block. The reagent will form an intractable gel if allowed to stand at room temperature.
Synthesis of Unmodified Oligonucleotides
3.6.7 Current Protocols in Nucleic Acid Chemistry
Supplement 1
Triethylammonium bicarbonate (TEAB), 50 mM and 2 M (pH 7.8) Place a 4-L bottle containing 3 L of Super-Q water in an ethanol/ice bath. Bubble carbon dioxide through the water. After 15 min add 279 mL of neat triethylamine every 2 hr for 8 hr (total 4 additions). After 8 hr of CO 2 saturation, check the pH on an aliquot. Continue bubbling CO2 until the pH reaches 7.8 then bring to 4 L with water. Store the buffer solution up to 6 months at 4°C. To prepare 50 mM TEAB, dilute 2M TEAB solution 40-fold with water. COMMENTARY Background Information
Oligoribonucleotides with 2′-O(tert-Butyldimethylsilyl) Groups
Synthesis of oligoribonucleotides Similar to that of oligodeoxyribonucleotides, the chemical synthesis of oligoribonucleotides on solid support is routinely performed via the phosphoramidite method (Fig. 3.6.1; also see UNITS 3.3 & 3.5). However, the additional 2′-hydroxyl function of the ribofuranosyl sugar requires suitable protection during oligoribonucleotide synthesis. Among the various protecting groups available, trialkylsilyl ethers (Ogilvie et al., 1976, 1977; Wincott and Usman, 1994), and particularly the tertbutyldimethylsilyl ether (TBDMS; Usman et al., 1985), have been the most extensively studied, since fluoride-mediated silyl ether deprotection is quite orthogonal to the other acid- and base-labile protecting groups commonly used in oligonucleotide chemistry. Because of the steric bulk introduced by the TBDMS group, coupling 2′-O-TBDMS protected ribophosphoramidites to a growing oligonucleotide chain is notoriously more sluggish as compared to their 2′-deoxy analogs. The elongation cycle for automated oligoribonucleotide synthesis is similar to that of oligodeoxynucleotides and consists of the detritylation, coupling, capping, and oxidation steps. Each of these steps is critical for successful RNA synthesis. One important difference regarding the detritylation step is the possibility of using higher concentrations of haloacids due to the reduced sensitivity of ribofuranosylnucleotides to acid-mediated depurination. The oxidation and capping steps do not differ significantly from traditional oligodeoxyribonucleotide synthesis. Conversely, the coupling step has been the focus of much attention through the development of a number of phosphate protecting groups (Usman et al., 1987; Sinha et al., 1983; Schwarz et al., 1984; Hamamoto et al., 1986; Kayakawa et al., 1990; Wada and Sekine, 1994; Ravikumar and Cole, 1994) and different phosphoramidite dialkylamino functions (Lyttle et al., 1991; Sinha et al., 1984; Beaucage and Caruthers,
1981) aimed at providing faster coupling rates. Although some of these modifications have been commercialized, the phosphoramidites carrying the 2-cyanoethyl-N,N-diisopropyl combination (Sinha et al., 1983, 1984) are predominantly used. According to this chemistry, the coupling time for 2′-O-TBDMS ribophosphoramidites is considerably longer than that of the 2′-deoxy series for synthesis scales ranging from 0.2 to 2.5 µmol. Particularly important to commercially available ribophosphoramidites is the acidic activation step that allows rapid conversion of stable N,N-diisopropyl phophoramidite to azolide intermediates. These highly reactive transient species are then coupled to the free 5′-hydroxyl of any oligonucleotide bound to a support to form phosphite triester internucleotidic bonds which are further oxidized to the acid-stable pentavalent phosphotriester linkages. Dramatic improvements in oligoribonucleotide synthesis are achieved when activators more acidic than the standard 1-H-tetrazole (pKa = 4.8) are used. Such activators may include 5-(4-nitrophenyl)1H-tetrazole (pKa = 3.7) (Sproat et al., 1989) or 5-ethylthio-1H-tetrazole (pKa = 4.28) (Wincott et al., 1995). These tetrazole derivatives are supposedly more efficient at protonating the trivalent phosphorus. Once protonated, this electrophilic phosphorus center reacts with a tetrazole molecule to displace an N,N-diisopropylamino group. 5-Ethylthio-1H-tetrazole (SET) became the preferred activator for oligoribonucleotides, and has been used in a number of reports describing successful RNA synthesis. However, the acidic properties of 5ethylthio-1H-tetrazole can cripple larger-scale oligoribonucleotide syntheses because of concomitant acidic activator–mediated detritylation of nucleoside phosphoramidites, occurring as a result of an extended coupling reaction time required for satisfactory coupling efficiency (Krotz et al., 1997). This problem spearheaded the development of less acidic but more nucleophilic activators (Vargeese et al., 1998) like 4,5-dicyanoimidazole (pKa = 5.2) or benzimi-
3.6.8 Supplement 1
Current Protocols in Nucleic Acid Chemistry
dazolium triflate (pKa = 4.5) (Hayakawa et al., 1996). Although no mechanistic studies have been presented, these activators are reported to speed up coupling reaction rates due to the increased nucleophilicity of their conjugated base while exhibiting sufficient acidity to protonate the tricoordinated phosphorus center. Automated oligoribonucleotide synthesis can be easily performed on long chain alkylamine controlled pore glass (CPG; Pon et al., 1988; UNITS 3.1 & 3.2). Non-swellable highly cross-linked polystyrene solid-supports have shown to be generally superior to CPG due to their increased mechanical and chemical resistance (McCollum and Andrus, 1991). Deprotection of oligoribonucleotides The deprotection of crude oligoribonucleotides traditionally requires a basic treatment, which allows for the transamination of the N-acyl exocyclic protecting groups, βelimination of the 2-cyanoethyl phosphate protecting group, and cleavage of the succinic ester bond linking the oligoribonucleotide to the solid support (Fig. 3.6.2). Of these three concomitant reactions, base deprotection is by far the most rate-limiting step. Once these reactions are accomplished, a fluoride treatment removes the substituted silyl ether function protecting the 2′-hydroxyl of the ribofuranose ring. Nucleobase deprotection In the early days of oligoribonucleotide chemistry, the heterocyclic amino function of each nucleobase was almost exclusively protected with the benzoyl (rA and rC) and isobutyryl (rG) groups. Although these protecting groups on synthetic DNA are efficiently removed by treatment with concentrated ammonium hydroxide, the presence of the 2′-OTBDMS group in synthesized RNA necessitated the use of ethanolic ammonia (Lyttle, 1993) or a solution of ammonium hydroxide in ethanol (3:1, v/v) for 12 to 16 hours at 55°C to minimize the cleavage of the silyl group (Stawinski, 1988; Wu et al., 1989). Premature deprotection of the 2′-hydroxyl under basic conditions results in extensive oligoribonucleotide chain cleavage from intramolecular nucleophilic attack of the 2′-hydroxyl group on the phophodiester function. To circumvent this unwanted side reaction and shorten the deprotection time, two strategies were investigated over the last decade. One of these strategies involves the use of various combinations of hydrazine, ethano-
lamine, and alcohol (Polushin et al., 1991) or more nucleophilic alkylamines (Wincott et al., 1995; Reddy et al., 1995) for oligoribonucleotide deprotection. For example, 40% aqueous methylamine, in place of or in addition to 30% ammonium hydroxide, cleaves the nucleobase N-acyl protecting groups in a few minutes at 65°C or ~1 hr at room temperature. However, this procedure requires the use of N4-acetyl cytidine phosphoramidite derivatives to avoid a well documented transamination side reaction (Reddy et al., 1994). The second strategy relates to the development of base-labile amino-protecting groups that would further shorten exposure of the 2′O-TBDMS group to basic conditions. These groups belong to the phenoxyacetyl (PAC) (Wu et al., 1988; Chaix et al., 1989) and amidinetype (McBride et al., 1986) protecting groups, mainly used for ribopurine phosphoramidites given that the N4-acetyl protection of cytidine appears quite optimal. Amidine protecting groups include acetamidines (McBride et al., 1986) and dialkylformamidines (Vinayak et al., 1992), which can be cleaved in 2 to 3 hours at 55°C using concentrated ammonium hydroxide/ethanol (3:1, v/v). The main advantage of the dimethylformamidine protecting group when used in conjunction with 2′-deoxyribonucleoside phosphoramidites (Vu et al., 1990) is that it confers an increased resistance towards depurination during the detritylation step. However, because oligoribonucleotides are inherently less sensitive to depurination, N-phenoxyacetyl protection has been preferred for the commercial manufacturing of these biomolecules. The phenoxyacetyl and 4-tert-butyl- or (4-isopropylphenoxy)acetyl protecting groups (Sinha et al., 1993) are considerably more labile than amidines under basic conditions. Typically, these can be quantitatively cleaved from the exocyclic amino function of nucleobases after a 15 min to 1 hr incubation in concentrated ammonium hydroxide/ethanol (3:1) at 65°C, or 2 to 4 hr at room temperature. The use of “fast deprotecting groups” of the PAC family does not preclude the concomitant use of more nucleophilic alkylamines. Indeed, combining these two strategies allows for expedited base-labile removal of protecting groups as exemplified in Alternate Protocol 1. 2′-O-tert-butyldimethylsilyl deprotection The fluoride-sensitive tert-butyldimethylsilyl group allows for an efficient orthogonal deprotection of the 2′-hydroxyl of synthetic RNA. The use of fluoride-based reagents is the
Synthesis of Unmodified Oligonucleotides
3.6.9 Current Protocols in Nucleic Acid Chemistry
Supplement 1
Oligoribonucleotides with 2′-O(tert-Butyldimethylsilyl) Groups
preferred methodology for the removal of the 2′-O-TBDMS group, although Sekine and colleagues (Kawahara et al., 1996) recently reported the application of an acid-catalyzed desilylation scheme to oligoribonucleotides. After completion of nucleobase and phosphotriester deprotection, and subsequent evaporation of the basic solution, addition of n-tetrabutylammonium fluoride (TBAF) in THF to the partially deprotected RNA cleaves the 2′-O-TBDMS group at room temperature within 24 hr (Basic Protocol 2). However, limited solubility of the RNA in this apolar solvent hampers the efficient deprotection of longer oligoribonucleotides. To circumvent this problem, RNA dissolution in either dimethylsulfoxide (Gasparutto et al., 1992) or 50% ethanol (Scaringe, 1995) has been investigated. The notorious water sensitivity of TBAF (Hogrefe et al., 1993) and the desalting step required after quenching the desilylation reaction have led to the development of other fluoride-based reagents. Triethylamine trihydrofluoride (Alternate Protocol 1) has been shown to be a superior reagent either neat (Pirrung et al., 1994; Westman and Stromberg, 1994) or in combination with polar aprotic solvents such as dimethylformamide (Vinayak et al., 1995) or 1-methyl2-pyrrolidinone (Wincott et al., 1995). This reagent promotes 2′-O-TBDMS deprotection within 30 to 90 min at 65°C or 4 to 8 hr at room temperature. Using triethylamine trihydrofluoride, the time-consuming desalting step may be replaced by a sodium acetate/1-butanol precipitation procedure (Wincott et al., 1995) that is not compatible with the high organic content present in TBAF deprotection mixtures. Further application of neat triethylamine trihydrofluoride in a “one-pot deprotection” procedure (Alternate Protocol 2; Bellon, 2000) that employs a mixture containing anhydrous ethanolic methylamine allows for expedititious RNA deprotection. This procedure requires a quenching step with ammonium bicarbonate if one desires to retain the trityl group on the oligonucleotide, and a subsequent desalting/purification on a reverse-phase cartridge because the presence of ethanol and dimethylsulfoxide prevent RNA precipitation from butanol. HPLC analysis and purification of synthetic RNA is now well-documented (Wincott et al., 1995; Sproat et al., 1995; and Vinayak et al., 1995). In particular, the use of perchloratebased buffer (Na or Li form) in conjunction with anion-exchange Nucleo Pac columns, allows for easy purification of full-length RNA product from truncated sequences.
Critical Parameters Automated oligoribonucleotide synthesis according to the phosphoramidite method has not significantly evolved over the last decade. Therefore, all precautions mentioned in the major textbooks (Gait, 1984; Eckstein, 1991; Agrawal, 1993) still remain valid. It is particularly important to emphasize that phosphoramidite chemistry is highly water sensitive. Great care should therefore be taken to ensure that the phosphoramidites and activator are dissolved in strictly anhydrous acetonitrile. All ancillary reagents (i.e., acetonitrile, detrilylation, capping, and oxidation solutions) are commercially available, guaranteeing high performance reproducibility in the syntheses and relieving the chemist from time-consuming anhydrous distillations. Sterile, disposable pipet tips and plastic tubes should be used for storing and handling RNA. Troubleshooting an oligoribonucleotide synthesis is a relatively easy task when the trityl assay is used to spectrophotometrically monitor the synthesis (Gait, 1984; see also APPENDIX 3C, Basic Protocol 1, Support Protocol 1). Deprotection of oligoribonucleotides according to the three protocols presented in this unit is quite straightforward. However, Alternate Protocol 2 or the “one-pot” deprotection protocol should not be used in conjunction with controlled-pore-glass (CPG) synthesized RNA because of the inherent incompatibility between triethylamine trihydrofluoride and the silyl components of CPG. Because all the basic solutions used are composed of gaseous amines dissolved in water or ethanol, freshly opened bottles will ensure that the effective concentration of the amine (i.e., 29% NH4OH or 40% methylamine in water) is close to its stated nominal value. Typically, reagent bottles should be replaced every two weeks if opened on a regular basis. This may be especially true for the TBAF solution in THF (used in Basic Protocol 2) because a low water content is critical for efficient desilylation. The deprotection times at 65°C are suggested for 2 mL of basic solution, and need to be extended if larger amounts of reagents are used. Finally, deprotected oligoribonucleotides are highly sensitive to nuclease degradation. Therefore, gloves should always be worn when manipulating deprotected synthetic RNA; sterile disposable containers and Milli-Q water should also always be used to limit potential exposure to nucleases. DEPC treated water should be used when desalting RNA on C18 cartridges.
3.6.10 Supplement 1
Current Protocols in Nucleic Acid Chemistry
Anticipated Results Because of the iterative nature of solidphase oligoribonucleotide synthesis, only modest chemical yields of oligoribonucleotide can be produced, especially for longer synthetic RNAs (i.e., >30 residues). When applying Basic Protocol 1 using 5-ethylthio-1H-tetrazole, a realistic averaged stepwise chemical yield (ASWY) of 97.5% can be routinely obtained for RNA synthesis. This ASWY is determined by the ratio (µmol FLR/µmol scale)1/n × 100 where µmol FLR is the amount of full length RNA in the crude mixture, µmol scale is the synthesis scale, and n is the number of synthesis cycles. This corresponds to an isolated yield of 41% for the all-RNA 36-mer pictured in Figure 3.6.3.A. Figure 3.6.3.B and C shows HPLC profiles of the same sequence synthesized according to Basic Protocol 1 using the alternate activators DCI and TET, respectively. Figure 3.6.3 indicates that 5-ethylthio-1H-tetrazole is the activator of choice for small scale RNA synthesis. At small scale (i.e., <10 µmol), the quality of oligoribonucleotides generated from the presented deprotection protocols does not vary much. Therefore, one should consider the time requirement as an important parameter in se-
lecting a particular protocol. However, given that oligoribonucleotide synthesis often incorporates one or more modified synthons that may be more or less sensitive to the basic or fluoride treatments used, a careful examination of chemical compatibility should be performed prior to selecting the optimal deprotection method.
Time Considerations
Typically, the duration of the 0.2 µmol elongation cycle of an oligoribonucleotide is ∼12 min. It will thus take ∼8 hr to synthesize an all-RNA 37-mer. It requires about 32 hr to perform oligoribonucleotide deprotection according to Basic Protocol 2, whereas processing time can be cut to <8 hrs when adopting Alternate Protocol 1. When using Alternate (“one-pot”) Protocol 2, deprotection time can be shortened to a mere 45 min from start to finish.
Acknowlegments The author gratefully acknowledges Chris Workman, Lara Maloney, Chris Shaffer, and Victor Mokler for their efforts in the development of the second alternative deprotection
Figure 3.6.3 HPLC chromatograms of a 36-mer oligoribonucleotide (5′- GUU UUC CCU GAU GAG GCC GAA AGG CCG AAA UUC UCC -3′) synthesized at the 0.2 µmol scale according to the basic synthesis protocol and deprotected using the “one-pot” deprotection protocol (Alternate Protocol 2). (A) 0.25 M SET, (B) 0.5 M DCI, (C) 0.45M TET. Results obtained using Dionex NucleoPac PA-100 22 × 250–mm column at 50°C. Buffer A (1 mM Tris, 20 mM NaClO4), buffer B (1 mM Tris, 300 mM NaClO4). Gradient 40% B to 70% B in 12 min, flow rate = 1.5 mL/min (see UNIT 10.5).
Synthesis of Unmodified Oligonucleotides
3.6.11 Current Protocols in Nucleic Acid Chemistry
Supplement 1
protocol, and Drs. Fran Wincott and Nassim Usman for continuous support.
Literature Cited Agrawal, S. 1993. Protocols for oligonucleotides and analogs: Synthesis and properties. Humana Press, Totowa, N.J. Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites: A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 37:1859-1862. Bellon, L. and Workman, C. 2000. Deprotection of RNA. US patent 6,054,576. Chaix, C., Molko, D., and Teoule, R. 1989. The use of labile base protecting groups in oligoribonucleotide synthesis. Tetrahedron Lett. 30:71-74. Ecktein, F. 1991. Oligonucleotides and analogues: A practical approach. IRL Press, New York. Gait, M.J. 1984. Oligonucleotide synthesis: A practical approach. IRL Press, Washington D.C. Gasparutto, D., Livache, T., Bazin, H., Duplaa, A.M., Guy, A., Khorlin, A., Molko, D., Roget, D., and Teoule, R. 1992. Chemical synthesis of a biologically active natural tRNA with its minor bases. Nucl. Acids Res. 20:5159-5166. Hamamoto, S. and Takaku, H. 1986. New approach to the synthesis of deoxyribonucleoside phosphoramidite derivatives. Chem. Lett. 1401-1404. Hayakawa, Y., Kataoka, M., and Noyori, R. 1996. Benzimidazolium triflate as an efficient promoter for nucleotide synthesis via the phosphoramidite method. J. Org. Chem. 61:79967997. Hogrefe, R., McCaffrey, A., Borodzine, L., McCampbell, E., and Vaghefi, M. 1993. Effect of excess water on the desilylation of oligoribonucleotides using tetrabutylammonium fluoride. Nucl. Acids Res. 21:4739-4741. Kawahara, S., Wada, T., and Sekine, M. 1996. Unprecedented mild acid-catalyzed desilylation of 2′-O-tert-butyldimethylsilyl group from chemically synthesized oligoribonucleotides intermediates via neighboring group participation of the internucleotidic phosphate residue. J. Am. Chem. Soc. 118:9461-9468. Kayakawa, Y., Wakabayashi, S., Kato, H., and Noyori, R. 1990. The allylic protection in solid-phase oligonucleotide synthesis: An efficient preparation of solid-anchored DNA oligomers. J. Am. Chem. Soc. 112:1691-1696. Krotz, A., Klopchin, P., Walker, K., Srivatsa, S., Cole, D., and Ravikumar, V. 1997. On the formation of longmers in phosphorothioate oligodeoxyribonucleotide synthesis. Tetrahedron Lett. 38:3875-3878.
Oligoribonucleotides with 2′-O(tert-Butyldimethylsilyl) Groups
Lyttle, M., Wright, P., Sinha, N., Bain, J., and Chamberlin, A. 1991. New nucleoside phosphoramidites and coupling protocols for solidphase RNA synthesis. J. Org. Chem. 56:46084615.
Lyttle, M. 1993. Chain cleavage during deprotection of RNA synthesized by the 2′-O-trialkylsilyl protection strategy. Nucleosides Nucleotides. 12:95-106. McBride, L.J., Kierzek, R., Beaucage, S.L., and Caruthers M.H. 1986. Amidine protecting groups in oligonucleotide synthesis. J. Am. Chem. Soc. 108:2040-2048. McCollum, C. and Andrus, A. 1991. An optimized polystyrene support for rapid efficient oligonucleotide synthesis. Tetrahedron Lett. 32:40694072. Ogilvie, K.K., Beaucage, S.L., Entwistle, D.W., Thompson, E.A., Quilliam, M.A., and Westmore, J.B. 1976. Alkylsilyl groups in nucleoside and nucleotide chemistry. J. Carbohydr. Nucleosides Nucleotides. 3:197-227. Ogilvie, K.K., Theriault, N., and Sadana, K. 1977. Synthesis of oligoribonucleotides. J. Am. Chem. Soc. 99:7741-7743. Pirrung, M., Shuey, S., Lever, D., and Fallon, L. 1994. A convenient procedure for the deprotection of silylated nucleosides and nucleotides using triethylamine trihydrofluoride. Tetrahedron Lett. 4:1345-1346. Polushin, N., Pashkova, I., and Efimov, V. 1991. Rapid deprotection procedures for synthetic oligonucleotides. Nucl. Acids Symp. Series. 24:4950. Pon, R., Usman, N., and Ogilvie, K. 1988. Derivatization of controlled pore glass beads for solidphase oligonucleotide synthesis. BioTechniques 6:768-775 Ravikumar, V., and Cole, D. 1994. 2-diphenylmethylsilylethyl (DPSE): A versatile protecting group for oligonucleotide synthesis. Gene 149:157-161. Reddy, M.P., Hanna, N.B., and Farooqui, F. 1994. Fast cleavage and deprotection of oligonucleotides. Tetrahedron Lett. 35:4311-4314. Reddy, M.P., and Hanna, N.B., Farooqui, F. 1995. Methylamine deprotection provides increased yield of oligoribonucleotides. Tetrahedron Lett. 35:4311-4314. Scaringe, S.A., Francklyn, C., and Usman, N. 1990. Chemical synthesis of biologically active oligoribonucleotides using β-cyanoethyl protected ribonucleoside phosphoramidites. Nucl. Acids Res. 18:5433-5441. Schwarz, M., and Pfleiderer, W. 1984. Solution synthesis of fully protected thymidine dimers using various phosphoramidites. Tetrahedron Lett. 24:5513-5516. Sinha, N., Biernat, J., and Koster, H. 1983. Cyanoethyl N,N-dialkylamino-N-morpholinomonochloro phosphoramidites: New phosphitylating agents facilitating ease of deprotection and work-up of synthesized oligonucleotides. Tetrahedron Lett. 24:5843-5846.
3.6.12 Supplement 1
Current Protocols in Nucleic Acid Chemistry
Sinha, N., Biernat, J., McManus, J., and Koster, H. 1984. Use of cyanoethyl-N,N-dialkylamine-/Nmorpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucl. Acids Res. 12:4539-4557. Sinha, N., Davis, P., Usman, N., Perez, J., Hodge, R., Kremsky, J., and Casale, R. 1993. Labile exocyclic amine protection of nucleosides in DNA, RNA and oligonucleotide analog synthesis facilitating deacylation, minimizing depurination and chain degradation. Biochimie. 75:1323. Sproat, B., Lamond, A., Beijer, B., Neuner, P., and Ryder, U. 1989. Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives: Novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucl. Acids Res. 17:33733386. Sproat, B., Colonna, F., Mullah, B., Tsou, D., Andrus, A., Hampel, A., and Vinayak, R. 1995. An efficient method for the isolation and purification of oligoribonucleotides. Nucleosides Nucleotides. 14:255-273. Stawinski, J., Stromberg, R., Thelin, M., and Westman, E. 1988. Studies on the t-butyldimethylsilyl group as 2′-O-protection in oligoribonucleotide synthesis via the H-phosphonate approach. Nucl. Acids Res. 16:9285-9298. Usman, N., Pon, R., and Ogilvie, K. 1985. Preparation of ribonucleoside 3′-O-phosphoramidites and their application to the automated solidphase synthesis of oligonucleotides. Tetrahedron Lett. 26:4567-4570. Usman, N., Ogilvie, K., Jiang, M.Y., and Cedergren, R. 1987. Automated chemical synthesis of long oligoribonucleotides using 2′-O-silylated ribonucleoside 3′-O-phosphoramidtes on CPG. J. Am. Chem. Soc. 109:7845-7854. Usman, N. and Cedergren, R. 1992. Exploiting the chemical synthesis of RNA. Trends Biochem. Sci. 17:334-339. Vargeese, C., Carter, J., Yegge, J., Krivjansky, S., Settle, A., Kropp, E., Peterson, K., and Pieken, W. 1998. Efficient activation of nucleoside phosphoramidites with 4,5-dicyanoimidazole during oligonucleotide synthesis. Nucl. Acids Res. 26:1046-1050.
Vinayak, R., Anderson P., McColum C., and Hampel, A. 1992. Chemical synthesis of RNA using fast oligonucleotide deprotection chemistry. Nucl. Acids Res. 20:1265-1269. Vinayak, R., Andrus, A., Mullah, B., and Tsou, D. 1995. Advances in the chemical synthesis and purification pf RNA. Nucl. Acids Symp. Series 33:123-125. Vu, H., McColum C., Jacobson K., Theisen P., Vinayak R., Spiess E., and Andrus, A. 1990. Fast oligonucleotide deprotection phosphoramidite chemistry for DNA synthesis. Tetrahedron Lett. 31:7269-7272. Wada, T. and Sekine, M. 1994. 2-(trimethylsilyl)ethyl as a phosphate protecting group in oligonucleotide synthesis. Tetrahedron Lett. 35:757-760. Westman, E. and Stromberg, R. 1994. Removal of t-butyldimethylsilyl protection in RNA synthesis: Triethylamine trihydrofluoride is a more reliable alternative to tetrabutylammonium fluoride. Nucl. Acids Res. 22:2430-2431. Wincott, F. and Usman, N. 1994. 2′-(trimethylsilyl)ethoxymethyl protection of the 2′-hydroxyl group in oligoribonucleotide synthesis. Tetrahedron Lett. 35:6827-6830. Wincott, F., DiRenzo, A., Shaffer, C., Grimm, S., Tracz, D., Workman, C., Sweedler, D., Gonzalez, C., Scaringe, S., and Usman, N. 1995. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucl. Acids Res. 23:2677-2684. Wu, T., Ogilvie, K.K., and Pon, R.T. 1988. N-phenoxyacetylated guanosine and adenosine phosphoramidites in the solid phase synthesis of oligoribonucleotides: synthesis of a ribozyme sequence. Tetrahedron Lett. 29:4249-4252. Wu, T., Ogilvie, K.K., and Pon, R.T. 1989. Prevention of chain cleavage in the chemical synthesis of 2′-O-silylated oligoribonucleotides. Nucl. Acids Res. 17:3501-3517.
Contributed by Laurent Bellon Ribozyme Pharmaceuticals Boulder, Colorado
Synthesis of Unmodified Oligonucleotides
3.6.13 Current Protocols in Nucleic Acid Chemistry
Supplement 1
Synthesis of Oligoribonucleotides Using the 2-Nitrobenzyloxymethyl Group for 2′-Hydroxyl Protection
UNIT 3.7
The methodology for oligoribonucleotide construction described in the Basic Protocol uses a DNA synthesizer to add protected ribonucleoside phosphoramidite monomers one after another in defined sequence to a 3′-terminal nucleoside that is attached to a solid support. The monomers used are the 3′-O-(2-cyanoethyl-N,N-diisopropyl) phosphoramidites of Nprotected 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl) ribonucleosides. Their structures are shown in Figure 3.7.1. After a target oligoribonucleotide has been synthesized, it is treated with ammonia to release it from the support and to remove protecting groups from its nucleobases and phosphates. Finally, it is irradiated with long-wave UV light, which removes the 2-nitrobenzyloxymethyl groups from the 2′-hydroxyls, to give the unmodified RNA. The preparation of the 3′-O-(2-cyanoethyl-N,N-diisopropyl) phosphoramidites is described in the Support Protocol. SYNTHESIS AND DEPROTECTION OF N-PROTECTED 2′-O-(2-NITROBENZYLOXYMETHYL) OLIGORIBONUCLEOTIDES
BASIC PROTOCOL
This protocol describes the steps involved in constructing oligoribonucleotides using a DNA synthesizer and starting with phosphoramidites of the 2′-O-(2-nitrobenzyloxymethyl) derivatives of the four common ribonucleosides U, C, A, and G. Details of those parts of the operation that are carried out on the synthesizer will vary depending on the make and model used. However, the above monomers are compatible with all the usual reagents used in these instruments and, with the few exceptions noted below, the manufacturer’s directions for setup and synthesis should be followed in each specific case. A generalized discussion of the use of DNA synthesizers can be found in APPENDIX 3C. In contrast, the deprotection methodology that constitutes the second section of the protocol is unique to oligoribonucleotides constructed from these particular monomers, and is set out in detail below. Materials 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-3′-O-(2-cyanoethylN,N-diisopropyl) phosphoramidites (U, C, A, and G; see Support Protocol) Phosphorus pentoxide Anhydrous acetonitrile (Aldrich) 0.45 M tetrazole (Amersham Pharmacia Biotech) in anhyrdous acetonitrile Pyridine, HPLC grade (Aldrich) Concentrated ammonium hydroxide, 4°C 50% (v/v) aqueous pyridine 50% (v/v) aqueous 2-methyl-2-propanol, HPLC grade 0.2 M formic acid 0.2 M ammonium hydroxide DNA synthesizer with ancillary reagents Amidite vials fitted with septa 5-mL syringes and 21-G needles Synthesis column containing support derivatized with O-acyl ribonucleosides (Glen Research; see Critical Parameters) 10.2-cm pressure tube (e.g., Ace Glass) fitted with Teflon screw-in cap and Teflon-encapsulated O ring Contributed by Tod J. Miller, Miriam E. Schwartz, and Geoffrey R. Gough Current Protocols in Nucleic Acid Chemistry (2000) 3.7.1-3.7.8 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Unmodified Oligonucleotides
3.7.1 Supplement 3
O O
HN NH
DMTrO
5'
N
O
DMTrO
O 3'
(i-Pr)2N
N N
O
O
2'
O
O
O
P
O
(i-Pr)2N NO2
OCH2CH2CN
O
P
O NO2
OCH2CH2CN
O O
HN N N
DMTrO
(i-Pr)2N
P
O O
O
OCH2CH2CN
N
N
N
DMTrO
N
O
(i-Pr)2N NO2
P
NH N
O O
O
O
N H
O
OCH2CH2CN
NO2
CH3O
DMTr =
C
CH3O
i-Pr, isopropyl
Figure 3.7.1 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-3′-O-phosphoramidites of the four common ribonucleosides. Chemical structures are shown for (clockwise from upper-left corner): uridine phosphoramidite, cytidine phosphoramidite, guanosine phosphoramidite, and adenosine phosphoramidite. DMTr, dimethoxytrityl group (bottom).
Synthesis of Oligoribonucleotides Using the 2-Nitrobenzyloxymethyl Group
Yellow lights Covered water bath, 55°C 30-mL Buchner funnel (medium porosity) 500-mL filter flask Vacuum aspirator 500-mL round-bottom flask Rotary evaporator connected to water aspirator, with bath temperature set <40°C 250-mL Pyrex Erlenmeyer flasks Long-wave (365-nm) UV lamp, containing two 15-W black-light tubes behind a UV-transmitting glass filter measuring ∼10 × 30 cm NOTE: The amidites are sensitive to UV light (see Critical Parameters).
3.7.2 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Synthesize oligoribonucleotides 1. Determine volumes of amidite solutions needed to carry out synthesis of the target oligoribonucleotide, following the manufacturer’s instructions for the DNA synthesizer. 2. Use the following concentrations to calculate the required weight of each amidite. U C A G
137 mg/mL 152 mg/mL 156 mg/mL 153 mg/mL.
These values correspond to a concentration of 0.15 M for each amidite.
3. Weigh out the calculated quantity of each 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl)-3′-O-(2-cyanoethyl-N,N-diisopropyl) phosphoramidite into a separate amidite vial. 4. Dry amidites 12 to 16 hr in a vacuum desiccator over phosphorus pentoxide, then cap vials with rubber septa. The phosphorus pentoxide should be allowed to absorb a little atmospheric moisture before being placed in the desiccator, so that the amidites are not contacted by loose dust from the compound’s surface.
5. Dissolve each amidite in the required volume of anhydrous acetonitrile (as determined in step 1), using a fresh 5-mL syringe and 21-G needle to deliver the solvent through the septum of the vial. A syringe and needle should be used to avoid moisture contamination.
6. Fit amidite vials onto the DNA synthesizer as part of the general setup procedure, following the manufacturer’s specific directions. 7. Use 0.45 M tetrazole in anhydrous acetonitrile as the phosphoramidite activator solution. 8. Set the coupling time at 3 min. 9. Install a synthesis column containing support derivatized with O-acyl ribonucleosides and carry out the synthesis. The amidites and growing oligoribonucleotide must be protected from light.
10. Perform the final detritylation on the machine, then remove the synthesis column and either begin the deprotection process immediately, or store the column up to 1 week at –20°C. Deprotect oligoribonucleotides 11. Empty derivatized support from the synthesis column into a 10.2-cm pressure tube containing 2 mL pyridine. Rinse column with pyridine if necessary, but do not allow total amount of pyridine in the pressure tube to exceed 4 mL. NOTE: Steps 11 through 16 should be carried out under yellow lights (see Critical Parameters).
12. Cool pressure tube in ice and fill with cold concentrated ammonium hydroxide to just below the level of the screw cap. A volume (∼16 mL) of ammonium hydroxide should be used that minimizes air space in the closed tube. Only full-strength ammonium hydroxide from a recently opened bottle should be used. The bottle should be sealed and stored at 4°C when not in use.
Synthesis of Unmodified Oligonucleotides
3.7.3 Current Protocols in Nucleic Acid Chemistry
Supplement 3
13. Screw in a Teflon cap fitted with a Teflon-encapsulated O ring, making sure seal is tight. Wrap tube in aluminum foil and heat 24 hr in a covered water bath at 55°C. Invert tube occasionally to mix contents. 14. Chill tube on ice, open carefully, and quickly filter contents through a 30-mL medium-porosity Buchner funnel into a 500-mL filter flask using a vacuum aspirator. CAUTION: This should be performed in a fume hood because the mixture bubbles violently as ammonia is released.
15. Transfer filtrate into a 500-mL round-bottom flask, using two 10-mL washes of 50% aqueous pyridine. 16. Evaporate solution to ∼10 mL using a rotary evaporator connected to a water aspirator. Add 100 mL water and again evaporate to 10 mL. The evaporation should be carried out at the lowest bath temperature (<40°C) consistent with efficient removal of solvent. The solution should not be evaporated to dryness.
17. Add 100 mL of 50% aqueous 2-methyl-2-propanol and evaporate to ∼5 mL. Repeat this process once more to remove traces of pyridine. 18. Transfer solution into a graduated beaker and dilute with 50% aqueous 2-methyl-2propanol so that the final volume corresponds to a concentration of 1 A260 unit of oligonucleotide/mL. Stir solution. The volume can be roughly calculated using the formula V = 10L × S, where V is the final volume in milliliters, L is the number of nucleotides in the oligomer, and S is the scale of the reaction in micromoles.
19. Adjust pH of the solution to 3.7 by careful dropwise addition of 0.2 M formic acid. Do not overshoot. Removal of the 2′-hydroxyl-protecting groups is pH dependent, and is most efficient at pH 3.7.
20. Place 50-mL aliquots of the solution in 250-mL Pyrex Erlenmeyer flasks. Pyrex is transparent to long-wave UV light.
21. In a 4°C cold room, set up flasks on the flat glass filter of a long-wave UV lamp. Irradiate solutions 4.5 hr with intermittent swirling. A brilliant sky-blue fluorescence develops as photolysis products derived from the 2-nitrobenzyl group accumulate in the solution. CAUTION: UV light can cause eye damage. Wear protective glasses and shield the irradiation setup with a sheet of aluminum foil to prevent inadvertent exposure of others.
22. Recombine solutions and adjust pH back up to 7 to 8 by careful addition of 0.2 M ammonium hydroxide with stirring. RNA is degraded by base at a pH above 8. Step 23 should be carried out immediately if too much ammonium hydroxide is added by mistake.
23. Evaporate solution to a volume of 1 to 2 mL under vacuum using the rotary evaporator. The deprotected oligoribonucleotide can now be purified by anion-exchange HPLC or by gel electrophoresis (UNITS 10.4 & 10.5). Synthesis of Oligoribonucleotides Using the 2-Nitrobenzyloxymethyl Group
3.7.4 Supplement 3
Current Protocols in Nucleic Acid Chemistry
SYNTHESIS AND PURIFICATION OF 3′-O-(2-CYANOETHYL-N,N-DIISOPROPYL) PHOSPHORAMIDITES OF 5′-O-(4,4′-DIMETHOXYTRITYL)-2′-O-(2-NITROBENZYLOXYMETHYL) RIBONUCLEOSIDES
SUPPORT PROTOCOL
This section describes a method for obtaining the phosphoramidite monomers of U, C, A, and G used in the Basic Protocol. Materials N-Protected 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl) ribonucleosides (UNIT 2.5) Pyridine, HPLC grade (Aldrich) Anhydrous toluene (Aldrich) Anhydrous tetrahydrofuran (Aldrich) N,N-Diisopropylethylamine (Aldrich) 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite (Aldrich) 99:1 (v/v) chloroform/methanol containing 3% (v/v) triethylamine Ethyl acetate 1 M sodium carbonate (for U, A, G) or 1 M sodium bicarbonate (for C), ice cold Merck 60 silica gel (230 to 400 mesh ASTM) 4:1 (v/v) ethyl acetate/hexane containing 0.1% (v/v) triethylamine (for A, C, and U) 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, and 3.0% (v/v) methanol in dichloromethane containing 5% (v/v) triethylamine (for G) Anhydrous diethyl ether Dry argon 100-mL flask fitted with a septum Rotary evaporator, with its air inlet connected to a Drierite gas-drying unit, connected interchangeably to water aspirator and vacuum pump 1-mL syringe and 21-C needle 3 × 60–cm flash chromatography column, with reservoir and flow controller 100-mL round-bottom flask Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) NOTE: Triethylamine, N,N-diisopropylethylamine, and pyridine should be kept dry over calcium hydride granules. Synthesize phosphoramidites 1. Using a rotary evaporator connected to a water aspirator, dry 1 mmol of any N-protected 5′-O-(4,4′-dimethoxytrityl)-2′-O-(2-nitrobenzyloxymethyl) ribonucleoside in a 100-mL flask by two successive co-evaporations with each of the following solvents: 20 mL pyridine, 20 mL anhydrous toluene, and 20 mL anhydrous tetrahydrofuran. 2. Dissolve residue in 3 mL anhydrous tetrahydrofuran and add 0.7 mL (4 mmol) N,N-diisopropylethylamine. Add a stir-bar, seal flask with a septum, and begin stirring. 3. Using a 1-mL syringe and 21-G needle, add 0.44 mL (2 mmol) 2-cyanoethyl-N,Ndiisopropylchlorophosphoramidite dropwise over a 2-min period through the septum. Continue stirring 2 hr at room temperature.
Synthesis of Unmodified Oligonucleotides
3.7.5 Current Protocols in Nucleic Acid Chemistry
Supplement 3
4. Examine reaction mixture by TLC (APPENDIX 3D) in 99:1 chloroform/methanol containing 3% triethylamine. The product should appear under short-wave UV light as two closely spaced bands of approximately equal intensity, corresponding to its two diastereomeric forms.
5. Dissolve reaction mixture in 150 mL ethyl acetate and extract three times with 75 mL ice-cold 1 M sodium carbonate (1 M sodium bicarbonate for phosphoramidite of C). 6. Evaporate ethyl acetate solution to an oil using the rotary evaporator with the water aspirator. Purify phosphoramidites 7. Prepare a 3 × 60–cm flash chromatography column with a 100-mL bed volume of Merck 60 silica gel packed in starting solvent. 8a. For phosphoramidites of U, C, and A: Dissolve phosphoramidite oil in 2 to 3 mL starting solvent and apply to chromatography column. Use 600 mL of 4:1 ethyl acetate/hexane containing 0.1% triethylamine to elute. Collect 15-mL fractions and assay by TLC in 99:1 chloroform/methanol containing 3% triethylamine. 8b. For phosphoramidites of G: Dissolve phosphoramidite oil in 2 to 3 mL starting solvent and apply to chromatography column. Use a stepwise gradient of 50 mL each of 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, and 3.0% methanol in dichloromethane containing 5% triethylamine to elute. Collect 15-mL fractions and assay by TLC in 99:1 chloroform/methanol containing 3% triethylamine. 9. Combine fractions containing pure product in a 100-mL round-bottom flask and evaporate solution to an oil using the rotary evaporator with the water aspirator. 10. Dissolve residue in 1 to 2 mL anhydrous diethyl ether. Concentrate solution on the rotary evaporator first using the water aspirator, and finally under high vacuum (i.e., with a vacuum pump) until a stable foam is formed. 11. Fill flask with dry argon, seal it, and wrap in aluminum foil. Store amidite up to 1 year at −80°C in the dark. COMMENTARY Background Information
Synthesis of Oligoribonucleotides Using the 2-Nitrobenzyloxymethyl Group
Ribonucleoside phosphoramidite monomers with their 2′-hydroxyls protected by 2-nitrobenzyloxymethyl groups (Schwartz et al., 1992) were introduced at a time when phosphoramidites with other modes of 2′-protection required very long coupling times on synthesizers, often >10 min per condensation. The nitrobenzyloxymethyl compounds were unique in needing coupling times not much longer than those of DNA amidites (i.e., ∼2 min). This enhanced reactivity may be due to the presence of the methylenedioxy “arm” that forms part of the 2-nitrobenzyloxymethyl group and allows it the flexibility to remain out of the way of the reactive phosphoramidite center. However, problems of low reactivity with other types of amidites have been largely
overcome by the introduction of newer, more powerful activating agents such as 5-ethylthioH1-tretrazole (Vinayak et al., 1994), and machine-assisted synthesis of RNA is now generally as rapid and simple as that of DNA. The protocol described in this unit, for example, has been used to prepare biologically functional RNA of up to 33 nucleotides in length.
Compound Characterization The 31P nuclear magnetic resonance (31PNMR) chemical shifts for the 2′-O-(2-nitrobenzyloxymethyl)-protected phosphoramidites of U, C, A, and G are given in Table 3.7.1. If these monomers have been properly prepared and purified, no extraneous peaks should be present in their NMR spectra. Oligoribonucleotides made from these monomers can be charac-
3.7.6 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Table 3.7.1 31P-NMR Chemical Shifts of 2′-O-(2-Nitrobenzyloxymethyl)-Protected Ribonucleoside Phosphoramiditesa
Ribonucleoside
Downfield (ppm)
Upfield (ppm)
A C G U
151.359 152.552 151.408 151.501
151.095 151.127 151.141 150.471
a
In acetonitrile-d3, relative to 85% H3PO4 as external standard at 0 ppm.
terized, after deprotection and purification, using an RNA sequencing kit (nuclease method, e.g., USB) or by digestion with snake venom phosphodiesterase and bacterial alkaline phosphatase followed by reversed-phase HPLC analysis of the digest.
Critical Parameters The techniques for RNA synthesis described in this protocol have been thoroughly tested using polystyrene supports in conjunction with an easily prepared universal adapter that allows any sequence, DNA or RNA, to be assembled on any kind of support (Schwartz et al., 1995). Consequently, this system is strongly recommended. Use of controlled-pore glass has been less well studied. Supports of this type should be chosen with caution as they are attacked by hot ammonia solutions, and the effects of significant amounts of dissolved silica on the deprotection of longer oligoribonucleotides by the methods described here are unknown. In any case, synthesis columns that contain a support derivatized with base-labile O-acyl ribonucleosides (e.g., the 3′-RNA supports supplied by Glen Research) should be used in this protocol. Only these nucleosides will be completely deprotected under the conditions specified. The ribonucleoside phosphoramidites are prepared using the method of Sinha et al. (1984). As in all such syntheses, it is essential to maintain anhydrous conditions. Make sure all glassware is dry and avoid exposing amidite reagents or their solutions to atmospheric moisture. Take further precautions when using these particular amidites because of their sensitivity to UV light. Enough of this radiation exists as a component of standard laboratory lighting to cause slow loss of 2-nitrobenzyloxymethyl groups. Loss of 2′-protecting groups in RNA leads to chain cleavage during the ammonia treatment that is part of the deprotection process. Take steps to minimize exposure not only
of the amidites but also of the synthesized oligoribonucleotides to UV light. This means replacing overhead fluorescent bulbs in a designated work area with yellow bulbs, such as GE or Sylvania Golds. Wrap amidite vials, synthesis columns, and the vessels used in the deprotection process (up to the point where ammonia is removed from the mixtures) in aluminum foil. Once the oligomers are deprotected, they become vulnerable to the action of ribonucleases, which are everywhere in the laboratory, including on the experimenter’s skin. Always wear latex gloves when handling RNA, heat all glassware at 250°C for a few hours before use, and maintain a supply of freshly distilled water in covered containers at 4°C. Store pH electrodes in solutions containing thymol crystals.
Anticipated Results Yields of ribonucleoside phosphoramidites should be 80% to 90%. In oligoribonucleotide syntheses, the amounts of isolated, deprotected oligoribonucleotides that are obtained decrease with increasing length. However, for products up to 20 nucleotides long, yields in the range of 10% to 30%, based on support-bound starting nucleoside, can be expected.
Time Considerations The ribonucleoside phosphoramidites each require one day for preparation and purification. Oligoribonucleotide synthesis takes a day, and deprotection requires a further 2 to 3 days.
Literature Cited Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., deBear, J.S., and Gough, G.R. 1992. Rapid synthesis of oligoribonucleotides using 2′-O-(2-nitrobenzyloxymethyl)-protected monomers. BioMed. Chem. Lett. 2:1019-1024. Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., and Gough, G.R. 1995. A universal adapter for chemical synthesis of DNA or RNA on any single type of solid support. Tetrahedron Lett. 36:27-30.
Synthesis of Unmodified Oligonucleotides
3.7.7 Current Protocols in Nucleic Acid Chemistry
Supplement 3
Sinha, N.D., Biernat, J., McManus, J., and Köster, H. 1984. Polymer support oligonucleotide synthesis XVIII: Use of β-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucl. Acids Res. 12:45394557. Vinayak, R., Colonna, F., Tsou, D., Mullah, B., Andrus, A., and Sproat, B. 1994. Large scale chemical synthesis and purification of RNA. Nucl. Acids Symp. Ser. 31:165–166.
Key References Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., deBear, J.S., and Gough, G.R. 1992. Rapid synthesis of oligoribonucleotides using 2′-O-(2- nitrobenzyloxymethyl)-protected monomers. Bio. Med. Chem. Lett. 2:1019-1024. Provides an overview of the use of 2-nitrobenzyloxymethyl as a 2′-hydroxyl-protecting group in oligoribonucleotide synthesis.
Contributed by Tod J. Miller, Miriam E. Schwartz, and Geoffrey R. Gough Purdue University West Lafayette, Indiana
Synthesis of Oligoribonucleotides Using the 2-Nitrobenzyloxymethyl Group
3.7.8 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Chemical Synthesis of RNA Sequences with 2′-O-[(Triisopropylsilyl)oxy]methylprotected Ribonucleoside Phosphoramidites
UNIT 3.8
This unit describes the chemical synthesis of oligoribonucleotides from 2′-O-[(triisopropylsilyl)oxy]methyl-protected phosphoramidites (TOM-phosphoramidites), including TOM-phosphoramidite preparation (see Basic Protocol 1), assembly on DNA synthesizers (see Basic Protocol 2), and subsequent deprotection (see Basic Protocol 3). The preparation of the TOM-protected phosphoramidite building blocks is carried out by introducing a 2-cyanoethyl-N,N-diisopropylaminophosphinyl group to the 3′-O position of N-acetyl-5′-O-(4,4′-dimethoxytrityl)-2′-O-[(triisopropylsilyl)oxy]methyl ribonucleosides. The preparation of these TOM-protected ribonucleosides is described in UNIT 2.9. The assembly of RNA sequences with TOM-phosphoramidites can be carried out under essentially the same conditions as the assembly of DNA sequences. With very minor exceptions, the same chemistry is employed and no additional equipment is required. Due to the minimal steric hindrance of the TOM protecting group, RNA syntheses with TOM-phosphoramidites are more efficient than syntheses with the traditional 2′- O-(tertbutyldimethylsilyl)phosphoramidites (TBDMS-phosphoramidites, UNIT 3.6). Specifically, better coupling yields are obtained with much shorter coupling times (99% at 2.5 min). This property, together with a reliable deprotection behavior, allows the efficient preparation of relatively long RNA sequences, even on a large scale and within a short time. The assembly of oligoribonucleotides is carried out by stepwise addition of phosphoramidite building blocks to an immobilized nucleoside until the desired sequence has been obtained. Each addition of a new building block requires four reactions (detritylation, coupling, capping, oxidation) that make up one cycle. After the assembly, the detachment of the sequence from the solid support and the removal of the nucleobaseand phosphodiester-protecting groups are carried out under basic nucleophilic conditions with methylamine/water/ethanol, followed by removal of the remaining 2′-O-TOM protecting groups with tetra-n-butylammonium fluoride. After workup by size-exclusion chromatography, crude sequences are obtained, which ultimatively can be purified by high-performance liquid chromatography (HPLC; UNIT 10.5) or polyacrylamide gel electrophoresis (PAGE; UNIT 10.4). CAUTION: All reactions must be performed in a well-ventilated fume hood to avoid exposure to 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite. NOTE: Always use the highest quality of solvents and reagents. All reagents and solvents used for deprotection must be sterile and free of RNases (e.g., Fluka reagents for molecular biology). PREPARATION OF 2′-O-TOM-PROTECTED PHOSPHORAMIDITES The conversion of N-acetyl-5′-O-DMTr-2′-O-TOM-protected ribonucleosides into the corresponding phosphoramidite building blocks is shown in Figure 3.8.1. The structure of the TOM protecting group prevents its migration from the 2′-O to the 3′-O position, even under basic reaction conditions. Without extraction, the products are directly purified by chromatography on silica gel. In order to obtain pure phosphoramidite building blocks, the starting materials and the reaction solvent should be as dry as possible. For a
BASIC PROTOCOL 1
Synthesis of Unmodified Oligonucleotides Contributed by Stefan Pitsch and Patrick A. Weiss Current Protocols in Nucleic Acid Chemistry (2001) 3.8.1-3.8.15 Copyright © 2001 by John Wiley & Sons, Inc.
3.8.1 Supplement 7
Figure 3.8.1 Preparation of the four 2′-O-TOM-protected ribonucleoside phosphoramidites S.2a-S.2d. D M Tr, 4,4′-dimethoxytrityl; i-Pr2NE t, N-ethyl-N,N-diisopropylamine; iPr2NP(Cl)OCH2CH2CN, 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite.
straightforward isolation, the reaction should be complete and the minimal amount of phosphitylation agent should be employed. NOTE: The products are very acid sensitive; any contact with acids must be completely avoided. Materials Nitrogen or argon gas source N-Acetyl-5′-O-(4,4′-dimethoxytrityl)-2′-O-[(triisopropylsilyl)oxy]methyl ribonucleosides (UNIT 2.9): N6-Ac-5′-O-DMTr-2′-O-TOM-adenosine (S.1a) N2-Ac-5′-O-DMTr-2′-O-TOM-guanosine (S.1b) N4-Ac-5′-O-DMTr-2′-O-TOM-cytidine (S.1c) 5′-O-DMTr-2′-O-TOM-uridine (S.1d) Dichloromethane N-Ethyl-N,N-diisopropylamine 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite (Aldrich) Ethyl acetate Hexane Methanol Anisaldehyde reagent (see recipe) Silica gel (230 to 400 mesh, Fluka or Merck) Sand 250-mL one-neck flask equipped with a stir bar Rubber septum Balloon 50-µL syringe TLC plates (Merck silica gel 60, 4 × 10–cm) 254-nm UV lamp 5-cm-diameter chromatography column Rotary evaporator with a vacuum pump or water aspirator Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and column chromatography (APPENDIX 3E)
Synthesis of RNA Sequences with 2′-O-TOM-protecte d Ribonucleoside Phosphoramidites
3.8.2 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Prepare phosphoramidites 1. In a 250-mL one-neck flask equipped with a stir bar, a balloon filled with nitrogen or argon gas, and a rubber septum, dissolve 20 mmol of each dry N-Ac-5′-O-DMTr2′-O-TOM-ribonucleoside (S.1a-d) in 70 mL dry dichloromethane. 2. While stirring, add 8.1 mL (50 mmol) N-ethyl-N,N-diisopropylamine and then slowly add 5.4 mL (25 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite. 3. Stir the clear reaction mixture overnight at room temperature. 4. Take ∼50 µL of the clear reaction mixture with a syringe and dilute it with 0.5 mL dichloromethane in a small tube. Analyze by TLC (APPENDIX 3D) using 1:4 (v/v) hexane/ethyl acetate for A, C, and U, and 19:1 (v/v) dichloromethane/methanol for G. Co-spot the starting material for comparison. Visualize by exposure to a 254-nm UV lamp and stain with anisaldehyde reagent. The product typically migrates slightly faster than the starting material. In this reaction, two epimeric products are formed; consequently, the two pyrimidines show two distinct product spots. Addition of triethylamine to solvents is not necessary at this step.
5. Optional: If the reaction is not nearly complete (>5% starting material remaining), add an additional portion (∼0.2 eq) of 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite, stir 2 hr at room temperature, and repeat TLC analysis. Try to limit the amount of phosphitylating agent as much as possible. If too much phosphitylating agent is used, it might be difficult to remove hydrolysis products (H-phosphonates) from the ribonucleoside phosphoramidites.
Isolate phosphoramidites 6. Prepare a slurry of 400 g silica gel (230 to 400 mesh) in 4:1 (v/v) hexane/ethyl acetate containing 3% triethylamine for A, C, and U, and in 1:1 (v/v) hexane/ethyl acetate containing 3% triethylamine for G. For detailed steps for column chromatography, see APPENDIX 3E.
7. Pour into a 5-cm-diameter chromatography column and add a layer of ∼3 cm sand on top of the column. 8. Concentrate the reaction mixture (step 3) to a volume of ∼40 mL in a rotary evaporator with a vacuum pump. 9. Load the reaction mixture carefully on top of the column and start the elution slowly using the same solvent mixture used to prepare the slurry. Continue until the dichloromethane (clearly visible as a transparent plug) has been eluted. 10. Continue eluting with gradually more polar solvent and collect 100-mL fractions. For A, C, and U, use 1 L each of hexane/ethyl acetate at 7:3, 6:4, 5:5, and so on. For G, use 1 L each of hexane/ethyl acetate at 1:1 and 1:3, then 100% ethyl acetate, and then add stepwise 1% methanol to the ethyl acetate. Always add 3% triethylamine to solvents.
11. Monitor fractions by TLC and pool fractions that contain pure 2′-O-TOM-substituted phosphoramidites. 12. Repeat column chromatography with the impure fractions on an appropriate smaller scale and combine fractions that contain pure products.
Synthesis of Unmodified Oligonucleotides
3.8.3 Current Protocols in Nucleic Acid Chemistry
Supplement 7
13. Evaporate to dryness in a rotary evaporator and dry overnight at high vacuum (<0.05 mbar). Typically, ∼90% pure 2′-O-TOM-protected phosphoramidites are obtained as a colorless, solid foam.
14. Check the purity of the material by 1H- and 31P-NMR. Only pure products should be employed for RNA synthesis (see Basic Protocol 2). Small amounts of an H-phosphonate species (hydrolysis product of the phosphitylation agent) with a characteristic signal around δ = 10 ppm (31P-NMR) can be tolerated. In pure and dry form, the products can be stored at −20°C for years without decomposition. N6-Ac-5′-O-DMTr-2′-O-TOM-adenosine 3′-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.2a): 17.9 g (90%). TLC (hexane/ethyl acetate 3:7) 0.75; λmax (acetonitrile): 270 (21,800), 235 (25,400); δH (CDCl3) 0.88-0.90 (21 H, m, i-Pr3Si), 1.09 and 1.18 and 1.19 (12 H, 3d, J = 6.8 Hz, Me), 2.38 (1 H, t, J = 6.4 Hz, CH2), 2.62 (3 H, s, CH3CO), 2.65 (1 H, dt, J = 3.3, 6.6 Hz, CH2), 3.35 (1 H, ddd, J = 4.6, 7.5 Hz, 11.7, CH2), 3.51-3.75 (5 H, m, CH2, CH, H-5′), 3.77 and 3.78 (6 H, 2s, 2 OCH3), 3.85-3.97 (1 H, m, CH2), 4.36 and 4.41 (2q, J = 4.0 Hz, H-4′), 4.68 (m, H-3′), 4.92 and 4.95 and 4.99 (2 H, 3d, J = 5.0 Hz, OCH2O), 5.17 and 5.20 (2t, J = 5.5 Hz, H-2′), 6.17 and 6.20 (2d, J = 5.8 Hz, H-1′), 6.76-6.80 (4 H, m, DMTr), 7.18-7.42 (9 H, m, DMTr), 8.12 and 8.15 (2s, H-2), 8.53 (br. s, HN), 8.54 and 8.56 (2s, H-8); δC (CDCl3) 11.8 (d), 17.5 (q), 17.6 (q), 17.7 (q), 20.1 and 20.3 (2t, JCP 7 Hz), 24.52 (q), 24.56 (q), 24.58 (q), 24.62 (q), 25.6 (q), 43.2 and 43.4 (2d, JCP 13 Hz), 55.1 (q), 55.2 (q), 58.0 and 58.9 (2t, JCP 18 Hz), 62.8 (t), 63.2 (t), 71.2 and 71.8, (2d, JCP 16 Hz), 77.0 and 77.6 (2d, JCP 4 Hz), 84.1 (d), 84.2 (d), 86.5 (s), 86.6 (s), 87.4 (d), 87.5 (d), 89.2 (t), 89.5 (t), 113.0 (d), 113.1 (d), 117.3 (s), 117.6 (s), 122.2 (s), 126.8 (d), 126.9 (d), 127.8 (d), 128.1 (d), 128.2 (d), 128.3 (d), 130.0 (d), 130.1 (d), 130.2 (d), 135.6 (s), 135.7 (s), 135.8 (s), 142.1 (d), 142.2 (d), 144.4 (s), 144.5 (s), 149.0 (s), 149.1 (s), 151.0 (s), 151.1 (s), 152.2 (d), 158.5 (s), 158.6 (s), 170.3 (s); δP (CDCl3) 150.8, 151.5; m/z 998 (30, MH+), 821 (63), 303 (100). Anal. calcd. for C52H72N7O9SiP: C, 62.57; H, 7.27; N, 9.82. Found: C, 62.62; H, 7.25; N, 9.72. N2-Ac-5′-O-DMTr-2′-O-TOM-guanosine 3′-(2-cyanoethyl-N,N-diisopropylphosphoramidite] (S.2b): 19.0 g (94%). TLC (CH2Cl2/methanol 19:1) 0.60; λmax (acetonitrile): 276 (13,500), 250sh (19,700), 237 (24,600); δH (CDCl3) 0.91-0.94 (21 H, m, Pri3Si), 1.02-1.19 (12 H, 5d, J = 7 Hz, Me), 1.73 and 1.82 (2s, COCH3), 2.25 and 2.75 (2m, 2 CH2), 3.22 (0.5 H, dd, J = 3.7, 10.7 Hz, H-5′), 3.28 (0.5 H, dd, J = 5.3, 10.6 Hz, H-5′), 3.47-3.62 (3.5 H, m, CH, H-5′, CH2), 3.68 (0.5H, m, CH2), 3.75 and 3.76 and 3.77 and 3.78 (4s, 4 OCH3), 3.92 and 4.04 (1.5 H, 2m, CH2), 4.23 (0.5 H, q, J = 2.5 Hz, H-4′), 4.32 (0.5 H, br. dt, J ≈ 5, 2 Hz, H-4′), 4.52 (0.5 H, ddd, J = 2.0, 4.8, 12.1 Hz, H-3′), 4.62 (0.5 H, ddd, J = 4.8, 5.8, 10.6 Hz, H-3′), 4.91 (1 H, s, OCH2O), 4.90 and 5.00 (1 H, 2d, J = 5.2 Hz, OCH2O), 5.02 (0.5H, dd, J = 4.8, 7.4 Hz, H-2′), 5.05 (0.5 H, t, J = 5.8 Hz, H-2′), 5.87 (0.5 H, d, J = 5.7 Hz, H-1′), 5.97 (0.5 H, d, J = 7.4 Hz, H-1′), 6.76-6.82 (4 H, m, DMTr), 7.14-7.52 (9 H, m, DMTr), 7.74 and 7.80 (1 H, 2s, H-8), 8.29 and 8.57 (1 H, 2br. s, HN), 11.89 (1 H, br. s, HN); δC (CDCl3) 11.8 (d), 17.6 (q), 17.7 (q), 17.8 (q), 20.1 (t, JCP 3 Hz), 20.2 (t), 23.5 (q), 23.6 (q), 24.5 (q), 24.6 (q), 24.7 (q), 43.1 and 43.3 (2d, JCP 13 Hz), 55.2 (q), 55.3 (q), 56.9 (t, JCP 19 Hz), 58.8 (t, JCP 13 Hz), 63.5 (t), 63.9 (t), 70.7 (d, JCP 17 Hz), 71.7 (d, JCP 14 Hz), 76.9 (d), 78.3 (d), 84.2 (d), 84.3 (d, JCP 4 Hz), 86.2 (d), 86.3 (s), 86.7 (s), 88.9 (d), 89.4 (t), 89.5 (t), 113.1 (d), 113.2 (d), 117.5 (s), 118.1 (s), 122.0 (s), 122.7 (s), 127.0 (d), 127.1 (d), 127.9 (d), 128.0 (d), 128.1 (d), 130.0 (d), 130.1 (d), 130.2 (d), 135.6 (s), 135.8 (s), 136.0 (s), 136.3 (s), 137.7 (d), 139.1 (d), 144.6 (s), 145.0 (s), 146.8 (s), 147.1 (s), 148.0 (s), 148.5 (s), 155.6 (s), 158.6 (s), 158.7 (s), 171.5 (s), 171.6 (s); δP (CDCl3) 149.9, 150.5; m/z 1014 (62, MH+), 303 (100). Anal. calcd. for C52H72N7O10SiP: C, 61.58; H, 7.15; N, 9.67. Found C, 61.22; H, 7.19; N, 9.55.
Synthesis of RNA Sequences with 2′-O-TOM-protecte d Ribonucleoside Phosphoramidites
N4-Ac-5′-O-DMTr-2′-O-TOM-cytidine 3′-(2-cyanoethyl-N,N-diisopropylphosphoramidite] (S.2c): 18.1 g (93%). TLC (hexane/ethyl acetate 3:7) 0.75; λmax (acetonitrile) 305 (6,700), 279 (6,200), 237 (29,000); δH (CDCl3) 0.87-1.11 (21 H, m, i-Pr3Si), 1.13 and 1.16 (2d, J = 6.8, 4 Hz, Me), 2.22 and 2.33 (2s, CH3CO), 2.38 and 2.59 (2 H, 2t, J = 6.5 Hz, CH2), 3.42-3.68 (5 H, m, CH2, CH, H-5′), 3.80 and 3.81 and 3.814 and 3.82 (6 H, 4s, OCH3), 3.91 (1 H, m, CH2), 4.28-4.41 (2 H, m, H-2′,4′), 4.50 (ddd, J = 4.8, 8.0, 9.9 Hz, H-3′),
3.8.4 Supplement 7
Current Protocols in Nucleic Acid Chemistry
5.15-5.22 (2 H, m, OCH2O), 6.15 (0.5 H, d, J = 1.8 Hz, H-1′), 6.16 (0.5 H, d, J = 2.4 Hz, H-1′), 6.82-6.88 (4 H, m, DMTr), 6.96 and 7.03 (2d, J = 7.4 Hz, H-5), 7.24-7.47 (9 H, m, DMTr), 8.36 and 8.45 (2d, J = 7.4 Hz, H-6), 9.52 and 9.60 (2br. s, HN); δC (CDCl3) 12.0 (d), 17.8 (q), 17.9 (q), 20.2 and 20.3 (2t, JCP 7 Hz), 24.48 (q), 24.54 (q), 24.58 (q), 24.61 (q), 24.64 (q), 24.7 (q), 24.9 (q), 43.2 and 43.3 (2d, JCP 7 Hz), 55.2 (q), 55.3 (q), 58.2 and 58.7 (2t, JCP 20 Hz), 60.9 (t), 61.6 (t), 69.4 and 69.7, (2d, JCP 14 Hz), 78.7 (d, JCP 3 Hz), 78.9 (d), 82.3 (d, JCP 3 Hz), 82.5 (d, JCP 5 Hz), 87.0 (s), 87.2 (s), 89.6 (d), 89.7 (d), 89.8 (t), 96.5 (d), 113.2 (d), 113.3 (d), 117.4 (s), 117.7 (s), 127.2 (d), 128.0 (d), 128.2 (d), 128.4 (d), 130.1 (d), 130.2 (d), 130.3 (d), 130.4 (d), 135.2 (s), 135.3 (s), 135.4 (s), 135.5 (s), 144.1 (s), 144.3 (s), 145.0 (d), 145.1 (d), 154.9 (s), 158.7 (s), 162.6 (s), 162.7 (s), 170.5 (s); δP (CDCl3) 150.6, 150.9; m/z 974 (21, MH+), 303 (100). Anal. calcd. for C51H72N5O10SiP: C, 62.88; H, 7.45; N, 7.19. Found: C, 62.74; H, 7.56; N, 7.00. 5′-O-DMTr-2′- O-TOM-u ridine 3′-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.2d): 17.1 g (92%). TLC (hexane/ethyl acetate 1:1) 0.65; λmax (acetonitrile) 264 (12,100), 236 (23,700); δH (CDCl3) 1.02-1.05 (21 H, m, i-Pr3Si), 1.06 and 1.17 (12 H, m, Me), 2.39 and 2.63 (2t, J = 6.7 Hz, CH2), 3.39 (m, H-5′), 3.53-3.70 (4 H, m, CH, H′-5′, CH2), 3.79 and 3.80 (6 H, 2 OCH3), 3.81-3.96 (m, CH2), 4.19 and 4.27 (2br. dt, J ≈ 5, 2 Hz, H-4′), 4.40-4.55 (m, H-2′,3′), 4.96-5.06 (2 H, m, OCH2O), 5.32 and 5.36 (2d, J = 8.1 Hz, H-5), 6.12 (0.5 H, d, J = 5.1 Hz, H-1′), 6.14 (0.5 H, d, J = 4.9 Hz, H-1′), 6.82-6.85 (4 H, m, DMTr), 7.05-7.47 (9 H, m, DMTr), 7.80 and 7.86 (2d, J = 8.1 Hz, H-6), 8.33 (br. s, HN); δC (CDCl3) 11.9 (d) 12.0 (d), 17.7 (q), 17.8 (q), 17.9 (q), 20.2 and 20.4 (2t, JCP 7 Hz), 24.52 (q), 24.55 (q), 24.58 (q), 24.62 (q), 43.2 and 43.4 (2d, JCP 12 Hz), 55.2 (q), 55.3 (q), 57.8 and 58.9 (2t, JCP 18 Hz), 62.1 and 62.5 (2t), 70.4 and 70.9, (2d, JCP 15 Hz), 77.4 and 78.1 (2d, JCP 4 Hz), 83.3 (d, JCP 4 Hz), 83.5 (d), 87.1 (s), 87.2 (s), 87.4 (d), 89.0 (d), 89.3 (t), 89.4 (t), 102.3 (d), 102.4 (d), 113.1 (d), 113.2 (d), 113.3 (d), 117.3 (s), 117.7 (s), 127.2 (d), 127.9 (d), 128.0 (d), 128.2 (d), 128.3 (d), 130.2 (d), 130.3 (d), 130.4 (d), 135.1 (s), 135.3 (s), 135.4 (s), 135.5 (s), 140.3 (d), 140.4 (d), 144.2 (s), 144.3 (s), 150.1 (s), 158.7 (s), 162.8 (s), 162.9 (s); δP (CDCl3) 150.9, 151.3; m/z 933 (57, MH+), 303 (100). Anal. calcd. for C49H69N4O10SiP: C, 63.07; H, 7.45; N, 6.00. Found: C, 62.84; H, 7.49; N, 5.98.
ASSEMBLY OF 2′-O-TOM-PROTECTED PHOSPHORAMIDITES ON DNA SYNTHESIZERS
BASIC PROTOCOL 2
This protocol describes the setup and steps required for automated assembly of RNA sequences from TOM-phosphoramidites on 1-µmol and 10-µmol scales. The protocol was developed for GeneAssemblers (Amersham Pharmacia Biotech), but can easily be adapted to other automated DNA synthesizers. The authors recommend coupling times of 2.5 to 3.5 min and 6 to 9 min for 1.0-µmol and 10-µmol syntheses, respectively. The TOM-phosphoramidites allow preparation of RNA sequences consisting of up to 100 nt; however, the authors recommend first preparing shorter sequences (e.g., 20 nt) to gain experience in the handling of the intermediate and product sequences. The reactions carried out in each cycle are shown in Figure 3.8.2. Any commercially available solid support containing the first immobilized ribonucleoside (or some modified ribonucleoside) can be employed. In the authors’ hands, controlledpore glass (CPG) supports give the best results, but polystyrene-based materials may be used with similar results. CPG supports with pore sizes of 500 and 1000 Å should be used for the synthesis of ≤47-mers and >47-mers, respectively. Materials 2′-O-TOM-phosphoramidites (0.1 M in acetonitrile; Glen Research; see Basic Protocol 1) Activator: 0.25 M 5-ethylthio-1H-tetrazole (SET, Glen Research) in acetonitrile Argon source Dry acetonitrile (<30 ppm water) 4A molecular sieves (optional)
Synthesis of Unmodified Oligonucleotides
3.8.5 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Figure 3.8.2 One coupling cycle—including detritylation, coupling, capping, and oxidation— required for the attachment of one nucleotide to the growing oligonucleotide chain. Additionally, after the last coupling cycle, the terminal dimethoxytrityl group is removed from the immobilized oligonucleotide. B, any N-protected nucleobase; Bz, benzoyl; CPG, controlled-pore glass; DMTr, 4,4′-dimethoxytrityl; TOM, [(triisopropylsilyl)oxy]methyl.
Detritylation solution (see recipe) Oxidation solution (see recipe) Capping solutions A and B (see recipes) 1,2-Dichloroethane (reagent grade) Solid support, e.g., long-chain alkylamine controlled-pore glass (CPG) supports (500 or 1000 Å) for RNA synthesis derivatized with 5′-O-4,4′-dimethoxytritylated ribonucleosides (Glen Research) Vials and bottles for attachment of the phosphoramidites and reagents to the synthesizer Automated DNA synthesizer (e.g., GeneAssembler; Amersham Pharmacia Biotech) Synthesis column for 1-µmol or 10-µmol synthesis Additional reagents and equipment for automated DNA synthesis (APPENDIX 3C) 1. Calculate the amount of phosphoramidites and activator (SET) required to assemble the desired sequence by multiplying the following by the number of nucleotides in the sequence, and adding an extra 50 mg phosphoramidites/50 mg SET to give enough material to purge the lines of the synthesizer. Synthesis of RNA Sequences with 2′-O-TOM-protecte d Ribonucleoside Phosphoramidites
1-µmol scale: 12 mg phosphoramidite, 12 mg SET/coupling 10-µmol scale: 40 mg phosphoramidite, 20 mg SET/coupling. 2. Place the calculated amounts of phosphoramidites and SET into the appropriate vials in an automated DNA synthesizer and flush with argon.
3.8.6 Supplement 7
Current Protocols in Nucleic Acid Chemistry
3. Use a syringe to add the amount of dry acetonitrile required to obtain ∼0.1 M phosphoramidite (i.e., 1 mL/100 mg solid phosphoramidite) and ∼0.25 M SET (1 mL/32 mg solid SET). Allow solids to dissolve. When working with the GeneAssembler, beads of 4A molecular sieves may also be added.
4. Create methods for the assembly of the desired sequence. In principle, methods employed for synthesis of DNA sequences can be used here. The authors recommend the steps listed in Table 3.8.1.
5. Connect the following reagents to the synthesizer according to the manufacturer’s instructions: detritylation solution oxidation solution capping solutions A and B 1,2-dichloroethane dry acetonitrile phosphoramidite solution SET solution. 6. Calculate the required amount of solid support (e.g., CPG support) according to its individual loading (as reported by the manufacturer) and the synthesis scale. Use a CPG support with a pore size of 500 Å for the synthesis of ≤47-mers, and a support with a pore size of 1000 Å for >47-mers. Load an empty synthesis column with the RNA support and connect it to the synthesizer. For example, when the loading is 40 ìmol/g, use 25 mg and 250 mg for 1-ìmol and 10-ìmol syntheses, respectively.
7. Purge the lines of the synthesizer with all solutions and solvents. 8. Carry out the assembly according to manufacturer’s instructions. Choose the option “DMTr off” in the setup menu. After the tenth coupling cycle, coupling yields of >99% can be expected by detritylation assay. If lower yields are obtained, see Troubleshooting.
9. Remove the synthesis column from the synthesizer and dry it by vacuum or under a stream of argon. 10. Deprotect the assembled, still fully protected oligoribonucleotide (see Basic Protocol 3). DEPROTECTION OF RNA SEQUENCES ASSEMBLED FROM 2′-O-TOM-PROTECTED PHOSPHORAMIDITES
BASIC PROTOCOL 3
This protocol describes the two-step deprotection of RNA sequences assembled according to Basic Protocol 2. The two steps are presented schematically in Figure 3.8.3. In the first step, 10 M methylamine in 50% ethanol is used to detach the sequence from the solid support, eliminate the cyanoethyl groups, and remove the acetyl protecting groups from the nucleobases. In the second step, 1 M tetra-n-butylammonium fluoride in tetrahydrofuran is used to remove the 2′-O-TOM protecting groups. This reaction is quenched by addition of aqueous Tris⋅Cl buffer, pH 7.4. A final desalting procedure with commercially available size-exclusion cartridges yields the crude RNA sequence.
Synthesis of Unmodified Oligonucleotides
3.8.7 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Table 3.8.1 Methods for Oligoribonucleotide Assembly on 1.0-µmol and 10-µmol Scales with TOM-Phosphoramiditesa
1.0-µmol scale Time (min)
Step
Detritylation 0.00 DETRIT 1.50 VALVE POS 2.50 VALVE POS 2.70 INTEGRATE 4.00 ML/MIN Coupling 4.00 LOOP TIMES 4.00 VALVE POS 4.05 ML/MIN 4.15 ML/MIN 4.15 VALVE POS 4.20 ML/MIN 4.30 ML/MIN 4.30 VALVE POS 4.35 ML/MIN 4.45 ML/MIN 4.45 END OF LOOP 4.45 VALVE POS 4.50 ML/MIN 4.60 ML/MIN 4.60 LOOP TIMES 4.60 STEP VALVE 4.60 END OF LOOP 4.65 ML/MIN 7.15 ML/MIN 7.15 STEP VALVE 7.20 ML/MIN 7.50 ML/MIN Capping 7.55 VALVE POS 7.60 ML/MIN 7.60 LOOP TIMES 7.60 VALVE POS 7.70 VALVE POS 7.80 END OF LOOP 7.80 ML/MIN 7.85 VALVE POS 7.85 ML/MIN Oxidation 8.15 VALVE POS 8.75 VALVE POS 10.25 ML/MIN 10.25 LOOP TIMES 10.25 STEP VALVE 10.25 END OF LOOP
10-µmol Valueb
2.1 2.3 0 0.00 2 1.8 0.90 0.00 1.X 0.60 0.00 1.8 0.90 0.00 1.1 1.00 0.00 7 3 2.50 0.00 3 2.50 0.00 2.5 1.00 4 2.5 2.6 0.00 2.3 2.50 2.4 2.3 0.00 7 3
Valueb Description
Time (min)
Step
0.00 3.00 4.00 5.00 8.00
10DETRIT VALVE POS VALVE POS INTEGRATE ML/MIN
8.00 8.00 8.05 8.15 8.15 8.20 8.30 8.30 8.35 8.45 8.45 8.45 8.50 9.00 9.00 9.00 9.00 9.05 16.05 16.05 16.10 17.10
LOOP TIMES VALVE POS ML/MIN ML/MIN VALVE POS ML/MIN ML/MIN VALVE POS ML/MIN ML/MIN END OF LOOP VALVE POS ML/MIN ML/MIN LOOP TIMES STEP VALVE END OF LOOP ML/MIN ML/MIN STEP VALVE ML/MIN ML/MIN
4 1.8 0.75 0.00 1.X 1.00 0.00 1.8 0.75 0.00
17.15 17.20 17.20 17.20 17.30 17.40 17.40 17.45 17.45
VALVE POS ML/MIN LOOP TIMES VALVE POS VALVE POS END OF LOOP ML/MIN VALVE POS ML/MIN
2.5 1.00 12 2.5 2.6
18.45 20.45 23.45 23.45 23.45 23.45
VALVE POS VALVE POS ML/MIN LOOP TIMES STEP VALVE END OF LOOP
2.4 2.3 0.00 7 3
2.1 2.3 0 0.00
Detritylation Dichloroethane wash Acetonitrile wash Trityl assay
Activator to column
Amidite to column
Activator to column
1.1 1.00 0.00 7 3 2.50 0.00 3 2.50 0.00
0.00 2.3 2.50
Coupling reaction
Acetonitrile wash
Capping A
Capping A Capping B
Acetonitrile wash
Oxidation Acetonitrile wash
Synthesis performed on a GeneAssembler (Amersham Pharmacia Biotech). For 1.0-µmol scale: synthesis: 120 µl phosphoramidite solution (12 eq) and 360 µl activator solution (90 eq); detritylation: 1.5 min; coupling: 2.5 min; capping: 0.8 min; oxidation: 0.3 min. For 10-µmol scale: synthesis: 400 µl phosphoramidite solution (4 eq) and 600 µl activator solution (15 eq); detritylation: 3.0 min; coupling: 7.0 min; capping: 2.4 min; oxidation: 1.0 min. b Description: VALVE POS 1.X: phosphoramidite (A, C, G, or U); 1.8: activator; 2.1: dichloroethane; 2.2: detritylation; 2.3: acetonitrile; 2.4: oxidation; 2.5: capping A; 2.6: capping B. a
Synthesis of RNA Sequences with 2′-O-TOM-protecte d Ribonucleoside Phosphoramidites
3.8.8 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Figure 3.8.3 Two-step deprotection of oligoribonucleotide sequences assembled from TOMphosphoramidites. B, any nucleobase; BAc, any N-acetylated nucleobase; CPG, controlled-pore glass; TBAF, tetra-n-butylammonium fluoride; TOM, [(triisopropylsilyl)oxy]methyl.
Materials TOM-protected oligoribonucleotide attached to solid support (see Basic Protocol 2), in synthesis cartridge 12 M aqueous methylamine 8 M methylamine in ethanol (Fluka) 50% and 100% (v/v) ethanol 1 M tetra-n-butylammonium fluoride trihydrate (TBAF.3H2O; Fluka) in tetrahydrofuran (THF) N-Methylpyrrolidone (NMP) or dimethylformamide (DMF; optional) 1 M Tris⋅Cl, pH 7.4, RNase free, sterile (Fluka, for molecular biology) 3 M sodium acetate (APPENDIX 2A) 1.5-, 2-, and 5-mL twist-top vials 35°C incubator or heating block Speedvac evaporator NAP-10 columns (Amersham Pharmacia Biotech) Additional reagents and equipment for oligoribonucleotide purification by HPLC (UNIT 10.5) or polyacrylamide gel electrophoresis (PAGE; UNIT 10.4)
Synthesis of Unmodified Oligonucleotides
3.8.9 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Remove acetyl and cyanoethyl groups and solid support 1. Remove solid support from the synthesis cartridge and transfer it into 1.5-mL twist-top vials. For syntheses performed on a 1-ìmol scale, a single 1.5-mL vial should suffice. For a 10-ìmol scale, divide the solid support into four portions and add each to a separate 1.5-mL vial.
2. Add 0.5 mL of 12 M aqueous methylamine and 0.5 mL of 8 M methylamine in ethanol to each 1.5-mL vial. 3. Incubate 6 hr at 35°C with periodic shaking. Sequences with <60 nt can be incubated 6 hr at room temperature.
4. Centrifuge 3 min at 10,000 × g, 25°C, and transfer supernatant from each 1.5-mL vial into a 2-mL twist-top vial. 5. Wash solid support two times with 0.3 mL of 50% ethanol and place the washing solutions in the same 2-mL vial. 6. Evaporate to dryness in a Speedvac evaporator. Remove TOM groups 7. To each 2-mL vial, add 1 mL of 1 M TBAF/THF and dissolve the crude intermediate sequence by vortexing or ultrasonicating. If intermediates are not dissolved after 10 min, add a few drops of NMP or DMF. The intermediates usually dissolve almost immediately. Short adenosine-rich RNA sequences or RNA hybrid sequences containing a majority of non-RNA nucleosides (e.g., DNA/2′-OMe-RNA-nucleosides) must be deprotected with 1 M TBAF in 1:1 THF/NMP.
8. Incubate the solution overnight at 35°C with periodic shaking. Sequences with <60 nt can be incubated overnight at room temperature.
9. Quench the reaction by adding 1 mL of 1 M Tris⋅Cl solution, pH 7.4. IMPORTANT NOTE: Deprotected oligoribonucleotides are highly sensitive to nuclease degradation. Therefore, gloves should always be worn when manipulating deprotected RNA. Sterile vials and pipets, nuclease-free reagents, and UV-treated sterile water should always be used to limit potential exposure to nucleases. Work quickly and store the oligoribonucleotides at –20°C.
10. Evaporate to a volume of 1 mL in a Speedvac evaporator. IMPORTANT NOTE: This evaporation takes 20 to 40 min (depending on the setup). Do not overevaporate to dryness. Check the remaining volume frequently.
Desalt oligoribonucleotide 11. Wash a NAP-10 column with 10 mL sterile water. 12. Place the oligoribonucleotide solution on top of the column and allow the solution to sink in slowly by gravity. 13. Place 1.5 mL sterile water on top of the column and collect the eluate (1.5 mL) in a 5-mL vial. Synthesis of RNA Sequences with 2′-O-TOM-protecte d Ribonucleoside Phosphoramidites
This step is required to remove excess TBAF. Alternatively, desalting can be carried out by ion-exchange chromatography according to the protocol in UNIT 3.6. If the oligoribonucleotide will be used in its crude form, it should first be precipitated (steps 14 to 16). If it will be purified before use (step 17), precipitation is not required.
3.8.10 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Precipitate (optional) 14. Evaporate eluate to dryness in a Speedvac evaporator and dissolve the residue in 0.5 mL sterile water. 15. Add 50 µl of 3 M sodium acetate solution followed by 3.5 mL of 100% ethanol. Store overnight at −20°C. 16. Centrifuge 3 min at 10,000 × g, 25°C, and carefully remove the supernatant. The precipitate consists of crude oligoribonucleotide in its sodium form.
Purify (optional) 17. Purify the oligoribonucleotide by HPLC (UNIT 10.5) or polyacrylamide gel electrophoresis (UNIT 10.4). REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Anisaldehyde reagent In a clean container, mix 10 mL anisaldehyde with 180 mL 100% ethanol. Add slowly, while stirring, 10 mL concentrated sulfuric acid, followed by 2 mL acetic acid. Store reagent up to 3 months in the dark at 25°C; avoid contamination with acetone. For staining, TLC plates are dipped into this mixture and heated with a heat-gun until dark spots, corresponding to the reaction products, appear on a pink to red background.
Capping solution A 100 mL acetic anhydride 800 mL tetrahydrofuran (THF) 100 mL 2,6-lutidine Store in a well-sealed bottle in a dark and cool (25°C) environment for up to 2 months Capping solution B 160 mL N-methylimidazole 840 mL tetrahydrofurant (THF) Store in a well-sealed bottle in a dark and cool (25°C) environment for up to 2 months Detritylation solution 40 mL dichloroacetic acid 960 mL dry 1,2-dichloroethane Store in a well-sealed bottle in a dark and cool (25°C) environment for up to 2 months Oxidation solution 12.7 g iodine 700 mL tetrahydrofuran (THF) 100 mL pyridine 200 mL water Dissolve iodine in THF, then add pyridine followed by water. Store in a well-sealed bottle in a dark and cool (25°C) environment for up to 2 months. Synthesis of Unmodified Oligonucleotides
3.8.11 Current Protocols in Nucleic Acid Chemistry
Supplement 7
COMMENTARY Background Information
Synthesis of RNA Sequences with 2′-O-TOM-protecte d Ribonucleoside Phosphoramidites
During the last decade, many research groups have contributed to the development of a reliable chemical synthesis of nucleic acids. The synthesis of oligodeoxyribonucleotides by the phosphoramidite method (UNITS 3.3, 3.5 & 3.6) is probably the most evolved chemical process known thus far, and has almost reached perfection in terms of efficiency and automation. This extremely powerful methodology can, in principle, also be applied to the synthesis of the structurally very similar RNA oligonucleotides. Compared to DNA, however, each nucleotide within an RNA strand contains an additional 2′-OH group, which is responsible for the instability of RNA under basic conditions (pH >12 at 25°C). This hydroxyl group must be protected during oligoribonucleotide assembly. Since the RNA products are base labile, the removal of these supplementary protecting groups is carried out separately, after removal of the 2-cyanoethyl groups and nucleobase-protecting groups and cleavage of the oligoribonucleotide from the support under basic nucleophilic conditions. As a consequence, the removal of these additional 2′-O-protecting groups must be completely orthogonal to all other acid-promoted and base-promoted deprotection conditions. The large number of reported 2′-O ribonucleoside-protecting groups can essentially be divided into acid-labile (Griffin and Reese, 1964; Reese et al., 1991; Scaringe et al., 1998), photo-labile (Ohtsuka et al., 1974; Schwarz et al., 1992; Pitsch, 1997; Pitsch et al., 1999a), and fluoride-labile groups (Ogilvie et al., 1974; Usman et al., 1985; Pitsch et al., 1999a, b). Among them, the fluoride-labile tert-butyldimethylsilyl (TBDMS) group (Ogilvie et al., 1974) has the widest application. This is well reviewed in Beaucage and Caruthers (1996) and in UNIT 3.6. However, several factors—including the relatively sluggish coupling observed with RNA phosphoramidites as compared to the corresponding DNA phosphoramidites—has limited the length of routinely synthesized RNA sequences (UNIT 3.6). A very attractive alternative that leads to better coupling yields under shorter coupling times was the photolabile 2-nitrobenzyloxymethyl (NBOM) group (Schwartz et al., 1992; UNIT 3.7). In a formal sense, the 2′-O-TOM protecting group represents a combination of the TBDMS and the NBOM protecting groups. It also displays some unique properties that render it a
very valuable 2′-O-protecting group for the chemical synthesis of oligoribonucleotides. It is completely stable under all reaction conditions required for assembly and deprotection of RNA sequences. Its excellent stability towards both strongly acidic conditions (employed during detritylation) and strongly basic conditions (employed for deprotection of the nucleobase) is a consequence of the sterically very hindered triisopropylsilyl group. In contrast, the TOM group is very labile towards TBAF and is completely removed even in the presence of up to 20% water (Pitsch et al., 2001). Complete removal of the TBDMS group, in contrast, occurs only in the absence of water and requires drying of the TBAF solution with molecular sieves (Hogrefe et al., 1993). Many interesting RNA sequences, such as tRNAs, ribozymes, and aptamers, consist of 60 to 80 nt. In order to obtain a reasonable overall product yield of ∼50%, an individual coupling yield of ∼99.3% must be achieved for each cycle in the assembly. Lower coupling yields result not only in small product yields, but also in complex crude products that are often very difficult to purify to homogeneity. The average coupling yields obtained with 2′-O-TOM phosphoramidites are generally >99% and, therefore, even relatively long RNA sequences (>70 nt) can be prepared routinely. Additionally, the short coupling times (<5 min) minimize side reactions during the coupling reaction. In addition to high coupling yields, a reliable deprotection scheme is crucial for the efficient synthesis of longer sequences. The combination of 2′-O-TOM and N-acetyl protecting groups allows, for both deprotection processes, reaction times that correspond to >100 individual half-lives (with respect to the removal of one protecting group) without destruction of the oligonucleotide product. Therefore, it is possible to carry out the deprotection reactions even for extremely prolonged periods of time, assuring complete deprotection without risking concomitant destruction of the product (Pitsch et al., 1999a, 2001). The chemical synthesis of oligonucleotides allows the more or less unrestricted incorporation of nucleobase, sugar, and backbone modifications, the preparation of hybrid sequences, and labeling with specific reporter groups. In this context, a great number of useful modified building blocks have been developed and are commercially available. By adapting the presented RNA chemistry to the established DNA
3.8.12 Supplement 7
Current Protocols in Nucleic Acid Chemistry
and RNA chemistry, the 2′-O-TOM-protected building blocks can be combined with all of these modifications and even with TBDMSprotected RNA phosphoramidites.
Critical Parameters Phosphoramidite chemistry is extremely water-sensitive. The phosphoramidites and the activator should be completely dry. Only acetonitrile that contains <30 ppm water should be used as solvent for the coupling reaction or to dissolve the phosphoramidites and the activator. If working with the GeneAssembler from Amersham Pharmacia Biotech, molecular sieves may be added to the corresponding vials and bottles. The synthesizer should be in good working condition. All lines should be washed after completion of each synthesis round. To prevent particles from reaching the valves, dust-free bottles, high-quality solvents and reagents, and appropriate filters should be used. Reagents should be replaced periodically with fresh supplies and should be stored in well-sealed bottles in a dark, cool environment. Only sterile, RNase-free solvents, reagents, containers, vials, pipets, and other equipment should be used. Any contact between the oligoribonucleotides and body fluids (e.g., sweat, saliva) should be avoided. In all aqueous solutions and buffers, RNase-producing microorganisms may live and grow. Keep such solutions as sterile as possible and replace them often. Good coupling yields should be obtained using the presented coupling conditions. Coupling times should not be significantly increased. Specifically, do not use the coupling conditions used for the assembly of 2′-OTBDMS phosphoramidites in combination with SET as activator. The deprotection under the presented conditions is straightforward. A longer deprotection time can be used, but the temperature should not exceed 35°C. Methylamine solutions should be stored at 4°C to prevent loss of concentration. The bottles should be opened only for a very brief time and should be replaced periodically. The TBAF solution should not be dried with molecular sieves, since this may lead to its decomposition. Ensure that the sequence is dissolved during TBAF treatment. If it is not, add a few drops of N-methylpyrrolidone (NMP), dimethylformamide (DMF), or dimethylsulfoxide (DMSO). Always quench the second deprotection reaction with Tris⋅Cl buffer according to the presented protocol.
The crude product should not be isolated by direct precipitation from the TBAF/THF solution. It should always be desalted by chromatography on Sephadex columns, NAP columns (see Basic Protocol 3), or ion-exchange cartridges (UNIT 3.6). When the analysis of the crude products by HPLC or PAGE shows not one main peak (band), but a variety of peaks (or bands) or broad features, the product may exist in a variety of secondary structures. For complete denaturation, HPLC analysis can be performed at a higher temperature (with NucleoPac columns at neutral pH values, up to 90°C). Alternatively, 6 M urea can be added to HPLC and PAGE buffers.
Troubleshooting Low coupling yield. Several conditions can lead to coupling yields that are <99% after the tenth coupling. (1) The acetonitrile may contain water. Substitute it with acetonitrile of better quality; add molecular sieves. (2) The synthesizer may be malfunctioning. Determine whether it is working properly by performing a DNA synthesis; also check the flow rate. (3) The phosphoramidites may contain water. Dry them under high vacuum (<0.05 mbar) overnight in a desiccator containing KOH pellets. Multiple product peaks. Several conditions can also lead to the observation of several main product peaks or spots when the crude product is analyzed. (1) The sequence may exist in several secondary structures. Perform analysis at higher temperature and/or in the presence of 6 M urea. Isolate materials corresponding to the different features, heat them briefly at 95°C (at neutral pH), and reanalyze them separately. If the same pattern is observed, the sequence is not folding uniformly. (2) Deprotection may be incomplete. Use new deprotection solutions and reagents. Check (e.g., by carefully smelling) whether vials are sealed tightly so that methylamine can not evaporate. Check whether the intermediate product obtained after the first deprotection step completely dissolves in TBAF/THF. If it does not, add some polar solvent (NMP, DMF, DMSO). (3) The sequence was degraded by RNases. All materials and liquids that come into contact with the sequence must be free of contamination by RNases or microorganisms. Replace the Tris⋅Cl buffer. Use a different source of sterile water. Autoclave all vials, pipet, and other materials. Synthesis of Unmodified Oligonucleotides
3.8.13 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Figure 3.8.4 Capillary gel electrophoresis analysis of the 34-mer RNA sequence r(GGCGACCCUGAUGAGGCCGAAAGGCCGAAACCGU) prepared at the 10-µmol scale according to Basic Protocols 2 and 3; (A) crude product; (B) product after HPLC purification. Chromatography performed with BioFocus 3000 (Bio-Rad), coated BioCap XL-column 75 µm × 40 cm, “run-buffer” containing 6 M urea, elution with 15 kV at 40°C, detection at 260 nm.
Anticipated Results With TOM-phosphoramidites, employing the methods presented here and observing the Critical Parameters, it should be possible to routinely obtain individual coupling yields >99% and complete deprotection. These properties allow routine preparation of oligoribonucleotides containing up to ∼80 nt. The purification efficiency with such long oligomers depends strongly on the individual structure, and
Synthesis of RNA Sequences with 2′-O-TOM-protecte d Ribonucleoside Phosphoramidites
therefore on the sequence. With up to ∼50 nt, HPLC purification with NucleoPac columns leads to very uniform products. Figure 3.8.4 shows the results from capillary gel electrophoresis analysis of a crude 34-mer and the HPLC-purified 34-mer (prepared on a 10-µmol scale). Oligoribonucleotides >50mers can be purified by PAGE; the purity of such oligoribonucleotide products usually exceeds 90%. In Figure 3.8.5, the gel analysis of
Figure 3.8.5 Polyacrylamide gel electrophoresis (PAGE) of five crude RNA sequences (sequence length indicated) prepared at the 1-µmol scale according to Basic Protocols 2 and 3. PAGE-conditions: 15% (w/v) acrylamide (29:1 acrylamide/bisacrylamide), 0.75 × 100 mm, 90 mM Tris-borate, pH 8.3, 7 M urea, 2 mM EDTA, elution at 200 V, stained with ethidium bromide.
3.8.14 Supplement 7
Current Protocols in Nucleic Acid Chemistry
five crude products with sequence lengths ranging from 40 to 81 nt is presented (all products were synthesized on a 1.5-µmol scale). Depending on the purification method, an overall yield of 10% to 40% purified RNA (based on solid support) can be expected.
Time Considerations Preparation of TOM-phosphoramidites takes ∼1 day each. Depending on the scale and the sequence length, the typical time for the assembly of an RNA sequence is 5 to 12 hr. It takes ∼1.5 days to perform the deprotections and the final desalting according to Basic Protocol 3, although at least five deprotections can be carried out in parallel during this time. Purification of an RNA sequence typically requires 1 day (1-µmol synthesis scale).
Pitsch, S. 1997. An efficient synthesis of enantiomeric oligoribonucleotides from D-glucose. Helv. Chim. Acta 80:2286-2314. Pitsch, S., Weiss, P.A., Wu, X., Ackermann, D., and Honegger, T. 1999a. Fast and reliable automated synthesis of RNA and partially 2′-O-protected precursors (‘caged RNA’) based on two novel, orthogonal 2′-O-protecting groups. Helv. Chim. Acta 82:1753-1761. Pitsch, S., Weiss, P.A., and Jenny, L. Nov. 1999b. Ribonucleoside-derivative and method for preparing the same. US Patent 5,986,084. Pitsch, S., Weiss, P.A., Jenny, L., Stutz, A., and Wu, X. 2001. Reliable chemical synthesis of oligoribonucleotides (RNA) with 2′-O-[(triisopropylsilyl)oxy]methyl (2′-O-TOM) protected phosphoramidites. Helv. Chim. Acta In press.
Literature Cited
Reese, C.B., Rao, M.V., Serafinowska, H.T., Thompson, E.A., and Yu, P.S. 1991. Studies in the solid phase synthesis of oligo- and poly-ribonucleotides. Nucleosides Nucleotides 10:8197.
Beaucage, S.L. and Caruthers, M.H. 1996. The chemical synthesis of DNA/RNA. In Bioorganic Chemistry: Nucleic Acids (S.M. Hecht, ed.) pp. 36-74. Oxford University Press, Oxford.
Scaringe, S.A., Wincott, F.E., and Caruthers, M.H. 1998. Novel RNA synthesis method using 5′-Osilyl-2′-O-orthoester protecting groups. J. Am. Chem. Soc. 120:11820-11821.
Griffin, B.E. and Reese, C.B. 1964. Oligoribonucleotide synthesis via 2′,5′-protected ribonucleoside derivatives. Tetrahedron Lett. 5:29252931.
Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., deBear, J.S., and Gough, G.R. 1992. Rapid synthesis of oligoribonucleotides using 2′-O-(ortho-nitrobenzyloxymethyl)-protec ted monomers. Bioorg. Med. Chem. Lett. 2:1019-1024.
Hogrefe, R.I., McCaffrey, A.P., Borozdine, L.U., McCampbell, E.S., and Vaghefi, M.M. 1993. Effect of excess water on the desilylation of oligoribonucleotides using tetrabutylammonium fluoride. Nucl. Acids Res. 21:4739-4741. Ogilvie, K.K., Sadana, K.L, Thompson, E.A., Quilliam, M.A., and Westmore, J.B. 1974. The use of silyl protecting groups in protecting the hydroxyl functions of ribonucleosides. Tetrahedron Lett. 15:2861-2863. Ohtsuka, E., Tanaka, S., and Ikehara, M. 1974. Ribooligonucleotide synthesis using a photosensitive o-nitrobenzyl protection at the 2′-hydroxyl group. Nucl. Acids Res. 1:1351-1357.
Usman, N., Pon, R.T., and Ogilvie, K.K. 1985. Preparation of ribonucleoside 3′-O-phosphoramidites and their application to the automated solid-phase synthesis of oligonucleotides. Tetrahedron Lett. 26:4567-4570.
Contributed by Stefan Pitsch Institut de Chimie Organique, EPFL Lausanne, Switzerland Patrick A. Weiss Xeragon AG Zürich, Switzerland
Synthesis of Unmodified Oligonucleotides
3.8.15 Current Protocols in Nucleic Acid Chemistry
Supplement 7
3-(N-tert-Butylcarboxamido)-1-propyl and 4-Oxopentyl Groups for Phosphate/Thiophosphate Protection in Oligodeoxyribonucleotide Synthesis
UNIT 3.9
This unit provides procedures for the preparation of deoxyribonucleoside phosphoramidites and appropriate phosphordiamidite precursors with P(III) protecting groups different than the standard 2-cyanoethyl group. Specifically, these phosphoramidites are functionalized with the 3-(N-tert-butylcarboxamido)-1-propyl or 4-oxopentyl groups. The usefulness of these novel deoxyribonucleoside phosphoramidites in the solid-phase synthesis of a 20-mer DNA oligonucleotide and its phosphorothioated analog will be demonstrated. It will also be shown that removal of the 3-(N-tert-butylcarboxamido)-1propyl phosphate/thiophosphate-protecting group from these oligonucleotides is rapidly effected under thermolytic conditions at neutral pH, whereas the 4-oxopentyl group is preferably removed by treatment with pressurized ammonia gas or concentrated ammonium hydroxide at ambient temperature. These detailed methods constitute an economical and alkylation-free approach to large-scale preparations of therapeutic oligonucleotides. PREPARATION OF OLIGODEOXYRIBONUCLEOTIDES USING 5′-O-(4,4′-DIMETHOXYTRITYL)-3′-O-(N,N-DIISOPROPYLAMINO)-[3-(N-tertBUTYLCARBOXAMIDO)-1-PROPYLOXY]PHOSPHINYL-2′-DEOXYRIBONUCLEOSIDES
BASIC PROTOCOL
The 3-(N-tert-butylcarboxamido)-1-propyl group for phosphate/thiophosphate protection in oligonucleotide synthesis is convenient in that it is removable under thermolytic conditions at a rate considerably faster than the 2-(N-formyl,N-methyl)aminoethyl group (Grajkowski et al., 2001; Wilk et al., 2002). Since these deprotection conditions produce alkylation-free oligodeoxyribonucleotides, they are recommended for large-scale production of therapeutic oligonucleotides. This protocol delineates a general method for the synthesis of deoxyribonucleoside phosphoramidites (S.3a-d) from N- and 5′-O-protected deoxyribonucleosides (S.1a-d) using N,N,N′,N′-tetraisopropyl-O-[3-(N-tert-butylcarboxamido)-1-propyl]phosphordiamidite (S.2; see Support Protocol) and 1H-tetrazole.
i -Pr2N DMTrO
O
B
P
i -Pr2N
H N
O
DMTrO 2
OH 1a b c d
O
O
1H -tetrazole/CH2Cl2
B = thymin-1-yl B = N 4-benzoylcytosin-1-yl B = N 6-benzoyladenin-9-yl B = N 2-isobutyrylguanin-9-yl
i -Pr2N
B
O P
O
O 3a-d
N H
Figure 3.9.1 Preparation of deoxyribonucleoside phosphoramidites S.3a-d. DMTr, 4,4′-dimethoxytrityl; i-Pr, isopropyl. Adapted from Wilk et al. (2002) with permission from the American Chemical Society.
Synthesis of Unmodified Oligonucleotides
Contributed by Andrzej Wilk, Marcin K. Chmielewski, Andrzej Grajkowski, Lawrence R. Phillips, and Serge L. Beaucage
3.9.1
Current Protocols in Nucleic Acid Chemistry (2002) 3.9.1-3.9.16 Copyright © 2002 by John Wiley & Sons, Inc.
Supplement 11
This approach to the preparation of S.3a-d is illustrated in Figure 3.9.1. In addition, procedures are described for using these precursors for DNA synthesis, and for analyzing the resulting oligonucleotides. Materials Protected deoxyribonucleoside (S.1a-d; Chem-Impex International): 5′-O-(4′,4′-Dimethoxytrityl)-2′-deoxythymidine N4-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxycytidine N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine N2-Isobutyryl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyguanosine Sublimed 1H-tetrazole (Aldrich) Argon gas Anhydrous methylene chloride (Aldrich) N,N,N′,N′-Tetraisopropyl-O-[3-(N-tert-butylcarboxamido)-1-propyl]phosphordiamidite (S.2; see Support Protocol) Benzene (Aldrich; optional) Triethylamine (Aldrich) Methylene chloride Hexane D2O (Aldrich) Silica gel (60 Å, 230 to 400 mesh; Merck) Anhydrous acetonitrile Reagents recommended for automated solid-phase oligonucleotide synthesis (PE Biosystems): Standard 2-cyanoethyl deoxyribonucleoside phosphoramidites (T, CBz, ABz, Gi-Bu) Activator solution (1H-tetrazole in acetonitrile) Oxidation solution (0.02 M iodine in tetrahydrofuran/pyridine/water) Cap A solution (acetic anhydride in tetrahydrofuran/pyridine) Cap B solution (1-methylimidazole in tetrahydrofuran) Deblocking solution (trichloroacetic acid in dichloromethane) 3H-1,2-Benzodithiol-3-one-1,1-dioxide (Glen Research) Ammonia gas (LB, Aldrich) 1× PBS, pH 7.2 (APPENDIX 2A) Loading buffer: 1:4 (v/v) 10 × TBE electrophoresis buffer (APPENDIX 2A) in formamide containing 2 mg/mL bromphenol blue Staining buffer: 1:5:20:0.1 (v/v/v/v) formamide/isopropyl alcohol/ddH2O/3.0 M Tris⋅Cl, pH 8.8 1 mg/mL Stains-All in formamide (both from Aldrich) 1.0 M Tris⋅Cl buffer, pH 9.0 (APPENDIX 2A) 1.0 M MgCl2 (Sigma) Snake venom phosphodiesterase (SVP, Crotallus durissus, Boehringer) Bacterial alkaline phosphatase (BAP, E. coli, Sigma) 0.1 M triethylammonium acetate buffer, pH 7.0 (2 M stock from Applied Biosystems)
3-(N-tert-Butylcarboxamido)-propyl and 4-Oxopentyl Protecting Groups
50-mL three-necked round-bottom flask with rubber septa High vacuum pump 15-mL powder-addition funnel 10-mL syringe 2.5 × 7.5–cm Whatman TLC plates precoated with a 250-µm layer of Diamond MK6F silica gel (60 Å) 2.5 × 20–cm disposable Flex chromatography columns (Kontes) DNA synthesizer (e.g., Applied Biosystems 380B) 200-mL pressure vessel container (Barrskogen)
3.9.2 Supplement 11
Current Protocols in Nucleic Acid Chemistry
1-mL syringes with Luer tip 4-mL screw-capped glass vials Heating block (VWR), 90° ± 2°C UV spectrophotometer 1.5-mL microcentrifuge tubes 37°C water bath 5-µm Supelcosil LC-18S HPLC column (25 cm × 4.6 mm, Supelco) Additional reagents and equipment for polyacrylamide gel electrophoresis (PAGE; UNIT 10.4 and APPENDIX 3B), thin-layer chromatography (TLC; APPENDIX 3D), column chromatography (APPENDIX 3E), solid-phase oligonucleotide synthesis (APPENDIX 3C), SVP and BAP digestion (UNIT 10.6), and reversed-phase HPLC (RP-HPLC; UNIT 10.5) NOTE: The composition of DNA synthesis reagents (i.e., activator, oxidation, capping, and deblocking solutions) varies by manufacturer and by instrument. It is important to use the DNA synthesis reagents recommended for the specific synthesizer used, according to manufacturer’s instructions. Prepare deoxyribonucleoside phosphoramidites S.3a-d 1. Dry 2 mmol of suitably protected deoxyribonucleoside (S.1a-d) in a 50-mL threenecked round-bottom flask for 2 hr at 25°C under high vacuum. Attach a 15-mL powder-addition funnel containing 140 mg (2 mmol) sublimed 1H-tetrazole, and seal remaining necks with rubber septa. 2. Under an argon atmosphere, using a 10-mL syringe, add 10 mL anhydrous methylene chloride followed by 818 mg (2.1 mmol) N,N,N′,N′-tetraisopropyl-O-[3-(N-tertbutylcarboxamido)-1-propyl]phosphordiamidite (S.2) and stir with a magnetic stirrer and stir bar. 3. While still stirring, add the 1H-tetrazole in the addition funnel over a period of 1 hr. 4. Monitor the progress of the reaction by TLC (APPENDIX 3D) using 9:1 (v/v) benzene/triethylamine or 3:6:1 (v/v/v) methylene chloride/hexane/triethylamine as the eluent. Phosphinylation of suitably protected 2′-deoxynucleosides S.1a-c is usually complete within 3 hr at ambient temperature. For best results, phosphinylation of S.1d should be allowed to proceed for 12 hr at 25°C. Rf [9:1(v/v) benzene/triethylamine]: S.3a: 0.35, 0.43; S.3b: 0.47, 0.55; S.3c: 0.18, 0.29; S.3d: 0.10, 0.13. Rf [3:6:1(v/v/v) methylene chloride/hexane/triethylamine]: S.3a: 0.25; S.3b: 0.21; S.3c: 0.14; S.3d: 0.08.
5. Concentrate the reaction mixture to a foam using a rotary evaporator connected to a vacuum pump. 6. Suspend the crude product in 1 mL of 1:8:1 methylene chloride/hexane/triethylamine and apply the suspension to a 2.5 × 20–cm disposable Flex chromatography column containing ∼20 g silica gel that has been equilibrated in 1:8:1 methylene chloride/hexane/triethylamine (APPENDIX 3E). 7. Elute the column first with 100 mL of 10:80:10 (v/v/v) methylene chloride/hexane/triethylamine and collect 10-mL fractions. Using 100 mL of each concentration and collecting 10-mL fractions throughout, increase the concentration of methylene chloride in 5% increments until final ratios of 30:60:10 (S.3a), 50:40:10 (S.3b), 70:20:10 (S.3c), and 80:10:10 (S.3d) elute pure phosphoramidites. Analyze fractions by TLC (step 4), pool appropriate fractions, and concentrate under reduced pressure (∼20 min).
Synthesis of Unmodified Oligonucleotides
3.9.3 Current Protocols in Nucleic Acid Chemistry
Supplement 11
Each deoxyribonucleoside phosphoramidite S.3a-d is isolated as a white amorphous foam in yields ranging from 70% to 90%. Phosphoramidites can be stored up to several months at −20°C. 5′-O-(4,4′-Dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-[3-(N-tert-butylcarboxamido)1-propyloxy]phosphinyl-2′-deoxythymidine (S.3a): 31P-NMR (121 MHz, C6D6): δ 148.3, 148.5. Fast atom bombardment/high-resolution mass spectrometry (FAB-HRMS): anal. calcd. for C45H61N4O9P (M+Na)+ 855.4074, found 855.4083. N4-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-[3-(N-tert-butylcarboxamido)-1-propyloxy]phosphinyl-2′-deoxycytidine (S.3b): 31P-NMR (121 MHz, C6D6): δ 146.3, 148.3. FAB-HRMS: anal. calcd. for C51H64N5O9P (M+Cs)+ 1054.3496, found 1054.3480. N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-[3-(N-tert-butylcarboxamido)-1-propyloxy]phosphinyl-2′-deoxyadenosine (S.3c): 31P-NMR (121 MHz, C6D6): δ 148.6, 148.7. FAB-HRMS: anal. calcd. for C52H64N7O8P (M+Na)+ 968.4453, found 968.4430. N2-Isobutyryl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-[3-(N-tert-butylcarboxamido)-1-propyloxy]phosphinyl-2′-deoxyguanosine (S.3d): 31P-NMR (121 MHz, C6D6): δ 148.2, 149.1. FAB-HRMS: anal. calcd. for C49H66N7O9P (M+Na)+ 950.4559, found 950.4560.
Synthesize oligonucleotides 8. Perform a 0.2-µmol-scale solid-phase synthesis of the desired oligonucleotide, or a 1-µmol-scale synthesis for its phosphorothioate analog, on an Applied Biosystems 380B DNA synthesizer (in trityl-off mode) according to the manufacturer’s recommendations (also see APPENDIX 3C). To compare coupling efficiency and the quality of the synthetic DNA produced using this protecting group, perform a parallel synthesis using standard 2-cyanoethyl deoxyribonucleoside phosphoramidites. Synthesis of d(ATCCGTAGCTAAGGTCATGC) is described in Wilk et al. (2002). 2-Cyanoethyl deoxyribonucleoside phosphoramidites and all the reagents pertaining to the automated preparation of oligonucleotides were purchased from Perkin-Elmer and used as recommended by the manufacturer. Like 2-cyanoethyl deoxyribonucleoside phosphoramidites, phosphoramidites S.3a-d are used as 0.1 M solutions in dry acetonitrile. The synthetic cycle used in the preparation of unmodified DNA oligonucleotides is slightly modified for the preparation of phosphorothioated DNA oligonucleotides in that the capping step is performed after the sulfurization reaction, which replaces the iodine oxidation step (see Iyer et al., 1990). The sulfurization reaction is effected by treatment with 0.05 M 3H-1,2-benzodithiol-3-one-1,1-dioxide (Glen Research) in acetonitrile using a wait step of 30 sec.
Deprotect oligonucleotide and release from support 9. Place the synthesis column in a 200-mL pressure vessel and fill the container with ammonia gas (∼10 bar, 25°C). Perform N-deprotection for 10 hr under these conditions. 10. Release gas from the pressure vessel and apply vacuum briefly (1 min) to the pressure vessel to remove traces of ammonia. 11. Using a 1-mL syringe with a Luer tip, carefully push back and forth 1.0 mL of 1× PBS, pH 7.2, through the synthesis column. Collect the solution in a 4-mL screwcapped glass vial. 3-(N-tert-Butylcarboxamido)-propyl and 4-Oxopentyl Protecting Groups
DNA oligonucleotides synthesized from commercial 2-cyanoethyl deoxyribonucleoside phosphoramidites are subjected to deprotection steps 9 though 11 only. Proceed to step 13.
3.9.4 Supplement 11
Current Protocols in Nucleic Acid Chemistry
12. Place the capped vial containing the oligonucleotide solution in a heating block preheated to 90° ± 2°C and continue heating at this temperature for 30 min to remove the phosphate-protecting group. Cool to room temperature. 13. Determine the concentration of the oligonucleotide by UV spectrophotometry at 260 nm. Analyze oligonucleotide by polyacrylamide gel electrophoresis 14. Pipet 0.25 OD260 units of the oligonucleotide solution into a 1.5-mL microcentrifuge tube and evaporate to dryness using a stream of air.
A
B
Figure 3.9.2 Polyacrylamide gel electrophoresis analysis of d(ATCCGTAGCTAAGGTCATGC) under denaturing conditions (7 M urea, 1× TBE buffer, pH 8.3). (A) A crude 20-mer synthesized from commercial 2-cyanoethyl deoxyribonucleoside phosphoramidites and deprotected as described in the Basic Protocol, steps 9 through 11. (B) A crude 20-mer synthesized from S.3a-d and deprotected as described in steps 9 through 12. Bromphenol blue is used as a marker and shows as a large band in each lane at the bottom of the gel. Reprinted from Wilk et al. (2002) with permission from the American Chemical Society.
A
B
0
10
20 Retention time (min)
30
40
Figure 3.9.3 R P - HP LC analysis of the enzymatic hydrolysis of cr ude d(ATCCGTTGCTAAGGTCATGC) by snake venom phosphodiesterase and bacterial alkaline phosphatase. (A) Chromatogram of the digest obtained from the crude 20-mer that was synthesized from commercial 2-cyanoethyl deoxyribonucleoside phosphoramidites and deprotected as described in the Basic Protocol, steps 9 through 11. (B) Chromatogram of the digest obtained from the crude 20-mer that was synthesized from S.3a-d and deprotected as described in steps 9 through 12. Identities of the RP-HPLC peaks from left to right are dC, dG, dT, and dA when compared to authentic commercial samples. Reprinted from Wilk et al. (2002) with permission from the American Chemical Society.
Synthesis of Unmodified Oligonucleotides
3.9.5 Current Protocols in Nucleic Acid Chemistry
Supplement 11
15. Add 10 µL of loading buffer. Vortex well and then centrifuge 5 sec at 14,000 × g. 16. Load the sample in a 2-cm-wide well of a 20 × 40–cm, 7 M urea/20% polyacrylamide gel (UNIT 10.4 and APPENDIX 3B). Electrophorese at 350 V until the bromphenol blue dye travels 75% of the length of the gel. 17. Dismantle the gel apparatus and immerse the gel in 250 mL staining buffer containing 10 mL of 1 mg/mL Stains-All in formamide. Agitate the gel for ∼1 hr in the dark. 18. Discard the staining solution and rinse the gel three times with 250 mL distilled water. 19. Expose the gel to natural light until the purple background disappears and photograph the blue bands against a white background (see Fig. 3.9.2). Characterize oligonucleotide by enzymatic hydrolysis 20. Pipet 1 OD260 unit of crude oligonucleotide in a 1.5-mL microcentrifuge tube and evaporate to dryness using a stream of air. 21. Add 6 µL of 1.0 M Tris⋅Cl buffer, pH 9.0, 8 µL of 1.0 M MgCl2, and 75 µL water. Mix well. 22. Add 5 µL (0.015 U) SVP and 6 µL (0.7 U) BAP and heat 16 hr in a 37°C water bath (also see UNIT 10.6). 23. Heat deactivate the enzyme 3 min at 90°C. Centrifuge 5 min at 14,000 × g, 25°C. 24. Analyze a 50-µL aliquot of the digest by RP-HPLC (UNIT 10.5) using a 5-µm Supelcosil LC-18S column and a linear gradient of 1% acetonitrile/min, starting from 0.1 M triethylammonium acetate, pH 7.0, at a flow rate of 1 mL/min. An RP-HPLC profile of a digest is shown in Figure 3.9.3.
Analyze phosphorothioated oligonucleotides by 31P-NMR spectroscopy 25. Analyze phosphorothioated oligonucleotide (synthesized from S.3a-d and deprotected as in steps 9 through 12) in D2O by 31P-NMR spectroscopy. A 31P-NMR spectrum of the phosphorothioated oligonucleotide d(ATCCGTAGCTAAGGTCATGC) is shown in Figure 3.9.4. The crude oligomer is shown as a broad singlet at ∼55 ppm. Insignificant amounts of partially desulfurized 20-mer are detected near 0 ppm.
200 190 180 170 160 150 140 130 120 110 100 90
80 70 60 50 40 30 20 10
0 −10
ppm
3-(N-tert-Butylcarboxamido)-propyl and 4-Oxopentyl Protecting Groups
Figure 3.9.4 A 121-MHz 31P-NMR spectrum of d(APSTPSCPSCPSGPSTPSAPSGPSCPSTPSAPSAPS GPSGPSTPSCPSAPSTPSGPSC) in D2O. The crude 20-mer is prepared from S.3a-d and deprotected as described in the Basic Protocol, steps 9 through 12. Reprinted from Wilk et al. (2002) with permission from the American Chemical Society.
3.9.6 Supplement 11
Current Protocols in Nucleic Acid Chemistry
PREPARATION OF N,N,N′,N′-TETRAISOPROPYL-O-[3-(N-tert-BUTYLCARBOXAMIDO)-1-PROPYL]PHOSPHORDIAMIDITE This protocol describes the generation of bis(N,N-diisopropylamino)chlorophosphine (S.4) in situ upon mixing phosphorus trichloride and N,N-diisopropylamine, and its subsequent reaction with (N-tert-butyl)-4-hydroxybutyramide (S.5) to give the desired phosphordiamidite S.2 (see Fig. 3.9.5). The amidoalcohol S.5 is prepared from γ-butyrolactone (S.6) and tert-butylamine (Fig. 3.9.6).
SUPPORT PROTOCOL
Additional Materials (also see Basic Protocol) γ-Butyrolactone (S.6; Aldrich) tert-Butylamine (Aldrich) Benzene Phosphorus trichloride (Aldrich), freshly distilled N,N-Diisopropylamine (Aldrich), anhydrous 90°C water bath 100-mL round-bottom flask, oven dried 60-mL sintered glass funnel (coarse porosity) Prepare N-tert-butyl-4-hydroxybutyramide (S.5) 1. Place 8.60 g (100 mmol) γ-butyrolactone (S.6) in a 200-mL glass-lined pressure vessel. 2. Add 11.0 g (150 mmol) tert-butylamine and stir 3 days at 90°C. CAUTION: The above reaction involves heating highly irritating tert-butylamine above its boiling point. Ensure that the pressure vessel is sealed tightly and is placed in a well-ventilated chemical fume hood. Use moist pH indicator paper to check for leaks.
O HO
PCl3
i -Pr2N
i -Pr2NH
P
C6H6
Cl
N H 5
2
+ i -PrNH2 ⋅ HCl
i -Pr2N 4
Figure 3.9.5 Preparation of N,N,N′,N′-tetraisopropyl-O-[3-(N-tert-butylcarboxamido)-1-propyl]phosphordiamidite (S.2).
O
O O
t -BuNH2
HO
N H
90°C, 3 days 6
5
Figure 3.9.6 Preparation of N-tert-butyl-4-hydroxybutyramide (S.5). Adapted from Wilk et al. (2002) with permission from the American Chemical Society.
Synthesis of Unmodified Oligonucleotides
3.9.7 Current Protocols in Nucleic Acid Chemistry
Supplement 11
3. Cool the vessel to ambient temperature and release residual pressure in a well-ventilated chemical fume hood. 4. Apply vacuum to the pressure vessel to remove excess tert-butylamine, and keep the remaining material under reduced pressure (2 mmHg) for 1 hr, yielding a semi-crystalline mass. N-tert-Butyl-4-hydroxybutyramide (S.5) is recrystallized from chloroform/hexane (mp 73°C) and is isolated in near quantitative yield (15.5 g, 97.0 mmol). 1H-NMR (300 MHz, DMSO-d6): δ 1.23 (s, 9H), 1.59 (dt, J = 7.5, 6.6 Hz, 2H), 2.04 (t, J = 7.5 Hz, 2H), 3.34 (t, J = 6.6 Hz, 2H), 3.38 (b, 1H), 7.35 (b, 1H). 13C-NMR (75 MHz, DMSO-d6): δ 28.5, 28.7, 32.9, 49.8, 60.3, 171.8. Electrospray ionization mass spectrometry (ESI-MS; 70 eV): m/z (% relative abundance), 159 (M+, 4), 144 (7), 115 (31), 87 (11), 86 (14), 59 (19), 58 (100), 57 (29).
Prepare N,N,N′,N′-tetraisopropyl-O-[3-(N-tert-butylcarboxamido)-1-propyl]phosphordiamidite (S.2) 5. To an oven-dried 100-mL round-bottom flask containing 50 mL dry benzene under a dry argon atmosphere, add 876 µL (10 mmol) freshly distilled phosphorus trichloride by syringe and needle through a rubber septum. 6. Cool to 5°C by immersion in an ice bath. While stirring, add by syringe 8.8 mL (70 mmol) anhydrous N,N-diisopropylamine over a 30-min period under an argon atmosphere. 7. Remove the ice bath and allow the stirred reaction to warm to 25°C under a positive pressure of argon until the formation of bis(N,N-diisopropylamino) chlorophosphine (S.4) is complete. The rate of the reaction is monitored by 31P-NMR spectroscopy; after ∼3 to 4 days, complete conversion of (N,N-diisopropylamino) dichlorophosphine (singlet, 168.2 ppm in benzened6 downfield relative to a phosphoric acid external standard) to S.4 (singlet, 134.1 ppm) is achieved.
8. Add 1.9 g (12 mmol) S.5 and stir 2 hr at 25°C under a positive pressure of argon. The 31P-NMR spectrum of the reaction mixture in benzene-d6 shows a singlet at 123.2 ppm, indicating the formation of S.2 in ∼95% yield.
9. Filter the suspension through a 60-mL sintered glass funnel (coarse porosity) and wash the collected salt with 20 mL dry benzene. 10. Evaporate the filtrates under reduced pressure to afford 3.5 g (9 mmol, 90%) S.2 as an oil. Crude S.2 can be used for the phosphinylation of S.1a-d without further purification. It is, however, recommended to purify S.2 by silica gel chromatography using 9:1 (v/v) benzene/triethylamine as an eluent. This purification step allows S.2 to be isolated as a white crystalline solid (mp 71°-72°C). 1H-NMR (300 MHz, C6D6): δ 1.19 (d, J = 6.8 Hz, 12H), 1.22 (d, J = 6.8 Hz, 12H), 1.25 (s, 9H), 2.00 (m, 2H), 2.05 (m, 2H), 3.48 (sept, J = 6.8 Hz, 2H), 3.52 (sept, J = 6.8 Hz, 2H), 3.63 (dt, J = 6.0 Hz, 3JPH = 7.3 Hz, 2H). 13C-NMR (75 MHz, C6D6): δ 24.0, 24.1, 24.7, 24.8, 28.1 (d, 3JPC = 8.5 Hz), 28.8, 34.0, 44.6, 44.7, 50.7, 63.71 (d, 2JPC = 21.2 Hz), 171.1. 31P-NMR (121 MHz, C6D6): δ 123.2
3-(N-tert-Butylcarboxamido)-propyl and 4-Oxopentyl Protecting Groups
3.9.8 Supplement 11
Current Protocols in Nucleic Acid Chemistry
PREPARATION OF OLIGODEOXYRIBONUCLEOTIDES USING 5′-O-(4,4′-DIMETHOXYTRITYL)-3′-O-(N,N-DIISOPROPYLAMINO)-(4-OXO-1PENTYLOXY)PHOSPHINYL-2′-DEOXYRIBONUCLEOSIDES
ALTERNATE PROTOCOL
Like the 3-(N-tert-butylcarboxamido)-1-propyl group (see Basic Protocol), the 4-oxopentyl group for phosphate protection in DNA oligonucleotide synthesis is convenient because it can be removed under thermolytic conditions with comparable deprotection rates. This group, however, has the additional convenience of being labile under pressurized ammonia, methylamine gas, or concentrated ammonium hydroxide (Wilk et al., 2001). The latter conditions are especially recommended for the removal of the 4-oxopentyl group from oligonucleoside phosphorothioates. This protocol thus delineates a general method for the synthesis of deoxyribonucleoside phosphoramidites (S.8a-d) from the reaction of N- and 5′-O-protected deoxyribonucleosides (S.1a-d) with N,N,N′,N′-tetraisopropyl-O-(4-oxopentyl)phosphordiamidite (S.7) and 1H-tetrazole. This approach to the preparation of S.8a-d is illustrated in Figure 3.9.7. Synthesis and characterization of oligonucleotides follows the general procedures described in the Basic Protocol. Additional Materials (also see Basic Protocol and Support Protocol) 3-Acetyl-1-propanol (Aldrich) Prepare N,N,N′,N′-tetraisopropyl-O-(4-oxopentyl)phosphordiamidite S.7 1. Prepare S.7 (Fig. 3.9.7) from S.4 and 3-acetyl-1-propanol using the procedure described for synthesis of S.2 (see Support Protocol, steps 5 through 10). Perform on a scale that is two times that described for S.2. The 31P-NMR spectrum of S.7 shows a singlet at 123.5 ppm in C6D6. Like S.2, S.7 is used without further purification in the synthesis of the deoxyribonucleoside phosphoramidites S.8a-d.
Prepare deoxyribonucleoside phosphoramidites S.8a-d 2. Prepare phosphoramidites S.8a-d as described for S.3a-d (see Basic Protocol, steps 1 to 5), but reduce sublimed 1H-tetrazole to 120 mg (1.6 mmol) and use 980 µL (∼3 mmol) S.7 in place of S.2. As for S.3a-d, the coupling time for S.8d is 12 hr, compared to 3 hr for S.8a-c.
i -Pr2N DMTrO
O
B
P
i -Pr2N
CH3
O 7
OH 1a b c d
B = thymin-1-yl B = N 4-benzoylcytosin-1-yl B = N 6-benzoyladenin-9-yl B = N 2-isobutyrylguanin-9-yl
DMTrO
O
O
1H -tetrazole/CH2Cl2
i -Pr2N
B
O P
O
O
CH3 8a-d
Figure 3.9.7 Preparation of deoxyribonucleoside phosphoramidites S.8a-d using N,N,N′,N′tetraisopropyl-O-(4-oxopentyl)phosphordiamidite (S.7). DMTr, 4,4′-dimethoxytrityl; i-Pr, isopropyl. Adapted from Wilk et al. (2001) with permission from Elsevier Science.
Synthesis of Unmodified Oligonucleotides
3.9.9 Current Protocols in Nucleic Acid Chemistry
Supplement 11
Rf [9:1 (v/v) benzene/triethylamine]: S.8a: 0.37, 0.41; S.8b: 0.45, 0.54; S.8c: 0.16, 0.27; S.8d: 0.09, 0.12. Rf [3:6:1(v/v/v) methylene chloride/hexane/triethylamine]: S.8a: 0.22; S.8b: 0.18; S.8c: 0.12; S.8d: 0.05.
3. Perform column chromatography (see Basic Protocol, steps 6 and 7), but use the following final solvent ratios: 50:40:10 (S.8a), 60:30:10 (S.8b), 70:20:10 (S.8c), and 90:00:10 (S.8d) (v/v/v) methylene chloride/hexane/triethylamine. Each deoxyribonucleoside phosphoramidite S.8a-d is isolated as a white amorphous foam in yields ranging from 68% to 80%. 5′-O-(4,4′-Dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-(4-oxo-1-pentyloxy)phosphinyl-2′-deoxythymidine (S.8a): 31P-NMR (121 MHz, C6D6 ): δ 148.4, 149.0. FAB-HRMS: anal. calcd. for C42H54N3O9P (M+Na)+ 798.3496, found 798.3541. N4-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-(4-oxo-1-pentyloxy)phosphinyl-2′-deoxycytidine (S.8b): 31P-NMR (121 MHz, C6D6 ): δ 148.9, 149.2. FAB-HRMS: anal. calcd. for C48H57N4O9P (M+Na)+ 887.3761, found 887.3682. N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-(4-oxo-1-pentyloxy)phosphinyl-2′-deoxyadenosine (S.8c): 31P-NMR (121 MHz, C6D6 ): δ 148.6, 148.8. FAB-HRMS: anal. calcd. for C49H57N6O8P (M+Na)+ 911.3873, found 911.3881. N2-Isobutyryl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(N,N-diisopropylamino)-(4-oxo-1-pentyloxy)phosphinyl-2′-deoxyguanosine (S.8d): 31P-NMR (121 MHz, C6D6 ): δ 148.0, 148.5. FAB-HRMS: anal. calcd. for C46H59N6O9P (M+Na)+ 893.3980, found 893.3965.
Synthesize oligonucleotides 4. Perform solid-phase synthesis as described in Basic Protocol (step 8), but use S.8a-d as 0.2 M solutions in dry acetonitrile, and increase the wait time for the coupling reaction to 150 sec.
A
B
C
0
3-(N-tert-Butylcarboxamido)-propyl and 4-Oxopentyl Protecting Groups
10
20 Retention time (min)
30
40
Figure 3.9.8 RP-HPLC analysis of crude d(ATCCGTAGCTAAGGTCATGC). (A) Crude 20-mer synthesized from standard 2-cyanoethyl deoxyribonucleoside phosphoramidites and deprotected by treatment with concentrated ammonium hydroxide as described in the Alternate Protocol, step 5 annotation. (B) Crude 20-mer synthesized from S.8a-d and deprotected as described in (A). (C) Crude 20-mer synthesized from S.8a-d and deprotected under pressurized ammonia gas as delineated in the Alternate Protocol, step 5. Adapted from Wilk et al. (2001) with permission from Elsevier Science.
3.9.10 Supplement 11
Current Protocols in Nucleic Acid Chemistry
0
10
20 Retention time (min)
30
40
Figure 3.9.9 R P - HP LC analysis of the enzymatic hydrolysis of cr ude d(ATCCGTTGCTAAGGTCATGC) by snake venom phosphodiesterase and bacterial alkaline phosphatase. The crude 20-mer is synthesized from S.8a-d and deprotected under pressurized ammonia gas as described in the Alternate Protocol, step 5. Identities of the RP-HPLC peaks from left to right are dC, dG, dT, dA, and benzamide (∼17 min) when compared to authentic commercial samples. Reprinted from Wilk et al. (2001) with permission from Elsevier Science.
A
200
150
100
50
ppm
200
150
100
50
ppm
B
Figure 3.9.10 Two 121-MHz 31P-NMR spectra of crude 20-mer d(APSTPSCPSCPSGPS TPSAPSGPSCPSTPSAPSAPSGPSGPSTPSCPSAPSTPSGPSC) in aqueous solvents. (A) A 20-mer synthesized from commercial 2-cyanoethyl deoxyribonucleoside phosphoramidites and deprotected by treatment with concentrated NH4OH (55°C, 10 hr). (B) A 20-mer prepared from S.8a-d and deprotected under pressurized NH3 as described in the Alternate Protocol, step 5. Reprinted from Wilk et al. (2001) with permission from Elsevier Science.
Synthesis of Unmodified Oligonucleotides
3.9.11 Current Protocols in Nucleic Acid Chemistry
Supplement 11
Perform oligonucleotide deprotection 5. Deprotect as described (see Basic Protocol, steps 9 and 10). Under these conditions, both nucleobase- and phosphate-protecting groups are removed, and the oligonucleotide is released from the support. Alternatively, push 1 mL of concentrated ammonium hydroxide back and forth through the synthesis column over a 1-hr period using two syringes with Luer tips. Then transfer the solution to a 4-mL screw-capped glass vial and heat at 55°C in the closed container for 10 hr. Cool to room temperature and proceed to step 7.
6. Using a 1-mL syringe with Luer tip, carefully push back and forth 0.5 mL of 0.1 M triethylammonium acetate buffer through the synthesis column. Collect the solution in a 4-mL screw-capped glass vial. 7. Determine the concentration of the oligonucleotide by UV spectrophotometry at 260 nm. Analyze oligonucleotide by RP-HPLC 8. Analyze ∼1 OD260 unit of the oligonucleotide on a 5-µm Supelcosil LC-18S HPLC column (UNIT 10.5) using a linear gradient of 1% acetonitrile/min starting from 0.1 M triethylammonium acetate, pH 7.0, at a flow rate of 1 mL/min. RP-HPLC profiles of oligonucleotides synthesized from S.8a-d or standard 2-cyanoethyl deoxyribonucleoside phosphoramidites, which were deprotected by treatment with pressurized ammonia gas or concentrated ammonium hydroxide, are presented in Figure 3.9.8.
Characterize oligonucleotide by enzymatic hydrolysis 9. Pipet 1 OD260 unit of crude oligonucleotide synthesized from S.8a-d in a 1.5-mL microcentrifuge tube and evaporate to dryness using a stream of air. Analyze as described (see Basic Protocol, steps 21 to 24). A RP-HPLC profile of the enzymatic hydrolysates is shown in Figure 3.9.9.
Analyze phosphorothioated oligonucleotide by 31P-NMR spectroscopy 10. Elute phosphorothioated oligonucleotide (synthesized from S.8a-d and deprotected as in step 5) from the synthesis column with 0.5 mL D2O and analyze by 31P-NMR spectroscopy. A 31P-NMR spectrum of the phosphorothioated oligonucleotide d(ATCCGTAGCTAAGGTCATGC) is shown in Figure 3.9.10.
COMMENTARY Background Information
3-(N-tert-Butylcarboxamido)-propyl and 4-Oxopentyl Protecting Groups
The demand for oligonucleotide syntheses has increased dramatically over the years, and the scales at which these syntheses are performed typically ranges from nanomole or micromole scale to millimole scale for therapeutic applications. The large-scale preparation of therapeutic oligonucleotides has challenged the suitability of 2-cyanoethyl deoxyribonucleoside phosphoramidites (Sinha et al., 1984) for such syntheses because acrylonitrile is produced as a side-product during oligonucleotide deprotection (Tener, 1961). Acrylonitrile is a potent DNA alkylating agent that can compromise the potency of oligonucleotide drug prod-
ucts (Wilk et al., 1999a). The authors have earlier reported a phosphoramidite approach to the solid-phase synthesis of DNA oligonucleotides that employs the 4-[N-methyl-N(2,2,2-trifluoroacetyl)amino]butyl group for phosphate/thiophosphate protection (Wilk et al, 1999a,b; UNIT 2.7). This group is easily removed from oligonucleotides by standard treatment with concentrated ammonium hydroxide or pressurized ammonia gas (Boal et al., 1996), and generates 2,2,2-trifluoroacetamide and Nmethylpyrrolidine as nonmutagenic side-products. Although these phosphoramidites lead to alkylation-free DNA oligonucleotide products, 4-(N-methylamino)butan-1-ol, which is a pre-
3.9.12 Supplement 11
Current Protocols in Nucleic Acid Chemistry
properties (Grajkowski et al., 2001; Wilk et al., 2002). This protecting group is prepared economically from γ -butyrolactone and tert-butylamine, and then converted to the phosphinylating reagent S.2 upon reaction with the chlorophosphine S.4 (see Support Protocol; Fig. 3.9.5). Condensation of suitably protected nucleosides S.1a-d with S.2 in the presence of 1H-tetrazole affords the 3-(N-tert-butylcarboxamido)-1-propyl deoxyribonucleoside phosphoramidites S.3a-d (see Basic Protocol; Fig. 3.9.1). These have been successfully used in the so lid-phase synthesis of the 20-mer d(ATCCGTAGCTAAGGTCATGC) and its phosphorothioated analog (Wilk et al., 2002). Following nucleobase deprotection and release of the oligonucleotide from the support, removal of the 3-(N-tert-butylcarboxamido)-1propyl phosphate/thiophosphate-protecting group is accomplished within 1 hr under thermolytic conditions at neutral pH. The deprotection reaction is considerably faster than that of the 2-(N-formyl-N-methyl)aminoethyl protecting group (3 hr) under identical conditions, and proceeds with the participation of the amidic carbonyl group in an intramolecular cyclodeesterification reaction, which, as shown in Figure 3.9.11, releases the phosphate/thiophosphate diester as its 2-tert-butyliminotetra-
cursor in the synthesis of the phosphoramidites, is not commercially available and must therefore be synthesized. Because of this added expenditure, the 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl deoxyribonucleoside phosphoramidites might not effectively compete with other phosphoramidites to produce oligonucleotide drugs at the most affordable cost per dose. This shortcoming prompted the investigation of P(III)-protecting groups for cost-effective syntheses of deoxyribonucleoside phosphoramidites. The authors found the 2-(N-formyl-N-methyl)aminoethyl group to be adequate for this purpose, and syntheses of oligodeoxyribonucleotides, such as dT18 and d(AG)10, have been reported (Grajkowski et al., 2001). Although the 2-(Nformyl-N-methyl)aminoethyl phosphate/thiophosphate-protecting group cannot be removed reliably by standard ammonolysis, it is easily cleaved from oligonucleotides via a unique thermolytic cyclodeesterification process (Wilk et al., 2000; Grajkowski et al., 2001). While the group is cleanly removed from phosphate or phosphorothioate triesters under neutral conditions, its deprotection is excessively time consuming (3 hr). The 3-(N-tert-butylcarboxamido)-1-propyl group also exhibits thermolytic deprotection
O
O
B
B
O
X
O
pH 7.0
P O
90°C, 1 hr
O
B O
HN
HN O
O
O
B
O X
P O
O
O
B
O
O
O
O
P X−
O
B
O
O
HN +
O O
O
Figure 3.9.11 Proposed mechanism for the removal of the 3-(N-tert-butylcarboxamido)-1-propyl phosphate/thiophosphate-protecting group under thermolytic conditions at neutral pH. X = O or S; B = any of thymin-1-yl, cytosin-1-yl, adenin-9-yl, or guanin-9-yl.
Synthesis of Unmodified Oligonucleotides
3.9.13 Current Protocols in Nucleic Acid Chemistry
Supplement 11
B1
O
O
B
O
X
O
NH3 (g)
P O
or NH4OH
O
B O CH3
CH3
CH3
O
O
O
B1
O X
H2 N
P O
O
O
B
O
O
O
OH
P
X−
O
N B
O
O
+ O
O
Figure 3.9.12 Proposed mechanism for the removal of the 4-oxopentyl phosphate/thiophosphateprotecting group under mild basic conditions. X = O or S; B1 = any of thymin-1-yl or N-protected nucleobases; B = any of thymin-1-yl, cytosin-1-yl, adenin-9-yl, or guanin-9-yl.
3-(N-tert-Butylcarboxamido)-propyl and 4-Oxopentyl Protecting Groups
hydrofuran salt. Neither nucleobase alkylation nor significant phosphorothioate desulfurization were detected under conditions that would mimic millimole-scale oligonucleotide deprotection (Wilk et al., 2002). The removal of phosphate/thiophosphate-protecting groups from DNA oligonucleotides in the absence of concentrated ammonium hydroxide is advantageous in that the handling of hazardous ammonium hydroxide can be completely eliminated from oligonucleotide processing. This advantage should certainly be appreciated when performing large-scale therapeutic oligonucleotide syntheses, as large quantities of concentrated ammonium hydroxide are needed for releasing oligonucleotides from the solid support and for nucleobase deprotection. Another attractive phosphate/thiophosphate-protecting group for synthetic oligodeoxyribonucleotides is the 4-oxopentyl group (Wilk et al., 2001). This protecting group is incorporated into deoxyribonucleoside phosphoramidites S.8a-d under conditions identical to those used for the preparation of S.3a-d (see Alternate Protocol; Fig. 3.9.7). The phosphoramidites S.8a-d are as efficient as S.3a-d or 2-cyanoethyl deoxyribonucleoside phosphoramidites in the solid-phase synthesis of the 20-mer d(ATCCGTAGCTAAGGTCATGC) and its phosphorothioated analog (Wilk et al., 2001). Unlike the 3-(N-tert-butylcarboxamido)-1-propyl and 2-(N-formyl-Nmethyl)aminoethyl groups, the 4-oxopentyl
group was rapidly and completely cleaved from these oligonucleotides under the conditions required for nucleobase deprotection using either pressurized ammonia gas or concentrated ammonium hydroxide (Wilk et al., 2001). The reaction of ammonia with the ketone function of the phosphate/thiophosphate-protecting group most likely leads to the formation of a hemiaminal intermediate as shown in Figure 3.9.12. This intermediate underwent rapid cyclodeesterification to release the phosphate/thiophosphate diester with the concomitant formation of 2-methyl-1-pyrroline as the major deprotection side-product (Wilk et al., 2001). This deprotection pathway is consistent with the removal of 4-N-methylaminobutyl phosphate/thiophosphate-protecting groups reported earlier under similar conditions (Wilk et al., 1999a,b). The generation of 2-methyl-1pyrroline during the course of oligonucleotide deprotection did not produce detectable nucleobase alkylation or significant phosphorothioate desulfurization even under conditions that would simulate large-scale oligonucleotide deprotection (Wilk et al., 2001). Thus, use of the 3-(N-tert-butylcarboxamido)-1-propyl or 4-oxopentyl group for phosphate/thiophosphate protection in the large-scale production of therapeutic oligonucleotides is an obvious choice as these groups offer economy in the manufacture of such biopolymers, provide versatility in the selection of oligonucleotide deprotection condi-
3.9.14 Supplement 11
Current Protocols in Nucleic Acid Chemistry
tions, and ensure alkylation-free drug product for optimal potency.
Critical Parameters and Troubleshooting Since the phosphordiamidites S.2 and S.7 are prepared using the bis(N,N-diisopropylamino) chlorophosphine intermediate S.4 (see Support Protocol, Fig. 3.9.5) in a manner similar to that reported for the N,N,N′,N′-tetraisopropyl-O-{2-[(N-formyl-N-methyl)amino]-ethylphosphordiamidite (UNIT 2.7, Fig. 2.7.4), the readers are referred to the section on Critical Parameters and Troubleshooting of UNIT 2.7, which addresses issues pertaining to the synthesis of phosphordiamidites. It is critically important that the formation of S.4 be carefully monitored by 31P-NMR spectroscopy to ensure complete exhaustion of phosphorus trichloride prior to adding the amidoalcohol S.5 or 3-acetyl-1-propanol. It is recommended that the purification of the deoxyribonucleoside phosphoramidites S.3a-d and S.8a-d be performed on a silica gel column using first a 1:8:1 (v/v/v) solution of methylene chloride/hexane/triethylamine as the eluent, and to carefully monitor by TLC the elution of fast-moving impurities. The concentration of methylene chloride should then be increased to elute the remaining fast-moving impurities until the final composition of the eluent is reached to elute the desired deoxyribonucleoside phosphoramidites. In order to ensure optimal coupling efficiency of individual deoxyribonucleoside phosphoramidites during conventional solidphase oligonucleotide synthesis, a number of parameters must be taken into consideration. These are addressed in the section on Critical Parameters and Troubleshooting of UNIT 2.7.
Anticipated Results The synthesis of deoxyribonucleoside phosphoramides S.3a-d and S.8a-d from their respective phosphordiamidites S.2 and S.7 is performed essentially as recommended by Barone et al. (1984). The condensation time is extended for the preparation of S.3d and S.8d to ensure optimal yields. The coupling efficiency of phosphoramidites S.3a-d and S.8a-d is comparable to that of standard 2-cyanoethyl deoxyribonucleoside phosphoramidites.
phosphordiamidites S.2 and S.7 also takes 4 days. The synthesis and purification of each of the deoxyribonucleoside phosphoramidites S.3a-d and S.8a-d requires 1 to 2 days to complete.
Literature Cited Barone, A.D., Tang, J.-T., and Caruthers, M.H. 1984. In situ activation of bis-dialkylaminophosphines—a new method for synthesizing deoxyoligonucleotides on polymer supports. Nucl. Acids Res. 12:4051-4061. Boal, J.H., Wilk, A., Harindranath, N., Max, E.E., Kempe, T., and Beaucage, S.L. 1996. Cleavage of oligodeoxyribonucleotides from controlledpore glass supports and their rapid deprotection by gaseous amines. Nucl. Acids Res. 24:31153117. Grajkowski, A., Wilk, A., Chmielewski, M.K., Phillips, L.R., and Beaucage, S.L. 2001. The 2-(Nformyl,N-methyl)aminoethyl group as a potential phosphate/thiophosphate protecting group in solid-phase oligodeoxyribonucleotide synthesis Organic Lett. 3:1287-1290. Iyer, R.P., Phillips, L.R., Egan, W., Regan, J.B., and Beaucage, S.L. 1990. The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one-1,1-dioxide as a sulfur-transfer reagent. J. Org. Chem. 55:46934699. Sinha, N.D., Biernat, J., McManus, J., and Köster, H. 1984. Polymer support oligonucleotide synthesis. 18. Use of β-cyanoethyl-N,N-dialkylamino/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucl. Acids Res. 12:45394557. Tener, G.M. 1961. 2-Cyanoethyl phosphate and its use in the synthesis of phosphate esters. J. Am. Chem. Soc. 83:159-168. Wilk, A., Grajkowski, A., Phillips, L.R., and Beaucage, S.L. 1999a. The 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl group as an alternative to the 2-cyanoethyl group for phosphate protection in the synthesis of oligodeoxyribonucleotides. J. Org. Chem. 64:7515-7522. Wilk, A., Grajkowski, A., Srinivasachar, K., and Beaucage, S.L. 1999b. Improved chemistry for the production of synthetic oligodeoxyribonucleotides. Antisense Nucleic Acid Drug Dev. 9:361-366. Wilk, A., Grajkowski, A., Phillips, L.R., and Beaucage, S.L. 2000. Deoxyribonucleoside cyclic Nacylphosphoramidites as a new class of monomers for the stereocontrolled synthesis of oligothymidylyl- and oligocytidylyl-phosphorothioates. J. Am. Chem. Soc. 122:21492156.
Time Considerations The preparation and purification of (N-tertbutyl)-4-hydroxybutyramide S.5 is accomplished within 4 days. The synthesis of the
Synthesis of Unmodified Oligonucleotides
3.9.15 Current Protocols in Nucleic Acid Chemistry
Supplement 11
Wilk, A., Chmielewski, M.K., Grajkowski, A., Phillips, L.R., and Beaucage, S.L. 2001. The 4oxopentyl group as a labile phosphate/thiophosphate protecting group for synthetic oligodeoxyr ibonucleotides. Te trahedron Lett. 42:5635-5639. Wilk, A., Chmielewski, M.K., Grajkowski, A., Phillips, L.R., and Beaucage, S.L. 2002. The 3-(Ntert-butylcarboxamido)-1-propyl group as an attractive phosphate/thiophosphate protecting group for solid-phase oligodeoxyribonucleotide synthesis. J. Org. Chem. 67:6430-6438.
Contributed by Andrzej Wilk, Marcin K. Chmielewski, Andrzej Grajkowski, and Serge L. Beaucage Food and Drug Administration Bethesda, Maryland Lawrence R. Phillips National Cancer Institute Frederick, Maryland
3-(N-tert-Butylcarboxamido)-propyl and 4-Oxopentyl Protecting Groups
3.9.16 Supplement 11
Current Protocols in Nucleic Acid Chemistry
DNA Synthesis Without Base Protection An ultimate goal in the chemical synthesis of DNA is the ability to form O-selective internucleotide bonds without the use of baseprotecting groups, as can be done by enzymatic synthesis using DNA polymerases. The current chemical synthesis of DNA fragments requires multistep procedures for the introduction and removal of protecting groups to guarantee the fidelity of the synthesis (Caruthers, 1991). Satisfactory results have in fact been reported for the synthesis of unmodified DNA oligomers (UNIT 3.1). In these post-genome days, however, there are increasing demands to accelerate manipulation for gene detection and diagnosis, so that it is increasingly desirable to find more straightforward methods for the synthesis of DNA fragments (Shena, 1999). For this purpose, a number of improvements in the widespread phosphoramidite approach, which is used as the most reliable method, have been reported (Beaucage and Iyer, 1992; UNIT 3.3). They involve the use of more base-labile N-phenoxyacetyl protecting groups (Schulhof et al., 1987) and methylamine (Boal et al., 1996) as a powerful deacylating reagent for rapid deprotection, as well as the use of protecting groups that can be removed under neutral conditions (Hayakawa et al., 2001). As an alternative to these types of improvements, O-selective internucleotide bond formation provides an entirely different approach; the methods described here will offer new insight into modern DNA synthesis. The feasibility of O-selective internucleotide bond formation using non-N-acylated nucleoside derivatives has been suggested based on the unique properties of the amino and hydroxy groups of nucleosides. Baddiley and Todd (1947) reported that 2 ,3 O-isopropylideneadenosine underwent 5 -Oselective phosphorylation with dibenzyl phosphorochloridate in pyridine (Fig. 3.10.1). In phosphorylation of nucleosides, it is well known that phosphorus oxychloride selectively reacts with nucleosides in triethyl phosphate to give 5 -O-phosphorylated nucleosides (Yoshikawa and Kato, 1967; Ikemoto et al., 1995). Partial acetylation of adenosine with acetic anhydride gives 3 ,5 -di-Oacetyladenosine (Kool et al., 1987). Silylation of deoxyribonucleotides gives exclusively Osilylated products (Ogilvie, 1973; Sekine et al.,
UNIT 3.10
1985). In contrast, it was also reported that deoxycytidine underwent selective N-acylation with various acylating reagents (Watanabe and Fox, 1966; Nikolenko et al., 1967; Hata and Kurihara, 1973). These apparently contradictory results could be explained through a comprehensive understanding that the difference in reactivity between the hydroxy and amino groups of nucleosides varies depending on the inherent Soft-Hard (Pearson, 1987, 1990) nature of nucleobases and electrophilic reagents, as well as reaction conditions such as solvents and additives. Therefore, to realize oligonucleotide synthesis without base protection, it is important to create the most reasonable intermediates that are capable of O-selective phosphorylation in the reaction system.
LIQUID-PHASE SYNTHESIS Several precedents concerning oligonucleotide synthesis without N-protecting groups have been reported for liquid-phase oligonucleotide synthesis (Fig. 3.10.1). Using his original phosphite triester approach (Yuodka et al., 1976), Letsinger found that the amino group of the adenine base moiety exhibited rather poor reactivity toward tervalent phosphitylating intermediates (Letsinger et al., 1976; Finnan et al., 1980). Using this method, these investigators synthesized an oligonucleotide with the sequence TAAAT. Adamiak reported the synthesis of tRNA anticodon loop fragments containing ureidonucleosides without protection of the adenine moiety by using 2,4,6triisopropylbenzensulfonyl 1H-tetrazolide as the condensing reagent in the phosphotriester approach (Adamiak and Stawinski, 1977; Adamiak et al., 1978). Fourrey and Varenne (1985) reported the synthesis of DNA dimers using N-unprotected dA and dC phosphoramidite building blocks with 2-chlorophenyl and morpholino groups. Hayakawa reported several methods for activation of alcoholic components by use of metalating reagents such as t-BuLi (Hayakawa et al., 1983a), tBuMgCl (Hayakawa et al., 1984, 1985), and LiAl(NiPr2 )4 (Hayakawa et al., 1983b). These agents accelerate displacement with active esters of nucleoside phosphotriester components without introduction of any protecting groups on the adenine base. Synthesis of Unmodified Oligonucleotides
Contributed by Mitsuo Sekine Current Protocols in Nucleic Acid Chemistry (2004) 3.10.1-3.10.15 C 2004 by John Wiley & Sons, Inc. Copyright
3.10.1 Supplement 18
Figure 3.10.1 Structure of oligonucleotide derivatives obtained by liquid-phase synthesis without base protection. Abbreviations: Ade, adenin-9-yl; Cyt, cytosin-1-yl; DMTr, 4,4 -dimethoxytrityl; Gua, guanin-9-yl; MMTr, 4-monomethoxytrityl; TBDMS, tert-butyldimethylsilyl; Thy, thymin-1-yl; Ura, uracil-1-yl. References: (1) Letsinger et al. (1976); (2) Adamiak and Stawinski (1977); (3) Fourrey and Varenne (1985); (4) Hayakawa et al. (1983a,b, 1984); (5) Hayakawa et al. (1987).
SOLID-PHASE SYNTHESIS USING THE PHOSPHORAMIDITE APPROACH Synthesis of Common Starting Nucleosides 5 -O-Dimethoxytrityldeoxyribonucleosides
DNA Synthesis Without Base Protection
There are two methods for the synthesis of deoxyribonucleosides with 5 -O-(4,4 dimethoxytrityl) (DMTr) protection. One is the direct introduction of the DMTr group into deoxyribonucleosides. The 5 -O-selective tritylation of dC in pyridine gives rise to 5 -ODMTr-dC in 89% yield, as first described by Michelson and Todd (1954). Jones reported that direct dimethoxytritylation of dA with 1.5 equiv of DMTr-Cl in pyridine gave 5 -ODMTr-dA in 77% yield (Fig. 3.10.2, method
A), and that the use of 2 equiv of DMTr-Cl for dC gave 5 -O-DMTr-dC and 5 -O,N-bisDMTrdC in 32% and 40% yields, respectively (Ti et al., 1982). Levin and colleagues also reported that dimethoxytritylation of dA, dC, and dG gave the corresponding 5 -O-DMTr derivatives in 61%, 48%, and 55% yields, respectively (Levin et al., 1991), although no details were described in the paper. In connection with 5 -O-selective dimethoxytritylation, Adamiak’s early paper concerning 5 -O-selective monomethoxytritylation of A, C, and G is quite positive (Okupniak et al., 1981). Reaction of dA, dC, or dG with 1.2 equiv of 4-monomethoxytrityl chloride (MMTr-Cl) in dimethylformamide (DMF) or dimethyl sulfoxide (DMSO) in the presence of 6-nitroquinoline (pKa = 2.7) or 3-bromopyridine (pKa = 2.9) gave
3.10.2 Supplement 18
Current Protocols in Nucleic Acid Chemistry
Figure 3.10.2 Synthesis of 5 -O-DMTr-N-unprotected deoxyribonucleosides using direct approaches (methods A to C) or transient dimethylaminomethylene (Dmf) base protection (method D). DMF, dimethylformamide.
5 -O-MMTr-dC, 5 -O-MMTr-dA, and 5 -OMMTr-dG in 85%, 92%, and 66% yields, respectively. The use of bases that are weaker than the dA and dC nucleobases is essential for high 5 -O-selectivity, because the nucleobases must be protonated to be converted to inert species under the reaction conditions used. Further application of this method to a series of deoxyribonucleosides should be studied in the future. Ishido reported that 5 -O-selective dimethoxytritylation of dC in the presence of dichloroacetic acid gave 5 -O-DMTr-dC in 71% yield (Ishido, 1989; Nishino et al., 1991; Fig. 3.10.2, method B). This procedure is applicable to the synthesis of 5 -O-DMTrdA but not 5 -O-DMTr-dG (A. Ohkubo, K. Seio, and M. Sekine, unpub. observ.). Hayakawa reported an improved method for the selective 5 -O-dimethoxytritylation of deoxyribonucleosides using DMTr-Cl/ triethylamine/imidazole in DMF, which gave 5 -O-DMTr-dC, 5 -O-DMTr-dA, and 5 -O-DMTr-dG in 76% to 85%, 82% to 89%,
and 74% to 78% yields, respectively (Kataoka and Hayakawa, 1999; Fig. 3.10.2, method C). A different method employed at an earlier stage by Jones involves transient Nprotection with the dimethylaminomethylene (Dmf) group (Froehler and Matteucci, 1983a) by reaction of deoxyribonucleosides with dimethylformamide dimethylacetal (Kung and Jones, 1992; Fig. 3.10.2, method D). Although this approach requires a three-step procedure to obtain the desired 5 -O-DMTrdeoxyribonucleosides, the transient protection and deprotection using the Dmf group proceed cleanly and quantitatively, so that purification is necessary for only the final product. This procedure has proved to be reliable and reproducible. In the case of dG, 5 -O,2-Nbis(DMTr)deoxyguanosine was used as the precursor of the 3 -phosphoromorpholidite derivative (Fourrey and Varenne, 1985). This ditritylated species can be obtained by reaction of dG with excess DMTr-Cl in pyridine (Schaller et al., 1963).
Synthesis of Unmodified Oligonucleotides
3.10.3 Current Protocols in Nucleic Acid Chemistry
Supplement 18
Figure 3.10.3 (left).
Synthesis of 5 -O,N-bis(DMTr)deoxyribonucleosides by successive tritylation (right) or direct tritylation
5 -O,N-Bis(dimethoxytrityl)deoxyribonucleosides for the 3 terminus
DNA Synthesis Without Base Protection
The general synthesis of oligodeoxyribonucleotides with appropriate sequences requires the synthesis of 3 -terminal deoxyribonucleoside building blocks that can be attached to resins via linkers. To introduce dA, dC, and dG into the 3 -terminal site, their 3 -succinate ester derivatives or other equivalents are required. Because succinic anhydride reacts with the nucleobases (Kume et al., 1984), the amino functions of these deoxyribonucleosides should be protected to avoid such side reactions. For this purpose, the best approach is to use 5 -O,N-bis(DMTr)deoxyribonucleoside derivatives (S.7g-S.7i; Fig. 3.10.3). Several approaches have been tested for the synthesis of these compounds. NDimethoxytritylation with DMTr-Cl in the presence of Me3 SiCl followed by successive 5 -O-dimethoxytritylation (right side of figure) gave N-DMTr-deoxyribonucleosides in high yields (Wada et al., 1998b). The direct preparation of these substances from deoxyribonucleosides (left) resulted in complex mixtures including the desired materials. To introduce these 5 -O,N-bis(DMTr) derivatives onto polymer supports, they were converted to 3 -succinate half-esters, which were linked to resins in situ by condensation using a phosphonium-type condensing reagent, 2-(benzotriazol-1-yloxy)1,1-dimethyl-2-(pyrrolidin-1-yl)-1,3,2diazaphospholidinium hexafluorophosphate
(BOMP; Wada et al., 1997). To mask unreacted amino groups on the resin, careful treatment with suitable acylating reagents is very important. When an N-DMTr-dG derivative was treated with acetic anhydride in pyridine in the presence of 4-(dimethylamino)pyridine, complete replacement of the DMTr group with an acetyl group took place (Fig. 3.10.4; Wada et al., 1998b). This inherent side reaction was overcome by using 1-acetylimidazole as the acylating reagent. This reagent did not react with the guanosine moiety but completely reacted with the unreacted amino groups on the resin. The N-DMTr group is generally more stable than the O-DMTr group. Complete deprotection for dA and dG required only 5 min when using 1% trifluoroacetic acid (TFA) in CH2 Cl2 . dC derivatives required a more prolonged time of 30 min for complete removal of the DMTr group using 3% TFA in CH2 Cl2 , but the glycosyl bond of these derivatives is sufficiently stable that this is not a problem. Several short oligodeoxyribonucleotides containing dA, dC, or dG at the 3 -terminal site were successfully synthesized using the Hphosphonate approach without base protection (Fig. 3.10.5; Wada et al., 1998b). Although the syntheses of relatively longer oligodeoxyribonucleotides (20- to 21-mers) having dG (Gryaznov and Letsinger, 1992; Hayakawa and Kataoka, 1998) and dC (Hayakawa and Kataoka, 1998) at the 3 -terminal position were reported, no details about how to solve the aforementioned problem were described.
3.10.4 Supplement 18
Current Protocols in Nucleic Acid Chemistry
Figure 3.10.4 The capping reaction prescribed for masking the unreacted amino groups on the resin also results in an undesired N-acetylation side reaction. This can be prevented by using 1-acetylimidazole (AcIm) instead of acetic anhydride (Ac2 O) and 4-(dimethylamino)pyridine (DMAP).
Figure 3.10.5 Synthesis of polymer-supported deoxyribonucleoside monomer building blocks. B and B2 are unprotected and N-DMTr-protected nucleobases, respectively.
Synthesis of Deoxyribonucleoside 3 -Phosphoramidite Building Blocks
The 3 -(O-methyl-N,N -tetraisopropylphosphoramidite) building blocks of Nunprotected deoxyribonucleosides (dC, dA, and dG) were synthesized in 85% to 90% yield by 3 -O-selective phosphitylation of the corresponding N-unprotected 5 -ODMTr-deoxyribonucleosides with methyl (N,N -tetraisopropyl)phosphorodiamidite in the presence of diisopropylammonium 1Htetrazolide (Fig. 3.10.6, method B; Gryaznov and Letsinger, 1991, 1992). The N-unprotected deoxyribonucleoside 3 -(O-cyanoethyl-N,N tetraisopropylphosphoramidite) building blocks were also synthesized by reaction of 5 -O-DMTr-deoxyribonucleosides with (i-Pr)2 NP(Cl)OCH2 CH2 CN in tetrahydrofuran in the presence of diisopropylethylamine (method A; Hayakawa and Kataoka, 1998). As far as the solubility of these synthetic units is
concerned, the guanosine 3 -(O-cyanoethyl)phosphoramidite is not completely soluble in acetonitrile, which is the most suitable solvent for DNA synthesizers because of its low viscosity. It is necessary to take this poor solubility into account when using an automated DNA synthesis approach, as it may cause clogging of the tubing.
Oligodeoxyribonucleotide Synthesis Using the Phosphoramidite Approach The first report of a solid-phase DNA synthesis without base protection was made by Ogilvie and Nemer (1981), who synthesized a short oligoribonucleotide, UGCA, in 80% yield using a polymer-bound non-N-acylated adenosine derivative and the phosphite triester approach. Later, Gryaznov and Letsinger (1991, 1992) reported a general method for the synthesis
Synthesis of Unmodified Oligonucleotides
3.10.5 Current Protocols in Nucleic Acid Chemistry
Supplement 18
Figure 3.10.6 Synthesis of N-unprotected deoxyribonucleoside 3 -O-phosphoramidite building blocks. DIPAT, diisopropylammonium 1H-tetrazolide; r.t., room temperature; THF, tetrahydrofuran.
Figure 3.10.7 Synthesis of oligodeoxyribonucleotides without base protection using the phosphoramidite approach, and postcondensation treatment for N-P bond cleavage of branched chains resulting from concomitant side reactions on dA and dC bases. BIT, benzimidazolium triflate; IMT, imidazolium triflate; Pyr-HCl, pyridinium hydrochloride.
DNA Synthesis Without Base Protection
of oligodeoxyribonucleotides using pyridinium hydrochloride as the activator and their original syringe method (Tanaka and Letsinger, 1982; Fig. 3.10.7). With this approach, they succeeded in synthesizing 20mers. Because they observed serious modifications of the dA and dC bases, the modified sites were reconverted to free amino groups after each condensation by treatment with aniline in the presence of pyridinium hydrochloride. When internucleotide bonds are formed using the phosphoramidite approach, it is noteworthy that the guanine moiety is not modified with activated phosphoramide species (Gryaznov and Letsinger, 1991, 1992). This is in sharp contrast to the fact that significant 6-O-phosphorylation of dG residues has been observed when the phosphotriester approach was employed (Sekine et al., 1982).
A newer phosphoramidite approach was reported using imidazolium triflate (IMT) as a new activator and using a somewhat swelled Tentagel as the resin (Hayakawa and Kataoka, 1998; Hayakawa et al., 2001). In this approach, a more powerful activator, benzimidazolium triflate (BIT; Hayakawa et al., 1996; Hayakawa, 2001), was used in methanol as a nucleophile to eliminate 5 O-DMTr-deoxyribonucleoside 3 -phosphityl residues from unavoidably modified base sites. By this method, 32-mer, 60-mer, and two 21-mer oligonucleotides were synthesized as the major products using a DNA synthesizer. The reproducibility of this approach has not been confirmed, however, as no applications of this method have appeared to date. As the solvent used for this synthesis was acetonitrile, it seems to be somewhat difficult to
3.10.6 Supplement 18
Current Protocols in Nucleic Acid Chemistry
Figure 3.10.8
Outline of the proton-block method using the activator 5-nitrobenzimidazolium triflate (NBT).
completely dissolve the guanosine building block. On the other hand, it has recently been reported that the BIT/MeOH treatment causes serious internucleotide bond fission (∼50%; Sekine et al., 2003) when highly cross-linked polystyrene (HCP; McCollum and Andrus, 1991) or controlled-pore glass (CPG; K¨oster et al., 1983) were employed as the resin in place of Tentagel. Another new strategy for oligodeoxyribonucleotide synthesis without base protection takes a completely different approach. It is called the “proton-block” method, because the simple proton is used for protection of base moieties (Fig. 3.10.8; Sekine et al., 2003). This strategy was developed based on the principle of acid-base reactions. It is well known that once amino functions are protonated they lose nucleophilicity because of the formation of inert ammonium salts. Adamiak’s successful 5 -O-monomethoxytritylation of ribonucleosides (Adamiak, 1981; see Synthesis of Common Starting Nucleosides) is the only precedent that utilizes this principle in nucleic acid chemistry. Based on this principle, a new activator, 5-nitrobenzimidazolium triflate (NBT), was synthesized. This new promoter has a pKa value of 2.76 and thus enables sufficient protonation of cytosine and adenine bases, which have pKBH+ values of 4.3 and 3.8, respectively (Hall, 1971). To date, such uses of a more acidic species as the promoter for the phosphoramidite approach have not been reported. It has been reported that 5-(4-nitrophenyl)-1H-tetrazole (Froehler and Matteucci, 1983b) is so acidic (pKa = 3.7) that it causes serious elimina-
tion of the DMTr group. When NBT was used in acetonitrile for the solid-phase synthesis of d[ApT], 3% of the product was obtained as d[ApApT]. This side reaction could be significantly suppressed, however, by using THF as the solvent. This solvent effect can be explained by the difference in basicity between acetonitrile and THF, which have pKBH+ values of −10 and −2, respectively (see Internet Resource). The 5 -DMTr ether linkage (DMTrO-CH2 -) was estimated to have a pKBH+ value that is between those of acetonitrile and THF, and probably nearer to THF, so that NBT cannot protonate the DMTr ether linkage in the presence of excess amounts of the more basic THF. It is important to choose the correct solvent in this strategy. The oligos d[CCCCCT] and d[AAAAAT] were synthesized without base protection and without postcondensation treatment with P-N bond-cleaving reagents. In the synthesis of d[CAGTCAGTCAGT], a mixed solvent of 9:1 (v/v) acetonitrile/Nmethylpyrrolidone (NMP) was used to avoid the competitive elimination of the DMTr group during the condensation. NMP has a pKBH+ value of −0.71, so that the excess promoter protonates this solvent predominantly over the 5 -etheral oxygen. Consequently, the 12-mer was obtained in 19% overall yield. The superiority of this strategy is evidenced by the fact that, when IMT was used as the promoter without the postcondensation treatment with BIT-MeOH, an extremely complicated HPLC profile was obtained (Sekine et al., 2003). Finally, a new strategy called the HOBT method has been developed (Fig. 3.10.9;
Synthesis of Unmodified Oligonucleotides
3.10.7 Current Protocols in Nucleic Acid Chemistry
Supplement 18
Figure 3.10.9 The HOBT method for oligodeoxyribonucleotide synthesis without base protection and without postcondensation treatment. HOBT, 1-hydroxybenzotriazole; NMP, N-methylpyrrolidone; r.t., room temperature.
DNA Synthesis Without Base Protection
Ohkubo et al., 2002). 1-Hydroxy-benzotriazole (HOBT) was previously used as the promoter in the phosphoramidite approach by van Boom (Claesen et al., 1984). However, because of the poor solubility of this reagent in acetonitrile, which is widely used for automated DNA synthesizers, syntheses using HOBT had not appeared until this HOBT strategy was reported. Based on the mechanism of the H-phosphonate approach without base protection, HOBT was the reagent of choice for the purpose. Because the intermediate of a previous H-phosphonate approach without base protection was thought to be a tervalent phosphorus species (Wada et al., 1997; UNIT 3.4), it was believed that this kind of tervalent phosphorus species would be essential for O-selective internucleotide bond formation, and suitable reagents that can convert phosphoramidite derivatives to tervalent phosphite triester intermediates were studied. Among the reagents tested, HOBT was found to be the best reagent for O-selective internucleotide bond formation. Because HOBT (pKa = 5.3) is more basic than 1H-tetrazole (pKa = 4.8), there is no risk of elimination of the DMTr group during condensation, unlike the proton-block method. The only drawback of this reagent is its inherent insolubility in acetonitrile, but this was overcome by using a mixed solvent of acetonitrile and NMP. Moreover, the insolubility of the dG phosphoramidite, another common problem in the Nunprotected strategy, was also overcome by the use of the mixed acetonitrile/NMP solvent, in which the dG building block is easily soluble. With the help of these improvements,
d[CAGTCAGTCAGT] was synthesized as the major product in high yield. The O-selectivity in the synthesis of dimers and trimers exceeded 99.8%, a most excellent result. This approach enabled the synthesis of up to 20-mer oligodeoxyribonucleotides. The coupling efficiency decreased to ∼98%, however, when the dG monomer was used. If this problem could be solved, the HOBT method would be more realistic and practical.
SOLID-PHASE SYNTHESIS USING THE H-PHOSPHONATE APPROACH Synthesis of Deoxyribonucleoside 3 -Phosphonate Building Blocks
Synthesis of 5 -O-DMTr-deoxyribo nucleoside 3 -H-phosphonates was reported by several research groups. Levin et al. (1991) reported synthesis using salicyl chlorophosphite (Marugg et al., 1986; Ven’yaminova et al., 1988) as the phosphitylating reagent (Fig. 3.10.10, method B). Phosphonylation of N-dimethylaminomethylene5 -O-DMTr-deoxyribonucleosides with tris(triazolyl)phosphine (method A) gave the 3 -phosphonylated products as 1,8diazabicyclo-[5,4,0]undec-7-ene (DBU) salts (Kung and Jones, 1992). In the case of dC, the N-unprotected product was obtained directly, as the amidine group was completely lost during silica gel column chromatography. In the case of dA and dG, however, concomitant elimination of the amidine group occurred, giving a mixture of N-protected and N-unprotected products.
3.10.8 Supplement 18
Current Protocols in Nucleic Acid Chemistry
Figure 3.10.10 Synthesis of N-unprotected deoxyribonucleoside 3 -O-phosphonate building blocks for oligonucleotide synthesis using the H-phosphonate approach.
Therefore, pretreatment of the crude products with ammonia before chromatography is necessary. Wada and Sekine reported the selective 3 -O-phosphonylation of 5 -ODMTr-deoxyribonucleosides with excess diphenyl phosphonate or with phosphonic acid in the presence of bis(2-oxo-3-oxazolidinyl)phosphinic chloride (methods C and D, respectively; Wada et al., 1997). The use of method C gave somewhat better yields of the 3 -O-phosphonylated products as DBU salts compared to method D (88% to 94% versus 78% to 87%, respectively).
Oligodeoxyribonucleotide Synthesis Using the H-Phosphonate Approach Levin et al. (1991) first reported the synthesis of oligodeoxyribonucleotides by the H-phosphonate method using N-unprotected 5 -O-DMTr-deoxyribonucleoside 3 -phosphonates. They synthesized d[TATTTGGCT], but no details concerning the reaction conditions were described. Kung and Jones (1992) reported the synthesis of DMTr-d[TCAGT] using the H-phosphonate approach with
pivaloyl chloride or adamantyl chloride as the coupling reagent (Fig. 3.10.11). In this synthesis, it was found that pivaloyl chloride reacted with base residues. Although the pivaloyl groups were removed by standard ammonia treatment, the necessity for such ammonia treatment eliminates one of the advantages to not using amino-protecting groups. In 1997, Wada and Sekine also reported the use of the H-phosphonate approach without base-protecting groups (Wada et al., 1997; Fig. 3.10.12). In their approach, a phosphoniumtype condensing reagent, BOMP, was developed and shown to be very effective for selective internucleotide bond formation. The synthesis of d[CAGTCAGTCAGT] was accomplished with an overall isolated yield of 19%. Of particular interest, a plausible explanation as to why the selective O-phosphorylation occurred was also reported. The detailed molecular orbital (MO) calculations of possible intermediates suggest that two sets of HOMO-LUMO (highest and lowest molecular orbital) interactions between an activated Hphosphonate species and the 5 -terminal HO function are involved. In the reaction of the
Synthesis of Unmodified Oligonucleotides
3.10.9 Current Protocols in Nucleic Acid Chemistry
Supplement 18
Figure 3.10.11 Use of pivaloyl chloride (trimethylacetyl chloride, R = t-Bu) for synthesis of oligodeoxyribonucleotides by the H-phosphonate approach without base protection.
Figure 3.10.12 Use of phosphonium-type condensing reagents for synthesis of oligodeoxyribonucleotides by the Hphosphonate approach without base protection. B is the unprotected nucleobase. BOMP, (2-benzotriazol-1-yloxy)-1,3dimethyl-2-pyrrolidin-1-yl-1,3,2-diazaphospholidinium hexafluorophosphate; BSA, N,O-bis(trimethylsilyl)acetamide; DMTrCl, 4,4 -dimethoxytrityl chloride.
DNA Synthesis Without Base Protection
activated species with amino functions of the nucleobases, the HOMO orbital on the hydrogen atom of the HO group is lacking, so that only a weaker interaction between the nitrogen atom and the phosphorus atom of the activated species is available. Later, it was reported that this strategy was accompanied by a serious side reaction that caused elimination of one nucleotide block during the condensation, resulting in the formation of significant amounts of (n-1)-mers (Wada et al., 1999).
ADVANTAGES AND PROSPECTS OF THE N-UNPROTECTED APPROACH Stability of N-Unprotected Deoxyribonucleoside Derivatives The stability of the glycosidic bond of Nunprotected deoxyribonucleoside derivatives is important. Several research groups have reported the kinetic data of N-protected and N-unprotected deoxyadenosine derivatives
3.10.10 Supplement 18
Current Protocols in Nucleic Acid Chemistry
(Butkus et al., 1983; Septak, 1996; Krotz et al., 2003). Froehler and Matteucci (1983a) reported that N-unprotected deoxyadenosine is more resistant to acids than is N-benzoyldeoxyadenosine. Specifically, Nbenzoyldeoxyadenosine has a T1/2 of 4 hr in 80% acetic acid at 25◦ C, whereas Nunprotected deoxyadenosine has a T1/2 of >5 days. The stability of the glycosidic bond of deoxyadenosine is similar to that of 6N-diisopropylformamidinedeoxyadenosine. It was also reported that unprotected deoxyguanosine is somewhat more unstable than deoxyadenosine under acidic conditions (Venner, 1964, 1966). This is in reverse order of the same series of N-acylated purine deoxyribonucleosides. In the current phosphoramidite approach using N-protected deoxyribonucleosides, it is important to balance the contradictory goals of obtaining maximum detritylation with minimum depurination at the final stage (Septak, 1996; Krotz et al., 2003).
Prospects of N-Unprotected Approach One promising advantage of the Nunprotected phosphoramidite approach is to make it possible to synthesize oligodeoxyribonucleotides directly on a resin or even on microchips or microarrays. The straightforward synthesis of DNA fragments on DNA microchips or microarrays will be realized in the near future. For this purpose, O-selectivity at the present level of internucleotide bond formation can be sufficiently utilized without difficulty. In gene diagnosis, success relies on the ability of a complementary sequence to bind to the patients’ target sequence on the DNA chip and not other sequences. In this respect, achievement of 99.8% to 99.9% O-selectivity (Ohkubo et al., 2002) in the chemical synthesis of DNA fragments means the high presence of the correct sequence relative to incorrect sequences. Because O-selectivity is nearly perfect in the HOBT method, the ratio of the correct sequence to each failure sequence is highly dependent on the efficiency of condensation at each cycle. As no capping treatment is carried out, the correct sequence is unavoidably contaminated with failure sequences lacking one nucleotide unit. If the coupling efficiency is 99%, then 1% failure sequences are obtained at each coupling. The ratio of the correct sequence to each shorter sequence is calculated to range from 89.5:1 to 99:1. Therefore, rather high base recognition can be expected. It is apparent that, with increasing
chain length of the DNA fragments, formation of N-branched DNA molecules increases exponentially. Therefore, the N-unprotected strategy has a certain limitation in this respect, although it seems that a 20-mer synthesis is at least achievable without significant difficulty. In addition to these advantages, there is a possibility that because the HOBT method can provide oligodeoxyribonucleotides with phosphotriester linkages directly on DNA microchips or microarrays, O-protected oligodeoxyribonucleotides can be used as neutral DNA probes that can bind to target DNA or RNA fragments of patients for gene diagnosis. This possibility should be tested in the near future. Several kinds of O-alkylated oligodeoxyribonucleotide derivatives maintain hybridization properties when bound to complementary oligodeoxyribonucleotides (Yamana et al., 1991; Iyer et al., 1995, 1996). For gene diagnosis using DNA microchips or microarrays, unlike gene therapy, there is no need to consider the reactivity of phosphotriester linkages as potential alkylating reagents toward target nucleic acids or other molecules such as proteins and lipids. In previous approaches to the synthesis of DNA oligomers containing base-labile functional groups, various N-protecting groups have been developed that are removable under neutral conditions (Dreef-Tromp et al., 1991; Iyer et al., 1995; Alvarez et al., 1999; Spinelli et al., 2002). The N-unblocked strategy described here would be useful as a more straightforward approach to base-labile modified DNA derivatives. For example, the Hphosphonate approach without base protection was successfully applied to the synthesis of oligodeoxyribonucleotides having base-labile N-acetyldeoxycytidine residues, which proved to form a Watson-Crick base pair with guanine more effectively than the unmodified base (Wada et al., 1998a). Several papers related to this application have also appeared (Wada et al., 2001a; Kobori et al., 2002b). Because the phosphoramidite approach uses tervalent phosphorous compounds as the monomer units, it is impossible to synthesize oligodeoxyribonucleotides having functions that react with them or the activated intermediates. For example, the azido group is a typical functional group that reacts with phosphoramidites or phosphites to undergo the Staudinger reaction. In such a case, the Hphosphonate approach without base protection is useful. An oligodeoxyribonucleotide derivative having 2-azidodeoxyadenosine was successfully synthesized by the BOMP strategy
Synthesis of Unmodified Oligonucleotides
3.10.11 Current Protocols in Nucleic Acid Chemistry
Supplement 18
(Wada et al., 2001b). On the other hand, the H-phosphonate method was used not only for isolation of base-labile H-phosphonate DNA oligomers (Wada et al., 1999) but also for the synthesis of hydroxymethylphosphonate DNA oligomers (Wada and Sekine, 1995). In the near future, the aforementioned N-unprotected strategies could be used for the synthesis of other targets, such as oligodeoxyribonucleotides having ester or aldehyde groups, that cannot be obtained directly by the use of modified deoxyribonucleoside 3 -phosphoramidites or 3 -phosphonates. For this purpose, suitable phosphate-protecting groups as well as linkers that are removable under neutral conditions should be developed. Some strategies described in recent papers (Kobori et al., 2002a; Ushioda et al., 2002) would be useful for further studies in this direction.
Literature Cited Adamiak, R.W. and Stawinski, J. 1977. A highly effective route to N,N -disubstituted ureas under mild conditions. An application to the synthesis of tRNA anticodon loop fragments containing ureidonucleosides. Tetrahedron Lett. 18:19351936. Adamiak, R.W., Biala, E., Grzeskowiak, K., Kierzek, R., Kraszewski, A., Markiewicz, W.T., Okupniak, J., Stawinski, J., and Wiewiorowski, M. 1978. The chemical synthesis of the anticodon loop of an eukaryotic initiator tRNA containing the hypermodified nucleoside N6 -/Nthreonylcarbonyl/-adenosine/t6 A/. Nucl. Acids Res. 5:1889-1905. Alvarez, K., Vasseur, J.-J., and Imbach, J.-L. 1999. Use of photolabile amino-protecting groups in the synthesis of base-sensitive DNA SATE-phosphotriesters. Nucleosides Nucleotides 18:1435-1436. Baddiley, J. and Todd, A.R. 1947. Nucleotides. I. Muscle adenylic acid and adenosine diphosphate. J. Chem. Soc. 648-651. Beaucage, S.L. and Iyer, R.P. 1992. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:2223-2311. Boal, J.H., Wilk, A., Harindranath, N., Max, E.E., Kempe, T., and Beaucage, S.L. 1996. Cleavage of oligodeoxyribonucleotides from controlledpore glass supports and their rapid deprotection by gaseous amines. Nucl. Acids Res. 24:31153117. Butkus, V., Kayushin, A.L., Berlin, Y.A., Kolosov, M.N., and Smirnov, I.V. 1983. Cleavage of 5 -Oprotecting trityl groups in oligodeoxynucleotide synthesis. Effect of substrate structure and reaction conditions on detritylation and depurination rates. Bioorg. Khim. 9:1518-1530. DNA Synthesis Without Base Protection
Caruthers, M.H. 1991. Chemical synthesis of DNA and DNA analogues. Acc. Chem. Res. 24:278284.
Claesen, C., Tesser, G.I., Dreef, C.E., Marugg, J.E., van der Marel, G.A., and van Boom, J.H. 1984. Use of 2-methylsulfonylethyl as a phosphorus protecting group in oligonucleotide synthesis via a phosphite triester approach. Tetrahedron Lett. 25:1307-1310. Dreef-Tromp, C.M., Van Dam, E.M.A., van den Elst, H., van den Boogaart, J.E., van der Marel, G.A., and van Boom, J.H. 1991. Solid-phase synthesis of RNA via a silyl-protecting-group strategy. Recl. Trav. Chim. Pays Bas 110:378383. Finnan, J.L., Varshney, A., and Letsinger, R.L. 1980. Developments in the phosphite-triester method of synthesis of oligonucleotides. Nucl. Acids Res. Symp. Ser. 7:133-145. Fourrey, J.-L. and Varenne, J. 1985. Preparation and phosphorylation reactivity of N-nonacylated nucleoside phosphoramidites. Tetrahedron Lett. 26:2663-2666. Froehler, B.C. and Matteucci, M.D. 1983a. Dialkylformamidines: Depurination resistant N6 protecting group for deoxyadenosine. Nucl. Acids Res. 11:8031-8036. Froehler, B.C. and Matteucci, M.D. 1983b. Substituted 5-phenyltetrazoles: Improved activators of deoxynucleoside phosphoramidites in deoxyoligonucleotide synthesis. Tetrahedron Lett. 24:3171-3174. Gryaznov, S.M. and Letsinger, R.L. 1991. Synthesis of oligonucleotides via monomers with unprotected bases. J. Am. Chem. Soc. 113:5876-5877. Gryaznov, S.M. and Letsinger, R.L. 1992. Selective O-phosphitylation with nucleoside phosphoramidite reagents. Nucl. Acids Res. 20:18791882. Hall, R.H. 1971. The Modified Nucleosides in Nucleic Acids. Columbia University Press, New York. Hata, T. and Kurihara, T. 1973. Preparation of intermediates in the synthesis of polynucleotides. II. N4 -Benzoylation of deoxycytidylic and cytidylic acids by 2-chloromethyl-4-nitrophenyl benzoate. Chem. Lett. 8:859-862. Hayakawa, Y. 2001. Toward an ideal synthesis of oligonucleotides: Development of a novel phosphoramidite method with high capability. Bull. Chem. Soc. Jpn. 74:1547-1565. Hayakawa, Y. and Kataoka, M. 1998. Facile synthesis of oligodeoxyribonucleotides via the phosphoramidite method without nucleoside base protection. J. Am. Chem. Soc. 120:1239512401. Hayakawa, Y., Aso, Y., Uchiyama, M., and Noyori, R. 1983a. Facile nucleoside phosphorylation via hydroxyl activation. Tetrahedron Lett. 24:11651168. Hayakawa, Y., Aso, Y., Uchiyama, M., and Noyori, R. 1983b. Chemoselective phosphorylation of N-unprotected nucleosides via aluminum alkoxides. Tetrahedron Lett. 24:5641-5644. Hayakawa, Y., Uchiyama, M., and Noyori, R. 1984. A convenient method for the formation of
3.10.12 Supplement 18
Current Protocols in Nucleic Acid Chemistry
internucleotide 25:4003-4006.
linkage.
Tetrahedron
Lett.
Hayakawa, Y., Uchiyama, M., Nobori, T., and Noyori, R. 1985. A convenient synthesis of 2 -5 linked oligoribonucleotides. Tetrahedron Lett. 26:761-764. Hayakawa, Y., Nobori, T., Noyori, R., and Imai, J. 1987. Synthesis of 2 -5 ,3 -5 linked triadenylates. Tetrahedron Lett. 28:2623-2626. Hayakawa, Y., Kataoka, M., and Noyori, R. 1996. Benzimidazolium triflate as an efficient promoter for nucleotide synthesis via the phosphoramidite method. J. Org. Chem. 61:7996-7997. Hayakawa, Y., Kawai, R., and Kataoka, M. 2001. Nucleotide synthesis via methods without nucleoside-base protection. Eur. J. Pharm. Sci. 13:5-16. Ikemoto, T., Haze, A., Hatano, H., Kitamoto, Y., Ishida, M., and Nara, K. 1995. Phosphorylation of nucleosides with phosphorus oxychloride in trialkyl phosphate. Chem. Pharm. Bull. 43:210215.
Ishido, R. 1989. Protection of 5 -hydroxy groups of cytidine derivatives. Jpn. Kokai Tokkyo Koho Jp Pat. 01308294; Chem. Abstr. 1990. 112:700. Iyer, R.P., Yu, D., Ho, N.-H., Devlin, T., and Agrawal, S. 1995. O- and S-Methyl phosphotriester oligonucleotides: Facile synthesis using N-pent-4-enoyl nucleoside phosphoramidites. J. Org. Chem. 60:8132-8133. Iyer, R.P., Yu, D., Devlin, T., Ho, N.-H., Johnson, S., and Agrawal, S. 1996. Synthesis, biophysical properties, and stability studies of mixed backbone oligonucleotides containing novel non-ionic linkages. Nucleosides Nucleotides 16:1491-1495. Kataoka, M. and Hayakawa, Y. 1999. A convenient method for the synthesis of N-free 5 -O(p,p -dimethoxytrityl)-2 -deoxyribonucleosides via 5 -O-selective tritylation of the parent substances. J. Org. Chem. 64:6087-6089. Kobori, A., Miyata, K., Ushioda, M., Seio, K., and Sekine, M. 2002a. A new silyl ether-type linker useful for the automated synthesis of oligonucleotides having base-labile protective groups. Chem. Lett. 31:16-17. Kobori, A., Miyata, K., Ushioda, M., Seio, K., and Sekine, M. 2002b. A new method for the synthesis of oligodeoxyribonucleotides containing 4N-alkoxycarbonyldeoxycytidine derivatives and their hybridization properties. J. Org. Chem. 67:476-485. Koole, L.H., Buck, H.M., Kanters, J.A., and Schouten, A. 1987. Molecular conformation of 2 -deoxy-3 ,5 -di-O-acetyladenosine. Crystal structure and high resolution proton nuclear magnetic resonance investigations. Can. J. Chem. 65:326-331. K¨oster, H., Stumpe, A., and Wolter, A. 1983. Polymer support oligonucleotide synthesis. 13. Rapid and efficient synthesis of oligodeoxynucleotides on porous glass support using triester approach. Tetrahedron Lett. 24:747-750.
Krotz, A.H., McElroy, B., Scozzari, A.N. Cole, D.L., and Ravikumar, V.T. 2003. Controlled detritylation of antisense oligonucleotides. Org. Process Res. Dev. 7:47-52. Kume, A., Iwase, R., Sekine, M., and Hata, T. 1984. Cyclic diacyl groups for protection of the N6 -amino group of deoxyadenosine in oligodeoxynucleotide synthesis. Nucl. Acids Res. 12:8525-8538. Kung, P.-P. and Jones, R.A. 1992. H-Phosphonate DNA synthesis without amino protection. Tetrahedron Lett. 33:5869-5872. Letsinger, R.L., Finnan, J.L., Jacobs, S.A., Juodka, B.A., and Varshney, A.K. 1976. Exploration of new procedures for the synthesis of polynucleotides. In Proceedings of the International Conference on Synthesis, Structure and Chemistry of Transfer Ribonucleic Acids and Their Components, Dymaczewo, Poland, September 13-17, 1976. Institute of Organic Chemistry, Polish Academy of Sciences. Levin, A.S., Tabatadze, E.R., and Komarova, N.I. 1991. Synthesis of oligodeoxyribonucleotides by H-phosphonate method using N-unblocked synthons. Sibirskii Khim. Z. 6:142-144 Marugg, J.E., Tromp, M., Kuyl-Yeheskiely, E., van der Marel, G.A., and van Boom, J.H. 1986. A convenient and general approach to the synthesis of properly protected d-nucleoside 3 hydrogen phosphonates via phosphite intermediates. Tetrahedron Lett. 27:2661-2664. McCollum, C. and Andrus, A. 1991. An optimized polystyrene support for rapid, efficient oligonucleotide synthesis. Tetrahedron Lett. 32:40694072. Michelson, M. and Todd, A.D. 1954. Nucleotides. Part XXIII. Mononucleotides derived from deoxycytidine. Note on the structure of cytidylic acids a and b. J. Chem. Soc. 34-40. Nikolenko, L.N., Nezavibat’ko, V.N., and Tolmacheva, N.S. 1967. Selective N-benzoylation of deoxycytidine and cytidine. Khim. Prir. Soedin. 3:359. Nishino, S., Nagato, Y., Hasegawa, Y., Yamamoto, H., Kamaike, K., and Ishido, Y. 1991. Partial protection of carbohydrate derivatives. Part 27. Efficient deanilidation of phosphoranilidates by the use of nitrites and acetic anhydride. Heteroatom. Chem. 2:187-196. Ogilvie, K.K. 1973. The tert-butyldimethylsilyl group as a protecting group in deoxynucleosides. Can. J. Chem. 51:3799-3807. Ogilvie, K.K. and Nemer, M. 1981. Nonaqueous oxidation of phosphites to phophates in nucleotide synthesis. Tetrahedron Lett. 22:2531-2532. Ohkubo, A., Ezawa, Y., Seio, K., and Sekine, M. 2002. A new strategy for the synthesis of oligodeoxynucleotides in the phosphoramidite method without base protection via phosphite intermediates. Nucl. Acids Res. Suppl. 2:2930. Okupniak, J., Adamiak R.W., and Wiewiorowski, M. 1981. New conditions for a selective
Synthesis of Unmodified Oligonucleotides
3.10.13 Current Protocols in Nucleic Acid Chemistry
Supplement 18
introduction of trityl type protective group into adenosine and cytidine 3 -phosphates. Pol. J. Chem. 55:679-682.
Venner, H. 1964. Studies on nucleic acids. IX. Stability of the N-glycosidic linkage in nucleosides. Z. Physiol. Chem. 339:14-27.
Pearson, R.G. 1987. Recent advances in the concept of hard and soft acids and bases. J. Chem. Educ. 64:561-567.
Venner, H. 1966. Research on nucleic acids. XII. Stability of the N-glycoside bond of nucleotides. Z. Physiol. Chem. 344:189-196.
Pearson, R.G. 1990. Hard and soft acids and bases— the evolution of a chemical concept. Coord. Chem. Rev. 100:403-425.
Ven’yaminova, A.G., Komarova, N.I., Levin, A.S., and Repkova, M.N. 1988. Synthesis of ribonucleoside-3 - and -5 -H-phosphonates via salicylchlorophosphine. Bioorg. Khim. 14:484489.
Schaller, H., Weimann, G., Lerch, B., and Khorana, H.G. 1963. Studies on polynucleotides. XXIV. The stepwise synthesis of specific deoxyribopolynucleotides. Protected derivatives of deoxyribonucleosides and new syntheses of deoxyribonucleoside 3 -phosphates. J. Am. Chem. Soc. 85:3821-3827. Schulhof, J.C., Molko, D., and Teoule, R. 1987. Facile removal of new base protecting groups useful in oligonucleotide synthesis. Tetrahedron Lett. 28:51-54. Sekine, M., Matsuzaki, J., Satoh, M., and Hata, T. 1982. Improved 3 -O-phosphorylation of guanosine derivatives by O6 -oxygen protection. J. Org. Chem. 47:571-573. Sekine, M., Masuda, N., and Hata, T. 1985. Introduction of the 4,4 ,4 -tris(benzoyloxy)trityl group into the exo amino groups of deoxyribonucleosides and its properties. Tetrahedron 41:5445-5453. Sekine, M., Ohkubo, A., and Seio, K. 2003. Protonblock strategy for the synthesis of oligodeoxynucleotides without base protection, capping reaction, and P-N bond cleavage reaction. J. Org. Chem. 68:5478-5492. Septak, M. 1996. Kinetic studies on depurination and detritylation of CPG-bound intermediates during oligonucleotide synthesis. Nucl. Acids Res. 24:3053-3058. Shena, M. 1999. DNA Microarrays: A practical approach. Oxford University Press, London. Spinelli, N., Meyer, A., Hayakawa, Y., Imbach, J.L., and Vasseur, J.-J. 2002. Use of allylic protecting groups for the synthesis of base-sensitive prooligonucleotides. Eur. J. Org. Chem. 4956. Tanaka, T. and Letsinger, R.L. 1982. Syringe method for stepwise chemical synthesis of oligonucleotides. Nucl. Acids Res. 10:32493260. Ti, G.S., Gaffney, B.L., and Jones, R.A. 1982. Transient protection: Efficient one-flask syntheses of protected deoxynucleosides. J. Am. Chem. Soc. 104:1316-1319.
DNA Synthesis Without Base Protection
Ushioda, M., Kadokura, M., Moriguchi, T., Kobori, A., Aoyagi, M., Seio, K., and Sekine, M. 2002. Unique participation of unprotected internucleotidic phosphodiester residues on unexpected cleavage reaction of the Si-O bond of the diisopropylsilandiyl group used as a linker for the solid-phase synthesis of 5 -terminal guanylated oligodeoxynucleotides. Helv. Chim. Acta 85:2930-2945.
Wada, T. and Sekine, M. 1995. Chemical synthesis of oligothymidylate having hydroxymethylphosphonate internucleotidic linkages. Tetrahedron Lett. 36:845-848. Wada, T., Sato, Y., Honda, F., Kawahara, S., and Sekine, M. 1997. Chemical synthesis of oligodeoxyribonucleotides using N-unprotected H-phosphonate monomers and carbonium and phosphonium condensing reagents: O-Selective phosphonylation and condensation. J. Am. Chem. Soc. 119:12710-12721. Wada, T., Kobori, A., Kawahara, S., and Sekine, M. 1998a. Synthesis and properties of oligodeoxyribonucleotides containing 4-N-acetylcytosine bases. Tetrahedron Lett. 39:6907-6910. Wada, T., Mochizuki, A., Sato, Y., and Sekine, M. 1998b. Functionalization of solid supports with N-unprotected deoxyribonucleosides. Tetrahedron Lett. 39:5593-5596. Wada, T., Honda, F., Sato, Y., and Sekine, M. 1999. First synthesis of H-phosphonate oligonucleotides bearing N-unmodified bases. Tetrahedron Lett. 40:915-918. Wada, T., Kobori, A., Kawahara, S., and Sekine, M. 2001a. Synthesis and hybridization ability of oligodeoxyribonucleotides incorporating N-acyldeoxycytidine derivatives. Eur. J. Org. Chem. 4583-4593. Wada, T., Mochizuki, A., Higashiya, S., Tsuruoka, H., Kawahara, S., Ishikawa, M., and Sekine, M. 2001b. Synthesis and properties of 2-azidodeoxyadenosine and its incorporation into oligodeoxynucleotides. Tetrahedron Lett. 42:9215-9219. Watanabe, K.A. and Fox, J.J. 1966. Simple method for selective acylation of cytidine on the 4-amino group. Angew. Chem. Int. Ed. Engl. 5:579-580. Yamana, K., Nishijima, Y., Negishi, K., Yoshiki, T., Nishio, K., and Nakano, H. 1991. Deoxyribonucleoside 3 -phosphorobisamidites in the synthesis of isopropyl phosphotriester oligodeoxyribonucleotide analogs. Tetrahedron Lett. 32:4721-4724. Yoshikawa, M. and Kato, T. 1967. Studies of phosphorylation. I. Phosphorylation of 2 ,3 -Oisopropylidene nucleoside by phosphoryl chloride. Bull. Chem. Soc. Jpn. 40:2849-2853. Yuodka, Y., Lunsford, W.B., and Letsinger, R.L. 1976. Oligonucleotides and nucleotidepeptides. XXV. New method for the synthesis of oligonucleotides. Bioorg. Chem. 2:12181324.
3.10.14 Supplement 18
Current Protocols in Nucleic Acid Chemistry
Internet Resource http://www.chfi.unipd.it/-chor/wisor/ lecture notes/Bagno acidbase.pdf A list of the basicity of common solvents, maintained by A. Bagno, Centro CNR, Padova, Italy.
Contributed by Mitsuo Sekine Tokyo Institute of Technology Yokohama, Japan
Synthesis of Unmodified Oligonucleotides
3.10.15 Current Protocols in Nucleic Acid Chemistry
Supplement 18
The 4-Methylthio-1-Butyl Group for Phosphate/Thiophosphate Protection in Oligodeoxyribonucleotide Synthesis
UNIT 3.11
This unit provides a detailed preparation of deoxyribonucleoside phosphoramidites functionalized with a 4-methylthio-1-butyl group for P(III) protection, and describes their use in the solid-phase synthesis of DNA oligonucleotides. Specifically, the efficiency of these phosphoramidites in the synthesis of a 20-mer DNA oligonucleotide and its phosphorothioated analog is demonstrated. The thermolytic cleavage of the 4-methylthio-1-butyl protecting group from these oligonucleotides, at neutral pH or under the standard basic conditions used for nucleobase deprotection, proceeds through a cyclodeesterification mechanism with the concomitant formation of a cyclic sulfonium salt (Cie´slak et al., 2004). The 4-methylthio-1-butyl protecting group is distinct from previously studied thermolytic groups (UNITS 2.7 & 3.9; Grajkowski et al., 2001) in terms of structural simplicity and ease of deprotection. Thus, this unit describes an attractive method for preparation of alkylation-free oligonucleotides for potential therapeutic applications, while bringing closer to reality the implementation of a “heat-driven” process for oligonucleotide synthesis on microarrays.
PREPARATION OF 4-METHYLTHIO-1-BUTYL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE IN SOLID-PHASE DNA SYNTHESIS
BASIC PROTOCOL
The 4-methylthio-1-butyl group for phosphate/thiophosphate protection can be thermolytically cleaved from oligonucleotides at a lower temperature and at a faster rate than the 4-oxopentyl (UNIT 3.9; Wilk et al., 2001), 3-(N-tert-butylcarboxamido)-1-propyl (UNIT 3.9; Wilk et al., 2002), and 2-(N-formyl,N-methyl)aminoethyl (Grajkowski et al., 2001) groups under neutral conditions. Moreover, the 4-methylthio-1-butyl group can also be removed from oligonucleotides under conditions (NH4 OH, 10 hr at 55◦ C) that are not suitable for removal of 3-(N-tert-butylcarboxamido)-1-propyl and 2-(N-formyl,Nmethyl)aminoethyl groups. As illustrated in Figure 3.11.1, this protocol outlines a general method for the preparation of deoxyribonucleoside phosphoramidites (S.3a-d) from commercial 5 -O- and N-protected deoxyribonucleosides (S.1a-d), O-(4-methylthio-1butyl)-N,N,N ,N -tetraisopropylphosphorodiamidite (S.2; see Support Protocol), and 1Htetrazole. Procedures for the use of S.3a-d in solid-phase DNA synthesis and for the analysis of synthetic oligonucleotides are also described.
Materials Protected deoxyribonucleosides (S.1a-d; Chem-Impex International): 5 -O-(4,4 -dimethoxytrityl)-2 -deoxythymidine N4 -benzoyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxycytidine N6 -benzoyl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxyadenosine N2 -isobutyryl-5 -O-(4,4 -dimethoxytrityl)-2 -deoxyguanosine Argon source Anhydrous dichloromethane (CH2 Cl2 ; Aldrich) O-(4-Methylthio-1-butyl)-N,N,N ,N -tetraisopropylphosphorodiamidite (S.2; see Support Protocol) 1H-Tetrazole, sublimed Triethylamine (TEA; Aldrich) Benzene (Aldrich)
Contributed by Jacek Cie´slak, Andrzej Grajkowski, Victor Livengood, and Serge L. Beaucage Current Protocols in Nucleic Acid Chemistry (2004) 3.11.1-3.11.14 C 2004 by John Wiley & Sons, Inc. Copyright
Synthesis of Unmodified Oligonucleotides
3.11.1 Supplement 19
Figure 3.11.1 Preparation of deoxyribonucleoside phosphoramidites S.3a-d. DMTr, 4,4 dimethoxytrityl; i-Pr, isopropyl. Adapted and reprinted from Cie´slak et al. (2004) with permission from the American Chemical Society.
4-Methylthio-1Butyl Group for Phosphate/ Thiophosphate Protection
Silica gel (60 Å, 230 to 400 mesh; Merck) Hexane (−20◦ C) Dry ice/acetone bath Reagents recommended for automated solid-phase oligonucleotide synthesis (Applied Biosystems and/or Glen Research): Standard 2-cyanoethyl deoxyribonucleoside phosphoramidites (T, CBz , ABz and Gi-Bu ) Activator solution: 1H-tetrazole in acetonitrile Oxidation solution: 0.02 M iodine in THF/pyridine/water Cap A solution: acetic anhydride in THF/pyridine Cap B solution: 1-methylimidazole in THF Deblocking solution: trichloroacetic acid in dichloromethane Acetonitrile 3H-1,2-Benzodithiol-3-one-1,1-dioxide (Glen Research) Concentrated ammonium hydroxide (NH4 OH; Fisher Scientific) 2 M triethylammonium acetate (TEAA) buffer, pH 7.0 (Applied Biosystems) 80% acetic acid (AcOH) Loading buffer: 1:4 (v/v) 10× TBE electrophoresis buffer (APPENDIX 2A) in formamide containing 2 mg/mL bromphenol blue 20 × 40–cm, 7 M urea/20% polyacrylamide gel (UNIT 10.4 and APPENDIX 3B) Staining buffer: 1:5:20:0.1 (v/v/v/v) formamide/isopropyl alcohol/ddH2 O/3.0 M Tris·Cl, pH 8.8 1 mg/mL Stains-All (Aldrich) in formamide 1.0 M Tris·Cl, pH 9.0 (APPENDIX 2A) 1.0 M MgCl2 (Sigma) Snake venom phosphodiesterase (SVPD, Crotalus adamanteus; Sigma) Bacterial alkaline phosphatase (BAP, E. coli; Sigma) 50-, 100-, and 250-mL round-bottom flasks Rubber septa for 14/20- and 24/40-glass joints Vacuum desiccator High-vacuum oil pump 1- and 10-mL glass syringes 5-mm NMR tube Rotary evaporator connected to a vacuum pump 2.5 × 20–cm disposable Flex chromatography columns (Kontes) 2.5 × 7.5–cm EMD TLC plates precoated with a 250-µm layer of silica gel 60 F254 Lyophilizer 392 DNA/RNA synthesizer (Applied Biosystems) 1-mL Luer-tipped syringes
3.11.2 Supplement 19
Current Protocols in Nucleic Acid Chemistry
4-mL screw-cap glass vials Heating block (VWR) 25 cm × 4.6–mm Supelcosil LC-18S HPLC column (5-µm; Supelco) 1.5-mL microcentrifuge tubes 37◦ C water bath Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D), column chromatography (APPENDIX 3E), automated DNA synthesis (APPENDIX 3C), DNA quantification by UV spectrophotometry (UNIT 10.3), reversed-phase HPLC (UNIT 10.5), and polyacrylamide gel electrophoresis (PAGE; UNIT 10.4 & APPENDIX 3B) Prepare deoxyribonucleoside phosphoramidites 1. Dry 2.2 mmol of a suitably protected deoxyribonucleoside (S.1a-d) by exposure to high vacuum for 2 hr at 25◦ C in a 50-mL round-bottom flask. Add a stir bar and seal flask with a rubber septum. 2. Under an argon atmosphere, add 10 mL anhydrous dichloromethane using a 10-mL glass syringe and ∼700 mg (∼2 mmol) O-(4-methylthio-1-butyl)-N,N,N ,N tetraisopropylphosphorodiamidite (S.2) via a 1-mL glass syringe. Stir the solution with a magnetic stirrer. 3. While stirring the solution under a positive pressure of argon, remove the rubber septum from the flask and quickly add 112 mg (1.6 mmol) sublimed 1H-tetrazole using a spatula. Seal the flask with the rubber septum. Other activators such as ethylthio-1H-tetrazole and dicyanoimidazole could theoretically be used, but have not been tested.
4. Carefully transfer ∼0.5 mL of the reaction mixture by syringe to a dry 5-mm NMR tube. Monitor the progress of the reaction in the NMR tube by 31 P NMR spectroscopy. Upon completion of the reaction, as seen by the disappearance of S.2, return the NMR sample to the main reaction mixture before proceeding with the next step. The 31 P NMR signal corresponding to S.2 (δ P 121 ppm) disappears within 2 hr at ambient temperature and thus indicates complete phosphinylation of S.1a-d.
5. Add 1 mL triethylamine and immediately concentrate the reaction mixture to a syrup using a rotary evaporator connected to a vacuum pump. 6. Suspend the crude product in ∼3 mL of 9:1 (v/v) benzene/triethylamine and apply the suspension to a 2.5 × 20–cm disposable Flex chromatography column containing ∼20 g silica gel that has been equilibrated in 9:1 (v/v) benzene/triethylamine (APPENDIX 3E). 7. For A, C, and T derivatives, elute the column with 9:1 (v/v) benzene/triethylamine and collect 6-mL fractions. For the G derivative, elute with 45:45:10 (v/v/v) benzene/dichloromethane/triethylamine. 8. Analyze fractions by TLC (APPENDIX 3D) on a 2.5 × 7.5–cm EMD silica gel 60 F254 TLC plate using 9:1 (v/v) benzene/triethylamine as the eluent. Pool appropriate fractions and rotoevaporate under reduced pressure (∼20 mmHg) until a white amorphous solid is obtained. TLC analysis of diastereomeric S.3a-d shows two tight spots. The Rf of each pair of spots ranges between 0.1 and 0.6 when 9:1 (v/v) benzene/triethylamine is used as the eluent. For the G derivative using 45:45:10 benzene/dichloromethane/triethylamine, the Rf is ∼0.3.
9. Dissolve the solid in ∼3 mL benzene and add the solution to ∼100 mL vigorously stirred cold (−20◦ C) hexane in a 250-mL round-bottom flask.
Synthesis of Unmodified Oligonucleotides
3.11.3 Current Protocols in Nucleic Acid Chemistry
Supplement 19
10. Allow the suspension to settle and carefully decant off most of the supernatant. 11. Rotoevaporate the wet material to dryness under reduced pressure and then dissolve in ∼10 mL benzene. 12. Transfer the solution to a 100-mL round-bottom flask, freeze in a dry ice/acetone bath, and lyophilize under high vacuum to afford triethylamine-free S.3a-d as white powders in yields ranging from 72% to 85%. 5 -O-(4,4 -Dimethoxytrityl)-3 -O-[(N,N-diisopropylamino)(4-methylthio-1-butyloxy)] phosphinyl-2 -deoxythymidine S.3a: 31 P NMR (121 MHz, CDCl3 ): δ 147.6, 147.9 Fast-atom bombardment high-resolution mass spectrometry (FAB-HRMS): anal. calcd. for C42 H56 N3 O8 PS (M+Cs)+ 926.2580, found 926.2537. N4 -Benzoyl-5 -O-(4,4 -dimethoxytrityl)-3 -O-[(N,N-diisopropylamino)(4-methylthio-1butyloxy)]phosphinyl-2 -deoxycytidine S.3b: 31 P NMR (121 MHz, CDCl3 ): δ 147.5, 147.9. FAB-HRMS: anal. calcd. for C48 H59 N4 O8 PS (M+Cs)+ 1015.2846, found 1015.2870. N6 -Benzoyl-5 -O-(4,4 -dimethoxytrityl)-3 -O-[(N,N-diisopropylamino)(4-methylthio1-butyloxy)]phosphinyl-2 -deoxyadenosine S.3c: 31 P NMR (121 MHz, CDCl3 ): δ 147.3, 147.7. FAB-HRMS: anal. calcd. for C49 H59 N6 O7 PS (M+Cs)+ 1039.2958, found 1039.2996. N2 -Isobutyryl-5 -O-(4,4 -dimethoxytrityl)-3 -O-[(N,N-diisopropylamino)(4-methylthio1-butyloxy)]phosphinyl-2 -deoxyguanosine S.3d: 31 P-NMR (121 MHz, CDCl3 ): δ 147.4, 147.8. FAB-HRMS: anal. calcd. for C46 H61 N6 O8 PS (M+Cs)+ 1021.3064, found 1021.3011. It is common practice to mix cesium iodide, potassium iodide, and/or sodium iodide with a sample to be analyzed by FAB-HRMS. The accuracy in mass determination can be better ascertained through the association of cesium (M+Cs)+ , potassium (M+K)+ , or sodium (M+Na)+ with the parent ion. The accurate mass is not always easy to determine as a (M+H)+ ion when the sample is dissolved in the traditional glycerol matrix in the absence of metallic salts.
Synthesize oligonucleotides 13. Perform a 0.2-µmol scale solid-phase synthesis of both d(ATCCGTAGCTAAGGTCATGC) and its phosphorothioate analog using an Applied Biosystems 392 DNA/RNA synthesizer in “trityl-on” mode according to the manufacturer’s recommendations (also see APPENDIX 3C). Perform parallel syntheses employing exclusively commercial 2-cyanoethyl deoxyribonucleoside phosphoramidites to serve as reference standards for comparing the overall quality of the synthetic oligonucleotides. As in the case of 2-cyanoethyl deoxyribonucleoside phosphoramidites, S.3a-d are used as 0.1 M solutions in dry acetonitrile. All ancillary reagents required for the automated preparation of oligonucleotides were purchased from Applied Biosystems and/or Glen Research and used as recommended by the manufacturer(s). The synthetic cycle recommended for the preparation of phosphorothioated DNA oligonucleotides differs from the conventional cycle used for the synthesis of unmodified oligonucleotides in that the “capping step” is performed after the oxidative sulfurization reaction (Iyer et al., 1990). The sulfur transfer reaction is effected by treatment with 0.05 M 3H1,2-benzodithiol-3-one-1,1-dioxide in acetonitrile using a wait step of 30 sec.
4-Methylthio-1Butyl Group for Phosphate/ Thiophosphate Protection
Cleave oligonucleotide from support 14. Using two 1-mL Luer-tipped syringes, one attached to each end of the synthesis column, push back and forth 0.5 mL of concentrated NH4 OH three times through the column every 10 min over a 30-min period. Transfer the solution to a 4-mL screwcap glass vial. Push back and forth 0.5 mL of fresh NH4 OH for 1 min through the synthesis column and pour the wash into the glass vial.
3.11.4 Supplement 19
Current Protocols in Nucleic Acid Chemistry
Complete oligonucleotide deprotection 15. Place the tightly capped vial containing each oligonucleotide solution in a heating block pre-heated to 55◦ C ± 2◦ C and continue heating at this temperature for 10 hr. Cool each sample to room temperature. 16. Determine the concentration of the oligonucleotide by UV spectrophotometry at 260 nm (UNIT 10.3).
Analyze oligonucleotide by RP-HPLC 17. Analyze ∼0.25 OD260 of each oligonucleotide on a 5-µm Supelcosil LC-18S HPLC column (UNIT 10.5) using a linear gradient of 1% acetonitrile/min starting from 0.1 M triethylammonium acetate, pH 7.0, at a flow rate of 1 mL/min for 40 min. Hold the gradient isocratically for 20 min. RP-HPLC profiles of oligonucleotides synthesized from S.3a-d and conventional 2-cyanoethyl deoxyribonucleoside phosphoramidites are presented in Figure 3.11.2. The two peaks for the PS-oligonucleotides are caused by the presence of a terminal 5 -DMTr group, which facilitates the hydrophobic resolution of two populations of diastereomers (RP -rich and SP -rich). The resolution of these diastereomeric populations is dependent
Figure 3.11.2 RP-HPLC chromatograms of crude 5 -O-DMTr-d(ATCCGTAGCTAAGGTCATGC) and 5 -O-DMTr-d(APS TPS CPS CPS GPS TPS APS GPS CPS TPS APS APS GPS GPS TPS CPS APS TPS GPS C). (A) 5 -O-DMTr-20-mer and (C) PS-5 -O-DMTr-20-mer synthesized via phosphoramidites S.3a-d and deprotected as described in the Basic Protocol. (B) 5 -O-DMTr-20-mer and (D) PS-5 -O-DMTr20-mer synthesized from commercial 2-cyanoethyl deoxyribonucleoside phosphoramidites and deprotected as described in Basic Protocol, steps 14 and 15. RP-HPLC analyses were performed as described in Basic Protocol, step 17. DMTr, 4,4 -dimethoxytrityl; PS, phosphorothioate diester. Adapted and reprinted from Cie´slak et al. (2004) with permission from the American Chemical Society.
Synthesis of Unmodified Oligonucleotides
3.11.5 Current Protocols in Nucleic Acid Chemistry
Supplement 19
on the sequence and size of the oligomer and will completely vanish upon removal of the 5 -DMTr group under acidic conditions. This phenomenon is not well understood, although it has consistently been observed in several laboratories.
Analyze oligonucleotide by PAGE 18. Pipet 0.25 OD260 of each oligonucleotide solution into a 1.5-mL microcentrifuge tube. Add 100 µL of 80% AcOH. After 30 min, evaporate to dryness using a Speedvac. 19. Add 10 µL of loading buffer. Vortex well and then centrifuge 5 sec at 14,000 × g. 20. Load the sample in a 2-cm-wide well of a 20 × 40–cm, 7 M urea/20% polyacrylamide gel (UNIT 10.4 and APPENDIX 3B). Electrophorese at 350 V until the bromphenol blue dye travels 75% of the length of the gel. 21. Dismantle the gel apparatus and immerse the gel in 250 mL staining buffer containing 10 mL of 1 mg/mL Stains-All in formamide. Agitate the gel for ∼1 hr in the dark. 22. Discard the staining solution and rinse the gel three times with 250 mL distilled water. 23. Expose the gel to natural light until the purple background disappears and photograph the blue bands against a white background. A photograph of the gel is presented in Figure 3.11.3.
4-Methylthio-1Butyl Group for Phosphate/ Thiophosphate Protection
Figure 3.11.3 PAGE analysis of d(ATCCGTAGCTAAGGTCATGC) and its phosphorothioated analog under denaturing conditions (7 M urea, 1× TBE buffer, pH 8.3). (A) Crude oligomer synthesized from commercial 2-cyanoethyl deoxyribonucleoside phosphoramidites. (B) Crude oligomer synthesized from phosphoramidites S.3a-d. (C) Crude phosphorothioated oligomer synthesized from S.3a-d. All were deprotected as described in Basic Protocol, steps 14, 15, and 18. Unmodified oligonucleotides are visualized as blue bands and fully thioated oligonucleotides as purple bands upon staining the gel with Stains-All. Bromphenol blue is used as a marker and shows as a large band at the bottom of each lane. Adapted and reprinted from Cie´slak et al. (2004) with permission from the American Chemical Society.
3.11.6 Supplement 19
Current Protocols in Nucleic Acid Chemistry
Characterize oligonucleotide by enzyme hydrolysis 24. Pipet 1 OD260 of each oligonucleotide solution into a 1.5-mL microcentrifuge tube. Add 100 µL of 80% AcOH. After 30 min, evaporate to dryness using a Speedvac. 25. Add 6 µL of 1.0 M Tris·Cl, pH 9.0, 8 µL of 1.0 M MgCl2 , and 75 µL water. Mix well. 26. Add 5 µL (0.015 U) SVPD and 6 µL (0.7 U) BAP and heat 16 hr in a 37◦ C water bath (also see UNIT 10.6). 27. Heat deactivate the enzyme 3 min at 90◦ C. Centrifuge 5 min at 14,000 × g, 25◦ C. 28. Analyze a 50-µL aliquot of the digest by RP-HPLC as in step 17. The RP-HPLC profile of the enzyme hydrolysates is shown in Figure 3.11.4.
Figure 3.11.4 RP-HPLC analysis of crude d(ATCCGTAGCTAAGGTCATGC) after digestion with SVPD and BAP (37◦ C, 16 hr). Hydrolysates were made from (A) a 20-mer synthesized using phosphoramidites S.3a-d and (B) a 20-mer synthesized using commercial 2-cyanoethyl deoxyribonucleoside phosphoramidites. Both were deprotected as described in Basic Protocol, steps 14 and 15. RP-HPLC analyses were performed as described in Basic Protocol, step 17. Identities of the RP-HPLC peaks are confirmed through co-injection with authentic 2 -deoxyribonucleosides. Adapted and reprinted from Cie´slak et al. (2004) with permission from the American Chemical Society.
Figure 3.11.5 121 MHz 31 P NMR spectrum of crude d(APS TPS CPS CPS GPS TPS APS GPS CPS TPS APS APS GPS GPS TPS CPS APS TPS GPS C) in NH4 OH. The crude 20-mer was prepared from S.3a-d and deprotected as described in Basic Protocol, steps 14 and 15. Adapted and reprinted from Cie´slak et al. (2004) with permission from the American Chemical Society.
Synthesis of Unmodified Oligonucleotides
3.11.7 Current Protocols in Nucleic Acid Chemistry
Supplement 19
Analyze phosphorothioated oligonucleotide by 31 P NMR spectroscopy 29. Analyze the crude phosphorothioated oligonucleotide (synthesized using S.3a-d and deprotected as described in steps 14 and 15) in NH4 OH by 31 P NMR spectroscopy. A 31 P NMR spectrum of phosphorothioated d(ATCCGTAGCTAAGGTCATGC) is shown in Figure 3.11.5. The crude oligomer appears as a broad singlet at ∼52 ppm. SUPPORT PROTOCOL
PREPARATION OF O-(4-METHYLTHIO-1-BUTYL)-N,N,N ,N TETRAISOPROPYLPHOSPHORODIAMIDITE This protocol delineates the preparation of bis(N,N-diisopropylamino)chlorophosphine (S.4) in situ from the reaction of phosphorus trichloride and N,N-diisopropylamine, and its condensation with 4-methylthio-1-butanol (S.5) to produce the phosphorodiamidite S.2 (see Fig. 3.11.6).
Additional Materials (also see Basic Protocol) Phosphorus trichloride (Aldrich) N,N-Diisopropylamine (Aldrich) 4-Methylthio-1-butanol (Aldrich) Drierite, 8 mesh (Aldrich) 10-µm stainless-steel frit (20 × 10–mm o.d.; Kontes) 3-mm-i.d. Teflon canula 1. To 100 mL of dry benzene in an oven-dried 250-mL round-bottom flask, add by syringe through a rubber septum 1.75 mL (20 mmol) of freshly distilled phosphorus trichloride under a dry argon atmosphere. 2. Cool the stirred solution to 5◦ C using an ice bath. Add by syringe 17.6 mL (140 mmol) anhydrous N,N-diisopropylamine over a period of 30 min under an argon atmosphere. 3. Remove the ice bath and allow the stirred reaction to warm to 25◦ C under a positive pressure of argon until the formation of bis(N,N-diisopropylamino)chlorophosphine (S.4) is complete. The progress of the reaction is monitored by 31 P NMR spectroscopy. The formation of S.4 (singlet, 135.5 ppm, downfield relative to a phosphoric acid external standard) is essentially complete (>96%) within 72 hr.
4. Add by syringe 2.7 mL (22 mmol) of 4-methylthio-1-butanol (S.5) to the suspension. Stir for 2 hr at 25◦ C under a positive pressure of argon. 31
P NMR spectrum of reaction mixture shows a singlet at 118.5 ppm indicating the near quantitative formation of S.2.
5. Using argon pressure, filter the suspension through a 10-µm stainless steel frit (20 × 10–mm o.d.) coupled to a 3-mm-i.d. Teflon canula into a 250-mL round-bottom flask. Wash the salt with 40 mL of dry benzene and resume filtration. To release gas pressure, pierce a 20-G needle through the rubber septum of the receiving flask. 6. Rotoevaporate the filtrates under reduced pressure to afford S.2 as an oil.
4-Methylthio-1Butyl Group for Phosphate/ Thiophosphate Protection
Crude O-(4-methylthio-1-butyl)-N,N,N ,N -tetraisopropylphosphorodiamidite (S.2) can be used for the phosphinylation of S.1a-d without further purification. 1 H NMR (300 MHz, C6 D6 ): δ 3.56 (m, 2H), 3.53 (sept, J = 6.9 Hz, 2H), 3.49 (sept, J = 6.9 Hz, 2H), 2.30 (m, 2H), 1.80 (s, 3H), 1.63 (m, 4H), 1.23 (d, J = 6.9 Hz, 12H), 1.19 (d, J = 6.9 Hz, 12H). 13 C NMR (75 MHz, C6 D6 ): δ 15.2, 24.0, 24.1, 24.7, 24.8, 26.2, 31.1 (d, JPC = 9.6 Hz), 34.2, 44.6, 44.7, 64.1 (d, 2 JPC = 21.5 Hz). 31 P NMR (121 MHz, C6 D6 ): δ 118.5.
3.11.8 Supplement 19
Current Protocols in Nucleic Acid Chemistry
Figure 3.11.6 Preparation of O-(4-methylthio-1-butyl)-N,N,N ,N -tetraisopropylphosphorodiamidite (S.2). Adapted and reprinted from Cie´slak et al. (2004) with permission from the American Chemical Society.
COMMENTARY Background Information The thermolabile 4-methylthio-1-butyl phosphate/thiophosphate-protecting group for DNA oligonucleotides has been investigated for its potential application to oligonucleotide synthesis on diagnostic microarrays and to the large-scale preparation of alkylation-free therapeutic oligonucleotides. With the advent of DNA microarrays as powerful diagnostic tools in clinical medicine (Rhodes and Chinnaiyan, 2002; Guo, 2003), the development of thermolytic groups for 5 -hydroxyl (Chmielewski et al., 2003) and phosphate (Grajkowski et al., 2001; Wilk et al., 2001, 2002; Cie´slak and Beaucage, 2003) protection toward the implementation of a “heat-driven” method (Grajkowski et al., 2003) for the synthesis of DNA oligonucleotides on planar glass surfaces is being investigated. Thermolabile 5 -/3 -hydroxyl- and phosphate-protecting groups are designed for rapid and efficient release from oligonucleotides when heated under neutral conditions. Such properties eliminate the use of harsh chemicals that are typically required for iterative oligonucleotide chain extension and final oligonucleotide deprotection. These chemicals, however, may damage the glass surface and result in oligonucleotide leaching, which would lead to a poorer performance of microarrays in terms of diagnostic sensitivity. In contrast, the large-scale preparation of oligonucleotides for therapeutic applications has challenged the suitability of 2-cyanoethyl deoxyribonucleoside phosphoramidites (Sinha et al., 1984) for such syntheses, given the potent DNA-alkylating properties of acrylonitrile (Wilk et al., 1999a,b) that is generated under the conditions used for nucleobase deprotection. DNA alkylation can permanently compromise the affinity of therapeutic oligonucleotides for their mRNA targets. To circumvent such a limitation, a number
of deoxyribonucleoside phosphoramidites functionalized with phosphorus-protecting groups that would prevent formation of DNAalkylating species during oligonucleotide deprotection have been reported. These groups include the 4-[(N-methyl,N-(2,2,2trifluoroacetyl)amino]butyl group (Wilk et al., 1999a,b; UNIT 2.7) and the 4-oxopentyl group (Wilk et al., 2001; UNIT 3.9), which can easily be removed from oligonucleotides by standard treatment with concentrated ammonium hydroxide or pressurized ammonia gas (Boal et al., 1996). The removal of these phosphate/thiophosphate-protecting groups occurred through an intramolecular cyclodeesterification reaction with the concomitant formation of side-products that were inoccuous to the nucleobases of DNA oligonucleotides (Wilk et al., 1999a,b; 2001). Deoxyribonucleoside phosphoramidites functionalized with phosphorus-protecting groups exhibiting thermolytic properties were also reported. Groups such as 2-(N-formyl,Nmethyl)aminoethyl (Grajkowski et al., 2001) and 3-[(N-tert-butyl)carboxamido]-1-propyl (Wilk et al., 2002) were cleaved from N-deprotected oligonucleotides upon heating at temperatures up to 90◦ C in an aqueous buffer at neutral pH. Under these conditions, the removal of these phosphate/thiophosphateprotecting groups was achieved within 3 hr and 1 hr, respectively. The thermolytic cleavage of the 3-[(N-tert-butyl)carboxamido]-1-propyl group is consistent with the participation of the amidic carbonyl group in an intramolecular cyclodeesterification reaction resulting in the release of a phosphate/thiophosphate diester as its 2-tert-butyliminotetrahydrofuran salt (UNIT 3.9; Wilk et al., 2002). The spatial arrangement of the amidic carbonyl group relative to the phosphate/thiophosphate leaving group is crucial in that it determines the thermolytic deprotection kinetics of the protecting group.
Synthesis of Unmodified Oligonucleotides
3.11.9 Current Protocols in Nucleic Acid Chemistry
Supplement 19
Figure 3.11.7 Proposed mechanism for the cleavage of the 4-methylthio-1-butyl group under thermolytic conditions at neutral pH. Reagents and conditions: (i) 0.45 M 1H-tetrazole in MeCN, 1 min; (ii) 0.02 M I2 in THF/pyridine/water or 0.05 M 3H-benzodithiol-3-one-1,1-dioxide in MeCN, 3 min; (iii) 3% TCA in CH2 Cl2 , 1 min; (iv) MeNH2 gas (2.5 bar), 3 min; (v) 0.1 M TEAA, pH 7.0, 55◦ C, 30 min. LCAA-CPG, succinyl long-chain alkylamine controlled-pore glass; TCA, trichloroacetic acid; Thy, thymin-1-yl; TEAA, triethylammonium acetate; THF, tetrahydrofuran. Adapted and reprinted from Cie´slak et al. (2004) with permission from the American Chemical Society.
4-Methylthio-1Butyl Group for Phosphate/ Thiophosphate Protection
Indeed, the thermolytic deprotection of the homologous 3-[(N-tert-butyl)carboxamido]1-butyl and 2-(N-tert-butylcarboxamido)ethyl thiophosphate-protecting group is, respectively, 25-fold and >2000-fold slower than that of the 3-[(N-tert-butyl)carboxamido]1-propyl group under identical conditions (Wilk et al., 2002). Thus, it is critically important to consider the spatial relationship between the nucleophilic function and the phosphate/thiophosphate leaving group when designing novel thermolytic groups. These findings prompted the search for phosphate/thiophosphate-protecting groups that would be removed under milder thermolytic conditions in either the presence or absence of ammonium hydroxide. The selection of the 4-methythio-1-butyl group was based on its structural simplicity and its potential compliance with the spatial requirements for optimal thermolytic deprotection kinetics, assuming an intramolecular cyclodeesterification process. The preparation of deoxyribonucleoside phosphoramidites functionalized with the 4-methylthio-1-butyl group for P(III) protection (S.3a-d) began with the synthesis of the phosphinylating
reagent S.2, which was achieved upon reaction of the chlorophosphine S.4 with commercial 4-methylthio-1-butanol (S.5; see Support Protocol). Condensation of commercial nucleosides (S.1a-d) with crude S.2 in the presence of 1H-tetrazole afforded the deoxyribonucleosides phosphoramidites S.3a-d (see Basic Protocol). The thermolytic properties of the 4methylthio-1-butyl group were evaluated using a dinucleotide model. Specifically, the reaction of phosphoramidite S.3a with thymidine covalently attached to long-chain alkylamine controlled-pore glass (LCAA-CPG, S.6) and 1H-tetrazole gave the dinucleoside phosphite triester S.7 (Fig. 3.11.7). Exposure of S.7 to an iodine solution or to 3H-1,2benzodithiol-3-one-1,1-dioxide in MeCN produced the support-bound dinucleoside phosphotriester S.8 or S.9, respectively (Cie´slak et al., 2004). Removal of the 5 -O-DMTr group under acidic conditions followed by release of the dinucleotide from LCAA-CPG upon treatment with methylamine gas afforded S.10 or S.11 as the major product. RP-HPLC analysis of crude S.10 revealed the presence of the corresponding dinucleoside phosphodiester S.12
3.11.10 Supplement 19
Current Protocols in Nucleic Acid Chemistry
to the extent of ∼10%, which is indicative of the facile removal of the 4-methylthio1-butyl phosphate protecting group. Heating either S.10 or S.11 in 0.1 M triethylammonium acetate (pH 7.0) for 30 min at 55◦ C, resulted in complete cleavage of the 4-methylthio-1-butyl group to give the dinucleoside phosphodiester S.12 or S.13 in near quantitative yield (>99%) on the basis of RP-HPLC analysis of the thermolytic deprotection reaction (Cie´slak et al., 2004). Alternatively, treatment of S.8 or S.9 with concentrated NH4 OH for 30 min at room temperature, followed by heating the ammoniacal solution for 2 hr at 55◦ C, produced comparable results. As shown in Figure 3.11.7, the thermolytic cleavage of the 4-methylthio-1-butyl group from S.10 or S.11 proceeds through an intramolecular cyclodeesterification reaction with the production of a sulfonium salt (S.14). To confirm the formation of S.14, the solidphase-linked dinucleoside phosphotriester S.8 was suspended in 0.1 M NaCl in D2 O and
heated for 30 min at 55◦ C. Analysis of the supernatant by 1 H NMR spectroscopy (Fig. 3.11.8A) revealed signals identical to those recorded for S.14 (Fig. 3.11.8B), which was also prepared as its chloride salt from the reaction of tetrahydrothiophene with methyl chloroformate (Byrne and Lafleur Lawter, 1986). These data convincingly demonstrate the participation of the 4-methylthio function in the thermolytic phosphate/thiophosphate deprotection of S.10 or S.11 (Cie´slak et al., 2004). The use of the 4-methylthio-1-butyl group for phosphate protection in solid-phase oligonucleotide synthesis was adequate only if the conventional 0.02 M iodine solution in THF/pyridine/H2 O was selected as the oxidant for iteratively converting phosphite to phosphate triester throughout oligonucleotide synthesis. The use of tert-butyl hydroperoxide or (1S)-(+)-(10-camphorsulfonyl)oxaziridine instead of iodine resulted in the partial conversion of the 4-methylthio-1-butyl group to its 4methylsulfinyl-1-butyl congener, which could
Figure 3.11.8 300 MHz 1 H NMR spectra of S.14 (as its chloride salt in D2 O). (A) S.14 produced by thermolytic deprotection of S.8 in D2 O containing 0.1 M NaCl. (B) S.14 prepared by reaction of tetrahydrothiophene with methyl chloroformate. Adapted and reprinted from Cie´slak et al. (2004) with permission from the American Chemical Society.
Synthesis of Unmodified Oligonucleotides
3.11.11 Current Protocols in Nucleic Acid Chemistry
Supplement 19
not be thermolytically cleaved from the parent dinucleoside phosphotriester even upon heating for 3 hr at 90◦ C in a neutral buffer (Cie´slak et al., 2004). These results further validate the participation of the 4-methylthio function in the thermolytic phosphate/thiophosphate deprotection of S.10 or S.11 through an intramolecular cyclodeesterification process. The deoxyribonucleoside phosphoramidites S.3a-d were successfully used in the small scale (0.2-µmol) solid-phase synthesis of d(ATCCGTAGCTAAGGTCATGC) and its phosphorothioated analog. Following release from the CPG support, the thermolytic cleavage of the 4-methylthio-1-butyl protecting group from crude oligonucleotides was performed along with complete removal of nucleobase-protecting groups by treatment with concentrated NH4 OH for 10 hr at 55◦ C. Neither nucleobase alkylation (see Fig. 3.11.4) nor significant phosphorothioate desulfurization were detected under these conditions. To further substantiate the absence of nucleobase alkylation under conditions that would simulate millimole-scale oligonucleotide deprotection, deoxyribonucleosides and their Nprotected counterparts were heated in concentrated NH4 OH for 10 hr at 55◦ C in the presence or absence of a representative concentration of the sulfonium salt S.14 (Cie´slak et al., 2004). RP-HPLC analyses of each reaction mixture did not show significant nucleobase modifica-
4-Methylthio-1Butyl Group for Phosphate/ Thiophosphate Protection
tions under these conditions (Fig. 3.11.9). Exposure of O,O-diethyl thiophosphate to S.14 under concentration conditions similar to those prevailing in large-scale oligonucleotide synthesis did not show, on the basis of 31 P NMR data, desulfurization of the phosphorothioate model in concentrated NH4 OH over a period of 10 hr at 55◦ C. Typically, no conversion of O,Odiethyl thiophosphate (δP ∼55 ppm) to O,Odiethyl phosphate (δP ∼2 ppm) was detected (see Fig. 3.11.10). Altogether, the results reported therein indicate that the 4-methythio1-butyl group is suitable for the large-scale preparation of therapeutic oligonucleotides as well as for the microscale synthesis of oligonucleotides on diagnostic microarrays.
Critical Parameters and Troubleshooting The phosphorodiamidite S.2 is prepared using the bis(N,N-diisopropylamino)chlorophosphine intermediate S.4 (see Support Protocol, Fig. 3.11.6) in a manner similar to that reported for N,N,N ,N -tetraisopropyl-O[3-(N-tert-butylcarboxamino)-1-propyl]phosphorodiamidite (UNIT 3.9, Figure 3.9.5). Readers are referred to the Critical Parameters and Troubleshooting section of UNIT 2.7, which addresses issues pertaining to the preparation of phosphorodiamidites. The formation of S.4 must be carefully monitored by 31 P NMR spectroscopy to ensure complete exhaustion of dichloro(N,N-diisopropylamino)phosphine
Figure 3.11.9 RP-HPLC analysis of the DNA-modifying properties of S.14. (A) Chromatogram of the reaction of T, dC, dA, dG, N 4 -Bz-dC, N 6 -Bz-dA, and N 2 -i-Bu-dG with S.14 in NH4 OH under conditions simulating large-scale oligonucleotide deprotection. (B) Chromatogram of an identical reaction in the absence of S.14. Chromatographic conditions for RP-HPLC analyses are as described in UNIT 3.9. Adapted and reprinted from Cie´slak et al. (2004) with permission from the American Chemical Society.
3.11.12 Supplement 19
Current Protocols in Nucleic Acid Chemistry
Figure 3.11.10 31 P NMR analysis (121 MHz) of the phosphorothioate desulfurization properties of S.14. (A) Reaction of O,O-diethyl thiophosphate (potassium salt) with S.14 under conditions simulating large-scale oligonucleotide deprotection in concentrated NH4 OH. (B) Potassium salt of O,O-diethyl thiophosphate in concentrated NH4 OH. Adapted and reprinted from Cie´slak et al. (2004) with permission from the American Chemical Society.
(δP ∼169 ppm in C6 D6 ) prior to adding 4-methylthio-1-butanol. It is recommended that the deoxyribonucleoside phosphoramidites S.3a-d be precipitated from cold hexane following silica gel purification. This precipitation step removes a hydrolyzed phosphinylating agent that often co-elutes with the desired phosphoramidite monomers. To ensure optimal coupling efficiency of individual deoxyribonucleoside phosphoramidites during solid-phase oligonucleotide synthesis, a number of parameters including exclusion of residual triethylamine and moisture must be taken into consideration. These issues are also addressed in UNIT 2.7. When using S.3a-d in solid-phase oligonucleotide synthesis, oxidants such as tert-butyl hydroperoxide and (1S)-(+)(10-camphorsulfonyl)oxaziridine should be avoided during chain assembly.
Anticipated Results The synthesis of deoxyribonucleoside phosphoramidites S.3a-d from phosphorodiamidite S.2 is performed essentially as recommended by Barone et al. (1984). The coupling efficiency of silica gel–purified and triethylamine-free phosphoramidites S.3a-d is comparable to that of commercial 2cyanoethyl deoxyribonucleoside phosphoramidites.
phosphoramidites S.3a-d require 1 to 2 days to complete.
Literature Cited Barone, A.D., Tang, J.-T., and Caruthers, M.H. 1984. In situ activation of bisdialkylaminophosphines—A new method for synthesizing deoxyoligonucleotides on polymer supports. Nucl. Acids Res. 12:4051-4061. Boal, J.H., Wilk, A., Harindranath, N., Max, E.E., Kempe, T., and Beaucage, S.L. 1996. Cleavage of oligodeoxyribonucleotides from controlledpore glass supports and their rapid deprotection by gaseous amines. Nucl. Acids Res. 24:31153117. Byrne, B. and Lafleur Lawter, L.M. 1986. The preparation of trimethylsulfonium chloride from methyl chloroformate and dimethyl sulfide. Tetrahedron Lett. 27:1233-1236. Chmielewski, M.K., March´an, V., Cie´slak, J., Grajkowski, A., Livengood, V., M¨unch, U., Wilk, A., and Beaucage, S.L. 2003. Thermolytic carbonates for potential 5 -hydroxyl protection of deoxyribonucleosides. J. Org. Chem. 68:10003-10012. Cie´slak, J. and Beaucage, S.L. 2003. Thermolytic properties of 3-(2-pyridyl)-1-propyl and 2-[N-methyl-N-(2-pyridyl)]aminoethyl phosphate/thiophosphate protecting groups in solid-phase synthesis of oligodeoxyribonucleotides. J. Org. Chem. 68:10123-10129.
Time Considerations
Cie´slak, J., Grajkowski, A., Livengood, V., and Beaucage, S.L. 2004. Thermolytic 4-methylthio-1-butyl group for phosphate/thiophosphate protection in solid-phase synthesis of DNA oligonucleotides. J. Org. Chem. 69:2509-2515.
The preparation of the phosphorodiamidite S.2 takes 3 to 4 days, whereas synthesis and purification of each of the deoxyribonucleoside
Grajkowski, A., Wilk, A., Chmielewski, M.K., Phillips, L.R., and Beaucage, S.L. 2001. The 2-(N-formyl,N-methyl)aminoethyl group as a
Synthesis of Unmodified Oligonucleotides
3.11.13 Current Protocols in Nucleic Acid Chemistry
Supplement 19
potential phosphate/thiophosphate protecting group in solid-phase oligodeoxyribonucleotide synthesis. Org. Lett. 3:1287-1290. Grajkowski, A., Cie´slak, J., Chmielewski, M.K., March´an, V., Phillips, L.R., Wilk, A., and Beaucage, S.L. 2003. Conceptual “heat-driven” approach to the synthesis of DNA oligonucleotides on microarrays. Ann. N.Y. Acad. Sci. 1002:1-11.
Wilk, A., Grajkowski, A., Srinivasachar, K., and Beaucage, S.L. 1999b. Improved chemistry for the production of synthetic oligodeoxyribonucleotides. Antisense Nucleic Acid Drug Dev. 9:361-366.
Guo, Q.M. 2003. DNA microarray and cancer. Curr. Opin. Oncol. 15:36-43.
Wilk, A., Chmielewski, M.K., Grajkowski, A., Phillips, L.R., and Beaucage, S.L. 2001. The 4-oxopentyl group as a labile phosphate/thiophosphate protecting group for synthetic oligodeoxyribonucleotides. Tetrahedron Lett. 42:5635-5639.
Iyer, R.P., Phillips, L.R., Egan, W., Regan, J.B., and Beaucage, S.L. 1990. The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one-1,1-dioxide as a sulfur-transfer reagent. J. Org. Chem. 55:46934699.
Wilk, A., Chmielewski, M.K., Grajkowski, A., Phillips, L.R., and Beaucage, S.L. 2002. The 3[(N-tert-butyl)carboxamido]-1-propyl group as an attractive phosphate/thiophosphate protecting group for solid-phase oligodeoxyribonucleotide synthesis. J. Org. Chem. 67:6430-6438.
Rhodes, D.R. and Chinnaiyan, A.M. 2002. DNA microarrays: Implications for clinical medicine. J. Invest. Surg. 15:275-279. Sinha, N.D., Biernat, J., McManus, J., and K¨oster, H. 1984. Polymer support oligonucleotide synthesis. 18. Use of β-cyanoethyl-N,N,dialkylamino/-N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucl. Acids Res. 12:4539-4557.
Contributed by Jacek Cie´slak, Andrzej Grajkowski, and Serge L. Beaucage Food and Drug Administration Bethesda, Maryland Victor Livengood National Institutes of Health Bethesda, Maryland
Wilk, A., Grajkowski, A., Phillips, L.R., and Beaucage, S.L. 1999a. The 4-[N-methyl-N(2,2,2-trifluoroacetyl)amino]butyl group as an alternative to the 2-cyanoethyl group for phosphate protection in the synthesis of oligodeoxyribonucleotides. J. Org. Chem. 64:75157522.
4-Methylthio-1Butyl Group for Phosphate/ Thiophosphate Protection
3.11.14 Supplement 19
Current Protocols in Nucleic Acid Chemistry
Nucleoside Phosphoramidites Containing Cleavable Linkers
UNIT 3.12
The first step in any solid-phase oligonucleotide synthesis is attachment of the first nucleoside to the surface of the support (see UNIT 3.2). Typically, this attachment is made via an ester linkage connecting the 3 -OH position to one end of a dicarboxylic acid linker arm. The other end of the dicarboxylic acid is anchored to an amino- or hydroxyl-derivatized solid-phase support through an amide or ester bond, respectively. Since the chemistry for forming ester and amide linkages is not compatible with the phosphoramidite coupling chemistry used on automated synthesizers (see APPENDIX 3C), the nucleoside-derivatized support is generally prepared in a separate process, and an inventory of separate prederivatized supports (one for each base) must be prepared or purchased. For many nucleosides, derivatized supports are conveniently prepackaged into synthesis columns ready for use on column-based synthesizers. Multi-well plate-based synthesizers (Lashkari et al., 1995; Sindelar and Jaklevic, 1995; Brennan et al., 1998; Rayner et al., 1998; Cheng et al., 2002) present an added challenge because they require placement of the correct prederivatized supports into the correct wells according to each set of sequences being made. Because this can be a tedious and error-prone step, much effort has gone into developing “universal” supports that can be used in any well, regardless of the nucleoside required. Two strategies have been developed to allow this universal functionality. In the first strategy (Fig. 3.12.1A), universal supports with various diol linker structures S.2 are employed (Debear et al., 1987; Scott et al., 1994; Schwartz et al., 1995; Nelson et al., 1997; Scheuerlarsen et al., 1997; Azhayev, 1999; Lyttle et al., 1999; Azhayev and Antopolsky, 2001; Guzaev and Manoharan, 2003). The first nucleoside is added using a conventional nucleoside-3 O-phosphoramidite (S.1), which forms a phosphodiester linkage to the universal support (S.3). After synthesis, the relatively stable phosphate ester linkage connecting the oligonucleotide to the support must be selectively cleaved to generate a product with a 3 -OH and not a 3 -phosphate terminus. The difficulty of this selective cleavage is the main drawback to this approach. In this unit, a second approach to universal supports is described (Fig. 3.12.1B) that uses modified phosphoramidite reagents (linker phosphoramidites, S.4; Pon and Yu, 2001, 2004) instead of modified solid-phase supports. These modified phosphoramidites contain the same protected nucleosides and the same activatable phosphoramidite groups used in conventional synthesis. However, an easily cleavable linker is inserted between the 3 -OH of the nucleoside and the phosphoramidite group in such a manner that oligonucleotide products with the desired 3 -OH ends can be generated without any additional cleavage or deprotection steps. This method also allows much less expensive, underivatized amino supports S.5 to act as universal supports. Basic Protocol 1 describes the synthesis of the four linker phosphoramidite reagents S.4a-d starting from readily available protected nucleosides. The Alternate Protocol provides a method for preparing simpler and slightly less costly reagents in which the sulfonyldiethanol group is replaced by ethylene glycol. Although DNA synthesis requires a set of four linker phosphoramidites (one for each base), these reagents are useful in two different ways, as will be discussed below. Both methods for synthesis of linker phosphoramidites can be adapted for use with modified nucleosides; however, the cost and effort may outway the benefits if the modified linker phosphoramidites will not be used frequently.
Contributed by Richard T. Pon Current Protocols in Nucleic Acid Chemistry (2005) 3.12.1-3.12.24 C 2005 by John Wiley & Sons, Inc. Copyright
Synthesis of Unmodified Oligonucleotides
3.12.1 Supplement 23
Figure 3.12.1 Comparison of universal support strategies. In route (A), a conventional 3 -O-phosphoramidite reagent is coupled to a CPG support with a modified diol linker arm. After completion of the synthesis, a difficult-to-cleave phosphate P-O bond must be hydrolyzed to release an oligonucleotide with the desired 3 -OH terminus. In route (B), a modified linker phosphoramidite reagent is coupled to an underivatized amino CPG support. After completion of the synthesis, the desired oligonucleotide product can be released by hydrolysis of a more easily cleaved ester C-O bond.
Basic Protocol 2 describes the use of linker phosphoramidite reagents for oligonucleotide synthesis in multi-well plates using inexpensive underivatized amino supports (S.5) in a procedure that eliminates the problems associated with 3 -dephosphorylation.
Nucleoside Phosphoramidites Containing Cleavable Linkers
Finally, in Basic Protocol 3, the linker phosphoramidites containing a sulfonyldiethanol group (S.4) are used to create long strings of oligonucleotides linked end-to-end via tandem oligonucleotide synthesis (Pon and Yu, 2005). The ability to make sets of oligonucleotides in a single automated tandem synthesis with linker phosphoramidite reagents is a major advantage when large sets of oligonucleotides are required, i.e., for PCR primers or double-stranded sequences. However, tandem synthesis is best used for applications
3.12.2 Supplement 23
Current Protocols in Nucleic Acid Chemistry
that are tolerant of minor impurities, since it is usually not practical to isolate and purify each component in the mixture. Fortunately, phosphoramidite coupling chemistry is efficient enough to allow most oligonucleotides to be used with only minimal purification (such as a desalting step), and the small amounts of truncated failure sequences present do not significantly affect their use in many applications.
SYNTHESIS OF LINKER PHOSPHORAMIDITES CONTAINING A CLEAVABLE SUCCINYL-SULFONYLDIETHANOL LINKER
BASIC PROTOCOL 1
This protocol describes the three synthetic steps (Fig. 3.12.2) required to convert protected 5 -O-dimethoxytrityl-N-acyl-2 -deoxyribonucleosides S.8a-d into linker phosphoramidite reagents S.4a-d. The first step involves reaction of the 3 -OH position with succinic anhydride S.9 to create nucleoside-3 -O-succinyl hemiesters S.10a-d. Then, the terminal carboxylic acid group is esterified with sulfonyldiethanol S.11 to create nucleosides with a 3 -O-linker ending in a hydroxyl group S.12a-d. Finally, nucleoside S.12 is converted to the desired linker phosphoramidite compound S.4a-d
Figure 3.12.2 Synthesis of linker phosphoramidites S.4a-d containing a 2,2 -sulfonyldiethanol spacer (see Basic Protocol 1). Synthesis of Unmodified Oligonucleotides
3.12.3 Current Protocols in Nucleic Acid Chemistry
Supplement 23
by phosphitylation of the terminal hydroxyl group with 2-cyanoethyl-N,N,N ,N tetraisopropylphosphorodiamidite S.13 and tetrazole S.14. The synthetic manipulations required for this procedure are quite straightforward. The conditions required for the succinylation and phosphitylation steps are widely used in the preparation of conventional solid-phase supports and 3 -O-phosphoramidite reagents. Only the addition of sulfonyldiethanol as a spacer between the succinic acid and phosphoramidite groups is unique to this protocol.
Materials Protected 2 -deoxyribonucleosides: 5 -O-(4,4 -Dimethoxytrityl)-N6 -benzoyl-2 -deoxyadenosine (S.8a) 5 -O-(4,4 -Dimethoxytrityl)-N4 -acetyl-2 -deoxycytidine or 5 -O-(4,4 -dimethoxytrityl)-N4 -benzoyl-2 -deoxycytidine (S.8b) 5 -O-(4,4 -Dimethoxytrityl)-N2 -isobutyryl-2 -deoxyguanosine (S.8c) 5 -O-(4,4 -Dimethoxytrityl)thymidine (S.8d) Succinic anhydride (S.9) Dichloromethane Triethylamine Methanol Chloroform (CHCl3 ) 0.5 M triethylammonium phosphate (TEAP) solution (see recipe) 60% to 65% (w/v) 2,2 -sulfonyldiethanol (S.11) solution in water Acetonitrile, anhydrous Pyridine, anhydrous 4-Dimethylaminopyridine (DMAP) O-Benzotriazol-1-yl-N,N,N ,N -tetramethyluronium hexafluorophosphate (HBTU) Diisopropylethylamine (DIPEA) Silica gel Diisopropylamine, anhydrous 2-Cyanoethyl-N,N,N ,N -tetraisopropylphosphorodiamidite (S.13) 0.45 M 1H-tetrazole (S.14) in anhydrous acetonitrile 5% (w/v) sodium bicarbonate in water Saturated aqueous sodium chloride Hexanes, distilled (remove dissolved oxygen by distilling under vacuum on a rotary evaporator just prior to use) 100-, 250-, and 500-mL round-bottom flasks Magnetic stirrer Fluorescent silica gel TLC plates, Merck 60 or similar 500-mL separatory funnels Rotary evaporator and warm water bath (60◦ C) Chromatography column, ∼3 in. (∼7.5 cm) diameter, with capacity for at least 9 in. (∼23 cm) silica gel Rubber septum Drying tube: an empty 10- or 20-mL syringe filled with Drierite (with indicator), with a small glass wool plug at each end Syringes Additional reagents and equipment for TLC (APPENDIX 3D) and flash chromatography (APPENDIX 3E) Nucleoside Phosphoramidites Containing Cleavable Linkers
3.12.4 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Couple nucleoside to succinic anhydride 1. For each protected nucleoside S.8a-d, combine 10 mmol nucleoside and 1.5 g (15 mmol) succinic anhydride (S.9) in a 250-mL round-bottom flask equipped with a magnetic stirrer. 2. Add 100 mL dichloromethane and then 4.2 mL (30 mmol) triethylamine. Stir at room temperature for 3 hr. 3. Monitor the reaction by TLC (APPENDIX 3D) using 5% and/or 10% (v/v) methanol/chloroform to verify the complete conversion of the starting nucleoside (faster moving) into the succinylated product (very slow moving). 4. If the starting nucleoside remains after 3 hr, continue stirring at room temperature. The reaction may take 5 hr or longer. The reaction can also be sped up by adding additional succinic anhydride (up to a total of 20 or 25 mmol).
5. When the reaction is complete, transfer the dichloromethane solution into a 500-mL separatory funnel, add 200 mL of 0.5 M aqueous TEAP solution, and mix. Aqueous TEAP is used to form the triethylammonium salt of the succinate hemiester S.10. It also helps to prevent an intractable emulsion from forming in the separatory funnel.
6. Remove the organic (lower) phase from the separatory funnel, and wash the aqueous TEAP phase two times with 100 mL dichloromethane. 7. Evaporate the combined dichloromethane solutions to furnish the nucleoside-3 -Osuccinate hemiester S.10 as a white foam. 8. Dry overnight under vacuum. The dried hemiester can be stored as a dry powder at room temperature, and can be used in the next step without further purification. Yield = 107%. Characterization data can be found in Gait et al. (1980) and Kumar et al. (1993).
Couple sulfonyldiethanol spacer to hemiester 9. Place 9.6 mL (50 mmol) of 65% (w/v) 2,2 -sulfonyldiethanol solution (S.11) and 50 mL anhydrous acetonitrile in a 500-mL round-bottom flask. 10. Using a rotary evaporator and a warm water bath (60◦ C), evaporate the solution until the solvent no longer comes off. Add another 50-mL portion of anhydrous acetonitrile and repeat the evaporation. 11. Repeat the evaporation step two more times using 30 mL (each) anhydrous pyridine. The purpose of the repeated co-evaporations is to remove all traces of water from the 2,2 -sulfonyldiethanol.
12. Redissolve the now anhydrous 2,2 -sulfonyldiethanol in 80 mL anhydrous pyridine and stir at room temperature to form a clear solution. 13. Add 10 mmol S.10, 1.59 g (13 mmol) DMAP, 4.93 g (13 mmol) HBTU, and 2.3 mL (13 mmol) DIPEA, and stir to dissolve. Continue stirring at room temperature for 10 min. 14. Check the reaction by TLC using 5% or 10% (v/v) methanol/CHCl3 . All of the starting material (very slow moving) should have been converted into a fastermoving spot (Rf ∼0.4 to 0.6).
15. When the reaction is complete (no starting material remains), concentrate the solution on a rotary evaporator until a slurry begins to form.
Synthesis of Unmodified Oligonucleotides
3.12.5 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Table 3.12.1
1
H NMR Chemical Shiftsa for Nucleoside Derivatives S.12a-d
S.12a (B = ABz )
S.12b (B = CBz )
S.12c (B = Gi-Bu )
S.12d (B = T)
6.54–6.50
6.29–6.25
6.22–6.15
6.40
H3 (br d, 1H)
5.58–5.56
5.44–5.42
5.55–5.53
5.49
-CO-O-CH2 -CH2 - SO2 - (t, 2H)
4.62–4.59
4.62–4.61
4.63
4.59
4.33
4.31–4.30 4.20–4.14
4.11
H1 (t, 1H)
H4 (br s, 1H)
H4 & -SO2 -CH2 -CH2 -OH (m, 3H) -SO2 -CH2 -CH2 -OH (br dd, 2H)
4.10–4.09
4.14–4.12
-OCH3 ×2 (s, 6H)
3.79
3.82–3.80
3.80–3.78
3.79
3.60–3.33
3.49
H5 , H5 & -CO-O-CH2 -CH2 -SO2 - (m, 4H)
3.50–3.46
3.55–3.48
-SO2 -CH2 -CH2 -OH (t, 2H)
3.28–3.25
3.31–3.28
-CH(CH3 )2 (m, 1H)
3.29 3.05–2.96
H2 (m, 1H)
3.08–3.00
2.79–2.77
2.65–2.59
2.49
H2 (m, 1H)
2.72–2.66
2.36–2.33
2.36–2.27
2.49
-CO-CH2 -CH2 -CO- (br s, 4H)
2.72
2.69
2.71
2.68
-CH3 (s, 3H)
1.37
CH3 -CH-CH3 (d, 3H)
1.13–1.10
CH3 -CH-CH3 (d, 3H)
1.05–1.03
a The internal reference for 1 H NMR spectra was tetramethylsilane at 0 ppm. The solvent was CDCl . All shifts are measured in ppm. 3
16. Remove the flask from the evaporator, redissolve the residue in 200 mL chloroform, and transfer to a 500-mL separatory funnel. Wash the chloroform solution four times with 200 mL water. 17. Evaporate the chloroform solution to dryness to yield the crude product S.12. 18. Purify the crude product by flash chromatography (APPENDIX 3E) on silica gel using a column of ∼3 in. (∼7.5 cm) diameter, containing ∼9 in. (∼23 cm) of silica gel, packed using a slurry in CHCl3 . Dissolve the crude product in 10 mL CHCl3 and apply to the column. Elute the column progressively with 1%, 2%, and 3% (v/v) MeOH/CHCl3 until the product elutes. 19. Monitor the fractions by TLC as above. Combine fractions containing the pure product S.12 and evaporate to dryness to yield a white or slightly yellowish foam. Expected yield: 70%–80%. For characterization data, see Table 3.12.1. Store as a dry powder at room temperature.
Synthesize linker phosphoramidite 20. Place 5 mmol nucleoside S.12 in a 100-mL round-bottom flask equipped with a magnetic stirrer. Seal the flask with a rubber septum and insert a drying tube filled with Drierite. It is important to exclude atmospheric moisture from this reaction. All liquid transfers are done using syringes.
Nucleoside Phosphoramidites Containing Cleavable Linkers
CAUTION: The drying tube filled with Drierite is essential to act as a vent for the flask. Do not forget to have this in place, especially when adding reagents.
3.12.6 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Table 3.12.2 TLC, UV, and 31 P NMR Chemical Shift Data for Phosphoramidites S.4a-d
S.4b (B = CBz )
S.4c (B = Gi-Bu )
S.4d (B = T)
EtOAc
10% TEA/CHCl3
EtOAc
0.50
0.67
0.75
0.25
UV (nm)
234.5, 280.5
236.5, 260.0, 305.5
237.0, 267.0, 276.0
267.0
31
150.85
150.88
150.97, 151.04
146.50
S.4a (B = ABz ) TLC solvent 10% TEA/CHCl3 Rf a
b
P NMR
a The solvent for UV spectra was 95% ethanol. b The solvent for 31 P NMR spectra was CDCl . Shifts are measured in ppm from H PO . 3 3 4
21. Add 60 mL anhydrous acetonitrile and stir at room temperature to dissolve. 22. While still stirring, add 0.82 mL (6 mmol) anhydrous diisopropylamine, 2.4 mL (7.5 mmol) 2-cyanoethyl-N,N,N ,N -tetraisopropylphosphorodiamidite (S.13), and finally 12.2 mL (5.5 mmol) 0.45 M 1H-tetrazole (S.14) in anhydrous acetonitrile. 23. Stir at room temperature for 2.5 hr and then remove an aliquot and analyze by TLC using 10% (v/v) triethylamine/chloroform. The starting nucleoside S.12 should be entirely consumed and converted into a slightly slower migrating product S.4.
24. When the reaction is complete, dilute with 150 mL dichloromethane and transfer to a 500-mL separatory funnel. 25. Wash the reaction mixture once with 200 mL of 5% (w/v) aqueous sodium bicarbonate and then twice with 200 mL saturated aqueous sodium chloride. 26. Concentrate the dichloromethane solution. 27. Purify by flash chromatography on silica gel. Use a solution of 42:52:6 (v/v/v) dichloromethane/hexanes/triethylamine to prepare the column and to load the crude sample. Elute the product with 5% to 6% (v/v) triethylamine/dichloromethane. It is important to pack the silica gel column using a solution containing triethylamine to neutralize the surface acidity of the silica gel before applying the crude phosphoramidite. The use of freshly degassed (distilled) hexanes is also recommended during this step to minimize accidental oxidation of the phosphoramidite.
28. Monitor fractions by TLC (Table 3.12.2). Combine the fractions containing the pure product S.4 and evaporate to dryness to produce a white foam. Expected yield: 70%–80%. For characterization data, see Table 3.12.2. Store as dry powders in screw-capped containers at –20◦ C for up to 1 year. The linker phosphoramidites (S.4 and S.16) have shorter solution stability than conventional phosphoramidites. The guanosine phosphoramidites (S.4c and S.16c) are the most sensitive, and should be used within 3 to 5 days of preparation. The other linker phosphoramidite solutions should be used within 1 to 2 weeks of preparation.
REPLACEMENT OF SULFONYLDIETHANOL WITH ETHYLENE GLYCOL 2,2 -sulfonyldiethanol
This alternative protocol replaces the labile spacer with a much simpler 1,2-ethanediol group (S.16; Fig. 3.12.3). Other similar alkyl diols such as 1,3propanediol or 1,4-butanediol can also be used. These alkyl diols are somewhat less expensive than sulfonyldiethanol and produce linker phosphoramidites with slightly greater stability. The resulting phosphoramidites are suitable for attachment to LCAACPG for standard oligonucleotide syntheses (see Basic Protocol 2), but should not be used for tandem syntheses (for further discussion, see Basic Protocol 3).
ALTERNATE PROTOCOL
Synthesis of Unmodified Oligonucleotides
3.12.7 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Figure 3.12.3 Protocol).
Synthesis of linker phosphoramidites S.16a-d containing an ethylene glycol spacer (see Alternate
Additional Materials (also see Basic Protocol 1) Nucleoside-3 -O-succinate hemiester (S.10; see Basic Protocol 1) p-Toluenesulfonyl chloride (p-TsCl) 1-Methylimidazole, anhydrous (N-methylimidazole; NMI) Ethylene glycol, anhydrous 250-mL separatory funnel 1. In a 250-mL round-bottom flask equipped with a magnetic stirrer, dissolve 4.4 mmol nucleoside-3 -O-succinate hemiester S.10 in 50 mL anhydrous acetonitrile and 2.9 mL (35 mmol) pyridine. 2. Add 1.64 g (8.6 mmol) p-TsCl and then 1.3 mL (15.8 mmol) NMI. Stir at room temperature to dissolve completely. 3. Add 0.25 mL (4.4 mmol) anhydrous ethylene glycol and continue stirring another 20 min at room temperature. 4. Concentrate the reaction mixture by evaporating off the solvent. 5. Redissolve the residue in 50 mL chloroform and transfer to a 250-mL separatory funnel. Nucleoside Phosphoramidites Containing Cleavable Linkers
6. Wash the chloroform solution with 50 mL water, 50 mL saturated aqueous NaCl solution, and then 50 mL water again.
3.12.8 Supplement 23
Current Protocols in Nucleic Acid Chemistry
7. Concentrate the crude material to a thick oil and then purify by flash chromatography on silica gel using 0% to 5% (v/v) methanol/chloroform (first 0%, then 2.5%, and finally 5%). 8. Monitor by TLC using 5% methanol/chloroform. Combine fractions containing the pure material S.15 (Rf = 0.40) and evaporate to dryness to form a foam. Expected yield: 70%–80%. Nucleosides S.15a-d are converted into phosphoramidites S.16a-d as described in Basic Protocol 1 for conversion of S.12 to S.4. TLC solvents and Rf values for S.16a-d are the same as for S.4a-d.
OLIGONUCLEOTIDE SYNTHESIS IN MULTI-WELL PLATES ON UNDERIVATIZED LCAA-CPG SUPPORTS
BASIC PROTOCOL 2
This protocol describes the synthesis of oligonucleotides in 96-well synthesis plates using an underivatized LCAA-CPG support instead of diol-based universal supports (S.2; Fig. 3.12.1). This protocol was developed using a MerMade 192 synthesizer (BioAutomation) equipped with ten phosphoramidite ports (A, C, G, T, and six additional positions). Other synthesizers can be similarly used, as long as there are sufficient phosphoramidite ports to accommodate four regular phosphoramidites and four linker phosphoramidites. A four-column ABI 394 synthesizer (Applied Biosystems) equipped with eight phosphoramidite ports has also been used successfully, especially when performing tandem oligonucleotide synthesis (see Basic Protocol 3). With this column-based instrument, empty plastic synthesis columns are used instead of 96-well plates to hold the LCAACPG support.
Materials Linker phosphoramidite reagents: S.4a-d (see Basic Protocol 1) or S.16a-d (see Alternate Protocol) Anhydrous acetonitrile Reagents for oligonucleotide synthesis: conventional 3 -O-phosphoramidites activator, deprotection, oxidizing, and capping solutions (APPENDIX 3C) Long-chain alkylamine controlled-pore glass (LCAA-CPG) support, ∼100 µmol/g ◦ amino group loading, 500 A pore size (S.5) 1:1 (v/v) ammonium hydroxide/40% (w/v) aqueous methylamine Automated DNA synthesizer for multi-well plates, with at least 8 monomer ports (e.g., MerMade 192 synthesizer, BioAutomation) 96-well Oro-Flex OF1100 polypropylene filter plate (0.7-mL wells; Orochem Technologies) with 96-well collection plate (1-mL wells) Centrifuge with 96-well plate adapters Clamping apparatus for multi-well plates (as recommended by synthesizer manufacturer) 65◦ C oven Centrifugal evaporator (e.g., Speedvac, Savant) that can accommodate 96-well plates Additional reagents and equipment for oligonucleotide synthesis (APPENDIX 3C) and for “dry” loading of the support (see Support Protocol) Set up and run synthesizer 1. Prepare solutions of the linker phosphoramidites S.4a-d or S.16a-d at the desired concentration (0.025 to 0.1 M) in anhydrous acetonitrile and install on unused phosphoramidite ports on the synthesizer (i.e., ports 5 to 8). See Commentary for guidelines in selecting the concentration to use.
Synthesis of Unmodified Oligonucleotides
3.12.9 Current Protocols in Nucleic Acid Chemistry
Supplement 23
2. Install sufficient amounts of the four regular 3 -O-phosphoramidites S.1a-d (ports 1 to 4), and activator, deprotection, oxidizing, capping, and wash solutions for the number and length of oligonucleotides being made. These reagents are exactly the same as required for conventional synthesis.
3. Create an electronic file of the oligonucleotide sequences to be made according to the particular synthesizer’s specifications. For the MerMade 192 synthesizer, create a simple text file with each line containing a sequence name, a comma or tab delimiter, and the desired sequence in the 5 -to-3 orientation. Modify the 3 -terminal nucleoside in each sequence to reflect the phosphoramidite port used for the corresponding linker phosphoramidite. For example, if the adenosine linker phosphoramidite (S.4a or S.16a) is installed on port 5, modify all sequences ending in “A” to a text string ending with “5”: AAGGCCTT5 instead of AAGGCCTTA. The substitution of the last base by the linker phosphoramidite port position is best done by creating a software routine. This can be done through a short custom program or by using a combination of the MID, IF, and CONCATENATE (&) functions in an Excel spreadsheet as shown by the following formula. =MID(cell ref, 1, LEN(cell ref)-1) & IF(MID(cell ref, LEN(cell ref), 1)="A", "5", IF(MID(cell ref, LEN(cell ref), 1)="C", "6", IF(MID(cell ref, LEN(cell ref), 1)="G", "7", IF(MID(cell ref, LEN(cell ref), 1)="T", "8", "- Error")))) This formula uses the parameter cell ref to denote the Excel spreadsheet cell location of the oligonucleotide sequence. The expression "MID(cell ref, 1, LEN(cell ref)-1)" extracts all of the sequence except for the last character, and the "&" operator concatenates a new character representing the ports for the corresponding linker phosphoramidites. This is determined by using "MID(cell ref, LEN(cell ref), 1)" to extract the last character of the sequence and a series of embedded "IF" functions to see if the last character is A, C, G, or T (case insensitive). When a match is found, the expression substitutes a value of 5, 6, 7, or 8, respectively (these values may be changed as required) as the last character in the sequence. If the sequence does not end in one of the four standard bases, the suffix “-Error” will be attached.
4. Using one of the “dry” loading methods described below (see Support Protocol), load LCAA-CPG into an OF1100 filter plate at ∼2 to 10 mg/well (depending upon the synthesis scale). Gently tap or briefly centrifuge the plate to bring down any CPG particles sticking to the sides of the wells. Install the plate in the synthesizer. If recommended by the instrument’s manufacturer, seal any unused synthesis wells. 5. Select the appropriate software option for universal supports (first coupling cycle begins with the 3 -terminal base) instead of conventional or prederivatized supports (first coupling cycle begins with the penultimate base from the 3 -end). This option is available on the MerMade 192. On some older instruments, such as the ABI 394, an additional “fake” base must be added to the 3 -end of each oligonucleotide, since the instrument always assumes the last nucleoside is already attached to the support. Such instruments were either developed before universal supports were available or their manufacturer did not include support for universal supports.
6. Prime the reagents and start the synthesizer, as per the manufacturer’s instructions.
Cleave and deprotect oligonucleotides 7. Remove the OF1100 filter plate from the synthesizer and transfer to a fume hood. Nucleoside Phosphoramidites Containing Cleavable Linkers
8. Place a 96 × 1-mL multi-well collection plate under the OF1100 filter plate. Add 120 µL of 1:1 (v/v) ammonium hydroxide/40% (w/v) aqueous methylamine solution to each well of the filter plate. Wait ∼5 min.
3.12.10 Supplement 23
Current Protocols in Nucleic Acid Chemistry
9. Add another 120-µL portion of ammonium hydroxide/methylamine solution to each well. Wait another 2 min. Deprotection with methylamine can only be performed if all of the cytosine bases are protected with N-acetyl protecting groups. If cytosine bases with N-benzoyl protecting groups are present, ammonium hydroxide without methylamine must be used (see APPENDIX 3C, deprotection of DNA oligonucleotides).
10. Transfer any remaining solution through the filter plate into the collection plate by briefly centrifuging (∼2 min at 12.6 × g or less) or applying vacuum (∼10 sec). When using a vacuum manifold, be careful not to remove too much of the volatile ammonia and methylamine, as complete deprotection may not occur.
11. Seal the plate tightly using the clamping apparatus recommended by the synthesizer manufacturer. Place in a preheated oven (65◦ C) and leave for 15 to 30 min. 12. Place the unopened plate assembly on ice until cooled to below room temperature (∼5 min). CAUTION: Do not attempt to open the collection plate while it is still warm. The wells are under pressure, and eye injury, cross-contamination, and loss of samples may result if the cover is removed without adequate cooling.
13. Place the collection plate in a centrifugal evaporator such as a Speedvac and evaporate off the methylamine and ammonia (∼1 hr). The residual aqueous solution containing the crude deprotected oligonucleotide product is ready for desalting or further purification (see Chapter 10).
DRY LOADING OF CPG SUPPORT INTO 96-WELL PLATES Adding the correct amount of each support to each synthesis well in a 96-well plate can be a tedious and error-prone task. This task is greatly simplified when a single universal support is used in every well. Originally, a suspension of CPG in a mixture of organic solvent blended to approximately the same density as the CPG beads (“wet” method) was used to transfer the CPG into each well (Lashkari et al., 1995; Cheng et al., 2002). However, this method is inconvenient and difficult to perform by hand, because the beads rapidly settle out of suspension and the solvent fumes are annoying. The wet method
Figure 3.12.4 Pipetter device for dry loading CPG into 96-well plates. An electric Pipet-Aid filler/dispenser is fitted with a 100-µL filter-type micropipet tip whose length is cut to deliver the required volume of CPG. A 1000-µL pipet tip is used to connect the 100-µL tip to the pipetter.
SUPPORT PROTOCOL
Synthesis of Unmodified Oligonucleotides
3.12.11 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Nucleoside Phosphoramidites Containing Cleavable Linkers
3.12.12 Supplement 23
Figure 3.12.5 Sliding dispenser for dry loading CPG into 96-well plates. This dispenser can be constructed from Plexiglas in any machine shop. The dimensions of the body are 45 mm × 55 mm × 18 mm (width by length by thickness) and the movable slide is 19 mm × 110 mm (width by length), with the portion between the stops machined to the exact thickness of the groove in which it slides. The distance between the fill and dispense holes is 20 mm. The amount (volume) of CPG dispensed depends upon the thickness of the slider and the diameter of the hole drilled into it. The bottom face of the dispenser contains nine wells drilled (∼1.5 mm deep) to align with the spacing of the synthesis plate being used. The authors thank Dr. John Hobbs, University of British Columbia, for suggesting the design of the sliding dispenser. Current Protocols in Nucleic Acid Chemistry
can be automated, but this requires a very expensive robotic or 96-tip multiple pipeting station (Rayner et al., 1998), which is difficult to justify when synthesizing only one or two plates per day. Instead, the CPG can be handled as a dry powder (“dry” method) using one of the two devices described below. In Figure 3.12.4, a simple and commonly available 100-µL pipet tip containing a filter (filter tip) is trimmed to hold a specific volume of CPG. The tip is then attached to an electric pipetting aid capable of applying either vacuum or mild air pressure. The pipet is inserted into a vial of CPG, the vacuum is applied to suck the beads into the tip, the tip is immediately placed in the synthesis well, and the beads are dispensed by switching from vacuum to air pressure. The amount of beads dispensed is determined by the length of the trimmed pipet tip. A tip of ∼0.5 cm will hold ∼2 to 3 mg support, which is suitable for ∼50 to 100 nmol-scale syntheses. Tips can be easily calibrated by dispensing the CPG onto an analytical balance. In Figure 3.12.5, a sliding dispenser for CPG is shown, which can be assembled from Plexiglas in most machine shops. This device has two advantages over the filter tip method. First, operation of the dispenser is faster because the dispenser has a built-in CPG reservoir and because the bottom is indexed for quick alignment with each well. Second, the dispenser can be built to dispense greater amounts of CPG than the filter tips. The dimensions of the loader and the slider are generally not critical, although the movable center “slider” should be machined to an exact thickness and flatness to prevent CPG beads from being jammed between the pieces. The volume of the hole drilled into the slider determines the amount of CPG to be dispensed. Either the thickness of the slider or the diameter of the hole can be adjusted. A slider that is 0.125 in. (∼3 mm) thick with a 5/32-in.-diameter (∼4 mm) hole will dispense ∼10 mg of CPG. To use the sliding dispenser, a polypropylene micro funnel (Aldrich) is inserted into the top port of the dispenser and filled with CPG. When the center slider is in the “fill” position, CPG will fall from the funnel into the slider and fill the cavity. The dispenser is then fitted over the well and the slider is pushed to the “dispense” position, which allows the CPG to fall into the well. The dispenser is moved to the next well and the slide is moved back and forth between the fill and dispense positions once more. By repeating this process, a 96-well plate can be filled with support quite quickly.
TANDEM SYNTHESIS OF MULTIPLE OLIGONUCLEOTIDES IN A SINGLE SYNTHESIS
BASIC PROTOCOL 3
This protocol describes how to attach an additional oligonucleotide sequence onto the 5 -end of another oligonucleotide by use of the S.4 linker phosphoramidites. This allows strings of oligonucleotides, linked end-to-end in tandem, to be synthesized in a single automated synthesis (Pon et al., 2002; Pon and Yu, 2005). The linkages between the oligonucleotides are simultaneously cleaved during cleavage from the support, so that the product is released as a mixture of oligonucleotides. This method eliminates the need to separately synthesize and deprotect each individual oligonucleotide before combining them into a desired mixture. It is useful for making pairs of PCR primers, sets of multiplexed primers, and double-stranded sequences, and for increasing the yield of a single sequence by making multiple copies simultaneously. It can also be combined with Basic Protocol 2 to perform tandem syntheses in a multi-well plate format. Tandem oligonucleotide synthesis should only be performed using the S.4 linker phosphoramidites, which contain the sulfonyldiethanol group. During cleavage, these residues undergo β-elimination to leave a monophosphate group on the support (S.20; Fig. 3.12.6B) and on the 5 -terminus of oligonucleotides synthesized in tandem
Synthesis of Unmodified Oligonucleotides
Current Protocols in Nucleic Acid Chemistry
Supplement 23
3.12.13
Figure 3.12.6 Cleavage mechanisms for linker phosphoramidites. (A) The linkage S.17 formed by coupling S.16 to LCAA-CPG is hydrolyzed at the succinyl ester groups to yield oligonucleotide S.7 with a 3 -OH end and the support S.18 with a phosphoroamidate monoester. (B) The linkage S.19 formed by coupling S.4 to LCAA-CPG undergoes rapid β-elimination from the sulfonyldiethanol group to release a 3 -succinylated oligonucleotide from the support. During base deprotection, simultaneous hydrolysis at the 3 -ester position generates oligonucleotide S.7 with a 3 -OH end. A phosphoramidate group is left behind on the support. (C) The linkage S.21 connects two oligonucleotides synthesized in tandem using S.4. It undergoes β-elimination and ester hydrolysis to leave a 5 -monophosphate on oligonucleotide 1 (S.23) and a 3 -OH on oligonucleotide 2 (S.22). Nucleoside Phosphoramidites Containing Cleavable Linkers
3.12.14 Supplement 23
Current Protocols in Nucleic Acid Chemistry
(S.23; Fig. 3.12.6C). In contrast, the alternative diol spacers in the S.16 phosphoramidites leave behind an unnatural 5 -alkyl phosphate group (S.18; Fig. 3.12.6A). These residues are harmless for attaching the first oligonucleotide to a support, because the alkyl phosphate group is discarded with the used support. In a tandem synthesis, however, the alkyl phosphate group will remain on the oligonucleotides.
Materials Linker phosphoramidites (S.4a-d; see Basic Protocol 1) Anhydrous acetonitrile Solid support: For column format: prepacked synthesis columns containing prederivatized solid-phase support For plate format: long-chain alkylamine controlled-pore glass (LCAA-CPG; ◦ S.5), ∼100 µmol/g amino group loading, 500 A pore size NAP-10 (prepacked Sephadex) column Additional reagents and equipment for oligonucleotide synthesis (APPENDIX 3C and Basic Protocol 2) 1. Prepare a 0.1 M solution of the required linker phosphoramidites S.4a-d in anhydrous acetonitrile. Install these on unused phosphoramidite ports on the synthesizer (i.e., ports 5 to 8). 2. Create an oligonucleotide sequence file by combining all of the sequences into a single text string. a. For underivatized LCAA-CPG supports: Modify the terminal 3 -position of each oligonucleotide sequence so that it corresponds to the desired linker phosphoramidite (see Basic Protocol 2, steps 3 to 5). b. For prepacked synthesis columns containing prederivatized supports: Substitute only the 3 -position of each additional oligonucleotide by a linker phosphoramidite reagent. For example, to synthesize the two 12-mer sequences 5 -AAA AAA AAA AAA-3 and 5 -TTT TTT TTT TTT-3 using a prepacked T-derivatized solid support, with linker phosphoramidite S.4a installed on phosphoramidite port 5, program the synthesizer to make AAA AAA AAA AA5 TTT TTT TTT TTT in a single automated synthesis. To perform the same synthesis on underivatized LCAA-CPG, with S.4d on port 6, program the synthesizer to make AAA AAA AAA AA5 TTT TTT TTT TT6.
3. Perform the automated synthesis, cleavage from the support, and deprotection steps in the usual fashion. Either ammonium hydroxide or ammonium hydroxide/methylamine deprotection protocols can be used. No other modifications to procedures are required.
4. Evaporate off the ammonium hydroxide or methylamine reagent, redissolve in 1 mL water, and desalt on a NAP-10 (prepacked Sephadex) column. The desalted product will be a mixture of each oligonucleotide sequence as well as all of the failure sequences normally produced (N–1, N–2, and so on). If the synthesis was successful and the high coupling yields typically expected (98% to >99%) were obtained, the product mixture is satisfactory for use in most applications. Purification of each individual component from this mixture is not recommended unless the tandem synthesis was performed to make multiple copies of a single sequence.
Synthesis of Unmodified Oligonucleotides
3.12.15 Current Protocols in Nucleic Acid Chemistry
Supplement 23
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Triethylammonium phosphate (TEAP) solution, 2 M In a chemical fume hood, set up a large (2- to 4-liter) beaker in an ice bath on top of a magnetic stirrer. Add 892 ml water and begin stirring. Carefully add 272 ml of 85% (w/v) aqueous phosphoric acid under continued stirring. Carefully add 836 ml triethylamine with continued stirring. The majority of the triethylamine will float on top of the aqueous solution. Stir the mixture in the ice bath until it forms a homogeneous solution (∼2 hr). Allow to warm to room temperature and then transfer to a sealed bottle for storage (stable for a year or more). Before use, dilute the 2 M stock solution to ∼0.5 M with distilled water. CAUTION: Eye and skin protection are required when handling 85% phosphoric acid, as it is a strong acid.
COMMENTARY Background Information The need for large numbers of oligonucleotides in a wide variety of applications has encouraged various means to reduce the cost of their production. In particular, development of highly parallel synthesis instruments using 96-, 384-, and 1536-well synthesis plates (Lashkari et al., 1995; Sindelar and Jaklevic, 1995; Brennan et al., 1998; Rayner et al., 1998; Cheng et al., 2002) has reduced the cost of labor, and reductions in synthesis scale have reduced reagent costs. Nonetheless, there is a continuing need to reduce costs by decreasing both the time and materials involved. This unit describes methods for doing so via two approaches.
Nucleoside Phosphoramidites Containing Cleavable Linkers
Universal supports Originally, solid-phase oligonucleotide synthesis began with the first nucleoside already attached to the solid-phase support, which is prepackaged into ready-to-use synthesis columns. Since there are only four common deoxyribonucleosides, it was not difficult to produce and maintain inventories of separate columns for each base. However, when multi-well plates are used, the process of placing the correct support into the correct position on each plate becomes quite tedious and errorprone. This difficulty spurred the search for a single universal support that could be used for any oligonucleotide sequence, so that all wells could be preloaded with a single material. The problem with this approach, however, is that the phosphoramidite reagents (S.1) used to synthesize the oligonucleotides would begin each oligonucleotide with a 3 -terminal phosphate group. This phosphate group inter-
feres with biological activity, since the natural configuration produced by enzymatic activity has 5 -phosphate and 3 -OH termini, not 5 -OH and 3 -phosphates. Fortunately, the linkage to a 3 -terminal monophosphate group can be cleaved if a cyclic phosphodiester configuration can be formed, as exemplified by RNA hydrolysis. A large number of different universal supports employing some type of diol-based configuration has been developed. Unfortunately, the dephosphorylation step required after synthesis on the first generation of these supports was slow, and prolonged conditions (longer times and higher temperatures) or additions of various metal salts were required (Debear et al., 1987; Scott et al., 1994; Schwartz et al., 1995; Nelson et al., 1997; Scheuerlarsen et al., 1997; Azhayev, 1999; Lyttle et al., 1999). Otherwise, the desired 3 -OH product was contaminated with the unwanted 3 -phosphorylated products. Recently, a second generation of improved universal supports has been developed (Azhayev and Antopolsky, 2001; Guzaev and Manoharan, 2003). These are superior to the first generation supports because the universal linker is designed to retain phosphorylated oligonucleotides and only release products with the desired 3 -OH ends. However, these supports still require some modification to the conventional cleavage and deprotection conditions, i.e., the use of dilute methanolic ammonia instead of concentrated aqueous ammonium hydroxide, and any material not released from the support reduces the recovered yield. To approach this problem from a different perspective, modified linker phosphoramidites
3.12.16 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Figure 3.12.7 Chemical 5 -phosphorylation using a commercially available 2,2 -sulfonyldiethanol-containing phosphoramidite S.25.
have been designed with an easily cleavable linker between the protected nucleoside and the phosphoramidite group. The first compounds used a succinyl-ethylene glycol combined linker (S.16; Fig. 3.12.3; Pon and Yu, 2001), but an improved reagent based on a succinyl-sulfonyldiethanol combination was eventually developed (S.4; Fig. 3.12.2; Pon and Yu, 2004). In both cases, the ester linkage on the 3 -position is identical to the succinyl ester attachment widely used to link nucleosides to prederivatized solid-phase supports. Thus, cleavage from the support can be done by standard methods, producing only S.7 with the desired 3 -OH groups (Fig. 3.12.6A and B). The phosphoramidate residues left behind (S.18 and S.20) remain attached to the support and are discarded with the used support. A major advantage to this approach is that underivatized amino supports, such as the widely used long-chain alkylamine controlledpore glass (LCAA-CPG) becomes a universal support (Fig. 3.12.1B; Pon et al., 1988). This material is much less expensive than other universal supports because a special linker arm does not have to be synthesized and attached to the support. Although, the phosphoramidate bond formed by attachment
of the linker phosphoramidite to the support in S.17 and S.19 is slightly different from the usual phosphate linkage, the P-N phosphoramidate linkage is completely stable to the conditions of oligonucleotide synthesis. Similar internucleotide phosphoramidate P-N bonds have been reported in the synthesis of various antisense oligonucleotides (Mag and Engels, 1989; Gryaznov and Letsinger, 1992). Substitution of the ethylene glycol group in S.16 with a 2,2 -sulfonyldiethanol group provides an improved linker phosphoramidite (S.4) because a second cleavage site is introduced. The sulfonyldiethanol group undergoes a β-elimination, very similar to the βelimination mechanism used to remove the 2cyanoethyl protecting groups from phosphate linkages. This facile deprotection to yield a free phosphoric acid group has been widely utilized to produce 5 -monophosphorylated oligonucleotides (Horn and Urdea, 1986) through use of the commercially available reagent S.25 (Fig. 3.12.7; Applied Biosystems, Glen Research, Chemgenes, or any supplier of phosphoramidites). Phosphoramidite S.25 has been used occasionally to initiate oligonucleotide synthesis on solid-phase supports (Gryaznov and Letsinger, 1993) and
Synthesis of Unmodified Oligonucleotides
3.12.17 Current Protocols in Nucleic Acid Chemistry
Supplement 23
on glass (Glazer et al., 2001) or polypropylene (Shchepinov et al., 1997) microarrays when synthesis of 3 -terminally phosphorylated products is acceptable. The identical βelimination mechanism results in the release of the oligonucleotide from the support when either S.25 or S.4 are used. In linker phosphoramidite S.4, βelimination and hydrolysis under basic conditions provides two advantages. First, the rapid β-elimination releases the product from the support after only a short treatment (5 min) with aqueous ammonium hydroxide (Fig. 3.12.6B and C). This is much faster than the 1 to 2 hr required to cleave a succinic acid linkage (Pon and Yu, 1997). The faster release time is especially convenient when deprotection is performed manually (as is the case for most 96-well plate syntheses). The slower hydrolysis of the 3 -O-succinyl ester occurs off the support at the same time as base deprotection. Second, β-elimination of S.4 generates a phosphate group on whatever S.4 has been attached to (Fig. 3.12.6C). This formation of both 3 -OH and 5 -monophosphate groups at the junction where S.4 is used is critical when more than one oligonucleotide sequence or copy is produced through tandem synthesis.
Nucleoside Phosphoramidites Containing Cleavable Linkers
Tandem oligonucleotide synthesis Tandem oligonucleotide synthesis was originally reported in 1994 when a special phosphoramidite for preparing “two oligonucleotides per synthesis” (TOPS) was described (Hardy et al., 1994). This linking phosphoramidite contained a pair of 1,4anhydroerythritol rings that resembled the diol linker arm on a universal support. However, instead of being the starting point for a single oligonucleotide, it was used to synthesize a second oligonucleotide on the 5 -end of a preceding sequence. Unfortunately, just like the first generation universal supports, this reagent required harsher deprotection conditions to remove the 3 -phosphate group from the second oligonucleotide. Two improved schemes for tandem oligonucleotide synthesis have eliminated the difficult dephosphorylation step. In the first approach, the introduction of a 3 phosphate group was avoided by not using phosphoramidite coupling chemistry to begin the second or subsequent oligonucleotides. Instead, reagents such as HATU, HBTU, or HCTU are used in combination with 4-dimethylaminopyridine to couple the nucleoside-3 -O-hemiesters of either succinic
or hydroquinone-O,O -diacetic acid onto the 5 -end of a support-bound oligonucleotide (Pon et al., 2002). This coupling procedure was found to be very rapid and suitable for automation in the development of a method for reusing solid-phase supports (Pon et al., 2001). However, this method was difficult to implement because it required an automated synthesizer that had five additional reagent positions (for four nucleoside hemiesters and an additional coupling reagent). Because not many instruments at that time had such capacity, the tandem synthesis method using linker phosphoramidite reagents was developed. This method is described in this unit. The linker phosphoramidite S.4 has been quite suitable for tandem oligonucleotide synthesis. It has been used to produce a variety of oligonucleotides for situations in which it is advantageous to synthesize an oligonucleotide mixture in a single synthesis, rather than performing multiple syntheses (and their associated deprotection and workup steps) before combining the products for use. Figure 3.12.8 illustrates how a set of linker phosphoramidites can be used to assemble a string of oligonucleotides, linked end-to-end in tandem, on the surface of a support. Examples of these applications include pairs of PCR primers, complementary sequences that spontaneously base-pair into double-stranded sequences upon deprotection, and single oligonucleotides when synthesis of multiple tandem copies is used to increase the amount of sequence produced by any single synthesis column. This latter application is potentially useful for the large-scale synthesis of pharmaceutical oligonucleotides. What is unique about this approach is that the phosphate group arising from the linker phosphoramidite is transferred onto the 5 position of the preceding oligonucleotide. This is different from the 3 -phosphate that occurs if a conventional phosphoramidite (S.1) is used, in that no difficult 3 -dephosphorylation steps are needed. Although, 5 -phosphorylated oligonucleotides are not as widely used as 5 OH oligonucleotides, they more closely resemble the biological products created by enzymes. Thus, the 5 -phosphate groups do not interfere with the oligonucleotide’s use in the same way 3 -phosphate groups do.
Critical Parameters As with any oligonucleotide synthesis or organic synthesis involving moisture-sensitive reactions, good results depend upon the successful exclusion of moisture. Methods
3.12.18 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Figure 3.12.8 Synthetic scheme showing the tandem synthesis of multiple oligonucleotides in a single automated synthesis. Linker phosphoramidite reagent S.4 is used to begin each new oligonucleotide sequence on the 5 -OH end of a preceding sequence. After N rounds of linker phosphoramidite addition and oligonucleotide synthesis, a string of oligonucleotides linked end-to-end on the surface of the support is obtained (S.31). Treatment with ammonium hydroxide simultaneously cleaves the linker joining the string to the support and each linker joining two oligonucleotides together. The product released contains a mixture of the final oligonucleotide (S.32) with both 5 -OH and 3 -OH ends, and all preceding oligonucleotides (S.33 and S.34) with 5 -monophosphate and 3 -OH ends. If desired, product S.32 can also be obtained as a 5 -monophosphate by using the phosphorylating reagent S.25 in the last coupling cycle.
for maintaining these conditions and evaluating oligonucleotide quality are described in APPENDIX 3C. This section will concentrate on other parameters that are critical to oligonucleotide syntheses as outlined in Basic Protocols 2 and 3. When using linker phosphoramidites S.4 or S.16 to make oligonucleotides on LCAACPG, the two main parameters to consider are the age of the solutions and the amount of reagent to add. Due to the labile sulfonyldiethanol group, solutions of linker phosphoramidites should be used as quickly as possible. When the linker phosphoramidite decomposes, there is less phosphoramidite present to couple to the support, and a reduced nucleoside loading occurs. Since this is used at the start of synthesis, a coupling de-
crease in the first coupling cycle will reduce the amount of any subsequent oligonucleotide. Solutions of S.4a-b and S.4d lead to an ∼10% to 20% decrease in the amount oligonucleotide recovered when they have been in solution at room temperature for two weeks. Thus, it is recommended that these solutions be used within 1 to 2 weeks of preparation. The linker phosphoramidite reagents with the least stability are the guanine derivatives S.4c and S.16c. These solutions should be used within 3 to 5 days of preparation. The synthesis scale (amount of oligonucleotide produced) depends upon a number of factors. These are related to both the solidphase support used and the linker phosphoramidite. For the support, the key factor is the number of amino groups available to react with
Synthesis of Unmodified Oligonucleotides
3.12.19 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Nucleoside Phosphoramidites Containing Cleavable Linkers
the linker phosphoramidite. This is affected by the amino group loading, the pore size (which affects accessibility to the bulky phosphoramidite reagent), and the mass of support used. For the linker phosphoramidite, it is the concentration and amount of reagent added. The effect of these parameters is discussed in greater detail in Pon and Yu (2004). In summary, CPG supports with amino group loadings of ∼100 µmol/g are recommended, with ◦ an average pore size of not less than 500 A. Only about one-half of the amino groups specified by the manufacturer are actually accessible for oligonucleotide synthesis, but this is the case for both prederivatization protocols and this universal protocol. Presumably, this is because there are pores that are too small to be accessible to phosphoramidite reagents, but are still titratable in the manufacturer’s loading determination. The pore size of CPG particles also affects their density,◦ and CPG particles with an average 1000 A pore size are light enough to be knocked out of the wells in 96-well synthesis plates. For synthesis on the ◦ MerMade 192, the heavier 500 A CPG, which remains in the wells, is therefore preferred. However, because of the smaller pore volume, the maximum oligonucleotide length is limited to ∼50 bases. The mass of CPG beads in each synthesis is another obvious factor controlling the scale, and increasing the mass of beads is the easiest way to increase synthesis scale. The amount of CPG used in each well of a 96-well synthesis plate can be increased from ∼1 or 2 mg to ∼10 mg without producing any affect on oligonucleotide quality or increasing the consumption of reagents. This is because the minimum volume usually dispensed by these synthesizers (∼20 to 25 µL) is still sufficient to completely cover the increased mass of support. Generally, ∼2 mg of◦CPG (∼100 µmol/g of NH2 groups with 500 A pores) can be used for synthesis on an ∼40-nmol scale, and 10 mg of CPG can be used for a 200-nmol scale. Because linker phosphoramidites S.4 and S.16 behave very similarly to conventional phosphoramidites, the coupling time and activation do not need to be modified. Typical conditions are 0.25 M 5-ethylthiotetrazole in acetonitrile as the activating reagent (mixed 1:1 v/v with the phosphoramidites at the time of coupling) and a coupling time of 60 sec. However, unlike conventional phosphoramidites, which require the highest possible coupling yields, addition of linker phosphoramidites does not have to be quantitative, i.e., coupling to 100% of the amino groups on the CPG is not required. Instead, the amount of cou-
pling can be adjusted to provide the synthesis scale desired. Any unreacted amino groups are acylated in the next capping step. It is recommended that the volume of linker phosphoramidite be reduced to either the minimum amount required to just cover the CPG or the minimum amount that can be reliably dispensed, since adding additional volume has little benefit. The concentration of the linker phosphoramidite is a much more important parameter. A concentration of 0.1 M (the concentration at which S.1 is typically used) is probably the maximum that needs be considered. Concentrations of 0.15 and 0.2 M only produce slightly higher synthesis scales, and then only when supports with very high loadings (>100 µmol/g) are employed. Lower concentrations, such as 0.05 or 0.025 M, can be considered, especially when only small-scale syntheses are required. Thus, linker phosphoramidite consumption can be significantly reduced. Compared to synthesis with 0.1 M linker phosphoramidite, synthesis with 0.025 and 0.05 M solutions will yield approximately one-third to two-thirds the amount of crude product. The oligonucleotide quality is unaffected by the reduction in yield of the first coupling step, and the decreased amount of material is still more than adequate for most applications. The synthesis of multiple oligonucleotides by tandem synthesis is very similar to the synthesis of a single oligonucleotide, but there are additional factors that must be considered. These relate to the maximum length of the string of tandem-linked oligonucleotides, the difference between the 5 -OH end of the last sequence and the 5 -phosphorylated end(s) of the preceding sequence(s), and the yield reduction that occurs with each subsequent tandem oligonucleotide. First, the number of tandem oligonucleotides that can be prepared in a single synthesis is limited by the same factors limiting the length of any single oligonucleotide. Thus, the average coupling efficiency (Zhou et al., 2004), detritylation efficiency (Habus and Agrawal, 1994; Paul and Royappa, 1996), depurination during detritylation (Septak, 1996), and limitations of the support’s pore volume (Efcavitch et al., 1986) limit the total number of couplings that can be performed. With good reagents, properly functioning instrumentation, and long-mer oligonucleotide synthesis protocols, it is possible to routinely synthesize single oligonucleotides of up to 120 to 150 bases (for further guidelines on synthesis of long
3.12.20 Supplement 23
Current Protocols in Nucleic Acid Chemistry
oligonucleotides, see discussion in APPENDIX 3C). This length is more than sufficient to accommodate the tandem synthesis of a pair of typical PCR primers. In Pon and Yu (2005), the tandem synthesis of a string of multiple oligonucleotides totaling up to 120 bases showed that oligonucleotide quality was very similar to that obtained by conventional syn◦ thesis. In that case, a wide-pore 1000 A CPG support with a reduced loading (10 µmol/g) was employed, and a milder 2% (v/v) solution of 1, 2-dichloroacetic acid was substituted for the 5% (v/v) solution regularly used. Second, as described in Background Information and illustrated in Figure 3.12.8, tandem oligonucleotide synthesis introduces a phosphate group onto the 5 -end of all but the final oligonucleotide. While this is not expected to have any adverse effects, it does limit the introduction of 5 -modifications such as fluorescent dyes or other labels. In this case, the 5 -modification can only be introduced onto the last oligonucleotide made, which has a 5 OH end. Finally, because automated oligonucleotide synthesis proceeds in a step-wise manner, the overall yield is highly dependent upon the coupling efficiency of every phosphoramidite addition. For the synthesis of single oligonucleotides, this dependence can be expressed by the equation:
where OY is overall yield, AY is average coupling yield, and N is oligonucleotide length. When tandem oligonucleotides are produced, the amount of each subsequent oligonucleotide can only be as much as the number of available 5 -ends of the preceding sequence (as defined by the above equation). Consequently, the amount of each oligonucleotide made in tandem will always be less than the amount of the preceding oligonucleotide. Fortunately, for most biological applications such as PCR primers, it is not critical to have both primers in an exact 1:1 proportion. Also, most applications are relatively insensitive to the small amounts of shorter failure sequences present in crude oligonucleotide preparations. Therefore, the crude products of tandem syntheses can be used without extensive purification or adjustment of the component proportions. Simple desalting of the crude tandem products on a Sephadex column is usually sufficient to remove low-molecular-weight impurities.
For large-scale oligonucleotide syntheses, tandem synthesis can be used to make multiple copies of the same sequence. This increases the amount of oligonucleotide that can be obtained from any individual synthesis column. Since the support is the single most expensive material in large-scale synthesis, strategies that either reuse the support or produce more material from a single synthesis are quite desirable. In the case of tandem synthesis, the amount of material produced is expressed by:
or
where M is the number of tandem oligonucleotides in the string being synthesized. Since the amount of material obtained decreases with each additional copy made in tandem, while the reagent consumption for each coupling step remains fixed, there is a diminishing economic return with each additional tandem synthesis. However, given the high cost of support and the high coupling efficiencies routinely obtained by commercial large-scale production facilities, making at least one extra copy in tandem is still beneficial. One possible difficulty with performing tandem oligonucleotide synthesis is the purification and analysis of the product mixture. Purification and isolation of individual products is not recommended when different sequences are made by tandem synthesis, especially when the products are of similar size, because similarly sized sequences may be impossible to resolve. However, purification and analysis of multiple copies of the same sequence is very similar to conventional analysis, especially if the last oligonucleotide in the tandem string is phosphorylated by reagent S.25 to match the other copies.
Troubleshooting Basic Protocol 1 and the Alternate Protocol both require some experience in organic synthesis. In particular, the reactions are sensitive to moisture contamination, and precaution must be taken to keep the anhydrous solvents and the sensitive reagents (i.e., HBTU, S.13, and S.14) dry. Each synthetic step should be monitored by TLC, including a sample of the starting material with the reaction mixture so
Synthesis of Unmodified Oligonucleotides
3.12.21 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Nucleoside Phosphoramidites Containing Cleavable Linkers
that their mobilities can be compared. Each step results in a significant mobility change, so identification of the reaction progress is straightforward. Basic Protocol 2 should also be straightforward to perform as long as the precautions for programming the synthesizer (as described in the protocol) and selecting the appropriate amounts of CPG and linker phosphoramidite (see Critical Parameters) are observed. It is essential that the correct parameter for the support type (universal support, not conventional support) be selected, and that the synthesis cycle not begin with a capping step. If an error is made in the first case, a linker phosphoramidite will not be used to start the synthesis and the resulting oligonucleotide will be one base short and irreversibly attached to the support through a phosphoramidate linkage. An error in the second case will cause the amino groups on the support surface to be acetylated before they can react with the linker phosphoramidite, so that no oligonucleotide synthesis can occur. If spare phosphoramidite ports are being used for the first time, one must also ensure that the injectors are properly calibrated and the synthesis scripts, cycles, and reagent files controlling the synthesizer are appropriately modified. Finally, all products should be quantitated by UV absorbance at 260 nm to ensure that the syntheses are proceeding satisfactorily and at the desired scale. Basic Protocol 3 is sensitive to the efficiency of the linker phosphoramidite coupling. If the amounts of additional oligonucleotides made in tandem seem lower than expected, the coupling efficiency of the linker phosphoramidite needs to be verified. The easiest way to do this is through collection of the trityl colors produced from coupling the 5 terminal base and the subsequent linker phosphoramidite (APPENDIX 3C for the trityl assay). The coupling yield of this step should be at least 75%, with more typical yields of 90% to 98%. Low yields may be caused by moisture contamination of the reagents, linker phosphoramidite decomposition (see Critical Parameters), or inadequate reagent delivery by the synthesizer. It is also difficult, if not impossible, to resolve oligonucleotides of the same length but different sequence. A test synthesis involving two products that differ in length by at least two bases, or where one product is labeled with a fluorescent dye, is recommended to make the products easily identifiable by HPLC or electrophoresis. This, along with trityl analysis, will confirm the success of the tandem synthesis.
Anticipated Results The yields recovered from Basic Protocol 1 are indicated in the protocol details. Experienced chemists may obtain greater yields, but generally a yield of 70% to 80% for each step is satisfactory. In Basic Protocol 2, the quality of the oligonucleotides should be identical to the quality obtained from conventional prederivatized supports. However, the synthesis scale can be varied considerably by alteration of the conditions chosen for the support and linker phosphoramidite. As described earlier, one can easily adjust the scale between 10 and 50 nmol. Synthesis at scales up to 200 nmol can be obtained by increasing the amount of CPG or by using CPG with a higher amino group loading. In Basic Protocol 3, the products obtained should be comparable to products made individually, when used in most applications. Thus, pairs of PCR primers made in tandem should give similar, if not identical, amplification to those made separately. Doublestranded fragments will spontaneously basepair with each other after deprotection, and the double-stranded nature of these products can be observed by comparing their mobility under denaturing versus non-denaturing conditions. Since at least one of the tandem products will be 5 -phosphorylated, the double-stranded fragment is also ready for enzymatic ligation.
Time Considerations The time required to prepare linker phosphoramidites will depend upon the experience of the researcher with chemical synthesis. However, because multiple steps are involved and the procedures must be repeated for each of the four common deoxynucleosides, preparation of the linker phosphoramidites is a major and labor-intensive task. This could easily take several months for a single person to complete. For this reason, the preparation of linker phosphoramidites from modified nucleosides is only practical if they will be used very frequently. Once the linker phosphoramidites are prepared, their use is quite straightforward and requires little extra preparation. Tandem oligonucleotide synthesis will require a much longer run time on an automated synthesizer because twice as many (if not more) automated couplings are required to make the multiple oligonucleotides. Since this can be scheduled to run overnight, the extra time on the synthesizer is not a significant drawback. However, when making large collections of multiple oligonucleotides, the time
3.12.22 Supplement 23
Current Protocols in Nucleic Acid Chemistry
and effort saved by not having to individually set up, prepare, deprotect, purify, and package all of the required oligonucleotides will be substantial.
Literature Cited Azhayev, A.V. 1999. A new universal support for oligonucleotide synthesis. Tetrahedron 55:787800. Azhayev, A.V. and Antopolsky, M.L. 2001. Amide group assisted 3 -dephosphorylation of oligonucleotides synthesized on universal A-supports. Tetrahedron 57:4977-4986. Brennan, T., Biddison, G., Frauendorf, A., Schwarcz, L., Keen, B., Ecker, D.J., Davis, P.W., Tinder, R., and Swayze, E.E. 1998. Twodimensional parallel array technology as a new approach to automated combinatorial solidphase organic synthesis. Biotechnol. Bioeng. 61:33-45. Cheng, J.Y., Chen, H.H., Kao, Y.S., Kao, W.C., and Peck, K. 2002. High throughput parallel synthesis of oligonucleotides with 1536 channel synthesizer. Nucl. Acids Res. 30:e93. Debear, J.S., Hayes, J.A., Koleck, M.P., and Gough, G.R. 1987. A universal glass support for oligonucleotide synthesis. Nucleosides Nucleotides Nucleic Acids 6:821-830. Efcavitch, J.W., McBride, L.J., and Eadie, J.S. 1986. Effect of pore diameter on the support-bound synthesis of long oligodeoxynucleotides. In Biophosphates and Their Analogues—Synthesis, Structure, Metabolism and Activity (K.S. Bruzik and W.J. Stec, eds.) p. 6570. Elsevier Science Publishers, Amsterdam. Gait, M.J., Singh, M., Heathcliffe, G.R., Atkinson, T.C., Newton, C.R., and Markham, M.F. 1980. Rapid synthesis of oligodeoxyribonucleotides. IV. Improved solid phase synthesis of oligodeoxyribonucleotides through phosphotriester intermediates. Nucl. Acids Res. 8:10811096. Glazer, M., Fidanza, J., McGall, G., and Frank, C. 2001. Colloidal silica films for high-capacity DNA probe arrays. Chem. Mater. 13:4773-4782. Gryaznov, S.M. and Letsinger, R.L. 1992. Synthesis and properties of oligonucleotides containing aminodeoxythymidine units. Nucl. Acids Res. 20:3403-3409. Gryaznov, S.M. and Letsinger, R.L. 1993. Anchor for one step release of 3 -aminooligonucleotides from a solid support. Tetrahedron Lett. 34:12611264. Guzaev, A.P. and Manoharan, M. 2003. A conformationally preorganized universal solid support for efficient oligonucleotide synthesis. J. Am. Chem. Soc. 125:2380-2381. Habus, I. and Agrawal, S. 1994. Improvement in the synthesis of oligonucleotides of extended length by modification of detritylation step. Nucl. Acids Res. 22:4350-4351. Hardy, P.M., Holland, D., Scott, S., Garman, A.J., Newton, C.R., and McLean, M.J. 1994.
Reagents for the preparation of two oligonucleotides per synthesis (TOPSTM ). Nucl. Acids Res. 22:2998-3004. Horn, T. and Urdea, M.S. 1986. A chemical 5 phosphorylation of oligodeoxyribonucleotides that can be monitored by trityl cation release. Tetrahedron Lett. 27:4705-4708. Kumar, P., Ghosh, N.N., Sadana, K.L., Garg, B.S. and Gupta, K.C. 1993. Improved methods for 3 O-succinylation of 2 -deoxyribo- and ribonucleosides and their covalent anchoring on polymer supports for oligonucleotides synthesis. Nucleosides Nucleotides 12:565-584. Lashkari, D.A., Hunicke-Smith, S.P., Norgren, R.M., Davis, R.W., and Brennan, T. 1995. An automated multiplex oligonucleotide synthesizer: Development of high-throughput, lowcost DNA synthesis. Proc. Natl. Acad. Sci. U.S.A. 92:7912-7915. Lyttle, M.H., Dick, D.J., Hudson, D., and Cook, R.M. 1999. A phosphate bound universal linker for DNA synthesis. Nucleosides Nucleotides Nucleic Acids 18:1809-1824. Mag, M. and Engels, J.W. 1989. Synthesis and selective cleavage of oligodeoxyribonucleotides containing non-chiral internucleotide phosphoramidate linkages. Nucl. Acids Res. 17:59735988. Nelson, P.S., Muthini, S., Vierra, M., Acosta, L., and Smith, T.H. 1997. RainbowTM universal CPG: A versatile solid support for oligonucleotide synthesis. Biotechniques 22:752-756. Paul, C.H. and Royappa, A.T. 1996. Acid binding and detritylation during oligonucleotide synthesis. Nucl. Acids Res. 24:3048-3052. Pon, R.T. and Yu, S. 1997. Hydroquinone-O,O diacetic acid (‘Q-linker’) as a replacement for succinyl and oxalyl linker arms in solid phase oligonucleotide synthesis. Nucl. Acids Res. 25:3629-3635. Pon, R.T. and Yu, S. 2001. Linker phosphoramidite reagents for oligonucleotide synthesis on underivatized solid-phase supports. Tetrahedron Lett. 43:8943-8947. Pon, R.T. and Yu, S. 2004. Linker phosphoramidite reagents for the attachment of the first nucleoside to underivatized solid-phase supports. Nucl. Acids Res. 32:623-631. Pon, R.T. and Yu, S. 2005. Tandem oligonucleotide synthesis using linker phosphoramidites. Nucl. Acids Res. 33:1940-1948. Pon, R.T., Usman, N., and Ogilvie, K.K. 1988. Derivatization of controlled pore glass beads for solid phase oligonucleotide synthesis. Biotechniques 6:768-775. Pon, R.T., Yu, S., Guo, Z., Deshmukh, R., and Sanghvi, Y.S. 2001. Reusable solid-phase supports for oligonucleotides and antisense therapeutics. J. Chem. Soc., Perkin Trans. 1 26382643. Pon, R.T., Yu, S., and Sanghvi, Y.S. 2002. Tandem oligonucleotide synthesis on solid-phase supports for the production of multiple oligonucleotides. J. Org. Chem. 67:856-864.
Synthesis of Unmodified Oligonucleotides
3.12.23 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Rayner, S., Brignac, S., Bumeister, R., Belosludtsev, Y., Ward, T., Grant, O., O’Brien, K., Evans, G.A., and Garner, H.R. 1998. MerMade: An oligodeoxyribonucleotide synthesizer for high throughput oligonucleotide production in dual 96-well plates. Genome Res. 8:741747. Scheuerlarsen, C., Rosenbohm, C., Jorgensen, T.J.D., and Wengel, J. 1997. Introduction of a universal solid support for oligonucleotide synthesis. Nucleosides Nucleotides Nucleic Acids 16:67-80. Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., and Gough, G.R. 1995. A universal adapter for chemical synthesis of DNA or RNA on any single type of solid support. Tetrahedron Lett. 36:27-30. Scott, S., Hardy, P., Sheppard, R.C., and McLean, M.J. 1994. A universal support for oligonucleotide synthesis. In Innovation and Perspectives in Solid-Phase Synthesis. Peptides, Proteins, and Nucleic Acids, Biological and Biomedical Applications (R. Epton, ed.) pp. 115-124. Mayflower Worldwide Ltd., Birmingham, Ala.
Septak, M. 1996. Kinetic studies on depurination and detritylation of CPG-bound intermediates during oligonucleotide synthesis. Nucl. Acids Res. 24:3053-3058. Shchepinov, M.S., Case-Green, S.C., and Southern, E.M. 1997. Steric factors influencing hybridisation of nucleic acids to oligonucleotide arrays. Nucl. Acids Res. 25:1155-1161. Sindelar, L.E. and Jaklevic, J.M. 1995. Highthroughput DNA synthesis in a multichannel format. Nucl. Acids Res. 23:982-987. Zhou, X., Cai, S., Hong, A., You, Q., Yu, P., Sheng, N., Srivannavit, O., Muranjan, S., Rouillard, J.M., Xia, Y., Zhang, X., Xiang, Q., Ganesh, R., Zhu, Q., Matejko, A., Gulari, E., and Gao, X. 2004. Microfluidic PicoArray synthesis of oligodeoxynucleotides and simultaneous assembling of multiple DNA sequences. Nucl. Acids Res. 32:5409-5417.
Contributed by Richard T. Pon University of Calgary Calgary, Alberta, Canada
Nucleoside Phosphoramidites Containing Cleavable Linkers
3.12.24 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Microwave-Assisted Functionalization of Solid Supports for Rapid Loading of Nucleosides
UNIT 3.13
The preparation and manufacture of macromolecules such as oligonucleotides, peptides, and carbohydrates are carried out using solid-phase synthesis (Beaucage and Iyer, 1992; Iyer and Beaucage, 1999). The assembly of these macromolecules involves step-wise coupling of individual monomer units to a leader monomer that is tethered to a functionalized solid support. Consequently, efficient approaches for functionalizing the solid support and tethering it to the leader monomer are critically important for successful solid-phase synthesis. Oligonucleotides are generally assembled on controlled-pore glass (CPG) or polystyrenebased supports that are tethered to the leader nucleoside via a linker and a spacer arm (Fig. 3.13.1). Typically, the underivatized solid supports are first derivatized with a reagent capable of incorporating an amino terminus on the support. Being highly versatile, the amino group can be reacted with a variety of reagents to provide supports carrying diverse functionalities such as hydroxyl, carboxyl, and so on. In turn, a carboxyl-terminated solid support can be linked to the 3 -hydroxy group of the leader nucleoside via an ester linkage. Such nucleoside-loaded supports, tethered via a succinic ester linkage to a solid support (Fig. 3.13.1), are most commonly employed in oligonucleotide synthesis. Commercially available nucleoside-loaded supports are very expensive, and many supports that carry modified nucleosides or specialized linkers are not commercially available. Consequently, many laboratories prefer to synthesize nucleoside-loaded supports from amino- or carboxyl-functionalized supports in-house. However, the reported protocols for functionalization and loading of supports are time-consuming, labor-intensive, and not very user-friendly. Clearly, it would be advantageous to have rapid and efficient protocols for the preparation of nucleoside-loaded supports starting from native, underivatized supports. This unit provides convenient and rapid protocols for the preparation of functionalized supports using microwave-assisted procedures starting from native, underivatized supports. The unit also describes improved protocols for the loading of nucleosides on functionalized supports. Thus, starting from underivatized CPG, protocols are described for: (1) the preparation of amino- and carboxyl-functionalized CPG, (2) the loading of nucleosides onto carboxyl-functionalized CPG, and (3) the recovery of excess
Figure 3.13.1 A leader nucleoside attached to a solid support via a succinyl linker and alkyl amino spacer arm.
Contributed by Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan, and John E. Coughlin Current Protocols in Nucleic Acid Chemistry (2005) 3.13.1-3.13.18 C 2005 by John Wiley and Sons, Inc. Copyright
Synthesis of Unmodified Oligonucleotides
3.13.1 Supplement 23
nucleosides following loading of supports. With suitable modifications, these protocols can be applied towards the functionalization and loading of other solid supports. Basic Protocol 1 describes ultra-fast microwave-assisted amination (MAA) of CPG using (3-aminopropyl)triethoxysilane (APTES) without the aid of a solvent (Padmanabhan et al., 2005). Other amination reagents such as (3-aminopropyl)trimethoxysilane (APTMS), aminopropyldimethyl ethoxysilane (APDES), and N-[3(trimethoxysilyl)propyl]ethylenediamine (APTED) can also be used in place of APTES. Basic Protocol 2 describes ultra-fast microwave-assisted succinylation (MAS) of aminofunctionalized CPG. Nucleosides tethered to CPG using a succinyl linkage are almost universally employed in oligonucleotide synthesis. With appropriate modifications, these protocols can also be employed for the rapid attachment of other specialized linkers such as N-methyl sarcosine, hydroquinone-O,O -diacetic acid, and oxalic acid. Basic Protocol 3 deals with loading of nucleosides on succinylated CPG using a LOTUS workstation (Iyer et al., 2005). The Alternate Protocol describes nucleoside loading on CPG using an orbital shaker without the use of LOTUS. This procedure, though less convenient, is suited for smaller-scale operations and can be adopted by laboratories that do not have access to the LOTUS workstation. Basic Protocol 4 outlines a process for the recovery of 5 -O-DMTr-N-protected nucleosides, which are employed in large excess during loading reactions on solid supports, through a simple aqueous workup. BASIC PROTOCOL 1
MICROWAVE-ASSISTED AMINATION OF CONTROLLED-PORE GLASS This protocol is used to attach 3-aminopropyl moieties to commercially available, native controlled-pore glass (S.1; Fig. 3.13.2) using APTES to produce S.2. Previously reported literature methods for amination of CPG (Majors and Hopper, 1974; Tundo and Venturello, 1979; Matteucci and Caruthers, 1981) involve refluxing CPG with APTES in toluene for 48 to 72 hr followed by capping of unreacted hydroxyl groups with trimethylsilyl chloride. Such heterogeneous reactions are difficult to manage on a large scale, require more time for completion, and are not reproducible. The microwave-assisted protocol described here is ultra-fast, efficient, reproducible, and can be performed without the aid of a solvent. The protocol can be employed using other silylating reagents such as APTMS (which also yields the aminated support S.2) or APDES or APTED (to produce the corresponding amino-derivatized supports S.3 and S.4; Fig. 3.13.3). These reagents are available from Alpha Aesar, Acros Organics, or Oakwood Products. For additional information, see
Figure 3.13.2
Microwave-assisted amination (MAA) of CPG using APTES or APTMS.
MicrowaveAssisted Functionalization of Solid Supports
3.13.2 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Figure 3.13.3
Microwave-assisted amination (MAA) of CPG using different silyl reagents.
Background Information, discussion of MAA. Other silica supports such as wide-pore silica can also be employed. Although the procedures described here pertain to largescale work, with appropriate modifications, they can be adapted towards smaller-scale operations.
Materials ◦
Native controlled-pore glass (CPG; 500 A; Prime Synthesis). Various lots of CPG supplied by the manufacturer have the following range of physical properties: ◦ Pore size: 340 to 535 A Bulk density: 0.25 to 0.35 g/cm3 Solid surface area: 101 to 163 m2 /g Pore volume: 1.1 cm3 /g Particle size: 120 to 200 mesh Loading: 184 µmol/g (3-Aminopropyl)triethoxysilane (APTES) Toluene, reagent grade
Synthesis of Unmodified Oligonucleotides
3.13.3 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Methanol, reagent grade Dichloromethane, reagent grade Hexanes, reagent grade Ninhydrin solution, 0.2% (w/v) in ethanol 500-mL thick-walled glass reactor (Spring Bank) fitted with a Teflon screw-cap stopper and chemically resistant O-ring (Chemraz) Domestic microwave oven (800 watt, high power setting) Safety shield (3/4-in. polycarbonate; e.g., VWR) Temperature laser gun (Raytek minitemp) Fritted funnels, medium porosity, small (60 mL) and large (19-cm height × 16-cm diameter) Filter flask Vacuum pump Large glass dish (14 × 23 cm; Anchor Hocking Co.) Aluminum foil Master heat gun (Master Appliance Corp.) 8 × 35–mm flat-bottom sample tubes Vacuum manifold Additional reagents and equipment for amino group estimation by trityl analysis (UNIT 3.2) CAUTION: All microwave reactions should be carried out behind a safety shield, and in a specially fabricated thick-walled glass reactor fitted with a Teflon stopper and chemically resistant O-ring. The safety shield is used to protect against injuries from minor explosions.
Perform amino loading on CPG 1. In a 500-mL thick-walled pressure reactor fitted with a Teflon screw-cap stopper ◦ and a chemically resistant O-ring, combine 100 g native CPG (500 A) and 350 mL APTES. Quickly close the reactor vessel with the Teflon plug and gently mix the contents by shaking. 2. Place the reactor in a domestic microwave oven. 3. Place a safety shield to cover the area around the microwave. 4. Start to heat in 1-min cycles at high power. After each heat cycle, remove the reactor from the microwave oven, mix the contents well by shaking, and measure the temperature by directing the beam of a Raytek laser gun at the upper body of the reactor. Allow the reaction mixture to cool to ∼64◦ to 71◦ C before proceeding with the next heating cycle. CAUTION: The reactor and its contents will be hot. After two heating cycles in the microwave, the outside temperature of the reactor usually rises to ∼82o to 90◦ C. If the reaction mixture is not cooled after each cycle, the O-ring may melt, allowing the contents of the reactor to leak out. The laser gun is a convenient device for measuring the outside temperature of reaction vessels.
5. At the end of a total reaction cycle of ∼8 min, allow the reaction mixture to cool to RT. 6. Carefully open the reactor and filter the reaction mixture in vacuo using a large fritted funnel of medium porosity. MicrowaveAssisted Functionalization of Solid Supports
7. Wash the support twice each with 125 mL toluene, 250 mL methanol, 250 mL DCM, and finally 250 mL hexanes.
3.13.4 Supplement 23
Current Protocols in Nucleic Acid Chemistry
8. Spread the resulting 3-aminopropyl-CPG support (S.2) in a thin layer in a large (14 × 23–cm) dish, cover the dish with perforated aluminum foil, and allow the support to dry for 2 days in a fume hood at ambient temperature. 9. Store the dried support in a closed container for up to 3 to 7 days at ambient temperature, or at 0◦ to 4◦ C for longer periods.
Perform qualitative analysis of amino loading 10. Treat 4 to 5 mg of 3-aminopropyl-CPG in a vial with a few drops of ninhydrin reagent and heat for a few seconds (to near boiling) using a heat gun. The presence of the amino group on the support is indicated by the formation of a strong purple color.
Perform quantitative analysis of amino loading 11. Place a sample (∼100 mg) of 3-aminopropyl-CPG in an 8 × 35–mm flat-bottom sample tube, cover the tube with a Kimwipe tissue and secure it around the neck of the tube, and place the tube in a jar attached to a vacuum manifold. Dry under high vacuum for 12 hr. Drying of the support should be done carefully in vacuo to remove traces of solvent. The use of a static gun (to prevent particles from flying) allows easier handling, weighing, and transferring of the support, which must be handled carefully since the particles are light and fluffy.
12. Determine amino loading by converting amino functions to dimethoxytrityl amino groups and performing trityl analysis (UNIT 3.2).
MICROWAVE-ASSISTED SUCCINYLATION OF 3-AMINOPROPYL-CPG This protocol describes microwave-assisted succinylation (Fig. 3.13.4) of 3-aminopropylCPG (S.2) to produce S.5 in an ultra-fast and efficient procedure. It is performed using reagent-grade dimethylformamide as solvent. The conventional procedure for preparation of succinylated LCAA-CPG (UNIT 3.2) requires overnight reaction in a shaker employing anhydrous pyridine as a solvent, and is less convenient.
BASIC PROTOCOL 2
Materials 3-Aminopropyl-CPG (S.2; see Basic Protocol 1) Succinic anhydride, reagent grade 4-Dimethylaminopyridine (DMAP), reagent grade N,N-Dimethylformamide (DMF), reagent grade, water content <15 ppm Methanol, reagent grade Dichloromethane (DCM), reagent grade Hexanes, reagent grade Ethyl acetate (EtOAc), reagent grade 500-mL thick-walled glass reactor (Spring Bank) fitted with Teflon screw-cap stopper and chemically resistant O-ring (Chemraz) Domestic microwave oven (800 watt, high power setting) Safety shield (3/4-in. polycarbonate; e.g., VWR) Temperature laser gun (Raytek minitemp) Fritted funnels, medium porosity, small (60 mL) and large (19-cm height, 16-cm diameter) Filtration flask 8 × 35–mm flat-bottom sample tubes Master heat gun (Master Appliance Corp.) Large glass dish (14 × 23 cm; Anchor Hocking Co.) Additional reagents and solutions for carboxyl group estimation (UNIT 3.2) Current Protocols in Nucleic Acid Chemistry
Synthesis of Unmodified Oligonucleotides
3.13.5 Supplement 23
Figure 3.13.4
Microwave-assisted succinylation (MAS) of 3-aminopropyl-CPG.
Perform succinylation 1. Place 150 g of 3-aminopropyl-CPG in a 500-mL thick-walled pressure reactor with a Teflon screw-cap stopper and O-ring. 2. Dissolve 60 g succinic anhydride and 7.2 g DMAP in 450 mL DMF (reagent grade, water content <15 ppm), and add this solution to the reactor containing the support. 3. Mix the contents well. Place the reactor in a microwave oven and set up the safety shield. Initiate eight 30-sec cycles of heating on high power (total time ∼5 min). Allow the dark-colored reaction mixture to cool in between heating cycles. CAUTION: Although temperature is not as critical as in the amination reaction, this microwave-assisted reaction is exothermic. Use shorter heating cycles if necessary.
Monitor succinylation 4. To test the support for the presence of unreacted amino groups, filter a small sample (∼5 mg) of the support under vacuum through a small fritted funnel of medium porosity, and then wash twice each with 10 mL methanol, 10 mL DCM, and 10 mL hexanes. 5. Place the washed succinylated support in a clean 8 × 35–mm flat-bottom sample tube and add 3 drops of ninhydrin solution. Heat the mixture with a heat gun to boiling. If any unreacted amino groups remain on the support, a purple color will develop. The absence of color indicates complete succinylation of the amino groups.
6. If any purple color appears, perform a few more heating cycles until the ninhydrin test is negative.
Filter product and analyze quantitatively 7. After completion of succinylation, let the reactor cool to room temperature. Carefully filter the purple-colored reaction mixture under vacuum through a large frit of medium porosity. 8. Wash the support three times each with 200 mL methanol, 200 mL DCM, 200 mL EtOAc, and finally 200 mL hexanes. 9. Spread the support in a thin layer in a 14 × 23–cm glass tray, cover with perforated aluminum foil, and dry for 48 hr at ambient temperature in a fume hood. 10. Determine the carboxyl loading of the support as described using 4-nitrophenol or N-monomethoxytrityl-6-amino-1-hexanol (see UNIT 3.2). MicrowaveAssisted Functionalization of Solid Supports
3.13.6 Supplement 23
Current Protocols in Nucleic Acid Chemistry
LOADING OF NUCLEOSIDES ON SUCCINYLATED CPG USING LOTUS As is well known, the loading of nucleosides on a solid support is a multi-phase reaction that involves mixing of the nucleoside and various reagents with the solid support in an inert atmosphere (for further discussion, see Background Information). The established protocol (UNIT 3.2) requires the use of anhydrous pyridine as solvent in the presence of an excess of nucleoside (10 mmol per 100 g succinylated support; reviewed in UNIT 3.2). The excess nucleoside used in the reaction cannot be readily recovered afterward. This protocol describes an efficient approach for loading nucleosides on a solid support that involves the use of a specially fabricated reactor known as LOTUS (Fig. 3.13.5) in conjunction with dimethylformamide as a solvent. The LOTUS workstation is ideally suited to perform loading of nucleosides in scales higher than 20 to 50 g of support.
BASIC PROTOCOL 3
Three design elements make the LOTUS workstation unique for performing multi-phase reactions: (1) orbital shaking of the solid and liquid phases, (2) fluidization of phases induced by inert gas, and (c) active recycling of the liquid phase. The mixing process in LOTUS is designated as “orbital shaking coupled with active recycling” (OSCAR) of the liquid phase. Consequently, solid-phase reactions can be performed efficiently in LOTUS. LOTUS has been designed to incorporate pneumatic systems for better control of fluid flow while maintaining an inert atmosphere. LOTUS I has two pneumatically controlled solenoid valves (McMaster Carr) for delivery of reagents from solvent reservoirs under argon. Pressure release valves placed in the argon line provide outlet for release of excess pressure. The activation of the solenoid valves forces pressurized gas into the solvent and reactant chambers, thus allowing liquids to enter into the reactor. The advantage of LOTUS is that the entire process—including loading, capping, filtration, washing, and drying—is carried out using a single assembly in an inert atmosphere with minimal human exposure to toxic solvents and air-borne support particles. In addition, the use of dimethylformamide as a solvent provides several advantages: (1) it allows loading to be carried out with a smaller molar excess of nucleoside, (2) it permits facile monitoring of the loading reaction, and (3) it facilitates the recovery of excess nucleoside following completion of the loading reaction. This feature is particularly useful when expensive nucleosides are employed. The following protocol uses the loading of DMTr-dABz on CPG as an example to illustrate the procedure.
Materials Succinylated CPG (S.5; see Basic Protocol 2) 5 -O-(4,4 -Dimethoxytrityl)-N6 -benzoyl-2 -deoxyadenosine (DMTr-dABz ) or other 5 -O-DMTr-N-protected deoxyribonucleoside (Reliable Biopharmaceutical Corporation; ChemGenes) 4-Dimethylaminopyridine (DMAP), reagent grade Anhydrous N,N-dimethylformamide (DMF), freshly distilled over CaH2 Argon gas Anhydrous triethylamine (TEA), freshly distilled over CaH2 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC), reagent grade Methanol, reagent grade Dichloromethane (DCM), reagent grade Hexanes, reagent grade CAP A and B capping solutions (American International Chemical; ChemGenes) LOTUS reactor workstation (Iyer et al., 2005; Fig. 3.13.5; Spring Bank Technologies) Solid addition funnels Current Protocols in Nucleic Acid Chemistry
Synthesis of Unmodified Oligonucleotides
3.13.7 Supplement 23
1-L round-bottom flask Rubber septa and syringe needles Fritted funnels, small size (60 ml), of medium porosity 8 × 35–mm flat-bottom sample tubes Vacuum manifold Additional reagents and equipment for trityl analysis (UNIT 3.2) CAUTION: DMTr-nucleosides and carbodiimide reagents such as EDC can cause severe skin and eye irritation and allergic reactions. Use appropriate skin and eye protection and wipe all work areas with a wet cloth immediately after use. NOTE: Anhydrous DMF and TEA are prepared by distilling reagent-grade solvents over ◦ calcium hydride and are stored over 4 A molecular sieves. They may also be purchased from commercial vendors (Aldrich, J.T. Baker). If procured from commercial sources, it is important to use certified solvents that have <5 ppm water.
Load nucleoside on CPG using LOTUS 1. Place 100 g succinylated CPG (S.5; 103 µmol carboxyl/g) into the LOTUS reactor through inlet d using a solid addition funnel. 2. Dissolve 19.7 g (3 eq, 30 mmol) DMTr-dABz and 3.66 g (3 eq, 30 mmol) DMAP in 400 mL anhydrous DMF in a 1-L round-bottom flask under argon atmosphere. If carbonyl determination has not been carried out, base reagent quantities on the amino loading of the CPG.
3. Introduce the solution into the LOTUS reactor through inlet port d under a blanket of argon. The inlet port d can be capped with a rubber septum to facilitate liquid transfer under argon. Carry out the transfer of all anhydrous solvents/reagents through a syringe needle or transfer tube (polypropylene) under a nitrogen/argon atmosphere.
4. Shake the contents using the orbital shaker at 100 rpm. 5. Introduce 4.2 mL (30 mmol) anhydrous triethylamine via a syringe needle through inlet port d. 6. Initiate “orbital shaking coupled with active recycling” (OSCAR) by turning on the pump and orbital shaker, and continue for 5-10 min. 7. Add 5.76 g (3 eq, 30 mmol) EDC through inlet port d. 8. Perform OSCAR by carrying out recycling in both the forward and reverse directions for 8 hr. Reverse recycling in an argon atmosphere helps to fluidize the reaction mixture and promote efficient mixing of the solid and liquid phases.
9. Stop recycling and continue orbital shaking alone for ∼8 hr. 10. Monitor the progress of the reaction by periodically removing an aliquot of recycling liquid through sample port o with a small spatula and performing trityl analysis (UNIT 3.2) to determine the amount of DMTr-dABz consumed.
MicrowaveAssisted Functionalization of Solid Supports
Typically a 10-µL aliquot, diluted to 10 mL with 5% DCA in DCM, is used to measure the absorbance of the trityl color and determine the concentration of unconsumed DMTr-dABz remaining in the reaction, using the formula: [DMTr-dABz ] (µmol/mL) = (A503 × D)/76 where A503 is absorbance at 503 nm and D is the dilution factor.
3.13.8 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Figure 3.13.5 Prototype LOTUS reactor and workstation. The LOTUS reaction vessel comprises an upper chamber (a) and a lower chamber (b) held together by a clamp (c). The upper chamber has a gas/solid/liquid inlet (d). Inlet d is used to introduce fresh chemical reactants into the reaction vessel under argon. A pressure release valve (e) is situated on the upper chamber. The lower chamber, equipped with a medium-porosity frit (f), is connected via a valve (s) and adapter (h) to the collection reservoir (i). The adapter also has a gas port (g), suitable for connecting to a vacuum line to draw excess reagents into the collection reservoir as desired. The contents of the collection reservoir can be drained through valve (r). The entire reaction vessel, including the collection reservoir, is mounted on an orbital shaker to ensure thorough and efficient mixing of the solid, liquid, and gas phases during the reaction. The reaction chamber and accessories are maintained under slightly positive inert atmosphere so that air- and moisture-sensitive reactions can be performed. The lower chamber comprises a sampling port (j) that allows a sample of solid matrix to be drawn for analysis during reactions and process operations. Liquid reactants can be independently sampled from an auxiliary port (k) in the recycle path. The online monitoring of both solid and liquid phases allows better process control during nucleoside loading. In order to ensure continuous and close contact between liquid and solid phases, the concept of active recycling is incorporated in the reactor design. Thus, the upper chamber is fitted with a recycled reagent inlet port (l) adapted for connection to flexible, chemically resistant tubing (m) that fits into the pump head of a peristaltic pump (n). The lower chamber also has a recycled reagent outlet port (o) that is adapted for connection to flexible tubing. Port o is connected to the recycled reagent inlet port (l) via tubing through the pump. The pump serves several functions: (1) it can be used to draw the reactants from a reservoir into the reaction vessel, (2) it helps recycle the liquid contents of the reaction vessel through recycled reagent ports o and l, (3) it helps modulate the delivery of reagents or the rate of recycling throughout the reaction via the flow controller (p). Recycling can be done in both forward and reverse directions and at different speeds. Forward recycling generates turbulent forces that assist in mixing of solid and liquid phases, and reverse recycling assists fluidization of solid and liquid phases, thereby aiding mixing. The combined fluid forces generated by forward and reverse recycling facilitates thorough mixing of the solid and liquid reaction phases, resulting in rapid reaction kinetics and efficient and reproducible loading without causing mechanical abrasion of the solid support. Reprinted from Iyer et al. (2005) with permission from Organic Preparations and Procedures International. Current Protocols in Nucleic Acid Chemistry
Synthesis of Unmodified Oligonucleotides
3.13.9 Supplement 23
11. After about 12 hr, remove a slurry sample (∼100 mg) of the support through port d, filter under vacuum through a small fritted funnel of medium porosity, and wash with 30 mL each methanol, DCM, and hexanes. Dry the support in vacuo using a vacuum pump, and perform trityl analysis on the dried support. Typically, loading of 60 to 70 µmol nucleoside/gram support is readily obtained after a 12-hr reaction.
12. If the loading is low, add (in order) 3.7 g DMAP (as a solution in 20 mL DMF), 5 mL triethylamine, and 2.95 g EDC, and continue OSCAR. It is critical that anhydrous solvents and reagents are employed in the reaction and solution. Also, reagents should be added sequentially as mentioned in order to obtain high loading within 24 hr.
Perform workup 13. At the end of the reaction, filter the contents of the reactor under vacuum through the medium-porosity frit f in the reactor, and collect the filtrate through port o. Set aside the filtrate for recovery of excess unreacted nucleoside (see Basic Protocol 4). 14. Wash the support (via port o) two times with 400 mL each methanol, then DCM, and finally hexanes. After each addition of solvent, initiate OSCAR for 10 min and perform filtration under vacuum. 15. Dry the support thoroughly under vacuum in the LOTUS apparatus. 16. Remove a sample of the solid support and perform trityl analysis (UNIT 3.2). Typically, nucleoside loadings of 75 to 80 µmol/g are obtained.
Cap support using LOTUS 17. Add 325 mL each of CAP A and CAP B to the nucleoside-loaded CPG through port d. 18. Perform OSCAR for 3 hr using both forward and reverse recycling. 19. Filter the capped support and then wash twice with 300 mL each methanol, then DCM, and then hexanes. 20. Place the support in an 8 × 35–mm flat-bottom sample tube, secure a Kimwipe tissue around the neck of the tube, and place it in a jar attached to a vacuum manifold. Dry the support in vacuo. Drying of support should be done carefully in vacuo to remove traces of solvent. Also, the use of a static gun allows easier handling and transferring of the support since the particles are light and fluffy.
21. Determine the nucleoside loading of dried support S.7 by trityl analysis. Typically, nucleoside loadings of 70 to 75 µmol/g are obtained.
22. Store the support in a closed container at ambient temperature for up to 3 to 7 days, or at 0◦ to 4◦ C for longer periods. ALTERNATE PROTOCOL
LOADING OF NUCLEOSIDES ON SUCCINYLATED CPG USING ORBITAL SHAKING This protocol deals with nucleoside loading on succinylated CPG using an orbital shaker instead of LOTUS. This procedure, though less convenient, can be followed in laboratories that do not have access to LOTUS.
MicrowaveAssisted Functionalization of Solid Supports
Additional Materials (also see Basic Protocol 3) 1-L single-neck round-bottom flasks Rubber septum
3.13.10 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Orbital shaker (e.g., Lab-Line Orbit Environ-Shaker) Fritted funnel, large size (19-cm height × 16-cm diameter), of medium porosity Load nucleoside on CPG 1. Load 65 g succinylated CPG (87 µmol carboxyl/g) in a 1-L single-neck round-bottom flask. 2. In a separate round-bottom flask, with stirring, dissolve 18.7 g (5 eq relative to carboxyl load of CPG) DMTr-dABz and 3.5 g DMAP in 260 mL anhydrous DMF (freshly distilled over CaH2 ). Add this solution to the support. Carry out the transfer of all anhydrous solvents/reagents through a syringe or transfer tube (polypropylene) under nitrogen/argon atmosphere.
3. Add 4 mL anhydrous triethylamine and then 5.47 g (5 eq) EDC to the above reaction mixture. 4. Seal the reaction flask with a rubber septum and mix under gentle orbital shaking (∼100 rpm) overnight. Set the orbital shaker at a low speed to enable a gentle rocking motion for mixing of the phases. Shaking at high speed can cause the fragile support particles to break up.
5. Monitor the coupling reaction by removing a small sample of reaction mixture (50 to 100 mg) using a disposable pipet. Filter under vacuum through a small fritted funnel of medium porosity and wash twice with 10 mL each methanol and then DCM. 6. Dry ∼20 mg sample and determine the loading by trityl analysis (UNIT 3.2). If the loading is not acceptable (>65 µmol/g), continue mixing for an extended period of time and, if necessary, add more DMAP (as solution in DMF) followed by TEA and then EDC to the reaction mixture.
Perform workup 7. When loading is complete, filter the reaction mixture through a large fritted funnel. 8. Wash the support twice with 300 mL each methanol, then DCM, and then hexanes. Dry in air overnight in the funnel.
Cap unreacted nucleophilic groups 9. Mix nucleoside-loaded CPG S.7 with 325 mL each of CAP A and CAP B mixtures in a 1-L single-neck round-bottom flask for 6 hr under orbital shaking. 10. Filter the capped support and wash with 300 mL each methanol, then DCM, and then hexanes twice. 11. Dry the support using a vacuum pump and determine the loading of dried support through trityl analysis (UNIT 3.2). Loading should typically be around 70 µmol/g.
12. Store the support in a closed container at ambient temperature for up to 3 to 7 days, or at 0◦ to 4◦ C for longer periods.
RECOVERY OF EXCESS UNREACTED NUCLEOSIDE 5 -O-DMTr-N-protected
A large excess of nucleosides are employed during loading reactions on solid supports. The use of DMF as a solvent for loading facilitates recovery of most of this excess nucleoside by simple aqueous workup. The following illustrative protocol deals with the recovery of excess DMTr-dABz from the filtrate obtained following the loading reaction in Basic Protocol 3 or the Alternate Protocol.
BASIC PROTOCOL 4
Synthesis of Unmodified Oligonucleotides
3.13.11 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Materials Nucleoside-containing DMF filtrate (e.g., Basic Protocol 3, step 13) Sodium chloride Chloroform, reagent grade 5% (w/v) aqueous citric acid, reagent grade 5% (w/v) aqueous sodium carbonate, reagent grade Brine (saturated aqueous NaCl) Anhydrous sodium sulfate, reagent grade Separatory funnel with stopper 24-cm Buchner funnel with Whatman no. 1 filter paper Rotary evaporator Vacuum pump 1. Measure the volume of DMF filtrate obtained after isolation of DMTr-dABz -loaded CPG. 2. Slowly pour the filtrate, under stirring, into 10 vol ice-cold water containing 2 to 5 g NaCl. A white solid begins to separate.
3. Let stand for 1 hr at 4◦ C. 4. Filter the solid that separates under vacuum using a 24-cm Buchner funnel with Whatman no. 1 filter paper and wash the solid with water. 5. Take up the wet solid in chloroform and transfer the dissolved solution to a separatory funnel. 6. Separate the lower organic layer and wash it with 300 mL each of 5% aqueous citric acid (to remove any dissolved DMAP), followed by 5% aqueous sodium carbonate, and finally brine. 7. Dry the chloroform layer over 20 g anhydrous sodium sulfate and filter through a funnel. 8. Concentrate the chloroform solution on a rotary evaporator to give the nucleoside as a white residue. 9. Dry in vacuo overnight using a vacuum pump to obtain DMTr-dABz as a white solid of acceptable purity. The recovery of the excess nucleoside is >70%. The 1 H NMR spectrum of recovered DMTr-dABz is found to be identical to a standard sample obtained from Reliable Biopharmaceuticals.
COMMENTARY Background Information
MicrowaveAssisted Functionalization of Solid Supports
Synthetic oligonucleotides find extensive applications in target validation, functional genomics, diagnostics, and therapeutics, and as experimental tools in molecular biology (Sproat, 1995; Vlassov et al., 1997; Verma and Eckstein, 1998). As potential therapeutic agents, synthetic oligonucleotides have been designed to down-regulate intracellular RNA expression through RNA interference and ribozyme- and antisense-
based approaches, as well as to inhibit protein function through the aptamer approach (Sharp, 2001; Hannon, 2002; Zamore, 2002; Iyer et al., 2003; Manoharan, 2004). Two oligonucleotide drugs, Vitravene (an antisense oligonucleotide) and Macugen (an aptamer), have been approved for clinical use. The synthesis and manufacture of oligonucleotides for various applications are carried out using solid-phase phosphoramidite chemistry or H-phosphonate chemistry in
3.13.12 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Figure 3.13.6
Strategies for the functionalization and loading of solid supports.
automated synthesizers (Beaucage and Caruthers, 1981; Beaucage and Iyer, 1992; Iyer and Beaucage, 1999; UNITS 3.3–3.5). In solid-phase oligonucleotide assembly, monomeric units are sequentially coupled to a leader nucleoside bound to a solid support through a series of reaction cycles. Consequently, the availability of appropriate nucleoside-loaded supports is critical for the manufacture of oligonucleotides. Although several improvements in oligonucleotide synthesis have been reported over the past two decades (Iyer and Beaucage, 1999), only limited reports exist for the functionalization of solid supports or for the preparation of support-bound nucleosides (Majors and Hopper, 1974; Tundo and Venturello, 1979; Matteucci and Caruthers, 1981; Damha et al., 1990; UNIT 3.2). The functionalization and loading of supports are traditionally carried out according to path A in Figure 3.13.6, wherein native controlled-pore glass (CPG; S.1) is derivatized to give the aminopropylsilyl derivative S.2, is succinylated to produce the carboxy-tethered CPG derivative S.5, and is finally coupled at the carboxyl terminus to a 5 -DMTr-protected nucleoside (S.6) by esterification to give S.7. Path B is followed as an alternate approach where S.2 is coupled with the presynthesized nucleoside hemisuccinate derivative S.8 to produce S.7. Although these reported protocols for producing S.7 from S.1 have helped advance oligonucleotide synthesis
technology, the protocols are time-consuming, labor-intensive, and show high batch-to-batch variability in loading. There are some reports of improved procedures for loading of nucleosides on functionalized supports, but their utility for routine use has not been fully explored. Over the past two decades, microwaveassisted procedures have been successfully employed for the rapid and efficient synthesis of different classes of organic compounds (for reviews see Chatti et al., 2001; Listrom et al., 2001; Bose et al., 2002). Microwave-assisted organic synthesis has several advantages: (1) ultra-fast reaction kinetics, (2) cleaner reactions with improved yields and reduced formation of side products, (3) ability to effect chemo-, regio-, and stereoselective transformations, (4) flexibility to perform reactions with or without solvents, (5) economical and eco-friendly processes compared to conventional reactions, and (6) successful product formation in reactions that fail under conventional conditions. There is only one prior report of the application of microwave-assisted procedures in the solid-phase synthesis of nucleic acids, involving rapid deprotection and cleavage of oligonucleotides (Kumar and Gupta, 1997). Microwave-assisted amination (MAA) of native CPG Microwave-assisted procedures have recently been applied as an alternative approach for the functionalization of CPG using
Synthesis of Unmodified Oligonucleotides
3.13.13 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Table 3.13.1 Influence of Solvents on Microwave-Assisted Amination of CPGa
Amination reagent
Solvent
Loading (µmol/g)
APTES
Neat
113
DMSO
116
DMF
86
a From Padmanabhan et al. (2005) with permission from Elsevier.
Table 3.13.2 Influence of Silyl Agents on Microwave-Assisted Amination of CPGa
Amination reagent
Reaction conditions
Loading (µmol/g)
APTES
Standard conditionsb
73
APTES
MAA, 5 min
98-113
APTMS
MAA, 5 min
110
APDES
MAA, 5 min
96
APTED
MAA, 5 min
79
a From Padmanabhan et al. (2005) with permission from Elsevier. b Loading with standard non-microwave methods (for comparison).
Table 3.13.3 Influence of Additives on MicrowaveAssisted Amination of CPGa
Reagent
Additiveb
APTES
DMAP
110
TFA
116
PTSA
128
BF3 ·Et2 O
45
Loading (µmol/g)
a From Padmanabhan et al. (2005) with permission form Elsevier. b Abbreviations: DMAP, 4-dimethylaminopyridine; PTSA, p-toluene-
sulfonic acid; TFA, trifluoroacetic acid.
MicrowaveAssisted Functionalization of Solid Supports
a domestic microwave oven (Padmanabhan et al., 2005). The microwave-assisted amination (MAA) protocol described in this unit is an optimized protocol that uses neat APTES without any solvent. The effect on loading of using different solvents in the MAA of CPG with APTES is given in Table 3.13.1. Although MAA can be conducted in DMF and DMSO, the use of CPG in neat APTES is more convenient and more eco-friendly. It is pertinent to mention that since an excess of APTES is used in this protocol, MAA of CPG has been attempted using APTES recovered from a previous MAA reaction. This procedure was unsuccessful, probably due to contamination of the recovered APTES with liberated ethanol. In attempts to see if higher amino loadings could be achieved with different amination reagents, MAA reactions were carried out (all neat) using (3-aminopropyl)trimethoxysilane
(APTMS) and N-[(3-trimethoxysilyl)propyl] ethylenediamine (APTED; Fig. 3.13.3). Although the corresponding aminated CPGs S.2 and S.4 were obtained, loading was not increased beyond that obtained with APTES. It is believed that amination involves the condensation of three hydroxyl groups on the CPG matrix with the three ethoxy groups of APTES to form S.2. It seemed reasonable that if each of the hydroxyl groups of CPG could be engaged in reaction with a single molecule of a monoethoxysilane derivative such as aminopropyldimethyl ethoxysilane (APDES), amino-CPG S.3 could be achieved with increased amino loading. However, although the MAA reaction of CPG with APDES did give the corresponding aminated product S.3, the loading was not increased beyond 96 µmol/g (Table 3.13.2). In another experiment, the amino-CPG obtained following the first MAA
3.13.14 Supplement 23
Current Protocols in Nucleic Acid Chemistry
with APDES was subjected to a second MAA using APTES. There was no further improvement in loading, suggesting that all available sites on the CPG had been functionalized during the first reaction. As a safety precaution, it should also be noted that during MAA of CPG with APDES in the presence of tin(IV) chloride as a catalyst, an explosive reaction resulted. The MAA of CPG with APTES was also evaluated using different additives (Table 3.13.3). The best results were obtained with ptoluenesulfonic acid and TFA, giving S.2 with amino loadings of 128 and 116 µmol/g, respectively. With boron trifluoride etherate as a catalyst, the product S.2 had considerably reduced loading (∼40 µmol/g). These results suggest that additives and solvents influence the amino loading on CPG and hence the final loading of nucleosides. It is pertinent to mention that the MAA protocol can be modified to prepare amino-functionalized supports with a predetermined loading level (unpub. observ.). Microwave-assisted succinylation (MAS) of aminated CPG Following the success of MAA of CPG, the MAS of the functionalized support was attempted under microwave conditions. Microwave-assisted reaction of aminated CPG with succinic anhydride without the aid of any solvent resulted in a very dark yellow-colored support, probably due to the formation of an imide rather than the expected acid. Nevertheless, with DMF as a solvent, the MAS of the aminated CPG (50 to 100 g scale) was achieved successfully to give S.5 in the presence of a catalytic amount of DMAP in less than 5 min. Completion of the reaction was ascertained by testing for the absence of the amino group on a sample of S.2. The use of DMF in place of pyridine makes the MAS procedure highly attractive for preparation of succinylated CPG. In addition to DMF, the succinylation can also be carried out using DMSO, dimethylacetamide, or acetonitrile. Loading of nucleosides on succinylated CPG Following the success of microwaveassisted protocols for ultra-fast preparation of functionalized CPG, the loading of nucleosides on solid supports under microwave conditions was also evaluated. Preliminary studies of nucleoside loading of functionalized supports S.2 and S.5 (Fig. 3.13.6, paths A and B) using microwave conditions have been en-
couraging. The protocols are being optimized, and will be reported in due course. With the succinylated CPG S.5 at hand, an improved protocol for efficient loading of nucleosides on S.5 was developed using a specially fabricated reactor in conjunction with DMF as a solvent (Iyer et al., 2004a,b, 2005). The use of DMF facilitated efficient recovery of excess nucleoside, thereby resulting in higher economy of operations. Efficient mixing and contact of the functionalized solid support with the nucleoside and various reagents are necessary to achieve a high loading. The LOTUS workstation (Fig. 3.13.5) is ideally suited to accomplish this task. LOTUS enables the performance of all operations in a closed system, thereby minimizing user exposure to toxic solvents and air-borne support particles. Three LOTUS design elements facilitate efficient solid-liquid mixing: (1) orbital shaking of the solid and liquid phases, (2) fluidization of phases induced by inert gas, and (3) active recycling of the liquid phase. The mixing process in LOTUS is designated as “orbital shaking coupled with active recycling” (OSCAR). LOTUS consists of a reaction chamber equipped with accessories and a workstation to control operations by which both recycling and orbital shaking can be optionally and independently controlled. As shown in Figure 3.13.5, since all operations are performed in a closed system, human exposure to reagents, solvents, and supports is minimized while anhydrous conditions and an inert atmosphere are maintained. Basic Protocol 3 describes the use of LOTUS for loading 5 -O-(4,4 -dimethoxytrityl)N6 -benzoyl-2 -deoxyadenosine (DMTr-dABz ) on succinylated CPG. Using 100 g support in each batch, high nucleoside loadings of 70 to 80 µmol/g were achieved with only three equivalents of nucleoside in 12 to 14 hr. Following the reaction, both filtration and drying operations were performed in LOTUS. The nucleoside-loaded CPG was then treated with CAP A and CAP B in LOTUS. Thus, nucleoside loading as well as the required process operations could be conveniently performed using LOTUS as a multi-task workstation. Additionally, the use of DMF instead of pyridine prevented any unpleasant odor and also aided the facile recovery of excess nucleoside, which is especially desirable when using expensive nucleosides. Indeed, the recovery of excess nucleoside was carried out by simple aqueous workup of the DMF filtrate. Subsequently, the recovered nucleoside (DMTr-dABz ) was successfully loaded onto
Synthesis of Unmodified Oligonucleotides
3.13.15 Current Protocols in Nucleic Acid Chemistry
Supplement 23
succinylated CPG. The efficient intermixing of phases, induced by OSCAR, and on-line monitoring are key to faster reactions and dramatically improved nucleoside loading on a solid support using LOTUS. The nucleosideloaded support thus obtained has been successfully used for large-scale solid-phase synthesis of dinucleotide analogs as potential anti-HBV agents (Iyer et al., 2004a,b). Nucleoside loading on succinylated CPG can also be carried out by orbital shaking using DMF as a solvent, although the disadvantages of this protocol have been mentioned previously. Loading was carried out on succinylated CPG (100 g batches) using 5 equivalents of DMTr-dABz . Using this protocol, nucleoside-loaded CPG was obtained with loadings ranging from 60 to 70 µmol/g. Using similar procedures, nucleoside loadings on carboxy-terminated wide-pore silica, Tentagel, and aminomethyl polystyrene have also been performed. For comparison, the CPG-loaded nucleoside S.7 prepared as above and that prepared by the conventional method have been employed in a 10-µmol synthesis of dimer and 20-mer oligonucleotides (PO and PS) in an Expedite Synthesizer. In both instances, the stepwise coupling yield was >98% as ascertained by trityl analysis. Following the synthesis, each of the CPGs was treated with 28% NH4 OH at 55◦ C for 12 hr to isolate the fully deprotected di- and polynucleotides. RP-HPLC analysis of the crude mixtures showed that the profiles of compounds prepared using both supports were similar.
In conclusion, a microwave-assisted protocol for rapid and efficient functionalization of CPG is presented in which CPG S.5 carrying a carboxy terminus can be obtained from native CPG within a few hours, in contrast to conventional procedures that require several days. Efficient processes for loading of nucleosides on the resulting functionalized support are also described using anhydrous DMF as a solvent. The use of a novel reactor in conjunction with recycling technology enables efficient loading. The methodologies described here can be applied for functionalization of other solid supports and for loading of supports with nucleosides, amino acids, and small molecules for solid-phase synthesis of oligonucleotides, peptides, and ligands, respectively. The approach described here can potentially be employed for rapid functionalization of other solid matrices in the form of beads, slides, pins for application in microarrays, combinatorial chemistry including medical diagnostics, environmental clean-up (removal of toxic materials), radioimmunoassays, fluorescent immunoassays, ELISAs, and affinity chromatography.
Critical Parameters and Troubleshooting MAA of CPG MAA is an exothermic reaction and attention should be paid to ensure that reaction contents do not overheat. Accordingly, it is advisable that heat cycles be adjusted, as needed, after a pilot run on a small scale. Table 3.13.4 shows the outside temperature of the reactor
Table 3.13.4 Temperature Measurements During MicrowaveAssisted Amination of CPG with APTESa
MicrowaveAssisted Functionalization of Solid Supports
Cycle no.
Temperature after microwave exposure
Cooling temperature
1
45
—
2
82
70
3
82
68
4
88
68
5
86
68
6
90
65
7
88
71
8
84
68
9
91
64
10
83
r.t.
a Temperature measurements were made using a Raytek Minitemp laser gun. r.t.,
room temperature.
3.13.16 Supplement 23
Current Protocols in Nucleic Acid Chemistry
during heating and cooling cycles during MAA of 20 g CPG in the presence of 80 mL APTES. MAS of CPG It is important to ensure that reagents and catalysts are fresh or have been properly stored under anhydrous conditions after being opened. Succinic anhydride is hygroscopic and new containers should be stored in a desiccator after being opened. Reagent-grade DMF should be properly sealed after use and stored over molecular sieves to prevent moisture build-up. Like MAA, MAS is an exothermic reaction and attention should be paid to ensure that reaction contents do not overheat. Accordingly, it is advisable that heat cycles be suitably adjusted after a pilot run. Nucleoside loading It is important to ensure that coupling reagents and catalysts are anhydrous and fresh, or have been properly stored under anhydrous conditions after being opened. Often, lower loading yields or failure in loading reactions are a result of moisture in the reaction medium. DMTr-protected nucleosides should also be securely closed and stored at −20◦ C and thawed before opening the container. DMF and TEA should be freshly distilled from CaH2 , and dry solvents should be stored over molecular sieves. The transfer of all anhydrous solvents/reagents should be carried out through a syringe or polypropylene transfer tube under nitrogen/argon atmosphere. It is critical that anhydrous solvents and reagents are employed in the reaction and solutions. Reagents should be added sequentially as mentioned in order to obtain high loading within 24 hr. When an orbital shaker is used for loading, it should be set at a low speed to enable a gentle rocking motion for mixing of the phases. Shaking at high speed can cause the fragile particles to break up. Success in solid-support reactions is dependent on reagent concentrations. Reducing solvent volume, while ensuring that the solid support remains properly suspended in the solution, can increase the concentration of nucleoside and/or coupling reagents. Handling of solid support The use of a static gun allows easier handling and transferring of the support since the particles are light and fluffy. Prior to performing trityl assays, drying of support should be done carefully in vacuo to remove traces of
solvent. Place the support in a sample tube, secure a Kimwipe tissue around the neck, and place it in a jar attached to a vacuum manifold. Always release the vacuum slowly to minimize particle losses. As mentioned previously, although CPG particles are more rigid than silica particles, they are nevertheless fragile. It is recommended that orbital shaking be carried out at low speed for effective mixing. Use of magnetic stirrers or overhead stirrers should be completely avoided for mixing. Capping of unreacted amino groups on the support Although each amino group on the aminated CPG is expected to be coupled to succinic acid following MAS, there is a slight possibility that some unreacted amino groups will remain on the support. Uncapped amino groups on a nucleoside-loaded CPG could potentially consume phosphoramidite reagents and lower the synthesis yields if employed in oligonucleotide synthesis. An excellent discussion on the deleterious effects of uncapped amino groups on CPG can be found in UNIT 3.2. A capping step at the end of loading is essential to convert each amino functionality to an acetamido group and prevent its reaction with reagents employed in oligonucleotide synthesis.
Anticipated Results The protocols described in this unit are extremely useful for the rapid preparation of highly loaded CPG supports in a reproducible fashion. The microwave-assisted protocols for solid support functionalization are very reliable and easy to execute, even for an inexperienced investigator. It is important to use microwave-specific glassware along with all precautions mentioned in the protocol. It is possible to scale up these processes further using commercial microwave workstations using continuous flow or batch process technologies. The highly loaded supports obtained using these protocols are especially beneficial in synthesis and manufacture of 20- to 30-mer oligonucleotides. Since larger amounts of oligonucleotide can be produced in each synthesis, both scale and economy of operation are greatly enhanced. The protocols have been evaluated for the preparation of other supports such as Tentagel and aminomethyl polystyrene. The protocol also illustrates the utility of the LOTUS workstation in performing solid-phase synthesis.
Synthesis of Unmodified Oligonucleotides
3.13.17 Current Protocols in Nucleic Acid Chemistry
Supplement 23
Time Considerations Starting from native CPG, amino and carboxy functionalization reactions are carried out within minutes using these protocols. The slower steps in the process are the workup steps such as filtration, washing, and final drying, which depend on the scale of the operation.
Acknowledgments Support of this research from the National Institutes of Health, under Research Project Cooperative Agreement Grant Award 5 UO1 AI058270-02, is gratefully acknowledged.
Literature Cited Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites: A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862. Beaucage, S.L. and Iyer, R.P. 1992. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:2223-2311. Bose, A.K., Manhas, M.S., Ganguly, S.N., Sharma, A.N., and Banik, B.K. 2002. MORE chemistry for less pollution: Applications for process development. Synthesis 11:1578-1591. Chatti, S., Bortolussi, M., and Loupy, A. 2001. Cation and leaving group effects in isosorbide alkylation under microwave in phase-transfer catalysis. Tetrahedron 57:4365-4370. Damha, M.J., Giannaris, P.A., and Zabarylo, S.V. 1990. An improved procedure for derivatization of controlled-pore glass beads for solidphase oligonucleotide synthesis. Nucl. Acids Res. 18:3813-3821. Hannon, G.J. 2002. RNA interference. Nature 418:244-251. Iyer, R.P. and Beaucage, S.L. 1999. Oligonucleotide synthesis. In Comprehensive Natural Products Chemistry, Vol. 7: DNA and Aspects of Molecular Biology (E.T. Kool, ed.) pp. 105-152. Elsevier Science, London. Iyer, R.P., Kuchimanchi, S.N., and Pandey, R.K. 2003. RNA interference: An exciting new approach for target validation, gene expression analysis and therapeutics. Drugs of the Future 28:51-59. Iyer, R.P., Jin, Y., Roland, A., Morrey, J.D., Mounir, S., and Korba, B. 2004a. Phosphorothioate Diand tri-nucleotides as a novel class of antiHBV agents. Antimicrob. Agents Chemother. 48:2199-2205.
MicrowaveAssisted Functionalization of Solid Supports
Iyer, R.P., Coughlin, J.E., and Padmanabhan, S. 2005. Efficient and rapid processes for loading of nucleosides on solid supports. Org. Prep. Proc. Intl. 37:205-212; Iyer, R.P., Coughlin, J.E., and Padmanabhan, S. Patent pending. Kumar, P. and Gupta, K.C. 1997. Microwaveassisted rapid deprotection of oligodeoxyribonucleotides. Nucl. Acids Res. 25:5127-5129. Listrom, P., Tierney, J., Wathey, B., and Westeman, J. 2001. Microwave assisted organic chemistry: A review. Tetrahedron 57:9225-9283. Majors, R.E. and Hopper, M.J. 1974. Studies of siloxane phases bonded to silica gel for use in high-performance liquid chromatography. J. Chrom. Sci. 12:767-778. Manoharan, M. 2004. RNA interference and chemicaly modified small interfering RNAs. Curr. Opin. Chem. Biol. 8:570-579. Matteucci, M.D. and Caruthers, M.H. 1981. The synthesis of deoxyoligonucleotides on a polymer support. J. Am. Chem. Soc. 103:3185-3190. Padmanabhan, S., Coughlin, J.E., and Iyer, R. P. 2005. Microwave-assisted rapid and efficient functionalization of solid supports. Tetrahedron Lett. 46:343-347; Padmanabhan, S., Iyer, R.P. Patent pending. Sharp, P.A. 2001. RNA interference. Genes Dev. 15:485-490. Sproat, B.S. 1995. Chemistry and applications of oligonucleotide analogues. J. Biotechnol. 41:221-238. Tundo, R.P. and Venturello, P. 1979. Synthesis, catalytic activity, and behavior of phase-transfer catalysts supported on silica gel. Strong influence of substrate adsorption on the polar polymeric matrix on the efficiency of the immobilized phosphonium salts. J. Am. Chem. Soc. 101:6606-6613. Vlassov, V.V., Vlassova, I.E., and Pautova, L.V. 1997. Oligonucleotides and polynucleotides as biologically active compounds. Prog. Nucleic Acids Res. Mol. Biol. 57:95-143. Verma, S. and Eckstein, F. 1998. Modified oligonucleotides: Synthesis and strategy for users. Annu. Rev. Biochem. 67:99-134. Zamore, P.D. 2002. Ancient pathways programmed by small RNAs. Science 296:1265-1269.
Contributed by Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan, and John E. Coughlin Spring Bank Technologies Milford, Massachusetts
Iyer, R.P., Roland, A., Jin, Y., Mounir, S., Korba, B., Julander, J.G., and Morrey, J.D. 2004b. Antihepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob. Agents Chemother. 48:2318-2320.
3.13.18 Supplement 23
Current Protocols in Nucleic Acid Chemistry
Solution-Phase Synthesis of Di- and Trinucleotides Using Polymer-Supported Reagents
UNIT 3.14
This unit describes an alternate methodology to chemically synthesize protected phosphodiester and phosphorothioate di- and trinucleotides in solution by means of solid-supported reagents (Dueymes et al., 2005). Such a synthesis uses commercially available 5 -O-dimethoxytrityl-3 -O-(2-cyanoethyl-N,N -diisopropyl)-N-protected2 -deoxynucleoside phosphoramidites and 3 -O-levulinyl-N-protected nucleosides in combination with polyvinyl pyridinium tosylate as the activator and polystyrene-bound trimethylammonium periodate or tetrathionate as the oxidizing or sulfurizing agent, respectively. The levulinyl group was chosen for 3 -O-protection because it is orthogonal to the other protecting groups borne by the dinucleotide, i.e., dimethoxytrityl, cyanoethyl, benzoyl, and isobutyryl. The coupling and oxidizing solid-supported reagents are commercially available or can be easily prepared from commercial ion-exchange resins, as described here. The original sulfurizing reagent is attached to Amberlyst A-26 anion-exchange resin by simple stirring of the resin in an aqueous solution of potassium tetrathionate. After completion of each reaction, the solid-supported reagents are removed by filtration. The fully protected building blocks are 5 -O-detritylated with 2% p-toluenesulfonic acid or 3 -O-delevulinylated by means of anionic-polymer-bound hydrazine. Reaction work-ups consist of filtrations, aqueous extractions, and precipitations. This approach avoids the use of any chromatography process. Generally, dimer synthesis is performed at up to a 10-mmol scale, requiring only the usual laboratory glassware.
SYNTHESIS OF 5 -OH-3 -O-LEVULINYL DINUCLEOSIDE CYANOETHYLPHOSPHOTRIESTERS
BASIC PROTOCOL
This protocol and Alternate Protocol 1 describe the solution-phase synthesis of 3 O-levulinylated dinucleotides with a phosphotriester or thionophosphotriester linkage, respectively, by means of the phosphoramidite method, according to the scheme shown in Figure 3.14.1. The procedures describe synthesis at a 10-mmol scale, although they can be scaled up. These protocols are also suitable for the synthesis of 3 -O-protected trinucleotides with phosphotriester or thionophosphotriester linkages. In this protocol, synthesis of a deoxyguanosine dinucleotide is presented as an example of a dinucleotide with a phosphotriester linkage.
Materials 3 -O-Levulinyl nucleosides (S.4; UNIT 2.11; Samchully Pharmaceuticals; Reese et al., 1998): 3 -O-Levulinyl-N 6 -benzoyl-2 -deoxyadenosine 3 -O-Levulinyl-N 4 -benzoyl-2 -deoxycytidine 3 -O-Levulinyl-N 2 -isobutyryl-2 -deoxyguanosine 3 -O-Levulinyl-thymidine Standard commercial 3 -phosphoramidites (S.3; e.g., Pierce, Cruachem): 5 -O-Dimethoxytrityl-3 -O-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]N 6 -benzoyl-2 -deoxyadenosine 5 -O-Dimethoxytrityl-3 -O-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]N 4 -benzoyl-2 -deoxycytidine 5 -O-Dimethoxytrityl-3 -O-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]N2 -isobutyryl-2 -deoxyguanosine 5 -O-Dimethoxytrityl-3 -O-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]thymidine Contributed by Franc¸ois Morvan and Jean-Jacques Vasseur Current Protocols in Nucleic Acid Chemistry (2006) 3.14.1-3.14.15 C 2006 by John Wiley & Sons, Inc. Copyright
Synthesis of Unmodified Oligonucleotides
3.14.1 Supplement 26
Acetonitrile (<10 ppm H2 O) Dichloromethane (<0.005% H2 O) Poly(4-vinylpyridinium-p-toluenesulfonate) resin (S.2; Aldrich; dry 10 hr at 80◦ C under 30 mbar vacuum over P2 O5 ; store in desiccator at room temperature up to several months under 10 mbar vacuum over P2 O5 ) Argon source 50 mM tetraethylammonium acetate (TEAA), pH 7.5 Amberlyst A-26 ion-exchange resin, periodate form (S.7; see Support Protocol 1) Methanol p-Toluenesulfonic acid Saturated aqueous NaHCO3 solution 0.2 M sodium bisulfite/0.5 M sodium chloride Na2 SO4 , anhydrous Diethyl ether P2 O5 Shaker (Edmund Buhler SM-30 or equivalent) ◦ HPLC column: Nucleosil C18, 5 µm, 100 A, 150 × 4.6 mm Fritted-glass funnel, 10 cm diameter, 15 cm height Rotary evaporator 2-L separatory funnel Vacuum desiccator Additional reagents and equipment for HPLC (UNIT 10.5), thin-layer chromatography (TLC; APPENDIX 3D), and MALDI-TOF mass spectrometry (UNIT 10.1) Perform coupling reaction 1. Azeotrope (coevaporate) 4.35 g (10.0 mmol) of 3 -O-levulinyl-N2 -isobutyryl-2 deoxyguanosine (S.4) and 10.74 g (13.0 mmol) of 5 -O-dimethoxytrityl-3 -[(2cyanoethyl)-N, N-diisopropylphosphoramidite]-N2 -isobutyryl-2 -deoxyguanosine (S.3) twice, each time with 100 mL acetonitrile, then dissolve in 100 mL dichloromethane. Before use, each nucleoside derivative is stored in a dessicator under reduced pressure (10 mbar) for 14 hr. For generation of other dimers, the phosphoramidite is generally used in an excess of 1.3 to 1.5 molar equivalents with respect to the 5 -OH nucleoside.
2. Add this solution to 30 g (100.0 mmol tosylate) of dry poly(4-vinylpyridinium-ptoluenesulfonate) (S.2) and shake with the shaker set at 150 rpm at room temperature under an argon atmosphere. Monitor the disappearance of the 5 -OH nucleoside unit (RT = 7.2 min) by HPLC (UNIT 10.5) using the following conditions: ◦
Column: Nucleosil C18, 5 µm, 100 A, 150 × 4.6 mm Flow rate: 1 mL/min Mobile phase A: acetonitrile Mobile phase B: 50 mM TEAA, pH 7.5 Linear gradient: 10% to 40% A in B over 5 min, then 40% to 80% A in B over 15 min.
Solution-Phase Synthesis Using PolymerSupported Reagents
For poly(4-vinylpyridinium-p-toluenesulfonate), Aldrich reports loading of the ptoluenesulfonate anion as determined by elemental analysis: N = 4.59%, S = 10.70%, corresponding to 3.34 mmol p-toluenesulfonate (tosyl) anion per g resin. Before use, the resin is dried over P2 O5 under vacuum (30 mbar) at 80◦ C for 10 hr and then stored in desiccator over P2 O5 under vacuum (10 mbar). The loading of each batch of resin must be checked by elemental analysis before use. The coupling reaction is performed under argon.
3.14.2 Supplement 26
Current Protocols in Nucleic Acid Chemistry
Figure 3.14.1 Synthesis of dinucleotide 5 -OH-3 -O-Lev phosphotriesters and thionophosphotriesters using polymerbound reagents via the phosphoramidite approach. Symbols: B1 , B2 , bases; ABz , N 6 -benzoyladenin-9-yl; CBz , N 4 -benzoylcytosin-1-yl, GiBu , N 2 -isobutyrylguanin-9-yl, T, thymin-1-yl; CE, 2-cyanoethyl; DMTr, 4,4 -dimethoxytrityl; Lev, levulinyl; PS, polystyrene; PV, polyvinyl.
3.14.3 Current Protocols in Nucleic Acid Chemistry
Supplement 26
3. When the coupling is complete (after 1 hr to 3 hr), add 0.5 mL water and shake for an additional 15 min until the hydrolysis of any excess phosphoramidite is complete (monitored by HPLC). The phosphoramidite (S.3; RT = 22.1, 22.3 min) is hydrolyzed to the cyanoethyl Hphosphonate diester (S.6; RT = 15.0 min).
4. Filter the mixture under vacuum using a fritted-glass funnel and wash the resin three times, each time with 50 mL dichloromethane. 5. Concentrate the combined organic phase on a rotary evaporator to ∼100 mL. Proceed to the next reaction without further purification.
Perform oxidation reaction 6. Add 8.0 g (20.0 mmol IO4 – ) of Amberlyst A-26, periodate form (S.7), and shake at room temperature (generally for 2 hr) until there is complete conversion of the phosphite triester to the phosphate triester as monitored by 31 P NMR. Check the loading of the resin by elemental analysis before use. S.5: δ 140.4, 141.8 ppm; S.8: δ –1.9, –1.8 ppm. CAUTION: Special care must be exercised when using the polymer-supported periodate, which is a strong oxidizer presenting a danger of fire or explosion when in contact with other materials.
7. Filter the mixture using a fritted-glass funnel and wash the resin three times, each time with 50 mL dichloromethane.
Perform detritylation reaction 8. Add 107.0 mL of methanol to the filtrate and cool to 0◦ C in an ice bath. 9. Add 90 mL of 10% (w/v) p-toluenesulfonic acid in 7:3 (v/v) dichloromethane/ methanol prechilled to 0◦ C. Stir 30 min. 10. Perform TLC analysis (APPENDIX 3D) using 95:5 (v/v) dichloromethane/methanol as the solvent to confirm the completion of the reaction. Rf 0.48 for 5 -O-DMTr dimer and 0.30 for 5 -OH dimer.
11. Add 100 mL water and vigorously stir for 10 min at 0◦ C. During step 9, partial conversion of the levulinyl protection into its dimethylacetal derivative occurs. The reaction in this step restores the dimethylacetal to the levulinyl compound.
12. Add 100 mL saturated aqueous NaHCO3 solution and stir 10 min at 0◦ C. 13. Pour the solution into a 2-L separatory funnel and add 100 mL dichloromethane and 200 mL saturated aqueous NaHCO3 solution. Shake and isolate the organic layer. 14. Wash the organic layer with 300 mL of 0.2 M sodium bisulfite/0.5 M sodium chloride. Isolate the organic layer. 15. Dry the organic solution over 40 g of anhydrous Na2 SO4 , filter using a fritted-glass funnel, wash twice, each time with 25 mL dichloromethane, then concentrate the filtrate on a rotary evaporator. 16. Add 50 mL dichloromethane to the concentrated filtrate, then add the resulting solution dropwise to 1 L of vigorously stirring diethyl ether prechilled to 0◦ C. Solution-Phase Synthesis Using PolymerSupported Reagents
17. Filter the white precipitate using a fritted-glass funnel, then wash with 500 mL prechilled diethyl ether and dry in a vacuum desiccator over P2 O5 .
3.14.4 Supplement 26
Current Protocols in Nucleic Acid Chemistry
18. Confirm the purity of the dimer by HPLC, (UNIT 10.1).
31 P
NMR, and MALDI-TOF-MS
5 -OH-dGiBu -dGiBu -3 -O-levulinyl cyanoethylphosphotriester (S.12): Yield of white amorphous solid, 7.5 g (76%). 31 P NMR: −1.82, −1.93 ppm. MALDI-TOF-MS (THAP matrix, + mode) m/z: exp. 888.3; calc. 888.3. RP-HPLC: purity at 260 nm, 95%; RT = 8.7 min.
SYNTHESIS OF 5 -OH-3 -O-LEVULINYL DINUCLEOSIDE CYANOETHYLTHIONOPHOSPHOTRIESTERS
ALTERNATE PROTOCOL 1
This protocol describes synthesis of thionophosphotriester-linked dinucleotides using the appropriate support-bound sulfurization reagent (S.10; Fig. 3.14.1). Synthesis of a 5 -OH, 3 -O-Lev dGiBu -T dinucleotide is presented as an example.
Additional Materials (also see Basic Protocol) Amberlyst A-26 ion-exchange resin, tetrathionate form (S.10; see Support Protocol 1) 2.5% (w/v) NaHCO3 2-L separatory funnel Perform coupling reaction 1. Perform coupling as in the Basic Protocol, steps 1 to 5, starting with 3.40 g (10.0 mmol) of 3 -O-levulinyl-thymidine and 12.40 g (15.0 mmol) of 5 -O-dimethoxytrityl-3 -O-[(2-cyanoethyl)-N, N-diisopropylphosphoramidite]N2 -isobutyryl-2 -deoxyguanosine. Perform sulfurization reaction 2. Add 26.6 g (50.0 mmol S4 O6 2– ) of Amberlyst A-26, tetrathionate form (S.10), and shake at room temperature (generally for 2 hr) until there is complete conversion of the phosphite triester to the thionophosphate triester as monitored by HPLC (see Basic Protocol, step 2) and 31 P NMR. S.5: 31 P NMR: δ 141.7, 143.5 ppm. RP-HPLC: RT = 16.0, 16.1 min. S.11: 31 P NMR: δ 68.2, 68.7 ppm. RP-HPLC: RT = 16.7, 17.0 min.
3. Filter the mixture using a fritted-glass funnel and wash the resin three times, each time with 50 mL dichloromethane.
Perform detritylation reaction 4. Carry out steps 8 to 12 of the Basic Protocol. Rf 0.55 for 5 -O-DMTr dimer and 0.37 for 5 -OH dimer.
5. Pour the solution into a 2-L separatory funnel and add 200 mL dichloromethane and 300 mL saturated aqueous NaHCO3 solution. Shake and isolate the organic layer. 6. Wash the organic layer three times, each time with 500 mL of 2.5% NaHCO3 . Extended washing is performed in order to remove the 5 -OH-3 -HP CE monomer.
7. Perform steps 15 to 18 of the Basic Protocol to complete the isolation. 5 -OH-dGiBu -T-3 -O-levulinyl cyanoethylthionophosphotriester (S.14): Yield of white amorphous solid, 7.37g (91%). 31 P NMR: 68.48 and 68.09 ppm. MALDI-TOF-MS (THAP matrix, + mode) m/z: exp. 809.7; calc. 809.8. RP-HPLC purity at 260 nm, 91%; RT = 9.7 min. Synthesis of Unmodified Oligonucleotides
3.14.5 Current Protocols in Nucleic Acid Chemistry
Supplement 26
ALTERNATE PROTOCOL 2
SYNTHESIS OF 3 -OH-5 -O-DIMETHOXYTRITYL DINUCLEOSIDE CYANOETHYLTHIONOPHOSPHOTRIESTERS This protocol describes the solution-phase synthesis of 3 -OH-5 -O-DMTr-N-protected dinucleotides with a thionophosphotriester linkage by means of phosphoramidite method according to the scheme shown in Figure 3.14.2. This protocol is also suitable for the synthesis of trinucleotides with thionophosphotriester linkages. Synthesis of a 3 -OH, 5 -O-DMTr dGiBu -dCBz dinucleotide is presented as an example.
Solution-Phase Synthesis Using PolymerSupported Reagents
Figure 3.14.2 Synthesis of dinucleotide 5 -O-DMTr-3 -OH thionophosphotriesters using polymerbound reagents via the phosphoramidite approach. Symbols: B1 , B2 , bases; ABz , N 6 benzoyladenin-9-yl; CBz , N 4 -benzoylcytosin-1-yl; GiBu , N 2 -isobutyrylguanin-9-yl; T, thymin-1-yl; CE, 2-cyanoethyl; DMTr, 4,4 -dimethoxytrityl; Lev, levulinyl; PS, polystyrene; PV, polyvinyl.
3.14.6 Supplement 26
Current Protocols in Nucleic Acid Chemistry
Additional Materials (also see Basic Protocol) Amberlyst A-26 ion-exchange resin, tetrathionate form (S.10; see Support Protocol 1) Pyridine Silica gel Acetic acid Amberlyst A-15 ion-exchange resin, hydrazinium form (S.16; see Support Protocol 1) Fritted-glass column, 5 cm diameter, 60 cm height Perform coupling reaction 1. Perform coupling as in the Basic Protocol, steps 1 to 5, starting with 4.36 g (10.0 mmol) 3 -O-levulinyl-N2 -isobutyryl-2 -deoxyguanosine and 14.5 g (17.4 mmol) 5 -O-dimethoxytrityl-3 -[(2-cyanoethyl)-N, N -diisopropylphosphoramidite]N4 -benzoyl-2 -deoxycytidine. Perform sulfurization reaction 2. Add 10 mL of pyridine and 26.6 g (50.0 mmol, S4 O6 2− ) of Amberlyst A-26, tetrathionate form (S.10). Shake at room temperature (generally for 2 to 6 hr) until there is complete conversion of the phosphite triester to the thionophosphate triester as monitored by HPLC (see Basic Protocol, step 2) and 31 P NMR. S.5: 31 P NMR: δ 136.6 ppm. RP-HPLC: RT = 18.9 min. S.11: 31 P NMR: δ 64.7, 66.0 ppm. RP-HPLC: RT = 19.9 min. Pyridine is added to avoid partial detritylation
3. Filter the mixture using a fritted-glass funnel and wash the resin three times, each time with 50 mL of dichloromethane. 4. Evaporate the combined organic layers to an oil on a rotary evaporator. 5. Dissolve the oil in 44 mL of dichloromethane, add 20 g (50.0 mmol IO4 – ) of Amberlyst A-26, periodate form (S.7), and shake for 2 hr. 6. Filter the mixture using a fritted-glass funnel, then wash the resin twice, each time with 200 mL dichloromethane. 7. In a 2-L separatory funnel, wash the organic layer with 300 mL of 0.2 M sodium bisulfite/0.5 M sodium chloride. Isolate the organic layer. 8. Dry the organic solution over 40 g of anhydrous Na2 SO4 , vacuum filter using a fritted-glass funnel, and concentrate to an oil on a rotary evaporator. 9. Dissolve the oil in 60 mL dichloromethane and pour into a fritted-glass column (5 cm diameter, 60 cm height) containing 60 g silica gel. 10. Wash with 200 mL of 97:3 (v/v) dichloromethane/methanol. 11. Evaporate on a rotary evaporator. 12. Perform steps 16 to 18 of the Basic Protocol to complete the isolation. 3 -O-Levulinyl-dGiBu -dCBz -5 -O-DMTr cyanoethylthionophosphotriester (S.11): Yield of white amorphous solid, 10.32 g (861%).31 P NMR: 68.4 and 68.7 ppm. MALDI-TOF-MS (THAP matrix, + mode) m/z: exp. 1200.25; calc. 1201.24. RP-HPLC purity at 260 nm, 96%; RT = 19.0 min.
Perform delevulinylation reaction 13. Dissolve 3.5 g (2.9 mmol) of dimer S.11 in a solution consisting of 69 mL pyridine and 17 mL of acetic acid.
Synthesis of Unmodified Oligonucleotides
3.14.7 Current Protocols in Nucleic Acid Chemistry
Supplement 26
14. Add 11.8 g (43.7 mmol N2 H5 + ) of Amberlyst A-15, hydrazinium form (S.16), and shake at 150 rpm for 4 hr at room temperature. Monitor by TLC (APPENDIX 3D) using 95:5 (v/v) CH2 Cl2 /MeOH as the solvent. Rf 0.65 for 3 -O-Lev dimer and 0.51 for 3 -OH dimer.
15. Filter the resin using a fritted-glass funnel, and wash with 300 mL of dichloromethane. 16. Add 250 mL of saturated aqueous NaHCO3 to the filtrate and gently stir. 17. Pour the solution into a 2-L separatory funnel and shake to separate the organic from the aqueous layer. Retain both layers. 18. Extract the aqueous layer three times, each time with 150 mL dichloromethane, and pool all organic layers. 19. Add anhydrous Na2 SO4 to the combined organic phase, filter using a fritted-glass funnel, and concentrate on a rotary evaporator. 20. Add 30 mL of dichloromethane to the concentrated filtrate, then add the resulting solution dropwise with vigorous magnetic stirring to 300 mL of prechilled (0◦ C) diethyl ether. 21. Filter the white precipitate using a fritted-glass funnel, then wash it with 200 mL prechilled diethyl ether and dry in a vacuum desiccator over P2 O5 . 22. Confirm the purity of the dimer by HPLC, (UNIT 10.1).
31 P
NMR, and MALDI-TOF-MS
3 -OH-dGiBu -dCBz -5 -O-DMTr cyanoethylthionophosphotriester (S.17): Yield of white amorphous solid, 2.9 g (90%). 31 P NMR: 68.3 and 68.6 ppm. MALDI-TOF-MS (THAP matrix, + mode) m/z: exp. 1102.5; calc. 1103.1.RP-HPLC purity at 260 nm, 95%; RT = 17.9, 18.3 min. ALTERNATE PROTOCOL 3
ALTERNATE COUPLING PROTOCOL WHEN USING 3 -O-LEVULINYLN4 -BENZOYL 2 -DEOXYCYTIDINE Since 3 -O-levulinyl-N4 -benzoyl 2 -deoxycytidine is not soluble in dichloromethane, DMF is used as cosolvent. However the authors have noticed that traces of water trapped in the polyvinyl pyridinium resin is released due to an enhanced swelling of the resin in DMF. Hence, a preliminary drying step is needed, which is performed by means of molecular sieves shaken overnight with this mixture. All the other steps are the same as those described in the Basic Protocol.
Additional Materials (also see Basic Protocol) Dimethylformamide (DMF), anhydrous 4A molecular sieves 1. Dissolve 4.3 g (10.0 mmol) of 3 -O-levulinyl-N4 -benzoyl-2 -deoxycytidine in 60 mL hot (∼40◦ C) 1:1 (v/v) DMF/dichloromethane. 2. Add 10 g of 4A molecular sieves and 30 g (100.0 mmol tosylate) of poly(4vinylpyridinium-p-toluenesulfonate) (S.2), and shake overnight at 150 rpm, room temperature. Solution-Phase Synthesis Using PolymerSupported Reagents
3. Add 15 mmol of 5 -O-dimethoxytrityl-3 -O-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] nucleoside in 45 mL of dichloromethane and shake at room temperature ∼2 hr.
3.14.8 Supplement 26
Current Protocols in Nucleic Acid Chemistry
4. Perform HPLC analysis (see Basic Protocol, step 2) to follow the disappearance of 3 -O-levulinyl-N4 -benzoyl-2 -deoxycytidine (RT = 8.6 min). 5. Continue with steps 3 to 5 of the Basic Protocol.
PREPARATION OF POLYMER-SUPPORTED REAGENTS Materials
SUPPORT PROTOCOL 1
Amberlyst A-26 ion-exchange resin, hydroxide (OH– ) form (Aldrich) Methanol Dichloromethane Sodium periodate P2 O5 Potassium tetrathionate (Aldrich) Amberlyst A-15 ion-exchange resin, H+ form (Aldrich) 2 M HCl Hydrazine monohydrate Absolute ethanol Fritted-glass filter funnel 4-L Erlenmeyer flask Shaker Vacuum desiccator To prepare oxidizing resin (periodate form) CAUTION: Special care must be exercised when preparing or using the polymersupported periodate, which is strong oxidizer presenting a danger of fire or explosion when in contact with other materials. 1a. On a fritted glass funnel, wash 10.0 g Amberlyst A-26 (OH– form) twice each with 25 mL methanol and then 25 mL dichloromethane. 2a. Pour the resin into a 4-L Erlenmeyer flask and add 10.0 g (43 mmol) sodium periodate in 200 mL deionized water. Shake 15 hr at 150 rpm. 3a. Filter using a fritted-glass funnel. Wash the resin with 1000 mL water once, followed by 30 mL of methanol twice, then 20 mL of dichloromethane twice. 4a. Dry in a desiccator under reduced pressure over P2 O5 . 5a. Determine the loading in periodate ion by elemental analysis. Store resin up to several years at room temperature in closed vials. Yield S.7: 8.5 g of dried resin. N = 3.40%, I = 27.16%, corresponding to 2.14 mmol of periodate ion per g of resin. Note that a similar oxidizing resin is available from Novabiochem.
To prepare sulfurizing resin (tetrathionate form) 1b. On a fritted glass funnel, wash 10.0 g Amberlyst A-26 (OH– form) twice each with 25 mL methanol and then 25 mL dichloromethane. 2b. Pour the resin into a 4-L Erlenmeyer flask and 30.35 g (100 mmol) potassium tetrathionate in 200 mL deionized water. Shake 20 hr at 150 rpm. 3b. Filter using a fritted-glass funnel. Wash the resin with 4000 mL of water once, followed by 100 mL of methanol twice, then 100 mL of dichloromethane twice.
Synthesis of Unmodified Oligonucleotides
3.14.9 Current Protocols in Nucleic Acid Chemistry
Supplement 26
4b. Dry in a desiccator under reduced pressure over P2 O5 . 5b. Determine the loading in tetrathionate ion by elemental analysis. Store resin up to several years at room temperature in closed vials. Yield S.10: 8.5 g of dried resin. N = 4.24%, S = 23.25%, K+ <100 ppm, corresponding to 1.81 mmol of tetrathionate ion per g of resin.
To prepare delevulinylating resin (hydrazinium form) 1c. On a fritted glass funnel, wash 200.0 g Amberlyst A-15 (H+ form) twice each with 1000 mL water, twice each with 500 mL of 2 M HCl, then twelve times (or as necessary to bring the filtrate to pH 6) with 500 mL water. 2c. Pour the resin into a 4-L Erlenmeyer flask and add 2.3 L of a solution of 200 mL (4.12 mol) hydrazine monohydrate in 2.1 L deionized water. Shake 2.5 hr at 150 rpm. 3c. Filter using a fritted-glass funnel. Wash resin twelve times with 500 mL water, then three times with 500 mL ethanol, and finally two times with 500 mL dichloromethane. 4c. Dry in a desiccator under reduced pressure over P2 O5 . 5c. Determine the loading in hydrazinium ion by elemental analysis. Store resin up to several years at room temperature in closed vials. Yield S.16: 232 g of dried resin. N = 11.14%, S = 12.57%, corresponding to 3.98 mmol hydrazinium ion per g of resin. SUPPORT PROTOCOL 2
REGENERATION OF COUPLING RESIN Materials Used coupling resin S.2 [poly(4-vinylpyridinium-p-toluenesulfonate) resin] Acetonitrile Dichloromethane Methanol p-Toluenesulfonic acid P2 O5 2-L Erlenmeyer flask Fritted-glass funnel Platform shaker Vacuum desiccator 1. Pour 50 g of used S.2 in a 2-L Erlenmeyer flask with 500 mL of acetonitrile and shake 1 hr at 150 rpm on a platform shaker. 2. Filter using a fritted-glass funnel. 3. Pour the resin into a 2-L Erlenmeyer flask with 500 mL of dichloromethane and shake 1 hr at 150 rpm. 4. Filter using a fritted-glass funnel. 5. Pour the resin in a 2-L Erlenmeyer flask with 500 mL of methanol and shake 1 hr at 150 rpm. 6. Filter using a fritted-glass funnel.
Solution-Phase Synthesis Using PolymerSupported Reagents
7. Dissolve 200 g of p-toluenesulfonic acid in 200 mL of warm methanol (40◦ C) in a 2-L Erlenmeyer flask and add the resin. Shake 16 hr at 150 rpm on a platform rotator.
3.14.10 Supplement 26
Current Protocols in Nucleic Acid Chemistry
8. Filter using a fritted-glass funnel and wash with 600 mL of methanol and 800 mL of dichloromethane. 9. Dry the resin under vacuum (∼30 mbar) over P2 O5 at 80◦ C for 10 hr, changing the hydrolyzed P2 O5 frequently.
COMMENTARY Background Information The studies that are reported here were originally driven to develop a convenient method for scaling up the synthesis of di- and trinucleosides with oxo- and thionophosphotriester internucleoside linkages without chromatographic purification. Synthesis of oligonucleotides is generally performed on a solid support according to the phosphoramidite approach (UNIT 3.3). Although very efficient, the cost of solid supports (Sanghvi et al., 2000) explains the quest for alternative synthetic methodologies, such as the HELP method described by Bonora (UNIT 4.27), which uses an MPEG soluble support, and the PASS methods (Mihaichuk et al., 2000), in which the growing oligonucleotide reacts with a phosphoramidite unit temporarily immobilized on a solid support. Compared to solid-phase synthesis, the scale-up of solution-phase synthesis is more conventional and economical, but involves purification and isolation procedures after each reaction step. A new approach where polymerbound reagents promote reactions, also called inverse solid-phase synthesis in combinatorial chemistry (Sherrington, 2001), prevails over these limitations, as the reagents are separated from the reaction mixtures by simple filtration (Ley et al., 2000). There are only a few examples of solutionphase synthesis of oligonucleotides involving solid-phase reagents. For instance, sulfonic acid resins were employed as substitutes for acetic acid/water mixtures to induce detritylation of 5 -O-DMTr phosphodiester oligonucleotides (Iyer et al., 1995). Polystyrenesulfonyl chloride was used as the coupling agent to create phosphodiester internucleoside linkages by the obsolete phosphodiester approach (Rubinstein and Patchornik, 1972, 1975). More recently, a polymer-supported xanthane hydride was used as a sulfur-transfer reagent for the solution-phase synthesis of phosphorothioate nucleotides (Zhang et al., 2002). It could be pointed out that the use of this reagent was not reported for oligonucleotide synthesis.
Coupling step Tetrazole, tetrazole salts, and heterocyclic analogs are commonly used as activators of the coupling reaction of 5 -OH nucleosides with nucleoside 3 -O-phosphoramidites (UNIT 3.3). Tetrazole, the most frequently employed activator, needs to be of high purity. Because of its predisposition to explosion (Eleuteri et al., 2000), especially during sublimation, tetrazole is no longer sold as a solid powder. Pyridinium acidic salts were occasionally used as safer and cheaper activators than tetrazole (Beier and Pfleiderer, 1999; Eleuteri et al., 2000). Their solid-supported analogs are readily accessible from commercial resins by simple ion-exchange washings. The pyridinium moiety could be ionically bound to polystyrene sulfonic acids such as Dowex 50W or Amberlyst 15 to give S.1, or could be covalently linked to the resin, as in polyvinylpyridinium tosylate (S.2). This last reagent was formerly used for the preparation of nucleoside 3 -Ophosphoramidites (Sanghvi et al., 2000). However, in the authors’ experience, this reagent has produced poor results with low conversion yields and extensive degradation. This unfavorable reactivity was explained by the low availability of the pyridinium moieties on the resin, but the residual water contained in the resin could explain, at least partially, the hydrolysis of the formed phosphoramidite in acidic medium. The coupling reactions between an excess of nucleoside 3 -phosphoramidite (S.3) and a 5 -OH nucleoside (S.4) are generally performed in dichloromethane to ensure adequate swelling of the polystyrene polymer. Reactions performed with insoluble 3 -Olevulinyl 5 -OH-N4 -benzoyl-2 -deoxycytosine require DMF as cosolvent. The reactions are followed by 31 P NMR and by reversedphase HPLC. 31 P NMR is used to follow the conversion of the phosphoramidites (δ 148 to 150 ppm) to dinucleotide 3 -5 phosphite triesters (S.5; δ 140 ppm), and HPLC is used to follow the disappearance of the 5 -OH nucleoside. Resins (S.1) gave unpredictable Synthesis of Unmodified Oligonucleotides
3.14.11 Current Protocols in Nucleic Acid Chemistry
Supplement 26
results in regard to the reaction times, while reliable results are observed with 10 molar equivalents of polymer (S.2). After 1 to 2 hr of coupling, the 5 -OH is totally consumed. Besides the signal of the phosphite triester, the 31 P NMR analysis of the medium shows the presence of an excess of starting phosphoramidites and of their cyanoethyl Hphosphonate diester analogs (S.6; δ 8 ppm) resulting from their partial hydrolysis by water held in the resin. Attempts to remove this water by washing, azeotropic coevaporation, or drying under high vacuum were ineffective. When DMF/dichloromethane is used (for 3 -O-levulinyl-5 -OH-N4 -benzoyl 2 deoxycytosine), extensive hydrolysis of the phosphoramidites is observed due to an additional release of trapped water from the resin. This results from a better swelling of the polymer in DMF compared to dichloromethane. To avoid this extensive hydrolysis, molecular sieves are added to the reaction mixtures before the addition of the coupling agent S.2. When the coupling is done, the excess phosphoramidite is totally converted to Hphosphonate (S.6) by addition of water in order to help the purification at the end of the overall process. The phosphite triesters (S.5) are not sensitive to this addition of water. At the end of the coupling, the resin is removed by filtration and the resulting mixtures are used directly for oxidation or sulfurization.
Solution-Phase Synthesis Using PolymerSupported Reagents
Oxidation or sulfurization step Oxidation and sulfurization of dinucleotide phosphite triesters give dinucleotide phosphotriesters and thionophosphotriesters, respectively. In solid-phase DNA synthesis, I2 /H2 O is typically used for oxidation, but other nonaqueous reagents such as tertbutylhydroperoxide are also employed successfully (for other examples, see UNIT 3.3). It was reported that the periodate anion bound to an anion-exchange resin is able to oxidize triphenylphosphane in triphenylphosphane oxide (Harrison and Hodge, 1982). This polymer-bound reagent could be used in a variety of solvents (Drewry et al., 1999), increasing the limited efficiency of periodate that results from its insolubility in nonpolar solvents. The oxidation of dinucleoside phosphite triesters (S.5) is carried out with polystyrene Amberlyst A-26, periodate form (S.7), in 2 hr, yielding dinucleoside phosphotriesters (S.8; δ −2 ppm). During the course of this reaction, the contaminating nucleoside H-phosphonate diesters (S.6) are oxidized to nucleoside cya-
noethyl phosphodiesters (S.9; δ 0 ppm). The resin is then filtered off. The ability of oligonucleotide phosphorothioates to act as inhibitors of gene expression is certainly the reason why many sulfur-transfer reagents have been employed in solid-phase oligonucleotide chemistry (UNIT 3.3) From these, the most extensively used is the commercially available 3-H-1,2-bendithiol-3-one 1,1-dioxide, referred to as Beaucage’s reagent (Iyer et al., 1990). There are far fewer examples of supported sulfur-transfer reagents reported for an inverse solid-phase synthesis. The 3-amino1,2,4-dithiazole-5-thione or xanthane hydride reported as a sulfur-transfer reagent for solid-phase synthesis of oligonucleotide phosphorothioates (Tang et al., 2000) was covalently linked to a methylacrylate-ethylene glycol copolymer to sulfurize nucleoside phosphite triesters (Zhang et al., 2002). Although efficient, this reagent is not regenerable. Consequently, its synthesis is costly and time-consuming compared to an ionically polymer-bound reagent. Attaching the tetrathionate ion to anionexchange polymer resins is an alternative to a covalently bound reagent. While sluggish, pyridinium tetrathionate was used as sulfurizing agent in oligonucleotide chemistry (Efimov et al., 1995). Because of its anionic character, the tetrathionate ion is easily bound to anion-exchange polymer resins through salt bridges with the pyridinium moieties of poly4-vinyl pyridine or with the quaternary ammonium cations of the polystyrenic Amberlyst A-26. This is performed by simple stirring of the resins in an aqueous solution of potassium tetrathionate. However, the ionic bond between tetrathionate and pyridinium ions is not sufficiently stable to consider the use of the polyvinyl pyridium resin. The loading of Amberlyst A-26 tetrathionate (S.10) determined by elemental analysis shows two ammonium cations on the resin bound to the dianion. The sulfurization of phosphite triesters is followed by 31 P NMR. In general, 5 molar equivalents of S.10 are able to convert dinucleotide phosphite triesters (S.5; δ 140 ppm) to dinucleotide thionophosphotriesters (S.11; δ 68 ppm) in 2 to 3 hr. The resin is then removed by filtration. Elemental analysis of the trithionate ion resulting from the reduction of the tetrathionate is bound to the resin. In contrast to the supported-periodate oxidation of phosphite triesters where the H-phosphonate diester side products (S.6) are oxidized to phosphodiesters (S.9), the
3.14.12 Supplement 26
Current Protocols in Nucleic Acid Chemistry
tetrathionate reaction is not able to sulfurize S.6. For the synthesis of 3 -OH dinucleotides, the sulfurization is followed with the oxidation of S.6 into the polar S.9 by the periodate resin S.7. This additional treatment does not alter the thionophosphotriester linkage of dinucleotide S.11. At this stage, nucleoside phosphodiesters (S.9) are removed from the reaction mixtures by filtration on a small pad of silica gel where they remain adsorbed. Detritylation or delevulinylation step As mentioned above, strong acid cationexchange resins have been employed for the detritylation of 5 -O-DMTr- oligonucleotide phosphodiesters in water (Iyer et al., 1995). The use of these resins in organic solvents has also been described for nucleoside chemistry (Patil et al., 1994). Their reactivity is considerably dependant on the nature of the polymers. Two main advantages have been pointed out for the use of these reagents in oligonucleotide chemistry. The trityl cation released during the acidic treatment is captured by the resin so that the oligonucleotide is obtained pure after filtration, and depurination is not observed during the course of the reaction. However, in the studies illustrated here, a large variety of sulfonic acid resins were tested, and extensive degradation of the dinucleotides was observed. Consequently, these solid-supported acids are not being investigated further. The crude mixtures obtained from oxidation or sulfurization are treated with 2% p-toluenesulfonic acid in a 7:3 (v/v) dichloromethane/methanol mixture at 0◦ C for 30 min to 1 hr. The course of the reactions is conventionally followed by TLC analysis. The detritylation of crude mixtures obtained after an oxidation step generates dinucleotide 5 -OH cyanoethyl phosphotriesters (S.12) contaminated with nucleoside 5 -OH3 -cyanoethyl phosphodiesters (S.13). The crude products from the sulfurization give dinucleotide 5 -OH thionophosphotriesters (S.14) with concomitant formation of nucleoside 5 OH-3 -H-phosphonate diesters (S.15). Standard aqueous NaHCO3 workup allows the removal of nucleotide contaminants (S.13 or S.15), which stay in solution in the aqueous phase. Finally, precipitation of the desired dinucleotides in diethyl ether allows the removal of the trityl residues. The results have been consistently good, as judged from the HPLC, 31 P NMR, and MALDI-TOF-MS analysis of the dinucleotides.
The 3 -O-levulinyl protection is generally removed with a solution of hydrazine in acetic acid/pyridine (van Boom and Burgers, 1976). In this approach, a polymer-supported hydrazine (S.16) is used to perform the deprotection. This reagent is prepared by washing the strong acid cation exchanger Amberlyst A-15 with an aqueous solution of hydrazine. Delevulinylation of 3 -O-Lev-5 -O-DMTr dinucleotides is directly performed from crude products containing oxo- or thionophosphotriesters (S.8 and S.11), respectively. The delevulinylation is complete in 3 hr and gives rise to dinucleotide 5 -O-DMTr-3 -OH cyanoethyl thionophosphotriesters (S.17). Standard aqueous NaHCO3 workup allows the removal of nucleotide (S.9) from the desired dinucleotides.
Critical Parameters and Troubleshooting The preparation of the polymer-supported reagents (Support Protocol 1) and the synthesis of the di- and trinucleotides (Basic and Alternate Protocols) are relatively simple and efficient. However, careful attention to details of basic organic procedures is required. Experience with chemical laboratory techniques such as extraction, filtration, evaporation, TLC, and HPLC is needed. Characterization of the products requires knowledge of elemental analysis, 31 P NMR, and MALDI-TOF mass spectrometry. General laboratory safety is of primary concern when hazardous compounds and solvents are involved. Strict anhydrous conditions are required for the coupling step, but not for the other steps involved in the process. Special attention must be paid to the shaking of the heterogeneous reaction in order to keep reaction times short. Stirring of the solution-phase reaction medium with polymer-supported reagents is best performed on a shaker at 150 rpm. Due to the low solubility of 3 -O-levulinyl4 N -benzoyl-2 -deoxycytidine in dichloromethane, coupling steps using this monomer are performed in DMF/dichloromethane (Alternate Protocol 3). Due to the presence of methanol during the detritylation, some dimethylacetalization of the keto group of the levulinyl protection is observed, with a higher retention time in HPLC and a higher mass (+46) in MALDITOF-MS. The addition of water at the end of the reaction (Basic Protocol, step 11) allows
Synthesis of Unmodified Oligonucleotides
3.14.13 Current Protocols in Nucleic Acid Chemistry
Supplement 26
conversion of this side product into the levulinyl derivative.
Anticipated Results The protocols described here for dimers can be successfully applied for the synthesis of trimers. Using these methods, di- and trinucleotides are obtained with good yields (76% to 96%) and high purities (90% to 96%) without chromatography. Synthesis of longer oligonucleotides such as hexamers is also possible, but increasing the length of the oligonucleotide decreases its solubility in dichloromethane and requires the addition of DMF to dissolve the intermediates during the coupling step, as well as addition of pyridine during the aqueous work-up after the detritylation step (Basic Protocol, step 12). Due to low yields and purities, the authors do not recommend use of the Basic Protocol for long oligonucleotides. However, the di- and trinucleotides can be converted into 3 -phosphoramidite or 3 -H-phosphonate monoester building blocks and used for solidphase synthesis on a DNA synthesizer. Since reagents are ionically attached to the polymers, the resins are easily regenerable (see Support Protocol 2). Therefore, their cost and their impact on the environment are moderate.
Time Considerations The synthesis of a dinucleotide using polymer-supported reagents can be accomplished in 1 to 2 days. The time for coupling comprises 1 to 3 hr, depending on the loading of the supported tosylate, and requires additional time for filtration, washing, and concentration. The time needed for oxidation is usually shorter (1 to 2 hr) than for sulfurization (2 to 6 hr). Use of 31 P NMR and HPLC to monitor the reactions could increase the time required for the overall process. Detritylation is usually fast (10 to 30 min), but work-up of the reaction, with extraction and precipitation, requires more time (∼2 hr depending on the scale). Delevulinylation requires about 4 hr, plus additional time for work-up and isolation (∼2 hr).
Literature Cited
Solution-Phase Synthesis Using PolymerSupported Reagents
Beier, M. and Pfleiderer, W. 1999. Pyridinium salts: An effective class of catalysts for oligonucleotide synthesis. Helv. Chim. Acta 82:879887. Drewry, D.H., Coe, D.M., and Poon, S. 1999. Solidsupported reagents in organic synthesis. Med. Res. Rev. 19:97-148.
Dueymes, C., Sch¨onberger, A., Adamo, I., Navarro, A.E., Meyer, A., Lange, M., Imbach, J.L., Link, F., Morvan, F., and Vasseur, J.J. 2005. Highyield solution-phase synthesis of di- and trinucleotide blocks assisted by polymer-supported reagents. Org. Lett. 7:3485-3488. Efimov, V.A., Kalinkina, A.L., Chakhmakhcheva, O.G., Hill, T.S., and Jayaraman, K. 1995. New efficient sulfurizing reagents for the preparation of oligodeoxyribonucleotides phosphorothioate analogs. Nucl. Acids Res. 23:4029-4033. Eleuteri, A., Capaldi, D.C., Krotz, A.H., Cole, D.L., and Ravikumar, V.T. 2000. Pyridinium trifluoroacetate/N-methylimidazole as an efficient activator for oligonucleotide synthesis via the phosphoramidite method. Org. Proc. Res. Dev. 4:182-189. Harrison, C.R. and Hodge, P. 1982. Polymersupported periodate and iodate as oxidizing agents. J. Chem. Soc. Perkin Trans. 1 509-511. Iyer, R.P., Phillips, L.R., Egan, W., Regan, J.B., and Beaucage, S.L. 1990. The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagent. J. Org. Chem. 55:46934699. Iyer, R.P., Jiang, Z., Yu, D., Tan, W., and Agrawal, S. 1995. Improved procedure for the detritylation of DMT-oligonucleotides: Use of Dowex. Synth. Comm. 25:3611-3623. Ley, S.V., Baxendale, I.R., Bream, R.N., Jackson, P.S., Leach, A.G., Longbottom, D.A., Nesi, M., Scott, J.S., and Taylor, S.J. 2000. Muti-step organic synthesis using solid-supported reagents as scavengers: A new paradigm in chemical library generation. J. Chem. Soc. Perkin Trans. 1 3815-4195. Mihaichuk, J.C., Hurley, T.B., Vagle, K.E., Smith, R.S., Yegge, J.A., Pratt, G.M., Tompkins, C.J., Sebesta, D.P., and Pieken, W.A. 2000. The dimethoxytrityl resin product anchored sequential synthesis method (DMT PASS): A conceptually novel approach to oligonucleotide synthesis. Org. Proc. Res. Dev. 4:214224. Patil, S.V., Mane, R.B., and Salunkhe, M.M. 1994. A facile method for detritylation of 5 -Odimethoxytrityl-3 -O-tert-butyldimethylsilyl2 -deoxynucleosides. Synth. Comm. 24:24232428. Reese, C.B., Song, Q.L., Rao, M.V., and Beckett, I. 1998. Preparation of an octadeoxyribonucleoside heptaphosphorothioate by the phosphotriester approach in solution. Nucleosides Nucleotides Nucl. Acids 17:451-470. Rubinstein, M. and Patchornik, A. 1972. Polymers as chemical reagents: The use of poly(3,5 diethylstyrene)-sulfonyl chloride for the synthesis of internucleotide bonds. Tetrahedron Lett. 13:2881-2884. Rubinstein, M. and Patchornik, A. 1975. Poly(3,5diethylstyrene) sulfonyl chloride: A new reagent for internucleotide bond synthesis. Tetrahedron 31:1517-1519.
3.14.14 Supplement 26
Current Protocols in Nucleic Acid Chemistry
Sanghvi, Y.S., Guo, Z., Pfundheller, H.M., and Converso, A. 2000. Improved process for the preparation of nucleosidic phosphoramidites using a safer and cheaper activator. Org. Proc. Res. Dev. 4:175-181. Sherrington, D.C. 2001. Polymer-supported reagents, catalysts, and sorbents: Evolution and exploitation–A personalized view. J. Polym. Sci.: Polym. Chem. 39:2364-2377. Tang, J.Y., Han, Y.X., Tang, J.X., and Zhang, Z.D. 2000. Large-scale synthesis of oligonucleotide phosphorothioates using 3-amino1,2,4-dithiazole-5-thione as an efficient sulfur-transfer reagent. Org. Proc. Res. Dev. 4:194-198. van Boom, J.H. and Burgers, P.M.J. 1976. Use of levulinic acid in the protection of oligonucleotides via the modified phosphotriester method: Synthesis of decaribonucleotide U-A-U-A-U-A-UA-A-A. Tetrahedron Lett. 52:4875-7878. Zhang, Z., Han, Y., Tang, J.X., and Tang, J.Y. 2002. A novel polymer-supported sulfurtransfer reagent for the synthesis of phosphorothioates. Tetrahedron Lett. 43:4347-4349.
Contributed by Franc¸ois Morvan and Jean-Jacques Vasseur Universit´e Montpellier II Montpellier, France
Synthesis of Unmodified Oligonucleotides
3.14.15 Current Protocols in Nucleic Acid Chemistry
Supplement 26
DNA Synthesis Without Base Protection Using the Phosphoramidite Approach
UNIT 3.15
The strategy for synthesis of oligodeoxynucleotides without the protection of base moieties has proven useful for the synthesis of oligodeoxynucleotide derivatives having base-labile functional groups (Wada et al., 2001; Kobori et al., 2002; Sekine et al., 2003; Ohkubo et al., 2004, 2005a). Elimination of the base-deprotecting step makes it possible for oligodeoxynucleotides on chips or microarrays to be prepared more rapidly. Recently, the high-throughput synthesis of DNA probes on glass plates has become more important (Shena, 1999; Gao et al., 2004). Several methods categorized as base-unprotected approaches are reviewed in UNIT 3.10. In the protocols that follow, detailed experimental procedures required for DNA synthesis without base protection are described. Basic Protocols 1 to 3 describe the synthesis of the 5 -O-(4,4 -dimethoxytrityl) 3 -phosphoramidites of dC, dA, and dG from the starting unprotected 2 -deoxynucleosides. Alternate Protocols 1 to 6 describe synthesis of the same phosphoramidites by removal of N-protecting groups from commercially available phosphoramidites. The typical procedure for the synthesis of oligodeoxyribonucleotides from N-unprotected phosphoramidites involves the use of benzimidazolium triflate in the presence of trifluoromethyl-1-hydroxylbenztriazole. The key details for automated oligodeoxyribonucleotide synthesis are described in Basic Protocol 4.
SYNTHESIS OF 5 -O-(4,4 -DIMETHOXYTRITYL)-2 -DEOXYCYTIDINE 3 -(2-CYANOETHYL-N,N-DIISOPROPYLPHOSPHORAMIDITE) FROM 2 -DEOXYCYTIDINE
BASIC PROTOCOL 1
The N-unprotected dC phosphoramidite is prepared by direct tritylation of deoxycytidine followed by phosphitylation, as illustrated in Figure 3.15.1.
Materials 2 -Deoxycytidine hydrochloride (S.1a; Yamasa Shoyu) ◦ Pyridine (anhydrous, dried over 4-A molecular sieves, distilled from CaH2 ) Argon source Triethylamine (Wako, distilled from CaH2 ) Dichloroacetic acid (Wako) 4,4 -Dimethoxytrityl chloride (DMTr-Cl) Chloroform (CHCl3 ) ◦ Methanol (MeOH; Wako, anhydrous, dried over 4-A molecular sieves) Brine (saturated aqueous NaCl) Sodium sulfate (Na2 SO4 , anhydrous) Hexane Silica gel (Wakogel C-200, 75 to 150 µm) ◦ Toluene (anhydrous, dried over 4-A molecular sieves) ◦ Dichloromethane (CH2 Cl2 , anhydrous, dried over 4-A molecular sieves) ◦ Tetrahydrofuran (THF, anhydrous, dried over 4-A molecular sieves, no stabilizer) Diisopropylethylamine (DIPEA, anhydrous, dried over CaH2 , distilled from CaH2 ) 2-Cyanoethoxy-(N, N-diisopropylamino)chlorophosphine (synthesized as described in Nagai et al., 1989; Tanimura et al., 1989) 200-mL round-bottom flasks with argon-filled balloon Rotary evaporator and vacuum pump Synthesis of Unmodified Oligonucleotides Contributed by Akihiro Ohkubo, Kohji Seio, and Mitsuo Sekine Current Protocols in Nucleic Acid Chemistry (2006) 3.15.1-3.15.22 C 2006 by John Wiley & Sons, Inc. Copyright
3.15.1 Supplement 26
Figure 3.15.1
Synthesis of N-unprotected 3 -phosphoramidites by direct tritylation and phosphitylation.
Thin-layer chromatography (TLC) silica plates (Kieselgel 60 F254 ; 0.2 mm thick; Merck) 500-mL separatory funnel No. 2 filter paper and glass funnel 5 × 6– and 5 × 7.5–cm chromatography columns Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare 5 -O-DMTr-2 -dC 1. Suspend 1.30 g (5 mmol) 2 -deoxycytidine hydrochloride (S.1a) in 3 mL pyridine in a 200-mL round-bottom flask and concentrate the suspension to dryness using a rotary evaporator and vacuum pump. Repeat this azeotropic drying process three times, each time with 3 mL pyridine. 2. Add 50 mL pyridine and a stir bar to the flask and attach a balloon filled with argon gas to create an argon atmosphere. 3. While stirring, add 699 µL (5 mmol) triethylamine and then slowly add 412 µL (5 mmol) dichloroacetic acid. 4. While stirring, add 1.86 g (5.5 mmol) DMTr-Cl. 5. Stir the mixture for 4 hr at room temperature and check the reaction by TLC (APPENDIX 3D) using 6:1 (v/v) CHCl3 /MeOH (Rf = 0.59). 6. Add 10 mL MeOH to quench the DMTr-Cl and stir 10 min. 7. Dissolve the mixture in 200 mL CHCl3 and wash with 200 mL brine in a 500-mL separatory funnel. 8. Dry the organic layer over anhydrous sodium sulfate, filter through no. 2 filter paper in a glass funnel, and evaporate using a rotary evaporator and vacuum pump. 9. Dissolve the crude product in a minimal amount of 7:3 (v/v) CHCl3 /hexane. 10. Carefully transfer the crude product to the top of a 5 × 6–cm silica gel column (APPENDIX 3E). Elute successively with the following eluents:
DNA Synthesis Without Base Protection Using Phosphoramidites
3.15.2 Supplement 26
a. 500 mL of 7:3 (v/v) CHCl3 /hexane containing 1% pyridine. b. 500 mL CHCl3 containing 1% (v/v) pyridine (to remove the residues of the reagents). c. 500 mL of 99:1 (v/v) CHCl3 /MeOH containing 1% (v/v) pyridine (to remove the byproducts). d. 2 L of 97:3 (v/v) CHCl3 /MeOH containing 1% (v/v) pyridine. Collect 100-mL fractions and analyze by TLC. Current Protocols in Nucleic Acid Chemistry
11. Combine fractions containing pure product. Evaporate under reduced pressure and remove last traces of pyridine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 . 12. Check the purity of the product. 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxycytidine (S.4a): 1.88 g as a white foam (71% yield from S.1a). TLC (6:1 [v/v] CHCl3 /MeOH), 0.59. 1 H NMR (270 MHz, CDCl3 ): 7.75 (d, J = 7.32 Hz, H6), 7.24 to 7.05 (m, DMTr), 6.69 to 6.64 (m, DMTr), 6.10 (t, J = 5.9 Hz, H1 ), 5.41 (d, J = 6.8 Hz, H5), 4.38 to 4.32 (m, H3 ), 3.91 to 3.81 (m, H4 ), 3.63 (s, MeO-), 3.34 to 3.22 (m, H5 ), 2.48 to 2.39 (m, H2 ), 2.10 to 2.01 (m, H2 ). This material is used for preparation of the 3 -phosphoramidite without further purification.
Prepare 5 -O-DMTr-2 -dC-3 -phosphoramidite 13. Suspend 2.65 g (5 mmol) S.4a in 3 mL pyridine in a 200-mL round-bottom flask and concentrate to dryness using a rotary evaporator and vacuum pump. Repeat this azeotropic drying process three times each with 3-mL portions of pyridine, toluene, and CH2 Cl2 . 14. Add 50 mL THF and a stir bar to the flask and attach a balloon filled with argon gas to create an argon atmosphere. 15. While stirring, add 1.23 mL (7.5 mmol) DIPEA. 16. Cool the mixture to −78◦ C in a dry ice/acetone bath and slowly add 1.23 mL (5.5 mmol) of 2-cyanoethoxy-(N,N-diisopropylamino)chlorophosphine. Continue stirring for 10 min. 17. Warm the flask gradually to room temperature and stir 30 min. Check the reaction by TLC using 9:1 (v/v) CHCl3 /MeOH (Rf = 0.54). 18. Add 2 mL water to quench the 2-cyanoethoxy-(N,N-diisopropylamino)chlorophosphine and stir 5 min. 19. Dissolve the mixture in 200 mL CHCl3 and wash with 200 mL brine in a 500-mL separatory funnel. 20. Dry over anhydrous sodium sulfate, filter through a no. 2 filter paper in a glass funnel, then evaporate under reduced pressure. 21. Dissolve the crude product in a minimal amount of 5:5 (v/v) CHCl3 /hexane. 22. Carefully transfer the crude product to the top of a 5 × 7.5–cm silica gel column. Elute successively with the following eluents: a. 500 mL of 7:3 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. b. 500 mL of 5:5 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the residues of the reagents). c. 500 mL of 4:6 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the byproducts). d. 500 mL of 3:7 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. e. 500 mL of CHCl3 containing 1% (v/v) triethylamine. f. 500 mL of 98:2 (v/v) CHCl3 /MeOH containing 1% (v/v) triethylamine. Collect 100-mL fractions and analyze by TLC. 23. Combine fractions containing pure product and evaporate under reduced pressure. Remove the last traces of triethylamine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 .
Synthesis of Unmodified Oligonucleotides
3.15.3 Current Protocols in Nucleic Acid Chemistry
Supplement 26
24. Check the purity of the product. 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxycytidine 3 -(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.5a): 3.02 g as a white foam (83% yield from S.4a). TLC (9:1 [v/v] CHCl3 /MeOH), 0.54. 1 H NMR (270 MHz, CDCl3 ): 7.90, 7.81 (2d, J = 7.6 Hz, H6), 7.38 to 7.34 (m, DMTr), 7.27 to 7.17 (m, DMTr), 6.79 (dd, J = 4.1, 8.9 Hz, DMTr), 6.26 (dd, J = 6.2, 12.4 Hz, H1 ), 5.37 (d, J = 7.6 Hz, H5), 4.65 to 4.48 (m, H3 ), 4.09 (d, J = 3.8 Hz, H4 ), 3.75 to 3.71 (m, DMTr, iPr2 CH), 3.58 to 3.32 (m, -CH2 CN, iPr2 CH, H5 ), 2.68 to 2.52 (m, -OCH2 CH2 CN, H2 ), 2.37 (t, J = 6.2 Hz, -OCH2 CH2 CN), 2.25 to 2.11 (m, H2 ), 1.13 to 0.99 (m, iPr). 13 C NMR (67.8 MHz, CDCl3 ): 165.6, 158.6, 155.8, 144.4, 141.2, 135.5, 135.4, 130.2, 130.1, 128.2, 127.9, 127.0, 117.5, 117.4, 113.2, 93.9, 86.7, 85.9, 85.1, 72.7, 72.0, 71..7, 62.6, 62.2, 58.4, 58.1, 55.2, 43.3, 43.2, 43.1, 41.0, 40.7, 24.6, 24.6, 24.5, 22.6, 20.4, 20.3, 20.2, 20.1. 31 P NMR (109.4 MHz, CDCl3 ): 149.7, 149.2. MS (ESI) m/z (M+Na) calcd. for C39 H48 N5 NaO7 P+ 752.3189, found 752.3194. ALTERNATE PROTOCOL 1
SYNTHESIS OF THE DEOXYCYTIDINE 3 -PHOSPHORAMIDITE BY REMOVAL OF BENZOYL PROTECTION This method is performed by starting with a commercially available base-protected phosphoramidite (S.6a) and is illustrated in Figure 3.15.2.
Additional Materials (also see Basic Protocol 1) 5 -O-(4,4 -Dimethoxytrityl)-4-N-benzoyl-2 -deoxycytidine 3 -(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.6a; Glen Research) 2 M methylamine (MeNH2 ; Aldrich) in THF 5 × 8–cm chromatography column 1. Dissolve 4.17 g (5 mmol) S.6a in 50 mL of 2 M MeNH2 /THF in a 200-mL roundbottom flask equipped with a stir bar. Seal flask with a glass stopper held in place by metal clamps (to avoid hazards posed by gas pressure), and keep in fume hood. 2. Stir for 12 hr at room temperature and check the reaction by TLC (APPENDIX 3D) using 9:1 (v/v) CHCl3 /MeOH (Rf = 0.54). 3. Evaporate the mixture under reduced pressure and dissolve the crude product in a minimal amount of 5:5 (v/v) CHCl3 /hexane.
BPro DMTrO
P
DMTrO
O
NH3
O N
BNH2
O
O OCH2CH2CN
6a, B = cytosin-1-yl, Pro = benzoyl 6b, B = adenin-9-yl, Pro = benzoyl 6c, B = guanin-9-yl, Pro = isobutyryl 7a, B = cytosin-1-yl, Pro = acetyl 8b, B = adenin-9-yl, Pro = phenoxyacetyl 9c, B = guanin-9-yl, Pro = 4-isopropylphenoxyacetyl
N
P
OCH2CH2CN
5a, B = cytosin-1-yl 5b, B = adenin-9-yl 5c, B = guanin-9-yl
Figure 3.15.2 Synthesis of N-unprotected 3 -phosphoramidites by removal of nucleobase protecting groups from commercial phosphoramidites.
3.15.4 Supplement 26
Current Protocols in Nucleic Acid Chemistry
4. Carefully transfer the crude product to the top of a 5 × 8–cm silica gel column. Elute successively with the following eluents: a. 500 mL of 7:3 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. b. 500 mL of 5:5 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. c. 500 mL of 4:6 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the residues of the reagents). d. 500 mL of 3:7 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. e. 500 mL of CHCl3 containing 1% (v/v) triethylamine. f. 500 mL of 98:2 (v/v) CHCl3 /MeOH containing 1% (v/v) triethylamine. Collect 100-mL fractions and analyze by TLC. 5. Combine fractions containing pure product and evaporate under reduced pressure. Remove the last traces of triethylamine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 . 6. Check the purity of the product. 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxycytidine 3 -(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.5a): 3.10 g as a white foam (85% yield from 6a). TLC (9:1 [v/v] CHCl3 / MeOH), 0.54.
SYNTHESIS OF THE DEOXYCYTIDINE 3 -PHOSPHORAMIDITE BY REMOVAL OF ACETYL PROTECTION
ALTERNATE PROTOCOL 2
This method is performed using the commercially available phosphoramidite S.7a and is illustrated in Figure 3.15.2.
Additional Materials (also see Basic Protocol 1) 5 -O-(4,4 -Dimethoxytrityl)-4-N-acetyl-2 -deoxycytidine 3 -(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.7a; Glen Research) 2 M NH3 in MeOH (Aldrich) 5 × 8–cm chromatography column 1. Dissolve 3.86 g (5 mmol) S.7a in 50 mL of 2 M NH3 /MeOH in a 200-mL roundbottom flask equipped with a stir bar. 2. Stir for 2 hr at room temperature and check the reaction by TLC (APPENDIX 3D) using 9:1 (v/v) CHCl3 /MeOH (Rf = 0.54). 3. Evaporate the mixture under reduced pressure and dissolve the crude product in a minimal amount of 5:5 (v/v) CHCl3 /hexane. 4. Carefully transfer the crude product to the top of a 5 × 8–cm silica gel column. Elute successively with the following eluents: a. 500 mL of 7:3 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. b. 500 mL of 5:5 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. c. 500 mL of 4:6 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the residues of the reagents). d. 500 mL of 3:7 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. e. 500 mL of CHCl3 containing 1% (v/v) triethylamine. f. 500 mL of 98:2 (v/v) CHCl3 /MeOH containing 1% (v/v) triethylamine. Collect 100-mL fractions and analyze by TLC.
Synthesis of Unmodified Oligonucleotides
3.15.5 Current Protocols in Nucleic Acid Chemistry
Supplement 26
5. Combine fractions containing pure product and evaporate under reduced pressure. Remove the last traces of triethylamine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 . 6. Check the purity of the product. 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxycytidine 3 -(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.5a): 3.43 g as a white foam (94% yield from S.7a). TLC (9:1 [v/v] CHCl3 / MeOH), 0.54. BASIC PROTOCOL 2
SYNTHESIS OF 5 -O-(4,4 -DIMETHOXYTRITYL-2 -DEOXYADENOSINE 3 -(2-CYANOETHYL-N,N-DIISOPROPYLPHOSPHORAMIDITE) FROM 2 -DEOXYADENOSINE The N-unprotected dA phosphoramidite is prepared by direct tritylation of deoxyadenosine followed by phosphitylation, as illustrated in Figure 3.15.1.
Materials 2 -Deoxyadenosine (S.1b; Yamasa Shoyu) ◦ Pyridine (anhydrous, dried over 4-A molecular sieves, distilled from CaH2 ) Argon source Triethylamine (Wako, distilled from CaH2 ) Dichloroacetic acid (Wako) 4,4 -Dimethoxytrityl chloride (DMTr-Cl) Chloroform (CHCl3 ) ◦ Methanol (MeOH; Wako, anhydrous, dried over 4-A molecular sieves) Brine (saturated aqueous NaCl) Sodium sulfate (Na2 SO4 , anhydrous) Hexane Silica gel (Wakogel C-200, 75 to 150 µm) ◦ Toluene (anhydrous, dried over 4-A molecular sieves) ◦ Dichloromethane (CH2 Cl2 , anhydrous, dried over 4-A molecular sieves) ◦ Tetrahydrofuran (THF, anhydrous, dried over 4-A molecular sieves, no stabilizer) Diisopropylethylamine (DIPEA, anhydrous, dried over CaH2 , distilled from CaH2 ) 2-Cyanoethoxy-(N, N-diisopropylamino)chlorophosphine (synthesized as described in Nagai et al., 1989; Tanimura et al., 1989) 200-mL round-bottom flasks with argon-filled balloon Rotary evaporator and vacuum pump Thin-layer chromatography (TLC) silica plates (Kieselgel 60 F254 ; 0.2 mm thick; Merck) 500-mL separatory funnel No. 2 filter paper and glass funnel 5 × 6– and 5 × 7.5–cm chromatography columns Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare 5 -O-DMTr-2 -dA 1. Suspend 1.26 g (5 mmol) 2 -deoxyadenosine (S.1b) in 3 mL pyridine in a 200-mL round-bottom flask and concentrate the suspension to dryness using a rotary evaporator and vacuum pump. Repeat this azeotropic drying process three times, each time with 3 mL pyridine. DNA Synthesis Without Base Protection Using Phosphoramidites
2. Add 50 mL pyridine and a stir bar to the flask and attach a balloon filled with argon gas to create an argon atmosphere.
3.15.6 Supplement 26
Current Protocols in Nucleic Acid Chemistry
3. While stirring, add 699 µL (5 mmol) triethylamine and then slowly add 412 µL (5 mmol) dichloroacetic acid. 4. While stirring, add 1.86 g (5.5 mmol) DMTr-Cl. 5. Stir the mixture for 4 hr at room temperature and check the reaction by TLC (APPENDIX 3D) using 6:1 (v/v) CHCl3 /MeOH (Rf = 0.68). 6. Add 10 mL MeOH to quench DMTr-Cl and stir 10 min. 7. Dissolve the mixture in 200 mL CHCl3 , wash with 200 mL brine in a 500-mL separatory funnel. 8. Dry organic layer over anhydrous sodium sulfate, filter through no. 2 filter paper in a glass funnel, and evaporate using a rotary evaporator and vacuum pump. 9. Dissolve the crude product in a minimal amount of 7:3 (v/v) CHCl3 /hexane. 10. Carefully transfer the crude product to the top of a 5 × 6–cm silica gel column (APPENDIX 3E). Elute successively with the following eluents: a. 500 mL of 7:3 (v/v) CHCl3 /hexane containing 1% (v/v) pyridine. b. 500 mL of CHCl3 containing 1% (v/v) pyridine (to remove the residues of the reagents). c. 500 mL of 99.5:0.5 (v/v) CHCl3 /MeOH containing 1% (v/v) pyridine. d. 500 mL of 99:1 (v/v) CHCl3 /MeOH containing 1% (v/v) pyridine (to remove the byproducts). e. 500 mL of 98.5:1.5 (v/v) CHCl3 /MeOH containing 1% (v/v) pyridine. f. 1 L of 97:3 (v/v) CHCl3 /MeOH containing 1% (v/v) pyridine. Collect 100-mL fractions and analyze by TLC. 11. Combine fractions containing pure product. Evaporate under reduced pressure and remove last traces of pyridine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 . 12. Check the purity of the product. 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxyadenosine (S.4b): 2.04 g as a white foam (74% yield from S.1b). TLC (6:1 [v/v] CHCl3 /MeOH), 0.68. 1 H NMR (270 MHz, CDCl3 ): 8.25 (s, H2), 7.97(s, H8), 7.39 to 7.15 (m, DMTr), 6.79 to 6.75 (m, DMTr), 6.44 (t, J = 6.75 Hz, H1 ), 6.15 (brs, NH2 ), 4.70 to 4.65 (m, H3 ), 4.19 to 4.15 (m, H4 ), 3.75 (s, MeO-), 3.42 to 3.36 (m, H5 ), 2.81 to 2.74 (m, H2 ), 2.57 to 2.50 (m, H2 ). This material is used for preparation of the 3 -phosphoramidite without further purification.
Prepare 5 -O-DMTr-2 -dA-3 -phosphoramidite 13. Suspend 2.88 g (5 mmol) S.4b in 3 mL pyridine in a 200-mL round-bottom flask and concentrate to dryness using a rotary evaporator and vacuum pump. Repeat this azeotropic drying process three times each with 3-mL portions of pyridine, toluene and CH2 Cl2 . 14. Add 50 mL THF and a stir bar to the flask and attach a balloon filled with argon gas to create an argon atmosphere. 15. While stirring, add 1.23 mL (7.5 mmol) DIPEA. 16. Cool the mixture to −78◦ C in a dry ice/acetone bath and slowly add 1.23 mL (5.5 mmol) of 2-cyanoethoxy-(N, N-diisopropylamino)chlorophosphine. Continue stirring for 10 min.
Synthesis of Unmodified Oligonucleotides
3.15.7 Current Protocols in Nucleic Acid Chemistry
Supplement 26
17. Warm the flask gradually to room temperature and stir the mixture 30 min. Check the reaction by TLC using 9:1 (v/v) CHCl3 /MeOH (Rf = 0.63). 18. Add 2 mL water to quench 2-cyanoethoxy-(N, N-diisopropylamino)chlorophosphine, and stir 5 min. 19. Dissolve the mixture in 200 mL CHCl3 , wash with 200 mL brine in a 500-mL separatory funnel. 20. Dry over anhydrous sodium sulfate, filter through a no. 2 filter paper in a glass funnel, then evaporate under reduced pressure. 21. Dissolve the crude product in a minimal amount of 5:5 (v/v) CHCl3 /hexane. 22. Carefully transfer the crude product to the top of a 5 × 7.5–cm silica gel column. Elute successively with the following eluents: a. 500 mL of 7:3 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. b. 500 mL of 5:5 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the residues of the reagents). c. 500 mL of 4:6 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the byproducts). d. 500 mL of 3:7 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. e. 1.5 L of CHCl3 containing 1% (v/v) triethylamine. Collect 100-mL fractions and analyze by TLC. 23. Combine fractions containing pure product and evaporate under reduced pressure. Remove the last traces of triethylamine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 . 24. Check the purity of the product. 5-O-(4,4-Dimethoxytrityl)-2 -deoxyadenosine3 -(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.5b): 3.46 g as a white foam (92% yield from S.4b). TLC (9:1 [v/v] CHCl3 /MeOH), 0.63. 1 H NMR (270 MHz, CDCl3 ): 8.26 (s, H2), 7.99, 7.96 (2s, H7), 7.39 to 7.16 (m, DMTr), 6.76 (dd, J = 3.78, 8.91 Hz, DMTr), 6.42 (t, J = 6.35 Hz, H1 ), 5.79 (brs, NH2 ), 4.76 to 4.68 (m, H3 ), 4.28 to 4.24 (m, H4 ), 3.83 to 3.54 (m, DMTr, iPr2 CH, -CH2 CN), 3.40 to 3.31 (m, H5 ), 2.91 to 2.82 (m, H2 ), 2.65 to 2.55 (m, -OCH2 CH2 CN, H2 ), 2.44 (t, -OCH2 CH2 CN), 1.20 to 1.08 (m, iPr). 13 C NMR (67.8 MHz, CDCl3 ): 158.5, 155.4, 153.0, 149.7, 149.6, 144.5, 139.0, 135.7, 135.6, 130.0, 128.2, 128.1, 127.8, 126.8, 120.1, 117.5, 117.4, 113.1, 86.4, 85.6, 84.4, 74.2, 74.0, 63.5, 63.3, 58.4, 58.1, 55.2, 43.3, 43.1, 39.5, 24.6, 24.5, 24.4, 20.4, 20.3, 20.2, 20.1. 31 P NMR (109.4 MHz, CDCl3 ): 149.4, 149.3. MS (ESI) m/z (M+Na) calcd. for C40 H48 N7 NaO6 P+ 776.3301, found 776.3340. ALTERNATE PROTOCOL 3
SYNTHESIS OF THE DEOXYADENOSINE 3 -PHOSPHORAMIDITE BY REMOVAL OF BENZOYL PROTECTION This method is performed using the commercially available base-protected phosphoramidite 6b and is illustrated in Figure 3.15.2.
Additional Materials (also see Basic Protocol 2)
DNA Synthesis Without Base Protection Using Phosphoramidites
3.15.8 Supplement 26
5 -O-(4,4 -Dimethoxytrityl)-6-N-benzoyl-2 -deoxyadenosine 3 -(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.6b; Glen Research) 2 M methylamine (MeNH2 ; Aldrich) in THF 5 × 8–cm chromatography column 1. Dissolve 4.29 g (5 mmol) S.6b in 50 mL of 2 M MeNH2 /THF in a 200-mL roundbottom flask equipped with a stir bar. Seal flask with a glass stopper held in place by metal clamps (to avoid hazards posed by gas pressure), and keep in fume hood. Current Protocols in Nucleic Acid Chemistry
2. Stir for 2 hr at room temperature and check the reaction by TLC (APPENDIX 3D) using 9:1 (v/v) CHCl3 /MeOH (Rf = 0.63). 3. Evaporate the mixture under reduced pressure and dissolve the crude product in a minimal amount of 5:5 (v/v) CHCl3 /hexane. 4. Carefully transfer the crude product to the top of a 5 × 8–cm silica gel column. Elute successively with the following eluents: a. 500 mL of 7:3 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. b. 500 mL of 5:5 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. c. 500 mL of 4:6 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the byproducts). d. 500 mL of 3:7 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. e. 1.5 L of CHCl3 containing 1% (v/v) triethylamine. Collect 100-mL fractions and analyze by TLC. 5. Combine fractions containing pure product and evaporate under reduced pressure. Remove the last traces of triethylamine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 . 6. Check the purity of the product. 5-O-(4,4-Dimethoxytrityl)-2-deoxyadenosine3-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.5b): 3.35 g as a white foam (89% yield from S.6b). TLC (9:1 [v/v] CHCl3 / MeOH), 0.63.
SYNTHESIS OF THE DEOXYADENOSINE 3 -PHOSPHORAMIDITE BY REMOVAL OF PHENOXYACETYL PROTECTION
ALTERNATE PROTOCOL 4
This method is performed using the commercially available base-protected phosphoramidite S.8b and is illustrated in Figure 3.15.2.
Additional Materials (also see Basic Protocol 2) 5 -O-(4,4 -Dimethoxytrityl)-6-N-phenoxyacetyl-2 -deoxyadenosine 3 -(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.8b; Glen Research) 2 M NH3 in MeOH (Aldrich) 1. Dissolve 4.43 g (5 mmol) S.8b in 50 mL of 2 M NH3 /MeOH in a 200-mL roundbottom flask equipped with a stir bar. 2. Stir for 1 hr at room temperature and check the reaction by TLC (APPENDIX 3D) using 9:1 (v/v) CHCl3 /MeOH (Rf = 0.63). 3. Evaporate the mixture under reduced pressure and dissolve the crude product in a minimal amount of 5:5 (v/v) CHCl3 /hexane. 4. Carefully transfer the crude product to the top of a 5 × 8–cm silica gel column. Elute successively with the following eluents: a. 500 mL of 7:3 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. b. 500 mL of 5:5 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. c. 500 mL of 4:6 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the byproducts). d. 500 mL of 3:7 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. e. 1.5 L of CHCl3 containing 1% (v/v) triethylamine. Collect 100-mL fractions and analyze by TLC.
Synthesis of Unmodified Oligonucleotides
3.15.9 Current Protocols in Nucleic Acid Chemistry
Supplement 26
5. Combine fractions containing pure product and evaporate under reduced pressure. Remove the last traces of triethylamine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 . 6. Check the purity of the product. 5-O-(4,4-Dimethoxytrityl)-2-deoxyadenosine3-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.5b): 3.69 g as a white foam (98% yield from S.8b). TLC (9:1 [v/v] CHCl3 /MeOH), 0.63. BASIC PROTOCOL 3
SYNTHESIS OF 5 -O-(4,4 -DIMETHOXYTRITYL)-2 -DEOXYGUANOSINE 3 -(2-CYANOETHYL-N,N-DIISOPROPYLPHOSPHORAMIDITE) FROM 2 -DEOXYGUANOSINE In contrast to the N-unprotected dA and dC phosphoramidites, the dG derivative is prepared from deoxyguanosine by a method involving N-dimethylaminomethylene (dmf) protection followed by tritylation, removal of the dmf group, and then phosphitylation. The entire four-step procedure is illustrated in Figure 3.15.3.
Materials 2 -Deoxyguanosine (S.1c; Yamasa Shoyu) ◦ Pyridine (anhydrous, dried over 4-A molecular sieves, distilled from CaH2 ) ◦ Methanol (MeOH; Wako, anhydrous, dried over 4-A molecular sieves) Argon source N,N-Dimethylformamide dimethyl acetal (Tokyo Kasei Co. Ltd.; http://www.tokyokasei.co.jp/) 4,4 -Dimethoxytrityl chloride (DMTr-Cl) Chloroform (CHCl3 ) Brine (saturated aqueous NaCl) Sodium sulfate (Na2 SO4 , anhydrous) Diisopropyl ether Ammonium hydroxide Silica gel (Wakogel C-200, 75 to 150 µm) Hexane ◦ Toluene (anhydrous, dried over 4-A molecular sieves) ◦ Dichloromethane (CH2 Cl2 , anhydrous, dried over 4-A molecular sieves) Diisopropylethylamine (DIPEA, anhydrous, dried over CaH2 , distilled from CaH2 ) 2-Cyanoethoxy-(N,N-diisopropylamino)chlorophosphine (synthesized as described in Nagai et al., 1989; Tanimura et al., 1989) Triethylamine (Wako, distilled from CaH2 ) 100- and 200-mL round-bottom flasks with argon-filled balloon Rotary evaporator and vacuum pump Thin-layer chromatography (TLC) silica plates (Kieselgel 60 F254 ; 0.2 mm thick; Merck) 60-mm Buchner funnel with filter paper 500-ml separatory funnel No. 2 filter paper and glass funnel 5 × 6– and 5 × 7.5–cm chromatography columns Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and column chromatography (APPENDIX 3E)
DNA Synthesis Without Base Protection Using Phosphoramidites
3.15.10 Supplement 26
Prepare 5 -O-DMTr-2 -dG 1. Suspend 1.33 g (5 mmol) 2 -deoxyguanosine (S.1c) in 3 mL pyridine in a 100-mL round-bottom flask and concentrate to dryness using a rotary evaporator and vacuum pump. Repeat this azeotropic drying process three times, each time with 3 mL pyridine. Current Protocols in Nucleic Acid Chemistry
Figure 3.15.3
Synthesis of N-unprotected 3 -phosphoramidites via transient N-dimethylaminomethylene protection.
2. Add 30 mL dry MeOH and a stir bar to the flask and attach a balloon filled with argon gas to create an argon atmosphere. 3. While stirring, add 1.81 mL (15 mmol) N,N-dimethylformamide dimethyl acetal. 4. Stir for 4 hr at 55◦ C and check the reaction by TLC (APPENDIX 3D) using 4:1 (v/v) CHCl3 /MeOH (Rf = 0.11). 5. Cool the mixture to room temperature, then collect the resulting colorless precipitates by filtration on a 60-mm Buchner funnel with filter paper and dry under suction. 6. Suspend the dried residue in 3 mL pyridine in a 200-mL round-bottom flask and concentrate to dryness using a rotary evaporator and vacuum pump. Repeat this azeotropic drying process three times, each time with 3 mL pyridine. 7. Add 50 mL pyridine and a stir bar to the flask and attach a balloon filled with argon gas to create an argon atmosphere. 8. While stirring, add 1.86 g (5.5 mmol) DMTr-Cl. 9. Stir the mixture for 4 hr at room temperature and check the reaction by TLC using 6:1 (v/v) CHCl3 /MeOH (Rf = 0.57). 10. Add 10 mL MeOH to quench DMTr-Cl and stir 10 min. 11. Dissolve the mixture in 200 mL CHCl3 and wash with 200 mL brine in a 500-mL separatory funnel. 12. Dry organic layer over anhydrous sodium sulfate, filter through no. 2 filter paper in a glass funnel, and evaporate using a rotary evaporator and vacuum pump. 13. Dissolve the crude product in a minimal amount of CHCl3 and add 200 mL diisopropyl ether. 14. Collect the resulting yellow precipitate by filtration on a 60-mm Buchner funnel with filter paper and dry under suction.
Synthesis of Unmodified Oligonucleotides
3.15.11 Current Protocols in Nucleic Acid Chemistry
Supplement 26
15. Dissolve the resulting material in 100 mL of 1:1 (v/v) pyridine/28% ammonium hydroxide. Stir 15 hr at room temperature and check the reaction by TLC using 6:1 (v/v) CHCl3 /MeOH (Rf = 0.52). 16. Evaporate the reaction mixture in a rotary evaporator and dissolve the crude product in a minimal amount of CHCl3 . 17. Carefully transfer the crude product to the top of a 5 × 6–cm silica gel column (APPENDIX 3E). Elute successively with the following eluents: a. 500 mL of 8:2 (v/v) hexane/CHCl3 containing 1% (v/v) pyridine. b. 500 mL of CHCl3 containing 1% (v/v) pyridine (to remove the residues of the reagents). c. 500 mL of 99:1 (v/v) CHCl3 /MeOH containing 1% (v/v) pyridine. d. 500 mL of 98:2 (v/v) CHCl3 /MeOH containing 1% (v/v) pyridine (to remove the byproducts). e. 1 L of 97:3 (v/v) CHCl3 /MeOH containing 1% (v/v) pyridine. f. 2 L of 95:5 (v/v) CHCl3 /MeOH containing 1% (v/v) pyridine. Collect 100-mL fractions and analyze by TLC. 18. Combine fractions containing pure product and evaporate under reduced pressure. Dissolve the mixture in 200 mL of 1:1 (v/v) pyridine/CHCl3 and wash with 200 mL brine in a 500-mL separatory funnel. 19. Dry organic layer over anhydrous sodium sulfate, filter through no. 2 filter paper in a glass funnel, and evaporate using a rotary evaporator and vacuum pump. 20. Coevaporate the resulting material three times each with 5 mL toluene and 5 mL CHCl3 . 21. Check the purity of the product. 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxyguanosine (4c): 1.65 g as a white foam (58% yield from S.1c). TLC (6:1 [v/v] CHCl3 /MeOH), 0.52. 1 H NMR (270 MHz, CDCl3 ): 10.58 (brs, NH), 7.76 (s, H8), 7.34 to 7.17 (m, DMTr), 6.81 (dd, J = 6.3, 8.8 Hz, DMTr), 6.42 (brs, NH2 ), 6.12 (dd, J = 6.3, 6.8 Hz, H1 ), 4.35 to 4.32 (m, H3 ), 3.91 to 3.81 (m, H4 ), 3.71 (s, MeO-), 3.15 to 3.09 (m, H5 ), 2.67 to 2.57 (m, H2 ), 2.31 to 2.22 (m, H2 ). This material is used for preparation of the 3 -phosphoramidite without further purification.
Prepare 5 -O-DMTr-2 -dG-3 -phosphoramidite 22. Suspend 2.65 g (5 mmol) S.4c in 3 mL pyridine in a 200-mL round-bottom flask and concentrate to dryness using a rotary evaporator and vacuum pump. Repeat this azeotropic drying process three times each with 3-mL portions of pyridine, toluene, and CH2 Cl2 . 23. Add 50 mL CH2 Cl2 and a stir bar to the flask and attach a balloon filled with argon gas to create an argon atmosphere. 24. While stirring, add 1.23 mL (7.5 mmol) DIPEA. 25. Add 1.23 mL (5.5 mmol) 2-cyanoethoxy-(N,N-diisopropylamino)chlorophosphine. 26. Stir for 30 min and check the reaction by TLC using 9:1 (v/v) CHCl3 /MeOH (Rf = 0.48). DNA Synthesis Without Base Protection Using Phosphoramidites
27. Add 2 mL water to quench 2-cyanoethoxy-(N,N-diisopropylamino)chlorophosphine and stir 5 min.
3.15.12 Supplement 26
Current Protocols in Nucleic Acid Chemistry
28. Dissolve the mixture in 200 mL CHCl3 and wash with 200 mL brine in a 500-ml separatory funnel. 29. Dry organic layer over anhydrous sodium sulfate, filter through no. 2 filter paper in a glass funnel, and evaporate under reduced pressure. 30. Dissolve the crude product in a minimal amount of 5:5 (v/v) CHCl3 /hexane. 31. Carefully transfer the crude product to the top of a 5 × 7.5–cm silica gel column. Elute successively with the following eluents: a. 500 mL of 7:3 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. b. 500 mL of 5:5 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the residues of the reagents). c. 500 mL of 4:6 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the byproducts). d. 500 mL of 3:7 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (500 mL). e. 500 mL of CHCl3 containing 1% (v/v) triethylamine. f. 500 mL of 98.5:1.5 (v/v) CHCl3 /MeOH containing 1% (v/v) triethylamine. g. 500 mL of 97:3 (v/v) CHCl3 /MeOH containing 1% (v/v) triethylamine. Collect 100-mL fractions and analyze by TLC. 32. Combine fractions containing pure product and evaporate under reduced pressure. Remove the last traces of triethylamine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 . 33. Check the purity of the product. 5-O-(4,4-Dimethoxytrityl)-2-deoxyguanosine 3-(2 -cyanoethyl-N,N-diisopropylphosphoramidite) (S.5c): 3.08 g as a white foam (80% yield from S.4c). TLC (9:1 [v/v] CHCl3 /MeOH), 0.48. 1 H NMR (270 MHz, CDCl3 ): 7.66, 7.64 (2s, H8), 7.41 to 7.38 (m, DMTr), 7.30 to 7.14 (m, DMTr), 6.78 (dd, J = 2.70, 8.64 Hz, DMTr), 6.21 (t, J = 7.02 Hz, H1 ), 6.02 (brs, NH2 ), 4.73 to 4.70 (m, H3 ), 4.29 to 4.22 (m, H4 ), 3.90 to 3.53 (m, DMTr, iPr2 CH, -CH2 CN), 3.40 to 3.29 (m, H5 ), 2.85 to 2.72 (m, H2 ), 2.61 to 2.44 (m, H2 , -OCH2 CH2 CN), 1.19 to 1.04 (m, iPr). 13 C NMR (67.8 MHz, CDCl3 ):159.1, 158.5, 153.5, 151.52, 151.48, 144.5, 135.7, 130.10, 130.06, 129.0, 128.21, 128.17, 127.8, 126.9, 125.3, 117.6, 117.5, 127.4, 117.4, 113.1, 86.4, 85.7, 85.4, 84.0, 77.2, 74.4, 74.1, 73.7, 73.5, 63.4, 63.3, 58.43, 58.37, 58.2, 58.1, 55.2, 46.2, 43.3, 43.2, 39.1, 24.6, 24.50, 24.45, 20.4, 20.3, 20.2, 20.1. 31 P NMR (109.4 MHz, CDCl3 ): 149.5, 149.3. MS (ESI) m/z (M+H) calcd. for C40 H49 N7 O7 P+ 770.3431, found 770.3501.
SYNTHESIS OF THE DEOXYGUANOSINE 3 -PHOSPHORAMIDITE BY REMOVAL OF ISOBUTYRYL PROTECTION
ALTERNATE PROTOCOL 5
This method is performed using the commercially available base-protected phosphoramidite S.6c and is illustrated in Figure 3.15.2.
Additional Materials (also see Basic Protocol 2) 5 -O-(4,4 -Dimethoxytrityl)-2-N-isobutyryl-2 -deoxyguanosine 3 -(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.6c; Glen Research) 2 M methylamine (MeNH2 ; Aldrich) in THF 5 × 8–cm chromatography column 1. Dissolve 4.20 g (5 mmol) S.6c in 50 mL of 2 M MeNH2 /THF in a 200-mL roundbottom flask equipped with a stir bar. Seal flask with a glass stopper held in place by metal clamps (to avoid hazards posed by gas pressure), and keep in fume hood.
Synthesis of Unmodified Oligonucleotides
3.15.13 Current Protocols in Nucleic Acid Chemistry
Supplement 26
2. Stir for 14 hr at room temperature and check the reaction by TLC (APPENDIX 3D) using 9:1 (v/v) CHCl3 /MeOH (Rf = 0.48). 3. Evaporate the mixture under reduced pressure and dissolve the crude product in a minimal amount of 5:5 (v/v) CHCl3 /hexane. 4. Carefully transfer the crude product to the top of a 5 × 8–cm silica gel column. Elute successively with the following eluents: a. 500 mL of 7:3 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. b. 500 mL of 5:5 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. c. 500 mL of 4:6 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the byproducts). d. 500 mL of 3:7 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. e. 500 mL of CHCl3 containing 1% (v/) triethylamine. f. 500 mL of 98.5:1.5 (v/v) CHCl3 /MeOH containing 1% (v/v) triethylamine. g. 500 mL of 97:3 (v/v) CHCl3 /MeOH containing 1% (v/v) triethylamine. Collect 100-mL fractions and analyze by TLC. 5. Combine fractions containing pure product and evaporate under reduced pressure. Remove the last traces of triethylamine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 . 6. Check the purity of the product. 5-O-(4,4-Dimethoxytrityl)-2-deoxyguanosine 3-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.5c): 2.88 g as a white foam (75% yield from S.6c). TLC (9:1 [v/v] CHCl3 /MeOH), 0.48. ALTERNATE PROTOCOL 6
SYNTHESIS OF THE DEOXYGUANOSINE 3 -PHOSPHORAMIDITE BY REMOVAL OF ISOPROPYLPHENOXYACETYL PROTECTION This method is performed using the commercially available base-protected phosphoramidite S.9c and is illustrated in Figure 3.15.2.
Additional Materials (also see Basic Protocol 1) 5 -O-(4,4 -Dimethoxytrityl)-2-N-(4-isopropylphenoxyacetyl)-2 -deoxyguanosine 3 -(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.9c; Glen Research) 2 M NH3 in MeOH (Aldrich) 5 × 8–cm chromatography column 1. Dissolve 4.80 g (5 mmol) S.9c in 50 mL of 2 M NH3 /MeOH in a 200-mL roundbottom flask equipped with a stir bar. 2. Stir for 2 hr at room temperature and check the reaction by TLC (APPENDIX 3D) using 9:1 (v/v) CHCl3 /MeOH (Rf = 0.54). 3. Evaporate the mixture under reduced pressure and dissolve the crude product in a minimal amount of 5:5 (v/v) CHCl3 /hexane. 4. Carefully transfer the crude product to the top of a 5 × 8–cm silica gel column. Elute successively with the following eluents: DNA Synthesis Without Base Protection Using Phosphoramidites
a. 500 mL of 7:3 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. b. 500 mL of 5:5 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. c. 500 mL of 4:6 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine (to remove the byproducts).
3.15.14 Supplement 26
Current Protocols in Nucleic Acid Chemistry
d. e. f. g.
500 mL of 3:7 (v/v) hexane/CHCl3 containing 1% (v/v) triethylamine. 500 mL of CHCl3 containing 1% (v/) triethylamine. 500 mL of 98.5:1.5 (v/v) CHCl3 /MeOH containing 1% (v/v) triethylamine. 500 mL of 97:3 (v/v) CHCl3 /MeOH containing 1% (v/v) triethylamine.
Collect 100-mL fractions and analyze by TLC. 5. Combine fractions containing pure product and evaporate under reduced pressure. Remove the last traces of triethylamine by coevaporating three times each with 5 mL toluene and 5 mL CHCl3 . 6. Check the purity of the product. 5-O-(4,4-Dimethoxytrityl)-2-deoxyguanosine 3-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.5c): 3.46 g as a white foam (90% yield from S.9c). TLC (9:1 [v/v] CHCl3 /MeOH), 0.48.
TYPICAL PROCEDURE FOR SOLID-PHASE SYNTHESIS OF OLIGODEOXYRIBONUCLEOTIDES
BASIC PROTOCOL 4
Materials 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxynucleoside 3 -(2-cyanoethylN,N-diisopropylphosphoramidite)s: C (S.5a), A (S.5b), G (S.5c), and T Thymidine-loaded HCP (28 µmol/g, succinate linker) 3% trichloroacetic acid in CH2 Cl2 (Glen Research) ◦ Dichloromethane (CH2 Cl2 , anhydrous, dried over 4-A molecular sieves) ◦ Acetonitrile (CH3 CN, anhydrous, dried over 3-A molecular sieves, distilled from CaH2 ) ◦ N-Methyl-2-pyrrolidone (NMP, anhydrous, Wako, dried over 4-A molecular sieves) 1-Hydroxybenzotriazole (HOBt, Dojindo Molecular Technologies) Oxidizing solution: 0.1 M I2 in 9:1 (v/v) pyridine/H2 O (for manual operation) or 0.1 M I2 in 2:1:7 (v/v/v) pyridine/H2 O/THF (Glen Research; for automated operation) ◦ Pyridine (anhydrous, dried over 4-A molecular sieves, distilled from CaH2 ) Concentrated NH3 , aqueous 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, anhydrous, dried over CaH2 , distilled from CaH2 ) Tetrabutylammonium fluoride (TBAF) Acetic acid (AcOH; Wako) ◦ Tetrahydrofuran (THF, anhydrous, dried over 4-A molecular sieves, no stabilizer) 1-Hydroxy-6-(trifluoromethyl)benzotriazole (HOtf Bt, Aldrich) Benzimidazolium triflate (BIT; Hayakawa et al., 1996) ABI 392 DNA synthesizer Manual Operation A thymidine-loaded highly cross-linked polystyrene or HCP (1 µmol, 28 µmol/g, succinate linker; ABI) is used. Each cycle of chain elongation consists of: 1. detritylation: 3% trichloroacetic acid in CH2 Cl2 , 2 mL, 1 min 2. washing: CH2 Cl2 (three times, each with 1 mL), CH3 CN (three times, each with 1 mL) 3. first coupling: appropriate phosphoramidite unit (10 µmol) in CH3 CN/NMP (150 µL, 9:1 v/v), followed by HOBt (6.3 mg, 20 µmol) in CH3 CN/NMP (150 µL, 9:1 v/v), 1 min 4. washing: CH3 CN (three times, each with 1 ml)
Synthesis of Unmodified Oligonucleotides
3.15.15 Current Protocols in Nucleic Acid Chemistry
Supplement 26
Table 3.15.1 ABI 392 DNA Synthesizer Program Using N-Unprotected Phosphoramidites
Step
Operation
Reagent(s)
Time (min)
1
Washing
CH3 CN
0.2
2
Detritylation
3% Cl3 CCOOH/CH2 Cl2
1.5
3
Washing
CH3 CN
0.4
4
Coupling
0.1 M amidite + 0.2 M HOtf Bt in 15:1 (v/v) CH3 CN/NMP
1.0
5
Coupling
0.1 M amidite + 0.2 M HOtf Bt in 15:1 (v/v) CH3 CN/NMP
1.0
6
Washing
CH3 CN
0.2
7
Oxidation
0.1 M I2 in 2:1:7 (v/v/v) pyridine/H2 O/THF
0.5
8
Washing
CH3 CN
0.4
5. second coupling: appropriate phosphoramidite unit (10 µmol) in CH3 CN/NMP (150 µL, 9:1 v/v), followed by HOBt (6.3 mg, 20 µmol) in CH3 CN/NMP (150 µL, 9:1 v/v), 1 min 6. washing: CH3 CN (three times, each with 1 mL) 7. oxidation: 0.1 M I2 in pyridine/H2 O, 9:1 (v/v), 2 min 8. washing: pyridine (three times, each with 1 mL), CH3 CN (three times, each with 1 mL), CH2 Cl2 (three times, each with 1 mL). Generally, the average yield per cycle has been estimated to be 98% to 99% by the DMTr cation assay (UNIT 10.3). After chain elongation is finished, the DMTr group is removed by treatment with 3% trichloroacetic acid in CH2 Cl2 (2 mL) for 1 min, and the resin is washed with CH2 Cl2 (three times, each with 1 mL) and CH3 CN (three times, each with 1 mL). The oligomer is deprotected and released from the polymer support by treatment with concentrated aqueous NH3 (500 µL) for 40 min. The polymer support is removed by filtration and washed with CH3 CN (three times, each with 1 mL). The filtrate is evaporated and purified by reversed-phase or anion-exchange HPLC.
Automated Operation The synthesis of oligodeoxyribonucleotides by use of the ABI 392 DNA synthesizer is carried out on a polymer support with a succinate-type linker according to the reaction cycle shown in Table 3.15.1. The unmodified oligomer after chain elongation is deprotected and released from the polymer support by treatment with concentrated aqueous NH3 (500 µL) for 40 min. The polymer support is removed by filtration and washed with CH3 CN (three times, each with 1 mL). The filtrate is evaporated and purified by reversed-phase or anion-exchange HPLC.
DNA Synthesis Without Base Protection Using Phosphoramidites
On the other hand, synthesis of an oligomer having alkaline-labile functional groups is performed on a polymer support with a silyl-type linker using the ABI 392 DNA synthesizer program shown in Table 3.15.2. After chain elongation, the oligomer is deprotected by treatment with a 10% DBU solution in CH3 CN (500 µL) for 1 min. The oligodeoxyribonucleotide mixture is then released from the resin by treatment with 500 µl of a 1:1 mixture of 1 M TBAF in AcOH and THF for 1 hr. The polymer support is removed by filtration and washed with CH3 CN (three times, each with 1 mL). The filtrate is evaporated and purified by reversed-phase or anion-exchange HPLC.
3.15.16 Supplement 26
Current Protocols in Nucleic Acid Chemistry
Table 3.15.2 ABI 392 DNA Synthesizer Program for Oligomers with Alkaline-Labile Functional Groups
Step
Number
Operation Name
Time (sec)
1
106
Begin
2
64
18 to Waste
3.0
3
42
18 to Column
10.0
4
2
Reverse Flush
10.0
5
1
Block Flush
4.0
6
101
Phos Prep
3.0
7
140
Column 1 On
8
111
Block Vent
2.0
9
58
Tet to Waste
1.7
10
33
B + Tet to Column
2.5
11
34
Tet to Column
1.0
12
33
B + Tet to Column
2.5
13
43
Push to Column
14
141
Column 1 Off
15
142
Column 2 On
16
64
18 to Waste
4.0
17
1
Block Flush
3.0
18
111
Block Vent
2.0
19
58
Tet to Waste
1.7
20
33
B + Tet to Column
2.5
21
34
Tet to Column
1.0
22
33
B + Tet to Column
2.5
23
43
Push to Column
24
143
Column 2 Off
25
103
Wait
15.0
26
2
Reverse Flush
0.1
27
5
Flush to Collect
0.1
28
103
Wait
15.0
29
2
Reverse Flush
0.1
30
5
Flush to Collect
0.1
31
103
Wait
15.0
32
2
Reverse Flush
0.1
33
5
Flush to Collect
0.1
34
103
Wait
15.0
35
58
Tet to Waste
1.7
36
33
B + Tet to Column
2.5
37
34
Tet to Column
1.0
38
33
B + Tet to Column
2.5
39
43
Push to Column continued
Synthesis of Unmodified Oligonucleotides
3.15.17 Current Protocols in Nucleic Acid Chemistry
Supplement 26
Table 3.15.2 ABI 392 DNA Synthesizer Program for Oligomers with Alkaline-Labile Functional Groups, continued
Step
DNA Synthesis Without Base Protection Using Phosphoramidites
Number
Operation Name
Time (sec)
40
143
Column 2 Off
41
103
Wait
15.0
42
2
Reverse Flush
0.1
43
5
Flush to Collect
0.1
44
103
Wait
15.0
45
2
Reverse Flush
0.1
46
5
Flush to Collect
0.1
47
103
Wait
15.0
48
2
Reverse Flush
0.1
49
5
Flush to Collect
0.1
50
103
Wait
15.0
51
64
18 to Waste
4.0
52
42
18 to Column
10.0
53
2
Reverse Flush
7.0
54
1
Block Flush
3.0
55
64
18 to Waste
10.0
56
2
Reverse Flush
7.0
57
1
Block Flush
3.0
58
41
15 to Column
8.0
59
64
18 to Waste
4.0
60
1
Block Flush
3.0
61
103
Wait
30.0
62
42
18 to Column
10.0
63
4
Flush to Waste
6.0
64
42
18 to Column
10.0
65
2
Reverse Flush
7.0
66
1
Block Flush
3.0
67
105
Start Detrityl
68
64
18 to Waste
4.0
69
42
18 to Column
10.0
70
2
Reverse Flush
7.0
71
1
Block Flush
3.0
72
112
Trityl Advance
73
109
Waste – Port
74
120
Advance FC
75
120
Advance FC
76
120
Advance FC
77
120
Advance FC
78
113
End Advance continued
3.15.18 Supplement 26
Current Protocols in Nucleic Acid Chemistry
Table 3.15.2 ABI 392 DNA Synthesizer Program for Oligomers with Alkaline-Labile Functional Groups, continued
Step
Number
Operation Name
Time (sec)
79
40
14 to Column
15.0
80
3
Trityl Flush
5.0
81
40
14 to Column
15.0
82
103
Wait
15.0
83
3
Trityl Flush
5.0
84
40
14 to Column
10.0
85
103
Wait
10.0
86
3
Trityl Flush
5.0
87
40
14 to Column
6.0
88
103
Wait
10.0
89
3
Trityl Flush
5.0
90
42
18 to Column
10.0
91
3
Trityl Flush
8.0
92
110
Waste – Bottle
93
42
18 to Column
8.0
94
2
Reverse Flush
7.0
95
1
Block Flush
4.0
96
107
End
COMMENTARY Background Information
The synthesis of N-unprotected 2 deoxynucleoside-3 -phosphoramidite building blocks was first reported as a four-step reaction with N-dimethylaminomethylene2 -deoxyribonucleosides (Zemlicka and Holy, 1967; Holy and Zemlicka, 1969; McBride et al., 1986) as the key intermediates (Gryaznov and Letsinger, 1991, 1992). The N-dimethylaminomethylene-2 -deoxyribonucleoside derivatives S.2a-c (Fig. 3.15.3) can be readily synthesized by the reaction of 2 -deoxyribonucleosides S.1a-c with dimethylformamide dimethyl acetal, and are converted to the corresponding 5 -Odimethoxytritylated compounds S.3a-c by the usual tritylation procedure. Treatment of the 5 -O-DMTr products S.3a-c with ammonia gives the N-unprotected species S.4a-c, which are phosphitylated to give the N-unprotected 2 -deoxynucleoside 3 -phosphoramidite building blocks S.5a-c. Although this four-step procedure is somewhat time consuming, it has proven to be the most reliable method for obtaining the pure building blocks. This
method is presented for the preparation of the N-unprotected 2 -deoxyguanosine derivative (S.5c) in Basic Protocol 3. The N-unprotected 5 -O-DMTr 2 -deoxynucleoside derivatives S.4a-c have also been synthesized by the direct introduction of the DMTr group onto the 5 -hydroxyl group of 2 -deoxyribonucleosides (Fig. 3.15.1). Ishido first reported this straightforward method to obtain S.4a and S.4b (Ishido, 1989; Nishino et al., 1991). The reaction of S.1a and S.1b with DMTr-Cl in pyridine in the presence of dichloroacetic acid gave S.4a and S.4b in good yields. These reactions have proven to be practical. Later, Kataoka and Hayakawa (1999) reported an alternative to this method using DMTr-Cl/triethylamine/imidazole. In this paper, O-selective direct tritylation of 2 deoxyguanosine was first reported. The reproducibility of this process, however, is very low. A four-step procedure involving the initial protection of the nucleobase with the dimethylaminomethylene protecting group is more practical for the synthesis of 5 -O-DMTr-2 deoxyguanosine, as shown in Figure 3.15.1
Synthesis of Unmodified Oligonucleotides
3.15.19 Current Protocols in Nucleic Acid Chemistry
Supplement 26
DNA Synthesis Without Base Protection Using Phosphoramidites
(Hayakawa and Kataoka, 1998). The 5 O-DMTr-2 -deoxyribonucleoside derivatives S.4a-c thus obtained are readily converted to the corresponding 3 -phosphoramidite derivatives. This process can be successfully carried out for all of the N-unprotected species. Basic Protocols 1 and 2 describe direct tritylation of 2 -deoxycytidine and 2 -deoxyadenosine using the method of Kataoka and Hayakawa, followed by phosphitylation to give the Nunprotected phosphoramidites S.5a-b. Quite recently, a new method for preparation of N-unprotected 5 -O-DMTr2 -deoxyribonucleoside 3 -phosphoramidites has been reported (Ohkubo et al., 2005b). It was found that first-generation Nprotected 2 -deoxyribonucleoside 3 -phosphoramidite derivatives such as N-benzoyl2 -deoxycytidine 3 -phosphoramidite (S.6a), N-acetyl-2 -deoxycytidine 3 -phosphoramidite (S.7a), N-benzoyl-2 -deoxyadenosine 3 phosphoramidite (S.6b), and N-isobutyryl-2 deoxyguanosine 3 -phosphoramidite (S.6c), as well as currently used reagents such as N-phenoxyacetyl-2 -deoxyadenosine 3 -phosphoramidite (S.8b) and N-isopropylphenoxylacetyl-2 -deoxyguanosine 3 -phosphoramidite (S.9c), could be converted to the N-unprotected 3 -phosphoramidite derivatives S.5a-c in high yields by treatment with ammonia in methanol (Fig. 3.15.2). These methods are presented as Alternate Protocols. The first-generation 3 -phosphoramidite reagents S.6a-c have not been used with DNA synthesis strategies developed recently to address the strong demand for shorter total reaction times. These approaches require the more base-labile N-acetylated (S.7a) and N-phenoxyacetylated (S.8b, S.9c) species. The classically N-protected 5 -O-DMTr-2 deoxyribonucleoside derivatives have been synthesized as key intermediates for the synthesis of phosphoramidites by wellestablished procedures, and the cost of these old reagents is rather cheap compared with the currently used PAC-phosphoramidite building blocks. Thereby, the total cost of the N-unprotected 2 -deoxyribonucleoside 3 phosphoramidite building blocks becomes even cheaper than that of the PAC phosphoramidite units. The successful deacylation of the first-generation phosphoramidite building blocks has provided a new potential use for N-unprotected 2 -deoxyribonucleoside 3 phosphoramidites as versatile intermediates in the construction of oligodeoxyribonucleotides with new functional groups. For example, the
reaction of S.5a with phenylisocyanate gives new N-modified building blocks that are useful for synthesis of oligodeoxyribonucleotides having aromatic rings as substituents on the nucleobase moiety (Ohkubo et al., 2005b). Since the reaction of the free amino group on cytosine with isocyanate derivatives proceeds smoothly without damage to other functional groups such as the phosphoramidite linkage, this reaction provides a powerful new tool for synthesizing a wide variety of modified DNA monomers.
Critical Parameters and Troubleshooting In Basic Protocols 1 to 3, for synthesis of N-unprotected phosphoramidites from unprotected nucleosides, the reactions should be carried out using DMTr-Cl or 2-cyanoethoxy(N,N-diisopropylamino)chlorophosphine derivatives under anhydrous conditions. In particular, the O-selective phosphitylation should be performed using the chlorophosphine (not 2-cyanoethoxy-bis(diisopropylamino)phosphine) at a low temperature to avoid N-phosphitylation of the nucleobases. The reactions are checked by TLC prespotted with one drop of triethylamine to prevent degradation of the target phosphoramidite units. After the reactions are completed, H2 O (not MeOH or EtOH) should be added to the reaction mixture to quench the chlorophosphine. In the Alternate Protocols, N-protected phosphoramidite compounds should be treated with methylamine or ammonia under anhydrous conditions to avoid the hydrolysis of the phosphoramidite residues.
Anticipated Results The N-unprotected DNA synthesis is very attractive for high-throughput synthesis of DNA molecules and synthesis of alkali-labile modified DNAs such as oligonucleotides containing DNA lesions, because this strategy allows the omission of the nucleobase deprotection step usually performed by treatment with concentrated NH3 at room temperature for 3 to 8 hr. In this approach, after the chain elongation is carried out using the four N-unprotected monomer building blocks on an ABI 392 DNA synthesizer used for synthesis of unmodified DNAs, the desired crude mixture is obtained by selective cleavage of the succinate linker from the polymer support using concentrated NH3 at room temperature only for 40 min. As an example, the anion-exchange HPLC profile of a crude mixture of the unmodified DNA
3.15.20 Supplement 26
Current Protocols in Nucleic Acid Chemistry
Figure 3.15.4 Anion-exchange HPLC profiles of crude mixtures obtained using a 0.2 M HOtf Bt + BIT solution under conditions used for the ABI 392 DNA synthesizer. (A) d(TTAAAAATTATTAAATTATT). Anion-exchange HPLC was done on a Waters Alliance system with a Waters 3D UV detector and a Gen-Pak FAX column (Waters, 4.6 × 100 mm). A linear gradient (10% to 80%) of solvent I (1 M NaCl in 25 mM phosphate buffer, pH 6.0) in solvent II (25 mM phosphate buffer, pH 6.0) was used at 50◦ C at a flow rate of 1.0 mL/min for 45 min. (B) d(TACCTGGiBuGTCCAT). A linear gradient (10% to 60%) of solvent I (1 M NaCl in 25 mM phosphate buffer, pH 6.0) in solvent II (25 mM phosphate buffer, pH 6.0) was used at 50◦ C at a flow rate of 1.0 mL/min for 45 min.
oligomer d[TAAAAATTATTAAATTATT] is shown in Figure 3.15.4A. Moreover, a method has been established for synthesizing oligonucleotides incorporating alkali-labile modified bases such as 4-Nacetylcytosine or 2-N-isobutyrylguanosine by the combined use of the N-unprotected approach and a new silyl-type linker that can be cleaved under neutral conditions. After the final condensation is finished, the cyanoethyl groups are removed by treatment with 10% DBU in MeCN for 1 min. The crude oligodeoxyribonucleotide is released from the resin by treatment with a 1 M TBAF/AcOH in THF and then analyzed by HPLC. As an example, the anion-exchange HPLC profile of a crude mixture of the modified DNA oligomer d[TACCTGGiBu GTCCAT] is shown in Figure 3.15.4B. In the near feature, the present Nunprotected strategy may make it possible to avoid the considerable and undesired release of DNA probes synthesized in situ on glass plates, which currently requires a final deprotection step using concentrated NH3 .
Time Considerations The time needed to synthesize an Nunprotected phosphoramidite unit is estimated to be 2 to 4 days. All N-unprotected phosphoramidite units are stable at the purification step. The synthesis and purification of oligonucleotides using the activated phosphite method
can be carried out in 2 to 4 days. The time needed for the Alternate Protocols is estimated to be 1 to 2 days.
Literature Cited Gao, X., Gulari, E., and Zhou, X. 2004. In situ synthesis of oligonucleotide microarrays. Biopolymers 73:579-596. Gryaznov, S.M. and Letsinger, R.L. 1991. Synthesis of oligonucleotides via monomers with unprotected bases. J. Am. Chem. Soc. 113:58765877. Gryaznov, S.M. and Letsinger, R.L. 1992. Selective O-phosphitylation with nucleoside phosphoramidite reagents. Nucl. Acids Res. 20:18791882. Hayakawa, Y., and Kataoka, M. 1998. Facile synthesis of oligodeoxyribonucleotides via the phosphoramidite method without nucleoside base protection. J. Am. Chem. Soc. 120:1239512401. Hayakawa, Y., Kataoka, M., and Noyori, R. 1996. Benzimidazolium triflate as an efficient promoter for nucleotide synthesis via the phosphoramidite method. J. Org. Chem. 61:79967997. Holy, A. and Zemlicka, J. 1969. Oligonucleotidic compounds. XXXIII. Hydrolysis of N-dimethyl-aminomethylenecytidine (DMC), N-dimethylaminomethyleneadenosine (DMA), and N-dimethylaminomethyleneguanosine (DMG) and related 2 deoxy compounds. Collect. Czech. Chem. Commun. 34:2449-2458. Ishido, R. 1989. Protection of 5 -hydroxy groups of cytidine derivatives. Jpn. Kokai Tokkyo Koho Jp Pat. 01308294.
Synthesis of Unmodified Oligonucleotides
3.15.21 Current Protocols in Nucleic Acid Chemistry
Supplement 26
Kataoka, M. and Hayakawa, Y. 1999. A convenient method for the synthesis of N-free 5 -O-(p,p dimethoxytrityl)-2 -deoxyribonucleosides via 5 -O-selective tritylation of the parent substances. J. Org. Chem. 64:6087-6089. Kobori, A., Miyata, K., Ushioda, M., Seio, K., and Sekine, M. 2002. A new method for the synthesis of oligodeoxyribonucleotides containing 4N-alkoxycarbonyldeoxycytidine derivatives and their hybridization properties. J. Org. Chem. 67:476-485. McBride, L.J., Kierzek, R., Beaucage, S.L., and Caruthers, M.H. 1986. Nucleotide chemistry. 16. Amidine protecting groups for oligonucleotide synthesis. J. Am. Chem. Soc. 108:20402048. Nagai, H., Fujiwara, T., Fujii, M., Sekine, M., and Hata, T. 1989. Reinvestigation of deoxyribonucleoside phosphorothioites: Synthesis and properties of deoxyribonucleoside-3 dimethyl phosphites. Nucl. Acids Res. 17:8581-8593. Nishino, S., Nagano, Y., Hasegawa, Y., Yamamoto, H., Kamaike, K., and Ishido, Y. 1991. Efficient deanilidation of phosphoranilidates by the use of nitrites and acetic anhydride. Heteroatom Chem. 2:187-196. Ohkubo, A., Ezawa, Y., Seio, K., and Sekine, M. 2004. O-selectivity and utility of phosphorylation mediated by phosphite triester intermediates in the N-unprotected phosphoramidite method. J. Am. Chem. Soc. 126:10884-10896. Ohkubo, A., Aoki, K., Ezawa, Y., Sato, Y., Taguchi, H., Seio, K., and Sekine, M. 2005a. Synthesis of oligodeoxyribonucleotides containing hydroxymethylphosphonate bonds in the phosphoramidite method and their hybridization properties. Tetrahedron Lett. 46:8953-8957.
Ohkubo, A., Sakamoto, K., Miyata, K., Taguchi, H., Seio, K., and Sekine, M. 2005b. Convenient synthesis of N-unprotected deoxynucleoside 3 -phosphoramidite building blocks by selective deacylation of N-acylated species and their facile conversion to other N-functionalized derivatives. Org. Lett. 7:5389-5392. Sekine, M., Ohkubo, A., and Seio, K. 2003. Protonblock strategy for the synthesis of oligodeoxynucleotides without base protection, capping reaction, and P-N bond cleavage reaction. J. Org. Chem. 68:5478-5492. Shena, M. 1999. DNA Microarrays: A Practical Approach. Oxford University Press, London. Tanimura, H., Maeda, M., Fukuzawa, T., Sekine, M., and Hata, T. 1989. Chemical synthesis of the 24 RNA fragments corresponding to hop stunt viroid. Nucl. Acids Res. 17:8135-8147. Wada, T., Kobori, A., Kawahara, S., and Sekine, M. 2001. Synthesis and hybridization ability of oligodeoxyribonucleotides incorporating N-acyldeoxycytidine derivatives. Eur. J. Org. Chem. 4583-4593. Zemlicka, J. and Holy, A. 1967. Preparation of Ndimethylaminomethylene derivatives as a new method of a selective substitution of nucleoside amino groups. Collect. Czech. Chem. Commun. 32:3159-3168.
Contributed by Akihiro Ohkubo, Kohji Seio, and Mitsuo Sekine Tokyo Institute of Technology Tokyo, Japan
DNA Synthesis Without Base Protection Using Phosphoramidites
3.15.22 Supplement 26
Current Protocols in Nucleic Acid Chemistry
A Universal and Recyclable Solid Support for Oligonucleotide Synthesis
UNIT 3.16
Franc¸ois Morvan,1 Albert Meyer,1 and Jean-Jacques Vasseur1 1
Universit´e Montpellier, Montpellier, France
ABSTRACT This unit provides a modified phosphoramidite method to synthesize oligodeoxyribonucleotides onto a universal and reusable hydroxyl solid support thanks to the use of deoxyribonucleoside tert-butyl and cyanoethyl phosphoramidites. The nucleoside tert-butyl phosphoramidite allows the introduction of an H-phosphonate diester linkage using the phosphoramidite method. After elongation, the H-phosphonate diester linker is cleaved by transesterification under mild basic conditions to yield an oligonucleotide with free 3 and 5 -hydroxyls and the starting solid support. Thus, the solid support is easily recycled and used for a subsequent synthesis. In addition, a nucleoside tert-butyl phosphoramidite could be introduced inside the oligonucleotide chain during the elongation to yield a second H-phosphonate diester linkage. After elongation, the two H-phosphonate diester linkages are cleaved, producing two oligonucleotides with free 3 - and 5 -hydroxyls. C 2007 by John Wiley & Sons, Inc. Curr. Protoc. Nucleic Acid Chem. 30:3.16.1-3.16.19. Keywords: phosphoramidite r H-phosphonate r automatized synthesis r tandem synthesis
INTRODUCTION This unit describes a modified phosphoramidite method to synthesize oligodeoxyribonucleotides onto a universal and reusable hydroxylated solid support through the use of deoxyribonucleoside tert-butyl- and 2-cyanoethyl-N,N-diisopropylphosphoramidites (Ferreira et al., 2005). Deoxyribonucleoside tert-butyl phosphoramidites are obtained from commercially available 5 -O, N-protected deoxyribonucleosides using tert-butyl tetraisopropylphosphorodiamidite. The coupling of a deoxyribonucleoside tert-butyl phosphoramidite with the hydroxylated solid support immediately followed by the detritylation step, without performing the oxidation step of the synthesis cycle, produces an H-phosphonate diester linkage. Then, standard deoxyribonucleoside 2cyanoethyl phosphoramidites are incorporated according to the phosphoramidite method (Beaucage and Caruthers, 1981; UNIT 3.3) with a few modifications that maintain the Hphosphonate diester linkage throughout the elongation of the oligonucleotide. Oxidations are done with tert-butyl hydroperoxide (Hayakawa et al., 1986) or 3H-1,2-benzodithiole3-one 1,1-dioxide (Iyer et al., 1990) to afford the phosphotriester or thionophosphorotriester, respectively, since these oxidizing reagents do not oxidize H-phosphonate diester linkages (Jung et al., 1994; Bologna et al., 1999). The capping step is performed with a phosphoramidite rather than the usual acetic anhydride to avoid P-acylation of the H-phosphonate linkage (UNIT 3.4), and dichloroacetic acid (DCA) is preferred for the detritylation step. At the end of chain elongation, a treatment with potassium carbonate in methanol releases the 3 -OH oligonucleotide from the starting hydroxylated solid support, which can be recycled and reused several times. Additionally, the nucleoside tert-butyl phosphoramidite can be introduced inside the oligonucleotide chain during elongation to yield a second H-phosphonate diester linkage and enable tandem oligonucleotide synthesis.
Current Protocols in Nucleic Acid Chemistry 3.16.1-3.16.19, September 2007 Published online September 2007 in Wiley Interscience (www.interscience.wiley.com). DOI: 10.1002/0471142700.nc0316s30 C 2007 John Wiley & Sons, Inc. Copyright
Synthesis of Unmodified Oligonucleotides
3.16.1 Supplement 30
CAUTION: All chemicals must be used in a chemical fume hood by qualified persons equipped with laboratory coats, safety glasses, and gloves. BASIC PROTOCOL 1
PREPARATION OF DEOXYRIBONUCLEOSIDE tert-BUTYL PHOSPHORAMIDITES Conversion of 5 -O- and N-protected deoxyribonucleosides into the corresponding tertbutyl phosphoramidites using tert-butyl tetraisopropylphosphorodiamidite is shown in Figure 3.16.1. Starting material, solvents, and glassware must be as dry as possible to obtain high yields.
Materials 5 -O-DMTr-N-protected nucleoside (Samchully Pharmaceuticals): 5 -O-(4,4 -Dimethoxytrityl)-N6 -benzoyl-2 -deoxyadenosine (S.1a) 5 -O-(4,4 -Dimethoxytrityl)-N4 -benzoyl-2 -deoxycytidine (S.1b) 5 -O-(4,4 -Dimethoxytrityl)-N2 -isobutyryl-2 -deoxyguanosine (S.1c) 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxythymine (S.1d) Diisopropylammonium tetrazolide Acetonitrile (dried over CaH2 and distilled) Anhydrous methylene chloride (CH2 Cl2 ; freshly distilled over P2 O5 ) tert-Butyl tetraisopropylphosphorodiamidite (Aldrich) Argon Molybde stain (see recipe), optional Ethyl acetate Saturated aqueous sodium chloride solution (brine) Anhydrous sodium sulfate Cyclohexane Triethylamine (Et3 N) Silica gel (0.04 to 0.06 mm) Dioxane 50-mL round-bottom flask equipped with stir bar and CaCl2 guard TLC silica plates (Kieselgel 60 F-254; Merck) 254-nm UV lamp 250-mL separatory funnel 5-cm-diameter chromatography column
Universal and Recyclable Solid Support
Figure 3.16.1 Synthesis of the four protected deoxyribonucleoside tert-butyl phosphoramidites (S.2a-d). DMTr, dimethoxytrityl.
3.16.2 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Vacuum evaporator Lyophilizer Additional reagents and equipment thin-layer chromatography (TLC; APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare deoxyribonucleoside tert-butyl phosphoramidites 1. In a 50-mL round-bottom flask, coevaporate 1.84 mmol of 5 -O-DMTr-N-protected nucleoside (S.1a-d) and 0.157 g (0.92 mmol) diisopropylammonium tetrazolide three times, each with 10 mL dry acetonitrile. Dissolve in 15 mL anhydrous methylene chloride. 2. While stirring, add 0.671 g (2.20 mmol) of tert-butyl tetraisopropylphosphorodiamidite under an argon atmosphere. 3. Stir the mixture overnight. Monitor by TLC. Before spotting the reaction mixture, TLC plates must be neutralized by dipping in the eluting solution and air-dried. After elution, direct visualization using a 254-nm UV lamp reveals the starting and final compounds. In addition, staining the TLC plate with molybde stain solution reveals phosphorous compounds (i.e., starting phosphine and resulting phosphoramidite) as blue spots. The plate is dipped in the molybde solution, washed with water, stamped with absorbent paper to remove excess water, and then slowly heated to dry the plate. For A and T: 2:7:1 (v/v/v) cyclohexane/EtOAc/Et3 N; Rf1a = 0.05; Rf2a = 0.5; Rf1d = 0.1; Rf2d = 0.7. For C: 5:4:1 (v/v/v) cyclohexane/CH2 Cl2 /Et3 N; Rf1b = 0.1; Rf2b = 0.6. For G: 2:7:1 (v/v/v) CH3 CN/CH2 Cl2 /Et3 N; Rf1c = 0.3; Rf2c = 0.6.
4. Dilute the reaction mixture with 50 mL ethyl acetate, pour into a 250-mL separatory funnel, and wash two times with 100 mL brine. 5. Collect the organic layer, dry it by adding ∼10 g solid anhydrous sodium sulfate, filter on cotton in a funnel, and concentrate on a rotary evaporator under reduced pressure to obtain a foam.
Purify by flash column chromatography 6. Dissolve the crude S.2a, S.2b, or S.2d in a minimal volume of 75:20:5 (v/v/v) cyclohexane/CH2 Cl2 /Et3 N and apply the solution to a 5-cm-diameter chromatography column containing 40 g silica gel (0.04 to 0.06 mm) equilibrated in the same solvent. For S.2c, use 25:75:5 (v/v/v) cyclohexane/CH2 Cl2 /Et3 N to equilibrate the column and dissolve the crude product. It is compulsory to have triethylamine in the elution solvent to avoid activation (and degradation) of the phosphoramidite due to the acidity of silica.
7. Gradually increase the concentration of methylene chloride in the eluent, still containing 5% of Et3 N. 8. Monitor fractions by TLC and combine those containing the pure compound. 9. Evaporate to dryness on a vacuum evaporator, and coevaporate with 20 mL dioxane. 10. Dissolve the foam in 30 mL dioxane, freeze the solution as a film in the flask, and lyophilize to afford the resulting phosphoramidite as a white powder. The phosphoramidites S.2a-d can be stored for several months at −20◦ C without decomposition.
Synthesis of Unmodified Oligonucleotides
3.16.3 Current Protocols in Nucleic Acid Chemistry
Supplement 30
11. Check phosphoramidite purity by 31 P NMR. Chemical shifts of the tert-butyl-N,N-diisopropylphosphoramidites are near 140 ppm (doublet) instead of 150 ppm for conventional phosphoramidites. Likewise, the chemical shift of hydrolyzed phosphine (tert-butyl H-phosphonate) when present is near 7 ppm (singlet) instead of 14 ppm for non-substituted alkyl H-phosphonates. 5 -O-(4,4 -Dimethoxytrityl)-N6 -benzoyl-2 -deoxyadenosine 3 -O-(tert-butyl)-N,N-diisopropylphosphoramidite (S.2a): yield 77%. TLC (cyclohexane/EtOAc/Et3 N 2/7/1 v/v/v) Rf : 0.50. 31 P NMR (CD3 CN): 139.3 and 139.5 ppm. 1 H NMR (CD3 CN): 1.08-1.36 (m, 21H), 2.52-2.69 (m, 1H), 2.99-3.14 (m, 1H), 3.27-3.41 (m, 2H), 3.56-3.69 (m, 2H), 3.75 (s, 6H), 4.21- 4.24 (m, 1H), 4.72-4.89 (m, 1H), 6.43-6.49 (m, 1H), 6.75-6.84 (m, 4H), 7.17-7.64 (m, 12H), 8.01 (m, 2H), 8.28 (d, J = 2.14 Hz, 1H), 8.59 (d, J = 1.35 Hz, 1H), 9.62 (br s, 1H). 5 -O-(4,4 -Dimethoxytrityl)-N6 -benzoyl-2 -deoxycytidine 3 -O-(tert-butyl)-N,N-diisopropylphosphoramidite (S.2b): yield 65%, TLC (cyclohexane/CH2 Cl2 /Et3 N 5/4/1 v/v/v) Rf : 0.60. 31 P NMR (CD3 CN): 139.7 and 139.6 ppm. 1 H NMR (CD3 CN): 1.07-1.34 (m, 21H), 2.25-2.36 (m, 1H), 2.53-2.62 (m, 1H), 3.39-3.46 (m, 2H), 3.56-3.67 (m, 2H), 3.79 (s, 6H), 4.16- 4.17 (m, 1H), 4.46-4.58 (m, 1H), 6.14-6.18 (m, 1H), 6.89-6.91 (m, 5H), 7.18-7.67 (m, 12H), 7.9 (pd, J = 8.6 Hz, 2H), 8.23 (d, J = 8.4 Hz, 1H), 8.34 (d, J = 8.6 Hz, 1H), 9.5 (br s, 1 H). 5-O-(4,4 -Dimethoxytrityl)-N2 -isobutyryl-2-deoxyguanosine 3 -O-(tert-butyl)-N,N-diisopropylphosphoramidite (S.2c): yield 79%. TLC (CH3 CN/CH2 Cl2 /Et3 N 2/7/1 v/v/v) Rf : 0.60. 31 P NMR (CD3 CN): 140.0 and 139.4 ppm. 1 H NMR (CD3 CN): 1.03-1.33 (m, 27H), 2.55-2.71 (m, 2H), 2.86-2.92 (m, 1H), 3.23-3.38 (m, 2H), 3.54-3.66 (m, 2H), 3.75 (s, 6H), 4.18- 4.21 (m, 1H), 4.52-4.99 (m, 1H), 6.23-6.26 (m, 1H), 6.75-6.82 (m, 4H), 7.19-7.42 (m, 9H), 7.85 (1d, 1H). 5 -O-(4,4 -Dimethoxytrityl)thymidine 3 -O-(tert-butyl)-N,N-diisopropylphosphoramidite (S.2d): yield 86%. TLC (cyclohexane/EtOAc/Et3 N 2/7/1 v/v/v) Rf : 0.70. 31 P NMR (CD3 CN): 139.8 and 139.0 ppm. 1 H NMR (CD3 CN): 1.06-1.52 (m, 21H), 2.21 (s, 3H), 2.34-2.42 (m, 2H), 3.31-3.38 (m, 2H), 3.55-3.67 (m, 2H), 3.8 (s, 6H), 4.09- 4.11 (m, 1H), 4.51-4.59 (m, 1H), 6.25-6.32 (m, 1H), 6.88-6.92 (m, 4H), 7.27-7.52 (m, 10H), 9.10 (br s, 1H). BASIC PROTOCOL 2
PREPARATION OF THE HEXANOL-LCAA-CPG SOLID SUPPORT The universal and reusable solid support S.5 is prepared from ◦commercially available long-chain alkylamine controlled-pore glass (LCAA-CPG; 500 A), which is converted ◦to a hydroxylated solid support (Fig. 3.16.2). A larger pore size (i.e., 1000 or 2000 A) is required for the synthesis of longer oligodeoxyribonucleotides (>50 mers). The hexanol-functionalized support is prepared from the LCAA-CPG according to the protocol described below. The loading of the alcohol function borne by the CPG solid support is determined by a trityl assay after coupling with a commercial deoxyribonucleoside 2-cyanoethyl phosphoramidite using a standard elongation cycle. The preparation of this universal solid support is easily scaled up to tens of grams, as long as there is efficient shaking during all the steps.
Materials ◦
Universal and Recyclable Solid Support
Long-chain alkylamine controlled-pore glass (LCAA-CPG, 500 A, 80 to 120 mesh, amino group, 80 to 90 µmol/g) 3% trichloroacetic acid (TCA) in methylene chloride (commercial deblocking solution) Triethylamine (Et3 N) Diisopropylethylamine (DIPEA) Anhydrous methylene chloride (CH2 Cl2 )
3.16.4 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Diethyl ether Phosphorous pentoxide (P2 O5 ) Anhydrous pyridine Succinic anhydride 4-Dimethylaminopyridine (DMAP) N-(3-Dimethylaminopropyl)-N -ethylcarbodiimide (DEC) N-Hydroxysuccinimide 6-Aminohexan-1-ol Anhydrous piperidine Methanol Deoxyribonucleoside phosphoramidite 0.1 M p-toluenesulfonic acid solution in acetonitrile 25-mL round-bottom flasks Frits (porosity 3) Vacuum desiccator DNA synthesis column 10-mL volumetric flasks Spectrophotometer Additional reagents and equipment for automated oligonucleotide synthesis and the trityl assay (APPENDIX 3C)
Figure 3.16.2 Preparation of the universal and reusable hexanol-LCA-CPG solid support (S.5). DEC, N-(3-dimethylaminopropyl)-N -ethylcarbodiimide; DMAP, 4-(dimethylamino)pyridine.
Synthesis of Unmodified Oligonucleotides
3.16.5 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Functionalize LCAA-CPG 1. In a 25-mL round-bottom flask, combine 1.0 g of LCAA-CPG and 5 mL of 3% trichloroacetic acid (TCA) in methylene chloride (commercial deblocking solution). Shake gently for 4 hr at room temperature. This step is performed to convert the resulting ammonium function, due to the acidic treatment, to the amino function, thereby activating the solid support.
2. Filter off the LCAA-CPG on a frit, and wash successively with 10 mL of 9:1 (v/v) Et3 N/DIPEA, 10 mL CH2 Cl2 , and 10 mL diethyl ether. 3. Dry in a vacuum desiccator over P2 O5 for 30 min at room temperature. 4. In a 25-mL round-bottom flask, combine successively 1.0 g of the activated LCAACPG, 6 mL anhydrous pyridine, 200 mg (2 mmol) succinic anhydride, and 40 mg (0.33 mmol) DMAP. Shake gently overnight at room temperature. 5. Filter off on a frit and wash with 3 mL pyridine followed by 5 mL CH2 Cl2 . 6. Dry in a vacuum desiccator over P2 O5 for 30 min at room temperature. 7. In a 25-mL round-bottom flask, combine successively the succinylated CPG (S.3), 5 mL CH2 Cl2 , 0.191 g (1 mmol) DEC, 60 mg (0.5 mmol) N-hydroxysuccinimide, and 40 µL Et3 N. Shake for 4 hr at room temperature. 8. Add 6 mg (0.05 mmol) of 6-aminohexan-1-ol and shake overnight at room temperature. 9. Add 5 mL piperidine and shake 15 min at room temperature. 10. Filter off on a frit, and wash successively with 3 mL pyridine, 5 mL methanol, and 5 mL CH2 Cl2 . 11. Dry the resulting hexanol-LCAA-CPG (S.5) in a vacuum desiccator over P2 O5 for 30 min at room temperature.
Determine loading 12. Weigh 20 mg of S.5 in an empty DNA synthesis column. 13. Couple a deoxyribonucleoside phosphoramidite to S.5 according to a standard elongation cycle in trityl-OFF mode, but omit the detritylation step that is usually performed before coupling. The first detritylation step actually can be performed, although the solid support has no trityl group.
14. Transfer the DMTr cation into a 10-mL volumetric flask and fill it up to 10 mL with a 0.1 M p-toluenesulfonic acid solution in acetonitrile. 15. Transfer 1 mL of the resulting solution to a 10-mL volumetric flask and add 9 mL of 0.1 M p-toluenesulfonic acid solution in acetonitrile. 16. Read the absorption at 498 nm (A498 ). 17. Calculate loading in micromole per gram CPG (µmol/g CPG) according to the following formula:
Universal and Recyclable Solid Support
3.16.6 Supplement 30
Current Protocols in Nucleic Acid Chemistry
where m is mass of S.5 (step 1), 70,000 is the extinction coefficient of the cation DMTr, and the two 10 values correspond to the total volume of the solution (step 14) and the factor of dilution (step 15). Loading of 6-aminohexan-1-ol is typically between 40 and 50 µmol/g CPG.
OLIGONUCLEOTIDE SYNTHESIS This protocol describes the synthesis of oligonucleotides with phosphodiester or phosphorothioate linkages starting from the universal hexanol solid support S.5 and the deoxyribonucleoside tert-butyl phosphoramidite building blocks S.2a-d, and then using commercial nucleoside phosphoramidites with either conventional or ultra-fast-deprotecting nucleobase-protecting groups. Alternate Protocols 1 and 2 describe tandem synthesis to yield two oligonucleotides per synthesis.
BASIC PROTOCOL 3
The synthesis of oligodeoxyribonucleotides is performed using an ABI 381A DNA synthesizer according to the customized elongation cycle shown in Table 3.16.1 (Fig. 3.16.3). Since the solid support S.5 has no DMTr group, the first detritylation step can be omitted. Detritylation is performed with 3% DCA in CH2 Cl2 , and activation of deoxyribonucleoside phosphoramidites is effected by 5-(benzylthio)-1H-tetrazole (BMT, 0.3 M in dry acetonitrile). Capping is performed with BMT-activated bis(2-cyanoethyl)-N,Ndiisopropylphosphoramidite (0.03 M in dry acetonitrile) for 15 sec. Oxidation is performed with 1.1 M tert-butyl hydroperoxide in CH2 Cl2 or 0.05 M 3H-1,2-benzodithiol3-one 1,1-dioxide in dry acetonitrile for 60 sec. The average coupling yields per cycle are typically between 98% and 99%, as determined by the DMTr cation assay (UNIT 10.3 and APPENDIX 3C). After oligonucleotide chain assembly, the column is treated with a 0.01 M potassium carbonate solution in methanol for 10 min to release the oligonucleotide from the solid support S.5, which is then recycled.
Table 3.16.1 Customized Oligonucleotide Elongation Cycle for Deoxyribonucleoside 3 -O-(tertButyl)- and 3 -O-(2-Cyanoethyl)-N,N-diisopropylphosphoramidite Building Blocksa
Step
Reagents and solvents
Time (sec)
For deoxyribonucleoside 3 -O-(tert-butyl)-N,N-diisopropylphosphoramidites Wash
CH3 CN
10
Detritylation
3% DCA in CH2 Cl2
60 15
Wash
CH3 CN
Coupling
0.09 M tert-butyl amidite S.2a-d in CH3 CN + 0.3 M BMT in CH3 CN 45
Wash
CH3 CN
20
Detritylation
3% DCA in CH2 Cl2
60
Wash
CH3 CN
15
For deoxyribonucleoside 3 -O-(2-cyanoethyl)-N,N-diisopropylphosphoramidites Coupling
0.09 M 2-cyanoethyl amidite in CH3 CN + 0.3 M BMT in CH3 CN
Cappinga
0.03 M i-Pr2 NP(OCH2 CH2 CN)2 in CH3 CN + 0.3M BMT in CH3 CN 15
Oxidation
1.1 M tBuOOH in CH2 Cl2 or 0.05 M Beaucage reagent in CH3 CN
60
Wash
CH3 CN
15
Detritylation
3% DCA in CH2 Cl2
60
Wash
CH3 CN
15
15
Synthesis of Unmodified Oligonucleotides
a Capping step is optional.
3.16.7 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Materials 5-Benzylthio-1H-tetrazole (BMT) Anhydrous acetonitrile (<10 ppm H2 O) Anhydrous tert-butyl hydroperoxide (tBuOOH; 5.5 M in decane; Fluka) Anhydrous methylene chloride (CH2 Cl2 ; freshly distilled over P2 O5 ) 3H-1,2-Benzodithiole-3-one 1,1-dioxide Bis(2-cyanoethyl)-N,N-diisopropylphosphoramidite 5 -O-(4,4 -Dimethoxytrityl)-N-protected-2 -deoxynucleoside 3 -O-(tert-butyl)-N,N-diisopropylphosphoramidite (S.2a-d; see Basic Protocol 1) Standard 3 -O-(2-cyanoethyl)-N,N-diisopropylphosphoramidites of 5 -O-(4,4 -dimethoxytrityl)-N-protected-2 -deoxyribonucleosides: 5 -O-DMTr-N6 -benzoyl-2 -deoxyadenosine (Pierce) 5 -O-DMTr-N4 -benzoyl-2 -deoxycytidine (Pierce) 5 -O-DMTr-N2 -isobutyryl-2 -deoxyguanosine (Pierce) 5 -O-DMTr-2 -deoxythymine (Pierce) 5 -O-DMTr-N6 -phenoxyacetyl-2 -deoxyadenosine (Glen Research) 5 -O-DMTr-N4 -acetyl-2 -deoxycytidine (Glen Research) 5 -O-DMTr-N2 -(isopropylphenoxyacetyl)-2 -deoxyguanosine (Glen Research) Hexanol-LCAA-CPG solid support (S.5; see Basic Protocol 2) 3% Dichloracetic acid (DCA) in CH2 Cl2 (Biosolve) 10 mM potassium carbonate (K2 CO3 ) in methanol (70 mg in 50 mL) Concentrated aqueous ammonia Methanol Phosphorous pentoxide (P2 O5 ) ABI 381A DNA synthesizer 1-mL syringes 2-mL microcentrifuge tubes Speed vacuum Sealed vial (vial with Teflon septum and screw top for HPLC sample preparations) 55◦ C dry bath Vacuum desiccator Additional reagents and equipment for automated oligonucleotide synthesis and the trityl assay (APPENDIX 3C) Synthesize oligonucleotide 1. Program the modified elongation cycle for an ABI 381A DNA synthesizer (Table 3.16.2). Create the user function USER F: 4,6,12,16,20,23 corresponding to Tet +12 TO COLM used for the capping step. 2. Prepare a 0.3 M solution of 5-benzylthio-1H-tetrazole in anhydrous acetonitrile (5.77 g in 100 mL). Place the bottle in position no. 9 using the change bottle procedure (see Table 3.16.3 for bottle positions). Place a solution of 3% DCA in CH2 Cl2 in position 14 for the detritylation step. 3. Prepare oxidizing solution and place the bottle in position no. 15 using the change bottle procedure. a. For phosphodiester oligonucleotides: Prepare a 1.1 M tert-butyl hydroperoxide solution by mixing 5 mL of anhydrous tert-butyl hydroperoxide (5.5 M in decane) with 20 mL methylene chloride. b. For phosphorothioate oligonucleotides: Prepare a 0.05 M solution of 3H-1, 2-benzodithiol-3-one 1,1-dioxide in dry acetonitrile (100 mg in 10 mL). Universal and Recyclable Solid Support
3.16.8
4. Prepare a 0.03 M solution of bis(2-cyanoethyl)-N,N-diisopropylphosphoramidite in anhydrous acetonitrile (81.3 mg in 10 mL). Place the bottle in position no. 12 using the change bottle procedure.
Supplement 30
Current Protocols in Nucleic Acid Chemistry
Figure 3.16.3 Oligonucleotide synthesis on the universal hydroxylated solid support. BMT, 5(benzylthio)-1H-tetrazole; CE, cyanoethyl; DCA, dichloroacetic acid; DMTr, dimethoxytrityl.
5. Prepare a 0.09 M solution (18 molar eq.) of S.2a, b, c, or d in dry acetonitrile and place the bottle in position no. 5 using the change bottle procedure.
Synthesis of Unmodified Oligonucleotides
3.16.9 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Table 3.16.2 Customized Phosphoramidite Elongation Cycle for 381A ABI DNA Synthesizer
Active for bases Step no. Function no. Name
Universal and Recyclable Solid Support
Step time A
G
C
T
X
1
10
#18 TO WASTE
2
Yes
Yes
Yes
Yes
Yes
2
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
Yes
3
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
Yes
4
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
Yes
5
28
PHOS PREP
3
Yes
Yes
Yes
Yes
Yes
6
90
TET TO COLM
3
Yes
Yes
Yes
Yes
Yes
7
19
B + TET TO COLM
3
Yes
Yes
Yes
Yes
Yes
8
90
TET TO COLM
3
Yes
Yes
Yes
Yes
Yes
9
19
B + TET TO COLM
3
Yes
Yes
Yes
Yes
Yes
10
90
TET TO COLM
3
Yes
Yes
Yes
Yes
Yes
11
19
B + TET TO COLM
3
Yes
Yes
Yes
Yes
Yes
12
90
TET TO COLM
3
Yes
Yes
Yes
Yes
Yes
13
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
Yes
14
10
#18 TO WASTE
2
Yes
Yes
Yes
Yes
Yes
15
4
WAIT
15
Yes
Yes
Yes
Yes
Yes
16
4
WAIT
30
No
No
No
No
Yes
17
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
Yes
18
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
Yes
19
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
Yes
20
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
Yes
21
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
Yes
22
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
Yes
23
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
Yes
24
28
PHOS PREP
3
Yes
Yes
Yes
Yes
No
25
90
TET TO COLM
3
Yes
Yes
Yes
Yes
No
a
26
97
USER F
3
Yes
Yes
Yes
Yes
No
27
90
TET TO COLM
3
Yes
Yes
Yes
Yes
No
a
28
97
USER F
3
Yes
Yes
Yes
Yes
No
29
90
TET TO COLM
3
Yes
Yes
Yes
Yes
No
a
30
97
USER F
3
Yes
Yes
Yes
Yes
No
31
90
TET TO COLM
3
Yes
Yes
Yes
Yes
No
32
4
WAIT
20
Yes
Yes
Yes
Yes
No
33
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
No
34
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
No
35
10
#18 TO WASTE
2
Yes
Yes
Yes
Yes
No
36
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
No
37
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
No
38
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
No continued
3.16.10 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Table 3.16.2 Customized Phosphoramidite Elongation Cycle for 381A ABI DNA Synthesizer, continued
Active for bases Step no. Function no. Name
Step time A
G
C
T
X
39
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
No
40
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
No
41
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
No
42
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
No
43
81
#15 TO WASTE
3
Yes
Yes
Yes
Yes
No
44
13
#15 TO COLM
10
Yes
Yes
Yes
Yes
No
45
10
#18 TO WASTE
2
Yes
Yes
Yes
Yes
No
46
4
WAIT
45
Yes
Yes
Yes
Yes
No
47
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
No
48
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
No
49
10
#18 TO WASTE
2
Yes
Yes
Yes
Yes
No
50
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
No
51
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
No
52
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
No
53
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
No
54
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
Yes
55
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
Yes
56
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
Yes
57
33
CYC ENTRY
1
Yes
Yes
Yes
Yes
Yes
58
10
#18 TO WASTE
2
Yes
Yes
Yes
Yes
Yes
59
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
Yes
60
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
Yes
61
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
Yes
62
5
ADVANCE FC
1
Yes
Yes
Yes
Yes
Yes
63
6
WASTE PORT
1
Yes
Yes
Yes
Yes
Yes
64
82
#14 TO WASTE
3
Yes
Yes
Yes
Yes
Yes
65
14
#14 TO COLM
10
Yes
Yes
Yes
Yes
Yes
66
108
FLUSH TO TRIT
1
Yes
Yes
Yes
Yes
Yes
67
14
#14 TO COLM
10
Yes
Yes
Yes
Yes
Yes
68
108
FLUSH TO TRIT
1
Yes
Yes
Yes
Yes
Yes
69
14
#14 TO COLM
10
Yes
Yes
Yes
Yes
Yes
70
108
FLUSH TO TRIT
1
Yes
Yes
Yes
Yes
Yes
71
14
#14 TO COLM
10
Yes
Yes
Yes
Yes
Yes
72
108
FLUSH TO TRIT
1
Yes
Yes
Yes
Yes
Yes
73
14
#14 TO COLM
10
Yes
Yes
Yes
Yes
Yes
74
108
FLUSH TO TRIT
1
Yes
Yes
Yes
Yes
Yes
75
14
#14 TO COLM
10
Yes
Yes
Yes
Yes
Yes continued
Synthesis of Unmodified Oligonucleotides
3.16.11 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Table 3.16.2 Customized Phosphoramidite Elongation Cycle for 381A ABI DNA Synthesizer, continued
Active for bases Step no. Function no. Name 76
108
77
9
78
Step time A
G
C
T
X
FLUSH TO TRIT
1
Yes
Yes
Yes
Yes
Yes
#18 TO COLM
10
Yes
Yes
Yes
Yes
Yes
108
FLUSH TO TRIT
1
Yes
Yes
Yes
Yes
Yes
79
7
WASTE BOTTLE
1
Yes
Yes
Yes
Yes
Yes
80
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
Yes
81
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
Yes
82
9
#18 TO COLM
10
Yes
Yes
Yes
Yes
Yes
83
2
REVERSE FLUSH
5
Yes
Yes
Yes
Yes
Yes
84
1
BLOCK FLUSH
3
Yes
Yes
Yes
Yes
Yes
85
34
CYC END
1
Yes
Yes
Yes
Yes
Yes
a USER F = 4,6,12,16,20,23 Tet +12 TO COLM.
Table 3.16.3 Bottle Positions for 381A ABI DNA Synthesizer
Bottle
Reagent
5
5 -O, N-protected deoxyribonucleoside tert-butyl phosphoramidite
9
0.3 M 5-benzylthio-1H-tetrazole in CH3 CN
12
0.03 M bis(2-cyanoethyl)-N,N-diisopropylphosphoramidite in CH3 CN (capping solution)
14
3% DCA in CH2 Cl2 (detritylation solution)
15
1.1 M tBuOOH in CH2 Cl2 for phosphodiester (PO oxidizing solution)
15
0.05 M 3H-1,2-benzodithiol-3-one 1,1-dioxide (Beaucage reagent) in CH3 CN (PS oxidizing solution)
6. Prepare a 0.09 M solution of commercial deoxyribonucleoside 2-cyanoethyl phosphoramidites in dry acetonitrile and place the corresponding bottles (no. 1 to 4) on the synthesizer using the change bottle procedure. 7. Enter the sequence of the desired oligonucleotide. Add an extra “dummy” base 3 to the sequence to account for the solid support. For example, enter ACTGTGTXX to obtain ACTGTGTX, where X is the nucleoside originating from building block S.2a-d.
8. Pack a column with 1 µmol of solid support S.5 (e.g., 20 mg if loading is 50 µmol/g). Place it on the synthesizer. 9. Run the synthesis. To save some deblocking solution, press the JUMP button during step 60 and go to step 77, then resume the synthesis; otherwise, let the synthesis cycle perform the detritylation steps. A jump from step 60 to 77 allows for the column to be washed with dry acetonitrile removing any trace of water, if present. Universal and Recyclable Solid Support
3.16.12 Supplement 30
Synthesize oligonucleotide 10. When the synthesis is complete, remove the column. Use two syringes to push 1 mL of 10 mM K2 CO3 in methanol back and forth through the solid support over a period of 10 min. Current Protocols in Nucleic Acid Chemistry
11. Withdraw the solution and transfer to a 2-mL microcentrifuge tube. Evaporate off the methanol under speed vacuum. 12. Add 1 mL of concentrated aqueous ammonia and transfer to a sealed vial for HPLC. Heat 5 hr in a 55◦ C dry bath. 13. Cool to room temperature and then evaporate the ammonia and water under speed vacuum. 14. Redissolve the residue in 300 µL pure water for further analysis and characterization.
Recycle hexanol solid support 15. Wash the synthesis column successively with 2 mL water and 2 mL methanol. 16. Dry the synthesis column under vacuum in a desiccator over P2 O5 for 2 hr. The dried column can be stored for months at room temperature in a dry place. The same synthesis column has been used four times without a noticeable decrease in quantity or quality of the final oligodeoxyribonucleotides.
TANDEM OLIGONUCLEOTIDE SYNTHESIS Tandem oligonucleotide synthesis can be used to synthesize two oligonucleotides in a row, each starting with the incorporation of a tert-butyl phosphoramidite (S.2a-d). The overall procedure is illustrated in Figure 3.16.4. The synthesis is carried out using the same materials and procedures as in Basic Protocol 3, with the only difference being that the two desired oligonucleotide sequences are entered sequentially in step 7 of Basic Protocol 3. For example, AGTGTXTGACGXX would be entered to obtain
Figure 3.16.4 Tandem synthesis of oligodeoxyribonucleotides (ODNs). * indicates N-acylated nucleobases. BMT, 5-(benzylthio)-1H-tetrazole; DCA, dichloroacetic acid.
ALTERNATE PROTOCOL 1
Synthesis of Unmodified Oligonucleotides
3.16.13 Current Protocols in Nucleic Acid Chemistry
Supplement 30
oligonucleotides AGTGTX (ODN2 ) and TGACGX (ODN1 ), where X is the nucleoside originating from building block S.2a-d. After elongation, treatment with K2 CO3 in methanol releases the two oligonucleotides in solution. This strategy is useful for the synthesis of PCR primers or to double the yield of a single oligonucleotide. ALTERNATE PROTOCOL 2
TANDEM OLIGONUCLEOTIDE SYNTHESIS WITH SELECTIVE RELEASE OF EACH OLIGONUCLEOTIDE This protocol describes the synthesis of two oligonucleotides in a row starting from a commercially available solid support loaded with a deoxyribonucleoside linked through a 3 -O-succinyl linker. Upon complete synthesis of the first oligonucleotide, the synthesis of the second oligonucleotide begins with the addition of a deoxyribonucleoside tert-butyl phosphoramidite (S.2a-d) by transesterification of the H-phosphonate diester linkage as shown in Figure 3.16.5. A first treatment with methanolic K2 CO3 at 0◦ C releases only the second oligonucleotide (ODN*2 ), which is isolated and treated with concentrated ammonium hydroxide for full deprotection. Next, the solid support is treated with concentrated ammonium hydroxide (90 min at 20◦ C) to release the first oligonucleotide (ODN*1 ).
Universal and Recyclable Solid Support
Figure 3.16.5 Tandem oligonucleotide synthesis on a standard deoxyribonucleoside 3 O-succinylated solid support with selective release of oligodeoxyribonucleotides. BMT, 5(benzylthio)-1H-tetrazole; DCA, dichloroacetic acid; ODN, oligodeoxyribonucleotide. * indicates N-acylated nucleobases.
3.16.14 Supplement 30
Current Protocols in Nucleic Acid Chemistry
The ammoniacal oligonucleotide solution is then heated for 5 hr at 55◦ C to complete oligonucleotide deprotection. Although this approach does not permit recycling of the solid support, it allows the use of any commercial succinylated solid support for the tandem synthesis of two oligonucleotides that can be obtained individually.
Additional Materials (also see Basic Protocol 3) Commercial 3 -O-succinylated solid support Concentrated ammonium hydroxide 1. Prepare solutions as in Basic Protocol 3, steps 1 to 6. 2. Enter the sequence of the two oligonucleotides in a row. For example, enter AGTGTXTGACGA to obtain AGTGTX and TGACGA, where X is the nucleoside originating from building block S.2a-d.
3. Place the nucleoside 3 -O-succinylated solid support on the synthesizer and run the synthesis. 4. When the tandem oligonucleotide synthesis is complete, remove the synthesis column. 5. Release the second oligonucleotide from the solid support by using two syringes to push back and forth 1 mL of cold 10 mM K2 CO3 in methanol through the solid support over a period of 20 min at 0◦ C. Since the two oligonucleotides are linked together by an H-phosphonate diester linkage, a selective release of the second oligonucleotide is performed by transesterification. During this short treatment, the ester function between the first oligonucleotide and the solid support is not hydrolyzed. Therefore, the first oligonucleotide remains on the solid support.
6. Withdraw the solution and transfer to a microcentrifuge tube. Evaporate the methanol under speed vacuum. 7. Add 1 mL concentrated ammonium hydroxide to the solution and transfer to a sealed vial. Heat 5 hr in a 55◦ C dry bath. 8. Release the first oligonucleotide from the solid support by using two syringes to push back and forth 1 mL of concentrated ammonium hydroxide through the solid support over a period of 30 min. Repeat two times, for a total of three times. 9. Combine the ammoniacal solutions in a sealed vial and heat 5 hr in a 55◦ C dry bath. 10. Cool each of the oligonucleotide solutions (steps 7 and 9) and evaporate under speed vacuum. 11. Redissolve the residues in pure water for further analysis and characterization.
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Molybde stain (Dittmer and Lester, 1964) Solution 1: Boil 40.11 g of MoO3 in 1 L of 25 N sulfuric acid until completely dissolved (3 to 4 hr). Allow the light yellow solution to cool slowly (overnight) to ambient temperature. Store up to several months in the dark. The solution will turn light blue. continued
Synthesis of Unmodified Oligonucleotides
3.16.15 Current Protocols in Nucleic Acid Chemistry
Supplement 30
Solution 2: Boil a suspension of 1.78 g molybdenum powder in 500 mL of solution 1 for 15 min. Cool and decant from the remaining residue. Store up to several months in the dark. Stain solution: Add one volume of each solution to 4.5 volumes of water. Prepare weekly and store in the dark. A dark green solution is formed.
COMMENTARY Background Information
Universal and Recyclable Solid Support
Oligonucleotides are widely used in research and as diagnostic probes. For many biological applications, the 3 -hydroxyl of oligonucleotides must be free. For convenience, universal solid supports are preferred since their use minimizes preparation and storage of solid supports functionalized with each of the four nucleobases, and also minimizes errors and manipulations. In addition, ∼40% of the cost of an oligonucleotide is from the solid support, which is wasted at the end of the synthesis. Thus, an obvious way to reduce the average cost of an oligonucleotide is to recycle the solid support. Furthermore, in the context of durable development, the amount of waste is reduced. It has been shown that the presence of an H-phosphonate diester linkage between an oligonucleotide and a universal hydroxylated solid support allows an efficient and clean release of the 3 -hydroxylated oligonucleotide under mild basic conditions (Ferreira et al., 2005). It has also been reported (Sobkowski et al., 1994) that ethanolamine and 3-aminopropanol cleave H-phosphonate diester linkages within 15 min. However, the removal of these aminoalcohols by evaporation is inconvenient due to their high boiling points. In contrast, methanolic K2 CO3 cleaves the H-phosphonate diester linkage with a better efficiency (10 min) and is easy to remove (Ferreira et al., 2005). The cleavage proceeds through a methanolmediated transesterification resulting in the formation of dimethylphosphite in addition to an oligonucleotide with a free 3 -hydroxyl group and a hydroxylated solid support (S.5, Fig. 3.16.3). This mild basic treatment does not damage the solid support, which can be reused after simple washing and drying steps. The H-phosphonate diester linkage can be formed using conventional nucleoside H-phosphonate monoesters, which require different reagents and solvents from those used in the phosphoramidite method. o-Methoxybenzyl (Meyer et al., 2004) or
tert-butyl (Ferreira et al., 2005) phosphite triesters produce H-phosphonate diester linkages through an Arbuzov-like mechanism under acidic conditions (Fig. 3.16.6). Thus, the advantage of using nucleoside tert-butyl phosphoramidites instead of classic nucleoside H-phosphonate monoesters in the formation of H-phosphonate diester linkages is that no reagents other than those used in the phosphoramidite chemistry are needed. The preparation of the deoxyribonucleoside tert-butyl phosphoramidite building blocks (S.2a-d) proceeds like that of conventional phosphoramidite derivatives starting from commercially available 5 -O, N-protected deoxyribonucleosides and tert-butyl tetraisopropylphosphorodiamidite. The coupling efficiency of these phosphoramidites is slightly lower due to the steric hindrance created by the tert-butyl group in the vicinity of the phosphorous atom. Thus, 5-methylthio-1H-tetrazole (pKa = 4.08; Wu and Pitsch, 1998), which is a more acidic activator than 1H-tetrazole (pKa = 4.89), is used for coupling reactions performed over a period of 45 sec. This strategy allows the synthesis of oligonucleotides (phosphodiester or phosphorothioate) that are comparable in terms of purity and quantity. Since the H-phosphonate diester linkage must be kept intact during the elongation cycle, the oxidation of phosphite triester linkages must be performed using tert-butyl hydroperoxide (Jung et al., 1994; Bologna et al., 1999) or the Beaucage reagent (Bologna et al., 1999), which are known to oxidize only phosphite triester linkages. The universal solid support can be reused several times after performing washes with water and methanol and subsequent drying under vacuum. The same oligonucleotide sequence has been synthesized four times on the same recycled solid support without any observed decrease in product quality and quantity from one synthesis to the next. Since methanolic K2 CO3 treatment removes the 2-cyanoethyl groups but only partially removes the nucleobase-protecting
3.16.16 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Figure 3.16.6
H-Phosphonate diester linkage formation through an Arbuzov-like mechanism.
groups, it is necessary to complete the nucleobase deprotection of the released oligonucleotides through the use of concentrated ammonium hydroxide. Alternatively, a single treatment with methanolic K2 CO3 (10 min at room temperature and 20 min at 50◦ C) fully deprotects oligonucleotides bearing ultra-fastdeprotecting groups, such as acetyl on cytidine, phenoxyacetyl on adenosine, or (4isopropyl)phenoxyacetyl on guanosine. Multiple syntheses For production of PCR primers, it is more efficient to synthesize two oligonucleotide primers during the same run and obtain them together in solution. This approach improves productivity by reducing both handling and storage. The universal support approach allows the preparation of both primers in tandem using a deoxyribonucleoside tert-butyl phosphoramidite building block to initiate the synthesis of each sequence. Upon completion of the synthesis, the two oligonucleotides are released together and are fully deprotected by treatment with methanolic K2 CO3 and concentrated ammonium hydroxide, respectively. Tandem oligonucleotide synthesis can also be applied to the production of larger quantities of a single oligonucleotide, when required. In that case, the same sequence is synthesized two times in a row to double the amount of oligonucleotide product. This strategy could also be applied to the synthesis of siRNA where two complementary RNA strands are required. Two strategies are reported in the literature for tandem oligonucleotide synthesis; one approach involves a complex synthesis of building blocks and requires harsher basic conditions for oligonucleotide deprotection (Hardy et al., 1994). The other strategy requires specific reagents not usually used on a DNA synthesizer (Pon et al., 2002). In addition, UNIT 3.12 reports the use of deoxyribonucleoside phosphoramidites containing cleavable linkers that provide, after deprotection, one oligonucleotide with free 3 - and 5 hydroxyls and one oligonucleotide bearing a
5 -phosphate monoester and a free 3 -hydroxyl group. Finally, tandem oligonucleotides can be synthesized in which the first oligonucleotide is initiated from a commercially available succinylated solid support, and the second is initiated by the coupling of a deoxyribonucleoside tert-butyl phosphoramidite building block according to the customized elongation cycle to generate an H-phosphonate linkage. Subsequent treatment with K2 CO3 /methanol at 0◦ C for 20 min cleaves the H-phosphonate linkage and thus selectively releases the second oligonucleotide while the first remains linked to the succinylated CPG. A standard treatment of the CPG beads with concentrated ammonium hydroxide then releases the first oligonucleotide. In this way, two oligonucleotides are synthesized in a row, but their release is selective and each is obtained individually.
Critical Parameters The purification of deoxynucleoside 3 -O-(tert-butyl)-N,N-diisopropylphosphoramidites by flash chromatography on silica gel must be carried out with triethylamine in the eluent to avoid degradation due to the acidity of silica. If possible, the chromatography must be done within 2 hr. Automated synthesis of oligonucleotides according to the phosphoramidite method is well established. Due to the sensitivity of the method to moisture, the phosphoramidite and activator solutions must be kept dry to ensure high coupling efficiencies. This is achieved by ◦ adding a few beads of 4-A molecular sieves to the solutions. The deoxyribonucleoside tertbutyl phosphoramidite building blocks are less reactive than standard 2-cyanoethyl phosphoramidites. To increase their coupling efficiency, the use of 5-benzylthio-1H-tetrazole and an extended coupling reaction time of 45 sec are recommended. Capping is performed using bis-(2-cyanoethyl)-N,N-diisopropylphosphoramidite, since the presence of an H-phosphonate diester linkage precludes the use of acetic
Synthesis of Unmodified Oligonucleotides
3.16.17 Current Protocols in Nucleic Acid Chemistry
Supplement 30
anhydride. This reagent leads to shorter oligonucleotide 5 -phosphate monoesters with increased hydrophilicity compared to that of the expected full-length oligonucleotides, and thus facilitates oligonucleotide purification by reversed-phase chromatography. Other phosphoramidites can be used as capping reagents, including diethyl N,N-diisopropyl phosphoramidite (Yu et al., 1994; Alvarez et al., 1999) or O-(2-cyanoethyl)-O-(n-octyl)-N,N-diisopropylphosphoramidite (Natt and Haner, 1997).
Anticipated Results For investigators who are familiar with the preparation of phosphoramidites, the synthesis of deoxyribonucleoside 3 -O-(tert-butyl)N,N-diisopropylphosphoramidites is straightforward and yields ranging between 65% and 86% are expected. The preparation of the solid support is straightforward since all steps are performed on the support; only filtrations and washes are necessary for the work-up. Synthesis of oligonucleotides on the universal solid support, starting with one deoxyribonucleoside tert-butyl phosphoramidite building block and then using commercially available deoxyribonucleoside phosphoramidites, is as efficient as syntheses carried out on a succinylated solid support in terms of quantity and purity. After recycling, the universal solid support can be reused several times without losing its functional properties. Synthesis of tandem oligonucleotides by this strategy leads to products of sufficient purity to be used directly as PCR primers.
Time Considerations
Universal and Recyclable Solid Support
The synthesis of a deoxyribonucleoside 3 -O-(tert-butyl)-N,N-diisopropylphosphoramidite, including purification, requires ∼1 full day, with one overnight reaction. Preparation of the hydroxylated universal solid support requires ∼2 days. Since it is recycled, its preparation is not required each time. Typically, the duration of the 1-µmol customized oligodeoxyribonucleotide elongation cycle is ∼8 min. This cycle is slightly longer than the conventional cycle since the oxidation step using either tert-butyl hydroperoxide or 3H-1,2-benzodithiol-3-one 1,1-dioxide requires 60 sec instead of 10 sec with the iodine/ water solution, and the capping step using a phosphoramidite takes longer than capping with acetic anhydride. The synthesis of a 20-mer requires ∼2.5 hr.
Release of the oligonucleotide from the hydroxylated solid support is faster (only 10 min) than release from a succinylated solid support (90 min). The complete removal of conventional benzoyl and isobutyryl protecting groups is achieved within 5 hr at 55◦ C using concentrated ammonium hydroxide. However, when using ultra-fast deprotecting groups (i.e., acetyl, phenoxyacetyl, and isopropylphenoxyacetyl) for nucleobase protection, complete removal of these groups and release of the oligonucleotide from the support required only 20 min at 50◦ C when treated with 50 mM potassium carbonate in methanol. Recycling the hydroxylated solid support requires ∼10 min for the washes and 2 hr of drying time. Since the solid support is kept in the synthesis column during oligonucleotide release and recycling steps, no additional time is needed for repacking the column.
Literature Cited Alvarez, K., Vasseur, J.J., Beltran, T., and Imbach, J.L. 1999. Photocleavable protecting groups as nucleobase protections allowed the solid-phase synthesis of base-sensitive SATEprooligonucleotides. J. Org. Chem. 64:63196328. Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862. Bologna, J.C., Morvan, F., and Imbach, J.L. 1999. The prooligonucleotide approach: Synthesis of mixed phosphodiester and SATE phosphotriester prooligonucleotides using H-phosphonate and phosphoramidite chemistries. Eur. J. Org. Chem. 2353-2358. Dittmer, J.C. and Lester, R.L. 1964. Simple specific spray for detection of phospholipids on thinlayer chromatograms. J. Lipid Res. 5:126-127. Ferreira, F., Meyer, A., Vasseur, J.J., and Morvan, F. 2005. Universal solid supports for the synthesis of oligonucleotides via a transesterification of H-phosphonate diester linkage. J. Org. Chem. 70:9198-9206. Hardy, P.M., Holland, D., Scott, S., Garman, A.J., Newton, C.R., and Mclean, M.J. 1994. Reagents for the preparation of two oligonucleotides per synthesis (TOPS). Nucl. Acids Res. 22:29983004. Hayakawa, Y., Uchiyama, M., and Noyori, R. 1986. Nonaqueous oxidation of nucleoside phosphite to the phosphates. Tetrahedron Lett. 27:41914194. Iyer, R.P., Phillips, L.R., Egan, W., Regan, J.B., and Beaucage, S.L. 1990. The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagent. J. Org. Chem. 55:46934699.
3.16.18 Supplement 30
Current Protocols in Nucleic Acid Chemistry
Jung, P.M., Histand, G., and Letsinger, R.L. 1994. Hybridization of alternating cationic/anionic oligonucleotides to RNA segments. Nucleosides Nucleotides 13:1597-1605. Meyer, A., Morvan, F., and Vasseur, J.-J. 2004. H-Phosphonate oligonucleotides from phosphoramidite chemistry. Tetrahedron Lett. 45:37453748. Natt, F. and Haner, R. 1997. Lipocap—A lipophilic phosphoramidite-based capping reagent. Tetrahedron 53:9629-9636. Pon, R.T., Yu, S., and Sanghvi, Y.S. 2002. Tandem oligonucleotide synthesis on solid-phase supports for the production of multiple oligonucleotides. J. Org. Chem. 67:856-864.
Sobkowski, M., Stawinski, J., Sobkowska, A., and Kraszewski, A. 1994. Studies on reactions of nucleoside H-phosphonates with bifunctional reagents. 2. Stability of nucleoside H-phosphonate diesters in the presence of amino alcohols. J. Chem. Soc., Perkin Trans. 118031808. Wu, X.L. and Pitsch, S. 1998. Synthesis and pairing properties of oligoribonucleotide analogues containing a metal-binding site attached to beta-D-allofuranosyl cytosine. Nucl. Acids Res. 26:4315-4323. Yu, D., Tang, J.Y., Iyer, R.P., and Agrawal, S. 1994. Diethoxy N,N-diisopropyl phosphoramidite as an improved capping reagent in the synthesis of oligonucleotides using phosphoramidite chemistry. Tetrahedron Lett. 35:8565-8568.
Synthesis of Unmodified Oligonucleotides
3.16.19 Current Protocols in Nucleic Acid Chemistry
Supplement 30
CHAPTER 4 Synthesis of Modified Oligonucleotides and Conjugates INTRODUCTION he genetic information encoded in either genomic DNA or transcribed mRNAs has become an enticing target for chemical modifications and potential therapeutic indications. Specifically, the search for methods that selectively prevent expression of unwanted genes has been actively pursued for more than a decade. Theoretically, it is possible to exploit the selective Watson-Crick hydrogen bond formation between complementary nucleic acid strands to control gene expression either by preventing transcription of genomic DNA (an antigene strategy) or by interfering with the translation of mRNAs (an antisense strategy) to gene products. With the advent of rapid and efficient methods for automated synthesis of oligonucleotides, it has indeed been possible to prepare modified oligonucleotides complementary to specific nucleotide sequences of mRNA targets. As a consequence of binding, and on the basis of particular cellular mechanisms, these oligonucleotides can disrupt the flow of genetic information from transcribed mRNAs to proteins. Thus, gene expression can be controlled at the mRNA level by modified oligonucleotides, and this antisense strategy has led, over the years, to the development of therapeutic oligonucleotides against cancer and various infectious diseases in humans. In this context, UNIT 4.1 reports recent advances in the application of oligonucleotides as drug candidates, describes the relationship between oligonucleotide modifications and their therapeutic profiles, and provides general guidelines for enhancing oligonucleotide drug properties.
T
Along similar lines, modern methods for the chemical synthesis of oligonucleotides have facilitated the covalent attachment of reporter and conjugate groups to DNA and RNA. Such modifications generate properties not normally present in native DNA or RNA oligonucleotides. For example, addition of a conjugate group to an oligonucleotide can be used to alter its solubility, charge, binding affinity, spectroscopic properties, and function. Furthermore, oligonucleotide conjugates can provide structural information on the nature of specific nucleic acid complexes such as protein-DNA(RNA) or ligand-DNA(RNA) complexes. Unlike enzymatic methods, chemical methods for the incorporation of modified nucleosides into oligonucleotides permit a precise control over the type, number, and placement of the reporter and conjugate groups within the sequence of interest. Typically, fluorescent markers, intercalators, cross-linkers, and DNA/RNA cleaving agents are added either to the 5 or 3 terminus of oligonucleotides, or inserted anywhere within an oligonucleotide sequence. These oligonucleotide conjugates can then be specifically dedicated to diagnostic or therapeutic applications. UNIT 4.2 presents an overview of the methods employed for the attachment of reporter and conjugate groups to the 5 terminus of oligonucleotides. The unit lists several reporter and conjugate groups that can be directly incorporated into oligonucleotides mainly via ligand phosphoramidite or H-phosphonate derivatives. This knowledge is reduced to practice in UNIT 4.3, which delineates step-by-step protocols for the synthesis of intercalating and photo-cross-linking ligand phosphoramidites as well as their addition to the 5 terminus of oligonucleotides. Reporter and conjugate groups are, however, not always stable to the conditions used during either oligonucleotide synthesis or the subsequent deprotection steps. Consequently,
Synthesis of Modified Oligonucleotides and Conjugates
Contributed by Serge L. Beaucage
4.0.1
Current Protocols in Nucleic Acid Chemistry (2007) 4.0.1-4.0.4 C 2007 by John Wiley & Sons, Inc. Copyright
Supplement 29
the incorporation of these groups into oligonucleotides must be accomplished according to an “indirect” approach. This method involves functionalization of the 5 terminus of oligonucleotides, mostly with nucleophilic groups. Although the indirect approach to the preparation of oligonucleotide conjugates is extensively reviewed in UNIT 4.2, procedures for the modification of oligonucleotides at the 5 terminus are outlined in UNIT 4.9. Following deprotection and purification, the functionalized oligonucleotides are then conjugated to selected electrophilic reporter or conjugate groups. Methods describing the incorporation of functional groups into ligands are reported in UNIT 4.8, and methods for conjugation of these ligands to the 5 -functionalized oligonucleotides are described in UNIT 4.10. Phosphoramidites tethered with single or multiple linkers denote a creative approach to the functionalization of oligonucleotides. These phosphoramidites are prepared from methoxyoxalamido (MOX)–derived secondary alcohol precursors, which are assembled upon reaction with amino alcohols or, repeatedly and sequentially, with aliphatic diamines and dimethyloxalate. This MOX phosphoramidite chemistry leads to oligonucleotides tethered with spacers varying in hydrophobicity, rigidity, and length, that are amenable to conjugation with diverse electrophilic ligands. This versatile functionalization method is featured in UNIT 4.29. An attractive method for the preparation of oligonucleotide conjugates consists of functionalizing the 5 -terminus of solid-phase-bound oligonucleotides with a diene phosphoramidite derivative followed by conjugation of the deprotected oligonucleotides with selected dienophile reporter groups via a Diels-Alder cycloaddition reaction. The details of this convenient conjugation method are provided in UNIT 4.18. For similar applications, a facile and efficient 5 -iodination of solid-phase-linked oligonucleotides is presented in UNIT 4.19. 5 -Iodo oligonucleotides allow conjugation with small molecules or macromolecules having a strongly nucleophilic group. While the functionalization of oligonucleotides at either the 5 - or 3 -terminus is invaluable in the preparation of oligonucleotide conjugates, the incorporation of uridine 2 -carbamates into oligonucleotides nicely complements these methods for direct or indirect attachment of various ligands to DNA or RNA. This versatile method is carefully detailed in UNIT 4.21. The purification of synthetic oligonucleotides from a mixture of shorter sequences is always a concern. Thus, purification methods that can easily provide oligonucleotides of high purity are of great value. UNIT 4.20 highlights a reversible biotinylation of the 5 -terminus of oligonucleotides, which allows simple and highly effective affinity purification of these biomolecules.
Introduction
This chapter is also intended to include overviews and step-by-step protocols addressing the attachment of reporter and conjugate groups to the nucleobase, the 3 terminus, and the carbohydrate portion of oligonucleotides for diagnostic applications. In this regard, UNIT 4.5 surveys a number of conjugation methods for oligonucleotides displaying various 3 functional groups, and UNIT 4.6 describes the step-by-step preparation of 3 -aminoalkylated or 3 -mercaptoalkylated oligonucleotides, and their respective conjugation to fluorescent reporter groups. UNIT 4.31 addresses the attachment of 1,4,7,10tetraazacyclododecane-1,4,7,10-tetracetic acid (DOTA) to deoxyuridine functionalized with an aminoalkylated linker at N3, and the conversion of the modified deoxyribonucleoside to its phosphoramidite derivative. This phosphoramidite is used in the preparation of a DOTA-labeled oligonucleotide and its gadolinium(III) chelate. This unit thus provides a straightforward method for site-specific incorporation of a magnetic resonance imaging contrast agent into oligonucleotides for target-specific applications. Other protocols describing the preparation of oligonucleotides with modified nucleobases, sugars, and internucleotide linkages for potential therapeutic applications will also be incorporated into this chapter to provide a comprehensive coverage of these cutting edge technologies. In
4.0.2 Supplement 29
Current Protocols in Nucleic Acid Chemistry
this context, UNIT 4.4 delineates the solid-phase synthesis of chimeric 2-5A-DNA oligonucleotide conjugates along with the preparation of the phosphoramidite monomers used for such synthesis. In addition, the synthesis and purification of oligonucleotides composed of N3 →P5 phosphoramidate and either phosphodiester or phosphorothioate linkages, as presented in UNIT 4.7, is a relevant example of such protocols. UNIT 4.11 provides manual and automated methods for the synthesis of peptide nucleic acids (PNAs), whereas UNIT 4.12 details the synthesis of locked nucleic acids (LNAs). These modified nucleic acids exhibit high affinity for complementary RNA and DNA strands, and are thus amenable to a wide range of biomedical applications. In this regard, a procedure for the incorporation of LNAs into cells is reported in UNIT 4.13. The conjugation of peptides to oligonucleotides to generate nucleopeptides is the focus of intense scrutiny given the reported abilities of these conjugates at enhancing intracellular delivery of therapeutic oligonucleotides. However, the preparation of peptide-oligonucleotide conjugates is challenging. An inspiring method for the stepwise solid-phase synthesis of nucleopeptides is delineated in UNIT 4.22, thus making these bioconjugates more available for further cell delivery studies. Another innovative approach to the preparation of peptide-oligonucleotide conjugates is based on the respective functionalization of oligonucleotides and peptides with either a free or activated thiol group. Conjugation of the functionalized entities occurs rapidly and efficiently through formation of a disulfide link. The specifics of this method are featured in UNIT 4.28. A different strategy for internalization and cell-specific targeting of therapeutic oligonucleotides relates to the covalent attachment of these molecules to carbohydrates. UNIT 4.26 includes methods for the preparation of a mannose-derived ligand and a non-nucleosidic phosphoramidite functionalized with phthalimidooxy groups as building blocks in the solid-phase construction of a multiantennary oligonucleotide glycoconjugate. Such glycocluster structures have recently attracted considerable attention in terms of potential biomedical applications, as these are a prerequisite for high-affinity cellular binding and internalization of their conjugates by endocytosis. Synthetic nucleic acids containing vicinal 2 ,5 - and 3 ,5 -phosphodiester linkages have been useful to investigations related to pre-mRNA splicing events and to studies assessing the specificity of RNA lariat debranching enzymes. These branched nucleic acids may also find applications in the development of biosensors and diagnostics, or may serve as “molecular anchors” in the formation of triplex and tetraplex structures. Two synthetic strategies for the preparation of branched oligonucleotides are outlined and developed in UNIT 4.14. An important class of uncharged P-chiral analogs of nucleic acids includes morpholino oligonucleotides. These synthetic oligonucleotide analogs are typically used to block translation of mRNA, alter the splicing of pre-mRNA, or prevent other interactions between biological macromolecules and RNA through base-pairing events. Morpholino oligonucleotides combine efficacy, specificity, stability, lack of non-antisense effects, and exhibit good water-solubility properties. Exquisite technical information on how to design and deliver morpholino oligonucleotides to control gene expression in cell cultures is given in UNIT 4.30. Transfer RNAs (tRNAs) incorporate a variety of modified nucleobases, which are known to affect the biological activity of tRNAs through structural changes. To better understand the role of these modified nucleobases, UNIT 4.23 reports on the synthesis of ribonucleoside phosphoramidites functionalized with either 6-methylthio purine or 2methylthio-6-chloro purine for incorporation into relatively short RNA oligonucleotide models. Following oligonucleotide synthesis using these phosphoramidites, the modified nucleobases are chemically converted to a number of native tRNA nucleobase modifications to further studies in this research area.
Synthesis of Modified Oligonucleotides and Conjugates
4.0.3 Current Protocols in Nucleic Acid Chemistry
Supplement 29
Modified nucleic acids such as 2 -deoxy-2 -fluoro-β-D-oligoarabinonucleotides are unique in that they form more stable duplex structures with RNA complements than identical unmodified DNA:RNA duplexes. In addition, the modified heteroduplexes are substrates for RNase H, an enzyme viewed by many as the major effector of antisense activity. Thus, given the promising antisense properties of 2 -fluoroarabinonucleic acids, methods for the synthesis of 2 -deoxy-2 -fluoro-β-D-arabinonucleoside phosphoramidites and their use in the automated synthesis of 2 -fluoroarabinonucleotides are included in UNIT 4.15. Substitution of native nucleobases with 7-deazapurines (pyrrolo[2,3-d]pyrimidines) functionalized with halogeno or alkynyl groups at C7 has been shown to stabilize DNA duplexes. This serves as a creative example in the design of therapeutic oligonucleotides with high-affinity binding for complementary nucleic acid targets. The preparation of these modified DNA oligonucleotides using phosphoramidite monomers is described in UNIT 4.25. Synthesis of the pyrrolo[2,3-d]pyrimidine 2 -deoxyribonucleoside precursors is provided in UNIT 1.10. An additional class of oligonucleotides for potential therapeutic applications includes phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotide analogs. These modified oligonucleotides are highly resilient to nucleases, and yet they are anionic, water soluble, and form hybrids with both native DNA and RNA complementary sequences. It is noteworthy that both oligonucleotide analogs stimulate RNase H–mediated hydrolysis of the complementary RNA strand of each DNA:RNA hybrid. UNIT 4.24 presents the detailed preparation of the deoxyribonucleoside phosphoramidites required for solidphase synthesis of phosphonoacetate and thiophosphonoacetate oligonucleotides, along with methods used for purification and characterization of these oligonucleotide analogs. Phosphorothioated oligonucleotides have also found therapeutic applications in antisense settings. Such modified oligonucleotides are chiral at phosphorous, and those exhibiting the Sp configuration are significantly more resistant to nucleases found in human plasma than P-diastereomeric or Rp -phosphorothioated oligonucleotides. Methods for the synthesis of oligonucleotides with stereodefined phosphorothioate linkages would therefore be valuable in the preparation of therapeutic oligonucleotides with optimal resistance to nucleases. UNIT 4.17 specifically describes the use of deoxyribonucleoside3 -O-(2-thio-1,3,2-oxathiaphospholane) derivatives in the P-stereocontrolled synthesis of phosphorothioated oligonucleotides. Another class of modified oligonucleotides with potential biomedical applications relates to phosphorothioated oligodeoxyribonucleotides expressing specific CpG motifs. These oligonucleotides strongly stimulate B cells, natural killers cells, and antigen-presenting cells to proliferate and/or secrete cytokines, chemokines, and immunoglobulins. Given that a number of structural factors influences the recognition of CpG-oligonucleotides and expression of their immunostimulatory properties, UNIT 4.16 provides an overview of the chemical strategies used to assess the significance of these factors toward the development of human therapies. With the incidence of therapeutic applications for phosphorothioated oligonucleotides, the large-scale preparation of these biopolymers through automated solid-phase techniques is increasingly important, but is challenging and costly in terms of reagent consumption. A new process whereby polyethylene glycol is employed as a soluble support for the large-scale synthesis of thioated oligonucleotides and selected conjugates is proposed in UNIT 4.27. Such a process offers several advantages over traditional solid-phase methods for oligonucleotide synthesis, and these are discussed in the unit. Introduction
Serge L. Beaucage
4.0.4 Supplement 29
Current Protocols in Nucleic Acid Chemistry
A Brief History, Status, and Perspective of Modified Oligonucleotides for Chemotherapeutic Applications Modification of oligonucleotides for drug applications has a very short history (for highlights see Table 4.1.1 and Table 4.1.2). Intensive efforts to modify short strands of nucleic acids to enhance their properties as drug candidates began in earnest in the late 1980s. The notion that oligonucleotides could be made into drugs along with the discovery and development of two essential enabling technologies— automated DNA sequencing (Connell et al., 1987) and commercial automated oligonucleotide synthesis and purification in the early 1980s—set the stage for oligonucleotide drug discovery (reviewed by Zon, 1993). Subsequently, oligonucleotide medicinal chemistry and pharmacology, which form the basis of structure-activity relationship studies, have been highly developed in the process of converting oligonucleotides into drugs. Before this, little value was given to synthetically changing the structure of short strands of DNA or RNA except for some early modifications primarily directed to enhance structural studies and diagnostic applications. Now great interest in making drugs out of oligonucleotides has spurred intense structure-activity/property relationship (SAPR) studies to optimize drug properties (Cook, 1998a,b). Given that oligonucleotides are gene-based materials (or informational materials; Cohen, 1991) and considering the emergence of genomic target selection, which is also gene-
Table 4.1.1
UNIT 4.1
based, it is surprising that it has taken so long for the drug discovery community to recognize the potential value of modified oligonucleotides as drugs. However, when traditional medicinal chemists first consider modifying oligonucleotides, they are confronted with a number of daunting chemical, biophysical, and biochemical properties of oligonucleotides (Table 4.1.3), which has surely slowed progress in this area. In addition to the need to apply novel ligands to drug discovery, the nucleic acid targets that serve as receptors, particularly RNA molecules, are novel as well. In spite of the early difficulties in exploring the use of oligonucleotides as drugs, however, much progress has been made in recent years. The first antisense oligonucleotide drug, Vitravene, was recently approved by the Food and Drug Administration (FDA) for treating cytomegalovirus retinitis in AIDS patients, and several additional oligonucleotides are in late phase II and III clinical studies for anti-cancer and antiinflammatory indications (Table 4.1.4).
OVERVIEW OF BASE PAIRING AND GENE EXPRESSION A single strand of nucleic acid has a polymeric sugar-phosphate backbone with ribofuranosyl (in RNA) or deoxyribofuranosyl (in DNA) residues connected at the 3′ and 5′ hydroxyls by phosphoric acid to form phosphodiester linkages. Each sugar residue has one of
Historical Listing of Oligo- and Polynucleotides as Therapeutic Agents
Milestone
References
DNA alkylating agents Poly(rI) • poly(rC) Macromolecular antimetabolites “Antitemplates” Antisense oligonucleotides (targeting RNA) Heterocycle modified oligonucleotides: prodrugs for nucleosides Antigene oligonucleotides: triple strand formers Aptamers
Belikova et al. (1967); Summerton (1979) De Clercq et al. (1969) Chandra and Bardos (1972); reviewed by Bardos and Ho (1978) See Table 4.1.2 Alderfer et al. (1985)
Sense approach
Moser and Dervan (1987); LeDoan et al. (1987) Ellington and Szostak (1990); Tuerk and Gold (1990) Morishita et al. (1995)
Contributed by P. Dan Cook Current Protocols in Nucleic Acid Chemistry (2000) 4.1.1-4.1.17 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.1.1
Table 4.1.2
Highlights of the Development of Chemotherapeutic Oligonucleotides
Milestone
References
Antisense experiments in cell culture
Stephenson and Zamecnik (1978); Zamecnik and Stephenson (1978) Merrifield, Letsinger, Caruthers (1962-1987) Ts’o et al. (1987) Eckstein, Stec, Zon (1967-1981) Cech (1986); Altman (1989) Isis Pharmaceuticals (1992-1994)
Automated synthesis, protocols, reagents Methylphosphonate oligonucleotides Phosphorothioates Ribozymes Initiation of first clinical trial; first report of clinical efficacy Twenty five oligonucleotides entered into clinical development First New Drug Application (NDA) for an antisense oligonucleotide First approved antisense oligonucleotide drug
five types of heterocycles (nucleobases) attached at the C1′ position of either the deoxyribofuranosyl or ribofuranosyl sugar. These heterocycles are the purines (guanine and adenine) and the pyrimidines (cytosine and thymine, with uracil replacing thymine in RNA). Complementary DNA describes a chemical complex of two strands of deoxyribonucleic acid that are bound together by WatsonCrick base-pair hydrogen bonding. This “essences of life” bonding specifies that guanine in one DNA strand specifically binds to cytosine in the other strand, and that adenine in one DNA strand specifically binds to thymine in the other strand (Fig. 4.1.1). In RNA, uracil specifically binds to adenine. A sequence (or a specific ordering of nucleobases) of an RNA or a DNA strand will bind specifically
(1992-present; see Table 4.1.4) Isis Pharmaceuticals (April 1998) Isis Pharmaceuticals (August 1998)
(hydrogen bond) to another sequence only if the nucleobases match up (base pair). The strands are then said to be complementary to one another. The complementary DNA strands twist into a helical motif with one strand having its bases ordered in the 3′ to 5′ direction and the other strand having its bases ordered in the opposite direction (5′ to 3′). This is referred to as antiparallel orientation (Fig. 4.1.2). The doublestranded DNA (dsDNA) serves as the template for synthesis of either complementary DNA molecules, to provide a process of self-replication, or complementary RNA molecules (from the sense strand) for the process of transcription. The complementary DNA strand, referred to as the antisense strand, is itself rarely transcribed to give an RNA molecule.
Table 4.1.3 Chemical, Biochemical, and Biophysical Properties of First-Generation Oligonucleotides
Parameter
Property
Molecular weight Charge Chirality in backbone Instabilities Solubility
High (20- to 25-mers, MW 7000 to 9000) Highly negative (19 to 24 charges) or neutral P=S, Me-P, N-Pa Biological and chemical (nucleases, pH, depurination, dethiation) Insoluble in common organic solvents depending on backbone modification (P=S versus Me-P)a No Complex synthesis of reactive monomers Unfamiliarity with instrument synthesis of oligomers Purification by ion exchange chromatography Analysis and characterization atypical
Crystalline? Ease of synthesis Modified Oligonucleotides for Chemotherapeutic Applications
aMe-P, methylphosphonate; N-P, phosphoramidate; P=S, phosphorothioate.
4.1.2 Current Protocols in Nucleic Acid Chemistry
Table 4.1.4
Oligonucleotides Entered into Clinical Developmenta
Disease indications
Oligonucleotide
Molecular target
ISIS 2105
HPV 6 and 11 E2 Genital warts genes product HCMV IE gene-2 CMV retinitis
ISIS 2922
Statusb
Sponsor
Terminated
Isis
NDA approved (August 1998) III, Crohn’s; II for others
Isis/Ciba Vision
Renal allograft, rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis Cancer II
Isis/Boehringer Ingleheim
Cancer
II
Isis/Novartis
HCMV IE gene Gp120 Ha-ras gag gene gag gene UL36 and UL37 Protein kinase A p53 c-myc c-myb gag gene HIV integrase Bcl-2 gag gene
CMV retinitis AIDS Cancer AIDS AIDS CMV retinitis Cancer Cancer Restenosis Cancer AIDS AIDS Cancer AIDS
I/II Terminated I Terminated I I II Terminated Terminated Terminated Terminated I/II II Terminated
Cancer
I
MG-98 Resten-NG
Ribonucleotide reductase R2 subunit DNA methylase c-myc
Isis Isis Isis Hybridon Hybridon Hybridon Hybridon Lynx/Inex Lynx/Inex Lynx/Inex Chugai Aronex Genta Novopharm Biotech GeneSense
Heptazyme
IRES region
Angiozyme
Vascular endothelial growth factor receptor Immune system
ISIS 2302
Intercellular adhesion molecule (ICAM-1)
ISIS 3521/CPG 64128A ISIS 5132/CPG 69846A ISIS 13312 ISIS 5320 ISIS 2503 GEM-91 GEM-92 GEM-132 GEM-231 OL(1)p53 LR-3280
Protein kinase C-α c-raf kinase
GPs 0193 Zintevir G3139 GPI-2A GTI 2040
CPG-x
Solid tumors I Restenosis and I proliferative diseases Hepatitis C virus I
Isis/Novartis
MethylGene AVI BioPharma
Antiangiogensis (cancer)
I
Ribozyme Pharmaceuticals Ribozyme
Hepatitis B
I
CpG
aAbbreviations: E, early gene; HCMV, human cytomegalovirus; HPV, human papillomavirus; IE, immediate early gene;
IRES, internal ribosomal entry site; NDA, New Drug Application; UL, unique long. bI, II, and III indicate phase of clinical trials at time of printing.
Synthesis of Modified Oligonucleotides and Conjugates
4.1.3 Current Protocols in Nucleic Acid Chemistry
H O O
O O
O
Figure 4.1.1
C
P
N
H
O P HO
N
O
H
O O O P
N O O
N
O
O
−
O
−
O O
HO
N H
O
Watson-Crick hydrogen-bonding (base-pairing) rules (G to C, A to U or T).
The transcribed RNA molecules, in turn, serve as the templates that allow the ordering of the amino acids within the polypeptide chain of proteins, during the process of translation. Translation is an appropriate term because the nucleotide sequence information (language) of nucleic acids is translated into the amino acid sequence (language) of protein. The complete process—DNA makes RNA makes protein— has been referred to as the central dogma of molecular biology. A more common term for the process is gene expression. Thus, the two stages of gene expression are transcription (the conversion of DNA to RNA) and translation (the conversion of RNA to proteins). DNA also self-replicates to maintain an organism’s genome. Furthermore, regulation of gene expression in living organisms involves extensive recognition and binding to specific nucleic acid sequences by nucleic acid–binding proteins.
INFORMATIONAL DRUG DISCOVERY APPROACHES AND THEIR SUCCESS
Modified Oligonucleotides for Chemotherapeutic Applications
H(CH3)
N U/T N O
N G
N
O
O
O
A N H N H N H O
P
O
−
N
O
O
−
N H
N
Disease states (genetic, oncogenic, or infective) are typically a result of the production of abnormal proteins, the end-stage product of gene expression. Thus, it is not surprising that drug discovery has historically focused on interfering with the functions of the abnormal proteins rather than on preventing abnormal protein formation—treating the disease symptoms rather than the cause. In contrast, treatment approaches involving informational chemicals, such as oligonucleotides, attempt to prevent the formation (gene expression) of abnormal protein by targeting DNA, RNA, or regulatory proteins that are required for transcription and translation of the abnormal protein. Having a set of binding rules (Watson-Crick base-pairing rules) that allows one to rapidly and precisely select a molecule to synthesize that will inhibit gene
expression at the DNA or RNA level, and that offers exquisite specificity for its receptor, is unique in the history of drug research. Thus, the employment of informational drugs to complement genomic target validation in modern drug discovery is revolutionary. Several discovery approaches are being pursued that employ the encoded information of modified oligonucleotides as the drug agent (Tables 4.1.1 and 4.1.2). In the process of transcription, complementary RNA (message RNA or mRNA) is derived from the sense DNA strand by Watson-Crick base-pair recognition and binding. The antisense approach targets the initial sense complementary RNA strand (primary transcript) as well as many downstream sites that are available as RNA is metabolized in the process of protein production (e.g., splicing, transport, translation; Fig. 4.1.2). A strict definition of the antisense approach describes the inhibition of gene expression through targeting of a predetermined sequence in an RNA. There are several types of antisense approaches, which may be differentiated on the basis of their modes of action (Fig. 4.1.2). Antisense oligonucleotides primarily operate by sequence-specific binding to the targeted RNA. The resultant heteroduplex recruits a ubiquitous endonuclease, ribonuclease H (RNase H), to cleave the targeted RNA strand. Other potential antisense modes of action are by direct sequence-specific binding of the oligonucleotides to the targeted RNA (or merely occupying a site on the RNA) such that the function of essential RNA-binding proteins is disrupted or that secondary structure required for gene expression of the RNA is disrupted. A variety of distinct sites in the intermediary metabolism of RNA can potentially be targeted by antisense oligonucleotides with RNase H– dependent or –independent modes of action depicted in Figure 4.1.2.
4.1.4 Current Protocols in Nucleic Acid Chemistry
Figure 4.1.2
Informational drug-targeting sites. CAP, m7Gppp; W/C, Watson-Crick.
RNase L, like RNase H, is another cellular nuclease that cleaves RNA. Its endonucleolytic cleavage is triggered by binding to (2′-5′)linked polyadenylic sequences (Fig. 4.1.3). Torrence and co-workers have conjugated the RNase L activating moiety to oligonucleotides to provide sequence-specific cleavage of targeted RNA (Torrence et al., 1994). Ribozymes are RNA molecules with catalytic RNA-cleaving activity (Cech, 1986) and thus represent another type of antisense oli-
gonucleotide. These are typically much longer RNA molecules that contain both a catalytic region (which can cleave another RNA segment) and an adjacent sequence or two sequence arms that allow Watson-Crick base-pair binding to the target. A variety of ribozymes have been described that differ primarily in their threedimensional structures and lengths (reviewed by Rossi, 1998). The sequence-specific cleavage of a predetermined RNA target is accomplished without assistance from any protein.
NH2 N O O O HO P O P O P O O O O
O
N
N
N NH2
HO
O O P O O
N O
N
N N NH2
HO
O O P O O
HO
Figure 4.1.3
(2′-,5′)-Adenylic oligonucleotides.
N N
O O
N N
oligonucleotide
Synthesis of Modified Oligonucleotides and Conjugates
4.1.5 Current Protocols in Nucleic Acid Chemistry
A X = O,S,C 5' Heterocycle
A,C,G,T
X
Sugar
3' O Linkage
R 2'-Position
O P O O
O
4'
Connection sites
O
R
A,C,G,T Pendants
Replace sugar-phosphate (e.g., amide linkage, PNA) Subunits of oligonucleotide to modify
B Phosphorous modifications a. b. O O O P O O P S O O
O O P BH3 O
d.
e. O O O P NHR O P OR O O
O O P CH3 O h.
g.
f.
c.
O O P Se O
O S P S O
Linkage modifications i. j. Me N O
NH O P O O
HN
n.
m.
l.
k.
CH2 O P O
S
O
O
S
O
O
Sugar modifications p.
o.
r.
q. base
base O
s.
O
O OMe
F
base
base
O
O
O
OMe NH2
t. u.
base
O
v.
base
O
base
O
base O
O
O O
w.
O
NMe2
x. base
O
N NMe2 O P NHR
O
O NMe2 base
O O
Heterocycle modifications y. Me
z. O
NH2 Me
NH N cc. Me
aa.
O
O
N N
N
O
NH
NH2
NH2
Connection modification ff.
O
N
NH2
N
O
N
O
Sugar-phosphate replacement gg.
base N
O
Modified Oligonucleotides for Chemotherapeutic Applications
N
NH
N N
N NH2
N
ee.
dd.
NH2
I
N
N
O
N
bb.
NH2
N
N
O
O base HN
base N
O
4.1.6 Current Protocols in Nucleic Acid Chemistry
Oligonucleotides may also inhibit gene expression at the DNA level by several antigene approaches. The most often examined approach is triple strand formation by oligonucleotides binding in the major groove of dsDNA via several Hoogsteen base-pairing rules (Helene, 1993). A less often examined approach is the use of oligonucleotides to bind via Watson-Crick base-pairing rules to a single strand of DNA available from the formation of a transcription bubble or locally open-chain site of dsDNA. Utilizing nucleic acids as decoys to compete with natural cis-acting sites on dsDNA for essential regulatory proteins is referred to as the sense approach. In this case, synthetic oligonucleotides (typically dsDNA) are designed to bind to proteins in a sequence-specific manner. In another protein-binding approach, aptamers, derived from nucleic acid selection processes (see Chapter 9), can specifically target regulatory proteins. Common steps to all selection methods for nucleic acid–binding species are: (1) generation of a large pool of sequence diversity from chemically synthesized DNA pools, (2) transformation of the pools by enzymatic manipulations such as polymerase chain reaction (PCR) or in vitro transcription, (3) selection of functional shapes, and (4) amplification. As each RNA sequence folds into a distinct three-dimensional shape, and because of the large number of structures (millions) generated, complementary binding to a protein target may occur, providing useful biological properties (reviewed by Bacher and Ellington, 1998). Of those drug discovery approaches based on oligonucleotides, the antisense efforts are clearly the most advanced, in that twenty three first-generation phosphorothioate oligonucleotides have entered human clinical trials and one antisense oligonucleotide has achieved FDA approval (Table 4.1.4). Much less success has been accomplished by targeting DNA with
triple-strand-forming oligonucleotides, antisense ribozymes, and RNase L–modified oligonucleotides. From a chemical point of view, these and other less successful approaches listed in Tables 4.1.1 and 4.1.2 suffer from not being amenable to the readily available, firstgeneration backbone-modified oligonucleotides such as methylphosphonates, amidates, phosphorothioates, and α oligomers (Fig. 4.1.4B). Success in these drug discovery approaches, assuming that the biological rationale is valid, will require much more intensive chemical efforts.
MODIFICATIONS AND DRUG PROPERTY ALTERATIONS A diverse range of modifications at all possible modification sites of an oligonucleotide have been reported (reviewed in Cook, 1998a). Figure 4.1.4A illustrates a dimer of an oligonucleotide depicting possible modifications for enhancing oligonucleotide drug properties. These include alterations of heterocycles, carbohydrates, linkages (backbones), and connection and conjugation sites, as well as the complete removal of the sugar-phosphate backbone. Most of the positions available in a GC or AT dimer (∼26 positions for each dimer) that do not directly interfere with Watson-Crick base-pair hydrogen bonding have been modified at one time or another. The nucleobases or heterocycles of nucleic acids provide the recognition points for Watson-Crick base pairing and must maintain this specific interaction in any modification. Thus, the scope of heterocyclic modifications is quite limited; this is verified by the fact that only five or six modified heterocycles have demonstrated useful oligonucleotide drug properties. These can be characterized as lipophilic modifications at C5 of pyrimidines and C7 of 7deazapurines. Enhanced stacking has been suggested to be the reason for increased binding
Figure 4.1.4 Oligonucleotide modification. (A) Dimer structure showing potential modification sites. (B) Examples of oligonucleotide modifications: (a) natural phosphate diester; (b) chiral phosphorothioate; (c) chiral methyl phosphonate; (d) chiral phosphoramidate; (e) chiral phosphate triester; (f) chiral boranophosphate; (g) chiral phosphoroselenoate; (h) phosphorodithioate; (i) methylenemethylimino (MMI); (j) 3′-amide; (k) 3′ achiral phosphoramidate; (l) 3′ archiral methylene phosphonate; (m) thioformacetal; (n) thioethyl ether; (o) 2′-fluoro; (p) 2′-O-methyl; (q) 2′-O-(3amino)propyl; (r) 2′-O-(2-methoxy)ethyl; (s) 2′-O-2-(N,N-dimethylaminooxy)ethyl (DMAOE); (t) 2′O-2-[2-(N,N-dimethylamino)ethyloxy]ethyl (DMAEOE); (u) 2′-O-N,N-dimethylacetamidyl; (v) N-morpholinophosphordiamidate; (w) hexose nucleic acid; (x) locked nucleic acid (LNA); (y) 5-propynyluracil-1-yl; (z) 5-methylcytosin-1-yl; (aa) 2-aminoadenin-9-yl; (bb) 7-deaza-7-iodoadenin-9-yl; (cc) 7-deaza-7-propynyl-2-aminoadenin-9-yl; (dd) phenoxazinyl; (ee) phenoxazinylG-clamp; (ff) α−deoxyribofuranosyl; (gg) peptide nucleic acid (PNA). See Cook (1999). Current Protocols in Nucleic Acid Chemistry
Synthesis of Modified Oligonucleotides and Conjugates
4.1.7
Modified Oligonucleotides for Chemotherapeutic Applications
affinity with this type of heterocycle modification. 2-Aminoadenine represents another type of modification that provides enhanced binding affinity. In this case, an additional hydrogen bond is formed to uracil, providing significant increases in melting temperature (Tm). All of these modifications—positioned to lie in the major or minor groove of the heteroduplex—do not affect sugar conformation of the heteroduplex, and do not provide useful nuclease resistances, but will support an RNase H cleavage mechanism. Modifications in the ribofuranosyl moiety have provided the most value in the quest to enhance oligonucleotide drug properties. In particular, certain 2′-O modifications have greatly increased binding affinity, increased nuclease resistance, and altered pharmacokinetics, and are potentially less toxic than phosphorothioate oligonucleotides (Cook, 1998a). Preorganization of the sugar into a 3′-endo pucker conformation is responsible for the increased binding affinity. Unfortunately, no sugar modification has been reported that is useful in supporting RNase H cleavage. Linkage or backbone modifications involve changes to the nonbridging oxygen atoms, such as phosphorothioate (P=S), methylphosphonate (Me-P), phosphoramidate (N-P), and others shown in Figure 4.1.4B, as well as extensive changes in which the entire four-atom linkage between sugar moieties is replaced. The most useful linkage-replacement modification, MMI (Fig. 4.1.4B), provides greatly enhanced binding affinities, removes the nuclease-cleavable phosphodiester linkage and the chirality of the phosphorothioate linkage, and allows adjustments of oligonucleotide lipophilicity by controlling the negative charge. Of the linkage changes, only phosphorothioates induce RNase H cleavage. Several examples of connection modifications in oligonucleotides are α-nucleoside linkage (reverse connection of the heterocycle at C1′) and (2′-5′)-phosphodiester bonds (in place of the normal (3′-5′)-phosphodiester bond). Peptide nucleic acid (PNA) is an example of the complete removal of the sugar-phosphate backbone and replacement with a peptide linkage. In addition to the above modifications, pendants or conjugation groups can be attached at many positions in the various subunits to enhance drug properties. The antisense concept implies well-defined structural requirements for the oligonucleotide ligand that binds to a reasonably characterized RNA receptor. Although this knowledge of
rather precise binding is of great value and certainly sets this drug discovery approach apart from current approaches, additional modifications are limited to modifications that do not interfere with Watson-Crick basepairing rules. Modifications of oligonucleotides may be expected to address essentially every facet of antisense drug properties. Biophysical and biochemical properties that may be affected by modifications include binding affinity, basepair specificity, nuclease resistance, chemical stability, lipophilicity, solubility, endonucleolytic cleavage of the RNA of a heteroduplex, biological pharmacokinetic properties, toxicological properties, and pharmacological properties. Drug properties that will be affected by altering biophysical and biochemical parameters include the general areas of pharmacokinetics, pharmacodynamics, and toxicology. In addition, certain modifications may represent cost and proprietary patent advantages. Modifications of short strands of DNA and RNA for drug purposes should be rationally directed by drug property deficiencies of the parent or first-generation oligonucleotides (Table 4.1.5). Biological deficiencies are exposed by pharmacologic, pharmacokinetic, and toxicologic studies of the parent oligonucleotides at the biophysical, biochemical, in vitro, in vivo, and clinical levels. In addition, as modified oligonucleotides move from discovery into the development pipeline, chemical development deficiencies in, for example, larger-scale synthesis, purification, and analytical processes will emerge that must be resolved. Finally, in contemplating research in oligonucleotides, one should search the patent literature in addition to examining the traditional scientific literature, as considerable proprietary positions of various aspects of the technology have been achieved. Hopefully, the days of incorporating nucleosides, novel or known, into oligonucleotides based merely on availability are over. This nonrational approach was of value in the beginning of oligonucleotide structure-activity modifications simply to develop an information base. Now that more knowledge is available about what is required to achieve enhanced properties, current and future oligonucleotide modifications and studies of their structure-activity relationships should be soundly and rationally based on the need to resolve one or more of the deficiencies listed in Table 4.1.5, or to overcome emerging drug process or production problems.
4.1.8 Current Protocols in Nucleic Acid Chemistry
Table 4.1.5
Limitations of First-Generation P=Sa Oligonucleotides
Area
Limitation
Pharmacodynamics
Low affinity per nucleotide unit: low potency limited sites to target Inhibition of RNase H at high concentrations RNase H mechanism implicated Limited oral bioavailability Limited blood-brain barrier penetration Dose-dependent pharmacokinetics Release of cytokines Complement-associated effects on blood pressure? Clotting effects Accumulation in kidneys?
Pharmacokinetics
Toxicologics
aP=S, phosphorothioate.
OPTIMIZATION OF BINDING AFFINITY AND NUCLEASE RESISTANCE Oligonucleotide Binding Affinities Based on the ligand-receptor theory of pharmacological activity, increasing the affinity of an oligonucleotide for its RNA target should increase potency. A relatively simple physicochemical experiment is employed to determine the level of binding and specificity of a modified oligonucleotide. A complementary oligonucleotide is the simplest target to which an antisense oligonucleotide can hybridize. Thus, using length-matched complementary oligonucleotides at stoichiometric concentrations in a medium that mimics the intracellular environment as closely as possible (salt, pH, temperature, concentration), melting curves are employed to determine how tightly a modified oligonucleotide binds to its complement. This involves a spectrophotometric analysis to measure absorbance versus temperature. The melting temperature (Tm—the temperature at which the mixture is half duplex and half single-stranded) is determined (Freier et al., 1992). Oligonucleotide affinity, as measured by melting curves, increases with the length of the oligonucleotide-RNA heteroduplex. Thus, 15to 25-mers are typically used in antisense experiments rather than shorter oligonucleotides, which may have Tm values close to or below physiological temperature and, therefore, may only form low levels of the required heteroduplex. A few short oligomers (12-mers or less) have exhibited interesting biological activity, and these require modifications leading to high affinity per nucleotide unit. One interesting
example was the report of potent and selective inhibition of gene expression by phosphorothioates (7- and 8-mers) containing only 5-propynyl-substituted uracil and cytosine bases (Fig. 4.1.4B; Wagner et al., 1996). Furthermore, several recent studies correlate binding affinities of a series of 2′-O-modified oligonucleotides with increased in vitro and in vivo activity (Kawasaki et al., 1993; Morvan et al., 1993; Monia et al., 1993, 1996; Altmann et al, 1996a,b,c, 1997). An extensive comparative listing of binding affinities of 2′-O modifications was provided by Freier and Altmann (1997).
Oligonucleotide Nuclease Resistance A number of in vivo pharmacokinetic studies in several animal species indicate that P=S oligonucleotides are not as stable as initially thought (Zhang et al., 1996; Nicklin, 1998). Although the stability of P=S oligonucleotides may be sufficient for many drug applications, greater stability will be helpful in expanding dosage regimens (longer duration of action relates to less frequent dosing) and in developing oral bioavailability. Additionally, less degradation of modified oligomers will minimize metabolite toxicity. In summary, the preponderance of published antisense biological data suggests that oligonucleotides with higher binding affinities and greater stabilities towards nucleases are important medicinal chemistry objectives.
STANDARDS ESTABLISHED BY RECENT SAPR STUDIES The intense oligonucleotide research performed in the 1990s has provided a remarkable enhancement of several of the desired antisense
Synthesis of Modified Oligonucleotides and Conjugates
4.1.9 Current Protocols in Nucleic Acid Chemistry
Modified Oligonucleotides for Chemotherapeutic Applications
drug properties. The results achieved with modified oligonucleotides concerning binding affinity, base-pair specificity, nuclease resistance, and support of RNase H cleavage of the targeted RNA is impressive. One should consider the level of binding affinity (as represented by Tm), nuclease resistance (as represented by t1/2), and support of an RNase H mechanism that a new modification should possess in order to be of interest as a potential drug. A number of “winners” have been identified (Fig. 4.1.4B) and discussed in several reviews (Cook, 1998a,b). Certain modifications of oligonucleotides provide an increase in Tm of >1.5°C/modification (°C/mod) relative to a P=S oligonucleotide (∼1.0°C/mod relative to an unmodified P=O oligonucleotide), and nuclease resistance (t1/2) of >24 hr with snake venom phosphorodiesterase (SVPD; about the same as for P=S). In view of these values, the author suggests that a novel modification should exhibit a Tm >1.5°C/mod compared to its P=S oligonucleotide parent. In evaluation of binding properties, the modified oligonucleotides should be hybridized with an RNA complement, as this is the receptor required for the antisense approach. A clear correlation between Tm values derived from hybridization to a DNA complement or to an RNA has not been established. Also, correlations of Tm values have not been established for oligonucleotides having just one modification (point or pendent modification) or several modifications distributed throughout the sequence, or for those having a contiguous placement of the modification in the sequence (Cook, 1991; Lesnik et al., 1993; Buhr et al., 1996; Matteucci and Krosigk, 1996). Since the application of a modification will likely require its uniform placement in the sequence, or at least several contiguous bases in a row for a gapmer strategy (described below, Cook, 1993), binding affinity measurements (Tm) should be taken with these types of modified oligonucleotides. Furthermore, the modification must not compromise base-pair specificity. In this regard, information from a number of papers suggests that base-pair specificity actually increases as Tm values are increased. A specificity that is comparable to base mismatches of a P=S phosphorothioate would appear to be a useful standard. Nuclease resistance of a novel modification in a P=O oligonucleotide backbone should at least be at the level of uniformly modified P=S oligonucleotides. Given that measurements of t1/2 values, unlike Tm measurements, are deter-
mined using several procedures (e.g., by incubation with heat-inactivated fetal bovine serum, purified enzymes such as SVPD, cell or tissue extracts; or by in vivo dosing followed by extraction and analysis) under different conditions, the use of P=S oligonucleotide controls (standards) is necessary. In addition, several concentrations of nuclease should be employed to identify and minimize complications leading to enzyme inhibition (Cummins et al., 1995). Half-lives of ∼24 hr are often reported for P=S oligonucleotides in SVPD assays. When the 3′ end of an oligonucleotide is modified to have sufficient resistance to 3′-exonucleases, endonucleolytic cleavage becomes evident. Thus, modifications should also protect against endonucleases. In a gapmer strategy, this is accomplished by a phosphorothioate gap, which will also support an RNase H cleavage mechanism. Nuclease resistance of a modified oligomer, if not provided by the modification, may in many cases be enabled by employing a P=S oligonucleotide backbone. In considering the relative importance of the nuclease resistance of an antisense oligomer and its affinity level for its RNA target, recent biological results suggest that it may be more important to enhance the stability of an oligonucleotide than its binding affinity (Crooke et al., 1996a). Modifications that provide highbinding oligonucleotides with low nuclease resistance have not provided significant biological activity, whereas oligonucleotides such as phosphorothioates have. Although some modifications provide high binding affinities and high nuclease resistance, they may not exhibit useful antisense activities because they do not support an RNase H mechanism. A modification that supports an RNase H mode of action and provides high Tm and nuclease resistance t1/2 values has not been reported. Thus, an ideal oligonucleotide modification would provide an oligomer that hybridizes to target RNA with high binding affinity and specificity, would be stable to nucleolytic degradation, and would allow RNase H cleavage of the RNA target. This has led to the theory that to optimize the antisense activity of an oligomer, a combination of oligonucleotide modifications will be required (Cook, 1991, 1993). As noted above, after high-binding, nuclease-resistant 2′-O-modified oligonucleotides were developed, it was rather disappointing that oligomers uniformly modified were inactive or less active than their first-generation parent phosphorothioates. It is now well known that uniformly 2′-O-modified oligonucleotides do
4.1.10 Current Protocols in Nucleic Acid Chemistry
not support RNase H cleavage: the 2′-O-modified oligonucleotide-RNA heteroduplex presents a structural conformation that is recognized by the enzyme but is not cleaved (Crooke et al., 1995; Lima and Crooke, 1997). This lack of activity has led to the development of a chimeric strategy (gapmer technology; Cook, 1993; Monia et al., 1993; Yu et al., 1996). This approach focuses on the design of highbinding, nuclease-resistant antisense oligonucleotides that are “gapped” with a contiguous sequence of 2′-deoxyribonucleoside phosphorothioates (2′-deoxy/PS)(Fig. 4.1.5). On hybridization to target RNA, a heteroduplex is presented that supports RNase H cleavage of the RNA strand. The stretch of the modified oligonucleotide-RNA heteroduplex that is recognized by RNase H may be placed anywhere within the modified oligonucleotide. The modifications in the flanking regions of the gap should not only provide nuclease resistance to exo- and endonucleases, but should also not compromise binding affinity and base-pair specificity (Hoke et al., 1991). Modifications of the phosphorus atom of the natural phosphodiester linkage (producing methylphosphonates, phosphorothioates, and phosphoramidates) destabilize heteroduplexes −0.7° to −1.5°C per modification (Fig. 4.1.4B; Agrawal et al., 1990; Dagle et al., 1991; Guinosso et al., 1991). The decreased binding affinity of these modified oligonucleotides could be expected to reduce antisense effectiveness. In the case of chimeric 2′-O-methyl- or 2′fluoro-modified oligonucleotides, an enhancement in the binding affinity of ∼2.0° to 2.3°C (compared to P=S oligonucleotides) for each modification is obtained (Sproat et al., 1989; Guinosso et al., 1991; Miller et al., 1991; Kawasaki et al., 1993). However, it is now clear that 2′-O-methyl- and 2′-F-modified DNA are not sufficiently nuclease resistant to have antisense value as P=O backbones (Sproat et al., 1989; Morvan et al., 1993; Sproat and Lamond, 1993; Sands et al., 1995; Prasmickaite et al., 1998). The potential problem in this area can be circumvented by the use of 2′-O-methyl- or 2′-F-modified phosphorothioates in the flanking regions (doubly modified; Miller et al., 1991; Kawasaki et al., 1993). Flank
More recent research has focused on 2′-O modifications such as methoxyethyl (Altmann et al., 1996a,b,c) and aminopropyl (Griffey et al., 1996), which not only provide relatively high binding affinities but also a level of nuclease resistance that allows replacement of thiophosphates with natural phosphodiester linkages. With a favorable combination of Tm and t1/2, 2′-O modifications can be employed in the chimeric strategy (gapmer technology; Fig. 4.1.5), which allows a significant portion of P=S linkages to be replaced with P=O linkages. Just how many sulfurs can be replaced depends on the length of the oligomer and the gap size or RNase H cleavage site. Typically, a 21-mer with a 7-nucleotide gap has 65% of the P=S linkages replaced with P=O linkages. As noted in the discussion of limitations of P=S oligonucleotides, reduction of the sulfur content in a P=S oligonucleotide could have important implications in the pharmacokinetic and pharmacodynamic properties as well as the toxicity profiles of oligonucleotides (Altmann et al., 1996a). A very important aspect of gapmer technology is that the gap or RNase H cleavage site must be protected from endonucleolytic cleavage. Phosphodiester linkages and even an alternating P=S/P=O motif do not provide a useful level of nuclease resistance for biological activity (Dagle et al., 1991; Hoke et al., 1991). The recently reported lack of activity of a “gapped” 3′-amidate phosphodiester is likely due to endonuclease degradation (Heidenreich et al., 1997). Phosphorothioates are the only useful modification to allow a reasonable combination of binding affinity and nuclease resistance and also support an RNase H mechanism. Hence, as noted above, most antisense activities require an RNase H mechanism, which in turn requires sulfur in the form of thiophosphate somewhere in the chimeric molecule for nuclease resistance. An additional issue that should be kept in mind is the impact that oligonucleotide modifications may have on the cost of future antisense drugs. Again, as a standard, the cost of P=S oligonucleotides should be considered. The cost of phosphorothioates has been dramatically reduced due to improvements in the process, cost reduction of key reagents, and eco-
Gap
5'- 2'-Modifications/PS or PO
Flank 2'-Modifications/PS or PO
2'-deoxy/PS
Figure 4.1.5
Gapmer technology. PO, phosphodiester; PS, phosphorothioate.
-3'
Synthesis of Modified Oligonucleotides and Conjugates
4.1.11 Current Protocols in Nucleic Acid Chemistry
nomics of larger-scale syntheses. As of 1999, the cost of materials for a 20-mer P=S oligonucleotide was <$300/gram; it is projected to decline to <$50/gram as larger quantities are required. The 2′-O-methoxyethyl-modified oligonucleotides are derived from ribonucleosides and should eventually be substantially less expensive than modified oligonucleotides derived from deoxyribofuranosyl nucleosides. P=S oligonucleotide antisense drugs are expected to be cost competitive when considering parenteral (intravenous) treatment three times/week with a 1 mg/kg dose. Modified oligonucleotides must be cost effective and will need to be less expensive to synthesize (e.g., shorter), or provide a greater therapeutic index (increased potency) or other important advantages to offset an increase in the cost of synthesis. When considering research to modify oligonucleotides, the author believes it is important to know the extent to which proprietary protection of a modification can be obtained. Important patent positions for many types of modifications have been established during the 1990s as designing drugs from oligonucleotides has become of interest (Crooke et al, 1996b; Sheffery and Gordon, 1996; Craig et al., 1997).
GENERAL GUIDELINES FOR ENHANCING OLIGONUCLEOTIDE DRUG PROPERTIES
Modified Oligonucleotides for Chemotherapeutic Applications
The excitement roused by the prospect of using oligonucleotides as drugs stems from the fact that, unlike other drug discovery approaches, they are informational materials— i.e., chemicals having a specific set of rules (the Watson-Crick base-pairing rules) that clearly govern their binding to a specific nucleic acid receptor. In addition, the fact that DNA and RNA molecules are, compared to proteins, relatively new molecular targets is of great interest. The first test in a SAPR study to determine whether a modified oligonucleotide is worth pursuing is whether it maintains its sequence specificity according to Watson-Crick rules (Fig. 4.1.6). A newly modified oligonucleotide that does not possess an acceptable level of specificity (comparable to that of the P=S oligonucleotide) is an immediate failure. The next step is to determine how tightly the modified oligonucleotide binds to its target nucleic acid. As noted, the binding affinity of a modified oligomer is a physicochemical property, determined by measuring the oligomer’s sequence-
specific interaction with its length-matched RNA complement. The hybridization or melting process is performed under a rather standard set of conditions designed to mimic an intracellular environment (Freier et al., 1992). Because this calculation is done under artificial conditions, it may not accurately represent the binding of an oligomer to a native RNA inside a cell. The next essential property of an oligonucleotide is sufficient resistance to degradation by exo- and endonucleolytic plasma and tissue nucleases (Fig. 4.1.6). Nuclease resistance is determined in various assays, such as incubating the oligonucleotide in heat-inactivated fetal bovine serum, cellular extracts, or purified exonucleases or endonucleases (also see Standards Established by Recent SAPR Studies). These results are also likely to differ from the stability of an oligomer in vivo. However, these Tm and t1/2 assays do allow SAPR studies to proceed, and thus provide reasonable methods to compare various oligonucleotide modifications at an early developmental stage. This is quite different from traditional drug discovery approaches.
CONJUGATED OLIGONUCLEOTIDES The sugar, heterocycle, and backbone (linkage) subunit modifications as depicted in Figure 4.1.4A are core modifications that greatly enhance binding affinities and nuclease resistance of antisense oligonucleotides. To enhance other antisense drug properties of an optimized, core-modified oligonucleotide, a variety of molecules (pendants) have been attached (conjugated) in a point-modification motif (i.e., only one pendant in an antisense oligonucleotide). Pendant modifications have primarily been directed to enhancing oligonucleotide uptake. Other potential applications of pendants include increased solubility, lipophilicity, and means to attach synthetic cleaving agents, intercalators (for improvements in binding affinity), and cross-linking and alkylating groups (see UNITS 4.2 & 4.3). Several reviews have discussed oligonucleotide pendants (Cook, 1991, 1993; Manoharan, 1993; De Mesmaeker et al., 1995).
PERSPECTIVE One P=S oligonucleotide drug (Vitravene) is available as of 1999, and others will follow in the next several years. However, to continually improve this novel and exciting drug class, and to overcome certain limitations, structural changes are required. In the 1990s a diverse range of modifications, at all possible modifi-
4.1.12 Current Protocols in Nucleic Acid Chemistry
• Synthesis of novel or known nucleosides • Synthesis of novel amidites with appropriate protection • Development of oligomerization protocol process/analysis • Synthesis of modified oligonucleotide in standard sequences • Synthesis of length-matched complementry RNA sequences and single base mismatches and appropriate control sequences • Obtain binding affinities (change in Tm in degrees/modification) of matched and mismatched modified oligonucleotide
Sequence-specificity or binding affinity of modification below standards
Abandon modification
Sequence-specificity and binding affinity of modification improved compared to standards
• Prepare appropriate modified oligonucleotides for nuclease studies • Determine relative nuclease resistance
Nuclease-resistance of modified oligonucleotides less than standards
Consider additional modifications, e.g., combination of modifications, for enhancing nuclease resistance while maintaining binding affinity
Modified oligonucleotide possess greater nuclease-resistance than standards
Examine modified oligonucleotide with target sequence (tissue culture reduction of message and/or protein)
Advanced pharmacology, pharmacokinetics and toxicology studies
Figure 4.1.6
General pathway for structure-activity/property relationship studies.
cation sites of an oligonucleotide (Fig. 4.1.4A), has been reported. This application of traditional medicinal chemistry (SAPR studies) to drug discovery in antisense oligonucleotides, and in oligonucleotides in general, has answered many important questions. For example, as a result of this rather intense effort, modifications are now known that stabilize oligonucleotides towards nucleolytic degradation (e.g., 2′-O-methoxyethyl and 2′-O-aminopropyl), that greatly enhance binding affinities while maintaining base-pair specificity (e.g., 2′-O-methoxyethyl), and that support endonucleolytic cleavage by RNase H (e.g., 5propynyl pyrimidines). Although these are biochemical and biophysical properties, a large volume of cellular and animal studies support the notion that enhancing these properties correlates with enhanced antisense biological ac-
tivity in vivo. Unfortunately, a single modification that provides high binding affinity nuclease-resistance and support of an RNase H mechanism is not available. A modification of this nature is of current interest in the antisense approach. It is also known that changing the structure of phosphorothioate oligonucleotides provides an opportunity to alter their pharmacokinetic profile. Structural changes that remove sulfur (as thiophosphate) and/or change lipophilicity (e.g., by 2′-O modifications) have resulted in more favorable toxicity profiles (Altmann et al., 1996a). Although research has revealed these important antisense properties (and there may be many more to learn about), and has shown how to control them, it has not yet determined the optimum values at which these modifications should be aimed. In addition, the lack of
Synthesis of Modified Oligonucleotides and Conjugates
4.1.13 Current Protocols in Nucleic Acid Chemistry
Modified Oligonucleotides for Chemotherapeutic Applications
antisense oligonucleotides that are orally available and/or penetrate the blood-brain barrier represents the most important deficiency of antisense oligonucleotides. Recent reports of antisense P=S oligonucleotides doubly modified at the 3′ and 5′ ends with 2′-O-methyl or 2′-O-methoxyethyl—to provide a high level of nuclease resistance—have provided encouraging results suggesting that these pharmacokinetic deficiencies will soon be solved by appropriate chemical modifications (Agrawal et al., 1995). One should be aware of the level of accomplishments achieved in oligonucleotide medicinal chemistry research in the course of the 1990s. Binding affinities, nuclease resistance, support of RNase H, and cost of synthesis have been discussed in this unit, and they should be considered (as standards) before initiating or continuing oligonucleotide modification research. In addition, understanding the proprietary patent positions that have been established is an important research consideration. The author believes that, at this stage of oligonucleotide medicinal chemistry, it is highly unlikely that a single modification will be discovered that will significantly affect all of the important drug properties described above. The types of modified oligonucleotides currently being pursued (going beyond P=S oligonucleotides) possess a combination of modifications, and this trend will certainly continue as pendants will be conjugated to oligonucleotides with optimized core subunits to obtain a “completely” optimized oligonucleotide drug. The current “winners,” or the first modifications most likely to be incorporated into antisense oligonucleotides that will undergo clinical trials, are the RNA mimics 2′-Omethoxyethyl and 2′-O-aminopropyl, and the backbone modification MMI (Fig. 4.1.4B). These will likely be utilized in a gapmer strategy. However, efforts to prepare uniform modifications, such as RNA mimics (2′-O-modifications), MMI, and PNA are of considerable interest, in that reliance on RNase H for a mode of action would not be required. In addition to these modifications that act either by direct binding (RNase H independent) or via RNase H, the author believes that subunit pendant modifications (such as cholesterol conjugates and folic acid conjugates) will become increasingly important for optimizing multiply modified oligonucleotides.
LITERATURE CITED Agrawal, S., Mayrand, S.H., Zamecnik, P.C., and Pederson, T. 1990. Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 87:1401-1405. Agrawal, S., Zhang, X., Lu, Z., Zhao, H., Tamburin, J.M., Yan, J., Cai, H., Diasio, R.B., Habus, I., Jiang, Z., Iyer, R.P., Yu, D., and Zhang, R. 1995. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50:571-576. Alderfer, J.L., Loomis, R.E., Soni, S.D., Sharma, M., Bernacki, R., and Hughes, R. Jr. 1985. Halogenated nucleic acids: Biochemical and biological properties of fluorinated polynucleotides. Polymeric Mater. Med. 32:125-138. Altman, S. 1989. Ribonuclease P: An enzyme with a catalytic RNA subunit. Adv. Enzymol. 62:1-36. Altmann, K.H., Dean, N.M., Fabbro, D., Freier, S.M., Geiger, T., Häner, R., Hüsken, D., Martin, P., Monia, B.P., Müller, M., Natt, F., Nicklin, P., Phillips, J., Pieles, U., Sasmor, H., and Moser, H.E. 1996a. Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals. Chimia 50:168-176. Altmann, K.H., Kesselring, R., and Pieles, U. 1996b. 6′-Carbon-substituted carbocyclic analogs of 2′deoxyribonucleosides: Synthesis and effect on DNA/RNA du plex stability. Tetrahedron 52:12699-12722. Altmann, K.H., Fabbrot, D., Dean, N.M., Geiger, T., Monia, B.P., Muller, M., and Nicklin, P. 1996c. Second-generation antisense oligonucleotides: Structure-activity/relationships and the design of improved signal-transduction inhibitors. Biochem. Soc. Trans. 24:630-637. Altmann, K.H., Martin, P., Dean, N.M., and Monia, B.P. 1997. Second generation antisense oligonucleotides—inhibition of pkc-α and c-raf kinase expression by chimeric oligonucleotides incorporating 6′-substituted carbocyclic nucleosides and 2′-O-ethylene glycol substituted ribonucleosides. Nucleosides Nucleotides 16:917. Bacher, J.M. and Ellington, A.D. 1998. Nucleic acid selection as a tool for drug discovery. Drug Discovery Today 3:265. Bardos, T.J. and Ho, Y.K. 1978. Chemical and Enzymatic Methods in the Synthesis of Modified Polynucleotides. In Symposium on the Chemistry and Biology of Nucleosides and Nucleotides (R.E. Harmon, R.K. Robins, and L. Townsend, eds.) pp. 55-68. Academic Press, Orlando, Fla. Belikova, A.M., Zarytova, V.F., and Grivneva, N.I. 1967. Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues. Tetrahedron Lett. 7:3557-3562. Buhr, C.A., Wagner, R.W., Grant, D., and Froehler, B.C. 1996. Oligodeoxynucleotides containing C-7 propyne analogs of 7-deaza-2′-deoxyguanosine and 7-deaza-2′-deoxyadenosine. Nucl. Acids Res. 24:2974-2980.
4.1.14 Current Protocols in Nucleic Acid Chemistry
Cech, T.R. 1986. RNA as an enzyme. Sci. Am. 255:64-75. Chandra, P. and Bardos, T.J. 1972. Inhibition of DNA polymerases from RNA tumor viruses by novel template analogs. Partially thiolated polycytidylic acid. Res. Commun. Chem. Pathol. Pharmacol. 4:615-622. Cohen, J.S. 1991. Informational drugs: A new concept in pharmacology. Antisense Res. Dev. 1:191-193. Connell, C., Fung, S., Heiner, C., Bridgham, J. Chakarian, V., Heron, E., Jones, R., Menchen, S., Mordan, W., Raff, M., Recknor, M., Smith, L., Springer, J., Woo, S., and Hunkapiller, M. 1987. Automated DNA sequence analysis. BioTechniques 5:342. Cook, P.D. 1991. Medicinal chemistry of antisense oligonucleotides—future opportunities. AntiCancer Drug Design 6:585-607. Cook, P.D. 1993. Medicinal chemistry strategies for antisense research. In Antisense Research and Applications (S.T. Crooke and B. Lebleu, eds.) pp. 149-187. CRC Press, Boca Raton, Fla. Cook, P.D. 1998a. Antisense medicinal chemistry. In Handbook of Experimental Pharmacology (S.T. Crooke, ed.) pp. 51-101. Springer-Verlag, Heidelberg, Germany. Cook, P.D. 1998b. Second generation antisense oligonucleotides: 2′-Modifications. Annu. Rep. Med. Chem. 33:313. Cook, P.D. 1999. Making drugs out of oligonucleotides: A brief review and perspective. Nucleosides Nucleotides 18:1141-1162. Craig, A., Vanstone, D., and Sudhir, A. 1997. Patent strategies in the antisense oligonucleotide based therapeutic approach. Expert Opin. Ther. 7:1175. Crooke, S.T., Lemonidis, K.M., Neilson, L., Griffey, R., Lesnik, E.A., and Monia, B.P. 1995. Kinetic characteristics of Escherichia coli RNase H1: Cleavage of various antisense oligonucleotideRNA duplexes. J. Biochem. 312:599-608. Crooke, S.T., Graham, M.J., Zuckerman, J.E., Brooks, D., Conklin, B.S., Cummins, L.L., Greig, M.J., Guinosso, C.J., Kornbrust, D., Manoharan, M., Sasmor, H.M., Schleich, T., Tivel, K.L., and Griffey, R.H. 1996a. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277:923-937. Crooke, S.T., Bernstein, L.S., and Boswell, H. 1996b. Progress in the development and patenting of antisense drug discovery technology. Expert Opin. Ther. 6:855-870. Cummins, L.L., Owens, S.R., Risen, L.M., Lesnik, E.A., Freier, S.M, McGee, D., Guinosso, C.J., and Cook, P.D. 1995. Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucl. Acids Res. 23:2019-2024. Dagle, J.M., Andracki, M.E., DeVine, R.J., and Walder, J.A. 1991. Physical properties of oligonucleotides containing phosphoramidate-modified internucleoside linkages. Nucl. Acids Res. 19:1805-1810.
De Clercq, E., Eckstein, F., and Merigan, T.C. 1969. Interferon induction increased through chemical modification of a synthetic polyribonucleotide. Science 165:1137-1139. DeMesmaeker, A., Haner, R., Martin, P., and Moser, H.E. 1995. Antisense oligonucleotides. Acc. Chem. Res. 28:366-374. Ellington, A.D. and Szostak, J.W. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822. Freier, S.M. and Altmann, K.-H. 1997. The ups and downs of nucleic acid duplex stability: Structure-stability studies on chemically-modified DNA: RNA duplexes. Nucl. Acids Res. 25:4429-4443. Freier, S.M., Lima, W.F., Sanghvi, Y.S., Vickers, T., Zounes, M., Cook, P.D., and Ecker, D.J. 1992. Thermodynamics of antisense oligonucleotide hybridization. In Gene Regulation: Biology of Antisense RNA and DNA, Vol. 1 (Series: Molecular Cellular Biology) (R.P. Erickson and J.G. Izant, eds.) pp. 95-107. Raven Press, New York. Griffey, R.H., Monia, B.P., Cummins, L.L., Freier, S., Greig, M.J., Guinosso, C.J., Lesnik, E., Manalili, S.M., Mohan, V., Owens, S., Ross, B.R., Sasmor, H., Wancewicz, E., Weiler, K., Wheeler, P.D., and Cook, P.D. 1996. 2′-O-aminopropyl ribonucleotides: A zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides. J. Med. Chem. 39:5100-5109. Guinosso, C.J., Hoke, G.D., Freier, S.M., Martin, J.F., Ecker, D.J., Mirabelli, C.K., Crooke, S.T., and Cook, P.D. 1991. Synthesis and biophysical and biological evaluation of 2′-modified antisense oliogonucleotides. Nucleosides Nucleotides 10:259-262. Heidenreich, O., Gryaznov, S., and Nerenberg, M. 1997. RNase H-independent antisense activity of oligonucleotide N3′-P5′ phosphorothioates. Nucl. Acids Res. 25:776. Helene, C. 1993. Control of gene expression by triple-helix-forming oligonucleotides: The antigene strategy. In Antisense Research and Applications (S.T. Crooke and B. Lebleu, eds.) pp. 375-385. CRC Press, Boca Raton, Fla. Hoke, G.D., Draper, K., Freier, S.M., Gonzalez, C., Driver, V.B., and Zounes, M.C. 1991. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucl. Acids Res. 19:5743. Kawasaki, A.M., Casper, M.D., Freier, S.M., Lesnik, E.A., Zounes, M.C., Cummins, L.L., Gonzalez, C., and Cook P.D. 1993. Uniformly modified 2′-deoxy-2′- f l u o r o p h o sphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36:831-841.
Synthesis of Modified Oligonucleotides and Conjugates
4.1.15 Current Protocols in Nucleic Acid Chemistry
LeDoan, T., Perrouault, L., Praseuth, D., Habhoub, N., Decout, J.L., Thuong, N.T., Lhomme, J., and Helene, C. 1987. Sequence-specific recognition, photocrosslinking and cleavage of the DNA double helix by an oligo-[α]-thymidylate covalently linked to an azidoproflavine derivative. Nucl. Acids Res. 15:7749.
Prasmickaite, L., Hogset, A., Maelandsmo, G., Berg, K., Goodchild, J., Perkins, T., Fodstad, O., and Hovig, E. 1998. Intracellular metabolism of a 2′-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or as free ribozyme. A study by capillary electrophoresis. Nucl. Acids Res. 26:4241-4248.
Lesnik, EA., Guinosso, C.J., Kawasaki, A.M., Sasmor, H., Zounes, M., Cummins, L.L., Ecker, D.J., Cook, P.D., and Freier, S.M. 1993. Oligodeoxynucleotides containing 2′-O-modified adenosine: Synthesis and effects on stability of DNA:RNA duplexes. Biochemistry 32:78327838.
Rossi, J.J. 1998. Therapeutic ribozymes: Principles, applications, and problems. In Applied Antisense Oligonucleotide Technology (C.A. Stein and A.M. Krieg, eds.) pp. 511-525. Wiley-Liss, New York.
Lima, W.F. and Crooke, S.T. 1997. Binding affinity and specificity of Escherichia coli RNase H1: Impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry 36:390-398. Manoharan, M. 1993. Designer antisense oligonucleotides: Conjugation chemistry and functionality placement. In Antisense Research and Applications (S.T. Crooke and B. Lebleu, eds.) pp. 303-349. CRC Press, Boca Raton, Fla. Matteucci, M.D. and von Krosigk, U. 1996. Hybridization properties of oligonucleotides bearing a tricyclic 2′-deoxycytidine analog based on a carbazole ring system. Tetrahedron Lett. 37:5057-5060. Miller, P.S., Bhan, P., Cushman, C.D., Kean, J.M., and Levis, J.T. 1991. Antisense oligonucleotide methylphosphonates and their derivatives. Nucleosides Nucleotides 10:37-46. Monia, B.P., Lesnik, E.A., Gonzalez, C., Lima, W.F., McGee, D., Guinosso, C.J., Kawasaki, A.M., Cook, P.D., and Freier, S.M. 1993. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:14514-14522. Monia, B.P., Johnston, J.F., Sasmor, H., and Cummins, L.L. 1996. Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J. Biol. Chem. 271:1453314540. Morishita, R., Givvons, G.H., Kaneda, Y., and Dzau, V.J. 1995. Pharmacokinetics of antisense oligodeoxynucleotides (cyclin B1 and cdc2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 149:13-19. Morvan, F., Porumb, H., Degols, G., Lefebvre, I., Pompon, A., Sproat, S., Rayner, B., Malvy, C., Lebleu, B., and Imbach, J.-L. 1993. Comparative evaluation of seven oligonucleotide analogues as potential antisense agents. J. Med. Chem. 36:280-287. Moser, H.E. and Dervan, P.B. 1987. Sequence-specific cleavage of double helical DNA by triple helix formation. Science 238:645-650. Modified Oligonucleotides for Chemotherapeutic Applications
Nicklin, P. 1998. Pharmacokinetics properties of phosphorothioates in animals. In Handbook of Experimental Pharmacology (S.T. Crooke, ed.) pp. 141-168. Springer-Verlag, Heidelberg, Germany.
Sands, H., Gorey-Feret, L.J., Ho, S.P., Bao, Y., Cocuzza, A.J., Chidester, D., and Hobbs, F.W. 1995. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3′,5′Blocked oligonucleotides. Therapeutics 47:636646. Sheffery, M. and Gordon, C.L. 1996. Leadership positions in antisense patents (company report). Mehta and Isaly Equity Research, New York. Sproat, B.S. and Lamond, A.I. 1993. 2′-O-Alkyloligoribonucleotides. In Antisense Research and Applications (S.T. Crooke and B. Lebleu, eds.) pp. 351-362. CRC Press, Boca Raton, Fla. Sproat, B.S., Lamond, A.I., Beijer, B., and Neuner, U. 1989. Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucl. Acids Res. 17:3373-3386. Stephenson, M.L. and Zamecnik, P.C. 1978. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U.S.A. 75:285-288. Summerton, J. 1979. Intracellular inactivation of specific nucleotide sequences: A general approach to the treatment of viral diseases and virally-mediated cancers. J. Ther. Biol. 78:77-99. Torrence, P.F., Xiao, W., Li, G., Lesnik, K., Khamnei, S., Maran, A., Maitra, R., Dong, B., and Silverman, R.H. 1994. 2′,5′-Oligoadenylate antisense chimeras for targeted ablation of RNA in carbohydrate modifications. In Antisense Research (Y.S. Sanghvi and P.D. Cook, eds.) pp. 118-132. American Chemical Society, Washington, D.C. Ts’o, P.O., Miller, P.S., Aurelian, L., Murakami, A., Agris, C., Blake, K.R., Lin, S.B., Lee, B.L., and Smith, C.C. 1987. An approach to chemotherapy based on base sequence information and nucleic acid chemistry. Matagen (masking tape for gene expression). Ann. N.Y. Acad. Sci. 507:220-241. Tuerk, C. and Gold, L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510. Wagner, R.W., Matteucci, M.D., Grant, D., Huang, T., and Froehler, B.C. 1996. Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nat. Biotechnol. 14:840-844.
4.1.16 Current Protocols in Nucleic Acid Chemistry
Yu, D., Iyer, R.P., Shaw, D.R., Lisziewicz, J., Li, Y., Jiang, Z., Roskey, A., and Agrawal, S. 1996. Hybrid oligonucleotides: Synthesis, biophysical properties, stability studies, and biological activity. Bioorg. Med. Chem. Lett. 4:1685-1692. Zamecnik, P.C. and Stephenson, M.L. 1978. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 75:280284.
Zhang, R., Iyer, R.P., Yu, D., Tan, W., Zhang, X., Lu, Z., Zhao, H., and Agrawal, S. 1996. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J. Pharmacol. Exper. Ther. 278:971-979. Zon, G. 1993. History of antisense drug discovery. In Antisense Research and Applications (S.T. Crooke and B. Lebleu, eds.) pp. 1-5. CRC Press, Boca Raton, Fla.
Contributed by P. Dan Cook Isis Pharmaceuticals Carlsbad, California
Synthesis of Modified Oligonucleotides and Conjugates
4.1.17 Current Protocols in Nucleic Acid Chemistry
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups Because of the base-pairing properties of oligomeric strands of DNA, which allow specific recognition of a particular base sequence by a complementary one in a single-stranded DNA or RNA target, such strands are used as nucleic acid probes for molecular biology, diagnostics in medicine, and as artificial regulators of gene expression according to the “antisense” strategy (Cohen, 1989; Hélène and Saison-Behmoaras, 1994). Recently, synthetic oligonucleotides have been used to regulate gene expression via the “antigene” approach upon hybridization with double-stranded DNA through Hoogsteen hydrogen-bonding interactions of an oligonucleotide third strand with the purine bases of the double helix (Thuong and Hélène, 1993; Soyfer and Potoman, 1996). To improve the performance of oligonucleotides, various molecules have been attached to them to provide the following properties: 1. Easy detection with high sensitivity; 2. Increased affinity to complementary nucleic acids sequences; 3. Ability to induce irreversible modifications of the target sequences; 4. Capacity to recognize and permeate target cell membranes. The structural, chemical, and physicochemical properties of the ligands used in these applications vary widely, and may range from very simple to very complex when a low-stability molecule, such as a protein, is involved. These different parameters must be taken into account when choosing the positions within each molecule that will be involved in the chemical reactions needed for their covalent linking. Care is essential when determining the best conjugation method for a chosen ligand, in order to preserve its chemical, physicochemical, and biochemical properties, without impairing the oligonucleotide’s ability to bind specifically with the nucleic acid target. As a general rule, it is necessary to insert a linker (L) between the ligand and the oligonucleotide to provide enough conformational freedom for the desired complex to form between the oligonucleotide-ligand conjugate
UNIT 4.2
and the nucleic acid or molecular target. The performance of the oligonucleotide-ligand conjugate depends on the attachment sites of the two entities as well as on the linker’s nature and size. A ligand can be covalently attached to the oligonucleotide chain through the 5′ or 3′ end, the nucleobases, the sugars, or the internucleotide bridges. Using too short a linker may induce steric hindrance or prevent the ligand from adopting the most favorable functional conformation (Asseline et al., 1996); using too large a linker may impair cooperative binding between the oligonucleotide-ligand conjugate and the nucleic acid target. However, the nature and size of the linker are less important to small ligands and, in particular, to reporter groups. This unit reviews the covalent attachment of various ligands to the 5′ end of oligonucleotides and the properties of these molecules. The synthesis of oligonucleotide-ligand conjugates involving the coupling of ligands to other oligonucleotidic sites will be presented elsewhere.
SYNTHESIS The two major techniques used for the synthesis of oligodeoxynucleotides are the “phosphotriester” (Michelson and Todd, 1955; Reese and Shaffhill, 1968; Itakura et al., 1975) and “phosphite” (Letsinger and Lunsford, 1976; Beaucage and Caruthers, 1981; UNIT 3.3) methods. Although the first is more convenient for syntheses in solution, the second, using phosphoramidite intermediates, is the best one for solid-phase synthesis. Both methods involve very reactive intermediates requiring appropriate protection for the functional groups not engaged in the coupling reaction, and deprotection conditions that do not affect the integrity of the oligonucleotide chain. Because of these constraints, the phosphotriester and phosphite methods are essentially used to introduce simple and chemically stable functional groups or ligands to the 5′ end of oligonucleotides. In the case of ligands with poor chemical stability or complex structures, the best conjugation method involves coupling to unblocked oligomers that have 5′ ends functionalized with potent electrophilic or nucleophilic groups.
Contributed by Nguyen T. Thuong and Ulysse Asseline Current Protocols in Nucleic Acid Chemistry (2000) 4.2.1-4.2.33 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.2.1
B'
HO
O
CN
O
H Z'LO P O O
Z'LO P R'O
N(i-Pr)2
1
2
3
O
O ZLO P O O
Z'LOH
B
N
O
4
6
5 O ZLNH2
N H
NC B'
O
7
DMTrO 9
ZL O O
B
n
O
CN
O H P O O
B'
DMTrO
HN O P O O
B' O
(i-Pr)2N
R'O
O
O P O
O
8
O P O O
O R'O
RO
ZL
B'
O
N
B' O
H2N
R'O
11
12
B
H2N 10
NC
O P O (i-Pr)2N
B' O N Tr H
13
Figure 4.2.1 Functionalization of oligodeoxynucleotides via phosphite and phosphotriester derivatives. Abbreviations used in figures: B, nucleic base; B′, protected base; DMF, dimethylformamide; DMSO, dimethyl sulfoxide; DMTr, 4,4′-dimethoxytrityl; Fmoc, 9-fluorenylmethyl; L, linker; MMTr, monomethoxytrityl; Px,9-phenylxanthen-9-yl(pixyl); R, oligodeoxynucleotide; R′, protected oligonucleotide; TCEP, tris-(2-carboxyethyl)phosphine; Tr, trityl; Z, functional group or ligand; Z′, protected functional group or ligand.
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
A protected oligonucleotide with a free hydroxyl group at the 5′ end immobilized on the support (S.1; Fig. 4.2.1) may easily be obtained by solid-phase synthesis using either nucleoside-3′-phosphoramidites or nucleoside-3′-Hphosphonates. The 5′-terminal hydroxyl can then be reacted with phosphoramidites (S.2), H-phosphonates (S.3), and 1,1′-carbonyldiimidazole.
Phosphoramidites and H-phosphonates often obtained from a molecule having a hydroxyl functionality (S.4), allow the direct introduction of a functional group or ligand (Z-L) via a phosphodiester bond (S.5) after oxidation and oligonucleotide deprotection. This synthetic route implies the preparation of “phophitylation reagents” and, if necessary, protection of the functional groups of the ligands not involved in the
4.2.2 Current Protocols in Nucleic Acid Chemistry
coupling reaction. When using 1,1′-carbonyldiimidazole, it is possible to introduce functional groups or ligands bearing a primary amino functionality to the 5′-terminus of oligonucleotides, without the need to prepare intermediate reagents or protecting the functional groups of the ligands not involved in the formation of the oligonucleotide-ligand conjugates, provided these are less reactive than the ligands’ primary amino group. The first step of this method is the formation of the carbonylimidazolide derivative (S.6) which then reacts with the primary amino functionality of ligand (S.7) to form the conjugate with a carbamate linkage (S.8) stable to the basic conditions used for oligonuleotide deprotection. An alternative to this conjugation method is to use modified supports derivatized with the ligand to assemble the oligonucleotide chain in the (5′→3′)-orientation via 5′-phosphoramidites (S.9; Horne and Dervan, 1990). This strategy is particularly well adapted for the modification of the 5′ end of oligodeoxyribonucleotide (N3′→P5′)-phosphoramidates (S.10), whose synthesis is achieved in the (5′→3′)-orientation by coupling the 3′-aminonucleoside (S.11) with 5′-H-phosphonate (S.12; Chen et al., 1995) or with the 5′-phosphoramidites (S.13; McCurdy et al., 1997).
Addition of Functional Groups to the 5′ End of Oligonucleotides Owing to the low reactivity of the 5′-hydroxyl functionality of oligonucleotides, its condensation with the functional group of ligands is not easily achieved without side reactions at the nucleic base level. Thus, the preparation of oligonucleotide-ligand conjugates from unblocked oligomers requires a reactive electrophilic or nucleophilic group at their 5′ end to react specifically, either directly or following activation, with a ligand bearing the appropriate functional group. Among the functional groups able to meet these requirements are the phosphoryl, thiophosphoryl, sufhydryl, amino, carboxylic, and cis-dihydroxyl groups. 5′-Terminal phosphate and phosphorothioate groups 5′-Phosphate (S.14; Fig. 4.2.2) or phosphorothioate (S.15) can be introduced either chemically during the oligonucleotide synthesis, or enzymatically on the 5′-hydroxyl group of an oligonucleotide chain through the use of T4 polynucleotide kinase, which transfers the γ-phosphoryl or thiophosphoryl of ATP (Eckstein, 1983) to the 5′-terminal hydroxy function
of oligodeoxyribonucleotides or oligoribonucleotides. The first chemical synthesis of dinucleotide 5′-phosphate (S.16) was achieved using the phosphotriester method in solution, by condensation of thymidine-5′-O-dibenzylphosphate (S.17) with 3′-acetyldeoxynucleotide (S.18) in the presence of dicyclohexylcarbodiimide followed by deblocking of the 3′-hydroxyl and the phosphate groups by alkaline hydrolysis and hydrogenolysis, respectively (Michelson and Todd, 1955). The 5′-phosphate-containing oligonucleotides are easily prepared on solid phase by condensation of the phosphoramidite S.19 (Uhlmann and Engels, 1986; Thuong and Chassignol, 1987), S.20 (Uhlmann and Engels, 1986; Schwarz and Pfleiderer, 1987), S.21 (Horn and Urdea, 1986), or S.22 (Guzaev et al., 1985) with the 5′-terminal hydroxyl of the oligonucleotide bound to the support, followed by oxidation and deprotection steps. The removal of the first ester group [2-cyanoethyl or 2-(4-nitrophenyl)ethyl] from the terminal phosphate triesters via β-elimination is achieved by treatment with concentrated aqueous ammonia, an approach similar to that used to deblock internucleotidic 2-cyanoethyl phosphate triesters. Deprotection of the second ester function of the terminal phosphate diesters, however, requires more drastic conditions, because of the increased electron density on the phosphodiester function making it a poorer leaving group. Although these phosphorylating methods are well adapted to oligodeoxyribonucleotides, they are difficult to use with oligoribonucleotides without inducing chain cleavage. Because of the inherent hydrophobicity of reagent S.22, it facilitated purification of the appended oligomers by reversed-phase chromatography. This protective group can be removed by detritylation followed by ammonium hydroxide treatment. It is worth noting that among these four phosphorylating reagents only S.19, which can be purified by “molecular distillation,” can be stored at −20°C for several months without decomposition (Thuong and Chassignol, 1987). The preparation of oligonucleotides containing a phosphorothioate group at the 5′ end is similarly achieved, by replacing the iodine oxidation step with a sulfurization one using a solution of elemental sulfur solution in CS2/pyridine (Horn and Urdea, 1986; Schwarz and Pfleiderer, 1987; Thuong and Chassignol, 1987). Since the original pioneering work, the sulfuriza-
Synthesis of Modified Oligonucleotides and Conjugates
4.2.3 Current Protocols in Nucleic Acid Chemistry
OH O P O O
OH S P O O
B O
OH O P O O
B O
RO
RO
14
15
Thy
O
O O P O O
O
B
HO OCH2Ph O P OCH2Ph Thy O O
16
OH O P O O
B O O
HO 17
O 18
O
NO2
CN
O (i-Pr)2N P
(i-Pr)2N P O
O
CN
NO2
19 20
DMTrO
O S O
O
CN
O P N(i-Pr)2 21
EtO2C CO2Et O DMTrO O P N(i-Pr)2
CN
22
Figure 4.2.2 Incorporation of 5′-phosphate and 5′-phosphorothioate groups into oligodeoxynucleotides. Abbreviations: Thy, thymin-l-yl. See Figure 4.2.1 for additional definitions of functional group abbreviations.
tion step has been carried out using easy-tohandle and more reactive reagents such as 3H1,2-benzodithiol-3-one 1,1-dioxide (Iyer et al., 1990), tetraethylthiuram disulfide (Vu and Hirschbein, 1991), or bis(O,O-diisopropoxyphosphinothioyl) disulfide (Stec et al., 1993).
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
5′-Thiol-containing oligonucleotides The introduction of a sulfhydryl group to the 5′ termini of oligonucleotides has been achieved using modified nucleoside derivatives S.23 (Fig. 4.2.3; Sproat et al., 1987a) or by using the nonnucleosidic derivatives S.24 (Connolly, 1985), S.25 (Kuijpers and van Boeckel, 1993), or S.26 (Gao et al., 1995).
The S-trityl protecting group can ultimately be removed by treatment with excess AgNO3, which must then be removed by precipitation with dithiothreitol (DTT). A simpler deblocking step can be accomplished by the use of the thioester derivative S.25 and the disulfide-containing compound S.26 upon incubation with aqueous ammonia and DTT, respectively. It is worth noting that the sulfhydryl group is easily oxidized by air at neutral or alkaline pH, so that oligomers obtained after purification are usually in the dimeric disulfide form. The free sulfhydryl must be liberated by reduction of the disulfide bridge just before conjugation. This reaction can be accomplished by treatment with DTT (Cleland, 1964) or tris-(2-carboxyethyl)phosphine (TCEP; Burns et al., 1991).
4.2.4 Current Protocols in Nucleic Acid Chemistry
B'
TrS
O
OMe O P N
TrS
(i-Pr)2N
O P
CN
O
O 24
23
S
O
O
O
S S
CN
O P N(i-Pr)2
O
CN
O
DMTrO
O P N(i-Pr)2
25 26 O S S N
N
N
B
S S L O P O O
27
O RO
28
Figure 4.2.3 Incorporation of 5′-thiol groups into oligodeoxynucleotides. See Figure 4.2.1 for definitions of functional group abbreviations.
An interesting approach is to deblock the protected sulfhydryl group in the presence of 2,2′-dithiodipyridine (S.27; Py-SS-Py), which reacts with a free sulfhydryl to form the pyridinyldisulfide derivative S.28 (Kuijpers and van Boeckel, 1993). This compound is air-stable and possesses an activated disulfide function that can either be used directly to achieve conjugation with thiol-containing compounds or easily reduced to the thiol form. During deprotection of oligonucleotides synthesized f r o m β-cyanoethylphosphoramidites, acrylonitrile released by β-elimination of cyanoethyl phosphotriesters reacts easily with a free sulfhydryl group to give the β-cyanoethylthioether derivative, greatly decreasing the synthesis yield of the 5′-thiol-containing oligonucleotides. This drawback can be circumvented by deblocking the oligonucleotide using a mixture of concentrated aqueous ammonia, 2,2′-dithiopyridine, and phenol (Asseline and colleagues, unpub. observ.). Using this method large amounts of the 5′-pyridinyldisulfide-containing oligonucleotides S.28 have been obtained both as phosphodiesters and phosphorothioates. 5′-Amino-containing oligonucleotides Addition of a primary amino group to the 5′ end of oligonucleotides has been performed via
5′-azido-2′,5′-dideoxyribonucleoside phosphorochloridites such as S.29 (Fig. 4.2.4; Mungall et al., 1975), 5′-masked amino-2′,5′-dideoxyribonucleoside phosphoramidites S.30 (Smith et al., 1985) and S.31 (Sproat et al., 1987b), or the non-nucleosidic phosphoramidite derivatives S.32 (Coull et al., 1986), S.33 (Connolly, 1987), and S.34 (Connel et al., 1987). The chlorophosphite S.29 was used for the synthesis of 5′-amino-oligothymidylate (P3′→N5′)-phosphoramidate (S.35) in solution. At the end of the oligonucleotide-chain assembly, the azido group is easily reduced to an amino function by triphenylphosphine in the presence of ammonium hydroxide. Alternatively, the phosphoramidites S.30, S.31, S.32, S.33, and S.34 are condensed with the 5′-terminal hydroxyl of oligonucleotides bound to the support using standard conditions. In the case of the N-trifluoroacetyl-containing compounds S.31, S.32, S.34, and the N-9-fluorenylmethoxycarbonyl (Fmoc)-containing compound S.30, release of the amino group is achieved during the deprotection of the oligonucleotide chain by concentrated aqueous ammonia treatment. Deprotection of the tritylated derivative S.33 requires acid treatment, which can be performed either while the oligonucleotide is still bound to the support or
Synthesis of Modified Oligonucleotides and Conjugates
4.2.5 Current Protocols in Nucleic Acid Chemistry
O
H Thy
N3
Cl
Thy
Fmoc N
O O
O
P
P
(i-Pr)2N
OPh
F3C
O
Thy
N H
O O
CN
O
P
(i-Pr)2N
30
29
H N
F3C
31
CN
O
MMtr
O P N(i-Pr)2
O
CN
O
32
OMe N H
O P N(i-Pr)2 33
H H N
O
O MeO P N O CF3 34
O
Thy H2N
O O P O H
H
n
N O
Thy
B'
O
nN
O R'O
36
HO 35
Figure 4.2.4 Incorporation of 5′-amino groups into oligodeoxynucleotides. See Figure 4.2.1 for definitions of functional group abbreviations.
after deblocking and purification of the tritylated oligonucleotide by reversed-phase chromatography. Another method consists of condensing the 5′-hydroxyl group of protected oligomers bound to the support with 1,1′-carbonyldiimidazole (similar to S.6) and then reacting the resulting imidazolide derivative with an alkylenediamine to afford the corresponding aminoalkylated oligonucleotides S.36 (Wachter et al., 1986).
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
5′-Carboxyl-containing oligonucleotides 5′-Carboxyl-containing oligonucleotides S.37 (Fig. 4.2.5) or S.38 were prepared, respectively, by condensation of the 5′-hydroxyl group of protected oligomers bound to a solid support with phosphoramidite (S.39; Kremsky et al., 1987), or by treatment with 1,1′-carbonyldiimidazole followed by reaction with an amino acid (Gotthikh et al., 1990). 5′-Diol-containing oligonucleotides By analogy with the specific activation of the 3′-terminal cis diol of RNA by periodate
oxidation, uridine was introduced at the 5′ end of oligonucleotides via a (5′-5′)-linkage (S.40; Fig. 4.2.6) generated from either the phosphodiester S.41 (Agrawal et al., 1986) or the phosphoramidites S.42 (Agrawal et al., 1986) and S.43 (Kuijpers et al., 1993). Conversion of one functional group to another Numerous processes allowing the conversion of one functional group to another are available. The 5′-phosphate linkers can be coupled with diamines and with aminothiols in the presence of condensing agents to give the 5′amino linker (Chu et al., 1983) and the 5′-sulfhydryl linkers (Chu and Orgel, 1988), respectively. The 5′-amino group reacts directly with iminothiolane (S.44; Fig. 4.2.7) to generate a sulfhydryl group via amidine bond formation (Jue et al., 1978). Heterobifunctional reagents such as succinimidyl 3-(2-pyridyldithio)propionate (SPDP; S.45; Cumber et al., 1985), succinimidyl trans-4-(N-maleimidylmethyl)cyclohexane-1-carboxylate (SMCC; S.46; Ghetie et al., 1990), succinimidyl (acetylthio)acetate (SATA; S.47; Julian et al., 1983;
4.2.6 Current Protocols in Nucleic Acid Chemistry
O
CO2H O O P O
B
HO2C
O
O
nN
B
O
H
RO
O RO
38
37
O
OMe O P
O
N(i-Pr)2 39
Figure 4.2.5 Incorporation of 5′-carboxyl groups into oligodeoxynucleotides. See Figure 4.2.1 for definitions of functional group abbreviations.
Ghetie et al., 1990), 4-[(succinimidyloxy)carboxyl]-α-methyl-α-(2-pyridyldithio)toluene (SMPT; S.48; Thorpe et al., 1987; Ghetie et al., 1990), succinimidyl 3-maleimidopropionate (S.49) succinimidyl 4-{[(iodoacetyl)amino]methyl}-cyclohexane-1-carboxylate (SIAC; S.50; Haugland, 1989), succinimidyl iodoacetate (S.51), and 4-nitrophenyl iodoacetate (S.52) can be used to introduce various activated functional groups. Activated esters S.45-S.52 react with primary amino groups to afford amide bonds. Alternatively, the pyridine disulfide derivatives S.45 and S.48 and the maleimido derivatives S.46 and S.49 react with the sulfhydryl groups to give disulfide and thioether derivatives, respectively. One of the two functional groups of these heterobifunctional reagents is used to couple the reagent to the oligonucleotide without affecting the other. The intact functional group is then reacted with selected ligands.
Phosphorothioate, amino, thiol, phosphate, carboxylic, and cis-diol groups possess very different reactivities. The first three are nucleophiles that can be used directly for the conjugation reaction. Conversely, the last three groups, being weakly nucleophilic, must be activated to enable their reaction with, for example, amino functions. In a general way, conjugation reactions are often performed in aqueous medium or in a mixture of water and organic solvents in which oligonucleotides are soluble. However, strong solvation of nucleophilic groups such as oxygenated anions and amines by water often led to slow and poor yield conjugation reactions; in such solvents. Generally, sulfhydryl and thiophosphoryl groups are only slightly deactivated in water, but the formation of amide and phosphoramidate is more strongly disfavored.
O
Ura
O B
O P O
Ura
O P O
O
O
O HO
Covalent Attachment of Ligands to Oligonucleotides Functionalized at the 5′ End
O
O Cl
OH
RO
PxO
40
41
H3CO
Ura
P O
NC
O
O
(i-Pr)2N
OPx
Ura
P O
O
(i-Pr)2N PxO
OPx AcO
42
OAc
43
Figure 4.2.6 Some structures involved in the incorporation of 5′-diol groups into oligodeoxynucleotides. See Figure 4.2.1 for definitions of functional group abbreviations.
Synthesis of Modified Oligonucleotides and Conjugates
4.2.7 Current Protocols in Nucleic Acid Chemistry
O NH2Cl
N
S S
O N
S O
44
O
SPDP 45
O
O
O
O
O
N O
O N
S
N O
O
O SMCC
SATA
46
47
O
O
O
O N O N S S
O O
O N
N O
O
SMPT
49
48
I
O
O NH
O
O
O
O
N O
O N I O
O
SIAC 50
51
O I
O
NO2 52
Figure 4.2.7 Heterobifunctional reagents for the conversion of one oligodeoxynucleotide 5′-functional group to another.
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
These drawbacks may be avoided by performing the coupling reactions in an organic medium. Solubilization of oligonucleotides in organic solvents can be achieved by exchange of phosphate counterions (NH4+, Et3NH+, Na+, K+) with lipophilic ammonium cations such as cetyltrimethylammonium (Zarytova et al., 1987), or by complexing the counterions (NH4+, Na+, or K+) with crown ethers (Odell, 1985; Thuong and Asseline, 1991) or Kryptofix (Dietrich et al., 1969). The latter method, easy to develop, generally gives good results. Possi-
ble organic solvents are methanol and dipolar aprotic solvents such as N,N-dimethylformamide (DMF) or dimethylsulfoxide (DMSO). It is worth noting that DMSO can oxidize thiols into disulfides (Tam et al., 1991) and hence is unsuitable for coupling reactions involving this functional group. Via a 5′-terminal phosphate Modification via the 5′-terminal phosphate is based on the specific activation of the phosphomonoester (which is much more nucleo-
4.2.8 Current Protocols in Nucleic Acid Chemistry
philic than internucleotidic phosphodiesters) to give an electrophilic intermediate that can then react with nucleophilic derivatives such as alcohols or amines to give esters and phosphoramidates, respectively. This method, initially described by Gilham and Khorana in 1958, consisted of the condensation of 5′-Otritylthymidine S.53 (Fig. 4.2.8) with 3′-Oacetylthymidine-5′-phosphate S.54 in the presence of dicyclohexylcarbodiimide (CDI) S.55a to give the dinucleoside monophosphate S.56. This method was then used to immobilize oligonucleotides on paper (Gilham, 1962). Due to the poor nucleophilicity of alcohols, this esterification reaction is not selective and leads to side reactions at the nucleic base level. Primary and secondary amines, which are much more nucleophilic than alcohols, selectively give phosphoramidate derivatives. More recently this method has been optimized by the use of a water-soluble carbodiimide S.55b in the presence of a catalyst such as imidazole, N-methylimidazole, or 4-dimethylaminopyridine. The use of these particular amines leads to the reactive intermediates S.57, S.58, and S.59, which will react in situ with primary and secondary aliphatic amines. (In these intermediates the corresponding phos-
OH O P O O
Thy
TrO
O HO
phate anion is not nucleophilic because one of its substituent group is electron withdrawing.) These two strategies can be used to couple ligands that are not sensitive to condensing agents to short nucleic acid segments. The conversion of the decanucleotide-5′-phosphate group S.60 (Fig. 4.2.9) to the aminated 5′-phosphoramidate S.61 was performed by direct coupling of ethylenediamine and S.60 in the presence of CDI, S.55b, and N-methylimidazole, or by reacting the phosphoimidazolide S.57 with the diamine (Chu et al., 1983) in aqueous medium. Using this method, cystamine S.62 (Chu and Orgel, 1988) and the orthophenanthroline (OP) derivative S.63 (Fig. 4.2.9; Chen and Sigman, 1986) have been linked to oligodeoxyribonucleotides via a phosphoramidate linkage. The same method was also applied to the conjugation of psoralen (Pso) to oligodeoxyribonucleotides S.64 and to oligodeoxyribonucleotide methylphosphonates S.65 (Lee et al., 1988; Bhan and Miller, 1990). In the case of longer nucleic acid chains or ligands involving functional groups able to react with CDI, such as proteins, it is necessary to prepare and isolate the phosphoimidazolide derivative S.57 prior to performing the coupling step (Chu et al., 1983; Chu and Orgel, 1988).
Thy O
55a, R1 = R2 =
AcO
55b, R1 = Et
54
53
R1 N C N R2
R2 =
TrO
O
O O P O O
HCl Me2N
Thy
O
N
Thy
O N P OR O
H3C
N
O N P OR O 58
57 AcO 56 O N P OR O
(Me)2N
59
Figure 4.2.8 Modification of oligonucleotides via 5′-terminal phosphate groups. See Figure 4.2.1 for definitions of functional group abbreviations.
Synthesis of Modified Oligonucleotides and Conjugates
4.2.9 Current Protocols in Nucleic Acid Chemistry
H2 N
OH O
S
O P O
O P O Thy
O
NH2
S
NH O
O
NH
Thy
O P O O
O
B
O
O
10
H
10
H
RO 62
61
60
N
O N H
N
H N
O NH H3 C
O P O O
B
O
O
B
CH3 RO
O 64
H N
O O H3 C
NH H3C P O O
O
NH O P O O
O
RO
63
O
O
B
CH3 O
O
H
n
65
Figure 4.2.9 Conjugation of ligands to oligonucleotides via 5′-terminal phosphate groups. See Figure 4.2.1 for definitions of functional group abbreviations.
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
Carbodiimide, which has a tendency to react with the nucleic bases and particularly with thymine (Chu et al., 1983), can advantageously be replaced by the triphenylphosphine/2,2′dipyridyldisulfide couple (Zarytova et al., 1987). Thus, when the cetyltrimethylammonium salt of oligonucleotides, N-methylimidazole or 4-dimethylaminopyridine (Zarytova et al., 1987) and the latter condensing reagent are mixed in DMF or DMSO, the zwitterionic derivatives S.58 and S.59, respectively, are easily generated. These react with amino-containing compounds to form phosphoramidates. This method has been used to conjugate the sulfhydryl group S.66 (Fig. 4.2.10; Boutorin et al., 1994), the coproporphyrin I chelate S.67 (Fedorova et al., 1990), the bleomycin A5 S.68 (Zarytova et al., 1993), and intercalating agents such as the phenazinium S.69 (Lokhov et al., 1992), 2methoxy-6-chloro-9-aminoacridine S.70 (Balbi et al., 1994), the ethidium S.71, the azidoethidium S.72 (Koshkin et al., 1994), the daunomycin S.73 (Dikalov et al., 1991), and the benzopyridoin-
dolium salt S.74 (Silver et al., 1997) to the 5′-terminus of oligonucleotides. Finally, it must be noted that ester bonds between 5′-phosphate-containing oligonucleotides and the free 3′-hydroxyl group of another oligonucleotide can easily be formed when using ligase and template oligonucleotide sequences.
Via a 5′-terminal phosphorothioate The nucleophilicity of the phosphorothioate group allows easy coupling with electrophilic reagents. Oligonucleotides bearing thiophosphate groups at the 5′ ends (S.15) react specifically with halogenoalkyl derivatives to afford the corresponding 5′-phosphothioloester. For example, various intercalating agents such as acridine (S.75; Fig. 4.2.11), proflavin (S.76; Praseuth et al., 1988a), daunomycin (S.77; Garbesi et al., 1997), thiazole orange (S.78; N.N.T. and U.A., unpub. observ.), azidophenacyl (S.79; Praseuth et al., 1988b), pyrene (S.80;
4.2.10 Current Protocols in Nucleic Acid Chemistry
H N O P O O
ZL
O
B
RO 66 to 74
ZL
=
HS 66
HO2C CO2H NH ZL
=
HO2C
N
N
HN O N H
67
Figure 4.2.10 Attachment of ligands to oligonucleotides via 5′-terminal phosphate groups. See Figure 4.2.1 for definitions of functional group abbreviations.
Ebata et al., 1995), and the cyclopropapyrroloindole subunit of the antitumor antibiotic CC-1065 (S.81; Lukhtanov et al., 1997a,b) have been linked to oligonucleotides in this manner. The kinetics and yields of these reactions depend on the nature of the ligands and the halogenoalkyl groups. In general, iodoacetamido derivatives [-NH-(CO)-CH2-I] are more reactive than the corresponding iodoalkyl derivatives. The weakly reactive chloroalkyl derivatives can be easily converted to the corresponding iodoalkyl derivatives via a halogen exchange reaction with sodium iodide in acetone or acetonitrile. It is noteworthy that the coupling reaction of orthophenanthroline to oligonucleotides sometimes gives very low yields. In one such case, the formation of a 5′-monophosphate (S.14) and a dimer with a disulfide bridge (S.82; Fig. 4.2.12) was observed (Thuong and Asseline, 1991). These side reactions are probably caused by superoxide anion O2− and H2O2 generated by the presence of OP, thiophosphate, oxygen, and traces
of divalent cations contained in the conjugation buffer. This is analogous to the mechanism proposed for the nucleolytic activity of the complex OP-Cu in the presence of thiol (Kuwabara et al., 1986; Hélène and Thuong, 1988). To prevent these side reactions it is necessary to eliminate traces of divalent cations contained in buffer solutions by chelation with, for example, Chelex 100 (Thuong and Asseline, 1991). Formation of the 5′-phosphothioloester (S.83) can also be obtained by reaction of the 5′-phosphorothioate oligomer with the maleimido derivative of OP (Shimizu et al., 1994). Another coupling reaction via the phosphorothioate group concerns the formation of the disulfides S.84a and S.84b, which is accomplished with ligands bearing a pyridinyldisulfide group (S.85; Chassignol and Thuong, 1998). One particularity of these conjugates is that oligonucleotide 5′-phosphorothioates can be regenerated by reduction of the disulfide linkages and, if necessary, transformed to the corresponding 5′-phosphate by oxidation.
Synthesis of Modified Oligonucleotides and Conjugates
4.2.11 Current Protocols in Nucleic Acid Chemistry
H2N
O
O
NH2
NH H2N ZL
N
N
N
=
O OH O
O
HO
H N
N H
O
O N
O HO
NH
HO
S
N
OH O
OH
O
HN
O HO
N H
H2N
NH
NH
Cu
S
OH O
O
NH2 68
OCH3 OH ZL
H N
N
=
ZL
= N
NH
69 Cl 70
ZL
=
H2N
NH
ZL
= N3
NH
N
N
72
71
O
OH
OH ZL
= H3CO
OH H
O
H3CO
O CH3
O
O
H3C
73
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
=
N N H CH3
OH
Figure 4.2.10
HN ZL
(L) = many different linkers 74
Continued
Via 5′-thiol oligonucleotides The sulfhydryl group, which is most widely used in the modification of proteins, is also often employed for the preparation of oligonucleotide conjugates. However, the tendency to form symmetrical dimers through disulfide bridge formation requires DTT or TCEP reduc-
tion. To improve coupling efficiency the reaction should be performed in oxygen-free solution. Conjugation via thiol groups can lead to the formation of either a chemically stable thioether linkage or a disulfide bridge that can be reduced to give the starting thiols.
4.2.12 Current Protocols in Nucleic Acid Chemistry
O ZL S P O
O
O
B
RO 75 to 81 OCH3
=
ZL
(CH2)n NH
N
(CH2)n R
N
NH
Cl 75 O
76
OH
O OH
H3CO
O
(CH2)n
CH3
N
O
OH H
S
O
H3C OH
HN
H3C
N
O 78 77
O HN
O N3 79
CH3 80
H3C N
O N
O O
N H
81
Figure 4.2.11 Conjugation of functonal groups to oligonucleotides via 5′-terminal phosphorothioate groups. See Figure 4.2.1 for definitions of functional group abbreviations.
The alkylation of thiol groups by iodoacetyl derivatives has been used to prepare the fluorescent conjugates derived from fluorescein (S.86a; Fig. 4.2.13; Ansorge et al., 1987) and N-(5-sulfo-1-naphtyl)ethylenediamine (S.86b; Connolly, 1985). This method has also been used to couple fullerene to the 5′-terminus of oligonucleotides (S.87; Boutorin et al., 1994). Alternatively, the pyrenyl S.88a (Kumar et al., 1991) and antibody-oligonucleotide conjugates S.88b (Kuijpers et al., 1993), have been formed by adding oligonucleotide 5′ thiols to the corresponding maleimido-ligands.
5′-Thiol-containing oligonucleotides also react easily with tresyl-activated or epoxy-activated Sepharose to form thioether linkages (Blanks and McLaughlin, 1988). Air oxidation of two sulfhydryl-containing compounds gives a mixture of homo- and heterodimers. The synthesis of conjugates via formation of cleavable disulfide bridges implies the reaction of one of the thiol groups with 2,2′-dithiodipyridine to form the R-S-SPyr intermediate, which exchanges with the other thiol group to complete conjugation. The reaction of peptide, peroxidase, and human IgG with iminothiolane afforded with thiol deriva-
Synthesis of Modified Oligonucleotides and Conjugates
4.2.13 Current Protocols in Nucleic Acid Chemistry
O O O P S S P O O O
B O OR
O
B
RO 82
N
O
N
O
H N
N H
O S P O O
N O O
O
B
RO
83 O ZL S S P O O
O
B
RO 84
O O ZL
= O O 84a
CH3 ZL
H N
= H2N
O
O
O
O N H
84b
N
S S L Z 85
Figure 4.2.12 Incorporation of functional groups into oligonucleotides via 5′-terminal phosphorothioate groups. See Figure 4.2.1 for definitions of functional group abbreviations.
tives S.89 (Fig. 4.2.14) condensation of these derivatives with the activated oligomers S.90 gave the conjugates S.91 (Chu and Orgel, 1988). Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
Via the 5′-amino group The alkylamino groups easily react at pH ≥ 8 with electrophilic reagents to form stable linkages. Thus, fluorescein isothiocyanate (S.92a; Fig. 4.2.15) and tetramethylrhodamine isothiocy-
anate (S.92b) have been coupled to 5′-aminooligonucleotides in aqueous solution to produce the thiourea derivatives S.93a and S.93b (Smith et al., 1985). The same reaction was used to link orthophenanthroline isothiocyanate S.92c to the 5′ end of oligonucleotides with (N3′→P5′)-linkages to afford S.93c (N.T.T. and U.A., unpub. observ.). Certain acyl chlorides or anhydrides such as dansyl chloride or ethylenediaminetraacetic di-
4.2.14 Current Protocols in Nucleic Acid Chemistry
O
HO
O
O
CO2
ZL =
ZL S (CH2)n O O P O
H
O
B
O
N
86a
HN
HO3S
RO ZL =
NH
86b
H O
O O
O
S
H N O P O O
B
O
O O P O O
O
B
87 RO O
S O
O
O
ZL N O
NH
N H
ZL N
OH O O P O O
S (CH2)2
O O
ZL = pyrenyl
N
B U
O O
RO
O P O O 88a
O
B
ZL = antibody RO 88b
Figure 4.2.13 Conjugation of ligands to oligonucleotides via 5′-thiol groups. See Figure 4.2.1 for definitions of functional group abbreviations.
anhydride (EDTA), and activated esters such as biotin-4-nitrophenylester, N-hydroxysuccinimido-biotin, and the N-hydroxysuccinimide ester of bathophenanthroline have been used to prepare oligonucleotide conjugates S.94 (Fig. 4.2.16), S.95a-c, S.96, and S.97 through the formation of either sulfonamide S.94 (Connolly, 1987) or amide bonds S.95a (Boutorin et
al., 1984; Chu et al., 1985), S.95b (Agrawal et al., 1986), S.95c (Schubert et al., 1995), S.96 (Wachter et al., 1986), and S.97 (Bannwarth et al., 1988). The 5′-arylazido-containing oligonucleotide S.98 (Fig. 4.2.17) has been obtained by arylation of the 5′-terminal amino group of oligonucleotides with 2,4-dinitro-5-az-
Synthesis of Modified Oligonucleotides and Conjugates
4.2.15 Current Protocols in Nucleic Acid Chemistry
Z
H N
SH NH 89
S S
H N
Z
N NH
O O P O O
O
O
S S
O
B
O P O O
R1
B
O
n
H
R1
O
Z = peptide or peroxidase or human IgG R1 = H or OH 91
n
H 90
Figure 4.2.14 Incorporation of conjugate groups into oligonucleotides via 5′-thiol groups. See Figure 4.2.1 for definitions of functional group abbreviations.
also enzymatically coupled to a 2-methy-9-hydroxyellipticinium salt in the presence of horseradish peroxidase to give the oxazolopyridocarbazole derivative S.100 (Mouscadet et al., 1994).
idofluorobenzene (Grimautdinova et al., 1984). In the same way the phenazinium derivatives S.99 were obtained by nucleophilic attack of 5′-amino alkylated oligonucleotides of the C2halogenated heterocycle (Lokhov et al., 1992). 5′-Amino-containing oligonucleotides were
Z N C S HO
O
O
(CH3)2N
N(CH3)2
O
N Z=
Z=
Z=
CO2
CO2
N
92c
92b
92a
Z
H N
H N
R
S
O
O (CH2)nO P O O
Thy
R1 =
HN
RO 93a, 93b
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
B
O
R1 =
O P O O
O
B
HN H
n
93c
Figure 4.2.15 Attachment of reporter and conjugate groups to oligonucleotides via 5′-amino groups. See Figure 4.2.1 for definitions of functional group abbreviations.
4.2.16 Current Protocols in Nucleic Acid Chemistry
Z
n O O P O
N H
O
B
O RO
94 to 95c
HO2C (Me)2N O S
Z=
HO2C
Z=
O N
N
HO2C
O
95a
94 O HN
N
NH
Z=
Z=
N
O
S
N
S O
95c
95b
O HN
NH O S
H N
H N 8
O O
O
B
O O P O O 96
O
B
RO O NH O
Thy
O O P O N
N
O
O
B
97 RO
Figure 4.2.16 Conjugation of functional groups to oligonucleotides via 5′-amino groups. See Figure 4.2.1 for definitions of functional group abbreviations.
Via a 5′-carboxyl group Like phosphates, carboxyl groups can be selectively activated and coupled to hydrazine or amine derivatives to give, for example, the biotin conjugate S.101 (Fig. 4.2.18; Kremsky et al., 1987) and the daunomycin conjugate S.102 (Gotthikh et al., 1990).
Via a 5′-terminal cis diol The 2′- and 3′-hydroxyl functionalities of the ribose-containing oligomer S.40, upon periodate oxidation, can easily be coupled with the hydrazino or primary amino groups of the ligands to give the unstable 3,5-dihydroxymorpholine derivative S.103 (Fig. 4.2.19). Sta-
Synthesis of Modified Oligonucleotides and Conjugates
4.2.17 Current Protocols in Nucleic Acid Chemistry
NO2 NO2
OH
NH
N
NH O P O
N3
O
O
NH
NH O P O O
B
O
B
RO
RO 99
98
H N H3C
N N
O
O O P O O
O
B
RO 100
Figure 4.2.17 Introduction of functional groups to oligonucleotides via 5′-amino groups. See Figure 4.2.1 for definitions of functional group abbreviations.
ble morpholine derivatives S.104 were obtained by reduction of S.103 with NaBH4 or NaBH3CN. Using this method, biotin was coupled via its hydrazino derivative to afford
S.104a (Agrawal et al., 1986). The 125I-labeled tyramine derivative S.104b (Kuijpers and van Boeckel, 1993) was also prepared in a similar manner. Furthermore, periodate oxida-
O HN
O
NH
OH
O CH3 OH
S H3CO
O
O
HO H O
H3C
HN NH
OH
O
O O
HN
nN
O
H
O
O
B
O O P O O
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
O
O O P O O
B
O
B
RO 101
102
RO
Figure 4.2.18 Conjugation of functional groups to oligonucleotides via 5′-carboxyl groups. See Figure 4.2.1 for definitions of functional group abbreviations.
4.2.18 Current Protocols in Nucleic Acid Chemistry
Ura HO Z
Ura
O
O
N
Z
N
OH O O P O O
O O P O O
B
O RO
O
B
RO 104a-b
103a-b O HN
NH
a, Z =
H N S O
(CH2)n
HO b, Z =
125
I
O
O HO OH
HN
N H
NH O
O O P O O
S
O
H N
H N
N H
O
B
RO 105
106
O O P O O
O
B
RO
Figure 4.2.19 Attachment of functional groups to oligonucleotides via 5′-terminal cis diols. See Figure 4.2.1 for definitions of functional group abbreviations.
tion of the 5′-vicinal diol–containing oligonucleotide S.105 (Fig. 4.2.16) followed by coupling with the hydrazinobiotin produced the conjugate S.106 (Kremsky et al., 1987).
Direct Addition of Ligands to the 5′ End of Oligonucleotides The synthesis of oligonucleotide conjugates derived from acridine, psoralen, and porphyrin was first achieved by the phosphotriester method in solution. Oligonucleotide-intercalator conjugates S.107 (Fig. 4.2.20; Thuong et al., 1984) and S.108 (Asseline and Thuong, 1988) were obtained by condensing oligonucleotides S.109 with the hydroxylated ligands
S.110 and S.111, respectively. Similarly, the porphyrin-oligonucleotide conjugate S.112 was synthesized from the protected oligomer S.113 and the hydroxylated porphyrin S.114 (Le Doan et al., 1986, 1987a) in the presence of a condensing reagent. Deprotection of the fully-protected oligonucleotides was achieved by successive treatment with the DBU salt of benzohydroxamic acid and concentrated ammonia or sodium hydroxide. Sodium hydroxide was used instead of aqueous ammonia for the N-deprotection of oligonucleotides covalently linked to acridine to avoid cleavage of the 9-aminoacridine linkage (Asseline et al., 1984; Thuong and Asseline, 1991).
Synthesis of Modified Oligonucleotides and Conjugates
4.2.19 Current Protocols in Nucleic Acid Chemistry
Oligonucleotides bearing a ligand at the 5′ end are easily prepared on solid-phase by condensation of the terminal 5′-hydroxyl group with those phosphoramidite or H-phosphonate derivatives of ligands that are stable to the conditions required for synthesis. Many functional groups have been coupled to the 5′ terminus of oligonucleotides using these methods. Among them are intercalating agents, photoreactive groups, and labels. The acridine and psoralen derivatives were first linked to the 5′ ends of oligonucleotides bound to a solid support by use of the phosphoramidites S.115 (Fig. 4.2.21; Thuong and Chassignol, 1988) and S.116 (Kurfürst et al., 1993; Dupret et al., 1994), respectively. The phosphoramidite derivatives of these compounds with different linkers S.117 and S.118 are now commercially available. The pyrene group was also conjugated to the 5′ terminus of oligonucleotides using its phosphoramidites derivatives S.119 and S.120 (Korskun et al., 1992); likewise, fagaronine was linked to the 5′ ends of oligonucleotides via the parent phosphoramidite S.121 (Chen et al., 1992). Anthraquinone and sapphyrin were similarly attached to oligonucleotides from their H-phosphonate derivatives S.122 (Lin and Matteucci, 1991) and S.123 (Sessler et al., 1996), respectively.
Oligonucleotide-biotin conjugates S.124a, S.124b, and S.124c (Fig. 4.2.22) were prepared via phosphoramidites S.125a, S.125b (Cocuzza and Zagorsky, 1991) and S.125c (Olejnik et al., 1996). Conjugate S.124c, which has a photocleavable linker to enable the release of the oligonucleotide from the conjugate under UV irradiation at a wavelength of 300 to 350 nm. Fluorescent oligonucleotide conjugates derived from fluorescein S.126a are easily obtained via phosphoramidite S.127. Replacing the hydrogen atoms of the fluorescein nucleus by chlorine leads to tetra- and hexachlorofluorescein derivatives S.126b and S.126c, the absorption and emission spectra of which are red shifted. Designed to exploit energy-transfer techniques, oligomers labeled at their 5′ ends with two chromophores were developed as either linear structures, S.128 (Fig. 4.2.23) and S.129 (Ju et al., 1995, 1996), or hairpin structures, S.130 (Fig. 4.2.24; Nazarenko et al., 1997). Fluorescence energy transfer is a dipole-dipole resonance interaction between two chromophores near to each other. One of these chromophores must be fluorescent and is called the “donor”, whereas the other identified as the “acceptor” may or may not be fluorescent. A spectral overlap between the acceptor’s excitation and donor’s emission wavelengths, and a
N
O
H3CO
O
O
HN
O (CH2)3 O O P O O
(CH2)5 O O P O O
O
B
O
(CH2)3 O O
107
B
n
O O P O O (CH2)5 HN OCH3
O Cl
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
O
n
O P O O
O
Cl
N 108
Figure 4.2.20 Direct addition of ligands to the 5′ ends of oligonucleotides by the phosphotriester coupling method. See Figure 4.2.1 for definitions of functional group abbreviations.
4.2.20 Current Protocols in Nucleic Acid Chemistry
O O
HO O
O O P OPhCl-4 B O O
O 110 Cl
n
O
HO
O P OPhCl-4 O
HN
N
109
H3CO 111
NH NH
N N
O
HN
HN HN (CH2)6 O OH
HN (CH2)6 O O O P O O
N
N
114
B O O P OPhCl-4 B O O
n
O O P O O H
N
O P OPhCL-4 O
OCH3 Cl
n
O
(CH2)5
H
N
N
(CH2)5
112
OCH3 Cl
N 113
Figure 4.2.20
Continued
proper distance between the two entities are necessary for the donor to transfer energy, upon light excitation, to the acceptor. The efficiency of energy transfer is inversely proportional to the sixth power of the distance between the two chromophores. In the case of the linear oligomers S.128 and S.129, the donor was 5-carboxyfluorescein
(FAM), whereas the acceptor was either FAM or its derivative 6-carboxy-4′,5′-dichloro-2′,7′dimethoxyfluorescein (JOE), or one of the two rhodamine derivatives 5-(and 6-)carboxyN,N,N′,N′-tetramethyl rhodamine (TAMRA) and 5-(and 6-)carboxy-X-rhodamine (ROX; all available from Molecular Probes). Upon irradiation at 488 nm, the energy emitted by FAM
Synthesis of Modified Oligonucleotides and Conjugates
4.2.21 Current Protocols in Nucleic Acid Chemistry
CN
O ZL O P N(i-Pr)2 OCH3
O O
ZL =
N
NH(CH2)5
O(H2C)6
ZL = O
Cl
116
115 OCH3
O
O
ZL =
N
H N
H3C ZL = CH3
O
DMTrO
O
Cl 117
118 H N
(CH2)4 O
ZL =
ZL =
ODMTr
120
119 (CH2)6 H3CO
OCH3
ZL =
N
H3CO
CH3
121
DMTrO
N H
N ODMTr
O N
O 122
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
HN NH
O O P O H 123
N
H O P O O
Figure 4.2.21 Direct addition of ligands to the 5′ end of oligonucleotides by the phosphoramidite coupling method. See Figure 4.2.1 for definitions of functional group abbreviations.
4.2.22 Current Protocols in Nucleic Acid Chemistry
O O
NH
HN
H N S O
NH
HN L
H N
O O P O
S
124a-c
O
B
O
H N
H N b
O
O P N(i-Pr)2
O 125a-c
RO
a
CN L
L
=
H N
L
=
H N H3C
H N
c
=
L
O
H N
NO2
N H
R2
R2 HO
O
O
R1 R1
CO2
C HN
R1
O
R1
(CH2)6
R2 OAc
O O
R1
O
O O P O B
O
R2 AcO
O
O
C HN (CH2)6
R1
O O P
126a R1 = R2 = H 126b R1 = Cl, R2 = H 126c R1 = R2 = Cl
CN
N(i-Pr)2
RO 127a 127b 127c
R1 = R2 = H R1 = Cl, R2 = H R1 = R2 = Cl
Figure 4.2.22 Additional examples of direct addition of ligands to the 5′ ends of oligonucleotides by the phosphoramidite coupling method. See Figure 4.2.1 for definitions of functional group abbreviations.
is transferred to the acceptors which in turn generated strong fluorescence at characteristic wavelengths. Typically, when FAM is separated from the acceptor by six consecutive 1′,2′-dideoxyribose phosphates, the emission spectra of S.128a-d showed a 2- to 12-fold enhancement in fluorescence intensity relative to that of the corresponding singly-labeled oligomers. The hairpin structure S.130 is functionalized with both the fluorescent dye FAM at the fluorescence quencher 4-[(4-(dimethylamino)-
phenyl] azobenzoic acid (DABCYL). The hairpin keeps both chromophores in close proximity to each other, causing the fluorescence of the fluorophore to be quenched by energy transfer to the quencher (the energy is dissipated as heat). When the probe S.130 encounters a complementary target molecule, it undergoes a spontaneous conformational change that causes the fluorophore and the quencher to move away from each other. Since the fluorophore is no longer in close proximity to the quencher, it fluoresces upon UV irradiation.
Synthesis of Modified Oligonucleotides and Conjugates
4.2.23 Current Protocols in Nucleic Acid Chemistry
FAM O O P O O
O
R1
n
O O P O O
A U
O
O O P O O
O
B
n1
O H
HO 128a
R1 = H
129a
R1 = B
O
A =
O
CO2
O HO
O
O
H3CO
128b
R1 = H
129b
R1 = B
OCH3 CO2
A =
O (CH3)2N
128c 129c
R1 = H
O
N(CH3)2
CO2
A =
R1 = B O
N 128d 129d
R1 = H
O
N _ SO3
A =
R1 = B
O
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
Figure 4.2.23 Direct addition of ligands to the 5′ terminus of oligonucleotides to permit sensitive fluorescence detection. Figure 4.2.1 for definitions of functional group abbreviations.
4.2.24 Current Protocols in Nucleic Acid Chemistry
DABCYL 3' 5' FAM 130
= (Me)2N
DABCYL
N
O N
Figure 4.2.24 An additional example of direct addition of ligands to the 5′ ends of oligonucleotides to provide fluorescence detection.
Lastly, the 5′ terminus of oligonucleotides can be modified to tether other oligonucleotides through a linker and enable formation of triplehelices upon recognition of an oligopurine stretch on each limb of the conjugates S.131 (Asseline and Thuong, 1994).
the conjugate. For oligonucleotide conjugates with the same number of negative charges, separation can be performed by reversed-phase chromatography. Retention times of the conjugates are increased with the introduction of hydrophobic groups. The length and nature of the linkers used to join oligonucleotides and ligands also affect the chromatographic mobility of the conjugates. Purification of the oligonucleotide conjugates can also be achieved by polyacrylamide gel electrophoresis (PAGE). After purification the nucleoside composition of each conjugate can be verified by hydrolysis with nucleases such as endonuclease P1 (from Penicillium citrinum), snake venom
CHARACTERIZATION Characterization of oligonucleotides bearing a ligand at the 5′ terminus can be achieved in different ways. The oligonucleotide-ligand conjugates can be purified by ion-exchange chromatography (Asseline et al., 1986; Thuong and Asseline, 1991); the retention time increases with the number of negative charges on
O O P O R O
O
N
O CH3
N H
N
O
O
N
H N
N
H3C
O
O O
R O P O O 131
Figure 4.2.25 Conjugation of two third oligonucleotide strands for triple helical formation with double-stranded DNA targets via alternate strand recognition. See Figure 4.2.1 for definitions of functional group abbreviations.
Synthesis of Modified Oligonucleotides and Conjugates
4.2.25 Current Protocols in Nucleic Acid Chemistry
phosphodiesterase (from Crotalus durissus), and alkaline phosphatase. The resulting hydrolysates are then analyzed by comparison with commercial nucleoside samples or previously characterized nucleosides. Such analysis is performed by TLC or preferably by reversed-phase HPLC. It should be pointed out that ligand attachment to the 5′ end of an oligonucleotide prevents hydrolysis of the conjugate by 5′-exonuclease. Thus, 5′-oligonucleotide conjugates should be resistant to digestion by calf spleen phosphodiesterase. Recent developments in mass spectrometry, namely matrix-assisted laser desorption/ionization time of flight (MALDI-TOF; UNIT 10.1) and electrospray ionization (ESI, UNIT 10.2) techniques have allowed molecular mass determination of derivatized oligonucleotides. Chromophore-oligonucleotide conjugates can also be characterized by UV/fluorescence spectroscopy and circular dichroism.
PROPERTIES Numerous physicochemical, biochemical, and biological studies devoted to oligonucleotide-ligand conjugates have been widely reviewed. The discussion below will cover just a few observations on the hybridization properties of conjugates, followed by a description of a few specific properties and applications of 5′-derivatized oligonucleotides.
Formation of Double-Stranded Duplexes
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
Hybrid stabilities The stability of hybrids formed between one oligonucleotide-ligand conjugate and its complementary nucleic acid sequence depends on factors, such as the nature of the ligand-linker combination and the site where the ligand is conjugated to the oligonucleotide chain. The importance of these parameters has been studied with oligonucleotide–intercalating agent conjugates. For example, phenazinium derivatives have been linked to the 5′ or 3′ end of oligonucleotides (Lokhov et al., 1992) as well as to the C-5 positions of deoxyuridine (Levina et al., 1993). Acridine has been conjugated to the 5′ and 3′ termini of oligonucleotides, the internucleotidic phosphodiesters, and the C-5 positions of deoxyuridine residues (Asseline et al., 1984, 1996). Ethidium derivatives have been attached to either the 5′ or 3′ ends of short oligonucleotide sequences (Koshkin et al., 1994). Results obtained with these different conjugates indicate that the attachment of the
intercalating agents to the 5′ or 3′ ends of oligonucleotides via a phosphodiester or a phosphoramide linkage generally leads to the formation of more stable hybrids. Specific properties 5′-Conjugated oligonucleotides with a free 3′-hydroxyl functionality are widely used as primers for polymerases. Thus, oligomers bearing a 5′-fluorescent label such as fluorescein or rhodamine were first used as primers for DNA sequencing by enzymatic methods to allow sensitive, fast fluorescence detection (Smith et al., 1985). The doubly labeled primers S.128 and S.129 recently introduced for sequencing not only increase detection sensitivity but allow detection at many wavelengths to simplify DNA sequencing readouts (Ju et al., 1995, 1996). The use of primers labeled with a fluorescent group and a quencher (like S.130) allows direct quantification of synthesized PCR fragments in which the fluorescence is restored during amplification (Nazarenko et al., 1997). DNA fragments obtained by PCR from primers containing two adenines and a psoralen derivative at their 5′ end easily give photocross-linking products under irradiation at 360 nm with the thymines of complementary sequences. This “Chemi-clamp” system (Appligene-Oncor), enables very sensitive detection of point mutations contained in genes (Costes et al., 1993; Dupret et al., 1994) by the use of denaturing gradient (denaturing gradient gel electrophoresis, or DGGE; Børresen-Dale et al., 1998).
Formation of Triple-Helical Complex Triple-helix stabilities Oligonucleotides can bind to the major groove of DNA polypurine⋅polypyrimidine sequences to form triple helices. Recognition involves the formation of Hoogsteen or reversed-Hoogsteen hydrogen bonds between bases of the oligonucleotide third strand and the purines of the target DNA. This sequencespecific recognition of double-helical DNA was first described for pyrimidine oligonucleotides (Le Doan et al., 1987b; Moser and Dervan, 1987), then for oligonucleotides containing G and T (Cooney et al., 1988), G and A (Beal and Dervan, 1991; Pilch et al., 1991), and T, C, and G (Giovannangeli et al., 1992a). The attachment of an acridine derivative (Collier et al., 1991; Sun et al., 1989) to the 5′ end of a pyrimidine oligonucleotide was shown to strongly stabilize the triple-helical complex
4.2.26 Current Protocols in Nucleic Acid Chemistry
formed with DNA by intercalation at the triplex-duplex junction. When attached to the 5′ end of a short oligopurine strand, oxazolopyridocarbazole was also shown to stabilize the triple-helical complex (Mouscadet et al., 1994). Another example of triple helix stabilization is demonstrated by conjugation of a daunorubicin derivative to the 5′ terminus of an oligopyrimidine oligonucleotide (Garbesi et al., 1997). Studies carried out with benzopyridoindole derivatives linked to C-5 of deoxyuridine located at either the 5′ or 3′ ends or at internal positions in the oligonucleotide chain, as well as on internucleotidic bridges, via phosphorothiolate or phosphoramidate linkages have shown that only the 5′ oligonucleotide conjugates induce triple-helical stabilization (unpub. observ.). Other results obtained with oligopyrimidine oligonucleotides linked to BePI, BgPI, BfPQ, and BhPQ derivatives through either the 5′ end or internal sites have shown that the 5′ end is the most favorable site for intercalator conjugation (Silver et al., 1997). Irreversible modification of nucleic acid target sequences The ability of oligonucleotides bearing an intercalating agent at their 5′ end to form stable triple-helical complexes with the DNA target by intercalation of the polycyclic ligand into the double-helix/triple-helix junction has been exploited to develop reactive oligomers able to induce irreversible localized modifications of the double-stranded DNA targets. Specifically, alkylating agents, cleaving reagents such as porphyrin or Cu-phenanthroline, and photocross-linking reagents have been conjugated to oligonucleotides to modify target nucleic acids. Cross-linking. Many of the intercalating agents attached to oligonucleotides have been shown to cross-link target nucleic acids upon UVA or visible light irradiation. These include proflavin and its azido derivative (Praseuth et al., 1988a,b), ethidium and its azido derivative (Koshkin et al., 1994), and psoralen (Takasugi et al., 1991; Giovannangeli et al., 1992b). In the first two cases, cross-links can be converted to cleavage products upon alkaline treatment. In addition, photooxidation of guanine bases by singlet oxygen production resulted from the reaction of an excited proflavin with molecular oxygen. In the case of psoralen, a photochemical [2+2]-cycloaddition reaction involves the furan or pyrone ring of psoralen and the 5,6double bond of thymine. The yield of crosslinked structures depends on the attachment site
and the linker used to tether the psoralen to the oligonucleotide. When the target is a DNA duplex, a psoralen derivative can be used to cross-link the two strands of the double helix when conjugated to the 5′ end of a pyrimidine triple-helix-forming oligonucleotide (Takasugi et al., 1991; Giovannangeli et al., 1992b). This reaction requires a 5′-TpA-3′ sequence at the junction between the duplex and triplex structures on the oligopurine-containing strand of the target duplex so that two thymines are properly located to form cyclobutane adducts with both the furan and the pyrone rings of a psoralen intercalated at the junction. Since the 5′-TpA-3′ sequence is self-complementary, one thymine is located in the duplex region on one strand and the other in the triplex region on the other duplex strand. The resulting product has psoralen linked to the three strands of the triplex structure (one covalent bond attaching psoralen to the oligonucleotide third strand and two photochemically generated bonds to thymines on the target DNA). Recently, N-5-methylcyclopropapyrroloindole—a structural analog of cyclopropapyrroloindole (CPI), the reactive subunit of antibiotic CC-1065, which alkylates adenines at N3—was conjugated to the 5′ end of an oligonucleotide (Lukhtanov et al., 1997b). This conjugate has proven capable of alkylating the target DNA duplex region immediately adjacent to its double-stranded complementary binding region with which it forms a triple helix. The remarkable stability of the CPI alkylating function to side reactions in physiological buffers allows the reactive oligonucleotide conjugate to rapidly and efficiently cross-link to the DNA target. Cleavage of the target DNA sequence. Cleaving reagents such as porphyrin, phenanthroline-Cu, or bleomycin-Cu have been linked to the 5′ ends of oligonucleotides in order to induce specific cuts on target nucleic acids. Among them orthophenanthroline (OP) used in the presence of Cu2+ and a reducing agent has proven to be the most efficient (Chen and Sigman, 1986, 1988; François et al., 1989). Using a 5′ oligonucleotide-OP conjugate bound to duplex DNA through a triple-helical structure, phenanthroline has been shown to intercalate at the triplex-duplex junction and induce cleavage of both DNA strands with high efficiency— up to 70% double-strand cleavage (François et al., 1989). Since OP is covalently linked to the oligonucleotide via its 5′ terminus, the oligonucleotide binds to the major groove of the DNA
Synthesis of Modified Oligonucleotides and Conjugates
4.2.27 Current Protocols in Nucleic Acid Chemistry
duplex. OP then intercalates at the duplex-triplex junction within the minor groove. Therefore, Cu2+ chelation and the cleavage reaction take place in the minor groove even though recognition of the duplex sequence occurs in the major groove. The cleavage reaction was shown to be sequence specific. Using SV40 circular DNA (5000 bp) as a target, a single double-stranded cut was induced by an OPoligonucleotide conjugate (François et al., 1989), providing a basis for sequence-specific artificial endonucleases. Inhibition of gene expression via triple-helix formation The synthesis of oligonucleotide-intercalator conjugates has paved the way for the development of new tools for molecular and cellular biology and for the design of new gene expression regulators. Oligonucleotides bearing an intercalator at their 5′ end have been used in the “antigene” strategy in which the target is double-helical DNA. The formation of a triplehelical complex within the promoter region of a selected gene may inhibit binding of transcription factors, thereby inhibiting transcription initiation (Grigoriev et al., 1992); this inhibition can be made irreversible when a psoralen conjugate is used in the presence of UV light (Grigoriev et al., 1993). Psoralen conjugates were also used as tools to demonstrate that DNA target sequences were accessible within the chromatin structure compressing genomic DNA in the cell nucleus (Giovannangeli et al., 1997). An acridine-oligonucleotide conjugate was recently shown to arrest the elongation of an RNA transcript when involved in a triplehelical complex formed downstream of the transcription initiation site (Escudé et al., 1996). Unconjugated oligomer did not exhibit any effect on transcription elongation and demonstrated that the gain in stability provided by the intercalator was required for a biological response to be observed.
CONCLUSION
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
Numerous ligands have been covalently linked to the 5′ end of oligonucleotides. Coupling at this location is among the easiest to perform and generally produces conjugates with good hybridization properties. These conjugates are very useful in the applications of oligonucleotides in various fields, as they possess specific properties. The presence of the free 3′-terminal hydroxyl group allows their use as primers for polymerases, and the strong
stabilization provided by intercalator ligands makes them efficient inhibitors of gene expression via triple-helix formation.
LITERATURE CITED Agrawal, S., Christodoulou, C., and Gait, M.J. 1986. Efficient method for attaching non-radioactive labels to the 5′ ends of synthetic oligodeoxyribonucleotides. Nucl. Acids Res. 14:6227-6245. Ansorge, W., Sproat, B., Stegemann, J., Schwager, C., and Zenke, M. 1987. Automated DNA sequencing: Ultrasensitive detection of fluorescent bands during electrophoresis. Nucl. Acids Res. 15:4593-4602. Asseline, U. and Thuong, N.T. 1988. Oligothymidylates substitués par un dérive de l’acridine en position 5′, à la fois en position 5′ et 3′ ou sur un phosphate internucleotidique. Nucleosides Nucleotides 7:431-455. Asseline, U. and Thuong, N.T. 1994. 5′-5′ tethered oligonucleotides via nucleic bases: A potential new set of compounds for alternate strand triplehelix formation. Tetrahedron Lett. 35:52215224. Asseline, U., Toulmé, F., Thuong, N.T., Delarue, M., Montenay-Garestier, T., and Hélène, C. 1984. Oligodeoxynucleotides covalently linked to intercalating dyes as base sequence–specific ligands. Influence of dye attachment site. EMBO J. 3:795-800. Asseline, U., Thuong, N.T., and Hélène, C. 1986. Oligothymidylates substitués en position 3′ par un dérivé de l’acridine. Nucleosides Nucleotides 5:45-63. Asseline, U., Bonfils, E., Dupret, D., and Thuong, N.T. 1996. Synthesis and binding properties of oligonucleotides covalently linked to an acridine derivative. A new study of the influence of the dye attachment site. Bioconjugate Chem. 7:369379. Balbi, A., Sottofattori, E., Grandi, T., and Mazzei, M. 1994. Synthesis and complementary complex formation properties of oligonucleotides covalently linked to new stabilizing agents. Tetrahedron 50:4009-4018. Bannwarth, W., Schmidt, D., Stallard, R.L., Hornung, C., Knorr, R., and Müller, F. 1988. Bathophenanthroline-ruthenium (II) complexes as non-radioactive labels for oligonucleotides which can be measured by time-resolved fluorescence techniques. Helv. Chim. Acta 71:20852099. Beal, P.A. and Dervan, P.B. 1991. Second structural motif for recognition of DNA by oligonucleotide directed triple-helix formation. Science 251:1360-1363. Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites. A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862.
4.2.28 Current Protocols in Nucleic Acid Chemistry
Bhan, P. and Miller, P.S. 1990. Photo-crosslinking of psoralen-derivatized oligonucleotide methylphosphonates to single-stranded DNA. Bioconjugate Chem. 1:82-88.
Cocuzza, A.J. and Zagorsky, R.J. 1991. A simple preparation of 5′-biotinylated oligonucleotides and their use as primers in dideoxy-sequencing of DNA. Nucleosides Nucleotides 10:413-414.
Blanks, R. and McLaughlin, L.W. 1988. An oligodeoxynucleotide affinity column for the isolation of sequence DNA binding. Nucl. Acids Res. 16:10283-10299.
Cohen, J.S. (ed.) 1989. Oligonucleotides antisense inhibitors of gene expression. In Topics in Molecular and Structural Biology, Macmillan, New York.
Børresen-Dale, A.-L., Hovig, E., and Smith-Sørensen, B. 1998. Detection of mutations by denaturing gradient gel electrophoresis. In Current Protocols in Human Genetics (N.C. Dracopoli, J.L. Haines, B.T. Korf, D.T. Moir, C.C. Morton, C.E. Seidman, J.G. Seidman, and D.R. Smith, eds.) pp. 7.5.1-7.5.12. John Wiley & Sons, New York.
Collier, D.A., Mergny, J.L., Thuong, N.T., and Hélène, C. 1991. Site-specific intercalation at the triplex-duplex junction induces a conformational change which is detectable by hypersensitivity to diethylpyrocabonate. Nucl. Acids Res. 19:4219-4224.
Boutorin, A.S., Vlassov, V.V., Kazakov, S.A., Kutyavin, I.V., and Podominogin, M.A. 1984. Complementary addressed reagents carrying EDTA-Fe(II) groups for directed cleavage of single-stranded nucleic acids. FEBS Lett. 172:43-46.
Connel, C., Fung, S., Heiner, C., Bridgham, J., Chakerian, V., Heron, E., Jones, S., Menchen, W., Mordan, M., Raff, M., Recknor, M., Smith, L., Springer, J., Woo, S., and Hunkapiller, M. 1987. Automated DNA sequence analysis. BioTechniques 5:342-348.
Boutorin, A.S., Tokuyama, H., Takasugi, M., Isobe, H., Nakamura, E., and Hélène, C. 1994. Fullerene-oligonucleotide conjugates: Photo-induced sequence-specific DNA cleavage. Angew. Chem. Int. Ed. Engl. 33:2462-2465.
Connolly, B.A. 1985. Chemical synthesis of oligonucleotides containing a free sulphydryl group and subsequent attachment of thiol specific probes. Nucl. Acids Res. 13:4485-4502.
Burns, J.A., Butler, J.C., Moran, J., and Whitesides, G.M. 1991. Selective reduction of disulfides by tris(2-carboxyethyl)phosphine. J. Org. Chem. 56:2648-2650.
Connolly, B.A. 1987. The synthesis of oligonucleotides containing a primary amino group at the 5′-terminus. Nucl. Acids Res. 15:3131-3139.
Chassignol, M. and Thuong, N.T. 1998. Phosphodisulfide bond: A new linker for the oligonucleotide conjugation. Tetrahedron Lett. 39:82718274. Chen, C.-H. and Sigman, D. 1986. Nuclease activity of 1,10-phenanthroline-copper: Sequence specific targeting. Proc. Natl. Acad. Sci. U.S.A. 83:7147-7151. Chen, C.-H. and Sigman, D. 1988. Sequence-specific scission of RNA by 1,10-phenanthrolinecopper linked to oligonucleotides. J. Am. Chem. Soc. 110:6570-6572. Chen, J.K., Carlson, D.V., Weith, H.L., O’Brien, J.A., Goldman, M.E., and Cushman, M. 1992. Synthesis of an oligonucleotide-intercalator conjugate in which the linker chain is attached via the phenolic hydroxyl group of fagaronine. Tetrahedron Lett. 33:2275-2278. Chen, J.-K., Schultz, R.N., Lloyd, D.H., and Gryaznov, S.M. 1995. Synthesis of oligodeoxyribonucleotide N3′→P5′ phosphoramidates. Nucl. Acids Res. 23:2661-2668. Chu, B. and Orgel, L. 1988. Ligation of oligonucleotides to nucleic acids or protein via disulfide bonds. Nucl. Acids Res. 16:3671-3691. Chu, B., Wahl, G., and Orgel, L. 1983. Derivatization of unprotected polynucleotides. Nucl. Acids Res. 11:6513-6529. Chu, B., et al. 1985. Nonenzymatic sequence-specific cleavage of single-stranded DNA. Proc. Natl. Acad. Sci. U.S.A. 82:963-967. Cleland, W.W. 1964. Dithiothreitol, a new protective reagent for SH groups. Biochemistry. 3:480-482.
Cooney, M., Czernuszewicz, G., Postel, E.H., Flint, S.J., and Hogan, M.E. 1988. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science 241:546549. Costes, B., Girodon, E., Ghanem, N., Chassignol, M., Thuong, N.T., Dupret, D., and Goossens, M. 1993. Psoralen-modified oligonucleotide primers improve detection of mutations by denaturing gradient gel electrophoresis and provide an alternative to GC-clamping. Hum. Mol. Genet. 2:393-397. Coull, J.M., Weith, H.L., and Bischoff, R. 1986. A novel method for the introduction of an aliphatic primary amino group at the 5′ terminus of synthetic oligonucleotides. Tetrahedron Lett. 27:3991-3994. Cumber, J.A., Forrester, J.A., Foxwell, B.M., Ross, W.C., and Thorpe, P.E. 1985. Preparation of antibody-toxin conjugates. Methods Enzymol. 112:207-225. Dietrich, B., Lehn, J.-M., and Sauvage, J.P. 1969. Diaza-polyoxa-macrocycles et macrobicycles. Tetrahedron Lett. 34:2885-2589. Dikalov, S.I., Rumyantseva, G.V., Weiner, L.M., Sergejev, D.S., Frolova, E.I., Godovikova, T.S., and Zarytova, V.F. 1991. Hydroxyl radical generation by oligonucleotide derivatives of anthracycline antibiotic and synthetic quinone. Chem. Biol. Interactions 77:325-329. Dupret, D., Gossens, M., Chassignol, M., and Thuong, N.T. 1994. European Patent 0596028 A1,1994, 05,11.
Synthesis of Modified Oligonucleotides and Conjugates
4.2.29 Current Protocols in Nucleic Acid Chemistry
Ebata, K., Masuko, M., Ohtani, H., and Kashiwasake-Jibu, M. 1995. Nucleic acid hybridization accompagned with excimer formation from two pyrene labeled probes. Photochem. Photobiol. 62:836-839.
Giovannangeli, C., Diviacco, S., Labrousse, V., Gryaznov, S., Charneau, P., and Hélène, C. 1997. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc. Natl. Acad. U.S.A. 94:79-84.
Eckstein, F. 1983. Phosphorothioate analogues of nucleotides. Tools for the investigation of biochemical processes. Angew. Chem. Int. Ed. Engl. 22:423-506.
Gotthikh, M., Asseline, U., and Thuong, N.T. 1990. Synthesis of oligonucleotides containing a carboxyl group at either their 5′ end or their 3′ end and their subsequent derivatization by an intercalating agent. Tetrahedron Lett. 31:6657-6660.
Escudé, C., Giovannangeli, C., Sun, J.S., Lloyd, D.H., Chen, J.K., Gryaznov, S.M., Garestier, T., and Hélène, C. 1996. Stable triple helices formed by oligonucleotide N3′- P5′ phosphoramidates inhibit transcription elongation. Proc. Natl. Acad. Sci. U.S.A. 93:4365-4369. Fedorova, O.S., Savitskii, A.P., Shoikhet, K.G., and Ponomarev, G.V. 1990. Palladium(II)-coproporphyrin I as a photoactive group in sequence-specific modification of nucleic acids by oligonucleotide derivatives. FEBS Lett. 259:335-337. François, J.C., Saison-Behmoaras, T., Barbier, C., Chassignol, M., Thuong, N.T., and Hélène, C. 1989. Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate. Proc. Natl. Acad. Sci. U.S.A. 86:9702-9706. Gao, H., Yang, M., and Cook., A.F. 1995. Stabilization of double-stranded oligonucleotides using backbone linked disulfide bridges. Nucl. Acids Res. 23:285-292. Garbesi, A., Bonazzi, S., Zanella, M.L., Capobianco, M.L., Giannini, G., and Arcamone, F. 1997. Synthesis and binding properties of conjugates between oligodeoxynucleotides and daunorubicin derivatives. Nucl. Acids Res. 25:21212128. Ghetie, V., Till, M.A., Ghetie, M.-A., Tucker, T., Porter, J., Patzer, E.J., Richardson, J.A. Uhr, J.W., and Vitetta, E.S. 1990. Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers. Bioconjugate Chem. 1:24-31. Gilham, P.T. 1962. An addition reaction specific for uridine and guanosine nucleotides and its application to the modification of ribonuclease action. J. Am. Chem. Soc. 84:687-688. Gilham, P.T. and Khorana, H.G. 1958. Studies on polynucleotides. A new and general method for the chemical synthesis of the C5′-C3′ internucleotidic linkage; syntheses of deoxyribo-nucleotides. J. Am. Chem. Soc. 80:6212.
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
Giovannangeli, C., Rougée, M., Garestier, T., Thuong, N.T., and Hélène, C. 1992a. Triplehelix formation by oligonucleotides containing the three bases thymine, cytosine and guanine. Proc. Natl. Acad. Sci. U.S.A. 113:8631-8635. Giovannangeli, C., Thuong, N.T., and Hélène, C., 1992b. Oligodeoxynucleotide-directed photoinduced cross-linking of HIV proviral DNA via triple-helix formation. Nucl. Acids Res. 20:42754281.
Grigoriev, M., Praseuth, D., Robin, P., Hémar, A., Saison-Behmoaras, T., Dautry-Versat, A., Thuong, N.T., Hélène, C., and Harel-Bellan, A. 1992. A triple helix–forming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NK kB binding to interleukin-2 receptor α-regulatory sequence. J. Biol. Chem. 267:3389-3395. Grigoriev, M., Praseuth, D., Guieysse, A.L., Robin, P., Thuong, N.T., Hélène, C., and Harel-Bellan, A. 1993. Inhibition of gene expression by triple helix-directed DNA cross-linking at specific sites. Proc. Natl. Acad. Sci. U.S.A. 90:35013505. Grimautdinova, O.I., Zenkova, M.L., Karpova, G.G., and Podust, L.M. 1984. Affinity labelling of ribosomes from Escherichia coli with photoactivated analogs of mRNA. Mol. Biol. 18:907-918. Guzaev, A., Salo, H., Azhayev, A., and Lonnberg, H. 1985. A new approach for chemical phosphorylation of oligonucleotides at the 5′-terminus. Tetrahedron 51:9375-9384. Haugland, R.P. 1989. Handbook of Fluorescent Probes and Research Chemicals, p. 54. Molecular Probes, Eugene, Ore. Hélène, C. and Saison-Behmoaras, T. 1994. La stratégie antisens: nouvelles approches thérapeutiques. Medecine/Science 10:257-273. Hélène, C. and Thuong, N.T. 1988. Oligo-alphadeoxyribonucleotides covalently linked to intercalating agents. A new family of sequence-specific nucleic acid reagents. In Nucleic Acids and Molecular Biology, Vol. 2 (F. Eckstein and D. Lilley, eds.) pp. 105-123. Springer-Verlag, Berlin. Horn, T. and Urdea, M.S. 1986. A chemical 5′-phosphorylation of oligodeoxyribo-nucleotides that can be monitored by trityl cation release. Tetrahedron Lett. 27:4705-4708. Horne, D.A. and Dervan, P.B. 1990. Recognition of mixed-sequence duplex DNA by alternatestrand triple-helix formation. J. Am. Chem. Soc. 112:2435-2437. Itakura, K., Katagiri, N., Bahl, C.P., Wightman, R.H., and Narang, S.A. 1975. Improved triester approach for the synthesis of pentadecathymidylic acid. J. Am. Chem. Soc. 97:7327-7246. Iyer, R.P., Egan, W., Regan, J., and Beaucage, S.L. 1990. 3H-1,2-benzidithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solidphase synthesis of oligodeoxyribonucleoside phosphorothioates. J. Am. Chem. Soc. 112:12531255.
4.2.30 Current Protocols in Nucleic Acid Chemistry
Ju, J., Ruan, C., Fuller, C.W., Glazer, A., and Mathies, R. 1995. Fluorescence energy transfer dye-labeled primers for DNA sequencing and analysis. Proc. Natl. Acad. Sci. U.S.A. 92:4347-4351. Ju, J., Glazer, A., and Mathies, R. 1996. Cassette labeling for facile construction of energy transfer fluorescent primers. Nucl. Acids Res. 24:11441148. Jue, R., Lambert, J.M., Pierce, L.R., and Traut, R.R. 1978. Addition of sulphydryl group to Escherichia coli ribosomes by protein modification with 2-iminothiolane (methyl 4-mercaptobutyrimidate). Biochemistry 17:5399-5406. Julian, R., Duncan, S., Weston, P.D., and Wrigglesworth, R. 1983. A new reagent which may be used to introduce sulphydryl groups into proteins, and its use in the preparation of conjugates for immunoassay. Anal. Biochem. 132:68-73. Korskun, V.A., Pestov, N.B., Birikh, K.R., and Berlin, Y.A. 1992. Reagent for introducing pyrene residues into oligonucleotides. Bioconjugate Chem. 3:559-562. Koshkin, A.A., Kropachev, K.Y., Mamaev, S.V., Bulychev, N.V., Lokhov, S.G., Vlassov, V.V., and Lebedev, A.V. 1994. Ethidium and azidoethidium oligonucleotide derivatives: Synthesis, complementary complex formation and sequence-specific photomodification of the singlestranded and double-stranded target oligo- and polynucleotides. J. Mol. Recognit. 7:177-188. Kremsky, J.N., Wooters, J.L., Dougherty, J.P., Meyers, R.E., Collins, M., and Brown, E.L. 1987. Immobilization of DNA via oligonucleotide containing an aldehyde or carboxylic group at the 5′ terminus. Nucl. Acids Res. 15:2891-2910. Kuijpers, W.H.A. and van Boeckel, C.A.A. 1993. A new strategy for the solid-phase synthesis of 5′-thiolated oligodeoxynucleotides. Tetrahedron 47:10931-10944. Kuijpers, W.H.A., Bos, E.S., Kasparen, F.M., Veenemam, G.H., and van Boeckel, C.A.A. 1993. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: A novel approach for two-step radioimmunotherapy of cancer. Bioconjugate Chem. 4:94102. Kumar, A., Advani, S., Dawar, H., and Talwar, G.P. 1991. A simple method for introducing a thiol group at the 5′-end of synthetic oligonucleotides. Nucl. Acids Res. 19:4561. Kurfürst, R., Roig, V., Chassignol, M., Asseline, U. and Thuong, N.T. 1993. Oligo-α-deoxyribonucleotides with a modified nucleic base and covalently linked to reactive agents. Tetrahedron 49:6975-6990. Kuwabara, M., Yoon, C., Goyne, T., Thederahn, T., and Sigman D.S. 1986. Nuclease activity of 1,10-phenanthroline-copper ion: Reaction with CGCGAATTCGCG and its complexes with Netropsin and EcoR I . Biochemistry 25:7401-7408.
Le Doan, T., Perrouault, L., Hélène, C., Chassignol, M., and Thuong, N.T. 1986. Targeted cleavage of polynucleotides by complementary oligonucleotides covalently linked to iron-porphyrins. Biochemistry 25:6736-6739. Le Doan, T., Perrouault, L., Chassignol, M., Thuong, N.T., and Hélène, C. 1987a. Sequencetargeted chemical modification of nucleic acids by complementary oligonucleotides covalently linked to porphyrins. Nucl. Acids Res. 15:86438659. Le Doan, T., Perrouault, L., Praseuth, D., Habhoub, N., Decout, J.L., Thuong, N.T., Lhomme, J., and Hélène, C. 1987b. Sequence-specific recognition, photocrosslinking and cleavage of the DNA double helix by an oligo-[α]-thymidylate covalently linked to an azidoproflavine derivative. Nucl. Acids Res. 15:7749-7760. Lee, B.L., Murakami, A., Blake, K.R., Lin, S.B., and Miller, P.S. 1988. Interaction of psoralen-derivatized oligodeoxyribonucleoside methylphosphonates with single-stranded DNA. Biochemistry 27:6736-6739. Letsinger, R.L. and Lunsford, W.B. 1976. Synthesis of thymidine oligonucleotides by phosphite triester intermediates. J. Am. Chem. Soc. 98:36553661. Levina, A.S., Tabatadse, D.R., Khalimskaya, L.M., Prichodko, T.A., Sishkin, G.V., Alexandrova, L.A., and Zarytova, V.P. 1993. Oligonucleotide derivatives bearing reactive and stabilizing groups attached to C5 of deoxyuridine. Bioconjugate Chem. 4:319-325. Lin, K.-Y. and Matteucci, M. 1991. Hybridization properties of deoxyoligonucleotides containing anthraquinone pseudonucleosides. Nucl. Acids Res. 19:3111-3114. Lokhov, S.G., Podyminogin, M.A., Sergeev, D.S., Silnikov, V.N., Kutyavin, I.V., Shishkin, G.V., and Zarytova, V.P. 1992. Synthesis and high stability of complementary complexes of N(2-hydroxyethyl)phenazinium derivatives of oligonucleotides. Bioconjugate Chem. 3:414419. Lukhtanov, E.A., Kutyavin, I.V., Gorn, V.V., Reed, M.W., Adams, A.D., Lucas, D.D., and Meyer, R.B. 1997a. Sequence and structure dependence of the hybridization-triggered reaction of oligonucleotides bearing conjugated cyclopropapyrroloindole. J. Am. Chem. Soc. 119:6214-6225. Lukhtanov, E.A., Kutyavin, I.V., Mills, A.G., Gorn, V.V., Reed, M.W., and Meyer, R.B. 1997b. Minor groove DNA alkylation directed by major groove triplex forming oligodeoxyribonucleotides. Nucl. Acids Res. 25:5077-5084. McCurdy, S.N., Nelson, J.S., Hirschbein, B.L., and Fearon, K.L. 1997. An improved method for the synthesis of N3′→P5′ phosphoramidate oligonucleotides. Tetrahedron Lett. 38:207-210. Michelson, A.M. and Todd, A.R. 1955. Synthesis of dithymidine dinucleotide containing a 3′-5′-internucleotidic linkage. J. Chem. Soc. 2632-2638.
Synthesis of Modified Oligonucleotides and Conjugates
4.2.31 Current Protocols in Nucleic Acid Chemistry
Moser, H.E. and Dervan, P.B. 1987. Sequence-specific cleavage of double helical DNA by triple helix formation. Science 238:645-650. Mouscadet, J.-F., Ketterlé, C., Goulaouic, H., Carteau, S., Subra, F., Le Bret, M., and Auclair, C. 1994. Triple helix formation with short oligonucleotide-intercalator conjugates matching the HIV-1 LTR end sequences. Biochemistry 33:4187-4196. Mungall, W.S., Greene, G.L., Heavner, G.A., and Letsinger, R.L. 1975. Use of the azido group in the synthesis of 5′ terminal aminodeoxythymidine oligonucleotides. J. Org. Chem. 40:16591662. Nazarenko, A., Bhatnagar, S.K., and Hohman, R.J. 1997. A closed tube format for amplification and detection of DNA based on energy tranfer. Nucl. Acids Res. 25:2516-2521. Odell, B. 1985. The dissolution of polynucleotides in non-aqueous solvents using macrocyclic polyethers. J. Chem. Soc. Chem. Commun. 858859. Olejnik, J., Krzymanska-Olejnik, E., and Rothschild, K.J. 1996. Photocleavage biotin phosphoramidite for 5′-end-labeling, affinity purification and phosphorylation of synthetic oligonucleotides. Nucl. Acids Res. 24:361-366. Pilch, D.S., Levensen, C., and Shafer, R.H. 1991. Structure, stability and thermodynamics of a short intermolecular purine-purine-pyrimidine triple-helix. Biochemistry 30:6081-6087. Praseuth, D., Le Doan, T., Chassignol, M., Decout, J.L., Habhoub, N., Lhomme, J., Thuong, N.T., and Hélène, C. 1988a. Sequence-targeted photosensitized reactions in nucleic acids by oligo[α]-deoxynucleotides and oligo-[β]-deoxynucleotides. Biochemistry 27:3031-3038. Praseuth, D., Perrouault, L., Le Doan, T., Chassignol, M., Thuong, N.T., and Hélène, C. 1988b. Sequence-specific binding and photocrosslinking of α and β oligodeoxynucleotides to the major groove of DNA. Proc. Natl. Acad. Sci. U.S.A. 85:1349-1353 Reese, C.B. and Saffhill, R. 1968. Oligonucleotide synthesis via phosphotriester intermediates: The phenyl-protecting group. J. Chem. Soc. Chem. Commun. 767-768. Schubert, F., Knaf, A., Möller, U., and Cech, D. 1995. Covalent attachment of methylene blue. Nucleosides Nucleotides 14:1437-1443.
Modification of the 5′ Terminus of Oligonucleotides for Attachment of Reporter and Conjugate Groups
Schwarz, M.W. and Pfleiderer, W. 1987. Synthesis of terminal nucleoside phosphates and thiophosphates via phosphoramidite chemistry. Nucleosides Nucleotides 6:537-539. Sessler, J.L., Sansom, P.I., Kral, V., O’Connor, D., and Iverson, B.L. 1996. Sapphyrin-oligonucleotide conjugates. Novel sequence-specific DNA photomodifying agents with increased binding affinity. J. Am. Chem. Soc. 118:12322-12330.
Shimizu, M., Inoue, H., and Ohtsuka, E. 1994. Detailed study of sequence-specific DNA cleavage of triplex-forming oligonucleotides linked to 1,10-phenanthroline. Biochemistry 33:606613. Silver, G.C., Sun, J.S., Nguyen, C.H., Boutorin, A.S., Bisagni, E., and Hélène, C. 1997. Stable triple-helical DNA complexes formed by benzopyridoindole- and benzopyridoquinoxalineoligonucleotide conjugates. J. Am. Chem. Soc. 119:263-268. Smith, L.M., Fung, S., Hunkapiller, M.W., Hunkapiller, T., and Hood, L.E. 1985. The synthesis of oligonucleotides containing an aliphatic amino group at the 5′ terminus: Synthesis of fluorescent DNA primers for use in DNA sequence analysis. Nucl. Acids Res. 13:23992412. Sproat, B.S., Beijer, B., Rider, P., and Neumer, P. 1987a. The synthesis of protected 5′-mercapto2′,5′-dideoxyribonucleoside-3′-O-phosphoram idites; uses of 5′-mercapto-oligo-deoxyribonucleotides. Nucl. Acids Res. 15:4837-4848. Sproat, B.S., Beijer, B., and Rider, P. 1987b. The synthesis of protected 5′-amino-2′,5′-dideoxyribonucleoside-3′-O-phosphoramidites; applications of 5′-amino-oligodeoxyribonucleotides. Nucl. Acids Res. 15:6181-6196. Soyfer, V.N. and Potoman, V.N. 1996. Possible spheres of applications of intermolecular triplexes. In Triple-Helical Nucleic Acids, pp. 253284. Springer-Verlag, New York. Stec, W.J., Uznanski, B., and Wilk, A. 1993. Bis(O,O-diisopropoxy phosphinothioyl)-disulfide-A highly efficient sulfurizing reagent for cost-effective synthesis of oligo(nucleoside phosphorothioate)s. Tetrahedron Lett. 34:53175320. Sun, J.S., Francois, J.C., Montenay-Garestier, T., Saison-Behmoaras, T., Roig, V., Thuong, N.T., and Hélène, C. 1989. Sequence-specific intercalating agents. Intercalation at specific sequences on duplex DNA via major groove recognition by oligonucleotide-intercalator conjugates. Proc. Natl. Acad. Sci. U.S.A. 86:9198-9202. Sun, J.S., Giovannangeli, C., Francois, J.C., Kurfürst, R., Montenay-Garestier, T., Asseline, U., Saison-Behmoaras, T., Thuong, N.T., and Hélène, C. 1991. Triple-helix formation by α oligodeoxynucleotides and α oligodeoxynucleotide-intercalator conjugates. Proc. Natl. Acad. Sci. U.S.A. 88:6023-6027. Takasugi, M., Guendouz, A., Chassignol, M., Decout, J.L., Lhomme, J., Thuong, N.T., and Hélène, C. 1991. Sequence-specific photo-induced cross-linking of the two strands of doublehelical DNA by a psoralen covalently linked to a triple helic forming oligonucleotide. Proc. Natl. Acad. Sci. U.S.A. 88:5602-5606. Tam, J.P., Wu, C.-R., Liu, W., and Zhang, J.-W. 1991. Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applications. J. Am. Chem. Soc. 113:6657-6662.
4.2.32 Current Protocols in Nucleic Acid Chemistry
Thorpe, P.E., Wallace, P.M., Knowles, P.P., Relf, M.G., Brown, A.N.F., Watson, G.J., Knyba, R.E., Wawrzynczak, E.J., and Blakey, D.C. 1987. New coupling agents for synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res. 47:59245931. Thuong, N.T. and Asseline, U. 1991. Oligonucleotides attached to intercalators, photoreactive and cleavage agents. In Oligonucleotides and Analogues: A Practical Approach (F. Eckstein, ed.) pp. 283-308. IRL Press, Oxford. Thuong, N.T. and Chassignol, M. 1987. Synthèse et reactivité d’oligothymidylates substitués par un agent intercalant et un groupe thiophosphate. Tetrahedron Lett. 28:4157-4160. Thuong, N.T. and Chassignol, M. 1988. Solid phase synthesis of oligo-α- and oligo-β deoxynucleotides covalently linked to an acridine. Tetrahedron Lett. 29:5905-5908. Thuong, N.T. and Hélène, C. 1993. Sequencespecific recognition and modification of doublehelical DNA by oligonucleotides. Angew. Chem. Int. Ed. Engl. 32:666-690. Thuong, N.T., Hélène, C., and Asseline, U. 1984. European Patent, 84-400143-8. United States Patent, 1989, 4-835-263.
Vu, H. and Hirschbein, B.L. 1991. Internucleotide phosphite sulfurization with tetraethylthiuram disulfide phosphorothioate oligonucleotide synthesis via phosphoramidite chemistry. Tetrahedron Lett. 32:3005-3008. Wachter, L., Jablonski, J.-A., and Ramachandran, K.L. 1986. A simple and efficient procedure for the synthesis of 5′-aminoalkyl oligodeoxynucleotides. Nucl. Acids Res. 14:7985-7994. Zarytova, V.F., Godovikova, T.S., Kutyavin, I.V., and Khalimskaya L.M. 1987. Reactive oligonucleotide derivatives as affinity reagents and probes in molecular biology. In Biophosphates and Their Analogues. Synthesis, Structure, Metabolism and Activity (K.S. Brusik and W.J. Stec, eds.) pp. 149-164. Elsevier Science Publishers, New York. Zarytova, V.F., Sergeyev, D.S., and Godovikova, T.S. 1993. Synthesis of bleomycin A5 oligonucleotide derivatives and site-specific cleavage of the DNA target. Bioconjugate Chem. 4:189-193.
Contributed by Nguyen T. Thuong and Ulysse Asseline Centre de Biophysique Moléculaire, CNRS Orléans, France
Uhlmann, E. and Engels, J. 1986. Chemical 5′-phosphorylation of oligonucleotides valuable in automated DNA synthesis. Terahedron Lett. 27:1023-1026.
Synthesis of Modified Oligonucleotides and Conjugates
4.2.33 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Direct Attachment of Conjugate Groups to the 5′ Terminus of Oligodeoxyribonucleotides
UNIT 4.3
The attachment of conjugate groups (intercalating and photoreactive groups) to the 5′ terminus of oligodeoxyribonucleotides can be achieved using either of two strategies. This unit presents one strategy, the direct incorporation of ligands during oligodeoxyribonucleotide synthesis using phosphoramidite derivatives. The second strategy, coupling of an unblocked oligomer with a ligand via a specific reaction between the reactive groups present in both entities, will be presented in future units. The protocols delineated below cover the direct addition of an intercalator, 2-methoxy-6-chloro-9-aminoacridine (see Basic Protocol 1), and a photo-cross-linking reagent, psoralen (see Basic Protocol 2), to the 5′ end of oligonucleotides via their phosphoramidite derivatives. These procedures require the following steps: the incorporation of hydroxylated linkers into ligands, the preparation of the phosphoramidite derivatives, and the addition of the latter to the 5 ′ ends of protected oligonucleotides bound to the support. After deprotection, the oligodeoxyribonucleotide conjugates are purified and characterized (see Support Protocol). Properties of a number of conjugates synthesized by these procedures are discussed in UNIT 4.2. CAUTION: All chemicals must be handled in a fume hood by individuals equipped with lab coats, glasses, and gloves. DIRECT ADDITION OF ACRIDINE DERIVATIVES TO THE 5′ END OF OLIGODEOXYRIBONUCLEOTIDES
BASIC PROTOCOL 1
This strategy (illustrated in Figs. 4.3.1, 4.3.2, and 4.3.3) involves the covalent attachment of a linker carrying a hydroxyl function to the acridine derivative S.1b, and the preparation of the acridinyl phosphoramidite derivative S.1c. The acridinyl phosphoramidite derivative can be coupled either automatically or manually to the 5′-terminal hydroxyl group of oligodeoxyribonucleotides bound to solid supports. After deprotection, the acridineoligodeoxyribonucleotide conjugate S.1d is purified and characterized as described in the Support Protocol.
OCH3
OCH3
H2N(CH2)6OH N
Cl
N
N H
6 OH
OH Cl
Cl 1a
1b
O
O
O
O
N HCl
O
O Br(CH2)6OH
OCH3 O
Figure 4.3.1 linkers.
K2CO3
6 OH
O
O 2a
O
OH
2b
2c
Synthesis of acridine and psoralen derivatives functionalized with hydroxylated
Contributed by Ulysse Asseline and Nguyen T. Thuong Current Protocols in Nucleic Acid Chemistry (2000) 4.3.1-4.3.16 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.3.1
OCH3 Cl
OCH3
CN
O P
N
N H
6 OH
N
N H
DIEA
Cl
6O
P N(i-Pr)2
Cl 1b
1c
O O
Cl O
O
CN
O
O
P
6 OH
CN
O
N(i-Pr)2 O
6O
DIEA
O
P N(i-Pr)2
O 2c
Figure 4.3.2
CN
O
N(i-Pr)2
2d
Synthesis of the phosphoramidite derivatives of acridine and psoralen ligands.
HO
B'
O O
O P O O
CN O
B'
n
O P OCH3 O
1. N
O NH (CH2)6 O P N(i-Pr)2 1c
Cl
O
CN 1.
(CH2)6 O P O
2d 1H-tetrazole
1H-tetrazole
3. NH4OH
3. NaOH
N
O
Cl
H3CO HN
O
O
O (CH2)6
(CH2)6
O
O
O P O O
O P O O
O
O
B'
n
O
H 1d
Figure 4.3.3
N(i-Pr)2
2. oxidation
2. oxidation
Direct Attachment of Conjugate Groups to the 5′ Terminus of Oligodeoxyribonucleotides
CN
O
O
O
B'
n
H 2e
Direct addition of ligands to the 5′ terminus of oligodeoxyribonucleotides.
4.3.2 Current Protocols in Nucleic Acid Chemistry
Materials 6-Amino-1-hexanol 6,9-Dichloro-2-methoxyacridine Phenol Dichloromethane (CH2Cl2), distilled from P2O5 and passed over activated, basic aluminum oxide Distilled methanol (MeOH) 2 M sodium hydroxide (NaOH) Acetonitrile (CH3CN), HPLC grade 2,6-Dibromo-4-benzoquinone-N-chloroimine (DBPNC; Prolabo) Ethanol, distilled P2O5 Acetonitrile (CH3CN), DNA synthesis grade, anhydrous and stored over 3-Å molecular sieves N,N-Diisopropylethylamine (DIEA), distilled from KOH 2-Cyanoethyl-N,N-diisopropylchlorophosphite Ethyl acetate, distilled Hexane, distilled Triethylamine (Et3N), distilled from KOH 10% (w/v) Na2CO3 Saturated NaCl (brine) MgSO4 Oligodeoxyribonucleotide bound to solid supports, such as controlled-pore glass (CPG; UNIT 3.1), synthesized by classic phosphoramidite chemistry (1-µmol scale; UNIT 3.3 and APPENDIX 3C) DNA synthesis reagents recommended by the synthesizer’s manufacturer 0.4 M sodium hydroxide (NaOH) in 50:50 (v/v) MeOH/H 2O Dowex 50 resin, pyridinium form (Aldrich) Round-bottomed flasks (various sizes) with rubber septa and glass stoppers Drying tube containing CaCl2 Reflux condenser Analytical thin-layer chromatography (TLC) setup and silica-gel plates: e.g., Merck 5554 Kieselgel 60F plates, including UV lamp for detection Desiccator Beakers, various sizes Silica gel for column chromatography: Merck 9387 Kieselgel 60 or Merck 7734 Kieselgel 60 Chromatographic column (3 cm × 45 cm) Argon Nitrogen gas Spectrophotometer Rotary evaporator with water bath Chemically inert syringes with replaceable needles Funnel Separatory funnels (various sizes) Filter (porosity 4) Vials and Teflon-faced septa Disposable filters for syringes and for filtration of HPLC buffers Liquid chromatography apparatus equipped with multiwavelength detector Melting-point apparatus
Synthesis of Modified Oligonucleotides and Conjugates
4.3.3 Current Protocols in Nucleic Acid Chemistry
Synthesize 2-methoxy-6-chloro-9-(ω-hydroxyhexylamino)-acridine S.1b 1. Place 840 mg (7.18 mmol) 6-amino-1-hexanol, 1 g (3.59 mmol) 6,9-dichloro-2methoxyacridine, and 2.5 g phenol in a 25-mL round-bottomed flask equipped with a magnetic stir-bar, a reflux condenser, and a calcium chloride drying tube. Heat 80 to 90 min at 100°C. 2. Perform TLC analysis on a silica-gel plate using 90:10 (v/v) CH 2Cl2/MeOH as the eluent to check that the reaction is complete. Dilute an aliquot 10-fold with MeOH and load 1 µl on the TLC plate. This should show the disappearance of 6,9-dichloro-2-methoxyacridine (Rf = 0.9) and the formation of a new compound (Rf = 0.18).
3. Allow the mixture to cool, dilute it with 2.5 mL MeOH, and add the solution dropwise to a magnetically stirred 2 M NaOH solution (20 mL contained in a 100-mL beaker). Maintain stirring for 15 min. 4. Filter the yellow precipitate using a porosity 4 filter and wash it with water until neutral. Crystallize twice from 20:80 (v/v) H2O/MeOH. Expected yield: 80% (1.03 g, 2.87 mmol).
5. Analyze the product by TLC using silica-gel plates and 75:25 (v/v) CH2Cl2/MeOH as eluent. Dilute 1 to 2 mg in 100 µl MeOH and use 1 µl for spotting. In addition to 2-methoxy-6-chloro-9-(w-hydroxyhexylamino)-acridine (S.1b, Rf = 0.58),TLC analysis will show three side products, identified as the starting material 6,9-dichloro-2-methoxyacridine (Rf = 0.85), 2-methoxy-6-chloro-9-acridone (Rf = 0.81), and an unidentified third product (Rf = 0.39). These three products do not react during subsequent steps and are easily removed from the conjugates during purification. Reversed-phase HPLC as reported in Asseline et al., 1986 can also be used. Purity should be ∼95%. Characterize the product by other analytical methods as desired. Melting point: 152° to 153°C. H-NMR (DMSO-d6): δ 1.15-1.40 (m, 6H, CH2CH2CH2), 1.60-1.75 (m, 2H, CH2), 3.203.33 (m, 3H, CH2N + NH), 3.61-3.75 (m, 2H, CH2OH), 3.90 (s, 3H, OCH3), 4.20-4.28, (m, 1H), 7.25-7.88 (m, 5H, Acr), 8.25-8.38 (m, 1H, H8 Acr).
1
Mass analysis: I.S. Polarity positive. Calculated for C20H23ClN2O2: M+H= 359.18 and 361.18. Found 359.5 and 361.5.
6. Check for the absence of sodium phenolate by TLC analysis using the conditions described in step 5. Place plate in fume hood and dry using a hair dryer. Spray the TLC plate with a solution of 50 mg 2,6-dibromo-4-benzoquinone-N-chloroimine (DBPNC) in 20 mL ethanol and heat with a TLC drying plate or in an oven at 100°–130°C for several minutes. Phenol will give a blue-colored spot.
Direct Attachment of Conjugate Groups to the 5′ Terminus of Oligodeoxyribonucleotides
Prepare [2-methoxy-6-chloro-9-(ω-hexylamino)-acridinyl]-(2-cyanoethyl)-N,N-diisopropyl-phosphoramidite, S.1c 7. Place 300 mg (0.83 mmol) 2-methoxy-6-chloro-9-(ω-hydroxyhexylamino)acridine, S.1b, in a 25-mL round-bottomed flask and dry it by three rounds of coevaporation with anhydrous acetonitrile (3 × 5 mL). 8. Place a stir bar in the flask and stopper it with a septum. Push a needle through the septum and leave the flask in a P2O5-containing desiccator under vacuum overnight.
4.3.4 Current Protocols in Nucleic Acid Chemistry
9. Fill the desiccator with nitrogen before opening it. 10. Under argon atmosphere and magnetic stirring, add with a syringe 6 mL anhydrous CH3CN, 0.32 mL DIEA (235 mg, 1.82 mmol), and 0.2 mL 2-cyanoethyl-N,N-diisopropylchlorophosphite (216 mg, 0.91 mmol) at room temperature. 11. Let reaction proceed 30 min. Monitor its progress by TLC on a silica-gel plate using 50:50:4 (v/v/v) ethyl acetate:hexane:Et3N as eluent. Pre-elute the TLC plate once with the eluent, then load 1 µl of the reaction mixture and elute. After 30 min the starting material S.1b (Rf = 0.10) is transformed into two new compounds, a main product (≈80%; Rf = 0.50) and a side-product (≈15%; Rf = 0.65). Trace amounts of the starting material are also observed.
12. Add 20 mL CH2Cl2 and wash the organic layer with 3 mL of 10% (w/v) aqueous Na2CO3 and then 3 mL of saturated NaCl (brine). Decant the organic phase, dry it over MgSO4, and concentrate it to dryness. 13. Apply the residue, diluted with 2 to 3 mL anhydrous CH3CN to a silica-gel chromatography column (3 cm × 45 cm, containing 60 g silica gel) and elute with 500 mL of 50:50:4 (v/v/v) ethyl acetate:hexane:Et 3N. Monitor the fractions by TLC analysis using 50:50:4 (v/v/v) ethyl acetate:hexane:Et 3N as eluent, and collect the main product (Rf = 0.50). 14. Pool the fractions containing the pure product, and remove the solvent under reduced pressure. Coevaporate the residue twice using 8 mL anhydrous CH3CN each time. Expected yield: 65% (300 mg, 0.54 mmol) of a yellow oil. Purified acridinyl phosphoramidite S.1c can be stored at −20°C for a few months and should be reconstituted in anhydrous acetonitrile just prior to use (add a few pearls of 3-Å molecular sieves and wait ∼30 min before using the solution). P-NMR (CDCl3): δ 143.52 ppm.
31
H-NMR (CDCl3): δ 1.09-1.20 (m, 12H-[C(H)(CH3)2]2), 1.35-1.50 (m, 2H, CH2), 1.561.68 (m, 4H, CH2CH2), 1.70-1.83 (m, 2H, CH2), 2.61 (t, 2H, J = 6.34 Hz, CH2CN), 3.20-3.33 (m, 3H, CH2N + NH), 3.50-3.87 (m, 6H, CH2OP, (2 CH)), 3.97 (s, 3H, OCH3), 7.17-8.10 (m, 6H, Acr) 1
Couple the acridinyl phosphoramidite S.1c to 5′ end of oligodeoxyribonucleotide chain Automated coupling: 15a. When employing standard solid-phase DNA oligonucleotide synthesis cycles (1µmol scale) according to the classical phosphoramidite method, perform an additional detritylation step. 16a. Place a 0.1 M solution of the acridinyl phosphoramidite S.1c in anhydrous CH3CN on the synthesizer. Carry out coupling by recycling a mixture of 0.1 mL of the acridinyl phosphoramidite, 0.5 mL of 0.4 M 1H-tetrazole in anhydrous CH3CN, and 0.1 mL anhydrous CH3CN for 5 min. Repeat. For synthesizers without a recycle program, perform a double coupling step. For optimal coupling yields, changes in phosphoramidite concentration may be required depending on the synthesizer used.
17a. Remove the excess phosphoramidite and tetrazole, and perform an iodine oxidation reaction according to the standard procedure (UNIT 3.3, APPENDIX 3C).
Synthesis of Modified Oligonucleotides and Conjugates
4.3.5 Current Protocols in Nucleic Acid Chemistry
Manual coupling: 15b. When performing standard solid-phase oligodeoxyribonucleotide synthesis (1µmol scale) according to the classical phosphoramidite method, place the oligonucleotide bound to the support in a short (4-mL) vial stoppered with a septum. Push a needle through the septum and leave the vial in a desiccator containing P 2O5 under vacuum overnight. The oligonucleotide must have a free 5′-hydroxy group.
16b. Fill the desiccator with nitrogen before opening it. With a syringe, add a mixture of phosphoramidite S.1c (0.15 mL of a 0.15 M solution in anhydrous CH3CN) and 1H-tetrazole (0.5 mL of a 0.5 M solution in anhydrous CH 3CN) to the support-linked oligonucleotide. Leave the mixture for 10 min, shaking gently by hand from time to time. 17b. Remove the excess reagents with a syringe and perform an oxidation reaction by adding 1 mL of an aqueous iodine solution that is normally used on the synthesizer. Remove the iodine solution after 1 min and wash the support extensively with CH3CN. Deprotect the acridine-oligodeoxyribonucleotide conjugates 18. Treat the support bearing the acridine-oligodeoxyribonucleotide conjugates with 5 mL of 0.4 M NaOH in 50:50 (v/v) MeOH/H2O at room temperature. 19. After 1 to 2 hr, remove the solid support by filtration. Wash it twice with 0.5 mL water. Maintain the yellow solution at room temperature until deprotection is complete. The time required for oligonucleotide deprotection depends on the base composition of the sequence and on the nature of the protective groups used to protect the nucleic bases. Removal of the isobutyryl group from guanine residues requires ∼30 to 35 hr under these conditions.
20. Neutralize the solution (containing the oligonucleotide conjugate S.1d) by adding Dowex 50 ion-exchange resin until the pH of the solution reaches 6. Remove the resin by filtration and wash it with water until the resin becomes pale yellow in color. 21. Concentrate the solution under vacuum to remove MeOH. Add ∼10 mL water, then extract the aqueous solution three times with 3 mL ethyl acetate each time. Concentrate the aqueous solution to ∼3 to 4 mL. 22. Filter the solution through a 0.45-µm disposable filter to remove any particulates and prevent the clogging of HPLC columns. Purify and characterize the oligonucleotideacridine conjugate (see Support Protocol). SUPPORT PROTOCOL
Direct Attachment of Conjugate Groups to the 5′ Terminus of Oligodeoxyribonucleotides
PURIFICATION AND CHARACTERIZATION OF OLIGONUCLEOTIDE-ACRIDINE CONJUGATES The following general procedure is applicable to the purification of 10- to 20-mer oligodeoxyribonucleotides-acridine conjugates, assuming that the sequences under consideration are not likely to form self-associated complexes such as G-tetrads. Should this be the case, a specific purification procedure—not provided in this unit—must be used. Purification can by improved by performing ion-exchange chromatography at pH 12 (Raynaud et al., 1996). Another solution to prevent the formation of G tetrads is to partially replace 2’-deoxyguanosine with 7-deaza-2′deoxyguanosine (Raynaud et al., 1996). Generally, the crude oligodeoxyribonucleotide conjugates obtained from the protocol described above are purified by ion-exchange chromatography. After a desalting step, the
4.3.6 Current Protocols in Nucleic Acid Chemistry
purity of the conjugates is verified on a reversed-phase column; in most cases this will show that sufficient purity has been achieved. Alternatively, reversed-phase chromatography allows easy purification of oligodeoxyribonucleotide-acridine conjugates when acridine is bound to the 5′ end of oligonucleotides (making the conjugates more lipophilic than the underivatized oligonucleotides). Sometimes the conjugate can be insufficiently pure and a second purification is required. Usually it is performed using the system that was not used for the first purification (i.e., a second purification step can be made using reversed-phase after a first purification by ion-exchange chromatography and vice versa). In all cases, oligodeoxyribonucleotide-acridine conjugates are detected during analysis and purification by measuring UV absorption at 254 or 260 nm and at 425 nm (only the acridine moiety of the conjugate absorbs light at that wavelength). Materials 0.01 bis-Tris, pH 6 or 0.01 M NaH2PO4, pH 6.8 (APPENDIX 2A), each containing 10% or 10% HPLC-grade methanol (MeOH) Sodium chloride (NaCl) 0.025 M Tris⋅Cl, pH 7 (APPENDIX 2A) Acetonitrile (CH3CN) 1 M triethylammonium acetate (TEAA) buffer, pH 7 (stock solution; see recipe) 0.01 M Tris⋅Cl, pH 8 (APPENDIX 2A) 1 U snake venom phosphodiesterase (3′ exonuclease) 10 µg alkaline phosphatase Ion-exchange columns: Mono Q HR 5/5 or HR 10/10 (Amersham Pharmacia Biotech) or DEAE (Waters) Reversed-phase columns: e.g., Lichrospher 100 RP 18 (5 µm, 125 × 4 mm, or 10 µm, 250 ×10 mm; Merck) or CC Nucleosil 100-5 C18 (125/4) column (Macherey-Nagel) Desalting columns: HR 10/10 columns (Amersham Pharmacia Biotech) packed with Lichroprep RP 18 (Merck) or Sephadex G-10 or G-25 resin 1. Analyze the crude oligonucleotide-acridine conjugate solution via chromatography by one of the following procedures, generally loading 10 to 20 µl of the crude solution onto the column: a. Ion-exchange chromatography with Mono Q HR 5/5 or HR 10/10 column: Use a linear gradient of 0 to 100% 1 M NaCl in 0.01 M bis-Tris, pH 6, containing 10% or 20% MeOH, or 0 to 100% 1.5 M NaCl in 0.01 M NaH2PO4, pH 6.8, containing 10% or 20% MeOH, with a flow rate of 1 mL/min (HR 5/5) or 4 mL/min (HR 10/10). b. Ion-exchange chromatography with DEAE column (100 × 10 mm) : Use a linear gradient of 0 to 100% 1.5 M NaCl in 0.025 M Tris⋅Cl, pH 7, containing 10% MeOH, with a flow rate of 1 mL/min. c. Reversed-phase chromatography with Lichrospher 100 RP 18 column (5 µm, 125 × 4 mm; or 10 µm, 250 × 10 mm): Use a linear gradient of CH3CN (5% to 80%) in 0.1 M aqueous triethylammonium acetate, pH 7, with a flow rate of 1 mL/min (5-µm column) or 4 mL/min (10-µm column). d. Reversed-phase chromatography with CC Nucleosil 100-5 C18 (125/4) column: Use a linear gradient of CH3CN (5% to 80%) in 0.1 M aqueous triethylammonium acetate, pH 7, with a flow rate of 1 mL/min. The gradients used must be chosen so as to afford the best separation. Usually an increasing concentration of 1% of 1 M or 1.5 M NaCl per minute is used for ion-exchange chromatography and an increasing concentration of ∼1% CH3CN per minute is used for reversedphase chromatography.
Synthesis of Modified Oligonucleotides and Conjugates
4.3.7 Current Protocols in Nucleic Acid Chemistry
2. Purify the remaining oligonucleotide-acridine conjugate by preparative reversedphase or ion-exchange chromatography column. Use any type of column that was described in step 1, according to the recommended conditions. Usually 1 mmol of crude oligonucleotide-acridine conjugates can be purified in two or three runs on Mono Q HR 10/10 column. On preparative reversed-phase columns, reasonable purification can be achieved in a single run, but it is better to perform two. Alternatively, purification can be achieved on analytical columns by performing five or more runs.
3. Pool the fractions containing the conjugate and remove the organic solvents by evaporation under reduced pressure. 4. If ion-exchange purification was used in step 2, desalt the conjugate using appropriate desalting column. If reversed-phase purification was used, remove triethylammonium acetate by three consecutive lyophilizations. Resuspend the sample in 1 to 2 mL water between lyophilizations. 5. Analyze the oligonucleotide-acridine conjugate by ion-exchange chromatography when the purification was performed by reversed-phase, or by reversed-phase when the purification was achieved by ion-exchange, using the columns and parameters described in step 1. For example, analyze on a Lichrospher 100 RP 18 (5 mm; 125 mm × 4 mm) column from Merck using a linear gradient of CH3CN (5% to 35% over 40 min) in 0.1 M aqueous triethylammonium acetate, pH 7, with a flow rate of 1 mL/min. Expected retention time is 28 min 18 sec for the acridine-oligonucleotide conjugate Acr(CH2)6pd5[T3C2T C2TCT]. After purification, UV spectra of oligodeoxyribonucleotide-acridine conjugates show absorptions characteristic to the ligand. A typical spectrum of an oligonucleotide-acridine conjugate is shown in Figure 4.3.4 (left). In addition, nuclease digestion of the conjugates and reversed-phase HPLC analysis of the resulting monomers can be used to ascertain full removal of the protective groups and base composition.
Direct Attachment of Conjugate Groups to the 5′ Terminus of Oligodeoxyribonucleotides
Figure 4.3.4 Absorption spectra of Acr(CH2)6pd[T3C2T C2TCT] (left) and Pso(CH2)6pd[T4 5-Me C2T5-MeCT5-MeC3T5-MeCT] (right) recorded in water.
4.3.8 Current Protocols in Nucleic Acid Chemistry
6. Hydrolyze the oligonucleotide-acridine conjugate S.1d with nucleases by placing the following in a 1.5-mL microcentrifuge tube: ∼1 OD unit conjugate S.1d in 10 µl H2O 50 µl 0.01 M Tris⋅Cl, pH 8 1 U snake venom phosphodiesterase 10 µg alkaline phosphatase. Incubate 2 to 3 hr at 37°C. 7. Inactivate the enzyme by heating the mixture at 90°C for 2 min. 8. Analyse the hydrolysate by reversed-phase HPLC: e.g., using a Lichrospher 100 RP 18 column with a gradient of CH3CN (0% for 10 min, then 0 to 24% CH3CN over 30 min, then 24% to 56% CH3CN over 20 min) in 0.1 M aqueous triethylammonium acetate, pH 7, with a flow rate of 1 mL/min. These conditions permit the separation of natural nucleosides and a variety of modified nucleosides. Identification can be made by comparison with authentic nucleosides. For example: RtdC ≈ 5 min, Rt 5-MedC ≈ 10 min, RtT ≈ 13 min, RtdG ≈ 14 min 30 sec, RtdA ≈ 17 min 30 sec. Under these conditions the retention time of the acridine-linker derivative S.1b is ∼51 min. Prolonged incubation at pH 8 induces degradation of S.1b. Additional characterization can be made by MALDI and ESI mass spectrometry (UNITS 10.1 & 10.2). Acr(CH2)6pd[T3C2T C2TCT] has been characterized by MALDI-TOF using 2,4,6-trihydroxyacetophenone as matrix in the presence of diammonium L-tartrate. Quantification of oligonucleotide-acridine conjugates can be made by using e = 8850 M−1 cm−1 at l = 425 nm (Asseline and Thuong, 1988). Usually when the synthesis is performed at the micromole scale ∼15 to 20 OD units of pure oligonucleotide-acridine conjugate 15-mer with mixed bases is obtained.
DIRECT ADDITION OF PSORALEN DERIVATIVES TO THE 5′ END OF OLIGODEOXYRIBONUCLEOTIDES
BASIC PROTOCOL 2
This strategy (illustrated in Figs. 4.3.1, 4.3.2, and 4.3.3) involves the attachment of a hydroxylated linker to the psoralen ligand. Specifically, 5-methoxypsoralen S.2a is demethylated to give the 5-hydroxypsoralen S.2b. The latter is reacted with 6-bromohexanol in the presence of K2CO3 (following a procedure adapted from that previously reported by Kurfürst et al., 1993) to give the psoralen derivative S.2c. Phosphitylation of S.2c affords S.2d (in another procedure adapted from the same reference). The phosphoramidite derivative S.2d is then condensed with the 5′-terminal hydroxyl of oligodeoxyribonucleotides bound to solid supports. This conjugation is completed by the deprotection, purification, and characterization of the psoralenyl-oligonucleotide conjugates S.2e. Materials 5-Methoxypsoralen (S.2a) Pyridine hydrochloride CaCl2 Dichloromethane (CH2Cl2), distilled from P2O5 and passed over activated, basic aluminum oxide Methanol (MeOH), distilled P2O5 N,N-Dimethylformamide, redistilled under vacuum over ninhydrin and stored over 4-Å molecular sieves 6-Bromo-1-hexanol Potassium carbonate, anhydrous
Synthesis of Modified Oligonucleotides and Conjugates
4.3.9 Current Protocols in Nucleic Acid Chemistry
Ethyl acetate Pyridine, anhydrous N,N-Diisopropylethylamine (DIEA), distilled from KOH Sodium sulfate, anhydrous 2-Cyanoethyl-N,N-diisopropylchlorophosphite Triethylamine (Et3N) 10% (w/v) aqueous sodium carbonate (NaHCO3) Cold saturated aqueous NaCl Acetonitrile (CH3CN), DNA synthesis grade, anhydrous and stored over 3 Å-molecular sieves Oligodeoxyribonucleotides bound to solid supports, such as controlled-pore glass (CPG; UNIT 3.1), synthesized by classic phosphoramidite chemistry (1-µmol scale) DNA synthesis reagents recommended by synthesizer manufacturer Concentrated (25%) aqueous ammonia 25-mL round-bottomed flask Reflux condenser Drying tube Nitrogen gas Oven Analytical thin-layer chromatography (TLC) setup and silica-gel plates: e.g., Merck 5554 Kieselgel 60F plates, including UV lamp for detection Filter funnel, porosity 4 Desiccator Argon Silica gel for column chromatography: Merck 9387 Kieselgel 60 or Merck 7734 Kieselgel 60 Chromatographic columns: (3 cm × 50 cm) and (1.5 cm × 40 cm) Prepare 5-(hydroxypsoralen), S.2b 1. Place 1 g (4.64 mmol) 5-(methoxypsoralen) S.2a and 4.27 g (37 mmol) pyridine hydrochloride in a 25-mL round-bottomed flask equipped with a reflux condenser and a calcium chloride drying tube, under a nitrogen atmosphere. 2. Verify that pyridine hydrochloride is at the bottom of the flask and heat the mixture 90 min at 180°C. Monitor the reaction by TLC using 90:10 (v/v) CH2Cl2/MeOH as eluent. The starting material S.2a (Rf = 0.9) will be transformed into S.2b (Rf = 0.50).
3. Allow the mixture to cool to room temperature. Solubilize the reaction mixture with 3 mL MeOH and slowly pour the solution in 50 mL cold water while stirring magnetically to precipitate S.2b. Filter the solid over a filter funnel (porosity 4) and dry it over P2O5 in a desiccator for 2 days. Analyze S.2b again by TLC. The Rf value of S.2b is 0.50 when 90:10 (v/v) CH2Cl2/MeOH is used as eluent, and 0.65 when 50:50 (v/v) CH2Cl2/ethyl acetate is the eluent. Expected yield: 95% (885 mg, 4.38 mmol). Characterize the product by appropriate analytical methods. Melting point: 280°C. Direct Attachment of Conjugate Groups to the 5′ Terminus of Oligodeoxyribonucleotides
H-NMR (DMSO-d6): δ 3.34 (br s, 1H), 6.23 (d, 1H, J = 9.7 Hz, C3 Pso), 7.14 (S, 1H, C8 Pso), 7.18 (d, 1H, J = 2.2 Hz, C4’ Pso), 7.89 (d, 1H, J = 2.3 Hz, C5’ Pso), 8.23 (d, 1H, J = 9.5 Hz, C4 Pso). 1
Mass analysis. I.S. polarity positive. Calculated for C11H6O4: M+H=203.0. Found 203.0.
4.3.10 Current Protocols in Nucleic Acid Chemistry
Prepare 5-(6-hydroxyhexyloxy)-psoralen, S.2c 4. Place a solution of 5-hydroxypsoralen S.2b (0.6 g, 2.97 mmol) in 10 mL anhydrous N,N-dimethylformamide in a 25-mL round-bottomed flask equipped with a reflux condenser and a calcium chloride drying tube. Add successively 1.16 mL 6-bromo1-hexanol (1.61 g, 8.91 mmol) and 0.61 g anhydrous potassium carbonate (4.45 mmol). 5. Heat the flask at 65°C in the dark under an argon atmosphere and stir for 4 hr. 6. Allow the mixture to cool to room temperature and remove insoluble salts by filtration, then concentrate the filtrate to dryness under reduced pressure. 7. Purify the residue (2.5 g) on a silica-gel column (3 cm × 50 cm, 70 g silica) using increasing concentrations of MeOH in CH 2Cl2 (1:100 to 3:97, v/v): 200 mL of 1% MeOH in CH2Cl2; 200 mL of 2% MeOH in CH2Cl2; 200 mL of 2.5% MeOH in CH2Cl2; and 200 mL of 3% MeOH in CH2Cl2. 8. Monitor the fractions by silica-gel TLC using 90:10 (v/v) CH2Cl2/MeOH or 50:50 (v/v) CH2Cl2/ethyl acetate as eluent. Collect the fractions containing the pure product and remove the solvent under reduced pressure. The Rf value of S.2c is 0.43 when 90:10 (v/v) CH2Cl2/MeOH is the eluent, and 0.45 when 50:50 (v/v) CH2Cl2/ethyl acetate is the eluent. Expected yield: 75% (672 mg, 2.22 mmol). Melting point: 100°C. H-NMR (CDCl3): @ 1.38-1.60 (m, 6H), 1.82-1.95 (m, 2Η, ΧΗ2), 3.60-3.71 (m, 2H, CH2OH), 4.45 (t, 2H, J = 6.4 Hz, -CH2OAr), 6.27 (d, 1H, J = 9.7 Hz, C3 Pso), 6.94 (d, 1H, J = 2.3 Hz, C4’ Pso), 7.26 (s, 1H, C8), 7.58 (d, 1H, J = 2.4 Hz, C5’ Pso), 8.15 (d, 1H, J = 9.5 Hz, C4 Pso) 1
Mass analysis. I.S. polarity positive. Calculated for C17H18O5: M+H=303.0. Found 303.0.
Prepare [5-(ω-hexyloxy)-psoralenyl]-(2-cyanoethyl)-N,N-diisopropylphosphoramidite S.2d 9. Place 0.30 g 5-(6-hydroxyhexyloxy)-psoralen (1 mmol; S.2c) in a 25-mL round-bottomed flask, dry it by coevaporation with anhydrous pyridine and leave under vacuum for at least 12 hr. See Basic Protocol 1, steps 7, 8 and 9, for procedure.
10. Under a nitrogen atmosphere and magnetic stirring at room temperature add using a syringe 6 mL dichloromethane, 0.35 mL DIEA (0.258 g, 2 mmol) and then dropwise 0.29 mL 2-cyanoethyl-N,N-diisopropylchlorophosphite (0.307 mg, 3 mmol). Leave 20 min at room temperature. Monitor the reaction by silica-gel TLC using 95:5 (v/v) ethyl acetate/Et3N as eluent. Pre-elute the TLC plate with eluent before spotting the samples. 11. Shake the solution twice with 2 mL of 10% (w/v) aqueous Na2CO3 and once with 2 mL of a cold saturated aqueous NaCl solution. Dry the organic layer over anhydrous sodium sulfate and concentrate it to dryness. 12. Purify the residue (500 mg) on a silica-gel column (1.5 cm × 40 cm, 20 g silica) using 95:5 (v/v) ethyl acetate/Et3N as eluent. Monitor the fractions by silica-gel TLC using 95:5 (v/v) ethyl acetate/Et3N as eluent. The Rf value of S.2d is 0.87.
Synthesis of Modified Oligonucleotides and Conjugates
4.3.11 Current Protocols in Nucleic Acid Chemistry
13. Pool the fractions containing the pure product. Remove the solvents under reduced pressure and coevaporate with anhydrous CH3CN. Expected yield: 65% (326 mg, 0.65 mmol) of a colorless oil. Purified psoralenyl phosphoramidite S.2d can be stored at −20°C for a few months and should be reconstituted in anhydrous acetonitrile just prior to use (add a few pearls of 3-Å molecular sieves and wait ∼30 min before using the solution). P-NMR (CDCl3): d 149.47 ppm
31
H-NMR (CDCl3): d 1.12-1.23 (m, 12H -[C(H)(CH3)2]2), 1.38-1.70 (m, 6H, (CH2)3), 1.82-1.85 (m, 2H, CH2), 2.60 (t, 2H, J = 6. Hz, CH2CN), 3.52-3.73 (m, 4H, CH2O, [C(H)]2), 3.74-3.90 (m, 2H, CH2OP), 4.45 (t, 2H, J = 6.33 Hz, -CH2OAr), 6.27 (d, 1H, J = 9.8 Hz, C3 Pso), 6.94 (d, 1H, J = 2 Hz, C4’ Pso), 7.13 (s, 1H, C8), 7.58 (d, 1H, J = 2.3 Hz, C5’ Pso), 8.15 (d, 1H, J = 9.8 Hz, C4 Pso). 1
Couple the psoralenylphosphoramidite S.2d to the 5′-end of oligodeoxyribonucleotides Automated coupling: 14a. After standard solid-phase DNA oligonucleotide synthesis (1-µmol scale) according to the classical phosphoramide method, perform an additional detritylation step. 15a. Place a 0.1 M solution of the psoralenyl phosphoramidite S.2d in anhydrous CH3CN on the synthesizer. Carry out coupling by recycling a mixture of 0.1 mL of the psoralenyl phosphoramidite, 0.5 mL of 0.4 M 1H-tetrazole in anhydrous CH3CN, and 0.1 mL anhydrous CH3CN for 5 min. Repeat. For synthesizers without a “recycle” program, perform a double coupling step. For optimal coupling yields changes in amidite concentration may be required, depending on the synthesizers used.
16a. Remove the excess phosphoramidite and tetrazole, and perform an aqueous iodine oxidation reaction according to the standard procedure. Manual coupling: 14b. When performing standard solid-phase oligodeoxyribonucleotide synthesis (1µmol scale) according to the classical phosphoramidite method, place the oligonucleotide bound to the support in a short (4-mL) vial stoppered with a septum. Push a needle through the septum and leave the vial in a desiccator containing P2O5 under vacuum overnight. The oligonucleotide must have a 5′-hydroxy group.
15b. Fill the desiccator with nitrogen before opening it. Using a syringe, add a mixture of phosphoramidite S.2d (0.15 mL of a 0.15 M solution in anhydrous CH3CN) and 1H-tetrazole (0.5 mL of a 0.5 M solution in anhydrous CH3CN) to the support-linked oligonucleotide. Leave the mixture at room temperature for 10 min, shaking gently by hand from time to time. 16b. Remove the excess reagents with a syringe and perform an oxidation reaction by adding 1 mL iodine solution that is normally used on the synthesizer. Remove the iodine solution after 1 min and wash the support extensively with CH3CN. Direct Attachment of Conjugate Groups to the 5′ Terminus of Oligodeoxyribonucleotides
Deprotect oligodeoxyribonucleotide-psoralen conjugates 17. Add 5 mL concentrated 25% aqueous ammonia to a vial containing the psoralen-oligodeoxyribonucleotide conjugate bound to the support and leave it 1 hr at 55°C.
4.3.12 Current Protocols in Nucleic Acid Chemistry
18. Discard the support and leave the ammonium hydroxide solution an additional 6 hr at 55°C. 19. Evaporate the ammoniacal solution to dryness. 20. Solubilize the crude material S.2e with 12 mL water and extract three times with 3 mL ethyl acetate each time. Reduce the volume of the solution to ∼3 to 4 mL under reduced pressure. 21. Purify and characterize the oligodeoxyribonucleotide-psoralen conjugates (see Basic Protocol 1; the conjugates can be detected at 260 and 320 nm). For example analysis performed on a Lichrospher 100 RP 18 (5 mm; 125 mm × 4 mm) column using a linear gradient of CH3CN (5% to 35% over 40 min) in 0.1 M aqueous triethylammonium acetate, pH 7, at a flow rate of 1 mL/min indicates a retention time of 30 min 16 sec for the psoralen-oligonucleotide conjugate Pso(CH2)6pd[T45-MeC2T5-MeCT5-MeC3T5-MeCT]. As for oligonucleotide-acridine conjugates, base composition can be verified by nuclease degradation (same protocol). In this case reversed-phase analysis of hydrolysates performed under the conditions described for the oligonucleotide-acridine conjugates indicates a retention time of 53 min 36 sec for S.2c. Quantification of oligonucleotide- psoralen conjugates can be made by using e ≈ 10 000 M−1 cm−1 at l = 320 nm (unpub. observ.). When the synthesis is performed at the micromole scale, ∼15 to 20 OD units of pure oligonucleotide-psoralen conjugates 15-mer with mixed bases are obtained. The absorption spectrum of the psoralen-oligonucleotide conjugate Pso(CH2)6pd[T45-MeC2T5-MeC T5-MeC3T5-MeCT] is represented in Figure 4.3.4 (right).
REAGENTS AND SOLUTIONS 1M triethylammonium acetate (TEAA) buffer, pH 7 (stock solution) In a fume hood, add successively to a 1 liter beaker (equipped with a stirring bar) distilled water (810 mL), triethylamine (134 mL) and glacial acetic acid (57 mL). Mix thoroughly and adjust to pH 7 by adding either a few drops of triethylamine or a few drops of glacial acetic acid. COMMENTARY Background Information Two strategies can be used to attach ligands to the 5′ end of oligodeoxyribonucleotides. This unit describes one of these strategies, which involves the direct addition of a ligand to the 5′ end of an oligodeoxynucleotide during its initial synthesis via the phosphoramidite approach. Although methods have been developed for derivatizing the 5′ terminus of oligodeoxyribonucleotides in homogenous solution (Thuong et al., 1984, 1987; Asseline and Thuong, 1984; Asseline et al., 1988), only conjugation reactions on solid supports are reported in this unit (Thuong and Chassignol 1988, Dupret et al., 1994; Asseline et al., 1996). This strategy is applicable when the ligand is available in sufficient amounts, and its solubility and chemical stability are compatible with the conditions required for the preparation of its phosphoramidite or H-phosphonate deriva-
tives. In addition, the ligand should be stable under the conditions required for the coupling reaction and to those conditions used for complete deprotection of the oligodeoxynucleotide chain and its release from the support. The second strategy, not covered here, involves the incorporation of appropriate functional groups into two unprotected reactants. The coupling of these functionalized reactants results in the formation of oligodeoxyribonucleotide conjugates. Various oligodeoxyribonucleotide conjugates can be prepared using this strategy from only one oligodeoxyribonucleotide synthesis, provided that the required amount for each conjugate is low. Future units will describe the coupling of a number of ligands (intercalators, photoreactive and cleavage reagents, and labels) to oligodeoxyribonucleotides post-synthetically. These ligands are typically 2-methoxy-6-choro-9-
Synthesis of Modified Oligonucleotides and Conjugates
4.3.13 Current Protocols in Nucleic Acid Chemistry
Direct Attachment of Conjugate Groups to the 5′ Terminus of Oligodeoxyribonucleotides
aminoacridine as an intercalator, psoralen as a photo-cross-linking reagent, and phenanthroline-Cu as a cleavage reagent. More recently, the authors have used thiazole orange as a reporter group. This strategy involves the incorporation of linkers carrying suitable functional groups into ligands and the addition of amino, phosphorothioate, phosphate, or sulfhydryl functions to the 5′ end of oligonucleotides, as well as coupling methods for linking both entities. Alternatively, many reporter groups bearing functional groups that will react with 5′-thiol, 5′-terminal phosphorothioate, and 5′-amino groups are available from commercial sources. Heterobifunctional reagents, which allow reaction with a thiol function and with the primary amino function of various ligands, are also available commercially. These reagents, listed in UNIT 4.2, are very useful when there is no need for conjugates to have a well-defined linker between the oligodeoxyribonucleotide and the ligand. The coupling methods developed in this unit and future units can be used to prepare oligodeoxyribonucleotide conjugates composed of natural β-deoxyribonucleosides (Thuong and Chassignol 1988, Dupret et al., 1994, Asseline et al., 1996), unnatural α-D-deoxyribonucleosides (Kurfürst et al., 1993), or 2′-Omethylribonucleosides (unpub. observ.). When the chain assembly is performed in the usual (3′→5′) orientation, the modifying steps (i.e., direct incorporation of the ligand or the masked 5′-terminal functional group) are carried out at the end of the chain assembly just prior to the deprotection step. Given that oligodeoxyribonucleotides can be purchased fully protected and bound to the support, 5′-end modification can be performed manually. Procedures reported in this unit may be used to prepare oligodeoxyribonucleotides covalently linked via their 5′ end to molecules such as intercalating agents, and other reactive compounds the properties of which are described in UNIT 4.2. In many examples, oligodeoxyribonucleotide conjugates properties, such as strong complex stabilization when the ligand is an intercalator (Asseline et al., 1984, 1996, Sun et al., 1989; Giovannangeli et al., 1996) or best cleavage or cross-linking efficiency when the ligand is a reactive group, are largely dependent on the geometry of the complex formed between the ligand and its target (Takasugi et al., 1991; Giovannangeli et al., 1992; Costes et al., 1993, Grigoriev et al., 1993). Using these procedures linkage parameters between the oli-
godeoxyribonucleotide and the ligand, such as the size and nature of the linker connecting the two entities, may be varied to prepare oligodeoxyribonucleotide-ligand conjugates exhibiting optimal properties for specific experimental needs.
Critical Parameters and Troubleshooting In the case of acridine-containing oligodeoxyribonucleotides, the use of ammonia for the deprotection step must be avoided since it induces cleavage of the C9-N bond between the acridine and the linker. Therefore, a 0.4 N sodium hydroxide solution in 50:50 (v/v) H2O/MeOH is recommended. It is also recommended that the oligonucleotide-acridine conjugate solutions be stored between pH 6 and 7. Storage at pH values between 7 and 9 leads to considerable degradation. Protection of flasks and columns from light during the different steps of these protocols is recommended because acridine and psoralen derivatives are light-sensitive. In any case, purification steps must be as short as possible. It is always possible that the conditions required for deprotection of the conjugates may be incompatible with the stability of some modified nucleoside incorporated into the sequence of interest. To avoid obtaining a low yield of oligonucleotide-ligand conjugates, it is possible to deprotect an aliquot of the conjugates to verify the coupling efficiency of the amidite derivatives. If the coupling efficiency is insufficient, it is possible to perform additional coupling of the ligand. At the micromole scale it is usual to obtain about 20 OD units of pure conjugates when working with mixed DNA sequences. In some cases, when working with oligonucleotides containing sequences, inducing self associated structure, the purification step can be particularly challenging. In such cases, it is advisable to purify the acridine-oligonucleotide conjugates on a Mono-Q column at pH 12. In the case of sequences containing stretches of dG, the better way to solve the problem is to partially replace the dGs with 7-deaza-2′-deoxyguanosines (Raynaud et al., 1996).
Anticipated Results The yields reported for the various steps can be different when the syntheses are performed at scales other than those described. Using the protocols provided here and starting with 300 mg of the acridine-linker derivative S.1b, 300 mg of the purified acridine phosphoramidite S.1c can be obtained. This can be used to
4.3.14 Current Protocols in Nucleic Acid Chemistry
synthesize acridine-oligodeoxyribonucleotide conjugates S.1d. Usually 15 to 20 OD units of purified conjugates S.1d can be expected when the synthesis is performed at the µmol scale. In the case of the psoralen derivatives, starting with 310 mg of the psoralen-linker derivative S.2c it is possible to obtain 325 mg of the purified psoralen phosphoramidite derivative S.2d. The latter is then used to prepare psoralenoligodeoxyribonucleotide conjugates S.2e. When DNA synthesis is performed at the µmol scale, the yields obtained for conjugates S.2e (15 to 20 OD units) are similar to those obtained for the preparation of the conjugates S.1d.
Time Considerations Providing all reagents and materials required for each step are available, most of the reactions are simple and rapid. Preparation of compounds S.1b and S.2b requires 3 days including the drying step, while only two days are necessary to obtain compound S.2c. The time required for the preparation of phosphoramidite derivatives S.1c or S.2d is one day provided that the ligand-linker derivatives have been dried the previous day and left under vacuum in a desiccator overnight. Oligonucleotides chain assemblies and the addition of the ligand to the 5′-end of the oligonucleotide can be performed the same day when the ligand is added directly with the synthesizer. Otherwise the manual coupling requires leaving the support bearing the oligonucleotide under vacuum overnight. The deprotection step for psoralen-oligodeoxyribonucleotide conjugates S.2e takes a few hours while the duration of the deprotection step for acridine-oligodeoxyribonucleotide conjugates S.1d can be extended to almost two days. The time required for the purification of the ligand-oligonucleotide conjugates S.1d and S.2e can vary depending on the sequences. When two successive purification steps are necessary the time can be from five to ten days including rounds of lyophilization (overnight) or desalting and additional analyses. Characterization of the purified conjugates S.1d and S.2e can be achieved in three or four days.
Literature Cited Asseline, U., Thuong, N.T., and Hélène, C. 1986. Oligothymidylates substitutés en position 3′ par un dérivè de l’acridine. Nucleosides Nucleotides 5:45-63.
Asseline, U. and Thuong, N.T. 1988. Oligothymidylates substitués par un dérive de l’acridine en position 5′, à la fois en position 5′ et 3′ ou sur un phosphate internucleotidique. Nucleosides Nucleotides 7:431-455. Asseline, U., Toulmé, F., Thuong, N. T., Delarue, M., Montenay-Garestier, T., and Hélène, C. 1984. Oligodeoxynucleotides covalently linked to intercalating dyes as base sequence–specific ligands. Influence of dye attachment site. EMBO J. 3:795-800. Asseline, U., Bonfils, E., Dupret, D., and Thuong, N.T. 1996. Synthesis and binding properties of oligonucleotides covalently linked to an acridine derivative: A new study of the influence of the dye attachment site. Bioconjugate Chemistry 7:369-379. Costes, B., Girodon, E., Ghanem, N., Chassignol, M., Thuong, N.T., Dupret, D., and Goossens, M. 1993. Psoralen-modified oligonucleotide primers improve detection of mutations by denaturing gradient gel electrophoresis and provide an alternative to GC-clamping. Hum. Mol. Genet. 2:393-397. Dupret, D., Gossens, M., Chassignol, M., and Thuong, N.T. 1994. European Patent No. 0596028 A1,1994,05,11. Giovannangeli, C., Thuong, N.T., and Hélène, C. 1992. Oligodeoxynucleotide-directed photo-induced cross-linking of HIV proviral DNA via triple-helix formation. Nucleic Acids Res. 20:4275-4281. Giovannangeli, C., Perrouault, L., Escudé, C., Thuong, N.T., and Hélène, C. 1996. Specific inhibition of in vitro transcription elongation by triplex-forming oligonucleotide-intercalator conjugates targeted to HIV proviral DNA. Biochemistry 35:10539-10548. Grigoriev, M., Praseuth, D., Guieysse, A.L., Robin, P., Thuong, N.T., Hélène, C., and Harel-Bellan, A. 1993. Inhibition of gene expression by triple helix–directed DNA cross-linking at specific sites. Proc. Natl. Acad. Sci. USA. 90:35013505. Kurfürst, R., Roig, V., Chassignol, M., Asseline, U., and Thuong, N.T. 1993. Oligo-α-Deoxyribonucleotides with a modified nucleic base and covalently linked to reactive agents. Tetrahedron 49:6975-6990. Raynaud, F., Asseline, U., Roig, V., and Thuong, N.T. 1996. Synthesis and characterization of O6modified deoxyguanosine-containing oligodeoxyribonucleotides for triplex helix formation. Tetrahedron 52:2047-2064. Sun, J.S., François, J.C., Montenay-Garestier, T., Saison-Behmoaras, T., Roig, V., Thuong, N.T., and Hélène, C. 1989. Sequence-specific intercalating agents. Intercalation at specific sequences on duplex DNA via major groove recognition by oligonucleotide-intercalator conjugates. Proc. Natl. Acad. Sci. USA. 86:9198-9202.
Synthesis of Modified Oligonucleotides and Conjugates
4.3.15 Current Protocols in Nucleic Acid Chemistry
Takasugi, M., Guendouz, A., Chassignol, M., Decout, J.L., Lhomme, J., Thuong, N.T., and Hélène, C. 1991. Sequence-specific photo-induced cross-linking of the two strands of doublehelical DNA by a psoralen covalently linked to a triple helix forming oligonucleotide. Proc. Natl. Acad. Sci. USA. 88:5602-5606. Thuong, N.T. and Chassignol, M. 1988. Solid phase synthesis of oligo-α- and oligo-β-deoxynucleotides covalently linked to an acridine. Tetrahedron Lett. 29:5905-5908. Thuong, N.T., Hélène, C., and Asseline, U. 1984. European Patent No. 84-400143-8. 1989. U.S. Patent No. 4-835-263. Thuong, N.T., Asseline, U., Roig, V., Takasugi, M., an d Hélène, C. 1 98 7. Oligo(α-deoxynucleotide)s covalently linked to intercalating agents: Differential binding to ribo- and deoxyribopolynucleotides and stability towards nuclease digestion. Proc. Natl. Acad. Sci. USA. 84:5129-5133.
Contributed by Ulysse Asseline and Nguyen T. Thuong Centre de Biophysique Moléculaire, CNRS Orléans, France The authors would like to express their appreciation to their collaborators M. Chassignol, V. Roig, and Y. Aubert for their contribution to the development of varied oligonucleotide sequences linked to acridine and psoralen derivatives. This work was supported by Rhône-Poulenc, the Agence Nationale de Recherches sur le SIDA, and bio-Mérieux.
Direct Attachment of Conjugate Groups to the 5′ Terminus of Oligodeoxyribonucleotides
4.3.16 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
UNIT 4.4
This unit describes the synthesis of chimeric oligonucleotides in which the small (2′-5′)oligoriboadenylate activator of RNase L is covalently joined through a butanediol phosphate linker to a deoxyribooligonucleotide (Fig. 4.4.1). The products are termed “2-5A-antisense” when the deoxyribonucleotide portion of the chimera is targeted against a specific RNA. The overall synthetic strategy (see Basic Protocol 1) is based on the phosphite-triester approach to DNA/RNA synthesis (UNITS 3.3 & 3.5). Appropriately protected 2-cyanoethylphosphoramidite derivatives of adenosine, the butanediol linker, and the usual four deoxyribonucleosides are used for chain elongation, and the solid-phase methodology is employed with protected deoxyribonucleosides covalently linked to controlled-pore glass (CPG) through a long-chain alkyl amine (lcaa) and a succinyl moiety. 5′-Phosphorylation of the chimera completes the basic synthesis. After deprotection, the chimera is purified (see Basic Protocol 2) and characterized by a number of independent methods (see Basic Protocols 2 to 4). Two Support Protocols describe the synthesis of the central building block for the 2-5A domain of 2-5A-antisense oligonucleotide (see Support Protocol 1) and preparation of the synthon for the linker between 2-5A and the antisense oligonucleotide (see Support Protocol 2). CAUTION: When working with radioactivity, take appropriate precautions to avoid contamination of the experimenter and the surroundings. Carry out the experiment and dispose of wastes in an appropriately designated area, following the guidelines provided by the local radiation safety officer.
5'-phosphomonoester
O HO P O − O
O HO
Ade
O − O P O O
O
Ade
2-5A domain HO
O − O P O O
HO
O
Ade
O − O P O O
HO
Ade
O
O − O P O O
O O P O O
−
linker domain
O O P O − O
O
Gua
O − O P O O
antisense domain
Thy
O
O − O P O 18-20
O
O
Ade
OH
Figure 4.4.1
General structure of 2-5A-antisense oligonucleotides.
Contributed by Mark R. Player and Paul F. Torrence Current Protocols in Nucleic Acid Chemistry (2000) 4.4.1-4.4.23 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.4.1 Supplement 1
BASIC PROTOCOL 1
AUTOMATED SYNTHESIS OF CHIMERIC 2-5A-ANTISENSE OLIGONUCLEOTIDES ACCORDING TO SOLID-PHASE PHOSPHORAMIDITE CHEMISTRY The standard 2-5A-antisense chimera has four regions (Fig. 4.4.1): (1) antisense DNA, (2) linker dimer, (3) 2-5A tetramer, and (4) 5′-terminal phosphate monoester. This procedure describes construction of the antisense domain, coupling of the butanediol linkers, addition of the (2′-5′)-oligoriboadenylate domain, and 5′-phosphorylation. Details are given for two different automated ABI DNA synthesizers. 5′-O-Solid supports from ABI are used and are listed below; 3′-O-Solid supports from Glen Research are also listed, and are used to synthesize oligonucleotides with terminal (3′-3′)-phosphodiester bonds. Materials Reagents for oligonucleotide synthesis: Acetonitrile (CH3CN; diluent; Cruachem) Tetrazole/acetonitrile (activator/coupling solution; PE Biosystems) Acetic anhydride/lutidine/tetrahydrofuran (capping solution; PE Biosystems) N-Methylimidazole/tetrahydrofuran (capping solution; PE Biosystems) Trichloroacetic acid/CH2Cl2 (detritylation solution; PE Biosystems) Iodine/H2O/pyridine/tetrahydrofuran (oxidizer; PE Biosystems) Tetraethylthiuram disulfide (TETD)/CH3CN (PE Biosystems; for sulfurization) 0.1 M phosphoramidite solutions (see recipe): Linker CE phosphoramidite: 4-O-(4,4′-dimethoxytrityl)oxybutyl-1[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] (see Support Protocol 2) RNA CE phosphoramidite (2-5A): N6-benzoyl-5′-O-(4,4′-dimethoxytrityl)3′-O-(tert-butyldimethylsilyl)adenosine-2′-(N,N-diisopropyl-2cyanoethyl)phosphoramidite (see Support Protocol 1) Phosphorylation reagent: 2-[2-(4,4′-Dimethoxytrityl)ethylsulfonyl]ethyl(2-cyanoethyl)-N,N-diisopropylphosphoramidite 5′-O-Dimethoxytrityl-N6-benzoyl-2′-deoxyadenosine-3′(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (dABz) 5′-O-Dimethoxytrityl-N2-isobutyryl-2′-deoxyguanosine-3′-(2-cyanoethylN,N-diisopropyl)phosphoramidite (dGi-Bu) 5′-O-Dimethoxytrityl-N4-benzoyl-2′-deoxycytidine-3′-(2-cyanoethyl-N,Ndiisopropyl)phosphoramidite (dCBz) 5′-O-Dimethoxytrityl-2′-deoxythymidine-3′-(2-cyanoethyl-N,Ndiisopropyl)phosphoramidite (T) 3:1 (v/v) concentrated NH4OH/ethanol 1 M n-tetrabutylammonium fluoride (TBAF)/tetrahydrofuran (THF; Aldrich) 10 mM n-tetrabutylammonium phosphate (TBAP), pH 7.5, in H2O
Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
Automated DNA synthesizer (ABI Biotechnologies model 391 or 392) with 5′ or 3′ solid supports: 5′-O-Dimethoxytrityl-N6-benzoyl-2′-deoxyadenosine-3′-lcaa-CPG (1 µmol; dABz-lcaa-CPG; ABI) 5′-O-Dimethoxytrityl-N4-benzoyl-2′-deoxycytidine-3′-lcaa-CPG (1 µmol; dCBz-lcaa-CPG; ABI) 5′-O-Dimethoxytrityl-N2-isobutyryl-2′-deoxyguanosine-3′-lcaa-CPG (1 µmol; dGi-Bu-lcaa-CPG; ABI) 5′-O-Dimethoxytritylthymidine-3′-lcaa-CPG (1 µmol; T-lcaa-CPG; ABI) 3′-O-Dimethoxytrityl-N6-benzoyl-2′-deoxyadenosine-5′-lcaa-CPG (1 µmol; Glen Research)
4.4.2 Supplement 1
Current Protocols in Nucleic Acid Chemistry
3′-O-Dimethoxytrityl-N4-benzoyl-2′-deoxycytidine-5′-lcaa-CPG (1 µmol; Glen Research) 3′-O-Dimethoxytritylthymidine-5′-lcaa-CPG (1 µmol; Glen Research) 3′-O-Dimethoxytrityl-N2-isobutyryl-2′-deoxyguanosine-5′-lcaa-CPG (1 µmol; Glen Research). Water bath at 55°C Speedvac evaporator NOTE: The above-mentioned 5′ solid supports are used in the steps below. The 3′ solid supports are used in place of the 5′ supports when synthesizing oligonucleotides with terminal (3′-3′)-phosphodiester bonds. Synthesize 2-5A-antisense chimera For ABI 391 DNA synthesizer: 1a. Perform automated synthesis of 2-5A-antisense oligonucleotide on an ABI 391 DNA synthesizer according to manufacturer’s instructions. Use manufacturer’s 1 µmol scale synthetic cycles for the antisense region and modify step 13 of the manufacturer’s protocol for the remaining regions (see Table 4.4.1). 2a. Synthesize remaining regions of the chimera by sequentially adding 0.1 M solutions of linker CE phosphoramidite, RNA CE phosphoramidite (2-5A), and phosphorylation reagent. Use monomer CE phosphoramidites that are <1 week old. To change reagents, sequentially place on bottle position no. 5 as follows: a. Remove the previous reagent and replace with 5 mL CH3CN. b. Remove the column feed line and dry the column by turning valve no. 14 ON for 3 min and then OFF, then turning function no. 105 ON (4 mL CH3CN to column with the feed line unhooked) and then OFF. Replace column feed line. c. Change bottle no. 5 to the next region’s CE phosphoramidite. d. Repeat for synthesis of each chimera domain. For ABI 392 DNA synthesizer: 1b. Perform automated synthesis of 2-5A-antisense oligonucleotide on an ABI 392 DNA synthesizer according to manufacturer’s instructions. 2b. Synthesize remaining regions of the chimera by adding linker CE phosphoramidite, RNA CE phosphoramidite (2-5A), and phosphorylation reagent using monomer
Table 4.4.1 Synthesis Conditions for Different Domains of the 2-5A-Antisense Chimera
Chimera region DNA antisense Linker 2-5A Phosphate
Sequence no. and monomer sequence
Cycle no. and coupling time
Monomer CE phosphoramidite
Trityl mode
Sequence 2 5′-(Nx)-3′ Sequence 4 5′-(LL)(Nx)-3′ Sequence 3 5′-(AAAA)(LLNx)-3′ Sequence 1 5′-(p)(AAAALLNx)
Cycle 2 15 sec Cycle 4 300 sec Cycle 3 600 sec Cycle 1 60 sec
0.1 M DNA CE phosphoramidite 0.1 M linker CE phosphoramidite 0.1 M 2′,5′-ABz or PAC RNA CE phosphoramidite 0.2 M phosphorylation reagent
ON ON ON OFF
Synthesis of Modified Oligonucleotides and Conjugates
4.4.3 Current Protocols in Nucleic Acid Chemistry
Supplement 1
positions 5, 6, and 7, respectively. Use monomer CE phosphoramidites that are <1 week old. On the ABI 392, multiple cycle chimera sequences are created and saved on the computer’s hard disk. The linker CE phosphoramidite, 2-5A CE phosphoramidite, and phosphorylation reagent are kept on monomer positions 5, 6, and 7, and need not be removed until they expire. This minimizes exposure to air. Average stepwise yield (ASWY) and overall yield are available for each synthesis. Several cycles were created with the appropriate wait times by modification of the standard 1 mmol CE cycle (1mmol linker, 1 mmol phosphorylation). These changes are summarized in Table 4.4.2.
Cleave 2-5A-antisense oligonucleotide from CPG and deprotect it 3. Add 3 mL of 3:1 (v/v) concentrated NH4OH/ethanol to the CPG support and incubate 2 hr at room temperature. 4. Transfer to 55°C and incubate 8 to12 hr. Alternatively, in the case of all phenoxyacetyl (PAC)-protected bases, incubate at room temperature for 1 hr, followed by 55°C for 1 hr.
5. Transfer solution to a test tube, cool to 0°C, and evaporate solvent in a Speedvac evaporator. 6. Remove 3′-O-TBDMS group from the 2-5A region of the chimera by adding 1 mL of 1 M TBAF/THF and incubating 12 to 18 hr at room temperature. The chimera will normally remain in solution at the end of the incubation, and the solution will be homogenous. If it is not, briefly sonicate to achieve solution and incubate for another 4 hr.
7. Add 2 mL of 10 mM TBAP, pH 7.5, and remove THF in the Speedvac evaporator. 8. Dissolve crude chimera in distilled, deionized water to a total volume of 6 mL, and purify by HPLC (see Basic Protocol 2). If purification cannot be performed immediately, the chimera can be stored at –70°C in the dry state for up to 2 weeks.
Table 4.4.2 Automated Synthesizer Coupling Times and Conditions
Chimera region
Cycle name and coupling time
5′-(Nx)-3′
1 µmol CE; 15 sec
Monomer CE phosphoramidite
0.1 M DNA CE phosphoramidite 1 µmol linker; 300 sec 0.1 M linker CE 5′-(LL)(Nx) -3′ phosphoramidite 2-5A 5′-(AAAA)(LLNx)-3′ 1 µmol RNA; 600 sec 0.1 M 2′,5′-ABz RNA CE phosphoramidite Phosphate 5′-(P)(AAAALLNx)-3′ 1 µmol phosphorylation; 0.2 M 60 sec phosphorylation reagent Sulfurization Any linkage 1 µmol phosphothioate; TETD/CH3CN bottle 25 sec, 5 sec delivery no. 10 DNA antisense Linker
Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
Monomer sequence
Trityl mode OFF
-
4.4.4 Supplement 1
Current Protocols in Nucleic Acid Chemistry
PREPARATION OF KEY INTERMEDIATE FOR SYNTHESIS OF THE (2′,5′)-OLIGOADENYLATE (2-5A) DOMAIN
SUPPORT PROTOCOL 1
This protocol describes the procedures used to generate the appropriately protected phosphoramidite, 5′-O-(4,4′-dimethoxytrityl)-3′-O-(tert-butyldimethylsilyl)-N6-benzoyladenosine-2′-(N,N-diisopropyl-2-cyanoethyl)phosphoramidite for adding adenosine through the formation of a 2′-5′ linkage to preformed antisense and linker domains. This phosphoramidite derivative may also be used to prepare unligated (2′-5′)-oligoadenylates using solid-phase synthesis. Materials Pyridine (Aldrich) dried over molecular sieves Adenosine (Aldrich) dried overnight in vacuo over P2O5 (Aldrich) 4-Dimethylaminopyridine (DMAP; Aldrich) Triethylamine (Aldrich) 4,4′-Dimethoxytrityl chloride (DMTr⋅Cl; Aldrich) Chloroform (CHCl3; Aldrich) Methanol (Aldrich) Trimethylsilyl chloride (Aldrich) Benzoyl chloride (Aldrich) Concentrated ammonium hydroxide (Aldrich) Diethyl ether (Aldrich) MgSO4 (anhydrous; Aldrich) Kieselgel 60 silica gel (220 to 440 mesh; Fluka) Ethyl acetate (Aldrich) Toluene (Aldrich) Imidazole (Aldrich) tert-Butyldimethylsilyl chloride (TBDMS⋅Cl; Aldrich) N,N-Dimethylformamide (DMF; anhydrous; Aldrich) Cyclohexane (Aldrich) 5% (w/v) aqueous Na2CO3 Methylene chloride (CH2Cl2; Aldrich) 1H-Tetrazole (Aldrich) P2O5 (Aldrich) Dry nitrogen 2-Cyanoethyl-(N,N,N′N′-tetraisopropyl)phosphoramidite (Aldrich) Benzene 250-mL flask with ground-glass stopper Rotary evaporator with vacuum pump 2 × 15-cm, 5 × 15-cm, and 5 × 20-cm chromatography columns 25-mL two-arm reaction flask fitted with a rubber septum 5-mL hypodermic syringe Additional reagents and equipment for thin-layer chromatography (TLC) and fast silica gel column (flash) chromatography Synthesize N6-benzoyl-5′-O-DMTr-adenosine 1. Mix the following in a 250-mL flask that can be sealed to the atmosphere: 100 mL dry pyridine 2.67 g (10 mmol) dry adenosine
Synthesis of Modified Oligonucleotides and Conjugates
4.4.5 Current Protocols in Nucleic Acid Chemistry
Supplement 1
61 mg (0.5 mmol) DMAP 1.9 mL (14 mmol) triethylamine 4.1 g (10 mmol) DMTr⋅Cl. Introduce a magnetic stirring bar, seal the flask with a ground-glass stopper, and stir 2 to 3 hr at room temperature. 2. Monitor the completeness of the reaction by analyzing an aliquot by silica gel TLC using 95:5 (v/v) CHCl3/CH3OH as the eluent. For comparison, run DMAP, adenosine, and DMTr⋅Cl as TLC standards. Use care to completely evaporate the pyridine from the TLC plate before development. 3. When the tritylation reaction is complete, place in an ice/water bath to maintain at 0°C, and slowly add 7.7 mL (60 mmol) trimethylsilyl chloride. Incubate 15 min. 4. Allow mixture to warm to room temperature, add 5.8 mL (50 mmol) benzoyl chloride, and stir ~2 hr at room temperature. 5. Cool mixture in the ice/water bath, add 20 mL cold water, and allow to stand for 5 min. 6. Add 20 mL concentrated ammonium hydroxide (final 2 M NH4OH), allow to warm to room temperature, and incubate 30 min at room temperature. 7. Concentrate to ~20 mL in a rotary evaporator in vacuo using a vacuum pump. 8. Add 700 mL diethyl ether, wash three times with 100 mL water, and dry the ether layer over 50 g anhydrous MgSO4. 9. Filter off MgSO4 and evaporate filtrate in a rotary evaporator. 10. Purify product by fast silica gel column (flash) chromatography using a 5 × 20-cm Kieselgel 60 (220 to 440 mesh) column and 2% methanol/0.2% pyridine/ethyl acetate as an eluent. Collect 5-mL fractions. 11. Analyze fractions by TLC as above, combine fractions that contain product (Rf = 0.6), and remove solvent in a rotary evaporator. 12. Remove last traces of residual pyridine by several additions and evaporations of toluene in 50-mL portions. Store, if necessary, dry at 4°C with a desiccant (stable at least 3 months). This is a critical step to obtain a solid product. The product should be obtained as a pale yellow solid foam (yield 50% to 70%): TLC Rf = 0.55 on silica gel (95:5 ethyl acetate/methanol); 1H NMR: (CDCl3) δ [ppm]: 3.34 (dd, 1H, H-5′ or 5′′), 3.49 (dd, 1H, H-5′ or 5′′), 4.39 (d, 1H, H-4′), 4.50 (dd, 1H, H-3′), 4.90 (t, 1H, H-2′), 6.13 (d, 1H, H-1′), 6.74-7.60 (m, aromatic protons), 8.02 and 8.04 (s, 1H, H-2 or H-8).
Synthesize N6-benzoyl-5′-O-DMTr-2′-O-TBDMS-adenosine and N6-benzoyl-5′-ODMTr-3′-O-TBDMS-adenosine 13. Dissolve the following and maintain at room temperature for 2.5 hr: 1.75 g (2.6 mmol) N6-benzoyl-5′-O-DMTr-adenosine Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
0.544 g (8 mmol) imidazole 0.60 g (5 mmol) TBDMS⋅Cl 10 mL anhydrous DMF.
4.4.6 Supplement 1
Current Protocols in Nucleic Acid Chemistry
14. Verify that all N6-benzoyl-5′-O-DMTr-adenosine has reacted by running an aliquot on a silica gel TLC plate using 95:5 (v/v) ethyl acetate/methanol or 1:1 (v/v) ethyl acetate/cyclohexane as the eluent. 15. Add 1.5 mL of 5% aqueous Na2CO3 at 0°C to stop the reaction. Stir 15 min at <10°C. 16. Evaporate DMF in a rotary evaporator in vacuo, dissolve the resulting residue in 50 mL CH2Cl2, and wash three times with 50 mL water. 17. Dry CH2Cl2 layer over anhydrous MgSO4 and then evaporate solvent using a rotary evaporator. 18. Dissolve residue in 10 mL of 1:1 (v/v) ethyl acetate/cyclohexane containing 0.2% pyridine and apply to a 5 × 15-cm Kieselgel 60 silica gel column. Elute with 49:49:2 (v/v/v) ethyl acetate/cyclohexane/pyridine. Collect 5-mL fractions. 19. Monitor elution of reaction products using silica gel TLC with 1:1:0.004 (v/v/v) ethyl acetate/cyclohexane/pyridine. The first product to elute is the 2′-O-silylated isomer: N6-benzoyl-5′-O-DMTr-2′-OTBDMS-adenosine (Rf = 0.47). After complete elution of the 2′-O-silylated isomer, the concentration of ethyl acetate must be increased to elute the 3′-O-silylated isomer.
20. Switch eluent to ethyl acetate/cyclohexane/pyridine 66:32:2 (v/v/v) and continue TLC monitoring for elution of the 3′-O-silylated isomer. N6-Benzoyl-5′-O-DMTr-3′-O-TBDMS-adenosine has an Rf of 0.24.
21. Pool appropriate fractions containing each of the respective products and remove the solvent by rotary evaporation in vacuo. Subsequently add and evaporate 50-mL portions of toluene to remove traces of pyridine as judged by smell. Store, if necessary, dry at 4°C with a desiccant (stable at least 3 months). The products are obtained as colorless foams (typical yields: 480 mg 2′-O-silylated isomer; 660 mg 3′-O-silylated isomer). By silica gel TLC using 1:1:0.004 ethyl acetate/cyclohexane/pyridine, the 2′-isomer has a Rf = 0.47 and the 3′-isomer has a Rf = 0.24. The product used for further synthesis of 2-5A and 2-5A-antisense oligonucleotide is the 3′-O-silylated isomer: 1H NMR: (CDCl3), δ (ppm): 0.02 and 0.10 (ds, 6H, CH3Si), 0.98 (s, 9H, t-butyl), 3.27 and 3.54 (dd, 1H, H-5′ or H-5′′), 3.77 (s,3H, CH3O), 4.21 (m, 1H, H-4′), 4.60 (t, 1H, H-3′), 4.80 (t,1H, H-2′), 6.10 (d, 1H, H-1′), 8.03 and 8.05 (s, 1H, H-2 or H-8), 6.78-7.60, 8.28, 8.77 (m, aromatic protons). It is critical that complete separation of the silylated isomers be accomplished at this stage. Separation will be impossible after generation of the phosphoramidite. This is the most common cause of difficulty in this procedure.
Synthesize N6-benzoyl-5′-O-DMTr-3′-O-TBDMS-adenosine-2′-(N,N-diisopropyl-2cyanoethyl)phosphoramidite 22. Combine 48 mg (0.68 mmol) of 1H-tetrazole and 540 mg (0.68 mmol) of N6-benzoyl-5′-O-DMTr-3′-O-TBDMS-adenosine in a 25-mL two-arm reaction flask fitted with a rubber septum and a hypodermic needle. For this reaction, additional care must be taken to ensure anhydrous reaction conditions. The hypodermic needle is used for evacuation of air and admission of dry nitrogen and reagents.
23. Place the flask, fittings, and contents in a vacuum desiccator and dry overnight in vacuo in the presence of P2O5. 24. Admit dry nitrogen to the desiccator and thus to the reaction flask. Immediately remove the hypodermic needle from the rubber septum.
Synthesis of Modified Oligonucleotides and Conjugates
4.4.7 Current Protocols in Nucleic Acid Chemistry
Supplement 1
25. Add a solution of 5 mL CH2Cl2 and 206 mg (0.68 mmol) of 2-cyanoethyl-(N,N,N′,N′tetraisopropyl)phosphoramidite through the rubber septum using a 5-mL hypodermic syringe and needle. 26. Incubate 4 hr at room temperature and then overnight at 4°C. 27. Evaporate reaction mixture in vacuo on a rotary evaporator. 28. Add 2 mL of 6:3:1 (v/v/v) benzene/cyclohexane/triethylamine to the residue and apply to a 2 × 15-cm silica gel (Kieselgel 60) column. Use the same solvent for product elution. Collect 5-mL fractions. 29. Monitor fractions by silica gel TLC using 6:3:1 (v/v/v) benzene/cyclohexane/triethylamine as eluent. Two major products are generated in this reaction, namely, the two P-chiral diastereomers. These two stereoisomers have Rf values of 0.61 and 0.53 by silica gel TLC with this solvent.
30. Combine product-containing fractions, concentrate to dryness in vacuo, and dry by addition and evaporation of 50-mL portions of toluene. The product can be stored at 4°C. A partial separation of these two diastereomers can be achieved, but in practice this is not necessary. The product, consisting of a mixture of both P-chiral diastereoisomers, is obtained as a colorless foam (~500 mg); 31P NMR: (CDCl3, 1% C5D5N):δ (ppm) 150.73 and 150.38. SUPPORT PROTOCOL 2
PREPARATION OF A LINKER INTERMEDIATE THAT JOINS (2′-5′)-OLIGOADENYLATE (2-5A) TO ANTISENSE (3′-5′)-OLIGODEOXYRIBONUCLEOTIDES This protocol describes the synthesis of 4-O-(4,4′-dimethoxytrityl)oxybutyl-1-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite], which is the moiety used in the prototype 2-5A-antisense chimera to join the 2-5A domain to the antisense domain. Materials 1,4-Butanediol (Aldrich) Pyridine (anhydrous; Aldrich) Dry argon or nitrogen (Aldrich) 4,4′-Dimethoxytrityl chloride (DMTr⋅Cl; Aldrich) Chloroform (Aldrich) Methanol (Aldrich) Ethyl acetate (Aldrich) MgSO4 (anhydrous; Aldrich) Kieselgel 60 silica gel (Fluka) Methylene chloride (CH2Cl2; Aldrich) Ethyldiisopropylamine (Aldrich) 2-Cyanoethyl-N,N-diisopropylphosphoramidic chloride (Aldrich) Benzene (Aldrich) Petroleum ether (Aldrich) Triethylamine (Aldrich)
Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
250-ml stoppered flask Rotary evaporator attached to a vacuum pump Hand-held UV lamp
4.4.8 Supplement 1
Current Protocols in Nucleic Acid Chemistry
Additional reagents and equipment for thin-layer chromatography (TLC) and fast silica gel column (flash) chromatography Synthesize 4-O-(4,4′-dimethoxytrityl)oxybutan-1-ol 1. Dissolve 9.0 g (100 mmol) of 1,4-butanediol in 50 mL anhydrous pyridine in a 250-ml stoppered flask. 2. Remove pyridine by evaporation at <40°C in a rotary evaporator attached to a vacuum pump. 3. Through the rotary evaporator stopcock, admit dry argon or nitrogen to the flask containing the butanediol, add an additional 50 mL dry pyridine, and repeat the evaporation procedure. 4. Repeat step 3 once more. Be certain to admit the dry nitrogen or argon after the final pyridine evaporation. A total of three evaporations will dry the butanediol sufficiently for the following tritylation reaction.
5. Dissolve dried 1,4-butanediol in 50 mL anhydrous pyridine. 6. Add 3.39 g (10 mmol) DMTr⋅Cl and allow the homogenous mixture to react 2 hr at room temperature in the stoppered flask. 7. Verify complete formation of the product by TLC using 99:1 (v/v) chloroform/methanol as developing solvent. 8. Pour the entire mixture onto 100 g ice in a beaker. Add a magnetic stirring bar and stir the mixure until the ice is completely melted. 9. Add 100 mL ethyl acetate and shake to extract the organic product. Separate the organic (top) and aqueous (bottom) layers. 10. Reextract the aqueous layer with an additional 50 mL ethyl acetate. Separate the organic layer again, and add the ethyl acetate layer to the one obtained from the previous extraction. 11. Add 10 g anhydrous MgSO4 to the combined organic layers to dry them. Filter off MgSO4 and evaporate all but ~10 mL ethyl acetate solution in a rotary evaporator at <40°C. 12. Add the concentrated ethyl acetate solution to the top of a column containing 250 g silica gel (Kieselgel 60). Elute with 99:1 (v/v) methylene chloride/methanol, collecting 10-mL fractions. 13. Check each fraction for product by spotting aliquots on a silica gel TLC plate and looking for the presence of UV-absorbing material with a hand-held UV lamp. If UV absorbance is detected, develop the plate using 99:1 (v/v) chloroform/methanol. Approximately 2.1 g (54% overall yield) of 4-O-(4,4′-dimethoxytrityl)oxybutan-1-ol can be obtained: 1H NMR (CDCl3, 1% deuteriopyridine):δ (ppm) 1.68(m, 4H, CH2); 3.10 (t, J = 5.7 Hz, 2H, CH2O); 3.62 (t, J = 5.8 Hz, 2H, CH2OH); 3.76 (s, 6H, CH3O); 6.79-7.46 (m, aromatic protons).
Synthesize 4-O-(4,4′-dimethoxytrityl)oxybutyl-1-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] 14. Prepare a solution of the following reagents under anhydrous conditions: 390 mg (1 mmol) 4-O-(4,4′-dimethoxytrityl)oxybutan-1-ol
Synthesis of Modified Oligonucleotides and Conjugates
4.4.9 Current Protocols in Nucleic Acid Chemistry
Supplement 1
510 mg (4 mmol) ethyldiisopropylamine 3 mL dry methylene chloride. Cool in an ice bath. 15. Slowly add 237 mg (1 mmol) of 2-cyanoethyl-N,N-diisopropylphosphoramidic chloride under anhydrous conditions. Allow to warm to room temperature and to react for 1 hr. 16. Evaporate solvent using a rotary evaporator at <40°C. 17. Dissolve residue in 5 mL benzene and add mixture to the top of a 1.8 × 14-cm silica gel column. Elute the product with 6:3:1 (v/v/v) benzene/petroleum ether/triethylamine. 18. Check fractions for product by silica gel TLC using 6:3:1 (v/v/v) benzene/petroleum ether/triethylamine as the eluent. 19. Evaporate solvent from product-containing fractions. Yield: 580 mg (98%) 4-O-(4,4′-dimethoxytrityl)oxybutyl-1-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]: 1H NMR (CDCl3, 1% deuteriopyridine):δ (ppm) 1.17 (t, J = 7.0 Hz, 12 H, CH3C); 1.70 (m, 4H, CH2C); 2.60 (t, J = 6.5 Hz, 2 H, CH2CN), 3.08 (t, J = 5.7 Hz, 2H, CH2O); 3.80 (m, 2H, CH); 6.80-7.49 (m, aromatic protons); 31P NMR (CDCl3, 1% deuteriopyridine):δ (ppm) 147.6. This phosphoramidite, like all phosphoramidites, is best stored in the presence of a desiccant at –20°C. BASIC PROTOCOL 2
PURIFICATION AND CHROMATOGRAPHIC CHARACTERIZATION OF CHIMERIC 2-5A ANTISENSE OLIGONUCLEOTIDES After deprotection, the chimera can be purified using either reversed-phase ion-pair chromatography or anion-exchange chromatography. The polystyrene reversed-phase ion-pair (PRP-1) column has a long lifetime, can tolerate extremes of pH and fluoride ions, and gives good recoveries of the 2-5A-antisense chimera. Desalting prior to ion-pair HPLC is not required, but is performed after. A typical chromatogram of a representative crude chimera is shown in Figure 4.4.2. The Nucleogen DEAE anion-exchange column has a shorter lifetime than the PRP-1 column, and cannot tolerate extremes of pH and fluoride ions. Preparative purification requires prior desalting. In addition, recoveries of chimera are poorer than those accomplished with the PRP-1 procedure. After purification by ion-pair or anion-exchange chromatography, the chimera is converted to a sodium salt by cation exchange, dialyzed, and filter sterilized. The purity of the chimera is estimated by capillary gel electrophoresis and ion-exchange HPLC.
Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
Materials Crude 2-5A-antisense chimera (see Basic Protocol 1) Solvent A: 10 mM n-tetrabutylammonium phosphate (TBAP), pH 7.5, in H2O (for ion-pair chromatography) Solvent B: 10 mM TBAP, pH 7.5, in 8:2 (v/v) CH3CN/H2O (for ion-pair chromatography) Methanol Solvent C: 20 mM potassium phosphate, pH 7.0, in 8:2 (v/v) CH3CN/H2O (for anion-exchange chromatography) Solvent D: 20 mM potassium phosphate, pH 7.0, in aqueous 1 M KCl (for anion-exchange chromatography) Dowex 50W (Na+ form; Bio-Rad) Tris/methanol running buffer: 75 mM Tris phosphate, pH 7.6, in 9:1 (v/v) H2O/methanol
4.4.10 Supplement 1
Current Protocols in Nucleic Acid Chemistry
Figure 4.4.2 Polystyrene reversed-phase ion-pair chromatography of the crude (post-deprotection) 2-5A-DNA chimera: 5′-pA(2′,5′-pA)3-2′-p[(CH2)4p]2d[TCT CCG CTT CTT CCT GCC AT]. A 33 × 7-mm PRP-1 column was used and elution was accomplished with a convex gradient of 5% to 80% solvent B in solvent A over 50 min, where solvent A was 10 mM n-tetrabutylammonium phosphate (TBAP), pH 7.5, and solvent B was 10 mM TBAP in 8:2 (v/v) methanol/water, pH 7.5. The flow rate was 1.5 mL/min. Detection was at 270 mm. The major peak at a retention time of ~39 min was collected.
Solvent E: 25 mM Tris⋅Cl, pH 7.0 (APPENDIX 2A) in 1:200 (v/v) CH3CN/H2O Solvent F: 25 mM Tris⋅Cl, 1 M ammonium chloride, pH 7.0, in 1:200 (v/v) CH3CN/H2O High-performance liquid chromatograph (HPLC) with 270-nm UV detection 300 × 7-mm polystyrene reversed-phase column (PRP-1 semi-prep column; 10 µm, 100 Å; Hamilton; for ion-pair chromatography) Speedvac evaporator SepPak C18 cartridge 125 × 4–mm Nucleogen DEAE 60-7 column (7 µm, 60 Å; Macherey-Nagel; for anion-exchange chromatography) PolyPrep column Millex-GV 0.22-µm filter unit (Millipore) SpectraPor dialysis chamber (Vt = 5 mL) with a 3500 MWCO membrane (Spectrum) Capillary electrophoresis instrument (ABI model 270A-HT) with MICRO-GEL100 gel-filled capillaries (50-µm i.d., 27-cm effective length) and UV detection at 260 nm 250 × 4-mm Dionex PA-100 column (Dionex) Additional reagents and equipment for determining OD260 (UNIT 10.3)
Synthesis of Modified Oligonucleotides and Conjugates
4.4.11 Current Protocols in Nucleic Acid Chemistry
Supplement 1
Purify 2-5A-antisense chimera For reversed-phase ion-pair chromatography: 1a. Inject 1 mL crude 2-5A-antisense chimera into a 300 × 7–mm polystyrene reversedphase column. 2a. Elute purified chimera using a convex gradient from 5:95 (v/v) solvents B/A to 80:20 solvents B/A over 45 min, at a flow rate of 1.5 mL/min. Collect 1-mL fractions and use UV detection at 270 nm. 3a. Combine fractions according to the UV profile, and evaporate to dryness in a Speedvac evaporator. 4a. Wash a SepPak C18 cartridge sequentially with 10 mL methanol and 10 mL H2O to remove shipping buffer. 5a. Dissolve chimera in 2 to 4 mL H2O and load onto the cartridge. 6a. Wash cartridge sequentially with 15 mL H2O, 10 mL of 5:95 (v/v) methanol/H2O, and 10 mL of 1:9 (v/v) methanol/H2O. 7a. Elute chimera with 10 mL of 1:1 (v/v) methanol/H2O and concentrate the eluate as needed in a Speedvac evaporator. Proceed to step 8. For anion-exchange chromatography: 1b. Desalt crude 2-5A-antisense chimera as described in steps 4a to 7a. 2b. Inject 1 mL chimera in water onto a 125 × 4–mm Nucleogen DEAE 60-7 column. 3b. Elute purified chimera using a linear gradient from 1:99 (v/v) solvents D/C to 100% solvent D over 30 min, followed by isocratic elution for 15 min, all at a flow rate of 1.0 mL/min. Collect 1-mL fractions and use UV detection at 260 nm. 4b. Combine fractions as indicated by the UV profile, and evaporate to dryness in a Speedvac evaporator. Proceed to step 8. Convert chimera to its sodium salt by cation exchange 8. Dissolve tetrabutylammonium salt (step 7a) or potassium salt (step 4b) of the chimera in 2 mL water. 9. Add 1 mL Dowex 50W slurry (Na + form) and stir 3 hr at 4°C. 10. Remove resin by passing the suspension through an empty PolyPrep column. 11. Elute chimera from the resin with 17 mL H 2O. Be sure to monitor the recovery by UV, as the oligonucleotide is retarded by the Dowex. Dialyze and sterilize chimera 12. Sterilize solution through a Millex-GV 0.22-µm filter unit. 13. Dialyze against water overnight at 4°C, using a SpectraPor dialysis chamber (Vt = 5 mL) with a 3500 MWCO membrane. 14. Repeat step 12. Determine OD260 (UNIT 10.3) to quantitate DNA. Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
These steps are necessary for removal of low-molecular-weight impurities and to prepare the chimera for biological evaluation.
4.4.12 Supplement 1
Current Protocols in Nucleic Acid Chemistry
Figure 4.4.3 Determination of 2-5A-antisense chimera purity by capillary gel electrophoresis on an ABI 270A-HT instrument using MICRO-GEL100 gel-filled capillaries (50-µm i.d., 27-cm effective length) with a running buffer of 75 mM Tris phosphate, pH 7.6, in 9:1 (v/v) H2O/methanol. The voltage was –14 kV and the operation T was 30°C. Detection was at 260 nm. The typical chromatogram shown is for the chimera: 5′-pA(2′,5′-pA)3-2′-p[(CH2)4p]2d[TCT CCG CTT CTT CCT GCC AT].
Estimate chimera purity by capillary gel electrophoresis 15. Determine oligonucleotide chimera purity on an ABI 270A-HT capillary electrophoresis instrument using MICRO-GEL100 gel-filled capillaries and Tris/methanol running buffer with UV detection at 260 nm. Run at –14 kV (17 µA) and at an operation temperature of 30°C. Typically, a chimera electropherogram can be obtained using a sample concentration of 0.06 OD260 and an electrokinetic injection of 2 s at –5 kV. A typical electropherogram is shown in Figure 4.4.3.
Estimate chimera purity by ion-exchange HPLC 16. Carry out ion-exchange HPLC using a 250 × 4–mm Dionex PA-100 column. Use an injection volume of 50 µL and ~0.1 OD260 of oligonucleotide. Employ a linear gradient from 1:9 (v/v) solvents F/E to 9:1 solvents F/E over 25 min, followed by isocratic elution for 25 min, all at a flow rate of 1.0 mL/min with UV detection at 270 nm. The Dionex PA-100 column gives better peak shape than many other ion-exchange columns.
COMPOSITION ANALYSIS OF CHIMERIC 2-5A-ANTISENSE OLIGONUCLEOTIDES USING SNAKE VENOM PHOSPHODIESTERASE DIGESTION AND REVERSED-PHASE HPLC When 2-5A-antisense chimeric oligonucleotides are digested by snake venom phosphodiesterase (SVPD), they yield 5′-AMP from the 2-5A domain, 5′-pA2′-p(CH2)4p(CH2)4OH from the terminal AMP of 2-5A and the linker moiety, and deoxyribonucleotide 5′-monophosphates from the antisense domain. This analysis provides a cornucopia of valuable information regarding the 2-5A-antisense chimera. It provides a compositional analysis (by providing the ratio of 5′-AMP to any or all of the constituent 5′-deoxyribonucleotides) and
BASIC PROTOCOL 3
Synthesis of Modified Oligonucleotides and Conjugates
4.4.13 Current Protocols in Nucleic Acid Chemistry
Supplement 1
also ascertains the completeness of 5′-phosphorylation (through the appearance of adenosine as a product of 5′-unphosphorylated chimera), which is vital for full activation of RNase L. Materials Purified 2-5A-antisense chimera (see Basic Protocol 2) Snake venom phosphodiesterase (SVPD, Crotallus adamanteus; Amersham Pharmacia Biotech) 1 M Tris⋅Cl, pH 8.0 (APPENDIX 2A) 1 M MgCl2 Solvent A: aqueous 100 mM ammonium phosphate, pH 5.5 Solvent B: 1:1 (v/v) methanol/H2O Microcon-10 concentrator (Amicon) High-performance liquid chromatograph (HPLC) with 250 × 4.6–mm Ultrasphere C18 ODS column (5 µm, 80 Å; Thomson Instrument) 1. Analyze the nucleotide composition of purified 2-5A-antisense chimera by digestion with SVPD. Mix the following and incubate 3 hr at 37°C: 0.2 OD260 units chimera 0.15 units SVPD 50 mM Tris⋅Cl, pH 8.0 0.5 mM MgCl2 water to 100 µL. 2. Wash the membrane of a Microcon-10 concentrator with 100 µL water and then with 100 µL solvent A to remove shipping buffer. Centrifuge each wash 5 min at 700 × g, 4°C (see manufacturer’s instructions). Each spin-rinse takes ~15 min.
3. Discard filtrate, apply 100 µL enzyme digestion mixture, and spin-rinse for 15 min. 4. Wash membrane three more times with 100-µL portions of solvent A to ensure that all nucleotides have passed through the membrane. 5. Analyze the centrifugate by reversed-phase HPLC using a 250 × 4.6–mm Ultrasphere C18 ODS column. Inject 20 to 30 µL. Separate the digestion products using the following solvent program at a flow rate of 0.5 mL/min: a. isocratic elution with 1:99 (v/v) solvents B/A for 20 min b. linear gradient elution from 1:99 solvents B/A to 45:55 solvents B/A over 30 min c. isocratic elution with 45:55 solvents B/A for 20 min. Typical retention times for various nucleotides are: 5′-dCMP (ε260 = 7,610), 9.7 min; 5′-TMP (ε260 = 8,158), 27.3 min; 5′-dGMP (ε260 = 9,969), 29.6 min; 5′-AMP (ε260 = 12,300), 31.7 min; 5′-dAMP (ε260 = 14,300), 41.2 min; 5′-pA2′-p(CH2)4p(CH2)4OH [AMP(pBu)2] (ε260 = 12,300), 39.5 min. A typical chromatogram of a digestion is shown in Figure 4.4.4.
Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
6. Normalize the absorbance of each peak by dividing by the extinction coefficient (ε260), and thereby ascertain the relative ratios of each nucleotide.
4.4.14 Supplement 1
Current Protocols in Nucleic Acid Chemistry
Figure 4.4.4 Digestion of a representative 2-5A-antisense chimera with snake venom phosphodiesterase and analysis by HPLC. A snake venom phosphodiesterase digest of the chimera 5′-pA(2′,5′-pA)3-2′p[(CH2)4p]2d[TCT CCG CTT CTT CCT GCC AT] was injected into a 250 × 4.6-mm Beckman Ultrasphere C18 ODS column. Elution was with 2% solvent B in 98% solvent A isocratically for 20 min, then a linear gradient of 2% to 50% solvent B in solvent A for 15 min, then 50% solvent B isocratically for 20 min. Solvent A was 100 mM ammonium phosphate, pH 5.5, and solvent B was 1:1 (v/v) methanol/H2O. The flow rate was 0.5 mL/min and detection was at 260 nm.
SEQUENCING CHIMERIC 2-5A-ANTISENSE OLIGONUCLEOTIDES ACCORDING TO A MODIFIED MAXAM-GILBERT PROCEDURE
BASIC PROTOCOL 4
Although the size and unusual chemical structure of 2-5A-antisense chimeras do not permit enzymatic sequencing, the Maxam-Gilbert procedure can be employed if certain modifications are followed. In this procedure, the chimera is 3′-end labeled using [α-32P]ddATP and terminal nucleotide transferase. Materials Purified 2-5A-antisense chimera (see Basic Protocol 2) 5× TNT buffer (see recipe) [α-32P]ddATP (3000 Ci/mmol, 10 mCi/mL; Amersham) 15 U/µL terminal deoxyribonucleotide transferase (TNT) from calf thymus (Life Technologies) 0.5 M EDTA, pH 8 (APPENDIX 2A) 1 mg/mL calf thymus DNA (Clontech) 0.5 M sodium phosphate buffer, pH 6.8 (see recipe) Scintillation fluid Diethyl pyrocarbonate (DEPC; Sigma) DEPC buffer (see recipe) Ethanol 0.3 and 3 M sodium acetate (Quality Biological), pH 6, in water 4 mg/mL yeast tRNA (Clontech) Dimethyl sulfate (DMS; Aldrich) DMS buffer (see recipe) DMS stop buffer (see recipe)
Synthesis of Modified Oligonucleotides and Conjugates
4.4.15 Current Protocols in Nucleic Acid Chemistry
Supplement 1
A>C buffer (see recipe) 1 N acetic acid Hydrazine (HZ; Aldrich) HZ stop buffer (see recipe) 5 M NaCl (Quality Biological) in water 1 M piperidine (Aldrich) in water, freshly prepared Denaturing gel-loading buffer (see recipe) 10× TBE electrophoresis buffer (APPENDIX 2A) Lyophilizer ChromaSpin-10 gel column (Clontech) Whatman DE81 filters Vacuum manifold Siliconized tubes Heating blocks at 25°, 60°, and 90°C Additional reagents and equipment for polyacrylamide gel electrophoresis (PAGE; APPENDIX 3B) 3′-End label 2-5A-antisense chimera 1. Lyophilize 10 pmol of purified 2-5A-antisense chimera. 2. Add the following in order: 10 µL 5× TNT buffer 32 µL ddH2O 6 µL [α-32P]ddATP (20 pmol) 2 µL 15 U/µL TNT. 3. Incubate 60 min at 37°C. 4. Stop reaction by adding 4 µL of 0.5 M EDTA, pH 8, and 6 µL of 1 mg/mL calf thymus DNA. Vortex gently. 5. Set aside 1 µL for determination of specific activity (steps 8 to 11). 6. Apply the remainder of the reaction to a precentrifuged ChromaSpin-10 gel column and elute with water by centrifuging 6 min at 700 × g, at 4°C. 7. Lyophilize eluted solution and store at –20°C until use (up to 2 weeks). Determine specific activity of labeled chimera 8. Dilute 1 µL labeling reaction (from step 5) in 99 µL of 0.2 M EDTA, pH 8. 9. Place quadruplicate 3-µL spots of diluted sample on separate Whatman DE81 filters. Dry at 50°C. 10. Wash two filters on a vacuum manifold with 30 mL of 0.5 M sodium phosphate buffer, pH 6.8, and dry them at 50°C. Washing will remove unincorporated nucleotide. The two unwashed filters are used to determine the total cpm in the sample. Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
11. Add scintillation fluid to each filter and count them in a liquid scintillation counter. Use the cpm from the filters to determine the following: % incorporation = cpm incorporated/total cpm
4.4.16 Supplement 1
Current Protocols in Nucleic Acid Chemistry
% 3′ ends labeled = % incorporation × 2 specific activity = % incorporation × total cpm added to reaction/µg chimera. Expected values are 10% to 15% incorporation, with 20% to 30% of 3′ ends labeled, and specific activity of ~108 cpm/mg chimera.
Perform sequencing reactions 12. Set up rA reaction to cleave primarily at riboadenosine residues: a. Place a siliconized tube containing 1⁄6 of the labeled chimera on ice. b. Add 150 µL DEPC buffer followed by 2 µL of 1:9 (v/v) DEPC/ethanol. c. Vortex and incubate 5 min at 90°C. d. Add 15 µL of 3 M sodium acetate, pH 6. e. Add 5 µL of 4 mg/mL yeast tRNA and 800 µL ethanol. f. Vortex and bring to –70°C. 13. Set up G reaction for primary cleavage at deoxyguanosine and minor cleavage at riboadenosine. a. Place a siliconized tube containing 1⁄6 of the labeled chimera on ice. b. Add 200 µL DMS buffer followed by 1 µL dimethyl sulfate. c. Vortex and incubate 20 min at 25°C. d. Add 50 µL DMS stop buffer and 800 µL ethanol. e. Vortex and bring to –70°C. 14. Set up A>C reaction for cleavage primarily at deoxyadenosine, with secondary cleavage at deoxycytidine and riboadenosine. a. Place a siliconized tube containing 1⁄6 of the labeled chimera on ice. b. Add 100 µL A>C buffer. c. Vortex and incubate 15 min at 90°C. d. Add 150 µL of 1 N acetic acid, 5 µL of 4 mg/mL yeast tRNA, and 800 µL ethanol. e. Vortex and bring to –70°C. 15. Set up A+G reaction for cleavage at riboadenosine, deoxyadenosine, and deoxyguanosine. a. Place a siliconized tube containing 1⁄6 of the labeled chimera on ice. b. Add 150 µL DEPC buffer followed by 2 µL of 1:9 (v/v) DEPC/ethanol. c. Vortex and incubate 5 min at 90°C. d. Add 15 µL of 3 M sodium acetate, pH 6. e. Add 5 µL of 4 mg/mL yeast tRNA and 800 µL ethanol. f. Vortex and bring to –70°C. 16. Set up T+C reaction for cleavage at deoxythymidine, deoxycytidine, and riboadenosine. a. Place a siliconized tube containing 1⁄6 of the labeled chimera on ice. b. Add 15 µL water followed by 30 µL hydrazine. c. Vortex and incubate 60 min at 25°C. d. Add 400 µL HZ stop buffer and 800 µL ethanol. e. Vortex and bring to –70°C. 17. Set up C reaction for strong cleavage at deoxycytidine and riboadenosine.
Synthesis of Modified Oligonucleotides and Conjugates
4.4.17 Current Protocols in Nucleic Acid Chemistry
Supplement 1
a. b. c. d. e.
Place a siliconized tube containing 1⁄6 of the labeled chimera on ice. Add 15 µL of 5M NaCl followed by 30 µL hydrazine. Vortex and incubate 60 min at 25°C. Add 400 µL HZ stop buffer and 800 µL ethanol. Vortex and bring to –70°C.
Wash all samples 18. Centrifuge 15 min at 12,000 × g, 4°C. 19. Withdraw and discard supernatant, checking with a survey meter that very little labeled chimera is removed. 20. Redissolve chimera in 400 µL of 0.3 M sodium acetate, pH 6. 21. Add 800 µL ethanol, vortex, bring to –70°C, and centrifuge 15 min at 12,000 × g, 4°C. 22. Repeat steps 19 and 21 (do not add sodium acetate). 23. Remove most of the supernatant and lyophilize pellet for 15 min. Cleave modified bases with piperidine 24. Add 100 µL of 1 M piperidine to DNA samples and vortex. 25. Make sure lids are securely shut and incubate 20 min at 60°C (for rA reaction) or 30 min at 90°C (for all other reactions). 26. Cool on ice and lyophilize for 15 min. 27. Add 15 µL water, vortex, and lyophilize again. Repeat. Perform polyacrylamide gel electrophoresis (PAGE) 28. Add 100 µL denaturing gel-loading buffer. 29. Denature samples 60 min at 90°C and then cool on ice. 30. Pour and set up 20% polyacrylamide/8 M urea sequencing gel (see APPENDIX 3B) using 1× TBE electrophoresis buffer and pre-run for 2 hr at 130 W constant power. Gel will heat to 55°C.
31. Load samples and run at 130 W constant power until the bromphenol blue has migrated ~19 cm down from the wells. Remove one or both plates. 32. Mark the upper left corner of the gel with radioactive ink and autoradiograph. A typical result is shown in Figure 4.4.5. REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
A>C buffer 0.480 mg sodium hydroxide (1.2 N) 20 µL 1 mM EDTA H2O to 10 mL Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
Aniline solution, 1 M, pH 4.5 931 µL aniline (Aldrich) 8.869 mL H2O
4.4.18 Supplement 1
Current Protocols in Nucleic Acid Chemistry
Figure 4.4.5. Maxam-Gilbert sequencing of the 2-5A-antisense chimera 5′-pA(2′,5′-pA)3-2′p[(CH2)4p]2d[TCT CCG CTT CTT CCT GCC AT]. Lane 1, rA; lane 2, G; lane 3, A>C; lane 4, A+G; lane 5, T+C; lane 6, C.
Adjust pH to 4.5 with acetic acid Store in the dark at –20°C Precipitate will clear upon addition of acetic acid.
ATP/dTTP stock solution 4.8 mg dTTP (final 1.0 mM) 0.55 mg ATP (final 0.1 mM) Adjust pH to 7.0 Add H2O to 10.0 mL Denaturing gel-loading buffer 8 mL formamide (Fluka; 80% v/v) 1 g sucrose (10% w/v) 40 µL 2 mM EDTA 0.2% (w/v) bromphenol blue (Sigma) Add H2O to 10 mL Diethyl pyrocarbonate (DEPC) buffer 166 µL 3 M sodium acetate, pH 6 (final 50 mM, pH 5) 20 µL 0.5 M EDTA (final 1 mM) H2O to 10 mL
Synthesis of Modified Oligonucleotides and Conjugates
4.4.19 Current Protocols in Nucleic Acid Chemistry
Supplement 1
Dimethyl sulfate (DMS) buffer 80 mg sodium cacodylate (Aldrich), pH 8.0 (final 50 mM) 20 µL 1 mM EDTA H2O to 10 mL DMS stop buffer 829 µL 1.5 M sodium acetate, pH 7.0 71 µL 1 M 2-mercaptoethanol 25 µL 100 µg/mL yeast tRNA 75 µL H2O Prepare fresh before use Hydrazine (HZ) stop buffer 400 µL 1.5 M sodium acetate, pH 7 (final 0.3 M) 200 µL 1 mM EDTA (final 0.1 mM) 15 µL 25 µg/mL yeast tRNA (final 0.2 µg/mL) H2O to 2 mL Prepare fresh before use Phosphoramidite solutions, 0.1 M Dry phosphoramidites over anhydrous P2O5 for ≥33 hr. Dilute in anhydrous acetonitrile to make each 0.1 M solution (see Table 4.4.3). Use within a week. Sodium phosphate buffer, 0.5 M, pH 6.8 4.73 g NaH2PO4 2.24 g Na2HPO4 H2O to 100 mL Terminal deoxyribonucleotide transferase (TNT) buffer, 5× 500 mM potassium cacodylate 1 mM dithiothreitol 10 mM CoCl2 Adjust pH to 7.2 COMMENTARY Background Information The 2-5A system (Johnston and Torrence, 1984; Player and Torrence, 1998) has been the basis of a targeted mRNA destruction method that derives from the covalent linkage of a (3′-5′)-antisense oligodeoxyribonucleotide
Table 4.4.3
Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
and a (2′-5′)-oligoadenylate activator of RNase L, the 2-5A-dependent RNase (Lesiak et al., 1993; Torrence et al., 1993). This composite nucleic acid (Fig. 4.4.1; Xiao et al., 1996) could, through the antisense domain, target the chimera to a particular mRNA sequence, which
Preparation of Automated Synthesizer Reagents
CE phosphoramidite
CH3CN (mL)
Molarity (M)
Coupling cycles
Sources
500 mg dABz 500 mg dGi-Bu 500 mg dCBz 500 mg T 0.25 g butanediol linker 500 mg 2-5A 0.25 g phosphorylation reagent
5.6 5.8 5.9 6.6 3.75 5.0 3.8
0.1 0.1 0.1 0.1 0.1 0.1 0.1
25 24 24 27 10 24 7
PE Biosystems PE Biosystems PE Biosystems PE Biosystems Support Protocol 2 Support Protocol 1 Glen Research
4.4.20 Supplement 1
Current Protocols in Nucleic Acid Chemistry
would then be targeted for destruction by the 2-5A component via a localized activation of the latent 2-5A-dependent RNase. The prototype 2-5A-antisense chimera consisted of an antisense domain made up of oligo(dT)18 connected to 2-5A through a linker (Lesiak et al., 1993; Torrence et al., 1993). The 2-5A and antisense moieties were joined together through phosphodiester bonds and two 1,4-butanediol molecules linked to each other by a phosphodiester function. Linkage to the 2-5A tetramer was at the 2′-terminal hydroxyl, and linkage to the antisense oligonucleotide was at the 5′-terminal hydroxyl. The mode of linkage to the 2-5A component was through the 2′ terminus of the oligomer, since a free 5′-monophosphate was required for maximal 2-5Adependent endonuclease activity (Johnston and Torrence, 1984; Player and Torrence, 1998). Linker elements were used to join 2-5A to the antisense DNA sequence rather than directly joining the terminal 2-5A adenosine nucleotide to the first nucleotide of the antisense sequence. Such a strategy was used because of the possibility that RNase L, once bound to the 2-5A component of the chimera, might disturb hybridization to target RNA, or conversely that the double helix generated by the antisense oligonucleotide and the sense RNA might interfere with binding to RNase L. The 2-5A antisense approach has led to sequence-specific cleavage of a modified human immunodeficiency virus RNA (Torrence et al., 1993) and of mRNA encoding the dsRNA-dependent protein kinase (PKR) in cell-free systems (Maitra et al., 1995), as well as ablation in intact HeLa cells of PKR mRNA, PKR protein, and the biological function of PKR (Maran et al., 1994). In addition, respiratory syncytial virus (RSV) replication has been inhibited by specific 2-5A-antisense targeting of the RSV M2 mRNA (Cirino et al., 1997). The actual chemical synthesis of 2-5A-antisense oligonucleotides involves the solid-support phosphite-triester approach to DNA/RNA synthesis (e.g., Beaucage and Caruthers, 1981). Appropriately protected 2-cyanoethylphosphoramidite derivatives of the riboadenosine, butanediol linker, and the usual four deoxyribonucleosides are used for chain elongation. Sugar protection consists of the usual 4,4′-dimethoxytrityl for 5′ hydroxyls and tert-butyldimethylsilyl for 2′ or 3′ hydroxyls. For base protection, ABz, CBz, and Gi-Bu have been used by this laboratory for some time with good success; however, the authors have used commercially available APAC, Ci-Bu, and GPAC,
which allow faster ammoniacal workup and yield slightly cleaner crude product. 2-Cyanoethylphosphoramidites are the functionality of choice for phosphodiester bond generation. The following generic oligonucleotide structural types are described in this unit: I: 5′-pA(2′,5′-pA)3-2′-p[(CH2)4p]2dN(3′,5′pdN)n II: 5′-pA(2′,5′-pA)3-2′-p[(CH2)4p]2dN(3′,5′pdN)m(3′,3′-pdN) Analytical results are somewhat different when the snake venom phosphodiesterase protocol is applied to a type II (Li et al., 1997) 2-5A-antisense chimera. Specifically, a (3′-3′)dinucleotide 5′-monophosphate derived from the last two nucleotides of the chimera’s 3′ terminus is produced. Structural information to corroborate the identity of the dinucleotide can be obtained by comparing their HPLC on-line UV spectra with the calculated spectra of the 1:1 summation of constituent mononucleotides. Finally, the structure of the (3′-3′)dinucleotide fragment can be corroborated by comparing the HPLC chromatogram of the enzymatically digested product with that of a synthetic dinucleotide produced by a DNA synthesizer using a nucleoside bound to CPG through the 5′-hydroxyl group. The retention times of the (3′-3′)-dinucleotide products vary depending upon their composition and, in some cases, can interfere with other peaks in the HPLC analysis of snake venom phosphodiesterase digests. Under these conditions, accurate analysis of these key digestion products can be problematic. In order to obviate this difficulty, digestion with snake venom phosphodiesterase can be carried out with the addition of bacterial alkaline phosphatase. This results in the removal of all noninternucleotide phosphates, so that digestion products consist of nucleosides and the (3′-3′)dinucleotide. Thus, this modified digestion procedure can result in a shift in retention times (Rt) such that each individual product is well separated from the others. This additional digestion procedure is not always necessary; its necessity depends on the composition of the dinucleotide product. Many (3′-3′)-dinucleotides can be resolved very well from all nucleotides, and can be easily identified by their on-line UV spectra and subsequently integrated. In general, the syntheses follow the strategies developed in Lesiak et al. (1993), Xiao et al. (1996), and Li et al. (1997). Type I 2-5A-antisense chimeras were the first structural type
Synthesis of Modified Oligonucleotides and Conjugates
4.4.21 Current Protocols in Nucleic Acid Chemistry
Supplement 1
synthesized (Lesiak et al., 1993; Torrence et al., 1993) and were used with success in cell-free systems and in intact cells (Torrence et al., 1993; Maran et al., 1994; Maitra et al., 1995). Type II 2-5A-antisense chimeras with 3′-terminally inverted phosphodiester bonds have proven to be of greater stability toward exonuclease degradation and have been exploited to block respiratory syncytial virus replication (Cirino et al., 1997).
Critical Parameters In the prototypical 2-5A antisense chimera, 2-5A and antisense DNA were joined through two linkers of 1,4-butanediol phosphate that arise from the key intermediate 4-O-(4,4′dimethoxytrityl)oxybutyl-1-[(2-cyanoethyl)N,N-diisopropylphosphoramidite]. The yield of this intermediate is improved significantly when using 2:10:1 (v/v) ethyl acetate/hexane/triethylamine as the flash purification chromatography solvent. Triethylamine in the purification may prevent decomposition of this acid-sensitive compound during exposure to silica gel. Key considerations in the characterization of 2-5A-antisense chimeras include: (1) that (2′,5′)-phosphodiester bonds in the RNA portion of the chimera are not isomerized to (3′,5′)phosphodiesters during or after synthesis; (2) that 1,4-butanediol phosphate linker connects 2-5A and antisense DNA in the anticipated position; and (3) that phosphorylation does, in fact, occur at the 5′ terminus in high yield. Approaches to address these questions may be found in Xiao et al. (1996).
Anticipated Results
Synthesis and Characterization of Chimeric 2-5A-DNA Oligonucleotides
Under the conditions described herein, the coupling efficiencies for different regions of the 2-5A-antisense molecule should be: antisense DNA, 98% to 99%; butanediol linkers, 97% to 98%; (2′,5′)-RNA, 94% to 98 %; and phosphorylation, 98% to 99%. The average stepwise coupling yield for 2-5A-antisense chimera should be 96% to 98%. When 2-5A-antisense oligonucleotides are synthesized and purified according to the procedures outlined herein, products of purities approaching 95% are possible. Isolated yields of purified chimeric oligonucleotides of 70 A260 units are achievable. The digestion of a representative 2-5A-antisense chimera with snake venom phosphodiesterase is shown in Figure 4.4.4. This HPLC picture of the snake venom digestion differs when the substrate for digestion contains a
(3′-3′)-phosphodiester-linked dinucleotide. When a representative (3′-3′)-tailed chimera, 5′-pA(2′5′-pA)3-2′p(Bup)2-pd[AAT GGG ATC CAT TTT GTC C(3′-3′)C], is digested under standard conditions with snake venom phosphodiesterase, the HPLC of digestion products will reveal seven major peaks with retention times of 10.8, 29.2, 31.1, 32.59, 39.3, 40.2, and 41.5 min. The first five correspond to, respectively, dCMP, dTMP, dGMP, rAMP, and AMP(pBu)2. At 40.2 min, a new product appears that is not observed in a similar digestion of a standard first-generation 2-5A-antisense chimera with no 3′-3′ linkage. Lastly, dAMP is at 41.5 min. The overall ratio of above nucleotidic digestion products is 3:7:4:3:4 for dCMP/dTMP/dGMP/rAMP/dAMP, revealing an underabundance of dCMP from what would be expected from complete digestion. However, the peak with retention time of 40.2 min possessed a UV spectrum that could be generated by 1:1 addition of the spectra of two mononucleotides, 2 × dCMP. Thus, the structure pdC3′p3′dC can be assigned to this new peak. The structure of this product (3′-3′)-dinucleotide can be corroborated by comparison of the HPLC chromatogram of enzymatically digested product with synthetic dinucleotide. Similar HPLC digestion patterns were obtained when other (3′-3′)-tailed chimeras were digested with snake venom phosphodiesterase. For instance, pA4-[pBu]2-pd[GCC CAC CGG GTC CAC CAT(3′-3′)C] gave the dinucleotide pdT3′p3′dC (Rt = 46.0 min) and pA4-[pBu]2pd[TGG GAA GCT GTC ACT GTA GAG(3′3′)C] yielded pdG3′p3′dC (Rt = 44.4 min). The (3′-3′)-dinucleotides can be assigned structures based on a comparison of their UV spectra with the calculated spectra from 1:1 summation of constituent mononucleotides. The retention times of the (3′-3′)-dinucleotide products varied depending upon their composition. For instance, the retention time of pdC3′p3′dC is close to that of other digestion products such as dAMP (Rt = 41.5 min) or AMP(pBu)2 (Rt = 40.2 min). Under these conditions, accurate analysis of these key digestion products may be problematic. To deal with this difficulty, digestion with snake venom phosphodiesterase can be carried out with the addition of bacterial alkaline phosphatase. This results in the removal of all non-internucleotide phosphates, so that digestion products consist of nucleosides and the (3′-3′)-dinucleotide. Thus, for instance, when the chimera 5′pA(2′,5′-pA)3-2′-(pBu)2-pd[AAT GGG ATC CAT TTT GTC C(3′-3′)C] is digested with
4.4.22 Supplement 1
Current Protocols in Nucleic Acid Chemistry
snake venom phosphodiesterase and bacterial alkaline phosphatase, the following products are obtained: dC (Rt = 25.6 min), dG (Rt = 42.8 min), dT (Rt = 44.8 min), dC3′p3′dC (Rt = 47.8 min), rA (Rt = 50.1 min), dA (Rt = 51.8 min), and A2′pBupBu (Rt = 54.9). Thus, this modified digestion procedure resulted in a shift in Rt values such that each individual product was well separated from the others. This additional digestion procedure is not always necessary, and its use depends on the constitution of the dinucleotide product.
Time Considerations The following are estimations of the time needed for various stages of the synthesis, purification, and characterization of a chimeric 2-5A-antisense oligonucleotide. Support Protocol 1 requires 6 days for synthesis of N6-benzoyl-5′-O-dimethoxytrityl-3′O-tert-butyldimethylsilyladenosine-2′-N,Ndiisopropylphosphoramidite. Support Protocol 2 requires 2 days for synthesis of 4-O(4,4′-dimethoxytrityl)oxybutyl-1-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite. Basic Protocol 1 requires 6 to 8 hr for automated 2-5A-antisense chimera synthesis on an ABI 391 or 392 synthesizer, and 3 hr to overnight for cleavage and deprotection of the chimera. Basic Protocol 2 requires 6 hr for purification of the chimera by polystyrene reversedphase ion-pair HPLC; 6 hr for desalting and concentration of the chimera; 3 hr for cation exchange; 24 to 48 hr for dialysis and sterilization; 12 hr for capillary gel electrophosesis (a large number of samples may be run in this time when using an autosampler); and 4 hr for the Dionex HPLC purity check. Basic Protocol 3 requires 6 to 8 hr for snake venom digestion and HPLC analysis of three samples. Basic Protocol 4 requires 4 hr for labeling the chimera with terminal nucleotide transferase; 4 hr for determining the specific activity of the radioactive chimera; 6 to 8 hr for MaxamGilbert sequencing; plus the necessary time for autoradiograph exposure.
Literature Cited Beaucage, S.L. and Caruthers, M.H. 1981. Deoxyribonucleotide phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862. Cirino, N.M., Li, G., Xiao, W., Torrence. P.F., and Silverman, R.H. 1997. Targeting RNA for decay in respiratory syncytial virus infected cells with 2′→5′ oligoadenylate antisense. Proc. Natl. Acad. Sci. U.S.A. 94:1937-1942. Johnston, M.I. and Torrence, P.F. 1984. The role of interferon-induced proteins, double-stranded RNA and 2′,5′-oligoadenylate in the interferonmediated inhibition of viral translation. In Interferon: Mechanism of Production and Action (R.M. Freidman, ed.) pp. 189-298. Elsevier/ North-Holland, Amsterdam. Lesiak, K., Khamnei, S., and Torrence, P.F. 1993. 2′,5′-Oligoadenylate:antisense chimeras—Synthesis and properties. Bioconjugate Chem. 4:467-472. Li, G., Xiao, W., and Torrence, P.F. 1997. Synthesis and properties of second generation 2-5A-antisense chimeras with enhanced resistance to exonucleases. J. Med. Chem. 40:2959-2966. Maitra, R.K., Li, G., Xiao, W., Dong, B., Torrence, P., and Silverman, R.H. 1995. Catalytic cleavage of an RNA target by 2-5A antisense and RNase L. J. Biol. Chem. 270:15071-15075. Maran, A., Maitra, R.K., Kumar, A., Dong, B., Xiao, W., Li, G., Williams, B.R.G., Torrence, P.F., and Silverman, R.H. 1994. Blockage of NF-kB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 265:789792. Player, M. and Torrence, P.F. 1998. The 2-5A system: Modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol. Therapeut. 78:55-113. Torrence, P.F., Maitra, R.K., Lesiak, K., Khamnei, S., Zhou, A., and Silverman, R.H. 1993. Targeting RNA for degradation with a (2′-5′)oligoadenylate-antisense chimera. Proc. Natl. Acad. Sci. U.S.A. 90:1300-1304. Xiao, W., Player, M.R., Li, G., Zhang, K., Lesiak, K., and Torrence, P.F. 1996. Synthesis and characterization of composite nucleic acids containing 2′,5′-oligoriboadenylate linked to antisense DNA. Antisense Nucleic Acid Drug Devel. 6:247-258.
Contributed by Mark R. Player and Paul F. Torrence Northern Arizona University Flagstaff, Arizona
Synthesis of Modified Oligonucleotides and Conjugates
4.4.23 Current Protocols in Nucleic Acid Chemistry
Supplement 1
Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides Applications of oligonucleotide conjugates encompass mechanistic and hybridization probes, antisense agents, and sensors. Consequently, methods for their synthesis constitute an active area of research. This unit focuses on methods for the preparation of oligonucleotides conjugated at their 3′ termini (Fig. 4.5.1, S.1). Conjugation at the 3′ terminus of an oligonucleotide has been noted as being less common than at other sites within oligonucleotides, because this position commonly serves as the site for covalent linkage to the solid phase synthesis support (Goodchild, 1990); however, the valuable physicochemical properties of 3′-oligonucleotide conjugates, such as their ability to stabilize nucleic acid hybridization complexes and to retard the activity of exonucleases, provides strong incentive to develop methods for their preparation. The synthesis of 3′-oligonucleotide conjugates was included in previous reviews published during the past decade, and therefore this author will try to minimize redundancy. The reader is referred to these previous reviews for further information (Goodchild, 1990; Agrawal, 1994; Beaucage and Iyer, 1993; Fidanza et al., 1994). Methods for the synthesis of 3′-oligonucleotide bioconjugates will be divided into three general categories: preparation of modified supports and phosphoramidites, postsynthetic modification of deprotected oligonucleotides, and the recently developed method utilizing solution phase conjugation of protected oligonucleotides. The latter two methods require modified solid phase synthesis supports which release oligonucleotides containing the appropriate 3′-terminal functional group. Such supports are described briefly in this review. The variety of new supports that produce oligonucleotides containing 3′-hydroxyl termini are not included. Due to the growing importance of nucleopeptides and surface/polymer supported oligonucleotides, methods for the synthesis of these two general
5'-HO
oligo
O
conjugant
1
Figure 4.5.1 jugate.
Generic oligonucleotide 3′-con-
UNIT 4.5
families of conjugates are presented separately. A representative, but not exhaustive, set of examples of each method is presented, and apologies are extended to any authors whose work is not cited.
MODIFIED SOLID PHASE SYNTHESIS SUPPORTS AND PHOSPHORAMIDITES Modifying the 3′ termini of oligonucleotides with polymers such as poly-L-lysine or polyethylene glycol (PEG) is desirable in order to improve the pharmacological properties of antisense probes. 3′-PEG-derivatized oligonucleotides have been prepared from a specially designed solid phase synthesis support in which the PEG serves as a linker between the controlled-pore glass (CPG) support and the growing oligonucleotide (Fig. 4.5.2, S.2; Jaschke et al., 1993). By loading the PEG onto the solid support as its succinato ester, 3′-PEG-derivatized oligonucleotides are released under standard aqueous ammonium hydroxide deprotection conditions. Succinato derivatives of smaller molecules, such as cholesterol, have also been used to prepare 3′-oligonucleotide conjugates (Fig. 4.5.2, S.3; MacKellar et al., 1992). A variety of solid phase supports have been prepared from a common amino derivative of glycerol (Nelson et al., 1992). The masked nucleophile was originally employed as it N-9fluorenylmethoxycarbonyl (Fmoc)–protected derivatives as a means for introducing 3′-alkylamines into oligonucleotides (Nelson et al., 1989). In later studies, the support was modified to contain a longer butylamine linker in order to alleviate potential steric interactions between the conjugated moiety and the remainder of the oligonucleotide backbone (Fig. 4.5.3, S.4 and S.5; Nelson et al., 1989). Recently, this modification was used for preparing doubledye-labeled oligonucleotides containing tetramethylrhodamine at their 3′ termini (Mullah and Andrus, 1997). In each of the above examples a new solid phase synthesis support must be prepared for each 3′ reporter group or conjugate. Recently, a method that circumvents this procedure was reported (Nelson et al., 1997). The method employs a universal solid phase support (Fig. 4.5.4, S.6) which releases an intermediate 3′-
Contributed by Marc M. Greenberg Current Protocols in Nucleic Acid Chemistry (2000) 4.5.1-4.5.19 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.5.1 Supplement 2
O O(CH2CH2O)nDMTr
(CH2)3NH O
O O
DMTrO O
N H
O DMTr, 4,4'-dimethoxytrityl
3
Figure 4.5.2 Solid phase supports for attaching polyethylene glycol (S.2) and cholesterol (S.3) to the 3′ termini of oligonucleotides.
tetrahydrofuranyl phosphodiester (Schwartz et al., 1995; Scheuer-Larsen et al., 1997). This intermediate undergoes subsequent cyclic phosphate formation and ultimately releases a 3′-hydroxyl oligonucleotide upon further alkaline treatment in a manner analogous to RNA hydrolysis. When a modified phosphoramidite is the first species coupled to the support, 3′modified oligonucleotides containing hydroxyl termini are produced upon cleavage. Although the method still requires the preparation of the appropriate modified phosphoramidite, it has the advantage that the same amidite can be used for introducing the respective modification at other sites within the oligonucleotide. Hence, one does not need to synthesize both a modified support and a modified phosphoramidite. Furthermore, when used in conjunction with a more labile diglycolate linker in lieu of the standard succinato moiety,
the oligonucleotides are cleaved using a mixture of t-butylamine, methanol, and water. The dye-labeled oligonucleotides prepared by the above methods have been used for detecting a polymerase chain reaction (PCR) product in real time (Mullah et al., 1998). In an earlier oligonucleotide conjugate synthesis method, attomolar oligonucleotide detection limits were achieved using multiple nonradioactive labels at the 3′ termini (Haralambidis et al., 1990a,b). The method relied upon linear synthesis of a polyamide on CPG, followed by incorporation of a linker molecule, which allows one to then carry out standard oligonucleotide synthesis. This strategy is useful for preparing nucleopeptides (see below), but more relevant to the present discussion is its utility for preparing oligonucleotides containing multiple labels via conjugation to alkylamine side chains of the polyamide portion of the mole-
O
O
O
O
NH
NH
HN
DMTrO
3
O
N H
2
S
4
O
DMTrO
O
O
NH
3
O
Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides
N H
O
5
Figure 4.5.3 Solid support for conjugating biotin (S.4) or other conjugants (S.5) to oligonucleotides at their 3′ termini.
4.5.2 Supplement 2
Current Protocols in Nucleic Acid Chemistry
O
H N
O
ODMTr
O 6
O
H N std. oligo synthesis
O O P O X
O O
prot. oligo
OH-5'
OR
O
O aq. NH4OH, LiCl
−
−
O
O O O P O X
oligo
OH-5'
HO aq. NH4OH, LiCl
O O
oligo
O P O X O
OH-5'
–
O
oligo
HO X
Figure 4.5.4
OH-5'
X = modified phosphoramidite R = phosphate protecting group
A universal support for preparing 3′-modified oligonucleotides.
cule. The labels can be incorporated prior to or after oligonucleotide synthesis, while the nucleic acid component is on the solid support or in solution. In contrast, the thioester support (Fig. 4.5.5, S.7) enables introduction of conjugation as part of the main chain of the polymer (Hovinen et al., 1995). The thioester support was preceded by other versatile solid phase supports from which oligonucleotides containing a variety of 3′ termini could be prepared (Hovinen et al., 1993a,b, 1994); however, by utilizing a thioester linkage, more homogeneous products were obtained in good yields using a large excess of alkylamine nucleophiles (Hovinen et al., 1995).
SOLID PHASE SYNTHESIS SUPPORTS FOR PRODUCING 3′-FUNCTIONAL GROUPS SUITABLE FOR CONJUGATION In order to carry out postsynthetic conjugation of oligonucleotides, the biopolymers must contain a suitable functional group at their 3′ termini. Utilization of the nucleophilicity of sulfur in conjugation chemistry has resulted in the preparation of numerous solid phase supports that release oligonucleotides containing thiols at their 3′ termini (e.g., Fig. 4.5.6, S.8; Asseline et al., 1992; Bonfils and Thuong,
1991; Gottikh et al., 1990; Gupta et al., 1990, 1991; Kumar, 1993a,b; Zuckerman et al., 1987). In some instances the initially cleaved 3′-thiol group is transformed into other functional groups that are also useful for preparing bioconjugates. These groups include 3′-phosphates, 3′-phosphorothioates, 3′-alkylamines, and 3′-alkyl carboxylic acids (Asseline et al, 1992; Gottikh et al., 1990; Gupta et al., 1991). 3′-Phosphorylated oligonucleotides can be obtained by a variety of supports, some of which are designed to be compatible with chemically unstable biopolymers (Gryaznov and Letsinger, 1992; Guzaev and Lönnberg, 1997). Preparation of oligonucleotides containing 3′-dialdehydes are readily prepared by utilizing a solid phase support containing a ribonucleoside, but this limits the structure of the tether between the oligonucleotide and 3′-electrophile. Consequently, supports designed to release alkyl aldehydes have been developed (e.g., Fig. 4.5.6, S.9; Urata and Akagi, 1993). This glyceryl support is designed to be universal, and to release a terminal, vicinal diol upon cleavage
O O
NH
S
8
NH
OAc O
NH
S
ODMTr
O
ODMTr O
ODMTr
O
O
O
S
Ac, acetyl
9
7
Figure 4.5.5 Thioester support for the preparation of 3′-modified oligonucleotides.
Figure 4.5.6 Supports for the release of oligonucleotides containing 3′-thiols (S.8) and 3′aldehydes (S.9).
Synthesis of Modified Oligonucleotides and Conjugates
4.5.3 Current Protocols in Nucleic Acid Chemistry
Supplement 2
O O
NH
ODMTr O
10
O O
NH
O
O
ODMTr O
11
O N H
O
O O
O
N H
OH S
O 12
Figure 4.5.7
Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides
O
ODMTr 4
13
Supports for the release of oligonucleotides containing various 3′-functional groups.
under standard concentrated aqueous ammonia conditions. Subsequent periodate oxidation generates the desired 3′-aldehyde. A versatile family of solid phase supports that enable one to introduce 3′-alkyl carboxylic acids, 3′-alkylamines, or 3′-alkyl thiols concomitantly with cleavage/deprotection of the oligonucleotides from the supports has also been reported (e.g., Fig. 4.5.7, S.10 and S.11; Hovinen et al., 1993a,b, 1994, 1995). In some instances differentiation of the cleavage and deprotection steps can be achieved by employing a thioester-based support (Fig. 4.5.5, S.7). An alternative variation that utilizes this concept appeared recently (Lyttle et al., 1997). In this instance, a common solid phase support (Fig. 4.5.7, S.12) is modified prior to oligonucleotide synthesis with an appropriate dimethoxytritylated tether to produce a support (e.g., Fig. 4.5.7, S.13) that will release oligonucleotides containing the desired 3′-terminal functional group upon cleavage/deprotection. In most instances, oligonucleotides are cleaved from the above supports under conditions that also result in cleavage of the exocyclic amines and phosphate diester protecting groups. In some instances, transamination is a competitive process (Hovinen et al., 1995). Orthogonal solid phase supports enable one to cleave oligonucleotides from the support without affecting the protecting groups throughout the biopolymer. These supports have proven invaluable in developing methods for bioconjugation using protected oligonu-
cleotides. The first reported series of orthogonal solid phase supports utilized UV-irradiation to induce cleavage. Oligonucleotides containing 3′-hydroxyl groups (Greenberg and Gilmore, 1994; Venkatesan and Greenberg, 1996), 3′-alkyl carboxylic acids (Yoo and Greenberg, 1995), 3′-alkylamines (McMinn and Greenberg, 1996), and 3′-phosphates (Avino et al., 1996; Dell ’Aquila et al., 1997; McMinn et al., 1998; Fig. 4.5.8, S.14 to S.17, respectively) were obtained using the o-nitrobenzyl photoredox reaction. More recently, Pd(0) labile supports that facilitate the release of 3′-phosphato, 3′-hydroxyl, and 3′-alkyl carboxylic acid containing oligonucleotides have been reported (Fig. 4.5.8, S.18, S.19, and S.20, respectively; Greenberg et al., 1998; Matray et al., 1997; Zhang et al., 1997).
POSTSYNTHETIC CONJUGATION Conjugation of 3′-Alkylamines The polyamide methods developed by Haralambidis (1990a,b) are compatible with conjugation to alkylamines in solution, following oligonucleotide deprotection. Common means of forming such conjugates involve in situ activation of carboxylic acids, or the use of the less reactive but more water tolerant N-hydroxysuccinimide esters (NHS-esters) or isothiocyanates. Using a support similar to those developed by the Clontech group (Fig. 4.5.9, S.21), Thaden and Miller (1993a,b) prepared an oli-
4.5.4 Supplement 2
Current Protocols in Nucleic Acid Chemistry
O H3C DMTrO
NH N
O O
O DMTrO
O
O n
O
NO2
O
CH3O
H3CO
O
NO2
n= 1-4
H N
O
O N H
O 14
DMTrO
H N
15
DMTrO
O
n
O
NO2
NO2
n= 4-6
CH3O
CH3O
H N
O
H N
O 2
2
O
O 17
16
O H3C DMTrO
O
NH N
O
O
DMTrO
O O
N H
3
O
O 3
O
7
O
N H
19
18
O DMTrO 3
O O
3
N H
20
Figure 4.5.8
Photolabile and Pd(0)-labile orthogonal oligonucleotide synthesis supports.
gonucleoside methylphosphonate containing a 3′-rhodamine reporter group. Coupling is achieved with ∼85% yield by reacting ten molar equivalents of rhodamine isothiocyanate with the biopolymer at room temperature for 18 hr (Thaden and Miller, 1993b). Oligonucleotides containing 3′-chlorin groups (Fig. 4.5.9, S.22) were prepared by activating the carboxylic acid on the chlorin component (Boutorine et al., 1996). The required alkylamine-containing oligonucleotide was prepared indirectly from the 3′-phosphorylated biopolymer via a redox con-
densation reaction with a diamine. The coupling proceeded in 30% to 40% conversion and, like the isothiocyanate example above, required several hours. In another example from the same contribution to the literature, the 3′phosphate of the oligonucleotide was activated with a symmetrical dihydrazide, and the free hydrazide was condensed with a chlorin containing an aldehyde (Boutorine et al., 1996). The resulting hydrazone also was obtained in modest overall yield.
Synthesis of Modified Oligonucleotides and Conjugates
4.5.5 Current Protocols in Nucleic Acid Chemistry
Supplement 2
O
DMTrO O
NH
O N 2
O
2
N H
O
21 H O HO H3C
CH3
N NH
HN N
H3C
CH3
HO2C O
N H
4
O N P O H − O
oligo
OH-5'
22
Figure 4.5.9
Introduction of dyes and porphyrins at the 3′ termini of oligonucleotides.
Conjugation of 3′-Alkyl Carboxylic Acids Oligonucleotides containing 3′-alkyl carboxylic acids can be conjugated to amines following activation in situ with standard peptide coupling agents (Gottikh et al., 1990); however, one should note that these conditions can give rise to significant amounts of nonspecific covalent modification. One can obtain the requisite 3′-alkyl carboxylic acid directly from designed supports, or this functional group can be introduced postsynthetically. For example, daunomycin was linked to the 3′ terminus of an oligonucleotide (Fig. 4.5.10, S.23) via amide bond formation. The multistep process started from a disulfide support which yields 3′-phosphorylated oligonucleotides (Fig. 4.5.10, S.8; Gottikh et al., 1990). Activation of the phosphate group was followed by reaction with an amino acid. In this particular instance, activation/coupling with carbodiimide took place over 5 hr at 4°C, and yields were not reported.
Conjugation of 3′-Alkyl Thiols Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides
Significant advantage has been taken of the nucleophilicity of sulfur for preparing oligonucleotide conjugates. As mentioned above, a variety of supports have been developed that result in the release of oligonucleotides containing 3′-alkyl thiols. Cleavage of 3′-alkyl
thiolated oligonucleotides from these supports can be effected under conditions that do not remove the exocyclic amine and phosphate diester protecting groups; however, the thiolcontaining oligonucleotides are typically cleaved/deprotected under reductive conditions in aqueous ammonia, and conjugated in aqueous solutions using the fully deprotected biopolymers. Excellent yields of sulfide linked conjugates are obtained by reacting thiolated oligonucleotides with α-halocarbonyl-containing conjugants (e.g., Fig. 4.5.11, S.24; Gupta et al., 1991). 3′-Oligonucleotide conjugates can also be prepared by reacting 3′-thiolated oligonucleotides with activated disulfides or maleimides (Gupta et al., 1991; Harrison and Balasubramanian, 1997; Kumar, 1993b). Reaction with a maleimide proceeds via the formation of a stable Michael adduct. In one approach, a variety of biologically useful conjugates was prepared in which the Michael acceptor (maleimide) was covalently attached to the 3′ terminus of the oligonucleotide, and the thiol-containing conjugant of interest was loaded on a solid support (Harrison and Balasubramanian, 1997). When preparing oligonucleotide conjugates containing 3′-disulfides, either the 3′-thiolated oligonucleotide or the conjugating species can be activated. Disul-
4.5.6 Supplement 2
Current Protocols in Nucleic Acid Chemistry
O
O O
NH
S
S
oligo
5'-HO
ODMTr
O P OH O
O
−
8
O oligo
5'-HO
O P O HN
O
−
n
oligo
5'-HO
O P O N O
CO2H
O
O P O HN
−
n
23
O
OH
O
N N
H3C
O oligo
5'-HO
OH
−
HO
R=
R O
H3C
O
O
OCH3
HO
Figure 4.5.10
Postsynthetic modification of oligonucleotide 3′-carboxylic acids.
fide transfer has been used for conjugating oligonucleotides at their 3′ termini to small or large molecules and surfaces (Asseline et al., 1992; Gupta et al., 1991; Harrison and Balasubramanian, 1997; Kumar, 1993b; Zuckerman et al., 1987). For example, hybrid enzymes that hydrolyze RNA sequences specifically have also been prepared via disulfide exchange (Zuckerman et al., 1988; Zuckerman and Schultz, 1988).
Conjugation of 3′-Phosphorothioates Conjugations at phosphorous atoms near the 3′ termini of oligonucleotides have been carried out by selectively oxidizing an H-phosphonate linkage with an appropriately substituted amine (Letsinger et al., 1989). The resulting phosphoramidate is carried through a conventional
O oligo
5'-HO
O P O
solid phase synthesis protocol using either phosphoramidite or H-phosphonate chemistry. Ammonolysis and chromatographic purification give a product containing >50% of the respective label. A more common approach to synthesizing 3′-oligonucleotide conjugates takes advantage of the nucleophilicity of phosphorothioates. In one example, 3′-phosphorothioate-containing oligonucleotides were prepared on a solid phase synthesis support (Fig. 4.5.6, S.8; Asseline et al., 1992). Following standard oligonucleotide synthesis and ammoniacal deprotection/cleavage under reducing conditions, the fully deprotected oligonucleotides were conjugated to halogenated substrates (Fig. 4.5.12). Conjugation to derivatives of daunomycin, fluorescein, and 1,10phenanthroline (S.25) containing alkyl halide
−
O
−
SO3 Na
SH
2
O
+
−
SO3 Na
+
oligo
O P O
−
O
S 3
O N H
NH
24
O
I
5'-HO
+
N H
Figure 4.5.11
NH
Postsynthetic modification of oligonucleotide 3′-thiols.
Synthesis of Modified Oligonucleotides and Conjugates
4.5.7 Current Protocols in Nucleic Acid Chemistry
Supplement 2
O oligo
5'-HO
O P OH S
−
N O
+
5'-HO
oligo
O
N
O
O P S
−
N H
N N
O I
N H
Figure 4.5.12
Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides
25
Postsynthetic modification of oligonucleotide 3′-phosphorothioates.
functional groups are believed to have proceeded in essentially quantitative yields over 24 hours in either protic organic solvents containing crown ethers to enhance biopolymer solubility, or mixtures of dimethylformamide and water. This strategy was utilized recently in studies on truncated derivatives of the potent antitumor antibiotics, CC-1065 and the duocarmycins, which alkylate deoxyadenosine at N-3 (Lukhtanov et al., 1996). The active pharmacophore, the cyclopropapyrroloindole, was covalently linked via an α-bromoacetamido linkage to a 3′-phosphorothioate in 50% to 60% yield. Several reports of template-mediated oligonucleotide ligation involving 3′-phosphorothioate DNA have also appeared. Oxidative coupling of a 3′-phosphorothioate oligonucleotide to a 5′-phosphorothioated biopolymer is achieved rapidly (5 min) under mild conditions (0°C) using 1 µM K3Fe(CN)6 (Gryaznov and Letsinger, 1993a). Little or no coupling is detected under these conditions in the absence of a template. In contrast, ligation of a 5′-phosphorothioated oligonucleotide to a 3′-bromoacetamide-containing oligonucleotide proceeded in ∼80% yield after 48 hr at 0°C in the absence of a template (Gryaznov and Letsinger, 1993b). As expected, the presence of a template, which increases the effective concentration of the reaction partners, significantly accelerated the reaction. Essentially quantitative yields of ligated product were obtained in only 20 minutes when a stoichiometric template was present. A distinct advantage of this latter coupling method is that the reaction does not require any exogenous condensing agents. In a subsequent investigation, autoligation was effectively carried out using reaction partners of the opposite polarity, 3′-phosphorothioate and 5′-bromoacetamide (Fig. 4.5.13; Gryaznov et al., 1994).
Conjugation to 3′-Aldehydes Template-mediated synthesis has also been very useful for the conjugation of oligonucleotides containing 3′-aldehydes (Goodwin and Lynn, 1992; Zhan and Lynn, 1997). Aldehydes are attractive electrophiles with which to form oligonucleotide conjugates. Condensation with primary amines under reductive conditions provides secondary amines which are stable to acid and base. Solid supports that produce oligonucleotides containing 3′-aldehydes directly are unknown. Consequently, 3′aldehydes are typically produced via periodate oxidation of a vicinal diol. A common practice for preparing 3′-oligonucleotide conjugates via aldehyde condensation takes advantage of incorporating a ribonucleoside at the 3′ terminus (Fig. 4.5.14; Leonetti et al., 1988). Periodate oxidation of the oligonucleotide containing a 3′-terminal ribonucleoside produces a dialdehyde which under reductive amination conditions generates a morpholine upon reaction with a primary amine. An often cited application of this method concerns the synthesis of poly-L-lysine conjugates of oligonucleotides (Leonetti et al., 1988, 1990). Haralambidis et al. (1994) have utilized this ability to introduce amino acids at the 3′ termini of oligonucleotides to enable attachment of a substituted benzaldehyde, which is then conjugated to an enzyme via reductive amination. Condensation of a dialdehyde with a primary amine was also used recently in the segmental synthesis of a biologically active hammerhead ribozyme (Bellon et al., 1996). Linkage of the two segments was carried out in a loop region of the hammerhead ribozyme which had been shown to not be crucial for catalytic activity. One segment was synthesized so as to incorporate a 5′-alkylamine, while the other half contained a 3′-terminal uridine which served as the source of the dialdehyde. Follow-
4.5.8 Supplement 2
Current Protocols in Nucleic Acid Chemistry
oligo
5'-HO
O
O − O P S OH
Br
oligo
N H
OH-3'
Template
5'-HO
oligo
O O P S O
Figure 4.5.13
O
−
oligo
N H
OH-3'
Template-mediated oligonucleotide coupling.
ing rapid and quantitative periodate oxidation, reductive condensation was carried out to 95% conversion over the course of seven days. In a more recent study, the electrophilic half of a ribozyme was synthesized on a glyceryl sup-
port (Fig. 4.5.6, S.9; Bellon et al., 1997; Urata and Akagi, 1993). In these experiments, conjugation of the two halves of a ribozyme within the loop II region of the unmodified hammerhead proceeded in as high as 81.2% yield
O 5'-DMTrO
prot. oligo
Prot.
O P O − O O
B
O
OTBDMS
O N H
O 1. deprotect 2. oxidize (NaIO4)
5'-HO
oligo
O O P O − O O
B
O H H
O
RNH2, NaCNBH3
5'-HO
oligo
O O P O − O
O
B
N R Prot., nucleobase protecting group TBDMS, tert-butyldimethylsilyl
Figure 4.5.14
Postsynthetic modification of oligonucleotides by reductive amination.
Synthesis of Modified Oligonucleotides and Conjugates
4.5.9 Current Protocols in Nucleic Acid Chemistry
Supplement 2
(48 hr) when borane pyridine was employed as a reducing agent.
Solution Phase Conjugation of Protected Oligonucleotides
Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides
The need for orthogonal linkers that enable the removal of fully protected oligonucleotides from the support for further elaboration in solution was recognized by at least one leader in the field of oligonucleotide synthesis a number of years ago (Zon and Geiser, 1991). The first reports of conjugating protected oligonucleotides in solution appeared in 1997 (McMinn et al., 1997; also see McMinn and Greenberg, 1998, 1999). This new method for synthesizing oligonucleotide conjugates was made possible by the development of a family of orthogonal solid phase synthesis supports (Fig. 4.5.8, S.14 to S.20). Using light or Pd(0), these supports enable one to release oligonucleotides containing 3′-alkylamines, 3′-alkyl carboxylic acids, or 3′-phosphate diesters which retain their exocyclic amine, phosphate diester, and 5′-hydroxyl protecting groups. One advantage of this method is that potential deleterious side reactions are eliminated by utilizing protected oligonucleotides. Nonspecific covalent modifications of unprotected oligonucleotides can be a significant problem when conjugating biopolymers (Bischoff et al., 1987; Erout et al., 1996; Ghosh and Musso, 1987; Lund et al., 1988). In addition, the rates at which conjugation reactions proceed are considerably faster than similar bond-forming reactions using unprotected oligonucleotides. An explanation for this acceleration is uncertain at this time, but may be related to the solvent conditions. Conjugation reactions of protected oligonucleotides are carried out in aprotic organic solvents, whereas unprotected oligonucleotides are often conjugated in aqueous solvents. Amide bond formation in aqueous solvents may be adversely affected by stronger solvation (hydrogen bonding) of the reactants, as well as a lower effective molarity of amines due to protonation. The original report of solution phase conjugation of protected oligonucleotides utilized a redox condensation or a Mukaiyama reaction to activate carboxylic acids (Fig. 4.5.15; McMinn et al., 1997; Mukaiyama, 1976). The oligonucleotides contained 3′-alkylamines. During the course of developing the conjugation chemistry, it was discovered that the “fast deprotecting” amides used to protect deoxyadenosine and deoxyguanosine underwent transamidation with the 3′-terminal alkyl-
amines (McMinn and Greenberg, 1997). Thus, phenoxyacetyl-protected phosphoramidites should not be used in conjunction with alkylamine modifiers. The observed transamidation is of general importance, because of the commercial availability of alkylamine modifiers for oligonucleotide synthesis. This problem was overcome by using isobutyryl exocyclic amine protecting groups for deoxyadenosine, deoxycytidine, and deoxyguanosine. Subsequently, a variety of biologically relevant reporter groups such as biotin and acridine were conjugated in excellent yields (88%) under mild reaction conditions (2 hr at 55°C) using only ten molar equivalents of carboxylic acids and activating reagents relative to oligonucleotide substrate. Only cholesterol coupled in <88% yield (i.e., 83%), and this may be attributed to difficulties in isolation of the very nonpolar conjugate. Optimization of the reaction process revealed that yields were not diminished by using as few as five molar equivalents of reagents relative to 3′-functionalized oligonucleotide, and were unaffected by increasing the length of the biopolymer (McMinn and Greenberg, 1998). N-Protected tripeptides also served as suitable coupling partners. For example, conjugation of N-Fmoc-Gly-Gly-His proceeded in 89% yield (Fig. 4.5.16, S.26) and, in contrast to other methods, prior chemical elaboration of the tripeptide were not required in order to introduce this nuclease mimic (McMinn et al., 1997; Truffert et al., 1996). Coupling under the Mukaiyama conditions did result in some epimerization of the α-amino acid. This limitation was overcome using benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) or 2-(1H-benzotriazolyl)1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) as activating agents, with no detriment to the yields of the conjugates (McMinn and Greenberg, 1998). The greater ease of using PyBOP or HBTU also proved useful for the efficient synthesis of (5′,3′)-bisconjugates (Fig. 4.5.16, S.27; Kahl et al., 1998). Protected oligonucleotides containing 3′-alkylamines also proved to be suitable substrates for isocyanates. Nearly quantitative yields of alkyl aryl ureas (e.g., Fig. 4.5.17, S.28) were obtained upon reaction with ten molar equivalents of aryl isocyanates. Coupling of the less reactive alkyl isocyanate generated slightly lower yield (88%), despite using twice the number of equivalents of isocyanate. The ability to conjugate isocyanates to protected oligonucleotides containing 3′-alkylamines facilitated the synthesis of oligonucleotide-peptide conju-
4.5.10 Supplement 2
Current Protocols in Nucleic Acid Chemistry
DMTrO
H N
O
6
O
NO2
CH3O
H N
O 2
O 16 1. std. oligo synthesis 2. photolysis
O DMTrO
prot. oligo
O P O (CH2)6NH2 O
CN
RCO2H, (PyS)2, PPh3, DMAP O
DMTrO
H O P O (CH2)6 N
prot. oligo
O
CN
R O
deprotection
HO
oligo
O H O P O (CH2)6 N O
R
−
O
Py, pyridin-2-yl DMAP, 4-dimethylaminopyridine Figure 4.5.15
Solution phase conjugation of protected oligonucleotides.
gates in which the 3′ terminus of the oligonucleotide was coupled to the N terminus of a peptide (McMinn and Greenberg, 1998). Conjugate S.29 (Fig. 4.5.17) was obtained in a 70% yield upon reaction of twenty molar equivalents of the respective isocyanate for 4 hr at 55°C; however, the method was limited with respect to the sequences of peptides that can be employed. For instance, peptides containing bulky side chains at their amino termini coupled poorly. The resulting conjugates contain the opposite topology between the oligonucleotide and peptide as that obtained from the amide-forming reaction described in Figure 4.5.18.
Conjugation of the 3′ termini of oligonucleotides to the amine terminus of tripeptides was achieved in a more general manner by using protected oligonucleotides containing 3′alkyl carboxylic acids (Kahl and Greenberg, 1999). In general, conjugation of protected oligonucleotides containing 3′-alkyl carboxylic acids to primary alkyl amines proceeded equally efficiently as analogous reactions involving 3′-alkylamine-containing oligonucleotides. Furthermore, the amide-forming reaction was essentially unaffected by steric hindrance during coupling to the amino termini of peptides. Conjugation of 3′-alkyl-carboxylicacid-containing oligonucleotides to the amino termini of peptides produces conjugates con-
Synthesis of Modified Oligonucleotides and Conjugates
4.5.11 Current Protocols in Nucleic Acid Chemistry
Supplement 2
O
O d(oligonucleotide) O P O − O
N H N
5
O
H N
NH2
N H
O N H
26 O RNH(CH2)6O P O − O
O d(oligonucleotide) O P O(CH2)6NHR' − O
O R=
HN
3
H N NH
R' =
O
N N H
S O
O
H N
NH2 O
27
Figure 4.5.16 cleotides.
Oligonucleotide conjugates and bis-conjugates prepared from protected oligonu-
taining the same topology as the urea bondforming reaction (Fig. 4.5.18). In contrast to the urea bond-forming method, oligonucleotide-peptide conjugates synthesized in this manner proceeded efficiently even when the N-terminal amino acid was sterically hindered. For instance, S.30 (Fig. 4.5.18) was obtained in 95% yield via a PyBOP mediated coupling, whereas the analogous conjugate formed via coupling of an oligonucleotide amine and isocyanate proceeded in <20% yield (McMinn and Greenberg, 1998).
The Synthesis of Nucleopeptides The importance of nucleopeptides and protein-nucleic acid interactions has provided the driving force behind several methods for synthesizing these bioconjugates. Consequently, many of the methods for preparing 3′-oligonucleotide conjugates described above have been applied to the synthesis of nucleopeptides. Recently, the method involving the solution phase coupling of protected oligonucleotides containing 3′-alkylamines to carboxyl-protected peptides was applied to the synthesis of a conjugate consisting of the operator site of the λ
O
O 5'-d(oligonucleotide) O P O − O
5
N H
N H
NO2
28
O 5'-d(oligonucleotide) O P O − O Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides
O
H N
N 5
N H
N H
O
O
O NH2 CH3
29 Figure 4.5.17 alkylamines.
Oligonucleotide conjugates prepared from protected substrates containing 3′-
4.5.12 Supplement 2
Current Protocols in Nucleic Acid Chemistry
O
O 5'-d(oligonucleotide) O P O O
(CH2)6 N H
−
R
O
H N
N H
O
N H
R'
O
+
R"
O
n
δ
O
(CH2)6 N H
−
R'
H N R
O
+
NH3
N H
O
n
−
R"
+
δ
δ
O 5'-d(oligonucleotide) O P O O
CH2Ph
O
H N
−
R'''
O
NH2
N H
3
3
+
O
−
δ
δ
30
−
δ O
O 5'-d(oligonucleotide) O P O
−
R'''= isobutyl
Figure 4.5.18
Topological control of nucleopeptide formation.
repressor helix-turn-helix protein and a modified version of the DNA-binding helix of λ repressor (McMinn and Greenberg, 1999). The desired bioconjugate (Fig. 4.5.19, S.31) was obtained in 72% yield using ten molar equivalents of peptide and PyBOP. Attempted synthesis of the related nucleopeptide (Fig. 4.5.19, S.32) containing the naturally occurring DNAbinding helix of λ repressor resulted in the isolation of S.33 (Fig. 4.5.19) in 96% yield. It was proposed that S.33 was formed via an N-
O
O 5'-d(CAG TGG TAT GAT A) O P O O
−
to O-transacylation during the concentrated aqueous ammonia deprotection of the initially formed conjugate. The fact that S.33 was not observed during the synthesis of S.31 suggests that even slight steric hindrance prevents the undesired transacylation process. Oligonucleotide conjugates of large proteins such as modified serum albumin have been prepared via disulfide exchange. In this study, a 3′-thiolated oligonucleotide obtained from a disulfide support was conjugated to a
(Gln-Ser-Ala-Val-Gly-Ala-Leu-Phe-Asn)NHCOCH3
N H
5
31 O
O 5'-d(CAG TGG TAT GAT A) O P O O
−
5
(Gln-Ser-Ala-Val-Gly-Ala-Leu-Phe-Asn)NHCOCH3
N H 32
O
O 5'-d(CAG TGG TAT GAT A) O P O O
−
5
N H
33
Figure 4.5.19
Solution phase synthesis of nucleopeptides.
(Gln-Ser)NH2
Synthesis of Modified Oligonucleotides and Conjugates
4.5.13 Current Protocols in Nucleic Acid Chemistry
Supplement 2
neoglycoprotein which was derivatized through an alkylamine on its surface with Nsuccinimidyl 3-(2-pyridyldithio)propionate (Bonfils et al., 1992). Alternatively, 3′-thiolated oligonucleotides were conjugated to peptides that were derivatized with maleimides (Arar et al., 1993; Soukchareun et al., 1998). Bioconjugates can be formed in high yield by this method; however, disadvantages include susceptibility of the thiolated oligonucleotides to oxidation, and difficulties in reactions with highly charged peptides due to aggregation (Soukchareun et al., 1998). Nucleopeptide conjugates have also been prepared via displacement of a 3′-iodoacetamide-substituted oligonucleotide by a cysteine-containing peptide (Tung et al., 1995). Two general methods have been developed for the synthesis of oligonucleotide-peptide conjugates on a single solid phase support. Bifunctional supports (e.g., Figs. 4.5.3 and 4.5.20, S.5 and S.34, respectively) can be employed for the synthesis of peptides (using N-Fmoc chemistry) and oligonucleotides sequentially (Basu and Wickstrom, 1995; Juby et al., 1991). This approach was also used for the synthesis of peptide libraries in which the oligonucleotide component on the bead served as a tag for identifying the peptide sequence (Nielsen et al., 1993). Alternatively, nucleopeptides can be synthesized in a linear fashion on a single support in which the peptide is synthesized first, followed by coupling of a transitional linking molecule, and then automated oligonucleotide synthesis (de la Torre, 1994; Soukchareun et al., 1995; Truffert et al., 1994, 1996). Typically, the linking molecule contains a protected primary alcohol and a carboxylic acid (or activated ester) at the other terminus. Finally, a convergent method for the synthesis of 3′-oligonucleotide-peptide conjugates was reported that takes advantage of a templatemediated transfer of a peptide from an intermediate thioester to a 3′-amine-containing oligonucleotide (Bruick et al., 1996).
Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides
NC
O O P O O
ODMTr NHFmoc
34
Figure 4.5.20 Support for the linear synthesis of nucleopeptides.
Conjugation of Oligonucleotides to Surfaces Via their 3′ Termini Usage of surface-bound oligonucleotides in applications such as sequencing by hybridization and as sensors has resulted in a variety of methods for covalently linking the biopolymers to surfaces (Drmanac et al., 1993). Methods have also been developed for in situ synthesis of oligonucleotides on surfaces (Caviani Pease et al., 1994; Chee et al., 1996; Cohen et al., 1997; Maskos and Southern, 1992; McGall et al., 1996; Southern et al., 1994); however, only methods which involve conjugation of a previously synthesized oligonucleotide to a surface will be discussed in this commentary. Furthermore, in keeping with the theme of this commentary, only those methods that involve coupling to the 3′ terminus of an oligonucleotide will be presented. As is the case for the synthesis of nucleopeptides, many of the methods for synthesizing bioconjugates catalogued above have been applied to the problem of preparing surface-bound oligonucleotides. In one application directed towards detecting hybridization, silica surfaces are activated with terminal alkyl epoxides (Lamture et al., 1994). Oligonucleotides containing 3′-alkylamines are then conjugated to the surface via nucleophilic ring opening of the epoxide. In a related example, patterned DNA surfaces containing covalently bound oligonucleotides are also prepared via chemical modification of silica surfaces (Fig. 4.5.21; Chrisey et al., 1996a,b). The three step process for immobilizing the oligonucleotides begins with introducing an alkylamine by modifying the silica surface with the appropriate trialkoxysilane. Following derivatization of the alkylamines with a maleimide, 3′-thiolated oligonucleotides are conjugated to the surface. When combined with masks and existing photoresist technology, this chemistry is useful for preparing patterned surfaces on the micrometer scale. In another application directed towards developing sequencing by hybridization, oligonucleotides containing 3′-dialdehydes or 3′-alkylamines were coupled to acrylamide gels containing the complementary functionality via reductive amination (Timofeev et al., 1996). Finally, an extremely sensitive method for detecting oligonucleotide hybridization was recently reported utilizing thiolated oligonucleotides (5′ and 3′) bound to gold particles (Elghanian et al., 1997; Storhoff et al., 1998). Hybridization to target oligonucleotides in solution mediates the formation of networked gold particle aggregates. Aggregates of the gold
4.5.14 Supplement 2
Current Protocols in Nucleic Acid Chemistry
oligo
S O
H2N H2N H2N
H2N
HN
HN
HN
Si
Si
HN
Si
O
Si
O
Figure 4.5.21
O
O
O HN H2N
H2 N
N
HN
O
Si
HN
HN
Si
Si
O
OH-5'
O
N
O HN H2N
HN
O
Si
HN
O
Si
Modification of surfaces by conjugation of 3′-derivatized oligonucleotides.
particles result in readily measured color changes on as little as 10 femtomoles of material.
SUMMARY Although the scope of this review was limited to the synthesis of oligonucleotide conjugates through their 3′ termini, it is clear that there has been significant activity during the past decade in the development of methods for the synthesis of oligonucleotide conjugates in general. As more oligonucleotide-based therapeutics enter the clinic, and other applications such as genome sequencing and gene function develop, the impetus for the development of oligonucleotide conjugate synthesis methods will certainly continue.
LITERATURE CITED Agrawal, S. 1994. Functionalization of oligonucleotides with amino groups and attachment of amino specific reporter groups. In Protocols for Oligonucleotide Conjugates, Vol. 26: Synthesis and Analytical Techniques, pp. 93-120. Humana Press, Totowa, N.J. Arar, K., Monsigny, M., and Mayer, R. 1993. Synthesis of oligonucleotide-peptide conjugates containing a KDEL signal sequence. Tetrahedron Lett. 34:8087-8090. Asseline, U., Bonfils, E., Kurfurst, R., Chassignol, M., Roig, V., and Thuong, N. T. 1992. Solidphase preparation of 5′,3′-heterobifunctional oligodeoxyribonucleotides using modified solid supports. Tetrahedron 48:1233-1254.
Avino, A., Garcia, R.G., Diaz, A., Albericio, F., and Eritja, R. 1996. A comparative study of supports for the synthesis of oligonucleotides without using ammonia. Nucleosides Nucleotides 15:18711889. Basu, S. and Wickstrom, E. 1995. Solid phase synthesis of a D-peptide-phosphorothioate oligodeoxynucleotide conjugate from two arms of a polyethylene glycol-polystyrene support. Tetrahedron Lett. 36:4943-4946. Beaucage, S.L. and Iyer, R.P. 1993. The functionalization of oligonucleotides via phosphoramidite derivatives. Tetrahedron 49:1925-1963. Bellon, L., Workman, C., Scherrer, J., Usman, N., and Wincott, F. 1996. Morpholino-linked ribozymes: A convergent synthetic approach. J. Am. Chem. Soc. 118:3771-3772. Bellon, L., Workman, C., Jarvis, T.C., and Wincott, F.E. 1997. Post-synthetically ligated ribozymes: An alternative approach to iterative solid-phase synthesis. Bioconjugate Chem. 8:204-212. Bischoff, R., Coull, J.M., and Regnier, F.E. 1987. Introduction of 5′-terminal functional groups into synthetic oligonucleotides for selective immobilization. Anal. Biochem. 164:336-344. Bonfils, E. and Thuong, N.T. 1991. Solid phase synthesis of 5′, 3′-bifunctional oligodeoxyribonucleotides bearing a masked thiol group at the 3′-end. Tetrahedron Lett. 32:3053-3056. Bonfils, E., Depierreux, C., Midoux, P., Thuong, N.T., Monsigny, M., and Roche, A.C. 1992. Drug targeting: Synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates. Nucl. Acids Res. 20:4621-4629.
Synthesis of Modified Oligonucleotides and Conjugates
4.5.15 Current Protocols in Nucleic Acid Chemistry
Supplement 2
Boutorine, A.S., Brault, D., Takasugi, M., Delgado, O., and Helene, C. 1996. Chlorin-oligonucleotide conjugates: Synthesis, properties, and red light-induced photochemical sequence-specific DNA cleavage in duplexes and triplexes. J. Am. Chem. Soc. 118:9469-9476. Bruick, R.K., Dawson, P.E., Kent, S.B.H., Usman, N., and Joyce, G.F. 1996. Template-directed ligation of peptides to oligonucleotides. Chem. Biol. 3:49-56.
Goodchild, J. 1990. Conjugates of oligonucleotides and modified oligonucleotides: A review of their synthesis and properties. Bioconjugate Chem. 1:165-187. Goodwin, J.T. and Lynn, D.G. 1992. Template-directed synthesis: Use of a reversible reaction. J. Am. Chem. Soc. 114:9197-9198.
Caviani Pease, A., Solas, D., Sullivan, E.J., Cronin, M.T., Holmes, C.P., and Fodor, S.P.A. 1994. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc. Natl. Acad. Sci. U.S.A. 91:5022-5026.
Gottikh, M., Asseline, U., and Thuong, N.T. 1990. Synthesis of oligonucleotides containing a carboxyl group at either their 5′ end or their 3′ end and their subsequent derivatization by an intercalating agent. Tetrahedron Lett. 31:6657-6660.
Chee, M., Yang, R., Hubbell, E., Berno, A., Huang, X.C., Stern, D., Winkler, J., Lockhart, D.J., Morris, M.S., and Fodor, S.P.A. 1996. Accessing genetic information with high-density DNA arrays. Science 274:610-614.
Greenberg, M.M. and Gilmore, J.L. 1994. Cleavage of oligonucleotides from solid-phase supports using o-nitrobenzyl photochemistry. J. Org. Chem. 59:746-753.
Chrisey, L.A., Lee, G.U., and O’Ferrall, C.E. 1996a. Covalent attachment of synthetic DNA to selfassembled monolayer films. Nucl. Acids Res. 24:3031-3039.
Greenberg, M.M., Matray, T.J., Kahl, J.D., Dong, J.Y., and McMinn, D.L. 1998. Optimization and mechanistic analysis of oligonucleotide cleavage from palladium-labile solid-phase synthesis supports. J. Org. Chem. 63:4062-4068.
Chrisey, L.A., O’Ferrall, C.E., Spargo, B.J., Dulcey, C.S., and Calvert, J.M. 1996b. Fabrication of patterned DNA surfaces. Nucl. Acids Res. 24:3040-3047.
Gryaznov, S.M. and Letsinger, R.L. 1992. A new approach to synthesis of oligonucleotides with 3′ phosphoryl groups. Tetrahedron Lett. 33:41274128.
Cohen, G., Deutsch, J., Fineberg, J., and Levine, A. 1997. Covalent attachment of DNA oligonucleotides to glass. Nucl. Acids Res. 25:911-912.
Gryaznov, S.M. and Letsinger, R.L. 1993a. Template controlled coupling and recombination of oligonucleotide blocks containing thiophosphoryl groups. Nucl. Acids Res. 21:1403-1408.
de la Torre, B.G., Avino, A., Tarrason, G., Piulats, J., Albericio, F., and Eritja, R. 1994. Stepwise solidphase synthesis of oligonucleotide-peptide hybrids. Tetrahedron Lett. 35:2733-2736. Dell’Aquila, C., Imbach, J.-L., and Rayner, B. 1997. Photolabile linker for the solid-phase synthesis of base-sensitive oligonucleotides. Tetrahedron Lett. 38:5289-5292. Drmanac, R., Drmanac, S., Strezoska, Z., Paunesku, T., Labat, I., Zeremski, M., Snoddy, J., Funkhouser, W.K., Koop, B., Hood, L., and Crkvenjakov, R. 1993. DNA sequence determination by hybridization: A strategy for efficient large-scale sequencing. Science 260:1649-1652. Elghanian, R., Storhoff, J.J., Mucic, R.C., Letsinger, R.L., and Mirkin, C.A. 1997. Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science 277:1078-1081. Erout, M.-N., Troesch, A., Pichot, C., and Cros, P. 1996. Preparation of conjugates between oligonucleotides and N-vinylpyrrolidine/N-acryloxysuccinimide copolymers and applications in nucleic acids assays to improve sensitivity. Bioconjugate Chem. 7:568-575.
Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides
Ghosh, S.S. and Musso, G.F. 1987. Covalent attachment of oligonucleotides to solid supports. Nucl. Acids Res. 15:5353-5372.
Fidanza, J.A., Ozaki, H., and McLaughlin, L.W. 1994. Functionalization of oligonucleotides by the incorporation of thio-specific reporter groups. In Protocols for Oligonucleotide Conjugates, Vol. 26: Synthesis and Analytical Techniques (S. Agrawal, ed.) pp. 121-143. Humana Press, Totowa, N.J.
Gryaznov, S.M. and Letsinger, R.L. 1993b. Chemical ligation of oligonucleotides in the presence and absence of a template. J. Am. Chem. Soc. 115:3808-3809. Gryaznov, S.M., Schultz, R., Chaturvedi, S.K., and Letsinger, R.L. 1994. Enhancement of selectivity in recognition of nucleic acids via chemical autoligation. Nucl. Acids Res. 22:2366-2369. Gupta, K.C., Sharma, P., Sathyanarayana, S., and Kumar, P. 1990. A universal solid support for the synthesis of 3′-thiol group containing oligonucleotides. Tetrahedron Lett. 31:2471-2474. Gupta, K.C., Sharma, P., Kumar, P., and Sathyanarayana, S. 1991. A general method for the synthesis of 3′-sulfhydryl and phosphate group containing oligonucleotides. Nucl. Acid Res. 19:3019-3025. Guzaev, A. and Lönnberg, H. 1997. A novel solid sup por t f or sy nthesis 3′-phosphorylated chimeric oligonucleotides containing internucleosidic methyl phosphotriester and methylphosphonate linkages. Tetrahedron Lett. 38:3989-3992. Haralambidis, J., Duncan, L., Angus, K., and Tregear, G.W. 1990a. The synthesis of polyamide-oligonucleotide conjugate molecules. Nucl. Acids Res. 18:493-499.
4.5.16 Supplement 2
Current Protocols in Nucleic Acid Chemistry
Haralambidis, J., Angus, K., Pownall, S., Duncan, L., Chai, M., and Tregear, G.W. 1990b. The preparation of polyamide-oligonucleotide probes containing multiple non-radioactive labels. Nucl. Acids Res. 18:501-505.
Leonetti, J.P., Rayner, B., Lemaitre, M., Gagnor, C., Milhaud, P.G., Imbach, J.-L., and Lebleu, B. 1988. Antiviral activity of conjugates between poly(L-lysine) and synthetic oligodeoxyribonucleotides. Gene 72:323-332.
Haralambidis, J., Lagniton, L., and Tregear, G.W. 1994. The preparation of enzyme-labelled oligonucleotides by reductive amination. Bioorg. Med. Chem. Lett. 4:1005-1010.
Leonetti, J.-P., Degols, G., and Lebleu, B. 1990. Biological activity of oligonucleotide-poly(L-lysine) conjugates: Mechanism of cell uptake. Bioconjugate Chem. 1:149-153.
Harrison, J.G. and Balasubramanian, S. 1997. A convenient synthetic route to oligonucleotide conjugates. Bioorg. Med. Chem. Lett. 7:10411046.
Letsinger, R.L., Zhang, G., Sun, D.K., Ikeuchi, T., and Sarin, P.S. 1989. Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficieny virus in cell culture. Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556.
Hovinen, J., Gouzaev, A.P., Azhayev, A.V., and Lönnberg, H. 1993a. A new method to prepare 3′-modified oligonucleotides. Tetrahedron Lett. 34:5163-5166. Hovinen, J., Guzaev, A., Azhayev, A., and Lönnberg, H. 1993b. Synthesis of 3′-functionalized oligonucleotides on a single solid support. Tetrahedron Lett. 34:8169-8172. Hovinen, J., Guzaev, A., Azhayev, A., and Lönnberg, H. 1994. Novel solid supports for the preparation of 3′-derivatized oligonucleotides: introduction of 3′-alkylphosphate tether groups bearing amino, carboxy, carboxamido, and mercapto functionalities. Tetrahedron 50:7203-7218. Hovinen, J., Guzaev, A., Azhayeva, E., Azhayev, A., and Lönnberg, H. 1995. Imidazole tethered oligodeoxyribonucleotides: Synthesis and RNA cleaving activity. J. Org. Chem. 60:2205-2209. Jaschke, A., Furste, J.P., Dieter, C., and Volker, A.E. 1993. Automated incorporation of polythylene glycol into synthetic oligonucleotides. Tetrahedron Lett. 34:301-304. Juby, C.D., Richardson, C.D., and Brousseau, R. 1991. Facile preparation of 3′ oligonucleotidepeptide conjugates. Tetrahedron Lett. 32:879882. Kahl, J.D. and Greenberg, M.M. 1999. Solution phase bioconjugate synthesis using protected oligonucleotides containing 3′-alkyl carboxylic acids. J. Org. Chem. 64:507-510. Kahl, J.D., McMinn, D.L., and Greenberg, M.M. 1998. High-yielding method for on-column derivatization of protected oligodeoxynucleotides and its application to the convergent synthesis of 5′,3′-bis-conjugates. J. Org. Chem. 63:48704871. Kumar, A. 1993a. A rapid solid phase method for the synthesis of 3′-thiol group containing oligonucleotides. Nucleosides Nucleotides 12:729-736. Kumar, A. 1993b. A versatile solid phase method for the synthesis of masked 3′-thiol group containing oligonucleotides. Nucleosides Nucleotides 12:1047-1059. Lamture, J.B., Beattie, K.L., Burke, B.E., Eggers, M.D., Ehrilch, D.J., Fowler, R., Hollis, M.A., Kosicki, B.B., Reich, R.K., Smith, S.R., Varma, R.S., and Hogan, M.E. 1994. Direct detection of nucleic acid hybridization on the surface of a charge coupled device. Nucl. Acids Res. 22:2121-2125.
Lukhtanov, E.A., Podyminogin, M.A., Kutyavin, I.V., Meyer, R.B. Jr., and Gamper, H.B. 1996. Rapid and efficient hybridization-triggered crosslinking within a DNA duplex by an oligodeoxyribonucleotide bearing a conjugated cyclopropapyrroloindole. Nucl. Acids Res. 24:683687. Lund, V., Schmid, R., Rickwood, D., and Hornes, E. 1988. Assessment of methods for covalent binding of nucleic acids to magnetic beads, Dynabeads, and the characteristics of the bound nucleic acids in hybridization reactions. Nucl. Acids Res. 16:10861-10880. Lyttle, M.H., Adams, H., Hudson, D., and Cook, R.M. 1997. Versatile linker chemistry for synthesis of 3′-modified DNA. Bioconjugate Chem. 8:193-198. MacKellar, C., Graham, D., Will, D.W., Burgess, S., and Brown, T. 1992. Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups. Nucl. Acids Res. 20:3411-3417. Maskos, U. and Southern, E.M. 1992. Parallel analysis of oligodeoxyribonucleotide (oligonucleotide) interactions. I. Analysis of factors influencing oligonucleotide duplex formation. Nucl. Acids Res. 20:1675-1678. Matray, T.J., Dong, J.Y., McMinn, D.L., and Greenberg, M.M. 1997. Synthesis of oligonucleotides containing 3′-alkylcarboxylic acids using a palladium labile oligonucleotide solid phase synthesis support. Bioconjugate Chem. 8:99-102. McGall, G., Labadie, J., Brock, P., Wallraff, G., Nguyen, T., and Hinsberg, W. 1996. Light-directed synthesis of high-density oligonucleotide arrays using semiconductor photoresists. Proc. Natl. Acad. Sci. U.S.A. 93:13555-13560. McMinn, D.L. and Greenberg, M. M. 1996. Novel solid phase synthesis supports for the preparation of oligonucleotides containing 3′-alkyl amines. Tetrahedron 52:3827-3840. McMinn, D.L. and Greenberg, M.M. 1997. Synthesis of oligonucleotides containing 3′-alkyl amines using N-isobutyryl protected deoxyadenosine phosphoramidite. Tetrahedron Lett. 38:3123-3126.
Synthesis of Modified Oligonucleotides and Conjugates
4.5.17 Current Protocols in Nucleic Acid Chemistry
Supplement 2
McMinn, D.L. and Greenberg, M. M. 1998. Postsynthetic conjugation of protected oligonucleotides containing 3’-alkylamines. J. Am. Chem. Soc. 120:3289-3294. McMinn, D.L. and Greenberg, M.M. 1999. Convergent solution-phase synthesis of a nucleopeptide using a protected oligonucleotide. Bioorg. Med. Chem. Lett. 9:547-550. McMinn, D.L., Matray, T.J., and Greenberg, M.M. 1997. Efficient solution phase synthesis of oligonucleotide conjugates using protected biopolymers containing 3′-terminal alkyl amines. J. Org. Chem. 62:7074-7075. McMinn, D.L., Hirsch, R., and Greenberg, M. M. 1998. An orthogonal solid phase support for the synthesis of oligonucleotides containing 3′phosphates and its application in the preparation of photolabile hybridization probes. Tetrahedron Lett. 39:4155-4158. Mukaiyama, T. 1976. Oxidation-reduction condensation. Angew. Chem. Int. Ed. Engl. 15:94-103. Mullah, B. and Andrus, A. 1997. Automated synthesis of double dye-labeled oligonucleotides using tetramethylrhodamine (TAMRA) solid supports. Tetrahedron Lett. 38:5751-5754. Mullah, B., Livak, K., Andrus, A., and Kenney, P. 1998. Efficient synthesis of double dye-labeled oligodeoxyribonucleotide probes and their application in a real time PCR assay. Nucl. Acids Res. 26:1026-1031. Nelson, P., Frye, R.A., and Liu, E. 1989. Bifunctional oligonucleotide probes synthesized using a novel CPG support are able to detect single base pair mutations. Nucl. Acids Res. 17:71877194. Nelson, P.S., Kent, M., and Muthini, S. 1992. Oligonucleotide labeling methods. 3. Direct labeling of oligonucleotides employing a novel, nonnucleosidic, 2-aminobutyl-1,3-propanediol backbone. Nucl. Acids Res. 20:6253-6259. Nelson, P., Muthini, S., Kent, M.A., and Smith, T.H. 1997. 3′-Terminal modification of oligonucleotides using a universal solid support. Nucleosides Nucleotides 16:1951-1959. Nielsen, J., Brenner, S., and Janda, K.D. 1993. Synthetic methods for the implementation of encoded combinatorial chemistry. J. Am. Chem. Soc. 115:9812-9813. Scheuer-Larsen, C., Rosenbohm, C., Jorgensen, T.J.D, and Wengel, J. 1997. Introduction of a universal solid support for oligonucleotide synthesis. Nucleosides Nucleotides 16:67-80. Schwartz, M.E., Breaker, R.R., Asteriadis, G.T., and Gough, G.R. 1995. A universal adapter for chemical synthesis of DNA or RNA on any single type of solid support. Tetrahedron Lett. 36:27-30. Attachment of Reporter and Conjugate Groups to the 3′ Termini of Oligonucleotides
Soukchareun, S., Tregear, G.W., and Haralambidis, J. 1995. Preparation and characterization of antisense oligonucleotide-peptide hybrids containing viral fusion peptides. Bioconjugate Chem. 6:43-55.
Soukchareun, S., Haralambidis, J., and Tregear, G. 1998. Use of Nα-Fmoc-cysteine(S-thiobutyl) derivatized oligodeoxynucleotides for the preparation of oligodeoxynucleotide-peptide hybrid molecules. Bioconjugate Chem. 9:466-475. Southern, E.M., Case-Green, S.C., Elder, J.K., Johnson, M., Mir, K.U., Wang, L., and Williams, J.C. 1994. Arrays of complementary oligonucleotides for analysing the hybridisation behaviour of nucleic acids. Nucl. Acids Res. 22:13681373. Storhoff, J.J., Elghanian, R., Mucic, R.C., Mirkin, C.A., and Letsinger, R.L. 1998. One-pot colorimetric differentiation of polynucleotides with single base imperfections using gold nanoparticle probes. J. Am. Chem. Soc. 120:1959-1964. Thaden, J. and Miller, P.S. 1993a. Automated synthesis of oligodeoxyribonucleoside methylphosphonates having [N-(3-aminoprop-1-yl)-N-(2hydroxyethyl)-2-aminoethyl] phosphate or methylphosphonic acid at the 3′ end using a modified controlled pore glass support. Bioconjugate Chem. 4:395-401. Thaden, J. and Miller, P.S. 1993b. Photoaffinity behavior of a conjugate of oligonucleoside methylphosphonate, rhodamine, and psoralen in the presence of complementary oligonucleotides. Bioconjugate Chem. 4:386-394. Timofeev, E.N., Kochetkova, S.V., Mirzabekov, A.D., and Florentiev, V.L. 1996. Regioselective immobilization of short oligonucleotides to acrylic copolymer gels. Nucl. Acids Res. 24:3142-3148. Truffert, J.-C., Lorthioir, O., Asseline, U., Thuong, N.T., and Brack, A. 1994. On-line solid phase synthesis of oligonucleotide-peptide hybrids using silica supports. Tetrahedron Lett. 35:23532356. Truffert, J.-C., Asseline, U., Brack, A., and Thuong, N.T. 1996. Synthesis, purification and characterization of two peptide-oligonucleotide conjugates as potential artificial nucleases. Tetrahedron 52:3005-3016. Tung, C.-H., Wang, J., Leibowtiz, M.J., and Stein, S. 1995. Dual-specificity interaction of HIV-1 TAR RNA with tat peptide-oligonucleotide conjugates. Bioconjugate Chem. 6:292-295. Urata, H. and Akagi, M. 1993. A convenient synthesis of oligonucleotides with a 3′-phosphoglycolate and 3′-phosphoglycaldehyde terminus. Tetrahedron Lett. 34:4015-4018. Venkatesan, H. and Greenberg, M. M. 1996. Improved utility of photolabile solid phase synthesis supports for the synthesis of oligonucleotides containing 3′-hydroxyl termini. J. Org. Chem. 61:525-529. Yoo, D.J. and Greenberg, M. M. 1995. Synthesis of oligonucleotides containing 3′-alkyl carboxylic acids using universal, photolabile solid phase synthesis supports. J. Org. Chem. 60:3358-3364. Zhan, Z.J. and Lynn, D.G. 1997. Chemical amplification through template-directed synthesis. J. Am. Chem. Soc. 119:12420-12421.
4.5.18 Supplement 2
Current Protocols in Nucleic Acid Chemistry
Zhang, X., Gaffney, B.L., and Jones, R.A. 1997. RNA synthesis using a universal, base-stable alkyl linker. Nucl. Acids Res. 25:3980-3983.
Zuckerman, R.N. and Schultz, P.G. 1988. A hybrid sequence-selective ribonuclease S. J. Am. Chem. Soc. 110:6592-6594.
Zon, G. and Geiser, T.G. 1991. Phosphorothioate oligonucleotides: Chemistry, purification, analysis, scale-up and future directions. Anti-Cancer Drug Des. 6:539-568.
Zuckerman, R.N., Corey, D.R., and Schultz, P.G. 1988. Site-selective cleavage of RNA by a hybrid enzyme. J. Am. Chem. Soc. 110:1614-1615.
Zuckerman, R., Corey, D., and Schultz, P. 1987. Efficient methods for attachment of thiol specific probes to the 3′-ends of synthetic oligodeoxyribonucleotides. Nucl. Acids Res. 15:5305-5321.
Contributed by Marc M. Greenberg Colorado State University Fort Collins, Colorado
Financial support of this work from the National Science Foundation (CHE-9732843), the CATI Center for RNA Chemistry, Dupont, and the Alfred P. Sloan Foundation is greatly appreciated.
Synthesis of Modified Oligonucleotides and Conjugates
4.5.19 Current Protocols in Nucleic Acid Chemistry
Supplement 2
3′-Modified Oligonucleotides and their Conjugates
UNIT 4.6
This unit describes synthetic methods for the preparation of three types of oligonucleotide 3′-modifications. The first two, aminoalkyl and sulfhydrylalkyl, are important because these groups offer specific points of attachment to a large variety of dyes and reporter groups. Their preparation is described in the Basic Protocol and Alternate Protocol 1, respectively. Alternate Protocol 2 deals with the 3′-attachment of polyethylene glycol (PEG) or other diols to the synthetic oligo. PEG-functionalized oligos are of interest because of their enhanced cell membrane permeability, which is important for antisense drug development. Implementation of the following procedures requires working knowledge of automated DNA synthesizers, high-performance liquid chromatographs (HPLCs), and UV/visible spectrophotometers. The use of derivatized supports requires the ability to pack DNA synthesis columns. In addition, access to a fume hood is required, as many of the preparations use malodorous, toxic, or otherwise hazardous reagents. CAUTION: Safe conduct in the laboratory when handling common solvents and chemicals, and working knowledge of equipment such as vacuum lines and rotary evaporators, is essential. Safety glasses and gloves should be worn to minimize risk of exposure. CAUTION: Many of the steps involve pyridine, which is extremely toxic and has a foul odor. Dichloroacetic acid causes severe burns when spilled on the skin. These steps should be performed in a fume hood with gloves and eye protection. Do not use magnetic stir bars with controlled-pore glass—it generates fine particles that can clog frits or valves in DNA synthesizers. PREPARATION OF 3′-AMINOALKYL-FUNCTIONALIZED DNA OLIGONUCLEOTIDES
BASIC PROTOCOL
The synthesis of an anhydride-functionalized CPG that can be used in the preparation of 3′-aminoalkyl, 3′-thioalkyl, or 3′-hydroxyalkyl DNA is delineated. The preparation of a support for 3′-aminoalkyl DNA synthesis is then described, followed by the synthesis and purification of a 3′-fluorescein-DNA conjugate. Materials 1000 Å aminopropyl-conjugated controlled-pore glass (aminopropyl-CPG; Biosearch Technologies) Pyridine Methylene chloride Trimellitic anhydride chloride (Aldrich) 100% and 20% (v/v) acetonitrile 6-Amino-1-hexanol N,N-Dimethylformamide (DMF) 4,4′-Dimethoxytrityl chloride (DMTr chloride; Aldrich) 3% (v/v) dichloroacetic acid in methylene chloride 28% (v/v) aqueous ammonia 5- and 6-Carboxy fluorescein succinimide ester (Molecular Probes) Dimethyl sulfoxide (DMSO) 1 M sodium carbonate/1 M sodium bicarbonate solution 0.05 M aqueous ammonium acetate Contributed by Matthew H. Lyttle Current Protocols in Nucleic Acid Chemistry (2000) 4.6.1-4.6.8 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.6.1 Supplement 3
Sephadex G-25 resin (Amersham Pharmacia Biotech) 1 M triethylammonium acetate (TEAA) 14% (v/v) aqueous ammonia (1 part concentrated ammonium hydroxide, 1 part water) 2.8% (v/v) aqueous ammonia (1 part concentrated ammonium hydroxide, 9 parts water) Buffer A: 0.025 M Tris⋅Cl and 0.01 M Tris base Buffer B: 0.025 M Tris⋅Cl, 0.01 M Tris base, and 1 M NaCl 125-mL Erlenmeyer flasks with stoppers 150-mL sintered glass funnels, coarse frit 1-liter side-arm filter flask with rubber gasket Water aspirator Heavy-walled vacuum tubing 3-way valve Speedvac (Savant) Spectrophotometer and 1-cm path length glass cuvettes (e.g., Beckman) Automated DNA synthesizer and reagents (e.g., PE Biosystems) 1.5-mL plastic screw-cap tubes 55°C water bath Reversed-phase DNA purification cartridges and reagents (e.g., Biosearch Technologies) 1 × 30–cm glass tube with a frit and valve on bottom 10-mL syringes High-performance liquid chromatograph (HPLC) with anion-exchange column Additional reagents and equipment for DNA purification with a reversed-phase cartridge (UNIT 10.7) Synthesize an anhydride-functionalized CPG 1. Weigh out 5 g aminopropyl-CPG and place in a 125-mL Erlenmeyer flask with stopper. 2. In a separate 125-mL Erlenmeyer flask, mix together 10 mL pyridine and 40 mL methylene chloride. Stopper the flask. 3. Weigh out 1 g trimellitic anhydride chloride and add it to the solution prepared in step 2. Swirl solution until the solid completely dissolves. 4. Pour solution into the flask containing CPG. Swirl and allow to stand 1 hr at ambient temperature. 5. In the meantime, assemble a 150-mL sintered glass funnel, rubber gasket, and a 1-liter side-arm filter flask, and connect these to a water aspirator with a piece of heavywalled vacuum tubing. Install a 3-way valve between the flask and aspirator to control the vacuum and prevent water from being drawn into the flask when the aspirator is turned off. 6. Pour the slurry containing the CPG into the sintered glass funnel and remove the solvent by suction through the frit. Wash the CPG with three 50-mL portions of methylene chloride followed by three 50-mL portions of acetonitrile. 3′-Modified Oligonucleotides and their Conjugates
For each wash, completely suspend the CPG in the solvent with a spatula before applying vacuum to ensure efficient washing.
7. Dry the CPG in a vacuum desiccator for several hours.
4.6.2 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Add hydroxylated aminohexyl linker to the anhydride-functionalized CPG 8. Weigh out 2 g of 6-amino-1-hexanol and dissolve in 10 mL DMF. 9. Add the solution to 2 g of the support obtained in step 7 and swirl briefly. Allow the slurry to stand for 3 hr at room temperature. 10. Repeat steps 6 and 7. Protect the linker hydroxy function with a DMTr group 11. Add 20 mL dry pyridine to the CPG obtained in step 10 and then add 1 g DMTr chloride. Swirl the mixture until the DMTr chloride dissolves, and allow to stand for at least 18 hr at room temperature. 12. Repeat steps 6 and 7. 13. To measure the amount of available hydroxyls on the support, now DMTr protected, weigh out 20 mg of the dry CPG material into a 125-mL Erlenmeyer flask and add exactly 100 mL of 3% dichloroacetic acid in methylene chloride. 14. Measure the absorbance of the orange solution at 498 nm, and multiply this number by the abbreviated extinction coefficient of DMTr (71.2). The result is the loading of the support, in micromoles per gram. Loading should be ≥25 mmol/g.
Synthesize DNA on aminohexyl-linked CPG 15. Calculate how many milligrams of the support obtained in step 12 will be required for a 0.2-µmol synthesis. Pack the calculated amount into a DNA synthesis column. The required amount of support should be between 3 and 10 mg.
16. Using an automated DNA synthesizer, add the desired sequence of nucleobases to the support. Remember that the 3′-terminal nucleobase must be added as an amidite, so use a dummy nucleobase in the sequence entry at the 3′ terminus. Leave the 5′-DMTr on when oligonucleotide synthesis is complete.
17. After synthesis, place the CPG containing the DNA in a 1.5-mL screw-cap tube and remove the DNA from the CPG by heating in 1 mL of 28% aqueous ammonia for 5 hr at 55°C. 5′-Terminal dG sequences are prone to detritylate at 55°C; these sequences give better results when deprotected for 48 hr at room temperature.
18. Allow the tube to cool to room temperature, and purify the DNA with a reversedphase cartridge according to the manufacturer’s instructions (see UNIT 10.7). Evaporate the purified DNA solution and then measure the absorbance at 254 nm in water. Conjugate 3′-aminoalkyl DNA oligonucleotides to 5- and 6-carboxyfluorescein 19. For each 10 OD254 units of 3′-aminohexyl DNA oligonucleotide measured, weigh out 1 mg of 5- and 6-carboxyfluorescein succinimide ester and dissolve in 100 µL DMSO. For >50 OD254 units of DNA, increase DMSO by 10 mL per additional 10 OD units.
20. Add this solution to a 1.5-mL plastic screw-cap tube containing the dried DNA, followed by 500 µL of 1 M sodium carbonate/1 M sodium bicarbonate solution. Close the tube and allow to stand 18 to 24 hr at room temperature. For >50 OD254 units of DNA, increase buffer by 100 mL per additional 10 OD units.
Synthesis of Modified Oligonucleotides and Conjugates
4.6.3 Current Protocols in Nucleic Acid Chemistry
Supplement 3
21. Evaporate the liquid in a Speedvac evaporator, and dissolve the residue in 1.5 mL of 0.05 M aqueous ammonium acetate. 22. Mix 20 g Sephadex G-25 resin with 100 mL of 0.05 M aqueous ammonium acetate, and pour the slurry into a 1 × 30–cm glass tube with a frit and valve at the bottom. Add enough of the slurry so that the settled bed volume is 20 to 25 cm long. Allow the liquid to elute from the column until the liquid is level with the Sephadex slurry. Use fresh Sephadex for each purification.
23. Add the DNA solution (step 21) to the column, and allow the liquid to elute from the column until the liquid is level with the Sephadex column. 24. Elute the column with 0.05 M aqueous ammonium acetate at a flow rate of ∼2 mL/min. Collect the first colored band that elutes after the first 10 to 15 mL. Evaporate the collected fraction in 1.5-mL tubes in a Speedvac. For many applications, the fluorescein-DNA oligonucleotide conjugate is pure enough for good results. Analysis of purity can be performed by PAGE (UNIT 10.4) or HPLC (UNIT 10.5). If necessary, purification can be performed using a reversed-phase cartridge (see below).
Purify fluorescein-DNA oligonucleotide conjugate 25. Preequilibrate a reversed-phase DNA purification cartridge by eluting with 4 mL acetonitrile followed by 4 mL of 1 M TEAA at a flow rate of ∼1 mL/min using a 10-mL syringe. 26. Dissolve the sample obtained in step 24 in 1 mL of 14% aqueous ammonia. Apply the solution to the cartridge. Collect the effluent and reload it onto the cartridge two times. 27. Elute the cartridge with 4 mL of 2.8% aqueous ammonia followed by 4 mL water at ∼1 mL/min. Discard noncolored eluant. 28. Elute the cartridge with 3 mL of 20% acetonitrile in water at ∼1 mL/min, and collect the strongly green effluent. 29. Evaporate in a Speedvac and store the purified 3′-fluorescein DNA oligonucleotide conjugate at −20°C until needed. Samples retain fluorescence for 2 to 3 months if kept in the dark.
Analyze conjugate by HPLC 30. Dissolve the sample in 500 µL of 20% acetonitrile in water, and inject 2 to 20 µL, depending on the concentration, onto an anion-exchange column. Elute the conjugate with a linear gradient of 100% buffer A to 100% buffer B over 20 min at a flow rate of 1 mL/min. The fluorescein conjugate will elute 2 to 4 min later than the underivatized 3′-aminohexyl DNA oligonucleotide. ALTERNATE PROTOCOL 1
3′-Modified Oligonucleotides and their Conjugates
PREPARATION OF 3′-THIOALKYL-FUNCTIONALIZED DNA OLIGONUCLEOTIDES This procedure uses many of the same reagents and steps as the Basic Protocol. However, the oxygen of the sulfur-bearing spacer must be protected, or else mixtures of products will be obtained after DNA synthesis and cleavage. A synthesis of these O-DMTr-protected thioalkyl spacers has been previously reported (Gupta et al., 1991).
4.6.4 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Additional Materials (also see Basic Protocol) 6-Mercapto-1-O-DMTr hexanol (Biosearch Technologies) Dithiothreitol (DTT) Triethylamine Fluorescein-5-maleimide (Molecular Probes) Sodium phosphate/sodium chloride buffer: 50 mM sodium phosphate and 150 mM sodium chloride, adjust to pH 7.2 (if necessary) Synthesize 3′-thiohexyl DNA oligonucleotides on CPG 1. Prepare anhydride-functionalized CPG (see Basic Protocol, steps 1 to 7) and place 2 g in a 125-mL Erlenmeyer flask with stopper. 2. In a separate 125-mL flask, dissolve 1 g of 6-mercapto-1-O-DMTr hexanol in 10 mL DMF, and add 1 mL of triethylamine. 3. Add this solution to the Erlenmeyer flask containing CPG. Stopper the flask and swirl the CPG until there is a uniform slurry in the flask. Allow the flask containing the CPG to stand for 3 hr at room temperature. 4. Perform washing and drying as described (see Basic Protocol, steps 6 and 7). 5. Assay the loading of the spacer on the CPG (see Basic Protocol, steps 13 and 14). Loading should be ≥20 mmol/g.
6. Synthesize DNA oligonucleotides on the CPG, and deprotect and purify the product (see Basic Protocol, steps 15 to 18), but add 2 to 3 mg DTT to the 28% aqueous ammonia solution (step 17) before heating to prevent oxidative dimerization of the thioakyl oligonucleotides. Conjugate 3′-thiohexyl DNA oligonucleotides to fluorescein-5-maleimide 7. Weigh out 2 mg fluorescein-5-maleimide for every 10 OD254 units of DNA oligonucleotide to be conjugated in a 1.5-mL plastic screw-cap tube, and dissolve in 100 µl DMF. 8. Add this solution to a 1.5-mL plastic screw-cap tube containing the thiohexyl DNA. 9. Add 500 µL sodium phosphate/sodium chloride buffer, pH 7.2, and allow to stand 18 to 24 hr in the dark at room temperature. 10. Perform Sephadex G-25 size exclusion (see Basic Protocol, steps 21 to 24). Reversed-phase cartridge purification does not work well for thiomaleimido fluoresceinDNA oligonucleotide conjugates. Purification of the conjugates can be accomplished by either preparative HPLC (UNIT 10.5) or preparative PAGE (UNIT 10.4).
PREPARATION OF 3′-POLYETHYLENE-GLYCOL-FUNCTIONALIZED DNA OLIGONUCLEOTIDES
ALTERNATE PROTOCOL 2
Dry solvents and equipment are essential for the key reaction in this sequence, which is the addition of a hydroxyl functionality to an anhydride. This procedure uses many of the same reagents and steps as previous protocols. Various polyethylene glycols are commercially available; selection depends on the experimental design. The example given below uses triethylene glycol. Additional Materials (also see Basic Protocol) Triethylene glycol (Aldrich) N-Methylimidazole (Aldrich)
Synthesis of Modified Oligonucleotides and Conjugates
4.6.5 Current Protocols in Nucleic Acid Chemistry
Supplement 3
1. Prepare anhydride-functionalized CPG (see Basic Protocol, steps 1 to 4), and place 2 g in a 125-mL Erlenmeyer flask with stopper. 2. In a separate 125-mL flask, dissolve 1 g triethylene glycol in 10 mL DMF, and add 500 µL N-methylimidazole. 3. Add this solution to the Erlenmeyer flask containing CPG. Stopper the flask and swirl the CPG until there is a uniform slurry in the flask. Allow the flask containing the CPG to stand for 18 to 24 hr at room temperature. 4. Perform washing and drying (see Basic Protocol, steps 6 and 7). 5. Assay the loading of the triethylene glycol spacer on the CPG (see Basic Protocol, steps 11 through 14). Loading should be ≥20 mmol/g.
6. Synthesize DNA oligonucleotides on the PEGylated CPG, and deprotect and purify the product (see Basic Protocol, steps 15 to 18). 7. Analyze 3′-PEGylated DNA oligonucleotides by ion-exchange HPLC (see Basic Protocol, step 30). The desired product will elute slightly later than the corresponding unmodified DNA.
COMMENTARY Background Information
3′-Modified Oligonucleotides and their Conjugates
The basic strategy employed in these protocols (Lyttle et al., 1997) calls for the synthesis of an anhydride-functionalized solid support as a common intermediate for each functional group attachment. A bifunctional molecule (spacer) that has an OH group at one end and an SH, NH2, or OH group at the other end is then added. The most nucleophilic functional group reacts with the anhydride to form a thioester, amide, or ester bond, respectively, while the OH group at the other end of the spacer is available to react with nucleoside phosphoramidites (see Figure 4.6.1). There is then an optional step of adding a 4,4′-dimethoxytrityl (DMTr) group to this alcohol group to spectrophotometrically gauge the amount of addition of the first phosphoramidite during automated oligonucleotide synthesis. In the case of the thiol functionality, this DMTr alcohol protection is mandatory, or else a mixture of products (resulting from SH and OH addition to the anhydride) will be obtained. The synthesis of the required O-DMTr-protected hydroxylalkylthiols is described in the literature (Gupta et al., 1991). 6-O-DMTr-hydroxyhexylthiol is available from Biosearch Technologies. Once the support is made, automated oligonucleotide synthesis is performed to construct the desired sequence, then the usual aqueous ammonia treatment is employed for DNA
deprotection and solid-support cleavage to provide the desired 3′-terminal functionality upon basic hydrolysis of the thioester, amide, or ester bonds. The product DNA is then purified with reversed-phase cartridges, and can be characterized by PAGE, HPLC, and matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). In the case of 3′-NH2- or SHmodified oligos, a procedure for the attachment of fluorescein is described, including an example of a successful reversed-phase cartridge purification of a 3′-amino-modified DNA-fluorescein conjugate.
Critical Parameters and Troubleshooting These protocols describe three techniques for the 3′-terminal labeling of DNA. Successful execution of each protocol depends on the skill and patience of the researcher, as well as the quality of reagents and solvents. The approximate expected loading is mentioned in each protocol; if loading is lower than expected, there are several points to check. For steps that require the immobilized anhydride, use a new bottle of trimellitic anhydride chloride for the coupling reaction. A negative ninhydrin test (Stewart and Young, 1984) will assure that the anhydride was quantitatively linked to the resin prepared according to the Basic Protocol. DMF must be dry (i.e., <0.05% water) and not have a noticeably fishy aroma;
4.6.6 Supplement 3
Current Protocols in Nucleic Acid Chemistry
O
NH2 N H
+ O
O O
O O
Cl
O O
H2N HS
OH or ODMTr / Et3N
or PEG / 1-Methylimidazole
O
O X(CH2)nOR OH
N H O DMTr, 4,4'-dimethoxytrityl; PEG, polyethylene glycol
Figure 4.6.1
1: X = NH, R = H, n = 6 2: X = S, R = DMTr, n = 6 3: X = O, X(CH2)nOR = PEG, R = H
An anhydride-functionalized solid support for the synthesis of 3′-modified DNA.
DMF slowly hydrolyzes to formic acid and dimethyl amine. The latter component has a fishy smell, and will have deleterious effects on the chemistry. Temperature of reactions should be close to 20°C; even a decrease of 10°C will slow down reaction rates. The DMTr chloride addition reactions are also moisture sensitive; therefore, use a freshly opened pyridine bottle (<0.05% water) and new DMTr chloride to improve the results if they are low. Finally, for the novice unfamiliar with organic chemical manipulations, the advice of a more experienced colleague can be indispensable.
Anticipated Results DNA fragments have been synthesized on three 3′-modification supports and compared to those DNA oligonucleotides synthesized from a conventional hemisuccinate nucleosidederivatized CPG. Stepwise coupling yields were similar in all cases. Yields of reversedphase cartridge purified DNA compared favorably with the amount normally obtained for cartridge purification at the 200-nmol and 1µmol synthesis scales. Anion exchange (AX)HPLC of 3′-modified 14-mers (5′-CCGAGTACTATTCA-3′) synthesized from the three CPGs showed that good quality products (i.e., 85% to 95% pure by AX-HPLC integration)
were obtained in the case of the 3′-thiohexyland 3′-triethylene-glycol-functionalized oligomers. In the case of the 3′-aminohexyl-derivatized 14-mer, a substantially slower eluting contaminant (20% to 30%) was present. The amount of this impurity can be decreased by prolonged heating (i.e., 24 to 48 hr) with aqueous ammonia, suggesting that this contaminant is DNA containing an unhydrolyzed amidemetallic linker at the 3′-terminus. This slowereluting contaminant did not interfere in subsequent reactions involving conjugation of the 3′-aminohexyl-functionalized oligonucleotide and was separated from the desired fluorescein conjugate by a reversed-phase cartridge purification. Due to the high loadings of the 3′-aminoalkyl CPG obtained with this procedure (i.e., 50 to 80 µmol/g), ample reactive material is still produced for subsequent conjugation steps. When the 3′-aminohexyl-linked 14-mer DNA fragment was prepared at a 200-nmol scale, ~75% conversion to the desired conjugate was obtained upon reaction with 50 equivalents of a mixture of fluorescein 5- and 6-carboxyhydroxysuccinimide active esters. The fluorescein conjugates elute 2 to 3 min slower by AX-HPLC than the unreacted 3′aminohexyl or thiolalkyl-modified DNA. The crude fluorescein conjugate could be purified
Synthesis of Modified Oligonucleotides and Conjugates
4.6.7 Current Protocols in Nucleic Acid Chemistry
Supplement 3
to 95% purity by the reversed-phase cartridge method described above. Better amine-fluorescein conjugation efficiency (>99%) was obtained at a 1-µmol synthesis scale, perhaps because of concentration considerations. Purified yields of 3′-fluorescein DNA at the 1-µmol synthesis scale should be 15 to 25 OD units. The corresponding 3′-thiolalkyl-modified DNA gave lower conjugation efficiencies (19% to 49%) even when reacted with 100 equivalents of fluorescein-5-maleimide. Cartridge purification of the thiol-linked fluorescein-DNA conjugates was also less effective. A 20% crosslinked polyacrylamide gel of 3′-conjugated DNA fragments that were prepared from both 3′-thiolalkyl and aminohexyl terminal modifications showed strongly fluorescent products exhibiting about the same gel mobility as that of underivatized DNA of the same length and sequence. The gel lanes of the thiolalkyl-linked conjugates contain some underivatized material, in agreement with HPLC analysis.
Time Considerations Most of the steps require a few hours at most and can be accomplished during an 8-hr day. The Sephadex columns usually require ≥4 hr for setup, chromatography, and analysis of the products. In general, only the immobilized an-
hydride-functionalized CPG cannot be stored for extended periods of time, and should be utilized as soon as possible. In all other steps involving a solid support, reagents should be washed away and the support washed with a neutral, volatile solvent before storage. When 18 to 24 hr of reaction time is recommended, it is best to mix the reagents for the reaction in the early evening (∼5 p.m.) and then work up the reaction mixture the following day.
Literature Cited Gupta, K.C., Sharma, P., Kumar, P., and Sathyanarayana, S. 1991. A general method for the synthesis of 3′-sulfhydryl and phosphate group containing oligonucleotides. Nucl. Acids Res.19:3019-3025. Lyttle, M.H., Adams, H., Hudson, D., and Cook, R.M. 1997. Versatile linker chemistry for synthesis of 3′-modified DNA. Bioconjug. Chem. 8:193-198. Stewart, J. and Young, J. 1984. Laboratory techniques in solid phase peptide synthesis. In Solid Phase Peptide Synthesis, pp. 105-107. Pierce Chemical Company, Rockford, Ill.
Contributed by Matthew H. Lyttle Biosearch Technologies, Inc. Novato, California
3′-Modified Oligonucleotides and their Conjugates
4.6.8 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates and their Phosphodiester and Phosphorothioate Chimeras
UNIT 4.7
Oligonucleotide N3′→P5′ phosphoramidates (pnODNs), wherein each 3′-oxygen is replaced by a 3′-amine in the 2′-deoxyribose ring (Figure 4.7.1), have shown significant therapeutic potential as antisense and antigene agents via duplex and triplex formation, respectively. Their binding properties also make them good candidates for oligonucleotide-based diagnostics and research tools. This unit describes the solid-phase synthesis of pnODNs (see Basic Protocol 1 and Alternate Protocol 1) using a method based on a phosphoramidite amine-exchange reaction wherein the key step is an exchange of a solid support–bound 3′-amino oligonucleotide for the amino group of a phosphoramidite monomer. Purification of these analogs is performed by either ion-exchange chromatography (IEC; see Basic Protocol 2) or reversed-phase high-performance liquid chromatography (RP-HPLC; see Alternate Protocol 2). The unit also describes the synthesis of required monomers and application of the method to preparation of phosphodiester- and phosphorothioate-containing chimeras of pnODNs. SOLID-PHASE CHAIN ASSEMBLY OF OLIGONUCLEOTIDE N3′→P5′ PHOSPHORAMIDATES FOR IEC PURIFICATION
BASIC PROTOCOL 1
The pnODN syntheses are performed in the 5′→3′ direction using a 3′-tritylamino nucleoside bound to aminopropyl controlled-pore glass (CPG) by a succinyl linker as the solid support (Figure 4.7.2). The trityl group was chosen as the amino-protecting group because it provides the requisite stability to the coupling, oxidation, and capping reagents, and is quantitatively removed by a relatively short treatment with dichloroacetic acid in dichloromethane. The resulting 3′-ammonium dichloroacetate salt is then coupled t o 3′-tritylamino-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxyl)]phosphinyl2′,3′-dideoxynucleoside monomer (Figure 4.7.3; S.1) in the presence of 1H-tetrazole. After neutralization, the resulting internucleotide phosphoramidite is oxidized to the stable, protected phosphoramidate. If phosphodiester or phosphorothioate chimeras are desired, the 3′-O-(4,4′-dimethoxytrityl)-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxy)]phosphinyl-2′-deoxyribonucleoside monomers (Figure 4.7.3; S.2) are used for those linkages, followed by either oxidation or sulfurization, respectively. A mixture of isobutyric anhydride and N-methylimidazole is used to cap any unreacted 3′-amines
5'
Base
O O O P O
Figure 4.7.1
O P S Base O
Base
O O
−
O
5'
O P O Base
Base
O NH
−
O
5'
− Base
O
O
O
3'
3'
Phosphodiester (po)
Phosphorothioate (ps)
3'
N3'→P5' Phosphoramidate (pn)
Structures of phosphodiester, phosphorothioate, and phosphoramidate linkages.
Contributed by Karen L. Fearon and Jeffrey S. Nelson Current Protocols in Nucleic Acid Chemistry (2000) 4.7.1-4.7.40 Copyright © 2000 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.1 Supplement 3
CPG
O
H N
O
O
O
O
H N
CPG
B1
O
Cl2CHCO2H
O
O CH2Cl2
NHTr
Cl2CHCOO
CH3 OCH2CH2CN P N O O
1. Isobutyric anhydride/NMI/2,6-lutidine/THF 2. Repeat synthesis cycle
B1
− +NH3
1H-Tetrazole CH3CN
B2
CH3 NHTr 1
CPG
O
H N
O
B1
O
O
O
H N
CPG
O
O
O
NH
O
O
NH
1. 20% C5H5N/CH3CN
O P OCH2CH2CN
P NCCH2CH2O
2. H2O2/H2O/C5H5N/THF
B2
B1
O
O
B2
NHTr NHTr
Figure 4.7.2 Synthetic steps in the preparation of pnODNs by the amine-exchange method. CPG, controlled-pore glass; Tr, triphenylmethyl; NMI, N-methylimidazole; THF, tetrahydrofuran.
because less hindered electrophiles, such as acetic anhydride, react with the tritylamino group of the oligonucleotide product. The method of purification needs to be decided on and planned for during the setup of the solid-phase synthesis. RP-HPLC purification of pnODNs using the hydrophobicity of the trityl group (Tr) is problematic because once the cyanoethyl groups are removed during ammonolysis, the phosphoramidate linkages are no longer stable to the acidic, post-RP-HPLC detritylation conditions. A new purification method requiring nonacidic conditions was therefore developed; however, it is only applicable to compounds terminating with a 3′-hydroxyl group. If a 3′-amine is desired, then IEC purification must be used. Chimera-containing phosphorothioate linkages are best purified by RP-HPLC because the phosphorothioate groups cause a severe loss of resolution during IEC. This
CH3 OCH2CH2CN
CH3 OCH2CH2CN N
P
O
O
B
P
N
CH3
1a, 2a: 1c, 2c: 1g, 2g: 1t, 2t:
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
O
O
B
CH3 NHTr
ODMTr
1
2
B = N 6-benzoyladenin-9-yl 4 B = N -benzoylcytosin-1-yl B = N 2-isobutyryl-O 6-(N,N-diphenylcarbamoyl)guanin-9-yl B = Thymin-1-yl DMTr = 4,4'-dimethoxytrityl
Figure 4.7.3
Structures of key phosphoramidite monomers.
4.7.2 Supplement 3
Current Protocols in Nucleic Acid Chemistry
protocol describes synthesis requiring IEC purification, whereas Alternate Protocol 1 describes synthesis requiring RP-HPLC purification. Materials 3% (v/v) dichloroacetic acid (Cl2CHCO2H) in dichloromethane (CH2Cl2; see recipe) Acetonitrile (CH3CN; ≤0.001% H2O) 0.1 M phosphoramidite monomer solutions (see recipe): 0.1 M 3′-tritylamino-5′-O-[(cis-2,6-dimethylpiperidino)(2cyanoethoxy)]phosphinyl-2′,3′-dideoxynucleoside monomers (ABz, CBz, Gi-Bu,DPC, T; S.1; see Support Protocol 7) 0.1 M 3′-O-(4,4′-dimethoxytrityl)-5′-O-[(cis-2,6-dimethylpiperidino)(2cyanoethoxy)]phosphinyl-2′-deoxyribonucleoside monomers (ABz, CBz, Gi-Bu,DPC, T; S.2; see Support Protocol 7; for phosphodiester or phosphorothioate chimera) 0.167 M 1H-tetrazole in CH3CN (see recipe) 20% (v/v) pyridine in CH3CN (see recipe) 1.5:3.5:20:75 (v/v/v/v) H2O2/H2O/pyridine/THF (see recipe) 0.2 M S-Tetra (Stec et al., 1993) in pyridine, prepared under argon, or 3H-1,2-benzodithiol-3-one-1,1-dioxide in acetonitrile (Beaucage reagent; Glen Research) 1:1:8 (v/v/v) isobutyric anhydride/2,6-lutidine/THF (see recipe) 16.5% (v/v) N-methylimidazole (NMI)/THF (see recipe) 3′-Tritylamino-2′,3′-dideoxynucleoside-5′-O-hemisuccinate conjugated to aminopropyl-controlled-pore glass (CPG; ABz, CBz, Gi-Bu,DPC, or T; see Support Protocol 6) Concentrated aqueous ammonia Column-mode DNA synthesizer capable of 1-µmol-scale syntheses (e.g., 392 or 394, PE Biosystems) with at least four monomer positions (preferably eight for synthesis of chimeras) Empty 1-µmol synthesis columns Desiccator with vacuum 4-mL glass screw-cap vials Heat block or oven set at 58°C Additional reagents and equipment for automated DNA synthesis (see manufacturer’s instructions and APPENDIX 3C) NOTE: This chemistry is extremely water sensitive. Oven-dry all bottles and syringes used for transferring solvents and solutions. Dissolve solids using a manifold or firestone valve to maintain an argon atmosphere. Perform all transfers under argon. Input oligonucleotide sequence 1. Enter the desired sequence into the automated synthesizer in backwards order. The pnODN syntheses are performed in the 5′-to-3′ direction instead of the 3′-to-5′ direction, which is standard for commercially available synthesizers. For instance, if the desired sequence is 5′-GGACCCTCCTCCGGAGCCOH-3′, then the synthesizer is programmed as follows: 5′-cCGAGGCCTCCTCCCAGG-3′, where lowercase letters represent 3′-O-dimethoxytrityl (3′-O-DMTr) monomers and uppercase letters represent 3′-trityl-amino monomers. If a pn/po/pn chimera of sequence 5′GGACCCpTpCpCpTpCpCGGAGCCOH-3′ is desired, where p is a phosphodiester linkage, then the synthesizer should be programmed as follows: 5′-cCGAGGCctcctcCCAGG-3′.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.3 Current Protocols in Nucleic Acid Chemistry
Supplement 3
2. For synthesis of a pn/ps/pn chimera, program each flank to end with the first residue of the subsequent flank. If this is overlooked, the attaching residues at the pn/ps and ps/pn junctions will contain a thioamidate and a phosphodiester linkage, respectively. For instance, if the desired sequence is 5′-GGACCsCsTsCsCsTsCsCsGGAGCCOH-3′, where s is a phosphorothioate linkage and the other linkages are phosphoramidate linkages, then the synthesizer should be programmed and run three times as follows: 5′-cCAGG-3′
with oxidation
5′-Gcctcctcc-3′
with sulfurization
5′-cCGAGG-3′
with oxidation.
This assumes that the synthesizer used requires the inclusion of the base already on the support when programming the sequence.
Program synthesizer 3. Program the synthesizer to perform the following cycle: a. 3% Cl2CHCO2H in CH2Cl2 for 60 sec for tritylamino or 90 sec for O-DMTr, then CH3CN wash (six times with 0.5 mL). b. Phosphoramidite monomer solution (S.1 or S.2; 0.1 M; 15 eq) + 1H-tetrazole (0.167 M; 65 eq) in CH3CN for 5 min. c. Neutralize and wash with 20% pyridine in CH3CN (six times with 0.4 mL). d. 1.5:3.5:20:75 H2O2/H2O/pyridine/THF (0.65 mL; 2 min) or, for a phosphorothioate linkage, 0.2 M (50 eq) S-Tetra in pyridine (220 sec), followed by CH3CN washes (six times with 0.5 mL). e. 1:1:8 isobutyric anhydride/2,6-lutidine/THF (0.5 mL) + 16.5% NMI/THF(0.5 mL) for 2 min, then CH3CN washes (six times with 0.5 mL). f. Repeat steps a to e. g. Repeat step a (“trityl-off”). The trityl-off step is not performed when RP-HPLC purification of ODN is required. Phosphoramidite/tetrazole deliveries should be modeled after the instrument manufacturer’s protocol for delivering these reagents during phosphodiester synthesis. Modifications may need to be made to accommodate differences between flow synthesizers that only deliver reagents (e.g., PE Biosystems) and those that can recirculate phosphoramidite monomers (e.g., Amersham Pharmacia Biotech). The above details refer to the former (PE-ABI) synthesizer. N,N-Diisopropylamino phosphoramidite monomers can be used in place of cis-2,6-dimethylpiperidino phosphoramidite monomers with the following changes. A coupleoxidize-couple-oxidize protocol (Nelson et al., 1997) must be used for the couplings to 3′-amino groups (i.e., repeat steps b through d before proceeding to step e for capping). Couplings to 3′-hydroxyls require only a single coupling. Also, the concentration of tetrazole in acetonitrile must be increased to 0.5 M because N,N-diisopropylamino phosphoramidites require more tetrazole for activation than cis-2,6-dimethylpiperidinophosphoramidites (Hirschbein et al., 1998). 3′-O-(4,4′-Dimethoxytrityl)-5′O[(N,N-diisopropylamino)(2-cyanoethoxy)]phosphinyl-2′-deoxyribonucleoside monomers (ABz, CBz, Gi-Bu, T) are available from Glen Research. Using a vortexing-mode synthesizer (e.g., PE Biosystems 390Z) on the 10-mmol scale, 3.6 eq of monomer and 9 eq of 1H-tetrazole is sufficient for complete coupling. Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
Commercially available 3H-1,2-benzodithiol-3-one-1,1-dioxide (Beaucage reagent) in acetonitrile can be used in place of S-Tetra/pyridine for sulfurization, if desired. Use the vendor’s protocol for this reagent.
4.7.4 Supplement 3
Current Protocols in Nucleic Acid Chemistry
4. Calculate the amount of monomer necessary for the desired syntheses by multiplying the number of couplings of each type of base by 15 µmol/coupling. Add 100 µmol to the total for each base in order to have enough solution to prime the lines and to cover the bottom of the bottle. Prepare and add reagents 5. Dissolve the monomers to a concentration of 0.1 M in CH3CN as described (see Reagents and Solutions). Due to the stability and expense of the monomers, dissolve only as much monomer as will be used in 1 week. If using N,N-diisopropylamino phosphoramidites, 30 mmol of monomer is used per coupling to 3′-amino groups because the couple-oxidize-couple-oxidize protocol must be performed.
6. Formulate a sufficient amount of each auxiliary reagent to complete the desired syntheses. Consumptions on a per-coupling basis are typically 0.4 mL for the tetrazole solution, 0.65 mL for the hydrogen peroxide formulation, 0.5 mL each for the capping reagents, and 2.4 mL for the 20% pyridine/CH3CN solution.
7. Load the reagents on the instrument, keeping them under argon at all times. a. Place the four 3′-tritylamino-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxyl)]phosphinyl-2′,3′-dideoxynucleoside monomers (ABz, CBz, Gi-Bu,DPC, T) (S.1) in monomer positions 1 to 4 and, for chimeras, place the four 3′-O-(4,4′dimethoxytrityl)-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxy)]phosphinyl2′-deoxyribonucleoside monomers (ABz, CBz, Gi-Bu,DPC, T) (S.2) in monomer positions 5 to 8. b. Place the hydrogen peroxide solution in the oxidation position. c. Place the S-Tetra or Beaucage reagent in the sulfurization position. d. Place the capping agents in their usual positions on the instrument. e. Place 20% pyridine/CH3CN in the position usually used for concentrated aqueous ammonia or, if available, an extra position on the synthesizer. 8. Weigh 1 µmol of 3′-tritylamino-2′,3′-dideoxynucleoside-5′-O-hemisuccinate-CPG corresponding to the 5′-terminal base. Place the CPG in an empty 1-µmol synthesis column and check the column thoroughly for leaks on the synthesizer by passing acetonitrile through it. Run synthesizer 9. Prime all of the lines with reagent and start the synthesizer according to the manufacturer’s guidelines. 10. At the end of the synthesis, remove the CPG column from the synthesizer and dry the CPG in a desiccator under vacuum for 15 min. 11. Carefully open the column and transfer the CPG to a 4-mL glass screw-cap vial. 12. Add 1 mL concentrated aqueous ammonia and deprotect the oligonucleotide for 8 to 12 hr at 58°C. 13. Store the deprotected pnODN in the ammonia solution at −20°C until purification (maximum of 4 weeks).
Synthesis of Modified Oligonucleotides and Conjugates
4.7.5 Current Protocols in Nucleic Acid Chemistry
Supplement 3
ALTERNATE PROTOCOL 1
SOLID-PHASE CHAIN ASSEMBLY FOR RP-HPLC PURIFICATION Additional Materials (also see Basic Protocol 1) 0.1 M 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-3′-O[(N,N-diisopropylamino)(2-cyanoethoxy)]phosphinyl uridine (see recipe) 0.5 M 1H-tetrazole in CH3CN 3:1 (v/v) concentrated aqueous ammonia/ethanol 1. Program, set up, and run the synthesizer as described (see Basic Protocol 1, steps 1 through 9), with the following modifications: a. Ensure that the terminal coupling is with a 3′-O-DMTr-protected deoxyribonucleoside (S.2) in order to ultimately have a terminal 3′-hydroxyl group on the oligonucleotide. Also, do not remove the DMTr group at the end of the synthesis (step 3g). b. Place 0.1 M 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-3′-O[(N,N-diisopropylamino)(2-cyanoethoxy)]phosphinyl uridine solution on the instrument in one of the monomer positions. Also, replace the 0.167 M 1H-tetrazole solution with 0.5 M 1H-tetrazole solution. It is important to use 0.5 M 1H-tetrazole for this coupling because the uridine monomer is an N,N-diisopropylamino phosphoramidite, which requires more tetrazole for activation than the cis-2,6-dimethylpiperidino phosphoramidites.
c. Program the synthesizer to couple the uridine monomer to the 3′ terminus of the pnODN or chimera (see Basic Protocol 1), but extend the coupling time to 10 min (step 3b). Once again, make sure not to remove the DMTr group at the end of the synthesis. 2. At the end of the synthesis, dry the CPG-column and deprotect the oligonucleotide as described (see Basic Protocol 1, steps 10 to 12), but use 1 mL of 3:1 (v/v) concentrated aqueous ammonia/ethanol in step 12. Do not heat >18 hr. The deprotected pnODN can be stored in the ammonia solution at −20°C until purification for a maximum of 1 week, although it is best to remove the ammonia and purify the crude oligonucleotide as soon as possible after synthesis. BASIC PROTOCOL 2
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
IEC PURIFICATION, ISOLATION, AND ANALYSIS The IEC purification method is used for pnODNs synthesized with a terminal 3′-amine or 3′-hydroxyl following removal of the trityl protecting group. Preparative IEC is able to separate failure sequences from the full-length product (n-mer). However, the resolution between the n-1 failure sequence and the product is not great; therefore, the main product peak must be fractioned and analyzed by analytical IEC or capillary gel electrophoresis (CGE) in order to decide which fractions to combine. Materials Deprotected oligonucleotide solution (see Basic Protocol 1), 4°C Buffer A: 0.01 M aqueous NaOH/0.01 M NaCl, pH 12 Buffer B: 0.01 M aqueous NaOH/1.5 M NaCl, pH 12 Concentrated aqueous ammonia, 4°C 0.5 M aqueous NaOH solution 100% ethanol UV/visible spectrometer
4.7.6 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Analytical IEC column (preferably a 4 × 250–mm Dionex PA-100 NucleoPac column) HPLC or FPLC system compatible with high pH buffer systems equipped with a UV detector, data collection system, and a 1- or 2-mL sample injection loop 3-mL disposable syringe with luer lock 0.45-µm filter that fits the end of a luer lock syringe Speedvac evaporator (Savant) Preparative IEC column (preferably a Pharmacia MonoQ 10/10 column) Sample holder with 1.5-mL centrifuge tubes or fraction collector Sephadex G-25 column (e.g., Pharmacia NAP-10; optional) Analyze quality of crude oligonucleotide 1. Dilute 10 µL cold, deprotected oligonucleotide solution in 990 µL water and scan from 200 to 400 nm using a UV spectrometer. Determine the absorbance at 260 nm and multiply by 100 (dilution factor) to determine the concentration of crude oligonucleotide in the 1 mL sample. To prevent loss of sample and to improve the accuracy of the dilution, make sure the ammonia solution is cold before opening the vial.
2. Dilute 0.5 OD260 units oligonucleotide into 0.5 mL water to serve as an analytical IEC sample. 3. Preequilibrate the analytical IEC column for ≥10 min with buffer A at a flow rate of 1 mL/min. 4. Program an HPLC or FPLC to run a gradient of 0% to 50% buffer B versus buffer A over 40 min at a flow rate of 1 mL/min and inject the 0.5-mL ODN sample. Monitor the run at 260 nm. Reequilibrate the column for ≥10 min with buffer A before performing a second run.
Prepare sample and IEC purify 5. Filter the CPG away from the remaining cold ammonia solution using a 3-mL disposable syringe with an attached 0.45-µm filter. 6. Wash the CPG twice with 0.5 mL cold, concentrated aqueous ammonia. 7. Add 10 µL of 0.5 M aqueous NaOH solution, and concentrate in a Speedvac evaporator to ∼0.5 mL. Do not completely dry the sample.
8. Filter the concentrated oligonucleotide again using a new 3-mL disposable syringe with an attached 0.45-µm filter and wash with 0.3 mL water. 9. Preequilibrate the preparative IEC column for ≥15 min with buffer A. Run a “blank” gradient if the column has not been used recently, and between purifications of samples with different sequences.
10. Program the HPLC to run a gradient ramping at 1%/min of buffer B versus buffer A at a flow rate of 1 mL/min. Use the analytical IEC (step 4) to determine the approximate percent of buffer B that will be needed to elute the sample. 11. Prepare a sample holder with at least ten 1.5-mL centrifuge tubes or use a fraction collector. This is necessary to obtain the highest level of purity; preparative IEC does not have the resolution of analytical IEC.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.7 Current Protocols in Nucleic Acid Chemistry
Supplement 3
12. Inject the entire crude ODN sample from the 1-µmol synthesis and monitor elution at 260 nm. Collect ∼0.5-mL fractions during the elution of the product peak. Store the fractions at 4°C until they have been analyzed and are ready for desalting. Analyze and desalt 13. Analyze a small amount (i.e., ∼0.1 OD260) of the fractions by analytical IEC. 14. Combine the fractions that are ≥85% pure and concentrate in a Speedvac evaporator to a volume of ~1 mL. Do not let the samples evaporate completely in the Speedvac evaporator; NaOH can potentially degrade pnODNs.
15. Precipitate the pnODN with 2.5 mL of 100% ethanol and cool for ≥30 min at −20°C. 16. Centrifuge for 2 min at 3000 × g, 4°C, and carefully remove the supernatant. 17. Dissolve the pellet in 1 mL of deionized water and repeat ethanol precipitation (steps 15 and 16) two more times to desalt the sample. Alternatively, desalt the sample on a Sephadex G-25 column using the manufacturer’s protocol.
18. Dissolve pellet in 1 mL of water and measure the OD260 as in step 1 to determine the yield of pnODN. 19. Inject a 0.2 OD260 sample on the analytical IEC column to determine the purity of the product. Alternatively, determine the purity using capillary gel electrophoresis (CGE) or polyacrylamide gel electrophoresis (PAGE; APPENDIX 3B).
20. Concentrate the pnODN to dryness and store up to 1 year at −20°C. ALTERNATE PROTOCOL 2
REVERSED-PHASE HPLC PURIFICATION, ISOLATION, AND ANALYSIS The RP-HPLC method developed for the pnODNs and their chimeras relies on the 3′-addition of a commercially available RNA monomer, 5′-O-(4,4′-dimethoxytrityl)-2′-Otert-butyldimethylsilyl-3′-O-[(N,N-diisopropylamino)(2-cyanoethoxy)]phosphinyl uridine, to the terminal 3′-OH via 1H-tetrazole activation, followed by oxidation to a 3′→3′ phosphodiester linkage (Figure 4.7.4). The DMTr group is retained at the end of the synthesis to enable hydrophobic purification. After the RP-HPLC purification, the 3′-terminal uridine phosphodiester is cleaved from the oligonucleotide product by treatment with fluoride and base. Additional Materials (also see Basic Protocol 2) Deprotected oligonucleotide solution (see Alternate Protocol 1), 4°C Buffer C: acetonitrile Buffer D (see recipe): 0.1 M TEAB/2% acetonitrile, pH 8 3:1 (v/v) concentrated aqueous ammonia/ethanol 1 M TEAB buffer, pH 8 (see recipe) Acetonitrile 1 M aqueous NaF (0.45-µm filtered)
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
Analytical RP-HPLC column (e.g., Polymer Laboratories 0.46 × 15–cm PLRP-S column) HPLC system compatible with reversed-phase buffers and solvents, equipped with a UV detector, data collection system, and a 2-mL sample injection loop
4.7.8 Supplement 3
Current Protocols in Nucleic Acid Chemistry
1. DCA/CH2Cl2 2. DMTrO
O
OTBDMS
O
i-Pr2N
Ura
P OCH2CH2CN
DMTrO
Ura
O
DMTrO
Ura
O
1H-tetrazole/CH3CN 3'-DMTrOpnDNA-5'-CPG
1. Purify by RP-HPLC 2. 1 M aq. NaF/NH4OH, o 58 C, 16 hr
O P O
3. Desalt
−
+
−
O-3'-pnDNA-5'
Ura
O
OH
O O P O
O-3'-pnDNA-5'
DMTrO 3'-HOpnDNA-5'
+
OTBDMS
O 3. H2O2/H2O/C5H5N/THF o 4. NH3/EtOH, 58 C, 8-12 hr
DMTrO
Ura
O
+ O O P O
OH
−
OH
HO
O O P O
−
OH
Figure 4.7.4 Method facilitating the purification of oligonucleotide phosphoramidates by RPHPLC. DCA, dichloroacetic acid; Ura, uracil-1-yl; TBDMS, tert-butyldimethylsilyl; i-Pr, isopropyl.
Semipreparative RP-HPLC column (e.g., Polymer Labs 0.8 × 30–cm PLRP-S column) Heat block or oven set at 58°C Analyze quality of crude oligonucleotide 1. Optional: Follow the procedure for measurement of the crude OD260 and analysis by analytical IEC (see Basic Protocol 2, steps 1 to 4). 2. Dilute a second 0.5 OD260 units of ODN sample into 0.5 mL water for analysis by analytical RP-HPLC. 3. Preequilibrate the analytical RP-HPLC column for ≥10 min with 5% buffer C versus buffer D at a flow rate of 1 mL/min. 4. Program the HPLC to run a gradient of 5% to 40% buffer C versus buffer D over 40 min, followed by holding at 40% buffer C for 10 min at 1 mL/min. 5. Inject the 0.5-mL ODN sample and monitor the run at 260 nm. Reequilibrate the column for ≥10 min with 5% buffer C versus buffer D before performing a second run. Typical analytical IEC and RP-HPLC chromatograms of a crude pnODN containing a hydrophobic 3′-terminal uridine phosphodiester are shown in Figure 4.7.5. There are two product peaks in the RP-HPLC chromatogram because of partial loss of the tert-butyldimethylsilyl (TBDMS) group from uridine. Add the two peaks together to determine the amount of ODN product present. The byproduct peak generated from diphenylcarbamoyl (DPC) deprotection of G is observed near the product at 260 nm.
Prepare ODN sample and RP-HPLC purify 6. Filter the CPG away from the remaining cold ammonia solution using a 3-mL syringe attached to a 0.45-µm filter. 7. Wash the CPG twice with 0.5 mL of 3:1 concentrated aqueous ammonia/ethanol. 8. Concentrate in a Speedvac evaporator to ~0.5 mL. Do not completely dry the sample.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.9 Current Protocols in Nucleic Acid Chemistry
Supplement 3
Figure 4.7.5 (A) Analytical IEC chromatogram (40.1% pure) and (B) RP-HPLC chromatogram (42.9% pure) of the phosphoramidate oligonucleotide, 5′-CCCTCCTCCGGAGCCpUDMTr where p is a (3′,3′)-phosphodiester linkage. Two ODN product peaks are seen in the RP-HPLC because some of the TBDMS group on the 3′-terminal uridine is removed prematurely by ammonia treatment and/or subsequent workup. Peak 1, product containing uridine with 5′-O-DMTr but not 2′-O-TBDMS; peak 2, byproduct generated from diphenylcarbamoyl (DPC) deprotection of G; peak 3, product containing uridine with 5′-O-DMTr and 2′-O-TBDMS.
Do not add 0.5 M aqueous NaOH to this sample as the hydrophobic 3′-terminal uridine phosphodiester will cleave prematurely.
9. Filter the concentrated oligonucleotide again using a new 3-mL syringe attached to a 0.45-µm filter and wash twice with 0.3 mL of water. 10. Add 0.2 mL of 1 M TEAB buffer, pH 8, and 25 µL acetonitrile. The sample, once concentrated and buffered, should be purified within 12 hr. Occasionally the byproduct produced from DPC deprotection of G continues to precipitate out after filtration, especially if the sample is frozen; refilter the solution just prior to purification, if necessary, to prevent clogging of the column.
11. Preequilibrate a semipreparative RP-HPLC column for ≥15 min in 5% buffer C versus buffer D at a flow rate of 2 mL/min. Run a “blank” gradient if the column has not been used recently, and between purifications of samples with different sequences.
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
TEAB (buffer D) is used because, unlike the more commonly used triethylammonium acetate (TEAA), it remains basic during the post-RP-HPLC concentration and enables the isolation of pure pnODN without accompanying acid-mediated degradation.
12. Program the HPLC to run a gradient of 5% to 40% buffer C versus buffer D over 40 min, followed by a hold for 10 min at 40% buffer C at a flow rate of 2 mL/min.
4.7.10 Supplement 3
Current Protocols in Nucleic Acid Chemistry
13. Inject 75 to 120 OD260 crude pnODN and collect both product peaks. Monitor the chromatography at 296 nm for preparative runs. The byproduct peak generated from DPC deprotection of G is not observed at 296 nm; the higher wavelength is used to attenuate the peak height. In general, there are some impurities just prior to the products, as well as a backside shoulder; both of these should be avoided during collection of the major fractions. It is usually best to collect only to approximately half the highest UV reading on the backside of the peak because this region contains more short-mer impurities. An example of a semipreparative RP-HPLC chromatogram and the fractionation of the peaks is shown in Figure 4.7.6.
14. Combine the two product peaks, concentrate in the Speedvac evaporator until the sample can be transferred to a 4-mL screw-cap vial, and then concentrate the sample to dryness. It is not necessary to add NaOH to the fractions; the TEAB buffer will stay basic during the concentration.
Remove 3′-terminal uridine phosphodiester, desalt, and analyze 15. Add 200 µL concentrated aqueous ammonia and 200 µL of 1 M aqueous NaF to the dry pnODN, vortex the mixture until the pnODN is dissolved, and heat the sample for 12 to 16 hr at 58°C. The fluoride removes the TBDMS group and the base causes intramolecular cleavage of the uridine phosphodiester function.
16. Cool the pnODN solution and check a small aliquot (0.2 OD260) by analytical IEC for complete cleavage. The retention time of the cleaved product is shorter than that of the uridine-containing product, and the two early-eluting uridine byproducts (see Fig. 4.7.4) are present.
17. Concentrate the solution to ∼200 µL in the Speedvac evaporator and precipitate the pnODN with 0.6 mL of 100% ethanol to remove the bulk of NaF. Freeze the sample for ≥30 min at –20°C. 18. Centrifuge for 2 min at 10,000 × g, room temperature, and carefully remove the supernatant.
Figure 4.7.6 Semipreparative RP-HPLC chromatogram of a pnODN with the sequence 5′CCCTCCTCCGGAGCCpUDMTr where p is a (3′,3′)-phosphodiester linkage.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.11 Current Protocols in Nucleic Acid Chemistry
Supplement 9
19. Dissolve the product in 1 mL of water and desalt the sample on a Sephadex G-25 column using the manufacturer’s protocol. The Sephadex G-25 column is necessary in this case because ethanol precipitation does not remove the uridine byproducts.
20. Measure the OD units at 260 nm to determine the yield of pnODN. Inject 0.2 OD260 units on an analytical IEC column to determine the purity of the product. Alternatively, determine ODN purity by CGE or PAGE (APPENDIX 3B).
21. Concentrate the pnODN to dryness in the Speedvac evaporator and store up to 1 year at −20°C. SUPPORT PROTOCOL 1
SYNTHESIS OF 3′-TRITYLAMINO-2′,3′-DEOXYTHYMIDINE The synthesis of 3′-tritylamino-2′,3′-deoxythymidine (S.5) from thymidine is shown in Figure 4.7.7. The 3′-azido-5′-O-(4-methoxybenzoyl)-2′,3′-deoxythymidine (S.3) is prepared as previously reported (Czernecki and Valéry, 1991). Materials Thymidine N,N-Dimethylformamide (DMF) Triphenylphosphine p-Anisic acid Diisopropylazodicarboxylate (DIAD) Diethyl ether, 5°C Lithium azide (LiN3) Ethyl acetate Saturated aqueous NaCl Sodium sulfate (Na2SO4, anhydrous) 8:2 (v/v) ethyl acetate/hexane 1:1 (v/v) ethanol/dichloromethane (CH2Cl2) Hydrogen 10% Pd/C catalyst (Aldrich) Pyridine (anhydrous) Triethylamine Trityl chloride Chromatography-grade silica gel, 70-230 mesh 60 Å (Aldrich) 0.5% to 5% (v/v) triethylamine in 2% (v/v) methanol/CH2Cl2 2% to 5% (v/v) methanol/CH2Cl2 5:95, 1:9, and 2:8 (v/v) methanol/CH2Cl2 57:43 (v/v) 1,4-dioxane/methanol 2 M aqueous NaOH (APPENDIX 2A) Dowex 50W-X8 cation-exchange resin (pyridinium H+ form; see recipe) Saturated aqueous NaHCO3 1:1 (v/v) ethyl ether/hexane
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
Heating mantle, variac, and temperature controller Mechanical overhead stirrer (Fisher) TLC plates (e.g., 0.2-mm-thick precoated Merck silica gel 60 F254 plates) Rotary evaporator Parr shaker-type hydrogenator able to hold pressures up to 60 psi
4.7.12 Supplement 9
Current Protocols in Nucleic Acid Chemistry
O HO
O
Thy
2. DIAD/Ph3P/DMF 3. LiN3/DMF, 110 oC
OH
O
1. DIAD/Ph3P/4-MeOC6H4CO2H
O
Thy
MeO
1. H2,10% Pd/C, EtOH/CH2Cl2 2. TrCl/Et3N/C5H5N
N3 3 (98%)
T
CH3 OCH2CH2CN O
N O
O
MeO
Thy
2 M aq. NaOH
HO
O
Thy
1,4-Dioxan/MeOH NHTr 4 (83%)
NHTr
P Cl CH3 1t
DBU/CH2Cl2
5 (90%)
Figure 4.7.7 Synthetic steps in the preparation of 3′-tritylamino-2′,3′-dideoxythymidine (S.5) from thymidine. Thy, thymin-1-yl; DIAD, diisopropylazodicarboxylate; DBU, 1,8-diazabicyclo[5.4.0]undec7-ene.
Additional reagents and equipment for thin-layer chromatography (TLC, APPENDIX 3D) and column chromatography (APPENDIX 3E) Synthesize 3′-azido-5′-O-(4-methoxybenzoyl)-2′,3′-deoxythymidine (S.3) 1. Dissolve 141.0 g (582.2 mmol) thymidine in 1125 mL DMF in a 3-liter round-bottom flask. 2. Add 183.2 g (698.4 mmol) triphenylphosphine and 106.3 g (698.4 mmol) p-anisic acid. 3. Add 137.5 mL (698.4 mmol) diisopropylazodicarboxylate, diluted in 150 mL DMF, over 35 min using an additional funnel. 4. After 40 min, add another 183.2 g (698.4 mmol) triphenylphosphine all at once, and another 141.3 g (698.4 mmol) diisopropylazodicarboxylate, dissolved in 150 mL DMF, over a 40-min period using an additional funnel. 5. Stir the resultant mixture for an additional 65 min. 6. Quench the reaction with 10 mL of water and concentrate the solution to a volume of ∼800 mL using a rotary evaporator equipped with a vacuum pump. 7. Precipitate the product by pouring it into 6000 mL cold diethyl ether, 5°C, with rapid stirring. 8. Filter the solid using a Büchner funnel and house vacuum, wash with 2000 mL cold diethyl ether, and dry in vacuo to give semipure 2,3′-anhydro-5′-O-(4-methoxybenzoyl)-2′,3′-deoxythymidine. Crude yield = 110% (230.2 g).
9. Using a mechanical stirrer, dissolve 230.0 g (642.5 mmol) of 2,3′-anhydro-5′-O-(4methoxybenzoyl)-2′,3′-deoxythymidine in 1200 mL DMF, add 47.2 g (963.8 mmol) lithium azide, and heat the mixture for 48 hr at 100° to 110°C. 10. Concentrate the solution on the rotary evaporator using a vacuum pump, dissolve the residue in 3000 mL ethyl acetate, and wash two times with 1000 mL water and three times with 600 mL saturated aqueous NaCl.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.13 Current Protocols in Nucleic Acid Chemistry
Supplement 9
11. Dry the organic solution over anhydrous Na2SO4, filter, and concentrate on the rotary evaporator with a vacuum line to afford 3′-azido-5′-O-(4-methoxybenzoyl)-2′,3′-deoxythymidine (S.3) as an amber foam. 12. Perform TLC analysis (APPENDIX 3D) on 0.2-mm-thick precoated Merck silica gel 60 F254 plates to confirm the purity of the product. Elute with 8:2 (v/v) ethyl acetate/hexane. Crude yield = 97.9% (228.9 g, 570.0 mmol). Rf (8:2 ethyl acetate/hexane) = 0.51. 1H NMR (CDCl3 /TMS): δ 9.36 (1H, br s), 7.98 (2H, d, J = 8.7 Hz), 7.22 (1H, s), 6.95 (2H, d, J = 8.7 Hz), 6.18 (1H, t, J = 6.5 Hz), 4.65 (1H, dd, J = 12.3, 3.3 Hz), 4.53 (1H, dd, J = 12.3, 3.6 Hz), 4.35 (1H, m), 4.21 (1H, dt, J = 3.6, 2.5 Hz), 3.87 (3H, s), 2.54 (1H, m), 2.35 (1H, m), 1.71 (3H, s).
Synthesize 5′-O-(4-methoxybenzoyl)-3′-tritylamino-2′,3′-deoxythymidine (S.4) 13. Dissolve 10.0 g (24.9 mmol) of S.3 in 500 mL of 1:1 (v/v) ethanol/CH2Cl2 and reduce via hydrogenation (60 psi H2) in the presence of 1 g of 10% Pd/C catalyst for 16 hr. 14. Remove the catalyst by vacuum filtration and evaporate the solvent in vacuo. Yield = 92% (8.6 g, 22.9 mmol) of the corresponding 3′-amine, which is taken directly to the next reaction.
15. Dry 8.6 g (22.9 mmol) of 3′-amino-5′-O-(4-methoxybenzoyl)-2′,3′-deoxythymidine by azeotropic removal of water two times with 50 mL pyridine, evaporating to dryness on a rotary evaporator each time. Dissolve in 50 mL anhydrous pyridine. 16. Add 6.17 mL (48.1 mmol) triethylamine and 7.0 g (25.2 mmol) trityl chloride. Stir this mixture for 2 hr at room temperature. Perform TLC analysis (see step 12), eluting with 5:95 (v/v) methanol/CH2Cl2, to determine if the reaction is complete 17. If the reaction is complete, go to step 18, otherwise add an additional 1.9 g (6.9 mmol) trityl chloride, if necessary, and continue stirring for an additional 2 hr. 18. Remove the solvents using a rotary evaporator equipped with a vacuum pump and purify the crude product (S.4) by gravity on a silica gel column (APPENDIX 3E) preequilibrated with 0.5% triethylamine in 2% methanol/CH2Cl2. Obtain product by eluting with 2% to 5% methanol/CH2Cl2. For acid-sensitive (trityl-containing and phosphoramidite) compounds, the column should be packed and equilibrated with 0.5% triethylamine.
19. Perform TLC analysis (step 12) to confirm the purity of the product. Elute with 5:95 (v/v) methanol/CH2Cl2. Yield = 90% (12.7 g, 20.6 mmol). Rf (5:95 methanol/CH2Cl2) = 0.45. 1H NMR (CDCl3 /TMS): δ 8.26 (1H, br s, exchanges with D2O), 7.84, 6.90 (4H, AB, J = 8.86 Hz), 7.55 (6H, d, J = 7.45 Hz), 7.29 (6H, t, J = 7.56 Hz), 7.21 (3H, t, J = 7.27 Hz), 7.02 (1H, s), 6.08 (1H, t, J = 6.19 Hz), 4.59 (1H, dd, J = 12.35, 2.35 Hz), 4.29 (1H, dd, J = 12.43, 3.94 Hz), 3.98 (1H, m), 3.88 (3H, s), 3.41 (1H, m), 1.97 (1H, br, exchanges with D2O), 1.65-1.75 (1H, m), 1.58 (3H, s), 1.30-1.40 (1H, m). HRMS (FAB+): calcd for [M + Cs]+, 750.1580, observed 750.1559.
Synthesize 3′-tritylamino-2′,3′-deoxythymidine (S.5) 20. Remove the 5′-O-anisoyl protecting group by dissolving 30.1 g (48.7 mmol) of S.4 in 150 mL of 57:43 (v/v) 1,4-dioxane/methanol, and then adding 73.1 mL (146.2 mmol) of 2 M aqueous NaOH. Stir the solution for 1.5 hr at room temperature. Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
21. Neutralize with ~150 g of Dowex 50W-X8 cation-exchange resin (dry pyridinium H+ form, 1.6 meq/g).
4.7.14 Supplement 9
Current Protocols in Nucleic Acid Chemistry
22. Once the pH is neutral (∼10 min), filter the resin, wash three times with 40 mL of 2:8 methanol/CH2Cl2, and concentrate the crude product on the rotary evaporator using a vacuum line. 23. Dissolve the residue in 500 mL ethyl acetate and extract two times with 250 mL saturated aqueous NaHCO3, once with 250 mL water, and once with 250 mL saturated aqueous NaCl. 24. Dry the organic phase over anhydrous Na2SO4 and filter. 25. Remove the solvents using a rotary evaporator with a vacuum line and dissolve the resulting foam in 300 mL of 5:95 methanol/CH2Cl2. 26. Add this solution slowly to 1250 mL of a rapidly stirring mixture of 1:1 (v/v) diethyl ether/hexane to precipitate the pure 3′-tritylamino-2′,3′-deoxythymidine (S.5). 27. Perform TLC analysis (step 12) to confirm the purity of the product. Elute with 1:9 (v/v) methanol/CH2Cl2. Yield = 90% (21.2 g, 43.8 mmol). Rf (1:9 methanol/CH2Cl2) = 0.50. 1H NMR (CDCl3 /TMS): δ 8.30 (1H, br s, exchanges with D2O), 7.52 (6H, d, J = 7.46 Hz), 7.29 (6H, t, J = 7.55 Hz), 7.21 (3H, t, J = 7.25 Hz), 7.16 (1H, s), 6.01 (1H, t, J = 6.38 Hz), 3.85 (1H, d, J = 11.71 Hz), 3.74 (1H, m), 3.65 (1H, dd, J = 11.99, 2.59), 3.34 (1H, q, J = 6.54 Hz), 1.80-2.00 (1H, br, exchanges with D2O), 1.83 (3H, s), 1.45-1.55 (1H, m), 1.30-1.40 (1H, m). HRMS (FAB+): calcd for [M + Cs]+, 616.1212, observed 616.1226.
SYNTHESIS OF N4-BENZOYL-3′-TRITYLAMINO-2′,3′-DIDEOXYCYTIDINE The synthesis of N4-benzoyl-3′-tritylamino-2′,3′-deoxycytidine (S.9) is shown in Figure 4.7.8. The C monomer is more readily and efficiently synthesized by the dU→dC route, rather than by lithium azide ring opening of a 2,3′-anhydro-2′-deoxycytidine derivative (Reese and Skone, 1984; Nelson et al., 1997).
SUPPORT PROTOCOL 2
Additional Materials (also see Support Protocol 1) 2′-Deoxyuridine 4-Dimethylaminopyridine tert-Butyldimethylsilyl (TBDMS) chloride 2:1 (v/v) ethanol/CH2Cl2 1,2,4-Triazole Phosphorus oxychloride (POCl3) 1,4-Dioxane Benzoyl chloride Concentrated aqueous ammonia (28%), 4°C Tetrahydrofuran (THF) 1 M tetra-n-butylammonium fluoride (TBAF) in THF 1% (v/v) triethylamine in 30% to 50% (v/v) ethyl acetate/hexane Synthesize 3′-azido-5′-O-(tert-butyldimethylsilyl)-2′,3′-dideoxyuridine (S.6) 1. Dry 11.4 g (50 mmol) of 2′-deoxyuridine two times thoroughly via co-evaporation with 100 mL anhydrous DMF in vacuo. 2. Add 100 mL DMF followed by 8.36 mL (60 mmol) triethylamine, 0.31 g (2.5 mmol) of 4-dimethylaminopyridine, and 8.29 g (55.0 mmol) tert-butyldimethylsilyl chloride. Stir the reaction mixture for 1 hr at room temperature. 3. Dilute with 600 mL CH2Cl2 and extract three times with 200 mL water and once with 200 mL saturated aqueous NaCl.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.15 Current Protocols in Nucleic Acid Chemistry
Supplement 9
O
O
NH
NH HO
O
N
O
1. TBDMS-Cl/cat. DMAP/Et3N/DMF
TBDMSO
2. DIAD/Ph3P/DMF 3. LiN3/ DMF/∆
OH
O
N
O
1. H2,10% Pd/C, EtOH/CH2Cl2 2. TrCl/Et3N/C5H5N
N3 6 (63%)
dU
NHBz
O
N
NH TBDMSO
O
N
O
1. POCl3/Et3N/1,2,4-triazole/MeCN 2. NH4OH/1,4-dioxan
TBDMSO
3. BzCl/C5H5N
NHTr
O
N
O TBAF/THF
NHTr
7 (85%)
8 (92%) NHBz N HO
O
N
O
CH3 OCH2CH2CN P N Cl CH3 1c DBU/CH2Cl2
NHTr 9 (88%)
Figure 4.7.8 Synthetic steps in the preparation of N4-benzoyl-3′-tritylamino-2′,3′-dideoxycytidine (S.9) from 2′-deoxyuridine. DMAP, 4-dimethylaminopyridine; Bz, benzoyl; TBAF, tetra-n-butylammonium fluoride.
4. Dry the organic layer over anhydrous Na2SO4, vacuum filter, and concentrate on a rotary evaporator using a vacuum pump. 5. Purify the resulting residue by gravity column chromatography (APPENDIX 3E) on silica gel with 2% to 10% methanol/CH2Cl2 to afford 5′-O-(tert-butyldimethylsilyl)-2′-deoxyuridine. Yield = 80% (13.7 g, 40.0 mmol).
6. Dissolve 13.7 g (40.0 mmol) of 5′-protected nucleoside and 16.8 g (64.0 mmol) triphenylphosphine in 100 mL DMF. While stirring, add 12.6 mL (64.0 mmol) diisopropylazodicarboxylate in 20 mL DMF. 7. Stir 2 hr at room temperature, concentrate the reaction mixture on a rotary evaporator using a vacuum pump to ∼30 mL, and pour into 1200 mL diethyl ether. The desired product precipitates out after ∼10 min of rapid stirring.
8. Place the resulting mixture overnight at 4°C. 9. Collect the precipitate by vacuum filtration, wash two times with 300 mL cold diethyl ether, and dry in vacuo to afford 2,3′-anhydro-5′-O-(tert-butyldimethylsilyl)-2′-deoxyuridine as a white solid. Yield = 90% (11.7 g, 36.0 mmol).
10. React 33.8 g (104.2 mmol) of 2,3′-anhydro-5′-O-(tert-butyldimethylsilyl)-2′-deoxyuridine with 7.65 g (156.3 mmol) LiN3 in 300 mL DMF for 48 hr at 95° to 100°C. Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
11. Cool the resulting brown homogeneous mixture to room temperature, and concentrate to an oil using a rotary evaporator and vacuum pump. 12. Dissolve the residue in 800 mL ethyl acetate and extract with 200 mL water.
4.7.16 Supplement 9
Current Protocols in Nucleic Acid Chemistry
13. Extract the aqueous layer twice more with 75 mL ethyl acetate and combine the organics. Wash three times with 250 mL water and once with 250 mL saturated aqueous NaCl. 14. Dry the ethyl acetate solution over anhydrous Na2SO4, vacuum filter, and concentrate on a rotary evaporator with a vacuum line to afford 3′-azido-5′-O-(tert-butyldimethylsilyl)-2′,3′-dideoxyuridine (S.6) as a brownish foam. Proceed directly to hydrogenation. 15. Perform TLC analysis (APPENDIX 3D) on 0.2-mm-thick precoated Merck silica gel 60 F254 plates to confirm the purity of the product. Elute with 8:92 (v/v) methanol/CH2Cl2. Yield = 87% (33.2 g, 90.3 mmol). Rf (8:92 methanol/CH2Cl2) = 0.57. 1H NMR (CDCl3 /TMS): δ 8.87 (1H, br s, exchanges with D2O), 7.91 (1H, d, J = 8.10 Hz), 6.23 (1H, t, J = 5.88 Hz), 5.71 (1H, d, J = 8.18 Hz), 4.25 (1H, q, J = 5.91 Hz), 3.95-4.05 (2H, m), 3.83 (1H, dd, J = 11.40, 1.68 Hz), 2.45-2.55 (1H, m), 2.25-2.35 (1H, m), 0.95 (9H, s), 0.15 (3H, s), 0.14 (3H, s). HRMS (FAB+): calcd for [M + H]+, 368.1754, observed 368.1747.
Synthesize 5′-O-(tert-butyldimethylsilyl)-3′-tritylamino-2′,3′-dideoxyuridine (S.7) 16. Dissolve 33.2 g (90.3 mmol) of crude S.6 in 300 mL of 2:1 (v/v) ethanol/CH2Cl2 and reduce via hydrogenation (60 psi H2) in the presence of 3.0 g of 10% Pd/C catalyst for 18 hr. 17. Remove the catalyst by vacuum filtration and evaporate the solvent on a rotary evaporator using a vacuum line to afford the corresponding 3′-amine. Proceed directly to the next reaction. Yield = 99.4% (30.4 g, 89.8 mmol).
18. Azeotrope 30.4 g (89.8 mmol) of 3′-amino-5′-O-(tert-butyldimethylsilyl)-2′,3′ -dideoxyuridine two times with 300 mL pyridine and dissolve the solid in a mixture of 600 mL CH2Cl2 and 70 mL anhydrous pyridine. 19. Add 25.0 mL (179.6 mmol) triethylamine and 30.0 g (125.7 mmol) trityl chloride to this solution and stir for 2 hr at room temperature. 20. Purify (see Support Protocol 1, step 18) to afford 5′-O-(tert-butyldimethylsilyl)-3′tritylamino-2′,3′-dideoxyuridine (S.7). 21. Perform TLC analysis (step 15) to confirm the purity of the product. Elute with 8:2 (v/v) ethyl acetate/hexane. Yield = 85% (44.3 g, 75.9 mmol). Rf (8:2 ethyl acetate/hexane) = 0.58. 1H NMR (CDCl3/TMS): δ 8.24 (1H, br s, exchanges with D2O), 7.73 (1H, d, J = 8.25 Hz), 7.52 (6H, d, J = 7.78 Hz), 7.31 (6H, m), 7.23 (3H, t, J = 7.23 Hz), 6.21 (1H, t, J = 6.69 Hz), 5.60 (1H, d, J = 8.17 Hz), 3.84 (1H, m), 3.76 (1H, dd, J = 11.34, 2.00 Hz), 3.48 (1H, dd, J = 11.37, 2.27 Hz), 3.32 (1H, m), 2.07 (1H, br, exchanges with D2O), 1.60-1.70 (1H, m), 1.45-1.55 (1H, m), 0.84 (9H, s), 0.01 (3H, s), −0.05 (3H, s). HRMS (FAB+): calcd for [M + Na]+, 606.2764, observed 606.2751.
Synthesize N4-benzoyl-5′-O-(tert-butyldimethylsilyl)-3′-tritylamino-2′,3′-dideoxycytidine (S.8) 22. Add 22.5 mL (161.1 mmol) triethylamine dropwise over a period of 10 min to a stirring mixture of 11.1 g (161.1 mmol) of 1,2,4-triazole and 3.5 mL (37.1 mmol) phosphorus oxychloride in 125 mL anhydrous CH3CN at 0°C. 23. To this cold stirring mixture, add 9.4 g (16.1 mmol) of S.7 as a solution in 50 mL acetonitrile. Stir 2 hr at room temperature.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.17 Current Protocols in Nucleic Acid Chemistry
Supplement 3
24. Quench the reaction with 30 mL triethylamine and 10 mL water. 25. Remove the solvents using a rotary evaporator and vacuum line. 26. Dissolve the resulting brown solid in 250 mL CH2Cl2. Extract three times with 150 mL saturated aqueous NaHCO3 and once with 150 mL saturated aqueous NaCl. 27. Dry the organic solution over anhydrous Na2SO4, vacuum filter, and concentrate on a rotary evaporator using a vacuum line to afford 4-(1,2,4-triazol-1-yl)-5′-O-(tertbutyldimethylsilyl)-3′-tritylamino-2′,3′-dideoxyuridine as an orange solid. Crude yield = 100% (10.2 g, 16.1 mmol).
28. Dissolve this crude material in 200 mL of 1,4-dioxane and add 50 mL concentrated NH4OH, 4°C. 29. Stir the reaction mixture for 4 hr at room temperature and concentrate on a rotary evaporator using a vacuum pump to afford 5′-O-(tert-butyldimethylsilyl)-3′-tritylamino-2′,3′-dideoxycytidine as a beige solid. Crude yield = 100% (9.4 g, 16.1 mmol).
30. Azeotrope the crude material two times with 200 mL anhydrous pyridine. 31. Dissolve in 200 mL pyridine, cool externally in a 0°C ice bath, and add 2.2 mL (19.3 mmol) benzoyl chloride. 32. Allow the reaction to slowly warm to room temperature and stir an additional 16 hr at room temperature. 33. Cool the reaction mixture externally to 0°C and quench with 40 mL water. Stir 5 min. 34. Add 40 mL concentrated aqueous ammonia, 4°C, and stir the reaction mixture for an additional 15 min at 0°C. 35. Remove the solvents using a rotary evaporator and vacuum pump, dissolve the residue in 125 mL CH2Cl2, and extract three times with 75 mL saturated aqueous NaHCO3. 36. Dry the organic phase over Na2SO4, vacuum filter, and evaporate the solvents using a rotary evaporator and vacuum line. 37. Purify the crude material (see Support Protocol 1, step 18) to afford N4-benzoyl-5′O-(tert-butyldimethylsilyl)-3′-tritylamino-2′,3′-dideoxycytidine (S.8). 38. Perform TLC analysis (step 15) to confirm the purity of the product. Elute with 5:95 (v/v) methanol/CH2Cl2. Yield = 92% (10.2 g, 14.8 mmol). Rf (5:95 methanol/CH2Cl2) = 0.71. 1H NMR (CDCl3 / TMS): δ 8.70 (1H, d, J = 7.36 Hz, exchanges with D2O), 8.27 (1H, d, J = 7.36 Hz), 7.91 (2H, d, J = 7.46 Hz), 7.62 (1H, t, J = 7.20 Hz), 7.50-7.60 (8H, m; with 6H, d, J = 7.74 Hz at 7.52), 7.42 (1H, br d, J = 7.41 Hz), 7.30 (6H, t, J = 7.39 Hz), 7.22 (3H, t, J = 7.39 Hz), 6.26 (1H, t, J = 6.26 Hz), 3.80 (1H, br m), 3.77 (1H, br d, J = 11.39 Hz), 3.49 (1H, dd, J = 11.24, 2.33 Hz), 3.30 (1H, m), 1.90-2.10 (2H, br m; 1H exchanges in D2O), 1.52 (1H, dt, J = 13.57, 6.76 Hz), 0.86 (9H, s), 0.04 (3H, s), −0.01 (3H, s). HRMS (FAB+): calcd for [M + Cs]+, 819.2343, observed 819.2366.
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
4.7.18 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Synthesize N4-benzoyl-3′-tritylamino-2′,3′-dideoxycytidine (S.9) 39. Remove the 5′-TBDMS protecting group by dissolving 2.0 g (2.85 mmol) S.8 in 15 mL THF and reacting it with 15 mL of 1 M TBAF in THF for 16 hr. 40. Concentrate the reaction mixture to a syrup on the rotary evaporator using a vacuum line and dissolve the residue in 25 mL CH2Cl2. Extract four times with 25 mL water and once with 25 mL saturated aqueous NaCl. 41. Dry the organic layer over Na2SO4, vacuum filter, and remove the solvent using the rotary evaporator and vacuum line. 42. Purify the crude product on a silica gel column preequilibrated with 1% triethylamine in 30% ethyl acetate/hexane, and elute with 30% to 50% ethyl acetate/hexane to afford N4-benzoyl-3′-tritylamino-2′,3′-dideoxycytidine (S.9). 43. Perform TLC analysis (step 15) to confirm the purity of the product. Elute with 5:95 (v/v) methanol/CH2Cl2. Yield = 88% (1.4 g, 2.50 mmol). Rf (5:95 methanol/CH2Cl2) = 0.55. 1H NMR (CDCl3 / TMS): δ 8.65 (1H, br s, exchanges with D2O), 8.19 (1H, d, J = 7.36 Hz), 7.87 (2H, d, J = 7.57 Hz), 7.62 (1H, t, J = 7.37 Hz), 7.47-7.57 (9H, m), 7.30 (6H, t, J = 7.50 Hz), 7.23 (3H, t, J = 7.24 Hz), 6.07 (1H, dd, J = 6.66, 4.31), 3.91 (1H, d, J = 12.00 Hz), 3.79 (1H, m), 3.73 (1H, d, J = 12.10 Hz), 3.30 (1H, q, J = 6.38 Hz), 1.80-2.00 (2H, m, 1 br H exchanges in D2O), 1.40 (1H, ddd, J = 13.89, 7.03, 4.41 Hz). HRMS (FAB+): calcd for [M + Na]+, 595.2321, observed 595.2310.
SYNTHESIS OF N2-ISOBUTYRYL-O6-(N,N-DIPHENYLCARBAMOYL)3′-TRITYLAMINO-2′,3′-DIDEOXYGUANOSINE
SUPPORT PROTOCOL 3
The synthesis of N2-isobutyryl-O6-(N,N-diphenylcarbamoyl)-3′-tritylamino-2′,3′-dideoxyguanosine (S.13) is depicted in Figure 4.7.9. The 3′-O-benzoyl-N2-isobutyryl- 2′-deoxyxyloguanosine (S.10) is synthesized as previously reported (Nishino et al., 1986; Herdewijn and Van Aerschot, 1989). Additional Materials (also see Support Protocol 1) N2-Isobutyryl-2′-deoxyguanosine Benzoyl chloride Trifluoromethanesulfonic anhydride 4-Dimethylaminopyridine tert-Butyldimethylsilyl chloride 1:1 (v/v) methanol/1,4-dioxane 1 M aqueous HCl Diethylazodicarboxylate Argon N,N-Diisopropylethylamine N,N-Diphenylcarbamyl chloride Triethylamine trihydrofluoride Toluene 7:3 and 6:4 (v/v) ethyl acetate/hexane 2-liter large-mouth Erlenmeyer flask
Synthesis of Modified Oligonucleotides and Conjugates
4.7.19 Current Protocols in Nucleic Acid Chemistry
Supplement 4
O N
O
NH N
HO
N
O
N
NHiBu
HO 2. (CF3SO2)2O/C5H5N/CH2Cl2, -15 oC 3. H2O
OH
NH
1. BzCl/C5H5N R O
dGiBu
N
N
NHiBu
10 R = OBz (35%) O N
1. TBDMS-Cl/DMAP/Et3N/DMF 2. 2 M NaOH, MeOH/dioxan (1:1 v/v), 5 oC
TBDMSO
3. LiN3/DEAD/Ph3P/DMF 4. H2,10% Pd/C, EtOH/CH2Cl2
O
N
NH N
NHiBu
TrCl/Et3N/C5H5N
NPh2
CH3 OCH2CH2CN P N Cl
NH2 11 (49%) O
O N R1O
O
N
O N
NH N
NHiBu 1. DPC-Cl/i-Pr NEt/C H N 2 5 5
HO
O
N
N N
NHiBu
CH3 1g
NHTr
2. Et3N•3HF/C5H5N/CH2Cl2
12 R1 = TBDMS (100%)
DBU/CH2Cl2
NHTr 13 (82%)
Figure 4.7.9 Synthetic steps in the preparation of N2-isobutyryl-O6-(N,N-diphenylcarbamoyl)-3′tritylamino-2′,3′-dideoxyguanosine (S.13) from N2-isobutyryl-2′-deoxyguanosine. DEAD, diethylazodicarboxylate; iBu, isobutyryl; DPC-Cl, N,N-diphenylcarbamyl chloride.
Synthesize 3′-O-benzoyl-N2-isobutyryl-2′-deoxyxyloguanosine (S.10) 1. Azeotrope 119.1 g (353.1 mmol) N2-isobutyryl-2′-deoxyguanosine two times with 600 mL pyridine and then add 1500 mL pyridine. The solid does not completely dissolve.
2. Add 45.1 mL (388.4 mmol) benzoyl chloride, dissolved in 250 mL pyridine, dropwise over 5 hr using an additional funnel, and then continue stirring for another 11 to 16 hr. 3. Quench the reaction with 20 mL water, then remove the solvent using a rotary evaporator and vacuum pump. 4. Dissolve the solid in 900 mL CH2Cl2, wash with 400 mL water, and then transfer the organic phase to a 2-liter large-mouth Erlenmeyer flask. 5. Add 400 mL water and stir vigorously to precipitate the white solid product. 6. Vacuum filter the solid and wash three times with 100 mL of water. 7. Dry the solid using a vacuum pump to obtain the 5′-O-benzoyl-N2-isobutyryl-2′-deoxyguanosine. Yield = 91.6% (142.7 g, 323.4 mmol). Rf (1:9 methanol/CH2Cl2) = 0.27.
8. Azeotrope 142.7 g (323.4 mmol) of 5′-O-benzoyl-N2-isobutyryl-2′-deoxyguanosine three times with 400 mL pyridine, and then add 240 mL pyridine and 2200 mL CH2Cl2. Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
9. Cool the mixture to −15°C and add, with stirring, 92.5 mL (549.7 mmol) trifluoromethanesulfonic anhydride dissolved in 500 mL CH2Cl2, dropwise over 1 hr, while maintaining the temperature between −10° and −15°C.
4.7.20 Supplement 4
Current Protocols in Nucleic Acid Chemistry
10. Perform TLC analysis (APPENDIX 3D) on 0.2-mm-thick precoated Merck silica gel 60 F254 plates to confirm that the reaction is complete. Elute with 1:9 (v/v) methanol/CH2Cl2 (Rf = 0.6). 11. When the reaction is complete (after ∼1.5 hr), slowly quench the reaction with 150 mL water, maintaining the reaction temperature below 10°C. 12. Allow the solution to warm to room temperature and continue stirring for an additional 16 hr to complete the inversion. 13. Wash the organic layer two times with 1000 mL water and once with 1000 mL saturated aqueous NaCl. 14. Dry the organic solution over anhydrous Na2SO4, vacuum filter, and concentrate on the rotary evaporator and vacuum line to a brown solid. 15. Dissolve the solid in 550 mL CH2Cl2, stir for 1 hr, and then cool overnight at 4°C. 16. Vacuum filter the white solid, wash with 750 mL cold CH 2Cl2, and then dry using a vacuum pump to afford 3′-O-benzoyl-N2-isobutyryl-2′-deoxyxyloguanosine (S.10). 17. Concentrate the mother liquor using a rotary evaporator and vacuum line and repeat the recrystallization to obtain a second crop of pure product. 18. Perform TLC analysis (step 10) to confirm the purity of the product. Combined yield = 38.6% (55.1 g, 124.9 mmol). Rf (1:9 methanol/CH2Cl2) = 0.27. 1H NMR (DMSO-d6): δ 12.04 (1H, s), 11.70 (1H, s), 8.16 (1H, s), 7.84 (2H, d, J = 7.79 Hz), 7.67 (1H, t, J = 7.54 Hz), 7.52 (2H, t, J = 7.69 Hz), 6.25 (1H, dd, J = 7.55, 2.00 Hz), 5.69 (1H, t, J = 4.3 Hz), 4.96 (1H, t, J = 5.49 Hz), 4.32 (1H, dt, J = 7.79, 5.88 Hz), 3.77 (2H, m), 3.00 (1H, m), 2.76 (2H, m), 1.11 (6H, d, J = 6.76 Hz). The product (S.10) coelutes by TLC with the 5′-O-benzoyl-N2-isobutyryl-2′-deoxyguanosine but can be distinguished by 1H NMR spectroscopy.
Synthesize 3′-amino-5′-O-(tert-butyldimethylsilyl)-N2-isobutyryl-2′,3′-dideoxyguanosine (S.11) 19. To a stirring solution of 4.86 g (11.0 mmol) S.10 in 20 mL DMF, add 3.4 mL (24.2 mmol) triethylamine, 54 mg (0.44 mmol) 4-dimethylaminopyridine, and 3.31 g (22.0 mmol) tert-butyldimethylsilyl chloride. 20. Stir the reaction for 2 hr at room temperature. 21. Add 10 mL methanol and, after stirring an additional 5 min, concentrate the reaction mixture on a rotary evaporator using a high vacuum. 22. Dissolve the residue in 150 mL CH2Cl2 and wash three times with 40 mL water and once with 60 mL saturated aqueous NaCl. 23. Dry the organic layer over Na2SO4, vacuum filter, and concentrate with a rotary evaporator using a vacuum line to afford 6.40 g (>100% crude yield) of 3′-O-benzoyl-5′-O-(tert-butyldimethylsilyl)-N2-isobutyryl-2′-deoxyxyloguanosine. 24. Dissolve the crude material in 100 mL 1:1 methanol/1,4-dioxane and cool to 5°C. 25. Add 44.0 mL (87.9 mmol) prechilled (5°C) 2 M aqueous NaOH and stir the reaction mixture for 15 to 20 min in an ice bath. Monitor this reaction carefully and neutralize the hydroxide as soon as possible in order to avoid loss of the isobutyryl group.
26. Neutralize the reaction with 97 mL of 1 M aqueous HCl to pH 6 to 7.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.21 Current Protocols in Nucleic Acid Chemistry
Supplement 3
27. Remove the ice bath and concentrate the reaction mixture to ∼50 mL on the rotary evaporator with a high vacuum. 28. Extract three times with 75 mL CH2Cl2. 29. Wash the combined organics three times with 50 mL saturated aqueous NaHCO3 and two times with 50 mL saturated aqueous NaCl. 30. Dry the organic solution over Na2SO4, vacuum filter, and concentrate with a rotary evaporator using a vacuum line to afford 5′-O-(tert-butyldimethylsilyl)-N2-isobutyryl-2′-deoxyxyloguanosine. Proceed to the next reaction without further purification. Yield = 82% (4.1 g, 9.1 mmol).
31. To 47.3 g (104.7 mmol) crude 5′-O-(tert-butyldimethylsilyl)-N2-isobutyryl-2′-deoxyxyloguanosine dissolved in 1000 mL anhydrous DMF, add 15.4 g (314.1 mmol) LiN3 and 41.2 g (157.1 mmol) triphenylphosphine. 32. Add 24.7 mL (157.1 mmol) diethylazodicarboxylate and stir the reaction mixture for 5 hr at room temperature under argon. 33. Quench the reaction with 20 mL water and concentrate the reaction mixture on the rotary evaporator using a vacuum pump. 34. Dissolve the residue in 1500 mL ethyl acetate. 35. Wash three times with 1000 mL water and once with 1000 mL saturated aqueous NaCl. 36. Dry the organic solution over Na2SO4, vacuum filter, and concentrate using a rotary evaporator and vacuum line. Proceed directly to hydrogenation and purification of the 3′-amine. 37. Dissolve ≤104.7 mmol crude azide in 1600 mL of 1:1 (v/v) ethanol/CH2Cl2 and hydrogenate (60 psi H2) in the presence of 2.5 g of 10% Pd/C catalyst for 16 hr at room temperature. 38. Remove the catalyst by vacuum filtration and evaporate the solvent using a rotary evaporator and vacuum line to afford the crude 3′-amine. 39. Purify by gravity on a silica gel column (APPENDIX 3E) using 2% to 6% methanol/CH2Cl2 and then 1% triethylamine/6% methanol/CH2Cl2 to afford 3′-amino-5′O-(tert-butyldimethylsilyl)-N2-isobutyryl-2′,3′-dideoxyguanosine (S.11) as an off-white foam. 40. Perform TLC analysis (step 10) to confirm the purity of the product. Yield = 60% (28.2 g, 63.2 mmol). Rf (1:9 methanol/CH2Cl2) = 0.14. 1H NMR (CDCl3/TMS): δ 8.01 (1H, s), 6.17 (1H, dd, J = 6.77, 3.98 Hz), 3.80-3.90 (4H, mm), 2.83 (1H, septet, J = 6.80 Hz), 2.59 (1H, ddd, J = 13.26, 6.16, 4.03 Hz), 2.33 (1H, dt, J = 13.19, 6.79 Hz), 1.26 (6H, dd, J = 6.86, 2.79 Hz), 0.88 (9H, s), 0.07 (3H, s), 0.06 (3H, s). HRMS (FAB+): calcd for [M + H]+, 451.2489, observed 451.2480.
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
Synthesize 5′-O-(tert-butyldimethylsilyl)-N2-isobutyryl-3′-tritylamino-2′,3′-dideoxyguanosine (S.12) 41. Dissolve 28.5 g (63.2 mmol) S.11 in 500 mL pyridine, add 17.6 mL (126.4 mmol) triethylamine and 28.2 g (101.1 mmol) trityl chloride, and stir for 16 hr at room temperature.
4.7.22 Supplement 3
Current Protocols in Nucleic Acid Chemistry
42. Concentrate the reaction product to a solid using a rotary evaporator and vacuum pump. 43. Purify crude product (see Support Protocol 1, step 18) to afford 5′-O-(tert-butyldimethylsilyl)-N2-isobutyryl-3′-tritylamino-2′,3′-dideoxyguanosine (S.12). 44. Perform TLC analysis (step 10) to confirm the purity of the product. Yield = 100% (43.8 g, 63.2 mmol). Rf (1:9 methanol/CH2Cl2) = 0.72. 1H NMR (CDCl3 / TMS): δ 11.90 (1H, br s, exchanges with D2O), 8.01 (1H, br s, exchanges with D2O), 7.58 (1H, s), 7.56 (6H, d, J = 7.39 Hz), 7.31 (6H, t, J = 7.58 Hz), 7.23 (3H, t, J = 7.28 Hz), 6.00 (1H, dd, J = 6.86, 4.63 Hz), 3.88 (1H, dt, J = 5.91, 3.01 Hz), 3.75 (2H, ABX, JAB = 11.25 Hz), 3.52 (1H, m), 2.57 (1H, septet, J = 6.91 Hz), 2.00- 2.10 (1H, br s, exchanges with D2O), 1.72 (1H, dt, J = 13.63, 6.89 Hz), 1.59 (1H, ddd, J = 13.73, 6.69, 4.87 Hz), 1.28 (6H, dd, J = 6.90, 3.22 Hz), 0.81 (9H, s), −0.03 (3H, s), −0.04 (3H, s). HRMS (FAB+): calcd for [M + Cs]+, 825.2561, observed 825.2540.
Synthesize O6-(N,N-diphenylcarbamoyl)-N2-isobutyryl-3′-tritylamino-2′,3′-dideoxyguanosine (S.13) 45. Dissolve 30.3 g (43.7 mmol) S.12 in 90 mL anhydrous pyridine. 46. Add 11.4 mL (65.6 mmol) N,N-diisopropylethylamine and 11.1 g (48.1 mmol) N,N-diphenylcarbamyl chloride under argon and stir for 1.5 hr at room temperature. 47. Concentrate the intensely red/purple reaction mixture in vacuo (see step 42). 48. Dissolve the residue in 600 mL CH2Cl2, extract two times with 400 mL water and once with 400 mL saturated aqueous NaCl. 49. Dry the CH2Cl2 solution over Na2SO4, vacuum filter, and concentrate in vacuo (see step 36) to afford impure 5′-O-(tert-butyldimethylsilyl)-O6-(N,N-diphenylcarbamoyl)-N2-isobutyryl-3′-tritylamino-2′,3′-dideoxyguanosine. This product is generally taken on directly to desilylation, although it can also be purified on silica.
50. Perform TLC analysis (step 10) using 6:4 (v/v) ethyl acetate/hexane. Crude yield > 100% (43.8 g). Rf (6:4 ethyl acetate/hexane) = 0.58. 1H NMR (CDCl3 /TMS): δ 8.03 (1H, s), 7.90 (1H, br s, exchanges with D2O), 7.55 (6H, d, J = 7.63 Hz), 7.24-7.50 (16H, mm), 7.21 (3H, t, J = 7.22 Hz), 6.29 (1H, t, J = 6.07 Hz), 3.89 (1H, m), 3.75 (2H, ABX, JAB = 11.25 Hz), 3.49 (1H, br m), 3.01 (1H, br m), 2.77 (1H, septet, J = 6.78 Hz), 2.00-2.10 (br s, exchanges with D2O), 1.65-1.75 (2H, m), 1.28 (6H, d, J = 6.64 Hz), 0.83 (9H, s), −0.01 (3H, s), −0.02 (3H, s). HRMS (FAB+): calcd for [M + Cs]+, 1020.3245, observed 1020.3281.
51. Dissolve ∼43.7 mmol crude 5′-O-(tert-butyldimethylsilyl)-O6-(N,N-diphenylcarbamoyl)-N2-isobutyryl-3′-tritylamino-2′,3′-dideoxyguanosine in 200 mL CH2Cl2 and 25 mL pyridine. 52. Add 49.8 mL (305.8 mmol) triethylamine trihydrofluoride, followed by a 25-mL CH2Cl2 rinse, and stir the reaction mixture for 20 hr under argon at room temperature. 53. Dilute the reaction mixture with 600 mL CH2Cl2 and extract two times with 400 mL water. 54. Back-extract the first aqueous layer with 50 mL CH2Cl2. 55. Dry the combined organics over Na2SO4, vacuum filter, and concentrate in vacuo (see step 36).
Synthesis of Modified Oligonucleotides and Conjugates
4.7.23 Current Protocols in Nucleic Acid Chemistry
Supplement 3
56. Dissolve the residue in 100 mL CH2Cl2 and azeotrope three times with 50 mL toluene to remove traces of pyridine using a rotary evaporator and vacuum pump. 57. Purify on silica gel, using a column packed in 2% triethylamine in 7:3 (v/v) ethyl acetate/hexane and eluting with 7:3 ethyl acetate/hexane, to afford O6-(N,N-diphenylcarbamoyl)-N 2-isobutyryl-3′-tritylamino-2′,3′-dideoxyguanosine (S.13). 58. Confirm the purity of the product by TLC analysis (step 10), eluting with 6:4 (v/v) ethyl acetate/hexane. Yield = 82% (27.6 g, 35.7 mmol). Rf (6:4 ethyl acetate/hexane) = 0.20. 1H NMR (CDCl3 / TMS): δ 7.95 (1H, s), 7.84 (1H, br s, exchanges with D2O), 7.55 (6H, d, J = 7.85 Hz), 7.25-7.45 (16H, mm), 7.21 (3H, t, J = 7.25 Hz), 6.15 (1H, t, J = 6.31 Hz), 3.77-3.87 (2H, br m), 3.69 (1H, m), 3.62 (1H, m), 3.19 (1H, m), 2.80 (1H, septet, J = 6.86 Hz), 1.92-2.05 (2H, mm, 1H exchanges with D2O), 1.65 (1H, m), 1.24 (6H, d, J = 6.86 Hz). HRMS (FAB+): calcd for [M + Cs]+, 906.2380, observed 906.2350. Do not use 1 M tetra-n-butylammonium fluoride in THF to remove the TBDMS group because the O6-(N,N-diphenylcarbamoyl) group is not stable to this reagent. SUPPORT PROTOCOL 4
SYNTHESIS OF N6-BENZOYL-3′-TRITYLAMINO- 2′,3′-DIDEOXYADENOSINE The synthesis of N6-benzoyl-3′-tritylamino-2′,3′-dideoxyadenosine (S.18) from adenosine is illustrated in Figure 4.7.10. The 5′-O-(tert-butyldimethylsilyl)-2′-deoxyxyloadenosine is synthesized by slightly modified literature procedures (Wagner et al., 1974; Hansske and Robins, 1983), which is more efficient than the inversion route that is used for the pyroration of S.10. Additional Materials (also see Support Protocol 1) (−)-Adenosine Dibutyltin oxide p-Toluenesulfonyl chloride tert-Butyldimethylsilyl chloride 1 M lithium triethyl borohydride in THF Ammonium chloride Benzoyl chloride 7:10 (v/v) methanol/1,4-dioxane Pyridinium hydrochloride Diethylazodicarboxylate Argon 4:6 (v/v) ethyl acetate/hexane Tetrahydrofuran (THF) 1.0 M tetrabutylammonium fluoride (TBAF) in THF Synthesize 2′-O-(p-toluenesulfonyl)adenosine (S.14) 1. Gently reflux 25.0 g (93.5 mmol) (−)-adenosine and 23.3 g (93.5 mmol) dibutyltin oxide in 1000 mL methanol for 2 hr, until the cloudy suspension becomes clear. 2. Cool the solution to 4°C, then cautiously add 53.5 g (281 mmol) p-toluenesulfonyl chloride and 39.1 mL (281 mmol) triethylamine, keeping the reaction temperature at 4°C. 3. Stir the resulting cloudy suspension overnight at room temperature.
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
4. Vacuum filter the white solid, wash two times with 100 mL cold methanol, and dry using a vacuum pump to afford 2′-O-p-toluenesulfonyladenosine (S.14).
4.7.24 Supplement 3
Current Protocols in Nucleic Acid Chemistry
NH2 N HO
N
N
O
NH2 N
N
1. Bu2SnO/MeOH/reflux
HO
N
N
O
1. TBDMS-Cl/C5H5N
N
2. 1M LiEt3BH/THF, 4 oC 3. NH4Cl
o
HO
2. Ts-Cl/Et3N, 4 C
OH
HO
OTs
14 (100% crude)
A NH2 N R1O
R O
NHBz N
N
N
1. BzCl/C5H5N
N
R1O
R O
N
N
N
o
2. 2 M NaOH, 4 C MeOH/dioxan (7:10 v/v) 16 R = OH (84%) R1 = TBDMS
15 R = OH (59%) R1 = TBDMS
NHBz
NHBz N TBDMSO
O
N
1. LiN3/DEAD/Ph3P/DMF 2. H2,10% Pd/C, EtOH/CH2Cl2 3. TrCl/Et3N/C5H5N
N
N HO
N 1 M TBAF/THF
NHTr 17 (67%)
O
N
N N
CH3 OCH2CH2CN P N Cl CH3 1a
NHTr
DBU/CH2Cl2
18 (94%)
Figure 4.7.10 Synthetic steps in the preparation of N6-benzoyl-3′-tritylamino-2′,3′-dideoxyadenosine (S.18) from adenosine. Bu, butyl; Ts, p-toluenesulfonyl.
Crude yield = 114% (45 g). 1H NMR (DMSO-d6): δ 8.19 (1H, s), 8.02 (1H, s), 7.37 (2H, s), 7.42 (2H, d), 7.03 (2H, d), 6.11 (1H, d), 6.03 (1H, d), 5.75 (1H, t), 5.49 (1H, dd), 4.39 (1H, ddd), 4.07 (1H, br d), 3.62 (2H, m), 2.25 (3 H, s).
Synthesize 5′-O-(tert-butyldimethylsilyl)-2′-deoxyxyloadenosine (S.15) 5. Dissolve 45 g (< 93.5 mmol) S.14 in 1000 mL pyridine, add 28.2 g (187 mmol) tert-butyldimethylsilyl chloride, and stir overnight at room temperature. 6. Quench the reaction with 100 mL methanol, concentrate on a rotary evaporator using a vacuum pump, and azeotrope three times with 25 mL toluene. 7. Dissolve the solid in 200 mL methanol, stir for 2 hr to desilylate the N6-amino group, and concentrate with a rotary evaporator and vacuum line. 8. Purify the reaction product by gravity on a silica gel column (APPENDIX 3E) using 3% to 4% methanol/CH2Cl2 to give 5′-O-(tert-butyldimethylsilyl)-2′-O-(p-toluenesulfonyl)adenosine. Yield = 75.6% (37.9 g, 70.7 mmol). TLC (1:9 methanol/CH2Cl2) Rf = 0.51.
9. Dissolve 37.9 g (70.7 mmol) 5′-O-(tert-butyldimethylsilyl)-2′-O-(p-toluenesulfonyl)adenosine in 100 mL anhydrous THF and cool to 4°C. 10. Add dropwise 283 mL (283 mmol) prechilled 1.0 M lithium triethyl borohydride in THF. 11. Stir the solution for 30 min at 4°C and then overnight at room temperature. 12. Cool the solution to 4°C, carefully quench with 11.3 g (212 mmol) NH4Cl, and concentrate on the rotary evaporator with a vacuum line. 13. Dissolve the residue first in 50 mL methanol and then 500 mL diethyl ether. 14. Wash with 100 mL saturated aqueous NaCl, and concentrate to a foam (see step 12).
Synthesis of Modified Oligonucleotides and Conjugates
4.7.25 Current Protocols in Nucleic Acid Chemistry
Supplement 3
15. Purify on silica (2% to 4% methanol/CH2Cl2) to afford 5′-O-(tert-butyldimethylsilyl)-2′-deoxyxyloadenosine (S.15). Yield = 77.5% (20.1 g, 54.8 mmol). TLC (1:9 methanol/CH2Cl2) Rf = 0.43. 1H NMR (CDCl3 / TMS): δ 8.35 (1H, s), 7.98 (1H, s), 7.08 (1H, d, J = 9.34 Hz), 6.14 (1H, dd, J = 9.36, 2.68 Hz), 5.98 (2H, br s), 4.47 (1H, m), 4.10 (1H, m ), 3.97 (2H, m), 2.88 (1H, ddd, J = 15.47, 9.40, 6.32 Hz), 2.56 (1H, dd, J = 15.35, 2.76 Hz), 0.88 (9H, s), 0.063 (3H, s), 0.060 (3H, s). Make sure the reaction is fully quenched before concentrating the solution because lithium triethyl borohydride is pyrophoric. Other solvents, such as ethyl acetate or CH2Cl2, should not be used for the extraction as they lead to severe emulsions.
Synthesize N6-benzoyl-5′-O-(tert-butyldimethylsilyl)-2′-deoxyxyloadenosine (S.16) 16. Dissolve 5.0 g (13.6 mmol) S.15 in 25 mL pyridine, add 3.28 mL (27.4 mmol) benzoyl chloride, and stir for 2 hr at room temperature. 17. Quench the reaction with 1 mL water and concentrate on a rotary evaporator with vacuum pump. 18. Dissolve the residue in 80 mL of 7:10 (v/v) methanol/1,4-dioxane, cool to 4 °C. 19. Add 34 mL (68 mmol) prechilled 2.0 M aqueous NaOH and stir for 5 min to selectively remove the 3′-benzoyl group. Monitor the hydrolysis carefully and neutralize the hydroxide as soon as possible in order to avoid loss of the N6-benzoyl group.
20. Neutralize the solution to pH 7 with 4.0 g (35 mmol) pyridinium hydrochloride and concentrate on a rotary evaporator with vacuum pump. 21. Dissolve the residue in 100 mL CH2Cl2, extract two times with 50 mL saturated aqueous NaHCO3 and two times with 50 mL saturated aqueous NaCl, and concentrate in vacuo (see step 7). 22. Purify on silica (2% methanol/CH2Cl2) to give N6-benzoyl-5′-O-(tert-butyldimethylsilyl)-2′-deoxyxyloadenosine (S.16). Yield = 84.6% (5.4 g, 11.5 mmol). TLC (5:95 methanol/CH2Cl2) Rf = 0.38. 1H NMR (CDCl3 / TMS): δ 9.00 (1H, br s), 8.82 (1H, s), 8.32 (1H, s), 8.02 (2H, d, J = 7.26 Hz), 7.63 (1H, t, J = 7.41 Hz), 7.54 (2H, t, J = 7.56 Hz), 6.31 (1H, dd, J = 9.06, 2.44 Hz), 5.95 (1H, d, J = 7.63 Hz), 4.55 (1H, m), 4.11 (1H, pseudo q, J = 6.21 Hz), 4.02 (2H, dd, J = 8.08, 2.68 Hz), 2.90 (1H, ddd, J = 15.22, 9.12, 5.93 Hz), 2.58 (1H, dd, J = 15.33, 2.47 Hz), 0.88 (9H, s), 0.07 (3H, s), 0.06 (3H, s).
Synthesize N6-benzoyl-5′-O-(tert-butyldimethylsilyl)-3′-tritylamino-2′,3′-dideoxyadenosine (S.17) 23. Dissolve 17.6 g (37.5 mmol) S.16 in 375 mL anhydrous DMF and add 5.5 g (113.0 mmol) LiN3 and 14.8 g (56.3 mmol) triphenylphosphine. 24. Add 8.9 mL (56.3 mmol) diethylazodicarboxylate and stir the reaction mixture for 6 hr under argon at room temperature. 25. Quench the reaction with 10 mL water and concentrate in a rotary evaporator with a vacuum pump. Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
26. Dissolve the residue in 500 mL ethyl acetate, and wash three times with 300 mL water and once with 300 mL saturated aqueous NaCl.
4.7.26 Supplement 3
Current Protocols in Nucleic Acid Chemistry
27. Dry the ethyl acetate solution over Na2SO4, filter, and concentrate with a rotary evaporator and vacuum line. This crude (triphenylphosphine oxide–contaminated) 3′-azido-N6-benzoyl-5′-O-(tertbutyldimethylsilyl)-2′,3′-dideoxyadenosine (18.8 g) is taken on directly to hydrogenation and purified as the 3′-amine.
28. Dissolve 18.8 g of the crude azide in 250 mL of 1:1 (v/v) ethanol/CH 2Cl2 and reduce by hydrogenation (60 psi H2) in the presence of 1.0 g of 10% Pd/C catalyst for 16 hr at room temperature. 29. Remove the catalyst by vacuum filtration, and evaporate the solvent in a rotary evaporator with vacuum line to afford the crude 3′-amine. 30. Purify on silica (preequilibrate with 2% methanol/CH2Cl2 and elute with 2% to 6% methanol/CH2Cl2 and then 1% triethylamine/6% methanol/CH2Cl2) to afford 3′amino-N6-benzoyl-5′-O-(tert-butyldimethylsilyl)-2′,3′-dideoxyadenosine as an offwhite foam. 31. Perform TLC analysis (APPENDIX 3D) on 0.2-mm-thick precoated Merck silica gel 60 F254 plates to confirm the purity of the product. Elute with 8:92 (v/v) methanol/CH2Cl2. Yield = 68% (12.0 g, 25.6 mmol). Rf (8:92 methanol/CH2Cl2) = 0.30. 1H NMR (CDCl3 / TMS): δ 8.95 (1H, br s, exchanges with D2O), 8.81 (1H, s), 8.40 (1H, s), 8.02 (2H, d, J = 7.23 Hz), 7.62 (1H, t, J = 7.43 Hz), 7.54 (2H, t, J = 7.48), 6.49 (1H, dd, J = 6.81, 3.68 Hz), 3.80-3.98 (4H, mm), 2.76 (1H, ddd, J = 13.27, 6.42, 3.69), 2.39 (1H, dt, J = 13.43, 6.93), 0.92 (9H, s), 0.11 (3H, s), 0.00 (3H, s). HRMS (FAB+): calcd for [M + Cs]+, 601.1360, observed 601.1373.
32. Protect 29.5 g (63.0 mmol) of 3′-amino-N6-benzoyl-5′-O-(tert-butyldimethylsilyl)2′,3′-dideoxyadenosine by reacting with 12.9 mL (94.5 mmol) triethylamine and 21.1 g (75.6 mmol) trityl chloride in 350 mL CH2Cl2 for 16 hr at room temperature. 33. Dilute the reaction mixture with an additional 150 mL CH2Cl2. 34. Extract once with 400 mL water, three times with 300 mL saturated aqueous NaHCO3, and two times with 300 mL saturated aqueous NaCl. 35. Concentrate to a glassy foam with a rotary evaporator and vacuum line. 36. Purify the crude product on a silica gel column preequilibrated with 1% triethylamine in 4:6 (v/v) ethyl acetate/hexane, and elute with 4:6 ethyl acetate/hexane to afford N6-benzoyl-5′-O-(tert-butyldimethylsilyl)-3′-tritylamino-2′,3′-dideoxyadenosine (S.17). 37. Perform TLC analysis (step 33) using 5:95 (v/v) methanol/CH2Cl2 as the eluent. Yield = 98% (44.1 g, 62.1 mmol). Rf (5:95 methanol/CH2Cl2) = 0.48. 1H NMR (CDCl3 / TMS): δ 8.99 (1H, br s, exchanges with D2O), 8.76 (1H, s), 8.12 (1H, s), 8.00 (2H, d, J = 7.29 Hz), 7.60 (1H, t, J = 7.41 Hz), 7.54 (6H, d, J = 7.44 Hz), 7.51 (2H, t, J = 7.28 Hz), 7.28 (6H, t, J = 7.56 Hz), 7.20 (2H, t, J = 7.22 Hz), 6.36 (1H, t, J = 5.96 Hz), 3.90 (1H, m), 3.82 (1H, dd, J = 11.28, 2.74 Hz), 3.67 (1H, dd, J = 11.26, 3.10 Hz), 3.50 (1H, br m), 2.00-2.10 (1H, br s, exchanges with D2O), 1.68-1.83 (2H, mm), 0.82 (9H, s), −0.02 (3H, s), −0.03 (3H, s). HRMS (FAB+): calcd for [M + Cs]+, 843.2455, observed 843.2477.
Synthesize N6-benzoyl-3′-tritylamino-2′,3′-dideoxyadenosine (S.18) 38. Remove the 5′-TBDMS protecting group by dissolving 43.7 g (61.5 mmol) S.17 in 123.0 mL THF and reacting with 123.0 mL (123.0 mmol) of 1.0 M TBAF in THF for 24 hr, room temperature.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.27 Current Protocols in Nucleic Acid Chemistry
Supplement 3
39. Concentrate the reaction mixture with vacuum line and dissolve the residue in 400 mL ethyl acetate. 40. Extract three times with 250 mL water and two times with 250 mL saturated aqueous NaCl. 41. Dry the organic layer over Na2SO4, vacuum filter, and remove the solvent with a rotary evaporator and vacuum line. 42. Purify the crude product on a silica gel column preequilibrated with 2% triethylamine in 8:2 (v/v) ethyl acetate/hexane, and elute with 8:2 ethyl acetate/hexane to 100% ethyl acetate to afford N6-benzoyl-3′-tritylamino-2′,3′-dideoxyadenosine (S.18). 43. Perform TLC analysis (step 33) using 5:95 (v/v) methanol/CH2Cl2 as the eluent. Yield = 94% (34.5 g, 57.9 mmol). Rf (5:95 methanol/CH2Cl2) = 0.40. 1H NMR (CDCl3 / TMS): δ 9.06 (1H, br s, exchanges with D2O), 8.68 (1H, s), 8.02 (1H, s), 8.01 (2H, d, J = 7.33 Hz), 7.60 (1H, t, J = 7.47 Hz), 7.53 (6H, d, J = 7.38 Hz), 7.51 (2H, t, J = 7.20 Hz), 7.29 (6H, t, J = 7.58 Hz), 7.21 (3H, t, J = 7.25 Hz), 6.24 (1H, dd, J = 7.56, 6.30 Hz), 4.85 (1H, dd, J = 9.87, 3.19 Hz, exchanges with D2O), 3 65-3.82 (3H, mm), 3.37 (1H, t, J = 10.16 Hz), 2.38 (1H, dt, J = 13.46, 7.02 Hz), 2.00-2.20 (1H, br s, exchanges with D2O), 1.75 (1H, ddd, J = 13.28, 5.96, 2.97 Hz). HRMS (FAB+): calcd for [M + Na]+, 619.2434, observed 619.2421. SUPPORT PROTOCOL 5
SYNTHESIS OF 3′-O-(4,4′-DIMETHOXYTRITYL)-PROTECTED DEOXYRIBONUCLEOSIDES An approach to the synthesis of 3′-O-(4,4′-dimethoxytrityl)-protected deoxyribonucleosides (S.20) is presented in Figure 4.7.11. These nucleosides are necessary for the synthesis of the phosphodiester or phosphorothioate portion of chimeric oligonucleotides. Additional Materials (also see Support Protocol 1) N6-Benzoyl-2′-deoxyadenosine N4-Benzoyl-2′-deoxycytidine N2-Isobutyryl-2′-deoxyguanosine Thymidine 4-Dimethylaminopyridine tert-Butyldimethylsilyl chloride Tetrahydrofuran (THF) 1 M tetrabutylammonium fluoride (TBAF) in THF N,N-Diisopropylethylamine
HO
O
1. TBDMS-Cl/DMAP/Et3N/C5H5N 2. DMTr-Cl/C5H5N
B
3. DPC-Cl/i-Pr2NEt/C5H5N iBu (only when B = G )
OH Bz
TBDMSO
Bz
B
DMTrO
iBu
B=A ,C ,G
O
, or T
19
CH3 OCH2CH2CN P N Cl HO
TBAF/THF (when B = ABz, CBz, T)
O
iBu,DPC
Et3N•3HF/C5H5N/CH2Cl2 (when B = G
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
)
B
CH3 2 DBU/CH2Cl2
DMTrO 20
Figure 4.7.11 General approach to the synthesis of 3′-O-(4,4′-dimethoxytrityl)-2′-deoxyribonucleosides (S.20) from N-protected 2′-deoxyribonucleosides.
4.7.28 Supplement 3
Current Protocols in Nucleic Acid Chemistry
N,N-Diphenylcarbamyl chloride 9:1 (v/v) CH2Cl2/pyridine Triethylamine trihydrofluoride 50% to 70% ethyl acetate/hexane Prepare 5′-O-(tert-butyldimethylsilyl)-2′-deoxyribonucleosides (S.19) 1. Azeotrope the N-protected 2′-deoxyribonucleoside (dABz, dCBz, dGi-Bu, or T) two times from 10 mL/g pyridine and suspend in pyridine at 10 mL/g. 2. To this stirring mixture, add sequentially 0.1 eq 4-dimethylaminopyridine, 1.2 eq triethylamine, and 1.05 to 1.2 eq tert-butyldimethylsilyl chloride. Stir for 8 to 24 hr at room temperature. 3. Remove the pyridine using a rotary evaporator and vacuum pump. 4. Dissolve the residue in 15 mL/g CH2Cl2 and extract two times with 10 mL/g water and one time with 10 mL/g saturated aqueous NaCl. 5. Dry the organic solution over anhydrous Na2SO4, vacuum filter, and concentrate under reduced pressure to a solid that is used in the next reaction without further purification. Prepare 5′-O-(tert-butyldimethylsilyl)-3′-O-(4,4′-dimethoxytrityl)-2′-deoxyribonucleosides 6. Azeotrope the 5′-O-(tert-butyldimethylsilyl)-protected 2′-deoxyribonucleoside two times from 10 mL/g pyridine and dissolve in pyridine at 10 mL/g. 7. While stirring this solution, add 1.2 to 1.3 eq 4,4′-dimethoxytrityl chloride. Stir the solution for 16 to 24 hr at room temperature. 8. Concentrate on a rotary evaporator using a vacuum pump. 9. Dissolve the residue in 15 mL/g CH2Cl2 and extract once each with 10 mL/g water, 10 mL/g saturated aqueous NaHCO3, and 10 mL/g saturated aqueous NaCl. 10. Dry the CH2Cl2 solution over Na2SO4, vacuum filter, and concentrate under reduced pressure to a foam. The product can be used directly in the next reaction (T) or purified on silica (dABz, dCBz, and dGi-Bu) using a gradient of 1% to 5% methanol in CH2Cl2.
Prepare 3′-O-(4,4′-dimethoxytrityl)-2′-deoxyribonucleosides (S.20) For dABz, dCBz, and T: 11a. Remove the 5′-TBDMS protecting group by dissolving the 5′-(tert-butyldimethylsilyl)-3′-O-(4,4′-dimethoxytrityl)-2′-deoxyribonucleoside in THF at 3 mL/g and reacting it with 1 M (2.0 eq) TBAF in THF for 16 to 24 hr, room temperature. 12a. Concentrate the solution under reduced pressure. 13a. Dissolve the residue in 15 mL/g CH2Cl2, and extract two times with 10 mL/g water and one time with 10 mL/g saturated aqueous NaCl. 14a. Dry the organic layer over Na2SO4, vacuum filter, and evaporate on a rotary evaporator with pump. 15a. Purify the crude 3′-O-(4,4′-dimethoxytrityl)-2′-deoxyribonucleosides (S.20) (see Support Protocol 1, step 18).
Synthesis of Modified Oligonucleotides and Conjugates
4.7.29 Current Protocols in Nucleic Acid Chemistry
Supplement 3
16a. Perform TLC analysis (APPENDIX 3D) on 0.2-mm-thick precoated Merck silica gel 60 F254 plates to confirm the purity of the product. Elute with 1:9 (v/v) methanol/CH2Cl2. N6-Benzoyl-3′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine (S.20). Yield from dABz = 56.7% (55.4 g). Rf (1:9 methanol/CH2Cl2) = 0.68. 1H NMR (CDCl3/TMS): δ 9.14 (1H, br s, exchanges with D2O), 8.72 (1H, s), 8.06 (1H, s), 8.02 (2H, d, J = 7.43 Hz), 7.62 (1H, t, J = 7.33 Hz), 7.53 (2H, d, J = 7.74 Hz), 7.50 (2H, d, J = 7.54 Hz), 7.39 (4H, d, J = 8.81 Hz), 7.34 (2H, t, J = 7.54 Hz), 7.26 (2H, t, J = 7.95 Hz), 6.87 (4H, dd, J = 8.91, 2.43 Hz), 6.37 (1H, dd, J = 9.95, 5.26 Hz), 5.79 (1H, br d, J = 10.38 Hz, exchanges with D2O), 4.66 (1H, d, J = 5.32 Hz), 4.08 (1H, s), 3.81 (6H, s), 3.76 (1H, d, J = 12.78 Hz), 3.35 (1H, t, J = 11.86 Hz), 2.73 (1H, ddd, J = 13.21, 10.10, 7.99 Hz), 1.76 (1H, dd, J = 13.31, 5.30 Hz). HRMS (FAB+): calcd for [M + H] +, 658.2666; found, 658.2666. N4-Benzoyl-3′-O-(4,4′-dimethoxytrityl)-2′-deoxycytidine (S.20). Yield from dCBz = 74.7% (70.0 g) including additional mixed fractions that were purified further by precipitation from CH2Cl2 into a 20× volume of 3:1 hexane/diethyl ether over 1.5 hr. Rf (1:9 methanol/CH2Cl2) = 0.66. 1H NMR (CDCl3/TMS): δ 8.66 (1H, br s, exchanges with D2O), 8.09 (1H, d, J = 7.35 Hz), 7.87 (2H, d, J = 7.43 Hz), 7.62 (1H, t, J = 7.36 Hz), 7.53 (2H, d, J = 7.80 Hz), 7.48 (2H, d, J = 7.63 Hz), 7.37 (4H, d, J = 8.86 Hz), 7.32 (2H, t, J = 7.53 Hz), 7.25 (1H, t, J = 7.17 Hz), 6.85 (4H, d, J = 8.76 Hz), 6.25 (1H, dd, J = 7.63, 6.12 Hz), 4.36-4.43 (1H, br m), 3.94 (1H, d, J = 2.19 Hz), 3.81 (6H, s), 3.66 (1H, br d, J = 11.86 Hz), 3.26 (1H, br d, J = 11.90 Hz), 2.48 (1H, br s, exchanges with D2O), 2.22 (1H, dd, J = 13.13, 5.20 Hz), 2.08 (1H, quintet, J = 6.94 Hz). HRMS (FAB+): calcd for [M +Na]+, 656.2373; found, 656.2383. 3′-O-(4,4′-Dimethoxytrityl)-thymidine (S.20). Yield from T = 81.8% (45.2 g). Rf (1:9 methanol/CH2Cl2) = 0.56. 1H NMR (CDCl3 /TMS): δ 8.61 (1H, br s, exchanges with D2O), 7.46 (2H, d, J = 7.47 Hz), 7.36 (4H, d, J = 8.83 Hz), 7.32 (2H, t, J = 7.94 Hz), 7.25 (1H, t, J = 7.43 Hz), 6.86 (4H, d, J = 7.39 Hz), 6.15 (1H, dd, J = 8.87, 5.76 Hz), 4.38 (1H, d, J = 6.20 Hz), 3.99 (1H, d, J = 2.13 Hz), 3.81 (6H, s), 3.68 (1H, br d, J = 11.79 Hz), 3.30-3.37 (1H, br m), 2.47-2.55 (1H, br m, exchanges with D2O), 1.95 (1H, ddd, J = 13.98, 8.42, 6.00 Hz), 1.87 (3H, s), 1.67-1.74 (1H, m). HRMS (FAB+): calcd for [M + Na] +, 567.2107; found, 567.2111.
For dGi-Bu,DPC: 11b. Prepare a stirring solution of 101.9 g (135.2 mmol) 5′-O-(tert-butyldimethylsilyl)3′-O-(4,4′-dimethoxytrityl)-N2-isobutyryl-2′-deoxyguanosine in 300 mL pyridine, add 26.6 g (206.1 mmol) N,N-diisopropylethylamine and 41.4 g (178.7 mmol) N,N-diphenylcarbamyl chloride. 12b. Stir the dark solution for 2 hr and then concentrate on a rotary evaporator with a vacuum pump. 13b. Dissolve the residue in 600 mL CH2Cl2 and extract two times with 250 mL water and once with 250 mL saturated aqueous NaCl. 14b. Dry the organic solution over Na2SO4, vacuum filter, and concentrate to a purplecolored foam with a vacuum line on a rotary evaporator. 15b. Dissolve the crude nucleoside in 800 mL of a 9:1 (v/v) CH2Cl2/pyridine solution, then add 155.0 g (961.5 mmol) triethylamine trihydrofluoride and react for 16 hr at room temperature.
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
16b. Remove the solvents with a rotary evaporator and vacuum pump, dissolve the residue in 600 mL CH2Cl2, and wash two times with 250 mL water and 250 mL saturated aqueous NaCl. 17b. Dry the organic solution over Na2SO4, vacuum filter, and concentrate to a dark red foam with a vacuum line on a rotary evaporator.
4.7.30 Supplement 3
Current Protocols in Nucleic Acid Chemistry
18b. Purify the crude product by gravity on a silica gel column (APPENDIX 3E) preequilibrated with 1% Et3N/50% ethyl acetate/hexane and elute with 50% to 70% ethyl acetate/hexane to afford the protected 2′-deoxyguanosine (S.20). 19b. Perform TLC analysis (step 16a), eluting with 75:25 (v/v) ethyl acetate/hexane. Yield from dGi-Bu = 35.6% (43.3 g). Rf (75:25 ethyl acetate/hexane) = 0.38. 1H NMR (CDCl3/TMS): δ 8.00 (1H, s), 7.91 (1H, br s, exchanges with D2O), 7.49 (2H, d, J = 7.75 Hz), 7.20-7.45 (19H, mm with 4H, d, J = 8.93 Hz at 7.38), 6.86 (4H, dd, J = 8.82, 2.09 Hz), 6.26 (1H, dd, J = 9.80, 5.12 Hz), 4.65 (1H, d, J = 5.25 Hz), 4.35 (1H, dd, J = 10.35, 3.26 Hz, exchanges with D2O), 4.04 (1H, s), 3.80 (6H, s), 3.73 (1H, br d, J = 11.48 Hz), 3.39 (1H, br t, J = 11.54 Hz), 2.64-2.80 (2H, m), 1.68 (1H, dd, J = 13.18, 5.16 Hz), 1.24 (6H, d, J = 6.93 Hz). HRMS (FAB+): calcd for [M + Na]+, 857.3275; found, 857.3270. Do not use 1 M tetra-n-butylammonium fluoride in THF to remove the TBDMS group because the O6-(N,N-diphenylcarbamoyl) group is not stable to this reagent.
SYNTHESIS OF 3′-AMINONUCLEOSIDE-CONTAINING SOLID SUPPORT
SUPPORT PROTOCOL 6
Additional Materials (also see Support Protocol 1) 3′-Tritylamino-2′,3′-dideoxynucleosides (S.5, S.9, S.13, or S.18; see Support Protocols 1 to 4) 4-Dimethylaminopyridine Succinic anhydride 10% (v/v) aqueous citric acid, cold 1-Hydroxybenzotriazole 1:1 (v/v) 1-methyl-2-pyrrolidinone (anhydrous)/dimethyl sulfoxide (anhydrous) N,N-Diisopropylethylamine 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate Aminopropyl-conjugated controlled-pore glass (aminopropyl-CPG; Sigma) 1:1:8 (v/v/v) acetic anhydride/2,6-lutidine/THF 16.5% (v/v) N-methylimidazole in THF (see recipe) Mechanical shaker Synthesize 3′-tritylamino-2′,3′-dideoxynucleoside-5′-O-hemisuccinates 1. To a solution of 1.5 mmol of 3′-tritylamino-2′,3′-dideoxynucleoside (S.5, S.9, S.13, or S.18;) in 5 mL CH2Cl2, add 0.22 g (1.8 mmol) 4-dimethylaminopyridine and 0.18 g (1.8 mmol) succinic anhydride. Stir for 1 hr at room temperature. 2. Quench the reaction with 0.6 mL methanol and dilute with 30 mL CH2Cl2. 3. Extract once each with 20 mL cold 10% aqueous citric acid, 20 mL water, and 20 mL saturated aqueous NaCl. 4. Dry the organic layer over Na2SO4, vacuum filter, and concentrate the product (S.21; Figure 4.7.12) to a foam on a rotary evaporator using a vacuum line. N6-Benzoyl-3′-tritylamino-2′,3′-dideoxyadenosine-5′-O-hemisuccinate: 100% yield (1.15 g). N4-Benzoyl-3′-tritylamino-2′,3′-dideoxycytidine-5′-O-hemisuccinate: 76% yield (0.77 g). 3′-Tritylamino-2′,3′-deoxythymidine-5′-O-hemisuccinate: 94% yield (0.82 g). O6-(N,N-Diphenylcarbamoyl)-N2-isobutyryl-3′-tritylamino-2′,3′-dideoxyguanosine5′-O-hemisuccinate: 78% yield (1.02 g).
Synthesis of Modified Oligonucleotides and Conjugates
4.7.31 Current Protocols in Nucleic Acid Chemistry
Supplement 9
O O
HO
O
B
O NHTr 21a 21c 21g 21t
Bz
B=A Bz B=C iBu,DPC B=G B= T
Figure 4.7.12 Structures of N-protected-3′-tritylamino-2′,3′-dideoxyribonucleoside-5′-O-hemisuccinates.
Conjugate 3′-tritylamino-2′,3′-dideoxynucleoside-5′-O-hemisuccinates to CPG 5. To a solution of 1 mmol 3′-tritylamino-2′,3′-dideoxynucleoside-5′-O-hemisuccinate and 0.13 g (0.95 mmol) of 1-hydroxybenzotriazole in 10 mL of 1:1 (v/v) 1-methyl2-pyrrolidinone/DMSO, add 0.35 mL (2.0 mmol) N,N-diisopropylethylamine and 0.36 g (0.95 mmol) 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate. 6. Stir the solution 5 min, add 10.0 g aminopropyl-CPG, and put on a shaker for 6 hr, room temperature. 7. Vacuum filter the CPG and wash successively with 20 mL each of DMF, methanol, and ethyl ether. 8. Prepare a 1:1 (v/v) mixture of 1:1:8 acetic anhydride/2,6-lutidine/THF and 16.5% N-methylimidazole/THF, add this mixture to the support on the funnel, and let stand for 30 min to cap any unreacted amino groups on the CPG. 9. Vacuum filter the CPG and wash successively with 20 mL each of acetonitrile, methanol, and diethyl ether. 10. Dry the CPG using a vacuum pump. The nucleoside loadings, determined by trityl assay at 432 nm in 20% TFA/CHCl3 using a molar extinction coefficient of 40.7 ìmol−1 cm−1, were 38.6 ìmol/g for A, 33.6 ìmol/g for C, 29.0 ìmol/g for T, and 39.0 ìmol/g for G. For larger scales, use an overhead stirrer instead of a shaker. Do not use a magnetic stir bar because the CPG will be crushed. SUPPORT PROTOCOL 7
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
PHOSPHORAMIDITE SYNTHESIS The preparation of nucleoside 5′-O-cis-(2,6-dimethylpiperidinyl)-2-cyanoethylphosphoramidite monomers is described below. While either cis-2,6-dimethylpiperidino phosphoramidites or N,N-diisopropylamino phosphoramidites can be prepared and used for the preparation of pnODNs, the former are preferred because they allow the use of significantly lower equivalents per coupling (Fearon et al., 1998). Additional Materials (also see Support Protocols 1 to 5) 3′-Tritylamino-2′,3′-dideoxynucleosides (see Support Protocols 1 to 4) or 3′-O-(4,4′-dimethoxytrityl)-2′-deoxyribonucleosides (see Support Protocol 5) Phosphorus trichloride 3-Hydroxypropionitrile 10% (w/v) aqueous KOH 1:4 (v/v) toluene/hexane
4.7.32 Supplement 9
Current Protocols in Nucleic Acid Chemistry
cis-2,6-Dimethylpiperidine 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), distilled from CaH2 before use Synthesize 2-cyanoethylphosphorodichloridite 1. To a solution of 500 mL (5.73 mol) phosphorus trichloride in 250 mL acetonitrile, add dropwise at room temperature, with stirring and bubbling argon, a solution of 47 mL (0.69 mol) 3-hydroxypropionitrile in 250 mL acetonitrile. 2. Stir the solution 15 min at room temperature, with absorption of evolving HCl into a solution of 10% aqueous KOH. 3. Concentrate on a rotary evaporator using a pump and vacuum filter, under argon, into a distillation flask. 4. Distill the product under reduced pressure. The 2-cyanoethylphosphorodichloridite distills as a colorless liquid at 78° to 80°C at 1.0 mmHg. Yield = 75.7% (88.5 g). 31P NMR (CDCl3): δ 180.3.
Synthesize 2-cyanoethyl-cis-(2,6-dimethylpiperidinyl)chlorophosphoramidite 5. To a solution of 35.0 g (203.6 mmol) 2-cyanoethylphosphorodichloridite in 300 mL of 1:4 toluene/hexane, add 55 mL (408.1 mmol) cis-2,6-dimethylpiperidine dropwise, with stirring at 4°C. 6. Stir the reaction for 2 hr at room temperature. 7. Vacuum filter and wash the solid with 40 mL of 1:4 toluene/hexane under argon. 8. Concentrate the filtrate using a rotary evaporator and vacuum pump. 9. To the resultant oil, add 5 mL CH2Cl2 and 300 mL hexane, and crystallize the product overnight at 4°C. 10. Filter the 2-cyanoethyl-cis-(2,6-dimethylpiperidinyl)chlorophosphoramidite under argon. 11. Crush with a spatula, wash with 100 mL of 100:3 (v/v) hexane/CH2Cl2, and dry using a rotary evaporator and vacuum pump. 12. Concentrate the mother liquor (step 3) and recrystallize again (step 9) to obtain a second crop of pale yellow 2-cyanoethyl-cis-(2,6-dimethylpiperidinyl)chlorophosphoramidite. Combined yield = 76.5% (38.8 g). 31P NMR (CDCl3): δ 172.7.
Synthesize nucleoside 5′-O-[cis-(2,6-dimethylpiperidinyl)(2-cyanoethyl)]phosphoramidite monomers (S.1 and S.2) 13. Azeotrope 10.0 mmol of 3′-tritylamino-2′,3′-dideoxynucleoside (S.5, S.9, S.13, or S.18) or 3′-O-(4,4′-dimethoxytrityl)-2′-deoxyribonucleoside (S.20) two times from 50 mL CH3CN. 14. Dissolve azeotroped nucleoside in 30 mL CH2Cl2 and then add 3.0 mL (20.0 mmol) DBU. 15. With stirring, add a solution of 3.0 g (12.0 mmol) 2-cyanoethyl-cis-(2,6-dimethylpiperidinyl)chlorophosphoramidite in 8 mL CH2Cl2, under an argon atmosphere. Stir the reaction mixture for 15 min at ambient temperature. 16. Check the reaction by TLC.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.33 Current Protocols in Nucleic Acid Chemistry
Supplement 3
In order to obtain accurate TLC of the product, pre-wet the TLC plate by immersing it in 10% triethylamine/CH2Cl2, quickly let it dry, then immediately spot the sample, and elute with 5:70:25 Et3N/ethyl acetate/hexane.
17. To avoid decomposition, desalt the crude reaction by loading the mixture directly onto a silica gel column (APPENDIX 3E) preequilibrated in 5% triethylamine/CH2Cl2 and quickly elute it in the same solvent system. These phosphoramidites are not stable to an aqueous workup after the reaction.
18. Remove solvents under reduced pressure and purify the crude product on a silica gel column preequilibrated with 0.5% to 5% triethylamine in 2% methanol/CH2Cl2. Elute as indicated below. N6-Benzoyl-3′-tritylamino-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxy)]phosphinyl-2′,3′-dideoxyadenosine (S.1). Purify on silica (60% to 70% ethyl acetate/hexane containing 3% triethylamine). Yield = 83.1% (6.72 g). 31P NMR (CD3CN): δ 148.82, 149.16. Rf = 0.45. N4-Benzoyl-3′-tritylamino-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxy)]phosphinyl2′,3′-dideoxycytidine (S.1). Purify on silica (70% ethyl acetate/hexane containing 3% triethylamine). Yield = 82.7% (6.50 g). 31P NMR (CD3CN): δ 149.31, 149.68. Rf = 0.43. O6-(N,N-Diphenylcarbamoyl)-N2-isobutyryl-3′-tritylamino-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxy)]phosphinyl-2′,3′-dideoxyguanosine (S.1). Purify compound on silica (60% ethyl acetate/hexane containing 3% triethylamine). Yield = 76.9% (7.58 g). 31P NMR (CD3CN): δ 148.93, 149.50. Rf = 0.57. 3′-Tritylamino-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxy)]phosphinyl-2′,3′-dideoxythymidine (S.1). Purify compound on silica (50% ethyl acetate/hexane containing 3% triethylamine). Yield = 79.4% (5.52 g). 31P NMR (CD3CN): δ 149.13, 149.49. Rf = 0.60. N6-Benzoyl-3′-O-(4,4′-dimethoxytrityl)-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxy)]phosphinyl-2′-deoxyadenosine (S.2). Purify compound on silica (60% to 70% ethyl acetate/hexane containing 3% triethylamine). Yield= 76.7% (6.67 g). 31P NMR (CD3CN): δ 149.26, 149.39. Rf = 0.47. N4-Benzoyl-3′-O-(4,4′-dimethoxytrityl)-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxy)] phosphinyl-2′-deoxycytidine (S.2). Purify compound on silica (60% to 75% ethyl acetate/hexane containing 3% triethylamine). Yield = 74.4% (6.29 g). 31P NMR (CD3CN): δ 149.37, 149.76. Rf = 0.43. O6-(N,N-diphenylcarbamoyl)-N2-isobutyryl-3′-O-(4,4′-Dimethoxytrityl)-5′-O-[(cis2,6-dimethylpiperidino)(2-cyanoethoxy)]phosphinyl-2′-deoxyguanosine (S.2). Purify compound on silica (50% ethyl acetate/hexane containing 3% triethylamine). Yield = 71.0% (7.43 g). 31P NMR (CD3CN): δ 149.32, 149.51. Rf = 0.60. 3′-O-(4,4′-Dimethoxytrityl)-5′-O-[(cis-2,6-dimethylpiperidino)(2-cyanoethoxy)]phosphinyl2′-deoxythymidine (S.2). Purify compound on silica (60% ethyl acetate/hexane containing 3% triethylamine). Yield = 74.1% (5.61 g). 31P NMR (CD3CN): δ 149.24, 149.65. Rf = 0.60. Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
4.7.34 Supplement 3
Current Protocols in Nucleic Acid Chemistry
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. The acetonitrile used for all formulations must contain ≤0.001% water. Oven-dry all bottles and syringes. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Buffer D: 0.1 M TEAB/2% acetonitrile, pH 8 Dilute 100 mL of 1 M TEAB buffer, pH 8 (see recipe), in 880 mL water and add 20 mL acetonitrile. Check that the pH is 8.0 and correct with triethylamine or dry ice, if necessary. Filter through a 0.2-µm filter before use on the HPLC. Store up to 6 months at 4°C. Dichloroacetic acid in CH2Cl2, 3% (v/v) Dissolve 12 mL of dichloroacetic acid in 388 mL of CH2Cl2. Store up to 1 week at room temperature. This solution should only be kept for about 1 week due to its potential to generate HCl, which is extremely detrimental to the pnODN synthesis. Also, only use bottles of DCA <6 months old.
5′-O-(4,4′-Dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-3′-O-[(N,N-diisopropylamino)(2-cyanoethoxy)]phosphinyl uridine, 0.1 M Dissolve 86 mg of uridine phosphoramidite (Glen Research) per milliliter of acetonitrile in an oven-dried bottle under argon. This solution can be used on the synthesizer for 1 week if kept under argon. Also remember that this monomer requires 0.5 M 1H-tetrazole in acetonitrile for activation.
cis-2,6-Dimethylpiperidinyl phosphoramidite monomer solutions, 0.1 M Weigh solid nucleoside 5′-O-[cis-(2,6-dimethylpiperidinyl)(2-cyanoethyl)]phosphoramidite monomer (see Support Protocol 7) and transfer it to a monomer bottle. Cap the bottle with a rubber septum, use vacuum to evacuate the bottle, and refill it with argon. Using a syringe, dissolve the monomer in the appropriate amount of acetonitrile under argon. Use the following amounts of monomer per milliliter acetonitrile for 0.1 M solutions: S.1: 80.8 mg A; 78.4 mg C; 98.5 mg G; 69.5 mg T; S.2: 85.7 mg A; 83.3 mg C; 104.6 mg G; 75.6 mg T. Store monomer solutions up to 5 days at room temperature under argon. Store the solid monomers in desiccated bags at −20°C and allow to warm up to room temperature before opening.
Dowex 50W-X8 cation-exchange resin (pyridinium H+ form) Suspend Dowex 50W-X8 cation-exchange resin (sulfonic acid form; Janssen Pharmaceutica) in pyridine and let cool to room temperature. Filter the resin and wash three times with methanol. Store the filtered resin in a sealed bottle until use. H2O2/H2O/pyridine/THF, 1.5:3.5:20:75 (v/v/v/v) Dissolve 5 mL of 30% aqueous H2O2 (v/v; Aldrich) in 20 mL pyridine and 75 mL tetrahydrofuran. The water in the formulation comes from the aqueous hydrogen peroxide solution. This solution is stable for 3 weeks on the synthesizer, but should be disposed of within a few days of removing it from the synthesizer due to its potential to form explosive peroxides.
Isobutyric anhydride/2,6-lutidine/THF, 1:1:8 (v/v/v) Dissolve 20 mL isobutyric anhydride and 20 mL of 2,6-lutidine in 160 mL anhydrous tetrahydrofuran under argon. This solution is stable on the instrument for 2 months as long as it is kept dry and under argon.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.35 Current Protocols in Nucleic Acid Chemistry
Supplement 3
N-Methylimidazole in THF, 16.5% (v/v) This solution can be bought directly from PE Biosystems or made by dissolving 33 mL of N-methylimidazole in 167 mL anhydrous tetrahydrofuran. This solution is stable on the instrument for 2 months as long as it is kept dry and under argon.
Pyridine in CH3CN, 20% (v/v) Dissolve 40 mL pyridine, previously dried over chunks of CaH2 for at least 24 hr, in 160 mL acetonitrile under argon. This formulation must be kept dry in order to prevent hydrolysis of the internucleotide phosphoramidite during synthesis; it can be kept on the instrument for 1 month under argon.
Tetrazole in CH3CN, 0.167 M Under argon, add 50 mL of a 0.5 M solution of tetrazole in acetonitrile (PE Biosystems) to 100 mL acetonitrile. This solution is stable on the instrument for 2 months as long as it is kept dry and under argon.
Triethylammonium bicarbonate (TEAB) buffer, 1 M, pH 8 Add 139 mL of triethylamine to ~800 mL of water. In a hood, slowly add dry ice to the stirring solution until the pH measures 8.0. Add enough water to make the final volume 1 L. Correct the pH to 8.0 with either triethylamine or dry ice, if necessary. Store the solution up to 6 months at 4°C and check the pH before use. Triethylamine will be immiscible in water at first. The solution gets very cold and CO2 is given off during the dissolution of dry ice.
COMMENTARY Background Information
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
Oligonucleotides are widely used in research and diagnostics and are rapidly gaining acceptance as potential therapeutic agents. Antisense oligonucleotides, which are complementary to selected sequences of mRNA associated with a disease, control gene expression either by sterically blocking translation or processing of the RNA or by the irreversible cleavage of the target RNA by endogenous RNase H (Uhlman and Peyman, 1990). Alternatively, antigene therapeutics are oligonucleotides that prevent gene transcription by forming a triple-helical structure with targeted polypurine:polypyrimidine sites in double-stranded (ds) DNA (Thuong and Hélène, 1993). Many oligonucleotide analogs have been investigated in an attempt to improve properties such as resistance to nuclease degradation, binding strength to RNA and/or dsDNA, cellular uptake, and pharmacokinetic parameters (Uhlman and Peyman, 1990). Unfortunately, phosphorothioates, and the majority of other firstgeneration analogs that possess increased resistance to nuclease degradation, have a decreased binding affinity for their RNA or dsDNA targets. Additionally, phosphorothioate
ODNs may exhibit nonspecific effects, presumably due to adventitious protein binding (Stein and Cheng, 1993). The fully modified oligonucleotide N3′→P5′ phosphoramidates (pnODNs), on the other hand, possess an increased stability to nucleases relative to both phosphodiester and phosphorothioate ODNs, the ability to tightly and sequence-specifically bind to both RNA and dsDNA, and have shown minimal sequence-independent protein binding (Gryaznov and Chen, 1994; Chen et al., 1995; Gryaznov et al., 1995). These improved properties have translated well in both cell culture and in vivo antisense studies where pnODNs have demonstrated efficacy at 10% of the comparably effective dose of phosphorothioate ODNs (Gryaznov et al., 1996; Heidenreich et al., 1997; Skorski et al., 1997). In addition, a pnODN sequence showed no toxicity in preliminary in vivo studies in mice up to dosages of 150 mg/kg administered intravenously six times over a period of two weeks, whereas kidney and liver toxicity were seen for the isosequential phosphorothioate ODN at the same (and lower) dose (Zon, pers. comm.). Consistent with most oligonucleotide analogs other than phosphorothioates, uniformly
4.7.36 Supplement 3
Current Protocols in Nucleic Acid Chemistry
modified pnODNs do not activate RNase H (DeDionisio and Gryaznov, 1995; Heidenreich et al., 1997). However, in many systems, RNase H activity has been necessary in order to obtain an “antisense” effect and is generally thought to increase the activity of such compounds. Although pnODNs have demonstrated significant RNase H–independent activity, the efficacy of chimeric ODNs that possess an RNase H-active core of 6 to 8 phosphorothioate linkages flanked by pnODN linkages is under investigation. The significantly increased and sequencespecific binding affinity of uniformly modified pnODNs for dsDNA renders these “antigene” compounds potentially useful for inhibition of gene expression via triplex helix formation. Hélène and coworkers (Escudé et al., 1996; Giovannangeli et al., 1997) have demonstrated that pnODNs work best when they are designed to form triple-helical DNA by Hoogsteen hydrogen bonding to the duplex with the third strand in a parallel orientation with respect to the polypurine target sequence. Using a eukaryotic transcription assay, they showed that a pnODN can arrest transcription at a specific triplex site in the type 1 human immunodeficiency virus nef gene under the control of a cytomegalovirus promoter. The synthetic method described herein (McCurdy et al., 1997; Nelson et al., 1997; Fearon et al., 1998), based on a phosphoramidite amine-exchange reaction, is 3 to 6 times more efficient than the oxidative phosphorylation-based method previously reported by Gryzanov and Chen (1994) and Chen et al. (1995). An advantage of the described method is that the monomer is activated and used in excess; thus, a small amount of inadvertent hydrolysis only wastes monomer and does not necessarily decrease the step yield of the coupling. Also, because the method is based on phosphoramidite chemistry, the synthesis of chimeras possessing any combination of phosphoramidate, phosphodiester, and/or phosphorothioate linkages at predefined positions is easily performed on a commercially available synthesizer with no instrument modifications. Fluorescent and other specialty phosphoramidites are also easily used in conjunction with this chemistry. This amine-exchange method was modified for use on a vortexing-mode synthesizer (e.g., PE Biosystems 390Z; 10 µmol-scale) and only ≤3.6 eq of the cis-2,6-dimethylpiperidinyl phosphoramidite monomers and 9 eq of 1Htetrazole were necessary to achieve optimal
coupling yields (Fearon et al., 1998). Even lower stoichiometric requirements may be possible using an activator other than 1H-tetrazole.
Compound Characterization Analytical IEC and/or capillary gel electrophoresis (CGE) is generally used to determine the chain-length purity of pnODNs and their chimeras (see Fig. 4.7.13). CGE was performed on a Beckman P/ACE 5510 system with 10% Microgel Capillaries (0.1 × 500 mm) in 35 mM Tris-borate buffer, pH 9.0, in the presence of 15% ethylene glycol, with a 5 sec injection at 10 kV and a running voltage of 25 kV. Alternatively, 20% polyacrylamide gel electrophoresis followed by visualization with Stains-All and densitometric scanning can also be used. If further characterization is desired, electrospray ionization mass spectrometry can be used to determine the molecular weight of the oligonucleotide synthesized; however, sodium counterions must first be exchanged for ammonium ions (Stultz and Marsters, 1991). In the case of chimeras, the number of phosphoramidate, phosphodiester, and/or phosphorothioate linkages can be determined by 31P-NMR spectroscopy in D2O.
Critical Parameters and Troubleshooting The phosphoramidite monomer, 1H-tetrazole, and 20% pyridine in acetonitrile solutions all must be kept rigorously anhydrous; the method is extremely sensitive to water. Additionally, the 5′-phosphoramidite monomers must have a purity of ≥99% by 31P-NMR spectroscopy in order to afford optimal coupling efficiency. The 2-cyanoethyl-protected phosphoramidate linkages are reasonably stable to acidic conditions; however, older formulations of 3% dichloroacetic acid in CH2Cl2 can degrade the protected phosphoramidate linkages and cause an increase in failure sequences. In general, only enough 3% dichloroacetic acid solution is formulated for a one week period. For the same reason, bottles of dichloroacetic acid from the vendor are generally used or discarded within 6 months of purchase. RP-HPLC using either the 3′-terminal tritylamino group or 3′-terminal O-DMTr group alone must be avoided because the use of acetic acid during post-HPLC detritylation severely degrades the pnODN. For this reason, the DMTr uridine incorporation method should be used for RP-HPLC purification and subsequent deprotection or IEC of the “trityl-off” pnODN should be performed. Do not add any base other
Synthesis of Modified Oligonucleotides and Conjugates
4.7.37 Current Protocols in Nucleic Acid Chemistry
Supplement 3
Figure 4.7.13 Analytical CGE of a crude pnODN with the sequence 5′-ATGACTGAGTACAAACOH-3′.
than concentrated aqueous ammonia to the uridine-containing pnODNs to prevent premature cleavage of the phosphodiester function. It is best to remove the ammonia and RP-HPLC purify the pnODN as soon as possible. The uridine RP-HPLC purification method should be used for pnODN/phosphorothioate ODN chimeras because the phosphorothioate portion of the molecule greatly reduces the resolution of the IEC. Additionally, avoid exposure of these chimeras to aqueous NaOH solutions, which can result in small amounts of inadvertent conversion of the phosphorothioate linkages to phosphodiester linkages. Also avoid concentrating the uridine-containing oligonucleotide to dryness before purification. Isolated pnODNs and their chimeras should be stored frozen (−20°C) as lyophilized powders or aqueous solutions in deionized water or buffer at pH ≥ 7.4. During purification and analysis, working solutions of pnODNs should be stored at 4°C. If the pH of the solution is <7.0, there is potential for the pnODN to degrade.
Anticipated Results
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
The isolated yield of pnODNs and their chimeras depends on both length, sequence, and number of phosphoramidate, phosphorothioate, and phosphodiester linkages, but is generally 15 to 30 OD260 units for pnODNs and 20 to 35 OD260 units for chimeras 12 to 25
nt in length with a purity of ≥85%. Occasionally, certain sequences require a second IEC purification after RP-HPLC to obtain purities ≥85%. Figure 4.7.14 shows a representative IEC and CE for the purified pnODN with the sequence 5′-CCCTCCTCCGGAGCCOH-3′. Table 4.7.1 shows the yields and purities of several pnODNs and chimeras synthesized by this method.
Time Considerations The formulation of reagents and set-up of the synthesizer generally take about 3 to 4 hr. The cycle time to introduce each nucleotide is 22 min, which is multiplied by the length of the oligonucleotide being synthesized to determine the overall synthesis time. Deprotection is usually performed overnight in an oven equipped with a timer set to turn off after 8 to 12 hr. Analysis of the quality of the synthesis, sample preparation, and either IEC or RP-HPLC purification take about 3 hr per sample; however for IEC purification, the analysis of the resulting fractions can take an additional 6 to 10 hr. For RP-HPLC, there is an additional 16 hr treatment with fluoride and base to cleave the uridine phosphodiester linkage. The work-up and analysis steps take another 4 to 8 hr, depending on the method used for desalting. Thus, a sample can be synthesized, purified, workedup, and analyzed in 4 to 5 days. Using the advantages of automation and a multi-column
4.7.38 Supplement 3
Current Protocols in Nucleic Acid Chemistry
A
B
instrument, the rather long turn-around time can be overcome by multiplexing the synthesis and purification steps. Generally, about 3 to 4 pnODNs can be synthesized and purified per week by one chemist, assuming an autosampler is utilized for fraction analysis. The synthesis of the monomers is a challenging task that will take a skilled organic chemist approximately 2 to 3 months for the four 3′tritylamino nucleoside monomers and 1 month for the four 3′-O-DMTr nucleoside monomers. Alternatively, the 3′-O-DMTr-nucleoside-5′O-(N,N,-diisopropylamino)phosphoramidite monomers and the 3′-tritylamino-nucleoside5′-O-(N,N-diisopropylamino)phosphoramidite monomers are available from Glen Research and Annovis, respectively, and can be used in place of the cis-(2,6-dimethylpiperidino) phosphoramidite monomers, as long as the coupleoxidize-couple-oxidize protocol is used for the couplings to 3′-amines. These monomers also require 0.5 M 1H-tetrazole in acetonitrile for activation.
Literature Cited Chen, J.-K., Schultz, R.G., Lloyd, D.H., and Gryaznov, S.M. 1995. Synthesis of oligodeoxyribonucleotide N3′→P5′ phosphoramidates. Nucl. Acids Res. 23:2661-2668. Czernecki, S. and Valéry, J.M. 1991. An efficient synthesis of 3′-azido-3′-deoxythymidine (AZT). Synthesis 1991:329-240. Figure 4.7.14 (A) Analytical IEC chromatogram and (B) CGE electropherogram of the RP-HPLC purified and deprotected phosphoramidate o l i g onuc leotide, 5′CCCTCCTCCGGAGCCOH-3′.
DeDionisio, L. and Gryaznov, S.M. 1995. Analysis of a ribonuclease H digestion of N3′→P5′ phosphoramidate-RNA duplexes by capillary gel electrophoresis. J. Chromatogr. B Biomed. Appl. 669:125-131.
Table 4.7.1 Yields and Purities of Phosphoramidate Oligonucleotides and Chimera Synthesized by the Amine-Exchange Method
Sequencea
Purification method
OD260 % Purity by CGE
CCCTCCTCCGGAGCCOH AGAGATTTTTACACCOH CCAGAGTCACACAACAOH CAGATCGTCCATGGTCOH CAGATpCpGpTpCpCpApTGGTCOH GGACCsCsTsCsCsTsCsCsGGAGCCOH TTGCCCACAsCsCsGsAsCsGsGsCGCCCACCAFAM
RP-HPLC IEC IEC IEC IEC RP-HPLC RP-HPLC
20 29 15 17 28 26 29
95% 98% 93% 99+% 85% 97% 70%b
a
The sequences are reported in the 5′→3′ direction. The linkages are phosphoramidate unless noted by “s” or “p,” which are phosphorothioate or phosphodiester linkages, respectively. CGE, capillary gel electrophoresis; FAM, fluorescein; IEC, ion-exchange chromatography; RP-HPLC, reversed-phase high-pressure liquid chromatography. b Polyacrylamide gel electrophoresis of this compound, followed by staining with Stains-All and densitometric scanning, indicated a purity of 90%.
Synthesis of Modified Oligonucleotides and Conjugates
4.7.39 Current Protocols in Nucleic Acid Chemistry
Supplement 3
Escudé, C., Giovannangeli, C., Sun, J.-S., Lloyd, D.H., Chen, J.-K., Gryaznov, S.M., Garestier, T., and Hélène, C. 1996. Stable triple helices formed by oligonucleotide N3′→P5′ phosphoramidates inhibit transcription elongation. Proc. Natl. Acad. Sci. U.S.A. 93:4365-4369. Fearon, K.L., Nelson, J.S., Hirschbein, B.L., Foy, M.F., Nguyen, M.Q., McCurdy, S.N., Frediani, J.E., Okruszek, A., DeDionisio, L.A., Raible, A.M., and Boyd, V. 1998. An improved synthesis of oligonucleotide N3′→P5′ phosphoramidates and their chimera using hindered phosphoramidite monomers and a novel handle for reverse phase purification. Nucl. Acids Res. 26:3813-3824. Giovannangeli, C., Diviacco, S., Labrousse, V., Gryaznov, S., Charneau, P., and Hélène, C. 1997. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc. Natl. Acad. Sci. U.S.A. 94:7984. Gryaznov, S. and Chen, J.-K. 1994. Oligodeoxyribonucleotide N3′→P5′ phosphoramidates: Synthesis and hybridization properties. J. Am. Chem. Soc. 116:3143-3144. Gryaznov, S.M., Lloyd, D.H., Chen, J.-K., Schultz, R.G., DeDionisio, L.A., Ratmeyer, L., and Wilson, W.D. 1995. Oligonucleotide N3′→P5′ phosphoramidates. Proc. Natl. Acad. Sci. U.S.A. 92:5798-5802.
Skorski, T., Perrotti, D., Nieborowska-Skorska, M., Gryaznov, S., and Calabretta, B. 1997. Antileukemia effect of c-myc N3′→P5′ phosphoramidate antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. U.S.A. 94:3966-3971. Stec, W.J., Uznanski, B., Wilk, A., Hirschbein, B.L., Fearon, K.L., and Bergot, B.J. 1993. Bis(O,O-diisopropoxy phosphinothioyl) disulfide: A highly efficient sulfurizing reagent for cost-effective synthesis of oligo(nucleoside phosphorothiaote)s. Tetrahedron Lett. 34:5317-5320. Stein, C.A. and Cheng, Y.-C. 1993. Antisense oligonucleotides as therapeutic agents: Is the bullet really magical? Science 261:1004-1012. Stultz, J.T. and Marsters, J.C. 1991. Improved electrospray ionization of synthetic oligonucleotides. Rapid Commun. Mass. Spectrom. 5:359-363. Thuong, N.T. and Hélène, C. 1993. Sequence-specific recognition and modification of doublehelical DNA by oligonucleotides. Angew. Chem. Int. Ed. Engl. 32:666-690. Uhlman, E. and Peyman, A. 1990. Antisense oligonucleotides: A new therapeutic principle. Chem. Rev. 90:544-584.
Gryaznov, S., Skorski, T., Cucco, C., NieborowskaSkorska, M., Chiu, C.Y., Lloyd, D., Chen, J.-K., Koziolkiewicz, M., and Calabretta, B. 1996. Oligonucleotide N3′→P5′ phosphoramidates as antisense agents. Nucl. Acids Res. 24:1508-1514.
Wagner, D., Verheyden, J.P.H., and Moffatt, J.G. 1974. Preparation and synthetic utility of some organotin derivatives of nucleosides. J. Org. Chem. 39:24-30.
Hansske, F. and Robins, M.J. 1983. A deoxygenative [1,2]-hydride shift rearrangement converting cyclic cis-diol monotosylates to inverted secondary alcohols. J. Am. Chem. Soc. 105:6736-6737.
Key References
Heidenreich, O., Gryaznov, S., and Nerenberg, M. 1997. RNase H-independent antisense activity of oligonucleotide N3′→P5′ phosphoramidates. Nucl. Acids Res. 25:776-780. Herdewijn, P. and Van Aerschot, A. 1989. Synthesis of 9-(3-azido-2,3-dideoxy-β-D-erythro-pentofuranosyl)- 2,6-diaminopurine (AzddDPA). Tetrahedron Lett. 30:855-858. McCurdy, S.N., Nelson, J.S., Hirschbein, B.L., and Fearon, K.L. 1997. An improved method for the synthesis of N3′→P5′ phosphoramidate oligonucleotides. Tetrahedron Lett. 38:207-210. Nelson, J.S., Fearon, K.L., Nguyen, M.Q., McCurdy, S.N., Frediani, J.E., Foy, M.F., and Hirschbein, B.L. 1997. N3′→P5′ Oligodeoxyribonucleotide phosphoramidates: A new method of synthesis based on a phosphoramidite amineexchange reaction. J. Org. Chem. 62:7278-7287.
Synthesis and Purification of Oligonucleotide N3′→P5′ Phosphoramidates
Reese, C.B. and Skone, P.A. 1984. The protection of thymine and guanine residues in oligodeoxyribonucleotide synthesis. J. Chem. Soc. Perkin Trans. I 1263-1271.
Nishino, S., Yamamoto, H., Nagato, Y., and Ishido, Y. 1986. Partial protection of carbohydrate derivatives. Part 19. Highly regioselective 5′-Oaroylation of 2′-deoxyribonucleosides in terms of dilution-drop-by-drop-addition procedure. Nucleosides Nucleotides 5:159-168.
Nelson et al., 1997. See above. This reference details the couple-oxidize-coupleoxidize amine-exchange method for synthesis of pnODNs, as well as the synthesis of the 3′-tritylamino protected nucleosides. Fearon et al., 1998. See above. This reference describes the optimized amine-exchange method for the synthesis of pnODNs and the synthesis of the 3′-O-DMTr-protected nucleosides and the cis-2,6-dimethylpiperidinyl phosphoramidite monomers. It also demonstrates the synthesis of pnODNs using low equivalents of monomer and 1H-tetrazole and describes the equilibrium and oxidation steps in detail.
Contributed by Karen L. Fearon and Jeffrey S. Nelson Lynx Therapeutics Hayward, California
4.7.40 Supplement 3
Current Protocols in Nucleic Acid Chemistry
Incorporation of Halogenoalkyl, 2-Pyridyldithioalkyl, or Isothiocyanate Linkers into Ligands
UNIT 4.8
In UNIT 4.3, the direct incorporation of ligands to the 5′ ends of oligodeoxyribonucleotides via their phosphoramidite derivatives is described. A second strategy for the addition of ligands to the 5′ ends of oligodeoxyribonucleotides involves the introduction of appropriate functional groups to two unprotected reactants. Specific coupling of these reactants results in the formation of oligodeoxyribonucleotide conjugates. Many different oligodeoxyribonucleotide conjugates can be prepared starting with only one oligodeoxyribonucleotide synthesis, provided that the required amount for each conjugate is low. This method is particularly useful when (1) a low amount of the ligand is available, (2) the ligand is unstable under the conditions required for oligonucleotide deprotection, or (3) the poor solubility of the ligand in solvents usually used for oligonucleotide synthesis does not allow the preparation of its phosphoramidite or H-phosphonate derivatives. In this approach, functional groups such as amino, phosphate, phosphorothioate, thiol, and carboxyl, that are capable of reacting with functionalized ligands, are attached to the 5′ ends of oligodeoxyribonucleotides. This unit describes the incorporation of linkers containing reactive groups such as halogenoalkyl, 2-pyridyldithioalkyl, or isothiocyanate into ligands. Halogenoalkyl (Asseline et al., 1992, 1996) and 2-pyridyldithioalkyl (Chassignol and Thuong, 1998) linkers can be reacted with either a phosphorothioate or a thiol group incorporated into the oligodeoxyribonucleotide, while the isothiocyanate can react with aminoalkylated oligodeoxyribonucleotides. These ligands are typically 2-methoxy-6-chloro-9-amino-acridine as an intercalator (see Basic Protocol 1), psoralen as a photo-cross-linking reagent (see Basic Protocol 2), phenanthroline-Cu as a cleaving reagent (see Basic Protocol 3), and thiazole orange as a label (see Basic Protocol 4). The addition of carboxyl, amino, phosporothioate, phosphate, and sulfhydryl functions to the 5′ ends of oligonucleotides, as well as methods for linking these functionalized oligonucleotides and ligands, are reported in UNITS 4.9 & 4.10. Alternatively, many labels carrying functional groups that react with 5′-thiol, 5′-terminal phosphorothioate, and 5′-amino groups are commercially available. Heterobifunctional reagents, which allow coupling between two compounds following two successive specific reactions, are also available from commercial sources. The latter compounds, listed in UNIT 4.2, are very useful when conjugates with a well-defined linker between the oligodeoxyribonucleotide and the ligand are not required. CAUTION: All chemicals must be handled in a fume hood. Investigators should be equipped with a laboratory coat, glasses, and gloves. FUNCTIONALIZATION OF AN ACRIDINE DERIVATIVE WITH A BROMOALKYL LINKER
BASIC PROTOCOL 1
The synthesis of 2-methoxy-6-chloro-9-(ω-bromohexylamino)acridine S.1e (Fig. 4.8.1) is achieved by bromination of 2-methoxy-6-chloro-9-(ω-hydroxyhexylamino)acridine S.1b (discussed in UNIT 4.3; Fig. 4.3.1). Synthesis of Modified Oligonucleotides and Conjugates Contributed by Ulysse Asseline and Nguyen T. Thuong Current Protocols in Nucleic Acid Chemistry (2001) 4.8.1-4.8.15 Copyright © 2001 by John Wiley & Sons, Inc.
4.8.1 Supplement 5
OCH3
N
NH(CH2)6OH
OCH3
CBr4, (C6H5)3P
N
NH(CH2)6Br
DMF
Cl
Cl 1b
Figure 4.8.1
1e
Bromination of an acridine derivative. DMF, N,N-dimethylformamide.
Materials 2-Methoxy-6-chloro-9-(ω-hydroxyhexylamino)acridine S.1b (UNIT 4.3) Acetonitrile distilled from P2O5, stored over 3A molecular sieves N,N-Dimethylformamide (DMF) redistilled in vacuo over ninhydrin, stored over 4A molecular sieves Triphenylphosphine (Aldrich) CBr4 (Aldrich) Dichloromethane (CH2Cl2) distilled from P2O5 and passed over basic aluminum oxide Methanol, distilled or synthesis grade Nitrogen source 10-mL round-bottom flask Magnetic stirrer with Teflon stir bars Vacuum pump (oil pump) capable of creating <0.1 mmHg pressure, with manifold and cold trap Preparative 20 × 20–cm glass-backed silica TLC plates (2-mm thickness; Merck) Short-wave UV light box Mortar and pestle 1.5 × 15–cm chromatography column (empty) 2.5 × 7–cm Kieselgel 60F analytical TLC plates (Merck) Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) 1. Place 138 mg (0.38 mmol) of 2-methoxy-6-chloro-9-(ω-hydroxyhexylamino)acridine S.1b into a 10-mL round-bottom flask, and dry by coevaporating three times with 5 mL acetonitrile. 2. Add 5 mL anhydrous DMF and stir with a Teflon stir bar and magnetic stirrer. 3. Add 105 mg (0.40 mmol) triphenylphosphine and 132 mg (0.40 mmol) CBr4 to the acridine solution, and stir the reaction mixture overnight at room temperature. 4. Concentrate the solution to dryness using a vacuum pump. 5. Purify 450 mg of residue by preparative TLC (APPENDIX 3D) using 20 × 20–cm glass-backed silica TLC plates and 85:15 (v/v) CH2Cl2/methanol as the eluent. Dry the plate in a fume hood and visualize by UV shadowing. Incorporation of Halogenoalkyl, 2Pyridyldithioalkyl, or Isothiocyanate Linkers into Ligands
Two distinct yellow bands should be visible. The upper one (which will also be the larger one if the yield is good) corresponds to S.1e; the band just below it corresponds to the residual starting material.
4.8.2 Supplement 5
Current Protocols in Nucleic Acid Chemistry
CAUTION: It is preferable to carry out steps 5 to 8 in a fume hood to avoid breathing solvent vapors and silica powder.
6. Scrape off the silica gel band corresponding to S.1e. Grind the silica gel to a fine powder using a mortar and pestle. 7. Transfer the silica to an empty 1.5 × 15–cm chromatography column and elute with 100 mL of 65:35 (v/v) CH2Cl2/methanol under slight pressure of nitrogen until the yellow color almost disappears. The pressure should be adjusted so that the solvent elutes from the bottom of the column at ~3 to 5 drops/sec.
8. Perform analytical TLC on a 2.5 × 7–cm Kieselgel 60F plate using 85:15 (v/v) CH2Cl2/methanol (Rf S1.b = 0.49, Rf S.1e = 0.54). When 8:2 (v/v) ethyl acetate/hexane is used as the eluent, the starting material S.1b and the product S.1e show an Rf of 0.1 and 0.38, respectively. The yield of S.1e is 60% (97 mg, 0.23 mmol). mp = 108°-110°C. 1H-NMR (CDCl3): δ: 1.55-1.56 (m, 4H, CH2CH2), 1.90 (m, 2H, CH2), 1.99 (m, 2H, CH2), 3.43 (t, 2H, J = 6.6 Hz, CH2Br), 3.94-3.98 (m, 3H, CH2N + NH), 4.0 (s, 3H, OCH3), 7.13-7.86 (m, 5H, Acr), 8.00-8.04 (m, 1H, H-8 Acr). 13C-NMR (DMSO-d6): δ: 31.50, 33.32, 35.61, 38.22, 41.22, 55.14, 62.30, 109.04, 118.14, 121.42, 127.50, 129.96, 132.30, 134.15, 143.06, 145.80, 149.44, 152.30, 160.04, 161.75. Mass analysis. Electrospray ionization mass spectrometry (ESI-MS) polarity positive. Calcd. for C20H22ClBrN2O: 420, 422, and 424; found: 421, 423, and 425 (M+H).
FUNCTIONALIZATION OF A PSORALEN DERIVATIVE WITH AN IODOALKYL OR 2-PYRIDYLDITHIOALKYL LINKER
BASIC PROTOCOL 2
These syntheses are illustrated in Figure 4.8.2. The 5-(6-iodohexyloxy) derivative of psoralen S.2f is obtained by condensation of the hydroxyl derivative S.2b (UNIT 4.3, Fig. 4.3.1) with 1,6-diiodohexane in the presence of K2CO3, following a procedure adapted from the authors’ previously published work (Takasugi et al., 1991). Replacement of the iodine atom of the 5-(6-iodohexyloxy) derivative S.2f by a 2-pyridyldithio group is achieved by a two-step procedure that differs from the one reported by Chassignol and Thuong (1998). First, a thioacetyl derivative S.2g is obtained by the reaction of S.2f with
O
O
O
O
I(CH2)6I, K2CO3 OH
O(CH2)6I
DMF, 65 oC
O
O 2b
2f
CH3COSK
acetone 50 oC
O
O
O
O
N O(CH2)6SS
S S
N O(CH2)6SCOCH3
N CH3CN/CH3OH, NH4OH O
O 2h
2g
Figure 4.8.2 Functionalization of 5-hydroxypsoralen (S.2b) with an iodoalkyl linker (S.2f) or a 2-pyridyldithioalkyl linker (S.2h). DMF, N,N-dimethylformamide.
Synthesis of Modified Oligonucleotides and Conjugates
4.8.3 Current Protocols in Nucleic Acid Chemistry
Supplement 5
potassium thioacetate. The product S.2g is then hydrolyzed in situ by ammonia treatment and the resulting thiol derivative is reacted with 2,2′-dipyridyl disulfide to give the psoralen derivative S.2h. Materials 5-Hydroxypsoralen S.2b (UNIT 4.3) N,N-Dimethylformamide redistilled in vacuo over ninhydrin, stored over 4A molecular sieves 1,6-Diiodohexane (Aldrich) Anhydrous potassium carbonate Argon source CH2Cl2 Distilled pentane (CE Instruments) Distilled methanol Nitrogen source Potassium thioacetate (Aldrich) Distilled acetone Distilled ethyl acetate Distilled hexane (CE Instruments) Sodium sulfate (Aldrich) 2,2′-Dipyridyl disulfide (Aldrich) Acetonitrile distilled from P2O5, stored over 3A molecular sieves 29% (v/v) aqueous ammonium hydroxide 2.5 mg/mL 2,6-dibromo-4-benzoquinone-N-chloroimine (DBPNC; Merck) in ethanol 100-mL and 25-mL round-bottom flasks and stoppers Reflux condenser CaCl2 drying tube Magnetic stirrer with temperature-controlled oil bath and Teflon stir bars 5-cm glass filter funnel (porosity 4) Vacuum pump (oil pump) capable of creating <0.1 mmHg pressure, with manifold and cold trap Kieselgel 60F chromatography column (e.g., 3-cm diameter, 50-cm height, 50 g silica gel; Merck) 2.5 × 7–cm analytical TLC plates (e.g., Kieselgel 60F plates, Merck) Short-wave UV light box Rotary evaporator with a water aspirator Desiccator containing P2O5 7-cm filter funnel with filter paper 25-mL flask with stopper Preparative 20 × 20–cm glass-backed silica gel TLC plates (2-mm thickness; e.g. Merck) Mortar and pestle 1.5 × 15–cm chromatography column (empty) Additional reagents and equipment for thin-layer chromatography (TLC, APPENDIX 3D) and column chromatography (APPENDIX 3E) Incorporation of Halogenoalkyl, 2Pyridyldithioalkyl, or Isothiocyanate Linkers into Ligands
Prepare 5-(6-iodohexyloxy)psoralen S.2f 1. Prepare a solution of 0.6 g (2.97 mmol) 5-hydroxypsoralen S.2b in 15 mL anhydrous N,N-dimethylformamide in a 100-mL round-bottom flask equipped with a reflux
4.8.4 Supplement 5
Current Protocols in Nucleic Acid Chemistry
condenser and a CaCl2 drying tube. Stir reaction with a Teflon stir bar on a magnetic stirrer. 2. Add successively 5.4 mL (11.15 g, 33 mmol) 1,6-diiodohexane and 0.6 g (4.35 mmol) anhydrous potassium carbonate. Heat the stirred reaction mixture at 65°C for 4 hr in the dark under an argon atmosphere. 3. Allow the mixture to cool to room temperature and filter off the insoluble mineral salts by suction using a 5-cm glass filter funnel (porosity 4). Concentrate the filtrate to dryness using a vacuum pump. 4. Dissolve 14 g residue in 7 mL CH2Cl2 and purify on a 50-g Kieselgel 60F chromatography column eluting first with 200 mL of 50:50 (v/v) CH2Cl2/pentane to eliminate the excess diiodohexane, and then with increasing concentrations (0:100 to 4:96, v/v) of methanol in CH2Cl2. Perform chromatography under slight pressure of nitrogen. The pressure should be adjusted so that the solvent elutes from the bottom of the column at ~3 to 5 drops/sec.
5. Monitor fractions by analytical TLC using 2.5 × 7–cm Kieselgel 60F plates and 9:1 (v/v) CH2Cl2/methanol as the eluent. Visualize by UV shadowing and collect fractions containing pure product (Rf = 0.85). 6. Remove the solvent in a rotary evaporator with a water aspirator and wash the white solid S.2f with 2 mL pentane. Dry in a desiccator containing P2O5 for ≥3 to 4 hr. Yield 78% (0.96 g, 2.33 mmol). m.p = 90°-95°C. 1H-NMR (CDCl3): d: 1.45-1.62 [m, 4H, (CH2)2], 1.81-1.94 [m, 4H, (CH2)2], 3.21 (t, 2H, J = 6.8 Hz,CH2I), 4.45( t, 2H, J = 6.4 Hz, -CH2OAr), 6.28 (d, 1H, J = 9.6 Hz, H-3 Pso), 6.94 (d, 1H, J = 2.45 Hz, H′-4 Pso), 7.1 (s, 1H, H-8 Pso), 7.58 (d, 1H, J = 2.5 Hz, H′-5 Pso), 8.16 (d, 1H, J = 9.8 Hz, H-4 Pso). 13 C-NMR (DMSO-d6): δ: 15.13, 30.50, 35.36, 35.78, 38.97, 78.70, 99.44, 111.80, 112.29, 118.64, 119.22, 145.70 (d, J = 95 Hz), 152.15 (d, J = 145.5 Hz), 154.98, 158.34, 163.84, 166.32, 152.30, 160.04, 161.75.
Prepare 5-[6-(acetylthio)hexyloxy]psoralen S.2g 7. Place the following in a 25-mL round-bottom flask equipped with a reflux condenser: 200 mg (0.48 mmol) 5-(6-iodohexyloxy)-psoralen S.2f 65.8 mg (0.57 mmol) potassium thioacetate 10 mL anhydrous acetone Heat at 50°C under magnetic stirring. 8. Monitor the reaction by analytical TLC and UV shadowing, using 3:1 (v/v) ethyl acetate/hexane as the eluent. After 2 hr, the iodinated compound S.2f (Rf = 0.45) is completely transformed into the thiol ester S.2g (Rf = 0.34). The reaction can also be monitored using 96:4 (v/v) CH2Cl2/acetone (Rf S.2f = 0.72, Rf S.2g = 0.60).
9. Remove the solid by gravity filtration through a 7-cm filter funnel fitted with filter paper. 10. Dilute the solution with 50 mL CH2Cl2 and wash the organic solution three times with 5 mL water. 11. Dry the organic phase over sodium sulfate and concentrate to dryness using a rotary evaporator with a water aspirator. 12. Stir residue with 2 mL hexane to obtain a solid.
Synthesis of Modified Oligonucleotides and Conjugates
4.8.5 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Yield 93% (163 mg, 0.44 mmol). mp = 68°-70°C. 1H-NMR (CDCl3): d: 1.42-1.70 (m, 6H, (CH2)3), 1.82-1.93 (m, 2H, CH2), 2.34 (s, 3H, CH3), 2.89 (t, 2H, J = 7.1 Hz, -CH2S), 4.34 (t, 2H, J = 6.4 Hz, -CH2OAr), 6.28 (d, 1H, J = 9.6 Hz, H-3 Pso), 6.94 (d, 1H, J = 2.4 Hz, H′-4 Pso), 7.13 (s, 1H, H-8 Pso), 7.58 (d, 1H, J = 2.3 Hz, H′-5 Pso), 8.15 (d, 1H, J = 9.6 Hz, H-4 Pso). 13C-NMR (DMSO-d6): d: 31.07, 34.01, 34.50, 35.30, 36.76, 61.10, 78.70, 99.40, 111.80, 112.26, 118.60, 119.20, 145.67 (d, J = 87.5 Hz), 152.11 (d, J = 138 Hz), 154.98, 158.34, 163.86, 166.32, 201.51. Mass analysis. ESI-MS polarity positive. Calcd. for C19H20O5S: 360; found: 361 (M+H).
Prepare 5-[6-(2-pyridyldithio)hexyloxy]psoralen S.2h 13. Place the following (in the order listed) in a 25-mL stoppered flask: 150 mg (0.41 mmol) 5-[(6-acetylthio)hexyloxy]psoralen S.2g 0.458 g (2.05 mmol) 2,2′-dipyridyl disulfide 10 mL 50:50 (v/v) acetonitrile/methanol 0.1 mL 29% aqueous ammonium hydroxide. Leave the mixture to react over 2 to 3 days at room temperature. 14. Monitor the reaction by analytical TLC and UV shadowing, using 3:7 (v/v) ethyl acetate/hexane as the eluent. Spray the TLC plate with 2.5 mg/mL DBPNC in ethanol and heat until color appears. After 60 hr, the starting material S.2g (Rf = 0.48) is totally transformed into a new product (Rf = 0.36). 5-[6-(2-Pyridyldithio)hexyloxy]psoralen S.2h appears as a bright yellow-colored spot.
15. Concentrate the solution under reduced pressure using a rotary evaporator with a water aspirator. 16. Purify 650 mg of residue by preparative TLC using 20 × 20–cm glass-backed silica gel TLC plates and 96:4 (v/v) CH2Cl2/acetone as the eluent. Elute plate two times. Visualize by UV shadowing at 365 nm. S.2h can be seen as a pale blue band. CAUTION: It is preferable to carry out steps 16 to 18 in a fume hood to avoid breathing solvent vapors and silica powder.
17. Scrape off the silica gel band corresponding to S.2h. Grind the silica gel to a fine powder using a mortar and pestle. 18. Transfer the silica to an empty 1.5 × 15–cm chromatography column and elute with 100 mL of 85:15 (v/v) CH2Cl2/acetone under slight pressure of nitrogen until the product is eluted (as monitored by TLC and UV shadowing). The pressure should be adjusted so that the solvent elutes from the bottom of the column at ~3 to 5 drops/sec.
Incorporation of Halogenoalkyl, 2Pyridyldithioalkyl, or Isothiocyanate Linkers into Ligands
Yield = 86% (140 mg, 0.35 mmol). 1H-NMR (CDCl3): d: 1.50-1.58 (m, 4H, (CH2)2), 1.72-1.78 (m, 2H, CH2), 1.81-1.89 (m, 2H, CH2), 2.81(t, 2H, J = 7.2 Hz, -CH2-S-S), 4.43 (t, 2H, J = 6.4 Hz, -CH2OAr), 6.27 (d, 1H, J = 9.8 Hz, H-3 Pso), 6.93 (d, 1H, J = 2.1 Hz, H′-4 Pso), 7.05-7.09 (m, 1H, Ar), 7.18 (s, 1H, H-8 Pso), 7.58 (d, 1H, J = 2.3 Hz, H′-5 Pso), 7.60-7.72 (m, 2H, Ar), 8.14 (d, 1H, J = 9.8 Hz, H-4 Pso), 8.45-8.47 (m, 1H, Ar). 13C-NMR (DMSO-d6): d: 31.14, 33.59, 34.42, 35.36, 44.16 (t, J = 153 Hz), 78.70, 99.44, 111.82, 112.27, 118.62, 119.21, 125.43 (d, J = 116.5 Hz), 127.25, 143.92 (d, J = 116.5 Hz), 145.67 (d, J = 94.5 Hz), 152.11 (d, J = 138.5 Hz), 154.99, 155.68, 158.3, 163.85, 165.61, 166.32. Mass analysis. ESI-MS polarity positive. Calcd. for C22H21NO4S2: 427; found: 429 (M+H).
4.8.6 Supplement 5
Current Protocols in Nucleic Acid Chemistry
FUNCTIONALIZATION OF AN ORTHOPHENANTHROLINE DERIVATIVE WITH A BROMOALKYL LINKER OR AN ISOTHIOCYANATE GROUP
BASIC PROTOCOL 3
These syntheses are illustrated in Figure 4.8.3. The preparation of 5-(ω-bromohexanoamido)-1,10-phenanthroline S.3c was adapted from a previously reported two-step procedure (Thuong and Asseline, 1991). Reduction of 5-nitro-1,10-phenanthroline S.3a by ammonium sulfide leads to the 5-amino derivative S.3b, and acylation of the latter with 6-bromohexanoyl chloride gives the bromoalkyl derivative S.3c. Alternatively, the isothiocyanate derivative S.3d is obtained by treatment of the amino derivative S.3b with carbon disulfide in the presence of dicyclohexylcarbodiimide in pyridine. Materials 20% (w/v) aqueous ammonium sulfide Nitrogen source 5-Nitro-1,10-phenanthroline (S.3a; Aldrich) Absolute ethanol, stored over 4A molecular sieves Chloroform Sodium sulfate, anhydrous (Aldrich) Acetonitrile distilled from P2O5, stored over 3A molecular sieves (for S.3c only) N,N-Diisopropylethylamine (Aldrich; for S.3c only) 6-Bromohexanoyl chloride (Aldrich; for S.3c only) 5% (v/v) aqueous NaHCO3 (for S.3c only) Dichloromethane (CH2Cl2) distilled from P2O5 and passed over basic aluminum oxide
N
NHCO(CH2)5Br
N
3c
Br(CH2)5COCl DIPEA, CH3CN
N
NO2
N
(NH4)2S
NH2
o
ethanol/water, 80 C
N
N
3a
3b
CS2, DCC C6H5N
N
N
C
S
N
3d
Figure 4.8.3 Derivatization of orthophenanthroline (S.3a) with a bromoalkyl linker (S.3c) or an isothiocyanate group (S.3d). DCC, 1,3-dicyclohexylcarbodiimide; DIPEA, N,N-diisopropylethylamine.
Synthesis of Modified Oligonucleotides and Conjugates
4.8.7 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Methanol Pyridine redistilled from p-toluenesulfonylchloride, stored over 3A molecular sieves (for S.3d only) 1,3-Dicyclohexylcarbodiimide (Aldrich; DCC; for S.3d only) CS2 (Merck; for S.3d only) Dioxane, freshly distilled (Aldrich; for S.3d only) 500-mL three-necked flask Reflux condenser 100-mL dropping funnel 0.5-cm nitrogen inlet tube Magnetic stirrer with temperature-controlled oil bath and Teflon stir bars 500-mL separatory funnel 7-cm filter funnel and filter paper Rotary evaporator with water aspirator 5-cm glass filter funnel (porosity 4) Desiccator containing P2O5 25-mL flask with rubber stopper Neutral-activated chromatography column, 1.6-cm diameter, 50-cm height (e.g., 40 g of Kieselgel 60 or Aluminumoxid 90; Merck; for S.3c only) 2.5 × 7–cm analytical TLC plates (e.g., Kieselgel 60F or Aluminumoxid 60F254 neutral, Type E; Merck) Short-wave UV light box 10-mL round-bottom flask with rubber septa and glass stoppers (for S.3d only) Silica gel column, 1.5-cm diameter, 45-cm height (17 g Kieselgel 60; Merck; for S.3d only) Additional reagents and equipment for thin-layer chromatography (TLC, APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare 5-amino-1,10-phenanthroline S.3b 1. Under an efficient fume hood, place 60 mL (0.17 mol) of 20% aqueous ammonium sulfide in a 500-mL three-necked flask equipped with a reflux condenser, a 100-mL dropping funnel, and a 0.5-cm nitrogen inlet tube. Heat the flask to 65°C under a nitrogen atmosphere. 2. Dissolve 1 g (4.48 mmol) of 5-nitro-1,10-phenanthroline (S.3a) in 40 mL boiling absolute ethanol and transfer this solution to the dropping funnel. Add this solution dropwise over 1 hr to the magnetically stirred 20% aqueous ammonium sulfide solution at 80°C. 3. Add another 25 mL of 20% aqueous ammonium sulfide and reflux for an additional hour. 4. Allow the stirred solution to cool to room temperature and extract four times with 70 mL chloroform. 5. Pool the chloroform extracts and back-extract two times with 20 mL water using a 500-mL separatory funnel. Incorporation of Halogenoalkyl, 2Pyridyldithioalkyl, or Isothiocyanate Linkers into Ligands
6. Dry the organic solution over anhydrous sodium sulfate and remove the drying agent by gravity filtration through a 7-cm funnel fitted with filter paper. Concentrate the filtrate in a rotary evaporator with a water aspirator. 7. Dissolve 680 mg yellow residue in 20 mL boiling absolute ethanol, filter, and add 15 mL water to the filtrate. Stopper the flask and let stand 2 days at 2° to 5°C.
4.8.8 Supplement 5
Current Protocols in Nucleic Acid Chemistry
8. Collect the yellow crystals by suction using a 5-cm glass filter funnel (porosity 4) and dry in a desiccator containing P2O5 for at least one night. Yield, 60% (520mg, 2.66 mmol). mp = 250°C (with decomposition at 255°-260°C). 1 H-NMR (DMSO-d6): d: ppm, 6.10 (b s, 2H, NH2), 6.85 (s, 1H), 7.47-7.50 (m, 1H), 7.70-7.73 (m, 1H), 8.02-8.04 (m, 1H), 8.65-8.67 (m, 2H), 9.03-9.05 (m, 1H). 13C-NMR (DMSO-d6): δ: 107.98 (d, J = 153 Hz), 128.09 (d, J = 58.5 Hz), 128.38, 129.40 (d, J = 65.5 Hz), 136.79, 137.01, 138.95 (d, J = 109 Hz), 146.67, 148.89, 150.96, 152.37, 155.54 (d, J = 73 Hz). Mass analysis. ESI-MS polarity positive. Calcd. for C12H9N3: 195; found: 197 (M+H).
Prepare 5-(w-bromohexanoamido)-1,10-phenanthroline S.3c 9a. Dry 5-amino-1,10-phenanthroline S.3b (step 8) by coevaporating three times with 10 mL anhydrous acetonitrile. 10a. Combine the following with magnetic stirring in a 25-mL stoppered flask: 0.195g (1 mmol) 5-amino-1,10-phenanthroline S.3b 0.297 g (0.4 mL, 2.30 mmol) N,N-diisopropylethylamine 15 mL acetonitrile. 11a. Add dropwise, at room temperature, a solution of 0.245 g (0.176 mL, 1.15 mmol) of 6-bromohexanoyl chloride in 0.3 mL anhydrous acetonitrile using a syringe and needle inserted through the rubber stopper. The mixture becomes homogeneous during the course of the addition.
12a. Add 5 mL of 5% aqueous NaHCO3 and extract three times with 20 mL dichloromethane. 13a. Pool the organic extracts and back-extract three times with 8 mL water. 14a. Dry the organic phase over anhydrous sodium sulfate and remove the drying agent by gravity filtration through a funnel fitted with filter paper. Evaporate in a rotary evaporator with a water aspirator. 15a. Dissolve 750 mg yellow residue in 1 mL CH2Cl2 and purify on a 40-g neutral-activated chromatography column, eluting with (in order) 200 mL each 99:1, 98:2, and 97:3 (v/v) CH2Cl2/methanol. Perform chromatography under slight pressure of nitrogen. The pressure should be adjusted so that the solvent elutes from the bottom of the column at ~3 to 5 drops/sec.
16a. Monitor by analytical TLC and UV shadowing, using Aluminumoxid 60F254 plates and 97:3 (v/v) CH2Cl2/methanol. Collect fractions containing pure product (Rf S.3c = 0.3). Since the compound decomposes after a few weeks of storage at –20°C, it should be stored at –70°C. Yield = 65% (0.230 g, 0.62 mmol). mp= 90°-95°C (decomposition). 1H-NMR (CDCl3) d ppm, 1.60-1.92 (m, 6H, (CH2)3), 2.58 (m, 2H, CH2C(O)), 3.43 (t, 2H, J = 6.4 Hz, CH2Br), 7.24 (s, 1H), 7.58-7.59 (m, 2H), 7.90 (bs, 1H), 8.15-8.17 (m, 1H), 8.29-8.31 (m, 1H), 9.08-9.13 (m, 2H). 13C-NMR (DMSO-d6): d: 30.58, 33.51, 38.26, 41.32, 41.97, 126.15, 129.10, 129.75, 130.86, 134.31, 137.88, 142.03, 149.94, 152.02, 155.43, 156.10, 178.48. Mass analysis. ESI-MS polarity positive. Calcd. for C18H18 N3BrO: 371 and 373; found: 372 and 374 (M+H). Synthesis of Modified Oligonucleotides and Conjugates
4.8.9 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Prepare 5-(1,10-phenanthroline) isothiocyanate S.3d 9b. Dry 5-amino-1,10-phenanthroline S.3b (step 8) by coevaporating two times with 5 mL anhydrous pyridine. 10b. Combine the following in a 10-mL round-bottom flask equipped with a stir bar: 97.6 mg (0.5 mmol) 5-amino-1,10-phenanthroline S.3b 412.6 mg (2 mmol) 1,3-dicyclohexylcarbodiimide 2.5 mL anhydrous pyridine 152.28 mg (126 µL, 2 mmol) CS2. 11b. Stir the mixture at room temperature and monitor the reaction by analytical TLC on a Kieselgel 60F plate using 9:1 (v/v) CH2Cl2/methanol as the eluent. Visualize by UV shadowing. The starting material S.3b (Rf = 0.23; yellow spot by UV shadowing at 254 nm) is transformed into the isothiocyanate derivative S.3d (Rf = 0.54; blue spot). S.3b and S.3d are poorly resolved on TLC plates.
12b. When the reaction is complete (usually 24 hr), remove pyridine and excess CS2 by evaporation. 13b. Take up the residue with 3 mL freshly distilled dioxane. Stir the mixture for 5 min and filter off the insoluble material by gravity using a funnel fitted with filter paper. Concentrate the filtrate using a rotary evaporator with a water aspirator. Dioxane should be freshly distilled to avoid peroxides.
14b. Purify 250 mg residue on a 17-g Kieselgel 60 column using the following eluents (in order): 100 mL CH2Cl2, 50 mL of 98:2 (v/v) CH2Cl2/methanol, and 100 mL of 95:5 (v/v) CH2Cl2/methanol. Perform chromatography under slight pressure (see step 15a). Yield 76% (90 mg, 0.38 mmol). mp = 91°-93°C. 1H-NMR (CDCl3): d: ppm, 7.27 (s, 1H), 7.54-7.57 (m, 1H), 7.63-7.66 (m, 1H), 8.11-8.13 (m, 1H), 8.57-8.59 (m, 1H), 9.06-9.07 (m, 1H), 9.18-9.19 (m, 1H). 13C-NMR (DMSO-d6): d: 119.06, 129.68, 131.47, 134.79, 138.20, 141.84, 144.07, 148.14, 150.08, 151.45, 152.19, 155.11, 156.61. Mass analysis. ESI-MS polarity positive. Calcd. for C13H7N3S: 237; found: 239 (M+H). BASIC PROTOCOL 4
FUNCTIONALIZATION OF A THIAZOLE ORANGE DERIVATIVE WITH AN IODOALKYL LINKER The preparation of iodooctylthiazole orange, illustrated in Figure 4.8.4, is achieved by a procedure adapted from the literature (Brooker et al., 1942; Benson et al., 1993). 3-Methyl-2-(methylthio)benzothiazolium iodide S.4b reacts with N-(8-iodooctyl)-4methylquinolium iodide S.4d to give iodooctylthiazole orange S.4e. Materials
Incorporation of Halogenoalkyl, 2Pyridyldithioalkyl, or Isothiocyanate Linkers into Ligands
3-Methyl benzothiazole-2-thione S.4a Methyl iodide (Fluka) Distilled methanol Diethyl ether, anhydrous 1,8-Diiodooctane (Aldrich) Dioxane, freshly distilled (Aldrich) Lepidine (Aldrich) CH2Cl2 Nitrogen source
4.8.10 Supplement 5
Current Protocols in Nucleic Acid Chemistry
CH3 N S S
CH3I
I
−
SCH3
CH3OH
4a
CH3 N+ (CH2)8I
S
I
− + N
4b TEA ethanol
S
(CH2)8I
N
I(CH2)8I
I
− + N
4e
dioxan, reflux CH3 4c
N H3C
CH3 4d
Figure 4.8.4 Thiazole orange derivative functionalized with an iodoalkyl linker (S.4e). TEA, triethylamine.
Ethanol, prewarmed (55°C) Triethylamine (Merck) 100-mL and 10-mL round-bottom flask and rubber septa/glass stoppers Magnetic stirrer with temperature-controlled oil bath and Teflon stir bars Reflux condenser 5-cm glass filter funnel (porosity 4) Desiccator containing P2O5 Two-necked round-bottom flask 10-mL dropping funnel Silica gel chromatography columns: 35 g, 2.5-cm diameter, 45-cm height; and 25 g, 1.2-cm diameter, 40-cm height (e.g., Kieselgel 60, Merck) 2.5 × 7–cm analytical TLC plates (e.g., Kieselgel 60F, Merck) Short-wave UV light box Additional reagents and equipment for thin-layer chromatography (TLC, APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare 3-methyl-2-(methylthio)benzothiazolium iodide S.4b 1. Mix the following in a 100-mL round-bottom flask equipped a Teflon stir bar, magnetic stirrer, and reflux condenser: 2.40 g (13.24 mmol) 3-methyl benzothiazole-2-thione S.4a 4.25 g (1.86 mL, 30 mmol) methyl iodide 30 mL distilled methanol. 2. Reflux the magnetically stirred reaction mixture for 3 hr. When S.4a dissolves, a yellowish precipitate appears.
3. Cool the reaction mixture in an ice bath and filter the precipitate by suction using a 5-cm glass filter funnel (porosity 4). 4. Wash the precipitate twice with 10 mL dry diethyl ether. Remove solvent using a rotary evaporator with a water aspirator, and then dry in a desiccator containing P2O5. CAUTION: Diethyl ether can form peroxides. It is a highly flammable solvent that should be handled with care.
Synthesis of Modified Oligonucleotides and Conjugates
4.8.11 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Yield 95% (4.04 g, 12.5 mmol). mp = 152°-154°C (148°-149°C). Rf = 0.20 by TLC and UV shadowing using CH2Cl2/methanol (9:1, v/v) as eluent. 1H-NMR (DMSO-d6): d ppm, 3.12 (s, 3H, SCH3), 4.10 (s, 3H, NCH3), 7.71 (t, 1H, J = 7.8 Hz), 7.82 (t, 1H, J = 7.8 Hz), 8.18 (d, J = 8 Hz, 1H), 8.40 (d, J = 8 Hz, 1H). 13C-NMR (DMSO-d6): d: 24.37 (d, J = 116.5 Hz), 42.76 (d, J = 87.5 Hz), 121.96 (d, J =87.5 Hz), 130.21 (d, J = 58 Hz), 133.24 (d, J = 109 Hz), 134.48, 135.40 (d, J = 116.5 Hz), 148.77, 187.48. Mass analysis. ESI-MS polarity positive. Calcd. for C9H10NS2: 196; found: 197 (M+H).
Prepare N-(8-iodooctyl)-4-methylquinolium iodide S.4d 5. Stir a solution of 9.15 g (4.97 mL, 25 mmol) of 1,8-diiodooctane in 10 mL of refluxing dioxane in a two-necked round-bottom flask equipped with a reflux condenser and a 10-mL dropping funnel. Add dropwise 0.69 mL (0.746 g, 5 mmol) lepidine S.4c over 30 min with continued heating, and maintaining heating (reflux) for an additional 3 hr. 6. Stop heating and stir mixture for 16 hr at room temperature. 7. Decant the resulting brown oil, wash with anhydrous diethyl ether, and dry under vacuum. 8. Purify on a 35-g silica gel chromatography column using 200 mL of 99:1 (v/v) CH2Cl2/methanol and then 400 mL of 98:2 (v/v) CH2Cl2/methanol as the eluents. Perform chromatography under slight pressure of nitrogen. The pressure should be adjusted so that the solvent elutes from the bottom of the column at ~3 to 5 drops/sec. Yield 53% (1.35 g, 2.6 mol). Brown oil Rf S.4d = 0.35 by TLC and UV shadowing using 9:1 (v/v) CH2Cl2/methanol as eluent. 1H-NMR (DMSO-d6) d ppm, 1.17-1.36 (m, 8H, (CH2)4), 1.68-1.73 (m, 2H, CH2), 1.90-1.93 (m, 2H, CH2), 2.99 (s, 3H, CH3), 3.24 (t, 2H, J = 7 Hz, CH2I), 4.99 (t, 2H, J = 7.8 Hz, NCH2), 8.03-8.07 (m, 2H, Ar), 8.23-8.26 (m, 1H, Ar), 8.53-8.60 (m, 2H, Ar), 9.41-9.42 (m, 1H). 13C-NMR (DMSO-d6): δ: 7.36, 15.31, 25.96 (d, J = 153 Hz), 31.85, 33.83, 34.46, 35.60, 38.94, 63.02 (d, J = 131.5 Hz), 125.54, 128.73 (d, J = 116.5 Hz), 133.40, 135.20, 135.80 (d, J = 109.5 Hz), 141.5 (d, J = 80 Hz), 142.96, 154.53 (d, J = 138.5 Hz), 164.76. Mass analysis. ESI-MS polarity positive. Calcd. for C18H25IN: 382; found: 382 (M+H).
Prepare 8-iodooctylthiazole orange S.4e 9. In a 10-mL round-bottom flask equipped with magnetic stirrer, dissolve 0.156 g (0.48 mmol) S.4b and 0.246 g (0.48 mmol) S.4d in 3 mL warm (55°C) absolute ethanol. 10. Add 20 µL (0.15 mmol) triethylamine and leave the red-colored mixture with magnetic stirring at room temperature. Monitor the reaction by analytical TLC using 9:1 (v/v) CH2Cl2/methanol as the eluent. Visualize by UV shadowing. The spots corresponding to S.4b (Rf = 0.20) and S.4d (Rf = 0.31) disappear while a new red-colored spot appears (Rf = 0.46). The reaction is complete after ~15 min.
11. Remove solvent using a rotary evaporator with a water aspirator, and dry compound in a desiccator containing P2O5. 12. Purify 450 mg residue on a 25-g silica gel chromatography column using 600 mL of 99:1 (v/v) CH2Cl2/methanol as the eluent. Perform chromatography under slight pressure of nitrogen. Incorporation of Halogenoalkyl, 2Pyridyldithioalkyl, or Isothiocyanate Linkers into Ligands
Yield 62% (0.208 g, 0.29 mmol). mp = 123°-124°C. Rf = 0.46 using 9:1 (v/v) CH2Cl2/methanol as the eluent. 1H-NMR (DMSO-d6) d ppm, 1.28-1.45 (m, 8H, (CH2)4), 1.75-1.78 (m, 2H, CH2), 1.85-1.88 (m, 2H, CH2), 3.15 (t, 2H, J = 7.3 Hz, CH2I), 3.99 (s, 3H, NCH3), 4.99 (t, 2H, J = 7.5 Hz, NCH2), 6.70 (s,1H), 7.24-7.25 (m, 1H), 7.27-7.32 (m,1H), 7.44-7.52 (m, 1H), 7.52 (d, J = 8Hz 1H), 7.62 (d, J = 8Hz 1H), 7.66-7.73 (m, 2H), 8.81(d, J = 8Hz, 1H),
4.8.12 Supplement 5
Current Protocols in Nucleic Acid Chemistry
8.90 (d, J = 8Hz, 1H). 13C-NMR (DMSO-d6): δ: 15.34, 31.95, 33.88, 34.52, 34.96, 35.88, 38.94, 40.10, 60.35, 94.33 (d, J = 145.5 Hz), 114.05, 119.21 (d, J = 116.5 Hz), 124.25, 129.11 (d, J = 116.5 Hz), 130.07, 130.47, 130.71, 132.07, 133.01 (d, J = 131 Hz), 134.47, 139.40, 143.24, 146.70, 150.55, 154.77, 166.26. Mass analysis. ESI-MS polarity positive. Calcd. for C26H30IN2S: 529; found: 529 (M+H).
COMMENTARY Background Information The attachment of conjugate groups to the 5′ terminus of oligodeoxyribonucleotides can be achieved following two strategies. The first strategy is direct incorporation using phosphoramidites of ligands. The second strategy involves the coupling of an unblocked oligomer with the ligand via a specific reaction between the reactive groups present in both entities. This requires the functionalization of ligands with halogenoalkyl, 2-pyridyldithioalkyl, or isothiocyanate groups (described here) and the addition of amino, carboxyl, thiophosphate, phosphate, and thiol groups to the 5′ ends of oligodeoxyribonucleotides (UNIT 4.9). The preparation oligonucleotide-ligand conjugates by coupling a functionalized ligand to an unprotected oligonucleotide carrying a suitable functional group offers many advantages over the direct incorporation of the ligands during the oligonucleotide synthesis. In particular, this method is very useful when only a small amount of ligand is available, when the ligand does not resist the chemical conditions required for oligonucleotide deprotection, or when its poor solubility in the solvents typically used for oligonucleotide synthesis does not allow preparation of phosphoramidite or Hphosphonate derivatives. Furthermore, provided that the required amount for each conjugate is low, this method is more convenient method than the direct method for obtaining many different oligodeoxyribonucleotide-ligand conjugates starting from only one oligodeoxyribonucleotide synthesis. This unit describes the attachment of a halogenoalkyl and 2-pyridyldithioalkyl linker to a ligand for coupling with an oligodeoxyribonucleotide functionalized with either a 5′-thiophosphate or a 5′-pyridyldisulfide group. The use of a halogenoalkylated ligand yields a conjugate with a stable phosphothioloester or thioether linkage. The use of a 2-pyridyldithioalkylated ligand yields a conjugate with a disulfide bond that can be cleaved by the use of a reducing agent. The third option reported in this unit is the attachment of an isothiocyanate group to a ligand for coupling with an oligodeoxyribonucleotide that carries an aminoalkylated linker.
Procedures reported in this unit with acridine, psoralen, orthophenanthroline, and thiazole orange may be used to prepare other families of ligands. Using these procedures, the parameters of linkage between the oligodeoxyribonucleotide and the ligand—such as the size and nature of the linker used to connect the two entities—may be varied to prepare oligodeoxyribonucleotide-ligand conjugates with optimal properties. For many examples reported, the properties of the oligodeoxyribonucleotideligand conjugates are largely dependent on the geometry of the complex formed between the ligand and its target (Takasugi et al., 1991; Giovannangeli et al., 1992; Costes et al., 1993; Grigoriev et al., 1993). For example, the strongest stabilization is achieved when the ligand is an intercalator (Sun et al., 1989; Asseline et al., 1996; Giovannangeli et al., 1996), the best efficiency of cleavage when the ligand is a cleaving agent (François et al. 1989a,b), or effective cross-linking when the ligand is a reactive group (Takasugi et al., 1991).
Critical Parameters and Troubleshooting Protection of flasks and columns from light throughout the steps of these protocols is recommended since acridine, psoralen, and thiazole orange derivatives are sensitive to light. This can be achieved by wrapping flasks and columns with aluminum foil. Purification steps must also be kept as short as possible. In order to avoid low yields during purification, it is important to completely remove solvents such as dimethylformamide, pyridine, and ethanol, and to pack the columns with extreme care. The use of nonanhydrous solvents can affect the yields obtained. Storing the products in hermetically sealed vials at –20°C in the dark is recommended. Under these conditions, good reactivity of these compounds is usually observed after months or even years of storage. The bromoalkylated phenanthroline derivative, however, may show significant degradation after a few months at –20°C. Flasks and vials containing functionalized ligands should always be allowed to reach room temperature before being opened in order to
Synthesis of Modified Oligonucleotides and Conjugates
4.8.13 Current Protocols in Nucleic Acid Chemistry
Supplement 5
avoid moisture, which can cause sticky compounds (instead of solids) to be obtained. These sticky compounds are difficult to handle and have reduced stability over time. Rf values given in this unit correspond to TLC analyses performed on 2.5 × 7–cm aluminum-backed sheets developed in jars (diameter 4.5 cm, height 8 cm) with caps, using the appropriate mixtures of solvents. The use of jars and plates with different sizes can give different Rf values.
Anticipated Results The yields reported for the various steps can be different when the syntheses are performed at scales other than those described. Using the protocols provided here and starting with 138 mg of the hydroxyalkylated acridine derivative S.1b, 97 mg of the purified bromoalkylated derivative S.1e can be obtained. In the case of the psoralen derivatives, starting with 600 mg of the 5-hydroxypsoralen S.2b, it is possible to obtain 970 mg of the iodoalkylated psoralen derivative S.2f. The latter (200 mg) is then used to prepare the acetylthio derivative S.2g (163 mg), which is then transformed into the 2-pyridyldithioalkylated compound S.2h (140 mg). Starting with 1 g of 5-nitro-1,10-phenanthroline S.3a, 520 mg of the amino derivative S.3b can be obtained. Using 195 mg of the latter, it is possible to obtain 245 mg of the bromoalkylated derivative S.3c. Alternatively, starting with 97 mg of the amino derivative S.3b, 90 mg of the isothiocyanate derivative S.3d can be obtained. In the case of the thiazole orange derivative preparation, starting with 2.4 g thione S.4a, 4.04 g of S.4b can be obtained; using 0.746 g of lepidine S.4c, it is possible to prepare 1.35 g of the iodoalkylated lepidine derivative S.4d. Reaction between 0.156 g of S.4b and 0.246 g of S.4d can give 0.208 g of thiazole orange S.4e.
Time Considerations
Incorporation of Halogenoalkyl, 2Pyridyldithioalkyl, or Isothiocyanate Linkers into Ligands
Provided that all reagents and materials required for each step are available, most of the procedures are simple and rapid. Preparation of compound S.1e requires 2 to 3 days while only 2 days are necessary for compound S.2f. Compound S.2g can be obtained, starting from derivative S.2f, in 1 day; its transformation into S.2g requires 3 to 4 days. The time required for the preparation of compound S.3b is usually 3 days (including 2 days for the crystallization step), and the time required for the synthesis of S.3c and S.3d is 1 and 2 days,
respectively. The synthesis of compounds S.4b and S.4d requires 1 and 2 days, respectively. Starting from S.4b and S.4d, compound S.4e is obtained in 1 day.
Literature Cited Asseline, U., Bonfils, E., Kurfürst, R., Chassignol, M., Roig, V., and Thuong, N.T. 1992. Solidphase preparation of 5′,3′-heterobifunctional oligodeoxyribonucleotides using modified solid supports. Tetrahedron 48:1233-1254. Asseline, U., Bonfils, E., Dupret, D., and Thuong, N.T. 1996. Synthesis and binding properties of oligonucleotides covalently linked to an acridine derivative. A new study of the influence of the dye attachment site. Bioconjugate Chem. 7:369379. Benson, S.C., Singh, P., and Glazer, A.N. 1993. Heterodimeric DNA-binding dyes designed for energy transfer: Synthesis and spectroscopic properties. Nucl. Acids Res. 21:5727-5735. Brooker, L.G., Keyer, G.H., and Williams, W.W. 1942. The absorption of unsymmetrical cyanines. Resonance as a basis for classification of dyes. J. Am. Chem. Soc. 64:199-210. Chassignol, M. and Thuong, N.T. 1998. Phosphodisulfide bond: A new linker for the oligonucleotide conjugation. Tetrahedron Lett. 39:82718274. Costes, B., Girodon, E., Ghanem, N., Chassignol, M., Thuong, N.T., Dupret, D., and Goossens, M. 1993. Psoralen-modified oligonucleotide primers improve detection of mutations by denaturing gradient gel electrophoresis and provide an alternative to GC-clamping. Hum. Mol. Genet. 2:393397. François, J.-C., Saison-Behmoaras, T., Barbier, C., Chassignol, M., Thuong, N.T., and Hélène, C. 1989a. Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate. Proc. Natl. Acad. Sci. U.S.A. 86:9702-9706. François, J.-C., Saison-Behmoaras, T., Chassignol, M., Thuong, N.T., and Hélène, C. 1989b. Sequence-targeted cleavage of single- and doublestranded DNA by oligothymidylates covalently linked to 1,10-phenanthroline. J. Biol. Chem. 264:5891-5898. Giovannangeli, C., Thuong, N.T., and Hélène, C., 1992. Oligodeoxynucleotide-directed photo-induced cross-linking of HIV proviral DNA via triple-helix formation. Nucl. Acids Res. 20:42754281. Giovannangeli, C., Perrouault, L., Escudé C., Thuong, N.T., and Hélène, C. 1996. Specific inhibition of in vitro transcription elongation by triplex-forming oligonucleotide-intercalator conjugates targeted to HIV proviral DNA. Biochemistry 35:10539-10548.
4.8.14 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Grigoriev, M., Praseuth, D., Guieysse, A.L., Robin, P., Thuong, N.T., Hélène, C., and Harel-Bellan, A. 1993. Inhibition of gene expression by triple helix-directed DNA cross-linking at specific sites. Proc. Natl. Acad. Sci. U.S.A. 90:35013505. Sun, J.S., François, J.C., Montenay-Garestier, T., Saison-Behmoaras, T., Roig, V., Thuong, N.T., and Hélène, C. 1989. Sequence-specific intercalating agents. Intercalation at specific sequences on duplex DNA via major groove recognition by oligonucleotide-intercalator conjugates. Proc. Natl. Acad. Sci. U.S.A. 86:9198-9202.
Takasugi, M., Guendouz, A., Chassignol, M., Decout, J.L., Lhomme, J., Thuong, N.T., and Hélène, C., 1991. Sequence-specific photo-induced cross-linking of the two strands of doublehelical DNA by a psoralen covalently linked to a triple helix forming oligonucleotide. Proc. Natl. Acad. Sci. U.S.A. 88:5602-5606. Thuong, N.T. and Asseline, U. 1991. Oligonucleotides attached to intercalators, photoreactive and cleavage agents. In Oligonucleotides and Analogues: A Practical Approach (F. Eckstein, ed.) pp. 283-308. IRL Press, Oxford.
Contributed by Ulysse Asseline and Nguyen T. Thuong Centre de Biophysique Moléculaire, CNRS Orléans, France
The authors would like to express their appreciation to their past and present collaborators for their contribution to the development of various families of oligonucleotide-ligand conjugates. This work was supported by Rhône-Poulenc, the Agence Nationale de Recherches sur le SIDA and bio-Mérieux.
Synthesis of Modified Oligonucleotides and Conjugates
4.8.15 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
UNIT 4.9
The chemical attachment of reporter and various conjugate groups (e.g., intercalators as well as photoreactive and cleaving agents) to the 5′ terminus of oligodeoxyribonucleotides can be achieved following two strategies. The first involves the direct addition of a ligand to the 5′ end of the oligodeoxyribonucleotide via its phosphoramidite or H-phosphonate derivative. This strategy has been described in UNIT 4.3. The second strategy involves the incorporation of appropriate functional groups into both the ligand and the 5′ terminus of an oligonucleotide. Specific coupling of these reactants results in the formation of oligodeoxyribonucleotide conjugates. Using the second strategy, many different oligodeoxyribonucleotide conjugates can be prepared starting from only one oligodeoxyribonucleotide, provided that the amount required for each conjugate is low. In this approach, functional groups (such as amino, phosphate, phosphorothioate, thiol, carboxyl, and cis-diol) that are capable of undergoing specific reactions with selected ligand functional groups are added to the 5′ end of oligodeoxyribonucleotides. Examples of incorporation of halogenoalkyl, 2-pyridyldithioalkyl, or isothiocyanate linkers into ligands have been reported in UNIT 4.8. This unit describes methods used in the authors’ laboratory for the preparation of oligodeoxyribonucleotides carrying the following 5′-terminal functional groups: carboxyl and amino (see Basic Protocol 1), phosphorothioate and phosphate (see Basic Protocol 2), and masked thiol (see Basic Protocol 3; see Alternate Protocols 1 and 2). The functional groups are incorporated upon completion of oligonucleotide chain assembly prior to deprotection and purification. Another strategy—adding functional groups after deprotection and purification—has been described elsewhere (Grimm et al., 2000). The coupling of these functionalized oligonucleotides with the reactive functions incorporated into the ligands reported in UNIT 4.8, and finally the purification and characterization of the oligodeoxyribonucleotide-ligand conjugates, is described in UNIT 4.10. CAUTION: All chemicals must be handled in a fume hood by personnel equipped with a laboratory coat, glasses, and gloves. NOTE: For each family of 5′-oligonucleotide modifications, a sample of detritylated oligodeoxyribonucleotide bound to the support is deprotected and purified separately using the general conditions described in APPENDIX 3C. These samples are used as references for chromatography and polyacrylamide gel electrophoresis analyses. ADDITION OF A CARBOXYLATED OR AMINOALKYLATED LINKER TO THE 5′ END OF OLIGODEOXYRIBONUCLEOTIDES
BASIC PROTOCOL 1
The addition of carboxylated or aminoalkylated linkers at the 5′ end of oligodeoxyribonucleotides is achieved via a two-step procedure adapted from Gottikh et al. (1990) and Wachter et al. (1986), respectively. The different steps involved are illustrated in Figure 4.9.1. In these procedures, the 5′-hydroxyl group of an oligonucleotide bound to a support (S.1) is activated by treatment with carbonyldiimidazole followed by reaction with either an amino acid (aminovaleric acid or aminocaproic acid) or a bis amine (1,5-diaminopentane or 1,6-diaminohexane). After deprotection and cleavage from the support, the oligodeoxyribonucleotides containing carboxylated or aminoalkylated linkers (S.3 and S.2, respectively) are purified by chromatography. Synthesis of Modified Oligonucleotides and Conjugates Contributed by Ulysse Asseline and Nguyen T. Thuong Current Protocols in Nucleic Acid Chemistry (2001) 4.9.1-4.9.28 Copyright © 2001 by John Wiley & Sons, Inc.
4.9.1 Supplement 5
H2N(CH2)mNHC(O)O
B
O O
1. Carbonyldiimidazole
O P O 2. H2N(CH2)mNH2, m = 5, 6 3. Deprotection
−
O
O
B
O HO
B'
O
n
H 2
O O P OCH2CH2CN O
B'
O O
n
P
−
1
O2C(CH2)mNHC(O)O
1. Carbonyldiimidazole
−
2. H2N(CH2)mCO2 DBU salt, m = 4, 5
B
O O
O P O
−
O
O
3. Deprotection
B
O H
n
3
Figure 4.9.1 Addition of a carboxyl or amino function to the 5′ end of an oligodeoxyribonucleotide. B, adenine, cytosine, guanine, or thymine; B′, thymine or any N-protected nucleobase; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; P, controlled-pore glass.
Materials 5′-Detritylated oligodeoxyribonucleotide bound to a controlled-pore glass (CPG) support Nitrogen gas 40 mg/mL anhydrous 1,1′-carbonyldiimidazole in anhydrous dioxane Anhydrous dioxane Amino acid or bis amine (select one): 10 mg/mL 5-aminovaleric acid or 6-aminocaproic acid, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) salt (Aldrich), in pyridine 12 mg/mL 1,5-diaminopentane or 1,6-diaminopentane in pyridine Pyridine, redistilled from p-toluenesulfonyl chloride, stored over 3A molecular sieves Acetonitrile (CH3CN), DNA synthesis grade, stored over 3A molecular sieves, and HPLC grade Concentrated ammonium hydroxide (25%) Ethyl acetate, distilled 1.5 M NaCl 25 mM Tris⋅Cl, pH 7 (APPENDIX 2A), containing 10% (v/v) distilled HPLC-grade methanol 1 M triethylammonium acetate (TEAA) buffer, pH 7 (stock solution) Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
8-mL vial with septum and screw cap 22-G hypodermic needle Desiccator containing P2O5 and KOH 50° and 55°C ovens or water baths
4.9.2 Supplement 5
Current Protocols in Nucleic Acid Chemistry
0.45-µm filter attached to a disposable syringe UV spectrophotometer Rotary evaporator with water bath and a water aspirator Ion-exchange chromatography system and column (select one): Mono Q HR 5/5 or HR 10/10 column (Amersham Pharmacia Biotech) DEAE column (8 µm, 100 × 10 mm; Waters) High-performance liquid chromatograph (HPLC) equipped with multiwavelength detector and reversed-phase column (select one): Lichrospher 100 RP 18 column (5 µm; 125 mm × 4 mm; Merck) Lichrospher 100 RP 18 column (10 µm; 250 mm × 10 mm; Merck) Delta-Pak C4 column (5 µm, 100 Å; 150 × 3.9 mm; Waters) Lyophilizer Additional reagents and equipment for analytical and preparative ion-exchange chromatography and reversed-phase HPLC (RP-HPLC), and for sample purification (UNIT 4.3) Activate 5′-hydroxyl group 1. Place 1 µmol of 5′-detritylated oligodeoxyribonucleotide bound to a CPG support in an 8-mL vial with a septum. Push a 22-G hypodermic needle through the septum and place the vial in a desiccator containing P2O5 and KOH. Keep under vacuum overnight. 2. Fill the desiccator with nitrogen before opening it. 3. Add 500 µL of 40 mg/mL anhydrous 1,1′-carbonyldiimidazole in anhydrous dioxane under nitrogen and allow to react for 25 min with occasional shaking. 4. Remove excess 1,1′-carbonyldiimidazole solution with a syringe and wash the support with 1 mL anhydrous dioxane. Add linker 5. Add 500 µL of one of the following solutions and incubate 3 to 4 hr with occasional shaking by hand. 10 mg/mL 5-aminovaleric acid or 6-aminocaproic acid (DBU salt) in pyridine (for S.3) 12 mg/mL 1,5-diaminopentane or 1,6-diaminopentane in pyridine (for S.2). Deprotect and remove from support 6. Remove liquid with a syringe. Wash support twice with 1 mL of 2:1 (v/v) pyridine in DNA synthesis–grade CH3CN, and twice with 1 mL CH3CN. 7. Add 5 mL concentrated ammonium hydroxide, seal the vial with a screw cap, and heat 1 hr at 50°C. 8. Cool the ammoniacal solution to room temperature. The solution should be cooled before opening the vial for safety and to prevent spillage and loss of product.
9. Discard the support, transfer the ammoniacal solution to a new vial, and incubate for an additional 6 hr at 55°C. 10. Cool solution to room temperature and evaporate to dryness under reduced pressure using a rotary evaporator with a water aspirator.
Synthesis of Modified Oligonucleotides and Conjugates
4.9.3 Current Protocols in Nucleic Acid Chemistry
Supplement 5
11. Solubilize crude material with 6 mL water and extract three times with 4 mL ethyl acetate. Discard the organic phase. 12. Filter solution using a 0.45-µm filter attached to a disposable syringe. Wash filter with 0.3 mL water and add wash to filtrate. 13. Dilute 25 µL crude deprotected oligonucleotide solution with 975 µL water and record the UV spectrum between 220 and 400 nm using a UV spectrophotometer. Determine absorbance at 260 nm and multiply by 40 (the dilution factor) to determine the concentration of the crude oligonucleotide solution. Analyze quality of synthesis 14. Analyze by ion-exchange chromatography and RP-HPLC. Set the instrument for detection at 260 nm. Preequilibrate columns with starting buffer for ≥15 min. Run a blank gradient before analysis and purification, and between analyses and purifications of samples with different sequences or different modifications. Analyze the unmodified oligonucleotide sequence for comparison. a. For ion-exchange chromatography: Use a Mono Q HR 5/5 or HR 10/10 column or a DEAE column with a linear gradient of 1.5 M NaCl (0% to 100%) in 25 mM Tris⋅Cl, pH 7, containing 10% (v/v) methanol. Elute at a flow rate of 1 mL/min with an HR 5/5 column or DEAE column, or at 4 mL/min with an HR 10/10 column. b. For RP-HPLC: Use a Lichrospher 100 RP 18 column with a linear gradient of HPLC-grade CH3CN (5% to 80%) in 0.1 M TEAA buffer, pH 7, at a flow rate of 1 mL/min. Alternatively, use a semipreparative Lichrospher 100 RP 18 column at a flow rate of 4 mL/min, or a Delta-Pak C4 column at a flow rate of 0.8 mL/min. The gradients must be chosen to afford the best separation. Usually 1 M NaCl is increased at 1% per minute for ion-exchange chromatography, and CH3CN is increased at 0.5% to 1% per minute for RP-HPLC. Characterization data can be found following step 17.
Purify sample 15. Using the system determined to give the best separation, purify the remaining crude 5′-modified oligonucleotide by preparative reversed-phase or ion-exchange chromatography. Because preparative chromatography columns do not have the resolution of analytical columns, the product peak should be fractionated to obtain good purification.
16. Proceed with sample purification as reported in UNIT 4.3 (steps 3 to 8 of the Support Protocol). Measure the OD260 to determine the yield of 5′-modified oligonucleotide. 17. Lyophilize the modified oligonucleotide and store up to two years at –20°C in a tightly sealed vial. Characterization of carboxylated oligodeoxyribonucleotides: Yield: 25 OD260 units.
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
The best separation was obtained by ion-exchange chromatography on a Mono Q column (HR 50 × 5 mm) using a linear gradient of NaCl (0.2 to 0.5 M over 40 min) in 25 mM Tris⋅Cl, pH 7, containing 10% methanol at a flow rate of 1 mL/min. Retention times were 22 min for –OOC(CH2)4-NH-CO-d[CTCTCGCACCCATCTCTC] and –OOC(CH2)5-NHCO-d[CTCTCGCACCCATCTCTC], and 21 min for d[CTCTCGCACCCATCTCTC]. Ionexchange analysis of a crude oligonucleotide derivatized with aminovaleric acid is shown in Figure 4.9.2.
4.9.4 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Figure 4.9.2 Ion-exchange chromatography analysis of crude HOOC(CH2)4-NH-COd[CTCTCGCACCCATCTCTC] (see Basic Protocol 1) on a Mono Q column.
RP-HPLC of carboxylated oligonucleotides on a Lichrospher 100 RP 18 (5 mm; 125 × 4 mm) column using a gradient of CH3CN (10% to 30% over 50 min) in 0.1 M TEAA buffer, pH 7, at 1 mL/min gives retention times of 11 min 25 sec for –OOC(CH2)4-NH-COd[CTCTC GC AC CCATCTCTC], 13 min 13 sec for –OOC(CH2)5-NH-COd[CTCTCGCACCCATCTCTC], and 9 min 40 sec for d[CTCTCGCACCCATCTCTC]. RP-HPLC performed on a Delta-Pak C4 (5 mm, 100 Å, 150 × 3.9 mm) column with a linear gradient of CH3CN (5% to 35% over 60 min) in 0.1 M TEAA buffer, pH 7, at 0.8 mL/min gives retention times of 12 min 10 sec for –OOC(CH2)5-NH-COd[CTCTCGCACCCATCTCTC], and 11 min 8 sec for d[CTCTCGCACCCATCTCTC]. Figure 4.9.3 shows a chromatogram obtained for a mixture of purified –OOC(CH2)5-NHCO-d[CTCTCGCACCCATCTCTC] and d[CTCTCGCACCCATCTCTC].
Figure 4.9.3 RP-HPLC analysis on a Delta Pak C4 column of a purified mixture of HOOC(CH2)5NH-CO-d[CTCTCGCACCCATCTCTC] and d[CTCTCGCACCCATCTCTC] (see Basic Protocol 1).
Synthesis of Modified Oligonucleotides and Conjugates
4.9.5 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Mass analysis. ESI-MS polarity negative. HOOC(CH2)5-NH-COd[CTCTCGCACCCATCTCTC]. Calcd. for C177H233N56O112P17: 5461 Da; found: 5460 ± 3 Da (M-H). HOOC(CH2)4-NH-CO-d[CTCTCGCACCCATCTCTC] Calcd. for C176H231N56O112P17: 5447 Da; found: 5446 Da (M-H). Denaturing 20% PAGE does not allow easy separation of 5′-modified oligonucleotides with carboxylated linkers from the corresponding unmodified oligonucleotide. Characterization of aminoalkylated oligodeoxyribonucleotides: Yield: 25-30 OD260 units. Ion-exchange chromatography of 5′-aminoalkylated oligonucleotides on a DEAE column (8 mm, 100 × 10 mm) using a linear gradient of NaCl (0 to 0.6 M over 60 min) in 25 mM Tris⋅Cl, pH 7, containing 10% methanol at 1 mL/min gives retention times of 44 min 54 sec for H2N(CH2)5-NH-CO-d[CCGCTTAATACTGA] and H2N(CH2)6-NH-COd[CCGCTTAATACTGA], and 45 min 48 sec for d[CCGCTTAATACTGA]. Figure 4.9.4 shows a chromatogram obtained for crude H2N(CH2)5-NH-CO-d[CCGCTTAATACTGA]. RP-HPLC on a Lichrospher 100 RP 18 column using the conditions described above gives retention times of 10 min 25 sec for H2N(CH2)5-NH-CO-d[CCGCTTAATACTGA], 10 min 54 sec for H2N(CH2)6-NH-CO-d[CCGCTTAATACTGA], and 9 min 42 sec for d[CCGCTTAATACTGA]. RP-HPLC on a Delta-Pak C4 column (5 mm, 100 Å, 150 × 3.9 mm) with a linear gradient of CH3CN (5% to 35% over 60 min) in 0.1 M TEAA buffer, pH 7, at 0.8 mL/min gives retention times of 11 min 40 sec for H2N(CH2)5-NH-CO-d[CCGCTTAATACTGA], 12 min 21 sec for H2N(CH2)6-NH-CO-d[CCGCTTAATACTGA], and 11 min 15 sec for d[CCGCTTAATACTGA]. Figure 4.9.5 shows a chromatogram for a mixture of purified H2N(CH2)6-NH-CO-d[CCGCTTAATACTGA] and d[CCGCTTAATACTGA]. Denaturing 20% PAGE (APPENDIX 3B) allows easy separation of 5′-modified oligonucleotides with aminoalkylated linkers from the corresponding unmodified oligonucleotide (Fig. 4.9.6). Mass analysis. ESI-MS polarity negative. H2N(CH2)5-NH-CO-d[CCGCTTAATACTGA]. Calcd. for C142H185N52O83P13: 4351 Da; found: 4351 ± 1 Da (M-H). H2N(CH2)6-NH-COd[CCGCTTAATACTGA]. Calcd. for C143H187N52O83P13: 4365 Da; found: 4365 ± 1 Da (M-H).
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
Figure 4.9.4 Ion-exchange chromatography on a DEAE column of crude H2N-(CH2)5-NH-COd[CCGCTTAATACTGA] (see Basic Protocol 1).
4.9.6 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Figure 4.9.5 RP-HPLC on a Delta Pak C4 column of a purified mixture of H2N-(CH2)6-NH-COd[CCGCTTAATACTGA] and d[CCGCTTAATACTGA] (see Basic Protocol 1).
ADDITION OF A PHOSPHOROTHIOATE OR PHOSPHATE GROUP TO THE 5′ TERMINUS OF OLIGODEOXYRIBONUCLEOTIDES
BASIC PROTOCOL 2
The phosphorothioate group is incorporated at the 5′ end of oligodeoxyribonucleotides via a two-step procedure involving the coupling of bis-(2-cyanoethyl)-diisopropylamidophosphite with the 5′-terminal hydroxyl function of an oligodeoxyribonucleotide bound to a support (S.4), followed by a sulfurization step, as seen in the bottom of Figure 4.9.7. The phosphate group is obtained by replacing the sulfurization step with a standard aqueous iodine oxidization (top). After deprotection and cleavage from the support, the 5′-phosphorothioate-containing (S.6) or 5′-phosphate-containing (S.5) oligodeoxyribonucleotide is purified by liquid chromatography. The procedure was adapted from a previously described procedure (Thuong and Asseline, 1991).
Figure 4.9.6 PAGE analysis of d[CCGCTTAATACTGA] (lane 1), H2N-(CH2)5-NH-COd[CCGCTTAATACTGA] (lane 2), and H2N-(CH2)6-NH-CO-d[CCGCTTAATACTGA] (lane 3; see Basic Protocol 1).
Synthesis of Modified Oligonucleotides and Conjugates
4.9.7 Current Protocols in Nucleic Acid Chemistry
Supplement 5
O HO P O O
−
B
O O
1. i-Pr2NP(OCH2CH2CN)2,1H-Tetrazole, MeCN
O P O 2. Oxidation 3. Deprotection
−
O
O
B
O HO
B'
O
n
H 5
O O P OCH2CH2CN O
B'
O O
n
P 4
O HO P O S
−
B
O O
1. i-Pr2NP(OCH2CH2CN)2,1H-Tetrazole, MeCN
O P O
2. Sulfurization 3. Deprotection
−
O
O
B
O H
n
6
Figure 4.9.7 Addition of a phosphorothioate or phosphate group to the 5′ end of an oligodeoxyribonucleotide.
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
Materials Diisopropylethylamine, distilled from KOH 2-Cyanoethanol Diethyl ether dried over sodium wires Nitrogen source N,N′-Diisopropylphosphoramidous dichloride (Aldrich) Argon atmosphere 5′-Detritylated oligodeoxyribonucleotide bound to a controlled-pore glass (CPG) support 0.5 M tetrazole in anhydrous CH3CN Anhydrous CH3CN 10 mg/mL Beaucage reagent in anhydrous CH3CN or 100 mg/mL tetraethylthiuram disulfide in anhydrous CH3CN (optional; for sulfurization) Iodine solution (same composition as for DNA synthesis; optional; for oxidation) Concentrated ammonium hydroxide (NH4OH; 25%) Dithiothreitol (DTT; optional) Ethyl acetate, distilled Isopropanol 2.5 mg/mL 2,6-dibromo-4-benzoquinone-N-chloroimine (DBPNC; Prolabo) in ethanol 1-liter three-neck round-bottom flask Dropping funnel Reflux condenser with a calcium chloride drying tube
4.9.8 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Gas inlet adapter Glass filter (porosity 4) Rotary evaporator with a water aspirator and a water bath Falling-film distillation head (Aldrich) or other vacuum distillation apparatus 50° and 55°C ovens or water baths Kieselgel 60F plates for analytical TLC (Merck) Additional reagents and equipment for automated oligonucleotide synthesis (APPENDIX 3C), thin-layer chromatography (TLC; APPENDIX 3D), and purification and characterization of the product (see Basic Protocol 1) Prepare bis-(2-cyanoethyl)diisopropylamidophosphite 1. Place 70 mL (51.6 g, 0.40 mol) diisopropylethylamine and 25.6 g (0.36 mol) 2-cyanoethanol in 300 mL dry diethyl ether in a three-neck 1-liter round-bottom flask equipped with a dropping funnel, a reflux condenser with a calcium chloride drying tube, and a gas inlet adapter connected to a nitrogen source. Cool to 0°C while stirring vigorously with a magnetic stir bar or by mechanical stirring. 2. Add 36 g (33.18 mL, 0.18 mol) N,N-diisopropylphosphoramidous dichloride to 50 mL dry diethyl ether. Add dropwise, under an argon atmosphere, to the solution in step 1 using a dropping funnel. 3. Allow the stirred mixture to warm to room temperature for 1 hr. 4. Remove the precipitated salt by vacuum filtration with a glass filter and wash it with 100 mL dry diethyl ether. Concentrate filtrate by evaporation under reduced pressure using a rotary evaporator with a water aspirator. 5. Purify the residue by vacuum distillation. An apparatus can be fashioned in the laboratory, or a falling-film distillation head can be used. Yield 60% (29.3 g, 0.108 mol). 1H-NMR (CDCl3), δ: 1.19 [d, 12H, J = 6.8 Hz, (CH3)2CH]; 2.64 [t, J = 6.2 Hz, (OCH2CH2CN)]; 3.55-3.68 [m, 2H, (CH3)2CH]; 3.78-3.94 [4H, m, OCH2CH2CN)]. 31P-NMR (CDCl3), δ: 150.2 ppm. 13C-NMR (DMSO-d6), δ: 25.25, 29.78, 48.06 (d, J = 36.5 Hz), 63.84 (d, J = 73 Hz), 124.36. Mass analysis. ESI-MS, polarity positive. Calcd. for C12H22N3O2P: 271; found: 272 (M+H). The purified product can be stored up to 1 year at –20°C without loss of coupling efficiency. However, when the reaction is performed on a small scale, bis-(2-cyanoethyl)diisopropylamidophosphite is purified by chromatography on a silica gel column using 4:1 (v/v) diethyl ether/hexane containing 2% to 3% triethylamine as the eluent, and the fractions are monitored by TLC using the same eluent (pre-elute the plate before analysis). After treating the plate with DBPNC (step 13), a pale-colored spot appears (Rf = 0.6). When purified this way, the product shows loss of coupling efficiency after 3 to 4 months of storage. Bis-(2-cyanoethyl)diisopropylamidophosphite is now commercially available from Chemgenes.
Couple to oligonucleotide 6. Place 0.1 M bis-(2-cyanoethyl)diisopropylamidophosphite in anhydrous CH3CN on the synthesizer. React a fully 5′-detritylated oligodeoxyribonucleotide bound to a CPG support for 5 min at a flow rate of 1 mL/min by recycling a mixture containing: 0.1 mL 0.1 M phosphoramidite in anhydrous CH3CN 0.5 mL 0.5 M tetrazole in anhydrous CH3CN 0.1 mL CH3CN.
Synthesis of Modified Oligonucleotides and Conjugates
4.9.9 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Perform this reaction twice. For synthesizers without a recycle program, perform a double coupling step. Alternatively, bis-(2-cyanoethyl)diisopropylamidophosphite can be manually added to the 5′ terminus of oligonucleotides bound to a solid support according to the method described for the phosphoramidites 1c and 2d in UNIT 4.3.
Perform sulfurization/oxidation 7a. For sulfurization: Treat product with 1 mL of 10 mg/mL Beaucage reagent in anhydrous CH3CN added at a rate of 1 mL/min, or with 15 mL of 100 mg/mL tetraethylthiuram disulfide in CH3CN added at 1 mL/min. 7b. For oxidation: Perform automated iodine oxidation step. Either the sulfurization or the oxidation step can be performed manually.
Deprotect and remove from support 8. Add 5 mL concentrated ammonium hydroxide and 100 eq (15 mg) DTT to the oligodeoxyribonucleotide 5′-bis-(2-cyanoethyl)phosphorothioate and heat 1 hr at 55°C. For the oligodeoxyribonucleotide 5′-bis-(2-cyanoethyl)phosphate, omit the DTT. DTT is used to prevent formation of an acrylonitrile adduct on the thiophosphate group.
9. Cool the ammoniacal solution to room temperature. The solution should be cooled before opening the vial for safety and to prevent spillage and loss of product.
10. Discard the support, transfer the ammoniacal solution to a new vial, and incubate for an additional 7 hr at 50°C. 11. Cool the ammoniacal solution and evaporate it to dryness under reduced pressure using a rotary evaporator and a water aspirator. 12. Solubilize the crude material with 6 mL water and extract four times with 4 mL ethyl acetate for the 5′-phosphorothioate, or three times for the 5′-phosphate. 13. For medium-sized oligodeoxyribonucleotides (10- to 25-mers), verify the presence of the phosphorothioate group by analyzing the crude deprotected oligodeoxyribonucleotide by analytical TLC (APPENDIX 3D) using isopropanol/concentrated NH4OH/H2O as eluent in varying proportions depending on the length and base composition of the oligodeoxyribonucleotide. Spray the plate with 2.5 mg/mL DBPNC in ethanol and heat until color appears. Typically, 65:9:15 (v/v/v) isopropanol/NH4OH/H2O is suitable for ≤10-mers, and 55:10:25 or 55:10:35 is suitable for 10- to 20-mers. Phosphorothioate-containing oligodeoxyribonucleotides give a pink-colored spot on the TLC plate after treatment with DBPNC and heating. (Eluent mixture must be prepared at least a half-day before use.)
Purify and characterize 14. Purify and characterize the 5′-phosphorothioate- or 5′-phosphate-containing oligodeoxyribonucleotide as described (see Basic Protocol 1, steps 12 to 17).
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
Ion-exchange chromatography of 5′-phosphorothioate- and 5′-phosphate-containing oligodeoxyribonucleotides using the conditions described above with a DEAE column gives retention times of 49 min 24 sec for sp-d[CCGCTTAATACTGA] (53 min 36 sec for oligonucleotide disulfide), 47 min 36 sec for p-d[TTCTCCCCCGCTTA], 46 min 12 sec for d[TTCTCCCCCGCTTA], and 45 min 48 sec for d[CCGCTTAATACTGA]. Figure 4.9.8
4.9.10 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Figure 4.9.8 Ion-exchange chromatography on a DEAE column of crude sp-d[CCGCTTAATACTGA] (see Basic Protocol 2).
shows the chromatogram of crude sp-d[CCGCTTAATACTGA], and Figure 4.9.9 shows the chromatogram of crude p-d[TTCTCCCCCGCTTA]. Denaturing 20% PAGE does not allow easy separation of oligonucleotide 5′-thiophosphates and 5′-phosphates from the corresponding unmodified oligonucleotide. In the case of 5′-thiophosphate oligonucleotides, however, the presence of a weak band with a mobility corresponding to that of a 30-mer confirmed that the peak observed at 53 min 36 sec is probably the chimeric oligonucleotide disulfide 3′-[AGTCATAATTCGCC]-ps-spd[CCGCTTAATACTGA]-3′. The 5′-thiophosphate oligonucleotide can be recovered by treatment of the chimera with DTT. RP-HPLC on a Lichrospher RP 18 column using the conditions described above gives retention times of 9 min for sp-d[CCGCTTAATACTGA], 9 min 42 sec for d[CCGCTTAATACTGA], 10 min 30 sec for p-d[TTCTCCCCCGCTTA], and 10 min 50 sec for d[TTCTCCCCCGCTTA].
Figure 4.9.9 Ion-exchange c hromatography on a DEAE column of cr ude pd[TTCTCCCCCGCTTA] (see Basic Protocol 2).
Synthesis of Modified Oligonucleotides and Conjugates
4.9.11 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Figure 4.9.10 RP - HP LC on a Delta Pak C4 column of a pur ified mixture of pd[TTCTCCCCCGCTTA] and d[TTCTCCCCCGCTTA] (see Basic Protocol 2).
RP-HPLC on a Delta-Pak C4 column (5 mm, 100 Å, 150 × 3.9 mm) using a linear gradient of CH3CN (5% to 16 % by volume over 30 min) in 0.1 M TEAA buffer, pH 7, at 0.8 mL/min gives retention times of 10 min 40 sec for sp-d[CCGCTTAATACTGA], 11 min 15 sec for d[CCGCTTAATACTGA], 11 min 36 sec for p-d[TTCTCCCCCGCTTA], and 12 min 26 sec for d[TTCTCCCCCGCTTA]. Figure 4.9.10 shows a chromatogram obtained for a mixture of purified p-d[TTCTCCCCCGCTTA] and d[TTCTCCCCCGCTTA]. Mass analysis. ESI-MS polarity negative. sp-d[CCGCTTAATACTGA]. Calcd. for C136H175N50O84P14S: 4319 Da; found: 4318 Da (M-H). Yield: 35-40 OD260 units. Mass analysis. ESI-MS polarity negative. p-d[TTCTCCCCCGCTTA]. Calcd. for C133H176N41O89P14: 4206 Da; found: 4205 ± 1 Da (M-H). Yield: 35-40 OD260 units. BASIC PROTOCOL 3
ADDITION OF A MASKED THIOL GROUP TO THE 5′ TERMINUS OF OLIGODEOXYRIBONUCLEOTIDES USING AN S-DIPHENYLPHOSPHINATE PHOSPHORAMIDITE Two strategies can be used to add a masked thiol group to the 5′ end of an oligodeoxyribonucleotide. This protocol presents the first strategy, which is illustrated on the left of Figure 4.9.11. In this approach, an S-diphenylphosphinate phosphoramidite (S.7a) is added to the 5′ terminus of a support-bound oligodeoxyribonucleotide. This gives a 5′ thiol group masked with an alkali-labile protecting group (S.7b). Addition of 2,2′-dithiodipyridine during oligonucleotide deprotection converts the released thiol function to a 2-pyridyldisulfide group (S.10). This strategy can also be performed using an S-acetyl phosphoramidite (S.8a) as described in Alternate Protocol 1. The second strategy (right side of Fig. 4.9.11) uses a tritylated alkyl disulfide-containing linker (S.9a) and is described in Alternate Protocol 2.
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
The preparation of the S-diphenylphosphinate derivative S.7a is included in the steps below and is illustrated in Figure 4.9.12. The synthesis of S.7a is achieved in four steps from the commercial methyldiphenylphosphinite S.11. Sulfurization of S.11 gives the methyldiphenylthionophosphinate S.12, which is then demethylated by treatment with trimethylamine. The resulting tetramethylammonium salt S.13 reacts with 2-[2-(2-io-
4.9.12 Supplement 5
Current Protocols in Nucleic Acid Chemistry
i-Pr2N P 1.
L
HO
OCH2CH2CN
B'
O
i-Pr2N
O
RS
1. DMTrO 7a R = Ph2P(O) 8a R = CH3CO
L
O
L
O
P
OCH2CH2CN
9a
O P OCH2CH2CN
1H-tetrazole 2. Oxidation
S S
O
1H-tetrazole 2. Oxidation
B'
O O
n
P
O
O RS
L
O P OCH2CH2CN O
B'
O
DMTrO
O DMTrO
L
S S
O P O L
−
S S
B
O
O
L
O
O
−
O
NH4OH O
B
O P OCH2CH2CN O
B'
O
n
H
n
7b R = Ph2P(O) 8b R = CH3CO
B'
O
O
O P
O
O
O P O
B'
O P OCH2CH2CN O
O
O O P OCH2CH2CN
L
P
n
9b
9c
DTT or TCEP, PySSPy
O N
S S
NH4OH Phenol PySSPy
O P O L
−
B
O
O
O O P O
−
O
O
B
O H
n
10
Figure 4.9.11 Addition of a masked thiol group to the 5′ end of an oligodeoxyribonucleotide. DTT, dithiothreitol; L, CH2CH2OCH2CH2OCH2CH2; PySSPy, 2,2′-dipyridyldisulfide; TCEP, tris(2-carboxyethyl)phosphine hydrochloride.
doethoxy)ethoxy]ethanol to give 2-{2-[2-(S-diphenylphosphinate)ethoxy]ethoxy}ethanol S.14. 2-[2-(2-Iodoethoxy)ethoxy]ethanol is obtained by treatment of 2-[2-(2-chloroethoxy)ethoxy]ethanol (S.15; Fig. 4.9.16) with NaI in acetone in the presence of NaHCO3. The alcohol S.14 is then treated with diisopropylethylamine and 2-cyanoethylN,N-diisopropylchlorophosphoramidite to give the phosphoramidite S.7a. Materials Methyldiphenylphosphinite (S.11; Aldrich) Toluene Elemental sulfur (S8) Hexane, distilled Ethyl acetate, distilled Triethylamine, distilled from KOH 2.5 mg/mL 2,6-dibromo-4-benzoquinone-N-chloroimine (DBPNC; Prolabo) in ethanol
Synthesis of Modified Oligonucleotides and Conjugates
4.9.13 Current Protocols in Nucleic Acid Chemistry
Supplement 5
O
S S8
P OMe
P
11
OMe
NMe3
P
− + NMe4 S
13
12 OH I
L
i-Pr2N P
O P
L S
OCH2CH2CN
O
O
i-Pr2NP(Cl)OCH2CH2CN
P
L
OH
S
DIPEA
7a
14
Figure 4.9.12 Preparation of the S-diphenylphosphinate phosphoramidite derivative S.7a. DIPEA, diisopropylethylamine; L, CH2CH2OCH2CH2OCH2CH2.
Celite 521 (Aldrich) 20% (w/v) trimethylamine/acetonitrile Diethyl ether, dried over sodium wires, ice cold and room temperature Dichloromethane (CH2Cl2) distilled over P2O5 and passed through a column of basic alumina Methanol, distilled 2-[2-(2-Chloroethoxy)ethoxy]ethanol (S.15; Fig. 4.9.16; Aldrich) NaI Sodium bicarbonate (NaHCO3) Acetone, anhydrous Anhydrous acetonitrile (CH3CN) Diisopropylethylamine, distilled from KOH 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite (Aldrich) Nitrogen gas 10% (w/v) aqueous sodium carbonate (Na2CO3) Saturated aqueous NaCl, ice cold Sodium sulfate, anhydrous 5′-Detritylated oligodeoxyribonucleotide bound to a controlled-pore glass (CPG) support 2,2′-Dithiodipyridine Phenol Concentrated ammonium hydroxide 1 M triethylammonium acetate (TEAA) buffer, pH 7 (stock solution) Tris-(2-carboxyethyl)phosphine (TCEP), hydrochloride
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
250-mL three-necked round-bottom flask Reflux condenser Magnetic stirrer with heating element Kieselgel 60F plates for analytical TLC (Merck) Rotary evaporator with a water aspirator Calcium chloride drying tube
4.9.14 Supplement 5
Current Protocols in Nucleic Acid Chemistry
3 × 50–cm chromatography column containing 40 g silica gel (e.g., Kieselgel 60; Merck) and 1.6 × 45–cm column containing 25 g silica gel 10-mL vial and stoppers Separatory funnel Spectrophotometer Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D); column chromatography (APPENDIX 3E); direct addition of an acridinyl phosphoramidite (UNIT 4.3); and analysis, purification, and characterization of product (see Basic Protocol 1) Prepare diphenylthiophosphinate salt S.13 1. Place 3 g (13.8 mmol) methyldiphenylphosphinite S.11 and 60 mL toluene in a 250-mL three-necked round-bottom flask equipped with a reflux condenser and a magnetic stir bar. Add 883 mg (27.6 mmol) S8 slowly to the stirring solution at room temperature. The reaction is slightly exothermic.
2. Heat suspension at 50°C and monitor reaction by analytical TLC (APPENDIX 3D) and UV shadowing using 90:10:4 (v/v/v) hexane/ethyl acetate/triethylamine as eluent. Spray the plate with 2.5 mg/mL DBPNC in ethanol and heat until color appears. The sulfur-containing compound S.12 (Rf = 0.43) gives a pink-colored spot on the TLC plate after treatment with DBPNC. The starting material S.11 (Rf = 0.70) appears as a white spot.
3. After the reaction is complete (1 to 2 hr), allow reaction mixture to cool to room temperature, filter through celite 521, and concentrate under reduced pressure using a rotary evaporator with a water aspirator. Yield 85% (2.92 g, 11.78 mmol). White solid. 31P-NMR (CDCl3), δ: 85.85 ppm. 1H-NMR (CDCl3), δ: 3.75 (d, 3H, J = 12.2 Hz, OCH3), 7.41-7.53 (m, 6H, Ar), 7.81-7.91 (m, 4H, Ar). 13C-NMR (DMSO-d6), δ: 56.81, 134.44, 136.21, 137.70. Mass analysis. ESI-MS polarity positive. Calcd. for C13H13OSP: 248; found: 249 (M+H).
4. Add 2 g (8.05 mmol) methyldiphenylthionophosphinate S.12 to 50 mL of 20% trimethylamine/acetonitrile in a 100-mL flask equipped with a stirring bar. Stopper the flask and stir 2 to 3 days at room temperature, monitoring the reaction by analytical TLC and UV shadowing, with 9:1 (v/v) hexane/ethyl acetate as eluent. A white precipitate appears (Rf = 0) and the starting material (Rf = 0.40) disappears. The reaction can be faster if performed at higher temperature (50°C for 10 hr) in a sealed reactor.
5. Filter precipitate by vacuum filtration and wash with 5 mL ice-cold diethyl ether. Analyze S.13 by TLC using 85:10:5 (v/v/v) CH2Cl2/methanol/triethylamine as eluent (Rf = 0.72). Yield 95% (2.35g, 7.65 mmol). 31P-NMR (DMSO-d6), δ: 52.36 ppm. 1H-NMR (DMSO-d6), δ: 3.06 (s, 12H, NMe4), 7.16-7.20 (m, 6H, Ar), 7.70-7.76 (m, 4H, Ar). 13C-NMR (DMSO-d6), δ: 59.85, 132.34, 133.42, 135.97. Mass analysis. ESI-MS polarity positive. Calcd. for C12H10OSP: 233; found: 235 (M+H).
Prepare 2-[2-(2-iodoethoxy)ethoxy]ethanol 6. Place the following in a 250-mL round-bottom flask equipped with a reflux condenser and magnetic stirring bar:
Synthesis of Modified Oligonucleotides and Conjugates
4.9.15 Current Protocols in Nucleic Acid Chemistry
Supplement 7
4 g (24 mmol) 2-[2-(2-choroethoxy)ethoxy]ethanol S.15 14.96 g (100 mmol) NaI 8.36 g (100 mmol) NaHCO3 140 mL anhydrous acetone. 7. Heat at 60°C until the reaction is complete. Monitor reaction by analytical TLC using 9:1 (v/v) CH2Cl2/methanol as eluent. After one night (5 to 6 hr) the starting chlorinated material (Rf = 42) is transformed into the iodinated compound (Rf = 0.56).
8. Remove solid by filtration and evaporate solvent under reduced pressure using a rotary evaporator with a water aspirator. 9. Precipitate excess NaI by adding 8 mL CH2Cl2. Remove solid by filtration and evaporate solvent under reduced pressure. Repeat for a total of four times with 8 mL CH2Cl2 and two times with 10 mL diethyl ether. Take care to use diethyl ether free of peroxides. Yield 83% (4.94 g, 19.9 mmol). Mass analysis ESI-MS polarity positive. Calcd. for C6H3IO3: 260; found: 261 (M+H). This compound can be prepared in advance and stored for months at –20°C.
Prepare S-diphenylphosphinate derivative 7a 10. Place 1 g (3.25 mmol) diphenylthiophosphinate salt S.13, 1.01 g (3.9 mmol) 2-[2-(2iodoethoxy)ethoxy]ethanol, and 30 mL anhydrous CH3CN in a 50-mL flask equipped with a magnetic stirring bar, reflux condenser, and a calcium chloride drying tube. Allow reaction to proceed 15 hr at 50°C. 11. Allow the mixture to cool, remove solid by filtration, and concentrate the solution to dryness. 12. Purify the residue S.14 (2 g) on a 3 × 50–cm column containing 40 g silica gel (APPENDIX 3E), using 100 mL each of 0% to 5% (v/v) methanol in CH2Cl2 in 1% increments. Elute under slight pressure of nitrogen. The pressure must be adjusted until the solvent elutes from the bottom of the column at ~3 drops/sec. Yield 70% (0.834g, 2.27 mmol). 1H-NMR (CDCl3), δ: 2.95-3.03 (2H, m, CH2S), 3.58-3.63 (6H, m, CH2O), 3.68-3.74 (4H, m, CH2O), 7.45-7.58 (6H, m, Ar), 7.85-7.92 (4H, m, Ar). 31 P-NMR (CDCl3), δ: 45.40 ppm. 13C-NMR (DMSO-d6), δ: 33.77, 65.64, 75.05, 77.78, 134.42, 136.35, 138.02. Mass analysis. ESI-MS polarity positive. Calcd. for C18H23O4SP: 366; found: 367 (M+H).
13. Dry S.14 by three rounds of coevaporation with 10 mL anhydrous CH3CN and leave under vacuum overnight. 14. Add 0.317 g (0.426 mL, 2.45 mmol) diisopropylethylamine to a solution of 0.30 g (0.82 mmol) S.14 in 5 mL CH2Cl2. Cool in an ice-water bath. 15. Add 0.23 mL (1.02 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite dropwise to the cold solution via a syringe under a nitrogen atmosphere. Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
16. Monitor reaction by analytical TLC and by UV shadowing, using 70:30:4 (v/v/v) ethyl acetate/hexane/triethylamine as eluent. Pre-elute the plate once with eluent, and then load 1 to 2 µl reaction mixture and elute.
4.9.16 Supplement 7
Current Protocols in Nucleic Acid Chemistry
After 15 to 20 min the starting material (Rf = 0.15) is completely transformed into compound S.7a (Rf = 0.31). TLC using 95:5 (v/v) ethyl acetate/triethylamine gives Rf = 0.33 for the starting material and Rf = 0.70 for the phosphoramidite derivative.
17. When the reaction is complete (15 to 20 min), dilute the reaction mixture with 45 mL ethyl acetate and wash the organic phase twice with 3 mL of 10% aqueous Na2CO3, and twice with 3 mL ice-cold saturated aqueous NaCl solution, using a separatory funnel. 18. Dry organic phase over 15 g sodium sulfate and evaporate to dryness under reduced pressure. 19. Purify the oily residue S.7a (0.8 g) on a 1.6 × 45–cm column containing 25 g silica gel, using 95:5 (v/v) ethyl acetate/triethylamine as eluent. Elute under slight pressure of nitrogen. Store up to two years (or more) at −20°C under argon. The pressure must be adjusted until the solvent elutes from the bottom of the column at ~2 drops/sec. Yield 75% (0.50 g, 0.61 mmol). 31P-NMR (CDCl3), δ: 39.13 and 144.11 ppm. 1H-NMR (CDCl3), δ: 1.13-1.16 (m, 12H, [CH(CH3)2]2), 2.59-2.62 (m, 2H, CH2CN), 2.93-2.98 (m, 2H, CH2SP), 3.51-3.65 (m, 8H, CH2O + CH2OP), 3.65-3.69 (m, 1H), 3.70-3.83 (m, 2H, CH2OP), 3.66-3.70 (m, 1H, C(H)), 7.43-7.47 (m, 4H, Ar), 7.50-7.52 (m, 2H, Ar), 7.83-7.88 (m, 4H, Ar). 13C-NMR (DMSO-d6), δ: 25.25, 29.79, 33.77, 47.87, 63.64, 67.80, 75.00, 75.92, 134.42, 135.51, 138.00. Mass analysis. ESI-MS polarity positive. Calcd. for C27H40N2O5SP2: 566; found: 568 (M+H).
Add masked thiol function to oligonucleotide 20. Couple the phosphoramidite S.7a to the 5′-terminal hydroxyl of a fully protected oligodeoxyribonucleotide bound to a CPG support according to the method described for direct addition of an acridinyl phosphoramidite (UNIT 4.3, steps 15a to 17b of Basic Protocol 1). Deprotect and remove from support 21. Place 1 µmol of the oligodeoxyribonucleotide bound to the support in a 10-mL vial and add successively: 26 mg (0.118 mmol, 120 eq) 2,2′-dithiodipyridine 17 mg (0.179 mmol, 10 eq/phosphate) phenol 3 mL methanol 3.5 mL concentrated ammonium hydroxide. Allow to stand at room temperature for 60 hr. 22. Remove support by vacuum filtration. Wash support successively with 1 mL concentrated ammonium hydroxide, 1 mL water, 1 mL methanol. Pool the original filtrate and the three washes and concentrate them under reduced pressure. 23. Add 6 mL water to the residue and extract four times with 4 mL ethyl acetate to remove organic contaminants. 24. Analyze, purify and characterize the product S.10 as described (see Basic Protocol 1, steps 12 to 17). Store up to two years (or more) at −20°C in a tightly sealed container. Yield: 35-40 OD260 units. Ion-exchange chromatography on a DEAE column using conditions described in Basic Protocol 1 gives retention times of 52 min for C5H5N-S-S-CH2CH2-(OCH2CH2)2-pd[CTCTCGCACCCATCTCTC], and 50 min 36 sec for d[CTCTCGCACCCATCTCTC]. Figure 4.9.13 shows a chromatogram obtained for crude C5H5N-S-S-CH2CH2(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC].
Synthesis of Modified Oligonucleotides and Conjugates
4.9.17 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Figure 4.9.13 Ion-exchange chromatography on a DEAE column of crude C5H5N-S-S-CH2CH2(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] (see Basic Protocol 3).
RP-HPLC on a Lichrospher RP 18 column using conditions described in Basic Protocol 1 gives retention times of 15 min 14 sec for C5H5N-S-S-CH2CH2-(OCH2CH2)2-pd[CTCTCGCACCCATCTCTC], and 9 min 40 sec for d[CTCTCGCACCCATCTCTC]. See Figure 4.9.14. Mass analysis. ESI-MS polarity negative. Calcd. for C182H238N56O114P18S2: 5652 Da; found: 5651 Da (M-H). The presence of the pyridyldisulfide group at the 5′ end of the oligomer can be detected by reductive cleavage of the disulfide bridge with dithiothreitol or tris-(2-carboxyethyl)phosphine, as described below. The 2-pyridinethione that is released can be detected spectrophotometrically at 343 nm (Carlsson et al., 1978).
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
Figure 4.9.14 RP-HPLC on a Lichrospher RP 18 column of crude C5H5N-S-S-CH2CH2(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] (see Basic Protocol 3).
4.9.18 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Figure 4.9.15 Absorption spectra of a solution of C5H5N-S-S-CH2CH2-(OCH2CH2)2-pd[CTCTCGCACCCATCTCTC] before (broken line) and after (solid line) reduction of the disulfide bridge (see Basic Protocol 3).
Verify presence of pyridyldisulfide group 25. Prepare an oligonucleotide solution in 0.1 M TEAA buffer, pH 7, that gives an absorbance of ∼0.5 or 1 OD260. Record the absorption spectrum of this solution between 220 and 450 nm using the same buffer as a reference. 26. Add 10 eq TCEP (dissolved in 5 µl water) to both the sample and reference. Wait 30 min and record the absorption spectrum again. A new absorption band is observed, corresponding to the 2-pyridinethione released (λmax = 343 nm). Knowing the ε value of the oligonucleotide at 260 nm, the absorbance ratio at 260 and 343 nm allows one to determine the quantity of 2-pyridyldisulfide group present in oligonucleotide S.10. Figure 4.9.15 illustrates results from this procedure applied to the oligonucleotide C5H5N-S-S-CH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC].
ADDITION OF A MASKED THIOL GROUP TO THE 5′ TERMINUS OF OLIGODEOXYRIBONUCLEOTIDES USING AN S-ACETYL PHOSPHORAMIDITE
ALTERNATE PROTOCOL 1
This protocol is a modification of the strategy in Basic Protocol 3 (Fig. 4.9.11, left side) that adds an S-acetyl phosphoramidite S.8a to the 5′ terminus of the support-bound oligodeoxyribonucleotide. The alcohol S.16, which is required for the preparation of S.8a (Fig. 4.9.16), is obtained in one step by reaction of 2-[2-(2-chloroethoxy)ethoxy]ethanol S.15 with potassium thioacetate. This procedure is a shortened version of that described by Kuijpers and Van Boeckel (1993). The synthesis can also be started with 2-[2-(2-iodoethoxy)ethoxy]ethanol, which is prepared as described in Basic Protocol 3. However, S.15 is commercially available and thus more convenient. Additional Materials (also see Basic Protocol 3) Potassium thioacetate 1.6 × 45–cm column containing 20 g silica gel (e.g., Kieselgel 60; Merck)
Synthesis of Modified Oligonucleotides and Conjugates
4.9.19 Current Protocols in Nucleic Acid Chemistry
Supplement 7
OH Cl
L
O
+
CH3C(O)SK
H3C
L
S
OH
16
15
i-Pr2NP(Cl)OCH2CH2CN
i-Pr2N
O H3C
DIPEA
S
L
O
P
OCH2CH2CN
8a
Figure 4.9.16 Preparation of the S-acetyl phosphoramidite derivative S.8a. DIPEA, diisopropylethylamine; L, CH2CH2OCH2CH2OCH2CH2.
Synthesize 2-[2-(2-acetylthioethoxy)ethoxy]ethanol S.16 1. Add 2 g (1.72 mL, 11.86 mmol) 2-[2-(2-chloroethoxy)ethoxy]ethanol S.15 to 2 g (17.5 mmol) potassium thioacetate and 35 mL anhydrous acetone in a 25-mL flask equipped with a reflux condenser and a magnetic stirring bar. 2. Heat the stirred mixture 12 hr at 50°C. 3. Allow the mixture to cool to room temperature. 4. Filter off the white precipitate and concentrate the filtrate under reduced pressure. 5. Purify the residue S.16 (2.4 g) on a 3 × 50–cm column containing 40 g silica gel (APPENDIX 3E) using a gradient of 98:2 to 9:1 (v/v) ethyl acetate/methanol. Elute under slight pressure of nitrogen. The pressure must be adjusted until the solvent elutes from the bottom of the column at ~2 to 3 drops/sec.
6. Perform analytical TLC (APPENDIX 3D) using 8:2 (v/v) ethyl acetate/hexane as eluent. Spray plate with 2.5 mg/mL DBPNC in ethanol and heat until the color appears. A pale yellow spot (Rf = 0.41) appears on the TLC plate after treatment with DBPNC. Yield 80% (1.97g, 9.48 mmol). 1H-NMR (CDCl3): δ: 3.73 (2H, m, CH2OH), 3.70-3.55 (8H, m, 4(CH2O)), 3.11 (2H, t, CH2S). 13C-NMR (DMSO-d6), δ: 34.49, 35.80, 36.72, 66.43, 75.12, 75.88, 78.56, 201.33. Mass analysis. ESI-MS polarity positive. Calcd. for C8H16O4S: 208; found: 209 (M+H).
Prepare S-acetyl phosphoramidite derivative S.8a 7. Dry 0.208 g (1 mmol) S.16 by three rounds of coevaporation with 5 mL anhydrous CH3CN and leave under vacuum overnight. 8. Add 0.387 g (0.522 mL, 3 mmol) diisopropylethylamine to a solution of 0.208 g (1 mmol) S.16 in 5 mL CH2Cl2. Cool in an ice-water bath. 9. Add 0.30 mL (1.3 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite dropwise to the cold solution via syringe under a nitrogen atmosphere.
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
10. Monitor reaction by analytical TLC using 80:20:4 (v/v/v) hexane/ethyl acetate/triethylamine as eluent. Pre-elute the TLC plate once with the eluent, then load 1 to 2 µl reaction mixture and elute. After 15 min, the starting material (Rf = 0.38) is completely transformed into compound S.8a (Rf = 0.70).
4.9.20 Supplement 7
Current Protocols in Nucleic Acid Chemistry
11. When the reaction is complete, dilute the reaction mixture with 45 mL ethyl acetate and wash the organic phase twice with 3 mL of 10% aqueous Na2CO3 and then twice with ice-cold saturated aqueous NaCl using a separatory funnel. 12. Dry the organic phase over 15 g sodium sulfate and evaporate it to dryness under reduced pressure. 13. Purify the residue S.8a (0.45g) on a 1.6 × 45–cm column containing 20 g silica gel using 80:15:5 (v/v/v) hexane/ethyl acetate/triethylamine as eluent. Elute under slight pressure of nitrogen. Store up to two years (or more) at −20°C under argon. The pressure must be adjusted until the solvent elutes from the bottom of the column at ~2 to 3 drops/sec. Yield 75% (0.306 g, 0.75 mmol). 31P-NMR (CDCl3), δ: 150.63 ppm. 1H-NMR (CDCl3), δ: 1.15-1.19 (m, 12H, [CH(CH3)2]2), 2.33 (s, 3H, CH3), 2.64 (t, 2H, J = 6.56 Hz, CH2CN), 3.08 (t, 2H, J = 6.40 Hz, CH2S) 3.57-3.72 (m, 12H, CH2O), 3.74-3.84 (m, 2 CH). Mass analysis. ESI-MS polarity positive. Calcd. for C17H33O5SN2P: 408; found: 409 (M+H).
Add masked thiol function to oligonucleotide 14. Couple the phosphoramidite S.8a to the oligonucleotide and then deprotect, purify, and characterize the product S.10 as described (see Basic Protocol 3, steps 20 to 26). Yield: 40-50 OD260 units. ALTERNATE PROTOCOL 2
ADDITION OF A MASKED THIOL GROUP TO THE 5′ TERMINUS OF OLIGODEOXYRIBONUCLEOTIDES USING A DISULFIDE PHOSPHORAMIDITE DERIVATIVE The second strategy for adding a masked thiol group to the 5′ end of an oligodeoxyribonucleotide is shown in the right side of Figure 4.9.11. The masked thiol is incorporated using a tritylated alkyl disulfide–containing linker (S.9a), which allows full deblocking of the oligodeoxyribonucleotide but not the thiol function. The 4,4′-dimethoxytrityl (DMTr) group makes it possible to monitor the incorporation yield of the linker, and facilitates the purification of the 5′-derivatized oligodeoxyribonucleotide. The phosphoramidite S.9a is obtained via a four-step procedure (Fig. 4.9.17) starting from of 2-[2-(2-acetylthioethoxy)ethoxy]ethanol S.16, which was prepared in Alternate Protocol 1. First, alkali treatment removes the acetyl group to release a thiol-containing linker (S.17), which dimerizes in contact with oxygen in the air (S.18). The dimerized linker is
O H3C
S
L
NH4OH OH
16
OH HS L
O2
HO L
S
17
S
L
OH
18 DMTrCl
i-Pr2N DMTrO
S S
L
O
L
P
i-Pr2NP(Cl)OCH2CH2CN OCH2CH2CN
9a
DIPEA
DMTrO L
S
S
L
OH
19
Figure 4.9.17 Preparation of the tritylated disulfide phosphoramidite derivative S.9a. DIPEA, diisopropylethylamine; DMTr, 4,4′-dimethoxytrityl; L, CH2CH2OCH2CH2OCH2CH2.
Synthesis of Modified Oligonucleotides and Conjugates
4.9.21 Current Protocols in Nucleic Acid Chemistry
Supplement 5
monotritylated (S.19) and then phosphinylated to give the phosphoramidite S.9a. This procedure is a shortened version of that described by Bonfils and Thuong (1991). Additional Materials (also see Basic Protocols 1, 2, and 3) 2-[2-(2-Acetylthioethoxy)ethoxy]ethanol S.16 (see Alternate Protocol 1) 5% ammonium hydroxide Anhydrous pyridine Dimethoxytrityl chloride (DMTr⋅Cl) 10% perchloric acid MgSO4 80% (v/v) acetic acid Ethanol 1 M triethylammonium acetate (TEAA) buffer, pH 6 (stock solution) Dithiothreitol (DTT) Methanol, HPLC grade 1.6 × 45–cm chromatography column containing 20 g silica gel (e.g., Kieselgel 60; Merck) 10-mL gel-filtration column Lyophilizer Additional reagents and equipment for gel-filtration chromatography Prepare dihydroxylated disulfide S.18 1. Solubilize 2-[2-(2-acetylthioethoxy)ethoxy]ethanol S.16 (1 g, 4.80 mmol) in 2 mL of 5% ammonium hydroxide. Magnetically stir the resulting thiol S.17 and allow to dimerize to the disulfide S.18 upon contact with air. 2. Monitor reaction by analytical TLC (APPENDIX 3D) using 9:1 (v/v) CH2Cl2/methanol as eluent. Spray with 2.5 mg/mL DBPNC in ethanol and heat until the color appears. The starting material (Rf = 0.54) appears as a pale-yellow colored spot on the TLC plate after treatment with DBPNC. The thiol derivative S.17 (Rf = 0.50) appears as a brown-colored spot, and its disulfide S.18 (Rf = 0.34) as an intense yellow spot.
3. When the reaction is complete (usually 24 hr), concentrate the mixture and purify the residue (1 g) by flash chromatography (APPENDIX 3E) on a 3 × 50–cm column containing 40 g silica gel using increasing concentrations of methanol in CH2Cl2 (0% to 6%) as eluent. Elute under slight pressure of nitrogen. Monitor elution by TLC. The pressure must be adjusted until the solvent elutes from the bottom of the column at ~2 to 3 drops/sec. Yield: 40% (0.633 g, 1.92 mmol).
Prepare tritylated disulfide S.19 4. Dry 0.7 g (2.09 mmol) S.18 by three rounds of coevaporation with 10 mL anhydrous pyridine and keep it stirring in 5 mL anhydrous pyridine under a nitrogen atmosphere. 5. Cool solution to 5° to 10°C and add 0.18 g (0.53 mmol) DMTr⋅Cl. 6. Allow solution to warm to room temperature. Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
7. Monitor reaction by analytical TLC using 9:1 (v/v) CH2Cl2/methanol as eluent. Spray the plate with 10% perchloric acid.
4.9.22 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Upon spraying the plate with perchloric acid, two orange-colored spots are obtained, corresponding to the monodimethoxytritylated compound S.19 (Rf = 0.65) and the bis-dimethoxytritylated compound (Rf = 0.95).
8. When the reaction is complete (6 to 8 hr), remove the solvent by evaporation under reduced pressure. 9. Dilute the residue with 10 mL CH2Cl2 and wash twice with 3 mL saturated aqueous NaCl and then twice with 3 mL water using a separatory funnel. 10. Dry the organic layer over MgSO4 and concentrate it to dryness. 11. Purify the residue S.19 (0.85 g) by chromatography on a 3 × 50–cm column containing 40 g silica gel using increasing concentrations of methanol in CH2Cl2 (0% to 4%) as eluent. Elute under slight pressure of nitrogen. Monitor elution by TLC. The pressure must be adjusted until the solvent elutes from the bottom of the column at ~2 to 3 drops/sec. Yield 75% (0.250 g, 0.397 mmol). 1H-NMR (CDCl3), δ: 2.80-2.92 (m, 4H, CH2S), 3.23 (t, J = 5.18 Hz, 2H), 3.58-3.80 (m, 18H, CH2O), 3.82 (s, 6H, OCH3), 6.80-7.47 (m, 13H, Ar). 13 C-NMR (DMSO-d6): δ: 35.14, 40.79, 43.40, 54.07, 60.48, 65.70, 68.35, 74.13, 75.20, 75.51, 77.83, 90.79, 118.61, 132.08, 133.23, 135.15, 141.28, 150.49, 163.51. Mass analysis. ESI-MS polarity positive. Calcd. for C33H44O8S2: 632; found 633 (M+H).
Prepare tritylated disulfide phosphoramidite derivative S.9a 12. Dry 0.30 g (0.47 mmol) S.19 by three rounds of coevaporation with 6 mL anhydrous CH3CN and leave under vacuum overnight. 13. Add 0.183 g (0.248 mL, 1.42 mmol) diisopropylethylamine to a solution of 0.30 g (0.47 mmol) S.19 in 4 mL CH2Cl2. Cool in an ice-water bath. 14. Add 0.137 mL (0.61 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite dropwise to the cold solution via a syringe under a nitrogen atmosphere. 15. Monitor reaction by analytical TLC using 50:50:4 (v/v/v) ethyl acetate/hexane/triethylamine as eluent. Pre-elute the TLC plate once with the eluent, then load 1 µl reaction mixture and elute. Visualize by UV shadowing and trityl detection. After 20 min the starting material (Rf = 0.15) is completely tranformed into the phosphoramidite S.9a (Rf = 0.59).
16. When the reaction is complete, dilute reaction mixture with 30 mL ethyl acetate and wash the organic phase twice with 3 mL of 10% aqueous Na2CO3 and then twice with 3 mL ice-cold saturated aqueous NaCl using a separatory funnel. 17. Dry the organic phase over sodium sulfate and concentrate it to dryness under reduced pressure. 18. Purify the oily residue S.9a (0.4 g) on a 1.6 × 45–cm column containing 20 g silica gel using 50:50:4 (v/v/v) ethyl acetate/hexane/triethylamine as eluent. Elute under slight pressure of nitrogen. Store up to two years (or more) at −20°C under argon. Yield 75% (0.293 g, 0.352 mmol). 31P-NMR (CDCl3), δ: 150.48 ppm. 1H-NMR (CDCl3), δ: 1.16-1.24 (m, 12H, [CH(CH3)2]2), 2.80 (t, 2H, J = 6 Hz, CH2CN), 3.20-3.24 (m, 4H, CH2S), 3.58-3.83 (m, 20H, CH2O, CH2OP +2 CH), 3.75 (s, 6H, OCH3), 6.80-7.47 (m, 13H, Ar). Mass analysis. ESI-MS polarity positive. Calcd. for C42H62O9S2N2P: 831; found: 832 (M+H).
Couple masked thiol function to oligonucleotide 19. Couple tritylated disulfide phosphoramidite S.9a to the 5′-terminal hydroxyl of a fully protected oligodeoxyribonucleotide bound to a CPG support according to the
Synthesis of Modified Oligonucleotides and Conjugates
4.9.23 Current Protocols in Nucleic Acid Chemistry
Supplement 7
method described for direct addition of an acridinyl phosphoramidite (UNIT 4.3, steps 15a to 17b of Basic Protocol 1). Detritylating a small amount of the support-bound oligonucleotide allows one to verify the coupling efficiency and, if necessary, to perform a second coupling to improve the yield.
20. Deprotect the oligodeoxyribonucleotide S.9b (Fig. 4.9.11) as described for the deprotection of the oligodeoxyribonucleotides with 5′-bis-(2-cyanoethyl)phosphate groups (see Basic Protocol 2, steps 8 to 11, of this unit) but without DTT in step 8. 21. Analyze, purify, and characterize the tritylated disulfide-containing oligodeoxyribonucleotide S.9c as described (see Basic Protocol 1, steps 11 to 17). Yield: 40-50 OD260 units. Ion-exchange chromatography on DEAE using conditions described in Basic Protocol 1 gives retention times of 52 min 12 sec for DMTrOCH2CH2-(OCH2CH2)2-S-S-CH2CH2(OCH2CH2)2- p- d[C TCTC GCAC CCATCCTC] and 50 min 36 sec for d[CTCTCGCACCCATCTCTC]. Figure 4.9.18 shows a chromatogram obtained for crude DMTrOCH2CH2-(OCH2CH2)2-S-S-CH2 CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC]. RP-HPLC on a Lichrospher RP 18 column using a linear gradient of CH3CN (5% to 50% over 60 min) in 0.1 M TEAA buffer, pH 7, at 1 mL/min gives retention times of 32 m i n 2 6 sec for DMTrOCH2CH2-(OCH2CH2)2-S-S-CH2CH2-(OCH2CH2)2-pd[CTCTCGCACCCATCTCTC] and 12 min for d[CTCTCGCACCCATCTCTC]. Figure 4.9.19 shows a chromatogram obtained for crude DMTrOCH2CH2-(OCH2CH2)2-S-SCH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC]. An additional peak with a retention time of 13 min 40 sec has been identified as the detritylated oligonucleotide HOCH2CH2-(OCH2CH2)2-S-S-CH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC]. Mass analysis. ESI-MS polarity negative. HOCH2CH2-(OCH2CH2)2-S-S-CH2CH2(OCH2CH2)2- p-d[CTCTCGCACCCATCTCTC]. Calcd. for C182H247N55O117S2P18: 5699; found: 5697 ± 4 (M-H). Sometimes a significant amount of detritylation occurs when handling the functionalized oligonucleotide. In this case, it is best to detritylate prior to purification by adding 4 mL of 80% acetic acid to the tritylated oligonucleotide. After 20 to 30 min incubation at room temperature, the acetic acid is removed by evaporation under reduced pressure. The residue
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
Figure 4.9.18 Ion-exchange chromatography on a DEAE column of crude DMTrO-CH2CH2(OCH2CH2)2-S-S-CH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] (see Alternate Protocol 2).
4.9.24 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Figure 4.9.19 RP-HPLC on a Lichrospher RP 18 column of crude DMTrO-CH2CH2-(OCH2CH2)2S-S-CH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] (see Alternate Protocol 2).
is then coevaporated three times with 4 mL ethanol, dissolved in 4 mL water, and extracted three times with 4 mL ethyl acetate. The purity of the detritylated oligonucleotide is verified by RP-HPLC using a linear gradient of CH3CN (0% to 30% over 60 min) in 0.1 M TEAA, pH 7, at 1 mL/min. If required, further purification is performed by RP-HPLC. When the modified oligodeoxyribonucleotide is purified at the tritylated step, detritylation should be performed before storage to avoid loss of trityl, resulting in a mixture of products. When transformation into oligomer S.10 is performed immediately after purification, the tritylated compound can be used. The chromatography data given above is for the tritylated compound; mass data is for detritylated product.
Transform disulfide-containing oligodeoxyribonucleotide into oligomer S.10 22. Prepare a solution of 10 OD260 units S.9c in 1 mL of 0.05 M TEAA buffer, pH 6. 23. Add 30 eq DTT or 3 eq TCEP and monitor cleavage of the disulfide bridge by RP-HPLC on an RP 18 column using the conditions described above (see Basic Protocol 1, step 14b). The thiol-containing oligodeoxyribonucleotide HS-CH2CH2-(OCH2CH2)2-pd[CTCTCGCACCCATCTCTC] is eluted first (11 min 30 sec) while the oligonucleotide containing the disulfide linker, HOCH2CH2-(OCH2CH2)2-S-S-CH2CH2-(OCH2CH2)2-pd[CTCTCGCACCCATCTCTC], is eluted ~2 min later (13 min 25 sec).
24. When the reaction is complete (overnight), extract excess DTT five times using 1 mL ethyl acetate. It is not necessary to remove the excess TCEP.
25. Load aqueous solution on a 10-mL gel-filtration column and elute with 0.05 M TEAA buffer, pH 6. Collect oligodeoxyribonucleotide in a solution containing 20 eq of 2,2′-dithiodipyridine in 2 mL HPLC-grade methanol. Monitor the elution of the oligonucleotide spectrophotometrically at 260 nm. The choice of Sephadex G-10 or G-25 depends on the molecular weight of the oligodeoxyribonucleotide. The oligonucleotide is usually eluted in the void volume (∼3 to 4 mL).
26. Allow eluent/dithiodipyridine/methanol mixture to incubate for 5 to 6 hr. 27. Remove methanol by evaporation, and extract excess 2,2′-dithiodipyridine four times using 2 mL ethyl acetate.
Synthesis of Modified Oligonucleotides and Conjugates
4.9.25 Current Protocols in Nucleic Acid Chemistry
Supplement 5
28. Verify formation of 2-pyridyldisulfide by RP-HPLC on RP 18 column using the conditions described (see Basic Protocol 1, step 14b). The 2-pyridyldithioalkylated oligodeoxyribonucleotide S.10 has a longer retention time (15 min 14 sec) than that of the mercaptoalkylated oligonucleotide (11 min 30 sec).
29. Purify the 5′-terminal 2-pyridyldithioalkylated oligodeoxyribonucleotide S.10 by RP-HPLC using the same column and conditions used for analysis. Purification can be achieved in three or four runs.
30. Remove organic solvent by evaporation and remove buffer by three consecutive lyophilizations. Store up to two years at −20°C in a tightly sealed container. Yield 60%. Mass analysis. ESI-MS polarity negative. Calcd. for C182H238N56O114P18S2: 5652 Da; found: 5651 Da (M-H).
COMMENTARY Background Information
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
This unit reports methods for the preparation of modified oligodeoxyribonucleotides containing 5′-terminal carboxyl, amino, phosphorothioate, phosphate, or masked thiol groups. These 5′-modified oligonucleotides may be used to prepare oligodeoxyribonucleotides covalently linked to a wide variety of molecules such as labels, intercalating agents, and reactive compounds, a number of which are reported in UNIT 4.10. The methods developed in this unit can be used to prepare 5′-modified oligodeoxyribonucleotides built with natural β-deoxyribonucleosides, phosphorothioate phosphodiesters (Aubert et al., 2000), unnatural α-D-deoxyribonucleosides (Kurfürst et al., 1993), or 2′-O-methyldeoxyribonucleosides. Given that oligodeoxyribonucleotides can be purchased fully protected and bound to a support, 5′-end modification can be performed manually. When oligonucleotide synthesis is performed in the 5′→ 3′ orientation as in the case of N3′→P5′ phosphoramidates, 5′-derivatization can be achieved using a support bearing either the ligand or the masked functional group. These methods can also be adapted to oligonucleotides containing modified nucleosides, but it must be verified that the conditions required for deprotection are compatible with the stability of the modified nucleosides. For oligoribonucleotides and modified oligonucleotides that are sensitive to basic conditions, it is recommended to introduce 5′-phosphate and 5′-thiophosphate groups enzymatically (Eckstein, 1983). Alternate methods reported by Grimm et al. (2000) use the properties of a terminal phosphomonoester group for the introduction of linkers ending with amino, carboxyl, or sulfhydryl functions into unprotected oligonu-
cleotides. These methods are mainly limited to the introduction of either one functional group at one end or two identical functional groups at both ends of the oligonucleotide. In contrast, the methods reported in this unit, including the incorporation of masked functional groups prior to deprotection, allow the incorporation of a wide combination of functional groups into oligonucleotides for specific subsequent coupling of various ligands. Masked amine, sulfhydryl, and carboxyl can be introduced via a linker to various sites of the oligonucleotide chain: base, sugar, internucleotidic phosphate, and 3′ terminus (UNIT 4.5), as well as phosphate and thiophosphate at the 3′ terminus or thiophosphate at one or many internucleotidic positions during the assembly steps; these groups are released during deprotection. Amine and masked thiol or thiophosphate are compatible as well as masked thiol and amine in the phosphorothioate series (Aubert et al., 2000). The procedure for incorporation of a thiophosphate at the 5′ terminus can be modified to introduce a masked thiol group at the 3′ terminus by using a modified support (Bonfils and Thuong, 1991). Using the S-acetyl-containing linker S.16, synthesis of 25-mer oligodeoxyribonucleotide in the phosphorothioate series has been performed at a 10-µmol scale with very good yields (70 OD260 units per µmol).
Critical Parameters and Troubleshooting The success of these procedures is dependent on a number of critical parameters. The methods reported include either carbonyldiimidazole activation or the use of phosphoramidite chemistry, both of which are highly water sensitive. For these reasons, strictly anhydrous
4.9.26 Supplement 5
Current Protocols in Nucleic Acid Chemistry
solvents and solutions should be used as well as dry starting material. Precautions should be taken to exclude moisture, as well as oxygen in the case of the phosphoramidite derivatives. Phosphoramidites such as S.7a, S.8a, S.9a, and bis-(2-cyanoethyl)diisopropylamidophosphite, as well as most of the intermediate compounds used for their preparation, should be stored in tightly closed flasks or vials at –20°C under argon atmosphere. Cold flasks and vials should always be allowed to reach room temperature before they are opened, and vials should remain open as little as possible. To avoid low yields of oligonucleotides containing 5′-terminal functional groups, extreme care should be taken when using a syringe to remove solutions from vials containing the support-bound oligonucleotide in order to avoid unnecessary loss. After modification of the 5′ termini, it is recommended to deprotect an aliquot of the oligonucleotide conjugates to verify the efficiency of the reaction. In the case of the addition of the tritylated disulfide phosphoramidite S.9a, the coupling yield can be evaluated by quantitative trityl analysis performed as reported in UNIT 3.2. If the yield of 5′-modification is not sufficient, it is possible to perform an additional coupling step with the appropriate phosphoramidite derivatives. After 26 months storage of the tritylated disulfide phosphoramidite S.9a under the conditions described above, 5′-modification of an oligonucleotide has been performed on a µmol scale (by using 20 eq of S.9a) with 90% to 95% yield as determined by trityl quantification. This result indicates that, although the compound contains both a disulfide linkage and a tricoordinated phosphorus, it is unlikely to self-destruct to a large extent. This behavior differs from that of TCEP used to reduce the disulfide bond, probably for the following reasons: (1) the reducing properties of the phosphoramidite derivatives are weaker than those of the TCEP derivative; (2) the reductive cleavage of the disulfide linkage by TCEP requires the presence of one water molecule (Burns et al., 1991) and it is unlikely that 1 eq of water can be present in the stock of phosphoramidite S.9a; (3) the oligoethylene glycol linker can adopt a crown ether–like structure that prevents close proximity of the disulfide linkage and the tricoordinated phosphorus. After deprotection and before loading chromatography columns, organic impurities are extracted from crude oligodeoxyribonucleotide solutions with organic solvents. Oligodeoxyribonucleotide solutions must be fil-
tered through a 0.45-µm disposable filter to remove any particulates and prevent the clogging of analytical chromatography columns. In order to prevent chelation of phosphorothioate oligodeoxyribonucleotides, all solvents and buffer solutions used for their purification must be passed through a column of Chelex 100 resin (Bio-Rad) to remove divalent cations. The crude oligodeoxyribonucleotides obtained from these protocols are purified by ion-exchange chromatography on Mono Q (Amersham Pharmacia Biotech) and DEAE (Waters) columns. After a desalting step, the purity of these oligonucleotides is verified on a Lichrospher 100 RP column. When purified by ion-exchange chromatography, oligodeoxyribonucleotides containing 5′-functional groups are, in most cases, sufficiently pure for subsequent coupling reactions with selected ligands. These purification procedures are suitable for 10- to 25-mers. They are not suitable for oligonucleotides that can form self-associated complexes such as G-tetrads. Purification of tritylated compounds such as the 5′-tritylated disulfide-containing oligonucleotide S.9c or the 2-pyridyldithioalkylated oligonucleotide S.10 can easily be carried out not only with a reversed-phase column but also with an ion-exchange column such as DEAE (Waters). In the latter case, the presence of a lipophilic group allows good separation between the full-length 5′-modified and 5′-unmodified oligodeoxyribonucleotides. For 5′sulfur-containing oligodeoxyribonucleotides, purification by RP-HPLC on a Lichrospher RP 18 column using a low gradient of CH3CN in TEAA buffer, pH 7, allows separation of 5′mercaptoalkylated and 5′-(2-pyridyldithioalkylated) oligodeoxyribonucleotides. For 5′carboxyalkylated or 5′-aminoalkylated oligodeoxyribonucleotides, the presence of the 5′-functional group can be verified by RPHPLC by comparison with unmodified oligodeoxyribonucleotides, which are eluted more quickly than their 5′-derivatized counterparts. The presence of the amino function on 5′-aminoalkylated oligodeoxyribonucleotides can be verified by TLC using ninhydrin. For oligodeoxyribonucleotide 5′-phosphates, the use of a Delta-Pak C4 or RP 18 HPLC column allows separation of unmodified oligodeoxyribonucleotides from 5′-phosphate-containing oligomers. Purification can be difficult when working with oligonucleotides containing particular sequences, e.g., stretches of G. The best solution may be to replace the difficult se-
Synthesis of Modified Oligonucleotides and Conjugates
4.9.27 Current Protocols in Nucleic Acid Chemistry
Supplement 5
quences, e.g., by replacing dG with 7-deaza-2′dG (Raynaud et al., 1996). Nuclease digestion of the conjugates and RP-HPLC analysis of the resulting monomers ascertain full removal of the protecting groups and base composition. Additional characterization can be made by matrix-assisted laser desorption/ionization MS (MALDI-MS) and electrospray ionization MS (ESI-MS). After purification and characterization, oligonucleotides should be lyophilized and stored in tightly closed vials at −20°C. Under these conditions, they are stable up to two years (or more).
Anticipated Results Protocols reported in this unit are given for syntheses at a 1-µmol scale. When purification requires only ion-exchange chromatography or RP-HPLC, yields of 25 to 45 OD260 units can be expected for oligonucleotides of medium size (12- to 16-mers). The 5′-modifications of oligonucleotides reported in this unit have also been performed at a 10-µmol scale with similar yields.
Time Considerations Provided that all reagents and materials required for each step are available, most of the procedures are simple and rapid. When all the phosphoramidite derivatives are ready to use, the time required to prepare one oligonucleotide modified at its 5′ terminus with a carboxylated or aminoalkylated linker, a phosphate, a thiophosphate, or a masked thiol group (including purification and characterization) is ∼1 week. The time required for the preparation of the S-acetyl phosphoramidite derivative S.8a and the tritylated disulfide phosphoramidite derivative S.9a is ∼3 days. The preparation of the S-diphenylphosphinate phosphoramidite derivative S.7a requires 1 week or more.
Literature Cited Aubert, Y., Bourgerie, S., Meunier, L., Mayer, R., Roche, A.-C., Monsigny, M., Thuong, N.T., and Asseline, U. 2000. Optimized synthesis of phosphorothioate oligodeoxyribonucleotides substituted with a 5′-protected thiol function and a 3′-amino group. Nucleic Acids Res. 28:818-825.
Modification of the 5′ Terminus of Oligodeoxyribonucleotides for Conjugation with Ligands
Bonfils, E. and Thuong, N.T. 1991. Solid-phase synthesis of 5′-3′-bifunctional oligodeoxyribonucleotides bearing a masked thiol group at their 3′-end. Tetrahedron Lett. 35:3053-3056. Burns, J.A., Butler, J.C., Moran, J., and Whitesides, G.M. 1991. Selective reduction of disulfides by tris(2-carboxyethyl)phosphine. J. Org. Chem. 56:2648-2650. Carlsson, J., Drevin, H., and Axen, R. 1978. Proteinthiolation and reversible protein-protein conjugation. Biochem. J. 173:723-737. Eckstein, F. 1983. Phosphorothioate analogues of nucleotides. Tools for investigation of biochemical processes. Angew. Chem. Int. Ed. Engl. 22:423-506. Gottikh, M., Asseline, U., and Thuong, N.T. 1990. Synthesis of oligonucleotides containing a carboxyl group at either their 5′-end or their 3′-end and their subsequent derivatization by an intercalating agent. Tetrahedron Lett. 31:6657-6660. Grimm, G.N., Boutorine, A.S., and Hélène, C. 2000. Rapid routes of synthesis of oligonucleotide conjugates from non-protected oligonucleotides and ligands possessing different nucleophilic or electrophilic functional groups. Nucleosides Nucleotides and Nucleic Acids 19:1943-1965. Kuijpers, W.H. and Van Boeckel, C.A. 1993. A new strategy for the solid-phase synthesis of 5′-thiolated oligodeoxyribonucleotides. Tetrahedron 49:10944-10944. Kurfürst, R., Roig, V., Chassignol, M., Asseline, U., and Thuong, N.T. 1993. Oligo-α-deoxyribonucleotides with a modified nucleic acid base and covalently linked to reactive agent. Tetrahedron 32:6975-6990. Raynaud, F., Asseline, U., Roig, V., and Thuong, N.T. 1996. Synthesis and characterization of O6modified deoxyguanosine-containing oligodeoxyribonucleotides for triple-helix formation. Tetrahedron 52:2047-2064. Thuong, N.T. and Asseline, U. 1991. Oligodeoxyribonucleotides attached to intercalators, photoreactive and cleavage agents. In Oligodeoxyribonucleotides and Analogues: A practical approach (F. Eckstein, ed.) pp. 283-308. IRL Press, Oxford. Wachter, L., Jablonski, J.A., and Ramachandran, K.L. 1986. A simple and efficient procedure for the synthesis of 5′-aminoalkyl oligonucleotides. Nucleic Acids Res. 14:7985-7994.
Contributed by Ulysse Asseline and Nguyen T. Thuong Centre de Biophysique Moléculaire, CNRS Orléans, France
We would like to express our appreciation to our past and present collaborators for their contribution to the development of varied oligonucleotide families over the past years. The work was supported by Rhône-Poulenc, Agence Nationale de Recherche contre le SIDA and Bio-Mérieux.
4.9.28 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Conjugation of 5′-Functionalized Oligodeoxyribonucleotides with Properly Functionalized Ligands
UNIT 4.10
This unit describes a collection of methods for the chemical attachment of reporter groups and various conjugate groups (e.g., intercalators, photoreactive agents, cleaving agents) to the 5′ terminus of oligodeoxyribonucleotides. Two strategies can be used. The first (described in UNIT 4.3) involves the direct addition of the ligand to the 5′ end of the oligodeoxyribonucleotide via its phosphoramidite or H-phosphonate derivative. This approach works well when there is a sufficient amount of the ligand and when its solubility and chemical stability are compatible with the conditions required for the preparation of the phosphoramidite or H-phosphonate derivative. In addition, the ligand should be stable under the conditions used for the coupling step and for the complete deprotection of the oligodeoxyribonucleotide, including its release from the support. The second strategy involves the incorporation of appropriate functional groups into both the ligand and the 5′ terminus of the oligodeoxyribonucleotide. Specific coupling of these reactants results in the formation of oligodeoxyribonucleotide conjugates. Using this strategy, several oligodeoxyribonucleotide conjugates can be prepared from only one oligodeoxyribonucleotide synthesis provided that the required amount for each conjugate is low. In this approach, appropriate functional groups on the ligand and oligonucleotide must be matched so that a conjugation reaction can be performed. This unit delineates methods used for the following coupling reactions: 5′-carboxylated oligonucleotides with aminoalkylated ligands (see Basic Protocol 1); 5′-aminoalkylated oligonucleotides with ligands that have been functionalized with an isothiocyanate or N-hydroxysuccinimidyl group (see Basic Protocol 2); oligonucleotide 5′-phosphorothioates with ligands functionalized with halogenoalkyl, 2-pyridyldithio, or iodoacetamidyl groups (see Basic Protocol 3); oligonucleotide 5′-phosphates with ligands functionalized with amino groups (see Basic Protocol 4); and 5′-mercaptoalkylated oligonucleotides with ligands functionalized with halogenoalkyl, 2-pyridiyldithio, or iodoacetamidyl groups (see Basic Protocol 5). The initial incorporation of these functional groups into the ligand and oligonucleotide has been described in UNITS 4.8 & 4.9, respectively. The ligands described in this unit are the intercalator 2-methoxy-6-chloro-9-aminoacridine, the photoreactive group psoralen, the cleaving reagent phenanthroline-Cu, and the label thiazole orange (UNIT 4.8). Alternatively, many labels carrying functional groups that react with 5′-thiol, 5′-terminal phosphorothioate, and 5′-amino groups are commercially available. Heterobifunctional reagents, which allow reactions with a thiol function and a primary amine, are also available from commercial sources. The latter compounds, listed in UNIT 4.2, are very useful when conjugates between the oligodeoxyribonucleotide and the ligand do not require a well-defined linker. The procedures reported in this unit are for 10- to 25-mer oligodeoxyribonucleotides derivatized at their 5′ termini by various ligands, and require that the sequences under consideration will not form self-associated complexes such as G-tetrads. Such oligonucleotide structures require a specific procedure that is not discussed in this unit. Purification can be improved by performing ion-exchange chromatography at pH 12 when the obligonucleotide-ligand conjugate is stable at the pH. Another solution to prevent the formation of G-tetrads is to partially replace 2′-deoxyguanosine with 7-deaza-2′-deoxyguanosine (Raymond et al., 1996) or with 7-chloro-7-deaza-2′-deoxyguanosine (Aubert et al., 2001). Contributed by Ulysse Asseline and Nguyen T. Thuong Current Protocols in Nucleic Acid Chemistry (2001) 4.10.1-4.10.23 Copyright © 2001 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.10.1 Supplement 7
CAUTION: All chemicals must be handled in a fume hood by personnel equipped with a laboratory coat, glasses, and gloves. NOTE: When purifying and handling phosphorothioate- or phenanthroline-containing oligodeoxyribonucleotides, it is necessary to mix solutions, buffers, and solvents with Chelex 100 resin in order to remove divalent cations. BASIC PROTOCOL 1
CONJUGATION OF 5′-CARBOXYLATED OLIGODEOXYRIBONUCLEOTIDES TO AMINOALKYLATED LIGANDS The conjugation of oligodeoxyribonucleotides containing a carboxyl group at the 5′ terminus with the primary amino function of a ligand (or with an amine-like function such as a hydrazine derivative) is accomplished in the presence of carbodiimide. It generally requires a large excess of both ligand and carbodiimide (100 to 500 eq). Usually the oligodeoxyribonucleotide is solubilized in buffer and the ligand is added to the solution in amine-free dimethylformamide (DMF) dimethylsulfoxide (DMSO). The procedure is illustrated in Figure 4.10.1, using the hydrazine derivative of Lucifer Yellow (LY) as an example. The coupling reaction is performed at pH 5.5 to 6 in order to prevent the modification of the nucleobase. At this pH, the hydrazine derivative remains reactive. When the coupling reaction is complete, as determined by thin-layer chromatography (TLC; APPENDIX 3D), the conjugate is isolated from the reaction mixture. Different strategies can be used depending on the solubility of the ligand in the solvent or mixture of solvents used to perform the conjugation reactions. A general procedure for analysis, purification, and characterization of conjugates is given for 10- to 25-mer non-self-associating oligodeoxyribonucleotides derivatized at the 5′ end by a variety of ligands.
−O C(CH ) NHC(O)O 2 2 m
B
O
RNHCO(CH2)mNHC(O)O
B
O
m = 4, 5 O
O RNH2
O P O− O
O
O P O−
EDC
B
O
B
O
O H
O
n
H
n
−O S 3 O
O
N
N NH H
R = LY = H2N −O 3S
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
O
Figure 4.10.1 Conjugation of 5′-carboxylated oligodeoxyribonucleotides with aminated ligands. Abbreviations: B, base (i.e., thymine, cytosine, adenine, or guanine); EDC, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride; LY, Lucifer Yellow (R).
4.10.2 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Materials Purified 5′-carboxylated oligodeoxyribonucleotide (UNIT 4.9) 0.5 M pyridine buffer, pH 5.5 to 6 (use pyridine redistilled from p-toluenesulfonyl chloride and stored over 3A molecular sieves; adjust pH with HCl) 10 to 20 mg/mL aminoalkylated ligand (UNIT 4.8; e.g., Lucifer Yellow hydrazine derivative) dissolved in water, dimethylsulfoxide (DMSO), or N,N-dimethylformamide (DMF; redistilled in vacuo over ninhydrin) 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) 80:20 or 50:50 (v/v) dichloromethane (CH2Cl2)/methanol 55:10:20 or 55:10:30 (v/v/v) isopropanol/NH4OH/H2O Sephadex G-10, G-15, or G-25 resin (Pharmacia; for H2O-soluble ligands) 0.5 M triethylammonium acetate (TEAA), pH 7 Dichloromethane or ethyl acetate (for very lipophilic ligands) 4% (w/v) LiClO4 in distilled acetone, or n-butanol (for ligands of medium lipophilicity) Mobile phase A: 5% (v/v) acetonitrile in 0.1 M aqueous TEAA, pH 7, all HPLC grade Mobile phase B: 80% (v/v) acetonitrile in 0.1 M aqueous TEAA, pH 7, all HPLC grade 2-mL vial equipped with Teflon-faced septum Analytical silica gel TLC plates (e.g., 5554 Kieselgel 60F plates; Merck) 5-mL column UV lamp and viewing box Rotary evaporator with water bath and vacuum pump High-performance liquid chromatography (HPLC) system, including: Chemically inert syringes with replaceable needles Reversed-phase column: 125-mm × 4-mm, 5-µm Lichrospher 100 RP18 (Merck), CC Nucleosil 100-5 C18 (125/4; Macherey-Nagel), or polystyrene reversed-phase (PRP-1; Hamilton) Multiwavelength detector capable of measuring UV-Vis absorption between 230 and 600 nm Spectrophotometer Lyophilizer Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) and purification and characterization of oligonucleotide-acridine conjugates (UNIT 4.3) NOTE: All buffered solutions used for HPLC purifications should be filtered through a 0.22- or 0.45-µm disposable filter. Couple ligand to oligonucleotide 1. In a 2-mL vial equipped with a Teflon-faced septum and magnetic stir bar, dissolve 5 OD260 units of purified 5′-carboxylated oligodeoxyribonucleotide in 0.1 mL of 0.5 M pyridine/HCl buffer, pH 5.5 to 6. 2. Add 0.1 mL of 10 to 20 mg/mL aminoalkylated ligand and 10 mg EDC. Stir 3 to 4 hr at room temperature. Water-soluble ligands should be prepared in water. Non-water-soluble ligands should be prepared in amine-free DMF or DMSO. EDC is a water soluble form of carbodiimide and is used to form amide bonds. Synthesis of Modified Oligonucleotides and Conjugates
4.10.3 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Evaluate coupling efficiency 3. Monitor the coupling reaction by thin-layer chromatography (TLC; APPENDIX 3D) on analytical silica gel plates, eluting first with either 80:20 or 50:50 (v/v) dichloromethane/methanol, and then with 55:10:20 or 55:10:30 (v/v/v) isopropanol/NH4OH/H2O. The Lucifer yellow conjugate is directly visible as a yellow spot. In most cases, the main excess chromophore travels to the top of the TLC plate while the conjugated oligodeoxyribonucleotide moves slightly faster (i.e., higher Rf) than the starting oligomer. When monitoring the coupling of Lucifer Yellow with the oligonucleotide HOOC(CH2)5NH-CO-d[CTCTCGCACCCATCTCTC], elute the TLC plate directly with 55:10:20 (v/v/v) isopropanol/NH4OH/H2O (not with dichloromethane/methanol). The Lucifer Yellow excess has an Rf of 0.62, while the starting oligodeoxyribonucleotide and the conjugated product have Rf values of 0.31 and 0.34, respectively. The coupling reaction can also be monitored by reversed-phase HPLC using the procedures described below. In most cases, the oligodeoxyribonucleotide-ligand conjugate exhibits a longer retention time than that of the unconjugated oligomer.
Recover oligodeoxyribonucleotide-ligand conjugate 4a. For water-soluble ligand (e.g., Lucifer Yellow): Remove excess ligand by gel filtration using a 5-mL column of Sephadex G-10, G-15, or G-25 resin, depending on the size of the oligodeoxyribonucleotide. Collect 0.5-mL fractions and monitor for presence of conjugate by spotting 3 µL on TLC plates. Visualize by UV shadowing at 254 nm. 4b. For very lipophilic ligand: Concentrate the reaction mixture to dryness under reduced pressure using a rotary evaporator with a water bath and a vacuum pump. Dissolve the residue in water or 0.5 M TEAA, pH 7. Remove excess ligand by extraction with organic solvents such as dichloromethane or ethyl acetate. 4c. For medium-lipophilicity ligand: Precipitate conjugate by adding 10 vol of 4% LiClO4 in distilled acetone or n-butanol. Vortex 1 min and centrifuge 5 min at 2000 × g, room temperature. Decant supernatant and resuspend pellet in 200 µL water. Perform gel filtration as in step 4a. Precipitation can also be performed using n-butanol prechilled at –30°C.
Purify and characterize conjugate 5. Preequilibrate a 125-mm × 4-mm, 5-µm Lichrospher 100 RP18 RP-HPLC column for at least 15 min with mobile phase A. 6. Before analysis and purification, run a blank linear gradient from 100% mobile phase A to 100% mobile phase B at a flow rate of 1 mL/min over 80 min. Repeat this step between analyses and purifications of samples having different DNA sequences or modifications.
7. Analyze sample by RP-HPLC using the flow rate and gradient in step 6. Detect the presence of oligodeoxyribonucleotide-ligand conjugates by measuring UV absorption at 254 or 260 nm.
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
This method allows easy separation of underivatized or 5′-functionalized oligodeoxyribonucleotides from oligodeoxyribonucleotide-ligand conjugates, which are, in most instances, more lipophilic. In most cases, RP-HPLC using a Lichrospher 100 RP18 column or a CC Nucleosil 100-5 C18 column is efficient for purifying the conjugate, and these columns give nearly equivalent results. A PRP-1 column can be used when these columns are not efficient, as in the case of oligonucleotide-orthophenanthroline conjugates. Detection is usually performed where the oligonucleotide absorbs light (254 or 260 nm) and at a second wavelength where the ligand absorbs light (usually in the visual range). It is also possible to record the UV-Vis spectrum corresponding to each peak of the chromatogram between 230 and 600 nm.
4.10.4 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Purification of conjugates can also be performed by ion-exchange chromatography (e.g., for oligonucleotide-orthophenanthroline conjugates; see Basic Protocol 2). Ion-exchange chromatography that requires a desalting step should only be used when RP-HPLC is not successful. Conjugates can also be purified by preparative polyacrylamide gel electrophoresis (PAGE; APPENDIX 3B). The conjugates have migrate more slowly through the gel than the starting oligonucleotides. For all compounds described in this unit, except for oligodeoxyribonucleotide-phenanthroline conjugates, UV detection can be achieved at any wavelength at which the ligand absorbs UV light. The steepness of the gradient used must be chosen empirically to afford the best chromatographic separation between the oligonucleotide conjugate and the 5′-functionalized oligonucleotide precursor. Usually a rate of increase of 1% acetonitrile per minute is used for RP-HPLC.
8. After determining the system that gives the best separation, purify the remaining crude 5′-modified oligonucleotide by preparative reversed-phase or ion-exchange chromatography. Alternatively, purify directly on an analytical column when the coupling reaction is achieved on a small scale (i.e., ∼5 OD units).
9. Purify and characterize as reported in UNIT 4.3 (steps 3 to 8 of Support Protocol), but analyze the purified conjugate by RP-HPLC. After purification, UV absorption spectra of purified oligodeoxyribonucleotide-ligand conjugates show absorptions that are characteristic to the ligand (acridine, psoralen, pyrene, fluorescein, thiazole orange).
10. Determine the extinction coefficient (ε) of the oligodeoxyribonucleotide-ligand conjugate. It is generally accepted that the ε value of the oligodeoxyribonucleotide-ligand conjugate at a given wavelength is the sum of the ε values of the oligodeoxyribonucleotide and the ligand at the same wavelength.
11. Measure the OD260 to determine the yield of the oligodeoxyribonucleotide-ligand conjugate.
Figure 4.10.2 UV-visible spectrum of the Lucifer Yellow–oligodeoxyribonucleotide conjugate LY-NH-CO(CH2)5-NH-CO-d[CTCTCGCACCCATCTCTC] recorded in water between 230 and 520 nm.
Synthesis of Modified Oligonucleotides and Conjugates
4.10.5 Current Protocols in Nucleic Acid Chemistry
Supplement 7
12. Lyophilize the conjugate and store at −20°C (stable for one to many years). Nuclease digestion of the conjugates and RP-HPLC analysis of the resulting monomers can also be performed to verify that base modifications did not occur during coupling. Moreover, these methods confirm the structure of oligodeoxyribonucleotide-ligand conjugates. Additional characterization can be made by matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI) mass spectrometry. Fo llow ing co nju ga tion of Lu cifer Yellow with HOOC(CH2)5-NH-COd[CTCTCGCACCCATCTCTC], analyses performed on a 125-mm × 4-mm, 5-ìm Lichrospher 100 RP18 column using a linear gradient of 5% to 42.5% acetonitrile in 0.1 M TEAA (100% to 50% mobile phase A versus B) over 50 min at a flow rate of 1 mL/min give a retention time of 15 min 59 sec for the product LY-NH-CO(CH2)5-NH-COd[CTCTCGCACCCATCTCTC], compared to 15 min 25 sec for the starting oligonucleotide. Detection was achieved at both 260 and 420 nm. Figure 4.10.2 shows the UV-visible spectrum of the LY-oligodeoxyribonucleotide conjugate in water. Ma ss an alysis: ESI po larity n egative, LY-NH-CO(CH2)5-NH-COd[CTCTCGCACCCATCTCTC]. Calcd. for C189H240N61O120P17S2: 5875 Da; found 5874 ± 2 Da (M–H). BASIC PROTOCOL 2
CONJUGATION OF 5′-AMINOALKYLATED OLIGODEOXYRIBONUCLEOTIDES TO LIGANDS FUNCTIONALIZED WITH AN ISOTHIOCYANATE OR N-HYDROXYSUCCINIMIDYL GROUP Whereas 5′-aminoalkylated oligodeoxyribonucleotides are conjugated with carboxylated ligands in the presence of a water-soluble carbodiimide, activated ligands such as pentafluorophenyl or N-hydroxysuccinimidyl esters or isothiocyanate derivatives are often used in a wide variety of solvents. The coupling step can be performed in a mixture of aqueous buffer and organic solvents (e.g., DMF, DMSO), or in pure organic solvents. In the latter case, oligodeoxyribonucleotides with lipophilic counter-ions such as cetyltrimethylammonium or triethylammonium are used to facilitate solubilization. The procedure is illustrated in Figure 4.10.3. When the coupling reaction is performed in organic solvent, a tertiary amine is added to ensure that the amino function on the oligodeoxyribonucleotide is unprotonated. This protocol describes the conjugation of 5′-aminoalkylated oligodeoxyribonucleotides with orthophenanthroline (OP) isothiocyanate, Oregon Green (OR) isothiocyanate, and the N-hydroxysuccinimidyl ester of 1-pyrene butanoic acid. Purification procedures are similar to those described in Basic Protocol 1. The optimal purification procedure must be determined empirically. Materials Purified 5′-aminoalkylated oligodeoxyribonucleotide (UNIT 4.9) 0.5 M sodium bicarbonate (NaHCO3) buffer, pH 9.5 5 to 10 mg/mL functionalized ligand (select one) in N,N-dimethylformamide (DMF): Orthophenanthroline (OP) isothiocyanate (UNIT 4.8, structure 3d) N-Succinimidyl ester of 1-pyrene butanoic acid (Molecular Probes) Oregon Green (OR) 5- and 6-isothiocyanate (mixed isomers; Molecular Probes) Ninhydrin 25 mM Tris⋅Cl, pH 7 (APPENDIX 2A), containing 10% (v/v) methanol: without NaCl and with 1 M NaCl (for ion-exchange with a Mono Q column) or with 1.5 M NaCl (for ion-exchange with a DEAE column)
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
2-mL vial equipped with Teflon-faced septum Mono Q HR 5/5 or HR 10/10 (Pharmacia; for OP isothiocyanate ion-exchange HPLC)
4.10.6 Supplement 7
Current Protocols in Nucleic Acid Chemistry
100-mm × 10-mm, 8-µm DEAE (Waters; for OP isothiocyante ion-exchange HPLC) HR 10/10 column packed with Lichroprep PR 18 (Art 13900, Merck) or Sephadex G-10 or G-25 (for desalting) Additional reagents and equipment for TLC (see Basic Protocol 1 and APPENDIX 3D) and for isolating, purifying, and characterizing the final conjugate (see Basic Protocol 1) Perform and monitor coupling reaction 1. In a 2-mL vial equipped with a Teflon-faced septum and magnetic stir bar, dissolve 5 OD260 units of purified 5′-aminoalkylated oligodeoxyribonucleotide in 0.2 mL of 0.5 M sodium bicarbonate buffer, pH 9.5. Oligonucleotides are typically purified as triethylammonium salts, in which case 10- to 12-mers are soluble in pure DMSO. Otherwise, counter-ion exchange can be performed to
R1NHC(S)NH(CH2)mNHC(O)O
B
O O
R1N C S
O P O−
NaHCO3 H2N(CH2)mNHC(O)O
O
O
B
B
O
O
m = 5, 6
n
H
O O P O− O
O
B
O H
n R2C(O)NH(CH2)mNHC(O)O
O
B
O
O R2
N O
NaHCO3
O O P O−
O
O
O
B
O n
H N R1 = OP = N HO
O
O
1
R = OR =
F
F COO−
R2 = PY =
Figure 4.10.3 Conjugation of 5′-aminoalkylated oligodeoxyribonucleotides with ligands functionalized with isothiocyanate or N-hydroxysuccinimidyl groups. Abbreviations: OP, orthophenanthroline; OR, Oregon Green; PY, 1-pyrenepropyl.
Synthesis of Modified Oligonucleotides and Conjugates
4.10.7 Current Protocols in Nucleic Acid Chemistry
Supplement 7
prepare cetyltrimethylammonium salts using a procedure adapted from Zarytova et al. (1987). Start with 5 to 10 OD260 units of oligonucleotide in a 100-ìL volume and add 10 vol of 4% LiClO4 in acetone. Vortex 2 min and then centrifuge 5 min at 2000 × g, room temperature. Wash pellet two to three times with distilled acetone to remove the LiClO4. Dry pellet and dissolve in 20 to 30 ìL deionized water. Add 3 ìL of 8% hexadecyltrimethylammonium bromide, vortex, and centrifuge again. Dry the pellet.
2. Add 0.2 mL of 5 to 10 mg/mL functionalized ligand in DMF. Stir the mixture at room temperature overnight. 3. Monitor the reaction by TLC (APPENDIX 3D) using the conditions described above (see Basic Protocol 1, step 3). The presence of OP, pyrene, and their corresponding oligodeoxyribonucleotide conjugates can be easily visualized on a TLC plate by irradiation at 254 or 365 nm. At 254 nm, unmodified and conjugated oligonucleotides can be visualized as grey or black spots, depending on their concentration. At 365 nm, OP-oligonucleotide conjugates appear as slightly fluorescent spots, and pyrene-oligonucleotide conjugates appear as gold fluorescent spots. OR and its oligodeoxyribonucleotide conjugates can be directly visualized on the TLC plate as yellow-green spots. After elution and drying of the TLC plate, the presence of the remaining 5′-amino-containing oligodeoxyribonucleotide can be detected as a grey or black spot by irradiation at 254 nm, or as a pink spot by spraying with ninhydrin and heating the plate.
Recover, purify, and characterize conjugate 4a. For orthophenanthroline: Recover, purify, and characterize conjugate as described above (see Basic Protocol 1, steps 5 to 12) using the appropriate modifications below. a. Reversed-phase HPLC: Use a PRP-1 column with a linear gradient from 100% to 50% mobile phase A versus B over 50 min, and a flow rate of 1 mL/min for both purification and evaluation of efficiency.
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
Figure 4.10.4 UV spectrum of the orthophenanthroline-oligodeoxyribonucleotide conjugate OP-NH-C(S)-NH(CH2)5-NH-CO-d[CCGCTTAATACTGA] recorded in water between 230 and 350 nm.
4.10.8 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Figure 4.10.5 UV-visible spectrum of the Oregon Green–oligodeoxyribonucleotide conjugate OR-NH-C(S)-NH(CH2)5-NH-CO-d[CCGCTTAATACTGA] recorded in water between 230 and 600 nm.
b. Ion-exchange HPLC using a Mono Q column: Use a Mono Q HR 5/5 or 10/10 column, a linear gradient of 1 M NaCl (0% to 60%) in 25 mM Tris⋅Cl, pH 7, containing 10% methanol over 40 min, and a flow rate of 1 mL/min (HR 5/5) or 4 mL/min (HR 10/10). After purification, desalt the conjugate using an HR 10/10 column packed with Lichroprep RP18, Sephadex G-10, or G-25, and eluting with water. c. Ion-exchange HPLC using a DEAE column: Use a 100-mm × 10-mm, 8-µm DEAE column, a linear gradient of 1.5 M NaCl (0% to 60%) in 25 mM Tris⋅Cl, pH 7, containing 10% methanol over 60 min, and a flow rate of 1 mL/min. After purification, desalt the conjugate using an HR 10/10 column packed with Lichroprep RP18, Sephadex G-10, or G-25, and eluting with water. For RP-HPLC of OP isothiocyanate coupled to the oligonucleotide H2N-(CH2)5-NH-COd[CCGCTTAATACTGA], analysis on an RP18 column using the conditions described above (see Basic Protocol 1) yields a higher retention time than that expected for oligomer conjugates exhibiting similar lipophilicity; however, peaks are poorly resolved. Therefore, analysis and purification of these conjugates are performed on a PRP-1 column. A retention time of 16 min 10 sec is observed for the conjugate OP-NH-C(S)-NH(CH2)5-NH-CO-
Figure 4.10.6 UV-visible spectrum of the pyrene-oligodeoxyribonucleotide conjugate PYC(O)-NH-(CH2)6-NH-CO-d[CCGCTTAATACTGA] recorded in water between 230 and 400 nm. Current Protocols in Nucleic Acid Chemistry
Synthesis of Modified Oligonucleotides and Conjugates
4.10.9 Supplement 7
d[CCGCTTAATACTGA] compared to a retention time of 12 min 30 sec for the starting oligonucleotide H2N(CH2)5-NH-CO-d[CCGCTTAATACTGA]. When the same conjugate and starting oligonucleotide are analyzed by ion exchange on a Mono Q HR 5/5 column using a linear gradient of 1 M NaCl (20% to 60%) in 25 mM Tris⋅Cl, pH 7, with 10% methanol over 40 min at a flow rate of 1 mL/min, a retention time of 19 min 30 sec is obtained for the conjugate compared to 17 min 30 sec for the starting oligodeoxyribonucleotide. The coupling of the OP derivative to the oligodeoxyribonucleotide does not induce a significant change in the absorption spectrum. Figure 4.10.4 shows the UV spectrum of OP-NH-C(S)-NH(CH2)5-NH-CO-d[CCGCTTAATACTGA] in water. Denaturing polyacrylamide gel electrophoresis allows resolution of the coupling product from the unreacted oligodeoxyribonucleotide. The mobility of the conjugate in the gel is more retarded than that of the starting oligodeoxyribonucleotide. The difference between the electrophoretic mobilities is similar to that observed between H2N(CH2)5-NH-COd[CCGCTTAATACTGA] and d[CCGCTTAATACTGA], shown in Figure 4.9.6.
S− O P O− O
B
O O
R1X
R2COCH2I
n
H R3SSPy
R1S
O
O P O−
O P O− O
B
O
O
O
B
O
n
H
N
HO
R1 =
B
n
H
O
O
O
O
R2 =
OCH3
O O
O n
H
Cl
R2COCH2S
R3SS
O P O−
O
R1 = R3 = COO−
NH
O
(CH2)6
(CH2)6 NH
Acr-NH-(CH2)6-
Pso-(CH2)6FLU O (CH2)8 − I N+
HN R1 =
R1 =
N S
N
N H3C TO-(CH 2)8-
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
OP-NHCO(CH2)5-
Figure 4.10.7 Conjugation of oligodeoxyribonucleotide 5′-phosphorothioates with halogenoalkylated ligands (left), an iodoacetamidylated ligand (right), and a 2-pyridyldithioalkylated ligand (center). For halogenoalkylated ligands, R1 = Acr-NH-(CH2)6- (UNIT 4.8, structure 1e); Pso(CH2)6- (UNIT 4.8, structure 2f), OP-C(O)-(CH2)5- (UNIT 4.8, structure 3c); and TO-(CH2)8- (UNIT 4.8, structure 4e). For the iodoacetamidylated ligand, R2 = FLU. For the 2-pyridyldithioalkylated ligand, R3 = P50-(CH2)6- (UNIT 4.8, structure 2h). Abbreviations: Acr, acridine; FLU, fluorescein; OP, orthophenanthroline; Pso, psoralen; PY, 2-pyridyl; TO, thiazole orange.
4.10.10 Supplement 7
Current Protocols in Nucleic Acid Chemistry
4b. For Oregon Green and N-hydroxysuccinimidyl ester of pyrene: Recover, purify, and characterize conjugate as described above (see Basic Protocol 1, steps 5 to 12). For coupling of Oregon Green (OR) 5- or 6-isothiocyanate with oligonucleotide H2N(CH2)5-NH-CO-d[CCGCTTAATACTGA], detection at both 260 and 500 nm yields two peaks for the conjugate OR-NH-C(S)-NH(CH2)5-NH-CO-d[CCGCTTAATACTGA], with retention times of 19 min 5 sec and 20 min 46 sec, corresponding to the two geometrical isomers of OR. The starting H2N-(CH2)6-NH-CO-d[CCGCTTAATACTGA] is eluted with a retention time of 14 min. Figure 4.10.5 shows the UV-visible spectrum of the OR-oligodeoxyribonucleotide conjugate in water. Ma ss an alysis: ESI polarity negative, OR-NH-C(S)-NH-(CH2)5-NH-COd[CCGCTTAATACTGA]. Calcd. for C163H194N53O88P13SF2: 4776 Da; found 4477 ± 1 Da (M–H). For coupling of the N-hydroxysuccinimidyl ester of pyrene (PY) with oligonucleotide H2N(CH2)6-NH-CO-d[CCGCTTAATACTGA], detection at both 260 and 350 nm gives a retention time of 35 min 42 sec for the conjugate PY-NH-C(O)-NH(CH2)6-NH-COd[CCGCTTAATACTGA], compared to 14 min for the starting oligonucleotide. Figure 4.10.6 shows the UV-visible spectrum of the PY-oligodeoxyribonucleotide conjugate in water. Mass analysis: ESI polarity negative, PY-C(O)-NH-(CH2)6-NH-CO-d[CCGCTTAATACTGA]. Calcd. for C163H201N52O84P13: 4636 Da; found 4636 Da (M–H).
CONJUGATION OF OLIGODEOXYRIBONUCLEOTIDE 5′-PHOSPHOROTHIOATES TO LIGANDS FUNCTIONALIZED WITH HALOGENOALKYL, 2-PYRIDYLDITHIO, OR IODOACETAMIDYL GROUPS
BASIC PROTOCOL 3
The derivatization of oligodeoxyribonucleotide 5′-phosphorothioates, illustrated in Figure 4.10.7, is achieved over a wide pH range (5 to 8) with ligands carrying iodoacetamidyl, halogenoalkyl, or 2-pyridyldithio groups. The conjugation reaction can be performed in water, aqueous DMF, or aqueous methanol. The reaction can also be performed in pure methanol in the presence of crown ethers to facilitate solubilization of the oligodeoxyribonucleotide salts (i.e., 18-crown-6 for potassium salts and 15-crown-5 for sodium salts). Procedures are presented for (1) halogenoalkyl derivatives of acridine, psoralen, orthophenanthroline, and thiazole orange; (2) a 2-pyridyldithio derivative of psoralen; and (3) an iodoacetamido derivative of fluorescein. The halogenoalkyl derivatives are reacted with oligodeoxyribonucleotide 5′-phosphorothioates in methanol in the presence of crown ether. The 2-pyridyldithio derivative of psoralen requires minor changes to the conjugation procedure. The protocol for the iodoacetamido derivative is identical to that for the halogenoalkyl-containing ligands; however, since iodoacetamido derivatives are, in general, more reactive than the halogenoalkyl containing ligands, the coupling times are often shorter. Iodoacetamido derivatives of numerous ligands are commercially available. The reader can also refer to Asseline et al. (1996) for preparation of an iodoacetamido derivative of acridine.
Synthesis of Modified Oligonucleotides and Conjugates
4.10.11 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Materials Purified lyophilized oligodeoxyribonucleotide 5′-phosphorothioates (Na+ or K+ salt; UNIT 4.9) 12.5 mg/mL 15-crown-5 or 18-crown-6 (Aldrich) in methanol Functionalized ligand (select one): Halogenoalkylated acridine, psoralen, orthophenanthroline, or thiazole orange (UNIT 4.8, structures 1e, 2f, 3c, and 4e, respectively) 2-Pyridyldisulfide psoralen (UNIT 4.8, structure 2h) Iodoacetamidylated fluorescein (Aldrich) Methanol (for halogenoalkylated ligands and iodoacetamidylated fluorescein) Dichloromethane 0.5 M sodium or potassium phosphate buffer, pH 7 (APPENDIX 2A) Sephadex G-10 or G-15 column 0.1 M triethylammonium acetate (TEAA) buffer, pH 7 2-mL vial equipped with a Teflon-faced septum 30° to 35°C water bath (optional; for halogenoalkylated ligands) UV-Vis spectrophotometer Additional reagents and equipment for TLC (see Basic Protocol 1and APPENDIX 3D) and for isolating, purifying, and characterizing the final conjugate (see Basic Protocol 1) NOTE: In order to prevent chelation of phosphorothioates and phenanthrolines attached to oligodeoxyribonucleotides, all solvents and buffer solutions used for their purification must be passed through a column of Chelex 100 resin to remove divalent cations. Prepare oligodeoxyribonucleotide 5′-phosphorothioate 1. In a 2-mL vial equipped with a Teflon-faced septum and magnetic stir bar, dissolve 5 OD260 units of purified lyophilized oligodeoxyribonucleotide 5′-phosphorothioate (sodium salt or potassium salt) in 0.4 mL of 12.5 mg/mL 15-crown-5 (for sodium salt) or 18-crown-6 (for potassium salt) in methanol. Perform conjugation For halogenalkylated derivatives: 2a. Dissolve 10 eq halogenoalkylated acridine, psoralen, orthophenanthroline, or thiazole orange in a minimal volume of methanol (enough to dissolve the ligand). Add to the oligodeoxyribonucleotide and seal the vial. For the psoralen derivative, also add 0.2 mL dichloromethane and vortex 20 or 30 sec to fully dissolve. 3a. Stir the mixture at room temperature or at 30° to 35°C. The conjugation is usually completed after a few hours (5 to 8 hr), but a longer reaction time is sometimes required (e.g., 24 hr).
4a. Monitor the reaction by TLC using the conditions described above (see Basic Protocol 1, step 3).
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
Acridine- and thiazole orange–oligodeoxyribonucleotide conjugates can be easily visualized on TLC plates as yellow and red spots, respectively. Psoralen and orthophenanthroline conjugates can be visualized by irradiation at 254 nm (grey or black spots) or 365 nm (pale fluorescent spots). The presence of unreacted oligodeoxyribonucleotide 5′-thiophosphates can be detected by spraying with DBPNC and heating; the 5′-thiophosphate-containing oligodeoxyribonucleotides give a pink spot.
4.10.12 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Figure 4.10.8 UV-visible spectrum of the acridine-oligodeoxyribonucleotide conjugate AcrNH(CH2)6-S-p-d[CCGCTTAATACTGA] recorded in water between 230 and 530 nm.
For 2-pyridydisulfide psoralen derivative: 2b. Dissolve 5 eq 2-pyridyldisulfide psoralen derivative in 0.2 mL dichloromethane. Add to the oligodeoxyribonucleotide and seal the vial. Vortex for 20 or 30 sec to completely solubilize the mixture. 3b. Stir the mixture at room temperature for 3 to 4 hr. 4b. Monitor the reaction by TLC (step 4a).
Figure 4.10.9 UV-visible spectrum of the psoralen-oligodeoxyribonucleotide conjugate Pso(CH2)6-S-p-d[CCGCTTAATACTGA] recorded in water between 220 and 400 nm.
Synthesis of Modified Oligonucleotides and Conjugates
4.10.13 Current Protocols in Nucleic Acid Chemistry
Supplement 7
For iodoacetamido fluorescein derivative: 2c. Dissolve 10 eq iodoacetamidylated fluorescein in a minimal volume of methanol (enough to dissolve the ligand). Add to the oligodeoxyribonucleotide and seal the vial. 3c. Stir the mixture at room temperature or at 30° to 35°C. The conjugation is usually completed after a few hours (5 to 8 hr), but a longer reaction time is sometimes required (e.g., 24 hr).
4c. Monitor the reaction by TLC (step 4a). Fluorescein conjugates can be visualized directly on the TLC plate as yellow spots.
Analyze, purify, and characterize conjugate 5. When the reaction is complete or nearly complete, add 0.4 mL of 0.5 M sodium or potassium phosphate buffer, pH 7. 6. Extract three times with 1 mL dichloromethane each to remove the bulk of the excess ligand. 7. Remove all remaining ligand by gel filtration on a Sephadex G-10 or G-15 column, eluting with water or 0.1 M TEAA buffer, pH 7. Monitor elution by detection at 260 nm using a UV-Vis spectrophotometer. The size of the column depends on the scale of the synthesis. Usually a 5-mL column is used.
8. Analyze, purify, and characterize the oligodeoxyribonucleotide-ligand conjugates as described above (see Basic Protocol 1, steps 5 to 12). For halogenoalkylated acridine derivative: The conjugate has a retention time of 19 min 32 sec, compared to 13 min 7 sec for the unreacted oligodeoxyribonucleotide 5′-thiophosphate. In addition to detection at 260 nm, a second detection at 425 nm confirms the presence of acridine. Figure 4.10.8 shows the UV-visible spectrum of the acridine-oligodeoxyribonucleotide conjugate in water. Mass analysis: ESI polarity negative, AcrNH(CH2)6-S-p-d[CCGCTTAATACTGA]. Calcd. for C156ClH197N52O85P14S: 4659 Da; found 4657 ± 2 Da (M–H).
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
Figure 4.10.10 UV-visible spectrum of the thiazole orange–oligodeoxyribonucleotide conjugate TO-(CH2)8-S-p-d[CCGCTTAATACTGA] recorded in water between 230 and 600 nm.
4.10.14 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Figure 4.10.11 UV-visible spectrum of the psoralen-oligodeoxyribonucleotide conjugate Pso(CH2)6-S-S-p-d[CCGCTTAATACTGA] recorded in water between 220 and 400 nm.
For halogenoalkylated psoralen derivative: The conjugate has a retention time of 25 min 19 sec. In addition to detection at 260 nm, a second detection at 340 nm confirms the presence of psoralen. Figure 4.10.9 shows the UV-visible spectrum of the psoralen-oligodeoxyribonucleotide conjugate recorded in water. Mass analysis: ESI polarity negative, Pso-(CH2)6-S-p-d[CCGCTTAATACTGA]. Calcd. for C153H192N50O88P14S: 4602 Da; found 4603 ± 1 Da (M–H). For halogenoalkylated thiazole orange derivative: The conjugate has a retention time of 26 min 19 sec. In addition to detection at 260 nm, a second detection at 510 nm confirms the presence of thiazole orange. Figure 4.10.10 shows the UV-visible spectrum of the thiazole orange–oligodeoxyribonucleotide conjugate in water. Mass analysis: ESI polarity negative, TO-(CH2)8-S-p-d[CCGCTTAATACTGA]. Calcd. for C162H205N52O84P14S: 4719 Da; found 4720 ± 1 Da (M–H). For halogenoalkylated orthophenanthroline derivative: As previously reported (see Basic Protocol 2), the phenanthroline-oligonucleotide conjugates are poorly eluted on an RP18 reversed-phase HPLC column. Thus, this conjugate is analyzed and purified as described in Basic Protocol 2 (step 4a, substep a) for the coupling of the orthophenanthroline isothiocyanate derivative with a 5′-aminoalkylated oligodeoxyribonucleotide. Analysis on
Figure 4.10.12 UV-visible spectrum of the fluorescein-oligodeoxyribonucleotide conjugate FLU-NH-C(O)-CH2-S-p-d[CCGCTTAATACTGA] recorded in 0.1 M sodium bicarbonate buffer, pH 9, between 230 and 600 nm.
Synthesis of Modified Oligonucleotides and Conjugates
4.10.15 Current Protocols in Nucleic Acid Chemistry
Supplement 7
a PRP-1 column using a gradient from 5% to 42.5% CH3CN in 0.1 M TEAA, pH 7, over 50 min at a flow rate of 1 mL/min gives a retention time of 15 min 24 sec for the conjugate OP-NH-C(O)-(CH2)5-S-p-d[CCGCTTAATACTGA], compared to 11 min 21 sec for the starting oligonucleotide 5′-thiophosphate. As in Basic Protocol 2, this coupling of orthophenanthroline halogenoalkyl derivative with the oligodeoxyribonucleotide 5′-thiophosphate does not induce significant changes in the absorption spectrum. For 2-pyridyldisulfide psoralen: Analysis under these conditions gives a retention time of 28 min 7 sec for the conjugate. As in the case of the halogenoalkyl derivative of psoralen, additional detection at 340 nm confirms the presence of psoralen. Figure 4.10.11 shows the UV-visible spectrum of the psoralen-oligodeoxyribonucleotide conjugate (via a disulfide bond) in water. Mass analysis: ESI polarity negative, Pso-(CH2)6-S-S-pd[CCGCTTAATACTGA]. Calcd. for C153H192N50O88P14SS: 4634 Da; found 4633 ± 1 Da (M–H). For 5′-iodoacetamidylated fluorescein: The conjugate of the 5′-iodoacetamidylated fluorescein (isomer 5; FLU) with S-p-d[CCGCTTAATACTGA] has a retention time of 17 min 18 sec using an RP18 reversed-phase HPLC column under the conditions described above. Figure 4.10.12 shows the UV-visible spectrum of the fluorescein-oligodeoxyribonucleotide conjugate in 0.1 M sodium hydrogen carbonate buffer, pH 7. Mass analysis: ESI polarity n ega tive, FLU-NH-C(O)-CH2- S- p- d[CCGCTTAATACTGA]. Calcd. for C158H189N51O90P14S: 4707 Da; found 4708 Da (M–H). Ion-exchange for halogenoalkylated ligand-oligodeoxyribonucleotide conjugates: Analysis and purification of these conjugates can also be performed on a Mono Q or DEAE ion-exchange column using the eluents and conditions described above (see Basic Protocol 2, step 4a, substeps b and c). The conjugate is retained more than the oligonucleotide 5′-thiophosphate because of the hydrophobicity of the ligand. For example, using a Mono Q column under the conditions described in Basic Protocol 2, the conjugate OP-NH-C(O)(CH2)5-S-p-d[CCGCTTAATACTGA] is eluted at 28 min 30 sec, compared to 26 min for the starting oligodeoxyribonucleotide 5′-phosphorothioate. PAGE of halogenoalkylated ligand-oligodeoxyribonucleotide conjugates: Denaturing polyacrylamide gel electrophoresis (UNIT 10.4) allows the resolution of the conjugate OP-NH-C(O)-(CH2)5-S -p -d[CCGCTTAATACTGA] from unreacted S-pd[CCGCTTAATACTGA]. The electrophoretic mobility of the conjugate on the gel is retarded when compared to that of the oligodeoxyribonucleotide 5′-thiophosphate. A third band with weak intensity and lower electrophoretic mobility relative to the other two bands is also observed. This band may correspond to the dimer of the oligodeoxyribonucleotide 5′-phosphorothioate. Mass analysis: ESI polarity negative, OP-NH-C(O)-(CH2)5-S-pd[CCGCTTAATACTGA]. Calcd. for C154H193N53O85P14S: 4609 Da; found 4610 ± 1 Da (M-H).
R OH
NH −
O P O−
O P O O
O
RNH2
B
O
O
B
EDC O
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
H
O n
H
n
Figure 4.10.13 Condensation reaction of oligodeoxyribonucleotide 5′-phosphates with aminated compounds. R, H2N(CH2)5CH2-.
4.10.16 Supplement 7
Current Protocols in Nucleic Acid Chemistry
CONJUGATION OF OLIGODEOXYRIBONUCLEOTIDE 5′-PHOSPHATES TO LIGANDS FUNCTIONALIZED WITH AMINO GROUPS
BASIC PROTOCOL 4
The conjugation of oligodeoxyribonucleotides carrying a phosphate group at the 5′ terminus with the primary amino function of a ligand is accomplished in the presence of carbodiimide. It generally requires a large excess of both ligand and carbodiimide (100 to 500 eq). Usually the oligodeoxyribonucleotide is solubilized in a buffer and the ligand is added to the solution in amine-free DMF. The procedure is illustrated in Figure 4.10.13 and exemplified by the coupling of 1,5-diaminopentane with oligodeoxyribonucleotide 5′-phosphates. Materials Purified oligodeoxyribonucleotide 5′-phosphate (UNIT 4.9) 0.5 M aqueous 1,5-diaminopentane, pH 4.5 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) 4% (w/v) LiClO4 in acetone Mobile phase A: 0.1 M triethylammonium acetate buffer pH 7, containing 5% CH3CN Mobile phase B: 0.1 M triethylammonium acetate (TEAA) buffer, pH 7 containing 80% CH3CN 2-mL vial equipped with a Teflon-faced septum HPLC system (also see Basic Protocol 1) Column: 150-mm × 3-mm, 5-µm RP8 glass cartridge system (Merck) Additional reagents and equipment for TLC (see Basic Protocol 1 and APPENDIX 3D) and for isolating, purifying, and characterizing the final conjugate (see Basic Protocol 1) 1. In a 2-mL vial equipped with a Teflon-faced septum and magnetic stir bar, dissolve 5 OD260 units of purified oligodeoxyribonucleotide 5′-phosphate in 0.2 mL of 0.5 M aqueous 1,5-diaminopentane, pH 4.5. 2. Add 10 mg water-soluble EDC and incubate with stirring at room temperature for 4 to 5 hr. 3. Divide the reaction mixture between two microcentrifuge tubes. 4. Add 1 mL of 4% (w/v) LiClO4 in acetone to each tube. Vortex for at least 1 min and centrifuge for 5 min at 2000 × g, room temperature. Discard supernatant and dissolve the residue in 0.1 mL water. Repeat three times. 5. Analyze condensation product by reversed-phase HPLC using a 150-mm × 3-mm, 5-µm RP8 glass cartridge system with a gradient from 100% to 50% mobile phase A versus B, over 50 min at a flow rate of 0.5 mL/min. Usin g these co nd ition s, the co nd en sation product H2N-(CH2)5-NH-pd[TTCTCCCCCGCTTA] shows one peak with a retention time of 15 min 34 sec, compared to 14 min 45 sec for the oligodeoxyribonucleotide 5′-phosphate. Mass analysis: ESI p ola rity neg ative, H2N-(CH2)5-NH-p-d[TTCTCCCCCGCTTA]. Calcd. for C138H189N43O88P14: 4289 Da; found 4289 ± 1 Da (M–H). The presence of the primary amino function at the end of the linker can be verified after TLC elution by spraying the plate with ninhydrin solution and heating.
Synthesis of Modified Oligonucleotides and Conjugates
4.10.17 Current Protocols in Nucleic Acid Chemistry
Supplement 7
BASIC PROTOCOL 5
CONJUGATION OF 5′-MERCAPTOALKYLATED OLIGODEOXYRIBONUCLEOTIDES TO LIGANDS FUNCTIONALIZED WITH HALOGENOALKYL, IODOACETAMIDYL, OR 2-PYRIDYLDITHIO GROUPS This coupling reaction can be performed in buffer (pH 7 to 9), in a mixture of buffer and DMF, or directly in DMF using oligodeoxyribonucleotides converted to their cetyltrimethylammonium salts. Solutions must be degassed by bubbling with argon or nitrogen. Halogenoalkylated, iodoacetamidylated, and 2-pyridyldithioalkylated derivatives of various ligands are conjugated with an oligodeoxyribonucleotide bearing a masked mercaptoalkylated linker at its 5′ end. The procedures are illustrated in Figure 4.10.14. The coupling of halogenoalkylated thiazole orange with HS-CH2CH2-(OCH2CH2)2-pd[CTCTCGCACCCATCTCTC] is performed in situ by treatment of C5H5N-S-SCH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] with the reducing agent Tris-(2-carboxyethyl)phosphine (TCEP). The coupling of iodoacetamidyl ligands with 5′-mercaptoalkylated oligodeoxyribonucleotides is performed using the same procedure.
O R1S
O P O L O− O
1. TCEP
O P O−
2. R 1X
O
O
S S
B
O
O N
B
O
O P O L O−
O
n
H
B
O O P O− O
B
O O
n
H
O R2S
S
O P O L O−
B
O O
1. TCEP
O P O−
2. R 2SSPy
O
O
B
O H
(CH2)8 − I N+
n
(CH2)6
R1 =
R2 =
O
S N
O
O
O
H3C TO-(CH 2)8-
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
Pso-(CH2)6-
Figure 4.10.14 Conjugation of oligodeoxyribonucleotides bearing a 5′-(2-pyridyldithioalkylated) linker with a halogenoalkylated ligand (top) or a 2-pyridyldithioalkylated ligand (bottom). R1 = TO-(CH2)8- (UNIT 4.8, structure 4e); R2 = Pso-(CH2)6- (UNIT 4.8, structure 2h). Abbreviations: T C E P, Tr i s - ( 2 - c a r box yet hy l ) ph os ph in e hy dr o c h lo r id e; X , I; P y, 1-pyr idyl; L, CH2CH2OCH2CH2OCH2CH2.
4.10.18 Supplement 7
Current Protocols in Nucleic Acid Chemistry
The coupling of 2-pyridyldithioalkylated ligands with 5′-(2-pyridyldithioalkylated)-oligodeoxyribonucleotides is quite similar, but in this case the amount of TCEP must be strictly controlled in order to prevent the cleavage of the product, which also contains a disulfide bridge. This protocol describes the condensation of C5H5N-S-S-CH2CH2(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] with 2-pyridyldithioalkylated psoralen. Conjugate Halogenoalkylated and Iodoacetamidylated Ligands to 5′-Mercaptoalkylated Oligodeoxyribonucleotides Materials Purified 5′-(2-pyridyldithioalkylated) oligodeoxyribonucleotide (UNIT 4.9) 30 mM sodium bicarbonate buffer, pH 9 Dimethylformamide (DMF) Nitrogen or argon gas Tris-(2-carboxyethyl)phosphine (TCEP) Halogenoalkylated or iodoacetamidylated ligand (e.g., halogenoalkylated thiazole orange; UNIT 4.8, structure 4e) Diisopropylethylamine (optional) 2-mL vial equipped with a Teflon-faced septum Additional reagents and equipment for TLC (see Basic Protocol 1 and APPENDIX 3D) and for isolating, purifying, and characterizing the final conjugate (see Basic Protocol 1) 1a. In a 2-mL vial equipped with a Teflon-faced septum and magnetic stir bar, dissolve 10 OD260 units of purified 5′-(2-pyridyldithioalkylated) oligodeoxyribonucleotide in 0.15 to 0.3 mL of the desired solvent—i.e., 30 mM sodium bicarbonate buffer, pH 9, buffer/DMF, or DMF. The solvent must be chosen empirically. The resulting reaction mixture must be homogeneous.
2a. Degas the solution by bubbling argon or nitrogen gas through it for 10 min. 3a. Dissolve 2 or 3 eq TCEP in a minimal volume (2 to 3 µl) of water and add to the degassed oligonucleotide solution. Leave 30 min at room temperature. 4a. Dissolve 5 to 20 eq halogenoalkylated or iodoacetamidylated ligand in 0.15 to 0.3 mL DMF and add to the degassed oligonucleotide solution. If the conjugation reaction is performed in DMF without buffer, also add 5 µl diisopropylethylamine. 5a. Stir the mixture at room temperature or at 30° to 35°C for 3 to 4 hr. Monitor reaction by TLC (see Basic Protocol 1, step 3). The thiazole orange conjugate is readily visible on the TLC plate as a red spot.
6a. Analyze, purify, and characterize the conjugate as described for condensation of halogenoalkylated ligands with oligodeoxyribonucleotide 5′-thiophosphates (see Basic Protocol 1, steps 5 to 12). Analysis of the coupling reaction between the thiazole orange (TO) derivative and C5H5NS-S-CH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] is performed on an RP18 (5% to 42.5% of CH3CN over 50 min in 0.1 M TEAA, pH 7 at a flow rate of 1 mL/min) reversed-phase HPLC column using the conditions described in Basic Protocol 3. The conjugate TO-(CH2)8-S-CH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] elutes with a retention time of 24 min 25 sec. A second peak at 18 min 11 sec corresponds to either th e th iol-co nta inin g o ligo deoxyrib on ucleotide HS-CH2CH2-(OCH2CH2)2-pd [CTCTCGCACCCATCTCTC] or its (5′-5′)- dimer d erivative 3′d[CTCTCTACCCACGCTCTC]-p-CH2CH2-(OCH 2CH2)2-S-CH2CH2-(OCH2CH2)2-pd[CTCTCGCACCCATCTCTC]. The presence of thiazole orange in the conjugate is
Synthesis of Modified Oligonucleotides and Conjugates
4.10.19 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Figure 4.10.15 UV-visible spectrum of the psoralen-oligodeoxyribonucleotide conjugate Pso(CH2)6-S-S-CH2CH2-(OCH2CH2 )2-p-d[CTCTCGCACCCATCTCTC] recorded in water between 230 and 400 nm.
detected at 260 and 510 nm. Mass analysis: ESI polarity negative, TO-(CH2)8-S-CH2CH2(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC]. Calcd. for C203H264N57O114S2P18: 5948 Da; found 5955 ± 3 Da (M–H).
Conjugate 2-Pyridyldisulfide-Containing Ligands With 5′-Mercaptoalkylated Oligodeoxyribonucleotides Materials Purified 5′-(2-pyridyldithioalkylated) oligodeoxyribonucleotides (UNIT 4.9) 30 mM sodium bicarbonate buffer, pH 9 Nitrogen or argon gas Tris-(2-carboxyethyl)phosphine (TCEP) 2-Pyridyldithioalkylated ligand (e.g., 2-pyridyldisulfide derivative of psoralen; UNIT 4.8, structure 2f) Dimethylformamide (DMF) 2-mL vial equipped with a Teflon-faced septum Additional reagents and equipment for TLC (see Basic Protocol 1 and APPENDIX 3D) and for isolating, purifying, and characterizing the final conjugate (see Basic Protocol 1) 1b. In a 2-mL vial equipped with a Teflon-faced septum and magnetic stir bar, dissolve 10 OD260 units of purified 5′-(2-pyridyldithioalkylated) oligodeoxyribonucleotide in 0.2 mL of 30 mM sodium bicarbonate buffer, pH 9. 2b. Degas the solution by bubbling argon or nitrogen through it for 10 min. 3b. Dissolve ≤2 eq TCEP in a minimal volume (2 to 3 µl) of water and add to the degassed oligonucleotide solution. Leave 90 min at room temperature.
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
4b. Dissolve 1.2 eq 2-pyridyldithioalkylated ligand in 360 µl DMF and add to the degassed oligonucleotide solution. 5b. Stir the mixture at room temperature for 4 hr. Monitor reaction by TLC (see Basic Protocol 1, step 3).
4.10.20 Supplement 7
Current Protocols in Nucleic Acid Chemistry
The psoralen conjugate can be visualized as a pale blue fluorescent spot by irradiation at 365 nm.
6b. Analyze, purify, and characterize the conjugate as described for condensation of halogenoalkylated ligands with oligodeoxyribonucleotide 5′-thiophosphates (see Basic Protocol 1, steps 5 to 12). Analysis of the coupling reaction between the psoralen derivative and the oligonucleotide HS-CH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] is performed on an RP18 reversed-phase HPLC column using the conditions described above (see Basic Protocol 1). The conjugate Pso-(CH2)6-S-S-CH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] has a retention time of 35 min 38 sec. A second peak with a retention time of 18 min 11 sec corresponds to either the thiol-containing oligodeoxyribonucleotide HS-CH2CH2(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC] or its (5′-5′)-dimer derivative 3′[CTCTCTACCCACGCTCTC]-p-CH2CH2-(OCH2CH2)2-S-S-CH2CH2-(OCH2CH2)2-pd[CTCTCGCACCCATCTCTC]. The psoralen-containing conjugate can be detected at 260 and 320 nm. The UV-visible spectrum of the psoralen-oligodeoxyribonucleotide conjugate in water is shown in Figure 4.10.15. Mass analysis: ESI polarity negative, Pso-(CH2)6-SCH2CH2-(OCH2CH2)2-p-d[CTCTCGCACCCATCTCTC]. Calcd. for C194H249N55O118S2P18: 5852 Da; found 5852 ± 2 Da (M–H).
COMMENTARY Background Information The methods reported in this unit describe the conjugation of ligands containing halog en oalkyl, iodoacetamidyl, and 2pyridylthioalkyl linkers with oligodeoxyribonucleotides functionalized with either a 5′thiophosphate or a 5′-pyridyldithio group. When using halogenoalkylated or iodoacetamidylated ligands, the conjugates obtained have irreversible phosphothioester or thioether linkages. In contrast, the conjugates obtained from 2-pyridylthioalkylated ligands have phosphodisulfide or disulfide bonds that can be cleaved by the use of a reducing agent such as TCEP or dithiothreitol (DTT). These reactions, which proceed without activation, can be performed either in organic solvents (using a crown ether to solubilize the oligonucleotides) or in a mixture of organic solvents and aqueous buffer. The conjugation of oligodeoxyribonucleotides carrying aminoalkylated linker is illustrated by examples using isothiocyanate or N-hydroxysuccinimidyl derivatives of ligands. In these cases, the amino function must be unprotonated and the reaction is carried out in the presence of buffer. The coupling of 5′-modified oligonucleotides with phosphate and carboxylated linker with nucleophilic ligands such as primary amine or hydrazino derivatives requires the use of a coupling reagent. Procedures reported in this unit may be used to prepare oligodeoxyribonucleotides covalently linked via their 5′ ends to a wide variety of molecules such as labels, intercalating
agents, and reactive compounds, the properties of which are reported in UNIT 4.2. In many cases, the properties of the oligodeoxyribonucleotideligand conjugates are largely dependent on the geometry of the complex formed between the ligand and its target. The linkage between the oligodeoxyribonucleotide and the ligand (i.e., the size and nature of the linker) may be varied to optimize the properties of oligodeoxyribonucleotide-ligand conjugates. The conjugation methods presented in this unit can be used to prepare oligonucleotide conjugates composed of natural β-deoxyribonucleosides, phosphorothioate oligodeo xy rib on ucleo tides, α-D-deoxyribonucleosides or 2′-O-methylribonucleosides, and many other modified oligonucleotides. The methods reported for conjugating 5′-modified oligodeoxyribonucleotides with appropriately functionalized ligands are also valid for coupling these ligands with the same functional groups incorporated into other positions of the oligonucleotides (i.e., phosphate thiophosphate, thiolcarboxyl, and amino at the 3′ end); or thiol carboxyl, and amino attached via a linker to the 2′ position of the sugar, nucleobase, or internucleotide phosphate. Ligands functionalized with an iodoacetamidyl group can also be reacted with internucleotide thiophosphate groups (Asseline et al., 1996). The methods reported in UNIT 4.9 for introducing functional groups at the 5′ ends of oligodeoxyribonucleotides are compatible in most cases with the presence of a second functional group at another position in the oligodeoxyri-
Synthesis of Modified Oligonucleotides and Conjugates
4.10.21 Current Protocols in Nucleic Acid Chemistry
Supplement 7
bonucleotide. It is thus possible to prepare bisderivatized oligonucleotides with two different ligands (Aubert et al., 2000). The conjugation of functionalized ligands to unprotected oligonucleotides carrying suited functional groups offers many advantages over the direct incorporation of the ligands during oligonucleotide synthesis (UNIT 4.3). In particular, this method is very useful when a limited amount of the ligand is available, when the ligand does not resist the chemical conditions required for oligonucleotide deprotection, or when it is only weakly soluble in the solvents needed for oligonucleotide synthesis, thus preventing the preparation of a phosphoramidite or H-phosphonate derivative. Furthermore, the purification of oligonucleotide-ligand conjugates, and particularly those involving two ligands, can be easier using this method, because the oligonucleotides are purified prior to their coupling with ligands, which is not the case when ligands are incorporated during oligonucleotide chain elongation before deprotection. Lastly, as long as only small amounts of conjugate are required, this method is the most convenient one for obtaining many different oligodeoxyribonucleotide-ligand conjugates starting from only one oligodeoxyribonucleotide synthesis.
Critical Parameters
Conjugation of Functionalized Oligodeoxyribonucleotides and Ligands
For TLC analyses of conjugation reactions, the reservoir containing the solvent mixture (including concentrated ammonia) must be well-saturated. It is better to prepare it at least half a day before use. Before loading HPLC columns, organic impurities, such as excess ligands and coupling reagents, should be extracted from crude oligodeoxyribonucleotide solutions with organic solvents or removed by gel filtration. The oligodeoxyribonucleotide solutions must then be filtered through a 0.45-µm disposable filter to remove any particulates and prevent the clogging of columns. An important parameter is the choice of the solvents used to perform the conjugation reactions since oligodeoxyribonucleotides are soluble in water and in buffer solutions, while most ligands are not. A second important parameter is the choice of the method used to recover the oligonucleotide-ligand conjugate prior to its purification by chromatography. When working with a new ligand, it is critical to experiment with different methods on an analytical scale in order to chose the best one.
When working with acridine-containing oligodeoxyribonucleotides, the pH of all solutions must be kept below 7 or above 9.5 in order to prevent the cleavage of the bond between the acridine ring and the linker. The coupling of halogenoalkylated orthophenanthroline derivatives with oligodeoxyribonucleotide 5′-thiophosphates sometimes gives low product yields. Liquid chromatography analysis (Thuong and Asseline, 1991) shows, in addition to the starting oligodeoxyribonucleotide 5′-thiophosphate and the expected oligodeoxyribonucleotide-phenanthroline conjugate, the presence of two other products identified as the (5′-5′)-oligodeoxyribonucleotide phosphorothioate dimer obtained by disulfide bond formation, and the corresponding oligodeoxyribonucleotide 5′-phosphate. The formation of these side-products can be explained by an oxidoreduction reaction triggered by the simultaneous presence of thiophosphate, oxygen, orthophenanthroline, and divalent cations. It is important to note that the characterization of orthophenanthroline-oligonucleotide conjugates by mass spectrometry is often difficult. Oligodeoxyribonucleotides containing a thiol function require degassing of solvents and buffer solutions in order to remove oxygen and any oxidizing reagents, which might lead to the formation of a dimer via disulfide bond formation. Under the conditions described in these protocols, reactivity of oligonucleotide and ligand functional groups with nucleobases should not be problematic. For 5′-carboxylated oligonucleotides, amide linkages should not form with the exocyclic amino function of the nucleobase at the recommended pH (5.5 to 6), as it has been reported that, under these conditions, nucleobases are not modified at pH ≤6 (Ivanovskaya et al., 1987). Ligands functionalized with isothiocyanate or N-hydroxysuccinimide ester groups should also not react with the primary amino function of the nucleobase, which is less reactive than the primary aliphatic amino function at the linker extremity. Succinimidyl esters have a high selectivity for reaction with aliphatic amines. Aromatic isothiocyanates have also been reported to selectively react with aliphatic primary amines (Smith et al., 1985). Finally, aminoalkylated compounds should not form phosphoramidate linkages with internucleotidic phosphodiesters, which are less reactive than the terminal phosphomonoester group. This modification has been reported to be highly selective, and internucleotidic phos-
4.10.22 Supplement 7
Current Protocols in Nucleic Acid Chemistry
phates are not affected (Ivanovskaya et al., 1987). Oligonucleotide-ligand conjugates should be lyophilized and stored in tightly closed vials at −20°C. The ligands should be protected from light at all times, since they are sensitive to light (UNIT 4.8). Under these conditions, they are stable for a year or more. RP-HPLC analyses of four oligonucleotide-ligand conjugates (Figs. 4.10.2, 4.10.8, 4.10.9, 4.10.10) that were stored as aqueous solutions for 18 months in the dark at –20°C showed no detectable degradation.
Anticipated Results The yields obtained for the conjugates are good, typically exceeding 80% for reactions involving 5′-thiophosphate-, 5′-amino-, and 5′thiol-containing oligonucleotides. The yields for 5′-carboxylated and 5′-phosphate oligonucleotides are more variable, ranging from 50% to 80%. The yield of recovered oligonucleotide-ligand conjugate after purification and desalting depends on the nature of the ligand and on the scale of the synthesis. When working on a micromolar scale, it is possible to obtain 20 to 25 OD260 units of the acridine- or psoralen-oligonucleotide conjugate. Purification of 5′-oligonucleotide conjugates by ionexchange chromatography leads to lower recovery yields because of the requirement for an additional desalting step. The thiazole orange– oligodeoxyribonucleotide conjugate is also obtained in good yield (6 OD260 units are recovered from 10 OD260 units of the 5′-modified oligodeoxyribonucleotide starting material); however, when reactions are performed with only 4 to 5 OD260 units of 5′-modified oligodeoxyribonucleotides, the amount of purified oligonucleotide-ligand conjugate obtained is ∼1.5 to 2 OD260 units.
Time Considerations Provided that all reagents and materials required for each step are available, most of the procedures described herein are simple and rapid. The time required to perform each protocol—including purification, characterization, and lyophylization—is ∼1 week.
Literature Cited Asseline, U., Bonfils, E., Dupret, D., and Thuong, N.T. 1996. Synthesis and binding properties of oligonucleotides covalently linked to an acridine derivative: New study of the influence of the dye attachment site. Bioconjugate Chem. 7:369-379. Aubert, Y., Bourgerie, S., Meunier, L., Mayer, R., Roche, A.-C., Monsigny, M., Thuong, N.T., and Asseline, U. 2000. Optimized synthesis of phosphorothioate oligodeoxyribonucleotides substituted with a 5′-protected thiol function and a 3′-amino group. Nucl. Acids Res. 28:818-825. Aubert, Y., Perrouault, L., Hélene, C., Giovannangeli, C., and Asseline, U. 2001. Synthesis and properties of triple helix-forming oligodeoxyribonucleotides containing 7-chloro-7-deaza-2′deoxyguanosine. Bioorg. Med. Chem. 9:16171624. Ivanovskaya, M.G., Gottihk, M.B., and Shabarova, Z.A. 1987. Modification of Oligo(poly)nucleotide Phosphomonoester groups in aqueous solutions. Nucleosides-Nucleotides 6:913-934. Raymond, F., Asseline, U., Roig, V., and Thuong, N.T. 1996. Synthesis and characterization of O6 modified deoxyguanosine-containing oligodeoxyribonucleotides for triple helix formation. Tetrahedon 52:2047-2064. Smith, L.M., Fung, S., Hunkapiller, M.W., Hunkapiller, T.J., and Hood, L.E. 1985. The synthesis of oligonucleotides containing an aliphatic amino group at the 5′ terminus: Synthesis of fluorescent DNA primers for use in DNA analysis. Nucl. Acids. Res. 13:2399-2412. Thuong, N.T. and Asseline, U. 1991. Oligodeoxyribonucleotides attached to intercalators, photoreactive and cleavage agents. In Oligodeoxyribonucleotides and Analogues: A Practical Approach (F. Eckstein, ed.) pp. 283-308. IRL Press, Oxford.
Contributed by Ulysse Asseline and Nguyen T. Thuong Centre de Biophysique Moleculaire, CNRS Orléans, France The authors would like to express their appreciation to past and present collaborators for their contribution to the development of varied families of oligonucleotide conjugates over the past years. This work was supported by Rhône-Poulenc, Agence Nationale de Recherche contre le SIDA, and bioMérieux.
Synthesis of Modified Oligonucleotides and Conjugates
4.10.23 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Synthesis and Purification of Peptide Nucleic Acids
UNIT 4.11
Peptide nucleic acids (PNAs) are DNA analogs in which the normal phosphodiester backbone is replaced by 2-aminoethyl glycine linkages (Fig. 4.11.1). In spite of this significant chemical modification, the hybridization of PNAs with DNA or RNA follows normal rules for Watson-Crick pairing and occurs with high affinity. The fact that PNAs possess a dramatically different backbone and bind efficiently has created enormous interest in their application. This unit describes the synthesis and purification of PNAs. PNAs can be synthesized using either automated procedures (see Basic Protocol 1; Mayfield and Corey, 1999) or manual procedures (see Basic Protocol 2; Norton et al., 1995). The goal here is to provide the reader with the basic information necessary to initiate experiments with PNAs. NOTE: It is essential that the reagents used for PNA synthesis, whether automated or manual, be kept as anhydrous as possible, because contamination with water will result in incomplete coupling of monomers during synthesis. AUTOMATED SYNTHESIS OF PEPTIDE NUCLEIC ACIDS The automated synthesis of PNAs is illustrated in Figure 4.11.2. Automated synthesis is a convenient strategy for obtaining PNAs, and is performed using the Expedite synthesizer (Applied Biosystems). This instrument has been specially adapted for PNA synthesis, with proprietary software for FMOC chemistry instead of the phosphoramidite chemistry used for typical oligonucleotide synthesis. It is probably possible to adapt other synthesizers for PNA synthesis; however, the investigator will need to consider whether the number of PNAs needed justifies the time and expense required to adapt the instrumentation.
BASIC PROTOCOL 1
The reagents used are available from Applied Biosystems separately or as an Expedite PNA kit. Two resins are available: a xanthen alkonic acid (XAL) resin and a peptide amide linker (PAL) resin. Although either is adequate for automated synthesis, the XAL resin is preferred because the cleavage step is considerably shorter (5 min according to Applied Biosystems, compared to 90 min for the PAL resin).
N 2H
base N O NH O base N O OH O
Figure 4.11.1 Structure of a peptide nucleic acid. Contributed by Dwaine A. Braasch, Christopher J. Nulf, and David R. Corey Current Protocols in Nucleic Acid Chemistry (2002) 4.11.1-4.11.18 Copyright © 2002 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.11.1 Supplement 9
coupling step base*
NHFMOC
P
O
deprotection 20% piperidine in DMF
base*
N
O N
HO
NH2
P
NHFMOC
O
HATU, 0.2 M DIPEA 0.3 M 2, 6-lutidine, DMF, NMP
N H
P
1. capping step 5% Ac2O, 6% 2, 6-lutidine in DMF 2. deprotection
n=n+1
n
base*
P
N H
coupling step
N
N H
O
N H
P
NHFMOC
O
trace of "capped" unreacted oligomer
+
N
NH2
O
1. deprotection 2. cleavage from the support 20% m -cresol in TFA
when n = n max
base
n max
base O
O
N
HO
O
O
N
n
base*
base*
O
NHFMOC
O
N
N H
O
NH2
O
PNA monomers NHBHOC
O
NH
N
N
N
N
O
O
N
O
O
HO
N
N
N
N
O
NHFMOC
HO
NH
N
NHBHOC
O N
N
NHFMOC
O
O
O N
HO
NHBHOC
O
N
NHFMOC
HO
O
NHFMOC
Figure 4.11.2 Automated PNA synthesis as described in Basic Protocol 1. Abbreviations: Ac2O, acetic anhydride; base*, N-protected nucleobase (see PNA monomers); BHOC, benzhydryloxycarbonyl; DIPEA, diisopropylethylamine; DMF, N,Ndimethylformamide; FMOC, 9-fluorenylmethoxycarbonyl; HATU, O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; NMP, N-methylpyrrolidone; P, FMOC-XAL-PEG-polystyrene; TFA, trifluoroacetic acid.
2-Aminoethoxy-2-ethoxy acetic acid (AEEA) is used as a linker molecule for PNA synthesis. A linker molecule is used to introduce a controlled space between PNAs or between a PNA and some other functional or spatially addressable large group, such as rhodamine or biotin. Linked PNAs (bis-PNAs) possess an enhanced ability to bind by strand invasion and are an important tool for recognition of duplex DNA. Linker coupling is often inefficient, so it is always done two times.
Synthesis and Purification of Peptide Nucleic Acids
Although the synthesis described here is an automated process, this does not excuse the experimenter from closely monitoring the various steps throughout the synthesis. Careful observation to ensure proper machine function can result in catching errors as they occur and allow manual intervention that can rescue the synthesis and prevent loss of reagents and time (see Critical Parameters).
4.11.2 Supplement 9
Current Protocols in Nucleic Acid Chemistry
Materials PNA Expedite reagents (Applied Biosystems) FMOC-PNA monomers (Fig. 4.11.2): 9-fluorenylmethoxycarbonyl-protected peptide nucleic acid monomers (A, T, C, and G), base protected with benzhydryloxycarbonyl (BHOC) Diluent: N-methylpyrrolidone (NMP) Activator: 7-aza-1-hydroxybenzotriazole (HOAt) or O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) Linker: 2-aminoethoxy-2-ethoxy acetic acid (AEEA) Base solution: 0.2 M diisopropylethylamine (DIPEA)/0.3 M 2,6-lutidine Deblocking solution: 20% (v/v) piperidine in N,N-dimethylformamide (DMF) Capping solution: 5% (v/v) acetic anhydride/6% (v/v) 2,6-lutidine in DMF N,N-Dimethylformamide (DMF), anhydrous (Burdick Jackson; wash A is Opti-Dry DMF from Fisher; wash B is anhydrous DMF from Applied Biosystems) Amino acids (Novabiochem, Advanced Chemtech) Isopropyl alcohol (optional) Cleavage cocktail: 20% (v/v) m-cresol (Sigma-Aldrich) in trifluoroacetic acid (TFA; Burdick Jackson) Diethyl ether, –20°C Expedite 8909 synthesizer (Applied Biosystems) FMOC-XAL-PEG-PS synthesis column (0.2 µmol prepacked; Applied Biosystems) 10-mL syringe 1.5-mL, 0.2-µm polytetrafluoroethylene (PTFE) or regenerated cellulose spin column (Millipore) Additional reagents and equipment for automated synthesis (see manufacturer’s instructions) and for purification and analysis of PNAs (see Basic Protocol 3) NOTE: Powdered reagents such as monomers, activator, and linker (AEEA) should be unpacked on arrival and stored at –20°C in a sealed container containing Drierite desiccant. Monomers should be inspected upon arrival. Clumps of reagent may indicate that water has been introduced during shipping. NOTE: The authors use three sources of DMF because the bottles from Fisher (Opti-Dry) and Applied Biosystems fit onto the input fitting and reagent port on the synthesizer, and the third can be used following synthesis. All DMF must be anhydrous and should have a low amine content to reduce the likelihood of side reactions. DMF should be purchased in 100-mL volumes to ensure that it is used quickly, minimizing the likelihood that contaminating water will interfere with synthesis. Prepare reagents 1. Dry all powdered reagents in vacuo overnight prior to solubilizing. Although the authors have found that drying in vacuo is most necessary during humid weather, it is always a worthwhile precaution.
2. Warm amber bottles in which FMOC-PNA monomers were shipped to room temperature prior to solubilization to prevent water from condensing inside the container. 3. Solubilize FMOC-PNA monomers by adding 3.25 mL NMP diluent directly to each amber bottle (final 216 mM monomer). Allow the mixture to sit undisturbed for 30 min at room temperature.
Synthesis of Modified Oligonucleotides and Conjugates
4.11.3 Current Protocols in Nucleic Acid Chemistry
Supplement 8
Premature vortexing of the monomer at this point will cause partially dissolved clumps of monomer to stick to the side of the bottle. If this occurs, extra time should be taken to bring the clumps to the bottom of the bottle. Typically, monomers A, T, and G do not require vortexing, and a gentle swirling of the bottle’s contents will suffice. Solubilization of monomer C often requires some assistance. Intermittent heating of monomer C in a shallow water bath at 37°C can assist in solubilization, as can occasional vortexing or sonication. The authors have also diluted the C monomer in an additional 0.5 mL of NMP and have observed that this facilitates dissolving the reagent without decreasing synthesis yield. Experimenters should note that solubility can be dependent on the lot number of PNA monomer; some lots can be more or less difficult to dissolve than others. The volumes indicated for reagent solubilization (steps 3 to 5) are adequate for 37 cycles, but the volumes prepared must ultimately accommodate the specific sequences and coupling events required for a given synthesis. Each cycle requires 90 ìL monomer, 90 ìL activator, 90 ìL base, 1.2 mL deblocking solution, 2.39 mL DMF wash A, 36 ìL DMF wash B, and 300 ìL capping solution. These volumes are estimates. The investigator should always load significantly more reagent on the synthesizer to ensure that no reagent runs out during the final coupling steps.
4. Dissolve PNA activator (HOAt or HATU) in 13.5 mL anhydrous DMF (final 182 mM). Although HOAt is generally less expensive, it is also less efficient as a coupling reagent than HATU, which was developed specifically for PNA synthesis. HOAt should only be used for shorter sequences (≤12 couplings). HATU has been used for syntheses requiring >40 couplings.
5. Dissolve AEEA linker in 2.4 mL NMP diluent (final 209 mM). Perform PNA synthesis 6. Load the above reagents as well as base solution, amino acids, deblocking solution, and capping solution onto an Expedite 8909 synthesizer with an FMOC-XAL-PEGPS column. Monomers, activator, and linker should not remain on the machine for >2 weeks. Amino acids should not be left on the machine for >2 days due to their tendency to crystallize. Amino acids are the least expensive reagent and it is cost effective to replace these solutions frequently rather than risk failed syntheses or damage to the instrument.
7. Perform synthesis according to manufacturer’s programs and specifications, stopping before removal of the final FMOC group. It is critical that the final FMOC be left on the PNA until a decision has been made to cleave the PNA from the resin or add another group. If synthesis is complete and the PNA is to be cleaved from the resin, proceed to step 9.
8. Optional: Perform any desired manual additions (e.g., see Support Protocols 1 and 2). 9. Implement the final deblock option in the prime menu of the Expedite PNA software. Cycle the final deblock procedure one time to complete the double deblock procedure. Wash and prepare PNA-bound resin 10. Remove the column from the synthesizer and wash four times with 10 mL DMF, reversing the direction of flow through the column each time. Synthesis and Purification of Peptide Nucleic Acids
11. Wash the column four times with 10 mL isopropyl alcohol, reversing the direction of flow through the column each time to facilitate drying of the resin.
4.11.4 Supplement 8
Current Protocols in Nucleic Acid Chemistry
12. Dry the resin in vacuo for a minimum of 30 min or by blowing filtered house air across the column for 3 to 5 min, reversing the ends frequently. Resin is sufficiently dry when the resin plug slides easily from end to end as the air input is reversed.
Cleave PNA from solid-phase resin 13. Transfer the dried, resin-bound, deprotected PNA to a 1.5-mL, 0.2-µm PTFE or regenerated cellulose spin column. 14. Add 250 µL cleavage cocktail and incubate 90 min at room temperature. Although cleavage of PNAs from the FMOC-XAL-PEG-PS resin occurs in 5 min, cleavage of the protecting groups on the PNA side-chains requires at least 90 min. Complete cleavage of the BHOC side chains can be verified by MALDI-TOF mass spectrometry. Incomplete cleavage will result in a mass that exceeds the expected value by increments of the BHOC mass (100.1). Also, in the authors’ experience, products that retain one or more protecting groups will have longer retention times by RP-HPLC (the protecting groups are hydrophobic). Uniform cleavage is dependent on the freshness of the TFA, while the m-cresol serves as a molecular scavenger. The quality of the TFA can be checked by observing the color of the solution. It should be clear to slightly yellow. If the color progresses to a more orangebrown color, it should not be used for cleavage, but may still be used in preparing RP-HPLC buffer A (see Basic Protocol 3). In addition to solution color, TFA should release a small amount of fume (smoke) when the container is opened. If this is not observed, it should not be used for any procedure involving PNAs. CAUTION: TFA is caustic and should be dispensed using only glass pipets or pipet tips containing a charcoal filter (Intermountain Scientific). The charcoal filter serves as a barrier that protects the pipettor seals from the TFA fumes.
15. Centrifuge 2 min at 1300 × g for a PTFE filter or 2 min at 8400 × g for a regenerated cellulose filter. 16. Repeat steps 14 and 15, but reduce cleavage time to 5 min. 17. Collect the cleavage filtrate, remove the filter unit, and precipitate the PNA by adding 1 mL cold (–20°C) diethyl ether. Invert the tube several times to ensure complete precipitation. If the synthesis has been successful, the precipitated PNA should be obvious.
18. Centrifuge precipitated PNA 2 min at 1300 × g. Discard the supernatant. 19. Wash the pellet three times with 1 mL diethyl ether, vortexing to suspend the pellet. 20. Centrifuge 2 min at 8400 × g to repack the pellet. Centrifugation speeds of more than 8400 × g should be avoided because tight packing of PNA makes it difficult to dissolve the pellet.
21. Remove as much of the supernatant as possible by aspiration and then air dry the pellet for 5 to 10 min in a chemical fume hood. 22. Hydrate the pellet with 200 µL sterile water (for a 2-µmol synthesis) and allow the tube to remain undisturbed for 10 to 15 min at 65°C. Only slight vortexing should be required to complete PNA solubilization.
23. Purify and analyze PNA (see Basic Protocol 3).
Synthesis of Modified Oligonucleotides and Conjugates
4.11.5 Current Protocols in Nucleic Acid Chemistry
Supplement 8
SUPPORT PROTOCOL 1
ADDING PEPTIDES TO PNAS The addition of peptide sequences to PNAs is a convenient method for obtaining conjugates in which the peptide domain enhances hybridization (Zhang et al., 2000) or cell uptake (Simmons et al., 1997) of the attached PNA . Peptides can be added to a PNA in a number of ways. If the peptide contains three or fewer different amino acids, it can be conveniently added immediately before or after automated synthesis using the three open ports on the Expedite 8909 synthesizer in addition to the four dedicated to PNA monomers. All amino acids should be double coupled since amino acid coupling is sometimes inefficient. Also, since amino acids are inexpensive relative to PNA monomers, generous use of amino acids during coupling is a cost-effective strategy for optimizing synthesis yields. If more than three different amino acids need to be added, it is often more convenient to contract a dedicated peptide synthesis facility to add the completed peptide. In this case, it is recommended that the first amino acid of the peptide be coupled to the newly synthesized PNA prior to shipping the resin. The authors have found that this procedure reduces the likelihood of the N terminus becoming blocked during shipping and storage. The synthesis of the PNA should be coordinated with the facility that will add the peptide, so that delays between syntheses are avoided. Delay between syntheses can result in the spontaneous loss of FMOC groups, exposing the N terminus to modification and preventing its extension. The facility adding the peptide should be instructed to double or triple couple the first amino acid that is added at their facility. Prior to shipping, the column should be washed with DMF and dried in vacuo overnight. The thiol group of cysteine provides a convenient reactive group for PNA modification. Additional care is required to adequately cleave PNAs or PNA conjugates containing sulfhydryl groups, as the authors and others (Goodwin et al., 1998) have noted that the sulfhydryl can be modified during deprotection and purification. To avoid modification of cysteine, the cleavage cocktail should be supplemented with 7.5 mg pure crystalline phenol (Fisher) and 250 µL ethanedithiol (Sigma-Aldrich) per 1 mL of cleavage cocktail. Cysteine-containing PNAs should be neutralized immediately after purification to avoid the formation of TFA adducts. Neutralization can be achieved by adding 0.5 mL of an aqueous solution of 0.1 M ammonium acetate to the RP-HPLC fraction collection tube prior to collecting the PNA fraction. Incomplete neutralization will result in a product that is 97 mass units higher than expected, corresponding to an adduct with TFA.
SUPPORT PROTOCOL 2
ADDITION OF BIOTIN Once a PNA is synthesized, fluorescent groups, biotin, or other labels can be added to the free N terminus prior to deprotection. The labeling of PNAs with biotin is described as an example. Additional Materials (also see Basic Protocol 1) Biotin (Sigma) 42°C water bath 1-mL syringe 1. Perform a normal automated PNA synthesis (see Basic Protocol 1, steps 1 to 8). 2. Dissolve 20 mg biotin, 6.1 mg HATU, and 1.4 mg HOAt in 800 µl DMF. Warm the solution to 42°C and vortex intermittently until completely dissolved.
Synthesis and Purification of Peptide Nucleic Acids
Biotin is not readily soluble and will require warming and vortexing. Due to its poor solubility, biotin solutions should never be put on the synthesizer, as it will clog the lines.
3. Add 200 µL PNA base solution and mix well. Allow components to activate for 5 min at 42°C.
4.11.6 Supplement 8
Current Protocols in Nucleic Acid Chemistry
4. Remove N-terminal FMOC group by performing the final two deblock cycles to remove the N-terminal cap of the resin-bound PNA (see Basic Protocol 1, step 9). 5. Wash the column two times from each end with 10 mL DMF. 6. Draw up the biotin solution into a 1-mL syringe and place into one end of the column. 7. Place a second syringe into the other end of the column and push the solution back and forth for 30 min. 8. Repeat steps 5 to 7 with another 1-mL preparation of biotin solution. Addition of biotin is repeated because of the inherently poor coupling efficiency of biotin.
9. Proceed to the procedure for cleavage of PNAs from solid-phase resin (see Basic Protocol 1, steps 10 to 23). MANUAL SYNTHESIS OF PEPTIDE NUCLEIC ACIDS The manual synthesis of PNAs is illustrated in Figure 4.11.3. Manual synthesis of PNAs is advantageous because PNAs can be obtained in larger amounts (>2 µmol) than on the Expedite synthesizer. By changing the amount of resin used, one can prepare as much or as little PNA as needed for each experiment. Manual synthesis also avoids the need for a dedicated automated synthesizer. As with automated synthesis, it is important to keep reagents and materials as anhydrous as possible. However, the coupling reactions are more exposed to atmospheric water. The authors have found that syntheses that use tert-butyloxycarbonyl (BOC) monomers generally produce better yields than syntheses using FMOC monomers.
BASIC PROTOCOL 2
Manual PNA synthesis is often so efficient that a capping step can be dispensed with. It is sometimes advisable, however, to include a capping step after coupling of the monomer to simplify the HPLC purification. The individual experimenter will have to determine the necessity for capping. It is typically necessary for long syntheses or for syntheses that have failed in the past. Many different types of apparatus can be used for manual peptide synthesis, and it is likely that these can be adapted for PNA synthesis. The apparatus described here (Fig. 4.11.4; Norton et al., 1995) uses common laboratory glassware and offers robust performance. While the details of manual synthesis will vary with apparatus, the outline of the procedure and the precautions that need to be taken will remain the same. Because a single missed step can ruin a labor-intensive synthesis, the authors follow a detailed checklist for each step. The checklist provides a written record that all steps were performed. A sample spreadsheet detailing the amount of reagent needed for synthesis is shown in Figure 4.11.5. Materials Nitrogen source N,N-Dimethylformamide (DMF; OptiDry; Fisher) 4-Hydroxymethylphenylamidomethyl (PAM) resin protected with tert-butyloxycarbonyl (BOC; Applied Biosystems) Carrier resin: PAM resin capped with an acetyl group (see Support Protocol 3) BOC-PNA monomers (Fig. 4.11.3; Applied Biosystems): tert-butyloxycarbonyl-protected peptide nucleic acid monomers (A, C, G, and T), base protected with benzyloxycarbonyl 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate (HBTU) and 1-hydroxybenzotriazole (HOBt) activators (Applied Biosystems) Fresh dichloromethane (DCM; Fisher) m-Cresol Trifluoroacetic acid (TFA; Burdick Jackson)
Synthesis of Modified Oligonucleotides and Conjugates
4.11.7 Current Protocols in Nucleic Acid Chemistry
Supplement 9
coupling step base*
NHBOC
P
O
deprotection 5% m -cresol in TFA P
base*
N
O N
HO
NH2
NHBOC
O
HBTU/HOBT/DIPEA in DMF
N H
P
n=n+1
n
base* O
P
N H
O
O
N H
n
base*
coupling step
N
O
N H
P
NHBOC
O
N
NH2
O
1. deprotection 2. cleavage from the support TFA/m -cresol/thioanisole/TFMSA
when n = n max
base
n max
base O
O
N
HO
deprotection
base*
N
NHBOC
O
N
N H
O
NH2
O
PNA monomers NHCO2Bn
O
NH
N
N
N
N
O
O
N
O
O
NHBOC
HO
N
N
N
O
NHBOC
HO
NH
N
NHCO2Bn
O N
N
O
N
O
O N
HO
NHCO2Bn
O
N
NHBOC
HO
O
NHBOC
Figure 4.11.3 Manual PNA synthesis as described in Basic Protocol 2. Although a capping step can be added, it is often not required and is not shown here. Abbreviations: base*, N-protected nucleobase (see PNA monomers); BOC, tert-butyloxycarbonyl; Bn, benzyl; DIPEA, diisopropylethylamine; DMF, dimethylformamide; HBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophospate; HOBt, 1hydroxybenzotriazole; P, PAM resin; TFA, trifluoroacetic acid; TFMSA, trifluoromethanesulfonic acid.
Pyridine Diisopropylethylamine (DIPEA) Methanol Thioanisole Trifluoromethanesulfonic acid (TFMSA; Aldrich) Diethyl ether, ice cold
Synthesis and Purification of Peptide Nucleic Acids
250°C oven 125-mL vacuum filtration side-arm flasks 24/40 rubber septa 15-mL medium (C) fritted Pyrex funnel Vacuum tubing 3-way valves 250-mL Wheaton bottles with caps
4.11.8 Supplement 9
Current Protocols in Nucleic Acid Chemistry
fritted filter
side-arm flask
coupling flask
deprotection flask
3-way valve
vacuum vacuum release valve N2
Figure 4.11.4 Apparatus for manual synthesis. Reprinted from Norton et al. (1995) with permission from Elsevier Science.
C-Terminus 1 2 3 4 5 6 7 8 9 10 11 12 13 14 N-Terminus
Monomer terminal amide lysine A A C A G A T T G G G A T
Molecular Weight g/mol 17.00 128.00 275.32 275.32 251.30 275.32 291.32 275.32 266.28 266.28 291.32 291.32 291.32 275.32 266.28
PNA mass after each coupling g/mol – 145.00 420.32 695.64 946.94 1222.26 1513.58 1788.90 2055.18 2321.46 2612.78 2904.10 3195.42 3470.74 3737.02 Total Mass
A Monomer G Monomer C Monomer T Monomer HBTU HOBt DIPEA DMF
Amount of Resin Used Substitution Number for Resin Total Active Sites PNA Mass
10 mg 0.66 mmol/g 0.0066 mmol 3737.02 mg/mmol
Amount of PNA to be Synthesized
24.6 mg
Equivalents 5.0 5.0 5.0 5.0 4.5 5.0 10.0 –
Amount Per Coupling 17.41 mg 17.94 mg 16.62 mg 12.68 mg 11.26 mg 4.46 mg 8.54 µL Up to 1 mL
3737.02
Figure 4.11.5 Example of a spreadsheet for the manual synthesis of a 14-base PNA including lysine at the C terminus. The resin used produces a theoretical yield of 24.6 mg of PNA upon cleavage.
Synthesis of Modified Oligonucleotides and Conjugates
4.11.9 Current Protocols in Nucleic Acid Chemistry
Supplement 8
Lyophilizer 10-mL flask with a ground glass joint Desiccator Additional reagents and equipment for purification and analysis of PNAs (see Basic Protocol 3) NOTE: All powdered reagents such as monomers and activator should be unpacked on arrival and stored at –20°C in a sealed container containing Drierite desiccant. Monomers should be inspected upon arrival. Clumps of reagent may indicate that water has been introduced during shipping. DMF should have a low amine content to reduce the likelihood of side reactions. Dry reagents and supplies 1. Dry all monomers and coupling reagents overnight in vacuo before beginning synthesis. To prevent accumulation of moisture, BOC-PNA monomers that have been refrigerated should be warmed to room temperature before opening.
2. Dry all glassware, pipet tips, and 1.5-mL microcentrifuge tubes in a 250°C oven overnight prior to use. Flush pipet tips and microcentrifuge tubes with nitrogen to ensure they are dry prior to synthesis. Set up apparatus 3. Clear a work area in a chemical hood. 4. Fit rubber septa over the tops of two 125-mL side-arm flasks and make a single hole in the middle of each septum to allow a 15-mL fritted funnel to be inserted without too much force. 5. Assemble the manual synthesis apparatus as in Figure 4.11.4 using vacuum tubing and 3-way valves such that the vacuum and nitrogen bubbling can be easily manipulated on and off. 6. Ensure that the 15-mL fritted funnel is clean and unclogged. Pull 5 mL DMF through the funnel to make sure it drains quickly. Prepare reagents 7. In a 1.5-mL microcentrifuge tube, weigh out the appropriate amount of BOC-protected PAM resin and add enough carrier resin to give ∼50 mg total resin weight. The purpose of the carrier resin is to facilitate handling of the resin by allowing researchers to handle larger volumes. The amount of PNA to be synthesized is dependent on the amount of resin used and the number of active sites on the resin. The number of active sites is based on the substitution number (Fig. 4.11.5), which should be listed on the resin bottle when purchased. The total number of active sites is based only on the amount the BOC-protected (noncarrier) PAM resin, as the carrier resin has been capped and contains no active sites. PAM resin can also be purchased with the first amino acid already attached (Advanced Chemtech).
8. Load 1.5-mL microcentrifuge tubes with the proper amount of dry monomer for each coupling reaction. Use a 5-fold excess of monomer over the resin active sites. Synthesis and Purification of Peptide Nucleic Acids
It is easiest to set up a spreadsheet (Fig. 4.11.5) with quantities of monomers, HBTU, HOBt, and DIPEA used for each activation/coupling reaction, checking them off during synthesis of the PNA.
4.11.10 Supplement 8
Current Protocols in Nucleic Acid Chemistry
9. For each coupling reaction, measure out a 5-fold excess of HOBt (relative to resin active sites), a 4.5-fold excess of HBTU, 10 eq DIPEA, and 1 mL DMF. Draw DMF from the bottle using a syringe under nitrogen or argon gas to keep it as anhydrous as possible. HOBt, HBTU, DIPEA, and DMF will be added to the monomer in each microcentrifuge tube just minutes before starting the coupling reaction (step 17). This method is the most efficient way of activating the monomers, and thus preventing deletions in the final product. Aldrich sells DMF in Sure/Seal bottles, which have a rubber opening on a crimped lid so that a syringe can be inserted without uncapping the bottle and exposing the contents to air. A nitrogen-filled balloon may also be inserted through the rubber opening to continually flush the bottle with nitrogen during the synthesis.
10. Prepare 200 mL fresh 50:50 (v/v) DMF/DCM for washing. Also prepare 100 mL of 5% (v/v) m-cresol/TFA and 100 mL pyridine in separate clean, dry 250-mL Wheaton bottles with caps. The pyridine is used to wash the resin with the base prior to coupling. CAUTION: TFA is caustic and should be dispensed using only glass pipets or pipet tips containing a charcoal filter (Intermountain Scientific). The charcoal filter serves as a barrier that protects the pipettor seals from the TFA fumes.
11. Assemble disposable glass pipets and bulbs, one for each reagent, and place near or on each reagent bottle. For convenience and to prevent contamination, the authors usually tape a test tube onto each bottle as a pipet holder.
12. Place the 15-mL fritted funnel into the deblocking flask. Wet the rubber septum and the funnel with a little methanol to help it slide in. 13. Add the dry resin to the 15-mL fritted funnel without solubilizing it in DMF. It is easier to get it all in this way.
Perform synthesis 14. Swell resin in 1 mL DMF for 1 hr with nitrogen bubbling. 15. Close and bleed vacuum line. 16. Add 1 mL of 5% m-cresol/TFA to begin deprotection. Stir 3 min with nitrogen bubbling. 17. While the BOC group is being removed, activate (esterify) the first monomer to be added by adding HOBt, HBTU, DMF, and DIPEA (from step 9) to the monomer tube (step 8). Vortex until everything has gone into solution. Typically, these solutions turn a tan color after vortexing. Failure to change color can sometimes be an indication that the activation step is not proceeding properly. As the synthesis progresses, liquid will accumulate in the flasks. It is important to watch the level of liquids in the coupling and deprotection flasks and empty them when the volumes approach the fritted funnel. The deprotection flask can be emptied during a coupling step and vice versa.
18. Vacuum off deblocking solution from the resin. 19. Wash resin two times with 1 mL of 50:50 DMF/DCM. 20. Close and bleed vacuum line.
Synthesis of Modified Oligonucleotides and Conjugates
4.11.11 Current Protocols in Nucleic Acid Chemistry
Supplement 8
21. Remove funnel from the deprotection flask and insert into the rubber septum over the coupling flask. 22. Add activated monomer to resin and mix 20 min, with nitrogen bubbling, to couple the monomer to the resin (or growing PNA). 23. Vacuum off solution. 24. Wash six times with 1 mL of 50:50 DMF/DCM. 25. Wash with 1 mL pyridine then with 1 mL dry DMF. If capping is necessary, add 1 mL of 1:1 (v/v) acetic anhydride/DMF to the resin and mix for 20 min. Wash well with DMF and proceed to the next step.
26. Vacuum off solution. 27. Close and bleed vacuum line. 28. Remove funnel from the coupling flask and insert into the septum over the deblocking flask. 29. Repeat steps 16 to 28 for remaining monomer additions. 30. Remove the final protecting group as in steps 15 and 16. 31. Vacuum off deblocking solution. 32. Wash six times with 1 mL of 50:50 DMF/DCM. 33. Wash six times with 1 mL methanol. 34. Lyophilize overnight. When the synthesis is complete, it is customary to wash the resin with methanol and to dry in vacuo overnight before the cleavage is carried out. If the synthesis takes >1 day, it will be necessary to store the resin. Stop the synthesis just prior to deblocking the PNA, leaving the protecting group on. Wash the resin several times with HPLC-grade methanol. Remove the funnel with the resin from the coupling flask, put a Kimwipe over the top, and secure it with a rubber band. Label the funnel and put it in a desiccator. Resume the synthesis the following day by starting with swelling of the resin in NMP and deblocking the PNA (steps 14 to 16).
Cleave PNA from resin 35. Connect a clean 125-mL vacuum flask to the synthesis apparatus in place of the coupling flask. 36. Attach a rubber septum over the top of the flask and insert the funnel that contains the resin. 37. Prepare 4 mL cleavage cocktail in a clean, dry 10-mL flask that has a ground glass joint. Mix 1 part m-cresol, 1 part thioanisole, and 6 parts TFA. Cap the flask, put on gloves and a shield, crack open a vial of TFMSA, and add 2 parts TFMSA. Typically, the cleavage cocktail turns brown at this point. CAUTION: TFMSA is corrosive and extremely destructive to mucous membranes, the upper respiratory tract, eyes, and skin. Avoid skin contact and inhalation. Always use suitable protection.
38. Using a pipettor, add 1 mL cleavage cocktail to the resin. Using a very small flow of nitrogen into the flask, allow solution to barely bubble for ∼1 hr. Synthesis and Purification of Peptide Nucleic Acids
4.11.12 Supplement 8
Current Protocols in Nucleic Acid Chemistry
39. Turn off the nitrogen and apply a vacuum to pull the cleavage solution into the clean flask. Remove as much of the cleavage solution as possible before proceeding to the precipitation. Excess TFA will make it more difficult to precipitate the PNA. Excess TFA can be removed from the solution by blowing a steady stream of nitrogen into the flask until most of the solution is gone, or by applying a vacuum to the flask for several minutes.
40. With most of the cleavage solution gone, add ≥45 mL ice-cold diethyl ether to the flask and set it on ice. 41. Take a spatula and scrape the sides of the flask to loosen all of the PNA into solution. There should be a white precipitate in the solution.
42. Pour the PNA/diethyl ether solution into a 50-mL conical centrifuge tube, cap tightly, and centrifuge 3 min at 1040 × g (e.g., 2500 rpm in a Beckman S4180 swinging bucket rotor), 5°C, pelleting the PNA to the bottom of the tube. 43. Carefully decant or aspirate off the diethyl ether. 44. Wash pellet three times by adding 50 mL ice-cold diethyl ether to the tube, vortexing, centrifuging, and removing the supernatant. 45. After decanting the last time, place a Kimwipe over the tube containing the wellwashed pellet and place it in a desiccator. Attach the house vacuum and allow PNA to dry overnight. 46. Purify and analyze PNA (see Basic Protocol 3). The PNA can be stored at −20°C as a lyophilized product or as an aqueous stock solution (in deionized water). Traces of TFA will slightly acidify the solution and readily dissolve the PNA.
PREPARATION OF CARRIER RESIN FOR MANUAL PNA SYNTHESIS Carrier resin is prepared by deprotecting a simple BOC-protected PAM resin and performing a capping step using acetic anhydride.
SUPPORT PROTOCOL 3
Additional Materials (also see Basic Protocol 2) tert-Butyloxycarbonyl-protected 4-hydroxymethylphenylamidomethyl resin (e.g., BOC-Ala-PAM, BOC-Val-PAM, BOC-Ile-PAM; Applied Biosystems) Acetic anhydride HPLC-grade dichloromethane HPLC-grade methanol 1. Set up the manual synthesis apparatus (Fig. 4.11.4) with a single flask. 2. Place ∼2 g BOC-protected PAM resin in the fritted funnel and swell with 1 mL DMF for 1 hr. 3. Vacuum off DMF. 4. Add a large excess (e.g., 1 mL) of 5% (v/v) m-cresol/TFA and deprotect the resin for 10 min with bubbling. 5. Wash two times with 1 mL DMF and repeat deprotection two more times. The resin should be fully deprotected at this point.
6. Wash five times with 1 mL DMF and once with 1 mL pyridine. 7. Add 1 mL of 1:1: (v/v) acetic anhydride/DMF and bubble for 20 min. 8. Wash once with 1 mL DMF and repeat step 7.
Synthesis of Modified Oligonucleotides and Conjugates
4.11.13 Current Protocols in Nucleic Acid Chemistry
Supplement 8
9. Wash once each with 1 mL DMF, 1 mL dichloromethane, and 1 mL methanol. 10. Dry overnight in a desiccator. The resin can be prepared in bulk and stored at 4°C in the desiccator. BASIC PROTOCOL 3
PURIFICATION AND ANALYSIS OF PEPTIDE NUCLEIC ACIDS PNAs can be purified by reversed-phase HPLC (RP-HPLC) followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) (Fig. 4.11.6). PNAs are not, however, purified or analyzed by standard procedures used for oligonucleotides. PNA purification and analysis is more similar to that for peptides. Materials PNA sample solution (see Basic Protocols 1 and 2) RP-HPLC buffer A: 0.1% (v/v) trifluoroacetic acid (TFA; Burdick Jackson) in water, passed through a 47-mm, 0.4-µm nylon membrane (Whatman) RP-HPLC buffer B: 0.1% (v/v) TFA in acetonitrile (Optima grade; Fisher), filtered through an Anodisc 47 filter (0.22-µm; Whatman) α-Cyano-4-hydroxycinnamic acid (Sigma) Isopropanol High-performance liquid chromatograph (HPLC) with C18 reversed-phase column (300-Å Microsorb-MV column; Varian Analytical Instruments) Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer (Voyager-DE workstation; Applied Biosystems) Lyophilizer UV spectrophotometer Additional reagents and equipment for HPLC and MALDI-TOF-MS
A 12.358
B m.w. 5144.58
%B 100
60 40 20
11.153
0
5
10.073
9.261 9.910
4.898
3.171
10.181 10.418
80
Retention time (min)
Synthesis and Purification of Peptide Nucleic Acids
Mass (amu)
Figure 4.11.6 Typical (A) HPLC and (B) MALDI-TOF mass spectrometry data.
4.11.14 Supplement 8
Current Protocols in Nucleic Acid Chemistry
Purify by HPLC 1. Centrifuge a PNA solution 3 min at 12,000 × g, room temperature, to remove particulate. 2. Heat a C18 reversed-phase HPLC column to 55°C. PNAs tend to form internal structure or higher order aggregates; sharper peaks will often be obtained if the column is maintained at 55°C using a heated water jacket.
3. Set up a gradient of 0% to 5% (v/v) RP-HPLC buffer B in buffer A for 6 min followed by 5% to 100% buffer B in buffer A for 24 min. 4. Inject sample. 5. Collect fractions corresponding to major peaks. Analyze by MALDI-TOF-MS 6. Spot a 1-µL aliquot of each HPLC fraction on the laser target of a MALDI-TOF mass spectrometer. 7. Overlay the sample with 1 µL matrix consisting of 10 mg/mL α-cyano-4-hydroxycinnamic acid in 25:75 (v/v) RP-HPLC buffers A/B. 8. Activate the laser and collect data. Resolution is best when lower laser energies are used (∼1400 mV) but higher energies are sometimes necessary, especially with long PNAs and PNA-peptide conjugates. Analytical scale analysis by HPLC or mass spectral analysis of the crude product often reveals that only one product has been formed. If this is the case, the PNA can be conveniently purified by Sep-Pak Vac 6-mL (1 g) C18 cartridge (Waters Chromatography). Alternatively, PNAs can be purified by preparative C18 HPLC (Baker Bond, J.T. Baker). PNAs typically elute between 32% and 37% RP-HPLC buffer B and are routinely >80% full-length material.
Solubilize and store PNA 9. Pool collected fractions containing the PNA with the appropriate mass. Freeze in an isopropanol/dry ice bath and lyophilize. PNAs that are not to be used immediately can be stored indefinitely in a lyophilized form at –20°C in a sealed storage box containing desiccant.
10. Dissolve the resulting pellet in 200 µL sterile water and allow the tube to sit 5 to 10 min undisturbed at room temperature. PNAs are readily soluble in aqueous solutions at pH 5.0 to 6.0 at high concentrations (millimolar) but are less soluble at higher pH’s. Solubility at neutral pH can be enhanced by the incorporation of charged amino acid residues at the termini of PNAs during synthesis. Heating solutions containing PNAs can also enhance solubility, and the authors recommend always heating PNAs to >50°C immediately prior to use to ensure that aggregation is minimized. The authors have repeatedly frozen and thawed solubilized PNAs without observing diminished hybridization, although for long-term storage it is best to store PNAs in lyophilized form.
Analyze by UV spectrophotometry 11. Heat PNA stock solutions 5 min at 65°C to reduce aggregation prior to dilution and measurement. PNAs readily aggregate because they are relatively hydrophobic. Heating is a convenient way to ensure that the measured concentration reflects the total concentration of PNA in the sample. Repeated heating of PNA samples does not affect their activity.
12. Observe the optical density at 260 nm (typically a 1:500 dilution).
Synthesis of Modified Oligonucleotides and Conjugates
4.11.15 Current Protocols in Nucleic Acid Chemistry
Supplement 8
13. Determine the concentration using the following equation: c (mM) = (A260 × 30 ng/µL × 500)/mol. wt. where 30 ng/µL is the extinction coefficient, 500 is the dilution factor, and mol. wt. is the molecular weight of the PNA. Alternatively, the concentration can be determined as a cumulative function of the extinction coefficients of the PNA monomers. While more time-consuming, the latter method is more accurate since it is based on the extinction coefficient for a specific PNA sequence. The authors have found that it yields concentrations that vary by as much as 50% to 60% from those derived from use of the standard conversion factor. To determine the concentration using extinction coefficients, add up the extinction coefficients for the PNA sequence [A =13.7, C = 6.06, G = 11.7, T= 8.6, mL/ìmol(cm)]. Calculate the OD260/mL of crude PNA and divide by the total extinction coefficient to obtain the millimolar concentration. Determination of melting temperature provides a useful functional analysis for PNAs. A clean melting curve ensures that the PNA is present in solution at the anticipated concentration and can hybridize to its target sequences. The Tm value also provides important information for optimizing annealing conditions and interpreting results.
COMMENTARY Background Information
Synthesis and Purification of Peptide Nucleic Acids
Peptide nucleic acids (PNAs; Nielsen et al., 1991) are DNA analogs that have a neutral amide backbone (Fig. 4.11.1) and possess physical properties that differ from those possessed by nucleic acids with traditional phosphodiester or phosphorothioate backbones. Although they hybridize with high affinity to DNA and RNA according to normal WatsonCrick base-pairing rules (Egholm et al., 1993), the neutral backbone eliminates the electrostatic repulsion that characterizes the hybridization of DNA and RNA strands. PNA hybridization to single-stranded DNA or RNA occurs with high affinity, and hybridization to duplex DNA is characterized by an outstanding potential for strand invasion (Smulevitch et al., 1996; Lohse et al., 1999; Nielsen, 2001). The absence of a negatively charged backbone also reduces the likelihood that PNAs will associate with cellular proteins (Hamilton et al., 1996) and generate misleading phenotypes. Another difference relative to DNA or RNA is that the strength of PNA hybridization is independent of salt concentration. Given the many nucleic acid derivatives available, why should researchers consider using PNAs? PNAs possess distinctive chemical properties that confer numerous favorable properties, including high-affinity binding, rapid rates of hybridization, efficient strand invasion, resistance to digestion by nucleases and proteases, and low propensity to bind to proteins. PNAs do not spontaneously enter cultured cells, but can be introduced through simple transfection protocols (Hamilton et al.,
1999; Herbert et al., 1999; Braasch and Corey, 2001; Doyle et al., 2001). PNA synthesis is efficient and versatile and PNAs can be readily purified by HPLC and characterized by mass spectral analysis. Most PNAs will be less soluble than DNA or RNA, but lower solubility can be overcome by adjusting the pH of stock solutions or by heating PNA solutions prior to use. Learning how to obtain and work with PNAs is not trivial, but the power of PNA recognition amply justifies the effort for many applications. Advantages and disadvantages of PNAs are summarized in Table 4.11.1. PNAs can also be purchased directly from Applied Biosystems. Other vendors throughout the world have been licensed to sell PNAs. Currently, international vendors include Nippon Flour Mill, Omgen, Sawady Technologies, and OSWEL-University of Southhampton. Applied Biosystems can supply information for the vendor most convenient to a particular laboratory. Obtaining PNAs from commercial sources will probably be a less expensive option for laboratories that require a limited number of PNAs on a 2-µmol scale, especially if the laboratories do not have experience making peptides.
Critical Parameters The solid-phase synthesis of PNAs uses protocols similar to those developed for peptide synthesis and the physical properties of PNAs are more similar to hydrophobic peptides than to DNA or RNA. PNA solubility at neutral pH is relatively low, and PNAs tend to aggregate upon storage. These properties can pose prob-
4.11.16 Supplement 8
Current Protocols in Nucleic Acid Chemistry
Table 4.11.1 Advantages and Disadvantages of Peptide Nucleic Acids
Advantages
Disadvantages
Synthesis by standard peptide synthesis protocols
Less soluble than DNA or RNA
Easy to derivatize at N or C terminus High-affinity hybridization
Tendency for some sequences to aggregate Requires carrier DNA and lipid for delivery into mammalian cells or attachment to import peptides
High rates of hybridization Exceptional potential for strand invasion Low potential for binding to proteins that bind negatively charged polymers
lems for researchers unfamiliar with PNAs, and methods for obtaining useful concentrations of soluble PNA will be discussed below. The authors have not found poor solubility to be a major barrier to experiments with PNAs since the solubility of PNAs is a pH-dependent property. PNAs are soluble to high concentrations at pH ≤5.0, and usually remain soluble at neutral pH when diluted to lower concentrations or when pH is slowly adjusted upward. A substantial advantage is that PNAs can be readily derivatized by peptides or other groups that can form a covalent linkage with the free amino terminus. For automated synthesis, proper maintenance of the instrument is essential. One common problem is clogged lines that can lead to reduced flow rate. Line-filters should be replaced monthly on all internal bottles to ensure that the flow of reagents is consistent for all syntheses. When bottles are removed or placed on the instrument, the open lip of each bottle should be wiped with a clean Kimwipe to prevent cross-contamination of bottles and reduce wear on the O-ring seals. The O-ring seals should be replaced every 3 months regardless of any appearance of physical stress.
Troubleshooting A PNA that has been correctly synthesized will usually give rise to predominantly one peak by HPLC purification. However, PNAs that possess a high likelihood for forming internal structure may give rise to multiple peaks. The potential for multiple peaks can be lessened by heating the HPLC column at 55°C. If mass spectral analysis shows that the major peaks share a single predominant product, multiple peaks may not be a cause for concern. The most
common problem with PNA synthesis is formation of truncated products. One cause of failed syntheses is use of reagents that are contaminated with water, leading to a reduction in coupling efficiency. PNA monomer and activator should be routinely dried in vacuo prior to synthesis. The authors also use fresh bottles of solvent, ≤14 days old. Alternatively, failed sequences could arise due to problems with automated synthesis or human error during manual synthesis. If truncated products are formed, the HPLC will show a series of peaks with shorter retention times than would be expected for full-length product. Another problem is failure to fully cleave protecting groups after completion of synthesis. Since the protecting groups are hydrophobic, a failure to cleave them results in products with longer retention times after RP-HPLC. PNAs that have this problem will appear to have at least two peaks upon HPLC analysis and can be salvaged by a second treatment with TFA and m-cresol. Retention of FMOC groups can also be confirmed by observation of a mass of 222 atomic mass units (amu) greater than expected. To avoid this problem, the authors use TFA within 1 month of first opening bottles. The solubility properties of PNA are discussed above. PNA oligomers have different solubility properties than analogous DNA oligonucleotides and will often be less soluble. Dissolving PNA stocks at pH ≤5.0 and heating solutions prior to use should alleviated this. The authors routinely check the concentration of PNA stocks by monitoring their absorbance at 260 nm to ensure that the expected concentration is being maintained.
Synthesis of Modified Oligonucleotides and Conjugates
4.11.17 Current Protocols in Nucleic Acid Chemistry
Supplement 8
Anticipated Results The authors’ laboratory has made several hundred PNAs. When the Expedite synthesizer is working properly and when all reagents are fresh and dry, an excellent yield of the desired product is almost invariably achieved. Crude material before purification contains ≥50% desired product, while HPLC-purified product contains >90%. PNAs and PNA-peptide conjugates that require as many as 40 coupling steps can be synthesized in good yield. It is possible to synthesize PNAs with long runs of purines or PNAs that are self-complementary as long as critical coupling steps are repeated. PNA synthesis is actually easier than peptide synthesis because the “personalities” of only four, rather than twenty, monomers are involved in determining coupling efficiency. With care, almost any PNA can be obtained.
Time Considerations Preparing the reagents for automated or manual PNA synthesis requires 1 to 2 hr. Automated PNA synthesis can be completed within hours, depending on the length of the PNA. Manual synthesis should take no more than 1 hr per cycle depending on whether a capping step is performed. Deprotection and purification can be accomplished in 1 day. HPLC analysis and purification should take 2 to 3 hr combined. MALDI-TOF-MS should require no more than 30 min.
Literature Cited Braasch, D.A. and Corey, D.R. 2001. Synthesis, analysis, purification, and intracellular delivery of peptide nucleic acids. Methods 23:97-107. Doyle, D.F., Braasch, D.A, Simmons, C.G., Janowski, B.A., and Corey, D.R. 2001. Intracellular delivery and inhibition of gene expression by peptide nucleic acids. Biochemistry 40:53-64.
Synthesis and Purification of Peptide Nucleic Acids
Hamilton, S.E., Simmons, C.G., Kathriya, I., and Corey, D.R. 1999. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol. 6:343-351. Herbert, B.-S., Pitts, A.E., Baker, S.I., Hamilton, S.E., Wright, W.E., Shay, J.W., and Corey, D.R. 1999. Inhibition of telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Nat. Acad. Sci. U.S.A. 96:14726-14281. Lohse, J., Dahl, O., and Nielsen, P.E. 1999. Doubleduplex invasion by peptide nucleic acid: A general principle for sequence-specific targeting of double-stranded DNA. Proc. Natl. Acad. Sci. U.S.A. 96:11804-11808. Mayfield, L.D. and Corey, D.R. 1999. Automated synthesis of peptide nucleic acids (PNAs) and peptide nucleic acid-peptide conjugates. Anal. Biochem. 268:401-404. Nielsen, P.E. 2001. Targeting double-stranded DNA with PNA. Curr. Med. Chem. 8:545-550. Nielsen, P.E., Egholm, M., Berg, R.H., and Buchardt, O. 1991. Sequence-selective recognition of double stranded DNA by a thymine-substituted polyamide. Science 254:1497-1500. Norton, J.C., Waggenspack, J.J., Varnum, E., and Corey, D.R. 1995. Targeting peptide nucleic acid protein conjugates to structural features within duplex DNA. Bioorg. Med. Chem. 3:437-445. Simmons, C.G., Pitts, A.E., Mayfield, L.D., Shay, J.W., and Corey, D.R. 1997. Synthesis and membrane permeability of PNA-peptide conjugates. Bioorg. Med. Chem. Lett. 7:3001-3007. Smulevitch, S.V., Simmons, C.G., Norton, J.C., Wise, T.W., and Corey, D.R. 1996. Enhanced strand invasion by oligonucleotides through manipulation of backbone charge. Nature Biotech. 14:1700-1704. Zhang, X., Ishihara, T., and Corey, D.R. 2000. Strand invasion by mixed base PNAs and PNApeptide chimera. Nucl. Acids Res. 28:3332-3338.
Internet Resources http://www.appliedbiosystems.com/ds/pna.taf
Egholm, M., Buchardt, O., Christensen, L., Behrens, C., Freier, S.M., Driver, D.A., Berg, R.H., Kim, S.K., Norden, B., and Nielsen, P.E. 1993. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogenbonding rules. Nature 365:566-568.
Ordering information and bibliography.
Goodwin, T.E., Holland, R.D., Lay, J.O., and Raney, K.D. 1998. A simple procedure for solid-phase synthesis of peptide nucleic acids with N-terminal cysteine. Bioorg. Med. Chem. Lett. 8:22312234.
PNA synthesis provider in The Netherlands.
Hamilton, S.E., Iyer., M., Norton, J.C., and Corey, D.R. 1996. Specific and nonspecific inhibition of RNA synthesis by DNA, PNA and phosphorothioate promoter analog duplexes. Bioorg. Med. Chem. Lett. 6:2897-2900.
http://www.horizonpress.com/gateway/pna.html Links to PNA-related sites. http://www.isogen.nl/pna.html
http://www.bostonprobes.com Supplier of PNA diagnostic probes.
Contributed by Dwaine A. Braasch, Christopher J. Nulf, and David R. Corey University of Texas Southwestern Medical Center at Dallas Dallas, Texas
4.11.18 Supplement 8
Current Protocols in Nucleic Acid Chemistry
Locked Nucleic Acids: Synthesis and Characterization of LNA-T Diol
UNIT 4.12
This unit describes the eleven-step convergent synthesis of the thymidine analog of locked nucleic acids (LNAs) starting from a commercially available sugar. The first five protocols describe the synthesis of a glycosyl donor suitable for synthesis of several LNA monomers; the overall procedure is illustrated in Figure 4.12.1. First, the starting sugar, 1,2:5,6-di-O-isopropylidene-α-D-allofuranose (S.1), is benzylated (S.2; see Basic Protocol 1 and Alternate Protocol). In the next set of procedures (see Basic Protocol 2), the 5,6-O-isopropylidene group is then selectively removed, the product (S.3) is treated with sodium periodate to give the aldehyde derivative (S.4), and a 4-C-hydroxymethyl group is introduced (S.5). The product is then mesylated (S.6; see Basic Protocol 3) and acetylated (see Basic Protocol 4), yielding the glycosyl donor, 1,2-di-O-acetyl-3-O-benzyl-5-O-methanesulfonyl-4-C-methanesulfonyloxymethyl-D-erythropentofuranose (S.7). Finally, the last protocol describes the synthesis of LNA-T diol from this sugar precursor (see Basic Protocol 5; Fig. 4.12.2). All procedures are experimentally simple and use readily available standard reagents. The synthesis of the other LNA monomers follows the same general pathway. Glycosylation reactions of adenine and guanine are known to give isomeric mixtures. Thus, chromatographic purification is to some extent necessary to obtain pure compounds. Furthermore, these nucleosides contain exocyclic amino groups that need protection. CAUTION: All the reactions should be carried out in a fume hood and contact with chemicals should be avoided. SYNTHESIS OF 3-O-BENZYL-1,2:5,6-DI-O-ISOPROPYLIDENE-α-D-ALLOFURANOSE USING BENZYL BROMIDE IN TETRAHYDROFURAN This protocol describes the benzylation of 1,2:5,6-di-O-isopropylidene-α-D-allofuranose (S.1) by treatment with sodium hydride and benzyl bromide resulting in 3-O-benzyl1,2:5,6-di-O-isopropylidene-α-D-allofuranose (S.2; Fig. 4.12.1). Purification is performed by a combination of extraction and crystallization.
BASIC PROTOCOL 1
CAUTION: Hydrogen gas, which can be explosive, is evolved in steps 5 and 9. Perform steps 2 through 9 under a nitrogen stream and use extreme care. Materials 60% (v/v) sodium hydride in mineral oil Hexane (stored over 3A molecular sieves) Nitrogen (N2) stream (or argon stream) Tetrahydrofuran (THF; stored over 3A molecular sieves) Dimethylformamide (DMF; stored over 3A molecular sieves) 1,2:5,6-Di-O-isopropylidene-α-D-allofuranose (Pfanstiehl Laboratories) Benzyl bromide Brine (saturated aqueous NaCl) MgSO4 500-mL three-neck round-bottom flask 250-mL dropping funnel Nitrogen inlet 20-mL syringe Sintered glass funnel, pore size 3 Contributed by Henrik M. Pfundheller and Christian Lomholt Current Protocols in Nucleic Acid Chemistry (2002) 4.12.1-4.12.16 Copyright © 2002 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.12.1 Supplement 8
Rotary evaporator connected to vacuum pump Generate 3-alkoxyde 1. Equip a 500-mL three-neck round-bottom flask with a 250-mL dropping funnel, nitrogen inlet, and a magnetic stir bar. 2. Place 11.2 g of 60% sodium hydride in the flask, add 30 mL hexane, and stir for a few minutes under a stream of nitrogen. 3. Stop stirring and allow sodium hydride to settle. Remove the excess hexane carefully with a 20-mL syringe and discard. 4. Add 25 mL THF and 5 mL DMF to the sodium hydride and cool the suspension in an ice bath. 5. Place 52 g (0.20 mol) of 1,2:5,6-di-O-isopropylidene-α-D-allofuranose dissolved in 100 mL THF in the 250-mL dropping funnel and add the solution dropwise over a 30-min period to the sodium hydride suspension. 6. Remove from the ice bath and stir for 1.5 hr at room temperature. Benzylate 3-alkoxyde 7. Over a 20-min period, add 25 mL benzyl bromide (in small portions) to the solution and then stir the mixture for 16 hr. 8. Cool the mixture in an ice bath for 15 min. 9. Destroy excess sodium hydride by careful addition of 100 mL water.
O O
O O O
O
1. NaH O
OH
HO HO O
80% AcOH
2. BnBr
O
O
OBn O
O
1
OBn O
2
3
O
HO
O
NalO4
H2CO, NaOH HO
O OBn O
MsO
Ac2O, AcOH, conc. H2SO4 O
OBn O
6
Locked Nucleic Acids: Synthesis and Characterization of LNA-T Diol
5
O
MsO
O OBn O
4
MsCl, Pyridine
O
MsO
O
OAc
MsO OBn OAc
7
Figure 4.12.1 Synthesis of the universal glycosyl donor. Bn, benzyl; Ms, methanesulfonyl.
4.12.2 Supplement 8
Current Protocols in Nucleic Acid Chemistry
Purify and isolate product 10. Separate phases and extract the aqueous phase (lower phase) with 75 mL THF. 11. Combine the two organic phases and wash two times with 100 mL brine. 12. Dry over MgSO4, remove the MgSO4 by vacuum filtration through a sintered glass funnel, and wash the solid with 50 mL THF. 13. Concentrate the filtrate in a rotary evaporator attached to a vacuum pump. 14. Dissolve the residue in 100 mL boiling hexane and place solution overnight at 5°C. 15. Isolate the formed crystals of 3-O-benzyl-1,2:5,6-di-O-isopropylidene-α-D-allofuranose (S.2) by filtration and dry under vacuum. Yield: 64 g (91%). An additional 4 g of product can be obtained from the mother liquor.
SYNTHESIS OF 3-O-BENZYL-1,2:5,6-DI-O-ISOPROPYLIDENE-α-D-ALLOFURANOSE USING BENZYL BROMIDE IN DIMETHYLFORMAMIDE
ALTERNATE PROTOCOL
This procedure describes the benzylation of 1,2:5,6-di-O-isopropylidene-α-D-allofuranose (S.1) using DMF as solvent. Using DMF instead of THF makes the reaction mixture less flammable, although DMF is toxic. Purification of the reaction mixture is obtained through precipitation of the product from the reaction mixture followed by crystallization. All reagents and materials are listed above (see Basic Protocol 1). CAUTION: Hydrogen gas, which can be explosive, is evolved in steps 5 and 9. Perform steps 2 through 9 under a nitrogen stream and use extreme care. Generate 3-alkoxyde 1. Equip a 500-mL three-neck round-bottom flask with a 250-mL dropping funnel, nitrogen inlet, and a magnetic stir bar. 2. Place 4.8 g of 60% sodium hydride in the flask, add 20 mL hexane, and stir for a few minutes under a stream of nitrogen. 3. Stop stirring and let the sodium hydride settle, then remove the excess hexane carefully with a 20-mL syringe and discard. 4. Add 20 mL DMF to the sodium hydride and cool the suspension in an ice bath. 5. Place 26 g (0.10 mol) of 1,2:5,6-di-O-isopropylidene-α-D-allofuranose dissolved in 30 mL DMF in the 250-mL dropping funnel and add solution dropwise over a 30-min period to the sodium hydride suspension. 6. Remove from the ice bath and stir for 1.5 hr at room temperature. Benzylate 3-alkoxyde 7. Over a 15-min period, add 14.3 mL benzyl bromide (in small portions) to the solution and then stir mixture for 1 hr at room temperature. 8. Cool the mixture in an ice bath. 9. Destroy excess sodium hydride by careful addition of 5 mL water. Purify and isolate product 10. Pour the reaction mixture into 175 mL ice water with stirring.
Synthesis of Modified Oligonucleotides and Conjugates
4.12.3 Current Protocols in Nucleic Acid Chemistry
Supplement 8
11. When the ice has melted, filter off the precipitate by vacuum filtration through a sintered glass funnel, and wash the solid three times with 100 mL ice-cold water. 12. Dry the solid using a rotary evaporator connected to a vacuum pump. 13. Add 150 mL boiling hexane and keep overnight at 5°C to allow crystal formation. 14. Isolate the formed crystals of 3-O-benzyl-1,2:5,6-di-O-isopropylidene-α-D-allofuranose (S.2) by filtration and dry under vacuum. Yield: 31 g (89%). BASIC PROTOCOL 2
SYNTHESIS OF 3-O-BENZYL-4-C-HYDROXYMETHYL-1,2-O-ISOPROPYLIDENE-α-DERYTHROPENTOFURANOSE In this protocol, selective removal of the 5,6-O-isopropylidene group is performed by treatment of S.2 with 80% acetic acid (steps 1 to 5) to give 3-O-benzyl-1,2-O-isopropylidene-α-D-allofuranose (S.3). The formed 5,6-diol is then oxidatively cleaved with sodium periodate (steps 6 to 11) to give the corresponding 5-aldehyde derivative (S.4). Treatment of S.4 with formaldehyde and aqueous sodium hydroxide in a mixed aldol condensation/Cannizzaro reaction (steps 12 to 19) introduces a 4-C-hydroxymethyl group, giving 3-O-benzyl-4-C-hydroxymethyl-1,2-O-isopropylidene-α-D-erythropentofuranose (S.5). Materials 3-O-Benzyl-1,2:5,6-di-O-isopropylidene-α-D-allofuranose (S.2; see Basic Protocol 1 or Alternate Protocol) Acetic acid Dichloromethane Ethyl acetate Toluene Tetrahydrofuran (THF) NaIO4 Brine (saturated aqueous NaCl) 1,4-Dioxane 37% (w/v) aqueous formaldehyde 4 M NaOH MgSO4 Hexane 1-L round-bottom flask Rotary evaporator connected to vacuum pump Sintered glass funnel, pore size 3 Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) Deprotect 5,6-O-isopropylidene group 1. Place 63.1 g (0.18 mol) of 3-O-benzyl-1,2:5,6-di-O-isopropylidene-α-D-allofuranose (S.2) into a 1-L round-bottom flask containing a magnetic stir bar.
Locked Nucleic Acids: Synthesis and Characterization of LNA-T Diol
2. Add 70 mL water and 290 mL acetic acid and stir at room temperature until no starting material can be observed (∼25 to 35 hr) as monitored by TLC (APPENDIX 3D) using 9:1 (v/v) dichloromethane/ethyl acetate.
4.12.4 Supplement 8
Current Protocols in Nucleic Acid Chemistry
3. Remove the magnetic stir bar and concentrate the solution in a rotary evaporator connected to a vacuum pump. Avoid temperatures that are >45°C in steps 3 and 4, since this will result in removal of the 1,2-O-isopropylidene group.
4. Co-evaporate the residue (S.3) under vacuum two times with 100 mL toluene. Perform periodate oxidation of vicinal 5,6-diol 5. Add 100 mL THF, 100 mL water, and a large magnetic stir bar to the residue. 6. Over a 30-min period, add 43 g NaIO4 in small portions under vigorous stirring. 7. Stir the mixture for 3 hr. 8. Filter off the solid by vacuum filtration through a sintered glass funnel, and wash two times with 50 mL ethyl acetate. 9. Separate the phases and extract the aqueous phase (lower layer) two times with 50 mL ethyl acetate. 10. Combine the two organic phases, wash with 50 mL brine, and concentrate the organic phase (containing S.4) under vacuum in the rotary evaporator. Perform mixed aldol condensation/Cannizzaro reaction 11. Dissolve the residue in 120 mL of 1,4-dioxane. Add a magnetic stir bar and 40 mL aqueous 37% formaldehyde. 12. Over a 40-min period, add dropwise 90 mL of 4 M NaOH and then stir the mixture overnight. 13. Separate the phases and extract the aqueous phase (lower layer) one time with 100 mL ethyl acetate and then two times with 50 mL ethyl acetate. 14. Combine the two organic phases, wash with 100 mL brine, and extract the brine with 50 mL ethyl acetate. 15. Dry the organic phase over MgSO4 and remove the MgSO4 by filtration. 16. Wash the solid two times with 50 mL ethyl acetate and concentrate the combined filtrates in the rotary evaporator. 17. Dissolve the residue in 50 mL dichloromethane and add this solution to 350 mL hexane under vigorous stirring. 18. Isolate the precipitated 3-O-benzyl-4-C-hydroxymethyl-1,2-O-isopropylidene-α-Derythropentofuranose (S.5) by filtration and dry under vacuum. Yield: 45.7 g (82%) of a white solid.
Synthesis of Modified Oligonucleotides and Conjugates
4.12.5 Current Protocols in Nucleic Acid Chemistry
Supplement 8
BASIC PROTOCOL 3
SYNTHESIS OF 3-O-BENZYL-1,2-O-ISOPROPYLIDENE-5-O-METHANESULFONYL-4-CMETHANESULFONYLOXYMETHYL-α-D-ERYTHROPENTOFURANOSE This protocol describes the mesylation of the two hydroxyl groups in 3-O-benzyl-4-Chydroxymethyl-1,2-O-isopropylidene-α-D-erythropentofuranose (S.5) with methanesulonylchloride, giving 3-O-benzyl-1,2-O-isopropylidene-5-O-methanesulfonyl4-C-methanesulfonyloxymethyl-α-D-erythropentofuranose (S.6). The resulting mesyl groups are used in later steps for both protection and functionalization. Materials 3-O-Benzyl-4-C-hydroxymethyl-1,2-O-isopropylidene-α-D-erythropentofuranose (S.5; see Basic Protocol 2) Dichloromethane (stored over 3A molecular sieves) Pyridine (stored over 3A molecular sieves) Methanesulfonylchloride (e.g., Aldrich) Brine (saturated aqueous NaCl) 1 M HCl Saturated aqueous NaHCO3 MgSO4 Methanol 500-mL round-bottom flask 250-mL dropping funnel Guard tube/nitrogen inlet Sintered glass funnel, pore size 3 Rotary evaporator connected to vacuum pump Perform mesylation 1. Place 43.5 g (0.14 mol) of 3-O-benzyl-4-C-hydroxymethyl-1,2-O-isopropylidene-αD-erythropentofuranose (S.5) in a 500-mL round-bottom flask equipped with a magnetic stir bar, 250-mL dropping funnel, and a guard tube/nitrogen inlet. This reaction must be performed under a dry atmosphere.
2. Add 75 mL dichloromethane and 55 mL pyridine and cool mixture in an ice bath. 3. Place 24 mL (0.31 mol) methanesulfonylchloride in the dropping funnel and add dropwise over a 45-min period. 4. Remove from the ice bath and stir 3 hr at room temperature. 5. Add 100 mL water and 100 mL brine and stir 45 min at room temperature. Purify and isolate product 6. Separate the phases and extract the aqueous phase (top layer) three times with 75 mL dichloromethane. 7. Combine the two organic phases and wash three times with 150 mL of 1 M HCl, one time with 150 mL of saturated aqueous NaHCO3, and one time with 150 mL brine. 8. Dry the organic phase over MgSO4 and remove the MgSO4 by vacuum filtration through a sintered glass funnel. Locked Nucleic Acids: Synthesis and Characterization of LNA-T Diol
9. Wash the solid two times with 25 mL dichloromethane and concentrate the combined filtrates in a rotary evaporator with a vacuum pump.
4.12.6 Supplement 8
Current Protocols in Nucleic Acid Chemistry
10. Dissolve the residue in 50 mL boiling methanol. Cool to room temperature and then let sit overnight at 5°C. 11. Isolate the formed crystals of 3-O-benzyl-1,2-O-isopropylidene-5-O-methanesulfonyl-4-C-methanesulfonyloxymethyl-α-D-erythropentofuranose (S.6) by filtration and dry under vacuum. Yield: 56.7 g (90%) of colorless crystals.
SYNTHESIS OF 1,2-DI-O-ACETYL-3-O-BENZYL-5-O-METHANESULFONYL-4-CMETHANESULFONYLOXYMETHYL-D-ERYTHROPENTOFURANOSE
BASIC PROTOCOL 4
This protocol describes the deprotection of the 1,2-O-isopropylidene group in 3-Obenzyl-1,2-O-isopropylidene-5-O-methanesulfonyl-4-C-methanesulfonyloxymethyl-αD-erythropentofuranose (S.6) followed by acetylation, giving the universal glycosyl donor 1,2-di-O-acetyl-3-O-benzyl-5-O-methanesulfonyl-4-C-methanesulfonyloxymethylD-erythropentofuranose (S.7) as a mixture of anomers. Deprotection and acetylation are performed in a one-pot procedure by treatment of S.6 with a mixture of acetic acid, acetic anhydride, and catalytic amounts of concentrated sulfuric acid. Materials 3-O-Benzyl-1,2-O-isopropylidene-5-O-methanesulfonyl-4-C-methanesulfonyloxymethyl-α-D-erythropentofuranose (S.6; see Basic Protocol 3) Acetic acid Acetic anhydride Concentrated H2SO4 Dichloromethane Saturated aqueous Na2CO3 Saturated aqueous NaHCO3 MgSO4, anhydrous 1-L round-bottom flask Guard tube/nitrogen inlet Sintered glass funnel, pore size 3 Rotary evaporator connected to vacuum pump Perform 1,2-O-isopropylidene acetolysis and acetylation 1. Place 46.6 g (0.10 mol) 3-O-benzyl-1,2-O-isopropylidene-5-O-methanesulfonyl-4C-methanesulfonyloxymethyl-α-D-erythropentofuranose (S.6) in a 1-L round-bottom flask equipped with a guard tube/nitrogen inlet and a magnetic stir bar. 2. Add 150 mL acetic acid and 30 mL acetic anhydride, and cool mixture in an ice bath. 3. Add 0.2 mL concentrated H2SO4 and let sit 5 min. 4. Remove from the ice bath and stir mixture for 18 hr at room temperature. Purify and isolate product 5. Add 150 mL dichloromethane to the reaction mixture followed by slow addition of 500 mL saturated aqueous Na2CO3. CAUTION: A large amount of CO2 gas is evolved in this step.
6. Stir the mixture for 3 hr at room temperature.
Synthesis of Modified Oligonucleotides and Conjugates
4.12.7 Current Protocols in Nucleic Acid Chemistry
Supplement 9
7. Separate phases and extract the aqueous phase (top layer) two times with 150 mL dichloromethane. 8. Combine the two organic phases, add 300 mL saturated aqueous NaHCO3, and stir 2 hr at room temperature. 9. Separate phases and extract the aqueous phase (top layer) two times with 75 mL dichloromethane. 10. Dry the combined organic phases over MgSO4 and remove the MgSO4 by vacuum filtration through a sintered glass funnel. 11. Wash the solid two times with 25 mL dichloromethane. 12. Concentrate the combined filtrates to an oil in a rotary evaporator connected to a vacuum pump. The product, 1,2-di-O-acetyl-3-O-benzyl-5-O-methanesulfonyl-4-C-methanesulfonyloxymethyl-D-erythropentofuranose (S.7; mixture of anomers), is obtained as a yellow oil. Yield: 51.0 g (100%). BASIC PROTOCOL 5
SYNTHESIS OF (1S,3R,4R,7S)-7-HYDROXY-1-HYDROXYMETHYL-3-(THYMIN-1-YL)-2,5DIOXABICYCLO[2.2.1]HEPTANE (LNA-T DIOL) This protocol describes the synthesis of LNA-T diol from the universal glycosyl donor (S.7); the procedure is illustrated in Figure 4.12.2. The coupling of S.7 with silylated thymine (steps 1 to 9) gives 1-(2-O-acetyl-3-O-benzyl-5-O-methanesulfonyl-4-Cmethanesulfonyloxymethyl-β-D-erythropentofuranosyl)thymine (S.8). Basic hydrolysis of the 2′-O-acetyl group in S.8 (steps 10 to 16) liberates the free 2′-OH group, which instantly attacks the 4′-C-methanesulfonyloxy group, thereby causing ring formation between 2′-O and 4′-C. The resulting (1S,3R,4R,7S)-7-benzyloxy-1-methanesulfonyloxymethyl-3-(thymin-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (S.9) constitutes the bicyclic LNA skeleton. Substitution of the methanesulfonyloxy group with benzoate (steps 17 to 22) and basic hydrolysis of the benzoate (steps 23 to 31) result in (1S,3R,4R,7S)-7-benzyloxy-1-hydroxymethyl-3-(thymin-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (S.11) . Finally, reductive removal of the benzyl group in S.11 using Pd(OH)2/C-ammonium formate yields LNA-T diol (S.12; steps 32 to 38).
Locked Nucleic Acids: Synthesis and Characterization of LNA-T Diol
Materials 1,2-Di-O-acetyl-3-O-benzyl-5-O-methanesulfonyl-4-C-methanesulfonyloxymethylD-erythropentofuranose (S.7; see Basic Protocol 4) Acetonitrile (stored over 3A molecular sieves) Thymine N,O-Bis(trimethylsilyl)acetamide (Fluka) Trimethylsilyl trifluoromethanesulfonate (Fluka) Saturated aqueous NaHCO3 Dichloromethane Brine (saturated aqueous NaCl) Tetrahydrofuran (THF) LiOH⋅H2O Acetic acid Ethyl acetate MgSO4, anhydrous Anhydrous dimethylformamide (DMF; stored over 3A molecular sieves) Sodium benzoate
4.12.8 Supplement 9
Current Protocols in Nucleic Acid Chemistry
Hexane Methanol 20% Pd(OH)2/C (palladium hydroxide catalyst on carbon; Fluka) Ammonium formate 2-cm-thick Celite pad 250-mL, 500-mL, and 1-L round-bottom flasks Rotary evaporator connected to vacuum pump Condensers Guard tubes/nitrogen inlets Sintered glass funnel, pore size 3 Glycosylate thymine 1. Place 25.5 g (50 mmol) of 1,2-di-O-acetyl-3-O-benzyl-5-O-methanesulfonyl-4-Cmethanesulfonyloxymethyl-D-erythropentofuranose (S.7) in a 500-mL round-bottom flask. Add 100 mL acetonitrile and concentrate the mixture using a rotary evaporator connected to a vacuum pump. It has been observed that skipping this evaporation step, which is performed to remove traces of water, can lead to lower yields from the reaction.
O
NH MsO
1. Thymine/BSA
O
MsO
OAc 2. TMS-OTf
MsO OBn OAc
N
O
O
MsO OBn OAc
7
8 O
O
NH LiOH MsO
N
NH
O
BzONa BzO
O
OBn O
N
OBn O
10
9 O
O
NH LiOH HO
N O
OBn O
11
O
O
NH
O
Pd(OH)2 /C NH4HCO2
HO
N
O
O
OH
O
12
Figure 4.12.2 Synthesis of LNA-T diol. Bn, benzyl; BSA, bis(trimethylsilyl)acetamide; Bz, benzoyl; Ms, methanesulfonyl; TMS-OTf, trimethylsilyl trifluoromethanesulfonate.
Synthesis of Modified Oligonucleotides and Conjugates
4.12.9 Current Protocols in Nucleic Acid Chemistry
Supplement 8
2. Dissolve in 100 mL acetonitrile, and add 7.0 g (55 mmol) thymine, 24.5 mL (10 mmol) N,O-bis(trimethylsilyl)acetamide, and a magnetic stir bar. 3. Equip the 500-mL round-bottom flask with a condenser and a guard tube/nitrogen inlet, and heat the mixture to reflux (∼90°C) for 45 min. 4. Cool the reaction mixture to room temperature and add 10 mL trimethylsilyl trifluoromethanesulfonate. 5. Heat the mixture to reflux (∼90°C) overnight. 6. Cool the mixture to room temperature and pour it into 200 mL saturated aqueous NaHCO3. Stir the mixture for 5 min. 7. Extract three times with 200 mL dichloromethane. 8. Combine the organic phases and wash with 200 mL saturated aqueous NaHCO3 and then 100 mL brine. 9. Concentrate the organic phase (containing S.8) in a 1-L round-bottom flask in the rotary evaporator. Form 2′-O, 4′-C ring 10. Dissolve the residue in 100 mL THF and add 200 mL water and 10 g LiOH⋅H2O. Stir the mixture for 1.5 hr at room temperature. 11. Neutralize to pH ∼8 with acetic acid (∼10 mL). 12. Extract the mixture three times with 200 mL ethyl acetate. 13. Combine the organic phases and wash with 100 mL brine. 14. Dry the organic phase over MgSO4 and remove the MgSO4 by vacuum filtration through a sintered glass funnel. 15. Wash the solid two times with 25 mL ethyl acetate and concentrate in the rotary evaporator. 16. Dissolve the residue (S.9) in 200 mL acetonitrile and concentrate two times in a 500-mL round-bottom flask. Substitute methanesulfonyloxy group with benzoyloxy group 17. Dissolve the residue in 250 mL anhydrous DMF and add 20 g sodium benzoate. 18. Equip the flask with a guard tube/nitrogen inlet and heat the mixture for 16 hr at 90°C. The reaction results in a gummy mixture. If effective stirring cannot be achieved, an additional 250 mL anhydrous DMF should be added.
19. Cool the reaction mixture to room temperature. 20. Add water until the formed precipitate dissolves. 21. Pour the reaction mixture into 800 mL of stirring ice water (1600 mL of ice water if 500 mL of DMF has been used as solvent). 22. Isolate the precipitated product (S.10) by filtration and wash the product two times with 100 mL water. Locked Nucleic Acids: Synthesis and Characterization of LNA-T Diol
4.12.10 Supplement 8
Current Protocols in Nucleic Acid Chemistry
Hydrolyze benzoyl ester 23. Suspend the solid in 200 mL THF and 300 mL water in a 1-L round-bottom flask containing a magnetic stir bar. 24. Add 10 g LiOH⋅H2O and stir the mixture for 5 hr at room temperature. 25. Neutralize to pH ∼8 with acetic acid (∼10 mL) and concentrate to half volume in the rotary evaporator. 26. Extract three times with 200 mL dichloromethane 27. Combine the organic phases and wash with 200 mL saturated aqueous NaHCO3 followed by 200 mL brine. 28. Dry over MgSO4 and remove MgSO4 by filtration. 29. Wash the solid two times with 25 mL dichloromethane and concentrate the combined filtrates in the rotary evaporator. 30. Dissolve the residue in a minimum of ethyl acetate (∼50 mL) and pour this solution slowly into 600 mL hexane under vigorous stirring. 31. Collect the precipitated product (S.11) by filtration. Yield: 14.2 g (79%) of a white solid.
Remove 3′-O-benzyl group 32. Dissolve 14.2 g of S.11 in 100 mL methanol in a 250-mL round-bottom flask equipped with magnetic stir bar and condenser. 33. Add 1.5 g of 20% Pd(OH)2/C and 8.0 g ammonium formate. 34. Heat the mixture for 1 hr at 60°C. 35. Vacuum filter the hot solution through a 2-cm-thick Celite pad. 36. Wash the Celite with 200 mL methanol. Combine the filtrates and concentrate in the rotary evaporator. 37. Dissolve the residue in 50 mL boiling methanol and add 200 mL ethyl acetate followed by 600 mL hexane. 38. Isolate the precipitated product (1S,3R,4R,7S)-7-hydroxy-1-hydroxymethyl-3(thymin-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (LNA-T diol; S.12) by filtration and dry under vacuum. Yield: 10.2 g (95%) as white precipitate.
COMMENTARY Background Information LNA oligonucleotides were introduced several years ago and were shown to have very high binding affinity and selectivity towards complementary nucleic acids (Koshkin et al., 1998b; Obika et al., 1998; Singh et al., 1998). These interesting properties have been evaluated in different diagnostic and therapeutic settings. LNA oligonucleotides have been used in diagnostic genotyping for the detection of the prothrombic mutations factor V Leiden (Ørum
et al., 1999) and have also been successfully evaluated in living rats for control of gene expression (Wahlestedt et al., 2000). Today, much effort is being put into the development of simple and reliable microarrays for multiplex genotyping in combination with multiplex target amplification using LNA oligonucleotides (Choleva et al., 2001). Furthermore, LNA oligonucleotides are successfully being investigated with respect to recognition of double-stranded DNA, as shown by inhibition of
Synthesis of Modified Oligonucleotides and Conjugates
4.12.11 Current Protocols in Nucleic Acid Chemistry
Supplement 8
the NF-κB transcription factor p50 (Obika et al., 2001). The key steps in the synthesis of LNA nucleosides are the introduction of the 4-C-hydroxymethyl functionality followed by selective derivatization of the resulting two diastereoto pic h yd ro xy methy l groups. 4′-C-Hydroxymethyl nucleosides have been synthesized using both linear (Youssefyeh et al., 1977; Jones et al., 1979) and convergent (Leland and Kotick, 1974; Youssefyeh et al., 1977, 1979) strategies based on aldol condensation of 5(′)-aldehydes with formaldehyde followed by a Cannizzaro reaction or sodium borohydride reduction. LNA nucleosides were previously synthesized following linear (Obika et al., 1997; Koshkin et al., 1998a) as well as convergent (Singh et al., 1998; Koshkin et al., 1998a,b) strategies. Due to the reported problems (i.e., low yields, workup difficulties) for th e p reparation of 5′-aldehydo/4′-C-hydroxymethyl nucleosides from natural ribonucleosides, the authors decided to focus on the convergent strategy for the large-scale synthesis of LNA nucleosides further stimulated by the possibilities of introducing a variety of different nucleobases. This unit describes the authors’ efforts to develop a simplified and efficient synthesis of a sugar intermediate (S.7; Figure 4.12.1; see Basic Protocols 1 to 4), which can be used as a glycosyl donor in the coupling reactions with different nucleobases. This is exemplified by the synthesis of LNA-T diol (S.12; Figure 4.12.2; see Basic Protocol 5). These protocols give high yields of the desired products (>79% for each step), are experimentally simple, and avoid the use of time-consuming column chromatography. The synthesis of the adenine, cytosine, and guanine derivatives of LNA follow the same strategy and are described elsewhere (Koshkin et al., 2001).
Locked Nucleic Acids: Synthesis and Characterization of LNA-T Diol
Synthesis of the universal glycosyl donor S.7 Standard benzylation (see Basic Protocol 1) of the commercially available 1,2:5,6-di-O-isopropylidene-α-D-allofuranose with THF as solvent results in the corresponding 3-O-benzylated derivative S.2 (Horton and Tindall, 1970) in almost quantitative yield after crystallization from hexanes. In order to simplify the workup, the mineral oil from the sodium hydride suspension is initially removed with a syringe after addition of hexanes. As an alternative to THF, DMF can be used as the solvent (see Alternate Protocol) as reported earlier (Brimacombe and Ching, 1968). The starting sugar is commer-
cially available but can also be synthesized from the gluco-epimer via oxidation and selective reduction (Sowa and Thomas, 1966). Using 80% acetic acid, the 5,6-O-isopropylidene protecting group is selectively removed (see Basic Protocol 2) to give S.3 as reported (Horton and Tindall, 1970). It is important to keep the reaction at a low temperature to avoid removal of the 1,2-O-isopropylidene protecting group. After evaporation of the reaction mixture, the 5,6-glycol is oxidatively cleaved by periodate, giving the 5-aldehydo derivative after a simple work-up procedure. Finally, the aldehyde is condensed with formaldehyde followed by in situ crossed Cannizzaro reaction with excess formaldehyde, giving the desired 4-C-hydroxymethyl derivative S.5 (Youssefyeh et al., 1977, 1979) in 82% yield (3 steps) after crystallization from hexanes. In the first publications describing the synthesis of LNA nucleosides using the convergent strategy (Koshkin et al., 1998b; Singh et al., 1998), 3-O-benzyl-4-C-hydroxymethyl-1,2O-isopropylidene-α-D-ribofuranose S.5 was regioselectively 5-O-benzylated (Waga et al., 1993) in 71% yield, taking advantage of the different positioning of the two diastereotopic hydroxymethyl groups on each face of the bicyclo[3.3.0]octane system. However, chromatographic purification of the reaction mixture was necessary to separate the two isomers. Acetylation (Koshkin et al., 1998b; Singh et al., 1998) or tosylation (Koshkin et al., 1998a) of the 4-C-hydroxymethyl group, acetolysis, and subsequent 1,2-di-O-acetylation was followed by nucleobase-coupling and ring-closing reactions to give the desired LNA nucleoside derivative. Based on these results, the authors decided to synthesize 1,2-di-O-acetyl-3-Obenzyl-4-C-methanesulfonoxymethyl-5-Omethanesulfonyl-D-erythropentofuranose S.7 to overcome the early chromatographic step and increase the overall yield of the synthesis. The diol S.5 is permesylated using standard conditions (see Basic Protocol 3) to give the desired compound in 90% yield after crystallization from methanol. Subsequent standard acetolysis and basic diacetylation (see Basic Protocol 4) quantitatively yield S.7 as an anomeric mixture (∼1:5) that can be used as a glycosyl donor in coupling reactions with different nucleobases. The overall yield from S.1 is 67%. Synthesis of LNA-T diol S.12 Following the method of Vorbrüggen (Vorbrüggen et al., 1981; Vorbrüggen and Höfle,
4.12.12 Supplement 8
Current Protocols in Nucleic Acid Chemistry
Table 4.12.1
Selected Rf Values and Melting Points
Compound number
Rf (90:10 CH2Cl2/ethyl acetate)a
1 2 3 4 5 6 7 8 9 10 11 12
0.30 0.70
0.55 0.40 + 0.35 0.05
Rf (95:5 CH2Cl2/methanol)a 0.78 0.14 0.40 0.16 0.70 0.60 + 0.55 0.25 0.22 0.45 0.13 0.05
Melting point (°C)b
65c
99d 109
169 196e
aSolvent ratios are given in v/v. TLC plates: Merck silica gel 60 F . 254 bUncorrected, measured on a Büchi melting point B-540. c64°C to 65°C (Brimacombe, 1968). d101°C to 102°C (Youssefyeh, 1979). e204°C to 205°C (Obika, 2001).
1981), S.7 is stereoselectively coupled (see Basic Protocol 5) with silylated thymine followed by a one-pot deacetylation and intramolecular ring-closing reaction upon treatment with LiOH, giving the LNA derivative S.9. This two-step one-pot procedure is fast and smooth compared to the two-step procedure originally described (Koshkin et al., 1998a,b). The methanesulfonyloxy group is substituted with benzoyl upon reaction of S.9 with sodium benzoate in hot DMF (Codington et al., 1960), followed by hydrolysis of the benzoate ester using LiOH to give S.11 in 79% yield (four steps) after crystallization from hexanes. Direct basic hydrolysis of the 5′-O-methanesulfonyl group was unsuccessful (Koshkin et al., 2001). Debenzylation with Pd(OH)2/C and ammonium formate as the H donor is fast and efficient, giving the desired LNA-T diol S.12 in 95% yield (50% from S.1) after a simple workup procedure and crystallization from ethyl acetate/hexanes. The corresponding phosphoramidite for use in automated oligonucleotide synthesis (Caruthers, 1991) can be synthesized via 5′-O-dimethoxytritylation and 3′-O-phosphitylation (Sinha et al., 1983; Koshkin et al., 1998b).
Compound Characterization All isolated compounds appear as one spot on a TLC plate except S.7, which exists as a mixture of anomers (∼1:5). Rf values and ap-
propriate solvent systems are given in Table 4.12.1. For bicyclic LNA structures, 1H-NMR shows three singlet signals for H1′, H2′, and H3′. This can be taken as verification of the formation of the rigid LNA bicyclic structure, as small coupling constants are indicative of H1′-C1′-C2′-H2′ dihedral angles close to 90°, which are characteristic of the N conformation (Altona and Sundaralingam, 1973; Obika et al., 1997; Koshkin et al., 1998b). Data for selected compounds S.2: 1H-NMR (CDCl3) δ 7.39-7.26 (m, 5H), 5.75 (d, J = 3.6 Hz, 1H), 4.78 (d, J = 12.2 Hz, 2H), 4.61-4.56 (m, 2H), 4.36 (m, 1H), 4.164.12 (m, 1H), 4.01-3.95 (m, 2H), 3.91-2.85 (m, 1H), 1.60 (s, 3H), 1.40 + 1.38 + 1.36 (3 × s, 9H). 13C-NMR (CDCl3) δ 137.5, 128.5, 128.3, 128.0, 112.9, 109.7, 103.9, 78.0, 77.8, 77.4, 74.7, 72.1, 64.9, 26.7, 26.4, 26.0, 25.0. MALDI-MS m/z: 351.2 [M+H]+. S.5: 1H-NMR (CDCl3) δ 7.37-7.26 (m, 5H), 5.76 (d, J = 3.9 Hz, 1H), 4.80 (d, J = 11.7 Hz, 1H), 4.63 (t, J = 4.0 Hz, 1H), 4.56 (d, J = 11.7 Hz, 1H), 4.20 (d, J = 5.2 Hz, 1H), 3.93 (d, J = 12.0 Hz, 1H), 3.85 (d, J = 12.0 Hz, 1H), 3.78 (d, J = 11.9 Hz, 1H), 3.54 (d, J = 12.0 Hz, 1H), 2.50 (br, 1H), 2.32 (br, 1H), 1.63 (s, 3H), 1.33 (s, 3H). 13C-NMR (CDCl3) δ 137.2, 128.4, 128.1, 127.7, 113.4, 104.3, 86.3, 78.3, 78.2,
Synthesis of Modified Oligonucleotides and Conjugates
4.12.13 Current Protocols in Nucleic Acid Chemistry
Supplement 8
72.6, 64.0, 63.0, 26.5, 25.8. MALDI-MS m/z: 311.1 [M+H]+. S.6: 1H-NMR (CDCl3) δ 7.38-7.26 (m, 5H), 5.73 (d, J = 3.8 Hz, 1H), 4.85 (d, J = 12.0 Hz, 1H), 4.75 (d, J = 11.6 Hz, 1H), 4.64 (t, J = 3.8 Hz, 1H), 4.55 (d, J = 11.6 Hz, 1H), 4.39 (d, J = 12.0 Hz, 1H), 4.30 (d, J = 11.0 Hz, 1H), 4.17 (d, J = 5.2 Hz, 1H), 4.12 (d, J = 11.0 Hz, 1H), 3.05 (s, 3H), 2.95 (s, 3H), 1.66 (s, 3H), 1.32 (s, 3H). 13C-NMR (CDCl3) δ 136.5, 128.4, 128.2, 127.9, 113.8, 104.3, 83.0, 78.2, 77.6, 72.6, 69.3, 68.5, 37.8, 37.2, 26.0, 25.4. MALDI-MS m/z: 467.1 [M+H]+. S.7 (main isomer): 1H-NMR (CDCl3) δ 7.37-7.28 (m, 5H), 6.17 (s, 1H), 5.37 (d, J = 4.8 Hz, 1H), 4.62 (d, J = 11.1 Hz, 1H), 4.52 (d, J = 11.1 Hz, 1H), 4.50 (d, J = 11.6 Hz, 1H), 4.42 (d, J = 4.8 Hz, 1H), 4.37 (d, J = 11.6 Hz, 1H), 4.30 (d, J = 10.6 Hz, 1H), 4.19 (d, J = 10.6 Hz, 1H), 3.01 (s, 6H), 2.14 (s, 3H), 2.10 (s, 3H). 13C-NMR (CDCl ) δ 169.1, 168.7, 136.3, 3 128.5, 128.3, 128.1, 97.2, 82.7, 78.6, 73.9, 73.1, 68.8, 68.4, 37.5, 37.3, 20.9, 20.5. MALDI-MS m/z: 511.1 [M+H]+. S.11: 1H-NMR (CDCl3) δ 9.28 (br, 1H), 7.45(d, J = 1.1 Hz, 1H), 7.38-7.22 (m, 5H), 5.66 (s, 1H), 4.67 (d, J = 11.6 Hz, 1H), 4.56 (d, J = 11.7 Hz, 1H), 4.54 (s, 1H), 4.05 (d, J = 7.9 Hz, 1H), 4.01 (d, J = 12.5 Hz, 1H), 3.96 (s, 1H), 3.95 (d, J = 12.6 Hz, 1H), 3.83 (d, J = 7.9 Hz, 1H), 1.88 (s, 3H). 13C-NMR (CDCl3) δ 163.9, 149.8, 137.0, 134.7, 128.5, 128.2, 127.8, 110.3, 88.2, 87.3, 76.9, 75.9, 72.3, 72.0, 57.6, 12.7. MALDI-MS m/z: 360.1 [M+H]+. S.12: 1H-NMR (DMSO-d6) δ 11.33 (br, 1H), 7.60 (d, J = 1.1 Hz, 1H), 5.68 (d, J = 4.1 Hz, 1H), 5.38 (s, 1H), 5.20 (br t, J = 5.6 Hz, 1H), 4.09 (s, 1H), 3.89 (d, J = 4.0 Hz, 1H), 3.80 (s, J = 7.8 Hz, 1H), 3.74 (d, J = 5.5 Hz, 2H), 3.61 (d, J = 7.8 Hz, 1H), 1.75 (d, J = 1.1 Hz, 3H). 13C-NMR (DMSO-d6) δ 164.1, 150.1, 135.1, 108.6, 89.0, 86.5, 79.1, 71.2, 68.9, 56.2, 12.6. Anal. calcd. for C11H14N2O6⋅2⁄3H2O: C 46.81, H 5.48, N 9.92; found: C 46.64, H 5.22, N 10.05. MALDI-MS m/z: 270.9 [M+H]+.
Critical Parameters and Troubleshooting
Locked Nucleic Acids: Synthesis and Characterization of LNA-T Diol
In general, the presented synthesis of LNAT has been developed to be tolerant to small changes in reaction conditions. Nonetheless, in some steps it is necessary to take precautions to ensure anhydrous conditions. When necessary, it was found sufficient to use solvents that were stored over molecular sieves. It is advisable to check all reactions by TLC (APPENDIX 3D; see Table 4.12.1 for Rf values)
before workup to ensure that complete conversion of starting material has been obtained. If the reaction has not gone to completion, a prolonged reaction time and/or additional reagent (typically 10% excess) will typically bring the reaction to completion. In Basic Protocol 1, the development of hydrogen gas demands a steady flow of inert atmosphere through the reaction flask. If such precaution is not taken, build up of hydrogen gas could potentially result in explosion of the reaction mixture. In Basic Protocol 2, steps 3 and 4, it is important to avoid temperatures higher than 45°C during the evaporation of acetic acid. If the temperature gets too high, the 1,2-O-isopropylidene group will be lost. A small amount of product that has lost the 1,2-O-isopropylidene group is acceptable in the following steps, but will lower the overall yield of the reaction. In steps 5 to 7, all the starting 5,6-diol S.4 must be consumed since unreacted starting material will be unaffected in subsequent reactions and is difficult to separate from the product during isolation of S.6. In Basic Protocols 3 and 4, the use of anhydrous reaction conditions is necessary to obtain a complete reaction. The use of anhydrous reaction conditions is essential during the glycosylation of S.7 with silylated nucleobases (see Basic Protocol 5, steps 1 to 5), since water will h yd ro lyze th e tr imethy lsilyl trifluoromethanesulfonate. It is also crucial to have anhydrous conditions during the substitution of the methanesulfonyloxy group with sodium benzoate (Basic Protocol 5, steps 17 to 18). It has been observed that even small amounts of water in the reaction mixture can not only slow down the reaction, but result in hydrolysis of the formed benzoate giving S.11, which will not be recovered during the precipitation step in the work-up procedure. If hydrolysis has occurred during the reaction, it is possible to extract S.11 from the aqueous phase by extraction with ethyl acetate. In Basic Protocol 5, step 34, it is advisable to keep the reaction at a temperature just below the boiling point. It has been observed that when the reaction mixture reaches the boiling point, large amounts of salt precipitate in the condenser.
Anticipated Results The overall yield for synthesis of LNA-T diol is 50% (eleven steps). Expected yields for isolated intermediates are S.2, 90%; S.5, 82%; S.6, 90%; S.7, 100%; S.11, 79%; and S.12,
4.12.14 Supplement 8
Current Protocols in Nucleic Acid Chemistry
95%. The scale of the synthesis can be increased to 1 mol for Basic Protocols 1 to 3 without any major problems. The synthesis was developed to avoid chromatographic purification. The yields can be increased slightly by purifying the mother liquors (e.g., by column chromatography); however, this is time consuming.
Time Considerations The time needed to complete the synthesis of LNA-T diol is estimated to be 10 to 14 days. Most of the reactions are not affected by a prolonged reaction time. Thus, one can leave the reaction mixtures overnight at room temperature. An exception is the removal of the 5,6-O-isopropylidene group from S.2 (see Basic Protocol 2, step 2), where extended exposure to acetic acid will result in loss of the 1,2-O-isopropylidene group. All isolated compounds are stable and can be stored without special precautions.
Literature Cited Altona, C. and Sundaralingam, M. 1973. Conformational analysis of the sugar ring nucleosides and nucleotides. Improved method for the interpretation of proton magnetic resonance coupling constants. J. Am. Chem. Soc. 95:2333-2344. Brimacombe, J.S. and Ching, O.A. 1968. Nucleophilic displacement reactions in carbohydrates. Carbohydr. Res. 8:82-88. Caruthers, M.H. 1991. Chemical synthesis of DNA and DNA analogues. Acc. Chem. Res. 24:278284. Choleva, Y., Nørholm, M., Pedersen, S., Mouritzen, P., Høiby, P.E., Nielsen, A.T., Møller, S., Jakobsen, M.H., and Kongsbak, L. 2001. Multiplex SNP genotyping using locked nucleic acids and microfluidics. J. Assoc. Lab. Automation 6:9297. Codington, J.F., Fecher, R., and Fox, J.J. 1960. Pyrimidine nucleosides. VII. Reactions of 2′,3′,5′-trimesyloxyuridine. J. Am. Chem. Soc. 82:2794-2803. Horton, D. and Tindall, C.G. Jr. 1970. Methyleneinsertion reactions with unsaturated sugars, synthesis of 4-C-cyclopropyl-D-ribo-tetrafuranose derivatives. Carbohydr. Res. 15:215-232. Jones, G.H., Taniguchi, M., Tegg, D., and Moffat, J.G. 1979. 4′-Substituted nucleosides. 5. Hydroxymethylation of nucleoside 5′-aldehydes. J. Org. Chem. 44:1309-1317. Koshkin, A.A., Rajwanshi, V.K., and Wengel, J. 1998a. Novel convenient syntheses of LNA [2.2.1]bicyclo nucleosides. Tetrahedron Lett. 39:4381-4384.
Koshkin, A.A., Singh, S.K., Nielsen, P., Rajwanshi, V.K., Kumar, R., Meldgaard, M., Olsen, C.E., and Wengel, J. 1998b. LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54:3607-3630. Koshkin, A.A., Fensholdt, J., Pfundheller, H.M., and Lomholt, C. 2001. A simplified and efficient route to 2′-O, 4′-C-methylene-linked bicyclic ribonucleosides (LNA). J. Org. Chem. 66:85048512. Leland, D.L. and Kotick, M.P. 1974. Studies on 4-C-(hydroxymethyl)pentofuranoses. Synthesis of 9-[4-C-(hydroxymethyl)-α-L-threo-pentofuranosyl]adenine. Carbohydr. Res. 38:C9-C11. Obika, S., Nanbu, D., Hari, Y., Morio, K., In, Y., Ishida, T., and Imanishi, T. 1997. Synthesis of 2′- O, 4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′endo sugar puckering. Tetrahedron Lett. 38:8735-8738. Obika, S., Nanbu, D., Hari, Y., Andoh, J., Morio, K., Doi, T., and Imanishi, T. 1998. Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conf o rm ation, 2′-O,4′-C-methyleneribonucleosides. Tetrahedron Lett. 39:5401-5404. Obika, S., Uneda, T., Sugimoto, T., Nanbu, D., Minami, T., Doi, T., and Imanishi, T. 2001. 2′-O,4′C-Methylene bridged nucleic acid (2′,4′-BNA): Synthesis and triplex-forming properties. Bioorg. Med. Chem. 9:1001-1011. Ørum, H., Jakobsen, M.H., Koch, T., Vuust, J., and Borre, M.B. 1999. Detection of the factor V Leiden mutation by direct allele-specific hybridization of PCR amplicons to photoimmobilized locked nucleic acids. Clin. Chem. 45:1898-1905. Singh, S.K., Nielsen, P., Koshkin, A.A., and Wengel, J. 1998. LNA (locked nucleic acids): Synthesis and high-affinity nucleic acid recognition. Chem. Commun. (1998):455-456. Sinha, N.D., Biernat, J., and Köster, H. 1983. β-Cyanoethyl N,N-dialkylamino/N-morpholinomonochloro phosphoramidites, new phosphitylating agents facilitating ease of deprotection and work-up of synthesized oligonucleotides. Tetrahedron Lett. 24:5843-5846. Sowa, W. and Thomas, G.H.S. 1966. The oxidation of 1,2:5,6-di-O-isopropylidene-D-glucose by dimethylsulfoxide-acetic anhydride. Can. J. Chem. 44:836-838. Vorbrüggen, H. and Höfle, G. 1981. On the mechanism of nucleoside synthesis. Chem. Ber. 114:1256-1268. Vorbrüggen, H., Krolikiewicz, K., and Bennua, B. 1981. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts. Chem. Ber. 114:1234-1255.
Synthesis of Modified Oligonucleotides and Conjugates
4.12.15 Current Protocols in Nucleic Acid Chemistry
Supplement 8
Waga, T., Nishizaki, T., Miyakawa, I., Ohrui, H., and Meguro, H. 1993. Synthesis of 4′-C-methylnucleosides. Biosci. Biotech. Biochem. 57:14331438. Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Høkfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., Ossipov, M., Koshkin, A., Jakobsen, N., Skouv, J., Oerum, H., Jacobsen, M.H., and Wengel, J. 2000. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. U.S.A. 97:5633-5638. Youssefyeh, R., Tegg, D., Verheyden, J.P.H., Jones, G.H., and Moffat, J.G. 1977. Synthetic routes to 4′-hydroxymethylnucleosides. Tetrahedron Lett. 5:435-438. Youssefyeh, R.D, Verheyden, J.P.H., and Moffat, J.G. 1979. 4′-Substituted nucleosides. 4. Synthesis of some 4′-hydroxymethyl nucleosides. J. Org. Chem. 44:1301-1309.
Key References Koshkin et al., 1998a,b. See above. This unit’s protocols were developed based on the synthetic results described in these papers. Wengel, J. 1999. Development of locked nucleic acid. Acc. Chem. Res. 32:301-310. This article describes the development of LNA.
Contributed by Henrik M. Pfundheller and Christian Lomholt Exiqon A/S Vedbaek, Denmark
Locked Nucleic Acids: Synthesis and Characterization of LNA-T Diol
4.12.16 Supplement 8
Current Protocols in Nucleic Acid Chemistry
Cellular Delivery of Locked Nucleic Acids (LNAs)
UNIT 4.13
This unit describes the introduction of locked nucleic acid (LNA) oligomers (Fig. 4.13.1; Koshkin et al., 1998; Obika et al., 1998; Wang et al., 1999; reviewed in Braasch and Corey, 2001) into cells. It is intended to extend the discussion of the synthesis and characterization of LNA that is found in UNIT 4.12. INTRODUCTION OF LNA OLIGOMERS INTO CELLS As is the case for most other types of oligonucleotide, there is little reason to believe that LNA oligomers will be able to spontaneously enter most types of cultured cells and locate a cellular target. Since LNAs possess a negatively charged backbone, one simple method for promoting uptake is the use of cationic lipid. A step-wise sample procedure for a 48-well plate format is given below and a schematic summary is provided in Figure 4.13.2.
BASIC PROTOCOL
NOTE: The conditions required for successful transfections will vary from one cell line to the next. It is impossible to predict which combination of lipid and oligonucleotide will be most effective; this must be determined empirically for each cell line. Materials Cells grown to confluence in 75-cm2 tissue culture flasks Complete growth medium (see recipe) 100 µM LNA stock solution (see Support Protocol 1) Opti-MEM I (Invitrogen Life Technologies; reduced-serum medium, containing L-glutamine and no phenol red) LipofectAMINE (Invitrogen Life Technologies) 48-well tissue culture plate (Costar) Repeating pipettor (e.g., Eppendorf) 12.5-mL Combitips (Eppendorf) 65° and 37°C water baths or a thermal cycler 12 × 75–mm round-bottom tubes 37°C, 5% CO2 incubator
base
RO O
O O
P
O O– base
O O
Figure 4.13.1 Structure of LNA.
Synthesis of Modified Oligonucleotides and Conjugates
Contributed by Dwaine A. Braasch and David R. Corey
4.13.1
R′O
Current Protocols in Nucleic Acid Chemistry (2002) 4.13.1-4.13.9 Copyright © 2002 by John Wiley & Sons, Inc.
O
Supplement 9
Additional reagents and equipment for trypsinizing and counting cells (e.g., CPMB APPENDIX 3F) NOTE: LipofectAMINE and Opti-MEM I are important to the success of the experiment and should not be substituted. Prepare cells 1. Beginning with a 75-cm2 tissue culture flask of cells grown to confluence, trypsinize the cells according to standard procedures (e.g., CPMB APPENDIX 3F). The total number of cells (and thus the number of flasks) will depend on the number of LNAs being transfected. For transfection of a single LNA, 33,000 to 39,000 cells are needed (11,000 to 13,000 cells per well at three different concentrations of LNA-LipofectAMINE complex).
2. Suspend the cells in fresh complete growth medium.
inhibitor (100 µM LNA) 6.4 µL
Opti-MEM 143.6 µL
step 9
1.9 µL
Opti-MEM 148.1 µL
step 10 step 11
LipofectAMINE
total volume =
300 µL
15 min
200 nM, V t = 3200 µL
add 2900 µL Opti-MEM
step 12 complex formation
step 14
100 nM, V t = 3000 µL 1500 µL 200 nM solution step 15 1500 µL Opti-MEM 25 nM, V t = 2000 µL 500 µL 100 nM solution 1500 µL Opti-MEM
dispense 200 µL/well
step 15
step 16
step 17 transfection overnight
Cellular Delivery of Locked Nucleic Acids (LNAs)
Figure 4.13.2 Preparation of LipofectAMINE-LNA complexes for cellular transfection, including subsequent dilutions of stock complexes. Vt = total volume. Volumes are sufficient for dispensing six replicates and have been optimized for COS-7 cells.
4.13.2 Supplement 9
Current Protocols in Nucleic Acid Chemistry
3. Draw up the entire volume of cell suspension into a 10-mL pipet and dispense back into the flask with the tip of the pipet pressed lightly against the bottom of the flask. Aggregates of cells will be disrupted, yielding a single-cell suspension that gives more accurate cell counts.
4. Perform a cell count in triplicate using a Coulter counter or hemacytometer (e.g., CPMB APPENDIX 3F) and average the results. 5. Prepare cell suspension in complete growth medium at a density of 44,000 to 52,000 cells/mL. 6. Plate cells 4 to 6 hr prior to transfection. For each LNA to be transfected, plate 250 µL cell suspension (11,000 to 13,000 cells) in three wells of a 48-well tissue culture plate. For accuracy with larger numbers of LNAs, use a repeating pipettor and a 12.5-mL Combitip.
7. Replace cover on plate and disperse cells evenly within the wells by sliding the plate back and forth, gently bumping it against the front lip of a laminar flow hood work surface. Keep cells 4 to 6 hr at 37°C in a 5% CO2 incubator for cells to attach to the surface. Prepare LNA-LipofectAMINE complexes 8. Warm 100 µM LNA stock solution 5 min at 65°C for a 15-mer or 95°C for a 25-mer to disrupt aggregates, and then maintain at 37°C until transfection. Also warm Opti-MEM I to 37°C. 9. In a 12 × 75–mm round-bottom tube, dilute 6.4 µL of 100 µM LNA with 143.6 µL Opti-MEM I. 10. In a separate 12 × 75–mm round-bottom tube, dilute 1.9 µL LipofectAMINE with 148.1 µL Opti-MEM I. This solution can be scaled up in a single tube depending on how many unique conditions are being tested. If, for example, five inhibitors (LNAs) are to be tested, then it would be advantageous to prepare sufficient lipid mix for seven conditions.
11. Add 150 µL LipofectAMINE from step 10 to each LNA in step 9 (total 300 µL) and tap the tube briskly 15 times to mix the reagents and initiate the formation of LNA-LipofectAMINE complexes. 12. Allow the tube to sit 15 min at room temperature in the dark. Opti-MEM I is light sensitive.
Transfect cells 13. While waiting for complexes to form, aspirate off the complete growth medium in each well of the tissue culture plate and replace with 250 µL Opti-MEM I per well. Also set up two tubes for a dilution series of LNA-LipofectAMINE complexes and add 1.5 mL Opti-MEM I to each. 14. When the incubation (step 12) is complete, add 2.9 mL Opti-MEM I to the LNALipofectAMINE complexes and mix well. This gives 3.2 mL at 200 nM LNA for the starting concentration for the serial dilution. The authors typically use 200 nM or 500 nM as the starting concentration.
Synthesis of Modified Oligonucleotides and Conjugates
4.13.3 Current Protocols in Nucleic Acid Chemistry
Supplement 8
15. Transfer 1.5 mL stock to one of the tubes in step 13 (final 3 mL at 100 nM) and mix well. Transfer 500 µL of this solution to the second tube (final 2 mL at 25 mM) and mix well. If 500 nM is used as the starting concentration, a 200 nM dilution should be included.
16. Aspirate the Opti-MEM I wash from the cells and immediately dispense 200 µL of each LNA-LipofectAMINE dilution to the appropriate wells, working backward through the dilution scheme for a given LNA. 17. Allow cells to incubate overnight at 37°C. 18. Aspirate off transfection solution and replace with 250 µL complete growth medium. 19. Incubate >24 hr at 37°C prior to conducting an assay for the effects of the LNA. When developing a protocol for delivering LNAs into cells, it is useful to obtain a fluorophore-labeled LNA. Delivery of the LNA can be visualized by microscopy, facilitating the evaluation and subsequent optimization of delivery conditions. SUPPORT PROTOCOL 1
PREPARATION OF LNA OLIGOMER STOCK SOLUTIONS LNA oligomers arrive lyophilized and should be handled like DNA or RNA oligomers. Materials Locked nucleic acid oligomers (LNAs; Proligo) DNase/RNase-free water (Life Technologies) Spectrophotometer 1. If LNAs have been refrigerated, allow them to equilibrate to room temperature. 2. Centrifuge the samples 2 min at 14,000 × g, room temperature, to collect LNA at the bottom of the tube. 3. Add DNase/RNase-free water to give a stock solution of ∼1 mM. Allow the oligomer to sit undisturbed for 10 to 15 min at room temperature. The estimated concentration is based on the volume, on the mass reported by the manufacturer, and on the molecular weight of a given LNA.
4. Vortex in 5-sec bursts several times. Heat to 65°C for up to 15 min and cool to room temperature. 5. Allow tubes to sit undisturbed for 5 min, room temperature. 6. Centrifuge 2 min at 14,000 × g, room temperature, to pellet any remaining undissolved material. Observe the tube contents carefully at this point, as occasionally there are insoluble materials that can interfere with cellular assays. It is best not to proceed with cellular assays if an LNA exhibits this behavior unless one has significant experience in desalting and purifying oligomers. Consult the manufacturer if solubility properties are not satisfactory.
7. Remove a 1-µL aliquot and dilute it with 144 µL distilled water. Ascertain the absorbance at 260 nm. 8. Calculate the concentration of the LNA using the following equation, where 33 ng/µL is the extinction coefficient of the LNA and 145 is the dilution factor: Cellular Delivery of Locked Nucleic Acids (LNAs)
c (mM) = (A260 × 33 ng/µL × 145)/mol. wt. of LNA
4.13.4 Supplement 8
Current Protocols in Nucleic Acid Chemistry
The value 33 ng/ìL assumes an average extinction coefficient based on an equal population of all bases. If the LNA contains a preponderance of one or two bases, the equation can be modified (e.g., see CPMB APPENDIX 3D) using the appropriate extinction coefficients. The extinction coefficients of the LNA nucleotide analogs are not available to the authors, but it may be reasonable to assume that they are the same as for DNA nucleotides (Proligo, pers. comm.).
9. Adjust concentration to 100 µM and store the stock solution for up to 1 year at 4°C. DETERMINATION OF Tm FOR LNA OLIGOMERS To understand the potential for LNA oligonucleotides to recognize intracellular targets, it is useful to determine Tm values for LNAs with complementary RNA or DNA oligomers.
SUPPORT PROTOCOL 2
Materials LNA oligonucleotides DNA or RNA oligomers 10× Ca2+- and Mg2+-free phosphate-buffered saline (CMF-PBS; Invitrogen Life Technologies or see recipe) 0.1 M Na2HPO4 buffer, pH 7.5 (Fisher) Mineral oil (Sigma) Stoppered cuvette (1-cm pathlength and 1.5-cm Z dimension; Spectrosil Far UV Quartz, Uvonic Instruments) Spectrophotometer with temperature-controlled cuvette holder 1. Calculate the concentration of each of the single-stranded components (LNA and either DNA or RNA). The concentration of LNAs can be determined from the A260 value of a diluted aliquot (see Support Protocol 1, step 8). It is sometimes useful to heat the LNAs to 65°C or higher, depending on the oligomer length and the number of LNA bases, to break up intra- and intermolecular hydrogen bonding and aggregation. When preparing oligonucleotide pairs for Tm analysis or tranfection, it is prudent to heat the samples and ensure that the concentrations are accurate.
2. Prepare a small volume (∼20 to 30 µL) of 100 µM heteroduplex nucleic acid in a solution containing 2.5× CMF-PBS final concentration. 3. Dilute a 5-µL aliquot of the 100 µM heteroduplex mixture with 145 µL of 0.1 M Na2HPO4 buffer, pH 7.5, in a 1-cm-pathlength stoppered cuvette. 4. Overlay this solution with 145 µL mineral oil to minimize evaporation. 5. Monitor the change in the absorbance at 260 nm every 5°C as the temperature is ramped from 100° to 12°C and also back up to 100°C. 6. Fit the data collected from these analyses using van’t Hoff thermal denaturation/renaturation curve analysis to determine the Tm values from the denaturation and renaturation curves (UNIT 7.3). It is not uncommon for entirely LNA oligomers with >11 bases to possess Tm values >95°C.
Synthesis of Modified Oligonucleotides and Conjugates
4.13.5 Current Protocols in Nucleic Acid Chemistry
Supplement 8
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
CMF-PBS (Ca2+- and Mg2+-free phosphate-buffered saline), 10× 10.4 mM KH2PO4 1551.7 mM NaCl 29.6 mM Na2HPO4⋅7H2O, pH 7.4 Store up to 1 year at 4°C Complete growth medium Dulbecco’s modified Eagle’s medium (DMEM) high-glucose without L-glutamine (e.g., Mediatech Cellgro, Fisher) containing: 20 mM HEPES buffer, pH 7.4 (cell-culture grade, Sigma) 10% (w/v) FBS (Atlanta Biologicals) 1× PSF (see recipe) 0.7 mg/mL tylosin (Sigma) 2 mM L-glutamine (Invitrogen Life Technologies) Store up to 4 months at 4°C PSF (penicillin/streptomycin/Fungizone), 100× 10,000 U penicillin 10 mg streptomycin 25 µg/mL amphotericin B (e.g., Fungizone, Invitrogen Life Technologies) Store up to 1 year at −20°C COMMENTARY Background Information LNAs offer several advantages for nucleic acid recognition (Table 4.13.1), which should encourage investigators to consider their use. Currently, oligonucleotides that contain LNA bases can be obtained commercially from Proligo (http://www.proligo.com). Synthesis is based on phosphoramidite chemistry and employs LNA monomers of A, T, G, and 5-methylC. The most striking advantage conferred by use of LNA bases is a dramatic increase in the
Table 4.13.1
Cellular Delivery of Locked Nucleic Acids (LNAs)
affinity of binding to complementary sequences (Table 4.13.2). A single LNA base can increase the melting temperature (Tm) of binding by 10°C, and oligomers that contain several strategically positioned LNA bases can bind with even higher affinity than analogous peptide nucleic acid (PNA) oligomers (Braasch and Elayadi, unpub. observ.). LNA bases are introduced into oligonucleotides by standard synthesis methods (UNIT 4.12), allowing LNA bases to be interspersed among DNA or RNA bases. As a result, important properties such as
Advantages of Locked Nucleic Acids
High affinity hybridization
Tight binding by short LNAs or at high temperatures
Synthesized like DNA/RNA
Enables ready adaptation of existing synthesizers. Simple to intersperse DNA or RNA bases to modulate Tm values or RNase H sensitivity.
Negatively charged backbone
Good solubility; investigators who work with DNA or RNA will find LNA easy to work with. Ability to incorporate phosphorothioate linkages to improve stability or pharmacokinetic properties.
4.13.6 Supplement 8
Current Protocols in Nucleic Acid Chemistry
Table 4.13.2 Melting Temperature (Tm) Values for LNAs and LNA-DNA Hybrids
LNA or LNA-DNAa
Tm
Tm(ref)b ∆Tm
∆Tm/LNA Reference base
GTGTTTTGC GTGTCCGAGACGTTG
52 72
28 59
24 13
5 1.5
Kumar et al. (1998) Wahlstedt et al. (2000)
GTGTCCGAGACGTTG GTGTCCGAGACGTTG
83 >90
59 59
24 >31
3 2
Wahlstedt et al. (2000) Wahlstedt et al. (2000)
CACTATACG CTGATATGC
40 36.8
29 27.2
11 9.6
3.3 9.6
Koshkin et al. (1998) Bondensgaard et al. (2000)
CTGATATGC AGGGTCGCTmeCGGTGT
51.6 >96
27.2 53
24.4 43
8.1 3
Bondensgaard et al. (2000) Braasch (unpub. observ.)
AGGGTCGCTmeCAATGT meCAGTTAGGGTTAG
83 81
NPc 50
— 31
— 3.1
Braasch (unpub. observ.) Braasch (unpub. observ.)
meCAGTTAGAATTAG
TAGGGT
65 56
NPc NDc
— —
— —
Braasch (unpub. observ.) Braasch (unpub. observ.)
TAGGGTTA AGGATmeCTAGGTGAA
74 >96
22 53
52 25
6.5 2.9
Braasch (unpub. observ.) Braasch (unpub. observ.)
AGGATmeCTAGG AGGATmeCTAGGTGAA
73 59
39 53
34 6
3.4 0.6
Braasch (unpub. observ.) Braasch (unpub. observ.)
aUnderlined bases are LNA. meC, 5-methylcytosine. All oligomers are shown from 5′ to 3′. bReference T values are for analogous DNA oligonucleotides. m cND, melting temperature not detected; NP, analysis not performed. ∆T and ∆T /LNA base could thus not be calculated. m m
Tm or RNase H activation can be tailored to meet the specifications of individual applications. This combination of high-affinity hybridization with standard synthesis protocols is powerful because it encourages adapting LNAs to existing protocols that use oligonucleotides.
Critical Parameters When designing oligonucleotides that are intended to function inside cells, the ability of the oligonucleotides to form duplexes that act as substrates for RNase H is a primary consideration (Crooke, 1999). RNase H degrades RNA-DNA hybrids, allowing oligonucleotides that contain DNA to promote the cleavage of mRNA. If antisense inhibition of gene expression is desired, this can be an advantage since the target mRNA is permanently inactivated, and the antisense oligomer can then move on to inactivate additional mRNA molecules. Oligonucleotides that cannot recruit RNase H (i.e., that do not contain DNA portions) can block the binding of the translation apparatus when targeted to the 5′ terminus of the untranslated region (Baker et al., 1997; Doyle et al., 2001). Oligomers that do not activate RNase H can also redirect splicing when targeted to splice
sites (Kang et al., 1998), but when they are targeted to other mRNA sequences, they are likely to be displaced by the ribosome. Oligomers that contain only LNA bases activate RNase H poorly (Wahlestedt et al., 2000). However, because LNAs are made using protocols similar to those used for DNA synthesis, it is straightforward to incorporate DNA bases into LNA-DNA chimera. This provides the experimenter with the choice of whether or not to incorporate RNase H sensitivity into oligonucleotide design by including a contiguous run of at least six DNA bases. If antisense gene inhibition is desired, this strategy may allow a wider range of sequences to be targeted. If simple steric blocking of the RNA target is required, the potential to direct RNase H cleavage is unnecessary and even counterproductive because it might lead to unintentional destruction of nontargeted RNA substrates. LNA bases confer some increase in the stability of oligomers to degradation by nucleases. However, to achieve maximal stability in animal studies, it is likely that one or two phosphorothioate (PS) linkages will need to be substituted at both the 3′- and 5′-terminal linkages. As noted above, LNA synthesis is similar to the
Synthesis of Modified Oligonucleotides and Conjugates
4.13.7 Current Protocols in Nucleic Acid Chemistry
Supplement 8
synthesis of DNA or RNA, allowing PS linkages to be added routinely (Kumar et al., 1998). Complete substitution of phosphodiester linkages with PS linkages has also been noted to improve the pharmacokinetic properties of antisense oligonucleotides (Geary et al., 2001). It is reasonable to believe that LNA-containing oligomers will also need to be modified with PS linkages to achieve in vivo efficacy, though animal studies will be necessary to establish if this truly is the case for LNA-containing chimeric oligonucleotides. The choice of whether or not to exploit the potential for RNase H activation influences how antisense activity will be examined on a case-by-case basis. LNA oligomers that contain DNA segments that can activate RNase H will cause RNA to be degraded, allowing efficacy to be judged by northern analysis. LNA oligomers that cannot activate RNase H can be evaluated by examining the expression of the protein target or by measuring its activity. As with any antisense experiment, use of control oligonucleotides that contain mismatched bases is necessary to support the belief that an effect is specific, i.e., due to binding to the intended mRNA target.
Troubleshooting
Cellular Delivery of Locked Nucleic Acids (LNAs)
When oligonucleotides are introduced into cells, they may prove to be toxic. This toxicity could be due to successful inhibition of the target gene function. However, toxicity could also be due to (1) binding to one or more nontarget proteins, (2) hybridization to one or more nontarget nucleic acid sequences, or (3) poisoning of the cells by small molecule impurities or endotoxins. The primary consideration is that the observed effects should be consistent with the biology of the system being examined. If cell death is observed, LNAs can be purified by desalting to remove small molecule contaminants. Alternatively, a fresh synthesis of LNA can be performed to determine if newly made material behaves similarly. Toxicity could also be caused by improper choice of transfection conditions, reagent concentrations, cell line, or lipids. The window between the conditions that produce optimal LNA delivery and those that cause cells to die is likely to be small. Use of fluorophore-labeled LNAs provides a convenient method for evaluating the success of a given protocol. The authors have also observed that some syntheses of LNAs are relatively insoluble. If this occurs, the experimenter should consult with the manufacturer.
Anticipated Results There are many effective antisense oligonucleotides that do not contain LNA bases. Why use LNA? Why not stay with standard oligonucleotide designs? The use of LNAs is only three years old, and there are no definitive answers to these questions. However, it is reasonable to speculate that the ability of LNA bases to dramatically improve the affinity of binding might increase the potency, specificity, and predictability of antisense action. The resulting increase in efficacy would allow “knock down” phenotypes to be generated more easily, and the fact that LNA bases can be easily incorporated into oligonucleotides allows this hypothesis to be readily tested. Microscopic examination of the delivery of a fluorophore-labeled LNA is a useful demonstration that transfection conditions are promoting LNA uptake by cells. In the authors’ experience, micrographs show that LNA is distributed throughout the cytoplasm and nucleus, with some punctate staining indicating areas of high concentration.
Time Considerations LNAs normally can be obtained within 2 weeks of placing an order with Proligo. LNAs should completely dissolve in water within 20 min. Quantification of LNA concentration by UV spectrophotometry and determination of a Tm value should take ∼2 hr. Transfection of LNA into cells should require an additional 2 to 4 hr. The time required for observation of a phenotype will vary from hours to days, depending on the gene being targeted.
LITERATURE CITED Baker, B.F., Lot, S.S., Condon, T.P., Cheng-Flournoy, S., Lesnik, E.A., Sasmor, H.M., and Bennett, C.F. 1997. 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272:11994-12000. Bondensgaard, K., Petersen, M., Singh, S.K., Rajwanshi, V.K., Kumar, R., Wengel, J., and Jacobsen, J.P. 2000. Structural studies of LNA:RNA duplexes by NMR: Conformations and RNase H activity. Chem. Eur. J. 6:2687-2695. Braasch, D.A. and Corey, D.R. 2001. Locked nucleic acids: Fine-tuning nucleic acid recognition. Chem. Biol. 8:1-7. Crooke, S.T. 1999. Molecular mechanisms of antisense drugs: Human RNase H. Antisense Nucl. Acid Drug Devel. 9:377-379.
4.13.8 Supplement 8
Current Protocols in Nucleic Acid Chemistry
Doyle, D.F., Braasch, D.A., Simmons, C.G., Janowski, B.A., and Corey, D.R. 2001. Inhibition of gene expression inside cells by peptide nucleic acids: Effect of mRNA target sequence, mismatched bases, and PNA length. Biochemistry 40:53-64.
Obika, S., Nanbu, D., Hari, Y., Andoh, J., Morio, K., Doi, T., and Imanishi, T. 1998. Stability and structural features of the duplexes containing the nucleoside analogues with a fixed N-type conf o rmation, 2′-O,4′-C-methyleneribonucleosides. Tetrahedron Lett. 39:5401-5404.
Geary, R.S., Yu, R.Z., and Levin, A.A. 2001. Pharmacokinetics of phosphorothioate antisense oligonucleotides. Curr. Opin. Investigational New Drugs 2:562-573.
Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hokfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., Ossipov, M., Koshkin, A., Jakobsen, N., Skouv, J., Oerum, H., Havsteen Jacobsen, M., and Wengel, J. 2000. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. U.S.A. 97:5633-5638.
Kang, S.H., Cho, M.J., and Kole, R. 1998. Up-regulation of luciferase gene expression with antisense oligonucleotides—Implications and applications in functional assay developments. Biochemistry 37:6235-6239. Koshkin, A.A., Singh, S.K., Nielsen, P., Rajwanshi, V.K., Kumar, R., Meldgaard, M., Olsen, C.E., and Wengel, J. 1998. LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine, and uracil bicyclonucleoside monomers, oligomerisation and unprecedented nucleic acid recognition. Tetrahedon 54:3607-3630. Kumar, R., Singh, S., Koshkin, A.A., Rajwanshi, V.K., Meldgaard, M. and Wengel, J. 1998. The first analogues of LNA (locked nucleic acids): Pho sphorothioate-LNA and 2′-thio-LNA. Bioorg. Med. Chem. Lett. 8:2219-2222.
Wang, G., Gunic, E., Girardet, J-L., and Stoisavljevic, V. 1999. Conformationally locked nucleosides. Synthesis and hybridization properties of oligodeoxynucleotides containing 2′4′-Cbridged 2′-deoxynucleosides. Bioorg. Med. Chem. Lett. 9:1147-1150.
Contributed by Dwaine A. Braasch and David R. Corey University of Texas Southwestern Medical Center at Dallas Dallas, Texas
Synthesis of Modified Oligonucleotides and Conjugates
4.13.9 Current Protocols in Nucleic Acid Chemistry
Supplement 8
Solid-Phase Synthesis of Branched Oligonucleotides
UNIT 4.14
This unit describes the synthesis of nucleic acids containing vicinal 2′,5′- and 3′,5′-phosphodiester bonds. These molecules occur in the cell nucleus, and are formed during the splicing of precursor messenger RNA (pre-mRNA). As such they have many potential applications in nucleic acid biochemistry, particularly as tools for probing the substrate specificity of lariat debranching enzymes, and as tools for studying pre-mRNA splicing (e.g., Nam et al., 1994; Carriero et al., 2001). The assembly of these branched nucleic acids (bNAs) on a solid support can be achieved by following two strategies (Damha and Zabarylo, 1989; Braich and Damha, 1997). The first, referred to as the convergent strategy, is based on well-established automated phosphoramidite chemistry (UNITS 3.3 & 3.5). This method uses a ribonucleoside bisphosphoramidite as the branch-introduction synthon (see Basic Protocol 1). The branching reagent serves to couple together solid-support-bound chains, thus forming a branch juncture with the desired vicinal 2′,5′- and 3′,5′-phosphodiester bonds (see Basic Protocol 2). For efficient branching to occur, CPG supports with high nucleoside loadings are used (see Support Protocol 1). With this approach, Y- and V-shaped molecules having identical 2′ and 3′ chains are readily assembled. The second method is a divergent approach that permits the regiospecific synthesis of bNAs using readily available phosphoramidite reagents (see Basic Protocol 3). An important feature of this method is the assembly of a linear DNA:RNA chimera containing a single 2′-O-silylribonucleoside residue in the middle of the chain. Subsequent removal of the 2-cyanoethyl and silyl protecting groups without detaching the nascent oligonucleotide from the solid support is another salient feature of this approach. This releases an internal 2′-OH group from which orthogonal synthesis of a branch can be carried out. This unit also describes methods used in the authors’ laboratory for the deprotection (see Support Protocol 2), purification, and characterization of branched oligonucleotides. Preferred methods for purification of bNAs are anion-exchange HPLC (see Support Protocol 3) and polyacrylamide gel electrophoresis (see Support Protocol 4). The branched nature of the molecule is confirmed by enzymatic hydrolysis of the bNA to its constituent nucleosides using nuclease P1 (see Support Protocol 3). Further characterization may be conducted via nucleoside composition analysis using snake venom phosphodiesterase (UNIT 10.6) or MALDI-TOF-MS (UNIT 10.1). SYNTHESIS AND CHARACTERIZATION OF THE ADENOSINE BRANCHING SYNTHON N6-BENZOYL-5′-O-(4,4′-DIMETHOXYTRITYL)ADENOSINE-2′,3′-BIS-O-(2-CYANOETHYL-N,N-DIISOPROPYL) PHOSPHORAMIDITE The authors’ group has been predominantly interested in the synthesis of branched RNA fragments related to the lariat intermediates formed during pre-mRNA splicing. Such intermediates contain almost exclusively adenosine at the branch point; therefore, the protocol given below describes the synthesis of the adenosine branching phosphoramidite synthon (BIS-A; S.3; Fig. 4.14.1) used for the synthesis of symmetrical, branched DNA and RNA oligonucleotides (Damha and Ogilvie, 1988). The same protocol may be adapted to the synthesis of the corresponding U, C, and G bisphosphoramidites. The starting protected nucleoside, N6-benzoyl-5′-O-(4,4′-dimethoxytrityl)adenosine (S.1), is commercially available (ChemGenes). Alternatively, it may be synthesized from adenosine using the transient benzoylation procedure of Ti et al. (1982), followed by dimethoxytritylation of the 5′-hydroxyl group (Hakimelahi et al., 1982; Wu et al., 1989). Contributed by Sandra Carriero and Masad J. Damha Current Protocols in Nucleic Acid Chemistry (2002) 4.14.1-4.14.32 Copyright © 2002 by John Wiley & Sons, Inc.
BASIC PROTOCOL 1
Synthesis of Modified Oligonucleotides and Conjugates
4.14.1 Supplement 9
O
[ABz] [DMTr]
Ph
HN O
N
N
OMe Ph
HN N N O
O
N N
N
i -Pr2N
DMTrO
N
O
P OCH2CH2CN
Cl 2
NCCH2CH2O
O
O
P
P
i -Pr2N
i -Pr2N
OCH2CH2CN
DMAP, DIPEA, THF OH
HO OMe
1
3 (4 diastereomers)
Figure 4.14.1 Reaction scheme demonstrating the synthesis of N6-benzoyl-5′-O-(4,4′-dimethoxytrityl)adenosine-2′,3′-Obis-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.3) from the starting protected nucleoside N6-benzoyl-5′-O-(4,4′-dimethoxytrityl)adenosine (S.1). The structure of the chlorophosphoramidite (S.2) is also shown. Abbreviations: Bz, benzoyl; DIPEA, N,N-diisopropylethylamine; DMAP, 4-dimethylaminopyridine; DMTr, 4,4′-dimethoxytrityl.
The synthesis of the branching synthon involves the phosphitylation of the 2′ and 3′ secondary hydroxyls of the ribose sugar (Fig. 4.14.1) using an excess of 2-cyanoethylN,N-diisopropylchlorophosphoramidite (S.2). Reaction conditions, workup, chromatographic purification, and characterization of the product N6-benzoyl-5′-O-(4,4′-dimethoxytrityl)adenosine-2′,3′-bis-O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.3) are described. Materials N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)adenosine (S.1; ChemGenes) 4-Dimethylaminopyridine (DMAP; 99%; Aldrich) Nitrogen or argon gas, dry Anhydrous THF (see recipe) in a septum-sealed distillation collection bulb Anhydrous DIPEA (see recipe) 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite (S.2; ChemGenes) 1:1 (v/v) dichloromethane/diethyl ether 20% (v/v) sulfuric acid (optional) Ethyl acetate prewashed with 5% (w/v) NaHCO3 NaCl solution, saturated Sodium sulfate (Na2SO4), anhydrous 50:47:3 (v/v/v) CH2Cl2/hexanes/triethylamine Silica gel (230- to 400-mesh) in 50:47:3 CH2Cl2/hexanes/triethylamine 95% (v/v) ethanol Diethyl ether
Solid-Phase Synthesis of Branched Oligonucleotides
50-mL oven- or flame-dried round-bottom flask with rubber septum Glass syringe and needle, oven dried 2 × 5 cm silica-coated thin-layer chromatography (TLC) plate with fluorescent indicator (e.g., Kieselgel 60 F254 aluminum sheets) 254-nm UV light source 500-mL separatory funnel Gravity filtration device and filter paper
4.14.2 Supplement 9
Current Protocols in Nucleic Acid Chemistry
250- and 500-mL round-bottom flasks Rotary evaporator with a water aspirator 5 × 25–cm glass chromatography column with solvent reservoir bulb Additional reagents and materials for thin-layer chromatography (TLC; APPENDIX 31 3D), column chromatography (APPENDIX 3E), P-NMR (UNIT 7.2), and mass spectrometry (UNITS 10.1 & 10.2) Phosphitylate 2′- and 3′-OH 1. Place 1.3 g (2.0 mmol) N6-benzoyl-5′-O-(4,4′-dimethoxytrityl)adenosine (S.1) and 84 mg (0.7 mmol) DMAP into a 50-mL oven- or flame-dried round-bottom flask. 2. Cap the flask with a rubber septum and purge the flask with dry nitrogen or argon. Care must be taken to avoid the presence of moisture throughout the entire reaction.
3. Withdraw anhydrous THF from a septum-sealed distillation collection bulb using an oven-dried glass syringe and needle. Add 6.0 mL THF to the purged flask with stirring until the starting material is completely dissolved. 4. Add 3.6 mL (21 mmol) anhydrous DIPEA and stir the mixture. 5. Slowly add 1.8 mL (8.3 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite (S.2). If the THF solution is sufficiently dry, a white precipitate should form after ∼1 min. This is the diisopropylethylammonium hydrochloride salt that forms during the reaction.
6. Stir the mixture 1 hr at room temperature or until the reaction is complete. Reaction of the secondary hydroxyls of the starting material with S.2 is fast. If TLC analysis (see below) reveals that the reaction is not complete after 1 hr, a further 0.5 mmol S.2 should be added dropwise and stirring continued until all of the starting material is consumed.
Monitor reaction by TLC 7. Spot the reaction mixture onto a precut 2 × 5–cm silica-coated TLC plate with fluorescent indicator and develop using 1:1 (v/v) dichloromethane/diethyl ether (APPENDIX 3D). Addition of 1% to 3% trietylamine may help prevent detritylation.
8. Visualize heterocyclic bases under a 254-nm UV light source. If desired, spray the plate with 20% sulfuric acid in order to visualize the dimethoxytrityl-bearing species. CAUTION: Wear protective eyewear. TLC analysis should indicate complete conversion to products, which exhibit larger Rf values than the starting protected nucleoside. Since the phosphitylation reaction gives rise to two new chiral centers (2′- and 3′-P), the product (S.3) consists of a mixture of four diastereomers. The products appear as two spots (Rf = 0.51 and 0.40) or as one dumbbellshaped spot, because the solvent system partially resolves the four diastereomeric products. A minor side product forms, which migrates between the product (S.3) and starting material (S.1). This is likely the nucleoside-2′,3′-H-bis-phosphonate (Rf = 0.25) that forms via hydrolysis of S.3.
Work up reaction 9. Transfer the reaction mixture to a 500-mL separatory funnel and add 100 mL prewashed ethyl acetate. The ethyl acetate is prewashed with 5% NaHCO3 in order to prevent detritylation and/or activation of the phosphoramidite moiety.
10. Wash the ethyl acetate layer five times each with 100 mL saturated NaCl solution. The diisopropylammonium hydrochloride salt dissolves.
Synthesis of Modified Oligonucleotides and Conjugates
4.14.3 Current Protocols in Nucleic Acid Chemistry
Supplement 9
11. Dry the organic layer over anhydrous Na2SO4. Add more Na2SO4 if the salt crystals clump together upon swirling. When the solution is dry, the nonhydrated crystals will float in solution upon swirling.
12. Gravity filter the resulting solution through filter paper into a 250-mL round-bottom flask. Rinse the Na2SO4 crystals with 10 to 20 mL ethyl acetate. 13. Remove the solvent under reduced pressure (i.e., in a rotary evaporator with a water aspirator) to yield the crude product as a yellow oil. Isolate and characterize product 14. Prepare a 5 × 25–cm glass chromatography column by adding a slurry of 40 g silica gel in 50:47:3 CH2Cl2/hexanes/triethylamine. Precondition with the same solvent. 15. Dissolve the crude material in a minimum amount of 50:47:3 CH2Cl2/hexanes/triethylamine and load on column. Perform chromatography at a rate of ∼1 in. solvent/min using a small amount of air pressure (APPENDIX 3E). Collect product in 10-ml fractions in small test tubes. 16. Combine product-containing fractions into a 500-mL round-bottom flask and concentrate to an oil on a rotary evaporator. 17. Remove residual triethylamine by co-evaporating the oil first with 50 mL of 95% ethanol followed by 50 mL diethyl ether, to provide the pure product as a pale yellow foam. 18. Store bisphosphoramidite at –20°C under an inert atmosphere protected from light. Phosphoramidites are particularly sensitive to UV light; therefore, it is best to store the bisphosphoramidite in a dark bottle (or a bottle covered with aluminum foil) in a –20°C freezer. Under these conditions, the phosphoramidite may be stored for an indefinite period of time. Prior to use, its purity may be verified via TLC analysis. If partial decomposition has occurred, or the coupling reactions with S.3 are poor, the compound should be subjected to chromatography again as described above.
19. Characterize by TLC (APPENDIX 3D), 31P-NMR (UNIT 7.2), and mass spectrometry (UNITS 10.1 & 10.2). 31
P-NMR spectra (400 MHz) of S.3 were measured on a Varian XL-400 spectrometer using CD3CN as the solvent (Fig. 4.14.2). Chemical shifts are reported in parts per million (ppm) and are downfield (positive value) from 85% H3PO4 (external standard). Fast atom bombardment mass spectrometry (FAB-MS) analysis was conducted on a Kratos MS25RFA high-resolution mass spectrometer using a p-nitrobenzyl alcohol (NBA) matrix. N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)adenosine-2′,3′-bis-O-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (S.3): yield 52% (560 mg); Rf (1:1 CH2Cl2/diethyl ether): 0.51 and 0.40; 31P-NMR (400 MHz, CD3CN): diastereomer 1, 152.3 and 150.7 ppm (5JP-P = 10.1 Hz); diastereomer 2, 151.9 and 150.5 ppm (5JP-P = 6.6 Hz); diastereomer 3, 151.8 and 151.0 ppm (5JP-P = 4.6 Hz); diastereomer 4, 151.3 and 151.2 ppm (5JP-P = 8.9 Hz); FAB-MS anal. calc’d.: 1074.17; observed: 1074.57; [M]+. BASIC PROTOCOL 2
Solid-Phase Synthesis of Branched Oligonucleotides
CONVERGENT SYNTHESIS OF SYMMETRICAL BRANCHED NUCLEIC ACIDS The procedure described below for the synthesis of bNAs is carried out on a 1-µmol scale using an ABI 381A DNA synthesizer (Damha and Zabarylo, 1989; Damha et al., 1992). The condensation of two adjacent linear oligonucleotides (prepared from standard RNA or DNA phosphoramidites; Fig. 4.14.3) with the adenosine bisphosphoramidite synthon (S.3; Fig. 4.14.1) produces bNAs that contain identical branches connected via vicinal 2′,5′- and 3′,5′-phosphodiester linkages (Fig. 4.14.4). The same protocol may be utilized for the synthesis of bNAs containing D-xylose or D-arabinose instead of D-ribose at the
4.14.4 Supplement 9
Current Protocols in Nucleic Acid Chemistry
branchpoint, using the appropriate bisphosphoramidite synthons (Damba and Ogilvie, 1988; Noronha, Carriero, Agha, and Damha, unpub. observ.). Branched nucleic acid synthesis works very well on commercially available solid supports (i.e., LCAA-CPG) containing 20 to 40 µmol nucleoside per gram support; however, even better yields are attainable on CPG supports with higher loadings (e.g., 90 µmol/g; Fig. 4.14.5). Such supports can be prepared using HATU/DMAP as the coupling reagents (see Support Protocol 1), and are ideal for the synthesis of short-length bNAs (e.g., trimers) since, in this case, high loadings ensure proper distance between the neighboring CPGbound nucleosides (Damha and Zabarylo, 1989). Materials 5′-O-(4,4′-Dimethoxytrityl)-N-protected-2′-deoxyribonucleoside- or -ribonucleoside-derivatized succinyl-LCAA-CPG (ChemGenes; also see Support Protocol 1) Cap A and B capping reagents (see recipes) DNA and/or RNA 3′-phosphoramidites (S.4a-d and S.5a-d; Fig. 4.14.3)
2 2 1 1
3
3 4
152.5
152.0
151.5
4
151.0
150.5 PPM
Figure 4.14.2 31P-NMR of N6-benzoyl-5′-O-DMTr-adenosine-2′,3′-bis-O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (S.3). Due to the two chiral phosphorus centers, the compound exists as a mixture of four diastereomers (22 = 4; Fig. 4.14.1). Each diastereomer displays two sets of phosphorus signals (4 isomers × 2 31P signals = 8 signals). The doubling or splitting of each signal (8 × 2 = 16) is due to long-range coupling between the two chiral 31P atoms (nuclear spin = 1⁄2) of the bisphosphoramidite. The spectrum was recorded on a Varian XL-400 spectrometer using CD3CN as the solvent. The chemical shift and coupling constants for the four diastereomers (shown as numbers near peaks) are as follows: diastereomer 1, 152.3 and 150.7 ppm (5JP-P = 10.1 Hz); diastereomer 2, 151.9 and 150.5 ppm (5JP-P = 6.6 Hz); diastereomer 3, 151.8 and 151.0 ppm (5JP-P = 4.6 Hz); diastereomer 4, 151.3 and 151.2 ppm (5JP-P = 8.9 Hz).
Synthesis of Modified Oligonucleotides and Conjugates
4.14.5 Current Protocols in Nucleic Acid Chemistry
Supplement 9
DNA 3′-phosphoramidites B
DMTrO
RNA 3′-phosphoramidites B
DMTrO
O O
i -Pr2N P
OCH2CH2CN 4a-d
DNA 5′-phosphoramidites OCH2CH2CN
O NCCH2CH2O
O
i -Pr2N
P
B
O
O
O Si
P
DMTrO
i -Pr2N
6a-d
5a-d
4-6a B = N 6-benzoyladenin-9-yl 4-6b B = N 2-isobutyrylguanin-9-yl 4-6c B = N 4-benzoylcytosin-1-yl 4d, 6d B = thymin-1-yl 5d B = uracil
Figure 4.14.3 Chemical structures of DNA and RNA phosphoramidites used for bNA synthesis: 5′-O-DMTr-N-protected-2′-deoxyribonucleoside-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidites (S.4a-d), 5′-O-DMTr-N-protected-2′-O-TBDMS-ribonucleoside-3′-O-(2-cyanoethylN,N-diisopropylamino)phosphoramidites (S.5a-d), and the inverted phosphoramidites 3′-O-DMTrN-protected-2′-deoxyribonucleoside-5′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidites (S.6a-d).
N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)adenosine-2′,3′-bis-O-(2-cyanoethyl-N,Ndiisopropyl)phosphoramidite (BIS-A; S.3; see Basic Protocol 1) Anhydrous acetonitrile (see recipe) Activator solution: 0.5 M 1H-tetrazole (sublimed) in anhydrous acetonitrile Oxidant solution (see recipe) Detritylation solution (see recipe) Nitrogen or argon gas (optional) Synthesis columns for 1-µmol scale synthesis, with seals and filters (PE Biosystems) and 13-mm aluminum seals (Chromatographic Specialties) ABI 381A automated DNA synthesizer (PE Biosystems) Synthesizer bottles for phosphoramidites, oven dried Fraction collector and 15-mL test tubes 50-mL buret Quartz cuvettes UV-Vis spectrophotometer Additional reagents and equipment for oligonucleotide synthesis (APPENDIX 3C), cleaving and deprotecting oligonucleotides (see Support Protocol 2), and anion-exchange HPLC (see Support Protocol 3) or denaturing PAGE (see Support Protocol 4) NOTE: 1H-Tetrazole is no longer commercially available in crystalline form. Solutions of 0.45 M 1H-tetrazole in anhydrous acetonitrile may be purchased from ChemGenes. For a list of supplementary phosphoramidite activating reagents, see UNIT 3.5. Solid-Phase Synthesis of Branched Oligonucleotides
CAUTION: All solutions for the DNA/RNA synthesizer should be prepared in a well-ventilated fume hood.
4.14.6 Supplement 9
Current Protocols in Nucleic Acid Chemistry
Prepare columns for synthesis 1. Transfer an accurately weighed amount of 5′-O-(4,4′-dimethoxytrityl)-N-protected2′-deoxyribonucleoside- or -ribonucleoside-derivatized succinyl-LCAA-CPG for a 1-µmol synthesis to an assembled synthesis column. The support-bound nucleoside represents the first nucleotide at the 3′-end of the oligonucleotide to be synthesized. See Support Protocol 1 for high-loading CPG supports.
NNNNNN 7 1. NH4OH/EtOH 2. TREAT-HF (RNA only)
DMTrON
DMTrON
DMTrON
DNA/RNA synthesis (3′→5′)
DMTrON
HON
HON
HON
HON
N N N N N
N N N N N
N N N N N
N N N N N
trityl off succinyl-LCAA-CPG 3
failure sequences N N N N N N
N N N N N N
HOABz 2′ 3′
HOABz 3′ 2′
N N N N N N
N N N N N N
N N N N N N
trityl off
failure sequences HOABz 3′ 2′
P*
AcON
DNA/RNA synthesis (3′→5′)
N N N N N
trityl off
HOABz 3′ 2′
N N N N N N
N N N N N N
N N N N N N
P*
N N N N N
1. NH4OH/EtOH 2. TREAT-HF (RNA only)
2′
NNNNNN
3′
1. NH4OH/EtOH 2. TREAT-HF (RNA only)
NNNNNN
A
2′
Y-shaped
NNNNNN
A 3′
NNNNNN
V-shaped NNNNNN
10 2′
NNNNNN
A 3′
8
P*
2′
+
AcON
NNNNNN
3′
NNNNNN
11a
11b
NNNNNN
A
2′
P*
2′
+
A P*
3′
NNNNNN
A 3′
NNNNNN 9a
P* 9b
NNNNNN
NNNNNN
7
7
Figure 4.14.4 Schematic representation demonstrating the convergent synthesis of V- and Yshaped bDNA or bRNA oligonucleotides on a solid support. The method can also be used for the synthesis of short branched sequences—e.g., tetranucleoside triphosphates, NpA(2′pN)3′pN— particularly when the nucleoside loading on the solid support approaches 90 µmol/g. Abbreviations: A, bisphosphoramidite; Bz, benzoyl; DMTr, 4,4′-dimethoxytrityl; N, any nucleotide (RNA or DNA); TREAT-HF, triethylammonium trihydrofluoride; S.7, linear oligonucleotide; S.8 and S.10, full-length bNAs (V- and Y-shaped); S.9a-b and S.11a-b, unbranched linear failure sequences. P* indicates the presence of a 2′- or 3′-linked phosphate to the adenosine branch point, which is formed by the hydrolysis and oxidation of the residual phosphoramidite during solid-phase synthesis.
Synthesis of Modified Oligonucleotides and Conjugates
4.14.7 Current Protocols in Nucleic Acid Chemistry
Supplement 9
(i) T10
A
T10
A
XC +
(ii) T10 (iii) T10
BPB
A
T10 T10 P* T10 T10 P*
Relative % oligonucleotide
CPG loading (µmol/g)
80 70 60 50 40 30 20 10 0 20
30
40
50
60
70
80
CPG loading (µmol/g) i: Branched DNA
ii: Extended isomeric DNA
Figure 4.14.5 Effect of CPG loading on yield of the Y-shaped bDNA, T10A2′,5′-T10 3′,5′-T10 synthesized via the convergent strategy (see Basic Protocol 2). (A) PAGE analysis of the amount of Y-shaped product (i; S.10) and failure sequences (ii; S.11a-b) formed as a function of CPG loading on a 20% denaturing polyacrylamide gel. P* indicates the presence of a 2′or 3′-linked phosphate. (B) Chart demonstrating the increase in the amount of S.10 (i) with increasing nucleoside-CPG loading. The chart also demonstrates the inverse relationship between the amount of extended isomeric linear failures (ii; S.11a-b) and nucleoside-CPG loading. The percentage oligonucleotide was determined by integration of the HPLC peak areas of the compounds in question (see Support Protocol 3) using gradient 3 (see Table 4.14.4).
Table 4.14.1 Automated Cycle on an ABI 381A DNA Synthesizer for Capping of Free CPG-Bound Amino and Hydroxyl Groupsa
Synthesis step
Function
Time (sec)
Column washing steps:
Solid-Phase Synthesis of Branched Oligonucleotides
1 2 3 4
Acetonitrile to waste Acetonitrile to column Argon reverse flush Argon block flush
Column capping steps: 5 6 7
Cap A + cap B to column Wait Repeat steps 5 and 6
Column washing steps: 8 9 10 11 12
Argon reverse flush Acetonitrile to column Repeat steps 8 and 9 Argon reverse flush Argon block flush
5 60 5 5 15 300
5 30 5 5
aAlternatively, CPG may be capped manually using acetic anhydride (see Support Protocol 1).
4.14.8 Supplement 9
Current Protocols in Nucleic Acid Chemistry
2. Acetylate any underivatized amino and hydroxyl groups on the solid support using an ABI 381A automated DNA synthesizer and the capping cycle given in Table 4.14.1 (APPENDIX 3C). This step also removes traces of water from the solid support. Alternatively, see Support Protocol 1 for the manual capping procedure on nucleosideloaded CPG.
Synthesize branched oligonucleotides 3. Weigh out the appropriate amount of DNA (S.4a-d) and/or RNA (S.5a-d) 3′-phosphoramidites (Fig. 4.14.3) and dilute to the appropriate concentration with anhydrous acetonitrile as indicated in Table 4.14.2. 4. Transfer 100 mg BIS-A (S.3) to an oven-dried synthesizer bottle and dilute to 0.03 M with anhydrous acetonitrile. Low concentrations of BIS-A should be employed in the branching reaction, as high concentrations minimize the yield of fully branched product (S.8 and S.10) and favor the extended isomeric side products (S.9a-b and S.11a-b). It is important to prepare the BIS-A stock solution using ≥100 mg material to ensure that (unavoidable) traces of moisture do not consume significant amounts of BIS-A during the coupling (branching) step and reduce the overall yield of bNA synthesis (Fig. 4.14.6E). When the ABI 381A DNA synthesizer is used, this stock solution can be used for as many as 18 branching reactions (170 ìL/addition). Once bNA synthesis is complete, the bottle containing the BIS-A reagent can be removed from the synthesizer, sealed, purged under an inert atmosphere, and left in a freezer (−20°C) for ∼2 weeks. Alternatively, the stock solution can be evaporated under vacuum, and the solid bisamidite recovered for future use.
5. Place all synthesizer reagents (i.e., activator, capping, oxidant, and detritylation solutions, and acetonitrile) and diluted phosphoramidites (step 3) on the appropriate ports of the synthesizer. 6. Place the BIS-A phosphoramidite bottle on the spare phosphoramidite port (the “X” port on the 381A synthesizer).
Table 4.14.2 Concentrations and Optimal Coupling Times of Phosphoramidites in Synthesis of bNAs on an ABI 381A DNA Synthesizer
Phosphoramiditea
Mol. wt. (g/mol)
Concentration (g/mL)
Coupling time (sec)
DNA phosphoramidites (0.1 M in CH3CN b): 857.7 S.4a, S.6a
86
90
S.4b, S.6b S.4c, S.6c S.4d, S.6d
839.7 833.7 744.6
84 83 74
120 90 90
RNA phosphoramidites (0.15 M in CH3CN): S.5a 988.2 S.5b 970.2 S.5c 964.2 S.5d 861.0
148 146 145 129
600 900 600 600
Bisphosphoramidite (0.03 M in CH3CN): S.3 1074.2
32.2
1800
aPhosphoramidite structures are shown in Figure 4.14.3. bFinal concentration of the first inverted DNA phosphoramidite coupled to the 2′-OH of the rA in divergent and
regiospecific synthesis is 0.3 M (see 5′-pD′′ in Fig. 4.14.8).
Synthesis of Modified Oligonucleotides and Conjugates
4.14.9 Current Protocols in Nucleic Acid Chemistry
Supplement 9
Table 4.14.3 Automated 1-µmol Synthesis Cycle for bDNA and bRNA on an ABI 381A DNA Synthesizer
Synthesis step
Function
Time (sec)
Detritylation of support-bound nucleoside: 1 Acetonitrile to waste 2 Acetonitrile to column 3 Argon reverse flush 4 Argon block flush 5 Advance fraction collector 6 3% TCA to waste 7 3% TCA to column 8 Acetonitrile to column 9 3% TCA to column 10 Argon block flush Column washing steps: 11 Acetonitrile to waste 12 Acetonitrile to column 13 Argon reverse flush 14 Argon block flush 15 Acetonitrile to waste 16 Acetonitrile to column 17 Argon reverse flush 18 Argon block flush Phosphoramidite coupling steps: 19 Phosphoramidite preparation 20 Activator to column 21 Phosphoramidite + activator to column 22 Repeat steps 20 and 21 two times 23 Activator to column 24 Waita 25 Argon reverse flush 26 Argon block flush Column capping steps: 27 Cap A + cap B to column 28 Wait 29 Repeat steps 27 and 28 30 Acetonitrile to waste 31 Argon block flush 32 Acetonitrile to waste 33 Argon reverse flush 34 Argon block flush Oxidation steps: 35 Oxidant to waste 36 Oxidant to column 37 Acetonitrile to waste 38 Argon block flush 39 Wait Column washing steps: 40 Acetonitrile to waste 41 Argon reverse flush 42 Argon block flush 43 Acetonitrile to waste 44 Acetonitrile to column 45 Argon reverse flush 46 Repeat steps 44 and 45 six times 47 Argon block flush Solid-Phase Synthesis of Branched Oligonucleotides
5 45 5 5 1 10 140 30 80 10 5 120 5 5 5 60 5 5 3 5 5 3 5 5 17 45 5 5 5 5 5 5 20 5 5 20 5 10 5 5 18 5 5
aSee Table 4.14.2 for coupling times of various phosphoramidites.
4.14.10 Supplement 9
Current Protocols in Nucleic Acid Chemistry
A
B (i) T10 A
GT9 GT9
i
ii
AU T10
(iii) linear failure sequences
0
10
+
(ii) T10
20
A
30
A
P* GT9 GT9
iii
P*
40 Time (min)
50
60
70
80
D
C (i) CCCUACUAA
(iii) linear failure sequences
GUAUGCCC GUAUGCCC
P* CCCUACUAA GUAUGCCC + (ii) GUAUGCCC CCCUACUAA P*
AU
0
10
20
30
40 Time (min)
E i
i
ii
ii
iii
50
60
70
iii
80
Figure 4.14.6 Analysis of bDNA and bRNA molecules synthesized using the convergent strategy (see Basic Protocol 2). (A-B) Analysis of a successful synthesis of the Y-DNA 5′-T10A2′,5′-GT9 3′,5′-GT9 by (A) anion-exchange HPLC (see Support Protocol 3) using gradient 3 (Table 4.14.4) and (B) 20% denaturing PAGE (see Support Protocol 4). (C-E) Analysis of a successful (C-D) and unsuccessful (E) synthesis of the mixed base Y-RNA 5′-CCCUACUAA2′,5′-GUAUGCCC3′,5′-GUAUGCCC by (C) anion-exchange HPLC (see A for conditions) and (D-E) 20% denaturing PAGE. The regioisomeric extended failure sequences (ii) are resolved into two peaks by HPLC (A and C), but appear as one band by gel analysis (B, D, and E). In panel E, the major product is the unbranched 8-mer 5′-GUAUGCCC-3′, which accumulates due to the unsuccessful branching of the bisphosphoramidite. P* indicates the presence of a 2′- or 3′-linked phosphate.
7. Enter the sequence to be synthesized in the 5′-to-3′ direction, where the 3′-nucleotide corresponds to the nucleoside bound to the CPG. For example, to synthesize the hypothetical V-shaped branched oligonucleotide (S.8) shown in Figure 4.14.4, enter the sequence 5′-XNNNNNN-3′, where X corresponds to the bisphosphoramidite and N is any base (phosphoramidite) of choice. If the hypothetical Y-shaped branched oligonucleotide (S.10) is desired, enter the sequence 5′NNNNNNXNNNNNN-3′.
8. Perform synthesis in the trityl-off mode according to the synthesis cycle outlined in Table 4.14.3 and utilizing the coupling times recommended in Table 4.14.2. Collect dimethoxytrityl solutions in 15-mL test tubes using an external fraction collector. Turning the trityl mode off ensures that the last nucleotide at the 5′ end has a free hydroxyl group, which is desirable for purification using anion-exchange HPLC (see Support Protocol 3).
Synthesis of Modified Oligonucleotides and Conjugates
4.14.11 Current Protocols in Nucleic Acid Chemistry
Supplement 9
9. Upon completion of the synthesis, dry the CPG by manually conducting an argon reverse flush operation on the synthesizer for 10 min. Alternatively, dry the CPG under a stream of nitrogen or argon, or in a vacuum desiccator for 30 min. 10. Cleave the oligonucleotides from the support and deprotect the exocyclic amino, phosphate, and 2′-silyl (RNA only) protecting groups (see Support Protocol 2). 11. Purify the bNAs from failure sequences by anion-exchange HPLC (see Support Protocol 3) or denaturing PAGE (see Support Protocol 4). Typical HPLC and PAGE profiles for the synthesis of branched V-shaped and Y-shaped DNA and RNA molecules are demonstrated in Figures 4.14.6 and 4.14.7.
Measure branching efficiency by trityl color analysis 12. Dilute the dimethoxytrityl solutions collected after each successive coupling (step 8) with 10 mL detritylation solution using a 50-mL buret. 13. Aliquot 100 µL into a quartz cuvette and dilute with 2 mL detritylation solution. Use only quartz cuvettes, as the 1,2-dichloroethane will dissolve disposable polystyrene cuvettes.
14. Measure the absorbance of the solution on a UV-Vis spectrophotometer between 450 and 550 nm, and record the absorbance peak at ∼505 nm for the dimethoxytrityl cation.
XC
d c a
a′ b
b
BPB
1
Solid-Phase Synthesis of Branched Oligonucleotides
2
3
4
Figure 4.14.7 PAGE analysis of bDNA molecules synthesized via the convergent strategy (see Basic Protocol 2), demonstrating the mobilities of bNAs through a cross-linked 20% polyacrylamide gel. Lane 1, crude linear DNA 12-mer 5′-TACTAAGTATGT-3′ (a); lane 2, crude V-DNA 13-mer 5′-A2′,5′-GTATGT3′,5′-GTATGT (c); lane 3, crude Y-DNA 18-mer TACTAA2′,5′-GTATGT3′,5′-GTATGT (d); lane 4, running dyes (xylene cyanol and bromphenol blue). The fastest-migrating sequence in lanes 2 and 3 is the 6-mer 5′-GTATGT-3′ (b), which is the immediate precursor of the V-shaped molecule (c). Notice the large gap between the failure sequence (b) and product V-DNA (c) in lane 2, owing to more than doubling the molecular weight upon branching. In lane 3, extension of the failure sequence yields a separate band (a′).
4.14.12 Supplement 9
Current Protocols in Nucleic Acid Chemistry
15. Determine the efficiency of each coupling step using the equation (Ax/Ax−1) × 100%, where Ax is the absorbance of the trityl cation released at any given step and Ax−1 is the release in the previous step. For efficient coupling, these values should be close to 100% for linear portions of the oligonucleotide (also see UNIT 10.3). For efficient branching, the value for the coupling of S.3 should be 50%, since one tritylated bisphosphoramidite is coupled to two nucleotide chains. For this step, trityl yields that are significantly greater than or less than 50% indicate little branch formation (e.g., 80% indicates the formation of mainly the extended isomeric compounds S.9a-d and S.11a-d).
REGIOSPECIFIC SYNTHESIS OF BRANCHED NUCLEIC ACIDS The protocol described below outlines the regiospecific and divergent synthesis of bNAs via phosphoramidite chemistry according to the method of Braich and Damha (1997; Fig. 4.14.8). This protocol allows for the synthesis of bNA molecules with different DNA sequences surrounding the branchpoint nucleotide. The methodology requires the use of standard DNA and RNA 3′-phosphoramidites (S.4a-d and S.5a-d) for the synthesis of a linear DNA strand incorporating a single ribonucleotide unit. Once this sequence is assembled, all of the 2-cyanoethyl phosphate-protecting groups are selectively removed by treatment with triethylamine. This step is necessary as phosphotriesters are susceptible to cleavage/modification by the ensuing fluoride treatment. The CPG-bound oligomer is then treated with fluoride ions to cleave the tert-butyldimethylsilyl group at the 2′ position of the ribose unit, from which another chain (2′-branch) can be synthesized. This is accomplished using “inverted” DNA phosphoramidites (deoxyribonucleoside 5′-phosphoramidites; S.6a-d), allowing branch synthesis to occur in the opposite (5′-to-3′) direction. With the exception of the decyanoethylation and desilylation steps, the entire process is conducted using an ABI 381A DNA synthesizer.
BASIC PROTOCOL 3
Materials 5′-O-(4,4′-Dimethoxytrityl)-N-protected-2′-deoxyribonucleoside-derivatized succinyl-LCAA-CPG (ChemGenes; also see Support Protocol 1) Cap A and B capping reagents (see recipes) DNA 3′-phosphoramidites (S.4a-d; Chem Genes; Fig. 4.14.3) Anhydrous acetonitrile (see recipe) RNA 3′-phosphoramidite (S.5a-d; ChemGenes; Fig. 4.14.3) Activator solution: 0.5 M 1H-tetrazole (sublimed) in anhydrous acetonitrile Oxidant solution (see recipe) Detritylation solution (see recipe) 4:6 (v/v) triethylamine/acetonitrile (see recipe) Anhydrous THF (see recipe) 1 M tetra-n-butylammonium fluoride (TBAF; Aldrich) in THF, fresh Inverted DNA 5′-phosphoramidites (S.6a-d; ChemGenes; Fig. 4.14.3) Argon or nitrogen gas (optional) Synthesis columns for 1 µmol scale synthesis, with seals and filters (PE Biosystems) and 13-mm aluminum seals (Chromatographic Specialties) ABI 381A automated DNA synthesizer (PE Biosystems) External fraction collector and 15-mL test tubes Empty DNA synthesizer bottles, oven-dried 10- and 1-mL disposable syringes 25-mL glass syringe Additional reagents and equipment for cleaving and deprotecting the oligonucleotide (see Support Protocol 2), anion-exchange HPLC (see Support
Synthesis of Modified Oligonucleotides and Conjugates
4.14.13 Current Protocols in Nucleic Acid Chemistry
Supplement 9
B
DMTrO
O OTBDMS
O
O P OCH2CH2CN O HOD
D D D D D D
D D D D D
DMTrOD
DNA synthesis (3′→5′)
3′-pR amidites
3′-pD amidites
succinylLCAA-CPG
1. DNA synthesis (3′→5′) 2. cap with Ac2O
AcO
AcOD
AcO
D D D D D D O
D D D D D D O
O P O− O
O
O P OCH2CH2CN
O P O−
extend from 2′-OH in 5′→3′ direction with 5′-pD′ amidites
B
D D D D D O B
O
O
O O
O P
O P O− O D D D D D D
OCH2CH2CN
O
OH
O P O−
O D″ D′ D′ D′ D′ D′
D D D D D D
1. cleave from support and deprotect 2. purify (3′-5′)
R
1. remove all 2cyanoethyl groups 2. remove 2′-OTBDMS group
O
B O O
OTBDMS
O P OCH2CH2CN
O
O
D D D D D D
D D D D D D
12
(2′-5′)
D″ D′ D′ D′ D′ D′
D D D D D D 13
Solid-Phase Synthesis of Branched Oligonucleotides
Figure 4.14.8 Schematic representation for the divergent and regiospecific synthesis of branched DNA. The branching synthon is a standard RNA phosphoramidite (S.5a-d; Fig. 4.14.3). Abbreviations: 3′-pD, DNA 3′-phosphoramidites (S.4a-d); 5′-pD′, inverted DNA 5′-phosphoramidites (S.6ad); 5′-pD′′, higher concentration (0.3M) of inverted DNA 5′−phosphoramidite as first nucleotide coupled to the ribose branch point; 3′-pR, RNA 3′-phosphoramidite (S.5a-d); DMTr, 4,4′-dimethoxytrityl; TBDMS, tert-butyldimethysilyl.
4.14.14 Supplement 9
Current Protocols in Nucleic Acid Chemistry
Protocol 3) or denaturing PAGE (see Support Protocol 4), and measuring coupling efficiency by trityl color analysis (see Basic Protocol 2) CAUTION: All solutions required for bNA solid-phase synthesis should be prepared in a well-ventilated fume hood. Synthesize linear DNA (S.12) 1. Prepare synthesis column (1 µmol) with the appropriate 5′-O-dimethoxytrityl-2′-deoxyribonucleoside-derivatized succinyl-LCAA-CPG (see Basic Protocol 2, steps 1 and 2). 2. Weigh out the proper amount of DNA 3′-phosphoramidites (S.4a-d; Fig. 4.14.3) and dilute to 0.1 M with anhydrous acetonitrile (see Table 4.14.2). For synthesis on the ABI 381A DNA synthesizer, the volume of each phosphoramidite addition to the column is 170 ìL.
3. Weigh out the appropriate amount of 3′-RNA phosphoramidite (S.5a-d; Fig. 4.14.3) and dilute to 0.15 M with anhydrous acetonitrile (see Table 4.14.2). The RNA 3′-phosphoramidite is the branching synthon. Any of the four standard RNA 3′-phosphoramidites (A, G, C, or U) may be used depending on the specific branch point to be introduced.
4. Install all reagents (i.e., activator, capping, oxidant, and detritylation solutions, and acetronitrile) and phosphoramidite solutions on the synthesizer, placing the RNA 3′-phosphoramidite on the spare port (the “X” port on the 381A synthesizer). 5. Enter the base sequence of the linear oligonucleotide to be synthesized in the 5′-to-3′ direction, where the last entry (3′ nucleotide) corresponds to the nucleoside bound to the CPG. For example, to synthesize the hypothetical linear oligonucleotide (S.12) shown in Figure 4.14.8, enter the sequence 5′-NNNNNNXNNNNNN-3′, where N is any deoxyribonucleoside phosphoramidite and X represents the branch point of the RNA.
6. Perform synthesis in the trityl off mode according to the synthesis cycle outlined in Table 4.14.3 and utilizing the coupling times shown in Table 4.14.2. Collect the dimethoxytrityl solutions in 15-mL test tubes in an external fraction collector. Turning the trityl mode off ensures that the last nucleotide at the 5′ end has a free hydroxyl group, which is desirable for purification using anion-exchange HPLC (see Support Protocol 3).
7. Acetylate the hydroxyl group at the 5′ terminus by running the automated capping cycle (Table 4.14.1). Capping the free 5′-OH is necessary as it ensures that extension from this functional group will not occur during the synthesis of the “’orthogonal” 2′-branch.
Cleave 2-cyanoethyl protecting group 8. Dry the CPG by manually conducting an argon reverse flush operation on the synthesizer for 10 min. 9. Remove the synthesis column from the synthesizer and connect it to a 10-mL disposable syringe filled with 4:6 (v/v) triethylamine/acetonitrile. Slowly push the deprotection solution through the column over a 90-min period. Deprotection of the 2-cyanoethyl phosphate-protecting group converts the phosphotriester to the more stable phosphodiester, which withstands the conditions required for desilylation in the ensuing step. To ensure complete decyanoethylation, push the solution slowly through the column and then pull in on the syringe slightly in order to displace the CPG beads from the base of the column.
Synthesis of Modified Oligonucleotides and Conjugates
4.14.15 Current Protocols in Nucleic Acid Chemistry
Supplement 9
10. Wash the CPG beads extensively with 30 mL acetonitrile followed by 30 mL THF using a 25-ml glass syringe attached to the column via the syringe adapter. Cleave 2′-O-TBDMS group 11. Push 1 mL of 1 M TBAF in THF through the column over a period of 10 min using a 1-mL disposable syringe. It is essential to use fresh TBAF. In order to ensure complete desilylation, push the solution slowly through the column and then pull in on the syringe slightly in order to displace the CPG beads from the base of the column. Prolonged treatment with TBAF results in cleavage of the oligonucleotide chain from the solid support (Braich and Damha, 1997). Incomplete desilylation results in the accumulation of silylated linear DNA (S.12; Fig. 4.15.8), which does not allow branch extension from the 2′ position of the branch point (see Fig. 4.14.9B).
12. Wash CPG beads with 50 mL THF followed by 50 mL acetonitrile. 13. Reinstall the column on the synthesizer. Synthesize 2′,5′-linked branch (S.13) 14. Modify the DNA synthesis cycle such that synthesis step 15 becomes the first step in the cycle. Steps 1 to 14 (TCA treatment) may be disregarded since the assembled chain lacks a dimethoxytrityl group.
15. Weigh out the appropriate amounts of inverted DNA 5′-phosphoramidites (S.6a-d; Fig. 4.14.3) into the amidite bottles. Add acetonitrile to the first DNA phophoramidite to prepare a 0.3 M solution. Add acetonitrile to make 0.1 M solutions of each of the remaining monomers. The first inverted DNA 5′-phosphoramidite is added as a 0.3 M solution due to steric hindrance around the ribose 2′-hydroxyl group.
16. Install all the inverted phosphoramidites on the synthesizer and place the first inverted phosphoramidite (0.3 M concentration) on the spare port (the “X” port on the 381A). 17. Enter the linear sequence to be synthesized in the 5′-to-3′ direction, where the last entry corresponds to the first phosphoramidite to be coupled to the 2′-hydroxyl of the branch point. For example, to synthesize the hypothetical branched DNA oligonucleotide (S.13) shown in Figure 4.14.8, enter the sequence 5′-NNNNNN-3′, where N is the first DNA 5′-phosphoramidite to be coupled to the 2′-hydroxyl group of ribose.
18. Synthesize the 2′-branch in the trityl off mode using the modified synthesis cycle starting from step 15 of Table 4.14.3, and utilizing the coupling times shown in Table 4.14.2, except for the first phophoramidite (0.3 M), which should have a coupling time of 30 min. 19. Upon completion of the synthesis, dry the CPG by reverse flushing the column with argon for 10 min. Alternatively, dry the CPG under a stream of nitrogen or argon, or in a vacuum desiccator for 30 min. 20. Cleave the oligonucleotides from the support and deprotect the amino- and phosphate-protecting groups (see Support Protocol 2). Solid-Phase Synthesis of Branched Oligonucleotides
4.14.16 Supplement 9
Current Protocols in Nucleic Acid Chemistry
21. Purify the bNAs from failure sequences by anion-exchange HPLC (see Support Protocol 3) or denaturing PAGE (see Support Protocol 4) and measure coupling efficiency by trityl color assay (see Basic Protocol 2, steps 12 to 15). Typical PAGE profiles for the successful and unsuccessful regiospecific synthesis of a branched Y-shaped DNA molecule are demonstrated in Figure 4.14.9.
PREPARATION OF LCAA-CPG SUPPORTS WITH HIGH NUCLEOSIDE LOADINGS
SUPPORT PROTOCOL 1
The method described allows for the rapid derivatization of LCAA-CPG having nucleoside loadings up to ∼90 µmol/g, which is 3 to 4 times the loading found in commercially available solid supports. While commercial samples provide more than adequate yields of bNAs (Damha et al., 1992), those with higher loadings (50 to 90 µmol/g) provide the best results (Fig. 4.14.5). For example, the synthesis of small bNAs (i.e., trimers and tetramers) requires that the CPG be densely loaded so that efficient branching may occur. The protocol below, adapted from the work of Pon et al. (1999) and Damha et al. (1990), allows for the rapid esterification of 5′-O-protected ribonucleosides and deoxyribonucleosides to succinyl-LCAA-CPG. The key condensing reagent is a mixture of HATU and 4-DMAP. Materials 5′-O-(4,4′-Dimethoxytrityl)-N-protected-ribonucleoside or -2′-deoxyribonucleoside (ChemGenes) O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU; PE Biosystems) 4-Dimethylaminopyridine (DMAP; 99%, Aldrich)
A (i) A
B
T10 T10
XC
XC (iii) TACTAA (iv) TACTAA
(ii) A
GTATGT CAAGTT Si CAAGTT
Si T10 BPB BPB 1
2
3
4
Figure 4.14.9 20% denaturing PAGE analysis of a successful (A) and a less successful (B) synthesis of bNAs. (A) Lane 1, pure bNA (i) prepared by the divergent synthesis method (see Basic Protocol 3); lane 2, pure bNA (i) prepared by the convergent synthesis method (see Basic Protocol 2); lane 3, crude bNA (i) prepared by the divergent synthesis method; lane 4, running dyes (xylene cyanol and bromphenol blue). (B) Preparative PAGE purification of bNA (iii) prepared via the divergent (regiospecific) approach. The diminutive amount of fully branched product (iii) is due to the incomplete desilylation of the 2′-O-TBDMS group (Si) on the RNA branching synthon, as seen by the significant amount of (iv) that remains.
Synthesis of Modified Oligonucleotides and Conjugates
4.14.17 Current Protocols in Nucleic Acid Chemistry
Supplement 9
Succinylated long-chain-aminoalkyl controlled-pore glass (succinyl-LCAA-CPG; UNIT 3.2) Anhydrous acetonitrile (see recipe) Dichloromethane, reagent grade (Fisher) Methanol, reagent grade (Fisher) Cap A and B capping reagents (see recipes) 15-mL glass bottle with septum 1-mL syringe and needle Wrist-action shaker Sintered glass funnel or Buchner funnel with filter paper Additional reagents and equipment for quantitation of released trityl groups (UNIT 3.2) and acetylation of support (UNIT 3.2; optional) 1. In a 15-mL glass bottle, combine the following: 0.1 mmol 5′-O-(4,4′-dimethoxytrityl)-N-protected-ribonucleoside or -2′-deoxyribonucleoside 0.1 mmol HATU 12 mg DMAP 250 mg succinyl-LCAA-CPG. 2. Cap the bottle with a septum and add 1 mL anhydrous acetonitrile via a 1-mL syringe and needle. 3. Shake 2 to 4 hr on a wrist-action shaker at room temperature. Do not stir the slurry with a magnetic stir bar as this will break up the glass beads into fine particles that may clog the frit on the DNA synthesizer.
4. Vacuum filter succinyl-LCAA-CPG into a side-arm filter flask through a sintered glass funnel or Buchner funnel with filter paper. 5. Wash the CPG sequentially with 25 mL reagent-grade dichloromethane, 25 mL methanol, and 25 mL dichloromethane. It has been reported that the free carboxylic groups are inconsequential and do not react during phosphoramidite synthesis (Lyttle et al., 1997).
6. Transfer the CPG to a glass vial and dry under vacuum using in a desiccator attached to a vacuum pump. The derivatized CPG may be stored indefinitely at room temperature, preferably in a vacuum desiccator.
7. Determine nucleoside loading through the quantitation of the released trityl groups from the support-bound nucleoside (UNIT 3.2). 8. Acetylate the solid support with cap A and B capping reagents on a DNA synthesizer using the capping cycle outlined in Table 4.14.1. Alternatively, perform capping as described in UNIT 3.2.
Solid-Phase Synthesis of Branched Oligonucleotides
4.14.18 Supplement 9
Current Protocols in Nucleic Acid Chemistry
COMPLETE DEPROTECTION OF BRANCHED OLIGONUCLEOTIDES (DNA AND RNA)
SUPPORT PROTOCOL 2
This protocol describes the steps necessary for cleaving the bNA from the solid support and removing the protecting groups from the heterocyclic bases and sugar-phosphate backbone. The first step is treatment of the solid support with concentrated aqueous ammonia to concomitantly cleave both the bNA from the support and the N-acyl and 2-cyanoethyl phosphate-protecting groups. A subsequent deprotection step with triethylammonium trihydrofluoride (TREAT-HF) cleaves the 2′-O-tert-butyldimethylsilyl (TBDMS) protecting groups from branched oligoribonucleotides (Gasparutto et al., 1992). The desilylated material is then precipitated directly using 1-butanol (Sproat et al., 1995). A procedure for the quantitation of oligonucleotides is also described. Materials Branched oligonucleotide attached to CPG (bNA-CPG; see Basic Protocols 2 and 3) 29% ammonium hydroxide, 4°C (store up to 1 month at 4°C) 70% and 100% (v/v) ethanol, former at 4°C DEPC-treated water (optional; APPENDIX 2A) Autoclaved water Triethylammonium trihydrofluoride (TREAT-HF; 98%; Aldrich) 3 M sodium acetate, pH 5.5 (APPENDIX 2A) 1-Butanol, analytical grade, 4°C 1.5-mL screw-cap microcentrifuge tubes with O-ring seals (preferred) Wrist-action shaker Speedvac evaporator (Savant) Double-beam UV spectrophotometer, calibrated Cleave and deprotect oligonucleotide 1. Transfer bNA-CPG to a 1.5-mL screw-cap microcentrifuge tube, preferably with an O-ring seal. 2. Add 750 µL cold 29% ammonium hydroxide and 250 µL of 100% ethanol, screw the cap on tightly, and incubate 24 to 48 hr at room temperature on a wrist-action shaker. If the branched oligonucleotide sequence contains isobutyryl-protected guanosine nucleotides, then deprotection must proceed for ≥48 hr, room temperature. The ammonium hydroxide should be relatively fresh (<1 month old). Seal the cap on the ammonium hydroxide solution tightly and store at 4°C.
3. Microcentrifuge 1 min at maximum speed, room temperature, and cool 30 min on dry ice or 1 to 2 hr at −20°C. The contents must be cooled before the screw cap is released to prevent volatile ammonium hydroxide from boiling over, which could result in loss of product.
4. Remove supernatant and transfer to a fresh 1.5-mL microcentrifuge tube. 5. Wash CPG pellet with 500 µL of 100% ethanol, microcentrifuge to settle the CPG, and transfer the supernatant wash to a second 1.5-ml tube. Repeat two more times (total four tubes). 6. Cool all four tubes for 1 hr on dry ice, then dry in a Speedvac evaporator. Introducing the vacuum too quickly will lead to bumping of the ammonia solution and sample loss.
Synthesis of Modified Oligonucleotides and Conjugates
4.14.19 Current Protocols in Nucleic Acid Chemistry
Supplement 9
7. Pool in a total of 1 mL water. For branched RNAs, use DEPC-treated water that has been autoclaved to remove residual DEPC. The product is a crude deprotected branched DNA or partially deprotected branched RNA. For RNA, DEPC-treated water should be used in all subsequent steps.
Quantitate oligonucleotide 8. Dilute crude bNA 10 or 100 fold with autoclaved water and measure the absorbance at 260 nm (A260) on a calibrated, double-beam, UV spectrophotometer using autoclaved water as a reference. If using a single-beam spectrophotometer, a baseline should be run with a sample containing autoclaved water (blank).
9. Determine the concentration of the stock solution using the dilution factor and Beer’s Law (A260 = εbc), where ε is the molar extinction coefficient, b is the UV cell pathlength (typically 1 cm), and c is the concentration of oligonucleotide present. The molar extinction coefficients (liter/mol cm) and molecular weights of the oligonucleotides can be obtained from http://paris.chem.yale.edu/extinct.html and http://medstat.med.utah.edu/masspec/oligoii.htm.
Cleave 2′-O-TBDMS group 10. Evaporate bRNA samples (step 7) using a Speedvac evaporator and resuspend in 5 µL TREAT-HF per A260 unit (step 8). 11. Cover the microcentrifuge tubes with aluminum foil and incubate 24 to 48 hr at room temperature on a wrist-action shaker. Alternatively, the 2′-O-TBDMS group may be removed using a mixture of TREAT-HF and N-methylpyrrolidinone according to the method of Wincott et al. (1995).
For large bRNAs (≥10-mers): 12a. Precipitate the oligonucleotides directly from the desilylation reaction by adding 25 µL of 3 M sodium acetate, pH 5.5, followed by 1 mL cold analytical-grade 1-butanol. Vortex 1 min and cool 3 to 6 hr at −20°C. A white precipitate should be clearly visible after addition of 1-butanol.
13a. Microcentrifuge 10 min at maximum speed, 4°C, carefully remove the supernatant, and wash the white pellet twice with 500 µL cold 70% ethanol each. Disruption of the pellet during washing steps could result in loss of sample.
14a. Dry the pellet in a Speedvac evaporator, resuspend in 1 ml autoclaved water, and requantitate the amount of crude oligonucleotide (steps 8 and 9). Once the 2′-O-TBDMS group has been removed, the fully deprotected RNA is sensitive to nucleases and base hydrolysis, which will cause strand cleavage. In order to prevent this, special considerations for working with RNA (APPENDIX 2A) must be observed. Water used for RNA dissolution and buffer preparation should be of the highest quality available (Milli-Q) and should be treated with DEPC.
For small bNAs (<10-mers): 12b. Quench the desilylation reaction with an equal volume of autoclaved water and evaporate in a Speedvac evaporator. Resuspend in 1 mL autoclaved water and requantitate the amount of crude oligonculeotide (steps 8 and 9). Solid-Phase Synthesis of Branched Oligonucleotides
Shorter sequences (i.e., trimers and tetramers) do not precipitate efficiently.
4.14.20 Supplement 9
Current Protocols in Nucleic Acid Chemistry
ANALYSIS AND PURIFICATION OF BRANCHED OLIGONUCLEOTIDES USING ANION-EXCHANGE HPLC
SUPPORT PROTOCOL 3
Branched oligonucleotides may be easily and efficiently analyzed and purified from the crude mixture by anion-exchange HPLC as described below (Fig. 4.14.6). bNAs of high purity are attainable (>95%; Fig. 4.14.10). The bNA of interest can be readily isolated from the reaction mixture failure sequences. The resultant product is precipitated directly by the addition of 1-propanol (Sproat et al., 1995). This direct precipitation method works very well for the direct isolation of large bNAs (>10 nt). Smaller bNAs do not precipitate out efficiently and must be further purified by size-exclusion chromatography (or reversed-phase Sep-Pak cartridges) subsequent to HPLC separation. As an alternative to HPLC purification, the bNAs may be purified by denaturing PAGE (see Support Protocol 4). Characterization of the bNAs is conveniently done via MALDI-TOF-MS as described in UNIT 10.1. The matrix and co-matrix typically used are 6-aza-2-thiothymine (ATT) and dibasic ammonium citrate, respectively (Lecchi et al., 1995). The branched nature of the molecules may also be confirmed via the yeast debranching enzyme (yDBR), a phosphodiesterase specific to hydrolysis of the 2′,5′-phosphodiester bond of oligonucleotides that contain vicinal 2′,5′- and 3′,5′-phosphodiester linkages (Nam et al., 1994; Ooi et al., 2001). Nucleoside composition analysis of bNA is carried out using snake venom phosphodiesterase (SVPD) according to the method of Eadie et al. (1987; UNIT 10.6). This enzyme cleaves bDNA or bRNA from the 3′ termini yielding 5′-monophosphates, which can then be converted to their constituent nucleosides by in situ treatment with alkaline phosphatase (AP). The resulting nucleoside mixture is analyzed by reversed-phase HPLC as described in UNIT 10.5. Alternatively, bNA can be digested with nuclease P1 from Penicillium citrinum, an endonuclease that cleaves bNA to produce the constituent nucleoside 5′-monophosphates and its branch core trinucleoside diphosphate—i.e., A(2′p5′N)3′p5′N (Damha et al., 1992). The released branched trinucleoside diphosphate structure can be readily synthesized (see Basic Protocol 2) and used as a standard during HPLC analysis of the enzyme digest (UNIT 10.6). NOTE: For branced RNAs, use DEPC-treated water throughout (APPENDIX 2A).
UACUAA
GUAUGU GUAUGU
95% purity AU
0.00
10.00
20.00
30.00
40.00 Time (min)
50.00
60.00
70.00
80.00
Figure 4.14.10 Analysis of the purity of a bNA synthesized via the convergent strategy. Purification was conducted using anion-exchange HPLC (see Support Protocol 3) with linear gradient 2 (Table 4.14.4). The chromatogram was obtained using the same conditions.
Synthesis of Modified Oligonucleotides and Conjugates
4.14.21 Current Protocols in Nucleic Acid Chemistry
Supplement 9
Table 4.14.4
Conditions for Separation of bNAs by Anion-Exchange HPLCa
Length of bNA (nt) <5 6-15 >15
Gradient
% Buffer A (H2O)
% Buffer B (1 M LiClO4)
Run time (min)
1
100-90
0-10
60
2 3
100-80 90-80
0-20 10-20
60 60
aPerformed on a Waters 7.5 × 75–mm Protein Pak DEAE-5PW column.
Materials Deprotected branched oligonucleotide (see Support Protocol 2) Autoclaved water 1 M LiClO4 (see recipe) Reagent-grade 1-propanol, 4°C (>5-mers; Fisher) Sephadex G-25 columns (Amersham Pharmacia Biotech) or Sep-Pak cartridges (Waters Chromatography) for <5-mers Nuclease P1 buffer (see recipe) 0.3 U/µL Penicillium citrinum nuclease P1 (NP1) 9 U/µL alkaline phosphatase (AP) 0.1 M triethylammonium acetate (TEAA), pH 7.0 Acetonitrile, HPLC grade 50°C water bath or heating block High-performance liquid chromatograph (HPLC) with: Anion-exchange column (7.5 × 75–mm Waters Protein-Pak DEAE-5PW) UV detector with adjustable range or dual-wavelength detection Sample loop Column heater Reversed-phase C18 column (e.g., Whatman Partisil ODS-2, 10-ìm, 4.6 × 250–mm; Chromatographic Specialties) Syringe Speedvac evaporator (Savant) Additional reagents and equipment for reversed-phase chromatography (UNIT 10.1 & 10.6) and quantitation of bNAs by UV spectrophotometry (see Support Protocol 2) Analyze bNAs by anion-exchange HPLC 1. Aliquot 0.3 to 0.6 A260 units of deprotected branched oligonucleotide (25 to 100 µL volume) into a sterile 1.5-mL microcentrifuge tube. 2. Heat the sample 1 min in a 50°C water bath or heating block. Heating the sample disrupts any intramolecular secondary structures.
3. To settle any particulates, microcentrifuge 2 min at maximum speed, room temperature. It is important to avoid loading any small particulates into the injector of the HPLC as they may clog the injection loop.
4. Preequilibrate HPLC anion-exchange column with initial buffer conditions (Table 4.14.4) and set the UV detector wavelength to 260 nm. Solid-Phase Synthesis of Branched Oligonucleotides
4.14.22 Supplement 9
Current Protocols in Nucleic Acid Chemistry
5. Load the sample into the sample loop using an appropriate syringe and inject. Elute bNA at 50°C with a flow rate of 1 mL/min and the gradient and run time specified in Table 4.14.4. Record the chromatogram. The branched DNA or RNA product should be very well resolved from the extended linear failure sequences and other failure sequences present in the crude mixture. Full-length bNAs elute last (i.e., highest retention time). Typical chromatograms for a 31-mer bDNA and 25-mer bRNA are demonstrated in Figure 4.14.6A and C. Note the excellent separation between the bNA of interest and the failure sequences.
Purify bNAs by anion-exchange HPLC 6. Dissolve 40 to 60 A260 units crude bNA mixture in 1 mL autoclaved water. Heat and microcentrifuge as in steps 2 to 3. Loading >60 A260 units may overload the column and compromise the separation of the bNA from the linear failure sequences.
7. Run the sample as described (steps 4 and 5), but set the detector to 290 nm and collect 1-ml fractions from the peaks of interest in sterile 1.5-mL microcentrifuge tubes. The detector wavelength is set to 290 nm in order to avoid saturation of the detector signal. If the HPLC is equipped with a detector capable of monitoring dual wavelengths, monitor both the 260- and 290-nm profiles. The anticipated retention time should be very similar to that obtained during routine HPLC analysis.
8. Pool peak fractions and dry them in a Speedvac evaporator. Add 250 µL autoclaved water. For large bRNAs (≥5-mers): 9a. Precipitate from perchlorate salts (in sample) by adding 4 vol (1 mL) reagent-grade cold 1-propanol and cooling 4 to 6 hr at −20°C. Lithium perchlorate (LiClO4) is much more soluble in organic solvents than other perchlorate salts, making precipitation easy and efficient, and thus preventing a final desalting step. The DNA or RNA isolated is in its lithium salt form.
10a. Microcentrifuge 10 min at maximum speed, room temperature, carefully remove the supernatant, and wash the white pellet twice with 500 µL cold 1-propanol. Disrupting the pellet during washing steps can result in loss of sample.
11a. Dry in a Speedvac evaporator, resuspend in 1 mL autoclaved water, and proceed to step 12. For small bNAs (<5-mers): 9b. Desalt by size-exclusion chromatography on Sephadex G-25 columns according to manufacturer’s instructions or by reversed-phase chromatography on Sep-Pak cartridges (UNIT 10.1). Proceed to step 12. Small bNAs do not precipitate out of solution efficiently.
Characterize bNAs 12. Quantitate the bNA sample by UV spectrophotometry (see Support Protocol 2, steps 8 and 9). 13. Dissolve 0.5 A260 units bNA in 20 mL of nuclease P1 buffer. 14. Add 3 µL (0.9 U) NP1 and 1 µL (9 U) AP. Mix well and incubate 24 hr at 37°C. The alkaline phosphatase may be contaminated with adenosine deaminase, which converts adenosine into inosine. The retention time of an appropriate inosine nucleoside control should be obtained prior to HPLC analysis of the digestion mixture (UNIT 10.6).
Synthesis of Modified Oligonucleotides and Conjugates
4.14.23 Current Protocols in Nucleic Acid Chemistry
Supplement 9
15. Dry the sample in a Speedvac evaporator and dissolve residue in 15 µL autoclaved water. 16. Analyze the mixture by reversed-phase HPLC on a C18 column using the mobile phases 0.1 M TEAA, pH 7.0, and acetonitrile with the gradient described in UNIT 10.6. 17. Calculate the relative ratios of nucleoside to branched trinucleotide diphosphate by dividing the area of each peak by the extinction coefficients specified in UNIT 10.6. The extinction coefficient for the branched trinucleotide diphosphate may be calculated using the oligonucleotide extinction coefficient calculator at http://paris.chem.yale.edu/ extinct.html. The extinction coefficients for bDNA and bRNA are assumed to be the same as their linear counterparts. SUPPORT PROTOCOL 4
ANALYSIS AND PURIFICATION OF BRANCHED OLIGONUCLEOTIDES BY DENATURING PAGE A method for the analysis and purification of bNAs by denaturing polyacrylamide gel electrophoresis (PAGE) is described (also see UNIT 10.4 and APPENDIX 3B). PAGE is a very convenient way to assess efficiency of bNA synthesis since the molecular weight of oligonucleotides bound on the solid support more than doubles after a convergent branching reaction—e.g., reaction of neighboring decathymidylic acid chains with bisphosphoramidite synthon S.3 to give a 21-unit-long bNA molecule (Fig. 4.14.4 and product ii in Fig. 4.14.6B). This generates a gap between the desired bNA product and its precursor molecules, greatly facilitating the separation process. Any type of standard laboratory electrophoresis equipment may be utilized. Most bNAs of >10 nucleotides in length are very well resolved on a 20% denaturing polyacrylamide gel. If shorter sequences must be purified, better resolution is achieved with a 24% denaturing polyacrylamide gel. Setup and polymerization of the gel along with electrophoretic separation conditions are described. The resultant bands may be visualized by UV shadowing and photographed. A technique for the rapid extraction of oligonucleotides from the gel matrix is also described (Chen and Ruffner, 1996). Materials 20% (w/v) denaturing acrylamide gel solution (see recipe) Deprotected branched oligonucleotide sample, dry (see Support Protocol 2) Formamide loading buffer (see recipe) Gel extraction buffer (see recipe) Running dye (see recipe)
Solid-Phase Synthesis of Branched Oligonucleotides
Gel electrophoresis equipment (APPENDIX 3B) with: 16 × 18–cm glass plates Spacers: 0.75 mm (analysis) or 1.5 mm (purification) Gel combs: 0.75 mm thick with 12 to 20 wells (analysis) or 1.5 mm thick with one to three large wells (purification) Sonicator or ∼50°C water bath (optional) 20 × 20–cm silica-coated thin-layer chromatography (TLC) plate with fluorescent indicator (e.g., Kieselgel 60 F254 aluminum sheets) Handheld UV lamp (254 nm) Camera equipped with UV filter (optional) 90°C water bath or heating block (optional) UV shadow box Wrist-action shaker (optional) Speedvac evaporator (Savant) Sephadex G-25 (Amersham Pharmacia Biotech) or reversed-phase cartridges (e.g., Sep-Pak cartridges; Waters Chromatography)
4.14.24 Supplement 9
Current Protocols in Nucleic Acid Chemistry
Additional reagents and equipment for denaturing PAGE (UNIT 10.4 and APPENDIX 3B), reversed-phase chromatography using Sep-Pak cartridges (UNIT 10.1), UV spectrophotometry (see Support Protocol 2), MALDI-TOF-MS (UNIT 10.1), and enzymatic digestion (see Support Protocol 3) CAUTION: Acrylamide and N,N′-methylenebisacrylamide are neurotoxins. Prepare all solutions containing these two reagents in a fume hood. Minimize exposure and contact to both crystalline forms and solutions by conducting all handling (including weighing) in a well-ventilated area and wearing disposable gloves at all times. Analyze bNAs by denaturing PAGE 1. Assemble a gel sandwich using 16 × 18–cm glass plates separated by 0.75-mm spacers. See APPENDIX 3B and UNIT 10.4 for a thorough description of denaturing PAGE.
2. Transfer 30 mL of 20% denaturing acrylamide gel solution to an Erlenmeyer flask and add 200 µL fresh 10% (w/v) APS immediately followed by 20 µL TEMED. Swirl and degas the solution by attaching the Erlenmeyer flask to a house vacuum line. Maintain rapid stirring to avoid bumping. The gel solution may also be degassed prior to APS and TEMED addition by placing the 20% acrylamide gel solution on a sonicator for 5 to 10 min. If using larger glass plates, adjust the volumes of acrylamide, APS, and TEMED accordingly.
3. Pour the solution between the plates, insert a 0.75-mm-thick comb, and allow gel to polymerize (30 to 45 min). 4. Place gel in electrophoresis apparatus, removing the comb and bottom spacer, rinse the wells, and prerun the gel 30 min at 500 V, room temperature. 5. Dissolve 0.6 A260 units deprotected bNA sample in 10 µL formamide loading buffer. If the dissolution process is not immediate, place the sample in a sonicator bath 1 to 2 min or heat the samples briefly at ∼50°C. 6. Load the samples into the wells. Load an equal amount of running dye in the first and last well as an external reference marker. Run the gel at 500 V until the bromphenol blue dye is 3⁄4 of the way down the gel. 7. Disassemble the glass plates and wrap the gel in plastic wrap. Place the wrapped gel over a 20 × 20–cm silica-coated TLC plate with fluorescent indicator and visualize the bands by shining a handheld UV lamp over the gel. Take a picture of the gel using a camera equipped with a UV filter. CAUTION: Wear safety glasses to avoid eye burn. A typical crude bNA reaction mixture will consist of at least three bands as shown in Figures 4.14.6 and 4.14.7. The fastest-migrating band is the linear precursor sequence (S.7; Fig. 4.14.4), followed by the extended isomeric failure sequences (S.9a-b for the synthesis of V-shaped bNAs and S.11a-b for the synthesis of Y-shaped bNAs), and finally the products (S.8 and S.10). If the coupling efficiencies between successive nucleotides is less than optimal, a ladder of failure sequences will be evident below the extended branch failure and linear sequences. Note that the extended isomeric failure sequences are a mixture of regioisomers (S.9a-b and S.11a-b) that are sometimes resolved into two close-moving bands (this is also evident by HPLC analyses). The slowest of the predominant bands is the bNA of interest. If linear markers are run alongside the purified bNA, one observes that bNA has retarded mobility relative to a linear oligonucleotide of identical composition (length and sequence composition). This is due to the increased frictional effects of the bNA relative to the linear sequences as they move through the highly cross-linked gel environment.
Synthesis of Modified Oligonucleotides and Conjugates
4.14.25 Current Protocols in Nucleic Acid Chemistry
Supplement 9
Purify bNAs by denaturing PAGE 8. Assemble and run a preparative gel as for the analytical gel (steps 1 to 6) with the following modifications: a. Increase gel thickness (spacers and comb) to 1.5 cm and scale up volume of gel to 50 mL gel solution, 350 µL APS, and 35 µL TEMED. b. Use up to 100 A260 units crude bNA dissolved in 100 µL formamide loading buffer. c. Use a comb with one large well to purify 60 to 100 A260 units, one well of a two-well comb for 30 to 60 units, and one well of a three-well comb for <30 units. 9. Disassemble the glass plates, remove the gel, and wrap it in plastic wrap. Place the wrapped gel over a silica-coated TLC plate and visualize the bands by shining UV light over the gel. If desired, photograph the gel using a camera equipped with a UV filter. CAUTION: Wear safety glasses to avoid eye burn.
10. Excise the slowest moving band and place the gel piece into a sterile 15-mL tube. Crush the gel piece using a sterile spatula and soak in 3 mL gel extraction buffer. 11. Heat 5 min in a 90°C water bath or heating block and rapidly freeze 5 min in dry ice. Thaw contents rapidly at 90°C and centrifuge 10 min at maximum speed × g in a tabletop centrifuge to settle the crushed gel pieces. Alternatively, after extracting in 3 mL gel extraction buffer (step 10) or water, shake the slurry 12 to 16 hr at room temperature on a wrist-action shaker. The rapid “crush and soak” method described has been outlined in a paper by Chen and Ruffner (1996).
12. Extract the supernatant and dry in a Speedvac evaporator. Desalt on a Sephadex G-25 column according to manufacturer’s instructions, or via reversed-phase chromatography using Sep-Pak cartridges according to UNIT 10.1. 13. Quantitate the amount of bNA recovered via UV spectrophotometry (see Support Protocol 2, steps 8 and 9). 14. Characterize bNAs by MALDI-TOF-MS (UNIT 10.1) and/or enzymatic digestion of the constituent nucleotides with SVPD/AP and NP1/AP (see Support Protocol 3). REAGENTS AND SOLUTIONS Use deionized, double-distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Acetonitrile, anhydrous Predry by refluxing over reagent-grade phosphorus pentoxide (Fisher) followed by refluxing and distillation over calcium hydride (Aldrich) under inert atmosphere. Prepare fresh before each use. Alternatively, low-water acetonitrile suitable for use on a DNA synthesizer can be purchased (VWR Canlabs or BDH) and used as such, or refluxed and distilled from calcium hydride under inert atmosphere.
Cap A capping reagent Prepare anhydrous 2,4,6-collidine (Aldrich) by refluxing and distillation over calcium hydride. Store up to 6 months at room temperature under inert atmosphere over activated 4A molecular sieves. Before use mix 1 part dry 2,4,6-collidine with 1 part acetic anhydride and 8 parts anhydrous THF (see recipe). Solid-Phase Synthesis of Branched Oligonucleotides
4.14.26 Supplement 9
Current Protocols in Nucleic Acid Chemistry
Cap B capping reagent Prepare anhydrous N-methylimidazole (Aldrich) by stirring over calcium hydride for 24 hr, followed by vacuum distillation. Dilute to 16% (v/v) in anhydrous THF (see recipe). Store up to 6 months at room temperature under inert atmosphere over activated 4A molecular sieves. Denaturing acrylamide gel solution, 20% (w/v) 20 g acrylamide 1 g N,N′-methylenebisacrylamide 21.02 g electrophoresis-grade urea (final 7 M) 5 mL 10× TBE electrophoresis buffer (APPENDIX 2A) H2O to 50 mL Store up to 1 to 2 months at 4°C CAUTION: Acrylamide and N,N′-methylenebisacrylamide are neurotoxins. Prepare all solutions in a well-ventilated fume hood, and take precautions to minimize exposure. Wear gloves at all times. To aid in dissolution, the acrylamide solution can be heated in a warm (<50°C) water bath with constant stirring. Do not overheat as this will cause the acrylamide to polymerize.
Detritylation solution 3% (w/v) trichloroacetic acid (TCA, 99%, Aldrich) 1,2-Dichloroethane (analytical grade, Fisher) Store up to 6 months at room temperature Diisopropylethylamine (DIPEA), anhydrous Dry by mild heating (50° to 60°C) and stirring 16 hr over calcium hydride followed by distillation under vacuum. Store up to 2 to 4 months at 4°C over 4A activated molecular sieves in septum-sealed bottles. Alternatively, 99.5% redistilled DIPEA can be purchased (Aldrich) and kept anhydrous by storage over activated 4A molecular sieves up to 1 year at 4°C.
Formamide loading buffer Deionize 10 mL formamide by adding 1 g mixed bed resin (Bio-Rad) and stirring 30 min. Filter through Whatman filter paper. Mix 4 vol deionized formamide with 1 vol of 10× TBE electrophoresis buffer (APPENDIX 2A). Store up to 1 year at −20°C. Gel extraction buffer 363 mg Tris base (final 30 mM) 1.75 g NaCl (final 300 mM) 112 mg disodium EDTA (final 3 mM) H2O to 100 mL Store up to 6 months at 4°C pH to 7.5 Lithium perchlorate (LiClO4), 1 M Dissolve 106.4 g LiClO4 (99%, Aldrich) in 1 liter water. Store up to 1 month at room temperature. Filter through a 0.45-µm filter before use. Nuclease P1 buffer 1.21 g Tris base (final 0.1 M Tris⋅Cl) 13.6 mg ZnCl2 (final 1 mM) H2O to 100 mL Adjust pH to 7.2 with HCl Store up to 6 months at −20°C
Synthesis of Modified Oligonucleotides and Conjugates
4.14.27 Current Protocols in Nucleic Acid Chemistry
Supplement 9
Oxidant solution 1.23 g iodine crystals (0.1 M) 25:20:2 (v/v/v) tetrahydrofuran/pyridine/water Store up to 6 months at room temperature Running dye 9.8 mL deionized formamide 0.2 mL 10× TBE electrophoresis buffer (APPENDIX 2A) 10 mg xylene cyanol (final 0.1%) 10 mg bromphenol blue (final 0.1%) Store up to 1 year at −20°C Tetrahydrofuran (THF), anhydrous Dry by continuous reflux and distillation over sodium metal and benzophenone under an inert atmosphere until a purple color persists. Prepare fresh before each use. Triethylamine/acetonitrile, 4:6 (v/v) Dry triethylamine by refluxing and distillation over calcium hydride. Store up to 1 year at 4°C over activated 4A molecular sieves. Mix 8 mL anhydrous triethylamine and 12 mL anhydrous acetonitrile (see recipe) in a septum bottle and seal. Prepare fresh. To use, withdraw via syringe through the septum. COMMENTARY Background Information
Solid-Phase Synthesis of Branched Oligonucleotides
Discovery and applications of bNAs The body of work devoted to branched nucleic acids (bNAs) indicates that they are of current interest in chemistry and biochemistry. Branched ribonucleic acids (bRNAs) were first detected in nuclear RNA in 1983 (Wallace and Edmonds, 1983). It was later discovered that an RNA “lariat” is the first biochemical intermediate in the splicing of precursor messenger RNA (Ruskin et al., 1984). Several other bRNA structures such as Y-shaped trans-splicing intermediates and multicopy single-stranded DNAs (msDNA) were subsequently discovered in eukaryotes and prokaryotes, respectively (Yee et al., 1984; Inouye et al. 1987). These branched molecules all contain a common structural feature, namely vicinal 2′,5′and 3′,5′-phosphodiester bonds at a branch point nucleotide. A novel polypeptide termed the RNA lariat debranching enzyme selectively hydrolyzes the 2′,5′-phosphodiester bond at the branch point of excised intron lariats, thus converting them into linear molecules (Ruskin and Green, 1985; Chapman and Boeke, 1991; Nam et al., 1994). The novelty of bRNAs has raised interest as to their possible role in regulating RNA processing. Recently, there has been increasing interest in synthetic bDNA and bRNA for use in
diagnostic applications (Urdea et al., 1991) and biosensor development (Uddin et al., 1997), as tools for studying mRNA splicing (Carriero et al., 2001) and debranching (Nam et al., 1994; Ooi et al., 2001), and as “molecular anchors” for inducing the formation of novel triplex (e.g., Hudson et al., 1995) and tetraplex structures (Robidoux et al., 1997). Chemical synthesis of bRNA The stepwise assembly of the vicinal 2′,5′and 3′,5′-internucleotide linkages present in bRNA via traditional phosphotriester methods can be difficult, as cyclic phosphate may be formed (see Damha et al., 1992, and references therein). This problem was circumvented by using phosphodiester intermediates, which are more stable to nucleophilic attack by vicinal 2′-OH groups relative to phosphotriesters. Short bRNA molecules were first prepared by solution-phase methods. Ogilvie and coworkers originally prepared branched tri- and tetranucleotides having identical nucleotides at the branch point 2′ and 3′ positions (symmetric bRNA; Damha et al., 1985; Damha and Ogilvie, 1988). Their method was also adapted to the synthesis of bRNA isomers having different nucleotide units at the 2′ and 3′ positions (Damha and Ogilvie, 1988). Regiospecific synthesis of a tetranucleotide of natural branch point sequence was performed by Kierzek et al.
4.14.28 Supplement 9
Current Protocols in Nucleic Acid Chemistry
(1986) by solution-phase phosphoramidite chemistry. Chattopadhyaya and co-workers have focused on several strategies for the synthesis of small bRNA and RNA lariats with self-cleavage properties (Rousse et al., 1994). The authors’ group has been describing in detail a methodology for the solid-phase synthesis of Y-shaped RNAs and DNAs, in which the branch point adenosine is linked to identical oligonucleotide chains via vicinal 2′,5′- and 3′,5′-phosphodiester linkages. Hyperbranched or “dendritic” structures have also been synthesized from this laboratory (Hudson and Damha, 1993; Hudson et al., 1998). The synthetic convergent strategy is based on the discovery that nucleoside 2′,3′-O-bisphosphoramidite synthons react with adjacent solid-support-bound chains yielding symmetric V-like molecules. Synthesis is then continued in the 3′-to-5′ direction from the apex of the V to yield Y-shaped structures. This method was adapted to the synthesis of bRNAs with 2′ and 3′ chains of different base composition (Ganeshan et al., 1995). All other synthetic strategies reported so far for the regiospecific assembly of branched oligonucleotides mimicking the natural lariat structures are based upon solution-phase phosphotriester methods, except for the recent work by Sproat et al. (1994), who use a divergent solid-phase phosphoramidite strategy. This strategy has permitted the synthesis of mediumsized branched oligoribonucleotides; however, it requires the use of nonstandard monomers and branch-point synthons. Given this limitation, and those of the authors’ current methods, alternative strategies for the regiospecific synthesis of branched oligonucleotides were sought. This led ultimately to the synthesis of multi-copy single-stranded DNA, a peculiar nucleic acid that is produced in E. coli and M. xantus (Damha and Braich, 1998). In this unit, general procedures for both convergent and divergent solid-phase synthesis of branched oligonucleotides are presented. The conditions of the branching reactions are crucial to the ultimate success of the overall procedure, and the protocols described in this unit should be followed carefully. In spite of these areas of caution, bNA sequences can now be prepared routinely using, for the most part, commercially available reagents and standard laboratory equipment. The novice should have no hesitation in setting forth!
Compound Characterization Analysis of crude and purified bNAs is conveniently carried out via anion-exchange
HPLC (see Support Protocol 3). The buffer concentration required for the elution of bNA is dependent upon the molecular weight and charge of the molecule being purified (Table 4.14.4). Separation of bNA from failure sequences is greatly facilitated by the relatively large molecular weight of the bNA species. Gel electrophoresis is another convenient way to isolate/purify bNA fragments (see Support Protocol 4). In this case, the bNA of interest exhibits significant retarded mobility relative to the failure sequences as a result of frictional effects as the bNA molecules migrate through the cross-linked gel environment. Further characterization is conducted by MALDI-TOF-MS (UNIT 10.1) using 6-aza-2-thiothymine (ATT) and dibasic ammonium citrate as matrices (Lecchi et al., 1995). Nucleoside composition analysis is conducted via enzymatic hydrolysis with the exonuclease snake venom phosphodiesterase (Eadie et al., 1987; UNIT 10.6) and the endonuclease nuclease P1 (see Support Protocol 3). The yeast debranching enzyme (yDBR), a phosphodiesterase specific to the 2′,5′-phosphodiester bond of oligonucleotides containing vicinal 2′,5′- and 3′,5′-phosphodiester linkages, may also be used to confirm the branched nature of the molecules according to the method of Ooi et al. (2001).
Critical Parameters and Troubleshooting Basic Protocol 1 The synthesis of the branch synthon (S.3) from 5′-O-DMTr-N6-benzoyl-riboadenosine is extremely moisture sensitive. Thus, it is imperative that all solvents, reagents, and apparatuses (e.g., syringes, needles, reaction vessel) be anhydrous. The phosphitylating reagent (stored at −20°C) should be warmed to room temperature in a desiccator prior to use. If the isolated yield of S.3 is significantly lower than expected, verify that the phosphitylating chlorophosphoramidite is a clear viscous liquid, and that no crystalline material is present (this residue is indicative of hydrolysis). Basic Protocol 2 There are two important considerations when synthesizing bNA by the convergent approach. Firstly, the yield of bNA is dependent upon the molar concentration of the branching bisphosphoramidite synthon S.3. Dilute solutions (0.03 M) of S.3 must be employed to maximize coupling with adjacent CPG-bound oligonucleotide chains (branching). If higher
Synthesis of Modified Oligonucleotides and Conjugates
4.14.29 Current Protocols in Nucleic Acid Chemistry
Supplement 9
concentrations are used, yields of branched products are reduced, and mainly extended isomeric side products are formed. The efficiency of the branching reaction can be assessed during synthesis by quantitation of the trityl cations released immediately before and after the branching reaction. Theoretically, 100% branch formation should give an apparent coupling yield of 50% since the trityl absorption following branching should be half of the previous absorption (during branching two nucleotide chains become joined to a single bisphosphoramidite synthon). Thus, trityl yields significantly greater or less than 50% indicate little branch formation (e.g., 80% apparent trityl yield indicates the formation of mainly the extended isomeric compounds). It is important to prepare the bisphosphoramidite stock solution (0.03 M) using at least 100 mg S.3. This ensures that (unavoidable) traces of moisture will not use up significant amounts of bisphosphoramidite during the branching step and reduce the overall yield of synthesis. The purity of the bisphosphoramidite can be assessed prior to use via TLC analysis or 31PNMR. If partial decomposition has occurred, or if the branching reactions during synthesis are poor, the compound should be rechromatographed as described (see Basic Protocol 1). Secondly, solid supports having a high degree of derivatization (>50 µmol/g) provide the best results for the synthesis of short bNA fragments (<7 nt). This is because highly substituted supports ensure the appropriate distance between the reactive 5′-OH end groups of the immobilized oligonucleotide chains. Supports with a nucleoside loading of 30 to 50 µmol/g give very good results for the synthesis of medium-size branched oligonucleotides.
Solid-Phase Synthesis of Branched Oligonucleotides
Basic Protocol 3 The divergent approach requires synthesis of a linear oligonucleotide chain followed by backward synthesis from the 2′-hydroxyl of an internal ribonucleotide residue. This is carried out with commercially available inverted nucleoside 5′-phosphoramidites. Key to the success of this synthesis is the ability to cleave the 2′-O-silyl protecting group of the internal ribonucleotide residue and the use of an excess of the first inverted 5′-phosphoramidite reagent to force the branching reaction to a maximal extent. This is in sharp contrast to the convergent strategy, where branching requires a delicate control of reaction conditions. Incomplete removal of the 2′-O-TBDMS group from the RNA branch point (Fig. 4.14.8)
results in the accumulation of the linear DNARNA-DNA precursor (S.12), which is easily detected by HPLC and PAGE. To ensure complete 2′-O-desilylation of the CPG-bound oligonucleotide, it is essential to use fresh TBAF reagent and to introduce the TBAF solution slowly to the synthesis column (via syringe), pushing and pulling the piston slightly to displace the CPG beads stuck at the base of the column. This allows all of the CPG-bound oligonucleotide to come in contact with the TBAF reagent. It is important not to expose the CPG-bound bNA to the TBAF reagent for >10 min, as prolonged treatment results in significant cleavage of the oligonucleotide from the solid support. After washing steps, the first inverted phosphoramidite is introduced as a 0.3 M acetonitrile solution (as opposed to 0.1 M for all other DNA 3′- and 5′-phosphoramidite couplings) and allowed to react with the CPGbound oligomer for 30 min (as opposed to 90 and 120 sec for all other DNA phosphoramidites).
Anticipated Results The anticipated results of a convergent bNA synthesis are provided in Figures 4.14.6 and 4.14.7. Syntheses carried out on a 1-µmol scale will characteristically yield 50 to 80 A260 units crude material, while the isolated yields (bNA) generally fall in the range of 5 to 20 A260 units. bNAs that have been purified by anion-exchange HPLC are of high purity, usually >95% (Fig. 4.14.10). In the case of divergent bNA synthesis, typical crude yields are in the range of 50 to 100 A260 units. A standard gel analysis of bNA prepared by the divergent method is shown in Fig. 4.14.9. After HPLC or gel purification, 5 to 20 A260 units of bNA are typically recovered from divergent syntheses (slightly higher yields are obtained with HPLC). As for convergent synthesis, purity is >95%.
Time Considerations Provided that all reagents and materials required for each step are available, most of the procedures are simple and rapid. The synthesis of S.3 from 5′-DMTr-N6-benzoyl-riboadenosine requires 2 to 4 hr to complete, including the workup. The reaction should not be allowed to proceed overnight, as decomposition may occur. Column chromatography requires ∼1 to 2 hr including setup. Ideally, column purification should be conducted immediately following the phosphitylation reaction. When the branching synthon S.3 and all the other phosphoramidite derivatives are ready to
4.14.30 Supplement 9
Current Protocols in Nucleic Acid Chemistry
use, the time required to prepare, purify, and isolate a Y-shaped RNA or DNA via the convergent approach is 3 days and 4 to 6 days, respectively. The preparation of bNA via the divergent approach requires 3 days or more.
Literature Cited Braich, R.S. and Damha, M.J. 1997. Regiospecific solid-phase synthesis of branched oligonucleotides. Effect of vicinal 2′,5′- (or 2′,3′-) and 3′,5′-phosphosdiester linkages on the formation of hairpin DNA. Bioconjugate Chem. 8:370377. Carriero, S., Braich, R.S., Hudson, R.H.E., Anglin, D., Friesen, J.D., and Damha, M.J. 2001. Inhibition of in vitro pre-mRNA splicing in S. cerevisiae by branched oligonucleotides. Nucleosides, Nucleotides, and Nucl. Acids. 20:873-877. Chapman, K.B. and Boeke, J.D. 1991 Isolation and characterization of the gene encoding yeast debranching enzyme. Cell 65:483-492. Chen, Z. and Ruffner, D.E. 1996. Modified crushand-soak method for recovering oligodeoxynucleotides from polyacrylamide gel. BioTechniques 21:820-822. Damha, M.J., and Braich, R.S. 1998. Synthesis of branched DNA/RNA chimera similar to the msDNA molecule of Myxoccus xanthus. Tetrahedron lett. 39:3907-3910. Damha, M.J. and Ogilvie, K.K. 1988. Synthesis and spectroscopic analysis of branched RNA fragments: Messenger RNA splicing intermediates. J. Org. Chem. 53:3710-3722. Damha, M.J. and Zabarylo, S.V. 1989. Automated solid-phase synthesis of branched oligonucleotides. Tetrahedron Lett. 30:6295-6298. Damha, M.J., Pon, R.T., and Ogilvie, K.K. 1985. Chemical synthesis of branched RNA: Novel trinucleoside diphosphates containing vicinal 2′5′ and 3′-5′ phosphodiester linkages. Tetrahedron Lett. 26:4839-4842. Damha, M.J., Giannaris, P.A., and Zabarylo, S.V. 1990. An improved procedure for derivatization of controlled-pore glass beads for solid-phase oligonucleotide synthesis. Nucl. Acids Res. 18:3813-3821. Damha, M.J., Ganeshan, K., Hudson, R.H.E., and Zabarylo, S.V. 1992. Solid-phase synthesis of branched oligoribonucleotides related to messenger RNA splicing intermediates. Nucl. Acids Res. 20:6565-6573. Eadie, J.S., McBride, L.J., Efcavitch, J.W., Hoff, L.B., and Cathcart, R. 1987. High-performance liquid chromatographic analysis of oligodeoxyribonucleotide base composition. Anal. Biochem. 165:442-447. Ganeshan, K., Tadey, T., Nam, K., Braich, R., Purdy, W.C., Boeke, J.D., and Damha, M.J. 1995. Novel approaches to the synthesis and analysis of branched RNA. Nucleosides & Nucleotides 14:1009-1013.
Gasparutto, D., Livache, T., Bazin, H., Duplaa, A.M., Guy, A., Khorlin, A., Molko, D., Roget, A., and Teoule, R. 1992. Chemical synthesis of a biologically active natural tRNA with its minor bases. Nucl. Acids Res. 20:5159-5166. Hakimelahi, G.H., Proba, Z.A., and Ogilvie, K.K. 1982. New catalysts and procedures for the dimethoxytritylation and selective silylation of ribonucleosides. Can. J. Chem. 60:1106-1113. Hudson, R.H.E. and Damha, M.J. 1993. Nucleic acid dendrimers: Novel biopolymer structures. J. Am. Chem. Soc. 115:2119-2124. Hudson, R.H.E., Uddin, A.H., and Damha, M.J. 1995. Association of branched nucleic acids: Structural and physicochemical analysis of antiparallel TAT triple-helical DNA. J. Am. Chem. Soc. 117:12470-12477. Hudson, R.H.E., Robidoux, S., and Damha, M.J. 1998. Divergent synthesis of nucleic acid dendrimers. Tetrahedron Lett. 32:1299-1302. Inouye, S., Furuichi, T., Dhundle, A., and Inouye, M. 1987. Molecular Biology of RNA: New Perspectives (M. Inouye and B. S. Dudock, eds.) pp. 271. Academic Press, San Diego. Kierzek, R., Kopp, D.W., Edmonds, M., and Caruthers, M.H. 1986. Chemical synthesis of branched RNA. Nucl. Acids Res. 14:4751-4764. Lecchi, P., Le, H.M.T., and Pannell, L.K. 1995. 6-Aza-2-thiothymine: A matrix for MALDI spectra of oligonucleotides. Nucl. Acids Res. 23:1276-1277. Lyttle, M.H., Adams, H., Hudson, D., and Cook, R.M. 1997. Versatile linker chemistry for synthesis of 3′-modified DNA. Bioconjugate Chem. 8:193-198. Nam, K., Hudson, R.H.E., Chapman, K.B., Ganeshan, K., Damha, M.J., and Boeke, J.D. 1994. Yeast lariat debranching enzyme: Substrate and sequence specificity. J. Biol. Chem. 269:20613-20621. Ooi, S.L., Dann, C. III, Nam, K., Leahy, D., Damha, M.J., and Boeke, J.D. 2001. Ribonucleases part A: Functional roles and mechanisms. Methods Enzymol. 342:233-250. Pon, R.T., Yu, S., and Sanghvi, Y.S. 1999. Rapid esterification of nucleosides to solid-phase supports for oligonucleotide synthesis using uronium and phosphonium coupling reagents. Bioconjugate Chem. 10:1051-1057. Robidoux, S., Klinck, R., Gehring, K., and Damha, M.J. 1997. Association of branched oligonucleotides into the i-motif. J. Biomol. Struct. Dyn. 15:517-527. Rousse, B., Puri, N., Viswanadham, G., Agback, P., Glemarec, C., Sandstroem, A., Sund, C., and Chattopadhyaya, J. 1994. Solution conformation of hexameric and heptameric lariat-RNAs and their self-cleavage reactions which give products mimicking those from some catalytic RNAs (ribozymes). Tetrahedron 50:1777-1810. Ruskin, B. and Green, M. 1985. An RNA processing activity that debranches RNA lariats. Science 229:135-140.
Synthesis of Modified Oligonucleotides and Conjugates
4.14.31 Current Protocols in Nucleic Acid Chemistry
Supplement 9
Ruskin, B., Krainer, A.R., Maniatis, T., and Green, M.R. 1984. Excision of an intact intron as a novel lariat structure during pre-mRNA spicing in vitro. Cell 38:317-331. Sproat, B.S., Beijer, B., Grotli, M., Ryder, U., Morand, K.L., and Lamond, A.I. 1994. Novel solidphase synthesis of branched oligoribonucleotides including a substrate for the RNA debranching enzyme. J. Am. Chem. Soc. Perkin. Trans. 1:419-431. Sproat, B., Colonna, F., Mullah, B., Tsou, D., Andrus, A., Hampel, A., and Vinayak, R. 1995. An efficient method for the isolation and purification of oligoribonucleotides. Nucleosides & Nucleotides 14:255-273. Still, W.C., Kahn, M., and Mitra, A. 1978. Rapid chromatographic technique for preparative separations with moderate resolution. J. Org. Chem. 43:2923-2925. Ti, G.S., Gaffney, B.L., and Jones, R.A. 1982. Transient protection: Efficient one-flask syntheses of protected deoxynucleosides. J. Am. Chem. Soc. 104:1316-1319. Uddin, A.H., Piunno, P.A.E., Hudson, R.H.E., Damha, M.J., and Krull, U.J. 1997. A fiber optic biosensor for fluorimetric detection of triplehelical DNA. Nucl. Acids Res. 25:4139-4146. Urdea, M.S., Horn, T., Fultz, T.J., Anderson, M., Running, J.A., Hamren, S., Ahle, D., and Chang, C.A. 1991. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucl. Acids Symp. Series. 24:197-200. Wallace, J.C. and Edmonds, M. 1983. Polyadenylated nuclear RNA contains branches. Proc. Natl. Acad. Sci. U.S.A. 80:950-954. Wincott, F., Di Renzo, A., Shaffer, C., Grimm, S., Tracz, D., Workman, C., Sweedler, D., Gonzalez, C., Scaringe, S., and Usman, N. 1995. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucl. Acids. Res. 23:2677-2684. Wu, T., Ogilvie, K.K., and Pon, R.T. 1989. Prevention of chain cleavage in the chemical synthesis of 2′-silylated oligoribonucleotides. Nucl. Acids Res. 17:3501-3517. Yee, T., Furuichi, T., Inouye, S., and Inouye, M. 1984. Multicopy single-stranded DNA isolated from a Gram-negative bacterium, Myxococcus xanthus. Cell 38:203-209.
Key References Damha and Zabarylo, 1989. See above.
Reports on the first general procedure for the convergent solid-phase synthesis of branched oligonucleotides via an adenosine bisphosphoramidite. Damha et al., 1992. See above. Reports on the convergent synthesis of branched RNA oligonucleotides using the standard silyl-phosphoramidite RNA synthesis methodology. The bNAs synthesized are related to the splicing intermediates derived from S. cerevisiae. Nam et al., 1994. See above. Reports on the substrate and sequence specificity of the yeast lariat debranching enzyme (yDBR), a unique 2′,5′-phosphodiesterase. The enzyme accepts a variety of substrates including group II intron lariats, msDNA, and synthetic bNAs. Padgett, R.A., Konarska, M.M., Grabowski, P.J., Hardy, S.F., and Sharp, P.A. 1984. Lariat RNA’s as intermediates and products in the splicing of messenger precursors. Science 225:898-903. This report provides evidence that the branched lariat structure is an intermediate of splicing of an adenovirus ML2 RNA transcript. Specifically demonstrated is that the excised intron contains an unusual nuclease-resistant core consisting of a branched trinucleotide structure with vicinal 2′,5′and 3′,5′-phosphodiester linkages. Sharp, P.A. 1994. Split genes and RNA splicing. Cell 77:805-815. A Nobel lecture. A paramount review describing the splicing of introns from nascent RNA, the evolutionary significance of introns, and the plethora of factors involved in post-transcriptional processing. Wallace and Edmonds, 1983. See above. A first account demonstrating the occurrence of a branched nuclear polyadenylated RNA containing vicinal 2′,5′- and 3′,5′-phosphodiester bonds. Such molecules were absent from cytoplasmic polyadenylated RNA, implicating these structures as intermediates during mRNA processing.
Internet Resources http://paris.chem.yale.edu/extinct.html A useful site for the calculation of molecular weights of oligonucleotides and peptides as well as the determination of extinction coefficients (ε).
Contributed by Sandra Carriero and Masad J. Damha McGill University Montreal, Canada
Solid-Phase Synthesis of Branched Oligonucleotides
4.14.32 Supplement 9
Current Protocols in Nucleic Acid Chemistry
Solid-Phase Synthesis of 2′-Deoxy-2′-fluoroβ-D-Oligoarabinonucleotides (2′F-ANA) and Their Phosphorothioate Derivatives
UNIT 4.15
This unit describes the chemical synthesis of 2′-deoxy-2′-fluoro-β-D-oligoarabinonucleotides (2′F-ANA), both with phosphodiester and phosphorothioate linkages. The protocols described herein include araF phosphoramidite preparation (see Basic Protocol 1), assembly on DNA synthesizers (see Basic Protocol 2), and final deprotection and purification of oligonucleotides (see Basic Protocol 3). The preparation of araF phosphoramidite building blocks is carried out by introducing a 2-cyanoethyl-N,N-diisopropylaminophosphinyl group at the 3′-O-position of conveniently protected araF nucleosides. The preparation of araF-protected nucleosides is described in UNIT 1.7. Assembly of 2′F-ANA sequences can be carried out under similar conditions as for DNA sequences, but longer coupling times for ara F phosphoramidite monomers are required. For phosphorothioate analogs, longer sulfurization times are also required, as compared to S-DNA synthesis. Assembly of the oligonucleotides is carried out by the stepwise addition of phosphoramidite building blocks to nucleoside or nucleotide hydroxyl termini preimmobilized on a solid support until the desired sequence is obtained (APPENDIX 3C). Each addition of new building block requires five steps: detritylation, coupling, capping, oxidation or sulfurization, and capping. The last capping reaction also serves to dry the column prior to the next coupling cycle. Cleavage of the sequence from the solid support and the removal of the nucleobase- and phosphodiester-protecting groups is carried out using an aqueous ammonia/ethanol mixture. Crude oligonucleotides obtained in this way can be purified by ion-exchange high-performance liquid chromatography (HPLC; UNIT 10.5) or denaturing polyacrylamide gel electrophoresis (PAGE; UNIT 10.4). NOTE: All glassware should be oven dried.
MMTrO
O F OH
MMTrO
B
B
i -Pr2NP(Cl)OCH2CH2CN O
i -Pr2NEt, THF i -Pr2N
1a b c d
O F
B = N 6-benzoyladenin-9-yl B = N 2-isobutyrylguanin-9-yl B = N 4-benzoylcytosin-1-yl B = thymin-1-yl
P
2a b c d
OCH2CH2CN (75%) (70%) (80%) (95%)
Figure 4.15.1 Synthesis of the four araF-protected nucleoside phosphoramidites (S.2a-d). MMTr, 4-monomethoxytrityl; i-Pr2NEt, N-ethyl-N,N-diisopropylamine; i-Pr2-NP(Cl)OCH2CH2CN, 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite.
Synthesis of Modified Oligonucleotides and Conjugates
Contributed by Ekaterina Viazovkina, Maria M. Mangos, Mohamed I. Elzagheid, and Masad J. Damha
4.15.1
Current Protocols in Nucleic Acid Chemistry (2002) 4.15.1-4.15.22 Copyright © 2002 by John Wiley & Sons, Inc.
Supplement 10
BASIC PROTOCOL 1
PREPARATION OF araF PHOSPHORAMIDITES Conversion of protected araF nucleosides into the corresponding phosphoramidite building blocks is shown in Figure 4.15.1 (Wilds and Damha, 2000). In order to obtain phosphoramidites in sufficiently high yields, the starting materials and reaction solvents should be as dry as possible and all glassware should be oven dried. Likewise, to simplify purification, the reaction should be completed using a minimal amount of phosphitylation reagent. Materials Protected araF nucleosides (UNIT 1.7): N6-Benzoyl-9-[2-deoxy-2-fluoro-5-O-(4-methoxytrityl)-β-D-arabinofuranosyl] adenine (S.1a) N2-Isobutyryl-9-[2-deoxy-2-fluoro-5-O-(4-methoxytrityl)-β-D-arabinofuranosyl] guanine (S.1b) 4 N -Benzoyl-1-[2-deoxy-2-fluoro-5-O-(4-methoxytrityl)-β-D-arabinofuranosyl] cytosine (S.1c) 1-[2-Deoxy-2-fluoro-5-O- (4-methoxytrityl)-β-D-arabinofuranosyl]thymine (S.1d) THF, anhydrous (see recipe) N-Ethyl-N,N-diisopropylamine (DIPEA; Aldrich), double distilled 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite (Chem Genes) Dichloromethane 1:9 and 1:19 (v/v) methanol/dichloromethane Saturated sodium bicarbonate solution Magnesium sulfate, anhydrous Solvent system: 1:99 (v/v) triethylamine/chloroform (for araF-T) 1:9:10 (v/v) triethylamine/dichloromethane/hexanes (for araF-A and araF-C) 1:99 (v/v) triethylamine/dichloromethane (for araF-G) Silica gel (230 to 400 mesh) Diethyl ether 50-mL round-bottom flask equipped with stir bar and rubber septum Syringe TLC Merck silica plates (Kieselgel 60 F-254) 254-nm UV lamp 500-mL separatory funnel Vacuum evaporator (e.g., Savant Speedvac) 3-cm-diameter chromatography column Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare araF phosphoramidite monomers 1. In a 50-mL round bottom flask equipped with a stir bar and rubber septum, dissolve 1 mmol of each protected araF nucleoside (S.1a-d) in 3 to 5 mL of anhydrous THF. 2. While stirring, add 0.63 mL (3.6 mmol) double distilled N-ethyl-N,N-diisopropylamine (DIPEA) followed by the slow addition of 0.24 mL (1.1 mmol) 2-cyanoethylN,N-diisopropylchlorophosphoramidite.
Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
A white precipitate of diisopropylethylammonium hydrochloride salts forms after 10 min and is indicative of sufficiently anhydrous conditions for a successful reaction.
4.15.2 Supplement 10
Current Protocols in Nucleic Acid Chemistry
3. Stir the reaction mixture for an additional 2 hr or until complete consumption of starting material is observed. For TLC analysis (APPENDIX 3D), remove 10 to 20 µL reaction mixture by syringe and dilute with 100 µL dichloromethane in a small tube. Analyze on a TLC Merck silica plate using 1:19 (v/v) methanol/dichloromethane for araF-T, -C, and -A, and 1:9 (v/v) methanol/dichloromethane for araF-G. Co-spot the starting material for comparison. Visualize by exposure with a 254-nm UV lamp. TLC solvents in this step do not include TEA. However, TLC solvents listed under step 11, can be substituted for those listed here. The phosphoramidites migrate faster than the starting material. In this reaction, two stereoisomeric products are formed, but they are not separable in the methanol/dichloromethane system.
4. If, as demonstrated by TLC, the reaction is not complete (i.e., more than ∼5% of starting material remaining), add an additional portion (∼0.2 eq.) of 2-cyanoethylN,N-diisopropylchlorophosphoramidite, stir for 2 hr more, and repeat TLC analysis (step 3). If the reaction looks complete by TLC analysis, start workup of the phosphoramidite. It is important to minimize the amount of phosphitylating reagent used, otherwise the excess is hydrolyzed during the workup to form H-phosphonate impurities (31P NMR: singlet, ∼14 ppm), which can cause difficulties during subsequent purification of the amidites.
5. Dilute the reaction mixture with 150 mL dichloromethane, transfer it to a 500-mL separatory funnel, and wash with 150 mL saturated sodium bicarbonate solution. 6. Collect the organic layer, dry it by adding solid anhydrous magnesium sulfate until it no longer clumps, and filter and concentrate under reduced pressure to obtain a crude product. Chromatographic purification of the crude amidite is recommended, but if the reaction mixture looks pure by TLC and evaporates easily to give a stable foam, this step may be omitted. In case of a second day purification, it is strongly recommended to evaporate the crude compound to a foam, dry it under high vacuum, and keep the product in a vacuum desiccator. If the product persists as an oil after these steps are taken, co-evaporate it with diethyl ether. A foam can usually be obtained after co-evaporation.
Purify phosphoramidite monomers by flash column chromatography 7. Redissolve the crude material in a minimal amount of one of the following solvent systems: 1:99 (v/v) triethylamine/chloroform for araF-T 1:9:10 (v/v) triethylamine/dichloromethane/hexanes for araF-A and araF-C 1:99 (v/v) triethylamine/dichloromethane for araF-G. 8. Apply sample to a 3-cm-diameter chromatography column containing 50 g 230- to 400-mesh silica gel, preconditioned with the appropriate chromatography solvent (step 7). Column chromatography is performed according to the method of Still et al. (1978) using a small amount of air pressure at a rate of ∼1 inch of solvent per minute (also see APPENDIX 3E).
Synthesis of Modified Oligonucleotides and Conjugates
4.15.3 Current Protocols in Nucleic Acid Chemistry
Supplement 10
9. Apply the sample to the column and begin eluting with the preconditioning solvent. a. For araF-C and araF-A: Elute in 1:9:10 (v/v) triethylamine/dichloromethane/hexanes. b. For araF-T: Follow a stepwise gradient of triethylamine/chloroform until a 1:31 ratio is reached. For 1 mmol crude sample, collect 100 mL eluate at 1% TEA, 100 mL at 2% TEA, and so on. c. For araF-G: Follow a step gradient of methanol/triethylamine/dichloromethane from 0:1:99 to 5:1:94 (v/v). For 1 mmol crude sample, collect 100 mL at 0% methanol, 100 mL at 1% methanol, and so on. Always add at least 0.5% of triethylamine to the chromatographic solvent mixtures used for elution and preconditioning of the column in order to avoid hydrolysis of the amidites to the H-phosphonates during purification. Step gradients indicated are only intended as guidelines and should be adjusted according to various factors including amount of crude product applied and flow rate of mobile phase.
10. Monitor fractions by TLC (APPENDIX phosphoramidite.
3D;
step 3) and pool those containing pure
11. Evaporate the phosphoramidite on a vacuum evaporator and dry under high vacuum to obtain a stable foam. If a foam does not form, try co-evaporation of the pure product with diethyl ether. Typically, a colorless or pale yellow foamy product forms easily. This can be stored in a vacuum desiccator over phosphorus pentoxide or at −20°C in a freezer for several months without decomposition. For araF-A (S.1a), the typical yield after chromatographic purification is ∼70% to 75%. TLC using 5:45:50 (v/v/v) triethylamine/hexanes/dichloromethane results in two spots corresponding to two isomers at Rf 0.22 and 0.33. 31P NMR (202.3 MHz, acetone-d6): 150.9 and 151.1, 19F NMR (470.27 MHz, acetone-d6, without external reference): yields −197.3 and –197.7 (ddd, J1′-F = 19 Hz, J′2′-F = 52 Hz, J3′-F = 19 Hz), and FAB-MS using an NBA matrix yields 846.34 [M+]. For araF-G (S.1b), the typical yield after chromatographic purification is ∼70% to 75%. TLC using 20:1 (v/v) chloroform/methanol yields a spot of Rf 0.54; 31P NMR (200.06 MHz, acetone-d6, 85% ortho-phosphoric acid as external reference): 151.8 and 151.0; 19F-NMR (282.32 MHz, acetone-d6, 99% trifluoroacetic acid as external reference): −119.7 and –119.4; and FAB-MS using an NBA matrix yields 822 [M+]. For araF-C (S.1c), the typical yield after chromatographic purification is ∼80% to 85%. TLC using 5:45:50 (v/v/v) triethylamine/hexanes/dichloromethane yields two spots, corresponding to two isomers, at Rf 0.26 and 0.34; 31P NMR (500 MHz, acetone-d6): 151.3 and 150.8; 19F NMR (470.27 MHz, acetone-d6, without external reference): −199.0 and –199.2 (ddd, J1′-F = 18 Hz, J′2′-F = 52 Hz, J3′-F = 18 Hz); and FAB-MS using an NBA matrix yields 828 [M+]. For araF-T (S.1d), typical yield after chromatographic purification is ∼90% to 95%. TLC using 10:9:1 (v/v/v) chloroform/ethyl acetate/ethanol yields two spots, corresponding to two isomers, at Rf 0.76 and 0.83; 31P NMR (500 MHz, acetone-d6): 151.3 and 150.8; 19F NMR (470.27 MHz, acetone-d6, without external reference): −199.0, –199.2 (ddd, J1′-F = 18 Hz, J′2′-F = 52 Hz, J3′-F = 18 Hz); and FAB-MS using an NBA matrix yields 822 [M+].
Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
4.15.4 Supplement 10
Current Protocols in Nucleic Acid Chemistry
SOLID-PHASE ASSEMBLY OF PROTECTED araF PHOSPHORAMIDITES This protocol describes the setup and step-by-step synthesis of araF oligonucleotides. The methodology has been optimized for use with the Expedite 8909 DNA synthesizer equipped with a workstation (PerSeptive Biosystems), but can easily be adapted to other automated DNA synthesizers. All syntheses have been performed on 1-µmol scales, both for phosphodiester- and phosphorothioate-containing araF oligonucleotides. The coupling time for araF nucleosides requires a 15-min “wait” step, as compared to 1.5 min for deoxynucleosides on the Expedite instrument. Likewise, the detritylation time has been extended to 150 sec to allow for effective removal of the monomethoxytrityl (MMTr) protection as opposed to the more labile dimethoxytrityl (DMTr) groups that are commonly used with standard DNA monomers. For thio-araF-oligonucleotide synthesis, the overall success of oligomer synthesis was evaluated with different sulfur-transfer reagents, including 3H-1,2-benzodithiol-3-one-1,1-dioxide (Beaucage reagent; Iyer et al., 1990), 3-ethoxy-1,2,4-dithiazoline-5-one (EDITH; Xu et al., 1996), and 3-amino-1,2,4dithiazoline-5-thione (ADTT; Tang et al., 2000). In all cases, the concentration of sulfurization reagent was increased ∼5 fold as compared to customized S-DNA synthesis, and the time required for the oxidation was prolonged to 10 min as opposed to 1 to 2 min for S-DNA synthesis. Current procedures can easily be adapted to the synthesis of molecules with mixed nucleotide composition (e.g., DNA/araF chimeras of variable gap sequences).
BASIC PROTOCOL 2
Materials AraF phosphoramidites (see Basic Protocol 1) Argon gas Acetonitrile, anhydrous (see recipe) Liquid Reagent kit for the Expedite 8909 instrument (PerSeptive Biosystems): Acetonitrile wash and amidite diluent: anhydrous acetonitrile Activator solution: dissolve 1.8 g sublimed tetrazole (0.5 M) in 50 mL acetonitrile; store up to 2 wks at room temperature. Cap A (see recipe) Cap B (see recipe) Oxidizer solution (see recipe) Deblock solution: 15 g trichloroacetic acid in 500 mL dichloromethane; store up to 1 yr at room temperature Sulfurization reagent (see recipe) Amidite column (see recipe) Synthesizer vials with caps Vacuum desiccator containing phosphorus pentoxide Syringe Automated DNA synthesizer (e.g., Expedite 8909, Perseptive Biosystems) with trityl monitor Additional reagents and equipment for oligonucleotide synthesis (APPENDIX 3C) Synthesize phosphodiester and phosphorothioate araF oligonucleotides 1. Calculate the amount of araF phosphoramidites required for the synthesis of a desired sequence. The typical concentration of amidites used with the Expedite synthesizer corresponds to 50 mg/mL. Note that the volume of amidite solution delivered to the column during each coupling step is ∼240 ìL. However, an excess of 50 mg amidite (i.e., 1 mL solution) should be included when preparing each amidite solution in order to purge the lines of the synthesizer.
Synthesis of Modified Oligonucleotides and Conjugates
4.15.5 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Table 4.15.1 Automated 1 µmol Synthesis Cycle for the Synthesis of Phosphodiester araF Oligonucleotides on the Expedite 8909 Instrumenta
Functionb Amountc Time (sec) Description Detritylation of the support bound nucleoside: Trityl monitor on/off
—
1
Deblock
10
0
Deblock
70
150
Diverted wash A
40
0
Trityl mon. on/off Diverted wash A
— 40
1 0
Coupling of phosphoramidite: Wash 5 Activator 5
0 0
A + activator
6
0
A + activator
9
500
Wash
8
400
Wash
7
0
Wash A
20
0
Cap A and B
7
0
Cap A and B
6
15
Wash A
6
15
Wash A
14
0
Trityl analysis monitor is turned on for data collection Detritylation solution is rapidly delivered to column Slow, prolonged delivery of detritylation solution to column Lines are flushed with anhydrous acetonitrile (wash A) Trityl quantitation is stopped Lines are flushed with anhydrous acetonitrile Lines are flushed with acetonitrile Lines are flushed with tetrazole solution Rapid addition of the phosphoramidite (A) and tetrazole solutions to the column Coupling of the free activated phosphoramidite to the support-bound terminal nucleoside Slow delivery of acetonitrile to the column to purge remaining phosphoramidite solution Lines and column are washed with acetonitrile
Capping of the column: System is flushed with anhydrous acetonitrile Equal volumes of cap A and cap B solutions are rapidly delivered to column Slower delivery of cap A and cap B to column (to maximize capping efficiency) Slow delivery of acetonitrile to column to purge remaining cap A and B solutions Lines and column are flushed with anhydrous acetonitrile
Oxidation of phosphoramidite: Oxidizer
20
0
Wash A
15
0
Cap A and B
7
0
Wash A
30
0
Oxidant is delivered to the column to oxidize the newly formed phosphite triester linkages Lines and column are flushed with anhydrous acetonitrile
Capping of the column:
Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
Equal volumes of cap A and B solutions are rapidly delivered to column Lines and column are flushed with anhydrous acetonitrile
aStandard DNA coupling cycles supplied by the manufacturer have been optimized for 2′-araF oligonucleotide assembly. bAll entries are as described in a typical cycle sequence for the Expedite instrument; see manufacturer’s directions for
further information.
cRepresents the number of pulses required for the corresponding step; each pulse has approximately 16 µL volume.
4.15.6 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Table 4.15.2 Automated 1-µmol Synthesis Cycle for the Synthesis of Phosphorothioate araF Oligonucleotides on Expedite 8909 Instrumenta
Function
Amountb
Time (sec)
Description
Detritylation of the support-bound nucleoside: Trityl monitor on/off Deblock
1 10
1 0
Trityl analysis monitor is turned on for data collection Detritylation solution is rapidly delivered to column
Deblock
70
150
Slow, prolonged delivery of detritylation solution to column
Diverted wash A
40
0
Lines are flushed with anhydrous acetonitrile (wash A)
Trityl monitor on/off
0
1
Trityl quantitation is stopped
Diverted wash A
40
0
Lines are flushed with anhydrous acetonitrile
Coupling of phosphoramidite: Wash
5
0
Lines are flushed with acetonitrile
Activator
5
0
Lines are flushed with tetrazole solution
A + activator
6
0
Rapid addition of the phosphoramidite (A) and tetrazole solutions to the column
A + activator
9
500
Coupling of the free activated phosphoramidite to the support-bound terminal nucleoside
Wash
8
400
Slow delivery of acetonitrile to the line to purge remaining phosphoramidite solution
Wash
7
0
Lines and column are rapidly washed with acetonitrile
Wash A
20
0
System is flushed with anhydrous acetonitrile
Cap A and B
7
0
Equal volumes of cap A and cap B solutions are rapidly delivered to column
Cap A and B
6
15
Slower delivery of cap A and cap B to column (to maximize capping efficiency)
Wash A
6
15
Slow delivery of acetonitrile to column to purge remaining cap A and B solutions
Wash A
14
0
Lines and column are rapidly flushed with anhydrous acetonitrile
Capping of the column:
Sulfurization of phosphoramidite: Sox
15
0
Sulfurizing reagent is rapidly pulsed through column to sulfurize the newly formed phosphite triester linkages
Sox
25
400
Slower delivery of sulfurizing reagent through column (to maximize sulfur transfer efficiency)
Wash A
15
200
Slow delivery of acetonitrile to column to purge remaining sulfurizing solution from system
Wash A
15
0
System is rapidly flushed with acetonitrile
Cap A and B
7
0
Equal volumes of cap A and B solutions are rapidly delivered to column
Wash A
30
0
Lines and column are flushed with anhydrous acetonitrile
Capping of the column:
aStandard DNA coupling cycles supplied by the manufacturer have been optimized for 2′-araF oligonucleotide assembly. bRepresents the number of pulses required for the corresponding step; each pulse has approximately 16 µL volume.
4.15.7 Current Protocols in Nucleic Acid Chemistry
Supplement 10
2. Weigh out the calculated amounts of phosphoramidites into the appropriate synthesizer vials and leave these to dry in a vacuum desiccator over phosphorus pentoxide overnight. 3. Flush the desiccator with argon gas before opening, and carefully remove the preweighed amidites. 4. Dissolve the phosphoramidites in anhydrous acetonitrile to a final concentration of 50 mg/mL. Use of syringe to transfer the acetonitrile through the rubber septum of each capped synthesizer vial to ensure the reagents are protected from humidity. Do not open the phosphoramidite vials until they are ready to be placed directly on the synthesizer.
5. Connect the solutions from the Liquid Reagents kit for the Expedite 8909 instrument, the phosphoramidite solutions, and the sulfurization reagent to the automated DNA synthesizer according to the manufacturer’s directions. The Expedite 8909 synthesizer is equipped with an extra position for the sulfur transfer reagent. If a synthesizer without this option is to be used, the sulfurization reagent may be placed at the position of the oxidizer, provided that the line has previously been washed with acetonitrile to avoid cross-contamination of the reagents.
6. Purge the lines of the synthesizer with all the solutions and solvents. 7. Install the appropriate amidite column. 8. Modify the synthetic cycles for araF phosphoramidites. Examples of synthesis cycles for phosphodiester and phosphorothioate araF oligonucleotides are given in Table 4.15.1 and Table 4.15.2. 9. Enter the sequence to be synthesized. 10. Carry out the assembly on the instrument according to the manufacturer’s instructions, choosing the “DMTr-off” (trityl-off) option. 11. Check the coupling efficiency periodically using the trityl monitor equipped with the instrument (also see APPENDIX 3C). 12. When the synthesis is complete, remove the column from the synthesizer and dry it under vacuum. 13. Deprotect and purify to obtain the desired oligonucleotide (see Basic Protocol 3). BASIC PROTOCOL 3
Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
DEPROTECTION AND PURIFICATION OF araF OLIGONUCLEOTIDES This protocol describes the steps necessary for cleavage of araF sequences, assembled as described above (see Basic Protocol 2), from the solid support and removal of the protecting groups from the heterocyclic bases and phosphates. The procedure for the quantitation of isolated oligonucleotides is also described. AraF oligonucleotides can be successfully analyzed and purified by anion-exchange HPLC or denaturing gel electrophoresis (PAGE; UNIT 10.4 and APPENDIX 3B), as described below. Analytical amounts of material can easily be isolated by gel electrophoresis, while large amounts require HPLC purification. Desalting of the oligomers after gel or chromatographic isolation completes the purification procedure. There are two different methods that may be employed to accomplish this, either size-exclusion chromatography or reversed-phase SepPak C18 cartridge purification.
4.15.8 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Materials Fully protected oligonucleotides, attached to the solid support of a synthesis column (see Basic Protocol 2) Ethanol, anhydrous 29% ammonium hydroxide Denaturing acrylamide gel stock solution (see recipe) Loading buffer (e.g., formamide/dye mix, UNIT 10.4) Sephadex G-25 column (Amersham Pharmacia Biotech) 1 M NaClO4 Anhydrous and 25% or 50% (v/v) acetonitrile 1.5 mL microcentrifuge tubes or screw-cap microcentrifuge tubes with O-ring seal Platform shaker 55°C heating block or water bath (optional) Vacuum evaporator (e.g., Savant Speedvac) with low and high vacuum sources UV spectrophotometer and cuvette 0.75- and 1.5-mm-thick gel plates TLC Merck silica plate (Kieselgel 60 F-254) Hand-held 254-nm UV lamp Camera with UV filter (optional) 0.45 µm hydrophilic fluid filter (Creative Medical) 0.22 µm membrane filter (Millipore; optional) Anion-exchange high-performance liquid chromatograph (HPLC) with: Gradient maker 0.5 mm × 7.5 cm Protein Pak DEAE 5PW column (Waters) Column heater Sep-Pak C18 cartridges (Waters Chromatography) 10 mL syringe Additional reagents and equipment for denaturing polyacrylamide gel electrophoresis (APPENDIX 3B and UNIT 10.4) Deprotect oligonucleotides 1. Remove the fully protected oligonucleotides attached to the solid support of the synthesis column, and place in a 1.5 mL microcentrifuge tube or a screw-cap microcentrifuge tube with O-ring seal (seal tightly) if deprotecting at increased speed and temperature (step 3). 2. Add 0.25 mL anhydrous ethanol and 0.75 mL of 29% ammonium hydroxide. 3. Place the tube on a platform shaker for 48 hr at room temperature. Alternatively, deprotect by incubating in a 55°C heating block or waterbath for 15 hr. 4. Once the deprotection is complete, cool the microcentrifuge tube ∼1 hr in the freezer (i.e., −20°C) before opening. 5. Microcentrifuge the samples briefly so that the CPG beads are allowed to settle, then transfer the supernatant to another microcentrifuge tube. Wash the CPG with ethanol twice and place the supernatant from each wash in additional microcentrifuge tubes. 6. Dry the samples in a vacuum evaporator, applying low vacuum first to remove all traces of ammonia. Introducing high vacuum to the ammonia/ethanol solution may cause bumping of the liquid and loss of the sample. Synthesis of Modified Oligonucleotides and Conjugates
4.15.9 Current Protocols in Nucleic Acid Chemistry
Supplement 10
7. When the ammonia has been evaporated and sample volumes are decreased enough, combine the supernatants from each microcentrifuge tube. Evaporate the final sample to dryness under high vacuum. Quantitate oligonucleotide 8. Dissolve the oligonucleotide from the previous step in 1 mL deionized water. Remove a 10-µL aliquot and dilute this to 1 mL with deionized water in a UV cuvette. 9. Measure the absorption of the sample at 260 nm. Calculate the amount of crude oligonucleotide obtained in A260 units. Typically, a 1-ìmol synthesis may give yields of 100 to 180 A260 units of crude material, depending on the sequence length and composition.
Analyze crude oligonucleotide by denaturing PAGE 10. Prepare a 24% denaturing polyacrylamide gel on a 0.75-mm-thick analytical gel plate for gel electrophoresis (APPENDIX 3B and UNIT 10.4). 11. Prepare samples of oligonucleotides to be analyzed (e.g., 0.5 to 1 A260 units per analysis). Dissolve each of these in 10 µL loading buffer. 12. Load the samples into wells and run these alongside loading buffer alone, which is placed in the first and last lanes of the gel. Connect the gel to the power supply and start running at 200 V until the dye has fully diffused into the gel. Increase the voltage to 500 V and maintain at this setting until the faster running dye marker has traveled 3⁄ down the length of the gel. 4 13. Turn off the current and dismantle the gel apparatus. Put the gel in plastic wrap. Place a fluorescing TLC Merck silica plate under the gel and examine by illumination with a hand-held 254-nm UV lamp. If necessary, photograph the gel using a camera with a UV filter. Oligonucleotides absorb UV light and appear as dark bands in the gel against a fluorescent background. Typically, crude FANA oligonucleotides, both diester and thio, consist of one intense band. The presence of multiple bands below the desired product usually indicates poor coupling efficiency.
Purify oligonucleotides by denaturing PAGE and desalt using Sephadex G-25 14. Prepare a 24% to 16% denaturing polyacrylamide gel on a 1.5-mm-thick gel plate for preparative analysis (APPENDIX 3B and UNIT 10.4). Compared to analytical separations, a lower percentage of acrylamide may be used in preparative analyses (from 16% to 24%), depending on the quality of the synthesis. For example, a crude oligonucleotide which migrates as one main band in analytical compositions can be sufficiently purified using 16% acrylamide in the preparative run. When multiple bands corresponding to failed sequences are present in the gel, a higher percentage of acrylamide solution should be used.
15. Prepare and dry the oligonucleotide sample to be purified (∼20 to 30 A260 units). Dissolve the sample in 100 µL loading buffer. Sample loading to the gel may vary, depending on the quality of the synthesis.
16. Load the sample on the gel and repeat steps 12 and 13 above. 17. Using a razor blade, cut out the segment of gel containing the band of interest. Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
18. Transfer the excised band to a 15-mL conical plastic tube with screw cap and crush with a spatula. Add 10 mL water and leave the tube on a platform shaker overnight to extract the oligonucleotide from the gel.
4.15.10 Supplement 10
Current Protocols in Nucleic Acid Chemistry
19. Filter the supernatant through a 0.45-µm hydrophilic fluid filter and concentrate on a vacuum evaporator. 20. Desalt the sample using a Sephadex G-25 column according to the manufacturer’s directions. 21. Quantitate the amount of oligonucleotide isolated via UV spectroscopy. 22. Lyophilize the oligonucleotide. The purified, dry oligonucleotide can be stored for long periods (e.g., >1 yr) at −20°C. If the oligonucleotide is to be used in combination with microbially sensitive materials (e.g., cell culture), filtration through a 0.22-ìm filter is recommended. Collect the filtrate in previously autoclaved tubes and lyophilize.
Analyze and purify oligonucleotide by anion-exchange HPLC and desalt on SepPak C18 cartridge 23. Prepare the anion-exchange HPLC by setting the detector wavelength to 260 nm, heating the column to 50°C, and equilibrating with buffer A (deionized water) using a flow rate of 1 mL/min or as specified by the manufacturer. See UNIT 10.5 and legends to Figures 4.15.2 to 4.15.4 for more details.
A
0.35 0.30
AU
0.25 0.20 0.15 0.10 0.05 0.00 0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
60.00
70.00
80.00
90.00
Minutes
B 0.50 0.40
AU
0.30 0.20 0.10 0.00 0.00
10.00
20.00
30.00
40.00
50.00
Minutes
Figure 4.15.2 Ion-exchange HPLC analysis of crude S-oligonucleotide ATA TCC TTg TCg TAT CCC (cap letters represent araF nucleotides, DNA residues in lowercase). (A) Sulfurization with Beaucage reagent. The small peak at ∼58 min represents S-oligonucleotides with one P-O insertion. The main peak at ∼62 min represents full S-FANA. (B) Sulfurization with ADTT. System: Waters 600E Multisolvent Delivery System with Waters 486 Tunable Absorbance detector and oven, driven by Millennium (V 3.20) software; column: Waters 0.5-mm × 7.5-cm Protein Pak DEAE 5PW, 50°C; solvent A: H2O; solvent B: 1 M NaClO4; flow rate: 1 mL/min; detection: 260 nm; gradient conditions: 0% B for 9 min, 0% to 15% B in 3 min, 15% to 50% B in 60 min, 50% to 80% B in 2 min, hold 80% B 10 min, 80% to 0% B in 2 min, hold 0% B 10 min.
Synthesis of Modified Oligonucleotides and Conjugates
4.15.11 Current Protocols in Nucleic Acid Chemistry
Supplement 10
24. Load ∼1 A260 unit crude oligonucleotide sample (steps 8 and 9) to the column. Wash 5 min with buffer A, then apply a linear gradient of 0% to 25% buffer B (1M NaClO4) in 60 min (i.e., 0.42%/min) to elute diester araF oligonucleotides, or of 0% to 50% buffer B in 60 min (i.e., 0.83%/min) for S-FANA oligonucleotides. Wash the column and re-equilibrate. The desired fraction should elute close to the end of the applied gradient.
25. Optimize the conditions for the next run. Examples of suitable chromatographic gradients that may be used are given in the legends to Figures 4.15.2 to 4.15.4. 26. Continue purification of the next portions of oligonucleotide using the previously optimized conditions. Increase the amount of oligonucleotide loaded to the column and set the detector at 280 to 290 nm depending on the amount of the sample to be loaded. Use higher wavelengths for larger samples to avoid saturating the UV detector. Sample loading to the column depends on the quality of the reaction mixture and type of oligonucleotide. Typical loading amounts for phosphodiester FANA oligonucleotides range from 10 to 30 A260 units of crude reaction mixture using the conditions described above. Loading for S-FANA oligonucleotides can be increased considerably as a result of their stronger adsorption on the ion-exchange column. The authors have been able to purify ∼100 A260 units of crude mixture in one loading.
27. Quantitate the total amount of oligonucleotide obtained.
A 0.060 0.050
AU
0.040 0.030 0.020 0.010 0.000 0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
50.00
60.00
70.00
80.00
Minutes
B 1.00
AU
0.80 0.60 0.40 0.20 0.00 0.00
10.00
20.00
30.00
40.00 Minutes
Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
Figure 4.15.3 Ion-exchange HPLC analysis of (A) crude and (B) purified S-oligonucleotide CTC TAg cgt ctT AAA (cap letters represent araF nucleotides, lowercase letters represent DNA residues). System: Waters Binary HPLC Pump with Waters 2487 Dual λ Absorbance detector, equipped with in-line degasser and oven, driven by Breeze (V 3.20) software; column: Waters 0.5-mm × 7.5-cm Protein Pak DEAE 5PW, 50°C; solvent A: H2O; solvent B: 1 M NaClO4; flow rate: 1 mL/min; detection: 260 nm; gradient conditions: 0% B for 9 min, 0% to 15% B in 3 min, 15% to 50% B in 45 min, 50% to 80% B in 2 min, hold 80% B 10 min, 80% to 0% B in 2 min, hold 0% B 10 min. Peaks at <20 min correspond to failure sequences and loss of protecting groups (e.g., benzoyl from A or C).
4.15.12 Supplement 10
Current Protocols in Nucleic Acid Chemistry
28. For the desalting step, prepare SepPak C18 cartridges first by washing them with 10 mL (each) water, then anhydrous acetonitrile, then water, using a 10-mL syringe. Make sure that the cartridges are well equilibrated with water; traces of acetonitrile will prevent adsorption of the oligonucleotide and may lead to substantial loss of material.
29. Load ∼20 to 30 A260 units of oligonucleotide per cartridge, wash the cartridge with 10 mL water, and then elute the pure desalted oligonucleotide with 5 mL of 25% or 50% acetonitrile in water for phosphodiester and phosphorothioate-oligonucleotides, respectively. Quantitate the amount of oligonucleotide obtained. Always collect water fractions from all desalting steps. If the cartridge was not equilibrated properly or was overloaded, the oligonucleotide may elute with the water fraction. If this occurs, load the water fraction with oligonucleotide to a new cartridge and repeat the desalting procedure.
30. Evaporate the oligonucleotide on a vacuum evaporator using low vacuum first to remove acetonitrile, followed by complete drying of the sample under high vacuum. 31. If necessary, filter the oligonucleotide through a 0.22 µm membrane filter (see comments in step 22). Desalting after HPLC purification can be done on Sephadex G-25 as well.
A 1.20 1.00
AU
0.80 0.60 0.40 0.20 0.00 0.00
10.00
20.00
30.00 Minutes
40.00
50.00
60.00
10.00
20.00
30.00 Minutes
40.00
50.00
60.00
B 0.70 0.60
AU
0.50 0.40 0.30 0.20 0.10 0.00 0.00
Figure 4.15.4 Ion-exchange HPLC analysis of (A) crude and (B) purified phosphodiester oligonucleotide ATg TCC TTg TCg gTg Agg TTA GG (cap letters represent araF nucleotides, lowercase for DNA residues). System: Waters Binary HPLC Pump with Waters 2487 Dual λ Absorbance detector, equipped with in-line degasser and oven, driven by Breeze (V 3.20) software; column: Waters 0.5-mm × 7.5-cm Protein Pak DEAE 5PW, 50°C; solvent A: H2O; solvent B: 1 M NaClO4; flow rate: 1 mL/min; detection: 260 nm; gradient conditions: hold 0% B 2 min, from 0% to 30% B in 40 min, from 30% to 45% B in 2 min, hold 45% B 10 min, 45% to 0% B in 2 min, hold 0% B 10 min.
Synthesis of Modified Oligonucleotides and Conjugates
4.15.13 Current Protocols in Nucleic Acid Chemistry
Supplement 10
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Acetonitrile, anhydrous Predry acetonitrile by refluxing and distilling over phosphorus pentoxide overnight. Reflux and distill over calcium hydroxide. Store sealed or on the synthesizer up to 1 month at room temperature. Amidite column Prepare a succinyl-LCAA-CPG support derivatized with 5′-(4-monomethoxytrityl) and the base-protected araF nucleoside of choice (S.1a-d; UNIT 3.2). Average nucleoside loadings are 20 to 40 µmol/g, according to trityl analysis in APPENDIX 3C. Cap A 10 mL acetic anhydride 10 mL 2,6-lutidine or 2,4,6-collidine 80 mL THF (see recipe) Store sealed or on synthesizer up to 1 month at room temperature Cap B 16 mL N-methylimidazole 84 mL THF (see recipe) Store sealed or on synthesizer up to 1 month at room temperature Denaturing acrylamide gel stock solution For 24% analytical gel: 120 g acrylamide 6 g N, N′-methylene-bisacrylamide 210 g urea 50 mL 10× TBE electrophoresis buffer (APPENDIX 2A) Water to 500 mL Store protected from light for up to 1 year at 4°C. Immediately before pouring, degas 50 mL stock solution for 10 min and add 20 µL TEMED and 200 µL freshly prepared 10% (w/v) ammonium persulfate. Allow gel to polymerize overnight at room temperature (also see APPENDIX 3B and UNIT 10.4 for pouring acrylamide gels). For 16% to 24% preparative gel: Prepare stock solution and gel as above, but use 80 g acrylaminde and 4 g N,N′-methylenebisacrylamide for 16% gel, or scale as appropriate for up to 24%. Immediately before pouring, degas 65 mL stock solution for 10 min and add 35 µL TEMED and 350 µL freshly prepared 10% (w/v) ammonium persulfate. Oxidizer solution 1.23 g iodine 25 mL THF (see recipe) 20 mL pyridine 2 mL H2O Store sealed up to 6 months at room temperature or on synthesizer up to 2 wks at room temperature. Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
4.15.14 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Sulfurization reagent Any of the reagents listed below can be used to sulfurize the phosphite triester linkage. Beaucage reagent: 2 g 3H-1,2-benzodithiol-3-one 1,1-dioxide (0.2 M) 50 mL anhydrous acetonitrile (see recipe) Store on the synthesizer up to 2 or 3 days at room temperature. Discard if precipitate is observed. EDITH reagent: 1 g 3-ethoxy-1,2,4-dithiazoline-5-one (0.125 M) 100 mL anhydrous acetonitrile (see recipe) Store up to 1 month at room temperature ADTT reagent: 1.5 g 3-amino-1,2,4-dithiazoline-5-thione (0.1 M) 50 mL anhydrous acetonitrile (see recipe) 50 mL pyridine Store up to 1 month at room temperature Tetrahydrofuran (THF), anhydrous Dry tetrahydrofuran by distillation over sodium and benzophenone. Storage of anhydrous THF is not recommended as peroxides may be formed. Always use freshly distilled. COMMENTARY Background Information Antisense oligonucleotides (AONs) represent an extensive class of biologically relevant, nonnatural polymeric nucleic acids that have potential utility as novel pharmaceuticals or in molecular diagnostics applications as probes of gene function. These analogs are specifically designed to induce selective gene interference via tight and specific associations with their intended genetic targets. For example, such a “bottleneck” approach can target the mRNA directly to inhibit the expression of a dysfunctional gene, and thereby transcend traditional approaches that control a disease phenotype by targeting the malformed protein (for review, see Myers and Dean, 2000, and references therein). Furthermore, with the complete sequence of the human genome now at hand, the future design of antisense-based therapeutics may be feasible without prior knowledge of the protein structure. Indeed, adequate optimization of the biological properties of chemically modified AONs is paramount to the success of this and related technologies. The most efficacious AON members are those that ideally possess remarkable stabilities against both general serum and cellular exo- and endonucleolytic activities, and adequate lipophilicity to ensure efficient cell permeation. They should also ex-
hibit high discrimination toward fully complementary host cell sequences and allow minimal residual expression of the target gene (see Lebedeva and Stein, 2001, and references therein). Additionally, suppression of gene activity in eukaryotic organisms may proceed catalytically with the assistance of intracellular ribonuclease H (RNase H), a ubiquitous enzyme implicated in DNA replication and repair processes (Walder and Walder, 1988; Crouch and Toulmé, 1998). In fact, the extent to which protein synthesis is inhibited via antisense action in vivo seems to correlate with the propensity of the preformed AON:RNA substrate to elicit RNase H destruction of the mRNA component. Thus, a single enzyme-active AON can be recycled by this pathway to silence multiple copies of an RNA transcript, and display superior inhibition to those that do not activate the enzyme (Uhlmann and Peyman, 1990). Importantly, these events hinge upon presentation of the correct hybrid shape by the substrate duplex to the enzyme for subsequent hydrolysis of the targeted species (Nakamura et al., 1991; Oda et al., 1993). However, most AONs lack the appropriate structural attributes for enzyme elicitation and typically display less than optimal cellular potencies (see for example, Lima and Crooke, 1997).
Synthesis of Modified Oligonucleotides and Conjugates
4.15.15 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Table 4.15.3 Thermal and Biological Properties of Oligonucleotide Analogsa
Oligonucleotide analogue
∆Tm/mod. RNase H activation (°C)
Reference
thioate-LNA LNA α-L-LNA 2′F-RNA N-methanocarba-NA MMI-2′OMe-RNA 2′-MOE-RNA 2′OMe-RNA RNA CeNA 2′F-ANA thioate-2′F-ANA DNA thioate-DNA ANA S-methanocarba-NA 2′β-Me-ANA [3.3.0]bc-ANA
+10.0 +5.6 +4.6 +3.0 +2.6 +2.0 +2.0 +1.7 +0.7 +2 +1.2 +0.5 +0.5 0 –0.5 –0.6 –2.8 –3.5c
Wengel et al., 1999 Wengel et al., 1999 Sørensen et al., 2002 Manoharan, 1999 Altmann et al., 1994a Sangvhi, 1998 Manoharan, 1999 Manoharan, 1999 Wilds and Damha, 2000 Wang et al., 2000 Wilds and Damha, 2000 Lok et al., 2002 Wilds and Damha, 2000 Wilds and Damha, 2000 Noronha et al., 2000 Altmann et al., 1994b Schmit et al., 1994 Christensen et al., 1998
No No Yes No n/ab No No No No Yes Yes Yes Yes Yes Yes n/ab No No
aAbbreviations: α-L-LNA, α-L-ribo-configured locked nucleic acid; 2′β-Me-ANA, 2′-deoxy-2′-O-
methylarabinonucleic acid; ANA, arabinonucleic acid; [3.3.0]bc-ANA, 2′,3′-[3.3.0]-bicycloarabinonucleic acid; CeNA, cyclohexene nucleic acid; 2′F-ANA, 2′-deoxy-2′fluoroarabinonucleic acid; 2′F-RNA, 2′-deoxy-2′fluororibonucleic acid; LNA, locked nucleic acid; N-methanocarba-NA, Northern-locked 4′,6′-methanocarbocyclic nucleic acid; S-methanocarba-NA, Southern-locked 1′,6′-methanocarbocyclic nucleic acid; MMI-2′OMe-RNA, methylene(methylimino)-2′-OMe-RNA; 2′-MOE-RNA, 2-O-(2-methoxyethyl) RNA; 2′OMe-RNA, 2′methoxyribonucleic acid; thioate-DNA, phosphorothioate DNA; thioate-2′F-ANA, phosphorothioate 2′-deoxy2′fluoroarabinonucleic acid; DNA, deoxyribonucleic acid; thioate-LNA, phosphorothioate locked nucleic acid. bData not available. cReported for the mixed base deoxy 9mer with 3 dispersed bc-ANA inserts; note that contiguous bc-ANA insertion enhances duplex stability up to +1.7°C / mod. relative to thioate-DNA.
Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
An important parameter that governs overall duplex geometry is the conformations adopted by the individual sugars in the AON. To this end, modifications at the 2′-position have proven most valuable as tools for influencing ring conformational equilibria. Additionally, much of the literature devoted to antisense modifications has shown that crude predictions of sugar gauche and anomeric effects can be made with some accuracy as to the effect a particular 2′-modification exerts on the pseudosugar equilibrium (e.g., Plavec et al., 1994; Thibaudeau et al., 1994; Damha et al., 1995; Thibaudeau and Chattopadhyaya, 1997; Noronha and Damha, 1998; Wilds and Damha, 1999). The authors’ evaluation of these effects indicated to them that a switch in chirality of the α-2′-OH group in ribose residues to the β-configuration in the arabinose epimers should drive
the N-to-S equilibrium to the southern hemisphere and enforce a noncanonical A:B topology in hybrids with RNA, in common with the native RNA:DNA hybrids. It is noteworthy that most 2′-modifications do not activate RNase H, as their double-stranded helices with RNA are tailored to adopt a pure A form—i.e., RNA:RNA-like (for reviews, see Manoharan, 1999, and references therein). In fact, arabinonucleic acids (ANAs) represent the first examples of sugar-modified antisense agents capable of eliciting RNase H–mediated hydrolysis of target RNA. Additionally, ANAs exhibit adequate hydrolytic stability as a result of the trans relationship of the 2′- and 3′-OH groups, which effectively retards internal nucleophilic participation of the 2′-OH group in chain isomerization and/or phosphodiester cleavage. Despite these appealing properties, oligoarabinonucleotides of
4.15.16 Supplement 10
Current Protocols in Nucleic Acid Chemistry
A MMTrO
O
B
MMTrO
O F
B
O
O O P O
O
X−
B
O P O
O F
X−
O
B
O
X = O, DNA X = S, S-DNA
X = O, 2’F-ANA X = S, S-2’F-ANA
B enzyme-active AON segment
HO O− O P O O
B O
O O P O O−
enzyme-active AON segment
3
enzyme-active AON segment
O O P O O− 4
O O P O O−
enzyme-active AON segment
Figure 4.15.5 (A) DNA and 2′F-ANA primary structures and backbone chemistries. (B) Illustration of linker-modified DNA or 2′F-ANA antisense constructs. Panel B reprinted from Mangos and Damha (2002) with permission from Bentham Science Publishers.
mixed base composition display weaker binding affinities relative to the native DNA:RNA heteroduplexes (Giannaris and Damha, 1994; Damha et al., 1998; Noronha et al., 2000). The observed thermal destabilization may arise from cis-placement of the sterically demanding β-C2′-OH group with respect to the base in the major groove of the helix, which purportedly weakens local π-stacking and/or normal Watson-Crick pairing by distorting the N-glycosyl orientation (Noronha et al., 2000). Alternatively, molecular dynamics simulations have suggested the arabinose sugars to be held in C2′-endo geometries by probable intrasugar hydrogen bonding between the 2′-α-substituent and the C5′-oxygen (Venkateswarlu and Ferguson, 1999). The strand topology is consequently forced to adopt a B-like conformation, which is disfavored for binding with RNA. This, however, contradicts recent NMR analyses (Trempe et al., 2001), which show a clear bias of the sugar conformation toward the eastern (O4′-endo) hemisphere and a lack of C2′OH/O5′ interactions in the arabinose sugars (Damha et al., 2001). Interestingly, the CD spectral profiles of DNA:RNA and ANA:RNA complexes reveal similar duplex helicities; however, the ability of the latter to direct RNase H–mediated phosphodiester hydrolysis of the target occurs with comparably lower efficiencies. This lower
processivity of the enzyme toward ANA:RNA hybrids may arise from a weaker tenacity of ANA for RNA targets and a correspondingly lower effective concentration of substrate duplex. Accordingly, the extent of cleavage increases significantly when substrate and enzyme are incubated at ambient rather than physiological temperatures (Noronha et al., 2000). Apart from conferring greater glycosyl stability towards potential depurination, a β-F atom in place of the ara-2′-OH group (i.e., 2′F-ANA) markedly increases the duplex melting temperature (Damha et al., 1998), imparting higher stability than hybrids of RNA and ANA, thioate-DNA or even DNA (Table 4.15.3). The origin of these effects likely stems from greater strand preorganization of the fluorinated strands relative to their singlestranded DNA counterparts. In fact, simple substitution with the more electronegative F atom almost exclusively forces the arabinosugar equilibrium to adopt an O4′-endo (or eastern) conformation (Berger et al., 1998; Trempe et al., 2001). Like the arabinose compounds, this predominance over a C2′-endo geometry is presumably forced to occur in order to minimize steric conflicts between the F atom and the proximal heterocycle (Berger et al., 1998). Rather, the 2′-substituent is conveniently accommodated in the major groove
Synthesis of Modified Oligonucleotides and Conjugates
4.15.17 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
by assuming a more eastern geometry, which displaces it sufficiently far from the enzyme’s locus of action while retaining other geometrical elements necessary for activity. In fact, 2′F-ANA, exhibits superior RNase H competency relative to ANA, probably by virtue of the sterically innocuous properties of fluorine and the higher thermal stability of FANA/RNA hybrids (Damha et al., 2001). Although much conformational work has been directed to the phosphodiester analogs (vide supra), many of these observations can be extended to 2′F-ANA oligomers with phosphorothioate (S) scaffolds. The dominant influence of fluorine on sugar-pucker profiles and subsequent enzyme hydrolytic susceptibility is retained in S-FANA (Lok et al., 2002), in which additional nuclease resistance is provided to the 2′-modified oligomers by the thioate backbone (reviewed by Cook, 1998). However, uniformly modified S-FANA containing hybrids are suboptimally recognized by RNase H as compared to their phosphodiester derivatives, but can greatly be improved with deoxy incorporation (Lok et al., 2002). Likewise, other oligonucleotide modifications that combine intervening enzyme-active AON segments with conformationally restricted “flanking” residues usually support cleavage of their intended targets. The peripheral segments also serve to provide added nuclease resistance to the core segment, which is usually a stretch of nuclease-labile deoxynucleotides. Although the entropic consequences imposed by the flanking segments on the antisense strand endow it with favorable duplexation properties, RNase-H-induction is invariably compromised (Shen et al., 1998). Accordingly, non-RNase H competent flanking backbone segments (e.g., 2′OMe-RNA) show strong dependencies on gap size, with a minimal requirement of six to eight contiguous deoxynucleotides within the core to elicit observable activities. These requirements are significantly relaxed for SFANA in which insertion of even a single deoxynucleotide as the “gap” restores high in vitro activities. In fact, fluoroarabino-deoxy chimeras comprising four or more neighboring deoxynucleotides exhibit remarkably greater potencies than uniform S-DNA sequences and show greater inhibition of luciferase expression in HeLa cells without affecting cell viability (Lok et al., 2002). Furthermore, cleavage occurs throughout the entire RNA chain, rather than specifically within the gap as for the methylated ribosyl congeners, which adopt a characteristic C3′-endo pucker and likely induce
local helical deformations spanning the methoxy regions of the AON:RNA chimera hybrids. These results further highlight the pivotal importance of the O4′-endo antipodal conformation as a major determinant for RNase H recognition. Consequently, the most promising antisense agents are hypothesized to be those in which the arabinose configuration at C2′ is retained (Venkateswarlu and Ferguson, 1999). However, other carbohydrate modified ANA derivatives with this same pseudosugar disposition have displayed poor RNase H–associated hydrolysis of target RNA. Significantly, various bicyclic ANAs possess an O4′-endo bias and could hypothetically induce RNase H at high concentrations, but generally show abolished activities under conditions representative of the intracellular environment (Minasov et al., 2000). Interestingly, the inherent flexibility of the sugar conformations strongly correlate with the relative processivity of the enzyme toward hybrids of ANA-derived AON and RNA according to the following: DNA (flexible) > 2′F-ANA/ANA >> bc-ANA (rigid). These trends, together with the activity enhancements observed upon introducing relatively flexible deoxy residues in the more rigid FANA strand (vide supra), prompted the authors to investigate the potential synergistic attributes of intermingling sites of flexibility within the 2′FANA polymers. Indeed, the incorporation of acyclic linkers with high degrees of flexibility in the AON strand, either a 2′,5′-linked secouridine residue S.3 or a butanediol linker S.4 (Figure 4.15.5), appear to better accommodate the stringent conformational requirements of the enzyme without disrupting other fundamental recognition elements within the enclosing AON segments (Mangos et al., unpub. observ.). Sizable increases in enzyme-mediated scission of target RNA occur upon substituting an acyclic linker in the middle of a known RNase H–competent analog (i.e., DNA or 2′F-ANA). Moreover, the susceptibility of the hybrid to RNA hydrolysis remains fully operative in other sequence contexts with up to eight-fold enhancements over strands lacking the acyclic insertion. For example, in sequences wherein the acyclic inserts are moved along the 2′F-ANA scaffold, a significant change in activity is observed that depends specifically on the insertion site. The greatest activity occurs in constructs with a centrally placed acyclic linker, although differences between 5′- versus 3′-end insertion are also observed, with a greater amount of enzyme proc-
4.15.18 Supplement 10
Current Protocols in Nucleic Acid Chemistry
essing occurring when the linker is placed near the 3′-end of the AON. The authors therefore speculate that RNase H induction can remarkably be improved by introducing subtle changes in local 2′F-ANA strand dynamics that enable better adherence and/or processing of the hybrid substrate by the enzyme. These and future studies with 2′F-ANA and their constructs should provide considerable insights as to the structural factors that comprise the “optimal” AON/RNA substrate. For these reasons, the protocols of this unit provide a method of quickly and conveniently preparing 2′-fluoroarabino oligonucleotides with any one or all of the structural modifications described herein. Although linker technologies are not discussed, these are quite simple to implement and exemplify the diversity with which the protocols can be applied to new AON designs that further exploit the interesting properties of 2′F-ANA.
Critical Parameters The synthesis of araF-phosphoramidites, as for other phosphoramidites, is very moisture and acid sensitive. Therefore, all reagents and apparatus should be anhydrous. If the product has to be isolated by flash column chromatography (APPENDIX 3E), it is absolutely necessary to include triethylamine in all solvent systems used to equilibrate the column and for subsequent sample elution. Heating the product above 40°C is not recommended during evaporation. If the phosphoramidite has been stored for a long period of time prior to oligomer synthesis, its purity should be verified by TLC (APPENDIX 3D) or 31P NMR. If necessary, the phosphoramidite can be repurified by flash chromatography. Phosphoramidite oligonucleotide chemistry is extremely water sensitive. All coupling reagents should be absolutely dry, and fresh reagents should be prepared as these are critical to the success of the synthesis. It is not recommended to keep the reagents on the synthesizer for longer than 1 week. Furthermore, the synthesizer should be in good working condition. All lines should be purged with each reagent and solvent prior to starting a synthesis and cleaned with acetonitrile afterward to prevent crystallization and blocking of the lines. If synthesis is performed on the Expedite instrument, a relatively low concentration of phosphoramidites can be used without loss of coupling efficiency. For example, commercial RNA protocols require 50 mg/mL phosphoramidite concentration, which is almost 3-
fold lower than for RNA synthesis on older instruments (e.g., 1.5 M amidite solutions are required for use with the ABI 381A DNA synthesizer). Phosphoramidite and activator solutions are continuously delivered to the column during the coupling step. Such permanent delivery is performed by slow pulses of reagents to the column, which permanently renew them and thereby increase the efficiency of the synthesis. If a synthesizer with stationary delivery of reagents is to be used, the amidite concentration should be increased to that used for RNA synthesis (or slightly lower). The authors were able to successfully synthesize diester araF oligonucleotides on the ABI 381A DNA instrument using 0.1 to 0.15 M concentrations of phosphoramidites. Many different sulfur-transfer reagents for S-DNA have been documented in the literature over the last several years. However, none of these reagents are able to give 100% P-S oxidation. As a consequence, a small percentage of phosphodiester bonds are inevitably present in S-oligonucleotides. The diester fragments are much less stable to hydrolysis, making them more susceptible to nucleolytic cleavage in cell culture, which limits certain biological applications of these antisense oligonucleotides. Fortunately, pure S-oligonucleotides can easily be analyzed and purified from P-O containing S-oligonucleotides by anion-exchange HPLC (Bergot and Egan, 1992). This method enables the isolation of S-oligonucleotides that contain even a single P-O linkage within the strand. The percentage of P-O bonds in the product is dependent on the source of sulfurizing reagent used, as different sources may lead to different percentages in the fully synthesized oligomers. Although undesired oxidation is not very problematic in S-DNA synthesis, 2′F-ANA oligonucleotides are intrinsically more difficult to sulfurize as a consequence of the electron-withdrawing effects of the fluorine substituent in the sugars. This limitation may be overcome by increasing the concentration of the sulfur-transfer reagent, accompanied by extended reaction times in order to obtain S-oligonucleotides of better quality. The authors of the current protocol applied several sulfurization reagents to S-araF synthesis, namely the Beaucage reagent, EDITH, and ADTT, and have found that the former normally gives a higher percentage of P-O bonds relative to the latter two reagents. EDITH and ADTT work very similarly and give oligomers of low P-O compositions. Figure 4.15.2 shows a chromatographic profile for a crude S-DNA/S-araF chimera synthesized
Synthesis of Modified Oligonucleotides and Conjugates
4.15.19 Current Protocols in Nucleic Acid Chemistry
Supplement 10
using either the Beaucage reagent or ADTT. As is shown, the S-FANA oligonucleotide synthesized with ADTT displays more uniform P-S incorporation (i.e., P-O insertions are minimal in this oligomer as detected by chromatography). However, EDITH and ADTT reagents are very expensive and not widely available commercially, which makes the Beaucage reagent a suitable alternative. It should also be emphasized that the limitations observed with the Beaucage reagent are reserved only for 2′FANA polymers; experimentally, sulfurization with this reagent proceeds much more efficiently with other types of modified oligonucleotides (e.g., S-DNA), thereby making it the reagent of choice for those applications. The amount of contaminating P-O linkages within S-FANA oligonucleotides does not typically exceed 1% per phosphate, even when using the Beaucage reagent, but may sometimes be significantly larger. Unfortunately, PO insertions cannot be detected by PAGE. Oligonucleotides with multiple phosphodiester bonds will migrate as a single narrow band through the gel, but present multiple peaks upon anion-exchange chromatographic analysis. Consequently, chromatographic purification of S-FANA oligonucleotides is strongly recommended. In general, both HPLC and PAGE purification can be applied to araF oligonucleotides. Sequences that consist entirely of phosphodiester backbones may be purified either by HPLC or PAGE, depending upon the scale used in the synthesis. If 1 to 20 A260 units are required, PAGE purification is sufficient; for preparative amounts ranging from 100 to 200 A260 units of purified oligomer, HPLC is recommended. For S-FANA oligonucleotides, ion-exchange purification is most convenient, regardless of the amount to be purified.
Troubleshooting
Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
Low coupling efficiency. Several conditions can cause poor monomer coupling yields. (1) The reagents and acetonitrile may contain water. This is minimized by drying the phosphoramidites and tetrazole in a vacuum desiccator over phosphorus pentoxide for one or two days prior to use. (2) Lines in the synthesizer may be partially blocked. Check delivery of each reagent to the lines by monitoring flow rates. Perform routine DNA synthesis first and monitor coupling efficiencies by trityl analysis. HPLC analysis of S-araF oligonucleotide gives multiple product peaks. This problem is usually caused by incomplete sulfurization, es-
pecially if the Beaucage reagent has been used. If so, the product may still migrate as one band under PAGE conditions. This can be circumvented by increasing the concentration of the Beaucage reagent or using another sulfurizing reagent. Beaucage reagent precipitates. The Beaucage reagent is known to be extremely sensitive to the quality of solvent and is decomposed rather easily. If this process is rapid, a switch to an acetonitrile source of better quality is recommended. Furthermore, the glass bottle for Beaucage reagent should be silanized by the investigator (APPENDIX 2A; Iyer et al., 1990) or obtained in silanized form from various commercial sources. Alternatively, acetonitrile solutions of Beaucage reagent can be placed in a 15-mL plastic conical tube, which is then deposited within an appropriate glass bottle and attached to the gene-machine to prevent direct contact of the reagent with the glass.
Anticipated Results Using araF phosphoramidites as building blocks in conjunction with the methods presented here, it should be possible to routinely obtain araF oligonucleotides with yields ranging from 120 to 180 A260 units of crude material for 1-µmol scale syntheses, and isolated yields of ∼30 to 100 A260 units. The sulfurization step with EDITH or ADTT reagents helps to minimize the extent of P-O insertions in S-oligonucleotides. These considerations, together with the optimized ion-exchange HPLC chromatographic procedures, should enable the facile isolation of araF oligonucleotides of high purity.
Time Considerations Preparation of araF phosphoramidites from the appropriately protected nucleosides usually takes ∼1 day per monomer. Depending on the type of chemistry (diester- versus thio-araF-oligonucleotides, or DNA/araF oligonucleotide chimeras), the time required for assembly of a 20-mer oligonucleotide (typical for antisense applications) on the Expedite instrument is from 6 to 12 hr. An additional 2 days are required to perform deprotection, followed by 3 to 5 days for isolation, desalting, and final analysis as described (see Basic Protocol 3), if purification is required.
4.15.20 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Literature Cited Altmann, K.-H., Kesselring, R., Francotte, E., and Rihs, G. 1994a. 4′,6′-Methano carbocyclic thymidine: A conformationally constrained building block for oligonucleotides. Tetrahedron Lett. 35:2331-2334. Altmann, K.-H., Imwinkelried, M., Kesselring, R., and Rihs, G. 1994b. 1′,6′-Methano carbocyclic thymidine: Synthesis, X-ray crystal structure, and effect on nucleic acid duplex stability. Tetrahedron Lett. 35:7625-7628. Berger, I., Tereshko, V., Ikeda, H., Marquez, V.E., and Egli, M. 1998. Crystal structures of B-DNA with incorporated 2′-deoxy-2′-fluoro-arabinofuranosyl thymines: Implications of conformational preorganization for duplex stability. Nucl. Acids Res. 26:2473-2480. Bergot, B.J. and Egan, W. 1992. Separation of synthetic phosphorothioate oligonucleotides from their oxygenated (phosphodiester) defect species by strong-anion-exchange high-performance liquid chromatography. J. Chromatogr. 599:35-42. Christensen, N.K., Petersen, M., Nielson, P., Jacobsen, J.P., Olsen, C.E., and Wengel, J. 1998. A novel class of oligonucleotide analogues containing 2′-O,3′-C-linked [3.2.0]bicycloarabinonucleoside monomers: Synthesis, thermal affinity studies and molecular modeling. J. Am. Chem. Soc. 120:5458-5463. Cook, P.D. 1998. Second generation antisense oligonucleotides: 2′-modifications. Annu. Rep. Med. Chem. 33:313-325. Crouch, R.J. and Toulmé, J.J. (eds.) 1998. Ribonucleases H. INSERM, Paris. Damha, M.J., Meng, B., Yannopoulos, C.G., Wang, D., and Just, G. 1995. Structural basis for the RNA selectivity of oligonucleotides containing alkylsulfide internucleoside linkages and 2′-Osubstituted 3′-deoxyribose. Nucl. Acids Res. 19:3967-3973. Damha, M.J., Wilds, C.J., Noronha, A., Brukner, I., Borkow, G., Arion, D., and Parniak, M.A. 1998. Hybrids of RNA and arabinonucleic acids (ANA and 2′F-ANA) are substrates of ribonuclease H. J. Am. Chem. Soc. 120:12976-12977. Damha, M.J., Noronha, A.M., Wilds, C.J., Trempe, J.-F., Denisov, A., and Gehring, K. 2001. Properties of arabinonucleic acids (ANA & 2′FANA): Implications for the design of antisense therapeutics that invoke RNase H cleavage of RNA. Nucleosides Nucleotides 20:429-440. Giannaris, P.A. and Damha, M.J. 1994. Hybridization properties of oligoarabinonucleotides. Can. J. Chem. 72:909-918. Iyer, R.P., Phillips, L.R., Egan, W., Regan, J.B., and Beaucage, S.L. 1990. The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagent. J. Org. Chem. 55:46934699.
Lebedeva, I. and Stein, C.A. 2001. Antisense oligonucleotides: Promise and reality. Annu. Rev. Pharmacol. Toxicol. 41:403-419. Lima, W.F. and Crooke, S.T. 1997. Binding affinity and specificity of Escherichia coli RNase H1: Impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry 36:390-398. Lok, C.-N., Viazovkina, E., Min, K-L., Nagy, E., Wilds, C.J., Damha, M.J., and Parniak, M.A. 2002. Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2′-deoxy-2′-fluoro-D-arabinose and 2′-deoxyribose nucleotides. Biochemistry 41:3457-3467. Mangos, M.M. and Damha, M.J. 2002. Flexible and frozen sugar-modified nucleic acids: modulation of biological activity through furanose ring dynamics in the antisense strands. Curr. Topics Med. Chem. 2:1145-1169. Manoharan, M. 1999. 2′-Carbohydrate modifications in antisense oligonucleotide therapy: Importance of conformation, configuration and conjugation. Biochim. Biophys. Acta 1489:117130. Minasov, G., Teplova, M., Nielsen, P., Wengel, J., and Egli, M. 2000. Structural basis of cleavage by RNase H of hybrids of arabinonucleic acids and RNA. Biochemistry 39:3525-3532. Myers, N.M. and Dean, K.J. 2000. Sensible use of antisense: How to use oligonucleotides as research tools. TIPS 21:19-23. Nakamura, H., Oda, Y., Iwai, S., Inoue, H., Ohtsuka, E., Kanaya, S., Kimura, S., Katsuda, C., Katayanagi, K., Morikawa, K., Miyashiro, H., and Ikehara, M. 1991. How does RNase H recognize a DNA:RNA hybrid? Proc. Natl. Acad. Sci. U.S.A. 88:11535-11539. Noronha, A. and Damha, M.J. 1998. Triple helices containing arabinonucleotides in the third (Hoogsteen) strand: Effects of inverted stereochemistry at the 2′-position of the sugar moiety. Nucl. Acids Res. 26:2665-2671. Noronha, A.M., Wilds, C.J., Lok, C.-N., Viazovkina, K., Arion, D., Parniak, M.A., and Damha, M.J. 2000. Synthesis and biophysical properties of arabinonucleic acids (ANA): Circular dichroic spectra, melting temperatures and ribonuclease H susceptibility of ANA:RNA hybrid duplexes. Biochemistry 39:7050-7062. Oda, Y., Iwai, S., Ohtsuka, E., Ishikawa, M., Ikehara, M., and Nakamura, H. 1993. Binding of nucleic acids to E. coli RNase HI observed by NMR and CD spectroscopy. Nucl. Acids Res. 21:46904695. Plavec, J., Thibaudeau, C., and Chattopadhyaya, J. 1994. How does the 2′-hydroxy group drive the pseudorotational equilibrium in nucleoside and nucleotide by the tuning of the 3′-gauche effect? J. Am. Chem. Soc. 116:6558-6560. Synthesis of Modified Oligonucleotides and Conjugates
4.15.21 Current Protocols in Nucleic Acid Chemistry
Supplement 10
Sangvhi, Y.S. 1998. Synthesis of nitrogen containing linkers for antisense oligonucleotides. In Carbohydrate Mimics (Y. Chapleur, ed.) pp. 523536. Wiley-VCH, Germany. Schmit, C., Bèvierre, M-O., De Mesmaeker, A., and Altmann, K.-H. 1994. The effects of 2′- and 3′-alkyl substituents on oligonucleotide hybridization and stability. Bioorg. Med. Chem. Lett. 4:1969-1974. Shen, L.X., Kandimalla, E.R., and Agrawal, S. 1998. Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by E. coli RNase H. Bioorg. Med. Chem. 6:1695-1705. Sørensen, M.D., Kvaernø, L., Bryld, T., Håkansson, A.E., Verbeure, B., Gaubert, G., Herdewijn, P., and Wengel, J. 2002. Alpha-L-ribo-configured locked nucleic acid (alpha-L-LNA): Synthesis and properties. J. Am. Chem. Soc. 124:21642176. Still, W.C., Kahn, M., and Mitra, A. 1978. Rapid chromatographic technique for preparative separation with moderate resolution. J. Org. Chem. 43:2923-2925. Tang, J.-Y., Han Y., Tang, J.X., and Zhang, Z. 2000. Large scale synthesis of oligonucleotide phosphorothioates using amino-1,2,4-dithiazoline-5thione as an efficient sulfur-transfer reagent. Org. Proc. Dev. 4:194-198.
Wilds, C.J. and Damha, M.J. 1999. Duplex recognition by oligonucleotides containing 2′-Deoxy2′-fluoro-D-arabinose and 2′-deoxy-2′-fluoroD-ribose. Intermolecular contacts versus sugar puckering in the stabilization of triple helical complexes. Bioconjug. Chem. 10:299-305. Wilds, C.J., and Damha M.J. 2000. 2′-deoxy-2′fluoro-β-D-arabinonucleosides and oligonucleotides (2′F-ANA): Synthesis and physicochemical studies. Nucl. Acids Res. 28:36253635. Xu, Q., Musier-Forsyth, K., Hammer, R.P., and Barany, G. 1996. Use of 1,2,4-dithiazolidine3,5-dione (DtsNH) and 3-ethoxy-1,2,4-dithiazoline-5-one (EDITH) for synthesis of phosphorothioate-containing oligodeoxyribonucleotides. Nucl. Acids Res. 24:1602-1607.
Key References Crouch and Toulmé, 1998. See above A comprehensive book on ribonucleases H, their sources, properties, biological utility, and antisense applications.
Thibaudeau, C. and Chattopadhyaya, J. 1997. The discovery of intramolecular stereoelectronic forces that drive the sugar conformation in nucleosides and nucleotides. Nucleosides Nucleotides 16:523-529.
Damha et al., 2001. See above.
Thibaudeau, C., Plavec, J., Garg, N., Papchikhin, A., and Chattopadhyaya, J. 1994. How does the electronegativity of the substituent dictate the strength of the gauche effect? J. Am. Chem. Soc. 116:4038-4043.
Freier, S.M. and Altmann, K.-H. 1997. The ups and downs of nucleic acid duplex stability: Structurestability studies on chemically-modified DNA:RNA duplexes. Nucl. Acids Res. 25:44294443.
Trempe, J.F., Wilds, C.J., Denisov, A.Y., Pon, R.T., Damha, M.J., and Gehring, K. 2001. NMR solution structure of an oligonucleotide hairpin with a 2′F-ANA/RNA stem: Implications for RNase H specificity toward DNA/RNA hybrid duplexes. J. Am. Chem. Soc. 123:4896-4903.
An extensive resource that relates duplex stabilities to nucleotide structure with 197 examples of oligonucleotide modifications.
Uhlmann, E. and Peyman, A. 1990. Antisense oligonucleotides: A new therapeutic principle. Chem. Rev. 90:543-584. Venkateswarlu, D. and Ferguson, D.M. 1999. Effects of C2′-substitution on arabinonucleic acid structure and conformation. J. Am. Chem. Soc. 121:5609-5610. Walder, R.Y. and Walder, J.A. 1988. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 85:5011-5015.
Synthesis of 2′-Deoxy-2′-fluoroβ-D-oligoarabinonucleotides (2′F-ANA)
Wengel, J., Koshkin, A., Singh, S.K., Nielsen, P., Meldgaard, M., Rajwanshi, V.K., Kumar, R., Skouv, J., Nielsen, C.B., Jacobsen, J.P., Jacobsen, N., and Olsen, C.E. 1999. LNA (Locked nucleic acid). Nucleosides Nucleotides 18:13651370.
Wang, J., Verbeure, B., Luyten, I., Lescrinier, E., Froeyen, M., Hendrix, C., Rosemeyer, H., Seela, F., Aerschot, A.V., and Herdewijn, P. 2000. Cyclohexene nucleic acids (CeNA): Serum stable oligonucleotides that activate RNase H and increase duplex stability with complementary RNA. J. Am. Chem. Soc. 122:8595-8602.
Highlights the role of the 2′-sugar position in ANA and 2′F-ANA conformations, and the origins of RNase H activity.
Kvaernø, L. and Wengel, J. 2001. Antisense molecules and furanose conformations—is it really that simple? Chem. Commun. 1419-1424. A concise review briefly comparing RNA binding versus cleavage with promising antisense candidates. Lebedeva and Stein, 2001. See above. Insightful discussion of antisense design that focuses on in vivo toxicity from nonspecific interactions and potential irrelevant cleavage of nontargeted RNA.
Contributed by Ekaterina Viazovkina, Maria M. Mangos, Mohamed I. Elzagheid, and Masad J. Damha McGill University Montreal, Canada
4.15.22 Supplement 10
Current Protocols in Nucleic Acid Chemistry
Chemistry of CpG DNA The innate immune system of vertebrates has evolved to recognize specific pathogenassociated molecular patterns (PAMPs) present in invading microorganisms through pattern recognition receptors (PRRs; Lien and Ingalls, 2002). One of several such PAMPs is the unmethylated CpG dinucleotide present in specific sequence contexts (CpG motifs) in pathogenic microorganisms (Hemmi et al., 2000). On sensing a CpG motif, PRRs trigger complex signal transduction pathways that ultimately activate a number of transcription factors, including NF-κB and AP-1. These induce specific patterns of gene expression associated with the development and maintenance of immune responses. The immune responses to bacterial and synthetic oligonucleotides containing CpG motifs include proliferation of B cells, production of cytokines IL-12, γ-IFN, IL-6, and TNF-α (Klinman et al., 1996; Zhao et al., 1997), and production of costimulatory molecules by monocytes/macrophages, B cells, dendritic cells (DCs), and natural killer (NK) cells.
HISTORY Tokunaga and coworkers were the first to report that DNA from Mycobacterium bovis induces production of interferons α, β, and γ (IFN-α, -β, and -γ), augments NK cell activity, and shows antitumor activity (Tokunaga et al., 1984). The same authors, using short synthetic DNA fragments, showed that palindromic sequences containing CpG dinucleotides efficiently induce NK cell activity and induce IFNs (Yamamoto et al., 1992a). Subsequent studies demonstrated that bacterial DNA, but not mammalian DNA, induces murine B cell proliferation and cytokine secretion (Messina et al, 1991; Yamamoto et al., 1992b). Later studies showed that unmethylated CpG dinucleotides in specific sequence contexts present in bacterial DNA, synthetic oligodeoxyribonucleotides, and DNA vaccines are responsible for the observed immune responses (Krieg et al., 1995; Sato et al., 1996). Compared to bacterial DNA, the occurrence of CpG motifs in vertebrate DNA is sparse. In addition, the vertebrate C residues usually carry a 5-methyl substituent (Bird, 1986), which enables the immune system to distinguish between its own DNA and bacterial DNA that signals an infection.
UNIT 4.16
RECEPTORS The recognition of CpG DNA has been shown to occur through Toll-like receptor 9 (TLR9), which belongs to a family of proteins called TLRs (Hemmi et al., 2000). The TLRs function as PRRs to initiate the innate immune response against invading microorganisms. However, direct evidence for binding of CpG DNA to TLR9 has not yet been documented. Although most other TLRs are membrane receptors, growing evidence suggests that TLR9 is localized in the cytoplasm (Takeshita et al., 2001; Ahmad-Nejad et al., 2002). Therefore, cellular uptake and endosomal localization seem to be prerequisites for CpG DNA recognition (Stacey et al., 2000).
Sequence and Structural Specificity of TLR9 TLR9 proteins from different vertebrates vary in the CpG DNA sequences they recognize (Bauer et al., 2001a). Therefore, a CpG motif that is active in one species may not be in another. For example, mouse TLR9 prefers an unmethylated CpG dinucleotide flanked by two purine bases on the 5′ side and two pyrimidine bases on the 3′ side, such as GACGTT (Krieg et al., 1995). CpG dinucleotides preceded by C or followed by G are generally less active in mice. Human immune cells respond optimally to GTCGTT or TTCGTT motifs (Hartmann et al., 2000). Certain other sequences, such as a palindromic AACGTT sequence, are known to induce immune responses in both mouse and human systems (Yamamoto et al., 1992a; Van Uden and Raz, 2000). Thus, TLR9 variants from different species recognize CpG dinucleotides flanked by a variety of sequences, though to different extents (Rankin et al., 2001; Zhang et al., 2001; Wernette et al., 2002).
Signaling Events Though the evidence suggests that TLR9 is the receptor for phosphorothioate CpG DNAs, the role of TLR9 in mediating the observed effects of phosphodiester CpG oligonucleotides and bacterial DNA is not yet clear. The signaling events initiated by TLR9 in response to CpG DNA include recruitment of MyD88, IRAK, and TRAF6, which leads to activation of IκB kinase, MAP kinase, the stress kinases JNK-1 and -2, and p38, which in turn causes activation of transcription factors ATF-
Contributed by Ekambar R. Kandimalla and Sudhir Agrawal Current Protocols in Nucleic Acid Chemistry (2003) 4.16.1-4.16.14 Copyright © 2003 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.16.1 Supplement 12
2, AP-1, and NF-κB (Fig. 4.16.1). The activated transcription factors induce the synthesis of several regulatory cytokines and costimulatory molecules.
SIGNIFICANCE OF CpG DINUCLEOTIDES AND CHEMISTRY OF CpG DNA A CpG dinucleotide present in specific sequence contexts is essential for immunostimulatory activity, whereas the inverted dimer, GpC, is inactive. As discussed above, the flanking sequences play an important role in determining activity of CpG DNA (Yamamoto et al., 1992a; Krieg et al., 1995; Pisetsky, 1999). Recently, other structural features that influence the activity of synthetic oligonucleotides have been reported, including the nature of the internucleotide linkage, the nature and conformation of the sugar ring, modification or removal of nucleobases, accessibility of the 5′ end, and the nature and size of any 5′-terminal blocking group.
DNA Backbone Shorter CpG DNA molecules with unmodified phosphodiester backbones may elicit potent immune stimulation in vitro (Sonehara et al., 1996; Iho et al., 1999). However, phosphorothioate-modified oligonucleotides are used more commonly to prevent rapid degradation by nucleases present in cells. Although phosphodiester and phosphorothioate CpG DNAs elicit superficially similar immune re-
sponses, recent studies showed certain distinct differences in the actions of these two backbones (Ballas et al., 2001; Rothenfusser et al., 2001; Verthelyi et al., 2001, 2002; Dalpke et al., 2002; Gursel et al., 2002), which are not well understood (Fig. 4.16.2 and Table 4.16.1). Phosphodiester backbone Phosphodiester CpG DNAs containing palindromic structures and/or poly(dG) sequences effectively activate NK cells (Yamamoto et al., 1992a, 2000; Iho et al., 1999) and induce IFN-α/β production from plasmacytoid DCs (Bauer et al., 2001b; Kadowaki et al., 2001; Krug et al., 2001a,b). The effects of phosphodiester CpG DNAs are generally similar to those of bacterial DNA, and the induction of type I IFN is far greater than with phosphorothioate CpG DNAs. However, B cell activation by phosphodiester CpG DNA appears minimal compared with bacterial and phosphorothioate CpG DNAs. Phosphodiester CpG DNAs induce high levels of IFN-γ and IL-12, but produce IL-6 only minimally. Phosphorothioate substitutions on either end of the phosphodiester CpG DNA improve resistance to nucleases (Dalpke et al., 2002). Incorporation of poly(dG) sequences at the ends of the phosphodiester DNA has been reported to enhance nuclease stability and increase cellular uptake through scavenger receptors (Pearson et al., 1993; Kimura et al., 1994; Agrawal et al., 1 996). CpG DNAs containing phosphorothioate poly(dG) sequences at the 5′ and
cytosol
CpG DNA bacterial DNA (CpG) CpG oligonucleotides plasmid DNA (CpG)
TIR domain
MAPK (p38, ERK, JNK)
TLR9
AP-1
TRAF6 IRAK ds viral RNA [poly(I⋅C)]
nucleus
TIR domain TLR3 MyD88
IκB NF-κB
Chemistry of CpG DNA
Figure 4.16.1 The two members of the Toll-like receptor (TLR) family that recognize bacterial CpG DNA and double-stranded (ds) viral RNA. Key components involved in the signaling pathways are shown. The activated transcription factors ultimately upregulate the expression of a number of cytokines and costimulatory molecules. Abbreviations: AP-1, activator protein 1; ERK, extracellular-signal-regulated protein kinase; IκB, inhibitor of κB; IRAK, IL-1 receptor associated kinase; JNK, c-jun N-terminal kinase; MAPK, mitogen activated protein kinase; MyD88, myeloid differentiation factor 88; NF-κB, nuclear factor κB; TIR, Toll/IL-1 receptor; TLR, Toll-like receptor.
4.16.2 Supplement 12
Current Protocols in Nucleic Acid Chemistry
R = O− phosphodiester
O
B
O O
R P O O
R = S− O
B
phosphorothioate
O
R = CH3 methylphosphonate
Figure 4.16.2 Chemical structure of a typical dinucleotide showing the internucleotide phosphate linkage (boxed) and the three backbone chemistries studied in CpG DNA for immunostimulatory activity. Some of the important immunostimulatory effects observed with each backbone modification are given in Table 4.16.2.
3′ ends and a palindromic phosphodiester in the middle are potent adjuvants in vitro and in vivo (Dalpke et al., 2002; Verthelyi et al., 2002). However, it is unclear whether activity is due to the phosphodiester backbone, the poly(dG) sequences, or secondary structures formed by palindromic and poly(dG) sequences. Recently, for the first time, the authors showed the use of phosphodiester CpG DNA without requiring palindromic structures and poly(dG) sequences for immunostimulatory activity (Yu et al., 2002a). For this study, two phosphodiester CpG oligodeoxynucleotides were attached via a glyceryl linker through their 3′ ends. These 3′-3′-linked CpG DNAs are referred to as immunomers. Phosphodiester immunomers showed remarkable stability against nucleases in medium containing 10% FBS that was not heat inactivated. Surprisingly, phosphodiester immunomers induced increased IL-12 secretion and minimal amounts of IL-6 secretion in mouse spleen cell cultures (Yu et al., 2002a). These studies suggest that it would be possible to modulate cytokine secretion profiles induced by CpG DNAs by using different backbone chemistries. In J774 cell cultures they activated NF-κB and induced cytokine secretion comparable to that of an unmodified 18-mer phosphorothioate CpG DNA containing the same CpG motif. Moreover,
phosphodiester immunomers showed antitumor activity in nude mice bearing human breast (MCF-7) and prostate (DU145) cancer xenografts, suggesting that single-stranded phosphodiester CpG DNA can be a potent pharmacological agent. Phosphorothioate backbone In contrast, phosphorothioate CpG DNAs do not require palindromic sequences to induce im mu ne respo nses. I n g en er al, phosphorothioate CpG oligonucleotides strongly stimulate B cell proliferation, as well as activate monocytes/macrophages, DCs, and B cells to produce cytokines and immunoglobulins (Branda et al., 1993; Krieg et al., 1995; Zhao et al., 1997; Stacey et al., 2000). Phosphorothioate CpG DNAs are the most extensively studied to date, and several are in clinical trials. Stereoenriched phosphorothioate backbone Substitution of a nonbridging oxygen with sulfur creates a chiral phosphorus center with Rp- and Sp-diastereomers. If there are n phosphorothioate linkages in the backbone, conventional automated synthesis yields 2n stereoisomers. Studies using stereoenriched all-Rp and all-Sp phosphorothioate CpG DNAs showed that the all-Rp analog induced lower cell pro-
Synthesis of Modified Oligonucleotides and Conjugates
4.16.3 Current Protocols in Nucleic Acid Chemistry
Supplement 12
liferation than all-Sp or racemic CpG DNA analogs (Yu et al., 2000a). However, it is not clear if this is because of their differential susceptibility to nucleases (Tang et al., 1995; Yu et al., 2000a) or because one of the diastereomers is preferentially recognized by the receptor. Role of backbone charge and nonionic methylphosphonate linkages Substitution of a nonbridging oxygen on the internucleotide phosphate with a methyl group produces a nonionic phosphorus center (Fig. 4.16.2). Recent studies show that an uncharged
Table 4.16.1
methylphosphonate internucleotide linkage between C and G of the CpG dinucleotide diminishes the immune response (Zhao et al., 1996). Further, methylphosphonate substitutions within the three internucleotide linkages to the 5′-side of the CpG dinucleotide also suppress activity (Yu et al., 2001b). It appears that a negative charge on these internucleotide linkages is important for recognition and/or interaction between the CpG DNA and its receptor. Surprisingly, substituting the fifth or sixth linkage on the 5′ side of the CpG dinucleotide significantly enhances immunostimu-
Properties of DNA Backbones with Different Linkagesa
Linkage
Property
Phosphodiester
Usually require longer length palindromic sequences to be stable against nucleases May require higher concentrations to compensate for nuclease degradation Often require phosphorothioate-end modifications Poly(dG) end modifications are extensively used Produce high levels of IL-12, IFN-γ, and IFN-α/β, and induce minimal IL-6 Potent activators of NK and dendritic cells, but weak activators of B cells Produce TH1-type immune responses. Potent adjuvants, and antitumor and antiasthmatic agents Stable against nucleases Strong activators of B cells. Also directly activate macrophages/monocytes and DCs, but do not directly activate NK and T cells. Produce a number of cytokines, including IL-12 Produce Ig Produce TH1 immune responses. Currently investigated for their potential in clinical trials as anticancer, antiallergic, and antiinfectious agents Only site-specific modifications have been studied CH3 between C and G of the CpG dinucleotide suppresses the immune response CH3 within three internucleotide linkages to 5′ of CpG suppresses the response CH3 at five or six linkages from 5′ of CpG enhances the response CH3 in 3′ flanking sequences has minimal effect May be possible to alter cytokine secretion by site-specific incorporation of one or two linkages in CpG DNA
Phosphorothioate
Methylphosphonate
aRefer to Figure 4.16.2 for graphical depiction of the linkages.
Chemistry of CpG DNA
4.16.4 Supplement 12
Current Protocols in Nucleic Acid Chemistry
latory activity, which may reflect tighter binding to the receptor. In contrast, the presence of nonionic internucleotide linkages to the 3′ side of the CpG dinucleotide has an insignificant effect on activity.
2′-Sugar modifications Replacing either nucleoside in the CpG dinucleotide with one that is modified at the 2′-hydroxyl group (R in Fig. 4.16.3A) impedes immunostimulatory activity (Zhao et al., 1996). However, 2′-O-methyl- or 2′-O-methoxyethylribonucleosides in the sequences flanking the CpG dinucleotide have different effects depending on the position of substitution (Zhao et al., 1999; 2000). In general, 2′-O-alkylribonucleosides adjacent to the CpG dinucleotide on the 5′ side impair activity, while the same substitution on the 3′ side has minimal effect. Importantly, activity increases when the substitutions are incorporated distal to the CpG dinucleotide on either side (Zhao et al., 1999, 2000; Agrawal and Kandimalla, 2001). Hence, the effects on receptor binding due to conformational changes within ribose are strongly dependent on the position of substitution relative to the CpG dinucleotide.
Sugar Modifications While TLR9 has been shown to be involved in CpG DNA immune activation, a closely related family member, TLR3, has been reported to specifically recognize viral and synthetic double-stranded RNA and induce immune responses (Alexopoulou et al., 2001). Ribose and deoxyribose sugar moieties adopt 2′- and 3′-endo conformations (Fig. 4.16.3) that attribute distinct structural, physicochemical, and biological properties to RNA and DNA, respectively. It appears that the vertebrate innate immune system has evolved to recognize both of these nucleic acid structures from invading microorganisms, but through different receptors (Fig. 4.16.1). The authors of this unit have extensively studied the effects of sugar modifications in CpG DNA, as discussed below.
A
3′-Sugar modifications The incorporation of unnatural 3′-deoxynucleosides results in the formation of 2′-5′-inter-
B 5′
O
5′
B
O
O
O
O O
P
S−
O
O
B
O
O O
B
O
P
S−
O
R
O2′ O
O
B
B
O
R
S−
O
P
P O
O3′ O
P O
S− O
B
O3′ S−
O
P
S−
O
Figure 4.16.3 (A) Chemical structure of a DNA chain containing a single ribonucleoside (boxed). R is –OH (RNA), –OCH3 (2′-O-methyl RNA), or –OCH2CH2OCH3 (2′-O-methoxyethyl RNA). (B) Chemical structure of a DNA chain with a 3′-deoxyribonucleoside (R = –H) or 3′-O-methylribonucleoside (R = –OCH3) (boxed). Note that the incorporation of a 3′-deoxy- or 3′-O-methylribonucleoside results in a 2′-5′-linkage in an otherwise 3′-5′-linked DNA.
Synthesis of Modified Oligonucleotides and Conjugates
4.16.5 Current Protocols in Nucleic Acid Chemistry
Supplement 12
3000
IL-12
2000
Cytokine (pg/mL)
1000
0 15000
IL-6
10000
5000 0 225
IL-10
150 75 0 2
1
3
M
5
4
6
CpG DNA
Figure 4.16.4 Effect of site-specific incorporation of a 3′-deoxyribonucleoside in different CpG DNA molecules (1 and 4) either in the 5′-flanking (2 and 5) or 3′-flanking sequence (3 and 6) on induction of cytokine (IL-12, -6, and -10) secretion in BALB/c mouse spleen cell cultures. Data for specific compounds is taken from Yu et al. (2002c). BALB/c mouse spleen cell cultures were incubated for 24 hrs with 1.0 µg/mL of CpG DNA. IL-12 secretion is not affected by either 5′ or 3′ modification. IL-6 and -10 secretion is increased when the modification is in the 5′-flanking sequence and either decreased or unaffected when the modification is in the 3′-flanking sequence. M is medium alone. Sequences of CpG DNA are: (1) 5′-d(CCTACTAGCGTTCTCATC)-3′; (2) 5′d(CCTAC*TAGCGTTCTCATC)-3′; (3) 5′-d(CCTACTAGCGTTCTC*ATC)-3′; (4) 5′-d(CTATCTGACG TTCTCTGT)-3′; (5) 5′-d(CTATC*TGACGTTCTCTGT)-3′; (6) 5′-d(CTATCTGACGTTCTC*TGT)-3′. CpG motifs are underlined. Italics indicate the 3′-deoxyribonucleosides. Asterisks indicate the position of the 2′-5′-linkages.
Chemistry of CpG DNA
nucleotide linkages in an otherwise 3′-5′-linked DNA (Fig. 4.16.3B). The presence of a 3′-deoxynucleoside either within the CpG dinucleotide or adjacent to it abrogates immunostimulatory activity (Yu et al., 2002b). However, the same modification distal to the CpG dinucleotide in the 5′-flanking sequence potentiates activity. In the 3′-flanking sequence, 3′deoxynucleosides have an insignificant effect on immunostimulation. Interestingly, 3′-deoxynucleosides in either the 5′- or the 3′-flanking sequence distal to the CpG dinucleotide result in different cytokine secretion profiles compared with unmodified CpG DNA (Fig. 4.16.4). It seems that changes in recognition
and/or interaction with the receptor that are brought about by introducing chemical changes in CpG DNA are reflected in downstream events such as cytokine secretion. However, it is not clear yet if these distinct effects are a consequence of the differences in structural and/or kinetic interactions between the modified CpG DNA and its receptor. Nonetheless, by incorporating appropriate chemical modifications into CpG DNA, it may be possible to modulate cytokine secretion in a desirable fashion for specific disease indications. Similar effects have been reported with 3′-O-methylribonucleosides (Zhao et al., 2000; Agrawal and Kandimalla, 2001).
4.16.6 Supplement 12
Current Protocols in Nucleic Acid Chemistry
Significance of Deoxycytidine and Deoxyguanosine in CpG Dinucleotides: Synthetic Nucleosides Although flanking sequences strongly influence the interaction of CpG DNA and its receptors, the principal determinant in receptor recognition of a CpG DNA molecule (single- or double-stranded) is the unmethylated CpG dinucleotide itself. Any chemical modification introduced within the CpG dinucleotide that changes the DNA conformation—such as substitution of deoxyribose with ribose, 2′-O-substituted ribose, or 3′-deoxyribose, neutralization of the anionic phosphate charge between C and G, or deletion of the C or G nucleobase— completely abolishes recognition by the receptor and the subsequent immune responses. In addition, a methyl substitution at the 5 position of cytosine results in loss of activity (Zhao et al., 1996). Synthetic pyrimidines By replacing cytosine with synthetic pyrimidines, the authors have carried out an extensive study to delineate the importance for immunostimulation of each functional group on the pyrimidine ring of a CpG dinucleotide (Fig. 4.16.5). This study showed that deletion of any of the functional groups of cytosine (i.e., 2-keto, 3-imino, and 4-amino) resulted in loss of activity, suggesting that all three groups are
important for recognition and/or interaction with the receptor (Kandimalla et al., 2001). Unlike a hydrophobic methyl group, a hydroxyl substituent at the 5 position of cytosine in CpG does not suppress immunostimulatory activity (Kandimalla et al., 2001). In addition, while the 4-amino group of cytosine is absolutely required, an alkyl substitution on the amino group does not interfere with recognition and subsequent activity (Kandimalla et al., 2001). Synthetic purines Similarly, a number of synthetic purine analogs substituted for guanine in a CpG dinucleotide have been studied (Fig. 4.16.6). Deletion or modification of functional groups at the 1, 2, and 6 positions result in the loss of immunostimulatory activity (Kandimalla et al., 2001). The deletion of nitrogen at the 7 position, however, does not, suggesting that N7 is not required for receptor recognition. These studies have provided important clues regarding the functional groups of guanine in a CpG dinucleotide that are required for recognition and/or binding to the receptor (Kandimalla et al., 2001). Importantly, these studies identified new, trademarked, synthetic dinucleotides (i.e., YpG, CpR, and YpR, where Y and R are the synthetic pyrimidine and purine analogs in Figs. 4.16.5 and 4.16.6, respectively) that alter cytokine secretion profiles compared with the
NH2 H3 C NH2 4
O
O
N
NH2
N
O
N
N
1 2
N
O
5-methylcytosine
O
O O P
O
HO
N
3
5 6
N N
NH2
O H 3C
S−
O
5-methylisocytosine
NHCH2CH3
uracil
O
O
N
N
NH N
5-hydroxycytosine
N
NH O
4-N -ethylcytosine
N
O
P-base
Figure 4.16.5 Structure of 2′-deoxycytidine showing hydrogen bond acceptor (inward arrows) and donor (outward arrow) groups on cytosine. Chemical structures of some of the synthetic pyrimidine analogs studied are shown.
Synthesis of Modified Oligonucleotides and Conjugates
4.16.7 Current Protocols in Nucleic Acid Chemistry
Supplement 12
O
O N
N
NH
N
N
N
hypoxanthine
NH
N N
NH2
N
7-deazaguanine
2-aminopurine
NH2
NH2 N N
O 7N 5 8
O
O
6
N 4 N 3
O
N
N
N
N
N
O
N H
N NH2
N H
1
NH purine
2
9
N
N
NH2
N
2,6-diaminopurine
isoguanine
NH2 CH3O
O
N
N N
N
NH2
N
O
N
NH
NH
O P S−
O
N H
N
O
7-deazaxanthine
K-base
H N N
N
NH2
8-bromoguanine O
O NH
O
NH
Br
N
8-oxoguanine
NH
N NH2
N
N
NH2
7-deaza-8-azaguanine
Figure 4.16.6 Structure of 2′-deoxyguanosine showing hydrogen bond acceptor (inward arrows) and donor (outward arrows) groups on guanine. Chemical structures of some of the synthetic purine analogs studied are shown.
natural CpG dinucleotide. Additionally, these studies indicate divergent synthetic nucleotide motif recognition patterns of the receptor and the possibility of modulating downstream cytokine secretion profiles using synthetic motifs placed appropriately in oligonucleotide sequences.
Role of Nucleobases
Chemistry of CpG DNA
Recently, the need for each nucleobase in a CpG DNA for immune stimulation in mice by using abasic or 1′,2′-dideoxynucleosides (Fig. 4.16.7A) has been reported. The presence of a nucleobase is absolutely required in both C and G positions of the CpG dinucleotide for activity. However, deletion of a nucleobase in the 5′-flanking region at a distance of three or more nucleosides from the CpG dinucleotide increases immunostimulatory activity (Yu et al.,
2001a). A similar deletion in the 3′-flanking sequence does not significantly affect activity, suggesting that not all nucleobases are involved in recognition. Possibly, nucleobases in certain positions cause steric hindrance when binding to the receptor. Deletion of one or two of them might relieve this strain, improving recognition and/or binding to the receptor. Moreover, nucleobase deletions in the 5′-flanking sequence increased IL-6 production compared with parent CpG DNA, while those in the 3′-flanking sequence had the opposite effect (Fig. 4.16.7B).
Requirement of Nucleosides Recently it has been shown that non-nucleoside linkers (Fig. 4.16.8) could replace certain nucleosides in the 5′- and 3′-flanking sequences (Yu et al., 2002c). An alkyl linker in the flanking sequence 5′ to the CpG dinucleotide potenti-
4.16.8 Supplement 12
Current Protocols in Nucleic Acid Chemistry
A
B 3000
5′
O
B
O
IL-12 2250
O P
1500
S−
O
Cytokine (pg/mL)
O
O
O O
P
0 4000
IL-6
3000
S−
O
750
O
B
2000 1000
O3′ O
P
0
S−
M
7
1
8
CpG DNA
O
Figure 4.16.7 (A) Chemical structure of a DNA chain with a 1′,2′-dideoxyribonucleoside (boxed). B indicates base. (B) Effect of site-specific incorporation of a 1′,2′-dideoxyribonucleoside in a CpG DNA molecule (1) in either in the 5′-flanking (7) or 3′-flanking (8) sequence on induction of cytokine (IL-12 and IL-6) secretion in BALB/c mouse spleen cell cultures. Data for specific compounds are taken from Yu et al. (2001a). BALB/c mouse spleen cell cultures were incubated for 24 hr with 1.0 µg/mL of CpG DNA. Note that IL-12 secretion is not affected by either 5′ or 3′ modification. IL-6 secretion is increased when the modification is in the 5′-flanking sequence and decreased when the modification is in the 3′-flanking sequence. M is medium alone. Sequences of CpG DNAs are: (1) 5′-d(CCTACTAGCGTTCTCATC)-3′; (7) 5′-d(CCTXCTAGCGTTCTCATC)-3′; (8) 5′-d(CCTACTAGCGTTCXCATC)-3′. CpG motifs are underlined. X indicates the position of 1′,2′-dideoxyribonucleoside.
ated immunostimulatory activity. Interestingly, the same substitution in the 3′-flanking sequence did not affect immunostimulatory activity compared with parent CpG DNA. While a C3-linker optimally improved activity, longer ethyleneglycol and branched alkyl linkers (Fig. 4.16.8) were also beneficial. A linker in the 5′-flanking sequence increased IL-6 secretion several fold (Yu et al., 2002c). However, it is not clear whether the differences observed resulted from altered recognition/binding events with the receptor or initiation of different downstream signaling and transcriptional events compared with the parent CpG DNA.
Accessibility to the 5′ End of CpG DNA is Required for Immunostimulatory Activity The findings discussed above clearly suggest that the sequence 5′ to the CpG dinucleotide plays a major role in immune stimulation, while that on the 3′ side has an insignificant effect. The authors’ recent studies using 3′-3′- and 5′-5′-linked CpG DNAs suggest that an accessible 5′ end of CpG DNA is required for immunostimulatory activity (Yu et al., 2000b). Increased activity is observed when two CpG DNAs are tethered through their 3′ ends, while little or none is seen when they are tethered through their 5′ ends (Yu et al., 2000b). Synthesis of Modified Oligonucleotides and Conjugates
4.16.9 Current Protocols in Nucleic Acid Chemistry
Supplement 12
O
B
O
alkyl linkers O(CH2)n O
O O
S−
P
n = 2, 3, 4, 6, or 9
O linker
ethylene glycol linkers
O O
P
S−
O
O(CH2CH2O)n CH2CH2O O
branched alkyl linkers
O O
P
n = 2 or 5
B
S−
NH2
OH
O O
O
or
O
O
Figure 4.16.8 Chemical structure of a DNA chain containing an alkyl linker. Structures of various linkers studied are shown. B indicates base.
Size of the 5′- or 3′-Attached Ligand Influences CpG DNA Activity
Chemistry of CpG DNA
Subsequent studies showed that accessibility at the 5′ end depends on the size of the ligand or moiety conjugated to this end of CpG DNA (Kandimalla et al., 2002). Conjugation of a small residue, such as a phosphorothioate group, at the 5′ end has an insignificant effect on immunostimulatory activity. However, conjugation of larger groups—including fluorescein, a mononucleotide, a tetramer, or a longer oligonucleotide (5′-5′-linked)—significantly interferes with activity. Surprisingly, conjugation of an oligonucleotide or a ligand to the 3′ end of CpG DNA (3′-3′-linked) has either an insignificant effect on activity or increases activity. Studies of cellular uptake and activation of transcription factor NF-κB in J774 cells using fluorescein-conjugated CpG DNAs suggest that both 5′- and 3′-conjugates have similar cellular uptake, but only the 3′-conjugate activates NF-κB, not the 5′-conjugate. CpG DNA has been shown to efficiently mediate antigen uptake and presentation by DCs only when antigen or allergen is conjugated to the CpG DNA (Shirota et al., 2000, 2001; Tighe et al., 2000a). CpG DNA conju-
gates are currently in clinical trials for allergies (Tighe et al., 2000a,b; Horner et al., 2002). Routinely, ligands are conjugated to oligonucleotides at the 5′ end because of convenient synthetic protocols. However, the conjugation of a macromolecule or incorporation of G-rich sequences at the 5′ end could interfere with the recognition of the CpG DNA by its receptor, thereby reducing activity. The authors’ studies suggest that the conjugation of functional ligands (e.g., antigen, antibody, allergen, another CpG DNA) at the 3′ end of CpG DNA not only contributes to increased stability against nuclease digestion but also increased immunostimulatory potency of CpG DNA in vivo.
CONCLUSIONS CpG DNA is a powerful tool that can be used to modulate the immune system for treatment of a wide variety of disease indications. Several first-generation CpG DNA molecules are in clinical trials for a number of diseases either as monotherapies, in combination with antigens, vaccines, or monoclonal antibodies, or as conjugates with antigens (Gurunathan et al., 2000; Agrawal and Kandimalla, 2002; Kandimalla and Agrawal, 2002; Krieg, 2002). Extensive
4.16.10 Supplement 12
Current Protocols in Nucleic Acid Chemistry
safety data is available from clinical studies of antisense oligonucleotides. Antisense oligonucleotides, which are used at several-fold higher concentrations than CpG DNA, have been administered to humans without serious adverse safety concerns. To date, several hundred people have been treated for up to two years without any evidence of anti-DNA antibody formation. Many of these molecules that are in clinical trials contain CpG dinucleotides. The presence of CpG dinucleotides in antisense oligonucleotides induces immune responses (Agrawal and Kandimalla, 2000; Lewis et al., 2000; Agrawal and Kandimalla, 2001; Jahrsdorfer et al., 2002), sometimes resulting in uncontrolled cytokine secretion, causing toxicity concerns (Agrawal and Zhao, 1998a,b; Agrawal, 1999a,b). A number of second-generation chemical modifications of CpG motifs in antisense oligonucleotides have been reported to suppress immune-related side effects (Agrawal and Zhao, 1998a,b; Agrawal, 1999a,b; Agrawal and Kandimalla, 2000). The study of CpG DNA chemistry is a step closer towards understanding the biological effects and development of CpG DNA for human therapies. The chemical studies discussed in this review suggest that, in addition to the CpG dinucleotide, a number of other factors in CpG DNA molecules influence recognition by receptors, secretion of cytokines, and the resulting immunological effects. The ability to regulate cytokine induction through the use of second-generation CpG DNA modifications discussed in this review is an important factor in advancing the use of CpG DNA for specific disease indications with reduced toxicity concerns. Further understanding of the biological effects of second-generation CpG DNAs will lead to the design of more potent CpG DNA pharmacological agents.
LITERATURE CITED Agrawal, S. 1999a. Factors affecting the specificity and mechanism of action of antisense oligonucleotides. Antisense Nucleic Drug Dev. 9:371375. Agrawal, S. 1999b. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim. Biophys. Acta 1489:53-68.
Agrawal, S. and Kandimalla, E.R. 2002. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 8:114-121. Agrawal, S. and Zhao, Q. 1998a. Antisense therapeutics. Curr. Opin. Chem. Biol. 2:519-528. Agrawal, S. and Zhao, Q. 1998b. Mixed backbone oligonucleotides: Improvement oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. 8:135-139. Agrawal, S., Iadarola, P.L., Temsamani, J., Zhao, Q., and Shaw, D. 1996. Effect of G-rich sequences on the synthesis, purification, binding, cell uptake, and hemolytic activity of oligonucleotides. Bioorg. Med. Chem. Let. 6:2219-2224. Ahmad-Nejad, P., Hacker, H., Rutz, M., Bauer, S., Vabulas, R.M., and Wagner, H. 2002. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32:1958-1968. Alexopoulou, L., Holt, A.C., Medzhitov, R., and Flavell, R.A. 2001. Recognition of doublestranded RNA and activation of NF-κB by Tolllike receptor 3. Nature 413:732-738. Ballas, Z.K., Krieg, A.M., Warren, T., Rasmussen, W., Davis, H.L., Waldschmidt, M., and Weiner, G.J. 2001. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167:48784886. Bauer, S., Kirschning, C.J., Hacker, H., Redecke, V., Hausmann, S., Akira, S., Wagner, H., and Lipford, G.B. 2001a. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U.S.A. 98:9237-9242. Bauer, M., Redecke, V., Ellwart, J.W., Scherer, B., Kremer, J.P., Wagner, H., and Lipford, G.B. 2001b. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J. Immunol. 166:5000-5007. Bird, A.P. 1986. CpG-rich islands and the function of DNA methylation. Nature 321:209-213. Branda, R.F., Moore, A.L., Mathews, L., McCormack, J.J., and Zon, G. 1993. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem. Pharmacol. 45:2037-2043. Dalpke, A.H., Zimmermann, S., Albrecht, I., and Heeg, K. 2002. Phosphodiester CpG oligonucleotides as adjuvants: Polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 106:102-112.
Agrawal, S. and Kandimalla, E.R. 2000. Antisense therapeutics: Is it as simple as complementary base recognition? Mol. Med. Today 6:72-81.
Gursel, M., Verthelyi, D., Gursel, I., Ishii, K.J., and Klinman, D.M. 2002. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides. J. Leukoc. Biol. 71:813-820.
Agrawal, S. and Kandimalla, E.R. 2001. Antisense and/or immunostimulatory oligonucleotide therapeutics. Current Cancer Drug Targets 1:197-209.
Gurunathan, S., Klinman, D.M., and Seder, R.A. 2000. DNA vaccines: Immunology, application, and optimization. Annu. Rev. Immunol. 18:927974.
Synthesis of Modified Oligonucleotides and Conjugates
4.16.11 Current Protocols in Nucleic Acid Chemistry
Supplement 12
Hartmann, G., Weeratna, R.D., Ballas, Z.K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W.L., Waldschmidt, M., Sajuthi, D., Purcell, R.H., Davis, H.L., and Krieg, A.M. 2000. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164:1617-1624. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745. Horner, A.A., Takabaysahi, K., Zubeldia, J.M., and Raz, E. 2002. Immunostimulatory DNA-based therapeutics for experimental and clinical allergy. Allergy 57:24-29. Iho, S., Yamamoto, T., Takahashi, T., and Yamamoto, S. 1999. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-γ production in vitro. J. Immunol. 163:3642-3652. Jahrsdorfer, B., Jox, R., Muhlenhoff, L., Tschoep, K., Krug, A., Rothenfusser, S., Meinhardt, G., Emmerich, B., Endres, S., and Hartmann, G. 2002. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J. Leukoc. Biol. 72:83-92. Kadowaki, N., Antonenko, S., and Liu, Y.J. 2001. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J. Immunol. 166:2291-2295. Kandimalla, E.R. and Agrawal, S. 2002. Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr. Op. Mol. Ther. 4:122-129. Kandimalla, E.R., Yu, D., Zhao, Q., and Agrawal, S. 2001. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: Structure-immunostimulatory activity relationships. Bioorg. Med. Chem. 9:807-813. Kandimalla, E.R., Bhagat, L., Yu, D., Cong, Y., Tang, J., and Agrawal, S. 2002. Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconj. Chem. 13:966-974. Kimura, Y., Sonehara, K., Kuramoto, E., Makino, T., Yamamoto, S., Yamamoto, T., Kataoka, T., and Tokunaga, T. 1994. Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. J. Biochem. 116:991-994. Klinman, D.M., Yi, A.K., Beaucage, S.L., Conover, J., and Krieg, A.M. 1996. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc. Natl. Acad. Sci. U.S.A. 93:28792883. Chemistry of CpG DNA
Krieg, A.M., Yi, A.K., Matson, S., Waldschmidt, T.J., Bishop, G.A., Teasdale, R., Koretzky, G.A., and Klinman, D.M. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549. Krug, A., Rothenfusser, S., Hornung, V., Jahrsdorfer, B., Blackwell, S., Ballas, Z.K., Endres, S., Krieg, A.M., and Hartmann, G. 2001a. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur. J. Immunol. 31:2154-2163. Krug, A., Towarowski, A., Britsch, S., Rothenfusser, S., Hornung, V., Bals, R., Giese, T., Engelmann, H., Endres, S., Krieg, A.M., and Hartmann, G. 2001b. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31:3026-3037. Lewis, E.J., Agrawal, S., Bishop, J., Chadwick, J., Cristensen, N.D., Cuthill, S., Dunford, P., Field, A.K., Francis, J., Gibson, V., Greenham, A.K., Kelly, F., Kilkuskie, R., Kreider, J.W., Mills, J.S., Mulqueen, M., Roberts, N.A., Roberts, P., and Szymkowski, D.E. 2000. Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Res. 48:187-196. Lien, E., and Ingalls, R.R. 2002. Toll-like receptors. Crit. Care Med. 30:S1-S11. Messina, J.P., Gilkeson, G.S., and Pisetsky, D.S. 1991. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147:1759-1764. Pearson, A.M., Rich, A., and Krieger, M. 1993. Polynucleotide binding to macrophage scavenger receptors depends on the formation of basequartet-stabilized four-stranded helices. J. Biol. Chem. 268:3546-3554. Pisetsky, D.S. 1999. The influence of base sequence on the immunostimulatory properties of DNA. Immunol. Res. 19:35-46. Rankin, R., Pontarollo, R., Ioannou, X., Krieg, A.M., Hecker, R., Babiuk, L.A., and van den Hurk, S.v.d.L. 2001. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 11:333-340. Ro thenfusser, S., Hornung, V., Krug, A., Towarowski, A., Krieg, A.M., Endres, S., and Hartmann, G. 2001. Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-α/-β. Eur. J. Immunol. 31:3525-3534. Sato, Y., Roman, M., Tighe, H., Lee, D., Corr, M., Nguyen, M.D., Silverman, G.J., Lotz, M., Carson, D.A., and Raz, E. 1996. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273:352-354.
Krieg, A.M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
4.16.12 Supplement 12
Current Protocols in Nucleic Acid Chemistry
Shirota, H., Sano, K., Kikuchi, T., Tamura, G., and Shirato, K. 2000. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J. Immunol. 164:5575-5582. Shirota, H., Sano, K., Hirasawa, N., Terui, T., Ohuchi, K., Hattori, T., Shirato, K., and Tamura, G. 2001. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J. Immunol. 167:66-74. Sonehara, K., Saito, H., Kuramoto, E., Yamamoto, S., Yamamoto, T., and Tokunaga, T. 1996. Hexamer palindromic oligonucleotides with 5′-CG3′ motif(s) induce production of interferon. J. Interferon Cytokine Res. 16:799-803. Stacey, K.J., Sester, D.P., Sweet, M.J., and Hume, D.A. 2000. Macrophage activation by immunostimulatory DNA. Curr. Top. Microbiol. Immunol. 247:41-58. Takeshita, F., Leifer, C.A., Gursel, I., Ishii, K.J., Takeshita, S., Gursel, M., and Klinman, D.M. 2001. Role of Toll-like receptor 9 in CpG DNAinduced activation of human cells. J. Immunol. 167:3555-3558. Tang, J.Y., Roskey, A.R., Li, Y., and Agrawal, S. 1995. Enzymatic synthesis of stereoregular (all Rp) oligonucleotide phosphorothioate and its properties. Nucleosides Nucleotides 14:985989. Tighe, H., Takabayashi, K., Schwartz, D., Van Nest, G., Tuck, S., Eiden, J.J., Kagey-Sobotka, A., Creticos, P.S., Lichtenstein, L.M., Spiegelberg, H.L., and Raz, E. 2000a. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106:124-134. Tighe, H., Takabayashi, K., Schwartz, D., Marsden, R., Beck, L., Corbeil, J., Richman, D.D., Eiden, J.J. Jr., Spiegelberg, H.L., and Raz, E. 2000b. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30:1939-1947. Tokunaga, T., Yamamoto, H., Shimada, S., Abe, H., Fukuda, T., Fujisawa, Y., Furutani, Y., Yano, O., Kataoka, T., Sudo, T., Makiguchi, N., and Suganuma, T. 1984. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72:955-962. Van Uden, J., and Raz, E. 2000. Introduction to immunostimulatory DNA sequences. Springer Semin. Immunopathol. 22:1-9. Verthelyi, D., Ishii, K., Gursel, M., Takeshita, F., and Klinman, D. 2001. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J. Immunol. 166:2372-2377.
Verthelyi, D., Kenney, R.T., Seder, R.A., Gam, A.A., Friedag, B., and Klinman, D.M. 2002. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 168:1659-1663. Wernette, C.M., Smith, B.F., Barksdale, Z.L., Hecker, R., and Baker, H.J. 2002. CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. Vet. Immunol. Immunopathol. 84:223-236. Yamamoto, S., Yamamoto, T., Kataoka, T., Kuramoto, E., Yano, O., and Tokunaga, T. 1992a. Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity. J. Immunol. 148:4072-4076. Yamamoto, S., Yamamoto, T., Shimada, S., Kuramoto, E., Yano, O., Kataoka, T., and Tokunaga, T. 1992b. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol. Immunol. 36:983-997. Yamamoto, S., Yamamoto, T., Iho, S., and Tokunaga, T. 2000. Activation of NK cell (human and mouse) by immunostimulatory DNA sequence. Springer Semin. Immunopathol. 22:35-43. Yu, D., Kandimalla, E.R., Roskey, A., Zhao, Q., Chen, L., Chen, J., and Agrawal, S. 2000a. Stereo-enriched phosphorothioate oligodeoxynucleotides: Synthesis, biophysical and biological properties. Bioorg. Med. Chem. 8:275-284. Yu, D., Zhao, Q., Kandimalla, E.R., and Agrawal, S. 2000b. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg. Med. Chem. Lett. 10:2585-2588. Yu, D., Kandimalla, E.R., Zhao, Q., Cong, Y., and Agrawal, S. 2001a. Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg. Med. Chem. Lett. 11:2263-2267. Yu, D., Kandimalla, E.R., Zhao, Q., Cong, Y., and Agrawal, S. 2001b. Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg. Med. Chem. 9:2803-2808. Yu, D., Zhu, F.G., Bhagat, L., Wang, H., Kandimalla, E.R., Zhang, R., and Agrawal, S. 2002a. Potent CpG oligonucleotides containing phosphodiester linkages: In vitro and in vivo immunostimulatory properties. Biochem. Biophys. Res. Commun. 297:83-90. Yu, D., Kandimalla, E.R., Zhao, Q., Cong, Y., and Agrawal, S. 2002b. Immunostimulatory properties of phosphorothioate CpG DNA containing both 3′-5′- and 2′-5′-internucleotide linkages. Nucl. Acids Res. 30:1613-1619. Yu, D., Kandimalla, E.R., Cong, Y., Tang, J., Tang, J.Y., Zhao, Q., and Agrawal, S. 2002c. Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: Role of nucleosides in the flanking sequences. J. Med. Chem. 45:4540-4548.
Synthesis of Modified Oligonucleotides and Conjugates
4.16.13 Current Protocols in Nucleic Acid Chemistry
Supplement 12
Zhang, Y., Shoda, L.K., Brayton, K.A., Estes, D.M., Palmer, G.H., and Brown, W.C. 2001. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif. J. Interferon Cytokine Res. 21:871-881. Zhao, Q., Temsamani, J., Iadarola, P.L., Jiang, Z., and Agrawal, S. 1996. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem. Pharmacol. 51:173-182. Zhao, Q., Temsamani, J., Zhou, R.Z., and Agrawal, S. 1997. Pattern and kinetics of cytokine productio n fo llowing administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug. Dev. 7:495-502.
Zhao, Q., Yu, D., and Agrawal, S. 1999. Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg. Med. Chem. Lett. 9:3453-3458. Zhao, Q., Yu, D., and Agrawal, S. 2000. Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg. Med. Chem. Lett. 10:1051-1054.
Contributed by Ekambar R. Kandimalla and Sudhir Agrawal Hybridon, Inc. Cambridge, Massachusetts
Chemistry of CpG DNA
4.16.14 Supplement 12
Current Protocols in Nucleic Acid Chemistry
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Phosphorothioate Linkages
UNIT 4.17
Phosphorothioate analogs of oligonucleotides (PS-oligos) constitute an important tool for studying the metabolism of nucleic acids (Eckstein, 2000, and references therein) and have been evaluated as potential therapeutics in the so-called “antisense” (Stein and Krieg, 1998) and “antigene” strategies (Thuong and Helene, 1993). In 1998, the U.S. Food and Drug Administration (FDA) approved the first PS-oligo, Fomirvirsen (trade name, Vitravene), for therapeutic application against cytomegalovirus (CMV) retinitis (Manoharan, 1999). Most of the second-generation antisense compounds that are currently undergoing clinical trials are PS-oligos (e.g., Isis Pharmaceuticals, Hybridon; Maier et al., 2000). PS-oligos are isoelectronic with natural oligonucleotides and, importantly, they are much more resistant towards intra- and extracellular nucleases (Wickstrom, 1986). These features are important with respect to their therapeutic applications. However, substitution of sulfur for one nonbridging oxygen in the internucleotide phosphate group induces asymmetry at the phosphorus atom, and standard chemical methods for the synthesis of oligo(deoxyribonucleoside phosphorothioate)s provide a mixture of 2n diastereomers, where n is the number of phosphorothioate linkages (Wilk and Stec, 1995). Therefore, even for relatively short PS-oligos (10- to 15-mers), thousands of diastereomers would be involved in interactions with other chiral biomolecules (e.g., DNA, RNA, or proteins) and, in principle, each diastereomer might interact in a slightly different manner. The enzymatic synthesis of PS-oligos allows for the preparation of PS-oligonucleotides of RP-configuration at each phosphorothioate linkage (all-RP-PS-oligos) due to the stereoselectivity of all DNA and RNA polymerases identified to date (Hacia et al., 1994; Lackey and Patel, 1997; Tang et al., 1995). The first method for stereocontrolled chemical synthesis of PS-oligos, which was elaborated in the authors’ laboratory (Stec et al., 1991), is based on a new chemistry employing P-diastereomerically pure nucleoside monomers possessing the 2-thio-1,3,2-oxathiaphospholane moiety attached to appropriately protected nucleosides at the 3′-O position (S.1; Fig. 4.17.1). Further studies resulted in the synthesis of monomers with the oxathiaphospholane ring substituted at position 4 with either two methyl groups (S.2; Stec et al., 1995) or a spiro pentamethylene ring (S.3; Stec et al., 1998). These substituents enhance a differentiation in chromatographic mobility of diastereomers, rendering their separation less laborious. The oxathiaphospholane monomers react in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) with the 5′-OH group of a nucleoside (or growing oligonucleotide attached at the 3′ end to a DBU-resistant solid support) to yield a dinucleotide (or an elongated oligomer) with an internucleotide phosphorothioate diester bond, as depicted in Figure 4.17.2. The process is fully stereospecific and occurs with retention of configuration at the phosphorus atom. The chemical yield of the condensation process is not as efficient as that of the phosphoramidite or H-phosphonate methods (UNITS 3.3 & 3.4), but repetitive yields of 92% to 94% allow syntheses of medium-sized oligomers (up to 15-mers). Longer oligonucleotides were obtained in poor yields and the syntheses were not reproducible. Oxathiaphospholanes that are 18O-labeled at the endocyclic position allowed for the synthesis of PS-oligos with internucleotide PS[18O]-phosphorothioate moieties of predetermined chirality (Guga et al., 2001). Synthesis of Modified Oligonucleotides and Conjugates Contributed by Piotr Guga and Wojciech J. Stec Current Protocols in Nucleic Acid Chemistry (2003) 4.17.1-4.17.28 Copyright © 2003 by John Wiley & Sons, Inc.
4.17.1 Supplement 14
For the synthesis of stereodefined PS-oligos via the oxathiaphospholane methodology presented in this unit, pure P-diastereomers of nucleoside oxathiaphospholane monomers are required. They are not commercially available, but can be efficiently obtained by phosphitylation of widely available 5′-O-DMTr-N-protected deoxyribonucleosides with oxathiaphospholane phosphitylating reagent followed by sulfurization. The methodology of their synthesis and use in solid-phase synthesis of PS-oligos is presented in consecutive protocols. Basic Protocol 1 describes a detailed procedure for the synthesis of the phosphitylating reagent 2-chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane. The procedure is general and may be applied to other analogs, depending on the aldehyde (or mercaptoalcohol) used. Alternate Protocol 1 describes a procedure for synthesis of 18O-labeled mercaptoalcohol, which is used to synthesize labeled phosphitylating reagent and, subsequently, 18O-labeled nucleoside monomers. These can be used for synthesis of stereodefined PS[18O]oligos, which are useful compounds in studying the mechanism(s) of enzymatic reactions. Support Protocol 1 describes a method for transfer of dry solvents, required for this procedure. Basic Protocol 2 outlines the synthesis of 5′-O-DMTr-N-protected-deoxyribonucleoside3′-O-(2-thio-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane)s (S.3) and their chromatographic separation into P-diastereomers. This method, although described for dA, dC, dG, and T derivatives, can be also used for derivatizing other appropriately protected nucleosides. For example, in the authors’ laboratory, N6-benzoyl-7-deaza-5′-O(4,4′-dimethoxytrityl)-3′-O-(2-thio-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane)2′-deoxyadenosine was obtained and separated into diastereomers (unpub.). Similarly, this method is suitable for phosphitylation of protected nucleosides with other oxathiaphospholane reagents containing different substituents, although the separation of diastereo-mers may be very difficult. Alternate Protocol 2 describes the conversion of 5′-O-DMTr-N-protected-deoxyribonucleoside-3′-O-(2-thio-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane)s to their 2oxo-analogs with selenium dioxide. These monomers can be used to elongate stereodefined PS-oligos and generate segments of unmodified nucleotide units possessing phosphate internucleotide linkages. This goal cannot be achieved with the phosphoramidite or H-phosphonate methods, because the phosphorothioate linkages already
DMTrO
O
B
O X P 1
O 1 2 3 4 Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
X = S, X = S, X = S, X = O,
S
3
R
5
R
R=H R = CH 3 R,R = −(CH 2)5− R,R = −(CH 2)5−
Figure 4.17.1 Structural features of deoxyribonucleoside oxathiaphospholane derivatives. Abbreviations: B, thymin-1-yl or N-protected nucleobase; DMTr, 4,4′-dimethoxytrityl. Adapted from Stec et al. (1998) with permission from the American Chemical Society.
4.17.2 Supplement 14
Current Protocols in Nucleic Acid Chemistry
−
S O
OR′
P OR S DBU
O S
OR
P
S
ψ O
−
S
OR′
P
S
−
S
R′O RO
OR′
OR
DMTrO R=
O
P
−
S
O
B
O
−
O
S R′O RO
P
−
S
B
R′ = O Sar
Figure 4.17.2 Mechanism of base-promoted oxathiaphospholane ring-opening condensation. Abbreviations: B, thymin-1yl or N-protected nucleobase; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; DMTr, 4,4′-dimethoxytrityl; ψ, pseudorotation; Sar, sarcosinylated or DBU-resistant solid support.
generated by the oxathiaphospholane method are diesters and would be oxidized in the I2/water/pyridine routinely used for conversion of phosphites to phosphates. Basic Protocol 3 outlines details of manual solid-phase synthesis of PS-oligos using oxathiaphospholane monomers. In principle, this synthesis can be performed on an automatic synthesizer, but the necessary modification of the manufacturer’s protocols is impossible for the majority of synthesizers. The protocol for 1-µmol-scale automated solid-phase synthesis using an ABI 391 synthesizer (Applied Biosystems) has been published (Stec et al., 1998), but in many instances the software does not allow for any changes in the protocol. Also, the instrument should be able to deliver an additional solvent (methylene chloride) to the column in order to wash delivery lines after coupling. This is necessary to avoid formation of deposits inside the tubing and valves, which may lead to major failure of the instrument and expensive replacement of the clogged valve blocks. One also has to consider that, in using an automated synthesizer, significant amounts of monomer solutions are wasted during optimization of the protocol, and due to the dead volumes of the system. Therefore, manual synthesis of a limited number of oligomers may be economically more justified. Support Protocol 2 describes preparation of solid supports for the synthesis of PS-oligos, which must be DBU-resistant because this strong base is necessary for the coupling step. This requirement is fulfilled by the use of Brown’s sarcosinyl-succinoyl linker (Brown et al., 1989).
Synthesis of Modified Oligonucleotides and Conjugates
4.17.3 Current Protocols in Nucleic Acid Chemistry
Supplement 14
H
O
O S2Cl2
H
H
S
S
O
−HCl
HO NaBH4
S
propan-2-ol 6 (70%)
5
OH S
OH SH
7 (85%)
O
LiAlH4
PCl3
diethyl ether
pyridine
P Cl S
8 (70%)
9 (70%)
Figure 4.17.3 Synthesis of 2-chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane (S.9) starting from cyclohexanecarboxaldehyde (S.5). Adapted from Stec et al. (1998) with permission from the American Chemical Society.
CAUTION: It is imperative that all reactions be run in a suitable fume hood with efficient ventilation. Many of the reactions in this unit are highly exothermic; safety glasses and reagent-impermeable protective gloves should be worn. BASIC PROTOCOL 1
SYNTHESIS OF PHOSPHITYLATING REAGENT: 2-CHLORO-spiro-4,4-PENTAMETHYLENE-1,3,2-OXATHIAPHOSPHOLANE The most simple oxathiaphosphitylating reagent, 2-chloro-1,3,2-oxathiaphospholane, can be obtained from the reaction of 2-mercaptoethanol with phosphorus trichloride in the presence of two molar equivalents of triethylamine (Martynov et al., 1969; Willson et al., 1975; Stec et al., 1991). Condensation of an appropriately protected 3′-OH-nucleoside with 2-chloro-1,3,2-oxathiaphospholane in pyridine solution, performed in the presence of dry elemental sulfur, provides nucleoside 3′-O-(2-thiono-1,3,2-oxathiaphospholane)s (S.1; Fig. 4.17.1). However, their separation as P-diastereomers is very laborious and requires several consecutive silica gel chromatographic runs of partially enriched fractions. Therefore, it is recommended to synthesize 2-chloro-spiro-4,4-pentamethylene1,3,2-oxathiaphospholane (S.9) starting from cyclohexanecarboxaldehyde (S.5), as depicted in Figure 4.17.3. Using isobutyraldehyde in the same sequence of reactions, 2-chloro-4,4-dimethyl-1,3,2-oxathiaphospholane can be obtained. However, the phosphitylating reagent S.9, when used for synthesis of nucleotide monomers, provides much more useful compounds in terms of chromatographic separability as pure P-diastereomers. It is important to note that the fast-eluting isomers of 4,4-dimethyl- and 4,4-pentamethylene-oxathiaphospholane monomers are precursors of RP internucleotidic phosphorothioate bonds. Conversely, analog internucleotide phosphorothioate bonds of RP configuration are formed from the slow-eluting isomer of S.1.
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
Using this methodology, different analogs can be synthesized. However, it is important to obtain a phosphitylating reagent without additional centers of asymmetry, as the number of diastereomers will double with each new center, rendering separation of P-diastereomers very difficult or impossible. The relationship between chromatographic mobility and absolute configuration of the monomers must be checked for each new analog.
4.17.4 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Materials 4 to 5 M and 1.5 M sodium hydroxide (NaOH) Sulfur monochloride (S2Cl2), freshly distilled over 2 g elemental sulfur (S8; dried ≥12 hr under vacuum) per 50 mL S2Cl2 Argon (or, optionally, nitrogen), dry Cyclohexanecarboxaldehyde (Fluka) Methylene chloride Diethyl ether, anhydrous Sodium borohydride (NaBH4) Isopropyl alcohol Anti-bumping granules 20% (w/v) hydrochloric acid Chloroform Magnesium sulfate, anhydrous Hexane Lithium aluminum hydride Ethyl acetate, dry Tetrahydrofuran (THF), with traces of added moisture 10% (v/v) H2O/THF Phosphorus trichloride (PCl3) Benzene, anhydrous Pyridine Dry molecular sieves (4A, 4- to 6-µm-o.d. beads, Aldrich) 250-mL absorber with safety flask (see Fig. 4.17.4) 250-mL four-neck round-bottom flask Heated oil bath capable of magnetic stirring Thermometer (capable of reading 150°C) 100-mL dropping funnel Reflux condensers Glass gas inlet adapter (preferred) or syringe needle and rubber septum Rotary evaporator with a water aspirator and a diaphragm vacuum pump (10 to 15 mmHg; optional) 500-mL Erlenmeyer flask (29/42 joint) 1-L two-neck round-bottom flask (two 29/42 joints) Stopcock, 29/42 Flexible adapter (glass M/F joints, 29/42, on corrugated Teflon tubing; optional) 500-mL separatory funnel Filter funnel and Whatman no.1 filter paper (or equivalent) High-vacuum fractional distillation apparatus High-vacuum oil pump (0.01 mmHg) NOTE: Upon storage, cyclohexanecarboxaldehyde undergoes polymerization. Order only the amount required for use within 2 to 3 weeks. NOTE: Within this unit, evaporation of solvents is performed using a rotary evaporator connected to a water aspirator, unless otherwise specified.
Synthesis of Modified Oligonucleotides and Conjugates
4.17.5 Current Protocols in Nucleic Acid Chemistry
Supplement 14
to the hood
4 M NaOH safety flask
absorber
thermometer NOTE: glass gas adapter not shown
aldehyde sulfur monochloride
magnetic stir bar
oil bath 567 4 8 3 2 1 119
4 567 3 8 2 9 1 1
magnetic stirrer
Figure 4.17.4 System assembly for synthesis of S.6. The glass gas adapter (or septum and needle) for delivery of dry argon should be mounted in the fourth neck of the flask (not shown).
Synthesize 2,2′-dithiobis(cyclohexanecarbaldehyde) (S.6) 1. Prepare a 250-mL absorber containing ∼150 mL of 4 to 5 M NaOH (see Fig. 4.17.4). 2. Assemble a reactor consisting of a 250-mL four-neck, round-bottom flask (to be heated in an oil bath with magnetic stirring) equipped with a thermometer, a 100-mL dropping funnel, a condenser, and a magnetic stir bar. Connect the outlet of the condenser via a safety flask to the absorber and be sure that the absorber vents into the hood. The capacity of the safety flask must be sufficient to accommodate the solution of sodium hydroxide from the absorber.
3. Add 30 g (17.8 mL, 0.22 mol) of freshly distilled sulfur monochloride to the flask. Make sure that the thermometer is in contact with the liquid. Deliver dry argon close to the bottom of the flask through the fourth joint either with a glass gas inlet adapter or with a syringe needle inserted through a rubber septum. Since gaseous hydrogen chloride is liberated from the reaction, the use of a glass inlet adapter, rather than a syringe needle, is recommended.
4. Apply heating until sulfur monochloride reaches 60°C. Stabilize the temperature. Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
5. Add, dropwise through the dropping funnel, 50 g (56 mL, 0.44 mol) of cyclohexanecarboxaldehyde over a 60-min period with stirring, keeping the temperature at 60°C. Remove the oil bath and allow the mixture to continue stirring another 10 min.
4.17.6 Supplement 14
Current Protocols in Nucleic Acid Chemistry
6. Stop stirring and remove the stir bar. Leave the reaction mixture until it reaches room temperature and solidifies (∼1 hr). 7. Dissolve the solid residue in 150 mL of methylene chloride, then evaporate to dryness using a rotary evaporator connected to a water aspirator. CAUTION: During evaporation gaseous hydrogen chloride is liberated.
8. Add 150 mL of diethyl ether and gently reflux until the solid residue is dissolved. Transfer the solution into a 500-mL Erlenmeyer flask and close the stopcock. Cool down the mixture (containing the synthesized S.6) and keep overnight in a refrigerator (4°C) to allow crystallization. Collect crystalline S.6 by filtration. Approximately 35 g of 2,2′-dithiobis(cyclohexanecarbaldehyde) (S.6) should be collected as a white solid (∼70% yield, m.p. 88° to 89°C). 1H NMR (CDCl3, δ): 8.98 ppm (s, 1H, CHO), 1.2-2.1 ppm (m, 10H). FAB MS (positive mode, Cs+, 13 keV, matrix NBA) m/z 286, [M]+, 25%; m/z 111, [C6H10CHO]+, 100%.
Synthesize 2,2′-dithiobis(cyclohexanemethanol) (S.7) 9. In a 1-L two-neck flask (two 29/42 joints), equipped with a reflux condenser and a stopcock, suspend 5.67 g (0.15 mol) of NaBH4 in 500 mL isopropyl alcohol. Add anti-bumping granules and heat to boiling. 10. While gently refluxing, remove the stopcock momentarily and add, with a chemical spoon, ∼2 g of S.6 every 3 to 5 min in 10 to 12 portions for a total of 21.5 g (0.075 mol). CAUTION: The addition of each portion of 2,2′-dithiobis(cyclohexanecarboxaldehyde) results in enhanced boiling and emission of vapors of isopropyl alcohol through the open neck. The stopcock should thus be closed as soon and possible. Alternatively, one can use a flexible adapter (glass M/F joints on corrugated Teflon tubing) for stepwise delivery of 2,2′-dithiobis(cyclohexanecarboxaldehyde) without opening the reactor.
11. Reflux the mixture for 1 hr, then evaporate to dryness and add 200 mL of 1.5 M sodium hydroxide. 12. Cautiously neutralize the mixture with 20% hydrochloric acid, checking pH with indicator strips. 13. Transfer the mixture to a 500-mL separatory funnel and extract the solution twice, each time with 150 mL chloroform. Dry the organic layer with anhydrous magnesium sulfate and evaporate the solvent. 14. Dissolve the product in 200 mL of diethyl ether and add, with stirring, a few 3- to 5-mL aliquots of hexane until the mixture becomes translucent. Leave in a refrigerator (4°C) overnight for crystallization. Collect crystalline S.7 by filtration. Approximately 19 g of 2,2′-dithiobis(cyclohexanemethanol) (S.7) should be collected as a colorless crystalline material (85% to 88% yield, m.p. 49° to 50°C). 1H NMR (CDCl3, δ): 3.54 ppm (s, 2H, CH2OH), 2.23 ppm (s, 1H, CH2OH), 1.2-1.8 ppm (m, 10H). 13C NMR (CDCl3, δ): 21.9, 25.73, 32.45, 56.18, 67.99 ppm. FAB MS (positive mode, Cs+, 13 keV, matrix NBA) m/z 290, [M]+, 45%; m/z 273, [M-OH]+, 25%; m/z 113, [C6H10CH2OH]+, 100%.
Synthesize 2-mercaptocyclohexanemethanol (S.8) 15. In a 1-L two-neck flask equipped with a reflux condenser and a dropping funnel (atmosphere of dry argon or nitrogen) suspend 5.9 g (0.16 mol) lithium aluminum hydride in 500 mL of dry diethyl ether. CAUTION: The suspension of lithium aluminum hydride in diethyl ether is highly flammable. Advise coworkers of the hazard and keep an appropriate fire extinguisher at hand.
Synthesis of Modified Oligonucleotides and Conjugates
4.17.7 Current Protocols in Nucleic Acid Chemistry
Supplement 14
16. Add dropwise through the dropping funnel a solution of 4.6 g (0.16 mol) S.7 in 150 mL of diethyl ether over 60 min with magnetic stirring. Continue stirring for an additional 60 min. The reaction is exothermic and mild reflux occurs.
17. Cautiously decompose excess reducing agent by adding dropwise through the funnel 3 mL of dry ethyl acetate, followed by 10 mL THF containing traces of moisture, and then ∼10 mL of 10% water/THF, until the solid suspension becomes gray and finally white. 18. Filter off inorganic salts using a filter funnel and Whatman no. 1 filter paper, and dry the filtrate over anhydrous magnesium sulfate. Filter off the drying agent and evaporate the filtrate to dryness. 19. Distill the residue in a high-vacuum fractional distillation apparatus under reduced pressure (0.05 mmHg, provided by high-vacuum oil pump). Collect the fraction boiling between 74° and 76°C, which contains S.8. CAUTION: Avoid overheating the vessel. Keep pressure below 0.1 mmHg. Approximately 3.2 g of 2-mercaptocyclohexanemethanol (S.8) should be collected as a colorless oil (70% yield, nD20 = 1.5188). 1H NMR (CDCl3, δ): 3.49 ppm (s, 2H, CH2OH), 2.15 ppm (bs, 1H, CH2OH), 1.31 ppm (s, 1H, CHSH), 1.15-1.85 ppm (m, 10H). 13C NMR (CDCl3, δ): 22.0, 26.07, 36.06, 52.34, 73.12 ppm. FAB MS (negative mode, Cs+, 13 keV, matrix GLY) m/z 145, [M]–, 100. FAB MS (positive mode, Cs+, 13 keV, matrix GLY) m/z 113, [C6H10CH2OH]+, 45%; m/z 129, [C6H10SHCH2]+, 20%.
Synthesize 2-chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane (S.9) 20. In a 1-L two-neck flask equipped with a thermometer and a dropping funnel, add 28.2 g (0.21 mol) PCl3 to 500 mL of dry benzene under an argon (optionally nitrogen) atmosphere. Cool the flask to 5°C with an ice bath. Add, dropwise through the funnel, a solution of 20 g (0.14 mol) S.8 and 22 mL (0.27 mol) pyridine in 35 mL dry benzene over a 15-min period with magnetic stirring. Keep the temperature of the reaction mixture below 10°C. 21. Continue stirring at room temperature for 30 min and filter off pyridine hydrochloride with exclusion of moisture. Load the reaction mixture in a filter funnel inside a bag filled with dry argon (or nitrogen) and gently apply suction to keep the bag slightly inflated with continuous delivery of dry gas. 22. Evaporate the solvent under reduced pressure with exclusion of moisture (preferably in a rotary evaporator equipped with a diaphragm vacuum). If a water aspirator must be used, insert a drying tube filled with blue indicator silica gel between the rotary evaporator and the aspirator to reduce the risk of hydrolysis of the product. Apply vacuum gently.
23. Distill the product in a high-vacuum fractional distillation apparatus under reduced pressure (0.01 mmHg, provided by a high-vacuum oil pump). Collect the fraction boiling between 82° and 84°C, which contains S.9. CAUTION: Avoid overheating the vessel. Keep pressure at 0.01 mmHg. When overheated, spontaneous decomposition of the crude product may occur, leading to destruction of the apparatus.
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
Approximately 20 g of 2-chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane (S.9) should be collected as a colorless liquid (70% to 75% yield). 31P NMR (C6D6; δ) 217.7 ppm; EI (electron impact) MS: (70 eV) m/z 210, [M]+, 12%; m/z 175, [M-Cl]+, 5.8%; m/z 90, 100%.
24. Store S.9 in a tightly closed vessel inside another tightly closed container filled with several grams of dry 4A molecular sieves at –20°C (stable for at least 1 year).
4.17.8 Supplement 14
Current Protocols in Nucleic Acid Chemistry
SYNTHESIS OF 2,2′-DITHIOBIS([18O]CYCLOHEXANECARBOXALDEHYDE) The 18O-labeled 2,2′-dithiobis(cyclohexanecarboxaldehyde), which can be further transformed into the corresponding phosphitylating reagent as described in Basic Protocol 1, is obtained by hydrolysis of the N-phenylimine derivative of 2,2′-dithiobis(cyclohexanecarboxaldehyde) with H2[18O], catalyzed with gaseous hydrogen chloride (Fig. 4.17.5). The N-phenylimine derivative is obtained from 2,2′-dithiobis(cyclohexanecarboxaldehyde) (S.6; see Basic Protocol 1, step 8) upon treatment with aniline.
ALTERNATE PROTOCOL 1
Additional Materials (also see Basic Protocol 1) 2,2′-Dithiobis(cyclohexanecarboxaldehyde) (S.6; see Basic Protocol 1, step 8) Aniline, freshly distilled in inert atmosphere 95:5 (v/v) chloroform/hexane H2[18O] (95 atom%) Hydrogen chloride, anhydrous Tetrahydrofuran (THF), dried over sodium hydride 250-mL two-neck round-bottom flasks Azeotropic trap (e.g., mini Dean-Stark trap, Aldrich) 8 × 40–cm chromatography column packed with silica gel 60, 230 to 400 mesh (Merck) Rubber septum TLC silica gel plates with UV indicator (Merck; also see APPENDIX 3D) High vacuum valve (e.g., Rotaflo, Quickfit) Drying tube (8 × 5⁄8 in. with connectors, Aldrich) 2- to 5-mL gas-tight syringe Rotary evaporator with water aspirator or membrane pump Buchner funnel with glass frit Additional reagents and equipment for column chromatography (APPENDIX 3E), thin-layer chromatography (TLC; APPENDIX 3D), and high-vacuum transfer of solvent (see Support Protocol 1)
O
H S
H S
O
PhN
NPh S
PhNH2
S
−H2O 6
10 18O
18
[ O ]-H2O
H S
H S
HCl
18O
18O
1. NaBH 4
P Cl S
2. LiAlH 4 3. PCl 3 11
12
Figure 4.17.5 Synthesis of 2-chloro-spiro-4,4-pentamethylene-1,3,2-[18O]oxathiaphospholane (S.12) starting from 2,2′-dithiobis(cyclohexanecarboxaldehyde) (S.6).
Synthesis of Modified Oligonucleotides and Conjugates
4.17.9 Current Protocols in Nucleic Acid Chemistry
Supplement 15
Synthesize N-phenylimine derivative of 2,2′-dithiobis(cyclohexanecarboxaldehyde) (S.10) 1. In a 250-mL two-neck flask equipped with an azeotropic trap, reflux condenser, and dropping funnel, dissolve 14.3 g (0.05 mol) of 2,2′-dithiobis(cyclohexanecarboxaldehyde) (S.6) in 150 mL benzene. Add anti-bumping granules and heat to boiling. 2. Add, dropwise through the dropping funnel, a solution of 10.0 mL (10.2 g, 0.11 mol) aniline in 25 mL benzene over a 30-min period. Continue the reaction for 30 min, keeping gently boiling with azeotropic removal of liberated water. The end of the reaction is confirmed by disappearance of a resonance line of the aldehyde proton in the 1H NMR spectrum.
3. Cool the reaction mixture to room temperature and evaporate the solvent under reduced pressure using a rotary evaporator with a water aspirator. 4. Dissolve the residue in 15 to 20 mL of benzene and apply to an 8 × 40–cm chromatography column packed with ∼200 g of 230 to 400 mesh silica gel. 5. Elute the column with chloroform and collect the eluate in 12- to 15-mL fractions. 6. Analyze fractions by TLC on silica gel plates (APPENDIX 3D). Develop TLC plates with 95:5 (v/v) chloroform/hexane. 7. Combine all fractions that contain the desired product (S.10; Rf = 0.55). Evaporate the solvent under reduced pressure. Typically 18 g (80% yield) of the N-phenylimine derivative (S.10; see Fig. 4.17.5) should be obtained. 1H NMR (CDCl3, δ): 6.67-6.80 ppm (m, 1H), 7.07-7.55 ppm (m, 4H), 3.6 ppm (very broad singlet, 1H, CH=NPh), 1.29-2.18 ppm (m, 10H). 13C NMR (CDCl3, δ): 22.8, 24.88, 25.22, 30.05, 30.15, 33.23, 56.13, 56.793, 60.13, 60.62, 76.38, 77.01, 77.65, 114.84, 118.14, 120.63, 120.69, 125.42, 125.69, 128.11, 128.78, 129.00, 146.28, 150.99, 151.33, 164.78, 165.62, 194.09, 194.77. This number of resonances in the 13C NMR spectrum reflects the presence of cis- and trans-isomers of the N-phenylimine derivative.
Synthesize labeled 2,2′-dithiobis([18O]cyclohexanecarboxaldehyde) (S.11) 8. Place 16 g (0.037 mol) S.10 in a 250-mL two-neck round-bottom flask with a magnetic stir bar inside, with a high-vacuum valve in one joint and a rubber septum in the other, and dry overnight at high vacuum (0.01 mmHg; provided by high-vacuum oil pump). At the end of drying, deliver dry argon gas to the flask through the septum. 9. Prepare an absorber containing ∼150 mL of 4 to 5 M NaOH (see Basic Protocol 1, step 1). 10. Using the vacuum line technique (see Support Protocol 1), transfer ∼100 mL of dry THF to the flask containing S.10. 11. Connect the vacuum valve with the absorber through an 8 × 5⁄8–in. drying tube (filled with anhydrous magnesium sulfate) and a safety flask (Fig. 4.17.4). 12. Add 1.8 mL (0.9 mol) H2[18O] (20% excess) with a 2- to 5-mL gas-tight syringe. 13. Flush the apparatus continously with dry argon and cool the mixture to <5°C in an ice bath.
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
14. Remove the septum and quickly install a glass gas inlet adapter for delivery of hydrogen chloride. Adjust the adapter so that its end is ∼1.5 to 2 cm above the level of the liquid. 15. Slowly deliver anhydrous hydrogen chloride with magnetic stirring of the mixture. Precipitation of anilinium hydrochloride should be observed during this process.
4.17.10 Supplement 15
Current Protocols in Nucleic Acid Chemistry
16. Continue hydrolysis until the reaction mixture becomes pale green-yellow. Remove ice bath and allow the mixture to reach room temperature. 17. Filter off the precipitate using a Buchner funnel. Wash twice with 20 to 30 mL THF. 18. Combine filtrates and evaporate solvent under reduced pressure. CAUTION: The THF vapor will be strongly acidic, as it is saturated with hydrogen chloride.
19. Dissolve the residue in 100 mL of THF and evaporate the solvent again. 20. Dissolve the residue in diethyl ether and crystallize by cooling (see Basic Protocol 1, step 8). 21. Analyze the product using electron impact (EI) mass spectrometry. Each aldehyde group of the final product is isotopically labeled to the extent of 87%. The spectrum should contain three peaks at m/z 286, 288, and 290, corresponding to the unlabeled, singly labeled, and doubly labeled compounds, respectively. The intensities of the ions are 1.7%, 22.6%, and 75.7%, respectively. The isotope content remains unchanged during subsequent reactions leading to the final phosphitylating reagent.
22. Continue the synthesis (see Basic Protocol 1, starting from step 9). HIGH-VACUUM TECHNIQUE FOR TRANSFER OF DRY SOLVENTS This technique allows for transfer of dry solvents from a reservoir (where the solvent is stored over a drying reagent such as sodium hydride) into a reaction flask with exclusion of moisture. For successful transfer, the quality of vacuum valves is absolutely essential. Figure 4.17.6 shows principal construction of the apparatus, which can be assembled from generic glassware. All components must be tested to make sure that they are safe for high-vacuum usage (i.e., at <0.5 mmHg).
SUPPORT PROTOCOL 1
1. Set up the apparatus as shown in Fig. 4.17.6, but leave the flask containing THF over NaH not yet immersed in the warm water bath and the receiving flask not yet immersed in the dry ice/isopropanol bath. 2. Close high-vacuum valves A and B. 3. Attach the apparatus to high vacuum (<0.5 mmHg). 4. Open valve B for several seconds. 5. Close valve B. 6. Open valve A for several seconds. If gentle boiling of THF is observed, go to step 9. 7. Close valve A. 8. Decrease the pressure in the system by repeating steps 4 to 7. 9. While valve B is closed, immerse the receiving flask in the dry ice/isopropanol bath. 10. Immerse the reservoir in the warm water bath (∼50° to 55°C). Alternatively, use a hair dryer to provide heat to the reservoir. 11. After the required volume of solvent has been transferred, stop heating and remove the dry ice bath. Allow both flasks to reach ambient temperature. 12. Disconnect the apparatus from the high vacuum and attach the outlet to a line with dry argon.
Synthesis of Modified Oligonucleotides and Conjugates
4.17.11 Current Protocols in Nucleic Acid Chemistry
Supplement 15
to high vacuum
valve B
valve A
dry ice/isopropanol bath THF over NaH warm water bath Figure 4.17.6 Apparatus for high-vacuum transfer of dry solvents.
13. Open valve B and fill the system with argon. 14. Close valves A and B. 15. Disconnect the flask with transferred solvent and close immediately with a stopcock or septum. BASIC PROTOCOL 2
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
SYNTHESIS OF 5′-O-DMTr-DEOXYRIBONUCLEOSIDE-3′-O-(2-THIO-4,4spiro-PENTAMETHYLENE-1,3,2-OXATHIAPHOSPHOLANE)S AND THEIR SEPARATION INTO P-DIASTEREOMERS The oxathiaphospholane method of stereocontrolled synthesis of PS-oligos, depicted in Figure 4.17.2, is based on availability of diastereomerically pure oxathiaphospholane monomers S.1-S.3. Separation of monomers S.1 and S.2 as pure P-diastereomers requires tedious silica gel column chromatography or costly preparative HPLC. Monomer S.3, obtained by introducing a pentamethylene substituent at position 4 of the oxathiaphospholane ring, possesses a satisfactory separability of diastereomers. Appropriate 5′-ODMTr-N-protected deoxyribonucleosides are phosphitylated at room temperature with S.9 or S.12 in acetonitrile, in the presence of diisopropylethylamine, to yield the corresponding phosphites, which are further sulfurized with elemental sulfur. Silica gel column chromatography affords S.3 (or its 18O-labeled analog) as a diastereomeric mixture in satisfactory yield (75% to 85%). The deoxyguanosine derivative of S.3 should be additionally protected at O6 with diphenylcarbamoyl chloride to improve the yield of the condensation step. Without this protection, the repetitive yield of condensation of the deoxyguanosine oxathiaphospholane monomer drops below 90%. The S.3 monomers (B = T, ABz, CBz, Gi-Bu,DPC) are separated by column chromatography into fast- and sloweluting species. The stereochemistry of the coupling has been checked for each of 32 combinations of diastereomeric dinucleotides NPSN (N = dG, dA, dC, T). All four fast-eluting diastereomers of S.3 are precursors of the dinucleoside 3′,5′-phosphorothioates of RP configuration. Slow-eluting isomers of S.3 yield phosphorothioate linkages of SP configuration.
4.17.12 Supplement 15
Current Protocols in Nucleic Acid Chemistry
NOTE: It is important to use acid-free eluents for all silica gel chromatography of the monomers to avoid partial detritylation of the products. This can be done by distillation of chloroform with 1 mL pyridine, and then by adding 2 to 3 mL pyridine per liter of all eluents (chloroform and mixtures of ethyl acetate, butyl acetate, and benzene). Materials 5′-O-DMTr-N-protected deoxyribonucleosides (Chemgenes): N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine (5′-O-DMTr-dABz) N2-Isobutyryl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyguanosine (5′-O-DMTr-dGi-Bu) N4-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxycytidine (5′-O-DMTr-dCBz) 5′-O-(4,4′-Dimethoxytrityl)-2′-deoxythymidine (5′-O-DMTr-T) Argon (or, optionally, nitrogen), dry Acetonitrile, anhydrous 2-Chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane (S.9 or labeled S.12; see Basic Protocol 1 or Alternate Protocol 1) Elemental sulfur, anhydrous (dried overnight at high vacuum) Chloroform (distilled with 1 mL pyridine per L) Toluene, dry Pyridine, anhydrous Diisopropylethylamine (Aldrich), anhydrous Diphenylcarbamoyl chloride (Aldrich) 9:1 (v/v) chloroform/methanol Merck 60H silica gel, particle size 5 to 40 µm Ethyl acetate Butyl acetate Benzene 25-mL two-neck round-bottom flasks High-vacuum valve (Rotaflo, Quickfit) Rubber septum High-vacuum oil pump (0.01 mmHg) 2-mL and 10-mL gas-tight syringes Buchner funnel 25 × 3–cm chromatography column packed with 20 g of 230 to 400 mesh silica gel TLC silica gel plates with UV indicator (Merck; also see APPENDIX 3D) Constant temperature water bath 30 × 2–cm chromatography column Filter paper (Whatman no. 1) High-performance TLC (HP-TLC) plates (silica gel 60 F254) with UV indicator (Merck; also see APPENDIX 3D) Additional reagents and equipment for column chromatography (APPENDIX 3E) and thin-layer chromatography (TLC; APPENDIX 3D) Phosphitylate protected deoxyribonucleosides 1. Place 10 mmol of 5′-O-DMTr-N-protected deoxyribonucleoside (dABz, dGi-Bu, T, or dCBz) in a 25-mL two-neck round-bottom flask containing a magnetic stir bar, with a high-vacuum valve in one joint and a rubber septum in the other, and dry overnight at high vacuum (0.01 mmHg; provided by high-vacuum oil pump). 2. Close the vacuum valve and fill the flask with dry argon (optionally nitrogen). 3. Using a gas-tight syringe, add 10 mL of anhydrous acetonitrile through the septum. 4. Using a gas-tight syringe, add 1.91 mL (11 mmol) of anhydrous diisopropylethylamine.
Synthesis of Modified Oligonucleotides and Conjugates
4.17.13 Current Protocols in Nucleic Acid Chemistry
Supplement 15
5. To the magnetically stirred solution, using a gas-tight syringe, add dropwise at room temperature 1.63 mL (2.32 g, 11 mmol) of 2-chloro-spiro-4,4-pentamethylene-1,3,2oxathiaphospholane (S.9) over a 5-min period. 6. Stir an additional 5 min and add ∼0.5 g (∼15 mmol) dry elemental sulfur. Continue stirring for 12 hr. 7. Filter off excess sulfur using a Buchner funnel. Evaporate the solvent and dissolve the residue in 4 mL of chloroform (distilled with pyridine). 8. Apply crude product to a 25 × 3–cm column packed with 20 g of 230 to 400 mesh silica gel. Elute the column with chloroform, collecting 8- to 10-mL fractions. Identify the appropriate fractions by TLC (APPENDIX 3D) using standard silica gel plates and 95:5 (v/v) CHCl3/methanol (Rf = 0.6575). Combine fractions and evaporate the solvents under reduced pressure (15 to 20 mmHg) with a water bath temperature not exceeding 30°C. 9. Add 5 to 6 mL of dry toluene and evaporate to dryness with exclusion of moisture using a membrane pump. Repeat this step twice. After the solvent is evaporated, apply high vacuum to the flask for 2 hr. Close the flask with a septum and pierce the septum with a needle. Store the flask in a desiccator and apply high vacuum for ≥12 hr. The monomers can be stored at room temperature in a desiccator for a month. Th e desired 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-thio-spiro-4,4-pentamethylene1,3,2-oxathiaphospholane)s are obtained in 75% to 85% yield. For the guanosine derivative, diphenylcarbamoyl protection at O6 is required (steps 10 to 15). The diastereomeric composition, 31P NMR chemical shifts, and TLC parameters (HP-TLC plates) of compounds S.3a to c are given in Table 4.17.1. Elemental analysis (found/calculated): S.3a (B = T) C 61.67%/60.79%, H 6.15%/5.77%, N 3.73%/3.73%, P 4.06%/4.13%, S 8.00%/8.54%; S.3b (B = ABz) C 62.84%/62.56%, H 5.48%/5.37%, N 7.73%/8.11%, P 3.41%/3.58%, S 6.74%/7.42%; S.3c (B = CBz) C 62.53%/62.92%, H 5.47%/5.52%, N 5.14%/5.00%, P 3.65%/3.69%, S 7.26%/7.63%.
Table 4.17.1 Characteristics of the 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-thio-spiro-4,4pentamethylene-1,3,2-oxathiaphospholane)sa
Base
Yield (%)
Composition (fast:slow)
δP (ppm, CD3CN)
Rf (TLC)b
T (3a)
84
50:50
ABz (3b)
84
49:51
CBz (3c)
86
48:52
Gi-Bu,DPC (3d)
78
52:48
105.3 (fast) 105.6 (slow) 104.7 (fast) 105.1 (slow) 105.3 (fast) 105.6 (slow) 106.2 (fast)d 106.9 (slow)d
0.61 (fast) 0.54 (slow) 0.54 (fast) 0.46 (slow) 0.60 (fast) 0.40 (slow) 0.37 (fast)c 0.26 (slow)c
aTable adapted from Stec et al. (1998) with permission from the American Chemical Society. bTLC performed on HP-TLC plates with UV indicator (Merck) and a developing system of 1:1 (v/v) butyl acetate/benzene
(T and Gi-Bu) or 1:2 (v/v) ethyl acetate/butyl acetate (ABz and CBz).
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
cR values reported for monomers before O6-protection with diphenylcarbamoyl chloride (DPC). After protection, R f f
values are 0.74 and 0.63 using the same solvent system. dδ values reported for monomers after O6-protection with DPC. P
4.17.14 Supplement 15
Current Protocols in Nucleic Acid Chemistry
Perform O6 protection of deoxyguanosine derivative 10. Place 0.85 g (1 mmol) of N2-isobutyryl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(2-thiospiro-4,4-pentamethylene-1,3,2-oxathiaphospholanyl)-2′-deoxyguanosine (from step 9) in a two-neck 25-mL round-bottom flask with a magnetic stir bar, with a high-vacuum valve in one neck and a rubber septum in the other, and dry overnight at high vacuum (0.01 mmHg). 11. Using a 10-mL gas-tight syringe, add 5 mL of anhydrous pyridine. 12. Using a 2-mL gas-tight syringe, add 0.26 mL (1.5 mmol) diisopropylethylamine and 0.46 g (2.0 mmol) diphenylcarbamoyl chloride, with stirring, at room temperature. Continue stirring mixture 1 hr. 13. Concentrate mixture to dryness, dissolve in 1.5 mL of chloroform, and apply on a 25 × 3–cm column packed with 20 g of 230 to 400 mesh silica gel. Elute the column with 300 mL chloroform, collecting 10- to 12-mL fractions. 14. Analyze fractions by TLC (APPENDIX 3D) on standard silica gel plates. Develop TLC plates with 9:1 (v/v) chloroform/methanol. 15. Combine all fractions that contain the desired product (Rf = 0.79). Evaporate the solvents under reduced pressure (15 to 20 mmHg) with the temperature of the water bath not exceeding 35°C. Dissolve the residue in dry toluene and evaporate the solvent. Store the pure product S.3d (a pale yellow oil) in a tightly closed vessel. Approximately 0.95 g (90% to 95% yield) should be isolated. MS. (+FAB) m/z 1041.6 (M+, 1%), m/z 1042.6 (M++1, 0.6%), m/z 303.2 (DMTr+, 100%). Elemental analysis(found/calculated): C 63.60%/63.44%, H 5.78%/5.52%, N 7.77%/8.08%, P 2.72%/2.98%, S 5.78%/6.15%. The diastereomeric composition, 31P NMR chemical shifts, and TLC parameters (HP-TLC plates) of S.3d are given in Table 4.17.1.
Separate diastereomers of S.3a to d 16. The day before separation, load a 30 × 2–cm column with a degassed suspension of ∼20 g of silica gel (Merck 60H, particle size 5 to 40 µm) in ∼100 mL of the appropriate mixture of solvents: 2:1:0.003 (v/v/v) ethyl acetate/butyl acetate/pyridine for dA and dC derivatives 1:2:0.003 (v/v/v) ethyl acetate/butyl acetate/pyridine for dG derivative 1:1:0.002 (v/v/v) butyl acetate/benzene/pyridine for T monomer. Gently cover the top surface of the gel with a disc of Whatman no.1 filter paper of diameter close to the inside diameter of the column. Flush the column with 150 mL of the eluant. Maintain a 2- to 3-mm layer of eluant over the gel. IMPORTANT NOTE: Because the differences in chromatographic mobilities of P-diastereomers are very small, the glass frit must be mounted within the cylindrical part of the column to assure undisturbed, laminar flow of the eluant. To achieve good resolution, the column should be packed with the silica gel suspension at least 24 hr before chromatography. Since isocratic elution is used for the separation, the same column may be used for two to three consecutive separations of a given monomer.
17. Dissolve ∼300 mg of a monomer (mixture of diastereomers) in 1.5 mL of the appropriate eluant (see step 16) and apply gently on the gel. 18. Elute the column with 300 mL of appropriate eluant and collect 10- to 12-mL fractions. Analyze fractions by TLC on HP-TLC plates (Table 4.17.1). Combine appropriate fractions and concentrate to dryness under reduced pressure (15 to 20 mmHg) with the temperature of the water bath not exceeding 35°C.
Synthesis of Modified Oligonucleotides and Conjugates
4.17.15 Current Protocols in Nucleic Acid Chemistry
Supplement 15
19. Evaporate the pure diastereomers twice with anhydrous toluene, with exclusion of moisture, and store in a tightly closed vessel for up to 1 month at room temperature. Typically, for dA, dT, and dC monomers, one passage gives 75% to 80% separated diastereomers of 96% to 100% diastereomeric purity, as assessed by 31P NMR. For the dG derivative, the “fast” isomer is usually obtained in lower yield (28% to 30%, 100% diastereomeric purity) while the “slow” isomer is obtained in ∼50% yield, but only of 90% diastereomeric purity, and must be rechromatographed. ALTERNATE PROTOCOL 2
SYNTHESIS OF 5′-O-DMTr-DEOXYRIBONUCLEOSIDE-3′-O-(2-OXO-spiro4,4-PENTAMETHYLENE-1,3,2-OXATHIAPHOSPHOLANE)S 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-oxo-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane)s (S.4) are synthesized from their corresponding 2-thio monomers (S.3; see Basic Protocol 2) and can be used to elongate PS-oligos obtained via the oxathiaphospholane approach and thereby generate short unmodified oligonucleotide segments. This goal cannot be achieved using standard phosphoramidite chemistry because, during the routine oxidation step by means of I2/water/pyridine, the diester phosphorothioate linkages already present in the oligomer would undergo PS-to-PO conversion. The oligonucleotide synthesis protocol differs from that used for the synthesis of PS-oligos in the following ways: (1) because of their relatively low stability, the 2-oxo-monomers should not be repurified before synthesis (see Basic Protocol 3, step 1); and (2) the amount of DBU necessary for condensation (step 16) may be reduced by 50%. Materials 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-thio-spiro-4,4-pentamethylene-1,3,2oxathiaphospholane)s (S.3; see Basic Protocol 2) Silica gel 60, 230 to 400 mesh Acetonitrile, anhydrous Argon (or, optionally, nitrogen), dry Selenium dioxide, anhydrous (dried overnight at high vacuum) 95:5 (v/v) chloroform/methanol (distill chloroform with 1 mL pyridine per L) Two-neck 10-mL round-bottom flask High-vacuum valve (e.g., Rotaflo, Quickfit) Rubber septum High-vacuum oil pump 10-µmol-scale DNA synthesis column 1- to 2-mL polypropylene syringes with luer ends 5-mL gas-tight syringe TLC silica gel plates with UV indicator (Merck; also see APPENDIX 3D) 10-mL gas-tight syringe Luer male-to-male adapter Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D) CAUTION: Selenium dioxide is toxic.
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
1. Place ∼300 mg of 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-thio-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane) (S.3) in a two-neck 10-mL round-bottom flask containing a magnetic stir bar, with a high-vacuum valve in one joint and a rubber septum in the other, and dry overnight at high vacuum (0.01 mmHg; provided by high-vacuum oil pump).
4.17.16 Supplement 15
Current Protocols in Nucleic Acid Chemistry
2. Assemble a 10-µmol-scale DNA synthesis column filled to 80% of its volume with silica gel 60 (230 to 400 mesh). Wash the gel three times, each time with 5 mL anhydrous acetonitrile. Apply a stream of dry argon and continue drying for 15 to 20 min after the gel loosens. Close both ends of the column with two 1- to 2-mL luer syringes to eliminate contact with atmospheric moisture. The dryness of the gel in the column is crucial for stability of the product. Every effort should be made to protect the dried gel from moisture.
3. Close the vacuum valve on the flask containing dried S.3 and fill the flask with dry argon. 4. Using a 5-mL gas-tight syringe, add 4 mL of anhydrous acetonitrile. 5. With continuous flow of dry argon, remove the vacuum valve and add, in several portions, ∼80 mg selenium dioxide. 6. Monitor the progress of the reaction by TLC (APPENDIX 3D) on silica gel plates. Develop TLC plates with 95:5 (v/v) chloroform/methanol (see Table 4.17.2 for Rf values of S.4). Because the differences in chromatographic mobilities are small, always apply the starting material on an adjacent lane as a reference.
7. After the reaction is complete, withdraw the supernatant with a 10-mL gas-tight syringe and remove the needle. 8. Attach a luer male-to-male adapter to the bottom of the silica gel column and gently load the withdrawn supernatant at the top. Collect the effluent in a dry flask with continuous flow of dry argon. Wash the silica gel with 1 to 2 mL of dry acetonitrile. As filtration progresses, an orange layer of selenium compounds moves through the gel to the bottom of the column. Stop the filtration when the layer reaches two-thirds of the column length from the top.
9. Replace the high-vacuum valve on the flask and evaporate acetonitrile at high vacuum. Apply the vacuum slowly while shaking the flask continuously until the oil residue makes a foam. 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-oxo-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane)s (S.4) are unstable and should be used for synthesis within a few hours after preparation. They are typically isolated at 40% to 55% yield. Their 31P NMR chemical shifts and TLC parameters are reported in Table 4.17.2.
Table 4.17.2 Characteristics of the 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-oxo-spiro-4,4pentamethylene-1,3,2-oxathiaphospholane)sa
Base T (4a) ABz (4b) CBz (4c) Gi-Bu,DPC (4d)
Yield (%)
δP (ppm, CD3CN)
Rf (TLC)b
55 41 45 54
44.7, 44.3 45.1, 44.9 44.6, 44.1 45.3, 44.5
0.71 0.71 0.70 0.74
aTable adapted from Stec et al. (1998) with permission from the American Chemical Society. bTLC performed on silica gel plates with UV indicator (Merck) and a developing system of 95:5 (v/v) chloroform/meth-
anol. The 2-oxo-monomers migrate slightly more slowly than their 2-thio-precursors.
Synthesis of Modified Oligonucleotides and Conjugates
4.17.17 Current Protocols in Nucleic Acid Chemistry
Supplement 15
BASIC PROTOCOL 3
MANUAL SOLID-PHASE SYNTHESIS OF STEREODEFINED OLIGO(NUCLEOSIDE PHOSPHOROTHIOATE)S Synthesis of oligo(nucleoside phosphorothioate)s using the oxathiaphospholane method can be performed either in a standard 1-µmol column (1-µmol-scale synthesis) or in a reassembled OPC column (2-µmol scale; see below). Because of the strong base used for the condensation step (1,4-diazabicyclo[5.4.0]undec-7-ene), a sarcosinylated solid support must be used (see Support Protocol 2). Typically, supports are functionalized with 25 to 40 µmol nucleoside per gram. A lower nucleoside concentration is not recommended, because a larger amount of support will be necessary to achieve the synthesis at the recommended scale, and may not leave enough space for efficient mixing with incoming reagents. The condensation step is extremely sensitive even to trace amounts of moisture. Therefore, the acetonitrile to be used as a solvent for DBU, and deoxyribonucleoside oxathiaphospholane monomers should be dried over P2O5 (5 g/L) and distilled under reduced pressure (∼200 mmHg) through a 20-cm Vigreux column with exclusion of moisture under an atmosphere of dry argon. At least one-third of the initial volume must remain in the flask. Acetonitrile dried in this way must be transferred using a gas-tight syringe under an atmosphere of dry argon, or by the vacuum line technique (see Support Protocol 1). This protocol describes a 2-µmol-scale synthesis. The synthesis proceeds from the 3 ′-end to the 5 ′-end of the sequence. The first nucleoside from the 3′-end is attached to the solid support. To avoid mistakes, the investigator is recommended to have a synthesis step check list to check off each of the executed steps during consecutive synthetic cycles, as illustrated in Table 4.17.3 for synthesis of the sequence 5′-TGACTGCA-3′. Notably, after the last condensation step, the capping procedure is not executed. Materials Deoxyribonucleoside oxathiaphospholane monomers (see Basic Protocol 2 and/or Alternate Protocol 2) Chloroform (optional), distilled with 1 mL pyridine per L Toluene, anhydrous Low-pressure argon or nitrogen, dried (see recipe) Sarcosinylated solid support functionalized with a nucleoside (first from the 3′ end of sequence to be synthesized) at a concentration ranging from 20 to 30 µmol/g support (see Support Protocol 2) Capping reagent A: 1:1:8 (v/v/v) acetic anhydride/pyridine/tetrahydrofuran (THF) Capping reagent B: 7 g 4-dimethylaminopyridine/93 mL THF Anhydrous acetonitrile (H2O < 20 ppm; see recipe) in bottle with rubber septum, with dry gas delivered inside through a line ending in a needle
Table 4.17.3 Sample Check List for Oligonucleotide Synthesis (Sequence 5′-TGACTGCA-3′)
Nucleoside monomer
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
— C-OTP monomer G-OTP monomer T-OTP monomer C-OTP monomer A-OTP monomer G-OTP monomer T-OTP monomer
Detritylation
Coupling
Capping
— √
— √
√
—
4.17.18 Supplement 15
Current Protocols in Nucleic Acid Chemistry
Detritylating reagent: 3.5% (w/v) dichloroacetic acid in methylene chloride Acetonitrile, HPLC grade (Baker) 1:4.5 (v/v) 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in anhydrous acetonitrile (H2O <20 ppm) Methylene chloride Aqueous ammonia, concentrated (Baker) 10 × 3–cm chromatography column packed with 10 g 230- to 400-mesh silica gel 60 (optional) 4-mL sample vials with open-top screw caps with Teflon-faced rubber septa 19- to 22-G, 1- to 1.5-in. luer-lock needles Vacuum desiccator (≤0.05 mmHg; provided by high-vacuum oil pump) with condenser cooled by liquid N2 1-, 2-, and 5-mL all-polypropylene luer-lock syringes 19- to 22-G, 2- to 3-in. luer-lock needles with blunt 90° tips Columns for DNA synthesis: For 1-µmol scale: Applied Biosystems DNA synthesis column (cat. no. 400407), empty, 1.0 µmol crimp-style For 2-µmol scale: emptied and reassembled Applied Biosystems oligonucleotide purification cartridge (OPC; cat. no. 400771) Column filters (two for each column; Applied Biosystems, cat. no. 400059) Aluminum seals (caps; two for each column; Aldrich cat. no. Z11413-8; Wheaton aluminum cap, 13 mm, tear-off) Crimper for aluminum seals (Aldrich, cat. no. z 11423) Polypropylene (or other chemically inert) luer male-to-male adapter 100- and 500-µL gas-tight syringes (Hamilton) Glass drying tube (∼2-cm i.d., 25-cm length), with three-way valve (or two independent valves) at the top and a rubber septum at the opposite side High-vacuum (0.05 mmHg) oil pump 500-mL filtering flask capped with a rubber septum pierced with a 3- to 4-mm i.d. hole Water aspirator with a manostat Two waste bottles: one for chlorinated waste (methylene chloride, detritylating reagent) and another for water-miscible wastes (acetonitrile, capping reagents A and B) 60°C water bath (optional) Speedvac concentrator with vacuum provided by water aspirator 19- to 22-G, 4- to 5-in. luer-lock needles with blunt 90° tips Additional reagents and equipment for column chromatography (optional; APPENDIX 3E) and purification of oligonucleotides (UNITS 10.3-10.5) CAUTION: The drying tube must be tested to make sure that it is safe for high-vacuum usage, i.e., at a pressure lower than 0.05 mmHg. Prepare monomers for synthesis 1. If the deoxyribonucleoside oxathiaphospholane monomers (S.3 only) have been stored for more than one week, repurify them by flash chromatography (APPENDIX 3E) on a 10 × 3–cm silica gel column using chloroform (distilled with pyridine) as eluant. Concentrate appropriate fractions with exclusion of moisture. Coevaporate the residue twice with anhydrous toluene and apply high vacuum to generate a foam. Repurification is necessary to keep repetitive yield at 92% to 94%. The 2-oxo-monomers (S.4) should not be repurified in this manner, and should be used within a few hours of synthesis (see Alternate Protocol 2).
Synthesis of Modified Oligonucleotides and Conjugates
4.17.19 Current Protocols in Nucleic Acid Chemistry
Supplement 14
2. If necessary, use a spatula to disaggregate the foam of oxathiaphospholane monomers. 3. Put ∼30 mg of given monomer (S.3 or S.4) in an appropriately marked 4-mL sample vial (one vial for each condensation step to be performed) and cover tightly with an open-top screw cap with a Teflon-faced rubber septum. Pierce each septum with a 19- to 22-G, 1- to 1.5-in. luer-lock needle. Before the vials are stored in the desiccator (step 4), be sure that none of the needles became clogged during piercing. This can be done by temporarily inserting a second needle to deliver a stream of dry argon to the vial. The unrestricted flow of argon from the first needle should be easily sensed.
4. Dry monomers in a vacuum desiccator at ≤0.05 mmHg for at least 12 hr. After the drying is complete, fill the desiccator with dry argon, open it cautiously, and immediately remove the needles from the vials. The condenser should be free of any solvents before the drying starts. It is recommended that the condenser be cooled with liquid nitrogen. It is imperative that the oil pump and the whole vacuum system intended for drying monomers be free of acidic impurities such as acetic or hydrochloric acid. Traces of acids would partially detritylate the monomers.
Perform initial setup procedures 5. Prepare and place a permanent mark upon all-polypropylene syringes for capping (2 mL), detritylation (5 mL), washing with acetonitrile (5 mL), and washing with methylene chloride (5 mL). Fit each with a 19- to 22-G, 2- to 3-in. needle with a blunt 90° tip. Use the syringes only for designated purposes, as cross-contamination may lead to poor synthesis yields. The needles should be blunted for safety reasons.
6. Fill a column with an appropriate support for synthesis and assemble it. Be sure to insert column filters at both ends of the column. Secure the aluminum caps with a crimper. Remove the middle part of each aluminum cap. Insert a luer male-to-male adapter into one outlet of the column and attach the outlet needle (19- to 22-G, 4- to 5-in. with a blunt 90° tip). Do not hesitate to apply significant force to secure aluminum caps. This is crucial for avoiding leakage of chemicals during synthesis. The long outlet needle (4- to 5-in.) is more convenient for swirling of the column during consecutive synthetic steps.
7. Set the manostat for the filtering flask at 400 to 450 mmHg. Start synthesis cycle 8. Mix 1 mL capping reagent A and 1 mL capping reagent B in the 2-mL dedicated syringe for capping (see step 5), remove the needle, and gently load the mixture into the column. Continue capping for 2 min with intermittent swirling of the column. Expel reagent from the column into a proper waste bottle. CAUTION: Avoid undue force when pushing the plunger. Excessively fast loading or expelling of the reagents may damage the column filters.
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
9. Fill the dedicated 5-mL syringe for acetonitrile washing (see step 5) with HPLC-grade acetonitrile. Remove the needle and flush the column with intermittent swirling. Collect the effluent in the proper waste bottle. Expel the remaining liquid, then insert the outlet needle of the column through the septum on the top of the filtering flask, deliver a stream of argon from the top of the column, and gently apply suction to the filtering flask. Continue drying until the support in the column becomes loose.
4.17.20 Supplement 14
Current Protocols in Nucleic Acid Chemistry
10. Fill the dedicated 5-mL syringe for detritylation (see step 5) with detritylating reagent. Remove the needle and flush the column with intermittent swirling. Collect the effluent in the proper waste bottle or in a test tube for quantitative cationic DMTr analyses. Expel the remaining liquid. IMPORTANT NOTE: Upon contact with the support, the detritylation solution becomes red due to the presence of DMTr cations removed from the nucleoside. If at the end of delivery the effluent is still colored, continue detritylation with an additional volume of fresh reagent to complete the detritylation process.
11. Wash the support with 5 mL of acetonitrile and dry it as described in step 9. 12. Put the column and gas-tight syringes (500 µL and 100 µL) in the drying tube, gently apply high vacuum, and continue drying for 10 min. Close the vacuum valve on the drying tube and deliver dry gas to the tube. Take the syringes out of the tube (leave the column inside), close the tube with the septum, close the gas valve, and apply vacuum again. Use the syringes only for designated purposes. CAUTION: Do not allow the rubber septum to be expelled from the bottom of the tube by excessively high gas pressure.
13. Withdraw 300 µL of dry acetonitrile (H2O <20 ppm) using the 500-µL gas-tight syringe and add the solvent to the vial containing the appropriate oxathiaphospholane monomer. 14. Close the vacuum valve on the drying tube and deliver dry gas to the tube. Take the column out of the tube, close the tube with the septum, and close the gas valve. Insert a dry 1-mL syringe into the inlet of the column. 15. Withdraw 90 µL of 1:4.5 (v/v) DBU/acetonitrile using the 100-µL gas-tight syringe and add the reagent to the vial containing the dissolved oxathiaphospholane monomer. Mix the contents of the vial for a few seconds. 16. Pierce the septum of the vial with the needle of the column and, using the syringe attached to the column, suck up the contents of the vial to fill the column. Swirl the column intermittently for 10 min. Expel the liquid to the waste bottle. 17. Wash the support with 5 mL of methylene chloride, followed by 5 mL of HPLC-grade acetonitrile, and dry as described in step 9. Complete synthesis cycle 18. Repeat steps 8 to 17 with each successive monomer until elongation is complete. 19. Execute a routine cleavage of the product from the support using a few milliliters of concentrated aqueous ammonia for 2 hr, followed (if necessary) by heating of the ammoniacal solution in a tightly closed vessel at 55°C for 12 hr to remove nucleobase-protecting groups. 20. Concentrate the sample under reduced pressure in a Speedvac concentrator using a water aspirator. 21. Purify the oligonucleotide according to published protocols (UNITS 10.3-10.5).
Synthesis of Modified Oligonucleotides and Conjugates
4.17.21 Current Protocols in Nucleic Acid Chemistry
Supplement 14
SUPPORT PROTOCOL 2
ATTACHMENT OF NUCLEOSIDE 3′-O-SUCCINYL HEMIESTERS TO SARCOSINYLATED SOLID-PHASE SUPPORT This protocol attaches 5′-O-DMTr-N-protected nucleoside-3′-O-succinyl hemiesters to long-chain alkylamine controlled-pore glass (LCAA-CPG) through a sarcosinyl linker. Since 5′-O-DMTr-N-protected nucleoside-3′-O-succinate hemiesters are commercially available, their syntheses are not described. Alternatively, one may prepare them by coupling succinic anhydride with a protected nucleoside according to published procedures (see UNIT 3.2 and references therein). Materials Long-chain alkylamine controlled-pore glass (LCAA-CPG) beads (80 to 120 mesh, 500 Å; Sigma) 9-Fluorenylmethoxycarbonyl (Fmoc)–sarcosine monohydrate (Fluka) Argon (or, optionally, nitrogen), dry 1,3-Dicyclohexylcarbodiimide (DCC; Aldrich) Dimethylformamide (DMF), anhydrous Pyridine, anhydrous 1:1:1 (v/v/v) acetonitrile/methanol (reagent grade)/pyridine Acetonitrile, anhydrous 10% (v/v) piperidine in pyridine 5′-O-DMTr-N-protected nucleoside-3′-O-succinyl hemiester (Sigma) 25-mL two-neck round-bottom flasks High-vacuum valve (e.g., Rotaflo, Quickfit) Rubber septum High-vacuum oil pump 1-mL and 10-mL gas-tight syringes Buchner funnel with glass frit Filter flask Vacuum source (e.g., water aspirator) 50-mL Erlenmeyer flask with stopcock CAUTION: 1,3-Dicyclohexylcarbodiimide can cause skin or eye irritation and allergic reactions. Use appropriate protection. Couple Fmoc-sarcosine to LCAA-CPG 1. Place 2 g LCAA-CPG beads and 0.5 g (1.6 mmol) Fmoc-sarcosine in a 25-mL two-neck round-bottom flask containing a magnetic stir bar, with a high-vacuum valve in one joint and a rubber septum in the other, and dry overnight at high vacuum (0.01 mmHg; provided by a high-vacuum oil pump). At the end of drying, deliver dry argon (or nitrogen) to the flask through the septum. 2. Open the flask, quickly add 0.5 g (2.4 mmol) DCC, and close the flask. 3. Using gas-tight syringes, add 5 mL anhydrous DMF followed by 0.5 mL anhydrous pyridine. 4. Stir the mixture at room temperature for 12 hr. 5. Transfer the suspension to a fritted-glass Buchner funnel and filter off the solution.
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
6. Wash support on the funnel three times, each time with 50 mL of 1:1:1 (v/v/v) acetonitrile/methanol/pyridine with gentle suction. 7. Wash with 50 mL acetonitrile and continue suction for 2 to 3 min.
4.17.22 Supplement 14
Current Protocols in Nucleic Acid Chemistry
8. Transfer the support to a 50-mL Erlenmeyer flask, add 20 mL of 10% piperidine in pyridine, and seal the flask. Shake occasionally over a 30-min period. Decant the liquid. 9. Filter and wash as in steps 5 to 7. 10. Allow the support to dry at room temperature in a fume hood. Couple nucleoside-3′-O-succinyl hemiesters to LCAA-CPG-Sar 12. Place 2 g LCAA-CPG-Sar and ∼0.35 g (∼0.5 mmol) 5′-O-DMTr-N-protected nucleoside-3′-O-succinyl hemiester in a 25-mL two-neck round-bottom flask containing a magnetic stir bar, with a high-vacuum valve in one joint and a rubber septum in the other, and dry overnight at high vacuum (0.01 mmHg; provided by a high-vacuum oil pump). At the end of drying, deliver dry argon (or nitrogen) to the flask through the septum. 13. Open the flask, quickly add 0.2 g (1 mmol) DCC, and close the flask. 14. Using gas-tight syringes, add 10 mL anhydrous DMF, followed by 0.8 mL anhydrous pyridine. 15. Stir the mixture at room temperature for 24 hr. 16. Filter and wash as in steps 5 to 7. 17. Allow the support to dry at room temperature in a fume hood. Typically, using long-chain alkylamine controlled-pore glass, 80 to 120 mesh, 500 Å (Sigma) a concentration of 25 to 40 ìmol of nucleoside per gram of support is obtained. The support should be stored in a tightly closed vessel in the dark. It is stable for several years at room temperature. IMPORTANT NOTE: The support should be prevented from contact with acidic vapors to avoid detritylation.
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Acetonitrile, anhydrous (H2O <20 ppm) Dry acetonitrile over 5 g P2O5 per L for at least 24 hr, then distill under reduced pressure through a 20-cm Vigreux column with exclusion of moisture under an atmosphere of dry argon; at least one-third of the initial volume must remain in the flask. Transfer to reaction vessels using gas-tight syringes under dry argon, or by vacuum line technique (see Support Protocol 1). IMPORTANT NOTE: For condensation steps in Basic Protocol 3, the water content of acetonitrile must be <20 ppm as measured by the Karl Fischer technique. “DNA/RNA synthesis grade” acetonitrile supplied by leading manufacturers is usually not suitable for this purpose unless dried as above.
Low-pressure argon or nitrogen, dried Dry the gas by passing it through a 0.5- to 0.7-m-long column (3- to 4-cm i.d.) filled with blue indicator silica gel (Aldrich cat. no. 336815), then through a similar column filled with granular molecular sieves covered with P2O5. Delivery of inert gas under a slight positive pressure is accomplished by attaching a source of gas via tubing to a T-shaped glass connector. One arm of the connector is attached to the inlet of the first drying column; the other arm is connected to a rubber balloon. After the balloon is inflated up to a diameter of 40 to 50 cm, the valve on the tank regulator is closed, and the internal pressure of the balloon will be sufficient to assure appropriate flow of the gas. The balloon needs to be reinflated from time to time.
Synthesis of Modified Oligonucleotides and Conjugates
4.17.23 Current Protocols in Nucleic Acid Chemistry
Supplement 14
The outlet of the second drying column should be attached through a bubbler (partially filled with mineral oil) to a manifold with 2 to 3 delivery lines, each ending with a valve and a male luer adapter. Typically, argon has lower water content than nitrogen, therefore the drying columns have a longer life-time if argon gas is used.
COMMENTARY Background Information
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
Oligo(nucleoside phosphorothioate)s are congeners of natural oligonucleotides where one of the two nonbridging oxygens in each internucleotide phosphate is replaced by sulfur. By virtue of asymmetry at the phosphorus atom, these constitute a mixture of P-diastereomers, and syntheses of such molecules with predetermined P-chirality at each internucleotide bond are challenging. While the stereocontrolled synthesis of PS-oligos is an art, even more challenging are studies on the properties of such P-stereodefined congeners, mainly with respect to their interactions with other biomolecules such as natural DNA, RNA, and proteins. The affinity of PS-oligos towards DNA and RNA seems to be dictated mainly by base pairing, but is also affected, to a certain extent, by their P-chirality. Notably, intuitive speculations (Zon et al., 1987) or molecular mechanics calculations (Jaroszewski et al., 1992; Hartmann et al., 1999) have led to conclusions contradicting the results of melting experiments performed with heteroduplexes involving P-stereodefined PS-oligos (Boczkowska et al., 2002). This underscores the importance of experimental verification of such hypotheses, which is possible only through access to stereodefined PS-oligos. Physicochemical studies demonstrated that stereoregular PS-oligos of the sequence d(CG)4 of opposite configurations at phosphorus differ significantly in their ability to adopt the Z-conformation in high concentrations of sodium chloride (Boczkowska et al., 2000). Preliminary studies demonstrated that PS-oligos of RP-configuration containing polyadenylate sequences are able to form unusually stable triplexes with two antiparallel complementary RNA strands. The molecular basis of this phenomenon is still unknown, but the role of sulfur in the Rp configuration is essential, as neither [all-SP]-PS-oligomers nor unmodified DNA oligomers are able to form corresponding triplexes of comparable stability (Stec, unpub. observ.) P-stereodefined (PS) oligos have been used for studying the mode of action of several bacterial and human enzymes (Koziolkiewicz
et al., 1997, 2001, 2002). The observation that plasma 3′-exonucleases—a class of proteins responsible for degradation of oligonucleotides in blood—are RP-selective enzymes provided the invaluable information that this enzymatic activity, detrimental toward antisense therapeutics, can be stopped by a single SP-phosphorothioate at the 3′ end of PS-oligonucleotides. Besides this practical aspect, elucidation of the mechanism of the nucleolytic cleavage by 3′-exonuclease(s) provided, for the first time, the information necessary for the classification of this family of proteins (Koziolkiewicz et al., 2002). The interactions of phosphate groups with proteins is well documented. Therefore, the presented method for stereodefined labeling of internucleotide phosphate groups with sulfur and stable oxygen isotopes opens a new avenue for mechanistic studies on DNA/protein interactions at atomic resolution. In this unit, experimental details of the oxathiaphospholane method, developed for stereocontrolled synthesis of oligo(nucleoside phosphorothioate)s, are presented. The method is based upon the synthesis of appropriately protected nucleoside 3′-O-(2-thiono-1,3,2oxathiaphospholane)s and their separation into diastereomerically pure species. It has been demonstrated that DBU-assisted condensation of these monomers with the 5′-OH group of a nucleoside or growing oligonucleotide in the iterative process of chain elongation on a solid support is stereospecific. Stereopurity of [allRP]- and [all-SP]-oligonucleotides has been validated via degradation with stereoselective nucleases such as snake venom phosphodiesterase (Eckstein et al., 1979) and nuclease P1 (Eckstein et al., 1983), respectively. Additional studies have also demonstrated that episulfide, which is released from the ring-opening condensation process, does not modify growing oligonucleotides. One has to realize that this methodology is laborious and costly, and suffers from numerous imperfections which do not allow for the preparation of long PS-oligonucleotides (>15mers). Nonetheless, the oxathiaphospholane
4.17.24 Supplement 14
Current Protocols in Nucleic Acid Chemistry
method has provided many stereodefined PSoligonucleotides suitable for many applications, including NMR studies (Kanehara et al., 1996; Furrer et al., 1999) and biological evaluation in cell cultures, although newcomers to the field may have found it difficult to use. It is clear to the authors of this unit that new modified oxathiaphospholane monomers are highly desirable, as they would not only allow improvement in the repetitive yield of a single condensation step, but would also provide a new and efficient method for protecting internucleotide phosphorothioate diesters against oxidation, necessary for effective combination of the oxathiaphospholane method with phosphoramidite chemistry. Such a combination may provide an effective access to so-called gap-mer or chimeric constructs (Metelev et al., 1994; Pickering et al., 1996; Maier et al., 2000) consisting of oligo(nucleoside phosphate)s and P-stereodefined oligo(nucleoside phosphorothioate) segments. Work on these extensions to the presented method is in progress. Various attempts at stereocontrolled synthesis of PS-oligos undertaken by other research establishments have been reported, among them efforts directed towards stereospecific sy nthesis of dinucleoside 3′,5′-phosphorothioates (Jin et al., 1996; Jin and Just, 1998; Wada et al., 1998; Wang and Just, 1999; Lu and Just, 2000; Oka et al., 2002), Agrawal’s work on the synthesis of nearly stereopure PS-oligos (Iyer et al., 1995, 1998), and the successful stereocontrolled synthesis of longmers reported by Beaucage’s laboratory (Wilk et al., 2000). These groups utilized the ingenious phosphoramidite methodology originally developed by Beaucage and Caruthers (1981). The availability of short P-stereodefined PSoligos (up to pentamers) following separation of diastereomers by means of RP-HPLC should also be noted (Murakami et al., 1994; Tamura, 1998).
neous decomposition of the material inside the vessels. One should frequently monitor the pressure in the system during distillation and keep temperature within the indicated range. For the synthesis of final phosphitylating reagent as well as for phosphitylation of nucleosides, the dryness of solvents and glassware is extremely important, because P(III) chlorides react instantly with traces of water. Like oligonucleotide synthesis via the phosphoramidite or H-phosphonate approach, the dryness of monomers, solvents, and equipment used for coupling is essential for good yields in the oxathiaphospholane approach. Here, the importance of this factor is further stressed because, even with all precautions taken, the repetitive yield of coupling is between 92% and 94%, and any further decrease in coupling yields due to the presence of traces of water may render oligonucleotide synthesis impractical. It is recommended that the cationic DMTr release be quantitated after each condensation step to check if the actual repetitive yield is acceptable.
Anticipated Results Synthesis of phosphitylating reagent, although not trivial, should furnish the consecutive products with reasonable yield (60% to 70%). The reagent is stable and can be stored for months. The same applies to the deoxyribonucleoside 2-thio-oxathiaphospholane monomers. They can be stored in a desiccator at room temperature for several months. Following flash chromatography, the material is recovered at >95% yield, and can then be used for oligonucleotide synthesis. Synthesis of a 15-mer PS-oligo at a 2-µmol scale usually provides 8 to 10 OD units of pure material. This is ∼5% of theoretical yield. It is important that during HPLC purification only the upper part of the oligonucleotide peak be collected (>40% of peak height) to obtain a more homogenous oligomer.
Critical Parameters and Troubleshooting
Time Considerations
Chemical synthesis of the phosphitylating reagent requires some skills to prevent release of the unpleasant odor characteristic of organosulfur compounds. It is recommended that glassware be cleaned using an oxidant, like sodium hypochlorite or hydrogen peroxide, to convert sulfhydryl or disulfide-containing compounds into sulfones. As mentioned in relevant protocols, overheating of the vessels during high-vacuum distillation is dangerous, as it may lead to sponta-
Since neither the oxathiaphosphitylating reagent nor the oxathiaphospholane monomers are commercially available, their preparation is necessary and takes a considerable amount of time. It is reasonable to assume that the synthesis o f 2 -chloro-spiro-4,4-pentamethylene1,3,2-oxathiaphospholane starting from cyclohexanecarboxaldehyde can be accomplished in 10 working days, provided that the technical staff prepares, simultaneously, the necessary anhydrous solvents.
Synthesis of Modified Oligonucleotides and Conjugates
4.17.25 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Phosphitylation/sulfurization of commercially available, appropriately protected nucleosides at 10 mmol scale, as well as preparation of sarcosinylated supports, require 10 additional days. Separation of nucleoside monomers into P-diastereomerically pure species is a very important and rather difficult step. Undoubtedly, some experience is necessary to obtain good results. It should be emphasized that proper loading of the chromatographic column, as well as very careful elution and TLC analysis of effluent, are crucial for yield and diastereomeric purity of the resolved monomers. It must also be taken into account that separation of diastereomers is a time-consuming step, as only ∼300 mg of monomer can be applied on a single silica gel column. The 100 to 120 mg of each pure diastereomer recovered from that amount is sufficient for 3 to 4 coupling steps. To avoid delay resulting from laborious chromatographic purifications, it is good practice to stockpile pure diastereomers, as they are chemically stable and can be stored for long periods of time. Once the monomers are made, the synthesis of PS-oligos proceeds much more rapidly, and typically one oligomer can be made and purified within 4 to 5 days. Usually, during manual synthesis, one can accomplish 8 to 10 couplings daily. If the synthesis is to be continued on the next day, it should be interrupted after the capping step, followed by washing and drying of the support. The synthetic column should then be stored in a desiccator.
Literature Cited Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites: A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862. Boczkowska, M., Guga, P., Karwowski, B., and Maciaszek, A. 2000. Effect of P-chirality of internucleotide bonds on B-Z conversion of stereodefined self-complementary phosphorothioate oligonucleotides of [PS]-d(CG)4 and [PS]-d(GC)4 series. Biochemistry 39:1105711064. Boczkowska, M., Guga, P., and Stec, W.J. 2002. Stereodefined phosphorothioate analogues of DNA: Relative thermodynamic stability of model PS-DNA/DNA and PS-DNA/RNA complexes. Biochemistry 41:12483-12487.
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
Brown, T., Pritchard, C.E., Turner, G., and Salisbury, S.A. 1989. A new base-stable linker for solidphase oligonucleotide synthesis. J. Chem. Soc. Chem. Commun. 891-893.
Eckstein, F. 2000. Phosphorothioate oligodeoxynucleotides: What is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. 10:117-121. Eckstein, F., Burgers, P.M.J., Sathyanarayana, B.K., and Saenger, W. 1979. Crystal and molecular structure of adenosine 5′-O-phosphorothioate OP-nitrophenyl ester (Sp diastereomer). Substrate stereospecificity of snake venom phosphodiesterase. Eur. J. Biochem. 100:585-591. Eckstein, F., Potter, B.V.L., and Connolly, B. 1983. Synthesis and configurational analysis of a dinucleoside phosphate isotopically chiral at phosphorus. Stereochemical course of Penicillium citrum nuclease P1 reaction. Biochemistry 22:1369-1377. Furrer, P., Billeci, T.M., Donati, A., Kojima, C., Karwowski, B., Sierzchala, A., Stec, W.J., and James, T.L. 1999. Structural effect of complete [RP]-phosphorothioate and phosphorodithioate substitution in the DNA strand of a model antisense inhibitor-target RNA complex. J. Mol. Biol. 285:1609-1621. Guga, P., Domanski, K., and Stec, W.J. 2001. Oxathiaphospholane approach to the synthesis of P-chiral, isotopomeric deoxy(ribonucleoside phosphorothioate)s and phosphates labeled with oxygen isotope. Angew. Chem. Int. Ed. Engl. 40:610-613. Hacia, J.G.,Wold, B.J., and Dervan, P.B. 1994. Phosphorothioate oligonucleotide-directed triple helix formation. Biochemistry 33:5367-5369. Hartmann, B., Bertrand, H.-O., and Fermandjian, S. 1999. Sequence effects on energetic and structural properties of phosphorothioate DNA: A molecular modelling study. Nucl. Acids Res. 27:3342-3347. Iyer, R.P., Yu, D., Ho, N.-H., Tan, W., and Agrawal, S. 1995. A novel nucleoside phosphoramidite synthon derived from 1R,2S-ephedrine. Tetrahedron: Asymmetry 6:1051-1054. Iyer, R.P., Guo, M.J., Yu, D., and Agrawal, S. 1998. Solid-phase stereoselective synthesis of oligonucleoside phosphorothioates: The nucleoside bicyclic oxazaphospholidines as novel synthons. Tetrahedron Lett. 39:2491-2494. Jaroszewski, J.W., Syi, J.-L., Maizel, J., and Cohen, J.S. 1992. Towards rational design of antisense DNA: Molecular modeling of phosphorothioate DNA analogues. Anticancer Drug Des. 7:253262. Jin, Y. and Just, G. 1998. Stereoselective synthesis of dithymidine phosphorothioates using xylose derivatives as chiral auxiliaries. J. Org. Chem. 63:3647-3654. Jin, Y., Biancotto, G., and Just, G. 1996. A stereoselective synthesis of dinucleotide phosphorothioates using chiral phosphoramidites as intermediates. Tetrahedron Lett. 37:973-976.
4.17.26 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Kanehara, H., Wada, T., Mizuguachi, M., and Makino, K. 1996. Influence of a thiophosphate linkage on the duplex stability: Does Sp configuration always lead to higher stability than Rp? Nucleosides Nucleotides 15:1169-1178.
Oka, N., Wada, T., and Saigo, K. 2002. Diastereocontrolled synthesis of dinucleoside phosphorothioates using a novel class of activators, dialkyl(cyanomethyl)ammonium tetrafluoroborates. J. Am. Chem. Soc. 124:4962-4963.
Koziolkiewicz, M., Wójcik, M., Kobylanska, A., Karwowski, B., Rebowska, B., Guga, P., and Stec, W.J. 1997. Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: Diastereoselectivity of plasma 3′-exonuclease. Antisense Nucleic Acids Drug Dev. 7:43-48.
Pickering, J.G., Isner, J.M., Ford, C.M., Weir, L., Lazarovits, A., Rocnik, E.F., and Chow, L.H. 1996. Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restenosis after angioplasty. Circulation 93:772-780.
Koziolkiewicz, M., Owczarek, A., Domanski, K., Nowak, M., Guga, P., and Stec, W.J. 2001. Stereochemistry of cleavage of internucleotide bond by Serratia marcescens endonuclease. Bioorg. Med. Chem. 9:2403-2409.
Stec, W.J., Grajkowski, A., Koziolkiewicz, M., and Uznanski, B. 1991. Novel route to oligo(deoxyribonucleoside phosphorothioates): Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioates). Nucl. Acids Res. 19:5883-5888.
Koziolkiewicz, M., Owczarek, A., Wójcik, M., Domanski, K., Guga, P., and Stec, W.J. 2002. Retention of the configuration in the action of human plasma 3′-exonuclease on oligo(deoxynucleoside phosphorothioate): A new method for assignment of absolute configuration at phosphorus in isotopomeric deoxyadenosine 5′-O[18O]phosphorothioate. J. Am. Chem. Soc. 124:4623-4627. Lackey, D.B. and Patel, J. 1997. Biochemical synthesis of chirally pure RP oligonucleotide phosphorothioates. Biotechnol. Lett. 19:475-478. Lu, Y. and Just, G. 2000. Stereoselective synthesis of RP- and SP-dithymidine phosphorothioates via chiral indolooxazaphosphorine intermediates derived from tryptophan. Angew. Chem. Int. Ed. Engl. 39:4521-4524. Maier, M.A., Guzaev, A.P., and Manoharan, M. 2000. Synthesis of chimeric oligonucleotides containing phosphodiester, phosphorothioate, and phosphoramidate linkages. Org. Lett. 2:1819-1822. Manoharan, M. 1999. 2′-Carbohydrate modifications in antisense oligonucleotide therapy: Importance of conformation, configuration and conjugation. Biochim. Biophys. Acta 1489:117130. Martynov, I.V., Kruglyak, Y.L., Leibovskaya, G.A., Khromova, Z.I., and Stukov, O.G. 1969. Phosphonylated oximes: IV. Reactions of 1,3,2-dioxa- and 1,3,2-oxathiaphospholanes with αhalogen nitroso alkanes. Zh. Obsch. Khim 39:996. Metelev, V., Lisziewicz, J., and Agrawal, S. 1994. Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-O-methyloligoribonucleotides. Bioorg. Med. Chem. Lett. 4:29292934. Murakami, A., Tamura, Y., Wada, H., and Makino, K. 1994. Separation and characterization of diastereoisomers of antisense oligodeoxyribonucleoside phosphorothioates. Anal. Biochem. 233:285-290.
Stec, W.J., Grajkowski, A., Karwowski, B., Kobylanska, A., Koziolkiewicz, M., Misiura, K., Okruszek, A., Wilk, A., Guga, P., and Boczkowska, M. 1995. Diastereomers of nucleoside 3′-O-(2thio-1,3,2-oxathia(selena)phospholanes): Building blocks for stereocontrolled synthesis of oligo(nucleoside phosphorothioate)s. J. Am. Chem. Soc. 117:12019-12029. Stec, W.J., Karwowski, B., Boczkowska, M., Guga, P., Koziolkiewicz, M., Sochacki, M., Wieczorek, M., and Blaszczyk, J. 1998. Deoxyribonucleoside 3′-O-(2-thio- and 2-oxo-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane)s: Monomers for stereocontrolled synthesis of oligo(deoxyribonucleoside phosphorothioate)s and chimeric PS/PO oligonucleotides. J. Am. Chem. Soc. 120:7156-7167. Stein, C.A. and Krieg, A.M. (eds.) 1988. Applied Antisense Oligonucleotide Technology. WileyLiss, New York. Tamura, Y., Miyoshi, L.H., Yokota, T., and Makino, K. 1998. Preparation of stereoregulated antis ens e oligode oxyribonucleoside phosphorothioate and interaction with its complementary DNA and RNA. Nucleosides Nucleotides 17:269-282. Tang, J., Roskey, A., Li, Y., and Agrawal, S. 1995. Enzymatic synthesis of stereoregular [all RP]oligonucleotide phosphorothioate and its properties. Nucleosides Nucleotides 14:985-990. Thuong, N.T. and Helene, C. 1993. Sequence-specific recognition and modification of doublehelical DNA by oligonucleotides. Angew. Chem. Int. Ed. Engl. 32:666-690. Wada, T., Kobayashi, N., Mori, T., and Sekine, M. 1998. Stereocontrolled synthesis of dithymidine phosphorothioates by use of a functionalized 5′-protecting group bearing an imidazole residue. Nucleosides Nucleotides 17:351-364. Wang, J.C. and Just, G. 1999. Indol-oxazaphosphorine precursors for stereoselective synthesis of dinucleotide phosphorothioates. J. Org. Chem. 64:8090-8097. Wickstrom, E. 1986. Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods 13:97-102.
Synthesis of Modified Oligonucleotides and Conjugates
4.17.27 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Wilk, A. and Stec, W.J. 1995. Analysis of oligo(deoxynucleoside phosphorothioate)s and their diastereomeric composition. Nucl. Acids Res. 23:530-534. Wilk, A., Grajkowski, A., Phillips, L.R., and Beaucage, S.L. 2000. Deoxyribonucleoside cyclic Nacylphosphoramidites as a new class of monomers for the stereocontrolled synthesis of oligothymidylyl- and oligodeoxycytidylylphosphorothioates. J. Am. Chem. Soc. 122:21492156. Willson, M., Goncalves, H., Boudjebel, H., and Burgada, R. 1975. Étude du méchanisme des réactions d’acidalyse, d’alcoolyse et d’aminolyse des oxathiaphosphalanes-1,3,2. Bull. Soc. Chim. Fr. Part 2, 615-620.
Zon, G., Summers, M.F., Gallo, K.A., Shao, K.-L., Koziolkiewicz, M., Uznanski, B., and Stec, W.J. 1987. Stereochemistry of oligodeoxyribonucleotide phosphate triesters. In Biophosphates and Their Analogues: Synthesis, Structure, Metabolism and Activity (K.S. Bruzik and W.J. Stec, eds.) pp. 165-178. Elsevier, Amsterdam.
Contributed by Piotr Guga and Wojciech J. Stec Polish Academy of Sciences Lodz, Poland
Synthesis of Phosphorothioate Oligonucleotides with Stereodefined Linkages
4.17.28 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Synthesis of Oligonucleotide Conjugates via Aqueous Diels-Alder Cycloaddition
UNIT 4.18
This unit describes in detail the preparation of 5′-labeled oligonucleotides via the aqueous Diels-Alder conjugation method. The unit is divided into three protocols: the first describing the preparation of the diene-amidite (see Basic Protocol 1); the second presenting the modification of oligonucleotides with the diene-amidite (see Basic Protocol 2); and the third describing the labeling of 5′-diene-modified oligonucleotides via Diels-Alder conjugation with TAMRA-5-maleimide (see Basic Protocol 3). All procedures are simple to perform with standard equipment and reagents. CAUTION: All reactions must be performed in a well-ventilated fume hood. The use of proper laboratory precautions when handling all chemicals is mandatory. In particular, exposure of personnel to tert-butyldimethylsilyl chloride, bromine, 1,1′-carbonyldiimidazole, 2-cyanoethyl diisopropylchlorophosphoramidite, and N,N-diisopropylethylamine must be avoided. SYNTHESIS OF THE DIENE-AMIDITE The five-step synthesis route for the diene-amidite (S.7) employs commercially available 3-cyclohexene-1-methanol (S.1) as the starting material (Fig. 4.18.1). In the first step, the hydroxyl group of S.1 is protected by silylation with tert-butyldimethylsilyl chloride (TBDMS⋅Cl) to give the alkene S.2. In the next step, bromine is added. The resulting dibromide (S.3) is subjected to a bis-dehydrohalogenation reaction with potassium tert-butoxide to form the diene S.4. Removal of the TBDMS protecting group with strongly acidic Dowex resin and subsequent distillation of the crude product leads to pure 2,4-cyclohexadiene-1-methanol (S.5). Conjugation of S.5 to 6-amino-1-hexanol is accomplished in reaction with 1,1′-carbonyldiimidazole (CDI). The crude carbamate S.6 is purified by crystallization. Finally, S.6 is converted into the phosphoramidite S.7 by treatment with 2-cyanoethyl diisopropylchlorophosphoramidite and N,N-diisopropylethylamine (DIPEA). Purification of the crude product is performed by flash chromatography. Materials 3-Cyclohexene-1-methanol (S.1; Aldrich) Imidazole Argon source N,N-Dimethylformamide (DMF) tert-Butyldimethylsilyl chloride (TBDMS⋅Cl; Aldrich) Hexanes Ethyl acetate (EtOAc) TLC stain (see recipe) Brine (saturated aqueous NaCl) Magnesium sulfate (MgSO4) Bromine Dichloromethane (CH2Cl2) 10% (w/v) sodium thiosulfate (Na2S2O3) Aliquat 336 (tricaprylylmethylammonium chloride; Aldrich) Tetrahydrofuran (THF) Potassium tert-butoxide (Aldrich) Saturated ammonium chloride (NH4Cl) Dowex 50WX4-50 strongly acidic ion-exchange resin (Aldrich) Contributed by Michael Leuck and Andreas Wolter Current Protocols in Nucleic Acid Chemistry (2003) 4.18.1-4.18.14 Copyright © 2003 by John Wiley & Sons, Inc.
BASIC PROTOCOL 1
Synthesis of Modified Oligonucleotides and Conjugates
4.18.1 Supplement 14
TBDMS⋅Cl/imidazole
OH
Br2, CH2Cl2
OTBDMS
1 hr, 96%
DMF, 20 hr, quant. 1
2
OTBDMS
KOt Bu/Aliquat 336
OTBDMS
THF, 2 hr
Br Br
4 3
O
Dowex-H +/MeOH
CDI
OH
2 hr, 84% (2 steps)
O
DMF, 1 hr
N
N
5
O 6-amino-1-hexanol, 16 hr
O
OH
N H
50%
6
O
i -Pr2NP(Cl)OCH2CH2CN/DIPEA THF, 1 hr, 75%
O
O
N H
P
O
CN
i-Pr2N 7
Figure 4.18.1 Preparation of diene-amidite (S.7). Abbreviations: Aliquat 336, tricaprylylmethylammonium chloride; CDI, 1,1′-carbonyldiimidazole; DIPEA, N,N-diisopropylethylamine; TBDMS⋅Cl, tert-butyldimethylsilyl chloride.
Methanol 1,1′-Carbonyldiimidazole (CDI; Aldrich) 6-Amino-1-hexanol (Aldrich) N,N-Diisopropylethylamine (DIPEA; Aldrich) 2-Cyanoethyl diisopropylchlorophosphoramidite (Aldrich) Saturated sodium bicarbonate (NaHCO3)
Synthesis of Oligonucleotide Conjugates via Diels-Alder Cycloaddition
100- and 250-mL round-bottom flasks with outlet stopcock adapters for gas line TLC plates: 7.5 × 5–mm silica gel 60 F254 precoated aluminum-backed TLC sheets (EM Science) Heat gun 1-L and 500-mL separatory funnels Rotary evaporator equipped with a vacuum pump and vacuum controller Rubber septa
4.18.2 Supplement 14
Current Protocols in Nucleic Acid Chemistry
10- and 50-mL vials 3- and 5-mL syringes with 2-in., 20-G stainless steel needles Shaker Short-path distillation apparatus (Aldrich) Biotage Flash 40 chromatography system with Flash 40M silica cartridge Additional reagents and equipment for TLC (APPENDIX 3D) and flash chromatography (APPENDIX 3E) Perform silylation 1. Weigh 2.78 g (24.8 mmol) of 3-cyclohexene-1-methanol (S.1) and 3.38 g (49.6 mmol) of imidazole into a 100-mL round-bottom flask equipped with a magnetic stir bar and an argon inlet. Apply an atmosphere of argon. 2. Add 25 mL of DMF and stir until all solids are dissolved. 3. Add 4.49 g (29.8 mmol) TBDMS⋅Cl to the reaction mixture and stir for 20 hr at room temperature. Monitor reaction by TLC (APPENDIX 3D) using 100:1 (v/v) hexanes/ethyl acetate. Visualize spots by treating plate with TLC stain and heating with a heat gun. TLC (hexanes/EtOAc 100:1): Rf = 0.05 for starting material (S.1); 0.29 for TBDMS-ether (S.2).
Perform aqueous workup of S.2 4. Pour the reaction mixture into a 1-L separatory funnel. Add 250 mL of brine and extract the product with 150 mL of hexanes. 5. Repeat the extraction twice with 150 mL each of hexanes. 6. Combine the hexanes fractions and wash with 250 mL of brine. 7. After separation dry the organic phase over MgSO4. 8. Remove the MgSO4 by filtration and wash it twice, each time with 20 mL of hexanes. 9. Concentrate the combined filtrates under vacuum using a rotary evaporator equipped with a vacuum pump. Typical yield of 4-(tert-butyldimethylsilyloxymethyl)cyclohex-1-ene (S.2): 5.62 g (100%) as colorless liquid. TLC (hexanes): Rf = 0.29; 13C NMR (CDCl3): δ 127.0, 126.2, 68.0, 36.3, 28.2, 26.0, 25.7, 25.3, 24.8, 18.4, –5.3.
Brominate alkene 10. Weigh 5.62 g (24.8 mmol) of S.2 into a 250-mL round-bottom flask equipped with a magnetic stir bar. 11. Add 50 mL of CH2Cl2, seal the flask with a rubber septum, and apply an atmosphere of argon. Dissolve the silyl ether (S.2) under stirring, then cool the solution with an ice bath to 0°C. 12. In a separate 10-mL vial, dissolve 1.3 mL (25.2 mmol) of bromine in 3 mL of CH2Cl2. Fill a 5-mL syringe with the bromine/CH2Cl2 solution. 13. Attach the syringe to the flask (step 11) using a 20-G stainless steel needle to pierce the septum, and add the bromine solution dropwise under cooling. At the beginning, the red color disappears immediately after addition. Finally, an orangered color remains.
14. After complete addition of the bromine solution, remove the ice bath and let the mixture stir for another 60 min. Monitor by TLC (see step 3). TLC (hexanes/EtOAc 100:1): Rf = 0.29 for TBDMS-ether (S.2); 0.15 for dibromide (S.3).
Synthesis of Modified Oligonucleotides and Conjugates
4.18.3 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Perform aqueous workup of S.3 15. Pour the reaction mixture into a 500-mL separatory funnel. 16. Rinse the flask with 150 mL of CH2Cl2 and add to the separatory funnel. 17. Wash the CH2Cl2 layer with 150 mL of 10% Na2S2O3, then with 150 mL of water. 18. Dry the organic phase over MgSO4. 19. Remove the MgSO4 by filtration and wash twice with 20 mL of CH2Cl2. 20. Concentrate the combined filtrates under vacuum in a rotary evaporator. Typical yield of trans-1,2-dibromo-4-tert-butyldimethylsilyloxymethylcyclohexane (S.3): 9.19 g (96%) as yellow oil. TLC (hexanes/EtOAc 100:1): Rf = 0.15. 13C NMR (CDCl3): δ 67.3, 53.6, 53.5, 34.2, 31.41, 3.12, 3.88, 2.25, 2.3, –5.4.
Perform bis-dehydrohalogenation 21. Weigh 9.19 g (23.8 mmol) of S.3 and 0.20 g (0.5 mmol) of Aliquat 336 into a 250-mL round-bottom flask equipped with a magnetic stir bar. 22. Add 70 mL of THF, seal the flask with an outlet stopcock adapter attached to an argon line, and apply an atmosphere of argon. Dissolve the dibromide (S.3) under stirring, then cool the solution with an ice bath to 0°C. 23. Open the reaction flask by removing the adapter, add 5.88 g (52.4 mmol) of potassium tert-butoxide in one portion, seal the flask again with the adapter, and apply an atmosphere of argon (a yellow precipitate is immediately formed). Remove the ice bath after 5 min and continue stirring for 2 hr. Monitor by TLC. TLC (hexanes/EtOAc 100:1): Rf = 0.15 for dibromide (S.3); 0.25 for diene (S.4).
Perform aqueous workup of S.4 24. Pour the reaction mixture into a 500-mL separatory funnel. 25. Rinse the flask with 100 mL of hexanes and add to the separatory funnel. 26. Wash the hexanes layer with 100 mL saturated NH4Cl. 27. After separation, extract the aqueous phase with 50 mL of hexanes and wash the combined hexanes phases with 100 mL of water. 28. Dry the organic phase over MgSO4. 29. Remove the MgSO4 by filtration and wash it twice, each time with 20 mL of hexanes. 30. Concentrate the combined filtrates under vacuum at 40°C, with pressure ≥180 mbar, in a rotary evaporator. Perform desilylation 31. Weigh 8.60 g of Dowex 50WX4-50 into a 50-mL vial and wash it carefully three times, each time with 20 mL methanol. After the third washing, the supernatant should be colorless.
32. Dissolve the S.4 residue from step 30 in 80 mL methanol, transfer it into a 250-mL round-bottom flask, and add the washed Dowex 50WX4-50 resin. 33. Attach the flask to a shaker and shake the reaction mixture for 2 hr at 200 rpm. Monitor by TLC using 3:1 (v/v) hexanes/ethyl acetate. Synthesis of Oligonucleotide Conjugates via Diels-Alder Cycloaddition
TLC (hexanes/EtOAc 3:1): Rf = 0.80 for diene (S.4); 0.20 for diene-alcohol (S.5).
4.18.4 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Purify diene-alcohol S.5 34. Remove the ion-exchange resin by filtration and wash it twice with 20 mL methanol. 35. Concentrate the combined filtrates under vacuum at 40°C, with pressure ≥180 mbar, in a rotary evaporator. 36. Transfer the residue into a round-bottom flask of appropriate size (5 or 10 mL) and attach it to a short-path distillation apparatus. Distill the product under vacuum, collecting the fraction ranging from b.p. 47°C (2.2 mbar) to 50°C (1.7 mbar). Typical yield of 2,4-cyclohexadiene-1-methanol (S.5): 2.20 g (84%) as colorless liquid. TLC (hexanes/EtOAc 3:1): Rf = 0.20. 1H NMR (CDCl3): δ 5.98 - 5.62 (m, 4 H), 3.58 (d, J = 5.9 Hz, 2 H), 2.56 - 2.42 (m, 1 H), 2.37 - 2.05 (m, 2 H), 1.50 (s, 1 H). 13C NMR (CDCl3): δ 126.9, 125.4, 125.0, 123.6, 64.6, 35.5, 24.9.
Conjugate diene-alcohol to 6-amino-1-hexanol 37. Weigh 2.20 g (20.0 mmol) of S.5 into a 100-mL round-bottom flask equipped with a magnetic stir bar. 38. Add 20 mL of DMF, seal the flask with an outlet stopcock adapter attached to an argon line, and apply an atmosphere of argon. Dissolve the diene (S.5) under stirring. 39. Open the reaction flask by removing the adapter, add 3.40 g (21.0 mmol) of CDI in one portion, seal the flask again with the adapter, and apply an atmosphere of argon. Continue stirring for 1 hr. Monitor by TLC using 1:1 (v/v) hexanes/ethyl acetate. TLC (hexanes/EtOAc 1:1): Rf = 0.32 for alcohol (S.5); 0.20 for the imidazolyl carbamate.
40. Open the reaction flask by removing the adapter, add 2.34 g (20.0 mmol) of 6-amino-1-hexanol in one portion, seal the flask again with the adapter, and apply an atmosphere of argon. Continue stirring overnight. Monitor by TLC using 1:2 (v/v) hexanes/ethyl acetate. TLC (hexanes/EtOAc 1:2): Rf = 0.56 for the imidazolyl carbamate; 0.44 for carbamate (S.6).
Perform aqueous workup of carbamate S.6 41. Concentrate the reaction mixture under vacuum in a rotary evaporator. 42. Dissolve the residue in 100 mL of CH2Cl2 and transfer the solution into a 250-mL separatory funnel. 43. Wash the CH2Cl2 layer twice, each time with 70 mL of water. 44. After separation, dry the organic phase over MgSO4. 45. Remove the MgSO4 by filtration and wash it twice, each time with 10 mL of CH2Cl2. 46. Concentrate the combined filtrates under vacuum in a rotary evaporator. 47. Recrystallize the crude product from CH2Cl2. Typical yield of 6-(cyclohexa-1,3-dien-5-yl)methylcarbamoylhexan-1-ol (S.6): 2.53 g (50%) as colorless crystals, m.p. 65°C. TLC (hexanes/EtOAc 1:2): Rf = 0.44. 1H NMR (300 MHz, CD3CN): δ 6.01-5.96 (m, 1H), 5.94-5.89 (m, 1H), 5.86-5.78 (m, 1H), 5.72-5.67 (m, 1H), 5.51 (bs, 1H), 3.96-3.89 (m, 2H), 3.49 (q, J = 5.6 Hz, 2H), 3.08 (q, J = 6.6 Hz, 2H), 2.68-2.50 (m, 1H), 2.49 (t, J = 5.6 Hz, 1H), 2.31-2.21 (m, 1H), 2.15-2.02 (m, 1H), 1.54-1.45 (m, 4H), 1.40-1.26 (m, 4H). 13C NMR (75 MHz, CD3 CN): δ 156.8, 127.0, 126.0, 125.6, 125.0, 61.7, 61.5, 40.7, 33.0, 32.8, 29.9, 26.5, 25.5, 25.0. MS (FAB): m/z 254 [M+H]+. Synthesis of Modified Oligonucleotides and Conjugates
4.18.5 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Perform phosphitylation 48. Weigh 2.53 g (10.0 mmol) of S.6 into an oven-dried 100-mL round-bottom flask equipped with a magnetic stir bar. 49. Add 25 mL of dry THF and 2.6 mL (15 mmol) of DIPEA, seal the flask with a septum, and apply an atmosphere of argon. Dissolve the alcohol (S.6) under stirring. 50. Weigh 2.49 g (10.5 mmol) of 2-cyanoethyl diisopropylchlorophosphoramidite into a 3-mL syringe. 51. Attach the syringe to the flask via the septum and add the chlorophosphoramidite dropwise. Rinse the syringe with 3 mL of dry THF and add this solution to the reaction mixture. Continue stirring for 1 hr. Monitor by TLC using ethyl acetate. TLC (EtOAc): Rf = 0.50 for carbamate (S.6); 0.83 for amidite (S.7).
Perform aqueous work-up and purification of S.7 52. Pour the reaction mixture into a 250-mL separatory funnel. 53. Add 75 mL of CH2Cl2 and wash the organic layer three times with 75 mL saturated NaHCO3. 54. Dry the organic phase over MgSO4. 55. Remove the MgSO4 by filtration and wash it twice with 10 mL CH2Cl2. 56. Concentrate the combined filtrates under vacuum in a rotary evaporator. 57. Dissolve the residue in 4 mL ethyl acetate and inject it on a Biotage Flash 40 chromatography system employing a Biotage Flash 40M silica gel cartridge equilibrated with ethyl acetate. Elute the product with ethyl acetate. 58. Concentrate the product-containing fractions under vacuum in a rotary evaporator. Dry the residue under high vacuum. Typical yield of 1-[(2-cyanoethoxy)diisopropylaminophosphinyloxy]-6-(cyclohexa-1,3dien-5-yl)methylcarbamoylhexane (S.7): 3.40 g (75%) as colorless oil. TLC (EtOAc): Rf = 0.83. 1H NMR (CD3CN): δ 6.01-5.87 (m, 2H), 5.83-5.77 (m, 1H), 5.71 (m, 1H), 5.52 (bs, 1H), 3.97-3.89 (m, 2H), 3.89-3.70 (m, 2H), 3.70-3.56 (m, 4H), 3.07 (q, J = 6.6 Hz, 2H), 2.70-2.53 (m, 1 H), 2.66 (t, J = 5.9 Hz, 2H), 2.31-2.15 (m, 1H), 2.15-2.01 (m, 1H), 1.64-1.26 (m, 8H), 1.20 (s, 3H), 1.19, (s, 3H), 1.18 (s, 3H), 1.17 (s, 3H). 13C NMR (CD3 CN): δ 156.7, 127.0, 125.8, 125.3, 124.0, 118.9, 65.7, 63.6, 63.4, 58.6, 58.4, 43.1, 42.9, 40.7, 33.2, 31.2, 31.1, 29.9, 26.3, 25.6, 25.0, 24.2, 24.1, 20.4, 20.3. 31P NMR (CD3 CN): δ 148.0. MS (FAB): m/z 455 [M+H]+. Anal. calcd. for C23H40N3O4P: C, 60.91; H, 8.89; N, 9.26; found: C, 60.55; H, 9.23; N, 9.10. RP-HPLC: Rt = 12.67 min; Waters Nova-Pak C18 column (4 ìm, 3.9 × 150 mm) eluting with a linear gradient from 40% to 100% A (solvent A, acetonitrile; solvent B, 250 mM triethylammonium acetate, pH 6.5) in 15 min with a flow rate of 1 mL/min; UV detection performed at λ = 254 nm.
Synthesis of Oligonucleotide Conjugates via Diels-Alder Cycloaddition
4.18.6 Supplement 14
Current Protocols in Nucleic Acid Chemistry
CPG
N1
n −1 standard synthesis cycles
standard synthesis cycle
N1.....Nn
O CPG
diene-amidite
N1.....Nn
P O
O
cleavage/deprotection conc. ammonia
CPG
N-amidite
3′ N1.....Nn
P
O −
O
+
H N
O
O O
CN
H N
O O
NH4
Figure 4.18.2 Synthesis of diene-modified oligonucleotides. Standard synthesis cycle: deblocking (deblock solution); coupling (N-amidite/DCI); capping (Cap A and B solutions); oxidation (oxidizer solution). N-amidite: standard dT, dC(bz), dA(bz), dG(ib) phosphoramidites.
SYNTHESIS OF 5′-DIENE-MODIFIED OLIGONUCLEOTIDES This protocol describes the setup and steps required for automated assembly of 5′-dienemodified oligonucleotides on a 1-µmol scale. The protocol was developed for the Expedite 8909 DNA synthesizer, but can easily be adapted to other automated DNA synthesizers. The reactions carried out in each cycle are shown in Figure 4.18.2. For further details on automated oligonucleotide synthesis, see APPENDIX 3C.
BASIC PROTOCOL 2
The instrument manufacturer’s synthesis protocol in DMTr-ON mode is applied for the assembly of the oligonucleotide with standard reagents for solid-phase oligonucleotide synthesis. The diene-amidite (S.7) is employed at a concentration of 50 mg/mL in acetonitrile in the last coupling cycle. After completion of the synthesis, the oligonucleotide is cleaved from the CPG support and subsequently deprotected by treatment with concentrated ammonium hydroxide. Desalting of the crude oligonucleotide is accomplished by alcohol precipitation. Materials Dry acetonitrile (DNA synthesis grade; H2O content <30 µg/mL) Deblock solution: trichloroacetic acid (TCA) in dichloromethane (Proligo) Cap A solution: acetic anhydride in tetrahydrofuran (Proligo) Cap B solution: 1-methylimidazole in tetrahydrofuran/pyridine (Proligo) Oxidizer solution: iodine in tetrahydrofuran/water/pyridine (Proligo) Activator: 0.25 M 4,5-dicyanoimidazole (DCI) in acetonitrile (Proligo) 50 mg/mL standard phosphoramidites [dT, dC(bz), dA(bz), and dG(ib); Proligo] in dry acetonitrile 50 mg/mL diene-amidite (S.7; see Basic Protocol 1) in dry acetonitrile Helium source Concentrated ammonium hydroxide (NH4OH) 3 M sodium acetate (APPENDIX 2A) Isopropanol 70% (v/v) ethanol
Synthesis of Modified Oligonucleotides and Conjugates
4.18.7 Current Protocols in Nucleic Acid Chemistry
Supplement 15
Automated DNA synthesizer (e.g., Expedite 8909, PerSeptive Biosystems) Synthesis column for 1-µmol scale (Proligo): controlled-pore glass (CPG; 500 Å for <50-mers, 1000 Å for ≥50-mers) Heating block Speedvac evaporator Additional reagents and equipment for quantitating oligonucleotides by OD260 measurement (UNIT 10.3) Perform automated synthesis 1. Install the bottles with all reagents (acetonitrile, deblock solution, cap A and B solutions, oxidizer solution, activator solution), phosphoramidite solutions [dT, dC(bz), dA(bz), and dG(ib)], and diene-amidite S.7 in an automated DNA sythesizer according to the manufacturer’s instructions (also see APPENDIX 3C). Flush with helium and prime the fluidics system three times. 2. Use the sequence editor to enter a new sequence or edit an existing sequence for synthesis. 3. Load the appropriate synthesis column for 1-µmol scale. 4. Choose the DMTr-ON option in the setup menu and perform the synthesis. The standard synthesis cycle is applied in the last cycle for the diene-amidite (S.7) coupling. Cycle steps are listed in Table 4.18.1.
5. Remove the synthesis column from the instrument. 6. Cleave the oligonucleotide from the solid support in the column by treatment with 1 mL concentrated ammonium hydroxide for 30 min at room temperature. 7. Collect the ammonia solution containing the oligonucleotide into a screw-cap tube and deprotect the oligonucleotide by heating in a heating block at 55°C for 8 hr or overnight. 8. Dry the deprotected oligonucleotide in a Speedvac evaporator. Desalt oligonucleotides 9. Dissolve ∼100 OD260 units of crude oligonucleotide in 100 µL of deionized water. 10. Add 11 µL of 3 M sodium acetate solution and mix. 11. Add 333 µL of isopropanol, then vortex. 12. Incubate overnight at room temperature. 13. Microcentrifuge 10 min at maximum speed (≥10,000 × g), room temperature. 14. Remove the supernatant and discard; avoid disturbing the pellet. 15. Add 300 µL of 70% ethanol, mix briefly, and place in a freezer at −20°C for 2 hr. 16. Microcentrifuge 5 min at maximum speed (≥10,000 × g), room temperature. 17. Remove the supernatant and discard. 18. Evaporate pellet to dryness in a Speedvac evaporator. 19. Quantify the oligonucleotide by OD260 measurement (UNIT 10.3). Synthesis of Oligonucleotide Conjugates via Diels-Alder Cycloaddition
4.18.8 Supplement 15
Current Protocols in Nucleic Acid Chemistry
Table 4.18.1 Standard Expedite 1-µmol DNA Synthesis Protocol Applied for Synthesis of Diene-Modified Oligonucleotides using Diene-Amidite (S.7).
Operation
Function
Mode
Amount
Time (sec) Description
Index Fract. Coll. Default Trityl Mon. On/Off Dblk Dblk Diverted Wsh A Trityl Mon. On/Off Diverted Wsh A Index Fract. Coll.
NA
1
0
Event out ON
WAIT NA
0 1
1.5 1
PULSE PULSE PULSE
10 50 40
0 49 0
NA
0
1
Wait START data collection Dblk to column Deblock Flush system with Wsh A STOP data collection
PULSE
40
0
NA
2
0
Deblocking 144 0 141 16 16 38 141 38 144
Flush system with Wsh A Event out OFF
Coupling 1
Wsh
PULSE
5
0
Flush system with Wsh Flush system with Act Monomer + Act to column Couple monomer Couple monomer Couple monomer Flush system with Wsh
2
Act
PULSE
5
0
22
S.7 + Act
PULSE
6
0
22 2 1 1
S.7 + Act Act Wsh Wsh
PULSE PULSE PULSE PULSE
1 4 7 8
8 32 56 0
12
Wsh A
PULSE
20
0
13 12 12
Caps Wsh A Wsh A
PULSE PULSE PULSE
8 6 14
0 15 0
Ox Wsh A
PULSE PULSE
15 15
0 0
Ox to column Flush system with Wsh A
Caps Wsh A
PULSE PULSE
7 30
0 0
Caps to column End of cycle wash
Capping Flush system with Wsh A Caps to column Cap Flush system with Wsh A
Oxidizing 15 12 Capping 13 12
aNA, not applicable.
Synthesis of Modified Oligonucleotides and Conjugates
4.18.9 Current Protocols in Nucleic Acid Chemistry
Supplement 14
BASIC PROTOCOL 3
LABELING OF A 5′-DIENE-MODIFIED OLIGONUCLEOTIDE WITH TAMRA-5-MALEIMIDE This protocol describes the conjugation of TAMRA-5-maleimide to a diene-modified oligonucleotide via aqueous Diels-Alder cycloaddition (Fig. 4.18.3). The crude 5′-dienemodified oligonucleotide is dissolved in sodium acetate buffer, pH 4.5, and treated with a 10-fold excess of TAMRA-5-maleimide. The mixture is heated at 60°C for 4 hr. Excess dye is removed by size-exclusion chromatography employing NAP-5 columns. The labeled oligonucleotides obtained can be purified by high-performance liquid chromatography (HPLC; UNIT 10.5) or polyacrylamide gel electrophoresis (PAGE; UNIT 10.4). Materials Diene-modified oligonucleotide (see Basic Protocol 2) 100 mM sodium acetate buffer, pH 4.5 (APPENDIX 2A) 40 mM TAMRA-5-maleimide solution: 5.0 mg TAMRA-5-maleimide (Molecular Probes) in 268 µL dimethylformamide (DMF) Heating block NAP-5 columns (Amersham Pharmacia Biotech) Speedvac evaporator Additional reagents and equipment for quantitating oligonucleotides by OD260 measurement (UNIT 10.3) Label diene-modified oligonucleotide 1. Prepare a 1 mM stock solution of the diene-modified oligonucleotide in deionized water. Calculations are based on the OD260 readings obtained (see Basic Protocol 2, step 19) and the calculated extinction coefficient of the oligonucleotide (UNIT 10.3).
O O 3′ N1.....Nn P
−
H N
O
+
O
N
O
O
NaOAc buffer pH 4.5
TAMRA
O
4 hr, 60 °C
O O 3′ N1.....Nn
P
−
O
Synthesis of Oligonucleotide Conjugates via Diels-Alder Cycloaddition
O
H N
O O
N
TAMRA
O
Figure 4.18.3 Labeling of diene-modified oligonucleotide with TAMRA-5-maleimide via aqueous Diels-Alder cycloaddition.
4.18.10 Supplement 14
Current Protocols in Nucleic Acid Chemistry
2. In a 1.5-mL microcentrifuge tube, prepare a mixture of: 20 µL 1 mM diene-modified oligonucleotide (20 nmol) 50 µL 100 mM sodium acetate buffer, pH 4.5 25 µL deionized water 5 µL 40 mM TAMRA-5-maleimide solution. 3. Incubate the mixture for 4 hr at 60°C in a heating block. If desired, store mixture up to 2 to 4 weeks at −20°C. Remove excess dye by size-exclusion chromatography 4. Remove the top of the NAP-5 column and discard the preservative solution into a waste container. Remove the bottom cap. 5. Equilibrate the NAP-5 column with 10 mL of deionized water. 6. Load 100 µL of the labeling solution and allow it to enter the NAP-5 gel bed completely. 7. Load 400 µL of deionized water; discard the eluate. 8. Elute twice, each time with 500 µL of deionized water, and collect 500-µL fractions in separate vials. 9. Identify product-containing fractions by OD260 measurement (UNIT 10.3). 10. Combine the product-containing fractions and evaporate to dryness in a Speedvac evaporator. 11. Optional: Purify crude oligonucleotide by RP-HPLC (UNIT 10.5) or PAGE (UNIT 10.4). REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
TLC stain Solution A: Weigh 0.2 g of 3-methoxyphenol (Aldrich) into a 250-mL beaker and add absolute ethanol to make 100 g of solution (0.2% w/w final). Solution B: Add 5.3 mL concentrated sulfuric acid (H2SO4) to a 250-mL beaker containing ∼50 mL of absolute ethanol. Add ethanol to make 100 mL (1 M H2SO4 final). TLC stain: In a 250-mL screw-cap vial, mix equal volumes of solutions A and B (usually 50 mL). Prepare fresh. CAUTION: Sulfuric acid is corrosive. Avoid skin and eye contact. Addition of the acid to ethanol is exothermic.
COMMENTARY Background Information The chemical synthesis of modified oligonucleotides is of increasing interest for studying biological processes in vivo and in vitro, in particular for diagnostic applications. Oligonucleotides are modified to prepare conjugates with reporter groups such as fluorophores or biotin, ligands for radioactive labeling, peptides, enzymes, antibodies, and carbohy-
drates (Goodchild, 1990). Other applications require the attachment of oligonucleotides to surfaces, e.g., to produce microarrays (Bowtell and Sambrook, 2002) or to conjugate oligonucleotides to nanoparticles (Letsinger et al., 2000). A number of strategies have been applied to chemically modify oligonucleotides at the 3′ and/or 5′ terminus (UNITS 4.2, 4.3, 4.5, & 4.6) or in the middle of the sequence. For 3′-modi-
Synthesis of Modified Oligonucleotides and Conjugates
4.18.11 Current Protocols in Nucleic Acid Chemistry
Supplement 14
fication, a branched linker is attached to the solid support employed for oligonucleotide synthesis. The linker either comprises a functional group for postsynthetic modification reactions or an attached reporter group or ligand that alleviates the need for postsynthetic modifications (UNITS 4.5 & 4.6). Functionalized nucleoside building blocks are used to incorporate a modification in the middle of the sequence (Telser et al., 1989) or at the 5′ terminus (Smith et al., 1985). For 5′-modification, a non-nucleosidic phosphoramidite such as fluorochrome amidite or a biotin-functionalized amidite can be coupled to the oligonucleotide in the last synthesis cycle (UNITS 4.2 & 4.3). Many fluorochrome-phosphoramidites and other amidites containing reporter groups of haptens are commercially available to allow on-support labeling. As an alternative method, the phosphoramidite employed in the last synthesis cy-
Protected FG
cle can contain a protected functional group. After its deprotection, the functional group is available for postsynthetic conjugation to a modifier containing the corresponding functionality for attachment (UNIT 4.2). Examples of standard conjugation methods are given in Figure 4.18.4. The Diels-Alder conjugation method (Hill et al., 2001) extends the portfolio of conjugation chemistries, as it contains some unique features. (1) The method is applicable for conjugation reactions in aqueous media and therefore allows postsynthetic labeling of oligonucleotides. (2) Protection of the functional group is not necessary, as the diene moiety is stable under the standard synthesis and deprotection conditions employed for solid-phase oligonucleotide synthesis.
Incoming FG
FG
O
Covalent linkage
O O
NHMMTr
NH2
N
O
NHTFA
NH O amine
NHS-ester
amide
O
O S
S
SR
SH
N
N
O disulfide
thiol
O
O
O P OR OR phosphate triester
O
maleimide
HO
O P
−
O
O
terminal phosphate
alcohol
phosphate diester O
N
N O
O diene
O −
O
Synthesis of Oligonucleotide Conjugates via Diels-Alder Cycloaddition
sulfide
O OH
P
O
maleimide
Diels-Alder adduct
Figure 4.18.4 Common oligonucleotide conjugation methods. Abbreviations: FG, functional group; MMTr, 4-monomethoxytrityl; TFA, 2,2,2-trifluoroacetyl.
4.18.12 Supplement 14
Current Protocols in Nucleic Acid Chemistry
(3) The Diels-Alder conjugation reaction is fast and selective for dienophiles, such as maleimides. (4) The method is orthogonal to other common methods (see Fig. 4.18.4) and therefore allows combination with other functionalities (e.g., amines) to prepare dual-labeled probes in one pot. Basic Protocol 3 allows for the conjugation of diene-modified oligonucleotides to any substrate containing maleimides or other suitable dienophiles and allows the preparation of modified oligonucleotides used in the spectrum of biological applications.
Critical Parameters Synthesis of diene-alcohol The synthesis of the diene-alcohol S.5 is straightforward and can be conveniently performed on a larger scale. It is not necessary to purify intermediates S.2 to S.4, as compound S.5 can be satisfactorily purified by fractional distillation. For successful performance of the bis-dehydrohalogenation, it is crucial to use fresh potassium tert-butoxide and to use anhydrous conditions; otherwise, prolonged reaction times or incomplete conversion will be observed. If the reaction is not complete after the time given in the protocol, an additional portion of potassium tert-butoxide (∼10% of the initial amount) should be added and the reaction mixture stirred for another hour. Compounds S.4 and S.5 appear to be volatile liquids. After evaporation of the organic phases containing these volatile intermediates, drying under high vacuum should be avoided. Purification and storage of diene-amidite If wet silica gel is used for the flash chromatography of diene-amidite S.7, the formation of byproducts may be observed. Equilibration of the column employing a 1% solution of triethylamine in EtOAc, instead of EtOAc alone, helps to buffer the acidic silica gel. Subsequently, the column should be treated with EtOAc to replace the triethylamine solution. After purification, the amidite (S.7) should be dried under high vacuum and stored under dry argon in a refrigerator at 4°C. It is advantageous to distribute the amidite to appropriate clean, dry synthesizer bottles immediately after preparation in order to avoid repeated opening of the amidite container. The bottles should be flushed with argon and sealed.
Oligonucleotide synthesis The synthesizer used for oligonucleotide synthesis should be operated and maintained according to the manufacturer’s instructions. It is crucial to use appropriate solvents and reagents and to prime all the lines carefully prior to synthesis. A freshly prepared solution of diene-amidite (S.7) should be used. It is not necessary to prolong the coupling time for the final diene-amidite coupling compared to coupling of standard amidites. Diels-Alder cycloaddition reaction The reaction conditions for the Diels-Alder conjugation reaction have given the best labeling results. For sensitive substrates, it could be desirable to carry out the Diels-Alder conjugation under different reaction conditions, such as lower temperature or higher pH. Successful conjugation may only be possible in exchange for a lower yield. Limitations are: (1) fast hydrolysis of maleimides at pH >8, (2) decreased reaction rates at temperatures <35°C, and (3) the requirement that DMF content not exceed 20%. Purification of crude oligonucleotide conjugates can be performed by standard methods such as reversed-phase high-performance liquid chromatography (RP-HPLC; UNIT 10.5) or polyacrylamide gel elctrophoresis (PAGE; UNIT 10.4).
Anticipated Results By applying the methods in this unit and observing the critical parameters, it is possible to prepare the diene-amidite (S.7) at a 30% overall yield, with a purity of ≥98%, determined by RP-HPLC and 31P NMR analysis (see Basic Protocol 2). Diene-functionalization of oligonucleotides employing pure phosphoramidite (S.7) usually provides coupling efficiencies >99%. The conjugation of dienefunctionalized oligonucleotides to maleimides typically proceeds with efficiencies >80%.
Time Considerations The preparation of diene-amidite (S.7) takes ∼2 weeks, if the scale given in the protocol is applied. The time for the assembly of a 5′-dienemodified oligonucleotide (synthesis of a 20mer on 1-µmol scale), including deprotection and desalting, takes ~3 days. The conjugation reaction, including size-exclusion chromatography, typically requires 2 days. Synthesis of Modified Oligonucleotides and Conjugates
4.18.13 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Literature Cited Bowtell, D. and Sambrook, J. (eds.) 2002. DNA Microarrays: A Molecular Cloning Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Goodchild, J. 1990. Conjugates of oligonucleotides and modified oligonucleotides: A review of their synthesis and properties. Bioconjugate Chem. 1:165-187. Hill, K.W., Taunton-Rigby, J., Carter, J.D., Kropp, E., Vagle, K., Pieken, W., McGee, D.P.C., Husar, G., Leuck, M., Anziano, D., and Sebesta, D.P. 2001. Diels-Alder bioconjugation of dienemodified oligonucleotides. J. Org. Chem. 66:5352-5358. Letsinger, R.L., Elghanian, R., Biswanadham, G., and Mirkin, C. 2000. Use of a steroid cyclic disulfide anchor in constructing gold nanoparticle-oligonucleotide conjugates. Bioconjugate Chem. 11:289-291.
Smith, L.M., Fung, S., Hunkapiller, M.W., Hunkapiller, T.J., and Hoo, L.E. 1985. The synthesis of oligonucleotides containing an aliphatic amino group at the 5′ terminus: Synthesis of fluorescent DNA primers for use in DNA sequence analysis. Nucl. Acids Res. 13:2399-2412. Telser, J., Cruickshank, K.A., Morrison, L.E., and Netzel, T.L. 1989. Synthesis and characterization of DNA oligomers and duplexes containing covalently attached molecular labels: Comparison of biotin, fluorescein, and pyrene labels by thermodynamic and optical spectroscopic measurements. J. Am. Chem. Soc. 111:6966-6976.
Contributed by Michael Leuck and Andreas Wolter Proligo LLC Boulder, Colorado
Synthesis of Oligonucleotide Conjugates via Diels-Alder Cycloaddition
4.18.14 Supplement 14
Current Protocols in Nucleic Acid Chemistry
5′-Iodination of Solid-Phase-Linked Oligodeoxyribonucleotides
UNIT 4.19
This unit describes a method for converting the 5′-hydroxyl of CPG-bound oligodeoxyribonucleotides to an iodo group. This procedure is useful when an electrophilic group is desired in the terminal 5′-position of an oligodeoxyribonucleotide. Because the iodo group is an efficient leaving group in SN2 displacement reactions, its introduction at the 5′-position allows for facile ligation to small molecules or macromolecules containing a strongly nucleophilic group. Additionally, 5′-iodo oligonucleotides can easily be converted to a wide variety of other functional groups. Two protocols are described in this unit. For both procedures, an oligonucleotide is prepared on an automated DNA synthesizer (see APPENDIX 3C) and is then iodinated in-column (i.e., while still protected and immobilized on the CPG resin in the column). The first method (see Basic Protocol) describes a manual procedure performed by adding reagents to the column after it is removed from the synthesizer. The second method (see Alternate Protocol) provides an automated method performed by programming the synthesizer to perform the same iodination reaction. The manual procedure is suitable for most applications, while the automated method may be preferable for carrying out multiple iodination reactions. CAUTION: All chemicals must be used in a fume hood by qualified individuals equipped with laboratory coats, safety glasses, and gloves. MANUAL PROCEDURE FOR 5′-IODINATION OF OLIGODEOXYRIBONUCLEOTIDES ON A SOLID SUPPORT This protocol outlines a method to convert the 5′-hydroxyl on protected CPG-bound oligodeoxyribonucleotides to an iodo group (Fig. 4.19.1). In this procedure, an iodination solution is passed between two syringes fitted to the ends of a DNA synthesis column containing the attached oligodeoxyribonucleotide, converting the 5′-hydroxyl to an iodo group. The 5′-iodo-modified oligodeoxyribonucleotide can subsequently be cleaved and deprotected using 28% aqueous NH4OH.
BASIC PROTOCOL
Materials Anhydrous N,N-dimethylformamide (DMF) Iodination solution (see recipe) Methylene chloride (CH2Cl2) 28% (v/v) ammonium hydroxide (NH4OH) DNA synthesizer (e.g., ABI; see APPENDIX 3C) 0.2 to 10 µmol DNA synthesis column with long-chain alkylamine controlled-pore glass (CPG) support 1- and 10-mL syringes Shaker, rocker, or other agitating device C18 reversed-phase HPLC column (UNIT 10.5) Speedvac evaporator Additional reagents and equipment for oligonucleotide synthesis (Chapters 3 and 4 and APPENDIX 3C) and reversed-phase HPLC (UNIT 10.5) Synthesis of Modified Oligonucleotides and Conjugates Contributed by Eric T. Kool and Gregory P. Miller Current Protocols in Nucleic Acid Chemistry (2003) 4.19.1-4.19.8 Copyright © 2003 by John Wiley & Sons, Inc.
4.19.1 Supplement 14
HO
I
B1
O O
O P
O
(PhO)3PCH3I OCH2CH2CN
O
O
O P dry DM F
CPG
OCH2CH2CN
O
B2
O
O
O N H
B1
O
O O
n CPG
N H
O
B2
n
O
Figure 4.19.1 Iodination of solid-phase-linked oligodeoxyribonucleotides. Abbreviations: B1 and B2, thymine and/or N-protected nucleobases; CPG, long-chain alkylamine controlled-pore glass (resin).
Synthesize oligonucleotide and obtain control sample 1. Using a DNA synthesizer, synthesize 0.2 to 10 µmol of CPG-bound protected oligodeoxyribonucleotide with the 5′-O-(4,4′-dimethoxytrityl) group removed (DMTr-OFF; see APPENDIX 3C). 2. Open DNA synthesis column, remove and set aside ∼1 mg of resin, then close column. This sample of the resin will be cleaved and deprotected without undergoing the iodination reaction and thus can be used as an HPLC reference to determine the retention time of the starting material and estimate the retention time of the 5′-iodinated product.
Dehydrate resin 3. Attach an empty 1.0-mL syringe to one end of the DNA synthesis column. To the other end, attach a 1.0-mL syringe filled with anhydrous DMF. 4. Slowly push DMF through column to the other syringe. This step should remove any water that may be adsorbed to the resin that would otherwise react with the water-sensitive iodination reagent.
Iodinate oligodeoxyribonucleotide 5. Remove the DMF-filled syringe and quickly replace with a 1.0-mL syringe filled with iodination solution. 6. Push iodination solution back and forth between the two syringes several times. 7. Seal the junctions between the column and the syringes with Parafilm to prevent leakage. 8. Put on shaker, rocker, or other agitating device for 15 to 20 min at room temperature. If the 5′-end of the oligonucleotide contains a bulky group, it may be desirable to increase the reaction time (see Critical Parameters and Troubleshooting for details).
9. Unwrap the column and use the syringes to remove the iodination solution from the column. 5′-Iodination of Solid-Phase-Linked Oligodeoxyribonucleotides
10. Using a 10-mL syringe, push 5 to 10 mL DMF through the column, followed by a few milliliters of CH2Cl2. Blow-dry beads using air. The CH2Cl2 is not mandatory, but it facilitates drying of the CPG beads, making it easier to remove them from the column.
4.19.2 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Cleave and deprotect iodinated deoxyribonucleotide 11. Open column and transfer beads to a sealed vial for deprotection. 12. Cleave and deprotect the iodinated product and the sample of starting material (from step 2) by soaking each resin in 28% NH4OH (∼1 mL for 1-µmol column) at room temperature for 18 to 24 hr. 13. Remove ammoniacal solution, rinse beads twice with small portions (e.g., 0.25 mL for 1-µmol column) of deionized water, combine portions, and evaporate liquids in a Speedvac evaporator. 14. Analyze purity by HPLC using a C18 reversed-phase column (UNIT 10.5). AUTOMATED PROCEDURE FOR 5′-IODINATION OF OLIGODEOXYRIBONUCLEOTIDES ON A SOLID SUPPORT
ALTERNATE PROTOCOL
This protocol involves the use of a DNA synthesizer to perform the same iodination reaction described in the Basic Protocol. The advantage of this automated procedure is that the iodination reaction can be conveniently run on the DNA synthesizer as a 15-min procedure following DNA synthesis. Depending on the number of columns on the particular synthesizer, multiple reactions may be run simultaneously. Although the iodination reagent is not harmful to the synthesizer, the reagent must be filtered prior to use to ensure that no particulates clog the lines. Because of this additional step, it is often more convenient to use the manual procedure if only one or two iodination reactions will be performed. If multiple reactions are to be performed, the automated procedure is generally faster and more convenient. Additional Materials (also see Basic Protocol) Glass wool or line filter (e.g., preparation and delivery line filter from ABI) Empty DNA synthesis column (e.g., 1000-Å CPG column; ABI) 10-mL syringes Clean, oven-dried phosphoramidite bottle compatible with synthesizer Reagent bottle compatible with synthesizer, filled with anhydrous DMF Synthesize oligonucleotide 1. Using a DNA synthesizer, synthesize 0.2 to 10 µmol CPG-bound protected oligodeoxyribonucleotide with the 5′-O-DMTr group removed (see APPENDIX 3C). Some resin (≤1 mg) may be removed at this point to use as a reference in HPLC.
Filter iodination solution for use in synthesizer 2. Filter iodination solution under anhydrous conditions as follows. Insert a small filter or glass wool into an empty DNA synthesis column. Take up iodination solution in a 5- or 10-mL syringe, and attach it to the column/filter. Attach another syringe to the opposite end of the column. Push solution through column/filter into the opposite syringe. Generally, each reaction requires ≤1 mL of iodination solution. The Preparation and Delivery Line Filter from ABI is the ideal size and shape to fit into a 1000-Å ABI CPG column. If the solution contains a large quantity of particulates, the filter may become clogged. If this happens, it may be necessary to remove the syringes (while making sure to minimize exposure to the air) and wash the filter. To wash it, simply push dry DMF through the column filter in the opposite direction from that in which the iodination solution was flowing. The above filtration system is only one of a variety of ways that the filtration can be performed.
Synthesis of Modified Oligonucleotides and Conjugates
4.19.3 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Table 4.19.1 IodoCycle Program for ABI 392 and 394 Synthesizersa
Step
Function
Time (sec)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Begin Prep DMF DMF to waste DMF to column Reverse flush Block flush Phos prep Iodo to column DMF to waste Block flush Wait Reverse flush Iodo to column DMF to waste Block flush Wait DMF to column Flush to waste DMF to column Flush to waste DMF to column Reverse flush Block flush CH3CN to waste CH3CN to column Reverse flush CH2Cl2 to waste CH2Cl2 to column Reverse flush Block flush End
15 4 15 10 4 3 20 3 4 300 10 20 3 4 300 15 10 20 10 20 10 4 3 20 10 3 20 10 4
aModified from Miller and Kool (2002) with permission from the American
Chemical Society.
3. Attach a needle to the syringe containing the iodination solution. 4. Inject the iodination solution into an oven-dried and septum-sealed phosphoramidite bottle. Prepare synthesizer for iodination reaction 5. Write an iodination procedure for the DNA synthesizer containing the following steps:
5′-Iodination of Solid-Phase-Linked Oligodeoxyribonucleotides
a. b. c. d. e.
Rinse beads with anhydrous DMF. Send iodination solution to column. Wait (5 min). Flush iodination solution to waste. Send iodination solution to column.
4.19.4 Supplement 14
Current Protocols in Nucleic Acid Chemistry
f. Wait (5 min). g. Rinse with anhydrous DMF. An example of a functional procedure for ABI 392 and 394 synthesizers is shown in Table 4.19.1.
6. Install the iodination reagent into one of the phosphoramidite positions and install a bottle of anhydrous DMF into one of the reagent positions on the DNA synthesizer. 7. Edit sequence: enter a single base as the sequence. If this is not done, the iodination cycle will repeat itself for each base in the sequence.
Iodinate oligodeoxyribonucleotide 8. Start synthesis. Due to differences between synthesizers, it is recommended that the column be observed while the cycle is run the first few times to make sure the “iodination solution to column” and “wash” sequences are of the correct length of time. A period of 20 to 30 sec for “iodination solution to column” should be sufficient to completely fill the columns on an ABI 392 or 394 synthesizer.
Cleave and deprotect iodinated deoxyribonucleotide 9. After the synthesis is complete, transfer the CPG resin to a sealed vial. Cleave and deprotect the iodinated product by soaking the resin in 28% NH4OH (∼1 mL for 1-µmol column) at room temperature for 18 to 24 hr. 10. Remove iodination solution and DMF from synthesizer. To ensure that the iodination reagent does not damage or contaminate the synthesizer, replace the iodination reagent bottle with one containing anhydrous DMF and use the manual functions to briefly rinse the lines. The unused iodination solution can be stored in the phosphoramidite bottle (see recipe for storage conditions).
11. Analyze purity using HPLC with a C18 reversed-phase column (UNIT 10.5). REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Iodination solution 0.226 g (0.5 mmol) methyltriphenoxyphosphonium iodide [(PhO)3PCH3I; Aldrich; 0.5 M final] 0.85 ml anhydrous N,N-dimethylformamide (DMF) Prepare fresh or store up to 3 months at –70°C If the solution will be used on a DNA synthesizer, it should be filtered before use (see Alternate Protocol). (PhO)3PCH3I reacts quickly with water and is light sensitive. Minimize exposure of the reagent to the atmosphere while weighing, and promptly flush the vial and the original reagent bottle with N2 or argon when finished. It is convenient to prepare the iodination solution during oligonucleotide synthesis. If the solution will be used within a few hours of its preparation, there is no need to protect it from light. If the iodination solution has been frozen, always refilter (see Alternate Protocol, step 2) after thawing. (PhO)3PCH3I is often the consistency of mud or a thick oil. Although this makes it more difficult to manipulate, it generally still works well.
Synthesis of Modified Oligonucleotides and Conjugates
4.19.5 Current Protocols in Nucleic Acid Chemistry
Supplement 14
COMMENTARY Background Information
5′-Iodination of Solid-Phase-Linked Oligodeoxyribonucleotides
In 1997, Xu and co-workers described a DNA-ligation method which allowed for the efficient ligation of a 5′-iodo-modified oligodeoxyribonucleotide with a 3′-phosphorothioated oligonucleotide (Xu and Kool, 1997). In the presence of a complementary template, ligation proceeded efficiently under mild conditions. The product of this ligation method is an oligonucleotide identical to natural DNA with the exception that one oxygen atom in the phosphodiester backbone is replaced by a sulfur atom; it therefore retains most of the chemical properties of natural DNA (Xu and Kool, 1998). The 5′-iodo-modified oligomers were prepared on a DNA synthesizer using a prev iou sly synthesized 5′-iodo-dT phosphoramidite. Unfortunately, 5′-iodo-modified phosphoramidites are time-consuming and expensive to synthesize, so the utility of this ligation system was significantly limited. It was subsequently found that the 5′-iodooligodeoxyribonucleotides are in fact accessible via a much simpler, more direct route (Miller and Kool, 2002). The protocols described in this unit are based on this new approach, in which 5′-iodination is carried out directly on the DNA column, before deprotection and cleavage. The protecting groups used on the DNA bases and backbone effectively prevent the very reactive (PhO)3PCH3I from reacting at any site other than the 5′-hydroxyl. This is true when using both Glen Research’s Sterling 2-cyanoethyl (CE) phosphoramidites (5′-DMTr-dABz, 5′-DMTr-dCBz, and 5′-DMTrdGi-Bu) or their Ultramild CE phosphoramidites (5′-DMTr-dAi-Bu or 5′-DMTr-dAAcOPh, 5′DMTr-dGAcOPh-i-Pr, and 5′-DMTr-dCAc). Also, it was found that when deprotection and cleavage are carried out at room temperature for 24 hr, very little hydrolysis of the iodo group occurs. This new method of iodinating the 5′end of oligodeoxyribonucleotides effectively makes the 5′-iodo/3′-phosphorothioate ligation system accessible to anyone with access to synthetic DNA. Unfortunately, it was found th at b oth 2′-O-tert-butyldimethylsilyl (TBDMS) and 2′-O-triisopropylsilyloxymethyl (TOM) protecting groups on protected oligoribonucleotides are cleaved by both (PhO)3PCH3I and another iodinating system, PPh3/I2/imidazole in DMF (Kool and Miller, unpub. observ.). In addition to their usefulness in DNA ligation reactions, the 5′-iodo oligomers are also
good intermediates for making other types of 5′-modifications. The 5′-iodo group is easily converted to thiols, amines, azides, thioethers, thiocyanates, and selenides while the oligomer is still attached to resin (Kool and Miller, unpub. observ.). 5′-Thiols and amines are convenient handles for attaching isothiocyanates, succinimidyl esters, maleimides, iodoacetamides, and other commercially available labels. Alternatively, thiol-containing moieties will react directly with 5′-iodo oligomers, forming very stable thioethers.
Critical Parameters and Troubleshooting The most important key to success in running this reaction is to keep the iodination reagent anhydrous. The large excess of reagent called for in this protocol should temper this potential problem. Care should nevertheless be taken to minimize the amount of time the reagent is exposed to the air, and the reagent and iodination solution should always be stored under an inert gas. Another important point is that the reaction time may need to be increased when bulkier groups are in the 5′-position. For example, when pyrene is in the 5′-position, the iodination reaction requires ∼25 min for completion. Additionally, if there is a modified base containing a strong nucleophile near the 5′-end, it may displace the iodo group, cyclizing the oligomer either during synthesis or during deprotection. This is often observed when the 5′-base is a purine, in which the N3 nitrogen attacks the 5′-carbon, resulting in some cyclized material (Dimitrijevich et al., 1979). This cyclized byproduct may be hydrolyzed back to the 5′hydroxy starting material upon treatment with NH4OH.
Anticipated Results The hydrophobicity of the iodo group allows for easy separation of 5′-modified oligodeoxyribonucleotides from their 5′-hydroxy starting materials via reversed-phase HPLC (UNIT 10.5). For example, using a gradient of 0% to 20% CH3CN in 50 mM triethylammonium acetate (TEAA), pH 7.0, over a 20-min period to elute the crude reaction mixture from an analytical C18 reversed-phase column, iodinated trimers elute 5 min later than their corresponding starting materials, while iodinated 13-mers elute ∼2 min after their respective starting materials (see Fig. 4.19.2). A chromatogram of the de-
4.19.6 Supplement 14
Current Protocols in Nucleic Acid Chemistry
protected 5′-hydroxyl starting material should therefore give an indication of when the iodinated product will come off of the column. Also, knowledge of the starting material retention time allows for calculation of percent conversion to the iodinated product. Electrospray ionization (ESI) mass spectrometry (UNIT 10.2) should be used to verify the identity of the product. The success of this iodination reaction appears to depend on the identity of the 5′-base,
3000
13T-I
12
but not the overall base composition, of a particular oligomer. Generally, 5′-pyrimidines afford the highest yields because they do not cyclize as easily as purines. Yields of 70% to 90% are typical for pyrimidines and 50% to 80% for purines, based on total integration of HPLC chromatograms (Miller and Kool, 2002, and unpub. observ.). Because the starting material will contain failure sequences from incomplete phosphoramidite coupling during oligomer synthesis, HPLC chromatograms will
13T-OH
13
14
15
16
17
3000
13C-I
13C-OH
2000
1000
0 11
12
13
13A-I
14
15
16
15
16
17
13A-OH
2000
1000
0 12
13
14
13G-I
13G-OH
2000
1000
0 12
13
14 Minutes
15
16
Figure 4.19.2 RP-HPLC profiles of 5′-d(NGTAGGCAAGAGT) before and after 5′-iodination. From top to bottom, N = T, C, A, and G, respectively. Reprinted from Miller and Kool (2002) with permission from the American Chemical Society.
Synthesis of Modified Oligonucleotides and Conjugates
4.19.7 Current Protocols in Nucleic Acid Chemistry
Supplement 14
contain multiple peaks. However, a single predominant product peak with a longer retention time should be observed when using a reversedphase column.
Time Considerations The manual procedure described in the Basic Protocol can be completed in less than an hour. The automated procedure requires more time to set up the reactions, but once the reagent and synthesizer are prepared, many reactions can be performed quickly. For example, if a 4-column synthesizer is used with a 15-min iodination cycle, 16 reactions can be performed per hour.
Miller, G.P. and Kool, E.T. 2002. A simple method for electrophilic functionalization of DNA. Org. Lett. 4:3599-3601. Xu, Y. and Kool, E.T. 1997. A novel 5′-iodonucleoside allows efficient non-enzymatic ligation of single-stranded and duplex DNAs. Tetrahedron Lett. 38:5595-5598. Xu, Y. and Kool, E.T. 1998. Chemical and enzymatic properties of bridging 5′-S-phosphorothioester linkages in DNA. Nucl. Acids Res. 26:31593164.
Key References Miller and Kool, 2002. See above. Reports a method to iodinate the 5′-carbon of oligodeoxyribonucleotides on a solid support.
Literature Cited Dimitrijevich, S.D., Verheyden, J.P.H., and Moffatt, J.G. 1979. Halo sugar nucleosides. 6. Synthesis of some 5′-deoxy-5′-iodo and 4′,5′-unsaturated purine nucleosides. J. Org. Chem. 44:400-406.
Contributed by Eric T. Kool and Gregory P. Miller Stanford University Stanford, California
5′-Iodination of Solid-Phase-Linked Oligodeoxyribonucleotides
4.19.8 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Reversible Biotinylation of the 5′-Terminus of Oligodeoxyribonucleotides and Its Application in Affinity Purification
UNIT 4.20
In UNIT 4.2, several methods for biotinylation of DNA are described (see structures 95b, 96, 101, 104a, 106, and 124a-c in that unit). Except for structure 124c, in which the biotin moiety can be removed nondestructively by UV irradiation, other biotinylation methods are irreversible. UNIT 4.3 presents protocols for direct attachment of acridine and psoralen derivatives to the 5′-terminus of DNA via their phosphoramidites. In this unit, protocols are given for the preparation of two reversible biotinylation phosphoramidites for direct labeling of the 5′-terminus of DNA (see Basic Protocols 1 and 2 and Support Protocol 2) and their applications in NeutrAvidin-coated microsphere-mediated affinity purification of synthetic oligodeoxyribonucleotides (see Support Protocol 1). The DNAs synthesized using these two phosphoramidites feature a diisopropyl silyl acetal linkage between biotin and their 5′-termini; these linkages can be readily broken by fluoride ions. The first of the two phosphoramidites yields 5′-OH unmodified DNA upon treatment with HF/pyridine, while the second phosphoramidite yields 5′-phosphate DNA on treatment with HF/pyridine followed by aqueous methylamine. CAUTION: All chemicals must be handled in a well-ventilated fume hood by individuals equipped with laboratory coats, safety glasses, and gloves. REVERSIBLE BIOTINYLATION VIA A DIISOPROPYL SILYL ACETAL LINKER YIELDING 5′-OH DNA This protocol describes the preparation of the reversible biotinylation phosphoramidite S.3 (see Fig. 4.20.1), its coupling to the 5′-end of DNA on an automatic solid-phase synthesizer, and postsynthetic cleavage/deprotection to afford the biotinylated DNA S.4 (see Fig. 4.20.1). A sample sequence is shown in S.5. Other appropriately protected deoxyribonucleosides, such as N6-benzoyldeoxyadenosine, N2-isobutyryldeoxyguanosine, and N4-acetyldeoxycytosine, should be able to be biotinylated using the same procedure. Materials Biotinyl alcohol S.1 (see Support Protocol 2 for preparation) Imidazole (99%) Argon and nitrogen gas N,N-Dimethylformamide (DMF, anhydrous) Diisopropylethylamine (DIEA) Diisopropyldichlorosilane (Fluka) Thymidine (99%+) Ethyl acetate 5% (w/v) sodium bicarbonate (NaHCO3) Sodium sulfate (Na2SO4, anhydrous) Chloroform (CHCl3) Methanol 40-µm silica gel (Baker) TLC plates: silica gel on aluminum (60F-254, 200-µm thickness) Methylene chloride (CH2Cl2, anhydrous) 2-Cyanoethyl-N,N,N′,N′-tetraisopropylphosphoramidite (2-cyanoethyltetraisopropylphosphorodiamidite, 97%) Contributed by Shiyue Fang and Donald E. Bergstrom Current Protocols in Nucleic Acid Chemistry (2003) 4.20.1-4.20.17 Copyright © 2003 by John Wiley & Sons, Inc.
BASIC PROTOCOL 1
Synthesis of Modified Oligonucleotides and Conjugates
4.20.1 Supplement 14
1H-Tetrazole (99%+, sublimed) Tetrahydrofuran (THF, 99%+) 5′-DMTr, 2-cyanoethyl phosphoramidite monomers: 5′-O-dimethoxytrityl-N6-benzoyl-2′-deoxyadenosine-3′-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (dABz) 5′-O-dimethoxytrityl-N2-isobutyryl-2′-deoxyguanosine-3′-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (dGi-Bu) 5′-O-dimethoxytrityl-N4-acetyl-2′-deoxycytidine-3′-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (dCAc) 5′-O-dimethoxytrityl-2′-deoxythymidine-3′-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite (T) Acetonitrile (CH3CN, anhydrous)
O S H
H NH
N O
O
N H
O
H N
OH O
1
O
1. i-Pr2SiCl2, imidazole, DIEA 2. thymidine, imidazole O S H N O
N H
H NH
O
NH
H N
O
O
O Si O
O
O
2 (92%)
O
O
N
OH
(i-Pr2N)2POCH2CH2CN, 1H-tetrazole O O
S H N O
N H
H NH
O
NH
H N
O
O Si O
N
O
O
O
O O
3 (85%)
NC
O
P
N
O O S H HN
N H
H NH
O
NH
H N
O
O Si O
O
O
N
O
O
O
4
O P
O−
O
O S H HN
H NH
N H
O
O
H N
O Si O TACAGTGACT O
5′
3′
OH
5
O
Reversible Biotinylation of the 5′-Terminus of Oligodeoxyribonucleotides
Figure 4.20.1 Preparation of reversible biotinylation phosphoramidite S.3 and structures of biotinylated 5′-OH DNAs S.4 and S.5.
4.20.2 Supplement 14
Current Protocols in Nucleic Acid Chemistry
∼29% (v/v) ammonium hydroxide (NH4OH) ∼40% (v/v) methylamine (CH3NH2) 50-mL one-neck round-bottomed flasks (oven dried) Vacuum pump 10-, 5-, 1-, 0.25-mL graduated glass syringes 20-G, 5-cm stainless steel needles Septa (14/20, 24/40) 250-mL separatory funnel Filter funnel and Whatman no. 1 filter paper Rotary evaporator equipped with a water aspirator Flash chromatography columns (4.5 × 12–cm, 3.0 × 12–cm) UV lamp 5-mL screw-cap vials Speedvac evaporator Additional reagents and equipment for thin-layer chromatography (TLC, APPENDIX 3D), column chromatography (APPENDIX 3E), solid-phase automatic DNA synthesis (APPENDIX 3C) using classical phosphoramidite method (UNIT 3.3), and purification of oligonucleotides by SDS-PAGE (UNIT 10.4) and reversed-phase HPLC (UNIT 10.5) Prepare biotinyl thymidine S.2 1. Dry 1.7 g (2.62 mmol) biotinyl alcohol S.1 in a 50-mL one-neck round-bottomed flask (equipped with a magnetic stir bar) under vacuum overnight at room temperature. 2. Add 211 mg (3.1 mmol) imidazole and then flush the flask with an argon flow for 10 min. 3. Add 5 mL of dry DMF and 2.7 mL (15.5 mmol) DIEA with 10-mL and 5-mL glass syringes attached to 20-G stainless steel needles, respectively, and cool the mixture to 0°C. 4. Add 839 µL (4.65 mmol) diisopropyldichlorosilane with a 1-mL glass syringe in one portion. Stir the mixture at 0°C for 1 hr, then at room temperature for 4 hr on a magnetic stir plate. The tertiary hydroxyl group in S.1 substitutes one of the two chlorine atoms in diisopropyldichlorosilane; the other chlorine atom will be substituted by the primary hydroxyl group of thymidine in the next step.
5. In another 50-mL oven-dried, one-neck round-bottomed flask, place 1.5 g (6.2 mmol) thymidine and 422 mg (6.2 mmol) imidazole. Seal the flask with a septum, flush with argon gas for ∼10 min, and then add 5 mL dry DMF with a 20-G needle attached to a 10-mL glass syringe. Shake and dissolve the solids. 6. Cool the solution prepared in step 4 to 0°C. Add the solution prepared in step 5 with a 10-mL glass syringe and stir the mixture at 0°C for 4 hr. 7. Add 50 mL ethyl acetate and 50 mL of 5% NaHCO3, transfer the mixture to a 250-mL separatory funnel, and separate the organic phase. 8. Extract the aqueous phase four times with 50 mL ethyl acetate. 9. Combine the organic phases, dry over ∼2 g anhydrous Na2SO4, and filter off the solids using a filter funnel and Whatman no. 1 filter paper. Concentrate the filtrate to dryness on a rotary evaporator with a water aspirator.
Synthesis of Modified Oligonucleotides and Conjugates
4.20.3 Current Protocols in Nucleic Acid Chemistry
Supplement 14
10. Dissolve the residue in ∼10 mL of 9:1 (v/v) CHCl3/methanol and apply to the top of a 4.5 × 12–cm flash chromatography column (APPENDIX 3E) prepared with a slurry of 40-µm silica gel in the same solvent system. Elute the column with the same solvent system. Monitor the fractions by TLC (APPENDIX 3D). 11. Pool the fractions that contain the UV-active spot with an Rf = 0.4 (9:1 CHCl3/methanol), concentrate to dryness on a rotary evaporator, and then dry under vacuum. S.2 is obtained with an expected yield of 92% (2.49 g). 1H NMR (CD3OD, 500 MHz) δ 0.91-1.05 (m, 14H), 1.19 (s, 6H), 1.28 (s, 9H), 1.28-1.29 (m, 1H), 1.40-1.43 (m, 2H), 1.58-1.83 (m, 5H), 1.81 (s, 3H), 2.12-2.30 (m, 4H), 2.94-3.05 (m, 2H), 3.25-3.33 (m, 5H), 3.46-3.51 (m, 4H), 3.56-3.57 (m, 4H), 3.90-4.00 (m, 3H), 4.23 (dd, 1H, J = 4.5, 7.7 Hz), 4.38-4.40 (m, 1H), 5.13 (dd, 1H, J = 4.8, 7.7 Hz), 7.37 (d, 2H, J = 8.1 Hz), 7.44 (d, 2H, J = 8.4 Hz), 7.47 (s, 1H); 13C NMR (CD3OD, 500 MHz) δ 12.7, 14.5, 14.7, 18.3, 18.3, 18.3, 18.4, 26.8, 29.4, 29.5, 29.8, 30.2, 31.6, 32.1, 32.5, 35.8, 36.7, 38.8, 40.2, 40.3, 41.0, 41.5, 56.0, 56.6, 59.2, 64.0, 64.1, 70.5, 70.6, 71.3, 71.9, 74.8, 86.0, 88.5, 111.5, 125.5, 129.7, 133.6, 137.5, 152.2, 156.0, 158.0, 166.2, 171.7, 176.0, 176.2, 211.4.
Prepare biotinyl thymidine phosphoramidite S.3 12. Dry 220 mg (0.22 mmol) S.2 in a 50-mL oven-dried, one-neck round-bottomed flask (equipped with a magnetic stir bar) under vacuum overnight at room temperature. 13. Flush the flask with an argon flow for ∼5 min, then add (in order) 5 mL dry CH2Cl2 and 76 µL (0.23 mmol) of 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphoramidite with 10-mL and 250-µL, respectively, glass syringes. Stir the mixture at room temperature until it becomes a clear solution. 14. Add 15.4 mg (0.22 mmol) of 1H-tetrazole in three portions over a period of 1 hr. For each addition, open the neck slightly, quickly add with a spatula, and then stop the flask immediately to minimize the introduction of air into the flask. 15. Stir the reaction mixture for an additional 4 hr, and then concentrate to ∼2 mL on a rotary evaporator. 16. Apply the suspension to the top of a 3.0 × 12–cm flash chromatography column prepared with a slurry of silica gel in 1:1 (v/v) CHCl3/THF. Elute the column with the same solvent system and monitor the fractions by TLC. 17. Pool the fractions that contain the UV-active spot with an Rf = 0.3 (1:1 CHCl3/THF), remove solvents on a rotary evaporator, and dry the product under vacuum. S.3 is obtained as a white foam with an expected yield of 85% (225 mg). 1H NMR (CDCl3, 250 MHz) δ 0.99–1.13 (m, 14H), 1.24 (d, 12H, J = 6.8 Hz), 1.28 (s, 6H), 1.36 (s, 9H), 1.36–1.90 (m, 8H), 1.90 (s, 3H), 2.21–2.39 (m, 6H), 2.75 (dt, 2H, J = 2.0, 5.8 Hz), 3.07–3.10 (m, 2H), 3.32–3.42 (m, 5H), 3.55–3.60 (m, 4H), 3.65 (s, 4H), 3.62–3.92 (m, 4H), 4.01–4.09 (m, 3H), 4.28–4.33 (m, 1H), 4.68–4.72 (m, 1H), 5.20–5.24 (m, 1H), 6.30 (t, 1H, J = 7.5 Hz), 7.49 (d, 4H, J = 7.8 Hz), 7.59 (s, 1H); 31P NMR (CDCl3, 250 MHz) δ 149.7, 149.8.
Couple phosphoramidite S.3 to 5′-end of oligodeoxyribonucleotide 18. Using the 5′-DMTr, 2-cyanoethyl phosphoramidites and following the classical phosphoramidite method (UNIT 3.3, APPENDIX 3C), synthesize the desired oligodeoxyribonucleotide on a DNA synthesizer. After completion, perform an additional detritylation step. Reversible Biotinylation of the 5′-Terminus of Oligodeoxyribonucleotides
For the example in Figure 4.20.1 (S.5), the sequence 3′-TCAGTGACA-5′ was synthesized on a 1-ìmol scale.
4.20.4 Supplement 14
Current Protocols in Nucleic Acid Chemistry
19. Place a solution of phosphoramidite S.3 (0.1 M in dry acetonitrile) on the synthesizer. Carry out coupling by recycling a mixture of 0.1 mL phosphoramidite solution and 0.5 mL of 1H-tetrazole solution (0.45 M in dry acetonitrile) for 15 min. 20. Remove the excess coupling reagents and perform iodine oxidation according to the standard procedure (UNIT 3.3, APPENDIX 3C). Dry the product on CPG under nitrogen flow. Cleave and deprotect biotinylated oligonucleotide 21. Place the oligonucleotide-bound CPG in a 5-mL screw-cap vial, add 500 µL of ∼29% NH4OH and 500 µL of ∼40% methylamine, and heat the suspension to 65°C for 30 min. 22. Cool the vial to –20°C, remove the supernatant, and save. Wash the CPG three times with 500 µL water, keeping all washes. Combine the supernatant and water washes, and dry on a Speedvac evaporator. 23. Purify the biotinylated DNA by gel electrophoresis or reversed-phase HPLC according to procedures in UNIT 10.4 and UNIT 10.5, respectively. The HPLC profile of crude biotinylated DNA S.5 (see Fig. 4.20.1) is illustrated in Figure 4.20.2.
REVERSIBLE BIOTINYLATION VIA A DIISOPROPYL SILYL ACETAL LINKER YIELDING 5′-PHOSPHATE DNA
BASIC PROTOCOL 2
Absorbance (260 nm)
This protocol describes the preparation of the reversible biotinylation phosphoramidites S.7 (see Fig. 4.20.3), its coupling to the 5′-end of DNA on a solid-phase synthesizer, and postsynthetic cleavage/deprotection to afford the biotinylated DNA S.8 (Fig. 4.20.3). A sample sequence is shown in S.9.
a b c d 0
5
10
15
20 25 30 Retention time (min)
35
40
45
50
Figure 4.20.2 HPLC profiles of DNAs S.5 (trace a), 5′-TACAGTGACT-3′ (trace b), S.9 (trace c), and 5′-H2O3PO-ACAGTGACT-3′ (trace d) generated on a C18 reversed-phase column (100 Å, 250 × 4.6 mm, Varian Analytical Instruments), using a linear gradient of 0% to 45% solvent B (90% acetonitrile) in solvent A (0.1 M triethylammonium acetate, 5% acetonitrile) over 60 min at a flow rate of 1 mL/min by detecting the absorbance of DNA at 260 nm. For a detailed protocol for performing reversed-phase HPLC, refer to UNIT 10.5. Synthesis of Modified Oligonucleotides and Conjugates
4.20.5 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Materials Biotinyl alcohol S.1 (see Support Protocol 2 for preparation) Imidazole (99%) Argon and nitrogen gas N,N-Dimethylformamide (DMF, anhydrous) Diisopropylethylamine (DIEA) Diisopropyldichlorosilane (Fluka) Diethyl bis(hydroxymethyl)malonate (97%) Methylene chloride (CH2Cl2) 5% (v/v) citric acid
O S H
H NH
N O
O
N H
H N
O
OH O
1
O
1. i-Pr2SiCl2, imidazole, DIEA 2. diethyl bis(hydroxymethyl)malonate, DIEA O S H
H NH
N O
O
N H
OH CO2Et
CN O
O
N H
H NH
CO2Et
H N
O
O
Si
O
O
O
O
P
N
CO2Et
7 (61%)
O S H HN
O
(i-Pr2N)2POCH2CH2 CN, 1H-tetrazole O
N
Si
6 (92%)
S
O
O O
O
H
CO2Et
H N
O
O
N H
H NH
CO2Et
H N
O
O
Si
O
O
O CO2Et
O O
P
O
−
B
O
O
O
8
O P
O−
O
O S H HN
H NH
N H
O
O
CO2Et
H N
O O
Si
O
O CO2Et
O P O−
O
ACAGTGACT 5′
3′
OH
O
9
Reversible Biotinylation of the 5′-Terminus of Oligodeoxyribonucleotides
Figure 4.20.3 Preparation of reversible biotinylation phosphoramidite S.7 and structures of biotinylated 5′-phosphate DNAs S.8 and S.9.
4.20.6 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Sodium sulfate (Na2SO4, anhydrous) Chloroform (CHCl3) Methanol 40-µm silica gel (Baker) TLC plates: silica gel on aluminum (60F-254, 200-µm thickness) Acetonitrile (distilled over CaH2) 2-Cyanoethyl-N,N,N′,N′-tetraisopropylphosphoramidite (2-cyanoethyltetraisopropylphosphorodiamidite, 97%) 0.45 M 1H-tetrazole (99%+, sublimed) in acetonitrile 5% (w/v) sodium bicarbonate (NaHCO3) Tetrahydrofuran (THF, 99%+) Triethylamine (TEA) 50-mL one-neck, round-bottomed flasks (oven dried) Vacuum pump 20-G, 5-cm stainless steel needles 5-, 1-, and 0.5-mL graduated glass syringes Septa (14/20, 24/40) 250-mL separatory funnels Filter funnel and Whatman no. 1 filter paper Rotary evaporator equipped with a water aspirator Flash chromatography columns (3.0 × 12–cm, 3.0 × 10–cm) UV lamp Additional reagents and equipment for thin-layer chromatography (TLC, APPENDIX 3D), column chromatography (APPENDIX 3E), and incorporation of biotinylated phosphoramidite into oligonucleotide (see Basic Protocol 1) Prepare biotin diethyl bis(hydroxymethyl)malonate conjugate S.6 1. Dry 605 mg (0.93 mmol) biotinyl alcohol S.1 in a 50-mL oven-dried, one-neck, round-bottomed flask (equipped with a magnetic stir bar) under vacuum overnight at room temperature. 2. Add 63 mg (0.93 mmol) imidazole and then flush the flask with an argon flow for 10 min. 3. Add 2 mL of dry DMF and 498 µL (2.79 mmol) DIEA with a 20-G needle attached to a 5-mL and 1-mL glass syringe, respectively, and cool the mixture to 0°C. 4. Add 252 µL (1.40 mmol) diisopropyldichlorosilane with a 500-µL glass syringe in one portion. Stir the mixture at 0°C for 1 hr, then at room temperature for 4 hr on a magnetic stir plate. 5. In another 50-mL oven-dried, one-neck, round-bottomed flask, place 500 mg (2.20 mmol) diethyl bis(hydroxymethyl)malonate and 126 mg (1.86 mmol) imidazole. Seal the flask with a septum, flush with an argon flow for ∼10 min, and then add 2 mL of dry DMF with a 5-mL glass syringe. Shake to dissolve the solids. 6. Cool the solution prepared in step 5 to 0°C. Add the reaction mixture obtained in step 4 with a 5-mL glass syringe very slowly (over at least a 30-min period) and stir the resulting solution at 0°C for 5 hr. 7. Add 30 mL CH2Cl2 and 50 mL of 5% citric acid, transfer the mixture to a 250-mL separatory funnel, and separate the organic phase. 8. Extract the aqueous phase four times with 30 mL CH2Cl2. 9. Combine the organic phases, dry over ∼2 g anhydrous Na2SO4, and filter off the solids using a filter funnel and Whatman no. 1 filter paper. Concentrate the filtrate to dryness on a rotary evaporator with a water aspirator.
Synthesis of Modified Oligonucleotides and Conjugates
4.20.7 Current Protocols in Nucleic Acid Chemistry
Supplement 14
10. Dissolve the residue in ∼8 mL of 19:1 (v/v) CHCl3/methanol and apply to the top of a 3.0 × 12–cm flash chromatography column (APPENDIX 3E) prepared with a slurry of 40-µm silica gel in the same solvent system. Elute the column with the same solvent system. Monitor the fractions by TLC (APPENDIX 3D) using 9:1 (v/v) CHCl3/methanol. 11. Pool the fractions that contain the UV-active spot with an Rf = 0.5 (9:1 CHCl3/methanol), concentrate to dryness on a rotary evaporator, and then dry under vacuum. The product, (S.6), has the highest Rf value, and is the major UV-active spot in the reaction mixture under these TLC conditions. The expected yield is 92% (839 mg). 1H NMR (CDCl3, 500 MHz) δ 0.88-1.01 (m, 14H), 1.24-1.27 (m, 12H), 1.32 (s, 9H), 1.47-1.53 (m, 2H), 1.65-1.85 (m, 6H), 2.18-2.31 (m, 4H), 3.03-3.10 (m, 2H), 3.25 (dt, 1H, J = 7.4, 4.7 Hz), 3.38-3.50 (m, 4H), 3.54-3.56 (m, 4H), 3.60 (s, 4H), 4.14-4.27 (m, 9H), 5.22-5.24 (m, 1H), 6.37 (t, 1H, J = 5.5 Hz), 6.58 (t, 1H, J = 5.3 Hz), 7.39 (d, 2H, J = 8.5 Hz), 7.57 (d, 2H, J = 8.5 Hz); 13C NMR (CDCl3, 500 MHz) δ 13.4, 14.2, 17.7, 27.8, 29.8, 30.5, 31.3, 32.0, 35.1, 35.6, 38.4, 39.2, 39.5, 40.0, 55.2, 57.5, 61.6, 61.7, 61.8, 62.7,70.0, 70.1 (X 2), 70.3, 73.8, 124.7, 129.1, 131.9, 155.1, 156.3, 169.2, 170.2, 173.3, 174.2.
Prepare biotin diethyl bis(hydroxymethyl)malonate conjugate phosphoramidite S.7 12. Dry 715 mg (0.72 mmol) S.6 in a 50-mL oven-dried, one-neck round-bottomed flask (equipped with a magnetic stir bar) under vacuum overnight at room temperature. 13. Flush the flask with an argon flow for ∼5 min, then sequentially add 2 mL dry acetonitrile and 264 µL (0.80 mmol) 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphoramidite with a 5-mL and 500-µL glass syringe, respectively. 14. Add 1.68 mL (0.76 mmol) of 0.45 M 1H-tetrazole (in acetonitrile) with a 5-mL glass syringe, stir the mixture at room temperature for 3 hr, and then quench the reaction with 50 mL of 5% NaHCO3. 15. Transfer the reaction mixture to a 250-mL separatory funnel, extract the mixture five times with 30 mL CH2Cl2, and combine the organic phases. 16. Dry over ∼2 g anhydrous Na2SO4, filter off the solids, and concentrate the filtrate to dryness on a rotary evaporator. 17. Dissolve the residue in ∼5 mL of 7:3:0.5 (v/v/v) CHCl3/THF/TEA, and apply to the top of a 3.0 × 10–cm flash chromatography column prepared with a slurry of silica gel in the same solvent. Elute the column with the same solvent system and monitor the fractions by TLC. 18. Pool the fractions that contain the UV-active spot with an Rf = 0.5 (7:3:0.5 CHCl3/THF/TEA), remove solvents on a rotary evaporator, and dry under vacuum. S.7 is obtained as a white foam with an expected yield of 61% (520 mg). 1H NMR (CDCl3, 250 MHz) δ 0.91-1.07 (m, 14H), 1.14-1.18 (m, 12H), 1.22-1.29 (m, 12H), 1.32 (s, 9H), 1.41-1.51 (m, 2H), 1.65-1.82 (m, 4H), 2.16-2.34 (m, 4H), 2.60 (t, 2H, J = 6.8 Hz), 3.04-3.06 (m, 2H), 3.21-3.26 (m, 1H), 3.40-3.48 (m, 4H), 3.52-3.61 (m, 8H), 3.76-3.82 (m, 2H), 4.05-4.25 (m, 11H), 5.19-5.22 (m, 1H), 6.28 (t, 1H, J = 5.5 Hz), 6.39 (t, 1H, J = 5.3 Hz), 7.39 (d, 2H, J = 8.0 Hz), 7.57 (d, 2H, J = 8.3 Hz); 31P NMR (CDCl3, 250 MHz) δ 166.36.
Synthesize biotinylated DNA 19. Perform oligonucleotide synthesis, coupling of the biotinylated phosphoramidite S.7, and cleavage and deprotection of the biotinylated DNA (S.8) as described (see Basic Protocol 1, steps 18 to 23). Reversible Biotinylation of the 5′-Terminus of Oligodeoxyribonucleotides
For the example in Figure 4.20.3 (S.9), the sequence 3′-TCAGTGACA-5′ was synthesized on a 1-ìmol scale prior to biotinylation. The HPLC profile of crude biotinylated S.9 is illustrated in Figure 4.20.2.
4.20.8 Supplement 14
Current Protocols in Nucleic Acid Chemistry
APPLICATION OF THE REVERSIBLE BIOTINYLATION METHOD IN AFFINITY PURIFICATION USING AVIDIN-COATED MICROSPHERES
SUPPORT PROTOCOL 1
This protocol describes the attachment of the reversibly biotinylated full-length DNAs S.4 and S.8 (see Figs. 4.20.1 and 4.20.3, respectively) to NeutrAvidin-coated microspheres, the removal of nonbiotinylated failure sequences resulting from inefficient coupling and other impurities, and the recovery of pure, unmodified DNAs S.10 and S.12 (see Fig. 4.20.4) from the solid microspheres. Materials UltraLink Immobilized NeutrAvidin (1000-Å pore size; 50- to 80-µm particle size; 0.08 µmol biotin/ml gel binding capacity; Pierce), prepared as 50% (v/v) slurry containing 0.02% (w/v) sodium azide PBS (APPENDIX 2A) Biotinylated DNA (see Basic Protocol 1 for S.4 or Basic Protocol 2 for S.8) Acetone (dried over anhydrous sodium sulfate) Tetrahydrofuran (THF, distilled over sodium/benzophenone ketyl) 70:30 (v/v) hydrogen fluoride in pyridine (HF/pyridine) Methoxytrimethylsilane ∼40% (v/v) methylamine (CH3NH2; for 5′-phosphate DNA S.8 only) 10- and 1.5-mL centrifuge tubes Lyophilizer or Speedvac evaporator 1. Transfer 5 mL (for 1-µmol scale DNA synthesis) UltraLink Immobilized NeutrAvidin gel (i.e., 10 mL of 50% gel slurry) into a 10-mL centrifuge tube, centrifuge 30 sec at 2100 × g, room temperature, and remove the supernatant. 2. Resuspend the gel in 5 mL PBS, centrifuge 30 sec at 2100 × g, room temperature, and remove the supernatant. Repeat wash two additional times. 3. Dissolve 1 µmol biotinylated DNA in 2 mL PBS and transfer the solution to the centrifuge tube containing the NeutrAvidin gel. Wash the DNA tube two times with 0.5 mL PBS and add to the gel suspension. Incubate at room temperature for 1 hr with occasional gentle shaking. 4. Centrifuge the suspension 30 sec at 2100 × g, room temperature, and remove the supernatant. Wash and then dry the gel as follows: at least three times with 3 mL PBS three times with 3 mL water two times with 5 mL acetone three times with 5 mL THF. 5. Suspend the gel in 5 mL THF, add 300 µL of 70:30 (v/v) HF/pyridine with a 500-µL pipet, and incubate the suspension 1 hr at room temperature with occasional gentle shaking. The fluoride ion cleaves the two Si-O bonds in S.4 and S.8 (see Fig. 4.20.4). CAUTION: HF reacts with glass and is toxic. The reaction must be performed in a plastic centrifuge tube in a well-ventilated fume hood.
6. Add 3 mL methoxytrimethylsilane with a 1-mL pipet, incubate at room temperature for 10 min, and then centrifuge the mixture 30 sec at 2100 × g and discard the supernatant. Methoxytrimethylsilane quenches the excess HF, giving the volatile side products fluorotrimethylsilane and methanol (see Fig. 4.20.4).
Synthesis of Modified Oligonucleotides and Conjugates
4.20.9 Current Protocols in Nucleic Acid Chemistry
Supplement 14
7a. For 5′-OH DNA (from S.4): Collect pure DNA S.10 by washing the gel six times with 0.5 mL water, saving each wash. Combine water washes and dry in a Speedvac evaporator or lyophilizer. Expected recovery yield is >80%. The purity of the DNA can be checked by reversed-phase HPLC (UNIT 10.5). A typical profile for the short sequence 5′-TACAGTGACT-3′ is illustrated in Figure 4.20.2.
7b. For 5′-phosphate DNA (from S.8): Wash the gel with 1 mL THF, then add 3 mL of ∼40% methylamine and incubate at room temperature for 30 min. Centrifuge the mixture 30 sec at 2100 × g, remove the supernatant, and wash the gel seven times with 1 mL water, saving each wash. Combine the supernatant and water washes, and dry the pure DNA S.12 in a Speedvac evaporator or lyophilizer.
O O
A
S H HN
O
N H
H NH
NH
H N
O
O
Si
O
N
O
O
O
O
O
4
O P
O−
O
1. HF/pyridine 2. Me 3SiOMe
O NH HO
O S H HN
O
N H
H NH
H N
O
OH O
+
F
Si
F
+
Me3SiF
+
O
O O−
O P
O
N
O
O
10
O
B
S H HN
O
N H
H NH
CO2Et
H N
O
O
Si
O
O
O
O
O
P
O
O
8
O P
CO2Et HO O H HN
O
N H
H NH
H N
O
OH
+
F
O−
O
1. HF/pyridine 2. Me 3SiOMe
S
B
O
O−
CO2Et
Si
F
O P
O
+
CO2Et
O−
Me3SiF
+
O
O
O
B
O O P
O−
O O CO2Et HO
O CO2Et
O P
O O
O
O−
−O
B
~40% MeNH2
P
O O P
11
Reversible Biotinylation of the 5′-Terminus of Oligodeoxyribonucleotides
O
O
O
O−
B
O O−
O P
12
O−
O
Figure 4.20.4 Removal of biotin from biotinylated DNAs S.4 and S.8 to generate unmodified 5′-OH DNA S.10 and unmodified 5′-phosphate DNA S.12, respectively.
4.20.10 Supplement 14
Current Protocols in Nucleic Acid Chemistry
O
2,2 -(ethylenedioxy)bis(ethylamine)
1. CH3MgBr
OH
O
O
2. AcOH
O levulinic acid
14 (75%)
O
tert-butylchlorodiphenylsilane
H NH
OH O
O OH
H N
O
13 (61%)
S H HN
O
H 2N
S H HN
DMAP
Ph O
H NH
Si
CMe3
1. 4-(tert-butyl)benzoyl chloride
Ph
2. K2CO3
O
O
biotin
15
O S H
OH
isobutyl chloroformate
H NH
N O
O S H
DIEA
O
O
16 (76%)
17
O S
14 , DMAP
O H NH
N O
O
O
H
H NH
N O
O
N H
O
O
H N
OH O
1 (66%)
Figure 4.20.5 Preparation of the biotinyl alcohol S.1.
Aqueous methylamine removes the 5′-tag in S.11 to generate the 5′-phosphate DNA S.12 (see Fig. 4.20.4). Expected recovery yield is >70%. The purity of the DNA can be checked by reversed-phase HPLC (UNIT 10.5). A typical profile for the short sequence 5′-H2O3POACAGTGACT-3′ is illustrated in Figure 4.20.2.
SYNTHESIS OF BIOTINYL ALCOHOL The biotinyl alcohol S.1 is required for the preparation of the reversible biotinylation phosphoramidites S.3 and S.7. This protocol describes its preparation, which is shown in Figure 4.20.5. Additional Materials (also see Basic Protocol 1) Levulinic acid (98%) Dry ice/acetone 3.0 M methyl magnesium bromide in ether Acetic acid (99.7%+) Magnesium sulfate (MgSO4, anhydrous)
SUPPORT PROTOCOL 2
Synthesis of Modified Oligonucleotides and Conjugates
4.20.11 Current Protocols in Nucleic Acid Chemistry
Supplement 14
2,2′-(Ethylenedioxy)bis(ethylamine) (98%) Ether Triethylamine Ninhydrin Ethanol (anhydrous) Biotin (AnaSpec) 4-(Dimethylamino)pyridine (DMAP) Pyridine (distilled from CaH2) t-Butylchlorodiphenylsilane (98%) 4-t-Butylbenzoylchloride (98%) Potassium carbonate (K2CO3) 5% citric acid Isobutylchloroformate (98%) 100-, 20-, 10-, 5-, and 1-mL graduated glass syringes 1000-mL two-neck round-bottomed flask, oven dried Condenser 500- and 250-mL separatory funnels Aldrich short-path distillation apparatus 50-, 100- and 250-mL one-neck round-bottomed flasks, oven dried Flash chromatography columns (4.5 × 30–cm and 4.5 × 10–cm) Heat gun Rubber septum 2- and 6-cm stainless steel needles Prepare lactone S.13 1. Add 14 mL (300 mmol) levulinic acid and 300 mL THF with a 20-mL and 100-mL glass syringe, respectively, to a 1000-mL oven-dried, two-neck, round-bottomed flask equipped with a magnetic stir bar, connected to an argon flow through a condenser. 2. Cool the flask to −78°C with a slurry of dry ice in acetone. Slowly add 100 mL (300 mmol) of 3.0 M methyl magnesium bromide in ether with a 100-mL glass syringe. Stir the mixture for 3 hr while gradually warming to room temperature, then heat to 50°C overnight. This should form a light yellow solution.
3. Cool the solution to room temperature, add ∼100 mL acetic acid with a disposable pipet, and stir the mixture for ∼12 hr. At this stage, maintaining an anhydrous atmosphere is unnecessary.
4. Add 40 mL water and then remove volatile components (ether and THF) on a rotary evaporator. 5. Transfer the red residue to a 500-mL separatory funnel and extract three times with 100 mL (each extraction) CH2Cl2. 6. Combine the organic phases, dry over ∼5 g anhydrous MgSO4, and filter off the solids. Concentrate the filtrate on a rotary evaporator. 7. Distill the residue by means of a short-path distillation apparatus using a vacuum of ∼0.6 mmHg. Collect the second fraction, which typically distills at 70°C (∼0.6 mmHg). Reversible Biotinylation of the 5′-Terminus of Oligodeoxyribonucleotides
The product 5,5-dimethyl-dihydrofuran-2-one (S.13) should be a colorless oil with an expected yield of 61% (9.5 g). 1H NMR (CDCl3, 250 MHz): δ 1.44 (s, 6H), 2.06 (t, 2H, J = 8.23 Hz), 2.63 (t, 2H, J = 8.3 Hz).
4.20.12 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Prepare amino alcohol S.14 8. Place 24.3 mL (166 mmol) 2,2′-(ethylenedioxy)bis(ethylamine), 9.5 g (83.2 mmol) S.13, and 10 mL water in a 100-mL one-neck, round-bottomed flask equipped with a condenser and a magnetic stir bar. Stir the mixture overnight at 90°C. This should give a light yellow solution.
9. Remove water and excess 2,2′-(ethylenedioxy)bis(ethylamine) by distilling at ∼70°C at 0.6 mmHg under vacuum as in step 7. 10. Dissolve the light yellow oily residue in 15 mL of 5:2:2:1 (v/v/v/v) ether/methanol/acetonitrile/triethylamine and apply the solution to the top of a 4.5 × 30–cm flash chromatography column prepared using a slurry of silica gel in the same solvent mixture. Elute the column and monitor the fractions by TLC using the same solvent mixture. Detect the product by rinsing the TLC plate briefly in a solution of 0.5 g ninhydrin in 200 mL ethanol and heat with a heat gun until purple spots appear (∼45 sec). The product should appear as a purple spot with an Rf = 0.8.
11. Pool the fractions containing the pure product, evaporate solvents on a rotary evaporator, and dry the light yellow oily product under vacuum. The expected yield of the product (S.14) is 75% (16.3 g). 1H NMR (CD3OD, 500 MHz): δ 1.20 (s, 6H), 1.78 (t, 2H, J = 8.1 Hz), 2.35 (t, 2H, J = 7.5 Hz), 2.88 (t, 2H, J = 4.5 Hz), 3.89-3.42 (m, 2H), 3.54-3.57 (m, 4H), 3.62 (s, 4H); 13C NMR (CD3OD, 500 MHz): δ 28.8, 31.0, 38.5, 38.8, 40.8, 69.0, 69.3, 69.6, 69.7, 72.0, 174.0.
Prepare N-t-butylbenzoylbiotin S.16 12. Place 2.44 g (10.0 mmol) biotin and 0.61 g (5.0 mmol) DMAP in a 250-mL oven-dried, one-neck, round-bottomed flask equipped with a magnetic stir bar and capped with a rubber septum. Connect the flask to an argon flow with a 2-cm stainless steel needle and flush the flask with argon for ∼5 min. 13. Sequentially add 15 mL dry pyridine and 3.0 mL (15 mmol) t-butylchlorodiphenylsilane with a 20- and 5-mL glass syringe, repectively, and stir the mixture overnight at room temperature. t-Butylchlorodiphenylsilane is used for temporary protection of the carboxylic acid group to form the intermediate S.15.
14. Add 3.0 mL (15 mmol) 4-t-butylbenzoylchloride with a 5-mL glass syringe, stir the mixture for 3 hr, and then quench the reaction by adding 2 mL methanol. 15. Remove volatile components on a rotary evaporator. Dissolve the residue in a mixture of the following: 12 mL THF 6 mL methanol 6 mL water 6.9 g (50 mmol) K2CO3. Stir 30 min at room temperature. This mild basic condition removes the t-butyldiphenylsilane group without affecting the 4-t-butylbenzoyl protecting group, to give S.16.
16. Quench the reaction with 50 mL of 5% citric acid. Extract the mixture six times with 20 mL ethyl acetate. Combine the organic extracts, dry over ∼2 g anhydrous MgSO4, filter off the solids, and concentrate the filtrate to dryness on a rotary evaporator.
Synthesis of Modified Oligonucleotides and Conjugates
4.20.13 Current Protocols in Nucleic Acid Chemistry
Supplement 14
17. Dissolve the residue in ∼4 mL CHCl3, place the solution on top of a 4.5 × 10–cm flash chromatography column, and elute first with ∼350 mL CHCl3 and then with 19:1 (v/v) CHCl3/methanol. Monitor the fractions by TLC using 9:1:10 (v/v/v) CHCl3/methanol/ether as the solvent system. 18. Pool fractions that contain the UV-active spot with an Rf = 0.5 (9:1:10 CHCl3/methanol/ether), concentrate to dryness on a rotary evaporator, and dry under vacuum. The expected yield of the product 1-(4-tert-butylbenzoyl)-biotin (S.16) is 76% (3.07 g). 1H NMR (CD3OD, 500 MHz) δ 1.15 (s, 9H), 1.27-1.63 (m, 6H), 2.14 (t, 2H, J = 7.4 Hz), 2.79-2.91 (m, 2H), 3.11-3.15 (m, 1H), 4.07 (dd, 1H, J = 4.6, 7.8 Hz), 4.98-5.00 (m, 1H), 7.25 (d, 2H, J = 8.5 Hz), 7.31 (d, 2H, J = 8.6 Hz); 13C NMR (CD3OD, 500 MHz) δ 26.1, 29.6, 29.9, 31.7, 34.8, 35.9, 38.9, 56.7, 59.3, 64.1, 125.7, 129.8, 133.8, 156.1, 158.2, 171.9, 177.6.
19. Place 1.9 g (4.8 mmol) S.16 in a 100-mL one-neck, round-bottomed flask equipped with a magnetic stir bar. Then place 292 mg (2.39 mmol) DMAP and 656 mg (2.5 mmol) S.14 in a separate 50-mL one-neck, round-bottomed flask equipped with a stir bar. Dry both on a vacuum pump overnight at room temperature. Prepare biotinyl alcohol S.1 20. Stop the neck of the flask containing S.16 with a rubber septum. Flush the flask with an argon flow with two 6-cm stainless steel needles (one inlet and one outlet) for ∼10 min and then remove the outlet needle. 21. Place the flask in an ice bath and sequentially add 4 mL dry DMF and 920 µL (5.28 mmol) DIEA with a 5-mL and 1-mL glass syringe, respectively. Let sit 10 min. 22. Add 684 µL (5.27 mmol) isobutylchloroformate with a 1-mL glass syringe and stir the mixture 1 hr at 0°C. This forms the intermediate S.17.
23. Flush the flask containing DMAP and S.14 (step 19) with an argon flow for 10 min, then add 4 mL dry DMF with a 5-mL glass syringe. 24. Very slowly add the solution of DMAP and S.14 to the solution of intermediate S.17 with a 10-mL glass syringe (at least over a 15-min period). After addition, stir the mixture 10 min at 0°C. 25. Quench the reaction with 2 mL water. Add 20 mL of 5% citric acid, transfer the mixture to a 250-mL separatory funnel, and extract six times with 30 mL (each extraction) ethyl acetate. 26. Pool the extracts, dry over ∼2 g anhydrous Na2SO4, filter off the solids, and evaporate the filtrate on a rotary evaporator. 27. Dissolve the residue in ∼10 mL of 19:1 (v/v) CH2Cl2/methanol and apply to the top of a 4.5 × 10–cm flash chromatography column prepared with a slurry of silica gel in the same solvent. Elute the column with the same solvent and monitor the fractions by TLC using a solvent system of 9:1 (v/v) CH2Cl2/methanol. 28. Collect the fractions that contain a UV-active spot with an Rf = 0.5 (9:1 CH2Cl2/methanol), pool these fractions, and evaporate to dryness on a rotary evaporator to give S.1.
Reversible Biotinylation of the 5′-Terminus of Oligodeoxyribonucleotides
Under vacuum, biotinyl alcohol (S.1) can form a white foam. Expected yield is 66% (2.1 g). 1H NMR (CD3OD, 500MHz) δ 1.24 (s, 6H), 1.38 (s, 9H), 1.46-1.55 (m, 2H), 1.65-1.85 (m, 6H), 2.28 (t, 2H, J = 7.3 Hz), 2.34 (t, 2H, J = 7.7 Hz), 3.06-3.13 (m, 2H), 3.36-3.43 (m, 5H), 3.55-3.66 (m, 8H), 4.31 (t, 1H, J = 6.9 Hz), 5.22 (t, 1H, J = 6.6 Hz), 7.48 (d, 2H, J = 8.2 Hz), 7.54 (d, 2H, J = 8.1 Hz); 13C NMR (CD3OD, 500 MHz) δ 26.9, 29.3, 29.5, 29.9, 31.8, 32.4, 35.9, 36.8, 38.9, 40.3, 40.4, 40.4, 56.7, 59.3, 64.0, 70.7, 70.7, 70.9, 71.4, 79.6, 125.6, 129.8, 133.7, 156.1, 158.1, 171.8, 176.1, 176.6.
4.20.14 Supplement 14
Current Protocols in Nucleic Acid Chemistry
COMMENTARY Background Information The strong noncovalent highly specific interaction between biotin and streptavidin or avidin (association constant = 1015/M) has found numerous applications in areas such as immunology, cell biology, and molecular biology (McInnes and Symons, 1989). Consequently, many methods have been developed for biotinylation of various target molecules. Biotinylation of DNA has been achieved either enzymatically (Langer et al., 1981) or chemically. Site-specific chemical biotinylation of DNA can be performed manually after solidphase synthesis, cleavage, and complete deprotection (Agrawal et al., 1986; Urdea et al., 1988; Gildea et al., 1990; De Vos et al., 1994) or automatically by the synthesizer during solidphase synthesis (Pon, 1991; Neuner, 1996; Olejnik et al., 1996). For the latter method, which is more convenient to perform, biotinylation reagents that are compatible with DNA synthesis, cleavage, and deprotection conditions are required. For some applications, releasing the target DNA from streptavidin or avidin may be necessary. For this purpose, cleavable linkers have been incorporated in between biotin and target DNA to avoid the harsh conditions required for breaking the biotin-streptavidin/avidin bonding. For example, a disulfide bond has been incorporated into the linker, which can be broken by reduction with dithiothreitol (Shimkus et al., 1985; Dawson et al., 1991). The drawback of this method is that part of the linker is left on the oligonucleotide, therefore modifying the oligonucleotide, which may not be further processed under biological and biochemical conditions. Another method is to incorporate an acid-labile linker in between biotin and DNA (Gildea et al., 1990). Although the DNA is not modified after cleavage from biotin, the synthesis of the reagent for biotinylation is complicated, and biotinylation is performed manually. A third method uses a photocleavable linkage between biotin and DNA (Olejnik et al., 1996). Using this method, biotinylation is performed automatically by the synthesizer during solid-phase synthesis and, after cleavage, unmodified DNA is obtained. The unsatisfactory feature of this method is that target DNA may be damaged by UV irradiation during photocleavage (Cadet and Vigny, 1990; Greenberg and Gilmore, 1994; Greenberg, 1995).
The biotinylation methods described in this unit use a fluoride-cleavable diisopropyl silyl acetal linkage between biotin and DNA (Fang and Bergstrom, 2003a,b). This method has several advantages over known methods. The biotinylation is automatically carried out by the synthesizer during solid-phase synthesis, no damage of target DNA during cleavage should occur, and, after cleavage, both unmodified 5′-OH (Fang and Bergstrom, 2003b) and unmodified 5′-phosphate DNA (Fang and Bergstrom, 2003a) can be obtained depending on which of the two phosphoramidites is used (see Figs. 4.20.1, 4.20.3, and 4.20.4). One of the potential applications of this reversible biotinylation method is affinity purification of synthetic oligonucleotides mediated by biotin-avidin/streptavidin binding, as demonstrated in Support Protocol 1. The biotinylated full-length DNA can be readily attached to the NeutrAvidin-coated microspheres, nonbiotinylated failure sequences and other impurities can be removed by simply washing with buffer and water, and high-quality unmodified DNA can be obtained by simple incubation with fluoride ions (followed by aqueous amine treatment in the case of 5′-phosphorylated DNA; Guzaev et al., 1995) under mild conditions, followed by a water wash (see Fig. 4.20.4). Currently, synthetic DNA is generally purified by HPLC and/or gel electrophoresis, which are considered time consuming. DMTr-selective cartridge purification is convenient, but the quality of DNA thus obtained is less satisfactory (UNIT 10.7). The affinity purification method described in this unit is convenient, and high quality DNA can be obtained. It is anticipated that the advantages of this method will be more obvious when it is required for purification of very long DNA sequences and/or isolation of target DNA from very complex mixtures.
Critical Parameters and Troubleshooting For the preparation of the two phosphoramidites (S.3 and S.7, see Basic Protocols 1 and 2 and Support Protocol 2), many steps must be carried out under strict anhydrous conditions. When this is the case, make certain that glassware and reagents, especially solvents, are dry. Although some reactions can be performed in open air, the authors recommend all transformations be performed under an argon or nitrogen atmosphere.
Synthesis of Modified Oligonucleotides and Conjugates
4.20.15 Current Protocols in Nucleic Acid Chemistry
Supplement 14
The oligonucleotide to be biotinylated must be synthesized using acetyl-protected C rather than benzoyl-protected C; otherwise, transamination may occur during the aqueous CH3NH2/NH4OH cleavage/deprotection (Reddy et al., 1994; Wincott et al., 1995). When using the biotinylation method for affinity purification of synthetic oligonucleotides, make sure to handle the NeutrAvidincoated microspheres gently. Vortexing of the gel should be avoided, as this may result in leaking of gel material and low recovery yield of full-length DNA.
Anticipated Results Yields reported for each step during the preparation of the phosphoramidites S.3 and S.7 may vary depending on how carefully the reaction, work-up, and purification are performed. Since these reactions can be easily performed on a gram scale, it is not difficult to obtain sufficient amounts of S.3 and S.7 for biotinylating several batches of DNA. The yield for biotinylation of the 5′-end of DNA on solid support is >99% in each case. For affinity purification by a NeutrAvidin-coated gel, a recovery yield of full-length unmodified DNA can be >70% in both cases.
Time Considerations The preparation of the phosphoramidites S.3 or S.7 requires ∼13 days including drying glassware and reagents, setting up and working up reactions, and purifying and drying products. DNA synthesis, 5′-biotinylation, and postsynthetic cleavage/deprotection can be achieved in 1 or 2 days depending on the length of the sequence. Affinity purification can be carried out within 6 hr, but drying the product may require ∼12 hr.
Literature Cited Agrawal, S., Christodoulou, C., and Gait, M.J. 1986. Efficient methods for attaching non-radioactive labels to the 5′ ends of synthetic oligodeoxyribonucleotides. Nucl. Acids Res. 14:6227-6245. Cadet, J. and Vigny, P. 1990. The photochemistry of nucleic acids. In Bioorganic Photochemistry (H. Morrison, ed.) Vol. 1, pp. 170-184. John Wiley & Sons, New York.
Reversible Biotinylation of the 5′-Terminus of Oligodeoxyribonucleotides
Dawson, B.A., Herman, T., Haas, A.L., and Lough, J. 1991. Affinity isolation of active murine erythroleukemia cell chromatin: Uniform distribution of ubiquitinated histone H2A between active and inactive fractions. J. Cell. Biochem. 46:166-173.
De Vos, M.J., Van Elsen, A., and Bollen, A. 1994. New non-nucleosidic phosphoramidites for the solid phase multi-labeling of oligonucleotides: Comb- and multifork-like structure. Nucleosides Nucleotides 13:2245-2265. Fang, S. and Bergstrom, D.E. 2003a. Reversible biotinylation phosphoramidite for 5′-end-labeling, phosphorylation and affinity purification of synthetic oligonucleotides. Bioconjugate Chem. 14:80-85. Fang, S. and Bergstrom, D.E. 2003b. Fluoridecleavable biotinylation phosphoramidite for 5′end-labeling, affinity purification of synthetic oligonucleotides. Nucl. Acids Res. 31:708-715. Gildea, B.D., Coull, J.M., and Koster, H. 1990. A versatile acid-labile linker for modification of synthetic biomolecules. Tetrahedron Lett. 31:7095-7098. Greenberg, M.M. 1995. Photochemical release of protected oligodeoxyribonucleotides containing 3′-glycolate termini. Tetrahedron 51:29-38. Greenberg, M.M. and Gilmore, J.L. 1994. Cleavage of oligonucleotides from solid-phase supports using o-nitrobenzyl photochemistry. J. Org. Chem. 59:746-753. Guzaev, A., Salo, H., Azhayev, A., and Lönnberg, H. 1995. A new approach for chemical phosphorylation of oligonucleotides at the 5′-terminus. Tetrahedron 51:9375-9384. Langer, P.R., Waldrop, A.A., and Ward, D.C. 1981. Enzymatic synthesis of biotin-labeled polynucleotides: Novel nucleic acid affinity probes. Proc. Natl. Acad. Sci. U.S.A. 78:6633-6637. McInnes, J.L. and Symons, R.H. 1989. Preparation and detection of nonradioactive nucleic acid and oligonucleotide probes. In Nucleic Acid Probes (R.H. Symons, ed.) pp. 33-80. CRC Press, Boca Raton, Fla. Neuner, P. 1996. New non nucleosidic phosphoramidite reagent for solid phase synthesis of biotinylated oligonucleotides. Bioorg. Med. Chem. Lett. 6:147-152. Olejnik, J., Krzymanska-Olejnik, E., and Rothschild, K.J. 1996. Photocleavable biotin phosphoramidite for 5′-end-labelling, affinity purification and phosphorylation of synthetic oligonucleotides. Nucl. Acids Res. 24:361-366. Pon, R.T. 1991. A long chain biotin phosphoramidite reagent for the automated synthesis of 5′-biotinylated oligonucleotides. Tetrahedron Lett. 32:1715-1718. Reddy, M.P., Hanna, N.B., and Farooqui, F. 1994. Fast cleavage and deprotection of oligonucleotides. Tetrahedron Lett. 35:4311-4314. Shimkus, M., Levy, J., and Herman, T. 1985. A chemically cleavable biotinylated nucleotide: Usefulness in the recovery of protein-DNA complexes from avidin affinity columns. Proc. Natl. Acad. Sci. U.S.A. 82:2593-2597.
4.20.16 Supplement 14
Current Protocols in Nucleic Acid Chemistry
Urdea, M.S., Warner, B.D., Running, J.A., Stempien, M., Clyne, J., and Horn, T. 1988. A comparison of non-radioisotopic hybridization assay methods using fluorescent, chemiluminescent and enzyme labeled synthetic oligodeoxyribonucleotide probes. Nucl. Acids Res. 16:49374956. Wincott, F., DiRenzo, A., Shaffer, C., Grimm, S., Tracz, D., Workman, C., Sweedler, D., Gonzalez, C., Scaringe, S., and Usman, N. 1995. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucl. Acids Res. 23:2677-2684.
Contributed by Shiyue Fang and Donald E. Bergstrom Purdue University West Lafayette, Indiana Walther Cancer Institute Indianapolis, Indiana
Synthesis of Modified Oligonucleotides and Conjugates
4.20.17 Current Protocols in Nucleic Acid Chemistry
Supplement 14
Uridine 2′-Carbamates: Facile Tools for Oligonucleotide 2′-Functionalization
UNIT 4.21
This unit contains procedures for synthesis of uridine 2′-carbamate phosphoramidites and oligonucleotides thereof. 3′,5′-Silyl-diprotected uridine can be converted into the corresponding 2′-carbamate by reaction with 1,1′-carbonyldiimidazole followed by treatment with an aliphatic amine. The 2′-carbamate can then be converted in several steps into a 3′-phosphoramidite suitable for machine-assisted oligonucleotide synthesis. The preparation of eleven different uridine 2′-carbamates and their phosphoramidites from several primary and secondary amines is described in the first two methods (see Basic Protocol 1 and Alternate Protocol). Their use in oligonucleotide synthesis is then described (see Basic Protocol 2). 2′-Carbamate modification is stable to conditions of standard phosphoramidite oligonucleotide synthesis. Although 2′-carbamate modification is somewhat destabilizing for DNA-DNA and DNA-RNA duplexes, it is suitable for the direction of ligands into the minor groove or into non-base-paired sites (e.g., loops, bulges) of oligo- and polynucleotides. Pyrene-modified oligonucleotide 2′-carbamates show a considerable increase in fluorescence intensity upon hybridization to a complementary RNA, and have interesting binding properties when hybridized to a mismatched DNA. CAUTION: Carry out all operations involving organic solvents and reagents in a wellventilated fume cupboard, and wear gloves and protective glasses. PREPARATION OF URIDINE 2′-CARBAMATE PHOSPHORAMIDITES FROM PRIMARY AND SECONDARY AMINES Nucleoside 2′-carbamates have been used previously in the syntheses of various modified nucleosides (McGee et al., 1996; Zhang et al., 2003) and oligonucleotides (Freier and Altmann, 1997; Seio et al., 1998; Dubey et al., 2000; Prhavc et al., 2001). The present protocol is based primarily on Korshun et al. (2002) and is illustrated in Figure 4.21.1. St able 2′-O-(imidazol-1-ylcarbonyl)-3′,5′-O-(tetraisopropyldisiloxan-1,3-diyl)uridine (S.3) is first prepared from uridine (S.1). It is then treated with primary or secondary aliphatic amines to give uridine 2′-carbamates (S.4) in high yield. Preparation of 2′-carbamates bearing a variety of N-substituents is described (S.4a-f; see Fig. 4.21.2). After 3′,5′-O-deprotection with triethylamine trihydrofluoride, 5′-O-dimethoxytritylation, and 3′-O-phosphinylation with bis(N,N-diisopropylamino)-2-cyanoethoxyphosphine, the corresponding phosphoramidites (S.7a-f) are obtained. They are used in machine-assisted synthesis of modified oligodeoxynucleotides containing uridine-2′-carbamate residues bearing these N-substituents. Strategic planning Formation of 2′-carbamates. In many cases, the imidazolide S.3 need not be isolated, but instead can be reacted in situ with an excess of the appropriate amine in dry dichloromethane (CH2Cl2). In the case of an amine hydrochloride (e.g., for S.4d), 1.1 eq triethylamine (TEA) or N,N-diisopropylethylamine (DIPEA) is added to the reaction mixture to liberate the free base. Reaction times differ vastly from one amine to another. Whilst propargylamine reacts rapidly in CH2Cl2 (<1 hr), N-methylpropargylamine, a secondary amine, requires overnight reaction. 2-Aminomethyl-15-crown-5 reacts very slowly in CH2Cl2. To accelerate the reaction, a change of solvent to acetonitrile (CH3CN) and a temperature increase to 55°C is advised. Thus, two general procedures for the preparation of carbamates S.4a-d versus S.4e-f are presented below. 3′,5′-O-Silyl-protected uridine 2′-carbamates are then isolated by column chromatography. Contributed by Vladimir A. Korshun, Dmitry A. Stetsenko, and Michael J. Gait Current Protocols in Nucleic Acid Chemistry (2003) 4.21.1-4.21.26 Copyright © 2003 by John Wiley & Sons, Inc.
BASIC PROTOCOL 1
Synthesis of Modified Oligonucleotides and Conjugates
4.21.1 Supplement 15
O NH HO
O OH
O
O
N
NH
NH
O
O O
OH
N
O
Si O
Si
O
O O
OH
Si
O
N
O 2
3
O
O NH
O
N
O
Si O
O
HO
N
O
NH
O
DMTrO
N
O
R
N
O
O NH
R Si
O
N
O
1
O
N
O
Si
OH
O
R
N
R1
R1
O
OH
5a-f
O
N R1
O
4a-f
O
O 6a-f
O NH DMTrO
N
O
O R
i-Pr2N
P
O
O
N R1 O
NCCH2CH2O 7a-f
Figure 4.21.1 General scheme for conversion of uridine into 2′-carbamate 3′-phosphoramidites (see Basic Protocol 1). For R and R1 groups, see Figure 4.21.2.
Desilylation. Tetrabutylammonium fluoride trihydrate (TBAF) in tetrahydrofuran (THF) was found unsuitable for removal of the Markiewicz protecting group from S.4, because of the observed 2′-3′ migration of the carbamate group under alkaline conditions (Korshun et al., 2002). Triethylamine trihydrofluoride, a nonbasic fluoride source, gave smooth silyl deprotection without any migration. Aromatic uridine 2′-carbamates S.5c and S.5d are crystalline solids. The other S.5 compounds are viscous oils, but are nevertheless suitable for 5′-dimethoxytritylation without further purification.
Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
Dimethoxytritylation. No 2′-3′ migration is detected when pyridine is used as a solvent for 5′-dimethoxytritylation or as an additive during column chromatography instead of TEA. The pyrene derivative S.6d and the dipeptide derivative S.6f show the highest propensity towards isomerization during column chromatography in the presence of TEA. Generally, 5′-O-DMTr-2′-carbamates S.6 show fast 2′-3′ migration under strong basic conditions, but slow migration rates in the presence of protic solvents. The 2′- and 3′-isomers are usually easily distinguishable by TLC. Column-purified 5′-O-DMTr-derivatives (S.6) are stable as dry amorphous solids for at least 12 months. Usually,
4.21.2 Supplement 15
Current Protocols in Nucleic Acid Chemistry
co-evaporation with dry CH2Cl2 is a convenient way to remove traces of other solvents; however, it must be thoroughly vented off to give S.6 as a foam. Phosphinylation. 5′-O-DMTr-uridine 2′-carbamates S.6 are phosphinylated with bis(N,Ndiisopropylamino)-2-cyanoethoxyphosphine in dry CH2Cl2 in the presence of diisopropylammonium tetrazolide to give phosphoramidites S.7, which are then isolated by column chromatography. None of the starting carbamates gave rise to isomerization products during the phosphinylation reaction. Compound characterization. Chemical characterization data are provided for all compounds. NMR spectra were recorded on a 300-MHz Bruker DRX300 NMR spectrometer in DMSO-d6 unless otherwise stated. Chemical shifts (δ) are given in ppm and referenced to tetramethylsilane as an internal standard and 85% phosphoric acid (H3PO4) as an external standard. Coupling constants (J) are given in Hertz and refer to apparent multiplicities. D2O exchange was carried out on all samples.
Compound
R
4a-7a
H
R2
4b-7b
CH3
R2
4c-7c
H
4d-7d
H
R1
I R2
R2
O
O
4e-7e
H
O
R2
O
O
O
4f-7f
4g-7g
H
4h-7h
H
4i-7i
H
4j-7j
R2
H
H
COCF3 N
R2
R2
O
COCF3 N
R2
R2
NH2
N H
O
O
NHCOCF3
N COCF3
O
O
NHCOCF3
NHFmoc S S
H N
O
O
NHCOCF 3
O
4l-7l
H
R2
O
O O
Figure 4.21.2 Side-chain substituents of uridine 2′-carbamates. R2 stands for the rest of the molecule; see Figures 4.21.1 and 4.21.3.
Synthesis of Modified Oligonucleotides and Conjugates
4.21.3 Current Protocols in Nucleic Acid Chemistry
Supplement 15
Materials Uridine (S.1), 99% pure Anhydrous pyridine, 99.8% pure (Aldrich) Nitrogen (or argon) gas Markiewicz reagent: 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane, 96% pure (Lancaster) Ethyl acetate (EtOAc), HPLC grade 5% (w/v) sodium hydrogencarbonate (NaHCO3) Sodium sulfate (Na2SO4), anhydrous Toluene, analytical grade Silica gel: 0.040- to 0.063-mm Macherey-Nagel Kieselgel 60 Chloroform (CHCl3), HPLC grade, ethanol free Anhydrous dichloromethane (CH2Cl2), distilled from powdered CaH2 (Fisher) Hexane, HPLC grade 1,1′-Carbonyldiimidazole, 95% pure (Sigma) Amine for S.3 conversion (select one): Propargylamine (for S.4a) N-Methylpropargylamine (for S.4b) 4-Iodobenzylamine (Lancaster; for S.4c) 1-Pyrenemethylamine hydrochloride (Aldrich; for S.4d) 2-Aminomethyl-15-crown-5 (for S.4e) H-Leu-Phe-NH2 hydrochloride (for S.4f) Triethylamine (TEA), ≥99% pure Acetonitrile (CH3CN), HPLC grade (optional; for S.4e and S.4f) N,N-Diisopropylethylamine (DIPEA), ≥99% pure (Aldrich; optional; for S.4f) 5% (w/v) citric acid Methanol (MeOH), analytical grade Acetone, analytical grade Dry tetrahydrofuran (THF), freshly distilled from LiAlH4 (store over 4A molecular sieves under nitrogen) Triethylamine trihydrofluoride Absolute ethanol, analytical grade (optional; for S.5c and S.5d) Diethyl ether, analytical grade (optional; for S.5c and S.5d) 4,4′-Dimethoxytrityl chloride (DMTr⋅Cl, 95% pure; Avocado Research Chemicals) Diisopropylammonium tetrazolide Bis(N,N-diisopropylamino)-2-cyanoethoxyphosphine, 98% pure (Fluka) 20% (w/v) sodium chloride (NaCl) Rotary evaporator equipped with a water aspirator 4 × 20–cm sintered glass chromatography column, porosity 3 Vacuum oil pump TLC plate: silica-coated aluminum plate with fluorescent indicator (Merck silica gel 60 F254) 254-nm UV lamp 30-mL screw-top Teflon bottle (Nalgene) Additional reagents and equipment for thin-layer chromatography (TLC, APPENDIX 3D) and column chromatography (APPENDIX 3E)
Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
4.21.4 Supplement 15
Current Protocols in Nucleic Acid Chemistry
Protect 3′- and 5′-hydroxy groups of uridine 1. Co-evaporate 3.663 g (15 mmol) uridine (S.1) twice with 30 mL anhydrous pyridine using a rotary evaporator equipped with a water aspirator, and then apply a dry nitrogen (or argon) atmosphere. 2. Dissolve the residue in 60 mL pyridine with magnetic stirring and rapidly add 5.0 g (15.8 mmol) Markiewicz reagent in one portion. Stopper the flask and continue stirring overnight. 3. Dilute the mixture with 300 mL EtOAc. Wash twice with 150 mL water and then once with 150 mL of 5% (w/v) NaHCO3. 4. Dry over anhydrous Na2SO4 and filter off the drying agent. Evaporate the solution to dryness and then co-evaporate three times with 40 mL toluene. 5. Pack a 4 × 20–cm sintered glass column with silica gel in CHCl3. Load the sample and elute minor side products with 1:9 (v/v) EtOAc/CHCl3. Elute desired compound (S.2) with 1:2 (v/v) EtOAc/CHCl3. 6. Evaporate fractions containing the product and co-evaporate three times with 40 mL anhydrous CH2Cl2. 7. Dry the resulting white foam 2 hr in vacuo (0.05 to 0.5 Torr). 8. Grind the foam with a stainless steel spatula and dry the resulting powder 12 to 16 hr using a vacuum oil pump. Make sure traces of chlorinated solvent are completely removed from the compound, otherwise some decomposition may occur, caused by the HCl traces generated.
9. Characterize the product by TLC (on silica gel; APPENDIX 3D) and 1H NMR. The compound is stable at least 12 months during storage at ambient temperature. 3′,5′-O-(Tetraisopropyldisiloxan-1,3-diyl)uridine (S.2). Yield of white amorphous solid 6.897 g (94%). Rf: 0.35 (1:1 v/v EtOAc/hexane). 1H NMR: 11.33 (s, 1H, H-3, exchangeable with D2O), 7.68 (d, 1H, J5,6 = 8.1 Hz, H-6), 5.55–5.50 (m, 3H, H-5, H-1′, 2′-OH), 4.16 (m, 1H, 2J = 8.6 Hz, J4,5′a = 4.9 Hz, H-5′a), 4.12 (m, 2H, H-4′, H-5′b), 3.97 (m, 1H, H-2′), 3.92 (dd, 1H, J2′,3′ = 2.5 Hz, J3′,4′ = 13.1 Hz, H-3′), 1.09–0.90 (m, 28H, Pri).
Activate 2′-hydroxy group 10. Dissolve 2.434 g (5.0 mmol) S.2 in 50 mL dry CH2Cl2 and add 852 mg (5.25 mmol) 1,1′-carbonyldiimidazole in one portion. This solution can be used directly for unhindered primary and secondary amines (step 16a). For hindered primary amines (step 16b), the product should be isolated first (steps 11 to 14).
11. Monitor reaction by TLC in 1:1 (v/v) EtOAc/hexane. The starting compound S.2 (Rf = 0.35) usually disappears after 0.5 to 2 hr.
12. Wash the solution twice with 50 mL water and dry over Na2SO4. 13. Filter off the Na2SO4, evaporate the solvent in vacuo, and co-evaporate the residue three times with 40 mL dry CH2Cl2 using a rotary evaporator. 14. Dry the residue in vacuo overnight using an oil pump. Synthesis of Modified Oligonucleotides and Conjugates
4.21.5 Current Protocols in Nucleic Acid Chemistry
Supplement 15
15. Characterize the compound by TLC and 1H NMR. 2′-O-(Imidazolylcarbonyl)-3′,5′-(tetraisopropyldisiloxan-1,3-diyl)uridine (S.3) is obtained as a white crystalline powder (2.872 g, 98.9%) that is pure according to TLC and 1 H NMR. Rf 0.18 (1:1 v/v EtOAc/hexane), m.p. 193°–195°C (recrystallized from EtOAc/CHCl3). 1H NMR: 11.44 (s, 1H, H-3), 8.39 (s, 1H, imidazole), 7.69 (s, 1H, imidazole), 7.64 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.09 (s, 1H, imidazole), 5.85 (s, 1H, H-1′), 5.79 (d, 1H, J2′,3′ = 5.4 Hz, H-2′), 5.61 (d, 1H, J5,6 = 8.0 Hz, H-5), 4.74 (m, 1H, H-3′), 4.13–3.92 (m, 3H, H-4′, H-5′), 1.10–0.80 (m, 28H, Pri). Imidazolide S.3 is stable during aqueous extraction, but hydrolyzed under both acidic and alkaline conditions. Considerable decomposition was also observed during silica gel chromatography (1:1:1 to 1:1:2 v/v/v CHCl3/EtOAc/acetone, 66% yield of impure product).
Treat S.3 with primary or secondary aliphatic amine For unhindered primary and secondary amines 16a. To the solution of S.3 (prepared from 5 mmol S.2 in step 10), add the appropriate amine and allow reaction to proceed for the appropriate amount of time at 25°C: For S.4a: 0.514 mL (7.5 mmol) propargylamine for 1 hr For S.4b: 0.633 mL (7.5 mmol) N-methylpropargylamine overnight For S.4c: 1.630 g (7.0 mmol) 4-iodobenzylamine for 30 hr For S.4d: 1.874 g (7.0 mmol) 1-pyrenemethylamine hydrochloride and 1.0 mL (7.2 mmol) TEA for 72 hr. Monitor the completion of the reaction by TLC using EtOAc to monitor the disappearance of the imidazolide, or the appropriate solvents in step 23 to monitor the accumulation of product. 17a. Dilute the reaction mixture with 50 mL CH2Cl2. Proceed to step 18. For hindered primary amines 16b. Prepare a solution of 1.162 g (2.0 mmol) imidazolide S.3 in 25 mL CH3CN. Add the appropriate amine and incubate at 55°C until all of the starting compound is consumed: For S.4e: 514 mg (2.0 mmol) 2-aminomethyl-15-crown-5 for 96 hr For S.4f: 942 mg (3.0 mmol) H-Leu-Phe-NH2 hydrochloride and 0.61 mL (3.5 mmol) DIPEA for 72 hr. Monitor progress by TLC using EtOAc to monitor the disappearance of the imidazolide, or the appropriate solvents in step 23 to monitor the accumulation of product. 17b. Cool the mixture to ambient temperature and evaporate to dryness. Dilute with 100 mL EtOAc. Proceed to step 18. Work up S.4 18. Wash with 100 mL water, followed by 100 mL of 5% (w/v) citric acid, and then another 100 mL water. 19. Dry over Na2SO4, filter off the Na2SO4, and evaporate the solution.
Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
4.21.6 Supplement 15
Current Protocols in Nucleic Acid Chemistry
20. Purify the residue by silica gel column chromatography (APPENDIX 3E) in the appropriate solvent system: For S.4a: 33% to 40% (v/v) EtOAc in CHCl3 For S.4b: 1:2 (v/v) EtOAc/CHCl3 For S.4c: 25% to 33% (v/v) EtOAc in CHCl3 For S.4d: 25% to 33% (v/v) EtOAc in CHCl3 For S.4e: 2% to 10% (v/v) MeOH in CHCl3 For S.4f: stepwise gradient of 33% to 50% (v/v) EtOAc in CHCl3, then 33% to 50% acetone in 1:1 (v/v) CHCl3/EtOAc. Typical volumes are 1 to 1.5 L for S.4a-e and ∼4 L for S.4f.
21. Monitor fractions by TLC, combine fractions containing product, and evaporate. 22. Co-evaporate the residue three times with 20 to 50 mL CH2Cl2, dry in vacuo for 2 hr, and grind the foam as described above (step 8). Dry in vacuo again to afford the compounds listed below as white amorphous solids. 23. Characterize the compound by TLC and 1H NMR. 2′-O-(Propargylaminocarbonyl)-3′,5′-O-(tetraisopropyldisiloxan-1,3-diyl)uridine (S.4a). Yield 2.780 g (97.9%). Rf: 0.49 (1:1 v/v CHCl3/EtOAc). 1H NMR: 11.42 (s, 1H, H-3), 7.84 (t, 1H, J = 5.4 Hz, OCONH), 7.69 (d, 1H, J5,6 = 8.0 Hz, H-6), 5.64 (s, 1H, H-1′), 5.59 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.34 (d, 1H, J2′,3′ = 4.9 Hz, H-2′), 4.50 (m, 1H, H-3′), 4.34–3.88 (m, 2H, H-5′), 3.85–3.69 (m, 3H, CH2N, H-4′), 3.06 (s, 1H, CH), 1.10–0.80 (m, 28H, Pri). 2′-O-(N-Methyl-N-propargylaminocarbonyl)-3′,5′-O-(tetraisopropyldisiloxan-1,3-diyl)uridine (S.4b). Yield 2.827 g (97.2%). Rf: 0.56 (1:1 v/v CHCl3/EtOAc). 1H NMR: 11.41(s, 1H, H-3), 7.66 (d, 1H, J5,6 = 8.1 Hz, H-6), 5.67 (s, 1H, H-1′), 5.59 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.35 (m, 1H, H-2′), 4.53 (dd, 1H, J2′,3′ = 6.0 Hz, J3′,4′ = 7.9 Hz, H-3′), 4.17–3.83 (m, 5H, H-4′, H-5′, CH2N), 3.21 (s, 1H, CH), 2.93 (s, 1.8H), 2.84 (s, 1.2H) (NCH3, rotamers), 1.07–0.82 (m, 28H, Pri). 2′-O-(4-Iodobenzylaminocarbonyl)-3′,5′-O-(tetraisopropyldisiloxan-1,3-diyl)uridine (S.4c). Yield 3.491 g (93.6%). Rf: 0.50 (1:1 v/v CHCl3/EtOAc). 1H NMR: 11.41 (s, 1H, H-3), 7.96 (br t, 1H, OCONH), 7.68 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.62 (d, 2H, J = 7.6 Hz, ArH), 7.05 (d, 2H, J = 7.6 Hz, ArH), 5.65 (s, 1H, H-1′), 5.58 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.35 (d, 1H, J2′,3′ = 5.4 Hz, H-2′), 4.48 (m, 1H, H-3′), 4.20–3.80 (m, 5H, CH2Ar, H-4′, H-5′), 1.08–0.88 (m, 28H, Pri). 2′-O-(Pyrene-1-ylmethylaminocarbonyl)-3′,5′-O-(tetraisopropyldisiloxan-1,3-diyl)uridi ne (S.4d). Yield 3.492 g (93.9%). Rf: 0.54 (1:1 v/v CHCl3/EtOAc). 1H NMR: 11.43 (s, 1H, H-3), 8.42 (d, 1H, J9′,10′ = 9.3 Hz, pyrene H-10′), 8.31–7.97 (m, 9H, ArH, OCONH), 7.69 (d, 1H, J5,6 = 8.1 Hz, H-6), 5.68 (s, 1H, H-1′), 5.59 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.40 (d, 1H, J2′,3′ = 5.8 Hz, H-2′), 4.91 (m, 2H, CH2Ar), 4.66 (m, 1H, H-3′), 4.04 (m, 1H, 2J5′a,5′b = 12.6 Hz, J4′,5′a = 3.2 Hz, H-5′a), 3.93–3.77 (m, 2H, H-4′, H-5′b), 1.04–0.67 (m, 28H, Pri). 2′-O-(1,4,7,10,13-Pentaoxacyclopentadecan-2-ylmethyl)-aminocarbonyl-3′,5′-O-(tetraisopropyldisiloxan-1,3-diyl)uridine (S.4e). Yield 1.165 g (76.4%). Rf: 0.32 (17:3 v/v CHCl3/MeOH). 1H NMR: 11.41 (s, 1H, H-3), 7.68 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.40 (t, 1H, J = 5.7 Hz, OCONH), 5.64 (s, 1H, H-1′), 5.59 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.33 (d, 1H, J2′,3′ = 5.7 Hz, H-2′), 4.48 (dd, 1H, J2′,3′ = 5.7 Hz, J3′,4′ = 8.2 Hz, H-3′), 3.99 (m, 2H, 2J5′a,5′b = 12.9 Hz, J4′,5′a = 2.7 Hz, J4′,5′b = 4.1 Hz, H-5′), 3.84 (m, 1H, H-4′), 3.64–3.36 (m, 19H#, CH(CH2OCH2)4CH2), 3.00 (m, 2H, CH2N), 1.06–0.82 (m, 28H, Pri). (#Calculated value; the signal of water is also present in the region).
Synthesis of Modified Oligonucleotides and Conjugates
4.21.7 Current Protocols in Nucleic Acid Chemistry
Supplement 15
Nα-[3′,5′-O-(Tetraisopropyldisiloxan-1,3-diyl)uridin-2′-O-ylcarbonyl]-L-leucyl-L-phenyl alaninamide (S.4f). Yield 610 mg (38.6%). Rf: 0.45 (EtOAc). ESI-MS: [M+H]+ calcd. 790.39, found 790.43. 1H NMR: 11.43 (s, 1H, H-3), 7.87 (d, 1H, J = 8.2 Hz, NHCHCH2Ph), 7.70 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.44 (d, 1H, J = 8.4 Hz, OCONH), 7.39 (br s, 1H, NH2), 7.19 (m, 5H, Ph), 7.06 (br s, 1H, NH2), 5.64 (s, 1H, H-1′), 5.59 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.35 (d, 1H, J2′,3′ = 5.1 Hz, H-2′), 4.47 (m, 2H, H-3′, CHCH2Ph), 4.15–3.83 (m, 4H, H-4′, H-5′, CHBui), 3.03–2.73 (m, 2H, 2J = 13.4 Hz, JAX = 4.7 Hz, JBX = 9.1 Hz, CH2Ph), 1.49 (m, 1H, CH2CHMe2), 1.29 (m, 2H, CH2Pri), 1.10–0.72 (m, 34H, SiCH(CH3)2, CH2CH(CH3)2). When S.4e and S.4f are prepared according to steps 16a and 17a, yields are 44% and 23%, respectively, after 90 days.
3′,5′-O-Desilylate uridine 2′-carbamates 24. Dissolve 2 mmol S.4 in 5 mL freshly distilled THF in a 30-mL screw-top Teflon bottle. Add 0.814 mL (5 mmol) triethylamine trihydrofluoride and magnetically stir the mixture 6 hr or overnight at ambient temperature. Monitor deprotection by TLC using 15% (v/v) MeOH/CHCl3. 25. Dilute the mixture with 25 mL hexane, shake the bottle well, and allow the two phases to separate. 26. Discard the upper layer and wash the residue three times by decantation with 25 mL of 1:1 (v/v) toluene/hexane. For uridine 2′-carbamates S.5a, S.5b, S.5e, and S.5f, the oily residues are co-evaporated first with toluene (step 27a) and then with pyridine (step 28) before dimethoxytritylation. For S.5c and S.5d, crystalline uridine 2′-carbamates are isolated by ethanol trituration (step 27b), and these are co-evaporated by pyridine only (step 28).
27a. For S.5a, S.5b, S.5e, and S5.f: Co-evaporate the crude oily uridine-2′-carbamates three times with 20 mL toluene. 27b. For S.5c and S.5d: Triturate the residue in 5 mL absolute ethanol, filter off the crystalline product, and wash it with 5 mL ethanol followed by 10 mL diethyl ether. Dry in vacuo. Characterize by TLC and 1H NMR. 2′-O-(4-Iodobenzylaminocarbonyl)uridine (S.5c). Yield 0.993 g (98.6%). Rf: 0.34 (17:3 v/v CHCl3/MeOH), m.p. 192°–197°C (EtOH). 1H NMR: 11.36 (s, 1H, H-3), 7.90 (m, 2H, H-6, OCONH), 7.65 (d, 2H, J = 7.4 Hz, ArH), 7.02 (d, 2H, J = 7.4 Hz, ArH), 5.99 (m, 1H, H-1′), 5.66 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.52 (d, 1H, J = 4.4 Hz, 3′-OH), 5.18 (m, 1H, 5′-OH), 5.05 (m, 1H, H-2′), 4.25–4.05 (m, 3H, H-3′, CH2N), 3.88 (m, 1H, H-4′), 3.59 (m, 2H, H-5′). 2′-O-(Pyren-1-ylmethylaminocarbonyl)uridine (S.5d). Yield 0.467 g (93.5%). Rf: 0.37 (17:3 v/v CHCl3/MeOH), m.p. 200°–208°C (EtOH). 1H NMR: 11.38 (s, 1H, H-3), 8.42– 7.90 (m, 11H, H-6, OCONH, ArH), 6.03 (d, 1H, J1′,2′ = 5.7 Hz, H-1′), 5.68 (d, 1H, J5,6 = 7.8 Hz, H-5), 5.57 (m, 1H, 3′-OH), 5.21 (m, 1H, 5′-OH), 5.14 (m, 1H, H-2′), 4.91 (m, 2H, CH2Ar), 4.24 (m, 1H, H-3′), 3.91 (m, 1H, H-4′), 3.60 (m, 2H, H-5′).
5′-O-Dimethoxytritylate uridine 2′-carbamates 28. Co-evaporate residue from step 27a or 27b three times with 20 mL pyridine. Dissolve in 30 mL pyridine and half-evaporate, then apply a dry nitrogen atmosphere.
Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
29. Cool the flask in an ice bath and add 0.85 g (2.5 mmol) DMTr⋅Cl in one portion. Monitor the reaction by TLC using 17:3 (v/v) CHCl3/MeOH for S.6e and EtOAC for all others. Add 0.17-g (0.5-mmol) portions of DMTr⋅Cl every 4 hr until the starting nucleoside S.5 disappears completely. The total amount of DMTr⋅Cl needed is dependent on the residual fluoride content and usually varies from 3 to 4 mmol.
4.21.8 Supplement 15
Current Protocols in Nucleic Acid Chemistry
30. After completion of the reaction, quench excess DMTr⋅Cl with 1 mL MeOH, wait 10 min, and dilute the mixture with 100 mL CHCl3. 31. Wash with 100 mL water, 100 mL of 5% NaHCO3, and again with 100 mL water. 32. Dry over Na2SO4, filter off the Na2SO4, and then evaporate the mixture. 33. Co-evaporate three times with 25 mL toluene and purify the residue on a silica gel column in the appropriate solvent system: For S.6a: 1% to 5% (v/v) MeOH/0.5% (v/v) TEA in CHCl3 For S.6b: 1% to 2% (v/v) MeOH/0.5% (v/v) TEA in 1:1 (v/v) CHCl3/EtOAc For S.6c: 0.5% to 2% (v/v) MeOH/0.5% (v/v) TEA in 1:1 (v/v) CHCl3/EtOAc For S.6d: 0.5% to 1.5% (v/v) MeOH/0.5% (v/v) pyridine in CHCl3 For S.6e: 3% to 9% (v/v) MeOH/0.5% (v/v) TEA in 2:1 (v/v) CHCl3/EtOAc For S.6f: 1% to 3% (v/v) MeOH/0.5% (v/v) pyridine in 2:1 (v/v) CHCl3/EtOAc. 34. Combine the fractions containing product S.6, evaporate, and then co-evaporate three times with 25 mL CH2Cl2. Dry the residue in vacuo to afford the compounds as amorphous solids. 35. Characterize the compounds by TLC and 1H NMR. 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(propargylaminocarbonyl)uridine (S.6a). Yield 1.156 g (92.1%). Rf: 0.60 (EtOAc). 1H NMR: 11.38 (br s, 1H, H-3), 7.85 (t, 1H, J = 5.7 Hz, OCONH), 7.66 (m, 1H, H-6), 7.40–7.19 (m, 9H, ArH), 6.89 (d, 4H, J = 8.7 Hz, ArH), 5.79 (d, 1H, J = 5.7 Hz, 3′-OH), 5.75 (s, 1H, H-1′), 5.39 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.11 (m, 1H, H-2′), 4.35 (m, 1H, H-3′), 4.06 (m, 1H, H-4′), 3.79 (m, 2H, CH2N), 3.73 (s, 6H, OCH3), 3.40–3.15 (m, 3H#, H-5′, CH). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(N-methyl-N-propargylaminocarbonyl)uridine (S.6b). Yield 1.097 g (85.5%). Rf: 0.73 (EtOAc). 1H NMR: 11.39 (s, 1H, H-3), 7.70 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.41–7.19 (m, 9H, ArH), 6.89 (d, 4H, J = 8.6 Hz, ArH), 5.89 (d, 1H, J1′,2′ = 3.3 Hz, H-1′), 5.54 (m, 1H, 3′-OH), 5.39 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.15 (m, 1H, H-2′), 4.32 (m, 1H, H-3′), 4.12–3.93 (m, 3H, H-4′, CH2N), 3.73 (s, 6H, OCH3), 3.35–3.16 (m, 3H#, H-5′, CH), 2.92 (s, 1.8H), 2.85 (s, 1.2H), (NCH3, rotamers). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(4-iodobenzylaminocarbonyl)uridine (S.6c). Yield 1.378 g (85.5%). Rf: 0.75 (EtOAc). 1H NMR: 11.42 (s, 1H, H-3), 7.95 (t, 1H, J = 6.0 Hz, OCONH), 7.70 (d, 1H, J5,6 = 8.1 Hz, H-6), 7.66 (d, 1H, J = 8.2 Hz, ArH), 7.40–7.18 (m, 9 H, ArH), 7.06 (d, 2H, J = 8.2 Hz, ArH), 6.88 (d, 4H, J = 8.8 Hz, ArH), 5.92 (d, 1H, J1′,2′ = 4.8 Hz, H-1′), 5.61 (d, 1H, J3′,OH = 5.6 Hz, 3′-OH), 5.38 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.17 (apparent t, 1H, J1′,2′ = J2′,3′ = 4.8 Hz, H-2′), 4.33 (m, 1H, H-3′), 4.14 (d, 2H, J = 6.0 Hz, NCH2), 3.98 (m, 1H, H-4′), 3.73 (s, 6H, OCH3), 3.35–3.16 (m, 2H#, H-5′). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(pyren-1-ylmethylaminocarbonyl)uridine (S.6d). Yield 1.482 g (92.2%). Rf: 0.75 (EtOAc). 1H NMR: 11.44 (s, 1H, H-3), 8.41 (d, 1H, J9′,10′ = 9.3 Hz, H-10′), 8.32–8.00 (m, 9H, ArH, OCONH), 7.73 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.42–7.10 (m, 9H, ArH), 6.88 (d, 4H, J = 8.6 Hz, ArH), 5.97 (d, 1H, J1′,2′ = 4.6 Hz, H-1′), 5.65 (d, 1H, J3′,OH = 5.6 Hz, 3′-OH), 5.39 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.26 (m, 1H, H-2′), 4.95 (d, 2H, J = 5.3 Hz, NCH2), 4.38 (m, 1H, H-3′), 3.99 (m, 1H, H-4′), 3.72 (s, 6H, OCH3), 3.35–3.15 (m, 2H#, H-5′). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(1,4,7,10,13-pentaoxacyclopentadecan-2-ylmethylaminocarbonyl)uridine (S.6e). Yield 1.248 g (85.5%). Rf 0.29 (17:3 v/v CHCl3/MeOH). 1H NMR: 11.39 (s, 1H, H-3), 7.69 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.41–7.12 (m, 10H, ArH, OCONH), 6.89 (d, 4H, J = 8.8 Hz, ArH), 5.90 (d, 1H, J1′,2′ = 4.7 Hz, H-1′), 5.53 (m, 1H, 3′-OH), 5.38 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.15 (m, 1H, H-2′), 4.32 (m, 1H, H-3′), 3.97 (m, 1H, H-4′), 3.73 (s, 6H, OCH3), 3.69–3.16 (m, 21H#, H-5′, CH(CH2OCH2)4CH2), 3.02 (m, 2H, CH2N).
Synthesis of Modified Oligonucleotides and Conjugates
4.21.9 Current Protocols in Nucleic Acid Chemistry
Supplement 15
Nα-[5′-O-(4,4′-Dimethoxytrityl)uridin-2′-yloxycarbonyl]-L-leucyl-L-phenylalaninamide (S.6f). Yield 0.706 g (83.1%). Rf: 0.45 (EtOAc). 1H NMR: 11.45 (s, 1H, H-3), 7.90 (d, 1H, J = 8.4 Hz, NHCHCH2Ph), 7.72 (d, 1H, J5,6 = 8.1 Hz, H-6), 7.48–7.10 (m, 12H, ArH, NH2,OCONH), 6.89 (d, 4H, J = 8.8 Hz, ArH), 5.90 (d, 1H, J1′,2′ = 4.4 Hz, H-1′), 5.52 (d, 1H, J3′,OH = 5.9 Hz, 3′-OH), 5.43 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.13 (m, 1H, H-2′), 4.47 (m, 2H, H-3′, CHCH2Ph), 4.37 (m, 1H, H-3′), 4.17 (m, 1H, CHBui), 3.98 (m, 1H, H-4′), 3.73 (s, 6H, OCH3), 3.52–3.10 (m, 2H#, H-5′), 3.05–2.70 (m, 2H, CH2Ph), 1.57–1.22 (m, 3H, CH2CHMe2), 0.86–0.69 (m, 6H, CH(CH3)2). (#Calculated value; the signal of water is also present in the region).
Phosphinylate 5′-O-DMTr-uridine 2′-carbamates 36. Co-evaporate 1.0 mmol S.6 two times with 20 mL dry CH2Cl2, dissolve in 40 mL dry CH2Cl2, and then apply a dry nitrogen atmosphere. 37. Add 171 mg (1.0 mmol) diisopropylammonium tetrazolide and 0.38 mL (1.2 mmol) bis(N,N-diisopropylamino)-2-cyanoethoxyphosphine and half-evaporate on a rotary evaporator. Stir the mixture 2 hr under nitrogen. Monitor by TLC using 25% acetone/1% TEA in CHCl3 (pair of diastereomers). 38. When conversion of S.6 is complete, dilute the mixture with 100 mL CHCl3 and wash with 100 mL of 5% NaHCO3 followed by 100 mL of 20% (w/v) NaCl. 39. Dry over Na2SO4, filter off the Na2SO4, and evaporate the solution to dryness. 40. Purify the residue on silica gel in the appropriate solvent system. For S.7a: 33% to 100% (v/v) EtOAc/1% (v/v) TEA in CHCl3 For S.7b: 30% to 70% (v/v) EtOAc/1% (v/v) TEA in CHCl3 For S.7c: 20% to 25% (v/v) acetone/1% (v/v) TEA in CHCl3 For S.7d: 5% to 25% (v/v) acetone/1% (v/v) TEA in CHCl3 For S.7e: 20% to 66% (v/v) acetone/1% (v/v) TEA in CHCl3 For S.7f: 50% to 100% (v/v) acetone/1% (v/v) TEA in 1:1 (v/v) CHCl3/EtOAc. 41. Combine fractions containing product S.7, evaporate, and dry in vacuo to afford the compounds as white amorphous solids. 42. Characterize the compounds by TLC and 1H and 31P NMR. 3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl)-2′O-(propargylaminocarbonyl)uridine (S.7a). Yield 1.029 g (82.8%). Faster moving diastereomer: Rf: 0.56 (EtOAc). 1H NMR: 11.45 (s, 1H, H-3), 7.95 (m, 1H, OCONH), 7.72 (d, 1H, J5,6 = 8.1 Hz, H-6), 7.41–7.18 (m, 9H, ArH), 6.88 (d, 4H, J = 8.5 Hz, ArH), 5.89 (d, 1H, J1′,2′ = 5.0 Hz, H-1′), 5.43 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.33 (apparent t, 1H, J1′,2′ = J2′,3′ = 5.0 Hz, H-2′), 4.56 (m, 1H, H-3′), 4.15 (m, 1H, H-4′), 3.85–3.68 (m, 8H, OCH3, CH2N), 3.63–3.44 (m, 4H, POCH2, CHCH3), 3.34–3.22 (m, 2H#, H-5′), 3.09 (t, 1H, 4J = 2.3 Hz, CH), 2.58 (t, 2H, J = 6.1 Hz, CH2CN), 1.19–0.95 (m, 12H, CHCH3). 31P NMR (CD3CN): 150.8. Slower moving diastereomer: Rf: 0.41 (EtOAc). 1H NMR: 11.44 (s, 1H, H-3), 7.90 (t, 1H, J = 5.7 Hz, OCONH), 7.73 (d, 1H, J5,6 = 8.1 Hz, H-6), 7.41–7.18 (m, 9H, ArH), 6.87 (m, 4H, ArH), 5.91 (d, 1H, J1′,2′ = 5.1 Hz, H-1′), 5.42 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.36 (apparent t, 1H, J1′,2′ = J2′,3′ = 5.1 Hz, H-2′), 4.55 (m, 1H, H-3′), 4.10 (m, 1H, H-4′), 3.82–3.68 (m, 10H, OCH3, CH2N, POCH2), 3.46 (m, 2H, CHCH3), 3.35–3.21 (m, 2H#, H-5′), 3.12 (m, 1H, CH), 2.74 (t, 2H, J = 5.8 Hz, CH2CN), 1.19–0.89 (m, 12H, CHCH3). 31 P NMR (CD3CN): 150.7. Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
4.21.10 Supplement 15
Current Protocols in Nucleic Acid Chemistry
3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl)-2′O-(N-methyl-N-propargylaminocarbonyl)uridine (S.7b). Yield 1.004 g (79.5%). Rf: 0.58, 0.69 (EtOAc). 1H NMR: 11.42 (s, 1H, H-3), 7.70 (m, 1H, H-6), 7.42–7.16 (m, 9H, ArH), 6.87 (m, 4H, ArH), 5.90 (m, 1H, H-1′), 5.47–5.18 (m, 2H, H-5, H-2′), 4.55 (m, 1H, H-3′), 4.20–3.92 (m, 3H, H-4′, CH2N), 3.73 (s, 6H, OCH3), 3.62–3.18 (m, 7H#, POCH2, CHCH3, H-5′, CH), 2.94–2.78 (m, 3H, NCH3), 2.74, 2.56 (2m, 2H, CH2CN), 1.20–0.88 (m, 12H, CHCH3). 31P NMR (CD3CN): 150.9 (26%), 150.8 (30%), 150.4 (44%), diastereomers and rotamers. 3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl)-2′O-(4-iodobenzylaminocarbonyl)uridine (S.7c). Yield 0.674 g (67%). Rf: 0.47, 0.62 (EtOAc). 1H NMR: 11.46 (s, 1H, H-3), 8.04 (m, 1H, OCONH), 7.73–7.61 (m, 3H, ArH, H-6), 7.42–7.18 (m, 9H, ArH), 7.07 (m, 2H, ArH), 6.87 (m, 4H, ArH), 5.93 (m, 1H, H-1′), 5.46–5.28 (m, 2H, H-5, H-2′), 4.53 (m, 1H, H-3′), 4.12 (m, 3H, H-4′, NCH2), 3.78–3.19 (m, 12H#, POCH2, CHN, H-5′, OCH3), 2.68, 2.58 (2m, 2H, CH2CN), 1.23–0.89 (m, 12H, CHCH3). 31P NMR (CD3CN): 149.3. 3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl)-2′O-(pyren-1-ylmethylaminocarbonyl)uridine (S.7d). Yield 0.978 g (97.4%). Rf: 0.55, 0.68 (EtOAc). 1H NMR: 11.47 (s, 1H, H-3), 8.41 (d, 1H, J9′,10′ = 9.3 Hz, H-10′), 8.36–7.98 (m, 9H, ArH, OCONH), 7.73 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.43–7.17 (m, 9H, ArH), 6.87 (d, 4H, J = 8.5 Hz, ArH), 5.95 (d, 1H, J1′,2′ = 5.1 Hz, H-1′), 5.42 (m, 2H, H-5, H-2′), 4.91 (d, 2H, J = 5.3 Hz, NCH2), 4.57 (m, 1H, H-3′), 4.17 (m, 1H, H-4′), 3.71 (s, 6H, OCH3), 3.42–3.35 (m, 6H, POCH2, CHN, H-5′), 2.88, 2.58 (2t, 2H, J = 5.8 Hz, CH2CN, diastereo- mers), 1.17, 1.02–0.89 (2m, 12H, CHCH3). 31P NMR (CD3CN): 149.3. 3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl)-2′O-(1,4,7,10,13-pentaoxacyclopentadecyl-2-methylaminocarbonyl)uridine (S.7e). Yield 0.955 g (93.4%). Rf: 0.11, 0.24 (EtOAc). 1H NMR: 11.44 (br s, 1H, H-3), 7.70 (m, 1H, H-6), 7.49–7.15 (m, 10H, ArH, OCONH), 6.87 (m, 4H, ArH), 5.91 (m, 1H, H-1′), 5.46–5.25 (m, 2H, H-5, H-2′), 4.53 (m, 1H, H-3′), 4.11 (m, 1H, H-4′), 3.80–3.19 (m, 31H#, POCH2, CHN, H-5′, CH(CH2OCH2)4CH2, OCH3), 3.00 (m, 2H, CH2N), 2.75, 2.59 (2m, 2H, CH2CN), 1.20–0.90 (m, 12H, CHCH3). 31P NMR (CD3CN): 149.28, 149.27 (diastereomers). (#Calculated value; the signal of water is also present in the region). Nα-[3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl) uridin-2′-yloxycarbonyl]-L-leucyl-L-phenylalaninamide (S.7f). Yield 0.271 g (51.6%). Rf: 0.13, 0.20 (EtOAc). 1H NMR: 11.47 (s, 1H, H-3), 8.08 (d, 2H, J = 11.7 Hz, NH2), 7.83 (d, 1H, J = 8.6 Hz, NHCHCH2Ph), 7.70 (d, 1H, J5,6 = 8.1 Hz, H-6), 7.43–7.07 (m, 15H, ArH, OCONH), 6.88 (d, 4H, J = 8.8 Hz, ArH), 5.86 (d, 1H, J1′,2′ = 4.8 Hz, H-1′), 5.46 (d, 1H, J5,6 = 7.8 Hz, H-5), 5.32 (t, 1H, J = 5.3 Hz, H-2′), 4.64 (m, 1H, CHCH2Ph), 4.46 (m, 1H, H-3′), 4.17 (m, 1H, CHBui), 3.95 (m, 1H, H-4′), 3.73 (s, 6H, OCH3), 3.58–3.46 (m, 4H, POCH2, CHN), 3.04–2.99 (m, 2H, H-5′), 2.87–2.81 (m, 2H, CH2Ph), 2.59 (m, 2H, CH2CN), 1.23–0.98 (m, 12H, NCHCH3), 0.83–0.72 (m, 3H, CH2CHMe2), 0.65–0.59 (m, 6H, CH2CH(CH3)2). 31P NMR (DMSO-d6): 148.9.
PREPARATION OF URIDINE 2′-CARBAMATE PHOSPHORAMIDITES FROM PRIMARY AMINES THAT REQUIRE ADDITIONAL SIDE-CHAIN PROTECTION With an excess of di- or polyamines, imidazolide S.3 reacts mostly in a 1:1 ratio. The reaction with N-(3-aminopropyl)-1,3-propanediamine and spermine affords exclusively primary amino-substituted products (see Figure 4.21.3). This observation is in agreement with the recently reported good selectivity of imidazolecarbonyl derivatives towards primary versus secondary amines (Rannard and Davis, 2000). The remaining amino groups are either protected by trifluoroacetylation or used for further reaction (e.g., with protected cysteine derivative in S.4j). Trifluoroacetyl (Tfa) and 9-fluorenylmethoxycarbonyl (Fmoc) are the most common amino-protecting groups used in oligonucleotide synthesis. Aminoalcohols also show high selectivity towards N-substitution. The primary hydroxyl group of carbamate S.4k is further protected by a trimethylacetyl group to give
ALTERNATE PROTOCOL
Synthesis of Modified Oligonucleotides and Conjugates
4.21.11 Current Protocols in Nucleic Acid Chemistry
Supplement 15
O NH O O Si
N
O
Si O
O COCF3
H N
O
N
NHCOCF3
O O
4g
NH O
N
O
Si
O COCF3
O
O
Si
H N
O
N
N
O
NHCOCF3
COCF3
4h
O
O
NH
NH O
O
Si O Si
N
O
O
O
O
Si O
N
N
O
O
Si
O
N H N
O
O
O
O
NHCOCF3
O
O 3
4i O NH O
N
O
Si
O NHFmoc
O Si
O
H N
O
O
H N
O
O
S S O
O 4j O
O
NH
NH O O Si
N
O
Si O
O
O
H N
O
O
OH
O Si
O
Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
H N
O O
O 4k
O
N
O
Si
O
O O
4l
Figure 4.21.3 Preparation of side-chain-protected 3′,5′-O-silylated uridine 2′-carbamates (see Alternate Protocol).
4.21.12 Supplement 15
Current Protocols in Nucleic Acid Chemistry
S.4l. This protecting group was found to be rather stable under oligonucleotide deprotection conditions (see Basic Protocol 2). NOTE: For Tfa 2′-carbamates (S.4g-S.4i), attempts to reduce the amine-to-imidazolide ratio to 1:1 give a decreased yield of the target compound and increased amounts of disubstituted byproducts. NOTE: Although Tfa derivatives are stable in the presence of TEA, a premature Fmoc release may occur from Fmoc compounds. Therefore, use of pyridine is advised as an additive in the column chromatography of Fmoc-containing intermediates. Additional Materials (also see Basic Protocol 1) 3′,5′-O-(Tetraisopropyldisiloxan-1,3-diyl)uridine (S.2; see Basic Protocol 1, step 9) Amine for S.3 conversion (select one): N-(3-Aminopropyl)-1,3-propanediamine, 98% pure (Aldrich; for S.4g) Spermine, 99% pure (Aldrich; for S.4h) 4,7,10-Trioxa-1,13-tridecanediamine, 97% pure (Sigma; for S.4i-S.4j) 2-(2-Aminoethoxy)ethanol (for S.4k) Reagent for amine protection (select one): S-Ethyl trifluorothioacetate, 97% pure (Aldrich; for S.4g-S.4i) Nα-Fmoc-S-tert-butylthio-L-cysteine pentafluorophenyl ester, 99% pure (Novabiochem; for S.4j) Trimethylacetyl chloride, 99% pure (Aldrich; for S.4l) Prepare di- and polyamine 2′-carbamates (S.4g-i) and protect by trifluoroacetylation For S.4g 1a. Prepare a solution of S.3 from 2.434 g (5.0 mmol) S.2 and 852 mg (5.25 mmol) 1,1′-carbonyldiimidazole in 50 mL dry CH2Cl2. Monitor the reaction by TLC (APPENDIX 3D) in 1:1 (v/v) EtOAc/hexane. 2a. Prepare a magnetically stirred, ice-cooled solution of 5.6 mL (40 mmol) N-(3-aminopropyl)-1,3-propanediamine in 100 mL CH2Cl2. 3a. Add the solution from step 1a dropwise to the solution in step 2a and incubate 2 hr. 4a. Remove the cooling bath and incubate the mixture overnight at room temperature. 5a. Wash the mixture with 200 mL water, 200 mL of 5% NaHCO3, and then another 200 mL water. 6a. Dry over Na2SO4, filter to remove the solid, and evaporate the solution to dryness. 7a. Co-evaporate the residue with 30 mL THF, dissolve in 10 mL dry THF, and add 5.0 mL (39 mmol) S-ethyl trifluorothioacetate in one portion. Incubate 20 hr. CAUTION: S-Ethyl trifluorothioacetate generates ethanethiol, which has a strong stench.
8a. Evaporate the mixture to dryness, co-evaporate the residue with CHCl3, and purify on a silica gel column using 1:1 to 1:3 (v/v) CHCl3/EtOAc (APPENDIX 3E). The product is obtained as a white amorphous solid. Trituration of S.4g in CH2Cl2/hexane gives colorless crystals.
Synthesis of Modified Oligonucleotides and Conjugates
4.21.13 Current Protocols in Nucleic Acid Chemistry
Supplement 15
9a. Analyze the product S.4g by TLC and 1H NMR. Proceed to step 12. 2′-O-[4-Trifluoroacetyl-7-(trifluoroacetylamino)-4-azaheptan-1-ylaminocarbonyl]-3′,5′O-(tetraisopropyldisiloxan-1,3-diyl)uridine (S.4g). Yield 2.558 g (61.2%), m.p. 74°–77°C. Rf: 0.69 (EtOAc). 1H NMR: 11.42 (s, 1H, H-3), 9.51, 9.43 (2 br t, 1H, NHTFA, rotamers), 7.69 (d, 1H, J5,6 = 8.1 Hz, H-6), 7.51, 7.45 (2m, 1H, OCONH, rotamers), 5.65 (d, 1H, J1′,2′ = 1.8 Hz, H-1′), 5.59 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.32 (m, 1H, H-2′), 4.50 (m, 1H, H-3′), 3.97 (m, 2H, 2J5′a,5′b = 12.5 Hz, J4′,5′a = 4.2 Hz, J4′,5′b = 2.4 Hz, H-5′), 3.83 (m, 1H, H-4′), 3.33 (m, 4H#, CH2NCH2), 3.19 (m, 2H, CH2NHTFA), 2.98 (m, 2H, OCONHCH2), 1.74 (m, 4H, CH2), 1.10–0.85 (m, 28H, Pri). (#Calculated value; the signal of water is also present in the region).
For S.4h 1b. Prepare a solution of S.3 as in step 1a. 2b. Prepare a magnetically stirred, ice-cooled solution of 2.63 g (13 mmol) spermine in 200 mL CH2Cl2. 3b. Add the solution from step 1b dropwise to the solution in step 2b and incubate 2 hr. 4b. Remove the cooling bath and stir the mixture overnight at room temperature. 5b. Dilute with 150 mL CHCl3 and wash two times with 200 mL of 20% NaCl. 6b. Dry over Na2SO4, filter, and evaporate the solution to dryness. 7b. Trifluoroacetylate the residue as in step 7a. 8b. Purify as in step 8a using 50% to 0% (v/v) CHCl3 in EtOAc. 9b. Analyze the product S.4h by TLC and 1H NMR. Proceed to step 12. 2′-O-[4,9-bis(Trifluoroacetyl)-12-(trifluoroacetylamino)-4,9-diazadodecan-1-ylaminocarbonyl]-3′,5′-O-(tetraisopropyldisiloxan-1,3-diyl)uridine (S.4h). Yield 2.457 g (49.0%). Rf: 0.67 (EtOAc). 1H NMR: 11.42 (s, 1H, H-3), 9.51, 9.44 (2 br t, 1H, NHTFA, rotamers), 7.69 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.51, 7.45 (2t, 1H, J = 5.2 Hz, OCONH, rotamers), 5.65 (s, 1H, H-1′), 5.59 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.32 (m, 1H, H-2′), 4.49 (m, 1H, H-3′), 3.98 (m, 2H, 2J5′a,5′b = 12.6 Hz, J4′,5′a = 4.2 Hz, H-5′), 3.83 (m, 1H, H-4′), 3.40–3.28 (m, 8H#, CH2N(TFA)CH2), 3.20 (m, 2H, CH2NHTFA), 2.98 (m, 2H, OCONHCH2), 1.86–1.60 (m, 4H, CH2CH2NH), 1.51 (m, 4H, CH2CH2CH2CH2), 1.06–0.80 (m, 28H, Pri). (#Calculated value; the signal of water is also present in the region).
For S.4i 1c. Prepare a solution of S.3 from 1.703 g (3.5 mmol) S.2 and 592 mg (3.65 mmol) 1,1′-carbonyldiimidazole in 30 mL dry CH2Cl2. Monitor the reaction by TLC in EtOAc. 2c. Prepare a magnetically stirred, ice-cooled solution of 3.9 mL (17.5 mmol) 4,7,10-trioxa-1,13-tridecanediamine in 100 mL CH2Cl2. 3c. Add the solution from step 1c dropwise to the solution in step 2c and incubate 2 hr. 4c. Remove the cooling bath and incubate the mixture overnight at room temperature. 5c. Wash the mixture with 150 mL water, 150 mL of 5% NaHCO3, and then another 150 mL water. 6c. Dry over Na2SO4, filter, and evaporate the solution to dryness. Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
7c. Dissolve the residue in 10 mL dry CH2Cl2 and add 3.0 mL (24 mmol) S-ethyl trifluorothioacetate in one portion. Incubate the mixture overnight. CAUTION: S-Ethyl trifluorothioacetate generates ethanethiol, which has a strong stench.
4.21.14 Supplement 15
Current Protocols in Nucleic Acid Chemistry
8c. Evaporate the mixture to dryness and purify on a silica gel column using 1:1 to 1:4 (v/v) CHCl3/EtOAc. 9c. Analyze the product S.4i by TLC and 1H NMR. Proceed to step 12. 2′-O-[13-(Trifluoroacetylamino)-4,7,10-trioxatridecan-1-ylaminocarbonyl]-3′,5′-O-(tetraisopropyldisiloxan-1,3-diyl)uridine (S.4i). Yield 1.888 g (65.1%) as colorless oil. Rf: 0.42 (EtOAc). 1H NMR: 11.41 (s, 1H, H-3), 9.36 (br s, 1H, NHTFA), 7.69 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.36 (t, 1H, J = 5.7 Hz, OCONH), 5.64 (d, 1H, J1′,2′ = 1.8 Hz, H-1′), 5.59 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.31 (m, 1H, H-2′), 4.49 (dd, 1H, J2′,3′ = 5.0 Hz, J3′,4′ = 7.9 Hz, H-3′), 3.99 (m, 2H, 2J5′a,5′b = 13.0 Hz, J4′,5′a = 2.7 Hz, J4′,5′b = 4.4 Hz, H-5′), 3.82 (m, 1H, H-4′), 3.55–3.30 (m, 12H#, (CH2OCH2)3), 3.22 (apparent q, 2H, J = 6.5 Hz, CH2NHTFA), 3.00 (m, 2H, OCONHCH2), 1.69 (apparent quintet, 2H, J = 6.8 Hz, CH2), 1.60 (apparent quintet, 2H, J = 6.6 Hz, CH2), 1.06–0.81 (m, 28H, Pri). (#Calculated value; the signal of water is also present in the region).
Prepare functionalized 2′-carbamate (S.4j) by acylation 1d. Prepare a solution of S.3 as in step 1a. 2d. Prepare a magnetically stirred, ice-cooled solution of 5.5 mL (25 mmol) 4,7,10-trioxa-1,13-tridecanediamine in 100 mL CH2Cl2. 3d. Add the solution from step 1d dropwise to the solution in step 2d and incubate 2 hr. 4d. Remove the cooling bath and incubate the mixture overnight at room temperature. 5d. Wash the mixture with 200 mL water, 200 mL of 5% NaHCO3, and then another 200 mL water. 6d. Dry over Na2SO4, filter, and evaporate the solution to dryness. 7d. Dissolve the crude amine in 20 mL dry CH2Cl2 and add 2.988 g (5.0 mmol) Nα-Fmoc-S-tert-butylthio-L-cysteine pentafluorophenyl ester. Incubate 2 hr. 8d. Dilute the mixture with 200 mL CHCl3 and wash with 150 mL of 5% NaHCO3, 150 mL of 5% citric acid, and 150 mL water. 9d. Dry as in step 6d and then purify the residue on a silica gel column using 1:1:0 to 1:3:0 to 1:2:1 (v/v/v) CHCl3/EtOAc/acetone. 10d. Pool the appropriate fractions, evaporate, and co-evaporate three times with 20 mL CH2Cl2. Dry in vacuo. 11d. Analyze the product S.4j by TLC and 1H NMR. Proceed to step 12. 2′-{O-13-[S-(tert-Butylthio)-N-(9-fluorenylmethoxycarbonyl)-L-cysteinylamino]-4,7,10trioxatridecan-1-ylaminocarbonyl}-3′,5′-O-(tetraisopropyldisiloxan-1,3-diyl)uridine (S.4j). Yield 3.732 g (65.2%), white amorphous solid. Rf: 0.41 (EtOAc). 1H NMR: 11.41 (s, 1H, H-3), 8.01 (t, 1H, J = 5.2 Hz, NHCOCH), 7.88 (d, 2H, J = 7.4 Hz, ArH (fluorene)), 7.75–7.64 (m, 4H, ArH (fluorene H-1,4,5,8), H-6, NHFmoc), 7.43–7.27 (m, 5 H, ArH (fluorene H-2,3,6,7), OCONHCH2), 5.64 (s, 1H, H-1′), 5.59 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.31 (d, 1H, J2′,3′ = 5.8 Hz, H-2′), 4.49 (m, 1H, H-3′), 4.32–4.13 (m, 4H, CHCH2O (Fmoc), COCHN), 3.98 (m, 2H, 2J5′a,5′b = 13.0 Hz, J4′,5′a = 4.2 Hz, J4′,5′b = 2.5 Hz, H-5′), 3.82 (m, 1H, H-4′), 3.50–3.26 (m, 12H#, (CH2OCH2)3), 3.15–2.82 (m, 6H, CH2N, CH2S), 1.60 (m, 4H, CH2CH2CH2), 1.28 (s, 9H, But), 1.06–0.81 (m, 28H, Pri). (#Calculated value; the signal of water is also present in the region). Synthesis of Modified Oligonucleotides and Conjugates
4.21.15 Current Protocols in Nucleic Acid Chemistry
Supplement 15
Prepare hydroxyalkyl 2′-carbamate (S.4k) and trimethylacetylate to give S.4l 1e. To obtain 2-(2-hydroxyethoxy)ethyl-3′,5′-silyl-2′-carbamate (S.4k), apply the procedure for unhindered primary amines (see Basic Protocol 1, steps 16a to 17a and 18 to 22), using 1.50 mL (15.0 mmol) 2-(2-aminoethoxy)ethanol in step 16a (∼3 hr) and 2:1:1 to 1:1:1 to 1:1:2 (v/v/v) CHCl3/EtOAc/acetone for chromatography in step 20. 2′-O-[2-(2-Hydroxyethoxy)ethylaminocarbonyl]-3′,5′-O-(tetraisopropyldisiloxan-1,3diyl)uridine (S.4k). Yield 2.269 g (73.5%). Rf: 0.28 (EtOAc). 1H NMR: 11.41 (s, 1H, H-3), 7.68 (d, 1H, J5,6 = 7.9 Hz, H-6), 7.40 (br s, 1H, OCONH), 5.64 (s, 1H, H-1′), 5.59 (d, 1H, J5,6 = 7.9 Hz, H-5), 5.31 (d, 1H, J2′,3′ = 5.4 Hz, H-2′), 4.55 (m, 2H, H-3′, OH), 4.12–3.79 (m, 3H, H-4′, H-5′), 3.53–3.27 (m, 6H#, CH2OCH2CH2), 3.12 (m, 2H, CH2N), 1.10–0.82 (m, 28H, Pri). (#Calculated value; the signal of water is also present in the region).
2e. To a stirred solution of 2.162 g (3.5 mmol) S.4k in 20 mL dry CH2Cl2, add 1.0 mL (12.5 mmol) pyridine and 0.615 mL (5 mmol) trimethylacetyl chloride. 3e. Keep the reaction at ambient temperature until the starting compound disappears, as monitored by TLC using EtOAc (∼20 hr). 4e. Dilute the mixture with 100 mL CH2Cl2. 5e. Wash with 100 mL water, 100 mL of 5% NaHCO3, and another 100 mL water. 6e. Dry over Na2SO4, filter, and evaporate to dryness. 7e. Purify the residue on silica gel using 10% to 50% (v/v) EtOAc/CHCl3. 8e. Combine the fractions, evaporate, and co-evaporate three times with 20 mL CH2Cl2. Dry in vacuo. 9e. Analyze the product S.4l by TLC and 1H NMR. Proceed to step 12. 2′-O-[2-(2-Pivaloyloxyethoxy)ethylaminocarbonyl]-3′,5′-O-(tetraisopropyldisiloxan-1,3diyl)uridine (S.4l). Yield 1.977 g (80.5%). Rf: 0.34 (1:1 v/v CHCl3/EtOAc). 1H NMR: 11.41 (s, 1H, H-3), 7.69 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.37 (br t, 1H, J = 4.6 Hz, OCONH), 5.64 (s, 1H, H-1′), 5.59 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.31 (d, 1H, J2′,3′ = 4.9 Hz, H-2′), 4.50 (m, 1H, H-3′), 4.17–3.78 (m, 5H, H-4′, H-5′, CH2OPiv), 3.59 (m, 2H, CH2OCH2), 3.40 (m, 2H#, CH2N), 3.10 (m, 2H, CH2OCH2), 1.12 (s, 9H, But), 1.07–0.83 (m, 28H, Pri). (#Calculated value; the signal of water is also present in the region).
Prepare 5′-O-dimethoxytritylated side-chain-protected 2′-carbamates (S.6g-j and S.6l) 12. Deprotect the 3′- and 5′-hydroxyl groups of side-chain-protected 2′-carbamates (S.4g-j and S.4l) by treatment with triethylamine trihydrofluoride in THF (see Basic Protocol, steps 24 to 26). Coevaporate with toluene (step 27a). 13. 5′-O-Dimethoxytritylate crude 3′,5′-unprotected side-chain-protected 2′-carbamates (S.5g-j and S.5l) by treatment with DMTr⋅Cl in pyridine, and purify S.6g-j and S.6l by column chromatography (see Basic Protocol 1, steps 28 to 34).
Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
For S.6g: stepwise gradient of 1% to 4% (v/v) MeOH/0.5% (v/v) TEA in 2:1 (v/v) CHCl3/EtOAc For S.6h: 1% to 5% (v/v) MeOH/0.5% (v/v) TEA in 2:1 (v/v) CHCl3/EtOAc For S.6i: 1% to 3.5% (v/v) MeOH/0.5% (v/v) TEA in 2:1 (v/v) CHCl3/EtOAc For S.6j: 0% to 6% (v/v) MeOH/1% (v/v) pyridine in 1:1 (v/v) CHCl3/EtOAc For S.6l: 0.5% to 2% (v/v) MeOH/0.5% (v/v) TEA in 2:1 (v/v) CHCl3/EtOAc.
4.21.16 Supplement 15
Current Protocols in Nucleic Acid Chemistry
14. Analyze the products by TLC and 1H NMR. 5′-O-(4,4′-Dimethoxytrityl)-2′-O-[4-trifluoroacetyl-7-(trifluoroacetylamino)-4-azaheptan-1ylaminocarbonyl]uridine (S.6g). Yield 1.556 g (86.8%), white amorphous solid. Rf: 0.49 (EtOAc). 1H NMR: 11.37 (br s, 1 H, H-3) (exchangeable with D2O), 9.51, 9.46 (2 br s, 1H, NHTFA, rotamers), 7.69 (m, 1H, H-6), 7.53–7.19 (m, 10H, ArH (DMTr), OCONH), 6.89 (m, 4H, ArH (DMTr)), 5.92 (m, 1H, H-1′), 5.56 (m, 1H, 3′-OH) (exchangeable with D2O), 5.37 (m, 1H, H-5), 5.15 (m, 1H, H-2′), 4.34 (m, 1H, H-3′), 3.97 (m, 1H, H-4′), 3.73 (s, 6H, OCH3), 3.40–3.14 (m, 8H#, H-5′, CH2NTFA), 3.00 (m, 2H, OCONHCH2), 1.73 (m, 4H, CH2CH2CH2). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-[4,9-bis(trifluoroacetyl)-12-(trifluoroacetylamino)- 4,9diazadodecan-1-aminocarbonyl]uridine (S.6h). Yield 1.773 g (83.4%). Rf: 0.50 (EtOAc). 1 H NMR: 11.40 (s, 1H, H-3), 9.51, 9.44 (2m, 1H, NHTFA rotamers), 7.69 (m, 1H, H-6), 7.51–7.18 (m, 10H, ArH, OCONH), 6.88 (d, 4H, J = 8.8 Hz, ArH), 5.92 (m, 1H, H-1′), 5.56 (m, 1H, 3′-OH), 5.37 (m, 1H, H-5), 5.15 (m, 1H, H-2′), 4.34 (m, 1H, H-3′), 3.96 (m, 1H, H-4′), 3.73 (s, 6H, OCH3), 3.44–3.14 (m, 12H#, H-5′, CH2NTFA), 3.01 (m, 2H, OCONHCH2), 1.73 (m, 4H, CH2CH2NH), 1.52 (m, 4H, CH2CH2CH2CH2). (#Calculated value; the signal of water is also present in the region). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-[13-(trifluoroacetylamino)-4,7,10-trioxatridecan-1ylaminocarbonyl]uridine (S.6i). Yield 1.427 g (80.3%). Rf: 0.22 (EtOAc). 1H NMR: 11.39 (s, 1H, H-3), 9.36 (br s, 1H, NHTFA), 7.70 (d, 1H, J5,6 = 8.1 Hz, H-6), 7.41–7.19 (m, 10H, ArH, OCONH), 6.89 (d, 4H, J = 8.8 Hz, ArH), 5.89 (d, 1H, J1′,2′ = 5.0 Hz, H-1′), 5.54 (d, 1H, J3′,OH = 5.6 Hz, 3′-OH), 5.38 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.13 (apparent t, 1H, J1′,2′ = J2′,3′ = 5.0 Hz, H-2′), 4.32 (m, 1H, H-3′), 3.96 (m, 1H, H-4′), 3.73 (s, 6H, OCH3), 3.53–3.36 (m, 12H, (CH2OCH2)3), 3.28–3.16 (m, 4H, H-5′, CH2NHTFA), 3.02 (m, 2H, OCONHCH2), 1.75–1.56 (m, 4H, CH2CH2CH2). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-{13-[S-(tert-butylthio)-N-(9-fluorenylmethyloxycarbonyl) cysteinylamino]-4,7,10-trioxatridecane-1-ylaminocarbonyl}uridine (S.6j). Yield 2.304 g (95.5%). Rf: 0.21 (EtOAc). 1H NMR: 11.39 (s, 1H, H-3), 8.02 (t, 1H, J = 5.5 Hz, NHCOCH), 7.88 (d, 2H, J = 7.5 Hz, ArH (fluorene)), 7.70 (m, 4H, ArH (fluorene), H-6, NHFmoc), 7.44–7.10 (m, 14H, ArH (fluorene H-2,3,6,7, DMTr), OCONHCH2), 6.88 (d, 4H, J = 8.9 Hz, ArH (DMTr)), 5.90 (d, 1H, J1′,2′ = 5.0 Hz, H-1′), 5.54 (d, 1H, J3′,OH = 5.6 Hz, 3′-OH), 5.38 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.14 (apparent t, 1H, J1′,2′ = J2′,3′ = 5.0 Hz, H-2′), 4.37–4.15 (m, 5H, CHCH2O (Fmoc), COCHN, H-3′), 3.96 (m, 1H, H-4′), 3.72 (s, 6H, OCH3), 3.50–3.33 (m, 12H, (CH2OCH2)3), 3.28–2.88 (m, 8H, CH2N, CH2S, H-5′), 1.61 (apparent quintet, 4H, J = 6.6 Hz, CH2CH2CH2), 1.28 (s, 9H, But). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-[2-(2-trimethylacetoxyethoxy)ethylaminocarbonyl] uridine (S.6l). Yield 1.377 g (90.4%). Rf: 0.60 (EtOAc). 1H NMR: 11.40 (s, 1H, H-3), 7.69 (d, 1H, J5,6 = 8.1 Hz, H-6), 7.41–7.19 (m, 10H, ArH, OCONH), 6.89 (d, 4H, J = 8.8 Hz, ArH), 5.90 (d, 1H, J1′,2′ = 5.0 Hz, H-1′), 5.53 (d, 1H, J3′,OH = 5.7 Hz, 3′-OH), 5.38 (d, 1H, J5,6 = 8.1 Hz, H-5), 5.12 (apparent t, 1H, J1′,2′ = J2′,3′ = 5.0 Hz, H-2′), 4.32 (m, 1H, H-3′), 4.11 (m, 2H, CH2OPiv), 3.97 (m, 1H, H-4′), 3.73 (s, 6H, OCH3), 3.57, 3.43 (2m, 4H, CH2OCH2), 3.27–3.02 (m, 4H, H-5′, CH2N), 1.11 (s, 9H, But).
Prepare phosphoramidites S.7g-j and S.7l 15. Phosphinylate S.6 compounds by treatment with bis(N,N-diisopropylamino)-2-cyanoethoxyphosphine and diisopropylammonium tetrazolide in dry CH2Cl2, and purify S.7 by column chromatography (see Basic Protocol 1, steps 36 to 41). For S.7g: 20% to 66% (v/v) acetone/1% (v/v) TEA in CHCl3 For S.7h: 20% to 50% (v/v) acetone/1% (v/v) TEA in CHCl3 For S.7i: 20% to 66% (v/v) acetone/1% (v/v) TEA in CHCl3 For S.7j: 20% to 40% (v/v) acetone/1% (v/v) pyridine in CHCl3 For S.7l: 1% (v/v) TEA in 1:1 (v/v) acetone/CHCl3.
Synthesis of Modified Oligonucleotides and Conjugates
4.21.17 Current Protocols in Nucleic Acid Chemistry
Supplement 15
16. Analyze the products by TLC and 1H and 31P NMR. 3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl)-2′O-[4-trifluoroacetyl-7-(trifluoroacetylamino)-4-azaheptan-1-ylaminocarbonyl]uridine (S.7g). Yield 1.396 g (93.8%). Rf: 0.14, 0.25 (EtOAc). 1H NMR: 11.40 (br s, 1H, H-3), 9.52, 9.44 (2 br s, 1H, NHTFA, rotamers), 7.70 (m, 1H, H-6), 7.53 (m, 1H, OCONH), 7.41–7.15 (m, 9H, ArH), 6.87 (m, 4H, ArH), 5.92 (m, 1H, H-1′), 5.45–5.22 (m, 2H, H-5, H-2′), 4.54 (m, 1H, H-3′), 4.12 (m, 1H, H-4′), 3.80–3.09 (m, 18H#, OCH3, POCH2, CHN, H-5′, CH2NTFA), 2.99 (m, 2H, OCONHCH2), 2.74, 2.57 (2m, 2H, CH2CN), 1.73 (m, 4H, CH2CH2CH2), 1.20–0.87 (m, 12H, CHCH3). 31P NMR (CD3CN): 150.74 (54%), 150.66 (22%), 150.58 (24%), diastereomers and rotamers. 3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl)-2′O-[4,9-bis(trifluoroacetyl)-12-(trifluoroacetylamino)-4,9-diazadodecyl-1-aminocarbonyl] uridine (S.7h). Yield 1.242 g (98.3%). Rf: 0.18, 0.32 (EtOAc). 1H NMR: 11.36 (br s, 1H, H-3), 9.52, 9.45 (2 br s, 1H, NHTFA, rotamers), 7.69 (m, 1H, H-6), 7.53 (m, 1H, OCONH), 7.41–7.16 (m, 9H, ArH), 6.87 (m, 4H, ArH), 5.92 (m, 1H, H-1′), 5.44–5.21 (m, 2H, H-5, H-2′), 4.53 (m, 1H, H-3′), 4.12 (m, 1H, H-4′), 3.80–3.12 (m, 22H#, OCH3, POCH2, CHN, H-5′, CH2NTFA), 2.99 (m, 2H, OCONHCH2), 2.74, 2.57 (2m, 2H, CH2CN), 1.74 (m, 4H, CH2CH2NH), 1.51 (m, 4H, CH2CH2CH2CH2), 1.19–0.86 (m, 12H, CHCH3). 31P NMR (CD3CN): 150.8 (56%), 150.7 (20%), 150.6 (24%), diastereomers and rotamers. 3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl)-2′O-[13-(trifluoroacetylamino)-4,7,10-trioxatridecan-1-ylaminocarbonyl]uridine (S.7i). Yield 1.069 g (98.2%). Rf: 0.20, 0.34 (EtOAc). 1H NMR: 11.44 (s, 1H, H-3), 9.37 (br s, 1H, NHTFA), 7.71 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.47–7.19 (m, 10H, ArH, OCONH), 6.87 (m, 4H, ArH), 5.91 (m, 1H, H-1′), 5.42 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.31 (m, 1H, H-2′), 4.55 (m, 1H, H-3′), 4.12 (m, 1H, H-4′), 3.80–3.16 (m, 24H#, (CH2OCH2)3, POCH2, CHN, H-5′, OCH3), 3.01 (m, 2H, OCONHCH2), 2.74, 2.57 (2m, 2H, CH2CN), 1.74–1.55 (m, 4H, CH2CH2CH2), 1.18–0.92 (m, 12H, CHCH3). 31P NMR (CD3CN): 149.35, 149.28 (diastereomers). 3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl)-2′O-{13-[S-(tert-butylthio)-N-(9-fluorenylmethyloxycarbonyl)cysteinylamino]-4,7,10- trioxatridecane-1-ylaminocarbonyl}uridine (S.7j). Yield 1.130 g (81.4%). Rf: 0.30, 0.53 (EtOAc). Faster moving diastereomer: 1H NMR: 11.44 (s, 1H, H-3), 8.02 (m, 1H, NHCOCH), 7.88 (d, 2H, J = 7.4 Hz, ArH (fluorene)), 7.70 (m, 4H, ArH (fluorene), H-6, NHFmoc), 7.47–7.08 (m, 14H, ArH (fluorene H-2,3,6,7, DMTr), OCONHCH2), 6.88 (d, 4H, J = 8.6 Hz, ArH (DMTr)), 5.89 (d, 1H, J1′,2′ = 5.1 Hz, H-1′), 5.42 (d, 1H, J5,6 = 7.9 Hz, H-5), 5.30 (m, 1H, H-2′), 4.55 (m, 1H, H-3′), 4.35–4.07 (m, 5H, CHCH2O (Fmoc), COCHN, H-4′), 3.72 (s, 6H, OCH3), 3.60–3.21 (m, 24H#, (CH2OCH2)3, POCH2, NCHCH3, H-5′), 3.15–2.85 (m, 6H, CH2N, CH2S), 2.57 (m, 2H, CH2CN), 1.59 (m, 4H, CH2CH2CH2), 1.28 (s, 9H, But), 1.13–0.93 (m, 12H, CHCH3). Slower moving diastereomer: 1H NMR: 11.44 (s, 1H, H-3), 8.02 (m, 1H, NHCOCH), 7.88 (d, 2H, J = 7.4 Hz, ArH (fluorene)), 7.70 (m, 4H, ArH (fluorene), H-6, NHFmoc), 7.42–7.12 (m, 14H, ArH (fluorene H-2,3,6,7, DMTr), OCONHCH2), 6.87 (d, 4H, J = 8.2 Hz, ArH (DMTr)), 5.91 (m, 1H, H-1′), 5.42 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.34 (m, 1H, H-2′), 4.53 (m, 1H, H-3′), 4.33–4.03 (m, 5H, CHCH2O (Fmoc), COCHN, H-4′), 3.80–3.20 (m, 24H#, (CH2OCH2)3, POCH2, NCHCH3, H-5′, OCH3), 3.12–2.87 (m, 6H, CH2N, CH2S), 2.74 (t, 2H, J = 5.7 Hz, CH2CN), 1.61 (m, 4H, CH2CH2CH2), 1.27 (s, 9H, But), 1.12–0.88 (m, 12H, CHCH3).
Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
3′-O-(N,N-Diisopropylamino-2-cyanoethoxyphosphinyl)-5′-O-(4,4′-dimethoxytrityl)-2′O-[2-(2-trimethylacetoxyethoxy)ethylaminocarbonyl]uridine (S.7l). Yield 0.947g (98.4%). Rf: 0.43, 0.57 (EtOAc). 1H NMR: 11.44 (s, 1H, H-3), 7.70 (d, 1H, J5,6 = 8.0 Hz, H-6), 7.47–7.19 (m, 10H, ArH, OCONH), 6.88 (m, 4H, ArH), 5.90 (m, 1H, H-1′), 5.43 (d, 1H, J5,6 = 8.0 Hz, H-5), 5.30 (m, 1H, H-2′), 4.55 (m, 1H, H-3′), 4.10 (m, 3H, H-4′, CH2OCO), 3.72 (s, 6H, OCH3), 3.62–3.01 (m, 12H#, POCH2, CHN, H-5′, NCH2CH2OCH2), 2.74, 2.57 (2m, 2H, CH2CN), 1.23–0.90 (m, 21H, CHCH3, But). 31P NMR (CD3CN): 149.5, 149.4, 149.3 (diastereomers and rotamers). (#Calculated value; the signal of water is also present in the region).
4.21.18 Supplement 15
Current Protocols in Nucleic Acid Chemistry
SYNTHESIS, ISOLATION, AND CHARACTERIZATION OF OLIGONUCLEOTIDES CONTAINING URIDINE 2′-CARBAMATES
BASIC PROTOCOL 2
3′-Phosphoramidites of 5′-dimethoxytritylated uridine 2′-carbamates are stable during prolonged storage at –20°C. The compounds are less reactive compared to standard 2′-deoxyribonucleoside phosphoramidites due to the steric bulk of the 2′-carbamate group. Therefore, the coupling time should be increased to 10 to 15 min to achieve a 97% to 98% yield, which is acceptable for introduction of one or a few modifications into an oligonucleotide chain. In all cases, a 2′-carbamate function is completely stable to the conditions of oligonucleotide synthesis as well as to final deprotection with concentrated aqueous ammonia (55°C, 8 to 16 hr). In general, an increased coupling time is the only change in oligonucleotide synthesis and isolation that is necessary for preparation of uridine-2′-carbamate-containing oligonucleotides. However, there are two important details that should be noted. First, the 2′-trimethylacetate ester obtained from phosphoramidite S.7l is unexpectedly stable to ammonia treatment. Only after 96 hr of standard deprotection does the MALDI-TOF spectrum show complete ester hydrolysis in a doubly modified oligo-2′-deoxyribonucleotide. Second, the phosphoramidite S.7f is sparingly soluble in acetonitrile and N,N-dimethylformamide and is highly prone to gel formation, which makes it difficult to use for standard oligonucleotide synthesis. All the other phosphoramidites can be used as 0.1 M solutions in anhydrous acetonitrile. Oligonucleotide synthesis can be carried out on any automated DNA/RNA synthesizer. The authors have used Applied Biosystems 380B and 394 on both a 0.2- and 1-µmol scale using 2′-deoxyribonucleoside and 2′-O-methyl-ribonucleoside phosphoramidites (Transgenomics), as well as 2′-TOM-ribonucleoside phosphoramidites (Glen Research; also see UNITS 2.9 & 3.8). A number of techniques may be used for isolation and purification of oligonucleotides with uridine 2′-carbamate modifications, such as reversed-phase or ion-exchange HPLC, on cartridges (e.g., PolyPak, Glen Research), or by denaturing PAGE. A standard vertical gel electrophoresis apparatus is suitable for PAGE of modified oligonucleotides. The molecular mass of the oligonucleotides was checked by MALDITOF mass spectrometry on an Applied Biosystems Voyager DE workstation in positive ion mode. Thermal denaturation experiments with oligonucleotide duplexes were performed on a Perkin Elmer Lambda 40 UV/Vis spectrophotometer with Peltier temperature programmer in the hybridization buffer. Fluorescence spectra were recorded using a Perkin Elmer LS 50B Luminescence Spectrometer in the same buffer. For evaporation of small volumes, a Speedvac evaporator is ideal. Materials Uridine 2′-carbamate phosphoramidite(s) (S.7a-j,l; see Basic Protocol 1 and Alternate Protocol) Acetonitrile, anhydrous Phosphoramidites: 2′-Deoxyribonucleoside phosphoramidites (Transgenomics) 2′-O-Methyl-ribonucleoside phosphoramidites (2′-OMe; Transgenomics) 2′-O-[(Triisopropylsilyl)oxy]methyl-ribonucleoside phosphoramidites (2′-O-TOM; Glen Research; also see UNITS 2.9 & 3.8) 30% ammonia Nitrogen Mobile phase A: 5% CH3CN in 0.1 M triethylammonium acetate (TEAA), pH 7.0 (DMTr-ON, HPLC) Mobile phase B: 100% CH3CN (DMTr-ON, HPLC) 1 to 400 mM sodium perchlorate in 20 mM Tris⋅Cl (pH 6.8; APPENDIX 2A)/25% formamide (DMTr-OFF, HPLC)
Synthesis of Modified Oligonucleotides and Conjugates
4.21.19 Current Protocols in Nucleic Acid Chemistry
Supplement 15
15% (w/v) polyacrylamide gel (APPENDIX 3D) containing 2 M urea in 0.5× TBE electrophoresis buffer (APPENDIX 2A) (DMTr-OFF, PAGE) 0.5 M LiClO4 (DMTr-OFF, PAGE) Matrix solution I: 40 mg/mL 2,6-dihydroxyacetophenone in methanol Matrix solution II: 80 mg/mL diammonium hydrogen citrate in water Water aspirator Screw-capped tube (Sarstedt) or vial Speedvac evaporator (Savant) Spin-X tube (Costar) Reversed-phase cartridges for DNA isolation (e.g., PolyPak, Glen Research; DMTr-ON) HPLC system (optional) with: Column: 3.9 × 300–mm Phenomenex Bondclone 10 C18 column (DMTr-ON) or 9 × 250–mm Dionex NucleoPac PA-100 column (DMTr-OFF) Detector: 254 nm (DMTr-ON) or 280 nm (DMTr-OFF) Lyophilizer Microcon tube (Millipore) or NAP-10 column (DMTr-OFF, PAGE) Additional reagents and equipment for automated solid-phase oligonucleotide synthesis (APPENDIX 3C) and purification of oligonucleotides (UNITS 10.1, 10.4, 10.5, 10.7 & APPENDIX 3B) 1. Dissolve the appropriate uridine 2′-carbamate phosphoramidite(s) in anhydrous CH3CN at up to 1.0 M. 2. Start the automated solid-phase oligonucleotide synthesis (APPENDIX 3C) from an appropriate solid support–filled column (e.g., on a 0.2- or 1-µmol scale). 3. Elongate the desired oligonucleotide chain using modified 2′-carbamate phosphoramidites (S.7a-j and S.7l) and standard 2′-deoxy-, 2′-OMe-, or 2′-O-TOM-ribonucleoside phosphoramidites in either DMTr-ON or -OFF mode. Allow at least 10 to 15 min for each 2′-carbamate phosphoramidite coupling. 4. After completion of the assembly, remove the column, wash with CH3CN (e.g., two times with 10 mL for 1-µmol synthesis), and quickly dry using a water aspirator. 5. Transfer the support into a screw-capped tube or vial and add 1 mL of 30% ammonia. 6a. For oligonucleotides prepared from phosphoramidites S.7a-j: Vortex the mixture and incubate at least 8 hr at 55°C or 24 hr at ambient temperature. 6b. For oligonucleotides prepared from phosphoramidite S.7l: Vortex the mixture and incubate at least 48 hr at 55°C per modified residue to ensure complete trimethylacetate ester deprotection. 7. Allow the solution to cool to ambient temperature, evaporate most of the ammonia under a stream of nitrogen, and dry the rest in vacuo using a Speedvac evaporator. For DMTr-ON oligonucleotides, it may be necessary to add 5 ìL TEA to completely preserve the DMTr group.
8. Add 0.5 mL deionized water, transfer the solution to the upper part of a Spin-X tube, and microcentrifuge 5 min at 13,000 rpm.
Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
9. Add 0.25 mL deionized water to the upper part of the tube, centrifuge again to wash, and then repeat. Concentrate the combined filtrates (sample and two washes) in vacuo.
4.21.20 Supplement 15
Current Protocols in Nucleic Acid Chemistry
10a. For DMTr-ON oligonucleotides: Purify on a reversed-phase cartridge following manufacturer’s recommendations (also see UNIT 10.7) or by RP-HPLC (UNIT 10.5) using the following recommended conditions: 3.9 × 300–mm Phenomenex Bondclone 10 C18 column Buffer A: 5% CH3CN in 0.1 M TEAA, pH 7.0 Buffer B: 100% CH3CN Gradient: 0% to 60% buffer B in 45 min Flow rate: 1 mL/min Detection: 254 nm. Pool the appropriate fractions, re-evaporate twice with water, and lyophilize. 10b. For HPLC of DMTr-OFF oligonucleotides: Purify by ion-exchange HPLC (UNIT 10.5) using the following recommended conditions: 9 × 250–mm Dionex NucleoPac PA-100 column Gradient: 1 to 400 mM sodium perchlorate in 20 mM Tris⋅Cl (pH 6.8)/25% formamide Flow rate: 1 mL/min Detection: 280 nm. Pool the appropriate fractions, desalt on a NAP-10 column, and lyophilize. 10c. For PAGE of DMTr-OFF oligonucleotides: Use denaturing gel electrophoresis (UNIT 10.4 & APPENDIX 3B) in 15% polyacrylamide containing 2 M urea in 0.5× TBE electrophoresis buffer. Cut the band(s) and elute the product with 0.5 M LiClO4. Desalt using a Microcon tube or a NAP-10 column, and lyophilize. 11. Dissolve the oligonucleotide in deionized water and quantitate by measuring UV absorbance at 260 nm. Store the solution up to 2 years frozen (i.e., −20°C). 12. Check the molecular mass of the oligonucleotides by MALDI-TOF-MS (UNIT 10.1) using a 1:1 (v/v) mixture of matrix solutions I and II. Prepare matrix just before loading the samples onto a plate. For a discussion of hybridization (duplex stability) studies and fluorescence measurements using 2′-carbamate-modified oligonucleotides, see Background Information. The optimal hybridization buffer for these experiments is 10 mM sodium phosphate, pH 7.0 (APPENDIX 2A) containing 0.1 mM EDTA and 100 mM NaCl. See Figure 4.21.4 for sample spectra and Table 4.21.1 for melting temperatures in a duplex stability study.
COMMENTARY Background Information Application of nucleoside carbamates The studies that are described here were originally driven by a desire to develop a convenient method for the introduction of various ligands into ribozymes. Use of ligands such as polyamines and amino acids together with the hairpin ribozyme was investigated as a possible way to enhance the ribozyme’s RNA cleavage potential under low metal ion concentration (Stolze et al., 2001). Since nucleobases in the core region are often involved in noncovalent
interactions important for maintaining structure and function, the sugar moiety of nucleosides, particularly the 2′-hydroxyl groups, seem to be attractive for ligand attachment, especially because 2′-functionalization already has proven value in various applications (Zatsepin et al., 2002). There are numerous examples of 2′-O-alkylnucleoside derivatives and their introduction into oligonucleotides. An irritating shortcoming is a sometimes poor yield of 2′-O-alkylation. An interesting opportunity for 2′-functionalization is via a carbamate function, easily
Synthesis of Modified Oligonucleotides and Conjugates
4.21.21 Current Protocols in Nucleic Acid Chemistry
Supplement 15
5015.60
A 30000
CUCCCAGGCUCAAAT O
2′ O
O
2′ O
HN
HN
Counts
20000
10000
0 3000
5000 Mass (m/z )
6000
7000
CUCCCAGGCUCAAAT 40000
2′ O O HN
5050.15
B
4000
2′ O
O
HN
Counts
30000
20000
10000
0 3000
4000
C
7000
CUCCCAGGCUCAAAT 20000
2′ O
4958.24 Counts
6000
5000 Mass (m/z )
O
O
2′ O HN
HN
HN
HN
NH
NH
10000 NH2
0 3000
Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
4000
5000 Mass (m/z )
6000
NH2
7000
Figure 4.21.4 MALDI-TOF mass spectra of 2′-carbamate oligodeoxyribonucleotides containing two modified uridines CU*CCCAGGCU*CAAAT, where U* is from phosphoramidites S.7d (A), S.7e (B), and S.7h (C) (see Figures 4.21.1 and 4.21.2 and Table 4.21.1).
4.21.22 Supplement 15
Current Protocols in Nucleic Acid Chemistry
Table 4.21.1 and RNA
Melting Temperatures of Duplexes of 2′-Carbamate Oligonucleotides with Complementary DNA
Sequence, 5′ to 3′
U* = U-2′-OCONHCH2R where R =
CTCCCAGGCU*C- Control, U* = 2′-deoxyuridine AAAT C≡CH 4-Iodophenyl 1-Pyrenyl 1,4,7,10,13-Pentaoxacyclopentadecan-2-yl CH2OCH2CH2OH (CH2)2[O(CH2)2]2O(CH2)3NH2 (CH2)2NH(CH2)3NH2 (CH2)2NH(CH2)4NH(CH2)3NH2 CU*CCCAGGCTC- Control, U* = 2′-deoxyuridine AAAT 4-Iodophenyl 1-Pyrenyl 1,4,7,10,13-Pentaoxacyclopentadecan-2-yl CH2OCH2CH2OH (CH2)2[O(CH2)2]2O(CH2)3NH2 (CH2)2NH(CH2)3NH2 (CH2)2NH(CH2)4NH(CH2)3NH2
generated from primary or secondary alcohols by successive treatment with 1,1′-carbonyldiimidazole (CDI) and an aliphatic amine. This chemistry has been used successfully for 5′modification of oligonucleotides (Wachter et al., 1986). Aliphatic 5′-carbamates are known to be stable to ammonia deprotection at 55°C, in contrast to aromatic nucleoside 3′-carbamates (Sproat and Brown, 1983). Oligonucleotides containing nucleoside 2′carbamates have been reported previously. Cytidine 2′-carbamate was obtained by CDI activation followed by amine treatment (Dubey et al., 2000). In general, 2′-carbamate modifications are detrimental to the stability of DNARNA duplexes (Freier and Altmann, 1997; Prhavc et al., 2001). Recently we have described the preparation of a number of uridine 2′-carbamates and their introduction into oligo2′-deoxy- and 2′-OMe-ribonucleotides, and studied their hybridization with complementary DNA and RNA. It was found that 2′-pyrene carbamate-modified oligonucleotides show interesting binding properties and remarkable
DNA
RNA
Tm (°C)
∆Tm/mod Tm (°C) (°C)
∆Tm/mod (°C)
56.4
—
59.1
—
50.0 49.9 54.7 49.8
−6.4 −6.5 −1.7 −6.6
54.5 54.7 57.8 53.9
−4.7 −4.5 −1.4 −5.3
50.1 49.8 51.5 51.4 56.2
−6.3 −6.6 −4.9 −5.0 —
53.7 53.9 53.4 55.1 58.8
−5.5 −5.3 −5.8 −4.0 —
53.4 57.5 53.5
−2.8 +1.3 −2.8
54.4 55.5 54.8
−4.4 −3.3 −4.0
52.8 52.6 53.1 54.1
−3.4 −3.6 −3.1 −2.3
56.2 55.5 55.9 59.0
−2.6 −3.3 −2.9 +0.2
DNA mismatch affinity (Korshun et al., 2002), and exhibit enhanced fluorescence when bound to complementary RNA, but not DNA (see Fig. 4.21.5). Synthesis of uridine 2′-carbamates and their phosphoramidites The authors developed a general approach for the preparation of uridine 2′-carbamates using 1,1′-carbonyldiimidazole (CDI) activation of the 2′-hydroxy group of 3′,5′Markiewicz-protected uridine (S.2; see Basic Protocol 1). The reaction with CDI in dry dichloromethane gives the corresponding activated imidazolide in nearly quantitative yield. Dichloromethane proved to be the best solvent for the transformation, whereas use of the more polar tetrahydrofuran and acetonitrile led to a much longer reaction time. Other investigators have described a successful preparation of 2′carbamates using disuccinimidyl carbonate (DSC) and triethylamine in acetonitrile (Prhavc et al., 2001). In the authors’ hands, however,
Synthesis of Modified Oligonucleotides and Conjugates
4.21.23 Current Protocols in Nucleic Acid Chemistry
Supplement 15
Fluorescence (arb. units)
25 20 15 10
3 5
2 1
0 350
400
nm
450
Figure 4.21.5 Fluorescence spectra of 2′-pyrene carbamate oligodeoxyribonucleotide CTCCCAGGCU*CAAAT (1) and its duplex with complementary DNA (2) and RNA (3) (see Table 4.21.1).
Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
DSC gave poorer results, requiring a higher excess of reagent and longer reaction times, while giving lower conversion yields. An additional advantage of CDI is that in many cases the imidazolide S.3 need not be isolated, but can be reacted in situ with an excess of amine. The corresponding Markiewicz-protected 2′-carbamates (S.4) are stable compounds that can be easily purified by column chromatography. A facile technique was developed to protect side-chain amino groups of di- and polyamine 2′-carbamate derivatives, which involved trifluoroacetylation without isolation of the unprotected intermediate (see Alternate Protocol). Initial attempts to remove the Markiewicz group from 2′-carbamates by tetrabutylammonium fluoride trihydrate (TBAF) in THF showed smooth silyl deprotection, but also the appearance of a by-product with similar mobility. After several hours of treatment, an equilibrium was reached where an ∼1:1 ratio of the two products was obtained. The side-product proved to be the corresponding 3′-carbamate, generated by carbamoyl migration in the 1,2diol system (Korshun et al., 2002). The possibility of carbamoyl migration has been discussed in a similar case, but the 3′-carbamate itself was neither detected nor isolated (Seio et al., 1998). Interestingly, those authors used a safer reagent by buffering TBAF solution with
acetic acid. In other cases, 0.1 M TBAF in THF was used (Dubey et al., 2000; Prhavc et al., 2001). In our hands, however, TBAF in THF always gave a mixture of regioisomers. However, using the alternative desilylating reagent triethylamine trihydrofluoride, only pure 2′carbamate product S.5 was obtained, even after overnight treatment. The following step of 5′-dimethoxytritylation required some modification. Although care was taken to get rid of most of the fluoride by repeated toluene/hexane washings, some of the latter apparently remained in the crude mixture, which thus consumed additional amounts of 4,4′-dimethoxytrityl chloride (DMTr⋅Cl; up to 3 eq). In one case (S.6e), this led to an increased formation of 3′,5′-ditritylated product and lower yield of the target compound. A new work-up procedure was recently adopted to obviate the need for higher excess of DMTr⋅Cl. It uses an excess of inexpensive ethoxytrimethylsilane to scavenge the remaining fluoride, with corresponding formation of only volatile products (Stetsenko, pers. comm.). Use of pyridine (0.5% v/v) instead of TEA as an additive for column chromatography of 5′DMTr-protected 2′-carbamates is strongly advised to prevent 2′,3′-carbamate migration on silica gel. The final 3′-phosphinylation went smoothly and uneventfully according to the published procedure (Caruthers et al., 1987).
4.21.24 Supplement 15
Current Protocols in Nucleic Acid Chemistry
Synthesis of oligonucleotides containing uridine 2′-carbamate residues Automated solid-phase oligonucleotide synthesis was accomplished using a manufacturer’s protocol that has been modified only by increasing the coupling time of the 2′-carbamate phosphoramidites to 10 to 15 min (see Basic Protocol 2). Uridine-2′-carbamate-modified oligonucleotides were routinely synthesized in DMTr-ON mode and isolated on a reversed-phase cartridge (PolyPak) following the supplier’s standard technique. The results were consistently good as judged from the MALDI-TOF mass spectra of doubly modified oligomers (see Fig. 4.21.4). Effect of 2′-carbamate modifications on duplex stability Melting studies with uridine-2′-carbamatemodified oligonucleotides (see Table 4.21.1) confirmed the overall destabilizing effect of the 2′-carbamate group in both the DNA-DNA and DNA-RNA series. Most carbamate modifications result in a considerable decrease in Tm values of the duplexes, but there was almost no correlation between the steric bulk of the carbamate group and the Tm of the corresponding duplexes. The least destabilizing is pyrene carbamate, especially in the case of DNA-DNA duplexes. As expected, a single modification close to the 5′-terminal position of the oligonucleotide caused less destabilization than one in the middle. A number of studies of pyrene attached to the 2′-position of individual nucleosides within duplexes have been published recently (Silverman and Cech, 1999; Yamana et al., 2001). Pyrene as well as other planar polyaromatic hydrocarbons often show a greater stabilizing effect in DNA-DNA duplexes than in DNA-RNA duplexes (Yamana et al., 2001). The pyrene 2′-carbamate modification is not an exception, giving a clear stabilizing effect of pyrene superimposed on the destabilizing influence of the 2′-carbamate group, while even the spermine carbamate, which should carry three positive charges under physiological pH, is only negligibly stabilizing in just one most favorable situation. That pyrene is more stabilizing in DNADNA duplexes than DNA-RNA duplexes might suggest the better fit of pyrene into the shallower DNA-DNA minor groove. This notion is strengthened by interesting fluorescent properties of pyrene 2′-carbamate oligonucleotides. The total fluorescence intensity upon duplex formation of single pyrene-labeled oli-
gomers with a complementary DNA does not change very much (see Fig. 4.21.5). By contrast, the binding to a complementary RNA gives a 5- to 30-fold increase in fluorescence for single-pyrene oligonucleotides and a 30fold increase for double-pyrene oligonucleotides. This gives evidence that the excited pyrene 2′-carbamate is effectively quenched in single-stranded oligodeoxyribonucleotides and in DNA-DNA duplexes, but not in DNARNA duplexes. Similar examples of fluorescence increases upon hybridization with a complementary RNA are demonstrated for probes containing 2′-attached pyrene (Yamana et al., 2001). Thus, uridine 2′-carbamate modification in a DNA strand is usually destabilizing for both DNA-DNA and DNA-RNA duplexes, and therefore might be less suitable for those cases where higher stability of a duplex is preferential (e.g., antisense applications). However, the 2′carbamate modification affords a convenient way to place various functional groups into the minor groove of a DNA-DNA duplex (e.g., crown ether for metal ion binding, or an aliphatic amino group for postsynthetic labeling with activated derivatives of fluorescent dyes). Other possible applications include the specific minor groove delivery of reactive functionalities (e.g., for site-directed protein cross-linking or conjugation with peptides or other biomolecules), as well as modifications of flexible parts of highly structured RNA molecules for studies of ribozyme catalysis or RNA folding.
Critical Parameters and Troubleshooting The synthesis of 2′-carbamate compounds (see Basic Protocol 1 and Alternate Protocol) is relatively short, straightforward, and fairly efficient. However, careful attention to details of basic organic synthesis procedures is required. Preparation of the various compounds requires prior experience with routine chemical laboratory techniques such as solvent evaporation, extraction, TLC, and column chromatography. HPLC and gel electrophoresis are the most widely used methods of modified oligonucleotide isolation. Characterization of the products demands knowledge of 1H and 31P NMR, UV and MALDI-TOF mass spectroscopy. General laboratory safety is also of primary concern when hazardous materials are involved. Strict adherence to the outlined methods is therefore highly recommended.
Synthesis of Modified Oligonucleotides and Conjugates
4.21.25 Current Protocols in Nucleic Acid Chemistry
Supplement 15
Anticipated Results Good to moderate yields of the final uridine 2′-carbamate 3′-phosphoramidites (S.7) from the parent Markiewicz-protected nucleoside (S.2) are expected following these procedures (see Basic Protocol 1 and Alternate Protocol). Analogously, others have reported good yields of 2′-carbamate nucleosides obtained by both similar (Dubey et al., 2000) and different chemistries (Prhavc et al., 2001). Basic Protocol 2 is intended to make use of the 2′-carbamate phosphoramidites to synthesize, purify, and characterize 2′-carbamate-containing oligonucleotides.
Time Considerations The synthesis of the 2′-carbamate 3′-phosphoramidites starting from Markiewicz-protected uridine (S.2) can be accomplished in 2 to 3 weeks per amine derivative, depending on the nature of the side chain and whether an additional protecting group is needed. The authors suggest, therefore, the preparation of a large batch of S.2 (from ∼30 mmol upwards) to use in portions as needed. The time for oligonucleotide synthesis varies from standard phosphoramidite methods only by the increased 2′-carbamate coupling time of 10 to 15 min per residue. The times needed for deprotection, isolation, purification, and analysis of modified oligonucleotides are the same as with standard techniques.
Literature Cited Caruthers, M.H., Barone, A.D., Beaucage, S.L., Dodds, D.R., Fisher, E.F., McBride, L.J., Matteucci, M., Stabinsky, Z., and Tang J.-Y. 1987. Chemical synthesis of deoxyoligonucleotides by the phosphoramidite method. Methods Enzymol. 154:287-313. Dubey, I., Pratviel, G., and Meunier, B. 2000. Synthesis and DNA cleavage of 2′-O-amino-linked metalloporphyrin-oligonucleotide conjugates. J. Chem. Soc., Perkin Trans. 1:3088-3095. Freier, S.M. and Altmann, K.-H. 1997. The ups and downs of nucleic acid duplex stability: Structurestability studies on chemically-modified DNA:RNA duplexes. Nucl. Acids Res. 25:44294443. Korshun, V.A., Stetsenko, D.A., and Gait, M.J. 2002. Novel uridin-2′-yl carbamates: Synthesis, incorporation into oligodeoxyribonucleotides, and remarkable fluorescence properties of 2′-pyren-1-ylmethylcarbamate. J. Chem. Soc., Perkin Trans. 1:1092-1104. Uridine 2′-Carbamates: Facile Tools For Oligonucleotide 2′-Functionalization
McGee, D.P.C., Sebesta D.P., O’Rourke, S.S., Martinez, R.L., Jung, M.E., and Pieken, W.A. 1996. Novel nucleosides via intramolecular functionalization of 2,2′-anhydrouridine derivatives. Tetrahedron Lett. 37:1995-1998. Prhavc, M., Lesnik, E.A., Mohan, V., and Manoharan, M. 2001. 2′-O-Carbamate-containing oligonucleotides: Synthesis and properties. Tetrahedron Lett. 42:8777-8780. Rannard, S.P. and Davis, N.P. 2000. The selective reaction of primary amines with carbonyl imidazole containing compounds: Selective amide and carbamate synthesis. Org. Lett. 2:2117-2120. Seio, K., Wada, T., Sakamoto, K., Yokoyama, S., and Sekine, M. 1998. Chemical synthesis and properties of conformationally fixed diuridine monophosphates as building blocks of the RNA turn motif. J. Org. Chem. 63:1429-1443. Silverman, S.K. and Cech, T.R. 1999. RNA tertiary folding monitored by fluorescence of covalently attached pyrene. Biochemistry 38:14224-14237. Sproat, B.S. and Brown, D.M. 1985. A new linkage for solid phase synthesis of oligodeoxyribonucleotides. Nucl. Acids Res. 13:2979-2987. Stolze, K., Holmes, S.C., Earnshow, D.J., Singh, M., Stetsenko, D.A., Williams, D., and Gait, M.J. 2001. Novel spermine-amino acid conjugates and basic tripeptides enhance cleavage of the hairpin ribozyme at low magnesium ion concentration. Bioorg. Med. Chem. Lett. 11:3007-3010. Wachter, A., Jablonski, J.-A., and Ramachandran, K.L. 1986. A simple and efficient procedure for the synthesis of 5′-aminoalkyl oligodeoxynucleotides. Nucl. Acids Res. 14:7985-7994. Yamana, K., Zako, H., Asazuma, K., Iwase, R., Nakano, H., and Murakami, A. 2001. Fluorescence detection of specific RNA sequences using 2′-pyrene-modified oligoribonucleotides. Angew. Chem. Int. Ed. Engl. 40:1104-1106. Zatsepin, T.S., Stetsenko, D.A., Arzumanov, A.A., Romanova, E.A., Gait, M.J., and Oretskaya, T.S. 2002. Synthesis of peptide-oligonucleotide conjugates with single and multiple peptides attached to 2′-aldehyde through thiazolidine, oxime and hydrazine linkages. Bioconjug. Chem. 13:822-830. Zhang, L., Cui, Z., and Zhang, B. 2003. An efficient synthesis of 3′-amino-3′-deoxyguanosine from guanosine. Helv. Chim. Acta 86:703-710.
Contributed by Vladimir A. Korshun Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Moscow, Russia Dmitry A. Stetsenko and Michael J. Gait Medical Research Council Laboratory of Molecular Biology Cambridge, United Kingdom
4.21.26 Supplement 15
Current Protocols in Nucleic Acid Chemistry
Stepwise Solid-Phase Synthesis of Nucleopeptides
UNIT 4.22
Modification of oligonucleotides by attachment of peptide chains has attracted considerable interest during the last few years. The covalent union of a peptide chain may have beneficial effects on synthetic oligonucleotides (Tung and Stein, 2000), such as (1) increasing their stability to exonucleases, (2) accelerating or enhancing hybridization to their target sequences, and (3) facilitating their transport through cell membranes, which is particularly important for antisense (or antigene) applications (Gait, 2003). No rules are established to name and describe the different types of peptide-oligonucleotide conjugates. The word nucleoprotein is used to describe both covalently and noncovalently linked nucleic acid–protein complexes. Since in the former a phosphate group links the 5′- or 3′-terminal hydroxyl group of a nucleic acid with the side-chain hydroxyl group of serine, threonine, or tyrosine of a protein, phosphodiester-linked peptide-oligonucleotide conjugates have often been denoted as nucleopeptides (Schattenkerk et al., 1984; Robles et al., 1991; Waldmann and Gabold, 1997). Some authors, however, have used the term nucleopeptide to refer to other types of conjugates (UNIT 4.5; McMinn and Greenberg, 1999), and still others have referred to nucleopeptides as peptide-oligonucleotide conjugates (see below; Stetsenko et al., 2002). This unit describes stepwise solid-phase methods to obtain nucleopeptides containing 2′-deoxynucleosides and any of the proteinogenic amino acids, including the trifunctional ones. The procedures reported here are also suitable for the preparation of other peptideoligonucleotide conjugates, since most of the critical points of the procedures are related to the presence of purine nucleosides and some trifunctional amino acids in the target molecule. Methods for synthesis of the desired support-bound peptide (see Basic Protocol 1) are followed by methods for preparing the solid support (see Support Protocol 1) and several protected amino acids that are not commercially available (see Support Protocols 2 to 5). This is followed by extension of the oligonucleotide and cleavage and deprotection of the nucleopeptide (see Basic Protocol 2), and analysis, purification, and characterization of the target molecule (see Basic Protocols 3 and 4). Additional methods are given for reduction of nucleopeptides containing sulfoxide-protected methionine (see Support Protocol 6) and deprotection and purification of cysteine-containing nucleopeptides (see Support Protocol 7). STRATEGIC PLANNING Synthesis Strategy The synthesis of any type of peptide-oligonucleotide conjugate is a chemical challenge, because two completely different chemical entities must be assembled in the same molecule. Since the beginning of this work, the aim of the authors was to develop the simplest possible methodology for the preparation of nucleopeptides. In this respect, it was clear that the use of solid-phase chemistry would be one of the keys to simplifying the overall procedure. Both peptides and oligonucleotides are usually obtained by well-established solid-phase procedures, but the two methodologies differ considerably in many aspects. First, the coupling step is obviously different. In peptide synthesis, carboxylic acids have to be activated to form amide bonds with the free amine groups immobilized on the solid support, while elongation of oligonucleotide chains requires a phosphoric ester to be formed between two hydroxyl groups. Second, the protecting groups required at every
Contributed by Anna Grandas, Vicente Marchán, Laurent Debéthune and Enrique Pedroso Current Protocols in Nucleic Acid Chemistry (2004) 4.22.1-4.22.54 Copyright © 2004 by John Wiley & Sons, Inc.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.1 Supplement 16
NH C CO
NH CH CO CHR O −
+
O P
O
CHR
base
O
O
HO
B
−
O P
O
O
O
B
O R = H : Ser R = CH3 : Thr
O
Figure 4.22.1 Base-promoted cleavage of nucleopeptides with serine- or threonine-nucleoside phosphodiester bonds.
step to mask the appropriate functionalities—and, consequently, the treatments necessary for their removal—are also quite different. Peptide chains are commonly obtained either by using groups that are labile to acids of different strength (the so-called Boc/benzyl strategy) or by using a combination of base-labile temporary α-amine-protecting groups and acid-labile permanent side-chainprotecting groups (Fmoc/tBu strategy). As most readers know, oligonucleotide synthesis combines the use of very mild acidic conditions to eliminate the temporary protecting groups (in order to prevent depurination) with that of a basic ammonia treatment to remove the permanent protecting groups (see UNIT 2.1). This scenario illustrates that the two methodologies cannot easily be made compatible, as the standard final treatment in peptide synthesis is a reaction in acidic conditions, under which an oligonucleotide chain would not survive. Another point of concern is the stability of the [hydroxylated amino acid]-nucleoside phosphodiester linkage, which can undergo a β-elimination process that degrades the target molecule (Shabarova, 1970). Figure 4.22.1 shows the β-elimination side reaction that may affect nucleopeptides (depurination is shown in Figure 2.1.8). The synthesis protocol described here is a stepwise approach (Fig. 4.22.2). It has been optimized so that the methodology is accessible to groups of nonspecialists in the field and, whenever possible, is compatible with commercially available synthons. Taking into account that peptide chains are normally elongated from the C to N terminus and oligonucleotides from the 3′ to 5′ terminus (although reverse elongation is also possible), elongation of the oligonucleotide chain at the side-chain hydroxyl of a resinlinked peptide seemed the best alternative. First, this allows greater stability, as the peptide is more robust than the oligonucleotide, particularly to acidic treatments. Second, this allows the linking amino acid to be placed at any position in the peptide chain. Stepwise assembly of the peptide moiety on a resin-linked oligonucleotide would only yield nucleopeptides with the linking amino acid at the C terminus. Moreover, difficulties in coupling amino acids onto resin-linked oligonucleotides have in some cases been reported (Bergmann and Bannwarth, 1995; Marchán et al., 2000). Stepwise Solid-Phase Synthesis of Nucleopeptides
4.22.2 Supplement 16
Current Protocols in Nucleic Acid Chemistry
A
−
+
Cl H3N CH
PS MBHA resin
CH3 1. 5% DIPEA/DCM 2. Fmoc-Phe-OH, DCC 3. Ac 2O Fmoc NH CH CO NH CH
PS
CH2 Ph IRAA
CH3 1. 20% piperidine/DMF 2. H-HMFS-OH, DCC
H-HMFS-
NH CO (CH2)2
CO NH CH CO NH CH
PS
CH2 Ph H O 1. Boc-Ala-OH, DCC, DMAP 2. Ac 2O, pyr
CH3
NH CO (CH2)2 CO NH CH CO NH CH
PS
CH2 Ph Boc
NH CH CO O CH3
CH3 Boc-Ala-HMFS-Phe-MBHA = Boc-Ala
Figure 4.22.2 (continues on next page) Stepwise solid-phase synthesis of nucleopeptide Ac-LysTrp-Lys-Hse(p3édGCATCG)-Ala-OH. (A) Preparation of the [C-terminal amino acid]-resin includes coupling of an IRAA and an HMFS linker (handle) to the resin (see Support Protocol 1), followed by coupling of the C-terminal amino acid (see Basic Protocol 1). (B) Peptide assembly (see Basic Protocol 1) followed by oligonucleotide assembly and final deprotection (see Basic Protocol 2) yield the crude target nucleopeptide. 1HOBt must be added to couple homoserine. Bases: B1 and B6, N2-isobutyrylguanin-9-yl; B2 and B5, N4-benzoylcytosin-1-yl; B3, N6-benzoyladenin-9-yl; B4, thymin1-yl. Other abbreviations: aa, amino acid; Boc, tert-butoxycarbonyl; CNE, 2-cyanoethyl; DCC, N,N′-dicyclohexylcarbodiimide; DCM, dichloromethane; DIPEA, N,N-diisopropylethylamine; DMAP, 4-(N,N-dimethylamino)pyridine; DMF, N,N-dimethylformamide; DMTr, 4,4′-dimethoxytrityl; dN, 2′deoxyribonucleoside; Fmoc, 9-fluorenylmethoxycarbonyl; For, formyl; HOBt, 1-hydroxybenzotriazole; Hse, homoserine; H-HMFS-OH, N-[9-(hydroxymethyl)-2-fluorenyl]succinamic acid; IRAA, internal reference amino acid; MBHA, p-methylbenzhydrylamine; NMI, N-methylimidazole; PS, polystyrene-co-1%-divinylbenzene; pyr, pyridine; TCA, trichloroacetic acid; Tfa, trifluoroacetyl; TFA, trifluoroacetic acid.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.3 Current Protocols in Nucleic Acid Chemistry
Supplement 16
B 1. 30% TFA/DCM 2. 5% DIPEA/DCM 4× 3. Boc-aa-OH, DCC 1 Boc Ala
Hse Ac Lys Trp
4. Ac 2O
Tfa For
Lys NH CH CO Ala CH2
Tfa
CH2 OH
H 1. 2. 3. 4.
DMTr-dN-O-P(OCNE)Ni Pr 2, tetrazole capping (Ac 2O, NMI) oxidation (1 M t -BuOOH) 3% TCA/DCM
n = 1–6
O
O
Bn
6× O O P OCH2CH2CN O Ac Lys Trp Tfa For
1:1 conc. NH 3 /dioxane overnight, 55°C
Lys Hse Ala Tfa
Ac-Lys-Trp-Lys-Hse(p 3′dGCATCG)-Ala-OH
Figure 4.22.2 continued.
Oligonucleotide assembly onto a resin-linked peptide is usually carried out with 3′-phosphoramidite nucleoside derivatives, which links the peptide to the 3′ end of the oligonucleotide. Substitution of 5′-phosphoramidites for the 3′-derivatives allows peptide-5′-oligonucleotides to be obtained.
Stepwise Solid-Phase Synthesis of Nucleopeptides
Choice of Protecting Groups The main concern in the overall process is the choice of protecting groups. They must be chosen so that the integrity of the target molecule is not affected by the final deprotection conditions. This means, as previously stated, avoiding the use of harsh acidic and basic treatments. Peptide assembly is compatible with the use of Nα-Boc-protected amino acids, and, although they are often commercially available with acid-labile side-chain-protecting groups, some derivatives with base-labile groups at the side chain are available. The only problem, then, is the peptide-oligonucleotide phosphate union, which in some cases can be particularly labile to bases. Since the data available at the outset of this work suggested that basic treatments could to some extent (though not completely) degrade nucleopeptides in which serine or threonine are the linking amino acids, it seemed possible to choose permanent protecting groups such that their removal under basic conditions would keep the side reaction to acceptable levels (<30%).
4.22.4 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Table 4.22.1
Recommended Permanent Protection Schemea,b All nucleopeptides
For base-stable nucleopeptides onlyc
Bz Ac Dmf —
Bz Bz i-Bu —
OFm — Fmoc (Fmoc)2 H, Tos (Dnp) Ac For (O)f S-tBug,h
OFm —c Tfa (Fmoc)2 Tos (Dnp) Ac For (O) —c
HMFS NH3/dioxane, room temperatureh
NPE NH3/dioxane, 55°C or (i) TBAF, (ii) NH3/dioxane, 55°C
Nucleobases A C G T Amino acids Asp, Glu Asn, Gln Lys Arg Hisd Ser, Thr, Tyre Trp Met Cys Other parameters Handle Cleavage conditions
aRefer to Figure 4.22.3 for abbreviations and structures of the amino acid protecting groups. Dash
indicates no protecting group needed. bAbbreviations for base protection: Ac, acetyl; Bz, benzoyl; Dmf, dimethylaminomethylene; i-Bu,
isobutyryl. cHomoserine or tyrosine nucleopeptides that do not contain Asn, Gln, or Cys. dHistidine is introduced protected with the tosyl (Tos) group, which is removed prior to oligonucleotide elongation. Dnp-protected histidine must be used if His is placed at the C-terminal position. Dnp removal requires overnight ammonia/dioxane treatment at room temperature. For further comments on histidine protection, see Strategic Planning. eThese residues are incorporated unprotected when they are the linking amino acid and protected as indicated when they are not. fThe crude nucleopeptide must be treated with N-methylmercaptoacetamide to reduce the sulfoxide to a thioether. gDTT must be added to the ammonia/dioxane solution to simultaneously remove the thiol protecting group. hThese very mild deprotection conditions must be used if serine or threonine are the linking residues or if the nucleopeptide contains asparagine and cysteine. In other circumstances, strongest deprotection treatments may be allowed (see Strategic Planning, discussion of final deprotection conditions).
All of the permanent protecting groups used in this procedure are shown in Table 4.22.1 and Fig. 4.22.3, and are discussed further below. They are chosen to be labile to the standard oligonucleotide-deprotecting reagent, aqueous ammonia. This is fully compatible with tyrosine nucleopeptides. Furthermore, if the nucleopeptide is not to reproduce the linking site of a naturally occurring nucleoprotein, the natural nonproteinogenic amino acid homoserine can be used as the linking residue (Fig. 4.22.2B), as first described in 1997 (Beltrán et al., 1997; Robles et al., 1997). No β-elimination can take place in this case, since the phosphate group is linked to the γ-carbon of the amino acid. Note, however, that the great tendency of homoserine to form γ-lactones precludes its use as the C-terminal amino acid. For the synthesis of serine and threonine nucleopeptides, the mildest final deprotection conditions must be used (see below).
Synthesis of Modified Oligonucleotides and Conjugates
4.22.5 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Amino acid
Side chain
Protected side chain
Structure of the protecting groups
Asp, Glu
(CH2)1-2 CO OH
(CH2)1-2 CO O Fm
Asn, Gln
(CH2)1-2 CO NH2
—
Lys
(CH2)4 NH Fmoc
Arg
Fm
(CH2)4 NH Tfa
(CH2)4 NH2
NH (CH2)3 NH
CO CF3
(CH2)3 NH NH2
NH Fmoc
N
His
CH2
N
N
CH2 NH
N
Ser
CH2 OH
CH2 O Ac
Thr
CH OH CH3
CH O Ac CH3
CH2
OH
CH2
Tos
CO
Dnp
SO2
O
Fmoc
N CH2
Tyr
Tfa
N Fmoc
NH
CH2
CH3 Tos NO2 Dnp
O2N O Ac
CO CH3
CH2
N For
Ac
O
Trp
For H
Met
CH2
CH2
Cys
CH2
SH
S CH3
O S CH3
CH2
CH2
CH2
S S t Bu
Figure 4.22.3 Structures of the unprotected and protected side chains of the trifunctional amino acids, and structures of the permanent protecting groups suitable for nucleopeptide synthesis. Abbreviations: Ac, acetyl; Dnp, 2,4-dinitrophenyl; Fm, 9-fluorenylmethyl; Fmoc, 9-fluorenylmethoxycarbonyl; For, formyl; Tfa, trifluoroacetyl; Tos, tosyl.
Solid Support Copolymers of styrene and 1% divinylbenzene are classic supports for peptide synthesis, while controlled-pore glass beads are typically used for the preparation of oligonucleotides. Polyethyleneglycol-polystyrene copolymers have been used in the synthesis of both types of molecules. In the authors’ hands, the best results have been achieved using the polystyrene-1%-divinylbenzene copolymer (Robles et al., 1999). The authors use the p-methylbenzhydrylamine resin (see Fig. 4.22.2A), but aminomethylpolystyrene should also work.
Stepwise Solid-Phase Synthesis of Nucleopeptides
Internal Reference Amino Acid Incorporation of an internal reference amino acid (IRAA; Fig. 4.22.2A) has two benefits. First, it allows one to adjust the substitution degree of the solid support to the desired level. Previous work (Montserrat et al., 1994) showed that substitution degrees of >0.20 mmol/g are not suitable for oligonucleotide synthesis, and that amine-functionalized polystyrene resins generally have higher loadings. The loading can be reduced by incompletely incorporating one amino acid and capping the unreacted amines. Use of Nα-Fmoc derivatives has the advantage that deprotection of an aliquot with piperidine and spectrophotometric quantitation of the resulting N-(9-fluorenylmethyl)piperidine easily allows the degree of substitution to be calculated.
4.22.6 Supplement 16
Current Protocols in Nucleic Acid Chemistry
The second benefit of incorporation of an IRAA is that it allows some reaction yields to be determined. On one hand, the yield of incorporation of the C-terminal amino acid can be assessed by the ratio of C-terminal amino acid to IRAA obtained after acid hydrolysis and amino acid analysis of an aliquot of resin. On the other hand, the comparison of the peptide/IRAA ratio before and after cleavage allows one to determine the cleavage yield. Obviously, the IRAA must be different from the nucleopeptide amino acids. Handle The handle permanently protects the carboxyl group of the C-terminal amino acid (Fig. 4.22.2A). It is a bifunctional molecule with one carboxyl and one hydroxyl group. The former forms a stable amide bond with the IRAA and the latter an ester with the C-terminal amino acid. Cleavage of the nucleopeptide-resin ester linkage requires basic conditions to which the nucleopeptide remains stable. The authors have tested two different handles: 2-nitrophenyl ester (NPE; Eritja et al., 1991) and fluorenylmethyl ester (HMFS; Albericio et al., 2001). The fluorenylmethyl ester is more labile than the 2-nitrophenyl ester, and is therefore the most adequate to synthesize serine and threonine nucleopeptides. Since mild cleavage conditions are required to prevent peptide-related side reactions (as well as to prevent base-promoted peptide-oligonucleotide cleavage, see below), the HMFS handle is now routinely used in the authors’ laboratory and is the recommended option. Protecting Groups for the Peptide Chain Peptide assembly is carried out using the tert-butoxycarbonyl (Boc) group to temporarily protect the α-amino function. Removal of this protecting group requires treatment with 30% to 40% trifluoroacetic acid (TFA) in dichloromethane, which is fully compatible with the base-labile ester that links the C-terminal amino acid to the resin. Protection of the trifunctional amino acid side chains is discussed for each type of residue (see Table 4.22.1 and Fig. 4.22.3). Aspartic and glutamic acids The β- and γ-carboxyl groups of these residues are protected as 9-fluorenylmethyl (Fm) esters, which have the same lability as the nucleopeptide-HMFS linkage. Boc-Asp(OFm)OH and Boc-Glu(OFm)-OH are commercially available. Side reactions associated with aspartimide formation in some peptide sequences (most notably, Asp-Gly) may take place during the final deprotection treatment (Jeyaraj et al., 2002). Asparagine and glutamine The primary carboxamides of these residues’ side chains can be left unprotected. Phosphitylation of these groups by tetrazole-activated phosphoramidites has been shown to be virtually nil (Garcia de la Torre et al., 1999; Debéthune et al., 2002a), so there is very little risk of obtaining branched nucleopeptides. Final deprotection must be carried out using the mildest conditions (see below) to prevent side reactions associated with the 55°C ammonia treatment of asparagine-containing nucleopeptides (Debéthune et al., 2002a). Lysine The ε-amino function can be protected with either the trifluoroacetyl (Tfa) or 9-fluorenylmethoxycarbonyl (Fmoc) groups (Robles et al., 1999). Tfa can only be removed by ammonia treatment at 55°C, while milder basic treatments eliminate the Fmoc groups. Both derivatives are commercially available.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.7 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Arginine The easiest way to prevent reactions at the guanidinium group is to keep it protonated. Washing with solutions of weak proton donors (e.g., 1-hydroxybenzotriazole, tetrazole) prior to amino acid or nucleoside coupling is required to ensure that the strongly basic guanidinium group is not free. Nevertheless, optimal results were achieved using the Boc-Arg(Fmoc)2-OH derivative (Debéthune et al., 2002a). Boc-Arg-OH⋅HCl can be purchased from commercial suppliers and the synthesis of Boc-Arg(Fmoc)2-OH is described in this unit (see Support Protocol 2). Histidine The imidazole ring must be protected during histidine incorporation to prevent racemization at the α-carbon. Two commercially available Boc-histidine derivatives can be used for nucleopeptide synthesis; they are imidazole-protected using either the tosyl (Tos) group or the 2,4-dinitrophenyl (Dnp) group (Beltrán et al., 1998). The tosyl group is labile to nucleopeptide deprotection conditions and can also be removed by treatment with 1-hydroxybenzotriazole (HOBt; Fujii and Sakakibara, 1974). Since the best-quality crude nucleopeptides were obtained when phosphoramidites were coupled onto histidine-unprotected peptide-resins, it is recommended that the experimenter (1) use Boc-His(Tos)OH for peptide synthesis, (2) treat with HOBt to deprotect the imidazole ring (if no HOBt has been used at any amino acid coupling step), and (3) proceed with the oligonucleotide assembly. In nucleopeptides with histidine at the C terminus, the imidazole ring should be kept protected throughout the entire synthesis process. This is best achieved using the Dnp group. Undesired detachment of the growing nucleopeptide chains from the resin, which can slowly take place if the imidazole ring is unprotected, can thus be avoided. The Dnp group is labile to fluoride treatment (see below) as well as ammonia treatment at either room temperature (overnight) or 55°C (6 hr). Serine, threonine, and tyrosine The side-chain hydroxyl of these amino acids (when they are not used as the linking residue) are protected with the acetyl (Ac) group (Fig. 4.22.3), which can be removed in the mildest final deprotection conditions. Boc-Ser(Ac)-OH and Boc-Tyr(Ac)-OH can be purchased from commercial suppliers. The preparation of Boc-Thr(Ac)-OH is described in this unit (see Support Protocol 5). Tryptophan Best results are achieved using the commercially available indole-protected derivative Boc-Trp(For)-OH, in which the indole ring is N-formylated (Robles et al., 1999). The formyl group can be removed by ammonia treatment at room temperature. Methionine The sulfide function of the methionine side chain can be alkylated during peptide elongation, and is oxidized at the nucleotide incorporation cycles. To prevent side reactions, the commercially available sulfoxide derivative Boc-Met(O)-OH is recommended (Marchán et al., 2000). After nucleopeptide synthesis and deprotection, the sulfoxide is reduced to a sulfide by reaction with N-methylmercaptoacetamide (see Support Protocol 6).
Stepwise Solid-Phase Synthesis of Nucleopeptides
4.22.8 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Cysteine Boc-Cys(S-tBu)-OH (where S-tBu is tert-butylthio), in which the thiol group has been transformed into a sterically hindered disulfide, allows cysteine-containing nucleopeptides to be obtained (Debéthune et al., 2002a). Care must be taken during the final deprotection step to avoid loss of HS-S-tBu by β-elimination. The target product is safely obtained if the final deprotection is carried out by treating the nucleopeptide-resin with ammonia at room temperature in the presence of 1,4-dithiothreitol (see Support Protocol 7). Boc-Cys(S-tBu)-OH can be easily obtained from the commercially available H-Cys(StBu)-OH derivative (see Support Protocol 3). Linking Amino Acid Serine, threonine, and tyrosine are introduced as Nα-Boc derivatives with the side-chain hydroxyl unprotected. No acylation of the free hydroxyl has been detected if the subsequent amino acids are incorporated using N,N′-dicyclohexylcarbodiimide (DCC) to activate the carboxyl group. Nα-Boc-protected homoserine derivatives are not available from commercial suppliers. The synthesis of the required compound is described here (see Support Protocol 4; Beltrán et al., 1997). This derivative, which is obtained as the triethylammonium salt Boc-Hse(DMTr)-O– HTEA+, will not couple onto the growing peptide chain unless a proton donor is added to the carbodiimide activator; therefore, this coupling is performed in the presence of HOBt. Peptide Assembly Peptide synthesis is carried out manually in polypropylene syringes fitted with polyethylene disks. An automatic synthesizer can also be used. As stated above, carbodiimides (N,N′-dicyclohexylcarbodiimide or N,N′-diisopropylcarbodiimide) are used to activate the carboxyl group of the incoming amino acid. 4-Dimethylaminopyridine must be added during the incorporation of the first (C-terminal) amino acid to achieve good esterification yields. Addition of HOBt is required to prevent side reactions during the activation and incorporation of asparagine, glutamine, and unprotected arginine, and to couple the homoserine derivative (HOBt can be replaced by tetrazole in this case). Some peptide sequences are particularly prone to form diketopiperazines (Pro-aa or aa-Pro, where aa is any amino acid, are typical examples; Gisin and Merrifield, 1972). This means that the free amine group of a dipeptide reacts with the resin-linked terminal carboxyl, releasing a cyclic dipeptide (diketopiperazine) and liberating free hydroxyl groups on the solid support. This unwanted side reaction can be minimized (Gairí et al., 1990) by reacting the third amino acid with the trifluoroacetate salt of the dipeptide-resin in the presence of a strong carboxyl activator reagent (PyAOP, 7-aza-benzotriazol-1-yloxytripyrrolidinephosphonium hexafluorophosphate) and an excess of N,N-diisopropylethylamine. Protecting Groups for the Oligonucleotide Moiety Standard DMTr and 2-cyanoethyl groups are used for temporary protection of the 5′-hydroxyl (or 3′-hydroxyl, if 5′-phosphoramidites are used) and for permanent protection of the phosphates, respectively. For the preparation of tyrosine and homoserine nucleopeptides, and if no side reaction–originating amino acids (Asn, Asp, or Cys) are present, standard nucleobase-protecting groups can be used: benzoyl (Bz) for A and C, and isobutyryl (i-Bu) for G. If base-labile nucleopeptides are to be obtained and/or the hybrid contains “delicate” amino acids, more labile nucleobase-protecting groups must be used. C is then protected with the acetyl (Ac) group, and the exocyclic amine of G is protected as formamidine with the dimethylaminomethylene group (Dmf). The structures of all of these protecting groups appear in Figures 2.1.7 and 2.1.10.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.9 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Oligonucleotide Elongation The oligonucleotide is assembled on an automatic DNA synthesizer (ABI 380B). Small modifications of the standard synthesis cycle are introduced to optimize performance with polystyrene resins (Bardella et al., 1990). The authors usually replace the standard iodine oxidation reagent with a 1 M solution of t-BuOOH, which facilitates washing of the resin after the oxidation step. Use of this reagent is absolutely mandatory when the nucleopeptide contains tyrosine or unprotected tryptophan, to prevent iodination of their aromatic side chains. Nucleopeptides with phosphorothioate internucleoside linkages have been obtained using the Beaucage reagent for the sulfurization step (Robles et al., 1999). Final Deprotection Conditions The polystyrene-divinylbenzene copolymer is hydrophobic and does not swell in aqueous medium. Consequently, treatments of nucleopeptide-resins with ammonia are not carried out using a 33% concentrated aqueous solution, but with a 1:1 (v/v) mixture of concentrated aqueous ammonia/dioxane. To cleave [base-stable nucleopeptide]-resin bonds, a two-step procedure is recommended: (1) treatment with tetrabutylammonium fluoride in anhydrous tetrahydrofuran, which detaches the nucleopeptide from the resin and removes most amino acid–protecting groups, and (2) treatment of the resulting filtrate with concentrated ammonia (or 1:1 ammonia/dioxane) to eliminate other remaining protecting groups. The authors have obtained better cleavage yields with this procedure than with an overnight treatment of the nucleopeptide-resin with ammonia at 55°C. The reaction with fluorides is a β-elimination process that yields the nucleopeptide with a C-terminal carboxylic acid function (Fig. 4.22.4A). The tyrosine-nucleoside phosphodiester bond remains unaffected by fluoride treatment.
A
O
H
NH CH C O R
base
+
O
NH CH C O − R
B
O
HO
NH CH C O R
NH3
+
O
NH CH C NH2 R
Stepwise Solid-Phase Synthesis of Nucleopeptides
Figure 4.22.4 Mechanisms of cleavage of the [C-terminal amino acid]-resin ester linkage. (A) Base-promoted β-elimination yields a C-terminal carboxylic acid function; (B) nucleophile-promoted cleavage yields a C-terminal carboxamide.
4.22.10 Supplement 16
Current Protocols in Nucleic Acid Chemistry
The nucleopeptide-HMFS linkage can also be cleaved under milder conditions by treatment with 1:1 ammonia/dioxane at room temperature. Although cleavage yields are lower than if the reaction is carried out at 55°C, this is the only alternative if the target nucleopeptide has serine or threonine as the linking residue, or if it contains amino acids (or peptide sequences) which are prone to give side reactions under these conditions (see above). An additional point of concern when the nucleopeptide-resin is treated directly with ammonia is that cleavage can take place either by β-elimination (Fig. 4.22.4A), which affords the nucleopeptide acid, or by nucleophilic attack of ammonia at the ester bond between the C-terminal amino acid and the HMFS handle (Fig. 4.22.4B). Nucleopeptides are then obtained as C-terminal carboxamides. Acid/carboxamide mixtures (in which the acid is the main component) are always obtained when glycine is the C-terminal amino acid (Debéthune et al., 2002a). The amount of amide is virtually nil when other residues occupy the C-terminal position. Summary As a general rule, the authors recommend assembling the nucleopeptide using a set of permanent protecting groups that can be removed using the mildest deprotection conditions, but little or no care has to be taken if tyrosine or homoserine is the linking amino acid and the nucleopeptide does not include “delicate” amino acids. However, even under the mildest possible final deprotection conditions, degradation of serine nucleopeptides by base-mediated cleavage of the serine-nucleoside phosphodiester bond can take place in some cases (Debéthune et al., 2002a). The data available indicate that this is a sequence-dependent reaction whose extent cannot as yet be predicted. From an operational point of view, the preparation of a nucleopeptide requires an adequately functionalized solid support and suitably protected amino acid and nucleoside derivatives. Access to an HPLC, a UV spectrophotometer, an electrospray or MALDITOF mass spectrometer, and an amino acid analyzer is required. Denaturing polyacrylamide gel electrophoresis (PAGE) facilities may also be necessary. STEPWISE MANUAL SOLID-PHASE SYNTHESIS OF THE PEPTIDE In this protocol, the C-terminal amino acid is first coupled to a solid support that has already been coupled with the internal reference amino acid (IRAA) and the HMFS linker (see Support Protocol 1 and Fig. 4.22.2A). Incorporation of the terminal amino acid is compared to the IRAA by amino acid analysis. After acylation of unreacted HMFS hydroxyl groups, the subsequent amino acids are added until the final support-bound peptide has been synthesized (Fig. 4.22.2B).
BASIC PROTOCOL 1
During synthesis, each coupling is monitored by a ninhydrin or chloranil test. The ninhydrin test (Kaiser et al., 1970) is only reliable for primary amines. For a qualitative coupling assay in the case of proline, the chloranil test (Christensen, 1979) should be used to assay for secondary amines. In general, the support-bound peptide (step 28) can be used directly for elongation of the oligonucleotide chain (see Basic Protocol 2). In some cases, especially with long peptides, analysis of the deprotected crude peptide by HPLC and mass spectrometry techniques (steps 29 to 41) is recommended to ensure peptide homogeneity before oligonucleotide elongation.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.11 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Materials Derivatized p-methylbenzhydrylamine solid support (H-HMFS-IRAA-MBHA-PS; see Support Protocol 1) Dichloromethane (DCM; peptide synthesis grade) N,N-Dimethylformamide (DMF; peptide synthesis grade) t-Butoxycarbonyl-protected amino acids (Boc-aa-OH): Ala, Arg⋅HCl, Asn, Asp(OFm), Gln, Glu(OFm), Gly, His(Dnp), His(Tos), Ile, Leu, Lys(Fmoc), Lys(Tfa), Met(O), Phe, Pro, Ser, Ser(Ac), Thr, Trp(For), Tyr, Tyr(Ac), and Val (Novabiochem, Bachem, Neosystem) Boc-Arg(Fmoc)2-OH (see Support Protocol 2) Boc-Cys(S-tBu)-OH (see Support Protocol 3) Boc-Hse(DMTr)-O–HNEt3+ (see Support Protocol 4) Boc-Thr(Ac)-OH (see Support Protocol 5) N,N′-Dicyclohexylcarbodiimide (DCC) or N,N′-diisopropylcarbodiimide (DiPC) 4-Dimethylaminopyridine (DMAP) Methanol (MeOH; HPLC grade) Concentrated HCl, analytical grade Propionic acid Phenol, crystalline 3 M aqueous p-toluenesulfonic acid containing 0.2% tryptamine 0.06 M citrate buffer, pH 2 Acetic anhydride Benzoyl chloride (optional) Pyridine, synthesis grade 30% (v/v) trifluoroacetic acid (TFA; peptide synthesis grade) in DCM 5% (v/v) N,N-diisopropylethylamine (DIPEA) in DCM 1-Hydroxybentotriazole (HOBt; for coupling unprotected Arg, Asn, Gln, Hse) 0.5 M HOBt in DCM (for coupling unprotected Arg) (Azabenzotriazole-1-yl-oxy-tris-pyrrolidino)phosphonium hexafluorophosphate (PyAOP; for coupling any aa onto Pro) N,N-Diisopropylethylamine (DIPEA) Ethyl acetate (EtOAc) 1 M sulfuric acid Sodium sulfate (Na2SO4), anhydrous Ninhydrin reagents A and B (see recipes) Saturated chloranil solution: ∼0.75 g of 2,3,5,6-tetrachloro-1,4-benzoquinone in 25 mL toluene Acetone Peroxide-free dioxane (see recipe) 1 M 1,4-dithiothreitol (DTT) in peroxide-free dioxane (for S-tBu-protected Cys) 32% (v/v) ammonium hydroxide (store at 4°C) HPLC mobile phase A: 0.045% TFA in water (HPLC grade) HPLC mobile phase B: 0.036% TFA in acetonitrile (HPLC grade) α-Cyano-4-hydroxycinnamic acid (CHA) or dihydroxybenzoic acid (DHB) matrix 0.1% TFA in 1:1 (v/v) acetonitrile/water (HPLC grade)
Stepwise Solid-Phase Synthesis of Nucleopeptides
2- to 10-mL disposable polypropylene syringes with porous polyethylene discs and Teflon two-way stop cocks (RTV SF2, Shimadzu Scientific Research) Vacuum filtration system Teflon stir rod Desiccator Pyrex tubes for amino acid analyses Methane/oxygen flame
4.22.12 Supplement 16
Current Protocols in Nucleic Acid Chemistry
110° and 155°C heating block Rotary evaporator equipped with a water aspirator or vacuum pump (use aspirator unless pump is indicated) 0.45-µm nylon filters Automatic amino acid analyzer (Beckman System 6300) 25-mL separatory funnel Filter paper 25- and 50-mL round-bottom flasks Small glass tubes for ninhydrin or chloranil tests 4-mL screw-cap pressure tubes, O-ring seal preferred Additional reagents for HPLC and MALDI-TOF-MS (see Basic Protocol 3 and Chapter 10) CAUTION: Trifluoroacetic acid is a very corrosive acid. Breathing the vapors is very harmful and it is possible to be quickly overcome by them. Always manipulate with extreme caution in a well-ventilated fume hood and wear appropriate protective clothing. Prepare syringe with solid support for peptide synthesis 1. Transfer an accurately weighed amount of H-HMFS-IRAA-MBHA-PS solid support for a 50-µmol synthesis into a 5- to 10-mL polypropylene syringe fitted with a porous polyethylene disc and equipped with a Teflon two-way stop cock. 2. Place the syringe on a vacuum filtration system. Incorporate C-terminal amino acid onto support 3. Wash the solid support using three 30-sec washes each of DCM, DMF, and then DCM again. For washes and for deprotection and neutralization treatments, a solvent volume of one or two times the volume of resin is recommended. For coupling, it is important to keep the reaction mixture as concentrated as possible. Coupling reactions must therefore be carried out in the minimum amount of solvent required to swell the resin and allow stirring. It is important to handle the polystyrene resin carefully to avoid mechanical degradation of the solid matrix. In all steps that require mixing, the resin should be stirred very carefully with a Teflon stir rod.
4. Weigh out the required amount of Boc-aa-OH (10 eq), DCC (10 eq), and DMAP (0.5 eq), and dissolve the mixture in a minimal volume of 1:1 (v/v) DCM/DMF. DiPC can replace DCC in all reactions described in this protocol and in the Support Protocols. The urea derivative formed after activation of the carboxyl group is more soluble in organic solvents. The esterification conditions employed for the incorporation of the C-terminal amino acid may cause some racemization, especially with amino acids such as unprotected histidine. In order to avoid this side reaction, glycine has been selected in most cases as the C-terminal amino acid. However, some problems may arise during the ammonium hydroxide deprotection (see Strategic Planning for more details).
5. Add the reaction mixture to the solid support and let stand 1.5 hr, occasionally stirring with a Teflon stir rod. 6. Wash the solid support successively with three 30-sec washes of DMF and three 30-sec washes of DCM. 7. Repeat steps 4 to 6 using 5 eq Boc-aa-OH, 5 eq DCC, and 0.25 eq DMAP and a reaction time of 1 hr. 8. Wash the solid support three times for 30 sec with MeOH and dry in a desiccator.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.13 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Determine C-terminal amino acid incorporation: General procedure for amino acid analysis 9. Withdraw a 5- to 10-mg aliquot of dry resin and place it in a Pyrex tube. 10. Add 300 µl of 1:1 (v/v) concentrated HCl/propionic acid to the resin. When tyrosine is present, add a phenol crystal to the mixture to prevent decomposition of this amino acid during acid hydrolysis. Some amino acids, such as cysteine, homoserine, serine, threonine, and tryptophan, are partially or completely destroyed during acid hydrolysis. Arginine is partially converted to ornithine, and asparagine and glutamine to aspartic and glutamic acids, respectively. When the determination of some of these particular residues is necessary, enzymatic digestion must be carried out (see Basic Protocol 3, step 51). When determining tryptophan incorporation, hydrolysis must be carried out with a 3 M p-toluenesulfonic acid solution containing 0.2% of 3-(2-aminoethyl)indole (tryptamine), for 12 hr at 110°C in a vacuumsealed Pyrex tube.
11. Close the Pyrex tube hermetically using a methane/oxygen flame and heat 1.5 hr in a 155°C heating block. 12. Cool to room temperature, open the Pyrex tube, and evaporate the acidic mixture to dryness in a rotary evaporator equipped with a vacuum pump. CAUTION: Always wear gloves and glasses and work in a well-ventilated fume hood when carrying out these operations. Be careful when closing and opening the tube.
13. Redissolve the dry residue in 500 µL of 0.06 M citrate buffer, pH 2, and filter the resulting solution through a 0.45-µm nylon filter. Inject in an automatic amino acid analyzer. The amount of sample necessary for carrying out the amino acid analysis depends on the analyzer. For some analyzers, 5 nmol amino acid is optimal. In that case, injection of 50 ìL of the resulting solution will give 2 to 10 nmol of each residue. Prior to analyzing the sample, a standard that contains all 20 natural amino acids is analyzed to calculate a response factor for each residue under the analysis conditions employed. The response factors are used to calculate the amount of each residue in the sample.
14. Compare incorporation of the C-terminal amino acid to incorporation of the IRAA. If (C-terminal amino acid/IRAA) < 0.9, repeat steps 7 to 13. If 0.9 ≤ (C-terminal amino acid/IRAA) ≤ 1, proceed with step 15. In general, a nearly quantitative incorporation is achieved.
Acylate unreacted hydroxyl groups of HMFS linker 15. Add the required amount of acetic anhydride or benzoyl chloride (10 eq), pyridine (10 eq), and DCM to the solid support and let stand 10 min with occasional stirring using a Teflon rod. As for the coupling steps, a minimum volume of DCM is used for this step. The volume should be sufficient to swell the resin and allow stirring with the Teflon rod.
16. Wash the resin three times for 30 sec with DCM and repeat steps 15 and 16 to ensure that all unreacted hydroxyl groups are capped. 17. Wash the resin successively with three 30-sec washes each of DMF, DCM, and MeOH. Dry directly on a vacuum filtration system.
Stepwise Solid-Phase Synthesis of Nucleopeptides
4.22.14 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Incorporate subsequent amino acids 18. Add the required volume of 30% (v/v) TFA in DCM (one or two times the resin volume) and let stand 5 min with occasional stirring using a Teflon rod. 19. Wash with DCM, add an equal volume of 30% TFA in DCM, and let stand 25 min with occasional stirring. 20. Wash thoroughly with DCM, then wash four times for 60 sec with 5% (v/v) DIPEA in DCM, and five times for 30 sec with DCM. 21. Weigh out the required amount of Boc-aa-OH (3 eq) and DCC (3 eq), and dissolve the mixture in the minimum quantity of 1:1 (v/v) DCM/DMF. Add to the solid support and let stand 1.5 hr with occasional stirring using a Teflon rod. Modify as necessary for the following amino acid–specific conditions. When coupling arginine with the side chain protonated, weigh out the required amount of Boc-Arg-OH⋅HCl⋅2H2O (3 eq), DCC (3 eq), and HOBt (6 eq), and dissolve the mixture in the minimum amount of 1:1 (v/v) DCM/DMF. To avoid undesired side reactions, wash the resin four times for 60 sec with 0.5 M HOBt in DCM between steps 20 and 21. For asparagine or glutamine, weigh out the required amount of Boc-Asn-OH or Boc-GlnOH (3 eq), DCC (3 eq), and HOBt (3 eq), dissolve in the minimum quantity of 1:1 (v/v) DCM/DMF, and let stand 10 min at 0°C before adding it to the resin. When coupling the second amino acid onto Pro-resin, skip the neutralization step with 5% (v/v) DIPEA in DCM (step 20), weigh out the required amount of Boc-aa-OH (5 eq) and PyAOP (5 eq), dissolve the mixture in the minimum quantity of 1:1 (v/v) DCM/DMF, and add it to the resin. Then add 10 eq DIPEA to the resin and let stand for 1.5 hr, stirring occasionally with a Teflon rod. An acidic additive is necessary for the incorporation of the triethylammonium salt of the homoserine derivative. Weigh out the required amount of Boc-Hse(DMTr)-O–HNEt3+ (3 eq), DCC (3 eq), and HOBt (3 eq), and dissolve the mixture in the minimum quantity of 1:1 (v/v) DCM/DMF. After incorporation onto the support, elimination of the tert-butoxycarbonyl group with trifluoroacetic acid removes the DMTr group, so it is possible to quantify the coupling yield by quantitating the released DMTr cation (see Basic Protocol 2, step 11). When using Boc-Thr(Ac)-O–DCHA+, a workup is necessary to isolate the protected amino acid in the neutral species. Suspend Boc-Thr(Ac)-O–DCHA+ in EtOAc (∼5 mL/mmol amino acid) and transfer to a 25-mL separatory funnel. Add the same volume of 1 M sulfuric acid. Shake to achieve complete dissolution of the amino acid derivative. Separate the organic layer, and extract the aqueous phase with more EtOAc (twice with 5 mL). Dry the organic layer over anhydrous Na2SO4. Add more Na2SO4 if the salt crystals clump together upon swirling. Gravity filter the resulting solution through filter paper into a 50-mL round-bottom flask. Rinse the Na2SO4 crystals with 5 to 10 mL EtOAc. Remove the solvent under reduced pressure (i.e., in a rotary evaporator) to yield a white solid. Perform several co-evaporations with DCM to eliminate traces of EtOAc.
22. Wash the resin successively with three 30-sec washes of DMF, DCM, and MeOH. Dry directly on a vacuum filtration system. Assess amino acid coupling 23. Withdraw a 0.5- to 1-mg aliquot of dry resin and place it in a small glass tube. 24a. For primary amines: Add 3 drops of ninhydrin reagent A and 1 drop of ninhydrin reagent B. Heat the tube 3 min in a 110°C heating block. Allow to cool to room temperature. Assess color and proceed to step 25. It is important to have good quality ninhydrin reagents in order to obtain a reliable result. See Reagents and Solutions for more specific details. This test was developed for the primary amines of amino acids and may not be reliable for other primary amines.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.15 Current Protocols in Nucleic Acid Chemistry
Supplement 16
24b. For proline: Add 5 drops saturated chloranil solution and 20 drops acetone. Stir 5 min at room temperature. Assess color and proceed to step 25. 25a. For negative tests: If the reaction mixture is yellow (indicative of a successful amino acid coupling), proceed with the incorporation of the next amino acid (step 26). 25b. For positive tests: If the reaction mixture is blue for ninhydrin or green-blue for chloranil (indicative of the presence of free primary or secondary amines, respectively), repeat the coupling of the amino acid using the same amounts and conditions (steps 18 to 22) and then repeat the ninhydrin or chloranil test. 25c. For repeated positive tests: If a blue or green-blue color persists after a second coupling of the amino acid, cap the unreacted amines by adding acetic anhydride (10 eq), DIPEA (10 eq), and DMF to the solid support. Let stand 10 min, stirring occasionally with a Teflon rod. Wash the resin sequentially using three 30-sec washes each of DMF followed by DCM. Repeat the ninhydrin or chloranil test to confirm that all unreacted amines are capped before proceeding with the incorporation of the next amino acid (step 26). 26. Perform incorporation of the second and subsequent amino acids (steps 18 to 22), confirming the success of each coupling (steps 23 to 25) before proceeding to the next. Some minor modifications have to be introduced depending on the desired functional group at the N-terminal position of the peptide. If the amino group has to be acylated, remove the tert-butoxycarbonyl group and acylate by treating with acetic anhydride (3 eq) in DMF for 15 to 25 min. A longer treatment could cause undesired acetylation of the free side chain of the hydroxylated amino acid. When a free N-terminal position is desired, incorporate the last residue as an Fmoc-protected amino acid instead of a Boc derivative. The fluorenylmethoxycarbonyl group will be removed during the final ammonium hydroxide treatment. In some cases the tert-butoxycarbonyl group can be used to block the N-terminal position of the peptide. If that is the case, no further modification is necessary to the standard procedure because the Boc group is stable to the final ammonium hydroxide treatment.
27. Once the final (N-terminal) amino acid has been successfully coupled, proceed with the amino acid analysis as described in steps 9 to 13. When an Fmoc-amino acid derivative is introduced at the N-terminal position of the peptide, it is recommended to eliminate the Fmoc group before carrying out acid hydrolysis. This is because the Fmoc group may not be completely removed during the acid hydrolysis treatment, especially when it protects some sterically hindered residues such as isoleucine. For removal of the Fmoc group, treat the resin aliquot with 20% (v/v) piperidine in DMF as described below (see Support Protocol 1).
28. Calculate the relative ratio of the amino acids according to their peak areas and response factors (see step 13). If the peptide was correctly elongated, the ratio of residues will be close to the theoretical value.
Perform cleavage and deprotection (optional) 29. Take a 5- to 10-mg aliquot of dry peptide-resin and place it in a 4-mL screw-cap pressure tube, preferably with an O-ring seal. 30. Add 1 mL peroxide-free dioxane and 1 mL of 32% ammonium hydroxide solution, screw the cap on tightly, and leave 6 hr at room temperature. Stepwise Solid-Phase Synthesis of Nucleopeptides
If the peptide sequence contains trifluoroacetyl-protected lysine, perform the deprotection at 55°C for 12 to 15 hr. If it contains tert-butylthio-protected cysteine, use 1 mL of 1 M 1,4-dithiothreitol in dioxane and 1 mL of 32% ammonium hydroxide.
4.22.16 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Table 4.22.2 Typical Gradient and Mobile Phase for RP-HPLC of Deprotected Crude Peptidea
Elapsed time (min)
Percent mobile phase Bb
0 30 31 35 36 45
10 50 100 100 10 10
aGradient conditions are based on a flow of 1 mL/min using a Kromasil reversed-phase
C18 column (5-µm-diameter spherical silica, 4.0 × 250 mm) at room temperature with a 45-min overall cycle. Mobile phase A: 0.045% trifluoroacetic acid (TFA) in water; mobile phase B: 0.036% TFA in acetonitrile. bPercentage is at elapsed time.
31. Filter through a 2-mL polypropylene disposable syringe with a polyethylene or cotton filter and collect the solution in a 25-mL round-bottom flask. 32. Wash the pressure tube several times with MeOH and pass through the syringe. With tert-butylthio-protected cysteine-containing peptides, removal of 1,4-dithiothreitol is required prior to HPLC analysis. Dilute the crude sample to 2 mL by adding water and wash three times with 2 mL EtOAc. Proceed with the aqueous phase.
33. Concentrate the combined solution under reduced pressure to a volume of ∼0.5 mL. Dilute the deprotected crude peptide with 0.5 mL HPLC mobile phase B and take an aliquot (10 to 50 µL) for HPLC analysis. Analyze crude peptide by HPLC (optional) 34. Program the gradient system to start with 10% mobile phase B, increasing the percentage of mobile phase B with time (Table 4.22.2). Ensure that there is sufficient mobile phase to keep intakes covered throughout the run. For more specific details about HPLC analysis, see Basic Protocol 3 and UNIT 10.5.
35. Set the UV detector wavelength at 220 nm. Equilibrate the HPLC system with the starting mobile phase composition (10% mobile phase B) until a flat baseline is achieved at this detection wavelength. 36. Inject the sample by programming the autosampler or by loading it into the sample loop using the appropriate syringe. Elute the sample by starting the gradient. Record the chromatogram. Typically, small peptides will elute at ∼10 to 15 min under the recommended conditions (Table 4.22.2). When long peptides are prepared, it is recommended to use a gradient from 10% to 70% or 80% mobile phase B over 30 min and then wash as usual. Ammonium hydroxide treatment gives a mixture of the C-terminal carboxylic acid and carboxamide peptides, which usually elute in this order. Some UV-absorbing compounds are eluted at high acetonitrile percentages. These peaks are associated with handle-derived products formed during ammonium hydroxide treatment.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.17 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Analyze crude peptide by MALDI-TOF-MS (optional) 37. Weigh 10 mg matrix (CHA or DHB) and place in a 1.5-mL microcentrifuge tube. A CHA matrix is recommended for small peptides (mol. wt. <500) and DHB for a wide range of masses.
38. Add 1 mL of 0.1% TFA in 1:1 (v/v) acetonitrile/water to the matrix. Vortex 30 sec to allow complete dissolution. Optimal results are obtained when the highest-purity matrices are used. Matrix solutions should be made fresh prior to use. Storage for more than 3 days is not recommended.
39. To a 0.5-mL microcentrifuge tube, add 1 µL peptide sample solution and 1 µL matrix solution. Mix by withdrawing and expelling the solution ten times with the pipet. 40. Spot 1 µL solution on a MALDI-TOF sample plate and dry. To allow homogeneous crystallization, do not disturb the spotted samples after they start to crystallize. 41. Perform peptide MALDI-TOF-MS analysis in positive mode. SUPPORT PROTOCOL 1
PREPARATION OF THE SOLID SUPPORT (H-HMFS-IRAA-MBHA-PS) This protocol describes the coupling of the internal reference amino acid and handle to the solid support used for nucleopeptide synthesis (see Fig. 4.22.2A). Additional Materials (also see Basic Protocol 1) p-Methylbenzhydrylamine resin: (α-amino-α-xylyl)-polystyrene reticulated with 1% divinylbenzene (f = 0.5 to 0.6 mmol/g; Novabiochem) 9-Fluorenylmethoxycarbonyl-protected internal reference amino acid (Fmoc-aa; Novabiochem, Bachem, Neosystem) 20% (v/v) piperidine in DMF N-[9-(Hydroxymethyl)-2-fluorenyl]succinamic acid (H-HMFS-OH; Alberico et al., 2001) 2- and 10-mL polypropylene syringes fitted with polyethylene discs Teflon two-way stopcocks 50-mL volumetric flasks Double-beam UV spectrophotometer, calibrated, and quartz cuvettes Wash solid support 1. Transfer an accurately weighed amount of p-methylbenzhydrylamine resin into a polypropylene syringe fitted with a polyethylene disc (i.e., 250 mg of resin into a 10-mL syringe). 2. Place the syringe on a vacuum filtration system. 3. Wash the solid support with three 30-sec washes of DCM. For general guidelines on volumes and handling resin, see Basic Protocol 1, step 3.
4. Add the required volume of 30% (v/v) trifluoroacetic acid in DCM and let stand 5 min, occasionally stirring with a Teflon rod. 5. Wash with DCM, add an equal volume of 30% (v/v) trifluoroacetic acid in DCM, and let stand 25 min. 6. Wash sequentially as follows:
Stepwise Solid-Phase Synthesis of Nucleopeptides
Three times for 30 sec with DCM Four times for 60 sec with 5% (v/v) DIPEA in DCM Five times for 30 sec with DCM.
4.22.18 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Incorporate internal reference amino acid 7. Weigh out the required amount of Fmoc-aa (0.5 eq) and DCC (0.5 eq), and dissolve the mixture in the minimum quantity of 1:1 (v/v) DCM/DMF. The internal reference amino acid must not be present in the target nucleopeptide sequence.
8. Add the reaction mixture to the solid support and let stand 25 min, stirring occasionally with a Teflon rod. Coupling time and amount of reactants are optimized to obtain a desired loading of ≤0.25 mmol/g. An increased coupling time will yield higher substitution degrees that are not adequate for oligonucleotide elongation.
9. Wash the solid support sequentially using three 30-sec washes each of DMF followed by DCM. Determine loading 10. Withdraw a 10-mg aliquot of dry resin and place it in a 2-mL polypropylene syringe fitted with a polyethylene disc and stopcock. 11. Add 1 mL of 20% (v/v) piperidine in DMF and let stand 3 min, occasionally stirring with a Teflon rod. 12. Open the stopcock and collect the filtrate in a 50-mL volumetric flask. Wash three times with 2 mL DCM and collect in the same flask. 13. Repeat the piperidine treatment for 7 min and wash again three times with DCM. Collect these filtrates together with the previous ones, and dilute with DCM to the 50-mL mark. Piperidine treatments quantitatively remove the fluorenylmethoxycarbonyl protecting group. An N-(9-fluorenylmethyl)piperidine (Fmp) adduct is formed during this treatment. Its molar extinction coefficient at 300 nm (ε300) is 7800. Its quantitation allows the loading of the solid support to be determined.
14. Prepare a reference solution by adding 2 mL of 20% (v/v) piperidine in DMF to a 50-mL volumetric flask and diluting to the mark with DCM. 15. Measure the sample absorbance at 300 nm (A300) on a calibrated, double-beam UV spectrophotometer using the above solution as a reference. If A300 >1, dilute sample as necessary to achieve a value <1. If using a single-beam spectrophotometer, a baseline should be run with a sample containing the reference solution (blank).
16. Calculate the solid support loading (f) as: f (mmol/g) =
A ×V ×1000 ε× l × m
Equation 4.22.1
where V is the total volume of the solution (in mL), ε is the molar extinction coefficient of the Fmp adduct at 300 nm (7800 L/mol/cm), l the absorbance path of the cuvette (in cm), and m is the amount of solid support (in mg). 17. If f ≈ 0.15 to 0.25 mmol/g, proceed according to step 18 with the entire support batch. If it is lower, repeat steps 7 to 9 with shorter coupling times.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.19 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Acylate unreacted amine groups and remove Fmoc 18. Add the required amount of acetic anhydride (10 eq), DIPEA (10 eq), and DMF to the solid support and let stand 10 min, stirring occasionally with a Teflon rod. 19. Wash the resin three times for 30 sec each with DCM and then repeat step 18. Perform the ninhydrin test with 0.5 to 1 mg of resin (see Basic Protocol 1, step 24a) to be sure that all unreacted amino groups are capped (solution should be yellow). 20. Wash the resin three times for 30 sec each with DMF, then DCM, and then MeOH. Dry directly on the vacuum filtration system. 21. Add the required volume of 20% (v/v) piperidine in DMF and leave 3 min, stirring occasionally with a Teflon rod. 22. Wash five times for 30 sec each with DCM and once again add the required volume of 20% (v/v) piperidine in DMF. Let stand 10 min, stirring occasionally with a Teflon rod. 23. Wash thoroughly three times for 30 sec each with DMF and then DCM. Dry directly on the vacuum filtration system. Incorporate handle 24. Weigh out the required amount of H-HMFS-OH (3 eq) and DCC (3 eq) and dissolve the mixture in the minimum quantity of 1:1 (v/v) DCM/DMF. The synthesis of N-[9-(hydroxymethyl)-2-fluorenyl]succinamic acid is carefully described elsewhere (see Albericio et al., 2001).
25. Add the reaction mixture to the solid support and let stand for 4 to 5 hr, stirring occasionally with a Teflon rod. 26. Wash the solid support successively (three times for 30 sec each) with DMF, then DCM, and finally MeOH. Dry directly on the vacuum filtration system. 27. Withdraw a 0.5- to 1-mg aliquot of dry resin and carry out the ninhydrin test (see Basic Protocol, step 24a). If the coupling is not complete (i.e., solution is blue, not yellow), repeat the handle incorporation using 1.5 eq for 1 to 2 hr. SUPPORT PROTOCOL 2
Stepwise Solid-Phase Synthesis of Nucleopeptides
PREPARATION OF Boc-Arg(Fmoc)2-OH Fmoc protection of Boc-Arg-OH is shown in Figure 4.22.5. Materials N-(tert-Butoxycarbonyl)-L-arginine hydrochloride (Novabiochem) Acetonitrile, anhydrous (see recipe) 9-Fluorenylmethyl chloroformate (Fmoc⋅Cl) Argon (Ar), dry Dichloromethane (DCM, anhydrous; see recipe) in a septum-sealed distillation collection bulb N,N-Diisopropylethylamine (DIPEA), anhydrous (see recipe) Chlorotrimethylsilane Dichloromethane (DCM; synthesis grade) Sodium sulfate (Na2SO4), anhydrous Methanol (MeOH) Acetic acid (AcOH) Hexanes 230- to 400-mesh silica gel
4.22.20 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Boc NH CH COOH (CH2)3 NH H 2N
1. TMS⋅Cl, DIPEA 2. Fmoc-Cl
Boc NH CH COOH (CH2)3 NH
DCM +
NH2− Cl
Fmoc NH
N Fmoc
Figure 4.22.5 Protection of the guanidinium group of Boc-arginine. Abbreviations: Boc, tert-butoxycarbonyl; DCM, dichloromethane; DIPEA, N,N-diisopropylethylamine; Fmoc, 9-fluorenylmethoxycarbonyl; TMS, trimethylsilyl.
250-mL oven-dried round-bottom flask and rubber septum Desiccator containing P2O5 Glass syringe and needle, oven dried 40°C heat block 250-mL separatory funnel Gravity and vacuum filtration devices and filter paper 500-mL round-bottom flasks 2 × 5–cm silica-coated thin-layer chromatography (TLC) plates 254-nm UV light source Rotary evaporator with a water aspirator 5 × 25–cm glass chromatography column with solvent reservoir bulb Additional reagents and equipment for TLC (APPENDIX 3D), column chromatography (APPENDIX 3E), NMR, IR, and mass spectrometry Fmoc-protect Boc-Arg-OH 1. Place 1.0 g (3.04 mmol) of N-(tert-butoxycarbonyl)-L-arginine hydrochloride in a 250-mL oven-dried round-bottom flask. 2. Co-evaporate three times with anhydrous acetonitrile. 3. Weigh 2.4 g (9.28 mmol) of Fmoc⋅Cl and dry overnight under vacuum in a desiccator containing P2O5. 4. Cap the flask with a rubber septum and purge the flask with dry Ar. 5. Withdraw anhydrous DCM from a septum-sealed distillation collection bulb using an oven-dried glass syringe and needle. Add 25 mL DCM to the purged flask with magnetic stirring. 6. Add 1.6 mL (9.4 mmol) anhydrous DIPEA and slowly add 1.5 mL (11.9 mmol) chlorotrimethylsilane. 7. Stir the reaction mixture 90 min at 40°C. The original suspension slowly becomes a solution.
8. Cool in an ice bath. Dissolve 2.4 g (9.28 mmol) Fmoc⋅Cl in a minimal amount of dry DCM. Add 1.6 mL DIPEA and the Fmoc⋅Cl to the cooled reaction. 9. Stir the mixture 20 min in the ice bath and then 6.5 hr at room temperature. Synthesis of Modified Oligonucleotides and Conjugates
4.22.21 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Work up reaction 10. Transfer the reaction mixture into a 250-mL separatory funnel and wash with 50 mL water. Wash the aqueous layer three times each with 50 mL DCM. 11. Dry the combined organic layer over anhydrous Na2SO4. Add more Na2SO4 if the salt crystals clump together upon swirling. When the solution is dry, the nonhydrated crystals will float in solution upon swirling.
12. Gravity filter the resulting solution through filter paper into a 500-mL round-bottom flask. Rinse the Na2SO4 crystals with 10 to 20 mL DCM. 13. Remove the solvent under reduced pressure (i.e., in a rotary evaporator with water aspirator) to yield an orange oil. Monitor reaction by TLC 14. Dissolve an aliquot of oil in a minimal amount of DCM, spot the solution onto a precut 2 × 5–cm TLC plate, and develop using 93:5:2 (v/v/v) DCM/MeOH/acetic acid (APPENDIX 3D). CAUTION: Wear protective eyewear.
15. Visualize the spots under a 254-nm UV light source. TLC analysis should indicate a main product with Rf = 0.54 that corresponds to the desired amino acid derivative. Minor amounts of fast-moving products are usually present in the mixture.
Isolate and characterize product 16. Dissolve the orange oil in 1.5 to 2 mL DCM and pour the solution onto 30 mL hexanes. A yellowish precipitate is obtained. This procedure partially eliminates the less polar contaminants.
17. Filter the precipitate under vacuum. 18. Prepare a 5 × 25–cm glass chromatography column with solvent reservoir bulb by adding a slurry of 50 g of 230- to 400-mesh silica gel in 1:1 (v/v) hexanes/DCM. Precondition with the same solvent. 19. Dissolve the crude material in a minimum amount of 1:1 hexanes/DCM and load onto the column. Perform chromatography using a small amount of air pressure (APPENDIX 3E) and eluting with solvent mixtures of increasing polarity: 1:1 (v/v) hexanes/DCM 25:75 (v/v) hexanes/DCM DCM 99:1, 98:2, 97:3, 96:4, and 95:5 (v/v) DCM/MeOH. 20. Combine the product-containing fractions into a 500-mL round-bottom flask and concentrate to a white solid (60% yield) on a rotary evaporator. 21. Determine the melting temperature. Characterize by TLC, 1H and 13C NMR, IR, and mass spectrometry. Boc-Arg(Fmoc)2-OH: Rf 0.54 (93:5:2 DCM/MeOH/AcOH); m.p. 106°-109°C; 1H NMR (300 MHz, CDCl3): δ 7.81-7.26 (m, 16H), 5.14 (m, 1H), 4.75 (m, 2H), 4.30 (m, 5H), 3.52 (m, 2H), 1.43 (s, 9H), 1.26 (m, 4H) ppm; 13C NMR (75 MHz, CDCl3): δ 161, 159, 157, 128, 120, 78, 68, 47, 44, 29, 28, 25 ppm; IR (film): 3800, 1720, 1620, 1515, 1460, 1260, 1110 cm–1; FAB-MS (positive mode, magic bullet, 3:1 dithiothreitol/dithioerythritol): m/z 719.4 [(Boc-Arg(Fmoc)2-OH)+H]+, calcd. mass for C41H42N4O8: 718.8. Stepwise Solid-Phase Synthesis of Nucleopeptides
4.22.22 Supplement 16
Current Protocols in Nucleic Acid Chemistry
H2N CH COOH CH2
t Bu S
S
(Boc)2O, NaOH
Boc NH CH COOH
dioxane, H 2O
CH2
t Bu S
S
Figure 4.22.6 Protection of the α-amine of H-Cys(S-tBu)-OH. Boc, tert-butoxycarbonyl.
PREPARATION OF Boc-Cys(S-tBu)-OH Boc-protection of cysteine is shown in Figure 4.22.6.
SUPPORT PROTOCOL 3
Materials S-(tert-Butylthio)-L-cysteine (H-Cys(S-tBu)-OH; Novabiochem) 2:1 (v/v) dioxane/water 1 M NaOH Di-tert-butyldicarbonate (Boc2O) Hexanes 1 M HCl Ethyl acetate (EtOAc) Sodium sulfate (Na2SO4), anhydrous 50-mL and 250-mL round-bottom flasks 100-mL separatory funnel Gravity filtration device and filter paper Rotary evaporator equipped with water aspirator Additional reagents and equipment for TLC (APPENDIX 3D), 1H NMR, and mass spectrometry Introduce Boc protecting group 1. Place 0.5 g (2.4 mmol) S-(tert-butylthio)-L-cysteine in a 50-mL round-bottom flask. 2. Suspend in 15 mL of 2:1 (v/v) dioxane/water and adjust the pH to 9 by addition of 1 M NaOH. 3. Add 0.60 g (2.74 mmol) di-tert-butyldicarbonate and keep the reaction overnight at room temperature with magnetic stirring. To avoid decomposition of di-tert-butyldicarbonate, store at –20°C.
Work up reaction 4. Transfer the reaction mixture to a 100-mL separatory funnel and wash twice with 50 mL hexanes. 5. Cool the aqueous phase in an ice bath and add 1 M HCl dropwise with manual stirring until the pH is 2 to 3. 6. Transfer the acidified aqueous phase to the 100-mL separatory funnel and extract three times with 50 mL EtOAc. 7. Wash the combined organic phases two times with 25 mL water. 8. Dry the organic layer over anhydrous Na2SO4. Add more Na2SO4 if the salt crystals clump together upon swirling.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.23 Current Protocols in Nucleic Acid Chemistry
Supplement 16
9. Gravity filter the resulting solution through filter paper into a 250-mL round-bottom flask. Rinse the Na2SO4 crystals with 10 to 20 mL EtOAc. 10. Remove the solvent under reduced pressure (i.e., in a rotary evaporator with a water aspirator) to yield a white solid (80% yield). Use without further purification. 11. Determine the melting temperature. Characterize by TLC, 1H NMR, and mass spectrometry. Boc-Cys(S-tBu)-OH: Rf 0.47 (95:5 DCM/MeOH); m.p. 119°-120°C; 1H NMR (300 MHz, CDCl3): δ 5.40 (d, 1H, J = 7.8 Hz), 4.61 (m, 1H), 3.20 (m, 2H), 1.47 (s, 9H), 1.34 (s, 9H) ppm; FAB-MS (positive mode, 4-nitrobenzyl alcohol): m/z 309.4 [(Boc-Cys(S-tBu)OH)+H]+ and 332.4 [(Boc-Cys(S-tBu)OH)+Na]+, calcd. mass for C12H23NO4S2: 309.5. SUPPORT PROTOCOL 4
PREPARATION OF Boc-Hse(DMTr)-O–HTEA+ Boc protection and tritylation of homoserine are shown in Figure 4.22.7. Materials L-Homoserine (Novabiochem) Pyridine, anhydrous (see recipe) Argon (Ar), dry Chlorotrimethylsilane Triethylamine Di-tert-butyldicarbonate (Boc2O) 32% ammonium hydroxide 4,4′-Dimethoxytrityl chloride (DMTr⋅Cl) Dichloromethane (DCM), neutralized (see recipe) Methanol (MeOH) Triethylamine Acetonitrile, anhydrous (see recipe) 250-mL oven-dried round-bottom flask with rubber septum Oven-dried glass syringes and needles Rotary evaporator equipped with a water aspirator 500-mL round-bottom flask Additional reagents and equipment for column chromatography (see Support Protocol 2 and APPENDIX 3E), TLC (APPENDIX 3D), 1H and 13C NMR, and mass spectrometry Introduce Boc protecting group 1. Place 0.5 g (4.20 mmol) of L-homoserine in a 250-mL oven-dried round-bottom flask. 2. Dry by co-evaporating twice with 25 mL anhydrous pyridine. 3. Cap the flask with a rubber septum and purge the flask with dry Ar. 4. Add 10 mL anhydrous pyridine and 3.50 mL (25.2 mmol) chlorotrimethylsilane with oven-dried glass syringes and needles. 5. Let the reaction stand 2 hr under an Ar atmosphere at room temperature. 6. Add 1.1 g (5 mmol) di-tert-butyldicarbonate and 0.7 mL (5 mmol) triethylamine, and stir continuously 20 hr at room temperature under an Ar atmosphere. 7. Slowly add 10 mL cold water and 7 mL concentrated ammonium hydroxide (32% v/v), and stir 30 min at room temperature.
Stepwise Solid-Phase Synthesis of Nucleopeptides
The final ammonium hydroxide concentration achieved (∼ 2 M) will ensure complete removal of silyl groups.
4.22.24 Supplement 16
Current Protocols in Nucleic Acid Chemistry
H2N CH COOH CH2
1. TMS⋅Cl 2. (Boc) 2O, TEA
CH2
− +
Boc NH CH COO NH4 aq NH3
CH2 CH2
Pyr
OH
OH −
+
Boc NH CH COO HNEt3 CH2
DMTr⋅Cl, Pyr (silica gel chromatography with 2% TEA)
CH2 DMTr
O
Figure 4.22.7 Synthesis of the homoserine derivative. Abbreviations: Boc, tert-butoxycarbonyl; DMTr, 4,4′-dimethoxytrityl; Pyr, pyridine; TEA, triethylamine; TMS, trimethylsilyl.
8. Evaporate to dryness under reduced pressure (i.e., in a rotary evaporator) to yield an oil. 9. Dry the remaining oil by co-evaporating twice with 25 mL anhydrous pyridine. 10. Dissolve in 10 mL anhydrous pyridine and add 1.75 g (5.2 mmol) DMTr⋅Cl. 11. Stir 24 hr at room temperature under an Ar atmosphere. 12. Evaporate to dryness under reduced pressure. Isolate and characterize the product 13. Perform silica gel column chromatography (see Support Protocol 2, steps 18 to 19, and APPENDIX 3E), eluting with neutralized DCM and increasing amounts of MeOH (0% to 10%) in the presence of 2% triethylamine. 14. Combine the product-containing fractions in a 500-mL round-bottom flask and concentrate to an oil in a rotary evaporator. 15. Remove residual triethylamine by co-evaporating the oil with anhydrous acetonitrile to provide the pure product as a white solid (35% yield). 16. Determine the melting temperature. Characterize by TLC, 1H and 13C NMR, and mass spectrometry. Boc-Hse(DMTr)-O–HNEt3+: Rf 0.62 (9:1 DCM/MeOH); m.p. 67°-68°C; [α]D = 9.93 (c 0.62, MeOH); 1H NMR (300 MHz, CDCl3): δ 7.44-7.15 (m, 9H), 6.82-6.78 (m, 4H), 5.55 (d, 1H, J = 7.2 Hz), 4.22 (m, 1H), 3.77 (s, 6H), 3.30-3.10 (m, 2H), 2.98 (q, 6H, J = 7.3 Hz), 2.17 (m, 1H), 1.99 (m, 1H), 1.39 (s, 9H), 1.19 (t, 9H, J = 7.3 Hz) ppm; 13C NMR (75 MHz, CDCl3): δ 176.1, 158.3, 155.2, 145.1, 135.4, 130.0-126.5, 113.0, 86.1, 60.8, 55.1, 52.8, 45.0, 32.7, 28.3, 8.4 ppm; FAB-MS (positive mode, Xe, magic bullet, 3:1 dithiothreitol/dithioerythritol): m/z 623.1 [(Boc-Hse(DMTr)-O–HNEt3+)+H]+ and 522.1 [(BocHse(DMTr)-OH)+H]+, calcd. mass for C38H50N2O7 (Boc-Hse(DMTr)-O–HNEt3+): 622.8, calcd. mass for C30H35NO7 (Boc-Hse(DMTr)-OH): 521.6.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.25 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Boc NH CH COOH
NO2 , TEA
BrCH2
H3C CH
Boc NH CH COOCH2
NO2
H3C CH
EtOAc
OH
OH Ac2O, DMAP EtOAc
Boc NH CH COOH
H2, 5% Pd/C
H3C CH
EtOAc/MeOH
O Ac
Boc NH CH COOCH2
NO2
H3C CH O Ac
NH
(DCHA)
hexanes/ether +
Boc NH CH COO − HDCHA H3C CH O Ac
Figure 4.22.8 Protection of the threonine hydroxyl group and preparation of its solid dicyclohexylammonium salt. Abbreviations: Boc, tert-butoxycarbonyl; DCHA, N,N-dicyclohexylamine; DMAP, 4-(N,N-dimethylamino)pyridine; TEA, triethylamine.
SUPPORT PROTOCOL 5
PREPARATION OF Boc-Thr(Ac)-OH Preparation of the protected threonine residue is shown in Figure 4.22.8. Materials N-(tert-Butoxycarbonyl)-L-threonine (Novabiochem) Ethyl acetate (EtOAc) 4-Nitrobenzyl bromide Triethylamine 1 M HCl 5% (w/v) aqueous sodium hydrogencarbonate (NaHCO3) solution Sodium sulfate (Na2SO4), anhydrous Dichloromethane (DCM) Methanol (MeOH) Acetic anhydride 4-Dimethylaminopyridine (DMAP) Argon (Ar), dry 5% (dry basis) palladium on activated carbon Hydrogen gas Hexanes Diethyl ether Dicyclohexylamine
Stepwise Solid-Phase Synthesis of Nucleopeptides
4.22.26 Supplement 16
Current Protocols in Nucleic Acid Chemistry
100-, 250-, and 500-mL round-bottom flasks Reflux condenser Gravity filtration device and filter paper 250- and 500-mL separatory funnels Rotary evaporator with a water aspirator 25-mL oven-dried round-bottom flask with rubber septum Additional reagents and equipment for column chromatography (see Support Protocol 2 and APPENDIX 3E), TLC (APPENDIX 3E), 1H and 13C NMR, IR, and mass spectrometry Prepare Boc-Thr-ONbn 1. Place 2.5 g (12.5 mmol) of N-(tert-butoxycarbonyl)-L-threonine in a 100-mL roundbottom flask. Add 20 mL EtOAc. 2. Add 3.4 g (15.7 mmol) 4-nitrobenzyl bromide and 1.6 g (15.7 mmol) triethylamine and reflux 6 hr. 3. Cool the resulting solution and gravity filter through filter paper. 4. Transfer the filtrate to a 500-mL separatory funnel and wash once with 50 mL water, once with 50 mL of 1 M HCl, and three times with 50 mL of 5% aqueous NaHCO3 solution. 5. Dry the organic layer over anhydrous Na2SO4. Add more Na2SO4 if the salt crystals clump together upon swirling. 6. Gravity filter the resulting solution through filter paper into a 250-mL round-bottom flask. Rinse the Na2SO4 crystals with 10 to 20 mL EtOAc. 7. Remove the solvent under reduced pressure (i.e., in a rotary evaporator with a water aspirator). 8. Perform silica gel column chromatography (see Support Protocol 2, steps 18 and 19, and APPENDIX 3E), eluting with DCM and increasing amounts of MeOH (0% to 5%). 9. Combine product-containing fractions into a 500-mL round-bottom flask and concentrate to a white solid (70% yield) on a rotary evaporator. 10. Determine the melting temperature. Characterize by TLC (APPENDIX 3D), 1H and 13C NMR, IR, and mass spectrometry. Boc-Thr-ONbn: Rf 0.60 (95:5 CHCl3/MeOH); m.p. 95°-98°C; [α]D = –9.8 (c 0.62, MeOH); 1H NMR (300 MHz, CDCl3): δ 8.2 (d, 2H, J = 8.8 Hz), 7.5 (d, 2H, J = 8.8 Hz), 5.4 (m, 1H), 5.3 (d, 1H, J = 3.2 Hz), 4.4 (m, 2H), 1.5 (s, 9H), 1.3 (d, 3H, J = 6.6 Hz) ppm; 13 C NMR (75 MHz, CDCl3): δ 171, 156, 152, 143, 128, 124, 80, 68, 66, 59, 28, 20 ppm; IR (KBr): 3450, 1760, 1670, 1520, 1350 cm–1; FAB-MS (positive mode, Xe, magic bullet): m/z 355.1 [(Boc-Thr-ONbn)+H]+, 377.0 [(Boc-Thr-ONbn)+Na]+, calcd. mass for C16H22N2O7: 354.36.
Prepare Boc-Thr(Ac)-ONbn 11. Place 3.2 g (9 mmol) of Boc-Thr-ONbn in a 100-mL round-bottom flask. Dissolve in 20 mL EtOAc. 12. Add 4.3 mL (45 mmol) acetic anhydride and 0.55 g (4.5 mmol) DMAP and stir for 2 hr at room temperature. 13. Add 10 mL MeOH and stir 10 min. 14. Concentrate to an oil in a rotary evaporator. 15. Perform silica gel column chromatography as in step 8. 16. Combine the product-containing fractions in a 500-mL round-bottom flask and concentrate to an oil (95% yield) in a rotary evaporator.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.27 Current Protocols in Nucleic Acid Chemistry
Supplement 16
17. Characterize by TLC, 1H and 13C NMR, IR, and mass spectrometry. Boc-Thr(Ac)-ONbn: Rf 0.84 (95:5 CHCl3/MeOH); [α]D = −7.2 (c 0.23, MeOH); 1H NMR (300 MHz, CDCl3): δ 8.2 (d, 2H, J = 8.8 Hz), 7.5 (d, 2H, J = 8.8 Hz), 5.4 (m, 1H), 5.2 (d,1H, J = 3.6 Hz), 4.5 (dd, 1H, J = 2.2, 9.4 Hz), 2.1 (s, 3H), 1.5 (s, 9H), 1.3 (d, 3H, J = 6.2 Hz), ppm; 13C NMR (75 MHz, CDCl3): δ 177, 170, 156, 148, 142, 129, 124, 81, 70, 66, 57, 28, 21 ppm; IR (film): 1750, 1710, 1610, 1530, 1350 cm−1; FAB-MS (positive mode, Xe, nitrobenzyl alcohol): m/z 397.0 [(Boc-Thr(Ac)-ONbn)+H]+, calcd. mass for C18H24N2O8: 396.40.
Prepare Boc-Thr(Ac)-OH (oil) 18. Place 0.95 g (2.4 mmol) Boc-Thr(Ac)-ONbn into a 25-mL oven-dried round-bottom flask. Cap the flask with a rubber septum and purge with dry Ar. 19. Dissolve in 10 mL of 1:1 (v/v) EtOAc/MeOH. 20. Add 0.18 mg of 5% palladium on activated carbon. Bubble hydrogen gas into the reaction mixture for 3 hr. CAUTION: Hydrogen is an extremely flammable gas. Keep the container in a well-ventilated place away from sources of ignition. Take precautionary measures against static discharges. Always manipulate in a well-ventilated fume hood and wear appropriate protective laboratory equipment.
21. Eliminate the catalyst by gravity filtration through filter paper. Rinse with 10 to 20 mL MeOH. 22. Concentrate the filtrate to dryness in a rotary evaporator. 23. Dissolve the resulting oil in 100 mL EtOAc and transfer to a 250-mL separatory funnel. 24. Wash the organic layer six times with 50 mL of 1 M HCl and then three times with 50 mL water. 25. Dry the organic layer over anhydrous Na2SO4. Add more Na2SO4 if the salt crystals clump together upon swirling. 26. Gravity filter the resulting solution through filter paper into a 250-mL round-bottom flask. Rinse the Na2SO4 crystals with 10 to 20 mL EtOAc. 27. Remove the solvent under reduced pressure (i.e., in a rotary evaporator). 28. Perform silica gel column chromatography as in step 8. 29. Combine the product-containing fractions into a 500-mL round-bottom flask and concentrate to an oil (55% yield) in a rotary evaporator. 30. Characterize by TLC, 1H and 13C NMR, and IR. Boc-Thr(Ac)-OH: Rf 0.71 (95:5 CHCl3/MeOH); 1H NMR (300 MHz, CDCl3): δ 5.75 (m, 1H), 4.39 (m, 1H), 4.26 (d, 1H, J = 8.6 Hz), 4.15 (m, 1H), 1.45 (s, 9H), 1.25 (d, 3H, J = 5.6 Hz) ppm; 13C NMR (75 MHz, CDCl3): 174, 170, 156, 81, 71, 57, 28, 21, 17 ppm; IR (film): 3400, 1750, 1710, 1520 cm–1.
Prepare Boc-Thr(Ac)-O–DCHA+ (solid) 31. Dissolve Boc-Thr(Ac)-OH in 1:1 (v/v) hexanes/diethyl ether and add an equimolar amount of dicyclohexylamine. Stir overnight at 0°C. Stepwise Solid-Phase Synthesis of Nucleopeptides
32. Filter and then wash with prechilled 1:1 (v/v) hexanes/diethyl ether to obtain a white solid (93% yield).
4.22.28 Supplement 16
Current Protocols in Nucleic Acid Chemistry
33. Characterize by TLC, 13C NMR, and mass spectrometry. Boc-Thr(Ac)-O–DCHA+: Rf 0.47 (85:10:5 CHCl3/MeOH/AcOH); m.p. 172°-173°C; 13C NMR (75 MHz, CDCl3): δ 174, 170, 156, 78, 73, 59, 53, 29, 28, 25, 24, 21, 17 ppm; FAB-MS (positive mode, Xe, magic bullet, 3:1 dithiothreitol/dithioerythritol): m/z 443.0 [(BocThr(Ac)-O–DCHA+)+H]+ and 465.0 [(Boc-Thr(Ac)-O–DCHA+)+Na]+, calcd. mass for C23H42N2O6: 442.60.
ELONGATION OF THE OLIGONUCLEOTIDE CHAIN AND CLEAVAGE AND DEPROTECTION OF THE NUCLEOPEPTIDE In this protocol, the peptide-bound support is added to an oligonucleotide synthesis column and the nucleotide is extended from the appropriate amino acid hydroxyl function (homoserine in Fig. 4.22.2B). In general, oligonucleotide synthesis follows standard automated DNA methods (see APPENDIX 3C); however, some minor modifications have to be introduced in the oligonucleotide synthesis cycle, since a polystyrene support is used instead of controlled-pore glass (CPG). The main washes are made with neutralized DCM rather than acetonitrile, and THF washes are used after certain steps. A 2% N,N-diisopropylethylamine solution is used to wash the support after detritylation. Washes with anhydrous acetonitrile are employed before phosphoramidite couplings. The synthesis cycle is outlined in Table 4.22.3. Oligonucleotide synthesis is monitored by the trityl assay, and the yield of the first incorporation is also determined.
BASIC PROTOCOL 2
Complete deprotection of the nucleopeptide can be carried out using ammonium hydroxide alone or using tetra-n-butylammonium fluoride (TBAF) followed by ammonium hydroxide. Ammonia treatment may give (especially with glycine at the C terminus) a mixture of the C-terminal carboxylic acid and carboxamide nucleopeptides. The TBAF procedure gives exclusively the C-terminal carboxylic acid nucleopeptide irrespective of the bifunctional spacer used. The TBAF treatment is recommended if nucleopeptides are sufficiently stable, but may not be compatible with nucleopeptides in which serine or threonine are the linking residues (see Strategic Planning). In some cases, presence of tetra-n-butylammonium counterions renders the reversed-phase HPLC analysis (see Basic Protocol 3) difficult. In those cases, it is recommended to obtain the sodium salt of the nucleopeptide as described below. PAGE analysis (see Basic Protocol 4) is also more reliable with desalted products. For additional requirements for deprotection, analysis, and purification, see Support Protocol 7. Materials Peptide-derivatized support (see Basic Protocol 1) DNA phosphoramidites (Glen Research): 5′-O-(4,4′-dimethoxytrityl)-N-protected2′-deoxyribonucleoside-3′-O-(2-cyanoethyl-N,N-diisopropyl)-phosphoramidites, where the nucleobases are: N6-benzoyladenin-9-yl N2-isobutyrylguanin-9-yl N2-dimethylaminomethyleneguanin-9-yl N4-benzoylcytosin-1-yl N4-acetylcytosin-1-yl thymin-1-yl Argon (Ar) and nitrogen (N2, optional) gas, dry Anhydrous acetonitrile (see recipe) in a septum-sealed distillation collection bulb Activator solution (see recipe) Cap A and B capping reagents (Glen Research) Oxidizer solution (see recipe) Peroxide-free THF (see recipe)
Synthesis of Modified Oligonucleotides and Conjugates
4.22.29 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Table 4.22.3 Automated 5-µmol Synthesis Cycle for the Oligonucleotide Chain Elongation on an ABI 380B DNA Synthesizer
Synthesis step
Function
Time (sec)
Detritylation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
DCM to waste DCM to column Ar reverse flush Ar block flush Waste port Advance fraction collector 3% TCA to waste 3% TCA to column Ar column flush 3% TCA to column Ar column flush DCM to waste DCM to column Ar column flush Ar block flush Waste to bottle 2% DIPEA to waste 2% DIPEA to column Ar reverse flush DCM to waste DCM to column Ar reverse flush
5 20 10 5 1 1 5 60 10 60 10 3 180 10 5 1 3 30 10 3 20 10
ACN to waste ACN to column Ar reverse flush Ar block flush ACN to waste ACN to column Ar reverse flush Ar block flush
5 45 30 5 5 45 45 5
Phosphoramidite preparation Activator to column Phosphoramidite + activator to column Activator to column THF to waste Wait THF to column Ar reverse flush Ar block flush
3 3 25 3 5 300 30 10 5
Column washing 23 24 25 26 27 28 29 30 Phosphoramidite coupling 30 31 32 33 34 35 36 37 38
continued Stepwise Solid-Phase Synthesis of Nucleopeptides
4.22.30 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Table 4.22.3 Automated 5-µmol Synthesis Cycle for the Oligonucleotide Chain Elongation on an ABI 380B DNA Synthesizer, continued
Synthesis step
Function
Time (sec)
Capping preparation Cap A + cap B to column Wait DCM to waste DCM to column Ar reverse flush Ar block flush
10 30 120 5 45 10 5
Column capping 39 40 41 42 43 44 45
Oxidation and column washing 46 47 48 49 50 51 52 53 54 55 56 57 58
Oxidizer to waste Oxidizer to column DCM to waste Wait THF to waste THF to column Ar reverse flush DCM to waste DCM to column Ar reverse flush Ar block flush Repeat steps 54 and 55 three times Ar block flush
7 30 5 60 5 60 10 5 30 10 5 5
Detritylation solution: 3% (w/v) trichloroacetic acid (TCA, 99%, Glen Research) in neutralized DCM 2% (v/v) N,N-diisopropylethylamine (DIPEA) in neutralized DCM Neutralized DCM (see recipe) 0.1 M p-toluenesulfonic acid monohydrate in acetonitrile 70% (v/v) perchloric acid Absolute ethanol (EtOH) Peroxide-free dioxane (see recipe) 32% ammonium hydroxide (store at 4°C) 1 M dithiothreitol (DTT) in peroxide-free dioxane Tetra-n-butylammonium fluoride (TBAF, Aldrich) Anhydrous tetrahydrafuran (see recipe) in a septum-sealed distillation collection bulb Methanol (MeOH), HPLC grade Glacial acetic acid 200- to 400-mesh Dowex 50WX4-400 ion-exchange resin (4.8 meq Na+/g; Fluka Chemic) 1 M NaOH Synthesis column for 5-µmol-scale synthesis: old empty OPC cartridge (ABI) with a body and two caps (13-mm aluminum seals; Chromatographic Specialties)
Synthesis of Modified Oligonucleotides and Conjugates
4.22.31 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Empty DNA synthesizer bottles, oven dried, with rubber septa Vacuum desiccator containing P2O5 Glass syringes and needles, oven dried ABI 380B automated DNA synthesizer External fraction collector and 15-mL test tubes Double-beam UV spectrophotometer, calibrated, and quartz cuvettes 20-mL screw-cap pressure tubes, O-ring seal preferred 55°C oven Disposable polypropylene syringes and polyethylene filters (cotton optional in some steps) 50-mL round-bottom flasks Teflon two-way stopcocks Rotary evaporator with a water aspirator Lyophilizer Vacuum filtration system Additional reagents and equipment for automated oligonucleotide synthesis (APPENDIX 3C) and amino acid analysis (see Basic Protocol 1) CAUTION: All solutions and reagents required for the DNA synthesizer should be manipulated and prepared in a well-ventilated fume hood. NOTE: Oxidizer solution, DIPEA solution, neutralized DCM, and peroxide-free THF should be filtered (Pro-XR nylon filters, 0.25 µm, 25 mm) before they are added to the synthesizer bottles. Prepare column 1. Transfer an accurately weighed amount of peptide-derivatized support for a 5-µmol synthesis (i.e., 100 mg peptide-support with a loading of 0.20 µmol/mg) to an assembled oligonucleotide synthesis column. The peptide-resin contains the hydroxyl function where the first nucleotide will be anchored and the oligonucleotide chain subsequently elongated. Standard 1-ìmol scale columns may fit enough a resin for a 1 to 2-ìmol-scale synthesis on polystyrene.
Perform oligonucleotide synthesis 2. Weigh the appropriate amount of DNA phosphoramidites in oven-dried synthesizer bottles, cap with rubber septa, insert a disposable needle, and dry them in a P2O5-containing desiccator under vacuum (6 hr minimum). 3. Open the desiccator under an Ar atmosphere. Using oven-dried glass syringes and needles, dissolve the compounds in sufficient anhydrous acetonitrile (from a septumsealed distillation collection bulb) to yield a 0.2 M concentration. Care must be taken to avoid the presence of moisture throughout the entire process.
4. Place the synthesizer reagents in the following ports of an ABI 380B synthesizer:
Stepwise Solid-Phase Synthesis of Nucleopeptides
Activator: port 9 Cap A and B: ports 11 and 12 Oxidizer: port 15 Peroxide-free THF: port 16 Detritylation solution: port 14 2% DIPEA in neutralized DCM: port 17 Neutralized DCM: port 18 Anhydrous acetonitrile: port 13 DNA phosphoramidite solutions (step 3): ports 1 to 4.
4.22.32 Supplement 16
Current Protocols in Nucleic Acid Chemistry
5. Enter the sequence to be synthesized. Introduce an additional nucleotide at the 3′ end that will correspond to the peptide-resin containing the hydroxyl function where the oligonucleotide will be anchored. For example, to synthesize the tryptophan-containing nucleopeptide shown in Figure 4.22.2B, enter the sequence 5′-GCTACGT-3′, where the 3′-T corresponds to the peptidelinked resin.
6. Perform synthesis in the DMTr-off mode using a synthesis cycle modified as outlined in Table 4.22.3. Collect DMTr cation solutions in 15-mL test tubes using an external fraction collector. When nucleopeptides with >10 nucleobases are prepared, synthesis in DMTr-on mode is recommended in order to facilitate the purification.
7. Upon completion of the synthesis, dry the resin by manually conducting an Ar reverse flush operation on the synthesizer for 2 to 3 min. Alternatively, dry the support under a stream of N2 or Ar. Monitor DNA synthesis by DMTr assay 8. Dilute the first three and last three DMTr cation solutions to 10 mL with 0.1 M p-toluenesulfonic acid monohydrate in acetonitrile. Mix thoroughly. CAUTION: Handle the solution containing trichloroacetic acid in DCM and acetonitrile with gloves, because it is corrosive as well as toxic. Always manipulate in a well-ventilated fume hood. The volume of DMTr solutions may change during the course of a synthesis because DCM is a volatile solvent. Fractions may sit for several days before being assayed without affecting the results. Samples that have gone to dryness must be thoroughly redissolved. Addition of the p-toluenesulfonic acid ensures ionization of the DMTr group, making the solutions more strongly colored.
9. Dilute each sample 20- to 50-fold with the same solution. Measure the absorbance at 498 nm (A498) versus the 0.1 M p-toluenesulfonic acid monohydrate solution in acetonitrile. These dilutions are necessary because high absorbance measurements are not reliable.
10. Calculate the rough stepwise coupling efficiency for the synthesis as a whole, using the following equation: (stepwise efficiency) n =
avg. absorbance last three fractions avg. absorbance first three fractions Equation 4.22.2
where n is the number of DMTr nucleotides in the oligonucleotide (equal to the length of the oligonucleotide for DMTr-off synthesis). Quantify incorporation yield of the first nucleotide 11. Evaporate the first DMTr cation solution to dryness and redissolve the remaining residue in a known volume of 3:2 (v/v) 70% perchloric acid/EtOH. CAUTION: Handle 3:2 (v/v) 70% perchloric acid/EtOH with gloves in a well-ventilated fume hood. Perchloric acid is very corrosive and can be explosive when it contacts organic materials. Perchloric-containing residues must be appropriately neutralized prior to disposal.
12. Dilute the sample 20- to 50-fold with the same solution in order to obtain an A498 <1. Measure the A498 of the sample versus the 3:2 (v/v) 70% perchloric acid/EtOH solution.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.33 Current Protocols in Nucleic Acid Chemistry
Supplement 16
13. Calculate loading as: loading =
A498 × DF × 1000 ε × l × m
Equation 4.22.3
where DF is the dilution factor, ε is the molar extinction coefficient of the DMTr cation at 498 nm (71,700 L/mol⋅cm), l is the absorbance path of the cuvette (in cm), and m is the amount of peptide-support introduced in the column (in mg). 14. Determine the incorporation yield of the first nucleotide onto the peptide-support as the ratio between the obtained loading value and the peptide-support loading determined by amino acid analysis. Perform complete deprotection of nucleopeptide With ammonium hydroxide treatment 15a. Open the column and transfer the nucleopeptide-support to a 20-mL screw-cap pressure tube, preferably with an O-ring seal. 16a. Add 5 mL peroxide-free dioxane and 5 mL of 32% ammonium hydroxide. Screw the cap on tightly, and incubate 15 hr at 55°C in an oven or 6 to 8 hr at room temperature (see Strategic Planning for more details). When the nucleopeptide contains Cys(S-tBu), use 5 mL of 1 M DTT in dioxane and 5 mL of 32% ammonium hydroxide and treat for 6 to 8 hr at room temperature (see Support Protocol 7). CAUTION: The 32% ammonium hydroxide solution must be kept at 4°C with the cap tightly sealed. Concentrated ammonium hydroxide is extremely caustic. Breathing the vapors is harmful. Always wear glasses and gloves when using this compound and work in a well-ventilated fume hood, as it is possible to be quickly overcome by ammonia fumes and be blinded.
17a. Cool the mixture to room temperature. Filter through a disposable polypropylene syringe with a polyethylene filter or cotton, and collect in a 50-mL round-bottom flask. 18a. Wash the pressure tube several times with MeOH and pass the washes through the syringe. Concentrate the resulting filtrate under reduced pressure to a volume of ∼2 mL. To prevent inadvertent detritylation of dimethoxytritylated nucleopeptides, avoid heat and acid during the evaporation step. Elimination of dioxane and ammonium hydroxide should be done at room temperature to preserve the 5′-DMTr on the oligonucleotide chain. Addition of triethylamine is recommended to ensure no loss of the DMTr group.
With TBAF and ammonium hydroxide treatment 15b. Open the column and transfer the nucleopeptide-support into a polypropylene disposable syringe with a polyethylene filter closed with a stopcock. 16b. Add 5 mL of 0.05 M TBAF in anhydrous THF and let stand 30 min, stirring occasionally. Stepwise Solid-Phase Synthesis of Nucleopeptides
17b. Collect the filtrate in a 50-mL round-bottom flask. Wash three times with 2 mL MeOH followed by 5 mL THF and add to the filtrate. Add a few drops of glacial acetic acid and evaporate to dryness using a rotary evaporator.
4.22.34 Supplement 16
Current Protocols in Nucleic Acid Chemistry
18b. Redissolve the residue in 10 mL of 1:1 (v/v) peroxide-free dioxane/32% ammonium hydroxide and place in a 55oC oven for 15 hr, or at room temperature for 6 to 8 hr, depending on the stability expected for the target nucleopeptides. Concentrate the resulting filtrate under reduced pressure to a volume of ~2 mL. Obtain sodium salt of nucleopeptide (optional; for TBAF only) 19. Add 200- to 400-mesh Dowex 50WX4-400 ion-exchange resin to a polypropylene syringe fitted with a polyethylene disc. 20. Wash with 200 mL water. 21. Wash with 200 mL of 1 M NaOH, added dropwise. 22. Wash with water until the solution has the pH of deionized water. 23. Dissolve deprotected nucleopeptide residue (step 18b) in a minimum amount of water (1 to 2 mL) and load onto the equilibrated Dowex resin. Elute with water until no UV-absorbing filtrate is obtained (check by measuring the absorbance at 260 nm versus water). Collect 1 to 2 mL fractions in disposable tubes. 24. Combine the product-containing fractions and lyophilize. Calculate cleavage yield 25. Wash the resin (resulting from ammonia or TBAF treatment; step 17a or 17b) with MeOH and dry directly on a vacuum filtration system. 26. Proceed with amino acid analysis as described (see Basic Protocol 1, steps 9 to 13). 27. Calculate the cleavage yield as the ratio between any amino acid in the nucleopeptide still attached to the solid support and the internal reference amino acid. Choose residues that are not destroyed or modified during the hydrolysis process, such as amino acids with aliphatic side chains, phenylalanine, or aspartic and glutamic acids.
ANALYSIS, PURIFICATION, AND CHARACTERIZATION OF NUCLEOPEPTIDES Crude nucleopeptides are first analyzed and then purified by liquid chromatography techniques. Analysis is routinely carried out using reversed-phase HPLC (RP-HPLC), although analytical PAGE (see Basic Protocol 4) can provide additional information, or may be required if the sample is highly impure. Purification is also generally performed by RP-HPLC. Medium-pressure systems (MPLC) may be the best option for relatively homogeneous crude nucleopeptides, since relatively large amounts of product (30 to 1000 OD units) can be purified in a single run. When this technique is inefficient, or if complicated crude nucleopeptides are obtained, the higher resolving power of high-pressure systems is required. Either analytical or semipreparative HPLC columns can be used, depending on the amount of pure product to be isolated. Preparative gel electrophoresis (see Basic Protocol 4) provides very good resolution and may allow pure nucleopeptides to be obtained when RP-HPLC fails. Its main disadvantage is low recovery of product from the gel. After purification, the overall synthesis yield is determined and the nucleopeptide is quantified by spectrophotometry at 260 nm. The nucleopeptide is then analyzed by MALDI-TOF or ESI mass spectrometry. Oligonucleotide analysis, purification, and characterization procedures are described in UNITS 10.1-10.7. Base composition is determined by digestion using a combination of alkaline phosphatase (AP) and either snake venom phosphodiesterase (SVPD) or calf spleen phosphodiesterase (SpPD). The assessment of base composition is more often carried out using SVPD than SpPD. Degradation with SVPD and AP can be performed in a single reaction mixture, because both enzymes work at the same slightly basic pH. Degradation with SpPD and AP requires two separate
BASIC PROTOCOL 3
Synthesis of Modified Oligonucleotides and Conjugates
4.22.35 Current Protocols in Nucleic Acid Chemistry
Supplement 16
treatments under different conditions. The same information is generally obtained using either protocol, and consistent results from both reinforce that the nucleoside composition is as expected. Finally, the product is analyzed by amino acid analysis after acid hydrolysis or enzymatic digestion of the peptide moiety. Enzymatic digestion is carried out in a sequential mode using three enzymes: papaine, microsomal leucin-aminopeptidase, and prolidase. (1) Papaine is a nonspecific enzyme that cleaves at -X-↑-Y-, where Y is not specific and X can be any residue, but is preferably arginine, lysine, or residues consecutive to phenylalanine. (2) Microsomal leucin-aminopeptidase is an exopeptidase that hydrolyzes peptide bonds adjacent to a free α-amine group (H2N-X-↑-Y-, where X is not proline and Y is not specific). It does not hydrolyze γ-amino groups. (3) Prolidase is a dipeptidase that hydrolyzes dipeptides with a proline or hydroxyproline residue at the C terminus (H2NX-↑-Y-, where X is not proline, but Y is proline or hydroxyproline). When coupled with amino acid analysis, this protocol allows the content of asparagine and aspartic acid to be determined, as well as other acid-labile amino acids (e.g., methionine, tryptophan). Materials Crude deprotected nucleopeptide (see Basic Protocol 2 or Support Protocol 7) 0.01 M ammonium acetate, pH 7.0 HPLC mobile phase A: 0.01 M ammonium acetate, pH 7.0 HPLC mobile phase B: 1:1 (v/v) acetonitrile/water Methanol (MeOH), HPLC grade MPLC mobile phase A: 0.05 M ammonium acetate, pH 7.0 MPLC mobile phase B: 70% (v/v) 0.05 M ammonium acetate solution, pH 7.0, in 1:1 (v/v) acetonitrile/water Matrix: 2′,4′,6′-trihydroxyacetophenone (THAP) or 3-hydroxypicolinic acid (3-HPA) Ammonium citrate Acetonitrile, HPLC grade 0.1% (v/v) triethylamine in water Isopropanol (optional) 0.1 M Tris⋅Cl, pH 8.0 (APPENDIX 2A) 0.1 M MgCl2 1.5 U/500 µL snake venom phosphodiesterase (SVDP; Boehringer-Mannheim; EC 3.1.4.1) 0.0337 U/µL bacterial alkaline phosphatase (AP; Sigma; EC 3.1.16.1) 0.2 M ammonium acetate, pH 5.4 and 8.3 0.23 U/µL calf spleen phosphodiesterase (SpPD; Sigma; EC 3.1.3.1) Concentrated HCl 0.1 M ammonium acetate, pH 5.3 1:32 (v/v) 2-mercaptoethanol/water 20 mg/mL (286 U/mL) papaine (from Papaya latex; Sigma; EC 3.4.22.2) Glacial acetic acid 3 mg/mL (72 U/mL) microsomal leucin aminopeptidase (mLAP type VI-S from kidney pork microsomes; Sigma; EC 3.4.11.2) 0.025 M MnCl2 buffer solution, pH 8.3 5 mg/mL (875 U/mL) prolidase (from pork kidney; Sigma; EC 3.4.13.9)
Stepwise Solid-Phase Synthesis of Nucleopeptides
High-performance liquid chromatograph (HPLC) with: Injector (autosampler preferred), sample loop, and syringe (for manual loading) 0.1 to 5 mL/min pumping system (binary) UV/Vis detector, variable wavelength between 190 and 600 nm (preferred) or dual-wavelength detection
4.22.36 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Data integrating system Gradient system: displays and stores for redisplay and reformatting (preferred) or programmable Analytical column: reversed-phase C18 column (i.e., Kromasil, 10 µm, 4.0 × 250 mm) Semipreparative column: reversed-phase C18 column (i.e., Kromasil, 10 µm, 10.0 × 250 mm) Automatic fraction collector (optional) Lyophilizer Double-beam UV spectrophotometer, calibrated Quartz cuvettes Preparative chromatographic system (medium-pressure liquid chromatography, MPLC): Piston pump Reversed-phase C18-filled glass column (i.e., Vydac 15 to 20-µm i.d., 300-Å porosity, 22 × 2 cm) Automatic fraction collector UV/Vis detector with fixed-wavelength detection Teflon tubing connectors and adapters Gradient-forming device with two equal-diameter cylinders and a Teflon stopcock between them Chart recorder Pyrex tubes 37°C water bath or heating block Benchtop centrifuge Additional reagents and equipment for reduction of sulfoxide-protected methionine (see Support Protocol 6; optional), deprotection of tert-butylthio-protected cysteine (see Support Protocol 7; optional), MALDI-TOF-MS (UNIT 10.1), ESI-MS (UNIT 10.2), and amino acid analysis (see Basic Protocol 1) Analyze crude nucleopeptide by analytical RP-HPLC 1. Take 0.05 to 0.10 OD units of crude deprotected nucleopeptide and dilute with 0.01 M ammonium acetate buffer, pH 7.0, to a volume of 25 to 100 µL. Typical injection volumes for analysis are 10 to 100 ìL depending on the sample loop size of the injector. For nucleopeptides containing tert-butylthio-protected cysteine, perform deprotection (see Support Protocol 7) prior to the analysis of the crude product.
2. Program the HPLC gradient system to start with 5% HPLC mobile phase B, increasing the percentage of HPLC mobile phase B with time (Table 4.22.4). Ensure that there is sufficient mobile phase to keep intakes covered throughout the run. For 5′-dimethoxytritylated nucleopeptides 5% to 60% mobile phase B in 30 min is the gradient recommended. For post-HPLC detritylation, see UNIT 10.5.
3. Set the UV detector wavelength at 260 nm. Using an analytical column, equilibrate the HPLC system with the starting mobile phase composition until a flat baseline is achieved at the desired detection wavelength. 4. Inject the sample by programming the autosampler or by loading it into the sample loop using an appropriate syringe. Elute the sample by starting the gradient. Record the chromatogram.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.37 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Table 4.22.4 Gradient and Mobile Phase for RP-HPLC of Crude Nucleopeptidea
Elapsed time (min)
Percent mobile phase Bb
0 30 31 35 36 45
5 35 100 100 5 5
aGradient conditions are based on a flow of 1 mL/min using an analytical
Kromasil reversed-phase C18 column (10-µm diameter spherical silica, 4.0 × 250 mm) at ambient temperature with a 45-min injection cycle. Mobile phase A: 0.01 M ammonium acetate, pH 7.0; mobile phase B: 1:1 (v/v) acetonitrile/water. bPercentage is at elapsed time.
Typically, nucleopeptides will elute at ∼12 to 18 min under the recommended conditions (Table 4.22.4). For 5′-dimethoxytritylated nucleopeptides, the elution time will be longer (∼18 to 25 min). In some cases, when the nucleopeptide is small (e.g., <8 nucleobases) and has been cleaved with ammonium hydroxide, it is possible to differentiate the nucleopeptides with C-terminal carboxylic acid and carboxamide groups. When the nucleopeptide contains sulfoxide-protected methionine or proline, it is possible to obtain two or more peaks (depending on the number of these residues) due to sulfoxide diastereomers or proline conformations (cis or trans).
5. For nucleopeptides containing sulfoxide-protected methionine, proceed with reduction (see Support Protocol 6) prior to purification. Purify crude nucleopeptide by analytical or semipreparative RP-HPLC 6a. For small amounts of nucleopeptide (1 to 10 OD units): Perform HPLC as in steps 1 to 4. Load the analytical column with ∼1 to 2 OD units at every injection and elute at a flow rate of 1 mL/min. Collect the desired fractions either with an automated fraction collector or by observing the chromatogram in real time and manually collecting the eluate. 6b. For larger amounts of nucleopeptide (>10 OD units): Use a semipreparative column under the described conditions. Elute at a flow rate of 3 mL/min. 7. Lyophilize the collected solution and quantify the amount of product obtained (steps 8 to 11). Quantify nucleopeptide 8. Dissolve the lyophilized nucleopeptide in 5 mL water. Take 20 µL and dilute to a volume of 1 mL with water. An adequate dilution factor has to be chosen to keep absorbance <1. Modify the dilution depending on the synthesis scale and expected yield.
9. Measure the absorbance of the diluted sample in a quartz cuvette at 260 nm (A260) on a calibrated, double-beam, UV spectrophotometer using water as a reference. Stepwise Solid-Phase Synthesis of Nucleopeptides
If using a single-beam spectrophotometer, a blank should be run with a sample containing water (blank).
4.22.38 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Table 4.22.5
Molar Extinction Coefficients of Nucleobases
Nucleobase (ni)
εi at 260 nm
T dC dG dA
8830 7700 11500 15200
10. Determine the amount of product (in OD260 units) and the concentration of the stock solution using the dilution factor and Beer’s Law (A260 = εlc), where ε is the molar extinction coefficient (see below), l is the path length of the UV cell (typically 1 cm), and c is the molar concentration of oligonucleotide. Lyophilize the nucleopeptide solution. In a nucleopeptide, the contribution of aromatic amino acids (tryptophan, phenylalanine, and tyrosine) to the global oligonucleotide absorbance at 260 nm is considered negligible in comparison with the absorption of the nucleobases. The molar extinction coefficient of the nucleopeptide is given by ε = εi × F, where εi represents the molar extinction coefficient of each nucleobase (see Table 4.22.5) and F is a correction factor (0.9 when the oligonucleotide is single-stranded and 0.8 when it is double-stranded or self-complementary).
11. Calculate the overall synthesis yield. From the ratio of product obtained (in OD units) to the theoretical amount (calculated from the loading of the C-terminal amino acid resin). Average yields for nucleopeptide synthesis, cleavage, and purification are ∼10% to 30%.
Purify crude nucleopeptide by preparative MPLC 12. Prepare a preparative chromatographic system as follows: a. Connect a piston pump to the top of a preparative reversed-phase C18-filled glass column. b. Connect the bottom to an automatic fraction collector through a UV/Vis detector. c. Connect the pump to the mixing chamber of a gradient-forming device. Connect the detector to a chart recorder using the appropriate ports. 13. Wash the column with 100 mL MeOH and 200 mL water by placing the pump entrance line in the appropriate bottles. 14. Set the UV detector wavelength at 260 nm with the appropriate lamp and filter. Turn on the detector and chart recorder. 15. Equilibrate the column with 200 mL MPLC mobile phase A at 3 to 4 mL/min. Stop the pump. 16. Place 600 mL MPLC mobile phase A and 600 mL MPLC mobile phase B in the appropriate compartments of the gradient-forming device. Place a magnetic stir bar in the mixing chamber (initially MPLC mobile phase A) and a magnetic stirrer below. 17. Place the pump solvent line inside the mixing chamber. 18. Dissolve the crude nucleopeptide sample in MPLC mobile phase A to a volume of 5 mL. 19. Remove the supernatant solution from the column cap position. Introduce the nucleopeptide sample solution onto the column and close.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.39 Current Protocols in Nucleic Acid Chemistry
Supplement 16
20. Turn on the pump (3 to 4 mL/min) and the magnetic stirrer. Open the stopcock of the gradient-forming device to generate the gradient. Turn on the automatic fraction collector. Preparative chromatographic elution profiles are very similar to analytical ones. The gradient conditions described above extrapolate the typical analytical gradient (from 5% to 35% HPLC mobile phase B in mobile phase A). When DMTr-on nucleopeptides are purified, MPLC mobile phase B should be changed to 40% 0.05 M ammonium acetate solution, pH 7.0, in 1:1 (v/v) acetonitrile/water.
21. Select the tubes containing the desired product. Reanalyze those solutions by analytical HPLC (steps 1 to 4). In general, the desired nucleopeptide (main chromatographic peak) is eluted within four or five tubes and has a high level of purity (>95% to 99% as assessed by analytical HPLC).
22. Pool the fractions with the same chromatographic profile and purity requirements. Lyophilize the collected solution and quantify (steps 8 to 11). Analyze nucleopeptide by MALDI-TOF-MS 23. Weigh 10 mg THAP matrix or 50 mg 3-HPA matrix into a 1.5-mL microcentrifuge tube. In a separate tube, weigh 50 mg ammonium citrate. Optimal results are obtained when the highest-purity matrices are used. Matrix and ammonium citrate solutions should be made fresh prior to use. Storage for >3 days is not recommended. In general, MALDI-TOF analysis of nucleopeptides is carried out following the same protocols as for simple oligonucleotides (UNIT 10.1). The standard matrices are used (THAP and 3-HPA) and negative-ionization mode is recommended because of the global negative charge of the nucleopeptides. For routine nucleopeptide analysis (up to 8 to 10 nucleobases), THAP is recommended. 3-HPA should be used when THAP does not give positive results.
24. Add 1 mL of 1:1 (v/v) acetonitrile/water to the THAP or 3-HPA matrix, and 1 mL water to the ammonium citrate salt. Vortex for 30 sec to allow complete dissolution. 25. Prepare a 50 to 100 µM nucleopeptide solution in water. 26. To a 0.5-mL microcentrifuge tube, add 1 µL nucleopeptide sample solution, 1 µL ammonium citrate solution, and 1 µL matrix solution. Mix by withdrawing and expelling the solution ten times with a pipet. 27. Spot 1 µL on the MALDI-TOF sample plate and dry. To allow for homogeneous crystallization, do not disturb the spotted sample after it starts to crystallize. Do not load the sample plate into the mass spectrometer before the plate is dry. Good signal can be obtained from anywhere around the edges of the crystallized spot.
28. Analyze by MALDI-TOF-MS (see UNIT 10.1). Analyze nucleopeptide by ESI-MS 29. Prepare a 100 to 200 µM stock nucleopeptide solution in water. The best concentration for carrying out ESI-MS analysis depends on the instrument used. In general, nucleopeptides are analyzed by ESI-MS in the negative mode, as with MALDITOF-MS. See UNIT 10.2 for more specific details.
30. Add 5 µL of 0.1% triethylamine to 100 µL nucleopeptide solution. Stepwise Solid-Phase Synthesis of Nucleopeptides
4.22.40 Supplement 16
Current Protocols in Nucleic Acid Chemistry
31. Mix 100 µL of the above solution with an equal volume of acetonitrile (preferred), isopropanol, or MeOH. In general, the aqueous nucleopeptide solution is mixed in a 1:1 (v/v) ratio with an organic solvent such as acetonitrile, MeOH, or isopropanol, because the solvent is readily evaporated and facilitates the transfer of the ion from the liquid to the gas phase. The solvent also allows for the generation of a large number of ions. Another issue is that, as the pH increases, more negative ions are produced and the signal intensity rises. Addition of an organic base such as triethylamine to the nucleopeptide solution increases the pH and also reduces the extent of cation adducts observed in the mass spectra.
32. Analyze by ESI-MS (UNIT 10.2). Analyze base composition by SVPD/AP digestion 33. Evaporate 0.5 to 1.0 OD unit of nucleopeptide sample to dryness under vacuum in an appropriate vessel (i.e., 1.5-mL microcentrifuge tube). 34. Add the following: 34 µL freshly deionized water 50 µL 0.1 M Tris⋅Cl, pH 8.0 10 µL 0.1 M MgCl2 1 µL 1.5 U/500 µL SVPD 5 µL 0.0337 U/µL bacterial AP. 35. Vortex the sample and centrifuge briefly to collect the liquid at the bottom of the tube. Incubate 8 to 15 hr at 37°C. 36. Vortex the sample and chill with dry ice at least 10 min. 37. Centrifuge 5 min in a benchtop centrifuge at maximum speed, room temperature. Carefully remove the supernatant with a pipet and transfer to a new labeled tube. Discard the original tube containing the pellet. 38. Evaporate the sample to complete dryness under vacuum. 39. Dissolve the dried sample in 50 µL water and vortex at least 30 sec.
Table 4.22.6 Digestsa
Gradient and Mobile Phase for RP-HPLC Analysis of Nucleopeptide
Elapsed time (min)
Percent mobile phase Bb
0 5 20 25 30 31 40
10 10 30 100 100 10 10
aGradient conditions are based on a flow of 1 mL/min using a Kromasil reversed-phase C18 column (10-µm
diameter spherical silica, 4.0 × 250 mm) at ambient temperature with a 40-min injection cycle. Mobile phase A: 0.01 M ammonium acetate, pH 7.0; mobile phase B: 1:1 (v/v) acetonitrile/water. bPercentage is at elapsed time
Synthesis of Modified Oligonucleotides and Conjugates
4.22.41 Current Protocols in Nucleic Acid Chemistry
Supplement 16
40. Perform reversed-phase HPLC of the digested sample on a C18 column. Load ∼0.2 OD unit per injection and elute with an acetonitrile/ammonium acetate/water gradient as specified in Table 4.22.6. Set the detector to 260 nm. See UNIT 10.6 for more specific details on RP-HPLC.
41. Collect data for 30 min. The nucleoside elution order depends on the column and HPLC system used. Approximate elution times are 5.0 min for dC, 6.0 min for dG, 6.7 min for T, and 13.1 min for dA.
42. To calculate the base composition, use the molar extinction coefficients from Table 4.22.5 and the integrated area of each peak. First calculate the average value of the ratio between the integrated area and the molar extinction coefficient (X): X = ∑ (peak area/εi ) / N Equation 4.22.4
where εi is the molar extinction coefficient of each nucleoside (Table 4.22.5) and N the number of every particular nucleobase in the sequence. Then calculate the composition for each nucleoside: n i = (peak area/εi ) / X Equation 4.22.5
where ni represents the experimental calculated value for the nucleoside i. Although SVPD is a 3′-exonuclease, it has been shown to degrade nucleopeptides where the 3′-hydroxyl function of the oligonucleotide chain is blocked by linkage to a peptide chain. This modification would prevent degradation during a short incubation time, but not after long treatments as described above. Also, SVPD contains some endonuclease contamination that favors complete degradation of the oligonucleotide chain. In general, the nucleoside composition calculated after enzymatic digestion is very similar to the expected composition. In some cases, the value of the 3′-nucleoside is low depending on the amino acid that links the peptide and oligonucleotide chain. When homoserine serine, or threonine is used, an extra peak, with higher retention time than that of simple nucleosides, may be observed in the RP-HPLC profile that corresponds to the 3′-nucleoside-peptide.
Analyze base composition by SpPD/AP digestion 43. Evaporate 0.5 to 1.0 OD unit of nucleopeptide sample to dryness under vacuum in an appropriate vessel (i.e., 1.5-mL microcentrifuge tube). 44. Add 30 µL of 0.2 M ammonium acetate buffer, pH 5.4, and 10 µL of 0.23 U/µL SpPD. 45. Vortex the sample and centrifuge briefly to collect the liquid at the bottom of the tube. Incubate 12 to 15 hr at 37°C. 46. Lyophilize and then add the following:
Stepwise Solid-Phase Synthesis of Nucleopeptides
34 µL freshly deionized water 50 µL 0.1 M Tris⋅Cl, pH 8.0 10 µL 0.1 M MgCl2 5 µL 0.0337 U/µL bacterial AP.
4.22.42 Supplement 16
Current Protocols in Nucleic Acid Chemistry
47. Continue as in steps 35 to 42. SpPD is a 5′-exonuclease enzyme, and degrades the oligonucleotide chain of the nucleopeptide starting from the 5′-terminal hydroxyl group. SpPD also degrades the 3′-nucleoside-peptide linkage, independently of the linking amino acid. In general, nucleoside composition after enzymatic digestion is very similar to the expected composition. In some cases, however, the deoxyadenosine value is lower than expected. This is because of deaminase contamination, and depends on the enzyme batch employed. In these cases, an extra peak appears in the HPLC trace, which is attributed to a modified deoxyadenosine nucleoside.
Perform amino acid analysis of nucleopeptide under acidic conditions 48. Place 5 OD260 units of purified nucleopeptide in a Pyrex tube. 49. Add 300 µL water and 300 µL concentrated HCl. 50. Determine amino acid content as described (see Basic Protocol 1, steps 11 to 13). When quantifying amino acids from peptide-oligonucleotide conjugates, high values of glycine are obtained due to co-elution with oligonucleotide hydrolysis side-products.
Perform enzymatic analysis of peptides and nucleopeptides 51. Evaporate 3 to 5 nmol peptide or nucleopeptide sample to dryness under vacuum in an appropriate vessel (i.e., a 1.5-mL microcentrifuge tube). 52. Dissolve the sample in 15 µL of 0.1 M ammonium acetate buffer, pH 5.3. Add 1 µL of 1:32 (v/v) 2-mercaptoethanol/water. 53. Add 3 µL of 20 mg/mL (286 U/mL) papaine solution and incubate 2 hr at 37°C. 54. Add one drop of glacial acetic acid and lyophilize. 55. Redissolve the sample in 15 µL of 0.2 M ammonium acetate buffer, pH 8.3, and 1 µL of 1:32 (v/v) 2-mercaptoethanol/water. 56. Add 3 µL of 3 mg/mL (72 U/mL) microsomal leucin aminopeptidase solution and incubate 3 hr at 37°C. 57. Repeat the addition of 3 µL enzyme solution and incubate another 12 hr at 37°C. 58. Add one drop of concentrated acetic acid and lyophilize. 59. Redissolve the sample in 15 µL of 0.1 M ammonium acetate and 0.025 M MnCl2 buffer solution, pH 8.3. 60. Add 3 µL of 5 mg/mL (875 U/mL) prolidase solution and incubate 3 hr at 37°C. 61. Add one drop of concentrated acetic acid and lyophilize. 62. Perform amino acid analysis as described (see Basic Protocol 1, step 13). REDUCTION OF SULFOXIDE-PROTECTED METHIONINE-CONTAINING NUCLEOPEPTIDES
SUPPORT PROTOCOL 6
Additional Materials (also see Basic Protocol 3) Deprotected crude nucleopeptide (see Basic Protocol 2) N-Methylmercaptoacetamide 1. Quantitate crude nucleopeptide as described (see Basic Protocol 3, steps 8 to 10). 2. Dissolve 50 OD260 units lyophilized crude nucleopeptide in 1 mL water. 3. Place at 37°C and add a 20- to 100-fold excess (2 to 10 µL) N-methylmercaptoacetamide. Stir occasionally.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.43 Current Protocols in Nucleic Acid Chemistry
Supplement 16
4. After 12 hr, monitor the reaction by reversed-phase C18 HPLC (see Basic Protocol 3, steps 1 to 4). In general, the methionine-reduced nucleopeptide is eluted after the sulfoxide-containing nucleopeptide (∼1 to 2 min).
5. If necessary, add more N-methylmercaptoacetamide to achieve complete reduction within 24 to 36 hr. 6. When complete reduction is achieved, lyophilize and proceed to isolate the desired reduced nucleopeptide (see Basic Protocol 3, step 6 or 12). SUPPORT PROTOCOL 7
DEPROTECTION AND PURIFICATION OF CYSTEINE-CONTAINING NUCLEOPEPTIDES Additional Materials (also see Basic Protocol 3) Nucleopeptide-support (see Basic Protocol 2, step 7) 1 M 1,4-dithiotreitol (DTT) in peroxide-free dioxane (see recipe) 32% ammonium hydroxide 0.05 M ammonium acetate buffer, pH 7.0 20-mL screw-cap pressure tube, O-ring seal preferred Disposable polypropylene syringe with polyethylene filter (or cotton) 50-mL round-bottom flask Peristaltic pump Sephadex G-10 column Deprotect cysteine-containing nucleopeptide 1. Open the synthesis column and transfer the nucleopeptide-support to a 20-mL screw-cap pressure tube, preferably with an O-ring seal. 2. Add 5 mL of 1 M DTT in peroxide-free dioxane and 5 mL of 32% ammonium hydroxide, screw the cap on tightly, and incubate 6 to 8 hr at room temperature. It is necessary to have a large excess of DTT during the ammonia deprotection step to remove the tert-butylthio protecting group from cysteine and to avoid secondary reactions such as β-elimination of HS-S-tBu. Dimethylaminomethylene-protected guanosine and acetyl-protected cytosine phosphoramidites must be used in combination with tertbutylthio-protected cysteine residues, and cleavage and deprotection must be performed at room temperature for 6 to 8 hr. Refer to safety recommendations and other notes above (see Basic Protocol 2).
3. Filter the solution through a disposable polypropylene disposable syringe with a polyethylene filter or cotton and collect the filtrate in a 50-mL round-bottom flask. 4. Wash the pressure tube three times with MeOH and pass the washes through the syringe into the same flask. 5. Concentrate the combined solution under reduced pressure (in a rotary evaporator with a water aspirator) to a volume of ∼2 mL. Perform gel filtration 6. Set up a purification system as described for MPLC purification (see Basic Protocol 3, step 12), but with a peristaltic pump. 7. Equilibrate a Sephadex G-10 chromatography column with 200 mL of 0.05 M ammonium acetate buffer, pH 7.0. Stepwise Solid-Phase Synthesis of Nucleopeptides
8. Dilute the crude nucleopeptide sample with 0.05 M ammonium acetate buffer, pH 7.0, to a volume of 5 mL.
4.22.44 Supplement 16
Current Protocols in Nucleic Acid Chemistry
9. Remove the supernatant solution from the column cap position. Introduce the nucleopeptide sample solution in the column and close. 10. Set the UV detector wavelength at 260 nm with the appropriate lamp and filter. Turn on the detector and chart recorder. Turn on the peristaltic pump and elute slowly (~1 mL/min) with 0.05 M ammonium acetate buffer, pH 7.0. Under the conditions described, the nucleopeptide-containing peak is eluted before the DTT-containing peak. This is because separation is based on molecular weight differences, with the larger compounds being eluted faster.
11. Observing the chromatogram, select the tubes where the nucleopeptide-containing peak is eluted and combine eluents. Lyophilize, analyze by HPLC, and purify as described (see Basic Protocol 3). It is important to point out that cysteine-containing nucleopeptides may dimerize very quickly because of oxidation by atmospheric oxygen, yielding a dimer in which two nucleopeptides are bonded through a disulfide bridge between the peptide chains. When two or more cysteine residues are present in the nucleopeptide, polymers can be formed. To prevent oxidation, avoid having samples in solution at room temperature. Keep frozen.
ANALYSIS AND PURIFICATION OF NUCLEOPEPTIDES BY POLYACRYLAMIDE GEL ELECTROPHORESIS
BASIC PROTOCOL 4
For more details on oligonucleotide polyacrylamide gel electrophoresis, see UNIT 10.4 and APPENDIX 3B. Materials Urea, ultrapure 38% (w/v) acrylamide/2% (w/v) bisacrylamide (see recipe) 10× TBE buffer (1.3 M Tris, 0.45 M boric acid, 25 mM EDTA) 10% (w/v) ammonium persulfate (store up to 1 week at 4°C) N,N,N′,N′-Tetramethylethylenediamine (TEMED) Bromphenol blue Xylene cyanol Glycerol Deprotected crude or purified nucleopeptide (see Basic Protocol 2 or 3) 50% (v/v) aqueous formamide Stains-all (Aldrich) Formamide Concentrated HCl Isopropanol 3 M Tris⋅Cl, pH 8.8 (APPENDIX 2A) 2 M ammonium acetate buffer, pH 7.0 Acetonitrile, HPLC grade 50% (v/v) aqueous methanol (MeOH) 250-mL Erlenmeyer flask 20- and 60-mL syringes 95° and 37°C water baths or heating blocks Sep-Pak cartridges (Waters) with clamps Polyethylene disc Disposable tubes Lyophilizer Additional reagents and equipment for polyacrylamide electrophoresis (UNIT 10.4 and APPENDIX 3B)
Synthesis of Modified Oligonucleotides and Conjugates
4.22.45 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Set up gel 1. Assemble gel plates, spacers, and combs as described in manufacturer’s instructions.
APPENDIX 3B
or following
2. In a 250-mL Erlenmeyer flask, combine the following: 12.6 g urea 15 mL 38% (w/v) acrylamide/2% (w/v) bisacrylamide (20% acrylamide) 1.5 mL 10× TBE buffer 30 mL water. CAUTION: Acrylamide and bisacrylamide are hazardous. Solutions of acrylamide deteriorate quickly, especially when exposed to light or left at room temperature (see Reagents and Solutions). For oligonucleotides with <25 bases, 20% is the optimum acrylamide concentration (UNIT 10.4). To speed dissolution of urea, the gel mixture can be heated before adding TEMED and ammonium persulfate; however, to prevent degradation of acrylamide, do not heat above 55°C. Allow to cool to room temperature before adding TEMED and ammonium persulfate to prevent polymerization while pouring the gel.
3. Add 300 µL of 10% (w/v) ammonium persulfate and 30 µL TEMED. Mix thoroughly and wait 30 sec. 4. Gently pull acrylamide solution into a 60-mL syringe, avoiding bubbles, and pour the gel, allowing it to flow slowly down between the gel plates (see APPENDIX 3B). 5. Insert the comb. Dislodge any trapped air bubbles, especially in the wells, by tapping gently on the glass plates. Set up electrophoresis apparatus 6. After the gel has polymerized (usually 30 to 60 min), remove bottom spacer of gel sandwich and remove extraneous polyacrylamide from around the combs. 7. Fill bottom reservoir of gel apparatus with 0.5× TBE buffer. Place the gel in the electrophoresis apparatus and clamp plates to support. 8. Pour 0.5× TBE buffer into the upper reservoir to ∼3 cm above the top of the gel. Using a Pasteur pipet, rinse wells thoroughly with 0.5× TBE buffer to remove stray fragments of polyacrylamide. 9. Preheat gel ∼1 hr by running at a constant 750 V. The ideal wattage of the gel should generate enough heat so that the gel plates are warm, but not too hot to touch.
Load and run the gel 10. To remove urea that has leached into them, flush the sample wells with 0.5× TBE buffer just prior to loading the gel. 11. Prepare a 5× stock solution with marker dyes: 0.25% (w/v) bromphenol blue 0.25% (w/v) xylene cyanol 30% (w/v) glycerol. Dilute to 1× with water before loading onto the gel. Stepwise Solid-Phase Synthesis of Nucleopeptides
In a 20% acrylamide gel, migration of bromphenol blue and xylene cyanol will be similar to 6-nt and 22-nt linear single-stranded oligonucleotides, respectively.
4.22.46 Supplement 16
Current Protocols in Nucleic Acid Chemistry
12. Dissolve each sample of crude or purified nucleopeptide (0.1 to 0.2 OD260 units) in 20 µL of 50% aqueous formamide by vortexing. Microcentrifuge the dissolved samples briefly to collect them at the bottom of the tube. 13. Heat samples at 95°C in covered microcentrifuge tubes. Place on ice. 14. Load 10 µL sample per well under the surface of the buffer and just above the surface of the well. 15. Load 5 µL of 1× marker dye solution (step 11). 16. Run gel immediately at 750 V constant voltage. Maintain a constant gel temperature of ∼65°C. Observe migration of marker dyes to determine electrophoresis time. Temperatures >65°C can result in cracked plates or smeared bands; temperatures that are too low can lead to incomplete denaturation.
Process gel 17. Prepare a 10% stock dye solution by dissolving 100 mg Stains-all in 100 mL formamide. Adjust pH to 7.3 to 7.4 by adding concentrated HCl. Store at 4°C, protected from light. 18. Mix the following: 10 mL 10% Stains-all solution 10 mL formamide 50 mL isopropanol 1 mL 3 M Tris⋅Cl, pH 8.8 129 mL water. 19. Remove the gel sandwich from the apparatus and carefully place the gel in a shallow pan containing enough staining solution to cover the gel. 20. Let stand 6 hr to overnight, then decant the stain and gently rinse the gel in water. If the background is too high, soaking the gel in water and exposing to infrared light can effect some destaining.
21. Photograph the gel under ambient light against a white background. Alternatively, dry using a gel dryer (APPENDIX 3B) and scan or photograph. Purify nucleopeptide by preparative gel electrophoresis 22. Prepare a denaturing polyacrylamide gel as described above and in APPENDIX 3B. Prepare twice the amount of reagents as required for analytical gel electrophoresis. 23. Load 2 to 8 OD260 units of nucleopeptide in 40 µL of 50% aqueous formamide and perform electrophoresis. 24. Remove the gel and visualize the nucleopeptide bands using a fluorescent TLC plate and UV lamp (APPENDIX 3B). 25. Slice the gel on the perimeter of the band with a clean razor blade, and transfer the fragment to a disposable tube. Crush the fragment with a spatula. 26. Add 3 to 4 mL of 2 M ammonium acetate buffer, pH 7.0, and vortex briefly. Let stand with vigorous stirring for 12 to 24 hr in a 37°C water bath. Alternatively, freeze and thaw at least three times to enhance extraction of the product from gel. 27. Mount a Sep-Pak cartridge with a clamp and insert an empty 20-mL syringe on top of the cartridge. 28. Fill the syringe barrel with 10 mL acetonitrile. Insert and depress the plunger to pass the solution through the Sep-Pak cartridge over an elapsed time of 15 to 30 sec.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.47 Current Protocols in Nucleic Acid Chemistry
Supplement 16
29. Repeat step 28 with 10 mL water and 10 mL of 2 M ammonium acetate buffer, pH 7.0. 30. Remove the syringe and insert a polypropylene syringe fitted with a polyethylene disc onto the top of Sep-Pak cartridge. Add the 3 to 4 mL buffer and gel (step 26) and let fluid pass through the column by gravity. 31. Wash the disposable tube (from the gel suspension) with 3 to 4 mL water and add to the syringe. Repeat wash three more times. 32. Insert a new disposable syringe and elute nucleopeptide with 5 to 7 mL of 50% MeOH. Collect 1-mL fractions in disposable tubes. 33. Use UV absorbance to identify the fractions where the nucleopeptide has eluted. Lyophilize and quantify. REAGENTS AND SOLUTIONS Use deionized, Milli-Q-purified water (Millipore, 18 mΩ × cm−1) in all recipes and protocol steps, unless otherwise noted. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Acetonitrile, anhydrous Reflux and distill over calcium hydride powder under an inert (i.e., N2 or Ar) atmosphere. Store over calcium hydride lumps under an Ar atmosphere. Prepare fresh before each use. Alternatively, DNA-synthesis-grade low-water-content acetonitrile can be purchased and used as such, or refluxed and distilled from calcium hydride under an inert atmosphere.
Acrylamide/bisacrylamide solution, 38%/2% (w/v) Dissolve 380 g acrylamide and 20 g bisacrylamide in water to a volume of 1 liter. Filter through a 0.5-µM membrane. Store 2 to 4 weeks at 4°C, protected from light. Activator solution Prepare 0.8 M sublimed 1H-tetrazole (see recipe) in anhydrous THF (see recipe) using a septum-sealed distillation collection bulb. For a complete dissolution of tetrazole, use an ultrasonic bath. Prepare fresh before each use. Dichloromethane (DCM), anhydrous Reflux and distill dichloromethane over reagent-grade phosphorus pentoxide under an inert (N2 or Ar) atmosphere. Store over calcium hydride lumps under Ar atmosphere. Prepare fresh before each use. DCM, neutralized Pass DCM through a basic alumina column in order to eliminate acid traces. Store up to one week at 20°C. N,N-Diisopropylethylamine (DIPEA), anhydrous Place under calcium hydride lumps under an Ar atmosphere for at least one night before use. Prepare fresh before each use. Dioxane, peroxide free Pass dioxane through a basic alumina column in order to eliminate all traces of peroxide. Store until a positive peroxide test is obtained (mix equal volumes of 5% (w/v) KI aqueous solution and dioxane). Stepwise Solid-Phase Synthesis of Nucleopeptides
A yellowish color indicates the presence of peroxides. No yellowish color should be observed if the solvent is peroxide-free.
4.22.48 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Ninhydrin reagent A Dissolve 40 g phenol in 10 mL absolute EtOH. Mix 2 mL of 2 mM potassium cyanide and 100 mL pyridine freshly distilled over ninhydrin. Mix each solution separately with 4 g Amberlite MB-3 resin (Merck) for 45 min. Filter and mix both solutions together to obtain the desired reagent A. Store up to 1 to 2 years at 4°C. Ninhydrin reagent B Dissolve 2.5 g ninhydrin in 50 mL absolute EtOH. Keep the solution protected from light in an amber glass container (up to 1 to 2 years at 4°C). Oxidizer solution Dilute 5.0 to 6.0 M anhydrous tert-butylhydroperoxide in decane (Aldrich or Fluka) to a final concentration of 1 M in anhydrous DCM (see recipe). Prepare fresh before each use. Pyridine, anhydrous Reflux and distill pyridine over reagent-ninhydrin powder under an inert (i.e., N2 or Ar) atmosphere. Reflux and distill again over calcium hydride powder. Place over calcium hydride lumps under an Ar atmosphere. Prepare fresh before each use. Tetrahydrofuran (THF), anhydrous Dry peroxide-free tetrahydrofuran (see recipe) by continuous reflux and distillation over sodium metal and benzophenone under inert atmosphere until purple color persists. Prepare fresh before each use. THF, peroxide free Pass THF through a basic alumina column in order to eliminate peroxides. Store until a positive test is obtained (see peroxide-free dioxane). Protect from light. 1H-Tetrazole, sublimed Transfer a commercial solution of 1H-tetrazole in acetonitrile into a round-bottom flask (this can be mixed with unused wet solutions of tetrazole from the DNA synthesizer). Evaporate to dryness under reduced pressure using a rotary evaporator with a water aspirator. Use a sublimation apparatus to sublime the remaining solid to obtain pure crystalline 1H-tetrazole. Store under Ar up to 5 years at ambient temperature. CAUTION: 1H-Tetrazole is an explosive compound. Never heat near the melting point (157°-159°C). Wear safety glasses and gloves during sublimation procedure. Manipulate with caution in a well-ventilated fume hood. 1H-Tetrazole is no longer commercially available in solid form. Solutions of 1H-tetrazole in acetonitrile may be purchased from typical organic chemical suppliers such as Aldrich.
COMMENTARY Background Information The methodologies for the preparation of various kinds of peptide-oligonucleotide conjugates have been reviewed by different authors (Tung and Stein, 2000; Zubin et al., 2002; UNIT 4.5). The research published since the last review report on adaptations, modifications, problems, or improvements of previously described methods (e.g., Chen et al., 2002, 2003; Drioli et al., 2002; Kachalova et al., 2002; Viladkar, 2002; Zatsepin et al., 2002), but no new synthesis design has been described. For these reasons,
as well as for space limitations, only a few comments on the preparation of nucleopeptides and on the use of stepwise solid-phase methodology to obtain peptide-oligonucleotide conjugates will be made here (i.e., only representative examples will be cited). All the methodologies used to prepare hybrids in which the two components are directly linked through phosphate diesters (here referred to as nucleopeptides) share a common outline: the key linking phosphodiester bond is
Synthesis of Modified Oligonucleotides and Conjugates
4.22.49 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Stepwise Solid-Phase Synthesis of Nucleopeptides
created having all the nonparticipating functional groups protected. This key phosphate has been formed using different chemistries that yield phosphodiester bonds, namely the phosphate triester (Kuyl-Yeheskiely et al., 1989; Ueno et al., 1993), the H-phosphonate (Kuyl-Yeheskiely et al., 1987), and the phosphite triester (Dreef-Tromp et al., 1992a; Sakakura and Hayakawa, 2000; Debéthune et al., 2002a; Jeyaraj et al., 2002) approaches. Synthesis of nucleopeptides has been carried out in solution and on solid supports, both by convergent (Dreef-Tromp et al., 1992a; Robles et al., 1995; Sakakura and Hayakawa, 2000) and stepwise strategies (Debéthune et al., 2002a). Protection schemes have included a large variety of permanent protecting groups that are either chemically or enzymatically (Flohr et al., 1999) removable. Many nucleopeptides have been prepared since the pioneering work of Z.A. Shabarova in the sixties (Shabarova, 1970). In 1992, van Boom’s group was able to obtain a nucleopeptide with up to ten nucleosides (Dreef-Tromp et al., 1992a) and two trifunctional amino acids besides the linking residue. The methodology described here has allowed the synthesis of nucleopeptides containing up to five amino acids with functionalized side chains (besides the linking residue), and to obtain a nucleopeptide with thirteen amino acids and fifteen nucleosides. In the authors’ opinion, one of the main advantages of this stepwise solid-phase methodology is that it circumvents the need to manipulate protected peptides. These are often highly insoluble in most organic solvents, which renders both the purification and the phosphitylation (or phosphorylation) difficult. Moreover, most of the monomers required can be purchased from commercial suppliers. Besides the trifunctional amino acid derivatives whose synthesis is described here, the only nucleoside synthons that should have to be synthesized in the laboratory are the 5′-phosphoramidites of 2′-deoxycytidine and 2′-deoxyguanosine. The commercially available 5′phosphoramidites of these nucleosides are only suitable for the preparation of nucleopeptides with 5′-oligonucleotide-homoserine or tyrosine linkages, and their standard nucleobaseprotecting groups are not compatible with baselabile nucleopeptides. Finally, it is worth emphasizing that compared to other methods the use of an amino acid to attach the two moieties has the advantage of allowing one to place the linking unit at any
position in the peptide chain, with no need to prepare a specially designed support. The only exception to this assertion, as previously mentioned, is that homoserine cannot be placed at the C-terminal position. The acid treatment that removes the Boc group simultaneously eliminates its DMTr hydroxyl-protecting group, and the propensity for homoserine to lactonize would easily provoke cleavage of the peptideresin bond, resulting in loss of peptide chains. As previously stated, peptide-oligonucleotide conjugates that are not directly linked or are linked through amide bonds have also been synthesized using stepwise procedures. In most cases, hybrids have been assembled onto insoluble matrices, but the modifiable solubility of polyethylene glycol has also been exploited (Drioli et al., 2002). Peptide assembly is more often carried out first, but synthesis starting with oligonucleotide elongation has also been reported (Bergmann and Bannwarth, 1995; Sarracino et al., 1998). In general, there is no need for concern about the stability of the linkage between the two moieties, but some degradation of the target molecule during the final deprotection treatment has been found to be associated with the use of immobilized trifunctional linkers (Basu and Wicsktrom, 1995). It is important to note that the protection scheme proposed here for the preparation of nucleopeptides is of general application and can be extended to the synthesis of any peptideoligonucleotide conjugate. In addition, when the target molecule contains trifunctional amino acids that may suffer side reactions, and/or base-labile linkers are used for their assembly, the recommendation to use the most labile set of permanent protecting groups also applies. The most common applications of peptideoligonucleotide conjugates have been discussed earlier (see unit introduction). Such molecules can also find application in structural studies (Ho et al., 1999; Gómez-Pinto et al., 2003), in studies on the structural requirements of an enzyme (Debéthune et al., 2002b), or in studies on the behavior of metal complexes (Civitello et al., 2001; Marchán et al., 2001). Hopefully, access to user-friendly synthesis procedures and the future development of newer, more convenient procedures will inspire an increasing number of laboratories to prepare more conjugates, and thus enlarge their fields of application.
4.22.50 Supplement 16
Current Protocols in Nucleic Acid Chemistry
A
0
B
35
0
C
35
0
D
35
0
35
Min.
Figure 4.22.9 Examples of HPLC profiles of nucleopeptides: (A) crude and (B) purified Ac-Lys-Trp-Lys-Hse(p3′dGCATCG)-Ala-OH, and (C) crude and (D) purified Ac-Tyr(p3′dTTTCAGAAAATCTAG)-Leu-Asp-Pro-Arg-Ile-Thr-Val-OH. See Basic Protocol 3 for gradient conditions, eluents, and column employed.
Critical Parameters As previously pointed out, the most critical point in nucleopeptide synthesis is the choice of protecting groups, which must be accompanied by appropriate selection of the final deprotection conditions (see Strategic Planning and Table 4.22.1). It is also important to ensure that oligonucleotide elongation is carried out on a homogeneous immobilized peptide. The amino acid composition should be checked before the oligonucleotide synthesis is begun. Depending on the peptide length and composition, HPLC and MS analysis of the crude product obtained after deprotection of an aliquot of peptide-resin may also be worthwhile. If large nucleopeptides or conjugates are to be prepared, leaving the DMTr group after incorporation of the last nucleoside synthon may facilitate the HPLC analysis and purification of the crude product. Two purification runs, both by HPLC or by combining HPLC and PAGE, may sometimes be required.
Troubleshooting Large nucleopeptides, especially depending on the amino acid composition, may show complex HPLC profiles. HPLC analysis at higher temperature (50° to 55°C) may reduce conformational equilibria, and in some cases simplify the HPLC profile of the crude product. As previously suggested, analysis by PAGE under denaturing conditions may also be a good alternative.
major peak in the crude nucleopeptide after cleavage and deprotection. The coupling yield of the first nucleoside phosphoramidite is variable, with an average value of 70%. Nearly quantitative yields, as in any other oligonucleotide synthesis, are obtained in the subsequent couplings. The cleavage yield with concentrated ammonia/dioxane treatment at 55°C usually ranges from 60% to 80%. An additional treatment with TBAF, if allowed by the nucleopeptide structure, leaves <5% of the nucleopeptide on the resin. The purity of the crude nucleopeptide varies depending on the nucleopeptide size and composition. In the HPLC profiles shown in Figure 4.22.9, the main peak (expected product) accounts for ∼75% of the total area in the case of the tryptophan-containing nucleopeptide, and ∼60% in the arginine-containing one. MALDITOF-MS analysis of the crude sample allows confirmation that it contains the target product. Purification can usually be accomplished in a single run by either reversed-phase MPLC or HPLC on semipreparative C18 columns. Overall yields (nucleopeptide assembly, deprotection, and purification) will also vary depending on the homogeneity of the crude product and whether purification requires one or two steps. The arginine-containing nucleopeptide, for instance, is an example of a nucleopeptide of medium difficulty, and was obtained in 17% yield.
Time Considerations Anticipated Results If peptide elongation has proceeded satisfactorily, the expected peptide should be the
The preparation of nucleopeptides using these procedures may be a time-demanding task if trifunctional amino acid derivatives, as well as
Synthesis of Modified Oligonucleotides and Conjugates
4.22.51 Current Protocols in Nucleic Acid Chemistry
Supplement 16
the handle linking the hybrid molecule to the resin, have to be prepared. With all of the precursors, reagents, and solutions in hand, the synthesis and purification of a nucleopeptide containing ten amino acids and a 10-mer oligonucleotide can be accomplished in ∼3 weeks, depending, for instance, on the availability of techniques such as amino acid analysis to assess that correct yields have been obtained, or on whether peptide purity is checked before proceeding with oligonucleotide elongation. The time required to purify the target molecule may vary depending on the scale of synthesis and, obviously, the quality of the crude product. A tentative schedule would be the following: Week 1: Preparation of solid support, manual synthesis of peptide chain, and analysis of peptide-resin. Week 2: Oligonucleotide elongation, deprotection and cleavage, and analysis of the crude nucleopeptide to set up the purification conditions. Week 3: Purification of the nucleopeptide and full characterization of the product (amino acid analysis after acid hydrolysis or enzymatic digestion, determination of the relative proportion of nucleosides after enzymatic digestion, and mass spectrometric analysis).
Literature Cited Albericio, F., Cruz, M., Debéthune, L., Eritja, R., Giralt, E., Grandas, A., Marchán, V., Pastor, J.J., Pedroso, E., Rabanal, F., and Royo, M. 2001. An improved synthesis of N-[(9-hydroxymethyl)-2fluorenyl]succinamic acid (HMFS), a versatile handle for the solid-phase synthesis of biomolecules. Synthetic Commun. 31:225-232. Bardella, F., Giralt, E., and Pedroso, E. 1990. Polystyrene-supported synthesis by the phosphitetriester approach: An alternative for the large scale synthesis of small oligodeoxyribonucleotides. Tetrahedron Lett. 31:6231-6234.
Stepwise Solid-Phase Synthesis of Nucleopeptides
Chen, C.-P., Li, X.-X., Zhang, L.-R., Min, J.-M., Chan, J.Y.-W., Fung, K.-P., Wang, S.-Q., and Zhang, L.-H. 2002. Synthesis of antisense oligonucleotide-peptide conjugate targeting to GLUT-1 in HepG-2 and MCF-7 cells. Bioconjugate Chem. 13:525-529. Chen, C.-P., Zhang, L.,-R., Peng, Y,-F., Wang, X.,B., Wang, S.,-Q., and Zhang, L.H. 2003. A concise method for the preparation of peptide and arginine-rich peptide-conjugated antisense oligonucleotide. Bioconjugate Chem. 14:532-538. Christensen, T. 1979. A qualitative test for monitoring coupling completeness in solid phase peptide synthesis using chloranil. Acta Chem. Scand. B33:763-766. Civitello, E.R., Leniek, R.J., Hossler, K.A., Haebe, K., and Stearns, D.M. 2001. Synthesis of peptide-oligonucleotide conjugates for chromium coordination. Bioconjugate Chem. 12:459-463. Debéthune, L., Marchán, V., Fábregas, G., Pedroso, E., and Grandas, A. 2002a. Towards nucleopeptides containing any trifunctional amino acid (II). Tetrahedron 58:6965-6978. Debéthune, L., Kohlhagen, G., Grandas, A., and Pommier, Y. 2002b. Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. Nucl. Acids Res. 30:1198-1204. Dreef-Tromp, C.M., van der Maarel, J.C.M., van den Elst, H., van der Marel, G.A., and van Boom, J.H. 1992a. Solid-phase synthesis of the nucleopeptide fragment H-Asp-Ser[pAAAGTAAGCC]-Glu-OH from the nucleoprotein of Bacillus subtilis phage φ29. Nucl. Acids Res. 20:4015-4020. Drioli, S., Adamo, I., Ballico, M., Morvan, F., and Bonora, G.M. 2002. Liquid-phase synthesis and characterization of a conjugated chimeric oligonucleotide-PEG-peptide. Eur. J. Org. Chem. 3473-3480. Eritja, R., Robles, J., Fernández-Forner, D., Albericio, F., Giralt, E., and Pedroso, E. 1991. NPE-resin, a new approach to the solid-phase synthesis of protected peptides and oligonucleotides I: Synthesis of the supports and their application to oligonucleotide synthesis. Tetrahedron Lett. 32:1511-1514.
Basu, S., and Wickstrom, E. 1995. Solid phase synthesis of a D-peptide-phosphorothioate oligodeoxynucleotide conjugate from two arms of a polyethylene glycol-polystyrene support. Tetrahedron Lett. 36:4943-4946.
Flohr, S., Jungmann, V., and Waldmann, H. 1999. Chemoenzymatic synthesis of nucleopeptides. Chem. Eur. J. 5:669-681.
Beltrán, M., Maseda, M., Robles, J., Pedroso, E., and Grandas, A. 1997. Homoserine derivatives for the preparation of base-stable nucleopeptide analogues. Lett. Pept. Sci. 4:147-155.
Fujii, T. and Sakakibara, S. 1974. Studies on the synthesis of histidine peptides. I. NIm-Tosylhistidine derivatives as starting materials. Bull. Chem. Soc. Jpn. 47:3146-3151.
Beltrán, M., Pedroso, E., and Grandas, A. 1998. A comparison of histidine protecting groups in the synthesis of peptide-oligonucleotide conjugates. Tetrahedron Lett. 39:4115-4118.
Gairí, M., Lloyd-Williams, P., Albericio, A., and Giralt, E. 1990. Use of BOP reagent for the suppression of diketopiperazine formation in boc/bzl solid-phase peptide synthesis. Tetrahedron Lett. 31:7363-7366.
Bergmann, F. and Bannwarth, W. 1995. Solid phase synthesis of directly linked peptide-oligodeoxynucleotide hybrids using standard synthesis protocols. Tetrahedron Lett. 36:1839-1842.
Gait, M.J. 2003. Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell. Mol. Life Sci. 60:1-10.
4.22.52 Supplement 16
Current Protocols in Nucleic Acid Chemistry
García de la Torre, B., Albericio, F., SaisonBehmoaras, E., Bachi, A., and Eritja, R. 1999. Synthesis and binding properties of oligonucleotides carrying nuclear localization sequences. Bioconjugate Chem. 10:1005-1012.
Ollivier, N., Olivier, C., Gouyette, C., Huynh-Dinh, T., Gras-Masse, H., and Melnyk, O. 2002. Synthesis of oligonucleotide-peptide conjugates using hydrazone chemical ligation. Tetrahedron Lett. 43:997-999.
Gisin, B.F. and Merrifield, R.B. 1972. Carboxylcatalyzed intramolecular aminolysis side reaction in solid-phase peptide synthesis. J. Am. Chem. Soc. 94:3102-3106.
Robles, J., Pedroso, E., and Grandas, A. 1991. Solid phase synthesis of a model nucleopeptide with a phosphodiester bond between the 5′ end of a trinucleotide and a serine residue. Tetrahedron Lett. 32:4389-4392.
Gómez-Pinto, I., Marchán, V., Gago, F., Grandas, A., and González, C. 2003. Solution structure and stability of tryptophan-containing nucleopeptide duplexes. ChemBiochem. 4:40-49. Ho, W.C., Steinbeck, C., and Richert, C. 1999. Solution structure of the aminoacyl-capped oligodeoxyribonucleotide du plex (WTGCGCAC)2. Biochemistry 38:12597-12606. Jeyaraj, D.A., Prinz, H.R., and Waldmann, H.R. 2002. Synthesis of nucleopeptides by employing an enzyme-labile urethane protecting group. Chem. Eur. J. 8:1879-1887. Kachalova, A.V., Stetsenko, D.A., Romanova, E.A., Tashlitsky, V.N., Gait, M.J., and Oretskaya, T.S. 2002. A new and efficient method for the synthesis of 5′-conjugates of oligonucleotides through amide-bond formation in solid phase. Helv. Chim. Acta 85:2409-2416. Kaiser, E., Colescott, R.L., Bossinger, C.D., and Cook, P.I. 1970. Color test for detection of free amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 34:595-598. Kuyl-Yeheskiely, E., Tromp, C.M., Schaeffer, A.HR., van der Marel, G.A., and van Boom, J.H. 1987. A model study directed towards the preparation of nucleopeptides via H-phosphonate intermediates. Nucl. Acids Res. 15:1807-1818. Kuyl-Yeheskiely, E., Dreef-Tromp, C.M., Geluk, A., van der Marel, G.A., and van Boom, J.H. 1989. Synthesis of the nucleopeptide H-PheTyr(pGC)-NH2 and H-Phe-Ser(pGC)-Ala-OH via a phosphotriester approach. Nucl. Acids Res. 17:2897-2905. Marchán, V., Rodríguez-Tanty, C., Estrada, M., Pedroso, E., and Grandas, A. 2000. Alternative procedures for the synthesis of methionine-containing peptide-oligonucleotide hybrids. Eur. J. Org. Chem. 2495-2500. Marchán, V., Moreno, V., Pedroso, E., and Grandas, A. 2001. Towards a better understanding of the cisplatin mode of action. Chem. Eur. J. 7:808815. McMinn, D.L. and Greenberg, M.M. 1999. Convergent solution-phase synthesis of a nucleopeptide using a protected oligonucleotide. Bioorg. Med. Chem. Lett. 9:547-550. Montserrat, F.X., Grandas, A., Eritja, E., and Pedroso, E. 1994. Criteria for the economic large scale solid-phase synthesis of oligonucleotides. Tetrahedron 50:2617-2622.
Robles, J., Pedroso, E., and Grandas, A. 1995. Solidphase synthesis of a nucleopeptide from the linking site of adenovirus-2 nucleoprotein, -Ser(p5′CATCAT)-Gly-Asp-. Convergent versus stepwise strategy. Nucl. Acids Res. 23:4151-4161. Robles, J., Maseda, M., Beltrán, M., Cocernau, M., Pedroso, E., and Grandas, A. 1997. Synthesis and enzymatic stability of phosphodiester-linked peptide-oligonucleotide hybrids. Bioconjugate Chem. 8:785-788. Robles, J., Beltrán, M., Marchán, V., Pérez, Y., Travesset, I., Pedroso, E., and Grandas, A. 1999. Towards nucleopeptides containing any trifunctional amino acid. Tetrahedron 55:13251-13264. Sakakura, A. and Hayakawa, Y. 2000. A novel synthesis of oligonucleotide-peptide conjugates with a base-labile phosphate linker between the two components according to the allyl-protected phosphoramidite strategy. Tetrahedron 56:44274435. Sarracino, D.A., Steinberg, J.A., Vergo, M.T., Woodworth, G.F., Tetzlaff, C.N., and Richert, C. 1998. 5′-Peptidyl substituents allow a tuning of the affinity of oligodeoxyribonucleotides for RNA. Bioorg. Med. Chem. Lett. 8:2511-2516. Schattenkerk, C., Wreesmann, C.T.J., de Graaf, M.J., van der Marel, G.A., and van Boom, J.H. 1984. Synthesis of naturally occurring nucleopeptide fragment via a phosphotriester approach. Tetrahedron Lett. 25:5197-5200. Shabarova, Z.A. 1970. Synthetic nucleotide-peptides. In Progress in Nucleic Acid Research and Molecular Biology, Vol. 10 (J.N. Davidson and W.E. Colum, eds.) pp. 145-182. Academic Press, London. Stetsenko, D.A., Malakhov, A.D., and Gait, M.J. 2002. Total stepwise solid-phase synthesis of oligonucleotide-(3′→N)-peptide conjugates. Org. Lett. 2002:3259-3262. Tung, C.-H. and Stein, S. 2000. Preparation and applications of peptide-oligonucleotide conjugates. Bioconjugate Chem. 11:605-618. Ueno, Y., Saito, R., and Hata, T. 1993. Studies on the synthesis of nucleotidyl-peptides. II. The preparation of a nucleotidyl-peptide having a 5′-nucleotidyl-(P-O)-serine phosphodiester bond. Nucl. Acids Res. 21:4451-4457. Viladkar, S.M. 2002. Guanine rich oligonucleotideamino acid/peptide conjugates: Preparation and characterization. Tetrahedron 58:495-502. Waldmann, H. and Gabold, S. 1997. Chemoenzymatic synthesis of nucleopeptides. Chem. Commun. 1861-1862.
Synthesis of Modified Oligonucleotides and Conjugates
4.22.53 Current Protocols in Nucleic Acid Chemistry
Supplement 16
Zatsepin, T.S., Stetsenko, D.A., Arzumanov, A.A., Romanova, E.A., Gait, M.J., and Oretskaya, T.S. 2002. Synthesis of peptide-oligonucleotide conjugates with single and multiple peptides attached to 2′-aldehydes through thiazolidine, oxime, and hydrazine linkages. Bioconjugate Chem. 13:822-830. Zubin, E.M., Romanova, E.A., and Oretskaya, T.S. 2002. Modern methods for the synthesis of peptide-oligonucleotide conjugates. Russ. Chem. Rev. 71:239-264.
Key References Dreef-Tromp, C.M., van den Elst, HR., van den Boogaart, J.E., van der Marel, G.A., and van Boom, J.H. 1992b. Solid-phase synthesis of an RNA nucleopeptide fragment from the nucleoprotein of poliovirus. Nucl. Acids Res. 20:24352439.
Largest phosphodiester-linked peptide-oligoribonucleotide hybrid synthesized to date. Tung and Stein, 2000. See above. Review covering synthesis and applications of peptide-oligonucleotide conjugates.
Contributed by Anna Grandas, Vicente Marchán, Laurent Debéthune, and Enrique Pedroso Universitat de Barcelona Barcelona, Spain
The authors wish to acknowledge the contribution of Dr. Jordi Robles, who set up the basic nucleopeptide stepwise solid-phase synthesis methodology, in addition to the contributions of many other people over the years.
Stepwise Solid-Phase Synthesis of Nucleopeptides
4.22.54 Supplement 16
Current Protocols in Nucleic Acid Chemistry
Synthesis of Oligoribonucleotides Containing N6-Alkyladenosine and 2-Methylthio-N6-Alkyladenosine
UNIT 4.23
This unit describes synthesis of 5 -O-(4,4 -dimethoxytrityl)-2 -O-tert-butyldimethylsilyl3 -O-[(2-cyanoethoxy)-(N,N-diisopropylamino)]phosphinyl-6-methylthiopurine riboside (S.9, Fig. 4.23.1; see Basic Protocol 1) and 5 -O-(4,4 -dimethoxytrityl)-2 -Otert-butyldimethylsilyl-3 -O-[(2-cyanoethoxy)-(N,N-diisopropylamino)]phosphinyl-2methylthio-6-chloropurine riboside (S.18, Fig. 4.23.2; see Alternate Protocol). Both modified phosphoramidites and natural ribonucleoside phosphoramidites are used for the synthesis of precursor forms of oligoribonucleotides, which are then converted into oligoribonucleotides containing N6 -alkyladenosine and 2-methylthio-N6 -alkyladenosine by treatment with an appropriate primary amine (Kierzek and Kierzek, 2003a,b; see Basic Protocol 2).
SYNTHESIS OF THE 6-METHYLTHIOPURINE RIBOSIDE PHOSPHORAMIDITE
BASIC PROTOCOL 1
The synthesis of 5 -O-DMTr-2 -O-TBDMS-3 -O-(2-cyanoethyl-N,N-diisopropyl)-6methylthiopurine riboside phosphoramidite starts with complete conversion of inosine (S.1; Fig. 4.23.1) into 2 ,3 ,5 -tri-O-acetylinosine (S.2) by reaction with acetic anhydride in pyridine. S.2 is quantitatively transformed into 2 ,3 ,5 -tri-O-acetyl-6-thiopurine riboside (S.3) by treatment with Lawesson’s reagent for 1.5 hr at 100◦ C (Cava and Levinson, 1985; Kierzek and Kierzek, 2003a). This product is transformed into 2 ,3 ,5 -tri-O-acetyl6-methylthiopurine riboside (S.4) with methyl iodide in the presence of potassium carbonate in N,N-dimethylformamide (DMF) over 2 hr at 50◦ C in ∼81% yield (Wetzel and Eckstein, 1975). Acetyl groups are removed with ammonium hydroxide in pyridine, and the resulting 6-methylthiopurine riboside (S.5) is treated with 4,4 -dimethoxytrityl chloride (DMTr-Cl). After purification by short-column chromatography, the 5 -O-DMTr-6methylthiopurine riboside (S.6) is obtained in ∼74% yield (Smith et al., 1962). This product is reacted with tert-butyldimethylsilyl chloride (TBDMS-Cl) in pyridine in the presence of imidazole to give a mixture of 2 - (S.7), 3 - (S.8), and 2 ,3 -silylated derivatives, which after purification and subsequent 3 -O-TBDMS derivative isomerization gives 5 O-DMTr-2 -O-TBDMS-6-methylthiopurine riboside (S.7) in ∼66% yield (Ogilvie at al., 1978). The phosphoramidite S.9 is prepared by reaction of S.7 with 2-cyanoethyl diisopropylchlorophosphoramidite in anhydrous acetonitrile in the presence of diisopropylethylamine (Beaucage and Caruthers, 1981). The product is obtained in ∼85% yield after purification by short-column chromatography on silica gel.
Materials Inosine (S.1) Pyridine (reagent grade or better) Acetic anhydride Dichloromethane (anhydrous) Methanol (anhydrous) Saturated aqueous sodium bicarbonate solution Sodium sulfate (anhydrous) Toluene
Contributed by Elzbieta Kierzek and Ryszard Kierzek Current Protocols in Nucleic Acid Chemistry (2004) 4.23.1-4.23.21 C 2004 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Oligonucleotides and Conjugates
4.23.1 Supplement 17
Figure 4.23.1 Acetylation, thiolation, methylation, acetyl deprotection, dimethoxytritylation, silylation, and phosphinylation of purine riboside derivative. Abbreviations: Ac, acetyl; DMTr, 4,4 -dimethoxytrityl; i-Pr, isopropyl; TBDMS, tertbutyldimethylsilyl.
1,4-Dioxane (anhydrous) Lawesson’s reagent (Aldrich) N,N-Dimethylformamide (DMF; anhydrous) Potassium carbonate (anhydrous), ground Methyl iodide Celite 545 Silica gel 60H (Merck) Concentrated aqueous ammonium hydroxide (NH4 OH; 28% to 30%) 4,4 -Dimethoxytrityl chloride (DMTr-Cl) Imidazole tert-Butyldimethylsilyl chloride (TBDMS-Cl) Ethyl acetate Hexanes (anhydrous) 10% (w/v) aqueous sodium phosphate, monobasic (NaH2 PO4 ) Benzene (anhydrous) Dry ice/ethanol bath Acetonitrile (commercial with <20 ppm water or dried over 3Å molecular sieves) Diisopropylethylamine (DIPEA; anhydrous) 2-Cyanoethyl diisopropylchlorophosphoramidite Acetone Triethylamine (TEA; anhydrous) Oligoribonucleotides with N6 -Alkyladenosine
250- and 25-mL round-bottom flasks Silica gel 60F thin-layer chromatography (TLC) plates (Merck)
4.23.2 Supplement 17
Current Protocols in Nucleic Acid Chemistry
250-mL and 1-L separatory funnels Rotary evaporator Vacuum pump and water aspirator Reflux condenser 100◦ and 50◦ C oil baths (silicone oil) 60- and 150-mL sintered glass funnels Rubber septa Vacuum adaptor for 250-mL round-bottom flask and appropriate traps Vacuum desiccator 1-mL and 10-mL glass syringes with needles Silanized silica gel 60F TLC plates (Merck), optional Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (UNIT 2.4 & APPENDIX 3E) Acetylate inosine 1. Suspend 8.01 g (30 mmol) inosine (S.1) in 75 mL anhydrous pyridine in a 250-mL round-bottom flask and begin stirring. Add 9.90 mL (105 mmol) acetic anhydride and leave 16 hr at room temperature. 2. Analyze the reaction mixture by TLC (APPENDIX 3D) on silica gel 60F TLC plates using 9:1 (v/v) dichloromethane/methanol (S.2 Rf = 0.54). The TLC analysis is performed with a short-wave length UV lamp at 254 nm.
3. Pour the reaction mixture carefully into a 1-L separatory funnel containing 400 mL saturated aqueous sodium bicarbonate solution and extract three times with 200 mL dichloromethane. 4. Dry combined organic layers with ∼10 g anhydrous sodium sulfate and evaporate on a rotary evaporator with a water aspirator. Coevaporate residue three times with ∼50 mL toluene. Dry under vacuum pump. 2 ,3 ,5 -Tri-O-acetylinosine (S.2): 11.89 g (100%). TLC (dichloromethane/methanol 9:1 [v/v]): Rf = 0.54. UV (MeOH): λmax = 224, 256 nm; λmin = 228 nm. 1 H NMR (CDCl3 ): δ 2.10 (s, 3H, CH3 ), 2.15 (s, 3H, CH3 ), 2.16 (s, 3H, CH3 ), 4.41–4.47 (m, 3H, H4 , H5 , H5 ), 5.61 (t, J = 5.8 Hz, 1H, H3 ), 5.88 (t, J = 6.5 Hz, 1H, H2 ), 6.19 (d, J = 5.1 Hz, 1H, H1 ), 8.11 (s, 1H, H2), 8.31 (s, 1H, H8). 13 C NMR (CDCl3 ): δ 20.3, 20.5, 20.7 (C(O)CH3 ), 63.0 (C5 ), 70.5 (C3 ), 73.3 (C2 ), 80.4 (C4 ), 86.6 (C1 ), 125.1 (C5), 138.6 (C8), 145.8 (C4), 148.7 (C2), 158.7 (C6), 169.3, 169.5, 170.3 (C(O)CH3 ).
Thionylate inosine derivative 5. Dissolve 11.83 g (30 mmol) S.2 in 100 mL 1,4-dioxane in a 250-mL round-bottom flask and add 7.28 g (18 mmol) Lawesson’s reagent. Attach a reflux condenser and reflux the reaction mixture in an oil bath for 1.5 hr at 100◦ C. CAUTION: Reaction must be run in an efficiently working hood.
6. Periodically analyze the reaction mixture by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol (S.3 Rf = 0.64). 7. On the rotary evaporator with water aspirator, remove approximately half the volume of dioxane. 8. Add 10 mL methanol followed by 200 mL saturated aqueous sodium bicarbonate solution. Cooling the reaction mixture and evaporation of dioxane result in gel formation, but addition of methanol dissolves the reaction mixture, thus allowing easy workup.
Synthesis of Modified Oligonucleotides and Conjugates
4.23.3 Current Protocols in Nucleic Acid Chemistry
Supplement 17
9. Extract the reaction mixture three times with 150 mL dichloromethane. 10. Dry combined organic layers with ∼20 g anhydrous sodium sulfate and rotary evaporate to a solid foam. 2 ,3 ,5 -Tri-O-acetyl-6-thiopurine riboside (S.3): TLC (dichloromethane/methanol 9:1 [v/v]): Rf = 0.64. UV (MeOH): λmax = 233, 325 nm; λmin = 268 nm.
Methylate 6-thioinosine derivative 11. Coevaporate the reaction mixture with 50 mL DMF in a 250-mL round-bottom flask and dissolve the residue in 50 mL DMF. 12. Add 24.4 g (33 mmol) ground anhydrous potassium carbonate and 2.07 mL (33 mmol) methyl iodide. Heat the reaction mixture in the oil bath for 2 hr at 50◦ C with intensive stirring. Anhydrous potassium carbonate must be ground to a powder before addition to the reaction mixture.
13. Periodically analyze the reaction mixture by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol (S.4 Rf = 0.86). 14. Cool the reaction mixture to room temperature and filter off potassium carbonate by vacuum filtration through a Celite 545 cake on a 60-mL sintered glass funnel. Transfer the filtrate to a 1-L separatory funnel and add 150 mL saturated aqueous sodium bicarbonate solution. 15. Extract the reaction mixture three times with 150 mL dichloromethane. Dry combined organic layers with ∼20 g anhydrous sodium sulfate and rotary evaporate with water aspirator. 16. Purify the reaction mixture by short-column chromatography (UNIT 2.4 & APPENDIX 3E). Prepare the column (150-mL sintered glass funnel, ∼100 g silica gel 60H) in dichloromethane, and form the gradient by increasing the amount of methanol by 0.5% (v/v) for every 100 mL dichloromethane, up to 2.5% methanol. Analyze composition of the fractions (∼30 mL) on silica gel 60F TLC plates in 9:1 (v/v) dichloromethane/methanol. 17. Combine the fractions containing product (S.4) and rotary evaporate with water aspirator. 2 ,3 ,5 -Tri-O-acetyl-6-methylthiopurine riboside (S.4): 10.27 g (81% relative to S.2). TLC (dichloromethane/methanol 9:1 [v/v]): Rf = 0.86. UV (MeOH): λmax = 221, 284 nm; λmin = 241 nm. 1 H NMR (CDCl3 ): δ 2.09 (s, 3H, CH3 ), 2.13 (s, 3H, CH3 ), 2.16 (s, 3H, CH3 ), 2.75 (s, 3H, SCH3 ), 4.35–4.49 (m, 3H, H4 , H5 , H5 ), 5.67 (t, J = 5.6 Hz, 1H, H3 ), 5.96 (t, J = 5.4 Hz, 1H, H2 ), 6.22 (d, J = 5.4 Hz, 1H, H1 ), 8.15 (s, 1H, H2), 8.76 (s, 1H, H8).
Remove acetyl groups and perform dimethoxytritylation 18. To 10.27 g (24.19 mmol) S.4 in a 250-mL round-bottom flask, add 40 mL pyridine and 20 mL concentrated aqueous NH4 OH. Close the flask with a rubber septum and leave for 16 hr at room temperature.
Oligoribonucleotides with N6 -Alkyladenosine
19. Analyze reaction mixture by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol (S.5 Rf = 0.33). 20. Rotary evaporate the reaction mixture and coevaporate residue three times with anhydrous pyridine (∼50 mL each time).
4.23.4 Supplement 17
Current Protocols in Nucleic Acid Chemistry
21. Dissolve the oily residue in 125 mL anhydrous pyridine and add 8.99 g (26.61 mmol) DMTr-Cl. Stir the reaction mixture for 1 to 1.5 hr at room temperature. 22. Periodically analyze reaction mixture by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol (S.6 Rf = 0.40). If reaction is not complete after 1.5 hr, add 5% to 10% (w/w) DMTr-Cl, based on the initial amount added, and stir 1 hr. 23. Carefully add the reaction mixture to 250 mL saturated aqueous sodium bicarbonate solution in a 1-L separatory funnel. Extract three times with 200 mL dichloromethane. 24. Dry combined organic layers with ∼20 g anhydrous sodium sulfate and rotary evaporate with water aspirator. Coevaporate residue three times with 50 mL toluene. 25. Purify the reaction mixture by short-column chromatography. Prepare the column (150-mL sintered glass funnel, ∼100 g silica gel 60H) in dichloromethane and make the gradient by increasing the amount of methanol by 0.5% (v/v) for every 100 mL dichloromethane, up to 2% methanol. 26. Analyze composition of fractions (∼30 mL) by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol. Combine fractions containing product (S.6) and rotary evaporate with water aspirator to a solid foam. 5 -O-(4,4 -Dimethoxytrityl)-6-methylthiopurine riboside (S.6): 10.73 g (74%). TLC (dichloromethane/methanol 9:1 [v/v]): Rf = 0.40. FAB-MS: m/z = 601.5. UV (MeOH): λmax = 215, 226, 280 nm; λmin = 220, 256 nm. 1 H NMR (CDCl3 ): δ 2.64 (s, 3H, SCH3 ), 3.31–3.36 (m, 1H, H5 ), 3.43–3.48 (m, 1H, H5 ), 3.72 (s, 6H, OCH3 ), 4.37 (d, J = 3.8 Hz, 1H, H4 ), 4.46–4.49 (m, 1H, H3 ), 4.85 (t, J = 7.0 Hz, 1H, H2 ), 6.06 (d, J = 6.0 Hz, 1H, H1 ), 6.73 (d, J = 9.0 Hz, 4H, DMTr), 7.14–7.28 (m, 9H, DMTr), 8.20 (s, 1H, H2), 8.54 (s, 1H, H8). 13 C NMR (CDCl3 ): δ 11.8 (SCH3 ), 55.2 (OCH3 ), 63.5 (C5 ), 72.9 (C3 ), 76.1 (C2 ), 86.3 (C4 ), 91.1 (C1 ), 113.2 (DMTr), 126.9 (C5), 127.8, 128.0, 129.1, 129.9, 135.4, 135.5 (DMTr), 140.9 (C8), 144.2 (C4), 151.2 (C2), 158.6 (C6).
Silylate 2 -OH 27. To a 250-mL round-bottom flask, add 10.56 g (17.59 mmol) S.6 and coevaporate twice with 50 mL anhydrous pyridine using the water aspirator. Dissolve the residue in 80 mL anhydrous pyridine. 28. Add 3.14 g (45.73 mmol) imidazole and 3.45 g (22.87 mmol) TBDMS-Cl. Stir the reaction mixture 2 hr at room temperature. 29. Periodically analyze reaction mixture by TLC on silica gel 60F plates using 1:1 (v/v) ethyl acetate/hexanes. If reaction is not complete after 2 hr, add 5% to 10% (w/w) TBDMS-Cl and 10% to 20% (w/w) imidazole, based on the original amounts added, and stir 1 hr. One should be able to observe the disappearance of substrate (S.6 Rf = 0.07) and appearance of the silylated derivatives. The reaction mixture contains the 2 -silylated isomer (S.7 Rf = 0.77) and 3 -silylated isomer (S.8 Rf = 0.58), as well as the 2 ,3 -disilylated derivative (Rf = 0.95).
30. Carefully add the reaction mixture to 250 mL saturated aqueous sodium bicarbonate solution in a 1-L separatory funnel and extract three times with 200 mL dichloromethane. 31. Extract combined organic layers twice with 200 mL of 10% aqueous NaH2 PO4 . During extraction with aqueous monobasic sodium phosphate, the reaction mixture forms an emulsion with relative ease. Vigorous shaking of the mixture should be avoided.
Synthesis of Modified Oligonucleotides and Conjugates
4.23.5 Current Protocols in Nucleic Acid Chemistry
Supplement 17
32. Dry combined organic layers with ∼10 g anhydrous sodium sulfate and rotary evaporate. Coevaporate residue three times with ∼50 mL toluene. 33. Purify the reaction mixture by short-column chromatography. Prepare the column (150-mL sintered glass funnel, ∼100 g silica gel 60H) in dichloromethane and make the gradient by increasing the amount of methanol by 0.25% (v/v) for every 200 mL dichloromethane, up to 0.5% methanol. This column chromatography is used to separate the mixture of 2 -silylated and 3 -silylated isomers (which run together) from the 2 ,3 -disilylated derivative and other impurities.
34. Analyze the composition of the fractions (∼30 mL) by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol. Collect only the fractions containing 2 and 3 -silylated isomers (Rf = 0.61), and rotary evaporate to a solid foam. Dispose of fractions carrying 2 ,3 -disilylated derivative (Rf = 0.81). 35. To purify the mixture of 2 - and 3 -silylated isomers, prepare a column (150-mL sintered glass funnel, ∼100 g silica gel 60H) in toluene and make the gradient by increasing the amount of ethyl acetate by 0.5% (v/v) for every 100 mL toluene, up to 4% ethyl acetate. 36. Analyze composition of the fractions (∼30 mL) by TLC on silica gel 60F plates using 1:1 (v/v) ethyl acetate/hexanes. Collect separate fractions for pure 2 -isomer, mixed fractions containing mostly the 2 -isomer, and mixed fractions containing mostly the 3 -isomer. 37. Add ∼100 mL methanol to the fraction containing mostly 3 -isomer and leave at room temperature for ∼2 days. Isomerization of tert-butyldimethylsilyl groups usually takes ∼2 days and gives similar amounts of 2 - and 3 -isomers.
38. Rotary evaporate methanol with water aspirator and combine the residue with the mixed fractions containing mostly 2 -isomer. Purify this mixture as described in steps 35 and 36. If the synthesis is run on a large scale, a second isomerization of the fraction containing mostly 3 -isomer should be carried out, and the purification should be repeated.
39. Combine the fractions containing pure product, rotary evaporate, and coevaporate three times with ∼30 mL benzene in a 250-mL round-bottom flask. Dissolve in ∼10 mL benzene per 1 g product. 40. To lyophilize the product, freeze benzene solution in a dry ice/ethanol bath, rotating the flask in such a way that the freezing liquid evenly covers most of the surface of the round-bottom flask. Connect flask with a vacuum adaptor to a vacuum line and apply vacuum for 10 to 16 hr. Be sure that vacuum traps are large enough to condense all benzene and that solid benzene will not clog the vacuum line. Lyophilized product is very stable and can be stored safely for many years at 4◦ C.
Oligoribonucleotides with N6 -Alkyladenosine
5 -O-(4,4 -Dimethoxytrityl)-2 -O-tert-butyldimethylsilyl-6-methylthiopurine riboside (S.7): 8.29 g (66%). TLC (ethyl acetate/hexanes 1:1 [v/v]): Rf = 0.77. 1 H NMR (CDCl3 ): δ −0.20 (s, 3H, SiCH3 ), −0.04 (s, 3H, SiCH3 ), 0.76 (s, 9H, t-butyl), 2.67 (s, 3H, SCH3 ), 3.30–3.36 (m, 1H, H5 ), 3.43–3.48 (m, 1H, H5 ), 3.73 (s, 6H, OCH3 ), 4.37 (d, J = 3.5 Hz, 1H, H4 ), 4.45–4.50 (m, 1H, H3 ), 4.85 (t, J = 6.1 Hz, 1H, H2 ), 6.06 (d, J = 5.4 Hz, 1H, H1 ), 6.73 (d, J = 9.0 Hz, 4H, DMTr), 7.14–7.28 (m, 9H, DMTr), 8.20 (s, 1H, H2), 8.54 (s, 1H, H8). 13 C NMR (CDCl3 ): δ −5.2, −5.0 (SiCH3 ), 11.7 (SCH3 ), 17.8 (C(CH3 )), 25.5 (C(CH3 )3 ), 55.2 (OCH3 ), 63.4 (C5 ), 71.6 (C3 ), 75.6 (C2 ), 84.2 (C4 ), 88.2 (C1 ), 113.2 (DMTr), 126.9 (C5), 127.9, 128.1, 129.1, 130.0, 131.8, 135.6 (DMTr), 140.3 (C8), 144.5 (C4), 152.0 (C2), 158.5 (C6).
4.23.6 Supplement 17
Current Protocols in Nucleic Acid Chemistry
Convert to phosphoramidite 41. Place 1.10 g (1.54 mmol) S.7 in a 25-mL round-bottom flask closed with rubber septum equipped with a ventilation needle. Dry overnight under vacuum in a desiccator. 42. With 1- and 10-mL glass syringes and needles, add the following:
7.5 mL anhydrous acetonitrile (<20 ppm water) 0.40 mL (2.31 mmol) DIPEA 0.44 g (1.85 mmol, 0.41 mL) 2-cyanoethyl diisopropylchlorophosphoramidite. Stir reaction mixture 1 hr at room temperature. Because of its high viscosity, the phosphine should be added through the rubber septum into the flask as it sits on a balance to accurately measure the amount added by weight. This is especially important for small-scale syntheses.
43. Analyze reaction mixture by TLC on silica gel 60F plates using 45:45:10 (v/v/v) acetone/hexanes/TEA (S.9 Rf = 0.73) or on silanized silica gel 60F TLC plates using 7:3 (v/v) acetone/water (Rf = 0.28). If reaction is not complete after 1 hr, add 10% to 20% (w/w) DIPEA followed by 5% to 10% (w/w) 2-cyanoethyl diisopropylchlorophosphoramidite, based on the original amounts added, and stir 30 min. Silica gel TLC plates should be saturated with 45:45:10 (v/v/v) acetone/hexanes/TEA and dried before spotting the reaction mixture.
44. Add the reaction mixture to 50 mL saturated aqueous sodium bicarbonate in a 250-mL separatory funnel and extract three times with 50 mL dichloromethane containing 1% (v/v) TEA. 45. Dry combined organic layers with ∼5 g anhydrous sodium sulfate and rotary evaporate with water aspirator to a foam. 46. Purify the reaction mixture by short-column chromatography. Prepare the column (60-mL sintered glass funnel, ∼30 g silica gel 60H) in 90:10:1 (v/v/v) hexanes/ethyl acetate/TEA and make the gradient by increasing the amount of ethyl acetate by 5% (v/v) for every 100 mL mixture, up to 30% ethyl acetate. Keep amount of triethylamine constant (1%) during the entire purification. 47. Analyze composition of the fractions (∼20 mL) by TLC on silica gel 60F plates in 45:45:10 (v/v/v) acetone/hexanes/TEA. Collect separate fractions containing the phosphoramidite (S.9) and evaporate. 48. Lyophilize the product as described in steps 39 and 40. Lyophilized product is very stable and can be stored safely for at least 2 years at −20◦ C. 5 -O-(4,4 -Dimethoxytrityl)-2 -O-tert-butyldimethylsilyl-3 -O-[(2-cyanoethoxy)-(N,Ndiisopropylamino)]phosphinyl-6-methylthiopurine riboside (S.9): 1.20 g (85%). TLC (acetone/hexanes/triethylamine 45:45:10 [v/v/v]): Rf = 0.73; on silanized plates (acetone/water 7:3 [v/v]): Rf = 0.28. FAB-MS: m/z = 915.2. 1 H NMR (CDCl3 ): δ −0.22 (d, 3H, SiCH3 ), −0.04 (d, 3H, SiCH3 ), 0.75 (s, 9H, t-butyl), 1.04–1.21 (m, 12H, 2i-Pr), 2.73 (s, 3H, SCH3 ), 3.28–3.35 (m, 1H, H5 ), 3.49–3.66 (m, 5H, H5 , CH2 CH2 ), 3.78 (s, 6H, OCH3 ), 3.85–4.00 (m, 2H, 2CH), 4.34–4.44 (m, 2H, H4 , H3 ), 5.08 (t, J = 5.6 Hz, 1H, H2 ), 6.01 (d, J = 6.0 Hz, 0.5H, H1 ), 6.07 (d, J = 6.0 Hz, 0.5H, H1 ), 6.79–6.83 (m, 4H, DMTr), 7.21–7.48 (m, 9H, DMTr), 8.17 (s, 0.5H, H2), 8.20 (s, 0.5H, H2), 8.60 (s, 0.5H, H8), 8.62 (s, 0.5H, H8). 13 C NMR (CDCl3 ): δ −5.2, −4.7 (Si(CH3 )), 11.7 (SCH3 ), 17.9 (C(CH3 )), 20.0, 20.4, 24.6, (NC(CH3 )2 ), 25.6 (C(CH3 )3 ), 42.9, 43.5 (NC(CH3 )2 ), 55.2 (OCH3 ), 57.6, 58.8 (CH2 CH2 O-), 63.3 (C5 ), 72.7 (C3 ), 73.4, 74.5 (CH2 CH2 O-), 75.2 (C2 ), 83.9 (C4 ), 88.1 (C1 ), 113.2 (DMTr), 117.4 (CN), 126.9 (C5), 127.9, 128.1, 129.1, 130.0, 131.9, 135.6 (DMTr), 140.6 (C8), 144.5 (C4), 151.9 (C2), 158.5 (C6). 31 P NMR (CDCl3 ): δ 149.4, 150.8.
Synthesis of Modified Oligonucleotides and Conjugates
4.23.7 Current Protocols in Nucleic Acid Chemistry
Supplement 17
Figure 4.23.2 Acetylation, chlorination, introduction of methylthio group, acetyl deprotection, dimethoxytritylation, silylation, and phosphinylation of purine riboside derivative. Abbreviations: Ac, acetyl; DMAP, 4-dimethylaminopyridine; DMF, N,N-dimethylformamide; DMTr, 4,4 -dimethoxytrityl; Et, ethyl; i-Pr, isopropyl; TBDMS, tert-butyldimethylsilyl.
ALTERNATE PROTOCOL
Oligoribonucleotides with N6 -Alkyladenosine
SYNTHESIS OF THE 2-METHYLTHIO-6-CHLOROPURINE RIBOSIDE PHOSPHORAMIDITE Guanosine (S.10; Fig. 4.23.2) is O-peracetylated with acetic anhydride in acetonitrile (Matsuda, 1986) and the resulting 2 ,3 ,5 -tri-O-acetylguanosine (S.11) is converted to 2 ,3 ,5 -tri-O-acetyl-2-amino-6-chloropurine riboside (S.12) by phosphorus oxychloride treatment (Robins and Uzna˜nski, 1981). The 2-amino group of S.12 is transformed into 2-methylthio with dimethyl disulfide and isoamyl nitrite in acetonitrile using a 45-min treatment at 45◦ C (Nair and Fasbender, 1993). After column purification, 2 ,3 ,5 -tri-Oacetyl-2-methylthio-6-chloropurine riboside (S.13) is obtained in ∼53% yield. Acetyl groups are removed with triethylamine (TEA) in methanol. The product, 2-methylthio6-chloropurine riboside (S.14) is treated with 4,4 -dimethoxytrityl chloride (DMTr-Cl) in pyridine for 2 hr at room temperature. After column chromatography, 5 -O-DMTr-2methylthio-6-chloropurine riboside (S.15) is obtained in ∼75% yield (Smith et al., 1962). The reaction of S.15 with tert-butyldimethylsilyl chloride (TBDMS-Cl) gives a mixture of 2 - and 3 -isomers (S.16 and S.17; Ogilvie et al., 1978). The 2 -O-TBDMS isomer (S.16) is separated (∼57% yield) and treated with 2-cyanoethyl diisopropylchlorophosphoramidite in anhydrous acetonitrile in the presence of diisopropylethylamine. After purification by silica gel column chromatography, the phosphoramidite S.18 is obtained in ∼84% yield (Beaucage and Caruthers, 1981).
4.23.8 Supplement 17
Current Protocols in Nucleic Acid Chemistry
Additional Materials (also see Basic Protocol 1) Guanosine (S.10; anhydrous) 4-Dimethylaminopyridine (DMAP) Phosphorus oxychloride (POCl3 ), freshly distilled N,N-Dimethylaniline Dimethyl disulfide Isoamyl nitrite 500-mL and 1-L round-bottom flasks 140◦ and 60◦ C oil baths (silicone oil) 250-µL and 5-mL glass syringes with needles Acetylate guanosine 1. Add 8.49 g (30 mmol) anhydrous guanosine (S.10) and 0.64 g (2.25 mmol) DMAP to 375 mL anhydrous acetonitrile in a 1-L round-bottom flask and begin stirring. It is important to use anhydrous guanosine and not the hydrated form.
2. Add 16.7 mL (118 mmol) TEA and 10.2 mL (108 mmol) acetic anhydride and stir 30 min at room temperature. After a few minutes, solid guanosine dissolves.
3. Analyze reaction mixture by TLC (APPENDIX 3D) on a silica gel 60F TLC plate using 9:1 (v/v) dichloromethane/methanol (S.11 Rf = 0.31). The TLC analysis is performed with a short-wavelength UV lamp at 254 nm.
4. Concentrate to ∼50 mL on a rotary evaporator equipped with a water aspirator. 5. Add the reaction mixture carefully to 400 mL saturated aqueous sodium bicarbonate solution in a 1-L separatory funnel and extract three times with 150 mL dichloromethane. 6. Dry combined organic layers with ∼10 g anhydrous sodium sulfate and rotary evaporate. 2 ,3 ,5 -Tri-O-acetylguanosine (S.11): TLC (dichloromethane/methanol 9:1 [v/v]): Rf = 0.31.
Introduce 6-chloro group 7. To dried residue of S.11 (30 mmol) in a 500-mL round-bottom flask, add 82.5 mL (900 mmol) freshly distilled POCl3 and 5.24 mL (36 mmol) N,N-dimethylaniline. Close flask with a reflux condenser and place in a 140◦ C oil bath. Continue heating until 4 min from the moment it starts to reflux. CAUTION: Phosphorous oxychloride can be dangerous and should be handled carefully. It is recommended to run the reaction first on a small scale.
8. Cool flask in a wet ice bath (∼10 min). 9. Remove excess phosphorous oxychloride on the rotary evaporator. It is important to clean the rotary evaporator very well with dichloromethane before and after evaporation of phosphorus oxychloride.
10. Add 200 mL dichloromethane to the residue and transfer to a 1-L separatory funnel. 11. Wash four to six times with 500 mL water to remove most of the hydrochloric acid (until pH is ∼4). For the final wash, use 500 mL saturated aqueous sodium bicarbonate.
Synthesis of Modified Oligonucleotides and Conjugates
4.23.9 Current Protocols in Nucleic Acid Chemistry
Supplement 17
12. Dry the combined organic layers with ∼30 g anhydrous sodium sulfate and rotary evaporate with water aspirator. 13. Purify the reaction mixture by short-column chromatography (UNIT 2.4 & APPENDIX 3E). Prepare the column (150-mL sintered glass funnel; ∼100 g silica gel 60H) in dichloromethane and wash with dichloromethane only. 14. Analyze composition of the fractions (∼20 mL) by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol (S.12 Rf = 0.71). 15. Pool fractions containing product and rotary evaporate. 2 ,3 ,5 -Tri-O-acetyl-2-amino-6-chloropurine riboside (S.12): 9.49 g (74% relative to S.10). TLC (dichloromethane/methanol 9:1 [v/v]): Rf = 0.71. UV (MeOH): λmax = 224, 247, 310 nm; λmin = 234, 268 nm. 1 H NMR (CDCl3 ): δ 2.05 (s, 3H, CH3 ), 2.07 (s, 3H, CH3 ), 2.11 (s, 3H, CH3 ), 4.31–4.49 (m, 3H, H4 , H5 , H5 ), 5.71 (t, J = 5.6 Hz, 1H, H3 ), 5.93 (t, J = 5.6 Hz, 1H, H2 ), 5.98 (d, J = 4.8 Hz, 1H, H1 ), 7.86 (s, 1H, H8). 13 C NMR (CDCl3 ): δ 20.3, 20.4, 20.6 (C(O)CH3 ), 62.6 (C5 ), 70.1 (C3 ), 72.9 (C2 ), 80.0 (C4 ), 87.0 (C1 ), 120.3 (C5), 142.2 (C8), 151.1 (C4), 151.9 (C6), 167.3 (C2), 169.2, 169.4, 170.2 (C(O)CH3 ).
Introduce 2-methylthio group 16. In a 500-mL round-bottom flask, dissolve 7.23 g (16.9 mmol) S.12 in 140 mL anhydrous acetonitrile. 17. Add 15.2 mL (169 mmol) dimethyl disulfide and 4.53 mL (33.8 mmol) isoamyl nitrite. Heat the reaction mixture in a 60◦ C oil bath under refluxing condenser for 45 min. CAUTION: The reaction must be run in a well-ventilated fume hood.
18. Periodically analyze the reaction mixture by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol (S.13 Rf = 0.64) or on silanized silica gel 60F TLC plates in 7:3 (v/v) acetone/water (Rf = 0.70). 19. Concentrate to ∼30 mL on the rotary evaporator with water aspirator. Add the reaction mixture to 300 mL saturated aqueous sodium bicarbonate in a 1-L separatory funnel and extract three times with 100 mL dichloromethane. 20. Dry combined organic layers with ∼30 g anhydrous sodium sulfate and rotary evaporate. 21. Purify the reaction mixture by short-column chromatography. Prepare the column (150-mL sintered glass funnel; ∼100 g silica gel 60H) in dichloromethane and make the gradient by increasing the amount of methanol by 0.25% (v/v) for every 100 mL mixture, up to 2% methanol. 22. Analyze the composition of the fractions (∼30 mL) by TLC on silica gel plates using 9:1 (v/v) dichloromethane/methanol. 23. Collect fractions containing product (S.13) and rotary evaporate with water aspirator.
Oligoribonucleotides with N6 -Alkyladenosine
2 ,3 ,5 -Tri-O-acetyl-2-methylthio-6-chloropurine riboside (S.13): 4.13 g (53%). TLC (dichloromethane/methanol 9:1[v/v]): Rf = 0.64; on silanized TLC plates (acetone/water 7:3 [v/v]): Rf = 0.70. UV (MeOH): λmax = 233, 263, 306 nm; λmin = 248, 281 nm. 1 H NMR (CDCl3 ): δ 2.10 (s, 3H, CH3 ), 2.11 (s, 3H, CH3 ), 2.15 (s, 3H, CH3 ), 2.65 (s, 3H, SCH3 ), 4.29–4.48 (m, 3H, H4 , H5 , H5 ), 5.65 (t, J = 5.8 Hz, 1H, H3 ), 5.99 (t, J = 5.0 Hz, 1H, H2 ), 6.12 (d, J = 4.5 Hz, 1H, H1 ), 8.10 (s, 1H, H8). 13 C NMR (CDCl3 ): δ 14.8 (SCH3 ), 20.3, 20.4, 20.6 (C(O)CH3 ), 62.7 (C5 ), 70.1 (C3 ), 72.9 (C2 ), 80.0 (C4 ), 87.0 (C1 ), 120.3 (C5), 142.1 (C8), 151.2 (C4), 151.9 (C6), 167.3 (C2), 169.2, 169.4, 170.2 (C(O)CH3 ).
4.23.10 Supplement 17
Current Protocols in Nucleic Acid Chemistry
Remove acetyl groups and perform dimethoxytritylation 24. To 7.96 g (17.34 mmol) S.13 in 250-mL round-bottom flask, add 140 mL of 9:1 (v/v) methanol/TEA and leave for ∼48 hr at room temperature. 25. Periodically analyze reaction mixture by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol (S.14 Rf = 0.17). 26. When the deprotection of acetyl groups is completed, evaporate reaction mixture on the rotary evaporator and coevaporate the residue three times with ∼30 mL anhydrous pyridine. 27. Dissolve the residue in 75 mL anhydrous pyridine and add 6.45 g (19.07 mmol) DMTr-Cl. Stir reaction mixture for 1 to 1.5 hr at room temperature. 28. Periodically analyze reaction mixture by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol (S.15 Rf = 0.59). If reaction is not complete after 1.5 hr, add 5% to 10% (w/w) DMTr-Cl, based on initial amount added, and stir 1 hr. 29. Add the reaction mixture to 350 mL saturated aqueous sodium bicarbonate solution in a 1-L separatory funnel. Extract three times with 250 mL dichloromethane. 30. Dry combined organic layers with ∼30 g anhydrous sodium sulfate and rotary evaporate with water aspirator. Coevaporate the residue three times with ∼50 mL toluene. 31. Purify the reaction mixture by short-column chromatography. Prepare the column (150-mL sintered glass funnel; ∼100 g silica gel 60H) in dichloromethane and make the gradient by increasing the amount of methanol by 0.25% (v/v) for every 100 mL dichloromethane, up to 3% methanol. 32. Analyze composition of the fractions (∼30 mL) by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol. Combine the fractions containing product (S.15) and rotary evaporate to a solid foam. 5 -O-(4,4 -Dimethoxytrityl)-2-methylthio-6-chloropurine riboside (S.15): 8.26 g (75%). TLC (dichloromethane/methanol 9:1 [v/v]): Rf = 0.59. FAB-MS: m/z = 635.3. 1 H NMR (CDCl3 ): δ 2.49 (s, 3H, SCH3 ), 3.37–3.40 (m, 2H, H5 , H5 ), 3.74 (s, 6H, OCH3 ), 4.34 (q, J = 3.2 Hz, 1H, H4 ), 4.46–4.49 (m, 1H, H3 ), 4.85 (t, J = 5.9 Hz, 1H, H2 ), 6.01 (d, J = 5.4 Hz, 1H, H1 ), 6.74 (d, J = 9.0 Hz, 4H, DMTr), 7.17–7.24 (m, 9H, DMTr), 8.14 (s, 1H, H8). 13 C NMR (CDCl3 ): δ 14.8 (SCH3 ), 55.2 (OCH3 ), 63.5 (C5 ), 72.4 (C3 ), 75.6 (C2 ), 81.4 (C4 ), 86.8 (C1 ), 113.2 (DMTr), 127.1 (C5), 127.8, 129.1, 129.9, 135.3, 139.5 (DMTr), 142.4 (C8), 144.1 (C4), 147.3 (C6), 158.6 (C2).
Silylate 2 -OH 33. To a 250-mL round-bottom flask, add 5.44 g (8.57 mmol) S.15 and coevaporate with 30 mL anhydrous DMF. 34. Add 70 mL anhydrous DMF followed by 1.50 g (21.44 mmol) imidazole and 1.54 g (10.28 mmol) TBDMS-Cl. Stir the reaction mixture 5 hr at room temperature. 35. Periodically analyze reaction mixture by TLC on silica gel 60F plates using 4:6 (v/v) ethyl acetate/hexanes. If reaction is not complete after 5 hr, add 5% to 10% (w/w) TBDMS-Cl and 10% to 20% (w/w) imidazole, based on the original amounts added, and stir 2 hr. Silylated derivatives should appear in the reaction mixture. After reaction is complete, the mixture is composed of the 2 -silylated isomer (S.16 Rf = 0.70), the 3 -silylated isomer (S.17 Rf = 0.45), and the 2 ,3 -disilylated derivative (Rf = 0.86).
36. Add the reaction mixture to 250 mL saturated aqueous sodium bicarbonate solution in a 1-L separatory funnel and extract three times with 100 mL dichloromethane.
Synthesis of Modified Oligonucleotides and Conjugates
4.23.11 Current Protocols in Nucleic Acid Chemistry
Supplement 17
37. Extract combined organic layers twice with 100 mL of 10% aqueous NaH2 PO4 . During extraction with aqueous monobasic sodium phosphate, the reaction mixture forms an emulsion with relative ease. Vigorous shaking of the mixture should be avoided.
38. Dry combined organic layers with ∼20 g anhydrous sodium sulfate and rotary evaporate with water aspirator. Coevaporate residue three times with 30 mL toluene. 39. Purify the reaction mixture by short-column chromatography. Prepare the column (60-mL sintered glass funnel; ∼30 g silica gel 60H) in dichloromethane and elute products with dichloromethane. This column chromatography separates 2 -silylated and 3 -silylated isomers (which run together) from the 2 ,3 -disilylated derivative and other impurities.
40. Analyze composition of the fractions (∼20 mL) by TLC on silica gel 60F plates using 9:1 (v/v) dichloromethane/methanol. Collect only the fractions containing 2 and 3 -silylated isomers (Rf = 0.59), and rotary evaporate to a solid foam. Dispose of fractions carrying 2 ,3 -disilylated derivative (Rf = 0.82). 41. Purify the mixture of 2 - and 3 -silylated isomers again. Prepare the chromatography column (60-mL sintered glass funnel; ∼30 g silica gel 60H) in toluene and make the gradient by increasing the amount of ethyl acetate by 0.5% (v/v) for every 100 mL toluene, up to 5% ethyl acetate. 42. Analyze composition of the fractions (∼30 mL) by TLC on silica gel plates using 4:6 (v/v) ethyl acetate/hexanes. Collect separate fractions for pure 2 -isomer, mixed fractions containing mostly 2 -isomer, and mixed fractions containing mostly 3 isomer. 43. Add ∼70 mL methanol to the fraction containing mostly 3 -isomer and leave at room temperature for ∼2 days. Isomerization usually takes ∼2 days and gives equimolar amounts of 2 - and 3 -isomers.
44. Evaporate methanol and combine the residue with the mixed fractions containing mostly 2 -isomer. Purify this mixture as described in steps 41 and 42. If the synthesis is run on a large scale, a second isomerization of the fraction containing mostly 3 -isomer should be carried out, and the purification should be repeated.
45. Combine the fractions containing product, rotary evaporate, and coevaporate three times with ∼30 mL benzene in a 250-mL round-bottom flask. Dissolve in ∼10 mL benzene per 1 g product. 46. To lyophilize the product, freeze benzene solution in a dry ice/ethanol bath, rotating the flask in such a way that the freezing liquid evenly covers most of the surface of the round-bottom flask. Connect flask with a vacuum adaptor to a vacuum line and apply vacuum for 10 to 16 hr. Be sure that vacuum traps are large enough to condense all benzene and that solid benzene will not clog the vacuum line. Lyophilized product is very stable and can be stored safely for many years at 4◦ C.
Oligoribonucleotides with N6 -Alkyladenosine
5 -O-(4,4 -Dimethoxytrityl)-2 -O-tert-butyldimethylsilyl-2-methylthio-6-chloropurine riboside (S.16): 3.66 g (57%). TLC (ethyl acetate/hexanes 4:6 [v/v]): Rf = 0.70. 1 H NMR (CDCl3 ): δ −0.15 (s, 3H, SiCH3 ), 0.12 (s, 3H, SiCH3 ), 0.85 (s, 9H, t-butyl), 2.55 (s, 3H, SCH3 ), 3.41–3.52 (m, 2H, H5 , H5 ), 3.79 (s, 6H, OCH3 ), 4.27 (q, J = 3.5 Hz, 1H, H4 ), 4.37 (q, J = 4.2 Hz, 1H, H3 ), 4.85 (t, J = 7.2 Hz, 1H, H2 ), 6.08 (d, J = 5.4 Hz, 1H, H1 ), 6.80 (d, J = 9.0 Hz, 4H, DMTr), 7.22–7.43 (m, 9H, DMTr), 8.20 (s, 1H, H8). 13 C NMR (CDCl3 ): δ −5.1, −4.9 (Si(CH3 )), 14.7 (SCH3 ), 17.9 (C(CH3 )), 25.5 (C(CH3 )3 ), 55.2 (OCH3 ), 63.4 (C5 ), 71.6 (C3 ), 75.3 (C2 ), 84.3 (C4 ), 88.1 (C1 ), 113.3 (DMTr), 127.1 (C5), 127.97, 128.02, 130.0, 135.3, 135.4 (DMTr), 142.1 (C8), 150.9 (C4), 158.6 (C6), 166.9 (C2).
4.23.12 Supplement 17
Current Protocols in Nucleic Acid Chemistry
Convert to phosphoramidite 47. Place 0.51 g (0.68 mmol) S.16 in a 25-mL round-bottom flask closed with rubber septum equipped with a ventilation needle. Dry overnight under vacuum in a desiccator. 48. With 250-µL and 5-mL glass syringes and needles, add the following:
4.0 mL anhydrous acetonitrile (<20 ppm water) 0.18 mL (1.02 mmol) DIPEA 0.19 g (0.82 mmol, 0.18 mL) 2-cyanoethyl diisopropylchlorophosphoramidite. Stir reaction mixture 1 hr at room temperature. Because of its high viscosity, the phosphine should be added through the rubber septum into the flask as it sits on a balance to accurately measure the amount added by weight. This is especially important for small-scale syntheses.
49. Analyze reaction mixture by TLC on silica gel 60F plates using 45:45:10 (v/v/v) acetone/hexanes/TEA (S.18 Rf = 0.72) or on silanized 60F plates using 8:2 (v/v) acetone/water (Rf = 0.32). If reaction is not complete after 1 hr, add 10% to 20% (w/w) DIPEA followed by 5% to 10% (w/w) 2-cyanoethyl diisopropylchlorophosphoramidite, based on original amounts added, and stir for 0.5 hr. Silica gel TLC plates should be saturated with 45:45:10 (v/v/v) acetone/hexanes/TEA and dried before spotting the reaction mixture. For silanized plates for this derivative, 8:2 (v/v) acetone/water is preferred.
50. Add the reaction mixture to 50 mL saturated aqueous sodium bicarbonate solution in a 250-mL separatory funnel and extract three times with 50 mL dichloromethane containing 1% (v/v) TEA. 51. Dry combined organic layers with ∼5 g anhydrous sodium sulfate and rotary evaporate. 52. Purify the reaction mixture by short-column chromatography. Prepare the column (60-mL sintered glass funnel; ∼30 g silica gel 60H) in 90:10:1 (v/v/v) hexanes/ethyl acetate/TEA and make the gradient by increasing the amount of ethyl acetate by 5% (v/v) for every 100 mL mixture, up to 30% ethyl acetate. Keep the amount of TEA constant (1%) during the entire purification. 53. Analyze composition of the fractions by TLC on silica gel 60F plates in 45:45:10 (v/v/v) acetone/hexanes/TEA. Collect fractions containing phosphoramidite (S.18) and rotary evaporate. 54. Lyophilize the product as described in steps 45 and 46. Lyophilized product is very stable and can be stored safely for at least 2 years at −20◦ C. 5 -O-(4,4 -Dimethoxytrityl)-2 -O-tert-butyldimethylsilyl-3 -O-[(2-cyanoethoxy)-(N,Ndiisopropylamino)]phosphinyl-2-methylthio-6-chloropurine riboside (S.18): 0.54 g (84%). TLC (acetone/hexanes/triethylamine 45:45:10 [v/v/v]): Rf = 0.72; on silanized TLC plates (acetone/water = 8:2 [v/v]): Rf = 0.32. FAB-MS: m/z = 949.6. 1 H NMR (CDCl3 ): δ −0.20 (s, 3H, SiCH3 ), −0.04 (s, 3H, SiCH3 ), 0.78 (s, 9H, t-butyl), 1.16–1.22 (m, 12H, 2i-Pr), 2.55 (s, 3H, SCH3 ), 3.33–3.40 (m, 1H, H5 ), 3.45–3.50 (m, 1H, H5 ), 3.58–3.70 (m, 4H, -CH2 CH2 -), 3.78 (s, 3H, OCH3 ), 3.79 (s, 3H, OCH3 ), 3.84–4.02 (m, 2H, 2CH), 4.33–4.41 (m, 2H, H4 , H3 ), 4.87–4.91 (m, 1H, H2 ), 6.08 (d, J = 6.0 Hz, 0.5H, H1 ), 6.11 (d, J = 6.0 Hz, 0.5H, H1 ), 6.80–6.84 (m, 4H, DMTr), 7.22–7.45 (m, 9H, DMTr), 8.22 (s, 1H, H8). 13 C NMR (CDCl3 ): δ −5.1, −4.7 (Si(CH3 )), 14.6 (SCH3 ), 17.9 (C(CH3 )), 20.37, 20.45, 24.6 (NC(CH3 )2 ), 25.5 (C(CH3 )3 ), 42.9, 43.5 (NC(CH3 )2 ), 55.2 (OCH3 ), 57.5, 58.7 (CH2 CH2 O-), 63.4 (C5 ), 72.8 (C3 ), 73.6, 75.3 (CH2 CH2 O-), 76.1 (C2 ), 83.9 (C4 ), 87.7 (C1 ), 113.3 (DMTr), 117.4 (CN), 127.1 (C5), 128.0, 128.1, 130.0, 135.2, 135.5 (DMTr), 142.2 (C8), 150.8 (C4), 158.7 (C6), 166.7 (C2). 31 P NMR (CDCl3 ): δ 149.7, 150.7.
Synthesis of Modified Oligonucleotides and Conjugates
4.23.13 Current Protocols in Nucleic Acid Chemistry
Supplement 17
BASIC PROTOCOL 2
SYNTHESIS OF OLIGORIBONUCLEOTIDES CONTAINING N6 -ALKYLADENOSINE OR 2-METHYLTHIO-N6 -ALKYLADENOSINE The procedure starts with chemical synthesis of a precursor oligoribonucleotide carrying the 6-methylthiopurine riboside (S.19; Fig. 4.23.3) or 2-methylthio-6-chloropurine riboside (S.23; Fig. 4.23.4), which is then postsynthetically converted into N6 -alkyladenosine (S.22) or 2-methylthio-N6 -alkyladenosine (S.24), respectively. The synthesis was performed on an Applied Biosystems 392 synthesizer but could be done on any commercially available synthesizer (see APPENDIX 3C for additional details on automated synthesis). Commercially available 5 -O-DMTr-2 -O-TBDMS-3 -O-[(2-cyanoethoxy)(N,N-diisopropylamino)]phosphinyl derivatives of uridine and N-protected cytidine, adenosine, and guanosine are used in addition to the modified precursor phosphoramidite S.9 or S.18. In both cases, the coupling yield of modified phosphoramidite based on the trityl assay (APPENDIX 3C) is comparable to that of standard commercial 2 -O-silylated phosphoramidites. When the synthesis is completed (with DMTr-OFF), the solid support carrying the precursor oligoribonucleotide S.19 is oxidized with a 20 mM solution of magnesium monoperoxyphtalate in 9:1 (v/v) dioxane/water for 2.5 hr at room temperature to give a mixture of sulfoxide (S.20) and sulfone (S.21) derivatives of the precursor oligoribonucleotide. Under these conditions, oxidation of the thiomethyl group does
Oligoribonucleotides with N6 -Alkyladenosine
Figure 4.23.3 Oxidation and aminolysis of precursor oligoribonucleotide carrying 6methylthiopurine riboside to give the modified oligoribonucleotide containing N6 -alkyladenosine. Abbreviations: DMTr, 4,4 -dimethoxytrityl; i-Pr, isopropyl; R, alkyl chain of primary amine; TBDMS, tert-butyldimethylsilyl.
4.23.14 Supplement 17
Current Protocols in Nucleic Acid Chemistry
Figure 4.23.4 Aminolysis of precursor oligoribonucleotide carrying 2-methylthio-6-chloropurine riboside to give the modified oligoribonucleotide containing 2-methylthio-N6 -alkyladenosine. Abbreviations: DMTr, 4,4 -dimethoxytrityl; i-Pr, isopropyl; R, alkyl chain of primary amine; TBDMS, tert-butyldimethylsilyl.
not cause any side reactions (e.g., modification of native nucleobases). The support is washed with 9:1 (v/v) dioxane/water followed by acetonitrile and is then dried. The oxidation procedure is not required for the solid support carrying the precursor oligoribonucleotide S.23. Next, the solid support (with S.20/S.21 or S.23) is treated with the appropriate primary amine in acetonitrile. After amine treatment, the samples are evaporated, and a mixture of 3:1 (v/v) aqueous ammonia/ethanol is used (8 hr at 55◦ C) to deprotect and cleave the modified oligomer from the support. The support is filtered off and the solution dried down. The residue is coevaporated with anhydrous pyridine and treated with 1 M triethylammonium fluoride in pyridine for 48 hr at 55◦ C. The reaction mixture is evaporated and desalted on a Sep-Pak cartridge, and modified oligonucleotides are purified by TLC (APPENDIX 3D), high-performance liquid chromatography (HPLC; UNIT 10.5), or polyacrylamide gel electrophoresis (PAGE; UNIT 10.4).
Materials Commercial phosphoramidites: 5 -O-(4,4 -dimethoxytrityl)-2 -O-tertbutyldimethylsilyl-3 -O-[(2-cyanoethoxy)-(N,N-diisopropylamino)]phosphinyl uridine and N-protected cytidine, adenosine, and guanosine Modified phosphoramidite: 5 -O-(4,4 -dimethoxytrityl)-2 -O-tertbutyldimethylsilyl-3 -O-[(2-cyanoethoxy)-(N,N-diisopropyl)]phosphinyl-6methylthiopurine riboside (S.9; see Basic Protocol 1) or -2-thiomethyl-6-chloropurine riboside (S.18; see Alternate Protocol) Acetonitrile, anhydrous Magnesium monoperoxyphthalate hexahydrate (for oligomers containing S.9)
Synthesis of Modified Oligonucleotides and Conjugates
4.23.15 Current Protocols in Nucleic Acid Chemistry
Supplement 17
Dioxane (for oligomers containing S.9) Primary amine: e.g., isopentenylamine hydrochloride and triethylamine (TEA; for i6 A or ms2 i6 A) or methylamine (for m6 A or ms2 m6 A) Pyridine (reagent grade or better) 2 M methylamine in tetrahydrofuran (for m6 A or ms2 m6 A) Concentrated aqueous ammonia (28% to 32%) Ethanol 1 M triethylammonium fluoride in pyridine (or other desilylating agent) 10 mM ammonium acetate Automated oligonucleotide synthesizer (Applied Biosystems 392) 1.5- and 5-mL screw-top tubes 15-mL sintered glass funnels Water aspirator 55◦ C water bath Speedvac evaporator (Savant) Spin filters Sep-Pak cartridges (Waters) 10-mL disposable syringes Additional reagents and equipment for automated oligoribonucleotide synthesis (APPENDIX 3C) Synthesize desired oligoribonucleotide 1. Synthesize precursor oligoribonucleotide (S.19 or S.23) on a 1-µmol scale in DMTrOFF mode on an automated oligonucleotide synthesizer using the protocol provided by the manufacturer (also see APPENDIX 3C). Use phosphoramidites (commercial and modified) at 0.1 M in anhydrous acetonitrile. To achieve a 0.1 M solution of modified phosphoramidite, dissolve 0.25 g S.9 in 2.73 mL acetonitrile or 0.25 g S.18 in 2.64 mL acetonitrile. Oxidize thiomethyl group (for S.19 only) 2. Transfer the oligoribonucleotide-support from the synthesis column to a 1.5-mL screw-top microcentrifuge tube. 3. Dissolve 98.8 mg (0.2 mmol) magnesium monoperoxyphthalate hexahydrate in 10 mL of 9:1 (v/v) dioxane/water. Add 1 mL of this solution to the solid support and leave for 2.5 hr at room temperature with occasional shaking. 4. Filter off the oxidizing solution using 15-mL sintered glass funnel. 5. Wash the solid support three times with 5 mL of 9:1 (v/v) dioxane/water and three times with 5 mL anhydrous acetonitrile. Dry support with a water aspirator.
Treat with primary amine 6. Transfer oligoribonucleotide-support (mixture of S.20 and S.21 from step 5 or S.23 from step 1) to a 5-mL screw-top tube.
Oligoribonucleotides with N6 -Alkyladenosine
a. For general procedure, add 0.45 mL anhydrous acetonitrile and 0.05 mL of the appropriate primary amine. Seal tube tightly and leave for 12 hr at room temperature with shaking. b. For N6 -isopentenyladenosine or 2-methylthio-N6 -isopentenyladenosine (S.22 or S.24; R = isopentenyl), use 25 mg (0.21 mmol) isopentenylamine hydrochloride in 0.45 mL anhydrous pyridine and 0.05 mL (0.42 mmol) TEA, and incubate 12 hr at 55◦ C with shaking for S.22 or 2 to 5 hr at 55◦ C for S.24.
4.23.16 Supplement 17
Current Protocols in Nucleic Acid Chemistry
c. For N6 -methyladenosine or 2-methylthio-N6 -methyladenosine (S.22 or S.24; R = methyl) use 0.5 mL of 2 M methylamine in tetrahydrofuran and incubate 12 hr at 55◦ C with shaking for S.22 or 2 to 5 hr at 55◦ C for S.24. To convert precursor oligoribonucleotides into oligomers containing N6 neopentylyladenosine, N6 -(1-methylpropyl)adenosine, N6 -(1-methylbutyl)adenosine, N6 isopentyladenosine, N6 -propargyladenosine, and 2-methylthio-N6 -isopentyladenosine, the following primary amines are used: neopentylamine (2,2-dimethylpropylamine), 1-methylpropylamine (sec-butylamine), 1-methylbutylamine, isoamylamine (3methylbutylamine), propargylamine, and isoamylamine (3-methylbutylamine), respectively. When synthesizing these or any other modified adenosines, conversion yields will be affected by the choice and concentration of the primary amine used, as well as the temperature and time of the substitution reaction. When S.19 is used, the oxidative activation of the SCH3 is also critically important (Kierzek and Kierzek, 2003a).
7. Cool the reaction mixture at −20◦ C for 5 min, carefully open the sealed screw-top tube, and evaporate to dryness in a Speedvac evaporator.
Deprotect and cleave oligomer from support 8. Add 0.8 mL of 3:1 (v/v) concentrated aqueous ammonia/ethanol and leave tightly sealed for 8 hr at 55◦ C. 9. Cool at −20◦ C for 5 min and filter off the solid support using a spin filter. Wash the support twice with 1 mL water. 10. Transfer combined filtrates to a 5-mL screw-top tube and evaporate to dryness in the Speedvac evaporator.
Desilylate oligomer 11. Coevaporate the residue with 0.5 mL anhydrous pyridine in the Speedvac evaporator. 12. Add 0.5 mL of 1 M triethylammonium fluoride in pyridine, close tightly, and leave for 48 hr at 55◦ C. Removal of tert-butyldimethylsilyl groups can also be performed with tetra-nbutylammonium fluoride or triethylamine trihydrofluoride according to standard procedures.
13. Evaporate pyridine in the Speedvac evaporator.
Desalt product 14. Connect a Sep-Pak cartridge to the end of a 10-mL disposable syringe. Use the syringe to pass 10 mL acetonitrile followed by 10 mL of 10 mM ammonium acetate through the cartridge. The reaction mixture can also be desalted with a Sephadex G-10 or G-25 column (Amersham Biosciences).
15. Dissolve the oligonucleotide residue in 10 mL of 10 mM ammonium acetate and load on the cartridge. Wash column with 10 mL of 10 mM ammonium acetate. 16. Elute crude mixture of modified oligoribonucleotide with 5 mL of 3:7 (v/v) acetonitrile/water and evaporate with the Speedvac evaporator. 17. Purify the modified oligoribonucleotide using any standard method, such as TLC (APPENDIX 3D), HPLC (UNIT 10.5), or PAGE (UNIT 10.4). After purification, from a 1-µmol-scale synthesis, ∼10 to 30 OD260 units of modified oligoribonucleotide containing N6 -alkyladenosine (S.22) or 2-methylthio-N6 -alkyladenosine (S.24) are obtained (Table 4.23.1).
Synthesis of Modified Oligonucleotides and Conjugates
4.23.17 Current Protocols in Nucleic Acid Chemistry
Supplement 17
Table 4.23.1 Retention Times, Synthesis Yields, and Spectrometric Mass Analysis of Oligoribonucleotides Obtained by Postsynthetic Modification
N6 -Alkyladenosine (A = R6 A) R6
Retention time (min)a
Yield (%)b
Massc
2-Methylthio-N6 -alkyladenosine (A = ms2 R6 A) Retention time (min)a
UACAUGUA H Methyl Neopentyl 1-Methylpropyl 1-Methylbutyl Isopentyl Isopentenyl Propargyl
24.0 24.2 33.8 30.4 34.3 34.6 33.0 25.8
64 40 47 42 61 52 41 40
24.0 24.5 32.6 29.1 33.2 33.2 31.4 25.2
64 47 51 72 71 45 56 64
2494.99 2508.93 2564.93 2550.90 2564.95 2564.78 2563.75 2532.64
26.9 30.0
49 35
2540.91 2554.79
44.7
24
2608.97
UACAUGUA 2494.99 2508.92 2564.87 2550.88 2565.01 2564.94 2562.92 2532.98
25.3 27.9
48 64
2541.02 2555.04
44.7
41
2608.93
UACAUGUA H Methyl Neopentyl 1-Methylpropyl 1-Methylbutyl Isopentyl Isopentenyl Propargyl
24.0 25.2 35.1 31.6 35.9 36.3 34.3 26.7
64 51 58 77 51 51 25 49
UACAUGUA 2494.99 2508.61 2564.90 2551.05 2564.84 2564.78 2563.30 2532.81
27.2 31.0
27 54
2541.01 2555.00
48.8
65
2608.57
ACAUGUA H Methyl Neopentyl 1-Methylpropyl 1-Methylbutyl Isopentyl Isopentenyl Propargyl Oligoribonucleotides with N6 -Alkyladenosine
26.0 27.1 38.5 34.6 39.2 39.7 38.0 26.0
74 49 69 75 91 55 65 42
Massc
UACAUGUA
UACAUGUA H Methyl Neopentyl 1-Methylpropyl 1-Methylbutyl Isopentyl Isopentenyl Propargyl
Yield (%)b
ACAUGUA 2188.35 2202.32 2258.49 2244.46 2258.52 2258.47 2256.11 2226.46
26.3 31.1
35 53
2234.65 2249.03
53.6
20
2302.92
continued
4.23.18 Supplement 17
Current Protocols in Nucleic Acid Chemistry
Table 4.23.1 Retention Times, Synthesis Yields, and Spectrometric Mass Analysis of Oligoribonucleotides Obtained by Postsynthetic Modification, continued
N6 -Alkyladenosine (A = R6 A) R6
Retention time (min)a
Yield (%)b
Massc
2-Methylthio-N6 -alkyladenosine (A = ms2 R6 A) Retention time (min)a
Yield (%)b
Massc
CCGGUCmUCCAAAACCGG H Methyl
29.9 32.9
16 24
5445.18 5459.53
a HPLC: Supelco RP C18; eluent A = 100 mM triethylammonium acetate; eluent B = 1:1 (v/v) acetonitrile/A; gradient
= 1% B/min. b Overall yield refers to precursor oligomer synthesis, postsynthetic modification, and deprotection and is based on C18
HPLC analysis. c Molecular weights measured by atmospheric pressure ionization–electrospray liquid chromatography/mass spectroscopy
(API-ES LC-MS) in the negative ionization mode.
COMMENTARY Background Information There are 96 different natural modifications of nucleotides occurring in all types of RNA (Limbach et al., 1994; Bjork, 1995). Transfer RNAs are particularly rich in modified nucleotides, with 80 different modified nucleotides known. The modifications are mostly present in single-stranded regions of tRNA such as hairpin and multibranch loops. Positions 34 and 37 of the anticodon arm are particularly highly modified. The functions of modified nucleotides are not clearly defined, but it is known that they affect structure and biological activities of RNA, influence the secondary and tertiary interactions of tRNA, change hydrogen bond and stacking interactions as well as puckering of ribose residues, and influence binding of divalent cations (Persson, 1993; Grosjean et al., 1998). Among 19 modifications of adenosine, 15 have either a substitution on the N6 -exocyclic amine group or a 2-methylthio group with a substitution on the N6 -exocyclic amine group at the same time. Examples include N6 threonylcarbamoyladenosine (t6 A), N6 -isopentenyladenosine (i6 A), N6 -methyladenosine (m6 A), 2-methylthio-N6 -isopentenyladenosine (ms2 i6 A), and 2-methylthio-N6 methyladenosine (ms2 m6 A). Because these residues are present at position 37 of the tRNA anticodon loop, studies of their biological function and of their influence on RNA structure are most important. The syntheses of oligoribonucleotides containing the last four modifications are performed by the methods described in this unit.
Studies of modified RNA activities are significantly limited by access to modified oligoribonucleotides. In the literature, syntheses of RNA carrying simple modifications are well described. Introduction of nucleosides bearing complex modifications is still challenging, however. In 1978, Wiewi´orowski and co-workers described the first chemical synthesis of an anticodon loop heptamer containing t6 A (Adamiak et al., 1978). Recently, several chemical syntheses of anticodon loops and arms containing t6 A were published (Sochacka, 1999; Boudou et al., 2000; Stuart et al., 2000; Sundaram et al., 2000). The most important improvement in the synthesis of oligoribonucleotides containing N6 -alkyladenosines and 2-methylthioN6 -alkyladenosines is the application of a postsynthetic approach to introducing the modification, which is the approach described in this unit. This allows very simple simultaneous synthesis of several modified oligoribonucleotides from only one precursor oligoribonucleotide. The first crucial element of this approach is selection and development of the efficient synthesis of the modified phosphoramidites S.9 and S.18. The second crucial element is setting conditions for postsynthetic modification of the precursor form of the oligoribonucleotides to obtain a very high yield of modification and at the same time keep elements of the oligoribonucleotides intact during the entire modification process. The longest modified oligoribonucleotides that have been obtained by the described
Synthesis of Modified Oligonucleotides and Conjugates
4.23.19 Current Protocols in Nucleic Acid Chemistry
Supplement 17
postsynthetic modification of precursor oligonucleotides are octadecamers, which correspond to the length of the anticodon arm of tRNA. Because of the high yield of transformation of the precursor oligonucleotides, however, the final length of the modified oligoribonucleotides should be limited only by the general reliability of chemical RNA synthesis and purification methods. This high yield also should allow the introduction of several N6 -alkyladenosines and/or 2-methylthio-N6 -alkyladenosines into an oligoribonucleotide, if the N6 -alkyl substituent is the same.
cubation time is used for the precursor oligoribonucleotides (2.5 hr at room temperature) because of the heterogeneous conditions of oxidation and because no side products of oxidation have been observed. During modification of the precursor form of the oligoribonucleotide, some problems may arise with transformation into N6 isopentenyladenosine and 2-methylthio-N6 isopentenyladenosine oligonucleotides (S.22 and S.24, respectively; R = isopentenyl). This is due to the low solubility of isopentenylamine hydrochloride in acetonitrile or even in pyridine. This makes the deprotection process inconvenient. This salt is removed using a SepPak cartridge before purification, however.
Critical Parameters
Oligoribonucleotides with N6 -Alkyladenosine
The synthesis of modified phosphoramidites and transformation of precursor oligoribonucleotides into oligonucleotides containing N6 -alkyladenosine and 2methylthio-N6 -alkyladenosine do not present significant difficulties. Some prior experience in the chemistry of nucleosides and oligonucleotides is nonetheless very useful. It is important to be very careful during synthesis of 2 ,3 ,5 -tri-O-acetyl-2-amino6-chloropurine riboside (S.12) because the reaction, particularly when performed on a large scale, uses several hundred milliliters of phosphorus oxychloride that has to be refluxed at 140◦ C for a short period of time only. It is best to perform this reaction first on a small scale for practice. In the next reaction, during synthesis of 2 ,3 ,5 -tri-O-acetyl-2-methylthio-6chloropurine riboside (S.13), 10% to 20% 2 ,3 ,5 ,N2 -tetraacetyl-6-chloropurine riboside is also formed, and this side product must be separated by short-column chromatography. It is also very important to carefully separate the 2 - and 3 -O-TBDMS isomers during synthesis of 5 -O-DMTr-2 -O-TBDMS ribosides S.7 and S.16. A first prepurification column allows for a relatively easy separation of both isomers during the second silica gel column purification. The oxidation of the 6-methylthio group with magnesium monoperoxyphthalate in Basic Protocol 2 must be complete, because only the oxidation products (6-methylsulfone and 6-methylsulfoxide derivatives) can be converted into N6 -alkylated adenosine derivatives by treatment with the appropriate amine. Experiments carried out by the authors with protected 6-methylthiopurine riboside in this oxidation solution demonstrate that the oxidation of the 6-methylthio group was completed within 1 hr at room temperature. A longer in-
Anticipated Results Synthesis of precursor phosphoramidites is not trivial but can be achieved by someone with basic experience in organic chemistry. The yield of particular steps of the synthesis ranges between 50% and 100%. Some reactions have high yield and no side products, which allows subsequent reaction without any purification of the intermediate. Precursor oligoribonucleotides are synthesized on an Applied Biosystems 392 synthesizer using a standard procedure of RNA synthesis. On the basis of HPLC analysis of the crude reaction mixture, the transformation of precursor oligoribonucleotide into oligoribonucleotide containing N6 -alkyladenosine or 2-methylthio-N6 -alkyladenosine proceeds with an 80% to 90% yield. The efficiency of transformation is dependent on structure (mostly a steric hindrance effect of the alkyl chain) and nucleophilicity of the primary amine. The modified oligoribonucleotides are purified from the entire crude reaction mixture by TLC or HPLC with a 20% to 60% overall yield (Table 4.23.1).
Time Considerations Synthesis of modified phosphoramidites (S.9 and S.18) takes ∼2 to 3 weeks for each precursor. The transformation of precursor oligoribonucleotides (S.19 and S.23) and purification of modified oligoribonucleotides (S.22 and S.24) requires ∼1 week.
Literature Cited Adamiak, R.W., Biala, E., Grzeskowiak, K., Kierzek, R., Kraszewski, A., Markiewicz, W.T., Okupniak, J., Stawinski, J., and Wiewi´orowski, M. 1978. The chemical synthesis of the anticodon loop of an eukaryotic initiator tRNA containing the hypermodified nucleoside N6 -/
4.23.20 Supplement 17
Current Protocols in Nucleic Acid Chemistry
N-threonylcarbamoyl/-adenosine/t6 A/1 . Acids Res. 5:1889-1905.
Nucl.
Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites—a new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862. Bj¨ork, G.R. 1995. tRNA: Structure, biosynthesis and function. In Biosynthesis and Function of Modified Nucleosides (D. S¨oll and U. RajBhandary, eds.) pp. 165-206. American Society for Microbiology Press, Washington, D.C. Boudou, V., Langridge, J., Van Aerchot, A., Hendrix, C., Millar, A., Weiss, P., and Herdewijn, P. 2000. Synthesis of the anticodon hairpin tRNAf Met containing N-{[9-(β-Dribofuranosyl)-9H-purin-6-yl]carbamoyl}L-threonine. Helv. Chim. Acta 83:152-161. Cava, M.P. and Levinson, M.J. 1985. Thionation reactions of Lawesson reagents. Tetrahedron 41:5061-5087. Grosjean, H., Houssier, C., Romby, P., and Marquet, R. 1998. Modulatory role of modified nucleotides in RNA loop-loop interaction. In Modification and Editing of RNA (H. Grosjean and R. Benne, eds.) pp. 113-133. American Society of Microbiology Press, Washington, D.C. Kierzek, E. and Kierzek, R. 2003a. The synthesis of oligoribonucleotides containing N6 -alkyladenosines and 2-methylthio-N6 alkyladenosines via post-synthetic modifications of precursor oligomers. Nucl. Acids Res. 31:4461-4471. Kierzek, E. and Kierzek, R. 2003b. The thermodynamic stability of RNA duplexes and hairpins containing N6 -alkyladenosines and 2-methylthio-N6 -alkyladenosines. Nucl. Acids Res. 31:4472-4480. Limbach, P.A., Crain, P.F., and McClosky, J.A. 1994. Summary: The modified nucleosides of RNA. Nucl. Acids Res. 22:2183-2196. Matsuda, A. 1986. A convenient method for the selective acylation of guanine nucleosides. Synthesis 5:385-386. Nair, V. and Fasbender, A.J. 1993. C-2 functionalized N6-cyclosubstituted adenosines—highly selective agonists for the adenosine-a1-receptor. Tetrahedron 49:2169-2184.
Ogilvie, K.K., Beaucage, S.L., Schifman, A.L., Theriault, N.Y., and Sadana, K.L. 1978. The synthesis of oligoribonucleotides. II. The use of silyl protecting groups in nucleoside and nucleotide chemistry. VIII. Can. J. Chem. 56:27682780. Persson, B.C. 1993. Modification of tRNA as a regulatory device. Mol. Microbiol. 8:1011-1016. Robins, M.J. and Uzna˜nski, B. 1981. Nucleic-acid related compounds. 33. Conversions of adenosine and guanosine to 2,6-dichloro, 2-amino-6chloro, and derived purine nucleosides. Can. J. Chem. 59:2601-2607. Smith, M., Rammler, D.H., Goldberg, I.H., and Khorana, H.G. 1962. Studies on polynucleotides. XVI. Specific synthesis of the C3-C5 internucleotide linkage. Synthesis of uridyl-(3 5 )-uridine and uridyl-(3 -5 )-adenosine. J. Am. Chem. Soc. 84:430-440. Sochacka, E. 1998. The chemical synthesis of E.coli tRNALys anticodon loop fragment and its analogues. Nucleosides Nucleotides 17:327338. Stuart, J.W., Gdaniec, Z., Guenther, R., Marszalek, M., Sochacka, E., Malkiewicz, A., and Agris, P.F. 2000. Functional anticodon architecture of human tRNALys3 includes disruption of intraloop hydrogen bonding by the naturally occurring amino acid modification, t6 A. Biochemistry 39:13396-13404. Sundaram, M., Crain, P.F., and Davis, D.R. 2000. Synthesis and characterization of the native anticodon domain of E. coli. Simultaneous incorporation of modified nucleosides mnm5 s2 U, t6 A, and pseudouridine using phosphoramidite chemistry. J. Org. Chem. 65:5609-5614. Wetzel, R. and Eckstein, F. 1975. Synthesis and reactions of 6-methylsulfonyl-9-β-Dribofuranosylpurine. J. Org. Chem. 40:658660.
Contributed by Elzbieta Kierzek and Ryszard Kierzek Institute of Bioorganic Chemistry, Polish Academy of Sciences Poznan, Poland
Synthesis of Modified Oligonucleotides and Conjugates
4.23.21 Current Protocols in Nucleic Acid Chemistry
Supplement 17
Oligodeoxyribonucleotide Analogs Functionalized with Phosphonoacetate and Thiophosphonoacetate Diesters
UNIT 4.24
Phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides are analogs wherein the phosphodiester backbone is replaced with phosphonoacetate or thiophosphonoacetate internucleotide linkages (Fig. 4.24.1). The reactive N,N(diisopropylamino)phosphinyl acetate monomers are convenient to prepare from standard protected nucleosides and give high-yield synthesis of oligodeoxyribonucleotides on solid supports. Phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides are highly stable to nucleases. They are water-soluble and anionic at neutral pH (pKa values of 3.8 and 3.9). They hybridize with complementary DNA or RNA to yield duplexes having stabilities comparable to those achieved with phosphorothioate DNA. Both analogs stimulate RNase H degradation of complementary RNA. Chimeric oligomers end-capped with phosphonoacetate or thiophosphonoacetate internucleotide linkages have been shown to be more active than natural DNA at stimulating RNase H in vitro.
Figure 4.24.1 Structures of phosphonoacetate, thiophosphonoacetate, phosphodiester, and phosphorothioate internucleotide linkages. B: thymin-1-yl, cytosin-1-yl, adenin-9-yl, or guanin-9-yl.
Contributed by Douglas J. Dellinger, Christina M. Yamada, and Marvin H. Caruthers Current Protocols in Nucleic Acid Chemistry (2004) 4.24.1-4.24.26 C 2004 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Oligonucleotides and Conjugates
4.24.1 Supplement 18
Figure 4.24.2
Synthesis of 1,1-dimethyl-2-cyanoethyl [bis(N,N-diisopropylamino)phosphinyl]acetate.
DMTrO
O OH
B
DMTrO
O
3 1H -tetrazole
4a B = thymin-1-yl b = 4-N -acetylcytosin-1-yl c = 6-N -benzoyladenin-9-yl d = 2-N -isobutyrylguanin-9-yl
B
O
O P
CH2
C
i -Pr2N
CH3 O
C
CH2CN
CH3 5a-d
Figure 4.24.3 Preparation of protected 2 -deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetates. DMTr, 4,4 dimethoxytrityl.
Modified oligodeoxyribonucleotides containing thiophosphonoacetate linkages with stable, intact esters are readily taken up by cells in the absence of cationic lipids. This unit describes the solid-phase synthesis and purification of modified oligodeoxyribonucleotides (ODNs) having phosphonoacetate (PACE) and thiophosphonoacetate (S-PACE) internucleotide linkages (Dellinger et al., 2003). The first protocol outlines the preparation of appropriate synthons (Figs. 4.24.2 and 4.24.3; see Basic Protocol 1). The next two protocols illustrate the synthesis of PACE or S-PACE modified DNA (Fig. 4.24.4; see Basic Protocol 2) and chimeric oligomers (Sheehan et al., 2003) having either of these analogs combined with natural or phosphorothioate internucleotide linkages (Fig. 4.24.5; see Basic Protocol 3). The final protocols describe the drying of monomers (see Support Protocol) in addition to the purification and characterization of ODNs (see Basic Protocol 4). CAUTION: All reactions should be carried out in a well-ventilated fume hood and contact with chemicals should be avoided. It is essential that reagents, solvents, and synthons be used under anhydrous conditions in order to maximize yield and success in preparing these oligomers. To avoid incompatibilities, a solvent-resistant Teflon head pump capable of 34 liter/min and a maximum vacuum of 1.5 torr is used for all solvent removals performed on a rotary evaporator. All intermediates and products are stored in desiccators at −20◦ C, which are allowed to warm to room temperature before they are opened. BASIC PROTOCOL 1 Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
SYNTHESIS OF PROTECTED 2 -DEOXYNUCLEOSIDE3 -O-(N,N-DIISOPROPYLAMINO)PHOSPHINYL ACETATES Generating protected 2 -deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetates requires three steps: (1) preparation of 1,1-dimethylcyanoethyl bromoacetate (S.2; Fig. 4.24.2), (2) condensation of S.2 with bis(diisopropylamino)chlorophosphine to yield the phosphinylating reagent 1,1-dimethyl-2-cyanoethyl [bis(N,Ndiisopropylamino)phosphinyl]acetate (S.3), and (3) synthesis and purification of
4.24.2 Supplement 18
Current Protocols in Nucleic Acid Chemistry
protected 2 -deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetates (S.5; Fig. 4.24.3). The first step is the synthesis of an appropriately protected bromoacetate. The 1,1dimethyl-2-cyanoethyl ester is recommended, and is prepared from 3-hydroxy-3methylbutyronitrile and bromoacetyl bromide. However, the reaction conditions for generating this reagent are quite general. Any number of alcohols can be used with these protocols to produce the corresponding esters. The second step is synthesis of 1,1-dimethyl-2-cyanoethyl [bis(N,N-diisopropylamino)phosphinyl]acetate. This phosphinylating reagent is prepared by a Reformatsky reaction (Bayless and Hauser, 1954) using the zinc bromide derivative of an ester-protected acetic acid and bis(N,N-diisopropylamino)chlorophosphine. The third step, preparation of protected 2 -deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetates, can be conveniently performed starting with standard 5 dimethoxytrityl-protected 2 -deoxynucleosides. For cost and convenience, the use of Nacetyl, N-benzoyl, and N-isobutyryl protection are recommended for dC, dA, and dG, respectively. These reagents can be obtained from ChemGenes. Other fast-deprotecting exocyclic amine–blocking groups can be used as well. As described in the accompanying protocols, the use of exocyclic amine–blocking groups compatible with fast deprotection conditions (such as methylamine for 15 min) is important because exposure of the oligodeoxyribonucleotide products to highly basic solutions must be limited. Prolonged exposure to strong base can result in decarboxylation of PACE/S-PACE internucleotide linkages and chain cleavage. The synthesis chemistry is compatible with most modified 2 -deoxynucleosides. The final protected 2 -deoxynucleoside-3 -O-(N,Ndiisopropylamino)phosphinyl acetates are purified by silica-gel column chromatography. CAUTION: Many phosphines are highly toxic or neuroactive agents. The phosphines described in these protocols are new reagents. Additional safety precautions should always be taken when working with novel reagents of this type, as they are uncharacterized relative to toxicity. It is extremely important to prevent inhalation or skin contact with these reagents. As in any laboratory situation, proper safety equipment should include a certified working fume hood, safety glasses, a lab coat, and reagent-impenetrable gloves. All glassware used in the synthesis or purification of these reagents should be thoroughly decontaminated before removal from the fume hood. CAUTION: Prior to initiating synthesis, prepare the fume hood to handle large amounts of gaseous HBr. It is important to know the local regulations regarding such hazardous material and the proper way to trap or vent this acid. When trapping HBr, be sure to carefully calculate the mole equivalents of generated acid and ensure that the trap has enough capacity. A variety of effective procedures for working with mineral acids can be found in common laboratory manuals; the method of choice will depend upon local regulations.
Materials Argon, dry Toluene, anhydrous (Aldrich) Bromoacetyl bromide (S.1, Fig. 4.24.2; Aldrich) Nitrogen, dry (optional) 50-g bottle of 3-hydroxy-3-methylbutyronitrile (Fluka) Bis(diisopropylamino)chlorophosphine (Digital Specialty Chemicals) Tetrahydrofuran, anhydrous (THF; Aldrich) Zinc metal, granular (Aldrich)
Synthesis of Modified Oligonucleotides and Conjugates
4.24.3 Current Protocols in Nucleic Acid Chemistry
Supplement 18
Acetonitrile, anhydrous Phosporic acid/CD3 CN NMR standard Reagent-grade hexanes, anhydrous 5 -O-(4,4 -Dimethoxytrityl)-protected 2 -deoxynucleoside (S.4; ChemGenes): 5 -O-DMTr-N6 -benzoyl-2 -deoxyadenosine 5 -O-DMTr-N4 -acetyl-2 -deoxycytidine 5 -O-DMTr-N2 -isobutyryl-2 -deoxyguanosine 5 -O-DMTr-2 -deoxythymidine Dichloromethane, anhydrous (Aldrich) 0.45 M tetrazole in acetonitrile (Glen Research) Ethyl acetate, reagent grade Diisopropylethylamine, anhydrous (DIPEA; Aldrich) Silica gel 60 for medium-pressure liquid chromatography (MPLC; 230 to 400 mesh; Aldrich) 120◦ C oven 500-mL and 1-liter round-bottom flasks with 24/40 joints Drying tubes containing calcium sulfate (Drierite) and equipped with a 24/40 joint PTFE-coated stir bar 125-mL, 250-mL, and 2-L Erlenmeyer flasks Top-loading balance Addition funnels with 24/40 joints, pressure-equalization arms (100- and 500-mL capacity), and PTFE stopcocks 325-mm Friedrich’s condensers with 24/40 joints (Labglass) Acid vapor trap and acid-resistant tubing Heating mantle to fit a 1-liter round-bottom flask, with controller Rotary evaporator with solvent-resistant Teflon head pump 1- and 2-liter recovery flasks (Labglass) Rotary evaporator trap (Labglass) Short-path distillation apparatus (Labglass) Three-flask distribution receiver Vacuum pump with an inlet acid vapor trap Capillary bleed tube (Kontes Glass) or needle valve attached to a Y-connector Powder funnels 24/40 rubber septa Hand-held heat gun (Aldrich) 500-mL separatory funnel Ground-glass 24/40 joint 50-mL glass pipet Glass-backed silica-gel TLC plates with fluorescent indicator (Aldrich) TLC developing tank (Aldrich) UV viewing cabinet (Aldrich) Flash-chromatography column (Aldrich cat) and flow controller Sea sand 350-mL fritted glass Buchner funnel, medium porosity, fitted with a 24/40 vacuum adapter (Labglass) Vacuum desiccator and solid PTFE vacuum pump with maximum vacuum of 1.5 torr (Aldrich) Additional reagents and equipment for 31 P NMR, thin-layer chromatography (TLC; APPENDIX 3D), column chromatography (APPENDIX 3E), and fast atom bombardment mass spectrometry (FAB-MS) Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
4.24.4 Supplement 18
Current Protocols in Nucleic Acid Chemistry
Synthesize 1,1-dimethylcyanoethyl bromoacetate 1. Dry all glassware overnight in an oven at 120◦ C. 2. Remove the 1-liter round-bottom flask with 24/40 joint from the oven and cool under a stream of dry argon. Place the flask in a fume hood and secure it on a magnetic stir plate. 3. Add 500 mL anhydrous toluene and a PTFE-coated stir bar to the flask. Cap with a drying tube. Secure the entire apparatus to the fume hood’s lattice support or a support stand. 4. Remove the 125-mL Erlenmeyer flask from the oven and cool to room temperature under a stream of dry argon. Tare the flask in the hood using a top-loading balance. 5. Weigh out 108 g (600 mmol) bromoacetyl bromide (S.1) into the flask and then quickly transfer to the toluene-containing flask by temporarily removing the drying tube, adding the bromoacetyl bromide, and then reattaching the drying tube. 6. Rinse the Erlenmeyer flask with anhydrous toluene and add the rinse to the solution. Stir on the magnetic stir plate to completely dissolve the bromoacetyl bromide. 7. Remove the 100-mL addition funnel from the oven and cool to room temperature using a stream of dry nitrogen or argon. Make sure that the PTFE stopcock is closed and tightened to prevent leaks. 8. Transfer the entire contents of a 50-g (500 mmol) bottle of 3-hydroxy-3methylbutyronitrile to the addition funnel. Rinse the reagent bottle with anhydrous toluene and add to the funnel. 9. Remove the drying tube from the 1-liter round-bottom flask and attach the addition funnel. Place the drying tube on the addition funnel, open the stopcock, and add 3-hydroxy-3-methylbutyronitrile dropwise to the stirred solution of bromoacetyl bromide. 3-Hydroxy-3-methylbutyronitrile is a tertiary alcohol that reacts very slowly with bromoacetyl bromide. This slow reactivity allows one to add the two components rapidly without cooling the flask. If another alcohol is used, especially a primary alcohol, the reaction can be highly exothermic at room temperature. When using another alcohol, it is important to first perform a test reaction on a small scale: cool the flask containing bromoacetyl bromide in an ice bath and add the alcohol dropwise to the stirred reaction mixture. This test reaction is used to determine how exothermic the reaction will become and how much cooling will be required for a larger-scale reaction. It is also important to remember that the efficiency of cooling the contents of a larger-volume flask with an external cooling bath decreases significantly as the ratio of surface area to volume decreases.
10. Remove the funnel and fit a 325-mm Friedrich’s condenser with attached drying tube to the flask. Fix an acid vapor trap to the drying tube using acid-resistant tubing. Place the flask in a mantle and heat the reaction mixture to reflux (∼110◦ C) overnight. 11. Cool the flask to room temperature and remove the toluene using a rotary evaporator. In order to minimize loss or contamination, transfer the solution to a 2-liter recovery flask and attach a rotary evaporator trap between the recovery flask and the evaporator. Toluene is often considered a difficult solvent to remove on a rotary evaporator due to its boiling point and tendency to “bump.”
12. Purify the product as an oil by vacuum distillation using a short-path distillation apparatus, three-flask distribution receiver, and vacuum pump with inlet acid vapor trap. Perform distillation at ∼0.1 mmHg using a capillary bleed tube inserted into the distillation flask or a needle valve attached to a Y-connector on the vacuum line.
Synthesis of Modified Oligonucleotides and Conjugates
4.24.5 Current Protocols in Nucleic Acid Chemistry
Supplement 18
Distill the oil into two components: an initial minor fraction with a wide boiling range and the major fraction at 120◦ to 122◦ C. Store the major fraction up to 6 months at −20◦ C. The product is black before distillation, colorless after, and yellow upon storage. It is important to place an acid vapor trap in the vacuum line in order to trap residual HBr, and to change the pump oil immediately following distillation, to prevent corrosion and seizure of the vacuum pump. The needle valve and Y-connector give better control over the distillation pressure. The constant boiling product (1,1-dimethylcyanoethyl bromoacetate; S.2) gave 97.3 g of clear, colorless liquid (88% yield). 1 H NMR (CDCl3 ): δ 3.75 (s, 2H), 2.86 (s, 2H), 1.53 (s, 6H). Electron impact mass spectrometry (EI-MS) generated molecular ions of 205 m/e and 207 m/e with isotopic abundances of 51% and 49%.
Synthesize phosphinylating reagent 13. Remove the 500-mL round-bottom flask with 24/40 joint from the oven. Cool under a stream of dry argon, place in the fume hood, and fit with a drying tube. 14. With a balance placed in the hood, weigh 20 g (75 mmol) bis(diisopropylamino)chlorophosphine into a plastic weighing boat and then quickly transfer the phosphine to the cool, dry 500-mL flask by temporarily removing the drying tube from the flask and adding the phosphine via a powder funnel. This reagent is moisture sensitive. It is therefore important to minimize its exposure to the atmosphere by working quickly.
15. Partially fill the flask with 300 mL anhydrous THF, add a stir bar, and place the flask on a magnetic stir plate. Cap the flask with the drying tube and secure to the fume hood’s lattice support or a support stand. 16. Stir the solution vigorously for 1 hr or until the phosphine has dissolved. The bis(diisopropylamino)chlorophosphine is often contaminated with small amounts of diisopropylamine hydrochloride and H-phosphonate hydrolysis products. These contaminants are less soluble in THF than the desired phosphine and can form an insoluble precipitate. To ensure effective conversion to the product, it is recommended that the bis(diisopropylamino)chlorophosphine be evaluated by 31 P NMR prior to use. The chlorophosphine should appear as a singlet in anhydrous CD3 CN with a chemical shift of 134.4 ppm. Peaks between 0 and 20 ppm represent various hydrolyzed or oxidized products. If peaks other than these appear in the spectrum, the reagent should be rejected or repurified (purity should be >90%). Purity of the chlorophosphine can be roughly estimated by integrating various peaks and using the results to determine the amount of impure phosphine to use in the reaction. The chlorophosphine can be synthesized and purified by recrystallization using the procedures described in Dellinger et al. (2003).
17. While the phosphine is being dissolved, remove the 1-liter three-neck round-bottom flask from the oven and cool under a stream of dry argon. Place it on a magnetic stir plate and secure it to the fume hood’s lattice support or a support stand. Fit a drying tube to the center joint and rubber septa to the side joints. 18. Weigh 7.2 g (110 mmol) granular zinc metal into a plastic weigh boat. Temporarily remove the drying tube from the flask, immediately transfer the zinc to the flask using a powder funnel, and replace the drying tube. Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
It is important to keep the zinc metal dry and under inert atmosphere, as the presence of large amounts of zinc oxide can inhibit the initiation of the Reformatsky coupling reaction.
19. Remove two 500-mL addition funnels, a 250-mL Erlenmeyer flask, and the 325-mm Friedrich’s condenser from the oven and cool to room temperature under a stream of
4.24.6 Supplement 18
Current Protocols in Nucleic Acid Chemistry
dry argon. Make sure that the PTFE stopcocks are closed and tightened to prevent leaks. 20. Working quickly, decant the THF/phosphine solution into one of the addition funnels while leaving any insoluble material in the flask. Cap the funnel with a rubber septum and place on one of the side joints of the three-neck flask. Slurry the residual insoluble precipitate into 50 mL anhydrous THF and pour onto the zinc in the three-neck roundbottom flask. It is important that this step be performed quickly, as the phosphine solution is moisture sensitive.
21. Place the Erlenmeyer flask on the top-loading balance and tare. Carefully weigh 18.2 g (82.5 mmol) 1,1-dimethylcyanoethyl bromoacetate (S.2) into the dry Erlenmeyer flask. Add 150 mL anhydrous THF and swirl the flask to dissolve the reagent. 22. Pour this solution into the second addition funnel, cap the funnel with a rubber septum, and place it on the third neck of the flask. 23. Place the Friedrich’s condenser in the center neck of the three-neck flask and insert a drying tube on top of the condenser. Connect the condenser to a water source and drain using appropriate tubing. Add a PTFE-coated magnetic stir bar to the three-neck flask. 24. Add one third of the phosphine (100 mL) and bromoacetate (50 mL) solutions to the flask and heat this mixture using a hand-held heat gun focused on the zinc, with the magnetic stir plate turned off, until boiling begins. It is important to focus the heat from the heat gun onto the zinc metal.
25. Once the THF boils, remove the heat gun and observe the reaction mixture. Assessment that the Reformatsky reaction has initiated is quite obvious as it will be noticeably exothermic, and the cloudy colorless mixture will become clear and slightly yellow. If the reaction does not initiate, activate the heat gun and locally heat the zinc until the THF once again begins to boil. Once the reaction has initiated, the solution will reflux without the use of a heat gun.
26. Continue the reaction at reflux by slowly adding the remainder of the phosphine and bromoacetate solutions. If the reaction becomes too vigorous, engage the magnetic stir plate, as stirring usually controls the rate. If it is still too vigorous, cool the flask using an ice bath. 27. Once addition is complete, keep the solution at reflux (which is lost as the reaction slows) for 30 min by using a heating mantle. Cool to room temperature. 28. Analyze by 31 P NMR for completeness by dissolving a few drops of the reaction mixture in an NMR tube containing anhydrous acetonitrile. First, lock the NMR instrument and shim the magnet on a phosphoric acid/CD3 CN standard. Then remove the standard, turn off the lock, insert the NMR tube with the crude sample into the instrument, and acquire experimental results. 31
P NMR samples of these crude mixtures are typically evaluated in anhydrous, nondeuterated acetonitrile with the deuterium lock turned off due to the difficulty and expense of obtaining absolutely anhydrous deuterated solvents. Commercial “anhydrous” deuterated solvents falsely indicate that a significant amount of the reaction products are hydrolyzed. With the same anhydrous, nondeuterated acetonitrile commonly used for bulk reactions, a more accurate evaluation of hydrolysis products has been obtained. The chlorophosphine (δ P = 135 ppm) should be completely consumed and converted to a single product (S.3; δ P = 48 ppm).
Synthesis of Modified Oligonucleotides and Conjugates
4.24.7 Current Protocols in Nucleic Acid Chemistry
Supplement 18
29. Cool reaction mixture and decant into a 1-liter recovery flask, leaving behind the unreacted metal. Remove THF using a rotary evaporator to yield a yellow/brown viscous oil.
Isolate phosphinylating reagent 30. To isolate the product by trituration, add 250 mL anhydrous reagent-grade hexanes, place a rubber septum in the flask’s 24/40 joint, and shake vigorously to dissolve the phosphine. Allow the oil and hexanes to settle and decant the hexane layer into a 2-liter recovery flask. Repeat for a total of three successive extractions. The oil will be converted to a solid.
31. Dissolve the resulting solid in 150 mL anhydrous acetonitrile, place in a 500-mL separatory funnel, and extract twice with 150-mL portions of anhydrous hexanes. 32. Analyze the acetonitrile solution by 48 ppm) and discard.
31 P
NMR for absence of the product (δP =
33. Combine all hexane fractions in the 2-liter recovery flask and concentrate the product on a rotary evaporator to a slightly yellow oil. Redissolve in 300 mL anhydrous hexanes and place the flask in a −20◦ C freezer overnight. 34. Decant the hexane solution into a clean, dry, 500-mL round-bottom flask and remove solvent using a rotary evaporator to give 16.4 g (88% yield) of a slightly yellow oil. Store up to 6 months at −20◦ C. The product, 1,1-dimethyl-2-cyanoethyl [bis(N,N-diisopropylamino)phospinyl]acetate (S.3), can be further purified by recrystallization in anhydrous pentane. 1 H NMR (CDCl3 ): δ 3.48 (m, 4H), 2.99 (s, 2H), 2.79 (d, J = 3.12 Hz, 2H), 1.30 (m, 24H). EI-MS generated a molecular ion of 371 m/e with fragmentation loss of CH2 COOC(CH3 )2 CH2 CN at 231 m/e. 31 P NMR (CD3 CN): δ 48.1 ppm. The authors typically only recrystalize with pentane to achieve good data from analysis by 1 H NMR.
Synthesize (N,N-diisopropylamino)phosphinyl acetate monomers 35. Remove a 500-mL round-bottom flask from the oven and cool under a stream of dry argon. Place the flask on a magnetic stir plate in the fume hood, add a stir bar, and attach a ground-glass joint capped with a drying tube. Fasten to the fume hood’s lattice support or a support stand. 36. Weigh 10.0 g DMTr-protected 2 -deoxynucleoside (S.4) into a plastic weighing boat. To avoid absorption of moisture, temporarily remove the drying tube from the flask, quickly transfer the nucleoside using a powder funnel, and return the drying tube to the flask. Add 250 mL anhydrous dichloromethane and begin stirring.
Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
Occasionally the protected 2 -deoxynucleosides from commercial suppliers contain a significant amount of absorbed water. Any water in the solution will preferentially react with the phosphinylating agent and reduce the final yield of product. It is therefore prudent to test the protected 2 -deoxynucleoside/dichloromethane solution for the amount of water present using a Karl-Fisher titration prior to performing the phosphinylation reaction. (Once the shipment has been shown to be anhydrous, it can be assumed subsequent solutions made from the same batch will be anhydrous as long as care has been taken in handling and storage.) The authors use an Aquastar V-200 Karl-Fischer titrator (VWR ). A small amount of water in the protected 2 -deoxynucleoside can be neutralized by using a molar equivalent excess of the phosphinylating agent as an internal desiccant. Larger amounts of water require that the 2 -deoxynucleoside solution be evaporated to dryness on a rotary evaporator, redissolved in anhydrous pyridine, and evaporated to dryness again. The excess water is thus removed as a pyridine/water azeotrope. This procedure should be repeated until the water content of the pyridine solution is similar to the anhydrous solvent alone. It is subsequently important to completely remove all the pyridine,
4.24.8 Supplement 18
Current Protocols in Nucleic Acid Chemistry
Table 4.24.1 Reactants Used to Prepare 2 -Deoxynucleoside-3 -O-(N,Ndiisopropylamino)phosphinyl Acetates
5 -DMTr-dABz
5 -DMTr-dC
5
Ac
-DMTr-dGi-Bu
5 -DMTr-T
Protected 2 -deoxynucleoside
Phosphinylating reagent
0.45 M tetrazole
10 g
6.8 g
27.2 mL
10 g
7.8 g
31.1 mL
10 g
7.0 g
27.9 mL
10 g
8.2 g
32.7 mL
as it will act as a base and neutralize the tetrazole acid catalyst. This is accomplished by using a similar azeotropic evaporation process with toluene. Once the protected 2 deoxynucleoside is free of pyridine, it is redissolved in anhydrous dichloromethane and the synthesis continued.
37. Place a top-loading balance in the hood and weigh the appropriate amount of phosphinylating reagent (S.3) into a plastic weighing boat (Table 4.24.1). Temporarily remove the drying tube, quickly transfer the phosphine to the 500-mL flask using a powder funnel, and return the drying tube to the flask. Continue stirring to dissolve completely (∼10 to 30 min). The phosphine is moisture sensitive, so it is important to minimize its exposure to the atmosphere.
38. Add the volume of 0.45 M tetrazole in anhydrous acetonitrile shown in Table 4.24.1 using a dry 50-mL glass pipet. Stir 24 hr at room temperature. The volume given provides 0.8 molar equivalents tetrazole to the reaction.
39. Spot the reaction mixture on a glass-backed silica-gel TLC plate with fluorescent indicator, alongside a dichloromethane solution of the appropriate starting material. Air dry the spots. 40. Carefully place the TLC plate in a developing tank pre-equilibrated with reagentgrade ethyl acetate and allow the solvent elution front to reach the top of the plate. Air dry the plate, place in a UV viewing cabinet, and illuminate using shortwave irradiation. The reaction is determined complete by spot-to-spot conversion to a faster eluting product. For additional details on TLC, see APPENDIX 3D.
41. Confirm conversion to product by loss of the 31 P NMR signal corresponding to S.3 (δ = 48.1 ppm). 42. If conversion is incomplete by these assays, allow the reaction mixture to stir another 24 hr. 43. Quench the reaction by adding 0.8 molar equiv anhydrous DIPEA and stirring 5 min. 44. Pour the solution into a 1-liter recovery flask and concentrate to a viscous oil using a rotary evaporator to remove solvent. Proceed to purification immediately.
Purify product by column chromatography 45. For each preparation, place ∼700 mL dry silica gel 60 (230 to 400 mesh) and 700 mL solvent (Table 4.24.2) in a 2-liter Erlenmeyer flask and swirl to equilibrate. If needed, use additional solvent to assure that the silica gel is completely solvated and easy to pour. Pour ∼16 cm solvated silica gel into a flash chromatography column and use solvent to wash any silica from the sides of the column. For additional details on column chromatography, see APPENDIX 3E.
Synthesis of Modified Oligonucleotides and Conjugates
4.24.9 Current Protocols in Nucleic Acid Chemistry
Supplement 18
Table 4.24.2 Column Elution Solvents for Various Synthons
2 -Deoxynucleoside base
% Ethyl acetate (v/v)
% Hexanes (v/v)
Adenine
100
0
Cytosine
50
50
Guanine
100
0
Thymine
100
0
46. Assemble the column in the fume hood by tightly clamping it to the fume hood’s lattice support or a support stand. Attach the flow controller. Push solvent through the column at a flow rate of ∼300 mL/min using air or nitrogen to compress the silica gel bed. Remove the pressure and flow controller when the solvent level reaches the compressed silica. Sprinkle sea sand on the silica gel bed to a depth of ∼2 cm. 47. Carefully pour an additional 500 mL solvent into the column without disturbing the compressed silica gel bed. Reattach the flow controller and push the liquid through the column at the same rate until it reaches the silica gel bed. Because most silica gels are acidic, it is typical to add a small percentage of triethylamine to the eluting solvent when purifying protected 2 -deoxynucleoside phosphoramidites. This prevents loss of the DMTr protecting group and acid-catalyzed hydrolysis of the phosphoramidite. However, the presence of triethylamine in the eluting solvent has a deleterious effect on the stability of the 2 -deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetates . As a result, losses in recovered yield are greater in the presence of triethylamine than when this base is not used. Therefore, addition of triethylamine to these solvents is not recommended. Typically, there is a considerable amount of diisopropylammonium tetrazolide in the crude 2 -deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetate products to help neutralize excess acid on the silica gel. However, detritylation has still been observed infrequently during column chromatography. Detritylation on the column is easily detectable as a bright orange band on the silica column. To eliminate this detritylation, a small amount of TEA may be used to neutralize excess acid on silica gel during column packing and equilibration, but excess amine should be thoroughly flushed from the column prior to adding the crude material to the top of the column. Under either of these conditions, it is important to run the column at a rapid flow rate and not leave the product in contact with the silica gel for prolonged periods of time. The DMTrprotected 2 -deoxythymidine-3 -O-(N,N-diisopropylamino)phosphinyl acetates seem to be most susceptible to degradation during prolonged exposure to silica gel. When purifying these synthons, it is important to elute the column rapidly but carefully and not pause during purification.
48. Dissolve the crude product (step 43) in a minimum volume of ethyl acetate and add to the column by slowly dropping the mixture onto the sand layer using a Pasteur pipet. Use a small volume of solvent (50 mL) to wash the flask and add this solution dropwise to the sand layer. 49. Push the reaction mixture and solvent onto the silica gel by briefly pressurizing the column until the solvent level once again reaches the top of the compressed bed. Carefully add an additional 50 mL solvent to the sand layer and once again push it onto the silica gel by briefly pressurizing the column until the liquid level has reached the compressed bed.
Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
50. Carefully fill the column with solvent without disturbing the compressed silica gel bed. Attach the flow controller and elute the reaction product at ∼300 mL/min. Collect 50-mL fractions. 51. Check for UV-absorbing material by spotting a small amount of eluted solvent onto a glass-backed TLC plate containing a fluorescent indicator. Air dry and view the plate
4.24.10 Supplement 18
Current Protocols in Nucleic Acid Chemistry
in the UV viewing cabinet using shortwave irradiation. Keep samples containing UV-absorbing material and discard those without. 52. For detailed analysis, spot TLC plates with column fractions that contain UV-absorbing material along with a dichloromethane solution of the appropriate starting material and the crude reaction mixture. Air dry the spots, place the plate in a developing tank pre-equilibrated with ethyl acetate, and elute until the solvent front reaches the top of the plate. Air dry and view in the UV viewing cabinet using shortwave irradiation. 53. Identify column fractions containing pure material suspected of being the product. Combine in a recovery flask and remove solvent on a rotary evaporator. The resulting products are usually glassy or foamed solids. The authors frequently elect to convert them to granular powders by precipitation into anhydrous hexanes (step 54), because powders are easier to manipulate for solid-phase DNA synthesis.
Work up final product 54. For each preparation, place 1 liter anhydrous hexanes in a 2-liter recovery flask. Redissolve the purified solid in a minimal amount of anhydrous dichloromethane and add dropwise to the hexanes using a Pasteur pipet. Add the DCM/product mixture a few drops at a time, rapidly swirling the solution. A white solid, corresponding to the product, precipitates from the hexanes.
55. Once addition is complete, isolate the solid by filtration using a 350-mL mediumporosity, fritted glass Buchner funnel fitted with a 24/40 vacuum adapter. During filtration, keep the solid submersed in solvent to prevent the granular precipitate from converting to a gum. 56. When filtration is complete, immediately place the funnel in a vacuum desiccator and attach to a two-stage vacuum pump or high-vacuum line. Make sure that the vacuum line or vacuum pump is “trapped” so that there is no chance that oil will back up into the vacuum desiccator. Allow the precipitate to be evacuated in the vacuum desiccator for at least 12 hr in order to remove all residual solvent. Rapid evacuation of solvent from the powder can often lead to an “explosion” of the product such that it covers the inside walls of the desiccator. This can be prevented by slowly evacuating the desiccator in stages. Additionally, covering the funnel with aluminum foil containing a few small holes can help prevent this unfortunate loss of product.
57. Once the precipitate has been dried under vacuum, close the stopcock to isolate the vacuum desiccator, remove the high-vacuum line, and bleed the desiccator slowly with dry argon or nitrogen. The resulting white powder is easily partitioned into DNA synthesizer reagent vials.
58. Identify and analyze each product for purity by 31 P NMR and FAB-MS. Store up to 6 months at −20◦ C. 1,1-Dimethyl-2-cyanoethyl 5 -O-(4,4 -dimethoxytrityl)-2 -deoxythymidine-3 -O-(N,Ndiisopropylamino)phosphinyl acetate (S.5a) is isolated with an average yield of 84%. 31 P NMR (CD3 CN): δ 120.3, 120.8 ppm. FAB-HRMS: calcd. for C44 H55 N4 O9 P (M+H)+ 815.3785, found 815.3775. 1,1-Dimethyl-2-cyanoethyl 5 -O-(4,4 -dimethoxytrityl)-N4 -acetyl-2 -deoxycytidine-3 -O(N,N-diisopropylamino)phosphinyl acetate (S.5b) is isolated with an average yield of 78%. 31 P NMR (CD3 CN): δ 121.3, 121.8 ppm. FAB-HRMS: calcd. for C45 H56 N5 O9 P (M+H)+ 842.3894, found 842.3914. 1,1-Dimethyl-2-cyanoethyl 5 -O-(4,4 -dimethoxytrityl)-N6 -benzoyl-2 -deoxyadenosine3 -O-(N,N-diisopropylamino)phosphinyl acetate (S.5c) is isolated with an average yield
Synthesis of Modified Oligonucleotides and Conjugates
4.24.11 Current Protocols in Nucleic Acid Chemistry
Supplement 18
of 75%. 31 P NMR (CD3 CN): δ 120.8, 121.6 ppm. FAB-HRMS: calcd. for C51 H58 N7 O8 P (M+H)+ 928.4163, found 928.4159. 1,1-Dimethyl-2-cyanoethyl 5-O-(4,4-dimethoxytrityl)-N2 -isobutyryl-2-deoxyguanosine3 -O-(N,N-diisopropylamino)phosphinyl acetate (S.5d) is isolated with an average yield of 89%. 31 P NMR (CD3 CN): δ 121.7, 122.0 ppm. FAB-HRMS: calcd. for C48 H60 N7 O9 P(M+H)+ 910.4268, found 910.4235.
BASIC PROTOCOL 2
AUTOMATED SYNTHESIS OF PHOSPHONOACETATE AND THIOPHOSPHONOACETATE DNA Phosphonoacetate DNA Synthesis The chemical synthesis of PACE ODNs (Fig. 4.24.4) can be accomplished manually, but the use of an automated DNA synthesizer is preferred. This protocol describes the synthesis as performed on an ABI model 394 automated DNA synthesizer. The chemistry is completed on a solid support with standard controlled-pore glass (CPG) DNA synthesis columns with long-chain alkylamino (LCAA) linker (1 µmol dA, Ac-dC, dG, dT; 500-Å glass pore size; Glen Research). When using a dC-containing CPG column, it is important that the dC be protected with an acetyl rather than benzoyl group. The use of the acetyl protecting group on dC allows for the rapid deprotection of the ODNs using methylamine at 55◦ C for 15 min without methylation of the N4 position of the cytosine residues. The use of the more typical benzoyl-protected dC monomers and CPG columns results in a small but detectable amount of methylation of the N4 position during ODN deprotection using these rapid conditions. The use of the typical benzoyl-protected dA and isobutyrylprotected dG is compatible with rapid ODN deprotection using methylamine and does not result in detectable methylation of these heterobases. The recommended synthesis cycle is adapted from a standard 1-µmol 2-cyanoethylphosphoramidite DNA cycle (Caruthers et al., 1987). The coupling wait-time is increased to 1998 sec by using two successive 999-sec wait steps. The oxidation step is accomplished prior to the capping step; the oxidation wait time is 180 sec. Table 4.24.3 summarizes the synthesis cycle as applied to the 394 automated synthesizer. A general description of automated DNA synthesis can be found in APPENDIX 3C. The monomers used for PACE ODN synthesis are the 1,1-dimethyl-2-cyanoethyl 5 O-(4,4 -dimethoxytrityl)-2 -deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetates described above (see Basic Protocol 1). They are also commercially available from MetaSense Technologies (see http://www.Metasensetechnologies.com for ordering and helpful information). It is important to dry the protected 2 -deoxynucleoside3 -O-(N,N-diisopropylamino)phosphinyl acetates overnight to remove any possible moisture before use (see Support Protocol). Indeed, prior to dissolving the synthons, researchers should familiarize themselves with techniques used for handling air-sensitive or moisture-sensitive reagents. The most common failure modes for DNA synthesis result from moisture contamination of amidites or activators. A good treatise on this subject, Aldrich Technical Bulletin: AL-134 Handling AirSensitive Reagents, can be obtained from Aldrich Chemical in PDF format at http://www.sigmaaldrich.com/aldrich/bulletin/al techbull al134.pdf.
Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
Freshly sublimed tetrazole dissolved in anhydrous acetonitrile at a concentration of 0.45 M is used as an activator. A prepared solution of 0.45 M tetrazole in acetonitrile can be purchased from Glen Research. Trichloroacetic acid (3% w/v in anhydrous dichloromethane; Glen Research) is used to deprotect the 5 -DMTr group prior to each round of coupling. Capping is accomplished using a two-part capping solution modified from Hogrefe et al. (1993). Cap A consists of 10% acetic anhydride in anhydrous tetrahydrofuran (Glen Research), and Cap B consists of 0.625% (w/v)
4.24.12 Supplement 18
Current Protocols in Nucleic Acid Chemistry
Figure 4.24.4 Synthesis scheme for preparing phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides. Circled P is the LCAA-CPG support (long-chain alkylamino controlled-pore glass hemisuccinate). Abbreviations: B, thymin1-yl, 4-N-acetylcytosin-1-yl, 6-N-benzoyladenin-9-yl, or 2-N-isobutyrylguanin-9-yl; BDT, 3H-1,2-benzodithiol-3-one 1,1dioxide; CSO, (1S)-(+)-(10-camphorsulfonyl)oxazaridine; DMAP, 4-dimethylaminopyridine; DMTr, 4,4 -dimethoxytrityl; Py, pyridine; TCA, trichloroacetic acid. Table 4.24.3 Synthesis Cycle for Phosphonoacetate or Thiophosphonoacetate DNA
Step
Delivery time (sec)
Wait time (sec)
Port
1. Dichloromethane
35
—
19
2. Detritylation
85
—
14
3. Acetonitrile
20
—
18
2.5 × 2
999 × 2
5-8, 9
10
—
18
8
180
15
8
60
10
7. Acetonitrile
40
—
18
8. Capping
10
10
11 and 12
9. Acetonitrile
30
—
18
4. Coupling
a
5. Acetonitrile 6. Oxidation or b
sulfurization
a Coupling involves simultaneous delivery of an appropriately protected 2 -deoxynucleoside-3 -O-(N,N-
diisopropylamino)phosphinyl acetate (ports 5 to 8) and tetrazole (port 9). b Synthesis of phosphonoacetate DNA requires placement of CSO at port 15, whereas synthesis of thio-
phosphonoacetate DNA requires BDT at port 10. The appropriate wait time is then programmed into the cycle.
4-N,N-dimethylaminopyridine (DMAP, Aldrich) in anhydrous pyridine (Aldrich). Oxidation of the nascent internucleotide phosphonite to the phosphonate is carried out with 0.1 M (1S)-(+)(10-camphorsulfonyl)oxaziridine (Aldrich) in anhydrous acetonitrile (1 g CSO in 43.6 mL CH3 CN). The acetonitrile used should be anhydrous synthesis grade, and dichloromethane should be certified ACS grade (both available from Fisher Biotech).
Thiophosphonoacetate DNA Synthesis With the exception of the sulfurization step, the synthesis of S-PACE ODNs is analogous to the procedure used for PACE DNA. Because the same synthons are used to prepare both
Synthesis of Modified Oligonucleotides and Conjugates
4.24.13 Current Protocols in Nucleic Acid Chemistry
Supplement 18
PACE and S-PACE ODNs, the synthesis cycle in Table 4.24.3 can be followed, except that 3H-1,2-benzodithiol-3-one-1,1-dioxide (BDT) is used as a sulfurization reagent in place of the CSO used for oxidation in PACE DNA synthesis. The sulfurization wait time is 60 sec, and the sulfurization solution is 0.05 M BDT (Glen Research) in anhydrous acetonitrile (1 g BDT in 100 mL CH3 CN). SUPPORT PROTOCOL
DRYING OF PHOSPHONOACETATE AND THIOPHOSPHONOACETATE MONOMERS Steps are provided to describe the drying and preparation of the starting monomers prior to ODN synthesis.
Materials 1,1-Dimethyl-2-cyanoethyl 5 -O-(4,4 -dimethoxytrityl)-2 -deoxynucleoside-3 -O(N,N-diisopropylamino)phosphinyl acetates (S.5a-d; see Basic Protocol 1; also available from MetaSense Technologies) Argon or nitrogen, anhydrous Anhydrous acetonitrile, synthesis grade (Fisher Biotech) Amber serum vials with rubber septa 18-G × 1-in. needle Vacuum desiccator Two-stage vacuum pump or high vacuum line, with trap Syringe, dry 1. Weigh the appropriate amount of each synthon into separate amber serum vials and place a rubber septum on each. Press an 18-G × 1-in. needle through each septum until it extends about half-way. Make sure that the needles do not contact any powder. 2. Place the vials in a vacuum desiccator attached to a two-stage vacuum pump or a high vacuum line, with a trap, and evacuate for at least 12 hr prior to use. 3. Close the stopcock to isolate the vacuum desiccator, remove the high vacuum line, and bleed the desiccator slowly with dry argon or nitrogen. Open the desiccator and quickly remove the needles from the rubber septa. 4. Dissolve dried synthons in synthesis-grade anhydrous acetonitrile at a concentration of 0.1 M by filling a dry syringe with the required amount of solvent (Table 4.24.4) and then transferring the solvent to the amber serum vial under dry nitrogen or argon. Store up to 6 months at −20◦ C. For the synthesis of an average 20-mer having five of each base (dC, dG, dT, dA) and on a 1-µmol CPG column, less than 250 mg of each synthon is required.
Table 4.24.4 Acetonitrile Solvent Requirements for 2 -Deoxynucleoside-3 -O(N,N-diisopropylamino)phosphinyl Acetates
Volume acetonitrile
Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
2 -Deoxynucleoside base
250 mg
1g
Adenine
2.7 mL
11.0 mL
Cytosine
3.0 mL
11.9 mL
Guanine
2.8 mL
11.0 mL
Thymine
3.1 mL
12.3 mL
4.24.14 Supplement 18
Current Protocols in Nucleic Acid Chemistry
AUTOMATED SYNTHESIS OF MODIFIED DNA CHIMERAS The protocol outlined in this section can be used to synthesize modified DNA having either PACE or S-PACE internucleotide linkages combined with phosphate and thiophosphate backbones (Fig. 4.24.5). Many oligomers having these four linkages in various combinations have been synthesized, including those presented in Table 4.24.5 (also see BioSpring GmbH, http://www.biospring.de).
BASIC PROTOCOL 3
Preparation for Synthesis of DNA Chimeras The reagents and preparations for synthesis of chimeras having either PACE or S-PACE internucleotide linkages in combination with phosphate or thiophosphate backbones are analogous to those outlined in Basic Protocol 2. In order to generate S-PACE and thiophosphate linkages, the sulfurization solution used is BDT in anhydrous acetonitrile. The concentration of BDT for sulfurization remains the same for synthesizing thiophosphate and S-PACE internucleotide linkages. Oxidation to PACE and phosphate backbones is carried out with CSO; however, the concentration of CSO required to oxidize a phosphite triester to a phosphotriester (producing a normal phosphate backbone) is significantly greater than the concentration required to oxidize the phosphonite diester to the phosphonate diester (producing the PACE backbone). Effective oxidization of phosphite triesters to phosphotriesters requires a 0.5 M solution of CSO and exposure for at least 3 min. This higher concentration of CSO is used to oxidize both phosphite and phosphonite internucleotide linkages during the preparation of chimeras. The use of CSO for the nonaqueous oxidation of phosphite triesters is described in a Glen Report (Glen Research, 1996), which can be downloaded as a PDF file from the Glen Research Web site (http://www.glenres.com). Synthons used to prepare PACE and S-PACE linkages (see Basic Protocol 1 or MetaSense Technologies) are dried as described in the Support Protocol, dissolved in anhydrous acetonitrile (see Table 4.24.4 for appropriate concentrations), and then transferred to ports 5 to 8 on the automated DNA synthesizer. For preparing phosphate and thiophosphate internucleotide linkages, standard base-protected synthons, 5 -O-(4,4 -dimethoxytrityl)-3 -O-[(N,N-diisopropylamino)(2-cyanoethoxy)phosphinyl]2 -deoxyribonucleoside monomers, are used according to published procedures (Caruthers et al., 1987). They are available from Glen Research (dT-CE, Ac-dC-CE, dG-CE, and dA-CE phosphoramidites). These synthons are dissolved as 0.1 M solutions in anhydrous acetonitrile and transferred to ports 1 to 4 on the DNA synthesizer. The capping solution is described in Basic Protocol 2.
Table 4.24.5 MALDI-TOF Mass Spectrometry of ODNsa
Abbreviation
Structure
Calculated mass
Observed mass
PACE
d(CaTaCaAaAaGaTaGaGaGaCaTaGaGaTaGaAaC)
6270.2
6271.3
S-PACE
d(CsTsCsAsAsGsTsGsGsGsCsTsGsGsTsGsAsC)
6542.1
6540.5
PACE EO
d(CaTCaAAaGTaGGaGCaTGaGTaGAaC)
5933.8
5933.1
S-PACE EO
d(CsT-CsA-AsG-TsG-GsG-CsT-GsG-TsG-AsC)
6205.8
6208.2
PACE Cap
d(CaTaCaAaAaGaT-G-G-G-C-TaGaGaTaGaAaC)
6139.9
6137.2
S-PACE Cap
d(CsTsCsAsA-G-T-G-G-G-C-T-G-GsTsGsAsC)
6163.8
6165.5
a Nomenclature: a, phosphonoacetate; s, thiophosphonoacetate; -, phosphorothioate; the absence of a symbol between
nucleoside letters corresponds to a normal phosphate linkage (e.g., CT).
Synthesis of Modified Oligonucleotides and Conjugates
4.24.15 Current Protocols in Nucleic Acid Chemistry
Supplement 18
Figure 4.24.5 Synthesis scheme for preparing oligodeoxyribonucleotide chimeras having phosphonoacetate or thiophosphonoacetate internucleotide linkages combined with phosphodiester or phosphorothioate backbones. See Figure 4.24.4 for abbreviations.
Synthesis of Oligodeoxyribonucleotide Chimeras A general synthesis plan for various chimeras is outlined in Table 4.24.6. This table includes two series of synthons—i.e., the standard 2 -deoxynucleoside-3 phosphoramidites and the 2 -deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetates—and two choices for the P(III) to P(V) oxidation of the internucleotide linkage—i.e., CSO and BDT. Each cycle, which outlines the steps for synthesizing one internucleotide linkage, uses only one synthon and oxidation condition. In some cases, chimeras having all four bases can be synthesized using one cycle. For example, phosphodiester/PACE or phosphorothioate/S-PACE chimeras are prepared using only one oxidant (CSO or BDT, respectively). Chimeric syntheses of phosphorothioate/PACE or phosphodiester/S-PACE ODNs require two separate cycles: one for the phosphorothioate and S-PACE linkages (using the sulfurizing reagent BDT) and another to generate phosphodiester and PACE internucleotide backbones (using the oxidant CSO). Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
A chimera requiring two cycles is illustrated by the PACE Cap ODN shown in Table 4.24.5. This oligomer has phosphorothioate linkages flanked by PACE at the 3 and 5 ends. In this case, a heptamer having a PACE backbone is first synthesized using appropriate 2 -deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetates as synthons and CSO as oxidant. At this point, BDT as a sulfurizing agent is substituted for CSO. This
4.24.16 Supplement 18
Current Protocols in Nucleic Acid Chemistry
Table 4.24.6 Synthesis Cycle for ODN Chimeras
Step
Delivery time (sec)
Wait time (sec)
Port
1. Dichloromethane
35
—
19
2. Detritylation
85
—
14
3. Acetonitrile
20
—
18
standard phosphoramidites
2.5 × 2
25
1-4, 9
phosphinoamidites
2.5 × 2
999 × 2
5-8, 9
10
—
18
8
180
15
8
60
10
7. Acetonitrile
40
—
18
8. Capping
10
10
11 and 12
9. Acetonitrile
30
—
18
4. Couplinga :
5. Acetonitrile 6. Oxidation or b
sulfurization
a For each cycle, coupling involves simultaneous delivery of a standard protected 2 -deoxynucleoside-3 -
phosphoramidite (ports 1 to 4) and tetrazole (port 9) or an appropriately protected 2 -deoxynucleoside-3 -O-(N,Ndiisopropylamino)phosphinyl acetate (ports 5 to 8) and tetrazole (port 9). b The choice of oxidation (CSO) or sulfurization (BDT) depends upon the synthesis plan.
is accomplished by reprogramming the cycle to use port 10 containing the BDT reagent in place of CSO at port 15. Synthesis then continues using appropriately protected standard 2 -deoxynucleoside-3 -phosphoramidites in order to prepare a 12-mer having five phosphorothioate and six PACE linkages. Once again the cycle is changed so that CSO (port 15) replaces BDT (port 10) in the synthesis program. The final PACE internucleotide linkages are added using 2 -deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetates to generate the PACE Cap ODN. Automated synthesis for certain types of chimeras that require two oxidants is therefore limited by the programming capabilities of the ABI 394 instrument. For preparing ODNs such as PACE Cap, this reprogramming problem is minor, as it must be done only twice.
DEPROTECTION, PURIFICATION, AND CHARACTERIZATION OF MODIFIED DNA
BASIC PROTOCOL 4
The following steps are used for PACE, S-PACE, and chimeric DNA. After partial deprotection and cleavage from the solid support, the ODNs are easily purified by reversedphase HPLC (RP-HPLC) using the 5 -DMTr protecting group for hydrophobic affinity (trityl-on purification). After detritylation and further RP-HPLC purification, they are analyzed by ion-exchange HPLC to determine yield and by matrix-assisted laser desorption/ionization time-of-flight mass spectometry (MALDI-TOF-MS) to obtain ODN mass information.
Materials DNA synthesis column containing oligodeoxyribonucleotides (ODN) linked to controlled-pore glass (CPG) Acetonitrile, anhydrous Argon or nitrogen, anhydrous 1.5% (v/v) 1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU; Aldrich) in anhydrous acetonitrile 40% methylamine, aqueous (Aldrich)
Synthesis of Modified Oligonucleotides and Conjugates
4.24.17 Current Protocols in Nucleic Acid Chemistry
Supplement 18
RP-HPLC mobile phases: A: 100 mM triethylammonium acetate, pH 8.0 B: acetonitrile 10 mM Tris·Cl, pH 8.0 (APPENDIX 2A) 80% acetic acid 50 mM triethylammonium acetate, pH 8 TE buffer, pH 8.0 (APPENDIX 2A) IEX-HPLC mobile phases: A: 10 mM NaOH/80 mM NaBr B: 10 mM NaOH/1.5 M NaBr 2,4,6-Trihydroxyacetophenone monohydrate (THAP) matrix Ammonium citrate 1:1 (v/v) acetonitrile/H2 O 10-mL Luer-tip syringe Male Luer-to-tubing connector (Aldrich) Conical vial: 3-mL Reacti-Vial sealed with Teflon-bonded silicon Tuf-Bond discs (Pierce), preferred 55◦ C heating block (e.g., Reacti-Block Aluminum Heat-Block, Pierce) or oven Speedvac evaporator (Savant) RP-HPLC apparatus with 25-cm × 9.4-mm-i.d. Zorbax 300SB-C18 column (Agilent Technologies) Ion-exchange (IEX)-HPLC apparatus with 1-mL RESOURCE Q column (Amersham Pharmacia Biotech) 100-well plate, gold plated Voyager-DE STR Biospectrometry Workstation mass analyzer (PerSeptive Biosystems) Recover CPG-bound ODN 1. Remove the DNA synthesis column containing the ODN linked to CPG from the synthesizer. Wash with 10 mL anhydrous acetonitrile using a 10-mL Luer-tip syringe to push the solvent through the column. 2. Flush with a low-pressure stream of dry argon or nitrogen using a male Luer-totubing connector fitted onto the inert gas line and placing the Luer-tip snugly into the DNA synthesis column. Blow a mild, low-pressure stream through the column until the CPG flows freely as the column is rotated. 3. Open the column and pour the contents into a conical glass vial (preferably a 3-mL Reacti-Vial).
Remove dimethylcyanoethyl group 4. Place 1 mL freshly prepared 1.5% DBU solution into the vial containing CPG and tighten the cap containing the Teflon-bonded silicon disc onto the vial. Vortex to stir the contents and incubate 60 min at room temperature. The vial can be vortexed occasionally during this deprotection reaction.
5. Vortex again and allow the CPG to settle into the conical portion of the vial. Remove the DBU solution using a clean Pasteur pipet and discard. Repeat three times using 1 mL acetonitrile each time to ensure complete removal of the DBU.
Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
Cleave ODN and remove exocyclic amine–protecting group 6. Add 1 mL aqueous 40% methylamine to the CPG and place the Teflon cap snugly on the vial. Heat the solution 15 min at 55◦ C by placing the vial in a preheated heating block or oven. 7. Remove the vial from the heat source, vortex, and place in an ice bucket.
4.24.18 Supplement 18
Current Protocols in Nucleic Acid Chemistry
8. Once cooled, remove the top of the vial and transfer the methylamine solution to a microcentrifuge tube using a glass Pasteur pipet. Be careful to allow the CPG to settle to the bottom of the glass vial before transferring the methylamine solution. The conical shape of the Reacti-Vial aids this process and prevents transfer of CPG. The residual CPG can be washed with an additional volume of cold methylamine solution to optimize recovery. Be careful, however, not to over-fill the microcentrifuge tube.
9. Evaporate solution to dryness, preferably in a centrifugal evaporator/concentrator (e.g., SpeedVac) without heating. Store dry mixture of oligodeoxyribonucleotide products in the sealed tube up to 6 months at −20◦ C.
Purify ODN by RP-HPLC and remove dimethoxytrityl group 10. Dissolve the crude oligodeoxyribonucleotide mixture in 0.5 mL water. Perform tritylon purification by RP-HPLC on a 25-cm Zorbax 300SB-C18 column. Elute with RP-HPLC mobile phases using the following gradient at a flow rate of 1.2 mL/min: Duration 0-2 min 2-27 min 27-52 min
Mobile phase B 8% 8% to 20% 20% to 80%.
Collect fractions containing the full-length product. 11. Concentrate under vacuum (e.g., SpeedVac) in a microcentrifuge tube and redissolve in 100 µL of 10 mM Tris·Cl, pH 8. It is important to use a buffered solution at pH 7 to 8 for dissolving these ODNs. At acidic pH, PACE and S-PACE ODNs are less soluble and can stick to the tube, which reduces recovery.
12. Remove the trityl group by treatment for 1 hr with 1 mL of 80% acetic acid. 13. Concentrate to dryness (e.g., in a SpeedVac) and dissolve in 0.5 mL of 50 mM triethylammonium acetate, pH 8. 14. Repeat preparative HPLC with the 25-cm × 9.4-mm-i.d. Zorbax 300SB-C18 column to isolate the fully deprotected ODNs. Use the same gradient conditions as for tritylon isolation of ODNs (step 10). Concentrate the resulting products under vacuum (e.g., Speedvac) and store up to 6 months at −20◦ C in ∼100 µl TE buffer, pH 8.0.
Characterize ODNs by IEX-HPLC 15. To determine synthetic yield of full-length product, analyze by ion-exchange HPLC using a 1-mL RESOURCE Q column. Elute with IEX-HPLC mobile phases using a gradient of 0% to 100% IEX-HPLC mobile phase B over 45 min at a flow rate of 1.5 mL/min. Analyze ODNs by mass spectrometry 16. Dissolve the modified ODN in water at a concentration of 100 µM. 17. Add 45 mg (0.2 mmol) THAP matrix and 2 mg (8.2 µmol) ammonium citrate to 500 µL of 1:1 (v/v) acetonitrile/water to form a supersaturated solution (a cloudy suspension). Allow suspended particles to settle to the bottom of the tube, forming a clear supernatant. 18. Pipet 1 µL THAP matrix supernatant onto a gold-plated 100-well plate. Pipet 1 µL ODN solution onto the same location. Allow spot to dry. There is no need for a desalting step because the ODN was purified by RP-HPLC.
Synthesis of Modified Oligonucleotides and Conjugates
4.24.19 Current Protocols in Nucleic Acid Chemistry
Supplement 18
19. Insert the plate into a Voyager Biospectrometry Workstation mass analyzer. Perform all MALDI-TOF-MS measurements in the positive ion mode. Table 4.24.5 lists the mass spectrometry results from a series of phosphonoacetate, thiophosphonoacetate, and chimeric oligomers.
COMMENTARY Background Information For many years now, oligodeoxyribonucleotides (ODNs) and their analogs have proven to be indispensable for most research in biology and biochemistry. They are used to study various biological processes through sequencing, PCR applications, and directed mutagenesis, as well as to diagnose diseases and study gene expression (DNA chips), identify single nucleotide polymorphisms, and modulate or control gene expression. The latter application has broad implications from basic research on gene function to the use of ODNs as therapeutic agents. As one would expect, success in these areas has been possible because of extensive research using a large number of ODNs. As each analog investigated thus far has a specific repertoire of advantages and disadvantages, it is worthwhile to continue developing new derivatives useful for biological research. This objective led to the PACE and SPACE oligomers whose synthesis chemistries are outlined in this manuscript.
Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
Synthesis using phosphonoacetic acid Phosphonoacetic acid has been known as an effective mimic of phosphoric acid and its derivatives for many decades. At neutral to basic pH, the three-dimensional structure and charge density of phosphonoacetate is remarkably similar to phosphate. The ability to mimic phosphate was demonstrated by the use of phosphonoacetic acid as an antiviral agent (Overby et al., 1977). Most methods for the synthesis of phosphonoacetic acid proceed through an oxidative transformation like an Arbuzov reaction (Arbuzov and Dunin, 1927), resulting in a phosphorus molecule in the oxidation state P(V). Once the carboxylic acid group is attached, the molecule becomes quite inactive to methods of coupling by activated transesterification. Even with these difficulties, phosphonoacetic acid was successfully coupled to a variety of nucleosides in an attempt to mimic 5 - and 3 -phosphorylated nucleosides; these molecules also demonstrated antiviral activity (Griengl et al., 1988; Lambert et al., 1989). The authors initially attempted to develop a method for synthesizing PACE ODNs using methyl 5 -O-(4,4 -dimethoxytrityl)-2 -
deoxythymidine-3 -O-phosphonoacetate prepared by the same methods developed for making phosphonoacetic acid–derived mononucleosides. This synthon was activated with various arylsulfonyl chlorides or 1-(2mesitylenesulfonyl)-3-nitro-1,2,4-triazole and condensed with 2 -deoxythymidine linked to a controlled-pore glass support. Unfortunately, coupling yields for these reactions never exceeded 5%, even after 24 hr (similar results were obtained with the acetic acid ethyl ester). A further problem with this approach was then discovered, namely that the alkaline conditions previously described to remove either the methyl or ethyl ester resulted in partial to complete destruction of the phosphonate internucleotide linkage. Due to these problems, it was concluded that P(V) coupling would never produce a useful method for PACE DNA synthesis. Rudolph et al. (1996) subsequently reported the ability to synthesize a 13-mer chimera having alternating phosphate and phosphonoacetate internucleotide linkages. Using the identical techniques previously described for making phosphonoacetic acid–derived mononucleosides, they were able to prepare a solutionphase 2 -deoxythymidine phosphonoacetate dimer as the acetic acid methyl ester and convert it to the 3 -phosphoramidite. Joining these dimers using classical phosphoramidite chemistry then produced the reported 13-mer chimera having alternating phosphonoacetate and phosphodiester linkages. Because the suspected 13-mer products were only characterized by relative HPLC retention times, it is unclear whether the methyl phosphonoacetate ester was completely removed from this molecule by extended base hydrolysis; however, this noteworthy manuscript reaffirmed the confidence that the successful synthesis of PACE oligodeoxyribonucleotides would require the development of novel P(III) methods. Synthesis using phosphinylacetic acid Although the literature is somewhat sparse, phosphinylacetic acids have been known for quite some time (Matrosov et al., 1972). These molecules were most often evaluated as potential solvents for charged heavy metal ions and used for applications such as the
4.24.20 Supplement 18
Current Protocols in Nucleic Acid Chemistry
purification of uranium by selective solvolysis. As a result, these types of compounds have been characterized for their chemical and physical properties, but have never been described as reactive synthons in organic chemistry or used to prepare analogs of peptides, oligosaccharides, oligodeoxyribonucleotides, or lipids. Based upon the literature and the authors’ experience, a potentially important reason for this lack of interest was the difficult challenge inherent in synthesizing these derivatives and the inaccurate characterization data based upon the early literature. A successful new approach was therefore developed as outlined in Figures 4.24.2 and 4.24.3. Initially, methyl 2 -deoxythymidine-3 -O-(N,Ndiisopropylamino)phosphinyl acetate was synthesized and used to prepare a dimer having a PACE internucleotide linkage. The high isolated yield of this dimer (81%) was extremely encouraging. Further studies, however, confirmed that removal of the methyl ester with various alkaline solutions led to degradation of the internucleotide linkage. As a consequence, the acetic acid 2-cyanoethyl ester was next investigated, as there was an expectation that it could be removed using a non-nucleophilic base such as DBU. Although this type of ester protection proved promising, it was not entirely satisfactory, as ∼8% of the PACE internucleotide linkages were further modified to phosphate under DBU treatment. These observations led the group to the sterically hindered acetic acid 1,1-dimethyl-2-cyanoethyl ester, which could be removed essentially quantitatively (<1% hydrolysis) with non-nucleophilic base. Removal of protecting groups A related early concern during the development of this chemistry was potential problems associated with removal of the amine-protecting groups commonly used on cytosine, adenine, and guanine. These blocking groups are routinely eliminated with mild base at elevated temperatures, conditions that are known to degrade alkyl phosphonate internucleotide linkages. An alternative was found in the method developed by Reddy et al. (1994), which uses 40% methylamine in water to rapidly remove exocyclic amine from ODNs containing N-acetyl-2 -deoxycytidine residues without methylation of the exocyclic amine groups. By slightly modifying these conditions, it was possible to achieve complete removal of the heterobase-protecting groups in 15 min at 55◦ C. The results showed that,
under these conditions, both PACE and SPACE ODNs were relatively stable, as 1.4% and 1.2%, respectively, of the internucleotide linkages were degraded in 15 min. Mass spectroscopy of the resulting ODN products also demonstrated no methylation of cytidine residues protected by acetyl groups. Although not entirely satisfactory (the problem is under further investigation), this procedure is currently used in the authors’ laboratory to remove the base-protecting groups.
Compound Characterization Both 1 H and 31 P NMR are indispensable for analyzing precursors and synthons used to prepare these ODNs. 1 H NMR spectra are recorded on Varian VXR-300 and Bruker 400 MHz spectrometers with tetramethylsilane as an internal standard. A Bruker 400 MHz spectrophotometer and an external 85% H3 PO4 capillary are used for recording oligomer 31 P NMR in D2 O. In the case of chimeras, the number of PACE, S-PACE, phosphate, and thiophosphate internucleotide linkages can be determined, as they have different 31 P NMR spectra. MALDI-TOF mass spectrometry (UNIT 10.1) should be used to analyze the molecular weight of these oligomers and to confirm that the correct base composition has been achieved. This is important because PACE and S-PACE ODNs are resistant toward degradation by nucleases. As a consequence, classical enzymatic methods cannot be used to characterize these ODNs. Further analysis of these ODNs is possible using standard 20% polyacrylamide gel electrophoresis (UNIT 10.4) followed by visualization and densitometric scanning. It is also possible to derivatize these oligomers with fluorescein and use this label to visualize ODNs on polyacrylamide gels (Dellinger et al., 2003). In all cases, PACE and S-PACE ODNs exhibit electrophoretic mobilities similar to natural DNA of the same length.
Critical Parameters and Troubleshooting Reagent quality All nucleic acid chemists know that water (preferably the lack thereof) is the most critical parameter for synthesizing DNA, RNA, and their analogs. Certainly this rule applies to the synthesis of PACE and S-PACE ODNs. Among the various sources of water contamination, the most significant is acetonitrile, which must be anhydrous for several key synthesis steps. These include its use as a solvent for the synthons and tetrazole. Acetonitrile
Synthesis of Modified Oligonucleotides and Conjugates
4.24.21 Current Protocols in Nucleic Acid Chemistry
Supplement 18
used to wash the CPG just prior to each condensation step should also be anhydrous. Currently, commercial synthesis-grade acetonitrile is usually sufficiently anhydrous for these steps. It should, however, be checked with a Karl Fisher titrator before use. In order to be absolutely sure that the acetonitrile is anhydrous, distillation from calcium hydride immediately before use is recommended. Another source of water is its adsorption on the synthons during storage. This can be minimized by storing the synthons at −20◦ C under dry argon in a desiccator equipped with Drierite. Prior to opening the desiccator, it should be allowed to attain room temperature. Following transfer of the synthons to vials for use on the synthesizer, the samples should be dried under vacuum overnight to remove final traces of water. In addition to water, there are other precautions that should be followed in order to ensure high repetitive yields during ODN synthesis. One is the quality of tetrazole used to activate the synthons. Commercially available material, if prepared specifically for oligodeoxyribonucleotide synthesis (0.45 M acetonitrile solution), is usually sufficiently pure for direct use; however, even reagent-grade tetrazole as obtained from various suppliers should be purified by sublimation before use in ODN synthesis. Another potential problem relates to the preparation of various synthons. During their synthesis, diisopropylammonium tetrazolide is generated. This salt must be completely removed during flash chromatography; otherwise, it will depress the overall ODN synthesis rate and yield by buffering the condensation reaction. Excessive amounts of this salt can be detected in the 1 H NMR spectra of the purified synthons.
Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
P(III) to P(V) oxidation Another potential problem that can be encountered during ODN synthesis is incomplete sulfurization or oxidation of P(III) to P(V). This leads to degradation of the oligomer, because trivalent phosphorus derivatives are known to be unstable to acid (a key step in the synthesis cycle is acid detritylation). It is difficult to monitor this problem during synthesis because the consequences (loss of stepwise trityl yields and overall deterioration of oligomer quality as observed by HPLC of the products) are common to several unrelated problems in DNA synthesis. If lack of complete oxidation is suspected, this step can be checked by 31 P gel-phase NMR (Greef et al., 1996); however, a more com-
mon solution is to simply replace the oxidation and sulfurization reagents with fresh samples. Once again, it is important to use the correct concentration of the oxidizing agent. The phosphonite internucleotide linkage produced after the phosphonamidite coupling reaction is more easily oxidized than the phosphite triester internucleotide linkage produced after a standard phosphoramidite coupling reaction. The phosphonite internucleotide linkage can be quantitatively oxidized by a 3-min oxidation using 0.1 M CSO in anhydrous acetonitrile. However, the phosphite triester internucleotide linkage requires 0.5 M CSO for at least 3 min. This is an important note for the synthesis of chimeric DNA sequences. Degradation It is well known that alkyl phosphonate internucleotide linkages are unstable toward basic conditions (Hogrefe et al., 1993). Phosphonoacetate and thiophosphonoacetate ODNs suffer from the same problem. For example, with aqueous 40% methylamine at 55◦ C, 1.4% and 1.2%, respectively, of the internucleotide linkages in these oligomers are degraded after 15 min. It is therefore important to limit the deprotection time with this reagent to the minimum required for effective removal of the exocyclic amine–protecting group on cytosine, guanine, and adenine bases. A related potential problem is the use of DBU to remove the dimethylcyanoethyl protecting group. These conditions must be anhydrous. It is recommended that the DBU be dried over 4-Å molecular sieves prior to use and careful attention be given to the concentration of DBU used for removal of the dimethylcyanoethyl protecting groups. The presence of water in the DBU solution will generate hydroxide anions, resulting in degradation of PACE and S-PACE internucleotide linkages, and can also lead to the premature cleavage of the ODN from the solid support. It is important that the concentration of DBU (1.5%) be accurately measured and that exposure of the CPG to this solution be limited to 60 min. Significantly higher concentrations of DBU (even in the absence of water) or very long exposure times can result in premature cleavage of the ODN from the CPG, reducing the recovery yields. Due to the deleterious effect of hydroxide ion on PACE and S-PACE internucleotide linkages, any base should be excluded from the chromatography solvents used to purify these synthons. As a consequence, chromatography must be carried out rapidly in order to minimize any detritylation, which can occur due to the acidity of the
4.24.22 Supplement 18
Current Protocols in Nucleic Acid Chemistry
silica gel. The acidity of silica gel can vary greatly from batch to batch and from manufacturer to manufacturer. In the authors’ experience, most batches of silica gel are not acidic enough to give any significant amount of detritylation. Furthermore, there is a considerable amount of diisopropylammonium tetrazolide in the crude 2 -deoxynucleoside-3 O-(N,N-diisopropylamino)phosphinyl acetate products to help neutralize some excess acid on the silica gel. Nonetheless, detritylation does occur, albeit infrequently, during column chromatography. Detritylation on the column is easily detectable as a bright orange band on the silica column. To eliminate this, a small amount of TEA may be used to neutralize excess acid on silica gel during column packing and equilibration, but excess amine should be thoroughly flushed from the column prior to adding the crude material to the top of the column. Deprotection of internucleotide linkages The use of anhydrous DBU deprotection of cyanoethyl protecting groups on ODNs can result in the undesired side product of N3 alkylation of thymidine residues from the production of acrylonitrile under these conditions. These products can easily be detected by mass spectroscopy (both MALDI-MS and LC/MS). This is one of the reasons that the use of the dimethylcyanoethyl protecting group is recommended over the more typical cyanoethyl protecting group. When protecting groups for the PACE and S-PACE internucleotide linkages were first evaluated, it was discovered that removal of the cyanoethyl protecting group using anhydrous DBU resulted in small amounts of these N3 alkylation products. By switching from cyanoethyl to dimethylcyanoethyl protection of the PACE and S-PACE internucleotide linkages, it was found that detectable amounts of N3 alkylation of the thymidine residues on the ODN products were eliminated, even as evaluated by highly sensitive LC/MS/MS techniques. Handling modified ODNs Once the PACE oligodeoxyribonucleotides are produced, it is important to realize that the internucleotide bond is a weaker acid (pKa ∼ = 3.8) than the phosphodiester bond of native DNA (pKa ∼ = 1.8). The implications in handling these modified oligodeoxyribonucleotides have to do with their solubility in water under acidic conditions. Phosphonoacetate internucleotide bonds can be protonated with weak acids such as acetic acid. Once proto-
nated, the oligodeoxyribonucleotide is significantly less soluble in aqueous solutions. It is important that working solutions are buffered at neutral to slightly higher pH in order to prevent loss by precipitation and adherence to surfaces. This is especially important during trityl-on purification of the oligodeoxyribonucleotide. The final step is removal of the DMTr group using 80% glacial acetic acid followed by desalting on a reversed-phase column. The acetic acid is removed in a vacuum evaporator, leaving behind the modified ODN in its protonated form. In order to completely dissolve the ODN, it is important to use a buffer with enough capacity to neutralize the acidic sites on the backbone. This is accomplished by vortexing the sample vigorously during the initial resuspension of the ODN in a pH 8.0 triethylammonium acetate (TEAA) buffer, evaporating to dryness, and then redissolving the sample once again in TEAA prior to desalting.
Anticipated Results
1,1-Dimethyl-2-cyanoethyl 5 -O-(4,4 dimethoxytrityl)-2 -deoxynucleoside-3 -O(N,N-diisopropylamino)phosphinyl acetates have been used to prepare ODNs up to 25 nt in length. These oligomers contain PACE, S-PACE, phosphorothioate, and phosphate internucleotide linkages in various combinations and have isolated yields of ∼30%. Several examples of those that have been synthesized, including their mass spectral analysis, are included in Table 4.24.5. A typical HPLC profile as obtained by reversed-phase column chromatography (trityl-on) is shown in Figure 4.24.6. Although the peaks are broad, as expected due to the large number of diastereomers, it is clear that the expected product dominates the HPLC profile of the crude reaction mixture. When this oligomer is repurified by column chromatography after removal of the 4,4 dimethoxytrityl group, very few additional side products appear. At this stage of purification, these oligomers are essentially homogeneous (confirmed by analytical ion-exchange HPLC; Dellinger et al., 2003) and can be used for various biochemical experiments. A typical mass spectrum for the PACE Cap ODN (Table 4.24.5) is shown in Figure 4.24.7. Oligomers with stable acetic acid esters (methyl and butyl) have also been prepared and tested for uptake by HeLa and SKBR3 cells. The results (Sheehan et al., 2003) show that these ODNs reversibly accumulate in the cytoplasm of cells (presumably
Synthesis of Modified Oligonucleotides and Conjugates
4.24.23 Current Protocols in Nucleic Acid Chemistry
Supplement 18
Figure 4.24.6 Reversed-phase column chromatography (trityl on) of the total reaction mixture obtained during the preparation of the PACE Cap ODN (see Table 4.24.5 for sequence). Gradient conditions and the column are described in the text.
Figure 4.24.7 MALDI-TOF-MS analysis of PACE Cap ODN. The mass spectrum was determined using conditions described in the text.
Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
by pinocytosis followed by ester hydrolysis). Current research in this area is focused upon enhancing in vivo acetic acid ester hydrolysis by using biologically relevant esters and studying these oligomers for antisense activity. The isolated yields of PACE and S-PACE ODNs depend upon the length, sequence, and number of analog internucleotide linkages. This is because both PACE and S-PACE internucleotide linkages are somewhat labile toward aqueous 40% methylamine. These yields for 18-mers, based upon the amount of
2 -deoxynucleoside attached to CPG, range from 20% to 30% following two reversedphase HPLC column purification steps (tritylon followed by trityl-off). The resulting oligomers are at least 95% homogeneous when evaluated by ion-exchange analytical column chromatography and are ready to be used for various biochemical experiments.
Time Considerations Synthesis of 1,1-dimethyl-2-cyanoethyl [bis(N,N-diisopropylamino)phosphinyl]acetate can take up to four days. The procedure begins
4.24.24 Supplement 18
Current Protocols in Nucleic Acid Chemistry
with the preparation of 1,1-dimethyl-2cyanoethyl bromoacetate, which requires an overnight reflux of bromoacetyl bromide with 3-hydroxy-3-methylbutyronitrile in toluene. The next morning the reflux is stopped and the reaction mixture evaporated to an oil. The 1,1-dimethyl-2-cyanoethyl bromoacetate is purified by distillation, which requires 3 to 4 hr, and the day ends with 1 H NMR analysis of the bromoacetate distillate and 31 P NMR examination of the bis(N,Ndiisopropylamino)chlorophosphine. Clean up of the reflux equipment and set up of the distillation apparatus can usually be accomplished during the evaporation process. The Reformatsky coupling reaction to yield 1,1-dimethyl-2-cyanoethyl [bis(N,Ndiisopropylamino)phosphinyl]acetate will require 3 to 5 hr to set up and complete. Initial isolation of the product by trituration and liquid/liquid extraction will take an additional 3 to 4 hr, including combining the hexane fractions and evaporating the hexane solutions to an oil. The product is then redissolved in hexanes and allowed to cool overnight to precipitate additional impurities. This solution is decanted, concentrated to an oil using a rotary evaporator, and characterized by NMR and mass spectroscopy. This final process can take at least 3 to 4 hr. If optional crystallization of the product from pentane is carried out, the total procedure will be extended by several hours to one day. Preparation of the protected 2 deoxynucleoside-3 -O-(N,N-diisopropylamino)phosphinyl acetates takes ∼2 days. Phosphinylation of the protected 2 -deoxynucleoside is generally completed overnight, and the reaction mixture is evaluated the next morning by TLC and 31 P NMR. If the reaction is complete, triethylamine is added to quench the reaction and the product is purified by medium-pressure silica-gel column chromatography. This purification and isolation procedure usually requires 3 to 4 hr. For ease of handling, the product should be converted to a powder by precipitation into hexanes. This process usually requires only 30 min, but the powder must be dried in a vacuum desiccator overnight in order to remove residual hexanes. Set up for DNA synthesis requires attachment of various reagents and solvents to the DNA synthesizer. These include dichloromethane, acetonitrile, tetrazole (0.45 M in acetonitrile) the detritylation mixture, the two-part capping solution, and both oxidation and sulfurization reagents. This
process requires ∼1 hr. The four appropriately protected 2 -deoxynucleoside-3 -O-(N,Ndiisopropylamino)phosphinyl acetates are dissolved in anhydrous acetonitrile and the bottles placed on the DNA synthesizer. The DNA synthesis cycle for adding one 2 -deoxynucleotide requires ∼45 min. Thus, the automated synthesis of a 20-mer requires ∼15 hr. Deprotection and cleavage of the ODN from CPG takes ∼2 hr. Major steps are removal of the dimethylcyanoethyl group with anhydrous DBU (60 min) and treatment with aqueous methylamine (15 min, 55◦ C), which cleaves the oligomer from CPG and removes exocyclic amine–protecting groups. Following these steps, the reaction mixture is cooled and transferred to a microcentrifuge tube for concentration to dryness (1 to 2 hr). The ODNs are purified by reversed-phase HPLC using the 4,4 -dimethoxytrityl group for hydrophobic affinity. The entire procedure requires ∼12 hr. The first step is trityl-on RPHPLC (50 min) followed by collection of appropriate product fractions and concentration to dryness (2 to 3 hr). Next, the 4,4 dimethoxytrityl group is removed with aqueous 80% glacial acetic acid (90 min, room temperature) followed by concentration to dryness in a centrifugal concentrator. The ODN is then repurified and desalted by RP-HPLC. The same column and gradient can be used for both purifications. Appropriate product fractions are collected, combined, and concentrated to dryness. The resulting products are usually stored up to 6 months at −20◦ C in TE buffer, pH 8.0.
Literature Cited
¨ Arbuzov, A.E. and Dunin, A.A. 1927. Uber phosphon-carbons¨auren. Ber. 60B:291-295. Bayless, P.L. and Hauser, C.R. 1954. A Reformatskii type condensation of aroyl chlorides with ethyl 2-bromoisobutyrate by means of zinc to form β-keto esters. J. Am. Chem. Soc. 76:2306-2308. Caruthers, M.H., Barone, A.D., Beaucage, S.L., Dodds, D.R., Fisher, E.F., McBride, L.J., Matteucci, M., Stabinsky, Z., and J.-Y. Tang. 1987. Chemical synthesis of deoxyoligonucleotides by the phosphoramidite method. Methods Enzymol. 154:287-313. Dellinger, D.J., Sheehan, D.M., Christensen, N.K., Lindberg, J.G., and Caruthers, M.H. 2003. Solid phase chemical synthesis of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides. J. Am. Chem. Soc. 125:940-950. Glen Research. 1996. Non-aqueous oxidation with 10-camphorsulfonyl-oxziridine. Glen Research Corporation Technical Report 9:8-9.
Synthesis of Modified Oligonucleotides and Conjugates
4.24.25 Current Protocols in Nucleic Acid Chemistry
Supplement 18
Greef, C.H., Seeberger, P.H., Caruthers, M.H., Beaton, G., and Bankaitis-Davis, D. 1996. Synthesis of phosphorodithioate RNA by the H-phosphonothioate method. Tetrahedron Lett. 37:4451-4454. Griengl, H., Hayden, W., Penn, G., Declercq, E., and Rosenwirth, B. 1988. Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2 -deoxyuridines—synthesis and antiviral activity. J. Med. Chem. 31:1831-1839. Hogrefe, R.I., Reynolds, M.A., Vaghefi, M.M., Young, K.M., Riley, T.A., Klem, R.E., and Arnold, L.J. Jr. 1993. An improved method for the synthesis and deprotection of methylphosphonate oligonucleotides. In Protocols for Oligonucleotides and Analogs, Vol. 20 (S. Agrawal, ed.) pp. 143-164. Humana Press, Totowa, New Jersey. Lambert, R.W., Martin, J.A., Thomas, G.J., Duncan, I.B., Hall, M.J., and Heimer, E.P. 1989. Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid-esters of 5-bromo2 -deoxyuridine and related pyrimidine nucleosides and acyclonucleosides. J. Med. Chem. 32:367-374. Matrosov, E.I., Tsvetlsov, E.N., Malevannaya, R.A., and Kabachnik, M.I. 1972. Infrared spectra and association of phosphinylacetic acid. Zh. Obshch. Khim. 42:1695-1700. Overby, L.R., Duff, R.G., and Mao, J.C. 1977. Antiviral potential of phosphonoacetic acid. Ann. N.Y. Acad. Sci. 284:310-320.
Rudolph, M.J., Reitman, M.S., MacMillan, E.W., and Cook. A.F. 1996. Phosphonoacetate derivatives of oligodeoxyribonucleotides. Nucleosides Nucleotides 15:1725-1739. Sheehan, D., Lunstad, B., Yamada, C.M., Stell, B., Caruthers, M.H., and Dellinger, D.J. 2003. Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides. Nucl. Acids Res. 31:4109-4118.
Key References Dellinger et al., 2003. See above. This reference outlines the chemistry used to prepare phosphonoacetate and thiophosphonoacetate ODNs from protected 2 -deoxynucleoside-3 O-(N,N-diisopropylamino)phosphinyl acetate synthons. Sheehan et al., 2003. See above. This reference presents initial biochemical and biophysical results with phosphonoacetate and thiophosphonoacetate ODNs.
Contributed by Douglas J. Dellinger Agilent Laboratories Boulder, Colorado Christina M. Yamada and Marvin H. Caruthers University of Colorado Boulder, Colorado
Reddy, M.P., Hanna, N.B., and Farooqui, F. 1994. Fast cleavage and deprotection of oligonucleotides. Tetrahedron Lett. 35:4311-4314.
Oligonucleotides with Phosphonoacetate and Thiophosphonoacetate Diesters
4.24.26 Supplement 18
Current Protocols in Nucleic Acid Chemistry
Base-Modified Oligodeoxyribonucleotides: Using Pyrrolo[2,3-d]pyrimidines to Replace Purines
UNIT 4.25
This unit describes the preparation of phosphoramidites and oligonucleotides derived from nucleosides related to the canonical DNA constituents 2 -deoxyadenosine (dA), 2 -deoxyguanosine (dG), and 2 -deoxyisoguanosine (iGd ). Because the 7-deazapurines (pyrrolo[2,3-d]pyrimidines) closely resemble purines in structure, these compounds are ideal shape mimics to be incorporated into DNA or RNA. Nucleosides may also have a halogen or alkynyl substituent at the 7 position of the 7-deazapurine moiety. Figure 4.25.1 shows a series of typical phosphoramidites used for oligonucleotide synthesis. The figure also compares systematic numbering, which is used for compound names in each protocol, with purine numbering, which is used elsewhere throughout the unit. Basic Protocols 1, 2, and 3 describe the preparation of the phosphoramidites of 7-deaza-7-iodo-2 -deoxyadenosine (I7 c7 Ad ; S.2d; Seela and Zulauf, 1998), 7-deaza7-iodo-2 -deoxyguanosine (I7 c7 Gd ; S.3d; Ramzaeva and Seela, 1996), and 7-deaza-2 deoxyisoguanosine (c7 iGd ; S.6a; Seela and Wei, 1999), respectively. These phosphoramidites are then employed in the solid-phase synthesis of 7-deazapurine-modified oligonucleotides (see Basic Protocol 4). The duplex stabilities of the modified oligonucleotides are subsequently measured (see Basic Protocol 5) and compared with the stabilities of oligonucleotide duplexes containing only the canonical DNA fragments. NOTE: Preparation of the starting nucleosides S.9d and S.12d is described in UNIT 1.10. The structure numbers in that unit do not correspond to the structure numbers used here. NOTE: Unless otherwise noted, use reagent-grade chemicals in all protocol steps. Store all phosphoramidites and oligonucleotides at –18◦ C.
SYNTHESIS OF THE PHOSPHORAMIDITE OF 7-DEAZA-7-IODO-2 -DEOXYADENOSINE
BASIC PROTOCOL 1
The synthesis of the phosphoramidite (S.2d) of 7-deaza-7-iodo-2 -deoxyadenosine (I7 c7 Ad ) is shown in Figure 4.25.2. The unprotected nucleoside S.9d serves as starting material; the preparation of this iodinated nucleoside is described in UNIT 1.10 (also see Seela and Zulauf, 1996). The preparation of the intermediates is straightforward, and the reaction steps presented result in high yields. Directions for preparing the phosphoramidites S.1a, S.1j, S.2a, and S.2f-S.2h (7-deazapurine derivatives of 2 -deoxyadenosine) are similar to those for preparing compound S.2d, with modifications that can be found by referring to the appropriate references (see Fig. 4.25.1). Synthesis of S.8 is similar to S.2 (also see Balow et al., 1998; Okamoto et al., 2002).
Materials 4-Amino-7-(2-deoxy-β-D-erythro-pentofuranosyl)-5-iodo-7H-pyrrolo[2,3d]pyrimidine (systematic numbering; S.9d; see UNIT 1.10), also known as 7-deaza-7-iodo-2 -deoxyadenosine (purine numbering) Methanol (MeOH) N,N-Dimethylformamide dimethylacetal Silica gel 60 for flash chromatography (particle size, <0.063 mm; Merck) Anhydrous dichloromethane (CH2 Cl2 ) Anhydrous pyridine
Contributed by Frank Seela and Xiaohua Peng Current Protocols in Nucleic Acid Chemistry (2005) 4.25.1-4.25.25 C 2005 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Oligonucleotides and Conjugates
4.25.1 Supplement 20
Using Pyrrolo[2,3d]pyrimidines to Replace Purines
Figure 4.25.1
Legend at right.
4.25.2 Supplement 20
Current Protocols in Nucleic Acid Chemistry
Figure 4.25.2 Synthesis of the phosphoramidite derivative of 7-deaza-7-iodo-2 -deoxyadenosine. DMTr, 4,4 -dimethoxytrityl.
4,4 -Dimethoxytrityl chloride (DMTr-Cl) 5% (w/v) sodium bicarbonate (NaHCO3 ) Brine (i.e., saturated aqueous NaCl) Anhydrous sodium sulfate (Na2 SO4 ) Anhydrous N,N-diisopropylethylamine (DIPEA; 99.5% pure) 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite Anhydrous triethylamine (Et3 N) Acetone 10-, 25-, 50-, and 100-mL round-bottom flasks Rotary evaporator connected to a vacuum pump 4 × 70–cm chromatography columns 0.2-mm-thick silica gel 60 F254 aluminum TLC plates (Merck) 254-nm UV lamp High-vacuum pump (final pressure, <1 mmHg) 100-mL separatory funnels 5-cm-diameter funnel with folded 10-cm-diameter Whatman no. 1 filter Argon source Additional reagents and equipment for flash chromatography (APPENDIX 3E) and thin-layer chromatography (TLC; APPENDIX 3D)
Figure 4.25.1 (at left) Selected phosphoramidites used for the synthesis of 7-deazapurinecontaining oligonucleotides. DMTr, 4,4 -dimethoxytrityl. References: S.1a (Seela and Kehne, 1985); S.1j (Seela et al., 2005a); S.2a (Seela et al., 1989); S.2d,f-h (Seela and Zulauf, 1998; Seela and Zulauf, 1999); S.3a (Seela and Driller, 1989); S.3c,d (Ramzaeva and Seela, 1996); S.3e (Seela and Shaikh, 2005), S.3f-h (Ramzaeva et al., 1997); S.3i (Seela and Chen, 1997); S.4a (Seela and Kaiser, 1986); S.5a (Seela et al., 2003); S.6a (Seela and Wei, 1999); S.7b,c and S.8a-d (Seela et al., 2005b).
Synthesis of Modified Oligonucleotides and Conjugates
4.25.3 Current Protocols in Nucleic Acid Chemistry
Supplement 20
Protect exocyclic 4-amine 1. In a 100-mL round-bottom flask equipped with a Teflon stir bar, suspend (with stirring) 400 mg (1.06 mmol) 4-amino-7-(2-deoxy-β-D-erythro-pentofuranosyl)-5iodo-7H-pyrrolo[2,3-d]pyrimidine (S.9d) in 20 mL MeOH at room temperature. 2. Add 1.34 mL (10.0 mmol) N,N-dimethylformamide dimethylacetal and stir the resulting mixture 10 hr at 40◦ C, using an oil bath and contact thermometer to maintain the temperature. 3. Adsorb the reaction mixture onto ∼2 g silica gel 60. Remove the solvent from the adsorbed sample using a rotary evaporator connected to a vacuum pump. 4. Load the dry material onto a 4 × 70–cm column packed with silica gel 60 (bed height, 10 cm). Perform flash chromatography (APPENDIX 3E) using 0.4 bar pressure and an elution gradient from 100% CH2 Cl2 (200 mL) to 90:10 (v/v) CH2 Cl2 /MeOH (400 mL). Collect 10-mL fractions. 5. Monitor fractions by TLC (APPENDIX 3D) on silica gel 60 F254 plates using 90:10 (v/v) CH2 Cl2 /MeOH as the eluent. Visualize products under 254-nm light using a UV lamp. 6. Pool all product fractions, evaporate the solvent using a rotary evaporator, and dry the resulting sample overnight under high vacuum. 7-(2-Deoxy-β-D-erythro-pentofuranosyl)-4-{[(dimethylamino)methylidene]amino}-5iodo-7H-pyrrolo[2,3-d]pyrimidine (S.10) is obtained as a colorless solid (389 mg, 85% yield). TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.5. UV (MeOH): λmax (ε) = 277 (10,400), 323 nm (19,000). 1 H NMR (DMSO-d6 ): δ 2.18 (m, 1H, 2 -Hα ), 2.47 (m, 1H, 2 -Hβ ), 3.18 and 3.22 (2 × s, 6H, Me2 N), 3.54 (m, 2H, 5 -H), 3.81 (m, 1H, 4 -H), 4.32 (m, 1H, 3 -H), 5.00 (t, J = 5.4 Hz, 1H, 5 -OH), 5.23 (d, J = 3.9 Hz, 1H, 3 -OH), 6.52 (t, J = 7.0 Hz, 1H, 1 -H), 7.70 (s, 1H, 6-H), 8.30 (s, 1H, 2-H), 8.82 (s, 1H, N=CH). Anal. calcd. for C14 H18 IN5 O3 : C, 38.99; H, 4.21; N, 16.24; found: C, 39.09; H, 4.27; N, 16.10.
Protect 5 -OH group 7. In a 25-mL round-bottom flask equipped with a Teflon stir bar, prepare a solution of 300 mg (0.70 mmol) compound S.10 in 3.0 mL anhydrous pyridine. 8. Add 256 mg (0.76 mmol) DMTr-Cl in a single portion (with stirring) and stir the resulting mixture 1 hr at 50◦ C, using an oil bath and contact thermometer to maintain the temperature. 9. Pour the reaction mixture into a 100-mL separatory funnel containing 20 mL of 5% NaHCO3 . 10. Extract the aqueous solution twice with 30 mL CH2 Cl2 . Combine the resulting organic layers, wash with brine, and then dry over 2 g anhydrous Na2 SO4 . 11. Filter off the Na2 SO4 by gravity filtration through a folded 10-cm-diameter filter. Evaporate the filtrate to dryness using a rotary evaporator. 12. Dissolve the crude product in ∼2 mL CH2 Cl2 , load it onto a 4 × 70–cm column packed with silica gel 60, and perform flash chromatography (step 4) using an elution gradient from 100% CH2 Cl2 (200 mL) to 90:10 (v/v) CH2 Cl2 /acetone (300 mL). Collect 10-mL fractions. 13. Monitor fractions by TLC (step 5) using 90:10 (v/v) CH2 Cl2 /MeOH as the eluent. Using Pyrrolo[2,3d]pyrimidines to Replace Purines
14. Pool all product fractions, evaporate the solvent using a rotary evaporator, and dry the resulting sample overnight under high vacuum.
4.25.4 Supplement 20
Current Protocols in Nucleic Acid Chemistry
7-[2-Deoxy-5-O-(4,4 -dimethoxytriphenylmethyl)-β-D-erythro-pentofuranosyl]-4{[(dimethylamino)methylidene]amino}-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (S.11) is obtained as a colorless foam (360 mg, 71% yield). TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.6. UV (MeOH): λmax (ε) = 236 (29,200), 275 (12,200), 322 nm (19,600). 1 H NMR (DMSO-d6 ): δ 2.24 (m, 1H, 2 -Hα ), 2.57 (m, 1H, 2 -Hβ ), 3.18 (m, 2H, 5 -H), 3.18 and 3.22 (2 × s, 6H, Me2 N), 3.72 (2 × s, 6H, 2 × MeO), 3.92 (m, 1H, 4 -H), 4.37 (m, 1H, 3 -H), 5.30 (d, J = 4.0 Hz, 1H, 3 -OH), 6.54 (t, J = 6.6 Hz, 1H, 1 -H), 6.84 (m, 4H, aromatic H), 7.22-7.38 (m, 9H, aromatic H), 7.56 (s, 1H, 6-H), 8.31 (s, 1H, 2-H), 8.82 (s, 1H, N=CH). Anal. calcd. for C35 H36 IN5 O5 : C, 57.30; H, 4.95; N, 9.55; found: C, 57.48; H, 5.12; N, 9.44.
Prepare phosphoramidite (S.2d) 15. In a 10-mL round-bottom flask equipped with a Teflon stir bar and kept under argon, prepare a solution of 300 mg (0.41 mmol) compound S.11 in 5 mL anhydrous CH2 Cl2 . 16. Add 104 µL (0.60 mmol) anhydrous N,N-diisopropylethylamine and 118 µL (0.53 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite and stir the resulting mixture 15 min at room temperature under argon. 17. Transfer the reaction mixture to a 100-mL separatory funnel and dilute with 30 mL CH2 Cl2 . Wash twice, each time with 20 mL of 5% NaHCO3 , wash once with 20 mL brine, and then dry over 3 g Na2 SO4 . 18. Filter off the Na2 SO4 and evaporate the filtrate to dryness (step 11). 19. Prewash a 4 × 70–cm silica gel 60 column (bed height, 8 cm) with 200 mL CH2 Cl2 containing 1% (v/v) anhydrous Et3 N and then with 100 mL of 100% CH2 Cl2 . 20. Dissolve the crude product in ∼2 mL CH2 Cl2 , load it onto the column, and perform flash chromatography (step 4) using 95:5 (v/v) CH2 Cl2 /acetone (400 mL) as the eluent. Collect 10-mL fractions. 21. Monitor fractions by TLC (step 5) using 90:10 (v/v) CH2 Cl2 /acetone as the eluent. 22. Pool all product fractions and evaporate the solvent using a rotary evaporator. 23. Dissolve in a small volume (∼2 mL) of CH2 Cl2 in a 25-mL round-bottom flask, evaporate the solvent using a rotary evaporator, and dry the resulting sample under high vacuum for 24 hr at 40◦ C. 7-[2-Deoxy-5-O-(4,4 -dimethoxytriphenylmethyl)-β-D-erythro-pentofuranosyl]-4{[(dimethylamino)methylidene]amino}-5-iodo-7H-pyrrolo[2,3-d]pyrimidine-3 -[(2cyanoethyl)-N,N-diisopropylphosphoramidite] (S.2d) is obtained as a colorless foam (222 mg, 58% yield). TLC (CH2 Cl2 /acetone, 9:1): Rf = 0.24 and 0.32. 31 P NMR (CDCl3 ): δ 149.0, 149.2.
24. If the synthesized phosphoramidite still contains impurities, remove those impurities in the following way. a. In a 100-mL round-bottom flask equipped with a Teflon stir bar, dissolve 0.3 to 1.0 g of the synthesized phosphoramidite in 1 to 2 mL CH2 Cl2 . b. Add ∼90 mL cyclohexane dropwise, with continuous shaking or stirring to dislodge any solid stuck to the walls of the flask. c. Refrigerate overnight. d. Remove the supernatant from the flask and dissolve the residue in 5 mL CH2 Cl2 . e. Transfer the contents of the flask to a 25-mL round-bottom flask, evaporate the solvent using a rotary evaporator, and dry the resulting sample under high vacuum for 24 hr at 40◦ C.
Synthesis of Modified Oligonucleotides and Conjugates
4.25.5 Current Protocols in Nucleic Acid Chemistry
Supplement 20
Figure 4.25.3 Synthesis of the phosphoramidite derivative of 7-deaza-7-iodo-2 -deoxyguanosine. DMTr, 4,4 dimethoxytrityl; i-Bu2 O, isobutyric anhydride.
BASIC PROTOCOL 2
SYNTHESIS OF THE PHOSPHORAMIDITE OF 7-DEAZA-7-IODO-2 -DEOXYGUANOSINE The synthesis of the phosphoramidite (S.3d) of 7-deaza-7-iodo-2 -deoxyguanosine (I7 c7 Gd ; Fig. 4.25.3) is performed as described for the phosphoramidite S.2d (see Basic Protocol 1), with the exception that protection of the 2-amino group is transient (Ti et al., 1982). The preparation of the iodinated nucleoside S.12d is described in UNIT 1.10 (also see Ramzaeva and Seela, 1995). Directions for preparing the phosphoramidites S.3a, S.3c, and S.3e-S.3i (7-deazapurine derivatives of 2 -deoxyguanosine) are similar to those for preparing compound S.3d, with modifications that can be found by referring to the appropriate references (see Fig. 4.25.1).
Materials
Using Pyrrolo[2,3d]pyrimidines to Replace Purines
4-Amino-7-(2-deoxy-β-D-erythro-pentofuranosyl)-5-iodo-7H-pyrrolo[2,3d]pyrimidin-2-one (systematic numbering; S.12d; see UNIT 1.10), also known as 7-deaza-7-iodo-2 -deoxyguanosine (purine numbering) Anhydrous pyridine Chlorotrimethylsilane (Me3 SiCl) Isobutyric anhydride 25% (v/v) ammonium hydroxide (NH4 OH) 4,4 -Dimethoxytrityl chloride (DMTr-Cl) 5% (w/v) sodium bicarbonate (NaHCO3 ) Anhydrous dichloromethane (CH2 Cl2 ) Anhydrous sodium sulfate (Na2 SO4 ) Silica gel 60 for flash chromatography (particle size, <0.063 mm; Merck) Acetone Methanol (MeOH) Anhydrous N,N-diisopropylethylamine (DIPEA) 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite Anhydrous triethylamine (Et3 N) Ethyl acetate (EtOAc)
4.25.6 Supplement 20
Current Protocols in Nucleic Acid Chemistry
10-, 25-, 50-, and 250-mL round-bottom flasks Rotary evaporator connected to a vacuum pump 3-cm-diameter Buchner funnel with filter paper circles High-vacuum pump (final pressure, <1 mmHg) 100-mL separatory funnels 5-cm-diameter funnel with folded 10-cm-diameter Whatman no. 1 filter 4 × 70–cm chromatography columns 0.2-mm-thick silica gel 60 F254 aluminum TLC plates (Merck) 254-nm UV lamp Argon source Additional reagents and equipment for flash chromatography (APPENDIX 3E) and thin-layer chromatography (TLC; APPENDIX 3D) Protect exocyclic 2-amine 1. In a 25-mL round-bottom flask equipped with a stir bar, prepare a solution of 300 mg (0.77 mmol) 4-amino-7-(2-deoxy-β-D-erythro-pentofuranosyl)-5-iodo-7Hpyrrolo[2,3-d]pyrimidin-2-one (S.12d) in 4 mL anhydrous pyridine. 2. Add 0.48 mL (3.78 mmol) Me3 SiCl and stir the resulting mixture 15 min at room temperature. 3. Add 0.62 mL (3.74 mmol) isobutyric anhydride and stir the resulting mixture 3 hr at room temperature. 4. Cool the reaction mixture in an ice bath. After cooling, add 1 mL cold H2 O and stir 5 min on ice. 5. Add 1 mL of 25% NH4 OH and stir the resulting mixture 15 min at room temperature. 6. Evaporate the contents of the round-bottom flask down to a small volume using a rotary evaporator. 7. Crystallize the product (S.13) by adding ∼10 ml H2 O, which should yield colorless crystals. Collect the crystals by vacuum filtration with a 3-cm Buchner funnel, wash twice with 2 mL H2 O, and then dry overnight under high vacuum. 7-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,7-dihydro-5-iodo-2-(isobutyrylamino)-4Hpyrrolo[2,3-d]pyrimidin-4-one (S.13) is obtained as colorless crystals (312 mg, 88% yield). TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.4. m.p. 188◦ C. 1 H NMR (DMSO-d6 ): δ 1.01 (s, 6H, 2 Me), 2.12 (m, 1H, 2 -Hα ), 2.37 (m, 1H, 2 -Hβ ), 2.73 (m, 1H, CH), 3.50 (m, 2H, 5 -H), 3.78 (m, 1H, 4 -H), 4.30 (m, 1H, 3 -H), 4.89 (t, J = 5.7 Hz, 1H, 5 -OH), 5.20 (d, J = 4.3 Hz, 1H, 3 -OH), 6.35 (t, J = 6.5 Hz, 1H, 1 -H), 7.43 (s, 1H, 6-H), 11.49 (s, 1H, NH), 11.76 (s, 1H, NH). Anal. calcd. for C15 H19 IN4 O5 : C, 38.98; H, 4.14; N, 12.12; found: C, 39.11; H, 4.37; N, 11.96.
Protect 5 -OH group 8. In a 25-mL round-bottom flask equipped with a Teflon stir bar, prepare a solution of 400 mg (0.87 mmol) compound 13 in 3.0 mL anhydrous pyridine. 9. Add 328 mg (0.97 mmol) DMTr-Cl and stir the resulting mixture 12 hr at room temperature. 10. Pour into a 100-mL separatory funnel containing 30 mL of 5% NaHCO3 . 11. Extract the aqueous solution twice, each time with 50 mL CH2 Cl2 . Combine the resulting organic layers and dry them over 5 g Na2 SO4 . 12. Filter off the Na2 SO4 by gravity filtration through a folded 10-cm-diameter filter. Evaporate the filtrate to dryness using a rotary evaporator.
Synthesis of Modified Oligonucleotides and Conjugates
4.25.7 Current Protocols in Nucleic Acid Chemistry
Supplement 20
13. Dissolve the crude product in ∼2 mL CH2 Cl2 and load it onto a 4 × 70–cm column packed with silica gel 60 (bed height, 10 cm). Perform flash chromatography (APPENDIX 3E) using 0.4 bar pressure and an elution gradient from 100% CH2 Cl2 (200 mL) to 85:15 (v/v) CH2 Cl2 /acetone (400 mL). Collect 10-mL fractions. 14. Monitor fractions by TLC (APPENDIX 3D) on silica gel 60 F254 plates using 5:1 (v/v) CH2 Cl2 /MeOH as the eluent. Visualize products under 254-nm light using a UV lamp. 15. Pool all product fractions, evaporate the solvent using a rotary evaporator, and dry the resulting sample overnight under high vacuum. 7-[2-Deoxy-5-O-(4,4 -dimethoxytriphenylmethyl)-β-D-erythro-pentofuranosyl]-3,7dihydro-5-iodo-2-(isobutyrylamino)-4H-pyrrolo[2,3-d]pyrimidin-4-one (S.14) is obtained as a colorless, amorphous solid (600 mg, 91% yield). TLC (CH2 Cl2 /MeOH, 5:1): Rf = 0.5. 1 H NMR (DMSO-d6 ): δ 1.13 (m, 12H, 4 Me), 2.24 (m, 2H, 2 -H), 2.77 (m, 1H, CH), 3.12 (m, 2H, 5 -H), 3.75 (s, 6H, 2 MeO), 3.93 (m, 1H, 4 -H), 4.35 (m, 1H, 3 -H), 5.30 (d, J = 4.5 Hz, 1H, 3 -OH), 6.39 (t, J = 6.5 Hz, 1H, 1 -H), 6.86-7.39 (m, 13H, aromatic H, 6-H), 11.54 (s, 1H, NH), 11.82 (s, 1H, NH). Anal. calcd. for C36 H37 IN4 O7 : C, 56.55; H, 4.88; N, 7.33; found: C, 56.42; H, 4.82; N, 7.30.
Prepare phosphoramidite (S.3d) 16. To a 25-mL round-bottom flask equipped with a Teflon stir bar, add 230 mg (0.30 mmol) compound S.14. Purge with argon, and then add 5.0 mL anhydrous CH2 Cl2 . 17. Add 100 µL (0.58 mmol) anhydrous N,N-diisopropylethylamine and 100 µL (0.45 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite and stir the resulting mixture 30 min at room temperature under argon. 18. Transfer the reaction mixture to a 100-mL separatory funnel and dilute with 30 mL CH2 Cl2 . Wash twice, each time with 20 mL of 5% NaHCO3 , and then dry over Na2 SO4 . 19. Filter off the Na2 SO4 and evaporate the filtrate to dryness using a rotary evaporator. 20. Prewash a 4 × 70–cm silica gel 60 column (bed height, 10 cm) with 200 mL CH2 Cl2 containing 1% (v/v) anhydrous Et3 N and then with 100 mL of 100% CH2 Cl2 . 21. Dissolve the crude product in ∼2 mL CH2 Cl2 , load it onto the column, and perform flash chromatography (step 13) using 95:5 (v/v) CH2 Cl2 /acetone (400 mL) as the eluent. Collect 10-mL fractions. 22. Monitor fractions by TLC (step 14) using 69:30:1 (v/v/v) CH2 Cl2 /EtOAc/Et3 N as the eluent. 23. Pool the S.3d-containing fractions and evaporate the solvent using a rotary evaporator. 24. Dissolve in a small volume (∼2 mL) of CH2 Cl2 . Transfer this solution to a 10-mL round-bottom flask, evaporate the solvent using a rotary evaporator, and dry the resulting sample under high vacuum for 24 hr at 40◦ C. 7-[(2-Deoxy-5-O-(4,4 -dimethoxytriphenylmethyl)-β-D-erythro-pentofuranosyl]3,7-dihydro-5-iodo-2-(isobutyrylamino)-4H-pyrrolo[2,3-d]pyrimidin-4-one-3 -[(2cyanoethyl)-N,N-diisopropylphosphoramidite] (S.3d) is obtained as a colorless foam (125 mg, 54% yield). TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.8. 31 P NMR (CDCl3 ): δ 148.0, 148.7. Using Pyrrolo[2,3d]pyrimidines to Replace Purines
4.25.8 Supplement 20
Current Protocols in Nucleic Acid Chemistry
25. If the synthesized phosphoramidite still contains impurities, remove those impurities in the following way. a. In a 100-mL round-bottom flask equipped with a Teflon stir bar, dissolve 0.3 to 1.0 g of the synthesized phosphoramidite in 1 to 2 mL CH2 Cl2 . b. Add ∼90 mL cyclohexane dropwise, with continuous shaking or stirring to dislodge any solid stuck to the walls of the flask. c. Refrigerate overnight. d. Remove the supernatant from the flask and dissolve the residue in 5 mL CH2 Cl2 . e. Transfer the contents of the flask to a 25-mL round-bottom flask, evaporate the solvent using a rotary evaporator, and dry the resulting sample under high vacuum for 24 hr at 40◦ C.
SYNTHESIS OF THE PHOSPHORAMIDITE OF 7-DEAZA-2 -DEOXYISOGUANOSINE
BASIC PROTOCOL 3
The synthesis of the phosphoramidite S.6a is performed as described for the phosphoramidite S.3d (see Basic Protocol 2), with the exception that the 2-oxo group of 7deaza-2 -deoxyisoguanosine (S.15a) must be protected with a diphenylcarbamoyl group (Fig. 4.25.4). To avoid the formation of the 2,5 -bis(diphenylcarbamoyl) derivative, the ratio of diphenylcarbamoyl chloride to compound S.15a should not exceed 3:2. The preparation of the starting nucleoside S.15a is described in Seela and Wei (1999). Directions for preparing the phosphoramidites S.7b and S.7c (7-deazapurine derivatives of 2 -deoxyisoguanosine) are similar to those for preparing compound S.6a, with modifications that can be found by referring to the appropriate references (see Fig. 4.25.1).
Materials 4-Amino-7-(2-deoxy-β-D-erythro-pentofuranosyl)-1,7-dihydro-2H-pyrrolo[2,3d]pyrimidin-2-one (systematic numbering; S.15a; see Seela and Wei, 1999), also known as 7-deaza-2 -deoxyisoguanosine (purine numbering) Anhydrous pyridine Diphenylcarbamoyl chloride Anhydrous N,N-diisopropylethylamine (DIPEA) Crushed ice 5% (w/v) sodium bicarbonate (NaHCO3 ) Anhydrous dichloromethane (CH2 Cl2 ) Anhydrous sodium sulfate (Na2 SO4 ) Silica gel 60 for flash chromatography (particle size, <0.063 mm; Merck) Methanol (MeOH) Chlorotrimethylsilane (Me3 SiCl) Isobutyryl chloride 25% (v/v) ammonium hydroxide (NH4 OH) 4,4 -Dimethoxtrityl chloride (DMTr-Cl) Acetone 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite Brine (i.e., saturated aqueous NaCl) Anhydrous triethylamine (Et3 N) 10-, 50-, 100-, and 250-mL round-bottom flasks 50- and 100-mL separatory funnels 5-cm-diameter funnel with folded 10-cm-diameter Whatman no. 1 filter Rotary evaporator connected to a vacuum pump 4 × 70–cm chromatography columns
Synthesis of Modified Oligonucleotides and Conjugates
4.25.9 Current Protocols in Nucleic Acid Chemistry
Supplement 20
Figure 4.25.4 Synthesis of the phosphoramidite derivative of 7-deaza-2 -deoxyisoguanosine. DMTr, 4,4 -dimethoxytrityl; i-Bu-Cl, isobutyryl chloride.
0.2-mm-thick silica gel 60 F254 aluminum TLC plates (Merck) 254-nm UV lamp High-vacuum pump (final pressure, <1 mmHg) Argon source Additional reagents and equipment for flash chromatography (APPENDIX 3E) and thin-layer chromatography (TLC; APPENDIX 3D)
Using Pyrrolo[2,3d]pyrimidines to Replace Purines
Protect exocyclic 2-oxo group 1. In a 100-mL round-bottom flask equipped with a Teflon stir bar, suspend (with stirring) 1.15 g (4.32 mmol) 4-amino-7-(2-deoxy-β-D-erythro-pentofuranosyl)-1,7dihydro-2H-pyrrolo[2,3-d]pyrimidin-2-one (S.15a) in 25 mL anhydrous pyridine.
4.25.10 Supplement 20
Current Protocols in Nucleic Acid Chemistry
2. Add 1.54 g (6.65 mmol) diphenylcarbamoyl chloride and 1.1 mL (6.32 mmol) anhydrous N,N-diisopropylethylamine and stir the resulting mixture 2 hr at room temperature. 3. Add ∼5 g crushed ice to the reaction mixture and stir 5 to 10 min. 4. Pour into a 100-mL separatory funnel containing 30 mL of 5% NaHCO3 . 5. Extract the aqueous solution twice, each time with 40 mL CH2 Cl2 . Combine the resulting organic layers and dry them over 5 g Na2 SO4 . 6. Filter off the Na2 SO4 by gravity filtration through a folded 10-cm-diameter filter. Evaporate the filtrate to dryness using a rotary evaporator. 7. Dissolve the crude product in ∼5 mL of 97:3 (v/v) CH2 Cl2 /MeOH and load it onto a 4 × 70–cm column packed with silica gel 60 (bed height, 10 cm). Perform flash chromatography (APPENDIX 3E) using 0.4 bar pressure and an elution gradient from 97:3 (v/v) CH2 Cl2 /MeOH (300 mL) to 90:10 (v/v) CH2 Cl2 /MeOH (500 mL). Collect 10-mL fractions. 8. Monitor fractions by TLC (APPENDIX 3D) on silica gel 60 F254 plates using 90:10 (v/v) CH2 Cl2 /MeOH as the eluent. Visualize products under 254-nm light using a UV lamp. 9. Pool all product fractions, evaporate the solvent using a rotary evaporator, and dry the resulting sample overnight under high vacuum. 4-Amino-7-(2-deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl diphenylcarbamate (S.16) is obtained as a colorless foam (1.58 g, 79% yield). TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.40. UV (MeOH): λmax (ε) = 269 nm (12900). 1 H NMR (DMSO-d6 ): δ 2.15 (m, 1H, 2 -Hα ), 2.42 (m, 1H, 2 -Hβ ), 3.53 (m, 2H, 5 -H), 3.80 (m, 1H, 4 -H), 4.33 (m, 1H, 3 -H), 4.96 (t, J = 5.5 Hz, 1H, 5 -OH), 5.25 (d, J = 4.0 Hz, 1H, 3 -OH), 6.39 (t, J = 6.8 Hz, 1H, 1 -H), 6.59 (d, J = 3.5 Hz, 1H, 5-H), 7.25-7.48 (m; 13H, 6-H; NH2 and aromatic H). Anal. calcd. for C24 H23 N5 O5 : C, 62.46; H, 5.02; N, 15.18; found: C, 62.63; H, 5.17; N, 15.08.
Protect exocyclic 4-amine 10. In a 100-mL round-bottom flask equipped with a Teflon stir bar, prepare a solution of 1.03 g (2.23 mmol) compound 16 in 20 mL anhydrous pyridine. 11. Add 2.0 mL (15.76 mmol) Me3 SiCl and stir the resulting mixture 25 min at room temperature. 12. Add 0.80 mL (7.64 mmol) isobutyryl chloride and stir the resulting mixture 2 hr at room temperature. 13. Cool the reaction mixture in an ice bath. After cooling, add 5.0 mL prechilled H2 O and stir 5 to 10 min on ice. 14. Add 12 mL of 25% NH4 OH and stir the resulting mixture 2.5 hr at room temperature. 15. Pour the mixture into a 100-mL separatory funnel containing 30 mL of 5% NaHCO3 . 16. Extract the aqueous solution four times, each time with 40 mL CH2 Cl2 . Combine the resulting organic layers and dry them over 5 g anhydrous Na2 SO4 . 17. Filter off the Na2 SO4 by gravity filtration through a folded 10-cm-diameter filter. Evaporate the filtrate to dryness using a rotary evaporator. 18. Dissolve the crude product in ∼5 mL of 98:2 (v/v) CH2 Cl2 /MeOH and perform flash chromatography (step 7) using an elution gradient from 98:2 (v/v) CH2 Cl2 /MeOH (300 mL) to 95:5 (v/v) CH2 Cl2 /MeOH (500 mL). Collect 10-mL fractions.
Synthesis of Modified Oligonucleotides and Conjugates
4.25.11 Current Protocols in Nucleic Acid Chemistry
Supplement 20
19. Monitor fractions by TLC (step 8) using 90:10 (v/v) CH2 Cl2 /MeOH as the eluent. 20. Pool all product fractions, evaporate the solvent using a rotary evaporator, and dry the resulting sample overnight under high vacuum. 7-(2-Deoxy-β-D-erythro-pentofuranosyl)-4-[(2-methylpropanoyl)amino]-7Hpyrrolo[2,3-d]pyrimidin-2-yl diphenylcarbamate (S.17) is obtained as a colorless foam (0.95 g, 80% yield). TLC (CH2 Cl2 /MeOH, 9:1): Rf = 0.52. UV (MeOH): λmax (ε) = 221 (40,000), 233 (36,500), 294 nm (7,200). 1 H NMR (DMSO-d6 ): δ 1.11 and 1.14 (2 × s, 6H, 2 Me), 2.21 (m, 1H, 2 -Hα ), 2.42 (m, 1H, 2 -Hβ ), 2.87 (m, 1H, CH), 3.54 (m, 2H, 5 -H), 3.83 (m, 1H, 4 -H), 4.36 (m, 1H, 3 -H), 4.92 (t, J = 5.3 Hz, 1H, 5 -OH), 5.31 (d, J = 4.2 Hz, 1H, 3 -OH), 6.55 (t, J = 6.5 Hz, 1H, 1 -H), 6.84 (d, J = 4.0 Hz, 1H, 5-H), 7.30-7.63 (m, 11H, 6-H and aromatic H), 11.0 (s, 1H, NH). Anal. calcd. for C28 H29 N5 O6 : C, 63.27; H, 5.50; N, 13.18; found: C, 63.19; H, 5.60; N, 13.07.
Protect 5 -OH group 21. In a 50-mL round-bottom flask equipped with a Teflon stir bar, prepare a solution of 531 mg (1.0 mmol) compound 17 in 10.0 mL anhydrous pyridine. 22. Add 373 mg (1.10 mmol) DMTr-Cl and stir the resulting mixture 3.5 hr at room temperature. 23. Add 5 mL MeOH and stir the resulting mixture 15 min at room temperature. 24. Pour into a 50-mL separatory funnel containing 15 mL of 5% NaHCO3 . 25. Extract the aqueous solution three times, each time with 15 mL CH2 Cl2 . Combine the resulting organic layers and dry them over Na2 SO4 . 26. Filter off the Na2 SO4 by gravity filtration through a folded 10-cm-diameter filter. Evaporate the filtrate to dryness using a rotary evaporator. 27. Dissolve the crude product in ∼2 mL CH2 Cl2 and load it onto a 4 × 70–cm column packed with silica gel 60 (bed height, 8 cm). Perform flash chromatography (step 7) using an elution gradient from 100% CH2 Cl2 (300 mL) to 90:10 (v/v) CH2 Cl2 /acetone (300 mL). Collect 10-mL fractions. 28. Monitor fractions by TLC (step 8) using 90:10 (v/v) CH2 Cl2 /acetone as the eluent. 29. Pool all product fractions, evaporate the solvent using a rotary evaporator, and dry the resulting sample overnight under high vacuum. 7-[2-Deoxy-5-O-(4,4 -dimethoxytriphenylmethyl)-β-D-erythro-pentofuranosyl]-4-[(2methylpropanoyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-2-yl diphenylcarbamate (S.18) is obtained as a colorless foam (622 mg, 75% yield). TLC (CH2 Cl2 /acetone, 9:1): Rf = 0.70. UV (MeOH): λmax (ε) = 221 (55,700), 233 (56,100), 294 nm (7,600). 1 H NMR (DMSO-d6 ): δ 1.13 and 1.15 (2 × s, 6H, 2 Me), 2.30 (m, 2H, 2 -H), 2.88 (m, 1H, CH), 3.16 (m, 2H, 5 -H), 3.72 (s, 6H, 2 MeO), 3.95 (m, 1H, 4 -H), 4.38 (m, 1H, 3 -H), 5.37 (d, J = 4.1 Hz, 1H, 3 -OH), 6.58 (t, J = 6.3 Hz, 1H, 1 -H), 6.58 (d, J = 4.0 Hz, 1H, 5-H), 7.22-7.46 (m, 24H, 6-H and aromatic H), 11.0 (s, 1H, NH). Anal. calcd. for C28 H29 N5 O6 : C, 70.57; H, 5.68; N, 8.40; found: C, 70.29; H, 5.65; N, 8.33.
Prepare phosphoramidite (S.6a) 30. In a 50-mL round-bottom flask equipped with a Teflon stir bar and kept under argon, prepare a solution of 320 mg (0.38 mmol) compound 18 in 11.0 mL anhydrous CH2 Cl2 .
Using Pyrrolo[2,3d]pyrimidines to Replace Purines
31. Add 104 µL (0.60 mmol) anhydrous N,N-diisopropylethylamine and 120 µL (0.54 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite and stir the resulting mixture 30 min at room temperature under argon.
4.25.12 Supplement 20
Current Protocols in Nucleic Acid Chemistry
32. Transfer the reaction mixture to a 100-mL separatory funnel and dilute with 30 mL CH2 Cl2 . Wash twice, each time with 20 mL of 5% NaHCO3 , wash once with 20 mL brine, and then dry over 3 g Na2 SO4 . 33. Filter off the Na2 SO4 by gravity filtration through a folded 10-cm-diameter filter. Evaporate the filtrate to dryness using a rotary evaporator. 34. Prewash a 4 × 70–cm silica gel 60 column (bed height, 10 cm) with 200 mL CH2 Cl2 containing 1% (v/v) anhydrous Et3 N and then with 100 mL of 100% CH2 Cl2 . 35. Dissolve the crude product in ∼2 mL CH2 Cl2 , load it onto the column, and perform flash chromatography (step 7) using 93:7 (v/v) CH2 Cl2 /acetone (400 mL) as the eluent. Collect 10-mL fractions. 36. Monitor fractions by TLC (step 8) using 93:7 (v/v) CH2 Cl2 /acetone as the eluent. 37. Pool all product fractions and evaporate the solvent using a rotary evaporator. 38. Dissolve in a small volume (∼2 mL) of CH2 Cl2 . Transfer this solution to a 25-mL round-bottom flask, evaporate the solvent using a rotary evaporator, and dry the resulting sample under high vacuum for 24 hr at 40◦ C. 7-[2-Deoxy-5-O-(4,4 -dimethoxytriphenylmethyl)-β-D-erythro-pentofuranosyl]-4-[(2methylpropanoyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-2-yl diphenylcarbamate 3 -[(2cyanoethyl)-N,N-diisopropylphosphoramidite] (S.6a) is obtained as a colorless foam (337 mg, 84% yield). TLC (CH2 Cl2 /acetone, 9:1): Rf = 0.8. 31 P NMR (CDCl3 ): δ 149.7, 149.9.
39. If the synthesized phosphoramidite still contains impurities, remove those impurities in the following way. a. In a 100-mL round-bottom flask equipped with a Teflon stir bar, dissolve 0.3 to 1.0 g of the synthesized phosphoramidite in 1 to 2 mL CH2 Cl2 . b. Add ∼90 mL cyclohexane dropwise, with continuous shaking or stirring to dislodge any solid stuck to the walls of the flask. c. Refrigerate overnight. d. Remove the supernatant from the flask and dissolve the residue in 5 mL CH2 Cl2 . e. Transfer the contents of the flask to a 25-mL round-bottom flask, evaporate the solvent using a rotary evaporator, and dry the resulting sample under high vacuum for 24 hr at 40◦ C.
SYNTHESIS AND PURIFICATION OF OLIGONUCLEOTIDES CONTAINING 7-DEAZA-2 -DEOXYRIBONUCLEOSIDES
BASIC PROTOCOL 4
This protocol describes the preparation and purification of oligonucleotides containing the 7-deaza-2 -deoxyribonucleosides shown in Figure 4.25.5. The oligonucleotides 20 to 58 (shown in Tables 4.25.1, 4.25.2, 4.25.3, 4.25.4, and 4.25.5) are prepared via phosphoramidite chemistry on a 1-µmol scale using standard reaction cycles on an automated DNA synthesizer (ABI 392-08; Applied Biosystems) operating in DMTr-on mode. The phosphoramidites S.1 to S.8 (Fig. 4.25.1) and other standard phosphoramidites are employed. The average coupling yield of the base-modified phosphoramidites is >95% in all cases. Oligonucleotides synthesized using this protocol are purified by reversed-phase HPLC (RP-HPLC), and composition analysis is subsequently performed. Product masses are determined by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (UNIT 10.1). The preparation of the oligonucleotide 5 -d(ATiC iCA15a
Synthesis of Modified Oligonucleotides and Conjugates
4.25.13 Current Protocols in Nucleic Acid Chemistry
Supplement 20
Figure 4.25.5 Base-modified nucleosides incorporated into the oligonucleotides shown in Tables 4.25.1, 4.25.2, 4.25.3, 4.25.4, and 4.25.5.
TTA T15aA)-3 (53; where iC = m5 iCd = 5-methyl-2 -deoxyisocytidine) is described below as a typical example (Table 4.25.5). The phosphoramidite S.6a was employed for the incorporation of S.15a. The synthesis and purification of oligonucleotides 20 through 52 and 54 through 58 are performed in a similar manner using the appropriate phosphoramidites. After standard cleavage from the solid support and deprotection of the cyanoethyl groups in 25% NH4 OH for 1 hr at room temperature, the oligonucleotides 53, 54, 55, 57, and 58 (all containing 2 -deoxyisoguanosine analogs) are base-deprotected by heating the ammonia solution to 60◦ C for 20 to 24 hr. (The standard base deprotection procedure calls for heating of the solution to 60◦ C for 16 hr.) The authors confirmed the homogeneity of each synthesized oligonucleotide by ion-exchange chromatography on a NucleoPac-PA-100 column (4 × 50 cm; Dionex).
Materials
Using Pyrrolo[2,3d]pyrimidines to Replace Purines
Phosphoramidite solutions (0.1 M in MeCN): 2 -deoxyadenylate, 2 -deoxythymidylate, 5-methyl-2 -deoxyisocytidylate, and 7-deaza-2 -deoxyisoguanylate (S.6a; see Basic Protocol 3) 25% (v/v) aqueous ammonium hydroxide (NH4 OH) Mobile phase A: acetonitrile (MeCN) Mobile phase B: 95:5 (v/v) 0.1 M TEAA buffer (pH 7.0)/acetonitrile (see recipe) 2.5% (v/v) dichloroacetic acid (Cl2 CHCOOH) in anhydrous dichloromethane (CH2 Cl2 ) Anhydrous triethylamine (Et3 N)
4.25.14 Supplement 20
Current Protocols in Nucleic Acid Chemistry
Methanol (MeOH) 0.1 M Tris·Cl, pH 8.9 (see recipe) 36.2 U/mL snake venom phosphodiesterase I (SVPD; EC 3.1.4.1; Crotalus adamanteus; Amersham) 1 U/µL alkaline phosphatase (EC 3.1.3.1; calf intestine; Roche Diagnostics) ABI 392-08 automated DNA synthesizer (Applied Biosystems) SpeedVac evaporator (Savant) HPLC apparatus, including: 4 × 125–mm and 4 × 250–mm RP-18 LiChrospher columns (Merck) 655A-12 HPLC pump (Merck/Hitachi) 655A variable-wavelength monitor (Merck/Hitachi) L-5000 controller unit (Merck/Hitachi) D-2000 chromatogram peak integrator (Merck/Hitachi) 5-mL polypropylene tubes 1-mL quartz cuvette (1-cm path length) UV-Vis spectrophotometer Additional reagents and equipment for automated oligonucleotide synthesis (APPENDIX 3C) using phosphoramidite chemistry (UNIT 3.3), reversed-phase high-performance liquid chromatography (RP-HPLC; UNIT 10.5), and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS; UNIT 10.1) NOTE: Phosphoramidites should be dried under high vacuum (<1 mmHg) for 20 to 24 hr at 40◦ C before being applied to the DNA synthesizer.
Synthesize and purify 5 -DMTr-protected oligonucleotide 1. Using phosphoramidite chemistry, prepare the oligonucleotide 5 -DMTr-53 on a 1-µmol scale in an ABI 392-08 synthesizer operating in DMTr-on mode (also see UNIT 3.3 and APPENDIX 3C). The oligonucleotide is automatically cleaved from the solid support by treatment for 1 hr with 25% (v/v) NH4 OH, and the cyanoethyl groups are removed from the oligonucleotide (at room temperature) as well.
2. Base-deprotect the oligonucleotide by heating to 60◦ C in 2 mL of 25% NH4 OH for 20 to 24 hr. 3. Evaporate the 5 -DMTr-53 solution to dryness in a SpeedVac evaporator. Dissolve the resulting sample in 500 µL H2 O. 4. Purify by RP-HPLC (UNIT 10.5) on a 4 × 250–mm RP-18 column with 260-nm detection, using the following elution gradient at a flow rate of 1.0 mL/min: 0-3 min 3-15 min 15-20 min
10% to 15% mobile phase B 15% to 50% mobile phase B 50% to 10% mobile phase B
Collect the desired fraction (retention time, ∼12 min) in a 5-mL polypropylene tube. 5. Evaporate the collected fraction to dryness in a SpeedVac evaporator.
Detritylate and purify 5 -OH oligonucleotide 6. Treat purified 5 -DMTr-53 with 200 µL of 2.5% Cl2 CHCOOH in CH2 Cl2 for 5 min at room temperature. 7. Neutralize the sample with 100 µL Et3 N and evaporate to dryness in a SpeedVac evaporator. Dissolve in 500 µL H2 O.
Synthesis of Modified Oligonucleotides and Conjugates
4.25.15 Current Protocols in Nucleic Acid Chemistry
Supplement 20
8. Purify by RP-HPLC (step 4) using the following gradient: 0-25 min 25-30 min 30-35 min
0% to 20% mobile phase B 20% mobile phase B 20% to 0% mobile phase B
Collect the desired fraction (retention time, ∼15 min) in a 5-mL polypropylene tube. 9. Evaporate the collected fraction to dryness in a SpeedVac evaporator. Dissolve the resulting sample in 500 µL H2 O.
Desalt purified oligonucleotide 10. Load the sample onto a 4 × 125–mm RP-18 column and desalt by performing RP-HPLC using H2 O to elute the salt (1 hr at 0.7 mL/min) followed by 3:2 (v/v) MeOH/H2 O to elute the oligonucleotide (∼3 to 5 min at 0.7 mL/min). Collect the oligonucleotide fraction in a 5-mL polypropylene tube. 11. Evaporate to dryness in a SpeedVac evaporator. Dissolve the resulting sample in 100 µL H2 O and store frozen at –18◦ C. As an alternative to steps 6 to 11, the oligonucleotide can be obtained as a sodium salt by (1) treating the evaporated fraction from step 5 with 250 µL of 80% (v/v) acetic acid for 30 min at room temperature; (2) evaporating the resulting solution to near-dryness using a SpeedVac evaporator (without heating); (3) adding 350 µL of 1 M NaCl; and (4) adding 1.1 mL ethanol and cooling in an ice bath for 15 min to precipitate the product. The precipitated oligonucleotide can then be collected by centrifugation for 15 min at 12,000 rpm, ∼10◦ C, with the supernatant being saved until an optical density measurement can be made.
Determine product yield 12. Add 2 µL of the product solution to 1 mL H2 O in a 1-mL quartz cuvette. Measure the optical density of the sample at 260 nm (OD260 ) in a UV-Vis spectrophotometer, using H2 O as a reference. Calculate the total amount of oligonucleotide synthesized by multiplying the measured OD260 /mL by the dilution factor (500) and the sample volume (0.1 mL). For 2 µL product in 1 mL H2 O, the authors measured an OD260 of 0.64, corresponding to a total yield of 0.64 OD260 /mL × 500 × 0.1 mL = 32 OD260 units.
13. Convert the calculated yield from OD units to mmol using the equation: yield (mmol) = yield (OD260 units)/[0.9 × ε260 (M−1 · cm−1 )]. The molar extinction coefficients (ε 260 ) of the nucleosides used to make oligonucleotide 53 are as follows: c7 iGd (S.15a), 7,400; dA, 15,400; dT, 8,800; m5 iCd , 6,300. Each coefficient is multiplied by the number of residues in the sequence. Thus, the total amount of oligonucleotide 53 obtained in this example is 32/[0.9 × (2 × 7400 + 2 × 6300 + 4 × 15400 + 4 × 8800)] = 0.29 × 10−3 mmol, corresponding to a yield of 29%.
Analyze oligonucleotide composition 14. Dissolve 0.5 OD260 units (4.5 nmol) of product in 300 µL of 0.1 M Tris·Cl, pH 8.9. 15. Add 5 µL SVPD and incubate 1 hr at 37◦ C. Snake venom phosphodiesterase I cleaves the phosphodiester bonds of the oligonucleotide from the 3 direction to give 5 monophosphates.
16. Add 5 µL alkaline phosphatase and incubate 1 hr at 37◦ C. Using Pyrrolo[2,3d]pyrimidines to Replace Purines
Alkaline phosphatase cleaves the 5 monophosphates to give free nucleosides.
4.25.16 Supplement 20
Current Protocols in Nucleic Acid Chemistry
17. Load the mixture onto a 4 × 250–mm RP-18 column and perform RP-HPLC using the following gradient at a flow rate of 0.7 mL/min: 0-20 min 20-40 min 40-60 min
100% mobile phase B 100% to 35% mobile phase B 35% to 100% mobile phase B.
To provide a reference for identifying peaks in the chromatogram yielded by the experimental mixture, chromatograms of the purified monomeric nucleosides are also obtained.
18. Calculate the relative amount of each constituent in the product solution by dividing the peak area by the molar extinction coefficient. Relevant molar extinction coefficients (λ = 260 nm) for analyzing product composition include the following: c7 iGd , 7,400; Cl7 c7 iGd , 6,350; Br7 c7 iGd , 5,840; iGd , 4,300; dA, 15,400; dT, 8,800; dG, 11,700; dC, 7,600; m5 iCd , 6,300.
19. Determine the molecular mass of the purified product by MALDI-TOF-MS (e.g., on a Bruker Biflex-III spectrometer operating in reflector mode; see UNIT 10.1). The observed mass of oligonucleotide 53 (3670.3 Da) is in good agreement with the calculated mass (3669.5 Da).
DETERMINATION OF TRANSITION (MELTING) TEMPERATURE AND THERMODYNAMIC DATA
BASIC PROTOCOL 5
The Tm values of duplexes containing the base-modified nucleosides S.9a (Seela and Kehne, 1983), S.9b,c,i (Seela and Thomas, 1994), S.9d,f (Seela and Zulauf, 1996), S.9j (F. Seela and K. Xu, unpub. observ.), S.12a-d,f,i (Winkeler and Seela, 1983; Ramzaeva and Seela, 1995; Seela and Chen, 1997), S.12e (Buhr et al., 1996), S.15a-c (Seela and Peng, 2004), and S.19a-d (Seela et al., 1987; Seela and Peng, 2004) were determined from absorbance-temperature profiles. Tm values (Tables 4.25.1, 4.25.2, 4.25.3, 4.25.4, and 4.25.5) were measured on a Cary-1/3 UV-Vis spectrophotometer (Varian) equipped with a thermoelectric controller. The temperature was increased by 1.0◦ C/min from 10◦ to 95◦ C, and the melting profile was monitored at 260 nm. UV absorbance was recorded every 30 sec, and Tm values were determined based on polynomial fits of the resulting UV absorbance curves. The temperature at which the first derivative of the UV melting curve was at a maximum was taken to be the Tm . Thermodynamic data were calculated using the program Meltwin 3.0 (McDowell and Turner, 1996). All experiments were performed in low-salt or high-salt buffer, pH 7.0 (see recipes).
Oligonucleotides Containing the 2 -Deoxyadenosine Analogs S.9a-d,f,i From Table 4.25.1, it is apparent that the replacement of the standard dA residue with the 7-deaza compound S.9a has only a minor influence on duplex stability (Tm = 0.25◦ C per modified base for duplex 21·21 versus 20·20). Incorporation of the 7-methylated nucleoside S.9i results in a slight increase in stability (Tm = 0.65◦ C per modified base for 25·25). However, when nucleosides containing 7-halogeno substituents (S.9b-d) or a 7-hexynyl group (S.9f) are introduced, Tm values increase significantly (Tm = 2◦ C per modified base for S.9b-c, 2.15◦ C for S.9d, and 1.55◦ C for S.9f). Oligonucleotides Containing the 2,6-Diaminopurine Derivatives S.19a-d A very similar situation is observed in the case of the 2,6-diamino derivatives S.19ad (Table 4.25.2). The replacement of the dA residue with the nucleoside S.19a (R = H) has no influence on duplex stability (duplex 29·30), while the incorporation of the 7-halogenated derivatives S.19b-d significantly increases the Tm value (Tm = 2.3◦ to 3.0◦ C per modified base; see duplexes 31·32, 33·34, and 35·36). Furthermore, compounds S.19a and S.19d result in higher Tm values compared with the
Synthesis of Modified Oligonucleotides and Conjugates
4.25.17 Current Protocols in Nucleic Acid Chemistry
Supplement 20
Table 4.25.1 Tm Values and Thermodynamic Data for Self-Complementary Oligonucleotides Containing 2 -Deoxyadenosine Analogs S.9a-d,f,ia
Duplex
Tm (◦ C)
[d(A-T)6 ]2 (20·20)
33
Tm b (◦ C)
H◦ (kcal/mol)
S◦ (cal/mol · K)
G◦ 310 (kcal/mol)
−45
−125
−6.3
36
+0.25
−65
−186
−6.8
c
57
+2
−60
−159
−10.6
c
57
+2
−62
−165
−10.9
[d(9d-T)6 ]2 (24·24)
59
+2.15
−65
−174
−11.4
c
41
+0.65
−45
−142
−8.0
52
+1.55
−47
−123
−9.3
[d(9a-T)6 ]2 (21·21) [d(9b-T)6 ]2 (22·22) [d(9c-T)6 ]2 (23·23) [d(9i-T)6 ]2 (25·25)
[d(9f-T)6 ]2 (26·26)
a Thermodynamic parameters are derived from the fitting of melting curves measured at 260 nm (see Basic Protocol 5).
In all assays, the concentration of each oligonucleotide strand was 5 µM in high-salt buffer (1.0 M NaCl), pH 7.0 (see recipe). b Change (per modified base) relative to duplex 20·20. c See Seela and Thomas (1995).
Table 4.25.2 Tm Values and Thermodynamic Data for Oligonucleotide Duplexes Containing S.19a-d or S.9a,d,ja
H◦ (kcal/mol)
S◦ (cal/mol · K)
G◦ 310 (kcal/mol)
−90
−257
−10.9
0
−80
−225
−10.4
55
+2.7
−92
−256
−12.9
5 -d(TAG GTC 19cAT ACT)-3 (33) 3 -d(ATC C19cG TT19c TGA)-5 (34)
56
+3.0
−95
−265
−13.4
5 -d(TAG GTC 19dAT ACT)-3 (35) 3 -d(ATC C19dG TT19d TGA)-5 (36)
54
+2.3
−83
−227
−12.3
5 -d(TAG GTC 9aAT ACT)-3 (37) 3 -d(ATC C9aG TT9a TGA)-5 (38)
44
−1.0
−81
−229
−9.9
5 -d(TAG GTC 9dAT ACT)-3 (39) 3 -d(ATC C9dG TT9d TGA)-5 (40)
51
+1.3
−89
−249
−11.7
5 -d(TAG GTC 9jAT ACT)-3 (39a) 3 -d(ATC C9jG TT9j TGA)-5 (40a)
49
+0.7
−81
−227
−11.1
Duplex
Tm (◦ C)
5 -d(TAG GTC AAT ACT)-3 (27) 3 -d(ATC CAG TTA TGA)-5 (28)
47
5 -d(TAG GTC 19aAT ACT)-3 (29) 3 -d(ATC C19aG TT19a TGA)-5 (30)
47
5 -d(TAG GTC 19bAT ACT)-3 (31) 3 -d(ATC C19bG TT19b TGA)-5 (32)
Tm b (◦ C)
a Thermodynamic parameters are derived from the fitting of melting curves measured at 260 nm (see Basic Protocol 5). In all assays, the concentration
of each oligonucleotide strand was 5 µM in low-salt buffer (0.1 M NaCl), pH 7.0 (see recipe). b Change (per modified base) relative to duplex 27·28.
corresponding nucleosides lacking the 2-amino group (S.9a and S.9d, respectively). In contrast to other halogenated derivatives, the incorporation of 7-deaza-2 -deoxyadenosine carrying a fluorine substituent at the 7 position (S.9j) stabilizes oligonucleotide duplexes only to a small extent.
Using Pyrrolo[2,3d]pyrimidines to Replace Purines
Hybridization experiments involving the pairing of S.9a or S.19a with each of the four canonical nucleosides (Table 4.25.3) show that nucleoside S.19a forms a rather stable base pair with dC (duplex 44·41; Okamoto et al., 2002), while S.9a does not (duplex 44·45). This indicates that the additional 2-amino group of S.19a plays a crucial role in
4.25.18 Supplement 20
Current Protocols in Nucleic Acid Chemistry
Table 4.25.3 Tm Values and Thermodynamic Data for Oligonucleotide Duplexes Containing S.9a or S.19a Opposite a Canonical Nucleosidea
H◦ (kcal/mol)
S◦ (cal/mol · K)
G◦ 310 (kcal/mol)
−90
−257
−10.9
0
−89
−252
−10.8
36
−11
−65
−185
−7.67
5 -d(TAG GGC AAT ACT)-3 (43) 3 -d(ATC C19aG TTA TGA)-5 (41)
45
−2
−87
−249
−10.1
5 -d(TAG GCC AAT ACT)-3 (44) 3 -d(ATC C19aG TTA TGA)-5 (41)
46
−1
−93
−266
−10.5
5 -d(TAG GTC AAT ACT)-3 (27) 3 -d(ATC C9aG TTA TGA)-5 (45)
46
−1
−86
−245
−10.4
5 -d(TAG GAC AAT ACT)-3 (41) 3 -d(ATC C9aG TTA TGA)-5 (45)
33
−14
−68
−196
−7.1
5 -d(TAG GGC AAT ACT)-3 (43) 3 -d(ATC C9aG TTA TGA)-5 (45)
45
−2
−85
−241
−10.1
5 -d(TAG GCC AAT ACT)-3 (44) 3 -d(ATC C9aG TTA TGA)-5 (45)
43
−4
−85
−243
−9.6
Duplex
Tm (◦ C)
5 -d(TAG GTC AAT ACT)-3 (27) 3 -d(ATC CAG TTA TGA)-5 (28)
47
5 -d(TAG GTC AAT ACT)-3 (27) 3 -d(ATC C19aG TTA TGA)-5 (41)
47
5 -d(TAG GAC AAT ACT)-3 (42) 3 -d(ATC C19aG TTA TGA)-5 (41)
Tm b (◦ C)
a Thermodynamic parameters are derived from the fitting of melting curves measured at 260 nm (see Basic Protocol 5). In all assays, the concentration
of each oligonucleotide strand was 5 µM in low-salt buffer (0.1 M NaCl), pH 7.0 (see recipe). b Change (per modified base) relative to duplex 27·28.
the observed pairing with dC; a bidentate base pair is suggested as the interaction between S.19a and dC (see Fig. 4.25.6, motif IIIa).
Oligonucleotides Containing the 2 -Deoxyguanosine Analogs S.12a,c-f,i Compared with dA analogs and 2,6-diaminopurine derivatives, the situation is quite different for the 7-deaza analogs of dG (Table 4.25.4). The incorporation of 7-deaza-2 deoxyguanosine (S.12a) in place of dG results in duplex destabilization compared with d(G-C)4 (46). The 7-methyl derivative S.12i and the 7-hexynyl nucleoside S.12f lead to duplex stabilization compared with the parent nucleoside S.12a (further destabilization compared with dG). When 7-bromo or 7-iodo derivatives (S.12c or S.12d) are incorporated, a further increase in the Tm value is observed. The increase in Tm amounts to ∼1◦ C per modified base in each case (octamers 48 and 49). Like the 7-halogeno derivatives, the 7-propynylated nucleoside S.12e also leads to duplex stabilization (27b·28b), as the small propynyl group is well accommodated in the major groove of DNA. Oligonucleotides Containing the 2 -Deoxyisoguanosine Analogs S.15a-c The influence of the 7-deazaisoguanosine series (S.15a-c) on oligonucleotide stability was studied with a parallel duplex (52·27) and an antiparallel duplex (56·52; Table 4.25.5). The 7-deazaisoguanine-containing parallel duplex (53·27) shows almost identical base pair stability compared with the duplex containing the parent isoguanine. However, the incorporation of chlorinated (S.15b) or brominated (S.15c) derivatives increases Tm by ∼2.0◦ C per modified base for both parallel and antiparallel duplexes. Motifs for the base-modified base pairs related to dG-dC, c7 iGd -iCd , and c7 iGd -dC are depicted in Figure 4.25.6.
Synthesis of Modified Oligonucleotides and Conjugates
4.25.19 Current Protocols in Nucleic Acid Chemistry
Supplement 20
Figure 4.25.6
Base pair motifs for 7-substituted 7-deazapurines paired with 2 -deoxythymidine or 2 -deoxycytidine.
Table 4.25.4 Tm Values and Thermodynamic Data for Self-Complementary Oligonucleotides Containing 2 -Deoxyguanosine Analogs S.12a,c-f,ia
H◦ (kcal/mol)
S◦ (cal/mol · K)
−81
−244
−0.88
−62
−190
67
+0.88
−72
−212
[d(12d-C)4 ]2 (49·49)
70
+1.25
−91
−266
[d(12i-C)4 ]2 (50·50)
58
−0.25
−82
−250
59
−0.13
−62
−189
−90
−257
Duplex
Tm (◦ C)
[d(G-C)4 ]2 (46·46)
60
[d(12a-C)4 ]2 (47·47)
53
[d(12c-C)4 ]2 (48·48)
[d(12f-C)4 ]2 (51·51)
Tm b (◦ C)
5 -d(TAG GTC AAT ACT)-3 (27) 3 -d(ATC CAG TTA TGA)-5 (28)
47
5 -d(TA12a 12aTC AAT ACT)-3 (27a) 3 -d(ATC CA12a TT12a TGA)-5 (28a)
44
−0.38
−104
−328
5 -d(TA12e 12eTC AAT ACT)-3 (27b) 3 -d(ATC CA12e TTA T12eA)-5 (28b)
55
+1.0
−91
−251
a Thermodynamic parameters are derived from the fitting of melting curves measured at 260 nm (see Basic Protocol 5).
Using Pyrrolo[2,3d]pyrimidines to Replace Purines
In all assays, the concentration of each oligonucleotide strand was 7.5 µM in low-salt buffer (0.1 M NaCl), pH 7.0 (see recipe). G data are unavailable. b Change (per modified base) relative to duplex 46·46 or 27·28.
4.25.20 Supplement 20
Current Protocols in Nucleic Acid Chemistry
Table 4.25.5 Tm Values and Thermodynamic Data for Duplexes Containing 2 -Deoxyisoguanosine Analogs S.15a-ca
H◦ (kcal/mol)
S◦ (cal/mol · K)
G◦ 310 (kcal/mol)
−74
−211
−8.8
0
−51
−135
−8.7
43
+2.0
−79
−225
−9.5
5 -d(ATiC iCA15c TTA T15cA)-3 (55) 5 -d(TAG GTC AAT ACT)-3 (27)
44
+2.5
−74
−208
−9.5
3 -d(TAiG iGTiC AAT AiCT)-5 (56) 5 -d(ATiC iCAiG TTA TiGA)-3 (52)
60
−94
−257
−14.8
3 -d(TA15b 15bTiC AAT AiCT)-5 (57) 5 -d(ATiC iCA15b TTA T15bA)-3 (54)
67
+1.8
−96
−255
−16.4
3 -d(TA15c 15cTiC AAT AiCT)-5 (58) 5 -d(ATiC iCA15c TTA T15cA)-3 (55)
68
+2.0
−83
−175
−14
Duplexb
Tm (◦ C)
5 -d(ATiC iCAiG TTA TiGA)-3 (52) 5 -d(TAG GTC AAT ACT)-3 (27)
39
5 -d(ATiC iCA15a TTA T15aA)-3 (53) 5 -d(TAG GTC AAT ACT)-3 (27)
39
5 -d(ATiC iCA15b TTA T15bA)-3 (54) 5 -d(TAG GTC AAT ACT)-3 (27)
Tm c (◦ C)
a Thermodynamic parameters are derived from the fitting of melting curves measured at 260 nm (see Basic Protocol 5). In all assays, the concentration
of each oligonucleotide strand was 5 µM in high-salt buffer (1.0 M NaCl), pH 7.0 (see recipe). b iC, 5-methyl-2 -deoxyisocytidine; iG, 2 -deoxyisoguanosine. c Change (per modified base) relative to duplex 52·27 or duplex 56·52.
Conclusion From the data shown above, it is apparent that the incorporation of 7-substituted 7deazapurine nucleosides into oligonucleotide duplexes leads to an increase in duplex stability, as indicated by the observed Tm values. Base pair stabilization was found to result from the increased stacking of the nucleobases, the hydrophobic character of the substituents at the 7 position, and the increased hydrogen bond strength, which is related to the pKa values of the nucleosides (see UNIT 1.10). REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
High-salt buffer (1.0 M NaCl), pH 7.0 To 900 mL H2 O, add: 58.5 g NaCl (1 M final) 9.5 g MgCl2 (100 mM final) 12.8 g (CH3 )2 AsO2 Na · H2 O (60 mM final) Adjust pH to 7.0 with 2 M HCl Add water to 1 L Store tightly capped for up to 2 years at room temperature Low-salt buffer (0.1 M NaCl), pH 7.0 To 900 mL H2 O, add: 5.85 g NaCl (0.1 M final) 0.95 g MgCl2 (10 mM final) 2.14 g (CH3 )2 AsO2 Na · H2 O (10 mM final) Adjust pH to 7.0 with 2 M HCl Add water to 1 L Store tightly capped for up to 2 years at room temperature
Synthesis of Modified Oligonucleotides and Conjugates
4.25.21 Current Protocols in Nucleic Acid Chemistry
Supplement 20
Triethylammonium acetate (TEAA) buffer, 0.1 M (pH 7.0)/acetonitrile, 95:5 (v/v) To 900 mL H2 O, add 14.0 mL triethylamine. Adjust the pH to between 7 and 7.5 with 90% (v/v) acetic acid, add water to 1.0 L, and then filter through RC membrane filter paper (pore size, 0.45 µm; diameter, 0.47 mm; Schleicher & Schuell). Add 50 mL acetonitrile to 950 mL of the filtrate and store tightly capped for up to 4 months at room temperature. Tris·Cl, pH 8.9 To 90 mL H2 O, add 1.21 g tris(hydroxymethyl)methylamine [(HOCH2 )3 CNH2 ] (0.1 M final). Adjust pH to 8.9 with 20% (v/v) HCl, and then add water to 100 mL. Store tightly capped for up to 2 years at 5◦ C. COMMENTARY Background Information
Using Pyrrolo[2,3d]pyrimidines to Replace Purines
7-Deazapurine-containing oligonucleotides have been used to inhibit gene expression (antisense oligonucleotides; Balow et al., 1998), and 7-deazapurine nucleosides have been used in DNA and RNA sequencing with labeled 2 -dNTPs and in 2 ,3 -ddNTPmediated termination of chain extension (Mizusawa et al., 1986). Moreover, 7 deazapurine nucleoside residues have been introduced into nucleic acids for studies of electron transfer (Latimer and Lee, 1991; Li et al., 2004). As N7 is absent in these basemodified oligonucleotides, neither dG quartet formation (Seela and Mersmann, 1993) nor the generation of mini-hairpins occurs, thereby preventing band compression during DNA or RNA sequencing (Barr et al., 1986). On the other hand, special supramolecular assemblies (Seela and Wei, 1997) and nanostructures (Seela et al., 2002) can be constructed with the help of 7-dezazapurine-containing DNA, with these structures showing superior properties compared with those containing regular purine bases. The 7 position of a 7-deazapurine is an ideal site for introducing reporter groups or (to enhance DNA duplex stability) introducing electron-withdrawing substituents of medium size (Ramzaeva and Seela, 1996; Seela and Zulauf, 1998). Such substituents (in particular, halogen or alkynyl substituents) are well accommodated in the major groove of duplex DNA, and some have the potential to be used for further chemical and functional manipulations of the oligonucleotides. The 7-iodo-substituted derivatives of 2 -deoxyadenosine (S.2d and S.9d) and 2 -deoxyguanosine (S.3d and S.12d) are particularly valuable, since they are readily alkynylated via Pd-catalyzed cross-coupling reactions. Alternatively, DNA modifications can be performed using
solid-phase methods that are applied during or after automated solid-phase synthesis. Over the past decade, efforts have also been made to modify canonical DNA by replacing purine bases with 7-deazapurines to improve binding of oligonucleotides to their DNA and RNA targets. The design and synthesis of modified oligonucleotides with increased duplex stability are of particular interest since improvements in antisense effects have been correlated with increases in Tm values. Efforts to investigate oligonucleotides containing 7-deazapurines, including the design and synthesis of appropriately protected phosphoramidites, have been undertaken in the authors’ laboratory for a number of years. Access to these systems became realistic with the development of stereoselective nucleobase anion glycosylation, which was first realized using 7-deazapurine-2 -deoxyribonucleosides (Winkeler and Seela, 1983; Seela et al., 1988). Because 7-deazapurines (pyrrolo[2,3d]pyrimidines) closely resemble purines in structure, they are ideal shape mimics of the canonical purine bases in nucleic acids. 7Deazapurine nucleosides show extraordinary stability in their N-glycosylic bonds, which makes them stable against acid- or enzymecatalyzed hydrolysis. On the other hand, 7deazpurines are more easily oxidized than purines. The syntheses of the phosphoramidites S.1-S.8 (Fig. 4.25.1) use well-established chemistry. Dialkylaminoalkylidene protection of the exocyclic amino groups is readily achieved by reaction with the corresponding acetal reagents, while acyl protection of the exocyclic amino groups is achieved using acyl chlorides or acid anhydrides. Protection of the 2-oxo group of 7-deaza-2 -deoxyisoguanosine is performed by diphenylcarbamoylation of S.15a-c with
4.25.22 Supplement 20
Current Protocols in Nucleic Acid Chemistry
Table 4.25.6
13
C NMR Chemical Shifts (δ) for 7-Deazapurine-2 -Deoxyribonucleosidesa,b
Sys Pur
C(2)c C(2)
9d
152.0 157.3 103.2
10
C(4)c C(6)
C(4a) C(5)
151.5 160.2 110.3
11
151.2 160.2 110.3
12d
152.7 157.7
C(5) C(7)
C(6) C(7a)c C(1 ) C(8) C(4)
51.9 126.9 149.8 53.6 128.6 150.9
C(2 )
C(3 )
C(4 ) C(5 )
83.0
—d
71.0
87.5
62.0
83.0
d
71.1
87.5
61.9
d
—
53.9 128.3 151.0
82.8
—
70.9
85.6
64.3
99.8 102.2 121.5 150.5
82.2
38.5
70.9
87.0
61.9
d
13
147.5 156.1 103.9
55.5 124.3 147.0
82.6
—
70.8
87.3
61.7
14
147.6 156.1 104.2
55.0 124.1 147.1
82.7
—d
70.6
85.5
64.1
15a
153.9 156.3
92.6 100.8 118.9 152.6
83.4
—d
71.1
87.2
62.0
16
158.8 155.8 100.9 100.1 121.6 150.7
82.7
—d
71.0
87.2
62.0
17
154.3 153.6 106.3 104.4 119.5 152.5
82.6
—d
70.9
87.4
61.9
18
158.0 153.6 106.2 104.6 123.8 151.4
82.2
—d
70.6
85.5
64.0
a Sys, carbon position in systematic numbering scheme; Pur, carbon position in purine numbering scheme. b Measured in ppm downfield from DMSO-d . 6 c Peak assignments are tentative. d Superimposed upon DMSO-d peak. 6
diphenylcarbamoyl chloride in pyridine. Dimethoxytritylation of 5 -hydroxy groups is achieved using a standard protocol, which always results in high yields. Protected nucleosides are easily converted to the desired phosphoramidites by treatment with 2-cyanoethylN,N-diisopropylchlorophosphoramidite. DNA syntheses using phosphoramidites S.1-S.8 employ conventional phosphoramidite chemistry. The coupling yield is always >95%. Purification of the resulting oligonucleotides is performed in DMTr-on and/or DMTr-off mode using an RP-18 column. The Tm values of oligonucleotide duplexes are determined by UV spectrophotometry, and thermodynamic data are determined by curve shape analysis. The duplex stability of 7-deazapurinecontaining DNA can then be compared with that of the corresponding unmodified DNA duplex. 7-Halogenated and 7-alkynylated 7-deazapurines stabilize DNA duplexes that have antiparallel or parallel chain orientation.
Compound Characterization 1
H, 13 C, and 31 P NMR spectra were obtained on AC-250 and AMX-500 spectrometers (Bruker), with δ values given in ppm downfield from internal tetramethylsilane (SiMe4 ) or external 85% (v/v) H3 PO4 solution (for 31 P NMR). UV spectra were measured on a U-3200 spectrometer (Hitachi; λmax in nm, ε in M−1 · cm−1 ). Melting points were determined using a Linstr¨om apparatus and are
not corrected. Elemental analyses were performed by the Mikroanalytisches Laboratorium Beller (G¨ottingen, Germany). Elemental analyses, UV data, 1 H and 31 P NMR data, and melting points are shown in the appropriate protocol steps. 13 C NMR data are shown in Table 4.25.6.
Critical Parameters Phosphoramidites are sensitive to hydrolysis when acid is present, but they are stable in neutral solution. Their purity can be checked in neutral aqueous buffer by HPLC. The 7deazapurine nucleosides, including their phosphoramidites, are more easily oxidized than are their parent purine compounds. However, all oligonucleotide syntheses have been performed using a standard oxidation reagent (0.02 or 0.1 M iodine in 90:5:5 [v/v/v] THF/pyridine/H2 O), and significant degradation has not been observed. The success of the DNA synthesis depends on the quality of the reagents; only reagent-grade chemicals should be used to synthesize the phosphoramidites described here. All phosphoramidite reagents should be stored under anhydrous conditions and should be dried under high vacuum at 40◦ C for 24 hr before use. Additional care must be taken with the phosphoramidites of 7-deazaguanosines and isoguanosines, which easily absorb water and are sensitive to oxidation upon exposure to light.
Synthesis of Modified Oligonucleotides and Conjugates
4.25.23 Current Protocols in Nucleic Acid Chemistry
Supplement 20
Troubleshooting If the phosphoramidite coupling yield is <90%, the following measures are strongly recommended: (1) repurify the phosphoramidites; (2) dry the phosphoramidites under high vacuum for >40 hr at 40◦ to 50◦ C; (3) increase the concentrations of the phosphoramidite solutions used; (4) dry all chemical reagents with 3-Å molecular sieves for 2 days prior to use; and (5) prolong the coupling time for modified phosphoramidites. High coupling yields can give confidence that the reagents used are of good quality.
Anticipated Results Using the procedures described in this unit, phosphoramidites of 7-substituted 7deazapurines can be prepared on a small or large scale. Oligonucleotide duplexes with increased stability can be obtained by incorporating 7-substituted 7-deazapurine2 -deoxyribonucleosides. With high-quality phosphoramidites, DNA synthesis is routine. Upon DMTr-on and DMTr-off purification by reversed-phase or ion-exchange HPLC, homogenous products are obtained.
Time Considerations The time needed for phosphoramidite synthesis depends on the time required for reaction and purification, and on the technical expertise of the investigator; the synthesis of phosphoramidites as described in these protocols takes ∼2 weeks for an experienced chemist. Oligonucleotide synthesis using these basemodified phosphoramidite reagents requires more time than does oligonucleotide synthesis using standard phosphoramidites.
Literature Cited Balow, G., Mohan, V., Lesnik, E.A., Johnston, J.F., Monia, B.P., and Acevedo, O.L. 1998. Biophysical and antisense properties of oligodeoxynucleotides containing 7-propynyl-, 7-iodo- and 7-cyano-7-deaza-2-amino-2 deoxyadenosines. Nucl. Acids Res. 26:33503357. Barr, P.J., Thayer, R.M., Laybourn, P., Najarian, R.C., Seela, F., and Tolan, D.R. 1986. 7Deaza-2 -deoxyguanosine-5 -triphosphate: Enhanced resolution in M13 dideoxy sequencing. Biotechniques 4:428-432.
Using Pyrrolo[2,3d]pyrimidines to Replace Purines
Buhr, C.A., Wagner, R.W., Grant, D., and Froehler, B.C. 1996. Oligodeoxynucleotides containing C-7 propyne analogs of 7deaza-2 -deoxyguanosine and 7-deaza-2 deoxyadenosine. Nucl. Acids Res. 24:29742980.
Latimer, L.J. and Lee, J.S. 1991. Ethidium-bromide does not fluoresce when intercalated adjacent to 7-deazaguanine in duplex DNA. J. Biol. Chem. 266:13849-13851. Li, H., Peng, X., and Seela, F. 2004. Fluorescence quenching of parallel-stranded DNA bound ethidium bromide: The effect of 7-deaza-2 deoxyisoguanosine and 7-halogenated derivatives. Bioorg. Med. Chem. Lett. 14:6031–6034. McDowell, J.A. and Turner, D.H. 1996. Investigation of the structural basis for thermodynamic stabilities of tandem GU mismatches: Solution structure of (rGAG GU CUC)2 by two-dimensional NMR and simulated annealing. Biochemistry 35:14077-14089. Mizusawa, S., Nishimura, S., and Seela, F. 1986. Improvement of the dideoxy chain termination method of DNA sequencing by use of deoxy-7deazaguanosine triphosphate in place of dGTP. Nucl. Acids Res. 14:1319-1324. Okamoto, A., Tanaka, K., and Saito, I. 2002. 2Amino-7-deazaadenine forms stable base pairs with cytosine and thymine. Bioorg. Med. Chem. Lett. 12:97-99. Ramzaeva, N. and Seela, F. 1995. 7-Substituted 7-deaza-2 -deoxyguanosines: Regioselective halogenation of pyrrolo[2,3-d]pyrimidine nucleosides. Helv. Chim. Acta 78:1083-1090. Ramzaeva, N. and Seela, F. 1996. Duplex stability of 7-deazapurine DNA: Oligonucleotides containing 7-bromo or 7-iodo-7-deazaguanine. Helv. Chim. Acta 79:1549-1558. Ramzaeva, N., Mittelbach, C., and Seela, F. 1997. 7Deazaguanine DNA: Oligonucleotides with hydrophobic or cationic side chains. Helv. Chim. Acta 80:1809-1822. Seela, F. and Chen, Y. 1997. Methylated DNA: The influence of 7-deaza-7-methylguanine on the structure and stability of oligonucleotides. Helv. Chim. Acta 80:1073-1086. Seela, F. and Driller, H. 1989. Alternating d(GC)3 and d(C-G)3 hexanucleotides containing 7deaza-2 -deoxyguanosine or 8-aza-7-deaza-2 deoxyguanosine in place of dG. Nucl. Acids Res. 17:901-910. Seela, F. and Kaiser, K. 1986. Phosphoramidites of base-modified 2 -deoxyinosine isosteres and solid-phase synthesis of d(GCI∗CGC) oligomers containing an ambiguous base. Nucl. Acids Res. 14:1825-1844. Seela, F. and Kehne, A. 1983. 2 -Desoxytubercidin: Synthese eines 2 -desoxyadenosin-isosteren durch phasentransferglycosylierung. Liebigs Ann. Chem. 876-884. Seela, F. and Kehne, A. 1985. 2 -Desoxytubercidin: Synthese des O-3 -phosphoramidites und kondensation zu 2 -desoxytubercidylyl(3 →5 )-2 desoxytubercidin. Tetrahedron 41:5387-5392. Seela, F. and Mersmann, K. 1993. 7Deazaguanosine: Synthesis of an oligoribonucleotide building block and disaggregation of the UGGGGU G4 structure by the modified base. Helv. Chim. Acta 76:1435-1449.
4.25.24 Supplement 20
Current Protocols in Nucleic Acid Chemistry
Seela, F. and Peng, X. 2004. Regioselective syntheses of 7-halogenated 7-deazapurine nucleosides related to 2-amino-7-deaza-2 -deoxyadenosine and 7-deaza-2 -deoxyisoguanosine. Synthesis 8:1203-1210.
Seela, F., Berg, H., and Rosemeyer, H. 1989. Bending of oligonucleotides containing an isosteric nucleobase: 7-Deaza-2 -deoxyadenosine replacing dA within d(A)6 tracts. Biochemistry 28:6193-6198.
Seela, F. and Shaikh, K.I. 2005. Oligonucleotides containing 7-propynyl-7-deazaguanine: Synthesis and base pair stability. Tetrahedron In press.
Seela, F., Wiglenda, T., Rosemeyer, H., Eickmeier, H., and Reuter, H. 2002. 7-Deaza-2 - deoxyxanthosine dihydrate forms water-filled nanotubes with C-H···O hydrogen bonds. Angew. Chem. Int. Ed. Engl. 41:603-605.
Seela, F. and Thomas, H. 1994. Synthesis of certain 5-substituted 2 -deoxytubercidin derivatives. Helv. Chim. Acta 77:897-903. Seela, F. and Thomas, H. 1995. Duplex stabilization of DNA: Oligonucleotides containing 7substituted 7-deazaadenines. Helv. Chim. Acta 78:94-108. Seela, F. and Wei, C. 1997. 7-Deazaisoguanine quartets: Self-assembled oligonucleotides lacking the Hoogsteen motif. Chem. Commun. 18691870. Seela, F. and Wei, C. 1999. The base-pairing properties of 7-deaza-2 -deoxyisoguanosine and 2 deoxyisoguanosine in oligonucleotide duplexes with parallel and antiparallel chain orientation. Helv. Chim. Acta 82:726-745. Seela, F. and Zulauf, M. 1996. Palladium-catalyzed cross coupling of 7-iodo-2 -deoxytubercidin with terminal alkynes. Synthesis 726-730. Seela, F. and Zulauf, M. 1998. 7-DeazaadenineDNA: Bulky 7-iodo substituents or hydrophobic 7-hexynyl chains are well accommodated in the major groove of oligonucleotide duplexes. Chem. Eur. J. 4:1781-1790. Seela, F. and Zulauf, M. 1999. Oligonucleotides containing 7-deazaadenines: The influence of the 7-substituent chain length and charge on the duplex stability. Helv. Chim. Acta 82:18781898. Seela, F., Steker, H., Driller, H., and Bindig, U. 1987. 2-Amino-2 -desoxytubercidin und verwandte pyrrolo[2,3-d]pyrimidinyl-2 desoxyribofuranoside. Liebigs Ann. Chem. 15-19. Seela, F., Westermann, B., and Bindig, U. 1988. Liquid-liquid and solid-liquid phase-transfer glycosylation of pyrrolo[2,3-d]pyrimidines: Stereospecific synthesis of 2-deoxy-β-Dribofuranosides related to 2 -deoxy-7carbaguanosine. J. Chem. Soc. Perkin Trans. I:697-702.
Seela, F., Shaikh, K., and Wiglenda, T. 2003. Synthesis and properties of halogenated 7-deaza2 - deoxyxanthosine and protected derivatives for oligonucleotides synthesis. Nucleosides Nucleotides Nucl. Acids 22:1239-1241. Seela, F., Chittepu, P., He, Y., He, J., and Xu, K. 2005a. 6-Azapyrimidine and 7-deazapurine 2 -deoxy-2 -fluoroarabinonucleosides: Synthesis, conformation and properties of oligonucleotides. Nucleosides Nucleotides Nucleic Acids In press. Seela, F., Peng, X., and Ming, X. 2005b. 7Deazapurine-2,6-diamine and 7-deazaguanine: Synthesis and property of 7-substituted nucleosides and oligonucleotides. Nucleosides Nucleotides Nucleic Acids In press. Ti, G.S., Gaffney, B.L., and Jones, R.A. 1982. Transient protection: Efficient one-flask syntheses of protected deoxynucleosides. J. Am. Chem. Soc. 104:1316-1319. Winkeler, H.D. and Seela, F. 1983. Synthesis of 2-amino-7-(2 -deoxy-β-D-erythropentofuranosyl)-3,7-dihydro-4H-pyrrolo[2,3d]pyrimidin-4-one, a new isostere of 2 deoxyguanosine. J. Org. Chem. 48:3119-3122.
Internet Resources http://www.seela.net Research web site of Dr. Frank Seela, author of this unit.
Contributed by Frank Seela and Xiaohua Peng Universit¨at Osnabr¨uck Osnabr¨uck, Germany and Center for Nanotechnology (CeNTech) M¨unster, Germany
Synthesis of Modified Oligonucleotides and Conjugates
4.25.25 Current Protocols in Nucleic Acid Chemistry
Supplement 20
An Aminooxy-Functionalized Non-Nucleosidic Phosphoramidite for the Construction of Multiantennary Oligonucleotide Glycoconjugates on a Solid Support
UNIT 4.26
This unit contains procedures for the synthesis of an aminooxy-functionalized nonnucleosidic phosphoramidite and fully acetylated 4-oxobutyl α-D-mannopyranoside, and a description of their use in the preparation of multivalent oligonucleotide glycoconjugates. Commercially available diethyl 2,2-bis(hydroxymethyl)malonate can be converted in six steps into a phosphoramidite that bears two phthaloyl-masked aminooxy groups in addition to a 4,4 -dimethoxytritylated hydroxyl group, and allows normal oligonucleotide chain elongation. After conventional chain assembly, the phthaloyl protecting groups can be removed by a hydrazinium acetate treatment and subsequently oximated with a carbohydrate building block carrying an anomeric aldehyde tether. Synthesis of the non-nucleosidic phosphoramidite and the carbohydrate building block are described in Basic Protocols 1 and 2, respectively. The use of these reagents for the preparation of oligonucleotide glycoconjugates is then presented as Basic Protocol 3. The phthaloyl protecting groups may be removed with hydrazinium acetate in pyridine, i.e., under conditions that cleave neither the commonly used succinyl linker nor the 2-cyanoethyl phosphate-protecting groups. Glycosidic aldehydes react readily with the exposed aminooxy groups, affording fully protected oxime conjugates that have been shown to withstand standard ammonolytic deprotection and cleavage from the support. Accordingly, a phthaloyl protection strategy may well be adopted for the construction of glycooligonucleotide conjugates on a solid support. CAUTION: Perform all operations involving organic solvents and reagents in a wellventilated fume hood, and wear gloves and protective glasses.
PREPARATION OF THE AMINOOXY-FUNCTIONALIZED PHOSPHORAMIDITE FROM DIETHYL 2,2-BIS(HYDROXYMETHYL)MALONATE Aminooxy-functionalized building blocks have been previously used for the solidphase 5 -conjugation of oligonucleotides. A 5 -terminal aminooxy group has been introduced as a 2-[(2-ureido)-4-(2-phthalimidooxyethoxy)quinoline]ethyl phosphoramidite (Hamma and Miller, 2003), an 11-phthalimidoxy-3,6,9-trioxaundecyl phosphoramidite (Salo et al., 1999), and an N-trityl-6-aminooxyhexyl phosphoramidite (Defrancq and Lhomme, 2001). The present protocol is based on Katajisto et al. (2004). The synthesis of the aminooxy-functionalized phosphoramidite (S.6) is outlined in Figure 4.26.1. Diethyl 2,2-bis(hydroxymethyl)malonate (S.1) is first converted to its di-O-methoxymethylene derivative (S.2) and the latter is aminolyzed with 3-aminopropanol to obtain S.3. The free hydroxy functions are then displaced with N-phthaloyl-protected aminooxy groups by a Mitsunobu reaction using N-hydroxyphthalimide as the nucleophile and diethyl azodicarboxylate (DEAD) and triphenylphosphine as activators. The crude product is subjected to acid-catalyzed hydrolysis to remove the methoxymethylene protection (S.4). 4,4 -Dimethoxytritylation of one of the exposed hydroxyl groups (S.5) followed by phosphitylation of the other with 2-cyanoethyl N,N-diisopropylphosphonamidic chloride completes the synthesis of the phosphoramidite (S.6). This building block is used Contributed by Johanna Katajisto, Pasi Virta, and Harri L¨onnberg Current Protocols in Nucleic Acid Chemistry (2005) 4.26.1-4.26.16 C 2005 by John Wiley & Sons, Inc. Copyright
BASIC PROTOCOL 1
Modified Oligonucleotides and Conjugates
4.26.1 Supplement 21
Figure 4.26.1 Synthesis of the non-nucleosidic phosphoramidite S.6 (see Basic Protocol 1). DMTr, 4,4 -dimethoxytrityl. Reprinted from Katajisto et al. (2004) with permission from the American Chemical Society.
in machine-assisted oligonucleotide synthesis to construct conjugates bearing protected aminooxy functions (see Basic Protocol 3).
Materials
An AminooxyFunctionalized Non-Nucleosidic Phosphoramidite for Oligonucleotide Glycoconjugates
Diethyl 2,2-bis(hydroxymethyl)malonate (S.1.), 95% pure (Acros) Dry tetrahydrofuran (THF), freshly distilled from sodium (store over 4-Å molecular sieves) Trimethyl orthoformate, 98% pure (Aldrich) p-Toluenesulfonic acid monohydrate, ≥98.5% pure (Aldrich) 5% (w/v) aqueous sodium hydrogen carbonate (NaHCO3 ) Diethyl ether Saturated aqueous sodium chloride (NaCl) Sodium sulfate (Na2 SO4 ), anhydrous Silica gel: 0.040- to 0.063-mm Fluka Kieselgel 60 (dry overnight in 150◦ C oven) Dichloromethane (CH2 Cl2 ), ≥99% pure Bromocresol green indicator: dissolve 0.04 g bromocresol green (Merck) in 100 mL ethanol and add 0.1 M aqueous NaOH until the blue color appears (store up to 1 month at room temperature) 3-Aminopropanol, 99% pure (Aldrich)
4.26.2 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Methanol (MeOH), ≥99.8% pure Dry benzene, distilled from powdered CaH2 (store over 4-Å molecular sieves) Triphenylphosphine, 99% pure (Aldrich) N-Hydroxyphthalimide, 97% pure (Aldrich) Diethyl azodicarboxylate (DEAD), ≥97% (Fluka) 2-Propanol (i-PrOH), Baker analyzed 80% (v/v) aqueous acetic acid (AcOH) Dry pyridine, distilled from powdered CaH2 (store over 4-Å molecular sieves) 4,4 -Dimethoxytrityl chloride (DMTr-Cl), 97% (Aldrich) Dry toluene, distilled from powdered CaH2 (store over 4-Å molecular sieves) Dry acetonitrile, HPLC grade (store over 4-Å molecular sieves) Phosphorus pentoxide (P2 O5 ), 97% pure (Aldrich) Dry nitrogen (or argon) Anhydrous triethylamine, distilled from powdered CaH2 (store over 4-Å molecular sieves) 2-Cyanoethyl N,N-diisopropylphosphonamidic chloride (TRC) Ethyl acetate (EtOAc), analytical grade Hexane, HPLC grade Separatory funnels Rotary evaporator equipped with a water aspirator 5 × 35–cm sintered glass chromatography column, porosity 2 TLC plate: silica-coated aluminium plate with fluorescent indicator (Merck silica gel 60 F254 ) 3 × 20–cm sintered glass chromatography column, porosity 3 254-nm UV lamp Vacuum desiccator Additional reagents and equipment for column chromatography (APPENDIX 3E) and thin-layer chromatography (TLC, APPENDIX 3D) Protect hydroxy groups of diethyl 2,2-bis(hydroxymethyl)malonate 1. Dissolve 10.0 g (45.4 mmol) diethyl 2,2-bis(hydroxymethyl)malonate (S.1) in 60 mL THF with magnetic stirring. Add 6.5 mL (59.0 mmol) trimethyl orthoformate and a catalytic amount (10 mg) of p-toluenesulfonic acid monohydrate to the reaction mixture. Stopper the flask and continue stirring overnight. 2. Pour the reaction mixture into 100 mL of magnetically stirred ice-cold 5% (w/v) aqueous NaHCO3 . Extract the mixture twice with 100 mL diethyl ether. Combine the organic phases and wash them in a separatory funnel with 100 mL saturated aqueous NaCl. 3. Dry the pooled organic phase over 15 g anhydrous Na2 SO4 and filter off the drying agent by gravity using filter paper. Evaporate the solution to dryness using a rotary evaporator equipped with a water aspirator. 4. Purify the residue by silica gel chromatography as follows. Pack a 5 × 35–cm glass column with 400 mL silica gel in CH2 Cl2 . Redissolve the residue from step 3 in 5 to 10 mL CH2 Cl2 , apply this sample to the column, and elute the column with CH2 Cl2 (typically 1.5 to 2 L). Collect fractions of ∼50 mL. Basic column chromatography techniques are described in APPENDIX 3E.
5. Monitor fractions by TLC (APPENDIX 3D) on a fluorescent indicator plate using CH2 Cl2 as solvent. Visualize the desired product by spraying plate with bromocresol green indicator and then warming it gently on a hot plate. The product (S.2) can be seen as an yellow spot on a blue background (Rf = 0.66).
Modified Oligonucleotides and Conjugates
4.26.3 Current Protocols in Nucleic Acid Chemistry
Supplement 21
6. Combine the fractions containing the product and evaporate to dryness using a rotary evaporator. 7. Characterize the product by 1 H and 13 C NMR and mass spectrometry. Diethyl 2-methoxy-1,3-dioxane-5,5-dicarboxylate (S.2): Yield of colorless oil: 11.2 g (94%). 1 H NMR: 5.28 (s, 1H), 4.54 (d, 2H, 2 JAB = 10.5 Hz), 4.04-4.52 (m, 6H), 3.38 (s, 3H), 1.23-1.34 (m, 6H). 13 C NMR: 169.5, 167.4, 108.9, 62.8, 62.1, 52.8, 13.9. HRMS (ESI): anal. calcd. for C11 H18 O7 [M + Na]+ 285.0945, found 285.0950.
Perform aminolysis with 3-aminopropanol 8. Reflux a mixture of 7.00 g (26.7 mmol) S.2 with 13.5 mL (160 mmol) 3aminopropanol for 48 hr. Monitor progress by TLC as in step 5 using 1:9 (v/v) MeOH/CH2 Cl2 as an eluent. By TLC analysis with bromocresol green, the unreacted starting material (S.2; Rf = 0.92), a monoamide intermediate (Rf = 0.52), and the desired product (S.3; Rf = 0.32) can all be detected.
9. Isolate and purify the desired diamide S.3 from the excess of 3-aminopropanol by silica gel column chromatography as follows. Pack a 5 × 35–cm glass column with 400 mL silica gel in 5% (v/v) MeOH/CH2 Cl2 . Apply the solution from step 8 directly onto the column and elute with 5% (v/v) MeOH/CH2 Cl2 (typically 1.5 to 2 L). Collect fractions of ∼50 mL. 10. Monitor fractions by TLC as in step 8. Combine the fractions containing the product and evaporate in vacuo with a rotary evaporator to yield S.3 as a clear oil. 11. Characterize the product by 1 H and 13 C NMR and mass spectrometry. N,N-Bis(3-hydroxypropyl)-2-methoxy-1,3-dioxane-5,5-dicarboxamide (S.3): Yield of a clear oil: 6.5 g (76% relative to S.2). 1 H NMR: 5.29 (s, 1H), 4.50 (d, 2H, 2 JAB = 13.6 Hz), 4.18 (d, 2H, 2 JAB = 13.6 Hz), 3.61-3.73 (m, 4H), 3.38-3.55 (m, 7H), 1.73 (m, 4H). 13 C NMR: 169.6, 169.6, 109.8, 65.1, 59.6, 58.3, 53.2, 36.9, 18.8. HRMS (ESI): anal. calcd. for C13 H24 N2 O7 [M + Na]+ 343.1476, found 343.1469.
Introduce phthaloyl-protected aminooxy groups and remove methoxymethylene protection 12. Coevaporate 1.10 g (3.43 mmol) S.3 twice with 20 mL dry benzene using a rotary evaporator equipped with a water aspirator. 13. Dissolve the residue in 20 mL anhydrous THF together with 1.98 g (7.55 mmol) triphenylphosphine and 1.23 g (7.55 mmol) N-hydroxyphthalimide. Add 1.17 mL (7.55 mmol) DEAD dropwise to the reaction mixture and continue stirring overnight. 14. Remove the solvent in vacuo with a rotary evaporator. Pack a 3 × 20–cm column with 100 mL silica gel in CH2 Cl2 . Redissolve the residue in a minimal amount (5 to 10 mL) of CH2 Cl2 , apply the residue to the column, then elute with a step gradient from neat CH2 Cl2 to 97:3 (v/v) CH2 Cl2 /i-PrOH (typically 300 to 400 mL) to separate the product from excess reagents and most of the triphenylphosphine oxide formed during the reaction. Collect fractions of ∼10 mL. 15. Monitor fractions by TLC on fluorescent indicator plates using 1:9 (v/v) MeOH/CH2 Cl2 and UV detection (Rf = 0.52). Combine the fractions containing the product and evaporate to dryness using a rotary evaporator. An AminooxyFunctionalized Non-Nucleosidic Phosphoramidite for Oligonucleotide Glycoconjugates
Purification of crude 2-methoxy-N,N-bis(3-phthalimidooxypropyl)-1,3-dioxane-5,5dicarboxamide was found to be seriously hampered by the presence of triphenylphosphine oxide formed during the Mitsunobu reaction. To avoid loss of the material by repeated purifications, the crude product is subjected to acid-catalyzed hydrolysis of the methoxymethylene protecting group (step 16).
4.26.4 Supplement 21
Current Protocols in Nucleic Acid Chemistry
The product, still contaminated by some triphenylphosphine oxide, exhibited the following NMR signals: 1 H NMR: 7.45-7.84 (m, 8H), 5.27 (s, 1H), 4.56 (d, 2H, 2 JAB = 10.3 Hz), 4.20-4.31 (m, 6H), 3.58 (m, 4H), 3.36 (s, 3H), 2.01 (m, 4H). 13 C NMR: 169.4, 168.9, 163.7, 134.5, 132.0, 123.0, 109.7, 76.1, 64.9, 62.1, 53.1, 36.5, 27.5. Identity of the compound was verified by HRMS (ESI): anal. calcd. for C29 H30 N4 O11 [M + Na]+ 633.1776, found 633.1803.
16. Dissolve the crude product in 20 mL of 80% (v/v) aqueous acetic acid and let stand 2 hr at room temperature. 17. Evaporate the solution in vacuo using a rotary evaporator. Coevaporate the residue three times with 50 mL water using a rotary evaporator. 18. Purify the compound (S.4) by silica gel chromatography as follows. Pack a 3 × 20–cm glass column with 100 mL silica gel in CH2 Cl2 . Redissolve the residue from step 17 in 2 to 3 mL CH2 Cl2 , load onto the column, then elute using a step gradient from neat CH2 Cl2 to 5% (v/v) MeOH/CH2 Cl2 (typically 300 to 400 mL). Collect fractions of ∼10 mL. 19. Monitor by TLC as in step 15 (Rf of S.4 = 0.37). Combine fractions containing pure product and evaporate to dryness using a rotary evaporator. 20. Characterize compound S.4 by 1 H and 13 C NMR and mass spectrometry. 2,2-Bis(hydroxymethyl)-N,N-bis(3-phthalimidooxypropyl)malondiamide (S.4): Yield of a colorless oil: 300 mg (15% starting from S.3). TLC (1:9 v/v MeOH/CH2 Cl2 ): Rf = 0.37. 1 H NMR: 7.72-7.91 (m, 8H), 4.26 (t, 4H, J = 5.7 Hz), 3.94 (broad s, 4H), 3.62 (dd, 4H, J = 7.5 and 11.3 Hz), 2.01 (m, 4H). 13 C NMR: 169.5, 168.9, 163.6, 134.6, 131.8, 123.5, 65.0, 55.0, 36.4, 27.8. HRMS (ESI): anal. calcd. for C27 H28 N4 O10 [M + H]+ 569.1878, found 569.1896. Compound S.4 contains four exchangable protons (two NH, two OH) that are not visible on the 1 H NMR spectrum.
Dimethoxytritylate S.4 21. Coevaporate 700 mg (1.23 mmol) S.4 twice with 10 mL anhydrous pyridine using a rotary evaporator, then dissolve residue in 10 mL dry pyridine. 22. Add 417 mg (1.23 mmol) DMTr-Cl, and continue stirring the mixture overnight at room temperature. 23. Evaporate the mixture in vacuo using a rotary evaporator, dilute the residue with 30 mL CH2 Cl2 , and wash twice in a separatory funnel, each time with 15 mL of 5% NaHCO3 . 24. Dry over 10 g anhydrous Na2 SO4 and filter off the drying agent by gravity using filter paper. Evaporate the solution to dryness, and then coevaporate three times with 20 mL dry toluene using a rotary evaporator. 25. Pack a 3 × 20–cm glass column with 100 mL silica gel in CH2 Cl2 . Redissolve the crude oily residue in 3 mL CH2 Cl2 , apply to the column, then elute using a step gradient from neat CH2 Cl2 to 3% MeOH/CH2 Cl2 (typically 300 to 400 mL). Collect fractions of ∼10 mL. 26. Monitor fractions by TLC on fluorescent indicator plates using 1:9 (v/v) MeOH/CH2 Cl2 . Visualize the product bearing the DMTr group, in addition to normal UV detection, by heating the TLC plate on a hot plate. Combine fractions containing the product and evaporate in vacuo using a rotary evaporator to yield the product as a white amorphous solid. Upon heating, the product (S.5) can be seen as a yellow spot on a white background (Rf = 0.41).
Modified Oligonucleotides and Conjugates
4.26.5 Current Protocols in Nucleic Acid Chemistry
Supplement 21
27. Characterize the compound (S.5) by 1 H and 13 C NMR and mass spectrometry. 2-(4,4 -Dimethoxytrityloxymethyl)-2-(hydroxymethyl)-N,N-bis(3-phthalimidooxy propyl)malonamide (S.5): Yield of white solid foam: 440 mg (40% relative to S.4). 1 H NMR: 7.78-7.83 (m, 4H), 7.71-7.76 (m, 4H), 7.66 (t, 2H, J = 6.4 Hz), 7.11-7.38 (m, 9H), 6.80 (m, 4H), 4.18 (m, 4H), 4.10 (d, 2H, J = 6.4 Hz), 3.81 (t, 1H, J = 6.4 Hz), 3.75 (s, 6H), 3.46-3.62 (m, 6H), 1.96 (m, 4H). 13 C NMR: 170.9, 163.5, 158.5, 144.3, 135.3, 134.5, 130.1, 128.9, 128.1, 127.9, 126.9, 123.6, 113.2, 86.5, 76.0, 65.1, 64.0, 58.7, 55.2, 36.4, 27.9. HRMS (ESI): anal. calcd. for C48 H46 N4 O12 [M + Na]+ 893.3004, found 893.3046.
Phosphitylate S.5 28. Dry 220 mg (0.25 mmol) S.5 overnight over P2 O5 in a vacuum desiccator. Dissolve this in 2 mL dry acetonitrile, and apply a dry nitrogen atmosphere. 29. Add 175 µL (1.26 mmol) triethylamine and 62 µL (0.28 mmol) 2-cyanoethyl N,Ndiisopropylphosphonamidic chloride to the reaction solution. Stir the mixture 45 min under nitrogen. Monitor the reaction by TLC in 60% (v/v) EtOAc/hexane, visualizing the product by heating the TLC plate on a hot plate. The product (S.6) can be seen as a yellow spot on a white background (Rf = 0.82).
30. Apply the reaction mixture to a 3 × 20–cm column containing 50 mL dried silica gel and isolate the pure compound by eluting with 60:39:1 (v/v/v) dry ethyl acetate/hexane/triethylamine (typically 150 to 200 mL). Collect fractions of ∼5 mL. 31. Monitor fractions by TLC as in step 26 (Rf for S.6 = 0.83). Combine fractions containing the phosphoramidite, and evaporate and dry in vacuo using a rotary evaporator to yield S.6 as a white solid foam. 32. Characterize the compound by 1 H and 13 C NMR and mass spectrometry. 2-Cyanoethyl 3-[(4,4 -dimethoxytrityl)oxy]-2,2-bis[2-aza-1-oxo-5-(phthalimidooxy) pentyl]propyl-N,N-diisopropylphosphoramidite (S.6) is stable during prolonged storage at −20◦ C. Yield of solid white foam: 230 mg (85%). 1 H NMR: 7.71-7.84 (m, 8H), 7.61 (t, 2H, J = 5.1 Hz), 7.10-7.45 (m, 9H), 6.80 (m, 4H), 4.03-4.45 (m, 6H), 3.69-3.78 (m, 10H), 3.25-3.57 (m, 6H), 2.56 (m, 2H, J = 7.2 Hz), 1.91-1.99 (m, 4H), 1.12 (d, 12H, J = 7.2 Hz). 13 C NMR: 170.7, 163.3, 159.5, 144.1, 135.1, 134.3, 129.9, 128.7, 127.9, 127.7, 123.3, 113.1, 86.4, 75.9, 64.8, 64.5, 53.5, 59.4, 58.7, 58.3, 55.0, 43.0, 36.2, 27.9, 24.3, 18.7. 31 P NMR: 146.6. MS (ESI): anal. calcd. for C57 H63 N6 O13 P [M + Na]+ 1093.4, found 1094.1.
BASIC PROTOCOL 2
An AminooxyFunctionalized Non-Nucleosidic Phosphoramidite for Oligonucleotide Glycoconjugates
PREPARATION OF THE MANNOSYL ALDEHYDE LIGAND The carbonyl group is known to be exceptionally susceptible to attack by an α-nucleophile such as an aminooxy group. Previous studies have shown that the oxime conjugates obtained withstand the standard ammonolysis performed upon completion of the oligonucleotide chain elongation to deprotect and cleave the product from the support (Salo et al., 1999). In the present protocol, based primarily on Katajisto et al. (2004), fully acetylated 4-oxobutyl α-D-mannopyranoside (S.9) is used as an example of a glycosyl aldehyde ligand with which the solid-supported oximation is carried out to obtain the desired oligonucleotide glycoconjugate. This compound can be easily prepared by a two-step procedure, as depicted in Figure 4.26.2. Boron trifluoride etherate–promoted glycosidation of commercially available peracetylated α-D-mannopyranose (S.7) with 1,4-butanediol yields a 4-hydroxybutyl mannoside peracetate (S.8), which is then subjected to Swern oxidation to yield S.9. This protocol enables easy preparation of the desired target compound in spite of the relatively low yield obtained in converting S.7 to S.8.
4.26.6 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Figure 4.26.2 Synthesis of the sugar ligand S.9 (see Basic Protocol 2). Ac, acetyl. Reprinted from Katajisto et al. (2004) with permission from the American Chemical Society.
Materials α-D-Mannose pentaacetate (S.7; Sigma) Dry benzene, distilled from powdered CaH2 (store over 4-Å molecular sieves) Dry nitrogen (or argon) Dry acetonitrile (MeCN), HPLC grade (store over 4-Å molecular sieves) 1,4-Butanediol, 99% pure (Aldrich) Boron trifluoride etherate (Merck) Dichloromethane (CH2 Cl2 ), ≥ 99% pure Sodium sulfate (Na2 SO4 ), anhydrous Silica gel: 0.040- to 0.063-mm Fluka Kieselgel 60 (dry overnight in oven at 150◦ C) Ethyl acetate (EtOAc), analytical reagent Hexane, HPLC grade 10% (v/v) H2 SO4 Oxalyl chloride, 99% pure (Aldrich) Dry argon Dry ice/isopropanol bath Dry dimethyl sulfoxide (DMSO; store over 4-Å molecular sieves) Triethylamine (TEA), freshly distilled from powdered CaH2 Diethyl ether 1 M aqueous HCl, ice cold Saturated aqueous sodium hydrogen carbonate (NaHCO3 ) Saturated aqueous sodium chloride (NaCl) Methanol (MeOH), ≥99.8% pure Separatory funnels Rotary evaporator equipped with a water aspirator 3 × 20–cm sintered glass chromatography column, porosity 3 TLC plate: silica-coated aluminium plate with fluorescent indicator (Merck silica gel 60 F254 ) 254-nm UV lamp Additional reagents and equipment for column chromatography (APPENDIX 3E) and thin-layer chromatography (TLC, APPENDIX 3D)
Modified Oligonucleotides and Conjugates
4.26.7 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Glycosidate S.7 with 1,4-butanediol 1. Coevaporate 5.00 g (12.8 mmol) α-D-mannose pentaacetate (S.7) twice with dry benzene using a rotary evaporator equipped with a water aspirator. Apply a dry nitrogen (or argon) atmosphere. 2. Dissolve the residue in 30 mL dry MeCN. Add 1.10 mL (12.8 mmol) 1,4-butanediol and then 4.82 mL (38.4 mmol) boron trifluoride etherate, and allow the reaction to proceed at room temperature for 2 hr. Extension of the reaction time gives a decreased yield of the target compound and increased amount of monoacetylated 1,4-butanediol as a byproduct. For further discussion, see Background Information.
3. Dilute the reaction mixture with 70 mL CH2 Cl2 and wash with 50 mL water in a separatory funnel. Dry over 10 g anhydrous Na2 SO4 , filter by gravity using filter paper to remove the solid, then evaporate the solution to dryness using a rotary evaporator with a water aspirator. 4. Separate the product from the unreacted starting material S.7 by silica gel chromatography as follows. Pack a 3 × 20–cm glass column with 100 mL silica gel in 2:1 (v/v) EtOAc/hexane. Redissolve sample in a minimal amount (∼5 mL) of 2:1 (v/v) EtOAc/hexane, apply to column, and elute with 2:1 (v/v) EtOAc/hexane (typically 300 to 400 mL). Collect fractions of ∼10 mL. Basic column chromatography techniques are described in APPENDIX 3E.
5. Monitor the fractions by TLC (APPENDIX 3D) on fluorescent indicator plates using 1:9 (v/v) MeOH/CH2 Cl2 . Visualize the desired product by dipping the TLC plate in 10% aqueous H2 SO4 and then heating it on a hot plate. The unreacted starting material and the desired product are both charred and can be visualized as black spots on the plate (S.7, Rf = 0.81; S.8, Rf = 0.55).
6. Combine the fractions containing the product (S.8) and evaporate to dryness using a rotary evaporator. 7. Characterize S.8 by 1 H and 13 C NMR and high-resolution mass spectrometry. 4-Hydroxybutyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (S.8): Yield of a colorless oil: 1.05 g (19%). 1 H NMR: 7.26 (6s, 1H) 5.33 (dd, 1H, J = 4.1 and 10.8 Hz), 5.29 (t, 1H, J = 10.8 Hz), 5.22 (dd, 1H, J = 4.3 and 1.6 Hz), 4.81 (d, 1H, J = 1.4 Hz), 4.28 (dd, 1H, J = 5.4 and 12.7 Hz), 4.10 (dd, 1H, J = 2.9 and 12.7 Hz), 3.98 (m, 1H), 3.73 (m, 1H), 3.68 (t, 2H, J = 5.4 Hz), 3.50 (m, 1H), 2.14, 2.10, 2.05, and 1.99 (each s, 3H), 1.72-1.63 (m, 4H). 13 C NMR: 170.7, 170.1, 169.9, 169.8, 97.6, 69.7, 69.1, 68.4, 68.3, 66.2, 62.5, 29.4, 25.7, 20.9, 20.8, 20.7. HRMS (ESI): anal. calcd. for C18 H28 O11 [M + Na]+ 443.1524, found 443.1516.
Perform Swern oxidation of S.8 8. Predry 1.00 g (2.38 mmol) S.8 overnight over P2 O5 in a vacuum desiccator. Dissolve in 10 mL dry CH2 Cl2 . 9. Prepare a magnetically stirred solution of 1.67 mL (19.1 mmol) oxalyl chloride in 5 mL dry CH2 Cl2 . Apply a dry argon atmosphere and cool the reaction mixture to −60◦ C using a dry ice/isopropanol bath. Add 2.70 mL (38.1 mmol) DMSO dropwise to the solution and allow the mixture to react under vigorous stirring 30 min at −60◦ C. An AminooxyFunctionalized Non-Nucleosidic Phosphoramidite for Oligonucleotide Glycoconjugates
10. Slowly add S.8 to the stirring solution and continue stirring at −60◦ C for 40 min. CAUTION: The reaction is violent and exothermic at ambient temperature. The reaction proceeds via an intermediate complex that is unstable at temperatures higher than −60◦ C. CAUTION: Dimethyl sulfide, which has a strong stench, is generated during the reaction; the reaction must therefore be carried out in a well-ventilted fume hood.
4.26.8 Supplement 21
Current Protocols in Nucleic Acid Chemistry
11. Add 7.91 mL (57.1 mmol) TEA, remove the cooling bath, and allow the solution to warm to 0◦ C. 12. Pour the mixture into 100 mL magnetically stirred, ice-cold water, and extract three times with 100 mL diethyl ether. 13. Combine the organic phases and wash in a separatory funnel successively with 50 mL ice-cold 1 M aqueous HCl, 50 mL saturated aqueous NaHCO3 , and finally with saturated aqueous NaCl. 14. Dry over 10 g anhydrous Na2 SO4 , filter by using filter paper to remove the solid, then evaporate in vacuo using a rotary evaporator. 15. Apply the reaction mixture to a 3 × 20–cm column containing 100 mL silica gel and isolate the pure compound by eluting with 2:1 (v/v) EtOAc/hexane (typically 300 to 400 mL). Collect fractions of ∼10 mL. 16. Monitor fractions by TLC in 1:9 (v/v) MeOH/CH2 Cl2 and visualize the product by charring with 10% H2 SO4 (see step 5). Combine the fractions containing the product (S.9) and evaporate to dryness using a rotary evaporator. The desired product is seen as a black spot (Rf = 0.53).
17. Characterize S.9 by 1 H and 13 C NMR and high-resolution mass spectrometry. 4-Oxobutyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (S.9): Yield of a clear oil: 595 mg (60%). 1 H NMR: 9.82 (s, 1H), 5.12-5.31 (m, 3H), 4.80 (s, 1H), 4.28 (dd, 1H, J = 5.6 and 12.9 Hz), 4.12 (m, 1H), 3.95 (m, 1H), 3.75 (m, 1H), 3.50 (m, 1H), 2.58 (m, 2H), 2.16, 2.11 and 2.05 (each s, 3H), 2.00-1.77 (m, 5H). 13 C NMR: 201.3, 170.6, 170.1, 169.9, 169.7, 97.5, 69.6, 68.9, 68.3, 67.9, 66.1, 62.4, 40.5, 22.3, 21.9, 20.9, 20.7, 20.4, 20.2. HRMS (ESI): anal. calcd. for C18 H26 O11 [M + Na]+ 441.13673, found 441.13667.
SYNTHESIS OF OLIGONUCLEOTIDE GLYCOCONJUGATES BY ON-SUPPORT OXIMATION
BASIC PROTOCOL 3
The standard phosphoramidite protocol can be applied to incorporate S.6 units into oligonucleotides, except that a prolonged coupling time (600 sec) should be used with S.6 to obtain an acceptable 95% coupling efficiency. For example, a protected heterosequence 5 -d(TXTXTGACGATCTCAT)-3 , where X stands for the non-nucleosidic residue S.6, may be synthesized as outlined in Figure 4.26.3. The support-bound oligonucleotide (S.10) is treated with 0.5 M hydrazinium acetate in pyridine for 30 min to remove the phthaloyl groups, and the exposed aminooxy groups are converted to stable oxime conjugates (S.11) upon reaction with the mannopyranosyl aldehyde building block (S.9). Final global deprotection and cleavage of the oxime conjugate S.12 from the support is accomplished by standard ammonolysis (33% aqueous NH3 , 7 hr at 55◦ C). The oligodeoxyribonucleotides can be assembled on any automated DNA/RNA synthesizer. The authors have used an Applied Biosystems 392 DNA synthesizer on 1.0-µmol scale with a commercial 1000-Å CPG-succinyl-thymidine support and standard phosphoramidite chemistry. Phosphoramidite S.6 was used as a 0.15 M solution in dry acetonitrile, the coupling time being 600 sec. After cleavage from the support, the oxime conjugates were evaporated, dissolved in water, purified by RP-HPLC, desalted, and characterized by ESI-MS.
Modified Oligonucleotides and Conjugates
4.26.9 Current Protocols in Nucleic Acid Chemistry
Supplement 21
An AminooxyFunctionalized Non-Nucleosidic Phosphoramidite for Oligonucleotide Glycoconjugates
Figure 4.26.3 Synthesis of the oligonucleotide glycoconjugate S.12 utilizing on-support oximation. Ac, acetyl; Pht, phthaloyl.
4.26.10 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Materials Phosphoramidite S.6 (see Basic Protocol 1) Dry acetonitrile (MeCN), HPLC grade (store over 4-Å molecular sieves) 2 -Deoxyribonucleoside phosphoramidites (Glen Research) 0.5 M hydrazinium acetate solution: 0.124:4:1 (v/v/v) mixture of hydrazine monohydrate (>98% pure, Aldrich), analytical-grade pyridine, and glacial acetic acid Pyridine, analytical grade Acetonitrile (MeCN), analytical grade Mannosyl aldehyde ligand S.9 (see Basic Protocol 2) 33% aqueous ammonia Mobile phase A: 0.05 M ammonium acetate, pH 7.0, in H2 O Mobile phase B: 0.05 M ammonium acetate in 65% (v/v) aqueous MeCN 55◦ C water bath Speedvac evaporator HPLC system with 4.6 × 150–mm analytical ThermoHypersil C18 column and 260-nm detector Desalting column: 7.5 mm × 30 cm TSKgel G 2000 size-exclusion chromatography column, particle size 10 µm (Toso-Haas) UV spectrophotometer Additional reagents and equipment for automated solid-phase oligonucleotide synthesis (APPENDIX 3C) and for purification (UNIT 10.5) and characterization (UNIT 10.2) of oligonucleotides Incorporate S.6 into oligodeoxyribonucleotide chain 1. Prepare a 0.15 M solution of phosphoramidite S.6 in anhydrous MeCN. 2. Start the automated solid-phase oligonucleotide synthesis (APPENDIX 3C) on a 1000-Å CPG-succinyl-thymidine support (1-µmol scale). 3. Elongate the desired oligonucleotide chain using standard 2 -deoxyribonucleoside phosphoramidites and phosphoramidite S.6 in DMTr-OFF mode (APPENDIX 3C). Extend the coupling time to 600 sec for every S.6 coupling. After coupling of S.6, the detritylation is carried out by using two consecutive detritylation steps (60 sec each) separated by a trityl flush step (5 sec). Otherwise stardard protocols are employed.
4. After completion of the assembly, remove the column and place under vacuum to dry the support.
Remove phthaloyl groups 5. Transfer the support to a 1.5-ml polypropylene microcentrifuge tube, add 1 mL of 0.5 M hydrazinium acetate solution, and leave 30 min at room temperature. 6. Vacuum filter the support into a DNA synthesizer column. Wash five times, each time with 10 mL pyridine, then wash an additional five times, each time with 10 mL MeCN. Dry in vacuo using an oil pump. Owing to the high nucleophilicity of the aminooxy functions, solvents of analytical grade, which do not contain any aldehydes or ketones as impurities, should be used for the washings to avoid premature oximation.
Modified Oligonucleotides and Conjugates
4.26.11 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Perform on-support oximation 7. Transfer the support to a 1.5-ml polypropylene microcentrifuge tube and add a solution of the aldehyde-tethered sugar ligand S.9 (100 µmol in 200 µL dry MeCN). Leave the mixture at room temperature for 16 hr to ensure complete oximation. 8. Vacuum filter the support into a DNA synthesizer column. Wash five times, each time with 20 mL MeCN. Dry in vacuo using an oil pump.
Cleave and isolate oligonucleotide glycoconjugate 9. Transfer the support to a 1.5-ml polypropylene microcentrifuge tube and add 1 mL of 33% aqueous ammonia. Vortex and then incubate ≥7 hr at 55◦ C. 10. Evaporate the ammonia and dry in vacuo using a Speedvac evaporator. 11. Add 200 µL deionized water and microcentrifuge 5 min at 12,000 rpm. 12. Purify the filtrate by RP-HPLC (UNIT conditions:
10.5)
using the following recommended
4.6 × 150–mm analytical ThermoHypersil C-18 column Mobile phase A: 0.05 M ammonium acetate in H2 O Mobile phase B: 0.05 M ammonium acetate in 65% MeCN Gradient: 0% to 100% B over 30 min Flow rate: 1 mL/min Detection: 260 nm. These conditions are suitable for the purification of oligos synthesized in DMTr-OFF mode.
13. Pool the appropriate fractions, desalt on a TSKgel G 2000 size-exclusion chromatography column, and evaporate the conjugate to dryness using a Speedvac evaporator. 14. Dissolve the oligonucleotide glycoconjugate in deionized water and quantify by measuring the UV absorbance at 260 nm. Store the solution frozen. 15. Characterize S.12 by ESI-MS (UNIT 10.2). MS (ESI): anal. calcd. 5898.4, found 5897.3. See Figure 4.26.4 for an RP-HPLC profile of crude S.12 (retention time, 15.8 min). Purity: 54% (percentage of S.12 in crude reaction mixture on the basis of HPLC signal areas). For a discussion of melting studies of S.12, see Background Information. The experiments were performed in 10 mM sodium phosphate, pH 7.0 (APPENDIX 2A), containing 100 mM NaCl. The concentration of the duplex of S.12 and its complementary sequence was 2µM.
COMMENTARY Background Information
An AminooxyFunctionalized Non-Nucleosidic Phosphoramidite for Oligonucleotide Glycoconjugates
The aim of the studies described in this unit has been to develop a strategy for the solidphase synthesis of structurally diverse oligonucleotide glycoconjugates. Interest in covalent conjugation of sugar ligands to oligonucleotides has increased during recent years, as it is expected that applications will be found in cell-specific targeting of antisense oligonucleotides or small interfering ribonucleic acids (siRNA; Wang et al., 2003). Recognition of various cell-surface lectins, and hence the cell type, is based on simultaneous interaction with several sugar ligands. Accordingly, a glycocluster structure is a prerequisite
for high-affinity binding and subsequent internalization of the conjugate by endocytosis. The number of protocols described for solidphase synthesis of covalent oligonucleotide glycoconjugates is still limited. The examples available include on-support glycosylation with trichloroacetimidates (Adinolfi et al., 1999) and use of base-glycosylated nucleoside phosphoramidites (De Kort et al., 1999; Hunziker, 1999; Matsuura et al., 2001) and glycoside phosphoramidites (Akhtar et al., 1995; Sheppard et al., 2000) as building blocks for the chain assembly. In a more recent study, a method for solid-phase synthesis of oligonucleotide conjugates bearing a tetraantennary
4.26.12 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Figure 4.26.4 RP-HPLC profile of crude S.12 at 260 nm. Reprinted from Katajisto et al. (2004) with permission from the American Chemical Society.
glycocluster at the 5 terminus has been described (Dubber and Fr´echet, 2003). Building blocks derived from pentaerythritol were used as branching units and glycoside phosphoramidites were used for insertion of the 5 terminal glycosyl groups. In contrast, the protocols in this unit are based on solution-phase synthesis of a nonnucleosidic phosphoramidite building block bearing two phthaloyl-masked aminooxy groups, the incorporation of this building block into oligonucleotides by conventional phosphoramidite chemistry, and solid-phase oximation of the deblocked aminooxy groups with glycosyl aldehydes. The final deprotection and cleavage from the solid support is achieved by conventional ammonolysis. This methodology allows variation of the number, site, and identity of the sugar ligands, and hence is suitable for the creation of conjugate libraries. Because the synthesized building block allows normal
oligonucleotide chain assembly, the distance between the sites of glycosyl attachment may be tuned with additional nucleosidic and nonnucleosidic phosphoramidite building blocks. Conversion of various sugars to peracetates and their subsequent glycosidation with a diol and oxidation to an aldehyde offers a straightforward method for conjugation of any desired sugar by simple and efficient oxime formation. The oxime conjugates are highly water soluble and stable at physiological pH, making them applicable to biological studies. Synthesis of the non-nucleosidic phosphoramidite building block Building block S.6 is synthesized from commercially available diethyl 2,2bis(hydroxymethyl)malonate (S.1). It has been shown previously (Guzaev et al., 1996) that S.1 and its mono-4,4 -dimethoxytrityl (DMTr) derivative are decomposed by release
Modified Oligonucleotides and Conjugates
4.26.13 Current Protocols in Nucleic Acid Chemistry
Supplement 21
of formaldehyde when treated with primary amines. Accordingly, it is necessary to protect both hydroxyl groups of S.1 prior to aminolysis with 3-aminopropanol to obtain S.3. Use of an orthoester protection for this purpose ensures easy deblocking by acid-catalyzed hydrolysis under mild conditions. Using an excess of 3-aminopropanol, the aminolysis of S.2 to the desired diol is almost quantitative. The Mitsunobu reaction (Mitsunobu, 1981) used for introduction of the phthaloylprotected aminooxy groups is the difficult step of the synthesis. Treatment of S.3 with a mixture of N-hydroxyphthalimide, triphenylphosphine, and diethyl azodicarboxylate over a period of 24 hr results in complete disappearance of the starting material without any marked formation of side products. The purification of the di-O-phthalimidooxy product is, however, problematic. Traces of triphenylphosphine oxide formed during the reaction tend to comigrate with the product even after repeated purifications by column chromatography on silica gel. To avoid extensive loss of the target compound, the crude product should be directly subjected to acid-catalyzed hydrolysis to remove the methoxymethylene protecting group. The resulting bis(hydroxymethyl) derivative S.4 can then be more easily separated from impurities by column chromatography on silica gel, although in a low yield. One of the hydroxy groups of S.4 is finally selectively protected as a monoDMTr ether (S.5) using an equivalent amount of DMTr-Cl. The remaining hydroxyl is phosphitylated with 2-cyanoethyl N,N-diisopropylphosphonamidic chloride to obtain S.6. The yield of dimethoxytritylation cannot be increased by using excess DMTr-Cl, since this leads to increased formation of the bis(dimethoxytritylated) product.
An AminooxyFunctionalized Non-Nucleosidic Phosphoramidite for Oligonucleotide Glycoconjugates
Synthesis of the glycosyl aldehyde ligand The glycosyl aldehyde ligand used for the solid-phase oximation is obtained by an easy two-step procedure. A fully acetylated sugar ligand is first subjected to conventional boron trifluoride etherate–promoted glycosidation (Salvador et al., 1995) with an α,ωalkanediol. MeCN appears to be the solvent of choice for this transformation, since less polar CH2 Cl2 or CHCl3 dissolve the diol poorly, leading to extensive formation of monoacylated diol as a byproduct whose mobility is similar to the desired product. The same side reaction takes place when either the reaction time is prolonged or the diol is used in excess. Despite the relatively low yield of this reac-
tion, the use of an unprotected diol shortens the route to the desired target compound, and hence increases the overall yield. In addition, the unreacted sugar peracetate can easily be recycled. The second step, a Swern oxidation of the hydroxy function to an aldehyde group, is a smooth and high-yielding reaction, as expected (Mancuso et al., 1978). Synthesis of the oligonucleotide conjugate and its hybridization properties The present protocol describes preparation of a multivalent oligonucleotide glycoconjugate containing four α-Dmannopyranosyl units. The key steps are introduction of non-nucleosidic bis(hydroxymethyl)malondiamide-derived phosphoramidites, each bearing two phthaloyl-masked aminooxy groups, into the oligonucleotide chain, and oximation of their deblocked aminooxy groups with a glycosyl aldehyde on the support. A standard phosphoramidite protocol can be applied to the coupling of the non-nucleosidic units, although a prolonged coupling time (600 sec) is needed to obtain a sufficiently high coupling yield (>95%). The aminooxy functions may be deblocked without difficulty by a hydrazinium acetate treatment. This treatment does not cleave the succinyl linker (Salo et al., 1999). Oximation of the exposed aminooxy groups with a large excess of peracetylated sugar aldehyde building block in MeCN proceeds essentially to completion within 16 hr at ambient temperature. The oxime conjugate may then be released in solution by normal ammonolysis, which simultaneously deprotects the base, sugar, and phosphate moieties of the conjugate. No signs of hydrolysis or degradation products can be observed by RP-HPLC analysis of the crude product (see Fig. 4.26.4). After normal RP-HPLC purification, the identity of the conjugate may be further verified by ESI-MS analysis. It should be noted that oxidation of the primary hydroxyl group of an otherwise protected sugar to an aldehyde group may appear to be an attractive alternative, but this is not recommended. Although such an aldehyde is easily obtained and solid-supported oximation using the aldehyde is high-yielding, upon standard ammonolytic cleavage, the sugar ligand evidently undergoes dehydration to a 4,5-ene derivative, in all likehood due to conjugation of the 4,5 double bond with the oxime group. Melting studies show that the synthesized oligonucleotide glycoconjugate forms a
4.26.14 Supplement 21
Current Protocols in Nucleic Acid Chemistry
stable duplex with a complementary 12-mer oligodeoxyribonucleotide when the glycosylated 5 terminus falls outside the duplex. The thermal stability of this duplex is only moderately lower than that of the respective fully complementary 12-mer duplex. The melting points were observed to be 44.9◦ C and 48.0◦ C, respectively. More marked destabilization was observed, as expected, on using a complementary 18-mer oligodeoxyribonucleotide carrying an A7 sequence at the 3 terminus, i.e., opposite the glycosylated part of the conjugate. A melting point of 41.9◦ C was observed for hybridization with the glycosylated conjugate.
Compound Characterization Basic Protocols 1 and 2. Chemical characterization data are provided for all compounds in the appropriate protocol steps. The NMR spectra were recorded on a Bruker 200 or JEOL JNM-GX 400- or 500-MHz spectrometer in CDCl3 . The chemical shifts (δ) are given in ppm from internal tetramethylsilane, and the coupling constants (J) are given in hertz (Hz). Mass spectra were recorded on an Applied Biosystems Mariner System 5272 using electrospray ionization (ESI). Basic Protocol 3. Oxime conjugates were characterized by ESI-MS on an Applied Biosystems Mariner System 5272. The melting curve (absorbance versus temperature) for S.12 in hybridization buffer was measured at 260 nm on a Perkin-Elmer Lambda 2 UV-Vis spectrometer equipped with Peltier temperature controller.
Critical Parameters and Troubleshooting The phosphoramidite S.6 and the sugar aldehyde ligand S.9 may be prepared starting from simple and inexpensive starting materials via a fairly straightforward selective transformation of functional groups. The individual steps are based on rather conventional chemistry. Nevertheless, most of the reactions are conducted under anhydrous conditions and, hence, careful attention to proper drying of the solvents and glassware is essential. Preparation of the compounds requires experience with routine chemical laboratory techniques such as extraction, TLC (APPENDIX 3D), and silica gel column chromatography (APPENDIX 3E). Knowledge of machine-assisted DNA synthesis (APPENDIX 3C) and isolation of the products by HPLC (UNIT 10.5) is needed. Characterization of the compounds demands
knowledge of 1 H, 13 C, and 31 P NMR spectroscopies and electrospray ionization mass spectrometry (ESI-MS; UNIT 10.2).
Anticipated Results Good to moderate yields of the individual steps of the total synthesis of building blocks S.6 and S.9 are expected. The total yield of S.6 may also be increased to some extent by avoiding repetitive column chromatographic purifications after the Mitsunobu reaction. These building blocks allow quite convenient synthesis of multivalent oligonucleotide glycoconjugates on a solid support as described in Basic Protocol 3. The target compound is expected to be clearly the main product, and its isolation by RP-HPLC is therefore fairly straightforward.
Time Considerations The synthesis of the phosphoramidite S.6 starting from diethyl 2,2bis(hydroxymethyl)malonate (S.1) can be accomplished in 2 weeks (including five overnight incubations) and the synthesis of the sugar ligand S.9 within 2 to 3 days. The time needed for machine-assisted oligonucleotide chain assembly differs from the standard protocol only by the extended coupling time of 600 sec per non-nucleosidic phosphoramidite unit. The phthaloyl deprotection and subsequent oximation by overnight treatment increase the total time of the conjugate synthesis by 24 hr. The times needed for deprotection and cleavage from the support, RP-HPLC purification, and characterization are the same as with standard methods.
Literature Cited Adinolfi, M., Barone, G., De Napoli, L., Guariniello, L., Iadonisi, A., and Piccialli, G. 1999. Solid-phase glycosidation of oligonucleotides. Tetrahedron Lett. 40:2607-2610. Akhtar, S., Routledge, A., and Patel, R. 1995. Synthesis of mono- and dimannoside phosphoramidate derivatives for the solid-phase conjugation to oligonucleotides. Tetrahedron Lett. 36:73337336. De Kort, M., Ebrahimi, E., Wijsman, E.R., Van der Marel, G.A., and Van Boom, J.H. 1999. Synthesis of oligodeoxynucleotides containing 5-(β-D-glycopyranosyloxymethyl)-2 deoxyuridine, a modified nucleoside in the DNA of Trypanosoma Brucei. Eur. J. Chem. 9: 2337-2344. Defrancq, E. and Lhomme, J. 2001. Use of an aminooxy linker for the functionalization of oligodeoxyribonucleotides. Bioorg. Med. Chem. Lett. 11:931-933.
Modified Oligonucleotides and Conjugates
4.26.15 Current Protocols in Nucleic Acid Chemistry
Supplement 21
Dubber, M. and Fr´echet, J.M.J. 2003. Solid-phase synthesis of multivalent glycoconjugates on a DNA synthesizer. Bioconjugate Chem. 14:239246.
Mitsunobu, O. 1981. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1-28.
Guzaev, A., Salo, H., Azhayev, A., and L¨onnberg, H. 1996. Novel nonnucleosidic building blocks for the preparation of multilabeled oligonucleotides. Bioconjugate Chem. 7:240-248.
Salo, H., Virta P., Hakala, H., Prakash, T.P., Kawasaki, A.M., Manoharan, M., and L¨onnberg, H. 1999. Aminoxy functionalized oligonucleotides: Preparation, on-support derivatization, and post-synthetic attachment to polymer support. Bioconjugate Chem. 10:815823.
Hamma, T. and Miller, P.S. 2003. 4-(2Aminoethoxy)-2-ethylureido)quinolineoligonucleotide conjugates: Synthesis, binding interactions, and derivatization with peptides. Bioconjugate Chem. 14:320-330. Hunziker, J. 1999. Synthesis of 5-(2-amino2-deoxy-D-glucopyranosyloxymethyl)-2 deoxyuridine and its incorporation into oligothymidylates. Bioorg. Med. Chem. Lett. 9:201-204. Katajisto, J., Virta, P., and L¨onnberg, H. 2004. Solidphase synthesis of multiantennary oligonucleotide glycoconjugates utilizing on-support oximation. Bioconjugate Chem. 15:890-896.
Salvador, L.A., Elofsson, M., and Kihlberg, J. 1995. Preparation of building blocks for glycopeptide synthesis by glycosylation of Fmoc amino acids having unprotected carboxyl groups. Tetrahedron 51:5643-5656. Sheppard, T.L., Wong, C., and Joyce, G.F. 2000. Neoglycoconjugates: Design and synthesis of a new class of DNA-carbohydrate conjugates. Angew. Chem. Int. Ed. Engl. 39:3660-3663.
Mancuso, A.J., Huang, S., and Swern, D. 1978. Oxidation of long-chain and related alcohols to carbonyls by dimethyl sulfoxide “activated” by oxalyl chloride. J. Org. Chem. 43:2480-2482.
Wang, L., Prakash, R.K., Stein, C.A., Koehn, R.K., and Ruffner, D.E. 2003. Progress in the delivery of therapeutic oligonucleotides: Organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Antisense Nucleic Acid Drug Dev. 13:169-189.
Matsuura, K., Hibino, M., Yamada, Y., and Kobayashi, K. 2001. Construction of glycoclusters by self-organization of site-specifically glycosylated oligonucleotides and their cooperative amplification of lectin-recognition. J. Am. Chem. Soc. 123:357-358.
Contributed by Johanna Katajisto, Pasi Virta, and Harri L¨onnberg University of Turku Turku, Finland
An AminooxyFunctionalized Non-Nucleosidic Phosphoramidite for Oligonucleotide Glycoconjugates
4.26.16 Supplement 21
Current Protocols in Nucleic Acid Chemistry
Large-Scale Preparation of Conjugated Oligonucleoside Phosphorothioates by the High-Efficiency Liquid-Phase (HELP) Method
UNIT 4.27
This unit describes the soluble-polymer-supported synthesis of phosphorothioated oligonucleotides and their postsynthetic conjugation with a new chain of high-molecularweight polyethylene glycol (PEG) or other polymers. The protocols give all the details of synthesis, deprotection, isolation, and modification of the oligonucleotides. Basic Protocol 1 outlines the step-by-step procedure of the liquid-phase process used for assembling the thioated oligonucleotide chain. The procedure is similar to classical solidphase synthesis, with the exception that all the reactions are performed in homogeneous solutions. Purification of intermediates, however, is very similar to methods performed in processes conducted on an insoluble support; the insolubility of PEG in diethyl ether or ethanol allows the selective precipitation of the supported nucleic acid product and the effective removal of all soluble byproducts. Alternate Protocol 1 describes the assembly of the chain using preassembled dimers to allow production of the oligonucleotides on a larger scale. The reduced number of procedural steps provides an increase in the yield of the final product. Basic Protocol 2 describes the introduction of a linker with a reactive amino-terminal function on the PEG-supported oligonucleotides and the final detachment of the modified oligonucleotides from the support. This is required because the terminal hydroxyl moiety of the oligonucleotide does not guarantee a successful condensation reaction with the large polymeric chain, whose reactivity generally decreases with increasing molecular weight. Basic Protocol 3 describes the conjugation of the modified oligonucleotide with a properly activated high-molecular-weight PEG in solution. The most convenient procedures for activation of the terminal hydroxyl of PEG are outlined. Alternate Protocol 2 describes a different method for activation of the PEG moiety to enable conjugation. This process, although less effective, can be used for conjugation should the one in Basic Protocol 3 not be implemented. ◦
NOTE: Store all anhydrous solvents under argon, over activated 4-A molecular sieves (<20 ppm water). Dry glassware to be used for oligonucleotide synthesis in an oven at 110◦ C and store in a desiccator over KOH pellets prior to use. Store all amidite solution bottles over desiccant in polypropylene containers. Allow all cold bottles to warm to room temperature before use.
PREPARATION OF PHOSPHOROTHIOATED OLIGONUCLEOTIDES VIA HELP This process, called high-efficiency liquid phase, or HELP, consists of three main steps: (1) functionalization of a soluble support with a 5 -DMTr-nucleoside via a succinyl linkage, (2) elongation of the oligonucleotide, and (3) cleavage of the succinyl linkage and removal of all protecting groups. Many advantages arise from this synthetic process. The
Contributed by Gian Maria Bonora Current Protocols in Nucleic Acid Chemistry (2005) 4.27.1-4.27.26 C 2005 by John Wiley & Sons, Inc. Copyright
BASIC PROTOCOL 1
Synthesis of Modified Oligonucleotides and Conjugates
4.27.1 Supplement 22
Figure 4.27.1 Preparation of the 5 -O-DMTr-nucleoside-3 -hemisuccinate and subsequent functionalization of MPEG.
oligonucleotide synthesis is carried out in homogeneous medium on a soluble polymeric support. The polymer-bound product is recovered from the reaction mixture by a simple precipitation that allows rapid and easy elimination of excess reagents and soluble byproducts. Preparation of the nucleoside succinate and functionalization of the support are illustrated in Figure 4.27.1. Polyethylene glycol (PEG) is used as a soluble support for oligonucleotide synthesis. The molecular weight of the PEG ranges from 5 to 20 kDa, depending on the final size of the desired oligonucleotide. In the process described herein, a 10kDa monomethoxy-PEG (MPEG) is employed because the monofunctional derivative is easier to handle during the synthetic procedures. A commercial bifunctional PEG may be used to increase production of the final product from the same molar amount of PEG support; however, this may lead to unpredictable results as a consequence of interference between two oligonucleotide chains growing on the same support. The well-established phosphoramidite-based chemistry is successfully employed in this procedure. The iterative coupling process is illustrated in Figure 4.27.2. As a general observation, the phase homogeneity allows for easy scaling up of the process and, in principle, requires smaller amounts of reagents because of the absence of the inherent diffusion problems that occur with insoluble resin beads. It is also worth noting that the spectral transparency and high solubility of the conjugate allow for a rapid and nondestructive spectrophotometric analysis of any synthetic step. The ammonia treatment at the end of this protocol cleaves the succinyl linkage with MPEG, removes cyanoethyl protecting groups from the phosphorothioate backbone, and removes any standard base-protecting groups, yielding a free, crude oligonucleotide. Should an additional conjugation reaction be performed on the support-bound oligonucleotide (see Basic Protocol 2 and 3), the cleavage process will be performed at the end of that reaction.
Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
Purification of the conjugated oligonucleotide is achieved by ion-exchange chromatography because the separation of the final conjugated oligonucleotide from the shorter failure sequences cannot be accomplished be reversed-phase chromatography. A broad, single peak is commonly observed due to the presence of the large PEG chain, which dominates the chromatographic behavior of the supported products.
4.27.2 Supplement 22
Current Protocols in Nucleic Acid Chemistry
Figure 4.27.2 HELP synthesis cycle for phosphorothioated oligonucleotides. Abbreviations: B, base (thymin-1-yl, N 4 benzoylcytosin-1-yl, N 6 -benzoyladenin-9-yl, N 2 -isobutyrylguanin-9-yl); DDD, diethoxydithiocarbonate disulfide; DMTr, 4,4 dimethoxytrityl; DNA, synthetic oligonucleoside phosphorothioate triester; MPEG, polyethylene glycol monomethyl ether; NMI, N-methylimidazole; TCA, trichloroacetic acid; DCE, 1,2-dichloroethane.
Materials 5 -O-(4,4 -Dimethoxytrityl)-protected nucleoside (for attachment to support; Fig. 4.27.1; Glen Research) ◦ Pyridine, dried using 4-A molecular sieves 4-Dimethylaminopyridine (DMAP) Succinic anhydride, recrystallized from chloroform Argon source Chloroform Ethanol (EtOH) 60% perchloric acid Toluene, anhydrous Dichloromethane, anhydrous 10% (w/v) citric acid, ice cold Na2 SO4 , anhydrous n-Hexane Diethyl ether, anhydrous KOH pellets Kieselgel 60, 70-230 mesh (Merck) Methanol (MeOH) ◦ 1,2-Dichloroethane (DCE), dried using 4-A molecular sieves
Synthesis of Modified Oligonucleotides and Conjugates
4.27.3 Current Protocols in Nucleic Acid Chemistry
Supplement 22
N,N -Dicyclohexylcarbodiimide (DCC) Polyethylene glycol monomethyl ether 10,000 (MPEG10000 ; Nektar Therapeutics) N-Methylimidazole (NMI) Acetone Ethyl acetate Iodine (I2 ), crystalline Methyl tert-butyl ether (MTBE) ◦ Acetonitrile (MeCN), dried using 4-A molecular sieves 2,6-Lutidine Acetic anhydride, distilled over anhydrous sodium acetate 6% (w/v) trichloroacetic acid (TCA) in dry DCE (store at 4◦ C in a dark bottle) 0.2 M base-protected 5 -O-(4,4 -dimethoxytrityl)-3 -O-(2-cyanoethyl-N,Ndiisopropyl) nucleoside phosphoramidites (dABz -CE, dCBz -CE, dGiBu -CE and dT-CE; Glen Research) in MeCN (see recipe for phosphoramidites) 0.5 M 1H-tetrazole in MeCN (see recipe) 0.5 M DDD in MeCN (see recipe) Concentrated (∼30%) ammonium hydroxide 80% (v/v) acetic acid 250-mL three-neck round-bottom flasks Rubber septa Calcium chloride drying tubes Precoated silica gel 60 TLC sheets (5 × 10 cm) with fluorescent indicator (F254 ; Merck) UV lamp (UVP Mineralight lamp UVG-11, 254 nm) 25- and 250-mL separatory funnels Filter paper Rotary evaporator with water aspirator as vacuum source Sintered glass filters (Gooch G-3 and G-4) Vacuum desiccator 100 × 35–mm column for flash chromatography 100-mL and 250-mL round-bottom flasks Spectrophotometer Three-way stopcock High-vacuum oil pump Syringes and needles Glass container with tight seal 60◦ C water bath Lyophilizer Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare 5 -DMTr-nucleoside-3 -hemisuccinate 1. Coevaporate 5 mmol of the appropriate 5 -DMTr-protected nucleoside twice with 10 mL dry pyridine in a 250-mL three-neck round-bottom flask sealed with rubber septa. Attach a calcium chloride drying tube and dissolve the final residue in 20 mL dry pyridine. 2. Add 0.5 eq DMAP and 1 eq succinic anhydride slowly over a 30-min period, with stirring. Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
3. Protect the solution against light and stir under argon atmosphere for 24 hr at room temperature.
4.27.4 Supplement 22
Current Protocols in Nucleic Acid Chemistry
4. Monitor the reaction by TLC (APPENDIX 3D) on precoated silica gel 60 F254 sheets using 90:10:0.05 (v/v/v) chloroform/ethanol/pyridine as eluent. Visualize spots using a 254-nm UV lamp and also by spraying plates with 3:2 (v/v) 60% perchloric acid/ethanol. Pyridine is included in the eluent to avoid detritylation. After spraying with acid solution, DMTr-bearing compounds appear as orange-colored spots, with the product running more slowly than the starting material. An additional orange spot running with the solvent front is due to some DMTr-OH byproduct originating from the hydrolysis of the starting DMTr-Cl.
5. Using a rotary evaporator and a water aspirator, evaporate the solution to dryness and then coevaporate twice with 50 mL toluene to remove traces of pyridine. Dissolve the thick oil in 20 mL dichloromethane and wash it in a 250-mL separatory funnel with 40 mL ice-cold 10% (w/v) citric acid. 6. Extract the aqueous solution twice with 50 mL dichloromethane, pool the organic layers, and wash twice with 50 mL water. Dry the organic layer over 5 to 10 g anhydrous Na2 SO4 , filter off the drying agent under gravity using filter paper, and evaporate to dryness using a rotary evaporator. 7. Dissolve the residue in 20 mL of 0.5% (v/v) pyridine/dichloromethane and add it slowly, with stirring, to 300 mL of a 1:1 (v/v) mixture of n-hexane and anhydrous diethyl ether cooled in an ice bath. Filter the white powder through a Gooch G-4 sintered glass filter and dry under vacuum in a vacuum desiccator over KOH pellets. 8. Purify the crude product by flash chromatography (APPENDIX 3E) using a 100 × 35– mm silica gel (Kieselgel 60, 70-230 mesh) column and a stepwise gradient of 0% to 10% methanol in chloroform containing 0.5% pyridine. Check each fraction by TLC (see step 4). Store the purified product (5 -DMTr-nucleoside-3 -hemisuccinate) at 4◦ C.
Functionalize MPEG with 5 -DMTr-nucleoside-3 -hemisuccinate 9. Coevaporate the 5 -DMTr-nucleoside-3 -hemisuccinate (0.3 mmol) twice with 10 mL dry pyridine, and dissolve the residue in 5 mL dry 0.5% (v/v) pyridine/DCE in a 100-mL round-bottom flask equipped with a calcium chloride drying tube. Always coevaporate the starting materials completely when reactions are performed with MPEG or MPEG-supported derivatives. MPEG is very hygroscopic!
10. Cool the solution in an ice bath, then add 0.15 mmol DCC with stirring. Continue stirring for 15 min. 11. While stirring, prepare a 100-mL round-bottom flask containing 1.0 g (0.1 mmol) MPEG10000 , previously coevaporated twice with 10 mL dry pyridine and dissolved in 5 mL dry 0.5% (v/v) pyridine/DCE. After stirring, filter the solution from step 10 through a G-3 sintered glass filter into this MPEG10000 solution. 12. Add 0.15 mmol NMI with stirring, protect the solution against light, and stir under an argon atmosphere overnight at room temperature. Monitor the reaction by TLC on precoated silica gel 60 F254 sheets using 10:5:1 (v/v/v) acetone/ethyl acetate/water as eluent. Visualize spots using a 254-nm UV lamp and by exposure to iodine, introduced as solid crystals at the bottom of the developing chamber, to detect MPEG-bearing compounds as a brown spot. Alternatively, visualize the DMTrbearing compounds with perchloric acid solution (see step 4). MPEG-bound derivatives always show an Rf = 0.
Synthesis of Modified Oligonucleotides and Conjugates
4.27.5 Current Protocols in Nucleic Acid Chemistry
Supplement 22
13. Filter the reaction mixture through a G-3 sintered glass filter into a 250-mL roundbottom flask and wash the solid with 5 mL of dry 0.5% (v/v) pyridine/DCE. Cool the solution in an ice bath and add 70 mL MTBE dropwise over a period of 30 min with vigorous stirring. 14. Filter the white powder through a G-3 glass filter. Wash the solid extensively with anhydrous diethyl ether (usually three times using 10 mL each time). Dry under vacuum in a vacuum desiccator over KOH pellets. 15. Suspend the crude product in 10 mL dry MeCN, filter through a G-4 glass filter, then wash the solid residue with 5 mL dry MeCN. Reduce the volume of the clear solution to 5 mL under vacuum, then cool the concentrate in an ice bath. Add 70 mL MTBE dropwise over 30 min with vigorous stirring. 16. Filter the white powder through a G-3 glass filter, wash the solid extensively with anhydrous diethyl ether, and dry it under vacuum in a vacuum desiccator over KOH pellets. Store the product (5 -DMTr-nucleoside-3 -succ-MPEG) at 4◦ C. The precipitation and filtration of all MPEG derivatives must be executed slowly and accurately to avoid any loss of material.
17. To measure the degree of functionalization, dissolve a 5-mg aliquot of product in 10 mL of 3:2 (v/v) 60% perchloric acid/ethanol, dilute the resulting solution 10fold with this same acid/ethanol solution, and read the absorbance at 498 nm in a spectrophotometer. Calculate the loading of MPEG from the equation: loading (µmol/g) = [A498 × 10 × 14.3]/mg weighed support where 10 is the cell path length (in mm) and 14.3 is the extinction coefficient at 498 nm (on a mg scale).
Acetylate functionalized MPEG (capping step) 18. Dissolve the 5 -DMTr-nucleoside-3 -succ-MPEG in 5 mL dry MeCN in a 100-mL round-bottom flask equipped with a calcium chloride drying tube. All volumes in this and subsequent steps are based on the starting amount of MPEG (1.0 g) in step 11. To proceed with different amounts of MPEG, all volumes should be scaled appropriately.
19. Cool the solution in an ice bath and add, with stirring, 0.5 mL 2,6-lutidine, 0.5 mL NMI, and 0.5 mL acetic anhydride. Let stand 3 min at 0◦ C. 20. Add 70 mL MTBE dropwise over a period of 10 to 15 min. Filter the reaction mixture through a G-3 glass filter and wash the precipitate extensively with anhydrous diethyl ether. Dry the solid under vacuum in a vacuum desiccator over KOH pellets. Store the product at 4◦ C. Capping is required to irreversibly block any unreacted MPEG or MPEG-nucleoside conjugates.
Detritylate 5 -DMTr-nucleoside-3 -succ-MPEG 21. Dissolve the 5 -DMTr-nucleoside-3 -succ-MPEG in 10 mL dry DCE in a 250-mL round-bottom flask equipped with a calcium chloride drying tube. Add 10 mL of 6% (w/v) TCA in DCE with vigorous stirring. Continuing stirring 15 min. Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
If the 5 -terminal residue is a purine (dG or dA), cool the solution on ice before adding the acidic solution, to avoid any depurination.
22. Precipitate the deprotected nucleoside-3 -succ-MPEG by dropwise addition of 70 mL MTBE at 0◦ C. Filter the solid product through a G-3 glass filter and wash it extensively with anhydrous diethyl ether.
4.27.6 Supplement 22
Current Protocols in Nucleic Acid Chemistry
23. To ensure complete detritylation, repeat TCA treatment (steps 21 to 22). Since incomplete (97% to 98%) detritylation sometimes occurs, the TCA treatment is always repeated.
24. Dry the solid under vacuum in a vacuum desiccator over KOH pellets. Store the product at 4◦ C.
Couple with 5 -DMTr-nucleoside-3 -phosphoramidite 25. Place the nucleoside-3 -succ-MPEG in a 250-mL three-neck round-bottom flask and seal the flask with rubber septa and a three-way stopcock. Coevaporate three times with 10 mL anhydrous MeCN and dry the material under vacuum using a highvacuum oil pump. Flush with argon for 4 to 5 min, then dissolve the dried residue in the minimum amount of MeCN required (usually <2 to 3 mL). 26. While stirring, add 3 eq (0.3 mmol) of the 5 -DMTr-protected nucleoside phosphoramidite to be coupled (from a 0.2 M solution in MeCN) and 10 eq (1.0 mmol) 1H-tetrazole (from a 0.5 M solution in MeCN) simultaneously via syringes through the septum. Stir the solution under an argon atmosphere for 5 min at room temperature. 27. Cool the reaction mixture in an ice bath and add 70 mL MTBE dropwise over a period of 10 to 15 min with vigorous stirring. Filter the white powder through a G-3 glass filter, rapidly wash it with ether, and dry it under vacuum in a vacuum desiccator over KOH pellets. Store the product at 4◦ C. The use of freshly prepared amidite solution (maximum 1 to 2 weeks old and stored in a freezer over molecular sieves) is a critical step for a good yield of the condensation reaction.
Sulfurize the phosphate triester group 28. Dissolve the 5 -DMTr-oligonucleotide-3 -succ-MPEG in 5 mL dry MeCN in a 100-mL round-bottom flask equipped with a calcium chloride drying tube. 29. While stirring, add 10 eq (1 mmol) DDD from a 0.5 M solution in MeCN. Continue stirring for 15 min at room temperature. 30. Add 70 mL ice-cold MTBE dropwise over a period of 10 to 15 min with vigorous stirring. Filter the white precipitate through a G-3 glass filter, wash it with anhydrous diethyl ether, and redissolve it in 5 mL dry MeCN. 31. Repeat precipitation by adding 70 mL ice-cold MTBE. Filter the precipitate through a G-3 glass filter, rapidly wash with anhydrous diethyl ether, and dry under vacuum in a vacuum desiccator over KOH pellets. 32. Dissolve the crude product in 100 mL ethanol, warming the solution up to a maximum of 38◦ C until the solid is completely dissolved. Recrystallize by letting the solution cool down in a 4◦ C refrigerator for 1 hr. 33. Filter the resulting white powder through a G-3 glass filter under vacuum and repeat crystallization until TLC analysis using 90:10:0.05 (v/v/v) chloroform/ethanol/pyridine does not reveal any orange spot at Rf > 0, indicating that all excess reagents have been removed. 34. Filter again, dry under vacuum in a vacuum desiccator over KOH pellets, and store the product at 4◦ C. Synthesis of Modified Oligonucleotides and Conjugates
4.27.7 Current Protocols in Nucleic Acid Chemistry
Supplement 22
Acetylate 5 -DMTr-oligonucleotide-3 -succ-MPEG (capping) 35. Dissolve the sulfurized 5 -DMTr-oligonucleotide-3 -succ-MPEG in 5 mL dry MeCN in a 100-mL round-bottom flask and cool it in an ice bath. Add, with stirring, 0.5 mL 2,6-lutidine, 0.5 mL NMI, and 0.5 mL acetic anhydride. Leave the solution at 0◦ C for 3 min. 36. Precipitate the capped product from its ice-cold solution by dropwise addition of 70 mL MTBE. 37. Filter the mixture through a G-3 glass filter and wash the precipitate extensively with anhydrous diethyl ether. 38. Dry the product under vacuum in a vacuum desiccator over KOH pellets. Store at 4◦ C. 39. Repeat steps 21 to 38 for each additional nucleotide residue until the desired sequence is completed.
Cleave succinyl linkage and remove all protecting groups 40. Dissolve the completed 5 -DMTr-oligonucleotide-3 -succ-MPEG in 5 mL of 30% ammonium hydroxide for each 20 mg product in a tightly closed glass container and leave the solution without stirring for 10 hr at 60◦ C. The reaction time in the ammonia solution is reduced from the usual 24 hr to only 10 hr, as a better-quality product is thus obtained.
41. Evaporate the solution to dryness, rinse with water, and evaporate again. Repeat the procedure until the material is free of any ammonia odor. 42. Dissolve the residue in 5 mL water and extract four times, each time with 5 mL anhydrous diethyl ether in a 25-mL separatory funnel. 43. Lyophilize the aqueous layer and dissolve the residue in 5 mL of 80% acetic acid for each 20 mg product in a 100-mL round-bottom flask. Stir for 30 min at room temperature. 44. Extract the resulting yellow solution five times with 5 mL anhydrous diethyl ether in a 25-mL separatory funnel, and evaporate the aqueous layer to dryness using a high-vacuum oil pump. 45. Rinse the residue with water, evaporate, and repeat the rinsing and evaporation until the material is free of acetic acid odor. 46. Dissolve the residue in water and lyophilize. Store at −15◦ C. 47. To utilize the crude oligonucleotide, separate it from the MPEG by suspending 1 g of the lyophilized residue in 10 mL acetone or MeOH and filtering the oligonucleotide on a G-4 glass filter under vacuum. MPEG is highly soluble in acetone and methanol. If further purification is desired, see Support Protocol. ALTERNATE PROTOCOL 1
Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
PREPARATION OF PHOSPHOROTHIOATED OLIGONUCLEOTIDES VIA HELP USING DIMER BLOCKS One of the main features of this protocol is the use of a “blockmer” strategy. The use of dimers may reduce the levels of shorter deletion sequences (failures) that are produced during synthesis. The (n–1)mer is especially difficult to purify using standard reversed-phase HPLC. Since incomplete coupling and sulfurization may be the reasons for its formation, one way to reduce this and similar byproducts is to use preformed dimeric units in the stepwise synthesis of the oligomer. An important advantage in the
4.27.8 Supplement 22
Current Protocols in Nucleic Acid Chemistry
use of dimeric units is the reduction of the number of steps required for oligonucleotide synthesis. When performing the liquid-phase procedure, all the intermediate purifications are achieved through a precipitation and filtration procedure that leads to a small but unavoidable loss of product. This loss becomes quite important when several operations are repeated, as in the synthesis of longer sequences. The synthesis of protected dimers is performed in a classical solution procedure using the standard phosphoramidite method (Beaucage and Caruthers, 1981). Dimer phosphoramidites used by the author were prepared by Isis Pharmaceuticals as part of a collaborative project and are not, to the author’s knowledge, commercially available. This protocol describes the detailed procedure for the synthesis of d(GPS GPS TPS T) starting from a cyanoethyl-protected dimer. Continued elongation of the chain follows the same sequence of reactions up to the desired sequence length.
Additional Materials (also see Basic Protocol 1) 5 -DMTr-thymidylyl-(3 →5 )-thymidine (2-cyanoethyl)thiophosphate (5 -DMTr-d(TPS(CE) T) dimer) 0.2 M 5 -DMTr-d(GiBu PS(CE) GiBu )-3 -phosphoramidite in MeCN Polyethylene glycol monomethyl ether 5000 (MPEG5000 ; Nektar Therapeutics) 250-mL and 1-L round-bottom flasks 1-L three-neck round-bottom flasks Synthesize 5 -DMTr-d(TPS(CE) T)-3 -succ 1. Coevaporate 3 g (3.3 mmol) 5 -DMTr-d(TPS(CE) T) dimer twice with 20 mL dry pyridine in a 250-mL three-neck round-bottom flask sealed with rubber septa. Attach a calcium chloride drying tube and dissolve the residue in 14 mL dry pyridine. 2. Add 0.202 g (1.65 mmol) DMAP and 0.33 g (3.3 mmol) succinic anhydride slowly over a 30-min period, with stirring. 3. Protect the solution against light and stir under argon atmosphere for 24 hr at room temperature. 4. Monitor the reaction by TLC (APPENDIX 3D) on precoated silica gel 60 F254 sheets using 90:10:0.05 (v/v/v) chloroform/ethanol/pyridine as eluent. Visualize spots using a 254-nm UV lamp and also by spraying plates with 3:2 (v/v) 60% perchloric acid/ethanol. Pyridine is included in the eluent to avoid detritylation. After spraying with acid solution, DMTr-bearing compounds appear as orange-colored spots, with the product running more slowly than the starting material. An additional orange spot running with the solvent front is due to some DMTr-OH byproduct originating from the hydrolyisis of the starting DMTr-Cl.
5. Using a rotary evaporator and a water aspirator, evaporate the solution to dryness and then coevaporate three times with 20 mL toluene to remove traces of pyridine. Dissolve the thick oil in 30 mL dichloromethane and wash it in a 250-mL separatory funnel with 60 mL ice-cold 10% (w/v) citric acid. 6. Extract the aqueous solution twice with 20 mL dichloromethane, pool the organic layers, and wash twice with 50 mL water. Dry the organic layer over 5 to 10 g anhydrous Na2 SO4 , filter off the drying agent under gravity using filter paper, and evaporate the filtrate to dryness using a rotary evaporator. 7. Dissolve the thick oil in 14 mL of 0.5% (v/v) pyridine/dichloromethane and add it slowly, with stirring, to 140 mL of a 1:1 (v/v) mixture of n-hexane and anhydrous diethyl ether cooled in an ice bath. Filter the white powder through a Gooch G-3 glass sintered funnel and dry under vacuum in a vacuum desiccator over KOH pellets. Store the product at 4◦ C. Current Protocols in Nucleic Acid Chemistry
Synthesis of Modified Oligonucleotides and Conjugates
4.27.9 Supplement 22
8. Purify the crude product by flash chromatography (APPENDIX 3E) using a 100 × 35– mm silica gel (Kieselgel 60, 70-230 mesh) column and a stepwise gradient of 0% to 10% methanol in chloroform containing 0.5% pyridine. Check each fraction by TLC (see step 4). 9. Pool product-containing fractions, evaporate to dryness using a high-vacuum oil pump, and dissolve in 10 mL dichloromethane. 10. Add dropwise, with stirring, to 100 mL cold (5◦ C) 1:1 n-hexane/anhydrous diethyl ether over a period of 5 to 10 min. 11. Filter the white powder through a G-4 sintered glass funnel and dry under vacuum in a vacuum desiccator over KOH pellets. Store the product at 4◦ C. From 3.0 g of starting dimer, 1.2 g of purified 5 -DMTr-d(TPS(CE) T)-3 -succ is obtained.
Functionalize MPEG with 5 -DMTr-d(TPS(CE) T)-3 -succ 12. Coevaporate the 5 -DMTr-d(TPS(CE) T)-3 -succ (0.9 mmol) twice with 10 mL dry MeCN, and dissolve the residue in 3 mL dry 0.5% (v/v) pyridine/DCE in a 100-mL round-bottom flask equipped with a calcium chloride drying tube. Always coevaporate the starting materials completely when reactions are performed with MPEG or MPEG-supported derivatives. MPEG is very hygroscopic!
13. Cool the solution in an ice bath, then add 0.5 mmol DCC with stirring. Continue stirring for 15 min. 14. While stirring, prepare a 250-mL round-bottom flask containing 1.5 g (0.3 mmol) MPEG5000 previously coevaporated twice with 10 mL dry MeCN and dissolved in 7.5 mL dry 0.5% (v/v) pyridine/DCE. After stirring, filter the solution from step 13 through a G-3 sintered glass filter into this MPEG5000 . 15. Add 0.6 mmol NMI with stirring, protect the solution against light, and stir overnight under argon atmosphere at room temperature. Monitor the reaction by TLC on precoated silica gel 60 F254 sheets using 10:5:1 (v/v/v) acetone/ethyl acetate/water as eluent. Visualize spots using a 254-nm UV lamp and by exposure to iodine, introduced as solid crystals at the bottom of the developing chamber, to detect MPEG-bearing compounds as a brown spot. Alternatively, visualize the DMTrbearing compounds with perchloric acid solution (see step 4). MPEG-bound derivatives always show an Rf = 0.
16. Filter the solution through a G-4 sintered glass funnel into a 250-mL round-bottom flask, and reduce the reaction volume to 1/3 of its original volume using a rotary evaporator and a water aspirator. 17. Cool the solution in an ice bath and add 70 mL MTBE dropwise with vigorous stirring to the cold solution over a period of 20 min. Filter the white powder through a G-4 sintered glass funnel and wash the solid extensively with anhydrous diethyl ether (usually three times with 10 mL each time). Dry under vacuum in a vacuum desiccator over KOH pellets. 18. Evaluate the complete removal of unreacted excess reagents by TLC as described in step 15. Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
5 -DMTr-d(TPS(CE) T)-3 -succ-MPEG has an Rf = 0.
19. Suspend the crude product in 100 mL EtOH at 38◦ C. Remove any undissolved white residue (unreacted dinucleotide succinate) by filtration through a G-3 sintered glass filter under vacuum, and place the filtrate in a refrigerator at 4◦ C for 2 hr.
4.27.10 Supplement 22
Current Protocols in Nucleic Acid Chemistry
20. Filter the white powder through a G-4 sintered glass funnel. Store the product at 4◦ C. From 1.5 g of starting MPEG, 1.6 g of functionalized polymer is collected.
Acetylate 5 -DMTr-d(TPS(CE) T)-3 -succ-MPEG (capping) 21. Dissolve the 5 -DMTr-d(TPS(CE) T)-3 -succ-MPEG in 8 mL dry MeCN in a 250-mL round-bottom flask and cool in an ice bath. 22. Add 0.8 mL 2,6-lutidine, 0.8 mL NMI, and 0.8 mL acetic anhydride with stirring. Leave the solution for 3 min at 0◦ C. 23. Add 70 mL MTBE dropwise to the cold and vigorously stirred solution. 24. Filter the white powder through a G-4 sintered glass funnel, wash the product extensively with anhydrous diethyl ether, and dry under vacuum in a vacuum desiccator over KOH pellets.
Detritylate 5 -DMTr-d(TPS(CE) T)-3 -succ-MPEG 25. Dissolve 5 -DMTr-d(TPS(CE) T)-3 -succ-MPEG (0.3 mmol) in 50 mL dry DCE in a 1-L round-bottom flask equipped with a calcium chloride drying tube. 26. Add 50 mL of 6% TCA solution in DCE dropwise with vigorous stirring over a period of 15 min. 27. Cool the solution in an ice bath, and precipitate the d(TPS(CE) T)-3 -succ-MPEG by dropwise addition of 350 mL MTBE over 10 to 15 min. Filter the mixture through a G-4 sintered glass funnel and wash the precipitate extensively with anhydrous diethyl ether. 28. Assess completion of detritylation by following the absorbance at 498 nm of the DMTr group (see Basic Protocol 1, step 17) and by observing any orange color after spraying a spot on a TLC sheet with acid/ethanol solution (step 4). If detritylation is incomplete, repeat the TCA treatment (steps 26 to 27). 29. Dry the white powder in a vacuum desiccator over KOH pellets. Eliminate any TCA residue in the fully detritylated product by recrystallization from DCE solution (50 mL) using MBTE (350 mL) as precipitating solvent. Filter product and dry in a vacuum desiccator over KOH pellets. Store product at 4◦ C.
Couple d(TPS(CE) T)-3 -succ-MPEG with dinucleotide phosphoramidite derivative 30. Place d(TPS(CE) T)-3 -succ-MPEG) (0.3 mmol) in a 1-L three-neck round-bottom flask sealed with rubber septa and equipped with a three-way stopcock. Coevaporate three times with 20 mL dry MeCN and dry under vacuum using a high-vacuum oil pump. Flush with argon for 4 to 5 min. 31. Dissolve the dried residue in 13.5 mL MeCN injected with a syringe through the septum. 32. While stirring, add 3 eq (0.9 mmol) 5 -DMTr-d(GiBu PS(CE) GiBu )-3 -phosphoramidite (from a 0.2 M solution in MeCN) and 10 eq (3 mmol) 1H-tetrazole (from a 0.5 M solution in MeCN) simultaneously via syringes through the septum. Stir the solution under argon atmosphere for 5 min at room temperature. 33. Cool the solution in an ice bath and add 350 mL MTBE dropwise with vigorous stirring over 10 to 15 min. Filter the white powder through a G-4 sintered glass funnel, rapidly wash with anhydrous diethyl ether, and dry under vacuum in a vacuum desiccator over KOH pellets. 34. Dissolve in 300 mL of warm (40◦ C) EtOH and leave in a refrigerator for 2 hr. Filter the crystals. Repeat this recrystallization process until TLC with 90:10:0.05 (v/v/v)
Synthesis of Modified Oligonucleotides and Conjugates
4.27.11 Current Protocols in Nucleic Acid Chemistry
Supplement 22
chloroform/ethanol/pyridine does not reveal any orange spot at Rf > 0, indicating that all excess reagent has been removed. 35. Filter and dry the resulting white powder under vacuum in a vacuum desiccator over KOH pellets. Store the product at 4◦ C.
Sulfurize the condensation product 36. Place the condensation product (0.3 mmol) in a 1-L round-bottom flask and dissolve it in 31 mL dry MeCN. While stirring, add 10 eq (3 mmol) DDD from a 0.5 M solution in MeCN. Stir the solution at room temperature for 15 min. 37. Add 400 mL ice-cold MTBE dropwise, with vigorous stirring. 38. Filter the white precipitate through a G-4 sintered glass funnel, wash with anhydrous diethyl ether, and dry under vacuum in a vacuum desiccator over KOH pellets. Store the product (5 -DMTr-d(GPS(CE) GPS(CE) TPS(CE) T)-3 -succ-MPEG) at 4◦ C. Starting from 5.0 g of fully protected MPEG-dimer, 5.6 g of fully protected MPEG-tetramer is obtained. To perform additional couplings, acetylate the MPEG-bound tetramer as in steps 39 to 42, then repeat steps 25 to 38 until the final sequence is obtained.
Acetylate 5 -DMTr-d(GPS GPS TPS T)-3 -succ-MPEG (capping) 39. Dissolve 5 -DMTr-d(GPS(CE) GPS(CE) TPS(CE) T)-3 -succ-MPEG in 30 mL dry MeCN in a 1-L round-bottom flask and cool in an ice bath. 40. Add 3 mL 2,6-lutidine, 3 mL NMI, and 3 mL acetic anhydride with stirring. Leave the solution for 3 min at 0◦ C. 41. Precipitate the product from its ice-cold solution by adding 400 mL MTBE dropwise over 10 to 15 min. 42. Filter the mixture through a G-4 sintered glass funnel, wash the precipitate extensively with anhydrous diethyl ether, and dry under vacuum in a vacuum desiccator over KOH pellets. Store the product at 4◦ C. A chromatogram of an octomer synthesized using this approach is shown in Figure 4.27.3. If further purification is desired, see Support Protocol.
Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
Figure 4.27.3 Analytical IE-FPLC of a fully deprotected octamer synthesized by the dimer blocks procedure (Alternate Protocol 1). (A) crude, (B) FPLC purified. Reprinted from Bonora et al. (2000) with permission from the American Chemical Society.
4.27.12 Supplement 22
Current Protocols in Nucleic Acid Chemistry
PREPARATION OF 5 -AMINOALKYLATED PHOSPHOROTHIOATE OLIGONUCLEOTIDES
BASIC PROTOCOL 2
To overcome the low nucleophilicity of the terminal 5 -OH group of oligonucleotides, and to increase the efficiency of a postsynthetic conjugation with these molecules, a linker carrying a primary amino group is required. This functional group is added to the HELP-synthesized oligonucleotide using a reagent that allows a standard amidite-based procedure and ensures high condensation yields and fast reaction times. It is important to underline that the same conjugation reaction between a high-molecular-weight polymer such as PEG and a biomolecule can, in principle, be extended to peptides or other biologically active molecules with a proper amino function. As described below and illustrated in Figure 4.27.4, a primary amino group is added to the 5 terminus of a fully thioated 15-mer obtained by liquid-phase synthesis on MPEG (HELP technique) following standard detritylation of the crude product. This reaction benefits from the advantages given by the soluble support polymer. As previously described, it is possible to drive the reaction to high yields using an excess of reagents; any unreacted material is easily removed by the usual precipitation and filtration procedures at the end of the reaction. Subsequently, the hydrolysis of the MPEG-oligonucleotide linker will permit the recovery of free aminoalkylated oligonucleotide.
Materials 5 -DMTr-oligonucleotide-3 -succ-MPEG (see Basic Protocol 1) 80% (v/v) acetic acid Diethyl ether, anhydrous ◦ Acetonitrile (MeCN), dried using 4-A molecular sieves 0.5 M 2-[2-(4-monomethoxytrityl)aminoethoxy]ethyl-(2-cyanoethyl)-N,Ndiisopropylphosphoramidite (Glen Research in MeCN) 0.5 M 1H-tetrazole in MeCN (see recipe) Argon source Methyl tert-butyl ether (MTBE) Ethanol (EtOH) KOH pellets TBHP solution: 80% tert-butyl hydroperoxide in 3:2 (v/v) di-tert-butylperoxide/water (Fluka Sigma-Aldrich) Concentrated NH4 OH Acetone 0.03 M 2,4,6-trinitrobenzenesulfonic acid (TNBS) in borate buffer, pH 9.3 Borate buffer, pH 9.3 100-mL round-bottom flask High-vacuum oil pump Lyophilizer 100-ml three-neck round-bottom flask and rubber septa Syringes and needles Sintered glass filters (Gooch G-3 and G-4) Vacuum desiccator Vessel with tight seal 50◦ C oven Refrigerated centrifuge Spectrophotometer Deprotect terminal 5 -hydroxyl group 1. Dissolve the 5 -DMTr-oligonucleotide-3 -succ-MPEG in 80% acetic acid at 5 mL/ 20 mg in a 100-mL round-bottom flask and stir 30 min at room temperature.
Synthesis of Modified Oligonucleotides and Conjugates
4.27.13 Current Protocols in Nucleic Acid Chemistry
Supplement 22
Figure 4.27.4 Functionalization of a thioated 15-mer DNA oligonucleotide with an aminoalkylated linker at the 5 terminus. Abbreviations: MMTr, 4-monomethoxytrityl; MPEG, polyethylene glycol monomethyl ether; MTBE, methyl tert-butyl ether.
2. Extract the resulting yellow mixture five times with 40 mL anhydrous diethyl ether, and evaporate the aqueous layer to dryness using a high-vacuum oil pump. 3. Dissolve the residue in 25 mL water and evaporate under vacuum using a rotary evaporator and water aspirator. 4. Repeat step 3 until the material is free of acetic acid odor. 5. Dissolve the residue in water and lyophilize.
Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
Conjugate with 5 -amino-modifier phosphoroamidite reagent 6. Coevaporate 1 g oligonucleotide-3 -MPEG (15.6 µmol of 5 -OH groups) three times with 5 mL anhydrous MeCN in a 100-mL three-neck round-bottom flask. 7. Dissolve the residue in 5.0 mL anhydrous MeCN by injecting with a syringe through a rubber septum.
4.27.14 Supplement 22
Current Protocols in Nucleic Acid Chemistry
8. Inject, simultaneously through the septa, 100 µmol of 2-[2-(4-monomethoxytrityl)aminoethoxy]ethyl-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (as a 5 -amino-modifier phosphoramidite) and 400 µmol of 1H-tetrazole (from a 0.5 M solution in MeCN). 9. Stir the mixture under an argon atmosphere 5 min at room temperature. 10. Precipitate the MPEG-bound product from its cold solution by adding 70 mL MTBE with vigorous stirring. Filter the white solid through a G-4 sintered glass filter and wash it with 100 mL anhydrous diethyl ether. 11. Recrystallize the solid from EtOH to remove any excess reagents from the product (see Alternate Protocol 1, step 34). 12. Collect the final product and dry it under vacuum in a vacuum desiccator over KOH pellets. Based on monomethoxytrityl (MMTr) absorbance at 472 nm [ε = 51900 in 70% HClO4 /EtOH 3/2 (v/v)], a functionalization degree of 67% is measured. The product can be reacted again with the 5 -amino-modifier phosphoramidite as described above, with the exception of a prolonged reaction time (15 min). A final 86.5% degree of functionalization is achieved and the product is recovered quantitatively. This procedure is recommended only when a higher yield is needed.
Oxidize phosphite triester function 13. Dissolve the tritylated 5 -aminoalkylated oligonucleotide-3 -MPEG in 7 mL anhydrous MeCN in an ice bath and stir the solution. 14. Add 0.6 mL TBHP solution and stir the reaction 15 min at 0◦ C. 15. Precipitate the product by adding 70 mL MTBE. Collect the white powder, wash it with anhydrous diethyl ether, and dry under vacuum over KOH pellets.
Deprotect phosphate and detach oligonucleotide from MPEG 16. Dissolve oxidized 5 -aminoalkylated oligonucleotide-3 -MPEG in 200 mL concentrated NH4 OH and place the solution in a tightly closed vessel in an oven at 50◦ C for 18 hr. 17. Coevaporate the solution repeatedly with 25 mL distilled water until the material is completely free of ammonia (approximately three times). Dissolve the residue in 100 mL distilled water and extract with four times with 100 mL anhydrous diethyl ether. 18. Lyophilize the aqueous solution and collect the white solid. 19. Remove MPEG by dissolving the solid in 10 mL of 0.5% NH4 OH and precipitating the oligonucleotide by addition of 150 mL acetone with vigorous stirring in an ice bath. 20. Centrifuge 20 min at 4000 rpm (3000 to 4000 × g should be sufficient), 0◦ C. Recover the precipitate containing the ammonium salt of the tritylated 5 -aminoalkylated oligonucleotide (15-mer), and lyophilize it. More than 70% of MPEG is recovered from the acetone solution after a single treatment. From 1.0 g of starting MPEG-oligonucleotide, 0.3 g of modified oligonucleotide can be obtained.
Deprotect terminal amino group 21. Dissolve the tritylated 5 -aminoalkyl-oligonucleotide in 80% acetic acid at 100 mL/g and stir 4 hr at room temperature. A pale yellow color should develop.
Synthesis of Modified Oligonucleotides and Conjugates
4.27.15 Current Protocols in Nucleic Acid Chemistry
Supplement 22
AU
A
26.7 min
13.3
40.0
AU
B
0
5
min
10
15
Figure 4.27.5 RP-HPLC (A) and GPC (B) of the aminoalkylated oligonucleotide. GPC was performed on a PL Aquagel-OH 30 (8 µm, 30 × 0.75–cm) eluted with Milli-Q purified water. The two peaks in panel A are due to intermolecular associations, as suggested by analyses performed under more diluted conditions. Adapted from Ballico et al. (2003) with permission from the American Chemical Society.
22. Add 10 mL distilled water and extract the solution five times with 25 mL anhydrous diethyl ether. Evaporate the aqueous phase to dryness under reduced pressure using a high-vacuum oil pump. Coevaporate with 10 mL distilled water until the material is free of acetic acid. 23. Dissolve in 10 mL distilled water per g residue and lyophilize. A white product should be quantitatively collected. Figure 4.27.5 shows chromatograms of an aminoalkylated oligonucleotide.
Quantitate free NH2 by TNBS test 24. Add 250 µL of 0.03 M TNBS in borate buffer, pH 9.3, to 1 mg of sample. Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
25. Dilute to 10 mL with borate buffer, pH 9.3, stir, and allow to stand 30 min at room temperature.
4.27.16 Supplement 22
Current Protocols in Nucleic Acid Chemistry
26. Read the absorbance at 421 nm (ε = 12860). This test reaction is very useful to determine if the starting MPEG-oligonucleotide is fully modified. The same reaction can be advantageously used to measure any further degree of modification of the starting amino groups.
5 -CONJUGATION OF PHOSPHOROTHIOATED OLIGONUCLEOTIDES WITH HIGH-MOLECULAR-WEIGHT POLYETHYLENE GLYCOLS: ACTIVATION WITH N,N -DISUCCINIMIDYL CARBONATE
BASIC PROTOCOL 3
To obtain a stable linkage between MPEG and an aminoalkylated oligonucleotide, the terminal hydroxyl of the polymer must be activated. As illustrated in Figure 4.27.6, two common procedures involve reaction of MPEG with N,N -disuccinimidyl carbonate (presented here) or with p-nitrophenyl chloroformate (see Alternate Protocol 2). Both procedures produce a reactive intermediate leading to the formation of a stable urethane linkage with the aminoalkylated biomolecule. If performed in organic solution, the conjugation is achieved under heterogeneous conditions, but solubilization of the MPEG-conjugated oligonucleotides can be expected owing to the amphiphilic nature of the polymer. On the other hand, the reaction performed in aqueous solution is characterized by a complete homogeneity, which offers better reactivity. The latter procedure is preferred. The presence of MPEG on the final product offers all the advantages given by the soluble polymer–supported procedures, in particular during the intermediate purifications, as reported in the experimental conditions.
Materials MPEG5000 (Nektar Therapeutics) Toluene, anhydrous Pyridine, anhydrous Dichloromethane (CH2 Cl2 ), anhydrous Acetonitrile (MeCN), anhydrous N,N -Disuccinimidyl carbonate Methyl tert-butyl ether (MTBE) Isopropanol, cold Diethyl ether, anhydrous, cold KOH pellets Ethanol (EtOH) Fully deprotected 5 -aminoalkylated oligonucleotide (see Basic Protocol 2) Na2 CO3 /NaHCO3 buffer, pH 9 Chloroform (CHCl3 ), anhydrous Rotary evaporator Vacuum desiccator G-3 and G-4 sintered glass filters High-vacuum oil pump Prepare MPEG-OSu carbonate 1. Coevaporate 5.0 g (1.0 mmol) of MPEG5000 twice with 15 mL anhydrous toluene per g, and leave the vessel on a rotary evaporator for 30 min to complete dehydration. 2. Add 1.0 mL anhydrous pyridine and dissolve the slurry by adding 5 mL anhydrous CH2 Cl2 and 2 mL anhydrous MeCN.
Synthesis of Modified Oligonucleotides and Conjugates
4.27.17 Current Protocols in Nucleic Acid Chemistry
Supplement 22
Figure 4.27.6 Conjugation of a 5 -aminoalkylated oligodeoxyribonucleoside phosphorothioate (15-mer) with a highmolecular-weight polyethylene glycol. Abbreviations: MPEG, polyethylene glycol monomethyl ether; MTBE, methyl tertbutyl ether.
3. While stirring at room temperature, add 0.13 g of N,N -disuccinimidyl carbonate for each gram of MPEG (2.5 molar equiv). Leave the reaction overnight. 4. Precipitate the product by adding 200 mL MTBE while stirring in an ice bath. Filter on a G-3 glass filter, wash the solid with 25 mL each of cold isopropanol and cold anhydrous diethyl ether, and dry under vacuum in a vacuum desiccator over KOH pellets. 5. Recrystallize MPEG-OSu carbonate from EtOH (see Alternate Protocol 1, step 34). Store product at 4◦ C. A quantitative recovery of MPEG-OSu carbonate is achieved.
Perform conjugation reaction 6. Dissolve 0.1 g (19 µmol) of fully deprotected 5 -aminoalkylated oligonucleotide in 1.0 mL of Na2 CO3 /NaHCO3 buffer, pH 9.0. 7. Add 0.11 g (21 µmol) MPEG-OSu carbonate and leave stirring at room temperature for 72 hr. For oligos of different lengths, the molar amount of oligo in step 6 should be held contast. A 10% molar excess of MPG over oligo should be used.
8. Evaporate the solution to dryness using a high-vacuum oil pump, and dissolve the residue in 20 mL CHCl3 .
Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
9. Filter the insoluble material through a G-4 sintered glass filter and precipitate the product from the filtrate by adding 100 mL MTBE while stirring vigorously in an ice bath. 10. Filter the white powder on a G-4 glass filter, wash it with 25 mL each of cold isopropanol and anhydrous diethyl ether, collect the powder, and dry it under vacuum in a vacuum desiccator over KOH pellets.
4.27.18 Supplement 22
Current Protocols in Nucleic Acid Chemistry
A yield of 0.12 g (0.015 mmol) crude MPEG-conjugated oligonucleotide is usually obtained. This activation gives the best condensation yields with high-molecular-weight PEGs. However, with PEGs larger than 5 kDa, the conjugation requires a large excess of activated PEG (e.g., 2- to 3-fold) to obtain a satisfactory yield.
5 -CONJUGATION OF PHOSPHOROTHIOATED OLIGONUCLEOTIDES WITH HIGH-MOLECULAR-WEIGHT POLYETHYLENE GLYCOLS: ACTIVATION WITH p-NITROPHENYL CHLOROFORMATE
ALTERNATE PROTOCOL 2
This method is an alternative to Basic Protocol 3 that uses the other common activating agent. Both procedures give a reactive intermediate that will form a stable urethane linkage with the NH2 group of the biomolecule. The activation used here appears less efficient than that in Basic Protocol 3, but can be useful as an option.
Additional Materials (also see Basic Protocol 3) p-Nitrophenyl chloroformate Triethylamine (TEA) Ethanol (EtOH) Prepare MPEG-p-nitrophenyl carbonate 1. Coevaporate 5.0 g (1.0 mmol) of MPEG5000 twice with 15 mL anhydrous toluene per g, and leave the vessel on a rotary evaporator for 30 min to complete dehydration. 2. Dissolve the solid residue in 20 mL anhydrous CH2 Cl2 . 3. While stirring, add 0.08 g p-nitrophenyl chloroformate per g MPEG (2 molar equiv) and 0.28 mL TEA per g MPEG (1 molar equiv). 4. Leave the reaction stirring for 24 hr at room temperature. Maintain the pH around 8 by adding TEA. 5. Precipitate the product by adding 200 mL MTBE while stirring in an ice-bath. Filter on a G-3 glass filter, wash the precipitate with 25 mL each of cold isopropanol and diethyl ether, and dry it under vacuum in a vacuum desiccator over KOH pellets. 6. Recrystallize the collected product from EtOH. A quantitative recovery of MPEG-p-nitrophenyl carbonate is achieved.
Perform conjugation reaction 7. Dissolve 0.1 g (19 µmol) of fully deprotected 5 -aminoalkylated oligonucleotide in 1.0 mL Na2 CO3 /NaHCO3 buffer, pH 9.0. 8. Add 0.11 g (21 µmol) of MPEG-p-nitrophenyl carbonate and leave the solution stirring at room temperature for 72 hr. 9. Evaporate the solution to dryness using a high-vacuum oil pump. Suspend the residue in 20 mL CHCl3 and stir for 10 min. 10. Filter the insoluble material through a G-4 glass filter and precipitate the product from the filtrate by additing 100 mL MTBE while stirring vigorously in an ice bath. 11. Filter the white powder on a G-4 glass filter, wash it with 25 mL each of cold isopropanol and anhydrous diethyl ether, collect the powder, and dry it under vacuum in a vacuum desiccator over KOH pellets. Synthesis of Modified Oligonucleotides and Conjugates
4.27.19 Current Protocols in Nucleic Acid Chemistry
Supplement 22
SUPPORT PROTOCOL
PURIFICATION AND ANALYSIS OF OLIGONUCLEOTIDES These methods are used to purify the final product at the end of Basic Protocol 1 and Alternate Protocol 1. NOTE: Prepare all HPLC solvents and buffers with double-distilled water filtered through a Millipore GS 0.22-µm sterile filter.
Materials 0.1 and 3.0 M NaCl, pH 11.5 (see recipe) Methanol 0.05 M triethylammonium acetate (TEAA), pH 7.0 (see recipe) 20:80 (v/v) TEAA/MeCN (see recipe) 0.22-µm sterile membrane filters Sonicator Centrifuge Chromatography system and column(s): Amersham Biosciences FPLC system with UV detector, MonoQ HR 5/5 ion-exchange column, and PepRPC HR 5/5 reversed-phase column Gilson HPLC system with UV detector and 15 × 0.46–cm Progel-TSK Oligo-DNA-RP column (Supelco) Hewlett Packard series 1100 HPLC system with Lambda-Max model 481 UV/vis detector and MEGA 2 integrator (Carlo Erba) and 15 × 0.46–cm Progel-TSK Oligo-DNA-RP column (Supelco) For preparative IE-FPLC 1a. Dissolve 2 mg of the completely deprotected 15-mer in 1.5 mL start buffer (mobile phase A; 0.1 M NaCl, pH 11.5), filter through a sterile 0.22-µm membrane filter, and degas by sonication. 2a. Perform ion-exchange purification using a MonoQ HR 5/5 column on an Amersham Biosciences FPLC system with the following conditions:
Mobile phase A: 0.1 M NaCl, pH 11.5 Mobile phase B: 3.0 M NaCl, pH 11.5 Elution gradient: 20% B for 3 min (hold) 20% to 80% B in 22 min Flow rate: 1.0 mL/min Temperature: room temperature UV detector: 260 nm. 3a. Collect the material of the peak corresponding to the 15-mer and desalt the product by reversed-phase chromatography using a PepRPC HR 5/5 column on an Amersham Biosciences FPLC system with the following conditions:
Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
Mobile phase A: water Mobile phase B: methanol Elution gradient: 100% A for 15 min (hold) 0% to 100% B in 15 min Flow rate: 0.7 mL/min UV detector: 260 nm.
4.27.20 Supplement 22
Current Protocols in Nucleic Acid Chemistry
For analytical IE-FPLC 1b. Dissolve 2 mg sample in 1.5 mL water, filter through a sterile 0.22-µm membrane filter, dilute the filtrate 10-fold with start buffer (mobile phase A; 0.1 M NaCl, pH 11.5), and degas the solution by sonication. 2b. Inject 100 µL of the degassed solution and perform analytical ion-exchange FPLC using a MonoQ HR 5/5 column on an Amersham Biosciences FPLC system using the following conditions: Mobile phase A: 0.1 M NaCl, pH 11.5 Mobile phase B: 3.0 M NaCl, pH 11.5 Elution gradient: 0% B for 5 min (hold) 0% to 100% B in 35 min Flow rate: 1.0 mL/min Temperature: room temperature UV detector: 260 nm.
For analytical RP-HPLC: Method 1 1c. Dissolve 2 mg sample in 1.5 mL water, filter through a sterile 0.22-µm membrane filter, dilute the filtrate 10-fold with start buffer (mobile phase A; 0.05 M TEAA, pH 7.0), and degas the solution by sonication. 2c. Inject 100 µL of the degassed solution and perform reversed-phase HPLC using a Progel-TSK Oligo-DNA-RP column (15 × 0.46 cm) on a Gilson HPLC system with the following conditions: Mobile phase A: 0.05 M TEAA, pH 7.0 Mobile phase B: 20:80 (v/v) TEAA/MeCN Elution gradient: 10% to 40% B in 40 min Flow rate: 1.0 mL/min Temperature: room temperature UV detector: 260 nm.
For analytical RP-HPLC: Method 2 1d. Prepare sample as in step 1c. 2d. Inject 100 µL of the degassed solution and perform reversed-phase HPLC using a Progel-TSK Oligo-DNA-RP column (15 × 0.46 cm) on a Hewlett Packard series 1100 system with the following conditions: Mobile phase A: 0.05 M TEAA, pH 7.0 Mobile phase B: 20:80 (v/v) TEAA/MeCN Elution gradient: 10% B for 2 min (hold) 10% to 40% B in 38 min Flow rate: 1.0 mL/min Temperature: room temperature UV detector: 260 nm.
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
DDD in MeCN, 0.5 M Dissolve 1.21 g diethoxydithiocarbonate disulfide (DDD; Isis Pharmaceutical; store ◦ at –20◦ C) in 10 mL MeCN (dried using 4-A molecular sieve) in a dark bottle. Store unused solution at 4◦ C.
Synthesis of Modified Oligonucleotides and Conjugates
4.27.21 Current Protocols in Nucleic Acid Chemistry
Supplement 22
NaCl, pH 11.5, 0.1 and 3.0 M 3.0 M solution: Dissolve 350.64 g (6 mol) NaCl in 2 L double-distilled water and adjust pH to 11.5 with 5 N NaOH. Filter through a Millipore GS 0.22-µm sterile filter and degas by sonication (30 min) prior to use. Store at 4◦ C. 0.1 M solution: Dilute 3 M NaCl with distilled water, readjust pH, and filter and degas as above. Store at 4◦ C.
Phosphoramidites in MeCN 0.1 M DMTr-protected nucleoside phosphoramidites: In a dark bottle sealed with◦ a rubber cap, dissolve 1 g phosphoramidite in 13.4 mL MeCN (dried using 4-A molecular sieves), injected with a syringe. Prepare immediately before use and keep under argon at –20◦ C. 0.2 M dimer-phosphoramidites: Prepare as above, but adjust volume of MeCN to give a final concentration of 0.2 M. As an example, 1.0 g of dT dimer is dissolved in 4.45 mL of dry MeCN.
TEAA, pH 7.0, 0.05 M Prepare a stock solution of 0.5 M triethylammonium acetate (TEAA) by adding 34.8 mL (0.25 mol) triethylamine (TEA) to 14.3 mL (0.25 mol) glacial acetic acid in 100 mL of double-distilled water. Dilute the mixture to 500 mL with water and adjust the pH to 7.0 using triethanolamine (TEA) or glacial acetic acid. Store at 4◦ C. Prepare 0.05 M working solution by diluting 100 mL of the 0.5 M stock solution to 1 L with double-distilled water, filtering through a Millipore GS 0.22-µm sterile membrane filter, and degassing by sonication for 30 min before use.
TEAA/MeCN, 20:80 (v/v) Mix 200 mL 0.05 M TEAA, pH 7.0 (see recipe), with 800 mL MeCN. Store at 4◦ C. Degas the solution by sonication for 30 min before use. 1H-Tetrazole in MeCN, 0.5 M In a bottle sealed with a rubber cap, dissolve 2 g of 1H-tetrazole in 57.1 mL dry MeCN (injected with a syringe). Store the solution under argon at room temperature. COMMENTARY Background Information
Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
The investigation of therapeutic properties of synthetic oligonucleotides and their chemically modified analogs has reached different stages of the clinical trial process, including the approval of the first antisense drug, Vitravene, a registered trademark of Isis Pharmaceuticals (Grillone and Lanz, 2001). The current studies, together with the prospect of successful commercialization, have triggered a demand for large-scale oligonucleotide synthesis. High coupling efficiency, low reagent consumption, and simple and cost-efficient purification are crucial factors
for successful production of oligonucleotidebased drugs (Seliger, 1993; Andrade et al., 1994). Solid-phase automated synthesis has been the method of choice due to ease of operation (Padmapriya et al., 1994; Ravikumar et al., 1995; Tsou et al., 1995). However, despite the development of new high-capacity synthesizers, the application of solid-phase automated synthesis for production of large quantities of oligonucleotides still remains problematic. The limitation is mainly due to the heterogeneity of the reaction, which leads to the use of quite a large excess of high-cost monomers in order to achieve high coupling
4.27.22 Supplement 22
Current Protocols in Nucleic Acid Chemistry
efficiencies. The liquid-phase synthesis was proposed as an answer to the abovementioned limitation (Bayer and Mutter, 1972). In this technique, sequential synthesis is performed with the growing oligonucleotide chain attached to a soluble polymer support, and chain elongation is then carried out in homogeneous medium. The polymer-bound oligomer is usually recovered from the reaction mixture by precipitation, thus allowing rapid elimination of excess reagent and soluble byproducts. In a new liquid-phase method called highefficiency liquid-phase (HELP), polyethylene glycol (PEG; mol. wt. 5 to 20 kDa) is used as a soluble support polymer for oligonucleotide synthesis (Bonora, 1995). The oligonucleotide chain is joined through a succinate linkage. Once completed, the oligonucleotide is released from the support under standard conditions and purified by chromatographic methods. Oligomers of up to 20 nucleotides in length have been synthesized by following this approach. This method has been applied for synthesis of phosphorothioate analogs (Scremin and Bonora, 1993) in which a nonbridging oxygen is formally replaced by a sulfur atom to overcome the instability of natural DNA toward degradative enzymes (Cohen, 1993). Usually, sulfurization of the phosphite backbone is carried out as a repeating step during each elongation cycle. Thus, conversion of the phosphite moiety to phosphorothioate needs to be performed at the highest efficiency in order to achieve high purity of oligonucleotide-based drugs. As a consequence, the improvement of the thiolation reaction by the use of a proper sulfurizing reagent represents one of the main aspects of research in this field. Alternatively, the introduction of fully protected phosphorothioate dimers instead of monomers during the coupling step reduces the number of coupling and thiolation steps, and consequently reduces the number of unconverted phosphite linkages. This will certainly result in higher homogeneity of the final phosphorothioate backbone, as recently demonstrated (Krotz et al., 1997). The dimeric synthons are fully protected 3 →5 phosphorothiate dinucleotides, with a phosphoroamidite group at the 3 position as a reacting moiety for coupling with the 5 -hydroxyl of the growing oligonucleotide chain. Sulfurization of the phosphite triester moiety is carried out during each synthetic cycle with the recently developed diethoxydithiocarbonate disulfide (DDD), which seems to offer advantages over traditional sulfurizing
reagents (Eleuteri et al., 1999). A higher sulfurization yield is expected. The pharmacological properties of synthetic oligonucleotides can be modulated by their conjugation with proper molecules (Manoharan, 2001). The rationale of these modifications is dictated by the necessity for better cellular uptake, biostability, and pharmacokinetic properties. Among the molecules described in the literature, it is possible to distinguish between low- and high-molecularmass units. Within the first group, lipophilic conjugates such as cholesterol and other steroids, vitamins, and folic acid have been widely employed (MacKellar et al., 1992). Oligosaccharides and peptides have been considered for their ability to deliver oligonucleotides specifically to the targeted cells (Garcia de la Torre et al., 1999). Cleaving and cross-linking agents have also been proposed to improve the overall biological performances (Magda et al., 1997). Furthermore, large conjugating molecules such as proteins and antibodies have been linked, and great attention has been turned to polyamines as polycationic carriers (Markiewicz et al., 1998). Among the different biocompatible polymers, polyethylene glycol (PEG) was extensively investigated on the basis of previous success achieved with the PEGylation of protein (Kodera et al., 1998). In fact, this procedure is well on its way to becoming a standard component of the pharmaceutical tool box, since PEG possesses a unique set of properties, including analytical methods for conjugate characterization; absence of toxicity, immunogenicity and antigenicity; low massdependent elimination via the kidney; and high solubility in water and other organic media. At the oligonucleotide level, the presence of highmolecular-weight PEGs has showed a minimal effect on hybridization behavior, while a clear enhancement of in vivo stability and cellular permeation has been observed without any adverse toxic effect (Pang, 1993). Additionally, taking advantage of the recently developed procedure for producing pure, selectively and reversibly protected, bifunctional PEGs (Drioli et al., 2001), it is easy to imagine the production of PEG conjugates carrying both an oligonucleotide and an additional molecule such as a peptide, steroid, intercalator, or whatever can be devised to further improve their pharmacological properties. The coupling of PEG to a bioactive molecule is achieved by a polymeric derivative having an activated functional group at
Synthesis of Modified Oligonucleotides and Conjugates
4.27.23 Current Protocols in Nucleic Acid Chemistry
Supplement 22
one or both termini (Zalipsky, 1995), chosen on the basis of the reactive groups of the molecule to be PEG-conjugated. In the case of oligonucleotides, which offer only low nucleophilic functionalities such as primary hydroxyl groups, it is quite difficult to attain an extensive modification through a direct reaction with PEG. Moreover, the introduction of a large PEG chain by classical solid-phase procedures, commonly used for many postsynthetic oligonucleotide modifications, suffers from the phase heterogeneicity of the process, which implies poor reactivity and unpredictable kinetic effects. An acceptable yield has been reported in the literature only for PEGs of lower molecular weight following standard phosphoramidite conditions (Tarasow et al., 1997). However, the adverse effects are enhanced with increasing mass of the conjugating polymer (J¨aschke et al., 1994), with better biological performances being observed with sizes up to 20 to 40 kDa. An oligonucleotide conjugation using a larger PEG molecule in a classical solution reaction has been reported; a very large excess of the ester-activated form of polymer was employed, but the yield of condensation was not discussed (Wlotzka et al., 2002). Very recently, a conjugation procedure similar to the one described here has been reported (Jeong et al., 2003). For all these reasons, the postsynthetic solution-phase PEG conjugation of synthetic oligonucleotides can be properly optimized to achieve an optimum level of modification. To avoid the low reactivity of the terminal hydroxyl group, and to extend this procedure, possibly, to the peptide level, a terminal amino function was introduced on the oligonucleotides.
Critical Parameters and Troubleshooting
Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
The favorable aspects of the HELP technique are: 1. The synthesis may easily be scaled at the bench over a range between 0.2 and 1.0 mmol. The upper limit for the synthesis scale may be larger than 1.0 mmol, since all steps are carried out in a classical solution approach. 2. The functionalization of the supporting polymer can be efficiently achieved both with a monomer and a protected dimeric unit. 3. The deblocking process has been efficiently completed following standard oligonucleotide deprotection conditions.
4. The fully deblocked oligomers are efficiently separated using standard ion-exchange procedures. 5. The overall and average yields, as judged from the final DMTr assay, are satisfactory and comparable regardless of the synthetic scales investigated thus far. 6. The overall recovery after all the dissolution and precipitation steps is acceptable. A higher amount of product should be expected when similar processes are carried out on a larger scale. The unfavorable aspects are: 1. The intermediate purification steps demand a relatively large volume of precipitating solvent. The solvent could, however, be fully recovered by devising a proper recycling process. 2. A reduced efficiency of the coupling reaction is commonly observed with increasing chain length. As a consequence, the repetition of a coupling step is often required in the preparation of 8-mer or longer oligonucleotides. A third coupling step has even been necessary for the final condensation leading to a 15-mer. 3. The desalting procedure demands a standard molecular sieving method. Selective precipitation does not work efficiently, likely due to the reduced length of the oligomer and hence its unfavorable solubility properties. 4. The molecular weight of the PEG used in the post-conjugation process is strictly related to the final condensation yield. A molecular weight higher than 5 kDa reduces the efficiency of this process. 5. The final postsynthetic conjugation works quite efficiently if a proper excess of activated PEG is employed. Subsequent separation of the conjugate from unreacted PEG is obviously necessary and demands a careful chromatographic process. The following precautions must be considered: 1. The size of the supporting MPEG must be commensurate with the size of the desired oligomers. An MPEG that has a molecular weight 30% higher than that of the desired oligonucleotide is acceptable (for example, a 10-kDa MPEG is recommended for the preparation of a 15-mer oligonucleotide). 2. The synthetic process works efficiently if absolute care is taken in drying all the materials employed—reagents and support—to avoid any possible water contamination. 3. The overall process is fully effective only if careful DMTr analysis of all the
4.27.24 Supplement 22
Current Protocols in Nucleic Acid Chemistry
Table 4.27.1 Expected Time for One Cycle of Thioate Oligonucleotide Synthesis via HELP Procedurea
Reaction step
Time (min)
Recovery step
Time (min)
Detritylation
15 + 15b
Precipitation
20 + 20c
Coupling
5 (15)d
Precipitation
20
Sulfurization
15
Precipitation
20 + 20c
Recrystallizatione
60
Capping
3
Precipitation
20
Total reaction time
53 (63)
Total recovery time
180
a Standard condensation cycle: detritylation-coupling-sulfurization-capping. b This process is usually repeated to ensure complete removal of the DMTr group. c Precipitations with ether are repeated to ensure complete removal of the reagents. d Because of solubility problems, coupling time can be extended up to 15 min when necessary. e Recrystallization from EtOH is suggested only for the complete removal of soluble intermediates.
intermediate coupling yields is done on strictly purified products to avoid any DMTr contribution from non-MPEG-bound contaminants that may still be present. 4. When the coupling yield is lower than near-quantitative, it is absolutely mandatory to repeat the coupling step before proceeding with the subsequent capping, oxidation/sulfurization, and detritylation steps. 5. A possible solution to the problem of low coupling yield could be the use of a higher excess of reagent. However, a more difficult intermediate purification can be expected in this case, owing to the need to remove a higher amount of non-MPEG-bound reagents. 6. A key step for a successful preparation of the desired oligonucleotide is the precipitation and filtration step; hence, great care is required for this operation. If conducted appropriately, <0.2% of product will be lost after each precipitation with ether. The recrystallization from ethanol has a higher expected loss (1% to 2%). For this reason, it must be executed only when essential for the overall purification.
Anticipated Results The efficiency of the reported HELP process is at least comparable to alternative standard procedures, if not higher. The possibility of increasing oligonucleotide synthesis to a scale that is unaffordable through solid-phase procedures can now be envisaged. A largerscale HELP-based production will be more efficiently evaluated in a pilot-scale study, since in that case, the simultaneous investigation of the recovery of support, unreacted reagents, and solvents can be better conceptualized. Future development could address the production of next-generation oligonucleotides of
different structures demanding new kinds of protected monomers. In that case, it is possible to foresee new, as yet unexpected, solubility and reactivity problems when these new reagents are applied to solid-phase procedures.
Time Considerations Preparation of the starting succinate usually takes 1 day, while the following derivatization of the supporting MPEG is achieved after an overnight reaction. The time demanded for a single cycle of the HELP synthesis of oligonucleotides is summarized in Table 4.27.1. The final conjugation procedure is quite time-consuming, since large PEG molecules are not very reactive. Consequently, to ensure the best condensation yield, a reaction time spanning a whole weekend is suggested. The deprotection and purification processes are the bottleneck of the overall procedure, since at least 1 week must be planned for the preparative purification.
Literature Cited Andrade, M., Scozzari, A.N., Cole, D.L., and Ravikumar, V.T. 1994. Efficient synthesis of antisense oligodeoxyribonucleotide phosphorothioates. Bioorg. Med. Chem. Lett. 4:2017-2022. Ballico, M., Cogoi, S., Drioli, S., and Bonora, G.M. 2003. Postsynthetic conjugation of biopolymers with high molecular mass poly(ethylene glycol): Optimization of a solution process tested on synthetic oligonucleotides. Bioconjugate Chem. 14:1038-1043. Bayer, E. and Mutter, M. 1972. Liquid-phase synthesis of peptides. Nature 237:513-514. Beaucage, S.L. and Caruthers, M.H. 1981. Deoxynucleoside phosphoramidites: A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1859-1862.
Synthesis of Modified Oligonucleotides and Conjugates
4.27.25 Current Protocols in Nucleic Acid Chemistry
Supplement 22
Bonora, G.M. 1995. Polyethylene-glycol: A highefficiency liquid-phase (help) for the largescale synthesis of the oligonucleotides. Appl. Biochem. Biotechnol. 54:3-17.
Manoharan, M. 2001. Oligonucleotide conjugates in antisense technology. In Antisense Drug Technology (S. Crooke, ed.) pp. 391-469. Marcel Dekker, New York.
Bonora, G.M., Rossin, R., Zaramella, S., Cole, D.L., Eleuteri, A., and Ravikumar, V.T. 2000. A liquid-phase process suitable for large-scale synthesis of phosphorothioate oligonucleotides. Org. Proc. Res. Dev. 14:225-231.
Markiewicz, W.T., Godzina, P., Markievicz, M., and Astriab, A. 1998. Synthesis of a polyamino-oligodeoxyribonucleotide combinatorial library. Nucleosides Nucleotides Nucleic Acids 17:1871-1880.
Cohen, J.S. 1993. Phosphorothioate oligodeoxynucleotides. In Antisense Research and Applications (S.T. Crooke and B. Lebleu, eds.) pp. 205222. CRC Press, Boca Raton, Fla.
Padmapriya, A.A., Tang, J.-Y., and Agrawal, S. 1994. Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates. Antisense Res. Dev. 4:185-199.
Drioli, S., Benedetti, F., and Bonora, G.M. 2001. Pure, homo-bifunctional poly(ethylene glycol) orthogonally protected: Synthesis and characterization. Reactive and Functional Polymers 48:119-128.
Pang, S.N.J. 1993. Final report on the safety assessment of polyethylene glycols. J. Am. Coll. Toxicol. 12:429-456.
Eleuteri, A., Cheruvallath, Z.S., Capaldi, D.C., Cole, D.L., and Ravikumar, V.T. 1999. Oligodeoxyribonucleotide phosphorothioates: Substantial reduction of (N-1)-mer content through the use of blockmer phosphoramidite synthons. Nucleosides Nucleotides Nucleic Acids 18:1803-1807. Garcia de la Torre, B., Albericio, F., SaisonBehmoaras, E., Bachi, A., and Eritja, R. 1999. Synthesis and binding properties of oligonucleotides carrying nuclear localization sequences. Bioconjugate Chem. 10:1005-1012. Grillone, L.R. and Lanz, R. 2001. Formivirsen. Drugs Today 37:245-255. J¨aschke, A., F¨urste, J.P., Nordhoff, E., Hillenkamp, F., Cech, D., and Erdmann, V.A. 1994. Synthesis and properties of oligodeoxyribonucleotidepolyethylene glycol conjugates. Nucl. Acids Res. 22:4810-4017. Jeong, J.H, Kim, S.W., and Park, T.G. 2003. A new antisense oligonucleotide delivery system based on self-assembled ODN-PEG hybrid conjugate micelles. J. Control. Release 93:183-191. Kodera, Y., Matsushima, A., Hiroto, M., Nishimura, H., Ishii, A., Ueno, T., and Inada, Y., 1998. PEGylation of proteins and bioactive substances for medical and technical applications. Prog. Polymer Sci. 23:1233-1271.
Conjugated Oligonucleoside Phosphorothioates Using the HELP Method
Ravikumar, V.T., Andrade, M., Wyrzykiewicz, T.K., Scozzari, A.N., and Cole, D.L. 1995. Large-scale synthesis of oligodeoxyribonucleotide phosphorothioate using controlled-pore glass as support. Nucleosides Nucleotides Nucleic Acids 14:1219-1226. Scremin, C.L. and Bonora, G.M. 1993. Liquidphase synthesis of phosphorothioate oligonucleotides on polyethylene-glycol support. Tetrahedron Lett. 34:4663-4666. Seliger, H. 1993. Protocols for Oligonucleotides and Analogs. In Methods in Molecular Biology, Vol. 20 (S. Agrawal ed.) pp. 391-435. Humana Press, Totowa, N.J. Tarasow, T.M., Tinnermeier, D., and Zyzniewski, C. 1997. Characterization of oligodeoxyribonucleotide-polyethylene glycol conjugates by electrospray mass spectrometry. Bioconjugate Chem. 8:89-93. Tsou, D., Hampel, A., Andrus, A., and Vinayak, P. 1995. Large-scale synthesize of oligoribonucleotides on high-loaded polystyrene (HLP) support. Nucleosides Nucleotides Nucleic Acids 14:1481-1492. Wlotzka, B., Leva, S., Eschgfaller, B., Burmeister, J., Kleinjung, F., Kaduk, C., Muhn, P., HessStumpp, H., and Klussmann, S. 2002. In vivo properties of an anti GnRG Spiegelmer: An example of an oligonucleotide-based therapeutic substance class. Proc. Natl. Acad. Sci. U.S.A. 99:8899-8902.
Krotz, A.H., Klopchin, P., Cole, D.L., and Ravikumar, V.T. 1997. Improved impurity profile of phosphorothioate oligonucleotides through the use of dimeric phosphoramidite synthons. Bioorg. Med. Chem. Lett. 7:73-78.
Zalipsky, S. 1995. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 16:157-182.
MacKellar, C., Grahham, D., Will, D.W., Burgess, S., and Brown, T. 1992. Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups. Nucl. Acids Res. 20:3411-3417.
Contributed by Gian Maria Bonora University of Trieste Trieste, Italy
Magda, D., Wright, M., Crofts, S., Lin, A., and Sessler, J.L. 1997. Metal complex conjugate of antisense DNA which displays ribozyme-like activity. J. Am. Chem. Soc. 119:6947-6948.
4.27.26 Supplement 22
Current Protocols in Nucleic Acid Chemistry
Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
UNIT 4.28
This unit contains detailed procedures for the conjugation of peptides to oligonucleotides and their analogs via a disulfide linkage. The first section discusses the strategic planning for disulfide conjugation and provides protocols for the preparation of various types of peptide and oligonucleotide analog materials to be conjugated. Then protocols are provided for the conjugation of well-known cell-penetrating peptides to various oligonucleotide analogs that maintain negatively charged phosphate groups (e.g., 2 -Omethyloligoribonucleotides, locked nucleic acids). The final protocol focuses on peptide conjugation to peptide nucleic acids (PNA), which do not contain negatively charged phosphates. The differences between these conjugation protocols, as well as the reasons for the differences, are highlighted.
STRATEGIC PLANNING Peptide Synthesis Peptides used for conjugation can be synthesized by the user or obtained from a commercial supplier. A requirement for the peptide is that it should contain a thiol group, either free or activated (if conjugating to a free thiol on the oligonucleotide cargo). This is almost always in the form of a cysteine residue that is attached to one of the peptide termini. Any peptide synthesis machine can be used for the assembly steps, but the authors have used Fmoc/tert-butyl solid-phase peptide chemistry on either an Applied Biosystems Pioneer peptide synthesizer (100-µmol scale) or an Advanced ChemTech APEX 396 robotic synthesizer (5- to 10-µmol scale). C-terminal carboxylic acid peptides were synthesized with the C-terminal amino acid attached to the solid support. For peptides where the cysteine is on the N-terminus, Boc-Cys(Npys)-OH can be used instead of standard Fmoc-Cys(Tr)-OH so that the peptide is activated on-resin without the need for activation after solid-phase synthesis and purification. With peptides where the thiol is not on the N-terminus, thiol activation can only be carried out after complete synthesis of the peptide due to the instability of the activated thiol to piperidine and other strong nucleophiles. Oligonucleotide Synthesis Oligonucleotides suitable for disulfide conjugation can have the thiol linker modification at either the 5 - or the 3 -end. These modified oligonucleotides can often be obtained from a commercial supplier or otherwise synthesized by the user. For 3 modifications, a modified solid support is used. 5 -Thiol modification is achieved using an appropriate commercial thiol-linker phosphoramidite. The authors found difficulties in removing the protecting group of a trityl thiol modifier, due to the need to use silver nitrate. Yields of the thiol product were much lower than when a disulfide-protected thiol was liberated. Furthermore, there were reproducibility problems with the conjugation reactions, which were often low yielding, presumably due to the presence of residual silver salts. Complete reproducibility was observed with a thiol derived from a disulfide-protected linker. Thiol deprotection should not be carried out at the same time as cleavage of the oligonuclotide from the solid support and removal of other protecting groups, since this will lead to significant amounts of acrylonitrile addition to the thiol moiety, forming an unreactive thioether. Furthermore, such action unnecessarily complicates the purification and can result in disulfide-linked dimer formation during the ensuing slow desalting process.
Contributed by John J. Turner, Donna Williams, David Owen, and Michael J. Gait Current Protocols in Nucleic Acid Chemistry (2006) 4.28.1-4.28.21 C 2006 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Oligonucleotides and Conjugates
4.28.1 Supplement 24
Figure 4.28.1
Formation of disulfide-linked conjugates of peptides and antisense cargoes.
Disulfide Bond Formation Originally, asymmetric disulfide conjugation between two different biomolecules was achieved by the oxidation of alkyl thiols by atmospheric oxygen or by a mild oxidizing reagent (e.g., “diamide”). However, this method produces mixtures of unwanted homodimers as well as the desired asymmetric disulfide. By pre-activation of one of the thiols, the requisite asymmetric disulfide can be obtained as the sole product. Thiol activation is typically achieved using either the pyridylsulfenyl (pys) or 3-nitropyridylsulfenyl (Npys) group (Fig. 4.28.1). Although a stoichiometric amount of both reagents is theoretically sufficient to produce the desired disulfide product, usually the more expendable of the two reagents (often the peptide) is used in excess to drive the conjugation reaction to completion. Thiol activation of peptides is initially the most obvious choice, since these are synthesized on a larger scale and the loss of material due to the extra step is less important. However, when reacting several different peptides with one antisense cargo, it is more appropriate to activate the oligonucleotide. Another advantage of this strategy is that thiol-containing peptides that are also highly basic (e.g., contain many Arg or Lys residues) do not readily form homodimers, presumably due to electrostatic repulsion. By contrast, oligonucleotide cargoes are susceptible to homodimer formation when stored as the free thiol. Activation with the pys group can prevent such homodimerization. However, even this may not be sufficient in all cases to prevent homodimer formation, especially when storing solutions for extended periods of time (>3 months).
Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
Purification of Conjugates Crucial to successful synthesis of peptide conjugates of oligonucleotides and their analogs is separation of the desired conjugate from the excess of components (usually the peptide). This is particularly difficult when a highly cationic peptide is conjugated to a negatively charged oligonucleotide because the excess peptide may bind to the conjugate, causing aggregation and precipitation from aqueous solution. A fluorophore on the oligonucleotide greatly assists in the monitoring of precipitation during the reaction. It is necessary to use a strong denaturing agent during conjugation and also during subsequent purification by anion-exchange chromatography. Furthermore, it is important to choose an ion-exchange column for purification that has a short path length and large pores, such
4.28.2 Supplement 24
Current Protocols in Nucleic Acid Chemistry
as Resource Q (Amersham Biosciences). Because of precipitation, it is not advisable to purify oligonucleotides and conjugates from peptides having strong cationic charge using reversed-phase purification techniques. CAUTION: Wear gloves and protective glasses and carry out all operations involving organic solvents and reagents in a well-ventilated chemical fume hood.
CONJUGATION OF PEPTIDES WITH OLIGONUCLEOTIDE ANALOGS CONTAINING NEGATIVELY CHARGED PHOSPHATES
BASIC PROTOCOL 1
The synthesis of peptides conjugated by disulfide bond to oligonucleotides and their analogs has been known for some years (Eritja et al., 1991; Bongartz et al., 1994; Corey, 1995; Viv`es and Lebleu, 1997; Antopolsky et al., 1999; Astriab-Fisher et al., 2000). The protocols shown here are based on the authors’ own synthetic methods (Turner et al., 2005a) that involve improvements in conjugation and purification conditions as well as analysis. Each of the precursor biomolecules is prepared separately by solid-phase synthesis and purified prior to the conjugation steps. The synthetic conjugate product must be carefully purified from the conjugation reaction and characterized. Alternate steps are given for the peptide synthesis, using two different kinds of synthesizer, and depending on whether the activated Cys is at the N- or C-terminus. Oligonucleotide assembly can be carried out on any automated DNA/RNA synthesizer. The authors used an Applied Biosystems 394 or 3400 four-column synthesizer on a 1-µmol scale. The molecular mass of the oligonucleotides should be checked by MALDI-TOF-MS, for example on an Applied Biosystems Voyager DE-PRO workstation in positive ion mode. For evaporations of small volumes, use of a Speedvac concentrator is ideal.
Materials Fmoc-protected amino acid monomers (Novabiochem) including: Fmoc-Arg(Pbf)-OH Fmoc-Asn(Tr)-OH Fmoc-Cys(Tr)-OH Fmoc-Gln(Tr)-OH Fmoc-Glu(OtBu)-OH Fmoc-His(Tr)-OH Fmoc-Lys(Boc)-OH Fmoc-Trp(Boc)-OH N,N-Dimethylformamide (DMF, AnalaR-grade, BDH Chemicals), freshly distilled PyBop (Novabiochem) N,N-Diisopropylethylamine (DIPEA, 99+%, Applied Biosystems) Piperidine (>99.5%, Romil) NovaSyn TGR resin (for C-terminal amide synthesis, Novabiochem) PEG-PS resin (for C-terminal carboxylic acid synthesis, Applied Biosystems) Boc-Cys(Npys)-OH (for N-terminal cysteine; Bachem Bioscience) Isopropanol Trifluoroacetic acid (TFA, >99.9%, Romil) Triisopropylsilane (TIS, >99%, Aldrich) Diethyl ether, 4◦ C Acetonitrile (MeCN, HPLC-grade, Fisher Scientific) Millipore water or double-distilled deionized water 1,2-Ethanedithiol (EDT, >98%, Fluka) Water (HPLC-grade) 1.0 M NH4 HCO3 solution (aq.) 10 mg/mL 2-aldrithiol (Aldrich) in DMF
Synthesis of Modified Oligonucleotides and Conjugates
4.28.3 Current Protocols in Nucleic Acid Chemistry
Supplement 24
Nucleoside phosphoramidites (as needed): 2 -Deoxyribonucleoside phosphoramidites (Glen Research) 2 -O-Me-ribonucleoside phosphoramidites (Transgenomics) Locked nucleic acid (LNA) phosphoramidites (Link Technologies) Anhydrous acetonitrile 3 -(6-Fluorescein)-CPG (for 3 -fluorescent oligonucleotides, Glen Research) Thiol modifier C6-S-S (for 5 -thiol modification, Glen Research) 0.02 M iodine solution in 78:2:20 (v/v/v) THF/pyridine/water (Proligo) 5-Ethylthio-1H-tetrazole (a 0.25 M solution in MeCN, Link Technologies) 30% (v/v) aq. ammonia Sodium perchlorate (AnalaR, BDH Chemicals) 2.0 M Tris·Cl, pH 6.8 Formamide (p.a. ≥99.0%, Fluka) Sterilized water 2.0 M triethylammonium acetate, pH 7 (TEAA, Glen Research) 1.0 M aqueous D/L-dithiothreitol (DTT, ≥99%, Aldrich) Triethylamine (TEA, ≥99.5%, Fluka) Peptide synthesizer (e.g., APEX 396 or Pioneer peptide synthesizer) Desiccator attached to vacuum 15-mL polyethylene syringe (IST empty reservoir, Kinesis) 20-µm polyethylene frit (Kinesis) Speedvac concentrator Benchtop centrifuge 15- and 50-mL centrifuge tubes (Falcon) 0.22- (water) and 0.45-µm (water and organic) filters (Millipore) HPLC system, chemically inert, suitable for ion-exchange chromatography, with: PEEK tubing throughout Injector, sample loop, and syringe (manual loading) UV/Vis detector, variable wavelength 190 and 500 nm (preferable) or dual-wavelength detection Helium for degassing Jupiter reversed-phase HPLC column with guard (analytical and semi-prep, Phenomenex) DNAPac PA-100 (9 × 250–mm) Dionex column (semi-prep) with guard attached Resource Q column (1 mL/min analytical or 6 mL/min semi-prep, Amersham Biosciences) Lyophilizer Rotary evaporator and water pump 1.5-mL screw-cap tube (Sarstedt) or vial 55◦ C bath or temperature block (optional) Spin-X tube (Costar) Dialysis tubing, 3500 MWCO (Medicell International Ltd.) UV spectrometer Sephadex NAP-25 column (Amersham Biosciences) 0.5-mL microcentrifuge tube Slide-a-lyzer (0.5- to 3-mL capacity, 3500 MWCO, Pierce)
Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
Additional reagents and equipment for peptide synthesis, MALDI-TOF-MS (see Support Protocol 1), Ellman’s test (see Support Protocol 2), oligonucleotide synthesis (APPENDIX 3C), and amino acid analysis (optional; see UNIT 4.22) NOTE: Amino acid protecting groups are tBu, tert-butyl; Boc, tert-butyloxycarbonyl; Fmoc, 9-fluorenylmethoxycarbonyl; Pbf, 2,2,4,6,7-pentamethyldihydrobenzofuran-5sulfonyl; pys, pyridylsulfenyl; Npys, 3-nitropyridylsulfenyl; and Tr, trityl.
4.28.4 Supplement 24
Current Protocols in Nucleic Acid Chemistry
Table 4.28.1 Synthesis Cycle for Peptide Synthesis on the APEX 396 Synthesizer
Synthesis step
Reagents and volumes (µL)
Time (min)
Deprotection
20% piperidine solution (1000)
3
20% piperidine solution (1000)
12
Wash (five times)
DMF (1000)
1
Couple (two times)
Amino acid (300)
25
PyBop (300) DIPEA (300) Wash (five times)
DMF (1000)
1
Synthesize peptide with an activated cysteine For an APEX 396 peptide synthesizer (N-terminal cysteine) 1a. Dissolve the amino acid derivatives in DMF to give 0.5 M solutions (allow 600 µL per amino acid residue). 2a. Dissolve PyBop in DMF to give a 0.5 M solution (allow 600 µL per amino acid residue). 3a. Make a 1 M DIPEA solution in DMF (allow 600 µL per amino acid residue). 4a. Make a 20% piperidine solution in DMF (allow 2 mL per amino acid residue). 5a. Weigh out 15 µmol resin, put in a reactor well of the peptide synthesizer, and swell the resin two times with 1 mL DMF (5 min each). Drain off the DMF from the well. 6a. Program the synthesizer for the desired sequence. 7a. Start the synthesis beginning with Fmoc deprotection and first coupling and continue until the sequence is completed. See Table 4.28.1. Ensure that there is sufficient DMF and nitrogen gas present for the whole synthesis.
8a. Carry out the final peptide coupling with Boc-Cys(Npys)-OH. Do not carry out final Fmoc deprotection. 9a. Wash the resin with 3 mL DMF, then 3 mL isopropanol, and dry the resin under vacuum in a desiccator for 4 hr. 10a. To simultaneously cleave the peptide from the support and deprotect, treat with 1 mL of 95% TFA/2.5% water/2.5% TIS for 4 to 6 hr (using the longer time with high Arg content). 11a. Filter off the resin using a 15-mL polyethylene syringe fitted with a 20-µm frit and wash with an additional 1 mL TFA. Concentrate the filtrate to ∼10% of the original volume using a rotary evaporator, and precipitate the peptide with 25 mL cold (4◦ C) diethyl ether. 12a. Vortex the mixture and compact the precipitate by centrifuging 5 min at 1666 × g (2500 rpm), room temperature. Carefully decant the diethyl ether solution and wash the precipitate with 25 mL cold diethyl ether three additional times, centrifuging the residue and decanting the supernatant each time. CAUTION: It is necessary to use sealed centrifuge buckets when centrifuging solutions of flammable liquids such as ether.
Synthesis of Modified Oligonucleotides and Conjugates
4.28.5 Current Protocols in Nucleic Acid Chemistry
Supplement 24
13a. Analyze the crude product and purify by HPLC on a Phenomenex Jupiter reversedphase column (analytical or semi-prep as appropriate) using the following conditions:
Buffer A: 0.1% TFA (aq.) Buffer B: 90:10 (v/v) acetonitrile/buffer A Gradient: 0% to 90% buffer B initially, optimizing according to peptide. All buffered solutions used for HPLC purifications should be filtered through a 0.45-µm disposable filter prior to use (see also UNIT 10.5).
14a. Collect appropriate fractions, lyophilize, redissolve in 1 mL water or buffer A, and analyze by HPLC and MALDI-TOF-MS (see Support Protocol 1). Continue with step 15.
For a Pioneer peptide synthesizer (N-terminal cysteine) 1b. Weigh 0.4 mmol of the appropiate amount of amino acid derivatives into separate tubes (4 equivalent excess per coupling). 2b. Dissolve PyBop in DMF to give a 0.395 M solution (calculated for 3.95 equivalents excess per coupling). 3b. Make a 0.79 M DIPEA solution in DMF (calculated for 7.9 equivalents excess per coupling). 4b. Make a 20% piperidine solution in DMF (calculated for 50 mL per amino acid residue). 5b. Weigh out 100 µmol resin (amino acid loading typically 0.2 mmol/g, thus 0.5 g resin). Place resin in the synthesis column and connect to the synthesizer. Swell the resin in 1 mL DMF for 2 min. 6b. Program synthesizer for the desired sequence. 7b. Start the synthesis beginning with Fmoc deprotection and the first coupling and continue, using manufacturer’s programs and specifications. Ensure that there is sufficient DMF and nitrogen gas present for the whole synthesis.
8b. Carry out steps 8a to 14a as above. Continue with step 15.
For a C-terminal cysteine 1c. Repeat steps 1a to 6a or 1b to 6b as above depending on the synthesizer type. 2c. Start the synthesis beginning with Fmoc deprotection and couple first with FmocCys(Tr)-OH in the same way as in 7a or 7b, depending on the synthesizer type. 3c. Do not add Boc-Cys(NPys)-OH as the final amino acid; do carry out the final deprotection of Fmoc. 4c. Wash the resin with 3 mL DMF, then 3 mL isopropanol, and dry the resin under vacuum in a desiccator. 5c. To simultaneously cleave the peptide from the support and deprotect, treat with 1 mL of 94% TFA/2.5% water/2.5% EDT/1% TIS for 4 to 6 hr (depending on Arg content). Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
6c. Carry out steps 11a to 14a. 7c. Quantify the peptide using the Ellman’s test (see Support Protocol 2).
4.28.6 Supplement 24
Current Protocols in Nucleic Acid Chemistry
8c. Activate the C-terminal cysteine-containing peptide as synthesized by dissolving in HPLC-grade water at a concentration between 1 and 5 mM. In the case of hydrophobic peptides, the solution should contain 10% to 30% acetonitrile to maintain solubility.
9c. Add 1 M aqueous NH4 HCO3 solution to make an overall concentration of 0.1 M buffer. 10c. Add 2-aldrithiol solution (10 equivalents), mix thoroughly by vortexing the solution, centrifuge briefly (5 sec) at 7412 × g (6000 rpm), and allow to stand for 2 to 3 hr at room temperature. 11c. Dilute with an equal volume of 0.1% aq. TFA (mobile phase A). 12c. Vortex thoroughly and centrifuge 3 min at 16,060 × g (13,000 rpm), room temperature. 13c. Purify the supernatant by RP-HPLC. Collect the product and lyophilize. Analyze by MALDI-TOF-MS (see Support Protocol 1) and by HPLC. 14c. Quantify either by weighing the product or, if the amount is too small, by using amino acid analysis (see general procedure for amino acid analysis in UNIT 4.22). Continue with step 15.
Synthesize oligonucleotide containing a thiol linker 15. Dissolve the appropriate phosphoramidites (standard 2 -deoxyribonucleoside, 2 -O-Me-ribonucleoside, LNA, or others) in anhydrous MeCN as 100 mM solutions. 16. Start the automated solid-phase oligonucleotide synthesis from an appropriate solid support-filled column, e.g., on a 1-µmol scale. See APPENDIX 3C for details on automated oligonucleotide synthesis. For 3 -fluorescent oligonucleotides, use 3 -(6-fluorescein)-CPG (Glen Research) for the support.
17. Elongate the oligonucleotide chain in DMTr-OFF mode following the standard operating procedures for the machine as directed by the manufacturer. Use 0.25 M 5-ethylthio-1H-tetrazole as the coupling agent. For LNA monomers, allow quadruple the time for iodine oxidation (60 sec cf. 15 sec for other monomers) and 15 min per coupling. Use the thiol modifier in the final coupling step. 18. After completion of the assembly, remove the column, wash with MeCN (two times with 10 mL for 1-µmol synthesis) and quickly dry on a water pump. 19. Transfer the support into a 1.5-mL screw-cap tube or vial and add 1 mL of 30% aq. ammonia. On some DNA synthesizers, such as the ABI 394 or 3400 machines, steps 18 and 19 are carried out automatically on the synthesizer and the product oligonucleotide is collected in a vial.
20. Vortex the mixture and incubate for at least 8 hr at 55◦ C or for 24 hr at ambient temperature. 21. Cool the solution in a −20◦ C freezer, and evaporate off the ammonia and dry in vacuo using a Speedvac concentrator. 22. Add 0.5 mL of deionized water, transfer the solution to a Spin-X tube, and centrifuge 5 min at 16,060 × g (13,000 rpm), room temperature. Wash the filter with deionized water (two times with 0.25 mL) and concentrate in vacuo. Current Protocols in Nucleic Acid Chemistry
Synthesis of Modified Oligonucleotides and Conjugates
4.28.7 Supplement 24
23. Purify DMTr-OFF oligonucleotides using an ion-exchange (IE) HPLC with the following conditions:
Column: 9 × 250–mm DNAPac PA-100 Buffer A: 1 mM sodium perchlorate, 20 mM Tris·Cl pH, 6.8, and 25% formamide Buffer B: 400 mM sodium perchlorate, 20 mM Tris·Cl, pH 6.8, and 25% formamide Gradient: 15% to 55% buffer B in 20 min Flow rate: 3 mL/min Detection at 260 nm wavelength. For oligonucleotides with fluorescein as the fluorophore, measurement at 480 nm is also possible. All buffered solutions used for HPLC purifications should be filtered through a 0.45-µm disposable filter prior to use (see also UNIT 10.5).
24. Pool the appropriate HPLC fractions. Desalt by dialysis against 2500 mL water at 4◦ C for 24 hr using a 3500 MWCO membrane, and changing the water three times. Lyophilize the dialysate. 25. Dissolve the oligonucleotide in deionized water and quantify by measuring the UV absorbance at 260 nm. Store the solution frozen at −20◦ C (stable at least 6 months). 26. Check the molecular mass of the oligonucleotide by MALDI-TOF-MS (see Support Protocol 1).
Liberate thiol on the oligonucleotide 27. Dissolve 300 nmol purified oligonucleotide in 292.5 µL sterilized water. 28. Add 7.5 µL of 2.0 M TEAA buffer, followed by 3 µL of 1 M DTT and 3 µL triethylamine. 29. Mix thoroughly by vortexing and allow to stand for 1.5 hr at room temperature. 30. Monitor thiol formation by HPLC (see step 23) and MALDI-TOF-MS (see Support Protocol 1). 31. Equilibriate a NAP-25 column with sterilized water. Load the sample, collect the desalted product, and lyophilize. 32. Quantify the absorbance value at 260 nm and carry out an Ellman’s test (see Support Protocol 2) to determine if there is any DTT impurity present.
Conjugate oligonucleotide thiol to activated peptide 33. Place 20 µL of a 1 mM aqueous solution of thiol oligonucleotide in a 0.5-mL microcentrifuge tube. 34. Add 70 µL formamide and 5 µL of 2 M TEAA buffer. Vortex and then microcentrifuge briefly. 35. Add the activated peptide (80 nmol in 8 µL) to the oligonucleotide, vortex, and allow to stand for 30 min.
Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
For conjugations to highly basic peptides, precipitation can occur. The supernatant should be removed and the residue redissolved in a mixture of formamide and 2 M TEAA buffer before being combined with the supernatant and purified.
4.28.8 Supplement 24
Current Protocols in Nucleic Acid Chemistry
36. Purify the conjugate using an IE-HPLC in one injection with the following conditions:
Column: Resource Q 1 mL/min Buffer A: 20 mM Tris·Cl, pH 6.8, and 50% formamide Buffer B: 400 mM sodium perchlorate, 20 mM Tris·Cl, pH 6.8, 50% formamide Gradient: 0% to 100% buffer B in 20 min Flow rate: 1 mL/min Detection: 280 nm wavelength. For oligonucleotides with fluorescein as fluorophore, simultaneous measurement at 480 nm can be done. Buffered solutions used for these HPLC purifications should be filtered through a 0.22µm disposable filter prior to use (see also UNIT 10.5). A fine filter is required because a guard column is not used.
37. Collect purified product, load in Slide-a-lyzer as directed, and dialyze for 24 hr against water at 4◦ C. 38. Recover sample and lyophilize. 39. Redissolve the conjugate in water or an appropriate buffer to analyze by HPLC and MALDI-TOF-MS (see Support Protocol 1). 40. Determine the yield by absorbance calculation at 260 nm.
CONJUGATION OF C-TERMINAL CYS-CONTAINING PEPTIDES TO OLIGONUCLEOTIDES VIA ACTIVATION OF THE OLIGONUCLEOTIDE
ALTERNATE PROTOCOL
In this protocol, the oligonucleotide is the activated species. Use the peptide thiol synthesized in Basic Protocol 1. A peptide with a C-terminal thiol is obtained from Basic Protocol 1, steps 1c to 7c. For peptides with an N-terminal thiol, again follow Basic Protocol 1, steps 1c to 7c, but in step 2c add the Fmoc-Cys(Tr)-OH in the last coupling step instead of the first.
Additional Materials (also see Basic Protocol 1) Sephadex NAP-10 column (Amersham Biosciences) Activate oligonucleotide 1. Dissolve 200 nmol oligonucleotide obtained from Basic Protocol 1, step 25, in 195 µL sterilized water. 2. Add 5 µL of 2 M TEAA buffer and 44 µL aldrithiol solution (2 µmol, 10 eq.). 3. Vortex and allow to stand 1 hr at room temperature. 4. Desalt using a Sephadex NAP-10 column. 5. Analyze and quantify (see Basic Protocol 1, steps 25 and 26).
Conjugate activated oligonucleotide to peptide thiol 6. Place 20 µL of a 1 mM aqueous solution of activated oligonucleotide in a 0.5-mL microcentrifuge tube. 7. Add 70 µL formamide and 5 µL of 2 M TEAA buffer. Vortex and then briefly centrifuge. 8. Add 50 nmol peptide thiol (see Basic Protocol 1, step 7c) in 5 µL to the oligonucleotide, vortex, and allow to stand for 30 min at room temperature.
Synthesis of Modified Oligonucleotides and Conjugates
4.28.9 Current Protocols in Nucleic Acid Chemistry
Supplement 24
For conjugations to highly basic peptides, precipitation can occur. The supernatant should be removed and the residue redissolved in a mixture of formamide and 2 M TEAA buffer before being combined with the supernatant and purified.
9. Purify and quantify as in Basic Protocol 1, steps 36 to 40. BASIC PROTOCOL 2
CONJUGATION OF PEPTIDES WITH PEPTIDE NUCLEIC ACIDS The conjugation of PNA oligomers to peptides using the disulfide route is more straightforward than with the oligonucleotide counterpart, since the likelihood of precipitation due to the addition of highly basic peptides is minimal. There have been a number of reports previously describing disulfide conjugation of PNA to peptides (Pooga et al., 1998; Braun et al., 2002; Kaushik et al., 2002; Koppelhus et al., 2002; Kilk et al., 2004), but this protocol is based on the authors’ own procedures (Turner et al., 2005b) that involve improvements in purification conditions and analysis. Synthesis of the activated PNA oligomer is achieved using the APEX 396 Robotic peptide synthesizer described in Basic Protocol 1. Oligomers synthesized should be analyzed and purified using a reversed-phase HPLC column heated to 45◦ C. Molecular mass can be verified by MALDI-TOF-MS using the CHCA matrix (see Support Protocol 1). For further information on the synthesis of PNA oligomers, see UNIT 4.11. It is well documented that a PNA oligomer can be sparingly soluble in aqueous solution, and that its conjugation to a sparingly soluble peptide (e.g., Transportan) may exacerbate this problem. Therefore, such behavior needs to be taken into consideration in PNA synthesis design. In order to assist in the solubility of the PNA oligomer, lysine residues are often added (typically three or four) to the C- and/or N-terminus (see UNIT 4.11).
Materials
Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
Fmoc (Bhoc) PNA monomers (Applied Biosystems) N-Methylpyrrolidinone (NMP, ≥99.5%, Fluka) PyBop (Novabiochem) N,N-Dimethylformamide (DMF, AnalaR-grade, BDH Chemicals), freshly distilled N,N-Diisopropylethylamine (DIPEA, 99+%, Applied Biosystems) 2,6-Lutidine (≥99%, Aldrich) Piperidine (>99.5%, Romil) Fmoc-PAL-PEG-PS amide resin (Applied Biosystems) Isopropanol Trifluoroacetic acid (TFA, >99.9%, Romil) Triisopropylsilane (TIS, >99%, Aldrich) Phenol Diethyl ether, 4◦ C 5% acetic anhydride/6% 2,6-lutidine solution in DMF (PNA capping solution, Applied Biosystems) 1.0 M aq. NH4 OAc (AnalaR-grade, BDH Chemicals) APEX 396 Robotic peptide synthesizer 1-mL polyethylene syringe (IST empty reservoir, Kinesis) 10-µm polyethylene frit (Kinesis) Plastic tap Filtration unit 15-mL centrifuge tube (Falcon) Heating jacket for HPLC column UV spectrometer Lyophilizer Additional reagents and equipment for reversed-phase HPLC (see Basic Protocol 1)
4.28.10 Supplement 24
Current Protocols in Nucleic Acid Chemistry
Table 4.28.2 Synthesis Cycle for PNA Synthesis on the APEX 396 Synthesizer
Synthesis step
Reagents and volumes (µL)
Time (min)
Deprotection
20% piperidine solution (800)
1
20% piperidine solution (800)
4
Wash (five times)
DMF (1000)
1
Couple (two times)
PNA or amino acid (100) PyBop (100) DIPEA/lutidine (100) DMF (100)
30
Wash (five times)
DMF (1000)
1
Cap (two times)
PNA capping solution (1000)
5
Wash (five times)
DMF (1000)
1
Synthesize PNA oligomer containing an activated (Npys) cysteine thiol 1. Dissolve PNA monomers in NMP to give 0.2 M solutions (allow 200 µL per PNA or amino acid residue). 2. Dissolve PyBop in DMF to give a 0.2 M solution (allow 200 µL per PNA or amino acid residue). 3. Make a 0.2 M DIPEA/0.2 M 2,6-lutidine solution in DMF (allow 200 µL per PNA or amino acid residue). 4. Make a 20% piperidine solution in DMF (allow 1.6 mL per PNA or amino acid residue). 5. Weigh out 5 µmol resin, place in a reactor well, and swell the resin two times with 1 mL DMF (5 min each). 6. Program the synthesizer for the desired sequence. Typically three lysine residues are added to the C-terminus and one is added to the N-terminus followed by the activated cysteine for the final coupling.
7. Start the synthesis beginning with Fmoc deprotection and the first coupling, and continue until the sequence is completed. See Table 4.28.2. Ensure that there is sufficient DMF and nitrogen gas present for the whole synthesis.
8. Carry out the final coupling with Boc-Cys(Npys)-OH. Do not carry out final Fmoc deprotection. 9. Wash the resin with 3 mL DMF, then 3 mL isopropanol, and dry the resin under vacuum in a desiccator for 4 hr. 10. Place resin in a 1-mL polyethylene syringe fitted with 10-µm frit and plastic tap. 11. To simultaneously cleave the PNA oligomer from the support and deprotect it, add 1 mL of a 95% TFA/2.5% water/2.5% triisopropylsilane solution containing 10% phenol for 4 hr. 12. Filter into a 15-mL centrifuge tube, washing the resin with an additional 0.5 mL TFA. Concentrate to ∼200 µL using a rotary evaporator and water pump, and precipitate the PNA oligomer with 10 mL cold (4◦ C) diethyl ether. 13. Vortex the mixture and compact the precipitate by centrifuging 5 min at 1666 × g (2500 rpm), room temperature. Carefully decant the diethyl ether solution and wash the precipitate with 10 mL diethyl ether three additional times, centrifuging the residue and carefully decanting the supernatant each time.
Synthesis of Modified Oligonucleotides and Conjugates
4.28.11 Current Protocols in Nucleic Acid Chemistry
Supplement 24
CAUTION: It is necessary to use sealed centrifuge buckets when centrifuging solutions of flammable liquids such as ether.
14. Analyze the crude product and purify by use of a Phenomenex Jupiter reversedphase HPLC column (analytical or semi-prep as appropriate) heated to 45◦ C. Monitor by UV at 260 nm. Use the same buffers as in Basic Protocol 1, step 13a. A typical gradient for a 16- to 18-mer with four lysines is 5% to 30% buffer B in 25 min.
15. Collect appropriate fractions, lyophilize, redissolve in water/acetonitrile as required, and analyze by HPLC and MALDI-TOF-MS (see Support Protocol 1). 16. Quantify at 260 nm. The extinction coefficient for individual nucleobases is different than for the corresponding oligonucleotides (see UNIT 4.11).
Conjugate PNA oligomer to thiol peptide 17. Place 20 µL of a 1 mM aqueous solution of oligonucleotide in a microcentrifuge tube. 18. Add 10 µL of 1.0 M NH4 OAc and then the thiol peptide to be conjugated (40 nmol, 4 µL of a 10 mM stock solution; see Basic Protocol 1 for synthesis of the thiol peptide). In the case of lipophilic peptides that are sparingly soluble in water at neutral pH (e.g., Transportan), add 50 µL of acetonitrile prior to peptide addition.
19. Mix the solution by vortexing, centrifuge briefly (5 sec at 7412 × g), and allow to stand for 30 min at room temperature. 20. Purify the resulting conjugate in one injection by reversed-phase HPLC using a Phenomenex Jupiter column as described in step 14, using a flow rate of 1.5 mL/min and a gradient of 5% to 30% buffer B in 25 min when conjugating to highly basic peptides, or a gradient of 5% to 50% buffer B when conjugating to more lipophilic peptides. Buffers are the same as for peptides (see Basic Protocol 1, step 13a).
21. Collect the product and lyophilize. 22. Redissolve in sterile water, analyze by HPLC and MALDI-TOF-MS (see Support Protocol 1), and quantify by measuring absorbance at 260 nm (see UNIT 4.11). SUPPORT PROTOCOL 1
DETERMINATION OF MOLECULAR MASS BY MALDI-TOF MASS SPECTROMETRY Although mass determination through MALDI-TOF analysis is dealt with in several existing units (UNIT 4.11 for PNA, UNIT 4.22 for peptides and oligonucleotides, and UNIT 10.1 for general protocols for machine use), a number of variations in the matrices have been found to work well for the various constructs described here. General operational procedures can be found in the manufacturer’s manual and in UNIT 10.1.
Materials Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
α-Cyano-4-hydroxycinnamic acid (CHCA, ≥99.0%, Aldrich) Acetonitrile 3% (v/v) aq. trifluoroacetic acid (TFA, >99.9%, Romil) 2,6-Dihydroxyacetophenone (DHAP, ≥99.0%, Fluka) Methanol Diammonium hydrogen citrate (≥99.0%, Fluka)
4.28.12 Supplement 24
Current Protocols in Nucleic Acid Chemistry
Millipore water or double-distilled deionized water 2,4,6-Trihydroxyacetophenone (THAP, ≥99%, Fluka) 1.5-mL solvent-resistant microcentrifuge tubes MALDI-TOF mass spectrometer Prepare matrix For peptides, PNA oligomers, and peptide-PNA conjugates 1a. Dissolve 10 mg CHCA in 0.5 mL acetonitrile in a 1.5-mL solvent-resistant microcentrifuge tube. 2a. Add 0.5 mL of 3% aq. TFA solution. 3a. Mix thoroughly. Continue with step 4.
For oligonucleotides and peptide-oligonucleotide conjugates (low salt content in sample) 1b. Dissolve 20 mg DHAP in 0.5 mL methanol in a 1.5-mL solvent-resistant mirocentrifuge tube. 2b. Dissolve 40 mg diammonium hydrogen citrate in 0.5 mL water in a separate tube. 3b. Mix the two solutions together thoroughly. Continue with step 4.
For oligonucleotides and peptide-oligonucleotide conjugates (high salt content in sample; also used to check for contamination by peptides) 1c. Add 0.5 mL acetonitrile to 60 mg THAP in a 1.5-mL solvent-resistant microcentrifuge tube and vortex for 1 min. 2c. Dissolve 5.7 mg diammonium hydrogen citrate in 0.5 mL water and add to THAP/acetonitrile mixture. 3c. Vortex for 30 sec and centrifuge 3 min at 16,060 × g (13,000 rpm), room temperature. Use the supernatant and continue with step 4. Excess THAP will be in pellet form at the bottom of the tube.
Prepare sample 4. Spot 1 µL of the matrix onto the plate. 5. Immediately (within 5 sec) add 0.1 µL of the sample and mix by pipetting the solution up and down five times with a pipet. The concentration of the sample is critical for good mass acquisition (see UNIT 10.1). Sample concentrations exceeding 1 mM can give inferior spectra. For THAP matrix (which is saturated), immediate crystallization can occur upon dispensing the sample. In this case, do not mix. In general, cease mixing the sample/matrix mixture if crystallization commences.
6. Allow to crystallize and dry completely. 7. Acquire spectra in positive ion mode (see UNIT 10.1).
Synthesis of Modified Oligonucleotides and Conjugates
4.28.13 Current Protocols in Nucleic Acid Chemistry
Supplement 24
SUPPORT PROTOCOL 2
DETERMINATION OF THIOL CONTENT BY THE ELLMAN’S TEST The Ellman’s test is a widely used and established technique for the quantitation of thiol content in a given solution.
Materials Ellman’s reagent: 2 mM dithio-bis-2-nitrobenzoic acid (DTNB) in 50 mM sodium acetate (NaOAc) 2.0 M Tris·Cl, pH 8.0 UV spectrometer with 1-mL, 1-cm path length quartz glass cuvette (Suprasil, Hellma) 1. Add 50 µL Ellman’s reagent, 100 µL of 2.0 M Tris·Cl, and water (850 µL minus the sample volume) to a quartz cuvette. 2. Mix thoroughly by carefully pipetting 200 µL of solution up and down ten times with a pipet. 3. Zero the UV spectrometer at 412 nm. 4. Repeat step 2 and check that the UV spectrometer still reads zero. If not, repeat steps 2 and 3 until it does. 5. Add the sample to the cuvette, mix carefully ten times, and take the reading. 6. Calculate absorbance as follows:
A(sample) = [total volume (µL)/sample volume (µL)] × A412 7. Repeat steps 1 through 6 two times, varying the amount of sample used (e.g., 10, 15, 20 µL), and take the average. 8. Calculate the thiol content as follows:
thiol (M) = average A(sample)/13,600 where 13,600 M−1 cm−1 is the extinction coefficient of the reagent. Due to the sensitivity of the test, when fluorophores are present (e.g., fluorescein, 492 nm maximum) ensure that a background check at pH 8.0 (i.e., no Ellman’s reagent present) at 412 nm is carried out so that the absorbance value reading can be adjusted if necessary.
COMMENTARY Background Information
Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
Antisense oligonucleotides and siRNA The antisense oligonucleotide field emerged some 25 years ago with the pioneering work of Zamecnik (Zamecnik and Stephenson, 1978). However, a severe limitation to biological activity of oligonucleotides and their analogs has been the poor cellular uptake and delivery into the right cell compartment. Most oligonucleotides and analogs are not taken up into cells in culture without use of an additional carrier, of which cationic lipids (such as Lipofectamine 2000) are the most popular (Bennett et al., 1992). The same problems of poor cell uptake extend
to siRNA and PNA. For therapeutic use, cationic lipids have disadvantages because of the need for careful formulation and difficulties in maintaining stability. Major efforts have been made to find alternative methods of oligonucleotide and siRNA drug delivery that do not require formulation, but merely involve chemical modification of the oligonucleotide itself. Peptide conjugates of oligonucleotides to enhance cell delivery One idea that has been pursued for several years is the covalent conjugation of cellpenetrating peptides (CPP), also known as protein transduction domains (PTD) (Lindgren
4.28.14 Supplement 24
Current Protocols in Nucleic Acid Chemistry
et al., 2000; Lindsay, 2002; Wadia and Dowdy, 2002; Lochmann et al., 2004; Zorko and Langel, 2005). Such peptides have been shown to translocate into mammalian cells in culture, but it has been controversial as to what extent such peptides are taken up by endocytotic pathways or by non-energy-dependent processes. It appears that some cationic peptides, such as Tat, are predominantly taken up by endocytosis (Richard et al., 2003), but even now the uptake mechanism is disputed (Potocky et al., 2003; Kaplan et al., 2005; Ziegler et al., 2005). It is also less clear for more hydrophobic peptides such as Transportan (Zorko and Langel, 2005). Methods of synthesis of peptide conjugates of oligonucleotides and analogs have been reviewed (Zubin et al., 2002; Zatsepin et al., 2005) and their applications for cell delivery covered extensively (Stetsenko et al., 2000; Gait, 2003; Thierry et al., 2003; Shi and Hoekstra, 2004; Juliano, 2005). Very recently there have been a couple of papers suggesting that peptide conjugates of siRNA are also useful for carrier-free delivery (Chiu et al., 2004; Muratovska and Eccles, 2004). Such peptide carrier–oligonucleotide or siRNA cargo conjugates can be synthesized either with a stable linkage (such as amide, thioether, oxime, or hydrazine) or with an unstable linkage (such as disulfide). Disulfide-linked peptide-oligonucleotide and peptide-PNA conjugates Very little information had been available as to whether unstable disulfide linkages may have any advantage over more stably linked conjugates. Recent evidence from the PNA-peptide field suggests, at least for this class of conjugates, that disulfide-linked conjugates may have higher activity (Koppelhus et al., 2002; Turner et al., 2005b). However, this has not been proven in the case of peptide conjugates of negatively charged oligonucleotides, where sufficient biological activity has been hard to achieve (Antopolsky et al., 1999; Astriab-Fisher et al., 2000; Turner et al., 2005a). Potentially, the disufide bond may be cleaved by reduction within a mammalian cell to allow cargo release linkage, but the rates of such intracellular cleavage are unknown and may vary depending on the cargo as well as the peptide type. Disulfide conjugates have become popular with laboratories studying the uptake and activity of peptideantisense cargo conjugates because the chemistry is simple and reasonably specific, and the thiol functional groups needed on each component are readily introduced. However,
with regards to the synthesis of highly cationic peptide-oligonucleotide conjugates, reliable protocols have been missing, and there have even been reports suggesting that such conjugations are impossible to achieve (Prater and Miller, 2004). The protocols provided here for synthesis, purification, and analysis of peptide-oligonucleotide (Turner et al., 2005a) and peptide-PNA (Turner et al., 2005b) conjugates should fill this gap and encourage others to explore a wider variety of peptides and oligonucleotides for conjugation, toward the goal of improved cell delivery. The authors’ results in this area have shown that conjugation by several types of CPP does indeed enhance cellular uptake into HeLa cells and fibroblasts in cell culture, but that biological activity levels in a model system involving steric block of HIV-1 Tat-dependent transactivation in the nucleus are limited in most cases by slow release from endosomal compartments (Turner et al., 2005a,b). However, recent exciting results suggest that disulfidelinked PNA-peptides targeting the HIV-1 TAR region have great potential as antiviral and virucidal agents (Tripathi et al., 2005) and also in the targeting of neuropeptide receptor mRNAs (Kilk et al., 2004). Disulfidelinked peptide-oligonucleotide conjugates are also useful for delivery into living cells for the detection of mRNA by a molecular beacons approach (Nitin et al., 2004).
Critical Parameters and Troubleshooting For the synthesis of peptides using the APEX or Pioneer machines, problematic sequences (often indicated by repeating motifs or large sections of hydrophobicity) should be identified and the use of double couplings or double-double couplings employed. Although the APEX machine can in theory synthesize 96 peptides in parallel, it is best to operate with smaller numbers due to the variation in exposure time to reagents in the different steps (e.g., piperidine). The authors have found that groups of four to six peptides at a time are manageable. Although the machine is by definition automated, it should be monitored as much as possible to catch any errors that may occur. Manual intervention at this stage can rescue the synthesis and prevent loss of reagents and time. The programming of the machine should also be double-checked before commencing the synthesis. The Pioneer peptide synthesizer, which is a flow-through instrument where one peptide is synthesized at a time, is less
Synthesis of Modified Oligonucleotides and Conjugates
4.28.15 Current Protocols in Nucleic Acid Chemistry
Supplement 24
prone to error, but is no longer commercially available. Reagent solutions should not be used if older than 3 days. This is especially true for PyBop. Any solutions exhibiting discoloration should be discarded. Masses of +170 and +50 are occasionally observed as a result of degraded resin. Replacing the resin solves this. For PNA synthesis, much of what has been described for the synthesis of peptides on the APEX machine also holds true (i.e., programming and monitoring the machine during synthesis). Several additional factors are also critical to the synthesis of the PNA oligomers. (1) A short piperidine treatment should be used for cleavage of the Fmoc protecting group. The Bhoc nucleobase protecting group is susceptible to cleavage when longer (standard peptide) reaction times are used. (2) The solubility of the PNA monomers and, in general, the growing chain can be maintained by the addition of N-methylpyrrolidone (NMP) to the reaction mixture, if necessary. (3) The quality of the coupling reagent is of greater importance in PNA synthesis than in peptide synthesis. Although an amide bond is formed in both cases, peptide synthesis and solutions are more tolerant in general to the presence of small amounts of water than PNA synthesis. Poor yields can in some cases be rectified by adding molecular sieves to the solutions for PNA synthe-
Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
sis. Stock solutions of thiol-containing peptides that are not highly cationic and of PNA oligomers should be stored in 0.1% aqueous TFA to inhibit dimerization. For both, acidic media may be required for solvation. Oligonucleotide synthesis is generally straightforward. With LNA, longer coupling times and a stronger activator (e.g., 5-ethylthiotetrazole) are used. For conjugations, it is important that the quality of both starting materials be high. Pure oligonucleotide or PNA and peptide suitable for conjugation will simplify the purification of the conjugate. It has been observed occasionally that the desalting procedure after the liberation of the oligonucleotide thiol with DTT can be incomplete. Traces of DTT in the final solution can diminish the coupling efficiency with activated peptides. Desalting again will resolve this problem. Alternatively, begin with a bigger Sephadex NAP column. It is not advisable to dialyze the thiol oligonucleotide, as dimer formation will occur. Maintaining solubility is vital for the smooth formation and purification of conjugates. The addition of a highly cationic peptide to a solution of oligonucleotide without formamide present will result in immediate aggregation. This is best visualized with fluorescently labeled materials. A high percentage of the solution should be formamide to ensure solubility. This percentage can rise to >90%
Figure 4.28.2 HPLC chromatogram of conjugate formation from peptide RQIKIWFQNRRMKWKKGGC with (pys)S-(CH2 )6 -5 -2 -O-Me/LNA[CUC CCA GGC UCA]-3 -fluorescein; peaks (i) salts and formamide, (ii) excess peptide, (iii) conjugate product, (iv) unconjugated oligo(pys). The solid trace is at 280 nm and the dashed trace is at 480 nm, which identifies the fluorescein label on the oligonucleotide.
4.28.16 Supplement 24
Current Protocols in Nucleic Acid Chemistry
Figure 4.28.3 MALDI-TOF mass spectra of GRKKKRRQRRRPC(S-)-S-(CH2 )6 -5 -2 -O-Me/LNA[CUC CCA GGC UCA]-3 -fluorescein conjugate: (A) purified and (B) pure conjugate with 0.5 eq. peptide added.
for reactions involving highly cationic peptides. It is best to keep highly concentrated stocks of peptides and oligonucleotides, so that the amount of formamide needed does not prevent single injection purification by HPLC. A high concentration is advisable to ensure quick reaction times. When purifying the conjugate, care must be taken when formamide and 2 M TEAA are used to resolubilize aggregated material. It has been observed that HPLC runthrough can occur when large amounts have been used. This material can be collected and re-injected in the following run.
Care must be taken when loading Slidea-Lyzer cassettes so as not to puncture the dialysis membrane. In addition, for highly basic peptide-oligonucleotide conjugates, there is a risk of self-aggregation onto the membrane during dialysis, resulting in a reduction in yield. The Slide-a Lyzer cassette can be washed with appropriate buffer (0.1 to 2 M TEAA) to solubilize the conjugate. This can then be lyophilized/concentrated or transferred into the appropriate buffer with a NAP column. Alternatively, dialysis can be carried out using an appropriate buffer instead
Synthesis of Modified Oligonucleotides and Conjugates
4.28.17 Current Protocols in Nucleic Acid Chemistry
Supplement 24
Figure 4.28.4 RP-HPLC of (A) the synthesis of RRRRRRRQIKIWFQNRRMKWKKGGCCK[CTCCCAGGCTCAGATC]PNA KKK and (B) analysis of the purified product.
Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
of water. Lyophilized conjugates can require a modest amount of salt to aid their solution. Often, adding a small amount of 2 M TEAA is sufficient—typically, enough to make a 10 mM solution, but in some cases up to 1 M TEAA is needed. For these latter, difficult cases, it is necessary to add concentrated
salt solution first and then dilute the solution with water. MALDI-TOF mass spectral analysis of conjugates dissolved in high salt may be problematic due to poor crystallization. Use THAP matrix (see Support Protocol 1), diluting a small amount of the sample, if necessary.
4.28.18 Supplement 24
Current Protocols in Nucleic Acid Chemistry
Figure 4.28.5
MALDI-TOF mass spectrum of the conjugate described in Figure 4.28.4.
The conjugation reaction and purification of PNA-peptide conjugates is less problematic, since aggregation with cationic peptides does not occur. However, the overall solubility of conjugates should be considered (e.g., the conjugation of hydrophobic peptides to PNA). Self-aggregation of PNA oligomers can occur at neutral pH. This is circumvented by the addition of formamide. A heated HPLC column is advisable to obtain good resolution with all conjugates synthesized. Provided that the oligonucleotide (or analog) and peptide remain soluble at the concentrations described, disulfide formation should be complete within 30 min. Reaction times significantly greater than this can cause scrambling of the disulfide bond and hence a reduction in yield. Due to the short reaction times, it is not necessary to remove oxygen from the aqueous solution.
purity ≥90%. Oligonucleotide-peptide conjugations proceed >90% according to HPLC (see Fig. 4.28.2 for an example). Due to the self-aggregation properties of some conjugates (discussed above), yields are often lower. Yields may vary between 12% for selfaggregating conjugates and 75% for minimally self-aggregating conjugates. The presence of excess peptide can be verified by MALDI-TOF mass spectral analysis using the THAP matrix (see Fig. 4.28.3). Note that mass M/2 is often observed with THAP matrix. Conversion of a PNA oligomer into a conjugate is typically 80% to 90% (see Fig. 4.28.4). Yields obtained are typically 45% to 70%. Purity of all conjugates is >90%. MALDITOF mass spectra of PNA conjugates typically show molecular mass of the conjugate, molecular mass of conjugate/2, PNA thiol, and peptide thiol (see Fig. 4.28.5).
Time Considerations Anticipated Results Good yields and good purity can be expected for both peptides and oligonucleotides. Activation of peptide or oligonucleotide thiol groups proceeds near quantitatively (as judged by HPLC analysis). However, after isolation of the desired activated material, a typical yield is ≥85%. Liberation of the thiol from oligonucleotides typically proceeds >90%, sometimes quantitatively. For PNA synthesis, yields of ∼20% are expected after purification, depending on the sequence and length, with
The assembly of peptides and PNA can be completed within hours depending on the length of the oligomer. Allow 1 to 3 hr to program and set up the machine as well as prepare reagents, and then ∼1 hr per cycle. Oligonucleotide synthesis is more rapid, with cycles of 15 to 30 min. Conjugations are typically finished within 30 min. HPLC purification for oligo-peptide conjugates is 30 min per run. Dialysis is usually achieved with one change of water allowing at least 6 hr between (resulting in
Synthesis of Modified Oligonucleotides and Conjugates
4.28.19 Current Protocols in Nucleic Acid Chemistry
Supplement 24
≥1 × 106 dilution of salt content). Purification of PNA-peptide conjuates takes 45 min. Starting with synthesis of the peptide and oligonucleotide (or analog), allow 2 to 3 weeks for the synthesis of conjugates altogether. Allow longer if experience is short in these areas and/or more than one peptide or oligonucleotide is being synthesized. If the oligonucleotide and peptide are obtained commercially, allow at least 1 week for the synthesis and analysis of conjugates.
Literature Cited Antopolsky, M., Azhayeva, E., Tengvall, U., Auriola, S., J¨aa¨ skel¨ainen, I., R¨onkk¨o, S., Honkakoski, P., Urtti, A., L¨onnberg, H., and Azhayev, A. 1999. Peptide-oligonucleotide phosphorothioate conjugates with membrane translocation and nuclear localization properties. Bioconjug. Chem. 10:598-606. Astriab-Fisher, A., Sergueev, D.S., Fisher, M., Shaw, B.R., and Juliano, R.L. 2000. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 60:83-90. Bennett, C.F., Chiang, M.-Y., Chan, H., Shoemaker, J.E.E., and Mirabelli, C.K. 1992. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1023-1033. Bongartz, J.P., Aubertin, A.M., Milhaud, P.G., and Lebleu, B. 1994. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucl. Acids Res. 22:4681-4688. Braun, K., Peschke, P., Pipkorn, R., Lampel, S., Wachsmuth, M., Waldeck, W., Friedrich, E., and Debus, J. 2002. A biological transporter for the delivery of peptide nucleic acids (PNAs) to the nuclear compartment of living cells. J. Mol. Biol. 318:237-243. Chiu, Y.-L., Ali, A., Chu, C., Cao, H., and Rana, T.M. 2004. Visualizing a correlation between siRNA, localization, cellular uptake and RNAi in living cells. Chem. Biol. 11:1165-1175. Corey, C.R. 1995. 48000-fold acceleration of hybridisation by chemically modified oligonucleotides. J. Amer. Chem. Soc. 117:93739374. Eritja, R., Pons, A., Escarceller, M., Giralt, E., and Albericio, F. 1991. Synthesis of defined peptide-oligonucleotide hybrids containing a nuclear transport signal sequence. Tetrahedron 47:4113-4120.
Disulfide Conjugation of Peptides to Oligonucleotides and Their Analogs
Gait, M.J. 2003. Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell. Mol. Life Sci. 60:1-10.
enters cells by macropinocytosis. J. Control Release 102:247-253. Kaushik, N., Basu, A., Palumbo, P., Nyers, R.L., and Pandey, V.N. 2002. Anti-TAR polyamide nucleotide analog conjugated with a membranepermeating peptide inhibits Human Immunodeficiency Virus Type I production. J. Virol. 76:3881-3891. Kilk, K., Elmquist, A., Saar, K., Pooga, M., Land, T., Bartfai, T., Soomets, U., and Langel, U. 2004. Targeting of antisense PNA oligomers to human galanin receptor type 1 mRNA. Neuropeptides 38:316-324. Koppelhus, U., Awasthi, S.K., Zachar, V., Holst, H.U., Ebbeson, P., and Nielsen, P.E. 2002. Celldependent differential cellular uptake of PNA, peptides and PNA-peptide conjugates. Antisense & Nucleic Acid Drug Dev. 12:51-63. Lindgren, M., H¨allbrink, M., Prochiantz, A., and Langel, U. 2000. Cell-penetrating peptides. Trends Pharmacol. Sci. 21:99-103. Lindsay, M.A. 2002. Peptide-mediated cell delivery: Application in protein target validation. Curr Opin Pharmacol 2:587-594. Lochmann, D., Jauk, E., and Zimmer, A. 2004. Drug delivery of oligonucleotides by peptides. Eur. J Pharm. Biopharm. 58:237-251. Muratovska, A. and Eccles, M.R. 2004. Conjugate for efficient delivery of short interfering RNA (siRNA) into mamalian cells. FEBS Lett. 558:63-68. Nitin, N., Santangelo, P.J., Kim, G., Nie, S., and Bao, G. 2004. Peptide-linked molecular beacons for efficient delivery and rapid mRNA detection in living cells. Nucl. Acids Res. 32:e58. Pooga, M., Soomets, U., H¨allbrink, M., Valkna, A., Saar, K., Rezaei, K., Kahl, U., Hao, J.-X., Xu, X.-J., Wiesenfeld-Hallin, Z., H¨okfelt, T., Bart¨ 1998. Cell penetrating fai, T., and Langel, U. PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16:857-861. Potocky, T.B., Menon, A.K., and Gellman, S.H. 2003. Cytoplasmic and nuclear delivery of a TAT-derived peptide and a β-peptide after endocytic uptake into HeLa cells. J. Biol. Chem. 278:50188-50194. Prater, C.E. and Miller, P. 2004. 3 Methylphosphonate-modified oligo-2 -Omethytlribonucleotides and their Tat peptide conjugates: Uptake and stability in mouse fibroblasts in culture. Bioconjug. Chem. 15:498-507. Richard, J.-P., Melikov, K., Viv`es, E., Ramos, C., Verbeure, B., Gait, M.J., Chernomordik, L.V., and Lebleu, B. 2003. Cell-penetrating peptides. A re-evaluation of the mechanism of cellular uptake. J. Biol. Chem. 278:585-590.
Juliano, R.L. 2005. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. Curr. Opin. Mol. Ther. 7:132-138.
Shi, F. and Hoekstra, D. 2004. Effective intracellular delivery of oligonucleotides in order to make sense of antisense. J. Control Release 97:189-209.
Kaplan, I.M., Wadia, J.S., and Dowdy, S.F. 2005. Cationic TAT peptide transduction domain
Stetsenko, D.A., Arzumanov, A.A., Korshun, V.A., and Gait, M.J. 2000. Peptide conjugates of
4.28.20 Supplement 24
Current Protocols in Nucleic Acid Chemistry
oligonucleotides as enhanced antisense agents: A review. Mol. Biol. (Russ.) 34:852-859. Thierry, A.R., Viv`es, E., Richard, J.-P., Prevot, P., Martinand-Mari, C., Robbins, I., and Lebleu, B. 2003. Cellular uptake and intracellular fate of antisense oligonucleotides. Curr. Opin. Mol. Ther. 5:133-138. Tripathi, S., Chaubey, B., Ganguly, S., Harris, D., Casale, R.A., and Pandey, P.K. 2005. Anti-HIV1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides. Nucl. Acids Res. 33:4345-4356. Turner, J.J., Arzumanov, A.A., and Gait, M.J. 2005a. Synthesis, cellular uptake and HIV1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides. Nucl. Acids Res. 33:27-42. Turner, J.J., Ivanova, G.D., Verbeure, B., Williams, D., Arzumanov, A., Abes, S., Lebleu, B., and Gait, M.J. 2005b. Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucl. Acids Res. 33:6837-6849. Viv`es, E. and Lebleu, B. 1997. Selective coupling of a highly basic peptide to an oligonucleotide. Tetrahedron Lett. 38:1183-1186. Wadia, J.S. and Dowdy, S.F. 2002. Protein transduction technology. Curr. Opin. Biotechnol. 13:52-56.
Zamecnik, P.C. and Stephenson, M.L. 1978. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 75:280-284. Zatsepin, T.S., Turner, J.J., Oretskaya, T.S., and Gait, M.J. 2005. Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. Curr. Pharm. Des. 11:3639-3654. Ziegler, A., Nervi, P., D¨urrenberger, M., and Seelig, J. 2005. The cationic cell-penetrating peptide CPPTat derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: Optical, biphysical, and metabolic evidence. Biochemistry 44:138-148. Zorko, M. and Langel, U. 2005. Cell-penetrating peptides: Mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 57:529-545. Zubin, E.M., Romanova, E.A., and Oretskaya, T.S. 2002. Modern methods for the synthesis of peptide-oligonucleotide conjugates. Russ. Chem. Rev. 71:239-264.
Contributed by John J. Turner, Donna Williams, David Owen, and Michael J. Gait Medical Research Council, Laboratory of Molecular Biology Cambridge, United Kingdom
Synthesis of Modified Oligonucleotides and Conjugates
4.28.21 Current Protocols in Nucleic Acid Chemistry
Supplement 24
Methoxyoxalamido Chemistry in the Synthesis of Tethered Phosphoramidites and Functionalized Oligonucleotides
UNIT 4.29
This unit elaborates on the synthesis of specialty phosphoramidites tethered with single or multiple linkers through the use of methoxyoxalamido (MOX) precursors. The strategy is based on the reaction of dimethyl oxalate with a proper aliphatic amine (phosphoramidite base) to form a MOX precursor that, in turn, is reacted with a selected primary aliphatic amine (linker) to form a simple tethered synthon for phosphoramidite preparation (Fig. 4.29.1). The strategy is quite general since a vast number of commercially available primary aliphatic amines can be employed. Basic Protocol 1 describes syntheses of exemplary phosphoramidites tethered with single linkers. Additional flexibility of the MOX strategy comes from the possibility of reiterating the dimethyl oxalate/primary diamine treatments leading to synthons with multiple linkers (Fig. 4.29.2). Synthesis of selected phosphoramidites with tethers is outlined in the Alternate Protocol. Finally, Basic Protocol 2 describes the use of tethered phosphoramidites for 5 -derivatization of oligonucleotides.
Figure 4.29.1 Synthetic pathway for phosphoramidites tethered with a single linker. MOX, methoxyoxalamido; DMTr, dimethoxytrityl; MMTr, monomethoxytrityl.
Synthesis of Modified Oligonucleotides and Conjugates
Contributed by Alan M. Morocho and Nikolai N. Polushin
4.29.1
Current Protocols in Nucleic Acid Chemistry (2006) 4.29.1-4.29.19 C 2006 by John Wiley & Sons, Inc. Copyright
Supplement 25
Figure 4.29.2 Synthetic pathway to phosphoramidites tethered with multiple linkers. MOX, methoxyoxalamido; DMTr, dimethoxytrityl; MMTr, monomethoxytrityl; n = number of cycles.
BASIC PROTOCOL 1
PREPARATION OF PHOSPHORAMIDITES TETHERED WITH SINGLE LINKERS Synthetic procedures for preparation of specialty phosphoramidites using MOX chemistry are all straightforward and robust. All necessary chemicals are commercially available and generally inexpensive. One of the starting reagents, 5 -amino-5 deoxythymidine, is somewhat expensive but can be prepared from inexpensive thymidine as described by Bannwarth (1988). There are four major steps in the synthesis of a phosphoramidite tethered with a single linker. First, the MOX derivative is prepared from a proper amino alcohol (phosphoramidite base). Second, the MOX precursor is treated with a primary aliphatic diamine or a primary amino alcohol to form an aminated or hydroxylated tether synthon. Next, the primary amino or hydroxyl group is protected with a monomethoxytrityl (MMTr) or dimethoxytrityl (DMTr) group, respectively. Lastly, the secondary hydroxyl of the MMTr/DMTr-protected intermediate is phosphinylated to give the final phosphoramidite.
Methoxyoxalamido Chemistry for Tethered Phosphoramidites
4.29.2 Supplement 25
Current Protocols in Nucleic Acid Chemistry
Figure 4.29.3 depicts structures of the initial MOX precursors S.1 and S.2. Figure 4.29.4 shows phosphoramidites tethered with single aminated linkers (S.3d-S.6d) and their intermediates (S.3a,c-S.6a,c). Figure 4.29.5 shows phosphoramidites tethered with single hydroxylated linkers (S.10d and S.11d) and their precursors (S.10a,c and S.11a,c). Note that the b intermediate for S.5, S.6, and S.8 is used only for the formation of the tethered compounds described in the Alternate Protocol. The following considerations are important in strategic planning for the syntheses described in this unit: Choice of starting material (phosphoramidite base). The choice of starting materials, trans-4-aminocyclohexanol hydrochloride and 5 -amino-5 -deoxythymidine, is based on their availability and the presence of secondary hydroxyl groups, which imparts stability to the corresponding phosphoramidites. Formation of MOX precursors. At least a 2-fold excess of dimethyl oxalate over the amino alcohol should be used to suppress formation of a dimer byproduct. Addition of triethylamine, although not necessary in the case of free amines, does accelerate the reaction. In the case of trans-4-aminocyclohexanol hydrochloride, at least one equivalent of triethylamine must be added to free the protonated amino group. Reaction of MOX precursor with an aliphatic primary diamine. To suppress dimer formation, at least a 4-fold molar excess of diamine over the MOX precursor (S.1 or S.2) should be used. Typically, simple precipitation of the product (S.3a-S.6a) in ether gives purity acceptable to perform the next step. If the diamine used is of a substantial value, it can be recovered from the supernatant by distillation or crystallization. Reaction of MOX precursor with an aliphatic primary amino alcohol. Since only one amino group is available to react with a MOX precursor, only one equivalent of an amino alcohol is needed. Again, the product (S.10a, S.11a) is purified simply by precipitation in ether. Protection of primary amino/hydroxyl group. Due to poor solubility of amino alcohols S.3a-S.6a in pyridine, reaction with MMTr-Cl is carried out in 1:1 (v/v) dimethylformamide (DMF)/pyridine. Even in this solvent composition, the starting materials are not fully soluble, and the reaction mixture is stirred for 2 to 3 days to ensure complete transformation. Diols S.10a and S.11a are soluble in 1:1 DMF/pyridine, and the reaction with DMTr-Cl is generally complete within 12 hr. After extraction and concentration, the product is precipitated into 3:2 (v/v) ether/pentane and is normally used in the next step without further purification. However, if the purity of the MMTr/DMTr-protected intermediate is <85% (based on NMR and TLC analyses), column purification is recommended.
Figure 4.29.3
Initial MOX precursors.
Synthesis of Modified Oligonucleotides and Conjugates
4.29.3 Current Protocols in Nucleic Acid Chemistry
Supplement 25
Figure 4.29.4
Phosphoramidites and precursors with simple or multiple aminated linkers. MMTr, monomethoxytrityl.
Phosphinylation. MMTr-protected amino alcohols S.3c-S.6c and DMTr-protected diols S.10c-S.11c are phosphinylated with 2-cyanoethyl-N,N,N ,N -tetraisopropylphosphorodiamidite in dry CH2 Cl2 in the presence of tetrazole. The corresponding phosphoramidites (S.3d-S.6d and S.10d-S.11d) are then purified by column chromatography on silica gel. Compound characterization 1 H and 31 P NMR spectra were recorded on a Varian XL-300 spectrometer at 300 and 121 MHz, respectively, in DMSO-d6 unless otherwise noted. Chemical shifts (δ) are reported in ppm downfield from tetramethylsilate (TMS) for 1 H NMR and from H3 PO4 for 31 P NMR. Electrospray ionization mass spectra (ESI-MS) were recorded on a Mariner spectrometry system (PerSeptive Biosystems) with samples dissolved in 1:1 (v/v) methanol/water.
Materials
Methoxyoxalamido Chemistry for Tethered Phosphoramidites
trans-4-Amino-1-cyclohexanol hydrochloride (97%; Aldrich) Triethylamine (Et3 N), ≥99% Methanol (MeOH), HPLC grade Dimethyl oxalate, 99% (Aldrich) Diethyl ether, anhydrous Chloroform (CHCl3 ), HPLC grade
4.29.4 Supplement 25
Current Protocols in Nucleic Acid Chemistry
◦
60 A silica gel, 200 to 400 mesh (EM Science) 5 -Amino-5 -deoxythymidine (Berry & Associates, http://www.berryassoc.com or Fidelity Systems, http://www.fidelitysystems.com) Aliphatic primary diamines Ethylenediamine (EDA), ≥99.5% (Aldrich) for S.3a 2,4,8,10-Tetraoxaspiro[5.5]undecane-3,9-dipropanamine (TUDA), 97% (Aldrich) for S.4a 4,7,10-Trioxa-1,13-tridecanediamine (TTDD), ≥98% (Aldrich) for S.5a and S.6a Aliphatic primary amino alcohols 6-Amino-1-hexanol (AH), 97% (Aldrich) for S.11a 2-(2-Aminoethoxy)ethanol (AEE), 98% (Aldrich) for S.10a Dichloromethane (CH2 Cl2 ), HPLC grade N,N-Dimethylformamide (DMF), anhydrous Pyridine, anhydrous, 99.8% (Aldrich) 4-Monomethoxytrityl chloride (MMTr-Cl; ChemGenes) Saline solution: 25% to 30% (w/v) aqueous NaCl Na2 SO4 , reagent grade, anhydrous Pentane, HPLC grade 4,4 -Dimethoxytrityl chloride (DMTr-Cl; ChemGenes) Tetrazole, dried Argon gas 2-Cyanoethyl-N,N,N ,N -tetraisopropylphosphorodiamidite (ChemGenes) 10% (w/v) aqueous sodium hydrogen carbonate (NaHCO3 ) Dichloromethane (CH2 Cl2 ), anhydrous Ethyl acetate (EtOAc), HPLC grade Toluene, anhydrous Phosphorus pentoxide (P2 O5 ) Rotary evaporator equipped with a vacuum pump or water aspirator (5 to 10 Torr) Buchner funnel, 140-mL capacity with glass frit (porosity 4 to 8 µm) Paper filters (coarse porosity) 4 × 40–cm sintered glass columns Vacuum oil pump (0.05 to 0.5 Torr) Separatory funnel Thin-layer chromatography (TLC) Kieselgel 60 F254 plates (EM Science) I2 -silica chamber 254-nm UV lamp Heat gun Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E) Prepare MOX precursors For compound S.1 from trans-4-aminocyclohexanol 1a. Prepare a solution of 3.03 g (20 mmol) trans-4-amino-1-cyclohexanol and 5.6 mL (40 mmol) Et3 N in 40 mL MeOH. 2a. In a separate flask dissolve 4.72 g (40 mmol) dimethyl oxalate in 20 mL MeOH. 3a. Add the solution of trans-4-amino-1-cyclohexanol and Et3 N dropwise over 2 hr to the stirring solution of dimethyl oxalate. 4a. Concentrate the reaction mixture on a rotary evaporator to ∼20 mL. Add 200 mL diethyl ether while stirring.
Synthesis of Modified Oligonucleotides and Conjugates
4.29.5 Current Protocols in Nucleic Acid Chemistry
Supplement 25
Figure 4.29.5
Phosphoramidites and precursors with simple or multiple hydroxylated linkers. DMTr, dimethoxytrityl.
5a. Filter the precipitate under vacuum using a Buchner funnel, and wash twice with 30 mL diethyl ether. Dissolve the precipitate in 60 mL CHCl3 . ◦
6a. Pack a 4 × 40–cm sintered glass column with 100 g of 60 A silica gel in CHCl3 . Load the sample and run a gradient of 0% to 10% MeOH in CHCl3 . Collect and pool fractions containing the desired compound. Identify the correct fractions by TLC using UV or I2 staining for visualization. Evaporate solvent on a rotary evaporator. The large sample volume does not require concentration before loading onto the column because the loading solvent is nonpolar and will not push the compound through the column.
7a. Dry the resulting white crystals overnight in vacuo (vacuum pump, 0.05 to 0.5 Torr) to yield 3.27 g (81%) of S.1 as a white solid. 8a. Characterize the product by TLC, 1 H NMR, and ESI-MS.
Methoxyoxalamido Chemistry for Tethered Phosphoramidites
S.1: TLC (9:1 CHCl3 /MeOH): Rf = 0.3. 1 H NMR (DMSO-d6 ): δ 8.67-8.82 (d, 1H, NH), 4.55-4.62 (d, 1H, OH), 3.73-3.80 (s, 3H, OCH3 ), 3.44-3.66 (m, 1H, H4), 3.25-3.44 (m, 1H, H1), 1.62-1.91 (m, 4H, 2CH2 ), 1.08-1.50 (m, 4H, 2CH2 ). ESI-MS: m/z 201.8 (M + H+ ), 223.7 (M + Na+ ), 239.8 (M + K+ ); calcd. for C5 H9 NO4 : 201.2.
4.29.6 Supplement 25
Current Protocols in Nucleic Acid Chemistry
For compound S.2 from 5 -amino-5 -deoxythymidine 1b. Prepare a solution of 4.82 g (20 mmol) 5 -amino-5 -deoxythymidine and 2.8 mL (20 mmol) Et3 N in 40 mL MeOH. 2b. In a separate flask dissolve 4.72 g (40 mmol) dimethyl oxalate in 20 mL MeOH. 3b. Add the solution of 5 -amino-5 -deoxythymidine and Et3 N dropwise over 2 hr to the stirring solution of dimethyl oxalate. 4b. Concentrate the reaction mixture on a rotary evaporator to ∼20 mL. Add 200 mL diethyl ether while stirring. 5b. Filter the precipitate under vacuum using a Buchner funnel, and wash twice with 30 mL diethyl ether. Dissolve the precipitate in 80 mL CHCl3 . ◦
6b. Pack a 4 × 40–cm sintered glass column with 100 g of 60 A silica gel in CHCl3 . Load the sample and run a gradient of 0% to 10% MeOH in CHCl3 . Collect and pool fractions containing the desired compound. Identify the correct fractions by TLC using UV or I2 staining for visualization. Evaporate solvent on a rotary evaporator. 7b. Dry the resulting white crystals overnight in vacuo (vacuum pump, 0.05 to 0.5 Torr) to yield 6.15 g (94%) of S.2 as a white solid. 8b. Characterize the product by TLC, 1 H NMR, and ESI-MS. S.2: TLC (8:2 CHCl3 /MeOH): Rf = 0.32. 1 H NMR (DMSO-d6 ): δ 11.27-11.37 (s, 1H, HN-3), 9.03-9.19 (t, 1H, COCONH), 7.49-7.54 (s, 1H, H6), 6.09-6.21 (t, 1H, H1 ), 5.305.38 (d, 1H, OH-3 ), 4.12-4.26 (m, 1H, H3 ), 3.74-3.93 (m, 4H, H4 +OCH3 ), 3.28-3.50 (m, 2H, CH2 -5 ), 1.95-2.23 (m, 2H, H2 ,2 ), 1.73-1.90 (s, 3H, CH3 -5). ESI-MS: m/z 349.9 (M + Na+ ); calcd. for C13 H17 N3 O7 : 327.29.
Derivatize MOX precursor 9. Dissolve an aliphatic primary diamine (40 mmol) or an aliphatic primary amino alcohol (12 mmol) in 50 mL MeOH and stir vigorously. 10. Dissolve 10 mmol of MOX precursor (S.1 or S.2) in 25 mL of 1:1 (v/v) MeOH/CH2 Cl2 (HPLC grade) and add to the diamine or amino alcohol solution in portions over 30 min. 11. Stir the reaction mixture for 2 hr. During this time a partial precipitation of product is typically observed.
12. Add 300 mL diethyl ether. Cool the suspension to 4◦ C for 2 hr to complete the precipitation. 13. Filter the precipitate under vacuum using a Buchner funnel. Wash the solid twice with 30 mL diethyl ether and dry overnight in vacuo (vacuum pump, 0.05 to 0.5 Torr). 14. Characterize the compound by TLC, 1 H NMR, and ESI-MS. From aliphatic primary diamine: S.3a from S.1 and EDA (95%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0. 1 H NMR (DMSOd6 ): δ 8.56-8.67 (t, 1H, CH2 -NH-COCO), 8.37-8.48 (d, 1H, COCO-NH-ACH), 4.48-4.58 (d, 1H, OH), 3.43-3.58 (m, 1H, H4 (ACH)), 3.25-3.40 (m, 1H, H1 (ACH)), 3.04-3.13 (q, 2H, CH 2 -NH-COCO), 2.55-2.63 (t, 2H, NH2 -CH 2 ), 1.72-1.85 (br d, 2H, 2 × CH (ACH)), 1.58-1.70 (br d, 2H, 2 × CH (ACH)), 1.29-1.48 (m, 2H, 2 × CH (ACH)), 1.081.26 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 230.4 (M + H+ ); calcd. for C10 H19 N3 O3 : 229.1.
Synthesis of Modified Oligonucleotides and Conjugates
4.29.7 Current Protocols in Nucleic Acid Chemistry
Supplement 25
S.4a from S.1 and TUDA (77%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0. 1 H NMR (DMSO-d6 ): δ 8.69-8.79 (t, 1H, CH2 -NH-COCO), 8.38-8.49 (d, 1H, COCO-NH-ACH), 4.40-4.53 (m, 2H, 2 × CH2 -CH-(O-)2 (spiro ring)), 4.19-4.31 (br d, 2H, 2 × CH (spiro ring)), 3.44-3.62 (m, 5H, 4 × CH (spiro ring) + H4 (ACH)), 3.27-3.40 (m, 3H, 2 × CH (spiro ring) + H1 (ACH)), 3.03-3.18 (q, 2H, CH 2 -NH-COCO), 2.46-2.52 (m, H2 NCH 2 ), 1.74-1.88 (m, 2H, 2 × CH (ACH)), 1.60-1.73 (m, 2H, 2 × CH (ACH)), 1.31-1.59 (m, 10H, 4 × CH2 + 2 × CH (ACH)), 1.09-1.29 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 444.1 (M + H+ ); calcd. for C21 H37 N3 O7 : 443.3. S.5a from S.1 and TTDD (85%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0. 1 H NMR (DMSO-d6 ): δ 8.67-8.80 (t, 1H, CH2 -NH-COCO), 8.40-8.55 (d, 1H, COCO-NH-ACH), 4.35-4.80 (br s, 1H, OH), 3.11-3.58 (m, 16H, 6 × CH2 -CH 2 -O + H4 (ACH) + H1 (ACH) + CH 2 -NH-COCO), 2.53-2.62 (t, 2H, NH2 -CH 2 ), 1.32-1.87 (m, 10H, 6 × CH (ACH) + 2 × CH2 -CH 2 -CH2 ), 1.10-1.28 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 390.0 (M + H+ ), 412.0 (M + Na+ ); calcd. for C18 H35 N3 O6 : 389.2. S.6a from S.2 and TTDD (82%). TLC (8:2 CHCl3 /MeOH, UV): Rf = 0. 1 H NMR (DMSOd6 ): δ 8.70-8.97 (m, 2H, (CH2 )3 -NH-COCO + COCO-NH-5 ), 7.42-7.51 (s, 1H, H6), 6.08-6.18 (t, 1H, H1 ), 4.15-4.23 (m, 1H, H3 ), 3.81-3.90 (m, 1H, H4 ), 3.28-3.56 (m, 14H, 6 × CH2 -CH 2 -O + H5 ,5 ), 3.13-3.26 (m, 2H, (CH2 )2 -CH 2 -NH-COCO), 2.522.62 (m, 2H, NH2 -CH 2 ), 1.97-2.15 (m, 2H, H2 ,2 ), 1.77-1.85 (s, 3H, CH3 -5), 1.49-1.75 (m, 4H, CH2 -CH 2 -CH2 ). ESI-MS: m/z 517.0 (M + H+ ); calcd. for C22 H37 N5 O9 : 515.3. From aliphatic primary amino alcohol: S.10a from S.1 and AEE (77%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.16. 1 H NMR (DMSO-d6 ): δ 8.58-8.65 (t, 1H, CH2 -NH-COCO), 8.45-8.52 (d, 1H, COCO-NH-ACH), 4.53-4.62 (m, 2H, HO-CH2 + ACH-OH), 3.23-3.59 (m, 10H, 3 × CH2 -CH 2 -O + H4 (ACH) + CH 2 -NH-COCO + H1 (ACH)), 1.75-1.86 (br d, 2H, 2 × CH (ACH)), 1.601.71 (br d, 2H, 2 × CH (ACH)), 1.32-1.49 (m, 2H, 2 × CH (ACH)), 1.10-1.27 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 275.6 (M + H+ ); calcd. for C12 H22 N2 O5 : 274.1. S.11a from S.1 and AH (60%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.18. 1 H NMR (DMSO-d6 ): δ 8.66-8.74 (t, 1H, CH2 -NH-COCO), 8.39-8.47 (d, 1H, COCO-NH-ACH), 4.52-4.57 (d, 1H, ACH-OH), 4.29-4.35 (t, 1H, HO-CH2 ), 3.43-3.59 (m, 1H, H4 (ACH)), 3.26-3.40 (m, 3H, CH 2 -OH + H1 (ACH)), 3.04-3.14 (q, 2H, CH 2 -NH-COCO), 1.741.85 (br d, 2H, 2 × CH (ACH)), 1.59-1.71 (br d, 2H, 2 × CH (ACH)), 1.09-1.50 (m, 12H, CH2 -(CH 2 )4 -CH2 + 4 × CH (ACH)). ESI-MS: m/z 287.7 (M + H+ ); calcd. for C14 H26 N2 O4 : 286.2.
Perform tritylation With MMTr-Cl for primary amine (S.3a-S.6a) 15a. Prepare a 10 mmol slurry of the amino alcohol in 100 mL of 1:1 (v/v) anhydrous DMF/pyridine and begin stirring. 16a. Add 11 mmol MMTr-Cl and stir at room temperature for 2 to 3 days. 17a. Dilute◦the mixture with 400 mL CHCl3 and filter through a thin (0.5 to 1 cm) layer of 60 A silica gel, under vacuum using a Buchner funnel. 18a. Transfer the filtrate to a separatory funnel and extract with 400 mL saline solution. 19a. Separate the organic layer and dry with anhydrous Na2 SO4 . Filter through a paper filter and concentrate the filtrate to ∼50 mL on a rotary evaporator. 20a. Add 300 mL diethyl ether and then 200 mL pentane with vigorous stirring. 21a. Cool the suspension to 4◦ C and maintain at this temperature for 2 hr. Methoxyoxalamido Chemistry for Tethered Phosphoramidites
22a. Filter the precipitate under vacuum using a Buchner funnel. Wash the solid twice with 30 mL of 1:1 (v/v) diethyl ether/pentane and dry overnight in vacuo (vacuum pump, 0.05 to 0.5 Torr).
4.29.8 Supplement 25
Current Protocols in Nucleic Acid Chemistry
23a. Characterize the compound by TLC, 1 H NMR, and MS. S.3c from S.3a (56%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.42. 1 H NMR (DMSO-d6 ): δ 8.75-8.84 (t, 1H, CH2 -NH-COCO), 8.40-8.48 (d, 1H, COCO-NH-ACH), 7.11-7.41 (m, 12H, MMTr), 6.78-6.86 (d, 2H, MMTr), 4.52-4.58 (d, 1H, OH), 3.69-3.74 (s, 3H, OCH3 ), 3.43-3.60 (m, 1H, H4 (ACH)), 3.20-3.40 (m, 3H, CH 2 -NH-COCO + H1 (ACH)), 2.86-2.95 (m, 1H, MMTr-NH), 2.03-2.15 (m, 2H, MMTr-NH-CH 2 ), 1.74-1.86 (br d, 2H, 2 × CH (ACH)), 1.60-1.72 (br d, 2H, 2 × CH (ACH)), 1.32-1.50 (m, 2H, 2 × CH (ACH)), 1.10-1.28 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 502.6 (M + H+ ); calcd. for C30 H35 N3 O4 : 501.3. S.4c from S.4a (67%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.45. 1 H NMR (DMSO-d6 ): δ 8.70-8.79 (t, 1H, CH2 -NH-COCO), 8.40-8.48 (d, 1H, COCO-NH-ACH), 7.11-7.41 (m, 12H, MMTr), 6.80-6.89 (d, 2H, MMTr), 4.53-4.58 (d, 1H, OH), 4.43-4.49 (t, 1H, CH2 CH-(O-)2 (spiro ring)), 4.35-4.42 (t, 1H, CH2 -CH-(O-)2 (spiro ring)), 4.19-4.28 (br d, 2H, 2 × CH (spiro ring)), 3.68-3.74 (s, 3H, OCH3 ), 3.44-3.60 (m, 5H, 4 × CH (spiro ring) + H4 (ACH)), 3.23-3.42 (m, 3H, 2 × CH (spiro ring) + H1 (ACH)), 3.05-3.16 (q, 2H, CH 2 -NH-COCO), 1.88-2.00 (m, 2H, MMTr-NH-CH 2 ), 1.75-1.86 (br d, 2H, 2 × CH (ACH)), 1.60-1.72 (br d, 2H, 2 × CH (ACH)), 1.32-1.58 (m, 10H, 4 × CH2 + 2 × CH (ACH)), 2H, 1.11-1.27 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 716.2 (M + H+ ), 738.2 (M + Na+ ); calcd. for C41 H53 N3 O8 : 715.4. S.5c from S.5a (65%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.43. 1 H NMR (DMSO-d6 ): δ 8.64-8.75 (t, 1H, CH2 -NH-COCO), 8.41-8.48 (d, 1H, COCO-NH-ACH), 7.11-7.41 (m, 12H, MMTr), 6.80-6.87 (d, 2H, MMTr), 4.53-4.58 (d, 1H, OH), 3.69-3.73 (s, 3H, OCH3 ), 3.27-3.56 (m, 14H, 6 × CH2 -CH 2 -O + H4 (ACH) + H1 (ACH)), 3.10-3.23 (q, 2H, CH 2 -NH-COCO), 2.53-2.62 (t, 1H, MMTr-NH), 1.97-2.08 (q, 2H, MMTr-NHCH 2 ), 1.74-1.86 (br d, 2H, 2 × CH (ACH)), 1.59-1.73 (m, 6H, 2 × CH2 -CH 2 -CH2 + 2 × CH (ACH)), 1.31-1.50 (m, 2H, 2 × CH (ACH)), 1.10-1.28 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 662.6 (M + H+ ), 684.6 (M + Na+ ); calcd. for C38 H51 N3 O7 : 661.4. S.6c from S.6a (83%). TLC (8:2 CHCl3 /MeOH, UV): Rf = 0.61. 1 H NMR (DMSO-d6 ): δ 11.25-11.33 (s, 1H, HN-3), 8.71-8.98 (m, 2H, (CH2 )3 -NH-COCO + COCO-NH-5 ), 7.46-7.51 (s, 1H, H6), 7.11-7.43 (m, 12H, MMTr), 6.79-6.88 (d, 2H, MMTr), 6.09-6.19 (t, 1H, H1 ), 5.29-5.36 (d, 1H, OH-3 ), 4.12-4.23 (m, 1H, H3 ), 3.82-3.91 (m, 1H, H4 ), 3.68-3.77 (s, 3H, OCH3 ), 3.28-3.59 (m, 14H, 6 × CH2 -CH 2 -O + H5 ,5 ), 3.11-3.24 (q, 2H, CH 2 -NH-COCO), 2.53-2.61 (t, 2H, MMTr-NH-CH 2 ), 1.98-2.10 (m, 2H, H2 ,2 ), 1.78-1.84 (s, 3H, CH3 -5), 1.61-1.76 (m, 4H, CH2 -CH 2 -CH2 ). ESI-MS: m/z 787.9 (M + H+ ), 810.9 (M + Na+ ); 826.9 (M + K+ ); calcd. for C42 H53 N5 O10 : 787.4.
With DMTr-Cl for primary hydroxyl (S.10a-S.11a) 15b. Dissolve 10 mmol of the alcohol in 100 mL of 1:1 (v/v) anhydrous DMF/pyridine and begin stirring. 16b. Add 3.73 g (11 mmol) DMTr-Cl and stir overnight at room temperature. Check the course of the reaction by TLC using 1:9 (v/v) MeOH/CHCl3 . Visualize TLC plates under UV or by I2 staining. If the reaction is incomplete, add an additional 0.2 equiv of DMTr-Cl and continue stirring for 5 hr. The starting compound has lower mobility and does not become orange upon heating the TLC plate with a heat gun.
17b. Dilute the mixture with 400 mL CHCl3 . 18b. Transfer the solution to a separatory funnel and extract with 400 mL saline solution. 19b. Separate the organic layer and dry with anhydrous Na2 SO4 . Filter through a paper filter and concentrate the filtrate to ∼50 mL on a rotary evaporator. 20b. Add 300 mL diethyl ether and then 200 mL pentane with vigorous stirring. 21b. Cool the suspension to 4◦ C and maintain at this temperature for 2 hr.
Synthesis of Modified Oligonucleotides and Conjugates
4.29.9 Current Protocols in Nucleic Acid Chemistry
Supplement 25
22b. Filter the precipitate under vacuum using a Buchner funnel. Wash the solid twice with 30 mL of 1:1 (v/v) diethyl ether/pentane and dry overnight in vacuo (vacuum pump, 0.05 to 0.5 Torr). 23b. Characterize the compound by TLC, 1 H NMR, and ESI-MS. S.10c from S.10a (78%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.54. 1 H NMR (DMSO-d6 ): δ 8.58-8.66 (t, 1H, CH2 -NH-COCO), 8.43-8.49 (d, 1H, COCO-NH-ACH), 7.17-7.42 (m, 9H, DMTr), 6.84-6.93 (d, 4H, DMTr), 4.52-4.56 (d, 1H, ACH-OH), 3.69-3.77 (s, 6H, OCH3 ), 3.43-3.60 (m, 5H, 2 × CH2 -CH 2 -O + H4 (ACH)), 3.25-3.39 (m, 3H, CH 2 -NHCOCO + H1 (ACH)), 2.99-3.07 (t, 2H, DMTr-O-CH 2 ), 1.73-1.85 (br d, 2H, 2 × CH (ACH)), 1.57-1.68 (br d, 2H, 2 × CH (ACH)), 1.30-1.47 (m, 2H, 2 × CH (ACH)), 1.091.26 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 599.7 (M + Na+ ); calcd. for C33 H40 N2 O7 : 576.3. S.11c from S.11a (85%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.56. 1 H NMR (DMSO-d6 ): δ 8.65-8.73 (t, 1H, CH2 -NH-COCO), 8.38-8.44 (d, 1H, COCO-NH-ACH), 7.17-7.39 (m, 9H, DMTr), 6.84-6.92 (d, 4H, DMTr), 4.52-4.57 (d, 1H, ACH-OH), 3.70-3.75 (s, 6H, 2 × OCH3 ), 3.42-3.59 (m, 1H, H4 (ACH)), 3.26-3.40 (m, 1H, H1 (ACH)), 3.02-3.13 (q, 2H, CH 2 -NH-COCO), 2.88-2.96 (t, 2H, DMTr-O-CH 2 ), 1.74-1.85 (br d, 2H, 2 × CH (ACH)), 1.60-1.70 (br d, 2H, 2 × CH (ACH)), 1.10-1.58 (m, 12H, CH2 -(CH 2 )4 -CH2 + 4 × CH (ACH)). ESI-MS: m/z 588.7 (M + H+ ); calcd. for C35 H44 N2 O6 : 588.3.
Phosphinylate secondary hydroxyl group 24. Prepare a mixture of 5 mmol dry secondary alcohol (from step 23) and 330 mg (4.75 mmol) tetrazole in 50 mL anhydrous CH2 Cl2 under a dry argon atmosphere. 25. Add 2.15 mL (6.5 mmol) 2-cyanoethyl-N,N,N,N -tetraisopropylphosphorodiamidite and stir the reaction mixture for at least 1 hr or until complete disappearance of the starting material as indicated by TLC analysis. 26. Dilute the reaction with 200 mL CH2 Cl2 (HPLC grade) and extract with 200 mL of 10% aqueous NaHCO3 . 27. Separate the organic layer, dry over anhydrous Na2 SO4 , filter off the drying agent, and concentrate to ∼20 mL on a rotary evaporator. 28. Precipitate the residue into 500 mL of 1:1 (v/v) diethyl ether/pentane and allow the product to settle. 29. Decant the supernatant and dissolve the residue in 50 mL CH2 Cl2 (anhydrous) containing 4% Et3 N. Purify the phosphoramidite by flash chromatography on 40 g silica gel (see APPENDIX 3E) using the appropriate elution solvent system:
20% to 60% (v/v) EtOAc/4% (v/v) Et3 N in pentane (for S.3d-S.5d and S.10d-S.11d) 5% to 50% (v/v) pyridine in EtOAc (for S.6d). 30. Collect and pool fractions containing the desired compound. Identify the correct fractions by TLC using UV or I2 staining for visualization. Evaporate solvent on a rotary evaporator and then co-evaporate twice with ∼50 mL toluene. 31. Dry the residue overnight in vacuo (vacuum pump, 0.05 to 0.5 Torr) over P2 O5 . 32. Characterize the compounds by TLC and 31 P NMR. S.3d from S.3c (85%). TLC (4% Et3 N in 1:1 ethyl acetate/pentane, UV): Rf = 0.50. 31 P NMR (DMSO-d6 ): δ 145.20. Methoxyoxalamido Chemistry for Tethered Phosphoramidites
S.4d from S.4c (87%). TLC (4% Et3 N in 1:1 ethyl acetate/pentane, UV): Rf = 0.35. 31 P NMR (DMSO-d6 ): δ 145.10.
4.29.10 Supplement 25
Current Protocols in Nucleic Acid Chemistry
S.5d from S.5c (91%). TLC (4% Et3 N in 1:1 ethyl acetate/pentane, UV): Rf = 0.39. 31 P NMR (DMSO-d6 ): δ 144.78. S.6d from S.6c (72%). TLC (2% Et3 N in 9:1 ethyl acetate/pyridine, UV): Rf = 0.34. 31 P NMR (DMSO-d6 ): δ 147.13, 147.09. S.10d from S.10c (85%). TLC (4% Et3 N in 1:1 ethyl acetate/pentane, UV): Rf = 0.53. 31 P NMR (DMSO-d6 ): δ 144.74. S.11d from S.11c (84%). TLC (4% Et3 N in 1:1 ethyl acetate/pentane, UV): Rf = 0.62. 31 P NMR (DMSO-d6 ): δ 145.20.
PREPARATION OF PHOSPHORAMIDITES TETHERED WITH MULTIPLE LINKERS
ALTERNATE PROTOCOL
Iterative treatment of the initial MOX precursor S.1 or S.2 with a diamine and dimethyl oxalate leads to MOX derivatives that can also be converted to phosphoramidites (Fig. 4.29.2). This protocol describes the synthesis of a number of tethered phosphoramidites when utilizing 4,7,10-trioxa-1,13-tridecanediamine (TTDD) as the linker. All of these compounds are prepared starting from S.5a and S.6a (see Basic Protocol 1) by performing a second MOX reaction to give the tethered MOX precursors S.5b and S.6b. The final iteration can be performed with a diamine to give a primary amino group (S.7a-S.9a; Fig. 4.29.4) or with an amino alcohol to give a primary hydroxyl group (S.12a-S.14a; Fig. 4.29.5). Tritylation and phosphinylation are then performed as in Basic Protocol 1. When an iteratively tethered MOX intermediate is prepared, a 4-fold excess of dimethyl oxalate is used (as opposed to a 2-fold excess in the case of MOX precursors S.1 and S.2) to minimize formation of a dimer byproduct. If needed, the excess dimethyl oxalate can be easily recovered from the reaction mixture by sublimation.
Perform second MOX reaction (prepare MOX precursors S.5b and S.6b) 1. Prepare a stirring solution of 40 mmol dimethyl oxalate and 20 mmol Et3 N in 50 mL MeOH. 2. Add 10 mmol amino alcohol S.5a or S.6a dissolved in 50 mL of 1:1 (v/v) MeOH/CH2 Cl2 to the stirring solution, portion-wise, over a 2-hr period. Portions should not exceed 5 mL. The amount of a dimer byproduct increases if the amino alcohol solution is added too quickly.
3. Stir the reaction mixture for an additional 1 hr and concentrate to dryness on a rotary evaporator. 4. Sublime the excess dimethyl oxalate at ∼5 Torr and 70◦ C. 5. Dissolve the residue in 50 mL CH2 Cl2 and purify by flash chromatography on a 4 × 40–cm column containing 60 g silica gel (APPENDIX 3E) using a 0% to 30% gradient of MeOH in CHCl3 for elution. 6. Collect and pool fractions containing the desired compound. Identify the correct fractions by TLC using UV or I2 staining for visualization. Evaporate solvent on a rotary evaporator. 7. Dry the residue overnight in vacuo (vacuum pump, 0.05 to 0.5 Torr). 8. Characterize the product by TLC, 1 H NMR, and ESI-MS. S.5b from S.5a (87%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.49. 1 H NMR (DMSO-d6 ): δ 8.83-8.93 (t, 1H, COCONH, MOX), 8.65-8.73 (t, 1H, NHCOCO), 8.38-8.46 (d, 1H, COCONH, ACH), 4.53-4.58 (d, 1H, OH, ACH), 3.73-3.78 (s, 3H, OCH3 , MOX), 3.433.57 (m, 9H, 4 × CH2 + CH), 3.25-3.43 (m, 5H, 2 × CH2 + CH), 3.10-3.24 (q, 8H, 2
Synthesis of Modified Oligonucleotides and Conjugates
4.29.11 Current Protocols in Nucleic Acid Chemistry
Supplement 25
× CH2 ), 1.58-1.84 (overlapping multiplets, 8H, + 2 × CH2 (ACH) + 2 × CH2 (ACH)), 1.30-1.49 (m, 2H, CH2 , ACH), 1.07-1.26 (m, 2H, CH2 , ACH). ESI-MS: m/z 476.3 (M + H+ ), 498.3 (M + Na+ ); calcd. for C21 H37 N3 O9 : 475.5. S.6b from S.6a (90%). TLC (8:2 CHCl3 /MeOH, UV): Rf = 0.54. 1 H NMR (DMSO-d6 ): δ 11.26-11.32 (s, 1H, HN-3), 8.81-8.94 (m, 2H, 2 × (CH2 )3 -NH-COCO), 8.69-8.80 (t, 1H, COCO-NH-5 ), 7.43-7.50 (s, 1H, H6), 6.09-6.18 (t, 1H, H1 ), 5.27-5.38 (br s, 1H, OH-3 ), 4.14-4.23 (br s, 1H, H3 ), 3.82-3.90 (m, 1H, H4 ), 3.73-3.79 (s, 3H, OCH3 ), 3.28-3.57 (m, 14H, 6 × CH2 -CH 2 -O + H5, 5 ), 3.13-3.25 (m, 4H, 2 × (CH2 )2 -CH 2 NH-COCO), 1.98-2.18 (m, 2H, H2 ,2 ), 1.78-1.86 (s, 3H, CH3 -5), 1.62-1.77 (m, 4H, CH2 -CH 2 -CH2 ). ESI-MS: m/z 625.0 (M + Na+ ); calcd. for C25 H39 N5 O12 : 601.3.
Perform second derivatization 9. Follow steps 9 to 14 of Basic Protocol 1 using TTDD to prepare amino alcohols (S.7a-S.8a) or using AEE to prepare diols (S.12a or S.13a) from S6.b and S.5b. S.7a from S.6b and TTDD (83%). TLC (8:2 CHCl3 /MeOH, UV): Rf = 0. 1 H NMR (DMSO-d6 ): δ 8.65-8.92 (m, 4H, 3 × NH-COCO + COCO-NH-5 ), 7.44-7.50 (s, 1H, H6), 6.07-6.17 (t, 1H, H1 ), 5.20-5.45 (br s, 1H, OH-3 ), 4.14-4.23 (m, 1H, H3 ), 3.813.90 (m, 1H, H4 ), 3.25-3.58 (m, 26H, 12 × CH2 -CH 2 -O + H5 ,5 ), 3.07-3.24 (m, 8H, 3 × (CH2 )2 -CH 2 -NH-COCO + NH2 -CH 2 ), 1.98-2.17 (m, 2H, H2 ,2 ), 1.77-1.85 (s, 3H, CH3 -5), 1.59-1.76 (m, 8H, CH2 -CH 2 -CH2 ). ESI-MS: m/z 790.7 (M + H+ ); calcd. for C34 H59 N7 O14 : 789.4. S.8a from S.5b and TTDD (85%). TLC (8:2 CHCl3 /MeOH, UV): Rf = 0. 1 H NMR (DMSO-d6 ): δ 8.66-8.76 (t, 3H, 3 × CH2 -NH-COCO), 8.40-8.47 (d, 1H, COCO-NHACH), 4.44-4.68 (br s, 1H, OH), 3.27-3.56 (m, 26H, 12 × CH2 -CH 2 -O + H4 (ACH) + H1 (ACH)), 3.12-3.24 (q, 6H, 3 × CH 2 -NH-COCO), 2.60-2.71 (t, 2H, NH2 -CH 2 ), 1.75-1.86 (m, 2H, 2 × CH (ACH)), 1.55-1.74 (m, 10H, 4 × CH2 -CH 2 -CH2 + 2 × CH (ACH)), 1.32-1.49 (m, 2H, 2 × CH (ACH)), 1.10-1.27 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 664.3 (M + H+ ); calcd. for C30 H57 N5 O11 : 663.4. S.12a from S.6b and AEE (89%). TLC (8:2 CHCl3 /MeOH, UV): Rf = 0.41. 1 H NMR (DMSO-d6 ): δ 11.25-11.32 (s, 1H, HN-3), 8.81-8.90 (t, 1H, (CH2 )3 -NH-COCO), 8.688.79 (m, 2H, COCO-NH-5 + NH-COCO), 8.56-8.65 (t, 1H, NH-COCO), 7.42-7.51 (s, 1H, H6), 6.08-6.18 (t, 1H, H1 ), 5.28-5.36 (d, 1H, OH-3 ), 4.55-4.64 (t, 1H, HO-CH2 ), 4.13-4.24 (m, 1H, H3 ), 3.80-3.90 (m, 1H, H4 ), 2.97-3.58 (m, 26H, 8 × CH2 -CH 2 -O + H5 ,5 + O-CH2 -CH 2 -NH-COCO + HO-CH 2 + 2 × O-CH2 -CH2 -CH 2 -N), 1.98-2.16 (m, 2H, H2 ,2 ), 1.78-1.85 (s, 3H, CH3 -5), 1.62-1.76 (m, 4H, CH2 -CH 2 -CH2 ). ESI-MS: m/z 675.8 (M + H+ ), 697.8 (M + Na+ ); calcd. for C28 H46 N6 O13 : 674.3. S.13a from S.5b and AEE (90%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.20. 1 H NMR (DMSO-d6 ): δ 8.67-8.79 (m, 2H, 2 × O-(CH2 )3 -NH-COCO), 8.58-8.65 (t, 1H, O(CH2 )2 -NH-COCO), 8.40-8.48 (d, 1H, COCO-NH-ACH), 4.53-4.63 (m, 2H, ACH-OH + HO-CH 2 ), 3.25-3.56 (m, 20H, H4 (ACH) + 8 × O-CH 2 + H1 (ACH) + O-CH2 CH 2 NHCOCO), 3.13-3.23 (m, 4H, 2 × (CH2 )2 CH 2 -NHCOCO), 3.01-3.12 (t, 2H, HO-CH 2 ), 1.60-1.86 (m, 8H, 4 × CH (ACH) + 2 × CH2 CH 2 CH2 ), 1.32-1.49 (m, 2H, 2 × CH (ACH)), 1.11-1.26 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 549.8 (M + H+ ), 571.8 (M + Na+ ); calcd. for C24 H44 N4 O10 : 548.3.
Perform third MOX reaction (prepare MOX precursor S.8b) 10. Follow steps 1 to 8 of this protocol to prepare S.8b from S.8a.
Methoxyoxalamido Chemistry for Tethered Phosphoramidites
S.8b from S.8a (71%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.48. 1 H NMR (DMSO-d6 ): δ 8.82-8.93 (t, 1H CH3 O-COCO-NH), 8.66-8.75 (t, 3H, 3 × CH2 -NH-COCO), 8.41-8.48 (d, 1H, COCO-NH-ACH), 4.53-4.57 (d, 1H, OH), 3.73-3.76 (s, 3H, CH3 O-COCO), 3.25-3.55 (m, 26H, 12 × CH2 -CH 2 -O + H4 (ACH) + H1 (ACH)), 3.11-3.21 (m, 8H, 3 × CH 2 -NH-COCO), 1.75-1.86 (m, 2H, 2 × CH (ACH)), 1.60-1.74 (m, 10H, 4 × CH2 -CH 2 -CH2 + 2 × CH (ACH)), 1.33-1.49 (m, 2H, 2 × CH (ACH)), 1.11-1.26 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 750.3 (M + H+ ); calcd. for C33 H59 N5 O14 : 749.4.
4.29.12 Supplement 25
Current Protocols in Nucleic Acid Chemistry
Perform third derivatization 11. Follow steps 9 to 14 of Basic Protocol 1 using TTDD to prepare the amino alcohol (S.9a) or using AEE to prepare the diol (S.14a) from S.8b. S.9a from S.8b and TTDD (87%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0. 1 H NMR (DMSO-d6 ): δ 8.67-8.75 (t, 5H, 5 × CH2 -NH-COCO), 8.40-8.47 (d, 1H, COCO-NHACH), 4.53-4.57 (d, 1H, OH), 3.25-3.55 (m, 38H, 18 × CH2 -CH 2 -O + H4 (ACH) + H1 (ACH)), 3.12-3.23 (q, 10H, 5 × CH 2 -NH-COCO), 2.55-2.62 (t, 2H, NH2 -CH 2 ), 1.31-1.86 (m, 18H, 6 × CH (ACH) + 6 × CH2 -CH 2 -CH2 ), 1.07-1.28 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 938.3 (M + H+ ); calcd. for C42 H79 N7 O16 : 937.6. S.14a from S.8b and AEE (91%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.16. 1 H NMR (DMSO-d6 ): δ 8.66-8.78 (m, 4H, O-(CH2 )3 -NH-COCO), 8.57-8.65 (t, 1H, O-(CH2 )2 NH-COCO), 8.40-8.47 (d, 1H, COCO-NH-ACH), 4.51-4.63 (m, 2H, HO-CH2 + ACHOH), 3.25-3.57 (m, 34H, H4 (ACH) + 16 × CH 2 + H1 (ACH)), 3.11-3.24 (q, 8H, 4 × (CH2 )2 CH 2 NHCOCO), 1.60-1.86 (m, 12H, 4 × CH (ACH) + 4 × CH2 CH 2 CH2 ), 1.30-1.49 (m, 2H, 2 × CH (ACH)), 1.09-1.27 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 845.3 (M + Na+ ); calcd. for C36 H66 N6 O15 : 822.5.
Tritylate primary amino or hydroxyl group 12. Follow steps 15a to 23a of Basic Protocol 1 to protect primary amino groups with MMTr-Cl, or steps 15b to 23b to protect primary hydroxyl groups with DMTr-Cl. S.7c from S.7a (72%). TLC (8:2 CHCl3 /MeOH, UV): Rf = 0.56. 1 H NMR (DMSO-d6 ): δ 11.25-11.33 (s, 1H, HN-3), 8.82-8.91 (t, 1H, (CH2 )3 -NH-COCO), 8.62-8.80 (m, 3H, COCO-NH-5 + 2 × NH-COCO), 7.45-7.52 (s, 1H, H6), 7.11-7.43 (m, 12H, MMTr), 6.80-6.88 (d, 2H, MMTr), 6.09-6.18 (t, 1H, H1 ), 5.29-5.36 (d, 1H, OH-3 ), 4.13-4.23 (m, 1H, H3 ), 3.82-3.90 (m, 1H, H4 ), 3.68-3.77 (s, 3H, OCH3 ), 3.28-3.59 (m, 26H, 12 × CH2 -CH 2 -O + H5 ,5 ), 3.12-3.26 (m, 6H, 3 × (CH2 )2 -CH 2 -NH-COCO), 2.53-2.61 (t, 2H, MMTr-NH-CH 2 ), 1.98-2.11 (m, 2H, H2 ,2 ), 1.78-1.84 (s, 3H, CH3 -5), 1.61-1.76 (m, 8H, CH2 -CH 2 -CH2 ). ESI-MS: m/z 1062.8 (M + H+ ); calcd. for C54 H75 N7 O15 : 1061.5. S.8c from S.8a (61%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.42. 1 H NMR (DMSO-d6 ): δ 8.66-8.75 (t, 3H, CH2 -NH-COCO), 8.41-8.48 (d, 1H, COCO-NH-ACH), 7.11-7.42 (m, 12H, MMTr), 6.80-6.88 (d, 2H, MMTr), 4.53-4.57 (d, 1H, OH), 3.69-3.74 (s, 3H, OCH3 ), 3.27-3.56 (m, 26H, 12 × CH2 -CH 2 -O + H4 (ACH) + H1 (ACH)), 3.12-3.23 (q, 6H, 3 × CH 2 -NH-COCO), 2.53-2.61 (t, 1H, MMTr-NH), 1.97-2.08 (q, 2H, MMTr-NH-CH 2 ), 1.75-1.86 (br d, 2H, 2 × CH (ACH)), 1.60-1.74 (m, 10H, 4 × CH2 -CH 2 -CH2 + 2 × CH (ACH)), 1.32-1.50 (m, 2H, 2 × CH (ACH)), 1.12-1.27 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 936.4 (M + H+ ); calcd. for C50 H73 N5 O12 : 935.5. S.9c from S.9a (66%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.40. 1 H NMR (DMSO-d6 ): δ 8.67-8.75 (t, 5H, CH2 -NH-COCO), 8.41-8.48 (d, 1H, COCO-NH-ACH), 7.11-7.42 (m, 12H, MMTr), 6.80-6.88 (d, 2H, MMTr), 4.52-4.57 (d, 1H, OH), 3.68-3.74 (s, 3H, OCH3 ), 3.25-3.56 (m, 38H, 18 × CH2 -CH 2 -O + H4 (ACH) + H1 (ACH)), 3.11-3.23 (q, 10H, 5 × CH 2 -NH-COCO), 2.53-2.60 (t, 1H, MMTr-NH), 1.97-2.08 (q, 2H, MMTr-NH-CH 2 ), 1.75-1.86 (br d, 2H, 2 × CH (ACH)), 1.60-1.74 (m, 14H, 6 × CH2 -CH 2 -CH2 + 2 × CH (ACH)), 1.30-1.50 (m, 2H, 2 × CH (ACH)), 1.12-1.27 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 1210.3 (M + H+ ); calcd. for C62 H95 N7 O17 : 1209.7. S.12c from S.12a (81%). TLC (8:2 CHCl3 /MeOH, UV): Rf = 0.66. 1 H NMR (DMSOd6 ): δ 11.27-11.30 (s, 1H, HN-3), 8.82-8.89 (t, 1H, (CH2 )3 -NH-COCO), 8.71-8.78 (m, 2H, COCO-NH-5 + NH-COCO), 8.58-8.65 (t, 1H, NH-COCO), 7.45-7.48 (s, 1H, H6), 7.19-7.41 (m, 9H, DMTr), 6.85-6.91 (d, 4H, DMTr), 6.09-6.15 (t, 1H, H1 ), 5.32-5.35 (d, 1H, OH-3 ), 4.15-4.22 (m, 1H, H3 ), 3.82-3.89 (m, 1H, H4 ), 3.71-3.75 (s, 6H, OCH3 ), 3.29-3.59 (m, 20H, 8 × CH2 -CH 2 -O + H5 ,5 + O-CH2 -CH 2 -NH-COCO), 3.14-3.23 (m, 4H, 2 × (CH2 )2 -CH 2 -NH-COCO), 3.01-3.11 (t, 2H, DMTr-O-CH 2 ), 1.99-2.15 (m, 2H, H2 ,2 ), 1.78-1.82 (s, 3H, CH3 -5), 1.62-1.74 (m, 4H, CH2 -CH 2 -CH2 ). ESI-MS: m/z 697.8 (M – DMTr + Na+ ), 999.9 (M + Na+ ); calcd. for C49 H64 N6 O15 : 976.4.
Synthesis of Modified Oligonucleotides and Conjugates
4.29.13 Current Protocols in Nucleic Acid Chemistry
Supplement 25
S.13c from S.13a (75%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.42. 1 H NMR (DMSO-d6 ): δ 8.59-8.79 (m, 3H, 2 × O-(CH2 )3 -NH-COCO + O-(CH2 )2 -NH-COCO), 8.41-8.47 (d, 1H, COCO-NH-ACH), 7.17-7.42 (m, 9H, DMTr), 6.85-6.91 (d, 4H, DMTr), 4.53-4.57 (d, 1H, ACH-OH), 3.70-3.77 (s, 6H, 2 × OCH3 ), 3.28-3.60 (m, 20H, H4 (ACH) + 8 × O-CH 2 + H1 (ACH) + O-CH2 CH 2 -NHCOCO), 3.12-3.23 (m, 4H, 2 × (CH2 )2 CH 2 NHCOCO), 3.00-3.07 (t, 2H, DMTr-O-CH 2 ), 1.75-1.87 (m, 2H, 2 × CH (ACH)), 1.611.74 (m, 6H, 2 × CH2 CH 2 CH2 + 2 × CH (ACH)), 1.32-1.49 (m, 2H, 2 × CH (ACH)), 1.10-1.27 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 571.6 (M – DMTr + Na+ ), 873.7 (M + Na+ ); calcd. for C45 H62 N4 O12 : 850.4. S.14c from S.14a (86%). TLC (9:1 CHCl3 /MeOH, UV): Rf = 0.41. 1 H NMR (DMSO-d6 ): δ 8.66-8.77 (m, 4H, 4 × O-(CH2 )3 -NH-COCO), 8.58-8.64 (t, 1H, O-(CH2 )2 -NH-COCO), 8.40-8.46 (d, 1H, COCO-NH-ACH), 7.17-7.42 (m, 9H, DMTr), 6.85-6.92 (d, 4H, DMTr), 4.52-4.56 (d, 1H, ACH-OH), 3.70-3.78 (s, 6H, 2 × OCH3 ), 3.28-3.60 (m, 32H, H4 (ACH) + 15 × CH 2 + H1 (ACH)), 3.14-3.28 (q, 8H, 4 × (CH2 )2 CH 2 NHCOCO), 3.02-3.08 (t, 2H, DMTr-O-CH 2 ), 1.75-1.86 (m, 2H, 2 × CH (ACH)), 1.61-1.74 (m, 10H, 4 × CH2 CH 2 CH2 + 2 × CH (ACH)), 1.32-1.50 (m, 2H, 2 × CH (ACH)), 1.09-1.28 (m, 2H, 2 × CH (ACH)). ESI-MS: m/z 845.3 (M – DMTr + Na+ ); calcd. for C57 H84 N6 O17 : 1124.6.
Phosphinylate secondary hydroxyl group 13. Follow steps 24 to 32 of Basic Protocol 1 to phosphinylate the secondary hydroxyl of the MMTr/DMTr-protected intermediates. To purify the phosphoramidites by flash chromatography, use the following elution solvent systems: 5% to 50% (v/v) pyridine in EtOAc (for S.7d and S.12d) 40% to 100% (v/v) EtOAc/4% (v/v) Et3 N in pentane (for S.8d, S.9d, S.13d, and S.14d). 7d from 7c (80%). TLC (2% Et3 N in 9:1 ethyl acetate/pyridine, UV): Rf = 0.35. 31 P NMR (DMSO-d6 ): δ 147.12, 147.10. 8d from 8c (83%). TLC (4% Et3 N in 1:1 ethyl acetate/pentane, UV): Rf = 0.37. 31 P NMR (DMSO-d6 ): δ 144.77. 9d from 9c (70%). TLC (4% Et3 N in 1:1 ethyl acetate/pentane, UV): Rf = 0.31. 31 P NMR (DMSO-d6 ): δ 144.78. 12d from 12c (68%). TLC (2% Et3 N in 9:1 ethyl acetate/pyridine, UV): Rf = 0.36. 31 P NMR (DMSO-d6 ): δ 147.12, 147.04. 13d from 13c (65%). TLC (4% Et3 N in 1:1 ethyl acetate/pentane, UV): Rf = 0.39. 31 P NMR (DMSO-d6 ): δ 144.74. 14d from 14c (69%). TLC (4% Et3 N in 1:1 ethyl acetate/pentane, UV): Rf = 0.36. 31 P NMR (DMSO-d6 ): δ 144.75. BASIC PROTOCOL 2
Methoxyoxalamido Chemistry for Tethered Phosphoramidites
SYNTHESIS, DEPROTECTION, AND PURIFICATION OF OLIGONUCLEOTIDES DERIVATIZED WITH TETHERED PHOSPHORAMIDITES All tethered phosphoramidites described in this unit are based on cyclic carbon scaffolds with a secondary hydroxyl, and are therefore as stable as standard phosphoramidites. They can be stored for years at −20◦ C. After phosphoramidite installation on the synthesizer, the coupling yields do not deteriorate for at least 2 weeks. The described phosphoramidites are generally as reactive as standard phosphoramidites. However, if tetrazole is used as a catalyst, it is recommended to increase coupling time to 3 to 5 min to ensure complete incorporation. If the more potent 5-ethyl-thio tetrazole (ETT) is used, coupling time could be reduced to 1 to 3 min. For higher-molecular-weight phosphoramidites tethered to multiple linkers (S.9d and S.14d) the coupling time should be set to 10 min with tetrazole and 5 min with ETT.
4.29.14 Supplement 25
Current Protocols in Nucleic Acid Chemistry
All tethers, including those with multiple oxalamido groups, are stable to final deprotection with neat ethanolamine (70◦ C, 15 to 30 min) or concentrated aqueous ammonia (70◦ C, 8 to 16 hr). Because the oxalamido group is not very stable in aqueous alkaline solutions, deprotection procedures involving NaOH treatment must be avoided. The ethanolamine-based deprotection procedure detailed below is fast, reliable, and does not necessitate tight sealing of the reaction vial. It should be stressed, however, that N4 -acetyl-protected deoxycytidine phosphoramidites must be used to prevent N4 -sideproduct formation (Polushin et al., 1994; Reddy et al., 1994). Oligonucleotide synthesis can be carried out on any automated DNA/RNA synthesizer. The authors have used the Biosset ASM-800 DNA/RNA synthesizer. The signature feature of this synthesizer is low reagent consumption, which becomes essential when valuable phosphoramidites are used. To purify crude 5 -modified oligonucleotides, a number of standard techniques can be employed, e.g., reversed-phase or ion-exchange HPLC, cartridge purification, or denaturing PAGE. Of these, PAGE is easy to implement and generally gives oligonucleotides of higher purity. For PAGE purification, the last MMTr/DMTr protecting group (from 5 -functionalization with tethered phosphoramidites) should be removed on the synthesizer (DMTr-OFF mode). The MMTr group is more stable, so the deprotecting time should be set to 3 to 5 min. The molecular mass of a number of functionalized oligonucleotides was assessed by MALDI-TOF-MS on a Voyager-DE mass spectrometer.
Materials Tethered phosphoramidites (S.3d-S.14d; see Basic Protocol 1 and Alternate Protocol) Acetonitrile (CH3 CN), anhydrous, DNA synthesis grade Standard 2 -deoxyribonucleoside phosphoramidites (Transgenomic) 0.5 M tetrazole in CH3 CN (Glen Research) or 0.25 M 5-ethylthio-1H-tetrazole (ETT, Glen Research) Ethanolamine (EA), ≥99% (Aldrich) 10% (w/v) LiClO4 in ethanol (EtOH) Ethanol (EtOH), 200 proof 7 M urea 15% (w/v) polyacrylamide gel (APPENDIX 3B) containing 7 M urea in 0.5× TBE electrophoresis buffer (APPENDIX 2A) 0.25 M triethyl ammonium bicarbonate (TEAB), aqueous solution 1.7-mL microcentrifuge tubes 70◦ C incubator or water bath Microcentrifuge Speedvac evaporator (Savant) Sephadex G-25 NAP-10 columns (Pharmacia) Lyophilizer Water aspirator or vacuum pump (5 to 10 Torr) Additional reagents and equipment for automated solid-phase oligonucleotide synthesis (APPENDIX 3C), purification of oligonucleotides (UNITS 10.1, 10.4, 10.5, 10.7 & APPENDIX 3B), and determination of molecular mass (UNIT 10.1) 1. Dissolve the desired tethered phosphoramidite in anhydrous CH3 CN at 0.1 M in an appropriate vial. Install the vial onto a DNA/RNA synthesizer. 2. Start the automated solid-phase oligonucleotide synthesis (APPENDIX 3C) from an appropriate solid-support-filled column.
Synthesis of Modified Oligonucleotides and Conjugates
4.29.15 Current Protocols in Nucleic Acid Chemistry
Supplement 25
3. Elongate the desired oligonucleotide chain using standard 2 -deoxyribonucleoside phosphoramidites. Use the selected specialty phosphoramidite for the last coupling. If tetrazole is used as a catalyst, allow 3 to 5 min for coupling phosphoramidites S.3d-S.8d and S.10d-S.13d, and 10 min for coupling phosphoramidites S.9d and S.14d. In the case of ETT, reduce the coupling times to 1 to 3 min and 5 min, respectively. 4. Remove the last MMTr/DMTr protecting group manually or by engaging the DMTrOFF mode. Allow 3 to 5 min for removal of the MMTr group. 5. Remove the column from the synthesizer and dry for 15 to 20 min in vacuo using a water aspirator or vacuum pump. 6. Remove the column filter and transfer the support into a 1.7-mL microcentrifuge tube (up to 10 mg per tube) and add 50 µL EA. Vortex briefly to make sure that all support is covered with EA and then microcentrifuge briefly at 13,000 rpm. 7. Incubate at 70◦ C for 20 to 25 min. For oligonucleotides >50 nt, increase the incubation time to 30 to 35 min. 8. Add 20 µl of 10% (w/v) LiClO4 in EtOH and vortex. Add 700 µL of EtOH, vortex, and leave at room temperature for at least 15 to 20 min to ensure full precipitation of the modified oligonucleotide. 9. Microcentrifuge 5 min at 13,000 rpm. Discard the supernatant. Wash the residue with 700 µL EtOH, microcentrifuge 5 min at 13,000 rpm, and discard the wash. 10. Add 200 µL deionized water, vortex, and microcentrifuge briefly at 13,000 rpm. Transfer the solution to a new 1.7-mL tube. Wash the remaining solid support with 200 µL deionized water, microcentrifuge, and transfer the wash to the main solution. 11. Concentrate the solution to dryness in vacuo on a Speedvac evaporator and dissolve the residue in 7 M urea. 12. Purify by denaturing polyacrylamide gel electrophoresis (PAGE; UNIT 10.4 & APPENDIX 3B) using 15% polyacrylamide and 7 M urea in 0.5× TBE electrophoresis buffer. 13. Cut out the band(s) and elute the product with 0.25 M TEAB. Desalt using a Sephadex G-25 NAP-10 column and lyophilize. 14. Dissolve the oligonucleotide in deionized water and quantitate by measuring UV absorbance at 260 nm. Store the solution at –20◦ C. 15. Analyze the products by MALDI-TOF-MS (UNIT mass.
10.1)
to determine molecular
COMMENTARY Background Information
Methoxyoxalamido Chemistry for Tethered Phosphoramidites
Use of specialty phosphoramidites, such as amino modifiers and spacers, is widespread in modern oligonucleotide synthesis. A number of phosphoramidites with aminated and hydroxylated linkers are commercially available (Glen Research), but they generally possess at least three limitations. First, these phosphoramidites are mainly derived from aliphatic primary alcohols and are thus not
very stable even at low temperatures due to susceptibility to Arbuzov rearrangement (Polushin, 2000). This instability leads to preparation and storage complications and also necessitates fairly rapid phosphoramidite consumption on automated DNA synthesizers, thus making the commercially available amino modifiers and spacers less than ideal for reliable large-scale oligonucleotide production. Second, the available amino modifier
4.29.16 Supplement 25
Current Protocols in Nucleic Acid Chemistry
and spacer phosphoramidites are quite limited in variety. They are primarily flexible in nature, since they contain methylene or oxyethylene units within the tether chain, and are rather short, not exceeding 19 atoms in length. Third, the production chemistry for these phosphoramidites is not amenable to constructing a vast number of distinctly different monomers, each possessing varying degrees of flexibility, hydrophobicity, and length. This unit elaborates on a general synthetic route toward phosphoramidite linkers. The method is based on methoxyoxalamido (MOX) chemistry, which is very robust in the synthesis of modified oligonucleotides (Polushin, 2000). MOX chemistry is easy to implement and offers great control over tether composition, rigidity, and length. All βcyanoethyl phosphoramidites in this unit are derived from secondary alcohols and can be used on the synthesizer for at least two weeks without any loss in coupling efficiency. Phosphoramidite synthesis The general synthetic routes towards novel phosphoramidites tethered with single or multiple linkers are outlined in Figures 4.29.1 and 4.29.2, respectively. Phosphoramidite preparations proceed by a single linker addition (for a single tether) or by serial linker additions (for a compound tether). In either case, the reactions proceed in a straightforward manner and the synthesis proves to be robust. The stepwise yields are high, and crystallization or precipitation effectively cleans up the majority of the reactions leading up to the phosphoramidite. Column chromatography is used only at the final phosphinylation step and to purify the MOX intermediates (S.5b, S.6b, and S.8b). The choice of starting compound (phosphoramidite base) for the synthesis of tethered phosphoramidites is based on two major considerations. First, it must have a primary amino group as a starting point for MOX chemistry. Second, the hydroxyl group for attachment of the phosphoramidite moiety should be secondary to impart greater stability to the phosphoramidite (Polushin, 2000). It is also essential that the starting material be commercially available and inexpensive, or can be easily prepared from an inexpensive reagent. The trans-4-aminocyclohexanol hydrochloride and 5 -amino-5 -deoxythymidine used as starting compounds in this unit both satisfy all the above demands.
Structural versatility The practical advantage of the described synthetic approach lies in its amenability to structural versatility by utilizing an arsenal of distinctly different, commercially available diamines and amino alcohols. It is possible to tailor the synthesis to suit practically any requirement in chemical or physical properties of the tethers. The selection of tethers for this unit encompasses only a short range of hydrophobicity, rigidity, and length, but the synthetic strategy can easily produce a much wider variety of chain features. Further flexibility comes from the possibility of assembling compound tethers through the use of oxalamido bonding. This modular assembly allows different combinations of available diamines to be used, and thus allows selective modification of the physical nature of the tether at each step. For example, if more rigidity is needed at the end of the tether, a diamine with a constrained configuration can be used at the last step of tether construction. By exploiting the serial addition strategy and a fairly long diamine such as the 15atom TTDD, one can easily prepare specialty phosphoramidites with extraordinarily long tethers. Through three iterations of MOX chemistry, phosphoramidites with a 56- or a 48-atom tether were synthesized (S.9d or S.14d, respectively). Theoretically, there is no limit to the length that can be achieved using this strategy. Recently biotin amino phosphoramidites with tethers up to 106 atoms in length have been synthesized (Polushin, unpub. observ.). It is essential to stress that all tethered compounds prepared through the MOX strategy are monodispersed, unlike previously described polydispersed tethers prepared from low-molecular-weight polyethylene glycol (PEG) polymer (Jaschke et al., 1994). Synthesis of modified oligonucleotides: Coupling and deprotection Most of the described phosphoramidites are solids and thus easier to handle. All are freely soluble in acetonitrile. The average coupling efficiency of the phosphoramidites at 0.1 M, when using ETT as a catalyst over a 3 to 5 min coupling time, was greater than 95%. The tethered phosphoramidites presented here have been used to synthesize a number of 5 -modified oligonucleotides. The modified oligonucleotides were observed as distinct bands on polyacrylamide gels, with mobilities
Synthesis of Modified Oligonucleotides and Conjugates
4.29.17 Current Protocols in Nucleic Acid Chemistry
Supplement 25
Figure 4.29.6 PAGE analysis of crude 5 -modified T10 oligonucleotides. Lane 1 of each gel corresponds to the unmodified T10 oligonucleotide. The other lanes correspond to oligonucleotides modified at the 5 terminus with the following phosphoramidites: S.3d (A2), S.4d (A3), S.5d (A4), S.6d (A5), S.8d (A6), S.7d (A7), S.9d (A8), S.10d (B2), S.11d (B3), S.13d (B4), S.12d (B5), S.14d (B6).
Table 4.29.1 MALDI-TOF-MS Data for Modified T10 Oligonucleotides
Starting oligonucleotide
Modifier
Lanea
MW (calculated)
MW (experimental)
(Tp)9 T
none
A1, B1
2978
2980
(Tp)9 T
3d
A2
3271
3274
(Tp)9 T
4d
A3
3485
3488
(Tp)9 T
5d
A4
3431
3433
(Tp)9 T
6d
A5
3557
3560
(Tp)9 T
8d
A6
3706
3709
(Tp)9 T
7d
A7
3832
3834
(Tp)9 T
9d
A8
3980
3983
(Tp)9 T
10d
B2
3316
3318
(Tp)9 T
11d
B3
3328
3330
(Tp)9 T
13d
B4
3590
3592
(Tp)9 T
12d
B5
3717
3719
(Tp)9 T
14d
B6
3865
3867
a Lane numbers correspond to Figure 4.29.6.
Methoxyoxalamido Chemistry for Tethered Phosphoramidites
4.29.18 Supplement 25
Current Protocols in Nucleic Acid Chemistry
less than those of unmodified counterparts. As an example, Figure 4.29.6 shows a series of crude T10 oligonucleotides modified by the addition of tethered phosphoramidites. MS data for these oligomers are presented in Table 4.29.1. To determine the effect of oligonucleotide deprotection conditions on tethered compounds, several MMTr-protected intermediate amino alcohols and DMTr-protected intermediate diols were subjected to neat ethanolamine, ammonia/methylamine (30% aq. ammonium hydroxide/2 M methanolic methylamine, 1:1, v/v), and aqueous NaOH (0.2 M NaOH in water/methanol, 1:1, v/v). Exposure to NaOH for even 1 hr at ambient temperature was too harsh, and some degradation of all tethers was detected under these conditions. However, the tethers did hold up to ammonia, methylamine, and ethanolamine, and they were stable at the temperature and duration required for complete deprotection of the modified oligonucleotides.
Critical Parameters and Troubleshooting The synthesis of tethered phosphoramidites is straightforward and efficient. However, familiarity with general chemical laboratory techniques such as filtration, extraction, concentration, TLC, and column chromatography is a must. General knowledge of standard analytical techniques (1 H NMR, 31 P NMR, UV, and mass spectroscopies) is necessary for characterization of products. The efficiency of specialty phosphoramidite incorporation may be influenced by the particular model of the DNA/RNA synthesizer; thus, some optimization of critical parameters (e.g., coupling time, delivery time) might be needed to maximize the coupling yields. Practical knowledge of gel electrophoresis is required for oligonucleotide purification. Laboratory safety must always be a primary concern. The amidites are quite stable in the presence of triethylamine and no special precautions are used prior to removal of triethylamine. Although triethylamine is known to reduce phosphoramidite coupling efficiency, the final toluene co-evaporations are sufficient to remove triethylamine completely.
prepared in 40% to 50% yields starting from the MOX precursors. Coupling efficiency of all phosphoramidites should be greater than 95%.
Time Considerations Each of the initial MOX precursors S.1 and S.2 can be prepared in 2 days. Since these precursors are the starting materials for all other compounds, at least 10-g preparations are recommended. The synthesis of a phosphoramidite with a single hydroxylated linker (S.10d-S.11d) generally takes 3 to 5 days, while synthesis of a phosphoramidite with a single aminated linker (S.3d-S.6d) takes 2 days longer. One round of tether elongation (diamine treatment followed by dimethyl oxalate treatment) can be accomplished in 2 to 3 days. Typically, only one or a few incorporations of specialty phosphoramidites are required in the synthesis of a modified oligonucleotide. Thus, the length of the oligonucleotide and the synthesizer throughput dictate the time needed for synthesis. On the ASM-800 DNA/RNA synthesizer, eight 5 -modified 20-mers can be synthesized in ∼2 hr. EA deprotection and desalting (by precipitation) takes less than an hour. PAGE purification and desalting requires 1 to 2 days.
Literature Cited Bannwarth, W. 1988. Solid phase synthesis of oligonucleotides containing phosphoramidate internucleotide linkages and their specific chemical cleavage. Helv. Chim. Acta 71:1517-1527. Jaschke, A., Furste, J.P., Nordhoff, E., Hillenkamp, F., Cech, D., and Erdmann, V.A. 1994. Synthesis and properties of oligodeoxyribonucleotidepolyethylene glycol conjugates. Nucl. Acids Res. 22:4810-4817. Polushin, N.N. 2000. The precursor strategy: Terminus methoxyoxalamido modifiers for single and multiple functionalization of oligodeoxyribonucleotides. Nucl. Acids Res. 28:31253133. Polushin, N.N., Morocho, A.M., Chen, B.C., and Cohen, J.S. 1994. On the rapid deprotection of synthetic oligonucleotides and analogs. Nucl. Acids Res. 22:639-645. Reddy, M.P., Hanna, N.B., and Farooqui, F. 1994. Fast cleavage and deprotection of oligonucleotides. Tetrahedron Lett. 35:4311-4314.
Anticipated Results Good to moderate yields of the final specialty phosphoramidites from the corresponding MOX precursors are expected. Phosphoramidites tethered with single linkers (S.3d-S.6d, S.10d, and S.11d) have been
Contributed by Alan M. Morocho and Nikolai N. Polushin Fidelity Systems, Inc. Gaithersburg, Maryland
Synthesis of Modified Oligonucleotides and Conjugates
4.29.19 Current Protocols in Nucleic Acid Chemistry
Supplement 25
Using Morpholinos to Control Gene Expression
UNIT 4.30
Morpholino oligos (Morpholinos) are synthetic uncharged P-chiral analogs of nucleic acids. They are typically constructed by linking together 25 subunits, each bearing one of the four nucleic acid bases. Figure 4.30.1 illustrates the structure of three Morpholino subunits joined by inter-subunit linkages. The morpholino phosphorodiamidate backbone of Morpholinos consists of morpholine rings that bear methylene groups and are bound through modified phosphates in which the anionic oxygen is replaced by a nonionic dimethylamino group. The substituted phosphate is bound through an oxygen atom to the morpholine’s exocyclic methylene group, and through a phosphorous-nitrogen bond to the nitrogen atom of another morpholine ring. One standard DNA nucleobase (adenine, guanine, cytosine, or thymine) is bound to each morpholine ring. The ends of Morpholinos are conventionally named 3 and 5 by analogy with the nomenclature for nucleic acids (though if one were to number the atoms of a morpholino oligonucleotide backbone by IUPAC rules, the numbers assigned to the ends would be different). The secondary amine of the morpholine ring at the end of an unmodified morpholino oligonucleotide is called the 3 end of the oligo, whereas the 5 end terminates with a chiral carboxamidated phosphorodiamidate group (Fig. 4.30.1). Antisense Morpholinos block the interactions of macromolecules with mRNA by base pairing with the targeted mRNA in a complementary fashion, thus preventing initiation
Figure 4.30.1
Structure of a Morpholino 3-mer.
Contributed by Jon D. Moulton Current Protocols in Nucleic Acid Chemistry (2006) 4.30.1-4.30.24 C 2006 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Oligonucleotides and Conjugates
4.30.1 Supplement 27
complex read-through or modifying splicing in cells ranging from bacterial (Geller et al., 2005) to human (Suwanmanee et al., 2002). In particular, antisense Morpholinos have become a standard tool for developmental biologists to manipulate gene expression in embryos such as zebrafish and Xenopus sp. (Ekker and Larson, 2001). These modified oligonucleotides combine efficacy, specificity, stability, lack of non-antisense effects, and good water-solubility properties. This unit presents three protocols for the design of a knockdown experiment using Morpholinos (Basic Protocol 1), preparation of Morpholino solutions (Basic Protocol 2), and introduction of Morpholinos into cells by endocytosis in the presence of an amphiphilic peptide (Basic Protocol 3). The Commentary provides a thorough discussion of conditions and considerations for the application of Morpholinos. BASIC PROTOCOL 1
DESIGN OF A MORPHOLINO KNOCKDOWN EXPERIMENT This protocol outlines the choices commonly encountered while designing a Morpholino knockdown experiment. Considerations for the steps are addressed in the Commentary. 1. Choose the target gene. 2. Choose the cells or organism into which the oligo will be delivered. 3. Choose between splice blocking or translation blocking, which determines the molecular assays available for measuring antisense activity. 4. Obtain the sequence of the target RNA. Use the mRNA 5 -UTR and the first 25 coding bases for translation blockers, or pre-mRNA with introns and exons defined for splice blockers. 5. Choose a delivery method. 6. Select control oligos. 7. Decide whether end-modification of any oligos is necessary. 8. For blocking splicing, select which pre-mRNA splice boundary (intron-exon) to block. 9. Select the oligo target (following the targeting rules described in the Commentary) and determine the Morpholino sequence (the inverse complement of the target). 10. Use a transcript database and a homology search tool such as BLAST to test the selected target for homologies with other RNAs. If the selected target is too homologous with a region of an off-target mRNA, a partially complementary Morpholino might affect the expression of that mRNA. Another target on the desired mRNA must be selected to prevent off-site Morpholino interaction.
11. Order the synthesis of the selected Morpholinos. BASIC PROTOCOL 2
PREPARATION AND VERIFICATION OF MORPHOLINO STOCK SOLUTIONS This protocol describes the preparation of stock aqueous solutions of Morpholinos at concentrations of 1 mM or 500 µM, if necessary.
Materials Using Morpholinos to Control Gene Expression
Lyophilized Morpholino oligonucleotide (Gene Tools) Distilled autoclaved water without DEPC, sterile 0.1 M HCl
4.30.2 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Glass or polypropylene/polyethylene tubes with labels 65◦ C water bath Quartz spectrophotometer cell (1 cm path length) Parafilm Lint-free lab tissues UV spectrophotometer (or UV colorimeter) capable of measurements at 265 nm Morpholino product information sheet Prepare Morpholino solution 1. Read the amount of Morpholino given on the vial label and, using sterile technique, add the appropriate volume of distilled sterile water to make a 1 mM stock solution (i.e., 0.1 mL water for a vial containing 100 nmol Morpholino). The aqueous solubility of Morpholinos is sequence-dependent, but most Morpholino sequences with G content below 36% will dissolve in water at the recommended stock concentration of 1 mM. Do not keep Morpholino solutions of <1 µM because submicromolar concentrations can lose significant activity by binding to glass and plastic surfaces. It is strongly recommended that Morpholino stock solutions be made with distilled water, but isotonic buffers (e.g., Ringer’s solution, Danieau buffer) can also be used. The use of distilled water facilitates the process of concentrating Morpholinos, should that be required. If water must be treated with diethylpyrocarbonate (DEPC), it is very important to autoclave the treated water to destroy residual DEPC before using it to dissolve Morpholinos. Otherwise, DEPC reacts with adenines and compromises the ability of Morpholinos to bind to their targets (Henderson et al., 1973).
2. Cap the vial, shake it, and wait 5 min. 3. Swirl and inspect the solution to see whether the oligo has dissolved. If it has not dissolved, warm the vial for 5 min in a water bath at 65◦ C. 4. If desired, dispense into several tubes. Label tube(s) with the concentration and oligo name, and store any tubes that will not be used immediately. Scrupulously avoid microbial contamination of the stock solutions. Store fluorescenttagged Morpholinos in a closed box so that light will not bleach fluorescent moieties. Morpholinos are stable in stock solutions stored at either 25◦ C or 4◦ C. Morpholinos can also be stored frozen. However, ice crystal formation during slow freezing can cause the concentration of the oligos in the bulk solution phase to increase until the Morpholinos precipitate. Thus, after thawing, Morpholino solutions should be heated for 10 min in a water bath at 65◦ C to ensure complete dissolution prior to use.
Check Morpholino concentration by UV absorbance 5. Turn on the UV spectrophotometer and let it warm up for a few minutes. Set the spectrophotometer to report absorbance at 265 nm. 6. Clean the quartz spectrophotometer cell, if needed, and rinse the inside twice with 0.1 M HCl. Carefully shake excess liquid from cell. Do not touch the outside of the quartz spectrophotometer cell on the surfaces where light will pass through, as skin oils can skew the measurements.
7. Pipet 995 µL of 0.1 M HCl into the quartz cell and place the cell in the spectrophotometer. Blank the spectrophotometer at 265 nm. Synthesis of Modified Oligonucleotides and Conjugates
4.30.3 Current Protocols in Nucleic Acid Chemistry
Supplement 27
8. Remove the cell from the spectrophotometer and pipet 5 µL aqueous Morpholino solution into the quartz cell. Like natural nucleic acids, the nucleobases of a Morpholino are stacked and produce a hypochromic effect. Without unstacking the bases, the use of the molar absorptivity of an individual nucleobase to calculate the concentration of the oligo would lead to an erroneously low value. Oligos with A, C, and G bases can be unstacked by dissolving the oligos in 0.1 M HCl. Under these conditions, A, C, and G bases are protonated and are out of the stacked state due to electrostatic repulsion. When the nucleobases of the oligo are unstacked, the molar absorptivity of each nucleobase can be applied to determine the concentration of the oligo.
9. Place a piece of Parafilm over the open end of the cell, placing a thumb over the Parafilm to seal the cell, and invert several times to mix. 10. Remove the Parafilm. Wipe the outside of the cell with a lint-free tissue, if needed. 11. Place the cell in the spectrophotometer and read the absorbance at 265 nm (A265 ). 12. Calculate the molar concentration (C) of the original Morpholino solution as: C = (A265 × 200)/(ε b) where 200 is the factor for dilution in HCl, ε is the molar absorptivity, and b is the path length of the cell (1 cm). The molar absorptivity (ε) of the Morpholino is provided on the product information sheet. Alternatively, ε can be calculated by multiplying the molar absorptivity of each nucleobase (A, C, G, and T) by the number of instances that the nucleobase is present in the oligo, and adding these products. This Beer’s law calculation works when absorbance ≤2, where the relationship of absorbance to concentration is linear. If the measured absorbance is >2, the sample should be diluted and remeasured. BASIC PROTOCOL 3
DELIVERY OF MORPHOLINOS INTO CELLS USING ENDO-PORTER Endo-Porter is an amphiphilic peptide. After co-endocytosis with Morpholinos, EndoPorter permeabilizes endosomal membranes, releasing the Morpholino from the endosomes to the cytosol (Summerton, 2005). Endo-Porter was optimized using a HeLa cell line. Because tolerance of other cell types toward Endo-Porter often varies, a range of Endo-Porter concentrations should be tested before beginning knockdown experiments.
Materials 1 mM Endo-Porter solution (aqueous or DMSO formulation; Gene Tools) Cell cultures in plates or flasks at 80% to 100% confluence 1 mM Morpholino stock solution (Gene Tools) 1 mM fluoresceinated dextran, 10 kDa Cell culture medium with 10% serum Fluorescence microscope Select amount of Endo-Porter for cell type 1. Prepare concentrations of 2, 4, 6, and 8 µM Endo-Porter by pipetting 2, 4, 6, and 8 µL of a 1 mM Endo-Porter solution into 1-mL aliquots of cell culture.
Using Morpholinos to Control Gene Expression
2. Add 10 µM fluorescently labeled Morpholino (10 µL of 1 mM stock per 990 µL cell culture) or 10 kDa fluoresceinated dextran (10 µL of 1 mM stock per 990 µL cell culture). 3. Allow endocytotic uptake to proceed over a period of 24 hr.
4.30.4 Supplement 27
Current Protocols in Nucleic Acid Chemistry
4. Observe intracellular fluorescence using a fluorescence microscope. See discussion on assessing delivery in the Commentary section.
5. Observe cells 72 hr after delivery to determine any cellular toxicity. For subsequent Morpholino delivery to the selected cell type, use the concentration of Endo-Porter that gave the best delivery without toxicity.
Deliver Morpholinos to cells 6. Using a cell culture not previously exposed to Endo-Porter, replace spent culture medium with fresh medium (with up to 10% serum). 7. Add the Morpholino stock solution to produce the desired concentration and swirl well to mix. For functional experiments (e.g., gene knockdown, splice blocking), Morpholinos are typically effective at concentrations as low as 1 µM. However, it is recommended that a range of concentrations be tested (such as 1, 4, and 10 µM Morpholino) to define optimal conditions.
8. Add Endo-Porter to produce the optimized concentration for the cell type and immediately swirl to mix. 9. Place the plates or flasks in the incubator. Wait at least 16 hr before assessing uptake by fluorescence, and at least 24 hr before measuring knockdowns by molecular assays. The delay needed to assay a knockdown depends on the stability of any preexisting protein encoded by the targeted mRNA; a protein with a long half-life will take longer to disappear from the cells.
COMMENTARY Background Information The morpholino phosphorodiamidate backbone of a Morpholino oligonucleotide has no significant ionic charge at neutral pH, in contrast with the polyanionic phosphodiester backbone of a natural nucleic acid. This favors the interaction of Morpholinos with nucleic acids, since there is no repulsion between anionic backbones as there is in duplexes of natural nucleic acids. Dissolved in pure water, nucleic acids lose their ability to form stable Watson-Crick bonds due to anionic repulsion between strands, whereas Morpholinos will still bind to complementary sequences (Summerton, 2004). Because Morpholinos are uncharged, they have no strong electrostatic interactions with proteins. Unmodified Morpholinos have little or no affinity for bovine or human serum albumin (H.M. Moulton, unpub. observ.). In contrast, interactions of anionic phosphorothioate oligos with proteins cause multiple physiological, non-antisense effects (Lebedeva and Stein, 2001). Proteins that bind nucleic acids generally interact electrostatically with the anionic phosphates of nucleic acids, stabilizing binding. Morpholinos appear to have little or no interaction with nucleic acid–binding proteins (Hudziak et al., 1996).
Morpholinos are very stable to nucleolytic enzymes. There are no known enzymes that degrade Morpholinos. Specifically, Morpholinos have been exposed to a range of nucleases (e.g., DNase I, DNase II, Benzonase, S1 nuclease, mung bean nuclease, Bal 31 nuclease, RNase A, RNase T1, phosphodiesterase I, and phosphodiesterase II) and proteases (e.g., pronase E, proteinase K, and pig liver esterase) under conditions where lytic enzymes would degrade their substrates. In no case was degradation of the Morpholinos detected (Hudziak et al., 1996). Morpholinos were incubated in serum and in liver homogenate without degradation (Summerton and Weller, 1997). When peptide-Morpholino conjugates were extracted from cells and analyzed by MALDITOF mass spectrometry, the Morpholino oligo entity was not degraded in the cells (Nelson et al., 2005). No crystal structure or high-resolution NMR structural analysis of phosphorodiamidate Morpholinos has been published. However, the study of a morpholino phosphorodiamidate ApA dimer using circular dichroic spectroscopy showed stacking of bases in aqueous phosphate buffer (Kang et al., 1992). On the basis of molecular modeling, the bases
Synthesis of Modified Oligonucleotides and Conjugates
4.30.5 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Table 4.30.1 RNA Binding Affinity of Various Oligo Types Ranked by Dissociation Temperature in Physiological Isotonic Buffers
Figure 4.30.2
Using Morpholinos to Control Gene Expression
Affinity
Type of oligo
Strongest
RNA:RNA, PNA:RNA, 2 -O-methyl-RNA:RNA (all very similar)
Strong
Morpholino:RNA
Medium
DNA:RNA
Weakest
Phosphorothioate:RNA
Comparison of RNase H–dependant, RISC-dependant, and steric blocking oligos.
of Morpholinos should stack in a fashion analogous to those of natural nucleic acids, allowing strong interactions with complementary nucleic acid sequences by Watson-Crick base pairing. A 400 MHz 1 H NMR analysis of a carbamate-linked Morpholino found the morpholine ring in the chair conformation (Stirchak et al., 1989). Molecular modeling of a Morpholino with the morpholine rings in the chair conformation suggests that a Morpholino and an RNA form an A-form heteroduplex with a helical pitch similar to that of an A-form RNA-RNA duplex (J.E. Summerton, unpub. observ.). Various types of antisense oligos are ranked by their affinity for binding to single strands of sense RNA based on their dissociation temperatures in physiological salt buffers (Table 4.30.1; Stein et al., 1997). The affinity of RNA for RNA is greater than the affinity of Morpholinos for RNA. However, single strands of mRNA folded into secondary structures contain single-stranded regions, such as the loops of stem-loops, with which Morpholinos can readily hybridize. Given that double-stranded regions of most RNA secondary structures are shorter than 25 base pairs, the overall binding affinity of Morpholinos for RNA is suffi-
cient to invade and displace those short doublestranded regions (Summerton, 1999). Antisense oligos such as DNA, RNA, and phosphorothioate (S-DNA) oligos recruit RNase H to degrade their mRNA targets (Summerton, 1999). RNAi and siRNA also employ an antisense mechanism to recognize a sense mRNA through interaction with a RISC complex, which leads to enzymatic degradation of complementary mRNA and translational blocking of partially complementary mRNA (Scacheri et al., 2004). In contrast, instead of degrading mRNA, antisense Morpholinos were designed to block the translation of mRNA into protein (Summerton and Weller, 1997). Figure 4.30.2 compares steric blocking, RNase H–dependant, and RISCdependant oligos. When comparing an RNase H– dependant oligo (a methylphosphonate diester/phosphodiester chimera) with a Morpholino, a CpGNNN motif was shown to induce apoptosis and cell cycle arrest when present in the RNase H–dependent oligo but not when present in the Morpholino (Tidd et al., 2001). There have been no reports of Morpholinos inducing either interferon production or induction of NF-κB
4.30.6 Supplement 27
Current Protocols in Nucleic Acid Chemistry
mediated inflammation, and Morpholinos containing CpG motifs do not stimulate immune responses (J.E. Summerton and A. Krieg, unpub. observ.), suggesting that Morpholino-RNA heteroduplexes do not stimulate Toll-like receptors. Morpholinos complementary to sequences in the 5 -UTR and the first 25 coding bases of an mRNA can halt the progression of the initiation complex toward the start codon, preventing assembly of the entire ribosome. This inhibits the translation of the mRNA sequence into a polypeptide. Morpholinos targeted downstream of the start codon are usually ineffective for blocking translation (Summerton, 1999). In addition to their application to knock down gene expression, because stericblocking oligos do not trigger degradation of RNA, Morpholinos are also widely used to block splicing of pre-mRNA. Splicing in eukaryotes is directed by snRNPs that bind to introns and mark the intron-exon boundaries. Morpholinos targeted to these snRNP-binding sites can modify splicing (Sazani et al., 2001), either preventing splicing and causing an intron inclusion (Giles et al., 1999) or redirecting splicing and causing an exon excision (Draper et al., 2001). Blocking a splice site can cause activation of a cryptic splice site, complicating interpretation of the splice modification by producing partial deletions of exons (Draper et al., 2001) or partial inclusions of introns. Morpholinos stimulate site-specific ribosome frameshifting when bound just downstream of a shift site on an mRNA, and they do so with far higher efficiency than RNA, phosphorothioate oligos, or 2 -O-methyl RNA oligos (Howard et al., 2004). Although Morpholinos are most often used to block the translation initiation complex or the snRNPs that direct splicing, there are other mRNA sequences that are attractive targets for steric blocking. Specifically, Morpholinos can block miRNA activity by binding to the miRNA and preventing it from binding its mRNA target (Kloosterman et al., 2004), or by binding to the site on the mRNA where the miRNA would otherwise bind. Along similar lines, Morpholinos targeted across the cleavage site of a hammerhead ribozyme inhibited auto-cleavage, leading to over two orders of magnitude increase in the expression of a downstream reporter gene (Yen et al., 2004). While Morpholinos have also been shown to block intronic splice silencers (Bruno et al., 2004) and exonic splice enhancers (McClorey
et al., 2006), no publications have yet explored other potential regulatory targets such as zipcode binding sites, riboswitches, or binding sites for elements of the nonsense-mediated mRNA decay pathway. Morpholinos are commonly microinjected into embryos at the single-cell or few-cell stages to block genes involved in development (Heasman et al., 2000; Nasevicius and Ekker, 2000; Nutt et al., 2001). Morpholinos are also commonly used in cell cultures (Tyson-Capper and Europe-Finner, 2006). Applications in intact adult organisms have until recently been limited by poor in vivo delivery into the cytosol of cells (Summerton, 1999; Sazani et al., 2002). However, very recent advances in conjugating Morpholinos to cell-penetrating peptides (Nelson et al., 2005) now allow effective systemic delivery into adult organisms (Alonso et al., 2005; Kinney et al., 2005; Neuman et al., 2005; Enterlein et al., 2006). Combinations of several oligonucleotide sequences can bind to several different RNA targets simultaneously if introduced together into embryos (Ekker, 2000) or cell cultures (Summerton, 2005), allowing multiple knockdowns or synergistic targeting of a single messenger. Targeting of viral RNA with Morpholinos has been reported for hepatitis C (Jubin et al., 2000; McCaffrey et al., 2003), dengue virus (Kinney et al., 2005), ebola virus (Enterlein et al., 2006; Warfield et al., 2006), SARS virus (Neuman et al., 2005), West Nile virus (Deas et al., 2005), equine arterivirus (van den Born et al., 2005), mouse hepatitis virus (Neuman et al., 2004), novirhabdovirus (Alonso et al., 2005), and vesivirus (Stein et al., 2001). In addition to translation start sites, successful targets for inhibition of viral replication include cyclization sequences (Deas et al., 2005), terminal stem loops (Deas et al., 2005), and internal ribosomal entry sites (IRES; Jubin et al., 2000). Radioisotope delivery into organisms can be pretargeted using Morpholinos (Mang’era et al., 2001). Practitioners of nuclear medicine strive to minimize radiation exposure of a patient while delivering radionuclides to target tissues for imaging or for therapeutic applications. By attaching radioisotopes to antibodies that are specific for target tissues, the antibodies can anchor isotopes on these tissues. Because the large antibody molecules diffuse slowly, the isotopes must be maintained in the plasma at high concentrations or for long durations to achieve good delivery of radioisotope-linked antibodies to their targets.
Synthesis of Modified Oligonucleotides and Conjugates
4.30.7 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Pretargeting with Morpholinos involves introducing an antibody-Morpholino conjugate into the bloodstream; this can be done using high concentrations or re-dosing to saturate the target without exposing the patient to radiation during this pretargeting stage. Next, a conjugate of a radioisotope (possibly chelated) with a complementary Morpholino is added to the blood. Because the Morpholino has a much smaller molecular mass than an antibody, the radionuclide-Morpholino conjugate diffuses relatively quickly and is captured at the target tissue more rapidly through MorpholinoMorpholino pairing. Unbound radionuclideMorpholino conjugate is rapidly eliminated through the kidneys. This technique allows delivery of radioisotopes to the targeted tissue while exposing the organism to lower doses of radiation away from the targeted region. In the process of developing these techniques, pharmacokinetics of Morpholino-radionuclide conjugates have been studied in vivo (Liu et al., 2002a,b; He et al., 2003). In a recent modification, signals are amplified by binding a polymer bearing many complementary Morpholinos to each Morpholino-conjugated antibody fragment, followed by delivering radioisotopelabeled Morpholino complementary to the polymer-linked Morpholinos (He et al., 2003, 2004).
Critical Parameters Choosing Morpholino sequences The parameters considered when selecting oligonucleotide target sequences include CG%, G%, self-complementarity, tetra-G
moieties, length of the oligo, and the intended temperature at which the oligo will be used. The targeting recommendations are summarized below and in Table 4.30.2. CG range. A range of 40% to 60% CG is considered ideal for 25-base Morpholinos in 37◦ C systems. Oligos with <40% CG may lack the affinity needed for effective steric blocking, while oligos with >60% CG are more likely to interact with off-target messengers through high-affinity subsequences. G content. G content affects aqueous solubility of an oligo, with higher G contents being less soluble, particularly when the oligo is dissolved in isotonic salt solutions. Oligos with G contents up to 36% should be soluble in the millimolar range in pure water or aqueous buffer. However, freeze-thaw cycles are likely to cause high-G oligos to precipitate and the oligos must be heated to redissolve (see Basic Protocol 2). Self-complementarity. Self-complementary sequences can cause either intramolecular interactions, forming stem-loops, or intermolecular interactions, forming dimeric Morpholinos. When a short sequence of one part of an oligo is complementary to another short sequence separated by an intervening sequence, stem-loops can form. If small selfcomplementary sequences are separated by zero to a few bases, formation of a stable stemloop is unlikely because a hairpin with a small loop is not energetically favored. To prevent loss of oligo activity through competition between self-pairing and target binding, it is prudent to limit self-complementary sequences in oligo designs to 16 contiguous hydrogen bonds
Table 4.30.2 Summary of Targeting Recommendations for 37◦ C Systems
Using Morpholinos to Control Gene Expression
Parameter
Recommendation
Comments
CG range
40%-60%
At lower GC, affinity may be too low to block processes; higher GC favors nonspecific binding of subsequences.
G content
Up to 36% G
Higher G causes loss of water solubility; avoid upper end of acceptable range, if possible.
Selfcomplementarity
16 contiguous H-bonds maximum
For intermolecular (complementary palindrome) and intramolecular (stem loop) binding. Example: AGCGCT has 16 H-bonds (2+3+3+3+3+2 = 16). Check for non-Watson-Crick G-T pairing, which can participate in self-complementarities.
Consecutive G
3 consecutive Gs maximum
Runs of ≥4 G can associate through Hoogsteen bonding to form oligo tetramers.
Oligo length
25 bases or shorter by only a few bases
Using shorter oligos can decrease the chance of off-target interaction for high CG oligos.
4.30.8 Supplement 27
Current Protocols in Nucleic Acid Chemistry
or less, where CG pairs contribute 3 hydrogen bonds and AT pairs contribute 2 hydrogen bonds. For instance, the short sequences ATGGC and GCCAT can form 13 contiguous hydrogen bonds (2+2+3+3+3 = 13). When analyzing sequences for self-complementarity, check for both Watson-Crick base-pairing and for GT base-pairing. Like an AT pair, a GT pair also forms two hydrogen bonds. However, because the overall stability of the GT pair is far lower than an AT pair, a GT pair can be scored as a single hydrogen bond when calculating its contribution to the stability of a self-complementary moiety (Aboul-ela et al., 1985). An oligo containing a self-complimentary sequence can form dimers. To prevent loss of oligo activity through competition between dimer formation and target binding, it is prudent to limit complimentary palindromes to 16 contiguous hydrogen bonds or less. For instance, if two oligos bearing the self-complimentary sequence ATGCATGCGT encounter each other, they can form 22 contiguous hydrogen bonds (2+1+3+3+2+2+3+3+1+2 = 22, taking into account the GT pairs) and would likely have poor antisense activity. G tetrads. Nucleic acids containing GGGG moieties can interact through Hoogsteen bonding to form oligo tetramers (Cheong and Moore, 1992). Morpholinos containing G tetrads have reduced activity, likely through the same mechanism. Because of this, contiguous stretches of four or more G bases should be avoided when designing Morpholinos. MIL and oligo length. The minimum inhibitory length (MIL) of an antisense oligo is the length needed to achieve 50% reduction in translation of a targeted gene at a concentration typically achieved in cells. The MIL of Morpholinos varies somewhat between targets, but averages about 14 bases for 37◦ C cell cultures (Summerton, 1999). To ensure good affinity between Morpholinos and their RNA targets, the oligos are usually synthesized as 25-mers. CG content can influence the MIL of an oligo, with a higher CG oligo having a shorter MIL. Oligos with high CG content might interact with off-target RNA; these oligos can be shortened by a few bases to lessen the likelihood of off-target interactions. The marginal loss of affinity resulting from shortening a high-CG oligo will not ruin activity but will slightly improve specificity. A more effective way to improve specificity is to choose a target with a lower CG content.
Temperature and oligo selection The targeting guidelines were developed for oligos to be used at 37◦ C. Many embryos are grown at lower temperatures. When temperatures are decreased appreciably, stability of base-pairing increases. The ideal CG content for oligos designed for use at lower temperatures is lower than the 40% to 60% CG recommended for 37◦ C systems. The ideal CG content for colder systems (e.g., fish and frogs) must be determined experimentally. Similarly, the allowable number of base pairs in self-complementary sequences should be reduced for colder systems. Solubility is also decreased at lower temperatures, so it is prudent to select oligos with lower G contents for use in colder systems. Targetable region for translation blockers To block translation, a 25-mer Morpholino can target anywhere between the 5 cap to 25 nucleotides into the coding sequence. The target can extend downstream into the coding sequence as long as the translational start codon is covered. In the first steps of translation, the initiation complex forms at the 5 cap and then scans through the UTR to the start codon (Fig. 4.30.3A). At the start codon, the large ribosomal subunit binds, the initiation factors dissociate, and translation proceeds through the coding region. If a Morpholino gets in the way of the initiation complex before the initiation complex reaches the start codon, it prevents assembly of the ribosome and translation of the mRNA. Nonetheless, it is preferable to target the start codon instead of upstream for two reasons. First, the quality of sequence deposited in public databases is often poor in the UTR, especially for older sequence records. Second, though rare in vertebrate genomes, internal ribosome entry sites (IRES) do exist and can allow a ribosome to enter and assemble downstream of a Morpholino bound in the 5 -UTR. Targetable region for splice blockers To block splicing, Morpholinos are targeted to pre-mRNA across or near the boundaries between exons and introns. A pre-mRNA that undergoes splicing has two flanking exons (the first and last exon) and an arbitrary number of internal exons. The first exon has a single splice site, a splice donor, where it contacts intron 1. The internal exons have two junctions each, a splice acceptor at the upstream end and a splice donor at the downstream end. The last exon has only a splice acceptor at its upstream end. Targeting the splice sites of the internal exons usually causes exon excision, resulting in an mRNA missing the exon with
Synthesis of Modified Oligonucleotides and Conjugates
4.30.9 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Figure 4.30.3
Using Morpholinos to Control Gene Expression
Targetable regions for translation blocking (A) and splice blocking (B).
the blocked splice site (Fig. 4.30.3B). Targeting splice sites of the flanking (first or last) exons usually causes intron inclusion, resulting in an mRNA containing the first or last intron. Sometimes blocking a splice site activates a cryptic splice site, resulting in an mRNA with an unexpected mass. The snRNPs that direct splicing bind at the intronic sides of the splice junctions, so Morpholinos are chosen that are complementary to more intronic sequence than exonic sequence. Morpholinos can have good activity if targeted entirely to intronic sequence near the splice junction, but activity decreases as the target is moved farther into the intron (P.A. Morcos, unpub. observ.). Splicing can also be modified by preventing excision of an arbitrary intron by blocking the nucleophilic adenosine that closes the splicing lariat (P.A. Morcos, unpub. observ.) or by targeting splice-regulatory sequences. It is often the goal of a splice-blocking experiment to eliminate activity of a protein. If the active site of the protein is known, a straightforward strategy is to target a Morpholino to the exon encoding the active site, causing the loss of that exon and of the active site. When the active site is not known, other useful strategies are available. One is to eliminate an upstream exon that has a number of nucleotides not evenly divisible by three, causing downstream translation to be frameshifted. Another is to trigger inclusion of the first intron, especially useful if it contains an in-frame stop codon or if its number of nucleotides is not evenly divisible by three. Sometimes causing a random exon exclusion or intron inclusion is
sufficient to eliminate activity of a protein, perhaps due to a resulting change in the protein’s tertiary structure. Quality of sequence Since a few mismatches can seriously decrease the activity of a Morpholino, the quality of the target sequence is an important consideration when designing Morpholinos. There are sometimes errors in sequence database files. Variations in sequence between strains of an organism can also present a problem. The most definitive way to ensure the correct target sequence is to sequence the targeted gene in the strain that will be used in the experiments. Mismatched unintentional targets and Morpholinos When a 25-base Morpholino is used near its lowest effective concentration, its effects are very specific. Under such conditions the oligo can also interact with sequences containing one or two mismatches when compared to the oligo’s perfectly complementary target, though even a single mismatch can decrease activity (Khokha et al., 2002). However, few to no such sequences are expected to occur randomly in a base pool the size of the Morpholino-targetable sites in the human transcriptome (Summerton, 1999). Effect of concentration on specificity When the concentration of any antisense oligo is increased well above its minimum effective concentration, it can interact with targets containing more mismatches; at some concentration a Morpholino will begin knocking down expression of off-target mRNAs.
4.30.10 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Therefore it is important that the oligo concentration be kept as low as practicable while still eliciting the desired targeted knockdown. The concentration at which off-target effects occur, the concentration at which targeted knockdown occurs, and the ratio of these concentrations are all sequence-specific and therefore unknown for each new oligo sequence. In most cases, an effective and specific concentration window exists such that, for complementary mRNA and off-target mispaired mRNA at similar concentrations, the onset of the targeted knockdown will occur at a lower concentration than the onset of the offtarget knockdown. However, knocking down high-copy-number mRNAs requires higher oligo concentrations, increasing the probability of knocking down low-copy-number offtarget mRNAs; such a situation can narrow or even close the effective and specific concentration window. Acceptable off-target homology A single mismatch in a Morpholino 25-mer may cause a significant decrease in antisense activity (Khokha et al., 2002), though many single-mismatched oligos have retained good activity. When used near the concentration at which a perfectly complementary oligo elicits a knockdown, five mismatches distributed throughout a 25-mer usually decreases activity of the mismatched oligo to near undetectable levels (S.T. Knuth, unpub. observ.). It is prudent to check the target sequence of a proposed oligo against a nucleotide sequence database in order to identify regions where the Morpholino might bind to off-target mRNA. When searching for homologous targets, keep in mind that 25-base Morpholinos will only block translation when targeted to the 5 -UTR and first 25 bases of coding sequence. Morpholinos can modify splicing if targeted in introns near intron-exon boundaries. If the Morpholino has homology to an off-target mRNA outside of these limited regions, binding of the oligo to the mRNA is not likely to affect expression of the off-target mRNA (though blocking miRNA targets or regulatory sequences such as exonic splice enhancers may affect expression). When comparing a 25-base Morpholino against an off-target sequence in a region where a Morpholino might have a biological effect, the fraction of homologous bases should always be below 80%. However, that percentage ignores important considerations about the distribution of the mismatches throughout the oligo. About 14 contiguous
bases of homology is the minimum inactivating length for a Morpholino (Summerton, 1999). However, if 10 bases of perfect homology are flanked with a mismatch at either side and some runs of homologous bases are just beyond the flanking single mismatches, the oligo may still bind sufficiently to block translation or splicing. High CG content can make shorter homologous sequences active, since CG pairs are more stable than AT pairs. Distributing five mismatches throughout a 25mer almost always results in loss of knockdown at low concentrations, so 5-mispair oligos are commonly used as specificity controls. If all five mismatches are at one end of the oligo, there are still 20 contiguous complementary bases in a 25-mer, and those 20 bases would retain considerable antisense activity. When checking a Morpholino target against a sequence database and finding a partially homologous region, following a rule of thumb like “<80% homology won’t cause off-target knockdown” can lead to trouble; it is important to consider the distribution of the mismatches. Additional factors to consider when analyzing partially homologous targets are that losing a CG pair due to a mismatch impacts the oligo activity more than losing an AT pair (three Hbonds compared to two), and that mismatches sometimes form GT pairs, which contribute about half the stability of an AT pair (Aboulela et al., 1985). Delivery of Morpholinos to the cytosol/nuclear compartment of cells Unmodified Morpholinos. Since unmodified Morpholinos diffuse between the cytosol and the nucleus, delivery of Morpholinos to the cytosol is sufficient to ensure entry into the nucleus (Morcos, 2001). However, unmodified Morpholinos do not readily diffuse across the plasma membrane of most cell types. If unmodified Morpholinos are added to cell cultures without delivery reagents, high concentrations and long exposure times must be used to achieve minimal delivery (Sazani et al., 2001). Further demonstrating plasma membrane impermeability, when Morpholinos are microinjected into one blastomere of a Xenopus laevis embryo at the two-cell stage, daughter cells of the injected cell will contain Morpholino activity while daughter cells of the uninjected cell contain no detectable Morpholino activity (Nutt et al., 2001). There have been some reports of particular cell types in tissue explants that take up experimentally useful concentrations of unmodified Morpholinos. These cell types include epithelial cells in
Synthesis of Modified Oligonucleotides and Conjugates
4.30.11 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Using Morpholinos to Control Gene Expression
mouse embryo pancreatic explant cultures during E11 through 13 (Prasadan et al., 2002) and liver cells in mouse embryo E10 liver explants (Monga et al., 2003). Using an engineered mouse with a stably integrated green fluorescent protein (GFP) up-regulation splicecorrection reporter system (see Up-regulation system, below), Sazani showed that there is scant uptake of unmodified Morpholinos into most tissues from the blood of adult mice (Sazani et al., 2002). Scrape loading. Scrape loading of Morpholinos into adherent cell cultures was an early method for introducing Morpholinos into cultured cells (Partridge et al., 1996). When adherent cells are gently lifted from the bottom of a well using a soft rubber scraper, the cells become transiently permeable, allowing Morpholinos to diffuse into the cytosol from the medium. This technique will not deliver oligos to all cells in a culture, and reproducibility depends on the technique of the experimenter. This method has fallen out of favor as more reproducible techniques producing more homogeneous delivery have been developed. Microinjection. Microinjection of Morpholinos into early embryos is a widely used technique for knocking down gene expression. Microinjection introduces Morpholinos directly into the cytosol. As the cytoplasm is apportioned into daughter cells at cell division, both daughter cells will contain Morpholinos. Some embryos, such as Xenopus sp., have strong permeability barriers that prevent appreciable leakage to the daughters of uninjected cells (Nutt et al., 2001). Other embryos such as the zebrafish, Danio rerio, allow diffusion of Morpholinos between cells through the first few cell divisions (for a good model of Morpholino diffusion in zebrafish embryos, see Kimmel and Law, 1985a,b). Electroporation. Electroporation has become a standard method for delivery of Morpholinos into chick embryos (Kos et al., 2003), especially for studies of neural tube development (Tucker, 2004). Electroporation has also been used to deliver Morpholinos into other embryos including mice (Mellitzer et al., 2002), into brains of developing rats (Takahashi et al., 2002), into zebrafish (Cerda et al., 2006), into clipped fins of zebrafish (Thummel et al., 2005), and into cell cultures (Jubin, 2005). Uncharged Morpholinos can be electroporated; the electroporation procedure makes cells transiently permeable so that Morpholinos can diffuse across the plasma membrane.
Endo-Porter. Endo-Porter is a reagent developed to deliver Morpholino oligos conveniently and reproducibly to the cytosol of cultured cells through an endocytotic pathway. Endo-Porter is an amphiphilic peptide that becomes cationic at low pH. In culture medium, Endo-Porter is uncharged but sticks to the surface of cells. Upon endocytosis, Endo-Porter is protonated in the acidic endosome and permeabilizes the endosomal membrane, releasing the endosomal contents into the cytoplasm. Morpholinos co-endocytosed with membraneassociated Endo-Porter are released into the cytoplasm when the endosome is permeabilized (Summerton, 2005). Endo-Porter allows simultaneous delivery of multiple Morpholinos. The concentration of Morpholinos can be varied independently of the Endo-Porter concentration, allowing dose-response antisense studies while holding the delivery reagent concentration constant. Cells treated with a 5 µM carboxyfluoresceinated Morpholino and 8 µM Endo-Porter gave transfection efficiencies of 82% for human amnion-derived WISH cells and 78% for human myometrial cells when assayed by confocal microscopy (TysonCapper and Europe-Finner, 2006), though concentrations too low to be detected by fluorescence might still be sufficient to have measurable antisense activity. Endo-Porter has been used successfully with traditionally hard-to-transfect cells such as cardiomyocytes (Masaki et al., 2005). It works well with unmodified Morpholinos or carboxyfluoresceinated Morpholinos, but best delivery is achieved with lissaminated Morpholinos (S.T. Knuth, unpub. observ.). Endo-Porter is commercially available in neat DMSO or in a less-effective aqueous formulation for cells sensitive to DMSO. The recommended concentration of EndoPorter is 6 µM, achieved by using 6 µL of a 1 mM Endo-Porter solution per milliliter of cell culture; this concentration gives good delivery without toxicity to many cell types. However, cell types vary in their tolerance to Endo-Porter, with some cells tolerating higher exposures while other cells are harmed by a 6 µM Endo-Porter solution. When trying Endo-Porter with a new cell type, it is prudent initially to test a range of Endo-Porter concentrations (e.g., 2, 4, 6, and 8 µM) to assess delivery and to check the tolerance of the cells for the reagent. Special Delivery. Morpholinos are sometimes delivered using cationic delivery reagents, such as ethoxylated polyethylenimine (EPEI) or Lipofectamine. However,
4.30.12 Supplement 27
Current Protocols in Nucleic Acid Chemistry
since Morpholinos are not charged they will not form electrostatic complexes with cationic delivery reagents. Without such complexation, the Morpholinos are poorly delivered to the cytosol of treated cell cultures. To overcome this limitation, Morpholinos can be annealed to complementary or partially complementary strands of anionic nucleic acids. Special Delivery oligos are heteroduplexes of Morpholinos and partially complementary DNA, and are delivered after complexation with EPEI (Morcos, 2001). Special Delivery oligos were designed as a replacement for scrape loading of adherent cells, but can also be used with cells in suspension. Special Delivery oligos provide a more homogeneous delivery than scrape loading, and many studies have been published using them. However, several problems are inherent in the system: (1) EPEI is somewhat toxic to cells; (2) the concentration ratio of heteroduplex to EPEI is fixed; (3) only a single oligo sequence can be delivered at an effective concentration at any one time; and (4) the complexation procedure, which must be done prior to each delivery, adds complexity and variability to the experiment. While Special Delivery oligos can be made by following a fairly simple protocol, they are no longer available commercially as paired heteroduplexes. This approach has mostly been supplanted by Endo-Porter, which is simpler to use, more versatile, more effective, and less toxic in most cell types. Peptide conjugates. Cell-penetrating peptides covalently conjugated to Morpholinos are in development to enhance cytosolic delivery of Morpholinos in cell culture (Neuman et al., 2005) and in vivo (Kinney et al., 2005; Neuman et al., 2005). Most published research describing Morpholino-peptide conjugates has used arginine-rich peptides (Moulton et al., 2004; Neuman et al., 2004; Deas et al., 2005; Kinney et al., 2005; Nelson et al., 2005; McClorey et al., 2006). Conjugation with arginine-rich peptides alters the specificity, target affinity, and toxicity of Morpholinos (Nelson et al., 2005). Due to the high density of cationic charges on the peptide moiety, Morpholinos conjugated with arginine-rich peptides associate with subcellular structures and with outer cell surfaces. This property might lead to falsepositive artifacts when assessing delivery of arginine-conjugated peptides by fluorescencebased methods, such as fluorescence microscopy, fluorometry, or flow cytometry. To determine the concentration of an internalized conjugate using fluorescence-based methods,
the membrane-associated conjugate should be removed in order to avoid overestimation. Trypsin treatment has been effective for eliminating binding of Morpholino-peptide conjugates to the outside of cells (Moulton and Moulton, 2003). Minimum effective Morpholino concentration To avoid off-target knockdowns, the lowest concentration of Morpholino producing the desired knockdown should be determined. When delivering Morpholinos to cell cultures using Endo-Porter, starting with a 10 µM Morpholino concentration for both fluorescent delivery assays and functional experiments increases the chances that the fluorescence will be visible in the cytosol and that the first functional experiment will produce measurable results. Because a Morpholino concentration of 10 µM might cause nonspecific effects due to interaction with nontarget genes, functional assays should be performed using a range of Morpholino concentrations. Determining the minimum Morpholino concentration that produces measurable results allows one, subsequently, to avoid off-target knockdowns and to conserve oligo. Effective Morpholino concentrations in culture medium for knockdown experiments are typically in the 1 to 10 µM range. Simultaneous oligo strategy Oligos can sometimes be delivered together to enhance their effects. Pairs of nonoverlapping translation-blocking Morpholinos targeting the same mRNA can be used simultaneously in order to decrease the concentration required for a knockdown (Ekker and Larson, 2001). If the paired oligos are simultaneously introduced into the same cells, they are sometimes effective at much lower concentrations than for either oligo alone. If oligos are individually toxic in zebrafish, their use in combination at concentrations below their toxicity thresholds might elicit the desired phenotype without toxicity. Efficiency of splice-blocking can be increased by blocking both donor and acceptor splice sites flanking a single exon (P.A. Morcos, unpub. observ.). Targeting several exons simultaneously is an effective way to deplete a wild-spliced mRNA (Draper et al. 2001). When designing oligos intended for co-delivery, check for complementarity between oligos that may cause them to form Morpholino heterodimers and lose activity (see Troubleshooting: Oligo activity decreases with pairs of oligos).
Synthesis of Modified Oligonucleotides and Conjugates
4.30.13 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Using Morpholinos to Control Gene Expression
Assessing oligo delivery It is best to begin a set of Morpholino experiments in a cell line by confirming and optimizing delivery. Most experimental problems involving Morpholinos in cell culture are due to insufficient delivery of oligo and can be solved by optimizing delivery to the particular type of cells used. Checking whether good cytosolic delivery can be achieved before starting to use custom-made Morpholinos is usually the most efficient use of time and resources. By fluorescence. Fluorescence can be measured by fluorescence microscopy, flow cytometry, or fluorometry. Only fluorescence microscopy can distinguish cytosolic and nuclear fluorescence (indicating successful delivery of a fluorescent Morpholino) from endosomal or surface-bound fluorescence (which does not contribute to antisense activity). A fluorescence microscope and a fluorescently labeled marker such as a Morpholino or a 10-kDa dextran are required for a reliable delivery assay. Using a 10-kDa fluoresceinated dextran or a carboxyfluoresceinated standard Morpholino control before using a more expensive, custom-made Morpholino produces reliable uptake assays at reduced cost. After delivery, live cells may be conveniently observed using an inverted epifluorescence microscope. Fixing cells can lead to false positives for delivery due to permeabilization of the plasma membrane and release of the oligo from endosomes during fixation. Using an objective with a higher numerical aperture increases the amount of light gathered from a cell and helps reveal dim fluorescence. If diffuse fluorescence is seen throughout the cytosol of the cells, the Morpholino has been delivered successfully. Bright punctate spots are likely labeled oligos trapped in endosomes. Punctate fluorescence does not indicate delivery, but it does not preclude it either. For delivery with Endo-Porter, start by assaying a range of Endo-Porter concentrations for delivery efficacy and cell tolerance (see Basic Protocol 3) or by trying a concentration of 6 µM Endo-Porter in the selected cell culture. After Endo-Porter delivery, antisense activity can be detected using as little as 1 µM Morpholino. However, although antisense activity can be achieved at Morpholino concentrations that do not produce detectable fluorescence, proof-of-delivery experiments do require detectable fluorescence. To accumulate enough fluorescence for microscopy, a concentration of about 10 µM Morpholino is needed. The Endo-Porter and labeled Morpholino should be left on the cells overnight
to allow time for endocytotic uptake and accumulation. By measuring antisense activity. If delivery is successful and a Morpholino targeting translation or splicing works as designed, a decrease in protein concentration or a shift in RT-PCR product mass (respectively) can be measured. Successful delivery might also be indicated by phenotypic effects, such as a decrease in targeted enzyme activity (Hayashi et al., 2005) or a change in morphology (Ekker, 2000). However, assaying only for a phenotypic effect becomes problematic if the expected change in phenotype does not occur; if antisense activity is not separately assessed at the level of protein concentration or mRNA mass, the experimenter will not be able to discern whether (1) the oligo failed to reach and interact with its target mRNA to produce the knockdown or splice-block, or (2) the knockdown or spliceblock was successful but did not cause the expected phenotypic change. Assaying translation blocking activity Activity of translation-blocking Morpholinos can be assayed using immunoblots. However, while Morpholinos can halt new translation, they do not cause degradation of existing protein; it therefore takes some time after Morpholino treatment before immunoblots will show evidence of a knockdown. The time required will vary with the half-life of the protein. If no antibody is available for the protein product when targeting an mRNA for translation blocking, then indirect assays such as the change in phenotype of an embryo must sometimes be used to assess the effectiveness of translation blocking. Morpholinos can phenocopy (mimic the phenotype of) many known mutations that affect morphology during development; embryos with phenotypes modified by Morpholino treatment are known as morphants (Ekker, 2000). In some cases, the enzymatic activity of a target protein can be assayed (Hayashi et al., 2005). An enzyme activity assay may serve as an assay for Morpholino activity, though there must be a delay between application of the Morpholino and the enzyme activity assay to allow for degradation of preexisting protein (see also the discussion of complementation in Troubleshooting). The effect of a Morpholino on target RNA stability varies with the sequence. Target mRNA concentrations in Morpholino-treated cells may be decreased, unchanged, or increased relative to untreated cells. Changes
4.30.14 Supplement 27
Current Protocols in Nucleic Acid Chemistry
in mRNA concentrations may be due to changes in the secondary structure of the mRNA on binding a Morpholino, thereby altering the availability of the mRNA for nucleolytic degradation. Consequently, mRNA assays such as Northern blots or RT-PCR are not suitable for assaying the activity of a translation-blocking Morpholino. Assaying splice blocking activity Because blocking splicing changes the mass of the mRNA produced, RT-PCR with appropriate choice of primers is a good molecular assay for detecting the activity of spliceblocking Morpholinos. However, it is important to keep in mind that it cannot be predicted with certainty whether a splice-blocking Morpholino will cause an exon deletion (most common), an intron insertion, or activation of a cryptic splice site (which can cause a partial insertion or deletion). Because cryptic sites often redirect splicing of only a fraction of the targeted pre-mRNA population, splice blocking might produce a mixture of RT-PCR product masses (Draper et al., 2001). To detect any of these changes, it is best to use primers targeted to the two exons flanking and closest to, but not including, the Morpholino’s splice junction. Targeting a splice junction on an internal exon is likely to cause exon deletion. Primers should be chosen so that, if an exon deletion occurs, the RT-PCR product will be large enough to detect easily on a gel (one hundred to several hundred bases). That means for the system exon1–intron1–(splice blocker target)–exon2– intron2–exon3, the RT-PCR primers should be targeted to exon 1 and exon 3 in order to detect either intron 1 insertions (unusual) or exon 2 deletions (common). If the first (most 5 ) or last (most 3 ) splice junction in an mRNA is targeted, the usual result is an intron insertion instead of an exon deletion. However, targeting the first splice junction might activate a cryptic splice site in the first exon, resulting in deletion of the 3 end of the first exon or inclusion of a 5 fragment of the first intron. When targeting the last exon, an intron insertion is a more likely outcome. This is because consensus sequences of splice acceptors are more complex than those of splice donors, so it is less likely that the last exon will contain a near-consensus cryptic splice acceptor. When assaying the activity of a spliceblocking Morpholino at the molecular level using RT-PCR, it is important to compare the expected size of the RT-PCR product after the splice modification with the size of the
RT-PCR product produced by an untreated cell or organism. For easiest detection, spliceblocked RT-PCR products would be about half or twice the size of the native-spliced product (for exon deletion or intron insertion, respectively). A real system usually won’t allow such a tidy result, but it is necessary for the change in mass to be clearly visible on the gel (e.g., a 5% change in mass can be difficult to detect). Fidelity of replication can be a problem in RT-PCR, so it is best to design shorter RTPCR products if all else is equal. This means for the knockdown of exon 2, targeting primers in exon 1 near the junction with intron 1 and in exon 3 near the junction with intron 2 would be the best choice. However, all else is not equal; since fragments should be large enough that they are clearly visible, it is prudent to move the primers farther into the flanking exons. When possible, primers should amplify RT-PCR products with lengths of hundreds of bases to ensure full-length replication and visible bands. Splice modifications can cause downstream frameshifts or inclusion of intronic sequence in the mature messenger. Either of these results can cause a range of complicating effects, including truncation of the protein product by appearance of in-frame stop codons, translation suppression by appearance of a miRNA target site, degradation or suppression of the messenger through siRNA or miRNA activity, and nonsense-mediated mRNA decay. Splice modification may or may not cause a change detectable by an immunochemical assay such as an ELISA or immunoblot, since the conformation of the modified protein around the antigenic site may or may not be changed by a splice modification. A large insertion or deletion might result in loss of antibody binding or at least a significant shift in the band position on a western blot, but a small insertion or deletion could be difficult to detect. It is possible that inserting an intron or deleting an exon will cause the protein product to lose function, but it is far from certain. If the active site of the protein is known and the exon encoding the active site is targeted, a loss of function is likely. However, if the active site is not known, then splice-blocking might not change the protein’s activity. A protein might be made that retains the conformation of its active site even though it has an inserted or deleted polypeptide moiety at a different part of the protein. This means that looking for a phenotypic change in an embryo or assaying enzyme activity is often inadequate for
Synthesis of Modified Oligonucleotides and Conjugates
4.30.15 Current Protocols in Nucleic Acid Chemistry
Supplement 27
assessing the splice-blocking activity of a Morpholino. This also means that while RT-PCR is a useful tool to confirm splice blocking activity, one should independently assay for protein function before concluding that a targeted gene is not required for a biological process, because successful splice-blocking may not alter the activity of the protein in the process. Up-regulation system Assaying antisense activity by knocking down a protein can lead to false positives, because toxicity can cause a decrease in gene expression and this can be misinterpreted as targeted gene knockdown unless careful controls are used. To address this problem and to provide an increased signal-to-noise ratio for antisense activity assays, Ryzard Kole’s group developed a set of signal up-regulation reporter systems based on splice modification. These systems use a mutation in human β-globin that creates a new splice site and causes thalessemia. The splice-mutant has a stop codon in-frame in the mRNA as well as a frameshift in the downstream coding region; blocking the mutant site splices out the stop and restores the correct reading frame. Constructs coupling this mutation to luciferase or GFP have been engineered. Of particular interest are the pLuc705 HeLa cell line (Schmajuk et al., 1999), which expresses luciferase when the mutant splice site is spliceblocked with control oligo, and the Sazani mouse (Sazani et al., 2002), which expresses GFP when splice-blocked with the appropriate oligo.
Using Morpholinos to Control Gene Expression
Controls When an oligo is used to target an mRNA, a parallel experiment should be done using a negative control oligo. Negative control oligos include the standard control oligo and an invert oligo. A 5-mispair specificity control oligo is also sometimes used as a negative control. The negative control shows that the effects observed during the antisense experiment are due to the sequence of the targeting oligo and not to the backbone chemistry of the Morpholino or the cytosolic delivery method used. Standard control oligo. A standard control Morpholino with the sequence CCTCCTACCTCAGTTACAATTTATA has been used in many organisms as a negative control sequence without triggering off-target or non-antisense effects. This negative control produced no toxic or teratogenic effects even when administered at considerably higher concentrations
than typically used for specific knockdown experiments. Any custom-sequence control oligo has some risk of interacting with off-target RNA; in contrast, the standard control has an established history of inactivity and is a reliable choice for a negative control oligo. The standard control Morpholino is designed to splice-block the mutant splice site used in the pLuc705 up-regulation reporter system. Invert control. If a negative control oligo needs to be related to the custom-made targeting oligo in terms of base composition, the invert oligo is a good choice of sequence. The invert has the same base sequence as the targeting oligo, but the sequence is reversed in the 5 -to-3 orientation (i.e., 5 -ACGGTGC would become 5 -CGTGGCA). The advantage of an invert over a scrambled sequence is that the invert sequence can be conveniently generated by a simple algorithm and will have the same CG content, G content, and selfcomplementarities as the targeting oligo. However, there is always a risk with any custommade oligo that the oligo may interact with unintended RNAs. Sense control. Sense Morpholinos have sometimes caused an increase in concentration of the mRNA targeted by an antisense oligo (P.A. Morcos, unpub. observ.). Thus, a sense sequence is not a good choice for a negative control Morpholino. 5-Mispair oligo. Off-target knockdown by any antisense molecule increases with increasing concentration. A 5-mispair oligo is used to define the effective and specific concentration window for a targeting oligo. Using the targeting oligo within its effective and specific concentration range decreases the chance of causing experimental artifacts by interaction with off-target RNA. A 5-mispair control oligo has nearly the same sequence as a targeting oligo, but has five mismatched bases distributed through the sequence. The mismatches should be distributed fairly evenly through a 25-mer oligo, starting a few bases in from each end. Ideally, the mismatches should be formed by exchanging C for G and G for C, since these mismatches disrupt the formation of three hydrogen bonds per base pair. Ideally, when a targeting oligo is used near the lowest concentration that produces a discernable effect, the 5-mispair oligo used at the same concentration will not produce the effect. However, as with any custom-sequence control oligo, there is a possibility that the 5-mispair oligo will interact with an untargeted RNA, triggering an off-target effect. If an
4.30.16 Supplement 27
Current Protocols in Nucleic Acid Chemistry
oligo targets a high-copy-number transcript, requiring relatively high Morpholino concentration for knockdown, and the mispair oligo interacts with a low-copy-number transcript, the mispair oligo might cause effects even at concentrations below the concentration at which the targeting oligo becomes effective. The 5-mispair oligo can be used in an experiment that determines the effective and specific window of concentrations for a targeting oligo, which is the concentration range between the onset of measurable activity for the targeting oligo and the onset of measurable activity for its 5-mispair oligo. The definition of the effective and specific concentration range based on a 5-mispair oligo evolved through trial and error. Originally a 4-mispair specificity control was recommended, but a 4-mispair oligo sometimes measurably decreased the target protein concentration at concentrations low enough that the corresponding targeting oligo was just becoming effective, so there was not a wide enough effective and specific concentration range to be consistently useful. Many investigators use the 5-mispair oligo as a negative control, but that was not its intended purpose. Assuming that adding the mismatches does not create too much complementarity to an important off-target mRNA and trigger an off-target knockdown, the 5-mispair oligo usually behaves as a negative control when used at concentrations low enough that the targeting oligo is just becoming effective. However, the 5-mispair oligo is intended as a specificity control that shows the targeting oligo is being used in its effective and specific range. To demonstrate specificity of the targeting oligo, the targeting oligo, a 5-mispair control oligo, and a true negative control oligo (such as the standard control) are used at the same concentration in parallel treatments. If the 5-mispair and negative control oligos produce the same results, and the targeting oligo produces a different result, the experiment indicates that the targeting oligo has been used within its effective and specific concentration range. Appearance of an effect due to interaction of a target RNA with the 5-mispair control oligo suggests that, at that same concentration, the targeting oligo might also interact with offtarget RNAs. Two nonoverlapping translation blockers. Another strategy for showing that the effect of a translation-blocking Morpholino is due to the knockdown of its targeted mRNA is to use a second oligo targeted to a different and nonoverlapping site in the 5 -UTR of the tar-
geted mRNA. If the second oligo has the same effect on the cells (or organism) as the first, this supports the hypothesis that the effect observed is due to the knockdown of the targeted gene. Two splice blockers targeting one internal exon. If a Morpholino targeting a splice donor site produces the same result as a Morpholino targeting the splice acceptor of the same exon, this supports the hypothesis that the effect observed is due to the excision of the targeted exon. However, failure of the two oligos to produce the same result may be due to activation of a cryptic splice site(s) by one or both of the oligos. mRNA rescue. A very strong proof of specificity involves the use of a rescue mRNA. A rescue mRNA codes for the same protein targeted by the Morpholino knockdown, but has a modified 5 -UTR that is not targeted by the Morpholino. For this experiment, the rescue mRNA and Morpholino are delivered to the cytosol together. If the co-delivered rescue mRNA and Morpholino produce the same wild-type phenotype as untreated cells or organisms, this supports the hypothesis that the morphant phenotype elicited by the Morpholino alone is due to interaction with the targeted RNA. Unfortunately, the mRNA rescue experiment cannot work for some genes when used in embryos. The timing of the onset of translation is crucial for some developmental genes, and the early onset of translation resulting from co-injection of Morpholino and rescue mRNA in the early zygote may alter the developmental process so that these embryos never recapitulate the wild-type phenotype. Furthermore, the location of gene expression is often crucial for development, but oocyte microinjection causes rescue mRNAs to be present in all cells of the embryo until degraded or diluted by growth. End modifications Several optional modifications attached to the ends of Morpholinos are commercially available. Carboxyfluorescein, lissamine, and primary amines (Fig. 4.30.4) are the most commonly used. Optional groups are usually added to the secondary amine on the 3 -end of the oligo, and are assumed to be 3 modifications unless explicitly declared to be 5 modifications. Fluorophores and biotin are attached to Morpholinos through flexible polyethyleneglycol spacers. The length of the spacers was chosen based on antisense activity studies to ensure that the fluorophores would not interfere with binding of the Morpholinos to their
Synthesis of Modified Oligonucleotides and Conjugates
4.30.17 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Figure 4.30.4
Using Morpholinos to Control Gene Expression
Commercially available 3 -end modifications of Morpholino oligos.
target RNA sequences. The primary amine modification includes a short spacer of two methylenes. Carboxyfluorescein. Carboxyfluorescein is a green-emitting fluorophore that was chosen from among the fluoresceins for its good chemical stability. While its photostability is better than that of many of the fluoresceins, all of the fluoresceins are subject to photobleaching, so carboxyfluorescein should not be exposed to intense light unnecessarily. The exci-
tation wavelength of a carboxyfluoresceinated Morpholino in water is 502 nm and its emission wavelength is 525 nm. Carboxyfluorescein has two negative charges at neutral pH. Lissamine. Lissamine is a red-emitting sulforhodamine B. The excitation wavelength of a lissaminated Morpholino in water is 575 nm, and the emission wavelength is 593 nm. Lissamine is a zwitterion at neutral pH, with one positive and one negative charge. Adding a lissamine to a Morpholino increases its delivery
4.30.18 Supplement 27
Current Protocols in Nucleic Acid Chemistry
efficiency with Endo-Porter, but adding lissamine to a Morpholino can decrease its aqueous solubility. It is therefore recommended to use a carboxyfluorescein tag when a fluorochrome is needed, especially for Morpholino sequences with relatively high G contents (>30% G). Primary amine. Morpholinos may be modified with a primary amine to provide a reactive site for attachment of other moieties to the oligo. An unmodified Morpholino has a secondary amine on the 3 end, the pKa of which is 6.5. The primary amine, with its pKa of 10.2, provides a more reactive site. When a primary amine is attached to the 3 end of the oligo, this converts the 3 -secondary amine of the morpholine ring to a tertiary amine as a consequence of the attachment of a short spacer tethering the new primary amine. When a primary amine is attached to the 5 end of the oligo, the 3 -secondary amine is acetylated so that a reagent added to react with the primary amine will not react with the 3 end of the oligo. When reacting a primary amine with a derivatizing reagent, it is prudent to include an additional short spacer to prevent steric hindrance between the moiety being added and the Morpholino. Morpholino stock solutions and reconcentrating Morpholinos Morpholino stock solutions in distilled water should be kept sterile and can be autoclaved. Do not use water containing diethylpyrocarbonate. Morpholino stock solutions can be dissolved in buffers such as Ringer’s solution or Danieau buffer, but this can cause problems later if the stock solution must be reconcentrated, since lyophilization can be more difficult from a buffer. Also, Morpholinos are substantially more soluble in distilled water than in isotonic salt solutions. A solution of Morpholino in water can be concentrated by using a Speedvac or by lyophilization (freeze-drying). Lyophilizing Morpholinos from water produces a fluffy solid that dissolves fairly readily if the sequence has good solubility properties. However, dissolution of Morpholinos concentrated with a Speedvac may be more difficult and will likely require patience and heating to 65◦ C. Temperature during handling Morpholinos are not degraded by nucleolytic enzymes. Solutions of DNA and RNA are normally kept on ice during experiments to prevent nucleolytic degradation, but this is not
a concern with Morpholinos. However, some Morpholino solutions have low enough solubility that icing a solution may cause a loss of activity, due to the oligo coming out of solution. Therefore, icing Morpholino solutions is not only unnecessary but can cause problems; Morpholinos should be kept at room temperature during experiments. Material affinity Morpholinos have some affinity for plastics, so passaging very dilute (submicromolar) solutions through plastic containers may cause appreciable decreases in activity. Similarly, filter sterilization may cause Morpholino solutions to lose some activity as some oligo binds to the filter. When put through the same procedures with the same exposure to plastic surfaces, high-concentration Morpholino solutions have a smaller fractional decrease in concentration than low-concentration Morpholino solutions. Therefore, if exposure to plastic surfaces is required, it is best to do the procedures with Morpholinos in a relatively concentrated state (>1 µM). Similarly, if Morpholinos are to be stored in solution for more than a few days, it is best to store them at high concentration. Since solutions of Morpholinos at very low concentrations (<1 µM) may lose activity over a time scale of minutes to hours, dilutions should be made just before use. If Morpholino solutions of less than about 100 µM are filtered, the concentration may be affected appreciably given the large surface area of filters. As the oligo bound is proportional to the surface it is exposed to, a small-diameter filter should be used to minimize oligo losses. Pall Acrodisc HT Tuffryn 0.2-µm membrane filters were found to bind less Morpholino per area than other filters tested (J.E. Summerton, unpub. observ.). The concentration of oligo in a solution can be measured spectrophotometrically just before and after performing a procedure to determine the loss of oligo caused by the procedure.
Troubleshooting Loss of antisense activity over time Morpholinos can be safely stored at temperatures ranging from room temperature to −80◦ C. Some Morpholino solutions lose activity when stored frozen, not due to degradation of the oligos but simply to aggregation. The activity can be recovered by heating the solution to 65◦ C for 10 min prior to use.
Synthesis of Modified Oligonucleotides and Conjugates
4.30.19 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Loss of fluorescence over time Fluorescent tags can be photobleached by exposure to bright light or prolonged exposure to dim light. Always store fluorescent materials in the dark. Wrapping aluminum foil around tubes containing fluorescent materials is an easy and prudent method for protecting fluorophores. Fluorescent materials can autoquench at high concentrations and decrease their light emission, so do not check for fluorescence at very high concentration. Labeled Morpholinos, as 10 µM solutions, are well below the concentration at which their fluorophores autoquench. No apparent activity If a Morpholino does not produce the anticipated result, there are several possibilities to consider. Has delivery been confirmed? If the oligo is not reaching the cytosol of the cells, no antisense activity will be observed. Is the activity checked by a molecular assay? If the selected activity assay determines a phenotype, such as a change in embryo morphology or in enzyme activity, the oligo may be successfully knocking down translation or modifying splicing, but a second protein may be complementing the lost activity of the target protein, thereby confounding the assay. Assaying translation blocking by immunoblot and splice blocking by RT-PCR can help determine whether the oligo is not interacting with its target or has not been delivered, or whether there is a more subtle reason for the failure to produce the expected phenotype, such as complementation by another protein. Feedback upregulation can also cause a knockdown to fail; greatly increased transcription of the targeted mRNA in response to an attempted knockdown can overwhelm the ability of the oligo to block all of the targeted messengers. Oligo activity decreases with pairs of oligos When two or more oligos are together in a cell, they may hybridize with each other if they share complementary sequences. If a pair of oligos has less activity than each individual oligo, check the sequences for complementarities. Sixteen contiguous hydrogen bonds of complementarity is the maximum recommended for oligos used together in cells or organisms at 37◦ C.
Using Morpholinos to Control Gene Expression
Clogging microinjectors If a Morpholino solution causes a microinjector to clog, one can: (1) heat the solution to disrupt tiny clumps (65◦ C for 10 min), (2) filter-sterilize the solution (although some oligo may be lost on the filter), or (3) try in-
jecting a higher volume of a less concentrated solution.
Anticipated Results Translation blockers If a translation-blocking Morpholino knocks down expression of a protein, this activity can be revealed by a delayed decrease in the protein signal on an immunoblot using an antibody to the protein. The successful knockdown should also decrease the activity of the targeted protein, though an assay for the activity of that protein can be confounded by complementation by another protein. Splice blockers If a splice-blocking Morpholino changes the mass of an mRNA, this activity can be revealed soon after delivery by a change in the mass of an RT-PCR product produced using appropriately chosen primers. A successful exon excision should also result in a delayed decrease of the activity encoded by the deleted exon as preexisting protein degrades. Spliceblocking may also decrease activities encoded on untargeted exons of a target RNA due to frameshifts, inserted stop codons, or changes in tertiary structure.
Time Considerations After delivery, wait for antisense effects to be measurable When a Morpholino is delivered into the cytosol of a cell, preexisting protein is not altered by the Morpholino. For a translation blocking oligo, this means that even if translation of a protein is immediately and completely halted on Morpholino delivery, an assay for protein concentration will not immediately reveal a successful knockdown. At least part of the existing protein must be degraded before the knockdown will be evident on an immunoblot. Similarly, although a splice-blocking oligo may cause a rapid change in the mass of an RT-PCR product, the protein produced prior to splice blocking will persist in the cell until degraded. Delivery systems using endocytotic uptake, such as Endo-Porter or Special Delivery, increase the lag between the start of delivery and the appearance of a knockdown or spliceblock signal. An overnight wait is generally sufficient to allow for endocytotic uptake. For embryonic studies, the presence of maternal transcripts in a zygote may delay the loss of protein activity when splice-blocking Morpholinos are used. Though a splice blocker
4.30.20 Supplement 27
Current Protocols in Nucleic Acid Chemistry
can modify splicing of pre-mRNA transcribed in the zygote, maternal transcripts are already spliced before the onset of zygotic transcription and will be expressed in their unmodified form. Translation-blockers can block both maternal and zygotic transcripts, and can thus provide a more rapid knockdown than splice blockers. Redelivery When translation of a protein is blocked by a Morpholino, existing protein in the cell persists until broken down. After delivery, as cells grow and divide, the concentration of Morpholino oligos in their cytoplasm decreases due to dilution. Because of these two processes, when Morpholinos are used to knock down genes that code for unusually abundant or stable proteins, redelivery of the oligos may be required before a significant decrease in protein levels can be detected by immunoblotting. After an initial treatment with a Morpholino at the start of day 1, redelivery on day 4 usually suffices to produce a clear knockdown of stable and abundant proteins by day 6. However, attempts to block translation of actin have so far failed to produce a decrease in actin levels on immunoblots, suggesting that Morpholinos cannot knockdown some very abundant proteins (P.A. Morcos, unpub. observ.).
Acknowledgements Thanks to Dr. Shannon T. Knuth for editing and for information from protocols she has written, and to Conrad Shultz and Drs. James E. Summerton, Hong M. Moulton, Yongfu Li, and Paul A. Morcos for their editing and suggestions.
Literature Cited Aboul-ela, F., Koh, D., Tinoco, I. Jr., and Martin, F.H. 1985. Base-base mismatches. Thermodynamics of double helix formation for dCA3XA3G + dCT3YT3G (X, Y = A,C,G,T). Nucl. Acids Res. 13:4811-4824. Alonso, M., Stein, D.A., Thomann, E., Moulton, H.M., Leong, J.C., Iversen, P., and Mourich, D.V. 2005. Inhibition of infectious haematopoietic necrosis virus in cell cultures with peptideconjugated morpholino oligomers. J. Fish Dis. 28:399-410. Bruno, I.G., Jin, W., and Cote, G.J. 2004. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum. Mol. Genet. 13:2409-2420. Cerda, G.A., Thomas, J.E., Allende, M.L., Karlstrom, R.O., and Palma, V. 2006. Electroporation of DNA, RNA, and morpholinos into zebrafish embryos. Methods 39:207-211.
Cheong, C. and Moore, P.B. 1992. Solution structure of an unusually stable RNA tetraplex containing G- and U-quartet structures. Biochemistry 31:8406-8414. Deas, T.S., Binduga-Gajewska, I., Tilgner, M., Ren, P., Stein, D.A., Moulton, H.M., Iversen, P.L., Kauffman, E.B., Kramer, L.D., and Shi, P.Y. 2005. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79:4599-4609. Draper, B.W., Morcos, P.A., and Kimmel, C.B. 2001. Inhibition of zebrafish fgf8 pre-mRNA splicing with Morpholino oligos: A quantifiable method for gene knockdown. Genesis 30:154156. Ekker, S.C. 2000. Morphants: A new systematic vertebrate functional genomics approach. Yeast 17:302-306. Ekker, S.C. and Larson, J.D. 2001. Morphant technology in model developmental systems. Genesis 30:89-93. Enterlein, S., Warfield, K.L., Swenson, D.L., Stein, D.A., Smith, J.L., Gamble, C.S., Kroeker, A.D., Iversen, P.L., Bavari, S., and Muhlberger, E. 2006. VP35 knockdown inhibits ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 50:984993. Geller, B.L., Deere, J., Tilley, L., and Iversen, P.L. 2005. Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis. J. Antimicrob. Chemother. 55:983988. Giles, R.V., Spiller, D.G., Clark, R.E., and Tidd, D.M. 1999. Antisense Morpholino oligonucleotide analog induces missplicing of c-myc mRNA. Antisense Nucleic Acid Drug Dev. 9:213-220. Hayashi, Y., Horibata, Y., Sakaguchi, K., Okino, N., and Ito, M. 2005. A sensitive and reproducible assay to measure the activity of glucosylceramide synthase and lactosylceramide synthase using HPLC and fluorescent substrates. Anal. Biochem. 345:181-186. He, J., Liu, G., Zhang, S., Rusckowski, M., and Hnatowich, D.J. 2003. Pharmacokinetics in mice of four oligomer-conjugated polymers for amplification targeting. Cancer Biother. Radiopharm. 18:941-947. He, J., Liu, G., Gupta, S., Zhang, Y., Rusckowski, M., and Hnatowich, D.J. 2004. Amplification targeting: A modified pretargeting approach with potential for signal amplification-proof of a concept. J. Nucl. Med. 45:1087-1095. Heasman, J., Kofron, M., and Wylie, C. 2000. Betacatenin signaling activity dissected in the early Xenopus embryo: A novel antisense approach. Dev. Biol. 222:124-134. Henderson, R.E., Kirkegaard, L.H., and Leonard, N.J. 1973. Reaction of diethylpyrocarbonate
Synthesis of Modified Oligonucleotides and Conjugates
4.30.21 Current Protocols in Nucleic Acid Chemistry
Supplement 27
with nucleic acid components. Adenosinecontaining nucleotides and dinucleoside phosphates. Biochim. Biophys. Acta 294:356-364. Howard, M.T., Gesteland, R.F., and Atkins, J.F. 2004. Efficient stimulation of site-specific ribosome frameshifting by antisense oligonucleotides. RNA 10:1653-1661. Hudziak, R.M., Barofsky, E., Barofsky, D.F., Weller, D.L., Huang, S.B., and Weller, D.D. 1996. Resistance of Morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug. Dev. 6:267-272. Jubin, R. 2005. Optimizing electroporation conditions for intracellular delivery of Morpholino antisense oligonucleotides directed against the hepatitis C virus internal ribosome entry site. Methods Mol. Med. 106:309-322. Jubin, R., Vantuno, N.E., Kieft, J.S., Murray, M.G., Doudna, J.A., Lau, J.Y., and Baroudy, B.M. 2000. Hepatitis C virus internal ribosome entry site (IRES) stem loop IIId contains a phylogenetically conserved GGG triplet essential for translation and IRES folding. J. Virol. 74:1043010437. Kang, H., Chou, P.J., Johnson, W.C. Jr., Weller, D., Huang, S.B., and Summerton, J.E. 1992. Stacking interactions of ApA analogues with modified backbones. Biopolymers 32:1351-1363. Khokha, M.K., Chung, C., Bustamante, E.L., Gaw, L.W., Trott, K.A., Yeh, J., Lim, N., Lin, J.C., Taverner, N., Amaya, E., Papalopulu, N., Smith, J.C., Zorn, A.M., Harland, R.M., and Grammer, T.C. 2002. Techniques and probes for the study of Xenopus tropicalis development. Dev. Dyn. 225:499-510. Kimmel, C.B. and Law, R.D. 1985a. Cell lineage of zebrafish blastomeres. II. Formation of the yolk syncytial layer. Dev. Biol. 108:86-93. Kimmel, C.B. and Law, R.D. 1985b. Cell lineage of zebrafish blastomeres. III. Clonal analyses of the blastula and gastrula stages. Dev. Biol. 108:94101. Kinney, R.M., Huang, C.Y., Rose, B.C., Kroeker, A.D., Dreher, T.W., Iversen, P.L., and Stein, D.A. 2005. Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with Morpholino oligomers. J. Virol. 79:5116-5128. Kloosterman, W.P., Wienholds, E., Ketting, R.F., and Plasterk, R.H. 2004. Substrate requirements for let-7 function in the developing zebrafish embryo. Nucl. Acids Res. 32:6284-6291. Kos, R., Tucker, R.P., Hall, R., Duong, T.D., and Erickson, C.A. 2003. Methods for introducing Morpholinos into the chicken embryo. Dev. Dyn. 226:470-477. Lebedeva, I. and Stein, C.A. 2001. Antisense oligonucleotides: Promise and reality. Annu. Rev. Pharmacol. Toxicol. 41:403-419.
Using Morpholinos to Control Gene Expression
Liu, G., He, J., Zhang, S., Liu, C., Rusckowski, M., and Hnatowich, D.J. 2002a. Cytosine residues influence kidney accumulations of 99mTclabeled Morpholino oligomers. Antisense Nucleic Acid Drug. Dev. 12:393-398.
Liu, G., Zhang, S., He, J., Liu, N., Gupta, S., Rusckowski, M., and Hnatowich, D.J. 2002b. The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTcMorpholinos in mice. Q. J. Nucl. Med. 46:233243. Mang’era, K.O., Liu, G., Yi, W., Zhang, Y., Liu, N., Gupta, S., Rusckowski, M., and Hnatowich, D.J. 2001. Initial investigations of 99mTc-labeled Morpholinos for radiopharmaceutical applications. Eur. J. Nucl. Med. 28:1682-1689. Masaki, M., Izumi, M., Oshima, Y., Nakaoka, Y., Kuroda, T., Kimura, R., Sugiyama, S., Terai, K., Kitakaze, M., Yamauchi-Takihara, K., Kawase, I., and Hirota, H. 2005. Smad1 protects cardiomyocytes from ischemia-reperfusion injury. Circulation 111:2752-2759. McCaffrey, A.P., Meuse, L., Karimi, M., Contag, C.H., and Kay, M.A. 2003. A potent and specific Morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 38:503-508. McClorey, G., Moulton, H.M., Iversen, P.L., Fletcher, S., and Wilton, S.D. 2006. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 13:1373-1381. Mellitzer, G., Hallonet, M., Chen, L., and Ang, S.L. 2002. Spatial and temporal ‘knock down’ of gene expression by electroporation of doublestranded RNA and Morpholinos into early postimplantation mouse embryos. Mech. Dev. 118:57-63. Monga, S.P., Monga, H.K., Tan, X., Mule, K., Pediaditakis, P., and Michalopoulos, G.K. 2003. Beta-catenin antisense studies in embryonic liver cultures: Role in proliferation, apoptosis, and lineage specification. Gastroenterology 124:202-216. Morcos, P.A. 2001. Achieving efficient delivery of Morpholino oligos in cultured cells. Genesis 30:94-102. Moulton, H.M. and Moulton, J.D. 2003. Peptideassisted delivery of steric-blocking antisense oligomers. Curr. Opin. Mol. Ther. 5:123-132. Moulton, H.M., Nelson, M.H., Hatlevig, S.A., Reddy, M.T., and Iversen, P.L. 2004. Cellular uptake of antisense Morpholino oligomers conjugated to arginine-rich peptides. Bioconjug. Chem. 15:290-299. Nasevicius, A. and Ekker, S.C. 2000. Effective targeted gene ‘knockdown’ in zebrafish. Nat. Genet. 26:216-220. Nelson, M.H., Stein, D.A., Kroeker, A.D., Hatlevig, S.A., Iversen, P.L., and Moulton, H.M. 2005. Arginine-rich peptide conjugation to Morpholino oligomers: Effects on antisense activity and specificity. Bioconjug. Chem. 16:959-966. Neuman, B.W., Stein, D.A., Kroeker, A.D., Paulino, A.D., Moulton, H.M., Iversen, P.L., and Buchmeier, M.J. 2004. Antisense Morpholinooligomers directed against the 5 end of the genome inhibit coronavirus proliferation and growth. J. Virol. 78:5891-5899.
4.30.22 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Neuman, B.W., Stein, D.A., Kroeker, A.D., Churchill, M.J., Kim, A.M., Kuhn, P., Dawson, P., Moulton, H.M., Bestwick, R.K., Iversen, P.L., and Buchmeier, M.J. 2005. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense Morpholino oligomers. J. Virol. 79:9665-9676. Nutt, S.L., Bronchain, O.J., Hartley, K.O., and Amaya, E. 2001. Comparison of morpholino based translational inhibition during the development of Xenopus laevis and Xenopus tropicalis. Genesis 30:110-113. Partridge, M., Vincent, A., Matthews, P., Puma, J., Stein, D., and Summerton, J. 1996. A simple method for delivering Morpholino antisense oligos into the cytoplasm of cells. Antisense Nucleic Acid Drug Dev. 6:169-175. Prasadan, K., Daume, E., Preuett, B., Spilde, T., Bhatia, A., Kobayashi, H., Hembree, M., Manna, P., and Gittes, G.K. 2002. Glucagon is required for early insulin-positive differentiation in the developing mouse pancreas. Diabetes 51:3229-3236. Sazani, P., Kang, S.H., Maier, M.A., Wei, C., Dillman, J., Summerton, J., Manoharan, M., and Kole, R. 2001. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucl. Acids Res. 29:3965-3974. Sazani, P., Gemignani, F., Kang, S.H., Maier, M.A., Manoharan, M., Persmark, M., Bortner, D., and Kole, R. 2002. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20:1228-1233. Scacheri, P.C., Rozenblatt-Rosen, O., Caplen, N.J., Wolfsberg, T.G., Umayam, L., Lee, J.C., Hughes, C.M., Shanmugam, K.S., Bhattacharjee, A., Meyerson, M., and Collins, F.S. 2004. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 101:1892-1897. Schmajuk, G., Sierakowska, H., and Kole, R. 1999. Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J. Biol. Chem. 274:2178321789. Stein, D., Foster, E., Huang, S.B., Weller, D., and Summerton, J. 1997. A specificity comparison of four antisense types: Morpholino, 2 -Omethyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 7:151-157. Stein, D.A., Skilling, D.E., Iversen, P.L., and Smith, A.W. 2001. Inhibition of Vesivirus infections in mammalian tissue culture with antisense Morpholino oligomers. Antisense Nucleic Acid Drug Dev. 11:317-325. Stirchak, E.P., Summerton, J.E., and Weller, D.D. 1989. Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucl. Acids Res. 17:6129-6141.
Summerton, J. 1999. Morpholino antisense oligomers: The case for an RNase Hindependent structural type. Biochim. Biophys. Acta 1489:141-158. Summerton, J. 2004. Morpholinos and PNAs compared. Lett. Pept. Sci. 10:215-236. Summerton, J. 2005. Endo-Porter: A novel reagent for safe, effective delivery of substances into cells. Ann. N.Y. Acad. Sci. 1058:1-14. Summerton, J. and Weller, D. 1997. Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7:187-195. Suwanmanee, T., Sierakowska, H., Fucharoen, S., and Kole, R. 2002. Repair of a splicing defect in erythroid cells from patients with betathalassemia/HbE disorder. Mol. Ther. 6:718726. Takahashi, M., Sato, K., Nomura, T., and Osumi, N. 2002. Manipulating gene expressions by electroporation in the developing brain of mammalian embryos. Differentiation 70:155-162. Thummel, R., Bai, S., Sarras, M.P. Jr, Song, P., McDermott, J., Brewer, J., Perry, M., Zhang, X., Hyde, D.R., and Godwin, A.R. 2005. Inhibition of zebrafish fin regeneration using in vivo electroporation of Morpholinos against fgfr1 and msxb. Dev Dyn. 235:336-346. Tidd, D.M., Giles, R.V., Broughton, C.M., and Clark, R.E. 2001. Expression of c-myc is not critical for cell proliferation in established human leukemia lines. BMC Mol. Biol. 2:13. Tucker, R.P. 2004. Antisense knockdown of the beta1 integrin subunit in the chicken embryo results in abnormal neural crest cell development. Int. J. Biochem. Cell Biol. 36:1135-1139. Tyson-Capper, A.J. and Europe-Finner, G.N. 2006. Novel targeting of cyclooxygenase-2 (COX-2) pre-mRNA using antisense morpholino oligonucleotides directed to the 3 acceptor and 5 donor splice sites of exon 4: Suppression of COX-2 activity in human amnion-derived WISH and myometrial cells. Mol Pharmacol. 69:796804. van den Born, E., Stein, D.A., Iversen, P.L., and Snijder, E.J. 2005. Antiviral activity of Morpholino oligomers designed to block various aspects of equine arteritis virus amplification in cell culture. J. Gen. Virol. 86:3081-3090. Warfield, K.L., Swenson, D.L., Olinger, G.G., Nichols, D.K., Pratt, W.D., Blouch, R., Stein, D.A., Aman, M.J., Iversen, P.L., and Bavari, S. 2006. Gene-specific countermeasures against ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2:e1. Yen, L., Svendsen, J., Lee, J.S., Gray, J.T., Magnier, M., Baba, T., D’Amato, R.J., and Mulligan, R.C. 2004. Exogenous control of mammalian gene expression through modulation of RNA selfcleavage. Nature 431:471-476. Synthesis of Modified Oligonucleotides and Conjugates
4.30.23 Current Protocols in Nucleic Acid Chemistry
Supplement 27
Key References Draper et al., 2001. See above. First description of splice blocking in a zebrafish, including an analysis of a cryptic splice site. Nelson et al., 2005. See above. Description of peptide-Morpholino conjugates now in use for in vivo experiments. Summerton, 1999. See above. Review article presenting data determining the effective region for targeting translation blocking oligos and presenting a detailed discussion of Morpholino specificity and minimum inhibitory length. Summerton and Weller, 1997. See above. Structure and early synthetic scheme for Morpholino oligos.
Internet Resources http://www.gene-tools.com Commercial source for Morpholinos.
http://p196.ezboard.com/bmorpholinos Discussion board for Morpholino users. http://www.zfin.org Zebrafish Information Network. References related to Morpholino use in zebrafish are searchable in an annotated database. http://zfin.org/cgi-bin/webdriver?MIval=aanewmrkrselect.apg Annotated database of zebrafish Morpholino sequences by gene name. http://www.avibio.com AVI BioPharma, Inc., Morpholino therapeutics company.
Contributed by Jon D. Moulton Gene Tools, LLC Philomath, Oregon
http://pubs.gene-tools.com Morpholino publication database. As of printing, >1500 publications have reported experiments with Morpholino oligos in a broad range of systems. Citations and many abstracts are searchable here.
Using Morpholinos to Control Gene Expression
4.30.24 Supplement 27
Current Protocols in Nucleic Acid Chemistry
Solid-Phase Oligonucleotide Labeling with DOTA
UNIT 4.31
This unit contains protocols for the synthesis of a nucleosidic phosphoramidite tethered to a protected DOTA ligand and a description of its use in the preparation of oligonucleotide conjugates. Commercial 5 -O-(4,4 -dimethoxytrityl)-2 -deoxyuridine is covalently bound to N-protected 1,4,7,10-tetraazacyclododecane by an N3 -aminoalkyl linker and then converted to its phosphoramidite derivative, allowing normal oligonucleotide chain elongation. Upon completion of the oligonucleotide syntheses, the conjugates are deprotected and converted to the corresponding gadolinium(III) chelates by treatment with gadolinium(III) citrate, and purified by polyacrylamide gel electrophoresis (PAGE). The Gd-DOTA-labeled oligonucleotides can be used in applications based on magnetic resonance imaging. Synthesis of the nucleosidic phosphoramidite building block is described in Basic Protocol 1, and its use in the preparation of oligonucleotide conjugates is detailed in Basic Protocol 2. CAUTION: Perform all operations involving organic solvents and reagents in a wellventilated chemical fume hood, and wear gloves and protective glasses.
PREPARATION OF THE NUCLEOSIDIC PHOSPHORAMIDITE TETHERED TO DOTA
BASIC PROTOCOL 1
The synthesis of the DOTA-labeled phosphoramidite building block S.8 is based on the procedure described in Jaakkola et al. (2006) and is outlined in Figure 4.31.1. First, S.1 (prepared as described in Heppeler et al., 1999) is converted to the tetraester S.2 by reaction with bromomethyl acetate. Subsequent hydrogenolysis gives S.3. Synthesis of the nucleoside S.6 starts from commercially available 5 -O-(4,4 -dimethoxytrityl)2 -deoxyuridine (S.4), which is initially converted to S.5 by Mitsunobu reaction with N-trifluoroacetyl-6-aminohexan-1-ol (Hovinen and Hakala, 2001). Ammonolysis of the trifluoroacetate S.5 gives rise to S.6. Condensation of S.3 and S.6 in the presence of O(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and N,N-diisopropylethylamine gives the nucleoside derivative S.7. Finally, conventional phosphitylation yields the phosphoramidite S.8.
Materials 1,4,7,10-Tetraazacyclododecane-1-carboxymethylbenzyl ester (S.1; Heppeler et al., 1999) Dry acetonitrile, ≥99.5% pure, ≤0.005% H2 O (Merck) Anhydrous potassium carbonate, p.a. (Merck) Methyl bromoacetate, 99% pure (Acros Organics) Silica gel 60, 0.063 to 0.200 nm (Merck) Methanol (MeOH), ≥99.9% pure (Merck) Dichloromethane (CH2 Cl2 ), 99% pure (Lab-Scan) 10% palladium on activated carbon (Pd/C; Aldrich) Hydrogen gas Celite 521 (Aldrich) 5 -O-(4,4 -Dimethoxytrityl)-2 -deoxyuridine (S.4; Sigma) N-Trifluoroacetyl-6-aminohexan-1-ol (Sinha and Striepeke, 1991) Triphenylphosphine, 99% pure (Aldrich) Dry tetrahydrofuran (THF), ≥99.5% pure, ≤0.0075% H2 O (Merck)
Contributed by Lassi Jaakkola, Alice Ylikoski, and Jari Hovinen Current Protocols in Nucleic Acid Chemistry (2007) 4.31.1-4.31.11 C 2007 by John Wiley & Sons, Inc. Copyright
Synthesis of Modified Oligonucleotides and Conjugates
4.31.1 Supplement 29
Figure 4.31.1 Synthesis of the DOTA-labeled nucleosidic phosphoramidite (see Basic Protocol 1). Bn, benzyl; DIAD, diisopropyl azodicarboxylate; DIPEA, N,N-diisopropylethylamine; DMF, N,N-dimethylformamide; DMTr, 4,4 -dimethoxytrityl; HATU, O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate. Modified from Jaakkola et al. (2006) with permission from the American Chemical Society.
Diisopropyl azodicarboxylate (DIAD), 95% pure (Aldrich) Diethyl ether, ≥99.7% pure (Merck) Aqueous ammonia, p.a. 28% to 30% (Merck) Sodium sulfate (Na2 SO4 ), anhydrous, ≥99.0% pure (Merck) N,N-Diisopropylethylamine (DIPEA), ≥99.5% pure (Aldrich) N,N-Dimethylformamide (DMF), dry, 99.8% pure, ≤0.01% H2 O (Lab-Scan) O-(7-Azabenzotriazol-1-yl)-N,N,N ,N -tetramethyluronium hexafluorophosphate (HATU; Applied Biosystems) Sodium hydrogen carbonate (NaHCO3 ) solutions, saturated and 5% (w/v) 2-Cyanoethyl-N,N,N ,N -tetraisopropylphosphordiamidite, 97% pure (Aldrich) 0.45 M 1H-tetrazole in acetonitrile (Applied Biosystems) Triethylamine (TEA), ≥99% pure (Merck) Glass filters (3-µm pore size) Rotary evaporator equipped with an oil pump Chromatography columns: 18 × 4 cm, 5 × 30 cm, 4 × 15 cm, and 4 × 2.5 cm TLC plate: silica-coated glass plate with fluorescent indicator (Merck silica gel 60 F254 ) Hydrogenation apparatus (Parr Instruments Company) Ultrasonic bath 254-nm UV lamp Reflux condenser Solid-Phase Oligonucleotide Labeling with DOTA
Additional reagents and equipment for TLC (APPENDIX 3D) and column chromatography (APPENDIX 3E)
4.31.2 Supplement 29
Current Protocols in Nucleic Acid Chemistry
Alkylate S.1 1. Dissolve 0.45 g (1.4 mmol) S.1 in 8 mL dry acetonitrile with stirring. 2. Add 0.79 g (5.7 mmol) anhydrous potassium carbonate. 3. Prepare a solution of 0.54 mL (5.7 mmol) methyl bromoacetate in 2 mL dry acetonitrile. Add this to the stirring S.1 solution over a 30-min period. 4. Stir for 2 hr at room temperature (∼25◦ C). 5. Filter off all solid material using a glass filter with a 3-µm pore size. 6. Concentrate the filtrate in vacuo on a rotary evaporator equipped with an oil pump. 7. Apply the residue onto a silica gel column (18 × 4–cm column) and elute with 1:9 (v/v) methanol/CH2 Cl2 . The typical volume for elution is 1 L and the size of the fractions is ∼20 mL.
8. Monitor fractions by TLC with 1:9 (v/v) MeOH/CH2 Cl2 . Visualize the desired product by staining the plates in an iodine chamber. The product S.2 can be seen as a dark spot with Rf = 0.41.
9. Combine the fractions containing the product and evaporate to dryness using a rotary evaporator connected to an oil pump. 10. Characterize by 1 H NMR spectroscopy and mass spectrometry. 1,4,7,10-Tetraazacyclododecane-4,7,10-tricarboxymethylmethyl ester 1-carboxymethylbenzyl ester (S.2): Yield of pale yellow oil: 0.45 g (60%). 1 H NMR (CDCl3 ): 7.35 (5H, m); 5.20 (2H, s); 3.76 (6H, s); 3.74 (3H, s); 3.49-2.35 (24 H). +ESI-TOF-MS: calcd. for C26 H40 N4 NaO8 + (M+Na)+ , 559.27; found, 559.27.
Reduce S.2 11. Dissolve 0.35g (0.64 mmol) S.2 in 50 mL methanol. 12. Add 55 mg of 10% Pd/C. 13. Hydrogenate in a hydrogenation apparatus overnight at atmospheric pressure. 14. Filter through Celite 521 and concentrate the filtrate in vacuo on a rotary evaporator. The product can be used for the next step without further purification.
15. Monitor the product by TLC in 2:8 (v/v) MeOH/CH2 Cl2 . Visualize by staining the plates in an iodine chamber. The product S.3 can be seen as a dark spot with Rf = 0.52.
16. Characterize the product by mass spectrometry. 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid trismethyl ester (S.3): +ESITOF-MS: calcd. for C19 H34 N4 NaO8 + (M+Na)+ , 469.23; found, 469.22.
Synthesize S.5 17. Dissolve 5.0 g (9.51 mmol) S.4, 2.61 g (12.2 mmol) N-trifluoroacetyl-6-aminohexan1-ol, and 2.98 g (11.46 mmol) triphenylphosphine in 50 mL dry THF. 18. Add 2.22 mL (11.2 mmol) DIAD to the stirring solution over a 15-min period. Continue stirring for 2.5 hr at room temperature. 19. Concentrate in vacuo using a rotary evaporator to obtain an oil. 20. Add 50 mL diethyl ether and keep the reaction mixture in an ultrasonic bath until all oil has been dissolved.
Synthesis of Modified Oligonucleotides and Conjugates
4.31.3 Current Protocols in Nucleic Acid Chemistry
Supplement 29
21. Allow to stand 1 hr at room temperature. 22. Remove the triphenylphosphine oxide that forms by filtration using a glass filter with a 3-µm pore size. 23. Concentrate the filtrate to half volume using a rotary evaporator connected to an oil pump. 24. Remove any remaining triphenylphosphine oxide by repeating the filtration. 25. Concentrate the filtrate to an oil in vacuo on a rotary evaporator. 26. Purify the oily crude residue on a silica gel column (5 × 30–cm column), eluting with 1:9 (v/v) MeOH/CH2 Cl2 . The typical volume for elution is 1 to 2 L, and the size of the fractions is ∼25 mL.
27. Monitor fractions by TLC in 1:9 (v/v) MeOH/CH2 Cl2 . The product bearing the DMTr group can be visualized, in addition to normal UV detection, by heating up the fluorescent indicator plate on a hot plate. The product can be seen as an orange spot on a white background (Rf = 0.49).
28. Combine fractions containing the product and evaporate in vacuo using a rotary evaporator to afford S.4 as a white amorphous solid. 29. Characterize the compound by 1 H and 13 C NMR spectroscopy and mass spectrometry. N3 -(6-Trifluoroacetamidohex-1-yl)-5 -O-(4,4 -dimethoxytrityl)-2 -deoxyuridine (S.5): Yield: 6.2 g (91%). 1 H NMR (DMSO-d6 ): 9.36 (1H, br, NH); 7.68 (1H, d, J = 8.1 Hz, H6); 7.35 (2H, DMTr); 7.25 (7H, DMTr); 6.87 (4H, d, DMTr); 6.17 (1H, t, J = 6.2 Hz, H1 ), 5.47 (1H, d, J = 8.1 Hz, H5), 5.38 (1H, d, J = 4.7 Hz, 3 -OH), 4.31 (1H, m, H3 ), 3.90 (1H, m, H4 ), 3.5 (1H, dd, H5 ), 3.80 (2H, t, NCH2 ), 3.71 (6H, s, 2 × OMe), 3.25 (1H, m, H5 ), 3.20 (1H, dd, H5 ); 3.15 (2H, q, CH2 NH), 2.23 (2H, m, H2 , H2 ), 1.47 (4H, m); 1.25 (4H, m). 13 C NMR (DMSO-d6 ): 161.7 (C4), 158.0 (C=O), 156.5 (q, CF3 ); 150.3 (C2); 144.8 (DMTr); 138.8 (C6); 129.7, 127.8, 127.7, 126.7, 113.1 (DMTr); 100.7 (C5), 85.7 (DMTr); 85.5 (C4 ); 85.2 (C1 ); 69.8 (C3 ); 63.3 (C5 ); 55.5 (2 × OMe); 40.1 (NCH2 ); 39.7 (C2 ); 39.0 (CH2 NHCO); 28.0, 25.9, 25.8 (CH2 ). +ESI-TOF-MS: calcd. for C38 H42 F3 N3 NaO8 + (M+Na)+ , 748.28; found, 748.27.
Ammonolyze S.5 30. Suspend 1.41 g (1.95 mmol) S.5 in a mixture of 50 mL methanol and 50 mL aqueous ammonia. Heat overnight at reflux at 80◦ C with stirring. 31. Allow to cool to room temperature and then remove all volatiles in vacuo using a rotary evaporator connected to an oil pump. 32. Add 100 mL water and 100 mL CH2 Cl2 . Shake vigorously and isolate the organic phase. 33. Dry over Na2 SO4 , filter off the drying agent, and concentrate the filtrate in vacuo using a rotary evaporator connected to an oil pump. The product can be used for the next step without further purification.
34. Characterize the product by 1 H NMR spectroscopy and mass spectrometry.
Solid-Phase Oligonucleotide Labeling with DOTA
N3 -(6-Aminohex-1-yl)-5 -O-(4,4 -dimethoxytrityl)-2 -deoxyuridine (S.6): 1 H NMR (CDCl3 ): 7.75 (1H, d, J = 8.3 Hz, H6); 7.40-7.23 (9H, DMTr); 6.84 (4H, d, J = 8.9 Hz, DMTr); 6.31 (1H, t, J = 6.2 Hz, H1 ); 5.45 (1H, d, J = 8.3 Hz, H5); 4.53 (1H, m, H3 ); 4.00 (1H, m, H4 ); 3.89 (2H, m); 3.78 (6H, s, OMe); 3.49 (1H, dd, J = 3.0, 10.6 Hz, H5 ); 3.41 (1H, dd, J = 3.3, 10.6 Hz, H5 ); 2.64 (2H, t, J = 6.5 Hz); 2.42 (1H, m, H2 ); 2.24 (1H, m, H2 ); 2.19 (3H, br); 1.62 (2H, qv, J = 6.4 Hz); 1.40 (2H, qv, J = 6.7 Hz); 1.34 (4H, m). +ESI-TOF-MS: calcd. for C36 H44 N3 O7 + (M+H)+ , 630.31; found, 630.34.
4.31.4 Supplement 29
Current Protocols in Nucleic Acid Chemistry
Introduce DOTA to S.6 35. Dissolve 0.26 g (0.58 mmol) S.3 and 100 µL DIPEA in 9 mL dry DMF. 36. Add 220 mg (0.58 mmol) HATU and stir the mixture for 30 min at room temperature. 37. Add 0.37 g (0.58 mmol) S.6 and stir the mixture for 4 hr at room temperature. 38. Concentrate the filtrate in vacuo using a rotary evaporator connected to an oil pump. 39. Dissolve the residue in 50 mL CH2 Cl2 and wash two times with 25 mL sat. NaHCO3 . 40. Dry over Na2 SO4 , filter off the drying agent, and concentrate the filtrate in vacuo. 41. Purify the oily crude residue on a silica gel column (4 × 15–cm column), eluting with 1:9 (v/v) MeOH/CH2 Cl2 . The typical volume for elution is 300 to 400 mL, and the size of the fractions is ∼15 mL.
42. Monitor fractions by TLC in 1:9 (v/v) MeOH/CH2 Cl2 . The product bearing the DMTr group can be visualized, in addition to normal UV detection, by heating up the fluorescent indicator plate on a hot plate. The product can be seen as an orange spot on a white background (Rf = 0.51).
43. Combine fractions containing the product and evaporate in vacuo using a rotary evaporator to afford S.6 as a white amorphous solid. 44. Characterize the compound by 1 H NMR spectroscopy and mass spectrometry. DOTA-labeled nucleoside (S.7): Yield 0.43 g (82%). 1 H NMR (CDCl3 ): 7.75 (1H, d, J = 8.3 Hz, H6); 7.40-7.22 (9H, DMTr); 6.84 (4H, d, J = 8.8 Hz); 6.47 (1H, br t, J = 4.7 Hz, NH); 6.32 (1H, t, J = 6.3 Hz, H1 ); 5.43 (1H, d, J = 8.0 Hz, H5); 4.59 (1H, m, H3 ); 4.05 (1H, m, H4 ); 3.89 (2H, m); 3.79 (6H, s, OMe); 3.74 (6H, s); 3.73 (3H, s); 3.42 (2H, d, J = 2.9 Hz, H5 and H5 ); 3.20 (8H); 2.60 (16H); 2.46 (1H, m, H2 ); 2.27 (1H, m, H2 ); 1.70 (1H, br); 1.62 (2H, m); 1.50 (2H, m); 1.35 (4H, m). +ESI-TOF-MS: calcd. for C55 H76 N7 O14 + (M+H)+ , 1058.54; found, 1058.54.
Phosphitylate S.7 45. Dry 300 mg (0.28 mmol) S.7 by coevaporating two times with 5 mL dry acetonitrile, and dissolve in 10 mL dry acetonitrile. 46. Add 127 mg (0.42 mmol) 2-cyanoethyl-N,N,N ,N -tetraisopropylphosphorodiamidite and 0.63 mL of 0.45 M 1H-tetrazole in dry acetonitrile. Stir the mixture for 30 min at room temperature. 47. Pour the reaction mixture into 25 mL of 5% NaHCO3 with vigorous stirring. 48. Extract twice with 25 mL CH2 Cl2 . 49. Dry the combined organic layers over Na2 SO4 , filter off the drying agent, and concentrate the filtrate in vacuo. 50. Purify the residue on a silica gel column (4 × 2.5–cm column), eluting with 5:95 (v/v) MeOH/CH2 Cl2 containing 1% (v/v) TEA as the eluent. Typical volume for elution is 300 to 400 mL and the size of the fractions is ∼10 mL.
51. Monitor fractions by TLC in 5:95 (v/v) MeOH/CH2 Cl2 containing 1% (v/v) TEA. The product bearing the DMTr group can be visualized, in addition to normal UV detection, by heating up the fluorescent indicator plate on a hot plate. The product can be seen as an orange spot on a white background (Rf = 0.32).
52. Combine fractions containing the phosphoramidite, evaporate and dry in vacuo using a rotary evaporator to afford S.8 as a white solid foam.
Synthesis of Modified Oligonucleotides and Conjugates
4.31.5 Current Protocols in Nucleic Acid Chemistry
Supplement 29
53. Characterize the compound by 31 P NMR spectroscopy and mass spectrometry. Phosphoramidite S.8 is stable for prolonged storage (at least 1 year) at −20◦ C. DOTA-labeled phosphoramidite (S.8): Yield of solid white foam: 230 mg (85%). 31 P NMR (CDCl3 ): 149.60; 149.20. +ESI-TOF-MS: calcd. for C64 H93 N9 O15 P [M + H]+ , 1258.65; found 1258.66. BASIC PROTOCOL 2
SYNTHESIS OF OLIGONUCLEOTIDE-DOTA CONJUGATES The standard phosphoramidite method can be applied to incorporate S.8 into oligonucleotides, except that a prolonged coupling time (10 min) should be used to achieve an acceptable 98% coupling efficiency. The oligodeoxyribonucleotides can be assembled on any automated DNA/RNA synthesizer. The overall strategy is outlined in Figure 4.31.2, and the synthesis of 5 -d(XTAATGTAGCCCCTGAA)-3 , where X stands for S.7, is presented as an example. This sequence was assembled on a 0.2-µmol scale using recommended protocols and DMTr-off synthesis. After chain assembly, the oligonucleotide conjugate is treated as described previously (Hovinen and Hakala, 2001). The support-bound oligonucleotide S.9 is treated with 0.1 M sodium hydroxide for 4 hr at room temperature to ensure complete hydrolysis of the ester protecting groups and to cleave the oligonucleotide conjugate from the support. After evaporation in the presence of ammonium chloride and treatment with aqueous ammonia for the final global deprotection, the oligonucleotide conjugate is treated with gadolinium(III) citrate. The chelate is then desalted, concentrated in vacuo, and purified by urea-PAGE. The purified product S.11 is concentrated using butanol, desalted, and characterized by UV spectroscopy and ESI-TOF-MS. Familiarity with automated DNA synthesis (APPENDIX 3C) and purification of oligonucleotides by urea-PAGE (APPENDIX 3B) is required to carry out this protocol. Characterization of the oligonucleotide conjugate requires knowledge of ESI-TOF-MS techniques (UNIT 10.2).
Figure 4.31.2 Synthesis of the oligonucleotide conjugate tethered to DOTA (see Basic Protocol 2). CPG, controlled-pore glass; DMTr, 4,4 -dimethoxytrityl. Modified from Jaakkola et al. (2006) with permission from the American Chemical Society. Solid-Phase Oligonucleotide Labeling with DOTA
4.31.6 Supplement 29
Current Protocols in Nucleic Acid Chemistry
Materials DOTA-labeled phosphoramidite (S.8; see Basic Protocol 1) Dry acetonitrile, ≥99.5%, ≤0.005% H2 O (Merck) Deoxyribonucleoside phosphoramidites (e.g., Proligo) 0.1 M NaOH 1 M NH4 Cl Aqueous ammonia, p.a. 28% to 30% (Merck) Gadolinium(III) citrate: 0.1 M Gd(III)Cl3 /0.2 M citric acid 20% polyacrylamide gel containing 7 M urea (APPENDIX 3B) 1 M Na2 CO3 , pH 9.8 1-Butanol, ≥99.5% pure (Merck) Sterile, nuclease-free, deionized water Automated DNA/RNA synthesizer (e.g., Applied Biosystems) ◦ 0.2-µmol DNA synthesis column (1000 A CPG; Applied Biosystems) 1-mL syringes 2-mL vials Speedvac evaporator (e.g., SPD121P, Savant) NAP5 gel filtration columns (GE Healthcare) Centrifuge (e.g., BR4i, JOUAN) Additional reagents and equipment for automated DNA synthesis (APPENDIX 3C) and urea-PAGE (APPENDIX 3B) Incorporate S.7 into oligodeoxyribonucleotide chain 1. Prepare a 0.2 M solution of S.8 in anhydrous acetonitrile. Dissolve the standard deoxyribonucleoside phosphoramidites in anhydrous acetonitrile according to the manufacturer’s instructions. 2. Start the automated solid-phase oligonucleotide synthesis according to the manufacturer’s instructions. Typically, use a 0.2-µmol synthesis column packed with a 1000 ◦ A CPG support, the recommended synthesis protocol for a 0.2-µmol scale, and the DMTr-off mode. Adjust the coupling time to 600 sec for S.8. 3. Upon completion of chain assembly (S.10), remove the synthesis column.
Cleave oligonucleotide conjugate from support and hydrolyze methyl ester protecting groups 4. Attach a 1 mL-syringe to one end of the synthesis column. Take up 1 mL of 0.1 M NaOH using another syringe and attach it to the other end of the synthesis column. Transfer the 0.1 M NaOH solution back and forth through the column every 30 min for 4 hr at ambient temperature. 5. Collect the NaOH solution containing the oligonucleotide conjugate into a clean 2-mL vial, add 100 µL of 1 M NH4 Cl, and evaporate to dryness using a Speedvac evaporator.
Ammonolyse and introduce gadolinium(III) 6. Dissolve the oligonucleotide conjugate in 1 mL of concentrated aqueous ammonia and incubate 16 hr at 55◦ C. Ammonium hydroxide is used for final global deprotection.
7. Add 15 mol equiv per ligand of gadolinium(III) citrate and keep at least overnight at ambient temperature.
Synthesis of Modified Oligonucleotides and Conjugates
4.31.7 Current Protocols in Nucleic Acid Chemistry
Supplement 29
Purify oligonucleotide conjugate S.11 8. Desalt the oligonucleotide conjugate containing gadolinium(III) using a NAP5 gel filtration column and sterile deionized water according to manufacturer’s instructions. 9. Concentrate the oligonucleotide conjugate in vacuo using a Speedvac evaporator. 10. Purify the oligonucleotide conjugate using a 20% polyacrylamide gel containing 7 M urea. 11. Inspect the gel under UV illumination and collect the area of the gel that contains the gadolinium(III) oligonucleotide conjugate. The main product with highest molecular weight is collected.
12. Elute the oligonucleotide conjugate passively from the gel pieces by soaking overnight in 10 mM aqueous Na2 CO3 , pH 9.8, at ambient temperature. 13. Collect the aqueous solution containing the oligonucleotide conjugate and concentrate the solution by adding 2 vol of 1-butanol per aqueous volume. Mix well and centrifuge for 2 min at 90 × g (700 rpm), room temperature. Discard the butanol layer and repeat the butanol concentration until the volume of the aqueous phase is <500 µL. 14. Desalt the gadolinium(III) oligonucleotide conjugate using a NAP5 gel filtration column and sterile deionized water according to the manufacturer’s instructions. Store the oligonucleotide solution frozen at −20◦ C (stable at least 2 years).
Characterize oligonucleotide conjugate 15. Quantify the amount of DNA by measuring its UV absorbance at 260 nm. The OD260 is 4.04 and the total yield of S.11 is 200 µg (19% relative to the 0.2-µmol scale of oligonucleotide synthesis).
16. Characterize the purified oligonucleotide conjugate by –ESI-TOF-MS. DOTA-labeled oligonucleotide S.11: –ESI-TOF MS: m/z 566.55 [M–10H]10– , 629.96 [M–9H]9– , 708.71 [M–8H]8– , 810.22 [M–7H]7– , 945.28 [M–6H]6– , 1134.32 [M–5H]5– , 1418.64 [M–4H]4– . Reconstitution of the data gives M = 5674.05, which is in accordance with the proposed structure.
COMMENTARY Background Information
Solid-Phase Oligonucleotide Labeling with DOTA
Because of its excellent metal-chelating properties and high in vivo and in vitro stability, 1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetic acid (DOTA) is widely used as an organic ligand in magnetic resonance imaging (MRI) and positron emission tomography (PET) (Aime et al., 1999; Caravan et al., 1999; Woods et al., 2002). Gd3+ -DOTA is one of the most commonly used clinical MRI contrast agents (Anderson and Welch, 1999; Runge, 2000). Bioactive molecules labeled with DOTA, in turn, have found applications as target-specific radiopharmaceuticals (Volkert and Hoffman, 1999). In several applications, covalent conjugation of DOTA to oligonucleotides is required. Although several bifunctional DOTA deriva-
tives permitting oligonucleotide conjugation are commercially available, oligonucleotide labeling is a multi-step procedure involving synthesis of an oligonucleotide bearing a tether functionalized with a nucleophilic ω-group, and its reaction with an activated DOTA derivative. Since the labeling reaction is performed in solution in the presence of an excess of an activated label, laborious purification procedures cannot be avoided. When attachment of several label molecules is necessary, the purification and characterization of the desired oligonucleotide conjugate may be extremely difficult. These problems can be avoided by performing the labeling reaction by oligonucleotide synthesis on a solid support. In the present method, described by Jaakkola et al. (2006), the DOTA-labeled
4.31.8 Supplement 29
Current Protocols in Nucleic Acid Chemistry
uridine phosphoramidite S.8 is synthesized from 1,4,7,10-tetraazacyclododecane-1-carboxymethylbenzyl ester (S.1; Heppeler et al., 1999) and N3 -(6-trifluoroacetamidohex-1-yl)5 -O-(4,4 -dimethoxytritly)-2 -deoxyuridine (S.5; Hovinen and Hakala, 2001). Subsequently, the phosphoramidite is incorporated into an oligonucleotide chain using a modified deprotection protocol, and the desired metal ion is introduced as a citrate salt. Although Basic Protocol 1 presents only the synthesis of the DOTA-uridine phosphoramidite, the method can also be used to prepare the corresponding thymidine derivative using N3 -(6-trifluoroacetamidohex-1-yl)-5 -O-(4,4 dimethoxytrityl)thymidine (Hovinen and Takalo, 2005) instead of S.5. The present method provides a number of significant advantages. (1) The phosphoramidite S.8 can be incorporated into the oligonucleotide structure using an oligonucleotide synthesizer and standard procedures. (2) The position of the label in the oligonucleotide chain is not restricted. (3) The method allows multilabeling. This feature is particularly advantageous in applications where high detection sensitivity is required. (4) Since the metal is introduced after completion of oligonucleotide chain assembly, the DOTA conjugate can be used in various applications by simply changing the metal. (5) Because oligonucleotide labeling is performed using a solid-phase synthesis strategy, the oligonucleotide conjugate is always free from unconjugated chelate. This is extremely important for in vivo applications. Compound characterization Phosphoramidite synthesis. Chemical characterization data are provided for all compounds in the appropriate protocol steps. 1 H NMR spectra were recorded in CDCl3 or DMSO-d6 on a JEOL JNM-GX spectrometer at 500 or 600 MHz. 13 C NMR spectra were recorded at 125.65 MHz. 31 P NMR spectra were recorded on a JEOL LA 400 spectrometer at 161.9 MHz. Chemical shifts (δ) are given in ppm from internal tetramethylsilane (1 H, 13 C) or external H3 PO4 (31 P), and coupling constants (J) are given in hertz. Mass spectral analyses were performed by generating positive ions using an electrospray ionization (ESI) time-of-flight (TOF) spectrometer (Applied Biosystems Mariner). Oligonucleotide synthesis. Oligonucleotide conjugates were characterized by mass spectrometry. Mass spectral analyses were per-
formed by generating negative ions using an ESI-TOF spectrometer (Applied Biosystems Mariner System 5272).
Critical Parameters and Troubleshooting Synthesis of nucleosidic phosphoramidite Although several strategies for the preparation of selectively alkylated cyclen derivatives have been published, only the method of Heppeler et al. (1999) was reproducible in the authors’ hands. For example, introduction of a single t-butyl carboxymethyl group in various solvents in the presence or absence of organic or inorganic bases was unsuccessful, and synthesis of a tris-carboxymethylated cyclen gave rise to a complex mixture of products. Even in those cases where the desired product was obtained as the major component, its purification by silica gel column chromatography was extremely difficult. Eventually, benzyl bromoacetate was identified as the alkylating agent of choice, and S.1 was prepared in 60% yield by following Heppeler’s procedure. Removal of the benzyl group of S.2 by hydrogenolysis gives the corresponding carboxylic acid derivative S.3 in high yield. It is essential to use methanol as the solvent to avoid transesterification. Furthermore, high pressures should not be used, as they may cause cleavage of the NCH2 COOR methylene groups. Since S.3 adsorbs tightly on silica gel, purification by column chromatography is not recommended. Fortunately, it is pure enough to be used for the next reaction without further purification. The nucleoside S.5 was prepared by a Mitsunobu reaction (Mitsunobu, 1981) between 5 -O-(4,4 -dimethoxytrityl)-2 -deoxyuridine and N-trifluoroacetyl-6-aminohexan-1-ol (Hovinen and Hakala, 2001). Here, diethyl azodicarboxylate (DEAD) was substituted with diisopropyl azodicarboxylate (DIAD) due to the limited availability of the former compound. Since the alkylation occurs exclusively at N3, protection of the 3 -hydroxy group is not needed, and the desired product can be obtained in good yield. However, purification of S.5 by column chromatography is problematic, since the triphenylphosphine oxide formed during the reaction tends to co-migrate with S.5 on silica gel. Accordingly, it is highly recommended to remove the major amount of triphenylphosphine oxide by precipitation from diethyl ether prior to chromatographic purification of the product.
Synthesis of Modified Oligonucleotides and Conjugates
4.31.9 Current Protocols in Nucleic Acid Chemistry
Supplement 29
S.5 can easily be converted to S.6 by treatment with methanolic ammonia. Due to the low solubility of S.5 in polar solvents, an overnight reaction under reflux conditions is required. Since the reaction is quantitative and clean, chromatographic purification of S.6 is not required. Reaction of S.3 with S.6 in the presence of HATU and DIPEA gives the DOTAnucleoside conjugate S.7 in high yield. Purification is easily performed by silica gel column chromatography. The reaction does not proceed with less reactive activators such as dicyclohexylcarbodiimide (DCC), in all likelihood due to the low reactivity of the carboxylic acid function of S.3. Furthermore, it is essential to preactivate S.3 with HATU for at least 10 min to prevent S.6 from forming guanidine derivatives. If the preactivation time of S.3 is too short, the separation of S.7 from the reaction mixture is difficult. The phosphoramidite S.8 is prepared in a straightforward manner. The individual steps are based on conventional chemistry. Since most of the reactions are conducted under anhydrous conditions, careful attention to proper drying of solvents and glassware is essential. Preparation of the compounds requires experience with routine chemical laboratory techniques such as extraction, TLC (APPENDIX 3D), and silica gel column chromatography (APPENDIX 3E). Synthesis of oligonucleotide conjugate The present protocol describes the preparation of an oligonucleotide conjugate containing a DOTA unit at the 5 -terminus. A standard phosphoramidite protocol can be applied to the coupling of S.8, although a prolonged coupling time (10 min) is needed to obtain a sufficiently high coupling yield (>98%). Labels attached at the N3 position of uracil residues naturally weaken hydrogen bonds in a duplex. Thus, these labels should only be used upstream or downstream of the coding sequence. Knowledge of automated DNA synthesis (APPENDIX 3C) and isolation of the products by gel electrophoresis (UNIT 10.4, APPENDIX 3B) is needed. Characterization of the compounds demands knowledge of 1 H, 13 C, and 31 P NMR spectroscopies and electrospray ionization mass spectrometry (ESI-MS; UNIT 10.2). Solid-Phase Oligonucleotide Labeling with DOTA
Metal ion chelation It is essential to treat the protected oligonucleotide with aqueous sodium hydroxide for at least 4 hr at room temperature (∼25◦ C) prior to
conventional ammonolysis to avoid formation of carboxamides that will result from reaction of ammonia with the DOTA ester groups. Although DOTA amides do chelate various metal ions, the amide chelates are known to be less stable than the corresponding carboxylic acid– derived chelates (Paul-Roth and Raymond, 1995). Furthermore, if saponification is incomplete, ammonolysis will result in the formation of a mixture containing mono-, di-, and triamides, which are complicated to separate by gel electrophoresis. The metal must be introduced as a citrate. Citric acid forms rather stable and soluble complexes with several metal ions, which do not dissociate even under the basic conditions needed for oligonucleotide deprotection. This is extremely important with lanthanide ions, since trivalent lanthanide(III) ions are powerful catalysts in the hydrolysis of phosphate esters (Butcher and Westheimer, 1955). Furthermore, a prolonged reaction time (overnight at room temperature) and an excess of gadolinium(III) citrate are required to ensure complete chelate formation. According to gel electrophoresis, the crude oligomer bearing the tethered DOTA is completely stable to the reaction conditions required for deprotection and chelate formation. The desired oligonucleotide conjugate (>95% of the crude reaction mixture) is easily isolated from the gel and characterized by mass spectrometry. The observed molecular weight is in accordance with the proposed structure. As shown here, the phosphoramidite S.8 is suitable for site-specific incorporation of MRI contrast agents into oligonucleotides. Although only the preparation of Gd3+ chelates is presented here, the method could also be used in applications based on PET and SPECT (single photon emission tomography) using, for example, 67/68 Ga3+ and 111 In3+ as central ions, respectively. Naturally, for PET and SPECT applications, the metal should be introduced just prior to analysis. The slow kinetics of DOTA chelate formation should be taken into account when short-lived radioisotopes must be used. However, as proposed by Velikyan et al. (2004), the complexation can be accelerated using microwave radiation.
Anticipated Results Good to moderate yields of the individual steps of the total synthesis of the DOTAphosphoramidite are expected. The building block allows convenient synthesis of oligonucleotide conjugates on a solid support. The
4.31.10 Supplement 29
Current Protocols in Nucleic Acid Chemistry
target compound is expected to be clearly the main product, and its isolation by gel electrophoresis is therefore fairly straightforward.
Time Considerations The synthesis of phosphoramidite S.8 starting from the cyclen S.3 and 5 -O-(4,4 dimethoxytriyl)-2 -deoxyuridine (S.4) can be accomplished in ∼10 days (including two overnight reactions). The time needed for automated oligonucleotide chain assembly differs from the standard protocol only by the extended coupling time of 600 sec per DOTA phosphoramidite unit. The deprotection and subsequent conversion of the oligonucleotide to the corresponding metal chelate increases the total time of the conjugate synthesis by 24 hr. The times needed for purification and characterization are the same as with standard methods.
Literature Cited Aime, S., Botta, M., Fasano, M., and Terreno, E. 1999. Lanthanide(III) chelates for NMR biomedical applications. Chem. Soc. Rev. 27:1929. Anderson, C.J. and Welch, M.J. 1999. Radiometallabeled agents (non-technetium) for diagnostic imaging. Chem. Rev. 99:2219-2234. Butcher, W.W. and Westheimer, F.H. 1955. The lanthanum hydroxide gel promoted hydrolysis of phosphate esters. J. Am. Chem. Soc. 77:24202424. Caravan, P., Ellison, J.J., McMurry, T.J., and Lauffer, R.B. 1999. Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications. Chem. Rev. 99:2293-2352. Heppeler, A., Froilevaux, S., M¨acke, H.R., Jermann, H.E., B´eh´e, M., Powell, P., and Hennig, M. 1999. Radiometal-labeled macrocyclic chelator-derivatised somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated tumor therapy. Chem. Eur. J. 5:1974-1981.
Hovinen, J. and Takalo, H. 2005. Oligonucleotide labeling reactants and their use. US Pat. 6,949,639. Jaakkola, L., Ylikoski, A., and Hovinen, J. 2006. Simple synthesis of a building block for solid phase labeling of oligonucleotides with 1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetic acid (DOTA). Bioconjug. Chem. 17:1105-1107. Mitsunobu, O. 1981. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1-28. Paul-Roth, C. and Raymond, K.N. 1995. Amide functional group contribution to the stability of gadolinium(III) complexes: DTPA derivatives. Inorg. Chem. 34:1408-1412. Runge, V.M. 2000. Safety of approved MR contrast media for intravenous injection. J. Magn. Reson. Imaging 12:205-213. Sinha, N.D. and Striepeke, S. 1991. Oligonucleotides with reporter groups attached to the 5 terminus. In Oligonucleotides and Analogues. A Practical Approach (F. Eckstein, ed.) p. 189. Oxford University Press, Oxford. Velikyan, I., Lendvai, G., V¨alil¨a, M., Roivainen, A., Yngve, U., Bergstr¨om, M., and L˚angstr¨om, B. 2004. Microwave-accelerated 68 Ga-labelling of oligonucleotides. J. Labeled Comp. Radiopharm. 47:79-89. Volkert, W.A. and Hoffman, T.J. 1999. Therapeutic radiopharmaceuticals. Chem. Rev. 99:22692292. Woods, M., Kovacs, Z., and Sherry, A.D. 2002. Targeted complexes of lanthanide(III) ions as therapeutic and diagnostic pharmaceuticals. J. Supramol. Chem. 2:1-15.
Contributed by Lassi Jaakkola, Alice Ylikoski, and Jari Hovinen PerkinElmer Life and Analytical Sciences Turku, Finland
Hovinen, J. and Hakala, H. 2001. Versatile strategy for oligonucleotide derivatization. Introduction of lanthanide(III) chelates to oligonucleotides. Org. Lett. 3:2474-2476.
Synthesis of Modified Oligonucleotides and Conjugates
4.31.11 Current Protocols in Nucleic Acid Chemistry
Supplement 29
CHAPTER 5 Methods for Cross-Linking Nucleic Acids INTRODUCTION
C
haracterization of synthetic oligonucleotides shapes much of our understanding of native, higher-molecular-weight DNA and RNA molecules. Although of immense utility, oligonucleotides usually possess lower structural and thermal stability and have greater end effects than the larger nucleic acid constructs they are intended to model. Hence, the physiochemical and biological properties of oligonucleotides may not always compare favorably to those of larger nucleic acids. One of the most successful strategies to stabilize oligonucleotides is to connect the strands that comprise elements of helical structure with an interstrand cross-link. Cross-linked oligonucleotides are often very resistant to denaturation (induced thermally or by changes in pH, salt, or oligonucleotide concentration) relative to their unmodified constructs. A wide variety of novel chemistries exist to introduce cross-links into nucleic acids. In nearly all of these methods, solid-phase synthesis of oligomers site-specifically labeled with modified nucleosides bearing the appropriate reactive functional groups is used to generate cross-links in high yield. In addition to providing increased structural stability, cross-links have been used to probe the geometry and conformational dynamics of both medium- and large-sized nucleic acids and have been used to explore the topology of protein-ligand complexes. In the units presented in this chapter, along with those in forthcoming supplements, the reader will be provided with state-of-the art protocols to form cross-links within nucleic acids and nucleic acid–ligand complexes. To provide the reader with a comprehensive array of techniques, the chapter will present the chemistry to synthesize both interstrand and intrastrand cross-links, cyclic nucleic acids, and nucleic acid–ligand complexes.
UNIT 5.1 presents protocols to postsynthetically modify 2-amino-containing oligoribonucleotides with either an alkyl-phenyl disulfide or an alkyl thiol group. These groups react under mild conditions to form disulfide cross-links by thiol-disulfide interchange. When incorporated on opposite faces of a short, continuous RNA helix, these reactants, as expected, do not form a disulfide bond. In contrast, when these reactive groups are placed in proximity, disulfide cross-links form rapidly. In addition, by incorporating these groups at various positions of large RNAs through semisynthesis, the dynamics of thermal motions can be detected. Such motions are believed to be linked to biological function, and the protocols presented are among the few simple ways to assess such dynamics.
Methods to synthesize small circular oligonucleotides for use in diagnostic, therapeutic, and laboratory operations are presented in UNIT 5.2. These systems have gained considerable attention in recent years because they form unusually strong and specific complexes with RNA and DNA strands. In addition to their properties as molecular recognition agents, synthetic circular DNAs 20 to 200 nucleotides in size can also serve as catalysts for the amplified synthesis of DNA and RNA, a process termed “rolling circle synthesis.” One of the most convenient methods for generating oligonucleotides possessing either intrastrand or interstrand cross-links is through incorporation of oligo(ethylene glycol) bridges by solid-phase synthesis as described in UNIT 5.3. Many of the reagents needed are either commercially available or can be prepared in a few easy synthetic steps. Unlike many other DNA and RNA cross-links, aspects of the structural and thermodynamic impact of modifying nucleic acids with oligo(ethylene glycol) has been studied. Contributed by Gary D. Glick Current Protocols in Nucleic Acid Chemistry (2003) 5.0.1-5.0.2 Copyright © 2003 by John Wiley & Sons, Inc.
Methods for Cross-Linking Nucleic Acids
5.0.1 Supplement 13
In UNIT 5.4, a second group of methods for incorporating disulfide cross-links within RNA structure is presented. These protocols describe methods for the synthesis of alkylthiolmodified ribonucleosides, their incorporation into synthetic RNA, and the formation of intramolecular disulfide bonds in RNA by air oxidation. The disulfide bonds can be formed in quantitative yields between thiols positioned in close proximity in either RNA secondary or tertiary structure. Disulfide cross-links are useful tools to probe solution structures of RNA, to monitor dynamic motions, to stabilize folded RNAs, and to study the process of tertiary structure folding. In UNIT 5.5, site-specific cross-links are introduced into oligodeoxyribonucleotides by electrophilic substitution. A nucleophilic base (deoxythiouridine) is incorporated into an oligodeoxyribonucleotide, and an electrophilic tether is used to cross-link that base to a complementary DNA strand. A variety of different electrophilic DNA strands can be generated from the same deoxythiouridine-containing oligodeoxyribonucleotide by changing the nature of the electrophilic tether. In UNIT 5.6, the preparation of short endcapped DNA duplexes is presented. Using this approach, the 5′ terminus of one strand of a duplex is cross-linked to the complementary 3′ strand with a hydrophobic or hydrophilic linker. Several different linkers are presented along with methods for their incorporation into DNA during solid-phase synthesis. Finally, in UNIT 5.7, terminal disulfide cross-links are generated by substituting the terminal bases of oligodeoxyribonucleotides with a modified thymidine residue. The usefulness of this approach is discussed, with a demonstration that the cross-links do not modify the structure of the oligodeoxyribonucleotides, and examples of applications. Gary D. Glick
Introduction
5.0.2 Supplement 13
Current Protocols in Nucleic Acid Chemistry
Engineering Disulfide Cross-Links in RNA Using Thiol-Disulfide Interchange Chemistry
UNIT 5.1
This unit presents methods for incorporating disulfide cross-links within RNA structures using thiol-disulfide interchange chemistry (Fig. 5.1.1). The alkyl phenyl disulfide S.1 and the alkyl thiol S.2 are incorporated at specific ribose 2′ positions within RNA, and then react through thiol-disulfide interchange to form the more stable dialkyl disulfide (see Basic Protocol 4). Such disulfide cross-linking can be used to prepare a simple covalent conjugate of two RNA molecules or, in more complex systems, to exert a specific conformational constraint to a dynamic RNA molecule. Compared to the approach previously used to obtain disulfide cross-linking of RNA—oxidation of two thiols (Goodwin et al., 1996; Sigurdsson et al., 1995)—thiol-disulfide interchange has the advantages that it proceeds under mild conditions without an oxidative catalyst and can be kinetically characterized. Preparation of disulfide cross-linking precursors S.1 and S.2 begins with a site-specific incorporation of a 2′-amino-2′-deoxy residue within each of the two RNA species that are to be cross-linked, achieved through standard solid-phase RNA synthesis with a protected 2′-amino-2′-deoxy nucleotide phosphoramidite (see Basic Protocol 1). After deprotection of the synthetic RNA, the 2′ amine is modified with N-succinimidyl-3-(2pyridyldithio) propionate (S.3), affording the alkyl pyridyl disulfide S.4 (Fig. 5.1.2). Thiol-disulfide interchange of S.4 with thiophenol affords the alkyl phenyl disulfide S.1 (see Basic Protocol 2); reduction of S.4 with dithiothreitol yields the alkyl thiol S.2 (Fig. 5.1.2; see Basic Protocol 3). The RNA system to be cross-linked by thiol-disulfide interchange is limited to a two-piece system. Because both cross-linking precursors arise from the same intermediate (S.4, Fig. 5.1.2), S.1 and S.2 cannot be differentiated synthetically on the same RNA molecule.
O
O
O
O
B HS
O N H O P O O O
H
N
O P O O
+
S S
O
B
O
2
1
O
O
B O
O
O N H O P O O O
S S
N
B
H
O
O P O O
O
HS
Figure 5.1.1 Disulfide cross-linking of RNA through thiol-disulfide interchange. B, nitrogenous base.
Methods For Cross-Linking Nucleic Acids
Contributed by Scott B. Cohen and Thomas R. Cech
5.1.1
Current Protocols in Nucleic Acid Chemistry (2000) 5.1.1-5.1.10 Copyright © 2000 by John Wiley & Sons, Inc.
O
O
B
O +
NH2 O O P O O
O
O
N O
S S
O
O
N
3
B
N O H O P O O O
S S
N
4 DTT HS
O
O
B
O
N O H O P O O O
S S
B
O
N O H O P O O O
SH
2
1 S
N H
Figure 5.1.2 Preparation of the alkyl phenyl disulfide S.1 and the alkyl thiol S.2 as precursors for thiol-disulfide interchange. B, nitrogenous base.
Therefore, the cross-linking system must be designed such that two components of the RNA molecule (two complementary strands, a ribozyme-substrate complex, etc.), containing either S.1 or S.2 separately, can be associated through base pairing or other noncovalent interaction. After the full RNA molecule is associated, initiation of crosslinking and the rate at which it proceeds are controlled by manipulating the pH of the reaction mixture. The RNA component containing the alkyl thiol S.2 is present in saturating excess over the RNA component containing the alkyl phenyl disulfide S.1 to discourage spurious cross-linking resulting from the presence of unassociated S.1. NOTE: Experiments involving RNA require careful precautions to prevent contamination and RNA degradation; see APPENDIX 2A (do not use DEPC; this should be unnecessary, and is inadvisable with 2′ amine chemistry). BASIC PROTOCOL 1
PREPARATION OF RNA OLIGONUCLEOTIDES CONTAINING A SITE-SPECIFIC 2′ AMINE GROUP
RNA Cross-Linking Using Thiol-Disulfide Interchange Chemistry
Solid-phase synthesis of the two RNA oligonucleotides containing a unique 2′ amine employs the same procedures used for standard RNA phosphoramidites with the inclusion of a 2′-amino-2′-deoxy nucleotide phosphoramidite. The 2′-amino-2′-deoxy C-, U-, and G-phosphoramidites are synthesized according to the procedures of Verheyden et al. (1971), Imazawa and Eckstein (1979), and Benseler et al. (1992) and are produced commercially by Nexstar Pharmaceuticals. The following protocol describes deprotection and purification procedures for the solid support–bound product. Treatment with ammonium hydroxide to remove the exocyclic and 2′ amine protecting groups remaining from the synthesis procedure is followed by removal of the 2′-O-silyl protecting groups with fluoride to liberate the 2′ hydroxyl. One RNA will then be radiolabeled and modified with
5.1.2 Current Protocols in Nucleic Acid Chemistry
an alkyl phenyl disulfide group (S.1) as described in Basic Protocol 2. The other RNA will be modified to contain an alkyl thiol group (S.2; Basic Protocol 3). For a general overview of oligonucleotide synthesis, see APPENDIX 3C. Materials Solid support–bound product of automated RNA synthesis (1-µmol synthesis scale) 3:1 (v/v) concentrated ammonium hydroxide (NH4OH)/absolute ethanol 24:46:30 (v/v/v) triethylamine/1-methyl-2-pyrrolidinone/triethylamine trihydrofluoride (see recipe) TE buffer, pH 7.5 (APPENDIX 2A) NAP-25 Sephadex column (Amersham Pharmacia Biotech) 1 M sodium chloride Absolute ethanol TBE buffer (APPENDIX 2A) 80% formamide/TBE solution (see recipe) Denaturing polyacrylamide gel: 20% polyacrylamide/8 M urea in TBE buffer, dimensions 20 cm long × 26 cm wide × 0.3 cm thick (see APPENDIX 3B, CPMB UNIT 7.6 or Sambrook et al., 1989) TEN buffer (see recipe) 4-mL screw-cap vial Teflon tape Water baths, 55° and 65°C Rotary drying system for microcentrifuge tubes (Savant) 40-mL Oak Ridge centrifuge tube Preparative centrifuge (Sorvall or Beckman) UV lamp (hand held) 50-mL polypropylene centrifuge tube 0.45-µm cellulose acetate filter Additional reagents and equipment for denaturing polyacrylamide gel electrophoresis and UV shadowing (APPENDIX 3B, CPMB UNIT 7.6 or Sambrook et al., 1989) Remove the RNA protecting groups 1. Transfer the solid support–bound RNA product into a 4-mL screw-cap vial. 2. Add 1.5 mL of 3:1 (v/v) NH4OH/ethanol. Seal the vial with Teflon tape and incubate 8 hr at 55°C. 3. Cool the vial to –20°C and decant the supernatant into a 1.5-mL microcentrifuge tube. Concentrate the supernatant under vacuum with a rotary drying system. 4. Dissolve the dry residue in 400 µL of 24:46:30 (v/v/v) triethylamine/1-methyl-2pyrrolidinone/triethylamine trihydrofluoride. Incubate 1.5 hr at 65°C. Heating at 65°C (as suggested by Wincott et al., 1995) will help dissolve the dry residue. For RNAs shorter than 10 nt, reduce the amount of fluoride solution to 100 mL and skip step 5.
Purify the crude RNA 5. Transfer the solution to 5 mL TE buffer, pH 7.5, and mix thoroughly. 6. Load 2.5 mL of the resulting solution onto each of two NAP-25 Sephadex columns. Elute the RNA from each column with 3.5 mL water, collecting the first 3.5 mL of eluate from each (7 mL total product solution).
Methods For Cross-Linking Nucleic Acids
5.1.3 Current Protocols in Nucleic Acid Chemistry
7. Add 1 mL of 1 M sodium chloride to the product solution and transfer to a 40-mL Oak Ridge centrifuge tube. 8. Precipitate the RNA by adding 24 mL absolute ethanol and then centrifuging 30 min at 10,000 × g, 2°C. Decant the supernatant and allow the RNA pellet to air dry. 9. Dissolve the RNA pellet in 150 µL TE buffer and 150 µL of 80% formamide/TBE (300 µL total). 10. Purify the RNA to single-nucleotide resolution by denaturing polyacrylamide gel electrophoresis at 25 W until the full-length product has migrated about two-thirds of the way down the gel, as indicated by the dye markers (see APPENDIX 3B, CPMB UNIT 7.6 or Sambrook et al., 1989, for standard procedures). A gel 20 cm long × 26 cm wide × 0.3 cm thick is sufficient for three separate RNA oligonucleotide preparations.
Isolate the pure RNA 11. Identify the full-length RNA band by UV shadowing and excise the gel slice. 12. Place the gel slice in a 50-mL polypropylene centrifuge tube, crush thoroughly, and add 15 mL TEN buffer. Place the suspension on a shaker for 24 hr at 2°C. 13. Pellet the polyacrylamide by centrifugation for 10 min at 2000 × g, 2°C. 14. Filter the supernatant through a 0.45-µm cellulose acetate filter. 15. Precipitate the RNA by adding 3 vol absolute ethanol and then centrifuging 30 min at 10,000 × g, 2°C. 16. Dissolve the RNA in 100 µL TE buffer, pH 7.5. Determine RNA concentration spectrophotometrically by measuring A260, and adjust to 100 µM. Store up to 6 months at −20°C or indefinitely at –80°C. BASIC PROTOCOL 2
PREPARATION OF 32P-LABELED RNA CONTAINING AN ALKYL PHENYL DISULFIDE GROUP The RNA component of the cross-linking system containing the alkyl phenyl disulfide S.1 is prepared as a 32P-labeled reagent to allow monitoring of the cross-linking reaction, indicated by a shift to a product that migrates more slowly under denaturing electrophoresis conditions. Labeling of the RNA at the 5′ end with 32P is followed by chemical modification of the 2′ amine with N-succinimidyl-3-(2-pyridyldithio) propionate (S.3), yielding the corresponding amide S.4. Thiol-disulfide interchange of the pyridyl disulfide moiety of S.4 with thiophenol yields the alkyl phenyl disulfide S.1 (Fig. 5.1.2).
RNA Cross-Linking Using Thiol-Disulfide Interchange Chemistry
Materials RNA oligonucleotide with 2′ amine group (100 µM in TE buffer; see Basic Protocol 1) ≥0.1 Ci/µL [γ-32P]ATP (6000 Ci/mmol) 10 U/µL T4 polynucleotide kinase and 10× buffer (New England Biolabs) 1 M sodium chloride Absolute ethanol 1 M sodium borate buffer, pH 8 500 mM N-succinimidyl-3-(2-pyridyldithio) propionate (S.3; Pierce Chemicals) in N,N-dimethylformamide (prepare solution just before use) 70 mM thiophenol in absolute ethanol TE buffer, pH 7.5 (APPENDIX 2A)
5.1.4 Current Protocols in Nucleic Acid Chemistry
1× TBE buffer (APPENDIX 2A) 80% formamide/TBE solution (see recipe) Denaturing polyacrylamide gel: 20% polyacrylamide/8 M urea in TBE buffer, dimensions 20 cm long × 10 cm wide × 0.05 cm thick (see APPENDIX 3B, CPMB UNIT 7.6 or Sambrook et al., 1989) TEN buffer (see recipe) 10 mM sodium acetate buffer, pH 4.5 (APPENDIX 2A) Preparative centrifuge (Sorvall or Beckman) X-ray film for autoradiography Water bath, 37°C Additional reagents and equipment for denaturing polyacrylamide gel electrophoresis (APPENDIX 3B, CPMB UNIT 7.6 or Sambrook et al., 1989) CAUTION: Step 8 should be performed in a fume hood because of the stench of thiophenol. Any labware that comes in contact with thiophenol should be soaked in bleach solution. Label the RNA 1. Mix the following in a 1.5-mL microcentrifuge tube (9 µL total volume): 1 µL 100 µM RNA oligonucleotide with 2′ amine 5 µL ≥0.1 Ci/µL [γ-32P]ATP (6000 Ci/mmol; ≥0.5 mCi total) 1 µL 10× T4 polynucleotide kinase buffer 2 µL H2O. Warm the solution to 37°C. 2. Add 1 µL of 10 U/µL T4 polynucleotide kinase and incubate 30 min at 37°C. 3. Add 200 µL water and 50 µL of 1 M sodium chloride; mix well. 4. Precipitate the labeled RNA by adding 900 µL absolute ethanol and centrifuging 20 min at 16,000 × g, 2°C. 5. Decant the supernatant and allow the RNA pellet to air dry. Modify the 2′ amine 6. Dissolve the labeled RNA in: 140 µL water 20 µL 1 M sodium borate buffer, pH 8 20 µL 1 M sodium chloride. Warm the solution to 37°C. 7. Add 20 µL freshly dissolved 500 mM N-succinimidyl-3-(2-pyridyldithio) propionate (S.3) in N,N-dimethylformamide and mix well. Incubate 20 min at 37°C. Upon addition of S.3, the solution will become cloudy because of the compound’s limited water solubility but will clear during the course of the reaction as a result of hydrolysis.
8. In a fume hood, add 200 µL of 70 mM thiophenol in ethanol. Incubate 2 min at 23°C. The reaction should display a light yellow color from formation of pyridine-2-thione.
9. Precipitate the RNA by adding 700 µL absolute ethanol and centrifuging 20 min at 16,000 × g, 2°C. 10. Decant the supernatant and allow the RNA pellet to air dry.
Methods For Cross-Linking Nucleic Acids
5.1.5 Current Protocols in Nucleic Acid Chemistry
Purify the modified RNA 11. Dissolve the crude product in 10 µL TE buffer and 10 µL of 80% formamide/TBE solution (20 µL total). 12. Purify the RNA by denaturing polyacrylamide gel electrophoresis at 15 W (see APPENDIX 3B, CPMB UNIT 7.6 or Sambrook et al., 1989, for standard procedures). A gel 20 cm long is sufficient to provide clean separation from the faster-migrating RNA that remains unmodified after treatment with S.3 (∼25%).
13. Identify the band by autoradiography and excise the gel slice. 14. Crush the gel slice thoroughly in a 1.5-mL microcentrifuge tube and add 500 µL TEN buffer. Incubate the suspension 10 min on ice, vortexing occasionally. 15. Pellet the polyacrylamide by centrifugation for 2 min at 16,000 × g, 2°C, and carefully withdraw the supernatant into a fresh 1.5-mL microcentrifuge tube. 16. Precipitate the RNA by adding 4 vol absolute ethanol and centrifuging 30 min at 16,000 × g, 2°C. 17. Dissolve the modified RNA in 100 µL 10 mM sodium acetate buffer, pH 4.5. Determine radioactivity level to confirm that it is ≥105 cpm/µL. Store in 20-µL aliquots at −80°C. BASIC PROTOCOL 3
PREPARATION OF RNA CONTAINING ALKYL THIOL GROUP The RNA component of the cross-linking system containing the alkyl thiol S.2 is prepared using similar chemistry as for S.1. The 2′ amine is modified with N-succinimidyl-3-(2pyridyldithio) propionate (S.3), yielding the corresponding amide S.4. Reduction of the pyridyl disulfide moiety of S.4 with dithiothreitol yields the alkyl thiol S.2 (Fig. 5.1.2). Materials 20 nmol RNA oligonucleotide with 2′ amine group (see Basic Protocol 1) 1 M sodium borate buffer, pH 8 1 M sodium chloride 500 mM N-succinimidyl-3-(2-pyridyldithio) propionate (S.3; Pierce Chemicals) in N,N-dimethylformamide (prepare just before use) Absolute ethanol 1 M dithiothreitol (DTT) in water (APPENDIX 2A) TEN buffer (see recipe) TE buffer, pH 7.5 (APPENDIX 2A) Water bath, 37°C Modify the 2′ amine 1. In a 1.5-mL microcentrifuge tube, precipitate 20 nmol of the RNA to be modified by mixing 200 µL of the 100 µM 2′-amine-modified RNA with 50 µL of 1 M sodium chloride followed by 750 µL absolute ethanol, then centrifuging 20 min at 16,000 × g, 2°C. 2. Dissolve the RNA pellet in:
RNA Cross-Linking Using Thiol-Disulfide Interchange Chemistry
120 µL H2O 40 µL 1 M sodium borate buffer, pH 8 20 µL 1 M sodium chloride. Warm the solution to 37°C.
5.1.6 Current Protocols in Nucleic Acid Chemistry
3. Add 20 µL freshly dissolved 500 mM S.3 in N,N-dimethylformamide and mix well. Incubate 20 min at 37°C. This reaction may be scaled up as needed, maintaining the following final concentrations: 200 mM NaB(OH)3, 100 mM NaCl, 100 mM RNA, and 50 mM S.3.
4. Precipitate the RNA by adding 600 µL absolute ethanol and centrifuging 20 min at 16,000 × g, 2°C. 5. Repeat steps 2 to 4. Double treatment with S.3 should modify ≥95% of the 2′ amines.
Liberate the thiol 6. Dissolve the RNA pellet in 140 µL water and 40 µL of 1 M sodium borate buffer, pH 8. Liberate the thiol by adding 20 µL of 1 M DTT. Incubate 30 min at 37°C. 7. Precipitate the RNA by adding 50 µL of 1 M sodium chloride and 750 µL absolute ethanol, and centrifuging 20 min at 16,000 × g, 2°C. 8. Dissolve the modified RNA in 300 µL TEN buffer. Precipitate the RNA by adding 900 µL absolute ethanol and then centrifuging again as in step 7. 9. Dissolve the modified RNA in 100 µL TE buffer. Determine RNA concentration spectrophotometrically by measuring A260, and adjust to 100 µM. Store up to 6 months at −20°C or indefinitely at –80°C. CROSS-LINKING OF RNA THROUGH THIOL-DISULFIDE INTERCHANGE The two RNA components containing S.1 and S.2 are associated at pH 4.5, where the nucleophilicity of the alkyl thiol S.2 is attenuated such that cross-linking before association is discouraged. Cross-linking is then initiated by increasing the pH, usually to the range of pH 7 to 8. The cross-linking reaction is conducted with the thiol component S.2 in saturating excess (up to 10 times the equilibrium dissociation constant) over the phenyl disulfide component S.1 to discourage spurious cross-linking resulting from the presence of unassociated S.1.
BASIC PROTOCOL 4
The following protocol is from original ribozyme cross-linking experiments by Cohen and Cech (1997). The concentrations of RNA components, cross-linking pH, and other experimental conditions can be adjusted to accommodate other experimental systems.
Materials 32 P-labeled RNA modified with phenyl disulfide S.1 (≥105 cpm/µL in 10 mM sodium acetate buffer, pH 4.5; see Basic Protocol 2) RNA modified with alkyl thiol S.2 (1 µM in TE buffer; see Basic Protocol 3) 100 mM sodium acetate buffer, pH 4.5 (APPENDIX 2A) 100 mM magnesium chloride 5 M sodium chloride Formamide quenching solution (see recipe) 1 M sodium HEPES buffer, pH 7.5 (APPENDIX 2A) 0.65-mL microcentrifuge tube Water bath, 30°C Additional reagents and equipment for denaturing polyacrylamide gel electrophoresis (APPENDIX 3B, CPMB UNIT 7.6 or Sambrook et al., 1989)
Methods For Cross-Linking Nucleic Acids
5.1.7 Current Protocols in Nucleic Acid Chemistry
1. In a 0.65-mL microcentrifuge tube, mix (90 µL total volume): 10 µL 1 µM S.2-modified RNA 20 µL 100 mM sodium acetate buffer, pH 4.5 10 µL 100 mM magnesium chloride 20 µL 5 M sodium chloride 30 µL H2O. Warm the solution to 30°C. 2. Add 10 µL of ≥105 cpm/µL 32P-labeled S.1-modified RNA. Incubate 30 min at 30°C. 3. Remove 5 µL of the reaction and transfer to a fresh microcentrifuge tube containing 25 µL formamide quenching solution. Store frozen on dry ice. This aliquot serves to measure the small amount of cross-linking (if any) that occurs during the association incubation at pH 4.5.
4. Initiate cross-linking by adding 10 µL of 1 M sodium HEPES buffer, pH 7.5, to attain a final reaction pH of ∼7.2. The absolute rates of cross-linking can be controlled by manipulating the pH of the cross-linking reaction (∆log k/∆pH ∼1 in the pH range of 4.5 to 8.0).
5. At the desired time intervals, transfer 5 µL of the reaction to separate tubes containing 25 µL formamide quenching solution. Store the time aliquots frozen on dry ice until analysis by denaturing polyacrylamide gel electrophoresis (see APPENDIX 3B, CPMB UNIT 7.6 or Sambrook et al., 1989). For example, in the original ribozyme cross-linking experiments, 3- to 5-min intervals were used.
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Formamide, 80%, in TBE To 40 mL formamide add 25 mg bromphenol blue and 25 mg xylene cyanol; mix well. Add 10 mL of 5× TBE buffer (APPENDIX 2A). Store up to 6 months at 23°C. The resulting 50 mL contains 80% formamide, 0.05% bromphenol blue, 0.05% xylene cyanol, 90 mM Tris-borate, and 1 mM EDTA.
Formamide quenching solution 800 µL formamide 0.5 mg bromphenol blue 0.5 mg xylene cyanol 100 µL 1 M sodium acetate buffer, pH 4.5 100 µL 0.5 M disodium EDTA Prepare fresh This must be prepared fresh on the day of use because EDTA will precipitate during extended storage at pH 4.5. The resulting 1.0 mL contains 80% formamide, 0.05% bromphenol blue, 0.05% xylene cyanol, 100 mM sodium acetate buffer (pH 4.5), and 50 mM EDTA. RNA Cross-Linking Using Thiol-Disulfide Interchange Chemistry
5.1.8
TEN buffer 10 mM Tris⋅Cl, pH 7.5 (APPENDIX 2A) 1 mM disodium EDTA (APPENDIX 2A) 250 mM sodium chloride Store indefinitely at room temperature (e.g., 23°C). Current Protocols in Nucleic Acid Chemistry
Triethylamine/1-methyl-2-pyrrolidinone/triethylamine trihydrofluoride, 24/46/30 (v/v/v) To a stirred solution of 12 mL triethylamine and 23 mL 1-methyl-2-pyrrolidinone (Aldrich), add dropwise 15 mL triethylamine trihydrofluoride (Aldrich). Continue stirring until the solution is homogeneous (1.4 M fluoride ion). Store in 1-mL aliquots up to 6 months at −20°C. CAUTION: Wear gloves when working with fluoride solutions. This solution is derived from Wincott et al. (1995).
COMMENTARY Background Information The authors’ goal was to use site-specific disulfide cross-linking to measure long-range conformational dynamics within a large (>300nt) catalytic RNA molecule (ribozyme). Existing methods of forming disulfide bonds had relied on chemical oxidation of two thiols, a reaction that is prohibitively slow in the absence of a catalyst. Redox-active metal complexes, such as copper(II) phenanthroline, are effective oxidants (Patai, 1974) but are incompatible with RNA because they promote oxidative cleavage of the ribose backbone (Chen and Sigman, 1988). In addition, large structured RNAs often contain binding sites for multivalent metal ions, further complicating analysis. Sulfoxide catalysis has been used to form disulfides in RNA (Sigurdsson et al., 1995), but the experimental conditions required (≥50% dimethyl sulfoxide) are not compatible with a folded and active ribozyme structure. The new disulfide cross-linking procedure (Cohen and Cech, 1997) that is presented in this unit can be applied to large RNAs and allows kinetic characterization of the cross-linking reaction. Incorporation of cross-linking precursors S.1 and S.2 within RNA relies on the presence of a 2′ amine, incorporated by use of the corresponding phosphoramidite during solid-phase RNA synthesis (Verheyden et al., 1971; Imazawa and Eckstein, 1979; Benseler et al., 1992). Modification of the 2′ amine is then performed after the RNA is deprotected, labeled with 32P, or otherwise manipulated. For example, a 2′ amine is compatible with T4 DNA ligase; ligation of a 41-nt synthetic RNA containing a 2′ amine to a 269-nt transcribed RNA as described by Moore and Sharp (1992) provided a route for preparing a 310-nt ribozyme containing the alkyl thiol S.2 (Cohen and Cech, 1997). Thiol-disulfide interchange chemistry (Fig. 5.1.1) proceeds under mild conditions (aqueous
solution, pH ∼7) without an oxidative catalyst and has been used to measure conformational dynamics between helical domains within a 310-nt ribozyme (Cohen and Cech, 1997). Association of the substrate domain containing S.1 with a set of ribozymes, each containing S.2 at a different position, afforded substrateribozyme cross-linking representing interhelical displacements of at least 50 Å. The kinetic profile of the cross-linking revealed the distribution of motions between the two domains. Cross-linking was achieved under a variety of experimental conditions (temperature 30° to 50°C; pH 6 to 8; NaCl concentration 0 to 1.0 M; MgCl2 concentration 0 to 100 mM) and allowed preparation of a series of conformationally constrained substrate-ribozyme complexes.
Critical Parameters Optimization of the modification reaction of the 2′ amine with S.3 revealed a strong temperature dependence: the efficiency of the reaction was significantly lower at 23°C than at 37°C. Allow ample time for the solution to warm to 37°C before addition of S.3. The absolute rates of cross-linking can be controlled by manipulating the pH of the crosslinking reaction (∆log k/∆pH ~1). The pH may require optimization. For example, if the crosslinking precursors S.1 and S.2 are in close proximity within the associated RNA molecule, then a reaction pH of 8 may result in cross-linking that is too fast to measure (<1 min). Lowering the pH from 8 to 7 will slow the reaction. Careful purification of the 32P-labeled RNA containing S.1 will enhance the yield of the cross-linking reaction. In the preparation of S.1, the concentration of RNA in the modification reaction with S.3 is relatively low (∼1 µM, compared to 100 µM when preparing S.2); as a consequence, the reaction is less efficient. With careful electrophoresis, it is possible to
Methods For Cross-Linking Nucleic Acids
5.1.9 Current Protocols in Nucleic Acid Chemistry
isolate the RNA containing the S.1 modification as a distinct band because it will migrate more slowly than the RNA left with a free 2′ amine. Complete separation has been achieved for RNAs up to 30 nt.
Anticipated Results The yield of cross-link is defined as the percentage of 32P-labeled RNA containing S.1 that becomes cross-linked to the RNA modified with S.2. Typically, cross-linking yields are ∼70%; yields as low as 40% and as high as 90% have been observed. Factors that may affect the yield of cross-link include the temperature (experiments at 2°C afforded lower yields than those at 30°C), the proximity of S.1 and S.2 within the RNA molecule (which influences the reaction rate), and the purity of the RNA components, particularly S.1.
Time Considerations Preparation of the RNA oligonucleotide containing a 2′ amine will take 2 to 3 days. Preparation of RNA modified with S.1 or S.2 can usually be done within a single day for each. The length of time required for cross-linking will depend on the experimental system; crosslinking reactions have been observed to be complete within minutes to several hours.
Literature Cited Benseler, F., Williams, D.M., and Eckstein, F. 1992. Synthesis of suitably-protected phosphoramidites of 2′-fluoro-2′-deoxyguanosine and 2′amino-2′-deoxyguanosine for incorporation into oligoribonucleotides. Nucleosides Nucleotides 11:1333-1351. Chen, C.B. and Sigman, D.S. 1988. Sequence-specific scission of RNA by 1,10-phenanthrolinecopper linked to deoxyoligonucleotides. J. Am. Chem. Soc. 110:6570-6572. Cohen, S.B. and Cech, T.R. 1997. Dynamics of thermal motions within a large catalytic RNA investigated by cross-linking with thiol-disulfide interchange. J. Am. Chem. Soc. 119:6259-6268.
Goodwin, J.T., Osborne, S.E., Scholle, E.J., and Glick, G.D. 1996. Design, synthesis, and analysis of yeast tRNAPhe analogs possessing intraand interhelical disulfide cross-links. J. Am. Chem. Soc. 118:5207-5215. Imazawa, M. and Eckstein, F. 1979. Facile synthesis of 2′-amino-2′-deoxyribo-furanosyl purines. J. Org. Chem. 44:2039-2041. Moore, M.J. and Sharp, P.A. 1992. Site-specific modification of pre-mRNA: the 2′-hydroxyl groups at the splice sites. Science 256:992-997. Patai, S. 1974. The Chemistry of the Thiol Group. John Wiley & Sons, New York, N.Y. Sambrook, J., Fritsch, E.F., and Maniatis, T. 1989. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Sigurdsson, S.T., Tuschl, T., and Eckstein, F. 1995. Probing RNA tertiary structure: Interhelical cross-linking of the hammerhead ribozyme. RNA 1:575-583. Verheyden, J.P.H., Wagner, D., and Moffatt, J.G. 1971. Synthesis of some pyrimidine 2′-amino2′-deoxynucleosides. J. Org. Chem. 36:250-254. Wincott, F., DiRenzo, A., Shaffer, C., Grimm, S., Tracz, D., Workman, C., Sweedler, D., Gonzalez, C., Scaringe, S., and Usman, N. 1995. Synthesis, deprotection, analysis, and purification of RNA and ribozymes. Nucl. Acids Res. 23:2677-2684.
Key References Cohen and Cech, 1997. See above. Describes the initial development of thiol-disulfide interchange chemistry and its application to measuring conformational dynamics within a 310-nt catalytic RNA. Sigurdsson et al., 1995. See above. Presents the first example of the use of chemistry derived from a 2′ amine to tag the RNA backbone in a sequence-specific fashion.
Contributed by Scott B. Cohen and Thomas R. Cech University of Colorado Boulder, Colorado
RNA Cross-Linking Using Thiol-Disulfide Interchange Chemistry
5.1.10 Current Protocols in Nucleic Acid Chemistry
Chemical and Enzymatic Methods for Preparing Circular Single-Stranded DNAs
UNIT 5.2
Each of the following three protocols for preparing single-stranded DNA (ssDNA) circles from 28 to at least 188 nucleotides (nt) in length involves a “one-pot” cyclization scheme using various chemical ligation reagents or enzymes and short synthetic DNA splints. Each ligation can proceed from two or more short linear DNAs (precursor segments), which are intermolecularly ligated to give a linear precircle. This DNA is then intramolecularly ligated to form a circular DNA. Alternatively, a single full-length cyclization starting material can be used, again using intramolecular ligation conditions to close it. Enzymatic ligation (see Basic Protocol) is based on the use of a double-helical splint complex with a complementary ssDNA splint (Fig. 5.2.1). This complex assists enzymatic ligation by juxtaposing reactive ends of precursor segments for subsequent ligation to a ssDNA circle using T4 DNA ligase. Chemical ligation with cyanogen bromide (see Alternate Protocol 1) involves an additional, alternative method of assistance through a triple-helical splint complex (Fig. 5.2.1). Chemical ligation occurs by simultaneous dimeric ligation of linear DNAs to circular form upon addition of cyanogen bromide. The final procedure (see Alternate Protocol 2) is a novel chemical autoligation method that also uses a double-helical splint complex. The reaction proceeds via nucleophilic displacement of iodide from 5′-iodothymidine by the 3′-phosphorothioate group to create a 5′-bridging phosphorothioate linkage. A series of five support protocols cover the preparation and purification (optional) of the end-modified DNAs required for all ligation methods.
Figure 5.2.1 Cyclization of ssDNAs requires a splint to assist in end joining. Representation of two types of splint complexes used for ligation: double-helical splint complex using conventional Watson-Crick hydrogen bonding, and triple-helical splint complex using both Watson-Crick and Hoogsteen hydrogen bonding.
Methods for Cross-Linking Nucleic Acids
Contributed by Amy M. Diegelman and Eric T. Kool
5.2.1
Current Protocols in Nucleic Acid Chemistry (2000) 5.2.1-5.2.27 Copyright © 2000 by John Wiley & Sons, Inc.
STRATEGIC PLANNING Each protocol can be used for the synthesis of single-stranded circles ranging in size from 28 to at least 188 nt. The enzymatic ligation method has no inherent sequence restrictions; however, the autoligation method requires a 5′-iodothymidine and 3′-phosphorothioate group at the ligation junction, which in turn requires preparation of this DNA using a modified phosphoramidite, 5-iodothymidine, as well as a sulfurizing reagent. The chemical ligation method using cyanogen bromide has been very effective for the synthesis of variously sized circles by dimeric ligation of triple-helical splint complexes (Ruben et al., 1995). It is possible to prepare circles by any of the three ligation methods; however, one method may be more suitable for a given circle based on certain considerations. Figure 5.2.2 is a decision tree designed to help in choosing a protocol. The first decision involves the size of the circle. Circles <28 nt are not covered by these protocols, and can best be prepared using methodology described by Alazzouzi et al. (1997). Small circles, 28 to 50 nt, are most easily synthesized using a single precursor segment and any of the three basic protocols, with particular steps omitted as noted (Fig. 5.2.2). Medium-sized circles, 50 to 140 nt, should be synthesized from two smaller precursor segments, as preparative yields for convergent or dimeric synthesis of this sort are usually significantly better than those obtained using single precursors. Any of the three protocols can be used for the synthesis of medium-sized circles—be sure to note the specific sequence and size considerations for each protocol, however. Large circles, >140 nt, are best prepared from at least three precursor segments. The basic two-step ligation protocol is the same for the synthesis of these large circles; however, all precursor segments and all but one splint are included in the first ligation and the last splint is incorporated in the second ligation. Along with the
Chemical and Enzymatic Methods
Figure 5.2.2 Strategic planning for DNA circle synthesis using a decision tree. First decision is circle size. This decision will determine the number of precursor segments to use. The next decision involves analysis of sequence requirements and choice of a ligation method. AP, Alternate Protocol; BP, Basic Protocol; THSC, triple-helical splint complex.
5.2.2 Current Protocols in Nucleic Acid Chemistry
Figure 5.2.3 Schematic representation of the steps in “one-pot” ligation for the enzymatic cyclization of ssDNAs by T4 DNA ligase. (A) Complementary splints 20-nt long are used to form double-helical splint complexes to juxtapose reactive 3′-hydroxyl and 5′-phosphate ends of linear ssDNAs for enzymatic ligation to a phosphodiester linkage (B) using T4 DNA ligase.
Methods for Cross-Linking Nucleic Acids
5.2.3 Current Protocols in Nucleic Acid Chemistry
specific considerations for each of the three protocols, it must be kept in mind that synthesis of large circles from multiple precursor segments proceeds with low efficiency; the enzymatic method gives the lowest yields, behind the chemical and autoligation methods, whose yields are somewhat better and fairly comparable to one another. Both the enzymatic and reagent-free ligation protocols operate on a 10- to 15-nmol scale and can easily be scaled up to 100 to 150 nmol. However, scales >150 nmol involve rather large volumes for lyophilization and can become quite costly. NOTE: If the cyclized oligonucleotides are to be transcribed, all solutions and equipment coming into contact with DNA must be autoclaved to be free of RNase contaminants. All water used should be ultrapure (at least distilled and deionized). BASIC PROTOCOL
DOUBLE-HELICAL SPLINT COMPLEX–ASSISTED ENZYMATIC CYCLIZATION OF OLIGONUCLEOTIDES USING T4 DNA LIGASE The basic protocol describes synthesis and purification of ssDNA circles using a complementary short ssDNA template (a splint) to juxtapose the reactive 3′-hydroxyl and 5′-phosphate groups of precursor segments for ligation by T4 DNA ligase. The protocol is applicable to circles in the size range of 28 to at least 188 nucleotides. This “one-pot” synthesis consists of a two-step ligation of two approximately equal-length precursor segments, which are first enzymatically ligated into a full-length precircle, without isolation, and subsequently enzymatically cyclized into a ssDNA circle (Fig 5.2.3). Circles <50 nt may be synthesized from a single precursor segment by a single enzymatic ligation and circles >140 nt by ligation of more than two precursor segments; see Strategic Planning for more information. The products are separated by preparative denaturing polyacrylamide gel electrophoresis (PAGE), and circularity is confirmed by endonuclease cleavage. CAUTION: Acrylamide and N,N′-methylenebisacrylamide are neurotoxins. Preparation of solutions with these compounds should be performed in a well-ventilated fume hood, and extreme precautions taken to minimize contact with solids or solutions. NOTE: To synthesize larger quantities, the first ligation reaction can be scaled up. The second ligation reaction can also be scaled up, but multiple reaction tubes should be used rather than a larger-scale one-pot synthesis. NOTE: For cyclization using a single precursor segment, skip steps 4 to 7 (i.e., omit the first ligation and proceed directly from DNA quantitation to the second ligation described).
Chemical and Enzymatic Methods
Materials 20 nt splint ssDNA(s) Precursor segments containing 5′-phosphate and 3′-hydroxyl groups Ultrapure (e.g., distilled, deionized) water 2× ligation buffer: 20 mM MgCl2/100 mM Tris⋅Cl (pH 7.5) 1 M dithiothreitol (DTT; APPENDIX 2A) 25 mM and 100 mM adenosine triphosphate (ATP) 400 U/µL T4 DNA ligase (New England Biolabs) 1× TBE (APPENDIX 2A) 10% denaturing polyacrylamide gel mix (see recipe or purchase) 10% (w/v) ammonium persulfate (APS) TEMED or TMEDA (Life Technologies) Formamide loading buffer (see recipe)
5.2.4 Current Protocols in Nucleic Acid Chemistry
0.2 N NaCl 5× S1 nuclease buffer: 50 mM NaCl/50 mM NaOAc/5 mM ZnCl2, pH 4.6 332 U/µL S1 nuclease (from Aspergillus oryzae; Amersham Pharmacia Biotech) Stop solution (see recipe) Stains-all dye solution (see recipe) UV spectrophotometer 1.5-mL microcentrifuge tubes and cap locks, autoclaved 15-mL screw-top centrifuge tubes, autoclaved 90°C heat block or thermal cycler Glass wool Dialysis tubing, MWCO 1000 (e.g., SpectraPor) Gel electrophoresis equipment: Vertical (sequencing) gel stand 2000-V power supply Glass plates: 13 × 15.5 cm, 13 × 16.5 cm, 6.5 × 15 cm, and 6.5 × 16 cm Gel combs: 1.5-mm-thick with 1.5-cm-wide wells and 0.4 mm thick with 5-mm-wide wells Spacers: 1.5 mm thick and 0.4 mm thick UV shadow box or light source Lyophilizer or SpeedVac Saran Wrap (or other UV-transparent plastic wrap) Razor blades, sterile Glass stir rod 50-mL filter tubes with 0.45-µm cellulose acetate filter (e.g., Spin-X II, Corning Costar) Obtain splint DNAs 1. Construct or purchase ssDNAs of the desired splint and precursor-segment sequences. Splint sequences should bridge, by 10 nt on each side, the gap between precursor segments for ligation (Fig. 5.2.3A). For ssDNAs purchased commercially, splints should be fully deprotected and precursor segments should be fully deprotected and 5′-phosphorylated. Alternatively, ssDNAs may be constructed on a DNA synthesizer using the standard DNA cycle and a 0.2-µmol scale; see Support Protocol 1 for synthesis of modified precursor segments, see Support Protocol 4 for deprotection, and see Support Protocol 5 for (optional) purification.
Quantitate DNA 2. Redissolve each DNA in 1.00 mL water. Prepare a 100× dilution sample by combining 10.00 µL of this stock solution with 990 µL water. Synthesized DNA after deprotection and lyophilization should be powdery and white and should readily redissolve in water. If the solution does not appear homogeneous, mild heating (∼60°C) and/or brief sonication (1 min) can be used to help dissolve the DNA. Insoluble material may cause some turbidity but is not cause for concern.
3. Use a properly calibrated UV spectrophotometer to obtain a measurement of the absorbance at 260 nm (A260) of the 100× dilution sample prepared in step 2. Calculate the concentration (c) of DNA for the stock sample prepared in step 2 in moles per milliliter (recalling the dilution factor from step 2 of 102) using Beer’s Law: A260 = ε × b × c b is generally 1, so c (in mol/mL) = (A260 × 102)/ε
Methods for Cross-Linking Nucleic Acids
5.2.5 Current Protocols in Nucleic Acid Chemistry
Extinction coefficients (ε) for each sequence can be calculated using the nearest-neighbor method (Borer, 1985). See also UNIT 7.3. IMPORTANT NOTE: If a single precursor segment is to be used (i.e., synthesis of a ssDNA circle <50 nt), omit the first ligation (steps 4 to 7) and begin with step 8.
Perform first ligation 4. Combine 125.0 µL of 2× ligation buffer with 15 nmol of each precursor segment and 18.3 nmol of one of the splints (splint 1) in an autoclaved 1.5-mL microcentrifuge tube. Final concentrations: 10 mM MgCl2, 50 mM Tris⋅Cl, 60 mM each precursor segment, 73 mM splint 1. IMPORTANT NOTE: For large DNA circles (>140 nt), use all precursor segments and all but one splint in step 4. It may not matter which splint is chosen for the first ligation here; however, more is required for the second ligation, so if one is limiting, it should be used here. If the combined volume of DNA (two precursor segments and splint) exceeds 119 mL, one or more DNAs must be lyophilized to reduce the volume.
5. Calculate the volume of water to add according to the following equation: volume water = 250 µL − (125.0 µL + volume DNA [step 4] + 5.40 µL) Add the calculated amount of water to the microcentrifuge tube, vortex briefly, and secure closed with a cap lock. The 250 mL represents the total reaction volume, 125.0 mL represents the 2× ligation buffer, volume DNA represents the combined volumes of precursor segments and splint, and 5.40 mL represents volumes of reagents to be added in step 7.
6. Incubate the capped tube 10 min in a 90°C heat block. After 10 min, turn the heat block off and allow it to slowly cool, with its contents, to room temperature (∼25°C). Step 6 takes ∼2 to 2.5 hr to complete. Alternatively, a PCR thermal cycler can be used. Set the cycler to heat for 10 min at 90°C, then slowly cool (0.5°C/min) to room temperature. The slow cooling allows the splints to bind their complementary targets efficiently, aligning reactive ends for ligation by the enzyme.
7. When the block and its contents have reached room temperature (∼25°C), add 2.50 µL of 1 M DTT, 1.00 µL of 25 mM ATP, and 1.88 µL of 400 U/µL T4 DNA ligase to the tube. Gently invert the tube and let stand 4 to 6 hr at room temperature. Final concentrations: 10 mM DTT, 100 mM ATP, 3 U/mL T4 DNA ligase. Perform second ligation
8. In autoclaved 15-mL centrifuge tube, combine 5.0 mL of 2× ligation buffer with either 167.0 µL of reaction from step 7 (2⁄3 vol) or 10 nmol full-length synthesized precursor segment (if cyclization is from a single precursor segment), plus 30 nmol of the remaining splint (splint 2). Final concentrations: 10 mM MgCl2, 50 mM Tris⋅Cl, 1 mM precircle, 3 mM splint 2, 1.2 mM splint 1. IMPORTANT NOTE: For circles >140 nt, the final splint is added in this step.
Chemical and Enzymatic Methods
The 167.0 mL of reaction from step 7 represents, in theory, a maximum yield of 10 nmol precircle from ligated precursor segments. Alternatively, if the circle size is <50 nt, 10 nmol of full-length synthesized precursor segment can be used. Note that DNA concentrations are much less for this second ligation (1 mM precircle) than for the first ligation (60 µM
5.2.6 Current Protocols in Nucleic Acid Chemistry
each precursor segment). This favors the intramolecular cyclization reaction over an intermolecular reaction that produces undesired multimeric linear species.
9. Calculate the volume of water to add according to the following equation: volume water = 10,000 µL − (5000 µL + volume DNA [step 8] + 118.3 µL) Add this volume of water to the 15-mL tube(s), vortex briefly, and secure closed. The 10,000 mL represents the total reaction volume; 5000 mL represents the 2× ligation buffer; volume DNA represents the combined volumes of either 167.0 mL of step 7 reaction or the synthesized precursor segment, plus splint; and 118.3 mL represents volumes of reagents to be added later. Normally it will not be necessary to lyophilize any of the components at this step, as the calculated volume of water often exceeds 4.5 mL.
10. Wrap the tube(s) thoroughly with glass wool and incubate 10 min in a 90°C heat block, inverting them every 2 min. After 10 min, turn the heat block off and allow it to cool, with its contents, to room temperature (∼25°C). The glass wool will allow even heating and cooling of the reagents to ensure an efficient slow annealing of splint and precircle. Inverting the tubes also ensures thorough heating of the contents. As before, this slow annealing takes ∼2 to 2.5 hr to complete.
11. When the block and its contents have reached room temperature (∼25°C), add 100.0 µL 1 M DTT, 10.00 µL of 100 mM ATP, and 8.33 µL of 400 U/µL T4 DNA ligase to each tube. Gently invert the tube and allow reaction to proceed 12 to 16 hr at room temperature. Final concentrations: 10 mM DTT, 100 mM ATP, 0.33 U/mL T4 DNA ligase. Note the different concentrations of enzyme and DNA used here compared to the first ligation. While the final ATP and DTT concentrations remain the same, the enzyme and DNA concentrations are lowered to favor the intramolecular cyclization reaction and to conserve enzyme and thus decrease cost.
Dialyze reaction products 12. Transfer the entire reaction volume from step 11 to MWCO 1000 dialysis tubing clamped at one end to make a bag. Secure the other end of the dialysis bag closed. Dialyze against 2 L ultrapure water for 3 hr. Repeat. 13. Lyophilize the dialysate to dryness. The dried residue should look off-white in color.
Gel purify reaction products 14. Prepare a vertical, 1.5-mm-thick (preparative), denaturing 10% polyacrylamide gel using a comb that produces 1.5-cm-wide wells. A gel prepared between plates used for sequencing (13 × 16.5 inch) allows for ample vertical loading of reaction mixture and sufficient migration length for separation and resolution of bands. For these conditions, prepare gel solution from 250 mL of 10% gel mix, 1.67 mL of 10% APS, and 53.3 mL TEMED. The gel should contain ∼12 wells for reaction solution plus a few for DNA markers. For more detailed description of procedures for denaturing PAGE, see APPENDIX 3B.
15. Place the gel in a gel electrophoresis apparatus, using 1× TBE in both top and bottom buffer reservoirs, and prerun 30 min at 30 W constant power, room temperature. 16. Redissolve each 10 mL lyophilized sample (from second ligation, step 13) in 60 µL water and 60 µL formamide loading buffer by brief vortexing.
Methods for Cross-Linking Nucleic Acids
5.2.7 Current Protocols in Nucleic Acid Chemistry
If the solution does not appear homogeneous, mild heating (∼60°C) and/or brief sonication (1 min) can be used to help dissolve the DNA mixture.
17. Load 10 µL of the solution from step 16 in each of the 1.5-cm-wide wells. Load DNA markers, step 2 solutions, and first ligation-reaction mixture (step 7) in separate adjacent wells (use ∼1 nmol of each to permit later visualization by UV shadowing). Use of DNA markers allows for confirmation of product lengths. Precursor segments (step 2) and solution from step 7 (first ligation) can be used to identify precursor segments and precircles in the reaction lanes.
18. Run the gel at 30 W constant power, room temperature, to the desired length. On a 10% gel bromphenol blue migrates similarly to a 26-nt linear DNA, so this band is usually run off, since most circles will be larger. Xylene cyanol runs like a 55-nt linear DNA, and for larger circles (>70 nt) should be run almost off the gel.
19. Disassemble the gel apparatus. Sandwich the prep gel between two pieces of Saran Wrap. View the gel under ultraviolet light with fluorescent white background (glass silica plates work well) to visualize the bands. The reaction lanes should show several bands. Figure 5.2.4 is a representation of a typical gel, with lane 6 containing second ligation reaction mixture. Depending on how far the gel is run, the splints (lane 1) will probably be run off, but the precursor segments may be visible and their identity can be confirmed by their co-migration with the precursor-segment markers (step 2 solutions) run alongside (lanes 2 and 3). The next band up (migrating more slowly) from the precursor segments should be the precircle band; this is confirmed by its co-migration with the largest band from the first ligation reaction (step 7) run alongside (lane 4). Although the secondary structure present in many DNA circles may cause them to migrate more slowly than their linear counterparts (Serwer and Allen, 1984), identification of the circle (lane 8) can be difficult, as there may be one or more products in between the linear precircle and monomer circle. These are likely to be ligation of an odd number of precursor segments (lane 7), and results are especially complex if precursor segments are of different sizes. Migration of circles is not always consistent and can be temperature dependent. Therefore, most bands migrating more slowly than confirmed precircle should be cut out for analysis.
Isolate purified DNAs after gel electrophoresis 20. Cut out the desired band with a clean, sterile razor blade and place the pieces in a 15-mL centrifuge tube. Using a glass stir rod, crush the gel pieces thoroughly. Combine crushed pieces with ∼5 to 10 mL of 0.2 N NaCl to make an easily shaken slurry. Repeat, in separate tubes, for each band of interest isolated. Shake each slurry for ∼12 hr. Precircle and higher bands should be isolated for reasons stated in step 19. Be sure all crushed gel pieces are transferred to the slurry. Conversion of precircle to circle may appear high by UV shadowing (step 19), but isolated yields after step 22 are often <50%; it is therefore important to ensure quantitative transfer of all materials.
21. Filter the slurry by brief (1- to 5-min) centrifugation through 50-mL filter tubes. Resuspend the gel pieces in 5 mL water, centrifuge again, and combine the filtrates. It is advisable to save the filtered gel pieces until after quantitation, as additional extractions with 0.2 N NaCl may be desired to increase isolated product yield, although only minimal (<10%) additional recoveries should be expected. Chemical and Enzymatic Methods
22. Dialyze the filtrate from step 21 as described in step 12, but using 2 L ultrapure water for 6 hr and repeating three times. 23. Quantitate as described in step 3 using the dialysate from step 22 with no dilution.
5.2.8 Current Protocols in Nucleic Acid Chemistry
Figure 5.2.4 Representation of a typical cyclization gel. Lanes 1 to 3 represent crude synthesized DNAs used for ligation; banding underneath attests to their impurity. Lane 4 represents the first ligation-reaction mixture; the largest (slowest-migrating) species is the precircle, shown after isolation in lane 5. Lane 6 represents the second ligation (cyclization) and the possible products as confirmed by their migration with isolated species [lanes 7 to 9: 1.5× precircle (from ligation of 3 precursor segments in a linear fashion), circle and dimer]. Note the migration of the bands isolated in lanes 7 to 9 is typical but may differ slightly with different methods and sequences. Note: While the ligation mechanism selects for correct sequence precursor segments, it is not unusual to see less than full-length impurities (n − 1, n − 2, etc.), and these impurities are often eliminated by careful isolation of the desired band.
Incorrect identification of bands may result in erroneous concentration calculations from the use of the wrong extinction coefficient. Confirmation of identification will be discussed in the next section. If a misidentification is discovered, simple recalculation with a different extinction coefficient is all that is required to correct the calculation error, as the absorbance is the same regardless of identification.
Confirm circularity of product 24. Place ∼0.2 nmol of the suspected circular DNA in each of two tubes and ∼0.2 nmol of isolated precircle in each of two tubes (four tubes total). Label one of each pair “control” and one “S1 nuclease reaction,” and lyophilize. 25. To each tube from step 24, add 0.60 µL of 5× S1 nuclease buffer. To the control tubes, add 2.50 µL water; to the reaction tubes, add 2.00 µL water. To the reaction tubes, add 0.50 µL diluted S1 nuclease (prepared from 0.50 µL of 332 U/µL enzyme stock +
Methods for Cross-Linking Nucleic Acids
5.2.9 Current Protocols in Nucleic Acid Chemistry
Figure 5.2.5 Representation of a typical characterization gel. Lanes 1 and 3 represent isolated precircle and circle controls. Lanes 2 and 4 represent precircle and circle cleavage by S1 nuclease, an endonuclease. As would be expected for endonuclease cleavage of a circle (lane 4), the initial cleavage produces a species that exhibits the same migration as the full-length cyclization precursor (precircle). Initial endonuclease cleavage of the linear precircle (see in lane 2 and also lane 4), by contrast, produces a continuous banding pattern.
373 µL water). Incubate all tubes 10 min at 37°C. Stop reactions by adding 1 vol (3.10 µL) stop solution to each. 26. Prepare a vertical, 0.4-mm-thick (analytical), denaturing 10% polyacrylamide gel using a comb that produces ∼5-mm-wide wells. Prerun the gel as in step 15. Using half-width sequencing plates (6.5 × 16 in) and 5-mm well width comb, the entire reaction volume (6.20 mL) can be analyzed. For these conditions, prepare gel solution from 50 mL of 10% gel mix, 333 mL of 10% APS, and 10.67 mL TEMED.
27. Load the entire reaction volume, 6.20 µL, on the gel and run dyes to the same distance as for the second ligation purification gel (step 18). 28. When electrophoresis is complete, disassemble the gel apparatus and transfer the analytical gel to a piece of Saran Wrap. Transfer the gel to an ultrapure water bath and soak 10 min to remove urea. Chemical and Enzymatic Methods
5.2.10 Current Protocols in Nucleic Acid Chemistry
29. Remove the water soak and add 200 mL of Stains-all dye solution. Wait 10 min for staining of bands. Background staining can be lightened by exposing the gel to incandescent light (100 W, held at 1 to 2 feet) while it is immersed in a fresh water bath.
30. Assess circularity of the DNA: this is confirmed by the absence of banding between the circle band and the precircle band (each confirmed by appropriate control). Initial cleavage of a circle produces a single band with the mobility of the full-length precursor, the precircle, Figure 5.2.5 (compare lanes 1 and 4). If the putative circular DNA is actually linear, as is the case for the precircle reaction lane (lane 2), banding will be seen directly under the suspected band (compare lanes 1 and 2).
TRIPLE-HELICAL SPLINT COMPLEX–ASSISTED CHEMICAL CYCLIZATION OF OLIGONUCLEOTIDES USING CYANOGEN BROMIDE
ALTERNATE PROTOCOL 1
The protocol for chemical ligation using cyanogen bromide involves synthesis and purification of ssDNA circles using a pyrimidine-rich triple-helical-forming ssDNA template (a splint) to juxtapose reactive 3′-hydroxyl and 5′-phosphate (or 5′-hydroxyl and 3′-phosphate) ends of linear ssDNAs for chemical ligation using cyanogen bromide. It is noteworthy that unlike in enzymatic ligation (see Basic Protocol), either orientation of phosphate or hydroxyl is usable (i.e., the precursor segments can be either 3′- or 5′-phosphorylated). The protocol is applicable for triplex-forming circles (TFCs) in the size range of 28 to ∼150 nt. The synthesis of TFCs begins with two approximately equal-length precursor segments that are highly pyrimidine rich at the ligation site, allowing for formation of a triple-helical splint complex with a purine-rich splint for simultaneous dimeric ligation into a ssDNA circle (see Fig. 5.2.6A). The basic chemistry of ligation can be either that depicted in Figure 5.2.3B or Figure 5.2.6B. The products are separated by preparative denaturing PAGE, and circularity confirmed by endonuclease cleavage. CAUTION: Cyanogen bromide is highly toxic and volatile; all work with this compound should be performed in a well-ventilated fume hood. Additional Materials (also see Basic Protocol) One purine-rich, triple-helical-forming splint ssDNA Two triplex-forming precursor segments containing either 3′- or 5′-phosphates 2× ligation buffer: 200 mM NiCl2/400 mM imidazole⋅HCl (pH 7.0) Cyanogen bromide (BrCN; solid) 1. Construct or purchase ssDNAs of the desired splint and precursor-segment sequences. Splint sequence should bridge, by 10 nt on each side, the gap between precursor segments for ligation (see Fig. 5.2.6A). For ssDNAs purchased commercially, splints should be fully deprotected and precursor segments should be fully deprotected and either 5′- or 3′-phosphorylated. For use of commercially purchased DNAs, proceed to step 2. Alternatively, ssDNAs may be constructed on a DNA synthesizer using the standard DNA cycle and a 0.2-mmol scale; see Support Protocol 2 for 3′-phosphate- or Support Protocol 1 for 5′-phosphate-containing precursor segments, Support Protocol 4 for deprotection, and Support Protocol 5 for (optional) purification.
Quantitate DNA 2. Quantitate DNA (see Basic Protocol, steps 2 and 3).
Methods for Cross-Linking Nucleic Acids
5.2.11 Current Protocols in Nucleic Acid Chemistry
Figure 5.2.6 Schematic representation of ligation steps for the chemical cyclization of ssDNAs using cyanogen bromide, BrCN. (A) A purine-rich ssDNA splint is used to form a triple-helical splint complex to juxtapose reactive 3′-phosphate and 5′-hydroxyl ends of linear DNAs for a simultaneous dimeric ligation to a phosphodiester linkage, (B), using BrCN. Note: For chemical ligation using BrCN, a 5′-phosphate and 3′-hydroxyl such as are used in Figure 5.2.3B are also suitable.
Ligation 3. Combine 750 µL of 2× ligation buffer with 75 nmol of each precursor segment and 82.5 nmol of the splint in an autoclaved 1.5-mL microcentrifuge tube Chemical and Enzymatic Methods
Final concentrations: 100 mM NiCl2, 200 mM imidazole⋅HCl, 50 mM each precursor segment or precircle, 55 mM splint.
5.2.12 Current Protocols in Nucleic Acid Chemistry
If combined volume of DNA (two precursor segments and splint) exceeds 750 µL, one or more DNAs must be lyophilized to reduce the volume.
4. Calculate the volume of water to add according to the following equation: volume water = 1500 µL − (750 µL + volume DNA [step 3]) Add the calculated amount of water to the microcentrifuge tube and vortex thoroughly. The 1500 mL represents the total reaction volume, 750 mL represents the 2× ligation buffer, and DNA represents the combined volumes of both precursor segments and the splint.
5. Weigh out 19.9 mg cyanogen bromide (125 mM final concentration) and add to the microcentrifuge tube. Thoroughly vortex to completely dissolve cyanogen bromide and allow to react at 23°C (room temperature) for 12 hr. CAUTION: Cyanogen bromide is highly toxic; all work with this compound should be performed in a well-ventilated fume hood. Do not let the reaction proceed beyond 12 hr, as degradation of DNA may become problematic.
Dialyze reaction after ligation 6. Dialyze the ligation-reaction mixture (see Basic Protocol, steps 12 and 13). Gel purify DNA products 7. Gel purify the dialyzed mixture (see Basic Protocol, steps 14 to 19). The reaction lanes should show several bands. Figure 5.2.4 is a representation of a typical gel, with lane 6 containing the ligation-reaction mixture. Depending on how far the gel is run, the splint will probably be run off, but the precursor segments or precircle may be visible and their identity can be confirmed by their co-migration with appropriate DNA markers from step 2 (lanes 1 to 3) run alongside. Although DNA circles usually migrate more slowly than their linear counterparts (Serwer and Allen, 1984), identification of circles is not trivial. Circle migration is not always consistent and can be temperature dependent. Triple-helical splint complexes can yield multimers from ligation of an odd number of precursor segments (lane 7), although the dimeric mechanism for ligation reduces this tendency. However, most bands migrating more slowly than precursor segments or precircle should be cut out for analysis.
Isolate purified DNAs 8. Isolate purified DNAs from the electrophoretic gel (see Basic Protocol, steps 20 to 23). Precircle and higher products should be isolated for reasons stated in step 7.
Confirm circularity 9. Confirm circularity of the desired DNA product (see Basic Protocol, steps 24 to 30). DOUBLE-HELICAL SPLINT COMPLEX–ASSISTED REAGENT-FREE CYCLIZATION OF OLIGONUCLEOTIDES USING A 3′-PHOSPHOROTHIOATE GROUP AND 5′-IODOTHYMIDINE The protocol describes synthesis and purification of ssDNA circles using a complementary ssDNA template (a splint) to create a double-helical splint complex to juxtapose reactive 3′-phosphorothioate group and 5′-iodothymidine of ssDNAs for autoligation by nucleophilic displacement. The protocol is applicable to circles in the size range of 28 to at least 188 nucleotides. The “one-pot” synthesis consists of two approximately equal-
ALTERNATE PROTOCOL 2
Methods for Cross-Linking Nucleic Acids
5.2.13 Current Protocols in Nucleic Acid Chemistry
Chemical and Enzymatic Methods
Figure 5.2.7 Schematic representation of “one-pot” autoligation steps for the reagent-free cyclization of ssDNAs. (A) Complementary splints are used to form double-helical splint complexes to juxtapose reactive 3′-phosphorothioate and 5′-iodothymidine ends of linear ssDNAs for autoligation via nucleophilic attack by phosphorothioate on iodothymidine. (B) Basic chemistry of autoligation.
5.2.14 Current Protocols in Nucleic Acid Chemistry
length linear precursor segments, which are ligated to form a linear precircle and subsequently cyclized into a ssDNA circle (see Fig. 5.2.7). Circles <50 nt may be synthesized from a single precursor segment by a single ligation and circles >140 nt may be synthesized by ligation of more than two precursor segments; see Strategic Planning for more information. The products are separated by preparative denaturing PAGE and circularity confirmed by endonuclease cleavage. NOTE: To synthesize larger quantities, the first ligation reaction can be scaled up. The second ligation reaction can also be scaled up, but multiple reaction tubes should be used rather than a larger-scale one-pot synthesis. NOTE: If a single precursor segment is to be used (i.e., synthesis of a ssDNA circle <50 nt), skip steps 3 to 5 (i.e., omit the first ligation and proceed directly from quantitation to the second ligation described). Additional Materials (also see Basic Protocol) 20 nt splint ssDNAs Precursor segments containing a 3′-phosphorothioate and 5′-iodothymidine 2× ligation buffer: 20 mM MgCl2/20 mM Tris⋅acetate, pH 7.00 Obtain the ssDNAs 1. Construct or purchase ssDNAs of the desired splint and precursor-segment sequences. Precursor segment oligos must be designed such that the chosen ligation junction contains a thymine on the 5′ side; this allows incorporation of the modified base, 5′-iodothymidine, for autoligation. Splint DNAs should bridge, by 10 nt on each side, the gap between precursor segments for ligation (see Fig. 5.2.7A). For ssDNAs purchased commercially, be sure splints are fully deprotected and precursor segments are fully deprotected and synthesized with a 5′-iodothymidine and 3′-phosphorothioate group. Alternatively, ssDNAs may be synthesized on a DNA synthesizer using the standard 0.2-mmol DNA cycle for splints and a slightly modified protocol for precursor segments and precircles; see Support Protocol 3 for 3′-phosphorothioate- and 5′-iodothymidine-containing precursor segments, and see Support Protocol 4 for deprotection.
Quantitate DNA 2. Quantitate DNA (see Basic Protocol, step 2). Perform first ligation
3. Combine 125.0 µL of 2× ligation buffer with 15 nmol of each precursor segment and 18.3 nmol of one of the splints (splint 1) in an autoclaved 1.5-mL microcentrifuge tube. IMPORTANT NOTE: For large DNA circles, >140 nt, use all precursor segments and all but one splint in step 3. Final concentrations: 10 mM MgCl2, 10 mM Tris⋅acetate, 60 mM each precursor segment, 73 mM splint 1. It may not matter which splint is chosen for the first ligation here; however, more is required for the second ligation, so if one is limiting, it should be used here. If combined volume of DNA (two precursor segments and splint) exceeds 125.0 mL, one or more DNAs must be lyophilized to reduce the volume.
4. Calculate the volume of water to add according to the following equation: volume water = 250 µL − (125.0 µL + volume DNA [step 3]) Add the calculated amount of water to the 1.5-mL tube, vortex briefly, and secure closed with a cap lock.
Methods for Cross-Linking Nucleic Acids
5.2.15 Current Protocols in Nucleic Acid Chemistry
The 250 mL represents the total reaction volume, 125.0 mL represents the 2× ligation buffer, and volume DNA represents the combined volumes of either precursor segments or precircle, plus the splint.
5. Incubate the capped tubes 18 hr at room temperature. Perform second ligation 6. In an autoclaved 15-mL centrifuge tube, combine 5 mL of 2× ligation buffer with either 167.0 µL (2⁄3 volume) of the reaction from step 5 or 10 nmol full-length synthesized precursor segment if cyclization is from a single precursor segment, and 30 nmol of remaining splint (splint 2). Final concentrations: 10 mM MgCl2, 10 mM Tris⋅acetate, 1 mM precircle, 3 mM splint 2, 1.2 mM splint 1. IMPORTANT NOTE: For circles >140 nt, the final splint is added in this step. The 167.0 mL of reaction from step 5 represents, in theory, a maximum yield of 10 nmol of precircle from ligated precursor segments. Alternatively, 10 nmol of synthesized full-length precursor segment can be used if circle size is <50 nt. Note that DNA concentrations are much lower for this second ligation (1 mM precircle) than for the first (60 mM each precursor segment). This is meant to favor the intramolecular cyclization reaction versus an intermolecular reaction that produces multimeric linear species.
7. Calculate the volume of water to add according to the following equation: volume water = 10,000 µL − (5000 µL + volume DNA [step 6]) Add this volume of water to the 15-mL tube(s), vortex briefly, and secure closed. The 10,000 mL represents the total reaction volume, 5000 mL represents the 2× ligation buffer, and volume DNA represents the combined volumes of either 167 mL step 5 reaction or synthesized precircle, plus the splint. Normally it will not be necessary to be lyophilized any of the components at this step, as the calculated volume of water often exceeds 4.5 mL.
8. Incubate the tubes 18 hr at room temperature. Dialyze reaction 9. Dialyze the reaction mixture from the second ligation (see Basic Protocol, steps 12 and 13). Gel purify DNA products 10. Gel purify the dialyzed mixture (see Basic Protocol, steps 14 to 19).
Chemical and Enzymatic Methods
The reaction lanes should show several bands. Figure 5.2.4 is a representation of a typical gel, with lane 6 containing cyclization mixture. Depending on how far the gel is run, the splints will probably be run off, but precursor segments may be visible and their identity can be confirmed by their co-migration with the splints and precursor-segment markers (step 2) run alongside (lanes 1 to 3). The next band up from precursor segments should be the precircle band and can be confirmed by co-migration with the largest band from the ligation reaction (step 5) run alongside (lane 4). There is the potential for non-unit-length linear multimers from the linear ligation of an odd number of precursor segments leading to products in-between precircle and circle (lane 7). Although DNA circles usually migrate more slowly than their linear counterparts (Serwer and Allen, 1984), identification of circles is not trivial. Circle migration is not always consistent and may be temperature dependent. Therefore, most bands migrating more slowly than confirmed precircle should be cut out for analysis.
5.2.16 Current Protocols in Nucleic Acid Chemistry
Isolate purified DNAs 11. Isolate purified DNAs from the electrophoretic gel (see Basic Protocol, steps 20 to 24). Precircle and higher products should be isolated for reasons stated in step 10.
Confirm circularity 12. Confirm circularity of the desired DNA product (see Basic Protocol, steps 24 to 30). AUTOMATED SYNTHESIS OF PRECURSOR SEGMENTS CONTAINING 5′-PHOSPHATE FOR LIGATION
SUPPORT PROTOCOL 1
The support protocol describes incorporation of 5′-phosphate end groups on precursor segments necessary for their use in the enzymatic ligation methodology presented in the Basic Protocol. While DNAs can be purchased containing the desired end groups, modification during automatic DNA synthesis is straightforward. Introduction of a 5′-phosphate is described. NOTE: Precursor segments will contain a 3′-hydroxyl and 5′-phosphate after deprotection (see Support Protocol 4). Materials DNA synthesis reagents for 0.2-µmol synthesis Phosphorylating reagent (Chemical Phosphorylating Reagent, Glen Research) DNA synthesizer with phosphoramidite chemistry 1. Synthesize all natural bases for precursor segments, with completion of the synthesis cycle retaining the 5′-DMT protecting group. 2. Place phosphorylating reagent in a synthesizer port. 3. Set up the synthesis cycle for normal DNA, using the DNA column from step 1 as the starting column. Enter the sequence with the first (3′) base as the last base added to the column in step 1 and the next added “nucleotide” as the port containing the phosphorylating reagent. Complete the synthesis cycle with DMT removal. This adds a 5′ phosphate to each of the precursor segments.
4. Proceed to deprotection (see Support Protocol 4). AUTOMATED SYNTHESIS OF PRECURSOR SEGMENTS CONTAINING 3′-PHOSPHATE FOR LIGATION
SUPPORT PROTOCOL 2
The support protocol describes incorporation of 3′-phosphate end groups on precursor segments necessary for their use in the chemical ligation methodology presented in Alternate Protocol 1. While DNAs can be purchased containing the desired end groups, modification during automatic DNA synthesis is straightforward. Introduction of a 3′-phosphate is described. Materials DNA synthesis reagents for 0.2-µmol synthesis Phosphorylating reagent (Chemical Phosphorylating Reagent, Glen Research) DNA synthesizer with phosphoramidite chemistry NOTE: This is analogous to addition of a 3′ phosphorothioate in Support Protocol 3, but standard oxidizing (rather than sulfurizing) conditions are used to afford a 5′-hydroxyl
Methods for Cross-Linking Nucleic Acids
5.2.17 Current Protocols in Nucleic Acid Chemistry
and 3′-phosphate, rather than a 3′-phosphorothioate, after deprotection (Support Protocol 4). 1. Begin synthesis of the precursor segment using any of the four base columns. Set up the synthesis cycle for normal DNA. 2. Place phosphorylating reagent in a synthesizer port. 3. Set up the synthesis cycle for normal DNA. Enter the sequence with the first (3′) base as the base located on the column and the next added “nucleotide” as the port containing phosphorylating reagent. Complete the cycle with DMT left on. This adds a 5′-phosphate to the column. Any normal base column can be used here, as deprotection of the finished product will cleave to the 5′ side of this initially added phosphate group, thus cleaving the finished oligo from the 3′ base present on the CPG bead. The DMT group should be left on for the next base to be added, which is the 3′ base in the sequence.
4. Add the first (3′) nucleotide for the desired sequence to the column. Complete synthesis of the remaining bases on the oligo with removal of the DMT protecting group. 5. Proceed to deprotection (see Support Protocol 4). SUPPORT PROTOCOL 3
AUTOMATED SYNTHESIS OF PRECURSOR SEGMENTS CONTAINING 3′-PHOSPHOROTHIOATE AND 5′-IODOTHYMIDINE FOR LIGATION This support protocol describes incorporation of 3′-phosphorothioate and 5′-iodothymidine end groups on precursor segments necessary for their use in the autoligation chemistry presented in Alternate Protocol 2. While DNAs can be purchased containing the desired end groups, modification during automatic DNA synthesis is straightforward. Phosphorylation at the 3′ end, subsequent modification of this end group to a 3′-phosphorothioate, and introduction of a 5′-iodothymidine are described. Materials DNA synthesizer with phosphoramidite chemistry DNA synthesis reagents for 0.2-µmol synthesis Phosphorylating reagent (S.1 in Fig. 5.2.8; Chemical Phosphorylating Reagent, Glen Research) Sulfurizing reagent (S.3; Applied Biosystems) Iodothymidine phosphoramidite (5′-I-dT-CE phosphoramidite, Glen Research) NOTE: Precursor segments will contain a 5′-iodothymidine and a 3′-phosphorothioate rather than 5′-hydroxyl and 3′-hydroxyl after deprotection (see Support Protocol 4). 1. Begin synthesis of the precursor segment using any of the four normal base columns. Set up the synthesis cycle for normal DNA. 2. Place phosphorylating reagent in a synthesizer port. 3. Enter the sequence with the first (3′) base as the base located on the column and the next added “nucleotide” as the port containing phosphorylating reagent. Complete the cycle with DMT left on. This adds a 5′-phosphate to the 3′ base of the column.
Chemical and Enzymatic Methods
Any base column can be used here, as deprotection of the finished product will cleave to the 5′ side of this initially added phosphate group (S.4), thus cleaving the finished oligo
5.2.18 Current Protocols in Nucleic Acid Chemistry
Figure 5.2.8 Schematic representation of steps involved in incorporation of a 3′-phosphorothioate group during DNA synthesis. First, a 3′-phosphate is coupled to the base on the CPG bead, S.1. Addition of the next base, S.2, the 3′ base of the desired sequence, proceeds with the trivalent phosphorus of this internucleotide bond converted to a phosphorothioate linkage using a sulfurizing reagent, S.3. Standard deprotection cleaves 3′ to this phosphorothioate linkage, S.4, creating a 3′-phosphorothioate group for coupling, S.5.
from the 3′-nucleotide present on the CPG bead (S.5). The DMT group should be left on for the next base to be added, which is the 3′ base in the sequence of interest. Alternatively, commercially available phosphate base columns can be used.
4. Set up the synthesizer to use a sulfurizing reagent (S.3) rather than an oxidizing reagent for this coupling only. 5. Proceed to add this next base and stop the synthesis after completion of this coupling. This modified synthesis cycle (involving S.2 and S.3) adds the first (3′) nucleotide for the sequence of interest to the column from step 3. The sulfurizing reagent converts the 3′ trivalent phosphorus linkage to a phosphorothioate linkage, S.4, rather than oxidized to a phosphodiester linkage as occurs during the standard DNA synthesis cycle. Subsequent
Methods for Cross-Linking Nucleic Acids
5.2.19 Current Protocols in Nucleic Acid Chemistry
deprotection will cleave 3′ to this linkage, leaving a 3′-phosphorothioate group as the nucleophile for autoligation (S.5).
6. Change the synthesis cycle back to standard (oxidizing agent instead of sulfurizing) and complete the synthesis of the desired precursor segments to the point at which synthesis of the natural bases (i.e., without iodothymidine) is complete, retaining the 5′-DMT protecting group. IMPORTANT NOTE: Do not forget to change the synthesis cycle back to oxidizing from sulfurizing.
7. Place the modified phosphoramidite (5′-I-dT-CE phosphoramidite) in a synthesizer port. 8. Set up the synthesis cycle for normal DNA using the DNA column from step 5 as the starting column. Enter the sequence with the first (3′) base as the last base added to the column from step 5, and the next added “nucleotide” as the port containing the modified phosphoramidite. Complete the synthesis cycle without DMT removal. This adds the modified phosphoramidite 5′-iodothymidine to each of the precursor segments. A DMT removal step is unnecessary because this phosphoramidite does not have a DMT protecting group.
9. Proceed to deprotection (see Support Protocol 4). SUPPORT PROTOCOL 4
DEPROTECTION OF PRECURSOR SEGMENTS After completion of synthesis, the oligonucleotides must be cleaved from the solid support and protecting groups which are needed during synthesis must be removed. The procedure is different for precursor segments that do and do not contain 3′-phosphorothioate and 5′-iodothymidine end groups in that gentler incubation conditions are used for the former. Materials Concentrated ammonium hydroxide Pasteur pipets Glass wool 1.5-mL screw-cap vial 1. Place DNA-loaded CPG beads from the column with 1 mL concentrated ammonium hydroxide in a 1.5-mL screw-cap vial. Incubate 24 hr at room temperature for precursors containing 3′-phosphorothioate and 5′-iodothymidine end groups, or 14 to 16 hr at at 55°C for precursors not containing those groups. 2. Filter the solution through a glass wool–plugged pipet to separate CPG beads. Use a second Pasteur pipet to transfer the solution.
3. Lyophilize the filtrate to remove ammonia and water. The crude DNA product should be powdery and white. SUPPORT PROTOCOL 5
Chemical and Enzymatic Methods
PURIFICATION OF DEPROTECTED PRECURSOR SEGMENTS (OPTIONAL) Slightly increased product yields may be possible through the use of purified products. However, this will result in some product loss and is not needed, as each splint complex– assisted ligation reaction mechanism selects for correct, full-length sequences, and the final product is gel purified to eliminate undesired DNAs. This support protocol is not recommended for precursor segments containing 3′-phosphorothioate or 5′-iodothymid-
5.2.20 Current Protocols in Nucleic Acid Chemistry
ine end groups. The protocol describes a standard denaturing acrylamide gel method for purification of deprotected oligonucleotides. CAUTION: Acrylamide and N,N′-methylenebisacrylamide are neurotoxins. Preparation of solutions containing these compounds should be performed in a well-ventilated fume hood, and extreme precautions taken to minimize contact with solids or solutions. Materials 10% denaturing polyacrylamide gel mix (see recipe or purchase) 10% (w/v) ammonium persulfate (APS) in water TEMED or TMEDA (Life Technologies) 1× TBE (APPENDIX 2A) Ultrapure (e.g., distilled, deionized) water Formamide loading buffer (recipe) 0.2 N NaCl Dialysis tubing, MWCO 1000 (e.g., SpectraPor) 50-mL filter tubes with 0.45-µm cellulose acetate filter (e.g., Spin-X II, Corning Costar) Gel electrophoresis equipment: Vertical (sequencing) gel stand 2000-V power supply Glass plates: 13 × 15.5 cm and 13 × 16.5 cm 2.5-mm-thick gel combs with 2.5-cm-wide wells 2.5-mm-thick spacers UV shadow box or light source Lyophilizer or SpeedVac Saran Wrap (or other UV-transparent plastic wrap) Sterile razor blades Glass stir rod 1. Prepare a vertical, 2.5-mm-thick (preparative), denaturing 10% polyacrylamide gel using a comb producing 2.5-cm-wide wells. The well size is not critical, and the walls can even be removed to create one large well. A gel prepared between plates used for sequencing (13 × 16.5 in.) allows for ample vertical loading of reaction mixture and sufficient migration length for separation and resolution of bands. For these conditions, prepare gel solution from 300 mL of 10% gel mix, 2 mL of 10% APS, and 64 mL TEMED. For more detailed description of procedures for denaturing PAGE, see APPENDIX 3B.
2. Place the gel in a gel electrophoresis apparatus, using 1× TBE in both top and bottom buffer reservoirs, and prerun 30 min at 30 W constant power, room temperature. 3. Redissolve each crude DNA (after deprotection and lyophilization) in 100 µL water and 100 µL formamide loading buffer by brief vortexing. Synthesized DNA after deprotection and lyophilization should be powdery and white and readily redissolve in water. If the solution does not appear homogeneous, mild heating (∼60°C) and/or brief sonication (1 min) can be used to help dissolve the DNA. Insoluble materials may cause some turbidity but are not cause for concern.
4. Load 25 µL of solution from step 3 in each of the 2.5-cm-wide wells; or, alternatively, remove well walls and load the entire sample in the large well created. 5. Run the gel at 30 W constant power, room temperature, to the desired length.
Methods for Cross-Linking Nucleic Acids
5.2.21 Current Protocols in Nucleic Acid Chemistry
Bromphenol blue migrates similarly to a 26-nt linear DNA on a 10% gel, and xylene cyanol runs like a 55-nt linear DNA.
6. Disassemble the gel apparatus, separate the plates, and sandwich the gel between two pieces of Saran Wrap. View the gel under ultraviolet light with fluorescent white background (glass silica plates work well) to visualize the DNA. There should be an intense, slow-migrating band, which is the desired sequence, as well as faster-migrating shorter sequences below.
7. Cut out the desired band with a clean, sterile razor blade and place the cut up pieces in three or four 15-mL centrifuge tubes. Using a glass stir rod, crush the gel pieces thoroughly. Combine crushed gel pieces in each tube with ∼5 to 10 mL of 0.2 N NaCl to make an easily shaken slurry. Repeat, in separate tubes, for each band isolated. Shake each slurry for ∼12 hr. Note that high-purity DNAs can be obtained by individually crushing thin vertical portions of the large piece isolated above. Be sure all crushed gel pieces are transferred to the slurry, as isolated yields are often <50%, and it is therefore important to ensure a quantitative transfer of all materials.
8. Filter the slurry by brief centrifuging 1 to 5 min through 50-mL filter tubes. Resuspend the gel pieces in 5 mL water, centrifuge again, and combine the filtrates. It is advisable to save the filtered gel pieces until after quantitation, as additional extractions with 0.2 N NaCl may be desired to increase isolated product yield, although only minimal (<10%) further recoveries should be expected.
9. Transfer the entire reaction volume from step 8 to MWCO 1000 dialysis tubing clamped at one end to make a bag. Secure the other end of the dialysis bag closed. Dialyze against 2 L of ultrapure water for 3 hr. Repeat. 10. Lyophilize the dialysate to dryness. The dried residue should powdery and white.
REAGENTS AND SOLUTIONS Use distilled, deionized water or other ultrapure water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX. Most of these reagents can be purchased premade from a biological supply company.
Denaturing polyacrylamide gel mix, 10% Dissolve 450 g urea, 95.0 g acrylamide, and 5.00 g N,N′-methylenebisacrylamide in 100.0 mL of 10× TBE (APPENDIX 2A) diluted to a final volume of 1.00 L with water. Filter using 0.45-µm nylon filter paper. CAUTION: Acrylamide and N,N′-methylenebisacrylamide are neurotoxins. Preparation of solutions with these compounds should be performed in a well-ventilated fume hood, and extreme precautions taken to minimize contact with compounds or solutions.
Formamide loading buffer Dissolve 10.0 mL of 10 mM EDTA, pH 8.0 (APPENDIX 2A), in 40 mL formamide. Add 5.00 mg each bromophenol blue and xylene cyanol dyes. Chemical and Enzymatic Methods
Stains-all dye solution Dissolve 20.0 mg stains-all (3,3′-diethyl-9-methyl-4,5,4′,5′-debenzothiacarbocyanine; Sigma) in 25.0 mL formamide and dilute to 200 mL with water.
5.2.22 Current Protocols in Nucleic Acid Chemistry
Stop solution Dissolve 5.77 g urea, 1.2 mg each bromophenol blue and xylene cyanol, and 720 µL of a stock (500 mM) EDTA solution in water to a final volume of 12 mL. Final concentrations are 8 M urea, 30 mM EDTA, and 0.1 mg/mL of each gel running dye.
COMMENTARY Background Information Circularized single-stranded deoxyribonucleotides (ssDNAs) are more resistant to nuclease activity than their linear counterparts (Rumney and Kool, 1992), a property that may be important for in vivo studies. Circular DNAs have been investigated for their unique DNA binding properties (Wang and Kool, 1994; Kool, 1996) and also as useful models in studying DNA structures such as hairpin motifs by NMR (Ippel et al., 1995). DNA circles are also currently being used for more diagnostic applications, such as the creation of padlock probes (Nilsson et al., 1994, 1997). Circular oligonucleotide templates have also been used for the synthesis of concatemeric polypeptides (Brown, 1997). Additionally, circular ssDNAs offer a novel means of both DNA and RNA amplification as these molecules are accepted as templates by both DNA and RNA polymerases (Fire and Xu, 1995; Liu et al., 1996; Daubendiek and Kool, 1997). Circular ssDNAs have been constructed using a range of chemical, enzymatic, and reagent-free ligation methods. Chemical ligation using cyanogen bromide has been effective for the synthesis of circles from triple-helical (Ruben et al., 1995) as well as double-helical splint complexes (Dolinnaya et al., 1993). Chemical ligation using carbodiimide chemistry (Ashley and Kushlan, 1991) is becoming a less common method of ligation despite reported higher yields as compared to cyanogen bromide (Dolinnaya et al., 1991), possibly because of the long reaction times required. Enzymatic ligation, which gives comparable yields albeit with higher cost, eliminates the need for either of these chemicals, which may be damaging to DNA. Novel approaches to the synthesis of small circular DNAs are becoming more common as solid-phase methodology improves (De Napoli et al., 1995; Alazzouzi et al., 1997). Of great interest are new autoligation, or reagent-free, methods (Herrlein and Letsinger, 1994; Herrlein et al., 1995), since these eliminate the need for a separate ligation reagent. The finite stability of the tosyl-modified DNAs required for these couplings limits the methods’ practical applications. A recent report
by Xu and Kool (1997) describes a novel 5′-iodonucleoside that eliminates this stability issue. While this method produces a non-natural bridging phosphorothioate, the transcription and replication ability of the DNAs does not appear to be affected, as the circles were transcribed and replicated successfully in a rollingcircle fashion (Y. Xu and E.T. Kool, unpub.observ.). It is noteworthy that this bridging 5′phosphorothioate linkage in DNA is stable for at least several months in the pH range 5 to 9. Each of the three protocols in this unit is potentially applicable to the synthesis of circles ranging in size from 28 nt to at least 188 nt; however, sequence and size may render one or another method more suitable in specific cases. The enzymatic ligation method (see Basic Protocol) has few sequence or size restrictions, though small circles, and larger circles that may have sequence-induced secondary structure, may not be good substrates for the enzyme. The chemical ligation approach using cyanogen bromide (see Alternate Protocol 1) has been very effective in the creation of pyrimidine-rich circles by ligation of triple-helical splint complexes (Ruben et al., 1995). It has not, however, proven effective to the authors’ satisfaction in creating DNA circles from a double-helical splint complex using the methodology described by Dolinnaya et al. (1993). The phosphorothioate autoligation method (see Alternate Protocol 2) requires segment precursors to contain a 5′-thymidine (from iodothymidine) and a 3′-phosphorothioate group at the ligation junction. For larger circles, another issue arises: the tradeoff between optimized ligation yields and DNA synthesis yields. Longer synthesized DNAs will be produced in lower yields than shorter ones, but ligation of shorter oligos may proceed in higher yields than their longer counterparts. Consider the synthesis of a 100-mer ssDNA circle. While an average stepwise coupling yield of 98% on the synthesizer results in 37% overall yield of each 50-mer precursor segment, the same coupling yields give only 14% of the full-length 100-mer precircle. If the single ligation of precircle to circle proceeds in a 40% overall yield, and the double ligation
Methods for Cross-Linking Nucleic Acids
5.2.23 Current Protocols in Nucleic Acid Chemistry
only in 30% overall yield, the overall yield of circle from this “convergent” (double-ligation) approach is still 2-fold greater. So in planning strategically for cyclization, one should take into account circle size and optimization of both DNA synthesis and ligation when designing starting materials. Enzymatic ligation proceeds via a 3′-hydroxyl and 5′-phosphate, affording a “natural” phosphodiester backbone. However, this “natural” method comes with an expensive price-tag and, with larger circles (>100 nt), potentially low yields. While the cyanogen bromide method uses the same starting materials for ligation, also yielding the desired “natural” linkage, the reagents for ligation, while substantially cheaper, may be moderately caustic to DNA. So although yields may be comparable to those from enzymatic ligation, the benefit of cheaper reagents may not outweigh the cost of possible product damage. The autoligation method has a cost advantage, since it eliminates the need for a separate ligation reagent, but creates a non-natural phosphorothioate linkage.
Compound Characterization As described in each individual protocol, confirmation of product circularity is quite rapid and simple and may be of critical importance when considering future applications. The analysis of this characterization is quite unambiguous, as described in the sections within each protocol on confirmation of circularity. Initial cleavage of a circle produces a single band with the mobility of the full-length cyclization precursor (Fig. 5.2.5). If the putative circular DNA is actually linear, banding will be seen directly under the suspected band. This type of banding should also be seen for the precircle reaction lane. This reaction, and/or one analogous to it, must be completed to ensure product quality.
Critical Parameters
Chemical and Enzymatic Methods
There are few complicating factors with these reactions, although several potential problems will be addressed in the troubleshooting section. However, there are a few “critical parameters” worth mentioning. For all syntheses, dialysis of the final ligation-reaction mixture to remove all salts prior to lyophilization and gel purification is critical, as excess salts can cause problems with gel migration. It is worthwhile to note that for all reactions done via a double ligation (i.e., with two precursor segments), the concentration of precircle in the
second step is purposely lowered to favor this intramolecular ligation producing circles as compared to the intermolecular ligation creating linear multimers. Another point to note is that while both enzymatic and autoligation occur via the same double-helical splint complex, only the enzymatic ligation protocol calls for slow annealing of precursor DNAs and splints prior to addition of ligation reagents (steps 6 and 10 of the Basic Protocol). This simply represents different methodologies consistently used in the authors’ lab, and while enzymatic ligation may proceed just as efficiently without these steps, this asyet-unexplored option has not been described in the protocol. For enzymatic ligation, the enzyme should be stored at −20°C prior to its use, and reaction temperature should be maintained consistently at ≤37°C, as higher temperatures may cause enzyme denaturation and inactivation. The only special precaution when using cyanogen bromide ligation is that, since this chemical is quite toxic and volatile, appropriate care must be taken when using it. By much the same token, the reaction should be stopped promptly when instructed, as prolonged exposure may increase the DNA’s susceptibility to damage. The only specific considerations for the phosphorothioate method are in the synthesis of the modified precursor segments. It is important to follow the directions for synthesis exactly, first phosphorylating the initial base column with subsequent addition of the desired 3′ base and sulfurization of only this internucleotide linkage. As for the 5′-iodothymidine phosphoramidite, this particular compound is unique—compared to other similar compounds designed to ligate ssDNAs via an SN2 mechanism—in having greatly enhanced stability, which significantly extends the shelf lives of both the phosphoramidite and the modified precursor-segment DNAs (Xu and Kool, 1997). For a discussion of common problems arising with these procedures, including their diagnosis and possible solutions, see Table 5.2.1.
Anticipated Results For all three methods, optimized yields after purification are modest, and often less than the observed qualitative conversion. For circles of ∼65 nt, yields of 33% for enzymatic ligation (Diegelman, pers. comm.) and 20% for autoligation (Xu et al., 1997) have been reported along with a comparable yield of 30% for
5.2.24 Current Protocols in Nucleic Acid Chemistry
Table 5.2.1 Troubleshooting Guide for Synthesis of Circular DNAs
Problem
Possible cause
Possible solution
Poor DNA synthesis yields
Reagents contaminated with water
Ensure reagents are anhydrous (distill solvents fresh) Boil 15 min in water and sonicate 30 min in methanol Use new phosphoramidites Distill fresh CH3CN to prepare phosphorylating reagent Purchase fresh reagents Briefly heat at 60°C and sonicate to dissolve DNA or briefly centrifuge crude DNA and work with supernatant Set absorbance at 260 nm; check that UV lamp is working properly Ensure cuvette is clean and unscratched and light passes through its clear sides Ensure instrument is properly zeroed with a cuvette containing only water Consult spectrophotometer manual on ensuring unimpeded light path See “Crude DNA not dissolving in water,” above If quantitating gel-purified products, try re-extracting the slurry mixture with 0.2 N NaCl Rerun reaction, ensuring addition of all DNAs needed Rerun reaction using a fresh batch of enzyme, and ensure proper storage (–20°C) after use Rerun reaction using fresh DTT or BrCN stock Rerun reaction for shorter period
Glass frits in synthesizer dirty Phosphoramidites degraded Poor phosphorylation yields Reagents contaminated with water
Crude DNA not dissolving in water
Phosphoramidites degraded Insoluble material found after deprotection
No/low absorbance seen for Measurement not at correct wavelength DNA quantitation Cuvette dirty or not inserted properly Instrument not properly zeroed Instrument not properly aligned No DNA in sample DNA concentration low after isolation of products from gel pieces No ligation seen by UV shadowing
One or more DNAs (especially splint) omitted from reaction mixture Enzyme old or inactive (enzymatic ligation) DTT or BrCN degraded (enzymatic ligation) Reaction allowed to proceed too long (chemical ligation) DNA modification (phosphorylation) poor, leading to reduced ligation yield (enzymatic and chemical ligation) Poor incorporation of the modified base, 5′-iodothymidine (autoligation)
Poor splint hybridization
Isolated product not behaving as expected for circular DNA
Isolated product is not a circular DNA
Isolated product is circular but has degraded significantly (less likely; check for circularity first)a
See “Poor phosphorylation yields,” above
Ensure coupling of modified phosphoramidite and sulfurization were effectiveb; rerun reaction, ensuring DNA synthesizer cycle is set up properly Rerun reaction; possibly redesign new splint junction (sequence context problem may exist) Rerun Sl nuclease reaction on other isolated bands Resynthesize DNA, taking greater precautions to avoid degradation
aCommon forms of damage are formation of abasic sites from depurination during synthesis, and degradation by reagents (e.g., BrCN) or heat or acid
treatments. bSulfurization can be examined by electrospray or MALDI-TOF MS (UNITS 10.1 & 10.2). Iodothymidine incorporation can be checked by comparing the
oligonucleotide to one without iodo-T added using either high-resolution sequencing PAGE (APPENDIX 3B) or C18-reversed-phase HPLC.
5.2.25 Current Protocols in Nucleic Acid Chemistry
Supplement 9
cyanogen bromide ligation of a 42-nt triplexforming circle (Ruben et al., 1995). For all syntheses involving more than one precursor segment and splint, and methodology involving a double ligation (two step, one pot) rather than a dimerization approach (triple-helical splintcomplex ligation with cyanogen bromide), intermediate, non-unit-length products (besides the desired circles) are often seen. In general, the observed yield—as determined by UV shadowing to estimate product conversion—is often twice the isolated yield. This apparently represents the inability to completely extract product from gel slurry; reextraction with additional eluent (0.2 N NaCl) may increase product yields somewhat, although only minimal (<10%) recoveries should be expected.
Time Considerations Completion of any of the above three protocols should take no longer than 7 days, and most can be completed in less time either by purchasing synthesized DNAs or by using fast-deprotection phosphoramidites. Actual hands-on work occupies much less total time, but several waiting periods are required. Synthesis of oligos, with overnight deprotection, followed by lyophilization and quantitation the next day should take ∼1.5 days. A double ligation set up to run the remainder of day 2 with the second ligation running overnight should take another 1.5 days, resulting in completion of the ligations by the middle of day 3. Dialysis for 6 hr and lyophilization overnight allows gel purification on day 4 and elution from gel pieces overnight to the morning of day 5. Following a 24-hr dialysis, the circular products should be ready partway through day 6 for quantitation and structural confirmation experiments.
Literature Cited Alazzouzi, E., Escaja, N., Grandas, A., and Pedroso, E. 1997. A straightforward solid-phase synthesis of cyclic oligodeoxyribonucleotides. Angew. Chem. Int. Ed. Engl. 36:1506-1508. Ashley, G.W. and Kushlan, D.M. 1991. Chemical synthesis of oligodeoxynucleotide dumbbells. Biochemistry 30:2927-2933.
Chemical and Enzymatic Methods
Borer, P.N. 1975. Optical properties of nucleic acids. In Handbook of Biochemistry and Molecular Biology, Vol. I, 3rd ed. (G.D. Fasman, ed.) p. 589. CRC Press, Boca Raton, Fla. Brown, S. 1997. Metal-recognition by repeating polypeptides. Nature Biotechnol. 15:269-272.
Daubendiek, S.L. and Kool, E.T. 1997. Generation of catalytic RNAs by rolling transcription of synthetic DNA nanocircles. Nature Biotechnol. 15:273-277. De Napoli, L., Galeone, A., Mayol, L., Messere, A., Montesarchio, D., and Piccialli, G. 1995. Automatic solid phase synthesis of cyclic oligonucleotides: A further improvement. Bioorg. Med. Chem. 3:1325-1329. Dolinnaya, N.G., Sokolova, N.I., Ashirbekova, D.T., and Shabarova, Z.A. 1991. The use of BrCN for assembling modified DNA duplexes and DNARNA hybrids: Comparison with water-soluble carbodiimide. Nucl. Acids Res. 9:3067-3072. Dolinnaya, N.G., Blumenfeld, M., Merenkova, I.N., O re tsk a y a, T.S., Kryn etsk aya, N.F., Ivanovskaya, M.G., Vasseur, M., and Shabarova, Z.A. 1993. Oligonucleotide circularization by splint-directed chemical ligation. Nucl. Acids Res. 21:5403-5407. Fire, A. and Xu, S.Q. 1995. Rolling replication of short DNA circles. Proc. Natl. Acad. Sci. U.S.A. 92:4641-4645. Herrlein, M.K. and Letsinger, R.L. 1994. Selective chemical autoligation on a double-stranded DNA splint. Nucl. Acids Res. 22:5076-5078. Herrlein, M.K., Nelson, J.S., and Letsinger, R.L. 1995. A covalent lock for self-assembled oligonucleotide conjugates. J. Am. Chem. Soc. 117:10151-10152. Ippel, J.H., Lanzotti, V., Galeone, A., Mayol, L., Van den Boogaart J.E., Pikkemaat, J.A., and Altona, C. 1995. Slow conformational exchange in DNA minihairpin loops: A conformational study of the circular dumbbell d
. Biopolymers 36:681-694. Kool, E.T. 1996. Circular oligonucleotides: New concepts in oligonucleotide design. Annu. Rev. Biophys. Biomol. Struct. 25:1-28. Liu, D., Daubendiek, S.L., Zillman, M.A., Ryan, K., and Kool, E.T. 1996. Rolling circle DNA synthesis: Small circular oligonucleotides as efficient templates for DNA polymerases. J. Am. Chem. Soc. 118:1587-1594. Nilsson, M., Malmgren, H., Samiotaki, M., Kwiatkowski, M., Chowdhary, B.P., and Landegren, U. 1994. Padlock probes: Circularizing oligonucleotides for localized DNA detection. Science 265:2085-2088. Nilsson, M., Krejci, K., Koch, J., Kwiatkowski, M., Gustavsson, P., and Landegren, U. 1997. Padlock probes reveal single-nucleotide differences, parent of origin and in situ distribution of centromeric sequences in human chromosomes 13 and 21. Nature Genet. 16:252255. Ruben, E., Rumney, S. IV, Wang, S., and Kool, E.T. 1995. Convergent DNA synthesis: A non-enzymatic dimerization approach to circular oligodeoxynucleotides. Nucl. Acids Res. 23:3547-3553.
5.2.26 Supplement 9
Current Protocols in Nucleic Acid Chemistry
Rumney, S. IV and Kool, E.T. 1992. DNA recognition by hybrid oligoether-oligodeoxynucleotide macrocycles. Angew. Chem. Int. Ed. Engl. 31:1617-1619. Serwer, P. and Allen, J.L. 1984. Conformation of double-stranded DNA during agarose gel electrophoresis: Fractionation of linear and circular molecules with molecular weights between 3 × 106 and 26 × 106. Biochemistry 23:922-927. Wang, S. and Kool, E.T. 1994. Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a comparison with circular DNAs. Nucl. Acids Res. 22:2326-2333. Xu, Y. and Kool, E.T. 1997. A novel 5′-iodonucleoside allows efficient nonenzymatic ligation of single-stranded and duplex DNAs. Tetrahedron Lett. 38:5595-5598.
Dolinnaya et al., 1993. See above. Reports the synthesis of medium-sized (∼40 nt) ssDNA circles from a double-helical splint complex with cyanogen bromide. Certain sequence requirements for successful ligation are described. Ruben et al., 1995. See above. Reports the cyanogen bromide–mediated synthesis of medium-sized (34- to 72-nt) ssDNA circles from two short segments using a triple-helical splint complex. Xu and Kool, 1997. See above. Reports an autoligation method incorporating a novel 5′-iodothymidine phosphoramidite (now commercially available) which possesses increased stability as compared to one previously described (Herrlein et al., 1995).
Key References Alazzouzi et al., 1997. See above. Reports a unique methodology for the solid-phase synthesis of small (<32 nt) ssDNA circles. No splint is needed, but yields are low for the larger circles in this size range.
Contributed by Amy M. Diegelman and Eric T. Kool University of Rochester Rochester, New York
Methods for Cross-Linking Nucleic Acids
5.2.27 Current Protocols in Nucleic Acid Chemistry
Engineering Specific Cross-Links in Nucleic Acids Using Glycol Linkers
UNIT 5.3
Simple glycol linkers can be used to cross-link nucleic acid sequences. In the most straightforward approach, such cross-links can be used in place of nucleotide sequences to bridge two domains of higher-order nucleic acid structures. Such linkers can also be viewed as tethers between two independently hybridizing nucleic acid sequences, or between a nucleic acid and some other ligand or reporter group. Although most any carbon chain can be employed to introduce cross-links in nucleic acids, the hydrophilic nature of the ethylene glycol chain gives it one particular advantage. Whereas simple carbon chains may tend to collapse on themselves as the result of the hydrophobic effect, the glycol chains’ alternating ethyl and oxygen ether subunits are more likely to be hydrated in aqueous solutions and thus maintain a more extended conformation, which permits them to easily bridge two different sites within the macromolecule. Additionally, a variety of ethylene glycol–based linkers are readily available (Fig. 5.3.1) and only require simple protection reactions in order to be used as cross-linking agents. Oligo(ethylene glycol) linkers have been used most commonly to replace a portion (Williams and Hall, 1996) or the entirety of the loop structure at the end of DNA (Durand et al., 1990; Altmann et al., 1995) or RNA helices (Benseler et al., 1993; Ma et al., 1993; Thomson et al., 1993; Fu et al., 1994; Hendry et al., 1994; Komatsu et al., 1996), essentially to achieve cross-linking of the terminal residues of the double-stranded helix. However, in some cases ethylene glycol linkers have been used to tether different strands of nucleic acids (Cload and Schepartz, 1991; Amaratunga and Lohman, 1993; Moses and Schepartz, 1996) or even to tether minor groove-binding ligands to the nucleic acid (Robles et al., 1996; Rajur et al., 1997; Robles and McLaughlin, 1997). In most cases, the glycol linker is incorporated as part of the nucleic acid backbone, such that at each terminus the linker is incorporated into a phosphodiester linkage that also incorporates either the 3′ or 5′ hydroxyl of the adjacent nucleoside residue. It is also possible to incorporate more than a single linker at the same site. Thus, two residues of tri(ethylene glycol) could be used instead of hexa(ethylene glycol) (Benseler et al., 1993; Fu et al., 1994)—in the former case a negatively charged phosphodiester would bridge the two linkers. This approach can be used to generate structures with varying linker lengths via the preparation of only a single linker building block. In the most common protocol, the linker is protected at one terminus as the 4,4′-dimethoxytrityl derivative (see Basic Protocol 1), and is converted to a phosphoramidite at the second terminus (see Basic Protocol 2). With such derivatives, the linker is simply incorporated into the DNA or RNA sequence by the same procedures as are used for common nucleoside phosphoramidites (see Basic Protocol 3). Preparation of the pro-
O O O O O O
Figure 5.3.1
O O O O O O
O O O O O
O O O O
O O O
O O
O
Varying lengths for readily available ethylene glycol–based linkers.
Contributed by Timothy O’Dea and Larry W. McLaughlin Current Protocols in Nucleic Acid Chemistry (2000) 5.3.1-5.3.8 Copyright © 2000 by John Wiley & Sons, Inc.
Methods for Cross-Linking Nucleic Acids
5.3.1
tected linker-phosphoramidites follows a common procedure regardless of length; protocols for the hexa(ethylene glycol) linker are presented here. BASIC PROTOCOL 1
PROTECTION OF THE GLYCOL CHAIN WITH A TRITYL GROUP The following protocol outlines the protection of one terminus of an ethylene glycol chain with a trityl group. The first reaction, illustrated in Figure 5.3.2, promotes monoprotection of the ethylene glycol chain with 4,4′-dimethoxytrityl chloride. Although the specific protocol for hexa(ethylene glycol) follows, this protocol has also been successful with glycol chains of various lengths: 1,3-propanediol, tri(ethylene glycol), the tetra- and penta-compounds, and so on. The monoprotected ethylene glycol product can be purified by silica-gel column chromatography. Materials Hexa(ethylene glycol) (HEG) Anhydrous pyridine (preferably freshly distilled) Nitrogen or argon gas 4,4′-Dimethoxytrityl chloride (DMT-Cl) 5% (v/v) methanol in dichloromethane 10% (v/v) aqueous sulfuric acid (H2SO4; Table A.2A.1) Triethylamine (Et3N, TEA) Dichloromethane (CH2Cl2, DCM; preferably freshly distilled) 5% (w/v) aqueous sodium hydrogen carbonate (NaHCO3) Sodium sulfate (Na2SO4) Methanol (CH3OH, MeOH) HO
O
O
O
O
OH
O
OCH3
O
O
O
O
O
OH
O
OCH3 OCH3
O
O
O
O
O
O
O
P OCH2CH2CN N(i-Pr)2
OCH3
O O
O
O
Engineering Specific Cross-Links in Nucleic Acids Using Glycol Linkers
G
G
C
C
C
C
G
G
O
O O
Figure 5.3.2 Reaction pathway for the preparation of a glycol linker and a sample nucleic acid sequence containing the linker.
5.3.2 Current Protocols in Nucleic Acid Chemistry
Non-acid-generating desiccant: e.g., sodium hydroxide or calcium carbonate 100-mL round-bottom flask and rubber stopper Device for maintaining nitrogen or argon atmosphere (e.g., balloon, syringe, and rubber stopper; see step 2) Needle and syringe Separatory funnel Silica gel Column for chromatography Rotary evaporator Thin-layer chromatography (TLC) apparatus (see APPENDIX 3D) CAUTION: Pyridine and its vapors are toxic; exposure to pyridine must be minimal. The reaction should be performed in a fume hood. Monoprotect ethylene glycol 1. Coevaporate 1.25 g (5 eq, 4.43 mmol) HEG twice with ∼10 mL anhydrous pyridine in a 100-mL flask. 2. Under an anhydrous nitrogen or argon atmosphere, add 10 mL anhydrous pyridine and a dry stir bar, and seal the 100 mL-flask with a rubber stopper. The easiest means to create a nitrogen or argon atmosphere is via a balloon sealed to a syringe with a needle. To construct: Remove plunger from syringe, cut off the now opened end, slip a balloon onto this end, and seal well with parafilm. Fill balloon with gas, attach needle, and punch needle through rubber stopper.
3. Begin stirring at ambient temperature. 4. In a separate flask under nitrogen, dissolve 300 mg (1 eq, 0.885 mmol) DMT-Cl in ∼3 mL anhydrous pyridine. 5. Using a syringe, puncture the rubber stopper and gradually add the DMT-Cl solution to the reaction flask. Useful increments are 0.5 mL every 5 min over a 30-min period. The reaction can be monitored by TLC (silica gel, 60 Å, see APPENDIX 3D) using 5% methanol in DCM as eluant. The Rf is 0.45. The product is visible under UV and turns orange when reacted with 10% aqueous H2SO4.
6. After 2 hr, add 2 mL TEA and dilute with ∼25 mL DCM. TEA neutralizes the acid that has been generated, which otherwise will cleave the mono-DMT derivative of the ethylene glycol linker.
7. Extract the organic layer twice with 5% NaHCO3 (∼40 mL) and once with distilled water (∼40 mL) using a separatory funnel. 8. Dry the organic layer over Na2SO4 and remove solvent with a rotary evaporator. The product remains as a clear or slightly colored oil.
Purify mono-DMT–ethylene glycol product 9. Pack a silica-gel column (~15 g, roughly 10× expected solute amount), using 0.5% TEA in DCM as eluant. Again, TEA reduces the acidic nature of the silica gel, thus reducing decomposition of the mono-DMT–ethylene glycol during chromatography.
10. Dissolve the mono-DMT–ethylene glycol product (from step 8) in a minimum quantity of DCM/TEA and pour onto the column. Elute with at least 400 mL of 0.5%
Methods for Cross-Linking Nucleic Acids
5.3.3 Current Protocols in Nucleic Acid Chemistry
TEA in DCM, followed by a step gradient using 400-mL aliquots of 0.5% TEA/DCM containing from 0.5% to 3% MeOH. The product will elute in <3% MeOH.
11. Test fractions by TLC (APPENDIX 3D; Rf = 0.45) using 5% MeOH in DCM as the eluant. 12. Combine fractions containing the correct product and remove solvent by rotary evaporation (high vacuum is needed to remove excess TEA in product). 13. Store in a sealed vial at ambient temperature over a desiccant. The 4,4′-dimethoxytrityl-protected hexa(ethylene glycol) product (DMT-HEG) is stable for several months with minimal decomposition provided it is not stored over a desiccant that liberates acid (e.g., P2O5). BASIC PROTOCOL 2
PHOSPHITYLATION OF THE MONOPROTECTED GLYCOL LINKER The following protocol details the phosphitylation of a 4,4′-dimethoxytrityl-protected glycol linker with 2-(cyanoethyl)-N,N-diisopropylchlorophosphoramidite. For an efficient reaction with high yield, conditions must be kept scrupulously anhydrous. While the following procedure outlines the use of a monoprotected hexa(ethylene glycol) linker, the protocol has been successful with monoprotected glycol compounds of various lengths. The reaction is illustrated in Figure 5.3.2. Materials 4,4′-Dimethoxytrityl-protected hexa(ethylene glycol) (DMT-HEG; see Basic Protocol 1) Anhydrous pyridine (preferably freshly distilled; UNIT 3.2) Non-acid-generating desiccant: e.g., sodium hydroxide or calcium carbonate Nitrogen or argon gas Anhydrous dichloromethane (CH 2Cl2, DCM; preferably freshly distilled) Diisopropylethylamine 2-(Cyanoethyl)-N,N-diisopropylchlorophosphoramidite Ethyl acetate 10% (v/v) triethylamine (Et3N, TEA) in ethyl acetate 5% (w/v) aqueous NaHCO3 Saturated aqueous NaCl Sodium sulfate (Na2SO4) 25-mL round-bottom flask and rubber stopper CAUTION: Pyridine and its vapors are toxic; exposure to pyridine must be minimal. The reaction should be performed in a fume hood. Phosphitylate DMT–ethylene glycol 1. Coevaporate 300 mg (1 eq, 0.51 mmol) of DMT-HEG twice with ∼10 mL anhydrous pyridine. Place under high vacuum over a non-acid-generating desiccant and leave overnight. 2. In a rubber-stoppered 25-mL round-bottom flask with a dry stir bar under an anhydrous nitrogen or argon atmosphere, dissolve the DMT-HEG in 1 mL anhydrous DCM and 0.22 mL (3 eq, 1.54 mmol, 157 mg) anhydrous diisopropylethylamine.
Engineering Specific Cross-Links in Nucleic Acids Using Glycol Linkers
A balloon sealed to a syringe provides an easy means to create a nitrogen or argon atmosphere (see Basic Protocol 1, step 2, for details). TEA may be used here as an alternative to diisopropylamine, if preferred.
5.3.4 Current Protocols in Nucleic Acid Chemistry
3. While stirring, add 0.115 mL (1 eq, 0.51 mmol, 121 mg) 2-(cyanoethyl)-N,N-diisopropylchlorophosphoramidite to the reaction flask using a syringe. The reaction can be monitored via TLC using 9:1 (v/v) ethyl acetate/TEA as the eluant. The Rf of DMT-HEG is 0.50 and that of DMT-HEG-phosphoramidite is 0.80. The product is visible under UV and turns orange when treated with 10% H2SO4.
4. After 25 min, dilute reaction with ∼20 mL ethyl acetate. 5. Extract the organic layer twice with 5% aqueous NaHCO3 and once with saturated aqueous NaCl. 6. Filter organic layer over Na2SO4 and evaporate solvent with rotary evaporator. Purify DMT–ethylene glycol–phosporamidite 7. Pack a silica-gel TLC column with 1% (v/v) TEA in ethyl acetate. 8. Elute the product with increasing percentages of TEA (1% to 5%) in ethyl acetate. 9. Test fractions by TLC (Rf = 0.80) using 10% TEA in ethyl acetate as the eluant. 10. Combine fractions containing the correct product and remove solvent using rotary evaporator (high vacuum is needed to remove the TEA). 11. Store in a sealed vial at −20°C The DMT-HEG-P will remain stable for several weeks.
PREPARATION OF ETHYLENE GLYCOL LINKERS FOR INCORPORATION INTO OLIGONUCLEOTIDES
BASIC PROTOCOL 3
The DMT-protected and phosphitylated glycol linkers can be inserted into DNA sequences using standard automated phosphoramidite synthesis. Since the glycol linker is an oil, several preparative steps facilitate its incorporation using an automated synthesizer. For an overview of oligonucleotide synthesis, see APPENDIX 3C. Materials Dimethoxytrityl-protected hexa(ethylene glycol) phosphoramidite (DMT-HEG-P) (see Basic Protocol 2) Anhydrous dichloromethane (CH2Cl2, DCM; preferably freshly distilled) Anhydrous acetonitrile (preferably freshly distilled) Bottle from DNA synthesizer, tared 1. Dissolve 266 mg DMT-HEG-P (0.34 mmol) in 1.00 mL anhydrous CH2Cl2 under an anhydrous nitrogen or argon atmosphere. A balloon sealed to a syringe provides an easy means to create a nitrogen or argon atmosphere (see Basic Protocol 1, step 2, for details).
2. Using a syringe, transfer 0.100 mL DMT-HEG-P solution to a suitable tared DNA synthesizer bottle. 3. Remove solvent on rotary evaporator and dry under high vacuum overnight. 4. Weigh DNA synthesis bottle to determine exact amount of DMT-HEG-P. 5. Dissolve 24 mg DMT-HEG-P (∼30 µmol) in 250 µL anhydrous acetonitrile. Care must be taken to ensure DMT-HEG-P is dissolved completely.
Methods for Cross-Linking Nucleic Acids
5.3.5 Current Protocols in Nucleic Acid Chemistry
6. Place the bottle on the automated DNA synthesizer and purge as recommended by the manufacturer. 7. The ethylene glycol linker can now be incorporated into oligonucleotides by solidsupport synthesis using standard phosphoramidite protocols. The oligonucleotide can be synthesized with the DMT group on and then purified by HPLC analysis, or with the DMT group off and then purified by gel electrophoresis. If poor coupling occurs, see Critical Parameters for possible solutions.
COMMENTARY Background Information
Engineering Specific Cross-Links in Nucleic Acids Using Glycol Linkers
The cross-linking agents described in this unit are those that are employed during the assembly of the DNA sequences—in this respect they are introduced at very specific sites. Other simple carbon-based linkers can also be employed in a similar manner, but as noted earlier, simple carbon chains may tend to collapse on themselves in an aqueous environment, while the glycol chains are more likely to be hydrated and thus maintain a more extended conformation. Other approaches to cross-linking are also available, most notably the introduction of thiol-based linkers, which upon oxidation form a disulfide cross-link between two sites within a higher-order nucleic acid complex (Ferentz and Verdine, 1991; Wolfe and Verdine, 1993; Goodwin and Glick, 1994; Cain and Glick, 1998; UNITS 5.1 & 5.4). It has been difficult to design effective protocols to confirm the presence of the linker within the nucleic acid sequence. With other types of modified sequences, DNA digests can often be used to confirm the presence of the modification. In the present case, the linkers are not easily identifiable, and such digests only confirm the presence of the nucleoside components. However, when the linker is present in RNA, it is possible to treat a small quantity of the nucleic acid fragment with T2 RNase and an alkaline phosphatase, which results in cleavage of all linkages save that between the linker and the 5′ terminus of the nucleotide (there is no requisite 2′-OH at this linkage). The resulting nucleoside attached to the linker can then be identified after the appropriate standard is prepared (Fu et al., 1994). Careful analysis of the digest by HPLC, with the use of an appropriate standard, can confirm the presence of the linker in the sequence of interest (Fu et al., 1994). However, this procedure can be tedious, and requires the preparation of the necessary standard(s). Recent work in the authors’ lab (D.J. Fu, G. Xiang, and L. McLaughlin, unpub. observ.) has indicated that MALDI-
TOF (UNIT 10.1) analyses of such nucleic acid analogues are much simpler and are effective in providing evidence for the presence of the linker in both DNA and RNA target sequences.
Critical Parameters The synthesis of these linkers should not present significant problems for anyone with even a moderate level of laboratory experience. As can be noted with the protocol, the glycol linkers tend to be quite inexpensive and are used in excess over the DMT-Cl reagent to ensure that only the mono-protected product results. These reactions can be performed with stoichiometries of 1:1, but usually some of the bis-protected DMT-linker results. This unwanted product can be removed during the purification step. For these protocols to succeed, the reactions must be performed under anhydrous conditions. Because of DMT-Cl’s sensitivity to water, great care must be taken to maintain a dry environment for the reaction. All ethylene glycol reagents should be coevaporated with pyridine and kept under vacuum before use. A nitrogen or argon atmosphere for the reaction helps maintain the anhydrous conditions while the reaction is being run. The simplest apparatus is a balloon fixed to a syringe body and filled with dry argon/nitrogen. The reaction flask is sealed with a rubber septum and a needle affixed to the syringe is pushed through the septum. This simple apparatus keeps the reaction mixture under a slight positive pressure with an anhydrous inert gas. High yields require that one be aware of the acid lability of the DMT-protecting group. To limit decomposition as a result of trace quantities of acid, a small amount of the organic base triethylamine (TEA) is added during work-up. It is also critical to have some TEA present (∼0.5%) during the chromatographic purification step employing a silica-gel column. TEA neutralizes the slight acidity of the silicic acid, promoting greater stability of the product when
5.3.6 Current Protocols in Nucleic Acid Chemistry
it is adsorbed on the column support. The ∼0.5% TEA does not significantly alter chromatographic mobility, and its presence results in a greater overall yield of recovered product. For the phosphitylation protocol, taking into consideration the lability of the phosphoramidite is critical for a successful experiment. Once synthesized, effort must be taken to minimize the exposure of the phosphoramidite to air and acidic compounds of any kind. Both the reagent and the isolated product should be stored in parafilm-sealed vials at −20°C. When the phosphoramidite reagent loses its pale-yellow color and becomes a deeper yellowish-orange color, the reagent has typically degraded and should not be used. Preparation of the linker for use with a DNA synthesizer is only complicated by the fact that it is an oil rather than a solid. The authors have found the simplest procedure is one in which some of the oil is transferred to a suitable flask, weighed, and dissolved in sufficient anhydrous solvent. From this solution, an aliquot corresponding to ∼30 µmol of linker (per coupling) is transferred to the DNA synthesis bottle. The solvent is then removed from the bottle under vacuum and the residue is kept under high vacuum overnight. The requisite amount of acetonitrile can then be added to the bottle before the latter is attached to the DNA synthesis machine—ensure that the residue in the bottle completely dissolves first. To obtain efficient coupling of the linker to a DNA strand, the synthesizer programming need not to be altered. However, if efficient coupling is not achieved, several parameters can be changed to attain better coupling. First, extended “wait” periods can be added to the cycle—these are typically the time periods during which the coupling reaction takes place. A second option is to perform two coupling steps in sequence without any intervening capping or oxidation steps.
Anticipated Results Yields for the protection of the glycol linker with DMT should be >70%. When isolated by column chromatography the DMT-ethylene glycol product is a pale-orange oil with Rf = 0.45 (5% MeOH in DCM). The yields expected for the phosphitylation protocol should be >70% when isolated from the column as a clear oil (Rf = 0.8, 1:9 TEA/ethyl acetate). Successful phosphitylation can be achieved without the column chromatography step. In this case, simply perform the aqueous work-up, dry the solution, and evaporate to an oil. 31P NMR will
confirm the ratio of the phosphitylated product to any phosphorus contaminants. So long as the latter are minimal in quantity, effective incorporation of the linker can be obtained with material prepared in this manner.
Time Considerations Monoprotection of ethylene glycol and its isolation can be accomplished in <5 hr. The phosphitylation protocol can be done in <2 hr when the DMT-ethylene glycol product is prepared ahead of time (see Basic Protocol 1). Incorporation of the ethylene glycol linker into the oligonucleotide will not require more than a half-hour beyond the normal coupling time required of a standard phosphoramidite.
LITERATURE CITED Altmann, S., Labhardt, A.M., Bur, D., Lehmann, C., Bannwarth, W., Billeter, M., Wuthrich, K., and Leupin, W. 1995. NMR studies of DNA duplexes singly cross-linked by different synthetic linkers. Nucl. Acids Res. 23:4827-4835. Amaratunga, M. and Lohman, T.M. 1993. Escherichia coli Rep helicase unwinds DNA by an active mechanism. Biochemistry 32:6815-6820. Benseler, F., Fu, D.J., Ludwig, J., and McLaughlin, L.W. 1993. Hammerhead-like molecules containing non-nucleoside linkers are active RNA catalysts. J. Am. Chem. Soc. 115:8483-8484. Cain, R.J. and Glick, G.D. 1998. Use of cross-links to study the conformational dynamics of triplex DNA. Biochemistry 37:1456-1464. Cload, S.T. and Schepartz, A. 1991. Polyether tethered oligonucleotide probes. J. Am. Chem. Soc. 113:6324-6326. Durand, M., Chevrie, K., Chassignol, M., and Thuong, N.T. 1990. Circular dichroism studies of an oligodeoxyribonucleotide containing a hairpin loop made of a hexaethylene glycol chain—conformation and stability. Nucl. Acids Res. 18:6353-6359. Ferentz, A.E. and Verdine, G.L. 1991. Disulfide cross-linked oligonucleotides. J. Am. Chem. Soc. 113:4000-4002. Fu, D.J., Benseler, F., and McLaughlin, L.W. 1994. Hammerhead ribozymes containing non-nucleoside linkers are active RNA catalysts. J. Am. Chem. Soc. 116:4591-4598. Goodwin, J.T. and Glick, G.D. 1994. Synthesis of a disulfide stabilized RNA hairpin. Tetrahedron Lett. 35:1647-1650. Hendry, P., Moghaddam, M.J., McCall, M.J., Jennings, P.A., Ebel, S., and Brown, T. 1994. Using linkers to investigate the spatial separation of the conserved nucleotides A9 and G12 in the hammerhead ribozyme. Biochim. Biophys. Acta 1219:405-412. Komatsu, Y., Kanzaki, I., and Ohtsuka, E. 1996. Enhanced folding of hairpin ribozymes with replaced domains. Biochemistry 35:9815-9820.
Methods for Cross-Linking Nucleic Acids
5.3.7 Current Protocols in Nucleic Acid Chemistry
Ma, M.Y.X., McCallum, K., Climie, S.C., Kuperman, R., Lin, W.C., Sumner-Smith, M., and Barnett, R.W. 1993. Design and synthesis of RNA miniduplexes via a synthetic linker approach. 2. Generation of covalently closed, double-stranded cyclic HIV-1 TAR RNA analogs with high Tat-binding affinity. Nucl. Acids Res. 21:2585-9. Moses, A.C., and Schepartz, A. 1996. Triplex tethered oligonucleotide probes. J. Am. Chem. Soc. 118:10896-10897. Rajur, S.B., Robles, J., Wiederholt, K., Kuimelis, R.W., and McLaughlin, L.W. 1997. Hoechst 33258 tethered by a hexa(ethylene glycol) linker to the 5′-termini of oligodeoxynucleotide 15mers: Duplex stabilization and fluorescence properties. J. Org. Chem. 62:523-529. Robles, J. and McLaughlin, L.W. 1997. DNA triplex stabilization using a tethered minor-groove binding Hoechst 33258 analogue. J. Am. Chem. Soc. 119:6014-6021.
Robles, J., Rajur, S.B., and McLaughlin, L.W. 1996. A parallel-stranded DNA triplex tethering a Hoechst 33258 analogue results in complex stabilization by simultaneous major groove and minor groove binding. J. Am. Chem. Soc. 118:58205821. Thomson, J.B., Tuschl, T., and Eckstein, F. 1993. Activity of hammerhead ribozymes containing non-nucleotidic linkers. Nucl. Acids Res. 21:5600-5603. Williams, D.J. and Hall, K.B. 1996. Thermodynamic comparison of the salt dependence of natural RNA hairpins and RNA hairpins with non-nucleotide spacers. Biochemistry 35:14665-14670. Wolfe, S.A. and Verdine, G.L. 1993. Ratcheting torsional stress in duplex DNA. J. Am. Chem. Soc. 115:12585-12586.
Contributed by Timothy O’Dea and Larry W. McLaughlin Boston College Chestnut Hill, Massachusetts
Engineering Specific Cross-Links in Nucleic Acids Using Glycol Linkers
5.3.8 Current Protocols in Nucleic Acid Chemistry
Engineering Disulfide Cross-Links in RNA Via Air Oxidation
UNIT 5.4
This unit describes methods for the synthesis of thiol-modified ribonucleosides, their incorporation into synthetic RNA, and the formation of intramolecular disulfide bonds in RNA by air oxidation. The disulfide bonds can be formed in quantitative yields between thiols positioned in close proximity in either RNA secondary or tertiary structure. Disulfide cross-links are useful tools to probe solution structures of RNA, monitor dynamic motions, and stabilize folded RNAs. Several steps are involved in the successful formation of a disulfide-cross-linked RNA. First, a location for incorporation of the disulfide bond is selected (Glick, 1998). For best results, this should be based on the highest-resolution structural data available for the particular RNA. In most cases, it is desirable to avoid interfering with interactions that stabilize structure, such as hydrogen bonding. Once the site for the disulfide bond has been chosen, the necessary thiol-modified nucleosides must be chemically synthesized. In most cases, the authors use alkylthiol linkers on the 2′ hydroxyl and the N3 position of pyrimidine residues, although linkers can be positioned at nearly any position of a nucleoside. The thiol-modified nucleoside phosphoramidites are synthesized with the thiol functionality protected as a tert-butyl disulfide, a protecting group that is stable under all conditions of solid-phase synthesis and subsequent manipulations. Incorporation of the thiol-modified nucleosides is accomplished by solid-phase chemical synthesis of the RNA. Following removal of both the exocyclic amine-protecting groups and the tert-butyldimethyl silyl groups used to protect the 2′ hydroxyls, the full-length oligoribonucleotide is purified by denaturing polyacrylamide gel electrophoresis (PAGE). Reduction of the mixed disulfide with dithiothreitol (DTT) liberates the free thiols. These are then oxidized by vigorous stirring in air to form an intramolecular disulfide bond in quantitative yield. The Basic Protocol describes the procedures for formation of intramolecular disulfide bonds by air oxidation of thiol-mediated RNA. Optimized protocols for solid-phase synthesis and deprotection of tRNAs (tRNA is used here as a model RNA) containing thiol-modified residues are presented in Support Protocol 1. Support Protocol 2 describes a method for purification of tRNAs containing thiol-modified residues. Support Protocol 3 describes a fluorescence assay to quantify the concentration of free thiol remaining during cross-link formation. Support Protocols 4, 7, and 8 describe the synthesis of three different thiol-containing nucleoside phosphoramidites, while Support Protocol 6 describes the synthesis of an intermediate compound needed for Support Protocols 7 and 8. Support Protocol 5 details the preparation of a thiol-modified controlled-pore glass (CPG) support used in the solid-phase synthesis of the modified RNA. NOTE: All procedures should be conducted using sterile techniques. When handling the RNA, suitable precautions should be taken to avoid RNase contamination. Gloves must be worn during handling of all equipment. Treatment of solutions with DEPC to inactivate RNases is not necessary, but could be done if preferred. CAUTION: Acrylamide is a neurotoxin, minimize inhalation and skin exposure. The reagents and solvents used in both solid-phase RNA synthesis and the synthesis of the thiol-modified phosphoramidites should be handled according to the manufacturer’s safety data sheet for each reagent.
Methods for Cross-Linking Nucleic Acids
Contributed by Emily J. Maglott and Gary D. Glick
5.4.1
Current Protocols in Nucleic Acid Chemistry (2000) 5.4.1-5.4.34 Copyright © 2000 by John Wiley & Sons, Inc.
BASIC PROTOCOL
FORMATION OF INTRAMOLECULAR DISULFIDE CROSS-LINKS IN RNA The RNA used in this protocol has been synthesized with the thiol groups protected as tert-butyl disulfides. Liberation of the free thiols is achieved by reduction of the mixed disulfides with DTT or other reducing agents, such as glutathione. Following removal of the DTT by continuous flow dialysis, the intramolecular disulfide bond is formed in the dilute RNA solution by air oxidation in a mildly basic solution (e.g., pH 8.0). Materials tert-Butyl-disulfide-modified RNA (see Support Protocol 1) 100 mM sodium phosphate buffer, pH 8.3 (see recipe) Dithiothreitol (DTT) Sodium phosphate buffer/NaCl, pH 7.0 (see recipe) 5000-molecular-weight-cutoff (MWCO) cellulose ester membrane 200 mM MgCl2 (see recipe) 0.1 N NaOH TE buffer (APPENDIX 2A) 1.5 M sodium acetate (NaOAc), pH 5.5 Absolute ethanol 10-well (500 µL) microdialyzer (e.g., Spectrum) 0.2-µm bottle-top filter Argon (Ar) tank Peristaltic pump 70°C water bath pH meter with microelectrode Additional reagents and equipment for denaturing polyacrylamide gel electrophoresis (e.g., CPMB UNIT 7.6 and APPENDIX 3B of this manual) or for derivatization and fluorescence spectroscopy for quantitation of thiols (see Support Protocol 3) Remove tert-butyl disulfide protecting groups to liberate free thiols 1. In a 0.5-mL microcentrifuge tube, dissolve the tert-butyl-disulfide-modified RNA (0.5 OD260 U) to a concentration of 50 µM in 16 µL of 100 mM sodium phosphate buffer, pH 8.3. 2. Add 0.054 mg DTT (200 eq per disulfide), close the tube, and incubate the mixture at 25°C for 12 hr. The authors have found that between 12 and 14 hr of incubation effects complete reduction of the tert-butyl disulfide protecting groups. This can be conveniently conducted overnight.
3. Open the tube and dilute the reaction mixture with 100 µL sodium phosphate buffer/NaCl, pH 7.0. 4. Assemble a 10-well continuous-flow microdialyzer with a 5000-MWCO cellulose ester membrane following the manufacturer’s instructions. Other types of dialysis assemblies should work as well.
Engineering Disulfide Cross-Links in RNA via Air Oxidation
5. Filter 3 L sodium phosphate buffer/NaCl through a 0.2-µm bottle-top filter and sparge the filtered buffer with Ar for ≥30 min before use. 6. Fill the dialysis chamber with sodium phosphate buffer/NaCl, removing all air bubbles from under the wells by forcing them out one of the flow ports as the chamber fills.
5.4.2 Current Protocols in Nucleic Acid Chemistry
7. Transfer the reduced RNA to a well of the microdialyzer and rinse the reaction tube with phosphate buffer/NaCl, adding the rinsings to the dialyzer well. Dialyze the RNA against the same buffer at a flow rate of 5.0 mL/min for 10 hr at room temperature. Control experiments show that this method completely removes the DTT.
8. Transfer the dialyzed RNA sample from the dialyzer well to a 1.5-mL microcentrifuge tube. Rinse the well of the dialyzer with 100 to 200 µL of sodium phosphate buffer/NaCl and add to the RNA sample. Form intramolecular disulfide bonds via air oxidation 9. Dilute the reduced, dialyzed tRNA sample to a final RNA concentration of 1 to 4 µM with sodium phosphate buffer/NaCl to prevent intermolecular disulfide bonds from forming. 10. Add 200 mM MgCl2 stock solution to 5 mM final concentration. Fold the RNA by heating the RNA sample to 70°C for 2 min in a water bath and then allowing the sample to cool to room temperature (15 to 30 min). This procedure has been optimized for yeast tRNAPhe samples; details of the folding protocol (i.e., time and temperature for refolding, with Mg2+ concentration) will be different for other RNAs.
11. Calibrate a microelectrode at pH 7.0. Immerse the electrode in the RNA sample. Adjust the pH of the sample to 8.0 with 0.1 N NaOH (typically 3 to 5 µL for a 400-µL sample). 12. Stir the RNA solution at room temperature exposed to air, loosely covering the tubes with a paper towel to minimize dust contamination. 13. Monitor disulfide bond formation by removing 5-µL aliquots of the reaction mixture and assessing them either by denaturing PAGE (e.g., CPMB UNIT 7.6) or by fluorescence spectroscopy after derivatization with 7-diethylamino-3-(4′-maleimidylphenyl)-4methylcoumarin (see Support Protocol 3). Disulfide bond formation is usually complete in ≤12 hr. Progress of cross-linking can be monitored throughout; however frequent monitoring is time-consuming and will decrease final yields. Cross-linked RNAs have slower gel mobility than the non-cross-linked RNAs (Sigurdsson and Eckstein, 1996). The fluorescence assay using 7-diethylamino-3-(4′-maleimidylphenyl)-4-methylcoumarin (Parvari et al., 1983) is more sensitive than with Ellman’s reagent.
14. Conduct native gel electrophoresis (e.g., CPMB UNIT 2.7) to verify formation of intramolecular cross-links. 15. Dialyze the cross-linked RNA against 1 L TE buffer using continuous-flow microdialysis as described in steps 4 to 8. Do not precipitate directly from the phosphate buffer, as recovered yields will be poor. Disulfide cross-link formation is usually quantitative, as judged by ethidium bromide staining of a sample analyzed by PAGE, and purification to remove non-cross-linked RNA is not necessary.
Methods for Cross-Linking Nucleic Acids
5.4.3 Current Protocols in Nucleic Acid Chemistry
Purify RNA from eluate 16. Add 1⁄5 vol of 1.5 M NaOAc, pH 5.5, and 3 vol absolute ethanol. Mix thoroughly and place at –20°C overnight. 17. Centrifuge 1 hr at 16,000 × g, 4°C. 18. Decant the solution and dry the pellet of RNA under vacuum. 19. Combine the RNA into one tube by dissolving the pellets in water and transferring to one tube. Rinse the tubes at least 3 times with water to ensure transfer of all RNA. Evaporate the RNA solutions dryness under vacuum and store at –20°C until use. 20. Store the precipitated RNA at −20°C (stable at least 1 year). SUPPORT PROTOCOL 1
SYNTHESIS OF RNA CONTAINING tert-BUTYLDISULFIDE-MODIFIED NUCLEOSIDES BY SOLID-PHASE METHODS Incorporation of modified nucleosides into an RNA can be accomplished with the necessary phosphoramidites and solid-phase synthesis technology. The following procedure has been optimized to use standard, commercially available ribonucleoside phosphoramidites and reagents combined with thiol-modified nucleoside phosphoramidites to allow total chemical synthesis of RNAs at least 76 nucleotides long. Careful handling to minimize exposure of the phosphoramidites and reagents to moisture throughout the procedure enables milligram quantities of 76-mer RNAs containing modified nucleosides to be obtained from a single 1-µmol-scale synthesis. Materials Methylene chloride (CH2Cl2) in CaH2 Acetonitrile (CH3CN) in CaH2 Thiol-modified nucleoside phosphoramidites (see Support Protocols 4, 7, and 8) Nucleoside phosphoramidites Argon (Ar) Anhydrous ethanol Absolute ethanol, room temperature and –20°C Brine (saturated aqueous NaCl) Nitrogen (N2) stream Ammonia gas (NH3) 1.0 M tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF) 1.5 M sodium acetate (NaOAc), pH 5.5 (see recipe) Ethyl acetate (EtOAc)
Engineering Disulfide Cross-Links in RNA via Air Oxidation
Rotoevaporator Automated nucleic acid synthesizer Trap-Pak molecular sieve bags (Perseptive Biosystems) Rubber septa Cannula CPG column loaded with appropriate nucleoside (purchased, or see Support Protocol 5) Desiccator 1- and 2-dram glass vials (oven dried >8 hr at 180°C) Teflon tape Dry bath, 55°C Speedvac evaporator or equivalent Spatula, RNase-free
5.4.4 Current Protocols in Nucleic Acid Chemistry
5-in. (12.5-cm) glass pipets Rotary shaker Prepare thiol-modified phosphoramidites for automated synthesis 1. At least 24 hr before beginning the RNA synthesis, distill 1 L CH2Cl2 and 100 mL CH3CN from CaH2. 2. Dry the necessary thiol-modified phosphoramidites by coevaporation with distilled CH3CN (~1 mL/50 mg) three times, then under high vacuum overnight. The quantity of phosphoramidite depends on both the RNA sequence (if the same or different nucleosides are used) and the number of sequences being synthesized at one time. One coupling typically takes 5 mg dissolved in 5 mL on a Perkin-Elmer Expedite 8909 synthesizer.
3. Prepare the automated nucleic acid synthesizer for RNA synthesis following the manufacturer’s suggested protocols. Replacing all reagent solutions on the synthesizer with newly opened bottles of reagents immediately prior to use significantly improves both the quality and the yield of the synthesis. Although commercial preparations of 3% TCA can be used, it is recommended that solutions of 3% TCA be made with freshly distilled CH2Cl2 immediately prior to synthesis. The use of Trap-Pak molecular sieve bags to remove residual water in the solvent in CH3CN solutions (one Trap-Pak per liter) is also recommended. The protocols described here have been conducted with both AN-Bz, CN-Bz, GN-iBu, and U 5′-O-dimethoxytrityl, 2′-O-tert-butyldimethylsilyl, 3′-O-diisopropyl-β-cyanoethyl phosphoramidites as well as AN-Pac and GN-Pac 5′-O-dimethoxytrityl, 2′-O-tert-butyldimethylsilyl, and 3′-O-diisopropyl-β-cyanoethyl phosphoramidites. Other exocyclic amine-protecting groups should also be suitable for these protocols.
4. Backfill the flask(s) containing the thiol-modified phosphoramidite(s) with Ar and quickly seal with a rubber septum. 5. Working under Ar, dilute the thiol-modified phosphoramidite(s) with distilled CH3CN to 50 mg/mL. Using a cannula, place the solution into an oven-dried bottle of appropriate size for the synthesizer and place on the synthesizer. This amidite concentration is recommended for an Expedite 8909 synthesizer (Perseptive Biosystems). Other synthesizers will also work; amidites should be diluted according to the manufacturer’s protocols.
6. Prime the delivery lines with all ancillary reagents twice, and then prime the delivery lines with the amidite solutions twice, to ensure that the flow lines from each bottle of reagent and from the amidite bottle are filled. 7. Place a CPG column loaded with the appropriate nucleoside onto the synthesizer. See Glick (1991) for details on the loading of thiol-modified supports.
8. Begin the RNA synthesis following the manufacturer’s protocols. Addition of CH2Cl2 wash steps both before and after TCA treatment improves coupling efficiencies (see Goodwin et al., 1996). RNA synthesis is very sensitive to water. Eliminate water from all reagents and handling procedures as much as possible. The use of freshly distilled CH3CN and CH2Cl2 and newly opened dry reagents improves coupling efficiencies and allows the synthesis of RNAs exceeding 75 residues. It is also recommended that phosphoramidites be handled under an Ar atmosphere in a glove bag, especially in humid conditions. While solutions of A, C, and U phosphoramidites are stable for at least 5 days, the coupling efficiency of G phosphoramidites is increased with fresh dilution on a daily basis. A typical RNA coupling cycle
Methods for Cross-Linking Nucleic Acids
5.4.5 Current Protocols in Nucleic Acid Chemistry
takes 15 min (Gait et al., 1991; Goodwin et al., 1994). The synthesis of one 76-mer tRNA sequence takes ∼19.5 hr.
Deprotect synthetic RNA 9. Cool a 2-dram oven-dried vial under N2. 10. Add 2 to 3 mL anhydrous ethanol to the vial and cool in a brine/ice water bath under N2 for 2 to 5 min. 11. Remove the N2 line and insert a needle attached to a lecture bottle of NH3 and a vent. Saturate the ethanol by constant bubbling with NH 3 for at least 30 min. This procedure should be conducted in a fume hood.
12. Open the synthesis column and pour the solid support into a 1-dram oven-dried vial. 13. Quickly pour ∼1 mL of the anhydrous ethanolic ammonia solution into the vial. Seal threads of the vial with Teflon tape and cap tightly. Seal the outside of the cap with Teflon tape and parafilm to prevent evaporation. The inner Teflon tape can be put on the vial before pouring the solution, but be careful not to pour the ethanolic ammonia onto the tape or the seal will not be adequate. Usually bubbling occurs as the solution is poured onto the resin.
14. Place the sealed vial in a 55°C dry bath for 18 hr. 15. Remove the vial from the dry bath and allow to cool to room temperature before opening. Carefully open the vial and pass a gentle stream of N2 over the solution for 5 to 15 min to remove the ammonia. When the cap is removed, there should be a small release of pressure; this indicates that the ethanolic ammonia solution was thoroughly saturated during deprotection. A significant portion of the ethanol may evaporate during this procedure. If the solution becomes viscous (typically, with less than ∼300 mL ethanol remaining), add 500 mL of anhydrous ethanol to the vial before proceeding to step 16.
16. Transfer the ethanol solution from the vial to an autoclaved 1.5-mL microcentrifuge tube and evaporate under vacuum to ≤400 µL total volume. Transfer any remaining solution to the microcentrifuge tube and then rinse the solid support with 500 µL anhydrous ethanol. Add the rinsing to the microcentrifuge tube and evaporate the solution under vacuum to ≤400 µL. 17. Thoroughly rinse the solid support with anhydrous ethanol five more times using 100 to 200 µL ethanol each time, adding the rinsings to the microcentrifuge tube. Evaporate the solution to dryness under vacuum. Coevaporate with 500 µL anhydrous ethanol. Repeat the coevaporation once more using 200 µL ethanol. The residue resulting from step 17 may be stored for a few days at −20°C before proceeding with the remainder of this protocol.
Desilylate synthetic RNA 18. Cool a 1-dram oven-dried vial in a desiccator.
Engineering Disulfide Cross-Links in RNA via Air Oxidation
19. Gently loosen the residue obtained after step 17 from the microcentrifuge tube with the tip of an RNase-free spatula. Carefully transfer the residue to the dried vial. 20. Add ∼400 µL of 1.0 M TBAF in THF to the microcentrifuge tube with a glass pipet. Vortex, centrifuge, and transfer the solution to the vial with a glass pipet. Repeat this rinsing procedure twice more using ∼300 µL TBAF each time.
5.4.6 Current Protocols in Nucleic Acid Chemistry
TBAF solutions should be of the highest purity and lowest water content possible. For optimal results, bottles of TBAF should only be used once. TBAF is light sensitive.
21. Seal the vial with Teflon tape, parafilm, and cover in foil. Place the vial on a rotary shaker and shake at low speed for 24 hr. 22. Open the vial and quench the reaction with 1 mL of 1.5 M NaOAc, pH 5.5. Transfer the solution in two approximately equal aliquots into two 1.5-mL microcentrifuge tubes. Rinse the vial 5 times with 150 µL water and add the rinsings to the tubes. 23. Evaporate the solutions to ∼600 µL total volume in each tube. Add 600 to 700 µL EtOAc to each tube and homogenize as thoroughly as possible. Centrifuge to separate the layers. Remove the upper layer (EtOAc) with a pipet and repeat the extraction a second time. Evaporate the solution under vacuum for ∼10 min to remove residual EtOAc. 24. Transfer about half of the solution in each tube to another 1.5-mL microcentrifuge tube, resulting in four tubes containing ∼300 µL solution each. 25. Add 1 mL absolute ethanol to each tube, mix thoroughly, and place at −20°C overnight. 26. Centrifuge all tubes for at least 1 hr at 16,000 × g, 4°C. Decant the supernatant from the pellet and then wash the pellet with 200 µL of –20°C absolute ethanol. Dry the pellet under vacuum. 27. Quantify the crude RNA by dissolving the pellets in water and measuring the absorbance of a 1-µL aliquot of the solution at 260 nm. Estimate the molar extinction coefficient (ε260) using nearest-neighbor calculations. The ε260 calculation is done as described by Breslauer et al. (1986); see UNIT 7.3. This assumes that the modified residues behave like their unmodified counterparts. Both crude and purified RNA samples should be stored either pelleted from ethanol precipitation or dried down from aqueous solutions at −20°C.
28. Purify the crude RNA to single-nucleotide resolution (see Support Protocol 2). PURIFICATION OF SYNTHETIC RNA CONTAINING tert-BUTYLDISULFIDE PROTECTED THIOL-MODIFIED NUCLEOSIDES
SUPPORT PROTOCOL 2
Single-nucleotide resolution of the products resulting from solid-phase synthesis, the fulllength oligomer as well as failed sequences, can be achieved using denaturing PAGE (also see APPENDIX 3B). The procedures that are outlined have been optimized for the purification of a 76-mer tRNA sequence. These protocols can be modified for sequences of other lengths by adjusting the percentage of acrylamide in the gel matrix until both the full-length RNA and the sequence resulting from incomplete synthesis one residue from the end are resolved. Materials Crude synthetic tRNA (see Support Protocol 1) 80% formamide containing 0.05% xylene cyanol (XC) tracking dye 8% denaturing polyacrylamide solution (see recipe) 1× TBE electrophoresis buffer ( APPENDIX 2A) 1× and 4× TAE electrophoresis buffer (APPENDIX 2A) 1.5 M sodium acetate (NaOAc), pH 5.5 Absolute ethanol Power supply Silica-gel plate
Methods for Cross-Linking Nucleic Acids
5.4.7 Current Protocols in Nucleic Acid Chemistry
UVG-11 Mineralight lamp (254 nm, 115 V) or equivalent Razor blade, RNase free Hoefer Six-Pac electroeluter or equivalent Inner elution tubes Porous polyethylene plugs Blotter-paper discs Additional reagents and equipment for denaturing polyacrylamide gel electrophoresis (e.g., see CPMB UNIT 7.6 and APPENDIX 3B of this manual) Separate RNA species by PAGE 1. Dissolve 20 to 40 OD260 U of crude synthetic tRNA in 60 µL water, mix thoroughly, and allow to stand for ∼1 hr to thoroughly dissolve the RNA. There will probably also be insoluble material present.
2. Add 60 µL of 80% formamide/0.05% XC and centrifuge briefly to separate the insoluble matter. 3. Prepare an 8% denaturing polyacrylamide gel 31.0 cm × 38.5 cm × 0.8 mm, with 14.6-mm-wide wells (e.g., see CPMB UNIT 7.6 and APPENDIX 3B). Electrophoresis conditions are outlined for the purification of a 76-nt tRNA sequence. For sequences of different lengths, adjust the percentage acrylamide and electrophoresis time accordingly.
4. Load 20 µL of the RNA sample into each of six wells, being careful not to load any insoluble material onto the gel. 5. Electrophorese the gel in 1× TBE at 55 W until the XC tracking dye has migrated ∼11 inches (∼4 to 4.5 hr). Under these conditions 76-mer RNA migrates with the XC—be careful not to run the RNA off the gel.
Electroelute full-length synthetic RNA from gel slice 6. Place the gel over a silica-gel plate in a dark location. Briefly shine 254-nm light on the gel to locate the RNA. With a clean RNase-free razor blade, excise the full-length RNA from the gel. RNA is photoreactive; minimize exposure of RNA to UV light.
7. Pack the RNA slices into three or four inner elution tubes containing 300 µL of 1× TAE using blotter-paper discs and porous polyethylene plugs according to manufacturer’s directions. Cut off the bottom tip of the inner elution tube and insert into a 1.5-mL microcentrifuge tube containing 200 µL of 4× TAE. Electroelute in a Hoefer Six-Pac eluter for 90 min at +50 V. For efficient electroelution, remove all air bubbles from the inner elution tubes. Also, the elutions work better if the inner elution tubes are packed tightly with gel slices, but it is important not to crush the slices. If the amperage does not decrease below 0.2 mA during the course of electroelution, the gel slices can be recovered from the inner elution tube and soaked in 400 mL of 4× TAE at room temperature overnight. The eluted RNA should then be ethanol precipitated as described in the next step and combined with the RNA eluted during electroelution. Engineering Disulfide Cross-Links in RNA via Air Oxidation
8. Remove the inner elution tube carefully, rinse the electrode with 20 µL water, and add to the eluted RNA. Remove the electrode and pipet all buffer remaining above the porous plug into the eluted RNA. The total volume should be ∼350 mL.
5.4.8 Current Protocols in Nucleic Acid Chemistry
Purify RNA from eluate 9. Add 70 µL of 1.5 M NaOAc, pH 5.5, and 1 mL absolute ethanol. Mix thoroughly and place at −20°C overnight. 10. Centrifuge 1 hr at 16,000 × g, 4°C. 11. Decant the solution and dry the pellet of RNA under vacuum. 12. Combine the RNA into one tube by dissolving the pellets in water and transferring to one tube. Rinse the tubes at least 3 times with water to ensure transfer of all RNA. Evaporate the RNA solutions dryness under vacuum and store at −20°C until use (stable at least 1 year). QUANTIFICATION OF THIOLS IN RNA USING 7-DIETHYLAMINO-3-(4′-MALEIMIDYLPHENYL)-4-METHYLCOUMARIN
SUPPORT PROTOCOL 3
Reaction of free thiols with 7-diethylamino-3-(4′-maleimidylphenyl)-4-methylcoumarin produces a fluorescent adduct that can be quantified spectroscopically (Parvari et al., 1983). This provides a convenient method to determine when the cross-linking reaction is complete. The method can be used to accurately determine thiol concentrations as low as 0.5 µM. Materials RNA solution containing free thiols (see Basic Protocol) 5× CPM buffer (see recipe) 0.4 mM CPM in isopropyl alcohol (see recipe) 1% Triton X-100 Sodium phosphate buffer/NaCl, pH 7.0 (see recipe) Fluorimeter and cuvette 1. To a 5-µL aliquot of an RNA solution containing free thiols, add 1 µL of 5× CPM buffer and 5 µL of 0.4 mM CPM in isopropyl alcohol. Incubate the sample 10 min at room temperature. 2. Dilute the reaction with 489 µL of 1% Triton X-100. 3. Prepare a blank consisting of: 5 µL sodium phosphate buffer/NaCl, pH 7.0 1 µL 5× CPM buffer 5 µL 0.4 mM CPM in isopropyl alcohol 489 µL Triton X-100. 4. Transfer blank solution to a fluorimeter cuvette and measure the fluorescence intensity at 480 nm (λex = 390 nm). 5. In the same way, measure the fluorescence intensity of the RNA solution from step 2, and correcting for background fluorescence. A calibration curve can be constructed using DTT as a standard (0.5 to 5 mM is a useful range).
Methods for Cross-Linking Nucleic Acids
5.4.9 Current Protocols in Nucleic Acid Chemistry
SUPPORT PROTOCOL 4
SYNTHESIS OF 5′-O-(4,4′-DIMETHOXYTRITYL)-2′-O-(tertBUTYLDIMETHYLSILYL)-N3-(ETHYL)URIDINE-3′-O-(N,N-DIISOPROPYLβ-CYANOETHYLPHOSPHORAMIDITE) tert-BUTYL DISULFIDE (S.5) The preparation of a thiol-containing nucleoside phosphoramidite modified at the N3 position of uridine is described. The synthesis of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tertbutyldimethylsilyl)-N3-(ethyl)uridine-3′-O-(N,N-diisopropyl-β-cyanoethylphosphoram idite) tert-butyl disulfide (S.5) proceeds in four sets of steps from uridine (Fig. 5.4.1). The 3′-O-tert-butyldimethylsilyl-protected isomer (S.4) obtained as a side product of the third set of steps is used to make a thiol-modified controlled-pore glass (CPG) support (Fig. 5.4.2; see Support Protocol 5). Materials Uridine Distilled acetonitrile (CH3CN) Distilled triethylamine (Et3N) N,N-Dimethylformamide (DMF) Chlorotrimethylsilane (TMSCl) N2 Petroleum ether Diethyl ether (Et2O) Sodium hydride (NaH) 1-Tosyl-2-benzoylmercaptoethanol (see Glick et al., 1991) 48% (w/v) aqueous HF Methylene chloride (CH2Cl2) Brine (saturated aqueous NaCl) Sodium sulfate (Na2SO4) O
O NH N
HO
a-d
O
N
HO
O HO
O SBz
N O
N
DMTrO
O HO
OH
SSt-Bu
N
e-f
OH
O
O HO
OH
1
2 O
O N
DMTrO
O
O
O Ot-BuDMS
HO
g
h
O
N
DMTrO
SSt-Bu
N
SSt-Bu
N
NC
3
t-BuDMSO
Ot-BuDMS N(i-Pr)2
SSt-Bu
N N
O P
5
O
DMTrO
O
O
O OH 4
Engineering Disulfide Cross-Links in RNA via Air Oxidation
Figure 5.4.1 Synthesis of 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N3-(ethyl)uridine-3′-O-(N,N-diisopropyl-β-cyanoethylphosphoramidite) tert-butyl disulfide. (a) TMSCl, Et3N, DMF; (b) NaH, DMF; (c) p-TsOCH2CH2SBz, DMF; (d) HF (aq); (e) DMTrCl, pyridine; (f) 1-(tert-butylthio)1,2-hydrazinedicarboxmorpholide, LiOH, CH3OH; (g) TBDMSCl, imidazole, DMF; (h) chloro-N,Ndiisopropylamine-β-cyanoethyl phosphine, 2,4,6-collidine, N-methylimidazole, THF. Abbreviations: Bz, benzoyl; DMF, dimethylformamide; DMTr, 4,4′-dimethoxytrityl; TBDMS, tert-butyldimethylsilyl; THF, tetrahydrofuran; Ts, tosyl.
5.4.10 Current Protocols in Nucleic Acid Chemistry
O
O SSt-Bu
N DMTrO
t-BuDMSO
N
O
a,b
O
O SSt-Bu
N DMTrO
OH
N
O
O
t-BuDMSO
O
O
SSt-Bu
N c DMTrO
N
O
O
t-BuDMSO
O
O
4 O
OC6Cl5 6
O
NH
CPG
7
Figure 5.4.2 Synthesis of 5′-O-(4,4′-dimethoxytrityl)-3′-O-(tert-butyldimethylsilyl)-2′-O-succinylCPG N3-(ethyl)uridine tert-butyl disulfide. (a) succinic anhydride, DMAP, pyridine; (b) pentachlorophenol, DCC, DMAP, CH2Cl2; (c) CPG (1000 Å), Et3N, DMF. Abbreviations: DCC, dicyclohexyl-carbodiimide; DMAP, 4-dimethylaminopyridine; DMF, dimethylformamide; DMSO, dimethyl sulfoxide.
Methanol (CH3OH) Pyridine 4,4′-Dimethoxytrityl chloride (DMTrCl) 1-(tert-Butylthio)-1,2-hydrazine carboxmorpholide (see Wünsch et al., 1982) LiOH⋅H2O Ethyl acetate (EtOAc) Imidazole tert-Butyldimethylsilyl chloride (TBDMSCl) Tetrahydrofuran (THF) 2,4,6-Collidine N-Methylimidazole Chloro-N,N-diisopropylamine-β-cyanoethyl phosphine Additional reagents and equipment for flash chromatography ( APPENDIX 3E) Prepare N3-(2-thiobenzoylethyl)uridine (S.1) 1. Dry 24.42 g uridine (100 mmol) by coevaporation with distilled CH3CN. 2. Dissolve the dried uridine in 83.6 mL freshly distilled Et3N (600 mmol, 6 eq) and 250 mL DMF. 3. Cool the solution to 4°C. 4. Slowly add 42 mL chlorotrimethylsilane (330 mmol, 3.3 eq) and stir the reaction under N2 for 2 hr. 5. Remove salts that precipitate during the course of the reaction by filtration under N2. 6. Triturate the residual salts in the filtrate with 1:1 (v/v) petroleum ether/diethyl ether. 7. Dissolve the residue in 400 mL DMF and cool to 4°C. 8. Add 4.40 g NaH (110 mmol, 1.1 eq) to the reaction mixture with stirring under N2. 9. After hydrogen evolution subsides, add 37 g 1-tosyl-2-benzoylmercaptoethanol (110 mmol, 1.1 eq) and stir the reaction overnight at 45°C. This step is based on the procedure detailed by Glick (1991).
10. Cool the solution to room temperature and remove the silyl groups by the addition of 5 mL of 48% aqueous HF.
Methods for Cross-Linking Nucleic Acids
5.4.11 Current Protocols in Nucleic Acid Chemistry
11. After 1 hr, dilute the reaction mixture with CH2Cl2 and wash successively with water and brine. 12. Dry the organic layer over Na2SO4 and concentrate under vacuum. 13. Purify the oily residue by flash chromatography ( APPENDIX 3E) using 19:1 (v/v) CH2Cl2/CH3OH to obtain S.1 as a white foam (26 g, 63% yield). Prepare 5′-O-(4,4′-dimethoxytrityl)-N3-(ethyl)uridine tert-butyl disulfide (S.2) 14. Coevaporate 15.0 g compound S.1 (37 mmol) once from 100 mL of 9:1 (v/v) CH3CN/pyridine, then dissolve in 185 mL pyridine. 15. Add 15.0 g 4,4′-dimethoxytrityl chloride (44 mmol, 1.2 eq) in 2.5-g portions over a 6-hr period at 4°C with stirring. 16. Allow the reaction to warm to room temperature overnight while stirring under N2. 17. Add 5 mL CH3OH and stir the mixture an additional 10 min. 18. Remove the solvents under vacuum, and coevaporate the residue with 100 mL CH3CN to yield a light yellow-orange foam. 19. Dissolve the crude tritylated product (14 g, 20 mmol) in 100 mL CH3OH and add 8.31 g 1-(tert-butylthio)-1,2-hydrazinedicarboxmorpholide (Wünsch et al., 1982) (24 mmol, 1.2 eq) and 2.52 g LiOH⋅H2O (60 mmol, 3.0 eq). 20. Stir the reaction under N2 for 12 hr and then concentrate the mixture under vacuum. 21. Dissolve the residue in EtOAc and wash with brine. 22. Dry the organic layer over Na2SO4 and concentrate under vacuum. 23. Purify the residue by flash chromatography ( APPENDIX 3E) using a step gradient of 3:2 to 2:3 (v/v) petroleum ether/EtOAc to obtain S.2 as a white foam (9.7 g, 70% yield). Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N3-(ethyl)uridine tert-butyl disulfide (S.3) and 5′-O-(4,4′-dimethoxytrityl)-3′-O-(tert-butyldimethylsilyl)-N3-(ethyl)uridine tert-butyl disulfide (S.4) 24. Dissolve 9.5 g compound S.2 (13.6 mmol) in 50 mL DMF. 25. Add 2.31 g imidazole (34 mmol, 2.5 eq) and 2.58 g tert-butyldimethylsilyl chloride (17.1 mmol, 1.25 eq). 26. Stir the mixture overnight under N2. 27. Dilute the reaction with EtOAc, wash the mixture with brine, dry over Na2SO4, and evaporate under vacuum. 28. Purify the residue by flash chromatography (APPENDIX 3E) using 9:1 (v/v) petroleum ether/EtOAc to obtain S.3 and S.4 as white foams (S.3: 3.9 g, 40% yield; S.4: 2.1 g, 25% yield).
Engineering Disulfide Cross-Links in RNA via Air Oxidation
Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N3-(ethyl)uridine3′-O-(N,N-diisopropyl-β-cyanoethylphosphoramidite) tert-butyl disulfide (S.5) 29. Dissolve 0.81 g compound S.3 (1.0 mmol) in 3.0 mL THF. 30. Add 1.0 mL 2,4,6-collidine (7.5 mmol, 7.5 eq) and 40 µL N-methylimidazole (0.5 mmol, 0.5 eq).
5.4.12 Current Protocols in Nucleic Acid Chemistry
31. Add 0.56 mL chloro-N,N-diisopropylamine-β-cyanoethyl phosphine (2.5 mmol, 2.5 eq) dropwise while stirring under N 2. 32. After 2 hr, dilute the reaction with EtOAc and wash the mixture with NaHCO3 and brine. 33. Dry the organic layer over Na2SO4, and concentrate under vacuum. 34. Purify the residue by flash chromatography (APPENDIX 3E) using 80:15:5 (v/v/v) petroleum ether/EtOAc/Et3N to obtain S.5 as a brittle white foam (0.82 g, 82% yield). SYNTHESIS OF 5′-O-(4,4′-DIMETHOXYTRITYL)-3′-O-(tert-BUTYLDIMETHYLSILYL)-2′-O-SUCCINYL-CPG N3-(ETHYL)URIDINE tert-BUTYL DISULFIDE CONTROLLED-PORE GLASS SUPPORT
SUPPORT PROTOCOL 5
5′-O-(4,4′-dimethoxytrityl)-3′-O-(tert-butyldimethylsilyl)-2′-O-succinyl-CPG N3-(ethyl)uridine tert-butyl disulfide (Fig. 5.4.2), a thiol-modified controlled-pore glass (CPG) support, is prepared using a side product (S.4) obtained in Support Protocol 4. This nucleoside support can be used to introduce a thiol modification at the 3′ terminus of an RNA species. The nucleoside loading concentration is usually 32 µmol/g (Schaller et al., 1963). Materials Compound S.4 (see Support Protocol 4) Pyridine Succinic anhydride 4-Dimethylaminopyridine (DMAP) Methylene chloride (CH2Cl2) Brine (saturated aqueous NaCl) Sodium sulfate (Na2SO4) Pentachlorophenol Dicyclohexylcarbodiimide (DCC) Petroleum ether Ethyl acetate (EtOAc) Long-chain alkyl amino controlled-pore glass (CPG), 1000-Å pore size, 100 µmol amino groups/g, 120/200 mesh N,N-Dimethylformamide (DMF) Triethylamine (Et3N) Methanol (CH3OH) Diethyl ether (Et2O) Acetic anhydride Additional reagents and equipment for flash chromatography (APPENDIX 3E) Prepare 5′-O-(4,4′-dimethoxytrityl)-3′-O-(tert-butyldimethylsilyl)-2′-O-pentachlorophenylsuccinate N3-(ethyl)uridine tert-butyl disulfide (S.6) 1. Dissolve 1.77 g compound S.4 (2.2 mmol) in 12.0 mL pyridine under N2. 2. Add 0.69 g succinic anhydride (6.6 mmol, 3.0 eq) and 0.133 g DMAP (1.1 mmol, 0.5 eq) and incubate 12 hr. 3. Concentrate the reaction mixture under vacuum. 4. Dissolve the residue in CH2Cl2 and wash with brine. 5. Dry the organic layer over Na2SO4 and concentrate under vacuum.
Methods for Cross-Linking Nucleic Acids
5.4.13 Current Protocols in Nucleic Acid Chemistry
6. Dissolve the crude succinate in 25 mL CH2Cl2 and add 0.88 g pentachlorophenol (3.3 mmol, 1.5 eq), 67 mg DMAP (0.55 mmol, 0.25 eq), and 0.91 g DCC (4.4 mmol, 2.0 eq). 7. After 8 hr, add petroleum ether to precipitate dicyclohexylurea. 8. Gravity filter the reaction mixture and concentrate under vacuum. 9. Purify the residue by flash chromatography (APPENDIX 3E) using 4:1 (v/v) petroleum ether/EtOAc to obtain S.6 as a white foam (2.3 g, 90% yield). Prepare 5′-O-(4,4′-dimethoxytrityl)-3′-O-(tert-butyldimethylsilyl)-2′-O-succinyl-CPG N3-(ethyl)uridine tert-butyl disulfide (S.7) 10. Suspend long-chain alkyl amino CPG in 4.0 mL DMF with 0.58 g compound S.6 (0.5 mmol, 5 eq) and 0.14 mL Et3N (1.0 mmol, 10 eq). 11. Gently swirl the mixture in the dark for 2 days. 12. Vacuum filter the support and rinse successively with 15 mL DMF, 50 mL CH3OH, and 50 mL Et2O. 13. Remove the residual solvents under vacuum. 14. Acetylate the unreacted amino groups by swirling the support for 1 hr with 0.70 mL acetic anhydride (7.0 mmol, 100 eq) and 10 mg DMAP (70 µmol, 1 eq) in 4 mL pyridine. 15. Rinse the support successively with 30 mL pyridine, 90 mL CH3OH, and 90 mL Et2O. 16. Remove the residual solvents under vacuum. SUPPORT PROTOCOL 6
SYNTHESIS OF 3′,5′-O-(TETRAISOPROPYLDISILOXANE-1,3-DIYL)-2′-OALLYL-O4-(2-NITROPHENYL) URIDINE (S.10) INTERMEDIATE Preparation of thiol-modified nucleoside phosphoramidite modified at the 2′-hydroxyl position of pyrimidines proceeds from preparation of 3′,5′-O-(tetraisopropyldisiloxane1,3-diyl)-2′-O-allyl-O4-(2-nitrophenyl)uridine. Preparation of this compound is described. First, uridine is converted to 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)O4-(2-nitrophenyl) uridine (S.9) in two sets of steps as described by Sproat and Lamond (1991). This compound is then allylated using the procedure described by Sproat et al. (1991).
Engineering Disulfide Cross-Links in RNA via Air Oxidation
Materials Uridine Pyridine 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane Methylene chloride (CH2Cl2) Methanol (CH3OH) Saturated aqueous sodium bicarbonate (NaHCO3) Sodium sulfate (Na2SO4) Triethylamine (Et3N) Chlorotrimethylsilane Brine (saturated aqueous NaCl) 2-Mesitylenesulfonyl chloride 4-Dimethylaminopyridine (DMAP) 2-Nitrophenol 1,4-Diazabicyclo[2.2.2]octane (DABCO)
5.4.14 Current Protocols in Nucleic Acid Chemistry
p-Toluenesulfonic acid monohydrate p-Dioxane Ethyl acetate (EtOAc) Petroleum ether Tetrahydrofuran (THF) Triphenylphosphine Tris(dibenzylideneacetone) dipalladium(0) Allyl ethyl carbonate Additional reagents and equipment for flash chromatography (APPENDIX 3E) Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-uridine (S.8) 1. Dissolve 499 mg uridine (2.04 mmol) in 5.1 mL pyridine. 2. Cool to 0°C under N2. 3. Dissolve 732 µL 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (2.29 mmol, 1.1 eq) in 0.5 mL CH2Cl2 and add dropwise to uridine solution. 4. Stir the reaction, allowing it to warm to room temperature, for 4 hr. 5. Dilute the reaction by adding 0.4 mL CH 3OH, and evaporate under vacuum. 6. Dissolve the residue in 15 mL CH2Cl2 and wash three times with saturated aqueous NaHCO3. 7. Dry the organic layer over Na2SO4 and evaporate under vacuum. 8. Dissolve the residue in toluene and evaporate under vacuum to obtain S.8 as a white foam (1.0 g, 100%). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-O4-(2-nitrophenyl) uridine (S.9) 9. Dissolve 3.4 g compound S.8 (6.9 mmol) in 35 mL CH2Cl2 and cool to 0°C. It may be necessary to repeat the synthesis of S.8 to obtain the necessary quantity for the synthesis of S.9.
10. Add 9 mL Et3N (64.6 mmol, 9.4 eq) followed by 6.4 mL chlorotrimethylsilane (50.4 mmol, 7.3 eq) and stir the reaction 4 hr under N2. 11. Pour the reaction onto 100 mL saturated aqueous NaHCO3 and stir for 10 min. 12. Wash the organic layer with brine, dry over Na 2SO4, and concentrate under vacuum to a peach foam (3.8 g, 100%). 13. Dissolve the residue in 36 mL CH2Cl2 and 4.8 mL Et3N (34.6 mmol, 5 eq). 14. Add 2.25 g 2-mesitylenesulfonyl chloride (10.3 mmol, 1.5 eq) and 0.5 g DMAP (3.5 mmol, 0.5 eq). Stir for 15 min. 15. Add 2.0 g 2-nitrophenol (14.4 mmol, 2.1 eq) and 0.42 g DABCO (3.7 mmol, 0.55 eq) and continue stirring for 3 hr. 16. Dilute the reaction with 40 mL CH2Cl2 and wash with saturated aqueous NaHCO3. 17. Backwash the aqueous layer twice with CH2Cl2. 18. Dry the combined organic layers over Na2SO4 and concentrate under vacuum. 19. Dissolve the residue in 21 mL CH 2Cl2 and add a solution of 2.70 g p-toluenesulfonic acid monohydrate in 21 mL p-dioxane.
Methods for Cross-Linking Nucleic Acids
5.4.15 Current Protocols in Nucleic Acid Chemistry
20. Stir the reaction for 2 min and then quench by adding 2.5 mL Et3N. 21. Pour the reaction onto saturated aqueous NaHCO3 and backwash the aqueous layer with CH2Cl2 twice. 22. Dry the combined organic layers over Na2SO4 and concentrate under vacuum. 23. Purify the residue by flash chromatography (APPENDIX petroleum ether to obtain S.9 (4.5 g, 6.9 mmol, 100%).
3E)
using 55% EtOAc in
Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2′-O-allyl-O4-(2-nitrophenyl) uridine (S.10) 24. Dissolve the 4.5 g compound S.9 in 37 mL THF (37 mL). 25. Add 371 mg triphenylphosphine (1.4 mmol, 0.2 eq) and 168 mg tris(dibenzylideneacetone) dipalladium(0) (0.2 mmol, 0.026 eq). 26. Add 1.9 mL allyl ethyl carbonate (14.0 mmol, 2 eq) dropwise. 27. Heat the reaction to reflux for 2 hr. 28. Cool the reaction to room temperature and concentrate under vacuum. 29. Purify the residue by flash chromatography (APPENDIX petroleum ether to obtain S.10 (3.3 g, 72%). SUPPORT PROTOCOL 7
3E)
using 18% EtOAc in
SYNTHESIS OF 5′-O-(4,4′-DIMETHOXYTRITYL)-N4-(BENZOYL)-2′-O(ETHYL)CYTIDINE-3′O-(N,N-DIISOPROPYL->-CYANOETHYLPHOSPHORAMIDITE) tert-BUTYL DISULFIDE (S.20) The intermediate prepared in Support Protocol 6 is converted to 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-N4-(benzoyl)-2′-O-allyl cytidine (S.11) using the method of Sproat and Lamond (1991) replacing isobutyryl chloride with benzoyl chloride. The synthesis of the fully protected phosphoramidite can be accomplished in nine sets of steps (Fig. 5.4.3).
Engineering Disulfide Cross-Links in RNA via Air Oxidation
Materials Compound S.10 (see Support Protocol 6) Tetrahydrofuran (THF) Ammonia (NH3) N2 Methanol (CH3OH) Petroleum ether Ethyl acetate (EtOAc) Pyridine N,N-Dimethylformamide (DMF) Benzoic anhydride Ammonium hydroxide (NH4OH) N-Methylmorpholine-N-oxide Acetone Osmium tetroxide (OsO4) Saturated aqueous sodium bisulfite Diethyl ether (Et2O) Saturated aqueous sodium bicarbonate (NaHCO3) Brine (saturated aqueous NaCl) Sodium sulfate (Na2SO4)
5.4.16 Current Protocols in Nucleic Acid Chemistry
O2N O O NH N
HO
N
O
a
O
N
O
O
(i-Pr)2Si
O HO
O
NH
O (i-Pr)2Si O
b-e
O (i-Pr)2Si O (i-Pr)2Si
OH
OH O2N
N
O
O O
OH
8 NHBz
9
O N N f
N
O (i-Pr)2Si O (i-Pr)2Si
O
N
O
g,h
O
O (i-Pr)2Si
O
O
i
O
(i-Pr)2Si
O
O
O
11 10 NHBz
NHBz
N
N
N
O
O
O O (i-Pr)2Si O (i-Pr)2Si O O
j
O
(i-Pr)2Si
N
OH
O (i-Pr)2Si
O
O
OH
12
H
NHBz
NHBz
N
N O O (i-Pr)2Si O (i-Pr)2Si O O
k
O
13
NHBz
N
O
O
N
O O (i-Pr)2Si O (i-Pr)2Si O O
l
OH
N O
N
O O (i-Pr)2Si O (i-Pr)2Si O O
m
OMs
15
14
NHBz
N N
HO
N O
o
O HO
O
SBz
16
NHBz
n
O
N
HO
HO
SBz
O
O O
SSt-Bu
18
17
NHBz NHBz N N p
N
DMTrO
O
O HO
O
SSt-Bu
N
DMTrO
NC
O
O
O
q O P
O
SSt-Bu
N(i-Pr)2
19 20
Figure 5.4.3 Synthesis of 5′-O-(4,4′-dimethoxytrityl)-N4-(benzoyl)-2′-O-(ethyl)cytidine tert-butyl disulfide 3′-O-(N,N-diisopropyl-β-cyanoethylphosphoramidite). (a) pyridine, 1,3-dichloro-1,1,3,3tetraisopropyldisiloxane, CH2Cl2; (b) chlorotrimethylsilane, Et3N, CH2Cl2; (c) 2-mesitylenesulfonyl chloride, DMAP, Et3N, CH2Cl2; (d) 2-nitrophenol, DABCO; (e) p-toluenesulfonic acid monohydrate, p-dioxane, CH2Cl2; (f) triphenylphosphine, tris(dibenzylideneacetone) dipalladium(0), allyl ethyl carbonate, THF; (g) NH3, THF; (h) pyridine, benzoic anhydride, DMF; (i) OsO4, N-methylmorpholine-N-oxide, acetone, H2O; (j) NaIO4, p-dioxane, H2O; (k) NaBH4, CH3OH; (l) methanesulfonyl chloride, pyridine; (m) thiobenzoic acid, Et3N, DMF; (n) HF (aq), CH3CN; (o) 1-(tert-butylthio)-1,2hydrazinedicarboxmorpholide, LiOH, CH3OH, THF; (p) DMTrCl, Et3N, DMF, DMAP; (q) chloro-N,Ndiisopropylamine-β-cyanoethyl phosphine, N,N-diisopropylethylamine, CH2Cl2. Abbreviations: Bz, benzoyl; DMAP, 4-dimethylaminopyridine; DMF, dimethylformamide; DMTr, 4,4′-dimethoxytrityl; Ms, methanesulfonyl; THF, tetrahydrofuran.
Methods for Cross-Linking Nucleic Acids
5.4.17 Current Protocols in Nucleic Acid Chemistry
Methylene chloride (CH2Cl2) p-Dioxane Sodium periodate (NaIO4) Sodium borohydrate (NaBH4) Methanesulfonyl chloride Triethylamine (Et3N) Thiobenzoic acid Acetonitrile (CH3CN) 48% (w/v) aqueous HF 1-(tert-Butylthio)-1,2-hydrazinedicarboxmorpholide (Wünsch et al., 1982) LiOH⋅H2O 1 N aqueous sodium citrate 4-Dimethylaminopyridine (DMAP) 4,4′-Dimethoxytrityl chloride (DMTrCl) N,N-Diisopropylethylamine Chloro-N,N-diisopropylamine-β-cyanoethyl phosphine Pressure tube (−78°C) CO2/isopropyl alcohol (i-PrOH) bath Additional reagents and equipment for flash chromatography (APPENDIX 3E) Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)- N4-(benzoyl)-2′-O-allyl cytidine (S.11) 1. Dissolve 1.94 g compound S.10 (2.99 mmol) in 8.5 mL THF in a pressure tube. 2. Cool the tube to −78°C using a CO2/i-PrOH bath. 3. Add 5 g NH3 (299 mmol, 100 eq). 4. Seal the reaction vessel and stir while allowing it to warm to room temperature for 62 hr. 5. Cool the reaction mixture to −78°C using CO2/i-PrOH bath and open the pressure tube. 6. Allow the mixture to warm under N 2 to room temperature. 7. Concentrate under vacuum. 8. Purify the residue by flash chromatography (APPENDIX 3E) using a step gradient of 0 to 10% CH3OH in 7:3 (v/v) petroleum ether/EtOAc. 9. Dissolve the purified residue in 14 mL pyridine and 6.5 mL DMF. 10. Add 0.72 g benzoic anhydride (3.20 mmol, 1.5 eq) and stir the reaction under N2 for 12 hr at room temperature. 11. Cool the reaction to 0°C and add 0.4 mL water. 12. Stir the reaction 5 min at 0°C, then add 0.3 mL NH4OH. Engineering Disulfide Cross-Links in RNA via Air Oxidation
13. Continue stirring the reaction 10 min at 0°C, then concentrate the mixture under vacuum. 14. Purify the residue by flash chromatography (APPENDIX 3E) using 3:2 (v/v) petroleum ether/EtOAc to obtain S.11 (1.42 g, 75% yield) as a white foam.
5.4.18 Current Protocols in Nucleic Acid Chemistry
Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)- 2′-O-(2,3-dihydroxypropyl)cytidine (S.12) 15. Dissolve 1.34 g compound S.11 (2.30 mmol) and 0.27 g N-methylmorpholine-N-oxide (2.34 mmol, 1.1 eq) in 21 mL of 6:1 (v/v) acetone/water. 16. Add 5 mg OsO4 (21 µmol, 0.01 eq) and stir the reaction mixture in the dark for 2.5 hr. 17. Add 1 mL saturated aqueous sodium bisulfite to precipitate osmium salts. 18. Decant the solution and dissolve the light-brown residue in Et 2O. 19. Wash the solution with saturated aqueous NaHCO3 and brine. 20. Dry the combined organic layers over Na2SO4 and concentrate under vacuum. 21. Purify the yellow residue by flash chromatography (APPENDIX 3E) using a step gradient of 19:1 to 37:3 CH2Cl2/CH3OH to obtain S.12 (1.27 g, 90% yield). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-N4-(benzoyl)-2′-O-(ethanal)cytidine (S.13) 22. Dissolve the 1.27 g compound S.12 (1.91 mmol) in 20 mL of 3:1 (v/v) p-dioxane/water. 23. Add 0.49 g NaIO4 (2.29 mmol, 1.2 eq) and stir the reaction mixture in the dark for 4.5 hr. 24. Dilute the reaction with Et2O and wash with water. 25. Dry the organic layer over Na2SO4 and concentrate under vacuum. 26. Purify the residue by flash chromatography (APPENDIX 3E) using 19:1 (v/v) CH2Cl2/CH3OH to obtain S.13 as a white foam (2.94 g, 97% yield). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-N4-(benzoyl)-2′-O(2-hydroxyethyl)cytidine (S.14) 27. Dissolve 1.17 g compound S.13 (1.85 mmol) in 19 mL CH3OH. 28. Add 21 mg NaBH4 (0.56 mmol, 0.3 eq) and stir the mixture in the dark under N2 for 90 min. 29. Dilute the solution with Et 2O and wash with saturated aqueous NaHCO3 and brine. 30. Wash the aqueous layer once with Et2O. 31. Dry the combined organic layers over Na2SO4 and concentrate under vacuum. 32. Purify the residue by flash chromatography (APPENDIX 3E) using 19:1 (v/v) CH2Cl2/CH3OH to obtain S.14 as a white foam (1.09 g, 93% yield). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-N4-(benzoyl)-2′-O-(ethyl-2methylsulfonate)cytidine (S.15) 33. Dissolve the 1.09 g compound S.14 (1.72 mmol) in 17 mL CH2Cl2 and 1.4 mL pyridine (17.2 mmol, 10 eq). 34. Cool under N2 to 0°C. 35. Add 0.19 mL methanesulfonyl chloride (2.41 mmol, 1.2 eq) dropwise. 36. Stir the mixture under N2 while gradually warming to room temperature overnight.
Methods for Cross-Linking Nucleic Acids
5.4.19 Current Protocols in Nucleic Acid Chemistry
37. Dilute the reaction with Et2O and wash with saturated aqueous NaHCO3 and brine. 38. Dry the organic layer over Na2SO4 and concentrate under vacuum. 39. Purify the residue by flash chromatography (APPENDIX 3E) using 24:1 (v/v) CH2Cl2/CH3OH to obtain S.15 as a white foam (1.13 g, 92% yield). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-N4-(benzoyl)-2′-O-(thiobenzoylethyl) cytidine (S.16) 40. Dissolve 1.04 g compound S.15 (1.46 mmol) in 5.8 mL DMF. 41. Add 2.0 mL Et3N (14.6 mmol, 10 eq) and 0.34 mL thiobenzoic acid (2.91 mmol, 2.0 eq). 42. Stir the mixture under N2 in the dark overnight. 43. Dilute the solution with Et2O and wash with saturated aqueous NaHCO3 and brine. 44. Dry the organic layer over Na2SO4 and concentrate under vacuum to a dark orangebrown solid. 45. Purify the residue by flash chromatography (APPENDIX 3E) using a step gradient of 0 to 10% CH3CN in 2:1 (v/v) petroleum ether/EtOAc to obtain S.16 as a white foam (0.84 g, 76% yield). Prepare N4-(benzoyl)-2′-O-(thiobenzoylethyl)cytidine (S.17) 46. Dissolve 0.37 g compound S.16 (0.49 mmol) in 4.3 mL CH3CN. 47. Add 0.5 mL of 48% aqueous HF and stir the reaction mixture for 7 hr. 48. Dilute the solution with Et2O and wash with H2O. 49. Dry the organic layer over Na2SO4 and concentrate under vacuum. 50. Purify the pink residue by flash chromatography (APPENDIX 3E) using 19:1 (v/v) CH2Cl2/CH3OH to obtain S.17 as a white foam (0.25 g, 100% yield). Prepare N4-(benzoyl)-2′-O-(ethyl)cytidine tert-butyl disulfide (S.18) 51. Dissolve the 0.25 g compound S.17 (0.49 mmol) in 3.8 mL of 1:1 (v/v) CH3OH/THF. 52. Add 0.20 g 1-(tert-butylthio)-1,2-hydrazinedicarboxmorpholide (Wünsch et al., 1982) (0.58 mmol, 1.2 eq) and 41 mg LiOH⋅H2O (0.97 mmol, 2.0 eq). 53. Stir the reaction under N2 at 0°C for 45 min. 54. Dilute the reaction with EtOAc, and then wash with 1 N aqueous sodium citrate and the saturated aqueous NaHCO3. 55. Dry the organic layer over Na2SO4 and concentrate under vacuum. 56. Purify the residue by flash chromatography (APPENDIX 3E) using 24:1 (v/v) CH2Cl2/CH3OH to obtain S.18 as a pink foam (0.18 g, 74% yield).
Engineering Disulfide Cross-Links in RNA via Air Oxidation
Prepare 5′-O-(4,4′-dimethoxytrityl)-N4-(benzoyl)-2′-O-(ethyl)cytidine tert-butyl disulfide (S.19) 57. Dissolve 0.10 g compound S.18 (0.21 mmol) and 13 mg DMAP (0.10 mmol, 0.5 eq) in 0.8 mL DMF and 26 µL pyridine (0.31 mmol, 1.5 eq). 58. Add 85 mg DMTrCl (0.25 mmol, 1.2 eq) and stir the reaction under N2 for 6 hr.
5.4.20 Current Protocols in Nucleic Acid Chemistry
59. Dilute the reaction with CH2Cl2 and wash with saturated aqueous NaHCO3 and brine. 60. Dry the organic layer over Na2SO4 and concentrate under vacuum. 61. Purify the residue by flash chromatography (APPENDIX 3E) using 1:1 (v/v) petroleum ether/acetone to obtain S.19 as a tan foam (0.13 g, 77% yield). Prepare 5′-O-(4,4′-dimethoxytrityl)-N4-(benzoyl)-2′-O-(ethyl)cytidine 3′-O-(N,N-diisopropyl->-cyanoethylphosphoramidite) tert-butyl disulfide (S.20) 62. Dissolve 55 mg compound S.19 (0.07 mmol) in 0.3 mL CH2Cl2 containing 60 µL N,N-diisopropylethylamine (0.35 mmol, 5 eq). 63. Cool under N2 to 0°C. 64. Add 23 µL chloro-N,N-diisopropylamine-β-cyanoethyl phosphine (0.10 mmol, 1.5 eq) dropwise and stir the reaction under N2 while allowing it to warm to room temperature. 65. After 2 hr, quench the excess chloridate with 0.3 mL CH3OH and concentrate the mixture under vacuum. 66. Purify the residue by flash chromatography (APPENDIX 3E) using 2:1 (v/v) petroleum ether/acetone to obtain S.20 as a white foam (58 mg, 84% yield). SYNTHESIS OF 5′-O-(4,4′-DIMETHOXYTRITYL)-2′-O-(ETHYL)URIDINE-3′O-(N,N-DIISOPROPYL->-CYANOETHYLPHOSPHORAMIDITE) tert-BUTYL DISULFIDE
SUPPORT PROTOCOL 8
The intermediate S.10 prepared in Support Protocol 6 can be converted to 3′,5′-O(tetraisopropyldisiloxane-1,3-diyl)-2′-O-allyl uridine (S.21) using nitrobenzaldoxime and 1,1,3,3-tetramethylguanidine as described by Sproat and Lamond (1991). The synthesis of the fully protected phosphoramidites can be accomplished in nine sets of steps (Fig. 5.4.4). Materials 2-Nitrobenzaldoxime 1,1,3,3-Tetramethylguanidine Acetonitrile (CH3CN) Compound S.10 (see Support Protocol 6) Ethyl acetate (EtOAc) Sodium sulfate (Na2SO4) Methanol (CH3OH) Methylene chloride (CH2Cl2) Acetone N-Methylmorpholine-N-oxide Osmium tetroxide (OsO4) Saturated aqueous sodium bisulfite Celite 1,4-Dioxane Sodium periodate (NaIO4) Diethyl ether (Et2O) Sodium bicarbonate (NaHCO3) Sodium borohydride (NaBH4) Brine (saturated aqueous NaCl) Pyridine
Methods for Cross-Linking Nucleic Acids
5.4.21 Current Protocols in Nucleic Acid Chemistry
O
O
a
10
N
O
b
O
O (i-Pr)2Si O
N
O
O
(i-Pr)2Si
N O O (i-Pr)2Si O (i-Pr)2Si O O
O
OH
HO
O
O
OMs
h
SBz
DMTrO
27
O 28
O NH
NH
O
O HO
SBz
O NH
N
SBz
i
g
O
N O O (i-Pr)2Si O (i-Pr)2Si O O 26
O NH
O
NH f
25
O
H
O
N O O (i-Pr)2Si O (i-Pr)2Si O O
24
HO
O O 23
NH e
O
O
O (i-Pr)2Si O
OH
O NH
O
O
22
O
N
O
N
(i-Pr)2Si
OH
O (i-Pr)2Si O
O
NH c
O
O
(i-Pr)2Si
21
d
O NH
NH
N
DMTrO
O
O HO
O
DMTrO
j
SSt-Bu
29
N
NC
O
O
O O P
O
SSt-Bu
N(i-Pr)2 30
Figure 5.4.4 Synthesis of 3′-O-(N,N-diisopropyl-β-cyanoethyl-phosphoramidite)-5′-O-(4,4′-dimethoxytrityl)-2′-O-(ethyl)uridine tert-butyl disulfide. (a) 2-Nitrobenzaldoxime, 1,1,3,3-tetramethylguanidine, CH3CN; (b) OsO4, N-methylmorpholine-N-oxide, acetone, H2O; (c) NaIO4, p-dioxane, H2O; (d) NaBH4, CH3OH; (e) methanesulfonyl chloride, pyridine; (f) thiobenzoic acid, Et3N, DMF; (g) HF (aq), CH3CN; (h) DMTrCl, Et3N, DMF, DMAP; (i) 1-(tert-butylthio)-1,2-hydrazine-dicarboxmorpholide, LiOH, CH3OH, THF; (j) chloro-N,N-diisopropylamine-β-cyanoethyl phosphine, N,Ndiisopropylethylamine, CH2Cl2. Abbreviations: Bz, benzoyl; DMAP, 4-dimethylaminopyridine; DMF, dimethylformamide; DMTr, 4,4′-dimethoxytrityl; Ms, methanesulfonyl.
Methanesulfonyl chloride N,N-Dimethylformamide (DMF) Triethylamine (Et3N) Thiobenzoic acid 48% (w/v) aqueous HF 4,4′-Dimethoxytrityl chloride (DMTrCl) 4-Dimethylaminopyridine (DMAP) Tetrahydrofuran (THF) LiOH⋅H2O 1-(tert-Butylthio)-1,2-hydrazinedicarboxmorpholide 1 N aqueous sodium citrate N,N-Diisopropylethylamine Chloro-N,N-diisopropylamine-β-cyanoethyl phosphine Petroleum ether Additional reagents and equipment for flash chromatography (APPENDIX 3E) Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2′-O-allyluridine (S.21) 1. Dissolve 2.1 g 2-nitrobenzaldoxime (12.3 mmol, 4 eq) and 1.4 mL 1,1,3,3-tetramethylguanidine (11.1 mmol, 3.6 eq) in 28 mL CH3CN. Engineering Disulfide Cross-Links in RNA via Air Oxidation
2. Stir this solution under N2. 3. Add the solution to 2.0 g compound S.10 (3.1 mmol).
5.4.22 Current Protocols in Nucleic Acid Chemistry
4. Stir the reaction for 30 min at room temperature and then concentrate under vacuum. 5. Dissolve the residue in EtOAc and wash with water. 6. Backwash the water layer 3 times with EtOAc. 7. Combine the organic layers and dry over Na2SO4. 8. Concentrate under vacuum. 9. Purify the residue by flash chromatography (APPENDIX 3E) using a step gradient of 0 to 5% CH3OH in CH2Cl2 to obtain S.21 (1.61 g, 99%). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2′-O-(2,3-dihydroxypropyl)uridine (S.22) 10. Dissolve 1.61 g compound S.21 (3.06 mmol) in 30 mL of 6:1 (v/v) acetone/water. 11. Add 394 mg N-methylmorpholine-N-oxide (3.4 mmol, 1.1 eq) and 7.7 mg OsO4 (0.03 mmol, 0.01 eq) and stir in the dark for 3 hr. 12. Precipitate the osmium salts with 2 mL saturated aqueous sodium bisulfite and pour the mixture through a funnel containing Celite. 13. Evaporate the solvent under vacuum to obtain S.22 as a white foam (1.77 g, 100% yield). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2′-O-(ethanal)uridine (S.23) 14. Dissolve 437 mg compound S.22 (0.8 mmol) in 7.8 mL of 3:1 (v/v) 1,4-dioxane/H2O. 15. Add 209 mg NaIO4 (1.0 mmol, 1.25 eq) and stir the reaction in the dark for 6 hr. 16. Dilute the solution with Et 2O and filter. 17. Wash the filtrate with saturated aqueous NaHCO 3, dry over Na2SO4, and concentrate under vacuum to obtain S.23 as a pale-yellow foam (400 mg, 97% yield). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2′-O-(2-hydroxyethyl)uridine (S.24) 18. Dissolve 470 mg compound S.23 (0.9 mmol) in 7.4 mL CH3OH. It may be necessary to repeat the synthesis of S.22 to obtain the necessary quantity for the synthesis of S.23.
19. Add 16 mg NaBH4 (0.4 mmol, 0.48 eq) and stir the mixture overnight under N2. 20. Dilute the mixture with Et2O, then wash once with saturated aqueous NaHCO3 and twice with brine. 21. Dry the combined organic layers over Na2SO4, filter, and evaporate under vacuum to obtain S.24 as a white foam (464 mg, 98% yield). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2′-O-(ethyl-2-methylsulfonate)uridine (S.25) 22. Dissolve 138 mg compound S.24 (0.3 mmol) in a mixture of 2.6 mL CH2Cl2 and 0.21 mL pyridine. 23. Cool to 0°C. 24. Add 28 µL methanesulfonyl chloride (0.4 mmol, 14 eq) dropwise while stirring under N2.
Methods for Cross-Linking Nucleic Acids
5.4.23 Current Protocols in Nucleic Acid Chemistry
25. Allow the reaction to warm to room temperature over 18 hr. 26. Dilute the mixture with CH2Cl2 and wash once with saturated aqueous NaHCO3. 27. Dry the organic layer over Na2SO4, filter, and evaporate under vacuum. 28. Purify the residue by flash chromatography (APPENDIX 3E) using 17:3 (v/v) CH2Cl2/acetone to obtain S.25 as a white foam (133 mg, 84% yield). Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2′-O-(thiobenzoylethyl)uridine (S.26) 29. Dissolve 552 mg compound S.25 (0.9 mmol) in a mixture of 3.6 mL DMF and 1.3 mL Et3N (9.1 mmol, 10.0 eq). It may be necessary to repeat the synthesis of S.25 to obtain the necessary quantity for the synthesis of S.26.
30. Add 0.21 mL thiobenzoic acid (1.8 mmol, 2 eq) and stir overnight under N2. 31. Dilute the mixture with Et2O, then wash once with saturated aqueous NaHCO3 and twice with brine. 32. Dry the combined organic extracts over Na2SO4, filter, and concentrate under vacuum. 34. Purify the residue by flash chromatography (APPENDIX 3E) using a step gradient of 47:3 to 4:1 (v/v) CH2Cl2/acetone to obtain S.26 as a white foam (472 mg, 80% yield). Prepare 2′-O-(thiobenzoylethyl)uridine (S.27) 35. Dissolve the 472 mg compound S.26 (0.7 mmol) in 5.8 mL CH3CN. 36. Add 1.3 mL of 48% aqueous HF and stir for 4 hr. 37. Dilute the mixture with EtOAc and wash once with H 2O. 38. Dry the organic layer over Na2SO4 and filter. 39. Evaporate under vacuum to obtain S.27 as a white foam (327 mg, 100% yield). Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(thiobenzoylethyl)uridine (S.28) 40. Dissolve 277 mg compound S.27 (0.7 mmol) in 2.7 mL DMF and 82 µL pyridine (1.0 mmol, 1.5 eq). 41. Add 280 mg DMTrCl (0.8 mmol, 1.2 eq) and 54 mg DMAP (0.4 mmol, 0.65 eq). 42. Stir the reaction overnight under N2. 43. Dilute the reaction with CH 2Cl2 and wash the solution once with saturated aqueous NaHCO3 and twice with brine. 44. Dry the combined organic extracts over Na2SO4, filter, and concentrate under vacuum. 45. Purify the residue by flash chromatography (APPENDIX 3E) using 48:1 (v/v) CH2Cl2/CH3OH) to obtain S.28 as a yellow foam (302 mg, 63% yield). Engineering Disulfide Cross-Links in RNA via Air Oxidation
Prepare 5′-O-(4,4′-dimethoxytrityl)-2′-O-(ethyl)uridine tert-butyl disulfide (S.29) 46. Dissolve 293 mg compound S.28 (0.4 mmol) in 3.3 mL of 1:1 (v/v) THF/CH3OH. 47. Add 26 mg LiOH⋅H2O (0.6 mmol, 1.5 eq).
5.4.24 Current Protocols in Nucleic Acid Chemistry
48. After stirring for 2 min, add 164 mg 1-(tert-butylthio)-1,2-hydrazinedicarboxmorpholide (0.5 mmol, 1.2 eq) (Wünsch et al., 1982). 49. Stir the mixture for an additional 10 min under N2. 50. Dilute the solution with CH2Cl2. 51. Wash the solution with 1 N aqueous sodium citrate, saturated aqueous NaHCO 3, and brine. 52. Dry the organic layer over Na2SO4. 53. Filter the solution and evaporate under vacuum. 54. Purify the residue by flash chromatography (APPENDIX 3E) using 49:1 (v/v) CH2Cl2/CH3OH to obtain S.29 as a white foam (285 mg, 100% yield). Prepare 3′-O-(N,N-diisopropyl->-cyanoethyl-phosphoramidite)-5′-O-(4,4′dimethoxytrityl)-2′-O-(ethyl)uridine tert-butyl disulfide (S.30) 55. Dissolve 49 mg compound S.29 (0.07 mmol) in 0.28 mL CH2Cl2 containing 62 µL N,N-diisopropylethylamine (0.4 mmol, 5 eq) and cool to 0°C. 56. Add 24 µL chloro-N,N-diisopropylamine-β-cyanoethyl phosphine (0.1 mmol, 1.5 eq) dropwise. 57. Stir the mixture for 2 hr under N2. 58. Dilute the solution with CH3OH. 59. Concentrate the solution under vacuum. 60. Purify the residue by flash chromatography (APPENDIX 3E) using 19:6 (v/v) petroleum ether/acetone to obtain S.30 as a white foam (49 mg, 78% yield). REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
CPM buffer, 5× 7.6 g Tris⋅Cl (250 mM) 38 g NaCl (2.6 mM) 46.5 mg Na2EDTA (0.5 mM) 0.38 mL Triton X-100 (0.15%, v/v) H2O to 200 mL Adjust pH to 7.5 with 1 N NaOH or HCl Add H2O to 250 mL Store up to 1 month at 25°C CPM in isopropanol, 0.4 mM Dissolve 1.6 mg of 7-diethylamino-3-(4′-maleimidylphenyl)-4-methylcoumarin (Molecular Probes) in 10 mL HPLC-grade isopropanol. Store up to 1 week at 25°C. Denaturing polyacrylamide gel solution, 8% 0.32 g bisacrylamide 9.28 g acrylamide 57.7 g urea (8 M final) 24 mL 5× TBE buffer (APPENDIX 2A) H2O to 120 mL Prepare fresh daily Current Protocols in Nucleic Acid Chemistry
Methods for Cross-Linking Nucleic Acids
5.4.25
MgCl2, 200 mM Dissolve 10.2 g magnesium chloride hexahydrate in 250 mL water. Store at room temperature (stable for several months). Sodium acetate, 1.5 M, pH 5.5 Dissolve 12.3 g anhydrous sodium acetate (NaOAc) in 100 mL water. Adjust pH to 5.5 with glacial acetic acid. Store up to 6 months at 25°C. Sodium phosphate buffer, 100 mM, pH 8.3 17.8 g Na2HPO4 H2O to 900 mL Adjust pH to 8.3 with 1 N H3PO4 or NaOH Add H2O to 1 L Store up to 6 months at 25°C Sodium phosphate buffer/NaCl, pH 7.0 100 mM sodium phosphate buffer, pH 7.0 (APPENDIX 2A) 5 mM NaCl (APPENDIX 2A) Check pH and adjust to 7.0 with 1 N H3PO4 or NaOH, if necessary Store up to 6 months at 25°C COMMENTARY Background Information
Engineering Disulfide Cross-Links in RNA via Air Oxidation
Generation of cysteine mutants in proteins capable of forming disulfide bonds is a useful technique to stabilize structure as well as to probe structure, folding, and dynamics. Disulfide cross-links have also been incorporated into DNA to examine ground-state structure, trap non-ground-state structures, and examine protein-DNA and DNA-DNA interactions (Glick, 1998). Disulfide cross-links have more recently been incorporated into RNA sequences to stabilize secondary structure (Goodwin and Glick, 1994; Allerson and Verdine, 1995), to examine dynamic motion between helices in the Tetrahymena ribozyme (Cohen and Cech, 1997), and to probe solution conformation of a tRNA, the hammerhead ribozyme, and the hairpin ribozyme (Sigurdsson et al., 1995; Goodwin et al., 1996; Earnshaw et al., 1997; Maglott and Glick, 1998). The methods that have been used to incorporate disulfide bonds into RNA have relied on either air oxidation or thiol-disulfide exchange. Although air oxidation is slower than thiol-disulfide exchange, using the methodology presented here it is possible to achieve quantitative conversion of the purified thiolmodified RNA to disulfide-cross-linked RNA. The ability to form intramolecular disulfide cross-links in quantitative yields makes it possible to produce milligram quantities of these constructs, which can then be used in a wide variety of biophysical and
biochemical experiments. In addition, attachment of the alkylthiol tethers at positions other than the 5′ or 3′ hydroxyls allows for radiolabeling of constructs modified at the termini of the RNA. Disulfide cross-links can be incorporated into RNA secondary and tertiary structures at many different locations. The specific thiolmodified nucleosides that are needed to create a particular cross-link depend on the location of the cross-links within the RNA. It is possible to form cross-links between two of the same thiol-modified nucleosides or between two different thiol-modified nucleosides. The preparation of nucleosides with thiol modifications at the N3 position of uridine as well as at the 2′ hydroxyl of both cytidine and uridine is described in this unit. Preparation of many other thiol-modified nucleosides has been reported, including those with alkylthiols on both G and A (Glick, 1998). Use of particular bases depends on the specific application (see Glick, 1998). The thiol group in each of these nucleosides is protected as a tert-butyl disulfide, which is stable to all conditions of solid-phase synthesis. These protocols involve relatively simple synthetic organic chemistry techniques and standard glassware and equipment. In addition to the thiol-modified nucleosides described here, synthesis of both adenosine and guanosine derivatized with 2′-O-alkyl linkers has been achieved (Manoharan et al., 1993; Douglas et al., 1994; Gundlach et al., 1997).
5.4.26 Current Protocols in Nucleic Acid Chemistry
Alkylthiol-modified nucleosides have also been described with linkers at, among others, the C5 position of pyrimidines (Sun et al., 1996), the C8 position of purines (Gundlach et al., 1997), and all exocyclic amine groups on both purines and pyrimidines (Allerson et al., 1997).
Compound Characterization N3-(2-Thiobenzoylethyl)uridine (S.1). TLC (9:1 CH2Cl2/CH3OH) Rf = 0.41. 1H NMR (300 MHz, CD3CN) δ 3.30 (2 H, t, J = 5 Hz, CH2SC(O)Ar), 3.65-3.81 (2H, 2 dd, J = 2.5, 10 Hz, 5′, 5′′), 3.96 (1H, m, 4′), 4.16-4.19 (4H, m, 2′, 3′, NCH2), 5.66 (1H, d, J = 8.1 Hz, 6), 5.80 (1H, d, J = 3.8 Hz, 1′), 7.43-7.62 (3H, m, Ar), 7.81 (1H, d, J = 8.1 Hz, 5), 7.88 (2H, d, J = 7.3 Hz, Ar). 13C NMR (75 MHz, CD3CN) δ 27.4 (CH2SC(O)Ar), 40.9 (NCH2), 62.1 (5′), 70.8 (3′), 75.6 (2′), 85.9 (4′), 91.8 (1′), 102.1 (5), 128.0, 129.9, 134.7, 138.0 (Ar), 140.3 (6), 152.4 (2), 163.9 (4), 192.4 (SC(O)Ar). IR (KBr) ν 3548, 3448, 3086, 3060, 2944, 2901, 1706, 1673, 1655, 1462, 1388, 1286, 1211, 1124, 1079, 919, 813, 779, 695, 647, 569 cm−1. MS (FAB, 3-NBA/trifluoroacetic acid) m/z 409 (M+ + 1). 5′-O-(4,4′-Dimethoxytrityl)-N3-(ethyl)uridine tert-butyl disulfide (S.2). 1H NMR (360 MHz, CD3CN) δ 1.31 (9H, s, SS(CH3)3), 2.90 (2H, t, J = 6.0 Hz, CH2SS), 3.36 (2H, m, 5′,5′′), 3.75 (6H, s, 2 OCH3), 4.02 (1H, m, 4′), 4.11 (2H, m, NCH2), 4.18 (1H, m, 2′), 4.32 (1H, m, 3′), 5.38 (1H, d, J = 8.1 Hz, 6), 5.78 (1H, d, J = 3.2 Hz, 1′), 6.85-7.44 (13H, m, Ar), 7.73 (1H, d, J = 8.1 Hz, 5). 13C NMR (90 MHz, CD3CN) δ 30.1 (SSC(CH3)3), 37.2 (CH2SS), 41.0 (NCH2), 48.5 (SSC(CH3)3), 56.0 (OCH3), 63.4 (5′), 70.5 (3′), 75.5 (2′), 83.8 (4′), 87.5 (OC(Ph)3), 91.4 (1′), 101.9 (5), 114.2 (Ar), 128.0, 129.0, 131.1, 136.5, 136.7 (Ar), 139.7 (6), 145.9 (Ar), 152.0 (2), 159.8 (Ar), 163.3 (4). IR (film; NaCl) ν 3452, 2959, 2940, 1708, 1665, 1608, 1509, 1457, 1252, 1177, 1103, 1035, 829, 810, 702 cm−1. MS (FAB, 3-NBA) m/z 695 (M+ + 1). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N3-(ethyl)uridine tert-butyl disulfide (S.3) TLC (4:1 petroleum ether/EtOAc) Rf = 0.30. 1H NMR (300 MHz, CD3CN) δ 0.12 (6H, s, Si(CH3)2), 0.90 (9H, s, SiC(CH3)3), 1.30 (9H, s, SSC(CH3)3), 2.88 (2H, t, J = 8.0 Hz, CH2HS), 3.38 (2H, 2 dd, J = 2.4, 11.0 Hz, 5′,5′′), 3.74 (6H, s, 2 OCH3), 4.05 (3H, m, 4′, NCH2), 4.24 (1H, m, 2′), 4.31 (1H, m, 3′), 5.35 (1H, d, J = 8.2 Hz, 6), 5.83 (1H, d, J = 4.0 Hz, 1′), 6.84-7.43 (13H, m, Ar), 7.74 (1H, d, J = 8.1
Hz, 5). 13C NMR (75 MHz, CD3CN) δ –4.4 (Si(CH3)2), 18.8 (SiC(CH3)3), 26.3 (SiC(CH3)3), 30.2 (SSC(CH3)3), 37.5 (CH2SS), 41.0 (NCH2), 48.4 (SSC(CH3)3), 55.9 (OCH3), 63.7 (5′), 71.2 (3′), 76.9 (2′), 84.1 (4′), 87.7 (OC(Ph)3), 90.6 (1′), 102.1 (5), 114.1 (Ar), 127.8, 128.8, 128.9, 130.9, 136.3, 136.5 (Ar), 139.3 (6), 145.6 (Ar), 151.7 (2), 159.7 (Ar), 162.8 (4). IR (film; NaCl) ν 3856, 3546, 2955, 2930, 2857, 2361, 2334, 1710, 1668, 1608, 1509, 1456, 1253, 1177, 1122, 1036, 836 cm−1. MS (FAB, 3-NBA) m/z 809 (M+ + 1). 5′-O-(4,4′-Dimethoxytrityl)-3′-O-(tert-butyldimethylsilyl)-N3-(ethyl)uridine tert-butyl disulfide (S.4) TLC (4:1 petroleum ether/EtOAc) Rf = 0.14. 1H NMR (300 MHz, CD3CN) δ 0.04, 0.05 (6H, 2 s, Si(CH3)2), 0.81 (9H, s, SiC(CH3)3), 1.30 (9H, s, SSC(CH3)3), 2.88 (1H, dd, J = 3.8, 11.1 Hz, 5′), 2.89 (2H, t, J = 7.6 Hz, CH2SS), 3.46 (1H, dd, J = 2.4, 11.0 Hz, 5′′), 3.74 (6H, s, 2 OCH3), 4.00 (1H, m, 4′), 4.10 (3H, m, 2′, NCH2), 4.33 (1H, m, 3′), 5.38 (1H, d, J = 8.1 Hz, 6), 5.80 (1H, d, J = 3.0 Hz, 1′), 6.84-7.42 (13H, m, Ar), 7.74 (1H, d, J = 8.1 Hz, 5). 13C NMR (75 MHz, CD3CN) δ –4.4, –4.1 (Si(CH3)2), 18.7 (SiC(CH3)3), 26.3 (SiC(CH3)3), 30.3 (SSC(CH3)3), 37.5 (CH2SS), 41.0 (NCH2), 48.3 (SSC(CH3)3, 56.0 (OCH3), 63.3 (5′), 72.0 (3′), 75.4 (2′), 84.1 (4′), 87.7 (OC(Ph)3), 92.0 (1′), 102.1 (5), 114.1 (Ar), 127.7, 128.7, 129.0, 131.0, 136.4 (Ar), 139.6 (6), 145.5 (Ar), 151.7 (2), 159.7 (Ar), 162.9 (4). IR (film; NaCl) ν 3869, 2955, 2929, 2858, 2364, 2334, 1710, 1670, 1509, 1456, 1252, 1176, 1116, 1035, 836 cm−1. MS (FAB, 3NBA) m/z 809 (M+ + 1). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(tert-butyldimethylsilyl)-N3-(ethyl)uridine-3′-O-(N,N-diisopropyl-β-cyanoethylphosphoramidite) tertbutyl disulfide (S.5). TLC (80:15:5 petroleum ether/EtOAc/Et3N) Rf = 0.28. 1H NMR (300 MHz, CD3CN) δ (two diastereomers) 0.09, 0.12 (6H, 2 s, Si(CH3)2), 0.83, 0.85 (9H, 2 s, SiC(CH3)3), 1.01, 1.14 (12H, d, J = 9 Hz, 2 NCH(CH3)2), 1.31 (9H, s, SSC(CH3)3), 2.45 (2H, m, OCH2CH2CN), 2.88 (2H, m, CH2SS), 3.40 (2H, m, 5′, 5′′), 3.50-3.90 (4H, m, OCH2CH2CN, 2 NCH(CH3)2), 3.75 (6H, s, 2 OCH3), 4.10 (2H, m, NCH2CH2SS), 4.20-4.42 (3H, m, 2′, 3′, 4′), 5.37, 5.39 (1H, d, J = 8.1 Hz, 6), 5.84, 5.89 (1H, d, J = 6.6 Hz, 1′), 6.83-7.46 (13H, m, Ar), 7.72, 7.77 (1H, d, J = 8.1 Hz, 5). 13C NMR (75 MHz, CD CN) δ (two dias3 tereomers) –4.2 (Si(CH3)2), 18.9 (SiC(CH3)3), 21.1 (OCH2CH2CN), 25.0, 25.1, 25.2, 25.3 (NCH(CH3)2), 26.4 (SiC(CH3)3), 30.4 (SC(CH3)3), 37.8 (CH2SS), 41.2 (NCH2
Methods for Cross-Linking Nucleic Acids
5.4.27 Current Protocols in Nucleic Acid Chemistry
Engineering Disulfide Cross-Links in RNA via Air Oxidation
CH2SS), 44.1, 44.3, 44.5, 44.6 (NCH(CH3)2), 48.5 (SSC(CH3)3), 56.2 (OCH3), 59.4, 60.0 (POCH2CH2CN), 64.0, 64.2 (5′), 73.5, 73.7 (3′), 76.1, 76.5 (2′), 83.9, 84.0 (4′), 88.1 (OC(Ph)3), 90.3, 90.4 (1′), 102.4, 102.5 (5), 114.4 (Ar), 128.1, 129.0, 129.2, 129.3, 131.2, 136.4, 136.5, 136.6 (Ar), 139.3, 139.4 (6), 145.7, 145.8 (Ar), 152.1 (2), 160.0 (Ar), 162.9, 163.0 (4). 31P NMR (202 MHz, CD3CN) δ (two diastereomers) 147.4, 146.8. IR (KBr) ν 2965, 2931, 2859, 2254, 1712, 1671, 1611, 1509, 1456, 1391, 1365, 1253, 1179, 1037, 979, 836 cm−1. MS (FAB, 3-NBA) m/z 1009.5 (M+ + 1). Anal. Calcd for C51H73N4O9PS2Si: C, 60.70; H, 7.28; N, 5.55. Found: C, 60.77; H, 7.24; N, 5.47. 5′-O-(4,4′-Dimethoxytrityl)-3′-O-(tert-butyldimethylsilyl)-2′-O-pentachlorophenylsuccinate N3-(ethyl)uridine tert-butyl disulfide (S.6). TLC (4:1 petroleum ether/EtOAc) Rf = 0.68. 1H NMR (360 MHz, CD3CN) δ –0.07, 0.01 (6H, s, Si(CH3)2), 0.79 (9H, s, SiC(CH3)3), 1.29 (9H, s, SSC(CH3)3), 2.79 (4H, m, succinate CH2), 3.03 (2H, m, CH2SS), 3.29-3.47 (2H, m, 5′, 5′′), 3.76 (6H, s, 2 OCH3), 3.96-4.12 (3H, m, 4′, NCH2), 4.38 (1H, m, 3′), 5.43 (2H, m, 6, 2′), 5.97 (1H, d, J = 4.8 Hz, 1′), 6.21-7.45 (13H, m, Ar), 7.65 (1H, d, J = 8.1 Hz, 5). 13C NMR (90 MHz, CD3CN) δ –4.4, –4.1 (Si(CH3)2), 18.6 (SiC(CH3)3), 26.1 (SiC(CH3)3), 29.4, 29.5 (succinate CH2), 30.2 (SSC(CH3)3), 37.0 (CH2SS), 41.1 (NCH2CH2SS), 48.5 (SSC(CH3)3), 56.0 (OCH3), 63.6 (5′), 71.4 (3′), 76.1 (2′), 85.3 (4′), 88.0 (OC(Ph)3), 88.7 (1′), 102.5 (5), 114.2 (Ar), 128.1, 129.0, 129.1, 131.2, 136.4 (Ar), 139.4 (6), 145.7 (Ar), 152.0 (2), 159.9 (Ar), 163.1 (4), 169.6, 171.8 (succinate CO2). IR (film; NaCl) ν 2956, 2931, 1786, 1751, 1713, 1672, 1608, 1509, 1455, 1390, 1363, 1253, 1229, 1177, 1154, 1107, 1036, 837 cm−1. MS (FAB, 3-NBA) m/z 1173 (M+ + 1). Anal. Calcd for C52H59N2O11S2SiCl5: C, 53.96; H, 5.10; N, 2.42. Found C, 54.03; H, 5.15; N, 2.40. 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)uridine (S.8). TLC (1:1 petroleum ether/ EtOAc) Rf 0.28; 1H NMR (300 MHz, CDCl3) δ 1.03-1.11 (28H, m, isopropyl), 3.56-4.40 (5H, m, 2′,3′,4′,5′,5′′), 5.70 (1H, dd, 5), 5.74 (1H, s, 1′), 7.71 (1H, d, 6), 8.83 (1H, s, NH); 13C NMR (90 MHz, CDCl ) δ 12.63-13.55 3 (isopropyl CHs), 16.98-17.65 (isopropyl CH3s), 60.29 (5′), 68.85 (3′), 75.32 (2′), 82.05 (4′), 91.15 (1′), 102.18 (5), 140.10 (6), 150.48 (2), 163.84 (4); IR (KBr pellet) ν 3434, 3200, 3063, 2946, 2868, 1703, 1465, 1388, 1270, 1211, 1123, 1091, 1060, 1038, 993, 907, 885,
861, 809, 774, 705, 553 cm−1; MS (CI, CH4) m/z 487 (MH+). 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)O4-(2-nitrophenyl) uridine (S.9). TLC (1:1 petroleum ether/EtOAc) Rf 0.27; 1H NMR (300 MHz, CDCl3) δ 1.00-1.11 (28H, m, isopropyl), 3.99-4.37 (5H, m, 2′,3′,4′,5′,5′′), 5.74 (1H, s, 1′), 6.21 (1H, d, 5), 7.32 (1H, d, Ar), 7.41 (1H, ddd, Ar), 7.67 (1H, ddd, Ar), 8.13 (1H, dd, Ar), 8.23 (1H, d, 6); 13C NMR (75 MHz, CDCl3) δ 12.89-13.70 (isopropyl CHs), 17.14-17.71 (isopropyl CH3s), 60.71 (5′), 69.28 (3′), 75.29 (2′), 82.34 (4′), 92.46 (1′), 94.78 (5), 125.76, 126.14, 126.81, 134.88, 141.90, 145.08 (Ar), 145.19 (6), 154.68 (2), 171.10 (4). 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)2′-O-allyl-O4-(2-nitrophenyl) uridine (S.10). TLC (1:1 petroleum ether/EtOAc) Rf 0.68. 1H NMR (300 MHz, CDCl3) δ 1.00-1.12 (28H, m, isopropyl), 3.93-4.44 (7H, m, 2′,3,4′,5′,5′′, allyl CH2), 5.16 (1H, ddd, =CH2a), 5.39 (1H, m, =CH2b), 5.76 (1H, s, 1′), 5.92 (1H, m, CH=), 6.19 (1H, d, 5), 7.33 (1H, dd,Ar), 7.41 (1H, ddd, Ar), 7.67 (1H, ddd, Ar), 8.13 (1H, dd, Ar), 8.38 (1H, d, 6); 13C NMR (75 MHz, CDCl3) δ 12.92-13.79 (isopropyl CHs), 17.16-17.79 (isopropyl CH3s), 59.85 (5′), 68.04 (3′), 71.51 (OCH2), 81.02 (2′), 82.16 (4′), 90.46 (1′), 94.50 (5), 117.29 (=CH2), 125.80, 126.13, 126.76, 134.73 (Ar), 134.82 (CH=), 142.00 (Ar), 144.77 (6), 145.26 (Ar) 154.72 (2), 171.06 (4); IR (KBr pellet) ν 3105, 2947, 2869, 1683, 1633, 1603,1549, 1531, 1454, 1365, 1351, 1288, 1220, 1166, 1126, 1073, 1041, 1014, 991, 886, 858, 780, 698 cm−1; MS (CI, CH4) m/z 648 (M+). 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)N4-(benzoyl)-2′-O-allyl cytidine (S.11). TLC (2:3 EtOAc/petroleum ether) Rf = 0.32. 1H NMR (300 MHz, CDCl3) δ 0.96-1.11 (28H, m, 4 (CH3)2HSi, 4 (CH3)2HSi), 3.95-4.02 (2H, m, 2′-H, 5′-Ha), 4.16 (1H, dd, J = 4.1, 9.6 Hz, 3′-H), 4.24-4.32 (2H, m, 4′-H, 5′-Hb), 4.39-4.52 (2H, m, 7-Ha,b), 5.19 (1H, d, J = 10.5 Hz, 9-Htrans), 5.42 (1H, d, J = 16.0 Hz, 9-Hcis), 5.84 (1H, s, 1′-H), 5.87-6.00 (1H, m, 8-H), 7.47-7.62 (4H, m, 5-H, ArH), 7.90-7.92 (2H, m, ArH), 8.39 (1H, d, J = 7.5 Hz, 6-H). 13C NMR (75 MHz, CDCl3) δ 12.6, 13.0, 13.2, 13.5 ((CH3)2)CHSi), 16.9, 17.0, 17.1, 17.4, 17.5 ((CH3)2)CHSi), 59.5 (5′), 67.8 (3′), 71.3 (7), 80.8 (2′), 81.9 (4′), 90.1 (1′), 96.1 (5), 117.2 (9), 127.5, 128.9 (Ar.), 133.0 (8, Ar.), 134.4 (6), 144.4 (2), 162.2 (4). IR (film; NaCl) ν 2946, 2868, 1699, 1667, 1620, 1553, 1488, 1264, 1126, 1040, 886 cm−1. FAB MS (3-NBA) m/z 630 (M+ + 1).
5.4.28 Current Protocols in Nucleic Acid Chemistry
3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)2′-O-(2,3-dihydroxypropyl)cytidine (S.12). TLC (19:1 CH2Cl2/CH3OH) Rf = 0.23; 1H NMR (360 MHz, CDCl3) δ (two diastereomers) 0.98-1.11 (28H, m, 4 (CH3)2)CHSi, 4 (CH3)2)CHSi), 3.66 (1H, dd, J = 5.2, 10.7 Hz, CH(OH)CH2aOH), 3.72-3.76 (2H, m, CH2CH(OH)CH2, CH(OH)CH2bOH), 3.884.06 (4H, m, 2′, 5′, OCH2CH(OH)), 4.15-4.28 (2H, m, 3′, 4′), 4.30 (1H, d, J = 13.5 Hz, 5′′), 5.83 (1H, s, 1′), 7.49-7.63 (4H, m, 5, Ar), 7.90-7.92 (2H, m, Ar), 8.31-8.34 (1H, m, 6), 8.94 (1H, br s, NH). 13C NMR (90 MHz, CDCl3) δ (two diastereomers) 12.5, 12.6, 12.9, 13.0 ((CH 3) 2CHSi), 16.8, 16.9, 17.0, 17.3, 17.4, 17.4, 17.6 ((CH2CHSi), 59.2 (5′), 63.6, 63.9 (CH(OH)CH2OH), 67.8 (3′), 70.4, 70.5 (OCH 2CH(OH)), 73.4, 74.3 (CH3)2CH(OH)CH2), 82.0 (2′), 83.1, 83.3 (4′), 89.9, 90.2 (1′), 96.3 (5), 127.6, 129.0, 132.8 (Ar), 133.3 (6), 144.3 (2), 162.5 (4). IR (film; NaCl) ν 3367, 2946, 2868, 1700, 1655, 1617, 1486, 1257, 1126, 1040, 886, 704 cm −1. MS (FAB, 3-NBA) m/z 664 (M + + 1). 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)N4-(benzoyl)-2′-O-(ethanal)cytidine (S.13). TLC (37:3 CH2Cl2/CH3OH) Rf = 0.50; 1H NMR (360 MHz, CDCl3) δ 0.98-1.11 (28H, m, 4 (CH3)2CHSi, 4 (CH3)2CHSi), 3.98-4.07 (2H, m, 2′, 5′), 4.18-4.31 (3H, m, 3′, 4′ ,5′′), 4.474.59 (2H, m, OCH2CHO), 5.86 (1H, s, 1′), 7.49-7.63 (4H, m, 5, Ar), 7.89-7.91 (2H, m, Ar), 8.37 (1H, d, J = 7.5 Hz, 6), 8.81 (1H, br s, NH), 9.81 (1H, s, CH2CHO). 13C NMR (90 MHz, CDCl3) δ 12.3, 12.9, 13.0, 13.4 ((CH3)2CHSi), 16.7, 16.9, 17.3, 17.4 ((CH3)2CHSi), 59.2 (5′), 68.1 (3′), 76.2 (OCH2CHO), 81.8 (2′), 83.0 (4′), 89.7 (1′), 96.2 (5), 127.5, 129.0, 132.8 (Ar), 133.2 (6), 144.3 (2), 162.4 (4), 200.7 (CH2CHO). IR (film; NaCl) ν 2946, 2868, 1700, 1667, 1619, 1484, 1253, 1130, 1064, 1040, 886, 703 cm−1. MS (FAB, 3-NBA) m/z 632 (M+ + 1). 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)N 4-(benzoyl)-2′-O-(2-hydroxyethyl)cytidine (S.14). TLC (37:3 CH2Cl2/CH3OH) Rf = 0.56. 1HNMR (360 MHz, CDCl ) δ 0.99-1.10 (28H, 3 m, 4 (CH3)2CHSi, 4 (CH3)2CHSi), 3.17 (1H, br s, CH2CH2OH), 3.72-3.77 (2H, m, CH2CH2OH), 3.93-4.03 (4H, m, 2′, 5′, OCH2CH2OH), 4.15-4.25 (2H, m, 3′, 4′), 4.30 (1H, d, J = 13.6 Hz, 5′′), 5.83 (1H, s, 1′), 7.49-7.63 (4H, m, 5, Ar), 7.89-7.92 (2H, m, Ar), 8.35 (1H, d, J = 7.5 Hz, 6), 8.92 (1H, br s, NH). 13C NMR (90 MHz, CDCl3) δ 12.6, 12.9, 13.0, 13.4 ((CH3)2CHSi), 16.8, 16.9,
17.0, 17.3, 17.4, 17.4 ((CH3)2CHSi), 59.3 (5′), 61.7 (CH2CH2OH), 68.0 (3′) , 7 3 .1 (OCH2CH2OH), 82.0 (2′), 82.3 (4′), 90.5 (1′), 96.2 (5), 127.5, 129.0, 132.9 (Ar), 133.2 (6), 144.3 (2), 162.4 (4). IR (film; NaCl) ν 2946, 2868, 1699, 1664, 1619, 1485, 1263, 1128, 1074, 1063, 1040, 886, 703 cm−1. MS (FAB, 3-NBA) m/z 634 (M+ + 1). 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)N4-(benzoyl)-2′-O-(ethyl-2-methylsul- fonate)cytidine (S.15). TLC (19:1 CH2Cl2/ CH3OH) Rf = 0.35. 1H NMR (360 MHz, CDCl3) δ 0.97-1.11 (28H, m, 4 (CH3)2CHSi, 4 (CH3)2CHSi), 3.14 (3H, s, CH3SO2), 3.97-4.01 (2H, m, 2′, 5′), 4.17-4.21 (4H, m, 3′, 4′, OCH2HH2OSO2), 4.30 (1H, d, J = 13.7 Hz, 5′′), 4.46-4.49 (2H, m, CH2CH2OSO2), 5.82 (1H, s, 1′), 7.50-7.62 (4H, m, 5, Ar), 7.89-7.92 (2H, m, Ar), 8.38 (1H, d, J = 7.5 Hz, 6). 13C NMR (90 MHz, CDCl3) δ 12.4, 12.9, 13.1, 13.4 ((CH3)2CHSi), 16.8, 16.9, 17.1, 17.3, 17.4, 17.4 ((CH3)2CHSi), 37.80 (CH3SO2), 59.3 (5′), 67.9 (3′), 69.0 (CH2CH2OSO2), 69.5 (OCH2 CH2OSO2), 81.9 (2′), 82.4 (4′), 89.5 (1′), 96.2 (5), 127.6, 129.1, 132.8 (Ar), 133.3 (6), 144.5 (2), 162.4 (4). IR (film; NaCl) ν 2945, 2868, 1664, 1484, 1170, 1128, 1074, 1063, 1040, 885, 704 cm−1 MS (FAB, 3-NBA) m/z 712 (M+ + 1). 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)N4-(benzoyl)-2′-O-(thiobenzoylethyl) cytidine (S.16). TLC (6:3:1 petroleum ether/EtOAc/CH3CN) Rf = 0.57. 1H NMR (360 MHz, CDCl3) δ 0.98-1.11 (28H, m, 4 (CH3)2CHSi, 4 (CH3)2CHSi), 3.35-3.43 (2H, m, CH2CH2SBz), 3.97-4.02 (2H, m, 2′, 5′), 4.09-4.13 (2H, m, OCH2CH2SBz), 4.18 (1H, dd, J = 3.9, 9.6 Hz, 3′), 4.25 (1H, dd, J = 2.0, 9.6 Hz, 4′), 4.30 (1H, d, J = 13.5 Hz, 5′′), 5.84 (1H, s, 1′), 7.40-7.62 (7H, m, 5, Ar), 7.91-7.99 (4H, m, Ar), 8.37 (1H, d, J = 7.4 Hz, 6), 8.97 (1H, br s, NH). 13C NMR (90 MHz, CDCl3) δ 12.5, 12.8, 13.1, 13.4 ((CH3)2CHSi), 16.8, 16.9, 17.1, 17.3, 17.4, 17.5 ((CH3)2CHSi), 29.1 (CH2CH2SBz), 59.4 (5′), 67.9 (3′), 69.9 (OCH2CH2SBz), 81.8 (2′), 81.9 (4′), 90.0 (1′), 96.0 (5), 127.2, 127.6, 128.5, 129.0, 133.0 (Ar), 133.2 (6), 137.1 (Ar), 144.6 (2), 162.3 (4), 191.5 (Ar). IR (film; NaCl) ν 2945, 2868, 1699, 1667, 1620, 1489, 1373, 1265, 1126, 1075, 1063, 1040, 691 cm−1. EI MS m/z 754 (M+ + 1). N4-(Benzoyl)-2′-O-(thiobenzoylethyl)cytidine (S.17). TLC (19:1 CH2Cl2/CH3OH) Rf = 0.21. 1H NMR (360 MHz, CDCl ) δ 3.25-3.42 (2H, 3 m, CH2SBz), 3.91-3.96 (2H, m, 2′, 5′), 4.054.19 (3H, m, 5′′, OCH2CH2SBz), 4.20-4.25
Methods for Cross-Linking Nucleic Acids
5.4.29 Current Protocols in Nucleic Acid Chemistry
Engineering Disulfide Cross-Links in RNA via Air Oxidation
(1H, m, 4′), 4.35-4.37 (1H, m, 3′), 5.87 (1H, s, 1′), 7.33-7.54 (7H, m, 5, Ar), 7.82-7.94 (4H, m, Ar), 8.57 (1H, d, J = 7.5 Hz, 6), 9.22 (1H, br s, NH). 13C NMR (90 MHz, CDCl3) δ 28.8 (CH2SBz), 59.8 (5′), 67.4 (3′), 69.4 (OCH2CH2SBz), 82.0 (2′), 84.6 (4′), 90.1 (1′), 96.7 (5), 126.8, 127.2, 127.6, 128.3, 128.6, 128.8, 132.9, 133.1 (Ar), 133.5 (6), 136.7 (Ar), 146.0 (2), 162.6 (4), 191.4 (Ar). IR (film; NaCl) ν 3345, 2928, 1699, 1658, 1617, 1558, 1485, 1379, 1258, 1111, 1067, 913, 705, 689 cm−1. MS (FAB, 3-NBA) m/z 512 (M+ + 1). N4-(Benzoyl)-2′-O-(ethyl)cytidine tert-butyl disulfide (S.18). TLC (24:1 CH2Cl2/ CH3OH) Rf = 0.29; 1H NMR (360 MHz, CDCl3) δ 1.32 (9H, s, C(CH3)3), 2.93 (2H, t, J = 5.8 Hz, CH2SS), 3.93-3.99 (2H, m, 2′, 5′), 4.09-4.18 (3H, m, 5′′, OCH2CH2SS), 4.24-4.30 (1H, m, 4′), 4.33-4.41 (1H, m, 3′), 5.84 (1H, d, J = 1.7 Hz, 1′), 7.48-7.62 (4H, m, 5, Ar), 7.87-7.89 (2H, m, Ar), 8.48 (1H, d, J = 7.5 Hz, 6), 9.01 (1H, br s, NH). 13C NMR (90 MHz, CDCl3) δ 29.8 (C(CH3)3), 40.3 (CH2SS), 48.0 (C(CH3)3), 60.3 (5′), 67.8 (3′), 69.0 (OCH2CH2SS), 81.7 (2′), 85.0 (4′), 90.9 (1′), 96.7 (5), 127.6, 129.0, 132.9 (Ar), 133.3 (6), 146.4 (2), 162.5 (4). IR (film; NaCl) ν 3374, 2960, 2922, 1699, 1648, 1617, 1558, 1487, 1379, 1260, 1110 cm−1. FAB MS (3-NBA) m/z 496 (M+ + 1). 5′-O-(4, 4′-Dimethoxytrityl)-N4)-benzoyl)2′-O-(ethyl)cytidine tert-butyl disulfide (S.19). TLC (1:1 acetone/petroleum ether) Rf = 0.23; 1H NMR (360 MHz, CD CN) δ 1.30 (9H, s, 3 C(CH3)3), 2.95 (2H, t, J = 6.3 Hz, CH2SS), 3.39-3.44 (2H, m, OCH2CH2SS), 3.76 (6H, s, 2 OCH3), 3.90-4.03 (3H, m, 2′, 5′, 5′′), 4.124.19 (1H, m, 4′), 4.39-4.47 (1H, m, 3′), 5.84 (1H, d, J = 1.7 Hz, 1′), 6.87-6.89 (4H, m, Ar), 7.15-7.61 (13H, m, 5, Ar), 7.92-7.95 (2H, m, Ar), 8.46 (1H, d, J = 7.6 Hz, 6). 13C NMR (90 MHz, CD3CN) δ 30.2 (C(CH3)3), 41.0 (CH2SS), 48.5 (C(CH3)3), 56.0 (OCH3), 62.1 (5′), 68.9 (3′), 70.1 (OCH2CH2SS), 83.3 (2′), 83.6 (4′), 87.7 (OC(Ph)3), 90.2 (1′), 97.2 (5), 114.3, 128.1, 129.1, 129.1, 129.2, 129.7, 131.0, 131.2, (Ar), 133.9 (6), 134.5, 136.6, 137.0, 145.5 (Ar), 145.9 (2), 155.7, 159.8 (Ar), 163.9 (4), 168.2 (Ar). IR (KBr) ν 3392, 2959, 2924, 1700, 1667, 1610, 1553, 1510, 1482, 1377, 1252, 1113, 1033, 704 cm−1. MS (FAB, 3NBA) m/z 798 (M+ + 1). 5′-O-(4, 4′-Dimethoxytrityl)-N4)-benzoyl)2′-O-(ethyl)cytidine tert-butyl disulfide 3′-O(N,N-diisopropyl β cyanoethylphosphoramidite) (S.20). TLC (2:1 petroleum ether/acetone) Rf = 0.40; 1H NMR (300 MHz,
CD3CN) δ (two diastereomers) 1.05-1.20 (12H, m, 2 NCH(CH3)2), 1.30 (9H, s, C(CH3)3), 2.50-2.67 (2H, m, OCH2CH2CN), 2.94-3.01 (2H, m, CH2SS), 3.41-3.71 (6H, m, OCH2CH2SS, OCH2CH2CN, 2 NCH(CH3)2), 3.79 (6H, s, 2 OCH3), 3.80-4.22 (4H, m, 2′, 4′, 5′, 5′′), 4.43-4.63 (1H, m, 3), 5.88 (1H, s, 1′), 6.87-6.92 (4H, m, Ar), 7.03-7.66 (13H, m, 5, Ar), 7.91-7.97 (2H, m, Ar), 8.42-8.55 (1H, 2 d, J = 7.6 Hz, 6). 13C NMR (75 MHz, CD3CN) δ (two diastereomers) 21.2, 21.3 (OCH2 CH2CN), 24.9, 25.0, 25.2, 25.3 (NCH(CH3)2), 30.3 (C(CH3)3), 41.4 (CH2SS), 44.1, 44.3 (NCH(CH3)2), 48.5 (C(CH3)3), 56.0 (OCH3), 59.3, 59.6 (OCH2CH2CN), 61.8, 62.2 (5′), 70.2, 70.4 (3′), 70.8 (OCH2CH2SS), 82.2 (2′), 83.1 (4′), 87.8 (OC(Ph)3), 90.8, 91.1 (1′), 97.3 (5), 114.2, 128.1, 129.0, 129.0, 129.3, 129.6, 131.2 (Ar), 133.8 (6), 134.5, 136.6, 136.7, 145.4 (Ar), 145.6 (2), 155.4, 159.8 (Ar), 163.6 (4). 31P NMR (202 MHz; CD3CN) δ 147.57, 146.51. IR (film; NaCl) ν 2967, 2934, 1708, 1686, 1509, 1510, 1462, 1251, 1180, 1035, 979 cm−1. MS (FAB, 3-NBA) m/z 998 (M+ + 1). Anal. Calcd for C52H64N5O9PS2: C, 62.56; H, 6.48; N, 7.02. Found: C, 62.41; H, 6.41; N, 6.92. 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)2′-O-allyluridine (S.21). TLC (1:1 petroleum ether/EtOAc) Rf 0.59; 1H NMR (360 MHz, CDCl3) δ 1.01-1.11 (28H, m, isopropyl), 3.88 (1H, m, 4′), 3.98 (1H, dd, OCH2a), 4.18 (2H, m, 2′,3′), 4.26 (1H, dd, OCH2b), 4.39 (2H, m, 5′,5′′), 5.21 (1H, ddd, =CH2a), 5.40 (1H, ddd, =CH2b), 5.68 (1H, dd, 5), 5.76 (1H, s, 1′), 5.93 (1H, m, CH=), 7.93 (1H, d, 6), 9.14 (1H, s, NH); 13C NMR (90 MHz, CDCl ) δ 12.68-13.63 3 (isopropyl CHs), 17.00-17.70 (isopropyl CH3s), 59.62 (5′), 68.25 (3′), 71.46 (OCH2), 81.27 (2′), 82.00 (4′), 89.29 (1′), 101.69 (5), 117.59 (=CH2), 134.51 (CH=), 139.77 (6), 150.06 (2), 163.61 (4); MS (DCI, CH4) m/z 527 (M+). 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)2′-O-(2,3-dihydroxypropyl)uridine (S.22). TLC (51:4 CH2Cl2/CH3OH) Rf = 0.22; 1H NMR (360 MHz, CDCl3) δ 1.02-1.10 (28H, m, 4 SiCH(CH3)2), 3.65-3.75 (3H, m, CH2CH(OH)CH2OH, CH2CH(OH)CH2OH), 3.86-4.04 (4H, m, 2′, 5′′, CH2CH(OH) CH2OH), 4.12-4.17 (2H, m, 3′, 4′), 4.25 (1H, d, J = 13.6 Hz, 5′), 5.71 (1H, dd, J = 1.4, 8.1 Hz, 5), 5.74 (1H, d, J = 1.6 Hz, 1′), 7.88 (1H, dd, J = 1.9, 8.1 Hz, 6). 13C NMR (75 MHz, CDCl3) δ 13.07-13.90 (SiCH(CH3)2), 17.1817.82 (SiCH(CH3)2), 59.66 (5′), 68.58 (3′), 70.94 (CH2CH(OH)CH2OH), 74.20 (CH2CH (OH)CH2OH), 82.22 (4′), 83.99 (CH2CH
5.4.30 Current Protocols in Nucleic Acid Chemistry
(OH)CH2OH), 89.43 (1′), 89.67 (2′), 102.33 (5), 139.24 (6), 150.82 (2), 163.33 (4). IR (Nujol) ν 3424, 3160, 3092, 2951, 2946, 2935, 2925, 2918, 2909, 2896, 2891, 2873, 2867, 2863, 2856, 2850, 2726, 1693, 1685, 1462, 1378, 1272, 1163, 1125, 1062, 1035, 1010, 991, 884, 703 cm−1. 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)2′-O-(ethanal)uridine (S.23) TLC (51:5 CH2Cl2/CH3OH) Rf = 0.48; 1H NMR (300 MHz, CDCl3) δ 1.03-1.12 (28 H, m, 4 SiCH(CH3)2), 3.71 (2 H, s, OCH2CHO), 3.954.01 (2 H, m, 2′, 5′′), 4.23-4.30 (2 H, m, 3′,4′), 4.45-4.47 (1 H, m, 5′ ), 5.70 (1 H, dd, J = 2.2, 8.1 Hz, 5), 5.78 (1 H, s, 1′), 7.90 (1 H, d, J = 8.1 Hz, 6), 8.93 (1 H, s, NH). 13C NMR (75 MHz, CDCl3) δ 12.87-13.82 (SiCH(CH3)2), 17.11-17.78 (SiCH(CH3)2), 59.64 (5′), 68.95 (3′), 76.62 (OCH2CHO), 82.00 (4′), 83.85 (2′), 89.32 (1′), 102.03 (5), 139.41 (6), 150.18 (2), 163.21 (4), 200.35 (OCH2CHO). IR (KBr) ν 3482, 2947, 2868, 1700, 1685, 1464, 1386, 1272, 1256, 1166, 1131, 1096, 1063, 1056, 1038, 1012, 991, 886, 704 cm−1. 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)2′-O-(2-hydroxyethyl)uridine (S.24). TLC (6:3:1 petroleum ether/EtOAc/CH3CN) Rf = 0.34; 1H NMR (360 MHz, CDCl3) δ 1.01-1.10 (28H, m, 4 SiCH(CH3)2), 3.74-3.76 (2H, m, CH2CH2OH), 3.92-4.00 (4H, m, 2′, 5′, CH2CH2OH), 4.17 (2H, m, 3′, 4′), 4.26 (1H, d, J = 13.7 Hz, 5′), 5.70 (1H, d, J = 8.1 Hz, 5), 5.75 (1H, s, 1′), 7.90 (1H, d, J = 8.1 Hz, 6), 9.96 (1H, s, NH). 13C NMR (90 MHz, CDCl3) δ 12.73-13.62 (SiCH(CH3)2), 16.97-17.65 (SiCH(CH3)2), 59.46 (5′), 61.78 (OCH2 CH2OH), 68.37 (3′), 73.20 (OCH2CH2OH), 81.99 (4′), 83.04 (2′), 89.62 (1′), 101.99 (5), 139.38 (6), 150.58 (2), 163.80 (4). IR (KBr) ν 2946, 2869, 1701, 1464, 1387, 1271, 1165, 1129, 1094, 1062, 1039, 992, 885, 705 cm−1. MS (CI, CH4) m/z 531 (M+). 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)2′-O-(ethyl-2-methylsulfonate)uridine (S.25) TLC (17:3 CH2Cl2/acetone) Rf = 0.48; 1H NMR (360 MHz, CDCl3) δ 1.03-1.12 (28H, m, 4 SiCH(CH3)2), 3.12 (3H, s, SCH3), 3.89 (1H, d, J = 4.1 Hz, 2′), 3.97 (1H, dd, J = 2.2, 13.6 Hz, 5′), 4.10-4.15 (3H, m, 4′, OCH2CH2S), 4.204.23 (1H, m, 3′), 4.26 (1H, d, J = 13.6 Hz, 5′′), 4.44-4.46 (2H, m, OCH2CH2S), 5.70 (1H, dd, J = 2.1, 8.2 Hz, 5), 5.73 (1H, s, 1′), 7.91 (1H, d, J = 8.2 Hz, 6), 8.95 (1H, s, NH). 13C NMR δ 12.85-13.74 (75 M Hz, CDCl3) (SiCH(CH3)2), 17.07-17.73 (SiCH(CH3)2), 38.00 (SCH3), 59.59 (5′), 68.63 (3′), 69.29 (OCH2CH2OMs), 69.44 (OCH2CH2OMs),
81.93 (4′), 83.27 (2′), 88.96 (1′), 101.97 (5), 139.38 (6), 150.33 (2), 163.60 (4). IR (KBr) ν 3213, 3065, 2947, 2869, 1699, 1465, 1355, 1272, 1179, 1129, 1095, 1065, 1040, 993, 885, 705 cm−1. 3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)2′-O-(thiobenzoylethyl)uridine (S.26). TLC (4:1 CH2Cl2/acetone) Rf = 0.68; 1H NMR (360 MHz, CDCl3) δ 1.00-1.10 (28H, m, 4 SiCH(CH3)2), 3.36 (2H, m, OCH2CH2S), 3.91 (1H, d, J = 3.3 Hz, 2′), 3.99 (1H, dd, J = 1.5, 13.6 Hz, 5′), 4.02-4.06 (2H, m, OCH2CH2S), 4.18 (2H, m, 3′, 4′), 4.25 (1H, d, J = 13.6 Hz, 5′′), 5.68 (1H, dd, J = 1.7, 8.2 Hz, 5), 5.73 (1H, s, 1′), 7.44 (2H, m, Ar), 7.56 (1H, m, Ar), 7.90 (1H, d, J = 8.2 Hz, 6), 7.96 (1H, m, Ar), 9.47 (1H, s, NH). 13C NMR (90 MHz, CDCl3) δ 12.71-13.62 (SiCH(CH3)2), 17.00-17.70 (SiCH(CH3)2), 29.16 (OCH2CH2S), 59.57 (5′), 68.45 (3′), 70.12 (OCH2CH2S), 81.88 (4′), 82.60 (2′), 89.34 (1′), 101.71 (5), 127.45, 128.74, 133.53, 137.18 (Ar), 139.73 (6), 150.14 (2), 163.92 (4), 191.67 (CO). IR (KBr) ν 3205, 3058, 2945, 2868, 1699, 1463, 1387, 1271, 1207, 1164, 1126, 1093, 1064, 1040, 914, 885, 705, 690 cm−1. 2′-O-(Thiobenzoylethyl)uridine (S.27). TLC (9:1 CH2Cl2/CH3OH) Rf = 0.14; 1H NMR (360 MHz, CD3OD) δ 3.27-3.38 (2H, m, OCH2CH2S), 3.75 (1H, dd, J = 3.0, 12.4 Hz, 5′), 3.82-3.96 (2H, m, 2′, 5′′), 3.99-4.02 (1H, m, 4′), 4.05-4.09 (2H, m, OCH2CH2S), 4.24 (1H, m, 3′), 5.67 (1H, d, J = 8.1 Hz, 5), 5.95 (1H, d, J = 3.7 Hz, 1′), 7.49 (2H, m, ArH), 7.62 (1H, m, ArH), 7.93 (2H, m, ArH), 8.06 (1H, d, J = 8.1 Hz, 6). 13C NMR (90 MHz, CD3OD) δ 29.70 (ΟΧΗ2CH2S), 61.77 (5′), 70.01 (3′), 70.65 (OCH2CH2S), 83.80 (4′), 86.26 (2′), 89.31 (1′), 102.74 (5), 128.27, 130.04, 134.94, 138.30 (Ar), 142.58 (6), 152.35 (2), 166.36 (4), 193.18 (CO). IR (KBr) ν 3473, 3422, 3168, 3107, 3051, 2954, 2916, 2874, 2860, 2572, 2540, 1693, 1672, 1647, 1615, 1446, 1388, 1267, 1209, 1143, 1111, 1098, 915, 770, 687 cm−1. MS (CI, CH4) m/z 409 (M+ + 1). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(thiobenzoylethyl)uridine (S.28). TLC (19:1 CH2Cl2/CH3OH) Rf = 0.59. 1H NMR (360 MHz, CD3CN) δ 3.30-3.41 (5H, m, 2′, 5′, 5′′, OCH2CH2S), 3.75 (6H, s, 2 OCH3), 3.87-3.99 (3H, m, 4′, OCH2CH2S) 4.01-4.04 (1H, m, 3′), 5.24 (1H, d, J = 8.2 Hz, 5), 5.83 (1H, d, J = 1.7 Hz, 1′), 6.87 (4H, m, ArH), 7.21-7.33 (9H, m, ArH), 7.41-7.52 (5H, m, ArH), 7.61-7.66 (1H, m, ArH), 7.74 (1H, d, J = 8.2 Hz, 6), 7.93-7.96 (4H, m, ArH). 13C NMR (90 MHz, CD3CN) δ
Methods for Cross-Linking Nucleic Acids
5.4.31 Current Protocols in Nucleic Acid Chemistry
Engineering Disulfide Cross-Links in RNA via Air Oxidation
17.03 (OCH2CH2S), 56.02 (OCH3), 63.11 (5′), 69.86 (3′), 70.28 (OCH2CH2S), 83.21 (2′), 84.04 (4′), 87.65 (OC(Ph)3), 88.68 (1′), 102.55 (5), 114.24 (Ar), 128.06, 129.02, 129.14, 129,98, 131.17, 131.64, 134.81, 136.49, 136.73, 137.89 (Ar), 141.17 (6), 145.87 (Ar), 151.41 (2), 159.86 (Ar), 161.07 (4), 192.35 (SC(O)Ph). MS (CI, CH4) m/z 710 (M+). 5′-O-(4,4′-Dimethoxytrityl)-2′-O-(ethyl)uridine tert-butyl disulfide (S.29) TLC (49:1 CH2Cl2/CH3OH) Rf = 0.12; 1H NMR (360 MHz, acetone-d6) δ 1.32 (9H, s, C(CH3)3) 3.00 (2H, t, J = 6.5 Hz, OCH2CH2S), 3.48 (2H, m, 5′, 5′′), 3.80 (6 H, s, OCH3), 3.94-4.07 (4H, m, 2′, 3′, OCH2CH2S), 4.15-4.17 (1H, m 4′), 5.29 (1H, d, J = 8.1 Hz, 5), 5.94 (1H, d, J = 2.5 Hz, 1′), 6.90-6.93 (4H, m, ArH), 7.32-7.37 (7H, m, ArH), 7.47-7.50 (2H, m, ArH), 7.92 (1H, d, J = 8.1 Hz, 6). 13C NMR (90 MHz, acetone-d6) δ 29.28-30.56 (acetone, C(CH3)3), 40.79 (OCH2CH2S), 48.32 (C (CH3)3), 55.61 (OCH3), 63.15 (5′), 69.94 (3′), 70.16 (OCH2CH2S), 83.30 (2′), 84.03 (4′), 87.58 (Ar), 88.75 (1′), 102.41 (5), 114.09, 127.83, 128.82, 129.13, 131.14, 136.37, 136.67 (Ar), 140.88 (6), 145.93 (Ar), 151.29 (2), 159.80 (Ar), 163.58 (4). MS (FAB, 3-NBA) m/z 695 (M+ + 1). 3′-O-(N,N-Diisopropyl-β-cyanoethylphosphoramidite)-5′-O-(4,4′-dimethoxytrityl)-2O-(ethyl)uridine tert-butyl disulfide (S.30). TLC (2:1 petroleum ether/acetone) Rf = 0.34; 1H NMR (360 MHz, CD CN) δ (two dias3 tereomers) 1.04-1.06 (4H, m, 2 NCH(CH3)2), 1.14-1.18 (12H, m, 2 NCH(CH3)2), 1.30, 1.31 (9H, 2 s, SSC(CH3)3), 2.51-2.69 (2H, m, OCH2CH2C N ) , 2 . 8 9 - 2 . 9 4 ( 2 H , m , 3.37-3.44 (2H, m, OCH2CH2S ) , OCH2CH2CN), 3.58-3.66 (2H, m, 5′, 5′′), 3.76, 3.77 (6H, 2 s, OCH3), 3.80-3.95 (2H, m, OCH2CH2S), 4.06-4.12 (2H, m, 2′,4′), 4.40-4.53 (1H, m, 3′), 5.20, 5.21 (1H, 2 d, J = 8.1 Hz, 5), 5.85 (1H, m, 1′), 6.86-6.90 (4H, m, ArH), 7.25-7.36 (7H, m, ArH), 7.42-7.47 (2H, m ArH), 7.73,7.82 (1H, 2 d, J = 8.1 Hz, 6). 13C NMR (75 MHz, acetone-d6) δ (two diastereomers) 20.96 (NCH(CH3)2), 25.0225.32 (NCH(CH3)2), 29.14-30.68 (acetone, SSC(CH3)3), 41.17 (OCH2CH2S), 44.07, 44.24 (CH2CN), 48.27 (SSC(CH3)3), 55.68 (OCH3), 59.25-59.92 (POCH2), 62.72, 63.00 (5′), 70.27, 70.41 (OCH2CH2S), 71.30, 71.48 (3′), 82.11, 82.81 (2′), 83.14-83.41 (4′), 87.78 (Ar), 89.04, 89.29 (1′), 102.53, 102.59 (5), 114.10 (Ar), 118.81, 118.96 (CN), 127.80, 128.72, 129.19, 131.15, 131.53, 136.27, 136.35, 136.45 (Ar), 140.65, 140.72 (6),
145.68, 145.75 (Ar), 151.21 (2), 159.80 (Ar), 163.37 (4). 31P NMR (202 MHz, CD3CN) δ 147.44, 146.90. IR (KBr) ν 3199, 3059, 2966, 2932, 2871, 2837, 2248, 1692, 1608, 1615, 1510, 1458, 1364, 1253, 1179, 1119, 1085, 1070, 1035, 980, 828, 810 cm−1. MS (FAB, 3-NBA) m/z 895 (M+ +1). Anal. Calcd for C45H59N4O9PS2: C, 60.38. H, 6.64. N, 6.26. Found: C, 60.59. H, 6.59. N, 5.95.
Critical Parameters There are three critical parameters for the formation of intramolecular disulfide bonds in RNA. First, prior to oxidation the reducing agent used to remove the thiol protecting groups, DTT, must be entirely removed from sample. Second, the concentration of the RNA must be very low (1 to 4 µM) to avoid intermolecular cross-link formation. Third, for efficient cross-link formation the pH of the solution must be maintained between 8.0 and 8.4. At pH values <8.0 the concentration of thiolate ion will be reduced and the rate of cross-link formation will be reduced. However, prolonged exposure of the RNA to pH values >8.4 may lead to degradation.
Troubleshooting See Table 5.4.1 for discussion of common problems encountered with these procedures and methods to identify, solve, and avoid them.
Anticipated Results The authors have achieved 100% conversion of tert-butyl disulfide–protected tRNAs to intramolecularly disulfide-cross-linked tRNAs at three different sites of disulfide incorporation. Similar results should be obtained for thiols positioned at proximal locations either in a folded tertiary structure or within secondary structure. The solid-phase synthesis of tRNAs containing the thiol-modified nucleosides described here results in yields of 0.5 mg tRNA after purification to single-nucleotide resolution. Each thiol-modified nucleoside is incorporated into the RNA oligomer as efficiently as commercially available phosphoramidites.
Time Considerations Conversion of the tert-butyl disulfide–protected RNA to disulfide-cross-linked RNA takes 36 to 48 hr; both the reduction of the tert-butyl disulfide protecting groups and the air oxidation can be done as overnight reactions. To ensure complete reduction of the tert-butyl disulfide protecting groups the
5.4.32 Current Protocols in Nucleic Acid Chemistry
Table 5.4.1
Troubleshooting Guide for Disulfide Cross-Linking
Problem
Possible causes
RNA does not cross-link or does not cross-link quantitatively
Protecting groups were not completely Add more DTT and/or incubate longer. reduced After DTT removal, thiols on the RNA can be quantified using the fluorescent assay. DTT was not completely removed Dialyze at a slower rate; use more before oxidation commenced buffer; monitor the dialysate with the fluorescence assay to determine when all DTT has been removed pH of the reaction was <8.0 Adjust pH to 8.0 RNA was not properly folded before Fold the RNA oxidation commenced RNA was not pure Repurify the starting thiol-modified RNA Thiols are not positioned close enough Select alternate positions for to react modification Resulting cross-linked RNA would be Select alternate positions for a strained, high-energy structure modification Moisture was present in Dry amidites by evaporation from phosphoramidite freshly distilled CH3CN several times Handle amidites under Ar Repurify the phosphoramidite Dilute the amidite with CH3CN immediately before coupling instead of at the beginning of the synthesis
Modified nucleosides incorporate poorly during RNA synthesis
RNA should be incubated with DTT for ≥12 hr, while >14 hr appears unnecessary. The slow rate of dialysis (5 mL/min), using 3 L of buffer over 10 hr, ensures that the DTT is completely removed and that the buffer exchange into the lower-salt buffer is complete. Cross-link formation between thiols positioned at locations that are proximal in the folded RNA generally occurs in <12 hr. It has taken up to 48 hr for completion of some cross-linking reactions; in such cases the pH is monitored periodically and adjusted as necessary, and water is also added to compensate for evaporation. Synthesis and purification of thiol-modified tRNA takes between 1 and 2 weeks depending on the amount of RNA to be purified before proceeding with the cross-linking reaction. This includes 1 day to synthesize the necessary phosphoramidites before commencing the solid-phase synthesis.
Solution
Literature Cited Allerson, C.R., Chen, S.L., and Verdine, G.L. 1997. A chemical method for site-specific modification of RNA: The convertible nucleoside approach. J. Am. Chem. Soc. 119:7423-7433. Allerson, C.R. and Verdine, G.L. 1995. Synthesis and biochemical evaluation of RNA containing an intrahelical disulfide crosslink. Chem. Biol. 2:667-675. Breslauer, K.J., Frank, R., Blöcker, H., and Markey, L.A. 1986. Predicting DNA duplex stability from the base sequence. Proc. Natl. Acad. Sci. U.S.A. 83:3746-3750. Cohen, S.B. and Cech, T.R. 1997. Dynamics of thermal motions within a large catalytic RNA investigated by crosslinking with thiol-disulfide interchange. J. Am. Chem. Soc. 119:6259-6268. Douglas, M.E., Beijer, B., and Sproat, B.S. 1994. An approach towards thiol mediated labelling in the minor groove of oligonucleotides. Bioorg. Med. Chem. Lett. 4:995-1000. Earnshaw, D.J., Masquida, B., Müller, S., Sigurdsson, S.T., Eckstein, F., Westhof, E., and Gait, M.J. 1997. Inter-domain cross-linking and molecular modelling of the hairpin ribozyme. J. Mol. Biol. 274:197-212.
Methods for Cross-Linking Nucleic Acids
5.4.33 Current Protocols in Nucleic Acid Chemistry
Gait, M.J., Pritchard, C., and Slim, G. 1991. Oligoribonucleotide synthesis. In Oligonucleotides and Analogues. A Practical Approach (F. Eckstein, ed.) pp. 25-48. Oxford University Press, Oxford. Glick, G.D. 1991. Synthesis of a conformationally restricted DNA hairpin. J. Org. Chem. 56:67466747. Glick, G.D. 1998. Design, synthesis, and analysis of conformationally restricted nucleic acids. Biopolymers 48:83-96. Goodwin, J.T., Osborne, S.E., Scholle, E.J., and Glick, G.D. 1996. Design, synthesis, and analysis of yeast tRNAPhe analogs possessing intraand interhelical disulfide cross-links. J. Am. Chem. Soc. 118:5207-5214.
Schaller, H., Weimann, G., Lerch, B., and Khorana, H.G. 1963. Studies on polynucleotides. XXIV. The stepwise synthesis of specific deoxyribopolynucleotides (4). Protected derivatives of deoxyribonucleosides and new syntheses of deoxyribonucleoside-3′ phosphates. J. Am. Chem. Soc. 85:3821-3827. Sigurdsson, S.T., Tuschl, T., and Eckstein, F. 1995. Probing RNA tertiary structure: Interhelical crosslinking of the hammerhead ribozyme. RNA 1:575-583. Sigurdsson, S.T. and Eckstein, F. 1996. Isolation of oligoribonucleotides containing intramolecular cross-links. Anal. Biochem. 235:241-242.
Goodwin, J.T., Stanick, W.A., and Glick, G.D. 1994. Improved solid-phase synthesis of long oligoribonucleotides: Application to tRNAPhe and tRNAGly. J. Org. Chem. 59:7941-7943.
Sproat, B.S. and Lamond, A.I. 1991. 2′-O-Methyloligoribonucleotides: Synthesis and application. In Oligonucleotides and Analogues. A Practical Approach (F. Eckstein, ed.) pp. 49-86. Oxford University Press, Oxford.
Gundlach, C.W. IV, Ryder, T.R., and Glick, G.D. 1997. Synthesis of guanosine analogs bearing pendant alkylthiol tethers. Tetrahedron Lett. 38:4039-4042.
Sproat, B.S., Iribarren, A., Beijer, B., Pieles, U., and Lamond, A.I. 1991. 2′-O-alkyloligoribonucleotides: Synthesis and applications in studying RNA splicing. Nucleosides Nucleotides 10:25-36.
Maglott, E.J. and Glick, G.D. 1998. Probing structural elements in RNA using engineered disulfide bonds. Nucl. Acids Res. 26:1301-1308.
Sun, S., Tang, X.-Q., Merchant, A., Anjaneyulu, P.S.R., and Piccirilli, J.A. 1996. Efficient synthesis of 5-(thioalkyl)uridines via ring opening of α-ureidomethylene thiolactones. J. Org. Chem. 61:5708-5709.
Manoharan, M., Johnson, L.K., Tivel, K.L., Springer, R.H., and Cook, P.D. 1993. Introduction of a lipophilic thioether tether in the minor groove of nucleic acids for antisense applications. Bioorg. Med. Chem. Lett. 3:2765-2770. Parvari, R., Pecht, I., and Soreq, H. 1983. A microfluorimetric assay for cholinesterases, suitable for multiple kinetic determinations of picomoles of released thiocholine. Anal. Biochem. 133:450-456.
Wünsch, E., Moroder, L., and Romani, S. 1982. 1-(tert-Butylthio)-1,2-hydrazinedicarboxoylic acid derivatives. New reagents for the introduction of the S-tert-butylthio group into cysteine and cysteine derivatives. Hoppe-Seylers Z. Physiol. Chem. 363:1461-1464.
Contributed by Emily J. Maglott and Gary D. Glick University of Michigan Ann Arbor, Michigan
Engineering Disulfide Cross-Links in RNA via Air Oxidation
5.4.34 Current Protocols in Nucleic Acid Chemistry
Use of Electrophilic Substitution to Form Site-Specific Cross-Links in DNA
UNIT 5.5
This unit describes the incorporation of a nucleophilic base into an oligodeoxyribonucleotide (ODN), and the use of electrophilic tethers to convert this ODN into an electrophilic probe capable of cross-linking a complimentary DNA strand (see Basic Protocol). The postsynthetic method that generates the electrophilic ODN allows the introduction of functionality not compatible with standard solid-phase synthetic conditions. It also allows the generation of a variety of different electrophilic DNA strands from the same deoxythiouridine-containing ODN by changing the nature of the electrophilic tether. In addition, the site of modification places the tether in intimate contact with the major groove, allowing structural features of the groove to aid in directing the electrophilic attack. The synthesis of the electrophile, N,N′-bis-bromoacetyl-1,2-diaminobenzene, is also described in this unit (see Support Protocol). FORMATION OF SITE-SPECIFIC CROSS-LINKS IN DNA The nucleophilic base used in these studies, 4-thio-2′-deoxyuridine (dS4U), is incorporated into an ODN using an S-(2-cyanoethyl)-protected phosphoramidite and standard solidphase synthesis conditions and reagents (Coleman and Siedlecki, 1991). The DNA is left on the column, and the S-cyanoethyl group is removed by treatment with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in dry acetonitrile. The ODN is then cleaved from the column and purified by a two-step process involving an initial trityl-on purification followed by a trityl-off purification. Cross-linking is performed by derivatizing the modified ODN with the desired electrophilic tether and incubating this probe with a 32 P-labeled target (Fig. 5.5.1; Coleman and Kesicki, 1995; Coleman and Pires, 1997).
BASIC PROTOCOL
Materials S-(2-Cyanoethyl)-protected 4-thio-2′-deoxyuridine (Glen Research) Dry solvent-grade acetonitrile 1.0 M DBU solution (see recipe) 50 mM NaSH/NH4OH solution (see recipe) Nitrogen gas (optional) HPLC buffer A (see recipe) HPLC buffer B: HPLC-grade acetonitrile 80% (v/v) distilled glacial acetic acid Dry ice
S
O NH
1) O
HO Nx O P O O–
N
O
NH HN Br
Br
NH
O Br
O
N
NH
O 2) complimentary DNA
S H
–
N
N
O O P O Ny OH
N
O
H N
dna
N N
H
O
O
dna
Figure 5.5.1 Cross-linking between 4-thio-2′-deoxyuridine and N,N′-bis-bromoacetyl-1,2diaminobenzene.
Methods for Cross-Linking Nucleic Acids
Contributed by Richard M. Pires and Robert S. Coleman
5.5.1
Current Protocols in Nucleic Acid Chemistry (2001) 5.5.1-5.5.6 Copyright © 2001 by John Wiley & Sons, Inc.
Supplement 6
Double-deionized water 2 mg/mL (1.5 U/mg) snake venom phosphodiesterase (SVP) from Crotalus durissus 1 U/µL alkaline phosphatase (AP) from calf intestine 0.1 M potassium phosphate buffer, pH 8.0 (APPENDIX 2A) Electrophile: N,N′-bis-bromoacetyl-1,2-diaminobenzene (see Support Protocol) Dimethylformamide (DMF) n-Butanol Radiolabeled complimentary DNA solution (1 to 5 OD/mL) DNA synthesizer with bottle (and septum) that fits a phosphoramidite inlet port Vacuum pump Desiccator Centrifugal evaporator Binary high-performance liquid chromatograph (HPLC) equipped with UV detector and recorder Polystyrene reversed-phase (PRP-1) HPLC column (Hamilton) Spectrophotometer Small spin column containing 0.3 ml Sephadex G-25 equilibrated with double-deionized water Additional reagents and equipment for DNA synthesis (APPENDIX 3C), SVP/AP digestion (UNIT 10.6), and denaturing polyacrylamide gel electrophoresis (PAGE; APPENDIX 3B) Synthesize dS4U-containing ODN 1. Dissolve 50 mg S-(2-cyanoethyl)-protected 4-thio-2′-deoxyuridine in 2 mL dry solventgrade acetonitrile in a bottle that fits a phosphoramidite inlet port of a DNA synthesizer. Use an empty bottle that previously contained a phosphoramidite standard. Wash and dry bottle thoroughly before reuse.
2. Place a septum on the bottle, and evaporate sample to dryness using a vacuum pump. Repeat this azeotropic drying procedure two times. 3. Add enough dry solvent-grade acetonitrile to prepare a 0.1 M phosphoramidite solution, and place the bottle on phosphoramidite port no. 5 of the synthesizer. Set the synthesizer to perform a standard synthesis (APPENDIX 3C), except do not remove the trityl group of the last base, and leave the DNA attached to the column. A 200-nmol or 100-mmol synthesis is appropriate.
4. After synthesis is complete, evaporate remaining phosphoramidite solution to dryness as in step 2, and store at −20°C in a desiccator (stable indefinitely). This storage method substantially increases the shelf life of the phosphoramidite.
5. Remove the column containing DNA from the synthesizer, and cleave the S-cyanoethyl group by passing 2 mL of 1.0 M DBU solution through the column over 2 hr using the double-syringe technique. The double-syringe technique is performed by placing a syringe at each end of the column and passing the reagent back and forth slowly. Use of Electrophilic Substitution to Form Site-Specific Cross-Links in DNA
6. Flush column two times with 3 mL dry solvent-grade acetonitrile. Residual DBU interferes with the purification of DNA.
7. Cleave DNA from column with 5 mL of 50 mM NaSH/NH4OH solution over 3 hr at room temperature using the double-syringe technique.
5.5.2 Supplement 6
Current Protocols in Nucleic Acid Chemistry
8. Allow sample to sit 16 hr at room temperature in 50 mM NaSH/NH4OH solution to remove the base-protecting groups. 9. Evaporate sample to dryness, either with a stream of nitrogen gas or under vacuum using a centrifugal evaporator. Purify dS4U-containing ODN 10. Redissolve sample in 100 µL HPLC buffer A and inject onto a PRP-1 column. Perform reversed-phase HPLC using 95% HPLC buffer A to 50% HPLC buffer A over 30 min at a flow rate of 1 mL/min. NaSH elutes from the column in ∼3 min and has a horrible odor. The untritylated failure sequences elute at ∼10 min, whereas the full-length tritylated product elutes at ∼20 min.
11. Collect purified product and evaporate to dryness using a centrifugal evaporator. Redissolve in 1 mL of 80% distilled glacial acetic acid. Allow sample to sit 20 min at room temperature. 12. Freeze sample using dry ice and evaporate to dryness under vacuum using a centrifugal evaporator. 13. Redissolve sample in 100 µL HPLC buffer A. The solution may turn cloudy, because the trityl alcohol produced is relatively insoluble in HPLC buffer A. If it turns cloudy, centrifuge to remove solid material.
14. Inject sample onto the PRP-1 column. Perform reversed-phase HPLC using 92% HPLC buffer A to 75% HPLC buffer A over 30 min at a flow rate of 1 mL/min. The purified ODN elutes at ∼12 min.
15. Evaporate sample to dryness with a centrifugal evaporator, redissolve in doubledeionized water, and determine the concentration by measuring A260. 16. Check sample for correct base composition by SVP/AP digestion (UNIT 10.6). 17. Perform HPLC using 95% HPLC buffer A to 90% HPLC buffer A over 12 min at a flow rate of 1 mL/min. Monitor dA, dG, dC, and dT at A254, and monitor dS4U at A332. Derivatize ODN with N,N′-bis-bromoacetyl-1,2-diaminobenzene 18. Dilute 5 µL dS4U-containing ODN stock solution obtained in step 17 to 95 µL with 0.1 M potassium phosphate buffer, pH 8.0. The ODN stock solution is usually close to 50 OD/mL.
19. Mix ∼1 mg electrophile in 30 µL DMF. 20. Add electrophilic solution to ODN stock solution and allow mixture to sit 1.5 hr at room temperature. 21. Terminate reaction by passing solution through a small spin column containing 0.3 mL Sephadex G-25 equilibrated with double-deionized water. 22. Concentrate sample to dryness by precipitating with n-butanol. 23. Place sample briefly under vacuum to remove any trace of n-butanol. Use derivatized ODN immediately after preparation.
Cross-link target DNA using electrophilic ODN 24. Dissolve electrophilic ODN in 4 µL of 0.1 M potassium phosphate buffer, pH 8.0.
Methods for Cross-Linking Nucleic Acids
5.5.3 Current Protocols in Nucleic Acid Chemistry
Supplement 6
25. Add 2.0 µL radiolabeled complimentary DNA solution. The radiolabeled ODN stock solution is usually between 1 and 5 OD/mL.
26. Incubate sample 15 min to 16 hr at room temperature. Maximum cross-linking usually requires an overnight incubation.
27. Analyze cross-linking using denaturing polyacrylamide gel electrophoresis (APPENDIX 3B). SUPPORT PROTOCOL
SYNTHESIS OF N,N′-BIS-BROMOACETYL-1,2-DIAMINOBENZENE To synthesize the electrophilic tether, the appropriate diamine reacts with bromoacetyl bromide (Skinner et al., 1967). Materials 1,2-Diaminobenzene Nitrogen gas Tetrahydrofuran (THF), freshly distilled Triethylamine (TEA), freshly distilled Bromoacetyl bromide Saturated aqueous NaHCO3 Ethyl acetate Saturated NaCl 5% (v/v) HCl MgSO4 Silica 9:1 (v/v) dichloromethane/methanol (CH2Cl2/CH3OH) Flame-dried 100-mL flask 3 × 15–cm glass column Additional reagents and equipment for flash column chromatography (APPENDIX 3E) 1. Place 500 mg 1,2-diaminobenzene in a flame-dried 100-mL flask under nitrogen gas. 2. Dissolve diamine in 50 mL freshly distilled THF. 3. Add 1.6 mL freshly distilled TEA. 4. Place flask under nitrogen gas and cool sample 5 min at −78°C. 5. Add 1 mL bromoacetyl bromide with a syringe over a 10-min period. 6. Stir mixture 30 min at −78°C, then 90 min at room temperature. 7. Add 50 mL saturated aqueous NaHCO3 to stop the reaction. 8. Dilute sample with 50 mL ethyl acetate. Extract organic layer with saturated NaCl, then with 5% HCl. 9. Dry organic phase over MgSO4.
Use of Electrophilic Substitution to Form Site-Specific Cross-Links in DNA
10. Evaporate sample onto 1 to 2 g silica for loading, and purify in a 3 × 15–cm glass column by flash column chromatography (APPENDIX 3E) using 9:1 CH2Cl2/CH3OH. Column-purified samples result in a higher percentage of cross-linking than recrystallized samples. The product should be used immediately.
5.5.4 Supplement 6
Current Protocols in Nucleic Acid Chemistry
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) solution, 1.0 M Dissolve 15.2 g DBU in 75 mL solvent-grade acetonitrile that has been freshly distilled from CaH2. Allow DBU to dissolve, then add acetonitrile to 100 mL final volume. Store up to 12 months at 25°C in a desiccator. HPLC buffer A Dissolve 69.7 mL triethylamine that has been freshly distilled from CaH2 in 850 mL double-deionized H2O. Adjust to pH 6.5 using distilled acetic acid. Adjust volume to 1 L. Then dilute 100 mL to 500 mL (final 0.1 M triethylamine). Store up to 6 months at 5°C. If acetic acid is not distilled, impurities may appear in the HPLC.
NaSH/NH4OH solution, 50 mM Add 0.28 g NaSH⋅H2O to 75 mL concentrated NH4OH from a freshly opened bottle. Allow NaSH to dissolve, then add NH4OH to 100 mL final volume. Store up to 6 months at 4°C. COMMENTARY Background Information
dS4U is a versatile modified DNA base that can be used to accomplish a variety of postsynthetic transformations in synthetic ODNs. However, if the 4-thio group is left unprotected during solid-phase synthesis of dS4U-containing ODNs, the yield of product is typically near 20% per step. The 2-cyanoethyl group is a convenient protecting group for sulfur that can be readily removed by treatment with a nonnucleophilic base such as DBU. Yields from ODN syntheses utilizing the 2-cyanoethyl protecting group are equivalent to those containing only the four naturally occurring bases (Coleman and Kesicki, 1994). In addition to its reaction with electrophiles, as described above, oxidation-reduction chemistry can be used to form disulfide-constrained hairpins and duplexes. dS4U can also be modified by strong nucleophiles.
Critical Parameters The location of the 4-thio group near the base-pairing atoms of the duplex places the electrophilic tether in intimate contact with the major groove. Because of this positioning of the tether, the efficiency of cross-linking depends not only on the nucleophilicity of the target base but also on the local steric and electronic environment of the duplex. The steric environment can significantly influence the accessibility of the target to the nucleophile. For instance, when deoxythiouridine is placed
in the sequence 5′-d(TAATACGACCXACTATA)-3′ (X = dS4U), lower than expected levels of cross-linking to the complimentary target occur (≤35%). Modeling studies indicate that the methyl group of the T that is base paired to the dA in the 3′ direction blocks the approach of electrophiles to N7 of dG in this duplex. This is supported by studies where this T was replaced by dU, resulting in higher levels of cross-linking (Coleman and Kesicki, 1994). The cross-linking efficiency also seems to mirror the local charge density of the major groove. Guanines that are expected to be in a more negative environment based on calculations also appear to cross-link more readily (Coleman and Pires, 1997). In addition, the linker design is of critical importance in cross-linking efficiency. Considerations important for linker design include the tether geometry, H-bonding ability, and reactivity. The most effective electrophile found has been N,N′-bis-bromoacetyl-1,2-diaminobenzene. Using the optimal sequence with this electrophile, >90% cross-linking of a duplex can be achieved (Coleman and Pires, 1997). One final consideration is duplex stability. As the cross-linking occurs in the context of the duplex, factors that destabilize the duplex are expected to reduce the efficiency of cross-linking. Melting studies have shown that substitution of dC with dS4U destabilizes a 17-mer duplex by 9°C. Melting studies on the same 17-mer containing a non-cross-linking model
Methods for Cross-Linking Nucleic Acids
5.5.5 Current Protocols in Nucleic Acid Chemistry
Supplement 6
of the electrophilic tether show a transition temperature that is an additional 3°C lower. Interpretation of data from melting experiments performed on the cross-linked duplex are complicated by the rapid depurination of the target strand that occurs as the temperature is raised, although the duplex appears to be intact up to ≥10°C above the transition temperature for the non-modified duplex (Coleman and Pires, 1997).
Anticipated Results The percent cross-linking obtained depends on the parameters discussed above. With the appropriate sequence and the most effective bis-electrophile, cross-linking efficiencies of between 80% and 95% are routinely obtained. Cross-linking levels of 30% to 80% have been obtained with less effective bis-electrophiles (e.g., N,N′-bis-bromoacetyl-1,3-diaminobenzene).
Time Considerations Synthesis of DNA, including cleavage and deprotection, generally takes 1 day. Purification is limited by the time required to remove solvent from samples, and generally requires 1.5 to 2 days. The cross-linking reaction takes ∼2 hr to set up for an overnight reaction. To prepare the electrophilic tether, 3 hr are re-
quired to set up and run the reaction, and another 2 hr are needed to purify the product.
Literature Cited Coleman, R.S. and Kesicki, E.A. 1994. Synthesis and postsynthetic modification of oligodeoxynucleotides containing 4-thio-2′-deoxyuridine (dS4U). J. Am. Chem. Soc. 116:11636-11642. Coleman, R.S. and Kesicki, E.A. 1995. Template-directed cross-linking of oligonucleotides: Site specific covalent modification of dG-N7 within duplex DNA. J. Org. Chem. 60:6252-6253. Coleman, R.S. and Pires, R.M. 1997. Covalent cross-linking of duplex DNA using 4-thio-2′-deoxyuridine as a readily modifiable platform for introduction of reactive functionalities into oligonucleotides. Nucl. Acids Res. 25:4771-4777. Coleman, R.S. and Siedlecki, J.M. 1991. Synthesis and stability of S-cyanoethyl protected thiouridine and 2′-deoxy-4-thiouridine. Tetrahedron Lett. 32:3033-3034. Skinner, W.A., Cory, M., Shellenberger, T.E., and Degraw, J.I. 1967. Effect of organic compounds on reproductive processes. V: Alkylating agents derived from aryl-, aralkyl-, and cyclohexylmethylenediamines. J. Med. Chem. 10:120-121.
Contributed by Richard M. Pires and Robert S. Coleman The Ohio State University Columbus, Ohio
Use of Electrophilic Substitution to Form Site-Specific Cross-Links in DNA
5.5.6 Supplement 6
Current Protocols in Nucleic Acid Chemistry
Synthesis of Endcap Dimethoxytrityl Phosphoramidites for Endcapped Oligonucleotides
UNIT 5.6
This unit describes the preparation of short endcapped DNA duplexes. Endcaps may be either aromatic (hydrophobic) or aliphatic (hydrophilic or hydrophobic) molecules that specifically cross-link the 5′ end of one strand with the 3′ end of the complementary strand in a DNA duplex. Endcaps may be viewed as a replacement of the loop region nucleotides of a DNA hairpin, with the added advantage of increased thermal stability. Specific cross-links at the terminus of a DNA duplex can be engineered through thiol-disulfide exchange with thiol-modified nucleosides incorporated at the end of the oligonucleotide strands (UNIT 5.1). The endcap approach, instead, requires the incorporation of the endcap into the sequence during oligonucleotide synthesis. Many different types of molecules may be used as endcaps, including oligo(ethylene glycol) linkers (UNIT 5.3), unsubstituted alkyl chains (Altmann et al., 1995), and aromatic molecules such as stilbene diethers (Lewis et al., 1999), carboxamides (Letsinger and Wu, 1995; Lewis et al., 2000), azobenzene (Yamana et al., 1996, 1998), and naphthalene diimides (Bevers et al., 1998, 2000). Basic Protocol 1 describes the synthesis of a naphthalene diimide hydrophobic endcap that prefers to base stack with GC base pairs. The phosphoramidite derivative of the endcap can be readily synthesized in three short steps for incorporation into an oligonucleotide sequence. The preparation of a terthiophene hydrophobic endcap is described in Basic Protocol 2, again requiring just three synthetic steps to obtain the phosphoramidite derivative. The terthiophene endcap has higher lipophilicity than the naphthalene diimide endcap and provides higher stability when stacked over an AT base pair. Finally, Basic Protocol 3 outlines the preparation of a hydrophilic 2,2′-oxydiacetamide endcap, which provides lower enhancement in stability as compared to either of the hydrophobic endcaps, but a more rigid and well-defined structure than the oligo(ethylene glycol) endcaps. Synthesis of endcapped oligonucleotides can be carried out using standard automated synthesis protocols with only minor modifications. The naphthalene diimide endcap is base sensitive and hence exposure to strong base such as ammonia must be avoided. Decomposition of the naphthalene diimide endcap can be avoided by using ultramild phosphoramidites (Glen Research) during oligonucleotide synthesis. The resulting oligonucleotide can be cleaved from the support as well as deprotected in a 0.05 M solution of potassium carbonate in methanol. The other requirement is to extend the time of the coupling cycle during the incorporation of the endcap phosphoramidite to 15 min during oligonucleotide synthesis. The endcapped oligonucleotides can be purified by denaturing PAGE (UNIT 10.4) or by reversed-phase HPLC (UNIT 10.5). MALDI-TOF mass spectrometry (UNIT 10.1) can be effectively used to characterize the endcapped oligonucleotides. SYNTHESIS OF N-[3-O-(2-CYANOETHYL-N,N-DIISOPROPYLPHOSHORAMIDITE)PROPYL]-N′-[3-(4,4′-DIMETHOXYTRITYLOXY)PROPYL]-NAPHTHALENE-1,4,5,8-TETRACARBOXYLIC DIIMIDE The sequence of reactions outlined in this protocol can be seen in Figure 5.6.1. The alkyl substituents of the naphthalene diimide central core are derived from 3-aminopropanol. This can be easily substituted by another aminoalcohol to provide an endcap that is either Contributed by Maneesh R. Pingle, Pei-Sze Ng, Xiaolin Xu, and Donald E. Bergstrom Current Protocols in Nucleic Acid Chemistry (2003) 5.6.1-5.6.15 Copyright © 2003 by John Wiley & Sons, Inc.
BASIC PROTOCOL 1
Methods for Cross-Linking Nucleic Acids
5.6.1 Supplement 12
O
O
O
O
O
O
3-aminopropanol HO
O
O
N
N
O
O
OH
2
1
DMTr ⋅ Cl HO
O
O
N
N
O
O
ODMTr
3
O
O
N
N
O
O
i -Pr2NP(Cl)OCH2CH2CN O N
P
O
ODMTr
CN
4
Figure 5.6.1 Synthetic scheme for the preparation of the phosphoramidite derivative of the naphthalene diimide endcap. Abbreviations: DMTr⋅Cl, 4,4′-dimethoxytrityl chloride; i-Pr2NP(Cl)OCH2CH2CN, 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite.
shorter (2-aminoethanol) or longer (4-aminobutanol), but this will yield slightly less stable duplexes.
Synthesis of Endcap DMTr Phosphoramidites for Endcapped Oligonucleotides
Materials Napthalene-1,4,5,8-tetracarboxylic dianhydride (S.1; Figure 5.6.1) 3-Aminopropanol 2 M sodium carbonate Chloroform, reagent grade Activated charcoal Methanol, reagent grade Dichloromethane, reagent grade Pyridine, anhydrous 4,4′-Dimethoxytrityl chloride (DMTr⋅Cl) 5% (w/v) sodium bicarbonate Sodium sulfate, anhydrous Silica gel (230 to 400 mesh, 60 Å, E Merck) Triethylamine, reagent grade Hexanes, reagent grade Ethyl acetate, reagent grade Dichloromethane, anhydrous Diisopropylethylamine
5.6.2 Supplement 12
Current Protocols in Nucleic Acid Chemistry
2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite Ethyl acetate, prewashed with 5% (w/v) sodium bicarbonate 25-, 50-, 100-, and 250-mL round-bottom flasks Buchner funnel Filtration flask Whatman no. 1 filter paper Vacuum oven Water-cooled reflux condenser Oil bath Filter funnel, prewarmed (∼50° to 60°C) Rotary evaporator equipped with a water aspirator and vacuum pump Nitrogen atmosphere (see inert atmosphere/vacuum manifold in UNIT 1.1, Fig. 1.1.3) 125-mL Erlenmeyer flasks 125-mL separatory funnels Glass funnel Glass wool 2 × 20–cm and 3 × 18–cm glass chromatography columns 25-mL pear-shaped flask 1-mL syringe and stainless steel needle Additional reagents and solutions for thin-layer chromatography (TLC; APPENDIX 3D) and flash chromatography (APPENDIX 3E) CAUTION: Exposure to pyridine and its vapors should be minimized. All reactions should be performed in a fume hood. The reactions for dimethoxytrityl protection and the phosphitylation of the dimethoxytrityl-protected endcap are sensitive to moisture and the glassware used for the reactions must be scrupulously dry. NOTE: All listed reagents are available from Sigma-Aldrich. Synthesize S.2 1. Suspend 2.14 g (8 mmol) naphthalene-1,4,5,8-tetracarboxylic dianhydride (S.1) in 150 mL water in a 250-mL round-bottom flask containing a stir bar. 2. Add 1.5 g (20 mmol) 3-aminopropanol drop-wise over 2 min while stirring the contents of the flask. Warm to 70°C and stir on a magnetic stirrer for 2 hr. 3. Cool the flask to room temperature and filter the solution using a Buchner funnel fitted with Whatman no. 1 filter paper attached to a filtration flask. Wash the residue on the filter paper with 50 mL of 2 M sodium carbonate and then with 200 mL of water. Allow the residue to dry on the filter paper. 4. Transfer the dry residue to a 100-mL round-bottom flask and dry overnight under vacuum (in a vacuum oven at <1 Torr and room temperature) to obtain a beige solid. 5. Dissolve the crude product in 25 mL chloroform and reflux the solution in the flask by attaching a water-cooled reflux condenser to the flask and heating the flask in an oil bath. When the solution begins refluxing (61°C), add 50 mg activated charcoal and reflux the solution for an additional 10 min. 6. Quickly filter the solution through a warm filter funnel (∼50° to 60°C) fitted with Whatman no. 1 paper. 7. Remove the solvent under reduced pressure on a rotary evaporator equipped with a water aspirator to yield N,N′-bis(3-hydroxypropyl)-naphthalene-1,4,5,8-tetracarboxylic diimide (S.2) as an off-white powder.
Methods for Cross-Linking Nucleic Acids
5.6.3 Current Protocols in Nucleic Acid Chemistry
Supplement 12
8. Analyze the product by TLC (APPENDIX 3D) on silica gel, developing the plate with 10% (v/v) methanol in reagent-grade dichloromethane (Rf = 0.4). Tritylate to give S.3 9. Coevaporate 382 mg (1 mmol) S.2 three times with 20-mL portions of anhydrous pyridine in a 50-mL round-bottom flask using a rotary evaporator connected to a vacuum pump. 10. Dissolve the contents of the flask in 20 mL anhydrous pyridine and add 406 mg (1.2 mmol) DMTr⋅Cl while maintaining the flask under a dry nitrogen atmosphere. Stir the contents of the flask for 2 hr under nitrogen. 11. Remove the solvent on a rotary evaporator connected to a vacuum pump and dissolve the mixture of crude products in 50 mL reagent-grade dichloromethane. 12. Transfer the solution to a 125-mL separatory funnel and wash with 50 mL of 5% sodium bicarbonate solution and then with three 50-mL portions of water. 13. Transfer the dichloromethane solution to a 125-mL Erlenmeyer flask and add 1 g anhydrous sodium sulfate. Swirl the solution for a few minutes and allow to stand for 10 min. 14. Remove the drying agent by filtering the solution through a glass funnel with a glass wool plug. 15. Remove the solvent under reduced pressure using a rotary evaporator and water aspirator. 16. Purify the product (S.3) by flash chromatography (APPENDIX 3E) on a 3 × 18–cm column of silica gel neutralized by pretreatment with 1% (v/v) triethylamine in hexanes. Elute with hexanes and ethyl acetate, starting with 100% hexanes and increasing the amount of ethyl acetate to 70% in 10% increments every 100-mL fraction. Although chromatography of the DMTr derivative can be performed without using any triethylamine in the mobile phase, it is recommended that between 0.5% and 1% triethylamine be incorporated in the elution solvent. For more details on the purification of DMTr derivatives see UNIT 2.3.
17. Analyze fractions by TLC on silica gel, developing the plates with 50% (v/v) ethyl acetate in hexanes. Pool all fractions containing the product (Rf = 0.3) in a 250-mL round-bottom flask and remove the solvent under reduced pressure (see step 15). 18. Dry the purified N-(3-hydroxypropyl)-N′-[3-(4,4′-dimethoxytrityloxy)propyl]-naphthalene-1,4,5,8-tetracarboxylic diimide (S.3) overnight under vacuum (in a vacuum oven at <1 Torr and room temperature) to produce a yellow foam. Synthesize phosphoramidite S.4 19. Dissolve 267 mg (0.379 mmol) S.3 in 5 mL anhydrous dichloromethane in a 25-mL pear-shaped flask under a stream of dry nitrogen. 20. Add 234 µL (1.346 mmol) diisopropylethylamine. Then add 100 µL (0.448 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite drop-wise through a 1-mL syringe while gently swirling the flask. Synthesis of Endcap DMTr Phosphoramidites for Endcapped Oligonucleotides
21. Stir the reaction gently under nitrogen at room temperature for 1 hr.
5.6.4 Supplement 12
Current Protocols in Nucleic Acid Chemistry
22. Pour the contents of the flask into 20 mL ethyl acetate (previously washed with 5% sodium bicarbonate solution) in a 125-mL separatory funnel. Wash the ethyl acetate solution with three 20-mL portions of 5% sodium bicarbonate solution and then with three 10-mL portions of water. 23. Dry the ethyl acetate solution over anhydrous sodium sulfate (steps 13 and 14). 24. Remove the solvent under reduced pressure (step 15). 25. Purify the product (S.4) by flash chromatography on a 2 × 20–cm silica gel column pretreated with 1% (v/v) triethylamine in hexanes, eluting with 40% ethyl acetate and 1% triethylamine in hexanes. Collect the eluate in 10-mL fractions. 26. Analyze by TLC on silica gel, developing the plates with 40% ethyl acetate and 1% triethylamine in hexanes. Pool all fractions containing the product (Rf = 0.85) in a 250-mL round-bottom flask. 27. Remove the solvent under reduced pressure on a rotary evaporator connected to a water aspirator to produce N-[3-O-(2-cyanoethyl-N,N-diisopropylphosphoramidite)propyl]-N′-[3-(4,4′-dimethoxytrityloxy)propyl]-naphthalene-1,4,5,8-tetracarboxylic diimide (S.4) as an oily residue. 28. Dissolve the residue in 2 mL anhydrous dichloromethane and evaporate under vacuum on a rotary evaporator connected to a water aspirator. Repeat this step until a yellow foam is obtained and dry the foam overnight under vacuum using a vacuum pump at <1 Torr. The phosphoramidite may be stored for short periods of time (<10 days) at 4°C under anhydrous conditions, but best results are obtained if it is incorporated into an oligonucleotide sequence within a few days of its preparation.
SYNTHESIS OF 5-[3-O-(2-CYANOETHYL-N,N-DIISOPROPYLPHOSPHORAMIDITE)PROPYL]-5′′-[3-(4,4′-DIMETHOXYTRITYLOXY)PROPYL]2,2′:5′,2′′-TERTHIOPHENE
BASIC PROTOCOL 2
The scheme in Figure 5.6.2 outlines the synthesis of the phosphoramidite derivative of a terthiophene endcap. Materials 2,2′:5′,2′′-Terthiophene (S.5; Fig. 5.6.2) Tetrahydrofuran (THF), anhydrous Dry ice/acetone freezing bath n-Butyllithium Boron trifluoride diethyl etherate Trimethylene oxide Saturated sodium bicarbonate Diethyl ether, reagent grade Brine solution (saturated aqueous NaCl) Sodium sulfate, anhydrous Silica gel (230 to 400 mesh, 60 Å, E Merck) Hexanes, reagent grade Ethyl acetate, reagent grade Pyridine, anhydrous 4,4′-Dimethoxytrityl chloride (DMTr⋅Cl) Dichloromethane, anhydrous 5% (w/v) sodium bicarbonate
Methods for Cross-Linking Nucleic Acids
5.6.5 Current Protocols in Nucleic Acid Chemistry
Supplement 12
5
S
2
2″ 2′
S
S
5″
S
1) n -butyllithium
5′
2) trimethylene oxide
HO
S OH
S
5
6
S DMTr ⋅ Cl
HO
S ODMTr
S 7
S
i -Pr2NP(Cl)OCH2CH2CN N
O
S ODMTr
S
P O CN 8
Figure 5.6.2 Synthetic scheme for the preparation of the phosphoramidite derivative of the terthiophene endcap. Abbreviations: DMTr⋅Cl, 4,4′-dimethoxytrityl chloride; i-Pr2NP(Cl)OCH2CH2CN, 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite.
Triethylamine Diisopropylethylamine 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite 25-mL round-bottom flasks Nitrogen atmosphere (see inert atmosphere/vacuum manifold in UNIT 1.1, Fig 1.1.3) 1-mL syringe and stainless steel needle 125-mL separatory funnels 125-mL Erlenmeyer flasks Glass funnel Glass wool Rotary evaporator with water aspirator and vacuum pump 2 × 20–cm and 4 × 20–cm glass chromatography columns Additional reagents and equipment for column chromatography (APPENDIX 3E) and thin-layer chromatography (TLC; APPENDIX 3D) NOTE: All listed reagents are available from Sigma-Aldrich. Synthesis of Endcap DMTr Phosphoramidites for Endcapped Oligonucleotides
5.6.6 Supplement 12
Current Protocols in Nucleic Acid Chemistry
Synthesize S.6 1. Dissolve 333 mg (1.3 mmol) 2,2′:5′,2′′-terthiophene (S.5) in 15 mL anhydrous THF in a 25-mL round-bottom flask containing a Teflon-coated 0.5-in. (1.3-cm) magnetic stir bar under a stream of nitrogen. 2. Cool the solution to −78°C by immersing the flask in a dry ice/acetone freezing bath. 3. Add 1.8 mL (1.3 mmol) n-butyllithium and warm the reaction to 0°C by transferring the flask to an ice bath. 4. Stir the reaction for 2 hr on a magnetic stirrer. 5. Add 384 µL (3 mmol) boron trifluoride diethyl etherate and then add 198 µL (3 mmol) trimethylene oxide with a 1-mL syringe. 6. Stir the reaction for 40 min on a magnetic stirrer. 7. Quench the reaction by addition of 10 mL saturated sodium bicarbonate solution and then allow the reaction to warm to room temperature. 8. Transfer the contents of the flask to a 125-mL separatory funnel and extract the aqueous layer with 30 mL diethyl ether. 9. Wash the ether layer with 25 mL brine solution. 10. Transfer the ether layer to a 125-mL Erlenmeyer flask and add 0.5 g anhydrous sodium sulfate. 11. Remove the drying reagent by filtering through a glass funnel fitted with a glass wool plug. 12. Remove the solvent under reduced pressure using a rotary evaporator and water aspirator. 13. Purify the product (S.6) by flash chromatography (APPENDIX 3E) on a 4 × 20–cm silica gel column, eluting first with hexanes, then with 35% (v/v) ethyl acetate in hexanes, and finally with 65% ethyl acetate in hexanes. 14. Analyze the fractions by TLC (APPENDIX 3D) on silica gel, developing the plates in 50% (v/v) ethyl acetate in hexanes. Combine all fractions containing the product (Rf = 0.13) and remove the solvent under reduced pressure (step 12). 15. Dry 5,5′′-bis(3-hydroxypropyl)-2,2′:5′,2′′-terthiophene (S.6) overnight under vacuum using a rotary evaporator with a water aspirator. Tritylate to give S.7 16. Coevaporate 138 mg (0.38 mmol) S.6 with 10 mL anhydrous pyridine in a 25-mL round-bottom flask using a rotary evaporator connected to a vacuum pump. 17. Dissolve the contents of the flask in 5 mL anhydrous pyridine and add 167 mg (0.49 mmol) DMTr⋅Cl while maintaining the flask under a dry nitrogen atmosphere. Stir the contents of the flask for 3 hr under nitrogen. 18. Remove the solvent on a rotary evaporator connected to a vacuum pump and dissolve the mixture of crude products in 25 mL anhydrous dichloromethane. 19. Transfer the solution to a 125-mL separatory funnel and wash with 25 mL of 5% sodium bicarbonate solution followed by three 20-mL portions of water. 20. Dry the solution with anhydrous sodium sulfate (steps 10 and 11).
Methods for Cross-Linking Nucleic Acids
5.6.7 Current Protocols in Nucleic Acid Chemistry
Supplement 12
21. Remove the solvent under reduced pressure (step 12). 22. Purify the product (S.7) by flash chromatography on a 2 × 20–cm silica gel column, neutralized by pretreatment with 1% (v/v) triethylamine in hexanes. Elute with 70% (v/v) ethyl acetate in hexanes. Although chromatography of the DMTr derivative can be performed without using any triethylamine in the mobile phase, it is recommended that between 0.5% and 1% triethylamine be incorporated in the elution solvent. For more details on the purification of DMTr derivatives see UNIT 2.3.
23. Analyze fractions by TLC using 50% (v/v) ethyl acetate in hexanes and combine all fractions containing the product (Rf = 0.31). Remove the solvent under reduced pressure (step 12). 24. Dissolve the residue in 2 mL anhydrous dichloromethane and evaporate under vacuum on a rotary evaporator connected to a water aspirator. Repeat this step until the product 5-(3-hydroxypropyl)-5′′-[3-(4,4′-dimethoxytrityloxy)propyl]-2,2′:5′,2′′terthiophene (S.7) solidifies into a foam. Synthesize phosphoramidite S.8 25. Dissolve 83 mg (0.125 mmol) S.7 in 5 mL anhydrous dichloromethane in a 25-mL round-bottom flask under a stream of nitrogen. 26. Add 78 µL (0.446 mmol) diisopropylethylamine to the flask and then add 50 µL (0.225 mmol) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite drop-wise through a 1-mL syringe while gently swirling the flask. 27. Stir the reaction gently under nitrogen for 1 hr. 28. Pour the contents of the flask into 20 mL ethyl acetate in a 125-mL separatory funnel. Wash the ethyl acetate solution with three 20-mL portions of 5% sodium bicarbonate solution followed by three 10-mL portions of water. 29. Dry the ethyl acetate solution over anhydrous sodium sulfate (see steps 10 and 11). 30. Remove the solvent under reduced pressure (step 12). 31. Purify the product S.8 by flash chromatography on a 2 × 20–cm silica gel column, eluting with 75% (v/v) ethyl acetate in hexanes. 32. Analyze by TLC using 25% ethyl acetate and 1% triethylamine in hexanes and combine all fractions containing the product (Rf = 0.5). Remove the solvent under reduced pressure (step 12). 33. Dissolve the residue in 2 mL anhydrous dichloromethane and evaporate under vacuum on a rotary evaporator connected to a water aspirator. Repeat this step until the product 5-[3-O-(2-cyanoethyl-N,N-diisopropylphosphoramidite)propyl]-5′′-[3(4,4′-dimethoxytrityloxy)propyl]-2,2′:5′,2′′-terthiophene (S.8) solidifies into a foam. The phosphoramidite may be stored for short periods of time (<10 days) at 4°C under anhydrous conditions, but best results are obtained if it is incorporated into an oligonucleotide sequence within a few days of its preparation.
Synthesis of Endcap DMTr Phosphoramidites for Endcapped Oligonucleotides
5.6.8 Supplement 12
Current Protocols in Nucleic Acid Chemistry
H2N
TBDMS ⋅ Cl
OH
H 2N
3-aminopropanol
TBDMSO
diglycolyl chloride
OTBDMS 9
H N
H N
O
OTBDMS
2.9% HCl in 95% ethanol
H N
HO
O
10
DMTr ⋅ Cl
OH
O
O
O
O
H N
11
HO
H N
H N
O O
ODMTr
O 12
(i -Pr2N)2OCH2CH2CN
N
H N
O P O
H N
O
ODMTr
O
O CN 13
Figure 5.6.3 Synthetic scheme for the preparation of the phosphoramidite derivative of the 2,2′-oxydiacetamide endcap. Abbreviations: DMTr⋅Cl, 4,4′-dimethoxytrityl chloride; (i-Pr2N)2OCH2CH2CN, 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphorodiamidite; TBDMS⋅Cl, tert-butyldimethylsilyl chloride.
SYNTHESIS OF N-[3-O-(2-CYANOETHYL-N,N-DIISOPROPYLPHOSPHORAMIDITE)PROPYL]-N′-[3-(4,4′-DIMETHOXYTRITYLOXY)PROPYL]-2,2′OXYDIACETAMIDE
BASIC PROTOCOL 3
The sequence of reactions in this protocol describes the synthesis of the phosphoramidite derivative of an aliphatic hydrophilic endcap. The synthetic scheme is shown in Figure 5.6.3. All intermediate compounds up to the trityl-protected endcap are stable for storage purposes and may be prepared in larger quantities. It is advisable to prepare the final phosphoramidite derivative in the required quantity only when needed for oligonucleotide synthesis. Materials 3-Aminopropanol Dichloromethane, anhydrous Triethylamine (TEA), anhydrous (preferably freshly distilled) tert-Butyldimethylsilyl chloride (TBDMS⋅Cl) 4,4-Dimethylaminopyridine Brine solution (saturated NaCl) Sodium sulfate, anhydrous Diglycolyl chloride 5% (v/v) acetic acid 5% (w/v) sodium bicarbonate
Methods for Cross-Linking Nucleic Acids
5.6.9 Current Protocols in Nucleic Acid Chemistry
Supplement 12
Concentrated HCl 95% (v/v) ethanol Methanol, reagent grade Hexanes, reagent grade Pyridine, anhydrous (preferably freshly distilled) 4,4′-Dimethoxytrityl chloride (DMTr⋅Cl) Silica gel (230 to 400 mesh, 60 Å, E Merck) Dichloromethane, reagent grade 1% (w/v) sodium hydroxide (optional) Acetonitrile, anhydrous 2-Cyanoethyl-N,N,N′,N′-tetraisopropylphosphorodiamidite 1H-Tetrazole 25-, 50-, 100- and 250-mL round-bottom flasks Nitrogen atmosphere (see inert atmosphere/vacuum manifold in UNIT 1.1, Fig. 1.1.3) 1-mL syringe and stainless steel needles 125- and 250-mL separatory funnels 125- and 250-mL Erlenmeyer flasks Glass funnels Glass wool Rotary evaporator with a water aspirator and vacuum pump 2 × 20–cm and 4 × 25–cm glass chromatography columns Additional reagents and equipment for column chromatography (APPENDIX 3E) and thin-layer chromatography (TLC; APPENDIX 3E) NOTE: All listed reagents are available from Sigma-Aldrich. Silylate 3-aminopropanol to give S.9 1. Dissolve 7 g (1 eq, 0.09 mol) 3-aminopropanol in 90 mL anhydrous dichloromethane in a dry 250-mL round-bottom flask containing a magnetic stir bar, under a stream of nitrogen. 2. Cool the flask in an ice bath and add 14.37 ml (1.1 eq, 0.1 mol) anhydrous triethylamine, 15.93 g (1.1 eq, 0.1 mol) TBDMS⋅Cl, and 0.5 g 4,4-dimethylaminopyridine to the flask. Stir the mixture overnight under nitrogen. Addition of TBDMS⋅Cl results in a vigorous reaction that generates heat and results in the formation of a white precipitate. It is important to cool the reaction flask in an ice bath. The contents of the reaction flask will slowly return to room temperature when the ice in the bath has melted, and the reaction will proceed at room temperature for the duration.
3. Add 50 mL water to the reaction mixture and stir vigorously for 10 min to dissolve the white precipitate. 4. Transfer the contents of the flask to a 250-mL separatory funnel and discard the aqueous layer. Wash the organic fraction with three 30-mL fractions of water followed by three 30-mL fractions of brine solution. 5. Transfer the dichloromethane solution to a 250-mL Erlenmeyer flask and add 1 g anhydrous sodium sulfate. Swirl the solution for a few minutes and then allow to stand for 10 min. 6. Remove the drying agent by filtering the solution through a glass funnel with a glass wool plug. Synthesis of Endcap DMTr Phosphoramidites for Endcapped Oligonucleotides
7. Remove the solvent under reduced pressure using a rotary evaporator and water aspirator at room temperature to obtain the product 3-tert-butyldimethylsilyloxypropylamine (S.9) as a colorless oil.
5.6.10 Supplement 12
Current Protocols in Nucleic Acid Chemistry
Synthesize diacetamide S.10 8. Dissolve 8.17 g (2 eq, 0.04 mol) S.9 in 30 mL anhydrous dichloromethane in a 100-mL round-bottom flask containing a dry stir bar. Cool the flask in an ice bath. 9. Add 7.6 mL (3 eq, 0.05 mol) anhydrous triethylamine to the flask and then add 2.26 mL (1 eq, 0.018 mol) diglycolyl chloride drop-wise while stirring the reaction mixture on a magnetic stirrer. The reaction mixture will turn brown on addition of the diglycolyl chloride.
10. After addition of diglycolyl chloride is complete, remove the flask from the ice bath and stir the contents overnight at room temperature. 11. Add 40 mL water to the reaction mixture and stir vigorously for 10 min. 12. Transfer to a 125-mL separatory funnel and discard the aqueous layer. Wash the organic layer with two 30-mL portions of 5% acetic acid solution, then with two 30-mL portions of 5% sodium bicarbonate solution, and finally with two 60-mL portions of brine solution. 13. Transfer the dichloromethane solution to a 125-mL Erlenmeyer flask containing 0.5 g anhydrous sodium sulfate, swirl the solution for a few minutes, and allow the solution to stand for 10 min. 14. Remove the drying agent by filtering the solution through a glass funnel with a glass wool plug. 15. Remove the dichloromethane under reduced pressure using a rotary evaporator and water aspirator at room temperature to obtain the product N,N′-bis(3-tert-butyldimethylsilyloxypropyl)-2,2′-oxydiacetamide (S.10) as a brown oil. Dry the oil overnight in a 25-mL round-bottom flask under high vacuum (in a vacuum pump at <1 Torr). Desilylate to give S.11 16. Prepare a 2.9% (w/w) solution of concentrated HCl in 95% ethanol. 17. Dissolve 7.63 g (0.016 mol) S.10 in 15 mL of 95% ethanol in a 50-mL round-bottom flask containing a stir bar. 18. Add 15 mL of the HCl solution to the flask and stir the contents of the flask for 20 min on a magnetic stirrer. 19. Remove the solvent under reduced pressure using a rotary evaporator and water aspirator at room temperature to produce a brown oil. 20. Dissolve the brown oil in 15 mL methanol and transfer to a 125-mL separatory funnel. Wash the methanol layer with three 20-mL portions of hexanes. 21. Remove the solvent under reduced pressure using a rotary evaporator and water aspirator at room temperature to obtain the product N,N′-bis(3-hydroxypropyl)-2,2′oxydiacetamide (S.11) as a brown oil. Tritylate to give S.12 22. Coevaporate 7.63 g (0.016 mol) S.11 three times with 20-mL portions of anhydrous pyridine in a 100-mL round-bottom flask using a rotary evaporator connected to a vacuum pump. Dissolve the contents of the flask in 30 mL anhydrous pyridine. 23. Maintain the solution under a nitrogen atmosphere and add 5.707 g (0.016 mol) DMTr⋅Cl. Stir the contents of the flask overnight under a nitrogen atmosphere.
Methods for Cross-Linking Nucleic Acids
5.6.11 Current Protocols in Nucleic Acid Chemistry
Supplement 12
24. Remove the solvent under reduced pressure using a rotary evaporator connected to a vacuum pump and purify the compound S.12 by flash chromatography (APPENDIX 3E) on a 4 × 25–cm silica gel column, eluting with 0% to 1% (v/v) methanol in dichloromethane containing 1% (v/v) triethylamine. Collect the effluent in 10-mL fractions. 25. Analyze by TLC (APPENDIX 3E) on silica gel, developing with 1% (v/v) methanol and 1% (v/v) triethylamine in dichloromethane. Combine the fractions that contain the desired product (Rf = 0.27) and evaporate the solvent under reduced pressure on a rotary evaporator connected to a water aspirator to obtain the product as a foam. 26. Optional: If the product does not foam, dissolve the oily residue in 50 mL dichloromethane and transfer to a 125-mL separatory funnel. Wash the dichloromethane solution with 25 mL of 1% sodium hydroxide. Dry the dichloromethane solution over anhydrous sodium sulfate and remove the solvent under reduced pressure (steps 13 to 15). 27. Dry the product N-(3-hydroxypropyl)-N′-[3-(4,4′-dimethoxytrityloxy)propyl]-2,2′oxydiacetamide (S.12) overnight in vacuo (in a vacuum pump at <1 Torr) to obtain a light brown foam. Synthesize phosphoramidite S.13 28. Coevaporate 123.5 mg (0.224 mmol) S.12 with anhydrous acetonitrile and then with anhydrous dichloromethane in a 25-mL round-bottom flask on a rotary evaporator connected to a water aspirator. Dry the material overnight under vacuum (in a vacuum pump at <1 Torr). 29. Dissolve the contents of the flask in 2 mL anhydrous dichloromethane and then add 0.078 mL (0.234 mmol) 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphorodiamidite (using a 1-mL syringe) and 15.9 mg (0.224 mmol) 1H-tetrazole over 15 min while maintaining the flask under nitrogen. Stir the contents of the flask under nitrogen for 2 hr. 30. Analyze the reaction by TLC on silica gel, developing the plate with 5:4:1 (v/v/v) hexanes/dichloromethane/triethylamine. 31. Puri fy the product N-[3-O-(2-cyanoethyl-N,N-diisopropylphosphoramidite)propyl]-N′-[3-(4,4′ -dimethoxytrityloxy)propyl]-2,2′-oxydiacetamide (S.13) on a 2 × 20–cm column of silica gel, eluting with 5:4:1 hexanes/dichloromethane/triethylamine. 32. Combine the fractions containing the product (Rf = 0.2) and remove the solvent under reduced pressure on a rotary evaporator connected to a water aspirator. Dry the product overnight under vacuum by connecting the flask to a vacuum pump (<1 Torr). The phosphoramidite may be stored for short periods of (<10 days) at 4°C under anhydrous conditions, but best results are obtained if it is incorporated into an oligonucleotide sequence within a few days of its preparation.
COMMENTARY Background Information
Synthesis of Endcap DMTr Phosphoramidites for Endcapped Oligonucleotides
Oligonucleotides bearing specific crosslinks generally display greater stability than their uncross-linked counterparts. This can be most easily observed in their melting behavior, with cross-linked oligonucleotides having higher melting temperature (Tm) values. The
authors’ goal was to develop both hydrophobic and hydrophilic endcaps that not only stabilize very short oligonucleotide duplexes (e.g., 4 bp) but also offer a variety of environments that may be appropriate for different applications. Hydrophobic endcaps such as stilbene diether and stilbene dicarboxamide (Letsinger
5.6.12 Supplement 12
Current Protocols in Nucleic Acid Chemistry
whereas the naphthalene diimide endcap shows the greatest enhancement in melting temperature when stacked over a GC base pair. In both cases, the endcapped duplexes show significantly higher melting temperatures than their hairpin counterparts. The hydrophilic 2,2′-oxydiacetamide linker displays lower Tm values than either of the aromatic endcaps or the hexa(ethylene glycol) linker. However, the 2,2′-oxydiacetamide linker may offer some advantage when it is important to have a very hydrophilic moiety of minimal size with greater rigidity than the hexa(ethylene glycol) linker. The length spanned by these endcaps can be tuned by changing the chain length of the hydroxyalkyl portion of the endcaps. However, the authors have found that the length provided by the aminopropyl unit is optimal for obtaining the highest Tm values.
and Wu, 1995; Lewis et al., 1995) have been used to both stabilize DNA hairpins as well as study photo-induced charge separation and charge recombination (Lewis et al., 2000) and charge transfer (Lewis et al., 1997, 2001). Endcapped oligonucleotides are capable of specific protein binding as demonstrated by a stilbene dicarboxamide–endcapped oligonucleotide that mimics the REV responsive element and binds with equal affinity to the REV protein of HIV-1 (Nelson et al., 1996). Stilbene diether– endcapped duplexes have been shown to crystallize in a pinwheel arrangement with four oligonucleotide duplexes per asymmetric subunit (Lewis et al., 1999, 2000). Naphthalene and perylene diimide endcaps have been used to stabilize both duplex and triplex oligonucleotides (Bevers et al., 1998, 2000). An azobenzene endcap has also been used to stabilize short duplexes (Yamana et al., 1996, 1998). Applications of aliphatic hydrophilic endcaps are discussed in UNIT 5.3. Table 5.6.1 shows the melting temperature values for hairpin sequences with 4-bp stems and 4-nt loops. Replacement of the nucleotide loop by an endcap gives the results shown in Table 5.6.2. Both aromatic hydrophobic endcaps provide an overall increase in Tm values over the aliphatic endcaps. The more lipophilic terthiophene endcap provides the highest stability when it is stacked over an AT base pair,
Compound Characterization N,N′-Bis(3-hydroxypropyl)-naphthalene1,4,5,8-tetracarboxylic diimide (S.2). 1H NMR (250 MHz, CDCl3, δ): 8.8 (s, 4H, ar), 4.38 (t, J = 6.3 Hz, 3H, CH2), 3.65 (t, J = 5.7 Hz, 3H, CH2), 2.02 (m, 3H, CH2). 13C NMR (250 MHz, DMSO, δ): 162.0 130.7 129.4 125.6 59.9 38.0 30.7. MS: (+ve ESI) (M+H) 383, (–ve ESI) (M) 382. HRMS (FAB): calc. 383.1243; actual 383.1249.
Table 5.6.1
Melting Temperatures for 4-bp Stem Hairpin Oligonucleotides
Sequencea
Tm
ATGCTTTTGCAT ATGCAAAAGCAT GCTATTTTTAGC GCTAAAAATAGC
58.4°C 62.0°C 38.5°C 50.9°C
aThe underlined nucleotides form the loop of the hairpin oligonucleotide.
Table 5.6.2
Melting Temperatures for Endcapped Oligonucleotides
Sequencea
Type of endcap
Tm
ATGC-X-GCAT ATGC-X-GCAT GCTA-X-TAGC ATGC-X-GCAT GCTA-X-TAGC ATGC-X-GCAT GCTA-X-TAGC
Hexa(ethylene glycol) Naphthalene diimide Naphthalene diimide Terthiophene Terthiophene 2,2′-Oxydiacetamide 2,2′-Oxydiacetamide
61.4°C 74.6°C 61.6°C 62.3°C 65.8°C 51°C 41.7°C
aX refers to the location of the endcap.
Methods for Cross-Linking Nucleic Acids
5.6.13 Current Protocols in Nucleic Acid Chemistry
Supplement 12
Synthesis of Endcap DMTr Phosphoramidites for Endcapped Oligonucleotides
N-(3-Hydroxypropyl)-N′-[3-(4,4′-dimethoxytrityloxy)propyl]-naphthalene-1,4,5,8-tetracarboxylic diimide (S.3). 1H NMR (250 MHz, CD2Cl2, δ): 8.69 (s, 4H. naphthalene), 7.43 – 7.18 (m, 9H, DMTr), 6.8 – 7.9 (m, 4H, DMTr), 4.2 (m, 4H, CH2), 3.74 (s, 6H, OCH3), 3.68 (m, 2H, CH2), 3.09 (t, J = 6.1 Hz, 2H, CH2), 2.1 (m, 4H, CH2). HRMS (FAB): calc. 684.2471; actual 684.2464. N-[3-O-(2-Cyanoethyl-N,N-diisopropylphosphoramidite)propyl]-N′-[3-(4,4′-dimethoxy trityloxypropyl]-naphthalene-1,4,5,8-tetracarb oxylic diimide (S.4). 31P NMR: 147.8 (referenced to external 85% H3PO4). 5,5′′-Bis(3-hydroxypropyl)-2,2′:5′,2′′-terthiophene (S.6). 1H NMR (250 MHz, CDCl3, δ): 6.90 (d, 4H), 6.70 (d, 2H), 3.75 (t, 4 H), 2.90 (t, 4H), 1.95 (m, 4H). 5-(3-Hydroxypropyl)-5′′-[3-(4,4′-dimethoxytrityloxy)propyl]-2,2′:5′,2′′-terthiophene (S.7). 1H NMR (250 MHz, CDCl3, δ): 6.6-7.5 (m, 19H), 3.8 (s, 6H), 3.7 (t, 2 H), 3.2 (t, 2H), 2.9 (m, 4H), 1.95 (m, 4H). 5-[3-O-(2-Cyanoethyl-N,N-diisopropylphosphoramidite)propyl]-5′′-[3-(4,4′-dimethoxytrityloxy)propyl]-2,2′:5′,2′′-terthiophene (S.8). 1H NMR: 6.6-7.2 (m, 19H), 2.63.9 (1s, 1m, 12H), 3.2 (t, 2H), 2.9 (m, 4H), 2.7 (t, 2H), 2.5 (m, 2H), 2.0 (m, 4H), 1.2 (d, 12H), 1.0 (t, 4H). 31P NMR: 170. 3-tert-Butyldimethylsilyloxypropylamine (S.9). 1H NMR (250 MHz, CDCl3, δ): –0.010 (s, 6H), 0.831 (s, 9H), 1.595 (p, 2H), 2.737 (t, 2H), 3.637 (t, 2H). 13C NMR (300 MHz, CDCl3, δ): -5.4173, 18.2349, 25.8746, 36.2497, 39.3576, 61.1958. HRMS (ESI, +): calc. 190.1627; actual 190.1630. N,N′-Bis(3-tert-butyldimethylsilyloxypropyl)-2,2′-oxydiacetamide (S.10). 1H NMR (250 MHz, CDCl3, δ): 2.019 (s, 10H), 2.854 (s, 18H), 3.709 (p, 4H), 5.380 (q, 4H), 5.686 (t, 4H), 5.976 (s, 4H). 13C NMR (300 MHz, CDCl3, δ): –5.476, 18.244, 25.848, 31.676, 37.352, 61.907, 71.270. HRMS (ESI, +): calc. 476.3102; actual 476.3091. N,N′-Bis(3-hydroxypropyl)-2,2′-oxydiacetamide (S.11). 1H NMR (250 MHz, CD3OD, δ): 744 (q, 4H), 3.37 (t, 4H), 3.60 (t, 4H), 4.039 (s, 4H). 13C NMR (250 MHz, CD3OD, δ): 33.098, 37.290, 60.547, 71.409, 171.729. HRMS (ESI, +): calc. 249.1450; actual 249.1446. N-(3-Hydroxypropyl)-N′-[3-(4,4′-dimethoxytrityloxy)propyl]-2,2′-oxydiacetamide (S.12). 1H NMR (250 MHz, CD2Cl2, δ): 1.602 (p, 2H), 1.805 (p, 2H), 3.164 (t, 2H), 3.283-
3.429 (m, 4H), 3.543 (t, 2H), 3.779 (s, 6H), 3.914, 3.943 (d, 4H), 6.817-7.365 (m, 13H). N-[3-O-(2-Cyanoethyl-N,N-diisopropylphosphoramidite)propyl]-N′-[3-(4,4′-dimethoxytrityloxy)propyl]-2,2′-oxydiacetamide (S.13). 31P NMR: 148 (referenced to external 85% H3PO4).
Critical Parameters Anyone with a moderate amount of experience in chemical synthesis should not find any difficulties in the synthesis of any of these endcaps. The reactions used to generate the DMTr and phosphoramidite derivatives are extremely sensitive to moisture and must be performed under anhydrous conditions. Additionally, the DMTr group is acid labile, and thus care must be taken to avoid any exposure to acid. As a precaution, small amounts of triethylamine can be used during chromatography. The tritylation reaction in each protocol yields a mixture of unreacted, monotritylated, and detritylated products. The ratio of reactants was chosen to maximize the yield of the monotritylated product. The reactant (untritylated), monotritylated, and ditritylated products can be distinguished by TLC. The ditrylated product runs at higher Rf, while the reactant migrates more slowly than the monotritylated products. The phosphoramidite derivative also requires careful handling, and exposure to air or acids must be avoided. It is preferable to synthesize the phosphoramidite derivative of the required endcap just before oligonucleotide synthesis.
Anticipated Results Yields of endcapped oligonucleotides should generally be >90% using standard automated synthesis procedures (see, e.g., APPENDIX 3C). The coupling time for the endcap phosphoramidite, however, should be increased to 15 min.
Time Considerations The phosphoramidite derivatives of the naphthalene diimide and terthiophene hydrophobic endcaps can each be prepared in 3 days including the time required for purification. The hydrophilic oxydiacetamide endcap synthesis requires significantly longer times and can be completed in 7 to 8 days.
5.6.14 Supplement 12
Current Protocols in Nucleic Acid Chemistry
Literature Cited Altmann, S., Labhardt, A.M., Bur, D., Lehmann, C., Bannworth, W., Billeter, M., Wuthrich, K., and Leupin, W. 1995. NMR studies of DNA duplexes singly cross-linked by different synthetic linkers. Nucl. Acids Res. 23:4827-4835.
Lewis, F.D., Letsinger, R.L., Wasielewski, M.R., and Egli, M. 2000a. Structure and electron transfer in synthetic DNA hairpins. Biophys. J. 78:817Symp.
Bevers, S., O’Dea, T.P., and McLaughlin, L.W. 1998. Perylene- and naphthalene-based linkers for duplex and triplex stabilization. J. Am. Chem. Soc. 120:11004-11005.
Lewis, F.D., Wu, T.F., Liu, X.Y., Letsinger, R.L., Greenfield, S.R., Miller, S.E., and Wasielewski, M.R. 2000b. Dynamics of photoinduced charge separation and charge recombination in synthetic DNA hairpins with stilbenedicarboxamide linkers. J. Am. Chem. Soc. 122:2889-2902.
Bevers, S., Schutte, S., and McLaughlin, L.W. 2000. Naphthalene- and perylene-based linkers for the stabilization of hairpin triplexes. J. Am. Chem. Soc. 122:5905-5915.
Lewis, F.D., Letsinger, R.L., and Wasielewski, M.R. 2001. Dynamics of photoinduced charge transfer and hole transport in synthetic DNA hairpins. Accounts Chem. Res. 34:159-170.
Letsinger, R.L. and Wu, T.F. 1995. Use of a stilbenedicarboxamide bridge in stabilizing, monitoring, and photochemically altering folded conformations of oligonucleotides. J. Am. Chem. Soc. 117:7323-7328.
Nelson, J.S., Giver, L., Ellington, A.D., and Letsinger, R.L. 1996. Incorporation of a non-nucleotide bridge into hairpin oligonucleotides capable of high-affinity binding to the Rev protein of HIV-1. Biochemistry 35:5339-5344.
Lewis, F.D., Wu, T.F., Burch, E.L., Bassani, D.M., Yang, J.S., Schneider, S., Jager, W., and Letsinger, R.L. 1995. Hybrid oligonucleotides containing stilbene units—Excimer fluorescence and photodimerization. J. Am. Chem. Soc. 117:87858792.
Yamana, K., Yoshikawa, A., and Nakano, H. 1996. Synthesis of a new photoisomerizable linker for connecting two oligonucleotide segments. Tetrahedron Lett. 37:637-640.
Lewis, F.D., Wu, T.F., Zhang, Y.F., Letsinger, R.L., Greenfield, S.R., and Wasielewski, M.R. 1997. Distance-dependent electron transfer in DNA hairpins. Science 277:673-676. Lewis, F.D., Liu, X.Y., Wu, Y., Miller, S.E., Wasielewski, M.R., Letsinger, R.L., Sanishvili, R., Joachimiak, A., Tereshko, V., and Egli, M. 1999. Structure and photoinduced electron transfer in exceptionally stable synthetic DNA hairpins with stilbenediether linkers. J. Am. Chem. Soc. 121:9905-9906.
Yamana, K., Yoshikawa, A. Noda, R., and Nakano, H. 1998. Synthesis and binding properties of oligonucleotides containing an azobenzene linker. Nucleosides Nucleotides 17:233-242.
Contributed by Maneesh R. Pingle, Pei-Sze Ng, Xiaolin Xu, and Donald E. Bergstrom Purdue University West Lafayette, Indiana
Methods for Cross-Linking Nucleic Acids
5.6.15 Current Protocols in Nucleic Acid Chemistry
Supplement 12
Engineering Terminal Disulfide Bonds Into DNA Characterization of synthetic oligonucleotides shapes much of the understanding of “native,” higher-molecular-weight DNA and RNA molecules. Although of immense utility, short oligonucleotides usually possess lower structural and thermal stability and have greater end effects than the larger nucleic acid constructs they are intended to model. Hence, the physiochemical properties of oligonucleotides may not always compare favorably to those of larger nucleic acids (Elson et al., 1970; Scheffler et al., 1970; Baldwin, 1971; Record and Lohman, 1978; Breslauer, 1986; Breslauer et al., 1986; Olmsted et al., 1991; MacGregor, 1996; SantaLucia et al., 1996). Arguably, the most successful approach to stabilize oligonucleotides is to connect the strands that comprise a helical structure with an interstrand cross-link (Pinto and Lippard, 1985; Borowy-Borowski et al., 1990; Kirchner and Hopkins, 1991; Boger et al., 1991; Sigurdsson et al., 1993; Willis et al., 1993). Methods to cross-link nucleic acids can generally be divided into two catagories. In the first category, cross-links are formed using an exogenous reagent, most commonly a (bis)electrophile. Because (bis)electrophiles can react with nearly all of the nucleophilic sites on the bases, these agents often have little or no sequence specificity and form complex mixtures of cross-linked aducts (Millard et al., 1990, 1991; Kirchner et al., 1992). Although some natural products (like mitomycin C) and synthetic compounds (such as cisplatin and psoralen) can form lesions at unique sites, these reagents require the presence of specific recognition sites within a target sequence to generate the cross-link, which limits their utility (Sherman et al., 1985; Tomasz et al., 1987; Teng et al., 1989; Lemaire et al., 1991). In some cases, cross-link formation by alkylating agents can also have undesirable effects such as disrupting base stacking (Sherman et al., 1985; Millard et al., 1990). In the second category, cross-links can be introduced into oligonucleotides through solidphase synthesis of oligomers site-specifically labeled with modified nucleosides that present reactive groups. Positioning the reactive groups in proximity on opposing strands of a helix allows for the formation of a cross-link. This general strategy requires appropriate selection of both loci to be bridged, as well as a chemistry
UNIT 5.7
to form the cross-link. In one of the most effective examples of this approach, Webb and Matteucci (1986) demonstrated that DNA oligomers containing cytosines bearing an aziridine group on the N4 position form cross-links after annealing to a complementary oligomer, followed by selective opening of the aziridine by the exocyclic amine of an opposing dC or dA. These cross-links have proved useful for some experiments, but this chemistry in particular, and related methods in general, have several limitations. For example, ethanobridged cross-links are not formed in high yield, the internal mismatch required to form the cross-link can give rise to (local) disruption of helical geometry, and the resulting crosslinks can potentially interfere with protein and drug binding (Catalano and Benkovic, 1989; Cowart et al., 1989; Cowart and Benkovic, 1991). An alternate approach involves incorporating an intrastrand cross-link at the terminus of a helical structure. For example, one end of a duplex can be covalently linked by bridging the 3′-and 5′-terminal hydroxyl groups with either oligonucleotide, oligoglycol, or alkyl linkers to form stem-loop structures or “hairpins” (Durand et al., 1990; Kool, 1991; Rumney and Kool, 1992; Salunkhe et al., 1992; Bannwarth et al., 1994; Gao et al., 1994, 1995; Williams and Hall, 1996). Both ends of a duplex can also be covalently capped with linkers to generate double hairpins or “dumbbells” (Germann et al., 1985; Wemmer and Benight, 1985; Erie et al., 1987, 1989; Benight et al., 1988; Ashley and Kushlan, 1991; Amaratunga et al., 1992; Doktycz et al., 1992; Paner et al., 1992). Because dumbbells denature in a monomolecular fashion and do not suffer from end effects, they are particularly useful in thermodynamic experiments (Erie et al., 1987, 1989). However, the synthesis of DNA dumbbells has in some cases proved to be quite challenging, thus limiting their utility (Erie et al., 1987). In addition, because the linkers are tethered to the terminal hydroxyl groups, some standard enzymatic manipulations such as end-labeling are not possible.
Contributed by Gary D. Glick Current Protocols in Nucleic Acid Chemistry (2003) 5.7.1-5.7.13 Copyright © 2003 by John Wiley & Sons, Inc.
Methods for Cross-Linking Nucleic Acids
5.7.1 Supplement 13
DESIGN OF AN IDEAL CROSS-LINK To develop a cross-linking approach that would be simple and general and would overcome the drawbacks of other methods, the author of this unit, and colleagues, chose eight important criteria that should be met (Table 5.7.1). It was clearly desirable to incorporate the cross-links by solid-phase synthesis to permit the modifications to be placed site-specifically and in close proximity within any given target sequence. Yet it was critical to find chemistry that would be specific and efficient for cross-link formation. Thiols were selected as the reactive functional groups because the mild Table 5.7.1
Requirements for an “Ideal” Nucleic Acid Cross-Linka
Requirementsb
Rationale
Potential solution
Increase the conformational stability towards thermal-, ionic-, pH-, and concentration-induced conformational changes Form interstrand cross-link site-specifically
Conformationally stable nucleic acids that are structurally homogeneous will facilitate their structural and thermodynamic analysis Limits undesired adduct formation resulting in high yields of cross-linked product Necessary if the structural aspects of cross-linked constructs are to be compared to their unmodified nucleic acid precursors
Covalent interstand cross-links confer a large degree of conformational stability
Allows for protein and ligand-nucleic acid interactions to be studied; maximizes (thermal) stability
Linkers at terminus of helix
Cross-link does not alter native geometry
Grooves of the helices, counter-ion binding, and hydration must remain unaltered
Engineering Terminal Disulfide Bonds Into DNA
redox chemistry used to form disulfide bonds from thiols is specific for sulfur. In addition, disulfide bonds are formed in high yield, often quantitatively, and are stable to a wide variety of solvents and reagents, yet are cleaved by reduction. Finally, the use of disulfide bonds to constrain macromolecular architecture has already been demonstrated in the peptide/protein literature (Clarke and Fersht, 1993, and references therein). The next step in developing this chemistry was to select appropriate loci for modification. Because cross-links residing in either the major or minor groove could interfere with ligand recognition and hydration, cross-links were de-
Position functional groups proximal to one another on opposing strands of a helix Position cross-link within a sterically accessible space
3′- and 5′-hydroxyl groups are Needed for wide range of free to [32P]-end-label biochemical assays (e.g., footprinting/sequencing) Prepared and isolated in large Allows for high-resolution quantities physical measurements such as NMR, DSCc, and X-ray diffraction studies
Cross-link located on the base rather than terminal hydroxyl groups Efficient cross-linking chemistry
Reversible
Assess structural and thermodynamic effects of base modification before and after cross-linking
Reversible disulfide cross-link
Flexible to a wide variety of nucleic acid structures
Broad applicability will be necessary if this methodology is to be used uniformly in nucleic acids
Position functional tether at any base or sugar site; cross-link within a sterically accessible space
aFrom Glick (1998). bRelative to the unmodified nucleic acid. cDSC, differential scanning calorimetry.
5.7.2 Supplement 13
Current Protocols in Nucleic Acid Chemistry
signed at the terminus of the helical structure (Figure 5.7.1). To avoid using the 3′- and 5′-hydroxyl groups, the terminal bases themselves were modified. This strategy exploited the fact that the terminal residues in duplexes have a reduced stability due to end effects, often referred to as “end fraying” (Patel and Hilbers, 1975). Therefore, altering the hydrogen bonding groups of the two opposing bases at the terminus of a duplex should not adversely affect helical stability, provided the thiol modifications do not disrupt base stacking. The free energy of a dT-dT mismatch located at the terminus of a duplex is ∼1.0 kcal/mol more stable than a dT-dT mismatch within a duplex (Aboul-ela et al., 1985; Freier et al., 1986). While this energetic penalty could be compensated for upon formation of the cross-link, it necessarily limits the overall (thermodynamic) stabilization the cross-link can provide. When two thymidine residues directly oppose each other in duplex DNA, their N3 positions project toward the center of the helix and converge to ∼4.5 Å. Based on this observation, replacing the terminal bases on one or both ends of a duplex with N3-(alkylthiol)thymidine should be an ideal way to form interstrand disulfide cross-links. Molecular modeling studies suggest that disulfide cross-links can form when the terminal bases of a duplex are
A
replaced with either N3-(methylthiol)thymidine or N3-(ethylthiol)thymidine. Since N3(methylthiol)thymidine is expected to decompose under the acidic conditions used to detritylate synthetic oligonucleotides, N3-(ethyl thiol)thymidine (T*SH) was chosen (Figure 5.7.1B). The following sections describe key aspects pertaining to the synthesis, structure, dynamics, thermodynamic stability, and in vitro biological properties of these disulfide crosslinked DNA oligonucleotides. Two applications of this cross-linking chemistry are then discussed, as are recent experiments using different thiol-modified nucleosides to generate disulfide cross-links within RNA secondary and tertiary structure. Lastly, other methods that have been developed to incorporate disulfide cross-links into nucleic acids are briefly outlined.
DISULFIDE CROSS-LINKED DNA DUPLEXES Synthesis The properties of disulfide cross-linked DNA duplexes were explored by synthesizing analogs of two previously well-studied oligonucleotides. The first is a hairpin whose sequence is derived from the ColE1 cruciform
B O SR N N
O
dRib s s
T*SH; R = H T*tBu; R = StBu T*2 ; R = ) 2
Figure 5.7.1 ((A) Synthetic strategy. To place cross-links within a duplex requires synthesizing thiol-modified nucleosides, incorporating the modified bases within a target by solid-phase synthesis, removal of all protecting groups, and air oxidation to form the cross-link. (B) Chemical structure of modified thymidine and cross-link. During synthesis, the thiol group on T*SH is protected as a tert-butyl mixed disulfide (T*tBu) and this protecting group is stable to all conditions of solid-phase synthesis, deprotection, and purification. The coupling efficiency of this base is indistinguishable from thymidine (>99% per cycle). To place T*tBu at the 3′ terminus, the 3′-hydroxyl group is attached to controlled-pore glass. For T*2, R is the disulfide cross-link. From Glick (1998).
Methods for Cross-Linking Nucleic Acids
5.7.3 Current Protocols in Nucleic Acid Chemistry
Supplement 13
5′ GGC A A T CC CCG T T AGG
1
C
A
CGCGA A T T CGC G T T
C
A C G C G A A T T C G C T*tBu
T
2
4a
5a
A T
T
T*tBu G C G A A T T C G C T*tBu
G C G C T T A A G C G T*tBu
T
T* G C A A T C C T* C G T T A G G
2b
3
T
C S S
GCGC T T A AGCG C
T
T*tBu G C A A T C C T*tBu C G T T A G G
2a
5′
C G C G A A T T C G C T* G C G C T T A A G C G T*
T
S S
S S
4b
T* G C G A A T T C G C T* T* C G C T T A A G C G T*
S S
5b
Figure 5.7.2 Duplex sequences and cross-linked analogs. From Glick (1998).
(S.1; Figure 5.7.2; Blatt et al., 1993), and the second is the Dickerson/Drew dodecamer (S.3; Wing et al., 1980). Synthesis of S.2a, S.4a, and S.5a is conducted using standard phosphoramidite chemistry using N-benzoyl- and N-isobutyryl-protected bases (Glick et al., 1992; Cain et al., 1995; Osborne et al., 1996). After deprotection and purification of each thiol-modified DNA by reversed-phase HPLC, the t-butyl mixed disulfide protecting groups on each sequence are cleaved with DTT (∼20 equiv per thiol, pH 8, overnight at 4°C). Reduced DNA samples are separated from the DTT by reversed-phase HPLC. Disulfide bond formation is performed by dissolving each sample (DNA concentration of ∼2 µM) in phosphate buffer (pH 8.3) and stirring vigorously at 25°C with exposure to air. The reactions are usually complete in 8 hr, as determined by a negative Ellman’s test. The cross-linked DNAs (S.2b, S.4b, and S.5b) are then isolated by either PAGE or HPLC, and incorporation of the modified bases is confirmed by enzymatic digestion. Importantly, disulfide bond formation is quantitative.
Structural Studies
Engineering Terminal Disulfide Bonds Into DNA
The effects of introducing the thiol modifications were first assessed by comparing UV thermal denaturation profiles of S.2a to that of the corresponding wild-type sequence (S.1). The melting temperatures (Tm) values are within 1°C and the transitions are nearly superimposable, which suggests that the thiol linkers
do not alter the stability or thermal denaturation pathways of the modified hairpin relative to its unmodified counterpart (Glick, 1991). These data also suggest that all of the stability conferred by the disulfide bond will be reflected in the cross-linked structure, since there is not a significant energetic penalty for replacing the terminal bases with the N3-thiol-modified thymidines. Introducing a disulfide cross-link in S.1 to generate S.2b increases the Tm from 65° to 81°C in low-ionic-strength buffers. If the concentration of Na+ is >100 mM, the crosslinked hairpin denatures above 96°C and Tm values cannot be measured by UV spectroscopy (Glick, 1991). To further investigate the structural effects of the disulfide modification, the solutionphase conformations of S.1 and S.2b were determined by NMR spectroscopy (Cain et al., 1995). The 8-bp-long stem of these sequences adopts a B-form helix, whereas the 5-bp-long single-stranded loop appears to be flexible and cannot be represented by a unique static conformation. NOESY cross-peak volumes, proton (both labile and non-labile) and phosphorus chemical shifts, as well as both homo- and heteronuclear coupling constants for the crosslinked hairpin are virtually identical to those measured for the unmodified sequence, even for the residues that are proximal to the crosslink. Thus, within the resolution of NMR spectroscopy, the two hairpins are structurally isomorphous.
5.7.4 Supplement 13
Current Protocols in Nucleic Acid Chemistry
Similar to the results described above for the ColE1 hairpin, replacing one or both of the term inal dG-dC base pairs in d(CGCGAATTCGCG)2 with the modified thymidine does not significantly alter the thermal stability of these duplexes relative to the parent sequence (Osborne, 1996; Osborne et al., 1996). When the exchangeable and non-exchangeable protons and the 31P resonances of S.5b are assigned and compared to those for the parent duplex, S.3, the spectra are virtually identical, which strongly indicates that these sequences also adopt very similar structures. (Because S.4b is not symmetric, a direct comparison with either S.3 or S.5b is not possible.) To provide further evidence of this point, 2-D NOESY spectra of S.5b as a function of mixing time can be measured and interproton distances obtained from initial build-up plots. These data for S.5b are nearly identical to those for the wild-type dodecamer. Based on these findings, along with the results of CD and nuclease-susceptibility experiments, these alkylthiol modifications, in either the disulfide cross-linked or reduced and protected forms, do not alter native structure (Osborne et al., 1996).
Thermodynamic Measurements To elucidate the thermal and thermodynamic consequences of modifying and constraining DNA duplexes via the disulfide chemistry, differential scanning calorimetry (DSC) measurements can be conducted to characterize their thermally induced denaturation. DSC measurements on duplexes S.3 to S.5 (Osborne et al., 1996) represent the first use of calorimetry to investigate the thermodynamic consequences of constraining DNA with disulfide cross-links. The use of calorimetry is critical here because S.3 does not denature in a twostate fashion and cannot be analyzed using a van’t Hoff treatment. Consistent with the NMR data, DSC data show that a large energetic penalty is not incurred by replacing the terminal base pair(s) with N3-(ethylthiol)thymidine: the Tm values of S.3, S.4a, and S.5a are within 11°C of each other. The overall free energies for S.3, S.4a, and S.5a are comparable; this similarity arises due to compensations in both enthalpy and entropy (Osborne, 1996). The DSC measurements suggest that introducing cross-link(s) into S.3 results in two changes. First, constraining the dodecamer results in a significant increase in thermal stability. A single disulfide cross-link changes the molecularity of the complex from bimolecular to monomolecular (S.4b). However, a second
disulfide cross-link (S.5b) results in a constrained conformation with a reduced entropy compared to S.4b. From the DSC data, the cross-link imparts ∼3 kcal/mol of stabilization. The change in entropy certainly reflects differences in the native and/or denatured states of S.5b compared to S.4b. On first inspection, it would appear that the most likely source for the observed decrease in entropy is the denatured state, since the conformational freedom of the denatured state of S.5b is less than that of S.4b. However, based on the data, differential entropic contributions from the native states, as well as influences from differential solvation in both the initial and the final states, cannot be excluded. Notwithstanding, the data show that the entropy value is responsible for the increase in thermal stability of S.5b relative to S.4b. This is the first conformationally constrained nucleic acid system where the increase in melting temperature is predominantly due to a decrease in entropy (Erie et al., 1987, 1989).
Dynamics Measurements The static structure of DNA can explain many aspects of its function and properties. However, a local base-pair opening is implicated in a number of important chemical, biological, and mechanical processes involving DNA (Frank-Kamenetskii, 1985; Ramstein and Lavery, 1988, 1990; Guéron and Leroy, 1995; Tari and Secco, 1995). Hence, defining the dynamics of base-pair opening is necessary to fully understand the physiochemical and biological properties of DNA. Although the opening kinetics for several different constructs have been measured, the opening kinetics for oligonucleotides constrained with cross-links (e.g., hairpin loops, glycol bridges) have not been reported (Gueron and Leroy, 1995). To address this, the base-pair lifetimes and apparent dissociation constants of S.1 and S.2b were measured (Cain and Glick, 1997). Comparison of the lifetimes and apparent dissociation constants for corresponding base-pairs of the two hairpins indicates that the cross-link neither increases the number of base-pairs involved in fraying nor alters the lifetime, dissociation constant, or the opened structure from which exchange occurs for the base-pairs that are not frayed. The cross-link does, however, stabilize the frayed penultimate base-pair of the stem duplex by increasing the closing rate of this base-pair. Significantly, the disulfide cross-link is more effective at preventing fraying than the 5-bp-long hairpin loop.
Methods for Cross-Linking Nucleic Acids
5.7.5 Current Protocols in Nucleic Acid Chemistry
Supplement 13
5′
5′
S S 3′
3′
Figure 5.7.3 A triplex schematic. From Glick (1998).
DISULFIDE CROSS-LINKED DNA TRIPLEXES Design
Engineering Terminal Disulfide Bonds Into DNA
Folding of DNA triple helices based on the pyrimidine⋅purine-pyrimidine motif (py⋅pupy; dot = Hoogsteen and dash = Watson-Crick base-pairing) is affected by a number of factors including sequence length (i.e., the number of triplets formed), composition, the presence of base-pair mismatches, as well as solution conditions including pH and monovalent and divalent counterion concentrations (Moser and Dervan, 1987; Pilch et al., 1990; Kiessling et al., 1992; Plum et al., 1995). For example, a major factor in the stability of triplexes that contain C+⋅G-C triplets is the necessity for protonation of the N3 position of cytosine, which generally limits the stability of small triple helices of this type to pH below 7 (Callahan et al., 1991; Singleton and Dervan, 1992). The narrow pH range required for folding of these triplexes has hampered efforts to assess the physical properties of this motif under physiological conditions. Such data are clearly needed to design triplex sequences of higher affinity and specificity for diagnostic purposes in vitro and for use in vivo. While methods exist to stabilize py⋅pu-py triple helices, they rely on modifications that may alter the native triplex structure (Sun and Hélène, 1993; Thuong and Hélène, 1993). Therefore, it became important to determine if covalently locking the third strand of a triplex to the major groove through a structurally nonperturbing disulfide cross-link would afford constructs that are stable under physiological conditions. In other words, can the constraint provided by a disulfide cross-link alter the apparent pKa of a triplex?
This question was tested by using an intramolecular triplex rather than an intermolecular construct because the former should require only one cross-link to link the Hoogsteen strand to the Watson-Crick duplex (Figure 5.7.3; Goodwin et al., 1994; Osborne et al., 1997). To place a cross-link between the Hoogsteen and Watson-Crick strands, sites of chemical modification on the terminal bases must first be identified. In a T⋅T-A triplet, which is analogous to the base-pair substitution used to crosslink the terminus of duplexes (see Figure 5.7.1), the N3 position on the Hoogsteen thymidine and the C5 position of the Watson-Crick thymidine converge. Since the cross-link used for B-form duplexes is inappropriate here, a triplex cross-link was designed using a C5alkylthiol-modified thymidine (C53S, where three is the number of atoms in the linker, including thiol) and N3-(ethylthiol)thymidine (Figure 5.7.4; Goodwin and Glick, 1993). The optimal pH for air oxidation of thiols to form disulfide bonds is generally above the pKa of the thiol of interest (∼8.5). At the pKa of many thiols, triple helices containing C+⋅G-C base triplets are unfolded because the N3 position of cytosine is not protonated. To form a disulfide cross-link in a py⋅pu-py triplet, it is necessary to identify a sequence that (partly) folds into a triplex at a pH where cross-link formation readily proceeds. Recently, Häner and Dervan (1990) reported a 34-bp-long intramolecular triple helix that remains partially folded at up to pH 7.5 at 24°C in a buffer containing 25 mM Mg2+. In principle, therefore, a disulfide crosslink can form under the conditions needed to fold a suitably modified variant of this oligonucleotide (Figure 5.7.5).
5.7.6 Supplement 13
Current Protocols in Nucleic Acid Chemistry
dR
N
O N
O
O H
H N
H T
N
dR
N
dR O T
N A
O
H
N O
N
N
N
dR
N H
H
O
H
N
N
N
T H
N
dR
N N
N
A
O
dR T dR
N
O N
H
O O
S T*S
H
N
S H
N N O
dR
N
N
dR
N N A
C53S
Figure 5.7.4 Chemical structure of triplex cross-link. From Glick (1998).
Preparation of triplex sequences containing T*tBu and C53StBu can be achieved via automated solid-phase DNA synthesis using standard protocols with an average stepwise coupling efficiency of >98.5%. Removal of the phosphate- and base-protecting groups followed by reversed-phase HPLC purification provides a ∼42% yield of S.7a (based on a 1-µmol synthesis). To form the cross-link, the tert-butylthiol protecting groups are removed with DTT and the reduced sample is vigorously stirred at room temperature in PBS (pH 7.25, 5 mM MgCl2) while exposed to air. After 24 hr, no starting material is observed by HPLC, and aliquots from the reaction mixtures test negative with Ellman’s reagent. Cross-linked DNA is purified by reversed-phase HPLC to give S.7b in ∼28% isolated overall yield (based on
a 1-µmol synthesis; ∼75% yield from S.7a). Enzymatic nucleoside composition analysis confirms incorporation of the modified bases and formation of the cross-link, and native and denaturing PAGE indicates that the structure formed is monomeric.
Structural Studies When imino proton spectra of S.6 and S.7b are assigned using standard 2-D techniques under conditions that favor triplex formation (pH 6, 0.5 mM Mg2+), the imino proton spectra of both sequences are virtually identical, which indicates that the modifications do not disrupt native triplex structure (Osborne et al., 1997). When S.6 or S.7a is titrated from pH 6 to 8, dissociation of the third strand is observed. By contrast, the cross-linked triplex S.7b is con-
Methods for Cross-Linking Nucleic Acids
5.7.7 Current Protocols in Nucleic Acid Chemistry
Supplement 13
+
+
+
T27 C28 T29 C30 T31 T32 C33 X34 T21-26 5′- A1 G2 A3 G4 A5 A6 G7 Y8 T20 C19 T18 C17 T16 T15 C14 A13
T9-12
6: X, Y = T 7a: X = T*tBu 7b: X = T*S disulfide cross-link Y = C53S-StBu Y = C 5 3S
Figure 5.7.5 Triplex sequence. From Glick (1998).
formationally stable over this pH range and only begins to unfold at pH ∼9. Moreover, S.7b is stable from pH 6 to 8 in the absence of Mg2+. Because of line broadening above 5°C, NMR cannot be used to study these triplexes. Therefore, CD spectroscopy is used. Monitoring the triplex CD signature band at 215 nm in the presence of Mg2+, S.7b does not begin to melt until ∼60°C at pH 6 (30°C for S.6 and S.7a) and 40°C at pH 8 (<20°C for S.6 and S.7a). Constructing titration curves from the CD data reveals that the apparent pKa for S.7b is ∼8.6, which is at least 1.5 pKa units greater than S.6 and S.7a. These results clearly demonstrate that the presented cross-link can be used to stabilize higher-order DNA structures.
Thermodynamic Measurements
Engineering Terminal Disulfide Bonds Into DNA
DSC measurements can be conducted to elucidate the thermodynamic consequences of modifying and constraining DNA triplexes with the disulfide chemistry (Völker et al., 1997). Cross-linked triplexes S.6 and S.7a melt in a biphasic manner above pH 6, with the initial triplex-to-duplex transition (Hoogsteen strand release) occurring at lower temperatures than melting of the hairpin. In contrast, cross-linking increases the thermal stability of the Hoogsteen transition such that the triplex and hairpin duplex denature simultaneously. Model-independent thermodynamic data obtained by DSC reveal that the cross-link-induced increase in triplex thermal stability corresponds to a free energy stabilization of ∼3 kcal/mol, with this stabilization being entirely entropic in origin. In other words, the cross-link is enthalpically neutral, but nevertheless induces a triplex stabilization of 3 kcal/mol due to a reduction in the entropy change associated with triplex melting. To deduce the origin(s) of this entropic impact, the pH and ionic strength dependence
of the melting transitions were measured. From a comparison of the melting transitions at different pH values and ionic strengths, it can be estimated that 0.4 more protons are associated with the cross-linked triplex state than with the uncross-linked triplex, and 1.3 fewer counterions are released on melting the cross-linked triplex. Thus, the entropic stabilization is not solely a result of a reduction in conformational entropy.
Dynamics Measurements At the start of this project, it was not known whether the base-pairs (Hoogsteen and Watson-Crick) that comprise triple-helical DNA open to any significant extent within a stable triplex. To address this question, the conformational dynamics of S.6 and S.7b were studied by 2-D exchange and NOE spectroscopy, and by measuring base-catalyzed imino-proton exchange rates (Cain and Glick, 1998). Under conditions that promote triplex formation (pH 6.0, 1°C), S.6 and S.7b exhibit a small and identical degree of conformational heterogeneity. However, at higher temperatures (pH 6.0, 37°C), S.6 exhibits more extensive heterogeneity than S.7b. The exchange times for WatsonCrick imino protons are ∼1 hr for both triplexes. However, the Hoogsteen base-pair lifetimes of S.6 could not be measured because this sequence is conformationally labile under the alkaline conditions necessary to conduct the exchange experiments. Due to the extraordinary pH stability conferred by the cross-link, it is possible to measure the Hoogsteen lifetimes for S.7b. The lifetimes of the these base-pairs range from ∼3 to 370 msec. As for Watson-Crick base-pairs, the Hoogsteen lifetimes are highest at the central region within the triplex and taper off towards the termini, which is suggestive of imino ex-
5.7.8 Supplement 13
Current Protocols in Nucleic Acid Chemistry
5′ GGC A A T CC CCG T T AGG
N
N N
N
N = A, 8 T, 9 G, 10 C, 11
N
Figure 5.7.6 Hairpin ligands for the binding study. From Glick (1998).
change mechanisms involving end effects. In all cases, the lifetime of a Hoogsteen base-pair is shorter than that of the Watson-Crick basepair in the same triplet, which is consistent with the greater stability of Watson-Crick over Hoogsteen base-pairs. The rate of triplex-toduplex conversion for S.7b at 1°C and pH 6.9 is low, with an upper bound of 3.2 × 10−4 sec−1. The imino protons of S.7b exchange slowly in PBS with exchange times as long as 1 hr, but the base-pair lifetimes are all <3 min, reflecting the fact that imino proton exchange is not opening-rate limited. Because the disulfide crosslink effectively prevents conformational heterogeneity associated with py⋅pu-py triple helices containing C+⋅G-C base triplets at neutral pH, constructs possessing this modification can serve as model systems to examine the structural and thermodynamic aspects of triplex formation in vitro, and to develop sequences that bind DNA with higher affinity and specificity.
APPLICATIONS Defining the biochemical, structural, dynamic, and thermodynamic impacts of constraining DNA with the disulfide chemistry described above opens the way for applying these cross-links in a host of different experiments. Uses of this chemistry include, among others, the joining of large pieces of DNA or RNA through disulfide bonds for the construction of nano-scale architectures, the design of redox-activated switches/devices, and the probing of secondary and tertiary structure. Below is a description of two representative applications of this chemistry. In the first, a disulfide bond was employed to stabilize or “trap” a DNA structure that would not be stable in its absence; in the second, a disulfide bond was used to report on conformational transitions in a protein binding study.
Stabilizing Non-Ground-State Structures In the absence of disulfide cross-links, the molecules described in the above sections are
themselves relatively stable with respect to conformational isomerization. In principle, however, it should also be possible to trap higherenergy non-ground-state structures with disulfide cross-links. Synthetic access to such constructs should be important in areas such as targeted drug delivery, protein-DNA recognition, and biophysical studies of alternate DNA geometries. The practicality of using disulfide cross-links in such endeavors can be demonstrated from the example of trapping the Dickerson/Drew dodecamer premelting intermediate with a disulfide cross-link. Both S.3 and S.5a (Figure 5.7.2) thermally denature in a biphasic manner in buffers containing 10 mM Na+ and 50 µM DNA (Marky et al., 1983). The first transition defines melting of the duplex to a hairpin structure, while the second transition represents denaturation of the hairpin to a random coil. The premelting intermediate is cross-linked by air oxidation of the sulfhydryl groups in S.5b at 50°C in diluted solution with low-salt buffer (Glick et al., 1992). Unlike the stem-loop intermediate produced by initial melting of the parent dodecamer, the hairpin does not denature as a result of increasing temperature, Na+ concentration, or DNA concentration (Glick et al., 1992; Wang et al., 1994). To address the structural consequences of the cross-link, the solution-phase conformation of the hairpin was determined by NMR spectroscopy (Wang et al., 1994, 1995). The stem region of this hairpin forms a B-form DNA duplex with a helical rise of 3.5 Å and a helical twist of 34.6°. The first three nucleotides in the loop stack over the 5′ end of the helix and are followed by a sharp turn at residue T8, which acts to close the loop. The conformation agrees with the “loop folding principle” advanced by Haasnoot, which predicts extension of the helix by 3 bases followed by a sharp bend in the loop (Haasnoot et al., 1986). The aromatic bases face into the major groove while the negatively charged backbone is in contact with solution.
Methods for Cross-Linking Nucleic Acids
5.7.9 Current Protocols in Nucleic Acid Chemistry
Supplement 13
Significantly, the cross-link does not alter the geometry of the stem duplex.
SYNTHESIS OF DISULFIDE CROSS-LINKED DNAs USING CONVERTIBLE NUCLEOSIDES
Probes in Molecular Recognition Experiments
The chemistry developed and advanced by Verdine and co-workers stands as the best method to place cross-links within the helical regions of DNA (Ferentz et al., 1991, 1993). Using convertible nucleoside chemistry, they showed that placing N6-thioalkyl derivatives of 2′-deoxyadenosine in consecutive base pairs on opposite strands of a duplex afforded disulfide cross-links upon air oxidation. These crosslinks reside in the major groove and impart increased stability with minimal distortion of native DNA geometry. This chemistry was extended several years latter to the synthesis of minor groove cross-links using modified dC residues. These major and minor groove crosslinks have been used with excellent effect in a variety of ways, such as studying protein-DNA interactions (Erlanson et al., 1993, 1997), stabilizing intrinsically bent DNA (Wolfe and Verdine, 1993), inducing torsional stress in short oligonucleotides (Wolfe et al., 1995), and cross-linking Z-DNA (Wolfe and Verdine, 1993).
DNA ligands often undergo conformational changes upon binding to proteins. In the absence of X-ray data, this “induced fit” can be difficult to observe. In principle, the constraint imposed by the disulfide bond should provide a way to investigate conformational changes in DNA structure that occur upon protein recognition. This point can be illustrated by the binding of monoclonal antibody BV04-01 to disulfide-cross-linked analogs of hairpins S.8 through S.11 (Figure 5.7.6; Stevens et al., 1993). This anti-DNA autoantibody was isolated from an autoimmune mouse that develops a syndrome related to human lupus, and BV0401 may be involved in the pathogenesis of this disorder in mice. BV04-01 binds only ssDNA, which can be modeled by the loop region of DNA hairpins (Stevens et al., 1993, and references therein). If conformational reorganization of the hairpin ligands is required for binding, then BV0401 should possess a lower affinity for the crosslinked sequences, since the disulfide bond renders them resistant to structural changes. However, if preorganization is important for the formation of complexes, then the more rigid oligomers should bind with equal or greater affinity than the unmodified ligands. Measurements of BV04-01 binding to cross-linked hairpins reveals a nearly 100-fold increase in Kd relative to S.8 through S.11. If the weaker affinity of BV04-01 for the cross-linked molecules results from the constraint imposed by the cross-link rather than as a result of a structural perturbation introduced by the alkylthiol linkers, then removing this constraint by reduction of the disulfide bond should afford a set of ligands that bind with roughly the same affinity as the unmodified hairpins. Indeed, BV04-01 recognition of the reduced hairpins is indistinguishable from binding to S.8 through S.11. DNA footprinting experiments show that, upon binding, residues within the duplex are recognized by single-strand-specific reagents, which provides further evidence that the stem duplex of the hairpin ligands is partially denatured (Swanson et al., 1994).
Engineering Terminal Disulfide Bonds Into DNA
Literature Cited Aboul-ela, F., Koh, D., Tinoco, I. Jr., and Martin, F.H. 1985. Base-base mismatches. Thermodynamics of double- helix f ormation for dCA3XA3G + dCT3YT3G (X, Y = A,C,G,T). Nucl. Acids Res. 13:4811-4824. Amaratunga, M., Snowden-Ifft, E., Wemmer, D.E., and Benight, A.S. 1992. Studies of DNA dumbbells. II. Construction and characterization of DNA dumbbells with a 16 base-pair duplex stem and Tn end loops (n = 2, 3, 4, 6, 8, 10, 14). Biopolymers 32:865-879. Ashley, G.W. and Kushlan, D.M. 1991. Chemical synthesis of oligodeoxynucleotide dumbbells. Biochemistry 30:2927-2933. Baldwin, R.L. 1971. Experimental tests of the theory of deoxyribonucleic acid melting with d(TA) oligomers. Acc. Chem. Res. 4:265-272. Bannwarth, W., Dorn, A., Iaiza, P., and Pannekouke, X. 1994. Short optimally capped duplex DNA as a conformationally restricted analog of B-DNA. Helv. Chim. Acta 77:182-193. Benight, A.S., Schurr, J.M., Flynn, P.F., Reid, B.R., and Wemmer, D.E. 1988. Melting of a self-complementary minicircle. Comparison of optical melting theory with exchange broadening of the nuclear magnetic resonance spectrum. J. Mol. Biol. 200:377-399. Blatt, N.B., Osborne, S.E., Cain, R.J., and Glick, G.D. 1993. Conformational studies from the ColE1 cruciform. Biochimie 75:433.
5.7.10 Supplement 13
Current Protocols in Nucleic Acid Chemistry
Boger, D.L., Munk, S.A., and Ishizaki, T. 1991. (+)-CC-1065 DNA alkylation: Observation of an unexpected relationship between cyclopropane electrophile reactivity and the intensity of DNA alkylation. J. Am. Chem. Soc. 113:2779-2780. Borowy-Borowski, H., Lipman, R., and Tomasz, M. 1990. Recognition between mitomycin C and specific DNA sequences for cross-link formation. Biochemistry 29:2999-3006.
Durand, M., Chevrie, K., Chassignol, M., Thuong, N.T., and Maurizot, J.C. 1990. Circular dichroism studies of an oligodeoxyribonucleotide containing a hairpin loop made of a hexaethylene glycol chain: Conformation and stability. Nucl. Acids Res. 18:6353-6359. Elson, E.L., Scheffler, I.E., and Baldwin, R.L. 1970. Helix formation by d(TA) oligomers. 3. Electrostatic effects. J. Mol. Biol. 54:401-415.
Breslauer, K.J. 1986. Thermodynamics of nucleic acids. In Thermodynamic Data for Biochemistry and Biotechnology (H.J. Hinz, ed.) pp 402-427. Springer-Verlag, New York.
Erie, D.A., Sinha, N., Olson, W.K., Jones, R.A., and Breslauer, K.J. 1987. A dumbbell-shaped double-hairpin structure of DNA: A thermodynamic investigation. Biochemistry 26:7150-7159.
Breslauer, K.J., Frank, R., Blöcker, H., and Marky, L.A. 1986. Predicting DNA duplex stability from the base sequence. Proc. Natl. Acad. Sci. U.S.A. 83:3746-3750.
Erie, D.A., Sinha, N.K., Olson, W.K., Jones, R.A., and Breslauer, K.J. 1989. Melting behavior of covalently closed, single-stranded, circular DNA. Biochemistry 28:268-273.
Cain, R.J. and Glick, G.D. 1997. The effect of cross-links on the conformational dynamics of duplex DNA. Nucl. Acids Res. 25:836-842.
Erlanson, D.A., Chen, L., and Verdine, G.L. 1993. DNA methylation through a locally unpaired intermediate. J. Am. Chem. Soc. 115:1258312584.
Cain, R.J. and Glick, G.D. 1998. Use of cross-links to study the conformational dynamics of triplex DNA. Biochemistry 37:1456-1464. Cain, R.J., Zuiderweg, E.R.P., and Glick, G.D. 1995. Solution structure of a DNA hairpin and its disulfide cross-linked analog. Nucl. Acids Res. 23:2153-2160. Callahan, D.E., Trapane, T.L., Miller, P.S., Ts’o, P.O.P., and Kan, L.-S. 1991. Comparative circular dichroism and fluorescence studies of oligodeoxyribonucleotide and oligodeoxyribonucleoside methylphosphonate pyrimidine strands in duplex and triplex formation. Biochemistry 30:1650-1655. Catalano, C.E. and Benkovic, S.J. 1989. Inactivation of DNA polymerase I (Klenow fragment) by adenosine 2′,3′-epoxide 5′-triphosphate: Evidence for the formation of a tight-binding inhibitor. Biochemistry 28:4374-4382. Clarke, J. and Fersht, A.R. 1993. Engineered disulfide bonds as probes of the folding pathway of barnase: Increasing the stability of proteins against the rate of denaturation. Biochemistry 32:4322-4329. Cowart, M. and Benkovic, S.J. 1991. A novel combined ch emical-enzymic synthesis of crosslinked DNA using a nucleoside triphosphate analog. Biochemistry 30:788-796. Cowart, M., Gibson, K.J., Allen, D.J., and Benkovic, S.J. 1989. DNA substrate structural requirements for the exonuclease and polymerase activities of prokaryotic and phage DNA polymerases. Biochemistry 28:1975-1983. Doktycz, M.J., Goldstein, R.F., Paner, T.M., Gallo, F.J., and Benight, A.S. 1992. Studies of DNA dumbbells. I. Melting curves of 17 DNA dumbbells with different duplex stem sequences linked by T4 endloops: Evaluation of the nearest-neighbor stacking interactions in DNA. Biopolymers 32:849-864.
Erlanson, D.A., Wolfe, S.A., Chen, L., and Verdine, G.L. 1997. Selective base-pair destabilization enhances binding of a DNA methyltransferase. Tetrahedron 53:12041-12056. Ferentz, A.E. and Verdine, G.L. 1991. Disulfidecross-linked oligonucleotides. J. Am. Chem. Soc. 113:4000-4002. Ferentz, A.E., Keating, T.A., and Verdine, G.L. 1993. Synthesis and characterization of disulfide cross-linked oligonucleotides. J. Am. Chem. Soc. 115:9006-9014. Frank-Kamenetskii, M.D. 1985. Flunctuational motility of DNA. In Structure & Motion: Membranes, Nucleic Acids, and Proteins (E. Clementi, G. Corongiu, M.H. Sarma, and R.H. Sarma, eds.) pp. 417-432. Adenine Press, Guilderland, N.Y. Freier, S.M., Kierzek, R., Caruthers, M.H., Neilson, T., and Turner, D.H. 1986. Free energy contributions of G⋅U and other terminal mismatches to helix stability. Biochemistry 25:3209-3213. Gao, H., Chidambaram, N., Chen, B.C., Pelham, D.E., Patel, R., Yang, M., Zhou, L., Cook, A., and Cohen, J.S. 1994. Double-stranded cyclic oligonucleotides with non-nucleotide bridges. Bioconjugate Chem. 5:445-453. Gao, H., Yang, M., and Cook, A.F. 1995. Stabilization of double-stranded oligonucleotides using backbone-linked disulfide bridges. Nucl. Acids Res. 23:285-292. Germann, M.W., Schoenwaelder, K.-H., and van de Sande, J.H. 1985. Right- and left-handed (Z) helical conformations of the hairpin d(CG)5T4(C-G)5 monomer and dimer. Biochemistry 24:5698-5702. Glick, G.D. 1991. Synthesis of a conformationally restricted DNA hairpin. J. Org. Chem. 56:67466747. Glick, G.D., 1998. Design, synthesis, and analysis of conformationally constrained nucleic acids. Biopolymers 48:83-96.
Methods for Cross-Linking Nucleic Acids
5.7.11 Current Protocols in Nucleic Acid Chemistry
Supplement 13
Glick, G.D., Osborne, S.E., Knitt, D.S., and Marino, J.P. Jr. 1992. Trapping and isolation of an alternate DNA conformation. J. Am. Chem. Soc. 114:5447-5448. Goodwin, J.T. and Glick, G.D. 1993. Incorporation of alkylthiol chains at C-5 of deoxyuridine Tetrahedron Lett. 34:5549-5552. Goodwin, J.T., Osborne, S.E., Swanson, P.C., and Glick, G.D. 1994. Synthesis of a disulfide crosslinked DNA triple helix. Tetrahedron Lett. 35:4527-4531. Guéron, M. and Leroy, J.L. 1995. Studies of base pair kinetics by NMR measurement of proton exchange. Methods Enzymol. 261:383-413. Haasnoot, C.A.G., Hilbers, C.W., van der Marel, G.A., van Boom, J.H., Singh, U.C., Pattabiraman, N., and Kollman, P.A. 1986. On loop folding in nucleic acid hairpin-type structures. J. Biomol. Struct. Dyn. 3:843-857.
Moser, H.E. and Dervan, P.B. 1987. Sequence-specific cleavage of double helical DNA by triple helix formation. Science 238:645-650. Olmsted, M.C., Anderson, C.F., and Record, M.T. Jr. 1991. Importance of oligoelectrolyte end effects for the thermodynamics of conformational transitions of nucleic acid oligomers: A grand canonical Monte Carlo analysis. Biopolymers 31:1593-1604. Osborne, S.E. 1996. Ph.D. Thesis, University of Michigan.
Häner, R. and Dervan, P.B. 1990. Single-stranded DNA triple-helix formation. Biochemistry 29:9761-9765.
Osborne, S.E., Völker, J., Stevens, S.Y., Breslauer, K.J., and Glick, G.D. 1996. Design, synthesis, and analysis of disulfide cross-linked DNA duplexes. J. Am. Chem. Soc. 118:11993-12003.
Kiessling, L.L., Griffin, L.C., and Dervan, P.B. 1992. Flanking sequence effects within the pyrimidine triple-helix motif characterized by affinity cleaving. Biochemistry 31:2829-2834.
Osborne, S.E., Cain, R.J., and Glick, G.D. 1997. Structure and dynamics of disulfide cross-linked DNA triple helices. J. Am. Chem. Soc. 119:11711182.
Kirchner, J.J. and Hopkins, P.B. 1991. Nitrous acid cross-links duplex DNA fragments through deoxyguanosine residues at the sequence 5′-CG. J. Am. Chem. Soc. 113:4681-4682.
Paner, T.M., Amaratunga, M., and Benight, A.S. 1992. Studies of DNA dumbbells. III. Theoretical analysis of optical melting curves of dumbbells with a 16 base-pair duplex stem and Tn end loops (n = 2, 3, 4, 6, 8, 10, 14). Biopolymers 32:881-892.
Kirchner, J.J., Sigurdsson, S.T., and Hopkins, P.B. 1992. Interstrand cross-linking of duplex DNA by nitrous acid: Covalent structure of the dG-todG cross-link at the sequence 5′-CG. J. Am. Chem. Soc. 114:4021-4027. Kool, E.T. 1991. Molecular recognition by circular oligonucleotides: Increasing the selectivity of DNA binding. J. Am. Chem. Soc. 113:62656266. Lemaire, M.-A., Schwartz, A., Rahmouni, A.R., and Leng, M. 1991. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc. Natl. Acad. Sci. U.S.A. 88:19821985. MacGregor, R.B. Jr. 1996. Chain length and oligonucleotide stability at high pressure. Biopolymers 38:321-327. Marky, L.A., Blumenfeld, K.S., Kozlowski, S., and Breslauer, K.J. 1983. Salt-dependent conformational transitions in the self-complementary deoxydodecanucleotide d(CGCAATTCGCG): Evidence for hairpin formation. Biopolymers 22:1247-1257. Millard, J.T., Raucher, S., and Hopkins, P.B. 1990. Mechlorethamine cross-links deoxyguanosine residues at 5′-GNC sequences in duplex DNA fragments. J. Am. Chem. Soc. 112:2459-2460. Engineering Terminal Disulfide Bonds Into DNA
Millard, J.T., Weidner, M.F., Kirchner, J.J., Ribeiro, S., and Hopkins, P.B. 1991. Sequence preferences of DNA interstrand crosslinking agents: Quantitation of interstrand crosslink locations in DNA duplex fragments containing multiple crosslinkable sites. Nucl. Acids Res. 19:18851891.
Patel, D.J. and Hilbers, C.W. 1975. Proton nuclear magnetic resonance investigations in doublestranded dApTpGpCpApT in aqueous solution. Biochemistry 14:2651-2656. Pilch, D.S., Levenson, C., and Shafer, R.H. 1990. Structural analysis of the d(A)10.2(dT)10 triple helix. Proc. Natl. Acad. Sci. U.S.A. 87:19421946. Pinto, A.L. and Lippard, S. 1985. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochem. Biophys. Acta 780:167-180. Plum, G.E., Pilch, D.S., Singleton, S.F., and Breslauer, K.J. 1995. Nucleic acid hybridization: Triplex stability and energetics. Annu. Rev. Biophys. Biomol. Struct. 24:319-350. Ramstein, J. and Lavery, R. 1988. Energetic coupling between DNA bending and base pair opening. Proc. Natl. Acad. Sci. U.S.A. 85:7231-7235. Ramstein, J. and Lavery, R. 1990. Base pair opening pathways in B-DNA. J. Biomol. Struct. Dyn. 7:915-933. Record, M.T. Jr. and Lohman, T.M. 1978. Semi-empirical extension of polyelectrolyte theory to treatment of oligoelectrolytes—application to oligonucleotide helix-coil transitions. Biopolymers 17:159-166. Rumney, S. IV and Kool, E.T. 1992. DNA recognition by hybrid oligoether-oligodeoxynucleotide macrocycles. Angew. Chem. Int. Ed. Engl. 31:1617-1619.
5.7.12 Supplement 13
Current Protocols in Nucleic Acid Chemistry
Salunkhe, M., Wu, T., and Lestinger, R.L. 1992. Control of folding and binding of oligonucleotides by use of a nonnucleotide linker. J. Am. Chem. Soc. 114:8768-8772. SantaLucia, J. Jr., Allawi, H.T., and Seneviratne, P.A. 1996. Improved nearest-neighbor parameters for predicting DNA duplex stability. Biochemistry 35:3555-3562. Scheffler, I.E., Elson, E.L., and Baldwin, R.L. 1970. Helix formation by d(TA) oligomers. II. Analysis of the helix-coil transitions of linear and circular oligomers. J. Mol. Biol. 48:145-171.
Tomasz, M., Lipman, R., Chowdary, D., Pawlak, J., Verdine, G.L., and Nakanishi, K. 1987. Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235:1204-1208. Völker, J., Osborne, S.E., Glick, G.D., and Breslauer, K.J. 1997. Thermodynamic properties of a conformationally constrained intramolecular DNA triple helix. Biochemistry 36:756-767. Wang, H., Osborne, S.E., Zuiderweg, E.R.P., and Glick, G.D. 1994. Three-dimensional structure of a disulfide-stabilized non-ground-state DNA hairpin. J. Am. Chem. Soc. 116:5021-5022.
Sherman, S.E., Gibson, D., Wang, A.H., and Lippard, S.J. 1985. X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2] (d(pGpG)). Science 230:412-417.
Wang, H., Zuiderweg, E.R.P., and Glick, G.D. 1995. Solution structure of a disulfide cross-linked DNA hairpin. J. Am. Chem. Soc. 117:2981-2991.
Sigurdsson, S.T., Rink, S.M., and Hopkins, P.B. 1993. Affinity crosslinking of duplex DNA by a pyrrole-oligopeptide conjugate. J. Am. Chem. Soc. 115:12633-12634.
Webb, T.R. and Matteucci, M.D. 1986. Sequencespecific cross-linking of deoxyoligonucleotides via hybridization-triggered alkylation. J. Am. Chem. Soc. 108:2764-2765.
Singleton, S.F. and Dervan, P.B. 1992. Influence of pH on the equilibrium association constants for oligodeoxyribonucleotide-directed triple helix formation at single DNA sites. Biochemistry 31:10995-11003.
Wemmer, D.E. and Benight, A.S. 1985. Preparation and melting of single-strand circular DNA loops. Nucl. Acids Res. 13:8611-8621.
Stevens, S.Y., Swanson, P.C., Voss, E.W. Jr., and Glick, G.D. 1993. Evidence for induced fit in antibody⋅DNA complexes. J. Am. Chem. Soc. 115:1585-1586.
Williams, D.J. and Hall, K.B. 1996. Thermodynamic comparison of the salt dependence of natural RNA hairpins and RNA hairpins with non-nucleotide spacers. Biochemistry 35:1466514670.
Sun, J.-S. and Hélène, C. 1993. Oligonucleotide-directed triple-helix formation. Curr. Opin. Struct. Biol. 3:345-356.
Willis, M.C., Hicke, B.J., Uhlenbeck, O.C., Cech, T.R., and Koch, T.H. 1993. Photocrosslinking of 5-iodouracil-substituted RNA and DNA to proteins. Science 262:1255-1257.
Swanson, P.C., Cooper, B.C., and Glick, G.D. 1994. High-resolution epitope mapping of an antiDNA autoantibody using model DNA ligands. J. Immunol. 152:2601-2612.
Wing, R., Drew, H., Takano, T., Broka, C., Tanaka, S., Itakura, K., and Dickerson, R.E. 1980. Crystal structure analysis of a complete turn of BDNA. Nature 287:755-758.
Tari, L.W. and Secco, A.S. 1995. Base-pair opening and spermine binding—B-DNA features displayed in the crystal structure of a gal operon fragment: Implications for protein-DNA recognition. Nucl. Acids Res. 23:2065-2073.
Wolfe, S.A. and Verdine, G.L. 1993. Ratcheting torsional stress in duplex DNA. J. Am. Chem. Soc. 115:12585-12586.
Teng, S.P., Woodson, S.A., and Crothers, D.M. 1989. DNA sequence specificity of mitomycin cross-linking. Biochemistry 28:3901-3907. Thuong, N.T. and Hélène, C. 1993. Sequence-specific recognition and modification of doublehelical DNA by oligonucleotides. Angew. Chem. Int. Ed. Engl. 32:666-690.
Wolfe, S.A., Ferentz, A.E., Grantcharova, V., Churchill, M.E.A., and Verdine, G.L. 1995. Modifying the helical structure of DNA by design: Recruitment of an architecture-specific protein to an enforced DNA bend. Chem. Biol. 2:213-221.
Contributed by Gary D. Glick University of Michigan Ann Arbor, Michigan
The author wishes to thank the talented group of associates in his laboratory who have so skillfully conducted the research described in this unit. He also thanks K.J. Breslauer, Jens Völker, and E.R.P. Zuiderweg, whose expertise and insight into nucleic acids has formed the basis for outstanding collaborations. The worked described here was supported by NIH Grants GM-52831 and GM43861.
Methods for Cross-Linking Nucleic Acids
5.7.13 Current Protocols in Nucleic Acid Chemistry
Supplement 13
CHAPTER 6 Chemical and Enzymatic Probes for Nucleic Acid Structure INTRODUCTION ver the past 10 years, significant progress has been made in elucidating the structure of nucleic acids to atomic resolution. By comparison with proteins, however, relatively few high-resolution nucleic structures have been determined. One main reason why crystallographic/NMR studies of nucleic acids have proven difficult is because oligonucleotides often self-associate and/or equilibrate between several different conformations at the concentrations required for many high-resolution biophysical measurements. To help circumvent these problems, an array of chemical and biochemical approaches have been developed to explore the conformation dynamics of oligonucleotides. Perhaps the most common way to assess structure is by chemical and enzymatic footprinting. In footprinting, the accessibility and/or reactivity of particular functional groups in either a secondary or tertiary structure is examined and compared to the same positions in the denatured state. Footprinting experiments often employ base- and phosphate-specific modifying reagents, hydroxyl radical and transition metal complexes, and a broad spectrum of nucleases. Based on the cleavage properties of these reagents, as determined in control experiments, local structure can be studied. The most critical point to bear in mind when designing footprinting experiments is that since chemical and enzymatic structure probing is indirect, several different reagents should be employed to examine any given region of structure.
O
This chapter will provide the reader with a comprehensive collection of protocols to examine the solution structures of both DNA and RNA by footprinting. The initial units focus more heavily on methods to study RNA structure, while units appearing in future supplements will integrate more DNA protocols. UNIT 6.1 provides an extremely thorough coverage of the most useful chemical and enzymatic probes to examine RNA secondary and tertiary structure. For the chemical probes, both strand scission and primer extension detection protocols are provided. Oftentimes, when RNA molecules adopt tertiary structure, distinct metal-binding pockets are created. Under appropriate conditions, this metal binding can be exploited to induce strand cleavage in the RNA backbone. This type of strand cleavage can be an exquisitely sensitive probe of local tertiary structure. UNITS 6.2-6.4 & 6.8 describe six of the most useful metal complexes for probing nucleic acid structure. describe the application of hydroxyl radicals to investigate RNA and DNA tertiary structure, respectively. Unlike nearly every other footprinting reagent, hydroxyl radicals cleave the sugar-phosphate backbone at every residue. This reagent possesses little or no sequence selectivity and will provide uniform cleavage at all positions in a given RNA or DNA secondary structure. Because some positions often become protected from cleavage upon tertiary folding, this reagent is useful to monitor global folding at equilibrium. Moreover, as will be described in Chapter 11, hydroxyl radical cleavage can also be used to follow the kinetics of RNA folding.
UNITS 6.5 & 6.7
Contributed by Gary D. Glick Current Protocols in Nucleic Acid Chemistry (2004) 6.0.1-6.0.2 C 2004 by John Wiley & Sons, Inc. Copyright
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.0.1 Supplement 17
presents a discussion of chemical reagents that can be used specifically to study the major groove of DNA. The unit focuses on the most commonly used and readily available reagents: dimethyl sulfate, diethylpyrocarbonate, potassium permanganate, osmium tetroxide, and bromine formed in situ from bromide and monoperoxysulfate. Characteristics of each reagent are reviewed, as are their applications to the study of DNA, DNA-protein complexes, and DNA-drug complexes.
UNIT 6.6
provides a method for analyzing RNA activity at the level of specific functional groups. In nucleotide analog interference mapping (NAIM), oligonucleotides with random phosphorothioate-tagged nucleotide analogs are assayed for an activity of interest (e.g., binding or folding). Inactive and active species are identified, and iodine cleavage of the phosphorothioate tag is used to identify the site of substitution. Modifications of the method, such as nucleotide interference analog suppression (NAIS), are also described. UNIT 6.9
Gary D. Glick
Introduction
6.0.2 Supplement 17
Current Protocols in Nucleic Acid Chemistry
Probing RNA Structure with Chemical Reagents and Enzymes
UNIT 6.1
The function of an RNA molecule in vivo and in vitro will often depend on its tertiary structure as well as the information encoded in its Watson-Crick base-pairing potential. There are now a number of powerful methods that can be used simultaneously to determine structural properties of small and large RNAs. This unit and subsequent units provide methods for RNA footprinting, detecting positions sensitive to chemical and enzymatic attack in the presence or absence of bound proteins. RNA footprinting differs profoundly from DNA footprinting in that the starting structure of the RNA cannot be taken for granted even in general terms, and the footprinting reactions are often carried out with structure-sensitive reagents precisely for the purpose of elucidating the RNA solution structure. When interpreting these structures, however, it is necessary to always consider whether the functional form of the RNA molecule is being examined. The first four protocols in this unit provide methods for modifying and cleaving RNA for the purpose of probing structure. Three of these protocols use structure-sensitive chemicals—dimethyl sulfate (DMS; see Basic Protocol 1), diethylpyrocarbonate (DEPC; see Alternate Protocol 1), and ethylnitrosourea (ENU; see Alternate Protocol 2). The fourth describes the use of various nucleases (see Table 6.1.1) to probe RNA structure (see Basic Protocol 2). Three other protocols can be used together to analyze the base-pairing status of RNA. The reagents modify Watson-Crick positions of nucleotides not involved in base pairing or tertiary hydrogen bonding. Dimethyl sulfate (see Basic Protocol 3) is used to probe unpaired adenines and cytidines, while kethoxal (see Alternate Protocol 3) and 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate (CMCT; see Alternate Protocol 4) are used to investigate unpaired guanosines and uridines, respectively. RNA cleavages and base modifications can be detected by primer extension (see Support Protocol 4), or cleavage sites can be detected by using RNA that has been labeled at the 5′ terminus with T4 polynucleotide kinase (see Support Protocol 1) or the 3′ terminus by T4 RNA ligase (see Support Protocol 2). Support Protocol 3 details the preparation of electrophoresis standards for use with end-labeled RNA. CAUTION: When working with radioactivity, take appropriate precautions to avoid contamination of the experimenter and the surroundings. Carry out the experiment and dispose of wastes in an appropriately designated area, following the guidelines provided by the local radiation safety officer. NOTE: Experiments involving RNA require careful precautions to prevent contamination and RNA degradation (see APPENDIX 2A). STRATEGIC PLANNING Footprinting with an Appropriate RNA Before undertaking these often labor-intensive footprinting experiments it is worthwhile to evaluate the extent to which all or most of the RNA sample to be examined is in an appropriate folded state (see Critical Parameters; for general guidelines for RNA folding, see UNIT 6.3). There are a number of ways of determining this when the RNA is to be probed in vitro; the method used depends on which experimental system is available to assess the structure of the RNA. In the simplest case, the RNA might have an assayable function that can be demonstrated in vitro. An example of this is an artificial RNA ligand selected for binding to a protein target in vitro. RNAs isolated from cells are generally more
Chemical and Enzymatic Probes for Nucleic Acid Structure
Contributed by William A. Ziehler and David R. Engelke
6.1.1
Current Protocols in Nucleic Acid Chemistry (2000) 6.1.1-6.1.21 Copyright © 2000 by John Wiley & Sons, Inc.
Table 6.1.1 RNA Structure-Probing Reagents and Their Specificities
Reagenta For cleavage: DMSc DEPCc ENUc Hydroxyl radicals Pb2+ Mung bean nucleased RNase A RNase CL3 RNase I(ONE) RNase Phy M RNase T1 RNase T2 RNase U2 RNase V1d S1 nucleased For modification: CMCT DMS Kethoxal
Targetb
Where discussed
ss or ds G (N7) ss or ds A (N7)
Basic Protocol 1 Alternate Protocol 1 Phosphate oxygens Alternate Protocol 2 Ribose sugar backbone UNIT 6.5 Phosphates of ss UNIT 6.3 nucleotides ss N/pN Basic Protocol 2 ss Cp/N and Up/N Basic Protocol 2 ss Cp/N Basic Protocol 2 ss Np/N Basic Protocol 2 ss Ap/N and Up/N Basic Protocol 2 ss Gp/N Basic Protocol 2 ss Np/N Basic Protocol 2 ss Ap/N Basic Protocol 2 ds N/pN Basic Protocol 2 ss N/pN Basic Protocol 2 Primarily U (N3) and possibly G (N1) A (N1) and C (N3) G (N1, 2-NH2)
Supplier Aldrich Sigma Sigma
Roche or Promega Roche USB Promega (RNase ONE) Pharmacia Life Technologies Life Technologies Pharmacia Pharmacia Roche or Promega
Alternate Protocol 4
Aldrich
Basic Protocol 3 Alternate Protocol 3
Aldrich ICN or Research Organics
aAbbreviations: CMCT, 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate; DEPC, diethylpyrocarbonate; DMS, dimethyl sulfate; ds, double-stranded; ENU, ethylnitrosourea; ss, single-stranded. bCleavage site indicated by shill. Specific position of cleavage or modification are indicated in parentheses. cThis reagent requires further chemical processing to cleave the RNA. dNuclease requires divalent cations for activity. For RNase V1, MgCl (10 mM final) is recommended, mung bean nuclease 2 and S1 nuclease require zinc acetate as per supplier’s instructions.
difficult to interpret. If an RNA is stripped of its native protein structure in the process of being isolated from cells, or if an RNA is made synthetically, it should be assumed that the folding of that RNA is suspect until proven otherwise. Small RNAs that are tightly structured, such as tRNAs, can often refold in functional form, but this cannot be assumed. The chances of misfolding increase dramatically for larger RNAs where there are more potential isoforms. An RNA that is isolated as part of a ribonucleoprotein (RNP) complex, such as a ribosomal subunit, is generally assumed to be correctly folded, but even that assumption should be viewed with caution. Choice of Structure-Sensitive Reagents
Probing RNA Structure with Chemical Reagents and Enzymes
The object in RNA footprinting is to determine which positions in the RNA are accessible to specific types of attack by chemical reagents or nucleases. Cleavage or modification by these reagents is normally performed under conditions where the target RNA is cleaved at most once per molecule, thus lowering the chance that the first cleavage/modification causes an RNA rearrangement that alters access for a second attack. The cleavage or modification specificities of individual nucleases and commonly used chemicals are listed in Table 6.1.1. It is worth considering the general advantages and disadvantages of different classes of reagents. Nucleases have the lowest resolution because their steric radii do not allow access to many sites that are solvated; however, they are easily used in a wide range of physiological buffers. Most of the nucleases described below are specific
6.1.2 Current Protocols in Nucleic Acid Chemistry
for nucleotides not involved in Watson-Crick pairing, with variable sensitivity to other types of structure and base specificity. The exception is cobra venom ribonuclease (V1), which is the only reagent described here that is specific for double-stranded regions. Even V1 is not exceptionally helpful in identifying double-stranded structures, however, because the ability of V1 to cleave helices is variable. Cleavage by V1 is infrequent, and V1 can cleave adjacent to rather than within helices. The available chemical reagents discussed in this and subsequent units allow better access to all regions of the RNA tertiary structure and cumulatively attack a wide range of nucleotide positions. In general, using a larger number of different reagents to probe allows a more detailed view of solvent-exposed positions. Exposure of phosphates, sugars, and aromatic ring positions can be probed. Reagents specific for Watson-Crick positions are often used as diagnostics for the existence of standard base pairing at contiguous nucleotides. Some of the protocols described below are based on methods described previously (Peattie and Gilbert, 1980; Knapp, 1989; Krol and Carbon, 1989). Location of chemical and nuclease cleavages can be determined using end-labeled RNA or primer extension. Hydroxyl radicals (UNIT 6.5) and Pb2+ (UNIT 6.3) will directly hydrolyze the phosphodiester backbone, as will the various nucleases according to their sequence and structural preferences. Other reagents, including DMS, DEPC, and ENU, require additional chemical steps, ultimately resulting in strand scission. Detection of Modifications or Cleavage Sites The method used to detect cleavages or modified positions varies with both the nature of the RNA being probed and the reagents being used. Short RNAs (<200 nucleotides) can be labeled at either the 5′ or 3′ end (Support Protocols 1 and 2), then folded and subjected to reagents that result in RNA strand cleavage. Separation of the cleaved RNA on denaturing polyacrylamide gels and determination of fragment sizes identifies the position of cleavage sites. Alternatively, a labeled DNA oligomer primer can be annealed at any point along the length of an unlabeled RNA and extended to a point of cleavage or Watson-Crick base modification (Support Protocol 4). Either case terminates extension and produces a labeled DNA fragment corresponding to the length from the label to the termination site. There are a variety of labels that can be used with these two general detection schemes. The most common label is 32P, which can be detected with either X-ray film or a phosphorimager. The question of whether to use end labeling or primer extension for detection depends on the RNA to be analyzed and how many reagents are needed. Primer extension is more often useful for longer RNAs, although end labeling is still widely used to probe small RNAs. The advantage of end labeling is that it requires fewer manipulations (i.e., no primer-extension reactions) after the cleavage reactions. Its disadvantages include that it can only be used for relatively short RNAs that can be labeled before cleavage reagent treatment and that it requires cleavage of the RNA strand for detection. Transfer RNAs, 5S rRNAs, and other small, structured RNAs have typically been investigated by end labeling. Primer extension has four main disadvantages. The first is that the extreme 3′ end of the RNA cannot be probed because the primer must anneal to the 3′ side of the region to be extended across. The second disadvantage is that sequence-dependent pausing and termination by the reverse transcriptase, even on intact RNA, tends to give a high background at some positions that obscures the true signal from cleavage or modification. This problem can be reduced by using different reverse transcriptases and/or extension conditions, but is never completely eliminated with structured RNAs. The third disadvan-
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.1.3 Current Protocols in Nucleic Acid Chemistry
tage is that additional manipulations are required to perform the primer-extension reactions following the cleavage or modification reactions. Finally, cellular RNAs may contain posttranscriptional modifications that will terminate the extension reaction. However, primer-extension RNA footprinting is potentially useful in many situations. For example, RNA of any size can be probed because a labeled primer can be placed anywhere along the length of RNA, and multiple primers can be used in separate reactions to detect cleavages or modifications along the entire length. The RNA also does not need to be purified or labeled in advance, allowing probing of preformed RNA-protein complexes even in crude cell lysates. Following the cleavage/modification reactions, protein is removed by organic extraction and the purified RNA is subjected to primer extension. Lastly, the extension reactions can be used to detect several chemical modifications at Watson-Crick positions in addition to any form of RNA strand cleavage. BASIC PROTOCOL 1
MODIFICATION AND CLEAVAGE OF RNA USING DIMETHYL SULFATE Dimethyl sulfate (DMS) alkylates the N7 cyclic amine of guanosine. The methylated nucleoside is reduced, opening the imidizole ring and weakening the glycosidic bond. Aniline treatment catalyzes the β-elimination of the ribose sugar, leaving the nucleotide 5′ of the displaced guanosine with a 3′ phosphate and the nucleotide 3′ of the guanosine with a 5′ phosphate. The N7 position is pointed into the major groove of an A-form RNA helix and is accessible to modification. Therefore, the N7 of double-stranded and single-stranded guanosines should be detected unless participating in tertiary structure or non-Watson-Crick base-pair interactions. See Strategic Planning for a discussion of choice of RNA, folding, and detection methods. Materials 1 M HEPES, pH 7.8 1 M KCl 0.1 M MgCl2 1 µg/µL carrier RNA (see recipe) Sample RNA, end labeled (see Support Protocol 1 or Support Protocol 2) or unlabeled RNase-free water (see recipe) ≥99% dimethyl sulfate (DMS) (Aldrich) 3 M sodium acetate, pH 5.2 (APPENDIX 2A) 100% and 70% (v/v) ethanol 1 M Tris⋅Cl, pH 8.0 (APPENDIX 2A) 0.2 M NaBH4, prepared fresh 1 M aniline acetate buffer (see recipe) FEXS solution (see recipe; for end-labeled RNA) Additional reagents and equipment for denaturing polyacrylamide gel electrophoresis (e.g., APPENDIX 3B or CPMB UNIT 2.12) or primer extension (see Support Protocol 4) NOTE: DMS is highly toxic and a suspected carcinogen; use appropriate precautions for handling, storage, and disposal. Methylate guanosine N7 1. Prepare reaction mix as follows:
Probing RNA Structure with Chemical Reagents and Enzymes
8 µL 1 M HEPES, pH 7.8 (final 200 mM) 4 µL 1 M KCl (100 mM) 4 µL 0.1 M MgCl2 (10 mM) 8 µL 1 µg/µL carrier RNA (0.2 µg/µL).
6.1.4 Current Protocols in Nucleic Acid Chemistry
2. Combine 50,000 cpm end-labeled sample RNA or 0.5 µg unlabeled sample RNA (for primer extension) with RNase-free water to make 15 µL total and add to reaction mix. 3. Add 1 µL of 99+% DMS, mix, and incubate 2 min at room temperature. 4. Stop the reaction by precipitating with 4 µL of 3 M sodium acetate and 120 µL of 100% ethanol on dry ice. Microcentrifuge 30 min at maximum speed (10,000 rpm), 4°C. Remove supernatant, rinse with 70% ethanol, and dry the pellet in a speedvac. Reduce methylated RNA and perform aniline cleavage 5. Resuspend pellet with 20 µL of 1 M Tris⋅Cl and 20 µL of 0.2 M NaBH4. 6. Incubate 30 min on ice in the dark. 7. Precipitate as in step 4. 8. Resuspend pellet in 40 µL of 1 M aniline acetate buffer and incubate 15 min in the dark at 60°C. 9. Precipitate as in step 4. 10. If end-labeled RNA was used, resuspend in 12 µL FEXS solution and proceed with direct gel electrophoresis (e.g., APPENDIX 3B). If RNA sample was unlabeled, see Support Protocol 4 and perform primer extension. See Support Protocol 3 for preparation of appropriate end-labeled RNA standards for electrophoresis.
MODIFICATION AND CLEAVAGE OF RNA USING DIETHYLPYROCARBONATE
ALTERNATE PROTOCOL 1
Diethylpyrocarbonate (DEPC) alkylates the N7 cyclic amine of adenosine. The mechanism and procedure are essentially identical to those described for DMS (see Basic Protocol 1), except that DEPC is used and the incubation time is increased (replace step 3 in Basic Protocol 1 with the following step). See Strategic Planning for discussions of choice of RNA, folding, and detection methods. Additional Materials (also see Basic Protocol 1) ≥97% diethylpyrocarbonate (DEPC) (store up to 1 year at 2° to 8°C) NOTE: DEPC is toxic. Handle with appropriate care. 3b. Add 1 µL DEPC, mix, and incubate 45 min at room temperature.
MODIFICATION AND CLEAVAGE OF RNA USING ETHYLNITROSOUREA
ALTERNATE PROTOCOL 2
Ethylnitrosourea (ENU) alkylates phosphate oxygens that are not involved in tertiary structure interactions. These include phosphates of both single-stranded and doublestranded nucleotides not participating in higher-ordered structure. Following alkaline treatment, the phosphotriester hydrolyzes resulting in RNA strand scission. See Strategic Planning for discussions of choice of RNA, folding, and detection methods. Additional Materials (also see Basic Protocol 1) ENU/ethanol solution (see recipe) 0.1 M Tris⋅Cl, pH 9.0 (APPENDIX 2A)
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.1.5 Current Protocols in Nucleic Acid Chemistry
Alkylate phosphates 1. Prepare reaction mix as follows: 2 µL 1 M HEPES, pH 7.8 (final 200 mM) 1 µL 1 M KCl (100 mM) 1 µL 0.1 M MgCl2 (10 mM) 2 µL 1 µg/µL carrier RNA (0.2 µg/µL) 2. Combine 50,000 cpm end-labeled sample RNA or 0.5 µg unlabeled sample RNA (for primer extension) with RNase-free water to make 3 µL total and add to reaction mix. 3. Add 1 µL of ENU/ethanol solution, mix, and incubate 30 min at room temperature. 4. Stop the reaction by precipitating with 1 µL of 3 M sodium acetate and 30 µL of 100% ethanol on dry ice. Microcentrifuge 30 min at maximum speed (10,000 rpm), 4°C. Remove supernatant, rinse with 70% ethanol, and dry the pellet in a speedvac. Hydrolyze phosphotriesters 5. Resuspend pellet in 10 µL of 0.1 M Tris⋅Cl, pH 9.0, and incubate 5 min at 50°C. 6. Precipitate as in step 4. 7. If RNA has been end-labeled, resuspend in 12 µL FEXS solution and proceed with gel electrophoresis (e.g., APPENDIX 3B or CPMB UNIT 2.12). If RNA sample was not labeled, perform primer extension (see Support Protocol 4). See Support Protocol 3 for preparation of appropriate end-labeled RNA standards for electrophoresis. BASIC PROTOCOL 2
CLEAVAGE OF RNA USING NUCLEASES Nucleases hydrolyze the RNA phosphodiester backbone resulting in strand scission. Cleavages can be identified using primer extension (see Support Protocol 4) or end-labeled RNA (see Support Protocol 1 and Support Protocol 2). Table 6.1.1 lists nuclease specificities and cleavage locations. Some nucleases use divalent metal cofactors to catalyze the reaction. Divalent-independent nucleases can be used to probe RNA in the presence and absence of divalent-dependent tertiary structures. Most nucleases are specific for single-stranded bases and require access to the base determinants for cleavage site recognition. Uncleaved nucleotide targets may be obscured from cleavage by tertiary structure or local steric hindrance. Being relatively large, nucleases may not penetrate some RNA structures completely, and it is common for some potential targets to remain uncleaved. The data obtained from one nuclease will identify general structural trends (e.g., single- or double-stranded character), but often needs to be corroborated using additional nucleases or chemical probes. See Strategic Planning for discussions of choice of RNA, folding, and detection methods.
Probing RNA Structure with Chemical Reagents and Enzymes
Materials One of the following nucleases (see Table 6.1.1): Mung bean nuclease RNase A RNase CL3 RNase I(ONE) RNase Phy M RNase T1
6.1.6 Current Protocols in Nucleic Acid Chemistry
RNase T2 RNase U2 RNase V1 S1 nuclease 0.1 M Tris⋅Cl, pH 7.5 (APPENDIX 2A) 1 M KCl (APPENDIX 2A) 0.1 M MgCl2 1 µg/µL carrier RNA (see recipe) Sample RNA, end labeled (see Support Protocol 1 or Support Protocol 2) or unlabeled RNase-free water (see recipe) 3 M sodium acetate, pH 5.2 (APPENDIX 2A) 100% and 70% (v/v) ethanol FEXS solution (see recipe) Additional reagents and equipment for direct gel electrophoresis (e.g., APPENDIX 3B or CPMB UNIT 2.12) or primer extension (see Support Protocol 4) 1. Prepare six reaction tubes, each containing: 1 µL 0.1 M Tris⋅Cl, pH 7.5 (final 10 mM) 1 µL 1 M KCl (100 mM) 1 µL 0.1 M MgCl2 (10 mM) 2 µL 1 µg/µL carrier RNA (0.2 µg/µL). 2. For each reaction mix, combine 50,000 cpm end-labeled sample RNA or 0.5 µg unlabeled sample RNA (for primer extension) with RNase-free water to make 4 µL total. Add to each reaction mix. 3. Dilute nuclease at six 5-fold serial dilutions (covering four orders of magnitude) with 10 mM Tris⋅Cl to give the appropriate amounts in a volume of 1 µL. Dilute RNase V1 with 10 mM Tris⋅Cl and 10 mM MgCl2. Nuclease activity varies by lot and by manufacturer. Thus, it is necessary to titrate the amount of nuclease necessary to cleave ∼10% of the RNA of interest. A second titration consisting of narrower increments may be necessary once the desired activity is found. Table 6.1.2 lists activity units that have produced 10% cleavage using the reaction conditions described above. These should be used as guidelines only. Table 6.1.2 Quantities of Nuclease That Achieve ~10% Cleavage in 10 min
Nuclease Mung bean nuclease RNase A RNase CL3 RNase I(ONE) RNase Phy M RNase T1 RNase T2 RNase U2 RNase V1 S1 nuclease aND, not determined
Quantitya ND
0.2 ng 0.025-0.100 U 0.012 U 1.0 U 0.138 U ND
1.0 U 0.047 U ND
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.1.7 Current Protocols in Nucleic Acid Chemistry
Fresh nuclease dilutions should be used each time, although dilutions of RNases T1, A, and I(ONE) can be frozen with minimal loss of activity.
4. Add 1 µL of each nuclease dilution to a reaction mix, mix well, and incubate 10 min at room temperature. 5. Add 1 µL of 3 M sodium acetate and 30 µL of 100% ethanol and precipitate on dry ice. Microcentrifuge 30 min at maximum speed (10,000 rpm), 4°C. Remove supernatant, rinse with 70% ethanol, and dry the pellet in a speedvac. 6. If the RNA sample was end-labeled, resuspend in 12 µL of FEXS solution and proceed with gel electrophoresis (e.g., APPENDIX 3B or CPMB UNIT 2.12). If sample RNA was not labeled, see Support Protocol 4 and perform primer extension. See Support Protocol 3 for preparation of appropriate end-labeled RNA standards for electrophoresis. SUPPORT PROTOCOL 1
LABELING THE 5′ RNA TERMINUS USING T4 POLYNUCLEOTIDE KINASE AND [C-32P]ATP Bacteriophage T4 polynucleotide kinase will transfer the γ phosphate of [γ-32P]ATP to an RNA substrate containing a 5′ hydroxyl group, or it will exchange the radiolabeled γ phosphate with a single 5′ phosphate present on the RNA substrate. The 5′ end of cellular RNAs may contain methyl guanosine cap structures that prohibit labeling by this method. Chemical solid-phase synthesis produces an RNA with a 5′ hydroxyl available for radiolabeling using [γ-32P]ATP and polynucleotide kinase, whereas RNA transcribed in vitro has a 5′ triphosphate that must first be removed with a phosphatase. Dephosphorylation is accomplished with bacterial alkaline phosphatase and its accompanying buffer. An alternate method, not described here, of generating 5′-labeled RNA by enzymatic synthesis is to transcribe in vitro with T7 RNA polymerase and [γ-32P]GTP, incorporating 32 P at only the 5′ terminal triphosphate (Milligan and Uhlenbeck, 1989). This protocol can also be used to produce 5′ end-labeled DNA oligomers to be used as primers in primer extension (see Support Protocol 4). This is done by performing the labeling reaction below (steps 8 to 11) with the appropriate DNA oligomer. Materials RNA of interest 150 U/µL bacterial alkaline phosphatase (BAP; Life Technologies) RNase-free water (see recipe) 10× dephosphorylation buffer: 100 mM Tris⋅Cl, pH 8.0 (APPENDIX 2A) 25:24:1 (v/v/v) phenol/chloroform/isoamyl alcohol (APPENDIX 2A) 3 M sodium acetate, pH 5.2 (APPENDIX 2A) 100% and 70% (v/v) ethanol 10 mM EDTA (APPENDIX 2A) 10× kinase buffer (see recipe) 0.1 M dithiothreitol (DTT) 150 µCi/µL [γ-32P]ATP (6000 Ci/mmol; NEN Life Sciences) 10,000 U/mL T4 polynucleotide kinase Stop mix (see recipe) Water baths, 37°C and 90° to 100°C
Probing RNA Structure with Chemical Reagents and Enzymes
Additional reagents and equipment for phenol/chloroform/isoamyl alcohol extraction (APPENDIX 2A)
6.1.8 Current Protocols in Nucleic Acid Chemistry
Dephosphorylate RNA (optional) 1. Calculate picomoles of RNA in 0.2 µg and set up the following reaction mix: 0.2 µg RNA of interest 10 µL of 10× dephosphorylation buffer RNase-free water to give 100 µL final volume. 70 U BAP per picomole RNA(dilute with 1x dephosphorylation buffer if necessary) Phosphate treatment is necessary if the RNA sample was generated by in vitro transcription. See also supplier’s technical bulletin for recommended reaction conditions.
2. Incubate 1 hr at 65°C. 3. Extract with 100 µL of 25:24:1 phenol/chloroform/isoamyl alcohol to stop the reaction. 4. Remove the aqueous phase to a new tube. Add 10 µL of 3 M sodium acetate and 300 µL of 100% ethanol. Precipitate on dry ice and then microcentrifuge 30 min at maximum speed (10,000 rpm), 4°C. Remove supernatant, rinse with 70% ethanol, and dry the pellet in a speedvac. 5. Bring 0.2 µg RNA to 18 µL with RNase-free water. Denature RNA sample (optional) 6. Add 2 µL of 10 mM EDTA. Heat 2 min at 90° to 100°C, then quickly transfer to an ice water bath and cool 5 min. Denaturation will increase labeling efficiency of base-paired or recessed 5′ termini; however, some RNA samples may be labeled more efficiently when folded.
7. Briefly microcentrifuge at maximum speed to collect any condensation. Label RNA 8. Combine the following and incubate 1 hr at 37°C. 13 µL denatured RNA (0.13 µg) 2 µL 10× kinase buffer 2 µL 0.1 M DTT 2 µL [γ-32P]ATP 1 µL T4 polynucleotide kinase (10 U). A crude preparation of [γ-32P]ATP is sufficient for this reaction and is less expensive. To label DNA primers, replace RNA with ~1 mg DNA oligomer and proceed through step 11.
9. Add 4 µL stop mix and 100 µL of 100% ethanol (5 vol). 10. Precipitate on dry ice, then microcentrifuge 30 min at maximum speed (10,000 rpm), 4°C. 11. Carefully remove supernatant (very radioactive) and dry the pellet in a speedvac. If the RNA is not going to be used immediately, resuspend the pellet in the appropriate buffer or water to reduce radiation-induced damage and freeze at −80°C. The length of time the RNA can be stored is limited by its activity; the half life of 32P is 14 days.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.1.9 Current Protocols in Nucleic Acid Chemistry
12. If a heterogeneous population exists, purify the radiolabeled RNA by denaturing gel electrophoresis (APPENDIX 3B). The RNA must have a discrete length to accurately identify nucleotide cleavages/modifications in the subsequent structure probing experiments. SUPPORT PROTOCOL 2
LABELING THE 3′ RNA TERMINUS USING T4 RNA LIGASE AND [32P]pCp Bacteriophage T4 RNA ligase will catalyze phosphodiester formation between a nucleotide 3′ hydroxyl and a nucleotide 5′ phosphate. The RNA of interest requires a 3′ hydroxyl that will be coupled to 5′-[32P]cytidine-3′,5′-bisphosphate ([32P]pCp). [32P]pCp can be purchased or generated using 3′-cytosine-monophosphate, [γ-32P]ATP, and T4 polynucleotide kinase (England et al., 1980; UNIT 6.3). The latter method is recommended because it generates the concentrated form needed at a reasonable cost. Enzymatically synthesized RNAs have a 3′ hydroxyl that can be directly ligated with radiolabeled [32P]pCp. Breakdown of RNA by nucleases, metal or alkaline hydrolysis, and cleavage by ribozymes (excluding RNase P) produces 2′-3′ cyclic phosphates, which subsequently hydrolyze to 3′ phosphates and cannot be directly 3′ end labeled. Dephosphorylation of 3′ phosphates is accomplished with bacterial alkaline phosphatase and accompanying buffer (see Support Protocol 1). Additional Materials (also see Support Protocol 1) 0.5 M HEPES, pH 7.9 at 50 mM 0.1 M MgCl2 0.1 mg/mL bovine serum albumin (BSA) 1 mM ATP Dimethyl sulfoxide (DMSO) 500 µM 5′-[32P]cytidine-3′,5′-bisphosphate ([32P]pCp; UNIT 6. 3 or Amersham) 20 to 25 U/µL T4 RNA ligase Dephosphorylate RNA (optional) 1. If necessary, dephosphorylate RNA as described (see Support Protocol 1, steps 1 to 4), but increase RNA to 2 µg and increase BAP accordingly. 2. Resuspend pellet in 10 µL RNase-free water to make 0.2 µg/µL (∼6 µM for a 100-nucleotide RNA). Label RNA 3. Mix the following (10 µL total volume): 1 µL 10 µM RNA of interest (final 1 µM) 1 µL 0.5 M HEPES, pH 7.9 at 50 mM (50 mM) 2 µL 0.1 M MgCl2 (20 mM) 1 µL 0.1 mg/mL BSA (10 µg/mL) 1 µL 30 mM DTT (3 mM) 1 µL 1 mM ATP (0.1 mM) 1 µL DMSO (10% v/v)
Probing RNA Structure with Chemical Reagents and Enzymes
1 µL 500 µM [32P]pCp (50 µM) 1 µL 20 to 25 U/µL T4 RNA ligase (2 to 2.5 U/ µL) 4. Incubate ≥12 hr at 4°C (typically overnight).
6.1.10 Current Protocols in Nucleic Acid Chemistry
5. Add 90 µL RNase-free water, mix, and extract with 100 µL of 25:24:1 phenol/chloroform/isoamyl alcohol. 6. Add 10 µL of 3 M sodium acetate and 300 µL of 100% ethanol. 7. Precipitate and purify as described (see Support Protocol 1, steps 10 to 12). PREPARING STANDARDS FOR ELECTROPHORESIS OF END-LABELED RNA CLEAVAGE PRODUCTS
SUPPORT PROTOCOL 3
Limited alkaline hydrolysis and digestion with RNase T1 under denaturing conditions are used to prepare two separate sets of electrophoresis standards in order to determine sites of end-labeled RNA cleavage. Alkaline hydrolysis results in a relatively even ladder of truncated RNAs. A denaturing RNase T1 digest cleaves the RNA 3′ of each guanosine. Comparison of the two products with the modified/cleaved end-labeled RNA after electrophoresis identifies guanosines along the alkaline hydrolysis ladder, and therefore the intervening products present in the alkaline hydrolysis reaction can be determined from the RNA sequence. End-labeled RNA cleavage products from structure-probing reactions can thus be identified. Materials RNA of interest, 32P-end-labeled to 50,000 cpm (see Support Protocol 1 or Support Protocol 2) 100% (v/v) ethanol 3 M sodium acetate, pH 5.2 (APPENDIX 2A) Na2CO3/EDTA solution (see recipe) CU buffer (see recipe) RNase T1 (Life Technologies) 2 µg/µL tRNA carrier (see recipe for carrier RNA) CEU buffer (see recipe) FEXS solution (see recipe) 95°C water bath Alkaline Hydrolysis of RNA 1. Ethanol precipitate 50,000 cpm of end-labeled RNA in 1/10 vol of 3M sodium acetate, pH 5.2 and 3 vol of 100% ethanol, microcentrifuge 30 min at maximum speed, 4°C (10,000 rpm), and dry the pellet in a speedvac. 2. Resuspend with 1.2 µL Na2CO3/EDTA solution and mix with a pipet. 3. Incubate between 90 and 120 sec at 95°C, then 1 min on ice. Initially, vary incubation time at 95°C to achieve a relatively even ladder of products following electrophoresis, thereafter use the most successful incubation time.
4. Add 2.8 µL of CU buffer and mix to neutralize. 5. Add 8 µL FEXS solution. Store frozen at −80°C, if necessary. The time the RNA can be stored is dependent on the signal detection and the 32P half life (14 days).
RNase T1 Digest of RNA 6. Add 5 µL of 2 µg/µL carrier tRNA to a second aliquot of 50,000 cpm end-labeled RNA. Ethanol precipitate with 1/10th vol 3 M sodium acetate, and 3 vol 100%
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.1.11 Current Protocols in Nucleic Acid Chemistry
ethanol, microcentrifuge 30 min at maximum speed (10,000 rpm), 4°C, and dry the pellet in a speedvac. 7. Resuspend with 3 µL CEU buffer and mix with a pipet. 8. Incubate 5 min at 50°C. 9. Add 1 µL RNase T1 diluted in CEU buffer and incubate 15 min at 50°C. The appropriate RNase T1 dilution will need to be determined by titration, but 1 to 3 U typically produces good results. Alternatively, other urea-tolerant nucleases, such as RNase A (C and U specific), can be used.
10. Add 8 µL FEXS solution. Store frozen at −80°C, if necessary. BASIC PROTOCOL 3
MODIFICATION OF RNA AT WATSON-CRICK POSITIONS USING DIMETHYL SULFATE Watson-Crick positions of adenosines (N1) and cytidines (N3) not involved in base pairing or tertiary-structure hydrogen bonding are alkylated by DMS. Primer extension (see Support Protocol 4) of modified RNA and comparison with dideoxynucleotide sequencing reactions identifies the modified bases. Used together, dimethyl sulfate (for A and C), kethoxal (for G; see Alternate Protocol 3), and CMCT (for U; see Alternate Protocol 4) provide a complete analysis of the base-pairing status (i.e., secondary structure) of the RNA of interest. See Strategic Planning for discussions of RNA sample source and folding. Materials 0.5 M HEPES, pH 7.8 1 M KCl (APPENDIX 2A) 0.1 M MgCl2 1 µg/µl RNA of interest RNase-free water (see recipe) 10.56 M dimethyl sulfate (DMS; 99+%) 100% and 70% (v/v) ethanol 3 M sodium acetate, pH 5.2 (APPENDIX 2A) Additional reagents and equipment for primer extension (see Support Protocol 4) CAUTION: DMS is highly toxic and a suspected carcinogen; appropriate precautions should be taken for handling, storage, and disposal. 1. Prepare four reaction tubes, each containing: 1 µL 0.5 M HEPES, pH 7.8 (final 50 mM) 1 µL 1 M KCl (100 mM) 1 µL 0.1 M MgCl2 (10 mM) 2 µL 1 µg/µL RNA of interest (0.2 µg/µL)
Probing RNA Structure with Chemical Reagents and Enzymes
4 µL RNase-free water 2. Just prior to use, dilute DMS in four 2-fold serial dilutions in 100% ethanol to give the appropriate amounts in a volume of 1 µL.
6.1.12 Current Protocols in Nucleic Acid Chemistry
DMS must initially be titrated to attain the desired RNA modification typically ~10%. The following dilutions are provided as examples only. Dilute 1 mL of 10.56 M DMS stock in 16.6 mL of 100% ethanol to give 600 mM. Further dilute 2-, 4-, and 8-fold with 100% ethanol to make 300, 150, and 75 mM dilutions, respectively. The final reaction concentrations will be 60, 30, 15, and 7.5 mM.
3. Add 1 µL of each DMS dilution to a reaction mix, mix well, and incubate 20 min at room temperature. 4. Add 1 µL of 3 M sodium acetate and 30 µL of 100% ethanol and precipitate on dry ice. Microcentrifuge 30 min at maximum speed (10,000 rpm), 4°C. Remove supernatant, rinse with 70% ethanol, and dry the pellet in a speedvac. 5. Resuspend pellet in 40 µL RNase-free water and proceed with primer extension (see Support Protocol 4) using 4 µL (0.2 µg) per reaction. MODIFICATION OF RNA AT WATSON-CRICK POSITIONS USING KETHOXAL
ALTERNATE PROTOCOL 3
Kethoxal alkylates the N1 and 2-NH2 Watson-Crick positions of guanosines not involved in base pairing or tertiary-structure hydrogen bonding. The procedure is the same as for modification with DMS (see Basic Protocol 3), except that step 2 is replaced with the following step. Used together, dimethyl sulfate (A & C; Basic Protocol 3), kethoxal (G), and CMCT (U; Alternate Protocol 4) provide a complete analysis of the base-pairing status (i.e., secondary structure) of the RNA of interest. See Strategic Planning for discussion of RNA sample source and folding. Additional Materials (also see Basic Protocol 3) 4.27 M kethoxal stock (ICN or Research Organics) 2b. Just prior to use, dilute 4.27 M kethoxal in four 2-fold serial dilutions in RNase-free water to give the appropriate amounts in a volume of 1 µL. Kethoxal must be titrated to attain the desired RNA modification. The following dilutions are provided as examples only. Dilute 1 mL of 4.27 M kethoxal stock in 20.35 mL water to give 200 mM. Further dilute 2-, 4-, and 8-fold with water to make 100, 50, and 25 mM dilutions, respectively. Final reaction concentrations will be 20, 10, 5, and 2.5 mM.
MODIFICATION OF RNA AT WATSON-CRICK POSITIONS USING CMCT 1-Cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate (CMCT) alkylates the N3 Watson-Crick position of uridines not involved in base pairing or tertiary-structure hydrogen bonding. The approach is essentially as described for modification with DMS (see Basic Protocol 3), except that the reactions are performed as outlined below. Used together, dimethyl sulfate (A & C; Basic Protocol 3), kethoxal (G; Alternate Protocol 3), and CMCT (U) provide a complete analysis of the base-pairing status (i.e., secondary structure) of the RNA of interest. See Strategic Planning for discussion of RNA sample source and folding. Additional Materials (also see Basic Protocol 3) 0.5 M potassium borate, pH 8.0 0.5 M 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate (CMCT) in RNase-free H2O (stable for several weeks at –20°C; Aldrich) 37°C water bath
ALTERNATE PROTOCOL 4
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.1.13 Current Protocols in Nucleic Acid Chemistry
1. Prepare three reaction tubes, each containing: 1 µL 0.5 M potassium borate, pH 8.0 (final 50 mM) 1 µL 1 M KCl (100 mM) 1 µL 0.1 M MgCl2 (10 mM) 2 µL 1 µg/µL RNA of interest (0.2 µg/µL) 2. Just prior to use, heat 0.5 M CMCT at 37°C and vortex to ensure the reagent is completely solubilized. Immediately dilute 0.5 M CMCT solution to 200 mM and 50 mM in RNase-free water. CMCT must be titrated to attain the desired RNA modification. The above dilutions can be used for the initial titration. Final reaction concentrations using the stock solution and the two dilutions will be 250, 100, and 25 mM, respectively.
3. Add 5 µL of each CMCT dilution to a reaction mix, mix well, and incubate 20 min at room temperature. 4. Precipitate and proceed to primer extension as described (see Basic Protocol 3, steps 4 and 5). SUPPORT PROTOCOL 4
DETECTION OF RNA CLEAVAGE OR MODIFICATION BY PRIMER EXTENSION Primer extension of a radiolabeled DNA oligomer will synthesize a complementary DNA strand to the RNA of interest. Reverse transcriptase will stop upon encountering alkylated Watson-Crick determinants, resulting in a product one base short of the modification. The enzyme will also run off RNA cleavage products, producing a DNA corresponding to the site of cleavage. Strong secondary structure, such as hairpin loops within the RNA, can cause the enzyme to pause, creating a prematurely terminated product. It is therefore essential to perform the reaction on unmodified/uncleaved RNA as a control. This enables pause sites from secondary structure to be subtracted from the modification/cleavage analysis. Because carrier RNA can affect the reverse transcription reaction, control reactions should include the carrier RNA as well. The reaction requires a DNA oligomer complementary to the RNA of interest, 3′ of the region to be examined. It might be necessary to use several DNA oligomers to examine an RNA several hundred nucleotides long. The extension products are resolved on standard DNA sequencing gels, allowing ∼200 nucleotides to be examined per DNA primer. Location of primer-extension terminations is determined by comparison to standard dideoxynucleotide sequencing reactions using the same primer and a template of the same sequence as the RNA being examined. The primer-extension reaction requires a 32P-labeled DNA oligomer that is generated using bacteriophage T4 polynucleotide kinase. Reaction conditions for labeling the primer are identical to those used for end labeling the 5′ RNA terminus (see Support Protocol 1), but substituting the DNA oligomer for the RNA.
Probing RNA Structure with Chemical Reagents and Enzymes
Materials [5′-32P]DNA oligomer (see Support Protocol 1) complementary to 3′ end of the sample RNA Sample RNA, cleaved or modified (see Basic Protocols 1 to 3 and Alternate Protocols 1 to 4) RNase-free water (see recipe) Sample RNA, uncleaved and unmodified 25 mM 4dNTP mix (see dNTPs in APPENDIX 2A) 0.1 M dithiothreitol (DTT)
6.1.14 Current Protocols in Nucleic Acid Chemistry
5× first strand buffer (see recipe) 200 U/µL Superscript II RNase H(−) Moloney murine leukemia virus reverse transcriptase (MMLV RT; Life Technologies; see Troubleshooting for alternative RTs) 3 M sodium acetate, pH 5.2 (APPENDIX 2A) 100% and 70% (v/v) ethanol FENXB solution (see recipe) Dideoxynucleotide sequencing reactions (e.g., CPMB UNIT 7.4A) of cDNA for sample RNA Sequencing gel: 6% (w/v) acrylamide (20:1 mono-/bis-), 8 M urea, 1× TBE buffer (APPENDIX 2A for TBE buffer) Water bath or heating block, 42° and 70°C Additional reagents and equipment for running a sequencing gel (APPENDIX 3B) Anneal primer 1. Mix the following: 100,000 cpm [5′-32P]DNA oligomer 0.2 µg sample RNA, cleaved or modified RNase-free water to 18.5 µL. It may be necessary to titrate the [32P]DNA oligomer and RNA concentrations to optimize the extension reaction conditions.
2. Set up a similar control reaction using unmodified, uncleaved RNA. This control should be performed to identify structure-induced terminations and to ensure that the majority of the DNA oligomer is being fully extended through the region of interest.
3. Incubate 10 min at 70°C, followed by 30 min at 42°C. 4. Briefly microcentrifuge down any condensation that forms. Extend DNA 5. To the primer/RNA mix add: 3 µL 25 mM 4dNTP mix 2 µL 0.1 M DTT 6 µL 5× first strand buffer. Total volume is now 29.5 µL.
6. Add 0.5 µL (100 U) Superscript II and mix. 7. Incubate 45 min at 42°C. 8. Add 3 µL of 3 M sodium acetate, and 90 µL of 100% ethanol. Precipitate on dry ice and microcentrifuge 30 min at maximum speed (10,000 rpm), 4°C. 9. Remove supernatant, rinse pellet with 70% ethanol, and dry the pellet in a speedvac. 10. Resuspend in 6 µL FENXB solution for resolution on a 6% acrylamide sequencing gel (APPENDIX 3B). Use dideoxynucleotide sequencing reactions as markers (e.g., CPMB Unit 7.4A). Typically a cDNA template, rather than an RNA template, is used for the sequencing reactions, allowing them to be performed with a DNA-dependent DNA polymerase (e.g., Sequenase; United States Biochemical).
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.1.15 Current Protocols in Nucleic Acid Chemistry
REAGENTS AND SOLUTIONS Use deionized water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Aniline acetate buffer, 1 M 10 µL of 99.5% aniline 93 µL H2O 6 µL glacial acetic acid Make fresh CAUTION: Aniline is highly toxic.
Carrier RNA, 1 mg/mL or 2 mg/mL Carrier RNA can be unlabeled RNA of interest or total yeast tRNA. Extract yeast tRNA with 25:24:1 (v/v/v) phenol/chloroform/isoamyl alcohol (APPENDIX 2A) and ethanol precipitate to remove any protein contaminants. Store at –20°C. Citrate/EDTA/urea (CEU) buffer For 100 mL: 10.25 mL 0.1 M citric acid 14.75 mL 0.1 M sodium citrate (final 25 mM citrate) 0.2 mL 0.5 M EDTA (APPENDIX 2A; final 1 mM) ∼30 mL H2O 42.04 g urea (final 7 M) Adjust to pH 4.7 to 5.0 with HCl Stable indefinitely at –20°C Citrate/urea (CU) buffer For 100 mL: 10.25 mL 0.1 M citric acid 14.75 mL 0.1 M sodium citrate (final 25 mM citrate) ∼30 mL of H2O 60.06 g urea (10 M final) Adjust to pH 4.7 to 5.0 with HCl Stable indefinitely at –20°C Ethylnitrosourea (ENU)/ethanol solution Add N-nitroso-N-ethylurea (ENU) to 100 µL of 100% ethanol until solution is saturated. Centrifuge to pellet insoluble reagent. Make fresh. CAUTION: ENU is highly toxic and a suspected carcinogen. follow appropriate precautions for handling, storage, and disposal.
FENXB solution 95% formamide, redistilled 20 mM EDTA (APPENDIX 2A) 2 mM NaOH 0.05% xylene cyanol 0.05% bromphenol blue Stable indefinitely at –5 to –20°C
Probing RNA Structure with Chemical Reagents and Enzymes
FEXS solution 95% formamide, redistilled 10 mM EDTA (APPENDIX 2A) 0.05% xylene cyanol 0.1% SDS Stable indefinitely at –5 to –20°C
6.1.16 Current Protocols in Nucleic Acid Chemistry
First strand buffer, 5× 250 mM Tris⋅Cl , pH 8.3 (APPENDIX 2A) 375 mM KCl 15 mM MgCl2 Stable indefinitely at –20°C Kinase buffer, 10× 700 mM Tris⋅Cl, pH 7.6 (APPENDIX 2A) 100 mM MgCl2 50 mM dithiothreitol (DTT) Stable indefinitely at –20°C Na2CO3/EDTA solution For 1 mL: 50 µL 1 M Na2CO3, pH 11.7 (final 50 mM) 2 µL 0.5 M EDTA (APPENDIX 2A; final 1 mM) 948 µL H2O Stable indefinitely at –20°C Stop mix 20 mM EDTA (APPENDIX 2A) 0.3 M NaCl 1 µg/µL glycogen Stable indefinitely at –20°C Water, RNase free Test water source for contaminating nuclease activity by incubating labeled RNA in water and buffers for intended reaction time. Ascertain integrity of sample by electrophoresis. Often deionized and glass-distilled water will be free of nucleases. However, if water and/or buffer reagents contain nuclease activity, treat with DEPC to inactivate (APPENDIX 2A). Autoclaved solutions are sometimes allowed to stand at room temperature, with loose caps, for several days to remove all DEPC. Trace DEPC can inhibit reverse transcriptase and other enzymes.
COMMENTARY Background Information Sensitivity to chemical and enzymatic reagents can often be used to test hypotheses regarding solution exposure and singlestranded versus double-stranded character along the folded RNA chain; however, the data generated in these experiments is most effective when used in reference to a secondary structure model for the RNA generated by other approaches. Computer-based energy-minimization algorithms have proven extremely useful in predicting simple RNA structures or in providing multiple local folding possibilities in larger RNAs (Zuker, 1989; Gautheret et al., 1990; Major et al., 1991; Malhotra et al., 1993; Walter et al., 1994; Gorodkin et al., 1997). These folding algorithms suffer from several
severe limitations in predicting longer RNAs, however, tending to miss long-distance interactions and lacking sufficient predictions of nonstandard interactions among nucleotides. In some instances, the physiologically relevant RNAs will also contain nucleoside modifications that are not necessarily known or taken into account. Perhaps most importantly, the functional form of the molecules might not be the most stable folded form under the conditions used to fold the RNA in vitro. It is possible that manipulation of the folding conditions might identify methods that drive the majority of a purified RNA into an appropriate structure, assuming that there is some method to determine what constitutes an appropriate structure.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.1.17 Current Protocols in Nucleic Acid Chemistry
Manipulation of folding conditions for RNAs synthesized in vitro will be discussed below. Structural analysis of RNAs and ribonucleoproteins (RNPs) can be used to determine secondary structure, facilitate modeling of tertiary structure, and identify RNA-protein contacts. The source of the material to be probed will often dictate which labeling and probing techniques are necessary. Primer extension is the preferred method for analysis of large or cellularly derived RNAs. The native RNA or RNP complex can be assayed without manipulations that may disrupt the integrity of the sample. Postmodification or cleavage products are assayed by extension of labeled DNA oligomers with reverse transcriptase. End labeling techniques can also sometimes be successful. However, in vivo–derived RNAs often possess 5′ methyl cap structures preventing labeling at that terminus, and one or both termini in the native RNA can be recessed or obscured by protein in RNP structures. Chemical or enzymatic synthesis of RNA permits incorporation of labeling groups during synthesis, or if necessary, labeling sites can be engineered in the synthetic RNAs. Studies involving novel sequences, subregions of larger RNAs, or RNP reconstitution experiments sometimes require the use of synthetic RNA. Chemical and enzymatic synthesis of RNA also provides an opportunity to incorporate nucleosides modified with fluorescent, antigenic, or crosslinking groups during synthesis.
Critical Parameters
Probing RNA Structure with Chemical Reagents and Enzymes
The first principle in RNA structure analysis is to begin with an RNA properly folded into its physiologically relevant structure. Synthetic RNA may or may not be in its properly folded state. Gentle purification techniques should retain the in vivo conformation of cellularly derived RNAs and RNPs. However, folding of many RNAs in vivo is not readily reproduced in vitro, in many instances because the RNAs require association of proteins to assume physiologically appropriate structures. In these cases it might be necessary to either isolate the RNAs from cells or to associate the appropriate proteins in vitro in a manner that can be demonstrated to cause the RNA to assume a functional structure. The best insurance that the RNA or RNP of interest is correctly folded is to test its functional or enzymatic activity. Other folding assays will be necessary if no functional assay exists. The number of folding isoforms of an RNA sample can sometimes be determined using
native polyacrylamide gel electrophoresis. RNAs with extensive self-complementarity often form multimers, which can be detected on the native gel. Heat denaturation can be used to melt present structures. Cooling rate, RNA concentration, and the presence of mono- and divalent cations all affect the subsequent folding isoform populations. In general, a faster cooling rate, the absence of cations, and low RNA concentrations favor intramolecular folding. Likewise, slow cooling in high salt with high RNA concentrations favors intermolecular folding and the formation of multimers. It should be noted that the RNA might need to adopt more than one structure to carry out its function(s) in vivo. Driving all of the RNA sample (or protein-RNA complex) into a single form might reflect only one aspect of the functional RNA structure. Once the RNA is properly folded, the structure-probing experiments can begin. There are four factors that are key to experiment reproducibility. The first is a consistent reaction mix. Make a batch of all ingredients minus the reagent, mix, then aliquot to the necessary number of tubes. Always make enough for the desired number of reactions plus one. This will ensure that the amount of each component, especially radiolabeled RNA, is identical between reactions. The second factor is reaction time. Many of the probing reactions are short (e.g., 10 min) to minimize the effect of any contaminating nuclease activity. The number of reactions attempted at once should not compromise strict adherence to the reaction time. Longer reaction times may be used effectively, but short times have been found to reduce secondary or nonspecific activities. The third factor is the use of unlabeled carrier RNA. Carrier RNA provides a constant substrate concentration for the probing reagents. The concentration of radiolabeled RNA is much less than the carrier and is negligible in most reactions. Therefore, any changes in labeling efficiency between RNA preparations will have little effect. Lastly, it is necessary to titrate the amount of reagent for each particular RNA of interest so that ∼10% of the RNA is cleaved. The likelihood of multiple cleavages per molecule is thereby reduced. Typically, the concentration of RNA is held constant and the amount of reagent is titrated until the desired extent of modification is achieved. If the RNA sample of interest is extremely limited, reagents are titrated using a different RNA with the identical unlabeled carrier RNA and buffer conditions.
6.1.18 Current Protocols in Nucleic Acid Chemistry
The presence of excess carrier RNA facilitates reproducibility of cleavage conditions.
Troubleshooting Primer-extension analysis of probing reactions can encounter several pitfalls. For example, breakdown in the sample results in termination products not produced by the probing reagents. Extension of unmodified, uncleaved RNA should identify these sites and allow for their subtraction from the probing data. However, extensive degradation or strong secondary structure–induced terminations may obscure cleavages or modifications at several nucleotides of interest. Synthetic RNA sample integrity can be improved by changing the original purification strategy or by further purification to ensure that a discrete population exists. RNA samples in crude cellular fractions should be prepared as rapidly as possible at 0° to 4°C and stored frozen (−80°C) when not in use to minimize degradation by endogenous nucleases. To alleviate secondary structure–induced terminations, the primer-extension reaction conditions and/or the reverse transcriptase can be changed. Superscript II has demonstrated an ability to proceed quite well through secondary structure, but other reverse transcriptases, such as AMV and Retrotherm, may function better on a particular RNA. The heat-stable Retrotherm can also be used at elevated temperatures to minimize RNA secondary structure. Achieving an interpretable amount of modification or cleavage is another problem often encountered. The desired modification or cleavage goal is 10% of the total RNA, in the realm of single-hit kinetics. This rule minimizes the presence of products resulting from multiple modifications or cleavages. Typically, the concentration of reagent is adjusted until the 10% goal is reached for a batch of RNA, carrier RNA, and reagent. Single cleavages or modifications per RNA molecule usually allow for detection of all available targets within the region of interest. However, a hyper-reactive site may exist that prevents further primer extension or observation of end-labeled RNA products larger than the hyper-reactive nucleotide. In this scenario, a new primer complementary to the region 5′ of the RNA modification will be needed, or in the case of end-labeled RNA, labeling the opposite end will allow analysis of the remaining RNA region of interest. All of the probing reactions are purposefully designed to have nearly identical buffer and salt conditions. RNA structure can change consid-
erably based on the amount and nature of counterions and pH. Consistency in reaction conditions between different probing reagents helps to ensure the same structure is being examined. The buffers and pH are changed only when they may interfere with the chemical nature of the reagent. It should be noted that the maximal activities of several reagents and most of the nucleases occur under different conditions than those listed, but all have been used successfully as described. The standard salt conditions can be altered as desired but consistency is important. Also, formation of RNA tertiary structures is often very dependent on the amount and type of counter-ions present. Uncharacteristic modifications or cleavages from probing reagents are sometimes observed. Interpretation of atypical activities should be regarded with appropriate caution. For example, reagents used outside their optimal reaction conditions or the presence of contaminating activities could be responsible. It is also possible to observe inconsistencies between reagents with the same targets. Thus, using two reagents that should cleave or modify an unpaired nucleotide might give the result that the nucleotide is sensitive to one but not the other. In all probability, the reagents are functioning properly, but subtle differences in substrate binding and recognition can favor one over the other.
Anticipated Results There are several cautionary notes that should be considered when interpreting RNA footprinting data. First, it should always be remembered that both purified RNAs and RNA-protein complexes can exist in multiple isoforms, whether folded and bound in vitro or isolated intact from cells. As far as possible, the heterogeneity of RNA sample of interest should be investigated and taken into account when interpreting sensitivity. Second, sensitivity to cleavage or modification reagents is far more useful in showing solution exposure than “protection” from reagents. Inaccessibility of even the same region of a base to an individual enzyme or chemical can vary from reagent to reagent, and can have a number of causes including involvement in hydrogen bonding, folding into the interior of the RNA where it is less exposed to the solvent, inappropriate chemical states, and direct blockage by interacting proteins. Thus, if protection is observed in a particular region when a protein is added, the protection might result from either direct coverage by the protein or indirect effects of
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.1.19 Current Protocols in Nucleic Acid Chemistry
the bound protein acting at a distance. It should be reemphasized that even detailed footprinting results are often consistent with multiple hypothetical structures, and for any complex RNA it is likely that additional, independent types of evidence will be needed to sort out the possibilities. Results of structure-probing experiments are useful to qualitatively model RNA structure. The more reagents employed, the more descriptive the analysis. Suspected anomalous modifications or cleavages by a single reagent can therefore be subtracted. Modification/cleavage products can be quantitated by phosphorimager analysis and analyzed using a computer (e.g., ImageQuant from Molecular Dynamics; visual inspection of autoradiograms is fine for qualitative analysis). The accessibility of an RNA target is directly proportional to the modification/cleavage product band intensity. End-labeled RNA or labeled primer-extension products have one label per product molecule. However, it is not simple to interpret the reason that one target is preferred over another. Targets on the surface of a molecule are likely to be more accessible than those buried within the interior of a tertiary structure, although local steric effects may have as much impact on reagent reactivity as global structure. Data obtained using multiple reagents will better uncover the true solution structure of a target, and the trend of several reagents should be regarded as the rule, rather than a single hit by one reagent. One should also keep in mind that solution structure is dynamic and that RNA molecular motion is dependent on temperature and ionic environment.
Time Considerations
Probing RNA Structure with Chemical Reagents and Enzymes
The design of structure-probing experiments is dictated by the stability of the RNA sample of interest and the half-life of radiolabeled material. Cellularly derived RNAs or RNPs often contain contaminating nuclease activities, and these can be considerable depending on the purification scheme employed. It is therefore imperative to preserve samples frozen at −80°C and to use them immediately upon thawing. Synthetic RNAs are often free of contaminating nucleases, depending on the handling and manipulations the sample has received. The structure-probing reactions are usually short (e.g., 10 min) to reduce the effects of any contaminating activities. Control reactions should identify extraneous cleavages, provided that the majority of the sample is not degraded in the reaction interval. A time course
incubation of the RNA of interest in the desired reaction buffer may prove beneficial in identifying sample integrity versus incubation time. Longer reaction times, allowing for more samples, might then be used. Modified/cleaved RNA intended for primerextension analysis can be stored frozen at −80°C while the radiolabeled DNA primer is made. End-labeled RNA should be resolved by electrophoresis promptly after modification/cleavage reactions are complete. Note that only 10% of the RNA sample should be modified/cleaved; therefore, the detectable radiolabel signal from the modified/cleaved products will only be 10% of the sample’s specific activity. Experiments should proceed readily to maximize signal from a batch of radiolabeled RNA. Once all reaction components are in hand, setting up the probing reactions, incubating, and terminating the reactions for a single reagent should take ∼1 to 3 hr. Primer extension typically takes 2 to 3 hr, and gel electrophoresis on standard sequencing (6%) polyacrylamide gels requires 2 to 3 hr.
Literature Cited England, T., Bruce, A., and Uhlenbeck, O. 1980. Specific labeling of 3′ termini of RNA with T4 RNA ligase. Methods Enzymol. 65:65-74. Gautheret, D., Major, F., and Cedergren, R. 1990. Computer modeling and display of RNA secondary and tertiary structures. Methods Enzymol. 183:318-330. Gorodkin, J., Heyer, L., and Stormo, G. 1997. Finding the most significant common sequence and structure motifs in a set of RNA sequences. Nucl. Acids Res. 25:3724-3732. Knapp, G. 1989. Enzymatic approaches to probing of RNA secondary and tertiary structure. Methods Enzymol. 180:192-212. Krol, A. and Carbon, P. 1989. A guide for probing native small nuclear RNA and ribonucleoprotein structures. Methods Enzymol. 180:212-227. Major, F., Turcotte, M., Gautheret, D., Lapalme, G., Fillion, E., and Cedergren, R. 1991. The combination of symbolic and numerical computation for three-dimensional modeling of RNA. Science 253:1255-1260. Malhotra, A., Gabb, H., and Harvey, S. 1993. Modeling large nucleic acids. Curr. Opin. Struct. Biol. 3:241-246. Milligan, J.F. and Uhlenbeck, O.C. 1989. Synthesis of small RNAs using T7 RNA polymerase. Methods Enzymol. 180:51-62. Peattie, D.A. and Gilbert, W. 1980. Chemical probes for higher-order structure in RNA. Proc. Natl. Acad. Sci. U.S.A. 77:4679-4682.
6.1.20 Current Protocols in Nucleic Acid Chemistry
Walter, A.E., Turner, D.H., Kim, J., Lyttle, M.H., Muller, P., Matthews, D.H., and Zuker, M. 1994. Coaxial stacking of helixes enhances binding of oligoribonucleotides and improves predictions of RNA folding. Proc. Natl. Acad. Sci. U.S.A. 91:9218-9222.
Contributed by William A. Ziehler and David R. Engelke University of Michigan Ann Arbor, Michigan
Zuker, M. 1989. On finding all suboptimal foldings of an RNA molecule. Science 244:48-52.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.1.21 Current Protocols in Nucleic Acid Chemistry
Probing Nucleic Acid Structure with Shape-Selective Rhodium and Ruthenium Complexes
UNIT 6.2
This unit describes the use of transition metal complexes, specifically rhodium and ruthenium compounds, as photochemical probes of the structure of DNA and RNA. Such complexes have proven to provide a versatile platform for the design of chemical reagents to probe nucleic acid structure. The central transition metal ion provides both a rigid, substitutionally inert framework and an octahedral geometry for ligand coordination. The metal complexes can be constructed to define shapes, symmetries, and functionalities that complement those of the nucleic acid target. In addition, the rich photochemistry of rhodium and ruthenium allows easy identification of sites of complex binding by lightinduced nucleic acid cleavage. The modular construction of such complexes, allowing use of a variety of commercially available or custom-synthesized ligands, makes it possible to generate many different probes to examine various subtle and not-so-subtle characteristics of nucleic acids. In the procedures that are described, end-labeled DNA or RNA is incubated with a single transition metal reagent and then irradiated with visible or ultraviolet light to promote cleavage of the nucleic acid polymer strand. The resulting cleavage products are then observed by polyacrylamide gel electrophoresis (PAGE). These common procedures are used with different metal complexes to probe various characteristics of nucleic acid systems. For rhodium compounds, strand cleavage is affected by direct metal complex photochemistry; for ruthenium compounds, cleavage is induced by singlet oxygen-induced damage followed by treatment with piperidine. Metal complexes of varied structure are utilized to explore different characteristics of the nucleic acids. Depending on the binding mode and specificity of the complexes, it is possible to explore characteristics such as groove width and depth (see Basic Protocol 1), the presence of unusual structures like cruciforms or Z DNA (see Basic Protocol 2), mismatches or abasic sites (see Basic Protocol 3), and tertiary folding of nucleic acids (see Basic Protocol 5). In addition, such complexes can be used as photofootprinting agents to study other molecules binding to nucleic acids (see Basic Protocol 4) and as singlet oxygen sensitizers for specific reaction with guanine bases in DNA or RNA (see Basic Protocol 6). Inorganic syntheses of the required metal complexes are included for each procedure (see Support Protocols 1 to 6). General guidelines for preparing labeled nucleic acids, for photolysis, and for mapping cleavage sites are also presented (see Support Protocols 7 to 9). CAUTION: The procedures described in this unit utilize strong acids, flammable liquids, glassware under vacuum, and cryogens. All reagents should be used with care, using appropriate personal and laboratory safety equipment, and in well-ventilated fume hoods. The syntheses of the transition metal reagents involve polycyclic aromatic compounds, most of which are either suspected or known carcinogens. All precautions recommended by suppliers should be taken in order to prevent undue exposure to dusts or solutions. The metal complexes made in these protocols bind to nucleic acids with high affinity and promote strand cleavage upon exposure to light. As a result, they should be handled with care and contact with them should be avoided. The light sources used in DNA photocleavage experiments produce high-intensity ultraviolet light. Focused light beams can cause skin burns and severe eye damage. The radioactivity used in nucleic acid labeling procedures must be used in compliance with all appropriate regulations and guidelines. When performing electrophoresis portions of the protocols, it must be remembered that unpolymerized acrylamide is a potent, cumulative neurotoxin and all contact with it must
Chemical and Enzymatic Probes for Nucleic Acid Structure
Contributed by Brian A. Jackson and Jacqueline K. Barton
6.2.1
Current Protocols in Nucleic Acid Chemistry (2000) 6.2.1-6.2.39 Copyright © 2000 by John Wiley & Sons, Inc.
be avoided. In all cases, the waste products produced by these syntheses and biochemical experiments should be disposed of according to good laboratory practices. BASIC PROTOCOL 1
MAPPING DNA MAJOR AND MINOR GROOVE CHARACTERISTICS Two metal complexes of differing structural characteristics, bis(1,10-phenanthroline)(9,10-phenanthrenequinone diimine)rhodium(III), [Rh(phen)2(phi)]3+, and tris(3,4,7,8-tetramethyl-1,10-phenanthroline)ruthenium(II), [Ru(TMP)3]2+, can be used to examine variations in structure and local conformation in stretches of putatively B-form DNA. For reference, the structures of the complexes are included as Figure 6.2.1. The two coordination compounds bind to DNA by different modes and, as a result, recognize different structural characteristics of the nucleic acid. [Rh(phen)2(phi)]3+ binds in the major groove by intercalation of its phi ligand, and thus recognizes sites on the DNA where the geometry of the double helix can accommodate its bulky phenanthroline ligands. Upon irradiation with UV light, it directly cleaves the DNA at its site of binding. Conversely, [Ru(TMP)3]2+ binds to the surface of the DNA minor groove and shows a preference for A-form helices. The ruthenium complex cleaves DNA by sensitizing singlet oxygen upon irradiation. When taken together, DNA cleavage patterns generated by both of these complexes serve as a straightforward method to map out the geometrical characteristics of a long DNA sequence. For the mapping of an isolated DNA sequence, end-labeled DNA is incubated with each metal complex and photolysed to promote strand cleavage. Because [Rh(phen)2(phi)]3+ directly cleaves the DNA, no subsequent treatment of those samples is required before electrophoresis. For [Ru(TMP)3]2+, samples must be subsequently treated with hot piperidine to convert the singlet oxygen damage to strand breaks. In addition, due to the diffusable nature of the singlet oxygen, [Ru(TMP)3]2+ cleavage must also be compared with cleavage by [Ru(phen)3]2+, which binds nonspecifically to DNA. The difference between the cleavage patterns of the two complexes reveals the sequence-specific recognition effect. Specific details for these rhodium and ruthenium photolysis reactions are given in this protocol. A more general yet thorough discussion of photolysis is given in Support Protocol 8, which should be consulted before carrying out this procedure. Materials Labeled DNA solution (see Support Protocol 7): for cleavage with [Rh(phen)2(phi)]3+, typically 100 µM base pairs in 2× buffer for cleavage with [Ru(TMP)3]2+ or [Ru(TMP)3]2+, typically 200 µM base pairs in 2× Tris/NaCl/imidazole buffer (see recipe)
CH3 3+
H N N H
CH3
N
Rh N
N
N
Ru
N
H3C
CH3
N
H3C
N
2+
H3C
N CH3
N
CH3
N
CH3
CH3
H3C CH3
Probing Nucleic Acid Structure
Figure 6.2.1
[Rh(phen)2(phi)]3+ and [Ru(TMP)3]2+.
6.2.2 Current Protocols in Nucleic Acid Chemistry
Metal complex solution (see recipe for preparation of stock solutions): rac- or ∆-[Rh(phen)2(phi)]3+ (typically 10 µM; see Support Protocol 1 for synthesis; see Support Protocol 2 for separation of enantiomers) rac-[Ru(TMP)3]2+ (typically 60 µM; see Support Protocol 3) rac-[Ru(phen)3]2+ (typically 60 µM; see Support Protocol 3) 1 M (10% v/v) piperidine solution in deionized water Dry ice Heating block or bath set to 90°C Speedvac (Savant) or lyophilizer Additional reagents and equipment for photolysing metal complexes (see Support Protocol 8) and mapping cleavage sites (see Support Protocol 9) Cleave DNA with [Rh(phen)2(phi)]3+ 1. Photolyse DNA/metal complexes as described (see Support Protocol 8, steps 1 to 4), mixing equal volumes of labeled DNA solution and rac- or ∆-[Rh(phen)2(phi)]3+ metal complex solution for a total volume of 10 to 50 µL. Include dark and light controls for each DNA of interest. Irradiate either 1 to 5 min at 313 nm or 5 to 20 min at 365 nm. It is best to separate the enantiomers and use only the ∆ enantiomer because it has better DNA-binding characteristics. If both are used, separate dark controls are required to ensure that one of the two enantiomers has not become contaminated in any way. The choice of irradiation paradigm is dependent on the light source available. The small differences in the results obtained at these two wavelengths are not relevant for these structure determinations.
2. Dry samples in a Speedvac evaporator or precipitate samples as described (see Support Protocol 8, steps 5 to 7). 3. Count samples and add loading buffer (see Support Protocol 8, step 8). 4. Map cleavage sites as described (see Support Protocol 9). Identify the specific bases of cleavage by comparing to Maxam-Gilbert sequencing reactions as described. Sites of [Rh(phen)2(phi)]3+ binding are indicated by cleavage bands in the experimental lanes. Although cleavage band intensity is related to the affinity of the complex for individual DNA sites, possible differences in photocleavage efficiency from site to site make direct comparisons difficult.
Cleave DNA with [Ru(TMP)3]2+ and [Ru(phen)3]2+ 5. Photolyse parallel samples using both rac-[Ru(TMP)3]2+ and rac-[Ru(phen)3]2+ complexes as described (see Support Protocol 8, steps 1 to 4), mixing equal volumes of metal complex solution and labeled DNA solution for a total volume of 10 to 50 µL. Include dark and light controls for each DNA and for each metal complex. Irradiate 20 to 40 min at 442 nm. Imidazole is used in DNA solutions for these reactions to help solubilize the ruthenium probe, which is extremely hydrophobic. The metal complex stock solutions prepared for this experiment can be close to saturation and may require a small amount of a co-solvent, such as ethanol, to keep the complexes in solution. Complex precipitation can be a source of experimental error and irreproducibility.
6. Dry samples in a Speedvac evaporator or precipitate samples as described (see Support Protocol 8, steps 5 to 7).
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.3 Current Protocols in Nucleic Acid Chemistry
7. Add 100 µL of piperidine solution to each of the dried samples and heat 30 min at 90°C. Treatment with hot piperidine causes strand scission at the sites of singlet oxygen damage on the DNA bases. CAUTION: Piperidine is a highly toxic liquid of high vapor pressure and is readily absorbed through the skin. Contact should be avoided and, if possible, manipulations should be made in a fume hood.
8. Freeze samples on dry ice and lyophilize off the piperidine solution. 9. Count samples and add loading buffer (see Support Protocol 8, step 8). 10. Map cleavage sites as described (see Support Protocol 9). 11. Subtract histograms of [Ru(TMP)3]2+ and [Ru(phen)3]2+ cleavage patterns to remove the guanine bias associated with singlet oxygen reactivity. Identify the specific bases of cleavage by comparison to Maxam-Gilbert sequencing reactions as described in Support Protocol 9. Cleavage by [Ru(phen)3]2+ is the same at all guanine residues due to its nonspecific binding behavior. Cleavage by the methylated complex is nonuniform as a result of preferential binding at individual sites. Cleavage by [Ru(TMP)3]2+is also observed at nonguanine residues near its binding sites. The difference between the cleavage patterns shows characteristic “bell-shaped” cleavage distributions as a result of high local concentrations of the diffusing singlet oxygen near the sites of [Ru(TMP)3]2+ binding. SUPPORT PROTOCOL 1
SYNTHESIS OF BIS(1,10-PHENANTHROLINE) (9,10-PHENANTHRENEQUINONE DIIMINE)RHODIUM(III) TRICHLORIDE Although several syntheses of [Rh(phen)2(phi)]3+ have been reported, the most reliable and highest-yielding procedure involves a three-step process. The synthetic scheme is summarized in Figure 6.2.2. In this preparation, the two ancillary phenanthroline ligands are added to the complex first (modified from Gillard et al., 1965). The resulting singly charged [Rh(phen)2(Cl)2]1+ is then converted to [Rh(phen)2(NH3)2]3+ by treatment with
1+
RhCl3•H2O
N
N
reflux
Cl
reflux
N
H3N
Rh
Cl
EtOH/H2O
N
Rh
H3N
N
N N
N
Hz•HCl N
3+
N
3+ O
O N H N
3:1 CH3CN/H2O 0.1 M NaOH
Probing Nucleic Acid Structure
Figure 6.2.2
N H
N
Rh N N
Synthesis of [Rh(phen)2(phi)]3+. Hz⋅HCl, hydrazine monohydrochloride.
6.2.4 Current Protocols in Nucleic Acid Chemistry
ammonium hydroxide (modified from Gidney et al., 1972). The bis-ammine complex is subsequently condensed with phenanthrene quinone to form the 9,10-phenanthrenequinone diimine (phi) intercalating ligand (modified from Mürner et al., 1998). All steps are carried out under ambient atmosphere and few extra precautions must be taken. Further details on the synthesis are available in Mürner et al. (1998). Materials Rhodium trichloride monohydrate 1,10-Phenanthroline Hydrazine monohydrochloride 95% (v/v) ethanol, denatured Concentrated (28% to 30%) ammonium hydroxide solution Phenanthrene quinone 3:1 (v/v) acetonitrile (reagent grade or better)/0.4 M NaOH solution in distilled water 1 M HCl solution (APPENDIX 2A) Sephadex SP-C25 cation-exchange resin 1 M MgCl2 solution (APPENDIX 2A) in distilled water HPLC-grade acetonitrile 0.1% (v/v) trifluoroacetic acid (TFA) in distilled water (for Sep-Pak elution) and in deionized, filtered water (for HPLC) Reflux condenser Temperature-controlled magnetic stir plate Oil bath or heating mantle 50- and 100-mL round-bottom flasks 60-mL medium-frit glass funnel 250-mL filter flasks Filter adapter Aspirator or vacuum pump Rotary evaporator Chromatography column: 1 to 2 feet (30 to 61 cm) long, 1 to 1.5 in. (2.5 to 3.8 cm) diameter 500-mL Erlenmeyer flasks Waters Sep-Pak 5-g C18 cartridges 15-mL plastic centrifuge tube or 25- to 50-mL round-bottom flask Lyophilizer (optional) High-pressure liquid chromatography (HPLC) system with C18 reversed-phase column Additional reagents and equipment for proton nuclear magnetic resonance (1H NMR), UV/visible spectrometry, and mass spectrometry Prepare [Rh(phen)2(Cl)2]Cl 1. Set up a reflux condenser with a temperature-controlled magnetic stir plate, an oil bath or heating mantle, and a 100-mL round-bottom flask containing a stir bar. 2. Combine 1 g rhodium trichloride monohydrate and 1.6 g of 1,10-phenanthroline (2 eq) in the 100-mL round-bottom flask. 3. Add 25 mg hydrazine monohydrochloride and 75 mL of a 1:1 (v/v) mixture of water and 95% ethanol.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.5 Current Protocols in Nucleic Acid Chemistry
4. Stir and bring the mixture to reflux. Continue refluxing until all material has gone into solution and the color has changed from violet to yellow (∼4 to 6 hr). Hydrazine monohydrochloride acts as a reductive catalyst. By reducing the Rh(III) to Rh(II), ligand substitution is facilitated.
5. Remove residual unreacted ligand by filtering the hot solution through a 60-mL medium-frit glass funnel using an aspirator or a vacuum pump. Discard the ligand and collect filtrate in a 250-mL filter flask. 6. Refrigerate the filtrate overnight. The product will precipitate as yellow, powdery crystals. The solubility of the singly charged dichloro product in water is quite low. Any traces of [Rh(phen)3]3+ that are formed in the course of the reaction remain in solution and are eliminated by filtration.
7. Save the crystal product by filtration as in step 5. Collect the mother liquor in a 250-mL filter flask and store at 4°C in case it is needed to form a second crop of crystals. 8. Dry the first crop of product under vacuum in a sealed flask, using an aspirator or vacuum pump. Typical yields for the first crop are in the range of 60%.
9. Characterize the product by 1H NMR and mass spectrometry. Spectroscopic data are included below (see Compound Characterization).
Prepare [Rh(phen)2(NH3)2]Cl3 10. Combine 0.5 to 1.0 g [Rh(phen)2(Cl2)]Cl and 30 to 50 mL concentrated ammonium hydroxide solution in a 100-mL round-bottom flask. 11. With rapid stirring, bring the solution to reflux. Continue heating until all the yellow solid has dissolved (∼15 to 30 min). Remove the reaction from the heat and allow to cool. As the complex is converted from the singly charged dichloride to the triply charged diammine, solubility in ammonium hydroxide increases. As a result, solubility can serve as a rough measure of the reaction’s progress.
12. Remove the solvent from the reaction mixture using a rotary evaporator with a vacuum pump. The diammine product, which appears as a translucent yellow scale in the flask, is typically recovered in 90% to 100% yield.
13. Characterize the product by 1H NMR, UV/visible spectrometry, and mass spectrometry. Spectroscopic data are included below (see Compound Characterization).
Prepare [Rh(phen)2(phi)]Cl3 14. Combine 50 mg [Rh(phen)2(NH3)2]Cl3 and 25 mg phenanthrene quinone (an excess) in a 50-mL round-bottom flask. 15. Add 30 to 40 mL of 3:1 acetonitrile/0.4 M NaOH solution and stir briskly. Probing Nucleic Acid Structure
Sometimes the two solvent components initially form immiscible layers, but with rapid stirring there is sufficient mixing for the reaction to progress.
6.2.6 Current Protocols in Nucleic Acid Chemistry
16. Stir at room temperature for 6 to 12 hr. During this time the solution will go from yellow to a deep orange. The reaction progresses by base deprotonation of the coordinated ammine ligands, which add to the quinone with subsequent loss of water. Although extreme precautions are not necessary, it is recommended that the reaction flask be covered with aluminum foil to avoid unnecessary exposure to light.
17. Stop the reaction by neutralizing the NaOH with an equimolar amount of 1 M HCl solution. Purify by cation exchange 18. Swell 10 to 25 g dry Sephadex SP-C25 resin with 100 to 200 mL of 0.05 M MgCl2 solution for ∼15 min. The resin should swell completely but not consume all the free MgCl2 solution. A volume of extra solution (~1 cm above the level of the swelled resin) is necessary for proper pouring of the column. If all the solution is consumed, more should be added to the mixture.
19. Swirl the slurry and prepare a cation-exchange column by pouring the slurry into a 1- to 2-foot-long chromatography column and allowing it to settle as the excess solvent flows through. Stop the flow from the bottom of the column when the MgCl2 solution level reaches the top of the packed column resin. For adequate purification, the column should be ≥6 inches (∼15 cm) high.
20. Dilute the reaction mixture into a large volume (300 to 400 mL) of distilled water. Add the solution slowly to the top of the column, taking care not to unduly disturb the resin surface. The metal complex will adhere to the resin at the very top of the packed column. Unreacted quinone will flow through immediately.
21. Elute metal complexes with increasing concentrations of MgCl2. Begin with 2 to 3 column vol of 0.05 M MgCl2 and increase steadily to 0.5 M. Collect all eluted bands in individual 500-mL Erlenmeyer flasks. At the lowest concentrations, any additional unreacted quinone will elute off the column. This will be followed, as the concentration increases, by any unreacted diammine complex. The orange product band will elute between 0.2 and 0.5 M MgCl2.
22. For each column fraction containing [Rh(phen)2(phi)]Cl3, wash a Waters Sep-Pak 5-g C18 cartridge with 1 vol HPLC-grade acetonitrile followed by 1 vol water. Isolation of the complex on the reversed-phase cartridge will remove excess MgCl2 from the desired product.
23. Load the product fractions onto the cartridges either by gravity or under suction. Allow the entire product fraction to be adsorbed onto the resin. 24. Wash with 2 to 3 vol distilled water. 25. Elute the desalted product band with 1:1 (v/v) acetonitrile/0.1% TFA. Collect the material in either a 15-mL plastic centrifuge tube or a 25- to 50-mL round-bottom flask, depending on which technique will be used to remove the solvent. 26. Isolate the metal complex from this solution by rotary evaporation or lyophilization. The complex purified by cation-exchange chromatography has a purity >95%. Nonetheless, in the authors’ laboratory it is customary to further purify the material by reversed-phase HPLC (RP-HPLC), as described below. If an HPLC apparatus is unavailable, other methods of verifying the purity of the metal complex can be used
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.7 Current Protocols in Nucleic Acid Chemistry
(e.g., thin-layer chromatography using silica gel and 4:1:1:0.1 M CH3CN/water/n-butanol/saturated KNO3).
Purify by RP-HPLC 27. Dissolve a small amount of the material (e.g., 1 to 2 mg) in a volume of water appropriate for the injection loop volume of the HPLC apparatus. Inject it onto a C18 reversed-phase HPLC column. Run a gradient from 0.1% TFA to a 1:1 (v/v) mixture of 0.1 % TFA and acetonitrile over 30 min. The metal complex elutes between 20% and 30% acetonitrile.
28. Collect the product peak and evaporate or lyophilize the solvent. 29. Characterize the product by 1H NMR, UV/visible spectrometry, and mass spectrometry. Spectroscopic data are included below (see Compound Characterization). SUPPORT PROTOCOL 2
SEPARATION OF ENANTIOMERS OF BIS(1,10-PHENANTHROLINE) (9,10-PHENANTHRNENEQUINONE DIIMINE)RHODIUM(III) TRICHLORIDE The rac- and ∆-enantiomers of [Rh(phen)2(phi)]Cl3 are separated by ion-exchange chromatography with a chiral eluent. Typically, the procedure calls for a solution of cobalt L-cysteine sulfinate, Co(lcysu)3, which is made by procedures described by Dollimore and Gillard (1973) and presented in this protocol. Although procedures for both separating the enantiomers and making the cobalt complex are summarized here, the reader is directed to the original papers (Yoshikawa and Yamasaki, 1979; Cartwright et al., 1987) for more comprehensive details. Alternatively, small amounts of the enantiomers of [Rh(phen)2(phi)]3+ can be separated using a commercially available chiral HPLC column. Although chiral HPLC cannot produce the same amount of material as the chromatographic separation described here, it is useful for small-scale preparations or analysis of materials resolved by other means. Additional Materials (also see Support Protocol 1) Hexamminecobalt(III) chloride Nitrogen or argon gas L-Cysteine Potassium hydroxide 30% (v/v) hydrogen peroxide [Rh(phen)2(phi)]Cl3 (see Support Protocol 1) Sephadex CM-C25 ion-exchange resin 0.1 M KCl solution in deionized water
Probing Nucleic Acid Structure
Thermometer 500-mL, 2- or 3-neck round-bottom flasks with appropriate stoppers Bubbler for nitrogen or argon gas, equipped with a long pipet pH paper 60-mL coarse-frit glass funnels 500-mL filter flasks 1000-mL Erlenmeyer flask Chromatography columns: 2 to 4 feet (61 to 122 cm) long, 1 to 1.5 in. (2.5 to 3.8 cm) diameter 0.5 to 1 feet (15 to 30 cm) long, 1 to 1.5 in. (2.5 to 3.8 cm) diameter Solvent bottles for reservoirs
6.2.8 Current Protocols in Nucleic Acid Chemistry
Recirculating column pump (optional) Column end caps and tygon tubing for connecting recirculating pump and solvent reservoirs Additional reagents and equipment for circular dichroism (CD) spectroscopy Prepare K[Co(lcysu)3]⋅6H2O 1. Set up a reflux condenser with an oil bath or heating mantle and a thermometer. 2. Dissolve 5.34 g hexamminecobalt(III) chloride in 140 to 150 mL distilled water in a 500-mL round-bottom flask. 3. Deoxygenate the solution by bubbling with inert gas (nitrogen or argon) for 15 to 30 min. 4. Add 12.12 g L-cysteine and 16.84 g potassium hydroxide and heat in the oil bath or heating mantle to 70°C. Monitor the presence of ammonia by holding moistened pH paper over the outlet of the reflux condenser, and maintain the temperature until no further evolution of gaseous ammonia can be detected. The total reaction time is typically 24 hr.
5. Add 140 to 150 mL of 95% ethanol to precipitate the green potassium (+)-tris(L-cysteinato-SN)cobaltate(III). 6. Cool the mixture in an ice bath, vacuum filter through a 60-mL coarse-frit funnel using a 500-mL filter flask, and wash the resulting solid with 95% ethanol. 7. Add 100 mL of 30% hydrogen peroxide to another 500-mL round-bottom flask, and slowly add the collected precipitate while rigorously maintaining the solution’s temperature below 10°C in an ice bath. The material reacts rapidly, producing a bright yellow solution.
8. Precipitate the potassium (+)-tris(lcysu)cobaltate(III)⋅6H2O product by adding 200 mL of 95% ethanol. 9. Collect the product by vacuum filtration using another 60-mL coarse frit, wash the solid with 95% ethanol, and dry under vacuum. The K[Co(lcysu)3]⋅6H2O complex is light sensitive and should be stored in the dark for up to 1 to 2 months at 4°C. In addition, columns run with solutions of the complex should be protected from light by aluminum foil to minimize breakdown of the eluent.
Perform ion exchange 10. Prepare a 150 mM K[Co(lcysu)3]3− stock solution by dissolving the dry solid at 110.7 g/L in deionized water. The solution should be used as soon as possible. However, if storage is necessary, it can be stored for up to 1 week at 4°C in the dark.
11. Dissolve 30 to 50 mg [Rh(phen)2(phi)]Cl3 in a small volume of water (e.g., ~10 mL or more, depending on solubility). 12. Swell 50 to 100 g Sephadex CM-C25 ion-exchange resin with 400 to 600 mL of 0.1 M KCl solution in a 1000-mL Erlenmeyer flask for ∼30 min. 13. Pour the resulting loose suspension into a 2- to 4-foot chromatography column and allow to settle. If an insufficient amount of resin has been added for the desired column length (2 to 4 feet), add additional resin before the column has packed down.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.9 Current Protocols in Nucleic Acid Chemistry
For enantiomer separation, a long column is required. If the column has settled completely and additional resin is added, an interface in the resin will be created that will affect band mobility. If the addition of more resin is necessary after complete column packing, add the resin and then mix the entire column by inversion before allowing it to pack again. This provides a more uniform column and better separation.
14. Wash the column thoroughly with several volumes of deionized water to remove any excess KCl solution. Drain excess water (i.e., to the level of the packed resin). If the potassium solution is not completely removed from the column, the cobalt eluent will precipitate on the resin.
15. Carefully load the rhodium solution (step 11) onto the top of the column, taking care not to disturb the resin surface. The colored complex should stick to the first 0.25 to 0.5 cm of column packing. If desired, an additional amount of swelled resin can be carefully layered over the product band with a long pipet to serve as a protective layer between the material and added solvent.
16. Run the column using a recirculating pump that circulates a small volume of cobalt eluent through the column at a flow rate of ∼1 mL/min. Begin eluting with a three-fold dilution of the 150 mM [Co(lcysu)3]3− stock solution (i.e., 50 mM), taking care not to disturb the resin bed. If a recirculating pump is unavailable, it is equally effective to prepare a larger volume of cobalt solution and recirculate it manually over time from a collection vessel at the base of the column to a reservoir above.
17. When the dilute cobalt solution begins to elute through the base of the column, increase the concentration of the eluent to 100 mM for an additional column volume, and then to 150 mM for an additional column volume. The stepwise equilibration of the column is necessary because the column resin will not contract uniformly if the ionic strength is increased too rapidly. Such nonuniform shrinkage will adversely affect the separation of the metal complex enantiomers.
18. Continue elution until two distinct, separated enantiomer bands are visible (usually a period of several days to two weeks, depending on the elution rate). Although the yellow color of the cobalt eluent makes it difficult to monitor the progress of the separation, the distinctively darker rhodium bands can usually be discerned.
19. When sufficient separation is obtained, stop elution and rinse the column thoroughly with several column volumes of distilled water to remove as much of the cobalt as possible. Once the excess eluent is washed out, the orange product bands should be easily located.
Isolate enantiomers 20. Allow the column to run dry and then expel the resin with air pressure onto a clean, flat surface.
Probing Nucleic Acid Structure
The column should come out as an intact cylinder with the product separation intact. If necessary, compressed air can be forced through the top of the column to remove all excess solvent before expelling the resin. In addition, it is often useful to mark the positions of the column bands on the outside of the column barrel before expelling the resin. The bands are often more difficult to locate in the dry resin, and comparison to the marked column can be very useful.
6.2.10 Current Protocols in Nucleic Acid Chemistry
21. Excise the bands of the separated enantiomers from the column with a laboratory spatula and place them into two 0.5- to 1-foot chromatography columns. With [Co(lcysu)3]3− as the eluent, the delta enantiomer of the rhodium complex elutes faster.
22. Wash with 0.1 M MgCl2 to remove any residual cobalt complex and ensure that the rhodium will have chloride counter ions when eluted from the resin. 23. Elute the separated enantiomers with 1 M MgCl2 and collect in 250-mL Erlenmeyer flasks. 24. Concentrate and desalt the products on Waters Sep-Pak C18 cartridges as described above (see Support Protocol 1, steps 22 to 26). 25. Characterize the product by CD spectroscopy to ensure the success of the enantiomeric separation. In addition, showing that the CD spectra of the two enantiomers are exact mirror images of one another demonstrates that no contaminating cobalt eluent is present. Spectroscopic data are included below (see Compound Characterization).
SYNTHESIS OF TRIS(PHENANTHROLINE) COMPLEXES OF RUTHENIUM(II)
SUPPORT PROTOCOL 3
In this protocol, modified from Lin et al. (1976), two tris(phenanthroline) complexes, [Ru(TMP)3]2+ and [Ru(phen)3]2+, are synthesized by analogous methods in a single step. The ruthenium trichloride starting material is combined with the appropriate phenanthroline ligands and refluxed to allow formation of complexes. The resulting materials are isolated by precipitation, purified by ion-exchange chromatography, and desalted on C18 reversed-phase cartridges. Additional Materials (also see Support Protocol 1) Ruthenium trichloride hydrate 6 M HCl solution (see Table A.2A.1) 3,4,7,8-Tetramethyl-1,10-phenanthroline (TMP) or 1,10-phenanthroline (phen) 30% (w/v) hypophosphorus acid solution 2 M NaOH solution 30-mL medium-frit glass funnels Prepare ruthenium complex 1. Set up a reflux condenser with a temperature-controlled magnetic stir plate, an oil bath or heating mantle, and a 100- to 200-mL round-bottom flask. Heat 60 to 75 mL distilled water in the flask to 90°C with stirring. 2. Add the following: 0.71 g ruthenium trichloride hydrate 2 drops 6 M HCl solution 2.1 g TMP or 1.7 g phen. NOTE: Stainless steel spatulas should not be used during the synthesis of this material as the phenanthroline ligands will complex with any dissolved iron impurities.
3. Continue heating for 10 to 20 min. During this time, the dark black solution will change to a dark green color.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.11 Current Protocols in Nucleic Acid Chemistry
4. Neutralize 1.7 mL hypophosphorus acid solution to pH 7 with ∼5 mL of 2 M NaOH solution and add to the reaction mixture. Continue to reflux for an additional 60 min. The color will change to orange-red.
5. Remove from heat and filter hot through a 30-mL medium-frit funnel. Discard the precipitate. 6. While stirring, slowly add 20 mL of 6 M HCl solution to the filtrate. Collect the orange precipitate that forms by suction filtration. 7. Dissolve the isolated precipitate in a small volume of water and acetonitrile. The exact mixture depends on solubility. A good procedure is to start with 10 mL water and add acetonitrile until all material is dissolved (typically 15 to 25 mL total volume).
Purify product 8. Prepare a cation-exchange column as described (see Support Protocol 1, steps 18 and 19). For adequate purification, this column should be ≥10 cm high.
9. Load the entire product solution onto the top of the column with a long pipet, taking care not to unduly disturb the resin surface. The metal complex will adhere to the resin at the very top of the packed column. Unreacted phenanthroline ligands and any uncharged or anionic side products will flow through immediately.
10. Begin to elute with distilled water. After two to three column volumes of water have passed through and most of the yellow ligand has eluted, change to 0.05 M MgCl2. Increase the salt concentration over time to 0.2 M. The product should come off as a single broad orange band.
11. Collect the fraction in a 500-mL Erlenmeyer flask and isolate the product on a Sep-Pak reversed-phase cartridge as described (see Support Protocol 1, steps 22 to 26). 12. Characterize the products by 1H NMR, UV/visible spectrometry, and mass spectrometry. Spectroscopic data are included below (see Compound Characterization). BASIC PROTOCOL 2
SHAPE-SELECTIVE CLEAVAGE OF UNUSUAL STRUCTURES IN NUCLEIC ACIDS
Probing Nucleic Acid Structure
Tris(4,7-diphenyl-1,10-phenanthroline)rhodium(III), [Rh(DIP)3]3+, is a shape-selective structure probe of nucleic acids. Because of the sterically bulky phenyl substituents on the phenanthroline ligands (Fig. 6.2.3), this complex, like [Ru(TMP)3]2+, cannot intercalate easily into B-form DNA. Instead, the hydrophobic complex specifically targets unusual, non-B-form structures. Like other rhodium complexes, the complex promotes direct, photo-induced strand cleavage at sites where it is intimately bound. With much lower efficiency, the complex also damages DNA oxidatively, yielding damage at 5′-GG3′ and 5′-GA-3′ sites analogous to that observed by DNA-mediated electron transfer chemistry (Hall et al., 1996). The unusual structures targeted by the complex have been shown to include cruciforms, Z DNA, and other tertiary sites whose structures are not yet well characterized (Müller et al., 1987; Kirshenbaum et al., 1988; Lee and Barton, 1993). As a result, cleavage at a particular site by [Rh(DIP)3]3+ does not establish the presence of a particular DNA structure, but rather that the conformation of the nucleic acid at that
6.2.12 Current Protocols in Nucleic Acid Chemistry
3+
N N
N
Rh
N
N N
Figure 6.2.3
[Rh(DIP)3]3+.
site is an unusual one that is neither B nor A form and is not single stranded. For a discussion of nucleic acid structure, see APPENDIX 1B. Because cleavage with [Rh(DIP)3]3+ is very specific, experiments mapping a large piece of DNA for unusual structural forms are usually performed at low resolution to first identify candidate sites before moving to single-nucleotide resolution. Such experiments can scan an entire plasmid that contains sequences of interest, using agarose gel electrophoresis rather than PAGE to determine whether a [Rh(DIP)3]3+ cleavage site exists and approximately where it is located. Such low-resolution experiments can be done more quickly than experiments at single-nucleotide resolution, and thus ensure that experimental effort is not dissipated scrupulously screening a piece of DNA with no [Rh(DIP)3]3+ cleavage sites. Furthermore, this two-stage methodology provides an opportunity to determine whether the rhodium cleavage occurs on both DNA strands or only one and whether it depends on DNA superhelicity. Once sites have been identified at low resolution, restriction fragments of the plasmid or synthetic oligonucleotides containing the identified sites can be photocleaved and assayed by PAGE to determine the individual bases where cleavage takes place. Materials Supercoiled plasmid DNA (either commercial or containing a specific site of interest) Appropriate restriction enzymes (see steps for details) and buffer systems (according to manufacturer’s specifications) 1 µg/mL ethidium bromide solution (APPENDIX 2A) in water or 1× TBE electrophoresis buffer 7.5 M ammonium acetate solution in deionized water Absolute ethanol (200 proof, dehydrated) Dry ice 10× Tris/acetate buffer, pH 7.0 (see recipe) Metal complex solution (see recipe): 20 µM rac-[Rh(DIP)3]Cl3 (for synthesis, see Support Protocol 4) S1 single-strand-specific nuclease and appropriate buffer systems (according to manufacturer’s specifications) 9 mM base pairs of calf thymus DNA solution in deionized water, buffered to pH 7 to 9 DNA molecular weight standards (e.g., commercially available 100-base ladder) 1× TBE electrophoresis buffer (APPENDIX 2A) Loading buffer (e.g., formamide loading buffer or urea loading buffer; see recipes)
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.13 Current Protocols in Nucleic Acid Chemistry
Maxam-Gilbert sequencing reactions on labeled, unirradiated samples of 250- to 500-bp DNA fragment of interest (see Support Protocol 9) UV transilluminator Speedvac evaporator (Savant) or lyophilizer UV/visible spectrometer 90°C heating block Phosphorimager (optional) Additional reagents and equipment for restriction digests (e.g., CPMB UNIT 3.1), agarose gel electrophoresis (e.g., CPMB UNIT 2.5), photolysis (see Support Protocol 8), radiolabeling DNA (see Support Protocol 7), nondenaturing PAGE (e.g., CPMB UNIT 2.7A), denaturing PAGE (sequencing gels; APPENDIX 3B), autoradiography (optional; e.g., CPMB APPENDIX 3A), and mapping cleavage sites (see Support Protocol 9) NOTE: Because of the low solubility of rac-[Rh(DIP)3]Cl3 in water, a more concentrated solution of the material may need to be made in ethanol (or an ethanol/water mixture) and diluted to the desired stock concentration (20 µM) with water. Low-resolution cleavage Linearize plasmid DNA 1. Linearize 20 to 30 µg supercoiled plasmid DNA with the appropriate single-cutting restriction enzyme according to manufacturer’s instructions (e.g., see CPMB UNIT 3.1). This amount of DNA should be sufficient for one analysis (e.g., eight sample and control tubes, as described in step 7 below). The enzyme chosen must have only a single cut site on the plasmid DNA of interest.
2. Verify that the plasmid sample is completely linearized by analyzing ∼1 µg on a 1% (w/v) agarose gel. Stain the gel in 1 µg/mL ethidium bromide solution and visualize the stained DNA with a UV transilluminator. If the sample is not completely digested, retreat with enzyme until it is linearized.
3. Precipitate the remaining DNA by adding 1⁄5th to 1⁄4th vol of 7.5 M ammonium acetate solution and 4 to 5 vol absolute ethanol, mixing well, and chilling 1 hr on dry ice. 4. Microcentrifuge 12 min at maximum speed (14,000 rpm), at either room temperature or 4°C. 5. Decant the supernatant carefully and dry the pellet 15 to 20 min in a Speedvac evaporator or a lyophilizer to remove residual ethanol. Avoid overdrying the pellet or it may adhere to the walls of the microcentrifuge tube. 6. Resuspend DNA in deionized water, determine its concentration (and the concentration of the supercoiled plasmid stock) by UV/visible spectrometry (ε260 = 6600 M−1 cm−1 per nucleotide), and dilute both to 400 µM nucleotides in 2× Tris/acetate buffer.
Probing Nucleic Acid Structure
Irradiation experiments with both the supercoiled and liner plasmid samples will immediately assess any supercoiling dependence of a structure recognized by [Rh(DIP)3]Cl3. This is particularly relevant in the case of some cruciform structures that are only extruded from the double-stranded form in the presence of supercoiling strain.
6.2.14 Current Protocols in Nucleic Acid Chemistry
Cleave DNA 7. Combine equal volumes of 20 µM rac-[Rh(DIP)3]Cl3 and 400 µM DNA stock solutions as described (see Support Protocol 8, steps 1 to 3), but mix samples only by gentle tapping of the tube. For each plasmid of interest, prepare a light and a dark control and two experimental samples for both the linear and supercoiled forms (total eight tubes). One half of the experimental samples will be treated with S1 nuclease (see step 11 below). If desired, the dark control can be performed with either linear or supercoiled DNA; both are not required, as they assess contaminants in the metal solution. Centrifugation of irradiation samples should be avoided because it may result in metal complex precipitation.
8. Irradiate 20 to 60 sec at 330 nm with a Hg-Xe arc lamp or 10 min with a transilluminator (see Support Protocol 8, step 4) and precipitate DNA (steps 3 to 5 above). Under these conditions, photolysis leads to partial or complete conversion of supercoiled samples to nicked or linear plasmid DNA.
9. Resuspend the supercoiled irradiation samples in the buffer appropriate for the enzyme used above and treat with the same restriction enzyme for the same total incubation time as used in step 1. 10. Precipitate samples as in steps 3 to 5. 11. Treat half of the experimental samples (including both supercoiled and linearized plasmid irradiations) with S1 nuclease according to manufacturer’s instructions. In the authors’ experiments this involves buffering DNA solutions to pH 6, adding ?? zinc sulfate, and treating with 10 to 20 units of nuclease for 20 min at 37°C. This enzymatic treatment converts any single-strand breaks caused by the complex into double-strand breaks that can be observed in a low-resolution agarose gel experiment. It also provides the opportunity to assess whether there is a supercoiling dependence to the type of strand break induced by the complex.
12. Precipitate samples as in steps 3 to 5. Analyze samples 13. Electrophorese 1 µg DNA/lane on a 1% (w/v) agarose gel. Run DNA molecular weight standards alongside the experimental samples to better assess the approximate position of any breaks vis-a-vis the restriction enzyme site used to linearize the plasmid. 14. Stain the gel in 1 µg/mL ethidium bromide solution and visualize using a transilluminator. If desired, record data photographically using a Polaroid camera. Negatives of the photographs can be quantitated using a densitometer to determine the exact amounts of conversion of various forms of the plasmid.
High-resolution cleavage Linearize plasmid DNA 15. Linearize DNA as described above (steps 1 to 6), but use an enzyme that has a single cut site within 100 to 300 bp of any interesting structures revealed in the low-resolution experiment. This will generate pieces that are short enough for adequate resolution.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.15 Current Protocols in Nucleic Acid Chemistry
Cleave DNA 16. Irradiate samples as described in steps 7 and 8 above. Irradiation times for high-resolution experiments must be optimized for a particular system to ensure that the amount of photocleavage is sufficient for PAGE analysis, but that the end-labeled DNA is not overcleaved. To determine an acceptable irradiation time, prepare a set of identical samples and irradiate each for steadily increasing times. A good starting point is ∼5 min at 330 nm. Select an irradiation time where the cleavage bands are easily observable on the gel but where most of the full-length DNA band (≥90%) remains uncleaved. At long irradiation times, in the absence of strong binding sites for the complex, non-structure-specific damage is observed at 5′-GG-3′ and 5′-GA-3′ sites. This should not be confused with structure-specific cleavage.
17. Precipitate all samples by adding 1 to 5 µL of 9 mM calf thymus DNA, 1⁄6th to 1⁄4th vol of 7.5 M ammonium acetate, and 5 vol absolute ethanol. Mix well and heat to 90°C for 5 min. Mix again and incubate on dry ice for 30 min. Heating ensures complete dissociation of the metal-DNA complex prior to precipitation. It is important to remove the metal complex as it can affect the electrophoretic mobility of the DNA products.
18. Microcentrifuge 12 min at maximum speed (14,000 rpm). 19. Carefully remove the supernatants, resuspend each pellet in 50 to 100 µL water, and repeat steps 17 and 18, but without heating. 20. Remove the supernatants, rinse the resulting pellets twice with cold 80% (v/v) ethanol, and dry under vacuum. 21. Treat supercoiled samples with restriction enzyme (as in step 15) and precipitate as described in steps 17, 18 and 20, but without heating. Analyze samples 22. Resuspend all samples in deionized water and label them with [32P]phosphate or [32P]nucleotides (see Support Protocol 7). Labeling of the 5′ end of the plasmid will require dephosphorylation with a phosphatase and then rephosphorylation with [g-32P]ATP. Labeling at the 3′ end is routinely done by filling in the overhang left by the restriction enzyme with an appropriate polymerase and radiolabeled nucleoside triphosphates.
23. Cut DNA with an additional restriction enzyme selected to excise the region of interest in a segment that is 250 to 500 bp long. 24. Isolate the desired fragment on a 5% to 10% nondenaturing polyacrylamide gel. 25. Identify the position of the band of interest by autoradiography, excise the gel band, and isolate the labeled DNA by soaking the gel slice 2 to 4 hr in 1× TBE electrophoresis buffer. The progress of elution can be monitored by comparing the amount of radiation in the supernatant to that remaining in the gel.
26. Precipitate the isolated DNA (steps 17 to 20).
Probing Nucleic Acid Structure
27. Resuspend in denaturing loading buffer, heat 2.5 to 5 min at 90°C, and resolve on a 6% to 8% denaturing polyacrylamide sequencing gel. Run with Maxam-Gilbert sequencing reactions on labeled, unirradiated samples of the same DNA fragment (see Support Protocol 9). Visualize results by autoradiography or by phosphorimagery.
6.2.16 Current Protocols in Nucleic Acid Chemistry
SYNTHESIS OF TRIS(4,7-DIPHENYL-1,10-PHENANTHROLINE) RHODIUM(III) TRICHLORIDE
SUPPORT PROTOCOL 4
In this protocol, which is modified from Gidney et al. (1972), [Rh(DIP)3]3+ is synthesized in a single step from rhodium trichloride and 4,7-diphenyl-1,10-phenathroline (DIP). The product is isolated by precipitation. Because of the low solubility of the complex in all solvents applicable for ion-exchange chromatography, the product is purified by recrystallization. Additional Materials (also see Support Protocol 1) 4,7-Diphenyl-1,10-phenanthroline (DIP) 2.5 mg/mL hydrazine monohydrochloride in water Saturated NaCl solution Acetone 100-mL Erlenmeyer flask 30-mL medium-frit glass funnel 100-mL filter flask 1. Set up a reflux condenser with a temperature-controlled magnetic stir plate and an oil bath or heating mantle. 2. Dissolve 50 mg rhodium trichloride monohydrate in 10 mL deionized water in a 50-mL round-bottom flask. 3. Dissolve 200 mg of 4,7-diphenyl-1,10-phenanthroline in 10 mL of hot (80°C) 95% ethanol in another 50-mL round-bottom flask. While stirring, add the ligand solution to the rhodium solution. Some precipitation may occur. NOTE: No stainless steel spatulas should be used during the synthesis of this material as the phenanthroline ligands will complex with any dissolved iron impurities.
4. Add 1 mL of 2.5 mg/mL hydrazine monohydrochloride to the reaction mixture. 5. Connect the reaction flask to the condenser and bring to reflux. Continue to reflux the mixture for 72 hr. After 30 min the solution should be clear yellow. Over the 72-hr period, it should become bright orange.
6. Allow the reaction to cool and remove the solvent using a rotary evaporator with a vacuum pump. This should yield a yellow-orange solid. A yellow side product of the reaction is often produced along with the desired complex. It has been assigned, by NMR and mass spectrometry, as [Rh(DIP)2Cl2]Cl. It is much less soluble in ethanol than the desired trischelate complex and can be separated on that basis in the following recrystallization step. Presence of red or pink coloration indicates contamination by iron complexes.
7. Transfer the solid to a 100-mL Erlenmeyer flask and recrystallize from 50 mL of hot 1:1 (v/v) ethanol/water containing 1 mL saturated NaCl solution. 8. Quickly decant the complex solution from any residual solid and allow to cool to room temperature. Chill at 4°C for several hours to ensure that crystallization is as complete as possible.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.17 Current Protocols in Nucleic Acid Chemistry
Because of the low solubility of the material, the crystals will come out very quickly once the solution begins to cool.
9. Collect the product by vacuum filtration using a 30-mL medium-frit glass funnel. This should yield peach-colored crystals. Impurities (e.g., red iron complexes) cause significant changes in color. If necessary, the resulting solid can be recrystallized by dissolving in a minimum volume of ethanol and pouring the resulting solution into a large volume (200 to 250 mL) of acetone. Because of the low solubility of this compound in all solvents applicable for ion-exchange chromatography, purification of the material using that methodology is not practical. Spectroscopic data are included below (see Compound Characterization). BASIC PROTOCOL 3
RECOGNITION OF MISMATCHES AND ABASIC SITES IN DNA In addition to the use of shape-selective ancillary ligands to probe the characteristics of the grooves or structures of DNA as discussed with [Ru(TMP)3]2+ and [Rh(DIP)3]3+, shape-selective intercalating ligands can be used to probe differences in base pairing at the core of the DNA helix. Bis(2,2′-bipyridine)(5,6-chrysenequinone diimine)rhodium(III), [Rh(bpy)2(chrysi)]3+ (see Fig. 6.2.4), is such a complex that utilizes a broad, four-ring chrysenequinone diimine intercalating ligand. Like [Rh(DIP)3]3+, where the size of substituents on the ancillary ligands only allows interaction at sites of tertiary structure, the steric bulk of the chrysi ligand prevents it from intercalating into DNA except at sites where disrupted base pairing opens up the structure of the helix. This selectivity has been applied to the recognition of the destabilized helical structures characteristic of both mismatched base pairs in DNA (Jackson and Barton, 1997) and abasic sites (B.A. Jackson and J.K. Barton, unpub. observ.). Although the recognition properties of the two enantiomers of the complex are different, racemic material is sufficient for routine experiments. Photocleavage experiments with [Rh(bpy)2(chrysi)]3+ are performed as described (see Support Protocol 8). Since the structures that are probed with this molecule (i.e., mismatches and abasic sites) are not generally found at specific sites of plasmid restriction fragments, experiments are routinely done on synthetic oligonucleotides. As a result, DNA concentrations are expressed in terms of polymers rather than concentration of base pairs or nucleotides. Materials Metal complex solution (see recipe): rac-[Rh(bpy) 2(chrysi)]Cl3 solution (typically 2 µM; for synthesis, see Support Protocol 5) Labeled DNA solution (see Support Protocol 7): typically 20 µM polymers in 2× buffer
H
N N H
Probing Nucleic Acid Structure
Figure 6.2.4
N
Rh
N N
N
[Rh(bpy)2(chrysi)]3+.
6.2.18 Current Protocols in Nucleic Acid Chemistry
Additional reagents and equipment for photolysis (see Support Protocol 8) and for mapping cleavage sites (see Support Protocol 9) 1. Mix equal volumes of rac-[Rh(bpy)2(chrysi)]Cl3 solution and labeled DNA solution for a total volume of 10 to 50 µL as described (see Support Protocol 8, steps 1 to 3). Set up dark and light controls for each DNA of interest. 2. Irradiate 5 min at 313 nm or 15 to 30 min at 365 nm and treat as described (see Support Protocol 8, steps 4 to 8). 3. Perform electrophoresis and autoradiography as described (see Support Protocol 9). Sites of [Rh(bpy)2(chrysi)]3+ binding are indicated by cleavage bands in the experimental lanes.
4. Identify specific sites of cleavage by comparing to Maxam-Gilbert sequencing reactions as described in Support Protocol 9. Although cleavage band intensity is related to the affinity of the complex for individual DNA sites, differences in photocleavage efficiency from site to site make direct comparisons difficult.
SYNTHESIS OF BIS(2,2′-BIPYRIDINE)(5,6-CHRYSENEQUINONE DIIMINE)RHODIUM(III) TRICHLORIDE
SUPPORT PROTOCOL 5
[Rh(bpy)2(chrysi)]3+ is synthesized using the same condensation chemistry described for the synthesis of [Rh(phen)2(phi)]3+ (see Support Protocol 1) and is modified from Mürner et al. (1998). The [Rh(bpy)2Cl2]Cl intermediate is made using the same protocol, except that bipyridine is substituted for the phenanthroline ancillary ligands. It is then converted to the diammine complex and condensed with chrysenequinone. Because chrysenequinone is not commercially available, its one-step synthesis from the parent aromatic hydrocarbon is also described (Mürner et al., 1998; originally from Greabe and Hönigsberger, 1900). Additional Materials (also see Support Protocol 1) Chrysene Sodium dichromate Glacial acetic acid 2,2′-Bipyridine Mortar and pestle 250- and 1000- to 2000-mL round-bottom flasks 250-mL beaker 60-mL coarse-frit glass funnels 250- and 1000-mL filter flasks 2000-mL Erlenmeyer flask Synthesize 5,6-chrysenequinone 1. Set up a reflux condenser with a temperature-controlled magnetic stir plate and an oil bath or heating mantle. 2. Grind 5 g chrysene into a fine powder with a mortar and pestle. This procedure ensures that the material will be oxidized efficiently, and is necessary when the chrysene is in the form of crystalline “chunks.” If it can be obtained as a fine powder, further grinding is not required.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.19 Current Protocols in Nucleic Acid Chemistry
CAUTION: To prevent exposure to the fine dust produced in this procedure, the grinding should be performed in a fume hood. In addition, appropriate personal safety devices should be used, including gloves, a laboratory coat, and a face mask.
3. Add the 5 g chrysene and 20 g sodium dichromate to a 250-mL round-bottom flask. 4. Add 50 g glacial acetic acid, connect the flask to a condenser, and bring the mixture to reflux with stirring. Continue refluxing for a total of 9 hr. As heating continues, the solution will change from the orange-yellow of the dichromate/chrysene to a deep green with visible orange-red crystals of the chrysenequinone product.
5. Remove the reaction mixture from heat and immediately add to a 250-mL beaker containing 75 to 100 mL boiling distilled water. The product will crash out of solution while the green chromium by-products remain soluble.
6. Collect the product by filtering the solution through a 60-mL coarse-frit glass funnel using a 250-mL filter flask and a water aspirator or vacuum pump. 7. Wash crystals thoroughly with 250 to 500 mL water. Recoveries at this step are typically 80% to 90%.
Recrystallize 5,6-chrysenequinone 8. Place ∼0.8 to 0.9 g product into a 1000-mL round-bottom flask and add ∼800 to 900 mL of 95% ethanol (∼1 liter per gram of solid). 9. Connect to the reflux condenser and bring to a boil with stirring. The solution should become a clear orange-red color. If there are still orange crystals that remain undissolved, more ethanol should be added. However, any yellow chrysene starting material should not dissolve.
10. Decant the hot solution away from any undissolved material into a 2000-mL Erlenmeyer flask. Allow the solution to cool to room temperature, then chill to 4°C for several hours to promote further crystallization. 11. Collect the product by filtration with a 60-mL coarse-frit glass funnel and a 1000-mL filter flask. 12. Rinse with a small volume of ethanol (e.g., 50 to 100 mL) and dry the isolated product under vacuum. 13. Characterize the product by 1H NMR and mass spectrometry. Spectroscopic data are included below (see Compound Characterization).
Synthesize [Rh(bpy)2(chrysi)]3+ 14. Prepare [Rh(bpy)2(NH3)2]Cl3 intermediate as described for [Rh(phen)2(NH3)2]Cl3 (see Support Protocol 1, steps 1 to 13), but substitute 2,2′-bipyridine for the phenanthroline ancillary ligands. Spectroscopic data are included below (see Compound Characterization).
Probing Nucleic Acid Structure
15. Prepare [Rh(bpy)2(chrysi)]3+ by condensation of [Rh(bpy)2(NH3)2]Cl3 with purified 5,6-chrysenequinone as described for the synthesis of [Rh(phen)2(phi)]Cl3 (see Support Protocol 1, steps 14 to 29), adjusting the amounts of materials commensurate with their different molecular weights.
6.2.20 Current Protocols in Nucleic Acid Chemistry
5,6-Chrysenequinone is less soluble in the acetonitrile/water solvent system but, as the reaction progresses, undissolved starting material goes into solution as the dissolved quinone is consumed. Unlike the previous synthesis, which went from yellow to orange, the color change here is more subtle. The formation of the diimine product gradually changes the red-orange of the quinone solution to a dark brown. After the reaction is completed, ion-exchange purification is done identically as described above. The products should be characterized by 1H NMR, UV/visible spectrometry, and mass spectrometry. Spectroscopic data are included below (see Compound Characterization).
PHOTOFOOTPRINTING OF DNA-BINDING MOLECULES The complex bis(9,10-phenanthrenequinone diimine)(2,2′-bipyridyl)rhodium(III), [Rh(phi)2(bpy)]3+, is a strong, sequence-neutral DNA-binding molecule. As with the complexes discussed above, it also cleaves DNA upon photoactivation. This neutral binding behavior and photocleavage can be applied to the footprinting of both DNA-binding proteins and small DNA-binding molecules. Because the cleavage chemistry involves direct reaction rather than a diffusible species, high-resolution footprints are obtained. Since the intercalative interaction of the molecule “senses” both grooves of the DNA helix, these molecules can be used to footprint molecules that bind in either the major or the minor groove (Uchida et al., 1989).
BASIC PROTOCOL 4
Materials Metal complex solution (see recipe): [Rh(phi)2(bpy)]Cl3 solution (typically 10 µM; for synthesis, see Support Protocol 6) Labeled DNA solution (see Support Protocol 7): typically 10 µM base pairs in a 2× buffer appropriate to the DNA binding molecule of interest Labeled DNA/binding molecule solution: labeled DNA solution containing DNA-binding molecule at twice the concentration desired in the photofootprinting experiment Additional reagents and equipment for photolysis (see Support Protocol 8) and mapping cleavage sites (see Support Protocol 9) 1. Mix equal volumes of [Rh(phi)2(bpy)]Cl3 and labeled DNA solutions for a total volume of 10 to 50 µL as described (see Support Protocol 8, steps 1 to 3). Set up dark and light controls of each DNA of interest. It is important to keep a 1:1 ratio between the rhodium complex and the DNA base pairs in the experiment to preserve the sequence neutrality of the cleavage reagent. Some selectivity is observed at low Rh/DNA ratios.
2. Set up separate reactions and controls using the labeled DNA/binding molecule solution. 3. Irradiate 5 to 10 min at 313 nm and treat as described (see Support Protocol 8, steps 4 to 8). 4. Perform electrophoresis and autoradiography as described (see Support Protocol 9). Sites of DNA binding by the molecule of interest will be obvious from the attenuation of rhodium complex cleavage.
5. Identify specific bases of protection by comparison with Maxam-Gilbert sequencing reactions as described in Support Protocol 9. For more complete characterization of a DNA-binding interaction, multiple footprinting reactions (with a set amount of DNA and rhodium complex) can be performed at different
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.21 Current Protocols in Nucleic Acid Chemistry
concentrations of DNA-binding molecule to titrate in the cleavage footprint. Weaker protection is observed at lower concentrations. SUPPORT PROTOCOL 6
SYNTHESIS OF BIS(9,10-PHENANTHRENEQUINONE DIIMINE)(2,2′-BIPYRIDYL)RHODIUM(III) TRICHLORIDE [Rh(phi)2(bpy)]3+ is synthesized in the two-step process shown in Figure 6.2.5. In this methodology, 9,10-diaminophenanthrene (phi) is used to generate a [Rh(phi)2Cl2]Cl complex (from Pyle et al., 1990). Before introduction of the third chelating ligand, the chloride ligands are removed with silver triflate. Preparation of [Rh(phi)2(bpy)]3+ is from Howells and McCown (1977) and Pyle et al. (1990). Although this reaction is described on a relatively large scale, it can be scaled down without difficulty. In addition to the procedure described here for the synthesis of [Rh(phi)2(bpy)]3+, a synthesis based on the condensation methodology described above for [Rh(phen)2(phi)]3+ (see Support Protocol 2) would also be an effective method to make this molecule. Although specific reaction conditions have not been determined to produce the bipyridyl complex, methods have been developed to make the very similar [Rh(phi) 2(phen)]3+. The conditions required to make this molecule are likely to be almost identical (Mürner et al., 1998). Additional Materials (also see Support Protocol 1) 9,10-Diaminophenanthrene Dimethylformamide Argon gas Absolute ethanol (anhydrous) Chloroform Silver trifluoromethanesulfonate (silver triflate) 2,2′-Bipyridine 50% (v/v) acetonitrile (reagent grade or better) in distilled water
1+
RhCl3•H2O H2N
H
1. reflux DMF/EtOH Hz•HCl
NH2
H N
N
Rh
N H
2. oxidation
N H
Cl Cl
3+
1. AgOTf DMF 70°C
H N
2. DMF 60°C
N H
N
Probing Nucleic Acid Structure
H
N N
Rh
H
N N
N
3+ Figure 6.2.5 Synthesis of [Rh(phi)2(bpy)] . AgOTf, silver triflate; DMF, dimethylformamide; Hz⋅HCl, hydrazine monohydrochloride.
6.2.22 Current Protocols in Nucleic Acid Chemistry
Sephadex QAE-25 anion-exchange resin 1 M HCl (APPENDIX 2A) Sephadex CM-C25 cation-exchange resin 1000-mL three-necked, round-bottom flasks Vacuum line with argon flush 100-, 250-,and 500-mL round-bottom flasks Septa to fit flasks Heat gun 60-mL gas-tight syringe with long needle 25-, 500-, and 1000-mL Erlenmeyer flasks 60-mL coarse- and fine-frit glass funnels Chromatography columns: 0.5 to 1 feet (15 to 30 cm) long, 1 to 1.5 in. (2.5 to 3.8 cm) diameter 1 to 2 feet (30 to 61 cm) long, 1 to 1.5 in. (2.5 to 3.8 cm) diameter Prepare [Rh(phi)2Cl2]Cl 1. Set up a reflux condenser with a temperature-controlled magnetic stir plate and an oil bath or heating mantle. 2. Combine 3.5 g of 9,10-diaminophenanthrene and 65 to 75 mg hydrazine monohydrochloride in a 1000-mL three-necked, round-bottom flask. 3. Add 250 mL dimethylformamide and immediately connect the flask to the reflux condenser, seal it with septa, and begin stirring the mixture to dissolve the reactants. 4. While stirring, deoxygenate the solution by pumping and backfilling with argon gas. Repeat deoxygenation at least three times. 5. In a 250-mL round-bottom flask, add 80 mL absolute ethanol to 1.6 g rhodium trichloride monohydrate. Dissolve the rhodium completely by swirling the flask and applying gentle heat with a heat gun. 6. Seal the flask with a septum and deoxygenate as described in step 4 by piercing the septum with a long syringe needle connected to the argon/vacuum line. 7. When both flasks are completely deoxygenated, transfer the rhodium solution to the three-neck reaction flask with a 60-mL gas-tight syringe. 8. Deoxygenate the reaction mixture again by repeated pumping down and backfilling with argon. 9. Heat the reaction at 80°C under argon for 16 to 24 hr. 10. Remove from heat and transfer to a 1000-mL Erlenmeyer flask. Open the mixture to air and stir for several days to allow oxidation of the coordinated amines to immine ligands. 11. Collect the product by filtration through a 60-mL coarse-frit glass funnel using a 250-mL filter flask and an aspirator or vacuum pump. 12. Wash with copious amounts (~100 mL each) of distilled water, ethanol, and chloroform (in that order). 13. Characterize the product by 1H NMR and mass spectrometry. Spectroscopic data are included below (see Compound Characterization). Spectroscopy shows that both a trans and a cis product are produced in this reaction. Both isomers, however, can go on to react with an additional chelating ligand to form the desired product.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.23 Current Protocols in Nucleic Acid Chemistry
Prepare [Rh(phi)2(bpy)]3+ 14. Dissolve 1 g [Rh(phi)2Cl2]Cl in 40 mL dimethylformamide in a 100-mL round-bottom flask. 15. In a 25-mL Erlenmeyer flask, dissolve 1.25 g silver triflate in 8 mL dimethylformamide. 16. Add the silver triflate solution to the rhodium complex, deoxygenate the reaction, and heat to 70°C. Continue heating for 48 hr under argon. 17. Remove the dark silver chloride precipitate by vacuum filtration, first through a 60 mL coarse and then through a 60-mL fine frit, using a 250-mL filter flask and an aspirator or vacuum pump. 18. Rinse the precipitate with 50 mL dimethylformamide to bring the total volume of the filtrate to ∼100 mL. 19. Transfer the triflate intermediate solution to a 250-mL round-bottom flask and add 0.5 g (2 eq) of 2,2′-bipyridine chelating ligand. To ensure as complete a reaction as possible, an excess of ligand should be added.
20. Deoxygenate the reaction mixture several times, then stir at 60°C under argon for 24 hr. 21. Remove the solvent using a rotary evaporator with a vacuum pump, and dissolve the product in 10 to 20 mL of 50% acetonitrile for chromatography. The product is now ready for anion-exchange chromatography, which exchanges any of the triflate counter-ions in the reaction for chloride ions. This will improve the solubility of the complex in water and help in the subsequent cation-exchange purification column.
Purify by anion exchange 22. Swell a small amount (10 to 20 g) of Sephadex QAE-25 anion-exchange resin in 50 to 100 mL of 50% acetonitrile containing 0.1 M HCl in a 500-mL Erlenmeyer flask. 23. Pour the slurry into a 0.5- to 1-foot column and allow it to pack to a height of 5 to 7 inches (13 to 18 cm). 24. Wash the column with one to two column volumes of 50% acetonitrile. When the level of the solvent approaches the top of the resin, pour the product solution into the column and immediately begin collecting the effluent. Although it is desirable to keep the packing as undisturbed as possible, it is not necessary to worry too much about agitating the top of the column. It is necessary to begin collecting immediately because the reaction mixture will flow straight through.
25. Collect all the metal complex off the anion-exchange column by washing it with one to two column volumes of 50% acetonitrile. 26. Transfer the fraction to a 500-mL round-bottom flask and remove the solvent using a rotary evaporator.
Probing Nucleic Acid Structure
Purify by cation exchange 27. Swell 25 to 50 g Sephadex CM-C25 cation-exchange resin in 200 to 400 mL of 50% acetonitrile containing 0.1 M HCl. Pour a 1- to 2-foot column and allow the resin to settle. 28. Wash the column with one to two column volumes of 50% acetonitrile.
6.2.24 Current Protocols in Nucleic Acid Chemistry
The mixture of acetonitrile, water, and Sephadex CM resin is used instead of the SP resin used in previous protocols to prevent the complex from sticking irreversibly to the chromatography column.
29. Dissolve the dried product (step 25) in a minimum volume of 50% acetonitrile (just enough to dissolve all the solid) and load carefully to the top of the cation-exchange column, taking care not to disturb the resin surface. All the orange metal complex should adhere to the top 1⁄4 to 1⁄2 inch of column packing. If desired, a small layer of swelled resin may be added over the top of the product band using a long pipet. This protective layer prevents disruption of the product band when solvent is subsequently added.
30. Begin eluting the column with 50% acetonitrile. Increase the concentration of HCl first to 0.05 M and then gradually to 0.25 M to elute the charged metal complexes. Typically 100 to 200 mL of each molarity are used, but this depends of the results obtained. If not bands move at a given molarity, the entire volume need not be used. If bands move at a reasonable rate, the volume can be increased to 400 to 500 mL to elute a given product band. Any ligand or ligand breakdown products that remained in the reaction mixture will come off the column immediately. Any remaining rhodium phi starting materials should elute next. The [Rh(phi)2(bpy)]Cl3 will elute last as an intense orange band.
31. To isolate the product from the appropriate fraction, evaporate the solvent to dryness by rotary evaporation or lyophilization. Residual hydrochloric acid can be removed by repeatedly dissolving the material in methanol and redrying. If desired, the product can be more completely desalted by dissolving in water and using a Waters Sep-Pak reversed-phase cartridge as described earlier (see Support Protocol 1, steps 22 to 26).
32. Characterize the product by 1H NMR, UV/visible spectrometry, and mass spectrometry. Spectroscopic data are included below (see Compound Characterization).
SHAPE-SELECTIVE CLEAVAGE OF RNA Some of the complexes described above for the shape-selective recognition of DNA can also be applied to the study of RNA structural forms. Their utility as structural probes of RNA is considerable, and the sites targeted tend to be unique for current RNA chemical probes. [Rh(phen)2(phi)]3+ (see Basic Protocol 1) is particularly valuable as a probe of RNA structure. Because of the preference of RNA duplexes to adopt the A form, recognition by [Rh(phen)2(phi)]3+ becomes much more specific on RNA than on B-form DNA. Because of its width and depth, the A-form region is not bound by [Rh(phen)2(phi)]3+. Hence, on folded RNA, the complex can bind only to areas of tertiary interaction or to sites where the major groove has become substantially opened and accessible to intercalation. At such points (e.g., the D-T loop on tRNAPhe, triply bonded sites, and helix-loop junctions), the major groove of the nucleic acid is accessible. This selective identification of sites of tertiary interactions is a very useful tool in exploring the three-dimensional structure of an unknown segment of RNA. It is noteworthy that sites that are opened in the major groove are often specific targets for RNA-binding proteins. As a result, such structural information could find application not only in the study of the nucleic acids themselves but in the rapidly expanding study of RNA-protein interactions.
BASIC PROTOCOL 5
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.25 Current Protocols in Nucleic Acid Chemistry
[Rh(DIP)3]3+ (see Basic Protocol 2) recognizes and cuts RNA in areas of folded loops. This recognition is similar to the recognition of DNA cruciforms, which is assumed to be a mostly hydrophobic interaction with areas of the molecule that are not purely double or single stranded. Of greatest utility is the fact that [Rh(DIP)3]3+ recognizes GU mismatches in RNA within double-helical regions (Chow and Barton, 1992). Recognition of RNA by [Ru(TMP)3]2+ and [Ru(phen)3]2+ (see Basic Protocol 1) is much less informative than by the rhodium complexes. Although one might expect strong binding of [Ru(TMP)3]2+ to the A-form helices of the RNA, very little selective cleavage is observed. Instead, photolytic cleavage with [Ru(phen)3]2+ provides a practical and clean chemical G sequencing reaction. Application of [Ru(phen)3]2+ in this context as a sequencing reagent is therefore described below (see Basic Protocol 6). In all cases, use of these metal complexes to probe RNA structure is analogous to the experiments described in the previous sections for DNA. Although the types of information the complexes provide are different, the solutions, procedures, and equipment are the same. BASIC PROTOCOL 6
SINGLET OXYGEN-MEDIATED CLEAVAGE AT GUANINE RESIDUES IN DNA AND RNA The use of [Ru(phen)3]2+ to control for the shape-selective recognition properties of [Ru(TMP)3]2+ described in Basic Protocol 5 is not the only use of the complex as a DNA probe. As a result of its nonspecific binding behavior and general oxidative reactivity, [Ru(phen)3]2+ can also be used as a guanine-specific photosequencing reagent to complement the chemical Maxam-Gilbert methods. By simply applying the protocol described in Basic Protocol 1 to a DNA or RNA of interest, specific and clean determinations of guanine positions in DNA and RNA can be made.
SUPPORT PROTOCOL 7
Probing Nucleic Acid Structure
PREPARATION AND LABELING OF DNA AND RNA The nucleic acid samples used in studies with these probes have been prepared synthetically using standard solid-phase chemistries or excised from plasmids using restriction endonucleases, or, in the case or RNA, sometimes produced by enzymatic run-off transcription. All samples must be stringently purified either by reversed-phase high-performance liquid chromatography (RP-HPLC) or by PAGE and labeled with 32P on either the 5′ or 3′ end by standard enzymatic methods. Comprehensive protocols for these activities are included elsewhere in this book and in Current Protocols in Molecular Biology, and the reader is directed there for specific details (for nucleic acid synthesis, see Chapter 3 and APPENDIX 3C of this book; for restriction digestion of plasmid DNA, see CPMB UNIT 3.1; for run-off transcription of RNA, see CPMB UNIT 3.8; for purification of restriction fragments, see CPMB UNIT 2.7; for labeling of nucleic acids, see CPMB UNITS 3.5-3.15 and also UNIT 6.1 of this book). The labeled DNA solution should contain unlabeled, sonicated calf thymus DNA or oligonucleotide DNA (carrier DNA; see below) with enough radiolabeled DNA so that the specific activity of a single irradiation sample is between 20,000 and 200,000 cpm. The appropriate amounts of DNA required are discussed in each Basic Protocol and refer to the amount of carrier DNA, as labeled DNA (on the picomole scale) is assumed not to affect the total DNA concentration. Since photocleavage is performed by mixing DNA and metal complexes at a 1:1 (v/v) ratio, the solution should be made at twice the concentration desired in the photocleavage experiment. Appropriate buffers include ammonium acetate buffer, sodium cacodylate/NaCl buffer, Tris/acetate/NaCl buffer, Tris/NaCl buffer, Tris/NaCl/imidazole buffer (see recipes), and TBE electrophoresis
6.2.26 Current Protocols in Nucleic Acid Chemistry
buffer (APPENDIX 2A). Concentrated, unlabeled, DNA stock solutions in buffer can be stored refrigerated for several weeks. Solid DNA samples are stable, either refrigerated or frozen, for several months. DNA stocks including radioactivity should be used within one half-life, as longer storage times are associated with larger amounts of nonspecific (background) DNA damage. Sonicated calf thymus DNA can be obtained commercially and dissolved in an appropriate buffer (pH 7 to 9). The concentration of a dilution of this stock solution should be determined spectrophotometrically using a value of 13,200 M−1 cm−1 per base pair at 260 nm. The stock solution can then be diluted to a concentration appropriate for its designated use. For oligonucleotides of known sequence, extinction coefficients can be estimated using additive values for each base. One such set of values includes A, 8600; C, 6800; G, 9700; and T, 8400 M−1 cm−1, and is based on the absorbance characteristics of homopolymers. A more stringent treatment is to make calculations based on each base step in the DNA, as described by Wilson et al. (1997). Once an estimate of the extinction coefficient is made, the concentration of a stock solution can be determined spectrophotometrically and appropriate dilutions can be made. In the design of an experiment, it is important to consider what will be used as the unlabeled carrier nucleic acid. In most cases this unlabeled nucleic acid is required to increase the concentration of the polymer and ensure good binding of the probe molecule. It is always best that the carrier DNA be of identical sequence to the labeled DNA strand being observed in the experiment. Therefore, in the case of oligonucleotides, extra unlabeled material is simply added to the reaction stocks. Because it is not practical to produce large amounts of plasmid restriction fragments, however, it is not always possible to use DNA of identical sequence as carrier. In that case, another commercially available unlabeled polymer is typically used. The most common alternative is sonicated calf thymus DNA because it is relatively inexpensive. It is important to consider how the selection of a carrier DNA will affect an experiment, however, because the distribution of DNA sites in one sample of DNA is unlikely to be the same as that in a specific labeled restriction fragment. Similar considerations apply to carrier RNA. In the case of run-off transcripts (where only RNA of a single sequence is made), it may be possible to use identical-sequence RNA as carrier. More likely, however, commercially available tRNA will be used as carrier.
PHOTOLYSIS OF METAL COMPLEXES Although the exact photolysis procedures that will be successful under any given set of experimental conditions depend on the individual light source used, the following description includes many of the possible options used in the authors’ laboratory and is likely to be generally adaptable. It is recommended that a new light system be appropriately tested to ensure that it is performing adequately before attempting any experimental trials. The most straightforward method for performing such tests is the photolysis of commercially available supercoiled plasmid DNA in the presence and absence of the metal complex probes. The results of the photolysis are monitored by agarose gel electrophoresis as described (see Basic Protocol 2). A properly performing lamp system should produce a large fraction of nicked and linearized plasmid DNA in the presence of metal complex and little to no damage in the absence of the probe. If insufficient photocleavage or too much complex-independent damage is observed, the light source must be modified to correct the problems. These modifications include filtering out short-wavelength UV light (<300 nm), changing the distance between the samples and the light source, and increasing the amount of time the samples are irradiated.
SUPPORT PROTOCOL 8
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.27 Current Protocols in Nucleic Acid Chemistry
After irradiation, nucleic acids can be isolated from the solutions either by drying the samples in a Speedvac evaporator or by ethanol precipitation. It is important to consider the consequences of precipitating DNA when designing a photocleavage experiment and interpreting the results. When DNA is isolated in this manner, the longest polymers are preferentially precipitated. As a result, shorter photocleavage products may be left in the supernatant and discarded. To eliminate this possible complication, it is preferable to dry samples down rather than precipitate them if the electrophoresis of the reactions is not hindered by high salt concentrations or interference of the metal complex (see Critical Parameters and Troubleshooting). Details for precipitation are given in the steps below. Materials Metal complex solution (prepared at twice the concentration desired in the photocleavage experiment; see recipe) DNA or RNA stock solution containing radiolabeled and unlabeled carrier DNA or RNA (see Support Protocol 7; prepared in buffered solution at twice the desired concentration of all components in the photocleavage experiment) 9 mM base pairs calf thymus DNA solution in deionized water, buffered to pH 7 to 9 (optional; see Support Protocol 7) 7.5 M ammonium acetate solution in deionized water (optional) Absolute ethanol (200 proof, dehydrated; optional) Dry ice Loading buffer (e.g., formamide loading buffer or urea loading buffer; see recipes) 1.7- or 0.65-mL silanized microcentrifuge tubes Light source, such as: Hg-Xe arc lamp (e.g., Oriel) equipped with an infrared (IR) filter, monochromator, and ultraviolet (UV) cut-off filter (<300 nm) He-Cd laser (e.g., Linconix model 4200 NB; 442 nm, 22 mW) Transilluminating light box (e.g., Spectroline model TR302 from Spectronics) with a broad band of irradiation centered at 302 nm Speedvac evaporator (Savant) or lyophilizer Liquid scintillation counter 1. Combine equal volumes of metal complex and DNA or RNA stock solutions in a silanized microcentrifuge tube, using a total volume of between 5 and 50 µL. Agitate the solution well to ensure complete mixing and then centrifuge the solution to the bottom of the tube. Reactions typically contain between 10,000 and 200,000 cpm of end-labeled nucleic acid fragment. Total nucleic acid concentrations (including unlabeled carrier DNA or RNA) are typically between 5 and 100 mM base pairs, depending on the binding constant of the metal complex being used and the desired ratio between the probe and nucleic acid. Additional details for nucleic acid solutions are given in the specific protocols.
2. Set up light and dark control experiments for each nucleic acid and metal complex sample used to ensure the reliability of the experimental results. For dark controls, mix metal complex with nucleic acid as in step 1. For light controls, add the same amount of nucleic acid to the tubes, but add an equal volume of deionized water instead of metal complex.
Probing Nucleic Acid Structure
Dark controls are incubated in the absence of light (i.e., are not irradiated) to assess any nuclease or other contamination. In light controls, nucleic acid is irradiated at the experimental wavelength in the absence of metal complex to measure the level of metal-independent damage.
6.2.28 Current Protocols in Nucleic Acid Chemistry
3. Allow all samples and controls to equilibrate 5 to 15 min in the dark at ambient temperature before irradiation. To ensure consistency throughout an experiment, all samples and controls should be allowed to equilibrate for the same amount of time before irradiation. As a result, if irradiations are being performed serially on a single light source, solutions should be mixed one by one as the experiment progresses.
4. Irradiate samples by positioning the open tubes in the output of a light source for between 5 and 30 min. Place the sample as close as possible to the light source or to the beam focal point of a focused source to maximize exposure to the radiation. After each sample is irradiated, store it in the dark until the experiment is completed. Typical wavelengths are 313 and 365 nm. The selection of irradiation wavelength is discussed in the individual experimental protocols. The exact irradiation time is dependent upon the strength of a given light source, the efficiency of the probe, and the wavelength used for irradiation. When a given source or wavelength is first used for an experiment, an irradiation time series should be performed to select the optimum irradiation time. For reference, a given sample irradiated at the focal point of a 313-nm beam produced by a Hg-Xe arc lamp might require 10 min for sufficient cleavage, but require two- or three-fold longer on a transilluminator. The optimal experimental irradiation time consists of the minimal time required to observe a significant level of metal-dependent cleavage. By keeping irradiation as short as possible, metal-independent light damage is minimized. The lid of the microcentrifuge tube must be open with the light entering through the mouth of the tube. Plastic absorbs strongly at most wavelengths used for these experiments. This requirement also puts an upper constraint on the length of sample irradiation time, as evaporation will occur during the course of photolysis.
5. After irradiation of all samples is completed, dry samples in a Speedvac concentrator (and proceed directly to step 8) or precipitate nucleic acids by adding 1 to 5 µL of 9 mM calf thymus DNA, 1⁄6th to 1⁄4th vol of 7.5 M ammonium acetate, and 5 vol absolute ethanol. Mix well and incubate on dry ice for 30 min. For example, for a 25-mL sample, add 1 mL calf thymus DNA, 5 mL ammonium acetate, and 125 mL absolute ethanol. Make sure to mix precipitation samples well before chilling on dry ice. If the ethanol and the buffer are not sufficiently combined, the water layer will freeze and no precipitation will occur. If complete dissociation of the metal complex is desired before electrophoresis, heat the samples 2 min at 90°C after addition of the ethanol.
6. Microcentrifuge 12 min at maximum speed (14,000 rpm). 7. Carefully remove the supernatant, rinse the resulting pellets twice with cold 80% (v/v) ethanol, and dry under vacuum. 8. Count samples in a liquid scintillation counter and resuspend in loading buffer to a constant concentration of radioactivity before electrophoresis (see Support Protocol 9).
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.29 Current Protocols in Nucleic Acid Chemistry
SUPPORT PROTOCOL 9
MAPPING CLEAVAGE SITES ON THE NUCLEIC ACID The electrophoretic techniques used in identifying nucleic acid cleavage sites are identical to those used in standard DNA sequencing. As a result, the reader is directed to sections of Current Protocols in Molecular Biology for specific procedures (see CPMB UNITS 7.1 & 7.4 and APPENDIX 3B of this book). In the authors’ laboratory, dried or precipitated photocleavage samples are resuspended in denaturing loading buffer (e.g., formamide loading buffer or urea loading buffer; see recipes) and electrophoresed in TBE electrophoresis buffer (APPENDIX 2A) on 8% to 20% (w/v) denaturing polyacrylamide gels cast from commercially available stock solutions (National Diagnostics). The polyacrylamide gel is pre-run until it is warm to the touch. In addition, the samples are heated to 90°C for 5 min before loading to promote denaturation of the nucleic acid strands and dissociation of the metal complex probes. To identify the specific sites of nucleic acid cleavage, photocleavage samples are run alongside samples of the same polymers that have been chemically sequenced using standard MaxamGilbert sequencing reactions (Maxam and Gilbert, 1980; e.g., CPMB UNIT 7.5). Gels are read using standard techniques of autoradiography or phosphorimagery. Because both Maxam-Gilbert sequencing reactions and metal complex photocleavage result in the loss of a base at the cleavage site, chemical sequencing products comigrate with analogous photocleavage products. Enzymatic sequencing methods, which do not involve base loss, will result in a systematic one-base shift in the positioning of the cleavage bands. REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Ammonium acetate buffer, 10× 19.3 g/L ammonium acetate (250 mM) Adjust to pH 9 with NH4OH and acetic acid Sterilize by filtering with a 0.22-µm filter Store up to several months at room temperature Formamide loading buffer 80% (v/v) deionized formamide 50 mM Tris base 50 mM boric acid 1 mM EDTA 0.025% (w/v) xylene cyanol 0.025% (w/v) bromphenol blue Adjust to pH 8.3 Store for up to several months at room temperature In the authors’ experience, this buffer performs better than the urea loading buffer for resuspending samples after drying or precipitation.
Probing Nucleic Acid Structure
Metal complex solution Prepare all metal complex solutions as concentrated stocks in deionized water from a sample of solid reagent immediately before use. Determine the concentration of the stock solution spectrophotometrically using the extinction coefficients provided in the Commentary (see Compound Characterization) and then make dilutions in deionized water to concentrations appropriate for the experiments. Store solutions in the dark for the duration of a single experiment and discarded immediately after use.
6.2.30 Current Protocols in Nucleic Acid Chemistry
Sodium cacodylate/NaCl buffer, 10× 15.9 g/L sodium cacodylate (100 mM) 23.4 g/L sodium chloride (400 mM) Adjust to pH 7 with NaOH and cacodylic acid Sterilize by filtering with a 0.22-µm filter Store up to several months at room temperature Tris/acetate buffer, 10× Prepare as for Tris/acetate/NaCl buffer (see recipe) but omit NaCl. Tris/acetate/NaCl buffer, 10× 60.6 g/L Tris base (500 mM) 16.4 g/L sodium acetate (200 mM) 10.5 g/L sodium chloride (180 mM) Adjust to pH 7 with NaOH and acetic acid Sterilize by filtering with a 0.22-µm filter Store up to several months at room temperature Tris/NaCl buffer, 10× 6.1 g/L Tris base (50 mM) 29.2 g/L sodium chloride (500 mM) Adjust to pH 7 with NaOH and HCl Sterilize by filtering with a 0.22-µm filter Store up to several months at room temperature Tris/NaCl/imidazole buffer, 10× 6.1 g/L Tris base (50 mM) 29.2 g/L sodium chloride (500 mM) 0.82 g/L imidazole (12 mM) Adjust to pH 7 with NaOH and HCl Sterilize by filtering with a 0.22-µm filter Store up to several months at room temperature Urea loading buffer 7 M urea 90 mM Tris base 90 mM boric acid 2.5 mM EDTA 0.025% (w/v) xylene cyanol 0.025% (w/v) bromphenol blue Adjust to pH 8.3 Store for up to several months at room temperature Refrigeration of this buffer is not recommended as the urea tends to crystallize out. In the authors’ experience, the formamide-based buffer performs better for resuspending samples after drying or precipitation.
COMMENTARY Background Information Recent results in NMR structure determination and X-ray crystallography of nucleic acids (Hartmann and Lavery, 1996) have shown that the structure of correctly matched, putatively canonical B-form DNA can be heterogeneous and polymorphic. When the additional helical
forms and the many possible DNA lesions (e.g., mismatches, bulges, abasic sites, DNA-drug adducts, and sites of base damage) are added, it is clear that what was once thought to be an uninteresting linear polymer can hide a wealth of structural variety. When the field of consideration is expanded to include RNA, whose
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.31 Current Protocols in Nucleic Acid Chemistry
Probing Nucleic Acid Structure
folding pathways and structures rival those of proteins in complexity, and the many heteroduplexes that now exist between DNA and other polymers, the structural determinations of nucleic acids becomes a very rich field indeed. Because of the time and resources that are involved in techniques for high-resolution structural determination, solution probes of nucleic acids have a very important role in the pursuit of a broad-based structural understanding of DNA and RNA. Unhindered by the concerns of size and system selection that sometimes make NMR difficult, and the need for crystals to determine a structure in the solid state, photochemical probes like those described here provide a rapid, relatively inexpensive method to probe the characteristics of DNA or RNA in solution. Furthermore, for larger macromolecules in particular, chemical probe studies can serve as a bridge to high-resolution structural information. The specific transition metal complex probes described in this unit therefore help fill a critical niche in the large body of chemical and photochemical probes for nucleic acid structure. Residing between probes that have been designed to identify specific sequences along a DNA or RNA strand or helix and the large body of chemical probes that cleave nucleic acids more nonspecifically at primarily solvent-accessible sites, it is the structure specificity of these complexes that makes them unique. The three-dimensional shapes of the complexes, which lead to their structural recognition properties, allow the identification of specific geometries without consideration of base sequence. One of the most well-defined rhodium complexes that has been used for a wide variety of purposes, [Rh(phen)2(phi)]3+, binds in the major groove of DNA by intercalation of the phi ligand between adjacent base pairs (Pyle et al., 1989). DNA strand cleavage is effected by direct hydrogen atom abstraction by the photoexcited phi ligand at the site of intercalation (Sitlani et al., 1992). The complex recognizes primarily two families of sites: 5′-pyrimidinepyrimidine-purine-purine-3′ and homopyrimidine-homopurine tracts. The two enantiomers of the complex demonstrate different recognition behaviors. The ∆ enantiomer, whose chirality is complementary to the right-handed DNA helix, favors the pyrimidine-pyrimidinepurine-purine tracts (Sitlani and Barton, 1994). Site selectivity of this complex is based on shape selection by the bulky aromatic phenanthroline ligands. Comparisons of crystallographic data on the sequences targeted by the
complex show that they are more open in the major groove, thus allowing both the stacking, intercalative interactions of the phi ligand and accommodation of the phen ancillary ligands. Enantioselectivity in cleavage correlates with the opening of sites and changes in the propeller twisting of the bases involved (Campisi et al., 1994). When [Rh(phen)2(phi)]3+ is applied to ribonucleic acids, the folding of complex RNA molecules can be assessed; in an application that crosses over the boundaries between the two types of nucleic acids, the same complex has been used to examine the structure of tDNAPhe (the DNA analog of tRNAPhe) to assess the similarities or differences between DNA copies and their RNA counterparts (Lim and Barton, 1993). The other molecule used as a geometrical probe of unknown DNA sequences, [Ru(TMP)3]2+, has very different behavior. It does not bind by intercalation but rather to the surface of the minor groove of DNA. The complex binds avidly to A-form helices and exhibits little binding to B- or Z-form synthetic oligonucleotides. There is some level of chiral discrimination in binding that favors the Λ-isomer of the complex (Mei and Barton, 1986). The basis of the binding selectivity of [Ru(TMP)3]2+, like [Rh(phen)2(phi)]3+, rests in shape selection, although in this case generated by a different type of interaction. The sterically bulky methyl groups on the TMP ligands not only prevent intercalation, which is observed for the unmethylated [Ru(phen)3]2+ parent complex, but also restrict binding to open and shallow areas of the minor groove. This explains the preferential binding to A-form DNA and RNA by [Ru(TMP)3]2+. In contrast to the direct photocleavage found with [Rh(phen)2(phi)]3+, where the cleavage chemistry involves reaction with the deoxyribose sugar and shows no sequence bias, irradiation of the ruthenium complexes sensitizes the formation of singlet oxygen, a diffusible species that reacts with nearby bases and preferentially with guanine residues (Mei and Barton, 1988). As a result, [Ru(TMP)3]2+ cleavage must be compared with [Ru(phen)3]2+, its sequence-neutral analog, to deduce areas of preferential TMP binding. The combination of [Rh(phen)2(phi)]3+ and [Ru(phen)3]2+ probes have been applied to mapping the conformation of DNA within an entire gene (Huber et al., 1991). The shape and structure specificity that is provided by simple steric exclusion has also been used for a variety of recognition tasks. The ability of [Rh(DIP)3]3+ to recognize cruciforms
6.2.32 Current Protocols in Nucleic Acid Chemistry
and other unusual tertiary structures is a relatively unique property that has been comprehensively explored in the authors’ laboratory. Experiments have shown that it is the cruciform structure, rather than any specific sequence, that is targeted by the molecule (Kirshenbaum et al., 1988). The molecule’s shape selectivity has also been applied to an examination of the DNA structures in the SV40 T antigen and adenovirus 2 E1A genes (Lee and Barton, 1993). This steric specificity mechanism has been applied to the design of the intercalating ligand [Rh(bpy)2(chrysi)]3+, which has been used to probe both the structures of DNA base mismatches (Jackson and Barton, 1997; Jackson et al., 1999) and abasic sites in DNA (B.A. Jackson and J.K. Barton, unpub. observ.). A comprehensive study of this molecule and its recognition behavior is currently in progress in the authors’ laboratory. When these probes are used to examine RNA structure, their unique properties lead to additional applications. From the studies performed on tRNAPhe, the authors’ laboratory has shown that the A-form configuration of RNA leads to much more specific recognition of ribonucleic acid structural features by this family of rhodium probes. The complex recognizes sites of tertiary structure, including bulges and triplex sites where the phi intercalating ligand can gain access to the major groove of the nucleic acid. It is becoming clear that RNA binding proteins also target sites that are opened in the major groove. As a result, use of [Rh(phen)2(phi)]3+ may find application in scanning unknown ribonucleic acids for possible protein-binding sites. The cleavage behavior of [Rh(phen)2(phi)]3+ has been used to examine structural domains in eukaryotic 5S rRNA (Chow et al., 1992) and to probe the conformations of TAR RNAs from human (Neenhold and Rana, 1995) and bovine (Lim and Barton, 1997) immunodeficiency viruses. Moving away from modes of structural recognition, the nonspecific [Rh(phi)2(bpy)]3+ complex is an important addition to the body of molecular tools for studying the interactions between DNA and other molecules. Because its DNA cleavage chemistry is photoinduced, it provides a unique opportunity to study systems where it is advantageous to combine all the components at one time and activate the footprinting reaction later. This compound has been used in the authors’ laboratory to footprint both DNA-binding proteins (like EcoRI) and small DNA binders (like distamycin; Uchida et al., 1989). Furthermore, [Rh(phi)2(bpy)]3+ is
unaffected by additives such as glycerol and Mg2+ at the levels that might be required to promote DNA binding by certain proteins. It can footprint both major and minor groove ligands, and, since no diffusible intermediate is involved in the cleavage, produces sharp, wellresolved footprint patterns. In spite of the breadth and number of tasks to which these reagents have been applied in the past, the many open questions about nucleic acid structure provide myriad opportunities where solution probes like those described here can be used. As recent crystal structures of DNA-protein complexes have made clear, the shape and geometry of a nucleic acid target site can play an instrumental role in specific DNAprotein interactions. As more is discovered about the unique structures of damaged or mispaired sites in DNA and the dramatic effects that DNA-binding proteins and small molecules can have on DNA geometry, the easily accessible information that can be provided by solution probes of structure becomes more and more valuable.
Compound Characterization Mapping DNA major and minor groove characteristics [Rh(phen)2(Cl2)]Cl 1H-NMR: d -dmso, 9.69 (d, 2H); 8.99 (d, 6 2H); 8.89 (d, 2H); 8.62 (t, 2H); 8.32 (t, 2H); 8.18, (t, 2H); 7.80 (d, 2H); 7.59 (t, 2H). [Rh(phen)2(NH3)2]Cl3 1H-NMR: d -acetone, 9.93 (d, 2H); 9.42 (d, 6 2H); 8.99 (d, 2H); 8.64 (m, 4H); 8.51 (d, 2H); 8.32 (d, 2H); 7.87 (dd, 2H); 5.18 (broad s, 6H). 13C-NMR: d -acetone, 154.1, 153.6, 147.6 6 q, 146.6 q, 142.9, 141.5, 133.2 q, 129.2, 129.1, 128.3, 127.7. UV/visible (acetonitrile/water 1:1, 1.9 × 10− −1 −1 −1 5 M): ε 302, 12,400 M cm , ε271, 51,500 M −1 −1 −1 cm , ε222, 51,800 M cm . [Rh(phen)2(phi)]Cl3 1H-NMR: d -dmso, 14.98 (s, N-H phi); 9.25 6 (d, H 4 phen); 9.12 d, H 2 phen); 9.03 (d, H 7 phen); 8.94 (d, H 5,6 phen); 8.54 (dd, H 4,5 phi); 8.47 (d, H 1,8 phi); 8.36 (dd, H 3 phen); 8.08 (d, H 9 phen); 7.91 (dd, H 8 phen); 7.84 (t, H 2,7 phi); 7.57 (t, H 3,6 phi). UV/visible: ε362, 19,400 M−1 cm−1 (pH isosbestic point); ε358, 19,400 M−1 cm−1; ε300, 34,000 M−1 cm−1; ε272, 116,200 M−1 cm−1.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.33 Current Protocols in Nucleic Acid Chemistry
CD: (∆ enantiomer, acetonitrile, 1.47 × 10−5 M) 261 (99), 275 (-179), 346 (-24). [Ru(TMP)3]Cl2 1H-NMR: CDCl , 8.20 (s, H 5,6); 7.98 (s, 3 H, 2,9); 2.74 (s, CH3, 4,7); 2.37 (s, CH3, 3,8). UV/visible: ε210, 94,500 M−1 cm−1; ε233, 64,000 M−1 cm−1; ε269, 114,600 M−1 cm−1; ε299(shoulder), 26,400 M−1 cm−1; ε438, 24,500 M−1 cm−1. [Ru(phen)3]Cl2 1H-NMR: d -dmso, 8.8 (d, H 4,7); 8.7 (d, H 6 2,9); 8.4 (s H 5,6); 7.7 (dd, H 3,8). UV/visible: ε222, 87,600 M−1 cm−1; ε262, 107,000 M−1 cm−1; ε291(shoulder), 22,500 M−1 cm−1; ε447, 19,000 M−1 cm−1. Shape-selective cleavage of unusual structures in nucleic acids
Photofootprinting of DNA-binding molecules [Rh(phi)2Cl2]Cl 1H-NMR: d -dmso, trans product: 14.89 (s, 6 4H); 8.75 (d, 4H); 8.53 (d, 4H); 7.92 (t, 4H); 7.82 (t, 4H); cis product, 14.53 (s, 2H); 13.19 (s, 2H); 9.23 (d, 2H); 8.5 (t, 4H); 8.37 (d, 2H); 7.95 (d, 2H); 7.8 (d, 2H); 7.75 (t, 2H); 7.58 (t, 2H).
[Rh(DIP)3]Cl3 1H-NMR: CDCl , 9.01 (d, 6H); 8.30 (s, 6H); 3 8.07 (s, 6H); 7.71-7.69 (m, 10H); 7.61-7.53 (m, 20H). UV/visible: ε296, 116,000 M−1 cm−1; ε334 (shoulder), 49,200 M−1 cm−1; ε370, 19,400 M−1 cm−1.
[Rh(phi)2(bpy)]Cl3 1H-NMR: d -dmso, 14.13 (s, 2H, N-H); 6 13.63 (s, 2H, N-H); 8.92 (d, 2H); 8.66 (m, 6H); 8.45 (d, 6H); 7.84 (m, 6H); 7.61 (t, 4H). UV/visible (Tris-acetate, pH 7.0): ε250, 67,400 M−1 cm−1; ε262, 62,400 M−1 cm−1; ε270, 64,200 M−1 cm−1; ε292, 43,200 M−1 cm−1; ε312, 30,000 M−1 cm−1; ε378, 28,200 M−1 cm−1; ε350, 23,600 M−1 cm−1 (pH isosbestic point).
Recognition of destabilized structures in DNA
Critical Parameters and Troubleshooting
5,6-chrysenequinone 1H-NMR: CD Cl , 9.39 (d, 1H); 8.16 (m, 2 2 4H); 7.92 (d, 1H); 7.77 (t of d, 2H); 7.57 (t of d, 2H).
Syntheses of transition metal probes Other than the general safety concerns involved with working with flammable liquids and strong acids, most of the synthetic work described in this unit has few concerns. In those reactions that require vacuum lines and evacuation of glassware, care must be taken to select equipment that can withstand the required changes in pressure, and appropriate protective eyewear and a laboratory coat should be worn. All reactions, even those that do not specifically mention it, should be performed in a well-functioning fume hood whenever possible. In the authors’ hands, the reactions described in this work have performed to produce their intended products in reliable yields. In all cases, if a reaction is not performing as it should, the correct course of action is to assess the identity and purity of all starting materials and reagents and try the reaction again.
[Rh(bpy)2(Cl2)]Cl 1H-NMR: d -dmso, 9.69 (d, 2H); 9.0 (d, 6 2H); 8.89 (d, 2H); 8.63 (t, 2H); 8.33 (t, 2H); 8.17 (t, 2H); 7.80 (d, 2H); 7.59 (t, 2H). [Rh(bpy)2(NH3)2]Cl3 1H-NMR: d -acetone, 9.45 (d, 2H); 9.05 (d, 6 2H); 8.89 (d, 2H); 8.79 (td, 2H); 8.45 (td, 2H); 8.30 (td, 2H); 8.05 (d, 2H); 7.74 (td, 2H); 5.06, (broad s, 6H).
Probing Nucleic Acid Structure
135.7, 132.3, 132.2, 132.0, 131.8, 130.9, 130.8, 130.6, 130.2, 129.4, 127.7, 127.6, 127.3, 126.9, 126.8, 123.9, 122.9, 120.8, 118.6, 116.3, 114.1. UV/visible (water, 7.8 × 10−6 M): ε271, 63,800 M−1 cm−1 (pH isosbestic point); ε303, 57,000 M−1 cm−1; ε315, 52,200 M−1 cm−1; ε391, 10,600 M−1 cm−1.
[Rh(bpy)2(chrysi)]Cl3 1H-NMR: CD OD, 8.94 (t, 2H); 8.86 (t, 2H); 3 8.80 (d, 1H); 8.77 (d, 1H); 8.56 (split t, 2H); 8.44 (m, 5H); 8.40 (d, 1H); 8.15 (m, 1H); 8.03 (m, 1H); 7.95, (m, 3H); 7.86, (d, 1H); 7.81, (d, 1H); 7.64, (m, 5H). 13C-NMR: CD OD, 183.3, 177.3, 175.4, 3 157.4, 157.2, 157.2, 153.8, 153.2, 152.1, 144.6, 144.5, 143.9, 143.8, 139.7, 138.8, 138.4, 136.2,
DNA photocleavage experiments To achieve success with any of the protocols for assaying DNA structure, all reagents must be of the highest possible purity. The DNA or
6.2.34 Current Protocols in Nucleic Acid Chemistry
RNA fragments in use must be scrupulously purified. In the case of restriction fragments and RNA transcripts, the nucleic acids must be purified by polyacrylamide gel electrophoresis, and the smallest possible gel band containing the labeled fragment should be excised from the gel. After the labeled polymer is removed from the gel, it must be purified from the various components that were present in the electrophoresis buffers. This should be done by ethanol precipitation or by using one of the many commercially available reversed-phase purification cartridges. In the case of synthetic oligonucleotides, the synthesized materials must be purified by HPLC and, after end labeling, also purified by either denaturing or nondenaturing PAGE. In the authors’ laboratory, the last trityl protecting group is typically left at the end of DNA synthesis and used as a hydrophobic handle for HPLC purification. After removing the protecting group, a second HPLC run is performed to ensure purity. In both cases, only the top portion of the major product peak is collected. If an experiment is run with insufficiently pure nucleic acid, the most obvious symptom is an absence of clear, clean banding in all experimental lanes. Such behavior will also be observed in the Maxam-Gilbert sequencing reactions. The metal complexes used for photolysis reactions must also be of the highest possible purity. If they are contaminated by synthetic side products or other material, the concentrations of prepared solutions will be incorrect and other reactivity (unrelated to the desired rhodium or ruthenium probe) may be observed. It is customary in the authors’ laboratory to HPLC purify all metal complexes after ion-exchange chromatography or enantiomer resolution to ensure their purity. If desired, enantiomeric purity can be verified by CD spectroscopy or by use of a commercially available chiral HPLC column. Furthermore, even if metal solutions are made from analytically pure material, it is critical that the solutions used in photocleavage be made as close as possible to the time the experiments are performed. With extended storage in solution, especially with exposure to light, the various metal complex probes can degrade. The degradation products may interact with or cleave DNA, with different specificities than that of the intended probes. All buffer solutions should be made with the highest purity materials available, treated carefully to ensure continuing purity, and remade frequently. In the authors’ laboratory it is also customary to filter all solutions through 0.22-
µm sterilizing filter units before use. Nuclease contamination in buffers can occur through environmental factors and can result in observed cleavage that is independent of irradiation. This is of particular concern with work relating to RNA. Other contaminants in stock solutions can lead to light-dependent damage to the target DNA as well. All the concerns regarding reagent and solution purity underscore the importance of running control samples as part of each photocleavage experiment. These must include both dark controls (DNA incubated with a metal complex probe in the absence of light) and light controls (DNA irradiated in the absence of metal complex). Without these important comparisons, it is impossible to assess the value of any given experimental result. Furthermore, even with the best techniques and intentions, single samples sometimes become contaminated and give anomalous results. This underscores the importance of repeating trials when experimental or control samples display unexpected behavior. Depending on the light source that is available for metal complex irradiation and the specific experimental plan, some troubleshooting of each new system must be done to obtain optimal results with these DNA probes. In all cases, if insufficient cleavage is observed in a given experiment, appropriate responses are to increase the concentrations of the complexes and DNA to promote more complete binding, increase the irradiation times for the experimental samples, and, depending on the sensitivity of the autoradiography technique being employed, increase the amount of radioactivity loaded in each gel lane. On the other hand, if too much photocleavage is observed, one can no longer trust the data extracted from a DNA photocleavage experiment, because at high levels of cleavage there is no reasonable guarantee that single-hit conditions prevail (i.e., that each cleaved polymer has been cut only once by a single metal complex). In the authors’ laboratory, excessive cleavage is defined as an experiment where >10% of the full-length polymer has been cleaved. Under multiple-hit conditions, cleavage bands that correspond to shorter polymers will be enriched at the expense of longer cleavage products. In this case, the exact opposite course of action is required as when too little cleavage is observed (reduce metal complex concentration or decrease irradiation times). In addition to these general concerns for all photocleavage protocols, a few procedures
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.35 Current Protocols in Nucleic Acid Chemistry
Table 6.2.1 Photocleavage Experiment Troubleshooting Guide
Problem Gels do not show clean banding, including in Maxam-Gilbert sequencing lanes
Possible cause Contamination of desired labeled DNA by fragments or shorter oligonucleotide synthetic products produces labeled DNA sample of heterogeneous length
Unexpected cleavage bands observed in experimental lanes but not light or dark controls
Damage is dependent on the addition of the Purify metal complex again by ion exchange or HPLC metal solution and irradiation. Likely contamination of the metal solution by a synthetic by-product or breakdown product
Likely cause is a contaminant in one of the Unexpected cleavage bands observed in experimental samples buffer solutions or solvents used in making and light control but not dark control up the experimental samples that causes light-induced damage to the nucleic acid.
Solution Purify DNA more stringently before running the experiment to ensure homogeneity
Prepare fresh buffer solutions and stocks from new materials of known purity
This behavior has also been observed when Use silanized microcentrifuge tubes nonsilanized tubes are used for irradiation reactions. Presumably some component in the plastic leaches into solution in sufficient concentration to promote light-induced DNA damage Damage is dependent on addition of metal Prepare fresh metal solutions from Unexpected cleavage bands observed in experimental lanes and solution but not on irradiation. Likely cause new materials of known purity is contamination of the metal solution by a dark control but not light control nuclease of some type Unexpected cleavage bands observed in experimental lanes, dark control, and light control
Likely cause is contamination of DNA stock Prepare fresh DNA and metal (or buffer/water stocks) by a nuclease that solutions from new materials of cleaves DNA independent of irradiation known purity
Damage observed in dark control Likely due to exposure of dark control to that is similar to experimental lanes ambient lighting
Keep samples dark before and after irradiation
Smearing observed in experimental Most likely due to problems with lanes but not in sequencing or light renaturation of nucleic acid strands or control interaction between the metal complex and nucleic acids
Heat samples to 90°C (5 min) before loading gel and pre-run the gel until very hot to ensure strand denaturation. If necessary, reprecipitate samples to remove metal complex.
Bands of interest too high or low on Gel run for inappropriate time the gel for adequate clarity
Run gel longer or shorter to affect position of bands in gel. For best resolution of cleaved bases and different polymer ends, bands of interest should be in the lower third of the gel.
Band intensity varies dramatically from gel lane to gel lane, specifically in the uncleaved DNA band
Gel lanes were not loaded with the same amount of radioactivity
Ensure samples are resuspended well and at the same concentration of radioactivity
continued
Probing Nucleic Acid Structure
6.2.36 Current Protocols in Nucleic Acid Chemistry
Table 6.2.1 Continued
Problem Possible cause High concentrations of salt in samples As bands progress down the gel, they compress towards the center of loaded on the gel can affect the mobility of the DNA the lane or run anomalously compared to Maxam-Gilbert sequencing reactions
Solution Reduce the effect/amount of loaded salt by: (1) precipitating samples with ammonium acetate and drying thoroughly under vacuum, (2) increasing the amount of radioactivity in each irradiation sample so a smaller fraction of the sample is loaded on the gel, (3) running the gel at a very low wattage (25 watts) for 30-60 min at the beginning of a gel run to allow some salt to separate from DNA, or (4) reducing the volume of irradiation samples to reduce the amount of salt that is dried down into the DNA
Insufficient DNA cleavage observed Concentration may be too low for effective in experimental lanes binding of complexes to DNA
Increase concentration of both metal solution and DNA
Ratio of total DNA concentration to the Increase concentration of metal solution metal complex probe may be too high to cleave an observable fraction of the labeled DNA Light source may be too weak to promote enough DNA cleavage
Increase power of the light source or increase the irradiation time per sample Amount of radioactivity loaded per gel lane Increase amount of labeled DNA may be too low for sensitivity of the loaded per lane autoradiography technique
Too much cleavage, resulting in >10% depletion of the full-length DNA band
Too much metal complex in the reaction for Reduce concentration of metal a given reaction time, resulting in extensive complex in the solution or reduce cleavage. This will likely involve more than the irradiation time one cleavage event per DNA polymer making the data unreliable
have more specific considerations. In particular, experiments with [Rh(DIP)3]3+ must control carefully for the superhelicity dependence of cleavage and whether the cleavage is single or double stranded. In addition, it must be carefully noted that in the absence of an unusual structure and at long irradiation times [Rh(DIP)3]3+ does induce nonspecific oxidative damage at 5′-GG-3′ and 5′-GA-3′ sites. If this behavior is not adequately controlled, incorrect conclusions may be drawn from observed cleavage data. In a related manner, when using [Rh(phi)2(bpy)]3+ for DNA footprinting, the binding behavior of the metal complex must be considered to ensure that experimental results are meaningful. The concentration of the probe
must be kept high to ensure nonspecific binding. Irradiation times must be kept short enough that there are not problems with excessive cleavage at these high loadings. Finally, one must also consider that the binding constant of rhodium phi intercalators for DNA is in the range of 106 to 108 M−1, making it possible for them to displace weaker DNA-binding molecules from the polymer. A troubleshooting guide for photocleavage experiments is given in Table 6.2.1.
Anticipated Results Using the numerous reagents and techniques described in these protocols, questions about the structure of an unknown nucleic acid sequence or lesion can be approached. In all
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.37 Current Protocols in Nucleic Acid Chemistry
cases, rapid and relatively inexpensive techniques lead to identification of binding sites on the polymer of interest and direct information about the geometry and conformations of the molecule in solution. Because of the large variety of assays and probes included in this unit, it is more efficient to direct the reader to those original papers that include examples of experimental results than to reproduce examples here. Appropriate citations are included below (see Key References).
Time Considerations Once the apparatus has been collected and is in place, most of the synthetic reactions described in this protocol can be completed within a single day. There are a few exceptions to this, including the synthesis of complexes involving 9,10-diaminophenanthrene. These procedures can require between a few days and a week, although the amount of hands-on time during these periods is minimal. Complex purification columns and enantiomer separation require an additional 1 day to 2 weeks of chromatography time. However, these time investments must be viewed with the knowledge that a single synthetic cycle will produce enough material for several hundred DNA structure experiments. Once a given metal complex of interest is made and purified, the biological experiments proceed much more rapidly. DNA can be made and purified within 3 days, and labeled and isolated in another day. Irradiation reactions can be completed in 2 to 12 hr, depending on the number of samples involved. Electrophoresis and autoradiography on one set of samples requires an additional 1 to 2 days.
Acknowledgments The work described here was supported by the NIH (GM33309) and performed by many able graduate students who are referenced as indicated. B.A.J. would also like to acknowledge the NSF for a predoctoral fellowship.
Literature Cited
Probing Nucleic Acid Structure
Campisi, D., Morii, T., and Barton, J.K. 1994. Correlations of crystal structures of DNA oligonucleotides with enantioselective recognition by [Rh(phen)2(phi)]3+: Probes of DNA propeller twisting in solution. Biochemistry 33:41304139.
Cartwright, P.S., Gillard, R.D., and Sillanpåå, E.R.J. 1987. Optically active coordination compounds—XLVI. Resolution of tris-diimmine compounds of chromium(III) using fac(+)tris[L-cysteinesulphinato(2-)SN]cobaltate (III). Polyhedron 6:105-110. Chow, C.S. and Barton, J.K. 1992. Recognition of G-U mismatches by tris(4,7-diphenyl-1,10phenanthroline)rhodium(III). Biochemistry 31:5423-5429. Chow, C.S., Behlen, L.S., Uhlenbeck, O.C., and Barton, J.K. 1992. Recognition of tertiary structure in tRNAs by [Rh(phen)2(phi)]3+, a new reagent for RNA structure-function mapping. Biochemistry 31:972-982. Dollimore, L.S. and Gillard, R.D., 1973. Optically active co-ordination compounds. Part XXXII. Potassium (+) tris-[L-cysteinesulphinato(2-)SN]cobaltate(III): A versatile agent for resolution of 3+ species. J. Chem. Soc. Dalton Trans. (1973):934-940. Gidney, P.M., Gillard, R.D., and Heaton, B.T. 1972. 1,10-Phenanthroline and 2,2′-bipyridyl complexes of rhodium(III). J. Chem. Soc. Dalton Trans. (1972):2621-2628. Gillard, R.D., Osborn, J.A., and Wilkinson, G. 1965. Catalytic approaches to complex compounds of rhodium(III). J. Chem. Soc. Dalton Trans. (1965):1951-1965. Greabe, V.C. and Hönisberger, F. 1900. Ueber die Oxydationsproducte des Chrysens. Ann. Chem. 311:257-265. Hall, D.B., Holmlin, R.E., and Barton, J.K. 1996. Oxidative DNA damage through long range electron transfer. Nature 382:731-735. Hartmann, B. and Lavery, R. 1996. DNA structural forms. Q. Rev. Biophys. 29:309-368. Howells, R.D. and McCown, J.D. 1977. Trifluormethanesulfonic acid and derivatives. Chem. Rev. 77:69-92. Huber, P.W., Morii, T., Mei, H.-Y., and Barton, J.K. 1991. Structural polymorphism in the major groove of a 5S RNA gene complements the zinc finger domains of transcription factor IIIA. Proc. Natl. Acad. Sci. U.S.A. 88:10801-10805. Jackson, B.A. and Barton, J.K. 1997. Recognition of mismatches by a rhodium intercalator. J. Am. Chem. Soc. 199:12986-12987. Jackson, B.A., Alekseyev, V.A., and Barton, J.K. 1999. A versatile recognition agent: Specific cleavage of a plasmid DNA at a single base mispair. Biochemistry 38:4655-4662. Kirshenbaum, M.R., Tribolet, R., and Barton, J.K. 1988. [Rh(DIP)3]3+: A shape-selective metal complex which targets cruciforms. Nucl. Acids Res. 16:7943-7960. Lee, I. and Barton, J.K. 1993. A distinct intronDNA structure in simian virus 40 T-antigen and a d e n ov i r u s 2 E 1 A g e nes. Biochemistry 32:6121-6127.
6.2.38 Current Protocols in Nucleic Acid Chemistry
Lim, A.-C. and Barton, J.K. 1993. Chemical probing of tDNAPhe with transition metal complexes: A structural comparison of RNA and DNA. Biochemistry 32:11029-11034. Lim, A.-C. and Barton, J.K. 1997. Targeting the Tat-binding site of bovine immunodeficiency virus TAR RNA with a shape-selective rhodium complex. Bioorg. Med. Chem. 5:1131-1136. Lin, C-T., Böttcher, W., Chou, M., Creutz, C., and Sutin, N. 1976. Mechanism of the quenching of the emission of substituted polypyridineruthenium(II) complexes by iron(III), chromium(III), and europium(III) ions. J. Am. Chem. Soc. 98:6536-6544. Maxam, A. and Gilbert, W. 1980. Sequencing endlabeled DNA with base-specific chemical cleavages. Methods Enzymol. 65:499-560. Mei, H.Y. and Barton, J.K. 1986. Chiral probe for A-form helices of DNA and RNA: Tris(tetramethylphenanthroline)ruthenium(II). J. Am. Chem. Soc. 108:7414-7416. Mei, H.Y. and Barton, J.K. 1988. Tris(tetramethylphenanthroline)ruthenium(II): A chiral probe that cleaves A conformations. Proc. Natl. Acad. Sci. U.S.A. 85:1339-1343. Müller, B.C., Raphael, A.L., and Barton, J.K. 1987. Evidence for altered DNA conformations in the simian virus genome: Site-specific DNA cleavage by the chiral complex Λ-tris(4,7-diphenyl1,10-phenanthroline)cobalt(III). Proc. Natl. Acad. Sci. U.S.A. 84:1764-1768. Mürner, H., Jackson, B.A., and Barton, J.K. 1998. A versatile synthetic approach to rhodium(III) diimine metallointercalators: Condensation of o-quinones with coordinated cis-ammines. Inorg. Chem. 37:3007-3012. Neenhold, H.R. and Rana, T.M. 1995. Major groove opening at the HIV-1 Tat-binding site of TAR RNA evidenced by a rhodium probe. Biochemistry 34:6303-6309. Pyle, A.M., Long, E.C., and Barton, J.K. 1989. Shape-selective targeting of DNA by (phenanthrenequinone)rhodium(III) photocleaving agents. J. Am. Chem. Soc. 111:4520-4522. Pyle, A.M., Chiang, M.Y., and Barton, J.K. 1990. Synthesis and characterization of physical, electronic, and photochemical aspects of 9,10-phenanthrenequinone diimine complexes of ruthenium(II) and rhodium(III). Inorg. Chem. 29:4487-4495. Sitlani, A. and Barton, J.K. 1994. Sequence-specific recognition of DNA by phenathrenequinone diimine complexes of rhodium(III): Importance of steric and van der Waals interactions. Biochemistry 33:12100-12108. Sitlani, A., Long, E.C., Pyle, A.M., and Barton, J.K. 1992. DNA photocleavage by phenanthrenequinone diimine complexes of rhodium(III): Shape selective recognition and reaction. J. Am. Chem. Soc. 114:2303-2312.
Uchida, K., Pyle, A.M., Morii, T., and Barton, J.K. 1989. High resolution footprinting of EcoRI and distamycin with [Rh(phi)2(bpy)]3+, a new photofootprinting reagent. Nucl. Acids Res. 17:10259-10279. Wilson, W.D., Tanious, F.A., Fernandez-Saiz, M., and Rigl, C.T. 1997. Evaluation of drug-nucleic acid interactions by thermal melting curves. In Methods in Molecular Biology, Vol. 90: DrugDNA Interaction Protocols (K.R. Fox, ed.) pp. 219-240. Humana Press, Totowa, N.J. Yoshikawa, Y. and Yamasaki, K. 1979. Chromatographic resolution of metal complexes on Sephadex ion exchangers. Coord. Chem. Rev. 28:205-229.
Key References Campisi et al., 1994. See above. Examples of mapping the major and minor grooves of DNA with [Rh(phen)2(phi)]3+ and [Ru(TMP)3]2+. Chow et al., 1992. See above. Examples of mapping RNA structure using rhodium probes. Hartmann and Lavery, 1996. See above. This is an excellent review of recent work in DNA structural determinations of A-, B-, and Z-form DNA, mismatches, abasic sites, and bulges. As such, it provides an excellent overview of many of the targets these metal complex probes can be used to elucidate. Jackson and Barton, 1997. See above. Examples of using [Rh(bpy)2(chrysi)]3+ as a probe for DNA mismatches. Kirshenbaum et al., 1988. See above. Examples of site-selective cleavage of unusual structures in nucleic acids using [Rh(DIP)3]3+. Lim and Barton, 1997. See above. Example of [Ru(phen)3]2+ used as a guanine-specific sequencing reagent for nucleic acids. Uchida et al., 1989. See above. Examples of footprinting both major groove– and minor groove–binding molecules using rhodium probes.
Contributed by Brian A. Jackson and Jacqueline K. Barton California Institute of Technology Pasadena, California
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.2.39 Current Protocols in Nucleic Acid Chemistry
Probing RNA Structure by Lead Cleavage
UNIT 6.3
This unit describes the probing of RNA structure using Pb(II) ions. The Pb(II) hydroxide species has a relatively low pK a (∼7.7), which allows it to extract the proton from a 2′-hydroxyl group. In RNA, abstraction of a 2′ proton increases the nucleophilicity of the 2′ oxygen, facilitating attack on an adjacent phosphodiester bond. This transesterification reaction breaks the 5′,3′ phosphodiester backbone of the RNA to generate 2′,3′ cyclic phosphate and 5′-hydroxyl products. Since the efficiency of 2′ hydroxyl proton abstraction is related to steric and chemical constraints on particular 2′ OH groups embedded in the RNA structure, the Pb2+ cleavage rate can be used to examine the structure of individual nucleotides within an RNA molecule. This method is a particularly sensitive probe of the tertiary structure of an RNA, provided that appropriate Pb2+ binding sites are created in the tertiary structure. In order to detect the cleavage site and the cleavage rate by Pb2+, RNAs are labeled with 32 P at either the 5′ or 3′ end (see Support Protocol 1 and 2). The labeled RNA is then subjected to Pb2+ cleavage (see Basic Protocol). The reaction mixture is analyzed on denaturing polyacrylamide gels containing 8 M urea. Partial alkaline hydrolysis reaction products and nuclease T1 digests of the same labeled sample are run alongside the cleavage reaction products to accurately locate the cleavage site (see Support Protocol 4). For optimal results, RNA should be renatured after labeling to ensure conformational homogeneity (see Support Protocol 3 to determine proper renaturation conditions). Reverse transcription runoff (UNIT 6.1) can also be applied to detect cleavages in larger RNAs. CAUTION: All personnel should be trained in working with radioactivity. NOTE: Extremely careful precautions should be taken in doing RNA work. Wear disposable gloves at all times to prevent nuclease contamination from your hands. Use the highest-quality water available and autoclave water prior to all solution preparation. It is not usually necessary to treat the water with diethyl pyrocarbonate (DEPC) if all possible precautions are taken to avoid nuclease contamination. NOTE: Use silanized (low-adhesion) tubes for the cleavage reaction to minimize adsorption of RNA to the tube wall. This is especially critical if the reaction products are to be quantitated. PROBING THE RNA STRUCTURE BY Pb2+ CLEAVAGE If one is to obtain interpretable and reproducible results, there is much more to the Pb 2+ cleavage reaction than simply mixing all the components and taking aliquots over time. Since RNA can have different conformations depending on a variety of external factors, Pb2+ cleavage under one set of conditions may not accurately reflect the biologically relevant structures one seeks to analyze. Therefore, to ensure correct interpretation, optimization of reaction conditions should be performed (see Critical Parameters) prior to conducting the final experiment. This section describes the basic protocol for a standard Pb2+ cleavage reaction.
BASIC PROTOCOL
Materials 5′ or 3′ 32P-labeled RNA in water (see Support Protocols 1 and 2) 0.3 M buffer (see Critical Parameters) Urea loading buffer (APPENDIX 2A) Contributed by Tao Pan Current Protocols in Nucleic Acid Chemistry (2000) 6.3.1-6.3.9 Copyright © 2000 by John Wiley & Sons, Inc.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.3.1
Pb(OAc)2 stock solution prepared at 10× desired final concentration in reaction (see recipe for 10 mM solution) Heating block 3-mm filter paper (Whatman) Phosphorimager with appropriate software and phosphor screens Additional reagents and equipment for RNA renaturation (see Support Protocol 3), partial alkaline hydrolysis and T1 nuclease digestion (see Support Protocol 4), and denaturing polyacrylamide gel electrophoresis (see APPENDIX 3B) Cleave RNA 1. If necessary, renature RNA sample (see Support Protocol 3 to determine proper renaturation conditions). Renaturation is advisable if the RNA or source cells have been subjected to any potentially denaturing conditions; see Support Protocol 3 for details. Renaturation, which refers to folding, is different for every RNA. To obtain proper tertiary structure in vitro, [RNA], [Mg2+], and temperature will need to be varied. The exact amount of RNA to use should be determined empirically, as should the other parameters, when experimental conditions are optimized; however, enough RNA to give a concentration of 0.1 to 1 mM in 50 mL is a good starting point. See Critical Parameters for further discussion.
2. Dilute RNA to 50 µL with water and enough 0.3 M buffer to provide a 20 mM final buffer concentration. Renaturation should leave the RNA appropriately diluted.
3. Take a 4.5-µL aliquot of the RNA/buffer mix and mix with an equal volume of denaturing-gel loading buffer. This is the time-zero RNA sample.
4. Add 5 µL of 10× Pb(OAc)2 solution to the remaining RNA to initiate cleavage. Pb(OAc)2 concentration should be optimized with other experimental conditions; see Critical Parameters for discussion.
5. Incubate at 20° to 40°C. See Critical Parameters for discussion of reaction temperature.
6. Remove samples at selected time points: e.g., 5-µL aliquots at 0.5, 1, 2, 4, 8, 15, 30, and 60 min. To stop the reaction, mix an equal volume of urea loading buffer with each aliquot as it is taken. 7. Perform partial alkaline hydrolysis and T1 nuclease digestion of the same RNA (see Support Protocol 4). 8. Analyze the Pb2+ reaction mixture on a high-resolution denaturing polyacrylamide gel containing 8 M urea. Include samples of partial alkaline hydrolysis and T1 nuclease digestion reactions on the same gel. The author uses a 15% gel for a 76-mer RNA. Probing RNA Structure by Lead Cleavage
9. Compare the cleavage product band with the partial alkaline hydrolysis and T1 nuclease reaction bands to determine the cleavage site.
6.3.2 Current Protocols in Nucleic Acid Chemistry
Analyze data 10. Transfer the sequencing gel to a piece of 3-mm Whatman filter paper, cover with Saran Wrap, and dry. 11. Expose the gel on a phosphorimager plate at ambient temperature. Exposing the gel in a freezer does not improve the result although exposure at 4°C can lead to sharper bands.
12. Scan the phosphor plate and quantitate the full-length RNA using volume count, cpm substrate (S), and any reaction products of interest, cpm product (P): %S = cpm(S)/[cpm(S) + cpm(P)] 13. Plot ln(%S) versus reaction time and fit with a linear equation. The slope of the curve is the observed cleavage rate (kobs). The cleavage reaction may be biphasic when all time points are plotted on the same graph. This observation is often due to the heterogeneity of RNA conformation (see Support Protocol 3). In this case, use only the early time points, until ∼20% to 50% of the RNA are cleaved.
14. Compare kobs values for reactions under different conditions for optimal interpretation (see Commentary). 5′ 32P-LABELING OF RNA INCLUDING DEPHOSPHORYLATION RNA can be 32P labeled at the 5′ end with [γ-32P]ATP and T4 polynucleotide kinase. Chemically synthesized oligoribonucleotides generally contain a free 5′ hydroxyl group, which can be labeled directly. RNAs made by in vitro transcription generally contain a 5′ triphosphate group that has to be removed with alkaline phosphatase prior to the 5′ labeling reaction.
SUPPORT PROTOCOL 1
Label enough RNA for both the cleavage reaction (Basic Protocol) and the preparation of T1 and partial alkaline hydrolysis standards for electrophoresis (Support Protocol 4). Materials RNA sample in water 1 M Tris⋅Cl, pH 8.0 (APPENDIX 2A) 1 U/µL calf-intestine alkaline phosphatase Soaking buffer: 50 mM potassium acetate ( APPENDIX 2A)/200 mM KCl, pH ∼7 1:1 (v/v) phenol/chloroform (APPENDIX 2A) Ethanol 10× T4 polynucleotide kinase buffer (see recipe) [γ-32P]ATP (use highest activity available) T4 polynucleotide kinase Urea loading buffer (see APPENDIX 2A) Polyacrylamide gel containing 8 M urea Sodium acetate, pH 5.2 (APPENDIX 2A) Micropipettor Speedvac evaporator (e.g., Savant) X-ray film RNase-free surgical blade Additional reagents and equipment for denaturing polyacrylamide gel electrophoresis (see APPENDIX 3B)
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.3.3 Current Protocols in Nucleic Acid Chemistry
NOTE: If phosphatase treatment is not needed, proceed directly to step 7. NOTE: All microcentrifugations are performed at full speed. Remove 5′ triphosphate group 1. To 10 to 50 pmol RNA dissolved in water, add 1.5 µL of 1 M Tris⋅Cl, pH 8.0, and water to 29 µL. 2. Add 1 µL of 1 U/µL calf-intestine alkaline phosphatase. Incubate 30 min at 37°C. Purify phosphatase-cleaved RNA 3. Add 20 µL soaking buffer; then extract alkaline phosphatase with 50 µL of 1:1 (v/v) phenol/CHCl3, mix, and let stand 1 min at room temperature. Microcentrifuge 1 min and collect the top layer into a fresh tube. 4. Add 140 µL ethanol and incubate 20 min at −20°C. 5. Microcentrifuge 20 min at 4°C. Align tubes in the microcentrifuge so that the hinges of the tubes are facing the center of the rotor. The pellet will adhere to the tube on the side opposite the hinge.
6. Carefully pipet out the liquid. Dry the RNA pellet in a Speedvac evaporator. The pellet may not be visible to the naked eye.
Label RNA at 5′ end with 32P 7. To the RNA add in following order (10 µL final volume): 1 µL 10× T4 polynucleotide kinase buffer H2O 1 to 1.5 mol equiv [γ-32P]ATP 3 to 5 U T4 polynucleotide kinase. 8. Incubate 30 min at 37°C. Purify 5′-labeled RNA 9. Add 10 µL denaturing-gel loading buffer and purify on a denaturing polyacrylamide gel containing 7 M urea. The author uses a 10% gel for a 76-nucleotide RNA; see APPENDIX 3B.
10. Locate the radioactive band by exposing the gel briefly on X-ray film. Use a fluorescent ruler for orientation. If the RNA did not become labeled with phosphatase in step 2.
32
P, repeat using a new batch of alkaline
11. Develop the film and make a template that will be used to locate the band containing your RNA. 12. Lay the template on the gel, using the rulers as a guide. Cut out the RNA band with an RNase-free surgical blade. Elute RNA in the soaking buffer for at least 1 hr at ambient temperature.
Probing RNA Structure by Lead Cleavage
13. Add sodium acetate, pH 5.2, to 0.25 M (final) and 2.5 vol ethanol to precipitate the RNA. Mix and incubate at least 5 min on crushed dry ice or 30 min at –20°C. Microcentrifuge to remove supernatant. Dry the pellet and redissolve in 10 µL water.
6.3.4 Current Protocols in Nucleic Acid Chemistry
3′ 32P LABELING OF RNA USING T4 RNA LIGASE AND [32P]pCp RNA can be labeled at the 3′ end with 5′ [32P]pCp and T4 RNA ligase. Steps 1 to 3 describe the synthesis of 5′ [32P]pCp. For additional detail on the reaction, see 3′ RNA labeling in UNIT 6.1. In general, the RNA should be labeled such that at least 20,000 cpm will be loaded per lane.
SUPPORT PROTOCOL 2
Be sure to label enough RNA to have extra for the preparation of the sizing standards for electrophoresis (Support Protocol 4) in addition to what will be needed for the Basic Protocol. This procedure is designed for labeling 20 to 100 pmol RNA. Materials 10× T4 polynucleotide kinase buffer (see recipe) [γ-32P]ATP 3′ cytosine monophosphate (3′ Cp) T4 polynucleotide kinase Dimethyl sulfoxide (DMSO) 100 µM nonradioactive ATP T4 RNA ligase RNA sample in water Soaking buffer: 50 mM potassium acetate (APPENDIX 2A)/200 mM KCl, pH ∼7 Urea loading buffer (APPENDIX 2A) Additional reagents and equipment for purification of ligated RNA (see Support Protocol 1) NOTE: If commercial 5′ [32P]pCp (e.g., New England Nuclear) is used, proceed directly to step 4. Depending on the concentration supplied, use a quantity sufficient to provide the same molar ratio as achieved with [γ-32P]ATP. 1. Mix in the following order (20 µl final volume): 2 µL 10× T4 polynucleotide kinase buffer H2O 1 mol equiv [γ-32P]ATP to 3′ Cp (∼1 to 2 mol equiv RNA to be ligated) 3 to 5 U T4 polynucleotide kinase. 2. Incubate 30 min at 37°C. 3. Heat at 75°C for 3 min to inactivate kinase, then immediately place on ice for at least 3 min. 4. Add the following (30 µL final volume including RNA added in step 5): 3 µL 10× T4 polynucleotide kinase buffer (1× final) 4.5 µL DMSO (15% final) 1.8 µL 100 µM nonradioactive ATP (6 µM final) 0.7 U/µL T4 RNA ligase 5. Add ≤3 µL of RNA sample in water and incubate 4 to 19 hr at 16°C. If the RNA sample is too dilute, concentrate the RNA first in a Speedvac.
6. Add 30 µL urea loading buffer. Purify the ligated RNA as described for 5′-labeled molecules (see Support Protocol 1, steps 9 to 12).
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.3.5 Current Protocols in Nucleic Acid Chemistry
SUPPORT PROTOCOL 3
OPTIMIZATION OF RNA RENATURATION It is generally not difficult to observe Pb2+ cleavage of an RNA; however, caution is necessary for proper interpretation. RNAs are capable of forming multiple conformations that may be kinetically trapped (Uhlenbeck, 1995). This is particularly true for RNAs that are purified from denaturing polyacrylamide gels. For those RNAs, a renaturation step is mandatory to ensure conformational homogeneity. For RNAs that are isolated from cell extracts and have not gone through any steps that are likely to cause denaturation, renaturation is probably not necessary. However, if the cell extract has been subjected to the presence of millimolar amounts of EDTA, high temperature (>60°C), or phenol extraction, the RNA may have been denatured and renaturation should be attempted. The following procedure should be used to determine optimal conditions for renaturing a particular RNA species. Materials RNA sample in water MES, MOPS, or HEPES buffer MgCl2 stock solution, prepared at 10× desired final concentration in reaction (APPENDIX 2A for 1 M stock solution) Heating block Additional materials for nondenaturing polyacrylamide gel electrophoresis (see e.g., CPMB UNIT 2.7) 1. Mix RNA with buffer and water to obtain a final RNA concentration of ∼0.1 to 1 µM. Prepare triplicate tubes. 2. Heat 2 min at 85° to 90°C using a heating block. This step should denature any alternate secondary-structure conformers in the absence of divalent ions.
3. Take the sample out of the heating block. Either leave tube at room temperature for 3 min and then microcentrifuge briefly, or turn the heat block off and let the sample slowly cool to room temperature. The best method for cooling the sample will depend on the RNA and has to be determined empirically. In general, it is best to start with the slow cooling.
4. Add 10× MgCl2 solution to the desired Mg2+ concentration. Incubate tubes at three different temperatures (recommended: ambient, 37°C, and 50°C) for 10 min. To prevent nonspecific Mg2+-induced hydrolysis, do not heat the RNA to above ∼60°C in the presence of Mg2+.
5. Add other components, if required (e.g., 0.1 M KCl, 1 mM spermine). Incubate again at 37°C for 5 min. 6. Analyze all samples on a nondenaturing polyacrylamide gel (see, e.g., CPMB UNIT 2.7). 7. Assess the gel to determine which conditions produced the best renaturation, and use these when renaturing samples of this RNA species.
Probing RNA Structure by Lead Cleavage
Properly renatured RNA should show the following general properties when run on a nondenaturing gel (although these may differ among individual RNAs): (1) a single band on the gel, suggesting conformational homogeneity, and (2) fast migration relative to RNA in the absence of Mg2+, suggesting compactness. Most, if not all, RNAs with tertiary structure require the presence of a divalent ion (e.g., Mg2+) to renature correctly.
6.3.6 Current Protocols in Nucleic Acid Chemistry
PARTIAL ALKALINE HYDROLYSIS AND NUCLEASE T1 DIGESTION Aliquots of the end-labeled RNA are used to generate markers to size and analyze the Pb cleavage products. A ladder of truncated RNAs is generated by alkaline hydrolysis, while the T1 nuclease cleaves the RNA at guanosines.
SUPPORT PROTOCOL 4
Materials 5′- or 3′-end-labeled RNA (≥200,000 cpm; see Support Protocols 1 and 2) 1 mg/mL E. coli tRNA mixture (Sigma), dissolved in water 5× alkaline hydrolysis (AH) buffer: 5 mM glycine/2 mM MgSO4, pH 9.5 1 U/µL ribonuclease T1, diluted in water from a 100 U/µl stock (store up to ∼1 month at −20°C) Urea loading buffer (APPENDIX 2A) 100°C water bath 1. To 0.2 to 1.0 µl 5′- or 3′-end-labeled RNA, add water to 3 µL. Prepare two duplicate tubes. The exact amount of RNA will depend on the level of radioactivity.
2. Add 1 µL E. coli tRNA to each tube. This ensures that all reactions are carried out at a similar ratio of RNA to nuclease T1.
3. To one tube (alkaline hydrolysis condition), add 1 µL of 5× AH buffer, then boil 1 min, in a 100°C water bath. 4. To the second tube (T1 digestion condition), add 1 µL nuclease T1 (1 U), then incubate 2 min at 65°C. 5. Quick-cool 3 min on ice. CAUTION: Do not keep the T1 reaction mixture for >30 min, as T1 continues to cut RNA, even on ice.
6. Microcentrifuge briefly. 7. Add 5 µL urea loading buffer to each tube. The samples are now ready for use as size standards for comparison with the Pb2+ cleavage products.
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps; prepare all buffers with autoclaved water and then reautoclave. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Pb(OAc)2, 10 mM Dissolve solid Pb(OAc)2 in autoclaved water. Filter through 0.22-µm filters into sterile plastic tubes. Divide into aliquots and store at −70°C. Thaw and use one aliquot at a time; thawed aliquots can be stored at −20°C and used for ∼1 week. T4 polynucleotide kinase buffer, 10× 0.5 M Tris⋅Cl, pH 7.6 (APPENDIX 2A) 100 mM MgCl2 100 mM 2-mercaptoethanol Store up to ~1 year at –20°C
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.3.7 Current Protocols in Nucleic Acid Chemistry
COMMENTARY Background Information The basic mechanism whereby Pb2+ cleaves
Probing RNA Structure by Lead Cleavage
RNA is proton abstraction by the polyhydrated Pb(OH)+ species. Because of its low pKa (∼7.7), Pb(OH)+ is present in relatively high proportions at neutral pH. Compared to other divalent metal ions with higher pKa (e.g., Mg(H2O)5(OH)+ with a pKa of ∼11.4), Pb(OH)+ base induces cleavage of the RNA backbone much more frequently to result in faster “background rates,” defined as the cleavage rate of an RNA of any sequence independent of secondary or tertiary structure. For example, background rates have been measured at 50 µM Pb(OAc)2, 10 mM MgCl2, pH 7.0, 25°C to be ∼0.003 min−1 (half-life ∼4 hr; Pan and Uhlenbeck, 1992) and at 10 mM MgCl2, pH 7.5, 25°C to be ∼1 × 10−6 min−1 (half-life ∼11,000 hr; Hertel et al., 1994). Thus, the background rate for Pb2+ cleavage is within the time scale for an impatient experimentalist, and Pb2+ cleavage can be easily carried out in reasonable amount of time. It should be emphasized, however, that due to the peculiar properties of hydrated Pb(OH)+, the background rate does not necessarily increase linearly with total Pb2+ concentration (Kragten, 1978; Pan et al., 1994). The actual observed Pb2+ cleavage rate (kobs) is of course dependent on the RNA structure. The helical regions in RNA do not have the appropriate geometry for an in-line attack of the 2′ oxygen on its adjacent phosphate. Therefore, cleavage rates for nucleotide residues within an RNA helix are slower than the background rate. The completely unstructured regions in an RNA should be cleaved at the background rate. Hence, Pb2+ cleavage is a useful means for differentiating doublestranded from single-stranded regions in RNA. On the other hand, the single-stranded regions in RNA often have some kind of structure that can either enhance or inhibit the cleavage mechanism. The observed cleavage rates for nonhelical regions are often uneven. Nevertheless, without a specific Pb2+ binding site on the RNA (see below), cleavage of nonhelical regions rarely exceeds 10-fold the background rate. Pb2+ ion(s) bound at well-defined sites in an RNA can significantly increase the cleavage rate at specific sites. These so-called “specific cleavage” reactions can have cleavage rates >1000-fold above the background rate (Pan and Uhlenbeck, 1992). Cleavage of yeast tRNAPhe is the most extensively studied case of a specific
cleavage reaction by Pb2+. Three Pb2+ binding sites have been found in the crystal structure of this tRNA, only one of which, Pb(1), results in specific RNA cleavage (Brown et al., 1985). Pb(1) is directly coordinated to nucleotides U59 and C60 in the TψC loop and cleaves the phosphodiester between U17 and G18 in the D loop. Site-directed mutagenesis of yeast tRNAPhe shows that the cleavage rate is sensitive to subtle changes in the tertiary structure of tRNA (Behlen et al., 1990). The Pb2+ cleavage rates are well-suited to assessment of structural changes in the tRNA tertiary fold upon mutations or site-specific modifications.
Critical Parameters The three essential components of the cleavage reaction, RNA, Pb2+, and Mg2+, can act cooperatively to influence the cleavage rate. As a polyanion, RNA can bind divalent ions nonspecifically to decrease the concentration of free divalent ions in solution, so high concentrations of RNA should be avoided. On the other hand, nonspecific adsorption of RNA on the wall of a test tube can cause inaccurate measurement of cleavage rates, and this is exacerbated by low RNA concentration (the use of silanized tubes alleviates, but does not eliminate, this problem). Therefore, the RNA concentration in the reaction should be kept at ∼20 to 200 µM in phosphate (e.g., yeast tRNAPhe = 76 phosphates). Use of >5 mM Pb2+ is not recommended since higher concentrations generate insoluble polyhydroxides that can coaggregate RNA, and aggregated RNA may be cleaved differently than RNA that is free in solution. How much Pb2+ to use in the reaction will depend on the concentration of Mg2+, which can compete with Pb2+ binding to RNA. The Pb2+/Mg2+ ratio is especially important for specific Pb2+ cleavage reactions since Mg2+ may bind at the same site or at an overlapping site to exclude simultaneous binding of Pb2+. To maintain the RNA structure, Mg2+ concentration should be kept at 1 to 100 mM. A 1:50 [Pb2+]/[Mg2+] ratio may be a good starting point for experimental optimization. pH and temperature of the reaction also play a role in producing optimal results. Since the cleavage rate is often proportional to Pb(OH)+ concentration, the reaction rate can be log-linearly dependent with pH below the pKa of Pb(OH)+. At pH above ∼7.5, Pb2+ is more prone to form polyhydroxide aggregates. Therefore, Pb2+ cleavage should be carried out between
6.3.8 Current Protocols in Nucleic Acid Chemistry
pH 6.0 and 7.7 (neutral pH is a good compromise). For the 0.3 M buffer, use MES, MOPS, or HEPES buffers prepared at an appropriate pH in autoclaved water, divided into aliquots, and reautoclaved. Inorganic buffers such as phosphates should not be used, since they may form insoluble salts with Pb2+. Higher temperature accelerates the cleavage rate but may destabilize the RNA structure to result in unintended cleavage sites. On the other hand, kinetically trapped alternate conformers of RNA are more stable at low temperature. Therefore, the reaction temperature should be kept between 20° and 40°C. Interpretation of cleavage results should be based only on primary cleavages, defined as the first cleavage event within the full-length molecule. It is possible, or even likely, that cleaving the backbone at one site can result in a conformational change in RNA to allow it be cleaved at other sites. These secondary cleavage sites are characterized by an initial lag in the kinetic analysis of the cleavage product. Therefore, it is crucial to perform time courses to ensure that interpretation is not based on secondary cleavage reactions.
Anticipated Results The cleavage rates at individual sites can be used to deduce information on the structure of RNA and on structural changes resulting from mutations or other modifications. Cleavage of residues is generally faster in nonhelical regions than in helical regions, so cleavage rates can reflect the involvement of particular residues in the secondary structure. Cleavage at specific sites can be sensitive to structural changes. Based on Pb2+ cleavage alone, however, the precise molecular nature of such structural changes is difficult to understand; it requires further investigation by other methods. Finally, protein binding to an RNA can sterically hinder the access of the reaction site. Therefore, it should be possible to deduce some
kind of “footprint” of a protein binding site by Pb2+ cleavage. Protein binding may also change the conformation of the RNA in the complex to enhance cleavage at other sites. The enhanced cleavage rates at such sites may be an excellent indication of conformational changes of RNA upon protein binding.
Time Considerations All procedures in this unit are simple and can be completed in 2 days. Day 1 involves 32P labeling and gel purification (see Support Protocols 1 and 2). Day 2 involves Pb2+ cleavage and gel analysis (see Basic Protocol). An extra day is needed for optimizing renaturation conditions (see Support Protocol 3).
Literature Cited Behlen, L.S., Sampson, J.R., DiRenzo, A.B., and Uhlenbeck, C. 1990. Lead-catalyzed cleavage of yeast tRNAPhe mutant. Biochemistry 29:25152523. Brown, R., Dewan, J., and Klug, A. 1985. Crystallographic and biochemical investigation of the lead(II)-catalyzed hydrolysis of yeast phenylalanine tRNA. Biochemistry 24:4785-4801. Hertel, K.J., Herschlag, D., and Uhlenbeck, O.C. 1994. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry 33:3374-3385. Kragten, J. 1978. Atlas of Metal-Ligand Equilibria in Aqueous Solution. Halsted Press, Chichester, UK. Pan, T. and Uhlenbeck, O.C. 1992. A small metalloribozyme with a two-step mechanism. Nature 358:560-563. Pan, T., Dichtl, B., and Uhlenbeck, O.C. 1994. Properties of an in vitro selected Pb2+ cleavage motif. Biochemistry 33:9561-9565. Uhlenbeck, O.C. 1995. Keeping RNA happy. RNA 1:4-6.
Contributed by Tao Pan University of Chicago Chicago, Illinois
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.3.9 Current Protocols in Nucleic Acid Chemistry
Probing Nucleic Acid Structure with Nickeland Cobalt-Based Reagents
UNIT 6.4
Use and application of nickel and cobalt reagents are described for characterizing the solvent exposure of guanine residues within DNA and RNA. These reagents promote guanine oxidation in the presence of a peracid such as monopersulfate, and the extent of reaction indicates the steric and electronic environment surrounding the N7 and aromatic face of this residue. Together with the complementary reagents described elsewhere in this chapter, the secondary and tertiary solution structure of polynucleotides may be deduced. Very low concentrations of the metal reagents are sufficient to promote guanine oxidation under near physiological conditions (see Basic Protocol). Nucleic acid recognition and oxidation does not perturb target structure or result in direct strand scission. Therefore, secondary procedures are necessary to identify sites of reaction. For polynucleotides of <200 to 300 residues, guanine oxidation is most conveniently detected by its induction of strand fragmentation upon treatment with piperidine (DNA; see Support Protocol) or aniline acetate (RNA; see UNIT 6.1). For larger polynucleotides, guanine oxidation is detected by its characteristic termination of primer extension (UNIT 6.1). Although the nickel reagent demonstrates the greatest specificity, the cobalt reagent maintains its selectivity at high temperatures and salt concentrations that are not compatible with the nickel reagent. NICKEL- AND COBALT-DEPENDENT OXIDATION OF NUCLEIC ACIDS This protocol describes a method for selectively oxidizing guanine residues (RNA or DNA) that do not stack within a double-helical structure. After excess oxidant is quenched and removed, the modified guanines are detected by procedures common to nucleic acid sequencing. These include either direct strand scission by subsequent treatment with piperidine (DNA) or aniline acetate (RNA) or termination of primer extension. The resulting polynucleotides are then separated and identified by denaturing gel electrophoresis.
BASIC PROTOCOL
CAUTION: Perchlorate is often used as a counter ion to the nickel complexes. Perchlorate salts containing organic materials are potentially explosive and should be handled carefully and in small quantities. Materials 1 µg/µL carrier DNA or RNA 100 mM potassium phosphate buffer, pH 7 (APPENDIX 2A) 1 M NaCl in water RNA or DNA sample: 30,000 cpm end-labeled (UNIT 6.1 or UNIT 6.3) or 1 pmol unlabeled 60 µM [NiCR](PF6)2 solution (see recipe and Fig. 6.4.1) or 60 µM CoCl2 in water 0.6 mg/mL OXONE solution (see recipe) 20 mM HEPES/100 mM EDTA, pH 7, in water NaOAc/EDTA/Tris solution (see recipe) 1 mM EDTA, pH 8 (APPENDIX 2A) Microdialyzer Lyophilizer Contributed by Steven E. Rokita and Cynthia J. Burrows Current Protocols in Nucleic Acid Chemistry (2000) 6.4.1-6.4.7 Copyright © 2000 by John Wiley & Sons, Inc.
Chemical and Enzymatic Probes For Nucleic Acid Structure
6.4.1
Additional reagents and equipment for phenol/chloroform extraction and ethanol precipitation (APPENDIX 2A and, e.g., CPMB UNIT 2.1A), piperidine treatment (see Support Protocol), aniline acetate treatment (UNIT 6.1), PAGE (e.g., APPENDIX 3B or CPMB UNIT 7.6), partial alkaline hydrolysis and T1 nuclease digestion (UNIT 6.1), and primer extension (UNIT 6.1) Oxidize nucleic acid 1. Combine the following in a microcentrifuge tube: 2 µL 100 mM potassium phosphate buffer 2 µL 1 M NaCl 6 µL 1 µg/µL carrier RNA or DNA. Other buffers may also be used (see Critical Parameters).
2. Add 30,000 cpm end-labeled RNA or DNA, or 1 pmol unlabeled RNA or DNA (for primer extension), and sufficient deionized water to obtain a total volume of 18 µL. If the sample is <250 residues in length, it should be 5′ or 3′ end labeled with 32P, permitting detection of the modified sites after chemical cleavage and electrophoretic separation. Longer samples should not be end labeled; these will be analyzed via primer extension. CPMB provides additional labeling methods, see e.g., CPMB UNITS 3.5, 3.6 & 3.10.
3. Initiate reaction by adding the following (total 20 µL/tube), vortexing, and incubating for 30 min at room temperature: 1 µL 0.6 mg/mL OXONE solution 1 µL 60 µM [NiCR](PF6)2 or CoCl2 This amount of OXONE results in a final concentration of 0.1 mM potassium peroxymonosulfate (KHSO5) in the reaction. The extent of target modification can be controlled by adjusting a number of parameters (see Critical Parameters).
Stop reaction and purify sample 4a. For subsequent piperidine treatment: Stop reaction by adding 2 µL of 20 mM HEPES/100 mM EDTA and vortex. Dialyze oxidized samples in a microdialyzer against 1 mM EDTA, pH 8 (twice) and deionized water (once) to remove the inorganic salts. Lyophilize the dialysate. The resulting material may be analyzed immediately or stored at −20°C for >1 week.
4b. For subsequent primer extension: Stop reaction by adding 180 µL NaOAc/EDTA/ Tris solution and vortexing. Extract with phenol/chloroform (see APPENDIX 2A and CPMB UNIT 2.1A). Precipitate DNA by adding 3 vol ethanol, incubating 60 min at −20°C, and microcentrifuging 10 min at 4°C. Remove supernatant, rinse with ethanol, microcentrifuge, and remove supernatant. Dry the pellet. (Also see CPMB UNIT 2.1A.)
2+ R N N
Probing Nucleic Acid Structure with Nickel- and Cobalt-Based Reagents
N Ni N H NiCR
Figure 6.4.1
NH2
N
NH N
DNA
N
KHSO5
III N N Ni N N
O
guanosine oxidation
OOSO3
The mechanistic basis for specific oxidation of guanine.
6.4.2 Current Protocols in Nucleic Acid Chemistry
Dialysis can be omitted for large RNA and for large DNA that is easily precipitated; however, precipitation alone is often not sufficient to purify RNA/DNA for subsequent analysis. The resulting material may be analyzed immediately or stored at −20°C for >1 week.
Identify sites of oxidation 5a. Chemical cleavage: For polynucleotides of <250 residues, assess modification sites by their characteristic strand scission after treatment with piperidine (for DNA; see Support Protocol; see CPMB UNIT 7.5) or aniline acetate (for RNA; Peattie and Gilbert, 1980; see DMS modification and cleavage of RNA, steps 8 and 9, in UNIT 6.1). Determine the ultimate profile of strand fragmentation by denaturing polyacrylamide gel electrophoresis (PAGE; e.g., APPENDIX 3B or CPMB UNIT 7.6). For RNA samples, subject aliquots of labeled RNA to partial alkaline hydrolysis and T1 nuclease digestion to use as sizing standards on the gel (UNIT 6.1). 5b. Termination of primer extension: For polynucleotides >250 residues, assess modified sites by determining their ability to terminate extension of a radiolabeled primer. Use this procedure for both DNA and RNA (Woodson et al., 1993; see UNIT 6.1).
DNA STRAND SCISSION BY PIPERIDINE TREATMENT DNA samples ≤250 nucleotides in length that were modified at exposed guanines using the nickel and cobalt reagents described in Basic Protocol 1 can be analyzed by treatment with piperidine. Piperidine causes strand scission at the modified guanine residues. The resulting DNA fragments can then be analyzed by denaturing polyacrylamide gel electrophoresis.
SUPPORT PROTOCOL
Materials Modified DNA sample pellet (see Basic Protocol) 0.2 M piperidine, freshly prepared in sterile water 1.5-mL screw-cap microcentrifuge tubes 90°C water bath Speedvac evaporator 1. Resuspend modified DNA sample pellets in 20 µL of 0.2 M piperidine. 2. Transfer samples to 1.5-mL screw-cap microcentrifuge tubes, tightly cap the tubes, and incubate 30 min at 90°C. During this reaction, the tubes must be tightly sealed to prevent piperidine loss.
3. Microcentrifuge tubes briefly to collect any condensate from the sides of the tubes. Transfer the tubes to a Speedvac evaporator and evaporate the piperidine to dryness. 4. Resuspend dried samples in 30 µL sterile water, transfer to new tubes, and dry in a Speedvac evaporator. 5. Repeat step 4 using 30 µL sterile water. Failure to completely remove piperidine will result in smearing of bands on the sequencing gel. The samples are now ready for gel fractionation by PAGE (e.g., APPENDIX 3B or CPMB UNIT 7.6).
Chemical and Enzymatic Probes For Nucleic Acid Structure
6.4.3 Current Protocols in Nucleic Acid Chemistry
REAGENTS AND SOLUTIONS Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
NaOAc/EDTA/Tris solution 0.3 M NaOAc 10 mM EDTA 10 mM Tris⋅Cl, pH 7.6 (APPENDIX 2A) 0.5% (w/v) SDS Store up to 1 month at 4°C [NiCR](PF6)2 solution, 60 mM This complex is prepared according to Karn and Busch (1969) except that NaPF6 is used in place of NaClO4 and HClO4 (see caution below). [NiCR](PF6)2 is also available from the authors’ laboratories upon written request. A concentrated aqueous solution of [NiCR](PF6)2 (0.3 mM; 0.36 mg/mL) is stable for several months when stored at 4°C and protected from ambient light. Aliquots may be diluted to a working stock solution of 60 µM as needed. [Ni(II)cyclam](ClO4)2 (see recipe) may be used as an alternative to [NiCR](PF6)2 . However, Ni(cyclam) is less efficient than [NiCR](PF6)2. CAUTION: Perchlorate is often used as a counter ion to the nickel complexes. Perchlorate salts containing organic materials are potentially explosive and should be handled carefully and in small quantities.
[Ni(II)cyclam](ClO4)2 Dissolve 0.110 g 1,4,8,11-tetraazacyclotetradecane (cyclam; 0.55 mmol) in 10 mL ethanol and heat to 60°C. In a separate container, dissolve 0.200 g (0.55 mmol) Ni(ClO4)2⋅6H2O in 5 mL ethanol, and add in a dropwise fashion to the warm cyclam solution. Stir the resulting orange suspension at 60°C for an additional 10 min and then cool to room temperature. Collect the yellow product by vacuum filtration and wash with ice-cold ethanol. Use in the same fashion as [NiCR](PF6)2. Ni(II)cyclam is easily prepared from commercially available materials (Martin et al., 1977) with a recovered yield of 0.243g (96%). CAUTION: Perchlorate is often used as a counter ion to the nickel complexes. Perchlorate salts containing organic materials are potentially explosive and should be handled carefully and in small quantities.
OXONE solution, 0.6 mg/mL Dissolve 6 mg 2KHSO5⋅KHSO4⋅K2SO4 (OXONE; Sigma, Aldrich) in 10 mL deionized water (final 2 mM KHSO5). Prepare fresh each day. The suggested concentration refers to KHSO5 only.
COMMENTARY Background Information
Probing Nucleic Acid Structure with Nickel- and Cobalt-Based Reagents
Chemical and enzymatic probes are essential for characterizing nucleic acid structure when nuclear magnetic resonance and crystallography are not appropriate or possible (Ehresmann et al., 1987; Knapp, 1989; Nielsen, 1990). The variable extent of modification induced by each reagent indicates the relative accessibility of its target site. Information on multiple sites may in turn be used to predict the three-dimensional structure of
a polynucleotide. Although a limited analysis may provide some conformational data, most reliable structures are derived from the results of a broad series of experiments using a variety of probes that examine each functional region of each residue. Such an effort is necessary because the accessibility of one region of a nucleotide will not necessarily predict the accessibility of another region. For example, exposure of the phosphoribose backbone and N7 of guanine in the Tetrahymena group I intron
6.4.4 Current Protocols in Nucleic Acid Chemistry
RNA were found to be independent (Chen et al., 1993). The use of multiple probes to characterize a particular site is also often recommended to compensate for the inherent limitations of each reagent (Zheng et al., 1998). The solvent accessibility of guanine N7 has typically been examined by its alkylation with dimethyl sulfate (Ehresmann et al., 1987; Nielsen, 1990; UNIT 6.1). Failure to react suggests that a polynucleotide tertiary structure blocks access to this site. In contrast, variation in secondary structure does not significantly affect this reaction. Diethylpyrocarbonate (DEPC; UNIT 6.1) is more sensitive to base stacking within helical polynucleotides, but it is also much more efficient at adenine N7 than guanine N7 modification (Conway and Wikens, 1989). The structural environment of guanine N7 in RNA may also be investigated with RNase T1 (UNIT 6.1), but this enzyme requires access to the N1, O6, and N7 positions of guanine for activity (Heinemann and Saenger, 1985) and may disrupt local structure during substrate turnover (Zheng et al., 1998). The nickel reagent appears to bind directly to guanine N7 and deliver its oxidizing equivalent specifically to this guanine (Fig. 6.4.1). The intermediate size of the nickel complex provides for greater selectivity than dimethyl sulfate, and provides access to more target sites than is possible for a macromolecule such as RNase T1. Nickel-dependent oxidation is selective for guanine residues that are not held within canonical A or B helices (Chen et al., 1992, 1993). Modification occurs at extrahelical and single-stranded guanines in addition to base-paired guanines at a helical terminus or junction (Chen et al., 1992, 1993). Since this probe does not affect the structure of its target, its relative ability to oxidize guanine has been a very strong indicator of both static and dynamic conformations of DNA and RNA (Chen et al., 1993; Shih et al., 1998). Cobalt provides a complementary probe for guanine structure by generating a diffusible rather than metal-bound oxidant. Simple inorganic salts of cobalt, in contrast to nickel, are sufficient to catalyze formation of the sulfate radical from KHSO5 (Muller et al., 1996). [CoII(H2O)5(OH)]+ + HSO5−→[CoIII(H2O)5O]+
+ SO•− 4 + H2O
This radical exhibits an inherent specificity for guanine relative to the other bases and the phosphoribose backbone. More importantly,
guanine residues with highly accessible aromatic faces are most rapidly oxidized. The profiles of cobalt- and nickel-induced modification are often similar (Muller et al., 1996; Zheng et al., 1998), but will differ significantly when the environments surrounding the N7 and aromatic face of guanine are not equivalent (e.g., tRNAPhe; Muller et al., 1996). Overall, the conformational selectivity of cobalt is less than that of nickel, as expected for the smaller size of the cobalt- versus nickel-dependent oxidants. Comparative investigations based on these two probes are also useful for determining the influence of electrostatic potential on modification. The anionic sulfate radical generated by cobalt and the cationic radical-nickel complex may respond to surface charge in the opposite manner.
Critical Parameters The oxidation protocol described in this unit may be used as a starting point or guide for characterizing a variety of polynucleotides under different conditions. Typically, nucleic acid structure should be examined under conditions optimized for the nucleic acid’s natural function rather than for chemical modification. Variations in reaction and quenching conditions are described in the cited literature and other studies based on these reagents. Buffers and temperature. Contamination of the nucleic acid may inhibit the oxidative process. Buffers such as phosphate, Tris, and cacodylate are compatible with the nickel- and cobalt-dependent reactions. However, the Good buffers (for example, MOPS, MES, HEPES), EDTA, and thiols quench the reaction. Borate also inhibits the guanine-specific reaction and seems instead to promote variable modification of all polynucleotides. In addition, the nickel reagent is inhibited by high concentrations of salt (>1 M NaCl or NaClO4) and appears to decompose in the presence of KHSO5 at temperatures above 35°C. Although the cobalt reagent is also inhibited by NaCl, it remains active in the presence of 4 M NaClO4 and at temperatures above 80°C. Both reagents tolerate the presence of MgCl2, a common counterion required to form native RNA structure. Finally, bromide salts should be avoided as KHSO5 will oxidize bromide, which in turn leads to modification of C residues (Ross and Burrows, 1996). Extent of reaction. Oxidation should be limited to approximately 10% of the initial target nucleic acid in order to minimize secondary reactions of the oxidized products. The extent
Chemical and Enzymatic Probes For Nucleic Acid Structure
6.4.5 Current Protocols in Nucleic Acid Chemistry
of target modification is best controlled by increasing or decreasing the concentration of KHSO5, although the concentration of nickel and cobalt reagents as well as incubation time and temperature may also be varied. A common cause for a lack of reaction is the use of a KHSO5 solution that is not prepared fresh daily or the use of a metal solution that has been stored for an excessive time (typically >3 months). Old reagents may also induce abnormal reactions of uridine residues in RNA. If primer extension is used to detect sites of oxidation, phenol/chloroform extraction of the polynucleotide is generally required. This procedure likely removes and quenches materials that might otherwise inhibit polymerase activity.
Anticipated Results
Probing Nucleic Acid Structure with Nickel- and Cobalt-Based Reagents
The nickel complexes most readily oxidize guanine residues with highly accessible N7 positions, and the extent of reaction is indicative of the relative accessibility and electrostatic environment surrounding this position. In Aand B-helical structures of DNA and RNA, guanine N7 resides on the surface of the major groove, but is protected from reaction with nickel. Guanine residues are similarly unreactive when stacked within a duplex structure and paired in a noncanonical manner (Schmidt et al., 1995; Zheng et al., 1998). In contrast, guanine residues that are base paired at a helical junction or terminus are subject to nickel-dependent oxidation. The N7 of guanine within a Z helix is also exposed and demonstrates predictably high reactivity (Burrows et al., 1995). Guanines exhibiting the greatest reactivity are commonly those in highly disordered loops or single-stranded regions, and all guanines within such regions are oxidized with an equally high efficiency. When multiple structures are formed by a target nucleic acid, modification reflects the relative accessibility of each guanine weighted by the fractional concentration of its alternative conformations (Shih et al., 1998). The cobalt reagent generates equivalent data on guanine, except the extent of reaction is more dependent on the exposure of its aromatic surface than its N7 position (Muller et al., 1996). The specificity for unstacked guanine residues is also lower for cobalt- than nickeldependent oxidation. In the absence of an exposed target, both reagents will begin to oxidize guanine residues within a duplex in accord with their ionization potential. Therefore, under these conditions, the 5′ guanine of a GG se-
quence will react preferentially (Sugiyama and Saito, 1996; Burrows and Muller, 1998). Only one anomalous result has yet been detected with NiCR, and this, too, may provide useful structural data. Uridine residues are subject to direct strand scission if they are on the 3′ side of an adjacent uridine that forms a wobble base pair with guanine (5′-UU paired to 3′-GA; Hickerson et al., 1998).
Time Considerations Probing the structure of nucleic acids with nickel and cobalt reagents can be accomplished very rapidly and performed in tandem with other typical modification reactions. Samples can be left overnight to dialyze if this method is used for purification. Product characterization by strand scission (using piperidine or aniline acetate) or primer extension, followed by gel electrophoresis, can be completed on the second day.
Literature Cited Burrows, C.J. and Muller, J.G. 1998. Oxidative nucleobase modifications leading to strand scission. Chem. Rev. 98:1109-1151. Burrows, C.J., Muller, J.G., Shih, H.-C., and Rokita, S.E. 1995. Recognition of B vs. Z-form DNA using nickel and cobalt complexes. In Supramolecular Stereochemistry (J.S. Siegel, ed.) pp. 57-62. Kluwer Academic Publishers, Dordrecht, the Netherlands. Chen, X., Burrows, C.J., and Rokita, S.E. 1992. Conformation specific detection of guanosine in DNA: Ends, mismatches, bulges and loops. J. Am. Chem. Soc. 114:322-325. Chen, X., Woodson, S.A., Burrows, C.J., and Rokita, S.E. 1993. A highly sensitive probe for guanine N7 in folded structures of RNA: Application to tRNAphe and Tetrahymena group I intron. Biochemistry 32:7610-7616. Conway, L. and Wickens, M. 1989. Modification interference analysis of reactions using RNA substrates. Methods Enzymol. 180:369-377. Ehresmann, C., Baudin, F., Mougel, M., Romby, P., Ebel, J.-P., and Ehresmann, B. 1987. Probing the structure of RNAs in solution. Nucl. Acids Res. 15:9109-9128. Heinemann, U. and Saenger, W. 1985. Mechanism of guanosine recognition and RNA hydrolysis by RNase T1. Pure Appl. Chem. 57:417-422. Hickerson, R.P., Watkins-Sims, C.D., Burrows, C.J., Atkins, J.F., Gesteland, R.F., and Felden, B. 1998. A nickel complex cleaves uridines in folded RNA structures: Application to E. coli tmRNA and related engineered molecules. J. Mol. Biol. 279:577-587.
6.4.6 Current Protocols in Nucleic Acid Chemistry
Karn, J.L. and Busch, D.H. 1969. Nickel(II) complexes of the new macrocyclic ligands meso- and rac-2,12-dimethyl-3,7,11,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-triene. Inorg. Chem. 8:1149-1153. Knapp, G. 1989. Enzymatic approaches to probing of RNA secondary and tertiary structure. Methods Enzymol. 180:192-212. Martin, L.Y., Sperati, C.R., and Busch, D.H. 1977. The spectrochemical properties of tetragonal complexes of high spin nickel(II) containing macrocyclic ligands. J. Am. Chem. Soc. 99:29682981. Muller, J.G., Zheng, P., Rokita, S.E., and Burrows, C.J. 1996. DNA modification promoted by [Co(H2O)6]Cl2: Probing temperature-dependent conformations. J. Am. Chem. Soc. 118:23202325. Nielsen, P.E. 1990. Chemical and photochemical probing of DNA complexes. J. Mol. Recognit. 3:1-25. Peattie, D.A. and Gilbert, W. 1980. Chemical probes for higher-order structure in RNA. Proc. Natl. Acad. Sci. U.S.A. 77:4679-4682. Ross, S.A., and Burrows, C.J. 1996. Cytosine-specific chemical probing of DNA using bromide and monoperoxysulfate. Nucl. Acids Res. 24:5062-5063. Schmidt, M., Zheng, P., and Delihas, N. 1995. Secondary structures of Escherichai coli antisense micF RNA, the 5′-end of the target ompF mRNA, and the RNA/RNA duplex. Biochemistry 34:3621-3631. Shih, H.-C, Tang, N., Burrows, C.J., and Rokita, S.E. 1998. Nickel-based probes of nucleic acid structure bind to guanine but do not perturb a dynamic equilibrium of extrahelical guanine residues J. Am. Chem. Soc. 120:3284-3288. Sugiyama, H. and Saito, I. 1996. Theoretical studies of GG-specific photocleavage of DNA via electron transfer: Significant lowering of ionization potential and 5′-localization of HOMO of GG bases in B-form DNA. J. Am. Chem. Soc. 118:7063-7068.
Woodson, S.A., Muller, J.G., Burrows, C.J., and Rokita, S.E. 1993. A primer extension assay for modification of guanine by Ni(II) complexes. Nucl. Acids Res. 21:5524-5525. Zheng, P., Burrows, C.J., and Rokita, S.E. 1998 Nickel- and cobalt-dependent reagents identify structural features of RNA that are not detected by dimethyl sulfate or RNase T1. Biochemistry 37:2207-2214.
Key References Burrows, C.J. and Rokita, S.E. 1994. Probing guanine structure in nucleic acid folding using nickel complexes. Acc. Chem. Res. 27:295-301. A comprehensive review on various nickel-based reagents. Burrows, C.J. and Rokita, S.E. 1995. Nickel complexes as probes of guanine sites in nucleic acid folding. In Metal Ions in Biological Systems (H. Sigel, ed.) pp. 537-560. Marcel Dekker, New York. The most recent review covering applications from various laboratories. Rokita, S.E., Zheng, P., Tang, N., Cheng, C.-C., Yeh, R.-H., Muller, J.G., and Burrows, C.J. 1995. Nickel complexes in modification of nucleic acids. In Genetic Response to Metals (B. Sarkar, ed.) pp. 201-216. Marcel Dekker, New York. A summary of initial mechanistic studies.
Contributed by Steven E. Rokita University of Maryland College Park, Maryland Cynthia J. Burrows University of Utah Salt Lake City, Utah
Chemical and Enzymatic Probes For Nucleic Acid Structure
6.4.7 Current Protocols in Nucleic Acid Chemistry
Probing RNA Structures with Hydroxyl Radicals
UNIT 6.5
Iron(II)-EDTA is the principal reagent whereby one can conveniently generate hydroxyl radicals to promote cleavage of RNA at nucleotide resolution. In this unit, the Basic Protocol describes the simplest cleavage conditions, whereby free radicals originate from solvated molecular oxygen, while the Alternate Protocol outlines a more elaborate procedure commonly used to generate free radicals from hydrogen peroxide added to solution. In both procedures, Fe(II)-EDTA is added to solution mixtures containing end-labeled RNA, either alone or equilibrated with another ligand (e.g., protein), to allow for oxidative strand scission of the RNA chain under neutral buffer conditions. A similar cleavage pattern is observed using either method. CAUTION: When working with radioactivity, take appropriate precautions to avoid contamination of the experimenter and the surroundings. Carry out the experiment and dispose of wastes in an appropriately designated area, following the guidelines provided by the local radiation safety officer. NOTE: Experiments involving RNA require careful precautions to prevent contamination and RNA degradation (see APPENDIX 2A). NOTE: All reagents should be ≥99% purity. All solutions must be prepared fresh in sterile water immediately before use and should be discarded thereafter. STRAND SCISSION OF RNA USING O2-DERIVED FREE RADICALS For strand scission of RNA using free radicals derived from solvated oxygen, 5′- or 3′-end-labeled RNA is equilibrated under the desired buffer or ligand-binding conditions. The Fe(II)-EDTA mixture and a suitable reducing agent are added to the RNA mixture to initiate the strand scission reaction and, after a 1- to 2-hr incubation, the free-radical reaction is quenched. The RNA is then directly processed alongside sequencing standards on a denaturing polyacrylamide gel to resolve the cleavage products.
BASIC PROTOCOL
Materials End-labeled RNA with a specific activity ≥2 × 106 dpm/pmol (UNIT 6.1) Appropriate buffers and RNA-binding ligands (see Critical Parameters) 1,4-Dithiothreitol (DTT; store at −20°C) (NH4)2Fe(II)(SO4)2⋅6H2O powder (store at room temperature) 200 mM Na2EDTA, pH 8.0 (APPENDIX 2A), prepared in sterile water 100 mM thiourea in sterile water (store at 4°C) 2× urea loading buffer (APPENDIX 2A) T1 nuclease digest and alkaline hydrolysis of end-labeled RNA ( UNIT 6.1) Distilled, deionized water, autoclaved before use 0.5- and 1.5-mL polypropylene microcentrifuge tubes, sterile RNase-free micropipettors and tips Water bath or suitable incubator Radioanalytic detection instrument or autoradiography film Additional reagents and equipment for denaturing polyacrylamide gel electrophoresis (PAGE; see APPENDIX 3B) Chemical and Enzymatic Probes for Nucleic Acid Structure Contributed by Daniel W. Celander Current Protocols in Nucleic Acid Chemistry (2000) 6.5.1-6.5.6 Copyright © 2000 by John Wiley & Sons, Inc.
6.5.1
1. Combine 0.1 pmol end-labeled RNA, the buffer components (e.g., buffers or simple salts), any additional RNA-binding ligands (e.g., proteins), and water to a total volume of 8 µL in a 0.5-mL polypropylene tube. Prepare an identical tube as a control. Incubate the mixture at the desired temperature until equilibrium is achieved. The buffers, incubation temperature, and the time required to achieve equilibration of the folded RNA with any additional ligands must be determined independently by the investigator (see Critical Parameters).
2. During equilibration, dissolve 7.7 mg DTT in 1 mL sterile water (final 50 mM) in a 1.5-mL microcentrifuge tube. This solution should be made fresh immediately before use.
3. Add 39.4 mg (NH4)2Fe(II)(SO4)2⋅6H2O to a sterile microcentrifuge tube and store in the dark until use. 4. Once the RNA solution has achieved equilibrium, prepare the Fe(II)-EDTA solution for immediate addition to the RNA solution. Add 1 mL sterile water to the tube containing (NH4)2Fe(II)(SO4)2⋅6H2O (final 100 mM) and vortex well to completely dissolve. In a separate polypropylene microcentrifuge tube, combine 10 µL of this solution with 10 µL of 200 mM Na2EDTA solution and 80 µL sterile water, yielding 10 mM Fe(II) and 20 mM EDTA. Vortex well. 5. Immediately add 1 µL Fe(II)-EDTA solution and 1 µL of 50 mM DTT solution to the RNA mixture to yield a final volume of 10 µL containing 1 mM Fe(II), 2 mM EDTA, and 5 mM DTT. Add 2 µL sterile water to the control tube. The remaining DTT and Fe(II)-EDTA solutions should be discarded following their use.
6. Incubate the reaction mixture for 1 to 2 hr at the desired temperature. The indicated time period is sufficient to generate a partial digest pattern of end-labeled RNA under single-hit conditions (see Commentary). The cleavage reaction displays a modest temperature dependence; nevertheless, suitable cleavage profiles have been obtained for reactions performed at temperatures ranging from 0° to 50°C (Celander and Cech, 1991).
7. Add 1 µL of 100 mM thiourea to quench the free radical reaction. Also add thiourea to the control tube. 8. Add an equal volume of 2× urea loading buffer to each tube. If larger reaction volumes are used, the RNA should be precipitated from ethanol before the addition of urea loading buffer. At this point, the reaction samples can be stored up to several days at −20°C.
9. Fractionate the reaction mixture on a denaturing polyacrylamide gel (8% to 20%; APPENDIX 3B), using a T1 digest and an alkaline hydrolysis of the original end-labeled RNA as a sequencing standard for the free-radical cleavage reactions. 10. Dry the gel and expose it to film by autoradiography or to a phosphor plate for quantitation using a radioanalytic detection instruments.
Probing RNA Structures with Hydroxyl Radicals
6.5.2 Current Protocols in Nucleic Acid Chemistry
STRAND SCISSION OF RNA USING H2O2-DERIVED FREE RADICALS This procedure is similar in several details to that described in the Basic Protocol. However, since the free radicals originate from hydrogen peroxide rather than from solvated molecular oxygen, the reaction proceeds at a more rapid pace.
ALTERNATE PROTOCOL
Additional Materials (also see Basic Protocol) 0.6% (w/w) hydrogen peroxide (H2O2) in sterile water, freshly prepared from 30% (w/w) commercial solution Sodium ascorbate powder 1. Prepare and equilibrate the RNA mixture as described (see Basic Protocol, step 1) but use a total volume of 7 µL. 2. During equilibration, dissolve 1.98 mg sodium ascorbate in 1 mL sterile water (final 10 mM). This solution should be made fresh immediately before use. It may be easier to prepare 10 mL solution.
3. Add 39.4 mg (NH4)2Fe(II)(SO4)2⋅6H2O to a sterile microcentrifuge tube and store in the dark until use. 4. Once the RNA solution has achieved equilibrium, prepare the Fe(II)-EDTA solution (see Basic Protocol, step 4). 5. Immediately add the following to the reaction mixture (total 10 µL): 1 µL Fe(II)-EDTA solution 1 µL 0.6% (w/w) H2O2 1 µL 10 mM sodium ascorbate. Add 3 µL sterile water to the control tube. Final reagent concentrations are 1 mM Fe(II), 2 mM EDTA, 0.06% H2O2, and 1 mM sodium ascorbate. The remaining sodium ascorbate, H2O2, and Fe(II)-EDTA solutions should be discarded following their use.
6. Incubate the reaction mixture for 1 to 3 min at the desired temperature. 7. Quench, fractionate, and observe the reaction as described (see Basic Protocol, steps 7 to 10). COMMENTARY Background Information The RNA strand scission reaction described here is initiated by a free radical, which originates from the reduction of an oxygen species in solution. The oxidation of the Fe(II)-EDTA reagent provides the source of electrons needed for reduction of molecular oxygen or hydrogen peroxide to form the reactive free radicals. The inclusion of a reducing agent, such as dithiothreitol or ascorbate, allows for the recycling of Fe(III)-EDTA to Fe(II)-EDTA. The formation of free radicals from solvated mo-
lecular oxygen can proceed via a hydroperoxide intermediate. The direct employment of a suitable concentration of hydrogen peroxide bypasses the requirement for an initial electron transfer to oxygen to generate the superoxide precursor of the hydroperoxide intermediate, as well as the ensuing bimolecular reactions giving rise to the peroxide. Consequently, the free radical cleavage reaction proceeds more rapidly in the Alternate Protocol than in the Basic Protocol. Before the RNA is loaded onto a denaturing polyacrylamide gel, a free-radical
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.5.3 Current Protocols in Nucleic Acid Chemistry
scavenger, such as thiourea, is added to quench the highly reactive hydroxyl radicals that are generated during the reaction. These reactions are as follows:
Probing RNA Structures with Hydroxyl Radicals
An analysis of nucleic acid products generated by the Fe(II)-EDTA cleavage reagent is consistent with the mechanism of strand scission beginning with hydrogen atom abstraction occurring at the C4′ position of ribose (Hertzberg and Dervan, 1984). Following oxidative damage of the ribose ring, a β-elimination-like reaction decomposes the ribose ring and directly leads to strand scission of the RNA chain. The C4′ hydrogen atoms are equally accessible on single- and double-stranded forms of RNA; therefore, it is not surprising that free radical–induced cleavage of RNA occurs with little preference for primary sequence or secondary structure (Celander and Cech, 1990). The folding of RNA tertiary structure often results in ribose moieties having different extents of accessibility to solvent. In the case of tRNAPhe and the group I intron from Tetrahymena thermophila, different regions of the RNA were found to be protected from cleavage by the Fe(II)-EDTA reagent (Latham and Cech, 1989). A striking correlation was found to exist for both RNA molecules in which the ribose positions that were underrepresented in the Fe(II)-EDTA cleavage reactions were found to possess low solvent-accessible surface areas (Latham and Cech, 1989; Cate et al., 1996). Thus, the Fe(II)-EDTA reagent can be used to discriminate solvent inaccessible surfaces within RNA molecules. Such surfaces arise whenever RNA tertiary structure forms a compact structure or through the binding of a ligand (e.g., a protein or an antibiotic drug) to RNA. The Fe(II)-EDTA cleavage reagent has been used to characterize the folded conformation and folding pathways of several ribozymes, including group I introns (Latham and Cech, 1989; Celander and Cech, 1991;
Heuer et al., 1991), RNase P RNAs (Pan, 1995; Westhof et al., 1996), and the delta virus ribozyme (Rosenstein and Been, 1996). Likewise, RNA regions that are protected by bound ligands have been elucidated in many systems with the use of the Fe(II)-EDTA cleavage reagent (Darsillo and Huber, 1991; Westhof et al., 1996). The chief utility and power of the Fe(II)-EDTA cleavage reagent lies in its ability to generate oxidative damage at every ribose moiety along the RNA chain, resulting in a pattern of strand scission with single-nucleotide resolution. Other chemical and enzymatic cleavage reagents commonly used today display primary sequence or secondary structure preference in their cleavage profile, so every nucleotide position along the RNA cannot be simultaneously monitored in a single experiment. It must be emphasized that the Fe(II)EDTA cleavage reagent protocols described here should only be used to monitor the solvent-accessible surfaces of RNA when folded in solution or when bound by a ligand under conditions of thermodynamic equilibrium. This particular reagent is not well suited to monitor folding transitions that occur on a more rapid scale than free radical formation by Fe(II)-EDTA. A higher flux of free radical formation is required to monitor the kinetics of RNA conformational changes or protein binding that occur on the millisecond time scale. Radiolysis of water by high-energy X rays produces hydroxyl radicals and free electrons. Irradiation of solutions by the high-flux “white light” X-ray beam, such as the X-19C at the National Synchrotron Light Source, yields sufficient concentrations of hydroxyl radicals so that cleavage kinetics required for quantitative nuclease protection studies of RNA can be done with exposures as short as 50 msec (Sclavi et al., 1997, 1998). This and similar sources are now available for characterizing conformational changes in RNA on a more rapid time scale.
Critical Parameters The successful application of either protocol relies on three critical parameters: (1) the quality of the end labeled RNA, (2) the reduction or elimination of substances from the reaction cocktail that act as free radical scavengers, and (3) the freshness of the Fe(II)EDTA cleavage reagent and companion reducing agent.
6.5.4 Current Protocols in Nucleic Acid Chemistry
RNA quality Any chemical modification procedure that generates a degradation product as the principal species requires that the investigator uses RNA of known length. For end-labeled RNA molecules, it is imperative that full-length species are subject to Fe(II)-EDTA cleavage. The reason for this criterion is that end-labeled RNA transcripts that are broken fragments of fulllength molecules may adopt conformations that differ from the population of full-length molecules. Since the Fe(II)-EDTA cleavage reagent cannot discriminate among these different populations of RNA transcripts, two or more different cleavage profiles will be superimposed upon the entire end-labeled RNA population if the RNA is not homogenous. The net result is a pattern of cleavage that is difficult to interpret because it is difficult to relate the cumulative cleavage profile to each RNA population present in the reaction. RNA fragmentation occurs readily through the use of nucleasecontaminated enzymes or by adventitious cleavage of RNA by metal ions in solution. The full-length, end-labeled RNA transcripts can be readily purified from any smaller products using denaturing PAGE (e.g., CPMB UNIT 2.12). Freshly labeled RNA is also recommended for use in these protocols. The very high specific end-labeling of RNA with 32P (3000 to 6000 Ci/mmol) results in molecules that are prone to degradation by either direct or watermediated autoradiolysis over time. A subtle degradation profile begins to emerge following storage of end-labeled RNA molecules for a period of 10 to 14 days at −20°C. The degradation pattern would not generally interfere with many studies performed with radiolabeled RNA, yet the intensity of the profile is significant enough to obscure the interpretation of the subtle cleavage profiles generated by Fe(II)EDTA. Free-radical scavengers can protect the RNA from water-mediated autoradiolysis; however, their inclusion in RNA storage buffers is discouraged because such compounds will interfere with the strand scission reaction promoted by the Fe(II)-EDTA cleavage reagent (see below). Free radical scavengers Three broad classes of compounds that are routinely used in RNA preparations are known to inhibit strand scission by Fe(II)-EDTA. (1) Polyribose compounds, like bulk RNA and glycogen, are frequently used as carrier agents to coprecipitate end-labeled RNA species from ethanol. These compounds do not ordinarily
pose a significant liability for most biochemical reactions involving RNA; however, they act as direct competitive inhibitors to strand scission by Fe(II)-EDTA since they contain the same highly reactive ribose moieties found in the end-labeled RNA. RNA transcripts can be precipitated from ethanolic solutions that contain low concentrations of simple salts, like 0.25 M NaCl or 0.30 M NaOAc, as one alternate precipitation procedure. (2) Glycerol, a cryoprotectant found in most protein storage buffers, is another efficient scavenger of free radicals. Glycerol is such an effective quencher of the Fe(II)-EDTA reaction that it can be used in place of thiourea (Latham and Cech, 1989). Glycerol is usually included in storage buffers to promote long-term stability of RNA-binding proteins, yet proteins often remain stable under short-term conditions with either no glycerol or low concentrations of glycerol present. One should evaluate whether the optimal reaction conditions require the presence of glycerol for studies that involve RNA-binding proteins. In the worst-case scenario, one may be able to empirically determine a low final concentration of glycerol that can be used to maintain the RNA-binding protein’s biochemical activity and to allow for optimal strand scission by Fe(II)-EDTA generated free radicals. (3) Buffers that are enriched with primary alcohols, e.g., Tris, are effective free-radical scavengers since they more readily undergo hydrogen-atom abstraction than other buffering compounds. One should reduce the concentration of such buffers in solution or replace them with an alternative buffering component (e.g., MOPS) so that efficient RNA strand scission occurs (Celander and Cech, 1990). Fe(II)-EDTA cleavage reagent freshness The most important ingredient to success in the strand-scission reaction is the use of fresh Fe(II)-EDTA and reducing agents. A common mistake made by those who cannot generate a decent cleavage pattern with end-labeled RNA is that the Fe(II)-EDTA reagent was prepared well before use (an hour or longer) or that old solutions of DTT or ascorbate were stored frozen from use in cleavage reactions performed at an earlier date. An Fe(II)-EDTA solution will undergo rapid oxidation to Fe(III)-EDTA, resulting in a yellow-colored solution in <1 hr after preparation. A fresh Fe(II)-EDTA solution should have a colorless to faint-blue tint, and such solutions are best prepared immediately before use. The chosen reducing reagent should
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.5.5 Current Protocols in Nucleic Acid Chemistry
also be prepared immediately before use and discarded thereafter.
Anticipated Results The interpretation of cleavage pattern on denaturing polyacrylamide gels is extremely straightforward. The cleavage pattern will be a fairly uniform banding pattern at each nucleotide position. The extent of cleavage varies little between reactions; most reactions generate 10% to 20% cleavage products. Since strand scission occurs with the loss of the ribose moiety for the affected nucleotide, the position at which the end-labeled RNA fragment migrates relative to sequencing standards is shifted by one nucleotide. For example, hydrogen atom abstraction at the ribose group of the seventeenth nucleotide in a 5′-[32P]-end-labeled RNA chain will generate an oxidative strandscission product that migrates like an end-labeled 16-mer. The usual controls should be included to ensure that the cleavage pattern obtained is correctly attributed to the Fe(II)EDTA reagent rather than to an adventitious cleavage event caused by another source.
Time Considerations This assay is extremely rapid to perform and requires little technical expertise or prior experience. The preparation of the end-labeled RNA is more time consuming than any aspect of the Fe(II)-EDTA cleavage protocols described herein. One can learn an enormous amount of structural information about a folded RNA molecule or its association with other ligands in the time it takes to conduct these reactions (<2 hr) and perform gel electrophoresis (3 to 5 hr).
Literature Cited Cate, J.H., Gooding, A.R., Podell, E., Zhou, K., Golden, B.L., Kundrot, C.E., Cech, T.R., and Doudna, J.A. 1996. Crystal structure of a group I ribozyme domain: principles of RNA packing. Science 273:1678-1685.
Celander, D.W. and Cech, T.R. 1990. Iron(II)ethylenediaminetetraacetic acid catalyzed cleavage of RNA and DNA oligonucleotides: Similar reactivity toward single- and double-stranded forms. Biochemistry 29:1355-1361. Celander, D.W. and Cech, T.R. 1991. Visualizing the higher order folding of a catalytic RNA molecule. Science 251:401-407. Darsillo, P. and Huber, P.W. 1991. The use of chemical nucleases to analyze RNA-protein interactions. The TFIIIA-5 S rRNA complex. J. Biol. Chem. 266:21075-21082. Hertzberg, R.P. and Dervan, P.B. 1984. Cleavage of DNA with methidiumpropyl-EDTA-iron(II): Reaction conditions and product analyses. Biochemistry 23:3934-3945. Heuer, T.S., Chandry, P.S., Belfort, M., Celander, D.W., and Cech, T.R. 1991. Folding of group I introns from bacteriophage T4 involves internalization of the catalytic core. Proc. Natl. Acad. Sci. U.S.A. 88:11105-11109. Latham, J.A. and Cech, T.R. 1989. Defining the inside and outside of a catalytic RNA molecule. Science 245:276-282. Pan, T. 1995. Higher order folding and domain analysis of the ribozyme from Bacillus subtilis ribonuclease P. Biochemistry 34:902-909. Rosenstein, S.P. and Been, M.D. 1996. Hepatitis delta virus ribozymes fold to generate a solventinaccessible core with essential nucleotides near the cleavage site phosphate. Biochemistry 35:11403-11413. Sclavi, B., Woodson, S., Sullivan, M., Chance, M.R., and Brenowitz, M. 1997. Time-resolved synchrotron X-ray "footprinting", a new approach to the study of nucleic acid structure and function: Application to protein-DNA interactions and RNA folding. J. Mol. Biol. 266:144-159. Sclavi, B., Sullivan, M., Chance, M.R., Brenowitz, M., and Woodson, S.A. 1998. RNA folding at millisecond intervals by synchrotron hydroxyl radical footprinting. Science 279:1940-1943. Westhof, E., Wesolowski, D., and Altman, S. 1996. Mapping in three dimensions of regions in a catalytic RNA protected from attack by an Fe(II)-EDTA reagent. J. Mol. Biol. 258:600-613.
Contributed by Daniel W. Celander Loyola University Chicago Chicago, Illinois
Probing RNA Structures with Hydroxyl Radicals
6.5.6 Current Protocols in Nucleic Acid Chemistry
Chemical Reagents for Investigating the Major Groove of DNA A wide array of chemical reagents have been developed over the past 25 years for characterizing DNA structure and its interaction with drugs and proteins. When first introduced, these reagents provided one of a very limited number of approaches for identifying nucleotide sequences that, for example, bound to proteins or formed unusual (non-B helical) structures. More recently, physical methods such as NMR (James, 1995; Addess and Feigon, 1996) and X-ray crystallography (Timsit and Moras, 1992; Sriram and Wang, 1996) have increasingly become viable alternatives since their application has become more routine, providing molecular details of unrivaled resolution. Despite these advances, chemical methods remain highly popular. Their lasting appeal is maintained in part by their low cost and ease of use. Few other techniques have proven as versatile for both defined and complex systems. Most chemical reagents used to characterize DNA either alkylate or oxidize a particular functional group within one or more of the four standard deoxyribonucleotides. A complementary set of reagents is therefore necessary if an analysis of all polynucleotide domains is desired. Although a single region of DNA such as its major groove may be examined successfully with a limited number of reagents, reliance on a single reagent is not recommended. Data from multiple reagents help to ensure that results truly reflect the state of DNA and are not a function of an unknown or unforeseen idiosyncracy of any one reagent. A number of excellent reviews describe the general specificity and utility of a broad range of reagents, and the most comprehensive of these cover the literature prior to the last decade (Nielsen, 1990; Tullius, 1991; Chow and Barton, 1992; Lilley, 1992). This field has continued to benefit from ongoing development of many additional reagents as illustrated throughout this chapter. The focus of this specific commentary centers on the most commonly used and readily available reagents that react in the major groove: dimethyl sulfate (DMS), diethylpyrocarbonate (DEPC), potassium permanganate (KMnO4), osmium tetroxide (OsO4), and bromine (Br2) formed in situ (Ross and Burrows, 1996) from bromide (Br–) and monoperoxysulfate (HSO5−). The characteristics of each reagent will be reviewed individually below, and then a sampling of their
UNIT 6.6
broad-ranging applications will be illustrated collectively in the final sections.
GENERAL CONSIDERATIONS FOR DATA ANALYSIS One of the most attractive features of experiments based on chemical modification is the ability to generate large quantities of data rapidly. However, accurate interpretation of the data is less assured. Assessment of the results requires some familiarity with the basic chemistry of modification, the origins of its specificity, and its potential for ambiguity. With these considerations, strategies may be chosen to distinguish between a limited set of alternative conformations or even explore unknown structures. Ambiguities may still arise when unanticipated variables dominate reaction or when initial modification of a target, or molecules bound to a target, promote one or more secondary reactions. Perhaps the greatest limitation generally affecting chemical modification is set by its ability to report on only the most reactive and not necessarily the most abundant species. These potential problems need not diminish the importance of this approach as long as caution is practiced during experimental design and data interpretation. For example, perturbations caused by secondary reactions can usually be avoided by simply adjusting conditions so that only a small fraction of molecules (<20%) are modified in each analysis. Of course no single experimental technique is ever likely to establish a significant conclusion without corroboration from alternative methods. Chemical modification provides a convenient complement to the more time-consuming procedures based on biological and physical methods.
EXPERIMENTAL PROCEDURES SUPPORTED BY CHEMICAL MODIFICATION Use of chemical probes typically follows one of three approaches identified as (1) modification protection or “footprinting,” (2) interference experiments, and (3) missing contact probing. The first essentially measures the extent of modification along a nucleotide sequence. Uniform reactivity indicates structural homogeneity within DNA, and, conversely, variable reactivity indicates structural heterogeneity at least to the extent of localized in-
Contributed by Steven E. Rokita Current Protocols in Nucleic Acid Chemistry (2001) 6.6.1-6.6.16 Copyright © 2001 by John Wiley & Sons, Inc.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.6.1 Supplement 5
*
*
1. DMS 2. pyridine/heat
* * *
1. KMnO4 2. pyridine/heat
Figure 6.6.1 Protein-dependent suppression and activation of DNA modification by conformation-specific probes.
Chemical Reagants for Investigating the Major Groove of DNA
creases or decreases in steric or electrostatic repulsion. For example, assembly of a proteinDNA complex may be expected to block access to nucleotides in a certain region of a helix and prevent reaction at this site uniquely (Fig. 6.6.1). Likewise, partial unwinding of duplex DNA resulting from a helical junction or bound protein will increase access and concomitant reaction of a selected number of neighboring nucleotides. These sites of interest are identified in both cases by their deviation from the basal level of reactivity established over many nucleotides. Although certain reagents such as hydroxyl radicals induce polynucleotide strand scission directly, the reagents reviewed below modify the pyrimidine and purine bases without causing spontaneous strand scission. The modified bases are instead detected by their diagnostic ability to (1) cause strand scission after subsequent treatment with heat and piperidine (Maxam and Gillbert, 1980; see CPMB UNIT 7.5) or (2) terminate polymerasebased primer extension (see CPMB UNIT 7.4A; Htun and Johnston, 1992). Interference and missing contact experiments both rely on chemical reagents to generate statistical populations or libraries of DNA that collectively contain a particular modification at various sites along a nucleotide sequence to block or remove potential contacts between
DNA and proteins (Brunelle and Schleif, 1987; Wissmann and Hillen, 1991). For example, DMS methylation of guanine N7 (G N7) will not inhibit protein binding to the major groove except for the subpopulation of DNA that is modified within its recognition domain. The crucial sites required for binding are then identified from the product distribution of the protein-bound and free sequences (Fig. 6.6.2). Alternatively, this same methylation process can be used to induce depurination and delete certain interactions that stabilize protein-DNA assembly (Brunelle and Schleif, 1987). In this case, sequence recognition is identified by the subpopulation of apurinic DNA that exhibits reduced affinity for the protein of interest. Any abasic site has the additional potential to condense with neighboring lysine residues and form protein-DNA cross-links. This provides yet another tool for analyzing DNA-protein association (Mirzabekov et al., 1989; Bavykin and Pruss, 1997). For all of the methods described above, success depends on selection of the appropriate chemical reagents that modify DNA in a highly predictable, reproducible, and selective manner.
*
*
*
*
chemical
…
modification
*
*
* …
+
* …
pyridine heat
Figure 6.6.2 An interference assay for characterizing protein-DNA interactions.
6.6.2 Supplement 5
Current Protocols in Nucleic Acid Chemistry
INDIVIDUAL CHARACTERISTICS OF REAGENTS COMMONLY USED TO PROBE THE MAJOR GROOVE OF DNA Despite the ever-growing number of reagents known to react in the major groove of DNA, none have maintained more prominence than DMS, DEPC, and KMnO4. The popularity of these and most reagents is a function of their reliable specificity and ready availability. The following section provides a brief overview of these reagents, as well as OsO4 and Br−/HSO5−, and explores the or igins and limitations of their selectivity. Specific examples illustrating concurrent application of these reagents are left for the final sections of this unit.
Dimethyl Sulfate (DMS) The small and simple methylating agent DMS was among the first in a set of reagents frequently used to characterize DNA, and was central to many of the initial efforts in nucleotide sequencing, protection interference, and missing contact experiments. Application of DMS remains widespread due in part to this versatility. The predominant site of methylation in duplex DNA is the N7 position of guanine on the surface of the major groove (Singer and Grunberger, 1983). The resulting N7 methyl derivative is only metastable, and ultimately generates an abasic site that can be detected by its diagnostic fragmentation after treatment with piperidine and heat (Fig. 6.6.3). This chemistry is the basis for the now famous Maxam-Gilbert sequencing reaction for guanine (Maxam and Gilbert, 1980; also see CPMB UNIT 7.5). Methylation of G N7 does not inhibit polymerase chain extension, and thus piperidine-dependent strand scission is a necessary prerequisite for detecting this modification with the Klenow fragment of polymerase I (Saluz and Jost, 1989; Htun and Johnston, 1992). With the advent of thermostable polymerases like Taq polymerase, the heat of thermo-
cycling is sufficient to fragment the methylated DNA and may now supersede the need for piperidine treatment (Brewer et al., 1990). The same characteristics that made DMS appealing for sequencing have also made it attractive for many other applications. DMS modifies G N7 with equal proficiency in singleand double-stranded DNA and does not exhibit sequence-dependent activation or inhibition (Hartley, 1993). Consequently, a relatively homogeneous profile of methylation can be generated with DMS. This in turn facilitates the interpretation of all sequencing and footprinting experiments. The intrinsic reactivity of DMS is quite high, and, as with most reagents that act on DNA, precautions must be taken to avoid contact with it (see CPMB UNIT 7.5). The danger of DMS is further compounded by its neutral and lipophilic nature, two properties that are largely responsible for its desirable lack of sequence specificity. The small size of DMS relative to DNA also provides it with unencumbered access to G N7, and the phosphoribose backbone neither shields the reagent from nor attracts it to particular regions or conformations of DNA. Other sites in DNA are also methylated by DMS, although at far lower efficiencies. For example, the N3 position of adenosine (A N3), located in the minor groove of duplex DNA, is subject to modification but reacts at a rate ~4-fold slower than that of G N7 (Singer and Grunberger, 1983). Other potential sites of alkylation are blocked by the formation of duplex DNA. The profile of methylation of single-stranded DNA is consistent with the nucleophilicity and electrostatic potential of the nitrogen heteroatoms (Pullman and Pullman, 1981). G N7 is significantly more reactive than the next most reactive position, A N1, and these are followed by A N7 > A N3 > G N3 (Singer and Grunberger, 1983). Theoretical and experimental investigations additionally confirm that A N7 is not nearly as nucleophilic as G N7 (Pullman and
Figure 6.6.3 DMS-dependent methylation of G N7 and subsequent strand scission promoted by piperidine and heat.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.6.3 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Pullman, 1981; Singer and Grunberger, 1983). DMS was even used to map the nucleophilic sites within the pyrimidine nucleobases, despite their modest reactivity at the nucleoside level and even weaker reactivity when assembled into duplex DNA (Singer and Grunberger, 1983). The preference of DMS for G N7 remains sufficient in most target sequences so that complications rarely arise from reaction at competing sites. Methylation is only effectively inhibited when the accessibility of G N7 is severely limited by drug, oligonucleotide, or protein binding in the major groove (Nielsen, 1990). This result in turn serves as the basis for interference studies that help to localize binding sites in DNA. Quadruplexes and other unusual structures of DNA that involve coordination of G N7 also exhibit protection from DMS (Sen and Gilbert, 1988; Williamson et al., 1989; Fig. 6.6.4). Two caveats that may effect data evaluation were noted in a review by Nielsen (1990), and are well worth repeating. First, DMS has the potential to disrupt DNA-ligand interaction by methylation of the ligand in competition with its methylation of DNA. Second, proteins have the potential to increase the local concentration of DMS since they may establish lipophilic binding pockets in the vicinty of DNA. The lack of charge on DMS also renders this reagent relatively insensitive to the electrostatic properties of DNA and the ionic strength of solution (Wurdeman and Gold, 1988). This is in direct contrast to the nature of other alkylating agents, such as nitrogen mustards, that modify G N7 through a cationic intermediate and consequently demonstrate electrostatic affinity for DNA (Hartley et al., 1990).
Diethylpyrocarbonate (DEPC) A N7 is the target most commonly associated with reaction of DEPC (Peattie, 1979; Nielsen, 1990). Initial carbethoxylation of N7
Chemical Reagants for Investigating the Major Groove of DNA
Figure 6.6.4
leads to cleavage of the imidazole ring and subsequent alkaline lability of the phosphoribose backbone (Fig. 6.6.5). Reaction profiles of DEPC are therefore typically examined after piperidine treatment of the modified DNA. Interest in DEPC as a probe for DNA originated from its earlier applications in determining RNA sequence and structure (Peattie, 1979; Peattie and Gilbert, 1980), which in turn evolved from its even earlier use as a histidinespecific reagent for protein modification (Lundblad, 1995). This ability to modify proteins should now remain a concern when using DEPC to map protein-DNA interactions. The conformational specificity of DEPC as characterized with RNA is very sensitive to base stacking and is severely inhibited in helical structures (Peattie and Gilbert, 1980; Ehrsemann et al., 1987; Weeks and Crothers, 1993). Single-stranded and nonhelical regions provide the most accessible targets of DEPC within RNA. Equivalent specificity was detected for DNA, although some reaction was additionally noted within duplex DNA (Herr et al., 1982; Furlong and Lilley, 1986). Adenine residues are not the exclusive target of DEPC. Guanine residues, particularly those with high solvent exposure at N7, may also react (Herr, 1985; Johnston and Rich, 1985; Runkel and Nordheim, 1986; Scholten and Nordheim, 1986). Early studies indicated that both pyrimidine and purine nucleosides were subject to carbethoxylation by DEPC (Leonard et al., 1971; Vincze et al., 1973), but only purines appear to maintain an observable reactivity in polynucleotides (Nielsen, 1990). Within helical DNA, DEPC generally favors modification of A over G when the accessibility of their N7 positions is similar (Herr, 1985). The origin of this selectivity has not yet been determined, and is certainly not based on nucleophilicity. Otherwise, guanine would have been most reactive as illustrated with DMS. Neither the general electrostatic nature of DNA
DMS reaction and protection for G-C and G-G base pairs and G-quartets.
6.6.4 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Figure 6.6.5 DEPC-dependent modification of A N7 and subsequent strand scission promoted by piperidine and heat.
nor the ionic conditions of reaction greatly affect the specificity of DEPC as expected for a neutral reactant (Klysik et al., 1990; NejedlO et al., 1998). The most predictable determinant for modification of A appears simply to be the steric accessibility of its N7 position.
Potassium Permanganate (KMnO4) and Osmium Tetroxide (OsO4) Both reagents selectively oxidize the C5, C6 double bond of thymine residues (Fig. 6.6.6) and support convenient methods for DNA sequencing and conformational analysis (Nielsen, 1990). The lack of charge on OsO4 minimizes its sensitivity to the electrostatic properties of DNA and may simplify interpretation of modification data relative to those based on KMnO4. However, OsO4 is somewhat volatile and quite hazardous (Pale?ek, 1992a), and is not applied as frequently as the safer alternative, KMnO4. Even though the ultimate oxidant MnO4− is charged, it remains cell-permeable for in vivo studies (Sasse-Dwight and Gralla, 1989). The anionic characteristic also suppresses reaction with DNA due to electrostatic
repulsion of DNA, despite the enduring focus in the general literature on the importance of sterics (Hänsler and Rokita, 1993). Oxidation of duplex DNA with KMnO4 and OsO4 is greatly inhibited relative to that of single-stranded DNA, and consequently these reagents are very useful for identifying regions of unusual and nonhelical structure. Perturbations of duplex DNA caused by association of proteins and drugs are also often sufficient for stimulating a local hyperreactivity (Fig. 6.6.2). Even minor distortions in DNA conformation resulting from single base mismatches can be detected by KMnO4 and OsO4 (Cotton et al., 1988; Roberts et al., 1997; Lambrinakos et al., 1999). The cis diol product of T oxidation is conveniently detected by either strand scission induced by piperidine and heat (Friedman and Brown, 1978; Rubin and Schmid, 1980) or termination of primer extension catalyzed by a variety of common DNA polymerases (Ide et al., 1985; Borowiec et al., 1987; Clark and Beardsley, 1987). The specificity and potential utility of MnO4− was noted very early in the quest for
Figure 6.6.6 KMnO4- and OsO4-dependent oxidation of thymine and subsequent strand scission promoted by piperidine and heat.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.6.5 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Chemical Reagants for Investigating the Major Groove of DNA
chemical probes of nucleic acids. Access to the target C5, C6 of T is an understandable requirement for efficient reaction, and hence may explain the preference for single- versus doublestranded DNA (Hayatsu and Ukita, 1967). Residues within duplex DNA that became sensitive to MnO4− after supercoiling or binding to a protein were originally considered indicative of helix distortions and base unpairing (Borowiec et al., 1987; O’Halloran et al., 1989). However, the enhanced exposure of T anticipated from chemical modification is not always evident in the crystal structure of protein-DNA complexes (Bochkarev et al., 1998). In some cases, only subtle changes in conformation have appeared responsible for the high reactivity of thymine residues. These unusual sites of modification might reflect protein-dependent shielding of the anionic charge of DNA from the anionic reagent MnO4− (Hänsler and Rokita, 1993). Permanganate oxidation of duplex DNA can be accelerated 25-fold by merely increasing the ionic strength of the reaction solution from 0.1 to 4.0 M (Hänsler and Rokita, 1993). Under these conditions, the high concentration of cations effectively diminishes charge repulsion between the reactants. This dependence on ionic strength is not an inherent characteristic of MnO4− since the oxidation of neutral thymidine is enhanced only 1.3-fold in a comparable study (Hänsler and Rokita, 1993). Similarly, oxidation of DNA by OsO4 is unaffected by ionic strength (NejedlO et al., 1998). Permanganate then serves as an example of how reagents with a charge may respond to both steric and electrostatic properties of DNA. The specificity of MnO4− for T was first demonstrated using mononucleotides (Hayatsu and Ukita, 1967). Under conditions that consumed 95% of TMP, the purines dGMP and dAMP were nearly inert, and the pyrimidine dCMP was only marginally reactive. Even uridine 5′-phosphate that only lacks the 5-methyl of TMP oxidized at a rate ~10-fold slower than TMP. The resulting product of oxidation, the cis 5,6-diol of T, readily hydrolyzes to an abasic site (Howgate et al., 1968). These favorable characteristics led MnO4− to become a standard reagent for chemical sequencing of DNA (Rubin and Schmid, 1980; McCarthy, 1989; Williamson and Celander, 1990). Occasionally, background oxidation of duplex DNA has been observed particularly at guanine residues (McCarthy et al., 1990; McCarthy and Rich, 1991). The origin of this has not yet been identified, and controversy remains on whether or not 8-oxoguanine is a product of this minor
pathway (Akman et al., 1990; Nawamura et al., 1994). Perhaps the background reactions are a result of prior modification or contamination of the parent DNA. For example, 8-oxoguanine residues and their neighboring bases, as well as guanine side products encountered during oligonucleotide synthesis, are all targets of MnO4− oxidation (Yeung et al., 1988; Koizume et al., 1998). The reactivity of OsO4 is uniquely activated by the presence of tertiary amine ligands, and thus this reagent is often used in the presence of pyridine or 2,2′-bipyridine (Pale?ek, 1992a). Such ligands dramatically stabilize the osmium ester intermediate (Fig. 6.6.6). Unlike MnO4− and OsO4, which generate the diol derivative of thymine, the OsO4-pyridine complex proceeds only to the cyclic ester (Neidle and Stuart, 1976). This species hydrolyzes in a manner equivalent to the diol under standard alkaline conditions to yield strand fragmentation. Alternatively, a primer-extension assay can be used to identify the sites of modification. The conformational specificity of oxidation can be controlled in part by the choice of amine used to coordinate to the osmium (Pale?ek, 1992a). The ultimate extension of this strategy is illustrated by the sequence-directed oxidation of a single thymine using an osmium complex derived from a bipyridine-oligonucleotide conjugate (Ford et al., 1981; Nakatani et al., 2000).
Bromide (Br–) with Monoperoxysulfate (HSO5−) A very promising method of detecting cytosine residues in nonhelical DNA has been recently developed and relies on generation of bromine (Br2) in situ by oxidation of Br– in the presence of HSO5− (Ross and Burrows, 1996; Fig. 6.6.7). Extrahelical C residues exhibit a 10-fold increase in reactivity above a low background level in duplex DNA. In single-stranded structures, modification of C is minimally 4fold more efficient than that of T, G, or A. Preferential reaction of C is also observed after equivalent addition of Br2, although its selectivity is reduced compared to that of Br− / HSO5− (Ross and Burrows, 1996). Both conditions result in the intermediate formation of 5-bromo C. This is susceptible to further addition by Br2, which in turn induces DNA strand fragmentation after treatment with piperidine and heat (Ross and Burrows, 1996, 1997). As more investigators begin to explore the utility of Br–/HSO5− (Stevens and Glick, 1999; Kasparkova et al., 2000; Kostrhunova
6.6.6 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Figure 6.6.7 and heat.
Oxidation of C by Br−/HSO5− and subsequent strand scission promoted by piperidine
and Brabec, 2000), this technique will likely become the MnO4− or OsO4 equivalent for C. Two alternative reagents, hydroxylamine (Rubin and Schmid, 1980; Johnston and Rich, 1985; Johnston, 1992) and bisulfite (Hayatsu, 1976; Gough et al., 1986), have been known for many years to react with C in a conformation-selective manner, but their use has been very limited. This lack of popularity may be due in part to the very high concentration of reagents (2 M) that is required for sufficient modification (Johnston and Rich, 1985; Gough et al., 1986). Interest in bisulfite has recently revived since its selectivity for C over 5-methyl C has provided a convenient method for mapping methylation patterns of CpG islands in DNA (Rother et al., 1995; Kinoshita et al., 2000). Bisulfite reaction with C has also become central to a protocol for mapping chromatin in vivo in concert with methyltransferases (Kladde and Simpson, 1996).
APPLYING CHEMICAL REAGENTS TO PROBE THE MAJOR GROOVE OF DNA Sample investigations based on chemical approaches to characterizing DNA structure, and particularly its major groove, are described below. The goal of this section is to illustrate the range of information that is made available by these methods, rather than provide a comprehensive survey of all major advances that have occurred since previous review of this subject (Nielsen, 1990; Tullius, 1991; Lilley, 1992; Chow and Barton, 1992). Topics are organized into four sections, DNA conformation, drug-DNA association, protein-DNA association, and in vivo footprinting. Most examples involve the use of multiple reagents, since definitive conclusions are often difficult to establish with only a single reagent. Complementary techniques of footprinting (protection) and interference or missing contacts are also often performed concurrently to substantiate the re-
sults of individual analyses. Although chemical modification does not offer the highest atomic resolution, it represents a very expedient method for defining key structural features of DNA and identifying the functional groups responsible for recognition and binding to proteins and drugs.
Conformational Analysis of Duplex DNA Uniform double-helical DNA typically yields an equally uniform pattern of modification, and even minor perturbations of groove dimensions or base pairing have the potential to promote or inhibit reaction of conformationspecific probes. For example, biological methylation of A to form N6-methyl A appears to weaken A-T pairing and stacking in duplex DNA, as detected by the greater susceptibility of its N7 position to reaction with DEPC (Guo et al., 1995). Numerous investigators have also used DEPC to characterize the properties of A-tract DNA. The N7 position of A is more reactive in A-tracts than in canonical duplex DNA. This is consistent with the wider major groove and narrower minor groove associated with A-tract DNA (McCarthy et al., 1990, 1993; NejedlO et al., 1998). In contrast, the complementary T-tract does not exhibit high reactivity with either OsO4-bipyridine or MnO4− and suggests that the widened major groove still maintains considerable steric and electrostatic repulsion (McCarthy et al., 1993; NejedlO et al., 1998). Some deviations from this general reaction profile, and hence helical structure of DNA, have additionally been noted at certain A-tract junctions and in natural variants of A-tract DNA (McCarthy et al., 1993; Chang et al., 1994; NejedlO et al., 1998). The sensitivity of DEPC, OsO4-pyridine, and MnO4− to nucleotide stacking extends to parallel-stranded duplex DNA (Klysik et al., 1990), and its helix-coil transition may be monitored by exposure to OsO4-pyridine. An-
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.6.7 Current Protocols in Nucleic Acid Chemistry
Supplement 5
tiparallel DNA forming a left-handed Z helix represents another highly unusual duplex structure that has been examined by chemical probes. DEPC readily reacts with the N7 positions of both A and G residues within Z-helical domains (Herr, 1985; Johnston and Rich, 1985; Runkel and Nordheim, 1986). This modification is relatively independent of base stacking, since the N7 position in Z DNA is oriented towards the outer edge of the helix and maintains much greater accessibility than it does in right-handed B DNA (Pullman and Pullman, 1981). B-Z and Z-Z helical junctions are readily modified by a variety of reagents including OsO4 and MnO4− in a manner consistent with a region of high disorder or conformational dynamics (NejedlO et al., 1985; Falazka et al., 1986; Jiang et al., 1991). All of the reagents introduced above except for DMS are quite useful in identifying extrahelical or weakly stacked bases within standard duplex DNA. DMS is insensitive to these perturbations because both single- and doublestranded DNA are methylated at G N7 with equal efficiency (Hartley, 1993). However, subtle changes in helical conformation caused by noncanonical structures such as base mismatches containing T may be detected by oxidation with MnO4− in the presence of tetralkylammonium salts (Gogos et al., 1990; Roberts et al., 1997; Lambrinakos et al., 1999). Addition of this type of salt appears to enhance selectivity for mismatches (Cotton, 1989). These conditions now serve as the basis for a protocol entitled “chemical cleavage of mismatch” for detecting point mutations (Gogos et al., 1990; Roberts et al., 1997; Lambrinakos et al., 1999). Interestingly, reaction is not limited to mispaired T. MnO4− additionally seems to oxidize some mismatched G and C residues, and both MnO4− and OsO4 oxidize normally paired T residues adjacent to mismatched bases (Cotton and Campbell, 1989; Lambrinakos et al., 1999).
Chemical Reagants for Investigating the Major Groove of DNA
Single-stranded regions of DNA formed by cruciform or hairpin structures are readily identified by conformational probes as well, and the presence of T, C, and A in these structures is typically identified by reaction with MnO4−, Br−/HSO5−, and DEPC, respectively (Scholten and Nordheim, 1986; Hänsler and Rokita, 1993; Stevens and Glick, 1999). These reagents have also been successfully applied to characterization of four-way helical junctions (Webb and Thomas, 1999), strand displacement and invasion by peptide nucleic acids (Egholm et al., 1995; Armitage et al., 1997), and equilibria of single-, double-, and triple-stranded species formed by naturally occurring triplet base repeats (Mäueler et al., 1998; Fig. 6.6.8). Once again, methylation of G N7 by DMS cannot discriminate between these forms of DNA. An alternative reagent for G N7, not discussed in this review but sensitive to secondary structure, involves nickel- or cobalt-dependent oxidation of G in the presence of HSO5− (UNIT 6.4). The first indication that G-rich telomeric sequences could form four-stranded structures was based on their unusual pattern of modification with DMS, MnO4−, and DEPC (Sen and Gilbert, 1988; Williamson et al., 1989; Venczel and Sen, 1993; Balagurumoorthy and Brahmachari, 1994). In this case, DMS was particularly useful, since the quadruplex assembled into a so-called G-quartet that is stabilized by Hoogsteen base pairs that involve G N7 (Sen and Gilbert, 1988; Williamson et al., 1989; Fig. 6.6.4). Thus, formation of the Gquartet inhibited methylation at this site and, conversely, methylation inhibited G-quartet formation. Nucleotides linking the G-rich regions were targets of DEPC and MnO4− reaction when looped between G-quartets, but were inert when stacked in the standard B duplex.
Drug-DNA Association The footprint of a low-molecular-weight drug on DNA often extends over only a few
Figure 6.6.8 Strand displacement increases exposure of target sequences to chemical probes. A peptide nucleic acid analog based on thymine and an anthraquinone intercalator (AQI) was used to recognize an A5 sequence (Armitage et al., 1997).
6.6.8 Supplement 5
Current Protocols in Nucleic Acid Chemistry
base pairs, and consequently chemical modification data are often difficult to interpret during the initial stages of characterizing drug-DNA interactions. Instead, reagents are most useful when applied to well-defined oligo- or polynucleotide model systems that are designed to address specific questions on drug binding. The reagents highlighted in this unit are also not typically the first employed, since majorgroove recognition is rather rare for either synthetic or natural compounds. Two notable exceptions to this generalization are triplex-forming oligonucleotides that are currently under development as gene-targeted drugs (Miller, 1996; Giovannangeli and Hélène, 1997; Fox, 2000) and cisplatin derivatives that have already proven highly successful in treatment of certain cancers (Jamieson and Lippard, 1999; Wong and Giandomenico, 1999). Assembly of a third DNA strand into the major groove of duplex DNA protects A N7 and G N7 from DEPC and DMS reaction, respectively (Collier et al., 1991; Beal and Dervan, 1992). Similarly, platinum coordinates to DNA through G N7, and hence protects this site from DMS-dependent methylation (Sip et al., 1992; Kasparkova et al., 2000). Interstrand cross-linking at d(GC/CG) sites by platinum does not appear to cause significant unstacking of DNA, at least as indicated by the reaction profile of DEPC and OsO4 (Sip et al., 1992). Structural perturbations are limited to the two C residues directly adjacent to the platinum, as identified by reaction of hydroxylamine. Intrastrand crosslinking by cisplatin and a related distamycin conjugate induced only a localized hyperreactivity of MnO4−, DEPC, and Br−/HSO5−, and this was consistent with an asymmetric and local unwinding of DNA (Marrot and Leng, 1989; Kasparkova et al., 2000; Kostrhunova and Brabec, 2000; Fig. 6.6.9).
Figure 6.6.9 Local distortion of duplex DNA induced by a dinuclear platinum complex. Relative reaction is designated as high (h), medium (m), and low (l). Adapted from Kasparkova et al. (2000) with permission from The American Society for Biochemistry and Molecular Biology.
A variety of intercalating agents such as ethidium, 9-aminoacridine, and N,N-di(9-acridinyl)spermidine stimulate unwinding of helical DNA as determined in part by reaction with DEPC and MnO4− (Jeppesen and Nielsen, 1988). These same probes similarly helped to identify the sequence-dependent binding properties of the natural bisintercalator echinomycin (Bailly et al., 1994). Even drugs such as bleomycin that do not directly interact with the major groove may still cause sufficient structural distortion of DNA to affect its subsequent reactivity (Fox and Grigg, 1988). In particular, footprinting by DEPC and MnO4− suggests that bleomycin enhances exposure of the nucleotide directly 3′ to its binding site. As expected, DMS is generally insensitive to such binding, since no steric barrier is created around G N7.
Protein-DNA Association The great majority of protection and interference experiments designed to probe proteinDNA interactions within the major groove rely on DMS and MnO4−. All reagents have the potential to react with protein in a competitive manner, but the greatest number of complications likely arise from alternative reagents such as DEPC and OsO4 (Pale?ek, 1992b; Lundblad, 1995). Consequently, DEPC and OsO4 are applied with less frequency to study protein-DNA complexes (Dobi and Agoston, 1998; Mäueler et al., 1998). Investigations based on Br–/ HSO5− have only just begun, and therefore their potential to map protein-DNA interactions is not yet known. However, these conditions have the potential to oxidize a variety of amino acid side chains that might disrupt protein-DNA association. DMS and MnO4− alone can still provide considerable information on DNA-protein interactions, since their reaction specificities are quite complementary. Methylation of G N7 by DMS is unaffected by the helical conformation of DNA, but can be suppressed by loss of major groove accessibility due to protein binding. In contrast, oxidation of T by MnO4− is suppressed in helical DNA and activated by relaxation of its conformational and electrostatic constraints due to protein binding. Such effects were observed after lac repressor bound to its operator sequences (Borowiec et al., 1987). DMS protection was evident at two repressor binding sites, while MnO4− reaction was enhanced in an intervening AT-rich sequence. Similarly, an open transcription complex formed by RNA polymerase and MerR protein bound with Hg2+ conferred hypersensitivity to MnO4− at nine T
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.6.9 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Chemical Reagants for Investigating the Major Groove of DNA
residues along a 14-nucleotide sequence (O’Halloran et al., 1989). In contrast, the Hg2+MerR protein complex in the absence of the polymerase appeared to unwind duplex DNA without affecting MnO4− reaction, and the polymerase in the absence of the MerR complex induced MnO4− reaction at only five T residues (O’Halloran et al., 1989; Ansari et al., 1992). Each of the intermediate DNA-protein complexes were characterized by their unique patterns of DMS protection. Surprisingly, a small number of G residues also became hyperreactive to DMS. Since DMS is insensitive to DNA unwinding, reaction efficiency might have increased due to the accumulation of DMS in hydrophobic pockets of the complexes. Open transcription complexes formed at other DNA sequences also exhibit hyperreactivity with MnO4− (Jeppesen and Nielsen, 1989), and this characteristic has since served as the basis for determining which amino acids within a series of σ70 mutants help to stabilize the open complex (Fenton et al., 2000). In addition, quantitative analysis of the DNA fragments generated in related experiments yielded information on the population distribution of alternative protein-DNA conformers (Tsodikov et al., 1998). The hyperreactivity observed for these systems may originate in part from a protein-dependent flipping of adenosine bases out of the DNA helix to expose their complementary T residues (Fenton et al., 2000). Related reaction is evident when T is held in an extrahelical position by enzymes that utilize a base-flipping mechanism during their processing of DNA (Serva et al., 1998; Reddy and Rao, 2000; Fig. 6.6.10). DMS-dependent methylation generates an equally diagnostic pattern of hyper- and hyporeactive G residues within a complex of MutY and DNA, which also involves nucleotide flipping (Chepanoske et al., 1999). At least for MnO4−, the basis of protein-dependent hyperreactivity is not always so evident. Two protein-DNA complexes characterized by X-ray crystallography do not reveal the extensive unpairing of T at sites that were previously shown to have a high sensitivity to MnO4− (König et al., 1996; Bochkarev et al., 1998). A single T proximal to the pseudo-dyad axis of nucleosomes was similarly found to be hyperreactive, but not necessarily extrahelical (Fitzgerald and Anderson, 1999). Perhaps the lysine-rich histone tails were instead able to attenuate the electrostatic repulsion of the anionic reagent and DNA and allow for efficient oxidation of T (Hänsler and Rokita, 1993).
Figure 6.6.10 Base flipping can be detected by chemical modification. KMnO4 was used to detect an extrahelical T formed by duplex DNA in the presence and absence of DNA adenineN6 methyltransferase (M. TaqI), S-adenosyl methionine (SAM), S-adenosyl homocysteine (SAH), and sinefungin (Sin; adenosyl ornithine). Densitometry traces of lanes 2, 3, and 4 are shown to the right. Reprinted from Serva et al. (1998) with permission from Oxford University Press.
Just as a protein may influence chemical modification of DNA, so too may chemical modification of DNA affect its association with a protein (Fig. 6.6.2). Accordingly, an enhancer factor R from Epstein-Barr virus could have been characterized through its ability to protect a region of DNA from DMS-dependent methylation, but, instead, methylation of G N7 was used to determine which sites block binding of the enhancer (Gruffat et al., 1990). Oxidation of T to its glycol derivative (Fig. 6.6.6) has similarly been used for interference analysis of GCN4 binding to the major groove of DNA (Pu and Struhl, 1992). This type of interference experiment represents a convenient and complementary alternative to the protection studies described above. Together, these approaches can establish a compelling model for specific protein-DNA complexes and even help discover new DNAprotein systems. For example, an 80-bp region of DNA and two associated nuclear factors that are involved in transcription control of histone H10 were identified through a combination of techniques including chemical footprinting, UV cross-linking, DMS interference, and sitedirected mutagenesis (Breuer et al., 1993). When studies are based solely on interference
6.6.10 Supplement 5
Current Protocols in Nucleic Acid Chemistry
assays, a series of reagents are often employed. In this manner, results based on DMS and DEPC were sufficient to detect distinct proteinDNA contacts with two consensus-sequence variants recognized by the M-lysozyme downstream enhancer (Nickel et al., 1995). The importance of using multiple reagents is further demonstrated by investigations on a series of hormone-responsive elements. DMS interference suggested that both the glucocorticoid and estrogen receptors form similar contacts to G N7, but MnO4− interference was able to determine that only the glucocorticoid receptor interacts with T (Truss et al., 1991; Fig. 6.6.11). Missing contact probing offers yet another complementary approach for examining protein-DNA complexes. In this case, chemical modification removes, rather than masks, functional groups of DNA that have the potential to interact with protein. A population of DNA lacking individual guanine bases can be generated by treatment with DMS and can be used to screen for individual G residues that are critical for stabilizing protein-DNA interactions. This was first applied to investigations
Figure 6.6.11 Protein contact sites can be mapped onto helical models of duplex DNA. Interference assays were used to differentiate DNA recognition by (A) the glucocorticoid receptor with a half-site of its responsive element and (B) the estrogen receptor with a half-site of its equivalent responsive element. DMS, KMnO4, and ethylnitrosourea were used to probe N7 of G, C5, C6 of T, and phosphate oxygens of the backbone, respectively. Reprinted from Truss et al. (1991) with permission from the American Society for Microbiology.
on the λ phage repressor protein (Brunelle and Schleif, 1987) and has more recently been combined with DMS and KMnO4 interference studies to ascertain the DNA binding properties of a nitrogen regulatory protein (Feng et al., 1993). Missing contact experiments are not limited to depurination of G by DMS. Depurination of G + A by formic acid, depyrimidation of T + C by hydrazine, and depyrimidation of T by KMnO4 have all been used to identify protein-DNA interactions (Brunelle and Schleif, 1987; McBoom and Sadowski, 1994). Any one of these procedures may be adequate to address a particular question on structure, but when used in concert with protection and interference analysis, a broad range of structural characteristics may be described in the absence of crystallography or NMR.
Applications of Chemical Modification In Vivo The vast majority of studies based on chemical modification are performed in vitro for obvious reasons including convenience and simplicity. However, questions regarding biological relevance can linger in the absence of complementary data for equivalent systems in vivo. One of the many procedures available to help forge the necessary connection to cellular conditions is none other than chemical modification. Such an approach might be initially dismissed out of concerns about cell permeability and target specificity, but numerous laboratories have successfully footprinted DNA in vivo. One of the first examples utilized methylation of G N7 by DMS to detect regulatory proteins binding to the lac operon (Nick and Gilbert, 1985). DNA modification depended on the ability of this neutral and low-molecularweight organic reagent to diffuse into bacterial cells. Subsequent mapping of the DNA reaction originally entailed chromatin isolation, restriction, separation, and Southern blotting. Primer extension soon replaced blotting (Borowiec and Gralla, 1986), and more recently ligationmediated PCR and use of AlkA protein, a glycosylase that hydrolyzes DNA at N3-methyl A and N7-methyl G, have been adopted to enhance the detection of chemical probing in vivo (Szabó et al., 2000). Despite the charge and high reactivity of MnO4−, this oxidant has similarly been used to examine complexes of lac promoter and RNA polymerase within Escherichia coli (SasseDwight and Gralla, 1989). The specificity of MnO4− for single-stranded DNA is especially
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.6.11 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Literature Cited
Addess, K.J. and Feigon, J. 1996. Introduction to 1H NMR spectroscopy of DNA. In Bioorganic Chemistry: Nucleic Acids (S.M. Hecht, ed.) pp. 163-185. Oxford University Press, New York. Akman, S.A., Doroshow, J.H., and Dizdaroglu, M. 1990. Base modification in plasmid DNA caused by potassium permanganate. Arch. Biochem. Biophys. 282:202-205. Ansari, A.Z., Chael, M.L., and O’Halloran, T.V. 1992. Allosteric underwinding of DNA is a critical step in positive control of transcription by Hg-MerR. Nature 355:87-89. Armitage, B., Koch, T., Frydenlund, H., Ørum, H., Batz, H.-G., and Schuster, G.B. 1997. Peptide nucleic acid-anthraquinone conjugates: Strand invasion and photoinduced cleavage of duplex DNA. Nucl. Acids Res. 25:4674-4678. Bailly, C., Gentle, D., Hamy, F., Purcell, M., and Waring, M.J. 1994. Localized chemical reactivity in DNA associated with the sequence-specific bisintercalation of echinomycin. Biochem. J. 300:165-173.
Figure 6.6.12 In vivo footprinting of open complexes formed by RNA polymerase and various mutant promoter complexes using KMnO4. Reprinted from Barrios et al. (1998); copyright (1998) National Academy of Sciences, U.S.A.
Chemical Reagants for Investigating the Major Groove of DNA
suited for detecting the open complex formed with RNA polymerase. Complexes containing alternative promoters and sigma factors have also been investigated in vivo with both DMS and MnO4− in relationship to transcription control for growth under anaerobic and aerobic conditions (Morett and Buck, 1989; Barrios et al., 1998; Fig. 6.6.12). OsO4 and its bipyridine complex provide alternative reagents for probing T in vivo (Pale?ek, 1992b). Although OsO4 is often used as a general stain for cells, DNA modification can be accomplished with concentrations lower than those needed for staining. The most notable success of OsO4 in vivo has been the detection of hyperreactive T residues that may result from the formation B-Z or Z-Z helical junctions within E. coli (Rahmouni and Wells, 1989). While these examples have certainly demonstrated the potential of chemical modification in vivo, widespread enthusiasm for this approach will likely depend on future development of reagents with much greater selectivity.
Balagurumoorthy, P. and Brahmachari, S.K. 1994. Structure and stability of human telomeric sequence. J. Biol. Chem. 269:21858-21869. Barrios, H., Grande, R., Olvera, L., and Morett, E. 1998. In vivo genomic footprinting analysis reveals that the complex Bradyrhizobium japonicum fixRnifA promoter region is differently occupied by two distinct RNA polymerase holoenzymes. Proc. Natl. Acad. Sci. U.S.A. 95:1014-1019. Bavykin, S.G. and Pruss, D. 1997. DNA-protein cross-linking studies: Beyond the seemingly invariable nucleosome core structure. Chemtracts; Biochem. Mol. Biol. 10:723-736. Beal, P.A. and Dervan, P.B. 1992. Recognition of double helical DNA by alternative strand triple helix formation. J. Am. Chem. Soc. 114:49764982. Bochkarev, A., Bochkareva, E., Frappier, L., and Edwards, A.M. 1998. The 2.2 Å structure of a permanganate-sensitive DNA site bound by the Epstein-Barr virus origin binding protein, EBNA1. J. Mol. Biol. 284:1273-1278. Borowiec, J.A. and Gralla, J.D. 1986. High-resolution analysis of lac transcription complexes inside cells. Biochemistry 25:5051-5057. Borowiec, J.A., Zhang, L., Sasse-Dwight, S., and Gralla, J.D. 1987. DNA supercoiling promotes formation of a bent repression loop in lac DNA. J. Mol. Biol. 196:101-111. Breuer, B., Steuer, B., and Alonso, A. 1993. Basal level transcription of the histone H10 gene is mediated by a 80 bp promoter fragment. Nucl. Acids Res. 21:927-934. Brewer, A.C., Marsh, P.J., and Patient, R.K. 1990. A simplified method for in vivo footprinting using DMS. Nucl. Acids Res. 18:5574.
6.6.12 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Brunelle, A. and Schleif, R.F. 1987. Missing contact probing of DNA-protein interactions. Proc. Natl. Acad. Sci. U.S.A. 84:6673-6676.
Ford, H., Chang, C.-H., and Behrman, E.J. 1981. Sequence-specific osmium reagents for polynucleotides. J. Am. Chem. Soc. 103:7773-7779.
Chang, C.-F., Tada, H., and Khalili, K. 1994. The role of a pentanucleotide repeat sequence, AGGGAAGGGA, in the regulation of JC virus DNA replication. Gene 148:309-314.
Fox, K.R. 2000. Targeting DNA with triplexes. Curr. Med. Chem. 7:17-37.
Chepanoske, C.L., Porello, S.L., Fujiwara, T., Sugiyama, H., and David, S.S. 1999. Substrate recognition by Escherichia coli MutY using substrate analogs. Nucl. Acids Res. 27:3197-3204. Chow, C.S. and Barton, J.K. 1992. Transition-metal complexes as probes of nucleic acids. Methods Enzymol. 212:219-242. Clark, J.M. and Beardsley, G.P. 1987. Functional effects of cis-thymine glycol lesions on DNA synthesis in vitro. Biochemistry 26:5398-5403. Collier, D.A., Mergny, J.-L., Thuong, N.T., and Hélène, C. 1991. Site-specific intercalation at the triplex-duplex junction induces a conformational change which is detectable by hypersensitivity to DEPC. Nucl. Acids Res. 19:4219-4224. Cotton, R.G.H. 1989. Detection of single base changes in nucleic acids. Biochem. J. 263:1-10. Cotton, R.G.H. and Campbell, R.D. 1989. Chemical reactivity of matched cytosine and thymine bases near mismatched and unmatched bases. Nucl. Acids Res. 17:4223-4233.
Fox, K.R. and Grigg, G.W. 1988. Diethyl pyrocarbonate and permanganate provide evidence for an unusual DNA conformation induced by binding of the antitumor antibiotics bleomycin and phleomycin. Nucl. Acids Res. 16:2063-2075. Friedman, T. and Brown, D.M. 1978. Base-specific r eactio ns useful for DNA sequencing: Methylene blue-sensitized photooxidation of guanine and osmium tetroxide modification of thymine. Nucl. Acids Res. 5:615-622. Furlong, J.C. and Lilley, D.M.J. 1986. Highly selective chemical modification of cruciform loops by diethyl pyrocarbonate. Nucl. Acids Res. 14:3995-4007. Giovannangeli, C. and Hélène, C. 1997. Progress in development of triplex-based strategies. Antisense & Nucleic Acid Drug Development 7:413421. Gogos, J.A., Karayiorgou, M., Aburatani, H., and Kafatos, F.C. 1990. Detection of single base mismatches of thymine and cytosine. Nucl. Acids Res. 18:6807-6814.
Cotton, R.G.H., Rodrigues, N.R., and Campbell, R.D. 1988. Reactivity of cytosine and thymine in single-base-pair mismatches. Proc. Natl. Acad. Sci. U.S.A. 85:4397-4401.
Gough, G.W., Sullivan, K.M., and Lilley, D.M.J. 1986. The structure of cruciforms in supercoiled DNA: Probing the single-stranded character of nucleotide bases with bisulfite. EMBO J. 1986:191-196.
Dobi, A. and Agoston, D.V. 1998. Submillimolar levels of calcium regulates DNA structure at the dinucleotide repeat (TG/AC)n. Proc. Natl. Acad. Sci. U.S.A. 95:5981-5986.
Gruffat, N., Manet, E., Rigolet, A., and Sergeant, A. 1990. The enhancer factor R of Epstein-Barr virus is a sequence-specific DNA binding protein. Nucl. Acids Res. 18:6835-6843.
Egholm, M., Christensen, L., Dueholm, K.L., Buchardt, O., Coull, J., and Nielsen, P.E. 1995. Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA. Nucl. Acids Res. 23:217-222.
Guo, Q., Lu, M., and Kallenbach, N.R. 1995. Effect of hemimethylation and methylation of adenine on the structure and stability of model DNA duplexes. Biochemistry 34:16359-16364.
Ehrsemann, C., Baudin, F., Mougel, M., Romby, P., Ebel, J.-P., and Ehresmann, B. 1987. Probing the structure of RNAs in solution. Nucl. Acids Res. 15:9109-9128. Falazka, G., Pale?ek, E., Wells, R.D., and Klysik, J. 1986. Site-specific OsO4 modification of the B-Z junctions formed at the (dA-dC)32 region in supercoiled DNA. J. Biol. Chem. 261:70937098. Feng, B., Xiao, X., and Marzluf, G.A. 1993. Recognition of specific nucleotide bases and cooperative DNA binding by the trans-acting nitrogen regulatory protein NIT2. Nucl. Acids Res. 21:3989-3996. Fenton, M.S., Lee, S.J., and Gralla, J.D. 2000. Escherichia coli promoter opening and -10 recognition: Mutational analysis of σ70. EMBO J. 19:1130-1137. Fitzgerald, D.J. and Anderson, J.N. 1999. DNA distortion as a factor in nucleosome positioning. J. Mol. Biol. 293:477-491.
Hänsler, U. and Rokita, S.E. 1993. Electrostatics rather than conformation control the oxidation of DNA by the anionic reagent permanganate. J. Am. Chem. Soc. 115:8554-8557. Hartley, J.A. 1993. Selectivity in alkylating agentDNA interactions. In Molecular Aspects of Anticancer Drug-DNA Interactions (S. Neidle and M. Waring, eds.) pp.1-31. CRC Press, Boca Raton, Fla. Hartley, J.A., Forrow, S.M., and Souhami, R.L. 1990. Effect of ionic strength and cationic DNA affinity binders on the DNA sequence selective alkylation of guanine N7-positions by nitrogen mustards. Biochemistry 29:2985-2991. Hayatsu, H. 1976. Bisulfite modification of nucleic acids and their constituents. Prog. Nucleic Acid Res. Mol. Biol. 16:75-124. Hayatsu, H. and Ukita, T. 1967. The selective degradation of pyrimidines in nucleic acids by permanganate oxidation. Biochem. Biophys. Res. Commun. 29:556-561.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.6.13 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Herr, W. 1985. Diethyl pyrocarbonate: A chemical probe for secondary structure in negatively supercoiled DNA. Proc. Natl. Acad. Sci. U.S.A. 82:8009-8013.
Koizume, S., Inoue, H., Kamiya, H., and Ohtsuka, E. 1998. Neighboring base damage induced by permanganate oxidation of 8-oxoguanine in DNA. Nucl. Acids Res. 26:3599-3607.
Herr, W., Corbin, V., and Gilbert, W. 1982. Nucleotide sequence of the 3′ half of AKV. Nucl. Acids Res. 10:6931-6943.
König, P., Giraldo, R., Chapman, L., and Rhodes, D. 1996. The crystal structure of the DNA-binding domain of yeast RAP1 in complex with telomeric DNA. Cell 85:125-136.
Howgate, P., Jones, A.S., and Tittensor, J.R. 1968. The permanganate oxidation of thymidine. J. Chem. Soc. C 275-279. Htun, H. and Johnston, B.H. 1992. Mapping adducts of DNA structural probes using transcription and primer extension approaches. Methods Enzymol. 212:272-294. Ide, M., Kow, Y.W., and Wallace, S.S. 1985. Thymine glycols and urea residues in M13 DNA constitute replicative blocks in vitro. Nucl. Acids Res. 13:8035-8052. James, T.L. 1995. Nuclear Magnetic Resonance and Nucleic Acids. Academic Press, New York. Jamieson, E.R. and Lippard, S.J. 1999. Structure, recognition and processing of cisplatin-DNA adducts. Chem. Rev. 99:2467-2498. Jeppesen, C. and Nielsen, P.E. 1988. Detection of intercalation-induced changes in DNA structure by reaction with diethyl pyrocarbonate or potassium permanganate. FEBS Lett. 231:172-176. Jeppesen, C. and Nielsen, P.E. 1989. Uranyl mediated photofootprinting reveals strong RNA polymerase-DNA backbone contacts in the +10 region of the DeoP1 promoter open complex. Nucl. Acids Res. 17:4947-4956. Jiang, H., Zacharias, W., and Amirhaeri, S. 1991. Potassium permanganate as an in situ probe for B-Z and Z-Z junctions. Nucl. Acids Res. 19:6943-6948. Johnston, B.H. 1992. Hydroxylamine and methoxylamine as probes of DNA structure. Methods Enzymol. 212:180-194. Johnston, B.H. and Rich, A. 1985. Chemical probes of DNA conformation: Detection of Z-DNA at nucleotide resolution. Cell 42:713-724. Kasparkova, J., Farrell, N., and Brabec, V. 2000. Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J. Biol. Chem. 275:1578915798. Kinoshita, H., Shi, Y., Sandefur, C., and Jarrard, D.F. 2000. Screening hypermethylated regions by methylation-sensitive single-strand conformational polymorphism. Anal. Biochem. 278:165169. Kladde, M.P. and Simpson, R.T. 1996. Chromatin structure mapping in vivo using methyltransferases. Methods Enzymol. 274:214-233.
Chemical Reagants for Investigating the Major Groove of DNA
Klysik, J., Rippe, K., and Jovin, T.M. 1990. Reactivity of parallel-stranded DNA to chemical modification reagents. Biochemistry 29:98319839.
Kostrhunova, H. and Brabec, V. 2000. Conformational analysis of site-specific DNA cross-links of cisplatin-distamycin conjugates. Biochemistry 39:12639-12649. Lambrinakos, A., Humphrey, K.E., Babon, J.J., Ellis, T.P., and Cotton, R.G.H. 1999. Reactivity of KMnO4 and tetraethylammonium chloride with mismatched bases and a simple mutation detection protocol. Nucl. Acids Res. 27:1866-1874. Leonard, N.J., McDonald, J.J., Henderson, R.E.L., and Reichmann, M.E. 1971. Reaction of diethyl pyrocarbonate with nucleic acid components. Adenosine. Biochemistry 10:3335-3342. Lilley, D.M. 1992. Probes of DNA structure. Methods Enzymol. 212:133-139. Lundblad, R.L. 1995. Techniques in Protein Modification. CRC Press, Boca Raton, Fla. Marrot, L. and Leng, M. 1989. Chemical probes of the conformation of DNA modified by cis-diamminedichlo ro platinu m(II). Biochemistry 28:1454-1461. Mäueler, W., Kyas, A., Keyl, H.-G., and Epplen, J.T. 1998. A genome-derived (gaa.ttc)24 trinucleotide block binds nuclear protein(s) specifically and forms triple helices. Gene 215:389403. Maxam, A.M. and Gillbert, W. 1980. Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol. 65:499-560. McBoom, L.D.B. and Sadowski, P.D. 1994. Contacts of the ABF1 protein of Saccharomyces cerevisiae with a DNA-binding site at MATa. J. Biol. Chem. 269:16455-16460. McCarthy, J.G. 1989. An improvement in thymine specific chemical DNA sequencing. Nucl. Acids Res. 17:7541. McCarthy, J.G. and Rich, A. 1991. Detection of an unusual distortion in A-tract DNA using KMnO4: Effect of temperature and distamycin on the altered conformation. Nucl. Acids Res. 19:3421-3429. McCarthy, J.G., Williams, L.D., and Rich, A. 1990. Chemical reactivity of KMnO4 and diethyl pyrocarbonate with B-DNA: Specific reactivity with short A-tracts. Biochemistry 29:6071-6081. McCarthy, J.G., Frederick, C.A., and Nicolas, A. 1993. A structural analysis of the bent kinetoplast DNA from Crithidia fasciculata by high resolution chemical probing. Nucl. Acids Res. 21:3309-3317. Miller, P.S. 1996. Development of antisense and antigene oligonucleotide analogs. Prog. Nucleic Acid Res. Mol. Biol. 52:261-291.
6.6.14 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Mirzabekov, A.D., Bavykin, S.G., Belyavsky, A.V., Karpov, V.L., Preobrazhenskaya, O.V., Shick, V.V., and Ebralidse, K.K. 1989. Mapping DNAprotein interactions by cross-linking. Methods Enzymol. 170:386-408.
Pu, W.T. and Struhl, K. 1992. Uracil interference, a rapid and general method for defining proteinDNA interactions involving the 5-methyl group of thymines: The GCN4-DNA complex. Nucl. Acids Res. 20:771-775.
Morett, E. and Buck, M. 1989. In vivo studies on the interaction of RNA polymerase-σ54 with the Klebsiella pneumoniae and Rhizobium meliloti nifH promoters. J. Mol. Biol. 210:65-77.
Pullman, A. and Pullman, B. 1981. Molecular electrostatic potential of the nucleic acids. Quart. Rev. Biophys. 14:289-380.
Nakatani, K., Hagihara, S., Sando, S., Miyazaki, H., Tanabe, K., and Saito, I. 2000. Site selective formation of thymine glycol-containing oligodeoxynucleotides by oxidation with osmium tetroxide and a bipyridine-tethered oligonucleotide. J. Am. Chem. Soc. 122:6309-6310. Nawamura, T., Negishi, K., and Hayatsu, H. 1994. 8-Hydroxyguanine is not produced by permanganate oxidation of DNA. Arch. Biochem. Biophys. 311:523-524. Neidle, S. and Stuart, D.I. 1976. The crystal and molecular structure of an osmium bispyridine adduct of thymine. Biochim. Biophys. Acta 418:226-231. NejedlO, K., Kwinkowski, M., Galazka, G., Klysik, J., and Pale?ek, E. 1985. Recognition of the structural distortions at the junctions between B and Z segments in negatively supercoiled DNA by osmium tetroxide. J. Biomol. Struct. Dyn. 3:467-478. NejedlO, K., Skorová, E., Diekmann, S., and Pale?ek, E. 1998. Analysis of a curved DNA constructed from alternating dAn:dTn-tracts in linear and supercoiled form by high resolution chemical probing. Biophys. Chem. 73:205-216. Nick, H. and Gilbert, W. 1985. Detection in vivo of protein-DNA interactions within the lac operon of Escherichia coli. Nature 313:795-798. Nickel, J., Short, M.L., Schmitz, A., Eggert, M., and Renkawitz, R. 1995. Methylation of the mouse M-lysozyme downstream enhancer inhibits heterotetrameric GABP binding. Nucl. Acids Res. 23:4785-4792. Nielsen, P.E. 1990. Chemical and photochemical probing of DNA complexes. J. Mol. Recogn. 3:1-25. O’Halloran, T.V., Frantz, B., Shin, M.K., Ralston, D.M., and Wright, J.G. 1989. The MerR heavy metal receptor mediates positive activation in a topologically novel transcription complex. Cell 56:119-129. Pale?ek, E. 1992a. Probing DNA structure with osmium tetroxide complexes in vitro. Methods Enzymol. 212:139-155. Pale?ek, E. 1992b. Probing of DNA structure in cells with osmium tetroxide-2,2′-bipyridine. Methods Enzymol. 212:305-318. Peattie, D.A. 1979. Direct chemical method for sequencing RNA. Proc. Natl. Acad. Sci. U.S.A. 76:1760-1764. Peattie, D.A. and Gilbert, W. 1980. Chemical probes for higher-order structure in RNA. Proc. Natl. Acad. Sci. U.S.A. 77:4679-4682.
Rahmouni, A.R. and Wells, R.D. 1989. Stabilization of Z-DNA in vivo by localized supercoiling. Science 246:358-363. Reddy, Y.V.R. and Rao, D.N. 2000. Binding of EcoP151 DNA methyltransferase to DNA reveals a large structural distortion within the recognition sequence. J. Mol. Biol. 298:597-610. Roberts, E., Deeble, V.J., Woods, C.G., and Taylor, G.R. 1997. KMnO4 and tetraethylammonium chloride are a safe and effective substitute for OsO4 in solid-phase fluorescent chemical cleavage of mismatch. Nucl. Acids Res. 25:33773378. Ross, S.A. and Burrows, C.J. 1996. Cytosine-specific chemical probing of DNA using bromide and monoperoxysulfate. Nucl. Acids Res. 24:5062-5063. Ross, S.A. and Burrows, C.J. 1997. Bromination of pyrimidines using bromide and monoperoxysulfate: A competition study between cytidine, uridine and thymidine. Tetrahedron Lett. 38:28052808. Rother, K.I., Silke, J., Georgiev, O., Schaffner, W., and Matsuo, K. 1995. Influence of DNA sequence and methylation status on bisulfite conversion of cytosine residues. Anal. Biochem. 231:263-265. Rubin, C.M. and Schmid, C.W. 1980. Pyrimidinespecific chemical reactions useful for DNA sequencing. Nucl. Acids Res. 8:4613-4619. Runkel, L. and Nordheim, A. 1986. Chemical footprinting of the interaction between left-handed Z-DNA and anti-Z-DNA antibodies by diethyl pyrocarbonate carbethoxylation. J. Mol. Biol. 189:487-501. Saluz, H. and Jost, J.-P. 1989. A simple high-resolution procedure to study DNA methylation and in vivo DNA-protein interactions on a single-copy gene level in higher eukaryotes. Proc. Natl. Acad. Sci. U.S.A. 86:2602-2606. Sasse-Dwight, S. and Gralla, J.D. 1989. KMnO4 as a probe for lac promoter DNA melting and mechanism in vivo. J. Biol. Chem. 264:80748081. Scholten, P.M. and Nordheim, A. 1986. Diethyl pyrocarbonate: A chemical probe for DNA cruciforms. Nucl. Acids Res. 14:3981-3993. Sen, D. and Gilbert, W. 1988. Formation of parallel four-stranded complexes by guanine-rich motifs in DNA and its implications for meiosis. Nature 334:364-366. Serva, S., Weinhold, E., Roberts, R.J., and Klimasauskas, S. 1998. Chemical display of thymine residues flipped out by DNA methyltransferease. Nucl. Acids Res. 26:3473-3479.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.6.15 Current Protocols in Nucleic Acid Chemistry
Supplement 5
Singer, B. and Grunberger, D. 1983. Reactions of directly acting agents with nucleic acids. In Molecular Biology of Mutagens and Carcinogens (B. Singer and D. Grunberger, eds.), Chapter 4, pp. 45-96. Plenum Press, New York.
Vincze, A., Henderson, R.E.L., McDonald, J.J., and Leonard, N.J. 1973. Reaction of diethyl pyrocarbonate with nucleic acid components. Bases and nucleosides derived from guanine, cytosine and uracil. J. Am. Chem. Soc. 95:2677-2682.
Sip, M., Schwartz, A., Vovelle, F., Ptak, M., and Leng, M. 1992. Distortions induced in DNA by cis-platinum interstrand adducts. Biochemistry 31:2508-2513.
Webb, M. and Thomas, J.O. 1999. Structure-specific binding of the two tandem HMG boxes of HMG1 to four-way junction DNA is mediated by the A domain. J. Mol. Biol. 294:373-387.
Sriram, M. and Wang, A.H.-J. 1996. Structure of DNA and RNA. In Bioorganic Chemistry: Nucleic Acids (S.M. Hecht, ed.) pp. 105-143. Oxford University Press, New York.
Weeks, K.M. and Crothers, D.M. 1993. Major groove accessibility of RNA. Science 261:15741577.
Stevens, S.Y. and Glick, G.D. 1999. Evidence for sequence-specific recognition of DNA by antisingle-stranded DNA autoantibodies. Biochemistry 38:560-568. Szabó, P., Pfeifer, G.P., Miao, F., O’Connor, T.R., and Mann, J.R. 2000. Improved in vivo dimethyl sulfate footprinting using AlkA protein: DNAprotein interactions at the mouse H19 gene promoter in primary embryo fibroblasts. Anal. Biochem. 283:112-116. Timsit, Y. and Moras, D. 1992. Crystallization of DNA. Methods Enzymol. 211:409-429. Truss, M., Chalepakis, G., Slater, E.P., Mader, S., and Beato, M. 1991. Functional interaction of hybrid response elements with wild-type and mutant steroid hormone receptors. Mol. Cell. Biol. 11:3247-3258. Tsodikov, O.V., Craig, M.L., Saecker, R.M., and Record, M.T. 1998. Quantitative analysis of multiple-hit footprinting studies to characterize DNA conformational changes in protein-DNA complexes. J. Mol. Biol. 283:757-769. Tullius, T.D. 1991. The use of chemical probes to analyze DNA and RNA structures. Curr. Opin. Struct. Biol. 1:428-434. Venczel, E.A. and Sen, D. 1993. Parallel and antiparallel G-DNA structures from a complex telomeric sequence. Biochemistry 32:62206228.
Williamson, J.R. and Celander, D.W. 1990. Rapid procedure for chemical sequencing of small oligonucleotides without ethanol precipatation. Nucl. Acids Res. 18:379. Williamson, J.R., Raghuraman, M.K., and Cech, T.R. 1989. Monovalent cation-induced structure of telomeric DNA: The G-quartet model. Cell 59:871-880. Wissmann, A. and Hillen, W. 1991. DNA contacts probed by modification protection and interference studies. Methods Enzymol. 208:365-379. Wong, E. and Giandomenico, C.M. 1999. Current status of platinum-based antitumor drugs. Chem. Rev. 99:2451-2466. Wurdeman, R.L. and Gold, B. 1988. The effect of DNA sequence, ionic strength, and cationic DNA affinity binder on the methylation of DNA by N-methyl-N-nitrosourea. Chem. Res. Toxicol. 1:146-147. Yeung, A.T., Dinehart, W.J., and Jones, B.K. 1988. Modification of guanine bases during oligonucleotide synthesis. Nucl. Acids Res. 16:45394554.
Contributed by Steven E. Rokita University of Maryland College Park, Maryland
Chemical Reagants for Investigating the Major Groove of DNA
6.6.16 Supplement 5
Current Protocols in Nucleic Acid Chemistry
Probing DNA Structure with Hydroxyl Radicals
UNIT 6.7
This unit describes how to use the hydroxyl radical (⋅OH) to gain information on the structure of a DNA molecule. Radiolabeled DNA is allowed to react with the hydroxyl radical, which causes strand breaks in the DNA. The broken DNA strands are separated by length via electrophoresis of the reaction products on a denaturing polyacrylamide gel. The cleavage pattern of the DNA is visualized by exposure of the gel to a phosphor imager plate. Quantitative analysis of the cleavage pattern results in an “image” of the shape of the surface of the DNA molecule. Expertise in the techniques of basic molecular biology is necessary to perform this procedure. CAUTION: This procedure should be performed only by personnel trained in the proper use of the 32P isotope, in Nuclear Regulatory Commission (NRC)–licensed sites. Standard precautions to prevent excessive exposure and radioactive contamination of personnel and equipment must be followed at all times. PREPARATION OF THE HYDROXYL RADICAL CLEAVAGE PATTERN OF A DNA MOLECULE This protocol describes how to perform hydroxyl radical cleavage of a DNA molecule and how to visualize the cleavage pattern by subjecting the reaction products to denaturing gel electrophoresis. A convenient source of the hydroxyl radical is the Fenton reaction of iron(II) EDTA with hydrogen peroxide (Fig. 6.7.1; Udenfriend et al., 1954). Sodium ascorbate is also present in the reaction, to reduce the iron(III) EDTA product of the Fenton reaction back to iron(II) EDTA. Thus, a catalytic cycle is established, which allows the use of very low concentrations of the iron reagent.
BASIC PROTOCOL
Materials 1 ng/µL radiolabeled DNA (5′-end-labeled with 32P on one strand; 3000 Ci/mmol; see, e.g., CPMB UNIT 3.5) dissolved in TE buffer, pH 8.0 (APPENDIX 2A) 1× Fe(II) EDTA (see recipe) 10 mM sodium ascorbate 0.3% (v/v) hydrogen peroxide (H2O2) 100 mM thiourea 3 M sodium acetate (APPENDIX 2A) 85% and 100% (v/v) ethanol Dry ice/acetone bath Formamide-containing dye mixture (e.g., loading buffer, UNIT 10.4) Denaturing poylacrylamide electrophoresis gel (∼30 × 40 × 0.04 cm; APPENDIX 3B) 1.5-mL microcentrifuge tubes, siliconized 25° and 90°C heating blocks SpeedVac evaporator
Figure 6.7.1 The Fenton reaction of iron(II) EDTA with hydrogen peroxide to generate the hydroxyl radical. Contributed by Thomas D. Tullius Current Protocols in Nucleic Acid Chemistry (2001) 6.7.1-6.7.8 Copyright © 2001 by John Wiley & Sons, Inc.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.7.1 Supplement 7
Phosphor imager with storage phosphor plate that corresponds to the size of the gel Phosphor imaging plate scanner Additional reagents and equipment for denaturing polyacrylamide gel electrophoresis (PAGE; APPENDIX 3B), drying of high-percentage acryamide denaturing gels (see Support Protocol 1), and image analysis (optional; see Support Protocol 2) Perform hydroxyl radical cleavage reaction 1. Add 7 µL of 1 ng/µL radiolabeled DNA in 10 mM TE buffer, pH 8.0, to a 1.5-mL siliconized microcentrifuge tube. 2. Place separate drops of the following solutions on the wall of the microcentrifuge tube, above the DNA solution: 1 µL 1× Fe(II) EDTA 1 µL 10 mM sodium ascorbate 1 µL 0.3% H2O2. These solutions make up the cleavage reagent.
3. Close the tube, tap the tube to mix the three drops with the DNA solution, and briefly vortex the solution. 4. Incubate the reaction mixture for 2 min in a heating block at 25°C. The reaction time may need to be adjusted to prevent overdigestion of the sample (see Critical Parameters). If overdigestion is suspected, the intensity of the full-length band in the sample can be compared to a control (step 6) and the reaction time or concentration of cleavage reagents can be reduced as appropriate.
Stop reaction and isolate cleaved DNA 5. Add 7 µL of 100 mM thiourea to the mixture to stop the reaction. Briefly vortex the mixture. 6. Combine 7 µL unreacted radiolabeled DNA with 10 µL TE buffer in a second tube as a control. A control is used to ensure that the starting DNA is intact (i.e., that there is no prior cleavage) and to evaluate the extent of cleavage in the sample (see Critical Parameters).
7. Add 3 µL of 3 M sodium acetate and 100 µL of 100% ethanol to the sample and the control, and place in a dry ice/acetone bath for 1 hr. 8. Microcentrifuge 30 min at maximum speed, 4°C, to pellet the DNA. 9. Rinse the DNA pellet twice with 85% ethanol, centrifuging for 5 min after each rinse. 10. Dry the DNA pellet in a SpeedVac evaporator under vacuum. If the DNA molecule under study is a short oligonucleotide (fewer than ∼20 base pairs), ethanol precipitation often is inefficient at pelleting the DNA. Therefore, for short oligonucleotides, steps 7 to 10 are skipped and the DNA is isolated directly by lyophilization of the sample in a SpeedVac evaporator. The disadvantage of this procedure is that any salts present in the reaction mixture are dried down along with the DNA, and problems with denaturing gel electrophoresis may occur. Such problems include poorly shaped gel bands and marked narrowing of the lane near the bottom of the gel. If these problems occur, steps should be taken to minimize the size of the sample and the concentration of salts in the sample.
Probing DNA Structure with Hydroxyl Radicals
6.7.2 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Separate DNA cleavage products by denaturing gel electrophoresis 11. Dissolve the DNA pellet in 4 µL formamide-containing dye mixture. 12. To denature the DNA, heat the DNA sample at 90°C for 3 min, and then quickly cool it by plunging it into ice. 13. Load the DNA sample onto a denaturing polyacrylamide gel that has been prepared in an apparatus suitable for sequencing DNA (see APPENDIX 3B for details on denaturing PAGE). To study short DNA molecules (~20 base pairs), use a high-percentage gel (20% or 25% acrylamide). Longer DNA fragments require a lower-percentage gel (e.g., 8% or 10%). CAUTION: Acrylamide is a neurotoxin; always wear gloves, safety glasses, and a surgical mask when working with acrylamide powder.
14. Electrophorese the sample for a time appropriate to separate the cleavage products of interest (usually ∼2 hr). The time of electrophoresis depends on the percentage of poylacrylamide in the gel, the size of the DNA fragments to be separated, and the current (i.e., at constant voltage, the wattage) at which the gel is run. The current should be set so that the gel runs fairly “hot” (~65°C) to ensure that the DNA sample remains denatured during electrophoresis. Be aware, though, that too much heat will cause the glass plates to crack!
15. Dry the gel using a gel dryer (see Support Protocol 1). 16. Expose the gel to a phosphor imager plate. This can take several hours to a few days, depending on the level of radioactivity of the bands on the gel.
17. Scan the phosphor imager plate. If desired, analysis of the gel can be performed using image analysis software (see Support Protocol 2).
DRYING A HIGH-PERCENTAGE POLYACRYLAMIDE DENATURING GEL Drying a low-percentage polyacrylamide gel (8% to 10% polyacrylamide) is straightforward (see APPENDIX 3B). Drying a high-percentage gel (20% to 25% polyacrylamide) can be tricky, because such a gel does not stick well to the filter paper that is used to pull the gel off the glass plate before drying. High-percentage gels are used for high-resolution separation of shorter DNA molecules (Balasubramanian et al., 1998), and so are important for use in chemical probe experiments to determine DNA structure.The author’s laboratory has developed a procedure that works well for drying high-percentage gels (Shafer et al., 1989). The key to the procedure is to first transfer the gel to plastic wrap, which clings well and provides mechanical support to the gel.
SUPPORT PROTOCOL 1
Materials Gel (see Basic Protocol) Plastic wrap: 12- or 18-in. (∼30- or 45-cm) Saran Wrap or Reynolds film Whatman 3MM filter paper Gel dryer 1. After running the gel, carefully lift the larger glass plate off the gel. 2. Cover the gel with plastic wrap. Trim the edges of the plastic wrap so that the wrap extends 2 in. (5 cm) beyond the edges of the gel plate. 3. Using the plastic wrap to support the gel, turn the gel plate over so that the second glass plate is now on top.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.7.3 Current Protocols in Nucleic Acid Chemistry
Supplement 7
4. Carefully pull the gel away from the glass plate, starting at the top of the gel. The gel should remain on the plastic wrap.
5. Trim two pieces of Whatman 3MM filter paper to fit the gel, and place on the gel. 6. Carefully invert the filter paper/gel/plastic wrap sandwich so that the plastic wrap is on top. Remove air bubbles by brushing the plastic wrap with a piece of filter paper. 7. Dry the gel using a gel dryer. SUPPORT PROTOCOL 2
ANALYSIS OF THE CLEAVAGE PATTERN While the image of the gel produced in the Basic Protocol can provide much information, hydroxyl radical cleavage patterns often exhibit subtle features. Small differences in cleavage between one nucleotide and another can be difficult to discern by eye alone. Fortunately, the image of the gel that is obtained by the scanning device can be further analyzed using software programs for image analysis. This protocol describes the basic steps involved in quantitative analysis of the cleavage pattern using readily available software. The goal of this method is to deconvolute the closely spaced bands in a cleavage pattern, and integrate each band. The author’s laboratory has found that the Lorentzian function provides a very good analytical description of the bands that are produced by phosphor imager analysis of a gel (Shadle et al., 1997). Each band in the cleavage pattern is fitted by a Lorentzian function using nonlinear least-squares fitting methods. One parameter of the Lorentzian function is directly proportional to the area of the band. These band areas are plotted as a histogram to provide a quantitative cleavage pattern. One benefit of this method of analysis is that once the bands of a lane are deconvoluted and integrated, it is a simple matter to compare one cleavage pattern to another, for normalization, subtraction, and other purposes. A similar but more elaborate whole-band analysis method, using the software program GelExplorer, is described in Shadle et al. (1997). See Internet Resources for the URL of the GelExplorer manual. Materials Computerized image of gel obtained by scanning the storage phosphor plate (see Basic Protocol) Personal computer running software for image analysis: ImageQuant (Molecular Dynamics) Origin, with Peak Fitting Module (OriginLab) Microsoft Excel (optional) 1. Perform a linescan of the gel lane of interest, using ImageQuant. 2. Transfer the linescan to Origin. 3. Using the Peak Fitting Module of Origin, simultaneously fit a Lorentzian function to each peak in the cleavage pattern. 4. Plot the integrals of the bands, using Origin or Microsoft Excel.
Probing DNA Structure with Hydroxyl Radicals
6.7.4 Supplement 7
Current Protocols in Nucleic Acid Chemistry
REAGENTS AND SOLUTIONS Use ultrapure (e.g., Milli-Q) water in all recipes and protocol steps. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Fe(II) EDTA, 1× 5× stock solution: Dissolve 0.098 g of ferrous ammonium sulfate hexahydrate [(NH4)2Fe(SO4)2⋅6H2O] and 0.186 g of Na2EDTA⋅2H2O in 50 mL of water. Vortex the solution for several minutes to dissolve as much solid as possible. Filter solution through a 0.45-ìm polypropylene filter—a very light greenish-yellow (or perhaps colorless) solution is obtained (concentration, 5 mM (NH4)2Fe(SO4)2/10 mM EDTA). Store in 100-µL aliquots in microcentrifuge tubes up to several months at –20°C. 1× working solution: Immediately before use, dilute 1 part 5× stock solution with 4 parts water (concentration, 1 mM (NH4)2Fe(SO4)2/2 mM EDTA). COMMENTARY Background Information The structure of any particular doublestranded DNA molecule differs from the canonical B-form structure, primarily due to stacking and other interactions between successive base pairs in the DNA double helix. The shape of the surface of a DNA molecule therefore is not perfectly regular, but instead reflects the underlying sequence-dependent structural variability of the DNA. Such structural variations in DNA, whether large or subtle, may contribute to the ability of a protein to recognize a particular DNA sequence, and so are important to characterize. DNA also can adopt structures radically different from the typical double helix, for example the four-stranded Holliday junction that is an intermediate in genetic recombination. Such unusual DNA structures can be difficult to study by standard methods. The hydroxyl radical has proven to be a highly useful probe of the shape of the surface of DNA. It works by causing strand breaks at each nucleotide in a DNA molecule. The main advantages of the hydroxyl radical as a chemical probe of DNA structure are that it reacts with every nucleotide in a DNA molecule that is exposed to the solvent, that it is a very small molecule, and that fine details of DNA structure can potentially be revealed. This highly reactive free radical causes a DNA strand to break by abstracting a hydrogen atom from a deoxyribose residue in the backbone of the DNA. The resulting strand breaks are detected by electrophoresis of the reaction products on a denaturing gel. Every nucleotide of a double-stranded DNA molecule is susceptible to attack by the hydroxyl radical. However, the nucleotides in a DNA molecule do not all react to precisely the same extent, because
the exposure of each deoxyribose residue to the solvent differs due to sequence-dependent structural variations in the DNA. Quantitation of the cleavage pattern provides an abstract “image” of the shape of the surface of the DNA molecule. Other chemical probes have been developed that recognize specific structural features of DNA, and are described in other units in Chapter 6. The hydroxyl radical has been used to study a wide variety of unusual DNA structures (Price and Tullius, 1992). Two examples are bent A-tract DNA (Burkhoff and Tullius, 1987, 1988; Price and Tullius, 1993) and the fourstranded Holliday junction recombination intermediate (Churchill et al., 1988; Kimball et al., 1990).
Critical Parameters Several parameters are critical for the success of the Basic Protocol. The DNA must be intact before the hydroxyl radical cleavage reaction is conducted. Because the hydroxyl radical cleaves DNA at every accessible nucleotide, any preexisting (background) cuts in the DNA strand interfere with analysis of the hydroxyl radical–induced cuts. To check the integrity of the starting DNA, include in the experiment a control sample of DNA that is not subjected to hydroxyl radical cleavage, and run this sample on the gel adjacent to the experimental samples. The control untreated sample should show no bands other than the band corresponding to the intact full-length DNA molecule. If cleavage is seen in this lane, the DNA should be further purified, or the DNA molecule should be prepared again. The reagents used to initiate hydroxyl radical cleavage must be active. Iron(II) EDTA is
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.7.5 Current Protocols in Nucleic Acid Chemistry
Supplement 7
not indefinitely stable, because iron(II) is subject to oxidation to iron(III) and the eventual formation of a precipitate. Iron(II) EDTA stock solutions should be stored frozen, and thawed for use immediately before the experiment. Sodium ascorbate also is subject to oxidation, both in the solid state and in solution. Oxidized ascorbate will not reduce the iron(III) product of the reaction back to iron(II), and so the cleavage reagent is not active. A fresh bottle of sodium ascorbate is used to prepare a stock solution, which is divided into aliquots in microcentrifuge tubes and kept frozen until needed for an experiment. The DNA must not be overdigested by the hydroxyl radical. The goal is to have one or fewer cleavages in any individual DNA strand. This can be achieved operationally by limiting the reaction so that <30% of the DNA molecules in the sample are cleaved. Thus, 70% of the DNA in the sample will run as intact, fulllength DNA in the gel. If overdigestion is suspected, compare the intensity of the full-length band in a control, untreated DNA sample with the intensity of the full-length band in a sample treated with hydroxyl radical. This can be accomplished by a short exposure of the gel to the phosphor imager plate. The intensity of the treated sample’s full-length band should be no less than 70% of the control band’s intensity. If
Probing DNA Structure with Hydroxyl Radicals
the sample is overdigested, adjust the time of reaction or the concentration of the iron(II) EDTA in the reaction mixture. This unit describes the use of 5′-radiolabeled DNA in a hydroxyl radical cleavage experiment. DNA singly end-labeled at the 3′ end could in principle also be used in this protocol. However, very high-resolution gel electrophoresis shows that a major product of DNA cleavage by the hydroxyl radical is a DNA strand terminated by a 5′ aldehyde group (Fig. 6.7.2; Balasubramanian et al., 1998). A DNA strand with this type of terminus has an anomalous gel mobility, making detailed quantitation of the gel pattern difficult. Therefore 5′-radiolabeled DNA is best for studies of DNA structure using the hydroxyl radical.
Troubleshooting Common problems that may arise in the course of probing DNA structure with hydroxyl radicals, along with their possible causes and solutions, are listed in Table 6.7.1.
Anticipated Results The results of this protocol will be a ladder of bands on a denaturing polyacrylamide gel for a sample treated with the hydroxyl radical, and a single intense full-length band for the control untreated sample. The bands in the
Figure 6.7.2 Hydroxyl radical cleavage using 5′- and 3′-end-labeled DNA. The major product for each is a DNA strand terminated by phosphate at the site of strand breakage. With 3′-labeled DNA, the aldehyde-terminated strand also is produced in substantial amounts, leading to difficulties in quantitation.
6.7.6 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Table 6.7.1 Troubleshooting Guide for Probing DNA Structure with Hydroxyl Radicals
Problem
Possible cause
Solution
No cleavage pattern is observed
Ascorbate reducing agent is inactive due to oxidation (see Critical Parameters)
Prepare a fresh ascorbate solution
DNA sample contains radical scavengers (glycerol is commonly used to stabilize proteins, and sometimes is used in other buffers, and is an excellent radical scavenger)
Remove radical scavengers from the buffer
DNA sample contains too much salt
Perform additional ethanol precipitations to remove salt, or use less salt in the reaction mixture Prepare fresh DNA. Do not store DNA for an extended time once it is radiolabeled, especially at high specific activity, as autoradiolysis can damage the DNA molecule.
Bands are poorly shaped, and become progressively more narrow toward the bottom of the gel Control (untreated) DNA shows cleavage
DNA sample has deteriorated
treated sample should be fairly uniform in intensity, since the hydroxyl radical cleaves each nucleotide in a B-form double helix to a nearly equal extent.
Time Considerations Radiolabeling the DNA, performing the hydroxyl radical cleavage reaction, and isolating the DNA can be accomplished in one working day or less. Preparing and running the denaturing gel to separate the cleavage products takes another day. The time of exposure of the gel to the phosphor plate varies depending on the radioactivity of the sample, but 1 to 3 days is typically sufficient. Quantitative analysis of a gel takes a day.
Literature Cited
Churchill, M.E.A., Tullius, T.D., Kallenbach, N.R., and Seeman, N.C. 1988. A Holliday recombination intermediate is twofold symmetric. Proc. Natl. Acad. Sci. U.S.A. 85:4653-4656. Kimball, A., Guo, Q., Lu, M., Cunningham, R.P., Kallenbach, N.R., Seeman, N.C., and Tullius, T.D. 1990. Construction and analysis of parallel and antiparallel Holliday junctions. J. Biol. Chem. 265:6544-6547. Price, M.A. and Tullius, T.D. 1992. Using the hydroxyl radical to probe DNA structure. Methods Enzymol. 212:194-219. Price, M.A. and Tullius, T.D. 1993. How the structure of an adenine tract depends on sequence context. A new model for the structure of TnAn DNA sequences. Biochemistry 32:127-136. Shadle, S.E., Allen, D.F., Guo, H., Pogozelski, W.K., Bashkin, J.S., and Tullius, T.D. 1997. Quantitative analysis of electrophoresis data: Novel curve fitting methodology and its application to the determination of a protein-DNA binding constant. Nucl. Acids Res. 25:850–861.
Balasubramanian, B., Pogozelski, W.K., and Tullius, T.D. 1998. DNA strand breaking by the hydroxyl radical is governed by the accessible surface areas of the hydrogen atoms of the DNA backbone. Proc. Natl. Acad. Sci. U.S.A. 95:97389743.
Shafer, G.E., Price, M.A., and Tullius, T.D. 1989. Use of the hydroxyl radical and gel electrophoresis to study DNA structure. Electrophoresis 10:397-404.
Burkhoff, A.M. and Tullius, T.D. 1987. The unusual conformation adopted by the adenine tracts in kinetoplast DNA. Cell 48:935-943.
Udenfriend, S., Clark, C.T., Axelrod, J., and Brodie, B.B. 1954. Ascorbic acid in aromatic hydroxylation. J. Biol. Chem. 208:731-739.
Burkhoff, A.M. and Tullius, T.D. 1988. Structural details of an adenine tract that does not cause DNA to bend. Nature 331:455-457.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.7.7 Current Protocols in Nucleic Acid Chemistry
Supplement 7
Key References Price and Tullius, 1992. See above. A comprehensive description of the use of the hydroxyl radical as a probe of DNA structure.
Internet Resources http://people.bu.edu/tullius/GelExplorer_Manual.pdf A detailed online manual that describes the use of the GelExplorer software for quantitative analysis of electrophoresis gel patterns.
Contributed by Thomas D. Tullius Boston University Boston, Massachussetts
Probing DNA Structure with Hydroxyl Radicals
6.7.8 Supplement 7
Current Protocols in Nucleic Acid Chemistry
Probing RNA Structure and Metal-Binding Sites Using Terbium(III) Footprinting Metal ions play a crucial role in RNA tertiary structure folding by neutralizing and bridging the negatively charged phosphoribose backbone. A folded RNA is stabilized by specific and nonspecific interactions with metal ions. The current unit describes the use of the lanthanide metal ion terbium(III) as a probe of both RNA structure and high-affinity metal-binding sites. Thus, it complements UNIT 6.3, since both the lead (Pb2+) and terbium (Tb3+) aqueous hydroxo complexes cleave the RNA backbone in a similar fashion. Specifically, terbium(III) binds to the same sites on RNA as magnesium(II), but with two to four orders of magnitude higher affinity. Low (micromolar) concentrations of terbium(III) will therefore displace magnesium and result in hydrolytic backbone cleavage at high-affinity magnesium-binding sites. At high (millimolar) concentrations of terbium(III), cleavage occurs in a largely sequence-independent manner, preferentially cutting single-stranded or non-Watson-Crick base-paired regions. The aqueous terbium(III) complex has a near-neutral pKa (∼7.9), which enables it to hydrolyze the RNA backbone around physiological pH. This metal ion–promoted RNA backbone cleavage occurs via deprotonation of the 2′-hydroxyl group and nucleophilic attack of the resulting oxyanion on the adjacent 3′,5′-phosphodiester bond to form 2′,3′-cyclic phosphate and 5′-hydroxyl termini (Figure 6.8.1). Since cleavage is dependent on terbium(III) being able to access the 2′-hydroxyl group, the terbium(III) cleavage pattern can be used to probe the secondary and tertiary structure within an RNA molecule.
UNIT 6.8
BASIC PROTOCOL
In the protocol below, which is a standard procedure for performing terbium(III)-mediated footprinting of an RNA molecule, RNA that has been end-labeled with 32P at either the 5′ or 3′ end is prefolded in an appropriate buffer including divalent cations (generally magnesium). Varying concentrations of terbium(III) are added to the RNA mixture to initiate the strand-scission reaction, and the mixture is incubated 30 min to 2 hr. The reaction is quenched, the cleaved RNA is separated on a denaturing polyacrylamide gel, and the cleavage pattern is visualized by exposure of the gel to a phosphor imager screen. Partial alkaline hydrolysis and ribonuclease (RNase) T1 digestion reactions of the radiolabeled RNA are analyzed alongside the terbium(III)-mediated cleavage reaction to accurately locate the cleavage sites (see UNIT 6.1). The intensities of cleaved bands are quantified and a footprint of the overall RNA molecule is obtained. CAUTION: When working with radioactive materials, take appropriate precautions to avoid contamination of the experimenter and the surroundings. Carry out the experiment and dispose of wastes in an appropriately designated area, following the guidelines provided by the local radiation safety officer. NOTE: As for experiments with RNA in general, care must be taken to avoid introducing ribonucleases (RNases) into the samples. This can be avoided by wearing gloves to avoid skin contact when handling samples and solutions; by using nuclease-free, sterilized pipet tips, sample tubes, and other disposable plasticware; by preparing all solutions from highest-purity (e.g., molecular-biology grade) components in double-deionized water (18 MΩ conductivity); and by filter-sterilizing (through a 0.22-µm filter) or autoclaving all solutions. Although less desirable, treatment with diethylpyrocarbonate (DEPC; APPENDIX 2A) may be used to block background nuclease activities. Chemical and Enzymatic Probes for Nucleic Acid Structure Contributed by Dinari A. Harris and Nils G. Walter Current Protocols in Nucleic Acid Chemistry (2003) 6.8.1-6.8.8 Copyright © 2003 by John Wiley & Sons, Inc.
6.8.1 Supplement 13
Materials RNA, gel-purified (UNIT 6.1), labeled at 5′ or 3′ end with 32P (conc. ≥50,000 cpm/µL; sp. act. ≥150,000 cpm/pmol) Appropriate buffers to fold RNA (usually Tris, MES, and/or HEPES buffer of desired pH; see Critical Parameters for discussion of optimization) 1 M MgCl2 (APPENDIX 2A) 100 mM TbCl3 (see recipe) 0.5 M EDTA, pH 8.0 (APPENDIX 2A) 3 M sodium acetate (APPENDIX 2A) 80% and 100% (v/v) ethanol Urea loading buffer (APPENDIX 2A) Heating block Water bath at optimized incubation temperature (25° to 45°C) Phosphor screens and phosphor imager with appropriate software (e.g., PhosphorImager Storm 840 with ImageQuant software; Molecular Dynamics) Additional reagents and equipment for partial alkaline hydrolysis and RNase T1 digestion of RNA (UNIT 6.1, Support Protocol 3), and denaturing polyacrylamide gel electrophoresis (APPENDIX 3B) Prepare reaction mixture and terbium(III) dilution series 1. Mix the desired amount of end-labeled RNA with appropriate buffer. Prepare a single pool containing 250,000 to 500,000 cpm (typically 0.5 to 2 pmol) RNA per aliquot, with a total volume that will be sufficient for duplicate 8-µL aliquots at each terbium(III) concentration (see steps 4 and 5). Denature 2 min in a 90°C heating block. A micromolar background of unlabeled RNA can be added to reduce nonspecific cleavage at low terbium(III) concentrations and to facilitate subsequent ethanol precipitation.
2. Slowly renature the RNA by incubating mixture at an optimized temperature between 25° and 45°C (see Critical Parameters) for ∼10 min. 3. Add MgCl2 from 1 M or other appropriately diluted stock solution to obtain desired Mg2+ concentration (see Critical Parameters) and continue to incubate at appropriate temperature for an additional 5 min. 4. Make a serial set of TbCl3 dilutions in water from the 0.1 M TbCl3 stock solution, ranging from micromolar to millimolar concentrations, calculated at 5× the final reaction concentration (see step 5). The TbCl3 dilutions in water should be made immediately prior to use. A serial set of dilutions is recommended to ensure consistency in cleavage band intensity between gel lanes. Use a fresh aliquot of 0.1 M TbCl3 stock solution each time. Final TbCl3 concentrations used in the cleavage reactions should be optimized together with other experimental conditions for the specific RNA and experimental goal (see Critical Parameters).
Run reaction 5. Initiate terbium(III)-mediated cleavage reactions by combining 8 µL RNA (step 3) with 2 µL of each TbCl3 dilution (step 4) to achieve the desired final Tb3+ concentrations (typically 0 to 5 mM). Perform each concentration in duplicate. Continue to incubate at the optimized temperature (25° to 45°C) for an optimized length of time (30 min to 2 hr; see Critical Parameters). Probing RNA Structure and Metal-Binding Sites Using Terbium
Incubation times between 30 min and 2 hr are sufficient to generate a partial digestion pattern of end-labeled RNA under single hit conditions. Avoid more extended incubation times to prevent secondary hits (see Critical Parameters).
6.8.2 Supplement 13
Current Protocols in Nucleic Acid Chemistry
6. Terminate the cleavage reaction by adding 0.5 M EDTA, pH 8.0, to a final concentration of 50 mM (or at least a 2-fold excess over the total concentration of multivalent metal ions). Collect RNA and analyze cleavage patterns 7. Add 3 M sodium acetate to the reaction to final concentration of 0.3 M, then add 2 to 2.5 vol of 100% ethanol and incubate overnight −20°C to precipitate the RNA. Centrifuge 30 min at 12,000 × g, 4°C. Decant supernatant, wash pellet with 80% ethanol, decant supernatant, and dry RNA in a Speedvac evaporator. Redissolve samples in 10 to 20 µL of urea loading buffer. 8. Using separate samples of the same end-labeled RNA, perform partial alkaline hydrolysis and RNase T1 digestion reactions (see UNIT 6.1, Support Protocol 3). Add 10 µL urea loading buffer to an equal volume (10 µL) of the partial hydrolysis reaction and the T1 digestion, and load each directly onto the gel. 9. Place all samples in a heating block at 90°C for 5 min, then snap cool in ice water. Analyze the cleavage products on a high-resolution denaturing (8 M urea) polyacrylamide gel (APPENDIX 3B), using the partial alkaline hydrolysis and RNase T1 digestion reactions as sequencing ladders to identify the specific terbium(III) cleavage products at nucleotide resolution. The authors use a 15% wedged gel, run at a constant power of 80 W, for separating an 80-mer RNA. Identical samples can be loaded at different times on the same gel to resolve different regions of the RNA.
10. Expose the gel to a phosphor imager screen. This can take several hours to overnight, depending on the level of radioactivity of the bands on the gel.
11. Scan the phosphor screen and quantify the full-length RNA and cleavage-product bands using a volume count method. At every Tb3+ concentration, calculate a normalized extent of cleavage (Π) by substituting the peak intensities in the equation:
Π=
band intensity at nucleotide x Σ band intensity at nucleotide i i y [Tb3+ ] band intensity at nucleotide x Σ band intensity at nucleotide i i 0 mM [Tb3+ ]
where y is the terbium(III) concentration in a particular cleavage reaction, x is the analyzed nucleotide position of the RNA, and “0 mM [Tb3+]” signifies a control reaction containing no terbium (III), incubated in the same fashion as reactions containing terbium(III). A Π value of ≥2 indicates significant cleavage over background degradation. By dividing the ratio of a single band intensity over total RNA in the presence of terbium(III) by the ratio of a single band intensity over total RNA in the absence of terbium(III), one normalizes for the effect of nonspecific background degradation. Chemical and Enzymatic Probes for Nucleic Acid Structure
6.8.3 Current Protocols in Nucleic Acid Chemistry
Supplement 13
REAGENTS AND SOLUTIONS Use double-deionized nuclease-free water (18 MΩ conductivity) in all recipes and protocol steps (also see General Considerations for Working with RNA in APPENDIX 2A). To eliminate traces of RNases on glassware, rinse in RNase-free water (APPENDIX 2A) and autoclave or bake 2 hr at 150°C. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Sodium cacodylate buffer, 5 mM (pH 5.5) Prepare 15.9 g/L sodium cacodylate (100 mM final). Adjust to pH 7 with NaOH or cacodylic acid. Dilute 100 mM stock solution to 5 mM, sterilize by filtering with a 0.22-µm filter, and store up to several months at room temperature. CAUTION: Be careful when handling the toxic cacodylate.
Terbium(III) chloride Dissolve 3.73 g solid TbCl3⋅6H2O (Aldrich; 99.9%) in 100 ml of 5 mM sodium cacodylate buffer (see recipe) to give a final concentration of 0.1 M. Filter through 0.22-µm filters into 1-mL aliquots and store up to 1 year at −20°C. The 0.1 M TbCl3 stock solution is prepared in a 5 mM sodium cacodylate buffer at pH 5.5 to prevent precipitation of terbium(III) hydroxide, which occurs at higher pH.
COMMENTARY Background Information
Probing RNA Structure and Metal-Binding Sites Using Terbium
Tertiary structure formation in RNA is highly influenced by metal ions, particularly divalents (Pyle, 2002). The lanthanide metal ion terbium(III) has proven to be a powerful probe of tertiary structure, as well as a tool for mapping metal-binding sites in RNA. Terbium(III) binds to sites on RNA in a manner similar to Mg2+, with an affinity two to four orders of magnitude higher (Walter et al., 2000). Terbium(III) has the ability to substitute for magnesium because hydrated Tb3+ ions have an ionic radius (0.92 Å) similar to that of hydrated Mg2+ (0.72 Å), and because terbium(III) and magnesium share the same preference for coordination to oxygen ligands (Saito and Suga, 2002). There are several classes of metal-binding sites found in RNA, ranging from diffuse to site-specific, and involving both inner- and outer-sphere coordination to the RNA. The most common ligands on the RNA are the nonbridging phosphate oxygens, the purine N7 positions, the base keto groups, and the ribose 2′-hydroxyls. Once bound to RNA, terbium(III) cleaves the phosphodiester backbone by abstracting the 2′-hydroxyl of a nearby nucleotide. This allows for nucleophilic attack of the resulting 2′-oxyanion on the juxtaposed phosphodiester bond, leading to strand cleavage (Ciesiolka et al., 1989; Matsumura and Komiyama, 1997; Figure 6.8.1). Tb3+ can effectively catalyze cleavage of an RNA backbone at physiological pH due to its lower pKa (∼7.9) compared to that of Mg2+ (Sigel et al., 2000).
By varying the concentration of Tb3+ used in the cleavage reaction, it is possible to obtain a map of metal-binding sites and a footprint of secondary and tertiary structure. Micromolar concentrations of Tb3+ bind to high-affinity metal binding sites within a folded RNA, leading to few specific cleavage sites. By contrast, millimolar concentrations of Tb3+ produce a footprinting pattern of solvent-accessible regions, mainly cleaving the RNA backbone in a sequence-independent manner. Under these conditions, the backbone is preferentially cut in single-stranded and non-Watson-Crick basepaired regions, possibly due to the better accessibility of ligands such as N7 positions of purines and the π-electron systems of all nucleobases (Walter et al., 2000). Therefore, it is critical to perform the cleavage reactions over a wide range of Tb3+ concentrations in order to acquire information on both high-affinity metal binding and secondary and tertiary structure folding. Terbium(III)-mediated footprinting and other properties of this lanthanide ion have provided for a versatile probe of RNA structure, function, and metal-ion binding. For example, micromolar concentrations of terbium(III) not only report a metal binding site in loop B of the hairpin ribozyme through backbone cleavage, but also permit the analysis of metal-binding affinity and kinetics through sensitized luminescence, and reversibly inhibit the ribozyme’s catalytic activity by competing for a crucial, yet nonselective, cation-binding site (Walter et al., 2000). Millimolar terbium(III) concentrations,
6.8.4 Supplement 13
Current Protocols in Nucleic Acid Chemistry
O δ− O
base
O
5′
5′ OH
O
P
Tb(OH)(aq)2+
δ−
O −O
pro-Rp
pro-Sp
O
O CH2
5′
base
O
Tb(H2O)(aq)3+
P
O−
base
O
O
O
δ− P O
δ− O
O O
3′
base
OH
BH+
CH2
3′
O
base
OH
HO
CH2
3′
O
base
OH
Figure 6.8.1 Terbium(III)-mediated RNA backbone cleavage. The aqueous terbium(III) hydroxo complex Tb(OH)(aq)2+ deprotonates the 2′-hydroxyl group, allowing for nucleophilic attack of the resulting oxyanion on the adjacent phosphodiester bond. This leads to formation of a trigonal-bipyramidal transition state (center), which, upon protonation by a general acid (BH+), breaks down to form 2′,3′-cyclic phosphate and a 5′-hydroxyl terminus.
in contrast, footprint the hairpin ribozyme’s secondary and tertiary structure and reveal a solvent-protected core similar to that observed in hydroxyl radical footprinting (Walter et al., 2000; also see Figure 6.8.2). At low Tb3+ concentrations, cleavage of human tRNALys,3 is restricted to nucleotides that were previously identified from X-ray crystallography as specific metal-binding pockets (Hargittai and Musier-Forsyth, 2000). The use of higher Tb3+ concentrations resulted in an overall footprint of the L-shaped tRNA structure, showing increased cleavage in the loop regions (D and anticodon loop; Hargittai and Musier-Forsyth, 2000). HIV nucleocapsid protein could then be shown to result in the disruption of the tRNA’s metal-binding pockets and, at higher concentrations, to induce subtle structural changes in, for example, the tRNA acceptor-TψC stem minihelix (Hargittai et al., 2001). Other RNAs that have similarly been studied by terbium(III)-mediated footprinting include the hammerhead (Feig et al., 1999), aminoacyltransferase (Flynn-Charlebois et al., 2001; Vaidya and Suga, 2001), RNase P (Kaye et al., 2002), and group II intron ribozymes (Sigel et al., 2000).
Critical Parameters Tb3+ can be a very useful chemical probe of metal binding and tertiary structure folding in
RNA. However, there are several parameters that are important to consider in order to obtain a reliable and reproducible RNA footprint. Prefolding the RNA under the correct buffer conditions and magnesium concentrations will ensure conformational homogeneity. When optimizing these components, the pH of the cleavage reaction should be kept near physiological pH (7.0 to 7.5), allowing for the accumulation of the cleavage-active Tb(OH)(aq)2+ species (Walter et al., 2000). At a pH above 7.5, Tb3+ increasingly forms insoluble polynuclear hydroxo aggregates (Baes and Mesmer, 1976; Matsumura and Komiyama, 1997), which should be avoided. Precipitation of such insoluble polynuclear species lowers the concentration of the cleavage-active mononuclear species, Tb(OH)(aq)2+, and potentially co-precipitates the RNA. The temperature at which the cleavage reaction is performed must be experimentally determined. Higher temperatures result in faster cleavage rates but also increase the amount of background degradation. Therefore, typical reaction temperatures range from 25° to 45°C. Since Tb3+ has the ability to displace Mg2+ in high-affinity binding pockets while also footprinting solvent-accessible regions, identifying a metal-binding site must be done with care. An effective means of locating a high-affinity binding site is to first decrease the Tb3+
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.8.5 Current Protocols in Nucleic Acid Chemistry
Supplement 13
A Lane no. S(dA −1) S(G+1A) Na+ Mg2+ Co(NH3)63+ spd3+ Tb3+ EDTA
B hinge H3
loop E motif H2
H4 H1
= strong hit = medium hit = weak hit = change upon tertiary structure folding = major hit at mM [Tb3+]
Probing RNA Structure and Metal-Binding Sites Using Terbium
Figure 6.8.2 Terbium(III)-mediated footprinting of the hairpin ribozyme (Walter et al., 2000). (A) Footprint of 5′-32P-labeled hairpin ribozyme (Rz) after incubation with terbium(III) for 2 hr at 25°C. Lanes 1 and 2, controls; lanes 3 and 4, sequencing ladders with RNase U2 (cutting after A) and RNase T1 (cutting after G); lane 5, partial alkali hydrolysis; lanes 6 to 19, order-of-addition experiments (numbers indicate order) with a 100-fold excess (500 nM) of noncleavable substrate analog S(dA–1) or S(G+1A), 100 mM Na+, 12 mM Mg2+, 12 mM Co(NH3)63+, and 12 mM spermidine (spd3+), 12 mM Tb3+, and 120 mM EDTA as chelator; lanes 20 to 27, incubation of 10 µM ribozyme-substrate complex, containing trace amounts of radiolabeled ribozyme, in the presence of 12 mM Mg2+ with varying concentrations of Tb3+, as indicated, and with noncleavable substrate analog, either S(dA–1) or S(G+1A). (B) Superposition of the observed backbone cleavage sites at 12 mM terbium(III) onto a schematic of the hairpin ribozyme. Strong, medium, and weak hits, together with changes caused by tertiary-structure formation, are indicated at the nucleotide 3′ to which cleavage occurs, as deduced from quantitation of lanes 8 (footprint of secondary structure; Tb3+ added before magnesium, thus preventing tertiary structure folding) and 10 (footprint of tertiary structure; magnesium added before Tb3+) in (A). The only major hit at micromolar concentrations of terbium(III) is 3′ to U37. Reproduced from Walter et al. (2000) with permission from Elsevier.
6.8.6 Supplement 13
Current Protocols in Nucleic Acid Chemistry
concentration until a very narrow cleavage pattern is observed (typically at 10 to 100 µM Tb3+), and then to perform a competition experiment with increasing concentrations of Mg2+. This can be done as in the Basic Protocol, but the concentration of Mg2+ is increased against a constant Tb3+ concentration. The residual terbium(III)-mediated cleavage bands should diminish as the Mg2+ concentration is increased. The optimal Tb3+ concentration(s) to use for structure probing are also an important consideration and must be determined for each individual RNA. The trivalent terbium(III) has been shown to induce slight perturbations in the RNA structure (Hargittai and Musier-Forsyth, 2000), but careful titration will reveal the optimal terbium(III):RNA ratio needed for detecting secondary and tertiary structure features in a given RNA molecule.
Anticipated Results A typical result involving both terbium(III)mediated structure probing and metal-bindingsite detection is shown in Figure 6.8.2 for the hairpin ribozyme (Walter et al., 2000). The cleavage pattern on such a denaturing polyacrylamide gel normally shows many bands of varying intensities. These varying intensities (or extents of cleavage) at each nucleotide position relate to the structure of the RNA. The extent of total cleavage should generally be no more than 20% of the uncleaved or full-length band. This ensures that the RNA undergoes a single hit and minimizes the presence of products resulting from multiple cleavage events. The normalized extent of cleavage (Π) is best quantified according to a modified form of the equation used in nucleotide analog interference mapping (NAIM) analysis (Ryder and Strobel, 1999), as given above (see Basic Protocol, step 11). It is important to note that terbium(III) footprinting may not reveal all high-affinity metal binding sites due to the geometrical requirement of Tb3+ accessibility to the 2′-hydroxyl group on the ribose (Figure 6.8.1). The rate and extent of cleavage depend on distance between the terbium(III) and the 2′-hydroxyl of the nearby nucleotide, which is unfavorable in a standard A-type RNA helix. Therefore, strong metal sites that occur in RNA helical regions may go undetected by Tb3+ cleavage (Sigel et al., 2000).
Time Considerations The procedure outlined in the Basic Protocol provides an easy and sensitive means of probing a wide variety of RNA structures. All procedures in this unit can be completed in 2 to 3 days. The most time-consuming aspect involved is the end labeling and careful gel purification of the RNA (UNIT 6.1). The cleavage reactions themselves take no more than 2 hr and are followed by gel electrophoresis (3 to 5 hr) and phosphorimager analysis (6 to 24 hr).
Literature Cited Baes, C.F. and Mesmer, R.E. 1976. The Hydrolysis of Cations. John Wiley & Sons, New York. Ciesiolka, J., Marciniec, T., and Krzyzosiak, W. 1989. Probing the environment of lanthanide binding sites in yeast tRNA(Phe) by specific metal-ion-promoted cleavages. Eur. J. Biochem. 182:445-450. Feig, A.L., Panek, M., Horrocks, W.D. Jr., and Uhlenbeck, O.C. 1999. Probing the binding of Tb(III) and Eu(III) to the hammerhead ribozyme using luminescence spectroscopy. Chem. Biol. 6:801-810. Flynn-Charlebois, A., Lee, N., and Suga, H. 2001. A single metal ion plays structural and chemical roles in an aminoacyl-transferase ribozyme. Biochemistry 40:13623-13632. Hargittai, M.R. and Musier-Forsyth, K. 2000. Use of terbium as a probe of tRNA tertiary structure and folding. RNA 6:1672-1680. Hargittai, M.R., Mangla, A.T., Gorelick, R.J., and Musier-Forsyth, K. 2001. HIV-1 nucleocapsid p r o tein zinc fin ger structures ind uce tRNA(Lys,3) structural changes but are not critical for primer/template annealing. J. Mol. Biol. 312:985-997. Kaye, N.M., Zahler, N.H., Christian, E.L., and Harris, M.E. 2002. Conservation of helical structure contributes to functional metal ion interactions in the catalytic domain of ribonuclease P RNA. J. Mol. Biol. 324:429-442. Matsumura, K. and Komiyama, M. 1997. Enormously fast RNA hydrolysis by lanthanide(III) ions under physiological conditions: Eminent candidates for novel tools of biotechnology. J. Biochem. 122:387-394. Pyle, A.M. 2002. Metal ions in the structure and function of RNA. J. Biol. Inorg. Chem. 7:679690. Ryder, S.P. and Strobel, S.A. 1999. Nucleotide analog interference mapping. Methods 18:38-50. Saito, H. and Suga, H. 2002. Outersphere and innersphere coordinated metal ions in an aminoacyltRNA synthetase ribozyme. Nucl. Acids Res. 30:5151-5159. Sigel, R.K., Vaidya, A., and Pyle, A.M. 2000. Metal ion binding sites in a group II intron core. Nat. Struct. Biol. 7:1111-1116.
Chemical and Enzymatic Probes for Nucleic Acid Structure
6.8.7 Current Protocols in Nucleic Acid Chemistry
Supplement 13
Vaidya, A. and Suga, H. 2001. Diverse roles of metal ions in acyl-transferase ribozymes. Biochemistry 40:7200-7210. Walter, N.G., Yang, N., and Burke, J.M. 2000. Probing non-selective cation binding in the hairpin ribozyme with Tb(III). J. Mol. Biol. 298:539555.
Contributed by Dinari A. Harris and Nils G. Walter University of Michigan Ann Arbor, Michigan
Probing RNA Structure and Metal-Binding Sites Using Terbium
6.8.8 Supplement 13
Current Protocols in Nucleic Acid Chemistry
Probing RNA Structure and Function by Nucleotide Analog Interference Mapping
UNIT 6.9
The chemistry of phosphorothioate interference has been expanded into a method to identify the specific chemical groups that are important for RNA activity (Eckstein, 1985; Gaur and Krupp, 1993; Strobel and Shetty, 1997). This approach, termed nucleotide analog interference mapping (NAIM), makes it possible to simultaneously, yet individually, test the contribution of a particular functional group at almost every position within the RNA molecule in an assay that is as simple as RNA sequencing. In a NAIM experiment the smallest mutable unit is not the base pair, but rather the individual functional groups that comprise the nucleotide. Because the deletion or modification of particular functional groups within an RNA can severely affect its activity, this approach makes it possible to determine the chemical basis of RNA structure and function (Ryder et al., 2000). Using phosphorothioate-tagged nucleotide analogs, all of the positions on the RNA can be simultaneously characterized. NAIM involves a four-step process: (1) the phosphorothioate-tagged nucleotide analog is randomly incorporated into the RNA by in vitro transcription; (2) the active members of the RNA population are selected from inactive transcripts; (3) the phosphorothioate linkage is cleaved by iodine treatment; and (4) the sites of analog substitution detrimental to activity are identified by gel electrophoresis and autoradiography. The approach is applicable to any RNA that can be transcribed in vitro and where active variants can be selected in some fashion. RNA functions include catalysis, protein or ligand binding, folding, and others.
STRATEGIC PLANNING Phosphorothioate-Tagged Nucleotide Analog Triphosphates (NTPαS) NAIM relies on the use of nucleotides in which one of the non-bridging α-phosphate oxygen atoms has been replaced with a sulfur (Eckstein, 1985). This modification does not drastically alter the RNA structure in the vast majority of cases, and any effects resulting from the sulfur are readily controlled. The NTPαS is randomly incorporated into the RNA molecule by in vitro transcription. The sulfur facilitates the direct detection of sites sensitive to analog incorporation because the phosphorothioate linkage can be selectively cleaved with iodine without affecting any of the other bonds within the RNA (Gish and Eckstein, 1988). The RNA fragments are separated by denaturing gel electrophoresis to identify the extent of analog incorporation and magnitude of interference at each position within the transcript. NAIM uses both parent and analog phosphorothioate-tagged nucleotides (Ryder et al., 2000). Any effects that arise from the phosphorothioate tag are controlled by comparison to the band intensity from the four parental 5 -O-(1-thio)nucleotide triphosphates (AαS, CαS, GαS, and UαS). The phosphorothioate substitution introduces an additional chiral center into the nucleotide. Synthesis of the phosphorothioate-tagged nucleotides results in a diastereomeric mixture of RP and SP isomers, of which only the SP diastereomer is recognized by RNA polymerase (Chamberlin et al., 1983; Griffiths et al., 1987). The transcription reaction proceeds with inversion of configuration at the α-phosphate, resulting in RNAs with RP phosphorothioate substitutions. It is possible to purify the SP diastereomer of the triphosphate by HPLC (Fischer et al., 1999), but the RP diastereomer is not recognized by the polymerase, nor does it inhibit the transcription reaction; therefore, its inclusion in the in vitro transcription reaction has no significant consequence. Contributed by Jesse C. Cochrane and Scott A. Strobel Current Protocols in Nucleic Acid Chemistry (2004) 6.9.1-6.9.21 C 2004 by John Wiley & Sons, Inc. Copyright
Chemical and Enzymatic Probes for Nucleic Aicd Structure
6.9.1 Supplement 17
Analog nucleotides contain modifications to the sugar or the base in addition to the phosphorothioate tag (Ryder et al., 2000). The range and variety of modifications are summarized in Table 6.9.1. Any analog that is amenable to transcriptional incorporation by RNA polymerase, even at low efficiency, can be used in this approach. To date, twelve adenosine analogs have been utilized in NAIM (Conrad et al., 1995; Hardt et al., 1996; Ortoleva-Donnelly et al., 1998; Soukup et al., 2002; Jones and Strobel, 2003; Schwans et al., 2003). Eight analogs modify the nucleotide base and four modify the ribose sugar. The base analogs include purine riboside (PurαS), N-methyladenosine (m6 AαS), 7-deazaadenosine (7dAαS), diaminopurine riboside (DAPαS), 2-aminopurine riboside (2APαS), formicin (FormαS), 3-deazaadenosine (c3 AαS), and 8-azaadenosine (n8 AαS). The ribose sugar analogs all modify the 2 -OH group and include 2 -deoxyadenosine (dAαS), 2 -deoxy-2 -fluoroadenosine (F AαS), 2 -O-methyladenosine (OMe AαS), and 2 deoxy-2 -thioadenosine (SH AαS). Each of these analogs provides specific information about the chemical basis of RNA activity at almost every incorporated position in the transcript. PurαS, 2APαS, and m6 AαS measure the effect of modifications to the N6 exocyclic amine of adenosine. The base analog 7dAαS replaces the N7 nitrogen with a C-H group. Interference with this analog indicates an important major groove contact to the ring nitrogen. Additionally, 7dAαS, FormαS, and n8 AαS can be used to probe important protonation events. DAPαS and 2APαS both add an additional amine to the C2 position of adenosine. dAαS